PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Boudreau, LH; Bertin, J; Robichaud, PP; Laflamme, M; Ouellette, RJ; Flamand, N; Surette, ME				Boudreau, Luc H.; Bertin, Jonathan; Robichaud, Philippe P.; Laflamme, Mark; Ouellette, Rodney J.; Flamand, Nicolas; Surette, Marc E.			Novel 5-lipoxygenase isoforms affect the biosynthesis of 5-lipoxygenase products	FASEB JOURNAL			English	Article						inflammation; lipid mediators; leukocytes; leukotrienes; eicosanoids	COACTOSIN-LIKE PROTEIN; ARACHIDONIC-ACID; ACTIVATING PROTEIN; HUMAN NEUTROPHILS; ENZYME-ACTIVITY; LEUKOTRIENE BIOSYNTHESIS; GENE PROMOTER; BINDING-SITE; STEM-CELLS; EXPRESSION	5-Lipoxygenase (5-LO) is the essential enzyme for the biosynthesis of leukotrienes, important mediators of inflammation. This study investigated whether variants of 5-LO exist in human leukocytes. 5-LO mRNA isoforms that are consistent with alternative splicing were identified by RT-PCR in a cell line or cell type-specific pattern. All evaluated cells expressed mRNA containing all 14 exons of 5-LO with the expected splicing sites. Individual isoforms that retained intron 10 (alpha-10), lacked exon 13 (Delta-13), and lacked exons 10 and 13 (Delta-10,13) or that lacked the first 96 base pairs of exon 10 (Delta-p10) were identified. Immunoreactive bands coeluting with the cloned alpha-10 and Delta-13 isoforms were measured in primary neutrophils and in Raji cells. When expressed in HEK293 cells, alternative proteins were without catalytic activity. However, when coexpressed with the active full-length 5-LO, alternative isoforms significantly decreased the biosynthesis of 5-LO products by up to 44%, as assessed by reverse-phase HPLC analysis. Additionally, in stimulated neutrophils the full-length active 5-LO was detected by immunoblot in both nuclear and nonnuclear compartments, while the Delta-13 isoform was only detected in the nuclear fraction. These alternative 5-LO isoforms may represent a new mechanism for the regulation of the 5-LO pathway and lipid mediator biosynthesis.-Boudreau, L. H., Bertin, J., Robichaud, P. P., Laflamme, M., Ouellette, R. J., Flamand, N., Surette, M. E. Novel 5-lipoxygenase isoforms affect the biosynthesis of 5-lipoxygenase products. FASEB J. 25, 1097-1105 (2011). www.fasebj.org	[Boudreau, Luc H.; Bertin, Jonathan; Robichaud, Philippe P.; Surette, Marc E.] Univ Moncton, Dept Chim & Biochim, Moncton, NB E1A 3E9, Canada; [Boudreau, Luc H.; Flamand, Nicolas] Univ Laval, Dept Med, Ctr Rech, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ G1K 7P4, Canada; [Boudreau, Luc H.; Flamand, Nicolas] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada; [Laflamme, Mark; Ouellette, Rodney J.] Atlantic Canc Res Inst, Moncton, NB, Canada; [Laflamme, Mark] Dept Fisheries & Oceans Canada, Moncton, NB, Canada	University of Moncton; Laval University; Laval University; Fisheries & Oceans Canada	Surette, ME (corresponding author), Univ Moncton, Dept Chim & Biochim, Moncton, NB E1A 3E9, Canada.	marc.surette@umoncton.ca	Flamand, Nicolas/H-5823-2019; Surette, Marc/AAW-1078-2021; Laflamme, MarK/B-5077-2010	Flamand, Nicolas/0000-0001-5944-7200; Laflamme, MarK/0000-0001-5955-7098; Boudreau, Luc H/0000-0002-3674-5026	Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada; Canada Research Chairs Program; Canadian Arthritis Network; Fonds de la Recherche en Sante du Quebec; Fonds de Recherche sur l'Arthrite et Les Maladies Rhumatismales de l'Universite Laval	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); Canada Research Chairs Program(Canada Research Chairs); Canadian Arthritis Network; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Fonds de Recherche sur l'Arthrite et Les Maladies Rhumatismales de l'Universite Laval	This work was supported by grants from the Canadian Institutes of Health Research (to M. E. S.) and the Heart and Stroke Foundation of Canada (to M. E. S.). M. E. S. is supported by the Canada Research Chairs Program. N.F. is the recipient of scholarship awards from the Canadian Arthritis Network and the Fonds de la Recherche en Sante du Quebec. L. H. B is the recipient of a scholarship from the Fonds de Recherche sur l'Arthrite et Les Maladies Rhumatismales de l'Universite Laval and a graduate student award from the Canadian Arthritis Network.	ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; Allard JB, 2005, CURR PROTEIN PEPT SC, V6, P125, DOI 10.2174/1389203053545417; Arseneau JR, 2009, BRIT J HAEMATOL, V147, P328, DOI 10.1111/j.1365-2141.2009.07859.x; Ben-Dov C, 2008, J BIOL CHEM, V283, P1229, DOI 10.1074/jbc.R700033200; BORGEAT P, 1990, METHOD ENZYMOL, V187, P98; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Chen YY, 2009, CELL CYCLE, V8, P3488, DOI 10.4161/cc.8.21.9852; Dishart D, 2005, BBA-MOL CELL BIOL L, V1738, P37, DOI 10.1016/j.bbalip.2005.11.008; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; Ferguson AD, 2007, SCIENCE, V317, P510, DOI 10.1126/science.1144346; Finkensieper A, 2010, CARDIOVASC RES, V86, P37, DOI 10.1093/cvr/cvp385; Flamand N, 2007, CELL MOL LIFE SCI, V64, P2657, DOI 10.1007/s00018-007-7228-2; Flamand N, 2006, J BIOL CHEM, V281, P129, DOI 10.1074/jbc.M506513200; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; Flamand N, 2009, J BIOL CHEM, V284, P306, DOI 10.1074/jbc.M805593200; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; Gao KP, 2008, NUCLEIC ACIDS RES, V36, P2257, DOI 10.1093/nar/gkn073; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; Jendraschak E, 1996, BIOCHEM J, V314, P733, DOI 10.1042/bj3140733; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Keren H, 2010, NAT REV GENET, V11, P345, DOI 10.1038/nrg2776; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Markwell M A, 1981, Methods Enzymol, V72, P296; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Michel AAY, 2008, PROTEIN EXPRES PURIF, V59, P110, DOI 10.1016/j.pep.2008.01.010; Newcomer ME, 2010, J BIOL CHEM, V285, P25109, DOI 10.1074/jbc.R110.125880; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Plante H, 2006, BIOCHEM J, V393, P211, DOI 10.1042/BJ20060669; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; Radmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002; Rakonjac M, 2006, P NATL ACAD SCI USA, V103, P13150, DOI 10.1073/pnas.0605150103; Ring WL, 1997, AM J PHYSIOL-CELL PH, V273, pC2057, DOI 10.1152/ajpcell.1997.273.6.C2057; Roos KLT, 2005, BIOCHEM BIOPH RES CO, V338, P62, DOI 10.1016/j.bbrc.2005.08.031; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; Seuter S, 2007, BBA-MOL CELL BIOL L, V1771, P864, DOI 10.1016/j.bbalip.2007.04.007; Seuter S, 2006, BIOCHEM BIOPH RES CO, V348, P1403, DOI 10.1016/j.bbrc.2006.08.011; Sorg BL, 2006, BBA-MOL CELL BIOL L, V1761, P686, DOI 10.1016/j.bbalip.2006.04.005; Tardif JC, 2010, CIRC-CARDIOVASC IMAG, V3, P298, DOI 10.1161/CIRCIMAGING.110.937169; Uhl J, 2002, J BIOL CHEM, V277, P4374, DOI 10.1074/jbc.M107665200; Werz O, 2005, P NATL ACAD SCI USA, V102, P13164, DOI 10.1073/pnas.0505991102; Werz O, 2000, EUR J BIOCHEM, V267, P1263, DOI 10.1046/j.1432-1327.2000.01000.x; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	51	20	21	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1097	1105		10.1096/fj.10-173856	http://dx.doi.org/10.1096/fj.10-173856			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21098726				2022-12-28	WOS:000287806200029
J	Suter, M; Bocock, P; Showalter, L; Hu, M; Shope, C; McKnight, R; Grove, K; Lane, R; Aagaard-Tillery, K				Suter, Melissa; Bocock, Philip; Showalter, Lori; Hu, Min; Shope, Cynthia; McKnight, Robert; Grove, Kevin; Lane, Robert; Aagaard-Tillery, Kjersti			Epigenomics: maternal high-fat diet exposure in utero disrupts peripheral circadian gene expression in nonhuman primates	FASEB JOURNAL			English	Article						Npas2; epigenetics; fetal origins of adult disease	REV-ERB-ALPHA; BODY-MASS INDEX; SUPRACHIASMATIC NUCLEUS; HISTONE ACETYLATION; CHROMATIN-STRUCTURE; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; CLOCK; FETAL; DNA	The effect of in utero exposure to a maternal high-fat diet on the peripheral circadian system of the fetus is unknown. Using mRNA copy number analysis, we report that the components of the peripheral circadian machinery are transcribed in the nonhuman primate fetal liver in an intact phase-antiphase fashion and that Npas2, a paralog of the Clock transcription factor, serves as the rate-limiting transcript by virtue of its relative low abundance (10- to 1000-fold lower). We show that exposure to a maternal high-fat diet in utero significantly alters the expression of fetal hepatic Npas2 (up to 7.1-fold, P<0.001) compared with that in control diet-exposed animals and is reversible in fetal offspring from obese dams reversed to a control diet (1.3-fold, P>0.05). Although the Npas2 promoter remains largely unmethylated, differential Npas2 promoter occupancy of acetylation of fetal histone H3 at lysine 14 (H3K14ac) occurs in response to maternal high-fat diet exposure compared with control diet-exposed animals. Furthermore, we find that disruption of Npas2 is consistent with high-fat diet exposure in juvenile animals, regardless of in utero diet exposure. In summary, the data suggest that peripheral Npas2 expression is uniquely vulnerable to diet exposure.-Suter, M., Bocock, P., Showalter, L., Hu, M., Shope, C., McKnight, R., Grove, K., Lane, R., Aagaard-Tillery, K. Epigenomics: maternal high-fat diet exposure in utero disrupts peripheral circadian gene expression in nonhuman primates. FASEB J. 25, 714-726 (2011). www.fasebj.org	[Aagaard-Tillery, Kjersti] Baylor Coll Med, Div Maternal Fetal Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; [McKnight, Robert; Lane, Robert] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA; [Grove, Kevin] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR USA	Baylor College of Medicine; Utah System of Higher Education; University of Utah; Oregon Health & Science University; Oregon National Primate Research Center	Aagaard-Tillery, K (corresponding author), Baylor Coll Med, Div Maternal Fetal Med, Dept Obstet & Gynecol, 1 Baylor Plaza,Jones 314, Houston, TX 77030 USA.	aagaardt@bcm.edu			U.S. National Institutes of Health (NIH) [DP2120OD001500-01]; National Institute of Child Health and Human Development/National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK080558-01, DK79194]; NIH [K12-GM084897]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080558, R01DK079194, R24DK090964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM084897] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD001500] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Child Health and Human Development/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors acknowledge the helpful comments of members of the Ignatia B. Van Den Veyver and Shannon M. Hawkins laboratories at Baylor College of Medicine. This work was supported by the U.S. National Institutes of Health (NIH) Director New Innovator Award (DP2120OD001500-01 to K. A. T.), National Institute of Child Health and Human Development/National Institute of Diabetes and Digestive and Kidney Diseases (grants R01-DK080558-01 to R. H. L and K. A. T and DK79194 to K. L. G.), and the NIH Research Education and Career Horizon Institutional Research and Academic Career Development Award (grant K12-GM084897 to M. S.). The authors report no conflicts of interest or financial disclosures.	Aagaard-Tillery KM, 2008, J MOL ENDOCRINOL, V41, P91, DOI 10.1677/JME-08-0025; Anttila S, 2003, CANCER RES, V63, P8623; Bae K, 2000, J NEUROSCI, V20, P1746; Barnea M, 2009, ENDOCRINOLOGY, V150, P161, DOI 10.1210/en.2008-0944; Bhargava SK, 2004, NEW ENGL J MED, V350, P865, DOI 10.1056/NEJMoa035698; Chen RM, 2009, MOL CELL, V36, P417, DOI 10.1016/j.molcel.2009.10.012; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Cox J, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.06.041; Curtis AM, 2004, J BIOL CHEM, V279, P7091, DOI 10.1074/jbc.M311973200; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; Debruyne J, 2008, J GENET, V87, P437, DOI 10.1007/s12041-008-0066-7; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Duez H, 2008, FEBS LETT, V582, P19, DOI 10.1016/j.febslet.2007.08.032; Duez H, 2009, J APPL PHYSIOL, V107, P1972, DOI 10.1152/japplphysiol.00570.2009; El-Hennamy R, 2008, J BIOL RHYTHM, V23, P435, DOI 10.1177/0748730408322635; Englund Ani, 2009, J Circadian Rhythms, V7, P5, DOI 10.1186/1740-3391-7-5; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Franks PW, 2010, NEW ENGL J MED, V362, P485, DOI 10.1056/NEJMoa0904130; Fu Q, 2004, PHYSIOL GENOMICS, V20, P108, DOI 10.1152/physiolgenomics.00175.2004; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gangwisch JE, 2009, OBES REV, V10, P37, DOI 10.1111/j.1467-789X.2009.00663.x; Grove KL, 2005, PHYSIOL BEHAV, V86, P646, DOI 10.1016/j.physbeh.2005.08.063; Hartil K, 2009, PEDIATR RES, V66, P368, DOI 10.1203/PDR.0b013e3181b33375; Herzog ED, 1998, NAT NEUROSCI, V1, P708, DOI 10.1038/3708; Hiragami-Hamada K, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-14; Horikawa K, 2005, NEUROSCIENCE, V134, P335, DOI 10.1016/j.neuroscience.2005.03.057; Ibuka N, 1980, Waking Sleeping, V4, P167; Kennaway DJ, 2002, TRENDS ENDOCRIN MET, V13, P398, DOI 10.1016/S1043-2760(02)00692-6; Kohsaka A, 2007, CELL METAB, V6, P414, DOI 10.1016/j.cmet.2007.09.006; Kovacikova Z, 2006, J BIOL RHYTHM, V21, P140, DOI 10.1177/0748730405285876; la Fleur SE, 2001, DIABETES, V50, P1237, DOI 10.2337/diabetes.50.6.1237; Lane RH, 1996, PEDIATR RES, V39, P390, DOI 10.1203/00006450-199603000-00003; Lane RH, 2000, PEDIATR RES, V47, P792, DOI 10.1203/00006450-200006000-00019; LeGates TA, 2009, PHYSIOL BEHAV, V98, P427, DOI 10.1016/j.physbeh.2009.07.007; Lemos DR, 2006, MOL ENDOCRINOL, V20, P1164, DOI 10.1210/me.2005-0361; Leroy G, 2008, MOL CELL, V30, P51, DOI 10.1016/j.molcel.2008.01.018; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loyola A, 2009, EMBO REP, V10, P769, DOI 10.1038/embor.2009.90; MacLennan NK, 2004, PHYSIOL GENOMICS, V18, P43, DOI 10.1152/physiolgenomics.00042.2004; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; McCurdy CE, 2009, J CLIN INVEST, V119, P323, DOI 10.1172/JCI32661; Mendoza J, 2008, J PHYSIOL-LONDON, V586, P5901, DOI 10.1113/jphysiol.2008.159566; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ohta H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002601; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Patton HM, 2006, J PEDIATR GASTR NUTR, V43, P413, DOI 10.1097/01.mpg.0000239995.58388.56; Plata MP, 2009, CHROMOSOMA, V118, P303, DOI 10.1007/s00412-008-0198-9; Popkin BM, 2004, INT J OBESITY, V28, pS2, DOI [10.1038/sj.ijo.0802804, 10.1038/sj.ijo.0802557]; Porterfield VM, 2009, NEUROSCI LETT, V463, P70, DOI 10.1016/j.neulet.2009.07.066; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rich-Edwards JW, 2005, BMJ-BRIT MED J, V330, P1115, DOI 10.1136/bmj.38434.629630.E0; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rudic RD, 2004, PLOS BIOL, V2, P1893, DOI 10.1371/journal.pbio.0020377; Ruger M, 2009, REV ENDOCR METAB DIS, V10, P245, DOI 10.1007/s11154-009-9122-8; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Schwimmer JB, 2005, HEPATOLOGY, V42, p610A; Seron-Ferre M, 2002, MOL CELL ENDOCRINOL, V186, P169, DOI 10.1016/S0303-7207(01)00682-7; Seron-Ferre Maria, 2007, Birth Defects Research, V81, P204, DOI 10.1002/bdrc.20101; SERONFERRE M, 1983, J CLIN ENDOCR METAB, V57, P1173, DOI 10.1210/jcem-57-6-1173; Siepka SM, 2007, COLD SPRING HARB SYM, V72, P251, DOI 10.1101/sqb.2007.72.052; Slyper AH, 2004, J CLIN ENDOCR METAB, V89, P2540, DOI 10.1210/jc.2003-031449; SOCOL ML, 1981, AM J OBSTET GYNECOL, V139, P712, DOI 10.1016/0002-9378(81)90493-2; Sosniyenko S, 2009, EUR J NEUROSCI, V30, P1802, DOI 10.1111/j.1460-9568.2009.06945.x; Speiser PW, 2005, J CLIN ENDOCR METAB, V90, P1871, DOI 10.1210/jc.2004-1389; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Strauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845; Suter M, 2010, METABOLISM, V59, P1481, DOI 10.1016/j.metabol.2010.01.013; Suter MA, 2009, SEMIN REPROD MED, V27, P380, DOI 10.1055/s-0029-1237426; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vollmers C, 2009, P NATL ACAD SCI USA, V106, P21453, DOI 10.1073/pnas.0909591106; WALSH SW, 1984, AM J OBSTET GYNECOL, V150, P745, DOI 10.1016/0002-9378(84)90679-3; Yamamoto T, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-18; Zvonic S, 2006, DIABETES, V55, P962, DOI 10.2337/diabetes.55.04.06.db05-0873	76	88	92	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					714	726		10.1096/fj.10-172080	http://dx.doi.org/10.1096/fj.10-172080			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21097519	Green Published			2022-12-28	WOS:000286724800029
J	Chen, YW; Qiao, SJ; Tuckermann, J; Okret, S; Jondal, M				Chen, Yongwen; Qiao, Shengjun; Tuckermann, Jan; Okret, Sam; Jondal, Mikael			Thymus-derived glucocorticoids mediate androgen effects on thymocyte homeostasis	FASEB JOURNAL			English	Article						testosterone; corticosterone; local glucocorticoid synthesis; glucocorticoid receptor-knockout mice; metyrapone	IMMUNE-SYSTEM; AGE; THYMOPOIESIS; EXPRESSION; RECONSTITUTION; RECEPTORS; MICE	Androgens contribute to the involution process of the aging thymus gland. However, molecular mechanisms behind this effect remain largely unknown. We have investigated the influence of testosterone on the ectopic synthesis of glucocorticoids (GCs) in thymocytes, an activity recently shown by us to be important for the homeostatic regulation of these cells. Castration, which leads to a strong increase in thymus tissue and function, was associated with a reduced GC release from thymocytes caused by down-regulated expression of several enzymes involved in GC synthesis, without affecting GC synthesis in the adrenals. Testosterone treatment of castrated male mice reversed these effects, also without affecting adrenal GC synthesis. The effects of testosterone in castrated mice on thymocyte homeostasis and GC release were strongly reduced in mice pretreated with the CYP11B1 enzyme inhibitor metyrapone, acting on the last step in the corticosterone synthesis. The androgen-induced thymic involution was dependent on GC action, because this was completely absent in mice lacking GC receptor (GR) expression specifically in thymocytes. We provide here an unrecognized mechanism how androgens contribute to thymic involution by stimulating local synthesis and release of GCs in the thymus.-Chen, Y., Qiao, S., Tuckermann, J., Okret, S., Jondal, M. Thymus-derived glucocorticoids mediate androgen effects on thymocyte homeostasis. FASEB J. 24, 5043-5051 (2010). www.fasebj.org	[Chen, Yongwen; Qiao, Shengjun; Okret, Sam] Karolinska Inst, Dept Biosci & Nutr, SE-14183 Stockholm, Sweden; [Chen, Yongwen; Qiao, Shengjun; Jondal, Mikael] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-14183 Stockholm, Sweden; [Tuckermann, Jan] FLI, Leibnitz Inst Age Res, Jena, Germany	Karolinska Institutet; Karolinska Institutet; Friedrich Loeffler Institute; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Chen, YW (corresponding author), Karolinska Inst, Dept Biosci & Nutr, SE-14183 Stockholm, Sweden.	yongwen.chen@ki.se			Swedish Cancer Society; European Union [HEALTH-F4-2008-202156]	Swedish Cancer Society(Swedish Cancer Society); European Union(European Commission)	This work was supported by grants from the Swedish Cancer Society and the European Union FP7 project TOLERAGE (HEALTH-F4-2008-202156).	Baschant U, 2010, J STEROID BIOCHEM, V120, P69, DOI 10.1016/j.jsbmb.2010.03.058; DASILVA JAP, 1993, J ENDOCRINOL, V136, P389, DOI 10.1677/joe.0.1360389; Dorshkind K, 2009, NAT REV IMMUNOL, V9, P57, DOI 10.1038/nri2471; Dudakov JA, 2010, TRENDS IMMUNOL, V31, P191, DOI 10.1016/j.it.2010.02.002; Dulos GJ, 2001, INT IMMUNOPHARMACOL, V1, P321, DOI 10.1016/S1567-5769(00)00029-1; Guevara Patino JA, 2000, EUR J IMMUNOL, V30, P2586; IZQUIERDO M, 1989, J IMMUNOL, V143, P2185; Jondal M, 2004, TRENDS IMMUNOL, V25, P595, DOI 10.1016/j.it.2004.09.003; Leposavic G, 2008, NEUROIMMUNOMODULAT, V15, P290, DOI 10.1159/000156473; Linton PJ, 2004, NAT IMMUNOL, V5, P133, DOI 10.1038/ni1033; Lynch HE, 2009, TRENDS IMMUNOL, V30, P366, DOI 10.1016/j.it.2009.04.003; Morrhaye G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005668; Noti M, 2010, FASEB J, V24, P1340, DOI 10.1096/fj.09-140913; Olsen NJ, 2001, ENDOCRINOLOGY, V142, P1278, DOI 10.1210/en.142.3.1278; Olsen NJ, 1998, ENDOCRINOLOGY, V139, P748, DOI 10.1210/en.139.2.748; OLSEN NJ, 1993, J STEROID BIOCHEM, V45, P327, DOI 10.1016/0960-0760(93)90001-D; Page DM, 1998, J IMMUNOL, V160, P120; Payne AH, 2004, ENDOCR REV, V25, P947, DOI 10.1210/er.2003-0030; Pazirandeh A, 2005, ENDOCRINOLOGY, V146, P2501, DOI 10.1210/en.2004-0943; Pfister G, 2008, NEUROIMMUNOMODULAT, V15, P351, DOI 10.1159/000156477; Pido-Lopez J, 2001, CLIN EXP IMMUNOL, V125, P409, DOI 10.1046/j.1365-2249.2001.01640.x; Qiao SJ, 2008, EXP CELL RES, V314, P3027, DOI 10.1016/j.yexcr.2008.06.014; Qiao SJ, 2009, ENDOCRINOLOGY, V150, P4163, DOI 10.1210/en.2009-0195; Rodewald HR, 2008, ANNU REV IMMUNOL, V26, P355, DOI 10.1146/annurev.immunol.26.021607.090408; Sauce D, 2009, J CLIN INVEST, V119, P3070, DOI 10.1172/JCI39269; Schmidt KL, 2008, GEN COMP ENDOCR, V157, P266, DOI 10.1016/j.ygcen.2008.03.025; Scott HM, 2009, ENDOCR REV, V30, P883, DOI 10.1210/er.2009-0016; Semposski GD, 2002, MOL IMMUNOL, V38, P841, DOI 10.1016/S0161-5890(01)00122-5; Sempowski GD, 2000, J IMMUNOL, V164, P2180, DOI 10.4049/jimmunol.164.4.2180; Sutherland JS, 2005, J IMMUNOL, V175, P2741, DOI 10.4049/jimmunol.175.4.2741; Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; van den Brink MRM, 2004, NAT REV IMMUNOL, V4, P856, DOI 10.1038/nri1484; Wiegers GJ, 2001, EUR J IMMUNOL, V31, P2293, DOI 10.1002/1521-4141(200108)31:8<2293::AID-IMMU2293>3.0.CO;2-I; Williams KA, 2007, SEMIN IMMUNOL, V19, P318, DOI 10.1016/j.smim.2007.10.004; Yager EJ, 2008, J EXP MED, V205, P711, DOI 10.1084/jem.20071140	36	35	35	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5043	5051		10.1096/fj.10-168724	http://dx.doi.org/10.1096/fj.10-168724			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20798244	Green Published			2022-12-28	WOS:000284824400042
J	Golfier, S; Kondo, S; Schulze, T; Takeuchi, T; Vassileva, G; Achtman, AH; Graler, MH; Abbondanzo, SJ; Wiekowski, M; Kremmer, E; Endo, Y; Lira, SA; Bacon, KB; Lipp, M				Golfier, Sven; Kondo, Shinichi; Schulze, Tobias; Takeuchi, Tomomi; Vassileva, Galya; Achtman, Ariel H.; Graeler, Markus H.; Abbondanzo, Susan J.; Wiekowski, Maria; Kremmer, Elisabeth; Endo, Yasuhisa; Lira, Sergio A.; Bacon, Kevin B.; Lipp, Martin			Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P(4)	FASEB JOURNAL			English	Article						platelets; lysophospholipids; receptor-deficient mice	SPHINGOSINE 1-PHOSPHATE RECEPTOR; WISKOTT-ALDRICH SYNDROME; PROTEIN; PLATELETS; IDENTIFICATION; STEM; THROMBOCYTOPENIA; TRANSDUCTION; PROGENITORS; ACTIVATION	Megakaryocytes, which mature from hematopoietic progenitors in the bone marrow, further differentiate by reorganizing their cytoplasm into long proplatelet extensions that release platelets into the circulation. The molecular mechanisms underlying this highly dynamic cytoplasmic and cytoskeletal remodeling process are only poorly understood. Here we report that sphingosine 1-phosphate receptor 4 (S1P(4)) is specifically up-regulated during the development of human megakaryocytes from progenitor cells and is expressed in mature murine megakaryocytes. Megakaryocytes generated from S1P(4)-deficient murine bone marrow showed atypical and reduced formation of proplatelets in vitro. The recovery of platelet numbers after experimental thrombocytopenia was significantly delayed in S1p4(-/-) mice. Remarkably, overexpression and stimulation of S1P(4) in human erythroleukemia HEL cells promoted endomitosis, formation of cytoplasmic extensions, and subsequent release of platelet-like particles. These observations indicate that S1P(4) is involved in shaping the terminal differentiation of megakaryocytes.-Golfier, S., Kondo, S., Schulze, T., Takeuchi, T., Vassileva, G., Achtman, A. H., Graler, M. H., Abbondanzo, S. J., Wiekowski, M., Kremmer, E., Endo, Y., Lira, S. A., Bacon, K. B., Lipp, M. Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P(4). FASEB J. 24, 4701-4710 (2010). www.fasebj.org	[Golfier, Sven; Schulze, Tobias; Achtman, Ariel H.; Graeler, Markus H.; Lipp, Martin] Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, D-13125 Berlin, Germany; [Kondo, Shinichi; Takeuchi, Tomomi; Bacon, Kevin B.] Res Ctr Kyoto, Kyoto, Japan; [Kremmer, Elisabeth] Helmholtz Zentrum Munchen, Inst Mol Immunol, Munich, Germany; [Endo, Yasuhisa] Kyoto Inst Technol Matsugasaki, Dept Appl Biol, Kyoto, Japan; [Lira, Sergio A.] Mt Sinai Sch Med, Immunobiol Ctr, New York, NY USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Kyoto Institute of Technology; Icahn School of Medicine at Mount Sinai	Lipp, M (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, Robert Rossle Str 10, D-13125 Berlin, Germany.	mlipp@mdc-berlin.de	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849; Lipp, Martin/0000-0002-0087-2672				BERRIDGE MV, 1985, BLOOD, V66, P76; Bunting S, 1997, BLOOD, V90, P3423, DOI 10.1182/blood.V90.9.3423; Chang Y, 2007, BLOOD, V109, P4229, DOI 10.1182/blood-2006-04-020024; Cheng EC, 2009, BLOOD, V113, P2826, DOI 10.1182/blood-2008-09-180596; CHOI ES, 1995, BLOOD, V85, P402; Cramer EM, 1997, BLOOD, V89, P2336, DOI 10.1182/blood.V89.7.2336; Deutsch VR, 2006, BRIT J HAEMATOL, V134, P453, DOI 10.1111/j.1365-2141.2006.06215.x; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Ito K, 2007, BIOCHEM BIOPH RES CO, V357, P212, DOI 10.1016/j.bbrc.2007.03.123; Kajiwara M, 1999, BRIT J HAEMATOL, V107, P254, DOI 10.1046/j.1365-2141.1999.01694.x; Kaushansky K, 2002, BLOOD, V99, P3573, DOI 10.1182/blood.V99.10.3573; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kaushansky K, 2005, J CLIN INVEST, V115, P3339, DOI 10.1172/JCI26674; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kohno T, 2003, GENES CELLS, V8, P685, DOI 10.1046/j.1365-2443.2003.00667.x; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; Motohashi K, 2000, FEBS LETT, V468, P189, DOI 10.1016/S0014-5793(00)01222-9; Nieswandt B, 2000, BLOOD, V96, P2520; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Patel SR, 2005, J CLIN INVEST, V115, P3348, DOI 10.1172/JCI26891; Rojnuckarin P, 2001, BLOOD, V97, P154, DOI 10.1182/blood.V97.1.154; SCHMUZIGER M, 1995, EUR J CARDIO-THORAC, V9, P393, DOI 10.1016/S1010-7940(05)80172-1; Schulze H, 2006, BLOOD, V107, P3868, DOI 10.1182/blood-2005-07-2755; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Spiegel S, 2003, BIOCHEM SOC T, V31, P1216; Teeling JL, 2001, BLOOD, V98, P1095, DOI 10.1182/blood.V98.4.1095; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Vidal C, 2002, BLOOD, V100, P4462, DOI 10.1182/blood.V100.13.4462; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; Yatomi Y, 1997, J BIOCHEM, V121, P969	39	52	56	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4701	4710		10.1096/fj.09-141473	http://dx.doi.org/10.1096/fj.09-141473			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20686109				2022-12-28	WOS:000284824400011
J	Gallazzini, M; Yu, MJ; Gunaratne, R; Burg, MB; Ferraris, JD				Gallazzini, Morgan; Yu, Ming-Jiun; Gunaratne, Ruwan; Burg, Maurice B.; Ferraris, Joan D.			c-Abl mediates high NaCl-induced phosphorylation and activation of the transcription factor TonEBP/OREBP	FASEB JOURNAL			English	Article						hypertonicity; kinase; NFAT5; signaling	ENHANCER-BINDING PROTEIN; OSMOTIC RESPONSE ELEMENT; DAMAGE-INDUCIBLE KINASE; TYROSINE KINASE; NUCLEAR-LOCALIZATION; PHOSPHOLIPASE C-GAMMA-1; ATM; CONTRIBUTES; GENE; AUTOPHOSPHORYLATION	The transcription factor TonEBP/OREBP promotes cell survival during osmotic stress. High NaCl-induced phosphorylation of TonEBP/OREBP at tyrosine-143 was known to be an important factor in increasing its activity in cell culture. We now find that TonEBP/OREBP also is phosphorylated at tyrosine-143 in rat renal inner medulla, dependent on the interstitial osmolality. c-Abl seemed likely to be the kinase that phosphorylates TonEBP/OREBP because Y143 is in a consensus c-Abl phosphorylation site. We now confirm that, as follows. High NaCl increases c-Abl activity. Specific inhibition of c-Abl by imatinib, siRNA, or c-Abl kinase dead drastically reduces high NaCl-induced TonEBP/OREBP activity by reducing its nuclear location and transactivating activity. c-Abl associates with TonEBP/OREBP (coimmunoprecipitation) and phosphorylates TonEBP/OREBP-Y143 both in cell and in vitro. High NaCl-induced activation of ataxia telangiectasia mutated, previously known to contribute to activation of TonEBP/OREBP, depends on c-Abl activity. Thus, c-Abl is the kinase responsible for high NaCl-induced phosphorylation of TonEBP/OREBPY143, which contributes to its increased activity.-Gallazzini, M., Yu, M.-J., Gunaratne, R., Burg, M. B., Ferraris, J. D. c-Abl mediates high NaCl-induced phosphorylation and activation of the transcription factor TonEBP/OREBP. FASEB J. 24, 4325-4335 (2010). www.fasebj.org	[Gallazzini, Morgan; Yu, Ming-Jiun; Gunaratne, Ruwan; Burg, Maurice B.; Ferraris, Joan D.] NHLBI, Kidney & Electrolyte Metab Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Gallazzini, M (corresponding author), 9000 Rockville Pike, Bethesda, MD 20892 USA.	gallazzinim@gmail.com	Gallazzini, Morgan/E-5465-2011	Gallazzini, Morgan/0000-0002-7185-7162; YU, MING-JIUN/0000-0003-0393-4696	NHLBI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006133, ZIAHL006134, ZICHL006019, ZIAHL001283] Funding Source: NIH RePORTER	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Martin Playford for suggestions on experimental design and Dr. Chris Combs and Dr. Daniela Malide of the National Heart, Lung, and Blood Institute (NHLBI) Light Microscopy Core Facility for help with microscopy. This research was supported by the Intramural Research Program of NHLBI.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006; Cha JH, 2001, J AM SOC NEPHROL, V12, P2221, DOI 10.1681/ASN.V12112221; Chen Y, 2007, AM J PHYSIOL-RENAL, V292, pP981, DOI 10.1152/ajprenal.00493.2005; Dahl SC, 2001, AM J PHYSIOL-CELL PH, V280, pC248, DOI 10.1152/ajpcell.2001.280.2.C248; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P16800, DOI 10.1073/pnas.222659799; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; Ferraris JD, 2007, METHOD ENZYMOL, V428, P279, DOI 10.1016/S0076-6879(07)28016-4; Gu JJ, 2009, IMMUNOL REV, V228, P170, DOI 10.1111/j.1600-065X.2008.00751.x; Irarrazabal CE, 2008, J BIOL CHEM, V283, P2554, DOI 10.1074/jbc.M703490200; Irarrazabal CE, 2006, P NATL ACAD SCI USA, V103, P8882, DOI 10.1073/pnas.0602911103; Irarrazabal CE, 2010, P NATL ACAD SCI USA, V107, P906, DOI 10.1073/pnas.0913415107; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Smith JM, 2002, FRONT BIOSCI, V7, pD31; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; VALTIN H, 1962, NATURE, V196, P1109, DOI 10.1038/1961109a0; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Yu MJ, 2006, MOL CELL PROTEOMICS, V5, P2131, DOI 10.1074/mcp.M600177-MCP200; Zhang Z, 2005, AM J PHYSIOL-RENAL, V289, pF506, DOI 10.1152/ajprenal.00417.2004	31	26	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4325	4335		10.1096/fj.10-157362	http://dx.doi.org/10.1096/fj.10-157362			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20585028	Green Published			2022-12-28	WOS:000283861100020
J	Ak, P; Levine, AJ				Ak, Prashanth; Levine, Arnold J.			p53 and NF-kappa B: different strategies for responding to stress lead to a functional antagonism	FASEB JOURNAL			English	Article						oxidative phosphorylation; oncogene; tumor suppressor gene; signal transduction; pathway nodes; O-GlcNAc; aerobic glycolysis	PROTEIN-KINASE; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CELL-SURVIVAL; O-GLCNAC; PHOSPHORYLATION; ACTIVATION; NUCLEAR; GAIN; DEGRADATION	The p53 transcription factor responds to a variety of intrinsic stresses, such as DNA damage, hypoxia, and even oncogene activation. NF-kappa B responds to a large number of extrinsic stresses such as cytokine activation and infectious diseases. The p53 tumor suppressor limits the consequences of stress by initiating cell death, senescence, or cell cycle arrest and promotes metabolic patterns in the cell to favor oxidative phosphorylation. NF-kappa B, the oncogene, promotes cell division, which initiates the innate and adaptive immune responses utilizing large amounts of glucose in aerobic glycolysis, resulting in the synthesis of substrates for cell division. Thus these two transcription factors, both of which have evolved to respond to different types of stress, have adopted opposite strategies and cannot function in the same cell at the same time. On activation of one of these transcription factors, the other is inactivated. This is achieved at several places in the p53 and NF-kappa B pathways where regulatory proteins act on both p53 and NF-kappa B with opposite functional consequences. These internodal sites create core regulatory circuits essential for integrating two central pathways in cells.-Ak, P., Levine, A. J. p53 and NF-kappa B: different strategies for responding to stress lead to a functional antagonism. FASEB J. 24, 3643-3652 (2010). www.fasebj.org	[Ak, Prashanth; Levine, Arnold J.] Inst Adv Study, Princeton, NJ 08540 USA	Institute for Advanced Study - USA	Levine, AJ (corresponding author), Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA.	alevine@ias.edu			NATIONAL CANCER INSTITUTE [P01CA087497] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bai D, 2009, INT J CANCER, V125, P2863, DOI 10.1002/ijc.24748; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Culmsee C, 2003, J NEUROSCI, V23, P8586; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fiordaliso F, 2001, DIABETES, V50, P2363, DOI 10.2337/diabetes.50.10.2363; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kawauchi K, 2009, P NATL ACAD SCI USA, V106, P3431, DOI 10.1073/pnas.0813210106; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Marwaha V, 2005, J BIOL CHEM, V280, P32379, DOI 10.1074/jbc.M503245200; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; PURDIE CA, 1994, ONCOGENE, V9, P603; Ravi R, 1998, CANCER RES, V58, P4531; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Sigal A, 2000, CANCER RES, V60, P6788; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Wells L, 2004, J BIOL CHEM, V279, P38466, DOI 10.1074/jbc.M406481200; Xia YF, 2009, P NATL ACAD SCI USA, V106, P2629, DOI 10.1073/pnas.0812256106; Yang WH, 2008, P NATL ACAD SCI USA, V105, P17345, DOI 10.1073/pnas.0806198105; Yang WH, 2006, NAT CELL BIOL, V8, P1074, DOI 10.1038/ncb1470; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350	61	140	146	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3643	3652		10.1096/fj.10-160549	http://dx.doi.org/10.1096/fj.10-160549			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20530750				2022-12-28	WOS:000285005900005
J	Saenz, A; Lopez-Sanchez, A; Mojica-Lazaro, J; Martinez-Caro, L; Nin, N; Bagatolli, LA; Casals, C				Saenz, Alejandra; Lopez-Sanchez, Almudena; Mojica-Lazaro, Jonas; Martinez-Caro, Leticia; Nin, Nicolas; Bagatolli, Luis A.; Casals, Cristina			Fluidizing effects of C-reactive protein on lung surfactant membranes: protective role of surfactant protein A	FASEB JOURNAL			English	Article						membrane fluidity; lipid domains; fluorescence; lipid-protein interaction; protein-protein interaction; lung injury	PULMONARY SURFACTANT; EXPRESSION; TRANSPLANTATION; DISEASE; OLIGOMERIZATION; FLUORESCENCE; INFLAMMATION; INHIBITION; PRESSURE; PHASES	The purpose of this study was to investigate how surfactant membranes can be perturbed by C-reactive protein (CRP) and whether surfactant protein A (SP-A) might overcome CRP-induced surfactant membrane alterations. The effect of CRP on surfactant surface adsorption was evaluated in vivo after intratracheal instillation of CRP into rat lungs. Insertion of CRP into surfactant membranes was investigated through monolayer techniques. The effect of CRP on membrane structure was studied through differential scanning calorimetry and fluorescence spectroscopy and microscopy using large and giant unilamellar vesicles. Our results indicate that CRP inserts into surfactant membranes and drastically increases membrane fluidity, resulting in surfactant inactivation. At 10% CRP/phospholipid weight ratio, CRP causes disappearance of liquid-ordered/ liquid-disordered phase coexistence distinctive of surfactant membranes. SP-A, the most abundant surfactant lipoprotein structurally similar to C1q, binds to CRP (K-d=56+/-8 nM), as determined by solid-phase binding assays and dynamic light scattering. This novel SP-A/ CRP interaction reduces CRP insertion and blocks CRP effects on surfactant membranes. In addition, intratracheal coinstillation of SP-A+CRP into rat lungs prevents surfactant inhibition induced by CRP, indicating that SP-A/ CRP interactions might be an important factor in vivo in controlling harmful CRP effects in the alveolus.-Saenz, A., Lopez-Sanchez, A., Mojica-Lazaro, J., Martinez-Caro, L., Nin, N., Bagatolli, L. A., Casals, C. Fluidizing effects of C-reactive protein on lung surfactant membranes: protective role of surfactant protein A. FASEB J. 24, 3662-3673 (2010). www.fasebj.org	[Saenz, Alejandra; Lopez-Sanchez, Almudena; Mojica-Lazaro, Jonas; Casals, Cristina] Univ Complutense Madrid, Fac Biol, Dept Bioquim & Biol Mol 1, Ctr Invest Biomed Red CIBER Enfermedades Resp, E-28040 Madrid, Spain; [Saenz, Alejandra; Lopez-Sanchez, Almudena; Mojica-Lazaro, Jonas; Casals, Cristina] Univ Complutense Madrid, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; [Martinez-Caro, Leticia; Nin, Nicolas] Hosp Univ Getafe, Serv Cuidados Intens, Madrid, Spain; [Martinez-Caro, Leticia; Nin, Nicolas] Hosp Univ Getafe, CIBER Enfermedades Resp, Madrid, Spain; [Bagatolli, Luis A.] Univ So Denmark, Dept Biochem & Mol Biol, MEMPHYS Ctr Biomembrane Phys, Odense, Denmark	CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Complutense University of Madrid; Complutense University of Madrid; Hospital Universitario de Getafe; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Hospital Universitario de Getafe; University of Southern Denmark	Casals, C (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Bioquim & Biol Mol 1, Ctr Invest Biomed Red CIBER Enfermedades Resp, E-28040 Madrid, Spain.	ccasalsc@bio.ucm.es	Casals, Cristina/H-4658-2015; Saenz, Alejandra/G-7275-2015; Martinez-Caro, Leticia/AAD-9010-2019; Nin, Nicolas/X-4938-2019; Bagatolli, Luis/L-5159-2016	Casals, Cristina/0000-0003-2696-0918; Saenz, Alejandra/0000-0001-8439-2985; Bagatolli, Luis/0000-0002-4727-8611; NIN, NICOLAS/0000-0001-6037-2357	Ministerio de Educacion y Ciencia [SAF2006-04434, SAF2009-07810]; Instituto de Salud Carlos III (CIBERES); Comunidad de Madrid [S-BIO-0260-2006]; Fundacion Medica MM	Ministerio de Educacion y Ciencia(Spanish Government); Instituto de Salud Carlos III (CIBERES)(Instituto de Salud Carlos III); Comunidad de Madrid(Comunidad de Madrid); Fundacion Medica MM	This work was supported by Ministerio de Educacion y Ciencia (SAF2006-04434 and SAF2009-07810), Instituto de Salud Carlos III (CIBERES), Comunidad de Madrid (S-BIO-0260-2006), and Fundacion Medica MM. Experiments in the laboratory of L.A.B. were supported by Forskningsradet for Natur og Univers (FNU; Denmark) and the Danish National Research Foundation.	AMIRKHANIAN JD, 1993, BIOCHIM BIOPHYS ACTA, V1165, P321, DOI 10.1016/0005-2760(93)90143-W; Bagatolli LA, 2006, BBA-BIOMEMBRANES, V1758, P1541, DOI 10.1016/j.bbamem.2006.05.019; Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200; Calvez P, 2009, BIOCHIMIE, V91, P718, DOI 10.1016/j.biochi.2009.03.018; Canadas O, 2008, BIOPHYS J, V95, P3287, DOI 10.1529/biophysj.108.137323; Casals C, 2003, AM J PHYSIOL-LUNG C, V284, pL466, DOI 10.1152/ajplung.00325.2002; Casals C, 1998, AM J RESP CRIT CARE, V157, P43, DOI 10.1164/ajrccm.157.1.9611106; Casas JP, 2008, J INTERN MED, V264, P295, DOI 10.1111/j.1365-2796.2008.02015.x; Christopeit T, 2009, ANAL BIOCHEM, V391, P39, DOI 10.1016/j.ab.2009.04.037; Dahl M, 2007, AM J RESP CRIT CARE, V175, P250, DOI 10.1164/rccm.200605-713OC; de la Serna JB, 2004, J BIOL CHEM, V279, P40715, DOI 10.1074/jbc.M404648200; Dong Q, 1996, J IMMUNOL, V156, P4815; Gould JM, 2001, INFECT IMMUN, V69, P1747, DOI 10.1128/IAI.69.3.1747-1754.2001; Gunther A, 2001, RESPIR RES, V2, P353, DOI 10.1186/rr86; *I AN LAB RES, 1996, GUID CAR US LAB AN; Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com; Ji SR, 2009, FASEB J, V23, P1806, DOI 10.1096/fj.08-116962; Levy H, 2007, PEDIATR PULM, V42, P256, DOI 10.1002/ppul.20563; LI JJ, 1989, J TRAUMA, V29, P1690, DOI 10.1097/00005373-198912000-00019; Lu JH, 2008, NATURE, V456, P989, DOI 10.1038/nature07468; Marnell L, 2005, CLIN IMMUNOL, V117, P104, DOI 10.1016/j.clim.2005.08.004; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; MCEACHREN TM, 1995, AM J PHYSIOL-LUNG C, V269, pL492, DOI 10.1152/ajplung.1995.269.4.L492; MCELHANEY RN, 1986, BIOCHIM BIOPHYS ACTA, V864, P361, DOI 10.1016/0304-4157(86)90004-3; Nag K, 2004, AM J PHYSIOL-LUNG C, V287, pL1145, DOI 10.1152/ajplung.00408.2003; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; Ramage L, 2004, INHAL TOXICOL, V16, P607, DOI 10.1080/08958370490464599; Rasmussen F, 2009, EUR RESPIR J, V33, P382, DOI 10.1183/09031936.00040708; Ruano MLF, 2000, BIOCHEMISTRY-US, V39, P6529, DOI 10.1021/bi000188z; Saenz A, 2007, BIOPHYS J, V92, P482, DOI 10.1529/biophysj.106.090217; Sanchez-Barbero F, 2005, J BIOL CHEM, V280, P7659, DOI 10.1074/jbc.M410266200; Sanchez-Barbero F, 2007, BIOCHEM J, V406, P479, DOI 10.1042/BJ20070275; Singh SK, 2008, ANN MED, V40, P110, DOI 10.1080/07853890701749225; Valino F, 2004, TRANSPLANTATION, V77, P812, DOI 10.1097/01.TP.0000116421.57232.81; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Vos R, 2009, J HEART LUNG TRANSPL, V28, pS108, DOI 10.1016/j.healun.2008.11.799; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Zuo YY, 2008, BBA-BIOMEMBRANES, V1778, P1947, DOI 10.1016/j.bbamem.2008.03.021	38	22	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3662	3673		10.1096/fj.09-142646	http://dx.doi.org/10.1096/fj.09-142646			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20484671				2022-12-28	WOS:000285005900007
J	Tsushima, K; Osawa, T; Yanai, H; Nakajima, A; Takaoka, A; Manabe, I; Ohba, Y; Imai, Y; Taniguchi, T; Nagai, R				Tsushima, Kensuke; Osawa, Tomoko; Yanai, Hideyuki; Nakajima, Akira; Takaoka, Akinori; Manabe, Ichiro; Ohba, Yusuke; Imai, Yasushi; Taniguchi, Tadatsugu; Nagai, Ryozo			IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin II-induced hypertension	FASEB JOURNAL			English	Article						cardiac remodeling; inflammation; heart failure	CONGESTIVE-HEART-FAILURE; SMOOTH-MUSCLE-CELLS; TOLL-LIKE RECEPTORS; MYOCARDIAL-INFARCTION; TRANSCRIPTION FACTORS; GENE INDUCTION; DIASTOLIC DYSFUNCTION; MECHANICAL STRETCH; ANTIVIRAL RESPONSE; VIRAL-INFECTION	Hypertension is a typical modern lifestyle-related disease that is closely associated with the development of cardiovascular disorders. Elevation of angiotensin II (ANG II) is one of several critical factors for hypertension and heart failure; however, the mechanisms underlying the ANG II-mediated pathogenesis are still poorly understood. Here, we show that ANG II-mediated cardiac fibrosis, but not hypertrophy, is regulated by interferon regulatory factor 3 (IRF3), which until now has been exclusively studied in the innate immune system. In a ANG II-infusion mouse model (3.0 mg/kg/d), we compared IRF3-deficient mice (Irf3(-/-)/Bcl2l12(-/-)) with matched wild-type (WT) controls. The development of cardiac fibrosis [3.95 +/- 0.62% (WT) vs. 1.41 +/- 0.46% (Irf3(-/-)/Bcl2l12(-/-)); P < 0.01] and accompanied reduction in left ventricle end-diastolic dimension [2.89 +/- 0.10 mm (WT) vs. 3.51 +/- 0.15 mm (Irf3(-/-)/Bcl2l12(-/-)); P=0.012] are strongly suppressed in Irf3(-/-)/Bcl2l12(-/-) mice, whereas hypertrophy still develops. Further, we provide evidence for the activation of IRF3 by ANG II signaling in mouse cardiac fibroblasts. Unlike the activation of IRF3 by innate immune receptors, IRF3 activation by ANG II is unique in that it is activated through the canonical ERK signaling pathway. Thus, our present study reveals a hitherto unrecognized function of IRF3 in cardiac remodeling, providing new insight into the progression of hypertension-induced cardiac pathogenesis.-Tsushima, K., Osawa, T., Yanai, H., Nakajima, A., Takaoka, A., Manabe, I., Ohba, Y., Imai, Y., Taniguchi, T., Nagai, R. IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin II-induced hypertension. FASEB J. 25, 1531-1543 (2011). www.fasebj.org	[Taniguchi, Tadatsugu] Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; [Nagai, Ryozo] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; [Ohba, Yusuke] Hokkaido Univ, Grad Sch Med, Lab Pathophysiol & Signal Transduct, Sapporo, Hokkaido, Japan; [Yanai, Hideyuki; Taniguchi, Tadatsugu] Japan Sci & Technol Agcy, Tokyo, Japan	University of Tokyo; University of Tokyo; Hokkaido University; Japan Science & Technology Agency (JST)	Taniguchi, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	tada@m.u-tokyo.ac.jp; nagai-tky@umin.ac.jp	Manabe, Ichiro/AAE-5105-2021; Yanai, Hideyuki/AGK-5933-2022; Manabe, Ichiro/E-1529-2014; Ohba, Yusuke/E-7944-2011	Yanai, Hideyuki/0000-0002-0115-9000; Tsushima, Kensuke/0000-0001-7338-7849	KAKENHI [17012005, 19041021, 19500492, 21790710]; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Grants-in-Aid for Scientific Research [23659196] Funding Source: KAKEN	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank A. Fukamizu (Tsukuba University, Tsukuba, Japan) for murine AT1a receptor expression vector and AT1a-293T cell line; S. Yamaoka (Tokyo Medical and Dental University, Tokyo, Japan) for Pin1 expression vector; M. Matsuda (Kyoto University, Kyoto, Japan) for RasV12 expression vector; D. Savitsky, T. Fujita, K. Maemura, K. Honda, T. Tamura, T. Suzuki, S. Kano, and H. Negishi for invaluable advice; and N. Yamanaka and M. Shishido for technical assistance. This work was supported in part by grants KAKENHI 17012005, 19041021, 19500492, and 21790710 and by the Global Center of Excellence Program Integrative Life Science Based on the Study of Biosignaling Mechanisms from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Bellini A, 2007, LAB INVEST, V87, P858, DOI 10.1038/labinvest.3700654; Borgland SL, 2000, J VIROL, V74, P3941, DOI 10.1128/JVI.74.9.3941-3947.2000; Cassis LA, 2007, ARTERIOSCL THROM VAS, V27, P380, DOI 10.1161/01.ATV.0000254680.71485.92; Deguchi J, 1999, CIRC RES, V85, P565, DOI 10.1161/01.RES.85.7.565; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Grande MT, 2009, NAT REV NEPHROL, V5, P319, DOI 10.1038/nrneph.2009.74; Hitomi H, 2007, CURR OPIN CARDIOL, V22, P311, DOI 10.1097/HCO.0b013e3281532b53; HOIT BD, 1995, J CLIN INVEST, V95, P1519, DOI 10.1172/JCI117824; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Ishida JJ, 1999, INT J MOL MED, V3, P263; Kai H, 2005, HYPERTENS RES, V28, P483, DOI 10.1291/hypres.28.483; Kannel W B, 2000, Heart Fail Rev, V5, P167; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lin M, 1995, Hypertens Res, V18, P151, DOI 10.1291/hypres.18.151; Liu JJ, 2011, APOPTOSIS, V16, P94, DOI 10.1007/s10495-010-0549-x; Malhotra R, 1999, CIRC RES, V85, P137, DOI 10.1161/01.RES.85.2.137; Matsumoto T, 2003, CIRCULATION, V107, P2555, DOI 10.1161/01.CIR.0000074041.81728.79; Moore BB, 2006, AM J RESP CELL MOL, V35, P175, DOI 10.1165/rcmb.2005-0239OC; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Nakajima A, 2009, P NATL ACAD SCI USA, V106, P12448, DOI 10.1073/pnas.0905702106; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rader DJ, 2008, NATURE, V451, P904, DOI 10.1038/nature06796; Rodriguez-Vita J, 2005, CIRCULATION, V111, P2509, DOI 10.1161/01.CIR.0000165133.84978.E2; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Saitoh T, 2006, NAT IMMUNOL, V7, P598, DOI 10.1038/ni1347; Sano M, 2000, J BIOL CHEM, V275, P29717, DOI 10.1074/jbc.M003128200; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Shishido T, 2003, CIRCULATION, V108, P2905, DOI 10.1161/01.CIR.0000101921.93016.1C; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Takaoka A, 2008, CANCER SCI, V99, P467, DOI 10.1111/j.1349-7006.2007.00720.x; Touyz RM, 2000, PHARMACOL REV, V52, P639; Tsutamoto T, 1998, J AM COLL CARDIOL, V31, P391, DOI 10.1016/S0735-1097(97)00494-4; Vasan RS, 2003, CIRCULATION, V107, P1486, DOI 10.1161/01.CIR.0000057810.48709.F6; Wang WS, 2006, CIRC RES, V98, P1032, DOI 10.1161/01.RES.0000218782.52610.dc; WEBER KT, 1989, J MOL CELL CARDIOL, V21, P121, DOI 10.1016/0022-2828(89)90778-5; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613	53	34	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1531	1543		10.1096/fj.10-174615	http://dx.doi.org/10.1096/fj.10-174615			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21266535				2022-12-28	WOS:000290023800011
J	Rabot, S; Membrez, M; Bruneau, A; Gerard, P; Harach, T; Moser, M; Raymond, F; Mansourian, R; Chou, CJ				Rabot, Sylvie; Membrez, Mathieu; Bruneau, Aurelia; Gerard, Philippe; Harach, Taoufiq; Moser, Mireille; Raymond, Frederic; Mansourian, Robert; Chou, Chieh J.			Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism	FASEB JOURNAL			English	Article						insulin sensitivity; obesity; inflammation	GUT MICROBIOTA; INDUCED OBESITY; LIVER; RECEPTOR; ALPHA; ABCG8; INFLAMMATION; MACROPHAGES; ABSORPTION; PROTECTION	Recent studies showed that germ-free (GF) mice are resistant to obesity when consuming a high-fat, high-carbohydrate Western diet. However, it remains unclear what mechanisms are involved in the antiobesity phenotype and whether GF mice develop insulin resistance and dyslipidemia with high-fat (HF) feeding. In the present study, we compared the metabolic consequences of HF feeding on GF and conventional (conv) C57BL/6J mice. GF mice consumed fewer calories, excreted more fecal lipids, and weighed significantly less than conv mice. GF/HF animals also showed enhanced insulin sensitivity with improved glucose tolerance, reduced fasting and nonfasting insulinemia, and increased phospho-Akt((Ser-473)) in adipose tissue. In association with enhanced insulin sensitivity, GF/HF mice had reduced plasma TNF-alpha and total serum amyloid A concentrations. Reduced hyperchole-sterolemia, a moderate accretion of hepatic cholesterol, and an increase in fecal cholesterol excretion suggest an altered cholesterol metabolism in GF/HF mice. Pronounced nucleus SREBP2 proteins and up-regulation of cholesterol biosynthesis genes indicate that enhanced cholesterol biosynthesis contributed to the cholesterol homeostasis in GF/HF mice. Our results demonstrate that fewer calorie consumption and increased lipid excretion contributed to the obesity-resistant phenotype of GF/HF mice and reveal that insulin sensitivity and cholesterol metabolism are metabolic targets influenced by the gut microbiota.-Rabot, S., Membrez, M., Bruneau, A., Gerard, P., Harach, T., Moser, M., Raymond, F., Mansourian, R., Chou. C. J. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 24, 4948-4959 (2010). www.fasebj.org	[Membrez, Mathieu; Harach, Taoufiq; Chou, Chieh J.] Nestle Res Ctr, Dept Nutr & Hlth, CH-1000 Lausanne 26, Switzerland; [Moser, Mireille; Raymond, Frederic; Mansourian, Robert] Nestle Res Ctr, Dept Bioanalyt Sci, CH-1000 Lausanne 26, Switzerland; [Rabot, Sylvie; Bruneau, Aurelia; Gerard, Philippe] INRA, Micalis UMR1319, Jouy En Josas, France	Nestle SA; Nestle SA; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Chou, CJ (corresponding author), Nestle Res Ctr, Dept Nutr & Hlth, Rte Jorat 57, CH-1000 Lausanne 26, Switzerland.	chieh-jason.chou@rdls.nestle.com	Gérard, Philippe/H-8138-2019; Eckhardt, Erik/G-1567-2010	Gérard, Philippe/0000-0001-9521-0067; Raymond, Frederic/0000-0002-6148-6898; Rabot, Sylvie/0000-0002-4603-2038	Nestec S.A.	Nestec S.A.	The authors thank Drs. Kevin Acheson and Katherine Mace for valuable scientific comments, Alain Joffre (Institut National de la Recherche Agronomique, Jouy-en-Josas, France) for breeding and husbandry of GF mice, Sylviane Metairon for microarry analysis, Sylvie Pridmore-Merten (Nestle Research Center, Lausanne, Switzerland) for providing mouse fecal sample and Irian Monnard of fecal sample analysis. Nestec S.A. Provided funding to S.R., A.B., and P.G. for the present work. M.M., T.H., M.M., F.R., S.M., R.M., and C.J.C. are employees of Nestec S.A.	Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Berggreen C, 2009, AM J PHYSIOL-ENDOC M, V296, pE635, DOI 10.1152/ajpendo.90596.2008; Calpe-Berdiel L, 2008, J LIPID RES, V49, P1904, DOI 10.1194/jlr.M700470-JLR200; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; CANI PD, 2007, SDA, V50, P2374; Chan MY, 2008, OBESITY, V16, P972, DOI 10.1038/oby.2008.32; Dam H, 1934, BIOCHEM J, V28, P820, DOI 10.1042/bj0280820; EYSSEN HJ, 1973, DSA, V36, P411; FLEISSNER CK, 2010, BR J NUTR, V5, P1; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gerard P, 2007, APPL ENVIRON MICROB, V73, P5742, DOI 10.1128/AEM.02806-06; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HOTAMISLIGIL GS, 1993, DFA, V259, P87; HWA JJ, 1992, J LIPID RES, V33, P711; Jahnel J, 2009, LIVER INT, V29, P1316, DOI 10.1111/j.1478-3231.2009.02044.x; Khovidhunkit W, 2003, J LIPID RES, V44, P1728, DOI 10.1194/jlr.M300100-JLR200; Larsen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009085; Lin CC, 2008, BRIT J NUTR, V99, P37, DOI 10.1017/S0007114507793881; Mansourian R, 2004, BIOINFORMATICS, V20, P2726, DOI 10.1093/bioinformatics/bth319; MCGILLICUDDY FC, 2009, DA, V119, P1135; Membrez M, 2008, FASEB J, V22, P2416, DOI 10.1096/fj.07-102723; *R DEV COR TEAM, 2007, R 2 6 1; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; ROUSSEEUW PJ, 1993, J AM STAT ASSOC, V88, P1273, DOI 10.2307/2291267; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003-0870; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; WOSTMANN BS, 1961, AM J PHYSIOL, V201, P1027, DOI 10.1152/ajplegacy.1961.201.6.1027; WOSTMANN BS, 1973, J NUTR, V103, P982, DOI 10.1093/jn/103.7.982; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Ye XY, 2009, J ENDOCRINOL INVEST, V32, P568, DOI [10.1007/BF03346510, 10.3275/6111]; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	39	408	442	5	79	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4948	+		10.1096/fj.10-164921	http://dx.doi.org/10.1096/fj.10-164921			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20724524				2022-12-28	WOS:000284824400033
J	Margadant, C; Charafeddine, RA; Sonnenberg, A				Margadant, Coert; Charafeddine, Rabab A.; Sonnenberg, Arnoud			Unique and redundant functions of integrins in the epidermis	FASEB JOURNAL			English	Review						adhesion; hair; hemidesmosome; stem cells; wound healing	GROWTH-FACTOR-BETA; JUNCTIONAL EPIDERMOLYSIS-BULLOSA; ACTIVATED PROTEIN-KINASE; EXTRACELLULAR-MATRIX PROTEINS; HAIR FOLLICLE INTEGRITY; KERATINOCYTE STEM-CELLS; ALPHA 3 BETA-1-INTEGRIN; ALPHA-3-BETA-1 INTEGRIN; MICE LACKING; ALPHA-6-BETA-4 INTEGRIN	The skin forms a barrier against the environment and protects us from mechanical trauma, pathogens, radiation, dehydration, and dangerous temperature fluctuations. The epithelium of the skin, the epidermis, is in a continuous equilibrium of growth and differentiation and has the remarkable capacity to self-renew completely, which relies on reservoirs of stem cells. Epidermal homeostasis is further dependent on proper repair after injury, and on tight adhesion to the underlying basement membrane. Epidermal adhesion is mediated primarily by integrins, cell-surface receptors that connect the extracellular matrix to the cytoskeleton. In addition, numerous in vitro reports have implicated integrins, integrin-associated proteins, or downstream integrin effectors in the regulation of a plethora of cellular processes other than adhesion. Over the past decade, a wealth of information on the function of these proteins has been gathered both from (conditional) knockout mice and from human skin disorders, allowing for a reconstruction of integrin signaling pathways in vivo. Here, we address how epidermal integrins and integrin-associated proteins regulate keratinocyte adhesion, proliferation, and differentiation, as well as signal transduction, re-epithelialization during wound healing, hair growth, and stem cell maintenance. Furthermore, we discuss human pathologies associated with altered integrin functions in the epidermis.-Margadant, C., Charafeddine, R. A., Sonnenberg, A. Unique and redundant functions of integrins in the epidermis. FASEB J. 24, 4133-4152 (2010). www.fasebj.org	[Margadant, Coert; Charafeddine, Rabab A.; Sonnenberg, Arnoud] Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Sonnenberg, A (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.sonnenberg@nki.nl		Charafeddine, Rabab/0000-0003-0056-0449				Ackerl R, 2007, J CELL SCI, V120, P2435, DOI 10.1242/jcs.004481; Akiyama M, 2000, J INVEST DERMATOL, V114, P321, DOI 10.1046/j.1523-1747.2000.00857.x; AlDahlawi S, 2006, WOUND REPAIR REGEN, V14, P289, DOI 10.1111/j.1743-6109.2006.00123.x; Alonso L, 2006, J CELL SCI, V119, P391, DOI 10.1242/jcs02793; Aluwihare P, 2009, J CELL SCI, V122, P227, DOI 10.1242/jcs.035246; Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; Araya J, 2006, AM J PATHOL, V169, P405, DOI 10.2353/ajpath.2006.060049; Ashton GHS, 2004, CLIN EXP DERMATOL, V29, P116, DOI 10.1111/j.1365-2230.2004.01465.x; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; BAADSGAARD O, 1990, J INVEST DERMATOL, V95, pS32, DOI 10.1111/1523-1747.ep12505715; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Bagutti C, 1996, DEV BIOL, V179, P184, DOI 10.1006/dbio.1996.0250; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Botchkarev VA, 2004, DIFFERENTIATION, V72, P512, DOI 10.1111/j.1432-0436.2004.07209005.x; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Brakebusch C, 2005, CANCER METAST REV, V24, P403, DOI 10.1007/s10555-005-5132-5; BREUSS JM, 1995, J CELL SCI, V108, P2241; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; CHANG EY, 1992, ARCH DERMATOL, V128, P1479, DOI 10.1001/archderm.128.11.1479; Chen JC, 2002, AM J PATHOL, V161, P337, DOI 10.1016/S0002-9440(10)64185-5; Choma DP, 2007, J INVEST DERMATOL, V127, P31, DOI 10.1038/sj.jid.5700505; Choma DP, 2004, J CELL SCI, V117, P3947, DOI 10.1242/jcs.01251; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Conti FJA, 2003, J CELL SCI, V116, P2737, DOI 10.1242/jcs.00475; Crew VK, 2004, BLOOD, V104, P2217, DOI 10.1182/blood-2004-04-1512; DeHart GW, 2003, EXP CELL RES, V283, P67, DOI 10.1016/S0014-4827(02)00028-9; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DiPersio CM, 2000, J CELL SCI, V113, P3051; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Dumesic PA, 2009, J CELL BIOL, V185, P409, DOI 10.1083/jcb.200804038; Essayem S, 2006, ONCOGENE, V25, P1081, DOI 10.1038/sj.onc.1209130; Evans RD, 2003, J CELL BIOL, V160, P589, DOI 10.1083/jcb.200209016; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Ferreira M, 2009, CANCER RES, V69, P1334, DOI 10.1158/0008-5472.CAN-08-3051; Fjellbirkeland L, 2003, AM J PATHOL, V163, P533, DOI 10.1016/S0002-9440(10)63681-4; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; GAILIT J, 1994, J INVEST DERMATOL, V103, P221, DOI 10.1111/1523-1747.ep12393176; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gao J, 2008, GENE DEV, V22, P2111, DOI 10.1101/gad.1689908; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; Grenache DG, 2007, J INVEST DERMATOL, V127, P455, DOI 10.1038/sj.jid.5700611; Grose R, 2002, DEVELOPMENT, V129, P2303; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Hakkinen L, 2000, J HISTOCHEM CYTOCHEM, V48, P985; Hakkinen L, 2004, AM J PATHOL, V164, P229, DOI 10.1016/S0002-9440(10)63113-6; HASHIRO M, 1991, Journal of Dermatology (Tokyo), V18, P252; Heinonen S, 1999, J CELL SCI, V112, P3641; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000; Huang XZ, 1998, J CELL SCI, V111, P2189; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Huang XZ, 2000, MOL CELL BIOL, V20, P755, DOI 10.1128/MCB.20.3.755-759.2000; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ILLC D, 1995, NATURE, V377, P539; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Jeong HW, 2004, J CELL BIOCHEM, V92, P770, DOI 10.1002/jcb.20110; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JUHASZ I, 1993, AM J PATHOL, V143, P1458; Kasperkiewicz M, 2007, CLIN REV ALLERG IMMU, V33, P67, DOI 10.1007/s12016-007-0030-y; Kaur P, 2000, J INVEST DERMATOL, V114, P413, DOI 10.1046/j.1523-1747.2000.00884.x; Kikkawa Y, 2000, J CELL SCI, V113, P869; KIM JP, 1992, J INVEST DERMATOL, V98, P764, DOI 10.1111/1523-1747.ep12499947; KINDLER T, 1954, BRIT J DERMATOL, V66, P104, DOI 10.1111/j.1365-2133.1954.tb12598.x; Kloepper JE, 2008, EXP CELL RES, V314, P498, DOI 10.1016/j.yexcr.2007.10.030; Koster J, 2001, J INVEST DERMATOL, V117, P1405, DOI 10.1046/j.0022-202x.2001.01567.x; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Kurata S, 2004, J BIOL CHEM, V279, P50069, DOI 10.1074/jbc.M406322200; Kuster JE, 1997, MAMM GENOME, V8, P673, DOI 10.1007/s003359900535; Lacy-Hulbert A, 2007, P NATL ACAD SCI USA, V104, P15823, DOI 10.1073/pnas.0707421104; Lamar JM, 2008, CANCER RES, V68, P7371, DOI 10.1158/0008-5472.CAN-08-1080; Lamar JM, 2008, J INVEST DERMATOL, V128, P575, DOI 10.1038/sj.jid.5701042; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Larjava H, 2008, EMBO REP, V9, P1203, DOI 10.1038/embor.2008.202; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; Li J, 2003, EMBO J, V22, P2400, DOI 10.1093/emboj/cdg239; Litjens SHM, 2006, TRENDS CELL BIOL, V16, P376, DOI 10.1016/j.tcb.2006.05.004; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; Lopez-Rovira T, 2005, J INVEST DERMATOL, V125, P1215, DOI 10.1111/j.0022-202X.2005.23956.x; Lorenz K, 2007, J CELL BIOL, V177, P501, DOI 10.1083/jcb.200608125; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; Margadant C, 2008, CURR OPIN CELL BIOL, V20, P589, DOI 10.1016/j.ceb.2008.05.001; Margadant C, 2010, EMBO REP, V11, P97, DOI 10.1038/embor.2009.276; Margadant C, 2009, J CELL SCI, V122, P278, DOI 10.1242/jcs.029108; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Massague J, 2000, GENE DEV, V14, P627; Mavilio F, 2006, NAT MED, V12, P1397, DOI 10.1038/nm1504; Meng XM, 2003, J INVEST DERMATOL, V121, P720, DOI 10.1046/j.1523-1747.2003.12515.x; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Meves A, 2009, TRENDS CELL BIOL, V19, P504, DOI 10.1016/j.tcb.2009.07.006; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mitchell K, 2009, J CELL SCI, V122, P1778, DOI 10.1242/jcs.040956; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Murayama K, 2007, ONCOGENE, V26, P4882, DOI 10.1038/sj.onc.1210274; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Nakano A, 2001, PEDIATR RES, V49, P618, DOI 10.1203/00006450-200105000-00003; Nakrieko KA, 2008, MOL BIOL CELL, V19, P1462, DOI 10.1091/mbc.E07-06-0526; Neurohr C, 2006, AM J RESP CELL MOL, V35, P252, DOI 10.1165/rcmb.2006-0013OC; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nickoloff BJ, 2007, CLIN REV ALLERG IMMU, V33, P45, DOI 10.1007/s12016-007-0039-2; Nikolopoulos SN, 2005, MOL CELL BIOL, V25, P6090, DOI 10.1128/MCB.25.14.6090-6102.2005; Nishie W, 2007, NAT MED, V13, P378, DOI 10.1038/nm1496; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Olasz Edit B., 2008, V10, P141, DOI 10.1159/000131452; Pankow S, 2006, J CELL SCI, V119, P4033, DOI 10.1242/jcs.03175; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Peters B, 2001, MOL BIOL CELL, V12, P1775, DOI 10.1091/mbc.12.6.1775; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Piwko-Czuchra A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005488; Pouliot N, 2002, EXP DERMATOL, V11, P387, DOI 10.1034/j.1600-0625.2002.110501.x; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Pullar CE, 2006, MOL BIOL CELL, V17, P4925, DOI 10.1091/mbc.E06-05-0433; Rabinovitz I, 2004, MOL CELL BIOL, V24, P4351, DOI 10.1128/MCB.24.10.4351-4360.2004; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Raymond K, 2005, J CELL SCI, V118, P1045, DOI 10.1242/jcs.01689; Reynolds LE, 2008, J CLIN INVEST, V118, P965, DOI 10.1172/JCI33538; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rodius S, 2007, J CELL PHYSIOL, V212, P439, DOI 10.1002/jcp.21040; Russell AJ, 2003, J CELL SCI, V116, P3543, DOI 10.1242/jcs.00663; Ruzzi L, 1997, J CLIN INVEST, V99, P2826, DOI 10.1172/JCI119474; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Sachs N, 2006, J CELL BIOL, V175, P33, DOI 10.1083/jcb.200603073; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Schneider H, 2007, EUR J CELL BIOL, V86, P701, DOI 10.1016/j.ejcb.2006.07.004; Schober M, 2007, J CELL BIOL, V176, P667, DOI 10.1083/jcb.200608010; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Scholl FA, 2007, DEV CELL, V12, P615, DOI 10.1016/j.devcel.2007.03.009; Sehgal BU, 2006, J BIOL CHEM, V281, P35487, DOI 10.1074/jbc.M606317200; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Singh P, 2004, J INVEST DERMATOL, V123, P1176, DOI 10.1111/j.0022-202X.2004.23485.x; Singh P, 2009, J INVEST DERMATOL, V129, P217, DOI 10.1038/jid.2008.201; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; Stepp MA, 1999, DEV DYNAM, V214, P216, DOI 10.1002/(SICI)1097-0177(199903)214:3<216::AID-AJA5>3.3.CO;2-W; Sugawara K, 2007, J HISTOCHEM CYTOCHEM, V55, P43, DOI 10.1369/jhc.6A6920.2006; Tarutani M, 2003, CANCER RES, V63, P319; Thomas GJ, 2006, J ORAL PATHOL MED, V35, P1, DOI 10.1111/j.1600-0714.2005.00374.x; Travis MA, 2007, NATURE, V449, P361, DOI 10.1038/nature06110; Tscharntke M, 2007, J CELL SCI, V120, P1480, DOI 10.1242/jcs.03426; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Uitto J, 2004, J INVEST DERMATOL, V123, pXII, DOI 10.1111/j.0022-202X.2004.23333.x; Underwood RA, 2009, J HISTOCHEM CYTOCHEM, V57, P123, DOI 10.1369/jhc.2008.952176; Ussar S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000289; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wang ZM, 1999, J CELL SCI, V112, P2925; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Wen TT, 2010, WOUND REPAIR REGEN, V18, P325, DOI 10.1111/j.1524-475X.2010.00590.x; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; White SJ, 2005, J DERMATOL SCI, V38, P169, DOI 10.1016/j.jdermsci.2004.12.026; Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006; Wilhelmsen K, 2007, MOL BIOL CELL, V18, P3512, DOI 10.1091/mbc.E07-04-0306; Wright MD, 2004, MOL CELL BIOL, V24, P5978, DOI 10.1128/MCB.24.13.5978-5988.2004; Wu XW, 2006, GENE DEV, V20, P571, DOI 10.1101/gad.361406; Yang ZW, 2007, J CELL BIOL, V176, P787, DOI 10.1083/jcb.200611044; Zaidel-Bar R, 2007, NAT CELL BIOL, V9, P858, DOI 10.1038/ncb0807-858; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; Zhang ZG, 2006, J CELL SCI, V119, P1886, DOI 10.1242/jcs.02921; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728; Zhu JW, 2002, DEVELOPMENT, V129, P2891; Zweers MC, 2007, J INVEST DERMATOL, V127, P467, DOI 10.1038/sj.jid.5700546	189	114	117	1	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4133	4152		10.1096/fj.09-151449	http://dx.doi.org/10.1096/fj.09-151449			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20624931	Bronze			2022-12-28	WOS:000283861100002
J	Nagy, NT; Sakamoto, T; Takacs, B; Gyimesi, M; Hazai, E; Bikadi, Z; Sellers, JR; Kovacs, M				Nagy, Nikolett T.; Sakamoto, Takeshi; Takacs, Balazs; Gyimesi, Mate; Hazai, Eszter; Bikadi, Zsolt; Sellers, James R.; Kovacs, Mihaly			Functional adaptation of the switch-2 nucleotide sensor enables rapid processive translocation by myosin-5	FASEB JOURNAL			English	Article						actomyosin; kinetics; nucleotide exchange; single molecule; sliding speed	HAND-OVER-HAND; MUSCLE-CONTRACTION; KINETIC MECHANISM; STEP-SIZE; MOLECULAR-MECHANISM; TRYPTOPHAN RESIDUE; PHOSPHATE RELEASE; FLUORESCENT-PROBE; MOTOR-ACTIVITY; NECK LENGTH	Active site loops that are conserved across superfamilies of myosins, kinesins, and G proteins play key roles in allosteric coupling of NTP hydrolysis to interaction with track filaments or effector proteins. In this study, we investigated how the class-specific natural variation in the switch-2 active site loop contributes to the motor function of the intracellular transporter myosin-5. We used single-molecule, rapid kinetic and spectroscopic experiments and semiempirical quantum chemical simulations to show that the class-specific switch-2 structure including a tyrosine (Y439) in myosin-5 enables rapid processive translocation along actin filaments by facilitating Mg2(+)-dependent ADP release. Using wild-type control and Y439 point mutant myosin-5 proteins, we demonstrate that the translocation speed precisely correlates with the kinetics of nucleotide exchange. Switch-2 variants can thus be used to fine-tune translocation speed while maintaining high processivity. The class-specific variation of switch-2 in various NTPase superfamilies indicates its general role in the kinetic tuning of Mg2(+)-dependent nucleotide exchange.-Nagy, N.T., Sakamoto, T., Takacs, B., Gyimesi, M., Hazai, E., Bikadi, Z., Sellers, J.R., Kovacs, M. Functional adaptation of the switch-2 nucleotide sensor enables rapid processive translocation by myosin-5. FASEB J. 24, 4480-4490 (2010). www.fasebj.org	[Nagy, Nikolett T.; Takacs, Balazs; Gyimesi, Mate; Kovacs, Mihaly] Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary; [Sakamoto, Takeshi; Sellers, James R.] NHLBI, Lab Mol Physiol, Bethesda, MD 20892 USA; [Hazai, Eszter; Bikadi, Zsolt] VirtuaDrug Ltd, Budapest, Hungary	Eotvos Lorand University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kovacs, M (corresponding author), Eotvos Lorand Univ, Dept Biochem, Pazmany P Stny 1-C, H-1117 Budapest, Hungary.	kovacsm@elte.hu	Kovacs, Mihaly/A-6841-2011; Gyimesi, Mate/I-2639-2017	Kovacs, Mihaly/0000-0002-1200-4741; Gyimesi, Mate/0000-0002-7195-1925	Fogarty International Center; National Heart, Lung, and Blood Institute [1 R01-TW007241]; Hungarian Scientific Research Fund (OTKA) [K71915, NNF78783]; European Molecular Biology Organization-Howard Hughes Medical Institute; FOGARTY INTERNATIONAL CENTER [R01TW007241] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004229] Funding Source: NIH RePORTER	Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Hungarian Scientific Research Fund (OTKA)(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); European Molecular Biology Organization-Howard Hughes Medical Institute(Howard Hughes Medical InstituteEuropean Molecular Biology Organization (EMBO)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Fogarty International Center and the National Heart, Lung, and Blood Institute (grant 1 R01-TW007241), Hungarian Scientific Research Fund (OTKA) grants K71915 and NNF78783, and a European Molecular Biology Organization-Howard Hughes Medical Institute startup grant to M.K.M.K. is a Bolyai Fellow of the Hungarian Academy of Sciences. The authors declare that they have no competing financial interests.	BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Dewar M.J.S., 1985, J AM CHEM SOC, P107; Durrwang U, 2006, J CELL SCI, V119, P550, DOI 10.1242/jcs.02774; Flores S, 2006, NUCLEIC ACIDS RES, V34, pD296, DOI 10.1093/nar/gkj046; Forgacs E, 2009, J BIOL CHEM, V284, P2138, DOI 10.1074/jbc.M805530200; Fujita-Becker S, 2005, J BIOL CHEM, V280, P6064, DOI 10.1074/jbc.M412473200; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Gyimesi M, 2008, J BIOL CHEM, V283, P8153, DOI 10.1074/jbc.M708863200; Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Libby RT, 2004, J CELL SCI, V117, P4509, DOI 10.1242/jcs.01316; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2001, J BIOL CHEM, V276, P19483, DOI 10.1074/jbc.M010886200; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Murphy CT, 2001, NAT CELL BIOL, V3, P311, DOI 10.1038/35060110; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2005, J BIOL CHEM, V280, P6072, DOI 10.1074/jbc.M412717200; Sakamoto T, 2005, BIOCHEMISTRY-US, V44, P16203, DOI 10.1021/bi0512086; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Sellers J. R., 1999, MYOSINS; Sellers JR, 2006, CURR OPIN CELL BIOL, V18, P68, DOI 10.1016/j.ceb.2005.12.014; Snyder GE, 2004, BIOPHYS J, V87, P1776, DOI 10.1529/biophysj.103.036897; Sweeney HL, 2004, PHILOS T R SOC B, V359, P1829, DOI 10.1098/rstb.2004.1576; Takagi Y, 2008, J BIOL CHEM, V283, P8527, DOI 10.1074/jbc.M709150200; Thomas C, 2007, MOL CELL, V25, P141, DOI 10.1016/j.molcel.2006.11.023; Toth J, 2005, J BIOL CHEM, V280, P30594, DOI 10.1074/jbc.M505209200; TRENTHAM DR, 1972, BIOCHEM J, V126, P635, DOI 10.1042/bj1260635; Tsiavaliaris G, 2008, J BIOL CHEM, V283, P4520, DOI 10.1074/jbc.M708113200; Urbanke C, 2001, BIOCHEM J, V358, P165, DOI 10.1042/0264-6021:3580165; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Veigel C, 2005, NAT CELL BIOL, V7, P861, DOI 10.1038/ncb1287; Wagner WG, 2003, J CELL BIOL, V163, P1193, DOI 10.1083/jcb.200311077; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yang Y, 2006, P NATL ACAD SCI USA, V103, P5746, DOI 10.1073/pnas.0509935103; Yang YT, 2007, STRUCTURE, V15, P553, DOI 10.1016/j.str.2007.03.010; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	52	11	11	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4480	4490		10.1096/fj.10-163998	http://dx.doi.org/10.1096/fj.10-163998			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20631329	Green Published			2022-12-28	WOS:000283861100033
J	Obican, SG; Finnell, RH; Mills, JL; Shaw, GM; Scialli, AR				Obican, Sarah G.; Finnell, Richard H.; Mills, James L.; Shaw, Gary M.; Scialli, Anthony R.			Folic acid in early pregnancy: a public health success story	FASEB JOURNAL			English	Article						folate; neural tube defects; congenital malformations; epidemiology; teratology	NEURAL-TUBE DEFECTS; METHYLENETETRAHYDROFOLATE REDUCTASE MTHFR; CONOTRUNCAL HEART-DEFECTS; AMNIOTIC-FLUID; VITAMIN SUPPLEMENTATION; PERICONCEPTIONAL USE; FOLATE METABOLISM; MULTIVITAMIN USE; DIETARY-FOLATE; MICE DEFICIENT	Folate is a water-soluble B vitamin that must be obtained in the diet or through supplementation. For >50 yr, it has been known that folate plays an integral role in embryonic development. In mice, inactivation of genes in the folate pathway results in malformations of the neural tube, heart, and craniofacial structures. It has been shown that diets and blood levels of women who had a fetus with a neural tube defect are low for several micronutrients, particularly folate. Periconceptional use of folic acid containing supplements decreased recurrent neural tube defects in the offspring of women with a previously affected child and the occurrence of a neural tube defect and possibly other birth defects in the offspring of women with no prior history. Based on these findings, the U. S. Public Health Service recommended that all women at risk take folic acid supplements, but many did not. Mandatory food fortification programs were introduced in numerous countries, including the United States, to improve folate nutritional status and have resulted in a major decrease in neural tube defect prevalence. The success story of folate represents the cooperation of embryologists, experimentalists, epidemiologists, public health scientists, and policymakers.-Obic. an, S. G., Finnell, R. H., Mills, J. L., Shaw, G. M., Scialli, A. R. Folic acid in early pregnancy: a public health success story. FASEB J. 24, 4167-4174 (2010). www.fasebj.org	[Scialli, Anthony R.] Tetra Tech Sci, Arlington, VA 22201 USA; [Obican, Sarah G.; Scialli, Anthony R.] George Washington Univ, Sch Med, Dept Obstet & Gynecol, Washington, DC USA; [Finnell, Richard H.] Univ Texas Austin, Dept Nutr, Austin, TX 78712 USA; [Mills, James L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD USA; [Shaw, Gary M.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA	George Washington University; University of Texas System; University of Texas Austin; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Stanford University	Scialli, AR (corresponding author), Tetra Tech Sci, 2200 Wilson Blvd,Ste 400, Arlington, VA 22201 USA.	ascialli@sciences.com	Finnell, Richard/D-8174-2018	Finnell, Richard/0000-0002-5962-8754; Mills, James/0000-0003-4496-332X; Shaw, Gary/0000-0001-7438-4914	National Institutes of Health (NIH), National Institute of Child Health and Human Development; NIH [DE016315, NS050249]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD002502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050249] Funding Source: NIH RePORTER	National Institutes of Health (NIH), National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by the Intramural Research Program, National Institutes of Health (NIH), National Institute of Child Health and Human Development, and in part by funds from NIH grants DE016315 and NS050249.	[Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; [Anonymous], 1996, FED REG, V61, P44; Arabelovic S, 2007, J AM COLL NUTR, V26, P453, DOI 10.1080/07315724.2007.10719635; Beaty TH, 2001, ANN EPIDEMIOL, V11, P434, DOI 10.1016/S1047-2797(01)00222-8; Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Blencowe H, 2010, INT J EPIDEMIOL, V39, P110, DOI 10.1093/ije/dyq028; Botto LD, 2000, AM J EPIDEMIOL, V151, P862; Botto LD, 1996, PEDIATRICS, V98, P911; Botto LD, 2006, BIRTH DEFECTS RES A, V76, P693, DOI 10.1002/bdra.20307; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Bukowski R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000061; Canfield MA, 2005, BIRTH DEFECTS RES A, V73, P679, DOI 10.1002/bdra.20210; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P962; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Christianson A., 2006, GLOBAL REPORT BIRTH; Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351; Czeizel AE, 1996, TERATOLOGY, V53, P345, DOI 10.1002/(SICI)1096-9926(199606)53:6&lt;345::AID-TERA5&gt;3.0.CO;2-Z; Czeizel AE, 1997, FOLIA PHONIATR LOGO, V49, P111, DOI 10.1159/000266446; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; De Marco P, 2003, EUR J HUM GENET, V11, P245, DOI 10.1038/sj.ejhg.5200946; Deng L, 2008, MOL GENET METAB, V94, P336, DOI 10.1016/j.ymgme.2008.03.004; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; Ebbing M, 2009, JAMA-J AM MED ASSOC, V302, P2119, DOI 10.1001/jama.2009.1622; ECONOMIDES DL, 1992, BRIT J OBSTET GYNAEC, V99, P23, DOI 10.1111/j.1471-0528.1992.tb14386.x; Elmore CL, 2007, MOL GENET METAB, V91, P85, DOI 10.1016/j.ymgme.2007.02.001; GARDIKIKOUIDOU P, 1988, CLIN GENET, V33, P441; GELINEAUVANWAES J, 2007, CHEM BIOL PTERIDINES, P483; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; Gorman EB, 2009, PTERIDINES, V20, P156; Greene NDE, 2009, PRENATAL DIAG, V29, P303, DOI 10.1002/pd.2206; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204; Hirsch S, 2009, EUR J GASTROEN HEPAT, V21, P346, DOI 10.1097/MEG.0b013e328306ccdb; HOLMESSIEDLE M, 1982, LANCET, V1, P276; Honein MA, 2001, JAMA-J AM MED ASSOC, V285, P2981, DOI 10.1001/jama.285.23.2981; KIRKE PN, 1993, Q J MED, V86, P703; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; Loffredo LCM, 2001, CLEFT PALATE-CRAN J, V38, P76, DOI 10.1597/1545-1569(2001)038<0076:OCAVS>2.0.CO;2; Logan RFA, 2008, GASTROENTEROLOGY, V134, P29, DOI 10.1053/j.gastro.2007.10.014; LUCOCK MD, 1994, BIOCHEM MED METAB B, V52, P101, DOI 10.1006/bmmb.1994.1040; Maberly G., 2008, Morbidity and Mortality Weekly Report, V57, P8; MacFarlane AJ, 2008, J BIOL CHEM, V283, P25846, DOI 10.1074/jbc.M802671200; Mason JB, 2007, CANCER EPIDEM BIOMAR, V16, P1325, DOI 10.1158/1055-9965.EPI-07-0329; Matsui EC, 2009, J ALLERGY CLIN IMMUN, V123, P1253, DOI 10.1016/j.jaci.2009.03.007; McLean E, 2008, FOOD NUTR BULL, V29, pS38, DOI 10.1177/15648265080292S107; Mills JL, 2003, AM J CLIN NUTR, V77, P1474, DOI 10.1093/ajcn/77.6.1474; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; MUNGER RG, 2002, CLEFT LIP PALATE ORI, P170; Piedrahita JA, 1999, NAT GENET, V23, P228, DOI 10.1038/13861; Pike ST, 2010, J BIOL CHEM, V285, P4612, DOI 10.1074/jbc.M109.079855; Salbaum JM, 2009, BIRTH DEFECTS RES A, V85, P303, DOI 10.1002/bdra.20537; Selhub J, 1999, ANN INTERN MED, V131, P331, DOI 10.7326/0003-4819-131-5-199909070-00003; SELLER MJ, 1984, J MED GENET, V21, P325, DOI 10.1136/jmg.21.5.325; SHAW GM, 1995, LANCET, V346, P393, DOI 10.1016/S0140-6736(95)92778-6; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; SHAW GM, 1995, AM J MED GENET, V59, P536, DOI 10.1002/ajmg.1320590428; SMITHELLS RW, 1976, ARCH DIS CHILD, V51, P944, DOI 10.1136/adc.51.12.944; SMITHELLS RW, 1983, LANCET, V1, P1027; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; Spiegelstein O, 2004, DEV DYNAM, V231, P221, DOI 10.1002/dvdy.20107; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; Swanson DA, 2001, MOL CELL BIOL, V21, P1058, DOI 10.1128/MCB.21.4.1058-1065.2001; Takacs P, 2005, INT J GYNECOL OBSTET, V89, P301, DOI 10.1016/j.ijgo.2004.11.036; van Rooij IALM, 2004, PREV MED, V39, P689, DOI 10.1016/j.ypmed.2004.02.036; vanderPut NMJ, 1997, QJM-INT J MED, V90, P505, DOI 10.1093/qjmed/90.8.505; VERGEL RG, 1990, PRENATAL DIAG, V10, P149, DOI 10.1002/pd.1970100303; Waes JGV, 2008, BIRTH DEFECTS RES A, V82, P494, DOI 10.1002/bdra.20453; WALLIS D, 2009, FOLATE HLTH DIS, P156; WEEKES EW, 1992, BIOL NEONATE, V61, P226; Weisberg I, 1998, MOL GENET METAB, V64, P169, DOI 10.1006/mgme.1998.2714; Weisberg IS, 2001, ATHEROSCLEROSIS, V156, P409, DOI 10.1016/S0021-9150(00)00671-7; Wen SW, 2008, CAN MED ASSOC J, V179, P1263, DOI 10.1503/cmaj.080859; Wen SW, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.06.067; Werler MM, 1999, AM J EPIDEMIOL, V150, P675, DOI 10.1093/oxfordjournals.aje.a010070; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; Whitrow MJ, 2009, AM J EPIDEMIOL, V170, P1486, DOI 10.1093/aje/kwp315; WILD J, 1993, BRIT J OBSTET GYNAEC, V100, P546, DOI 10.1111/j.1471-0528.1993.tb15306.x; Williams LJ, 2002, TERATOLOGY, V66, P33, DOI 10.1002/tera.10060; Wlodarczyk B, 2001, TOXICOL APPL PHARM, V177, P238, DOI 10.1006/taap.2001.9303; YATES JRW, 1987, CLIN GENET, V31, P279; Zhao RB, 2001, J BIOL CHEM, V276, P10224, DOI 10.1074/jbc.C000905200; Zhu HP, 2007, BIRTH DEFECTS RES A, V79, P257, DOI 10.1002/bdra.20347	83	60	66	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4167	4174		10.1096/fj.10-165084	http://dx.doi.org/10.1096/fj.10-165084			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20631328	Green Published			2022-12-28	WOS:000283861100004
J	Rudrabhatla, P; Grant, P; Jaffe, H; Strong, MJ; Pant, HC				Rudrabhatla, Parvathi; Grant, Philip; Jaffe, Howard; Strong, Michael J.; Pant, Harish C.			Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQ	FASEB JOURNAL			English	Article						neurofilament-M/H; phosphorylation sites; iTRAQ; MS/MS mass spectrometry; TiO2; proline-directed kinases	PAIRED HELICAL FILAMENTS; AMYOTROPHIC LATERAL SCLEROSIS; WEIGHT NEUROFILAMENT PROTEIN; CEREBROSPINAL-FLUID; AXONAL-TRANSPORT; PHOSPHORYLATION; ANTIBODIES; SUBUNIT; IDENTIFICATION; ACCUMULATION	Aberrant hyperphosphorylation of neuronal cytoskeletal proteins is one of the major pathological hallmarks of neurodegenerative disorders such as Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Human NFM/H display a large number of multiple KSP repeats in the carboxy-terminal tail domain, which are phosphorylation sites of proline-directed serine/threonine (pSer/Thr-Pro, KS/T-P) kinases. The phosphorylation sites of NF-M/H have not been characterized in AD brain. Here, we use quantitative phosphoproteomic methodology, isobaric tag for relative and absolute quantitation (iTRAQ), for the characterization of NFM/H phosphorylation sites in AD brain. We identified 13 hyperphosphorylated sites of NF-M; 9 Lys-Ser-Pro (KSP) sites; 2 variant motifs, Glu-Ser-Pro (ESP) Ser-736 and Leu-Ser-Pro (LSP) Ser-837; and 2 non-S/T-P motifs, Ser-783 and Ser-788. All the Ser/Thr residues are phosphorylated at significantly greater abundance in AD brain compared with control brain. Ten hyperphosphorylated KSP sites have been identified on the C-terminal tail domain of NF-H, with greater abundance of phosphorylation in AD brain compared with control brain. Our data provide the direct evidence that NFM/H are hyperphosphorylated in AD compared with control brain and suggest the role of both proline-directed and non-proline-directed protein kinases in AD. This study represents the first comprehensive iTRAQ analyses and quantification of phosphorylation sites of human NF-M and NF-H from AD brain and suggests that aberrant hyperphosphorylation of neuronal intermediate filament proteins is involved in AD.-Rudrabhatla, P., Grant, P., Jaffe, H., Strong, M. J., Pant, H. C. Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQ. FASEB J. 24, 4396-4407 (2010). www.fasebj.org	[Pant, Harish C.] NINDS, Cytoskeletal Regulatory Prot Sect, Neurochem Lab, NIH, Bethesda, MD 20892 USA; [Jaffe, Howard] NINDS, Prot Peptide Sequencing Facil, NIH, Bethesda, MD 20892 USA; [Strong, Michael J.] Univ Western Ontario, Mol Brain Res Grp, Robarts Res Inst, London, ON, Canada; [Strong, Michael J.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Western University (University of Western Ontario); Western University (University of Western Ontario)	Pant, HC (corresponding author), NINDS, Cytoskeletal Regulatory Prot Sect, Neurochem Lab, NIH, Bldg 49,Rm 2A28, Bethesda, MD 20892 USA.	panth@ninds.nih.gov	Strong, Michael/AAU-5699-2020; Strong, Michael J/H-9689-2012	Strong, Michael/0000-0003-1988-6262; Rudrabhatla, Parvathi/0000-0002-7537-3130	National Institutes of Health of the National Institute of Neurological Diseases and Stroke; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002725] Funding Source: NIH RePORTER	National Institutes of Health of the National Institute of Neurological Diseases and Stroke; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the National Institutes of Health Intramural research programs of the National Institute of Neurological Diseases and Stroke. The authors thank the Harvard Brain Resource Center (Boston, MA, USA) and the National Institute of Child Health and Human Development Brain and Tissue Bank (Bethesda, MD, USA) for providing human brain tissue.	Brettschneider J, 2006, DEMENT GERIATR COGN, V21, P291, DOI 10.1159/000091436; COOK LC, 1986, J NEUROPATHOL EXP NE, V45, P56; DAHL D, 1982, J NEUROSCI, V2, P113; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Dosemeci A, 2010, BIOCHEM BIOPH RES CO, V391, P78, DOI 10.1016/j.bbrc.2009.10.167; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FORNO LS, 1986, NEUROSCI LETT, V64, P253, DOI 10.1016/0304-3940(86)90337-X; Ghoshal N, 1999, AM J PATHOL, V155, P1163, DOI 10.1016/S0002-9440(10)65219-4; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; Griffin TJ, 2007, J PROTEOME RES, V6, P4200, DOI 10.1021/pr070291b; Jaffe H, 1998, BIOCHEMISTRY-US, V37, P3931, DOI 10.1021/bi972518u; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KRINKS MH, 1988, J NEUROSCI, V8, P2172; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; MATA M, 1992, RANVIER NEUROCYTOLOG, V21, P199; MILLER CCJ, 1986, EMBO J, V5, P269, DOI 10.1002/j.1460-2075.1986.tb04209.x; MORRISON JH, 1987, BRAIN RES, V416, P331, DOI 10.1016/0006-8993(87)90914-0; MUNOZ DG, 1988, J NEUROPATH EXP NEUR, V47, P9, DOI 10.1097/00005072-198801000-00002; Munton RP, 2007, MOL CELL PROTEOMICS, V6, P283, DOI 10.1074/mcp.M600046-MCP200; NUKINA N, 1987, P NATL ACAD SCI USA, V84, P3415, DOI 10.1073/pnas.84.10.3415; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; Pant AC, 1997, BRAIN RES, V765, P259, DOI 10.1016/S0006-8993(97)00561-1; Pant HC, 1995, BIOCHEM CELL BIOL, V73, P575, DOI 10.1139/o95-063; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PERRY G, 1988, LANCET, V2, P746; POLLANEN MS, 1994, ACTA NEUROPATHOL, V88, P1, DOI 10.1007/BF00294352; Rudrabhatla P, 2009, J NEUROSCI, V29, P14869, DOI 10.1523/JNEUROSCI.4469-09.2009; Shea TB, 2004, J NEUROSCI RES, V76, P795, DOI 10.1002/jnr.20099; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOBUE G, 1990, ACTA NEUROPATHOL, V79, P402, DOI 10.1007/BF00308716; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43; Tannu NS, 2006, PROG BRAIN RES, V158, P41, DOI 10.1016/S0079-6123(06)58003-3; Thangavel R, 2009, NEUROSCIENCE, V160, P427, DOI 10.1016/j.neuroscience.2009.02.037; Veeranna, 2008, J NEUROCHEM, V107, P35, DOI 10.1111/j.1471-4159.2008.05547.x; Vickers JC, 1996, EXP NEUROL, V141, P1, DOI 10.1006/exnr.1996.0133; WONG PC, 1995, J CELL BIOL, V130, P1413, DOI 10.1083/jcb.130.6.1413; Wu J, 2007, J PROTEOME RES, V6, P4684, DOI 10.1021/pr070481m; YAMASAKI H, 1991, ACTA NEUROPATHOL, V82, P427, DOI 10.1007/BF00293376; ZHANG H, 1989, P NATL ACAD SCI USA, V86, P8045, DOI 10.1073/pnas.86.20.8045	46	51	53	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4396	4407		10.1096/fj.10-157859	http://dx.doi.org/10.1096/fj.10-157859			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20624930	Green Published			2022-12-28	WOS:000283861100026
J	Singh, SK; Kurfurst, R; Nizard, C; Schnebert, S; Perrier, E; Tobin, DJ				Singh, Suman K.; Kurfurst, Robin; Nizard, Carine; Schnebert, Sylvianne; Perrier, Eric; Tobin, Desmond J.			Melanin transfer in human skin cells is mediated by filopodia-a model for homotypic and heterotypic lysosome-related organelle transfer	FASEB JOURNAL			English	Article						pigmentation; myosin-X; Cdc42; phagocytosis; UV	MYOSIN-X; MELANOSOME TRANSFER; ACTIN CYTOSKELETON; HUMAN MELANOCYTES; MOLECULAR MOTOR; CYTOCHALASIN-B; CUTTING EDGE; PIGMENTATION; RECEPTOR; MOTILITY	Transfer of the melanocyte-specific and lysosome-related organelle, the melanosome, from melanocytes to keratinocytes is crucial for the protection of the skin against harmful ultraviolet radiation (UVR)-our main physiological cutaneous stressor. However, this commonplace event remains a most enigmatic process despite several early hypotheses. Recently, we and others have proposed a role for filopodia in melanin transfer, although conclusive experimental proof remained elusive. Using known filopodial markers (MyoX/Cdc42) and the filopodial disrupter, low-dose cytochalasin-B, we demonstrate here a requirement for filopodia in melanosome transfer from melanocytes to keratinocytes and also, unexpectedly, between keratinocytes. Melanin distribution throughout the skin represents the key phenotypic event in skin pigmentation. Melanocyte filopodia were also necessary for UVR-stimulated melanosome transfer, as this was also inhibited by MyoX knockdown and low-dose cytochalasin-B. Knockdown of keratinocyte MyoX protein, in its capacity as a phagocytosis effector, resulted in the inhibition of melanin uptake by keratinocytes. This indicates a central role for phagocytosis by keratinocytes of melanocyte filopodia. In summary, we propose a new model for the regulation of pigmentation in human skin cells under both constitutive and facultative (post-UVR) conditions, which we call the "filopodial-phagocytosis model." This model also provides a unique and highly accessible way to study lysosome-related organelle movement between mammalian cells.-Singh, S. K., Kurfurst, R., Nizard, C., Schnebert, S., Perrier, E., Tobin, D. J. Melanin transfer in human skin cells is mediated by filopodia-a model for homotypic and heterotypic lysosomerelated organelle transfer. FASEB J. 24, 3756-3769 (2010). www.fasebj.org	[Singh, Suman K.; Tobin, Desmond J.] Univ Bradford, Ctr Skin Sci, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England; [Kurfurst, Robin; Nizard, Carine; Schnebert, Sylvianne; Perrier, Eric] LVMH Rech, St Jean De Braye, France	University of Bradford	Tobin, DJ (corresponding author), Univ Bradford, Ctr Skin Sci, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England.	d.tobin@bradford.ac.uk	Tobin, Desmond/A-5228-2009	Tobin, Desmond/0000-0003-4566-9392				Baluska F, 2004, TRENDS CELL BIOL, V14, P404, DOI 10.1016/j.tcb.2004.07.001; Berens W, 2005, PIGM CELL RES, V18, P370, DOI 10.1111/j.1600-0749.2005.00263.x; Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Bohil AB, 2006, P NATL ACAD SCI USA, V103, P12411, DOI 10.1073/pnas.0602443103; BOUSQUET PF, 1990, CANCER RES, V50, P1431; Bukoreshtliev NV, 2009, FEBS LETT, V583, P1481, DOI 10.1016/j.febslet.2009.03.065; Burnette DT, 2007, NAT CELL BIOL, V9, P1360, DOI 10.1038/ncb1655; Byers HR, 2000, J INVEST DERMATOL, V114, P990, DOI 10.1046/j.1523-1747.2000.00957.x; Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779; Costin GE, 2007, FASEB J, V21, P976, DOI 10.1096/fj.06-6649rev; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; Dalby MJ, 2004, CELL BIOL INT, V28, P229, DOI 10.1016/j.cellbi.2003.12.004; Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002; FITZPATRICK T B, 1963, Dermatol Wochenschr, V147, P481; Fitzpatrick T. B., 1971, MOD TRENDS DERMATOL, V4, P122; FLAXMAN BA, 1973, J INVEST DERMATOL, V60, P321, DOI 10.1111/1523-1747.ep12723167; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Hessen DO, 2008, SOLAR RAD HUMAN HLTH, P123, DOI DOI 10.1038/NRG2897; Hoashi T, 2006, J BIOL CHEM, V281, P21198, DOI 10.1074/jbc.M601643200; Homma K, 2001, J BIOL CHEM, V276, P34348, DOI 10.1074/jbc.M104785200; Kauser S, 2003, J INVEST DERMATOL, V120, P1073, DOI 10.1046/j.1523-1747.2003.12242.x; Kawakami A, 2008, J INVEST DERMATOL, V128, P143, DOI 10.1038/sj.jid.5700964; Linch CA, 2001, J FORENSIC SCI, V46, P844; Ma HJ, 2010, EXP DERMATOL, V19, pE282, DOI 10.1111/j.1600-0625.2009.00956.x; Mallavarapu A, 1999, J CELL BIOL, V146, P1097, DOI 10.1083/jcb.146.5.1097; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Menasche G, 2003, J CLIN INVEST, V112, P450, DOI 10.1172/JCI200318264; Menna E, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000138; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Nagy S, 2008, P NATL ACAD SCI USA, V105, P9616, DOI 10.1073/pnas.0802592105; Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Rhodes LE, 2009, FASEB J, V23, P3947, DOI 10.1096/fj.09-136077; Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; Scott G, 2001, J INVEST DERMATOL, V117, P1412, DOI 10.1046/j.0022-202x.2001.01575.x; Scott G, 2002, J CELL SCI, V115, P1441; Seiberg M, 2000, EXP CELL RES, V254, P25, DOI 10.1006/excr.1999.4692; SEIJI M, 1963, NATURE, V197, P1082, DOI 10.1038/1971082a0; Singh SK, 2008, EXP DERMATOL, V17, P418, DOI 10.1111/j.1600-0625.2008.00702.x; SLOMINSKI A, 1993, J THEOR BIOL, V164, P103, DOI 10.1006/jtbi.1993.1142; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Sousa AD, 2005, TRENDS CELL BIOL, V15, P533, DOI 10.1016/j.tcb.2005.08.006; Thong HY, 2003, BRIT J DERMATOL, V149, P498, DOI 10.1046/j.1365-2133.2003.05473.x; Tobin DJ, 2006, CHEM SOC REV, V35, P52, DOI 10.1039/b505793k; Tokuo H, 2007, J CELL BIOL, V179, P229, DOI 10.1083/jcb.200703178; Trichet L, 2008, J CELL BIOL, V181, P19, DOI 10.1083/jcb.200710168; Van den Bossche K, 2006, TRAFFIC, V7, P769, DOI 10.1111/j.1600-0854.2006.00425.x; Vancoillie G, 2000, J INVEST DERMATOL, V114, P421, DOI 10.1046/j.1523-1747.2000.00897.x; Vidulescu C, 2004, J CELL MOL MED, V8, P388, DOI 10.1111/j.1582-4934.2004.tb00328.x; Virador VM, 2001, FASEB J, V15, P105, DOI 10.1096/fj.01-0518fje; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yonezawa S, 2003, DEV GROWTH DIFFER, V45, P175; Zhang RZ, 2004, PIGM CELL RES, V17, P62, DOI 10.1046/j.1600-0749.2003.00111.x; Zheng JQ, 1996, J NEUROSCI, V16, P1140; Zhuravlev PI, 2009, P NATL ACAD SCI USA, V106, P11570, DOI 10.1073/pnas.0812746106; ZURIER RB, 1973, P NATL ACAD SCI USA, V70, P844, DOI 10.1073/pnas.70.3.844	60	84	89	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3756	3769		10.1096/fj.10-159046	http://dx.doi.org/10.1096/fj.10-159046			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20501793				2022-12-28	WOS:000285005900015
J	Rathinakumar, R; Wimley, WC				Rathinakumar, Ramesh; Wimley, William C.			High-throughput discovery of broad-spectrum peptide antibiotics	FASEB JOURNAL			English	Article						antimicrobial peptide; combinatorial chemistry; high-throughput screening; membrane permeabilization	RATIONAL COMBINATORIAL DESIGN; PORE-FORMING PEPTIDES; ANTIMICROBIAL PEPTIDES; DEFENSINS; MEMBRANES	Membrane-permeabilizing peptide antibiotics are an underutilized weapon in the battle against drug-resistant microorganisms. This is true, in part, because of the bottleneck caused by the lack of explicit design principles and the paucity of simple high-throughput methods for selection. In this work, we characterize the requirements for broad-spectrum antimicrobial activity by membrane permeabilization and find that different microbial membranes have very different susceptibilities to permeabilization by individual antimicrobial peptides. Broad-spectrum activity requires only that an AMP have at least a small amount of membrane-permeabilizing activity against multiple classes of microbes, a feature that we show to be rare in a peptide library containing many members with species-specific activity. We compare biological and vesicle-based high-throughput strategies for selecting such broad-spectrum AMPs from combinatorial peptide libraries and demonstrate that a simple in vitro, lipid vesicle-based high-throughput screen is the most effective strategy for rapid discovery of novel, broad-spectrum antimicrobial peptides.-Rathinakumar, R., Wimley, W. C. High-throughput discovery of broad-spectrum peptide antibiotics. FASEB J. 24, 3232-3238 (2010). www.fasebj.org	[Rathinakumar, Ramesh; Wimley, William C.] Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA	Tulane University	Wimley, WC (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem SL43, New Orleans, LA 70112 USA.	wwimley@tulane.edu			U.S. National Institutes of Health [GM060000]; Louisiana Board of Regents Support Fund [RC/EEP-05(2007-10)]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060000] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Board of Regents Support Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Christopher Bishop for peptide synthesis and purification and William F. Walkenhorst and Paulo F. Almeida for critically reading the manuscript. This work was supported by U.S. National Institutes of Health grant GM060000 and by Louisiana Board of Regents Support Fund grant RC/EEP-05(2007-10).	Almeida PF, 2009, BIOCHEMISTRY-US, V48, P8083, DOI 10.1021/bi900914g; Arias CA, 2009, NEW ENGL J MED, V360, P439, DOI 10.1056/NEJMp0804651; Bechinger B, 2009, CURR OPIN COLLOID IN, V14, P349, DOI 10.1016/j.cocis.2009.02.004; Easton DM, 2009, TRENDS BIOTECHNOL, V27, P582, DOI 10.1016/j.tibtech.2009.07.004; Gardy JL, 2009, TRENDS IMMUNOL, V30, P249, DOI 10.1016/j.it.2009.03.009; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Hong RW, 2003, ANTIMICROB AGENTS CH, V47, P1, DOI 10.1128/AAC.47.1.1-6.2003; Imura Y, 2008, BIOPHYS J, V95, P5757, DOI 10.1529/biophysj.108.133488; Klein E, 2007, EMERG INFECT DIS, V13, P1840, DOI 10.3201/eid1312.070629; Pittet D, 2008, J HOSP INFECT, V68, P285, DOI 10.1016/j.jhin.2007.12.013; Rathinakumar R, 2008, J AM CHEM SOC, V130, P9849, DOI 10.1021/ja8017863; Rathinakumar R, 2009, J AM CHEM SOC, V131, P7609, DOI 10.1021/ja8093247; Rausch JM, 2005, P NATL ACAD SCI USA, V102, P10511, DOI 10.1073/pnas.0502013102; Rausch JM, 2001, ANAL BIOCHEM, V293, P258, DOI 10.1006/abio.2001.5137; Rausch JM, 2007, BIOCHEMISTRY-US, V46, P12124, DOI 10.1021/bi700978h; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; VANABEL RJ, 1995, INT J PEPT PROT RES, V45, P401; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Yount NY, 2004, P NATL ACAD SCI USA, V101, P7363, DOI 10.1073/pnas.0401567101	22	48	50	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3232	3238		10.1096/fj.10-157040	http://dx.doi.org/10.1096/fj.10-157040			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20410445	Green Published			2022-12-28	WOS:000281446400012
J	Kalogeropoulos, M; Varanasi, SS; Olstad, OK; Sanderson, P; Gautvik, VT; Reppe, S; Francis, RM; Gautvik, KM; Birch, MA; Datta, HK				Kalogeropoulos, Michail; Varanasi, Satya S.; Olstad, Ole K.; Sanderson, Paul; Gautvik, Vigdis T.; Reppe, Sjur; Francis, Roger M.; Gautvik, Kaare M.; Birch, Mark A.; Datta, Harish K.			Zic1 transcription factor in bone: neural developmental protein regulates mechanotransduction in osteocytes	FASEB JOURNAL			English	Article						mechanical stress; fluid flow; shear stress; mechanosensors	MECHANICAL STRAIN; GENE-EXPRESSION; CILIA; SKELETOGENESIS; POLYCYSTIN-1; OSTEOGENESIS; DROSOPHILA; RESPONSES; PATHWAYS; ABLATION	A transcriptome analysis compared gene expression in human bone biopsy samples taken from lumbar spine and iliac crest, sites that experience high and low levels of mechanical stress, respectively. The analysis revealed that the zinc finger protein of cerebellum (Zic) family member transcription factor Zic1 was the most up-regulated gene in the lumbar spine (202-fold; P<10(-7)) in comparison with the iliac crest. Software analysis of differential gene expression in the biopsy samples identified the ciliary-related proteins PATCH1 and GLI-Kruppel family members Gli1 and Gli3 as part of a potential molecular network associated with Zic1. RT-PCR confirmed the expression of Zic1, Gli1, and Gli3 and other related key signaling mediators in osteoblastic cells and osteocytes in vitro. Zic1 was immunolocalized in the cytosol and nucleus of the murine osteocyte cell line MLO-Y4 and osteoblast-like cells MC3T3-E1 and in primary rat osteoblasts. MLO-Y4 cells subjected to prolonged oscillatory fluid flow showed increased localization of Zic1 in the nucleus with diminished levels in the cytosol, but no such changes were seen in MC3T3-E1 cells. A shear stress-induced increase in T-cell factor/lymphoid enhancer factor transcriptional activity was abolished by Zic1 gene silencing. These results suggest that Zic1, perhaps together with Gli1 and Gli3, may act as a link between mechanosensing and Wnt signaling. We conclude that Zic1, a neural developmental transcription factor, plays an important role in shear flow mechanotransduction in osteocytes.-Kalogeropoulos, M., Varanasi, S. S., Olstad, O. K., Sanderson, P., Gautvik, V. T., Reppe, S., Francis, R. M., Gautvik, K. M., Birch, M. A., Datta, H. K. Zic1 transcription factor in bone: neural developmental protein regulates mechanotransduction in osteocytes. FASEB J. 24, 2893-2903 (2010). www.fasebj.org	[Kalogeropoulos, Michail; Varanasi, Satya S.; Birch, Mark A.; Datta, Harish K.] Newcastle Univ, Sch Med, ICM, Musculoskeletal Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Francis, Roger M.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Olstad, Ole K.; Gautvik, Kaare M.] Oslo Univ Hosp, Dept Clin Chem, Oslo, Norway; [Sanderson, Paul] Newcastle Upon Tyne NHS Fdn Trust Hosp, Dept Orthopaed Surg, Newcastle Upon Tyne, Tyne & Wear, England; [Gautvik, Vigdis T.; Reppe, Sjur; Gautvik, Kaare M.] Lovisenberg Deacon Hosp, Dept Clin Chem, Oslo, Norway; [Gautvik, Kaare M.] Univ Oslo, Inst Basic Med Sci, Oslo, Norway	Newcastle University - UK; Newcastle University - UK; University of Oslo; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Oslo	Datta, HK (corresponding author), Newcastle Univ, Sch Med, ICM, Musculoskeletal Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	h.k.datta@ncl.ac.uk	Datta, Harish/AAN-5621-2020		European Union [FP6-502491]; Newcastle University	European Union(European Commission); Newcastle University	The authors are grateful to the participants who volunteered for the study, and gratefully acknowledge the contribution of the nursing and theater staff of Newcastle General and Freeman Hospitals. H.K.D. thanks Professor Lynda Bonewald (University of Missouri-Kansas Ciy, Kansas City, MO, USA) for the gift of MLO-Y4 cells. The work was supported by a grant from the European Union, project OSTEOGENE (FP6-502491) under FP6 (K.M.G. and H.K.D.), and from Newcastle University (H.K.D. and M.B.).	Al-oanzi ZH, 2006, CLIN CHEM, V52, P248, DOI 10.1373/clinchem.2005.059568; Aruga J, 1998, J NEUROSCI, V18, P284; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Aruga J, 2004, MOL CELL NEUROSCI, V26, P205, DOI 10.1016/j.mcn.2004.01.004; Bonewald L., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P331; Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224; Bonewald Lynda F, 2006, Bonekey Osteovision, V3, P7; Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; DATTA HK, 2009, 31 ANN M AM SOC BON; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Grinberg I, 2004, NAT GENET, V36, P1053, DOI 10.1038/ng1420; Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116; Inoue T, 2007, DEV BIOL, V306, P669, DOI 10.1016/j.ydbio.2007.04.003; Kamel MA, 2006, J BONE MINER RES, V21, pS92; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; Koyama E, 2007, DEVELOPMENT, V134, P2159, DOI 10.1242/dev.001586; Kraiss LW, 2000, AM J PHYSIOL-HEART C, V278, pH1537, DOI 10.1152/ajpheart.2000.278.5.H1537; LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415; Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104; Mannion AF, 2000, SPINE, V25, P842, DOI 10.1097/00007632-200004010-00013; Merzdorf CS, 2006, INT J DEV BIOL, V50, P611, DOI 10.1387/ijdb.052110cm; Noble BS, 2008, ARCH BIOCHEM BIOPHYS, V473, P106, DOI 10.1016/j.abb.2008.04.009; Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Reppe S, 2007, AM J PHYSIOL-ENDOC M, V292, pE1465, DOI 10.1152/ajpendo.00487.2006; Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; SKERRY TM, 1989, J BONE MINER RES, V4, P783, DOI 10.1002/jbmr.5650040519; Sprowson AP, 2008, J ORTHOP RES, V26, P1256, DOI 10.1002/jor.20606; Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001; Taylor AF, 2007, AM J PHYSIOL-CELL PH, V292, pC545, DOI 10.1152/ajpcell.00611.2005; Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064; Vezeridis PS, 2006, BIOCHEM BIOPH RES CO, V348, P1082, DOI 10.1016/j.bbrc.2006.07.146; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Xiao ZS, 2008, J BIOL CHEM, V283, P12624, DOI 10.1074/jbc.M710407200; Xiao ZS, 2006, J BIOL CHEM, V281, P30884, DOI 10.1074/jbc.M604772200; Yang WC, 2005, J BIOL CHEM, V280, P20680, DOI 10.1074/jbc.M500104200; Yang WC, 2009, BONE, V44, P32, DOI 10.1016/j.bone.2008.08.133; You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047; Zhang KQ, 2006, MOL CELL BIOL, V26, P4539, DOI 10.1128/MCB.02120-05; Zhang QH, 2003, DEV DYNAM, V227, P78, DOI 10.1002/dvdy.10289; Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068; SKELETAL SITE RELATE	49	32	33	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2893	2903		10.1096/fj.09-148908	http://dx.doi.org/10.1096/fj.09-148908			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20354137				2022-12-28	WOS:000285005400029
J	Regner, KR; Nozu, K; Lanier, SM; Blumer, JB; Avner, ED; Sweeney, WE; Park, F				Regner, Kevin R.; Nozu, Kandai; Lanier, Stephen M.; Blumer, Joe B.; Avner, Ellis D.; Sweeney, William E., Jr.; Park, Frank			Loss of activator of G-protein signaling 3 impairs renal tubular regeneration following acute kidney injury in rodents	FASEB JOURNAL			English	Article						accessory proteins; renal epithelial cells; signal transduction	RECEPTOR-INDEPENDENT ACTIVATORS; GUANINE-NUCLEOTIDE EXCHANGE; ADENYLYL-CYCLASE; EPITHELIAL-CELLS; BETA-GAMMA; ISCHEMIA-REPERFUSION; POSTISCHEMIC KIDNEY; AGS3; BINDING; FAILURE	The intracellular mechanisms underlying renal tubular epithelial cell proliferation and tubular repair following ischemia-reperfusion injury (IRI) remain poorly understood. In this report, we demonstrate that activator of G-protein signaling 3 (AGS3), an unconventional receptor-independent regulator of heterotrimeric G-protein function, influences renal tubular regeneration following IRI. In rat kidneys exposed to IRI, there was a temporal induction in renal AGS3 protein expression that peaked 72 h after reperfusion and corresponded to the repair and recovery phase following ischemic injury. Renal AGS3 expression was localized predominantly to the recovering outer medullary proximal tubular cells and was highly coexpressed with Ki-67, a marker of cell proliferation. Kidneys from mice deficient in the expression of AGS3 exhibited impaired renal tubular recovery 7 d following IRI compared to wild-type AGS3-expressing mice. Mechanistically, genetic knockdown of endogenous AGS3 mRNA and protein in renal tubular epithelial cells reduced cell proliferation in vitro. Similar reductions in renal tubular epithelial cell proliferation were observed following incubation with gallein, a selective inhibitor of G beta gamma subunit activity, and lentiviral overexpression of the carboxyl-terminus of G-protein-coupled receptor kinase 2 (GRK2ct), a scavenger of G beta gamma subunits. In summary, these data suggest that AGS3 acts through a novel receptor-independent mechanism to facilitate renal tubular epithelial cell proliferation and renal tubular regeneration.-Regner, K. R., Nozu, K., Lanier, S. M., Blumer, J. B., Avner, E. D., Sweeney, Jr., W. E., Park, F. Loss of activator of G-protein signaling 3 impairs renal tubular regeneration following acute kidney injury in rodents. FASEB J. 25, 1844-1855 (2011). www.fasebj.org	[Park, Frank] Med Coll Wisconsin, Dept Med, Kidney Dis Ctr, Div Nephrol, Milwaukee, WI 53226 USA; [Nozu, Kandai; Avner, Ellis D.; Sweeney, William E., Jr.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Avner, Ellis D.; Park, Frank] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; [Lanier, Stephen M.; Blumer, Joe B.] Med Univ S Carolina, Dept Pharmacol & Expt Therapeut, Charleston, SC 29425 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical University of South Carolina	Park, F (corresponding author), Med Coll Wisconsin, Dept Med, Kidney Dis Ctr, Div Nephrol, 8701 Watertown Plank Rd,HRC 4100, Milwaukee, WI 53226 USA.	fpark@mcw.edu	Nozu, Kandai/Q-9383-2019; Regner, Kevin/AAQ-1073-2020; Park, Frank/I-4590-2019	Park, Frank/0000-0003-2324-2937; Lanier, Stephen/0000-0002-2740-7607; Blumer, Joe/0000-0002-0020-3815	U.S. National Institutes of Health [P50DK079306, NS24821, DA025896, GM086510]; Advancing a Healthier Wisconsin; PKD Foundation; Clinical Translational Science Institute; Research Affairs Committee; Medical College of Wisconsin; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK079306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086510] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH065092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA025896] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Advancing a Healthier Wisconsin; PKD Foundation; Clinical Translational Science Institute; Research Affairs Committee; Medical College of Wisconsin(General Electric); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Dr. J. L. Benovic (Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA) for the pcDNA3-GRK2ct plasmid, Ms. Christine Naughton for her help with the immunohistochemistry, Mr. G. Jia for his expertise in generating the lentiviral vectors, Ms. M. Kwon for her molecular biological expertise, Ms. S. White for her technical assistance with the rodent surgeries, and Mr. N. Kampa for his help with the maintenance of the AGS3 mice. This work was supported, in part, by departmental funding (F.P., K.R.R.); U.S. National Institutes of Health grants P50DK079306 (E.D.A.), NS24821 (S.M.L.), DA025896 (S.M.L.), and GM086510 (J.B.B.); Advancing a Healthier Wisconsin (F.P.); the PKD Foundation (F.P.); and the Clinical Translational Science Institute (K.R.R.) and Research Affairs Committee (K.R.R.) at the Medical College of Wisconsin.	Adhikari A, 2003, J BIOL CHEM, V278, P51825, DOI 10.1074/jbc.M306300200; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Blumer JB, 2005, TRENDS PHARMACOL SCI, V26, P470, DOI 10.1016/j.tips.2005.07.003; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Blumer JB, 2008, ENDOCRINOLOGY, V149, P3842, DOI 10.1210/en.2008-0050; Blumer JB, 2007, PHARMACOL THERAPEUT, V113, P488, DOI 10.1016/j.pharmthera.2006.11.001; Bonventre JV, 2003, J AM SOC NEPHROL, V14, pS55, DOI 10.1097/01.ASN.0000067652.51441.21; Bonventre JV, 2003, J AM SOC NEPHROL, V14, P2199, DOI 10.1097/01.ASN.0000079785.13922.F6; Bowers MS, 2008, P NATL ACAD SCI USA, V105, P12533, DOI 10.1073/pnas.0706999105; Bowers MS, 2004, NEURON, V42, P269, DOI 10.1016/S0896-6273(04)00159-X; Calvet JP, 2008, CLIN J AM SOC NEPHRO, V3, P1205, DOI 10.2215/CJN.05651207; Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; De Deyn PP, 2001, KIDNEY INT, V59, pS77, DOI 10.1046/j.1523-1755.2001.59780077.x; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Devarajan P, 2006, J AM SOC NEPHROL, V17, P1503, DOI 10.1681/ASN.2006010017; Duffield JS, 2005, J CLIN INVEST, V115, P1743, DOI 10.1172/JCI22593; Fan PD, 2009, MOL PHARMACOL, V76, P526, DOI 10.1124/mol.109.057802; Humphreys BD, 2008, CELL STEM CELL, V2, P284, DOI 10.1016/j.stem.2008.01.014; KATSETOS CD, 1994, ARCH PATHOL LAB MED, V118, P633; Kim J, 2010, AM J PHYSIOL-RENAL, V298, pF1118, DOI 10.1152/ajprenal.00701.2009; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kroeze WK, 2003, J CELL SCI, V116, P4867, DOI 10.1242/jcs.00902; Lameire N, 2006, NAT CLIN PRACT NEPHR, V2, P364, DOI 10.1038/ncpneph0218; Liang HL, 2009, AM J PHYSIOL-RENAL, V296, pF266, DOI 10.1152/ajprenal.90533.2008; Nadella R, 2010, J AM SOC NEPHROL, V21, P1275, DOI 10.1681/ASN.2009121224; Nony PA, 2003, J PHARMACOL EXP THER, V304, P905, DOI 10.1124/jpet.102.035022; Oner SS, 2010, J BIOL CHEM, V285, P33949, DOI 10.1074/jbc.M110.138073; Oner SS, 2010, J BIOL CHEM, V285, P20588, DOI 10.1074/jbc.C109.088070; Park F, 2000, NAT GENET, V24, P49, DOI 10.1038/71673; Park F, 2009, AM J PHYSIOL-RENAL, V296, pF575, DOI 10.1152/ajprenal.90705.2008; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Qian Z, 2006, MOL THER, V13, P694, DOI 10.1016/j.ymthe.2005.11.016; Regner KR, 2009, KIDNEY INT, V75, P511, DOI 10.1038/ki.2008.600; Sanada K, 2005, CELL, V122, P119, DOI 10.1016/j.cell.2005.05.009; Sato M, 2004, J BIOL CHEM, V279, P13375, DOI 10.1074/jbc.M312660200; Sato Motohiko, 2010, Pathophysiology, V17, P89, DOI 10.1016/j.pathophys.2009.03.011; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SILVA FG, 1993, ARCH PATHOL LAB MED, V117, P1233; Sweeney WE, 2003, KIDNEY INT, V64, P1310, DOI 10.1046/j.1523-1755.2003.00232.x; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tall GG, 2005, P NATL ACAD SCI USA, V102, P16584, DOI 10.1073/pnas.0508306102; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; Thomas CJ, 2008, J BIOL CHEM, V283, P23150, DOI 10.1074/jbc.M802422200; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; WATANABE M, 1981, J HISTOCHEM CYTOCHEM, V29, P779, DOI 10.1177/29.7.7053086; Westhoff JH, 2010, J AM SOC NEPHROL, V21, P327, DOI 10.1681/ASN.2009010072; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214	52	30	30	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1844	1855		10.1096/fj.10-169797	http://dx.doi.org/10.1096/fj.10-169797			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21343176	Green Published			2022-12-28	WOS:000291023800008
J	Carracedo, J; Merino, A; Briceno, C; Soriano, S; Buendia, P; Calleros, L; Rodriguez, M; Martin-Malo, A; Aljama, P; Ramirez, R				Carracedo, Julia; Merino, Ana; Briceno, Carolina; Soriano, Sagrario; Buendia, Paula; Calleros, Laura; Rodriguez, Mariano; Martin-Malo, Alejandro; Aljama, Pedro; Ramirez, Rafael			Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells	FASEB JOURNAL			English	Article						chronic kidney disease; genomic damage; premature cellular senescence; angiogenesis; atherosclerotic disease	TELOMERE; MICROINFLAMMATION; ATHEROSCLEROSIS; INFLAMMATION; MITOCHONDRIA; PROTEIN; REPAIR; UREMIA; DAMAGE; DEATH	Carbamylated low-density lipoprotein (cLDL) plays a role in atherosclerosis. In this study we evaluate the effect of uremia on LDL carbamylation and the effect of cLDL and oxidized LDL (oxLDL; 200 mu g/ml) on number, function, and genomic stability of endothelial progenitor cells (EPCs) obtained from healthy volunteers. cLDL was generated after incubation of native LDL (nLDL) with uremic serum from patients with chronic kidney disease (CKD) stages 2-4. Oxidative stress was measured by flow cytometry and fluorescent microscopy, mitochondrial depolarization by flow cytometry, senescence by beta-galactosidase activity and telomere length, and DNA damage by phosphorylated histone H2AX (gamma H2AX). The percentage of cLDL by uremic serum was related to the severity of CKD. Compared with nLDL, cLDL induced an increase in oxidative stress (62 +/- 5 vs. 8 +/- 3%, P<0.001) and cells with mitochondrial depolarization (73 +/- 7 vs. 9 +/- 5%, P<0.001), and a decrease in EPC proliferation and angiogenesis. cLDL also induced accelerated senescence (73 +/- 16 vs. 12 +/- 9%, P<0.001), which was associated with a decrease in the expression of gamma H2AX (62 +/- 9 vs. 5 +/- 3%, P<0.001). The degree of injury induced by cLDL was comparable to that observed with oxLDL. This study supports the hypothesis that cLDL triggers genomic damage in EPCs, resulting in premature senescence. We can, therefore, hypothesize that EPCs injury by cLDL contributes to an increase in atherosclerotic disease in CKD.-Carracedo, J., Merino, A., Briceno, C., Soriano, S., Buendia, P., Calleros, L., Rodriguez, M., Martin-Malo, A., Aljama, P., Ramirez, R. Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J. 25, 1314-1322 (2011). www.fasebj.org	[Carracedo, Julia; Merino, Ana; Briceno, Carolina; Buendia, Paula; Rodriguez, Mariano; Aljama, Pedro; Ramirez, Rafael] Hosp Univ Reina Sofia, Unidad Invest, Inst Maimonides Invest Biomed Cordoba, Fdn Invest Biomed Cordoba, Cordoba 14004, Spain; [Soriano, Sagrario; Rodriguez, Mariano; Martin-Malo, Alejandro; Aljama, Pedro] Reina Sofia Univ Hosp, Nephrol Unit, Cordoba, Spain; [Carracedo, Julia; Merino, Ana; Briceno, Carolina; Soriano, Sagrario; Buendia, Paula; Calleros, Laura; Rodriguez, Mariano; Martin-Malo, Alejandro; Aljama, Pedro; Ramirez, Rafael] Inst Salud Carlos III, Madrid, Spain; [Calleros, Laura] Univ Alcala de Henares, Dept Fisiol, Madrid, Spain	Hospital Universitario Reina Sofia - Cordoba; Hospital Universitario Reina Sofia - Cordoba; Instituto de Salud Carlos III; Universidad de Alcala	Ramirez, R (corresponding author), Hosp Univ Reina Sofia, Unidad Invest, Inst Maimonides Invest Biomed Cordoba, Fdn Invest Biomed Cordoba, Avda Menendez Pidal S-N, Cordoba 14004, Spain.	manuelr.ramirez.sspa@juntadeandalucia.es	Ramirez, Rafael/B-3249-2019; Carracedo, Julia/ABG-2464-2020; Carracedo, Julia/L-2012-2015; Rodriguez, teresa/H-5452-2011; Merino, Ana/L-8347-2017; Calleros, Laura/L-3122-2015	Carracedo, Julia/0000-0002-8422-812X; Carracedo, Julia/0000-0002-8422-812X; Calleros, Laura/0000-0001-7739-1319; Rafael, Ramirez/0000-0003-4598-339X; Rodriguez, Mariano/0000-0002-9380-6614	Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III [FIS PI06/0724, PI06/0747, PI07/0204, PI08/1038, PS09/00836, RD06/0016/0007]; Junta de Andalucia [PI-JA0235/2009, PI-JA0227/2009, P06-CVI-02172, P08-CTS-3797]; Fundacion Nefrologica; Fundacion de Investigaciones Biomedicas de Cordoba (FIBICO);  [I3SNS]	Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III(Instituto de Salud Carlos III); Junta de Andalucia(Junta de Andalucia); Fundacion Nefrologica; Fundacion de Investigaciones Biomedicas de Cordoba (FIBICO); 	The authors are grateful to M. J. Jimenez and M. J. Montenegro for technical assistance. This work was supported by grants from Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III (FIS PI06/0724, PI06/0747, PI07/0204, PI08/1038, PS09/00836, RETICs Red Renal RD06/0016/0007), Junta de Andalucia (PI-JA0235/2009, PI-JA0227/2009, P06-CVI-02172, P08-CTS-3797), and Fundacion Nefrologica. J. C. was supported by a contract from Fundacion de Investigaciones Biomedicas de Cordoba (FIBICO; Programa I3SNS, Linea de estabilizacion de investigadores del Instituto de Salud Carlos III/Fundacion Progreso y Salud).	Apostolov EO, 2009, ARTERIOSCL THROM VAS, V29, P1622, DOI 10.1161/ATVBAHA.109.189795; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; de Groot K, 2004, KIDNEY INT, V66, P641, DOI 10.1111/j.1523-1755.2004.00784.x; Dernbach E, 2004, BLOOD, V104, P3591, DOI 10.1182/blood-2003-12-4103; Erusalimsky JD, 2009, J APPL PHYSIOL, V106, P326, DOI 10.1152/japplphysiol.91353.2008; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Giannotti G, 2010, HYPERTENSION, V55, P1389, DOI 10.1161/HYPERTENSIONAHA.109.141614; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; HORKKO S, 1992, KIDNEY INT, V41, P1175, DOI 10.1038/ki.1992.179; Ishigaki Y, 2009, CURR OPIN LIPIDOL, V20, P363, DOI 10.1097/MOL.0b013e32832fa58d; Izuta H, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-45; Kakkar P, 2007, MOL CELL BIOCHEM, V305, P235, DOI 10.1007/s11010-007-9520-8; Kipling D, 1999, NAT BIOTECHNOL, V17, P313, DOI 10.1038/7827; Krenning G, 2009, TRENDS MOL MED, V15, P180, DOI 10.1016/j.molmed.2009.02.001; KUZUYA M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P198; Merino A, 2008, CONTRIB NEPHROL, V161, P83, DOI 10.1159/000130412; Minamino T, 2002, CIRCULATION, V105, P1541, DOI 10.1161/01.CIR.0000013836.85741.17; Ok E, 2005, KIDNEY INT, V68, P173, DOI 10.1111/j.1523-1755.2005.00391.x; Ramirez R, 2007, KIDNEY INT, V72, P108, DOI 10.1038/sj.ki.5002250; Ramirez R, 2009, J MOL CELL CARDIOL, V47, P781, DOI 10.1016/j.yjmcc.2009.09.005; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Satoh M, 2009, CLIN SCI, V116, P827, DOI 10.1042/CS20080404; Thukkani AK, 2003, J BIOL CHEM, V278, P36365, DOI 10.1074/jbc.M305449200; Tousoulis D, 2008, ATHEROSCLEROSIS, V201, P236, DOI 10.1016/j.atherosclerosis.2008.05.034; Trepanier DJ, 1996, CLIN BIOCHEM, V29, P347, DOI 10.1016/0009-9120(96)00038-0; Verma S, 2004, CIRCULATION, V109, P2058, DOI 10.1161/01.CIR.0000127577.63323.24; Wang Z, 2007, NAT MED, V13, P1176, DOI 10.1038/nm1637; Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081	30	74	80	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1314	1322		10.1096/fj.10-173377	http://dx.doi.org/10.1096/fj.10-173377			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21228221				2022-12-28	WOS:000288982800020
J	Ivanova, MM; Luken, KH; Zimmer, AS; Lenzo, FL; Smith, RJ; Arteel, MW; Kollenberg, TJ; Mattingly, KA; Klinge, CM				Ivanova, Margarita M.; Luken, Kristen H.; Zimmer, Amber S.; Lenzo, Felicia L.; Smith, Ryan J.; Arteel, Maia W.; Kollenberg, Tara J.; Mattingly, Kathleen A.; Klinge, Carolyn M.			Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites	FASEB JOURNAL			English	Article						breast cancer; estradiol ER alpha; PGC-1 alpha; Tfam; RNA polymerase; apoptosis	CONTROLLING MITOCHONDRIAL BIOGENESIS; GROWTH-FACTOR; ER-ALPHA; FACTOR-I; RESPONSE ELEMENTS; DISTINCT CLASSES; GENE-EXPRESSION; BREAST; CANCER; MECHANISMS	Little is known about endogenous estrogen receptor beta (ER beta) gene targets in human breast cancer. We reported that estradiol (E-2) induces nuclear respiratory factor-1 (NRF-1) transcription through ER alpha in MCF-7 breast cancer cells. Here we report that 4-hydroxytamoxifen (4-OHT), with an EC50 of similar to 1.7 nM, increases NRF-1 expression by recruiting ER beta, cJun, cFos, CBP, and RNA polymerase II to and dismissing NCoR from the NRF1 promoter. Promoter deletion and transient transfection studies showed that the estrogen response element (ERE) is essential and that an adjacent AP-1 site contributes to maximal 4-OHT-induced NRF-1 transcription. siRNA knockdown of ER beta revealed that ER beta inhibits basal NRF-1 expression and is required for 4-OHT-induced NRF-1 transcription. An AP-1 inhibitor blocked 4-OHT-induced NRF-1 expression. The 4-OHT-induced increase in NRF-1 resulted in increased transcription of NRF-1 target CAPNS1 but not CYC1, CYC2, or TFAM despite increased NRF-1 coactivator PGC-1 alpha protein. The absence of TFAM induction corresponds to a lack of Akt-dependent phosphorylation of NRF-1 with 4-OHT treatment. Overexpression of NRF-1 inhibited 4-OHT-induced apoptosis and siRNA knockdown of NRF-1 increased apoptosis, indicating an antiapoptotic role for NRF-1. Overall, NRF-1 expression and activity is regulated by 4-OHT via endogenous ER beta in MCF-7 cells.-Ivanova, M. M., Luken, K. H., Zimmer, A. S., Lenzo, F. L., Smith, R. J., Arteel, M. W., Kollenberg, T. J., Mattingly, K. A., Klinge, C. M. Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites. FASEB J. 25, 1402-1416 (2011). www.fasebj.org	[Klinge, Carolyn M.] Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Ctr Genet & Mol Med, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Ctr Environm Genom & Integrat Biol, Louisville, KY 40292 USA	University of Louisville; University of Louisville	Klinge, CM (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Ctr Genet & Mol Med, Louisville, KY 40292 USA.	carolyn.klinge@louisville.edu	Ivanova, Margarita/AAM-4510-2021	Klinge, Carolyn/0000-0002-3358-4378; Ivanova, Margarita/0000-0002-6197-8606	U.S. National Institutes of Health (NIH) [R01 DK53220]; NIH [5T35 DK072923, 5P30ES014443]; American Recovery and Reinvestment Act supplement NIH [R01 DK53220-02S1]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053220, T35DK072923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES014443] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Recovery and Reinvestment Act supplement NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Dr. Richard C. Scarpulla (Northwestern University Medical School, Chicago, IL, USA) for providing the pSG5NRF-1, Sumata Bhamani for her participation in H1793 experiments, and Dr. Barbara J. Clark for her suggestions to improve this manuscript. This work was supported by U.S. National Institutes of Health (NIH) grant R01 DK53220 to C.M.K. A.S.Z. and R.J.S. were supported by NIH grant 5T35 DK072923. F.L.L. and T.J.K. were supported by American Recovery and Reinvestment Act supplement NIH R01 DK53220-02S1 to C.M.K. The DNA core for the Center for Environmental Genomics and Integrative Biology is supported by NIH grant 5P30ES014443.	Asangani IA, 2008, GENE, V410, P197, DOI 10.1016/j.gene.2007.12.009; Baron S, 2007, J BIOL CHEM, V282, P11732, DOI 10.1074/jbc.M610079200; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Bourdoncle A, 2005, J MOL BIOL, V347, P921, DOI 10.1016/j.jmb.2005.01.048; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; Bruni F, 2010, J BIOL CHEM, V285, P3939, DOI 10.1074/jbc.M109.044305; Buck MB, 2004, MOL ENDOCRINOL, V18, P1643, DOI 10.1210/me.2003-0278; Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Charn TH, 2010, MOL ENDOCRINOL, V24, P47, DOI 10.1210/me.2009-0252; Cheung E, 2005, P NATL ACAD SCI USA, V102, P559, DOI 10.1073/pnas.0407113102; Choi YS, 2004, ANN NY ACAD SCI, V1011, P69, DOI 10.1196/annals.1293.008; Covaleda AMS, 2008, TOXICOL SCI, V105, P303, DOI 10.1093/toxsci/kfn141; Delaunay F, 2000, MOL PHARMACOL, V58, P584, DOI 10.1124/mol.58.3.584; Duong V, 2006, ONCOGENE, V25, P1799, DOI 10.1038/sj.onc.1209102; DuSell CD, 2010, MOL ENDOCRINOL, V24, P33, DOI 10.1210/me.2009-0339; Felty Q, 2005, BIOCHEMISTRY-US, V44, P6900, DOI 10.1021/bi047629p; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; Flageng MH, 2009, BRIT J CANCER, V101, P1253, DOI 10.1038/sj.bjc.6605324; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Hodges-Gallagher L, 2008, BREAST CANCER RES TR, V109, P241, DOI 10.1007/s10549-007-9640-6; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Jayachandran M, 2010, AGE, V32, P109, DOI 10.1007/s11357-009-9119-y; Jordan VC, 2009, CANCER RES, V69, P1243, DOI 10.1158/0008-5472.CAN-09-0029; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kininis M, 2007, MOL CELL BIOL, V27, P5090, DOI 10.1128/MCB.00083-07; Kisanga ER, 2004, CLIN CANCER RES, V10, P2336, DOI 10.1158/1078-0432.CCR-03-0538; Klinge CM, 1999, MOL CELL ENDOCRINOL, V150, P99, DOI 10.1016/S0303-7207(99)00019-2; KLINGE CM, 1992, CANCER RES, V52, P1073; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kulakosky PC, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290137; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Levy N, 2010, MOL CELL ENDOCRINOL, V315, P201, DOI 10.1016/j.mce.2009.08.030; Lewis JS, 2005, MUTAT RES-FUND MOL M, V591, P247, DOI 10.1016/j.mrfmmm.2005.02.028; Li JJ, 1997, CANCER RES, V57, P3569; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Liu Y, 2008, P NATL ACAD SCI USA, V105, P2604, DOI 10.1073/pnas.0712085105; Liu ZW, 2008, TOXICOL APPL PHARM, V228, P286, DOI 10.1016/j.taap.2007.12.017; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Mattingly KA, 2008, MOL ENDOCRINOL, V22, P609, DOI 10.1210/me.2007-0029; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mohamood AS, 1997, J SUBMICR CYTOL PATH, V29, P1; Monroe DG, 2002, MOL ENDOCRINOL, V16, P1322, DOI 10.1210/me.16.6.1322; Nehra R, 2010, FASEB J, V24, P2040, DOI 10.1096/fj.09-138305; O'Lone R, 2007, MOL ENDOCRINOL, V21, P1281, DOI 10.1210/me.2006-0497; O'Malley BW, 2009, MOL ENDOCRINOL, V23, P587, DOI 10.1210/me.2009-0015; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Peekhaus NT, 2004, J MOL ENDOCRINOL, V32, P987, DOI 10.1677/jme.0.0320987; Perumal SS, 2005, CANCER CHEMOTH PHARM, V56, P105, DOI 10.1007/s00280-004-0943-6; Piantadosi CA, 2006, J BIOL CHEM, V281, P324, DOI 10.1074/jbc.M508805200; Picard N, 2008, MOL ENDOCRINOL, V22, P317, DOI 10.1210/me.2007-0281; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103; Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006; Shah YM, 2005, MOL ENDOCRINOL, V19, P732, DOI 10.1210/me.2004-0298; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sripathy SP, 2008, ONCOGENE, V27, P6376, DOI 10.1038/onc.2008.235; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Uht Rosalie M, 2004, Nucl Recept, V2, P2, DOI 10.1186/1478-1336-2-2; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Vivar OI, 2010, J BIOL CHEM, V285, P22059, DOI 10.1074/jbc.M110.114116; Vladusic EA, 2000, ONCOL REP, V7, P157; Welboren WJ, 2009, ENDOCR-RELAT CANCER, V16, P1073, DOI 10.1677/ERC-09-0086; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yoo YA, 2008, BBA-MOL CELL RES, V1783, P438, DOI 10.1016/j.bbamcr.2007.12.001; Zhao CY, 2007, CANCER RES, V67, P3955, DOI 10.1158/0008-5472.CAN-06-3505; Zhao CY, 2010, J BIOL CHEM, V285, P39575, DOI 10.1074/jbc.R110.180109	72	24	26	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1402	1416		10.1096/fj.10-169029	http://dx.doi.org/10.1096/fj.10-169029			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21233487	Green Published			2022-12-28	WOS:000288982800029
J	Sung, CK; Dahl, J; Yim, H; Rodig, S; Benjamin, TL				Sung, Chang K.; Dahl, Jean; Yim, Hyungshin; Rodig, Scott; Benjamin, Thomas L.			Transcriptional and post-translational regulation of the quiescence factor and putative tumor suppressor p150(Sal2)	FASEB JOURNAL			English	Article						TGF beta, AP4; ubiquitination; E3 ligase; polyoma	TOWNES-BROCKS-SYNDROME; EMBRYONIC STEM-CELLS; TISSUE GROWTH-FACTOR; RADIAL RAY SYNDROME; E3 LIGASE COMPLEX; OKIHIRO-SYNDROME; DROSOPHILA EMBRYO; UBIQUITIN LIGASES; POLYOMA-VIRUS; HOMEOTIC GENE	The evolutionarily conserved SALL genes encode transcription factors with roles in embryonic development. The product of the SALL2 gene was first identified as a binding partner of the mouse polyoma virus large T antigen and later shown to possess tumor suppressor-like functions. Independent studies identified SALL2 as a factor regulating the quiescent state in human fibroblasts. Here, we investigate factors that regulate the expression of SALL2 and turnover of p150(Sal2) in growing vs. resting cells. The transcription factor AP4 increases along with SALL2 in quiescent cells and positively regulates SALL2 expression. TGF beta effectively inhibits expression of SALL2 and its regulator AP4 when added to quiescent fibroblasts. TGF beta repression of SALL2 and AP4 is independent of the induction of connective tissue growth factor (CTGF) by TGF beta. p150(Sal2) disappears rapidly on restoration of serum. In both growing fibroblasts and established ovarian surface epithelial cells, p150(Sal2) undergoes polyubiquitination and proteosomal degradation. A CUL4/DDB1 E3 ligase containing RBBP7 as the p150(Sal2) receptor has been identified as mediating the destruction of p150(Sal2) as cells transition from a quiescent to an actively growing state.-Sung, C. K., Dahl, J., Yim, H., Rodig, S., Benjamin, T. L. Transcriptional and post-translational regulation of the quiescence factor and putative tumor suppressor p150(Sal2). FASEB J. 25, 1275-1283 (2011). www.fasebj.org	[Sung, Chang K.; Dahl, Jean; Yim, Hyungshin; Benjamin, Thomas L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Rodig, Scott] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Benjamin, TL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Pathol NRB-939,77th Ave Louis Pasteur, Boston, MA 02115 USA.	thomas_benjamin@hms.harvard.edu	Rodig, Scott/Y-3889-2019		National Cancer Institute [RO1-CA 92520]; NATIONAL CANCER INSTITUTE [R01CA092520] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by U.S. Public Health Service grant RO1-CA 92520 from the National Cancer Institute. The authors kindly thank Dr. J. Wade Harper (Harvard Medical School, Boston, MA, USA) for the DN-Cul3, DN-Cul4B, pEBB-Ub, myc-CUL4A, and myc-CUL4B constructs.	Al-Baradie R, 2002, AM J HUM GENET, V71, P1195, DOI 10.1086/343821; Bard JD, 2009, FASEB J, V23, P1405, DOI 10.1096/fj.08-117721; Benjamin TL, 2001, VIROLOGY, V289, P167, DOI 10.1006/viro.2001.1124; Bohm J, 2008, AM J PATHOL, V173, P1455, DOI 10.2353/ajpath.2008.071039; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Clauss A, 2010, NEOPLASIA, V12, P161, DOI 10.1593/neo.91542; de Celis JF, 1999, DEVELOPMENT, V126, P2653; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Drapkin R, 2005, CANCER RES, V65, P2162, DOI 10.1158/0008-5472.CAN-04-3924; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; He YZJ, 2006, GENE DEV, V20, P2949, DOI 10.1101/gad.1483206; Hu J, 2008, GENE DEV, V22, P866, DOI 10.1101/gad.1624008; Huang J, 2008, ONCOGENE, V27, P4056, DOI 10.1038/onc.2008.44; Jackson S, 2009, TRENDS BIOCHEM SCI, V34, P562, DOI 10.1016/j.tibs.2009.07.002; Jung P, 2009, CELL CYCLE, V8, P982, DOI 10.4161/cc.8.7.7949; Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105; JURGENS G, 1988, EMBO J, V7, P189, DOI 10.1002/j.1460-2075.1988.tb02799.x; Kiefer SM, 2003, HUM MOL GENET, V12, P2221, DOI 10.1093/hmg/ddg233; Kohlhase J, 2005, HUM MUTAT, V26, P176, DOI 10.1002/humu.20215; Kohlhase J, 1999, AM J HUM GENET, V64, P435, DOI 10.1086/302238; Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81; Kohlhase J, 1996, GENOMICS, V38, P291, DOI 10.1006/geno.1996.0631; Koster R, 1997, DEVELOPMENT, V124, P3147; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Leask A, 2009, J CELL COMMUN SIGNAL, V3, P89, DOI 10.1007/s12079-009-0037-7; Li DW, 2004, MOL CELL BIOL, V24, P3885, DOI 10.1128/MCB.24.9.3885-3893.2004; Li DW, 2001, P NATL ACAD SCI USA, V98, P14619, DOI 10.1073/pnas.251447198; Liu H, 2007, PLOS GENET, V3, P996, DOI 10.1371/journal.pgen.0030091; Ma YP, 2001, J BIOL CHEM, V276, P48223, DOI 10.1074/jbc.M106468200; Mason RM, 2009, J CELL COMMUN SIGNAL, V3, P95, DOI 10.1007/s12079-009-0038-6; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; MOSES HL, 1987, J CELL PHYSIOL, P1, DOI 10.1002/jcp.1041330403; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Murzina NV, 2008, STRUCTURE, V16, P1077, DOI 10.1016/j.str.2008.05.006; Nilsson Eric E, 2002, Reprod Biomed Online, V5, P254; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Pincheira R, 2009, EMBO J, V28, P261, DOI 10.1038/emboj.2008.274; Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Sweetman D, 2006, DEV BIOL, V293, P285, DOI 10.1016/j.ydbio.2006.02.009; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326; Yang JC, 2008, P NATL ACAD SCI USA, V105, P19756, DOI 10.1073/pnas.0809321105; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhou Q, 2007, P NATL ACAD SCI USA, V104, P16438, DOI 10.1073/pnas.0701014104; Zou YX, 2009, J BIOL CHEM, V284, P33320, DOI 10.1074/jbc.M109.050427	51	16	17	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2011	25	4					1275	1283		10.1096/fj.10-173674	http://dx.doi.org/10.1096/fj.10-173674			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21228219	Green Published			2022-12-28	WOS:000288982800016
J	D'Addario, C; Johansson, S; Candeletti, S; Romualdi, P; Ogren, SO; Terenius, L; Ekstrom, TJ				D'Addario, Claudio; Johansson, Sofia; Candeletti, Sanzio; Romualdi, Patrizia; Ogren, Sven Ove; Terenius, Lars; Ekstrom, Tomas J.			Ethanol and acetaldehyde exposure induces specific epigenetic modifications in the prodynorphin gene promoter in a human neuroblastoma cell line	FASEB JOURNAL			English	Article						chromatin modification; DNA methylation; SH-SY5Y cells	HISTONE H3; DNA HYPERMETHYLATION; DOWN-REGULATION; METHYLATION; CHROMATIN; ALCOHOL; EXPRESSION; BINDING; QUANTIFICATION; PLURIPOTENT	Ethanol alters neural activity through interaction with multiple neurotransmitters and neuro-modulators. The endogenous opioid system seems to play a key role, since the opioid receptor antagonist naltrexone (ReVia (R)) attenuates craving for alcohol. We recently reported that ethanol and acetaldehyde, the first product of ethanol metabolism, affect transcription of opioid system genes in human SH-SY5Y neuroblastoma cells. In the current study, potential epigenetic mechanisms were investigated to clarify these effects on prodynorphin gene expression. DNA methylation was analyzed by bisulfite pyrosequencing, and chromatin immunoprecipitation was used to assess putative specific histone modifications at the prodynorphin gene promoter. The results demonstrated a temporal relationship between selective chromatin modifications induced by ethanol and acetaldehyde and changes in prodynorphin gene expression quantitated by real-time qPCR. DNA methylation was not altered in any of the experimental conditions used. The epigenetic changes may precede gene transcription, and histone modifications might keep the prodynorphin gene in a poised state for later reactivation. A link has been observed between gene expression alterations and selective epigenetic modulation in the prodynorphin promoter region, demonstrating a specificity of the changes induced by ethanol and acetaldehyde. The latter may be mediating ethanol effects at the genomic level.-D'Addario, C., Johansson, S., Candeletti, S., Romualdi, P., Ogren, S. O., Terenius, L., Ekstrom, T. J. Ethanol and acetaldehyde exposure induces specific epigenetic modifications in the prodynorphin gene promoter in a human neuroblastoma cell line. FASEB J. 25, 1069-1075 (2011). www.fasebj.org	[D'Addario, Claudio; Candeletti, Sanzio; Romualdi, Patrizia] Univ Bologna, Dept Pharmacol, I-40125 Bologna, Italy; [D'Addario, Claudio; Johansson, Sofia; Terenius, Lars; Ekstrom, Tomas J.] Karolinska Univ Hosp, Dept Clin Neurosci, Stockholm, Sweden; [Ogren, Sven Ove] Karolinska Inst, Dept Neurosci, Stockholm, Sweden	University of Bologna; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	D'Addario, C (corresponding author), Univ Bologna, Dept Pharmacol, Via Irnerio 48, I-40125 Bologna, Italy.	claudio.daddario@unibo.it	Romualdi, Patrizia/AAR-7403-2021; Ekström, Tomas/B-7764-2013; DAddario, Claudio/A-5970-2010	Ogren, Sven Ove/0000-0003-2573-5276; Romualdi, Patrizia/0000-0002-3610-2928; d'addario, claudio/0000-0002-1275-098X	Alcohol Research Council of the Swedish Retailing Monopoly; Karolinska Institutet; Swedish Cancer Society; Swedish Labor Market Insurance (AFA); Swedish Science Research Council; University of Bologna [2007R93XF_004]	Alcohol Research Council of the Swedish Retailing Monopoly; Karolinska Institutet(Karolinska Institutet); Swedish Cancer Society(Swedish Cancer Society); Swedish Labor Market Insurance (AFA); Swedish Science Research Council; University of Bologna	This work was supported by grants from the Alcohol Research Council of the Swedish Retailing Monopoly, the Karolinska Institutet, the Swedish Cancer Society, the Swedish Labor Market Insurance (AFA), the Swedish Science Research Council, and the University of Bologna RFO 2008 and PRIN 2007 (2007R93XF_004). The authors declare no conflicts of interest.	Asher O, 2002, J PHARMACOL EXP THER, V301, P66, DOI 10.1124/jpet.301.1.66; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bleich S, 2006, ALCOHOL CLIN EXP RES, V30, P587, DOI 10.1111/j.1530-0277.2006.00068.x; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Bonsch D, 2005, NEUROREPORT, V16, P167; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Cowen M. S., 2006, CNS & Neurological Disorders-Drug Targets, V5, P233, DOI 10.2174/187152706776359646; D'Addario C, 2008, FASEB J, V22, P662, DOI 10.1096/fj.07-8346com; Dahl JA, 2007, STEM CELLS, V25, P1037, DOI 10.1634/stemcells.2006-0430; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Furuta T, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-39; GARRO AJ, 1991, ALCOHOL CLIN EXP RES, V15, P395, DOI 10.1111/j.1530-0277.1991.tb00536.x; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jope RS, 1998, J NEUROCHEM, V70, P763; Kim JS, 2006, ALCOHOL ALCOHOLISM, V41, P126, DOI 10.1093/alcalc/agh248; Koob GF, 1998, ALCOHOL CLIN EXP RES, V22, P3, DOI 10.1097/00000374-199802000-00001; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee TD, 2004, ALCOHOL CLIN EXP RES, V28, P173, DOI 10.1097/01.ALC.0000108654.77178.03; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo J, 1997, BRAIN RES, V770, P139, DOI 10.1016/S0006-8993(97)00762-2; Lyon E, 2001, CLIN CHEM, V47, P844; Maas JW, 2005, J NEUROSCI, V25, P4118, DOI 10.1523/JNEUROSCI.4273-04.2005; Mahadev K, 1998, NEUROCHEM RES, V23, P1179, DOI 10.1023/A:1020778018149; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Pal-Bhadra M, 2007, LIFE SCI, V81, P979, DOI 10.1016/j.lfs.2007.07.030; Pan LN, 2007, CANCER, V109, P1676, DOI 10.1002/cncr.22585; Park PH, 2003, BIOCHEM BIOPH RES CO, V306, P501, DOI 10.1016/S0006-291X(03)01040-4; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103; Rozen S, 2000, Methods Mol Biol, V132, P365; SHUKLA SD, 2007, NOVARTIS FDN S, V285; Shukla SD, 2006, WORLD J GASTROENTERO, V12, P5265, DOI 10.3748/wjg.v12.i33.5265; Yoshimura M, 2006, ALCOHOL CLIN EXP RES, V30, P1824, DOI 10.1111/j.1530-0277.2006.00219.x; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004	41	31	31	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1069	1075		10.1096/fj.10-168534	http://dx.doi.org/10.1096/fj.10-168534			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21106935				2022-12-28	WOS:000287806200026
J	Yang, L; Katchman, A; Morrow, JP; Doshi, D; Marx, SO				Yang, Lin; Katchman, Alexander; Morrow, John P.; Doshi, Darshan; Marx, Steven O.			Cardiac L-type calcium channel (Ca(v)1.2) associates with gamma subunits	FASEB JOURNAL			English	Article						ion channel; electrophysiology; immunoprecipitation; auxiliary subunit; macromolecular complex	GATED CA2+ CHANNELS; KINASE-C ISOFORMS; SKELETAL-MUSCLE; FUNCTIONAL-CHARACTERIZATION; AMPA RECEPTORS; BETA-SUBUNITS; GENE; EXPRESSION; FAMILY; CELLS	The cardiac voltage-gated Ca2+ channel, Ca(v)1.2, mediates excitation-contraction coupling in the heart. The molecular composition of the channel includes the pore-forming alpha 1 subunit and auxiliary alpha 2/delta-1 and beta subunits. Ca2+ channel gamma subunits, of which there are 8 isoforms, consist of 4 transmembrane domains with intracellular N- and C-terminal ends. The gamma 1 subunit was initially detected in the skeletal muscle Ca(v)1.1 channel complex, modulating current amplitude and activation and inactivation properties. The gamma 1 subunit also shifts the steady-state inactivation to more negative membrane potentials, accelerates current inactivation, and increases peak currents, when coexpressed with the cardiac alpha 1c subunit in Xenopus oocytes and human embryonic kidney (HEK) 293 cells. The gamma 1 subunit is not expressed, however, in cardiac muscle. We sought to determine whether gamma subunits that are expressed in cardiac tissue physically associate with and modulate Ca(v)1.2 function. We now demonstrate that gamma 4, gamma 6, gamma 7, and gamma 8 subunits physically interact with the Ca(v)1.2 complex. The gamma subunits differentially modulate Ca2+ channel function when coexpressed with the beta 1b and alpha 2/delta-1 subunits in HEK cells, altering both activation and inactivation properties. The effects of gamma on Ca(v)1.2 function are dependent on the subtype of beta subunit. Our results identify new members of the cardiac Ca(v)1.2 macromolecular complex and identify a mechanism by which to increase the functional diversity of Ca(v)1.2 channels.-Yang, L., Katchman, A., Morrow, J. P., Doshi, D., Marx, S. A. Cardiac L-type calcium channel (Ca(V)1.2) associates with gamma subunits. FASEB J. 25, 928-936 (2011). www.fasebj.org	[Yang, Lin; Katchman, Alexander; Morrow, John P.; Doshi, Darshan; Marx, Steven O.] Columbia Univ, Coll Phys & Surg, Div Cardiol, Dept Med, New York, NY 10032 USA; [Marx, Steven O.] Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University	Marx, SO (corresponding author), Columbia Univ, Coll Phys & Surg, Div Cardiol, Dept Med, 622 W 168th St,PH-3 Ctr, New York, NY 10032 USA.	sm460@columbia.edu		Morrow, John/0000-0002-9264-5273	U.S. National Institutes of Health [HL068093]; American Heart Association; Arlene and Arnold Goldstein Family Foundation; Louis V. Gerstner, Jr. Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068093] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Arlene and Arnold Goldstein Family Foundation; Louis V. Gerstner, Jr. Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Susumu Tomita (Yale University, New Haven, CT, USA) for the gamma 8 cDNA and Henry Colecraft (Columbia University, New York, NY, USA) for providing cDNA constructs for beta 1b and beta 2b and helpful discussions. S.O.M. is supported by grants from the U.S. National Institutes of Health (HL068093), the American Heart Association, and the Arlene and Arnold Goldstein Family Foundation. S.O.M. is an Established Investigator of the American Heart Association. J.P.M. is supported by the Louis V. Gerstner, Jr. Foundation.	Arikkath J, 2003, J BIOL CHEM, V278, P1212, DOI 10.1074/jbc.M208689200; Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; CAMPBELL KP, 1989, ANN NY ACAD SCI, V560, P251, DOI 10.1111/j.1749-6632.1989.tb24102.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chu PJ, 2001, GENE, V280, P37, DOI 10.1016/S0378-1119(01)00738-7; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; Eberst R, 1997, PFLUG ARCH EUR J PHY, V433, P633, DOI 10.1007/s004240050324; FABIATO A, 1979, ANNU REV PHYSIOL, V41, P473, DOI 10.1146/annurev.ph.41.030179.002353; Ferron L, 2008, J NEUROSCI, V28, P10604, DOI 10.1523/JNEUROSCI.2709-08.2008; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Freise D, 2000, J BIOL CHEM, V275, P14476, DOI 10.1074/jbc.275.19.14476; Fuller-Bicer GA, 2009, AM J PHYSIOL-HEART C, V297, pH117, DOI 10.1152/ajpheart.00122.2009; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hansen JP, 2004, J MOL CELL CARDIOL, V37, P1147, DOI 10.1016/j.yjmcc.2004.08.005; JAY SD, 1991, J BIOL CHEM, V266, P3287; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; Kang MG, 2003, J BIOL CHEM, V278, P21315, DOI 10.1074/jbc.R300004200; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Kato AS, 2007, J NEUROSCI, V27, P4969, DOI 10.1523/JNEUROSCI.5561-06.2007; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Lerche H, 1996, PFLUG ARCH EUR J PHY, V431, P461, DOI 10.1007/s004240050021; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Lin ZJ, 2008, J PHYSIOL-LONDON, V586, P5349, DOI 10.1113/jphysiol.2008.159111; Moss FJ, 2002, EMBO J, V21, P1514, DOI 10.1093/emboj/21.7.1514; POWERS PA, 1993, J BIOL CHEM, V268, P9275; Ren DJ, 1997, J BIOL CHEM, V272, P22393, DOI 10.1074/jbc.272.36.22393; Sandoval A, 2007, CELL MOL NEUROBIOL, V27, P901, DOI 10.1007/s10571-007-9210-9; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; WEI XY, 1991, J BIOL CHEM, V266, P21943; Yang L, 2005, J BIOL CHEM, V280, P207, DOI 10.1074/jbc.M410509200; Yang L, 2007, CIRC RES, V101, P465, DOI 10.1161/CIRCRESAHA.107.156976; Yang L, 2009, BIOCHEMISTRY-US, V48, P6674, DOI 10.1021/bi900322a	38	52	54	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2011	25	3					928	936		10.1096/fj.10-172353	http://dx.doi.org/10.1096/fj.10-172353			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21127204	Green Published			2022-12-28	WOS:000287806200013
J	Dickhout, JG; Lhotak, S; Hilditch, BA; Basseri, S; Colgan, SM; Lynn, EG; Carlisle, RE; Zhou, J; Sood, SK; Ingram, AJ; Austin, RC				Dickhout, Jeffrey G.; Lhotak, Sarka; Hilditch, Brooke A.; Basseri, Sana; Colgan, Stephen M.; Lynn, Edward G.; Carlisle, Rachel E.; Zhou, Ji; Sood, Sudesh K.; Ingram, Alistair J.; Austin, Richard C.			Induction of the unfolded protein response after monocyte to macrophage differentiation augments cell survival in early atherosclerotic lesions	FASEB JOURNAL			English	Article						atherosclerosis; apoptosis; ER stress; GRP78; cellular transformation	ENDOPLASMIC-RETICULUM STRESS; COLONY-STIMULATING FACTOR; APOE-DEFICIENT MICE; ACUTE CORONARY SYNDROME; APOLIPOPROTEIN-E; ACCELERATES ATHEROSCLEROSIS; FOLIC-ACID; ER STRESS; ENHANCED ATHEROSCLEROSIS; QUANTITATIVE ASSESSMENT	Endoplasmic reticulum (ER) stress causes macrophage cell death within advanced atherosclerotic lesions, thereby contributing to necrotic core formation and increasing the risk of atherothrombotic disease. However, unlike in advanced lesions, the appearance of dead/apoptotic macrophages in early lesions is less prominent. Given that activation of the unfolded protein response (UPR) is detected in early lesion-resident macrophages and can enhance cell survival against ER stress, we investigated whether UPR activation occurs after monocyte to macrophage differentiation and confers a cytoprotective advantage to the macrophage. Human peripheral blood monocytes were treated with monocyte colony-stimulating factor to induce macrophage differentiation, as assessed by changes in ultrastructure and scavenger receptor expression. UPR markers, including GRP78, GRP94, and spliced XBP-1, were induced after macrophage differentiation and occurred after a significant increase in de novo protein synthesis. UPR activation after differentiation reduced macrophage cell death by ER stress-inducing agents. Further, GRP78 overexpression in macrophages was sufficient to reduce ER stress-induced cell death. Consistent with these in vitro findings, UPR activation was observed in viable lesion-resident macrophages from human carotid arteries and from the aortas of apoE(-/-) mice. However, no evidence of apoptosis was observed in early lesion-resident macrophages from the aortas of apoE(-/-) mice. Thus, our findings that UPR activation occurs during macrophage differentiation and is cytoprotective against ER stress-inducing agents suggest an important cellular mechanism for macrophage survival within early atherosclerotic lesions.-Dickhout, J. G., Lhotak, S., Hilditch, B. A., Basseri, S., Colgan, S. M., Lynn, E. G., Carlisle, R. E., Zhou, J., Sood, S. K., Ingram, A. J., Austin, R. C. Induction of the unfolded protein response after monocyte to macrophage differentiation augments cell survival in early atherosclerotic lesions. FASEB J. 25, 576-589 (2011). www.fasebj.org	[Austin, Richard C.] McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON L8N 4A6, Canada; [Dickhout, Jeffrey G.; Lhotak, Sarka; Basseri, Sana; Lynn, Edward G.; Carlisle, Rachel E.; Sood, Sudesh K.; Ingram, Alistair J.; Austin, Richard C.] St Josephs Healthcare Hamilton, Hamilton, ON L8N 4A6, Canada	McMaster University; McMaster University	Austin, RC (corresponding author), McMaster Univ, Dept Med, Div Nephrol, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	austinr@taari.ca	Dickhout, Jeffrey/R-2606-2019	Lynn, Edward/0000-0002-8011-5558; Carlisle, Rachel/0000-0002-4266-1953	Heart and Stroke Foundation of Ontario [T-6146]; Canadian Institutes of Health Research [MOP-74477]; Ontario Research and Development Challenge Fund; St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton Division of Nephrology; Heart and Stroke Foundation of Canada	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Research and Development Challenge Fund(General Electric); St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton Division of Nephrology; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	This work was supported in part by research grants to R.C.A. from the Heart and Stroke Foundation of Ontario (T-6146), the Canadian Institutes of Health Research (MOP-74477), and the Ontario Research and Development Challenge Fund. Financial support from St. Joseph's Healthcare Hamilton is acknowledged. J.G.D. is supported by the St. Joseph's Healthcare Hamilton Division of Nephrology Junior Research Award. S.B. is supported by a doctoral scholarship from the Heart and Stroke Foundation of Canada. R.C.A. is a Career Investigator of the Heart and Stroke Foundation of Ontario and holds the Amgen Canada Research Chair in the Division of Nephrology at St. Joseph's Healthcare and McMaster University.	Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027; Arai S, 2005, CELL METAB, V1, P201, DOI 10.1016/j.cmet.2005.02.002; Armitage JM, 2010, JAMA-J AM MED ASSOC, V303, P2486, DOI 10.1001/jama.2010.840; Basseri S, 2009, J LIPID RES, V50, P2486, DOI 10.1194/jlr.M900216-JLR200; Boesten LSM, 2006, FASEB J, V20, P953, DOI 10.1096/fj.05-4530fje; Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Cenci S, 2007, FEBS LETT, V581, P3652, DOI 10.1016/j.febslet.2007.04.031; Chitu V, 2006, CURR OPIN IMMUNOL, V18, P39, DOI 10.1016/j.coi.2005.11.006; CLINTON SK, 1992, AM J PATHOL, V140, P301; Dickhout JG, 2007, ANTIOXID REDOX SIGN, V9, P1863, DOI 10.1089/ars.2007.1780; Dickhout JG, 2007, CIRCULATION, V116, P1214, DOI 10.1161/CIRCULATIONAHA.107.728378; Dickhout JG, 2005, ARTERIOSCL THROM VAS, V25, P2623, DOI 10.1161/01.ATV.0000189159.96900.d9; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; GILBERT HS, 1989, BLOOD, V74, P1231; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hegyi L, 1996, J PATHOL, V180, P423, DOI 10.1002/(SICI)1096-9896(199612)180:4<423::AID-PATH677>3.0.CO;2-1; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; Hori O, 2002, J CELL BIOL, V157, P1151, DOI 10.1083/jcb.200108103; Hossain GS, 2003, J BIOL CHEM, V278, P30317, DOI 10.1074/jbc.M212897200; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Kawahara K, 2001, FEBS LETT, V506, P135, DOI 10.1016/S0014-5793(01)02898-8; Kockx MM, 1996, AM J PATHOL, V148, P1771; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu J, 2005, ARTERIOSCL THROM VAS, V25, P174, DOI 10.1161/01.ATV.0000148548.47755.22; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Ma YJ, 2003, NAT IMMUNOL, V4, P310, DOI 10.1038/ni0403-310; Misra UK, 2005, J LEUKOCYTE BIOL, V78, P187, DOI 10.1189/jlb.1104685; Miyamoto M, 2000, CELL TRANSPLANT, V9, P681, DOI 10.1177/096368970000900514; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Myoishi M, 2007, CIRCULATION, V116, P1226, DOI 10.1161/CIRCULATIONAHA.106.682054; Naito M, 2008, PATHOL INT, V58, P143, DOI 10.1111/j.1440-1827.2007.02203.x; NAKAI A, 1995, CELL STRUCT FUNCT, V20, P33, DOI 10.1247/csf.20.33; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Pang ZJ, 1999, ATHEROSCLEROSIS, V147, P33, DOI 10.1016/S0021-9150(99)00159-8; Plesner A, 2003, J IMMUNOL METHODS, V279, P287, DOI 10.1016/S0022-1759(03)00234-5; Qiao JH, 1997, AM J PATHOL, V150, P1687; Rajavashisth T, 1998, J CLIN INVEST, V101, P2702, DOI 10.1172/JCI119891; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f; Tabas I, 2002, J CLIN INVEST, V110, P583, DOI 10.1172/JCI200216381; Tabas I, 2009, ANN NY ACAD SCI, V1173, pE40, DOI 10.1111/j.1749-6632.2009.04957.x; Takahashi Kiyoshi, 2002, Medical Electron Microscopy, V35, P179, DOI 10.1007/s007950200023; Thorp E, 2009, CELL METAB, V9, P474, DOI 10.1016/j.cmet.2009.03.003; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; van Vlijmen BJM, 2001, CIRC RES, V88, P780, DOI 10.1161/hh0801.089261; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; Wang YC, 2008, CANCER RES, V68, P2820, DOI 10.1158/0008-5472.CAN-07-1336; Watson LM, 2003, J BIOL CHEM, V278, P17438, DOI 10.1074/jbc.M301006200; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhou J, 2005, CIRCULATION, V111, P1814, DOI 10.1161/01.CIR.0000160864.31351.C1; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97; Zhou J, 2003, ATHEROSCLEROSIS, V168, P255, DOI 10.1016/S0021-9150(03)00138-2; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582; Zhou J, 2008, FASEB J, V22, P2569, DOI 10.1096/fj.07-105353	68	37	37	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					576	589		10.1096/fj.10-159319	http://dx.doi.org/10.1096/fj.10-159319			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20966213				2022-12-28	WOS:000286724800016
J	Breton, B; Lagace, M; Bouvier, M				Breton, Billy; Lagace, Monique; Bouvier, Michel			Combining resonance energy transfer methods reveals a complex between the alpha(2A)-adrenergic receptor, G alpha(i1)beta(1)gamma(2), and GRK2	FASEB JOURNAL			English	Article						bioluminescence; fluorescence; G-protein-coupled receptors; arrestins; signaling	PROTEIN-COUPLED-RECEPTOR; BETA-GAMMA-SUBUNITS; REAL-TIME DETECTION; SELECTIVE REGULATION; SIGNAL-TRANSDUCTION; GABA(B) RECEPTOR; HORMONE RECEPTOR; HOMOLOGY DOMAIN; LIVING CELLS; KINASE 2	Traditionally, G-protein-coupled receptor (GPCR) interactions with their G proteins and regulatory proteins, GPCR kinases (GRKs) and arrestins, are described as sequential events involving rapid assemblies/disassemblies. To directly monitor the dynamics of these interactions in living cells, we combined two spectrally resolved bioluminescence and one fluorescence resonance energy transfer (RET) methods. The RET combination analysis revealed that stimulation of the alpha(2A)-adrenergic receptor (alpha(2A)AR) leads to the recruitment of GRK2 at a receptor still associated with the G alpha(i1)beta(1)gamma(2) complex. The interaction kinetics of GRKs with G gamma(2) (2.8 +/- 0.4 s) and alpha(2A)AR (5.2 +/- 0.5 s) were similar to that of the receptor-promoted change in RET between G alpha(i1) and G gamma(2) (5.2 +/- 1.2 s), and persisted until the translocation of beta arrestin2 to the receptor, indicating that GRK2 remains associated to the receptor/G-protein complex for longer periods than anticipated. Moreover, GRK2 or a kinase-deficient GRK2 mutant, but not GRK5, potentiated the receptor-promoted changes in RET between G alpha(i1) and G gamma(2) and abrogated the alpha(2A)AR-stimulated calcium response, suggesting that the recruitment of GRK2 to the complex contributes to the structural rearrangement and functional regulation of the signaling unit, independently of the kinase activity. RET combination analysis revealed unanticipated dynamics in GPCR signaling and will be applicable to many biological systems.-Breton, B., Lagace, M., Bouvier, M. Combining resonance energy transfer methods reveals a complex between the alpha(2A)-adrenergic receptor, G alpha(i1)beta(1)gamma(2), and GRK2. FASEB J. 24, 4733-4743 (2010). www.fasebj.org	[Bouvier, Michel] Univ Montreal, IRIC, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Univ Medicament, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Bouvier, M (corresponding author), Univ Montreal, IRIC, Dept Biochem, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	michel.bouvier@umontreal.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100	Canadian Institute for Health Research; Heart and Stroke Foundation of Canada; Fonds de la Recherche en Sante du Quebec; Canada Research Chair in Signal Transduction and Molecular Pharmacology	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Canada Research Chair in Signal Transduction and Molecular Pharmacology	The authors thank Herve Paris and Celine Gales (Institut National de la Sante et de la Recherche Medicale, Toulouse, France) for the gift of the alpha<INF>2A</INF>AR-venus plasmid, Stephane Laporte (McGill University, Montreal, QC, Canada) for the gift of GRK2-eYFP, and M. Heroux and C. Le Gouill for critical reading of the manuscript. This work was supported by a grant from Canadian Institute for Health Research and the Heart and Stroke Foundation of Canada. B.B. holds a studentship from the Fonds de la Recherche en Sante du Quebec, and M.B. is the recipient of the Canada Research Chair in Signal Transduction and Molecular Pharmacology.	Aiyar N, 2000, EUR J PHARMACOL, V403, P1, DOI 10.1016/S0014-2999(00)00419-2; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Audet N, 2008, J BIOL CHEM, V283, P15078, DOI 10.1074/jbc.M707941200; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; CAMPBELL AK, 1975, BIOCHEM SOC T, V3, P709, DOI 10.1042/bst0030709; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Carriba P, 2008, NAT METHODS, V5, P727, DOI 10.1038/nmeth.1229; Charest PG, 2003, J BIOL CHEM, V278, P41541, DOI 10.1074/jbc.M306589200; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Digby GJ, 2006, P NATL ACAD SCI USA, V103, P17789, DOI 10.1073/pnas.0607116103; Diviani D, 1996, J BIOL CHEM, V271, P5049; Eichmann T, 2003, J BIOL CHEM, V278, P8052, DOI 10.1074/jbc.M204795200; Evanko DS, 2005, CELL SIGNAL, V17, P1218, DOI 10.1016/j.cellsig.2004.12.008; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; Galperin E, 2004, NAT METHODS, V1, P209, DOI 10.1038/NMETH720; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAGA T, 1993, LIFE SCI, V52, P421, DOI 10.1016/0024-3205(93)90297-G; Hamdan FF, 2007, J BIOL CHEM, V282, P29089, DOI 10.1074/jbc.M700577200; Hamdan Fadi F, 2006, Curr Protoc Neurosci, VChapter 5, DOI 10.1002/0471142301.ns0523s34; Hasbi A, 2004, MOL ENDOCRINOL, V18, P1277, DOI 10.1210/me.2003-0440; Hebert TE, 2006, CELL BIOCHEM BIOPHYS, V45, P85, DOI 10.1385/CBB:45:1:85; Heroux M, 2007, J BIOL CHEM, V282, P31610, DOI 10.1074/jbc.M701790200; Iacovelli L, 2003, J BIOL CHEM, V278, P12433, DOI 10.1074/jbc.M203992200; Iacovelli L, 1999, MOL PHARMACOL, V56, P316, DOI 10.1124/mol.56.2.316; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; Kara E, 2006, MOL ENDOCRINOL, V20, P3014, DOI 10.1210/me.2006-0098; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Klein S, 2000, P NATL ACAD SCI USA, V97, P3219, DOI 10.1073/pnas.050015797; Lee HJ, 2007, BIOCHEM J, V404, P141, DOI 10.1042/BJ20061826; LEVITZKI A, 1986, PHYSIOL REV, V66, P819, DOI 10.1152/physrev.1986.66.3.819; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Lopez-Gimenez JF, 2007, MOL PHARMACOL, V71, P1015, DOI 10.1124/mol.106.033035; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; PAO CS, 2002, SCI STKE, pE42; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Pfleger KDG, 2006, NAT METHODS, V3, P165, DOI 10.1038/nmeth841; Pfleger KDG, 2006, NAT PROTOC, V1, P337, DOI 10.1038/nprot.2006.52; Pfleger KDG, 2006, CELL SIGNAL, V18, P1664, DOI 10.1016/j.cellsig.2006.01.004; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Premont RT, 2007, ANNU REV PHYSIOL, V69, P511, DOI 10.1146/annurev.physiol.69.022405.154731; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Rosenzweig DH, 2007, J NEUROSCI, V27, P5484, DOI 10.1523/JNEUROSCI.1421-07.2007; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Shyu YJ, 2008, P NATL ACAD SCI USA, V105, P151, DOI 10.1073/pnas.0705181105; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Tesmer VM, 2005, SCIENCE, V310, P1686, DOI 10.1126/science.1118890; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Usui K, 2000, INT J MOL MED, V5, P335; Villemure JF, 2005, BIOCHEM J, V388, P47, DOI 10.1042/BJ20041435; Vrecl M, 2004, J BIOMOL SCREEN, V9, P322, DOI 10.1177/1087057104263212; Willets JM, 2003, TRENDS PHARMACOL SCI, V24, P626, DOI 10.1016/j.tips.2003.10.003; Zimmermann T, 2002, FEBS LETT, V531, P245, DOI 10.1016/S0014-5793(02)03508-1	61	19	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4733	4743		10.1096/fj.10-164061	http://dx.doi.org/10.1096/fj.10-164061			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20696855				2022-12-28	WOS:000284824400014
J	Hewitt, SC; Kissling, GE; Fieselman, KE; Jayes, FL; Gerrish, KE; Korach, KS				Hewitt, Sylvia C.; Kissling, Grace E.; Fieselman, Karen E.; Jayes, Friederike L.; Gerrish, Kevin E.; Korach, Kenneth S.			Biological and biochemical consequences of global deletion of exon 3 from the ER alpha gene	FASEB JOURNAL			English	Article						estrogen receptor; uterus; knockout	ESTROGEN-RECEPTOR-ALPHA; KNOCKOUT MICE; GROWTH-FACTOR; REPRODUCTIVE PHENOTYPES; VASCULAR INJURY; CROSS-TALK; IN-VIVO; MOUSE; BONE; SPECIFICITY	To address issues resulting from alpha estrogen receptor-knockout (alpha ERKO) residual N-terminal truncated estrogen receptor alpha, and to allow tissue-selective deletion of ER alpha, we generated loxP-flanked exon 3 mice. Initial characterization of global sox2 cre-derived exon 3-deleted Ex3 alpha ERKO mice indicated no ER alpha protein in uterine tissue and recapitulation of previously described female phenotypes, confirming successful ablation of ER alpha. Body weights of Ex3 alpha ERKO female mice were 1.4-fold higher than wild-tupe (WT) females and comparable to WT males. Microarray indicated the Ex3 alpha ERKO uterus is free of residual estrogen responses. RT-PCR showed Nr4a1 is increased 41-fold by estrogen in WT and 7.4-fold in alpha ERKO, and not increased in Ex3 alpha ERKO. Nr4a1, Cdkn1a, and c-fos transcripts were evaluated in WT and Ex3 alpha ERKO mice following estrogen, IGF1, or EGF injections. All 3 were increased by all treatments in WT. None were increased by estrogen in Ex3 alpha ERKO. Nr4a1 increased 24.5- and 14.7-fold, Cdkn1a increased 14.2- and 12.3-fold, and c-fos increased 20.9-fold and 16.2-fold after IGF1 and EGF treatments, respectively, in the Ex3 alpha ERKO mice, confirming that growth factor regulation is independent of ER alpha. Our Ex3 alpha ER alpha model will be useful in studies of complete or selective ablation of ER alpha in target tissues.-Hewitt, S. C., Kissling, G. E., Fieselman, K. E., Jayes, F. L., Gerrish, K. E., Korach, K. S. Biological and biochemical consequences of global deletion of exon 3 from the ER alpha gene. FASEB J. 24, 4660-4667 (2010). www.fasebj.org	[Hewitt, Sylvia C.; Fieselman, Karen E.; Jayes, Friederike L.; Korach, Kenneth S.] NIEHS, Lab Reprod & Dev Toxicol, NIH, Res Triangle Pk, NC 27709 USA; [Kissling, Grace E.] NIEHS, Biostat Branch, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hewitt, SC (corresponding author), 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	curtiss@niehs.nih.gov	Hewitt, Sylvia/W-8752-2019	Hewitt, Sylvia/0000-0001-7713-0805; Jayes, Friederike/0000-0001-8862-9345; Korach, Kenneth/0000-0002-7765-418X	U.S. National Institutes of Health, National Institute of Environmental Health Sciences [Z01ES 70065]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZICES102445, ZIAES070065, ZICES102425] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank David Monroy for breeding expertise and for collecting animal weights; the National Institute of Environmental Health Sciences (NIEHS) Microarray Core for microarray studies and analysis; the NIEHS Histology Core for tissue sample preparation; Dr. Manas K. Ray and Mr. Greg Scott (NIEHS Knockout Mice Core) for generating the floxed Ex3 ER alpha mice; Comparative Medicine Branch surgeons James Clark, Page Myers, and David Goulding for ovariectomies and implanting osmotic pumps; and Karina Rodriguez for the hormone assays. This research was supported (in part) by the Intramural Research Program of the U.S. National Institutes of Health, National Institute of Environmental Health Sciences project number Z01ES 70065.	Bielmeier SR, 2004, TOXICOL SCI, V77, P101, DOI 10.1093/toxsci/kfh017; Chen M, 2009, MOL CELL BIOCHEM, V321, P145, DOI 10.1007/s11010-008-9928-9; Couse J, 1999, BIOL REPROD, V60, P88; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; Dupont S, 2000, DEVELOPMENT, V127, P4277; Hayashi S, 2002, MECH DEVELOP, V119, pS97, DOI 10.1016/S0925-4773(03)00099-6; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Hewitt SC, 2006, ENDOCRINOLOGY, V147, P2203, DOI 10.1210/en.2005-1292; Hewitt SC, 2005, MOL ENDOCRINOL, V19, P657, DOI 10.1210/me.2004-0142; Hewitt SC, 2003, MOL ENDOCRINOL, V17, P2070, DOI 10.1210/me.2003-0146; Hewitt SC, 2002, CANCER RES, V62, P2798; Hewitt SC, 2009, MOL ENDOCRINOL, V23, P2111, DOI 10.1210/me.2009-0356; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; LESHNER AI, 1973, PHYSIOL BEHAV, V11, P671, DOI 10.1016/0031-9384(73)90253-9; Lindberg MK, 2001, J ENDOCRINOL, V171, P229, DOI 10.1677/joe.0.1710229; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; Ohlsson C, 2000, BIOCHEM BIOPH RES CO, V278, P640, DOI 10.1006/bbrc.2000.3827; ORNOY A, 1994, BONE MINER, V24, P43, DOI 10.1016/S0169-6009(08)80130-4; Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA; Tromp AM, 2006, CALCIFIED TISSUE INT, V79, P404, DOI 10.1007/s00223-006-0045-z; Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003-0003; Vidal O, 2000, P NATL ACAD SCI USA, V97, P5474, DOI 10.1073/pnas.97.10.5474	25	107	109	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2010	24	12					4660	4667		10.1096/fj.10-163428	http://dx.doi.org/10.1096/fj.10-163428			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20667977	Green Published			2022-12-28	WOS:000284824400007
J	Li, H; Zhao, ZW; Wei, G; Yan, LB; Wang, DM; Zhang, H; Sandusky, GE; Turk, J; Xu, Y				Li, Hui; Zhao, Zhenwen; Wei, Gang; Yan, Libo; Wang, Dongmei; Zhang, Hong; Sandusky, George Earl; Turk, John; Xu, Yan			Group VIA phospholipase A(2) in both host and tumor cells is involved in ovarian cancer development	FASEB JOURNAL			English	Article						calcium-independent phospholipase A(2)beta; iPLA(2)beta(-/-) mice; lysophosphatidic acid; tumor microenvironment	LYSOPHOSPHATIDIC ACID PRODUCTION; LYSOPHOSPHOLIPASE-D; ACTIVATING FACTOR; ARACHIDONIC-ACID; EXPRESS GROUP; MIGRATION; INHIBITION; INVASION; MICE; PROLIFERATION	Host-tumor cell interactions are recognized to be critical in tumor development. We have shown that group VIA phospholipase A(2) [calcium-independent phospholipase A(2)beta (iPLA(2)beta)] is important in regulating extracellular lysophosphatidic acid (LPA) levels around human epithelial ovarian cancer (EOC) cells. To explore the role of iPLA(2)beta in host-tumor cell interactions, we have used immunocompetent iPLA(2)beta knockout (iPLA(2)beta(-/-)) mice and the mouse EOC cell line ID8. Tumorigenesis and ascites formation were reduced in iPLA(2)beta(-/-) mice compared with wild-type (WT) mice by more >50% and were reduced further when ID8 cell iPLA(2)beta levels were lowered (by>95%) with shRNA. LPA and lysophosphatidylcholine (LPC) levels in the tumor microenvironment were reduced to similar to 80% of WT levels in iPLA(2)beta(-/-) mice. LPA, but not LPC, stimulated ID8 cell migration and invasion with cells in which iPLA(2)beta expression had been down-regulated in vitro. LPA, but not LPC, also enhanced in vivo ascites formation (by similar to 5-fold) and tumorigenesis in iPLA(2)beta(-/-) mice. This is the first demonstration of a role for host cell iPLA(2)beta in cancer, and these findings suggest that iPLA(2)beta is a potential target for developing novel antineoplastic therapeutic strategies.-Li, H., Zhao, Z., Wei, G., Yan, L., Wang, D., Zhang, H., Sandusky, G. E., Turk, J., Xu, Y. Group VIA phospholipase A(2) in both host and tumor cells is involved in ovarian cancer development. FASEB J. 24, 4103-4116 (2010). www.fasebj.org	[Li, Hui; Zhao, Zhenwen; Wei, Gang; Yan, Libo; Wang, Dongmei; Zhang, Hong; Xu, Yan] Indiana Univ, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; [Zhang, Hong; Sandusky, George Earl] Indiana Univ, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Zhang, Hong; Sandusky, George Earl] Jilin Univ, Dept Gen Surg, Hosp 2, Changchun 130023, Jilin, Peoples R China; [Turk, John] Washington Univ, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Jilin University; Washington University (WUSTL)	Xu, Y (corresponding author), Indiana Univ, Dept Obstet & Gynecol, 975 W Walnut St,IB355A, Indianapolis, IN 46202 USA.	xu2@iupui.edu	yan, libo/H-9533-2013; Yan, Libo/H-2328-2012	Yan, Libo/0000-0002-4204-3397	U.S. National Institutes of Health [RO1 CA095042]; Indiana University Cancer Center; Mary Fendrich Hulman Charitable Trust; U.S. Public Health Service [R37-DK-34388, P41-RR-00954, P60-DK-20579, P30-DK-56341]; NATIONAL CANCER INSTITUTE [R01CA095042] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, R37DK034388, P30DK056341] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Indiana University Cancer Center; Mary Fendrich Hulman Charitable Trust; U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by U.S. National Institutes of Health grant RO1 CA095042, an Indiana University Cancer Center Translational Research Acceleration Collaboration grant, and the Mary Fendrich Hulman Charitable Trust (to Y.X.). It was also supported by U.S. Public Health Service grants R37-DK-34388, P41-RR-00954, P60-DK-20579, R37-DK-34388, and P30-DK-56341 (to J.T). The authors declare no conflicts of interest.	Aoki J, 2008, BBA-MOL CELL BIOL L, V1781, P513, DOI 10.1016/j.bbalip.2008.06.005; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Bao SZ, 2006, J BIOL CHEM, V281, P20958, DOI 10.1074/jbc.M600075200; Bao SZ, 2006, J BIOL CHEM, V281, P187, DOI 10.1074/jbc.M509105200; Bao SZ, 2004, DIABETES, V53, pS186, DOI 10.2337/diabetes.53.2007.S186; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bissell MJ, 1999, CANCER RES, V59, p1757S; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; Chou CH, 2005, CARCINOGENESIS, V26, P45, DOI 10.1093/carcin/bgh301; Eder AM, 2000, CLIN CANCER RES, V6, P2482; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Gil OD, 2008, GYNECOL ONCOL, V108, P361, DOI 10.1016/j.ygyno.2007.10.027; Gupta GP, 2004, J CLIN INVEST, V114, P1691, DOI 10.1172/JCI200423823; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Holmes CE, 2009, CLIN EXP METASTAS, V26, P653, DOI 10.1007/s10585-009-9264-9; Hyde CAC, 2009, INT IMMUNOPHARMACOL, V9, P701, DOI 10.1016/j.intimp.2009.02.003; Kim KS, 2006, CANCER RES, V66, P7983, DOI 10.1158/0008-5472.CAN-05-4381; Kobayashi N, 2009, J BIOL CHEM, V284, P21192, DOI 10.1074/jbc.M109.006163; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kudo I, 1999, Tanpakushitsu Kakusan Koso, V44, P1013; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Li H, 2009, MOL CANCER THER, V8, P1692, DOI 10.1158/1535-7163.MCT-08-1106; Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; Murph MM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005583; Ramanadham S, 2008, AM J PATHOL, V172, P868, DOI 10.2353/ajpath.2008.070756; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Schmid G, 2007, J CELL BIOCHEM, V101, P259, DOI 10.1002/jcb.21181; Sengupta S, 2007, ONCOGENE, V26, P2894, DOI 10.1038/sj.onc.1210093; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Sengupta S, 2004, SEMIN CELL DEV BIOL, V15, P503, DOI 10.1016/j.semcdb.2004.05.003; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Song Y, 2007, BIOCHEM J, V406, P427, DOI 10.1042/BJ20070631; Teo ST, 2009, IUBMB LIFE, V61, P791, DOI 10.1002/iub.220; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; VANCORVEN FJ, 1989, G PROTEINS, V59, P45; VARGAFTIG BB, 1973, NATURE-NEW BIOL, V244, P114, DOI 10.1038/newbio244114a0; Wang D, 2008, MOL CANCER THER, V7, P1993, DOI 10.1158/1535-7163.MCT-08-0088; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xiao YJ, 2000, ANN NY ACAD SCI, V905, P242; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Xu Y., 2006, CELL SCI REV, V3, P168; Xu Yan, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P23, DOI 10.2174/1568008033340414; Zhao XX, 2006, J BIOL CHEM, V281, P29357, DOI 10.1074/jbc.M513105200; Zhao ZW, 2010, J LIPID RES, V51, P652, DOI 10.1194/jlr.D001503; Zhao ZW, 2009, J CHROMATOGR B, V877, P3739, DOI 10.1016/j.jchromb.2009.08.032	51	42	43	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2010	24	10					4103	4116		10.1096/fj.10-161356	http://dx.doi.org/10.1096/fj.10-161356			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20530749	Green Published			2022-12-28	WOS:000285005900045
J	Fanelli, F; Seeber, M				Fanelli, Francesca; Seeber, Michele			Structural insights into retinitis pigmentosa from unfolding simulations of rhodopsin mutants	FASEB JOURNAL			English	Article						GPCR; in silico mutagenesis; protein structure network; retinal diseases; steered molecular dynamics	PROTEIN-COUPLED RECEPTORS; MOLECULAR-DYNAMICS SIMULATIONS; MEMBRANE-PROTEINS; BOVINE RHODOPSIN; TRANSMEMBRANE DOMAIN; INTRADISCAL DOMAIN; CRYSTAL-STRUCTURE; POINT MUTANTS; MUTATIONS; GENE	Disease-causing missense mutations in membrane proteins, such as rhodopsin mutations associated with the autosomal dominant form of retinitis pigmentosa (ADRP), are often linked to defects in folding and/or trafficking. The mechanical unfolding of wild-type rhodopsin was compared with that of 20 selected ADRP-linked mutants more or less defective in folding and retinal binding. Rhodopsin fold is characterized by networks of amino acids in the retinal and G-protein binding sites likely to play a role in the stability and function of the protein. The distribution of highly connected nodes in the network reflects the existence of a diffuse intramolecular communication inside and between the 2 poles of the helix bundle, which makes pathogenic mutations share similar phenotypes irrespective of topological and physicochemical differences between them. Because of this communication, the ADRP-linked rhodopsin mutations share a more or less marked ability to impair selected hubs in the protein structure network. The extent of this structural effect relates to the severity of the biochemical defect caused by mutation. The investigative strategy employed in this study is likely to apply to all structurally known membrane proteins particularly susceptible to misassembly-causing mutations.-Fanelli, F., Seeber, M. Structural insights into retinitis pigmentosa from unfolding simulations of rhodopsin mutants. FASEB J. 24, 3196-3209 (2010). www.fasebj.org	[Fanelli, Francesca] Dulbecco Telethon Inst, I-41100 Modena, Italy; Univ Modena, Dept Chem, I-41100 Modena, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); Universita di Modena e Reggio Emilia	Fanelli, F (corresponding author), Dulbecco Telethon Inst, Via Campi 183, I-41100 Modena, Italy.	fanelli@unimo.it	Seeber, Michele/AAJ-8036-2021; Fanelli, Francesca/O-8807-2014	Fanelli, Francesca/0000-0002-7620-6895; Seeber, Michele/0000-0003-4666-8834	Telethon-Italy [S00068TELU]	Telethon-Italy(Fondazione Telethon)	The authors are grateful to Angelo Felline for his contribution to the PSN analysis code and for computing the normalization factor for retinal. The authors also thank Emanuele Paci and Amedeo Caflisch for helpful discussions. This study was supported by Telethon-Italy grant S00068TELU (to F. F.). The employment of the PyMOL 0.99rc6 software for the achievement of all drawings is acknowledged.	Andres A, 2003, BIOCHEM BIOPH RES CO, V303, P294, DOI 10.1016/S0006-291X(03)00328-0; Bosch L, 2003, J BIOL CHEM, V278, P20203, DOI 10.1074/jbc.M301319200; Breikers G, 2002, BIOCHEM BIOPH RES CO, V297, P847, DOI 10.1016/S0006-291X(02)02308-2; Briscoe AD, 2004, GENE, V332, P107, DOI 10.1016/j.gene.2004.02.037; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; BUNGE S, 1993, GENOMICS, V17, P230, DOI 10.1006/geno.1993.1309; Dryja TP, 2000, INVEST OPHTH VIS SCI, V41, P3124; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Fanelli F, 2005, CHEM REV, V105, P3297, DOI 10.1021/cr000095n; Felline A, 2009, J CHEM THEORY COMPUT, V5, P2472, DOI 10.1021/ct900145u; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FUCHS S, 1994, HUM MOL GENET, V3, P1203, DOI 10.1093/hmg/3.7.1203; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 1999, P NATL ACAD SCI USA, V96, P1932, DOI 10.1073/pnas.96.5.1932; Im W, 2003, BIOPHYS J, V85, P2900, DOI 10.1016/S0006-3495(03)74712-2; INGLEHEARN CF, 1992, HUM MOL GENET, V1, P41, DOI 10.1093/hmg/1.1.41; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; Kanna N, 1999, J MOL BIOL, V292, P441, DOI 10.1006/jmbi.1999.3058; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Kedrov A, 2007, ANNU REV BIOPH BIOM, V36, P233, DOI 10.1146/annurev.biophys.36.040306.132640; KEEN TJ, 1994, HUM MOL GENET, V3, P367, DOI 10.1093/hmg/3.2.367; Kennan A, 2005, TRENDS GENET, V21, P103, DOI 10.1016/j.tig.2004.12.001; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; MACKE JP, 1993, AM J HUM GENET, V53, P80; Mendes HF, 2005, TRENDS MOL MED, V11, P177, DOI 10.1016/j.molmed.2005.02.007; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Oesterhelt F, 2000, SCIENCE, V288, P143, DOI 10.1126/science.288.5463.143; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; Rader AJ, 2004, P NATL ACAD SCI USA, V101, P7246, DOI 10.1073/pnas.0401429101; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; RICHARDS JE, 1995, OPHTHALMOLOGY, V102, P669, DOI 10.1016/S0161-6420(95)30972-4; RODRIGUEZ JA, 1994, AM J HUM GENET S, V53, pA239; Sanders CR, 2004, ANNU REV BIOPH BIOM, V33, P25, DOI 10.1146/annurev.biophys.33.110502.140348; Sapra KT, 2008, LANGMUIR, V24, P1330, DOI 10.1021/la702299z; Sapra KT, 2006, J MOL BIOL, V358, P255, DOI 10.1016/j.jmb.2006.02.008; Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330; Seeber M, 2007, BIOINFORMATICS, V23, P2625, DOI 10.1093/bioinformatics/btm378; Seeber M, 2006, BIOPHYS J, V91, P3276, DOI 10.1529/biophysj.106.088591; Sotomayor M, 2007, SCIENCE, V316, P1144, DOI 10.1126/science.1137591; SOUIED E, 1994, HUM MOL GENET, V3, P1433, DOI 10.1093/hmg/3.8.1433; Stojanovic A, 2003, J BIOL CHEM, V278, P39020, DOI 10.1074/jbc.M303625200; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; VAITHINATHAN R, 1994, GENOMICS, V21, P461, DOI 10.1006/geno.1994.1301; Vendruscolo M, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.061910; Vishveshwara S., 2002, J THEOR COMPUT CHEM, V1, P187, DOI DOI 10.1142/S0219633602000117; Vishveshwara S, 2009, CURR PROTEIN PEPT SC, V10, P146, DOI 10.2174/138920309787847590	55	31	31	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3196	3209		10.1096/fj.09-151084	http://dx.doi.org/10.1096/fj.09-151084			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20395457				2022-12-28	WOS:000281446400009
J	Manes, S; Fuentes, G; Peregil, RM; Rojas, AM; Lacalle, RA				Manes, Santos; Fuentes, Gloria; Peregil, Rosa M.; Rojas, Ana M.; Ana Lacalle, Rosa			An isoform-specific PDZ-binding motif targets type I PIP5 kinase beta to the uropod and controls polarization of neutrophil-like HL60 cells	FASEB JOURNAL			English	Article						cell migration; NHERF-1; PIPK; polarization	SCAFFOLDING PROTEIN NHERF1; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; EUKARYOTIC CHEMOTAXIS; PLASMA-MEMBRANE; FOCAL ADHESIONS; FERM DOMAIN; EZRIN; TALIN; PHOSPHORYLATION; PHAGOCYTOSIS	Type I phosphatidylinositol 4-phosphate 5-kinase (PIP5KI)-beta participates in establishing polarity during leukocyte chemotaxis. Its final 83 amino acids localize PIP5KI beta to the uropod of chemotaxing neutrophils and T cells, and interact with ezrin-radixin-moesin (ERM) proteins and EBP50 (4.1-ERM-binding phosphoprotein 50), a scaffold protein with 2 PDZ (PSD-95, disc large, ZO-1) domains. The structural motifs at the PIP5KI beta C terminus that confer signaling specificity are, nonetheless, unknown. We show that the last 4 residues of PIP5KI beta constitute an atypical PDZ-binding motif, which steers PIP5KI beta to the uropod by binding to both EBP50 PDZ domains. Molecular modeling and mutagenesis indicated that PDZ-binding motif is necessary for PIP5KI beta localization and for chemoattractant-induced neutrophil polarization. Polarity in cells that express PIP5KI beta mutants lacking the PDZ-binding motif was restored by overexpression of PIP5KI beta, but not of PIP5KI gamma_i2, another isoform that localizes to the neutrophil uropod. Our results identify an isoform-specific PDZ-binding motif in PIP5KI beta, which confers specificity for PIP5KI beta signaling at the uropod during leukocyte chemotaxis.-Manes, S., Fuentes, G., Peregil, R. M., Rojas, A. M., Lacalle, R. A. An isoform-specific PDZ-binding motif targets type I PIP5 kinase beta to the uropod and controls polarization of neutrophil-like HL60 cells. FASEB J. 24, 3381-3392 (2010). www.fasebj.org	[Manes, Santos; Peregil, Rosa M.; Ana Lacalle, Rosa] CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; [Fuentes, Gloria] ASTAR, Bioinformat Inst, Biomol Modelling & Design Div, Singapore, Singapore; [Rojas, Ana M.] Inst Predict & Personalized Med Canc, Computat Cell Biol Grp, Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII)	Manes, S (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Darwin 3,Campus Cantoblanco, E-28049 Madrid, Spain.	smanes@cnb.csic.es; rlacalle@cnb.csic.es	IBIS, BIOINFORMATICA/O-1882-2015; Rojas, Ana M./I-2882-2019; fuentes, gloria/A-5018-2010; Manes, Santos/E-4725-2011; Rojas, Ana M/D-5777-2011	Rojas, Ana M./0000-0003-0750-9099; fuentes, gloria/0000-0003-3676-9666; Rojas, Ana M/0000-0003-0750-9099; Lacalle, Rosa Ana/0000-0003-0082-167X; Manes, Santos/0000-0001-8023-957X	Spanish Ministry of Science and Innovation [SAF2008-00649]; Carlos III Health Institute RIER network [RD08/0075/0007]; European Union [LSHB-CT-2005-518167]; ERAnet program (e-rare) [PI07/1314]; Comunidad de Madrid (DIFHEMAT) [S-SAL-0304-2006]; Genoma Espana Foundation (MEICA)	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Carlos III Health Institute RIER network; European Union(European Commission); ERAnet program (e-rare); Comunidad de Madrid (DIFHEMAT)(Comunidad de Madrid); Genoma Espana Foundation (MEICA)	We thank A. Huttenlocher (University of Wisconsin-Madison, Madison, WI, USA), E. J. Weinman and D. A. Steplock (University of Maryland, School of Medicine, Baltimore, MD, USA), M. M. Georgescu (University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA), and T. Fischer (Centro Nacional de Biotecnologia/CSIC, Madrid, Spain) for generous gifts of plasmids and advice, I. Merida for critical reading of the manuscript, and C. Mark for editorial assistance. This work was supported, in part, by the Spanish Ministry of Science and Innovation (SAF2008-00649), the Carlos III Health Institute RIER network (RD08/0075/0007), the European Union FP6 (INNOCHEM, LSHB-CT-2005-518167), the ERAnet program (e-rare, PI07/1314), the Comunidad de Madrid (DIFHEMAT, S-SAL-0304-2006), and the Genoma Espana Foundation (MEICA).	Lacalle RA, 2007, J CELL BIOL, V179, P1539, DOI 10.1083/jcb.200705044; Bagorda A, 2008, J CELL SCI, V121, P2621, DOI 10.1242/jcs.018077; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Carro A, 2006, NUCLEIC ACIDS RES, V34, pW110, DOI 10.1093/nar/gkl203; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Chen MZ, 2009, J BIOL CHEM, V284, P23743, DOI 10.1074/jbc.M109.036509; Cheng H, 2009, STRUCTURE, V17, P660, DOI 10.1016/j.str.2009.03.009; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; de Pereda JM, 2005, J BIOL CHEM, V280, P8381, DOI 10.1074/jbc.M413180200; de Vries SJ, 2006, PROTEINS, V63, P479, DOI 10.1002/prot.20842; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Divecha N, 2000, EMBO J, V19, P5440, DOI 10.1093/emboj/19.20.5440; Doughman RL, 2003, J MEMBRANE BIOL, V194, P77, DOI 10.1007/s00232-003-2027-7; Elkins JM, 2010, PROTEIN SCI, V19, P731, DOI 10.1002/pro.349; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Finnerty CM, 2004, J CELL SCI, V117, P1547, DOI 10.1242/jcs.01038; Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101; Grembecka J, 2006, BIOCHEMISTRY-US, V45, P3674, DOI 10.1021/bi052225y; Hubbard SJ, 1993, NACCESS COMPUTER PRO; ISHII K, 1998, ENG DESIGN AUTOMATIO, V4, P5; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kanaho Y, 2007, BIOL PHARM BULL, V30, P1605, DOI 10.1248/bpb.30.1605; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Li JQ, 2009, J MOL BIOL, V392, P166, DOI 10.1016/j.jmb.2009.07.005; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Lokuta MA, 2007, MOL BIOL CELL, V18, P5069, DOI 10.1091/mbc.E07-05-0428; Mao YS, 2009, J CELL BIOL, V184, P281, DOI 10.1083/jcb.200806121; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Morales FC, 2007, MOL CELL BIOL, V27, P2527, DOI 10.1128/MCB.01372-06; Morales FC, 2004, P NATL ACAD SCI USA, V101, P17705, DOI 10.1073/pnas.0407974101; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Saxena A, 2009, METHOD ENZYMOL, V467, P307, DOI 10.1016/S0076-6879(09)67012-9; Schill NJ, 2009, BIOCHEM J, V422, P473, DOI 10.1042/BJ20090638; Smith A, 2005, J CELL BIOL, V170, P141, DOI 10.1083/jcb.200412032; Sorin EJ, 2005, BIOPHYS J, V88, P2472, DOI 10.1529/biophysj.104.051938; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Tonikian R, 2008, PLOS BIOL, V6, P2043, DOI 10.1371/journal.pbio.0060239; van den Bout I, 2009, J CELL SCI, V122, P3837, DOI 10.1242/jcs.056127; Vasudevan L, 2009, J CELL SCI, V122, P2567, DOI 10.1242/jcs.048124; Wang YF, 2008, P NATL ACAD SCI USA, V105, P14064, DOI 10.1073/pnas.0804139105; Wang YF, 2008, J CLIN INVEST, V118, P812, DOI 10.1172/JCI34239; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050; Weinman EJ, 2003, BIOCHEMISTRY-US, V42, P12662, DOI 10.1021/bi035244l	49	11	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3381	3392		10.1096/fj.09-153106	http://dx.doi.org/10.1096/fj.09-153106			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20442317				2022-12-28	WOS:000281446400026
J	Rosenberg, D; Kartvelishvily, E; Shleper, M; Klinker, CMC; Bowser, MT; Wolosker, H				Rosenberg, Dina; Kartvelishvily, Elena; Shleper, Maria; Klinker, Chanda M. C.; Bowser, Michael T.; Wolosker, Herman			Neuronal release of D-serine: a physiological pathway controlling extracellular D-serine concentration	FASEB JOURNAL			English	Article						serine racemase; neurotransmission; microdialysis; NMDA receptor	METHYL-D-ASPARTATE; RAT-BRAIN; RECEPTOR AGONISTS; GLUTAMATE; RACEMASE; NMDA; LOCALIZATION; TRANSPORTER; GLYCINE; ASC-1	D-Serine is thought to be a glia-derived transmitter that activates N-methyl D-aspartate receptors (NMDARs) in the brain. Here, we investigate the pathways for D-serine release using primary cultures, brain slices, and in vivo microdialysis. In contrast with the notion that D-serine is exclusively released from astrocytes, we found that D-serine is released by neuronal depolarization both in vitro and in vivo. Veratridine (50 mu M) or depolarization by 40 mM KCl elicits a significant release of endogenous D-serine from primary neuronal cultures. Controls with astrocyte cultures indicate that glial cells are insensitive to veratridine, but release D-serine mainly by the opening of volume-regulated anion channels. In cortical slices perfused with veratridine, endogenous D-serine release is 10-fold higher than glutamate receptor-evoked release. Release of D-serine from slices does not require internal or external Ca2+, suggesting a nonvesicular release mechanism. To confirm the neuronal origin of D-serine, we selectively loaded neurons in cortical slices with D-[H-3] serine or applied D-alanine, which specifically releases D-serine from neurons. Depolarization with veratridine promotes D-serine release in vivo monitored by high temporal resolution microdialysis of the striatum. Our data indicate that the neuronal pool of D-serine plays a major role in D-serine dynamics, with implications for the regulation of NMDAR transmission. Rosenberg, D., Kartvelishvily, E., Shleper, M., Klinker, C. M. C., Bowser, M. T., Wolosker, H. Neuronal release of D-serine: a physiological pathway controlling extracellular D-serine concentration. FASEB J. 24, 2951-2961 (2010). www.fasebj.org	[Rosenberg, Dina; Kartvelishvily, Elena; Shleper, Maria; Wolosker, Herman] Technion Israel Inst Technol, Dept Biochem, B Rappaport Fac Med, IL-31096 Haifa, Israel; [Klinker, Chanda M. C.; Bowser, Michael T.] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Minnesota System; University of Minnesota Twin Cities	Wolosker, H (corresponding author), Technion Israel Inst Technol, Dept Biochem, B Rappaport Fac Med, IL-31096 Haifa, Israel.	hwolosker@tx.technion.ac.il	Bowser, Michael/HCI-4724-2022	Wolosker, Herman/0000-0001-5508-9194	Israel Science Foundation; Rappaport Institute of Medical Research; NARSAD; The Sternheim Research Fund; The L. Aronberg Research Fund in Neurology; ISF-Legacy Heritage Fund; Ministry of Health; U.S. National Institutes of Health [GM 063533]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043304] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Rappaport Institute of Medical Research; NARSAD(NARSAD); The Sternheim Research Fund; The L. Aronberg Research Fund in Neurology; ISF-Legacy Heritage Fund; Ministry of Health; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the Israel Science Foundation, the Rappaport Institute of Medical Research, NARSAD, The Sternheim Research Fund, The L. Aronberg Research Fund in Neurology, the ISF-Legacy Heritage Fund, and the Ministry of Health to H.W.; and from the U.S. National Institutes of Health (GM 063533) to M.T.B.	Abdullaev IF, 2006, J PHYSIOL-LONDON, V572, P677, DOI 10.1113/jphysiol.2005.103820; Basu AC, 2009, MOL PSYCHIATR, V14, P719, DOI 10.1038/mp.2008.130; BAUGHMAN RW, 1981, J NEUROSCI, V1, P427; Ciriacks CM, 2006, NEUROSCI LETT, V393, P200, DOI 10.1016/j.neulet.2005.09.080; Ciriacks CM, 2004, ANAL CHEM, V76, P6582, DOI 10.1021/ac0490651; Danysz W, 1998, PHARMACOL REV, V50, P597; DE MJ, 2002, P NATL ACAD SCI USA, V99, P14542; Dun Y, 2008, J NEUROCHEM, V104, P970, DOI 10.1111/j.1471-4159.2007.05015.x; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; GONZALEZALVEAR GM, 1994, J PHARMACOL EXP THER, V271, P212; Gustafson EC, 2007, J NEUROPHYSIOL, V98, P122, DOI 10.1152/jn.00057.2006; HAAS J, 1991, GLIA, V4, P111, DOI 10.1002/glia.440040113; HASHIMOTO A, 1992, J CHROMATOGR-BIOMED, V582, P41, DOI 10.1016/0378-4347(92)80300-F; Hashimoto A, 2000, BRAIN RES BULL, V53, P347, DOI 10.1016/S0361-9230(00)00357-9; Helboe L, 2003, EUR J NEUROSCI, V18, P2227, DOI 10.1046/j.1460-9568.2003.02966.x; Henneberger C, 2010, NATURE, V463, P232, DOI 10.1038/nature08673; Inoue R, 2008, J NEUROSCI, V28, P14486, DOI 10.1523/JNEUROSCI.5034-08.2008; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kartvelishvily E, 2006, J BIOL CHEM, V281, P14151, DOI 10.1074/jbc.M512927200; KIRPEKAR SM, 1979, P NATL ACAD SCI USA, V76, P2081, DOI 10.1073/pnas.76.4.2081; Klinker CC, 2007, ANAL CHEM, V79, P8747, DOI 10.1021/ac071433o; Labrie V, 2009, HUM MOL GENET, V18, P3227, DOI 10.1093/hmg/ddp261; LEVI G, 1992, J NEUROCHEM, V58, P1943, DOI 10.1111/j.1471-4159.1992.tb10073.x; Matsuo H, 2004, NEUROSCI LETT, V358, P123, DOI 10.1016/j.neulet.2004.01.014; Miya K, 2008, J COMP NEUROL, V510, P641, DOI 10.1002/cne.21822; Mongin AA, 2005, AM J PHYSIOL-CELL PH, V288, pC204, DOI 10.1152/ajpcell.00330.2004; Mothet JP, 2005, P NATL ACAD SCI USA, V102, P5606, DOI 10.1073/pnas.0408483102; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Mulligan Sean J, 2006, Sci STKE, V2006, ppe42; NEAL MJ, 1979, BRAIN RES, V167, P337, DOI 10.1016/0006-8993(79)90827-8; O'Brien KB, 2006, ELECTROPHORESIS, V27, P1949, DOI 10.1002/elps.200500770; Oliet SHR, 2009, NEUROSCIENCE, V158, P275, DOI 10.1016/j.neuroscience.2008.01.071; Panatier A, 2006, CELL, V125, P775, DOI 10.1016/j.cell.2006.02.051; Price P.J., 2001, PROTOCOLS NEURAL CEL, P255, DOI 10.1385/1-59259-207-4:255; Puyal J, 2006, J COMP NEUROL, V497, P610, DOI 10.1002/cne.21016; Ribeiro CS, 2002, BRAIN RES, V929, P202, DOI 10.1016/S0006-8993(01)03390-X; Rutter AR, 2007, EUR J NEUROSCI, V25, P1757, DOI 10.1111/j.1460-9568.2007.05446.x; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Shleper M, 2005, J NEUROSCI, V25, P9413, DOI 10.1523/JNEUROSCI.3190-05.2005; Stevens ER, 2003, P NATL ACAD SCI USA, V100, P6789, DOI 10.1073/pnas.1237052100; Takano T, 2005, P NATL ACAD SCI USA, V102, P16466, DOI 10.1073/pnas.0506382102; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 2008, FEBS J, V275, P3514, DOI 10.1111/j.1742-4658.2008.06515.x; Wolosker H, 2007, MOL NEUROBIOL, V36, P152, DOI 10.1007/s12035-007-0038-6; Yasuda E, 2001, NEUROSCI LETT, V299, P162, DOI 10.1016/S0304-3940(01)01502-6; Yoshikawa M, 2007, ARCH HISTOL CYTOL, V70, P127, DOI 10.1679/aohc.70.127	46	94	96	3	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2951	2961		10.1096/fj.09-147967	http://dx.doi.org/10.1096/fj.09-147967			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371631	Green Published			2022-12-28	WOS:000285005400034
J	Kwakman, PHS; te Velde, AA; de Boer, L; Speijer, D; Vandenbroucke-Grauls, CMJE; Zaat, SAJ				Kwakman, Paulus H. S.; te Velde, Anje A.; de Boer, Leonie; Speijer, Dave; Vandenbroucke-Grauls, Christina M. J. E.; Zaat, Sebastian A. J.			How honey kills bacteria	FASEB JOURNAL			English	Article						antibacterial agents; drug resistance; isolation and purification; methicillin-resistant Staphylococcus aureus; peptides	APIS-MELLIFERA L; POLYACRYLAMIDE-GEL ELECTROPHORESIS; DEPENDENT ROLE CHANGE; HYPOPHARYNGEAL GLAND; NEW-ZEALAND; IDENTIFICATION; PURIFICATION; EXPRESSION; PATHOGENS; PROTEIN	With the rise in prevalence of antibiotic-resistant bacteria, honey is increasingly valued for its antibacterial activity. To characterize all bactericidal factors in a medical-grade honey, we used a novel approach of successive neutralization of individual honey bactericidal factors. All bacteria tested, including Bacillus subtilis, methicillin-resistant Staphylococcus aureus, extended-spectrum beta-lactamase producing Escherichia coli, ciprofloxacin-resistant Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus faecium, were killed by 10-20% (v/v) honey, whereas >40% (v/v) of a honey-equivalent sugar solution was required for similar activity. Honey accumulated up to 5.62 +/- 0.54 mM H2O2 and contained 0.25 +/- 0.01 mM methylglyoxal (MGO). After enzymatic neutralization of these two compounds, honey retained substantial activity. Using B. subtilis for activity-guided isolation of the additional antimicrobial factors, we discovered bee defensin-1 in honey. After combined neutralization of H2O2, MGO, and bee defensin-1, 20% honey had only minimal activity left, and subsequent adjustment of the pH of this honey from 3.3 to 7.0 reduced the activity to that of sugar alone. Activity against all other bacteria tested depended on sugar, H2O2, MGO, and bee defensin-1. Thus, we fully characterized the antibacterial activity of medical-grade honey.-Kwakman, P.H.S., te Velde, A.A., de Boer, L., Speijer, D., Vandenbroucke-Grauls, C.M.J.E., Zaat, S.A.J. How honey kills bacteria. FASEB J. 24, 2576-2582 (2010). www.fasebj.org	[Kwakman, Paulus H. S.; de Boer, Leonie; Vandenbroucke-Grauls, Christina M. J. E.; Zaat, Sebastian A. J.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Ctr Infect & Immun Amsterdam, NL-1105 AZ Amsterdam, Netherlands; [te Velde, Anje A.] Univ Amsterdam, Acad Med Ctr, Lab Expt Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands; [Speijer, Dave] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands; [Vandenbroucke-Grauls, Christina M. J. E.] Vrije Univ Amsterdam, Med Ctr, Dept Med Microbiol & Infect Dis, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Zaat, SAJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Ctr Infect & Immun Amsterdam, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	s.a.zaat@amc.uva.nl	Vandenbroucke-Grauls, Christina/AAO-7953-2020; Speijer, Dave/AAE-4613-2019	Vandenbroucke-Grauls, Christina/0000-0003-2074-1597; Speijer, Dave/0000-0002-2340-2753				Adams CJ, 2008, CARBOHYD RES, V343, P651, DOI 10.1016/j.carres.2007.12.011; Bonn D, 2003, LANCET INFECT DIS, V3, P608, DOI 10.1016/S1473-3099(03)00794-1; Cooper RA, 2002, J APPL MICROBIOL, V93, P857, DOI 10.1046/j.1365-2672.2002.01761.x; Cooper RA, 2002, J BURN CARE REHABIL, V23, P366, DOI 10.1097/00004630-200211000-00002; DANKERT J, 1995, INFECT IMMUN, V63, P663, DOI 10.1128/IAI.63.2.663-671.1995; Dixon B, 2003, LANCET INFECT DIS, V3, P116, DOI 10.1016/S1473-3099(03)00524-3; EFEM SEE, 1988, BRIT J SURG, V75, P679, DOI 10.1002/bjs.1800750718; FUJIWARA S, 1990, J BIOL CHEM, V265, P11333; Gallardo-Chacon JJ, 2008, J APICULT RES, V47, P131, DOI 10.1080/00218839.2008.11101439; HARWIG SSL, 1993, ANAL BIOCHEM, V208, P382, DOI 10.1006/abio.1993.1065; JONES R, 2001, HONEY HEALING, P1; Klaudiny J, 2005, INSECT BIOCHEM MOLEC, V35, P11, DOI 10.1016/j.ibmb.2004.09.007; KNECHT D, 1990, APIDOLOGIE, V21, P457, DOI 10.1051/apido:19900507; Kwakman PHS, 2008, CLIN INFECT DIS, V46, P1677, DOI 10.1086/587892; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LENSKY Y, 1983, COMP BIOCHEM PHYS B, V75, P607, DOI 10.1016/0305-0491(83)90104-9; Lusby P E, 2002, J Wound Ostomy Continence Nurs, V29, P295, DOI 10.1067/mjw.2002.129073; Majno G., 1975, MAN WOUND ANCIENT WO; Mavric E, 2008, MOL NUTR FOOD RES, V52, P483, DOI 10.1002/mnfr.200700282; MOLAN PC, 1992, BEE WORLD, V73, P5, DOI 10.1080/0005772X.1992.11099109; MOLAN PC, 2001, HONEY HEALING, P5; Mundo MA, 2004, INT J FOOD MICROBIOL, V97, P1, DOI 10.1016/j.ijfoodmicro.2004.03.025; Nathan C, 2004, NATURE, V431, P899, DOI 10.1038/431899a; Ohashi K, 1999, EUR J BIOCHEM, V265, P127, DOI 10.1046/j.1432-1327.1999.00696.x; Ohashi K, 1997, EUR J BIOCHEM, V249, P797, DOI 10.1111/j.1432-1033.1997.t01-1-00797.x; RACKER E, 1951, J BIOL CHEM, V190, P685; SASAGAWA H, 1989, APPL ENTOMOL ZOOL, V24, P66, DOI 10.1303/aez.24.66; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Weston RJ, 2000, FOOD CHEM, V70, P427, DOI 10.1016/S0308-8146(00)00127-8; White J. W., 1963, J APICULT RES, V2, P93, DOI [10.1080/00218839.1963.11100066, DOI 10.1080/00218839.1963.11100066]; Yatsunami K., 1984, Honeybee Science, V5, P125	32	255	268	3	142	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2576	2582		10.1096/fj.09-150789	http://dx.doi.org/10.1096/fj.09-150789			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20228250				2022-12-28	WOS:000279343600044
J	Avale, ME; Chabout, J; Pons, S; Serreau, P; De Chaumont, F; Olivo-Marin, JC; Bourgeois, JP; Maskos, U; Changeux, JP; Granon, S				Avale, Maria Elena; Chabout, Jonathan; Pons, Stephanie; Serreau, Pierre; De Chaumont, Fabrice; Olivo-Marin, Jean-Christophe; Bourgeois, Jean-Pierre; Maskos, Uwe; Changeux, Jean-Pierre; Granon, Sylvie			Prefrontal nicotinic receptors control novel social interaction between mice	FASEB JOURNAL			English	Article						acetylcholine; prelimbic cortex; executive behavior; gene rescue	MEDIAL FRONTAL-CORTEX; BEHAVIORAL FLEXIBILITY; COGNITIVE FUNCTIONS; RAT; ACETYLCHOLINE; EXPRESSION; LACKING; SYSTEM; STIMULATION; INVOLVEMENT	Social behavior is a defining mammalian feature that integrates emotional and motivational processes with external rewarding stimuli. It is thus an appropriate readout for complex behaviors, yet its neuronal and molecular bases remain poorly understood. In this study, we investigated the role of the mouse prefrontal area, particularly the involvement of beta 2-subunit nicotinic receptors (beta 2*-nAChRs) in a paradigm of social behavior with concurrent motivations. We previously observed that mice lacking beta 2*-nAChRs (beta 2(-/-)) display increased time in social contact and exaggerated approach movements toward the novel conspecific. Here, combining behavioral analysis, localized brain lesions, and lentiviral gene rescue, we found that c-Fos expression is specifically activated in the prelimbic (PrL) area of the prefrontal cortex (PFC) of mice exposed to a novel conspecific; lesions of the PrL area in wild-type mice produce the same social pattern as in beta 2(-/-) mice; and virally mediated reexpression of the beta 2-subunit in the PrL area of beta 2(-/-) mice rescues behavioral components in the social interaction task up to normal levels. Together, these data reveal that social interactions particularly mobilize the PrL area of the mouse PFC and that the presence of functional PrL beta 2*-nAChRs is necessary for this integrated behavior to emerge.-Avale, M. E., Chabout, J., Pons, S., Serreau, P., De Chauont, F., Olivo-Marin, J-C., Bourgeois, J-P., Maskos, U., Changeux, J-P., Granon, S. Prefrontal nicotinic receptors control novel social interaction between mice. FASEB J. 25, 2145-2155 (2011). www.fasebj.org	[Chabout, Jonathan; Serreau, Pierre; Granon, Sylvie] Univ Paris 11, Team Neurobiol Prise Decis, F-91405 Orsay, France; [Chabout, Jonathan; Serreau, Pierre; Granon, Sylvie] CNRS, Ctr Neurosci Paris Sud, UMR 8620, F-91405 Orsay, France; [Avale, Maria Elena; Pons, Stephanie; Serreau, Pierre; Bourgeois, Jean-Pierre; Maskos, Uwe; Changeux, Jean-Pierre; Granon, Sylvie] CNRS, Unite Neurobiol Integrat Syst Cholinerg, URA 2182, Paris, France; [De Chaumont, Fabrice; Olivo-Marin, Jean-Christophe] Inst Pasteur, Lab Anal Imagerie Dynam, Paris, France	UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Granon, S (corresponding author), Univ Paris 11, Team Neurobiol Prise Decis, Bat 425, F-91405 Orsay, France.	sylvie.granon@u-psud.fr	Granon, Sylvie/J-9224-2019; Olivo-Marin, Jean-Christophe/K-4428-2015	Olivo-Marin, Jean-Christophe/0000-0001-6796-0696; de Chaumont, Fabrice/0000-0001-7613-7204; Granon, sylvie/0000-0001-9384-3119; Avale, Maria Elena/0000-0002-0251-0093	Institut Pasteur; Centre National de la Recherche Scientifique; Universite Paris Sud XI; Agence Nationale de la Recherche [NT09_446810]; Biocortech master grant	Institut Pasteur(European Commission); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Universite Paris Sud XI; Agence Nationale de la Recherche(French National Research Agency (ANR)); Biocortech master grant	The authors thank Martine Soudant for excellent technical assistance. This work was supported by the Institut Pasteur, the Centre National de la Recherche Scientifique, and the Universite Paris Sud XI (excellence chair to S. G.). Part of the work was funded by an Agence Nationale de la Recherche grant to S. G. (NT09_446810) and a Biocortech master grant to J.C.	ADOLPHS R, NEURON, V65, P752; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Avale ME, 2008, P NATL ACAD SCI USA, V105, P15991, DOI 10.1073/pnas.0807635105; BALLESTEROSYANE.I, P NATL ACAD SCI US, V107, P11567; Besson M, 2008, BEHAV GENET, V38, P503, DOI 10.1007/s10519-008-9216-1; Birrell JM, 2000, J NEUROSCI, V20, P4320; Bisler S, 2002, J CHEM NEUROANAT, V23, P187, DOI 10.1016/S0891-0618(01)00155-7; Changeux JP, 2010, NAT REV NEUROSCI, V11, P389, DOI 10.1038/nrn2849; Changeux JP, 2005, SCIENCE, V308, P1424, DOI 10.1126/science.1108595; Couey JJ, 2007, NEURON, V54, P73, DOI 10.1016/j.neuron.2007.03.006; Deaner RO, 2005, CURR BIOL, V15, P543, DOI 10.1016/j.cub.2005.01.044; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; Del Arco A, 2009, J NEURAL TRANSM, V116, P941, DOI 10.1007/s00702-009-0243-8; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; Floresco SB, 2009, BEHAV BRAIN RES, V204, P396, DOI 10.1016/j.bbr.2008.12.001; Gorelova N, 1997, NEUROSCIENCE, V76, P689, DOI 10.1016/S0306-4522(96)00380-6; Granon S, 1996, BEHAV BRAIN RES, V78, P147, DOI 10.1016/0166-4328(95)00242-1; Granon S, 2000, PSYCHOBIOLOGY, V28, P229; Granon S, 2003, P NATL ACAD SCI USA, V100, P9596, DOI 10.1073/pnas.1533498100; GRANON S, 1995, PSYCHOPHARMACOLOGY, V119, P139, DOI 10.1007/BF02246154; HILL JA, 1993, J NEUROSCI, V13, P1551; Howe WM, 2010, NEUROPSYCHOPHARMACOL, V35, P1391, DOI 10.1038/npp.2010.9; Ito M, 2009, J NEUROSCI, V29, P9861, DOI 10.1523/JNEUROSCI.6157-08.2009; Izuma K, 2008, NEURON, V58, P284, DOI 10.1016/j.neuron.2008.03.020; Kording K, 2007, SCIENCE, V318, P606, DOI 10.1126/science.1142998; Lambe EK, 2003, NEUROPSYCHOPHARMACOL, V28, P216, DOI 10.1038/sj.npp.1300032; Mameli-Engvall M, 2006, NEURON, V50, P911, DOI 10.1016/j.neuron.2006.05.007; Mansvelder HD, 2009, SEMIN CELL DEV BIOL, V20, P432, DOI 10.1016/j.semcdb.2009.01.007; Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694; Maskos U, 2007, J NEUROCHEM, V100, P596, DOI 10.1111/j.1471-4159.2006.04224.x; Mogensen J, 2004, BRAIN RES BULL, V63, P217, DOI 10.1016/j.brainresbull.2004.02.008; Moroni M, 2006, MOL PHARMACOL, V70, P755, DOI 10.1124/mol.106.023044; Olivo-Marin JC, 2002, PATTERN RECOGN, V35, P1989, DOI 10.1016/S0031-3203(01)00127-3; Panksepp JB, 2007, GENES BRAIN BEHAV, V6, P661, DOI 10.1111/j.1601-183X.2006.00295.x; Paxinos G., 2001, MOUSE BRAIN STEREOTA; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Ragozzino ME, 1999, J NEUROSCI, V19, P4585; Rasband W., 2006, IMAGEJ; Rich EL, 2009, J NEUROSCI, V29, P7208, DOI 10.1523/JNEUROSCI.6068-08.2009; Robbins TW, 1996, PHILOS T ROY SOC B, V351, P1463, DOI 10.1098/rstb.1996.0131; Ross RS, 2005, LEARN MEMORY, V12, P302, DOI 10.1101/lm.91605; Sarter M, 1997, BRAIN RES REV, V23, P28, DOI 10.1016/S0165-0173(96)00009-4; Sesack SR, 2010, NEUROPSYCHOPHARMACOL, V35, P27, DOI 10.1038/npp.2009.93; SMITH DV, J NEUROSCI, V30, P2490; Tolu S, 2010, FASEB J, V24, P723, DOI 10.1096/fj.09-139790; Uylings HBM, 2003, BEHAV BRAIN RES, V146, P3, DOI 10.1016/j.bbr.2003.09.028; Vertes RP, 2004, SYNAPSE, V51, P32, DOI 10.1002/syn.10279; Wiklund A, 2008, ANESTHESIOLOGY, V109, P790, DOI 10.1097/ALN.0b013e31818a379a; Yoshida W, 2006, NEURON, V50, P781, DOI 10.1016/j.neuron.2006.05.006; Zahn R, 2009, CEREB CORTEX, V19, P276, DOI 10.1093/cercor/bhn080; Zoli M, 1999, EMBO J, V18, P1235, DOI 10.1093/emboj/18.5.1235	51	73	73	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2145	2155		10.1096/fj.10-178558	http://dx.doi.org/10.1096/fj.10-178558			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21402717				2022-12-28	WOS:000292242200007
J	Lecosnier, S; Cordier, C; Simon, P; Francois, JC; Saison-Behmoaras, TE				Lecosnier, Sabine; Cordier, Celine; Simon, Philippe; Francois, Jean-Christophe; Saison-Behmoaras, Tula E.			A steric blocker of translation elongation inhibits IGF-1R expression and cell transformation	FASEB JOURNAL			English	Article						peptide nucleic acid; IGF signaling; triplex structure; prostate cancer	FACTOR-I RECEPTOR; GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; PEPTIDE NUCLEIC-ACIDS; PROSTATE-CANCER; TUMOR-GROWTH; ANTISENSE OLIGONUCLEOTIDES; PANCREATIC-CANCER; KINASE INHIBITOR; GENE-EXPRESSION	The insulin-like growth factor 1 receptor (IGF-1R) is involved in transformation, survival, mitogenesis and differentiation. It is overexpressed in many tumors and a validated target for anticancer therapy. In cell-free systems, polypyrimidic peptide nucleic acids (PNAs) can form triplex-like structures with messenger RNAs and halt the ribosomal machinery during the translation elongation. A 17-mer PNA that formed a PNA(2): mRNA complex with a purine-rich sequence located in the coding region of IGF-1R mRNA induced the synthesis of a truncated IGF-1R in vitro. This PNA down-regulated expression of the receptor by 70-80% in prostate cancer cells without affecting insulin receptor expression that exhibits high homology with IGF-1R. Inhibition occurs at the translational level, since the IGF-1R mRNA level measured by quantitative RT-PCR was not affected by PNA treatment. In addition, IGF-1R knockdown by PNA led to an attenuation of phosphorylation of downstream signaling pathways, PI3K/AKT and MAPK, involved in survival and mitogenesis and also to a decrease in cell transformation. Of the steric blockers tested, which included phosphorodiamidate morpholino oligomers and locked nucleic acids, PNA was unique in its ability to form triplex structures with mRNA and to arrest translation elongation.-Lecosnier, S., Cordier, C., Simon, P., Francois, J.-C., Saison-Behmoaras, T. E. A steric blocker of translation elongation inhibits IGF-1R expression and cell transformation. FASEB J. 25, 2201-2210 (2011). www.fasebj.org	[Lecosnier, Sabine; Cordier, Celine; Simon, Philippe; Francois, Jean-Christophe; Saison-Behmoaras, Tula E.] Museum Natl Hist Nat, CNRS, UMR7196, F-75231 Paris 05, France; [Lecosnier, Sabine; Cordier, Celine; Simon, Philippe; Francois, Jean-Christophe; Saison-Behmoaras, Tula E.] INSERM, U565, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Museum National d'Histoire Naturelle (MNHN); Institut National de la Sante et de la Recherche Medicale (Inserm)	Saison-Behmoaras, TE (corresponding author), Museum Natl Hist Nat, CNRS, UMR7196, 57 Rue Cuvier,CP 26, F-75231 Paris 05, France.	francois@mnhn.fr; tula@mnhn.fr	SIMON, Philippe/GXZ-4688-2022; FRANCOIS, Jean-Christophe/O-1659-2018	FRANCOIS, Jean-Christophe/0000-0003-4480-1822	Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique; French Ministry for Research	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); French Ministry for Research(Ministry of Research, France)	The authors thank Loic Perrouault and Karen Haug for their technical assistance. The authors are grateful to Dr. Renato Baserga (Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA) for providing human IGF-IR cDNA. This work was supported by the Institut National de la Sante et de la Recherche Medicale and the Centre National de la Recherche Scientifique. S.L. and C.C. are doctoral fellows supported by the French Ministry for Research.	Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Armitage BA, 2003, DRUG DISCOV TODAY, V8, P222, DOI 10.1016/S1359-6446(03)02611-4; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Bendifallah N, 2006, BIOCONJUGATE CHEM, V17, P750, DOI 10.1021/bc050283q; Boudvillain M, 1997, BIOCHEMISTRY-US, V36, P2925, DOI 10.1021/bi962695f; Boutimah-Hamoudi F, 2007, NUCLEIC ACIDS RES, V35, P3907, DOI 10.1093/nar/gkm374; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Chernicky CL, 2002, J CLIN PATHOL-MOL PA, V55, P102, DOI 10.1136/mp.55.2.102; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; D'cunja J, 2007, EUR J CANCER, V43, P1581, DOI 10.1016/j.ejca.2007.03.003; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Dias N, 1999, J MOL BIOL, V294, P403, DOI 10.1006/jmbi.1999.3277; Dias N, 2002, J MOL BIOL, V320, P489, DOI 10.1016/S0022-2836(02)00474-6; EGHOLM M, 1995, NUCLEIC ACIDS RES, V23, P217, DOI 10.1093/nar/23.2.217; Faria M, 2001, NAT BIOTECHNOL, V19, P40, DOI 10.1038/83489; Francois JC, 2000, METHOD ENZYMOL, V313, P74; Furukawa J, 2010, PROSTATE, V70, P206, DOI 10.1002/pros.21054; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; Gee JE, 1998, ANTISENSE NUCLEIC A, V8, P103, DOI 10.1089/oli.1.1998.8.103; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Hellawell GO, 2002, CANCER RES, V62, P2942; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Ji QS, 2007, MOL CANCER THER, V6, P2158, DOI 10.1158/1535-7163.MCT-07-0070; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; Kwon J, 2009, CANCER RES, V69, P1350, DOI 10.1158/0008-5472.CAN-08-1328; Mayfield LD, 1999, ANAL BIOCHEM, V268, P401, DOI 10.1006/abio.1998.3052; Min YF, 2003, CANCER RES, V63, P6432; Moser C, 2008, EUR J CANCER, V44, P1577, DOI 10.1016/j.ejca.2008.04.003; Nickerson T, 2001, CANCER RES, V61, P6276; Nielsen Peter E, 2002, Methods Mol Biol, V208, P3; Nulf CJ, 2004, NUCLEIC ACIDS RES, V32, P3792, DOI 10.1093/nar/gkh706; Oussedik K, 2010, FASEB J, V24, P2235, DOI 10.1096/fj.09-132324; Reinmuth N, 2002, LAB INVEST, V82, P1377, DOI 10.1097/01.LAB.0000032411.41603.C2; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Resnik JL, 1998, CANCER RES, V58, P1159; Reynolds A, 2006, RNA, V12, P988, DOI 10.1261/rna.2340906; Roberts J, 2006, MOL THER, V14, P471, DOI 10.1016/j.ymthe.2006.05.017; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Rogers FA, 2002, P NATL ACAD SCI USA, V99, P16695, DOI 10.1073/pnas.262556899; Sachdev D, 2003, CANCER RES, V63, P627; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; Senamaud-Beaufort C, 2003, OLIGONUCLEOTIDES, V13, P465, DOI 10.1089/154545703322860780; Shiraishi T, 2008, NUCLEIC ACIDS RES, V36, P4424, DOI 10.1093/nar/gkn401; Shyu AB, 2008, EMBO J, V27, P471, DOI 10.1038/sj.emboj.7601977; Steller MA, 1996, CANCER RES, V56, P1761; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732; Wu B, 2008, P NATL ACAD SCI USA, V105, P14814, DOI 10.1073/pnas.0805676105; Yin HF, 2010, MOL THER, V18, P819, DOI 10.1038/mt.2009.310; Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712	52	9	9	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2201	2210		10.1096/fj.10-169540	http://dx.doi.org/10.1096/fj.10-169540			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21402719				2022-12-28	WOS:000292242200012
J	McCann, JC; Ames, BN				McCann, Joyce C.; Ames, Bruce N.			Adaptive dysfunction of selenoproteins from the perspective of the triage theory: why modest selenium deficiency may increase risk of diseases of aging	FASEB JOURNAL			English	Review						nutrition; micronutrients; cancer; heart disease; infection	HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; SELENOCYSTEINE TRANSFER-RNA; THIOREDOXIN REDUCTASE 1; EARLY EMBRYONIC LETHALITY; DEIODINASE THR92ALA POLYMORPHISM; METHIONINE SULFOXIDE REDUCTASE; THYROID-HORMONE METABOLISM; TYROSINE-PHOSPHATASE 1B; PROSTATE-CANCER RISK; KASHIN-BECK-DISEASE	The triage theory proposes that modest deficiency of any vitamin or mineral (V/M) could increase age-related diseases. V/M-dependent proteins required for short-term survival and/or reproduction (i.e., "essential") are predicted to be protected on V/M deficiency over other "nonessential" V/M-dependent proteins needed only for long-term health. The result is accumulation of insidious damage, increasing disease risk. We successfully tested the theory against published evidence on vitamin K. Here, we review about half of the 25 known mammalian selenoproteins; all of those with mouse knockout or human mutant phenotypes that could be used as criteria for a classification of essential or nonessential. Five selenoproteins (Gpx4, Txnrd1, Txnrd2, Dio3, and Sepp1) were classified as essential and 7 (Gpx1, Gpx 2, Gpx 3, Dio1, Dio2, Msrb1, and SelN) nonessential. On modest selenium (Se) deficiency, nonessential selenoprotein activities and concentrations are preferentially lost, with one exception (Dio1 in the thyroid, which we predict is conditionally essential). Mechanisms include the requirement of a special form of tRNA sensitive to Se deficiency for translation of nonessential selenoprotein mRNAs except Dio1. The same set of age-related diseases and conditions, including cancer, heart disease, and immune dysfunction, are prospectively associated with modest Se deficiency and also with genetic dysfunction of nonessential selenoproteins, suggesting that Se deficiency could be a causal factor, a possibility strengthened by mechanistic evidence. Modest Se deficiency is common in many parts of the world; optimal intake could prevent future disease.-McCann, J. C., Ames, B. N. Adaptive dysfunction of selenoproteins from the perspective of the triage theory: why modest selenium deficiency may increase risk of diseases of aging. FASEB J. 25, 1793-1814 (2011). www.fasebj.org	[McCann, Joyce C.; Ames, Bruce N.] Childrens Hosp Oakland Res Inst, Nutr & Metab Ctr, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	McCann, JC (corresponding author), Childrens Hosp Oakland Res Inst, Nutr & Metab Ctr, 5700 Martin Luthur King Jr Way, Oakland, CA 94609 USA.	jmccann@chori.org; bames@chori.org						Aachmann FL, 2010, J BIOL CHEM, V285, P33315, DOI 10.1074/jbc.M110.132308; Akbaraly NT, 2007, EPIDEMIOLOGY, V18, P52, DOI 10.1097/01.ede.0000248202.83695.4e; Akbaraly NT, 2005, CLIN CHEM, V51, P2117, DOI 10.1373/clinchem.2005.055301; Akbaraly TN, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-21; Al-Taie OH, 2004, NUTR CANCER, V48, P6, DOI 10.1207/s15327914nc4801_2; ALFTHAN GA, 2010, NATIONWIDE SUPPLEMEN; Allamand V, 2006, EMBO REP, V7, P450, DOI 10.1038/sj.embor.7400648; Amaral AFS, 2010, CANCER EPIDEM BIOMAR, V19, P2407, DOI 10.1158/1055-9965.EPI-10-0544; Ames BN, 2007, AM J CLIN NUTR, V86, P522, DOI 10.1093/ajcn/86.2.522; Ames BN, 2006, P NATL ACAD SCI USA, V103, P17589, DOI 10.1073/pnas.0608757103; Ames BN, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/725071; Arbogast S, 2010, ANTIOXID REDOX SIGN, V12, P893, DOI 10.1089/ars.2009.2890; Arnaud J, 2007, J NUTR BIOCHEM, V18, P482, DOI 10.1016/j.jnutbio.2006.09.004; Arner ESJ, 2010, EXP CELL RES, V316, P1296, DOI 10.1016/j.yexcr.2010.02.032; Arner ESJ, 2009, BBA-GEN SUBJECTS, V1790, P495, DOI 10.1016/j.bbagen.2009.01.014; Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Ashton K, 2009, AM J CLIN NUTR, V89, p2025S, DOI 10.3945/ajcn.2009.27230F; Baek IJ, 2007, J MOL HISTOL, V38, P237, DOI 10.1007/s10735-007-9092-7; Baliga MS, 2007, BIOL TRACE ELEM RES, V115, P227, DOI 10.1007/BF02685998; Baliga MS, 2008, MOL NUTR FOOD RES, V52, P1300, DOI 10.1002/mnfr.200800020; Banning A, 2005, MOL CELL BIOL, V25, P4914, DOI 10.1128/MCB.25.12.4914-4923.2005; Banning A, 2008, ANTIOXID REDOX SIGN, V10, P1491, DOI 10.1089/ars.2008.2047; Barnes KM, 2009, J NUTR, V139, P199, DOI 10.3945/jn.108.098624; Bassett JHD, 2010, P NATL ACAD SCI USA, V107, P7604, DOI 10.1073/pnas.0911346107; Bates CJ, 2002, J TRACE ELEM MED BIO, V16, P1, DOI 10.1016/S0946-672X(02)80002-5; Baum MK, 1997, J ACQ IMMUN DEF SYND, V15, P370, DOI 10.1097/00042560-199708150-00007; Beck MA, 1998, FASEB J, V12, P1143, DOI 10.1096/fasebj.12.12.1143; Beckett GJ, 2005, J ENDOCRINOL, V184, P455, DOI 10.1677/joe.1.05971; BECKETT GJ, 1993, AM J CLIN NUTR, V57, P240; BEECH SG, 1993, J ENDOCRINOL, V136, P361, DOI 10.1677/joe.0.1360361; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Bellinger FP, 2009, BIOCHEM J, V422, P11, DOI 10.1042/BJ20090219; Bermano G, 2007, GENES NUTR, V2, P225, DOI 10.1007/s12263-007-0052-3; BERMANO G, 1995, BIOCHEM J, V311, P425, DOI 10.1042/bj3110425; Bermano G, 1996, BIOL TRACE ELEM RES, V51, P211, DOI 10.1007/BF02784076; Bermano G, 1996, FEBS LETT, V387, P157, DOI 10.1016/0014-5793(96)00493-0; Berndt C, 2007, AM J PHYSIOL-HEART C, V292, pH1227, DOI 10.1152/ajpheart.01162.2006; Berry MJ, 2005, NAT GENET, V37, P1162, DOI 10.1038/ng1105-1162; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Blankenberg S, 2003, NEW ENGL J MED, V349, P1605, DOI 10.1056/NEJMoa030535; Bleys J, 2008, ARCH INTERN MED, V168, P404, DOI 10.1001/archinternmed.2007.74; Bleys J, 2007, DIABETES CARE, V30, P829, DOI 10.2337/dc06-1726; BOITANI C, 2008, MOL MECH SPERMATOGEN, P1; Bondareva AA, 2007, FREE RADICAL BIO MED, V43, P911, DOI 10.1016/j.freeradbiomed.2007.05.026; Boosalis MG, 2008, NUTR CLIN PRACT, V23, P152, DOI 10.1177/0884533608314532; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Brenneisen Peter, 2005, Molecular Aspects of Medicine, V26, P256, DOI 10.1016/j.mam.2005.07.004; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Brigelius-Flohe R, 2001, BIOFACTORS, V14, P101, DOI 10.1002/biof.5520140114; Brigelius-Flohe R, 2008, CHEM BIODIVERS, V5, P389, DOI 10.1002/cbdv.200890039; Brigelius-Flohe R, 2006, BIOL CHEM, V387, P1329, DOI 10.1515/BC.2006.166; Brigelius-Flohe R, 2009, BBA-GEN SUBJECTS, V1790, P1555, DOI 10.1016/j.bbagen.2009.03.006; Budiman ME, 2009, MOL CELL, V35, P479, DOI 10.1016/j.molcel.2009.06.026; Bunevicius R, 2010, CURR OPIN PSYCHIATR, V23, P363, DOI 10.1097/YCO.0b013e3283387b50; Burk RF, 2009, BBA-GEN SUBJECTS, V1790, P1441, DOI 10.1016/j.bbagen.2009.03.026; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; BURK RF, 1972, J NUTR, V102, P1049, DOI 10.1093/jn/102.8.1049; BURK RF, 1991, AM J PHYSIOL, V261, pE26, DOI 10.1152/ajpendo.1991.261.1.E26; Cao J, 2008, OSTEOARTHR CARTILAGE, V16, P680, DOI 10.1016/j.joca.2007.09.002; Carlson BA, 2005, TOP CURR GENET, V12, P431, DOI 10.1007/b106652; Carlson BA, 2005, J BIOL CHEM, V280, P5542, DOI 10.1074/jbc.M411725200; Carlson BA, 2007, J BIOL CHEM, V282, P32591, DOI 10.1074/jbc.M707036200; Carlson BA, 2010, P NUTR SOC, V69, P300, DOI 10.1017/S002966511000176X; Carlson BA, 2009, MOLECULES, V14, P3509, DOI 10.3390/molecules14093509; CHANOINE JP, 1993, J CLIN INVEST, V91, P2709, DOI 10.1172/JCI116510; Chariot P, 2003, MUSCLE NERVE, V27, P662, DOI 10.1002/mus.10304; Cheng ZY, 2010, TRENDS ENDOCRIN MET, V21, P589, DOI 10.1016/j.tem.2010.06.005; Chidakel A, 2005, THYROID, V15, P899, DOI 10.1089/thy.2005.15.899; Chittum HS, 1997, BBA-MOL CELL RES, V1359, P25, DOI 10.1016/S0167-4889(97)00092-X; Chu FF, 2004, FREE RADICAL BIO MED, V36, P1481, DOI 10.1016/j.freeradbiomed.2004.04.010; CHU FF, 1993, J BIOL CHEM, V268, P2571; Chu FF, 2004, CANCER RES, V64, P962, DOI 10.1158/0008-5472.CAN-03-2272; Chu FF, 1996, GENOMICS, V32, P272, DOI 10.1006/geno.1996.0115; Comhair SAA, 2005, ANTIOXID REDOX SIGN, V7, P72, DOI 10.1089/ars.2005.7.72; Conrad M, 2005, MOL CELL BIOL, V25, P7637, DOI 10.1128/MCB.25.17.7637-7644.2005; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Conrad M, 2007, BIOL CHEM, V388, P1019, DOI 10.1515/BC.2007.130; Conrad M, 2010, ANTIOXID REDOX SIGN, V12, P851, DOI 10.1089/ars.2009.2912; Conrad M, 2009, BBA-GEN SUBJECTS, V1790, P1575, DOI 10.1016/j.bbagen.2009.05.001; CONRAD MC, 2011, SELENIUM IT IN PRESS; Cooper ML, 2008, CANCER RES, V68, P10171, DOI 10.1158/0008-5472.CAN-08-1827; Crosley LK, 2007, ARCH BIOCHEM BIOPHYS, V459, P178, DOI 10.1016/j.abb.2006.12.029; Czernichow S, 2006, AM J CLIN NUTR, V84, P395; DAMMEYER P, 2010, BIOCHIM BIOPHYS ACTA, V1810, P111; Dayan CM, 2009, NAT REV ENDOCRINOL, V5, P211, DOI 10.1038/nrendo.2009.19; de Grooth GJ, 2004, J LIPID RES, V45, P1967, DOI 10.1194/jlr.R400007-JLR200; de Haan JB, 2004, FREE RADICAL BIO MED, V36, P53, DOI 10.1016/j.freeradbiomed.2003.10.020; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; Demelash A, 2004, EUR J ENDOCRINOL, V150, P841, DOI 10.1530/eje.0.1500841; DIAMOND AM, 1993, J BIOL CHEM, V268, P14215; Dittrich AM, 2010, EUR RESPIR J, V35, P1148, DOI 10.1183/09031936.00026108; Diwadkar-Navsariwala V, 2006, P NATL ACAD SCI USA, V103, P8179, DOI 10.1073/pnas.0508218103; Donovan J, 2010, J MOL BIOL, V400, P659, DOI 10.1016/j.jmb.2010.05.026; Donovan J, 2010, ANTIOXID REDOX SIGN, V12, P881, DOI 10.1089/ars.2009.2878; Dora JM, 2010, EUR J ENDOCRINOL, V163, P427, DOI 10.1530/EJE-10-0419; Downey CM, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000616; Drevet JR, 2006, MOL CELL ENDOCRINOL, V250, P70, DOI 10.1016/j.mce.2005.12.027; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Duffield AJ, 1999, AM J CLIN NUTR, V70, P896; Dumitrescu AM, 2010, ANTIOXID REDOX SIGN, V12, P905, DOI 10.1089/ars.2009.2892; Dusinska M, 2002, FOOD CHEM TOXICOL, V40, P1119, DOI 10.1016/S0278-6915(02)00055-8; Ekholm R, 1997, ENDOCRINOLOGY, V138, P2871, DOI 10.1210/en.138.7.2871; Fang WF, 2010, CARCINOGENESIS, V31, P1360, DOI 10.1093/carcin/bgq114; Flores-Mateo G, 2006, AM J CLIN NUTR, V84, P762, DOI 10.1093/ajcn/84.4.762; Fomenko DE, 2009, J BIOL CHEM, V284, P5986, DOI 10.1074/jbc.M805770200; Forgione MA, 2002, CIRCULATION, V106, P1154, DOI 10.1161/01.CIR.0000026820.87824.6A; Galton VA, 2009, ENDOCRINOLOGY, V150, P2957, DOI 10.1210/en.2008-1572; Gao SJ, 2007, AM J EPIDEMIOL, V165, P955, DOI 10.1093/aje/kwk073; Gereben B, 2008, ENDOCR REV, V29, P898, DOI 10.1210/er.2008-0019; Gogakos AI, 2010, ARCH BIOCHEM BIOPHYS, V503, P129, DOI 10.1016/j.abb.2010.06.021; GOLSTEIN J, 1988, ACTA ENDOCRINOL-COP, V118, P495, DOI 10.1530/acta.0.1180495; Gromer S, 2005, CELL MOL LIFE SCI, V62, P2414, DOI 10.1007/s00018-005-5143-y; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; GU BQ, 1983, CHINESE MED J-PEKING, V96, P251; Guo TW, 2004, J MED GENET, V41, P585, DOI 10.1136/jmg.2004.019190; Hadley KB, 2001, J NUTR BIOCHEM, V12, P693, DOI 10.1016/S0955-2863(01)00189-9; Hansel A, 2005, BBA-PROTEINS PROTEOM, V1703, P239, DOI 10.1016/j.bbapap.2004.09.010; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hatfield DL, 2006, PROG NUCLEIC ACID RE, V81, P97, DOI 10.1016/S0079-6603(06)81003-2; Hatfield DL, 2009, BBA-GEN SUBJECTS, V1790, P1541, DOI 10.1016/j.bbagen.2009.03.001; Havel RJ, 1997, P NUTR SOC, V56, P659, DOI 10.1079/PNS19970065; Heemstra KA, 2010, J BONE MINER RES, V25, P1385, DOI 10.1002/jbmr.27; Hernandez A, 2006, J CLIN INVEST, V116, P476, DOI 10.1172/JCI26240; Hernandez A, 2005, THYROID, V15, P865, DOI 10.1089/thy.2005.15.865; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2004, J NUTR, V134, P157, DOI 10.1093/jn/134.1.157; Hill KE, 1996, J NUTR, V126, P138, DOI 10.1093/jn/126.1.138; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HILL KE, 1987, J NUTR, V117, P99, DOI 10.1093/jn/117.1.99; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Hoeflich J, 2010, BRIT J NUTR, V104, P1601, DOI 10.1017/S0007114510002618; Hoffmann FW, 2010, J NUTR, V140, P1155, DOI 10.3945/jn.109.120725; Hoffmann PR, 2008, MOL NUTR FOOD RES, V52, P1273, DOI 10.1002/mnfr.200700330; Hoffmann PR, 2005, THYROID, V15, P769, DOI 10.1089/thy.2005.15.769; Holmgren A, 2010, BIOCHEM BIOPH RES CO, V396, P120, DOI 10.1016/j.bbrc.2010.03.083; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Hrdina J, 2009, J NUTR BIOCHEM, V20, P638, DOI 10.1016/j.jnutbio.2008.06.009; Hurst R, 2010, AM J CLIN NUTR, V91, P923, DOI 10.3945/ajcn.2009.28169; Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8; Irons R, 2006, J NUTR, V136, P1311, DOI 10.1093/jn/136.5.1311; Jacob C, 2003, ANGEW CHEM INT EDIT, V42, P4742, DOI 10.1002/anie.200300573; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865; Karunasinghe N, 2004, CANCER EPIDEM BIOMAR, V13, P391; Kelner MJ, 2000, GENE, V248, P109, DOI 10.1016/S0378-1119(00)00137-2; Kenet G, 1999, ARTERIOSCL THROM VAS, V19, P2017, DOI 10.1161/01.ATV.19.8.2017; Kiermayer C, 2007, BIOL CHEM, V388, P1091, DOI 10.1515/BC.2007.133; Kipp A, 2009, MOL NUTR FOOD RES, V53, P1561, DOI 10.1002/mnfr.200900105; Kirkwood TBL, 2008, J INTERN MED, V263, P117, DOI 10.1111/j.1365-2796.2007.01901.x; Klivenyi P, 2000, J NEUROSCI, V20, P1; Kohrle J, 2009, BEST PRACT RES CL EN, V23, P815, DOI 10.1016/j.beem.2009.08.002; Kohrle J, 2005, THYROID, V15, P841, DOI 10.1089/thy.2005.15.841; KramerGuth A, 1996, NEPHRON, V74, P378, DOI 10.1159/000189339; Labunskyy VM, 2011, ANTIOXID REDOX SIGN, V14, P2327, DOI 10.1089/ars.2010.3526; Laclaustra M, 2010, ATHEROSCLEROSIS, V210, P643, DOI 10.1016/j.atherosclerosis.2010.01.005; Laclaustra M, 2009, ENVIRON HEALTH PERSP, V117, P1409, DOI 10.1289/ehp.0900704; Latreche L, 2009, NUCLEIC ACIDS RES, V37, P5868, DOI 10.1093/nar/gkp635; Lee BC, 2009, BBA-GEN SUBJECTS, V1790, P1471, DOI 10.1016/j.bbagen.2009.04.014; Lee OJ, 2005, NEOPLASIA, V7, P854, DOI 10.1593/neo.05328; LEI XG, 1995, J NUTR, V125, P1438; Lei XG, 2007, ANNU REV NUTR, V27, P41, DOI 10.1146/annurev.nutr.27.061406.093716; Lescure A, 2008, CHEM BIODIVERS, V5, P408, DOI 10.1002/cbdv.200890041; Lescure A, 2009, BBA-GEN SUBJECTS, V1790, P1569, DOI 10.1016/j.bbagen.2009.03.002; Letsiou S, 2009, BIOL TRACE ELEM RES, V128, P8, DOI 10.1007/s12011-008-8252-2; LEVANDER OA, 1983, AM J CLIN NUTR, V37, P887, DOI 10.1093/ajcn/37.6.887; Liang HY, 2009, J BIOL CHEM, V284, P30836, DOI 10.1074/jbc.M109.032839; Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864; Loh K, 2009, CELL METAB, V10, P260, DOI 10.1016/j.cmet.2009.08.009; Low SC, 2000, EMBO J, V19, P6882, DOI 10.1093/emboj/19.24.6882; Lu J, 2009, J BIOL CHEM, V284, P723, DOI 10.1074/jbc.R800045200; Lu J, 2009, FASEB J, V23, P2394, DOI 10.1096/fj.08-127662; Lu JX, 2005, ANTIOXID REDOX SIGN, V7, P1715, DOI 10.1089/ars.2005.7.1715; Lubos E, 2010, ATHEROSCLEROSIS, V209, P271, DOI 10.1016/j.atherosclerosis.2009.09.008; Maiti B, 2009, HUM MUTAT, V30, P411, DOI 10.1002/humu.20879; Mandal PK, 2010, CANCER RES, V70, P9505, DOI 10.1158/0008-5472.CAN-10-1509; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; McCann JC, 2009, AM J CLIN NUTR, V90, P889, DOI 10.3945/ajcn.2009.27930; McClung JP, 2004, P NATL ACAD SCI USA, V101, P8852, DOI 10.1073/pnas.0308096101; Meplan C, 2009, ANTIOXID REDOX SIGN, V11, P2631, DOI [10.1089/ars.2009.2533, 10.1089/ARS.2009.2533]; Meplan C, 2010, CARCINOGENESIS, V31, P1074, DOI 10.1093/carcin/bgq076; Meulenbelt I, 2008, HUM MOL GENET, V17, P1867, DOI 10.1093/hmg/ddn082; Meulenbelt I, 2011, ANN RHEUM DIS, V70, P164, DOI 10.1136/ard.2010.133660; Miniard AC, 2010, NUCLEIC ACIDS RES, V38, P4807, DOI 10.1093/nar/gkq247; Misu H, 2010, CELL METAB, V12, P483, DOI 10.1016/j.cmet.2010.09.015; Mitchell JH, 1996, J MOL ENDOCRINOL, V16, P259, DOI 10.1677/jme.0.0160259; Mitchell JH, 1997, J ENDOCRINOL, V155, P255, DOI 10.1677/joe.0.1550255; Mitchell J, 2009, FREE RADICAL BIO MED, V46, P202, DOI 10.1016/j.freeradbiomed.2008.09.041; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Mosfegh A., 2009, WHAT WE EAT AM NHANE; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Mueller AS, 2008, J NUTR, V138, P2328, DOI 10.3945/jn.108.089482; Mueller AS, 2009, J NUTR BIOCHEM, V20, P235, DOI 10.1016/j.jnutbio.2008.02.007; MUELLER AS, 2009, FREE RADICAL RES, V43, P1; Naithani R, 2008, MINI-REV MED CHEM, V8, P657, DOI 10.2174/138955708784567368; Nakayama A, 2007, J NUTR, V137, P690, DOI 10.1093/jn/137.3.690; *NAS DRI, 2000, DIET REF INT VIT C V; Nawrot TS, 2007, EUR HEART J, V28, P628, DOI 10.1093/eurheartj/ehl479; Nicholson P, 2010, CELL MOL LIFE SCI, V67, P677, DOI 10.1007/s00018-009-0177-1; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Novoselov SV, 2010, ANTIOXID REDOX SIGN, V12, P829, DOI 10.1089/ars.2009.2895; Novoselov SV, 2005, ONCOGENE, V24, P8003, DOI 10.1038/sj.onc.1208940; Okuno T, 2006, BIOL TRACE ELEM RES, V109, P155, DOI 10.1385/BTER:109:2:155; Olson GE, 2010, AM J PHYSIOL-RENAL, V298, pF1244, DOI 10.1152/ajprenal.00662.2009; Olson GE, 2005, BIOL REPROD, V73, P201, DOI 10.1095/biolreprod.105.040360; Panicker V, 2009, J CLIN ENDOCR METAB, V94, P1623, DOI 10.1210/jc.2008-1301; Papp LV, 2010, ANTIOXID REDOX SIGN, V12, P793, DOI 10.1089/ars.2009.2973; Peeters RP, 2006, EUR J ENDOCRINOL, V155, P655, DOI 10.1530/eje.1.02279; Peeters RP, 2005, J CLIN ENDOCR METAB, V90, P256, DOI 10.1210/jc.2004-1301; Persson-Moschos M, 1998, EUR J CLIN NUTR, V52, P363, DOI 10.1038/sj.ejcn.1600565; Peters U, 2008, CANCER EPIDEM BIOMAR, V17, P1144, DOI 10.1158/1055-9965.EPI-07-2947; Ray AL, 2006, J NUTR, V136, P172, DOI 10.1093/jn/136.1.172; Rayman MP, 2008, BRIT J NUTR, V100, P254, DOI 10.1017/S0007114508939830; Rayman MP, 2009, BBA-GEN SUBJECTS, V1790, P1533, DOI 10.1016/j.bbagen.2009.03.014; Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Reeves MA, 2009, CELL MOL LIFE SCI, V66, P2457, DOI 10.1007/s00018-009-0032-4; Renko K, 2008, BIOCHEM J, V409, P741, DOI 10.1042/BJ20071172; Rollins MF, 2010, J CELL SCI, V123, P2402, DOI 10.1242/jcs.068106; Sachdev SW, 2001, BIOCHEM J, V357, P851; Savaskan NE, 2007, BIOL CHEM, V388, P1007, DOI 10.1515/BC.2007.126; Schmutzler C, 2007, BIOL CHEM, V388, P1053, DOI 10.1515/BC.2007.122; Schneider M, 2009, FASEB J, V23, P3233, DOI 10.1096/fj.09-132795; Schneider MJ, 2001, MOL ENDOCRINOL, V15, P2137, DOI 10.1210/me.15.12.2137; Schneider MJ, 2006, ENDOCRINOLOGY, V147, P580, DOI 10.1210/en.2005-0739; Schnurr K, 1996, J BIOL CHEM, V271, P4653; Schoenmakers E, 2010, J CLIN INVEST, V120, P4220, DOI 10.1172/JCI43653; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; Schomburg L, 2010, MOL CELL ENDOCRINOL, V322, P114, DOI 10.1016/j.mce.2010.01.011; Schomburg L, 2009, BBA-GEN SUBJECTS, V1790, P1453, DOI 10.1016/j.bbagen.2009.03.015; Schriever SC, 2009, EXP BIOL MED, V234, P513, DOI 10.3181/0812-RM-369; Schweizer U, 2005, IUBMB LIFE, V57, P737, DOI 10.1080/15216540500364255; Schweizer U, 2004, BRAIN RES REV, V45, P164, DOI 10.1016/j.brainresrev.2004.03.004; Schweizer U, 2008, MOL CELL ENDOCRINOL, V289, P1, DOI 10.1016/j.mce.2008.04.007; Schweizer U, 2008, ANTIOXID REDOX SIGN, V10, P1577, DOI 10.1089/ars.2008.2054; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Selenius M, 2010, ANTIOXID REDOX SIGN, V12, P867, DOI 10.1089/ars.2009.2884; Sengupta A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012249; Sherwood L., 2006, FUNDAMENTALS PHYSL H; Singh A, 2006, AM J RESP CELL MOL, V35, P639, DOI 10.1165/rcmb.2005-0325OC; Soerensen J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001813; Speckmann B, 2010, FREE RADICAL BIO MED, V49, P777, DOI 10.1016/j.freeradbiomed.2010.05.035; Speckmann B, 2008, HEPATOLOGY, V48, P1998, DOI 10.1002/hep.22526; Squires JE, 2008, IUBMB LIFE, V60, P232, DOI 10.1002/iub.38; Squires JE, 2007, MOL CELL BIOL, V27, P7848, DOI 10.1128/MCB.00793-07; St Germain DL, 2005, THYROID, V15, P905, DOI 10.1089/thy.2005.15.905; Stadtman ER, 2003, ANTIOXID REDOX SIGN, V5, P577, DOI 10.1089/152308603770310239; Steevens J, 2010, GASTROENTEROLOGY, V138, P1704, DOI 10.1053/j.gastro.2009.12.004; Steinbrecher A, 2010, CANCER EPIDEM BIOMAR, V19, P2958, DOI 10.1158/1055-9965.EPI-10-0364; Steinbrenner H, 2011, J CLIN BIOCHEM NUTR, V48, P40, DOI 10.3164/jcbn.11-002FR; Steinbrenner H, 2009, BBA-GEN SUBJECTS, V1790, P1478, DOI 10.1016/j.bbagen.2009.02.014; Stranges S, 2007, ANN INTERN MED, V147, P217, DOI 10.7326/0003-4819-147-4-200708210-00175; Stranges S, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-564; Sunde RA, 2005, J NUTR, V135, P2144, DOI 10.1093/jn/135.9.2144; Sunde RA, 2010, J NUTR BIOCHEM, V21, P665, DOI 10.1016/j.jnutbio.2009.11.012; Sunde RA, 2009, J TRACE ELEM MED BIO, V23, P132, DOI 10.1016/j.jtemb.2009.02.002; Sutherland A, 2010, GENES NUTR, V5, P215, DOI 10.1007/s12263-010-0176-8; Thomson CD, 2004, EUR J CLIN NUTR, V58, P391, DOI 10.1038/sj.ejcn.1601800; Torrance CJ, 1997, ENDOCRINOLOGY, V138, P1204, DOI 10.1210/en.138.3.1204; Turanov AA, 2006, J BIOL CHEM, V281, P22953, DOI 10.1074/jbc.M604326200; Turanov AA, 2010, BIOCHEM J, V430, P285, DOI 10.1042/BJ20091378; Udler M, 2007, J CLIN ONCOL, V25, P3015, DOI 10.1200/JCO.2006.10.0099; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Uthus EO, 2007, BIOL TRACE ELEM RES, V115, P265, DOI 10.1007/BF02686001; Venardos K, 2004, J TRACE ELEM MED BIO, V18, P81, DOI 10.1016/j.jtemb.2004.01.001; Verma S, 2011, J IMMUNOL, V186, P2127, DOI 10.4049/jimmunol.1002878; Vernet P, 2004, MOL CELL ENDOCRINOL, V216, P31, DOI 10.1016/j.mce.2003.10.069; Voetsch B, 2008, STROKE, V39, P303, DOI 10.1161/STROKEAHA.107.490094; Voetsch B, 2007, STROKE, V38, P41, DOI 10.1161/01.STR.0000252027.53766.2b; Wagner MS, 2009, MICROSC RES TECHNIQ, V72, P796, DOI 10.1002/jemt.20759; Walshe J, 2007, CANCER RES, V67, P4751, DOI 10.1158/0008-5472.CAN-06-4192; Wang CM, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-55; Wang XD, 2008, DIABETOLOGIA, V51, P1515, DOI 10.1007/s00125-008-1055-3; Wasson GR, 2008, MUTAGENESIS, V23, P153, DOI 10.1093/mutage/gen003; Wei WQ, 2004, AM J CLIN NUTR, V79, P80; WEITZEL F, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88, DOI 10.1016/0304-4165(90)90018-R; Westphal K, 2009, FREE RADICAL BIO MED, V47, P1652, DOI 10.1016/j.freeradbiomed.2009.09.017; Whanger PD, 2004, BRIT J NUTR, V91, P11, DOI 10.1079/BJN20031015; Wingler K, 1999, EUR J BIOCHEM, V259, P149, DOI 10.1046/j.1432-1327.1999.00012.x; Wingler K, 1999, BIOFACTORS, V10, P245, DOI 10.1002/biof.5520100223; Winterbourn CC, 2008, FREE RADICAL BIO MED, V45, P549, DOI 10.1016/j.freeradbiomed.2008.05.004; Wolf N, 2005, EXP EYE RES, V81, P276, DOI 10.1016/j.exer.2005.01.024; Wu QZ, 2004, BIOL TRACE ELEM RES, V98, P73, DOI 10.1385/BTER:98:1:73; Wu QZ, 2003, J INORG BIOCHEM, V94, P301, DOI 10.1016/S0162-0134(03)00058-8; Xia YM, 2010, AM J CLIN NUTR, V92, P525, DOI 10.3945/ajcn.2010.29642; Xia YM, 2005, AM J CLIN NUTR, V81, P829, DOI 10.1093/ajcn/81.4.829; XIA YM, 1989, J NUTR, V119, P1318, DOI 10.1093/jn/119.9.1318; Xiong YM, 2010, OSTEOARTHR CARTILAGE, V18, P817, DOI 10.1016/j.joca.2010.02.004; YANG JG, 1989, J NUTR, V119, P1010, DOI 10.1093/jn/119.7.1010; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6; Yoo MH, 2010, METHOD ENZYMOL, V474, P255, DOI 10.1016/S0076-6879(10)74015-5; Yu L, 2011, BIOL TRACE ELEM RES, V141, P254, DOI 10.1007/s12011-010-8726-x; Zhuo P, 2009, BBA-GEN SUBJECTS, V1790, P1546, DOI 10.1016/j.bbagen.2009.03.004	292	85	85	0	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1793	1814		10.1096/fj.11-180885	http://dx.doi.org/10.1096/fj.11-180885			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21402715				2022-12-28	WOS:000291023800004
J	Rossini, L; Hashimoto, Y; Suzuki, H; Kurita, M; Gianfriddo, M; Scali, C; Roncarati, R; Franceschini, D; Pollio, G; Trabalzini, L; Terstappen, GC; Matsuoka, M; Caricasole, A				Rossini, Lara; Hashimoto, Yuichi; Suzuki, Hiroaki; Kurita, Megumi; Gianfriddo, Marco; Scali, Carla; Roncarati, Renza; Franceschini, Davide; Pollio, Giuseppe; Trabalzini, Lorenza; Terstappen, Georg C.; Matsuoka, Masaaki; Caricasole, Andrea			VSTM2L is a novel secreted antagonist of the neuroprotective peptide Humanin	FASEB JOURNAL			English	Article						protein-protein interaction; neurodegenerative disease; neurotrophic factor	NEURONAL CELL-DEATH; RESCUE FACTOR HUMANIN; ALZHEIMERS-DISEASE; ACTIVATION DOMAIN; BINDS; APOPTOSIS; PROTEINS; SURVIVAL; NETWORK; ATAXIAS	Humanin (HN) is a 24-residue peptide displaying a protective activity in vitro against a range of cytotoxic and neurotoxic insults, as well as mediating in vivo amelioration of Alzheimer disease (AD)-related memory impairment in experimental models. Published evidence suggests that the mechanisms through which HN exerts its cyto- and neuroprotective activity may include its secretion and binding to membrane-associated receptors. Here, we describe the identification of a new modulator of HN neuroprotective activity, V-set and transmembrane domain containing 2 like (VSTM2L), previously known as C20orf102. VSTM2L interacts with HN in both yeast and mammalian cells, is secreted in cultured cells, is present in serum, and is selectively expressed in the central nervous system. VSTM2L colocalizes with HN in distinct brain areas as well as in primary cultured neurons, where it plays a role in the modulation of neuronal viability. When tested in HN neuroprotection bioassays, VSTM2L acts as a strong antagonist of HN neuroprotective activity. In summary, VSTM2L is the first example of a secreted antagonist of HN and may play a role in the modulation of HN biological functions-Rossini, L., Hashimoto, Y., Suzuki, H., Kurita, M., Gianfriddo, M., Scali, C., Roncarati, R., Franceschini, D., Pollio, G., Trabalzini, L., Terstappen, G. C., Matsuoka, M., Caricasole, A. VSTM2L is a novel secreted antagonist of the neuroprotective peptide Humanin. FASEB J. 25, 1983-2000 (2011). www.fasebj.org	[Caricasole, Andrea] Siena Biotech SpA, Dept Neurosci, I-53100 Siena, Italy; [Hashimoto, Yuichi; Suzuki, Hiroaki; Kurita, Megumi; Matsuoka, Masaaki] Tokyo Med Univ, Dept Pharmacol, Tokyo 1608402, Japan; [Trabalzini, Lorenza] Univ Siena, Dept Mol Biol, I-53100 Siena, Italy	Siena Biotech; Tokyo Medical University; University of Siena	Caricasole, A (corresponding author), Siena Biotech SpA, Dept Neurosci, Str Petriccio Belriguardo 35, I-53100 Siena, Italy.	sakimatu@tokyo-med.ac.jp; acaricasole@sienabiotech.it	Hashimoto, Yuichi/N-1508-2015	Hashimoto, Yuichi/0000-0001-5863-3618; Trabalzini, Lorenza/0000-0002-0850-7186	Grants-in-Aid for Scientific Research [22590247] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Aho S, 1997, ANAL BIOCHEM, V253, P270, DOI 10.1006/abio.1997.2394; Arakawa T, 2008, CURR MED CHEM, V15, P2086, DOI 10.2174/092986708785747616; Ballas N, 2005, CURR OPIN NEUROBIOL, V15, P500, DOI 10.1016/j.conb.2005.08.015; Caricasole A, 2002, FASEB J, V16, P1331, DOI 10.1096/fj.02-0018fje; Chan KC., 2004, CLIN PROTEOM, V1, P101, DOI [DOI 10.1385/CP:1:2:101, 10.1385/CP:1:2:101]; Copani A, 1999, FASEB J, V13, P2225, DOI 10.1096/fasebj.13.15.2225; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Durr A, 2010, LANCET NEUROL, V9, P885, DOI 10.1016/S1474-4422(10)70183-6; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Halsey TA, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r104; Hashimoto Y, 2005, LIFE SCI, V77, P3092, DOI 10.1016/j.lfs.2005.03.031; Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Hashimoto Y, 2001, BIOCHEM BIOPH RES CO, V283, P460, DOI 10.1006/bbrc.2001.4765; Hashimoto Y, 2009, MOL BIOL CELL, V20, P2864, DOI 10.1091/mbc.E09-02-0168; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Kariya S, 2005, ACTA NEUROPATHOL, V109, P367, DOI 10.1007/s00401-004-0965-5; Kariya S, 2005, J MOL NEUROSCI, V25, P165, DOI 10.1385/JMN:25:2:165; Kariya S, 2005, NEUROPEPTIDES, V39, P97, DOI 10.1016/j.npep.2004.11.004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lim J, 2006, CELL, V125, P801, DOI 10.1016/j.cell.2006.03.032; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; Luciano F, 2005, J BIOL CHEM, V280, P15825, DOI 10.1074/jbc.M413062200; Mortazavi A, 2006, GENOME RES, V16, P1208, DOI 10.1101/gr.4997306; Muzumdar RH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006334; Niikura T, 2006, CURR NEUROPHARMACOL, V4, P139, DOI 10.2174/157015906776359577; Niikura T, 2004, MOL NEUROBIOL, V30, P327, DOI 10.1385/MN:30:3:327; Niikura T, 2003, EUR J NEUROSCI, V17, P1150, DOI 10.1046/j.1460-9568.2003.02553.x; Nishimoto I, 2004, TRENDS MOL MED, V10, P102, DOI 10.1016/j.molmed.2004.01.001; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; Pollio G, 2008, J NEUROSCI METH, V172, P34, DOI 10.1016/j.jneumeth.2008.03.018; Saille C, 1999, NEUROSCIENCE, V92, P1455, DOI 10.1016/S0306-4522(99)00089-5; Staub E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-37; Tajima H, 2002, NEUROSCI LETT, V324, P227, DOI 10.1016/S0304-3940(02)00199-4; Terashita K, 2003, J NEUROCHEM, V85, P1521, DOI 10.1046/j.1471-4159.2003.01797.x; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Xu XS, 2008, BRAIN RES, V1227, P12, DOI 10.1016/j.brainres.2008.06.018; Yamagishi Y, 2003, PEPTIDES, V24, P585, DOI 10.1016/S0196-9781(03)00106-2; YAVIN Z, 1980, DEV BIOL, V75, P454, DOI 10.1016/0012-1606(80)90176-1; Ying GG, 2004, J IMMUNOL, V172, P7078, DOI 10.4049/jimmunol.172.11.7078; Zambrano A, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-82	43	17	20	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1983	2000		10.1096/fj.10-163535	http://dx.doi.org/10.1096/fj.10-163535			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21393573				2022-12-28	WOS:000291023800021
J	Yim, PD; Gallos, G; Xu, DB; Zhang, Y; Emala, CW				Yim, Peter D.; Gallos, George; Xu, Dingbang; Zhang, Yi; Emala, Charles W.			Novel expression of a functional glycine receptor chloride channel that attenuates contraction in airway smooth muscle	FASEB JOURNAL			English	Article						membrane potential; isoproterenol; organ bath; guinea pig; FLIPR	PHYSIOLOGICAL ROLES; RELAXATION; ACTIVATION; MECHANISMS; RELEASE	Airway smooth muscle (ASM) contraction is an important component of the pathophysiology of asthma. Taurine, an agonist of glycine receptor chloride (GlyR Cl(-)) channels, was found to relax contracted ASM, which led us to question whether functional GlyR Cl(-) channels are expressed in ASM. Messenger RNA for beta (GLRB), alpha 1 (GLRA1), alpha 2 (GLRA2), and alpha 4 (GLRA4) subunits were found in human (Homo sapiens) and guinea pig (Cavia porcellus) tracheal smooth muscle. Immunoblotting confirmed the protein expression of GLRA1 and GLRB subunits in ASM. Electrical activity of cultured human ASM cells was assessed using a fluorescent potentiometric dye and electrophysiological recordings. Glycine increased current and significantly increased fluorescence in a dose-dependent manner. The GlyR Cl(-) channel antagonist strychnine significantly blocked the effects of glycine on potentiometric fluorescence in ASM cells. Guinea pig airway ring relaxation of ACh-induced contractions by isoproterenol was significantly left-shifted in the presence of glycine. This effect of glycine was blocked by pretreatment with the GlyR Cl(-) channel antagonist strychnine. Glycine treatment during tachykinin- and acetylcholine-induced contractions significantly decreased the maintenance of muscle force compared to control. GlyR Cl(-) channels are expressed on ASM and regulate smooth muscle force and offer a novel target for therapeutic relaxation of ASM.-Yim, P. D., Gallos, G., Xu, D., Zhang, Y., Emala, C. W. Novel expression of a functional glycine receptor chloride channel that attenuates contraction in airway smooth muscle. FASEB J. 25, 1706-1717 (2011). www.fasebj.org	[Yim, Peter D.; Gallos, George; Xu, Dingbang; Zhang, Yi; Emala, Charles W.] Columbia Univ, Dept Anesthesiol, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Yim, PD (corresponding author), Columbia Univ, Dept Anesthesiol, Coll Phys & Surg, 650 168th St,Rm 713, New York, NY 10032 USA.	pdy1@columbia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008464] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED T, 1988, J ALLERGY CLIN IMMUN, V81, P133, DOI 10.1016/0091-6749(88)90232-1; Ben-Chaim Y, 2003, J BIOL CHEM, V278, P22482, DOI 10.1074/jbc.M301146200; DENEYNDEN JV, 2009, FRONT MOL NEUROSCI, V2, P9; Elster L, 1998, NEUROSCIENCE, V84, P519, DOI 10.1016/S0306-4522(97)00535-6; Froh M, 2002, AM J PHYSIOL-GASTR L, V283, pG856, DOI 10.1152/ajpgi.00503.2001; Gallos G, 2008, AM J PHYSIOL-LUNG C, V295, pL1040, DOI 10.1152/ajplung.90330.2008; Gosens R, 2006, AM J PHYSIOL-LUNG C, V291, pL523, DOI 10.1152/ajplung.00013.2006; Huang F, 2009, P NATL ACAD SCI USA, V106, P21413, DOI 10.1073/pnas.0911935106; Imtiaz MS, 2010, FEBS J, V277, P278, DOI 10.1111/j.1742-4658.2009.07437.x; Janssen LJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1757, DOI 10.1152/ajpcell.1997.272.6.C1757; Janssen LJ, 2004, AM J PHYSIOL-LUNG C, V287, pL852, DOI 10.1152/ajplung.00130.2004; Janssen LJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1161, DOI 10.1152/ajplung.00452.2001; Jensen AA, 2005, EUR J PHARMACOL, V521, P39, DOI 10.1016/j.ejphar.2005.08.002; Jooste E, 2005, ANESTHESIOLOGY, V102, P117, DOI 10.1097/00000542-200501000-00020; Kotlikoff MI, 1996, ANNU REV PHYSIOL, V58, P115, DOI 10.1146/annurev.ph.58.030196.000555; Liu QH, 2009, P NATL ACAD SCI USA, V106, P11418, DOI 10.1073/pnas.0813307106; Lynch JW, 2009, NEUROPHARMACOLOGY, V56, P303, DOI 10.1016/j.neuropharm.2008.07.034; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Mahaut-Smith MP, 2008, TRENDS PHARMACOL SCI, V29, P421, DOI 10.1016/j.tips.2008.05.007; Michoud MC, 2009, AM J RESP CELL MOL, V40, P217, DOI 10.1165/rcmb.2006-0444OC; Mizuta K, 2008, AM J PHYSIOL-LUNG C, V294, pL1206, DOI 10.1152/ajplung.00287.2007; Nassar T, 2010, AM J RESP CELL MOL, V43, P703, DOI 10.1165/rcmb.2009-0257OC; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Sahan-Firat S, 2005, EUR J PHARMACOL, V528, P169, DOI 10.1016/j.ejphar.2005.10.055; Simon J, 2004, J BIOL CHEM, V279, P41422, DOI 10.1074/jbc.M401354200; Wang YX, 1997, AM J PHYSIOL-CELL PH, V273, pC509, DOI 10.1152/ajpcell.1997.273.2.C509; Wijesinghe M, 2009, EUR RESPIR J, V34, P803, DOI 10.1183/09031936.00159708	27	23	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1706	1717		10.1096/fj.10-170530	http://dx.doi.org/10.1096/fj.10-170530			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21282206	Green Published			2022-12-28	WOS:000290023800026
J	Toh, YC; Voldman, J				Toh, Yi-Chin; Voldman, Joel			Fluid shear stress primes mouse embryonic stem cells for differentiation in a self-renewing environment via heparan sulfate proteoglycans transduction	FASEB JOURNAL			English	Article						microfluid; HSPG; mESC	FIBROBLAST-GROWTH-FACTOR; SUSPENSION-CULTURE; ENDOTHELIAL-CELLS; EXPANSION; MECHANOTRANSDUCTION; BIOREACTORS; RECEPTOR; SYSTEM; FORCES; STATE	Shear stress is a ubiquitous environmental cue experienced by stem cells when they are being differentiated or expanded in perfusion cultures. However, its role in modulating self-renewing stem cell phenotypes is unclear, since shear is usually only studied in the context of cardiovascular differentiation. We used a multiplex microfluidic array, which overcomes the limitations of macroperfusion systems in shear application throughput and precision, to initiate a comprehensive, quantitative study of shear effects on self-renewing mouse embryonic stem cells (mESCs), where shear stresses varying by >1000 times (0.016-16 dyn/cm(2)) are applied simultaneously. When compared with static controls in the presence or absence of a saturated soluble environment (i.e., mESC-conditioned medium), we ascertained that flow-induced shear stress specifically up-regulates the epiblast marker Fgf5. Epiblast-state transition in mESCs involves heparan sulfate proteoglycans (HSPGs), which have also been shown to transduce shear stress in endothelial cells. By disrupting (with sulfation inhibitors and heparinase) and partially reconstituting (with heparin) HSPG function, we show that mESCs also mechanically sense shear stress via HSPGs to modulate Fgf5 expression. This study demonstrates that self-renewing mESCs possess the molecular machinery to sense shear stress and provides quantitative shear application benchmarks for future scalable stem cell culture systems.-Toh, Y.-C., Voldman, J. Fluid shear stress primes mouse embryonic stem cells for differentiation in a self-renewing environment via heparan sulfate proteoglycans transduction. FASEB J. 25, 1208-1217 (2011). www.fasebj.org	[Toh, Yi-Chin; Voldman, Joel] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Toh, Yi-Chin; Voldman, Joel] MIT, Elect Res Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Voldman, J (corresponding author), MIT, Dept Elect Engn & Comp Sci, Rm 36-824,77 Massachusetts Ave, Cambridge, MA 02139 USA.	voldman@mit.edu		Toh, Yi-Chin/0000-0002-4105-4852	U.S. National Institutes of Health [EB007278]; A*STAR; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB007278] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); A*STAR(Agency for Science Technology & Research (A*STAR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	The authors thank Katarina Blagovic for technical assistance and Lily Y. Kim for developing the initial concept and first version of a multi-flowrate device. Y.-C.T. contributed to conception and design, collection and assembly of data, data analysis and interpretation, and manuscript writing. J.V. contributed to conception and design, financial support, data analysis and interpretation, manuscript writing, and final approval of manuscript. This work was supported by U.S. National Institutes of Health grant EB007278 and an A*STAR International Fellowship.	Abranches E, 2007, BIOTECHNOL BIOENG, V96, P1211, DOI 10.1002/bit.21191; Adamo L, 2009, NATURE, V459, P1131, DOI 10.1038/nature08073; BLAGOVIC K, 2008, P MICR TOT ANAL SYST, V1, P677; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chau L, 2009, LAB CHIP, V9, P1897, DOI 10.1039/b823180j; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Cool SM, 2006, J CELL BIOCHEM, V99, P1040, DOI 10.1002/jcb.20936; Cormier JT, 2006, TISSUE ENG, V12, P3233, DOI 10.1089/ten.2006.12.3233; Davey RE, 2006, STEM CELLS, V24, P2538, DOI 10.1634/stemcells.2006-0216; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5; Fok EYL, 2005, STEM CELLS, V23, P1333, DOI 10.1634/stemcells.2005-0112; Graf T, 2008, CELL STEM CELL, V3, P480, DOI 10.1016/j.stem.2008.10.007; Gutierrez E, 2008, LAB CHIP, V8, P1486, DOI 10.1039/b804795b; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; Kehoe DE, 2010, TISSUE ENG PT A, V16, P405, DOI [10.1089/ten.tea.2009.0454, 10.1089/ten.TEA.2009.0454]; Kim L, 2006, LAB CHIP, V6, P394, DOI 10.1039/b511718f; King JA, 2007, CURR OPIN CHEM BIOL, V11, P394, DOI 10.1016/j.cbpa.2007.05.034; Kunath T, 2007, DEVELOPMENT, V134, P2895, DOI 10.1242/dev.02880; LANGER R, 1982, SCIENCE, V217, P261, DOI 10.1126/science.7089564; Lanner F, 2010, STEM CELLS, V28, P191, DOI 10.1002/stem.265; Lock LT, 2009, TISSUE ENG PT A, V15, P2051, DOI 10.1089/ten.tea.2008.0455; Mansergh FC, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-5; Mochizuki S, 2003, AM J PHYSIOL-HEART C, V285, pH722, DOI 10.1152/ajpheart.00691.2002; Oh SKW, 2009, STEM CELL RES, V2, P219, DOI 10.1016/j.scr.2009.02.005; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Pera MF, 2010, NATURE, V465, P713, DOI 10.1038/nature09228; Schaff UY, 2007, LAB CHIP, V7, P448, DOI 10.1039/b617915k; Sikavitsas VI, 2003, P NATL ACAD SCI USA, V100, P14683, DOI 10.1073/pnas.2434367100; Song JW, 2005, ANAL CHEM, V77, P3993, DOI 10.1021/ac050131o; Stolberg S, 2009, BIOTECHNOL PROGR, V25, P10, DOI 10.1002/btpr.124; Tarbell JM, 2006, J INTERN MED, V259, P339, DOI 10.1111/j.1365-2796.2006.01620.x; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Toyooka Y, 2008, DEVELOPMENT, V135, P909, DOI 10.1242/dev.017400; Walker GM, 2004, LAB CHIP, V4, P91, DOI 10.1039/b311214d; Yamamoto K, 2005, AM J PHYSIOL-HEART C, V288, pH1915, DOI 10.1152/ajpheart.00956.2004; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; zur Nieden NI, 2007, J BIOTECHNOL, V129, P421, DOI 10.1016/j.jbiotec.2007.01.006	38	88	90	0	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2011	25	4					1208	1217		10.1096/fj.10-168971	http://dx.doi.org/10.1096/fj.10-168971			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21183594	Green Published			2022-12-28	WOS:000288982800010
J	Llorens, F; Gil, V; del Rio, JA				Llorens, Franc; Gil, Vanessa; Antonio del Rio, Jose			Emerging functions of myelin-associated proteins during development, neuronal plasticity, and neurodegeneration	FASEB JOURNAL			English	Review						MAIs; neural stem cells; synapse formation	AMYOTROPHIC-LATERAL-SCLEROSIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EPIDERMAL-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; NEURAL STEM-CELLS; SOLUBLE NOGO-A; AFFINITY NEUROTROPHIN RECEPTOR; OCULAR-DOMINANCE PLASTICITY; MULTIPLE-SCLEROSIS	Adult mammalian central nervous system (CNS) axons have a limited regrowth capacity following injury. Myelin-associated inhibitors (MAIs) limit axonal outgrowth, and their blockage improves the regeneration of damaged fiber tracts. Three of these proteins, Nogo-A, MAG, and OMgp, share two common neuronal receptors: NgR1, together with its coreceptors [p75(NTR), TROY, and Lingo-1]; and the recently described paired immunoglobulin-like receptor B (PirB). These proteins impair neuronal regeneration by limiting axonal sprouting. Some of the elements involved in the myelin inhibitory pathways may still be unknown, but the discovery that blocking both PirB and NgR1 activities leads to near-complete release from myelin inhibition, sheds light on one of the most competitive and intense fields of neuroregeneration study in recent decades. In parallel with the identification and characterization of the roles and functions of these inhibitory molecules in axonal regeneration, data gathered in the field strongly suggest that most of these proteins have roles other than axonal growth inhibition. The discovery of a new group of interacting partners for myelin-associated receptors and ligands, as well as functional studies within or outside the CNS environment, highlights the potential new physiological roles for these proteins in processes, such as development, neuronal homeostasis, plasticity, and neurodegeneration.-Llorens, F., Gil, V., del Rio, J. A. Emerging functions of myelin-associated proteins during development, neuronal plasticity, and neurodegeneration. FASEB J. 25, 463-475 (2011). www.fasebj.org	[Llorens, Franc; Gil, Vanessa; Antonio del Rio, Jose] Inst Bioengn Catalonia, Barcelona, Spain; [Llorens, Franc; Gil, Vanessa; Antonio del Rio, Jose] Univ Barcelona, Dept Cell Biol, Barcelona, Spain; [Llorens, Franc; Gil, Vanessa; Antonio del Rio, Jose] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Barcelona, Spain	Barcelona Institute of Science & Technology; Institut de Bioenginyeria de Catalunya; University of Barcelona; University of Barcelona; CIBERNED	del Rio, JA (corresponding author), Inst Bioengn Catalonia IBEC, Baldiri Reixac 15-21, E-08028 Barcelona, Spain.	jadelrio@ibec.pcb.ub.es	gil, vanessa/N-5013-2014; del rio, jose antonio/L-9232-2014; Del Rio Fernandez, Jose A/AAD-1121-2020	gil, vanessa/0000-0002-7782-5575; del rio, jose antonio/0000-0002-5214-4909; , Franc/0000-0002-9756-7497	Ministerio de Ciencia e Innovacion (MICINN) [BFU2009-10848]; Instituto Carlos III; Generalitat de Catalunya [SGR2009-366]; EU-FP7	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Instituto Carlos III(Instituto de Salud Carlos III); Generalitat de Catalunya(Generalitat de Catalunya); EU-FP7(European Commission)	This work was supported by grants from Ministerio de Ciencia e Innovacion (MICINN; BFU2009-10848), Instituto Carlos III, Generalitat de Catalunya (SGR2009-366), and the EU-FP7 PRIORITY to J.A.D.R. The authors also thank all of the members of their lab for their contributions during these years. The authors apologize to researchers whose work has not been cited due to space limitations.	Aberg K, 2006, P NATL ACAD SCI USA, V103, P7482, DOI 10.1073/pnas.0601213103; Afshari FT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001288; Alabed YZ, 2007, J NEUROSCI, V27, P1702, DOI 10.1523/JNEUROSCI.5055-06.2007; Aloy EM, 2006, BRAIN CELL BIOL, V35, P137, DOI 10.1007/s11068-007-9014-3; Askanas V, 2007, ANN NEUROL, V62, P676, DOI 10.1002/ana.21245; Atwal JK, 2008, SCIENCE, V322, P967, DOI 10.1126/science.1161151; Bai Y, 2008, MOL CELL PROTEOMICS, V7, P15, DOI 10.1074/mcp.M700077-MCP200; Bandtlow CE, 2004, EUR J NEUROSCI, V20, P195, DOI 10.1111/j.1460-9568.2004.03470.x; Barley K, 2009, SCHIZOPHR RES, V112, P54, DOI 10.1016/j.schres.2009.04.019; Bourquin C, 2008, EUR J PHARMACOL, V588, P99, DOI 10.1016/j.ejphar.2008.04.026; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Budel S, 2008, J NEUROSCI, V28, P13161, DOI 10.1523/JNEUROSCI.3828-08.2008; Buffo A, 2000, J NEUROSCI, V20, P2275; Bullard TA, 2008, PHYSIOL GENOMICS, V32, P182, DOI 10.1152/physiolgenomics.00200.2007; Busch SA, 2007, CURR OPIN NEUROBIOL, V17, P120, DOI 10.1016/j.conb.2006.09.004; Cao ZX, 2010, MOL CELL NEUROSCI, V43, P1, DOI 10.1016/j.mcn.2009.07.008; Chakravarthy B, 2010, J ALZHEIMERS DIS, V19, P915, DOI 10.3233/JAD-2010-1288; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Chang K, 2010, J NEUROSCI RES, V88, P266, DOI 10.1002/jnr.22209; Chen YC, 2006, BIOCHEM BIOPH RES CO, V348, P923, DOI 10.1016/j.bbrc.2006.07.166; Chivatakarn O, 2007, J NEUROSCI, V27, P7117, DOI 10.1523/JNEUROSCI.1541-07.2007; Christie KJ, 2010, J NEUROSCI, V30, P9306, DOI 10.1523/JNEUROSCI.6271-09.2010; Costantini C, 2005, EXP CELL RES, V311, P126, DOI 10.1016/j.yexcr.2005.09.004; Craveiro LM, 2008, EUR J NEUROSCI, V28, P1808, DOI 10.1111/j.1460-9568.2008.06473.x; D'Alfonso S, 2002, J NEUROIMMUNOL, V126, P196, DOI 10.1016/S0165-5728(02)00061-9; Da Silva JS, 2003, J CELL BIOL, V162, P1267, DOI 10.1083/jcb.200304021; Datwani A, 2009, NEURON, V64, P463, DOI 10.1016/j.neuron.2009.10.015; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; David S, 2008, TRENDS NEUROSCI, V31, P221, DOI 10.1016/j.tins.2008.02.002; Davis KL, 2003, ARCH GEN PSYCHIAT, V60, P443, DOI 10.1001/archpsyc.60.5.443; de Anda FC, 2005, NATURE, V436, P704, DOI 10.1038/nature03811; de Anda FC, 2008, J CELL SCI, V121, P178, DOI 10.1242/jcs.023143; Dengler R, 2005, NEURODEGENER DIS, V2, P177, DOI 10.1159/000089623; Di Cristo G, 2007, CLIN GENET, V72, P1, DOI 10.1111/j.1399-0004.2007.00822.x; Dillon C, 2005, ANNU REV NEUROSCI, V28, P25, DOI 10.1146/annurev.neuro.28.061604.135757; Dimou L, 2006, J NEUROSCI, V26, P5591, DOI 10.1523/JNEUROSCI.1103-06.2006; Dodd DA, 2005, J BIOL CHEM, V280, P12494, DOI 10.1074/jbc.M411827200; Dunham JS, 2009, J PSYCHIATR RES, V43, P1175, DOI 10.1016/j.jpsychires.2009.03.008; Dupuis L, 2002, NEUROBIOL DIS, V10, P358, DOI 10.1006/nbdi.2002.0522; Endo T, 2007, BRAIN, V130, P2951, DOI 10.1093/brain/awm237; Endo T, 2009, NEUROSCIENTIST, V15, P291, DOI 10.1177/1073858408329508; FAUX CH, 2007, SCI STKE, pPE62; Fazi B, 2009, ONCOGENE, V28, P3814, DOI 10.1038/onc.2009.233; Fergani A, 2005, NEURODEGENER DIS, V2, P185, DOI 10.1159/000089624; Fontoura P, 2004, J IMMUNOL, V173, P6981, DOI 10.4049/jimmunol.173.11.6981; Fuentes F, 2009, MOL BIOL CELL, V20, P1878, DOI 10.1091/mbc.E08-07-0675; Gao Y, 2010, STEM CELLS DEV, V19, P53, DOI 10.1089/scd.2008.0357; Gao Y, 2009, NEUROSCI LETT, V458, P132, DOI 10.1016/j.neulet.2009.04.034; Giger RJ, 2008, RESTOR NEUROL NEUROS, V26, P97; Gil V, 2006, J NEUROPATH EXP NEUR, V65, P433, DOI 10.1097/01.jnen.0000222894.59293.98; Gil V, 2010, CEREB CORTEX, V20, P1769, DOI 10.1093/cercor/bhp246; Grunewald E, 2009, MOL CELL NEUROSCI, V42, P363, DOI 10.1016/j.mcn.2009.08.007; Guren TK, 1999, BIOCHEM BIOPH RES CO, V258, P565, DOI 10.1006/bbrc.1999.0684; Habib AA, 1998, ONCOGENE, V16, P1525, DOI 10.1038/sj.onc.1201683; Harel NY, 2009, BIOMARKERS, V14, P414, DOI 10.1080/13547500903056051; Harris VK, 2009, MOL DIAGN THER, V13, P225, DOI 10.2165/11313470-000000000-00000; He WX, 2006, J MOL BIOL, V363, P625, DOI 10.1016/j.jmb.2006.07.094; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Heraud P, 2010, NEUROIMAGE, V49, P1180, DOI 10.1016/j.neuroimage.2009.09.053; Hoffman PN, 2010, EXP NEUROL, V223, P11, DOI 10.1016/j.expneurol.2009.09.006; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Hou T, 2010, INT J NEUROSCI, V120, P201, DOI 10.3109/00207450903506502; Hsu R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001234; Hu FH, 2008, J NEUROSCI, V28, P1262, DOI 10.1523/JNEUROSCI.1068-07.2008; Hu XY, 2002, EXP NEUROL, V178, P104, DOI 10.1006/exnr.2002.8018; Inoue H, 2007, P NATL ACAD SCI USA, V104, P14430, DOI 10.1073/pnas.0700901104; Itoh M, 2006, ONCOGENE, V25, P1195, DOI 10.1038/sj.onc.1209149; Iwahashi J, 2003, Cell Mol Biol (Noisy-le-grand), V49 Online Pub, pOL467; Ji BX, 2008, MOL CELL NEUROSCI, V39, P258, DOI 10.1016/j.mcn.2008.07.004; Jokic N, 2006, EMBO REP, V7, P1162, DOI 10.1038/sj.embor.7400826; Josephson A, 2003, CELL TISSUE RES, V311, P333, DOI 10.1007/s00441-002-0695-8; Jurewicz A, 2007, NEUROLOGY, V68, P283, DOI 10.1212/01.wnl.0000252357.30287.1d; Karnezis T, 2004, NAT NEUROSCI, V7, P736, DOI 10.1038/nn1261; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Kuang E, 2005, J CELL PHYSIOL, V204, P549, DOI 10.1002/jcp.20340; Kuang E, 2006, EXP CELL RES, V312, P1983, DOI 10.1016/j.yexcr.2006.02.024; Lee HJ, 2008, J NEUROSCI, V28, P2753, DOI 10.1523/JNEUROSCI.5586-07.2008; Lee JK, 2010, NEURON, V66, P663, DOI 10.1016/j.neuron.2010.05.002; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; Li X, 2009, NEUROREPORT, V20, P708, DOI 10.1097/WNR.0b013e32832aa942; Lindsey JW, 2008, NEUROLOGY, V71, P35, DOI 10.1212/01.wnl.0000314831.08803.21; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Liu Y, 2008, J BIOL CHEM, V283, P6561, DOI 10.1074/jbc.M708096200; Liu YY, 2003, NEUROSCI LETT, V346, P153, DOI 10.1016/S0304-3940(03)00508-1; Llorens F, 2008, DEV NEUROBIOL, V68, P521, DOI 10.1002/dneu.20607; Low K, 2008, J NEUROSCI, V28, P1099, DOI 10.1523/JNEUROSCI.4906-07.2008; Lowry KS, 2001, AMYOTROPH LATERAL SC, V2, P127, DOI 10.1080/146608201753275463; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Martin I, 2009, BRAIN RES, V1284, P22, DOI 10.1016/j.brainres.2009.05.070; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; Meng J, 2007, J NEURAL TRANSM, V114, P249, DOI 10.1007/s00702-006-0538-y; Mi S, 2007, NAT MED, V13, P1228, DOI 10.1038/nm1664; Mimura F, 2006, J BIOL CHEM, V281, P15970, DOI 10.1074/jbc.M510934200; Mingorance A, 2004, MOL CELL NEUROSCI, V26, P34, DOI 10.1016/j.mcn.2004.01.001; MINGORANCELE M, 2007, CEREB CORTEX, V17, P2375; Miyazaki K, 2009, NEUROL RES, V31, P316, DOI 10.1179/174313208X325173; Montani L, 2009, J BIOL CHEM, V284, P10793, DOI 10.1074/jbc.M808297200; Mu YL, 2010, CURR OPIN NEUROBIOL, V20, P416, DOI 10.1016/j.conb.2010.04.010; Nataf S, 1998, J NEUROSCI RES, V52, P83; Niederost B, 2002, J NEUROSCI, V22, P10368; Novak G, 2002, MOL BRAIN RES, V107, P183, DOI 10.1016/S0169-328X(02)00492-8; Novak G, 2006, BRAIN RES, V1120, P161, DOI 10.1016/j.brainres.2006.08.071; O'Brien GS, 2009, CURR BIOL, V19, P2086, DOI 10.1016/j.cub.2009.10.051; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; Park JH, 2006, J NEUROSCI, V26, P13279, DOI 10.1523/JNEUROSCI.4504-06.2006; Park JH, 2006, J NEUROSCI, V26, P1386, DOI 10.1523/JNEUROSCI.3291-05.2006; Park KK, 2010, EXP NEUROL, V223, P45, DOI 10.1016/j.expneurol.2009.12.032; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Pasterkarnp RJ, 2006, PHILOS T R SOC B, V361, P1499, DOI 10.1098/rstb.2006.1892; Pastrana E, 2009, P NATL ACAD SCI USA, V106, P6387, DOI 10.1073/pnas.0810407106; Pehar M, 2004, J NEUROCHEM, V89, P464, DOI 10.1111/j.1471-4159.2004.02357.x; Petratos S, 2004, GLIA, V48, P64, DOI 10.1002/glia.20056; Petrinovic MM, 2010, DEVELOPMENT, V137, P2539, DOI 10.1242/dev.048371; Pinto L, 2007, PROG NEUROBIOL, V83, P2, DOI 10.1016/j.pneurobio.2007.02.010; Pool M, 2009, EXP NEUROL, V217, P371, DOI 10.1016/j.expneurol.2009.03.014; Pradat PF, 2007, ANN NEUROL, V62, P15, DOI 10.1002/ana.21122; Prior M, 2010, NEUROSCI BIOBEHAV R, V34, P1201, DOI 10.1016/j.neubiorev.2010.01.017; Qi B, 2003, J CELL PHYSIOL, V196, P312, DOI 10.1002/jcp.10297; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Rajan P, 1998, J NEUROSCI, V18, P3620; Reindl M, 2003, J NEUROIMMUNOL, V145, P139, DOI 10.1016/j.jneuroim.2003.09.010; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; ROWLAND LP, 1995, NEUROLOGY, V45, P827, DOI 10.1212/WNL.45.4.827; Satoh J, 2007, NEUROPATH APPL NEURO, V33, P99, DOI 10.1111/j.1365-2990.2006.00787.x; Satoh JI, 2005, J NEUROPATH EXP NEUR, V64, P129, DOI 10.1093/jnen/64.2.129; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Schweigreiter R, 2007, PROTEOMICS, V7, P4457, DOI 10.1002/pmic.200700499; Seboun E, 1999, NEUROGENETICS, V2, P155, DOI 10.1007/s100480050076; Seira O, 2010, J NEUROCHEM, V113, P1644, DOI 10.1111/j.1471-4159.2010.06726.x; Selmaj K, 2009, NEUROLOGY, V72, P1708, DOI 10.1212/01.wnl.0000346741.75149.9d; Shim SY, 2008, J NEUROSCI, V28, P3604, DOI 10.1523/JNEUROSCI.5278-07.2008; Silver J, 2009, CURR BIOL, V19, pR444, DOI 10.1016/j.cub.2009.04.026; Sinibaldi Lorenzo, 2004, Hum Mutat, V24, P534, DOI 10.1002/humu.9292; Syken J, 2006, SCIENCE, V313, P1795, DOI 10.1126/science.1128232; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; Tang BL, 2007, J NEUROCHEM, V100, P314, DOI 10.1111/j.1471-4159.2006.04215.x; Teng FYH, 2008, J CELL PHYSIOL, V216, P303, DOI 10.1002/jcp.21434; Teng FYH, 2005, J NEUROCHEM, V94, P865, DOI 10.1111/j.1471-4159.2005.03238.x; TERASAKI M, 1994, P NATL ACAD SCI USA, V91, P7510, DOI 10.1073/pnas.91.16.7510; Thomas R, 2010, J NEUROSCI, V30, P6607, DOI 10.1523/JNEUROSCI.5147-09.2010; Tom VJ, 2009, J NEUROSCI, V29, P14881, DOI 10.1523/JNEUROSCI.3641-09.2009; Trifunovski A, 2004, NEUROREPORT, V15, P2397, DOI 10.1097/00001756-200410250-00019; Valdo P, 2002, J NEUROPATH EXP NEUR, V61, P91, DOI 10.1093/jnen/61.1.91; Valiente M, 2010, CURR OPIN NEUROBIOL, V20, P68, DOI 10.1016/j.conb.2009.12.003; Vedrenne C, 2006, TRAFFIC, V7, P639, DOI 10.1111/j.1600-0854.2006.00419.x; Vedrenne C, 2005, MOL BIOL CELL, V16, P1928, DOI 10.1091/mbc.E04-07-0554; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Voineskos AN, 2008, PSYCHIAT GENET, V18, P143, DOI 10.1097/YPG.0b013e3282fa1874; Voineskos AN, 2009, J NEUROSCI, V29, P5045, DOI 10.1523/JNEUROSCI.0477-09.2009; Vourc'h P, 2003, J NEUROCHEM, V85, P889, DOI 10.1046/j.1471-4159.2003.01764.x; Wan CL, 2005, NEUROSCI LETT, V388, P126, DOI 10.1016/j.neulet.2005.06.051; Wan QW, 2007, APOPTOSIS, V12, P319, DOI 10.1007/s10495-006-0574-y; Wang B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001856; Wang H, 2006, BRAIN RES, V1114, P212, DOI 10.1016/j.brainres.2006.07.056; Wang J, 2010, BRAIN RES, V1306, P8, DOI 10.1016/j.brainres.2009.10.018; Wang XX, 2002, J NEUROSCI, V22, P5505; Willi R, 2010, J NEUROSCI, V30, P556, DOI 10.1523/JNEUROSCI.4393-09.2010; Worter V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005218; Wojcik S, 2006, Acta Myol, V25, P116; Xiang R, 2009, MOL CELL BIOCHEM, V331, P225, DOI 10.1007/s11010-009-0163-9; Yang YH, 2010, ANN NEUROL, V67, P498, DOI 10.1002/ana.21935; Yang YS, 2009, J NEUROSCI, V29, P13850, DOI 10.1523/JNEUROSCI.2312-09.2009; Ylera B, 2009, CURR BIOL, V19, P930, DOI 10.1016/j.cub.2009.04.017; Zhang L, 2009, J NEUROSCI, V29, P6348, DOI 10.1523/JNEUROSCI.5040-08.2009; Zhang T, 2000, MOL CELL BIOL, V20, P7132, DOI 10.1128/MCB.20.19.7132-7139.2000; Zhou B, 2009, CLIN CHIM ACTA, V400, P21, DOI 10.1016/j.cca.2008.09.028; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zhou ZK, 2009, NEUROPHARMACOLOGY, V56, P81, DOI 10.1016/j.neuropharm.2008.07.031; Zhu HY, 2007, HUM PATHOL, V38, P426, DOI 10.1016/j.humpath.2006.09.010	172	55	59	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					463	475		10.1096/fj.10-162792	http://dx.doi.org/10.1096/fj.10-162792			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21059749				2022-12-28	WOS:000286724800005
J	Kapoor, R; van Hogerlinden, M; Wallis, K; Ghosh, H; Nordstrom, K; Vennstrom, B; Vaidya, VA				Kapoor, Richa; van Hogerlinden, Max; Wallis, Karin; Ghosh, Himanish; Nordstrom, Kristina; Vennstrom, Bjorn; Vaidya, Vidita A.			Unliganded thyroid hormone receptor alpha 1 impairs adult hippocampal neurogenesis	FASEB JOURNAL			English	Article						neural stem cell; hypothyroidism; neuronal progenitor	DENTATE GYRUS; DOUBLECORTIN EXPRESSION; BINDING-CAPACITY; GRANULE CELLS; RAT BRAIN; C-ERBA; HYPOTHYROIDISM; PLASTICITY; BEHAVIOR; MEMORY	Thyroid hormone regulates adult hippocampal neurogenesis, a process involved in key functions, such as learning, memory, and mood regulation. We addressed the role of thyroid hormone receptor TR alpha 1 in adult hippocampal neurogenesis, using mice harboring a TR alpha 1 null allele (TR alpha 1(-/-)), overexpressing TR alpha 1 6-fold (TR alpha 2(-/-)), and a mutant TR alpha 1 (TR alpha 1(+/m)) with a 10-fold lower affinity to the ligand. While hippocampal progenitor proliferation was unaltered, TR alpha 1(-/-) mice exhibited a significant increase in doublecortin-positive immature neurons and increased survival of bromodeoxyuridine-positive (BrdU(+)) progenitors as compared to wild-type controls. In contrast, the TR alpha 1(+/m) and the TR alpha 2(-/-) mice, where the over-expressed TR alpha 1 acts as an aporeceptor, showed a significant decline in surviving BrdU(+) progenitors. TR alpha 1(-/-) and TR alpha 2(-/-) mice showed opposing effects on neurogenic markers like polysialylated neural cell adhesion molecule and stathmin. The decreased progenitor survival in the TR alpha 2(-/-) and TR alpha 1(+/m) mice could be rescued by thyroid hormone treatment, as was the decline in neuronal differentiation seen in the TR alpha 1(+/m) mice. These mice also exhibited a decrease in NeuroD(+) cell numbers in the dentate gyrus, suggesting an effect on early postmitotic progenitors. Our results provide the first evidence of a role for unliganded TR alpha 1 in modulating the deleterious effects of hypothyroidism on adult hippocampal neurogenesis.-Kapoor, R., van Hogerlinden, M., Wallis, K., Ghosh, H., Nordstrom, K., Vennstrom, B., Vaidya, V. A. Unliganded thyroid hormone receptor alpha 1 impairs adult hippocampal neurogenesis. FASEB J. 24, 4793-4805 (2010). www.fasebj.org	[Kapoor, Richa; Ghosh, Himanish; Vaidya, Vidita A.] Tata Inst Fundamental Res, Dept Biol Sci, Bombay 400005, Maharashtra, India; [van Hogerlinden, Max; Wallis, Karin; Nordstrom, Kristina; Vennstrom, Bjorn] Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	Tata Institute of Fundamental Research (TIFR); Karolinska Institutet	Vaidya, VA (corresponding author), Tata Inst Fundamental Res, Dept Biol Sci, Homi Bhabha Rd, Bombay 400005, Maharashtra, India.	bjorn.vennstrom@ki.se; vvaidya@tifr.res.in		Vaidya, Vidita/0000-0002-3907-8580	TIFR; Wellcome Trust [04082003114133]; Swedish Research Council; Swedish Cancer Society; Wallenberg Foundations; Swedish Society for Medical Research (SSMF)	TIFR(Tata Institute of Fundamental Research (TIFR)); Wellcome Trust(Wellcome TrustEuropean Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Wallenberg Foundations; Swedish Society for Medical Research (SSMF)	This work was supported by intramural funds from TIFR and a Wellcome Trust Senior Overseas Fellowship in biomedical sciences to V.A.V. (04082003114133). Support to B.V. was obtained from the Swedish Research Council, the Swedish Cancer Society, and the Wallenberg Foundations. M.V. received a Swedish Society for Medical Research (SSMF) fellowship. The authors are grateful to Professor T. Seki (Juntendo University School of Medicine, Tokyo, Japan) for the gift of the PSA-NCAM antibody.	Ambrogini P, 2005, NEUROENDOCRINOLOGY, V81, P244, DOI 10.1159/000087648; Baldini IM, 1997, PROG NEURO-PSYCHOPH, V21, P925, DOI 10.1016/S0278-5846(97)00089-4; Becker S, 2007, TRENDS COGN SCI, V11, P70, DOI 10.1016/j.tics.2006.10.013; Bernal J, 2002, J ENDOCRINOL INVEST, V25, P268, DOI 10.1007/BF03344003; Bernal J, 2007, NAT CLIN PRACT ENDOC, V3, P249, DOI 10.1038/ncpendmet0424; Brandt MD, 2003, MOL CELL NEUROSCI, V24, P603, DOI 10.1016/S1044-7431(03)00207-0; Calza L, 1997, BRAIN RES BULL, V44, P549, DOI 10.1016/S0361-9230(97)00241-4; Chantoux F, 2002, MOL CELL ENDOCRINOL, V194, P157, DOI 10.1016/S0303-7207(02)00133-8; Clos J, 1990, GROWTH FACTORS, V3, P205, DOI 10.3109/08977199009043905; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Daury L, 2001, FEBS LETT, V508, P236, DOI 10.1016/S0014-5793(01)03063-0; Desouza LA, 2005, MOL CELL NEUROSCI, V29, P414, DOI 10.1016/j.mcn.2005.03.010; Dugbartey AT, 1998, ARCH INTERN MED, V158, P1413, DOI 10.1001/archinte.158.13.1413; ErcanFang S, 1996, ENDOCRINOLOGY, V137, P3228, DOI 10.1210/en.137.8.3228; FUNDARO A, 1989, PROG NEURO-PSYCHOPH, V13, P927, DOI 10.1016/0278-5846(89)90044-4; Fuss J, 2010, HIPPOCAMPUS, V20, P364, DOI 10.1002/hipo.20634; Gao ZL, 2009, NAT NEUROSCI, V12, P1090, DOI 10.1038/nn.2385; Gilbert ME, 2003, DEV BRAIN RES, V145, P19, DOI 10.1016/S0165-3806(03)00191-3; Guadano-Ferraz A, 2003, MOL PSYCHIATR, V8, P30, DOI 10.1038/sj.mp.4001196; Hodge RD, 2008, J NEUROSCI, V28, P3707, DOI 10.1523/JNEUROSCI.4280-07.2008; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Jin KL, 2004, FASEB J, V18, P287, DOI 10.1096/fj.03-0973com; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kitabatake Y, 2007, NEUROSURG CLIN N AM, V18, P105, DOI 10.1016/j.nec.2006.10.008; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Kulikov A, 1997, NEUROSCI LETT, V234, P111, DOI 10.1016/S0304-3940(97)00664-2; Lemkine GF, 2005, FASEB J, V19, P863, DOI 10.1096/fj.04-2916fje; Liu M, 2000, P NATL ACAD SCI USA, V97, P865, DOI 10.1073/pnas.97.2.865; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Montero-Pedrazuela A, 2006, MOL PSYCHIATR, V11, P361, DOI 10.1038/sj.mp.4001802; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; OSTERWEIL D, 1992, J AM GERIATR SOC, V40, P325, DOI 10.1111/j.1532-5415.1992.tb02130.x; Paxinos G, 2004, MOUSE BRAIN STEREOTA; Pilhatsch M, 2010, BEHAV BRAIN RES, V214, P187, DOI 10.1016/j.bbr.2010.05.016; Salto C, 2001, MOL ENDOCRINOL, V15, P2115, DOI 10.1210/me.15.12.2115; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; SEKI T, 1993, J NEUROSCI, V13, P2351, DOI 10.1523/JNEUROSCI.13-06-02351.1993; Seki T, 2002, J NEUROSCI RES, V70, P327, DOI 10.1002/jnr.10387; Tinnikov A, 2002, EMBO J, V21, P5079, DOI 10.1093/emboj/cdf523; Vaidya Vidita A, 2007, Expert Rev Neurother, V7, P853, DOI 10.1586/14737175.7.7.853; Venero C, 2005, GENE DEV, V19, P2152, DOI 10.1101/gad.346105; WALLIS K, 2010, MOL ENDOCRI IN PRESS; Wang JW, 2008, J NEUROSCI, V28, P1374, DOI 10.1523/JNEUROSCI.3632-07.2008; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097	48	43	46	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4793	4805		10.1096/fj.10-161802	http://dx.doi.org/10.1096/fj.10-161802			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20709911	Green Accepted			2022-12-28	WOS:000284824400019
J	Nassini, R; Materazzi, S; Andre, E; Sartiani, L; Aldini, G; Trevisani, M; Carnini, C; Massi, D; Pedretti, P; Carini, M; Cerbai, E; Preti, D; Villetti, G; Civelli, M; Trevisan, G; Azzari, C; Stokesberry, S; Sadofsky, L; McGarvey, L; Patacchini, R; Geppetti, P				Nassini, Romina; Materazzi, Serena; Andre, Eunice; Sartiani, Laura; Aldini, Giancarlo; Trevisani, Marcello; Carnini, Chiara; Massi, Daniela; Pedretti, Pamela; Carini, Marina; Cerbai, Elisabetta; Preti, Delia; Villetti, Gino; Civelli, Maurizio; Trevisan, Gabriela; Azzari, Chiara; Stokesberry, Susan; Sadofsky, Laura; McGarvey, Lorcan; Patacchini, Riccardo; Geppetti, Pierangelo			Acetaminophen, via its reactive metabolite N-acetyl-p-benzo-quinoneimine and transient receptor potential ankyrin-1 stimulation, causes neurogenic inflammation in the airways and other tissues in rodents	FASEB JOURNAL			English	Article						primary sensory neurons; substance P; asthma; chronic obstructive pulmonary disease	GENE-RELATED PEPTIDE; PARACETAMOL USE; BENZOQUINONE IMINE; SENSORY NERVES; ASTHMA; CHILDREN; RISK; ACTIVATION; DISEASE; TRPA1	Acetaminophen [N-acetyl-p-aminophenol (APAP)] is the most common antipyretic/analgesic medicine worldwide. If APAP is overdosed, its metabolite, N-acetyl-p-benzo-quinoneimine (NAPQI), causes liver damage. However, epidemiological evidence has associated previous use of therapeutic APAP doses with the risk of chronic obstructive pulmonary disease (COPD) and asthma. The transient receptor potential ankyrin-1 (TRPA1) channel is expressed by peptidergic primary sensory neurons. Because NAPQI, like other TRPA1 activators, is an electrophilic molecule, we hypothesized that APAP, via NAPQI, stimulates TRPA1, thus causing airway neurogenic inflammation. NAPQI selectively excites human recombinant and native (neuroblastoma cells) TRPA1. TRPA1 activation by NAPQI releases proinflammatory neuropeptides (substance P and calcitonin gene-related peptide) from sensory nerve terminals in rodent airways, thereby causing neurogenic edema and neutrophilia. Single or repeated administration of therapeutic (15-60 mg/kg) APAP doses to mice produces detectable levels of NAPQI in the lung, and increases neutrophil numbers, myeloperoxidase activity, and cytokine and chemokine levels in the airways or skin. Inflammatory responses evoked by NAPQI and APAP are abated by TRPA1 antagonism or are absent in TRPA1-deficient mice. This novel pathway, distinguished from the tissue-damaging effect of NAPQI, may contribute to the risk of COPD and asthma associated with therapeutic APAP use.-Nassini, R., Materazzi, S., Andre, E., Sartiani, L., Aldini, G., Trevisani, M., Carnini, C., Massi, D., Pedretti, P., Carini, M., Cerbai, E., Preti, D., Villetti, G., Civelli, M., Trevisan, G., Azzari, C., Stokesberry, S., Sadofsky, L., McGarvey, L., Patacchini, R., Geppetti, P. Acetaminophen, via its reactive metabolite N-acetyl-p-benzo-quinoneimine and transient receptor potential ankyrin-1 stimulation causes neurogenic inflammation in the airways and other tissues in rodents. FASEB J. 24, 4904-4916 (2010). www.fasebj.org	[Nassini, Romina; Materazzi, Serena; Andre, Eunice; Sartiani, Laura; Pedretti, Pamela; Cerbai, Elisabetta; Trevisan, Gabriela; Geppetti, Pierangelo] Univ Florence, Dept Preclin & Clin Pharmacol, I-50139 Florence, Italy; [Massi, Daniela] Univ Florence, Dept Human Pathol & Oncol, I-50139 Florence, Italy; [Azzari, Chiara] Univ Florence, Dept Pediat, I-50139 Florence, Italy; [Aldini, Giancarlo; Carini, Marina] Univ Milan, Dept Pharmaceut Sci, Milan, Italy; [Trevisani, Marcello] Pharmeste Srl, Ferrara, Italy; [Carnini, Chiara; Villetti, Gino; Civelli, Maurizio; Patacchini, Riccardo] Chiesi Farmaceutici SpA, Dept Pharmacol, Parma, Italy; [Preti, Delia] Univ Ferrara, Dept Pharmaceut Chem, I-44100 Ferrara, Italy; [Stokesberry, Susan; McGarvey, Lorcan] Queens Univ Belfast, Ctr Infect & Immun, Belfast, Antrim, North Ireland; [Sadofsky, Laura] Univ Hull, Castle Hill Hosp, Div Cardiovasc & Resp Studies, Kingston Upon Hull HU6 7RX, N Humberside, England	University of Florence; University of Florence; University of Florence; University of Milan; Chiesi Pharmaceuticals Inc; University of Ferrara; Queens University Belfast; University of Hull	Geppetti, P (corresponding author), Univ Florence, Dept Preclin & Clin Pharmacol, Viale Pieraccini 6, I-50139 Florence, Italy.	geppetti@unifi.it	Sartiani, Laura/ABF-5576-2020; aldini, giancarlo/C-3533-2013; Trevisan, Gabriela/AAE-9573-2019; Nassini, Romina/AAC-5051-2022; Sadofsky, Laura/AAK-2029-2020; Geppetti, Pierangelo/AHA-7897-2022; preti, delia/G-9916-2015; Andre, Eunice/AAZ-9417-2021; Trevisan, Gabriela GT/K-8120-2014; Cerbai, Elisabetta/J-2663-2013; Sartiani, Laura/M-1364-2015; Azzari, Chiara/AAB-8584-2019; CARINI, MARINA/D-3084-2015	Sartiani, Laura/0000-0002-4208-0913; aldini, giancarlo/0000-0002-2355-6744; Trevisan, Gabriela/0000-0003-0137-5034; Nassini, Romina/0000-0002-9223-8395; preti, delia/0000-0002-1075-3781; Trevisan, Gabriela GT/0000-0003-0137-5034; Cerbai, Elisabetta/0000-0001-7839-1361; Sartiani, Laura/0000-0002-4208-0913; Azzari, Chiara/0000-0001-7236-1655; CARINI, MARINA/0000-0003-3407-5425; Andre, Eunice/0000-0001-9524-1576	Ministero dell'Istruzione, dell'Universita e della Ricerca, Rome [RBIP06YM29]; Programmi di Ricerca di Interesse Nazionale [2003054380]; Ente Cassa di Risparmio di Firenze; Fondazione Amici Facolta di Medicina di Firenze	Ministero dell'Istruzione, dell'Universita e della Ricerca, Rome(Ministry of Education, Universities and Research (MIUR)); Programmi di Ricerca di Interesse Nazionale; Ente Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); Fondazione Amici Facolta di Medicina di Firenze	The authors are grateful to David Julius (University of California, San Francisco, CA, USA) for TRPA1 heterozygous mice, and to Marco Marchi (University of Florence, Florence, Italy) for advice on statistical analysis. This work was supported by grants from Ministero dell'Istruzione, dell'Universita e della Ricerca, Rome (Fondo per gli Investimenti della Ricerca di Base, RBIP06YM29 to P.G. and R.P.), Programmi di Ricerca di Interesse Nazionale (2003054380), Ente Cassa di Risparmio di Firenze (to P.G), and Fondazione Amici Facolta di Medicina di Firenze (to P.G).	Allmers H, 2009, CURR ALLERGY ASTHM R, V9, P164, DOI 10.1007/s11882-009-0024-3; Andre E, 2008, J CLIN INVEST, V118, P2574, DOI 10.1172/JCI34886; ARROWSMITH JB, 1987, PEDIATRICS, V79, P858; BALUK P, 1995, AM J PHYSIOL-LUNG C, V268, pL263, DOI 10.1152/ajplung.1995.268.2.L263; Banvolgyi A, 2004, NEUROSCIENCE, V125, P449, DOI 10.1016/j.neuroscience.2004.01.009; Barr RG, 2004, AM J RESP CRIT CARE, V169, P836, DOI 10.1164/rccm.200304-596OC; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Bertrand C, 1996, TRENDS PHARMACOL SCI, V17, P255, DOI 10.1016/S0165-6147(96)10027-4; Bessac BF, 2008, J CLIN INVEST, V118, P1899, DOI 10.1172/JCI34192; Bessac BF, 2009, FASEB J, V23, P1102, DOI 10.1096/fj.08-117812; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BUCKLEY TL, 1991, BRIT J PHARMACOL, V103, P1515, DOI 10.1111/j.1476-5381.1991.tb09819.x; Caceres AI, 2009, P NATL ACAD SCI USA, V106, P9099, DOI 10.1073/pnas.0900591106; Chen WQ, 1999, BIOCHEMISTRY-US, V38, P8159, DOI 10.1021/bi990125k; Cottrell GS, 2007, J BIOL CHEM, V282, P12260, DOI 10.1074/jbc.M606338200; Cover C, 2005, J PHARMACOL EXP THER, V315, P879, DOI 10.1124/jpet.105.088898; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x; Del-Rio-Navarro BE, 2007, J INVEST ALLERG CLIN, V17, P77; Dykewicz MS, 2009, J ALLERGY CLIN IMMUN, V123, P519, DOI 10.1016/j.jaci.2009.01.061; Eneli I, 2005, CHEST, V127, P604, DOI 10.1378/chest.127.2.604; Etminan M, 2009, CHEST, V136, P1316, DOI 10.1378/chest.09-0865; FIGINI M, 1995, BRIT J PHARMACOL, V115, P128, DOI 10.1111/j.1476-5381.1995.tb16329.x; Geppetti P, 2006, EUR J PHARMACOL, V533, P207, DOI 10.1016/j.ejphar.2005.12.063; Geppetti P, 1996, NEUROGENIC INFLAMMAT; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Joos GF, 2000, ALLERGY, V55, P321, DOI 10.1034/j.1398-9995.2000.00112.x; Krishna MT, 1997, AM J RESP CRIT CARE, V156, P943, DOI 10.1164/ajrccm.156.3.9612088; Louhivuori LM, 2009, J CELL PHYSIOL, V221, P67, DOI 10.1002/jcp.21828; Malo JL, 2009, AM J RESP CRIT CARE, V179, P923, DOI 10.1164/rccm.200810-1550OC; McKeever TM, 2005, AM J RESP CRIT CARE, V171, P966, DOI 10.1164/rccm.200409-1269OC; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Nuttall SL, 2003, J CLIN PHARM THER, V28, P251, DOI 10.1046/j.1365-2710.2003.00492.x; Sadofsky LR, 2008, EXP LUNG RES, V34, P681, DOI 10.1080/01902140802339623; Sartiani L, 2004, CIRCULATION, V109, P419, DOI 10.1161/01.CIR.0000109497.73223.4D; Shaheen S, 2008, EUR RESPIR J, V32, P1231, DOI 10.1183/09031936.00039208; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; Taylor-Clark TE, 2009, AM J RESP CELL MOL, V40, P756, DOI 10.1165/rcmb.2008-0292OC; Taylor-Clark TE, 2009, MOL PHARMACOL, V75, P820, DOI 10.1124/mol.108.054445; Trevisani M, 2002, NAT NEUROSCI, V5, P546, DOI 10.1038/nn852; Trevisani M, 2007, P NATL ACAD SCI USA, V104, P13519, DOI 10.1073/pnas.0705923104; Vargas MH, 1998, J APPL PHYSIOL, V84, P1749, DOI 10.1152/jappl.1998.84.5.1749	50	92	93	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4904	4916		10.1096/fj.10-162438	http://dx.doi.org/10.1096/fj.10-162438			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20720158				2022-12-28	WOS:000284824400029
J	Remels, AHV; Gosker, HR; Schrauwen, P; Hommelberg, PPH; Sliwinski, P; Polkey, M; Galdiz, J; Wouters, EFM; Langen, RCJ; Schols, AMWJ				Remels, A. H. V.; Gosker, H. R.; Schrauwen, P.; Hommelberg, P. P. H.; Sliwinski, P.; Polkey, M.; Galdiz, J.; Wouters, E. F. M.; Langen, R. C. J.; Schols, A. M. W. J.			TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia?	FASEB JOURNAL			English	Article						inflammation; nuclear factor kappa B; peroxisome proliferator-activated receptors; mitochondrial transcription factor A	OBSTRUCTIVE PULMONARY-DISEASE; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; SKELETAL-MUSCLE; MITOCHONDRIAL-FUNCTION; SYSTEMIC INFLAMMATION; NUTRITIONAL DEPLETION; VASTUS LATERALIS; COPD; EXPRESSION	Chronic obstructive pulmonary disease (COPD) is characterized by weight loss, muscle wasting (in advanced disease ultimately resulting in cachexia), and loss of muscle oxidative phenotype (oxphen). This study investigates the effect of inflammation (as a determinant of muscle wasting) on muscle oxphen by using cell studies combined with analyses of muscle biopsies of patients with COPD and control participants. We analyzed markers (citrate synthase, beta-hydroxya-cyl-CoA dehydrogenase, and cytochrome c oxidase IV) and regulators (PGC-1 alpha, PPAR-alpha, and Tfam) of oxphen in vastus lateralis muscle biopsies of patients with advanced COPD and healthy smoking control participants. Here 17 of 73 patients exhibited elevated muscle TNF-alpha mRNA levels. In these patients, significantly lower mRNA levels of all oxidative markers/regulators were found. Interestingly, these patients also had a significantly lower body mass index and tended to have less muscle mass. In cultured muscle cells, mitochondrial protein content and myosin heavy chain isoform I (but not II) protein and mRNA levels were reduced on chronic TNF-alpha stimulation. TNF-alpha also reduced mitochondrial respiration in a nuclear factor kappaB (NF kappa B) -dependent manner. Importantly, TNF-alpha-induced NF-kappa B activation decreased promoter transactivation and transcriptional activity of regulators of mitochondrial biogenesis and muscle oxphen. In conclusion, these results demonstrate that TNF-alpha impairs muscle oxphen in a NF-kappa B-dependent manner.-Remels, A. H. V., Gosker, H. R., Schrauwen, P., Hommelberg, P. P. H., Sliwinski, P., Polkey, M., Galdiz, J., Wouters, E. F. M., Langen, R. C. J., Schols, A. M. W. J. TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? FASEB J. 24, 5052-5062 (2010). www.fasebj.org	[Remels, A. H. V.; Gosker, H. R.; Wouters, E. F. M.; Langen, R. C. J.; Schols, A. M. W. J.] Maastricht Univ Med Ctr, Dept Resp Med, NUTRIM Sch Nutr Toxicol & Metab, NL-6202 AZ Maastricht, Netherlands; [Schrauwen, P.; Hommelberg, P. P. H.] Maastricht Univ Med Ctr, Dept Human Biol, NUTRIM Sch Nutr Toxicol & Metab, NL-6202 AZ Maastricht, Netherlands; [Sliwinski, P.] Inst TB & Lung Dis, Dept Resp Med, Warsaw, Poland; [Polkey, M.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Resp Med, London, England; [Galdiz, J.] Univ Basque Country, Cruces Hosp, Dept Pneumol, Baracaldo, Spain; [Galdiz, J.] Univ Basque Country, Cruces Hosp, Res Unit, Baracaldo, Spain; [Wouters, E. F. M.] Ctr Integrated Rehabil Organ Failure CIRO, Horn, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Imperial College London; Royal Brompton Hospital; Hospital Universitario Cruces; University of Basque Country; Hospital Universitario Cruces; University of Basque Country	Schols, AMWJ (corresponding author), Maastricht Univ Med Ctr, Dept Resp Med, NUTRIM Sch Nutr Toxicol & Metab, POB 5800, NL-6202 AZ Maastricht, Netherlands.	a.schols@pul.unimaas.nl	Wouters, Emiel/ABD-6200-2021; Dispositivos, Desarrollo/E-5176-2012; Galdiz, Juan Bautista/G-4977-2012	schrauwen, patrick/0000-0002-0973-847X; Gosker, Harry/0000-0002-7659-0225	Netherlands Asthma Foundation (NAF) [3.4.05.038, 3.2.08.061]; Royal Netherlands Academy of Arts and Sciences; VENI [VENI 916.56.112]; ENIGMA [QLK6-CT-2002-02285]	Netherlands Asthma Foundation (NAF); Royal Netherlands Academy of Arts and Sciences; VENI(Netherlands Organization for Scientific Research (NWO)); ENIGMA(European Commission)	The authors thank Dr. S. Wagers for critical and careful reviewing of the content of the paper and assistance with English. The authors also thank Dr. Marc van Bilsen (Maastricht University, Maastricht, The Netherlands) for delivering constructs encoding PPAR isoforms and PGC-1 alpha. The authors acknowledge E. Phielix for excellent technical support in cellular respiration measurements and M. Kelders for practical help in carrying out QPCR procedures. The authors have no conflicting financial interests. Funding sources had no involvement in collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The research of H. R. G. is supported by a grant from the Netherlands Asthma Foundation (NAF 3.4.05.038). The research of P. Schrauwen has been made possible by fellowships of the Royal Netherlands Academy of Arts and Sciences. R.C.J.L. was sponsored by a VENI grant (VENI 916.56.112). A. H. V. R. is supported by a grant from Numico Research and a travel fellowship from the Netherlands Asthma Foundation (NAF 3.2.08.061). The ENIGMA study was sponsored by ENIGMA grant QLK6-CT-2002-02285.	Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; Bakkar N, 2008, J CELL BIOL, V180, P787, DOI 10.1083/jcb.200707179; Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008; Barreiro E, 2008, THORAX, V63, P100, DOI 10.1136/thx.2007.078030; Broekhuizen R, 2005, THORAX, V60, P376, DOI 10.1136/thx.2004.030858; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; CERAMI A, 1985, IMMUNOL LETT, V11, P173, DOI 10.1016/0165-2478(85)90165-8; Chabi B, 2009, J APPL PHYSIOL, V107, P1730, DOI 10.1152/japplphysiol.91451.2008; Couillard A, 2005, EUR RESPIR J, V26, P703, DOI 10.1183/09031936.05.00139904; Crul T, 2007, EUR J CLIN INVEST, V37, P897, DOI 10.1111/j.1365-2362.2007.01867.x; de Oca MM, 2005, EUR RESPIR J, V26, P390, DOI 10.1183/09031936.05.00107404; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Fabbri Leonardo, 2004, COPD, V1, P105; Gan WQ, 2004, THORAX, V59, P574, DOI 10.1136/thx.2003.019588; Gosker HR, 2007, THORAX, V62, P944, DOI 10.1136/thx.2007.078980; Gosker HR, 2009, AM J RESP CELL MOL, V40, P710, DOI 10.1165/rcmb.2008-0312OC; Gosker HR, 2006, AM J PHYSIOL-ENDOC M, V290, pE976, DOI 10.1152/ajpendo.00336.2005; Gosker HR, 2002, EUR RESPIR J, V19, P617, DOI 10.1183/09031936.02.00762001; Gosker HR, 2002, AM J CLIN NUTR, V76, P113, DOI 10.1093/ajcn/76.1.113; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Jia L, 1996, BLOOD, V87, P2401, DOI 10.1182/blood.V87.6.2401.bloodjournal8762401; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; Langen RCJ, 2006, AM J RESP CELL MOL, V35, P689, DOI 10.1165/rcmb.2006-0103OC; Langen RCJ, 2001, FASEB J, V15, pA1080; Lanza IR, 2010, ACTA PHYSIOL, V199, P529, DOI 10.1111/j.1748-1716.2010.02124.x; LEE MD, 1987, P NATL ACAD SCI USA, V84, P2590, DOI 10.1073/pnas.84.9.2590; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Lyons CN, 2004, BIOCHEM CELL BIOL, V82, P391, DOI 10.1139/O04-040; Marin-Garcia J, 2001, CARDIOVASC RES, V52, P103, DOI 10.1016/S0008-6363(01)00368-6; Mensink M, 2007, INT J OBESITY, V31, P1302, DOI 10.1038/sj.ijo.0803567; Pajak B, 2008, J PHYSIOL PHARMACOL, V59, P251; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Petersen AM, 2009, J CLIN ENDOCR METAB, V94, P294, DOI 10.1210/jc.2008-1110; Puente-Maestu L, 2009, EUR RESPIR J, V33, P1045, DOI 10.1183/09031936.00112408; Rabinovich RA, 2007, EUR RESPIR J, V29, P643, DOI 10.1183/09031936.00086306; Remels AH, 2007, EUR RESPIR J, V30, P245, DOI 10.1183/09031936.00144106; Remels AHV, 2009, AM J PHYSIOL-ENDOC M, V297, pE174, DOI 10.1152/ajpendo.90632.2008; Safdar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010778; Schols AMWJ, 2005, AM J CLIN NUTR, V82, P53, DOI 10.1093/ajcn/82.1.53; SCHOLS AMWJ, 1993, AM REV RESPIR DIS, V147, P1151, DOI 10.1164/ajrccm/147.5.1151; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Sin DD, 2007, CAN J PHYSIOL PHARM, V85, P141, DOI 10.1139/Y06-093; Tang K, 2010, J CELL PHYSIOL, V222, P320, DOI 10.1002/jcp.21955; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; Valerio A, 2006, J CLIN INVEST, V116, P2791, DOI [10.1172/JCI28570, 10.1172/JCI28570.]; van der Velden JLJ, 2007, AM J PHYSIOL-CELL PH, V292, pC1636, DOI 10.1152/ajpcell.00504.2006; van Wetering CR, 2010, J AM MED DIR ASSOC, V11, P179, DOI 10.1016/j.jamda.2009.12.083; Vermeeren MAP, 2006, RESP MED, V100, P1349, DOI 10.1016/j.rmed.2005.11.023; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Wust Rob C I, 2007, Int J Chron Obstruct Pulmon Dis, V2, P289; Zhao Cai-Yan, 2005, Zhonghua Gan Zang Bing Za Zhi, V13, P96	55	96	97	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5052	5062		10.1096/fj.09-150714	http://dx.doi.org/10.1096/fj.09-150714			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20807714	Green Submitted			2022-12-28	WOS:000284824400043
J	Boles, KS; Schmieder, AH; Koch, AW; Carano, RAD; Wu, Y; Caruthers, SD; Tong, RK; Stawicki, S; Hu, G; Scott, MJ; Zhang, HY; Reynolds, BA; Wickline, SA; Lanza, GM				Boles, Kent S.; Schmieder, Anne H.; Koch, Alexander W.; Carano, Richard A. D.; Wu, Yan; Caruthers, Shelton D.; Tong, Raymond K.; Stawicki, Scott; Hu, Grace; Scott, Michael J.; Zhang, Huiying; Reynolds, Benton A.; Wickline, Samuel A.; Lanza, Gregory M.			MR angiogenesis imaging with Robo4-vs. alpha(V)beta(3)-targeted nanoparticles in a B16/F10 mouse melanoma model	FASEB JOURNAL			English	Article						magnetic resonance imaging; integrin; neovasculature; roundabout; tumor	INHIBITS TUMOR-GROWTH; VX-2 RABBIT TUMORS; MAGNETIC-RESONANCE; IN-VIVO; MAGIC ROUNDABOUT; INTEGRINS; EXPRESSION; ULTRASOUND; RECEPTOR; CLONING	The primary objective of this study was to utilize MR molecular imaging to compare the 3-dimensional spatial distribution of Robo4 and alpha(V)beta(3)-integrin as biosignatures of angiogenesis, in a rapidly growing, syngeneic tumor. B16-F10 melanoma-bearing mice were imaged with magnetic resonance (MR; 3.0 T) 11 d postimplantation before and after intravenous administration of either Robo4- or alpha(V)beta(3)-targeted paramagnetic nanoparticles. The percentage of MR signal-enhanced voxels throughout the tumor volume was low and increased in animals receiving alpha(V)beta(3)- and Robo4-targeted nanoparticles. Neovascular signal enhancement was predominantly associated with the tumor periphery (i.e., outer 50% of volume). Microscopic examination of tumors coexposed to the Robo4- and alpha(V)beta(3)-targeted nanoparticles corroborated the MR angiogenesis mapping results and further revealed that Robo4 expression generally colocalized with alpha(V)beta(3)-integrin. Robo4- and alpha(V)beta(3)-targeted nanoparticles were compared to irrelevant or nontargeted control groups in all modalities. These results suggest that alpha(V)beta(3)-integrin and Robo4 are useful biomarkers for noninvasive MR molecular imaging in syngeneic mouse tumors, but alpha(V)beta(3)-integrin expression was more detectable by MR at 3.0 T than Robo4. Noninvasive, neovascular assessments of the MR signal of Robo4, particularly combined with alpha(V)beta(3)-integrin expression, may help define tumor character prior to and following cancer therapy.-Boles, K. S., Schmieder, A. H., Koch, A. W., Carano, R. A. D., Wu, Y., Caruthers, S. D., Tong, R. K., Stawicki, S., Hu, G., Scott, M. J., Zhang, H., Reynolds, B. A., Wickline, S. A., and Lanza, G. M. MR angiogenesis imaging with Robo4- vs. alpha(V)beta(3)-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J. 24, 4262-4270 (2010). www.fasebj.org	[Boles, Kent S.; Schmieder, Anne H.; Caruthers, Shelton D.; Hu, Grace; Scott, Michael J.; Zhang, Huiying; Reynolds, Benton A.; Wickline, Samuel A.; Lanza, Gregory M.] Washington Univ, Sch Med, St Louis, MO 63108 USA; [Wu, Yan; Stawicki, Scott] Genentech Inc, Prot Chem, San Francisco, CA 94080 USA; [Koch, Alexander W.; Tong, Raymond K.] Genentech Inc, Biomed Imaging Grp, Dept Tumor Biol & Angiogenesis, San Francisco, CA 94080 USA; [Carano, Richard A. D.] Genentech Inc, Antibody Engn, San Francisco, CA 94080 USA	Washington University (WUSTL); Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Lanza, GM (corresponding author), Washington Univ, Sch Med, Campus Box 8215,4320 Forest Pk Ave, St Louis, MO 63108 USA.	greg@cvu.wustl.edu			NATIONAL CANCER INSTITUTE [U54CA119342] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL094470] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA119342] Funding Source: Medline; NHLBI NIH HHS [R01 HL094470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Ahrens ET, 2005, NAT BIOTECHNOL, V23, P983, DOI 10.1038/nbt1121; BOTTOMLEY PA, 1989, RADIOLOGY, V170, P1; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Caruthers SD, 2006, INVEST RADIOL, V41, P305, DOI 10.1097/01.rli.0000199281.60135.6a; CHERESH DA, 1991, BIOCHEM SOC T, V19, P835, DOI 10.1042/bst0190835; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; Ellegala DB, 2003, CIRCULATION, V108, P336, DOI 10.1161/01.CIR.0000080326.15367.0C; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Helluin O, 2000, J BIOL CHEM, V275, P18337, DOI 10.1074/jbc.M001529200; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hu G, 2007, INT J CANCER, V120, P1951, DOI 10.1002/ijc.22581; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Huminiecki L, 2000, GENOME RES, V10, P1796, DOI 10.1101/gr.150700; Itoh A, 1998, MOL BRAIN RES, V62, P175, DOI 10.1016/S0169-328X(98)00224-1; Itoh H, 1997, J VASC SURG, V25, P1061, DOI 10.1016/S0741-5214(97)70130-7; Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742; Kageshita T, 2000, INT J CANCER, V89, P153, DOI 10.1002/(SICI)1097-0215(20000320)89:2<153::AID-IJC9>3.0.CO;2-1; Keupp J, 2009, P INT SOC MAGN RESON, V17, P223; Keupp J, 2007, P INT SOC MAGN RESON, V15, P1334; Keupp J, 2006, P INT SOC MAGN RESON, V14, P102; Lanza GM, 2002, CIRCULATION, V106, P2842, DOI 10.1161/01.CIR.0000044020.27990.32; Legg JA, 2008, ANGIOGENESIS, V11, P13, DOI 10.1007/s10456-008-9100-x; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Lijowski M, 2009, INVEST RADIOL, V44, P15, DOI 10.1097/RLI.0b013e31818935eb; Meoli DF, 2004, J CLIN INVEST, V113, P1684, DOI 10.1172/JCI200420352; Morawski AM, 2004, MAGN RESON MED, V51, P480, DOI 10.1002/mrm.20010; Mulder WJM, 2005, FASEB J, V19, P2008, DOI 10.1096/fj.05-4145fje; Neubauer AM, 2007, J CARDIOVASC MAGN R, V9, P565, DOI 10.1080/10976640600945481; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Partlow KC, 2007, FASEB J, V21, pA379; Rahmer J, 2009, P INT SOC MAGN RESON, P611; Rahmer J, 2009, P INT SOC MAGN RESON, V17, P4611; RAHMER J, 2008, P INT SOC MAGN RESON, V16, P1471; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Schmieder AH, 2005, MAGN RESON MED, V53, P621, DOI 10.1002/mrm.20391; Schmieder AH, 2008, FASEB J, V22, P4179, DOI 10.1096/fj.08-112060; Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250; Weissleder R, 2001, BIOCONJUGATE CHEM, V12, P213, DOI 10.1021/bc000091p; Winter PM, 2008, FASEB J, V22, P2758, DOI 10.1096/fj.07-103929; Winter PM, 2006, ARTERIOSCL THROM VAS, V26, P2103, DOI 10.1161/01.ATV.0000235724.11299.76; Winter PM, 2003, CANCER RES, V63, P5838; Winter PM, 2003, CIRCULATION, V108, P2270, DOI 10.1161/01.CIR.0000093185.16083.95; Yu X, 2000, MAGNET RESON MED, V44, P867, DOI 10.1002/1522-2594(200012)44:6<867::AID-MRM7>3.0.CO;2-P	48	28	28	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4262	4270		10.1096/fj.10-157933	http://dx.doi.org/10.1096/fj.10-157933			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20585027	Green Published			2022-12-28	WOS:000283861100014
J	Cabodi, S; Tinnirello, A; Bisaro, B; Tornillo, G; Camacho-Leal, MD; Forni, G; Cojoca, R; Iezzi, M; Amici, A; Montani, M; Eva, A; Di Stefano, P; Muthuswamy, SK; Tarone, G; Turco, E; Defilippi, P				Cabodi, Sara; Tinnirello, Agata; Bisaro, Brigitte; Tornillo, Giusy; Camacho-Leal, Maria del Pilar; Forni, Guido; Cojoca, Rodica; Iezzi, Manuela; Amici, Augusto; Montani, Maura; Eva, Alessandra; Di Stefano, Paola; Muthuswamy, Senthil K.; Tarone, Guido; Turco, Emilia; Defilippi, Paola			p130Cas is an essential transducer element in ErbB2 transformation	FASEB JOURNAL			English	Article						breast cancer; tumorigenesis; invasion; metastasis; signaling	CELL-PROLIFERATION; EPITHELIAL-CELLS; TRANSGENIC MICE; CANCER-CELLS; PROTEIN; SRC; KINASE; INVASION; INDUCTION; RECEPTOR	The ErbB2 oncogene is often overexpressed in breast tumors and associated with poor clinical outcome. p130Cas represents a nodal scaffold protein regulating cell survival, migration, and proliferation in normal and pathological cells. The functional role of p130Cas in ErbB2-dependent breast tumorigenesis was assessed by its silencing in breast cancer cells derived from mouse mammary tumors overexpressing ErbB2 (N202-1A cells), and by its reexpression in ErbB2-transformed p130Cas-null mouse embryonic fibroblasts. We demonstrate that p130Cas is necessary for ErbB2-dependent foci formation, anchorage-independent growth, and in vivo growth of orthotopic N202-1A tumors. Moreover, intranipple injection of p130Cas-stabilized siRNAs in the mammary gland of Balbc-NeuT mice decreases the growth of spontaneous tumors. In ErbB2-transformed cells, p130Cas is a crucial component of a functional molecular complex consisting of ErbB2, c-Src, and Fak. In human mammary cells, MCF10A. B2, the concomitant activation of ErbB2, and p130Cas overexpression sustain and strengthen signaling, leading to Rac1 activation and MMP9 secretion, thus providing invasive properties. Consistently, p130Cas drives N202-1A cell in vivo lung metastases colonization. These results demonstrate that p130Cas is an essential transducer in ErbB2 transformation and highlight its potential use as a novel therapeutic target in ErbB2 positive human breast cancers.-Cabodi, S., Tinnirello, A., Bisaro, B., Tornillo, G., Camacho-Leal, M. P., Forni, G., Cojoca, R., Iezzi, M., Amici, A., Montani, M., Eva, A., Di Stefano, P., Muthuswamy, S. K., Tarone, G., Turco, E., Defilippi, P. p130Cas is an essential transducer element in ErbB2 transformation. FASEB J. 24, 3796-3808 (2010). www.fasebj.org	[Cabodi, Sara; Tinnirello, Agata; Bisaro, Brigitte; Tornillo, Giusy; Camacho-Leal, Maria del Pilar; Forni, Guido; Cojoca, Rodica; Di Stefano, Paola; Tarone, Guido; Turco, Emilia; Defilippi, Paola] Univ Turin, Ctr Mol Biotechnol, I-10126 Turin, Italy; [Eva, Alessandra] Ist Giannina Gaslini, Mol Biol Lab, Genoa, Italy; [Muthuswamy, Senthil K.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Iezzi, Manuela] Univ G DAnnunzio, Ctr Aging Sci CESI, Aging Res Ctr, Chieti, Italy; [Amici, Augusto; Montani, Maura] Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, Italy	University of Turin; University of Genoa; IRCCS Istituto Giannina Gaslini; Cold Spring Harbor Laboratory; G d'Annunzio University of Chieti-Pescara; University of Camerino	Defilippi, P (corresponding author), Univ Turin, Ctr Mol Biotechnol, Via Nizza 52, I-10126 Turin, Italy.	paola.defilippi@unito.it	Tornillo, Giusy/AAZ-8165-2020; DEFILIPPI, Paola/L-2232-2014; Iezzi, Manuela/AAB-7939-2019; Muthuswamy, Senthil K/AGY-2834-2022; Eva, Alessandra/J-8268-2016	Tornillo, Giusy/0000-0002-3934-3567; Iezzi, Manuela/0000-0002-6296-6498; Muthuswamy, Senthil K/0000-0001-6564-9634; Eva, Alessandra/0000-0003-2949-078X; Defilippi, Paola/0000-0001-6427-4906; Tarone, Guido/0000-0003-4805-086X; Amici, Augusto/0000-0002-4634-1500; Cabodi, Sara/0000-0003-1248-6549	Association for International Cancer Research (AICR); AIRC, Associazione Italiana Ricerca Cancro; EU; Ministero Universita e Ricerca; Programma di Ricerca di Rilevante Interesse Nazionale; Regione Piemonte-Progetti Sanita; Oncoprot; Piattaforma Staminali; Druidi; Comitato Interministeriale per la Programmazione Economica, Compagnia San Paolo, Progetto Alfieri-Fondazione Cassa Risparmio Torino, Turin, Italy; European Molecular Biology Organization	Association for International Cancer Research (AICR); AIRC, Associazione Italiana Ricerca Cancro(Fondazione AIRC per la ricerca sul cancro); EU(European Commission); Ministero Universita e Ricerca(Ministry of Education, Universities and Research (MIUR)); Programma di Ricerca di Rilevante Interesse Nazionale; Regione Piemonte-Progetti Sanita; Oncoprot; Piattaforma Staminali; Druidi; Comitato Interministeriale per la Programmazione Economica, Compagnia San Paolo, Progetto Alfieri-Fondazione Cassa Risparmio Torino, Turin, Italy(Compagnia di San Paolo); European Molecular Biology Organization(European Molecular Biology Organization (EMBO))	The authors thank Dr. Pier Giorgio Lollini (University of Bologna, Bologna, Italy) for the N202-1A cells, Dr. Nancy Hynes (Friedrich Miescher Institute, Basel, Switzerland) for human mutated ErbB2, Roberto Piva (University of Torino, Turin, Italy) for shRNA vectors, and Elisa Penna (Molecular Biotechnology Center, University of Torino) for the transmigration assays. M.P.C.-L. is supported by the Association for International Cancer Research (AICR), and A.T. received a short-term European Molecular Biology Organization fellowship for her stay in S.K.M.'s lab. This work was supported by AIRC, Associazione Italiana Ricerca Cancro, EU FP7 Metafight, Ministero Universita e Ricerca, Programma di Ricerca di Rilevante Interesse Nazionale, Regione Piemonte-Progetti Sanita, Oncoprot, Piattaforma Staminali, Druidi, and Comitato Interministeriale per la Programmazione Economica, Compagnia San Paolo, Progetto Alfieri-Fondazione Cassa Risparmio Torino, Turin, Italy.	Ambrogio C, 2005, BLOOD, V106, P3907, DOI 10.1182/blood-2005-03-1204; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; CABODI S, 2006, INTEGRINS SIGNAL TRA; Cabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909; Cappello P, 2003, CANCER RES, V63, P2518; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; Di Stefano P, 2007, EMBO J, V26, P2843, DOI 10.1038/sj.emboj.7601724; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Kim IY, 2009, CANCER LETT, V275, P227, DOI 10.1016/j.canlet.2008.10.013; Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; Nanni P, 2000, INT J CANCER, V87, P186, DOI 10.1002/1097-0215(20000715)87:2<186::AID-IJC5>3.0.CO;2-1; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Trono D, 2003, SCIENCE, V300, P1670, DOI 10.1126/science.1086238; Vanni C, 2005, CELL CYCLE, V4, P1675, DOI 10.4161/cc.4.11.2170; Yarden Y, 2004, SEMIN ONCOL, V31, P6, DOI 10.1053/j.seminoncol.2004.07.016; Zaidel-Bar R, 2005, J CELL SCI, V118, P3997, DOI 10.1242/jcs.02523	41	33	37	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3796	3808		10.1096/fj.10-157347	http://dx.doi.org/10.1096/fj.10-157347			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20505116	Green Accepted			2022-12-28	WOS:000285005900018
J	Wolf, J; Reimer, TA; Schuck, S; Ruder, C; Gerlach, K; Muller, EC; Otto, A; Dorken, B; Rehm, A				Wolf, Jana; Reimer, Tatiana A.; Schuck, Sebastian; Rueder, Constantin; Gerlach, Kerstin; Mueller, Eva-Christina; Otto, Albrecht; Doerken, Bernd; Rehm, Armin			Role of EBAG9 protein in coat protein complex I-dependent glycoprotein maturation and secretion processes in tumor cells	FASEB JOURNAL			English	Article						vesicle trafficking; mechanisms of disease; tumor pathogenesis; secretory pathway; immunomodulation	TO-GOLGI TRANSPORT; O-LINKED OLIGOSACCHARIDES; CANINE KIDNEY-CELLS; ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; IMMUNE-RESPONSES; COPI VESICLES; LIVING CELLS; INTERMEDIATE COMPARTMENT; MOLECULAR-CLONING	Many proteins mature within the secretory pathway by the acquisition of glycans. Failure to maintain the proper distribution of the glycosylation machinery might lead to disease. High expression levels of the ubiquitous Golgi protein estrogen receptor-binding fragment-associated gene 9 (EBAG9) in human tumors correlate with poor clinical prognosis, and EBAG9 overexpression in epithelial cell lines induces truncated glycans, typical of many carcinomas. Here, we addressed the pathogenetic link between EBAG9 expression and the alteration of the cellular glycome. We applied confocal microscopy, live imaging, pulse-chase labeling in conjunction with immunoprecipitation, and enzymatic activity assays in a variety of EBAG9-overexpressing or depleted epithelial tumor cell lines. EBAG9 shuttles between the ER-Golgi intermediate compartment and the cis-Golgi, and we demonstrate association of EBAG9 with coat protein complex I (COPI)-coated transport vesicles. EBAG9 overexpression imposes delay of endoplasmic reticulum-to-Golgi transport and mislocalizes components of the ER quality control and glycosylation machinery. Conversely, EBAG9 down-regulation accelerates glycoprotein transport through the Golgi and enhances mannosidase activity. Thus, EBAG9 acts as a negative regulator of a COPI-dependent ER-to-Golgi transport pathway in epithelial cells and represents a novel pathogenetic principle in which interference with intracellular membrane trafficking results in the emergence of a tumor-associated glycome.-Wolf, J., Reimer, T. A., Schuck, S., Ruder, C., Gerlach, K., Muller, E.-C., Otto, A., Dorken, B., Rehm, A. Role of EBAG9 protein in coat protein complex I-dependent glycoprotein maturation and secretion processes in tumor cells. FASEB J. 24, 4000-4019 (2010). www.fasebj.org	[Schuck, Sebastian] Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany; [Wolf, Jana; Reimer, Tatiana A.; Rueder, Constantin; Gerlach, Kerstin; Mueller, Eva-Christina; Otto, Albrecht; Doerken, Bernd; Rehm, Armin] Max Delbruck Ctr Mol Med, Dept Hematol Oncol & Tumorimmunol, D-13125 Berlin, Germany; [Doerken, Bernd; Rehm, Armin] Charite, Dept Hematol Oncol & Tumorimmunol, Virchow Clin, D-13353 Berlin, Germany	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rehm, A (corresponding author), Max Delbruck Ctr Mol Med, Dept Haematol Oncol & Tumorimmunol, Robert Rossle Str 10, D-13125 Berlin, Germany.	arehm@mdc-berlin.de		Schuck, Sebastian/0000-0002-6388-0661	Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Jennifer Lippincott-Schwartz (National Institute of Child Health and Human Development, Bethesda, MD, USA), Ludger Johannes (Institut Curie, Paris, France), Thomas Sudhof (University of Texas Southwestern Medical Center, Dallas, TX, USA), Brian Storrie (University of Arkansas for Medical Sciences, Little Rock, AR, USA), Mark A. McNiven (Mayo Clinic, Rochester, MN, USA), Richard D. Cummings (Emory University School of Medicine, Atlanta, GA, USA), Jean Gruenberg (Universite de Geneve, Geneva, Switzerland), and Ingo Morano (Max Delbruck Center for Molecular Medicine, Berlin, Germany) for providing essential reagents, and K. Simons for continuous support. The authors also thank U. Karsten and U.E. Hopken for critical evaluation of the manuscript. This work was supported by a grant from Deutsche Forschungsgemeinschaft (to A.R).	Akahira J, 2004, BRIT J CANCER, V90, P2197, DOI 10.1038/sj.bjc.6601832; Aoe T, 1999, J BIOL CHEM, V274, P20545, DOI 10.1074/jbc.274.29.20545; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Beck R, 2009, FEBS LETT, V583, P2701, DOI 10.1016/j.febslet.2009.07.032; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Brockhausen I, 2006, EMBO REP, V7, P599, DOI 10.1038/sj.embor.7400705; Cai HQ, 2007, DEV CELL, V12, P671, DOI 10.1016/j.devcel.2007.04.005; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Cichon G, 1999, J GENE MED, V1, P360, DOI 10.1002/(SICI)1521-2254(199909/10)1:5<360::AID-JGM54>3.0.CO;2-Q; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cudic M, 2002, BIOORGAN MED CHEM, V10, P3859, DOI 10.1016/S0968-0896(02)00388-7; Daniels R, 2004, CELL BIOCHEM BIOPHYS, V41, P113, DOI 10.1385/CBB:41:1:113; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dube DH, 2005, NAT REV DRUG DISCOV, V4, P477, DOI 10.1038/nrd1751; EGEA G, 1993, J CELL SCI, V105, P819; Engelsberg A, 2003, J BIOL CHEM, V278, P22998, DOI 10.1074/jbc.M301361200; Gilchrist A, 2006, CELL, V127, P1265, DOI 10.1016/j.cell.2006.10.036; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hauri HP, 2000, J CELL SCI, V113, P587; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hong XJ, 2009, CANCER SCI, V100, P961, DOI 10.1111/j.1349-7006.2009.01129.x; Jensen T, 2001, EUR J IMMUNOL, V31, P3197, DOI 10.1002/1521-4141(200111)31:11<3197::AID-IMMU3197>3.0.CO;2-5; Johannes L, 2002, AM J PHYSIOL-GASTR L, V283, pG1, DOI 10.1152/ajpgi.00088.2002; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200; Khvotchev MV, 2003, J NEUROSCI, V23, P10531; Klumperman J, 1998, J CELL SCI, V111, P3411; KTISTAKIS NT, 1995, MOL BIOL CELL, V6, P135, DOI 10.1091/mbc.6.2.135; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Liu W, 2005, J CELL BIOL, V168, P1053, DOI 10.1083/jcb.200410142; Luna A, 2002, MOL BIOL CELL, V13, P866, DOI 10.1091/mbc.01-12-0579; Malsam J, 2005, SCIENCE, V307, P1095, DOI 10.1126/science.1108061; Marra P, 2007, MOL BIOL CELL, V18, P1595, DOI 10.1091/mbc.E06-10-0886; Marth JD, 2008, NAT REV IMMUNOL, V8, P874, DOI 10.1038/nri2417; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Moelleken J, 2007, P NATL ACAD SCI USA, V104, P4425, DOI 10.1073/pnas.0611360104; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Newsom-Davis TE, 2009, CANCER RES, V69, P2018, DOI 10.1158/0008-5472.CAN-08-3589; Ogushi T, 2005, CANCER RES, V65, P3700, DOI 10.1158/0008-5472.CAN-04-3497; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Pernet-Gallay K, 2002, TRAFFIC, V3, P822, DOI 10.1034/j.1600-0854.2002.31107.x; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rabouille C, 2005, NAT REV MOL CELL BIO, V6, P812, DOI 10.1038/nrm1735; Razi M, 2009, J CELL BIOL, V185, P305, DOI 10.1083/jcb.200810098; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Reimer TA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-47; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8; Ruder C, 2005, MOL BIOL CELL, V16, P1245, DOI 10.1091/mbc.E04-09-0817; Ruder C, 2009, J CLIN INVEST, V119, P2184, DOI 10.1172/JCI37760; Rutz C, 2009, TRAFFIC, V10, P994, DOI 10.1111/j.1600-0854.2009.00934.x; Sannerud R, 2003, CURR OPIN CELL BIOL, V15, P438, DOI 10.1016/S0955-0674(03)00077-2; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Schietinger A, 2006, SCIENCE, V314, P304, DOI 10.1126/science.1129200; Schuck S, 2007, TRAFFIC, V8, P47, DOI 10.1111/j.1600-0854.2006.00506.x; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Spang A, 2002, CURR OPIN CELL BIOL, V14, P423, DOI 10.1016/S0955-0674(02)00346-0; Stephens DJ, 2000, J CELL SCI, V113, P2177; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Storrie B, 2002, TRAFFIC, V3, P521, DOI 10.1034/j.1600-0854.2002.30802.x; Suzuki T, 2004, CANCER RES, V64, P4670, DOI 10.1158/0008-5472.CAN-04-0250; Takahashi S, 2003, INT J CANCER, V106, P310, DOI 10.1002/ijc.11205; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Tsuboi S, 1998, J BIOL CHEM, V273, P30680, DOI 10.1074/jbc.273.46.30680; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; Tsuchiya F, 2001, BIOCHEM BIOPH RES CO, V284, P2, DOI 10.1006/bbrc.2001.4892; Tsuiji H, 2003, GLYCOBIOLOGY, V13, P521, DOI 10.1093/glycob/cwg065; Tsuneizumi M, 2001, CLIN CANCER RES, V7, P3526; Ungar D, 2006, TRENDS CELL BIOL, V16, P113, DOI 10.1016/j.tcb.2005.12.004; van Kooyk Y, 2008, NAT IMMUNOL, V9, P593, DOI 10.1038/ni.f.203; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Wendler F, 2001, TRAFFIC, V2, P606, DOI 10.1034/j.1600-0854.2001.20903.x; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Zhang XL, 2006, CURR MED CHEM, V13, P1141, DOI 10.2174/092986706776360897	90	4	4	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					4000	4019		10.1096/fj.09-153452	http://dx.doi.org/10.1096/fj.09-153452			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20570965				2022-12-28	WOS:000285005900037
J	Fukumoto, H; Tokuda, T; Kasai, T; Ishigami, N; Hidaka, H; Kondo, M; Allsop, D; Nakagawa, M				Fukumoto, Hiroaki; Tokuda, Takahiko; Kasai, Takashi; Ishigami, Noriko; Hidaka, Hiroya; Kondo, Masaki; Allsop, David; Nakagawa, Masanori			High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients	FASEB JOURNAL			English	Article						amyloid-beta protein; dementia; ELISA; size-exclusion chromatography	MILD COGNITIVE IMPAIRMENT; A-BETA; PROTEIN AGGREGATION; PRECURSOR PROTEIN; BRAIN-TISSUE; DISEASE; DIAGNOSIS; CSF; PEPTIDE; TAU	There is accumulating evidence that soluble amyloid-beta (A beta) oligomers, rather than amyloid fibrils, are the principal pathogenic species in Alzheimer disease (AD). Here, we have developed a novel enzyme-linked immunosorbent assay (ELISA) specific for high-molecular-weight (HMW) A beta oligomers. Analysis of A beta oligomers derived from synthetic A beta 1-42, by size-exclusion chromatography (SEC), revealed that our ELISA specifically detected HMW A beta oligomers of 40-200 kDa. Using this ELISA, we detected significantly higher (P<0.0001) signals in cerebrospinal fluid (CSF) samples from 25 patients with AD or mild cognitive impairment (MCI), compared to 25 age-matched controls. As a test for discriminating between the AD/MCI and control groups, the area under the curve in receiver operating characteristic analysis for the CSF HMW A beta oligomers was greater than that for CSF A beta x-42. Furthermore, the CSF levels of HMW A beta oligomers showed a negative correlation with Mini-Mental State Examination scores in the AD/MCI group. We conclude that the CSF HMW A beta oligomers detected by our ELISA could be useful as a diagnostic marker for AD, and also as a potential surrogate marker for disease severity. Our results support the idea that soluble HMW A beta oligomers play a critical role in the pathogenesis and progression of AD.-Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., Nakagawa, M. High-molecular weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24, 2716-2726 (2010). www.fasebj.org	[Tokuda, Takahiko] Kyoto Prefectural Univ Med, Dept Neurol, Kamigyo Ku, Kyoto 6028566, Japan; [Fukumoto, Hiroaki] Takeda Pharmaceut Co, Pharmacol Res Div, Osaka, Japan; [Hidaka, Hiroya] Shinshu Univ, Sch Med, Sch Hlth Sci, Dept Biomed Lab Sci, Matsumoto, Nagano 390, Japan; [Allsop, David] Univ Lancaster, Sch Hlth & Med, Div Biomed & Life Sci, Lancaster, England	Kyoto Prefectural University of Medicine; Takeda Pharmaceutical Company Ltd; Shinshu University; Lancaster University	Tokuda, T (corresponding author), Kyoto Prefectural Univ Med, Dept Neurol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	ttokuda@koto.kpu-m.ac.jp	Allsop, David/B-9725-2008	Allsop, David/0000-0002-0513-5575	Ministry of Health, Labor, and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology [20591007]; Japan Society for the Promotion of Science; Research Committee of CNS Degenerative Disease	Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Research Committee of CNS Degenerative Disease	This work was supported in part by a Grant-in-Aid from the Research Committee of CNS Degenerative Disease, the Ministry of Health, Labor, and Welfare of Japan (to M.N.) and by a Grant-in-Aid for Scientific Research (C) (20591007) from the Ministry of Education, Culture, Sports, Science, and Technology and the Japan Society for the Promotion of Science (to T.T.).	American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x; Bateman RJ, 2007, NEUROLOGY, V68, P666, DOI 10.1212/01.wnl.0000256043.50901.e3; Bernstein SL, 2009, NAT CHEM, V1, P326, DOI [10.1038/NCHEM.247, 10.1038/nchem.247]; Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; El-Agnaf OMA, 2000, BIOCHEM BIOPH RES CO, V273, P1003, DOI 10.1006/bbrc.2000.3051; El-Agnaf OMA, 2003, LANCET NEUROL, V2, P461, DOI 10.1016/S1474-4422(03)00481-2; Englund H, 2007, J NEUROCHEM, V103, P334, DOI 10.1111/j.1471-4159.2007.04759.x; Fukumoto H, 1999, NEUROREPORT, V10, P2965, DOI 10.1097/00001756-199909290-00017; Fukumoto H, 2003, ARCH NEUROL-CHICAGO, V60, P958, DOI 10.1001/archneur.60.7.958; Galasko D, 1997, NEUROLOGY, V48, P632, DOI 10.1212/WNL.48.3.632; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KAMBOH MI, 1988, J LIPID RES, V29, P1535; Kanai M, 1998, ANN NEUROL, V44, P17, DOI 10.1002/ana.410440108; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 2006, NATURE, V443, P774, DOI 10.1038/nature05290; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LeVine H, 2004, ANAL BIOCHEM, V335, P81, DOI 10.1016/j.ab.2004.08.014; Lewczuk P, 2004, NEUROBIOL AGING, V25, P273, DOI 10.1016/S0197-4580(03)00086-1; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; Ono K, 2009, P NATL ACAD SCI USA, V106, P14745, DOI 10.1073/pnas.0905127106; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shaw LM, 2007, NAT REV DRUG DISCOV, V6, P295, DOI 10.1038/nrd2176; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Sunderland T, 2003, JAMA-J AM MED ASSOC, V289, P2094, DOI 10.1001/jama.289.16.2094; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tamaoka A, 1997, J NEUROL SCI, V148, P41, DOI 10.1016/S0022-510X(96)00314-0; Tokuda T, 1997, ANN NEUROL, V41, P271, DOI 10.1002/ana.410410220; Tokuda T, 2002, NEUROLOGY, V58, P1415, DOI 10.1212/WNL.58.9.1415; van Helmond Z, 2009, J NEUROSCI METH, V176, P206, DOI 10.1016/j.jneumeth.2008.09.002; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; Xia WM, 2009, ARCH NEUROL-CHICAGO, V66, P190, DOI 10.1001/archneurol.2008.565	48	194	204	2	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2716	2726		10.1096/fj.09-150359	http://dx.doi.org/10.1096/fj.09-150359			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20339023				2022-12-28	WOS:000285005400013
J	Rauch, A; Gossye, V; Bracke, D; Gevaert, E; Jacques, P; Van Beneden, K; Vandooren, B; Rauner, M; Hofbauer, LC; Haegeman, G; Elewaut, D; Tuckermann, JP; De Bosscher, K				Rauch, Alexander; Gossye, Valerie; Bracke, Debby; Gevaert, Elien; Jacques, Peggy; Van Beneden, Katrien; Vandooren, Bernard; Rauner, Martina; Hofbauer, Lorenz C.; Haegeman, Guy; Elewaut, Dirk; Tuckermann, Jan P.; De Bosscher, Karolien			An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation	FASEB JOURNAL			English	Article						GR; osteoporosis; interleukin 11	FACTOR-KAPPA-B; SUPPRESS BONE-FORMATION; RHEUMATOID-ARTHRITIS; OSTEOCLAST DIFFERENTIATION; SYNOVIAL FIBROBLASTS; GENE REPRESSION; PLANT-ORIGIN; CATHEPSIN-K; CELLS; MECHANISMS	Glucocorticoids (GCs) are in widespread use to treat inflammatory bone diseases, such as rheumatoid arthritis (RA). Their anti-inflammatory efficacy, however, is accompanied by deleterious effects on bone, leading to GC-induced osteoporosis (GIO). These effects include up-regulation of the receptor activator of NF-kappa B ligand/osteoprotegerin (RANKL/OPG) ratio to promote bone-resorbing osteoclasts and include inhibition of bone-forming osteoblasts. We previously identified suppression of osteoblast differentiation by the monomer glucocorticoid receptor (GR) via the inhibition of Il11 expression as a crucial mechanism for GIO. Here we show that the GR-modulating substance compound A (CpdA), which does not induce GR dimerization, still suppresses proinflammatory cytokines in fibroblast-like synovial cells from patients with RA and in osteoblasts. In contrast to the full GR agonist dexamethasone, it does not unfavorably alter the RANKL/OPG ratio and does not affect Il11 expression and subsequent STAT3 phosphorylation in these cells. Notably, while dexamethasone inhibits osteoblast differentiation, CpdA does not affect osteoblast differentiation in vitro and in vivo. We describe here for the first time that selective GR modulators can act against inflammation, while not impairing osteoblast differentiation.-Rauch, A., Gossye, V., Bracke, D., Gevaert, E., Jacques, P., Van Beneden, K., Vandooren, B., Rauner, M., Hofbauer, L. C., Haegeman, G., Elewaut, D., Tuckermann, J. P., De Bosscher, K. An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J. 25, 1323-1332 (2011). www.fasebj.org	[Rauch, Alexander; Tuckermann, Jan P.] Fritz Lipmann Inst, Leibniz Inst Age Res, Grp Tissue Specif Hormone Act, D-07745 Jena, Germany; [Gossye, Valerie; Bracke, Debby; Gevaert, Elien; Haegeman, Guy; De Bosscher, Karolien] Univ Ghent, Dept Physiol, Lab Eukaryot Gene Express & Signal Transduct, B-9000 Ghent, Belgium; [Jacques, Peggy; Van Beneden, Katrien; Vandooren, Bernard; Elewaut, Dirk] Ghent Univ Hosp, Dept Rheumatol, B-9000 Ghent, Belgium; [Rauner, Martina; Hofbauer, Lorenz C.] Tech Univ Dresden, Med Ctr, Dresden, Germany; [Rauner, Martina; Hofbauer, Lorenz C.] Ctr Regenerat Therapies Dresden, Dresden, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Ghent University; Ghent University; Ghent University Hospital; Technische Universitat Dresden; Technische Universitat Dresden	Tuckermann, JP (corresponding author), Fritz Lipmann Inst, Leibniz Inst Age Res, Grp Tissue Specif Hormone Act, Beutenbergstr 11, D-07745 Jena, Germany.	jan@fli-leibniz.de; karolien.debosscher@vib-ugent.be	Elewaut, Dirk/K-6831-2014; Rauch, Alexander/AAY-5235-2021; Rauner, Martina/A-1665-2015; Hofbauer, Lorenz C/G-2490-2010	Rauch, Alexander/0000-0002-9429-7356; Hofbauer, Lorenz C/0000-0002-8691-8423; De Bosscher, Karolien/0000-0001-5059-9718; Jacques, Peggy/0000-0001-9227-257X	Deutsche Forschungsgemeinschaft [SP1468, Tu220/6-1, HO1875/8-1]; Boehringer Ingelheim Stiftung; FWO-Vlaanderen; IWT-Vlaanderen	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Boehringer Ingelheim Stiftung(Boehringer Ingelheim); FWO-Vlaanderen(FWO); IWT-Vlaanderen(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT))	The authors thank Susanne Ostermay for excellent technical assistance. This work was supported by grants from the Deutsche Forschungsgemeinschaft by the priority program SP1468 (Tu220/6-1 to J.P.T. and HO1875/8-1 to L. C. H. and M. R.), the Boehringer Ingelheim Stiftung (to J.P.T.), the FWO-Vlaanderen (to K. D. B), and the IWT-Vlaanderen (to V. G.). The authors declare no competing financial interests.	ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baschant U, 2010, J STEROID BIOCHEM, V120, P69, DOI 10.1016/j.jsbmb.2010.03.058; Beck IME, 2009, ENDOCR REV, V30, P830, DOI 10.1210/er.2009-0013; Berris Karen Koenig, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P446, DOI 10.1097/MED.0b013e3282f15407; Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198-007-0394-0; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; De Bosscher K, 2005, P NATL ACAD SCI USA, V102, P15827, DOI 10.1073/pnas.0505554102; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Dewint P, 2008, J IMMUNOL, V180, P2608, DOI 10.4049/jimmunol.180.4.2608; Frijters R, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-359; Gossye V, 2010, ANN RHEUM DIS, V69, P291, DOI 10.1136/ard.2008.102871; Gossye V, 2008, FRONT BIOSCI-LANDMRK, V13, P4122, DOI 10.2741/2997; Gossye V, 2009, ARTHRITIS RHEUM-US, V60, P3241, DOI 10.1002/art.24963; Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P376, DOI 10.1530/eje.0.1400376; Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002-9440(10)63068-4; Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004; Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074; Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006-0459; Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673; Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084; Kondo T, 2008, J CELL BIOCHEM, V103, P335, DOI 10.1002/jcb.21414; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Muller-Ladner U, 2000, CURR OPIN RHEUMATOL, V12, P186, DOI 10.1097/00002281-200005000-00005; MULLERLADNER, 1996, AM J PATHOL, V149, P1607; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Pap T, 2005, ANN RHEUM DIS, V64, P52, DOI 10.1136/ard.2005.042424; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005; Rauner M, 2011, ENDOCRINOLOGY, V152, P103, DOI 10.1210/en.2010-0456; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rosen J, 2005, ENDOCR REV, V26, P452, DOI 10.1210/er.2005-0002; Schacke H, 2008, EXPERT OPIN THER PAT, V18, P339, DOI 10.1517/13543776.18.3.339; Schaecke H, 2007, MOL CELL ENDOCRINOL, V275, P109, DOI 10.1016/j.mce.2007.05.014; Schett G, 2010, ANN RHEUM DIS, V69, P1415, DOI 10.1136/ard.2010.135061; SEITZ M, 1994, BRIT J RHEUMATOL, V33, P613; Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith TJ, 2005, CLIN EXP IMMUNOL, V141, P388, DOI 10.1111/j.1365-2249.2005.02824.x; Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005-0717; Tohjima E, 2003, J BONE MINER RES, V18, P1461, DOI 10.1359/jbmr.2003.18.8.1461; Trepicchio WL, 1998, ANN NY ACAD SCI, V856, P12, DOI 10.1111/j.1749-6632.1998.tb08308.x; VANLOO G, 2009, MOL ENDOCRINOL, V24, P1; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Wust S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008202; Zhang ZR, 2009, J IMMUNOL, V183, P3081, DOI 10.4049/jimmunol.0901088; Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200	47	58	58	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1323	1332		10.1096/fj.10-173393	http://dx.doi.org/10.1096/fj.10-173393			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21233489				2022-12-28	WOS:000288982800021
J	Chung, CY; Bien, H; Sobie, EA; Dasari, V; McKinnon, D; Rosati, B; Entcheva, E				Chung, Chiung-yin; Bien, Harold; Sobie, Eric A.; Dasari, Vikram; McKinnon, David; Rosati, Barbara; Entcheva, Emilia			Hypertrophic phenotype in cardiac cell assemblies solely by structural cues and ensuing self-organization	FASEB JOURNAL			English	Article						cardiomyocytes; cell culture; electrophysiology; natriuretic peptides	ATRIAL-NATRIURETIC-PEPTIDE; RAT VENTRICULAR MYOCYTES; ACUTE MYOCARDIAL-INFARCTION; MESSENGER-RNA EXPRESSION; ACUTE HEART-FAILURE; GENE-EXPRESSION; DOWN-REGULATION; I-F; CARDIOMYOCYTE NETWORKS; K+ CURRENT	In vitro models of cardiac hypertrophy focus exclusively on applying "external" dynamic signals (electrical, mechanical, and chemical) to achieve a hypertrophic state. In contrast, here we set out to demonstrate the role of "self-organized" cellular architecture and activity in reprogramming cardiac cell/tissue function toward a hypertrophic phenotype. We report that in neonatal rat cardiomyocyte culture, subtle out-of-plane microtopographic cues alter cell attachment, increase biomechanical stresses, and induce not only structural remodeling, but also yield essential molecular and electrophysiological signatures of hypertrophy. Increased cell size and cell binucleation, molecular up-regulation of released atrial natriuretic peptide, altered expression of classic hypertrophy markers, ion channel remodeling, and corresponding changes in electrophysiological function indicate a state of hypertrophy on par with other in vitro and in vivo models. Clinically used antihypertrophic pharmacological treatments partially reversed hypertrophic behavior in this in vitro model. Partial least-squares regression analysis, combining gene expression and functional data, yielded clear separation of phenotypes (control: cells grown on flat surfaces; hypertrophic: cells grown on quasi-3-dimensional surfaces and treated). In summary, structural surface features can guide cardiac cell attachment, and the subsequent syncytial behavior can facilitate trophic signals, unexpectedly on par with externally applied mechanical, electrical, and chemical stimulation.-Chung, C., Bien, H., Sobie, E. A., Dasari, V., McKinnon, D., Rosati, B., Entcheva, E. Hypertrophic phenotype in cardiac cell assemblies solely by structural cues and ensuing self-organization. FASEB J. 25, 851-862 (2011). www.fasebj.org	[Chung, Chiung-yin; Bien, Harold; Dasari, Vikram; Entcheva, Emilia] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; [McKinnon, David; Rosati, Barbara] SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; [Sobie, Eric A.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Icahn School of Medicine at Mount Sinai	Entcheva, E (corresponding author), SUNY Stony Brook, Dept Biomed Engn, HSC T18-30, Stony Brook, NY 11794 USA.	emilia.entcheva@sunysb.edu			American Heart Association [0430307N]; National Science Foundation [BES-0503336, 0235467T, T2390172]; National Institutes of Health [GM071558]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071558, T32GM008444] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Zhiheng Jia and Jacqueline Gunther for help with some experiments. This work was supported by grants from the American Heart Association (0430307N), the National Science Foundation (BES-0503336, 0235467T, and T2390172), and the National Institutes of Health (GM071558).	ADACHI S, 1995, AM J PHYSIOL-HEART C, V268, pH162, DOI 10.1152/ajpheart.1995.268.1.H162; Ahuja P, 2007, PHYSIOL REV, V87, P521, DOI 10.1152/physrev.00032.2006; ANVERSA P, 1980, CIRC RES, V46, P495, DOI 10.1161/01.RES.46.4.495; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; BAY BK, 1995, J ORTHOPAED RES, V13, P258, DOI 10.1002/jor.1100130214; Bien H, 2006, BIOPHYS J, V90, P2628, DOI 10.1529/biophysj.105.063321; Bien H, 2003, IEEE ENG MED BIOL, V22, P108, DOI 10.1109/MEMB.2003.1256279; Bodi I, 2003, J AM COLL CARDIOL, V41, P1611, DOI 10.1016/S0735-1097(03)00244-4; Cadre BM, 1998, J MOL CELL CARDIOL, V30, P2247, DOI 10.1006/jmcc.1998.0788; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chung CY, 2007, J CARDIOVASC ELECTR, V18, P1323, DOI 10.1111/j.1540-8167.2007.00959.x; Domenighetti AA, 2007, J MOL CELL CARDIOL, V42, P63, DOI 10.1016/j.yjmcc.2006.09.019; Dunn AK, 1996, APPL OPTICS, V35, P3441, DOI 10.1364/AO.35.003441; Eghbali M, 2005, CIRC RES, V96, P1208, DOI 10.1161/01.RES.0000170652.71414.16; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Entcheva E, 2005, LAB CHIP, V5, P179, DOI 10.1039/b409478f; Entcheva E, 2003, BIOMED MICRODEVICES, V5, P163, DOI 10.1023/A:1024551614629; Fernandez-Velasco M, 2003, J PHYSIOL-LONDON, V553, P395, DOI 10.1113/jphysiol.2003.041954; Fernandez-Velasco M, 2006, PFLUG ARCH EUR J PHY, V452, P146, DOI 10.1007/s00424-005-0024-7; Folch A, 2000, ANNU REV BIOMED ENG, V2, P227, DOI 10.1146/annurev.bioeng.2.1.227; Gaughan JP, 1998, AM J PHYSIOL-HEART C, V275, pH577, DOI 10.1152/ajpheart.1998.275.2.H577; Geiger B, 2001, SCIENCE, V294, P1661, DOI 10.1126/science.1066919; GELADI P, 1986, ANAL CHIM ACTA, V185, P1, DOI 10.1016/0003-2670(86)80028-9; GidhJain M, 1996, CIRC RES, V79, P669, DOI 10.1161/01.RES.79.4.669; Goltz D, 2007, CARDIOVASC RES, V74, P85, DOI 10.1016/j.cardiores.2007.01.001; Gong NL, 2006, J BIOL CHEM, V281, P38498, DOI 10.1074/jbc.M607774200; Hardt SE, 2004, CARDIOVASC RES, V63, P500, DOI 10.1016/j.cardiores.2004.03.015; Hayashi M, 2001, J AM COLL CARDIOL, V37, P1820, DOI 10.1016/S0735-1097(01)01233-5; Hesse M, 2007, CARDIOVASC RES, V75, P498, DOI 10.1016/j.cardiores.2007.04.009; Hill JA, 2003, TRENDS CARDIOVAS MED, V13, P316, DOI 10.1016/j.tcm.2003.08.002; Hiramatsu M, 2002, J CARDIOVASC PHARM, V39, P866, DOI 10.1097/00005344-200206000-00012; Horio T, 2000, HYPERTENSION, V35, P19, DOI 10.1161/01.HYP.35.1.19; Kecskemeti V, 1996, MOL CELL BIOCHEM, V161, P53, DOI 10.1007/BF00240031; KINNUNEN P, 1990, BRIT J PHARMACOL, V99, P701, DOI 10.1111/j.1476-5381.1990.tb12992.x; Kitashiro S, 1999, J CARDIOVASC PHARM, V33, P948, DOI 10.1097/00005344-199906000-00016; Koyanagi T, 2008, AM J PHYSIOL-HEART C, V295, pH220, DOI 10.1152/ajpheart.00289.2008; Kuga H, 2003, CIRC J, V67, P443; Lalevee N, 2005, CARDIOVASC RES, V67, P216, DOI 10.1016/j.cardiores.2005.05.009; Lau YH, 2001, PHYS MED BIOL, V46, P1297, DOI 10.1088/0031-9155/46/4/326; Lee JK, 1999, AM J PHYSIOL-HEART C, V277, pH1725, DOI 10.1152/ajpheart.1999.277.5.H1725; Makhlouf AA, 1998, AM J PHYSIOL-HEART C, V274, pH2133, DOI 10.1152/ajpheart.1998.274.6.H2133; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; McGrath MF, 2005, TRENDS ENDOCRIN MET, V16, P469, DOI 10.1016/j.tem.2005.10.007; Rosenberg SS, 2008, P NATL ACAD SCI USA, V105, P14662, DOI 10.1073/pnas.0805640105; Shi WM, 1999, CIRC RES, V85, pE1; Sobie EA, 2009, BIOPHYS J, V96, P1264, DOI 10.1016/j.bpj.2008.10.056; Strait JB, 2000, J MOL CELL CARDIOL, V32, P1553, DOI 10.1006/jmcc.2000.1191; Suwa M, 2005, CIRC J, V69, P283, DOI 10.1253/circj.69.283; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; TOHSE N, 1995, BRIT J PHARMACOL, V114, P1076, DOI 10.1111/j.1476-5381.1995.tb13316.x; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; Walsh KB, 2001, J MOL CELL CARDIOL, V33, P1233, DOI 10.1006/jmcc.2001.1386; Wang ZY, 2001, CIRCULATION, V104, P1657, DOI 10.1161/hc3901.095766; Wolk R, 2000, EUROPACE, V2, P216, DOI 10.1053/eupc.2000.0110; Yasui K, 2001, CIRC RES, V88, P536, DOI 10.1161/01.RES.88.5.536; Yin LH, 2004, AM J PHYSIOL-HEART C, V287, pH1276, DOI 10.1152/ajpheart.01120.2003; Yoshizumi M, 1997, FEBS LETT, V419, P255, DOI 10.1016/S0014-5793(97)01470-1; Zhang TT, 2004, ACTA PHARMACOL SIN, V25, P226; Zhuang JP, 2000, CIRC RES, V87, P316, DOI 10.1161/01.RES.87.4.316; Zobel C, 2007, CARDIOLOGY, V107, P281, DOI 10.1159/000099063	60	23	23	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2011	25	3					851	862		10.1096/fj.10-168625	http://dx.doi.org/10.1096/fj.10-168625			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21084696	Green Published			2022-12-28	WOS:000287806200006
J	Labeit, S; Ottenheijm, CAC; Granzier, H				Labeit, Siegfried; Ottenheijm, Coen A. C.; Granzier, Henk			Nebulin, a major player in muscle health and disease	FASEB JOURNAL			English	Review						muscle contraction; regulation; calcium sensitivity; nemaline myopathy; sarcolipin	THIN FILAMENT LENGTH; RECESSIVE NEMALINE MYOPATHY; SKELETAL-MUSCLE; STRIATED-MUSCLE; AMPHIOXUS NEBULIN; CARDIAC-MUSCLE; GENE SEQUENCE; Z-DISC; MUTATIONS; PROTEIN	Nebulin is a giant 600- to 900-kDa filamentous protein that is an integral component of the skeletal muscle thin filament. Its functions have remained largely nebulous because of its large size and the difficulty in extracting nebulin in a native state from muscle. Recent improvements in the field, especially the development of knockout mouse models deficient in nebulin (NEB-KO mice), indicate now that nebulin performs a surprisingly wide range of functions. In addition to a major role in thin-filament length specification, nebulin also functions in the regulation of muscle contraction, as indicated by the findings that muscle fibers deficient in nebulin have a higher tension cost, and develop less force due to reduced myofilament calcium sensitivity and altered crossbridge cycling kinetics. In addition, the function of nebulin extends to a role in calcium homeostasis. These novel functions indicate that nebulin might have evolved in vertebrate skeletal muscles to develop high levels of muscle force efficiently. Finally, the NEB-KO mouse models also highlight the role of nebulin in the assembly and alignment of the Z disks. Notably, rapid progress in understanding the roles of nebulin in vivo provides clinically important insights into how nebulin deficiency in patients with nemaline myopathy contributes to debilitating muscle weakness.-Labeit, S., Ottenheijm, C. A. C., Granzier, H. Nebulin, a major player in muscle health and disease. FASEB J. 25, 822-829 (2011). www.fasebj.org	[Labeit, Siegfried] Heidelberg Univ, Univ Med Mannheim, Dept Integrat Pathophysiol, D-68167 Mannheim, Germany; [Ottenheijm, Coen A. C.] Univ Amsterdam, VU Univ Med Ctr, Inst Cardiovasc Res, Physiol Lab, NL-1012 WX Amsterdam, Netherlands; [Granzier, Henk] Univ Arizona, Dept Physiol, Tucson, AZ USA	Ruprecht Karls University Heidelberg; University of Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Arizona	Labeit, S (corresponding author), Heidelberg Univ, Univ Med Mannheim, Dept Integrat Pathophysiol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	labeit@embl.de			Wilhelm-Muller Foundation; European Union, European Research Area Network; Dutch Organization for Scientific Research; U.S. National Institutes of Health [R01 1AR053897]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053897] Funding Source: NIH RePORTER	Wilhelm-Muller Foundation; European Union, European Research Area Network; Dutch Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was funded by the Wilhelm-Muller Foundation (S.L.), the European Union FP7 European Research Area Network on rare diseases for nemaline myopathies (S.L. and C.O.), a Dutch Organization for Scientific Research VENI grant (C.O.), and U.S. National Institutes of Health grant R01 1AR053897 (H.G.).	Agrawal PB, 2007, AM J HUM GENET, V80, P162, DOI 10.1086/510402; Anderson SL, 2004, HUM GENET, V115, P185, DOI 10.1007/s00439-004-1140-8; Bang ML, 2009, FASEB J, V23, P4117, DOI 10.1096/fj.09-137729; Bang ML, 2002, J STRUCT BIOL, V137, P119, DOI 10.1006/jsbi.2002.4457; Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; BUCK D, J STRUCT BIOL, V170, P325; Burgoyne T, 2008, CARDIOVASC RES, V77, P707, DOI 10.1093/cvr/cvm117; Castillo A, 2009, BIOPHYS J, V96, P1856, DOI 10.1016/j.bpj.2008.10.053; Chandra M, 2009, J BIOL CHEM, V284, P30889, DOI 10.1074/jbc.M109.049718; Chereau D, 2008, SCIENCE, V320, P239, DOI 10.1126/science.1155313; Chitose R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/108495; Conover GM, 2009, MOL BIOL CELL, V20, P834, DOI 10.1091/mbc.E08-07-0753; Donner K, 2004, EUR J HUM GENET, V12, P744, DOI 10.1038/sj.ejhg.5201242; Gokhin DS, 2009, AM J PHYSIOL-CELL PH, V296, pC1123, DOI 10.1152/ajpcell.00503.2008; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; Hanashima A, 2009, GENE, V443, P76, DOI 10.1016/j.gene.2009.04.020; Hanashima A, 2009, J EXP BIOL, V212, P668, DOI 10.1242/jeb.022681; JIN JP, 1991, J BIOL CHEM, V266, P21215; Johnston JJ, 2000, AM J HUM GENET, V67, P814, DOI 10.1086/303089; Kazmierski ST, 2003, J MOL BIOL, V328, P835, DOI 10.1016/S0022-2836(03)00348-6; Kee AJ, 2008, ADV EXP MED BIOL, V644, P143; KRUGER M, 1991, J CELL BIOL, V115, P97, DOI 10.1083/jcb.115.1.97; LABEIT S, 1991, FEBS LETT, V282, P313, DOI 10.1016/0014-5793(91)80503-U; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; Labeit S, 2006, J MOL BIOL, V362, P664, DOI 10.1016/j.jmb.2006.07.077; Lehtokari VL, 2006, HUM MUTAT, V27, P946, DOI 10.1002/humu.20370; Lehtokari VL, 2009, NEUROMUSCULAR DISORD, V19, P179, DOI 10.1016/j.nmd.2008.12.001; Littlefield RS, 2008, SEMIN CELL DEV BIOL, V19, P511, DOI 10.1016/j.semcdb.2008.08.009; McElhinny AS, 2005, J CELL BIOL, V170, P947, DOI 10.1083/jcb.200502158; McElhinny AS, 2001, J BIOL CHEM, V276, P583, DOI 10.1074/jbc.M005693200; Millevoi S, 1998, J MOL BIOL, V282, P111, DOI 10.1006/jmbi.1998.1999; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; Nakagawa H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007530; Ochala J, 2008, J MOL MED-JMM, V86, P1197, DOI 10.1007/s00109-008-0380-9; Ogut O, 2003, J BIOL CHEM, V278, P3089, DOI 10.1074/jbc.M205853200; Ono Y, 2005, DEV BIOL, V282, P336, DOI 10.1016/j.ydbio.2005.03.015; OTTENHEIJM CA, J STRUCT BIOL, V170, P334; Ottenheijm CAC, 2008, FASEB J, V22, P2912, DOI 10.1096/fj.07-104372; Ottenheijm CAC, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/968139; Ottenheijm CAC, 2009, HUM MOL GENET, V18, P2359, DOI 10.1093/hmg/ddp168; Pappas C. T., J CELL BIOL, V189, P859; Pappas CT, 2008, MOL BIOL CELL, V19, P1837, DOI 10.1091/mbc.E07-07-0690; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; Pelin K, 2008, ADV EXP MED BIOL, V642, P28; Romero NB, 2009, NEUROLOGY, V73, P1159, DOI 10.1212/WNL.0b013e3181bacf45; ROOT DD, 1994, BIOCHEMISTRY-US, V33, P12581, DOI 10.1021/bi00208a008; Shah SB, 2004, BIOPHYS J, V86, P2993, DOI 10.1016/S0006-3495(04)74349-0; Solaro RJ, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/105648; Stedman H, 1988, GENOMICS, V2, P1, DOI 10.1016/0888-7543(88)90102-4; TONINO P, J CELL SCI, V123, P384; Wallgren-Pettersson C, 2004, NEUROMUSCULAR DISORD, V14, P461, DOI 10.1016/j.nmd.2004.03.006; Wallgren-Pettersson C, 1999, NEUROMUSCULAR DISORD, V9, P564, DOI 10.1016/S0960-8966(99)00061-9; Wallgren-Pettersson Carina, 2006, Neuromuscul Disord, V16, P54, DOI 10.1016/j.nmd.2005.10.006; WANG K, 1980, P NATL ACAD SCI-BIOL, V77, P3254, DOI 10.1073/pnas.77.6.3254; WANG K, 1982, MUSCLE DEV MOL CELLU, P439; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Witt CC, 2006, EMBO J, V25, P3843, DOI 10.1038/sj.emboj.7601242; WOOD MJ, BRAIN, V133, P957; Yadavalli VK, 2009, LANGMUIR, V25, P7496, DOI 10.1021/la9009898; Zieseniss A, 2008, CELL MOTIL CYTOSKEL, V65, P59, DOI 10.1002/cm.20244	62	51	53	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2011	25	3					822	829		10.1096/fj.10-157412	http://dx.doi.org/10.1096/fj.10-157412			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21115852	Green Published			2022-12-28	WOS:000287806200003
J	Diep, TA; Madsen, AN; Holst, B; Kristiansen, MM; Wellner, N; Hansen, SH; Hansen, HS				Diep, Thi Ai; Madsen, Andreas Nygaard; Holst, Birgitte; Kristiansen, Martin Morch; Wellner, Niels; Hansen, Steen Honore; Hansen, Harald Severin			Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor	FASEB JOURNAL			English	Article						oleoylethanolamide; OEA; linoleoylethanolamide; LEA; high-fat diet; isocaloric diet; food intake	N-ACYL-ETHANOLAMINE; PHOSPHOLIPASE-D; FOOD-INTAKE; MOLECULAR CHARACTERIZATION; OLEOYLETHANOLAMIDE; ANANDAMIDE; BIOSYNTHESIS; ACYLPHOSPHATIDYLETHANOLAMINE; PALMITOYLETHANOLAMIDE; DEGRADATION	This study was undertaken to investigate the link between dietary fat content and intestinal levels of anorectic N-acylethanolamines (NAEs), including oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and linoleoylethanolamide (LEA). Male rats were fed high-fat diets (HFDs) with variable percentages of fat [20-45% of total energy (E%)] for 1-7 d; afterward, the jejunums were isolated, and jejunal NAE levels were measured by liquid-chromatography mass spectrometry. Enzyme activities and mRNA expression levels were measured for two synthesizing enzymes, N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and glycerophosphodiesterase (GDE1), and one degrading enzyme, fatty acid amide hydrolase (FAAH). We found a dose-response relation between the quantity/percentage of dietary fat, irrespective of the energy density, and the reduction of intestinal levels of OEA, PEA, and LEA. The reductions were present after 1 d of 45E% HFD. LEA, the major NAE species, was shown to have an anorectic potency slightly less than that of OEA but higher than PEA. Regulation at the enzyme level seems not to explain the changes in NAE levels. The results suggest the presence of a fat sensor, mediating the reduced intestinal NAE levels. The intestinal NAE levels are reduced in a dose- and time-dependent manner in response to dietary fat intake, and this may contribute to the well-known hyperphagic effect of HFDs.-Diep, T. A., Madsen, A. N., Holst, B., Kristiansen, M. M., Wellner, N., Hansen, S. H., Hansen, H. S. Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor. FASEB J. 25, 765-774 (2011). www.fasebj.org	[Diep, Thi Ai; Kristiansen, Martin Morch; Wellner, Niels; Hansen, Harald Severin] Univ Copenhagen, Dept Pharmacol & Pharmacothe, Copenhagen, Denmark; [Hansen, Steen Honore] Univ Copenhagen, Dept Pharmaceut & Analyt Chem, Fac Pharmaceut Sci, Copenhagen, Denmark; [Madsen, Andreas Nygaard; Holst, Birgitte] Univ Copenhagen, Dept Neurosci & Pharmacol, Fac Hlth Sci, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen	Hansen, HS (corresponding author), Univ Pk 2, DK-2100 Copenhagen O, Denmark.	hsh@farma.ku.dk	Hansen, Steen Honoré/A-5179-2011	Diep, Thi Ai/0000-0003-2681-1090; Holst, Birgitte/0000-0001-7432-097X; Hansen, Harald S./0000-0001-7360-7418	Augustinus Foundation; Novo Nordisk Foundation; Danish Ministry of Science, Technology, and Innovation	Augustinus Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Ministry of Science, Technology, and Innovation	The authors are grateful to Jytte Palmgren-Salomonsson, Line Olesen, Pernille Lyderik, and Christine Petersen for their excellent technical assistance. This project was supported by the Augustinus Foundation and the Novo Nordisk Foundation, and parts of the study were carried in collaboration with the Rodent Metabolic Phenotype Center [Universitetsforskningens Investerings Kapital (UNIK): Food, Fitness, and Pharma for Health and Diseases; http://www.foodfitnesspharma.ku.dk]. The UNIK project is supported by the Danish Ministry of Science, Technology, and Innovation.	Artmann A, 2008, BBA-MOL CELL BIOL L, V1781, P200, DOI 10.1016/j.bbalip.2008.01.006; Aviello G, 2008, J MOL MED, V86, P413, DOI 10.1007/s00109-008-0305-7; Blondeau N, 2007, CIRC RES, V101, P176, DOI 10.1161/CIRCRESAHA.107.154443; Blondeau N, 2009, NEUROPSYCHOPHARMACOL, V34, P2548, DOI 10.1038/npp.2009.84; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cluny NL, 2009, NEUROGASTROENT MOTIL, V21, P420, DOI 10.1111/j.1365-2982.2008.01248.x; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; Collino M, 2006, FREE RADICAL BIO MED, V41, P1619, DOI 10.1016/j.freeradbiomed.2006.09.013; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; de Vogel-van den Bosch HM, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-231; FLEIGE S, MOL ASPECTS MED, V27, P126; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Fu J, 2008, AM J PHYSIOL-REG I, V295, pR45, DOI 10.1152/ajpregu.00126.2008; Fu J, 2007, J BIOL CHEM, V282, P1518, DOI 10.1074/jbc.M607809200; Gaetani S, 2003, NEUROPSYCHOPHARMACOL, V28, P1311, DOI 10.1038/sj.npp.1300166; Gillum MP, 2008, CELL, V135, P813, DOI 10.1016/j.cell.2008.10.043; GUIJARRO A, 2009, PHARM RES, V61, P27; Guzman M, 2004, J BIOL CHEM, V279, P27849, DOI 10.1074/jbc.M404087200; Hansen HS, 2010, EXP NEUROL, V224, P48, DOI 10.1016/j.expneurol.2010.03.022; Hansen HS, 2009, BIOCHEM PHARMACOL, V78, P553, DOI 10.1016/j.bcp.2009.04.024; Iqbal J, 2009, AM J PHYSIOL-ENDOC M, V296, pE1183, DOI 10.1152/ajpendo.90899.2008; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; Kehrer JP, 2001, BIOCHEM J, V356, P899, DOI 10.1042/0264-6021:3560899; Khan NA, 2009, BBA-MOL CELL BIOL L, V1791, P149, DOI 10.1016/j.bbalip.2009.01.001; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Little TJ, 2007, AM J CLIN NUTR, V86, P531, DOI 10.1093/ajcn/86.3.531; Liu Q, 2002, CHEM PHYS LIPIDS, V115, P77, DOI 10.1016/S0009-3084(02)00015-4; Lo Verme J, 2005, CELL MOL LIFE SCI, V62, P708, DOI 10.1007/s00018-004-4494-0; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; MIYAUCHI S, J PHARM SCI, V112, P19; Moesgaard B, 2002, COMP BIOCHEM PHYS B, V131, P475, DOI 10.1016/S1096-4959(02)00003-9; Movahed P, 2005, J BIOL CHEM, V280, P38496, DOI 10.1074/jbc.M507429200; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004; Petersen G, 2006, BBA-MOL CELL BIOL L, V1761, P143, DOI 10.1016/j.bbalip.2005.12.011; Petersen G, 2009, CHEM PHYS LIPIDS, V162, P53, DOI 10.1016/j.chemphyslip.2009.08.005; Poirier H, 1996, EUR J BIOCHEM, V238, P368, DOI 10.1111/j.1432-1033.1996.0368z.x; Poppitt SD, 1996, APPETITE, V26, P153, DOI 10.1006/appe.1996.0013; Rodriguez de Fonseca F., 2001, NATURE, V414, P209, DOI DOI 10.1038/35102582; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, pVII; Schwartz GJ, 2008, CELL METAB, V8, P281, DOI 10.1016/j.cmet.2008.08.005; Simon GM, 2008, J BIOL CHEM, V283, P9341, DOI 10.1074/jbc.M707807200; Simon GM, 2006, J BIOL CHEM, V281, P26465, DOI 10.1074/jbc.M604660200; Simon GM, 2010, MOL BIOSYST, V6, P1411, DOI 10.1039/c000237b; Skonberg C, 2010, J LIPID RES, V51, P3062, DOI 10.1194/jlr.D004606; Solorzano C, 2009, P NATL ACAD SCI USA, V106, P20966, DOI 10.1073/pnas.0907417106; Tang-Christensen M, 2000, NAT MED, V6, P802, DOI 10.1038/77535; Thomas C, 2009, CELL METAB, V10, P167, DOI 10.1016/j.cmet.2009.08.001; Wang XB, 2005, J PHYSIOL-LONDON, V564, P541, DOI 10.1113/jphysiol.2004.081844; Wellendorph P, 2009, MOL PHARMACOL, V76, P453, DOI 10.1124/mol.109.055244	52	85	86	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					765	774		10.1096/fj.10-166595	http://dx.doi.org/10.1096/fj.10-166595			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20959516				2022-12-28	WOS:000286724800033
J	Beraldo, FH; Arantes, CP; Santos, TG; Machado, CF; Roffe, M; Hajj, GN; Lee, KS; Magalhaes, AC; Caetano, FA; Mancini, GL; Lopes, MH; Americo, TA; Magdesian, MH; Ferguson, SSG; Linden, R; Prado, MAM; Martins, VR				Beraldo, Flavio H.; Arantes, Camila P.; Santos, Tiago G.; Machado, Cleiton F.; Roffe, Martin; Hajj, Glaucia N.; Lee, Kil S.; Magalhaes, Ana C.; Caetano, Fabiana A.; Mancini, Gabriel. L.; Lopes, Marilene H.; Americo, Tatiana A.; Magdesian, Margaret H.; Ferguson, Stephen S. G.; Linden, Rafael; Prado, Marco A. M.; Martins, Vilma R.			Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin gamma 1 chain	FASEB JOURNAL			English	Article						GPI-anchored proteins; G-coupled protein receptors; signal transduction; multiprotein complexes; neurotrophic signals	STRESS-INDUCIBLE PROTEIN-1; CELLULAR PRION; PROMOTING DOMAIN; KDI-DOMAIN; CALCIUM; PHOSPHORYLATION; DIFFERENTIATION; INTERNALIZATION; IDENTIFICATION; TRAFFICKING	The prion protein (PrPC) is highly expressed in the nervous system, and its abnormal conformer is associated with prion diseases. PrPC is anchored to cell membranes by glycosylphosphatidylinositol, and transmembrane proteins are likely required for PrPC-mediated intracellular signaling. Binding of laminin (Ln) to PrPC modulates neuronal plasticity and memory. We addressed signaling pathways triggered by PrPC-Ln interaction in order to identify transmembrane proteins involved in the transduction of PrPC-Ln signals. The Ln gamma 1-chain peptide, which contains the Ln binding site for PrPC, induced neuritogenesis through activation of phospholipase C (PLC), Ca2+ mobilization from intracellular stores, and protein kinase C and extracellular signal-regulated kinase (ERK1/2) activation in primary cultures of neurons from wild-type, but not PrPC-null mice. Phage display, coimmunoprecipitation, and colocalization experiments showed that group I metabotropic glutamate receptors (mGluR1/5) associate with PrPC. Expression of either mGluR1 or mGluR5 in HEK293 cells reconstituted the signaling pathways mediated by PrPC-Ln gamma 1 peptide interaction. Specific inhibitors of these receptors impaired PrPC-Ln gamma 1 peptide-induced signaling and neuritogenesis. These data show that group I mGluRs are involved in the transduction of cellular signals triggered by PrPC-Ln, and they support the notion that PrPC participates in the assembly of multiprotein complexes with physiological functions on neurons.-Beraldo, F. H., Arantes, C. P., Santos, T. G., Machado, C. F., Roffe, M., Hajj, G. N., Lee, K. S., Magalhaes, A. C., Caetano, F. A., Mancini, G. L., Lopes, M. H., Americo, T. A., Magdesian, M. H., Ferguson, S. S. G., Linden, R., Prado, M. A. M., Martins, V. R. Metabotropic glutamate receptors trans-duce signals for neurite outgrowth after binding of the prion protein to laminin gamma 1 chain. FASEB J. 25, 265-279 (2011). www.fasebj.org	[Beraldo, Flavio H.; Arantes, Camila P.; Santos, Tiago G.; Machado, Cleiton F.; Hajj, Glaucia N.; Lee, Kil S.; Mancini, Gabriel. L.; Lopes, Marilene H.; Martins, Vilma R.] Hosp Alemao Oswaldo Cruz, Ludwig Inst Canc Res, Sao Paulo, Brazil; [Arantes, Camila P.] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil; [Santos, Tiago G.; Machado, Cleiton F.] Hosp AC Camargo Fund Antonio Prudente, Ctr Tratamento & Pesquisa, Sao Paulo, Brazil; [Roffe, Martin] Univ Fed Sao Paulo, Dept Microbiol Imunol & Parasitol, Sao Paulo, Brazil; [Beraldo, Flavio H.; Magalhaes, Ana C.; Caetano, Fabiana A.; Ferguson, Stephen S. G.; Prado, Marco A. M.] Univ Western Ontario, J Allyn Taylor Ctr Cell Biol, Mol Brain Res Grp, Robarts Res Inst, London, ON, Canada; [Beraldo, Flavio H.; Magalhaes, Ana C.; Caetano, Fabiana A.; Ferguson, Stephen S. G.; Prado, Marco A. M.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Prado, Marco A. M.] Univ Western Ontario, Dept Anat & Cell Biol, London, ON, Canada; [Caetano, Fabiana A.] Univ Fed Minas Gerais, Program Mol Pharmacol, Belo Horizonte, MG, Brazil; [Americo, Tatiana A.; Linden, Rafael] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil; [Magdesian, Margaret H.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio De Janeiro, Brazil	Ludwig Institute for Cancer Research; Universidade de Sao Paulo; A.C.Camargo Cancer Center; Universidade Federal de Sao Paulo (UNIFESP); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Universidade Federal de Minas Gerais; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Martins, VR (corresponding author), Ludwig Inst Canc Res, Rua Joao Juliao 245 1A, BR-01323903 Sao Paulo, Brazil.	mprado@robarts.ca; vmartins@ludwig.org.br	dos Santos, Tiago Goss/A-1538-2019; Fisiologia, Ciencias Biologicas/C-2407-2012; Santos, Tiago Goss/AAQ-4272-2020; Martins, Vilma/N-5446-2019; Neurociencia, Inct/I-1011-2013; Roffé, Martín/I-1864-2013; Santos, Tiago/F-2387-2012; Linden, Rafael/F-2275-2011; Martins, Vilma R/E-2547-2012; Lee, Kil S/D-3678-2012; Prado, Marco Antonio Maximo/K-7638-2013; Machado, Cleiton/I-5907-2014; Hajj, Glaucia N M/I-8176-2015; Roffe, Martin/S-1124-2019; Lee, Kil Sun/AAL-8564-2020; Lopes, Marilene/GLV-4734-2022	dos Santos, Tiago Goss/0000-0001-6641-7413; Santos, Tiago Goss/0000-0001-6641-7413; Roffé, Martín/0000-0001-7247-3067; Santos, Tiago/0000-0001-6641-7413; Linden, Rafael/0000-0003-3287-336X; Martins, Vilma R/0000-0002-2909-8502; Lee, Kil S/0000-0002-2390-2774; Prado, Marco Antonio Maximo/0000-0002-3028-5778; Machado, Cleiton/0000-0002-3313-3868; Hajj, Glaucia N M/0000-0003-2342-7384; Roffe, Martin/0000-0001-7247-3067; Lopes, Marilene/0000-0003-2496-0674	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03-13189-2]; Programa Institutos Nacionais de Ciencia e Tecnologia; do Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq/MCT); PrioNet-Canada; CNPq; Canada Department of Foreign Affairs and International Trade; Canadian Institute of Health Research (CIHR) [MA-15506]; Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Programa Institutos Nacionais de Ciencia e Tecnologia; do Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq/MCT)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); PrioNet-Canada; CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Canada Department of Foreign Affairs and International Trade; Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 03-13189-2), Programa Institutos Nacionais de Ciencia e Tecnologia, do Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq/MCT), and PrioNet-Canada. V. R. M. is an International Scholar of the Howard Hughes Medical Institute. Fellowships from FAPESP to F. H. B., C. P. A., M. R., T. G. S., C. F. M., K. S. L., G.N.H.; from CNPq to G. L. M.; and the Canada Department of Foreign Affairs and International Trade to F. H. B. are gratefully acknowledged. A. C. M. is supported by the Canadian Institute of Health Research (CIHR). R. L., T. A. A., and M. M. are supported by CNPq and Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro, and S. S. G. F. is funded by CIHR grant MA-15506. S. S. G. F is a Canada Research Chair in Molecular Neurobiology and a Career Investigator of the Heart and Stroke Foundation of Ontario. The authors are also grateful to Dr. Joao Bosco Pesquero (Universidade Federal de Sao Paulo, Sao Paulo, Brazil) for providing bradykinin for some experiments.	Anborgh PH, 2005, J BIOL CHEM, V280, P34840, DOI 10.1074/jbc.M504508200; Babwah AV, 2003, J BIOL CHEM, V278, P5419, DOI 10.1074/jbc.M211053200; Balducci C, 2010, P NATL ACAD SCI USA, V107, P2295, DOI 10.1073/pnas.0911829107; Brini M, 2005, MOL BIOL CELL, V16, P2799, DOI 10.1091/mbc.E04-10-0915; Brugger B, 2004, J BIOL CHEM, V279, P7530, DOI 10.1074/jbc.M310207200; Bruno V, 2001, J CEREBR BLOOD F MET, V21, P1013, DOI 10.1097/00004647-200109000-00001; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Caetano FA, 2008, J NEUROSCI, V28, P6691, DOI 10.1523/JNEUROSCI.1701-08.2008; Calella AM, 2010, EMBO MOL MED, V2, P306, DOI 10.1002/emmm.201000082; Castiglione M, 2008, NEUROPHARMACOLOGY, V55, P560, DOI 10.1016/j.neuropharm.2008.05.021; Chen ZL, 2009, DEV BIOL, V327, P158, DOI 10.1016/j.ydbio.2008.12.006; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Coitinho AS, 2006, EUR J NEUROSCI, V24, P3255, DOI 10.1111/j.1460-9568.2006.05156.x; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; Ferraguti F, 2008, PHARMACOL REV, V60, P536, DOI 10.1124/pr.108.000166; Francesconi A, 2009, J NEUROSCI, V29, P3590, DOI 10.1523/JNEUROSCI.5824-08.2009; Fuhrmann M, 2006, J NEUROCHEM, V98, P1876, DOI 10.1111/j.1471-4159.2006.04011.x; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Gimbel DA, 2010, J NEUROSCI, V30, P6367, DOI 10.1523/JNEUROSCI.0395-10.2010; Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4; Hager G, 1998, NEUROSCIENCE, V86, P1145, DOI 10.1016/S0306-4522(98)00082-7; Hagg T, 1997, BRAIN RES, V764, P17, DOI 10.1016/S0006-8993(97)00419-8; Hajj GNM, 2007, J CELL SCI, V120, P1915, DOI 10.1242/jcs.03459; Hannan AJ, 2001, NAT NEUROSCI, V4, P282, DOI 10.1038/85132; Huber KM, 2001, J NEUROPHYSIOL, V86, P321, DOI 10.1152/jn.2001.86.1.321; Ido H, 2008, J BIOL CHEM, V283, P28149, DOI 10.1074/jbc.M803553200; Jen A, 2010, J CELL SCI, V123, P246, DOI 10.1242/jcs.058099; Kessels HW, 2010, NATURE, V466, pE3, DOI 10.1038/nature09217; Kingston AE, 2002, NEUROSCI LETT, V330, P127, DOI 10.1016/S0304-3940(02)00751-6; Krebs B, 2007, J NEUROCHEM, V100, P358, DOI 10.1111/j.1471-4159.2006.04256.x; KRISTENSSON K, 1993, NEUROLOGY, V43, P2335, DOI 10.1212/WNL.43.11.2335; Laube G, 2002, MOL CELL NEUROSCI, V19, P459, DOI 10.1006/mcne.2001.1078; Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761; LIESI P, 1985, EMBO J, V4, P1163, DOI 10.1002/j.1460-2075.1985.tb03755.x; Liesi P, 2001, J NEUROSCI RES, V66, P1047, DOI 10.1002/jnr.1250; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007; Lopes MH, 2005, J NEUROSCI, V25, P11330, DOI 10.1523/JNEUROSCI.2313-05.2005; LuckenbillEdds L, 1997, BRAIN RES REV, V23, P1, DOI 10.1016/S0165-0173(96)00013-6; Magalhaes AC, 2002, J BIOL CHEM, V277, P33311, DOI 10.1074/jbc.M203661200; Maiese K, 2005, CURR NEUROVASC RES, V2, P425, DOI 10.2174/156720205774962692; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Martins VR, 2010, CURR ISSUES MOL BIOL, V12, P63; Martins VR, 2002, FEBS LETT, V512, P25, DOI 10.1016/S0014-5793(02)02291-3; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Parkin ET, 2007, P NATL ACAD SCI USA, V104, P11062, DOI 10.1073/pnas.0609621104; Policha A, 2006, J BIOL CHEM, V281, P26340, DOI 10.1074/jbc.M605437200; Putney JW, 2001, J CELL SCI, V114, P2223; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Renner M, 2010, NEURON, V66, P739, DOI 10.1016/j.neuron.2010.04.029; Ribeiro FM, 2009, J BIOL CHEM, V284, P23444, DOI 10.1074/jbc.M109.000778; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Romano SA, 2009, FASEB J, V23, P4308, DOI 10.1096/fj.09-138974; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Schrock Y, 2009, FEBS LETT, V583, P389, DOI 10.1016/j.febslet.2008.12.038; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; Vaananen AJ, 2006, J NEUROSCI RES, V84, P655, DOI 10.1002/jnr.20961; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Wiksten M, 2004, J NEUROSCI RES, V78, P411, DOI 10.1002/jnr.20158; Wiksten M, 2003, J NEUROSCI RES, V71, P338, DOI 10.1002/jnr.10495; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325	64	97	97	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					265	279		10.1096/fj.10-161653	http://dx.doi.org/10.1096/fj.10-161653			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20876210				2022-12-28	WOS:000285869500024
J	Bublil, EM; Pines, G; Patel, G; Fruhwirth, G; Ng, T; Yarden, Y				Bublil, Erez M.; Pines, Gur; Patel, Gargi; Fruhwirth, Gilbert; Ng, Tony; Yarden, Yosef			Kinase-mediated quasi-dimers of EGFR	FASEB JOURNAL			English	Article						growth factor; kinase inhibitor; oncogene; receptor tyrosine kinase; receptor dimerization	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR EGFR; TYROSINE KINASE; CRYSTAL-STRUCTURE; EXTRACELLULAR REGION; ERBB RECEPTORS; DOMAIN; ACTIVATION; MECHANISM; INHIBITOR	Ligand-induced dimerization of the epidermal growth factor receptor (ErbB-1/EGFR) involves conformational changes that expose an extracellular dimerization interface. Subsequent alterations within the cytoplasmic kinase domain, which culminate in tyrosine phosphorylation, are less understood. Our study addressed this question by using two strategies: a chimeric receptor approach employed ErbB-3, whose defective kinase domain was replaced by the respective part of EGFR. The implanted full-length kinase, unlike its subdomains, conferred dimerization and catalysis. The data infer that the kinase function of EGFR is restrained by the carboxyl tail; once grafted distally to the ectopic tail of ErbB-3, the kinase domain acquires quasi-dimerization and activation. In an attempt to alternatively refold the cytoplasmic tail, our other approach employed kinase inhibitors. Biophysical measurements and covalent cross-linking analyses showed that inhibitors targeting the active conformation of EGFR, in contrast to a compound recognizing the inactive conformation, induce quasi-dimers in a manner similar to the chimeric ErbB-3 molecule. Collectively, these observations unveil kinase domain-mediated quasi-dimers, which are regulated by an autoinhibitory carboxyl tail. On the basis of these observations, we propose that quasi-dimers precede formation of ligand-induced, fully active dimers, which are stabilized by both extracellular and intracellular receptor-receptor interactions.-Bublil, E. M., Pines, G., Patel, G., Fruhwirth, G., Ng, T., Yosef Yarden. Kinase-mediated quasi-dimers of EGFR. FASEB J. 24, 4744-4755 (2010). www.fasebj.org	[Bublil, Erez M.; Pines, Gur; Yarden, Yosef] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Patel, Gargi; Fruhwirth, Gilbert; Ng, Tony] Kings Coll London, Randall Div, Richard Dimbleby Dept Canc Res, London WC2R 2LS, England; [Patel, Gargi; Fruhwirth, Gilbert; Ng, Tony] Kings Coll London, Div Canc Studies, London WC2R 2LS, England	Weizmann Institute of Science; University of London; King's College London; University of London; King's College London	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty Bldg,Room 302,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Pines, Gur/X-7501-2019; YARDEN, YOSEF/K-1467-2012; Patel, Gargi/AAG-2715-2019; Fruhwirth, Gilbert/AAP-5559-2021	Pines, Gur/0000-0002-1757-6722; Fruhwirth, Gilbert/0000-0002-1438-2674; Patel, Gargi/0000-0002-5268-4753; Ng, Tony/0000-0003-3894-5619	Cancer Research UK; Engineering and Physical Sciences Research Council; Medical Research Council; UK Department of Health; U.S. National Cancer Institute (NCI) [CA072981]; German Science Foundation; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE [R37CA072981, R01CA072981] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department of Health; U.S. National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); German Science Foundation(German Research Foundation (DFG)); Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank members of their groups for insightful comments. G.P. is supported by a Cancer Research UK Clinical Training Fellowship. G.F. is supported by the King's College London-University College London Comprehensive Cancer Imaging Centre, funded by Cancer Research UK and the Engineering and Physical Sciences Research Council, in association with the Medical Research Council and the UK Department of Health. Y.Y. is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. The EGFR-mGFP plasmid was a kind gift of Melanie Keppler (Richard Dimbleby Laboratory, King's College London). The multiphoton FLIM systems with in-house acquisition/analysis software were built by Simon Ameer-Beg (King's College London), Paul Barber (Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK), and Borivoj Vojnovic (Gray Institute). This work is supported by grants from the U.S. National Cancer Institute (NCI; CA072981), the German Science Foundation, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.	Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Barber PR, 2009, J R SOC INTERFACE, V6, pS93, DOI 10.1098/rsif.2008.0451.focus; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Berger MB, 2004, FEBS LETT, V569, P332, DOI 10.1016/j.febslet.2004.06.014; Boerner JL, 2003, EXP CELL RES, V284, P111, DOI 10.1016/S0014-4827(02)00096-4; Bose R, 2009, EXP CELL RES, V315, P649, DOI 10.1016/j.yexcr.2008.07.031; Bouyain S, 2005, P NATL ACAD SCI USA, V102, P15024, DOI 10.1073/pnas.0507591102; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Frederick L, 2000, CANCER RES, V60, P1383; Gan HK, 2007, J BIOL CHEM, V282, P2840, DOI 10.1074/jbc.M605136200; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Landau M, 2008, BBA-REV CANCER, V1785, P12, DOI 10.1016/j.bbcan.2007.08.001; Landgraf R, 2000, BIOCHEMISTRY-US, V39, P8503, DOI 10.1021/bi000953+; Makrogianneli K, 2009, MOL CELL BIOL, V29, P2997, DOI 10.1128/MCB.01008-08; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Peter M, 2005, BIOPHYS J, V88, P1224, DOI 10.1529/biophysj.104.050153; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Prag S, 2007, MOL BIOL CELL, V18, P2935, DOI 10.1091/mbc.E06-11-1031; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Red Brewer M, 2009, MOL CELL, V34, P641, DOI 10.1016/j.molcel.2009.04.034; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; Spector N, 2008, CLIN BREAST CANCER, V8, pS94, DOI 10.3816/CBC.2008.s.005; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yokoe S, 2007, CANCER RES, V67, P1935, DOI 10.1158/0008-5472.CAN-06-3023; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	43	39	40	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4744	4755		10.1096/fj.10-166199	http://dx.doi.org/10.1096/fj.10-166199			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20682838	Green Published			2022-12-28	WOS:000284824400015
J	Knowles, HJ; Cleton-Jansen, AM; Korsching, E; Athanasou, NA				Knowles, Helen J.; Cleton-Jansen, Anne-Marie; Korsching, Eberhard; Athanasou, Nicholas A.			Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4	FASEB JOURNAL			English	Article						osteoblast; proliferation; differentiation; osteoclastogenesis; pathological bone resorption	ENDOTHELIAL-CELL ADHESION; GENE-EXPRESSION; TARGET GENE; IN-VITRO; TUMOR; ANGIOGENESIS; INHIBITION; MICE; DIFFERENTIATION; ADIPONECTIN	Hypoxia and the hypoxia-inducible factor (HIF) transcription factor regulate angiogenic-osteogenic coupling and osteoclast-mediated bone resorption. To determine how HIF might coordinate osteoclast and osteoblast function, we studied angiopoietin-like 4 (ANGPTL4), the top HIF target gene in an Illumina HumanWG-6 v3.0 48k array of normoxic vs. hypoxic osteoclasts differentiated from human CD14(+) monocytes (14.3-fold induction, P<0.0004). ANGPTL4 mRNA and protein were induced by 24 h at 2% O-2 in human primary osteoclasts, monocytes, and osteoblasts. ANGPTL4 protein was observed by immunofluorescence in osteoclasts and osteoblasts in vivo. Normoxic inducers of HIF (CoCl2, desferrioxamine, and L-mimosine) and 100 ng/ml ANGPTL4 stimulated osteoclastic resorption 2- to 3-fold in assays of lacunar dentine resorption, without affecting osteoclast viability. Isoform-specific HIF-1 alpha small interfering RNA ablated hypoxic induction of ANGPTL4 and of resorption, which was rescued by addition of exogenous ANGPTL4 (P<0.001). In the osteoblastic Saos2 cell line, ANGPTL4 caused a dose-dependent increase in proliferation (P<0.01, 100 ng/ml) and, at lower doses (1-25 ng/ml), mineralization. These results demonstrate that HIF is sufficient to enhance osteoclast-mediated bone resorption and that ANGPTL4 can compensate for HIF-1 alpha deficiency with respect to stimulation of osteoclast activity and also augments osteoblast proliferation and differentiation.-Knowles, H. J., Cleton-Jansen, A.-M., Korsching, E., and Athanasou, N.A. Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. FASEB J. 24, 4648-4659 (2010). www.fasebj.org	[Knowles, Helen J.] Univ Oxford, Nuffield Orthopaed Ctr, Botnar Res Ctr, Oxford OX3 7LD, England; [Athanasou, Nicholas A.] Univ Oxford, Nuffield Orthopaed Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Dept Pathol, Oxford, England; [Cleton-Jansen, Anne-Marie] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands; [Korsching, Eberhard] Univ Munster, Inst Pathol, Munster, Germany	Nuffield Orthopaedic Centre; University of Oxford; Nuffield Orthopaedic Centre; University of Oxford; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Munster	Knowles, HJ (corresponding author), Univ Oxford, Nuffield Orthopaed Ctr, Botnar Res Ctr, Oxford OX3 7LD, England.	helen.knowles@ndorms.ox.ac.uk	Knowles, Helen/F-3857-2018	Knowles, Helen/0000-0002-9575-6067	EuroBoNeT; European Commission [LSH-CCT-2006-018 814]; Arthritis Research UK [MP/19200]; Oxford National Institute Health Research Biomedical Research Unit (NIHR BRU); German Bundesministerium fur Bildung und Forschung [01GM0869]; Versus Arthritis [19200] Funding Source: researchfish	EuroBoNeT(European CommissionEuropean Commission Joint Research Centre); European Commission(European CommissionEuropean Commission Joint Research Centre); Arthritis Research UK(Versus Arthritis); Oxford National Institute Health Research Biomedical Research Unit (NIHR BRU); German Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Versus Arthritis(Versus Arthritis)	This study was funded by EuroBoNeT, a European Commission-granted European Network of Excellence for studying the pathology and genetics of bone tumors (LSH-CCT-2006-018 814). H.J.K. is also funded by Arthritis Research UK (MP/19200). H.J.K. and N.A.A. acknowledge support from the Oxford National Institute Health Research Biomedical Research Unit (NIHR BRU). E.K. is also funded by the German Bundesministerium fur Bildung und Forschung (01GM0869).	Adachi H, 2009, BIOCHEM BIOPH RES CO, V379, P806, DOI 10.1016/j.bbrc.2008.12.018; ADERKA D, 1989, J IMMUNOL, V143, P3517; Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008; Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Camenisch G, 2002, J BIOL CHEM, V277, P17281, DOI 10.1074/jbc.M109768200; Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91; Chomel C, 2009, FASEB J, V23, P940, DOI 10.1096/fj.08-115170; Cornish J, 2006, BONE, V38, pS9, DOI 10.1016/j.bone.2006.01.071; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201; Fuller K, 2007, CLIN SCI, V112, P567, DOI 10.1042/CS20060274; Gaber T, 2005, ANN RHEUM DIS, V64, P971, DOI 10.1136/ard.2004.031641; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002; Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198-007-0477-y; Hallor KH, 2009, CLIN CANCER RES, V15, P2685, DOI 10.1158/1078-0432.CCR-08-2330; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; Hermann LM, 2005, CLIN IMMUNOL, V115, P93, DOI 10.1016/j.clim.2004.12.002; Hu ZY, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-9; Ito Y, 2003, CANCER RES, V63, P6651; JOYNER CJ, 1992, BONE MINER, V16, P37, DOI 10.1016/0169-6009(92)90820-4; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Knowles HJ, 2008, J PATHOL, V215, P56, DOI 10.1002/path.2319; Knowles HJ, 2009, HISTOL HISTOPATHOL, V24, P337, DOI 10.14670/HH-24.337; Knowles HJ, 2009, J PATHOL, V218, P256, DOI 10.1002/path.2534; Komatsu DE, 2007, J BONE MINER RES, V22, P366, DOI 10.1359/JBMR.061207; Kurosaka D, 2003, ANN RHEUM DIS, V62, P677, DOI 10.1136/ard.62.7.677; Lau YS, 2005, HUM PATHOL, V36, P945, DOI 10.1016/j.humpath.2005.07.005; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Li C, 2006, CURR OPIN LIPIDOL, V17, P152, DOI 10.1097/01.mol.0000217896.67444.05; Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; Mandard S, 2006, J BIOL CHEM, V281, P21575; Murata M, 2009, J ORTHOP RES, V27, P50, DOI 10.1002/jor.20703; Muzylak M, 2006, CALCIFIED TISSUE INT, V79, P301, DOI 10.1007/s00223-006-0082-7; Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013; Patel SD, 2004, SCIENCE, V304, P1154, DOI 10.1126/science.1093466; Patntirapong S, 2009, BIOMATERIALS, V30, P548, DOI 10.1016/j.biomaterials.2008.09.062; Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198-007-0492-z; Seitz S, 2006, GENE CHROMOSOME CANC, V45, P612, DOI 10.1002/gcc.20325; Shen X, 2009, J ORTHOP RES, V27, P1298, DOI 10.1002/jor.20886; Shomento SH, 2010, J CELL BIOCHEM, V109, P196, DOI 10.1002/jcb.22396; Sowter HM, 2003, CANCER RES, V63, P6130; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Thommesein L, 2006, J CELL BIOCHEM, V99, P824, DOI 10.1002/jcb.20915; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105; Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672; Wang B, 2007, PFLUG ARCH EUR J PHY, V455, P479, DOI 10.1007/s00424-007-0301-8; Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581; Warnecke C, 2008, EXP CELL RES, V314, P2016, DOI 10.1016/j.yexcr.2008.03.003; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Xia K, 2006, PLOS COMPUT BIOL, V2, P1482, DOI 10.1371/journal.pcbi.0020145; Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000	64	82	87	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2010	24	12					4648	4659		10.1096/fj.10-162230	http://dx.doi.org/10.1096/fj.10-162230			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20667978	Green Published			2022-12-28	WOS:000284824400006
J	Le, LQ; Mahler, V; Scheurer, S; Foetisch, K; Braun, Y; Weigand, D; Enrique, E; Lidholm, J; Paulus, KE; Sonnewald, S; Vieths, S; Sonnewald, U				Le, Lien Q.; Mahler, Vera; Scheurer, Stephan; Foetisch, Kay; Braun, Yvonne; Weigand, Daniela; Enrique, Ernesto; Lidholm, Jonas; Paulus, Kathrin E.; Sonnewald, Sophia; Vieths, Stefan; Sonnewald, Uwe			Yeast profilin complements profilin deficiency in transgenic tomato fruits and allows development of hypoallergenic tomato fruits	FASEB JOURNAL			English	Article						Lyc e 1; RNA interference; tomato allergy; genetically modified food	SACCHAROMYCES-CEREVISIAE; REDUCED ALLERGENICITY; CROSS-REACTIVITY; PLANT PROFILINS; IDENTIFICATION; REDUCTION; EPITOPES; GENE; RNA	Gene silencing of Lyc e 1 leads to reduced allergenicity of tomato fruits but impaired growth of transgenic tomato plants. The aim of the study was to restore growth of Lyc e 1-deficient tomato plants while retaining reduced allergenicity by simultaneous complementation of profilin deficiency by expression of nonallergenic yeast profilin. Transgenic plants were generated and tested by RT-PCR and immunoblotting; allergenicity of yeast profilin and transgenic fruits was investigated by IgE binding, basophil activation, and skin-prick tests. Lyc e 1 content of transgenic tomato fruits was <5% of that of wild-type plants, causing significantly reduced IgE antibody binding. Simultaneous coexpression of yeast profilin restored growth and biomass production almost to wildtype levels. Yeast profilin, sharing 32.6% amino acid sequence identity with Lyc e 1, displayed low IgE-binding capacity and allergenic potency. Among 16 tomato-allergic patients preselected for sensitization to Lyc e 1, none showed significant reactivity to yeast profilin. Yeast profilin did not induce mediator release, and coexpression of yeast profilin did not enhance the allergenicity of Lyc e 1-reduced fruits. Simultanous coexpression of yeast profilin allows silencing of tomato profilin and generation of viable plants with Lyc e 1-deficient tomato fruits. Therefore, a novel approach to allergen avoidance, genetically modified foods with reduced allergen accumulation, can be generated even if the allergen fulfills an essential cellular function in the plant. In summary, our findings of efficiently complementing profilin-deficient tomato plants by coexpression of low allergenic yeast profilin demonstrate the feasibility of creating low-allergenic food even if the allergen fulfills essential cellular functions.-Le, L. Q., Mahler, V., Scheurer, S., Foetisch, K., Braun, Y., Weigand, D., Enrique, E., Lidholm, J., Paulus, K. E., Sonnewald, S., Vieths, S., Sonnewald, U. Yeast profilin complements profilin deficiency in transgenic tomato fruits and allows development of hypoallergenic tomato fruits. FASEB J. 24, 4939-4947 (2010). www.fasebj.org	[Le, Lien Q.; Paulus, Kathrin E.; Sonnewald, Sophia; Sonnewald, Uwe] Univ Erlangen Nurnberg, Dept Biol, Univ Hosp Erlangen, D-91058 Erlangen, Germany; [Mahler, Vera] Univ Erlangen Nurnberg, Dept Dermatol, Univ Hosp Erlangen, D-91058 Erlangen, Germany; [Scheurer, Stephan; Foetisch, Kay; Braun, Yvonne; Weigand, Daniela; Vieths, Stefan] Paul Ehrlich Inst, Div Allergol, D-6070 Langen, Germany; [Enrique, Ernesto] Hosp Gen Castellon, Castellon de La Plana, Spain; [Lidholm, Jonas] Phadia AB, Res & Dev, Uppsala, Sweden	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Paul Ehrlich Institute; Thermo Fisher Scientific; Phadia	Paulus, KE (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Biochem, Staudtstr 5, D-91058 Erlangen, Germany.	kpaulus@biologie.uni-erlangen.de	Sonnewald, Uwe/J-7875-2012; Scheurer, Stephan/A-6509-2019	Sonnewald, Uwe/0000-0003-1835-5339; Scheurer, Stephan/0000-0002-2859-562X; Lidholm, Jonas/0000-0002-7779-3411	Deutsche Forschungsgemeinschaft (DFG) [PAK 132]; German Research Foundation [DFG-Vi 165/6-1, DFG-Ma 1997/3-1, DFG-So 300/13-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Research Foundation(German Research Foundation (DFG))	The authors thank Mechthild Retzek, Andrea Wust, Robert Kammermeier, and Jasmin Drobietz for the excellent technical assistance and Dr. Philippe Deviller (Lyon, France) for providing the anti-ragweed PFN serum. The authors thank Dr. Kamiri (University Gent, Ghent, Belgium) for providing the RNAi-vector p7GWIWG2(II). In addition, the authors thank Andrea Knospe and Sybille Freist for taking care of tissue culture plants and Stefan Hoglander for performing experimental ImmunoCAP couplings of yeast and tomato PFN. The work was funded by Deutsche Forschungsgemeinschaft (DFG) grant PAK 132. This study was supported by grants DFG-Vi 165/6-1, DFG-Ma 1997/3-1, and DFG-So 300/13-1 from the German Research Foundation. None of the authors has a financial relationship with a biotechnology or pharmaceutical manufacturer that has an interest in the subject matter or materials discussed in the submitted manuscript.	BALDO BA, 1988, INT ARCH ALLER A IMM, V86, P201, DOI 10.1159/000234572; BelchiHernandez J, 1996, J ALLERGY CLIN IMMUN, V97, P131, DOI 10.1016/S0091-6749(96)70293-2; Christensen HEM, 1996, PLANT J, V10, P269, DOI 10.1046/j.1365-313X.1996.10020269.x; Codex Alimentarious Commission, 2003, 25 SESS ROM IT 30 JU; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; Dodo HW, 2008, PLANT BIOTECHNOL J, V6, P135, DOI 10.1111/j.1467-7652.2007.00292.x; Dreborg S., 1989, ALLERGY S10, V44, P31; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; Gilissen LJWJ, 2005, J ALLERGY CLIN IMMUN, V115, P364, DOI 10.1016/j.jaci.2004.10.014; Goodman RE, 2008, NAT BIOTECHNOL, V26, P73, DOI 10.1038/nbt1343; HOFGEN R, 1990, PLANT SCI, V66, P221, DOI 10.1016/0168-9452(90)90207-5; Karakesisoglou I, 1996, CELL MOTIL CYTOSKEL, V34, P36; KORTEKANGASSAVOLAINEN O, 1993, CLIN EXP ALLERGY, V23, P179, DOI 10.1111/j.1365-2222.1993.tb00879.x; Le LQ, 2006, J ALLERGY CLIN IMMUN, V118, P1176, DOI 10.1016/j.jaci.2006.06.031; Le LQ, 2006, PLANT BIOTECHNOL J, V4, P231, DOI 10.1111/j.1467-7652.2005.00175.x; Ling HQ, 1998, PLANT CELL REP, V17, P843, DOI 10.1007/s002990050495; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; Lopez-Torrejon G, 2007, J ALLERGY CLIN IMMUN, V119, P1481, DOI 10.1016/j.jaci.2007.02.004; Lorenz Y, 2006, J ALLERGY CLIN IMMUN, V118, P711, DOI 10.1016/j.jaci.2006.05.014; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; McKinney EC, 2001, PLANT CELL, V13, P1179, DOI 10.1105/tpc.13.5.1179; Radauer C, 2006, CLIN EXP ALLERGY, V36, P920, DOI 10.1111/j.1365-2222.2006.02521.x; Radauer C, 2007, J ALLERGY CLIN IMMUN, V120, P518, DOI 10.1016/j.jaci.2007.07.024; Ramachandran S, 2000, PLANT PHYSIOL, V124, P1637, DOI 10.1104/pp.124.4.1637; Rothkegel M, 1996, J CELL SCI, V109, P83; Scheurer S, 2001, J CHROMATOGR B, V756, P315, DOI 10.1016/S0378-4347(01)00090-1; SHIMADA J, 2005, SCI TECH TRENDS, V16, P26; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Singh MB, 2008, TRENDS PLANT SCI, V13, P257, DOI 10.1016/j.tplants.2008.04.004; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Westphal S, 2004, ALLERGY, V59, P526, DOI 10.1046/j.1398-9995.2003.00413.x	31	12	14	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4939	4947		10.1096/fj.10-163063	http://dx.doi.org/10.1096/fj.10-163063			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20709910				2022-12-28	WOS:000284824400032
J	Mehrara, BJ; Avraham, T; Soares, M; Fernandez, JG; Yan, A; Zampell, JC; Andrade, VP; Cordeiro, AP; Sorrento, CM				Mehrara, Babak J.; Avraham, Tomer; Soares, Marc; Fernandez, John G.; Yan, Alan; Zampell, Jamie C.; Andrade, Victor P.; Cordeiro, Andrew P.; Sorrento, Cristina M.			p21(cip/WAF) is a key regulator of long-term radiation damage in mesenchyme-derived tissues	FASEB JOURNAL			English	Article						p21; mesenchymal stem cell; differentiation; radiation injury; skin fibrosis	DEPENDENT KINASE INHIBITOR; STEM-CELLS; CELLULAR SENESCENCE; IONIZING-RADIATION; BONE; DIFFERENTIATION; P21; GROWTH; EXPRESSION; CYCLIN	This study aimed to determine the mechanisms responsible for long-term tissue damage following radiation injury. We irradiated p21-knockout (p21(-/-)) and wild-type (WT) mice and determined the long-term deleterious effects of this intervention on mesenchyme-derived tissues. In addition, we explored the mechanisms of radiation-induced mesenchymal stem cell (MSC) dysfunction in isolated bone marrow-derived cells. p21 expression was chronically elevated >200-fold in irradiated tissues. Loss of p21 function resulted in a >4-fold increase in the number of skin MSCs remaining after radiation. p21(-/-) mice had significantly less radiation damage, including 6-fold less scarring, 40% increased growth potential, and 4-fold more hypertrophic chondrocytes in the epiphyseal plate (P<0.01). Irradiated p21(-/-) MSCs had 4-fold increased potential for bone or fat differentiation, 4-fold greater proliferation rate, and nearly 7-fold lower senescence as compared to WT MSCs (P<0.01). Ectopic expression of p21 in knockout cells decreased proliferation and differentiation potential and recapitulated the WT phenotype. Loss of p21 function markedly decreases the deleterious effects of radiation injury in mesenchyme-derived tissues and preserves tissue-derived MSCs. In addition, p21 is a critical regulator of MSC proliferation, differentiation, and senescence both at baseline and in response to radiation.-Mehrara, B. J., Avraham, T., Soares, M., Fernandez, J. G., Yan, A., Zampell, J. C., Andrade, V. P., Cordeiro, A. P., Sorrento, C. M. p21(cip/WAF) is a key regulator of long-term radiation damage in mesenchyme-derived tissues. FASEB J. 24, 4877-4888 (2010). www.fasebj.org	[Mehrara, Babak J.; Avraham, Tomer; Soares, Marc; Fernandez, John G.; Yan, Alan; Zampell, Jamie C.; Cordeiro, Andrew P.; Sorrento, Cristina M.] Mem Sloan Kettering Canc Ctr, Div Plast & Reconstruct Surg, Dept Surg, New York, NY USA; [Andrade, Victor P.] Mem Sloan Kettering Canc Ctr, Div Breast Surg, Dept Surg, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Mehrara, BJ (corresponding author), 1275 York Ave,Rm MRI 1005, New York, NY 10065 USA.	mehrarab@mskcc.org	Andrade, Victor/K-6514-2012	Andrade, Victor/0000-0002-2243-8834	Plastic Surgery Education Foundation	Plastic Surgery Education Foundation	Funding for this study was provided in part by a Plastic Surgery Education Foundation National Endowment grant to B.J.M.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bellosta P, 2003, J BONE MINER RES, V18, P818, DOI 10.1359/jbmr.2003.18.5.818; Carrington JL, 2005, BIOCHEM BIOPH RES CO, V328, P700, DOI 10.1016/j.bbrc.2004.12.041; Chang SF, 2009, MOL ENDOCRINOL, V23, P1827, DOI 10.1210/me.2009-0143; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Clavin NW, 2008, AM J PHYSIOL-HEART C, V295, pH2113, DOI 10.1152/ajpheart.00879.2008; Clavin NW, 2008, PLAST RECONSTR SURG, V122, P739, DOI 10.1097/PRS.0b013e318180edaa; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Crigler L, 2007, FASEB J, V21, P2050, DOI 10.1096/fj.06-5880com; Dickhut A, 2005, ANN HEMATOL, V84, P722, DOI 10.1007/s00277-005-1067-8; Djojosubroto MW, 2003, MOL CELLS, V15, P164; Enomoto K, 2006, INVEST OPHTH VIS SCI, V47, P4330, DOI 10.1167/iovs.05-1581; Fan YP, 2003, MOL CANCER THER, V2, P773; Flanders KC, 2003, AM J PATHOL, V163, P2247, DOI 10.1016/S0002-9440(10)63582-1; Francois S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005-0260; Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001; Galotto M, 1999, EXP HEMATOL, V27, P1460, DOI 10.1016/S0301-472X(99)00076-4; George RJ, 2009, AM J PHYSIOL-GASTR L, V296, pG245, DOI 10.1152/ajpgi.00021.2008; Inoue N, 2008, J BIOL CHEM, V283, P21220, DOI 10.1074/jbc.M801824200; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Ito T, 2007, BIOCHEM BIOPH RES CO, V359, P108, DOI 10.1016/j.bbrc.2007.05.067; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Ju ZY, 2007, ANN NY ACAD SCI, V1100, P333, DOI 10.1196/annals.1395.036; Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305; Kishimoto H, 2006, NAT MED, V12, P1213, DOI 10.1038/nm1404; Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116; Legrier ME, 2001, NEUROREPORT, V12, P3127, DOI 10.1097/00001756-200110080-00029; Mehlhorn AT, 2007, CELL PROLIFERAT, V40, P809, DOI 10.1111/j.1365-2184.2007.00473.x; Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007-1122; Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427; Molchadsky A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003707; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Mora AL, 2008, J CELL BIOCHEM, V105, P641, DOI 10.1002/jcb.21890; Mueller SM, 2001, J CELL BIOCHEM, V82, P583, DOI 10.1002/jcb.1174; Naaz A, 2004, FASEB J, V18, P1925, DOI 10.1096/fj.04-2631fje; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Park SH, 2008, CANCER BIOL THER, V7, P2015, DOI 10.4161/cbt.7.12.7069; PASILOVA M, 2009, PLAST RECONSTR SUR S, V123, pS149; Petschnik AE, 2010, BRIT J DERMATOL, V162, P380, DOI 10.1111/j.1365-2133.2009.09512.x; Rao MS, 2001, MECH AGEING DEV, V122, P713, DOI 10.1016/S0047-6374(01)00224-X; Rousseau D, 1999, ONCOGENE, V18, P3290, DOI 10.1038/sj.onc.1202681; Schonmeyr BH, 2008, PLAST RECONSTR SURG, V122, P64, DOI 10.1097/PRS.0b013e31817743cd; Schonmeyr BH, 2010, TISSUE ENG PT A, V16, P653, DOI 10.1089/ten.TEA.2009.0426; Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002; Tauchmanova L, 2002, J CLIN ENDOCR METAB, V87, P5058, DOI 10.1210/jc.2002-020800; Tiede S, 2007, EUR J CELL BIOL, V86, P355, DOI 10.1016/j.ejcb.2007.03.006; Van Zant G, 2003, EXP HEMATOL, V31, P659, DOI 10.1016/S0301-472X(03)00088-2; Wagner W, 2008, EXP GERONTOL, V43, P974, DOI 10.1016/j.exger.2008.04.007; Weiss RH, 2007, J UROLOGY, V177, P63, DOI 10.1016/j.juro.2006.08.073; Welle S, 2004, EXP GERONTOL, V39, P369, DOI 10.1016/j.exger.2003.11.011; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226; Zhang J, 2008, J BIOMED SCI, V15, P585, DOI 10.1007/s11373-008-9256-9; Zhou JX, 2004, CELL BIOL INT, V28, P523, DOI 10.1016/j.cellbi.2004.04.007; Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474-9726.2008.00377.x	57	20	22	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4877	4888		10.1096/fj.10-155762	http://dx.doi.org/10.1096/fj.10-155762			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20720160				2022-12-28	WOS:000284824400027
J	Goetzl, EJ; Huang, MC; Kon, J; Patel, K; Schwartz, JB; Fast, K; Ferrucci, L; Madara, K; Taub, DD; Longo, DL				Goetzl, Edward J.; Huang, Mei-Chuan; Kon, Junko; Patel, Kalpesh; Schwartz, Janice B.; Fast, Katharine; Ferrucci, Luigi; Madara, Karen; Taub, Dennis D.; Longo, Dan L.			Gender specificity of altered human immune cytokine profiles in aging	FASEB JOURNAL			English	Article						T cells; monocytes; immunodeficiency; autoimmunity	REGULATORY T-CELLS; INTERFERON-GAMMA-PRODUCTION; IFN-GAMMA; CLONAL EXPANSIONS; ELDERLY-PEOPLE; OLD SUBJECTS; IN-VITRO; AGE; LYMPHOCYTES; ACTIVATION	Cytokine generation by T cells and monocytes was determined for 50 subjects aged 65 yr or older and concurrently studied young subjects individually matched to each old subject for sex, race, and national origin. Highly significant differences between cytokine levels of old and young subjects all were gender specific. For T cells stimulated with anti-CD3 plus anti-CD28 antibodies, mean ratios of IFN-gamma generation for healthy old to young subjects were 0.22 for men (P<0.001; n=15) and 3.35 for women (P<0.001; n=13), and those of IL-17 were 0.30 for men (P<0.001) and no difference for women. CD8 T cells were the source of high IFN-gamma in healthy old women. For old men with an inflammatory or immune disease (n=10), mean old to young ratios of T-cell-generated IFN-gamma and IL-17 increased with disease severity up to 5.78 and 2.97 (both P<0.01), respectively, without changes for old women with similar diseases (n=12). For differentiated LPS-stimulated monocytes, old to young ratios of TNF-alpha and IL-6 generation were high only in women with immune or inflammatory disease (2.38, P<0.05 and 1.62, P<0.01, respectively), whereas ratios of IFN-gamma-evoked IP-10 chemokine were low in all groups. Alterations in immune cytokine profiles with aging show significant gender specificity.-Goetzl, E. J., Huang, M.-C., Kon, J., Patel, K., Schwartz, J. B., Fast, K., Ferrucci, L., Madara, K., Taub, D. D., Longo, D. L. Gender specificity of altered human immune cytokine profiles in aging. FASEB J. 24, 3580-3589 (2010). www.fasebj.org	[Goetzl, Edward J.; Huang, Mei-Chuan; Kon, Junko; Schwartz, Janice B.; Fast, Katharine] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Goetzl, Edward J.; Huang, Mei-Chuan; Kon, Junko; Schwartz, Janice B.; Fast, Katharine] Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA; [Goetzl, Edward J.; Patel, Kalpesh; Ferrucci, Luigi; Madara, Karen; Taub, Dennis D.; Longo, Dan L.] NIA, NIH, Baltimore, MD 21224 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, Rm UB8B,UC Box 0711,533 Parnassus & 4th Ave, San Francisco, CA 94143 USA.	edward.goetzl@ucsf.edu	Patel, Kalpesh/G-6685-2012; Longo, Dan L./F-6022-2011; Schwartz, Janice/K-6354-2019	Patel, Kalpesh/0000-0002-2952-6773; 	National Institute on Aging; Kenneth Rainin Foundation; National Institutes of Health [HL31809]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000015, ZIAAG000104] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Kenneth Rainin Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by the Intramural Research Program of the National Institute on Aging, a grant from the Kenneth Rainin Foundation, and National Institutes of Health RO-1 grant HL31809. E.J.G., M. C. H., J.B.S., D. D. T., and D. L. L. designed research; E.J.G., J.B.S., K. F., L. F., and K. M. evaluated and selected subjects; E.J.G., M. C. H., J.K., and K. P. performed laboratory research; E.J.G., M. C. H., J.B.S., and D. L. L. analyzed data and wrote the paper. The authors are grateful to Judith H. Goetzl for preparation of the figures and tables.	ABB J, 1984, BLUT, V48, P285; ALRAYES H, 1992, J ALLERGY CLIN IMMUN, V90, P630, DOI 10.1016/0091-6749(92)90136-P; Bryl E, 2004, EXP GERONTOL, V39, P587, DOI 10.1016/j.exger.2003.10.029; Bujak M, 2009, CIRC RES, V105, P973, DOI 10.1161/CIRCRESAHA.109.199471; CANDORE G, 1993, AUTOIMMUNITY, V16, P275, DOI 10.3109/08916939309014646; Caruso C, 1996, IMMUNOL RES, V15, P84, DOI 10.1007/BF02918286; Cone RE, 2007, IMMUNOLOGY, V120, P112, DOI 10.1111/j.1365-2567.2006.02486.x; Cosmi L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397; COSSARIZZA A, 1989, FEBS LETT, V248, P141, DOI 10.1016/0014-5793(89)80449-1; Dixit VD, 2007, J CLIN INVEST, V117, P2778, DOI 10.1172/JCI30248; FAGIOLO U, 1993, EUR J IMMUNOL, V23, P2375, DOI 10.1002/eji.1830230950; FOX HS, 1991, J IMMUNOL, V146, P4362; Gerlini G, 2008, J IMMUNOL, V181, P2999, DOI 10.4049/jimmunol.181.5.2999; GILLIS S, 1981, J CLIN INVEST, V67, P937, DOI 10.1172/JCI110143; Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x; Gupta Sudhir, 2006, Immun Ageing, V3, P5, DOI 10.1186/1742-4933-3-5; Huang MC, 2010, FASEB J, V24, P2558, DOI 10.1096/fj.09-153148; Karpuzoglu-Sahin E, 2001, CYTOKINE, V14, P208, DOI 10.1006/cyto.2001.0876; Lages CS, 2008, J IMMUNOL, V181, P1835, DOI 10.4049/jimmunol.181.3.1835; Lu BF, 1998, P NATL ACAD SCI USA, V95, P8233, DOI 10.1073/pnas.95.14.8233; Matalka KZ, 2003, NEUROENDOCRINOL LETT, V24, P185; McGillicuddy FC, 2009, J BIOL CHEM, V284, P31936, DOI 10.1074/jbc.M109.061655; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Nakaya M, 2006, BIOSCI BIOTECH BIOCH, V70, P47, DOI 10.1271/bbb.70.47; Nishikawa H, 2005, J IMMUNOL, V175, P4433, DOI 10.4049/jimmunol.175.7.4433; OGarra A, 1996, CHEM IMMUNOL, V63, P1; Pawelec G, 2007, EMBO REP, V8, P220, DOI 10.1038/sj.embor.7400922; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; Rea IM, 1996, GERONTOLOGY, V42, P69, DOI 10.1159/000213775; Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893, DOI 10.4049/jimmunol.168.11.5893; Taub DD, 1996, J IMMUNOL, V156, P2095; Tsaknaridis L, 2003, J NEUROSCI RES, V74, P296, DOI 10.1002/jnr.10766; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Wack A, 1998, INT IMMUNOL, V10, P1281, DOI 10.1093/intimm/10.9.1281; Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013; Yen CJ, 2000, J BIOMED SCI, V7, P317; Zheng YH, 2000, FASEB J, V14, P2387	37	71	71	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3580	3589		10.1096/fj.10-160911	http://dx.doi.org/10.1096/fj.10-160911			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20453111	Green Published			2022-12-28	WOS:000281446400045
J	Ibrahim, M; Al Masri, A; Navaratnarajah, M; Siedlecka, U; Soppa, GK; Moshkov, A; Abou Al-Saud, S; Gorelik, J; Yacoub, MH; Terracciano, CMN				Ibrahim, Michael; Al Masri, Abeer; Navaratnarajah, Manoraj; Siedlecka, Urszula; Soppa, Gopal K.; Moshkov, Alexey; Abou Al-Saud, Sara; Gorelik, Julia; Yacoub, Magdi H.; Terracciano, Cesare M. N.			Prolonged mechanical unloading affects cardiomyocyte excitation-contraction coupling, transverse-tubule structure, and the cell surface	FASEB JOURNAL			English	Article						Ca2+-induced Ca2+ release; scanning ion conductance microscope; confocal microscope	VENTRICULAR ASSIST DEVICE; SCANNING ION-CONDUCTANCE; T-TUBULES; REDUCED SYNCHRONY; CA2+ RELEASE; HEART-TRANSPLANTATION; FAILING HUMAN; CALCIUM; RECOVERY; MYOCYTES	Prolonged mechanical unloading (UN) of the heart is associated with detrimental changes to the structure and function of cardiomyocytes. The mechanisms underlying these changes are unknown. In this study, we report the influence of UN on excitation-contraction coupling, Ca2+-induce Ca2+ release (CICR) in particular, and transverse (t)-tubule structure. UN was induced in male Lewis rat hearts by heterotopic abdominal heart transplantation. Left ventricular cardiomyocytes were isolated from the transplanted hearts after 4 wk and studied using whole-cell patch clamping, confocal microscopy, and scanning ion conductance microscopy (SICM). Recipient hearts were used as control (C). UN reduced the volume of cardiomyocytes by 56.5% compared with C (UN, n = 90; C, n = 59; P<0.001). The variance of time-to-peak of the Ca2+ transients was significantly increased in unloaded cardiomyocytes (UN 227.4+/-24.9 ms(2), n = 42 vs. C 157.8+/-18.0 ms(2), n = 40; P<0.05). UN did not alter the action potential morphology or whole-cell L-type Ca2+ current compared with C, but caused a significantly higher Ca2+ spark frequency (UN 3.718+/-0.85 events/100 mu m/s, n = 47 vs. C 0.908+/-0.186 events/100 mu m/s, n = 45; P<0.05). Confocal studies showed irregular distribution of the t tubules (power of the normal t-tubule frequency: UN 8.13+/-1.12x10(5), n = 57 vs. C 20.60+/-3.174x10(5), n = 56; P<0.001) and SICM studies revealed a profound disruption to the openings of the t tubules and the cell surface in unloaded cardiomyocytes. We show that UN leads to a functional uncoupling of the CICR process and identify disruption of the t-tubule-sarcoplasmic reticulum interaction as a possible mechanism.-Ibrahim, M., Al Masri, A., Navaratnarajah, M., Siedlecka, U., Soppa, G. K., Moshkov, A., Abou Al-Saud, S., Gorelik, J., Yacoub, M. H., Terracciano, C. M. N. Prolonged mechanical unloading affects cardiomyocyte excitation-contraction coupling, transverse-tubule structure, and the cell surface. FASEB J. 24, 3321-3329 (2010). www.fasebj.org	[Ibrahim, Michael; Navaratnarajah, Manoraj; Siedlecka, Urszula; Soppa, Gopal K.; Moshkov, Alexey; Abou Al-Saud, Sara; Gorelik, Julia; Yacoub, Magdi H.; Terracciano, Cesare M. N.] Univ London Imperial Coll Sci Technol & Med, Harefield Heart Sci Ctr & Cardiovasc Sci, London, England; [Al Masri, Abeer; Abou Al-Saud, Sara] King Saud Univ, Coll Med, King Fahad Cardiac Ctr, Riyadh 11461, Saudi Arabia	Imperial College London; King Saud University	Terracciano, CMN (corresponding author), Harefield Hosp, Harefield Heart Sci Ctr, Harefield UB9 6JH, Middx, England.	c.terracciano@imperial.ac.uk	Moshkov, Alexey/AAO-9902-2020; Moshkov, Alexey/C-2825-2014; Al-Masri, Abeer/AAL-3389-2020	Moshkov, Alexey/0000-0002-1858-6738; Moshkov, Alexey/0000-0002-1858-6738; Gorelik, Julia/0000-0003-1148-9158; Al-Masri, Abeer/0000-0002-3981-2132	British Heart Foundation [FS/09/025/27468]	British Heart Foundation(British Heart Foundation)	This work was supported by a British Heart Foundation M.B.-Ph.D. studentship to M. I. (FS/09/025/27468).	BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BERS DM, 1991, EXCITATION CONTRACTI; Birks EJ, 2006, NEW ENGL J MED, V355, P1873, DOI 10.1056/NEJMoa053063; Brette F, 2003, CIRC RES, V92, P1182, DOI 10.1161/01.RES.0000074908.17214.FD; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; Cheng HP, 2008, PHYSIOL REV, V88, P1491, DOI 10.1152/physrev.00030.2007; Dandel M, 2005, CIRCULATION, V112, pI37, DOI 10.1161/CIRCULATIONAHA.104.525352; DUBELL WH, 1991, J PHYSIOL-LONDON, V436, P347, DOI 10.1113/jphysiol.1991.sp018554; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; Gorelik J, 2006, CARDIOVASC RES, V72, P422, DOI 10.1016/j.cardiores.2006.09.009; Gu YC, 2002, FASEB J, V16, P748, DOI 10.1096/fj.01-1024fje; He JQ, 2001, CARDIOVASC RES, V49, P298, DOI 10.1016/S0008-6363(00)00256-X; Heinzel FR, 2008, CIRC RES, V102, P338, DOI 10.1161/CIRCRESAHA.107.160085; Ito K, 2003, CIRCULATION, V107, P1176, DOI 10.1161/01.CIR.0000051463.72137.96; Korchev YE, 2000, BIOPHYS J, V78, P2675, DOI 10.1016/S0006-3495(00)76811-1; Korchev YE, 1997, J MICROSC-OXFORD, V188, P17, DOI 10.1046/j.1365-2818.1997.2430801.x; Lenaerts I, 2009, CIRC RES, V105, P876, DOI 10.1161/CIRCRESAHA.109.206276; Louch WE, 2004, CARDIOVASC RES, V62, P63, DOI 10.1016/j.cardiores.2003.12.031; Louch WE, 2006, J PHYSIOL-LONDON, V574, P519, DOI 10.1113/jphysiol.2006.107227; Lyon AR, 2009, P NATL ACAD SCI USA, V106, P6854, DOI 10.1073/pnas.0809777106; Mancini DM, 1998, CIRCULATION, V98, P2383, DOI 10.1161/01.CIR.98.22.2383; Maybaum S, 2007, CIRCULATION, V115, P2497, DOI 10.1161/CIRCULATIONAHA.106.633180; Meethal SV, 2007, CELL CALCIUM, V41, P123, DOI 10.1016/j.ceca.2006.05.006; Mohapatra B, 2010, J HEART LUNG TRANSPL, V29, P98, DOI 10.1016/j.healun.2009.06.030; Novak P, 2009, NAT METHODS, V6, P279, DOI [10.1038/NMETH.1306, 10.1038/nmeth.1306]; Ogletree ML, 2010, J HEART LUNG TRANSPL, V29, P554, DOI 10.1016/j.healun.2009.10.015; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Orchard C, 2008, CARDIOVASC RES, V77, P237, DOI 10.1093/cvr/cvm002; Oriyanhan W, 2007, J HEART LUNG TRANSPL, V26, P16, DOI 10.1016/j.healun.2006.10.016; Protasi F, 1996, DEV BIOL, V173, P265, DOI 10.1006/dbio.1996.0022; Ritter M, 2000, J MOL CELL CARDIOL, V32, P577, DOI 10.1006/jmcc.2000.1101; Siedlecka U, 2008, AM J PHYSIOL-HEART C, V295, pH1917, DOI 10.1152/ajpheart.00258.2008; Song LS, 2006, P NATL ACAD SCI USA, V103, P4305, DOI 10.1073/pnas.0509324103; Soppa GKR, 2008, J HEART LUNG TRANSPL, V27, P882, DOI 10.1016/j.healun.2008.05.005; Soppa GKR, 2008, CURR OPIN CARDIOL, V23, P206, DOI 10.1097/HCO.0b013e3282fc7010; Soppa GKR, 2008, CARDIOVASC RES, V77, P695, DOI 10.1093/cvr/cvm106; Stagg MA, 2008, CIRC RES, V103, P855, DOI 10.1161/CIRCRESAHA.108.176461; STERN MD, 1992, FASEB J, V6, P3092, DOI 10.1096/fasebj.6.12.1325933; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; Stolen TO, 2009, CIRC RES, V105, P527, DOI 10.1161/CIRCRESAHA.109.199810; SUN XH, 1995, J CELL BIOL, V129, P659, DOI 10.1083/jcb.129.3.659; Swift F, 2008, CARDIOVASC RES, V78, P71, DOI 10.1093/cvr/cvn013; TERRACCIANO CM, 2010, ANN REV MED, V61; Terracciano CMN, 2004, CIRCULATION, V109, P2263, DOI 10.1161/01.CIR.0000129233.51320.92; Wang SQ, 2004, CIRC RES, V94, P1011, DOI 10.1161/01.RES.0000125883.68447.A1; Xydas S, 2006, J HEART LUNG TRANSPL, V25, P7, DOI 10.1016/j.healun.2005.08.001; Yacoub MH, 2001, EUR HEART J, V22, P534, DOI 10.1053/euhj.2001.2613; Yacoub MH, 2001, TRANSPL P, V33, P2762, DOI 10.1016/S0041-1345(01)02183-2; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656; Zhang RL, 2009, HUM MOL GENET, V18, P4130, DOI 10.1093/hmg/ddp362	51	57	59	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3321	3329		10.1096/fj.10-156638	http://dx.doi.org/10.1096/fj.10-156638			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20430793	Green Published			2022-12-28	WOS:000281446400020
J	Western, PS; van den Bergen, JA; Miles, DC; Sinclair, AH				Western, Patrick S.; van den Bergen, Jocelyn A.; Miles, Denise C.; Sinclair, Andrew H.			Male fetal germ cell differentiation involves complex repression of the regulatory network controlling pluripotency	FASEB JOURNAL			English	Article						Oct4; Nanog; Sox2; mitotic arrest; methylation	GENE-EXPRESSION; SELF-RENEWAL; STEM-CELLS; SOX2; NANOG; OCT4; MEIOSIS	Mammalian germ cells are derived from the pluripotent epiblast and share features with pluripotent stem cells, including the expression of key genes that regulate developmental potency. The core genes Oct4, Sox2, and Nanog that regulate pluripotency in stem cells also perform important roles in regulating germ cell development and potentially in occurrence of germ line tumors in humans. Despite this, our understanding of the regulation of these genes during germ cell development remains limited. In this study we examine the regulation of pluripotency in the mouse fetal germ line. We show that male-specific methylation occurs in key functional elements of the Nanog and Sox2 promoters, and these genes are suppressed during early male germ cell differentiation. Furthermore, Oct4 translation is suppressed post-transcriptionally as germ cells differentiate down the male lineage and enter mitotic arrest. Combined, our data strongly support the conclusion that repression of the core machinery regulating pluripotency is a robust and early event involved in the differentiation of the male germ cell lineage. We hypothesize that active repression of pluripotency is required for fetal male germ cell differentiation and that failure of this mechanism may render germ cells susceptible to tumor formation.-Western, P. S., van den Bergen, J. A., Miles, D. C., Sinclair, A. H. Male fetal germ cell differentiation involves complex repression of the regulatory network controlling pluripotency. FASEB J. 24, 3026-3035 (2010). www.fasebj.org	[Western, Patrick S.] Univ Melbourne, Royal Childrens Hosp, ARC Ctr Excellence Biotechnol & Dev, Murdoch Childrens Res Inst,Dept Paediat, Melbourne, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Western, PS (corresponding author), Univ Melbourne, Royal Childrens Hosp, ARC Ctr Excellence Biotechnol & Dev, Murdoch Childrens Res Inst,Dept Paediat, Flemington Rd, Melbourne, Vic 3052, Australia.	patrick.western@mcri.edu.au	Sinclair, Andrew H/A-3598-2010	Sinclair, Andrew H/0000-0003-2741-7992; Western, Patrick/0000-0002-7587-8227	Australian Research Council Centre of Excellence for Biotechnology and Development	Australian Research Council Centre of Excellence for Biotechnology and Development(Australian Research Council)	The authors thank Prof. George Enders (University of Kansas Medical Center, Kansas City, KS, USA) for the GCNA antibody, Dr. Nick Wong for advice on bisulfite sequencing, Dr. Matt Burton for FACS sorting, and Christine Hall and the MCRI animal staff for animal care. The authors also thank Dr. Stefan White for critical comments on the manuscript. This project was supported through the Australian Research Council Centre of Excellence for Biotechnology and Development. Authors' contributions were as follows: P.S.W.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript preparation, final approval of manuscript. J.A.V.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript preparation, final approval of manuscript. D.C.M.: conception and design, collection and assembly of data, data analysis and interpretation, final approval of manuscript. A.H.S.: conception and design, financial support, final approval of manuscript.	Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886; Bullejos M, 2004, MOL REPROD DEV, V68, P422, DOI 10.1002/mrd.20105; Catena R, 2004, J BIOL CHEM, V279, P41846, DOI 10.1074/jbc.M405514200; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Ewen KA, 2010, MOL CELL ENDOCRINOL, V323, P76, DOI 10.1016/j.mce.2009.12.013; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697; Hata K, 2002, DEVELOPMENT, V129, P1983; Imamura M, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-34; Kehler J, 2004, EMBO REP, V5, P1078, DOI 10.1038/sj.embor.7400279; Kocer A, 2009, MOL HUM REPROD, V15, P205, DOI 10.1093/molehr/gap008; Kossack N, 2009, STEM CELLS, V27, P138, DOI 10.1634/stemcells.2008-0439; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; La Salle S, 2004, DEV BIOL, V268, P403, DOI 10.1016/j.ydbio.2003.12.031; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Maldonado-Saldivia J, 2007, STEM CELLS, V25, P19, DOI 10.1634/stemcells.2006-0269; McLaren A, 2003, DEV BIOL, V262, P1, DOI 10.1016/S0012-1606(03)00214-8; Miles DC, 2010, CELL CYCLE, V9, P408, DOI 10.4161/cc.9.2.10691; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Oatley JA, 2008, ANNU REV CELL DEV BI, V24, P263, DOI 10.1146/annurev.cellbio.24.110707.175355; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Rajpert-De Meyts E, 2003, APMIS, V111; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Saxe JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004467; Seandel M, 2007, NATURE, V449, P346, DOI 10.1038/nature06129; Shinohara T, 2003, BIOL REPROD, V68, P1064, DOI 10.1095/biolreprod.102.009977; Spiller CM, 2010, BIOL REPROD, V82, P433, DOI 10.1095/biolreprod.109.078691; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Suzuki A, 2008, GENE DEV, V22, P430, DOI 10.1101/gad.1612708; Szabo PE, 2002, MECH DEVELOP, V115, P157, DOI 10.1016/S0925-4773(02)00087-4; Tanaka SS, 2000, GENE DEV, V14, P841; van den Bergen JA, 2009, BIOL REPROD, V81, P362, DOI 10.1095/biolreprod.109.076224; Voorhoeve PM, 2007, ADV EXP MED BIOL, V604, P17, DOI 10.1007/978-0-387-69116-9_2; Western P, 2005, STEM CELLS, V23, P1436, DOI 10.1634/stemcells.2005-0146; Western PS, 2008, STEM CELLS, V26, P339, DOI 10.1634/stemcells.2007-0622; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yamaguchi S, 2005, GENE EXPR PATTERNS, V5, P639, DOI 10.1016/j.modgep.2005.03.001; Youngren KK, 2005, NATURE, V435, P360, DOI 10.1038/nature03595	41	56	59	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					3026	3035		10.1096/fj.09-151555	http://dx.doi.org/10.1096/fj.09-151555			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20395456				2022-12-28	WOS:000285005400040
J	Zheng, B; Ohkawa, S; Li, HY; Roberts-Wilson, TK; Price, SR				Zheng, Bin; Ohkawa, Sakae; Li, Haiyan; Roberts-Wilson, Tiffany K.; Price, S. Russ			FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy	FASEB JOURNAL			English	Article						diabetes; transcription	INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; GROWTH-FACTOR-I; PROTEIN-DEGRADATION; PROTEASOME; ACTIVATION; PATHWAY; RAT; TRANSCRIPTION; BINDING	Muscle atrophy is a consequence of chronic diseases (e.g., diabetes) and glucocorticoid-induced insulin resistance that results from enhanced activity of the ubiquitin-proteasome pathway. The PI3K/Akt pathway inhibits the FOXO-mediated transcription of the muscle-specific E3 ligase atrogin-1/MAFbx (AT-1), whereas the MEK/ERK pathway increases Sp1 activity and ubiquitin (UbC) expression. The observations raise a question about how the transcription of these atrogenes is synchronized in atrophic muscle. We tested a signaling model in which FOXO3a mediates crosstalk between the PI3K/Akt and MEK/ERK pathways to coordinate AT-1 and UbC expression. In rat L6 myotubes, dexamethasone (>= 24 h) reduced insulin receptor substrate (IRS)-1 protein and PI3K/Akt signaling and increased AT-1 mRNA. IRS-2 protein, MEK/ERK signaling, Sp1 phosphorylation, and UbC transcription were simultaneously increased. Knockdown of IRS-1 using small interfering RNA or adenovirus-mediated expression of constitutively activated FOXO3a increased IRS-2 protein, MEK/ERK signaling, and UbC expression. Changes in PI3K/Akt and MEK/ERK signaling were recapitulated in rat muscles undergoing atrophy due to streptozotocin-induced insulin deficiency and concurrently elevated glucocorticoid production. IRS-1 and Akt phosphorylation were decreased, whereas MEK/ERK signaling and expression of IRS-2, UbC and AT-1 were increased. We conclude that FOXO3a mediates a reciprocal communication between the IRS-1/PI3K/Akt and IRS-2/MEK/ERK pathways that coordinates AT-1 and ubiquitin expression during muscle atrophy.-Zheng, B., Ohkawa, S., Li, H., Roberts-Wilson, T.-K., Price, S. R. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J. 24, 2660-2669 (2010). www.fasebj.org	[Zheng, Bin; Ohkawa, Sakae; Li, Haiyan; Price, S. Russ] Emory Univ, Div Renal, Sch Med, Atlanta, GA 30322 USA; [Roberts-Wilson, Tiffany K.] Emory Univ, Grad Div Biol & Biomed Sci, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Price, SR (corresponding author), Emory Univ, Div Renal, Sch Med, Rm 3319A,Woodruff Mem Res Bldg,1639 Pierce Dr, Atlanta, GA 30322 USA.	russ.price@emory.edu		Roberts, Tiffany/0000-0003-0770-9568	U.S. National Institutes of Health [DK-50740, DK-61521, DK-73476]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050740, P01DK061521, R01DK073476] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. C. Ronald Kahn (Harvard University, Boston, MA, USA) for providing the p85 alpha adenovirus. The authors also thank Dr. H.A. Franch and Sara Zoromsky for performing experiments for the revised manuscript. Financial support was from U.S. National Institutes of Health grants DK-50740 (to S.R.P.), DK-61521 (to S.R.P.), and DK-73476 (to H.F.).	Alroy I, 1999, MOL CELL BIOL, V19, P1961; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Auclair D, 1997, AM J PHYSIOL-CELL PH, V272, pC1007; Bailey JL, 2006, J AM SOC NEPHROL, V17, P1388, DOI 10.1681/ASN.2004100842; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bondesen BA, 2004, AM J PHYSIOL-CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Chrysis D, 1999, ENDOCRINOLOGY, V140, P5635, DOI 10.1210/en.140.12.5635; Combaret L, 2004, BIOCHEM J, V378, P239, DOI 10.1042/BJ20031660; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; FOJAS DB, 2001, EMBO J, V20, P5737; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Franch HA, 2004, AM J PHYSIOL-RENAL, V287, pF700, DOI 10.1152/ajprenal.00440.2003; Gao YM, 2008, J APPL PHYSIOL, V105, P1772, DOI 10.1152/japplphysiol.90636.2008; Garcia A, 2000, J BIOL CHEM, V275, P9385, DOI 10.1074/jbc.275.13.9385; Gazdag AC, 1999, DIABETES, V48, P1930, DOI 10.2337/diabetes.48.10.1930; Giorgino F, 1997, J BIOL CHEM, V272, P7455, DOI 10.1074/jbc.272.11.7455; GIORGINO F, 1993, J CLIN INVEST, V91, P2020, DOI 10.1172/JCI116424; GULVE EA, 1989, BIOCHEM J, V260, P377, DOI 10.1042/bj2600377; Guo SD, 2006, MOL ENDOCRINOL, V20, P3389, DOI 10.1210/me.2006-0092; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HALLANGERAS M, 1991, SURGERY, V109, P468; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; HAYASHI T, 1994, BBA-GENE STRUCT EXPR, V1218, P232, DOI 10.1016/0167-4781(94)90020-5; Hu ZY, 2009, J CLIN INVEST, V119, P3059, DOI 10.1172/JCI38770; Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200; Ibrahim NM, 2000, BIOTECHNIQUES, V29, P782, DOI 10.2144/00294st04; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Isozaki Y, 1996, P NATL ACAD SCI USA, V93, P1967, DOI 10.1073/pnas.93.5.1967; JURKOVITZ CT, 1992, KIDNEY INT, V42, P595, DOI 10.1038/ki.1992.323; KONAGAYA M, 1986, ENDOCRINOLOGY, V119, P375, DOI 10.1210/endo-119-1-375; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lee JA, 2005, J BIOL CHEM, V280, P28061, DOI 10.1074/jbc.M414134200; Leis H, 2004, MOL ENDOCRINOL, V18, P303, DOI 10.1210/me.2003-0350; Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200; Marinovic AC, 2000, BIOCHEM BIOPH RES CO, V274, P537, DOI 10.1006/bbrc.2000.3171; Marinovic AC, 2007, AM J PHYSIOL-RENAL, V292, pF660, DOI 10.1152/ajprenal.00178.2006; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Nakao R, 2009, MOL CELL BIOL, V29, P4798, DOI 10.1128/MCB.01347-08; Plum L, 2005, PHYSIOLOGY, V20, P152, DOI 10.1152/physiol.00049.2004; PRICE SR, 1994, AM J PHYSIOL-CELL PH, V267, pC955, DOI 10.1152/ajpcell.1994.267.4.C955; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Shabek N, 2009, P NATL ACAD SCI USA, V106, P11907, DOI 10.1073/pnas.0905746106; Shirakami A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740309; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sun XY, 2002, AM J PHYSIOL-REG I, V282, pR509, DOI 10.1152/ajpregu.00509.2001; Thirone ACP, 2006, TRENDS ENDOCRIN MET, V17, P70, DOI 10.1016/j.tem.2006.01.005; Waddell DS, 2008, AM J PHYSIOL-ENDOC M, V295, pE785, DOI 10.1152/ajpendo.00646.2007; Workeneh BT, 2006, J AM SOC NEPHROL, V17, P3233, DOI 10.1681/ASN.2006020131; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	59	92	98	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2660	2669		10.1096/fj.09-151480	http://dx.doi.org/10.1096/fj.09-151480			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371624	Green Published			2022-12-28	WOS:000285005400008
J	Kielbasa, OM; Reynolds, JG; Wu, CL; Snyder, CM; Cho, MY; Weiler, H; Kandarian, S; Naya, FJ				Kielbasa, Ondra M.; Reynolds, Joseph G.; Wu, Chia-Ling; Snyder, Christine M.; Cho, Min Y.; Weiler, Hartmut; Kandarian, Susan; Naya, Francisco J.			Myospryn is a calcineurin-interacting protein that negatively modulates slow-fiber-type transformation and skeletal muscle regeneration	FASEB JOURNAL			English	Article						costamere; scaffolding protein; transgenic mice; calcineurin inhibitor; signaling	SIGNALING PATHWAYS; GENE-EXPRESSION; NFAT ACTIVATION; STRIATED-MUSCLE; BINDING PARTNER; PHOSPHORYLATION; IDENTIFICATION; STIMULATION; DYSTROPHIN; GROWTH	The calcium-calmodulin-regulated protein phosphatase calcineurin plays an important regulatory role in muscle differentiation, fiber-type determination, hypertrophy, and muscle regeneration. Because calcineurin functions in numerous processes in muscle, multiple mechanisms are likely necessary to ensure that the activity of this phosphatase is appropriately regulated. Here we demonstrate that the muscle-specific scaffolding protein myospryn modulates calcineurin signaling by inhibiting calcineurin-dependent transcriptional activity in C2C12 myoblasts through direct interaction with the enzyme via its noncanonical tripartite motif (TRIM-like). Consistent with these data, transgenic mice overexpressing both the TRIM-like domain of myospryn and constitutively active calcineurin displayed a severe attenuation in the ability of calcineurin to induce a slow-fiber phenotype. Furthermore, transgenic mice overexpressing the TRIM-like domain of myospryn displayed attenuated muscle regeneration after cardiotoxin-induced muscle injury. These results indicate that myospryn functions as a novel inhibitor of the calcineurin signaling pathway in skeletal muscle.-Kielbasa, O. M., Reynolds, J. G., Wu, C-l., Snyder, C. M., Cho, M. Y., Weiler, H., Kandarian, S., Naya, F. J. Myospryn is a calcineurin-interacting protein that negatively modulates slow-fiber-type transformation and skeletal muscle regeneration. FASEB J. 25, 2276-2286 (2011). www.fasebj.org	[Kielbasa, Ondra M.; Reynolds, Joseph G.; Snyder, Christine M.; Cho, Min Y.; Naya, Francisco J.] Boston Univ, Dept Biol, Program Cell & Mol Biol, Boston, MA 02215 USA; [Wu, Chia-Ling; Kandarian, Susan] Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA; [Weiler, Hartmut] BloodCtr Wisconsin, Blood Res Inst, Milwaukee, WI USA	Boston University; Boston University; Versiti Blood Center of Wisconsin	Naya, FJ (corresponding author), Boston Univ, Dept Biol, Program Cell & Mol Biol, 24 Cummington St, Boston, MA 02215 USA.	fnaya@bu.edu			U.S. National Institutes of Health/National Heart, Lung, and Blood Institute; Muscular Dystrophy Association	U.S. National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Muscular Dystrophy Association(Muscular Dystrophy Association)	This work was supported by grants from the U.S. National Institutes of Health/National Heart, Lung, and Blood Institute and the Muscular Dystrophy Association to F.J.N. The authors are grateful to Jeffery Molkentin (Cincinnati Children's Hospital, Cincinnati, OH, USA) for the NFAT reporter construct. The authors also thank Eric Olson and Rhonda Bassel-Duby (University of Texas Southwestern, Dallas, TX, USA) for the FLAG-calcineurin constructs.	Abrenica B, 2009, J MOL CELL CARDIOL, V46, P674, DOI 10.1016/j.yjmcc.2009.01.018; Bassel-Duby R, 2003, BIOCHEM BIOPH RES CO, V311, P1133, DOI 10.1016/j.bbrc.2003.09.020; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Benson MA, 2004, J BIOL CHEM, V279, P10450, DOI 10.1074/jbc.M312664200; Durham JT, 2006, J BIOL CHEM, V281, P6841, DOI 10.1074/jbc.M510499200; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Fernandes JMO, 2005, PHYSIOL GENOMICS, V22, P327, DOI 10.1152/physiolgenomics.00087.2005; Frey N, 2008, J CLIN INVEST, V118, P3598, DOI 10.1172/JCI36277; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Kouloumenta A, 2007, J BIOL CHEM, V282, P35211, DOI 10.1074/jbc.M704733200; Li JL, 2010, J MOL CELL CARDIOL, V48, P387, DOI 10.1016/j.yjmcc.2009.10.023; LYONS GE, 1991, DEVELOPMENT, V113, P1017; Martinez-Martinez S, 2006, J BIOL CHEM, V281, P6227, DOI 10.1074/jbc.M513885200; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Oh M, 2005, MOL CELL BIOL, V25, P6629, DOI 10.1128/MCB.25.15.6629-6638.2005; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Reynolds JG, 2008, J BIOL CHEM, V283, P8070, DOI 10.1074/jbc.C700221200; Reynolds JG, 2007, BBA-MOL CELL RES, V1773, P891, DOI 10.1016/j.bbamcr.2007.04.004; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Sakuma K, 2003, ACTA NEUROPATHOL, V105, P271, DOI 10.1007/s00401-002-0647-0; Sanna B, 2006, P NATL ACAD SCI USA, V103, P7327, DOI 10.1073/pnas.0509340103; Sardiello M, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-225; Sarparanta J, 2010, J BIOL CHEM, V285, P30304, DOI 10.1074/jbc.M110.108720; Sarparanta J, 2008, J MUSCLE RES CELL M, V29, P177, DOI 10.1007/s10974-008-9165-6; Schiaffino S, 2007, PHYSIOLOGY, V22, P269, DOI 10.1152/physiol.00009.2007; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; SENTER L, 1995, BIOCHEM BIOPH RES CO, V206, P57, DOI 10.1006/bbrc.1995.1009; Spandidos A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-633; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; Stupka N, 2008, AM J PHYSIOL-REG I, V294, pR983, DOI 10.1152/ajpregu.00375.2007; Stupka N, 2007, AM J PHYSIOL-REG I, V293, pR686, DOI 10.1152/ajpregu.00612.2006; Talmadge RJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-28; Vega RB, 2003, J BIOL CHEM, V278, P36981, DOI 10.1074/jbc.R300023200; WALSH MP, 1995, BIOCHEMISTRY-US, V34, P5561, DOI 10.1021/bi00016a030; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527	41	29	30	2	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2276	2286		10.1096/fj.10-169219	http://dx.doi.org/10.1096/fj.10-169219			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21427212	Green Published, Bronze			2022-12-28	WOS:000292242200019
J	Marquer, C; Devauges, V; Cossec, JC; Liot, G; Lecart, S; Saudou, F; Duyckaerts, C; Leveque-Fort, S; Potier, MC				Marquer, Catherine; Devauges, Viviane; Cossec, Jack-Christophe; Liot, Geraldine; Lecart, Sandrine; Saudou, Frederic; Duyckaerts, Charles; Leveque-Fort, Sandrine; Potier, Marie-Claude			Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis	FASEB JOURNAL			English	Article						Alzheimer's disease; amyloid peptide; fluorescence microscopy	FLUORESCENCE CORRELATION SPECTROSCOPY; CLATHRIN-DEPENDENT MECHANISM; ALZHEIMERS-DISEASE; BETA-SECRETASE; MEMBRANE CHOLESTEROL; HIPPOCAMPAL-NEURONS; BACE; MICROSCOPY; RECEPTOR; PATHWAY	Amyloid peptide (A beta) is generated by sequential cleavage of the amyloid precursor protein (APP) by beta-secretase (Bace1) and gamma-secretase. A beta production increases after plasma membrane cholesterol loading through unknown mechanisms. To determine how APP-Bace1 proximity affects this phenomenon, we developed a fluorescence lifetime imaging microscopy-Forster resonance energy transfer (FLIM-FRET) technique for visualization of these molecules either by epifluorescence or at the plasma membrane only using total internal reflection fluorescence. Further, we used fluorescence correlation spectroscopy to determine the lipid rafts partition of APP-yellow fluorescent protein (YFP) and Bace1-green fluorescent protein (GFP) molecules at the plasma membrane of neurons. We show that less than 10 min after cholesterol exposure, Bace1-GFP/APP-mCherry proximity increases selectively at the membrane and APP relocalizes to raft domains, preceded by rapid endocytosis. After longer cholesterol exposures, APP and Bace1 are found in proximity intracellularly. We demonstrate that cholesterol loading does not increase A beta production by having a direct impact on Bace1 catalytic activity but rather by altering the accessibility of Bace1 to its substrate, APP. This change in accessibility is mediated by clustering in lipid rafts, followed by rapid endocytosis.-Marquer, C., Devauges, V., Cossec, J.-C., Liot, G., Lecart, S., Saudou, F., Duyckaerts, C., Leveque-Fort, S., Potier, M.-C. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J. 25, 1295-1305 (2011). www.fasebj.org	[Marquer, Catherine; Cossec, Jack-Christophe; Duyckaerts, Charles; Potier, Marie-Claude] UPMC, Hop La Pitie Salpetriere, CRICM, INSERM UMR S975,CNRS UMR7225, F-75013 Paris, France; [Devauges, Viviane; Lecart, Sandrine; Leveque-Fort, Sandrine] Univ Paris 11, Ctr Laser, Ctr Photon Biomed, FR2764, Orsay, France; [Devauges, Viviane; Leveque-Fort, Sandrine] Univ Paris 11, CNRS UMR8214, Inst Sci Mol Orsay, Orsay, France; [Liot, Geraldine; Saudou, Frederic] CNRS, INSERM, Inst Curie, Unite Signalisat Neurobiol & Canc,UMR3306,U1005, F-91405 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Potier, MC (corresponding author), UPMC, Hop La Pitie Salpetriere, CRICM, INSERM UMR S975,CNRS UMR7225, F-75013 Paris, France.	marie-claude.potier@upmc.fr	SAUDOU, Frédéric/L-3454-2014	SAUDOU, Frédéric/0000-0001-6107-1046; Potier, Marie-Claude/0000-0003-2462-7150; Cossec, Jack-Christophe/0000-0002-0836-1009; Leveque-Fort, Sandrine/0000-0002-9218-3363; Liot, Geraldine/0000-0002-4784-7693	Ministere de la Recherche; Fondation pour la Recherche Medicale; Agence Nationale de la Recherche; Fondation Institut du Cerveau et de la Moelle	Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Agence Nationale de la Recherche(French National Research Agency (ANR)); Fondation Institut du Cerveau et de la Moelle	The authors gratefully acknowledge Ghislaine Grange and Emilie Jaumain for expert technical help. The authors thank Diana Zala and Adina Lazar for fruitful discussions, and Dr. Bradley Hyman (Massachusetts General Hospital, Charlestown, MA, USA), Dr. Frederic Checler (Institut de Pharmacologie Moleculaire et Cellulaire, Valbonne, France), and Dr. Christoph Kaether (Fritz Lipmann Institute, Leibniz, Germany) for their kind gifts of plasmid. V. D. had a fellowship from Ministere de la Recherche. J.C.C. had a fellowship from Ministere de la Recherche and Fondation pour la Recherche Medicale. This work was supported by a grant from Agence Nationale de la Recherche. The authors are also grateful to the Fondation Institut du Cerveau et de la Moelle for their financial support. The authors declare no conflict of interest.	Abad-Rodriguez J, 2004, J CELL BIOL, V167, P953, DOI 10.1083/jcb.200404149; Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; ALLINQUANT B, 1994, J NEUROSCI, V14, P6842; Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Bacia K, 2004, BIOPHYS J, V87, P1034, DOI 10.1529/biophysj.104.040519; Beel AJ, 2008, BIOCHEMISTRY-US, V47, P9428, DOI 10.1021/bi800993c; Blandin P, 2009, APPL OPTICS, V48, P553, DOI 10.1364/AO.48.000553; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cossec JC, 2010, BBA-MOL CELL BIOL L, V1801, P846, DOI 10.1016/j.bbalip.2010.05.010; Cossec JC, 2010, BBA-MOL CELL BIOL L, V1801, P839, DOI 10.1016/j.bbalip.2010.03.010; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Deinhardt K, 2006, J CELL BIOL, V174, P459, DOI 10.1083/jcb.200508170; Eggert S, 2009, J BIOL CHEM, V284, P28943, DOI 10.1074/jbc.M109.038646; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Gralle M, 2009, J BIOL CHEM, V284, P15016, DOI 10.1074/jbc.M808755200; Hansen GH, 2005, BIOCHEMISTRY-US, V44, P873, DOI 10.1021/bi047959+; Hudry E, 2010, MOL THER, V18, P44, DOI 10.1038/mt.2009.175; Kaether C, 2000, MOL BIOL CELL, V11, P1213, DOI 10.1091/mbc.11.4.1213; Kahya N, 2003, J BIOL CHEM, V278, P28109, DOI 10.1074/jbc.M302969200; Kalvodova L, 2005, J BIOL CHEM, V280, P36815, DOI 10.1074/jbc.M504484200; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Liu WW, 2009, J NEUROCHEM, V108, P341, DOI 10.1111/j.1471-4159.2008.05753.x; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Morris DP, 2008, J BIOL CHEM, V283, P2973, DOI 10.1074/jbc.M705795200; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Munter LM, 2007, EMBO J, V26, P1702, DOI 10.1038/sj.emboj.7601616; Panchal M, 2010, J LIPID RES, V51, P598, DOI 10.1194/jlr.M001859; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Rajendran L, 2008, SCIENCE, V320, P520, DOI 10.1126/science.1156609; Requejo-Isidro J, 2004, OPT LETT, V29, P2249, DOI 10.1364/OL.29.002249; Rollason R, 2007, J CELL SCI, V120, P3850, DOI 10.1242/jcs.003343; Sarnataro D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005829; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; Schneider A, 2008, J NEUROSCI, V28, P2874, DOI 10.1523/JNEUROSCI.5345-07.2008; Selkoe Dennis J, 2008, Handb Clin Neurol, V89, P245, DOI 10.1016/S0072-9752(07)01223-7; Sharma P, 2002, SEMIN CELL DEV BIOL, V13, P205, DOI 10.1016/S1084-9521(02)00049-6; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; Vetrivel KS, 2010, BBA-MOL CELL BIOL L, V1801, P860, DOI 10.1016/j.bbalip.2010.03.007; von Arnim CAF, 2008, BIOCHEM BIOPH RES CO, V370, P207, DOI 10.1016/j.bbrc.2008.03.047; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; Xiong HQ, 2008, NEUROBIOL DIS, V29, P422, DOI 10.1016/j.nbd.2007.10.005; Yanagisawa K, 1998, NEUROBIOL AGING, V19, pS65, DOI 10.1016/S0197-4580(98)00032-3; Yoon IS, 2007, FASEB J, V21, P2742, DOI 10.1096/fj.07-8114com	51	124	131	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1295	1305		10.1096/fj.10-168633	http://dx.doi.org/10.1096/fj.10-168633			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21257714				2022-12-28	WOS:000288982800018
J	Kwak, HB; Kim, JH; Joshi, K; Yeh, A; Martinez, DA; Lawler, JM				Kwak, Hyo-Bum; Kim, Jong-hee; Joshi, Kumar; Yeh, Alvin; Martinez, Daniel A.; Lawler, John M.			Exercise training reduces fibrosis and matrix metalloproteinase dysregulation in the aging rat heart	FASEB JOURNAL			English	Article						TIMP-1; collagen; remodeling	COLLAGEN CROSS-LINKING; EXTRACELLULAR-MATRIX; MYOCARDIAL COLLAGEN; CARDIAC FIBROBLASTS; CALORIC RESTRICTION; DIASTOLIC FUNCTION; PHYSICAL-ACTIVITY; GENE-EXPRESSION; LEFT-VENTRICLE; GROWTH-FACTOR	Aging impairs function in the nonischemic heart and is associated with mechanical remodeling. This process includes accumulation of collagen (i.e., fibrosis) and dysregulation of active matrix metalloproteinases (MMPs). Exercise training (ET) improves cardiac function, but the pathways of protection remain poorly understood. Young (3 mo) and old (31 mo) FBNF1 rats were assigned into sedentary and exercise groups, with ET group rats training on a treadmill 45 min/d, 5 d/wk for 12 wk. Nonlinear optical microscopy (NLOM), histology, immunohistochemistry (IHC), and Western blot analyses were performed on the left ventricle and septum. NLOM, IHC, and histological imaging revealed that ET reduced age-associated elevation of collagen type I fibers. Active MMP-1, active MMP-2, and MMP-14 in the ECM fraction of the left ventricle were reduced by aging, an effect abrogated by ET. Tissue inhibitor of MMP (TIMP-1) was elevated with age but protected by ET. Transforming growth factor-beta (TGF-beta), upstream regulator of TIMP-1, increased with age but was attenuated by ET. Therefore, exercise training could protect the aging heart against dysregulation of MMPs and fibrosis by suppressing elevation of TIMP-1 and TGF-beta.-Kwak, H.-B., Kim, J.-H., Joshi, K., Yeh, A., Martinez, D. A., Lawler, J. M. Exercise training reduces fibrosis and matrix metalloproteinase dysregulation in the aging rat heart. FASEB J. 25, 1106-1117 (2011). www.fasebj.org	[Lawler, John M.] Texas A&M Univ, Redox Biol & Cell Signaling Lab, Dept Hlth & Kinesiol, Dept Biomed Engn, College Stn, TX 77843 USA; [Kwak, Hyo-Bum] E Carolina Univ, E Carolina Diabet & Obes Inst, Dept Exercise & Sports Sci, Dept Physiol,Brody Sch Med, Greenville, NC USA; [Martinez, Daniel A.] Univ Houston, Dept Mech Engn, Connect Tissue Physiol Lab, Houston, TX USA	Texas A&M University System; Texas A&M University College Station; University of North Carolina; East Carolina University; University of Houston System; University of Houston	Lawler, JM (corresponding author), Texas A&M Univ, Redox Biol & Cell Signaling Lab, Dept Hlth & Kinesiol, Dept Biomed Engn, 276B Read Bldg, College Stn, TX 77843 USA.	jml2621@neo.tamu.edu		Kwak, Hyo Bum/0000-0003-0451-4554	American Heart Association [0555064Y, 0855158F]; U.S. National Institutes of Health [AR054084]; Sydney and J. L. Huffines Institute for Sports Medicine; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR054084] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sydney and J. L. Huffines Institute for Sports Medicine; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Funding for this study was provided by support from the American Heart Association (0555064Y, 0855158F), the U.S. National Institutes of Health (AR054084), and the Sydney and J. L. Huffines Institute for Sports Medicine.	Arbab-Zadeh A, 2004, CIRCULATION, V110, P1799, DOI 10.1161/01.CIR.0000142863.71285.74; Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; BERLEW BS, 2004, AM J GERIATR CARDIOL, V13, P29; Bing Oscar H L, 2002, Heart Fail Rev, V7, P71; Bonnema DD, 2007, J CARD FAIL, V13, P530, DOI 10.1016/j.cardfail.2007.04.010; Booth FW, 2000, J APPL PHYSIOL, V88, P774, DOI 10.1152/jappl.2000.88.2.774; Camelliti P, 2005, CARDIOVASC RES, V65, P40, DOI 10.1016/j.cardiores.2004.08.020; CAPASSO JM, 1990, AM J PHYSIOL, V259, pH1086, DOI 10.1152/ajpheart.1990.259.4.H1086; Chen MM, 2000, J MOL CELL CARDIOL, V32, P1805, DOI 10.1006/jmcc.2000.1215; Choi SY, 2009, J KOREAN MED SCI, V24, P32, DOI 10.3346/jkms.2009.24.1.32; Chung EH, 2006, FASEB J, V20, pA1447; de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486; Debessa CRG, 2001, MECH AGEING DEV, V122, P1049; DICENTURIONE L, 2005, MECH AGEING DEV, V124, P957; EGHBALI M, 1989, CARDIOVASC RES, V23, P723, DOI 10.1093/cvr/23.8.723; Fedak PWM, 2003, AM J PHYSIOL-HEART C, V284, pH626, DOI 10.1152/ajpheart.00684.2002; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gielen Stephan, 2005, Heart Fail Monit, V4, P130; Goldsmith EC, 2002, J CARD FAIL, V8, pS314, DOI 10.1054/jcaf.2002.129258; Goldspink DF, 2005, ERGONOMICS, V48, P1334, DOI 10.1080/00140130500101247; Hwang HS, 2007, J GERONTOL A-BIOL, V62, P382, DOI 10.1093/gerona/62.4.382; Jin HK, 2000, AM J PHYSIOL-HEART C, V279, pH2994, DOI 10.1152/ajpheart.2000.279.6.H2994; Jugdutt Bodh I., 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P1, DOI 10.2174/1568006033337276; Kassiri Z, 2005, THROMB HAEMOSTASIS, V93, P212, DOI 10.1160/TH04-08-0522; Kim JH, 2008, EXP GERONTOL, V43, P317, DOI 10.1016/j.exger.2007.12.012; KWAK HB, 2008, FASEB J, V22; Kwak HB, 2006, FASEB J, V20, P791, DOI 10.1096/fj.05-5116fje; Lalu MM, 2005, EUR HEART J, V26, P27, DOI 10.1093/eurheratj/ehi007; Lawler JM, 2009, AM J PHYSIOL-REG I, V296, pR1496, DOI 10.1152/ajpregu.90314.2008; Lee PF, 2009, EXP CELL RES, V315, P396, DOI 10.1016/j.yexcr.2008.10.040; Lovelock JD, 2005, AM J PHYSIOL-HEART C, V288, pH461, DOI 10.1152/ajpheart.00402.2004; Lumens J, 2006, AM J PHYSIOL-HEART C, V291, pH1573, DOI 10.1152/ajpheart.00074.2006; Lunardi M, 1993, G Ital Cardiol, V23, P673; Martinez DA, 2007, AM J PHYSIOL-REG I, V293, pR1552, DOI 10.1152/ajpregu.00423.2007; Masson S, 2005, MED INTELL UNIT, P97; Nottin S, 2004, ACTA PHYSIOL SCAND, V181, P209, DOI 10.1111/j.1365-201X.2004.01284.x; Olfert IM, 2004, J GERONTOL A-BIOL, V59, P801; Prasad A, 2007, AM J CARDIOL, V99, P1629, DOI 10.1016/j.amjcard.2007.01.050; Pugh KG, 2001, DRUG AGING, V18, P263, DOI 10.2165/00002512-200118040-00004; Quindry J, 2005, EXP GERONTOL, V40, P416, DOI 10.1016/j.exger.2005.03.010; Robert V, 1997, LAB INVEST, V76, P729; Rohrbach S, 2006, EXP GERONTOL, V41, P525, DOI 10.1016/j.exger.2006.02.001; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Sivasubramanian N, 2001, CIRCULATION, V104, P826, DOI 10.1161/hc3401.093154; Starnes JW, 2003, AM J PHYSIOL-HEART C, V285, pH347, DOI 10.1152/ajpheart.00952.2002; Stewart S, 2003, HEART, V89, P49, DOI 10.1136/heart.89.1.49; TAKEMOTO KA, 1992, AM HEART J, V124, P143, DOI 10.1016/0002-8703(92)90932-L; Tanaka H, 2008, J PHYSIOL-LONDON, V586, P55, DOI 10.1113/jphysiol.2007.141879; Taylor RP, 2003, ACTA PHYSIOL SCAND, V178, P107, DOI 10.1046/j.1365-201X.2003.01132.x; Thomas CV, 1998, CIRCULATION, V97, P1708, DOI 10.1161/01.CIR.97.17.1708; Thomas DP, 2000, J APPL PHYSIOL, V89, P1462, DOI 10.1152/jappl.2000.89.4.1462; Thomas DP, 2001, EUR J APPL PHYSIOL, V85, P164, DOI 10.1007/s004210100447; Tikellis C, 2004, ENDOCRINOLOGY, V145, P860, DOI 10.1210/en.2003-0967; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Torella D, 2004, CIRC RES, V94, P514, DOI 10.1161/01.RES.0000117306.10142.50; Tsuruda T, 2004, HEART FAIL REV, V9, P53, DOI 10.1023/B:HREV.0000011394.34355.bb; Tsutsui H, 2007, HYPERTENS RES, V30, P439, DOI 10.1291/hypres.30.439; Van Linthout S, 2008, BASIC RES CARDIOL, V103, P319, DOI 10.1007/s00395-008-0715-2; VINCENTI MP, 2001, MATRIX METALLOPROTEI, V151, P5; Woodiwiss AJ, 1998, EUR J APPL PHYSIOL, V78, P148, DOI 10.1007/s004210050400; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	61	68	77	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1106	1117		10.1096/fj.10-172924	http://dx.doi.org/10.1096/fj.10-172924			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21148111	Green Published			2022-12-28	WOS:000287806200030
J	Lee, MH; Padmashali, R; Koria, P; Andreadis, ST				Lee, Meng-Horng; Padmashali, Roshan; Koria, Piyush; Andreadis, Stelios T.			JNK regulates binding of alpha-catenin to adherens junctions and cell-cell adhesion	FASEB JOURNAL			English	Article						beta-catenin; junctional actin	HUMAN EPIDERMAL-CELLS; E-CADHERIN; BETA-CATENIN; ACTIN POLYMERIZATION; TUMOR-SUPPRESSOR; CONTACTS; MECHANISM; ACTIVATION; CAVEOLAE; CANCER	We recently reported that c-Jun N-terminal kinase (JNK) is associated with adherens junctions and phosphorylates beta-catenin at serine 33/37 and threonine 41. Here, we report that inhibition of JNK led to formation of adherens junctions, which was accompanied by dissociation of alpha-catenin from the beta-catenin/E-cadherin complex and increased association of alpha-catenin with the cytoskeleton. Conversely, activation of JNK increased binding of alpha-catenin to beta-catenin, which was blocked by the JNK inhibitor SP600125 or JNK siRNA. In addition, inhibition of JNK failed to lead to adherens junction formation in cells where alpha-catenin was absent or knocked down. Conversely, introduction of alpha-catenin restored the responsiveness of cells to JNK inhibition and led to cell-cell adhesion. Experiments with domain deletion mutants showed that binding of alpha-catenin to beta-catenin was required for transport of adherens junction complexes to the cell surface, while binding to actin was required for translocation to the cell-cell contact sites. Collectively, our results suggest that JNK affects the association of alpha-catenin with the adherens junction complex and regulates adherens junctions.-Lee, M.-H., Padmashali, R., Koria, P., Andreadis, S. T. JNK regulates binding of alpha-catenin to adherens junctions and cell-cell adhesion. FASEB J. 25, 613-623 (2011). www.fasebj.org	[Lee, Meng-Horng; Padmashali, Roshan; Koria, Piyush; Andreadis, Stelios T.] SUNY Buffalo, Bioengn Lab, Dept Chem & Biol Engn, Amherst, NY 14260 USA; [Andreadis, Stelios T.] SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Amherst, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Andreadis, ST (corresponding author), SUNY Buffalo, Bioengn Lab, Dept Chem & Biol Engn, 908 Furnas Hall, Amherst, NY 14260 USA.	sandread@buffalo.edu			U.S. National Institutes of Health [R01 EB000876]; National Science Foundation [BES- 0354626]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000876] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was supported by grants from the U.S. National Institutes of Health (R01 EB000876) and National Science Foundation (BES- 0354626) to S.T.A.	Atkinson SJ, 2004, J BIOL CHEM, V279, P5194, DOI 10.1074/jbc.M306973200; Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; Bajpai S, 2009, J BIOL CHEM, V284, P18252, DOI 10.1074/jbc.M109.000661; Bajpai S, 2008, P NATL ACAD SCI USA, V105, P18331, DOI 10.1073/pnas.0806783105; Bek S, 2002, J CELL SCI, V115, P4743, DOI 10.1242/jcs.00154; Brevier J, 2008, PHYS BIOL, V5, DOI 10.1088/1478-3975/5/1/016005; Cavey M, 2008, NATURE, V453, P751, DOI 10.1038/nature06953; Chu YS, 2004, J CELL BIOL, V167, P1183, DOI 10.1083/jcb.200403043; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Koria P, 2006, J INVEST DERMATOL, V126, P1834, DOI 10.1038/sj.jid.5700325; Lee MH, 2009, FASEB J, V23, P3874, DOI 10.1096/fj.08-117804; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Liu JY, 2008, CARDIOVASC RES, V79, P24, DOI 10.1093/cvr/cvn059; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Orlichenko L, 2009, MOL BIOL CELL, V20, P4140, DOI 10.1091/mbc.E08-10-1043; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Pokutta S, 2008, BIOCHEM SOC T, V36, P141, DOI 10.1042/BST0360141; Pokutta S, 2007, ANNU REV CELL DEV BI, V23, P237, DOI 10.1146/annurev.cellbio.22.010305.104241; Scott JA, 2006, MOL BIOL CELL, V17, P1085, DOI 10.1091/mbc.e05-07-0644; Serres M, 1997, EXP CELL RES, V231, P163, DOI 10.1006/excr.1996.3443; Stickney JT, 2004, CANCER RES, V64, P2717, DOI 10.1158/0008-5472.CAN-03-3798; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Tian J, 2008, MOL THER, V16, P1146, DOI 10.1038/mt.2008.79; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Zhang JK, 2005, J CELL SCI, V118, P5549, DOI 10.1242/jcs.02639; Zhu Y, 2003, BBA-MOL CELL BIOL L, V1635, P117, DOI 10.1016/j.bbalip.2003.10.011	29	31	31	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					613	623		10.1096/fj.10-161380	http://dx.doi.org/10.1096/fj.10-161380			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21030692	Green Published			2022-12-28	WOS:000286724800019
J	Beattie, JR; Pawlak, AM; Boulton, ME; Zhang, JY; Monnier, VM; McGarvey, JJ; Stitt, AW				Beattie, J. Renwick; Pawlak, Anna M.; Boulton, Michael E.; Zhang, Jianye; Monnier, Vincent M.; McGarvey, John J.; Stitt, Alan W.			Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane	FASEB JOURNAL			English	Article						advanced glycation endproducts; advanced lipoxidation endproducts; hemoglobin; Raman spectroscopy; aging	GLYCATION END-PRODUCTS; RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; RAMAN-SPECTROSCOPY; AREA CENTRALIS; VITAMIN-E; MICROSCOPY; PREDICTION; RECEPTORS; DISEASE	Aging of the human retina is characterized by progressive pathology, which can lead to vision loss. This progression is believed to involve reactive metabolic intermediates reacting with constituents of Bruch's membrane, significantly altering its physiochemical nature and function. We aimed to replace a myriad of techniques following these changes with one, Raman spectroscopy. We used multiplexed Raman spectroscopy to analyze the age-related changes in 7 proteins, 3 lipids, and 8 advanced glycation/lipoxidation endproducts (AGEs/ALEs) in 63 postmortem human donors. We provided an important database for Raman spectra from a broad range of AGEs and ALEs, each with a characteristic fingerprint. Many of these adducts were shown for the first time in human Bruch's membrane and are significantly associated with aging. The study also introduced the previously unreported up-regulation of heme during aging of Bruch's membrane, which is associated with AGE/ALE formation. Selection of donors ranged from ages 32 to 92 yr. We demonstrated that Raman spectroscopy can identify and quantify age-related changes in a single nondestructive measurement, with potential to measure age-related changes in vivo. We present the first directly recorded evidence of the key role of heme in AGE/ALE formation.-Beattie, J. R., Pawlak, A. M., Boulton, M. E., Zhang, J., Monnier, V. M., McGarvey, J. J., Stitt, A. W. Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane. FASEB J. 24, 4816-4824 (2010). www.fasebj.org	[Beattie, J. Renwick; Pawlak, Anna M.; Stitt, Alan W.] Queens Univ Belfast, Ctr Vis & Vasc Sci, Sch Med & Dent, Belfast BT12 6BA, Antrim, North Ireland; [McGarvey, John J.] Queens Univ Belfast, Sch Chem & Chem Engn, Belfast BT12 6BA, Antrim, North Ireland; [Boulton, Michael E.] Univ Florida, Gainesville, FL USA; [Zhang, Jianye; Monnier, Vincent M.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	Queens University Belfast; Queens University Belfast; State University System of Florida; University of Florida; Case Western Reserve University	Stitt, AW (corresponding author), Queens Univ Belfast, Ctr Vis & Vasc Sci, Sch Med & Dent, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.	a.stitt@qub.ac.uk	Beattie, James Renwick/I-4506-2015; Stitt, Alan/A-9842-2009; Pawlak, Anna/A-7904-2016	Beattie, James Renwick/0000-0002-0205-717X; Stitt, Alan/0000-0002-8647-9918; Pawlak, Anna/0000-0002-2911-6125	UK Medical Research Council [G0600053]; Leverhume Trust [EM/2006/0049]; Research and Development Office of Northern Ireland [SPI/2384/03]; U.S. National Institutes of Health [ES011985]; UK Biotechnology and Biological Sciences Research Council [JREI 18471]; Medical Research Council [G0600053] Funding Source: researchfish; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011985] Funding Source: NIH RePORTER; MRC [G0600053] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Leverhume Trust; Research and Development Office of Northern Ireland; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Research was supported by the UK Medical Research Council (G0600053), the Leverhume Trust (EM/2006/0049), the Research and Development Office of Northern Ireland (SPI/2384/03), and the U.S. National Institutes of Health (ES011985). Purchase of the Raman microscope was assisted by funding from the UK Biotechnology and Biological Sciences Research Council (JREI 18471). The authors also thank the Bristol Eye Bank (Bristol, UK) for the donation of clinical material used in this study. Creation of the AGE/ALE database was dependent on the generosity of several individuals: Prof. Uchida (Nagoya University, Japan), Prof. Nagaraj (Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH, USA), and Dr. Rozanowska (School of Optometry and Visual Sciences, Cardiff University, Cardiff, UK).	Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4; Bazan N G, 1989, Prog Clin Biol Res, V312, P95; BAZAN NG, 1982, VISION RES, V22, P1539, DOI 10.1016/0042-6989(82)90221-8; Beattie JR, 2007, MOL VIS, V13, P1106; Beattie JR, 2007, FASEB J, V21, P766, DOI 10.1096/fj.06-7028com; Beattie JR, 2009, J RAMAN SPECTROSC, V40, P429, DOI 10.1002/jrs.2146; Beattie JR, 2005, MOL VIS, V11, P825; Beattie JR, 2004, LIPIDS, V39, P407, DOI 10.1007/s11745-004-1245-z; Beattie RJ, 2004, MEAT SCI, V66, P903, DOI 10.1016/j.meatsci.2003.08.012; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9; Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002; BORCHMAN D, 1995, CURR EYE RES, V14, P511, DOI 10.3109/02713689509003763; Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8; Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212; Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265; de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326; Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055; Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com; Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016; Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200; Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200; Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t; Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3; Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775; Harding J., 1991, CATARACT BIOCH EPIDE; Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709; Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z; Howes KA, 2004, INVEST OPHTH VIS SCI, V45, pU906; Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011; Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629; Januszewski AS, 2003, BIOCHEM SOC T, V31, P1413; Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468; Karachalias N, 2010, DIABETOLOGIA, V53, P1506, DOI 10.1007/s00125-010-1722-z; Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6; Long EK, 2010, FREE RADICAL BIO MED, V49, P1, DOI 10.1016/j.freeradbiomed.2010.03.015; MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607; MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781; Monnier VM, 2003, ARCH BIOCHEM BIOPHYS, V419, P1, DOI 10.1016/j.abb.2003.08.014; Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373; Pauleikhoff D, 2000, OPHTHALMOLOGE, V97, P243, DOI 10.1007/s003470050520; Pawlak AM, 2008, ANN NY ACAD SCI, V1126, P59, DOI 10.1196/annals.1433.066; Pawlak AM, 2008, J RAMAN SPECTROSC, V39, P1635, DOI 10.1002/jrs.2011; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448; SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002; Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172; Sell DR, 2007, BIOCHEM J, V404, P269, DOI 10.1042/BJ20061645; Sen S, 2005, BIOPHYS CHEM, V113, P289, DOI 10.1016/j.bpc.2004.05.005; Shih S, 2003, ARCH BIOCHEM BIOPHYS, V420, P79, DOI 10.1016/j.abb.2003.09.015; Sideroudi TI, 2006, LASER SURG MED, V38, P695, DOI 10.1002/lsm.20360; Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984; Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066; Stitt AW, 1997, AM J PATHOL, V150, P523; Suttnar J, 1997, ANAL BIOCHEM, V249, P20, DOI 10.1006/abio.1997.2157; Tanito M, 2009, J LIPID RES, V50, P807, DOI 10.1194/jlr.M800170-JLR200; Tezel TH, 2009, INVEST OPHTH VIS SCI, V50, P1911, DOI 10.1167/iovs.07-1372; Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102; Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376; Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005	62	48	48	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2010	24	12					4816	4824		10.1096/fj.10-166090	http://dx.doi.org/10.1096/fj.10-166090			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20686107	Green Published			2022-12-28	WOS:000284824400021
J	Yang, X; Xie, XQ; Chen, L; Zhou, H; Wang, Z; Zhao, WJ; Tian, R; Zhang, RG; Tian, CL; Long, JF; Shen, YQ				Yang, Xue; Xie, Xingqiao; Chen, Liu; Zhou, Hao; Wang, Zheng; Zhao, Weijing; Tian, Ran; Zhang, Rongguang; Tian, Changlin; Long, Jiafu; Shen, Yuequan			Structural basis for tandem L27 domain-mediated polymerization	FASEB JOURNAL			English	Article						cell polarity; MAGUK protein; tripartite complex; paramagnetic relaxation enhancement	CELL POLARITY COMPLEXES; LARGE TUMOR-SUPPRESSOR; MAGUK PROTEIN; LIN-7; BINDS; LOCALIZATION; MECHANISMS; JUNCTIONS; ADHESION; HOMOLOG	The establishment of epithelial cell polarity requires the assembly of multiprotein complexes and is crucial during epithelial morphogenesis. Three scaffolding proteins, Dlg1, MPP7, and Mals3, can be assembled to form a complex that functions in the establishment and maintenance of apicobasal polarity in epithelial tissues through their L27 domains. Here we report the crystal structure of a 4-L27-domain complex derived from the human tripartite complex Dlg1-MPP7-Mals3 in combination with paramagnetic relaxation enhancement measurements. The heterotrimer consists of 2 pairs of heterodimeric L27 domains. These 2 dimers are asymmetric due to the large difference between the N- and C-terminal tandem L27 domain of MPP7. Structural analysis combined with biochemical experiments further reveals that the loop alpha A-alpha B and helix alpha B of the C-terminal L27 domain of MPP7 play a critical role in assembling the entire tripartite complex, suggesting a synergistic tandem L27-mediated assembling event.-Yang, X., Xie, X., Chen, L., Zhou, H., Wang, Z., Zhao, W., Tian, R., Zhang, R., Tian, C., Long, J., Shen, Y. Structural basis for tandem L27 domain- mediated polymerization. FASEB J. 24, 4806-4815 (2010). www.fasebj.org	[Yang, Xue; Xie, Xingqiao; Zhou, Hao; Wang, Zheng; Zhao, Weijing; Tian, Ran; Long, Jiafu; Shen, Yuequan] Nankai Univ, Tianjin Key Lab Prot Sci, Coll Life Sci, Tianjin 300071, Peoples R China; [Chen, Liu; Tian, Changlin] Univ Sci & Technol China, Sch Life Sci, Hefei, Anhui, Peoples R China; [Zhang, Rongguang] Chinese Acad Sci, Inst Biophys, Beijing 100080, Peoples R China	Nankai University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Long, JF (corresponding author), Nankai Univ, Tianjin Key Lab Prot Sci, Coll Life Sci, Tianjin 300071, Peoples R China.	jflong@nankai.edu.cn; yuequan74@yahoo.com	Zhou, Hao/G-9693-2019; Shen, Yuequan/C-8950-2013; Tian, Changlin/P-1469-2014; Long, Jiafu/B-7420-2012	Zhou, Hao/0000-0001-6813-648X; Shen, Yuequan/0000-0002-3775-0900; Long, Jiafu/0000-0002-6625-0147	973 Program [2007CB914301, 2009CB825504, 2006CB910204]; 863 Program [2006AA02A319, 2006AA02A321]; National Natural Science Foundation of China (NSFC) [30940015, 30700122]; TBR Program [08QTPTJC28200, 08SYSYTC00200, 08JC-ZDJC20500]; New Century Excellent Talents in University (NCET) [NCET-07-0458, NCET-07-0456]	973 Program(National Basic Research Program of China); 863 Program(National High Technology Research and Development Program of China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); TBR Program; New Century Excellent Talents in University (NCET)(Program for New Century Excellent Talents in University (NCET))	The authors thank Dr. Mingjie Zhang (Hong Kong University of Science and Technology, Hong Kong, China) for critical comments, and the staff at the beamline 3W1A of the Beijing Synchrotron Radiation Facility (Beijing, China) and at the beamline 19-ID of the Advanced Photon Source in Argonne National Laboratory (Argonne, IL, USA) for excellent technical assistance during data collection. This work was funded by the 973 Program (grants 2007CB914301, 2009CB825504, and 2006CB910204), the 863 Program (grants 2006AA02A319 and 2006AA02A321), the National Natural Science Foundation of China (NSFC; grants 30940015 and 30700122), and the TBR Program (grants 08QTPTJC28200, 08SYSYTC00200, and 08JC-ZDJC20500). Both Y.S. and J.L. were also supported by New Century Excellent Talents in University (NCET) programs (NCET-07-0458 and NCET-07-0456).	Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Banks L, 2008, ONCOGENE, V27, P6876, DOI 10.1038/onc.2008.339; Battiste JL, 2000, BIOCHEMISTRY-US, V39, P5355, DOI 10.1021/bi000060h; Bhoj EJ, 2009, MOL CYTOGENET, V2, DOI 10.1186/1755-8166-2-5; Bohl J, 2007, J BIOL CHEM, V282, P9392, DOI 10.1074/jbc.M610002200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W.L, PYMOL MOL GRAPHICS S; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Feng W, 2005, P NATL ACAD SCI USA, V102, P6861, DOI 10.1073/pnas.0409346102; Feng W, 2004, NAT STRUCT MOL BIOL, V11, P475, DOI 10.1038/nsmb751; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Hamanoue H, 2009, AM J MED GENET A, V149A, P336, DOI 10.1002/ajmg.a.32656; Harris BZ, 2002, J BIOL CHEM, V277, P34902, DOI 10.1074/jbc.M205856200; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Karnak D, 2002, J BIOL CHEM, V277, P46730, DOI 10.1074/jbc.M208781200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Li YH, 2004, EMBO J, V23, P2723, DOI 10.1038/sj.emboj.7600294; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Nakagawa T, 2004, NEURON, V44, P453, DOI 10.1016/j.neuron.2004.10.012; Olsen O, 2007, J CELL BIOL, V179, P151, DOI 10.1083/jcb.200702054; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Schock F, 2002, ANNU REV CELL DEV BI, V18, P463, DOI 10.1146/annurev.cellbio.18.022602.131838; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; Straight SW, 2006, J BIOL CHEM, V281, P37738, DOI 10.1074/jbc.M607059200; Stucke VM, 2007, MOL BIOL CELL, V18, P1744, DOI 10.1091/mbc.E06-11-0980; Van Horn WD, 2010, BBA-BIOMEMBRANES, V1798, P140, DOI 10.1016/j.bbamem.2009.08.022; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Zwart Peter H., 2008, V426, P419, DOI 10.1007/978-1-60327-058-8_28	38	9	12	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4806	4815		10.1096/fj.10-163857	http://dx.doi.org/10.1096/fj.10-163857			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20702775				2022-12-28	WOS:000284824400020
J	Idris, AI; Krishnan, M; Simic, P; Landao-Bassonga, E; Mollat, P; Vukicevic, S; Ralston, SH				Idris, Aymen I.; Krishnan, Maala; Simic, Petra; Landao-Bassonga, Euphemie; Mollat, Patrick; Vukicevic, Slobodan; Ralston, Stuart H.			Small molecule inhibitors of I kappa B kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo	FASEB JOURNAL			English	Article						IKK; TAK1; NF kappa B; osteoblast; osteoporosis	HIGHLY SELECTIVE INHIBITOR; MICE; DIFFERENTIATION; ARTHRITIS; APOPTOSIS; BLOCKS; ALPHA; INFLAMMATION; PARTHENOLIDE; BMS-345541	The NF kappa B pathway plays a critical role in the regulation of osteoclast activity, and activation of the pathway is dependent on I kappa B kinase (IKK), which phosphorylates I kappa B, targeting it for proteasomal degradation. Pharmacological inhibitors of IKK exhibit anti-inflammatory properties and prevent bone erosions in models of inflammatory arthritis. However, the effects of these agents on osteoblast function and ovariectomy-induced bone loss remain unknown. Here we examined the effects of the IKK inhibitors celastrol, BMS-345541, and parthenolide on bone cell function in vitro and ovariectomy-induced bone loss in vivo. All three compounds inhibited RANKL-induced signaling in osteoclasts, caused osteoclast apoptosis, and inhibited osteoclast formation. Although parthenolide and BMS-345541 had no inhibitory effects on osteoblast function, celastrol prevented IL1 beta-induced TAK1 activation and inhibited osteoblast growth, differentiation, and bone nodule formation. The selective IKK inhibitors parthenolide and BMS-345541 prevented ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption. We conclude that pharmacological inhibitors of IKK inhibit several critical signaling pathways in osteoclasts necessary for cell survival, formation, and activity in vitro and bone loss in vivo. Accordingly, IKK inhibitors may be of value in the prevention and treatment of bone diseases characterized by increased bone loss such as postmenopausal osteoporosis.-Idris, A. I., Krishnan, M., Simic, P., Landao-Bassonga, E., Mollat, P., Vukicevic, S., Ralston, S. H. Small molecule inhibitors of I kappa B kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. FASEB J. 24, 4545-4555 (2010). www.fasebj.org	[Idris, Aymen I.; Krishnan, Maala; Landao-Bassonga, Euphemie; Ralston, Stuart H.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland; [Simic, Petra; Vukicevic, Slobodan] Univ Zagreb, Sch Med, Dept Anat, Zagreb 41001, Croatia; [Mollat, Patrick] Galapagos Soc Act Simplifiee Unipersonnelle, Romainville, France	University of Edinburgh; University of Zagreb	Ralston, SH (corresponding author), Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	stuart.ralston@ed.ac.uk	Vukicevic, Slobodan/AEG-2646-2022; Idris, Aymen I/AAX-1138-2020	Vukicevic, Slobodan/0000-0003-4076-0285; Idris, Aymen I/0000-0003-4327-5306; Landao-Bassonga, Euphemie/0000-0002-5142-2946	Arthritis Research Campaign (UK) (ARC) [17687, 15389]; European Calcified Tissue Society (ECTS)/Amgen	Arthritis Research Campaign (UK) (ARC)(Versus Arthritis); European Calcified Tissue Society (ECTS)/Amgen(Amgen)	These studies were supported in part by grants from the Arthritis Research Campaign (UK) (ARC 17687 and 15389) and by an European Calcified Tissue Society (ECTS)/Amgen fellowship grant to A.I.I.	Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200; Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200; Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924; Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Hehner SP, 1999, J IMMUNOL, V163, P5617; Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Idris A, 2008, BIOCHEM BIOPH RES CO, V371, P94, DOI 10.1016/j.bbrc.2008.04.014; Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008-0150; Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223-008-9104-y; Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158/1535-7163.MCT-09-0133; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320; Karin M, 2008, CELL RES, V18, P334, DOI 10.1038/cr.2008.30; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459; McIntyre KW, 2003, ARTHRITIS RHEUM-US, V48, P2652, DOI 10.1002/art.11131; Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002-9440(10)63016-7; Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081; Schopf L, 2006, ARTHRITIS RHEUM-US, V54, P3163, DOI 10.1002/art.22081; Sethi G, 2007, BLOOD, V109, P2727, DOI 10.1182/blood-2006-10-050807; Stewart TL, 2005, CALCIFIED TISSUE INT, V77, P113, DOI 10.1007/s00223-004-0188-8; Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; VANTHOF RJ, 2003, BONE RES PROTOCOLS, P145; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yang JM, 2006, CLIN CANCER RES, V12, P950, DOI 10.1158/1078-0432.CCR-05-1220; Yip KH, 2004, J BONE MINER RES, V19, pS284	36	36	36	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4545	4555		10.1096/fj.10-164095	http://dx.doi.org/10.1096/fj.10-164095			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20647545				2022-12-28	WOS:000283861100039
J	Kivela, R; Silvennoinen, M; Lehti, M; Rinnankoski-Tuikka, R; Purhonen, T; Ketola, T; Pullinen, K; Vuento, M; Mutanen, N; Sartor, MA; Reunanen, H; Koch, LG; Britton, SL; Kainulainen, H				Kivela, Riikka; Silvennoinen, Mika; Lehti, Maarit; Rinnankoski-Tuikka, Rita; Purhonen, Tatja; Ketola, Tarmo; Pullinen, Katri; Vuento, Meri; Mutanen, Niina; Sartor, Maureen A.; Reunanen, Hilkka; Koch, Lauren G.; Britton, Steven L.; Kainulainen, Heikki			Gene expression centroids that link with low intrinsic aerobic exercise capacity and complex disease risk	FASEB JOURNAL			English	Article						skeletal muscle; complex metabolic disease; oxygen metabolism; mitochondria; lipid metabolism	ENDURANCE RUNNING CAPACITY; HUMAN SKELETAL-MUSCLE; OXIDATIVE-PHOSPHORYLATION; ARTIFICIAL SELECTION; RATS; MITOCHONDRIAL; INTERLEUKIN-6; MORTALITY; NETWORKS; MODELS	A strong link exists between low aerobic exercise capacity and complex metabolic diseases. To probe this linkage, we utilized rat models of low and high intrinsic aerobic endurance running capacity that differ also in the risk for metabolic syndrome. We investigated in skeletal muscle gene-phenotype relationships that connect aerobic endurance capacity with metabolic disease risk factors. The study compared 12 high capacity runners (HCRs) and 12 low capacity runners (LCRs) from generation 18 of selection that differed by 615% for maximal treadmill endurance running capacity. On average, LCRs were heavier and had increased blood glucose, insulin, and triglycerides compared with HCRs. HCRs were higher for resting metabolic rate, voluntary activity, serum high density lipoproteins, muscle capillarity, and mitochondrial area. Bioinformatic analysis of skeletal muscle gene expression data revealed that many genes up-regulated in HCRs were related to oxidative energy metabolism. Seven mean mRNA expression centroids, including oxidative phosphorylation and fatty acid metabolism, correlated significantly with several exercise capacity and disease risk phenotypes. These expression-phenotype correlations, together with diminished skeletal muscle capillarity and mitochondrial area in LCR rats, support the general hypothesis that an inherited intrinsic aerobic capacity can underlie disease risks.-Kivela, R., Silvennoinen, M., Lehti, M., Rinnankoski-Tuikka, R., Purhonen, T., Ketola, T., Pullinen, K., Vuento, M., Mutanen, N., Sartor, M. A., Reunanen, H., Koch, L. G., Britton, S. L., Kainulainen, H. Gene expression centroids that link with low intrinsic aerobic exercise capacity and complex disease risk. FASEB J. 24, 4565-4574 (2010). www.fasebj.org	[Kivela, Riikka; Silvennoinen, Mika; Rinnankoski-Tuikka, Rita; Pullinen, Katri; Vuento, Meri; Mutanen, Niina; Kainulainen, Heikki] Univ Jyvaskyla, Dept Biol Phys Act, Neuromuscular Res Ctr, Jyvaskyla 40014, Finland; [Purhonen, Tatja; Ketola, Tarmo; Reunanen, Hilkka] Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla 40014, Finland; [Kivela, Riikka; Silvennoinen, Mika; Lehti, Maarit; Rinnankoski-Tuikka, Rita; Kainulainen, Heikki] Res Ctr Sport & Hlth Sci, Liikunnan Ja Kansaterveyden Edistamissaatio LIKES, Jyvaskyla, Finland; [Sartor, Maureen A.] Univ Michigan, Ctr Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Koch, Lauren G.; Britton, Steven L.] Univ Michigan, Dept Anesthesiol, Sch Med, Ann Arbor, MI 48109 USA	University of Jyvaskyla; University of Jyvaskyla; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kainulainen, H (corresponding author), Univ Jyvaskyla, Dept Biol Phys Act, Neuromuscular Res Ctr, POB 35, Jyvaskyla 40014, Finland.	heikki.kainulainen@sport.jyu.fi	Lehti, Maarit/T-3824-2019; Sartor, Maureen/L-2902-2019; Lehti, Maarit/ABB-1812-2021; Kivelä, Riikka/AAD-9636-2020; Ketola, Tarmo/AAD-2609-2019; Kivelä, Riikka/I-2859-2016	Kivelä, Riikka/0000-0002-2686-8890; Ketola, Tarmo/0000-0001-5151-7980; Kivelä, Riikka/0000-0002-2686-8890; Silvennoinen, Mika/0000-0002-5389-8251; Kainulainen, Heikki/0000-0001-5102-4350; Lehti, Maarit/0000-0002-9063-6541	LIKES Foundation for Promotion of Sport and Health Sciences; Ministry of Education of Finland; Academy of Finland; National Center for Research Resources of the National Institutes of Health (NIH), U.S. Department of Health and Human Services [RR17718]; NIH [1R01DK077200]; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR017718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077200] Funding Source: NIH RePORTER	LIKES Foundation for Promotion of Sport and Health Sciences; Ministry of Education of Finland; Academy of Finland(Academy of Finland); National Center for Research Resources of the National Institutes of Health (NIH), U.S. Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The study was financially supported by LIKES Foundation for Promotion of Sport and Health Sciences, the Ministry of Education of Finland, and the Academy of Finland. L.G.K. and S.L.B. were supported by grant RR17718 from the National Center for Research Resources of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. M.A.S. was supported by NIH grant 1R01DK077200. The authors acknowledge the expert care of the LCR/HCR rat colony provided by Lori Gilligan and Nathan Kanner. The authors thank Raija Vassinen, Virpi Miettinen, Veijo Kinnunen, Leena Salminen, and Sira Torvinen for help in the cutting and analysis of EM samples. The authors thank Paavo Niutanen for help with electron micrographs. Microarray experiments were conducted at the Finnish DNA Microarray Center at Turku Center for Biotechnology. The microarray data accession number in GEO is GSE17190.	Andersen JL, 2000, MUSCLE NERVE, V23, P1095; Bray MS, 2009, MED SCI SPORT EXER, V41, P34, DOI 10.1249/MSS.0b013e3181844179; BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; Carlborg O, 2006, NAT GENET, V38, P418, DOI 10.1038/ng1761; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Glund S, 2007, DIABETES, V56, P1630, DOI 10.2337/db06-1733; HENDRIX LJ, 1982, BIOMETRICS, V38, P641, DOI 10.2307/2530045; Howlett RA, 2003, J APPL PHYSIOL, V94, P1682, DOI 10.1152/japplphysiol.00556.2002; Howlett RA, 2009, J APPL PHYSIOL, V106, P1819, DOI 10.1152/japplphysiol.00914.2007; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Koch LG, 2001, PHYSIOL GENOMICS, V5, P45, DOI 10.1152/physiolgenomics.2001.5.1.45; Kokkinos P, 2008, CIRCULATION, V117, P614, DOI 10.1161/CIRCULATIONAHA.107.734764; Lessard SJ, 2009, ENDOCRINOLOGY, V150, P4883, DOI 10.1210/en.2009-0158; Liu Zhenqi, 2009, Endocrine Metabolic & Immune Disorders-Drug Targets, V9, P38; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Naples SP, 2010, APPL PHYSIOL NUTR ME, V35, P151, DOI 10.1139/H09-139; Newman AB, 2006, JAMA-J AM MED ASSOC, V295, P2018, DOI 10.1001/jama.295.17.2018; Novak CM, 2010, HORM BEHAV, V58, P355, DOI 10.1016/j.yhbeh.2010.03.013; Novak CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005869; Packard GC, 1999, COMP BIOCHEM PHYS A, V122, P37, DOI 10.1016/S1095-6433(98)10170-8; Riant E, 2009, ENDOCRINOLOGY, V150, P2109, DOI 10.1210/en.2008-0971; Sartor MA, 2009, BIOINFORMATICS, V25, P211, DOI 10.1093/bioinformatics/btn592; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thyfault JP, 2009, J PHYSIOL-LONDON, V587, P1805, DOI 10.1113/jphysiol.2009.169060; Timmons JA, 2010, J APPL PHYSIOL, V108, P1487, DOI 10.1152/japplphysiol.01295.2009; Ways JA, 2002, GENOMICS, V80, P13, DOI 10.1006/geno.2002.6797; Ways JA, 2007, PHYSIOL GENOMICS, V29, P91, DOI 10.1152/physiolgenomics.00027.2006; Weigert C, 2004, J BIOL CHEM, V279, P23942, DOI 10.1074/jbc.M312692200; Wisloff U, 2005, SCIENCE, V307, P418, DOI 10.1126/science.1108177; Wright DC, 2007, APPL PHYSIOL NUTR ME, V32, P840, DOI 10.1139/H07-062; Zhu J, 2008, NAT GENET, V40, P854, DOI 10.1038/ng.167	35	43	43	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2010	24	11					4565	4574		10.1096/fj.10-157313	http://dx.doi.org/10.1096/fj.10-157313			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20643908	Green Published, hybrid			2022-12-28	WOS:000283861100041
J	Mukherjee, A; Soyal, SM; Li, J; Ying, Y; He, B; DeMayo, FJ; Lydon, JP				Mukherjee, Atish; Soyal, Selma M.; Li, Jie; Ying, Yan; He, Bin; DeMayo, Francesco J.; Lydon, John P.			Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression	FASEB JOURNAL			English	Article						progesterone receptor knockout; cell-type specific expression; doxycycline; induction-deinduction; minichromosome maintenance protein	CYCLIN D1 EXPRESSION; NORMAL HUMAN BREAST; GLAND DEVELOPMENT; OSTEOPROTEGERIN-LIGAND; DNA-REPLICATION; TRANSGENIC MICE; PROLIFERATION; ESTROGEN; DIFFERENTIATION; ABNORMALITIES	Despite support for receptor of activated NF-kappa B ligand (RANKL) as a mediator of mammary progesterone action, the extent to which this cytokine can functionally contribute to established progesterone-induced mammary morphogenetic responses in the absence of other presumptive effectors is still unclear. To address this uncertainty, we developed an innovative bigenic system for the doxycycline-inducible expression of RANKL in the mammary epithelium of the progesterone receptor knockout (PRKO) mouse. In response to acute doxycycline exposure, RANKL is specifically expressed in the estrogen receptor alpha (ER) positive/progesterone receptor negative (ER+/PR-) cell type in the PRKO mammary epithelium, a cell type that is equivalent to the ER+/PR+ cell type in the wild-type (WT) mammary epithelium. Notably, the ER+/PR+ mammary cell normally expresses RANKL in the WT mammary epithelium during pregnancy. In this PRKO bigenic system, acute doxycycline-induced expression of RANKL results in ordered mammary ductal side branching and alveologenesis, morphological changes that normally occur in the parous WT mouse. This mammary epithelial expansion is accompanied by significant RANKL-induced luminal epithelial proliferation, which is driven, in part, by indirect induction of cyclin D1. Collectively, our findings support the conclusion that RANKL represents a critical mediator of mammary PR action and that restricted expression of this effector to the ER+/PR+ mammary cell-type is necessary for a spatially ordered morphogenetic response to progesterone.-Mukherjee, A., Soyal, S. M., Li, J., Ying, Y., He, B., DeMayo, F. J., Lydon, J. P. Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression. FASEB J. 24, 4408-4419 (2010). www.fasebj.org	[Mukherjee, Atish; Soyal, Selma M.; Li, Jie; Ying, Yan; He, Bin; DeMayo, Francesco J.; Lydon, John P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Lydon, JP (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Rm 733A,1 Baylor Plaza, Houston, TX 77030 USA.	jlydon@bcm.tmc.edu	DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	U.S. National Institutes of Health [CA077530]; NATIONAL CANCER INSTITUTE [R29CA077530, R01CA077530] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Jie Han for her technical expertise, and the Darwin Transgenic Core Facility, Baylor College of Medicine, for its DNA microinjection services. The authors also thank Dr. Daniel Medina (Baylor College of Medicine) for his expertise in mammary histopathology. The authors are grateful to Dr. Lewis A. Chodosh (Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA, USA) for providing the p-Tet-Splice cloning vector, as well as for the transgenic MTB and TZA reporter mouse. This research was funded by U.S. National Institutes of Health grant CA077530 (to J.P.L.).	Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Aupperlee MD, 2007, ENDOCRINOLOGY, V148, P2290, DOI 10.1210/en.2006-1721; Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107; BRANSTETTER D, 2008, SAN ANT BREAST CANC; Brisken C, 2000, GENE DEV, V14, P650; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Clarke RB, 1997, CANCER RES, V57, P4987; Davies CR, 2006, PROTEOMICS, V6, P5694, DOI 10.1002/pmic.200600202; Endl E, 2001, J PATHOL, V195, P457, DOI 10.1002/path.978; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fernandez-Valdivia R, 2008, ENDOCRINOLOGY, V149, P6236, DOI 10.1210/en.2008-0768; Fernandez-Valdivia R, 2009, DEV BIOL, V328, P127, DOI 10.1016/j.ydbio.2009.01.019; Gonzalez-Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298-06; Graham JD, 2009, ENDOCRINOLOGY, V150, P3318, DOI 10.1210/en.2008-1630; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Ha SA, 2004, CLIN CANCER RES, V10, P8386, DOI 10.1158/1078-0432.CCR-04-1029; Ismail PM, 2004, J ENDOCRINOL, V180, P287, DOI 10.1677/joe.0.1800287; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kim HJ, 2002, J BIOL CHEM, V277, P5339, DOI 10.1074/jbc.M108342200; Kim NS, 2006, MOL CELL BIOL, V26, P1002, DOI 10.1128/MCB.26.3.1002-1013.2006; Lydon JP, 2009, ENDOCRINOLOGY, V150, P2988, DOI 10.1210/en.2009-0383; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mukherjee A, 2007, GENESIS, V45, P639, DOI 10.1002/dvg.20336; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Pan HY, 2006, P NATL ACAD SCI USA, V103, P14021, DOI 10.1073/pnas.0601271103; Poole AJ, 2006, SCIENCE, V314, P1467, DOI 10.1126/science.1130471; Rosen Jeffrey M, 2003, Breast Dis, V18, P3; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; Satoh K, 2007, ONCOGENE, V26, P7526, DOI 10.1038/sj.onc.1210555; Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; Soling A, 2005, CLIN CANCER RES, V11, P249; Srivastava S, 2003, J BIOL CHEM, V278, P46171, DOI 10.1074/jbc.M308545200; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359-6101(03)00027-3	41	65	66	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2010	24	11					4408	4419		10.1096/fj.10-157982	http://dx.doi.org/10.1096/fj.10-157982			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20605949	Green Published			2022-12-28	WOS:000283861100027
J	Sisquella, X; de Pourcq, K; Alguacil, J; Robles, J; Sanz, F; Anselmetti, D; Imperial, S; Fernandez-Busquets, X				Sisquella, Xavier; de Pourcq, Karel; Alguacil, Javier; Robles, Jordi; Sanz, Fausto; Anselmetti, Dario; Imperial, Santiago; Fernandez-Busquets, Xavier			A single-molecule force spectroscopy nanosensor for the identification of new antibiotics and antimalarials	FASEB JOURNAL			English	Article						malaria; 2-C-methyl-D-erythritol-4-phosphate pathway; 1-deoxy-D-xylulose 5-phosphate synthase; pyruvate; glyceraldehyde-3-phosphate; drug discovery	1-DEOXY-D-XYLULOSE 5-PHOSPHATE SYNTHASE; ESCHERICHIA-COLI; ISOPRENOID BIOSYNTHESIS; THIOREDOXIN CATALYSIS; NONMEVALONATE PATHWAY; ALZHEIMERS-DISEASE; PHOSPHATE-PATHWAY; INHIBITORS; ENZYME; MICROSCOPY	An important goal of nanotechnology is the application of individual molecule handling techniques to the discovery of potential new therapeutic agents. Of particular interest is the search for new inhibitors of metabolic routes exclusive of human pathogens, such as the 2-C-methyl-D-erythritol-4-phosphate (MEP) pathway essential for the viability of most human pathogenic bacteria and of the malaria parasite. Using atomic force microscopy single-molecule force spectroscopy (SMFS), we have probed at the single-molecule level the interaction of 1-deoxy-D-xylulose 5-phosphate synthase (DXS), which catalyzes the first step of the MEP pathway, with its two substrates, pyruvate and glyceraldehyde-3-phosphate. The data obtained in this pioneering SMFS analysis of a bisubstrate enzymatic reaction illustrate the substrate sequentiality in DXS activity and allow for the calculation of catalytic parameters with single-molecule resolution. The DXS inhibitor fluoropyruvate has been detected in our SMFS competition experiments at a concentration of 10 mu M, improving by 2 orders of magnitude the sensitivity of conventional enzyme activity assays. The binding of DXS to pyruvate is a 2-step process with dissociation constants of k(off) = 6.1 x 10(-4) +/- 7.5 x 10(-3) and 1.3 x 10(-2) +/- 1.0 x 10(-2) s(-1), and reaction lengths of x(beta) = 3.98 +/- 0.33 and 0.52 +/- 0.23 angstrom. These results constitute the first quantitative report on the use of nanotechnology for the biodiscovery of new antimalarial enzyme inhibitors and open the field for the identification of compounds represented only by a few dozens of molecules in the sensor chamber.-Sisquella, X., de Pourcq, K., Alguacil, J., Robles, J., Sanz, F., Anselmetti, D., Imperial, S., Fernandez-Busquets, X. A single-molecule force spectroscopy nanosensor for the identification of new antibiotics and antimalarials. FASEB J. 24, 4203-4217 (2010). www.fasebj.org	[Fernandez-Busquets, Xavier] Inst Bioengn Catalonia, Nanobioengn Grp, E-08028 Barcelona, Spain; [Sisquella, Xavier] Barcelona Sci Pk, Nanotechnol Platform, Barcelona, Spain; [Imperial, Santiago] Univ Barcelona, Dept Biochem & Mol Biol, Nanosci & Nanotechnol Inst, Barcelona, Spain; [Alguacil, Javier; Robles, Jordi] Univ Barcelona, Dept Organ Chem, Nanosci & Nanotechnol Inst, Barcelona, Spain; [Sanz, Fausto] Univ Barcelona, Dept Phys Chem, Nanosci & Nanotechnol Inst, Barcelona, Spain; [Imperial, Santiago; Fernandez-Busquets, Xavier] Univ Barcelona, Biomol Interact Team, Nanosci & Nanotechnol Inst, Barcelona, Spain; [Anselmetti, Dario] Univ Bielefeld, Bielefeld, Germany	Barcelona Institute of Science & Technology; Catalan Institute of Nanoscience & Nanotechnology (ICN2); Institut de Bioenginyeria de Catalunya; University of Barcelona; University of Barcelona; University of Barcelona; University of Barcelona; University of Barcelona; University of Bielefeld	Fernandez-Busquets, X (corresponding author), Inst Bioengn Catalonia, Nanobioengn Grp, Baldiri Reixac 10-12, E-08028 Barcelona, Spain.	xfernandez_busquets@ub.edu	Robles, Jordi/K-6653-2014; imperial, santiago/K-4963-2017; Anselmetti, Dario/F-1664-2011; Fernàndez-Busquets, Xavier/K-1323-2014	Robles, Jordi/0000-0002-8583-4930; imperial, santiago/0000-0001-8749-1428; Anselmetti, Dario/0000-0002-8720-4369; Fernàndez-Busquets, Xavier/0000-0002-4622-9631; Alguacil, Javier/0000-0002-5681-0323	Ministerio de Ciencia e Innovacion, Spain [BIO2002-00128, BIO2002-04419-C02-02, BIO2005-01591, BIO2008-01184, CSD2007-00036, CSD2006-00012]; Generalitat de Catalunya, Spain [2009SGR-760, 2009SGR-0026, 2005SGR-00914]	Ministerio de Ciencia e Innovacion, Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Generalitat de Catalunya, Spain(Generalitat de Catalunya)	This work was supported by grants BIO2002-00128, BIO2002-04419-C02-02, BIO2005-01591, BIO2008-01184, CSD2007-00036, and CSD2006-00012 from the Ministerio de Ciencia e Innovacion, Spain, which included FEDER funds, and by grants 2009SGR-760, 2009SGR-0026, and 2005SGR-00914 from the Generalitat de Catalunya, Spain. We thank the Nanotechnology Platform of the Barcelona Scientific Park and Marta Taules (Scientific and Technical Services of the University of Barcelona) for technical assistance.	Allen S, 1997, BIOCHEMISTRY-US, V36, P7457, DOI 10.1021/bi962531z; Altincicek B, 2000, FEMS MICROBIOL LETT, V190, P329, DOI 10.1111/j.1574-6968.2000.tb09307.x; Anselmetti D., 2000, Single Molecules, V1, P53, DOI 10.1002/(SICI)1438-5171(200004)1:1<53::AID-SIMO53>3.0.CO;2-U; Bartels FW, 2003, J STRUCT BIOL, V143, P145, DOI 10.1016/S1047-8477(03)00127-8; BEYTIA ED, 1976, ANNU REV BIOCHEM, V45, P113, DOI 10.1146/annurev.bi.45.070176.000553; Bizzarri AR, 2010, CHEM SOC REV, V39, P734, DOI 10.1039/b811426a; Bonanni B, 2006, J PHYS CHEM B, V110, P14574, DOI 10.1021/jp0610315; Borrmann S, 2006, ANTIMICROB AGENTS CH, V50, P2713, DOI 10.1128/AAC.00392-06; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bustamante C, 2000, NAT REV MOL CELL BIO, V1, P130, DOI 10.1038/35040072; Eckel R, 2005, ANGEW CHEM INT EDIT, V44, P3921, DOI 10.1002/anie.200500152; Eisenreich W, 2001, TRENDS PLANT SCI, V6, P78, DOI 10.1016/S1360-1385(00)01812-4; Eubanks LM, 2003, BIOCHEMISTRY-US, V42, P1140, DOI 10.1021/bi0205303; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; Evans E, 2004, P NATL ACAD SCI USA, V101, P11281, DOI 10.1073/pnas.0401870101; FINBERG JPM, 1995, ACTA PSYCHIAT SCAND, V91, P8, DOI 10.1111/j.1600-0447.1995.tb05918.x; Fiorini M, 2001, BIOPHYS J, V80, P2471, DOI 10.1016/S0006-3495(01)76215-7; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Frey BL, 1996, ANAL CHEM, V68, P3187, DOI 10.1021/ac9605861; Frisoni GB, 2001, J NEUROL, V248, P551, DOI 10.1007/s004150170131; Funari G, 2010, J MOL RECOGNIT, V23, P343, DOI 10.1002/jmr.999; Garcia-Manyes S, 2006, J BIOL CHEM, V281, P5992, DOI 10.1074/jbc.M507878200; Ghosh AK, 2002, CURR MED CHEM, V9, P1135, DOI 10.2174/0929867023370149; Green JBD, 1999, APPL PHYS LETT, V74, P1489, DOI 10.1063/1.123590; HEGNER M, 1993, SURF SCI, V291, P39, DOI 10.1016/0039-6028(93)91474-4; Hibbert H, 1929, J AM CHEM SOC, V51, P3115, DOI 10.1021/ja01385a034; Hoeffler JF, 2002, EUR J BIOCHEM, V269, P4446, DOI 10.1046/j.1432-1033.2002.03150.x; Jain KK, 2005, DRUG DISCOV TODAY, V10, P1435, DOI 10.1016/S1359-6446(05)03573-7; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kamper SG, 2007, LANGMUIR, V23, P12561, DOI 10.1021/la702148v; Kaubisch A, 2000, CANCER J, V6, P192; Kraut DA, 2003, ANNU REV BIOCHEM, V72, P517, DOI 10.1146/annurev.biochem.72.121801.161617; Kuhner F, 2004, BIOPHYS J, V87, P2683, DOI 10.1529/biophysj.104.048968; Lebon F, 2000, CURR MED CHEM, V7, P455, DOI 10.2174/0929867003375146; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; LYUBCHENKO Y, 1993, P NATL ACAD SCI USA, V90, P2137, DOI 10.1073/pnas.90.6.2137; Maki T, 2007, LANGMUIR, V23, P2668, DOI 10.1021/la0627011; Mao JL, 2008, BIOORG MED CHEM LETT, V18, P5320, DOI 10.1016/j.bmcl.2008.08.034; Mathijssen RHJ, 2002, CURR CANCER DRUG TAR, V2, P103, DOI 10.2174/1568009023333890; Meadows PY, 2003, LANGMUIR, V19, P9566, DOI 10.1021/la035217w; Menard J, 2001, ADV PROTEIN CHEM, V56, P13; Moghadasian MH, 1999, LIFE SCI, V65, P1329, DOI 10.1016/S0024-3205(99)00199-X; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nair V, 2002, REV MED VIROL, V12, P179, DOI 10.1002/rmv.350; Neuert G, 2006, FEBS LETT, V580, P505, DOI 10.1016/j.febslet.2005.12.052; OLANOW CW, 1993, ADV NEUROL, V60, P666; Palumbi SR, 2001, SCIENCE, V293, P1786, DOI 10.1126/science.293.5536.1786; Perez-Jimenez R, 2009, NAT STRUCT MOL BIOL, V16, P890, DOI 10.1038/nsmb.1627; Porter-Peden L, 2008, LANGMUIR, V24, P11556, DOI 10.1021/la801477a; Prendergast GC, 2000, SEMIN CANCER BIOL, V10, P443, DOI 10.1006/scbi.2000.0335; Querol J, 2001, BIOCHEM BIOPH RES CO, V289, P155, DOI 10.1006/bbrc.2001.5957; Ralph SA, 2001, DRUG RESIST UPDATE, V4, P145, DOI 10.1054/drup.2001.0205; Rico F, 2007, J MOL RECOGNIT, V20, P495, DOI 10.1002/jmr.841; Rief M, 2002, CHEMPHYSCHEM, V3, P255, DOI 10.1002/1439-7641(20020315)3:3<255::AID-CPHC255>3.0.CO;2-M; Rodriguez-Concepion M, 2004, CURR PHARM DESIGN, V10, P2391, DOI 10.2174/1381612043384006; Rohdich F, 2001, CURR OPIN CHEM BIOL, V5, P535, DOI 10.1016/S1367-5931(00)00240-4; Santos-Magalhaes NS, 2010, ADV DRUG DELIVER REV, V62, P560, DOI 10.1016/j.addr.2009.11.024; Sauret-Gueto S, 2006, FEBS LETT, V580, P736, DOI 10.1016/j.febslet.2005.12.092; Schmidt D, 1999, CLIN EXP ALLERGY, V29, P99; Schurmann M, 2002, J MOL CATAL B-ENZYM, V19, P247, DOI 10.1016/S1381-1177(02)00174-1; Schurmann M., 2001, THESIS U DUSSELDORF; Schwesinger F, 2000, P NATL ACAD SCI USA, V97, P9972, DOI 10.1073/pnas.97.18.9972; Simpson ER, 2002, RECENT PROG HORM RES, V57, P317, DOI 10.1210/rp.57.1.317; Sletmoen M, 2005, CARBOHYD RES, V340, P2782, DOI 10.1016/j.carres.2005.09.020; Sodhi RNS, 2004, ANALYST, V129, P483, DOI 10.1039/b402607c; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; Taranta M, 2008, J MOL RECOGNIT, V21, P63, DOI 10.1002/jmr.869; Thomas T, 2000, NEUROBIOL AGING, V21, P343, DOI 10.1016/S0197-4580(00)00100-7; Vane JR, 1998, INFLAMM RES, V47, pS77; Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727; Wiesner J, 2003, PARASITOL RES, V90, pS71, DOI 10.1007/s00436-002-0770-9; Wiita AP, 2007, NATURE, V450, P124, DOI 10.1038/nature06231; Wilkinson TA, 2000, J PEPT RES, V55, P140, DOI 10.1034/j.1399-3011.2000.00164.x; Xiang S, 2007, J BIOL CHEM, V282, P2676, DOI 10.1074/jbc.M610235200; Yingge Z, 2001, J PHARMACOL EXP THER, V297, P798; Zlatanova J, 2000, PROG BIOPHYS MOL BIO, V74, P37, DOI 10.1016/S0079-6107(00)00014-6	78	23	23	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4203	4217		10.1096/fj.10-155507	http://dx.doi.org/10.1096/fj.10-155507			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20634351	Bronze			2022-12-28	WOS:000283861100009
J	Kadekaro, AL; Leachman, S; Kavanagh, RJ; Swope, V; Cassidy, P; Supp, D; Sartor, M; Schwemberger, S; Babcock, G; Wakamatsu, K; Ito, S; Koshoffer, A; Boissy, RE; Manga, P; Sturm, RA; Abdel-Malek, ZA				Kadekaro, Ana Luisa; Leachman, Sancy; Kavanagh, Renny J.; Swope, Viki; Cassidy, Pamela; Supp, Dorothy; Sartor, Maureen; Schwemberger, Sandy; Babcock, George; Wakamatsu, Kazumasa; Ito, Shosuke; Koshoffer, Amy; Boissy, Raymond E.; Manga, Prashiela; Sturm, Richard A.; Abdel-Malek, Zalfa A.			Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation	FASEB JOURNAL			English	Article						DNA repair; melanoma susceptibility; MC1R variants; cAMP pathway	CUTANEOUS MALIGNANT-MELANOMA; DNA-DAMAGE; STIMULATING HORMONE; RECEPTOR VARIANTS; CDKN2A MUTATIONS; HUMAN EPIDERMIS; RISK; MC1R; PIGMENTATION; FAMILIES	The melanocortin 1 receptor gene is a main determinant of human pigmentation, and a melanoma susceptibility gene, because its variants that are strongly associated with red hair color increase melanoma risk. To test experimentally the association between melanocortin 1 receptor genotype and melanoma susceptibility, we compared the responses of primary human melanocyte cultures naturally expressing different melanocortin 1 receptor variants to alpha-melanocortin and ultraviolet radiation. We found that expression of 2 red hair variants abolished the response to alpha-melanocortin and its photoprotective effects, evidenced by lack of functional coupling of the receptor, and absence of reduction in ultraviolet radiation-induced hydrogen peroxide generation or enhancement of repair of DNA photoproducts, respectively. These variants had different heterozygous effects on receptor function. Microarray data confirmed the observed differences in responses of melanocytes with functional vs. nonfunctional receptor to alpha-melanocortin and ultraviolet radiation, and identified DNA repair and antioxidant genes that are modulated by alpha-melanocortin. Our findings highlight the molecular mechanisms by which the melanocortin 1 receptor genotype controls genomic stability of and the mutagenic effect of ultraviolet radiation on human melanocytes.-Kadekaro, A. L., Leachman, S., Kavanagh, R. J., Swope, V., Cassidy, P., Supp, D., Sartor, M., Schwemberger, S., Babcock, G., Wakamatsu, K., Ito, S., Koshoffer, A., Boissy, R. E., Manga, P., Sturm, R. A., Abdel-Malek, Z. A. Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J. 24, 3850-3860 (2010). www.fasebj.org	[Abdel-Malek, Zalfa A.] Univ Cincinnati, Dept Dermatol, Coll Med, Cincinnati, OH 45267 USA; [Supp, Dorothy; Schwemberger, Sandy; Babcock, George] Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA; [Sartor, Maureen] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Leachman, Sancy; Cassidy, Pamela] Univ Utah, Dept Dermatol, Salt Lake City, UT USA; [Leachman, Sancy; Cassidy, Pamela] Univ Utah, Huntsman Canc Ctr, Salt Lake City, UT USA; [Supp, Dorothy; Babcock, George] Shriners Burns Hosp, Cincinnati, OH USA; [Wakamatsu, Kazumasa; Ito, Shosuke] Fujita Hlth Univ, Dept Chem, Sch Hlth Sci, Toyoake, Aichi, Japan; [Manga, Prashiela] NYU, Ronald O Perelman Dept Dermatol, New York, NY USA; [Sturm, Richard A.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Fujita Health University; New York University; University of Queensland	Abdel-Malek, ZA (corresponding author), Univ Cincinnati, Dept Dermatol, Coll Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	abdelmza@ucmail.uc.edu	Wakamatsu, Kazumasa/AAZ-5877-2020; Koshoffer, Amy E/N-2278-2014; Sartor, Maureen/L-2902-2019; Supp, Dorothy/ABQ-7999-2022; Sturm, Richard A/C-9943-2009	Wakamatsu, Kazumasa/0000-0003-1748-9001; Koshoffer, Amy E/0000-0001-8130-103X; Supp, Dorothy/0000-0002-2429-6630; Sturm, Richard A/0000-0003-1301-0294; Ito, Shosuke/0000-0001-9182-5144	U.S. National Institutes of Health [R01ES009110, R011ES017561, P30 ES06096]; University of Cincinnati Cancer Center; Procter and Gamble Co. (Cincinnati, OH, USA); Japan Society for the Promotion of Sciences [20591357]; Dermatology Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009110, P30ES006096, R01ES017561] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Cincinnati Cancer Center; Procter and Gamble Co. (Cincinnati, OH, USA); Japan Society for the Promotion of Sciences(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Dermatology Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Silva Terzieva for technical assistance, Toshio Mori (Nara Medical University, Kashihara, Japan) for donating TDM-2 antibody, Jose Carlos Garcia Borron (University of Murcia, Murcia, Spain) for his gift of the pMC1R-WT plasmid, and David Fisher (Harvard University, Cambridge, MA, USA) for providing the Mitf antibody. This work was supported in part by U.S. National Institutes of Health grants R01ES009110 (Z.A.M.), R011ES017561 (Z.A.M. and S.L.), and P30 ES06096 (Z.A.M. and D.S.); the University of Cincinnati Cancer Center Pilot Project (Z.A.M.); Procter and Gamble Co. (Cincinnati, OH, USA) (Z.A.M.), a Dermatology Foundation research grant (S.L.); Ohio Cancer Research Associates (A.L.K.); and the Japan Society for the Promotion of Sciences, KAKENHI grant 20591357 (K.W. and S.I.).	ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ABDELMALEK Z, 1993, J CELL SCI, V106, P1323; April CS, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030009; Bohm M, 2005, J BIOL CHEM, V280, P5795, DOI 10.1074/jbc.M406334200; Borchers MT, 2008, TOXICOL SCI, V105, P188, DOI 10.1093/toxsci/kfn106; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; BUSTAMANTE J, 1993, PIGM CELL RES, V6, P348, DOI 10.1111/j.1600-0749.1993.tb00612.x; de Vries E, 2004, EUR J CANCER, V40, P2355, DOI 10.1016/j.ejca.2004.06.003; Garcia-Borron JC, 2005, PIGM CELL RES, V18, P393, DOI 10.1111/j.1600-0749.2005.00278.x; Geller AC, 2002, JAMA-J AM MED ASSOC, V288, P1719, DOI 10.1001/jama.288.14.1719; Goldstein AM, 2005, CANCER EPIDEM BIOMAR, V14, P2208, DOI 10.1158/1055-9965.EPI-05-0321; Healy E, 2001, HUM MOL GENET, V10, P2397, DOI 10.1093/hmg/10.21.2397; Hennessy A, 2005, PIGM CELL RES, V18, P220, DOI 10.1111/j.1600-0749.2005.00233.x; HUNT G, 1995, PIGM CELL RES, V8, P202, DOI 10.1111/j.1600-0749.1995.tb00664.x; HUNT G, 1994, J CELL SCI, V107, P205; Im SB, 1998, CANCER RES, V58, P47; Kadekaro AL, 2005, CANCER RES, V65, P4292, DOI 10.1158/0008-5472.CAN-04-4535; Kaldis P, 2005, CELL CYCLE, V4, P1491, DOI 10.4161/cc.4.11.2124; Kanetsky PA, 2006, CANCER RES, V66, P9330, DOI 10.1158/0008-5472.CAN-06-1634; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; KONDA Y, 1994, J BIOL CHEM, V269, P13162; Landi MT, 2006, SCIENCE, V313, P521, DOI 10.1126/science.1127515; Linos E, 2009, J INVEST DERMATOL, V129, pS59; Lovejoy CA, 2006, MOL CELL BIOL, V26, P7977, DOI 10.1128/MCB.00819-06; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; McKay BC, 2004, P NATL ACAD SCI USA, V101, P6582, DOI 10.1073/pnas.0308181101; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Park HY, 1996, EXP CELL RES, V227, P70, DOI 10.1006/excr.1996.0251; Prosperi E, 2006, FASEB J, V20, P833, DOI 10.1096/fj.05-5469hyp; Purdue MP, 2008, J INVEST DERMATOL, V128, P2905, DOI 10.1038/jid.2008.159; Sarkar-Agrawal P, 2004, JNCI-J NATL CANCER I, V96, P1790, DOI 10.1093/jnci/djh307; Scott MC, 2002, J CELL SCI, V115, P2349; Smith AG, 2008, J BIOL CHEM, V283, P12564, DOI 10.1074/jbc.M800480200; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; Song XZ, 2009, PIGM CELL MELANOMA R, V22, P809, DOI 10.1111/j.1755-148X.2009.00615.x; Stang A, 2006, INT J CANCER, V119, P380, DOI 10.1002/ijc.21836; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Tornaletti S, 2005, MUTAT RES-FUND MOL M, V577, P131, DOI 10.1016/j.mrfmmm.2005.03.014; van der Velden PA, 2001, AM J HUM GENET, V69, P774, DOI 10.1086/323411; Wakamatsu K, 1997, PIGM CELL RES, V10, P288, DOI 10.1111/j.1600-0749.1997.tb00688.x; Wang RS, 2006, P NATL ACAD SCI USA, V103, P353, DOI 10.1073/pnas.0509822102; Wei QY, 2003, J NATL CANCER I, V95, P308, DOI 10.1093/jnci/95.4.308; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yamamura K, 1996, CANCER RES, V56, P3546	47	100	102	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2010	24	10					3850	3860		10.1096/fj.10-158485	http://dx.doi.org/10.1096/fj.10-158485			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20519635	Green Published			2022-12-28	WOS:000285005900023
J	Mardaryev, AN; Ahmed, MI; Vlahov, NV; Fessing, MY; Gill, JH; Sharov, AA; Botchkareva, NV				Mardaryev, Andrei N.; Ahmed, Mohammed I.; Vlahov, Nikola V.; Fessing, Michael Y.; Gill, Jason H.; Sharov, Andrey A.; Botchkareva, Natalia V.			Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle	FASEB JOURNAL			English	Article							SMALL INTERFERING RNA; STEM-CELL ACTIVATION; COMPREHENSIVE GUIDE; GROWTH MODULATION; PROTEIN-SYNTHESIS; IN-VITRO; MICRORNA; MORPHOGENESIS; CLASSIFICATION; KERATINOCYTES	The hair follicle is a cyclic biological system that progresses through stages of growth, regression, and quiescence, which involves dynamic changes in a program of gene regulation. Micro-RNAs (miRNAs) are critically important for the control of gene expression and silencing. Here, we show that global miRNA expression in the skin markedly changes during distinct stages of the hair cycle in mice. Furthermore, we show that expression of miR-31 markedly increases during anagen and decreases during catagen and telogen. Administration of antisense miR-31 inhibitor into mouse skin during the early-and midanagen phases of the hair cycle results in accelerated anagen development, and altered differentiation of hair matrix keratinocytes and hair shaft formation. Microarray, qRT-PCR and Western blot analyses revealed that miR-31 negatively regulates expression of Fgf10, the components of Wnt and BMP signaling pathways Sclerostin and BAMBI, and Dlx3 transcription factor, as well as selected keratin genes, both in vitro and in vivo. Using luciferase reporter assay, we show that Krt16, Krt17, Dlx3, and Fgf10 serve as direct miR-31 targets. Thus, by targeting a number of growth regulatory molecules and cytoskeletal proteins, miR-31 is involved in establishing an optimal balance of gene expression in the hair follicle required for its proper growth and hair fiber formation.-Mardaryev, A. N., Ahmed, M. I., Vlahov, N. V., Fessing, M. Y., Gill, J. H., Sharov, A. A., and Botchkareva, N. V. Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle. FASEB J. 24, 3869-3881 (2010). www.fasebj.org	[Mardaryev, Andrei N.; Ahmed, Mohammed I.; Vlahov, Nikola V.; Fessing, Michael Y.; Botchkareva, Natalia V.] Univ Bradford, Ctr Skin Sci, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England; [Gill, Jason H.] Univ Bradford, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England; [Sharov, Andrey A.] Boston Univ, Dept Dermatol, Boston, MA 02215 USA	University of Bradford; University of Bradford; Boston University	Botchkareva, NV (corresponding author), Univ Bradford, Ctr Skin Sci, Sch Life Sci, Richmond Rd, Bradford BD7 1DP, W Yorkshire, England.	n.botchkareva@bradford.ac.uk	Mardaryev, Andrei/AAC-8944-2022; Ahmed, Mohammed/AAU-7535-2021; Ahmed, Mohammed/T-5898-2019	Mardaryev, Andrei/0000-0002-7826-5506; Ahmed, Mohammed/0000-0002-9051-7681; Fessing, Michael/0000-0002-3120-8707; Gill, Jason/0000-0002-7564-7787	Royal Society [2007/R2]; Wellcome Trust; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR056771] Funding Source: NIH RePORTER	Royal Society(Royal Society of London); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the Royal Society (research grants 2007/R2 to N.V.B.) and the Wellcome Trust (vacation scholarship to N.V.V.). Prof. D. Tobin is acknowledged for his support and critical comments on the manuscript.	Alonso L, 2006, J CELL SCI, V119, P391, DOI 10.1242/jcs02793; Andl T, 2006, CURR BIOL, V16, P1041, DOI 10.1016/j.cub.2006.04.005; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernot KM, 2002, J INVEST DERMATOL, V119, P1137, DOI 10.1046/j.1523-1747.2002.19518.x; Botchkarev VA, 2003, J EXP ZOOL PART B, V298B, P164, DOI 10.1002/jez.b.00033; Botchkarev VA, 2001, FASEB J, V15, P2205, DOI 10.1096/fj.01-0207com; Botchkarev VA, 1999, J INVEST DERMATOL, V113, P878, DOI 10.1046/j.1523-1747.1999.00791.x; Botchkarev VA, 2003, J INVEST DERM SYMP P, V8, P46, DOI 10.1046/j.1523-1747.2003.12171.x; Botchkareva NV, 2000, AM J PATHOL, V156, P1041, DOI 10.1016/S0002-9440(10)64972-3; Botchkareva NV, 2001, FASEB J, V15, P645, DOI 10.1096/fj.00-0368com; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Fan W, 2003, EXP DERMATOL, V12, P832, DOI 10.1111/j.0906-6705.2003.00099.x; Fessing MY, 2006, AM J PATHOL, V169, P2075, DOI 10.2353/ajpath.2006.060227; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009; HANSEN LS, 1984, ANAT REC, V210, P569, DOI 10.1002/ar.1092100404; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hwang J, 2008, DEVELOPMENT, V135, P3149, DOI 10.1242/dev.022202; Jave-Suarez LF, 2002, J BIOL CHEM, V277, P3718, DOI 10.1074/jbc.M101616200; Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Kim VN, 2005, MOL CELLS, V19, P1; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kurek D, 2007, DEVELOPMENT, V134, P261, DOI 10.1242/dev.02721; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Lindner G, 1997, AM J PATHOL, V151, P1601; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; McGowan KM, 2002, GENE DEV, V16, P1412, DOI 10.1101/gad.979502; Mecklenburg L, 2000, J INVEST DERMATOL, V114, P909, DOI 10.1046/j.1523-1747.2000.00954.x; Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Paladini RD, 1998, J CELL BIOL, V142, P1035, DOI 10.1083/jcb.142.4.1035; Panteleyev AA, 1997, J INVEST DERMATOL, V108, P324, DOI 10.1111/1523-1747.ep12286476; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Peters EMJ, 2001, J INVEST DERMATOL, V116, P236, DOI 10.1046/j.1523-1747.2001.01232.x; Plikus MV, 2008, NATURE, V451, P340, DOI 10.1038/nature06457; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rendl M, 2008, GENE DEV, V22, P543, DOI 10.1101/gad.1614408; Schneider MR, 2009, CURR BIOL, V19, pR132, DOI 10.1016/j.cub.2008.12.005; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Sharov AA, 2006, P NATL ACAD SCI USA, V103, P18166, DOI 10.1073/pnas.0608899103; Singh SK, 2008, NATURE, V453, P223, DOI 10.1038/nature06863; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Van Mater D, 2003, GENE DEV, V17, P1219, DOI 10.1101/gad.1076103; Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070; Winkler DG, 2004, J BIOL CHEM, V279, P36293, DOI 10.1074/jbc.M400521200; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Yu J, 2008, P NATL ACAD SCI USA, V105, P19300, DOI 10.1073/pnas.0803992105; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	64	125	142	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3869	3881		10.1096/fj.10-160663	http://dx.doi.org/10.1096/fj.10-160663			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20522784	Green Published			2022-12-28	WOS:000285005900025
J	Neumann, S; Geras-Raaka, E; Marcus-Samuels, B; Gershengorn, MC				Neumann, Susanne; Geras-Raaka, Elizabeth; Marcus-Samuels, Bernice; Gershengorn, Marvin C.			Persistent cAMP signaling by thyrotropin (TSH) receptors is not dependent on internalization	FASEB JOURNAL			English	Article						G-protein-coupled receptors; receptor-mediated endocytosis; sustained signaling; beta-arrestin-2; dynamin	HORMONE RECEPTOR; ENDOCYTOSIS; DYNAMIN; ALPHA	Evidence was presented that thyrotropin [thyroid-stimulating hormone (TSH)]-stimulated persistent cAMP signaling is dependent on receptor (with G-protein alpha subunits and adenylyl cyclase) internalization. Because it is not clear whether G proteins and adenylyl cyclase internalize with receptors, we tested whether persistent cAMP signaling by TSH receptor (TSHR) is dependent on internalization. We measured persistent TSHR signaling as an accumulation of cAMP in HEK-EM293 cells permanently expressing human TSHRs incubated with isobutylmethylxanthine for 30 min after washing the cells to remove unbound TSH, and TSHR internalization by fluorescence microscopy using Alexa-tagged TSH and binding assays using I-125-TSH. TSHRs, but not the closely related lutropin or follitropin receptors, exhibit persistent cAMP signaling. TSHRs were not internalized by 30 min incubation with unlabeled TSH; however, expression of beta-arrestin-2 promoted TSHR internalization that was inhibited by dynasore, a dynamin inhibitor. Expression of beta-arrestin-2 had no effect on TSHR cAMP signaling, dynasore inhibited TSHR cAMP signaling in the absence or presence of TSHR internalization, and expression of a dominant-negative mutant dynamin, which inhibited internalization, had no effect on persistent cAMP signaling. Persistent cAMP signaling was specifically inhibited by a small molecule TSHR antagonist. We conclude that TSHRs do not have to be internalized to exhibit persistent cAMP signaling.-Neumann, S., Geras-Raaka, E., Marcus-Samuels, B., Gershengorn, M. C. Persistent cAMP signaling by thyrotropin (TSH) receptors is not dependent on internalization. FASEB J. 24, 3992-3999 (2010). www.fasebj.org	[Neumann, Susanne; Geras-Raaka, Elizabeth; Marcus-Samuels, Bernice; Gershengorn, Marvin C.] NIDDK, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gershengorn, MC (corresponding author), NIDDK, Clin Endocrinol Branch, NIH, 50 South Dr, Bethesda, MD 20892 USA.	marving@intra.niddk.nih.gov			U.S. National Institutes of Health [1 Z01 DK011006]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011006, ZIADK011006] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported by the Intramural Research Program of the U.S. National Institutes of Health (1 Z01 DK011006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen JA, 2005, MOL PHARMACOL, V67, P1493, DOI 10.1124/mol.104.008342; Calebiro D, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000172; Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206; Frenzel R, 2006, ENDOCRINOLOGY, V147, P3114, DOI 10.1210/en.2005-0687; Hanyaloglu AC, 2008, ANNU REV PHARMACOL, V48, P537, DOI 10.1146/annurev.pharmtox.48.113006.094830; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Jalink K, 2010, BIOESSAYS, V32, P13, DOI 10.1002/bies.200900153; Jones BW, 2008, MOL PHARMACOL, V74, P195, DOI 10.1124/mol.108.045948; Kirchhausen T, 2008, METHOD ENZYMOL, V438, P77, DOI 10.1016/S0076-6879(07)38006-3; Merlen C, 2006, FEBS LETT, V580, P5697, DOI 10.1016/j.febslet.2006.09.021; Mullershausen F, 2009, NAT CHEM BIOL, V5, P428, DOI 10.1038/nchembio.173; NEUMANN S, 2010, ENDOCRINOLOGY; Neumann S, 2009, P NATL ACAD SCI USA, V106, P12471, DOI 10.1073/pnas.0904506106; Rapoport B, 2007, THYROID, V17, P911, DOI 10.1089/thy.2007.0170; Robbins J, 1978, Recent Prog Horm Res, V34, P477; Russell W, 2008, J CLIN ENDOCR METAB, V93, P2300, DOI 10.1210/jc.2007-2674; Scarselli M, 2009, J BIOL CHEM, V284, P3577, DOI 10.1074/jbc.M806819200; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	18	18	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3992	3999		10.1096/fj.10-161745	http://dx.doi.org/10.1096/fj.10-161745			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20538910	Green Published			2022-12-28	WOS:000285005900036
J	Wang, DY; Govindaiah, G; Liu, RJ; De Arcangelis, V; Cox, CL; Xiang, YK				Wang, Dayong; Govindaiah, G.; Liu, Ruijie; De Arcangelis, Vania; Cox, Charles L.; Xiang, Yang K.			Binding of amyloid beta peptide to beta(2) adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity	FASEB JOURNAL			English	Article						Alzheimer's disease; cAMP; EPSC; FRET; GluR1	PROTEIN-KINASE-A; ALZHEIMERS-DISEASE; ELECTROPHYSIOLOGICAL CHANGES; GLUTAMATE RECEPTORS; MOUSE MODEL; CAMP; OLIGOMERS; NEURONS; BETA(2)-ADRENOCEPTOR; NEUROTOXICITY	Progressive decrease in neuronal function is an established feature of Alzheimer's disease (AD). Previous studies have shown that amyloid beta (A beta) peptide induces acute increase in spontaneous synaptic activity accompanied by neurotoxicity, and A beta induces excitotoxic neuronal death by increasing calcium influx mediated by hyperactive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. An in vivo study has revealed subpopulations of hyperactive neurons near A beta plaques in mutant amyloid precursor protein (APP)-transgenic animal model of Alzheimer's disease (AD) that can be normalized by an AMPA receptor antagonist. In the present study, we aim to determine whether soluble A beta acutely induces hyperactivity of AMPA receptors by a mechanism involving beta(2) adrenergic receptor (beta(2)AR). We found that the soluble A beta binds to beta(2)AR, and the extracellular N terminus of beta(2)AR is critical for the binding. The binding is required to induce G-protein/cAMP/protein kinase A (PKA) signaling, which controls PKA-dependent phosphorylation of GluR1 and beta(2)AR, and AMPA receptor-mediated excitatory postsynaptic currents (EPSCs). beta(2)AR and GluR1 also form a complex comprising postsynaptic density protein 95 (PSD95), PKA and its anchor AKAP150, and protein phosphotase 2A (PP2A). Both the third intracellular (i3) loop and C terminus of beta(2)AR are required for the beta(2)AR/AMPA receptor complex. A beta acutely induces PKA phosphorylation of GluR1 in the complex without affecting the association between two receptors. The present study reveals that non-neurotransmitter A beta has a binding capacity to beta(2)AR and induces PKA-dependent hyperactivity in AMPA receptors.-Wang, D., Govindaiah, G., Liu, R., De Arcangelis, V., Cox, C. L., Xiang, Y. K. Binding of amyloid beta peptide to beta(2) adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J. 24, 3511-3521 (2010). www.fasebj.org	[Wang, Dayong; Govindaiah, G.; Liu, Ruijie; De Arcangelis, Vania; Xiang, Yang K.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; [Cox, Charles L.] Univ Illinois, Beckman Inst, Urbana, IL 61801 USA; [Cox, Charles L.; Xiang, Yang K.] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Xiang, YK (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 407 S Goodwin Ave, Urbana, IL 61801 USA.	kevinyx@illinois.edu	LIU, ruijie/K-7376-2012	Wang, Dayong/0000-0002-2086-1663; liu, ruijie/0000-0002-2468-0579; Cox, Charles/0000-0002-1179-7014	National Eye Institute [EY014024]; National Institute of Heart, Blood, and Lung [HL082846]; National Alliance for Research on Schizophrenia and Depression; Illinois Department of Public Health; NATIONAL EYE INSTITUTE [R01EY014024, R56EY014024] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082846] Funding Source: NIH RePORTER	National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); National Institute of Heart, Blood, and Lung; National Alliance for Research on Schizophrenia and Depression(NARSAD); Illinois Department of Public Health; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Dennis J. Selkoe (Harvard Medical School, Cambridge, MA, USA) for kindly providing the 7PA2-transgenic CHO cell line and the plasmid, and Dr. Richard Clark (University of Texas Medical Center, Houston, TX, USA) for anti-beta<INF>2</INF>AR S261/262 antibody. The authors thank Dr. Venkata R. P. Ratnala (Departments of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA) for performing the [<SUP>35</SUP>S] GTP gamma S binding assay. The authors thank Mr. Mingwei Ding, Branden Skarpiak, Elaine Wu, and other members of the Y.K.X. laboratory for assistance. This work was supported by National Eye Institute grant EY014024 (C. L. C.) and National Institute of Heart, Blood, and Lung grant HL082846 (Y.K.X.). D. W. is a recipient of a National Alliance for Research on Schizophrenia and Depression award and an Illinois Department of Public Health grant.	AbdAlla S, 2009, J BIOL CHEM, V284, P6554, DOI 10.1074/jbc.M807746200; Abramov E, 2009, NAT NEUROSCI, V12, P1567, DOI 10.1038/nn.2433; Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; Beene DL, 2007, CURR OPIN CELL BIOL, V19, P192, DOI 10.1016/j.ceb.2007.02.011; Blanchard BJ, 2004, P NATL ACAD SCI USA, V101, P14326, DOI 10.1073/pnas.0405941101; Busche MA, 2008, SCIENCE, V321, P1686, DOI 10.1126/science.1162844; Carulla N, 2005, NATURE, V436, P554, DOI 10.1038/nature03986; Chen CJ, 2003, J NEUROCHEM, V85, P443, DOI 10.1046/j.1471-4159.2003.01691.x; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DAVIES CA, 1987, J NEUROL SCI, V78, P151, DOI 10.1016/0022-510X(87)90057-8; Echeverria V, 2005, NEUROSCIENCE, V135, P1193, DOI 10.1016/j.neuroscience.2005.06.057; Englund H, 2007, DEMENT GERIATR COGN, V24, P369, DOI 10.1159/000109215; Francis P T, 2009, Curr Mol Pharmacol, V2, P77; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Gallardo G, 2008, NAT NEUROSCI, V11, P301, DOI 10.1038/nn2058; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Govindaiah G, 2006, J NEUROSCI, V26, P13443, DOI 10.1523/JNEUROSCI.3578-06.2006; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hoogendijk W J, 2001, Tijdschr Gerontol Geriatr, V32, P17; Hoogendijk WJG, 1999, ANN NEUROL, V45, P82, DOI 10.1002/1531-8249(199901)45:1<82::AID-ART14>3.0.CO;2-T; Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035; Hu HL, 2007, CELL, V131, P160, DOI 10.1016/j.cell.2007.09.017; Igbavboa U, 2006, NEUROSCIENCE, V142, P655, DOI 10.1016/j.neuroscience.2006.06.056; Iijima-Ando K, 2008, J BIOL CHEM, V283, P19066, DOI 10.1074/jbc.M710509200; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; Joiner MLA, 2010, EMBO J, V29, P482, DOI 10.1038/emboj.2009.344; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kornischka J, 2007, FORTSCHR NEUROL PSYC, V75, P199, DOI 10.1055/s-2006-944295; Kuchibhotla KV, 2008, NEURON, V59, P214, DOI 10.1016/j.neuron.2008.06.008; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Liu RJ, 2009, J BIOL CHEM, V284, P32279, DOI 10.1074/jbc.M109.021428; Louzada PR, 2001, NEUROSCI LETT, V301, P59, DOI 10.1016/S0304-3940(01)01585-3; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Ni YX, 2006, NAT MED, V12, P1390, DOI 10.1038/nm1485; Nimmrich V, 2008, J NEUROSCI, V28, P788, DOI 10.1523/JNEUROSCI.4771-07.2008; Parameshwaran K, 2008, EXP NEUROL, V210, P7, DOI 10.1016/j.expneurol.2007.10.008; Pettit DL, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-01-j0003.2001; Rosenberg PB, 2008, AM J GERIAT PSYCHIAT, V16, P883, DOI 10.1097/JGP.0b013e318181276a; RussoNeustadt A, 1997, J NEUROSCI, V17, P5573; Satoh Y, 2001, NEUROSCI LETT, V302, P97, DOI 10.1016/S0304-3940(01)01665-2; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Tao JC, 2003, EMBO J, V22, P6419, DOI 10.1093/emboj/cdg628; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Vekovischeva OY, 2007, PHARMACOL BIOCHEM BE, V87, P241, DOI 10.1016/j.pbb.2007.04.020; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang DY, 2007, NEUROPSYCHOPHARMACOL, V32, P1261, DOI 10.1038/sj.npp.1301256; Wang Y, 2008, J BIOL CHEM, V283, P1799, DOI 10.1074/jbc.M705747200; Wang YY, 2007, MOL PHARMACOL, V72, P429, DOI 10.1124/mol.107.037747; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104; Xiang Y, 2005, P NATL ACAD SCI USA, V102, P909, DOI 10.1073/pnas.0405263102; Ye CP, 2004, NEUROSCI LETT, V366, P320, DOI 10.1016/j.neulet.2004.05.060; Yu JT, 2008, BRAIN RES, V1210, P216, DOI 10.1016/j.brainres.2008.03.019; Zhang J, 2005, NATURE, V437, P569, DOI 10.1038/nature04140	60	62	65	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3511	3521		10.1096/fj.10-156661	http://dx.doi.org/10.1096/fj.10-156661			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20395454	Green Published			2022-12-28	WOS:000281446400038
J	Weissmann, G				Weissmann, Gerald			Filter the Dogs: Microbial Mishaps in Massachusetts	FASEB JOURNAL			English	Editorial Material							ESCHERICHIA-COLI						Weissmann, Gerald/N-5273-2015	Weissmann, Gerald/0000-0002-4285-4552				BARKER F, 1857, NEW YORK J MED COLL, V105, P348; CHANGEUX JP, 1960, CR HEBD ACAD SCI, V250, P1575; CHARCOT JM, 1995, PASTEUR COSMOPOLITAN, V18, P271; HOLMES OW, 1963, AM J MED SCI, V45, P157; Holmes OW., 1843, NEW ENGL Q J MED, V1, P503; HOLMES OW, 1927, COMPANIA GEN DE TABA; Holmes OW., 1855, PUERPERAL FEVER PRIV; KAZARIAN C, 2010, FALMOUTH ENTERP 0709, P1; KENNEDY EP, 1992, ANNU REV BIOCHEM, V61, P1; KENNEDY EP, 2010, COMMUNICATION   0618; KNOWLES AS, 2010, COMMUNICATION   0620; Kornberg HL, 2003, J BIOL CHEM, V278, P9993, DOI 10.1074/jbc.X200008200; LEDERBERG J, 2000, PROJECT SYNDICATE; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; MILLER KJ, 1986, SCIENCE, V231, P48, DOI 10.1126/science.3941890; *NATIONMASTER, WAT CONT DIS MOST RE; *NATIONMASTER, MAT MOR MOST REC COU; OSLER W, 1994, B J HOPKINS HOSP, V42, P85; PARDEE AB, 1952, ARCH BIOCHEM BIOPHYS, V40, P222, DOI 10.1016/0003-9861(52)90090-8; Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109; Riley M, 2006, NUCLEIC ACIDS RES, V34, P1, DOI 10.1093/nar/gkj405; SOGIN M, 2010, FALMOUTH ENTERP 0625, pA4; STERLING EJ, 2009, MILST SCI S AM MUS N; TATUM EL, 1947, J BACTERIOL, V53, P673, DOI 10.1128/JB.53.6.673-684.1947; *TOWN FALM, BOIL ORD INF HIST; *TRAILS, FALM TOWN FOR LONG P; WICKETT S, 2010, BOSTON GLOBE    0617, pB3	27	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3113	3116		10.1096/fj.10-0901ufm	http://dx.doi.org/10.1096/fj.10-0901ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20807715				2022-12-28	WOS:000281446400001
J	Solinas, G; Karin, M				Solinas, Giovanni; Karin, Michael			JNK1 and IKK beta: molecular links between obesity and metabolic dysfunction	FASEB JOURNAL			English	Review						type 2 diabetes; glucotoxicity; lipotoxicity; metabolic inflammation; metabolic stress	INSULIN-RECEPTOR SUBSTRATE-1; ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; JUN NH2-TERMINAL KINASE; GLYCATION END-PRODUCTS; INTERLEUKIN-2 MESSENGER-RNA; HEXOSAMINE PATHWAY LEADS; SKELETAL-MUSCLE CELLS; WHITE ADIPOSE-TISSUE	Inflammation is thought to underlie the pathogenesis of many chronic diseases. It is now established that obesity results in a state of chronic low-grade inflammation thought to contribute to several metabolic disorders, including insulin resistance and pancreatic islet dysfunction. The protein kinases JNK1 and IKK beta have been found to serve as critical molecular links between obesity, metabolic inflammation, and disorders of glucose homeostasis. The precise mechanisms of these linkages are still being investigated. However, as we discuss here, JNK1 and IKK beta are activated by almost all forms of metabolic stress that have been implicated in insulin resistance or islet dysfunction. Furthermore, both JNK1 and IKK beta are critically involved in the promotion of diet-induced obesity, metabolic inflammation, insulin resistance, and beta-cell dysfunction. Understanding the molecular mechanisms by which JNK1 and IKK beta mediate obesity-induced metabolic stress is likely to be of importance for the development of new treatments for a variety of obesity-associated diseases.-Solinas, G., Karin, M. JNK1 and IKK beta: molecular links between obesity and metabolic dysfunction. FASEB J. 24, 2596-2611 (2010). www.fasebj.org	[Solinas, Giovanni] Univ Fribourg, Dept Med, Lab Metab Stress Biol, CH-1700 Fribourg, Switzerland; [Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, San Diego, CA 92103 USA	University of Fribourg; University of California System; University of California San Diego	Solinas, G (corresponding author), Univ Fribourg, Dept Med, Lab Metab Stress Biol, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	giovanni.solinas@unifr.ch	Solinas, Giovanni/R-4777-2019; Solinas, Giovanni/P-6596-2017	Solinas, Giovanni/0000-0002-0140-2621; Solinas, Giovanni/0000-0002-0140-2621	Swiss National Science Foundation [SNF31003A-118172]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This review is supported by a Swiss National Science Foundation grant SNF31003A-118172 to G.S. The authors thank Barbara Becattini and Clive M. Brown for their critical comments.	Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Andreozzi F, 2004, ENDOCRINOLOGY, V145, P2845, DOI 10.1210/en.2003-0939; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Borradaile NM, 2006, J LIPID RES, V47, P2726, DOI 10.1194/jlr.M600299-JLR200; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Cancello R, 2005, DIABETES, V54, P2277, DOI 10.2337/diabetes.54.8.2277; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chavakis T, 2004, MICROBES INFECT, V6, P1219, DOI 10.1016/j.micinf.2004.08.004; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; Ciaraldi TP, 1999, ENDOCRINOLOGY, V140, P3971, DOI 10.1210/en.140.9.3971; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Copps KD, 2010, CELL METAB, V11, P84, DOI 10.1016/j.cmet.2009.11.003; Cottet S, 2002, DIABETES, V51, P1805, DOI 10.2337/diabetes.51.6.1805; Diakogiannaki E, 2008, BIOCHEM SOC T, V36, P959, DOI 10.1042/BST0360959; Diakogiannaki E, 2008, J ENDOCRINOL, V197, P553, DOI 10.1677/JOE-08-0041; Dulloo AG, 2004, INT J OBESITY, V28, pS29, DOI 10.1038/sj.ijo.0802861; Ehses JA, 2007, DIABETES, V56, P2356, DOI 10.2337/db06-1650; Eldor R, 2006, P NATL ACAD SCI USA, V103, P5072, DOI 10.1073/pnas.0508166103; Eriksson JW, 2007, FEBS LETT, V581, P3734, DOI 10.1016/j.febslet.2007.06.044; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Fleischman A, 2008, DIABETES CARE, V31, P289, DOI 10.2337/dc07-1338; Fukuda K, 2008, BIOCHEM BIOPH RES CO, V366, P710, DOI 10.1016/j.bbrc.2007.12.007; Furuhashi M, 2008, J CLIN INVEST, V118, P2640, DOI 10.1172/JCI34750; Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Giannoukakis N, 2000, J BIOL CHEM, V275, P36509, DOI 10.1074/jbc.M005943200; Goh SY, 2008, J CLIN ENDOCR METAB, V93, P1143, DOI 10.1210/jc.2007-1817; Guo W, 2007, AM J PHYSIOL-ENDOC M, V293, pE576, DOI 10.1152/ajpendo.00523.2006; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Han MS, 2008, J LIPID RES, V49, P84, DOI 10.1194/jlr.M700184-JLR200; He JY, 2006, MOL ENDOCRINOL, V20, P114, DOI 10.1210/me.2005-0107; Herschkovitz A, 2007, J BIOL CHEM, V282, P18018, DOI 10.1074/jbc.M610949200; Hevener AL, 2007, J CLIN INVEST, V117, P1658, DOI 10.1172/JCI31561; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Ho FM, 2000, CIRCULATION, V101, P2618, DOI 10.1161/01.CIR.101.22.2618; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Inoguchi T, 2003, J AM SOC NEPHROL, V14, pS227, DOI 10.1097/01.ASN.0000077407.90309.65; Jaeschke A, 2007, MOL CELL, V27, P498, DOI 10.1016/j.molcel.2007.07.008; Jager J, 2007, ENDOCRINOLOGY, V148, P241, DOI 10.1210/en.2006-0692; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Kaneto H, 2007, CURR MOL MED, V7, P674, DOI 10.2174/156652407782564408; Kaneto H, 2007, ANTIOXID REDOX SIGN, V9, P355, DOI 10.1089/ars.2006.1465; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kawamori D, 2003, DIABETES, V52, P2896, DOI 10.2337/diabetes.52.12.2896; Kim KA, 2009, FRONT BIOSCI-LANDMRK, V14, P657, DOI 10.2741/3271; King GL, 2004, HISTOCHEM CELL BIOL, V122, P333, DOI 10.1007/s00418-004-0678-9; Kleinridders A, 2009, CELL METAB, V10, P249, DOI 10.1016/j.cmet.2009.08.013; Klover PJ, 2005, ENDOCRINOLOGY, V146, P3417, DOI 10.1210/en.2004-1468; Kodama Y, 2009, GASTROENTEROLOGY, V137, P1467, DOI 10.1053/j.gastro.2009.06.045; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Lefkowitch JH, 2002, MODERN PATHOL, V15, P699, DOI 10.1097/01.MP.0000019579.30842.96; Lesniewski LA, 2007, NAT MED, V13, P455, DOI 10.1038/nm1550; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Lin L, 2006, CELL MOL IMMUNOL, V3, P351; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lumeng CN, 2009, NAT MED, V15, P846, DOI 10.1038/nm0809-846; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maedler K, 2002, P NATL ACAD SCI USA, V99, P8236, DOI 10.1073/pnas.122686299; Maedler K, 2001, DIABETES, V50, P1683, DOI 10.2337/diabetes.50.8.1683; Maedler K, 2008, FASEB J, V22, P1905, DOI 10.1096/fj.07-101824; Malhi H, 2006, J BIOL CHEM, V281, P12093, DOI 10.1074/jbc.M510660200; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011; Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340; Medina-Gomez G, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030064; Miele C, 2003, J BIOL CHEM, V278, P47376, DOI 10.1074/jbc.M301088200; Morino K, 2008, DIABETES, V57, P2644, DOI 10.2337/db06-0454; Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001; Nawano M, 2000, AM J PHYSIOL-ENDOC M, V278, pE535, DOI 10.1152/ajpendo.2000.278.3.E535; Nawano M, 1999, BIOCHEM BIOPH RES CO, V266, P252, DOI 10.1006/bbrc.1999.1797; Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200; Nguyen MTA, 2005, J BIOL CHEM, V280, P35361, DOI 10.1074/jbc.M504611200; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Oku A, 2001, AM J PHYSIOL-ENDOC M, V280, pE816, DOI 10.1152/ajpendo.2001.280.5.E816; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Ozcan L, 2009, CELL METAB, V9, P35, DOI 10.1016/j.cmet.2008.12.004; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Patsouris D, 2008, CELL METAB, V8, P301, DOI 10.1016/j.cmet.2008.08.015; Pedersen BK, 2008, PHYSIOL REV, V88, P1379, DOI 10.1152/physrev.90100.2007; Pedersen BK, 2007, J APPL PHYSIOL, V102, P814, DOI 10.1152/japplphysiol.01208.2006; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Poggi M, 2007, DIABETOLOGIA, V50, P1267, DOI 10.1007/s00125-007-0654-8; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; REID J, 1957, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5053.1071; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Saberi M, 2009, CELL METAB, V10, P419, DOI 10.1016/j.cmet.2009.09.006; Sabio G, 2008, SCIENCE, V322, P1539, DOI 10.1126/science.1160794; Sabio G, 2010, GENE DEV, V24, P256, DOI 10.1101/gad.1878510; Sabio G, 2010, MOL CELL BIOL, V30, P106, DOI 10.1128/MCB.01162-09; Sabio G, 2009, CELL METAB, V10, P491, DOI 10.1016/j.cmet.2009.09.007; Sauter NS, 2008, ENDOCRINOLOGY, V149, P2208, DOI 10.1210/en.2007-1059; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260; Schernthaner GH, 2006, OBES SURG, V16, P709, DOI 10.1381/096089206777346763; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schumann DM, 2007, P NATL ACAD SCI USA, V104, P2861, DOI 10.1073/pnas.0611487104; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Senn JJ, 2006, J BIOL CHEM, V281, P26865, DOI 10.1074/jbc.M513304200; Sharfi H, 2008, AM J PHYSIOL-ENDOC M, V294, pE307, DOI 10.1152/ajpendo.00534.2007; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Solinas G, 2007, CELL METAB, V6, P386, DOI 10.1016/j.cmet.2007.09.011; Solinas G, 2006, P NATL ACAD SCI USA, V103, P16454, DOI 10.1073/pnas.0607626103; Spranger J, 2003, DIABETES, V52, P812, DOI 10.2337/diabetes.52.3.812; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Takahashi K, 2008, AM J PHYSIOL-ENDOC M, V294, pE898, DOI 10.1152/ajpendo.00131.2007; Taniguchi CM, 2007, MOL CELL BIOL, V27, P2830, DOI 10.1128/MCB.00079-07; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Temkin V, 2007, IMMUNOL REV, V220, P8, DOI 10.1111/j.1600-065X.2007.00560.x; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595; Tuncman G, 2006, P NATL ACAD SCI USA, V103, P10741, DOI 10.1073/pnas.0603509103; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003-0870; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; URANO F, 2000, SCIENCE, V287, P664, DOI [DOI 10.1126/SCIENCE.287.5453.664, 10.1126/science.287.5453.664, DOI 10.1126/science.287.5453.664]; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Vallerie SN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003151; Veerababu G, 2000, DIABETES, V49, P2070, DOI 10.2337/diabetes.49.12.2070; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Virtue S, 2008, PLOS BIOL, V6, P1819, DOI 10.1371/journal.pbio.0060237; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Wei YR, 2006, AM J PHYSIOL-ENDOC M, V291, pE275, DOI 10.1152/ajpendo.00644.2005; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Werstruck GH, 2006, DIABETES, V55, P93, DOI 10.2337/diabetes.55.01.06.db05-0633; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Williamson RT, 1901, BRIT MED J, V1901, P760, DOI 10.1136/bmj.1.2100.760; Winer S, 2009, NAT MED, V15, P921, DOI 10.1038/nm.2001; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yang L, 2008, CELL, V135, P20, DOI 10.1016/j.cell.2008.09.030; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhang SP, 2003, J BIOL CHEM, V278, P52810, DOI 10.1074/jbc.M308244200; Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	173	244	256	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2596	2611		10.1096/fj.09-151340	http://dx.doi.org/10.1096/fj.09-151340			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371626				2022-12-28	WOS:000285005400002
J	Tarry-Adkins, JL; Chen, JH; Jones, RH; Smith, NH; Ozanne, SE				Tarry-Adkins, Jane L.; Chen, Jian-Hua; Jones, Richard H.; Smith, Noel H.; Ozanne, Susan E.			Poor maternal nutrition leads to alterations in oxidative stress, antioxidant defense capacity, and markers of fibrosis in rat islets: potential underlying mechanisms for development of the diabetic phenotype in later life	FASEB JOURNAL			English	Article						hyperglycemia; fibrosis; type 2 diabetes	LOW-PROTEIN-DIET; LOW-BIRTH-WEIGHT; PANCREATIC-ISLETS; INSULIN-RESISTANCE; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; HEME OXYGENASE-1; PROTECTIVE ROLE; NADPH OXIDASES; FREE-RADICALS	Low birth weight is associated with glucose intolerance, insulin resistance, and type 2 diabetes (T2D) in later life. Good evidence indicates that the environment plays an important role in this relationship. However, the mechanisms underlying these relationships are defined poorly. Islets are particularly susceptible to oxidative stress, and this condition combined with fibrosis is thought to be instrumental in T2D pathogenesis. Here we use our maternal low-protein (LP) rat model to determine the effect of early diet on oxidative stress and fibrosis in pancreatic islets of male offspring at 3 and 15 mo of age. Islet xanthine oxidase (XO) expression was increased in 15-mo LP offspring, which suggests increased oxidative-stress. Manganese superoxide-dismutase (MnSOD), copper-zinc superoxide dismutase (CuZnSOD), and heme oxygenase-1 (HO-1) (antioxidant enzymes) were reduced significantly in LP offspring, which indicated impairment of oxidative defense. Expression of fibrosis markers collagen I and collagen III also increased in 15-mo LP offspring. Angiotensin II receptor type I (AT(II)R(I)), induced by hyperglycemia and oxidative-stress, was significantly up-regulated in 15-mo LP offspring. Lipid peroxidation was also increased in 15-mo LP animals. We conclude that maternal protein restriction causes age-associated increased oxidative stress, impairment of oxidative defense, and fibrosis. These findings provide mechanisms by which suboptimal early nutrition can lead to T2D development later in life.-TarryAdkins, J. L., Chen, J.-H., Jones, R. H., Smith, N. H., Ozanne, S. E. Poor maternal nutrition leads to alterations in oxidative stress, antioxidant defense capacity, and markers of fibrosis in rat islets: potential underlying mechanisms for development of the diabetic phenotype in later life. FASEB J. 24, 2762-2771 (2010). www.fasebj.org	[Tarry-Adkins, Jane L.; Chen, Jian-Hua; Jones, Richard H.; Smith, Noel H.; Ozanne, Susan E.] Univ Cambridge, Metab Res Labs, Inst Metab Sci, Addenbrookes Treatment Ctr,Addenbrookes Hosp, Cambridge CB2 0QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Tarry-Adkins, JL (corresponding author), Univ Cambridge, Metab Res Labs, Inst Metab Sci, Addenbrookes Treatment Ctr,Addenbrookes Hosp, Level 4,Box 289,Hills Rd, Cambridge CB2 0QQ, England.	janeadkins@googlemail.com		Tarry-Adkins, Jane/0000-0001-9569-6132; Ozanne, Susan/0000-0001-8753-5144	British Heart Foundation; Biotechnology and Biological Sciences Research Council; Medical Research Council Centre for Obesity and Related Metabolic Diseases; Parthenon Trust; BBSRC [BB/D007909/1, BB/E002161/1, BB/F015364/1, BB/E00797X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D007909/1, BB/E00797X/1, BB/E002161/1, BB/F015364/1] Funding Source: researchfish; British Heart Foundation [PG/09/037/27387, FS/09/029/27902] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council Centre for Obesity and Related Metabolic Diseases(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Parthenon Trust; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation)	The authors thank A. Wayman and D. Hawkes for their technical expertise. This work was supported by the British Heart Foundation, the Biotechnology and Biological Sciences Research Council, the Medical Research Council Centre for Obesity and Related Metabolic Diseases, and the Parthenon Trust.	Apte MV, 1998, GUT, V43, P128, DOI 10.1136/gut.43.1.128; Armitage JA, 2004, J PHYSIOL-LONDON, V561, P355, DOI 10.1113/jphysiol.2004.072009; Azevedo-Martins AK, 2003, DIABETES, V52, P93, DOI 10.2337/diabetes.52.1.93; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bo S, 2000, DIABETIC MED, V17, P365, DOI 10.1046/j.1464-5491.2000.00288.x; Bonnefont-Rousselot D, 2000, DIABETES METAB, V26, P163; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Chen HN, 2005, DIABETES, V54, P1437, DOI 10.2337/diabetes.54.5.1437; Chu KY, 2006, DIABETES, V55, P367, DOI 10.2337/diabetes.55.02.06.db05-1022; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; Garofano A, 1999, DIABETOLOGIA, V42, P711, DOI 10.1007/s001250051219; GRANKVIST K, 1981, BIOCHEM J, V173, P83; Grunnet L, 2007, J INTERN MED, V262, P96, DOI 10.1111/j.1365-2796.2007.01793.x; Guichard C, 2008, BIOCHEM SOC T, V36, P920, DOI 10.1042/BST0360920; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Hong OK, 2007, J CELL BIOCHEM, V101, P665, DOI 10.1002/jcb.21222; Kajimoto Y, 2004, ANN NY ACAD SCI, V1011, P168, DOI 10.1196/annals.1293.017; KARAWICZBINISKA A, 2008, MED SCI MONITOR, V8, pCR211; Karger A, 2008, CELL SIGNAL, V20, P1865, DOI 10.1016/j.cellsig.2008.06.016; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; Leung KK, 2008, J PANCREAS, V9, P290; Li YX, 2006, CHINESE MED J-PEKING, V119, P1639, DOI 10.1097/00029330-200610010-00008; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Lodovici M, 2009, TOXICOL IND HEALTH, V25, P337, DOI 10.1177/0748233709106464; Manea A, 2005, BIOL CELL, V97, P723, DOI 10.1042/BC20040107; Masamune A, 2008, AM J PHYSIOL-GASTR L, V294, pG99, DOI 10.1152/ajpgi.00272.2007; MCMILLEN C, 2005, AM PHYSL J, V85, P571; Memisogullari R, 2003, CELL BIOCHEM FUNCT, V21, P291, DOI 10.1002/cbf.1025; Morgan D, 2007, DIABETOLOGIA, V50, P359, DOI 10.1007/s00125-006-0462-6; Nagashio Y, 2004, AM J PHYSIOL-GASTR L, V287, pG170, DOI 10.1152/ajpgi.00005.2004; Nakayama M, 2005, BIOCHEM BIOPH RES CO, V332, P927, DOI 10.1016/j.bbrc.2005.05.065; Newsholme P, 2009, DIABETOLOGIA, V52, P2489, DOI 10.1007/s00125-009-1536-z; NEWSHOLME P, 2007, J PHYSL, V581, P9; Ong KK, 2004, DIABETOLOGIA, V47, P1064, DOI 10.1007/s00125-004-1405-8; Ozanne SE, 2005, DIABETOLOGIA, V48, P547, DOI 10.1007/s00125-005-1669-7; Ozanne SE, 2003, J ENDOCRINOL, V177, P235, DOI 10.1677/joe.0.1770235; Petrik J, 1999, ENDOCRINOLOGY, V140, P4861, DOI 10.1210/en.140.10.4861; Petry C J, 2001, Int J Exp Diabetes Res, V2, P139; Petry CJ, 2000, HORM METAB RES, V32, P233, DOI 10.1055/s-2007-978627; Pileggi A, 2001, DIABETES, V50, P1983, DOI 10.2337/diabetes.50.9.1983; Poulsen P, 1997, DIABETOLOGIA, V40, P439, DOI 10.1007/s001250050698; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; Shao JQ, 2007, ACTA PHARMACOL SIN, V28, P246, DOI 10.1111/j.1745-7254.2007.00492.x; Shepherd PR, 1997, BRIT J NUTR, V78, P121, DOI 10.1079/BJN19970124; Shimizu K, 2008, J RHEUMATOL, V35, P2214, DOI 10.3899/jrheum.080191; Simmons RA, 2005, J BIOL CHEM, V280, P28785, DOI 10.1074/jbc.M505695200; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Tanioka H, 2006, J GASTROEN HEPATOL, V21, P537, DOI 10.1111/j.1440-1746.2005.03999.x; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wenzel P, 2008, FREE RADICAL BIO MED, V45, P619, DOI 10.1016/j.freeradbiomed.2008.05.009; Won KC, 2006, J KOREAN MED SCI, V21, P418, DOI 10.3346/jkms.2006.21.3.418; Ye J, 1998, ENDOCRINOLOGY, V139, P4155, DOI 10.1210/en.139.10.4155	55	63	65	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2762	2771		10.1096/fj.10-156075	http://dx.doi.org/10.1096/fj.10-156075			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20388698				2022-12-28	WOS:000285005400017
J	Delluc, S; Ravot, G; Maillere, B				Delluc, Stephanie; Ravot, Gilles; Maillere, Bernard			Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors	FASEB JOURNAL			English	Article						humanization; immunogenicity; naive	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CLINICAL-RESPONSE; RITUXIMAB TREATMENT; TRANSGENIC MICE; HEMOPHILIA-A; FACTOR-VIII; IFN-BETA; IMMUNOGENICITY; TOLERANCE; ETANERCEPT	Therapeutic antibodies are generally partially to fully humanized, yet they can show unwanted immunogenicity and lead to antibody response and adverse effects when administered to humans. As immunogenicity relies on a T-cell-dependent mechanism, we have evaluated in vitro the size of the preexisting CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. Specific CD4 T cells of individuals with different HLA-DR allotypes were amplified by in vitro stimulation and quantified. Well-known immunogenic proteins, KLH and a murine antibody, exhibited a strong in vitro T-cell response characterized by a mean of preexisting T cells >1 cell/10(6) cells. In contrast, the preexisting CD4 T-cell repertoires specific to 2 chimeric, 2 humanized, and 2 fully human antibodies remained generally inferior to this value, confirming the role of species-specific sequences in their shaping. Mean values ranged from 0.01 to 0.3 cell/10(6) cells and varied not necessarily in relationship with the humanization level of the therapeutic antibodies. Relationship with their known immunogenicity is discussed. These results contribute to a better understanding and prediction of immunogenicity of therapeutic antibodies in humans.-Delluc, S., Ravot, G., Maillere, B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J. 25, 2040-2048 (2011). www.fasebj.org	[Delluc, Stephanie; Ravot, Gilles] Proteus, F-30035 Nimes 1, France; [Maillere, Bernard] Commissariat Energie Atom & Energies Alternat, Inst Biol & Technol Saclay, Serv Ingn Mol Prot, Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Maillere, B (corresponding author), CEA, iBiTecS, Serv Ingn Mol Prot, F-91191 Gif Sur Yvette, France.	sdelluc@proteus.fr; bernard.maillere@cea.fr			Proteus; Commissariat a l'Energie Atomique et aux Energies Alternatives	Proteus; Commissariat a l'Energie Atomique et aux Energies Alternatives	The authors thank Prof. J.-L. Prugnaud (St. Antoine Hospital, Paris, France) and Dr. Ingrid Marchal-Gerez (Proteus) for advice. The authors also thank Prof. J.-L. Prugnaud, Prof. A. Buzyn (Necker-Enfants Malades Hospital, Paris, France), Prof. M. Breban (Ambroise Pare Hospital, Boulogne-Billancourt, France) and Prof. S. Oudard (European Georges Pompidou Hospital, Paris, France) for the kind gift of therapeutic antibodies. This work was supported by Proteus and the Commissariat a l'Energie Atomique et aux Energies Alternatives.	Antonelli G, 1996, CLIN EXP IMMUNOL, V104, P384, DOI 10.1046/j.1365-2249.1996.43747.x; Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Barbosa MDFS, 2006, CLIN IMMUNOL, V118, P42, DOI 10.1016/j.clim.2005.08.017; Bartelds GM, 2007, ANN RHEUM DIS, V66, P921, DOI 10.1136/ard.2006.065615; Bender NK, 2007, RHEUMATOL INT, V27, P269, DOI 10.1007/s00296-006-0183-7; Bendtzen K, 2006, ARTHRITIS RHEUM-US, V54, P3782, DOI 10.1002/art.22214; BOGEN B, 1993, EMBO J, V12, P357, DOI 10.1002/j.1460-2075.1993.tb05664.x; BOULAIN JC, 1982, SCIENCE, V217, P732, DOI 10.1126/science.7100919; BRAY GL, 1993, AM J HEMATOL, V42, P375, DOI 10.1002/ajh.2830420408; Casadevall N, 2002, NEW ENGL J MED, V346, P469, DOI 10.1056/NEJMoa011931; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CIBOTTI R, 1992, P NATL ACAD SCI USA, V89, P416, DOI 10.1073/pnas.89.1.416; De Groot AS, 2008, BLOOD, V112, P3303, DOI 10.1182/blood-2008-02-138073; de Vries MK, 2009, ANN RHEUM DIS, V68, P531, DOI 10.1136/ard.2008.089979; de Vries MK, 2007, ANN RHEUM DIS, V66, P1252, DOI 10.1136/ard.2007.072397; Delluc S, 2010, BLOOD, V116, P4542, DOI 10.1182/blood-2010-04-280875; Denton CP, 2009, ANN RHEUM DIS, V68, P1433, DOI 10.1136/ard.2008.096123; Dore RK, 2007, CLIN EXP RHEUMATOL, V25, P40; Duda PW, 2000, J IMMUNOL, V165, P7300, DOI 10.4049/jimmunol.165.12.7300; Geiger R, 2009, J EXP MED, V206, P1525, DOI 10.1084/jem.20090504; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Hanauer SB, 2004, CLIN GASTROENTEROL H, V2, P542, DOI 10.1016/S1542-3565(04)00238-1; Hansel TT, 2010, NAT REV DRUG DISCOV, V9, P325, DOI 10.1038/nrd3003; Haribhai D, 2003, J IMMUNOL, V170, P3007, DOI 10.4049/jimmunol.170.6.3007; HLA Colombani J, 1993, HLA FONCTIONS IMMUNI; Jacquemin M, 2003, BLOOD, V101, P1351, DOI 10.1182/blood-2002-05-1369; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; Klein L, 2009, NAT REV IMMUNOL, V9, P833, DOI 10.1038/nri2669; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Li JZ, 2001, BLOOD, V98, P3241, DOI 10.1182/blood.V98.12.3241; Lippolis JD, 2002, J IMMUNOL, V169, P5089, DOI 10.4049/jimmunol.169.9.5089; Loirat D, 2003, INT IMMUNOL, V15, P1125, DOI 10.1093/intimm/dxg117; Looney RJ, 2004, ARTHRITIS RHEUM, V50, P2580, DOI 10.1002/art.20430; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; Peng A, 2009, J PHARM SCI-US, V98, P4480, DOI 10.1002/jps.21765; Pijpe J, 2005, ARTHRITIS RHEUM-US, V52, P2740, DOI 10.1002/art.21260; Piro LD, 1999, ANN ONCOL, V10, P655, DOI 10.1023/A:1008389119525; Radstake TRDJ, 2009, ANN RHEUM DIS, V68, P1739, DOI 10.1136/ard.2008.092833; Sandborn WJ, 2007, GUT, V56, P1232, DOI 10.1136/gut.2006.106781; Schmidt E, 2009, CLIN IMMUNOL, V132, P334, DOI 10.1016/j.clim.2009.05.007; Schmitt N, 2009, IMMUNITY, V31, P158, DOI 10.1016/j.immuni.2009.04.016; Smith KGC, 2006, ARTHRITIS RHEUM-US, V54, P2970, DOI 10.1002/art.22046; Tanaka Yoshiya, 2007, Mod Rheumatol, V17, P191; Thurlings RM, 2010, ANN RHEUM DIS, V69, P409, DOI 10.1136/ard.2009.109041; Tyring S, 2007, ARCH DERMATOL, V143, P719, DOI 10.1001/archderm.143.6.719; Valmori D, 2005, CLIN IMMUNOL, V117, P161, DOI 10.1016/j.clim.2005.07.004; Van Walle I, 2007, EXPERT OPIN BIOL TH, V7, P405, DOI 10.1517/14712598.7.3.405; Wolbink GJ, 2006, ARTHRITIS RHEUM-US, V54, P711, DOI 10.1002/art.21671; Yeung VP, 2004, J IMMUNOL, V172, P6658, DOI 10.4049/jimmunol.172.11.6658; YULE TD, 1993, J IMMUNOL, V151, P3057; Zhang Y, 2005, EUR J IMMUNOL, V35, P1066, DOI 10.1002/eji.200425847	54	45	45	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					2040	2048		10.1096/fj.10-173872	http://dx.doi.org/10.1096/fj.10-173872			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21368101				2022-12-28	WOS:000291023800026
J	Long, KK; Montano, M; Pavlath, GK				Long, Kimberly K.; Montano, Monty; Pavlath, Grace K.			Sca-1 is negatively regulated by TGF-beta 1 in myogenic cells	FASEB JOURNAL			English	Article						skeletal muscle; regeneration; fibrosis	TRANSFORMING-GROWTH-FACTOR; SKELETAL-MUSCLE REGENERATION; BETA TGF-BETA; STEM-CELL; INFLAMMATORY MYOPATHIES; CYTOKINE EXPRESSION; DIFFERENTIATION; PROLIFERATION; TRANSCRIPTION; PATHWAY	Sca-1 (stem cell antigen-1) is a member of the Ly-6 family of proteins and regulates cell proliferation, differentiation, and self-renewal in multiple tissues. In skeletal muscle, Sca-1 inhibits both proliferation and differentiation of myogenic cells. Sca-1 expression is dynamically regulated during muscle regeneration, and mice lacking Sca-1 display increased fibrosis following muscle injury. Here, we show that Sca-1 expression is negatively regulated by TGF-beta 1 and that this inhibition is dependent on Smad3. We demonstrate that levels of TGF-beta 1 in skeletal muscle rapidly increase on injury and that the majority of this TGF beta 1 is produced by infiltrating macrophages. Sca-1 is expressed in multiple cell types, and we demonstrate that TGF-beta 1 represses Sca-1 expression in T cells and other immune cell populations derived from the spleen, indicating that regulation by TGF-beta 1 is a general feature of Sca-1 expression in multiple cell types. Elucidation of the mechanisms by which Sca-1 expression is regulated may aid in the understanding of muscle homeostasis, potentially identifying novel therapeutic targets for muscle diseases.-Long, K., Montano, M., Pavlath, G. K. Sca-1 is negatively regulated by TGF-beta 1 in myogenic cells. FASEB J. 25, 1156-1165 (2011). www.fasebj.org	[Long, Kimberly K.; Pavlath, Grace K.] Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; [Long, Kimberly K.; Montano, Monty] Boston Med Ctr, Dept Infect Dis, Boston, MA USA	Emory University; Boston Medical Center	Pavlath, GK (corresponding author), Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA.	gpavlat@emory.edu		Montano, Monty/0000-0002-1473-887X	U.S. National Institutes of Health [AR051372, AR055115]; Muscular Dystrophy Association; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR055115, R01AR051372] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by U.S. National Institutes of Health grants AR051372 (G. K. P.) and AR055115 (M. M.), as well as a development grant from the Muscular Dystrophy Association (K.K.L.).	Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Andreetta F, 2006, J NEUROIMMUNOL, V175, P77, DOI 10.1016/j.jneuroim.2006.03.005; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; BAMEZAI A, 1995, J IMMUNOL, V154, P4233; Bamezai A, 2004, ARCH IMMUNOL THER EX, V52, P255; Bondesen BA, 2004, AM J PHYSIOL-CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004; Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Calura E, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-630; Chazaud B, 2009, EXERC SPORT SCI REV, V37, P18, DOI 10.1097/JES.0b013e318190ebdb; Choy L, 2003, J BIOL CHEM, V278, P9609, DOI 10.1074/jbc.M212259200; Epting CL, 2008, EXP CELL RES, V314, P1125, DOI 10.1016/j.yexcr.2007.11.010; Hayes SA, 2001, CANCER RES, V61, P2112; Henderson SC, 2002, J IMMUNOL, V168, P118, DOI 10.4049/jimmunol.168.1.118; Holmes C, 2007, STEM CELLS, V25, P1339, DOI 10.1634/stemcells.2006-0644; Huard J, 2002, J BONE JOINT SURG AM, V84A, P822, DOI 10.2106/00004623-200205000-00022; Ito CY, 2003, BLOOD, V101, P517, DOI 10.1182/blood-2002-06-1918; Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015; Kafadar KA, 2009, DEV BIOL, V326, P47, DOI 10.1016/j.ydbio.2008.10.036; Khodadoust MM, 1999, J IMMUNOL, V163, P811; Kollias HD, 2008, J APPL PHYSIOL, V104, P579, DOI 10.1152/japplphysiol.01091.2007; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; LEHTO M, 1986, ARCH ORTHOP TRAUM SU, V104, P366, DOI 10.1007/BF00454432; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Li Y, 2004, AM J PATHOL, V164, P1007, DOI 10.1016/S0002-9440(10)63188-4; LI Y, 2001, CURR OPIN ORTHOP, V12, P409, DOI DOI 10.1097/00001433-200110000-00008; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Mitchell PO, 2005, DEV BIOL, V283, P240, DOI 10.1016/j.ydbio.2005.04.016; Mitchell PO, 2001, AM J PHYSIOL-CELL PH, V281, pC1706, DOI 10.1152/ajpcell.2001.281.5.C1706; Moustakas A, 2001, J CELL SCI, V114, P4359; Mutsaers SE, 1997, INT J BIOCHEM CELL B, V29, P5, DOI 10.1016/S1357-2725(96)00115-X; O'Connor RS, 2007, J CELL SCI, V120, P149, DOI 10.1242/jcs.03307; Otis JS, 2005, EXP CELL RES, V310, P417, DOI 10.1016/j.yexcr.2005.08.009; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; ROBERTSON TA, 1993, EXP CELL RES, V207, P321, DOI 10.1006/excr.1993.1199; Ruscetti FW, 2005, ONCOGENE, V24, P5751, DOI 10.1038/sj.onc.1208921; SANSILVESTRI P, 1995, BLOOD, V86, P1729, DOI 10.1182/blood.V86.5.1729.bloodjournal8651729; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tajbakhsh S, 1996, DEV DYNAM, V206, P291, DOI 10.1002/(SICI)1097-0177(199607)206:3<291::AID-AJA6>3.0.CO;2-D; Tews DS, 1996, J NEUROPATH EXP NEUR, V55, P342, DOI 10.1097/00005072-199603000-00009; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YUTOKU M, 1974, J IMMUNOL, V112, P1774; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	49	16	17	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1156	1165		10.1096/fj.10-170308	http://dx.doi.org/10.1096/fj.10-170308			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21156809	Green Published			2022-12-28	WOS:000288982800005
J	Kang, S; Kwon, H; Wen, H; Song, Y; Frueh, D; Ahn, HC; Yoo, SH; Wagner, G; Park, S				Kang, Sunmi; Kwon, Hyuknam; Wen, He; Song, Youngmin; Frueh, Dominique; Ahn, Hee-Chul; Yoo, Seung Hyun; Wagner, Gerhard; Park, Sunghyouk			Global dynamic conformational changes in the suppressor domain of IP3 receptor by stepwise binding of the two lobes of calmodulin	FASEB JOURNAL			English	Article						IP3R; protein interaction; regulation	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; NUCLEAR-MAGNETIC-RESONANCE; LIGAND-BINDING; TRISPHOSPHATE RECEPTORS; CA2+ RELEASE; CALCIUM-BINDING; CA2+-INDEPENDENT INHIBITION; TARGET RECOGNITION; RYANODINE RECEPTOR; MOLECULAR-BASIS	The roles of calmodulin (CaM) have been key points of controversy in the regulation of inositol-1,4,5-trisphosphate receptor (IP3R). To address the issue, we studied the interaction between CaM and the suppressor domain of IP3R, a key allosteric regulatory domain. First, by means of a pulldown and a fluorescence titration experiment, we confirmed the interaction. Through subsequent NMR binding experiments, we observed dramatic peak disappearances of the suppressor domain on interaction with apo-CaM. The data indicated that apo-CaM induces large-scale dynamic conformational changes in the suppressor domain, involving partial unfolding and subdomain rearrangement. Analysis of the NMR data of CaM surprisingly revealed that its C lobe alone can cause such changes. Further binding experiments showed that calcium allows the free N lobe to bind to the suppressor domain, which induces extra conformational changes in both of the proteins. These results were also confirmed with CaM deletion mutants with either the N or C lobe. On the basis of this novel binding mechanism, we propose a model in which the partial unfolding of the suppressor domain by apo-CaM and the stepwise binding of the N lobe of CaM to the suppressor domain are important elements of calcium/CaM inhibition of IP3R. We believe that our working model encompasses previous regulation mechanisms of IP3R by calcium/CaM and provides new insights into the CaM-target interaction.-Kang, S., Kwon, H., Wen, H., Song, Y., Frueh, D., Ahn, H.-C., Yoo, S. H., Wagner, G., Park, S. Global dynamic conformational changes in the suppressor domain of IP3 receptor by stepwise binding of the two lobes of calmodulin. FASEB J. 25, 840-850 (2011). www.fasebj.org	[Kang, Sunmi; Kwon, Hyuknam; Wen, He; Song, Youngmin; Yoo, Seung Hyun; Park, Sunghyouk] Inha Univ, Sch Med, Dept Biochem, Inchon 400712, South Korea; [Kang, Sunmi; Kwon, Hyuknam; Wen, He; Song, Youngmin; Yoo, Seung Hyun; Park, Sunghyouk] Inha Univ, Sch Med, Ctr Adv Med Educ Project BK21, Inchon 400712, South Korea; [Frueh, Dominique; Wagner, Gerhard] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Ahn, Hee-Chul] Korea Inst Sci & Technol, Adv Anal Ctr, Seoul, South Korea	Inha University; Inha University; Harvard University; Harvard Medical School; Korea Institute of Science & Technology (KIST)	Park, S (corresponding author), Inha Univ, Sch Med, Dept Biochem, Chungsuk Bldg,Rm 505 Shinheung Dong, Inchon 400712, South Korea.	spark@inha.ac.kr	Kwon, Hyuk Nam/V-2301-2018; Wen, He/GZL-8825-2022; Frueh, Dominique P/A-6462-2008	Kwon, Hyuk Nam/0000-0003-4096-4712; Frueh, Dominique P/0000-0003-4605-3776	Korean government [2009-0076692]; Ministry for Health and Welfare, Republic of Korea [A092006]; Korean Ministry of Science and Technology [E28070]; KIST [2V01250]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445] Funding Source: NIH RePORTER	Korean government(Korean Government); Ministry for Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Korean Ministry of Science and Technology(Ministry of Science & Technology (MOST), Republic of Korea); KIST(Korea Institute of Science & Technology Information (KISTI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a National Research Foundation of Korea grant, funded by the Korean government (2009-0076692). This study was also supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A092006). The authors sincerely appreciate the excellent technical support by Dr. Kyoung-Seok Ryu (Korea Basic Science Institute, Daejeon, Korea) in running the 900-MHz NMR machine there. The Korea Basic Science Institute NMR facility is supported by the Bio-MR Research Program of the Korean Ministry of Science and Technology (E28070). Time on the Korea Institute of Science and Technology (KIST) 900-MHz NMR was supported by KIST (grant 2V01250).	Adkins CE, 2000, BIOCHEM J, V345, P357, DOI 10.1042/0264-6021:3450357; Battiste JL, 2000, BIOCHEMISTRY-US, V39, P5355, DOI 10.1021/bi000060h; Bosanac I, 2004, BBA-MOL CELL RES, V1742, P89, DOI 10.1016/j.bbamcr.2004.09.016; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; Cardy TJA, 1998, BIOCHEM J, V334, P447, DOI 10.1042/bj3340447; Chan J, 2010, J BIOL CHEM, V285, P36092, DOI 10.1074/jbc.M110.140160; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Devogelaere B, 2008, CELL CALCIUM, V43, P17, DOI 10.1016/j.ceca.2007.04.005; Foskett JK, 2007, PHYSIOL REV, V87, P593, DOI 10.1152/physrev.00035.2006; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Ishida H, 2002, J BIOMOL NMR, V23, P323, DOI 10.1023/A:1020230712212; Iwai M, 2007, J BIOL CHEM, V282, P12755, DOI 10.1074/jbc.M609833200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kainosho M, 2006, NATURE, V440, P52, DOI 10.1038/nature04525; Kang S, 2008, J BIOL CHEM, V283, P25567, DOI 10.1074/jbc.M803321200; Kang S, 2007, J PEPT SCI, V13, P237, DOI 10.1002/psc.837; Kasri NN, 2004, MOL PHARMACOL, V66, P276, DOI 10.1124/mol.66.2.276; Kasri NN, 2004, EMBO J, V23, P312, DOI 10.1038/sj.emboj.7600037; Li CM, 2009, J BIOL CHEM, V284, P2472, DOI 10.1074/jbc.M806513200; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; Matsubara M, 1997, J BIOL CHEM, V272, P23050, DOI 10.1074/jbc.272.37.23050; Maximciuc AA, 2006, STRUCTURE, V14, P1547, DOI 10.1016/j.str.2006.08.011; Mehboob S, 2001, BIOCHEMISTRY-US, V40, P12457, DOI 10.1021/bi010984k; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Missiaen L, 2000, MOL PHARMACOL, V57, P564, DOI 10.1124/mol.57.3.564; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Park S, 2002, BLOOD, V100, P283, DOI 10.1182/blood.V100.1.283; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Patterson RL, 2004, P NATL ACAD SCI USA, V101, P2328, DOI 10.1073/pnas.0308567100; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Rodriguez-Castaneda F, 2010, EMBO J, V29, P680, DOI 10.1038/emboj.2009.373; Rossi AM, 2004, MOL PHARMACOL, V66, P199, DOI 10.1124/mol.104.002592; Schug ZT, 2006, J BIOL CHEM, V281, P24431, DOI 10.1074/jbc.M604190200; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Tang RH, 2007, SCIENCE, V315, P1423, DOI 10.1126/science.1134457; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2004, TRENDS BIOCHEM SCI, V29, P210, DOI 10.1016/j.tibs.2004.02.010; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; Velyvis A, 2003, NAT STRUCT BIOL, V10, P558, DOI 10.1038/nsb938; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Wu N, 2006, J MOL BIOL, V364, P955, DOI 10.1016/j.jmb.2006.09.075; Xiong LW, 2010, J BIOL CHEM, V285, P8094, DOI 10.1074/jbc.M109.065243; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yamazaki H, 2010, J BIOL CHEM, V285, P36081, DOI 10.1074/jbc.M110.140129; Yoo SH, 2000, TRENDS NEUROSCI, V23, P424, DOI 10.1016/S0166-2236(00)01621-0; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200	59	14	14	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2011	25	3					840	850		10.1096/fj.10-160705	http://dx.doi.org/10.1096/fj.10-160705			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21084695	Bronze			2022-12-28	WOS:000287806200005
J	Deng, YM; Edin, ML; Theken, KN; Schuck, RN; Flake, GP; Kannon, MA; DeGraff, LM; Lih, FB; Foley, J; Bradbury, JA; Graves, JP; Tomer, KB; Falck, JR; Zeldin, DC; Lee, CR				Deng, Yangmei; Edin, Matthew L.; Theken, Katherine N.; Schuck, Robert N.; Flake, Gordon P.; Kannon, M. Alison; DeGraff, Laura M.; Lih, Fred B.; Foley, Julie; Bradbury, J. Alyce; Graves, Joan P.; Tomer, Kenneth B.; Falck, John R.; Zeldin, Darryl C.; Lee, Craig R.			Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice	FASEB JOURNAL			English	Article						CYP2J2; CYP2C8; EPHX2; EETs; eicosanoids; inflammation	NF-KAPPA-B; ACUTE LUNG INJURY; ACUTE PSEUDOMONAS PNEUMONIA; BLOOD-PRESSURE REGULATION; ARACHIDONIC-ACID; CYTOCHROME-P450 EPOXYGENASES; CORONARY-ARTERIES; EPOXYEICOSATRIENOIC ACIDS; THERAPEUTIC TARGET; MOLECULAR-CLONING	Cytochrome P-450 (CYP)-derived epoxyeicosatrienoic acids (EETs) possess potent anti-inflammatory effects in vitro. However, the effect of increased CYP-mediated EET biosynthesis and decreased soluble epoxide hydrolase (sEH, Ephx2)-mediated EET hydrolysis on vascular inflammation in vivo has not been rigorously investigated. Consequently, we characterized acute vascular inflammatory responses to endotoxin in transgenic mice with endothelial expression of the human CYP2J2 and CYP2C8 epoxygenases and mice with targeted disruption of Ephx2. Compared to wild-type controls, CYP2J2 transgenic, CYP2C8 transgenic, and Ephx2(-/-) mice each exhibited a significant attenuation of endotoxin-induced activation of nuclear factor (NF)-kappa B signaling, cellular adhesion molecule, chemokine and cytokine expression, and neutrophil infiltration in lung in vivo. Furthermore, attenuation of endotoxin-induced NF-kappa B activation and cellular adhesion molecule and chemokine expression was observed in primary pulmonary endothelial cells isolated from CYP2J2 and CYP2C8 transgenic mice. This attenuation was inhibited by a putative EET receptor antagonist and CYP epoxygenase inhibitor, directly implicating CYP epoxygenase-derived EETs with the observed anti-inflammatory phenotype. Collectively, these data demonstrate that potentiation of the CYP epoxygenase pathway by either increased endothelial EET biosynthesis or globally decreased EET hydrolysis attenuates NF-kappa B-dependent vascular inflammatory responses in vivo and may serve as a viable anti-inflammatory therapeutic strategy.-Deng, Y., Edin, M. L., Theken, K. N., Schuck, R. N., Flake, G. P., Kannon, M. A., DeGraff, L. M., Lih, F. B., Foley, J., Bradbury, J. A., Graves, J. P., Tomer, K. B., Falck, J. R., Zeldin, D. C., Lee, C. R. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J. 25, 703-713 (2011). www.fasebj.org	[Deng, Yangmei; Theken, Katherine N.; Schuck, Robert N.; Kannon, M. Alison; Lee, Craig R.] UNC, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27599 USA; [Edin, Matthew L.; Flake, Gordon P.; DeGraff, Laura M.; Lih, Fred B.; Foley, Julie; Bradbury, J. Alyce; Graves, Joan P.; Tomer, Kenneth B.; Zeldin, Darryl C.] Natl Inst Environm Hlth Sci, Natl Inst Hlth, Div Intramural Res, Res Triangle Pk, NC USA; [Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Southwestern Medical Center Dallas	Lee, CR (corresponding author), UNC, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, CB 7569,Kerr Hall, Chapel Hill, NC 27599 USA.	craig_lee@unc.edu	Falck, John R/B-3030-2011; Theken, Katherine N/H-1098-2012; Theken, Katherine/AAD-7831-2022; Tomer, Kenneth B/E-8018-2013; Zeldin, Darryl C/Y-7091-2018; Edin, Matthew/AAI-1934-2019	Falck, John R/0000-0002-9219-7845; Zeldin, Darryl C/0000-0002-2087-7307; Theken, Katherine/0000-0001-9918-9170; Lee, Craig/0000-0003-3595-5301; Edin, Matthew/0000-0002-7042-500X	American Foundation for Pharmaceutical Education; NIH [GM31278, GM088199, P30 DK34987]; Robert A. Welch Foundation; NIH, NIEHS [Z01 ES050167, Z01 ES025034]; American Heart Association; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226, P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050167, Z01ES025034, ZIAES025034, Z01ES050167, ZIGES102505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088199, R01GM031278] Funding Source: NIH RePORTER	American Foundation for Pharmaceutical Education; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); NIH, NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This publication was made possible by a predoctoral fellowship from the American Foundation for Pharmaceutical Education to K.N.T., NIH grant GM31278 and support from the Robert A. Welch Foundation to J.R.F., funds from the Intramural Research Program of the NIH, NIEHS, to K. B. T. (Z01 ES050167) and D.C.Z. (Z01 ES025034), a Beginning Grant-in-Aid from the American Heart Association and NIH grant GM088199 to C. R. L., and NIH grant P30 DK34987. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, National Institute of General Medical Sciences, or NIH. D. C. Z. is a coinventor on U.S. Patent No. 6,531,506 B1 (issued March 11, 2003), Inhibition of Epoxide Hydrolases for the Treatment of Hypertension, and on U. S. Patent No. 6,916,843 B1 (issued July 12, 2005), Anti-inflammatory Actions of Cytochrome P450 Epoxygenase-Derived Eicosanoids. No other authors declare conflicts of interest.	Asti C, 2000, PULM PHARMACOL THER, V13, P61, DOI 10.1006/pupt.2000.0231; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Card JW, 2006, J IMMUNOL, V177, P621, DOI 10.4049/jimmunol.177.1.621; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; de Winther MPJ, 2005, ARTERIOSCL THROM VAS, V25, P904, DOI 10.1161/01.ATV.0000160340.72641.87; DeLozier TC, 2007, DRUG METAB DISPOS, V35, P682, DOI 10.1124/dmd.106.012823; Deng YM, 2010, J MOL CELL CARDIOL, V48, P331, DOI 10.1016/j.yjmcc.2009.10.022; Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995; Fang X, 2001, J BIOL CHEM, V276, P14867, DOI 10.1074/jbc.M011761200; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Garrean S, 2006, J IMMUNOL, V177, P4853, DOI 10.4049/jimmunol.177.7.4853; Gauthier KM, 2002, CIRC RES, V90, P1028, DOI 10.1161/01.RES.0000018162.87285.F8; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Haegens A, 2009, J IMMUNOL, V182, P7990, DOI 10.4049/jimmunol.0800377; Imig JD, 2009, NAT REV DRUG DISCOV, V8, P794, DOI 10.1038/nrd2875; Kabir K, 2002, SHOCK, V17, P300, DOI 10.1097/00024382-200204000-00010; Kerfoot SM, 2005, J LEUKOCYTE BIOL, V77, P862, DOI 10.1189/jlb.1004607; King LM, 2002, MOL PHARMACOL, V61, P840, DOI 10.1124/mol.61.4.840; Kiss L, 2010, EUR RESPIR J, V36, P1088, DOI 10.1183/09031936.00000309; Lau D, 2006, PHARMACOL THERAPEUT, V111, P16, DOI 10.1016/j.pharmthera.2005.06.023; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Lee CR, 2007, PHARMACOGENET GENOM, V17, P145, DOI 10.1097/01.fpc.0000236340.87540.e3; Lee CR, 2010, FASEB J, V24, P3770, DOI 10.1096/fj.10-160119; Lim YC, 2003, AM J PATHOL, V162, P1591, DOI 10.1016/S0002-9440(10)64293-9; Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005; Liu Y, 2005, P NATL ACAD SCI USA, V102, P16747, DOI 10.1073/pnas.0508081102; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luria A, 2007, J BIOL CHEM, V282, P2891, DOI 10.1074/jbc.M608057200; Michaelis UR, 2005, J CELL SCI, V118, P5489, DOI 10.1242/jcs.02674; Morin C, 2008, AM J RESP CELL MOL, V38, P192, DOI 10.1165/rcmb.2007-0232OC; Mosha KS, 2008, J CELL PHYSIOL, V215, P771, DOI 10.1002/jcp.21356; Newman JW, 2002, J LIPID RES, V43, P1563, DOI 10.1194/jlr.D200018-JLR200; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Rojas M, 2005, AM J PHYSIOL-LUNG C, V288, pL333, DOI 10.1152/ajplung.00334.2004; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Schmelzer KR, 2005, P NATL ACAD SCI USA, V102, P9772, DOI 10.1073/pnas.0503279102; Seubert JM, 2006, CIRC RES, V99, P442, DOI 10.1161/01.RES.0000237390.92932.37; Sinal CJ, 2000, J BIOL CHEM, V275, P40504, DOI 10.1074/jbc.M008106200; Smith KR, 2005, P NATL ACAD SCI USA, V102, P2186, DOI 10.1073/pnas.0409591102; Spector AA, 2007, AM J PHYSIOL-CELL PH, V292, pC996, DOI 10.1152/ajpcell.00402.2006; Theken KN, 2011, DRUG METAB DISPOS, V39, P22, DOI 10.1124/dmd.110.035287; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; Wu S, 1996, J BIOL CHEM, V271, P3460; Yaghi A, 2003, AM J PHYSIOL-LUNG C, V285, pL1099, DOI 10.1152/ajplung.00039.2003; Yaghi A, 2001, J PHARMACOL EXP THER, V297, P479; Yang BC, 2001, MOL PHARMACOL, V60, P310, DOI 10.1124/mol.60.2.310; Yang SL, 2007, AM J PHYSIOL-HEART C, V293, pH142, DOI 10.1152/ajpheart.00783.2006; Zeldin DC, 1996, ARCH BIOCHEM BIOPHYS, V330, P87, DOI 10.1006/abbi.1996.0229; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438	52	97	101	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					703	713		10.1096/fj.10-171488	http://dx.doi.org/10.1096/fj.10-171488			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21059750	Green Published			2022-12-28	WOS:000286724800028
J	Palczewski, K				Palczewski, Krzysztof			Focus on vision: 3 decades of remarkable contributions to biology and medicine	FASEB JOURNAL			English	Review						G protein-coupled receptors; phototransduction; rhodopsin; membrane receptors; blindness; Ca2+; signaling	ENDOTHELIAL GROWTH-FACTOR; LEBERS CONGENITAL AMAUROSIS; LIGHT-DEPENDENT PHOSPHORYLATION; HUMAN COLOR-VISION; ROD OUTER SEGMENT; GENE-THERAPY; MACULAR DEGENERATION; VISUAL CYCLE; DIABETIC-RETINOPATHY; MOLECULAR-GENETICS	THE FASEB JOURNAL is a pillar among biomedical publications, contributing greatly by disseminating the results of vision research during its lifetime. Progress over this period has been remarkable. George Wald (1) provided the first chemical understanding of the fundamental processes governing vision: the photoisomerization of 11-cis-retinal to all-trans-retinal and the enzymatic regeneration of this chromophore. Contributions of this extraordinary scientist (2, 3) set the stage for discoveries ranging from gross recording of various electrical responses to light to elucidation of signal transduction at a structural level, and from characterization of retinal diseases to successful treatments. FASEB J. 25, 439-443 (2011). www.fasebj.org	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Palczewski, K (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu			U.S. National Institutes of Health [R01-EY0008061]; NATIONAL EYE INSTITUTE [R01EY008061] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The author thanks Dr. Leslie T. Webster, Jr. (Case Western Reserve University) and members of his laboratory for valuable comments on the manuscript. This work was supported in part by U.S. National Institutes of Health grant R01-EY0008061. The author has also solicited the opinions of his colleagues in the field, including Drs. Anthony Adamis, Anand Swaroop, Maurine Neitz, Jack Saari, Vadim Arshavsky, King-Wai Yau, Robert Molday, Thomas Sakmar, Gordon Fain, Sam Wu, Wolfgang Baehr and Janet Sparrow. While the author is grateful for their advice and their views have shaped his opinion, they are not responsible for the final selection of the topics presented.	Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; BITENSKY MW, 1984, ADV CYCLIC NUCL PROT, V17, P227; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; Dowling JE, 1997, NATURE, V387, P356, DOI 10.1038/387356a0; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; Filipek S, 2003, ANNU REV BIOPH BIOM, V32, P375, DOI 10.1146/annurev.biophys.32.110601.142520; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; Gillies MC, 2007, NEW ENGL J MED, V356, P748; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GREEN DG, 1975, J GEN PHYSIOL, V65, P483, DOI 10.1085/jgp.65.4.483; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hubbard R, 1999, Novartis Found Symp, V224, P5; HUBBARD R, 1999, NOVART FDN SYMP, V224, P18; Kiser PD, 2009, P NATL ACAD SCI USA, V106, P17325, DOI 10.1073/pnas.0906600106; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Luo DG, 2008, P NATL ACAD SCI USA, V105, P9855, DOI 10.1073/pnas.0708405105; Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829; Nishiguchi KM, 2004, NATURE, V427, P75, DOI 10.1038/nature02170; OVCHINNIKOV YA, 1983, BIOORG KHIM+, V9, P1331; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225; von Lintig J, 2010, TRENDS BIOCHEM SCI, V35, P400, DOI 10.1016/j.tibs.2010.01.005; Wald G, 1935, J GEN PHYSIOL, V19, P351, DOI 10.1085/jgp.19.2.351; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WERBLIN FS, 1969, J NEUROPHYSIOL, V32, P339, DOI 10.1152/jn.1969.32.3.339; Yau KW, 2009, CELL, V139, P246, DOI 10.1016/j.cell.2009.09.029	61	3	3	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					439	443		10.1096/fj.11-0202ufm	http://dx.doi.org/10.1096/fj.11-0202ufm			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21282210	Bronze, Green Published			2022-12-28	WOS:000286724800002
J	Strub, GM; Paillard, M; Liang, J; Gomez, L; Allegood, JC; Hait, NC; Maceyka, M; Price, MM; Chen, Q; Simpson, DC; Kordula, T; Milstien, S; Lesnefsky, EJ; Spiegel, S				Strub, Graham M.; Paillard, Melanie; Liang, Jie; Gomez, Ludovic; Allegood, Jeremy C.; Hait, Nitai C.; Maceyka, Michael; Price, Megan M.; Chen, Qun; Simpson, David C.; Kordula, Tomasz; Milstien, Sheldon; Lesnefsky, Edward J.; Spiegel, Sarah			Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration	FASEB JOURNAL			English	Article						SphK2; oxidative phosphorylation; cytochrome-c oxidase	PROTEIN-COUPLED RECEPTORS; CYTOCHROME-C-OXIDASE; CELL-PROLIFERATION; CRISTAE MORPHOGENESIS; ELECTRON-TRANSPORT; MEMBRANE; APOPTOSIS; STRESS; GROWTH; ROLES	The potent lipid mediator sphingosine-1-phosphate (S1P) regulates diverse physiological processes by binding to 5 specific GPCRs, although it also has intracellular targets. Here, we demonstrate that S1P, produced in the mitochondria mainly by sphingosine kinase 2 (SphK2), binds with high affinity and specificity to prohibitin 2 (PHB2), a highly conserved protein that regulates mitochondrial assembly and function. In contrast, S1P did not bind to the closely related protein PHB1, which forms large, multimeric complexes with PHB2. In mitochondria from SphK2-null mice, a new aberrant band of cytochrome-c oxidase was detected by blue native PAGE, and interaction between subunit IV of cytochrome-c oxidase and PHB2 was greatly reduced. Moreover, depletion of SphK2 or PHB2 led to a dysfunction in mitochondrial respiration through cytochrome-c oxidase. Our data point to a new action of S1P in mitochondria and suggest that interaction of S1P with homomeric PHB2 is important for cytochrome-c oxidase assembly and mitochondrial respiration.-Strub, G. M., Paillard, M., Liang, J., Gomez, L., Allegood, J. C., Hait, N. C., Maceyka, M., Price, M. M., Chen, Q., Simpson, D. C., Kordula, T., Milstien, S., Lesnefsky, E. J., Spiegel, S. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J. 25, 600-612 (2011). www.fasebj.org	[Strub, Graham M.; Liang, Jie; Allegood, Jeremy C.; Hait, Nitai C.; Maceyka, Michael; Price, Megan M.; Kordula, Tomasz; Milstien, Sheldon; Lesnefsky, Edward J.; Spiegel, Sarah] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, Richmond, VA 23298 USA; [Paillard, Melanie; Gomez, Ludovic; Chen, Qun; Lesnefsky, Edward J.] Virginia Commonwealth Univ, Dept Med, Sch Med, Richmond, VA 23298 USA; [Simpson, David C.] Virginia Commonwealth Univ, Dept Chem, Sch Med, Richmond, VA 23298 USA; [Strub, Graham M.; Liang, Jie; Allegood, Jeremy C.; Hait, Nitai C.; Maceyka, Michael; Price, Megan M.; Kordula, Tomasz; Spiegel, Sarah] Virginia Commonwealth Univ, Massey Canc Ctr, Sch Med, Richmond, VA 23298 USA; [Chen, Qun; Lesnefsky, Edward J.] McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Paillard, Melanie; Gomez, Ludovic] Univ Lyon 1, Inst Natl Sante & Rech Med INSERM, U886, F-69365 Lyon, France	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Hunter Holmes McGuire Veterinary Affairs Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Paillard, Mélanie/ABF-7686-2020; Maceyka, Michael/B-9277-2008; Gomez, Ludovic/O-6807-2017; Chen, Qun/HGD-0868-2022; Simpson, David/D-4677-2009	Gomez, Ludovic/0000-0001-8509-4955; Simpson, David/0000-0002-1189-0833; Paillard, Melanie/0000-0002-4912-4915	U.S. National Institutes of Health (NIH) [R37GM043880]; Medical Research Service Department of Veterans Affairs; National Research Service [F30NS058008]; NIH-National Cancer Institute Cancer Center [5P30CA016059];  [P01AG15885];  [EXPLORA'DOC 2009];  [5P30 NS047463]; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS058008, P30NS047463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Service Department of Veterans Affairs(US Department of Veterans Affairs); National Research Service; NIH-National Cancer Institute Cancer Center; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by U.S. National Institutes of Health (NIH) grant R37GM043880 (S.S.) and, in part, by P01AG15885 and a Medical Research Service Department of Veterans Affairs Merit Review grant (E.J.L.). G.S. was supported by National Research Service Award F30NS058008. M.P. was supported by French grant EXPLORA'DOC 2009. The authors thank Dr. Richard Proia (NIH, Bethesda, MD, USA) for a generous gift of SphK antibodies and the Lipidomics/Metabolomics facility for lipid analyses. Microscopy was performed at the Virginia Commonwealth University Microscopy Facility, supported, in part, by grant 5P30 NS047463 and NIH-National Cancer Institute Cancer Center Core grant 5P30CA016059.	Ahn CS, 2006, PLANT J, V46, P658, DOI 10.1111/j.1365-313X.2006.02726.x; Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128; Artal-Sanz M, 2009, TRENDS ENDOCRIN MET, V20, P394, DOI 10.1016/j.tem.2009.04.004; Artal-Sanz M, 2009, NATURE, V461, P793, DOI 10.1038/nature08466; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Chen Q, 2006, J PHARMACOL EXP THER, V319, P1405, DOI 10.1124/jpet.106.110262; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Coursol S, 2003, NATURE, V423, P651, DOI 10.1038/nature01643; Da Cruz S, 2008, BBA-MOL CELL RES, V1783, P904, DOI 10.1016/j.bbamcr.2008.02.006; Ding G, 2007, J BIOL CHEM, V282, P27493, DOI 10.1074/jbc.M701641200; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; Fernandez-Vizarra E, 2009, BBA-MOL CELL RES, V1793, P200, DOI 10.1016/j.bbamcr.2008.05.028; Fisher PW, 2005, CIRCULATION, V111, P1601, DOI 10.1161/01.CIR.0000160359.49478.C2; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; He B, 2008, MOL ENDOCRINOL, V22, P344, DOI 10.1210/me.2007-0400; Heringdorf DMZ, 2003, FEBS LETT, V554, P443, DOI 10.1016/S0014-5793(03)01219-5; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Kasashima K, 2006, J BIOL CHEM, V281, P36401, DOI 10.1074/jbc.M605260200; Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05; Kuramori C, 2009, BIOCHEM BIOPH RES CO, V379, P519, DOI 10.1016/j.bbrc.2008.12.103; Lesnefsky EJ, 2004, J BIOL CHEM, V279, P47961, DOI 10.1074/jbc.M409720200; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Matas J, 2009, J MOL CELL CARDIOL, V46, P420, DOI 10.1016/j.yjmcc.2008.10.020; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Merkwirth C, 2008, GENE DEV, V22, P476, DOI 10.1101/gad.460708; Merkwirth C, 2009, BBA-MOL CELL RES, V1793, P27, DOI 10.1016/j.bbamcr.2008.05.013; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Oskouian B, 2004, SEMIN CELL DEV BIOL, V15, P529, DOI 10.1016/j.semcdb.2004.05.009; Osman C, 2009, J CELL SCI, V122, P3823, DOI 10.1242/jcs.037655; Osman C, 2009, J CELL BIOL, V184, P583, DOI 10.1083/jcb.200810189; Paillard M, 2009, J MOL CELL CARDIOL, V46, P902, DOI 10.1016/j.yjmcc.2009.02.017; Pandey S, 2004, PLANT CELL, V16, P1616, DOI 10.1105/tpc.020321; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Sankala HM, 2007, CANCER RES, V67, P10466, DOI 10.1158/0008-5472.CAN-07-2090; Sanz MA, 2003, J BIOL CHEM, V278, P32091, DOI 10.1074/jbc.M304877200; Schleicher M, 2008, J CELL BIOL, V180, P101, DOI 10.1083/jcb.200706072; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Tsutsumi T, 2009, HEPATOLOGY, V50, P378, DOI 10.1002/hep.22998; Wittig I, 2007, MOL CELL PROTEOMICS, V6, P1215, DOI 10.1074/mcp.M700076-MCP200; Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62	51	242	248	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					600	612		10.1096/fj.10-167502	http://dx.doi.org/10.1096/fj.10-167502			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20959514	Green Published			2022-12-28	WOS:000286724800018
J	Bao, B; Jiang, J; Yanase, T; Nishi, Y; Morgan, JR				Bao, Brian; Jiang, Jean; Yanase, Toshihiko; Nishi, Yoshihiro; Morgan, Jeffrey R.			Connexon-mediated cell adhesion drives microtissue self-assembly	FASEB JOURNAL			English	Article						aggregation; 3D; spheroid; gap junction	GAP-JUNCTION; INTERCELLULAR COMMUNICATION; MIMETIC PEPTIDES; N-CADHERIN; CONNEXIN-43; MORPHOGENESIS; KERATINOCYTES; ORGANIZATION; MIGRATION; ZEBRAFISH	Microtissue self-assembly is thought to be driven primarily by cadherins, while connexons have been examined mainly in intercellular coupling. We investigated whether connexon 43 (Cx43)-mediated cell adhesion modulates self-assembly of human KGN granulosa cells, normal human fibroblasts (NHFs), and MCF-7 breast cancer cells seeded into nonadhesive agarose gels. We found that treatment with anti-Cx43 E2 (112 mu g/ml), which suppresses Cx43 docking, significantly inhibited the kinetics of KGN and NHF self-assembly compared to the preimmune sera control (41.1 +/- 4.5 and 24.5 +/- 10.4% at 8 h, respectively). Likewise, gap junction inhibitor carbenoxolone also inhibited self-assembly of KGN, NHF, and MCF-7 cells in a dose-dependent manner that was specific to cell type. In contrast, Gap26 connexin mimetic peptide, which inhibits channel permeability but not docking, accelerated self-assembly of KGN and NHF microtissues. Experiments using selective enzymatic digestion of cell adhesion molecules and neutralizing N-cadherin antibodies further showed that self-assembly was comparably disrupted by inhibiting connexin-and cadherin-mediated adhesion. These findings demonstrate that connexon-mediated cell adhesion and intercellular communication differentially influence microtissue self-assembly, and that their contributions are comparable to those of cadherins.-Bao, B., Jiang, J., Yanase, T., Nishi, Y., Morgan, J. R. Connexon-mediated cell adhesion drives microtissue self-assembly. FASEB J. 25, 255-264 (2011). www.fasebj.org	[Bao, Brian; Morgan, Jeffrey R.] Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Ctr Biomed Engn, Providence, RI 02912 USA; [Jiang, Jean; Yanase, Toshihiko; Nishi, Yoshihiro] Univ Texas San Antonio, Dept Biochem, Univ Texas Hlth Sci Ctr, San Antonio, TX USA; Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan	Brown University; University of Texas System; University of Texas at San Antonio (UTSA); University of Texas Health San Antonio; Kyushu University	Morgan, JR (corresponding author), Brown Univ, Biomed Ctr, G-B 393,171 Meeting St, Providence, RI 02912 USA.	jeffrey_morgan@brown.edu		Nishi, Yoshihiro/0000-0001-7529-1103; Morgan, Jeffrey/0000-0002-7546-3443; Jiang, Jean/0000-0002-2185-5716	Brown University; Rhode Island Research Alliance; National Institutes of Health (NIH) [RO1EB008664-01A1t, AR46798]; Welch Foundation [AQ-1507]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR046798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB008664] Funding Source: NIH RePORTER	Brown University; Rhode Island Research Alliance; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was funded, in part, by the Brown University M.D./Ph.D. program, a Rhode Island Research Alliance collaborative grant, National Institutes of Health (NIH) grant RO1EB008664-01A1t, NIH grant AR46798, and Welch Foundation grant AQ-1507.	ANDERSON E, 1976, J CELL BIOL, V71, P680, DOI 10.1083/jcb.71.2.680; BASTIAANSE EML, 1993, J MEMBRANE BIOL, V136, P135, DOI 10.1007/BF02505758; BEAUPAIN R, 1993, IN VITRO CELL DEV-AN, V29A, P893; BRAUN J, 1984, NATURE, V310, P316, DOI 10.1038/310316a0; Buauskas F. F., 2000, P NATL ACAD SCI USA, V97, P2556; Chalabi N, 2007, J HISTOCHEM CYTOCHEM, V55, P877, DOI 10.1369/jhc.7A7185.2007; Cotrina ML, 2008, GLIA, V56, P1791, DOI 10.1002/glia.20728; De Maio A, 2002, J CELL PHYSIOL, V191, P269, DOI 10.1002/jcp.10108; Dean DM, 2009, CELL MOTIL CYTOSKEL, V66, P129, DOI 10.1002/cm.20335; Dean DM, 2008, TISSUE ENG PT A, V14, P1989, DOI 10.1089/ten.tea.2007.0320; Duguay D, 2003, DEV BIOL, V253, P309, DOI 10.1016/S0012-1606(02)00016-7; Elias LAB, 2007, NATURE, V448, P901, DOI 10.1038/nature06063; Evans WH, 2007, CELL COMMUN ADHES, V14, P265, DOI 10.1080/15419060801891034; FITZGERALD DJ, 1990, TERATOGEN CARCIN MUT, V10, P89; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; Fonseca PC, 2006, CYTOM PART A, V69A, P487, DOI 10.1002/cyto.a.20255; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Foty RA, 1996, DEVELOPMENT, V122, P1611; Foty RA, 2005, DEV BIOL, V278, P255, DOI 10.1016/j.ydbio.2004.11.012; Gotz M, 1996, NEURON, V16, P551, DOI 10.1016/S0896-6273(00)80074-4; Grazul-Bilska, 1997, BIOL REPROD, V57, P947; Guan XJ, 1996, MOL CARCINOGEN, V16, P157; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Huang GY, 1998, DEV BIOL, V198, P32, DOI 10.1006/dbio.1998.8891; Isakson BE, 2001, AM J PHYSIOL-LUNG C, V280, pL221, DOI 10.1152/ajplung.2001.280.2.L221; Krieg M, 2008, NAT CELL BIOL, V10, P429, DOI 10.1038/ncb1705; Langlois S, 2008, MOL BIOL CELL, V19, P912, DOI 10.1091/mbc.E07-06-0596; LARSEN WJ, 1979, J CELL BIOL, V83, P576, DOI 10.1083/jcb.83.3.576; Leckband D, 2006, ANNU REV BIOMED ENG, V8, P259, DOI 10.1146/annurev.bioeng.8.061505.095753; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Mese G, 2007, J INVEST DERMATOL, V127, P2516, DOI 10.1038/sj.jid.5700770; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; MOSCONA A, 1952, J ANAT, V86, P287; Napolitano AP, 2007, TISSUE ENG, V13, P2087, DOI 10.1089/ten.2006.0190; Niessen CM, 2002, J CELL BIOL, V156, P389, DOI 10.1083/jcb.200108040; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Oliveira R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-7; Perkins GA, 1998, J MOL BIOL, V277, P171, DOI 10.1006/jmbi.1997.1580; Preus, 1981, J ULTRASTRUCT RES, V77, P263; Rago AP, 2009, TISSUE ENG PT A, V15, P387, DOI 10.1089/ten.tea.2008.0107; Siller-Jackson AJ, 2008, J BIOL CHEM, V283, P26374, DOI 10.1074/jbc.M803136200; Sosinsky GE, 2005, BBA-BIOMEMBRANES, V1711, P99, DOI 10.1016/j.bbamem.2005.04.001; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Wei CJ, 2005, J BIOL CHEM, V280, P19925, DOI 10.1074/jbc.M412921200; Wright CS, 2009, WOUND REPAIR REGEN, V17, P240, DOI 10.1111/j.1524-475X.2009.00471.x; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047; Zalik SE, 1999, BIOCHEM CELL BIOL, V77, P527, DOI 10.1139/bcb-77-6-527	49	55	60	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					255	264		10.1096/fj.10-155291	http://dx.doi.org/10.1096/fj.10-155291			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20876208	Green Published			2022-12-28	WOS:000285869500023
J	Boal, F; Laguerre, M; Milochau, A; Lang, JC; Scotti, PA				Boal, Frederic; Laguerre, Michel; Milochau, Alexandra; Lang, Jochen; Scotti, Pier A.			A charged prominence in the linker domain of the cysteine-string protein Csp alpha mediates its regulated interaction with the calcium sensor synaptotagmin 9 during exocytosis	FASEB JOURNAL			English	Article						chaperone; FRET-FLIM; insulin; DnaJ-like protein; calcium-binding protein; C(2)A domain; SNARE	SYNAPTIC VESICLE PROTEIN; ENDOCRINE BETA-CELLS; INSULIN EXOCYTOSIS; NEUROTRANSMITTER RELEASE; DEPENDENT INTERACTION; PLASMA-MEMBRANE; CA2+ CHANNELS; C-TERMINUS; DROSOPHILA; SECRETION	The cochaperone cysteine-string protein (Csp) is located on vesicles and participates in the control of neurotransmission and hormone exocytosis. Csp contains several domains, and our previous work demonstrated the requirement of the Csp linker domain in regulated exocytosis of insulin in rodent pancreatic beta cells. We now address the molecular details to gain insight into the sequence of events during exocytosis. According to pulldown experiments and in vitro binding assays, Csp alpha interacts indirectly with SNAP-25 and directly with the calcium sensor synaptotagmin 9 (Syt9), which could be an intermediate between the chaperone and the t-SNARE. The C(2)A calcium binding domain of Syt9 and the linker domain of Csp alpha constituted the minimal interacting module. FRET-FLIM experiments confirmed the interaction between Syt9 and Csp alpha. Moreover, the point mutation E93V in the linker domain of Csp alpha significantly reduced the interaction between the two proteins. Molecular modeling revealed that this point mutation abolished a charged prominence on the surface of Csp alpha required for interaction. Strikingly, free calcium in the physiological low micromolar range enhanced the interaction between Syt9 and the linker domain of Csp alpha in vitro. These data indicate that Csp alpha interacts with Syt9, and such a complex may be relevant in the calcium-mediated control of a late stage of exocytosis by triggering the specific recruitment of a folding catalyst at the fusion point.-Boal, F., Laguerre, M., Milochau, A., Lang, J., Scotti., P. A. A charged prominence in the linker domain of the cysteine-string protein CSP alpha mediates its regulated interaction with the calcium sensor synaptotagmin 9 during exocytosis. FASEB J. 25, 132-143 (2011). www.fasebj.org	[Scotti, Pier A.] Univ Bordeaux 1, CNRS, Inst Europeen Chim & Biol, UMR 5248, F-33607 Pessac, France; [Boal, Frederic] Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite de Bordeaux; University of Bristol	Scotti, PA (corresponding author), Univ Bordeaux 1, CNRS, Inst Europeen Chim & Biol, UMR 5248, 2 Av Robert Escarpit, F-33607 Pessac, France.	p.scotti@iecb.u-bordeaux.fr	Boal, Frédéric/O-6306-2018; Lang, Jochen/B-1215-2010; Lang, Jochen/F-5782-2014	Boal, Frédéric/0000-0001-7607-4573; Lang, Jochen/0000-0001-6847-5641; Lang, Jochen/0000-0001-6847-5641; SCOTTI, Pier-Arnaldo/0000-0003-4427-3695				Boal F, 2004, BIOCHEMISTRY-US, V43, P16212, DOI 10.1021/bi048612+; Boal F, 2007, BBA-MOL CELL RES, V1773, P109, DOI 10.1016/j.bbamcr.2006.08.054; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Bronk P, 2005, J NEUROSCI, V25, P2204, DOI 10.1523/JNEUROSCI.3610-04.2005; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; Chamberlain LH, 1998, BIOCHEM J, V335, P205, DOI 10.1042/bj3350205; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 1996, J BIOL CHEM, V271, P19514, DOI 10.1074/jbc.271.32.19514; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chamberlain LH, 2001, J CELL SCI, V114, P445; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Chapman ER, 2008, ANNU REV BIOCHEM, V77, P615, DOI 10.1146/annurev.biochem.77.062005.101135; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Dawson-Scully K, 2000, J NEUROSCI, V20, P6039, DOI 10.1523/JNEUROSCI.20-16-06039.2000; de Wit H, 2009, CELL, V138, P935, DOI 10.1016/j.cell.2009.07.027; Evans GJO, 2006, J BIOL CHEM, V281, P1564, DOI 10.1074/jbc.M503628200; Evans GJO, 2003, TRAFFIC, V4, P653, DOI 10.1034/j.1600-0854.2003.00127.x; Evans GJO, 2002, BIOCHEM J, V364, P343, DOI 10.1042/BJ20020123; Evans GJO, 2001, J BIOL CHEM, V276, P47877, DOI 10.1074/jbc.M108186200; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fernandez-Chacon R, 2004, NEURON, V42, P237, DOI 10.1016/S0896-6273(04)00190-4; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Greaves J, 2008, J BIOL CHEM, V283, P25014, DOI 10.1074/jbc.M802140200; Grise F, 2007, BIOCHEM J, V403, P483, DOI 10.1042/BJ20061182; Gut A, 2001, J CELL SCI, V114, P1709; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Iezzi M, 2004, J CELL SCI, V117, P3119, DOI 10.1242/jcs.01179; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; JONAS JC, 1994, BIOCHEM J, V301, P523, DOI 10.1042/bj3010523; Laffray S, 2007, EUR J NEUROSCI, V25, P1402, DOI 10.1111/j.1460-9568.2007.05398.x; Laguerre M, 1997, PHARM SCI, V3, P217; Lajus S, 2006, J BIOL CHEM, V281, P5522, DOI 10.1074/jbc.M510528200; Lang J., 1997, BACT TOXINS, P217; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Leveque C, 1998, J BIOL CHEM, V273, P13488, DOI 10.1074/jbc.273.22.13488; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; Matos MF, 2000, EUR J CELL BIOL, V79, P377, DOI 10.1078/0171-9335-00063; Monterrat C, 2006, BBA-MOL CELL RES, V1763, P73, DOI 10.1016/j.bbamcr.2005.11.008; Nie ZP, 1999, J NEUROSCI, V19, P10270; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Rapoport I, 2008, MOL BIOL CELL, V19, P405, DOI 10.1091/mbc.E07-09-0870; Rizo J, 2006, TRENDS CELL BIOL, V16, P339, DOI 10.1016/j.tcb.2006.04.006; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Ruiz R, 2008, EUR J NEUROSCI, V27, P3118, DOI 10.1111/j.1460-9568.2008.06301.x; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Shin OH, 2004, P NATL ACAD SCI USA, V101, P2554, DOI 10.1073/pnas.0308477100; Shu XK, 2006, BIOCHEMISTRY-US, V45, P9639, DOI 10.1021/bi060773l; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Thoumine O, 2008, CHEM REV, V108, P1565, DOI 10.1021/cr078204m; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Tobaben S., 2003, J BIOL CHEM, V23, P23; Tramier M, 2006, MICROSC RES TECHNIQ, V69, P933, DOI 10.1002/jemt.20370; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; VALLAR L, 1987, J BIOL CHEM, V262, P5049; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Zhang H, 1998, FEBS LETT, V437, P267, DOI 10.1016/S0014-5793(98)01233-2; Zhang H, 1999, J CELL SCI, V112, P1345; Zhang Z, 2010, MOL BIOL CELL, V21, P2821, DOI 10.1091/mbc.E10-04-0285; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	68	19	22	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					132	143		10.1096/fj.09-152033	http://dx.doi.org/10.1096/fj.09-152033			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20847230				2022-12-28	WOS:000285869500013
J	Hong, JM; Huang, YY; Li, J; Yi, F; Zheng, J; Huang, HA; Wei, N; Shan, YQ; An, MR; Zhang, HY; Ji, JG; Zhang, PZ; Xi, Z; Du, QA; Liang, ZC				Hong, Junmei; Huang, Yuanyu; Li, Jun; Yi, Fan; Zheng, Jie; Huang, Huang; Wei, Na; Shan, Yongqiang; An, Mingrui; Zhang, Hongyan; Ji, Jianguo; Zhang, Peizhuo; Xi, Zhen; Du, Quan; Liang, Zicai			Comprehensive analysis of sequence-specific stability of siRNA	FASEB JOURNAL			English	Article						serum degradation; chemical modification; cleavage site; restrictive endonuclease	HUMAN PANCREATIC RIBONUCLEASE; DOUBLE-STRANDED-RNA; MAMMALIAN-CELLS; INTERFERENCE; TARGETS; DEGRADATION; DUPLEXES; SITES; SERUM	Double-stranded small interfering RNAs (siRNAs) are important modulators of biological processes and hold great promise for therapeutic applications. However, serum processing of synthetic siRNAs is still largely unknown. To address this issue, serum degradation assays of 125 siRNAs were first performed in this study. Four siRNA categories of distinct serum stability were identified, including a group of siRNAs that were stable in their native form for both in vitro and in vivo assays. Fine mapping of the cleavage events occurring in serum treatment demonstrated that most occurred at two vulnerable sites, leading to a speculation that rational modification of these sites might protect most siRNAs from serum degradation. For proof of concept, an exhaustive siRNA modification study was performed. In addition to the consistent stabilization pattern revealed at these sites, our study further showed that a single modification made at the cleavage site stabilized the siRNAs to a large extent, highlighting the importance of these sites in siRNA degradation. In summary, the present study provided a comprehensive picture of serum processing of siRNA as well as a starting point for a rational siRNA modification strategy, both of which are of great importance to in vivo and therapeutic applications of siRNA.-Hong, J., Huang, Y., Li, J., Yi, F., Zheng, J., Huang H., Wei, N., Shan, Y, An, M., Zhang, H., Ji J., Zhang, P., Xi, Z., Du, Q., Liang, Z. Comprehensive analysis of sequence-specific stability of small interfering RNA. FASEB J. 24, 4844-4855 (2010). www.fasebj.org	[Hong, Junmei; Huang, Yuanyu; Li, Jun; Yi, Fan; Zheng, Jie; Huang, Huang; Wei, Na; Shan, Yongqiang; Du, Quan; Liang, Zicai] Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China; [An, Mingrui; Ji, Jianguo] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China; [Zhang, Hongyan] Suzhou Ribo Life Sci Co Ltd, Kunshan, Jiangsu, Peoples R China; [Zhang, Peizhuo] Suzhou GenePharma Co Ltd, Suzhou, Peoples R China; [Xi, Zhen] Nankai Univ, State Key Lab Elementoorgan Chem, Tianjin 300071, Peoples R China	Peking University; Peking University; Nankai University	Du, QA (corresponding author), Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China.	quan.du@pku.edu.cn; liangz@edu.pku.cn	Huang, Huang/AAG-6281-2019; Liang, Zicai/A-2646-2013; Huang, Yuanyu/H-8466-2014	Huang, Yuanyu/0000-0003-3935-7245; Huang, Huang/0000-0002-8377-4823	National Natural Science Foundation of China [30873187, 30771085, 30871385]; Beijing Natural Science Foundation [5092011]; National High-Tech R&D Program of China [2006AA02Z104, 2007AA02Z165, 2009ZX09503-022]; National Basic Research Program of China [2007CB512100]; National 985 Program; Department of Education of China [20070001011, 200800010019]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); National High-Tech R&D Program of China(National High Technology Research and Development Program of China); National Basic Research Program of China(National Basic Research Program of China); National 985 Program; Department of Education of China	The authors thank Dr. Iain C. Bruce for critically reading this manuscript. This work was supported by the National Natural Science Foundation of China (30873187, 30771085, and 30871385), the Beijing Natural Science Foundation (5092011), the National High-Tech R&D Program of China (2006AA02Z104, 2007AA02Z165, and 2009ZX09503-022), the National Basic Research Program of China (2007CB512100), the National 985 Program, and the Department of Education of China (grants 20070001011 and 200800010019).	Allerson CR, 2005, J MED CHEM, V48, P901, DOI 10.1021/jm049167j; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; Braasch DA, 2003, BIOCHEMISTRY-US, V42, P7967, DOI 10.1021/bi0343774; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Choung S, 2006, BIOCHEM BIOPH RES CO, V342, P919, DOI 10.1016/j.bbrc.2006.02.049; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P2705, DOI 10.1093/nar/gkg393; Du Q, 2005, NUCLEIC ACIDS RES, V33, P1671, DOI 10.1093/nar/gki312; Dykxhoorn DM, 2006, P NATL ACAD SCI USA, V103, P5953, DOI 10.1073/pnas.0601309103; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Geary RS, 2001, J PHARMACOL EXP THER, V296, P890; Haupenthal J, 2006, BIOCHEM PHARMACOL, V71, P702, DOI 10.1016/j.bcp.2005.11.015; Huang HY, 2009, NUCLEIC ACIDS RES, V37, pD150, DOI 10.1093/nar/gkn852; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; KAZUNOBU F, 2008, ANAL BIOCHEM, V385, P386; Kurreck J, 2009, ANGEW CHEM INT EDIT, V48, P1378, DOI 10.1002/anie.200802092; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Lopez-Fraga M., 2008, Infectious Disorders - Drug Targets, V8, P262; Loverix S, 2003, CURR MED CHEM, V10, P779, DOI 10.2174/0929867033457845; MASSIMO L, 1992, MOL CELL BIOCHEM, V117, P139; Rodriguez M, 2008, ARCH BIOCHEM BIOPHYS, V471, P191, DOI 10.1016/j.abb.2007.12.016; Sorrentino S, 2003, BIOCHEMISTRY-US, V42, P10182, DOI 10.1021/bi030040q; Volkov AA, 2009, OLIGONUCLEOTIDES, V19, P191, DOI 10.1089/oli.2008.0162; Yakovlev G, 1997, J BIOMOL STRUCT DYN, V15, P243, DOI 10.1080/07391102.1997.10508189; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	25	33	37	2	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4844	4855		10.1096/fj.09-142398	http://dx.doi.org/10.1096/fj.09-142398			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20732955				2022-12-28	WOS:000284824400024
J	Yin, FF; Dumont, M; Banerjee, R; Ma, Y; Li, HH; Lin, MT; Beal, MF; Nathan, C; Thomas, B; Ding, AH				Yin, Fangfang; Dumont, Magali; Banerjee, Rebecca; Ma, Yao; Li, Huihong; Lin, Michael T.; Beal, M. Flint; Nathan, Carl; Thomas, Bobby; Ding, Aihao			Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia	FASEB JOURNAL			English	Article						neurodegeneration; TDP-43; ubiquitin; transgenic mice	LOBAR DEGENERATION; EPITHELIN PRECURSOR; HOST-DEFENSE; INFLAMMATION; INCLUSIONS; ACROGRANIN; MUTATIONS; DISEASE; REPAIR; ROLES	Progranulin haploinsufficiency causes frontotemporal dementia with tau-negative, ubiquitin-positive neuronal inclusion pathology. In this study, we showed that progranulin-deficient mice displayed increased depression- and disinhibition-like behavior, as well as deficits in social recognition from a relatively young age. These mice did not have any deficit in locomotion or exploration. Eighteen-month-old progranulin-deficient mice demonstrated impaired spatial learning and memory in the Morris water maze. In addition to behavioral deficits, progranulin-deficient mice showed a progressive development of neuropathology from 12 mo of age, including enhanced activation of microglia and astro-cytes and ubiquitination and cytoplasmic accumulation of phosphorylated TDP-43. Thus, progranulin deficiency induced FTD-like behavioral and neuropathological deficits. These mice may serve as an important tool for deciphering underlying mechanisms in frontotemporal dementia.-Yin, F., Dumont, M., Banerjee, R., Ma, Y., Li, H., Lin, M. T., Beal, M. F., Nathan, C., Thomas, B., Ding, A. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J. 24, 4639-4647 (2010). www.fasebj.org	[Yin, Fangfang; Ma, Yao; Li, Huihong; Nathan, Carl; Ding, Aihao] Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10065 USA; [Dumont, Magali; Banerjee, Rebecca; Lin, Michael T.; Beal, M. Flint; Thomas, Bobby] Cornell Univ, Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA; [Yin, Fangfang; Nathan, Carl; Ding, Aihao] Cornell Univ, Weill Grad Sch Med Sci, Grad Program Immunol & Microbial Pathogenesis, New York, NY 10021 USA; [Ma, Yao] Chinese Acad Med Sci, Inst Materia Med, Beijing 100037, Peoples R China	Cornell University; Cornell University; Cornell University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS	Ding, AH (corresponding author), Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10065 USA.	ahding@med.cornell.edu	瑶, 马/GYV-3500-2022	DUMONT, MAGALI/0000-0001-9990-6512	National Institutes of Health [GM061710, AI030165, NS060885, NS062165]; Cancer Research Institute; Appel Established Investigatorship; William Randolph Hearst Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030165, R29AI030165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS062165, R01NS060885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020729] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Institute; Appel Established Investigatorship; William Randolph Hearst Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institutes of Health grants GM061710 and AI030165 (to A.D.), NS060885, NS062165 (to B.T.), a predoctoral fellowship from the Cancer Research Institute (to F.Y.), and an Appel Established Investigatorship (to C.N.). The Department of Microbiology and Immunology is supported by the William Randolph Hearst Foundation. The authors thank Dr. Haruhiko Akiyama, Masato Hasegawa, and Tetsuaki Arai (Tokyo Institute of Psychiatry, Tokyo, Japan) for antibody against phosphorylated TDP-43 (pS409/410).	Ahmed Z, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-7; Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Chiba S, 2009, J REPROD DEVELOP, V55, P518, DOI 10.1262/jrd.20239; Christian LM, 2009, BRAIN BEHAV IMMUN, V23, P750, DOI 10.1016/j.bbi.2009.02.012; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; de Vugt ME, 2006, DEMENT GERIATR COGN, V22, P35, DOI 10.1159/000093102; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Godbout JP, 2008, NEUROPSYCHOPHARMACOL, V33, P2341, DOI 10.1038/sj.npp.1301649; Goodman WK, 2006, PSYCHIAT CLIN N AM, V29, P445, DOI 10.1016/j.psc.2006.02.003; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; Josephs KA, 2007, J NEUROPATH EXP NEUR, V66, P142, DOI 10.1097/nen.0b013e31803020cf; Lipton AM, 2004, ACTA NEUROPATHOL, V108, P379, DOI 10.1007/s00401-004-0900-9; Mackenzie IRA, 2006, ACTA NEUROPATHOL, V112, P551, DOI 10.1007/s00401-006-0123-3; Moy SS, 2007, BEHAV BRAIN RES, V176, P4, DOI 10.1016/j.bbr.2006.07.030; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Rao R, 2007, AIDS CARE, V19, P828, DOI 10.1080/09540120601133659; Ryan CL, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-130; Suzuki M, 2009, J REPROD DEVELOP, V55, P351, DOI 10.1262/jrd.20249; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; Viskontas IV, 2007, ANN NY ACAD SCI, V1121, P528, DOI 10.1196/annals.1401.025; Witt Rochelle M, 2009, J Vis Exp, DOI 10.3791/949; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	27	125	128	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4639	4647		10.1096/fj.10-161471	http://dx.doi.org/10.1096/fj.10-161471			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20667979	Green Published			2022-12-28	WOS:000284824400005
J	Kithcart, AP; Cox, GM; Sielecki, T; Short, A; Pruitt, J; Papenfuss, T; Shawler, T; Gienapp, I; Satoskar, AR; Whitacre, CC				Kithcart, Aaron P.; Cox, Gina M.; Sielecki, Thais; Short, Abigail; Pruitt, James; Papenfuss, Tracey; Shawler, Todd; Gienapp, Ingrid; Satoskar, Abhay R.; Whitacre, Caroline C.			A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease	FASEB JOURNAL			English	Article						experimental autoimmune encephalomyelitis; multiple sclerosis; blood-brain barrier	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; FACTOR MIF; T-CELLS; INTERLEUKIN-7 RECEPTOR; CEREBROSPINAL-FLUID; NATALIZUMAB; THERAPIES; REVEALS	Multiple sclerosis (MS) is a chronic, debilitating disease of the central nervous system (CNS) characterized by demyelination and axon loss. The proinflammatory cytokine macrophage migration inhibitory factor (MIF) has been shown to be elevated in the cerebrospinal fluid of patients during relapses. The purpose of this study was to evaluate a new small-molecule inhibitor of MIF and its ability to reduce the severity of an animal model of MS, experimental autoimmune encephalomyelitis (EAE). We utilized 2 structurally related isoxazolines, which show in vitro inhibition of MIF tautomerase activity. We found that administration of an inhibitor of MIF to mice with established EAE immediately reduced the severity of clinical signs and expanded a population of regulatory T lymphocytes. We also noted that the inhibitor reduced relapses of disease in a relapsing/remitting model of EAE. An analysis of leukocyte migration into the brain revealed that administration of inhibitor reduced entry of these cells. No effects on inflammatory cytokine production or T-cell activation in the periphery were noted. From these studies, we conclude that a small-molecule inhibitor of MIF reduces the severity of EAE and prevents access of immune cells into the CNS, which could be of therapeutic relevance to MS.-Kithcart, A. P., Cox, G. M., Sielecki, T., Short, A., Pruitt, J., Papenfuss, T., Shawler, T., Gienapp, I., Satoskar, A. R., Whitacre, C. C. A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J. 24, 4459-4466 (2010). www.fasebj.org	[Kithcart, Aaron P.; Cox, Gina M.; Short, Abigail; Shawler, Todd; Gienapp, Ingrid; Whitacre, Caroline C.] Ohio State Univ, Dept Mol Virol Immunol & Mol Genet, Columbus, OH 43210 USA; [Papenfuss, Tracey] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Satoskar, Abhay R.] Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; [Sielecki, Thais; Pruitt, James] Cytokine PharmaSci, King Of Prussia, PA USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Whitacre, CC (corresponding author), 208 Bricker Hall,190 N Oval Mall, Columbus, OH 43210 USA.	whitacre.3@osu.edu	Papenfuss, Tracey/E-3814-2011; Satoskar, Abhay/AAB-7748-2019		U.S. National Institutes of Health [AI 064320]; National MS Society [RG3272]; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR022198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064320] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National MS Society(National Multiple Sclerosis Society); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank additional members of the C.C.W. laboratory for their support and scientific discussion, including Kristen Smith, Jessica Williams, Amy Lovett-Racke, and Michael Racke. This project was supported by U.S. National Institutes of Health grant AI 064320 and National MS Society grant RG3272.	AROCA P, 1991, BIOCHEM J, V277, P393, DOI 10.1042/bj2770393; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Bo L, 1996, J NEUROPATH EXP NEUR, V55, P1060, DOI 10.1097/00005072-199655100-00006; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; CHOU YK, 1992, J NEUROIMMUNOL, V38, P105, DOI 10.1016/0165-5728(92)90095-3; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Denkinger CM, 2003, J IMMUNOL, V170, P1274, DOI 10.4049/jimmunol.170.3.1274; Engelhardt Britta, 2006, V43, P259, DOI 10.1007/020; Fitzgerald DC, 2007, J IMMUNOL, V179, P3268, DOI 10.4049/jimmunol.179.5.3268; Flores M, 2008, FASEB J, V22, P3661, DOI 10.1096/fj.08-111666; Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; Kleemann R, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/610479; Lundmark F, 2007, NAT GENET, V39, P1108, DOI 10.1038/ng2106; Matsunaga J, 1999, J BIOL CHEM, V274, P3268, DOI 10.1074/jbc.274.6.3268; McFarland HF, 2007, NAT IMMUNOL, V8, P913, DOI 10.1038/ni1507; Meyer-Siegler KL, 2007, GENES IMMUN, V8, P646, DOI 10.1038/sj.gene.6364427; Miller A, 1997, SOUTH MED J, V90, P367, DOI 10.1097/00007611-199704000-00001; Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939; Niino M, 2000, J NEUROL SCI, V179, P127, DOI 10.1016/S0022-510X(00)00397-X; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Peterson JW, 2005, NEUROL CLIN, V23, P107, DOI 10.1016/j.ncl.2004.09.008; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Popa C, 2006, CYTOKINE, V36, P51, DOI 10.1016/j.cyto.2006.10.011; Powell ND, 2005, J IMMUNOL, V175, P5611, DOI 10.4049/jimmunol.175.9.5611; Racke MK, 2008, CURR OPIN NEUROL, V21, pS9, DOI 10.1097/01.wco.0000313359.61176.15; Rodriguez-Sosa M, 2003, INFECT IMMUN, V71, P1247, DOI 10.1128/IAI.71.3.1247-1254.2003; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Sanchez-Zamora Y, 2010, FASEB J, V24, P2583, DOI 10.1096/fj.09-147066; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; Schober A, 2008, J MOL MED, V86, P761, DOI 10.1007/s00109-008-0334-2; Stromnes IM, 2006, NAT PROTOC, V1, P1810, DOI 10.1038/nprot.2006.285; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; Wingerchuk DM, 2001, LAB INVEST, V81, P263, DOI 10.1038/labinvest.3780235; Yousry TA, 2006, NEW ENGL J MED, V354, P924, DOI 10.1056/NEJMoa054693; Zernecke A, 2008, CIRCULATION, V117, P1594, DOI 10.1161/CIRCULATIONAHA.107.729125	39	39	40	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4459	4466		10.1096/fj.10-162347	http://dx.doi.org/10.1096/fj.10-162347			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20624927	Green Published			2022-12-28	WOS:000283861100031
J	Lee, CR; Imig, JD; Edin, ML; Foley, J; DeGraff, LM; Bradbury, JA; Graves, JP; Lih, FB; Clark, J; Myers, P; Perrow, AL; Lepp, AN; Kannon, MA; Ronnekleiv, OK; Alkayed, NJ; Falck, JR; Tomer, KB; Zeldin, DC				Lee, Craig R.; Imig, John D.; Edin, Matthew L.; Foley, Julie; DeGraff, Laura M.; Bradbury, J. Alyce; Graves, Joan P.; Lih, Fred B.; Clark, James; Myers, Page; Perrow, A. Ligon; Lepp, Adrienne N.; Kannon, M. Alison; Ronnekleiv, Oline K.; Alkayed, Nabil J.; Falck, John R.; Tomer, Kenneth B.; Zeldin, Darryl C.			Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice	FASEB JOURNAL			English	Article						CYP2J2; CYP2C8; epoxygenase; EETs; transgenic	SOLUBLE EPOXIDE HYDROLASE; SALT-SENSITIVE HYPERTENSION; ARACHIDONIC-ACID METABOLISM; ANGIOTENSIN-II; NITRIC-OXIDE; EPOXYEICOSATRIENOIC ACIDS; HYPERPOLARIZING FACTORS; CORONARY-ARTERIES; MOLECULAR-CLONING; GENE-EXPRESSION	Renal cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) regulate sodium transport and blood pressure. Although endothelial CYP-derived EETs are potent vasodilators, their contribution to the regulation of blood pressure remains unclear. Consequently, we developed transgenic mice with endothelial expression of the human CYP2J2 and CYP2C8 epoxygenases to increase endothelial EET biosynthesis. Compared to wild-type littermate controls, an attenuated afferent arteriole constrictor response to endothelin-1 and enhanced dilator response to acetylcholine was observed in CYP2J2 and CYP2C8 transgenic mice. CYP2J2 and CYP2C8 transgenic mice demonstrated modestly, but not significantly, lower mean arterial pressure under basal conditions compared to wild-type controls. However, mean arterial pressure was significantly lower in both CYP2J2 and CYP2C8 transgenic mice during coadministration of N-nitro-L-arginine methyl ester and indomethacin. In a separate experiment, a high-salt diet and subcutaneous angiotensin II was administered over 4 wk. The angiotensin/high-saltinduced increase in systolic blood pressure, proteinuria, and glomerular injury was significantly attenuated in CYP2J2 and CYP2C8 transgenic mice compared to wild-type controls. Collectively, these data demonstrate that increased endothelial CYP epoxygenase expression attenuates afferent arteriolar constrictor reactivity and hypertension-induced increases in blood pressure and renal injury in mice. We conclude that endothelial CYP epoxygenase function contributes to the regulation of blood pressure.-Lee, C. R., Imig, J. D., Edin, M. E., Foley, J., DeGraff, L. M., Bradbury, J. A., Graves, J. P., Lih, F. B., Clark, J., Myers, P., Perrow, A. L., Lepp, A. N., Kannon, M. A., Ronnekleiv, O. K., Alkayed, N. J., Falck, J. R., Tomer, K. B., Zeldin, D. C. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 24, 3770-3781 (2010). www.fasebj.org	[Lee, Craig R.; Edin, Matthew L.; Foley, Julie; DeGraff, Laura M.; Bradbury, J. Alyce; Graves, Joan P.; Lih, Fred B.; Clark, James; Myers, Page; Perrow, A. Ligon; Tomer, Kenneth B.; Zeldin, Darryl C.] NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; [Lee, Craig R.; Kannon, M. Alison] Univ N Carolina, Div Pharmacotherapy & Expt Therapeut, Eshelman Sch Pharm, Chapel Hill, NC USA; [Imig, John D.; Lepp, Adrienne N.] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; [Ronnekleiv, Oline K.; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA; [Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA; [Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; Medical College of Wisconsin; Oregon Health & Science University; Oregon Health & Science University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zeldin, DC (corresponding author), NIEHS, Div Intramural Res, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Tomer, Kenneth B/E-8018-2013; Zeldin, Darryl C/Y-7091-2018; Falck, John R/B-3030-2011; Edin, Matthew/AAI-1934-2019	Zeldin, Darryl C/0000-0002-2087-7307; Falck, John R/0000-0002-9219-7845; Edin, Matthew/0000-0002-7042-500X; Imig, John/0000-0002-9668-2899; Lee, Craig/0000-0003-3595-5301	American Heart Association; U.S. National Institutes of Health (NIH) [DK38826]; Advancing a Healthier Wisconsin; Robert A. Welch Foundation; NIH [P01 NS049210, GM31278]; NIH, National Institute of Environmental Health Sciences (NIEHS) [Z01 ES050167, Z01 ES025034]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226, R01DK038826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025034, ZIGES102505, Z01ES050167, ZIAES050167, ZIAES025034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088199, R01GM031278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070837, R01NS044313, P01NS049210] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Advancing a Healthier Wisconsin; Robert A. Welch Foundation(The Welch Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH, National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors gratefully acknowledge the technical assistance of Dr. Taiping Jia in completion of the in situ hybridization studies, and Drs. Anton Jetten and Robert Langenbach for their helpful comments during the preparation of this manuscript. This publication was made possible by a Beginning Grant-in-Aid from the American Heart Association to C.R.L.; U.S. National Institutes of Health (NIH) grant DK38826 and an Advancing a Healthier Wisconsin grant to J.D.I.; NIH grant P01 NS049210 to O.K.R. and N.J.A.; NIH grant GM31278 and support from the Robert A. Welch Foundation to J.R.F., and funds from the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (NIEHS) to K.B.T. (Z01 ES050167) and D.C.Z. (Z01 ES025034). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS or NIH. D.C.Z. is a coinventor on U.S. Patent 6,531,506 B1 (issued March 11, 2003), Inhibition of Epoxide Hydrolases for the Treatment of Hypertension, and on U.S. Patent 6,916,843 B1 (issued July 12, 2005), Anti-inflammatory Actions of Cytochrome P450 Epoxygenase-Derived Eicosanoids. J.D.I. is a coinventor on U.S. Patent 7,550,617 (issued June 23, 2009), Compositions and Methods for the Treatment of Renal and Cardiovascular Disease. No other authors have conflicts of interest to disclose.	Athirakul K, 2008, FASEB J, V22, P4096, DOI 10.1096/fj.08-114413; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Campbell WB, 2007, HYPERTENSION, V49, P590, DOI 10.1161/01.HYP.0000255173.50317.fc; Capdevila JH, 2007, KIDNEY INT, V72, P683, DOI 10.1038/sj.ki.5002394; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; DeLozier TC, 2007, DRUG METAB DISPOS, V35, P682, DOI 10.1124/dmd.106.012823; Deng YM, 2010, J MOL CELL CARDIOL, V48, P331, DOI 10.1016/j.yjmcc.2009.10.022; Elmarakby AA, 2006, HYPERTENSION, V47, P557, DOI 10.1161/01.HYP.0000198545.01860.90; Fava C, 2008, HYPERTENSION, V52, P373, DOI 10.1161/HYPERTENSIONAHA.108.114199; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Gainer JV, 2005, CIRCULATION, V111, P63, DOI 10.1161/01.CIR.0000151309.82473.59; Gauthier KM, 2002, CIRC RES, V90, P1028, DOI 10.1161/01.RES.0000018162.87285.F8; Hartner A, 2003, NEPHROL DIAL TRANSPL, V18, P1999, DOI 10.1093/ndt/gfg299; Hercule HC, 2009, ARTERIOSCL THROM VAS, V29, P54, DOI 10.1161/ATVBAHA.108.171298; Imig JD, 2005, HYPERTENSION, V46, P975, DOI 10.1161/01.HYP.0000176237.74820.75; Imig JD, 2001, J VASC RES, V38, P247, DOI 10.1159/000051053; Imig JD, 2002, AM J PHYSIOL-RENAL, V283, pF415, DOI 10.1152/ajprenal.00351.2001; Imig JD, 2002, HYPERTENSION, V39, P690, DOI 10.1161/hy0202.103788; Imig JD, 1996, J AM SOC NEPHROL, V7, pA1570; Imig JD, 1999, BRIT J PHARMACOL, V127, P1399, DOI 10.1038/sj.bjp.0702662; Imig JD, 2009, NAT REV DRUG DISCOV, V8, P794, DOI 10.1038/nrd2875; Inoue K, 2009, AM J PHYSIOL-RENAL, V297, pF875, DOI 10.1152/ajprenal.00364.2009; Kaergel E, 2002, HYPERTENSION, V40, P273, DOI 10.1161/01.HYP.0000029240.44253.5E; King LM, 2002, MOL PHARMACOL, V61, P840, DOI 10.1124/mol.61.4.840; King Lorraine M, 2005, Pharmacogenet Genomics, V15, P7, DOI 10.1097/01213011-200501000-00002; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Larsen BT, 2006, AM J PHYSIOL-HEART C, V290, pH491, DOI 10.1152/ajpheart.00927.2005; Lee CR, 2007, PHARMACOGENET GENOM, V17, P145, DOI 10.1097/01.fpc.0000236340.87540.e3; Lim YC, 2003, AM J PATHOL, V162, P1591, DOI 10.1016/S0002-9440(10)64293-9; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma J, 2004, MOL PHARMACOL, V65, P730, DOI 10.1124/mol.65.3.730; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; Manhiani M, 2009, AM J PHYSIOL-RENAL, V297, pF740, DOI 10.1152/ajprenal.00098.2009; Mills PA, 2000, J APPL PHYSIOL, V88, P1537, DOI 10.1152/jappl.2000.88.5.1537; Minuz P, 2008, HYPERTENSION, V51, P1379, DOI 10.1161/HYPERTENSIONAHA.107.105395; Muller DN, 2004, AM J PATHOL, V164, P521, DOI 10.1016/S0002-9440(10)63142-2; Nakagawa K, 2006, J CLIN INVEST, V116, P1696, DOI 10.1172/JCI27546; Newman JW, 2002, J LIPID RES, V43, P1563, DOI 10.1194/jlr.D200018-JLR200; Ohashi Y, 1998, J CLIN INVEST, V102, P2061, DOI 10.1172/JCI4394; Peebles RS, 2000, AM J RESP CRIT CARE, V162, P676; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Seubert JM, 2006, CIRC RES, V99, P442, DOI 10.1161/01.RES.0000237390.92932.37; Singh H, 2007, HYPERTENSION, V50, P123, DOI 10.1161/HYPERTENSIONAHA.107.089599; Theken KN, 2007, PHARMACOGENOMICS, V8, P1369, DOI 10.2217/14622416.8.10.1369; Torok J, 2008, PHYSIOL RES, V57, P813, DOI 10.33549/physiolres.931581; Wang JS, 2006, CIRC RES, V98, P962, DOI 10.1161/01.RES.0000217283.98806.a6; Wu S, 1996, J BIOL CHEM, V271, P3460; Yu ZG, 2000, CIRC RES, V87, P992, DOI 10.1161/01.RES.87.11.992; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zhao XY, 2004, J AM SOC NEPHROL, V15, P1244; Zhao XY, 2003, HYPERTENSION, V41, P709, DOI 10.1161/01.HYP.0000047877.36743.FA	53	117	120	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3770	3781		10.1096/fj.10-160119	http://dx.doi.org/10.1096/fj.10-160119			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20495177	Green Published			2022-12-28	WOS:000285005900016
J	Mukherjee, R; Colbath, GP; Justus, CD; Bruce, JA; Allen, CM; Hewett, KW; Saul, JP; Gourdie, RG; Spinale, FG				Mukherjee, Rupak; Colbath, Gregory P.; Justus, Charles D.; Bruce, James A.; Allen, Claire M.; Hewett, Kenneth W.; Saul, J. Philip; Gourdie, Robert G.; Spinale, Francis G.			Spatiotemporal induction of matrix metalloproteinase-9 transcription after discrete myocardial injury	FASEB JOURNAL			English	Article						myocardial injury; structure; remodeling	MATRIX-METALLOPROTEINASE INHIBITION; LEFT-VENTRICULAR ENLARGEMENT; TARGETED DELETION; TISSUE INHIBITOR; CARDIAC RUPTURE; GAP-JUNCTIONS; INFARCTION; EXPRESSION; CONDUCTION; FIBROSIS	Radiofrequency (RF) ablation of the myocardium causes discrete sites of injury. RF scars can expand, altering the extracellular matrix (ECM) structure and the continuity of the electrical syncytium of the adjacent myocardium. Matrix metalloproteinases (MMPs), such as MMP-9, contribute to ECM remodeling. However, whether and to what degree transcriptional induction of MMP-9 occurs after myocardial RF injury and the association with electrical conduction patterns after RF injury remains unexplored. This study examined MMP-9 gene promoter (M9PROM) activation after myocardial RF injury using mice in which the M9PROM was fused to a beta-galactosidase (beta-gal) reporter. RF lesions (0.5-mm probe, 80 degrees C, 30 s) were created on the left ventricular (LV) epicardium of M9PROM mice (n=62) and terminally studied at 1 h, 1 d, 3 d, 7 d, 14 d, and 28 d after RF injury. M9PROM activation was localized through beta-gal staining. The RF scar area and the area of beta-gal staining were measured and normalized to LV area (planimetry). RF scar size increased from 1 h post-RF-injury values by 7 d and remained higher at 28 d. M9PROM activation became evident at 3 d and peaked at 7 d. Electrical conduction was measured (potentiometric dye mapping) at 7 d after RF injury. Heterogeneities in action potentials and electrical impulse propagation coincident with M9PROM activation were observed after RF injury. For example, conduction proximal to the RF site was slower than that in the remote myocardium (0.15+/-0.02 vs. 0.83+/-0.08 mm/ms, P<0.05). Thus, a unique spatiotemporal pattern of MMP-9 transcriptional activation occurred after discrete myocardial injury, which was associated with the development of electrical heterogeneity. Therefore, these findings suggest that changes in a key determinant of extracellular matrix remodeling, in addition to changes in myocardial structure, can contribute to arrhythmogenesis around the region of myocardial injury.-Mukherjee, R., Colbath, G. P., Justus, C. D., Bruce, J. A., Allen, C. M., Hewett, K. W., Saul, J. P., Gourdie, R. G., Spinale, F. G. Spatiotemporal induction of matrix metalloproteinase-9 transcription following discrete myocardial injury. FASEB J. 24, 3819-3828 (2010). www.fasebj.org	[Mukherjee, Rupak; Colbath, Gregory P.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA; [Mukherjee, Rupak; Bruce, James A.; Allen, Claire M.; Saul, J. Philip; Spinale, Francis G.] Med Univ S Carolina, Div Pediat Cardiol, Charleston, SC 29425 USA; [Justus, Charles D.; Hewett, Kenneth W.; Gourdie, Robert G.] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; [Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Mukherjee, R (corresponding author), Med Univ S Carolina, Div Cardiothorac Surg, Strom Thurmond Res Bldg,770 MUSC Complex,Ste 625, Charleston, SC 29425 USA.	mukherr@musc.edu			U.S. National Institutes of Health [HL-66029, HL-45024, HL-97012, P01-48788, HL-56728]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066029, R03HL097012, R29HL045024, R01HL056728] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by U.S. National Institutes of Health grants HL-66029 (to R.M.), HL-45024, HL-97012, and P01-48788 (to F.G.S.), and HL-56728 (to R.G.G.).	Bergman MR, 2003, BIOCHEM J, V369, P485, DOI 10.1042/BJ20020707; Cavasin MA, 2006, AM J PHYSIOL-HEART C, V290, pH2043, DOI 10.1152/ajpheart.01121.2005; Cavasin MA, 2004, LIFE SCI, V75, P2181, DOI 10.1016/j.lfs.2004.04.024; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Cleutjens JPM, 2002, J CARD FAIL, V8, pS344, DOI 10.1054/jcaf.2002.129261; CLEUTJENS JPM, 1995, J MOL CELL CARDIOL, V27, P1281, DOI 10.1016/S0022-2828(05)82390-9; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; Danik SB, 2004, CIRC RES, V95, P1035, DOI 10.1161/01.RES.0000148664.33695.2a; Danik SB, 2008, FASEB J, V22, P1204, DOI 10.1096/fj.07-8974com; DOLBER PC, 1992, J MOL CELL CARDIOL, V24, P1443, DOI 10.1016/0022-2828(92)91085-J; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Hayashidani S, 2003, AM J PHYSIOL-HEART C, V285, pH1229, DOI 10.1152/ajpheart.00207.2003; Hewett KW, 2005, CARDIOVASC RES, V67, P548, DOI 10.1016/j.cardiores.2005.04.002; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Hunter AW, 2003, CELL COMMUN ADHES, V10, P211, DOI 10.1080/714040429; Jalife J, 1998, J CARDIOVASC ELECTR, V9, P1358, DOI 10.1111/j.1540-8167.1998.tb00111.x; Li JF, 2005, CIRC RES, V97, P474, DOI 10.1161/01.RES.0000181132.11393.18; Li XP, 2008, MED HYPOTHESES, V70, P317, DOI 10.1016/j.mehy.2007.04.046; Lindsey ML, 2006, CIRCULATION, V113, P2919, DOI 10.1161/CIRCULATIONAHA.106.612960; Lindsey ML, 2002, CIRCULATION, V105, P753, DOI 10.1161/hc0602.103674; Mohan R, 1998, J BIOL CHEM, V273, P25903, DOI 10.1074/jbc.273.40.25903; Mukherjee R, 2005, J MOL CELL CARDIOL, V39, P259, DOI 10.1016/j.yjmcc.2005.03.012; Mukherjee R, 2004, AM J PHYSIOL-HEART C, V286, pH1242, DOI 10.1152/ajpheart.00437.2003; Mukherjee R, 2003, CIRCULATION, V107, P618, DOI 10.1161/01.CIR.0000046449.36178.00; Mukherjee R, 2006, AM J PHYSIOL-HEART C, V291, pH2216, DOI 10.1152/ajpheart.01343.2005; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; PETERS NS, 1995, J MOL CELL CARDIOL, V27, P37, DOI 10.1016/S0022-2828(08)80005-3; Peters NS, 1997, CIRCULATION, V95, P988; Peterson JT, 2000, CARDIOVASC RES, V46, P307, DOI 10.1016/S0008-6363(00)00029-8; Poelzing S, 2004, AM J PHYSIOL-HEART C, V287, pH1762, DOI 10.1152/ajpheart.00346.2004; Rohde LE, 1999, CIRCULATION, V99, P3063, DOI 10.1161/01.CIR.99.23.3063; Sivak JM, 2002, PROG RETIN EYE RES, V21, P1, DOI 10.1016/S1350-9462(01)00015-5; Spach MS, 2007, CIRC RES, V101, P743, DOI 10.1161/CIRCRESAHA.107.163956; Spach MS, 2001, J ELECTROCARDIOL, V34, P69, DOI 10.1054/jelc.2001.28833; Strom M, 2010, AM J PHYSIOL-HEART C, V298, pH787, DOI 10.1152/ajpheart.00887.2009; Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981; Tanaka K, 2007, CIRC RES, V101, P839, DOI 10.1161/CIRCRESAHA.107.153858; Tao ZY, 2004, LIFE SCI, V74, P1561, DOI 10.1016/j.lfs.2003.09.042; Vaidya D, 2001, CIRC RES, V88, P1196, DOI 10.1161/hh1101.091107; van Veen TAB, 2005, CIRCULATION, V112, P1927, DOI 10.1161/CIRCULATIONAHA.105.539072; Wilson EM, 2003, CIRCULATION, V107, P2857, DOI 10.1161/01.CIR.0000068375.40887.FA	41	8	8	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3819	3828		10.1096/fj.10-155531	http://dx.doi.org/10.1096/fj.10-155531			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20530752	Green Published			2022-12-28	WOS:000285005900020
J	Wang, BX; Mao, YK; Diorio, C; Pasyk, M; Wu, RY; Bienenstock, J; Kunze, WA				Wang, Bingxian; Mao, Yu-Kang; Diorio, Caroline; Pasyk, Michael; Wu, Richard You; Bienenstock, John; Kunze, Wolfgang A.			Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes	FASEB JOURNAL			English	Article						enteric nervous system; small intestine; probiotics	GAMMA-AMINOBUTYRIC-ACID; SEGMENTED FILAMENTOUS BACTERIA; CA2+-ACTIVATED K+ CHANNEL; ENTERIC NERVOUS-SYSTEM; PIG MYENTERIC NEURONS; POTASSIUM-CHANNELS; INTESTINAL MUSCLE; PROBIOTIC THERAPY; AFFERENT-FIBERS; BLOOD-PRESSURE	Gut commensals modulate host immune, endocrine, and metabolic functions. They also affect peripheral and central neural reflexes and function. We have previously shown that daily ingestion of Lactobacillus reuteri (LR) for 9 d inhibits the pseudoaffective cardiac response and spinal single-fiber discharge evoked by visceral distension, and decreases intestinal motility and myenteric AH cell slow afterhyperpolarization (sAHP) by inhibiting a Ca-activated K (IKCa) channel. We tested whether luminal LR could acutely decrease motility in an ex vivo perfusion model of naive Balb/c jejunum. Live LR dose dependently decreased motor complex pressure wave amplitudes with 9- to 16-min onset latency and an IC50 of 5 x 10(7) cells/ml Krebs. Heat-killed LR or another live commensal, Lactobacillus salivarius, were without effect. The IKCa channel blocker TRAM-34, but neither the opener (DCEBIO) nor the hyperpolarization-activated cationic channel inhibitor ZD7288 (5 mu M) (or TTX 1 mu M), mimicked the LR effect on motility acutely ex vivo. We provide evidence for a rapid, strain-specific, dose-dependent action of a live Lactobacillus on small intestinal motility reflexes that recapitulates the long-term effects of LR ingestion. These observations may be useful as a first step to unraveling the pathways involved in bacteria to the nervous system communication.-Wang, B., Mao, Y.-K., Diorio, C., Pasyk, M., Wu, R.Y., Bienenstock, J., Kunze, W.A. Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes. FASEB J. 24, 4078-4088 (2010). www.fasebj.org	[Wang, Bingxian; Mao, Yu-Kang; Diorio, Caroline; Pasyk, Michael; Wu, Richard You; Bienenstock, John; Kunze, Wolfgang A.] St Josephs Healthcare, McMaster Brain Body Inst, Hamilton, ON L8N 4A6, Canada; [Kunze, Wolfgang A.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Wang, Bingxian] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Bienenstock, John] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University; McMaster University	Kunze, WA (corresponding author), St Josephs Healthcare, McMaster Brain Body Inst, Juravinsky Innovat Tower,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	kunzew@mcmaster.ca		Diorio, Caroline/0000-0002-8005-3836	Natural Sciences and Engineering Council of Canada; Guglietti Family Foundation; Abbott Nutrition	Natural Sciences and Engineering Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Guglietti Family Foundation; Abbott Nutrition(Abbott Laboratories)	This study was supported by a grant from the Natural Sciences and Engineering Council of Canada, the Guglietti Family Foundation, and Abbott Nutrition.	Abdu F, 2002, AM J PHYSIOL-GASTR L, V282, pG624, DOI 10.1152/ajpgi.00354.2001; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Bian XC, 2004, AM J PHYSIOL-GASTR L, V287, pG134, DOI 10.1152/ajpgi.00532.2003; Biel M, 2009, PHYSIOL REV, V89, P847, DOI 10.1152/physrev.00029.2008; BIENENSTOCK J, 1989, ADV EXP MED BIOL, V257, P19; BULBRING E, 1958, J PHYSIOL-LONDON, V140, P381; Burley JR, 2000, NEUROPHARMACOLOGY, V39, P1740, DOI 10.1016/S0028-3908(99)00266-X; Bush TG, 2000, AUTON NEUROSCI-BASIC, V84, P162, DOI 10.1016/S1566-0702(00)00201-0; CERVERO F, 1988, J PHYSIOL-LONDON, V401, P381, DOI 10.1113/jphysiol.1988.sp017168; CHERUBINI E, 1984, BRIT J PHARMACOL, V82, P93, DOI 10.1111/j.1476-5381.1984.tb16445.x; Chiocchetti R, 2008, CELL TISSUE RES, V332, P185, DOI 10.1007/s00441-008-0583-y; Collins SM, 2009, GASTROENTEROLOGY, V136, P2003, DOI 10.1053/j.gastro.2009.01.075; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; D'Souza AL, 2002, BRIT MED J, V324, P1361, DOI 10.1136/bmj.324.7350.1361; Das J, 2009, CELL, V136, P337, DOI 10.1016/j.cell.2008.11.051; Davies PJ, 2006, AUTON NEUROSCI-BASIC, V124, P26, DOI 10.1016/j.autneu.2005.10.006; Ferens D, 2007, NEUROGASTROENT MOTIL, V19, P383, DOI 10.1111/j.1365-2982.2007.00898.x; Forsythe P, 2008, THERAPEUTIC MICROBIOLOGY: PROBIOTICS AND RELATED STRATEGIES, P285; Forsythe P, 2010, BRAIN BEHAV IMMUN, V24, P9, DOI 10.1016/j.bbi.2009.05.058; Frank DN, 2008, CURR OPIN GASTROEN, V24, P4, DOI 10.1097/MOG.0b013e3282f2b0e8; Furness J.B., 2006, ENTERIC NERVOUS SYST; Furness JB, 2004, CELL TISSUE RES, V317, P1, DOI 10.1007/s00441-004-0895-5; FURUKAWA K, 1986, J NEUROPHYSIOL, V55, P1395, DOI 10.1152/jn.1986.55.6.1395; Gallego D, 2008, NEUROGASTROENT MOTIL, V20, P1306, DOI 10.1111/j.1365-2982.2008.01201.x; Gionchetti P, 2006, WORLD J GASTROENTERO, V12, P3306, DOI 10.3748/wjg.v12.i21.3306; Guarner F, 2008, WORLD GASTROENTEROLO; Hanani M, 2000, AM J PHYSIOL-GASTR L, V278, pG644, DOI 10.1152/ajpgi.2000.278.4.G644; Hashiguchi-Ikeda M, 2003, ANESTHESIOLOGY, V99, P1340, DOI 10.1097/00000542-200312000-00015; Hayakawa K, 2004, BRIT J NUTR, V92, P411, DOI 10.1079/BJN20041221; HIRST GDS, 1974, J PHYSIOL-LONDON, V236, P303, DOI 10.1113/jphysiol.1974.sp010436; Huizinga JD, 1998, J PHYSIOL-LONDON, V506, P843, DOI 10.1111/j.1469-7793.1998.843bv.x; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Iyer LM, 2004, TRENDS GENET, V20, P292, DOI 10.1016/j.tig.2004.05.007; JESSEN KR, 1981, MOL CELL BIOCHEM, V38, P69, DOI 10.1007/BF00235689; Kamiya T, 2006, GUT, V55, P191, DOI 10.1136/gut.2005.070987; Kamm K, 2004, NEUROGASTROENT MOTIL, V16, P53, DOI 10.1046/j.1365-2982.2003.00458.x; KEAST JR, 1984, GASTROENTEROLOGY, V86, P637; Kinross James M, 2008, Curr Gastroenterol Rep, V10, P396, DOI 10.1007/s11894-008-0075-y; KRANTIS A, 1987, EUR J PHARMACOL, V141, P291, DOI 10.1016/0014-2999(87)90274-3; Krantis A, 2000, NEWS PHYSIOL SCI, V15, P284; Kuhn A, 2004, J NEUROSCI, V24, P2345, DOI 10.1523/JNEUROSCI.3349-03.2004; KUNZE WA, 2007, EE11 ANN M SOC NEUR; KUNZE WAA, 1994, PFLUG ARCH EUR J PHY, V428, P300, DOI 10.1007/BF00724511; KUNZE WAA, 1993, NEUROSCIENCE, V55, P685, DOI 10.1016/0306-4522(93)90434-H; Kunze WAA, 1999, J PHYSIOL-LONDON, V517, P547, DOI 10.1111/j.1469-7793.1999.0547t.x; Kunze WA, 2009, J CELL MOL MED, V13, P2261, DOI 10.1111/j.1582-4934.2009.00686.x; Ma XL, 2009, AM J PHYSIOL-GASTR L, V296, pG868, DOI 10.1152/ajpgi.90511.2008; Mao YK, 2006, J NEUROPHYSIOL, V96, P998, DOI 10.1152/jn.00204.2006; Mazzia C, 1997, NEUROSCIENCE, V80, P925, DOI 10.1016/S0306-4522(97)00058-4; Mazzuoli G, 2009, J PHYSIOL-LONDON, V587, P4681, DOI 10.1113/jphysiol.2009.177105; McCarthy E L, 1934, Science, V80, P100, DOI 10.1126/science.80.2065.100; Mignini F., 2003, Autonomic & Autacoid Pharmacology, V23, P1, DOI 10.1046/j.1474-8673.2003.00280.x; MINOCHA A, 1993, EUR J PHARMACOL, V230, P187, DOI 10.1016/0014-2999(93)90801-N; Morimura K, 2006, J PHARMACOL SCI, V100, p121P; Motulsky H., 1999, ANAL DATA GRAPHPAD P; Namba T, 2000, EUR J PHARMACOL, V395, P95, DOI 10.1016/S0014-2999(00)00254-5; Neal KB, 2009, J PHYSIOL-LONDON, V587, P567, DOI 10.1113/jphysiol.2008.160416; Nguyen TV, 2007, J NEUROPHYSIOL, V97, P2024, DOI 10.1152/jn.00935.2006; NORTH RA, 1987, J PHYSIOL-LONDON, V386, P333, DOI 10.1113/jphysiol.1987.sp016537; Nurgali K, 2004, J COMP NEUROL, V468, P112, DOI 10.1002/cne.10948; Nurgali K, 2007, J PHYSIOL-LONDON, V583, P593, DOI 10.1113/jphysiol.2007.135947; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; ODORISIO MS, 1988, INT J NEUROSCI, V38, P189, DOI 10.3109/00207458809000497; Park KB, 2007, BIORESOURCE TECHNOL, V98, P312, DOI 10.1016/j.biortech.2006.01.004; Pedarzani P, 2005, J BIOL CHEM, V280, P41404, DOI 10.1074/jbc.M509610200; Powley TL, 2008, NEUROGASTROENT MOTIL, V20, P69, DOI 10.1111/j.1365-2982.2007.00990.x; Ren JH, 2003, J PHYSIOL-LONDON, V552, P809, DOI 10.1113/jphysiol.2003.047944; Rong WF, 2004, J PHYSIOL-LONDON, V560, P867, DOI 10.1113/jphysiol.2004.071746; Rousseaux C, 2007, NAT MED, V13, P35, DOI 10.1038/nm1521; Rugiero F, 2002, J PHYSIOL-LONDON, V538, P447, DOI 10.1113/jphysiol.2001.013051; Salinas E, 2006, PLOS BIOL, V4, P2383, DOI 10.1371/journal.pbio.0040387; Sarna SK, 2007, AM J PHYSIOL-GASTR L, V292, pG572, DOI 10.1152/ajpgi.00332.2006; Schemann M, 2010, AUTON NEUROSCI-BASIC, V153, P21, DOI 10.1016/j.autneu.2009.08.003; Shanahan F, 2005, AM J PHYSIOL-GASTR L, V288, pG417, DOI 10.1152/ajpgi.00421.2004; Siragusa S, 2007, APPL ENVIRON MICROB, V73, P7283, DOI 10.1128/AEM.01064-07; Stanisz AM, 2000, ANN NY ACAD SCI, V917, P268; Studinger P, 2007, J PHYSIOL-LONDON, V583, P1041, DOI 10.1113/jphysiol.2007.139204; Sudo N, 2004, J PHYSIOL-LONDON, V558, P263, DOI 10.1113/jphysiol.2004.063388; Talham GL, 1999, INFECT IMMUN, V67, P1992; Tanida M, 2005, NEUROSCI LETT, V389, P109, DOI 10.1016/j.neulet.2005.07.036; Umesaki Y, 1999, INFECT IMMUN, V67, P3504, DOI 10.1128/IAI.67.7.3504-3511.1999; Verdu EF, 2006, GUT, V55, P182, DOI 10.1136/gut.2005.066100; Verdu EF, 2004, GASTROENTEROLOGY, V127, P826, DOI 10.1053/j.gastro.2004.06.007; WALKER R, 2006, PROBIOTIC MICROBES S; Wang B, 2010, NEUROGASTROENT MOTIL, V22, P98, DOI 10.1111/j.1365-2982.2009.01384.x; WANG B, 2009, NEUROGASTROENT MOTIL, V22, pE33; WATERMAN SA, 1994, J PHYSIOL-LONDON, V474, P539, DOI 10.1113/jphysiol.1994.sp020043; WOOD JD, 1972, AM J PHYSIOL, V222, P118, DOI 10.1152/ajplegacy.1972.222.1.118; Xiao J, 2004, NEUROSCIENCE, V129, P603, DOI 10.1016/j.neuroscience.2004.08.027; Yamano T, 2006, LIFE SCI, V79, P1963, DOI 10.1016/j.lfs.2006.06.038; Yanagida H, 2000, AM J PHYSIOL-CELL PH, V278, pC40, DOI 10.1152/ajpcell.2000.278.1.C40; Zholos AV, 2002, AUTON NEUROSCI-BASIC, V96, P93, DOI 10.1016/S1566-0702(01)00364-2; Zhou XP, 2000, J AUTONOM NERV SYST, V78, P122, DOI 10.1016/S0165-1838(99)00065-X	93	72	74	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					4078	4088		10.1096/fj.09-153841	http://dx.doi.org/10.1096/fj.09-153841			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20519636				2022-12-28	WOS:000285005900043
J	Boyer, A; Lapointe, E; Zheng, XF; Cowan, RG; Li, HG; Quirk, SM; DeMayo, FJ; Richards, JS; Boerboom, D				Boyer, Alexandre; Lapointe, Evelyne; Zheng, Xiaofeng; Cowan, Robert G.; Li, Huaiguang; Quirk, Susan M.; DeMayo, Francesco J.; Richards, JoAnne S.; Boerboom, Derek			WNT4 is required for normal ovarian follicle development and female fertility	FASEB JOURNAL			English	Article						granulosa cell; conditional gene targeting; CTNNB1; microarray	GRANULOSA-CELL TUMOR; ENDOTHELIAL GROWTH-FACTOR; MULLERIAN-DUCT REGRESSION; STRESS-INDUCIBLE GENE; SIGNALING PATHWAY; INTESTINAL POLYPOSIS; REGULATED EXPRESSION; MESSENGER-RNA; BETA; PROTEIN	To study the role of WNT4 in the postnatal ovary, a mouse strain bearing a floxed Wnt4 allele was created and mated to the Amhr2(tm3(cre)Bhr) strain to target deletion of Wnt4 to granulosa cells. Wnt4(flox/-); Amhr2(tm3(cre)Bhr/+) mice had reduced ovary weights and produced smaller litters (P<0.05). Serial follicle counting demonstrated that Wnt4(flox/-); Amhr2(tm3(cre)Bhr/+) mice were born with a normal ovarian reserve and maintained normal numbers of small follicles until puberty but had only 25.2% of the normal number of healthy antral follicles. Some Wnt4(flox/-); Amhr2(tm3(cre)Bhr/+) mice had no antral follicles or corpora lutea and underwent premature follicle depletion. RT-PCR analyses of Wnt4(flox/-); Amhr2(tm3(cre)Bhr/+) granulosa cells and cultured granulosa cells that overexpress WNT4 demonstrated that WNT4 regulates the expression of Star, Cyp11a1, and Cyp19, steroidogenic genes previously identified as downstream targets of the WNT signaling effector CTNNB1. Decreased serum progesterone levels were found in immature, gonadotropin-treated Wnt4(flox/-); Amhr2(tm3(cre)Bhr/+) mice (P<0.05). WNT4-and CTNNB1-overexpressing cultured granulosa cells were analyzed by microarray for alterations in gene expression, which showed that WNT4 regulates additional genes involved in late follicle development via the WNT/CTNNB1 signaling pathway. Together, these data indicate that WNT4 is required for normal antral follicle development and may act by regulating granulosa cell functions including steroidogenesis.-Boyer, A., Lapointe, E., Zheng, X., Cowan, R. G., Li, H., Quirk, S. M., DeMayo, F. J., Richards, J. S., Boerboom, D. WNT4 is required for normal ovarian follicle development and female fertility. FASEB J. 24, 3010-3025 (2010). www.fasebj.org	[Boyer, Alexandre; Lapointe, Evelyne; Zheng, Xiaofeng; Boerboom, Derek] Univ Montreal, Fac Med Vet, Ctr Rech Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada; [Boyer, Alexandre; Li, Huaiguang; DeMayo, Francesco J.; Richards, JoAnne S.; Boerboom, Derek] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Cowan, Robert G.; Quirk, Susan M.] Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA	Universite de Montreal; Baylor College of Medicine; Cornell University	Boerboom, D (corresponding author), Univ Montreal, Fac Med Vet, Ctr Rech Reprod Anim, CP 5000, St Hyacinthe, PQ J2S 7C6, Canada.	derek.boerboom@umontreal.ca	DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	Canadian Institutes of Health Research; Canada Research Chair in Ovarian Molecular Biology and Functional Genomics; U.S. National Institutes of Health [HD16272, HD07495]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016272, P30HD007495] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chair in Ovarian Molecular Biology and Functional Genomics(Canada Research Chairs); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors thank Dr. Lisa White, Dr. John Lydon, Dr. Marilene Paquet, Dr. Bruce D. Murphy, Dr. Alan K. Goff, Celine Forget, Mayra Tsoi, Janet DeMayo, Mira Dobias-Goff, and Aron Cory for expertise and technical assistance with microarray analyses, targeting vector design, embryonic stem cell procedures, histopathological analyses, mouse colony management, steroid hormone radioimmunoassays, statistical analyses, dissections, and follicle counting. Amhr2<SUP>tm3(cre)Bhr</SUP> and Ctnnb1<SUP>tm1Mmt</SUP> mice were kindly provided by Dr. Richard R. Behringer (University of Texas, Houston, TX, USA) and Dr. Makoto M. Taketo (Kyoto University, Kyoto, Japan), respectively. The R1 embryonic stem cell line was provided by Dr. Andras Nagy, Reka Nagy, Dr. Janet Rossant, and Dr. Wanda Abramow-Newerly (University of Toronto, Toronto, ON, Canada). This work was supported by a Canadian Institutes of Health Research operating grant and the Canada Research Chair in Ovarian Molecular Biology and Functional Genomics (D.B.) and U.S. National Institutes of Health grants HD16272 and HD07495 (J.S.R.).	Abramovich D, 2010, FERTIL STERIL, V93, P1369, DOI 10.1016/j.fertnstert.2009.01.127; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Bernard P, 2007, INT J BIOCHEM CELL B, V39, P31, DOI 10.1016/j.biocel.2006.06.007; Biason-Lauber A, 2004, NEW ENGL J MED, V351, P792, DOI 10.1056/NEJMoa040533; Boerboom D, 2006, CANCER RES, V66, P1964, DOI 10.1158/0008-5472.CAN-05-3493; Boerboom D, 2005, CANCER RES, V65, P9206, DOI 10.1158/0008-5472.CAN-05-1024; Boyer A, 2009, CARCINOGENESIS, V30, P869, DOI 10.1093/carcin/bgp051; Britt KL, 2001, J STEROID BIOCHEM, V79, P181, DOI 10.1016/S0960-0760(01)00158-3; BYSKOV AGS, 1974, J REPROD FERTIL, V37, P277, DOI 10.1530/jrf.0.0370277; Chen B, 2006, J BIOL CHEM, V281, P2764, DOI 10.1074/jbc.M507330200; Chen M, 2006, HORM METAB RES, V38, P549, DOI 10.1055/s-2006-950500; Colgan Sean P, 2006, Purinergic Signal, V2, P351, DOI 10.1007/s11302-005-5302-5; Coveney D, 2008, GENE EXPR PATTERNS, V8, P529, DOI 10.1016/j.gep.2008.05.006; Das S, 2008, CELL CYCLE, V7, P154, DOI 10.4161/cc.7.2.5236; Devine PJ, 2000, BIOL REPROD, V63, P1245, DOI 10.1095/biolreprod63.5.1245; Douglas DA, 1998, BIOL REPROD, V58, P1163, DOI 10.1095/biolreprod58.5.1163; FISCHER B, 1992, EUR J OBSTET GYN R B, V43, P39, DOI 10.1016/0028-2243(92)90241-P; Fukuda S, 2001, BIOCHEM BIOPH RES CO, V280, P407, DOI 10.1006/bbrc.2000.4111; Gevry NYH, 2004, MOL ENDOCRINOL, V18, P1778, DOI 10.1210/me.2003-0323; Gifford JAH, 2009, BIOL REPROD, V80, P1282, DOI 10.1095/biolreprod.108.072280; Greenaway J, 2005, BIOL REPROD, V72, P1071, DOI 10.1095/biolreprod.104.031120; Greenaway J, 2004, ENDOCRINOLOGY, V145, P2896, DOI 10.1210/en.2003-1620; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Heikkila M, 2002, ENDOCRINOLOGY, V143, P4358, DOI 10.1210/en.2002-220275; Hsieh M, 2005, BIOL REPROD, V73, P1135, DOI 10.1095/biolreprod.105.042739; Hsieh M, 2003, ENDOCRINOLOGY, V144, P4597, DOI 10.1210/en.2003-0048; Hsieh M, 2002, ENDOCRINOLOGY, V143, P898, DOI 10.1210/en.143.3.898; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Jamnongjit M, 2006, CELL CYCLE, V5, P1178, DOI 10.4161/cc.5.11.2803; Jeays-Ward K, 2003, DEVELOPMENT, V130, P3663, DOI 10.1242/dev.00591; Jirawatnotai S, 2003, J BIOL CHEM, V278, P17021, DOI 10.1074/jbc.M301206200; Jorgez CJ, 2004, MOL ENDOCRINOL, V18, P953, DOI 10.1210/me.2003-0301; Joyce IM, 2001, ENDOCRINOLOGY, V142, P3187, DOI 10.1210/en.142.7.3187; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kultz D, 2005, ANNU REV PHYSIOL, V67, P225, DOI 10.1146/annurev.physiol.67.040403.103635; Lague MN, 2008, CARCINOGENESIS, V29, P2062, DOI 10.1093/carcin/bgn186; LI Z, 2004, CURRENT PROTOCOLS S, V58; Liu Y, 2006, CELL STRESS CHAPERON, V11, P379, DOI 10.1379/CSC-210.1; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Lyons JP, 2004, EXP CELL RES, V298, P369, DOI 10.1016/j.yexcr.2004.04.036; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Natesampillai S, 2008, AM J PHYSIOL-ENDOC M, V294, pE385, DOI 10.1152/ajpendo.00480.2007; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Oh-hashi K, 2009, BIOCHEM BIOPH RES CO, V387, P504, DOI 10.1016/j.bbrc.2009.07.047; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Parakh TN, 2006, P NATL ACAD SCI USA, V103, P12435, DOI 10.1073/pnas.0603006103; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555; PELUSO JJ, 1980, CELL TISSUE RES, V211, P105; Pradervand S, 2004, EMBO J, V23, P4517, DOI 10.1038/sj.emboj.7600454; PUTOWSKI LT, 1995, J SOC GYNECOL INVEST, V2, P735, DOI 10.1016/1071-5576(95)00028-D; Richards JS, 2005, BIOL REPROD, V72, P1241, DOI 10.1095/biolreprod.104.038083; Ricken A, 2002, ENDOCRINOLOGY, V143, P2741, DOI 10.1210/en.143.7.2741; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; Ronen-Fuhrmann T, 1998, ENDOCRINOLOGY, V139, P303, DOI 10.1210/en.139.1.303; Roy L, 2009, ENDOCRINOLOGY, V150, P5036, DOI 10.1210/en.2009-0771; Sambook J, 1989, MOL CLONING LAB MANU; Sedding DG, 2008, BIOL CHEM, V389, P279, DOI 10.1515/BC.2008.033; Segi E, 2003, BIOL REPROD, V68, P804, DOI 10.1095/biolreprod.102.003590; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Terada Y, 2003, J AM SOC NEPHROL, V14, P1223, DOI 10.1097/01.ASN.0000060577.94532.06; Tevosian SG, 2008, DEV DYNAM, V237, P3672, DOI 10.1002/dvdy.21784; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Wahlberg P, 2008, ENDOCRINOLOGY, V149, P5070, DOI 10.1210/en.2007-1736; Yao HHC, 2004, DEV DYNAM, V230, P210, DOI 10.1002/dvdy.20042; ZELEZNIK AJ, 1974, ENDOCRINOLOGY, V95, P818, DOI 10.1210/endo-95-3-818	67	108	114	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					3010	3025		10.1096/fj.09-145789	http://dx.doi.org/10.1096/fj.09-145789			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371632	Green Published, Bronze			2022-12-28	WOS:000285005400039
J	Costa, B; Dettori, D; Lorenzato, A; Bardella, C; Coltella, N; Martino, C; Cammarata, C; Carmeliet, P; Olivero, M; Di Renzo, MF				Costa, Barbara; Dettori, Daniela; Lorenzato, Annalisa; Bardella, Chiara; Coltella, Nadia; Martino, Cosimo; Cammarata, Cristina; Carmeliet, Peter; Olivero, Martina; Di Renzo, Maria Flavia			Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis	FASEB JOURNAL			English	Article						hypoxia inducible factor; mitochondrial tumor suppressors; tyrosine kinase oncogenes	RENAL-CELL CARCINOMA; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; SMALL-MOLECULE INHIBITOR; C-MET; HEREDITARY LEIOMYOMATOSIS; ACTIVATOR INHIBITOR; SOMATIC MUTATIONS; INVASIVE GROWTH; SCATTER-FACTOR; CANCER CELLS	Loss of the fumarate hydratase (FH) tumor suppressor gene results in the development of benign tumors that rarely, but regrettably, progress to very aggressive cancers. Using mouse embryo fibroblasts (MEFs) to model transformation, we found that fh knockdown results in increased expression of the met oncogene-encoded tyrosine kinase receptor through hypoxia-inducible factor (hif) stabilization. MET-increased expression was alone able to stabilize hif, thus establishing a feed forward loop that might enforce tumor progression. The fh-defective MEFs showed increased motility and protection from apoptosis. Motility, but not survival, relied on hif-1 alpha and was greatly enhanced by MET ligand hepatocyte growth factor. Met cooperated with a weakly oncogenic ras in making MEFs transformed and tumorigenic, as shown by in vitro and in vivo assays. Loss of fh was not equally effective by itself but enhanced the transformed and tumorigenic phenotype induced by ras and MET. Consistently, the rescue of fumarase expression abrogated the motogenic and transformed phenotype of fh-defective MEFs. In conclusion, the data suggest that the progression of tumors where FH is lost might be boosted by activation of the MET oncogene, which is able to drive cell-autonomous tumor progression and is a strong candidate for targeted therapy.-Costa, B., Dettori, D., Lorenzato, A., Bardella, C., Coltella, N., Martino, C., Cammarata, C., Carmeliet, P., Olivero, M., Di Renzo, M. F. Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB J. 24, 2680-2688 (2010). www.fasebj.org	[Di Renzo, Maria Flavia] Univ Turin, Inst Canc Res & Treatment, IRCC, Sch Med,Dept Oncol Sci, I-10060 Turin, Italy; [Cammarata, Cristina] Inst Canc Res & Treatment, Lab Med Oncol, Candiolo, Italy; [Costa, Barbara; Dettori, Daniela; Lorenzato, Annalisa; Bardella, Chiara; Coltella, Nadia; Martino, Cosimo; Olivero, Martina; Di Renzo, Maria Flavia] Inst Canc Res & Treatment, Canc Genet Lab, Candiolo, Italy; [Dettori, Daniela; Carmeliet, Peter] Vesalius Res Ctr VIB, Louvain, Belgium; [Carmeliet, Peter] Katholieke Univ Leuven, Vesalius Res Ctr, Leuven, Belgium	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; IRCCS Fondazione del Piemonte per l'Oncologia; Flanders Institute for Biotechnology (VIB); KU Leuven	Di Renzo, MF (corresponding author), Univ Turin, Inst Canc Res & Treatment, IRCC, Sch Med,Dept Oncol Sci, SP142 Km 3-95, I-10060 Turin, Italy.	mariaflavia.direnzo@unito.it	Carmeliet, Peter/AAQ-5140-2020; Coltella, Nadia/AAO-3671-2020; DI RENZO, Maria Flavia/B-6091-2012; olivero, martina/J-4811-2018; bardella, chiara/AAG-6272-2021	Carmeliet, Peter/0000-0001-7961-1821; DI RENZO, Maria Flavia/0000-0002-5093-3373; olivero, martina/0000-0002-6815-3498; Lorenzato, Annalisa/0000-0002-9324-2337; Costa, Barbara/0000-0001-5958-5099; Martino, Cosimo/0000-0002-7286-9755; Bardella, Chiara/0000-0002-7780-2541	Italian Association for Cancer Research; Regione Piemonte	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Regione Piemonte(Regione Piemonte)	The authors thank Enzo De Sio and Raffaella Albano for technical help. This work was supported by grants from the Italian Association for Cancer Research and from Regione Piemonte (to M.F.D). The authors declare no financial conflicts of interest.	Amendola M, 2005, NAT BIOTECHNOL, V23, P108, DOI 10.1038/nbt1049; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Baysal BE, 2003, TRENDS ENDOCRIN MET, V14, P453, DOI 10.1016/j.tem.2003.08.004; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Bertotti A, 2003, TRENDS BIOCHEM SCI, V28, P527, DOI 10.1016/j.tibs.2003.09.001; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blum R, 2005, CANCER RES, V65, P999; Bramwell VHC, 2005, CANCER BIOL THER, V4, P1336, DOI 10.4161/cbt.4.12.2166; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Christensen JG, 2003, CANCER RES, V63, P7345; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Ide T, 2006, INT J CANCER, V119, P2750, DOI 10.1002/ijc.22178; Inoue K, 1998, VIRCHOWS ARCH, V433, P511, DOI 10.1007/s004280050282; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Kataoka H, 2003, CANCER METAST REV, V22, P223, DOI 10.1023/A:1023051500010; Knudsen BS, 2008, CURR OPIN GENET DEV, V18, P87, DOI 10.1016/j.gde.2008.02.001; KOSKI TA, 2009, GENE CHROMOSOME CANC, V16, P16; Li W, 2007, EMBO J, V26, P1221, DOI 10.1038/sj.emboj.7601579; Long IS, 2003, MOL CANCER RES, V1, P393; Lorenzato A, 2002, CANCER RES, V62, P7025; Lorenzato A, 2008, INT J CANCER, V122, P947, DOI 10.1002/ijc.23209; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Miyata Y, 2006, CLIN CANCER RES, V12, P4876, DOI 10.1158/1078-0432.CCR-06-0362; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Pollard P, 2005, J PATHOL, V205, P41, DOI 10.1002/path.1686; Pollard PJ, 2007, CANCER CELL, V11, P311, DOI 10.1016/j.ccr.2007.02.005; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Rohwer N, 2008, CANCER RES, V68, P10113, DOI 10.1158/0008-5472.CAN-08-1839; RONG S, 1995, CANCER RES, V55, P1963; Ryan HE, 2000, CANCER RES, V60, P4010; Scarpino S, 2004, J PATHOL, V202, P352, DOI 10.1002/path.1522; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Scotlandi K, 1996, AM J PATHOL, V149, P1209; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SUDARSHAN S, 2009, MOL CELL BIOL, V26, P26; Tacchini L, 2004, CARCINOGENESIS, V25, P2089, DOI 10.1093/carcin/bgh227; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Yamauchi M, 2004, J UROLOGY, V171, P890, DOI 10.1097/01.ju.0000092861.21122.d2; Yang Y, 2008, MOL CANCER THER, V7, P952, DOI 10.1158/1535-7163.MCT-07-2045	52	10	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2680	2688		10.1096/fj.09-146928	http://dx.doi.org/10.1096/fj.09-146928			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20354140				2022-12-28	WOS:000285005400010
J	Stokes, L; Fuller, SJ; Sluyter, R; Skarratt, KK; Gu, BJ; Wiley, JS				Stokes, Leanne; Fuller, Stephen J.; Sluyter, Ronald; Skarratt, Kristen K.; Gu, Ben J.; Wiley, James S.			Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1 beta secretion	FASEB JOURNAL			English	Article						purinergic receptor; inflammation	IL-1-BETA SECRETION; POTENT ANTAGONIST; ALA POLYMORPHISM; P2X7 RECEPTOR; ION-CHANNEL; ATP; RELEASE; GENE; ACTIVATION; SUSCEPTIBILITY	The P2X(7) receptor is an ATP-gated cation channel expressed in immune cells and plays a role in proinflammatory cytokine release from monocytes and macrophages. This study investigated the coinheritance of 12 functionally relevant single nucleotide polymorphisms (SNPs) in the human P2X(7) gene (P2RX7), and the functional effect of each singly and in combination was assessed by measurements of ATP-induced currents and ethidium(+) uptake. Genotyping of 3430 Caucasian subjects identified 4 common haplotypes in addition to the common (wild-type) P2X(7)-1. Two haplotypes (denoted P2X(7)-2 and P2X(7)-4) contained various combinations of gain-of-function SNPs. P2X(7)-4 was identified uniquely by the Gln-460 to Arg polymorphism (rs2230912). When expressed in HEK-293 cells, recombinant P2X(7)-2, and P2X(7)-4 haplotypes displayed a 3-fold and 5-fold increase, respectively, in receptor function compared to the wildtype P2X(7)-1. Both P2X(7) haplotypes contained the Ala-348>Thr polymorphism (rs1718119), and this mutation was critical for the gain-of-function effect. Peripheral blood monocytes and erythrocytes from subjects homozygous for gain-of-function P2X(7) haplotypes exhibited increased ATP-induced ethidium(+) uptake and Rb-86(+) efflux, respectively, and this correlated with increased IL-1 beta secretion from LPS-primed monocytes. Inheritance of these P2X(7) haplotypes predisposing to increased proinflammatory cytokine secretion may be important in genetic association studies of inflammatory, infectious, and psychiatric disorders.-Stokes, L., Fuller, S. J., Sluyter, R., Skarratt, K. K., Gu, B. J., Wiley, J. S. Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1 beta secretion. FASEB J. 24, 2916-2927 (2010). www.fasebj.org	[Gu, Ben J.; Wiley, James S.] Univ Melbourne, Florey Neurosci Inst, Melbourne, Vic 3010, Australia; [Stokes, Leanne; Fuller, Stephen J.; Sluyter, Ronald; Skarratt, Kristen K.; Gu, Ben J.; Wiley, James S.] Univ Sydney, Nepean Clin Sch, Nepean Hosp, Dept Med, Penrith, NSW, Australia; [Sluyter, Ronald] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; Nepean Hospital; University of Sydney; University of Wollongong	Wiley, JS (corresponding author), Univ Melbourne, Florey Neurosci Inst, Level 3 Alan Gilbert Bldg, Melbourne, Vic 3010, Australia.	james.wiley@florey.edu.au	Skarratt, Kristy/AAN-1479-2020; Sluyter, Ronald/B-5798-2009; Fuller, Stephen/W-6646-2019; Stokes, Leanne/B-9580-2008	Sluyter, Ronald/0000-0003-4909-686X; Fuller, Stephen/0000-0003-4637-7391; Gu, Ben/0000-0001-5500-4453; Wiley, James/0000-0001-9421-4154; Skarratt, Kristy/0000-0003-4971-2773; Stokes, Leanne/0000-0003-4013-6781	National Health and Medical Research Council of Australia; Leukemia Research Foundation (Australia); Cure Cancer Australia; University of Sydney Faculty of Medicine; Nepean Medical Research Foundation	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Leukemia Research Foundation (Australia); Cure Cancer Australia; University of Sydney Faculty of Medicine(University of Sydney); Nepean Medical Research Foundation	L.S. conducted the majority of experiments and analyzed data; L.S., B.J.G., and J.S.W. designed experiments; S.J.F. conducted haplotype analysis; K.K.S. performed genotyping; R.S. contributed data for Fig. 6; L.S. and J.S.W. wrote the manuscript; and S.J.F., K.K.S, R.S., and B.J.G. contributed to the writing of the manuscript. The authors are grateful to Leah McKinnon for collection of blood for experiments on native cells. This work is funded by the National Health and Medical Research Council of Australia, Leukemia Research Foundation (Australia), and Cure Cancer Australia. The authors acknowledge equipment grants awarded by the University of Sydney Faculty of Medicine and Nepean Medical Research Foundation to L.S. and J.S.W. for the purchase of electrophysiology equipment.	Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101; Barden N, 2006, AM J MED GENET B, V141B, P374, DOI 10.1002/ajmg.b.30303; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Basso AM, 2009, BEHAV BRAIN RES, V198, P83, DOI 10.1016/j.bbr.2008.10.018; Cabrini G, 2005, J IMMUNOL, V175, P82, DOI 10.4049/jimmunol.175.1.82; Cheewatrakoolpong B, 2005, BIOCHEM BIOPH RES CO, V332, P17, DOI 10.1016/j.bbrc.2005.04.087; Church LD, 2008, NAT CLIN PRACT RHEUM, V4, P34, DOI 10.1038/ncprheum0681; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Denlinger LC, 2006, CLIN CHEM, V52, P995, DOI 10.1373/clinchem.2005.065425; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Egan TM, 2006, PFLUG ARCH EUR J PHY, V452, P501, DOI 10.1007/s00424-006-0078-1; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Feng YH, 2006, J BIOL CHEM, V281, P17228, DOI 10.1074/jbc.M602999200; Fernando SL, 2005, J INFECT DIS, V192, P149, DOI 10.1086/430622; Fernando SL, 2007, AM J RESP CRIT CARE, V175, P360, DOI 10.1164/rccm.200607-970OC; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Fuller SJ, 2009, PURINERG SIGNAL, V5, P257, DOI 10.1007/s11302-009-9136-4; Gargett CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/sj.bjp.0701081; Green EK, 2009, AM J MED GENET B, V150B, P1063, DOI 10.1002/ajmg.b.30931; Grigoroiu-Serbanescu M, 2009, AM J MED GENET B, V150B, P1017, DOI 10.1002/ajmg.b.30952; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2006, BLOOD, V107, P4946, DOI 10.1182/blood-2005-07-2994; Gu BJ, 2004, J BIOL CHEM, V279, P31287, DOI 10.1074/jbc.M313902200; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Jursik C, 2007, J IMMUNOL METHODS, V325, P67, DOI 10.1016/j.jim.2007.06.002; Kahlenberg JM, 2005, J IMMUNOL, V175, P7611, DOI 10.4049/jimmunol.175.11.7611; Kawamura H, 2006, J IMMUNOL, V176, P2152, DOI 10.4049/jimmunol.176.4.2152; Kawate T, 2009, NATURE, V460, P592, DOI 10.1038/nature08198; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lester S, 2008, ARTHRITIS RHEUM, V58, pS792; Li MF, 2008, NAT NEUROSCI, V11, P883, DOI 10.1038/nn.2151; Lucae S, 2006, HUM MOL GENET, V15, P2438, DOI 10.1093/hmg/ddl166; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; McQuillin A, 2009, MOL PSYCHIATR, V14, P614, DOI 10.1038/mp.2008.6; Mehta VB, 2001, J BIOL CHEM, V276, P3820, DOI 10.1074/jbc.M006814200; Nagy G, 2008, PROG NEURO-PSYCHOPH, V32, P1884, DOI 10.1016/j.pnpbp.2008.08.021; Nelson DW, 2006, J MED CHEM, V49, P3659, DOI 10.1021/jm051202e; Nicke A, 2009, J BIOL CHEM, V284, P25813, DOI 10.1074/jbc.M109.033134; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Piccini A, 2008, P NATL ACAD SCI USA, V105, P8067, DOI 10.1073/pnas.0709684105; Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; ROGER S, 2009, PSYCHIAT RES, DOI DOI 10.1016/J.JPSYCHIRES.2009.10.005; Sharp AJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-33; Shemon AN, 2006, J BIOL CHEM, V281, P2079, DOI 10.1074/jbc.M507816200; Skarratt KK, 2005, FEBS LETT, V579, P2675, DOI 10.1016/j.febslet.2005.03.091; Sluyter R, 2004, GENES IMMUN, V5, P588, DOI 10.1038/sj.gene.6364127; Sluyter R, 2004, J BIOL CHEM, V279, P44749, DOI 10.1074/jbc.M405631200; Sluyter R, 2004, J IMMUNOL, V172, P3399, DOI 10.4049/jimmunol.172.6.3399; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Stokes L, 2006, BRIT J PHARMACOL, V149, P880, DOI 10.1038/sj.bjp.0706933; Sun CQ, 2010, PURINERG SIGNAL, V6, P31, DOI 10.1007/s11302-009-9168-9; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200	59	128	133	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2916	2927		10.1096/fj.09-150862	http://dx.doi.org/10.1096/fj.09-150862			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20360457	Bronze			2022-12-28	WOS:000285005400031
J	Labonte, ED; Pfluger, PT; Cash, JG; Kuhel, DG; Roja, JC; Magness, DP; Jandacek, RJ; Tschop, MH; Hui, DY				Labonte, Eric D.; Pfluger, Paul T.; Cash, James G.; Kuhel, David G.; Roja, Juan C.; Magness, Daniel P.; Jandacek, Ronald J.; Tschoep, Matthias H.; Hui, David Y.			Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A(2) and diet-induced obesity	FASEB JOURNAL			English	Article						energy expenditure; lipid absorption; peroxisome proliferator-activated receptors	BRUSH-BORDER MEMBRANES; ENERGY-EXPENDITURE; GENE-EXPRESSION; ABSORPTION; MICE; CARBOHYDRATE; TRANSPORT; GLUCOSE; PPAR; PHOSPHATIDYLCHOLINE	Decrease in fat catabolic rate on consuming a high-fat diet contributes to diet-induced obesity. This study used group 1B phospholipase A(2) (Pla2g1b)-deficient mice, which are resistant to hyperglycemia, to test the hypothesis that Pla2g1b and its lipolytic product lysophospholipid suppress hepatic fat utilization and energy metabolism in promoting diet-induced obesity. The metabolic consequences of hypercaloric diet, including body weight gain, energy expenditure, and fatty acid oxidation, were compared between Pla2g1b(+/+) and Pla2g1b(-/-) mice. The Pla2g1b(-/-) mice displayed normal energy balance when fed chow, but were resistant to obesity when challenged with a hypercaloric diet. Obesity resistance in Pla2g1b(-/-) mice is due to their ability to maintain elevated energy expenditure and core body temperature when subjected to hypercaloric diet, which was not observed in Pla2g1b(-/-) mice. The Pla2g1b(-/-) mice also displayed increased postprandial hepatic fat utilization due to increased expression of peroxisome proliferator-activated receptor (PPAR)-alpha, PPAR-delta, PPAR-gamma, cd36/Fat, and Ucp2, which coincided with reduced postprandial plasma lysophospholipid levels. Lysophospholipids produced by Pla2g1b hydrolysis suppress hepatic fat utilization and down-regulate energy expenditure, thereby preventing metabolically beneficial adaptation to a high-fat diet exposure in promoting diet-induced obesity and type 2 diabetes.-Labonte, E.D., Pfluger, P.T., Cash, J.G., Kuhel, D.G., Rojas, J.C., Magness, D.P., Jandacek, R.J., Tschop, M.H., Hui, D.Y. Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A(2) and diet-induced obesity. FASEB J. 24, 2516-2524 (2010). www.fasebj.org	[Labonte, Eric D.; Cash, James G.; Kuhel, David G.; Roja, Juan C.; Magness, Daniel P.; Jandacek, Ronald J.; Hui, David Y.] Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA; [Pfluger, Paul T.; Tschoep, Matthias H.] Univ Cincinnati, Coll Med, Dept Med, Metab Dis Inst, Cincinnati, OH 45237 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol ML0507, 2120 E Galbraith Rd, Cincinnati, OH 45237 USA.	huidy@ucmail.uc.edu	Pfluger, Paul T/A-3770-2019; Tschoep, Matthias H/I-5443-2014	Pfluger, Paul T/0000-0002-8118-7588; Tschoep, Matthias/0000-0002-4744-371X	U.S. National Institutes of Health [RO1 DK69967]; American Heart Association [0525340B]; National Institute of Diabetes and Digestive and Kidney Diseases [DK59630]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059630, R01DK069967] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Eliza Wynn and Beth Coburn for their superb technical assistance. The authors also thank Josh Basford, Dr. Dean Gilham, Dr. Diego Perez-Tilve, and Dr. Susanna Hofmann for their helpful discussions and advice. This work was supported by U.S. National Institutes of Health grant RO1 DK69967 (to D.Y.H.) and a Postdoctoral Fellowship (0525340B) from the Ohio Affiliates of the American Heart Association to E.D.L. Energy expenditure and fat absorption measurements were performed in the Cincinnati Mouse Metabolic Phenotype Center, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (DK59630).	ABBOTT WGH, 1990, AM J PHYSIOL, V258, pE347, DOI 10.1152/ajpendo.1990.258.2.E347; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002; Coutant F, 2004, J IMMUNOL, V172, P54, DOI 10.4049/jimmunol.172.1.54; de Jonge L, 1997, OBES RES, V5, P622, DOI 10.1002/j.1550-8528.1997.tb00584.x; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; Feingold KR, 2008, J LIPID RES, V49, P2179, DOI 10.1194/jlr.M800233-JLR200; Galili O, 2007, AM J PHYSIOL-HEART C, V292, pH904, DOI 10.1152/ajpheart.00628.2006; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Gilham D, 2007, J BIOL CHEM, V282, P24642, DOI 10.1074/jbc.M702530200; Hofmann SM, 2007, J CLIN INVEST, V117, P3271, DOI 10.1172/JCI31929; Huggins KW, 2002, AM J PHYSIOL-ENDOC M, V283, pE994, DOI 10.1152/ajpendo.00110.2002; Hui DY, 2009, BRIT J PHARMACOL, V157, P1263, DOI 10.1111/j.1476-5381.2009.00308.x; HURNI M, 1982, BRIT J NUTR, V47, P33, DOI 10.1079/BJN19820006; IKEDA I, 1987, BIOCHIM BIOPHYS ACTA, V921, P245; Jandacek RJ, 2004, GASTROENTEROLOGY, V127, P139, DOI 10.1053/j.gastro.2004.04.007; Kirchner H, 2009, NAT MED, V15, P741, DOI 10.1038/nm.1997; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; KLEIBER M, 1961, Annu Rev Physiol, V23, P5; Kleiner S, 2009, J BIOL CHEM, V284, P18624, DOI 10.1074/jbc.M109.008797; Labonte ED, 2006, DIABETES, V55, P935, DOI 10.2337/diabetes.55.04.06.db05-1286; LEAN MEJ, 1988, INT J OBESITY, V12, P15; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mackay K, 1997, J BIOL CHEM, V272, P13380, DOI 10.1074/jbc.272.20.13380; Pietilainen KH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000218; PIND S, 1991, BIOCHEM CELL BIOL, V69, P346, DOI 10.1139/o91-054; RABINI RA, 1994, DIABETES, V43, P915, DOI 10.2337/diabetes.43.7.915; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011; Schoonjans K, 1996, J LIPID RES, V37, P907; SCHWARTZ RS, 1985, METABOLISM, V34, P285, DOI 10.1016/0026-0495(85)90014-9; Tojo H, 1998, J BIOL CHEM, V273, P2214, DOI 10.1074/jbc.273.4.2214; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Villarroya F, 2007, PPAR RES, V2007, DOI 10.1155/2007/74364; West GB, 1999, SCIENCE, V284, P1677, DOI 10.1126/science.284.5420.1677; Wilson SG, 2006, EUR J HUM GENET, V14, P340, DOI 10.1038/sj.ejhg.5201551; Young SC, 1999, BIOCHEM J, V339, P615, DOI 10.1042/0264-6021:3390615	39	45	45	2	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2010	24	7					2516	2524		10.1096/fj.09-144436	http://dx.doi.org/10.1096/fj.09-144436			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20215528	Green Published			2022-12-28	WOS:000279343600038
J	Noda, K; Melhorn, MI; Zandi, S; Frimmel, S; Tayyari, F; Hisatomi, T; Almulki, L; Pronczuk, A; Hayes, KC; Hafezi-Moghadam, A				Noda, Kousuke; Melhorn, Mark I.; Zandi, Souska; Frimmel, Sonja; Tayyari, Faryan; Hisatomi, Toshio; Almulki, Lama; Pronczuk, Andrzej; Hayes, K. C.; Hafezi-Moghadam, Ali			An animal model of spontaneous metabolic syndrome: Nile grass rat	FASEB JOURNAL			English	Article						type 2 diabetes; nutrition; hypertension; atherosclerosis; dyslipidemia; leptin	ARVICANTHIS-NILOTICUS; DIURNAL RODENT; ONSET OBESITY; UP-REGULATION; IN-VIVO; ADIPONECTIN; FAT; PATHOPHYSIOLOGY; ASSOCIATIONS; ADIPOCYTES	Metabolic syndrome (MetS) is a prevalent and complex disease, characterized by the variable coexistence of obesity, dyslipidemia, hyperinsulinaemia, and hypertension. The alarming rise in the prevalence of metabolic disorders makes it imperative to innovate preventive or therapeutic measures for MetS and its complications. However, the elucidation of the pathogenesis of MetS has been hampered by the lack of realistic models. For example, the existing animal models of MetS, i.e., genetically engineered rodents, imitate certain aspects of the disease, while lacking other important components. Defining the natural course of MetS in a spontaneous animal model of the disease would be desirable. Here, we introduce the Nile grass rat (NGR), Arvicanthis niloticus, as a novel model of MetS. Studies of over 1100 NGRs in captivity, fed normal chow, revealed that most of these animals spontaneously develop dyslipidemia (P<0.01), and hyperglycemia (P<0.01) by 1 yr of age. Further characterization showed that the diabetic rats develop liver steatosis, abdominal fat accumulation, nephropathy, atrophy of pancreatic islets of Langerhans, fatty streaks in the aorta, and hypertension (P<0.01). Diabetic NGRs in the early phase of the disease develop hyperinsulinemia, and show a strong inverse correlation between plasma adiponectin and HbA1c levels (P<0.01). These data indicate that the NGR is a valuable, spontaneous model for exploring the etiology and pathophysiology of MetS as well as its various complications.-Noda, K., Melhorn, M.I., Zandi, S., Frimmel, S., Tayyari, F., Hisatomi, T., Almulki, L., Pronczuk, A., Hayes, K.C., Hafezi-Moghadam, A. An animal model of spontaneous metabolic syndrome: Nile grass rat. FASEB J. 24, 2443-2453 (2010). www.fasebj.org	[Noda, Kousuke; Melhorn, Mark I.; Zandi, Souska; Frimmel, Sonja; Tayyari, Faryan; Hisatomi, Toshio; Almulki, Lama; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA; [Noda, Kousuke; Melhorn, Mark I.; Zandi, Souska; Frimmel, Sonja; Tayyari, Faryan; Hisatomi, Toshio; Almulki, Lama; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA; [Pronczuk, Andrzej; Hayes, K. C.] Brandeis Univ, Dept Biol, Foster Biomed Res Lab, Waltham, MA 02254 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Brandeis University	Hafezi-Moghadam, A (corresponding author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.	ali_hafezi-moghadam@hms.harvard.edu	Tayyari, Faryan/AAS-9020-2020	Hafezi-Moghadam, Ali/0000-0002-5336-0697; Hisatomi, Toshio/0000-0003-2552-9595; Zandi, Souska/0000-0001-9351-4278	U.S. National Institute of Health [AI050775]; American Health Assistance Foundation; Malaysian Palm Oil Board; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Health Assistance Foundation(BrightFocus Foundation); Malaysian Palm Oil Board; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Rebecca C. Garland for her help with manuscript preparation and insightful discussions. This work was supported by U.S. National Institute of Health grant AI050775 (A.H.-M.), the American Health Assistance Foundation (A.H.-M.), and the Malaysian Palm Oil Board.	Ayyobi AF, 2003, AM J CARDIOL, V92, p27J, DOI 10.1016/S0002-9149(03)00613-1; Blanchong JA, 1999, J BIOL RHYTHM, V14, P364, DOI 10.1177/074873099129000777; Bobu C, 2006, INVEST OPHTH VIS SCI, V47, P3109, DOI 10.1167/iovs.05-1397; Borch-Johnsen K, 2009, DIABETOLOGIA, V52, P2247, DOI 10.1007/s00125-009-1526-1; Cho YR, 2007, AM J PHYSIOL-ENDOC M, V293, pE327, DOI 10.1152/ajpendo.00376.2006; Clee Susanne M, 2005, Am J Ther, V12, P491, DOI 10.1097/01.mjt.0000178781.89789.25; Combs TP, 2003, DIABETES, V52, P268, DOI 10.2337/diabetes.52.2.268; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004; Goldstein BJ, 2004, J CLIN ENDOCR METAB, V89, P2563, DOI 10.1210/jc.2004-0518; Hafezi-Moghadam A, 2007, FASEB J, V21, P464, DOI 10.1096/fj.06-6390com; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hanley AJG, 2007, J CLIN ENDOCR METAB, V92, P2665, DOI 10.1210/jc.2006-2614; Hiraoka-Yamamoto J, 2004, CLIN EXP PHARMACOL P, V31, P107, DOI 10.1111/j.1440-1681.2004.04121.x; Kolovou GD, 2005, POSTGRAD MED J, V81, P358, DOI 10.1136/pgmj.2004.025601; Lambert CM, 2005, J BIOL RHYTHM, V20, P206, DOI 10.1177/0748730405275135; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Novak CM, 2002, BRAIN RES, V951, P255, DOI 10.1016/S0006-8993(02)03168-2; Novak CM, 2007, PHYSIOL BEHAV, V90, P125, DOI 10.1016/j.physbeh.2006.09.012; Ouedraogo R, 2007, J CLIN INVEST, V117, P1718, DOI 10.1172/JCI29623; Qi NR, 2005, HYPERTENSION, V45, P1004, DOI 10.1161/01.HYP.0000161995.64192.2b; Raskin P, 2005, DIABETES CARE, V28, P260, DOI 10.2337/diacare.28.2.260; Reilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0; Scherer PE, 2006, DIABETES, V55, P1537, DOI 10.2337/db06-0263; Schwartz MD, 2005, J BIOL RHYTHM, V20, P526, DOI 10.1177/0748730405280924; SHIMABUKURO M, 1997, P NATL ACAD SCI US; Tkac I, 2005, DIABETES RES CLIN PR, V68, pS2, DOI 10.1016/j.diabres.2005.03.002; Wang MY, 2005, P NATL ACAD SCI USA, V102, P18011, DOI 10.1073/pnas.0509001102; Wang Y, 2007, EPIDEMIOL REV, V29, P6, DOI 10.1093/epirev/mxm007; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	44	45	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2443	2453		10.1096/fj.09-152678	http://dx.doi.org/10.1096/fj.09-152678			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20335226	Green Published			2022-12-28	WOS:000279343600031
J	Parkitna, JR; Bilbao, A; Rieker, C; Engblom, D; Piechota, M; Nordheim, A; Spanagel, R; Schutz, G				Parkitna, Jan Rodriguez; Bilbao, Ainhoa; Rieker, Claus; Engblom, David; Piechota, Marcin; Nordheim, Alfred; Spanagel, Rainer; Schuetz, Guenther			Loss of the serum response factor in the dopamine system leads to hyperactivity	FASEB JOURNAL			English	Article						activity-dependent transcription; Egr; SRF; murine; motor activity; striatum	C-FOS GENE; CRE RECOMBINASE; BINDING SITE; TRANSCRIPTION; EXPRESSION; SRF; PROTEIN; STIMULATION; NEURONS; IDENTIFICATION	The serum response factor (SRF) is a key regulator of neural development and cellular plasticity, which enables it to act as a regulator of long-term adaptations in neurons. Here we performed a comprehensive analysis of SRF function in the murine dopamine system. We found that loss of SRF in dopaminoceptive, but not dopaminergic, neurons is responsible for the development of a hyperactivity syndrome, characterized by reduced body weight into adulthood, enhanced motor activity, and deficits in habituation processes. Most important, the hyperactivity also develops when the ablation of SRF is induced in adult animals. On the molecular level, the loss of SRF in dopaminoceptive cells is associated with altered expression of neuronal plasticity-related genes, in particular transcripts involved in calcium ion binding, formation of the cytoskeleton, and transcripts encoding neuropeptide precursors. Furthermore, abrogation of SRF causes specific deficits in activity-dependent transcription, especially a complete lack of psychostimulant-induced expression of the Egr genes. We inferred that alterations in SRF-dependent gene expression underlie the observed hyperactive behavior. Thus, SRF depletion in dopaminoceptive neurons might trigger molecular mechanisms responsible for development of psychopathological conditions involving hyperactivity.-Parkitna, J.R., Bilbao, A., Rieker, C., Engblom, D., Piechota, M., Nordheim, A., Spanagel, R., Schutz, G. Loss of the serum response factor in the dopamine system leads to hyperactivity. FASEB J. 24, 2427-2435 (2010). www.fasebj.org	[Parkitna, Jan Rodriguez; Rieker, Claus; Engblom, David; Schuetz, Guenther] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Parkitna, Jan Rodriguez; Piechota, Marcin] Polish Acad Sci, Inst Pharmacol, Dept Mol Neuropharmacol, Krakow, Poland; [Bilbao, Ainhoa; Spanagel, Rainer] Cent Inst Mental Hlth, Dept Psychopharmacol, D-6800 Mannheim, Germany; [Nordheim, Alfred] Univ Tubingen, Inst Cell Biol, Dept Mol Biol, Tubingen, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Polish Academy of Sciences; Central Institute of Mental Health; Eberhard Karls University of Tubingen	Schutz, G (corresponding author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	g.schuetz@dkfz.de	Piechota, Marcin/G-9464-2011; Bilbao, Ainhoa/AAW-6230-2020; Rodriguez, Jan/I-2910-2012	Rodriguez, Jan/0000-0003-0367-2331; Nordheim, Alfred/0000-0003-4680-0778; Piechota, Marcin/0000-0003-2468-151X	Deutsche Forschungsgemeinschaft (DFG) [SFB 488, SFB 636, NO120/12-3]; Sachbeihilfe Schu [51/7-2]; Fonds der Chemischen Industrie; European Union [LSHM-CT-2005-018652, LSHM-CT-2004-005166]; Bundesministerium fur Bildung und Forschung [FZK 01GS01117, FZK 01GS0477, KGCV1/01GS0416]; German-Polish Cooperation [01GZ0310]; Systems Biology [0313074C]; Polish Ministry of Science and Higher Education [PBZ-MNiI-2/1/2005]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Sachbeihilfe Schu; Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission); European Union(European Commission); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); German-Polish Cooperation; Systems Biology; Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	The authors thank Dr. Bernd Knoll for commenting on the manuscript. The authors thank Tabea Arnsperger, Katja Lankisch, Magdalena Westphal, and Ralph Klaren for their excellent technical assistance. The authors also thank Dr. Norbert Gretz for his assistance in performing the DNA microarray experiments. A.B., J.R.P., C.R., D.E., and G.S. were supported by the Deutsche Forschungsgemeinschaft (DFG) through Collaborative Research Centres SFB 488 and SFB 636 and Sachbeihilfe Schu 51/7-2; the Fonds der Chemischen Industrie; the European Union through grant LSHM-CT-2005-018652 (CRESCENDO); the Bundesministerium fur Bildung und Forschung through Nationales Genomforschungsnetz Deutschland grants FZK 01GS01117, FZK 01GS0477, and KGCV1/01GS0416; German-Polish Cooperation project 01GZ0310; and Systems Biology projects 0313074C (HepatoSys) and NW5 (CoReNe). A.B. and R.S. were supported by an EU (IMAGEN) grant to R.S. M.P. was supported by EU grant LSHM-CT-2004-005166 and Polish Ministry of Science and Higher Education grant PBZ-MNiI-2/1/2005. A.N. acknowledges financial support from DFG grant NO120/12-3. The authors declare no conflicts of interest.	Alberti S, 2005, P NATL ACAD SCI USA, V102, P6148, DOI 10.1073/pnas.0501191102; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Antrop I, 2000, J CHILD PSYCHOL PSYC, V41, P225, DOI 10.1017/S0021963099005302; Bilbao A, 2008, P NATL ACAD SCI USA, V105, P17549, DOI 10.1073/pnas.0803959105; Brudno M, 2003, GENOME RES, V13, P721, DOI 10.1101/gr.926603; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Erdmann G, 2008, ENDOCRINOLOGY, V149, P3446, DOI 10.1210/en.2007-1786; Etkin A, 2006, NEURON, V50, P127, DOI 10.1016/j.neuron.2006.03.013; Faraone SV, 2005, BIOL PSYCHIAT, V57, P1313, DOI 10.1016/j.biopsych.2004.11.024; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Guan L, 2009, MOL PSYCHIATR, V14, P546, DOI 10.1038/sj.mp.4002139; HERDEGEN T, 1994, MOL BRAIN RES, V26, P259, DOI 10.1016/0169-328X(94)90098-1; Herdegen T, 1997, NEUROSCIENCE, V81, P199, DOI 10.1016/S0306-4522(97)00170-X; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kalita K, 2006, J NEUROSCI, V26, P10020, DOI 10.1523/JNEUROSCI.2644-06.2006; Knoll B, 2009, TRENDS NEUROSCI, V32, P432, DOI 10.1016/j.tins.2009.05.004; Knoll B, 2006, NAT NEUROSCI, V9, P195, DOI 10.1038/nn1627; Lasky-Su J, 2008, AM J MED GENET B, V147B, P1345, DOI 10.1002/ajmg.b.30867; Lemberger T, 2008, FASEB J, V22, P2872, DOI 10.1096/fj.08-107888; Lemberger T, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-4; Lenhard B, 2002, BIOINFORMATICS, V18, P1135, DOI 10.1093/bioinformatics/18.8.1135; Li DW, 2006, HUM MOL GENET, V15, P2276, DOI 10.1093/hmg/ddl152; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Nikitin V P, 2007, Neurosci Behav Physiol, V37, P83, DOI 10.1007/s11055-007-0153-x; Niu Z, 2008, P NATL ACAD SCI USA, V105, P17824, DOI 10.1073/pnas.0805491105; Parkitna Jan Rodriguez, 2009, V530, P325, DOI 10.1007/978-1-59745-471-1_17; Parlato R, 2006, GENESIS, V44, P454, DOI 10.1002/dvg.20236; Ramanan N, 2005, NAT NEUROSCI, V8, P759, DOI 10.1038/nn1462; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stringer JL, 2002, DEV BRAIN RES, V138, P81, DOI 10.1016/S0165-3806(02)00467-4; Stritt C, 2009, NAT NEUROSCI, V12, P418, DOI 10.1038/nn.2280; Suehiro J, 2010, BLOOD, V115, P2520, DOI 10.1182/blood-2009-07-233478; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Weinhold B, 2000, EMBO J, V19, P5835, DOI 10.1093/emboj/19.21.5835; Wiebel FF, 2002, GENESIS, V32, P124, DOI 10.1002/gene.10049	42	37	37	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2427	2435		10.1096/fj.09-151423	http://dx.doi.org/10.1096/fj.09-151423			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20223941				2022-12-28	WOS:000279343600029
J	Derichs, N; Jin, BJ; Song, YL; Finkbeiner, WE; Verkman, AS				Derichs, Nico; Jin, Byung-Ju; Song, Yuanlin; Finkbeiner, Walter E.; Verkman, A. S.			Hyperviscous airway periciliary and mucous liquid layers in cystic fibrosis measured by confocal fluorescence photobleaching	FASEB JOURNAL			English	Article						CFTR; mucins; diffusion; FRAP	SURFACE LIQUID; SUBMUCOSAL GLANDS; TRANSPORT; MUCINS; DEPTH; ION; PATHOGENESIS; SECRETIONS; EPITHELIUM; DIFFUSION	Airway surface liquid (ASL) volume depletion and mucus accumulation occur in cystic fibrosis (CF). The ASL comprises a superficial mucus layer (ML) overlying a periciliary fluid layer (PCL) that contacts surface epithelial cells. We measured viscosity of the ML and PCL from the diffusion of FITC-dextran dissolved in the ASL of unperturbed, well-differentiated primary cultures of human bronchial epithelia grown at an air-liquid interface. Diffusion was measured by fluorescence recovery after photobleaching, using a perfluorocarbon immersion lens and confocal fluorescence detection. Bleaching of an in-plane 6-mu m-wide region was done in which diffusion coefficients were computed using solution standards of specified viscosity and finite-element computations of 2-layer dye diffusion in 3 dimensions. We found remarkably elevated viscosity in both ML and PCL of CF vs. non-CF bronchial epithelial cell cultures. Relative viscosities (with saline = 1) were in the range 7-10 in the non-CF ML and PCL, and 25-30 in both ML and PCL in CF, and greatly reduced by amiloride treatment or mucin washout. These data indicate that the CF airway surface epithelium, even without hyperviscous secretions from submucosal glands, produces an intrinsically hyperviscous PCL and ML, which likely contributes to CF lung disease by impairment of mucociliary clearance. Our results challenge the view that the PCL is a relatively watery, nonviscous fluid layer in contact with a more viscous ML, and offer an explanation for CF lung disease in the gland-free lower airways.-Derichs, N., Jin, B. -J., Song, Y., Finkbeiner, W. E., Verkman, A. S. Hyperviscous airway periciliary and mucous liquid layers in cystic fibrosis measured by confocal fluorescence photobleaching. FASEB J. 25, 2325-2332 (2011). www.fasebj.org	[Derichs, Nico; Jin, Byung-Ju; Song, Yuanlin; Verkman, A. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Derichs, Nico; Jin, Byung-Ju; Song, Yuanlin; Verkman, A. S.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Finkbeiner, Walter E.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, 1246 HSE,Box 0521, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu			U.S. National Institutes of Health [HL73856, DK72517, DK86125, DK35124, EB00415, EY13574]; Cystic Fibrosis Foundation; Cystic Fibrosis Research Inc.; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, RC1DK086125, R37DK035124, R01DK035124] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); Cystic Fibrosis Research Inc.; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants HL73856, DK72517, DK86125, DK35124, EB00415, and EY13574 from the U.S. National Institutes of Health, and a Research Program Development grant from the Cystic Fibrosis Foundation. N.D. was supported in part by Cystic Fibrosis Research Inc.	Amaral MD, 2007, TRENDS PHARMACOL SCI, V28, P334, DOI 10.1016/j.tips.2007.05.004; Anderson Paula, 2010, Ther Adv Respir Dis, V4, P177, DOI 10.1177/1753465810371107; Blouquit-Laye S, 2007, RESP PHYSIOL NEUROBI, V159, P278, DOI 10.1016/j.resp.2007.03.007; Boucher RC, 2007, ANNU REV MED, V58, P157, DOI 10.1146/annurev.med.58.071905.105316; Chen Y, 2004, AM J RESP CELL MOL, V30, P155, DOI 10.1165/rcmb.2003-0103OC; Davies JR, 2007, INT J BIOCHEM CELL B, V39, P1943, DOI 10.1016/j.biocel.2007.05.013; Dix JA, 2008, ANNU REV BIOPHYS, V37, P247, DOI 10.1146/annurev.biophys.37.032807.125824; Donaldson Scott H, 2007, Proc Am Thorac Soc, V4, P399, DOI 10.1513/pats.200703-042BR; Evans CM, 2009, PHARMACOL THERAPEUT, V121, P332, DOI 10.1016/j.pharmthera.2008.11.001; Gray T, 2004, AM J PHYSIOL-LUNG C, V286, pL320, DOI 10.1152/ajplung.00440.2002; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Jayaraman S, 2001, J CLIN INVEST, V107, P317, DOI 10.1172/JCI11154; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; Joo NS, 2009, AM J PHYSIOL-LUNG C, V296, pL811, DOI 10.1152/ajplung.90636.2008; Levin MH, 2006, J BIOL CHEM, V281, P25803, DOI 10.1074/jbc.M604332200; Mall MA, 2008, J AEROSOL MED PULM D, V21, P13, DOI 10.1089/jamp.2007.0659; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Periasamy N, 1998, BIOPHYS J, V75, P557, DOI 10.1016/S0006-3495(98)77545-9; ROSE MC, 1987, PEDIATR RES, V22, P545, DOI 10.1203/00006450-198711000-00015; RUBINSTEIN M, 2010, 24 AM CF C, V24; Salinas D, 2004, FASEB J, V18, P431, DOI 10.1096/fj.04-2879fje; Sheehan John K, 2006, Novartis Found Symp, V279, P155; Song YL, 2006, AM J PHYSIOL-CELL PH, V290, pC741, DOI 10.1152/ajpcell.00379.2005; Song YL, 2009, AM J PHYSIOL-LUNG C, V297, pL1131, DOI 10.1152/ajplung.00085.2009; Tajima M, 2010, J BIOL CHEM, V285, P8163, DOI 10.1074/jbc.M109.093948; Tarran R, 2006, J GEN PHYSIOL, V127, P591, DOI 10.1085/jgp.200509468; Tarran R, 2001, J GEN PHYSIOL, V118, P223, DOI 10.1085/jgp.118.2.223; Thiagarajah JR, 2010, J GEN PHYSIOL, V136, P353, DOI 10.1085/jgp.201010490; Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002	31	65	67	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2325	2332		10.1096/fj.10-179549	http://dx.doi.org/10.1096/fj.10-179549			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21427214	Green Published			2022-12-28	WOS:000292242200024
J	Kavaler, S; Morinaga, H; Jih, A; Fan, WQ; Hedlund, M; Varki, A; Kim, JJ				Kavaler, Sarah; Morinaga, Hidetaka; Jih, Alice; Fan, WuQiang; Hedlund, Maria; Varki, Ajit; Kim, Jane J.			Pancreatic beta-cell failure in obese mice with human-like CMP-Neu5Ac hydroxylase deficiency	FASEB JOURNAL			English	Article						diabetes; sialic acid; pancreatic islet	N-GLYCOLYLNEURAMINIC ACID; SIALIC-ACID; INSULIN-RESISTANCE; HUMAN-EVOLUTION; RECEPTOR; GLUCOSE; DIETARY; SECRETION; BIOLOGY	Type 2 diabetes is highly prevalent in human populations, particularly in obese individuals, and is characterized by progressive pancreatic beta-cell dysfunction and insulin resistance. Most mammals, including Old World primates, express two major kinds of sialic acids, N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc), typically found at the distal ends of glycoconjugate chains at the cell surface. Humans are uniquely unable to produce endogenous Neu5Gc due to an inactivating mutation in the CMP-Neu5Ac hydroxylase (CMAH) gene. The CMAH enzyme catalyzes the generation of CMP-Neu5Gc by the transfer of a single oxygen atom to the acyl group of CMP-Neu5Ac. Here, we show that mice bearing a human-like deletion of the Cmah gene exhibit fasting hyperglycemia and glucose intolerance following a high-fat diet. This phenotype is caused not by worsened insulin resistance but by compromised pancreatic beta-cell function associated with a 65% decrease in islet size and area and 50% decrease in islet number. Obese Cmah-null mice also show an similar to 40% reduction in response to insulin secretagogues in vivo. These findings show that human evolution-like changes in sialic acid composition impair pancreatic beta-cell function and exacerbate glucose intolerance in mice. This may lend insight into the pathogenesis of type 2 diabetes in obese humans.-Kavaler, S., Morinaga, H., Jih, A., Fan, W. Q., Hedlund, M., Varki, A., Kim, J. J. Pancreatic beta-cell failure in obese mice with human-like CMP-Neu5Ac hydroxylase deficiency. FASEB J. 25, 1887-1893 (2011). www.fasebj.org	[Kim, Jane J.] Univ Calif San Diego, Dept Pediat, Div Pediat Endocrinol & Diabet, La Jolla, CA 92093 USA; [Morinaga, Hidetaka; Fan, WuQiang; Hedlund, Maria; Varki, Ajit] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Hedlund, Maria; Varki, Ajit] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Hedlund, Maria; Varki, Ajit] Univ Calif San Diego, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; [Kim, Jane J.] Rady Childrens Hosp San Diego, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego	Kim, JJ (corresponding author), Univ Calif San Diego, Dept Pediat, Div Pediat Endocrinol & Diabet, 9500 Gilman Dr,MC 0673, La Jolla, CA 92093 USA.	janekim@ucsd.edu		Kim, Jane/0000-0002-0228-0128	U.S. National Institutes of Health [DK075479, DK063491, GM32373]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK075479, P30DK063491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373, R37GM032373] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health grants DK075479 (J.K.), DK063491 DERC Pilot and Feasibility Award (J.K.), and GM32373 (A.V.). The authors thank Nissi Varki [University of California-San Diego (UCSD) Histology Core] for immunohistochemistry studies on pancreatic tissues. Thanks are due also to Jerrold Olefsky (UCSD) for helpful discussions and support.	Arabkhari M, 2010, GLYCOBIOLOGY, V20, P603, DOI 10.1093/glycob/cwq010; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8633, DOI 10.1074/jbc.275.12.8633; Carter JD, 2009, BIOL PROCED ONLINE, V11, P3, DOI 10.1007/s12575-009-9021-0; Chandrasekharan K, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000692; HANSEN BC, 1990, AM J PHYSIOL, V259, pR612, DOI 10.1152/ajpregu.1990.259.3.R612; Hedlund M, 2007, MOL CELL BIOL, V27, P4340, DOI 10.1128/MCB.00379-07; JONES S M, 1974, Laboratory Animals (London), V8, P161, DOI 10.1258/002367774781005788; Kim A, 2009, ISLETS, V1, P129, DOI 10.4161/isl.1.2.9480; Kim JJ, 2007, AM J PHYSIOL-ENDOC M, V292, pE1694, DOI 10.1152/ajpendo.00430.2006; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LEROITH D, 2004, DIABETES MELLITUS FU; Levy J, 1998, DIABETIC MED, V15, P290, DOI 10.1002/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M; Marcelli-Tourvieille S, 2006, DIABETES METAB, V32, P295, DOI 10.1016/S1262-3636(07)70283-5; Martin MJ, 2005, P NATL ACAD SCI USA, V102, P12819, DOI 10.1073/pnas.0503819102; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MORDES JP, 1981, AM J MED, V70, P353, DOI 10.1016/0002-9343(81)90772-5; Naito Y, 2007, MOL CELL BIOL, V27, P3008, DOI 10.1128/MCB.02047-06; Ohtsubo K, 2005, CELL, V123, P1307, DOI 10.1016/j.cell.2005.09.041; Okamoto H, 2006, J CLIN INVEST, V116, P775, DOI 10.1172/JCI24967; PERLEY MJ, 1967, J CLIN INVEST, V46, P1954, DOI 10.1172/JCI105685; PIMENTA W, 1995, JAMA-J AM MED ASSOC, V273, P1855, DOI 10.1001/jama.273.23.1855; Tahara H, 2010, J IMMUNOL, V184, P3269, DOI 10.4049/jimmunol.0902857; Tangvoranuntakul P, 2003, P NATL ACAD SCI USA, V100, P12045, DOI 10.1073/pnas.2131556100; Teta M, 2005, DIABETES, V54, P2557, DOI 10.2337/diabetes.54.9.2557; Varki A, 2007, NATURE, V446, P1023, DOI 10.1038/nature05816; Varki A, 2010, P NATL ACAD SCI USA, V107, P8939, DOI 10.1073/pnas.0914634107; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Xuan SH, 2002, J CLIN INVEST, V110, P1011, DOI 10.1172/JCI200215276	29	23	24	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2011	25	6					1887	1893		10.1096/fj.10-175281	http://dx.doi.org/10.1096/fj.10-175281			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21350118	Green Published			2022-12-28	WOS:000291023800012
J	Ohnishi, M; Kato, S; Akiyoshi, J; Atfi, A; Razzaque, MS				Ohnishi, Mutsuko; Kato, Shigeko; Akiyoshi, Junko; Atfi, Azeddine; Razzaque, M. Shawkat			Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions	FASEB JOURNAL			English	Article						insulin; liver; vitamin D	HIGH-FAT-DIET; SOFT-TISSUE CALCIFICATION; ENDOTHELIAL DYSFUNCTION; PHOSPHATE HOMEOSTASIS; INSULIN-RESISTANCE; MICE LEADS; OB/OB MICE; NULL MICE; EXPRESSION; MOUSE	Klotho is a multifunctional protein involved in numerous biological functions, ranging from mineral ion metabolism to signaling activities. Recent studies have identified klotho as a target gene for peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a master regulator of adipocyte differentiation, and an adipogenesis-promoting factor. In a similar line of observation, eliminating klotho function from mice resulted in the generation of lean mice with almost no detectable fat tissue. In contrast to the klotho-knockout mice (11.7 +/- 0.3 g at 9 wk), leptin-deficient (ob/ob) mice are severely obese (49.3 +/- 0.6 g at 9 wk), due to excessive fat accumulation. To study the in vivo role of klotho in obesity, we have generated and characterized ob/ob mice lacking klotho activity [ob/ob-klotho double-knockout (DKO) mice]. The ob/ob mice started to get bigger from 3 wk onward and gained almost 2 times more weight than their wild-type (WT) counterparts (WT vs. ob/ob: 34.8 +/- 1.3 vs. 65.5 +/- 1.2 g at 21 wk). The generated ob/ob-klotho DKO mice were not only viable throughout their adulthood but also showed markedly reduced fat tissue accumulation compared to their ob/ob littermates. The ob/ob-klotho DKO mice had significantly (P<0.01) less retroperitoneal, mesenteric, and epididymal fat accumulation, compared to their ob/ob counterparts. Similarly, the fatty liver that was consistently observed in the ob/ob mice was eliminated in the ob/ob-klotho DKO mice. Such structural improvement in the liver was also evident from markedly reduced fasting blood glucose levels in ob/ob-klotho DKO mice, compared to their ob/ob counterparts (ob/ob vs. ob/ob-klotho DKO: 266 +/- 36 vs. 65 +/- 2 mg/dl). Finally, to study whether the absence of klotho can induce resistance to high-fat-diet-induced obesity, we provided a high-fat (60%) diet to klotho-knockout mice and compared them with normal-fat (20%) diet-fed klotho-knockout mice. No significant difference in body weight was detected in klotho-knockout mice fed either the normal-fat diet or high-fat diet, while WT mice fed the high-fat diet gradually gained body weight, compared to the normal-fat-diet-fed counterparts. The results of our dietary and genetic manipulation studies provide in vivo evidence for a role of klotho in obesity and offer a novel target to manipulate obesity and associated complications.-Ohnishi, M., Kato, S., Akiyoshi, J., Atfi, A., Razzaque, M. S. Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions. FASEB J. 25, 2031-2039 (2011). www.fasebj.org	[Ohnishi, Mutsuko; Kato, Shigeko; Akiyoshi, Junko; Atfi, Azeddine; Razzaque, M. Shawkat] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA	Harvard University; Harvard School of Dental Medicine	Razzaque, MS (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Res & Educ Bldg,Rm 304,190 Longwood Ave, Boston, MA 02115 USA.	mrazzaque@hms.harvard.edu	Razzaque, Mohammed S./K-4282-2019		U.S. National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases) [R01-DK077276]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077276] Funding Source: NIH RePORTER	U.S. National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Part of the research is supported by grant R01-DK077276 to M.S.R. from the U.S. National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases).	Cha SK, 2009, MOL PHARMACOL, V76, P38, DOI 10.1124/mol.109.055780; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Chihara Y, 2006, ENDOCRINOLOGY, V147, P3835, DOI 10.1210/en.2005-1529; Cioffi F, 2010, FASEB J, V24, P3451, DOI 10.1096/fj.10-157115; Flicker L, 2010, J AM GERIATR SOC, V58, P234, DOI 10.1111/j.1532-5415.2009.02677.x; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Haluzik M, 2004, ENDOCRINOLOGY, V145, P3258, DOI 10.1210/en.2004-0219; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kawaguchi H, 1999, J CLIN INVEST, V104, P229, DOI 10.1172/JCI5705; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91; Matsunuma A, 2004, ENDOCRINOLOGY, V145, P1367, DOI 10.1210/en.2003-1010; Mizuno I, 2001, LIFE SCI, V68, P2917, DOI 10.1016/S0024-3205(01)01092-X; Moon BC, 1997, GENOMICS, V42, P152, DOI 10.1006/geno.1997.4701; Mori K, 2000, BIOCHEM BIOPH RES CO, V278, P665, DOI 10.1006/bbrc.2000.3864; Nabeshima Y, 2002, AGEING RES REV, V1, P627, DOI 10.1016/S1568-1637(02)00027-2; Nagai R, 2000, CELL MOL LIFE SCI, V57, P738, DOI 10.1007/s000180050038; Nakatani T, 2009, FASEB J, V23, P3702, DOI 10.1096/fj.08-123992; Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08-114397; Ohnishi M, 2010, FASEB J, V24, P3562, DOI 10.1096/fj.09-152488; Ohnishi M, 2009, CIRC-CARDIOVASC GENE, V2, P583, DOI 10.1161/CIRCGENETICS.108.847814; Ohnishi M, 2009, KIDNEY INT, V75, P1166, DOI 10.1038/ki.2009.24; Rabot S, 2010, FASEB J, V24, P4948, DOI 10.1096/fj.10-164921; Razzaque MS, 2011, KIDNEY INT, V79, P708, DOI 10.1038/ki.2010.432; Razzaque MS, 2011, CLIN SCI, V120, P91, DOI 10.1042/CS20100377; Razzaque MS, 2009, NAT REV ENDOCRINOL, V5, P611, DOI 10.1038/nrendo.2009.196; Razzaque MS, 2009, AM J PHYSIOL-RENAL, V296, pF470, DOI 10.1152/ajprenal.90538.2008; Razzaque MS, 2011, IUBMB LIFE, V63, P240, DOI 10.1002/iub.437; Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05-5432fje; Saito Y, 2000, BIOCHEM BIOPH RES CO, V276, P767, DOI 10.1006/bbrc.2000.3470; Saito Y, 1998, BIOCHEM BIOPH RES CO, V248, P324, DOI 10.1006/bbrc.1998.8943; Sato M, 2010, FASEB J, V24, P2375, DOI 10.1096/fj.09-145466; Tozuka Y, 2009, FASEB J, V23, P1920, DOI 10.1096/fj.08-124784; Utsugi T, 2000, METABOLISM, V49, P1118, DOI 10.1053/meta.2000.8606; Yamagishi T, 2001, HYPERTENS RES, V24, P705, DOI 10.1291/hypres.24.705; Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200; Zadravec D, 2010, FASEB J, V24, P4366, DOI 10.1096/fj.09-152298; Zha Y, 2006, ENDOCRINOLOGY, V147, P5690, DOI 10.1210/en.2006-0302; Zhang H, 2008, KIDNEY INT, V74, P732, DOI 10.1038/ki.2008.244	39	32	34	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2011	25	6					2031	2039		10.1096/fj.10-167056	http://dx.doi.org/10.1096/fj.10-167056			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21382979	Green Published			2022-12-28	WOS:000291023800025
J	Guillet, V; Gueguen, N; Cartoni, R; Chevrollier, A; Desquiret, V; Angebault, C; Amati-Bonneau, P; Procaccio, V; Bonneau, D; Martinou, JC; Reynier, P				Guillet, Virginie; Gueguen, Naig; Cartoni, Romain; Chevrollier, Arnaud; Desquiret, Valerie; Angebault, Claire; Amati-Bonneau, Patrizia; Procaccio, Vincent; Bonneau, Dominique; Martinou, Jean-Claude; Reynier, Pascal			Bioenergetic defect associated with mK(ATP) channel opening in a mouse model carrying a mitofusin 2 mutation	FASEB JOURNAL			English	Article						Charcot-Marie-Tooth type 2A; succinate dehydrogenase; F0F1-ATP synthase; mitochondria; potassium channel	SENSITIVE POTASSIUM CHANNELS; MARIE-TOOTH-DISEASE; NEUROPATHY TYPE 2A; MITOCHONDRIAL FUSION; SUCCINATE OXIDATION; ATP SYNTHASE; RAT-HEART; DIAZOXIDE; MFN2; INHIBITOR	Charcot-Marie-Tooth disease type 2A (CMT2A) is an autosomal dominant axonal form of peripheral neuropathy caused by mutations in the mitofusin 2 gene (MFN2), which encodes a mitochondrial outer membrane protein that promotes mitochondrial fusion. Emerging evidence also points to a role of MFN2 in the regulation of mitochondrial metabolism. To examine whether mitochondrial dysfunction is a feature of CMT2A, we used a transgenic mouse model expressing in neurons a mutated R94Q form of human MFN2 shown to induce a CMT2A phenotype. Oxygraphic and enzymatic measurements both revealed a combined defect of mitochondrial complexes II and V (40 and 30% decrease, respectively) in the brain of Tg-R94 mice, leading to a drastic decrease of ATP synthesis. These deficiencies were reversed by the mitochondrial ATP-sensitive potassium channel (mK(ATP)) inhibitor 5-hydroxydecanoate. Conversely, in controls and wild-type human MFN2 mice, the mK(ATP) activator diazoxide mimicked the deficiency observed with the R94Q mutation. The physical links between complexes II and V, previously proposed as part of mK(ATP), were reinforced in Tg-R94Q mice. Our results show that the R94Q MFN2 mutation induces a combined defect of complexes II and V linked to the opening of mK(ATP), which could participate in the pathophysiology of the disease.-Guillet, V., Gueguen, N., Cartoni, R., Chevrollier, A., Desquiret, V., Angebault, C., Amati-Bonneau, P., Procaccio, V., Bonneau, D., Martinou, J.-C., Reynier, P. Bioenergetic defect associated with mKATP channel opening in a mouse model carrying a mitofusin 2 mutation. FASEB J. 25, 1618-1627 (2011). www.fasebj.org	[Guillet, Virginie; Gueguen, Naig; Chevrollier, Arnaud; Angebault, Claire; Amati-Bonneau, Patrizia; Procaccio, Vincent; Bonneau, Dominique; Reynier, Pascal] CNRS, UMR 6214, INSERM, U771, Angers, France; [Guillet, Virginie; Angebault, Claire; Procaccio, Vincent; Bonneau, Dominique; Reynier, Pascal] Univ Angers, Sch Med, Angers, France; [Guillet, Virginie; Gueguen, Naig; Chevrollier, Arnaud; Desquiret, Valerie; Amati-Bonneau, Patrizia; Procaccio, Vincent; Bonneau, Dominique; Reynier, Pascal] Univ Hosp Angers, Dept Biochem & Genet, Angers, France; [Cartoni, Romain; Martinou, Jean-Claude] Univ Geneva, Dept Cell Biol, Geneva, Switzerland; [Cartoni, Romain] Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Cartoni, Romain] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Universite d'Angers; Universite de Franche-Comte; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; University of Geneva; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Gueguen, N (corresponding author), CHU Angers, Lab Biochim & Biol Mol, F-49000 Angers, France.	naiggueguen@yahoo.fr	amati-bonneau, patrizia/K-6198-2015; CHEVROLLIER, Arnaud/K-2853-2015; CHEVROLLIER, Arnaud/P-6630-2019; CHEVROLLIER, Arnaud/GSD-3887-2022; Desquiret-Dumas, Valérie/K-2695-2015; Bonneau, Dominique/K-6110-2015; Reynier, Pascal/K-3677-2015; LENAERS, Guy/K-2421-2015	CHEVROLLIER, Arnaud/0000-0002-5135-6643; CHEVROLLIER, Arnaud/0000-0002-5135-6643; CHEVROLLIER, Arnaud/0000-0002-5135-6643; LENAERS, Guy/0000-0003-2736-3349; Desquiret-Dumas, Valerie/0000-0001-9551-9400; Reynier, Pascal/0000-0003-0802-4608; Bonneau, Dominique/0000-0002-6886-0969; procaccio, Vincent/0000-0002-1537-4684; martinou, Jean-claude/0000-0002-9847-2051	Institut National de la Sante et de la Recherche Medicale (INSERM); University Hospital of Angers [PHRC 04-12]; University of Angers; Association Contre les Maladies Mitochondriales (AMMi); Retina France, Ouvrir les Yeux (OLY); Union Nationale des Aveugles et Deficients Visuel (UNADEV)	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University Hospital of Angers; University of Angers; Association Contre les Maladies Mitochondriales (AMMi); Retina France, Ouvrir les Yeux (OLY); Union Nationale des Aveugles et Deficients Visuel (UNADEV)	This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM), the University Hospital of Angers (PHRC 04-12), the University of Angers, and grants from the following associations of patients: Association Contre les Maladies Mitochondriales (AMMi), Retina France, Ouvrir les Yeux (OLY), and Union Nationale des Aveugles et Deficients Visuel (UNADEV). The authors are grateful to C. Wetterwald, to the technicians of the laboratory for technical assistance, and to Kanaya Malkani for critical reading and comments on the manuscript.	Ala-Rami A, 2003, BASIC RES CARDIOL, V98, P250, DOI 10.1007/s00395-003-0413-z; Amiott EA, 2008, EXP NEUROL, V211, P115, DOI 10.1016/j.expneurol.2008.01.010; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Bajgar R, 2001, J BIOL CHEM, V276, P33369, DOI 10.1074/jbc.M103320200; Baloh RH, 2007, J NEUROSCI, V27, P422, DOI 10.1523/JNEUROSCI.4798-06.2007; Briere JJ, 2005, CELL MOL LIFE SCI, V62, P2317, DOI 10.1007/s00018-005-5237-6; Cairns CB, 1998, AM J PHYSIOL-REG I, V274, pR1376, DOI 10.1152/ajpregu.1998.274.5.R1376; Cartoni R, 2010, BRAIN, V133, P1460, DOI 10.1093/brain/awq082; Cartoni R, 2009, EXP NEUROL, V218, P268, DOI 10.1016/j.expneurol.2009.05.003; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Comelli M, 2007, AM J PHYSIOL-HEART C, V292, pH820, DOI 10.1152/ajpheart.00366.2006; Contessi S, 2004, BIOCHEM PHARMACOL, V67, P1843, DOI 10.1016/j.bcp.2004.02.001; Costa ADT, 2006, AM J PHYSIOL-HEART C, V290, pH406, DOI 10.1152/ajpheart.00794.2005; de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534; Detmer SA, 2007, J CELL BIOL, V176, P405, DOI 10.1083/jcb.200611080; Fritz S, 2001, J CELL BIOL, V152, P683, DOI 10.1083/jcb.152.4.683; Guillery O, 2008, BIOL CELL, V100, P315, DOI 10.1042/BC20070110; Hanley PJ, 2002, J PHYSIOL-LONDON, V542, P735, DOI 10.1113/jphysiol.2002.023960; HEDERSTEDT L, 1989, BIOCHEM J, V260, P491, DOI 10.1042/bj2600491; Horiguchi T, 2003, STROKE, V34, P1015, DOI 10.1161/01.STR.0000063404.27912.5B; Kijima K, 2005, HUM GENET, V116, P23, DOI 10.1007/s00439-004-1199-2; Kis B, 2003, J NEUROCHEM, V87, P969, DOI 10.1046/j.1471-4159.2003.02072.x; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Kopustinskiene DM, 2003, J BIOENERG BIOMEMBR, V35, P141, DOI 10.1023/A:1023746103401; Lim KHH, 2002, J PHYSIOL-LONDON, V545, P961, DOI 10.1113/jphysiol.2002.031484; Loiseau D, 2007, ANN NEUROL, V61, P315, DOI 10.1002/ana.21086; Neusch C, 2007, EUR J NEUROL, V14, P575, DOI 10.1111/j.1468-1331.2006.01688.x; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Pasdois P, 2006, J BIOENERG BIOMEMBR, V38, P101, DOI 10.1007/s10863-006-9016-3; Pich S, 2005, HUM MOL GENET, V14, P1405, DOI 10.1093/hmg/ddi149; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; SCHAFER G, 1969, BIOCHEM PHARMACOL, V18, P2678; SKRE H, 1974, CLIN GENET, V6, P98; Vallat JM, 2008, J NEUROPATH EXP NEUR, V67, P1097, DOI 10.1097/NEN.0b013e31818b6cbc; Verhoeven K, 2006, BRAIN, V129, P2093, DOI 10.1093/brain/awl126; Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62; Wojtovich AP, 2008, BBA-BIOENERGETICS, V1777, P882, DOI 10.1016/j.bbabio.2008.03.025; Wojtovich AP, 2009, BASIC RES CARDIOL, V104, P121, DOI 10.1007/s00395-009-0001-y; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341; 2004, P NATL ACAD SCI US, V101, P11880	42	36	38	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1618	1627		10.1096/fj.10-173609	http://dx.doi.org/10.1096/fj.10-173609			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21285398	Green Published			2022-12-28	WOS:000290023800019
J	Kellermayer, R; Dowd, SE; Harris, RA; Balasa, A; Schaible, TD; Wolcott, RD; Tatevian, N; Szigeti, R; Li, ZJ; Versalovic, J; Smith, CW				Kellermayer, Richard; Dowd, Scot E.; Harris, R. Alan; Balasa, Alfred; Schaible, Tiffany D.; Wolcott, Randy D.; Tatevian, Nina; Szigeti, Reka; Li, Zhijie; Versalovic, James; Smith, C. Wayne			Colonic mucosal DNA methylation, immune response, and microbiome patterns in Toll-like receptor 2-knockout mice	FASEB JOURNAL			English	Article						metagenomics; inflammatory bowel diseases; metabolic syndrome; epigenetics; Tlr2	INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; METABOLIC SYNDROME; GUT MICROBIOTA; GROWTH-FACTOR; TLR2; EXPRESSION; BACTERIA; COLITIS; COMMUNICATION	The connection between intestinal microbiota and host physiology is increasingly becoming recognized. The details of this dynamic interaction, however, remain to be explored. Toll-like receptor 2 (Tlr2) is important for its role in bacterial recognition, intestinal inflammation, and obesity-related metabolic changes. Therefore, we sought to determine the epigenomic and metagenomic consequences of Tlr2 deficiency in the colonic mucosa of mice to gain insights into biological pathways that shape the interface between the gut microbiota and the mammalian host. Colonic mucosa from wild type (WT) and Tlr2(-/-) C57BL/6 mice was interrogated by microarrays specific for DNA methylation and gene expression. The mucosal microbiome was studied by next-generation pyrosequencing of bacterial 16S rRNA. The expression of genes involved in immune processes was significantly modified by the absence of Tlr2, a number of which correlated with DNA methylation changes. The epigenomic and transcriptomic modifications associated with alteration in mucosal microbial composition. Several bacterial species, including members of the Firmicutes were significantly different in abundance between WT and Tlr2(-/-) animals. This manuscript highlights the intimate interrelationships between expression of immune-related genes and immunity pathways in the host with compositional and functional differences of the mammalian microbiome.-Kellermayer, R., Dowd, S. E., Harris, R. A., Balasa, A., Schaible, T. D., Wolcott, R. D., Tatevian, N., Szigeti, R., Li, Z., Versalovic, J., Smith, C. W. Colonic mucosal DNA methylation, immune response, and microbiome patterns in Toll-like receptor 2-knockout mice. FASEB J. 25, 1449-1460 (2011). www.fasebj.org	[Kellermayer, Richard] Texas Childrens Hosp, Baylor Coll Med, Sect Pediat Gastroenterol Hepatol & Nutr, Dept Pediat, Houston, TX 77030 USA; [Harris, R. Alan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Szigeti, Reka; Versalovic, James] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Dowd, Scot E.; Wolcott, Randy D.] Res & Testing Lab, Lubbock, TX USA; [Tatevian, Nina] Univ Texas Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX USA; [Smith, C. Wayne] Baylor Univ, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; Baylor University; United States Department of Agriculture (USDA)	Kellermayer, R (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Sect Pediat Gastroenterol Hepatol & Nutr, Dept Pediat, 6621 Fannin St,CC1010-00, Houston, TX 77030 USA.	kellerma@bcm.edu	Harris, R. Alan/AAI-2784-2020; Dowd, Scot E/M-5386-2017	Harris, R. Alan/0000-0002-7333-4752; Dowd, Scot E/0000-0002-6296-1427	Crohn's and Colitis Foundation of America-Children's Digestive Health and Nutrition Foundation/North American Society of Pediatric Gastroenterology Hepatology and Nutrition [CCFA 2426]; Broad Medical Research Program; Broad Foundation [IBD-0252]; U.S. Department of Agriculture/Agriculture Research Service Child Health Research Center [6250-51000-055]; National Human Genome Research Initiative ENCODE [U54HG004592]; National Institute of Diabetes, Digestive, and Kidney Disease [R01 DK065075, UH3 DK083990, P30 DK56338]; National Center for Complementary and Alternative Medicine [R01 AT004326]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT004326] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG004592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065075, P30DK056338, UH3DK083990] Funding Source: NIH RePORTER	Crohn's and Colitis Foundation of America-Children's Digestive Health and Nutrition Foundation/North American Society of Pediatric Gastroenterology Hepatology and Nutrition; Broad Medical Research Program; Broad Foundation; U.S. Department of Agriculture/Agriculture Research Service Child Health Research Center(United States Department of Agriculture (USDA)); National Human Genome Research Initiative ENCODE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institute of Diabetes, Digestive, and Kidney Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Stefi Lee for her outstanding technical support. R. K. was supported by a young investigator joint award from the Crohn's and Colitis Foundation of America-Children's Digestive Health and Nutrition Foundation/North American Society of Pediatric Gastroenterology Hepatology and Nutrition, (CCFA 2426), and the Broad Medical Research Program, the Broad Foundation (IBD-0252). C. W. S. was supported by a U.S. Department of Agriculture/Agriculture Research Service Child Health Research Center, Current Research Information System Project grant (6250-51000-055). DNaseI mapping data were funded through a National Human Genome Research Initiative ENCODE grant (U54HG004592) to John A. Stamatoyannopoulos (University of Washington, Seattle, WA, USA). J.V. was supported by the National Institute of Diabetes, Digestive, and Kidney Disease (R01 DK065075, UH3 DK083990, and P30 DK56338) and the National Center for Complementary and Alternative Medicine (R01 AT004326). The authors declare no conflicts of interest.	Al-Shahrour F, 2006, NUCLEIC ACIDS RES, V34, pW472, DOI 10.1093/nar/gkl172; Andoh A, 2007, INFLAMM BOWEL DIS, V13, P955, DOI 10.1002/ibd.20151; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Bailey MT, 2010, BRAIN BEHAV IMMUN, V24, P577, DOI 10.1016/j.bbi.2009.12.010; Balasa A, 2010, INT J COLORECTAL DIS, V25, P553, DOI 10.1007/s00384-010-0874-0; Barnett M, 2010, MUTAT RES-FUND MOL M, V690, P71, DOI 10.1016/j.mrfmmm.2010.02.006; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Carey R, 2008, INFLAMM BOWEL DIS, V14, P446, DOI 10.1002/ibd.20342; Cario E, 2007, GASTROENTEROLOGY, V132, P1359, DOI 10.1053/j.gastro.2007.02.056; CHESA PG, 1986, AM J SURG PATHOL, V10, P829, DOI 10.1097/00000478-198612000-00001; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Dowd SE, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-93; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Ehses JA, 2010, DIABETOLOGIA, V53, P1795, DOI 10.1007/s00125-010-1747-3; Ey B, 2009, J BIOL CHEM, V284, P22332, DOI 10.1074/jbc.M901619200; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Friswell MK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008584; Frolova L, 2008, J HISTOCHEM CYTOCHEM, V56, P267, DOI 10.1369/jhc.7A7303.2007; Fyderek K, 2009, WORLD J GASTROENTERO, V15, P5287, DOI 10.3748/wjg.15.5287; Gophna U, 2006, J CLIN MICROBIOL, V44, P4136, DOI 10.1128/JCM.01004-06; Halfvarson J, 2003, GASTROENTEROLOGY, V124, P1767, DOI 10.1016/S0016-5085(03)00385-8; Hashida H, 2002, GASTROENTEROLOGY, V122, P376, DOI 10.1053/gast.2002.31095; Heimesaat MM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000662; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Himes RW, 2010, FASEB J, V24, P731, DOI 10.1096/fj.09-141929; Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067; Kellermayer R, 2010, HUM MOL GENET, V19, P2168, DOI 10.1093/hmg/ddq095; Kim H, 2007, GASTROENTEROLOGY, V133, P875, DOI 10.1053/j.gastro.2007.06.063; Kleessen B, 2002, SCAND J GASTROENTERO, V37, P1034, DOI 10.1080/003655202320378220; Lees Charlie W, 2009, Expert Rev Gastroenterol Hepatol, V3, P513, DOI 10.1586/egh.09.45; Loh G, 2008, ENVIRON MICROBIOL, V10, P709, DOI 10.1111/j.1462-2920.2007.01493.x; Lowe EL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013027; Lozupone C, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-371; Lundin A, 2008, CELL MICROBIOL, V10, P1093, DOI 10.1111/j.1462-5822.2007.01108.x; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; McMahon LA, 2010, VET IMMUNOL IMMUNOP, V135, P158, DOI 10.1016/j.vetimm.2009.11.012; Messlik A, 2009, J PROTEOME RES, V8, P4406, DOI 10.1021/pr9000465; Mowat AM, 2010, EUR J IMMUNOL, V40, P318, DOI 10.1002/eji.200940232; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Packey CD, 2009, CURR OPIN INFECT DIS, V22, P292, DOI 10.1097/QCO.0b013e32832a8a5d; Paclik D, 2008, J MOL MED, V86, P1395, DOI 10.1007/s00109-007-0290-2; Pierik M, 2006, INFLAMM BOWEL DIS, V12, P1, DOI 10.1097/01.MIB.0000195389.11645.ab; Podolsky DK, 2009, GASTROENTEROLOGY, V137, P209, DOI 10.1053/j.gastro.2009.03.007; Preidis GA, 2009, GASTROENTEROLOGY, V136, P2015, DOI 10.1053/j.gastro.2009.01.072; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Selvarajoo K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003430; Sepulveda AR, 2010, GASTROENTEROLOGY, V138, P1836, DOI 10.1053/j.gastro.2009.12.042; Shiraga T, 2005, EXP CELL RES, V308, P41, DOI 10.1016/j.yexcr.2005.04.008; Smith AE, 2007, NUCLEIC ACIDS RES, V35, P740, DOI 10.1093/nar/gkl1053; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Szebeni B, 2008, CLIN EXP IMMUNOL, V151, P34, DOI 10.1111/j.1365-2249.2007.03531.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Vamadevan AS, 2010, INNATE IMMUN-LONDON, V16, P93, DOI 10.1177/1753425909339231; Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721; Waterland RA, 2009, HUM MOL GENET, V18, P3026, DOI 10.1093/hmg/ddp241; Wiese AH, 2007, CANCER DETECT PREV, V31, P282, DOI 10.1016/j.cdp.2007.07.003; Wolcott R D, 2009, J Wound Care, V18, P317; Wu F, 2007, INFLAMM BOWEL DIS, V13, P807, DOI 10.1002/ibd.20110; Yoshioka T, 2001, J INT MED RES, V29, P409, DOI 10.1177/147323000102900505; Zhang SS, 2009, EUR J GASTROEN HEPAT, V21, P1145, DOI 10.1097/MEG.0b013e32830edb29; Zhang Z, 2006, CELL MOL LIFE SCI, V63, P2901, DOI 10.1007/s00018-006-6189-1	65	100	102	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1449	1460		10.1096/fj.10-172205	http://dx.doi.org/10.1096/fj.10-172205			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21228220	Green Published			2022-12-28	WOS:000290023800004
J	Milagro, FI; Campion, J; Cordero, P; Goyenechea, E; Gomez-Uriz, AM; Abete, I; Zulet, MA; Martinez, JA				Milagro, Fermin I.; Campion, Javier; Cordero, Paul; Goyenechea, Estibaliz; Gomez-Uriz, Ana M.; Abete, Itziar; Zulet, Maria A.; Alfredo Martinez, J.			A dual epigenomic approach for the search of obesity biomarkers: DNA methylation in relation to diet-induced weight loss	FASEB JOURNAL			English	Article						CD44; ATP10A; WT1; PBMC; microarray	HIGH-FAT DIET; GENE-EXPRESSION; ADIPOSE-TISSUE; RESTRICTION; INFLAMMATION; EPIGENETICS; MECHANISMS; OXIDATION; RESPONSES; PATHWAYS	Epigenetics could help to explain individual differences in weight loss after an energy-restriction intervention. Here, we identify novel potential epigenetic biomarkers of weight loss, comparing DNA methylation patterns of high and low responders to a hypocaloric diet. Twenty-five overweight or obese men participated in an 8-wk caloric restriction intervention. DNA was isolated from peripheral blood mononuclear cells and treated with bisulfite. The basal and endpoint epigenetic differences between high and low responders were analyzed by methylation microarray, which was also useful in comparing epigenetic changes due to the nutrition intervention. Subsequently, MALDI-TOF mass spectrometry was used to validate several relevant CpGs and the surrounding regions. DNA methylation levels in several CpGs located in the ATP10A and CD44 genes showed statistical baseline differences depending on the weight-loss outcome. At the treatment endpoint, DNA methylation levels of several CpGs on the WT1 promoter were statistically more methylated in the high than in the low responders. Finally, different CpG sites from WT1 and ATP10A were significantly modified as a result of the intervention. In summary, hypocaloric-diet-induced weight loss in humans could alter DNA methylation status of specific genes. Moreover, baseline DNA methylation patterns may be used as epigenetic markers that could help to predict weight loss.-Milagro, F. I., Campion, J., Cordero, P., Goyenechea, E., Gomez-Uriz, A. M., Abete, I., Zulet, M. A., Martinez, J. A. A dual epigenomic approach for the search of obesity biomarkers: DNA methylation in relation to diet-induced weight loss. FASEB J. 25, 1378-1389 (2011). www.fasebj.org	[Milagro, Fermin I.; Campion, Javier; Cordero, Paul; Gomez-Uriz, Ana M.; Abete, Itziar; Zulet, Maria A.; Alfredo Martinez, J.] Univ Navarra, Dept Nutr & Food Sci Physiol & Toxicol, Pamplona 31008, Spain; [Goyenechea, Estibaliz] Hosp Donostia, Dept Neurol, San Sebastian, Spain	University of Navarra; University Hospital Donostia	Martinez, JA (corresponding author), Univ Navarra, Dept Nutr & Food Sci Physiol & Toxicol, C Irunlarrea 1, Pamplona 31008, Spain.	jalfmtz@unav.es	Zulet, M. Angeles/H-1317-2017; Milagro, Fermin/F-2315-2015; Abete, Itziar/H-4827-2017; Martinez Hernandez, J Alfredo/K-8709-2014	Zulet, M. Angeles/0000-0002-3926-0892; Milagro, Fermin/0000-0002-3228-9916; ESTIBALIZ, GOYENECHEA/0000-0001-7990-5192; Campion, Javier/0000-0002-6522-8271; Abete, Itziar/0000-0002-6475-5387; Martinez Hernandez, J Alfredo/0000-0001-5218-6941	Asociacion de Amigos de la Universidad de Navarra; Basque Department of Education, Universities, and Research; Linea Especial (University of Navarra) [LE/97]; Spanish Ministerio de Ciencia e Innovacion [SAF2010-16887]; Navarra Department of Health (RESMENA-S); Department of Education	Asociacion de Amigos de la Universidad de Navarra; Basque Department of Education, Universities, and Research; Linea Especial (University of Navarra); Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Navarra Department of Health (RESMENA-S); Department of Education(US Department of Education)	The technical assistance of A. Lorente, V. Fernandez, and J. A. Ayala is gratefully acknowledged. P.C. and A.M.G.-U. have fellowships from the Asociacion de Amigos de la Universidad de Navarra. E.G. had a fellowship from the Basque Department of Education, Universities, and Research. The authors thank the Linea Especial (University of Navarra; LE/97), the Spanish Ministerio de Ciencia e Innovacion (SAF2010-16887), and the Navarra Department of Health (RESMENA-S) and Department of Education for financial support. The authors thank all the volunteers who participated in this study. The authors also thank Enrique Buso [Unidad Central de Investigacion de la Facultad de Medicina (UCIM), University of Valencia, Spain] for his expert support and feedback. The authors declare no conflicts of interest.	Abete I, 2008, J HUM NUTR DIET, V21, P591, DOI 10.1111/j.1365-277X.2008.00902.x; Abete I, 2009, J MED FOOD, V12, P100, DOI 10.1089/jmf.2007.0700; Backdahl L, 2009, INT J BIOCHEM CELL B, V41, P176, DOI 10.1016/j.biocel.2008.08.023; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bertola A, 2009, DIABETES, V58, P125, DOI 10.2337/db08-0400; Bork S, 2010, AGING CELL, V9, P54, DOI 10.1111/j.1474-9726.2009.00535.x; Bouchard L, 2010, AM J CLIN NUTR, V91, P309, DOI 10.3945/ajcn.2009.28085; Campion J, 2009, OBES REV, V10, P383, DOI 10.1111/j.1467-789X.2009.00595.x; Campion J, 2010, PROG MOL BIOL TRANSL, V94, P291, DOI 10.1016/S1877-1173(10)94011-8; Campion J, 2009, OBESITY, V17, P1293, DOI 10.1038/oby.2008.679; Cerda S, 1997, MUTAT RES-REV MUTAT, V386, P141, DOI 10.1016/S1383-5742(96)00050-6; Crujeiras AB, 2008, OMICS, V12, P251, DOI 10.1089/omi.2008.0001; Dhar M, 2002, OBES RES, V10, P695, DOI 10.1038/oby.2002.94; Dhar MS, 2004, J NUTR, V134, P799, DOI 10.1093/jn/134.4.799; DuBose AJ, 2010, NEUROGENETICS, V11, P145, DOI 10.1007/s10048-009-0226-9; Fischbach BV, 2005, PEDIATRICS, V116, P984, DOI 10.1542/peds.2004-0467; Gallou-Kabani C, 2007, CLIN CHEM LAB MED, V45, P321, DOI 10.1515/CCLM.2007.081; Gluckman PD, 2008, INT J OBESITY, V32, pS62, DOI 10.1038/ijo.2008.240; Jackman MR, 2008, AM J PHYSIOL-REG I, V294, pR1117, DOI 10.1152/ajpregu.00808.2007; Konstantinidou V, 2010, FASEB J, V24, P2546, DOI 10.1096/fj.09-148452; Larsen TM, 2010, OBES REV, V11, P76, DOI 10.1111/j.1467-789X.2009.00603.x; Larsen TM, 2010, NEW ENGL J MED, V363, P2102, DOI 10.1056/NEJMoa1007137; Lillycrop KA, 2011, INT J OBESITY, V35, P72, DOI 10.1038/ijo.2010.122; Lomba A, 2010, MOL GENET METAB, V101, P273, DOI 10.1016/j.ymgme.2010.07.017; MacLean PS, 2009, AM J PHYSIOL-REG I, V297, pR793, DOI 10.1152/ajpregu.00192.2009; Margulies KB, 2009, CLIN CHEM, V55, P1897, DOI 10.1373/clinchem.2009.131649; Marti A, 2010, WORLD REV NUTR DIET, V101, P21, DOI 10.1159/000314508; McMillen IC, 2009, ADV EXP MED BIOL, V646, P71, DOI 10.1007/978-1-4020-9173-5_8; Milagro FI, 2009, J PHYSIOL BIOCHEM, V65, P1, DOI 10.1007/BF03165964; Mutch DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001344; Ostergaard M, 2004, BRIT J HAEMATOL, V125, P590, DOI 10.1111/j.1365-2141.2004.04952.x; Pogribny IP, 2009, J HEPATOL, V51, P176, DOI 10.1016/j.jhep.2009.03.021; Redinger Richard N, 2009, J Ky Med Assoc, V107, P211; Sansom OJ, 2007, NAT CLIN PRACT ONCOL, V4, P305, DOI 10.1038/ncponc0812; Satoh T, 2000, J GASTROEN HEPATOL, V15, P402, DOI 10.1046/j.1440-1746.2000.02164.x; Sigurdsson MI, 2009, EPIGENETICS-US, V4, P43, DOI 10.4161/epi.4.1.7603; Steege A, 2008, KIDNEY INT, V74, P458, DOI 10.1038/ki.2008.194; Thompson RF, 2010, EXP GERONTOL, V45, P255, DOI 10.1016/j.exger.2009.12.013; Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382; Tremblay A, 2005, INT J OBESITY, V29, P1295, DOI 10.1038/sj.ijo.0803019; Valledor L, 2007, PLANT CELL TISS ORG, V91, P75, DOI 10.1007/s11240-007-9262-z; Vaquero A, 2009, GENE DEV, V23, P1849, DOI 10.1101/gad.1807009; Wang CF, 2010, BRAIN RES, V1336, P66, DOI 10.1016/j.brainres.2010.04.013; Wang CF, 2010, AM J PHYSIOL-REG I, V298, pR1320, DOI 10.1152/ajpregu.00844.2009; Wang YL, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-59; Wardle J, 2008, AM J CLIN NUTR, V87, P398, DOI 10.1093/ajcn/87.2.398; Waterland RA, 2008, INT J OBESITY, V32, P1373, DOI 10.1038/ijo.2008.100; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Yang J, 2009, ANN NY ACAD SCI, V1177, P185, DOI 10.1111/j.1749-6632.2009.05027.x; Yang L, 2007, LEUKEMIA, V21, P868, DOI 10.1038/sj.leu.2404624	50	161	167	1	50	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1378	1389		10.1096/fj.10-170365	http://dx.doi.org/10.1096/fj.10-170365			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21209057				2022-12-28	WOS:000288982800027
J	Jia, WW; Wang, SW; Horner, JW; Wang, N; Wang, HY; Gunther, EJ; DePinho, RA; Zhu, JY				Jia, Wenwen; Wang, Shuwen; Horner, James W.; Wang, Ning; Wang, Huayan; Gunther, Edward J.; DePinho, Ronald A.; Zhu, Jiyue			A BAC transgenic reporter recapitulates in vivo regulation of human telomerase reverse transcriptase in development and tumorigenesis	FASEB JOURNAL			English	Article						transgenic mouse; hTERT gene; mammary tumor; bioluminescent imaging	MOUSE TELOMERASE; STEM-CELLS; CATALYTIC SUBUNIT; IMMORTAL CELLS; HTERT GENE; C-MYC; CANCER; EXPRESSION; MICE; ACTIVATION	Telomerase is tightly regulated in humans relative to mice, owing to the differential regulation of TERT genes. To explore hTERT regulation in vivo, we engineered mice with a 160-kb transgenic bacterial artificial chromosome (BAC) spanning the hTERT locus with a Renilla luciferase (Rluc) cassette downstream of its promoter. Analysis of multiple founder lines revealed that the Rluc expression profile from the transgenic hTERT reporter locus reproduced that of the native hTERT gene in all tissues and organs examined, demonstrating that genetic sequence determined the species-specific developmental regulation of the hTERT gene and that mouse epigenetic and transcription machineries faithfully regulated hTERT transcription. Thus, these mice allowed detailed analyses of developmental hTERT regulation. Both the transgenic hTERT reporter and the endogenous mTERT locus were expressed in early embryonic stages, and their mRNA levels progressively decreased throughout embryonic and postnatal development. Whereas hTERT transcription was much lower than mTERT expression in most organs, it increased significantly during postnatal development of thymus, testis, and ovary. In testis, the Rluc mRNA was enriched in elongating spermatids of seminiferous tubules. In addition, the transcription of transgenic hTERT reporter, but surprisingly not the endogenous mTERT gene, was activated during Wnt1-induced mammary tumorigenesis, allowing the monitoring of tumor development via noninvasive bioluminescent imaging. Collectively, our results demonstrate that the hTERT transgenic reporter system recapitulates the developmental regulation of the hTERT gene in a chromosomal position-independent manner and serves as a legitimate model to explore telomerase regulation in the development of normal and neoplastic tissues in vivo.-Jia, W., Wang, S., Horner, J. W., Wang, N., Wang, H., Gunther, E. J., DePinho, R. A., Zhu, J. A BAC transgenic reporter recapitulates in vivo regulation of human telomerase reverse transcriptase in development and tumorigenesis. FASEB J. 25, 979-989 (2011). www.fasebj.org	[Jia, Wenwen; Wang, Huayan] NW Agr & Forestry A&F Univ, Coll Vet Med, Shaanxi Ctr Stem Cell Engn & Technol, Yangling, Shaanxi, Peoples R China; [Jia, Wenwen; Wang, Shuwen; Wang, Ning; Zhu, Jiyue] Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; [Gunther, Edward J.] Penn State Univ, Coll Med, Jake Gittlen Canc Res Fdn, Hershey, PA 17033 USA; [Horner, James W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [DePinho, Ronald A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Zhu, JY (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr,C4605, Hershey, PA 17033 USA.	jozl@psu.edu	zhu, ji/HDM-1538-2022	DePinho, Ronald/0000-0002-5625-577X	U.S. National Institutes of Health [R21CA106470, R01GM071725]; Chinese National Programs for Fundamental Research and Development [2009CB941002]; Chinese Ministry of Education; NATIONAL CANCER INSTITUTE [R21CA106470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071725] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chinese National Programs for Fundamental Research and Development; Chinese Ministry of Education(Ministry of Education, China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Longgui Chen for technical assistance, Aimin Liu for RNA in situ hybridization, and Kang Li for the preparation of tissue cryosections. The authors also thank the Macromolecular and Molecular Genetics Core Facilities at Penn State College of Medicine for the excellent services. The work was supported in part by U.S. National Institutes of Health grants R21CA106470 and R01GM071725 (J.Z.), a 973 grant (2009CB941002) from the Chinese National Programs for Fundamental Research and Development (H.W.), and a Ph.D. student scholarship from the Chinese Ministry of Education (W.J.). None of the authors have professional or financial affiliations that can be perceived to bias the presentation of this work.	Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Bieche I, 2000, CLIN CANCER RES, V6, P452; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; Coussens M, 2006, BIOL REPROD, V75, P785, DOI 10.1095/biolreprod.106.052167; De Rooij DG, 1998, INT J EXP PATHOL, V79, P67, DOI 10.1046/j.1365-2613.1998.00057.x; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Ducrest AL, 2001, CANCER RES, V61, P7594; Forsyth NR, 2005, MECH AGEING DEV, V126, P685, DOI 10.1016/j.mad.2005.01.003; Gestl SA, 2007, MOL CELL BIOL, V27, P195, DOI 10.1128/MCB.01525-06; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Hammoud SS, 2009, NATURE, V460, P473, DOI 10.1038/nature08162; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HESS RA, 1998, ENCY REPROD, V4, P539; Horikawa L, 2005, P NATL ACAD SCI USA, V102, P18437, DOI 10.1073/pnas.0508964102; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Marion RM, 2009, CELL STEM CELL, V4, P141, DOI 10.1016/j.stem.2008.12.010; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Mathew R, 2010, FASEB J, V24, P2702, DOI 10.1096/fj.09-148973; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nash SR, 1998, RECEPTOR CHANNEL, V6, P113; Nissim S, 2007, DEV BIOL, V304, P9, DOI 10.1016/j.ydbio.2006.12.010; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Ritz JM, 2005, CANCER RES, V65, P1187, DOI 10.1158/0008-5472.CAN-04-3046; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Tanemura K, 2005, DEV BIOL, V281, P196, DOI 10.1016/j.ydbio.2005.02.025; Venteicher AS, 2009, SCIENCE, V323, P644, DOI 10.1126/science.1165357; Vooijs M, 2002, CANCER RES, V62, P1862; Wang SW, 2007, MOL BIOL CELL, V18, P669, DOI 10.1091/mbc.E06-09-0840; Wang SW, 2009, MOL BIOTECHNOL, V42, P110, DOI 10.1007/s12033-009-9142-3; Wang SW, 2004, GENE, V343, P69, DOI 10.1016/j.gene.2004.09.006; Wang SW, 2004, J BIOL CHEM, V279, P55401, DOI 10.1074/jbc.M411352200; Wang SW, 2003, J BIOL CHEM, V278, P18842, DOI 10.1074/jbc.M209544200; Weng NP, 2008, MECH AGEING DEV, V129, P60, DOI 10.1016/j.mad.2007.11.005; Wilson MD, 2008, SCIENCE, V322, P434, DOI 10.1126/science.1160930; Wright WE, 1996, DEV GENET, V18, P173; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhu JY, 2010, PROTEIN CELL, V1, P22, DOI 10.1007/s13238-010-0014-1	50	20	20	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					979	989		10.1096/fj.10-173989	http://dx.doi.org/10.1096/fj.10-173989			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21135040	Green Published			2022-12-28	WOS:000287806200018
J	Pan, D; Pramanik, M; Senpan, A; Allen, JS; Zhang, HY; Wickline, SA; Wang, LV; Lanza, GM				Pan, Dipanjan; Pramanik, Manojit; Senpan, Angana; Allen, John S.; Zhang, Huiying; Wickline, Samuel A.; Wang, Lihong V.; Lanza, Gregory M.			Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons	FASEB JOURNAL			English	Article						optoacoustics; molecular imaging; diagnostic imaging; gold nanoparticles	VX-2 RABBIT TUMORS; IN-VIVO; ALPHA(V)BETA(3); EXPRESSION; NANOPARTICLES; TOMOGRAPHY; NANOCAGES; NEOVASCULARIZATION; VASCULATURE; MELANOMA	Photoacoustic tomography (PAT) combines optical and acoustic imaging to generate high-resolution images of microvasculature. Inherent sensitivity to hemoglobin permits PAT to image blood vessels but precludes discriminating neovascular from maturing microvasculature. alpha(v)beta(3)-Gold nanobeacons (alpha(v)beta(3)-GNBs) for neovascular molecular PAT were developed, characterized, and demonstrated in vivo using a mouse Matrigel-plug model of angiogenesis. PAT results were microscopically corroborated with fluorescent alpha(v)beta(3)-GNB localization and supporting immunohistology in Rag1(tm1Mom) Tg(Tie-2-lacZ) 182-Sato mice. alpha(v)beta(3)-GNBs (154 nm) had 10-fold greater contrast than blood on an equivolume basis when imaged at 740 nm to 810 nm in blood. The lowest detectable concentration in buffer was 290 nM at 780 nm. Noninvasive PAT of angiogenesis using a 10-MHz ultrasound receiver with alpha(v)beta(3)-GNBs produced a 600% increase in signal in a Matrigel-plug mouse model relative to the inherent hemoglobin contrast pretreatment. In addition to increasing the contrast of neovessels detected at baseline, alpha(v)beta(3)-GNBs allowed visualization of numerous angiogenic sprouts and bridges that were undetectable before contrast injection. Competitive inhibition of alpha(v)beta(3)-GNBs with alpha(v)beta(3)-NBs (no gold particles) almost completely blocked contrast enhancement to pretreatment levels, similar to the signal from animals receiving saline only. Consistent with other studies, nontargeted GNBs passively accumulated in the tortuous neovascular but provided less than half of the contrast enhancement of the targeted agent. Microscopic studies revealed that the vascular constrained, rhodamine-labeled alpha(v)beta(3)-GNBs homed specifically to immature neovasculature (PECAM(+), Tie-2(-)) along the immediate tumor periphery, but not to nearby mature microvasculature (PECAM(+), Tie-2(+)). The combination of PAT and alpha(v)beta(3)-GNBs offered sensitive and specific discrimination and quantification of angiogenesis in vivo, which may be clinically applicable to a variety of highly prevalent diseases, including cancer and cardiovascular disease.-Pan, D., Pramanik, M., Senpan, A., Allen, J. S., Zhang, H., Wickline, S. A., Wang, L. V., Lanza, G. M. Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB J. 25, 875-882 (2011). www.fasebj.org	[Pan, Dipanjan; Senpan, Angana; Allen, John S.; Zhang, Huiying; Wickline, Samuel A.; Lanza, Gregory M.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63108 USA; [Pramanik, Manojit; Wickline, Samuel A.; Wang, Lihong V.; Lanza, Gregory M.] Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL)	Pan, D (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63108 USA.	dpan@dom.wustl.edu; lhwang@seas.wustl.edu	Wang, Lihong V./A-7147-2009; Pramanik, Manojit/F-7681-2013	Wang, Lihong V./0000-0001-9783-4383; Pramanik, Manojit/0000-0003-2865-5714; Pan, Dipanjan/0000-0003-0175-4704	American Heart Association [0835426N]; U.S. National Institutes of Health [NS059302, CA119342, HL073646, U54 CA136398, R01 EB000712, R01 EB008085]; Microphotoacoustics, Inc.; Endra, Inc.; NATIONAL CANCER INSTITUTE [U54CA119342, U54CA136398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB008085, R01EB000712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059302] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Microphotoacoustics, Inc.; Endra, Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors greatly appreciate the financial support from the American Heart Association (grant 0835426N, to D.P.) and the U.S. National Institutes of Health (grants NS059302 and CA119342, to G.M.L.; HL073646, to S.A.W.; and U54 CA136398, R01 EB000712, and R01 EB008085, to L.W.). L.W. has a financial interest in Microphotoacoustics, Inc., and Endra, Inc.; neither provided material, financial, or intellectual support. D.P., G.M.L., M.P., and L.V.W. conceived the research and contributed to the experimental design. D.P. and A.S.P. performed the chemical syntheses, and M.P. performed the PA imaging and postprocessing. J.S.A. and M.P. created and managed the Matrigel rodent model. All authors contributed analysis and interpretation of the data. D.P., M.P., and G.L. wrote the manuscript. All authors read and edited the manuscript.	BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Cho EC, 2009, J PHYS CHEM C, V113, P9023, DOI 10.1021/jp903343p; Choi HS, 2010, NAT NANOTECHNOL, V5, P42, DOI [10.1038/NNANO.2009.314, 10.1038/nnano.2009.314]; De La Zerda A, 2008, NAT NANOTECHNOL, V3, P557, DOI 10.1038/nnano.2008.231; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; Dupas B, 2001, INVEST RADIOL, V36, P509, DOI 10.1097/00004424-200109000-00002; Fathers KE, 2005, AM J PATHOL, V167, P1753, DOI 10.1016/S0002-9440(10)61256-4; Helluin O, 2000, J BIOL CHEM, V275, P18337, DOI 10.1074/jbc.M001529200; Hu G, 2007, INT J CANCER, V120, P1951, DOI 10.1002/ijc.22581; Hu J, 2005, GUT, V54, P1473, DOI 10.1136/gut.2005.070904; HU S, 2010, P SPIE, V7564; Imhof BA, 2006, NAT MED, V12, P171, DOI 10.1038/nm0206-171; Itoh H, 1997, J VASC SURG, V25, P1061, DOI 10.1016/S0741-5214(97)70130-7; Jose J, 2009, J BIOPHOTONICS, V2, P701, DOI 10.1002/jbio.200910025; Kageshita T, 2000, INT J CANCER, V89, P153, DOI 10.1002/(SICI)1097-0215(20000320)89:2<153::AID-IJC9>3.0.CO;2-1; Ku G, 2005, APPL OPTICS, V44, P770, DOI 10.1364/AO.44.000770; Ku G, 2004, PHYS MED BIOL, V49, P1329, DOI 10.1088/0031-9155/49/7/018; Lao YQ, 2008, PHYS MED BIOL, V53, P4203, DOI 10.1088/0031-9155/53/15/013; Laser Institute of America, 2000, Z13612000 ANSI LAS I; Li ML, 2008, P IEEE, V96, P481, DOI 10.1109/JPROC.2007.913515; Lungu GF, 2007, INT J ONCOL, V30, P45; Maslov K, 2005, OPT LETT, V30, P625, DOI 10.1364/OL.30.6.000625; Maslov K, 2008, OPT LETT, V33, P929, DOI 10.1364/OL.33.000929; Meoli DF, 2004, J CLIN INVEST, V113, P1684, DOI 10.1172/JCI200420352; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; Pan DPJ, 2010, BIOMATERIALS, V31, P4088, DOI 10.1016/j.biomaterials.2010.01.136; Pan DP, 2009, ANGEW CHEM INT EDIT, V48, P4170, DOI 10.1002/anie.200805947; Schmieder AH, 2005, MAGN RESON MED, V53, P621, DOI 10.1002/mrm.20391; Schmieder AH, 2008, FASEB J, V22, P4179, DOI 10.1096/fj.08-112060; Siphanto RI, 2005, OPT EXPRESS, V13, P89, DOI 10.1364/OPEX.13.000089; Siphanto RI, 2004, LASER SURG MED, V35, P354, DOI 10.1002/lsm.20100; Song KH, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2818045; Song KH, 2009, NANO LETT, V9, P183, DOI 10.1021/nl802746w; Song L, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976141; Wang LHV, 2005, P ANN INT IEEE EMBS, P190, DOI 10.1109/IEMBS.2005.1616374; Wang XD, 2003, NAT BIOTECHNOL, V21, P803, DOI 10.1038/nbt839; Wang XD, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192804; Weissleder R, 2001, BIOCONJUGATE CHEM, V12, P213, DOI 10.1021/bc000091p; Winter PM, 2008, FASEB J, V22, P2758, DOI 10.1096/fj.07-103929; Winter PM, 2006, ARTERIOSCL THROM VAS, V26, P2103, DOI 10.1161/01.ATV.0000235724.11299.76; Winter PM, 2003, CANCER RES, V63, P5838; Xiang LZ, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3078809; Xie XY, 2006, PROC SPIE, V6086, DOI 10.1117/12.645121; Xie XY, 2005, PROC SPIE, V5697, P107, DOI 10.1117/12.589670; Yavuz MS, 2009, NAT MATER, V8, P935, DOI [10.1038/NMAT2564, 10.1038/nmat2564]; Zhang EZ, 2009, PHYS MED BIOL, V54, P1035, DOI 10.1088/0031-9155/54/4/014	47	137	140	2	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					875	882		10.1096/fj.10-171728	http://dx.doi.org/10.1096/fj.10-171728			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21097518	Green Published			2022-12-28	WOS:000287806200008
J	Liang, WG; Ouyang, SY; Shaw, N; Joachimiak, A; Zhang, RG; Liu, ZJ				Liang, Wenguang; Ouyang, Songying; Shaw, Neil; Joachimiak, Andrzej; Zhang, Rongguang; Liu, Zhi-Jie			Conversion of D-ribulose 5-phosphate to D-xylulose 5-phosphate: new insights from structural and biochemical studies on human RPE	FASEB JOURNAL			English	Article						oxidative stress; pentose phospate pathway; metalloenzyme	PENTOSE-PHOSPHATE PATHWAY; ENZYME D-RIBULOSE-5-PHOSPHATE 3-EPIMERASE; SITE-DIRECTED MUTAGENESIS; OXIDATIVE-STRESS; SACCHAROMYCES-CEREVISIAE; HYDROGEN-PEROXIDE; MECHANISM; CHLOROPLASTS; REFINEMENT; PROTECTION	The pentose phosphate pathway (PPP) confers protection against oxidative stress by supplying NADPH necessary for the regeneration of glutathione, which detoxifies H2O2 into H2O and O-2. RPE functions in the PPP, catalyzing the reversible conversion of D-ribulose 5-phosphate to D-xylulose 5-phosphate and is an important enzyme for cellular response against oxidative stress. Here, using structural, biochemical, and functional studies, we show that human D-ribulose 5-phosphate 3-epimerase (hRPE) uses Fe2+ for catalysis. Structures of the binary complexes of hRPE with D-ribulose 5-phosphate and D-xylulose 5-phosphate provide the first detailed molecular insights into the binding mode of physiological ligands and reveal an octahedrally coordinated Fe2+ ion buried deep inside the active site. Human RPE folds into a typical (beta/alpha)(8) triosephosphate isomerase (TIM) barrel with a loop regulating access to the active site. Two aspartic acids are well positioned to carry out the proton transfers in an acid-base type of reaction mechanism. Interestingly, mutating Ser-10 to alanine almost abolished the enzymatic activity, while L12A and M72A mutations resulted in an almost 50% decrease in the activity. The binary complexes of hRPE reported here will aid in the design of small molecules for modulating the activity of the enzyme and altering flux through the PPP. -Liang, W., Ouyang, S., Shaw, N., Joachimiak, A., Zhang, R., Liu, Z-J. Conversion of D-ribulose 5-phosphate to D-xylulose 5-phosphate: new insights from structural and biochemical studies on human RPE. FASEB J. 25, 497-504 (2011). www.fasebj.org	[Liang, Wenguang; Ouyang, Songying; Shaw, Neil; Zhang, Rongguang; Liu, Zhi-Jie] Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China; [Liang, Wenguang] Chinese Acad Sci, Grad Univ, Beijing 100101, Peoples R China; [Joachimiak, Andrzej] Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; United States Department of Energy (DOE); Argonne National Laboratory	Liu, ZJ (corresponding author), Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China.	zjliu@ibp.ac.cn	Liu, Zhi-Jie/A-3946-2012	Liu, Zhi-Jie/0000-0001-7279-2893; Shaw, Neil/0000-0003-2722-9967	Ministry of Science and Technology of China [2006AA02A316, 2009DFB30310, 2006CB910901]; National Natural Science Foundation of China [30670427, 30721003]; Ministry of Health of China [2008ZX10404]; Chinese Academy of Sciences (CAS) [KSCX2-YW-R-127, INFO-115-D01-2009]; CAS [2010Y1SA1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM094585] Funding Source: NIH RePORTER	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Health of China; Chinese Academy of Sciences (CAS)(Chinese Academy of Sciences); CAS(Chinese Academy of Sciences); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Keming Tan (Structural Biology Center, Argonne National Laboratory) for the help in collecting anomalous data at the edge of Fe. This work was funded by the Ministry of Science and Technology of China (grants 2006AA02A316, 2009DFB30310, and 2006CB910901), the National Natural Science Foundation of China (grants 30670427 and 30721003), the Ministry of Health of China (grant 2008ZX10404), a Chinese Academy of Sciences (CAS) research grant (KSCX2-YW-R-127 and INFO-115-D01-2009), and a CAS fellowship for young international scientists (grant 2010Y1SA1). Crystallographic data were collected at beamline 19-ID of APS (Argonne National Laboratory).	Akana J, 2006, BIOCHEMISTRY-US, V45, P2493, DOI 10.1021/bi052474m; Caruthers J, 2006, PROTEINS, V62, P338, DOI 10.1002/prot.20764; Chen YR, 1999, J BIOL CHEM, V274, P2132, DOI 10.1074/jbc.274.4.2132; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DAVIS L, 1972, J BIOL CHEM, V247, P5862; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; He Y, 2007, ACTA CRYSTALLOGR D, V63, P793, DOI 10.1107/S0907444907023451; Herrmann KM, 1999, ANNU REV PLANT PHYS, V50, P473, DOI 10.1146/annurev.arplant.50.1.473; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jelakovic S, 2003, J MOL BIOL, V326, P127, DOI 10.1016/S0022-2836(02)01374-8; Juhnke H, 1996, MOL GEN GENET, V252, P456, DOI 10.1007/BF02173011; Kopp J, 1999, J MOL BIOL, V287, P761, DOI 10.1006/jmbi.1999.2643; Kruger NJ, 2003, CURR OPIN PLANT BIOL, V6, P236, DOI 10.1016/S1369-5266(03)00039-6; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ng CH, 2008, FREE RADICAL BIO MED, V44, P1131, DOI 10.1016/j.freeradbiomed.2007.12.008; Nowitzki U, 1995, PLANT MOL BIOL, V29, P1279, DOI 10.1007/BF00020468; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Tan SX, 2009, MOL BIOL CELL, V20, P1493, DOI 10.1091/mbc.E08-07-0697; Temple MD, 2005, TRENDS CELL BIOL, V15, P319, DOI 10.1016/j.tcb.2005.04.003; Terwilliger TC, 2008, ACTA CRYSTALLOGR D, V64, P61, DOI 10.1107/S090744490705024X; Thorpe GW, 2004, P NATL ACAD SCI USA, V101, P6564, DOI 10.1073/pnas.0305888101; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; WILLIAMSON WT, 1966, METHODS ENZYMOLOGY, V9; Wise EL, 2004, ACTA CRYSTALLOGR D, V60, P1687, DOI 10.1107/S0907444904015896; WOOD T, 1986, CELL BIOCHEM FUNCT, V4, P241, DOI 10.1002/cbf.290040403	26	16	18	5	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					497	504		10.1096/fj.10-171207	http://dx.doi.org/10.1096/fj.10-171207			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20923965	Green Published			2022-12-28	WOS:000286724800008
J	Pasmant, E; Sabbagh, A; Vidaud, M; Bieche, I				Pasmant, Eric; Sabbagh, Audrey; Vidaud, Michel; Bieche, Ivan			ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS	FASEB JOURNAL			English	Review						long ncRNA; susceptibility locus; p15/CDKN2B-p16/CDKN2A-p14/ARF gene cluster	GENOME-WIDE ASSOCIATION; CORONARY-ARTERY-DISEASE; INTRACRANIAL ANEURYSM; SUSCEPTIBILITY LOCI; IDENTIFIES 3; RISK; MELANOMA; EXPRESSION; DELETION	A large noncoding RNA called ANRIL (for antisense noncoding RNA in the INK4 locus) has been identified within the p15/CDKN2B-p16/CDKN2A-p14/ARF gene cluster. While the exact role of ANRIL awaited further elucidation, common disease genome-wide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. Expression studies have confirmed the coregulation of p15/CDKN2B, p16/CDKN2A, p14/ARF, and ANRIL. Among the cluster, ANRIL expression showed the strongest association with the multiple phenotypes linked to the 9p21.3 region. More recent GWAS also identified ANRIL as a risk locus for gliomas and basal cell carcinomas in accordance with the princeps observation. Moreover, a mouse model has confirmed the pivotal role of ANRIL in regulation of CDKN2A/B expression through a cis-acting mechanism and its implication in proliferation and senescence. The implication of ANRIL in cellular aging has provided an attractive unifying hypothesis to explain its association with various susceptibility risk factors. ANRIL identification emphasizes the underestimated role of long noncoding RNAs. Many GWAS have identified trait-associated SNPs that felt in noncoding genomic regions. It is conceivable to anticipate that long, noncoding RNAs will map to many of these "gene deserts."-Pasmant, E., Sabbagh, A., Vidaud, M., Bieche, I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 25, 444-448 (2011). www.fasebj.org	[Pasmant, Eric; Sabbagh, Audrey; Vidaud, Michel; Bieche, Ivan] Univ Paris 05, INSERM, UMR745, Fac Sci Pharmaceut & Biol, F-75006 Paris, France; [Pasmant, Eric; Sabbagh, Audrey; Vidaud, Michel; Bieche, Ivan] Hop Beaujon, Serv Biochim & Genet, Clichy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Pasmant, E (corresponding author), Univ Paris 05, INSERM, UMR745, Fac Sci Pharmaceut & Biol, 4 Ave Observ, F-75006 Paris, France.	eric.pasmant@gmail.com	Pasmant, Eric/O-7249-2017; Bièche, Ivan/O-7399-2017; Vidaud, Michel/O-7346-2017	Pasmant, Eric/0000-0002-1881-8762; Bièche, Ivan/0000-0002-2430-5429; SABBAGH, Audrey/0000-0003-0283-8803				Bei JX, 2010, NAT GENET, V42, P599, DOI 10.1038/ng.601; Berezikov E, 2006, NAT GENET, V38, pS2, DOI 10.1038/ng1794; Bilguvar K, 2008, NAT GENET, V40, P1472, DOI 10.1038/ng.240; Broadbent HM, 2008, HUM MOL GENET, V17, P806, DOI 10.1093/hmg/ddm352; Cunnington MS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000899; Folkersen L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007677; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Helgadottir A, 2008, NAT GENET, V40, P217, DOI 10.1038/ng.72; Holdt LM, 2010, ARTERIOSCL THROM VAS, V30, P620, DOI 10.1161/ATVBAHA.109.196832; Jarinova O, 2009, ARTERIOSCL THROM VAS, V29, P1671, DOI 10.1161/ATVBAHA.109.189522; KAUFMAN DK, 1993, NEUROLOGY, V43, P1728, DOI 10.1212/WNL.43.9.1728; Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092; Liu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005027; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; Mattick JS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000459; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; MESSAOUDIAUBERT SE, 2010, NAT STRUCT MOL BIOL, V17, P862, DOI DOI 10.1038/NSMB.1824; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; Popov N, 2010, EPIGENETICS-US, V5, P685, DOI 10.4161/epi.5.8.12996; Rodriguez C, 2010, BIOCHEM BIOPH RES CO, V392, P129, DOI 10.1016/j.bbrc.2009.12.159; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241; Shete S, 2009, NAT GENET, V41, P899, DOI 10.1038/ng.407; Stacey SN, 2009, NAT GENET, V41, P909, DOI 10.1038/ng.412; Turnbull C, 2010, NAT GENET, V42, P504, DOI 10.1038/ng.586; Visel A, 2010, NATURE, V464, P409, DOI 10.1038/nature08801; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Yasuno K, 2010, NAT GENET, V42, P420, DOI 10.1038/ng.563; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364	30	346	371	0	52	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					444	448		10.1096/fj.10-172452	http://dx.doi.org/10.1096/fj.10-172452			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20956613				2022-12-28	WOS:000286724800003
J	Brekhman, V; Lugassie, J; Zaffryar-Eilot, S; Sabo, E; Kessler, O; Smith, V; Golding, H; Neufeld, G				Brekhman, Vera; Lugassie, Jennie; Zaffryar-Eilot, Shelly; Sabo, Edmond; Kessler, Ofra; Smith, Victoria; Golding, Hana; Neufeld, Gera			Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2	FASEB JOURNAL			English	Article						LOXL2; RAMP3; invasion; tumor progression	TUMOR PROGRESSION; CANCER-CELLS; CALCITONIN RECEPTOR; MOLECULAR ROLE; IN-VIVO; ADRENOMEDULLIN; AMYLIN; GROWTH; INVASION; ANGIOGENESIS	Lysyl oxidase-like protein-2 (LOXL2) induces epithelial to mesenchymal transition and promotes invasiveness. To understand the mechanisms involved, we examined the effect of LOXL2 overexpression in MCF-7 cells on gene expression. We found that LOXL2 up-regulated the expression of receptor activity modifying protein-3 (RAMP3). Expression of RAMP3 in MDA-MB-231 cells in which LOXL2 expression was inhibited restored vimentin expression, invasiveness, and tumor development. Inhibition of RAMP3 expression in MDA-MB-231 cells mimicked the effects produced by inhibition of LOXL2 expression and was accompanied by inhibition of p38 phosphorylation. LOXL2 overexpression in these cells did not restore invasiveness, suggesting that RAMP3 functions downstream to LOXL2. LOXL2 and RAMP3 are strongly coexpressed in human colon, breast, and gastric carcinomas but not in normal colon or gastric epithelial cells. RAMP3 associates with several G-protein-coupled receptors forming receptors for peptides, such as adrenomedullin and amylin. We hypothesized that RAMP3 could function as a transducer of autocrine signals induced by such peptides. However, the proinvasive effects of RAMP3 could not be abrogated following inhibition of the expression or activity of these peptides. Our experiments suggest that the protumorigenic effects of LOXL2 are partially mediated by RAMP3 and that RAMP3 inhibitors may function as antitumorigenic agents.-Brekhman, V., Lugassie, J., Zaffryar-Eilot, S., Sabo, E., Kessler, O., Smith, V., Golding, H., Neufeld, G. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2. FASEB J. 25, 55-65 (2011). www.fasebj.org	[Brekhman, Vera; Lugassie, Jennie; Zaffryar-Eilot, Shelly; Sabo, Edmond; Kessler, Ofra; Neufeld, Gera] Technion Israel Inst Technol, Canc Res & Vasc Biol Ctr, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; [Sabo, Edmond] Rambam Med Ctr, Haifa, Israel; [Smith, Victoria] Arresto Biosci Inc, Palo Alto, CA USA; [Golding, Hana] Food & Drug Adm, Ctr Biol Evaluat & Res, Bethesda, MD USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; US Food & Drug Administration (FDA)	Neufeld, G (corresponding author), Technion Israel Inst Technol, Canc Res & Vasc Biol Ctr, Bruce Rappaport Fac Med, POB 9679,1 Efron St, IL-31096 Haifa, Israel.	gera@tx.technion.ac.il	Neufeld, Gera/F-1524-2019		Arresto Biosciences Inc. (Palo Alto, CA, USA); U.S. Army [W81XWH-04-1-0430]	Arresto Biosciences Inc. (Palo Alto, CA, USA); U.S. Army(United States Department of DefenseUnited States Army)	This work was funded, in part, by a grant from Arresto Biosciences Inc. (Palo Alto, CA, USA; G.N.) and in part by a grant from the U.S. Army (W81XWH-04-1-0430; G.N. and H. G.). The authors thank Dr. Scott Ogg for critically reading the manuscript. The authors thank Dr. Robert Kerbel (Women's College Health Sciences Centre, Toronto, ON, Canada) and Dr. Israel Vlodavsky (Faculty of Medicine, Technion, Haifa, Israel) for gifts of cells.	Akiri G, 2003, CANCER RES, V63, P1657; Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; BAE SN, 1993, BREAST CANCER RES TR, V24, P241, DOI 10.1007/BF01833264; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Born W, 2002, RECEPTOR CHANNEL, V8, P201, DOI 10.1080/10606820213683; Bouschet T, 2005, J CELL SCI, V118, P4709, DOI 10.1242/jcs.02598; BOYER B, 1989, INT J CANCER, P69; Brekhman V, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-415; DEEMS RO, 1991, BIOCHEM BIOPH RES CO, V181, P116, DOI 10.1016/S0006-291X(05)81389-0; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663; Gibbons C, 2007, MOL ENDOCRINOL, V21, P783, DOI 10.1210/me.2006-0156; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; Harikumar KG, 2009, BIOCHEMISTRY-US, V48, P11773, DOI 10.1021/bi901326k; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kigel B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003287; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kumar B, 2010, CANCER RES, V70, P832, DOI 10.1158/0008-5472.CAN-09-2918; Lerner U. H., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P87; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Matsushita A, 2007, CANCER RES, V67, P10309, DOI 10.1158/0008-5472.CAN-07-3256; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924; Munoz R, 2006, CANCER RES, V66, P3386, DOI 10.1158/0008-5472.CAN-05-4411; Nakamura M, 2006, CURR CANCER DRUG TAR, V6, P635, DOI 10.2174/156800906778742442; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Parameswaran N, 2006, TRENDS BIOCHEM SCI, V31, P631, DOI 10.1016/j.tibs.2006.09.006; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Peng L, 2009, CARCINOGENESIS, V30, P1660, DOI 10.1093/carcin/bgp178; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Piao FL, 2004, REGUL PEPTIDES, V117, P159, DOI 10.1016/j.regpep.2003.10.005; Popa I, 2007, INT IMMUNOL, V19, P1249, DOI 10.1093/intimm/dxm092; Samonina G.E., 2004, Pathophysiology, V11, P1, DOI 10.1016/j.pathophys.2003.10.008; Schietke R. E., 2009, J BIOL CHEM; Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408; Wookey PJ, 2006, THESCIENTIFICWORLDJO, V6, P1642, DOI 10.1100/tsw.2006.263	43	35	36	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					55	65		10.1096/fj.10-162677	http://dx.doi.org/10.1096/fj.10-162677			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20802105				2022-12-28	WOS:000285869500006
J	Huijbers, EJM; Ringvall, M; Femel, J; Kalamajski, S; Lukinius, A; Abrink, M; Hellman, L; Olsson, AK				Huijbers, Elisabeth J. M.; Ringvall, Maria; Femel, Julia; Kalamajski, Sebastian; Lukinius, Agneta; Abrink, Magnus; Hellman, Lars; Olsson, Anna-Karin			Vaccination against the extra domain-B of fibronectin as a novel tumor therapy	FASEB JOURNAL			English	Article						therapeutic; immunization; neovascularization; extracellular matrix; angiogenesis	HUMAN-ANTIBODY; ISOFORM; ANGIOGENESIS; MARKER; EXPRESSION; MICE; NEOVASCULATURE; RESPONSES; CELLS; IGE	Monoclonal antibody-based therapies have made an important contribution to current treatment strategies for cancer and autoimmune disease. However, the cost for these new drugs puts a significant strain on the health-care economy, resulting in limited availability for patients. Therapeutic vaccination, defined as induction of immunity against a disease-related self-molecule, is therefore an attractive alternative. To analyze the potential of such an approach, we have developed a vaccine against the extra domain-B (ED-B) of fibronectin. This 91-aa domain, inserted by alternative splicing, is expressed during vasculogenesis in the embryo, but essentially undetectable under normal conditions in the adult. However, ED-B is highly expressed around angiogenic vasculature, such as in tumorigenesis. Here, we demonstrate that it is possible to break self-tolerance and induce a strong antibody response against ED-B by vaccination. Nineteen of 20 vaccinated mice responded with production of anti-ED-B antibodies and displayed a 70% reduction in tumor size compared to those lacking anti-ED-B antibodies. Analysis of the tumor tissue revealed that immunization against ED-B induced several changes, consistent with an attack by the immune system. These data show that tumor vascular antigens are highly interesting candidates for development of therapeutic vaccines targeting solid tumors.-Huijbers, E. J. M., Ringvall, M., Femel, J., Kalamajski, S., Lukinius, A., Abrink, M., Hellman, L., Olsson, A.-K. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J. 24, 4535-4544 (2010). www.fasebj.org	[Olsson, Anna-Karin] Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, SE-75123 Uppsala, Sweden; [Hellman, Lars] Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, SE-75123 Uppsala, Sweden; [Lukinius, Agneta] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75123 Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University	Olsson, AK (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, Husargatan 3,Box 582, SE-75123 Uppsala, Sweden.	anna-karin.olsson@imbim.uu.se	Åbrink, Magnus/AAK-8346-2020; Huijbers, Elisabeth J.M./K-7764-2013	Huijbers, Elisabeth J.M./0000-0002-7742-9839; Kalamajski, Sebastian/0000-0002-6600-9302; Abrink, Magnus/0000-0002-1335-3927	Swedish Research Council; Swedish Cancer Society; Swedish Society of Medicine; Jeansson's Foundation; Ake Wiberg Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Society of Medicine; Jeansson's Foundation; Ake Wiberg Foundation	The authors thank Dr. Lene Uhrbom (Department of Genetics and Pathology, Uppsala University) for providing tissue sections of normal mouse brain and glioma and Prof. Dario Neri (Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland) for providing SIP anti-ED-B antibodies. The authors also thank Prof. Wilhelm Jahnen-Dechent and Dr. Daniela Dreymuller (Institute for Biomedical Engineering, RWTH Aachen, Aachen, Germany) for generously teaching us the wound-healing model. Financial support was provided by The Swedish Research Council, The Swedish Cancer Society, The Swedish Society of Medicine, Jeansson's Foundation, and the Ake Wiberg Foundation.	[Anonymous], 1988, LAB ANIM-UK, V22, P195; Astrof S, 2009, ANGIOGENESIS, V12, P165, DOI 10.1007/s10456-009-9136-6; Birchler MT, 2003, LARYNGOSCOPE, V113, P1231, DOI 10.1097/00005537-200307000-00023; BurtonWurster N, 1997, MATRIX BIOL, V15, P441, DOI 10.1016/S0945-053X(97)90018-4; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.3.CO;2-D; Castellani P, 2002, AM J PATHOL, V161, P1695, DOI 10.1016/S0002-9440(10)64446-X; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; Demartis S, 2001, EUR J NUCL MED, V28, P534, DOI 10.1007/s002590100480; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Halin C, 2002, NAT BIOTECHNOL, V20, P264, DOI 10.1038/nbt0302-264; Haller BK, 2010, ONCOGENE, V29, P4276, DOI 10.1038/onc.2010.176; HAUPTMANN S, 1995, LAB INVEST, V73, P172; HELLMAN L, 1994, EUR J IMMUNOL, V24, P415, DOI 10.1002/eji.1830240222; Hellman L, 2008, EXPERT REV VACCINES, V7, P193, DOI 10.1586/14760584.7.2.193; KACZMAREK J, 1994, INT J CANCER, V59, P11, DOI 10.1002/ijc.2910590104; Le Buanec H, 2007, VACCINE, V25, P7206, DOI 10.1016/j.vaccine.2007.07.029; Ma YB, 2007, AM J RESP CRIT CARE, V176, P439, DOI 10.1164/rccm.200610-1405OC; Magnusson SE, 2009, FASEB J, V23, P875, DOI 10.1096/fj.08-120394; Midulla M, 2000, CANCER RES, V60, P164; Neri D, 2005, NAT REV CANCER, V5, P436, DOI 10.1038/nrc1627; Peters JH, 1996, CELL ADHES COMMUN, V4, P127, DOI 10.3109/15419069609010767; Ridolfi L, 2009, IMMUNOBIOLOGY, V214, P61, DOI 10.1016/j.imbio.2008.03.003; Ringvall M, 2009, VACCINE, V28, P48, DOI 10.1016/j.vaccine.2009.09.122; Santimaria M, 2003, CLIN CANCER RES, V9, P571; Sauer S, 2009, BLOOD, V113, P2265, DOI 10.1182/blood-2008-06-160416; Schliemann C, 2009, BLOOD, V113, P2275, DOI 10.1182/blood-2008-05-160747; Tarli L, 1999, BLOOD, V94, P192, DOI 10.1182/blood.V94.1.192.413k22_192_198; Tchougounova E, 2009, ONCOGENE, V28, P1537, DOI 10.1038/onc.2009.9; Vernersson M, 2002, FASEB J, V16, P875, DOI 10.1096/fj.01-0879fje; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	31	36	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4535	4544		10.1096/fj.10-163022	http://dx.doi.org/10.1096/fj.10-163022			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20634349				2022-12-28	WOS:000283861100038
J	Namkung, W; Thiagarajah, JR; Phuan, PW; Verkman, AS				Namkung, Wan; Thiagarajah, Jay R.; Phuan, Puay-Wah; Verkman, A. S.			Inhibition of Ca2+-activated Cl- channels by gallotannins as a possible molecular basis for health benefits of red wine and green tea	FASEB JOURNAL			English	Article						CaCC; TMEM16A; tannic acid; CFTR; diarrhea; hypertension	AGE-DEPENDENT DIARRHEA; TMEM16A; BIOAVAILABILITY; EXPRESSION; OXIDATION; FAMILY; CELLS	TMEM16A was found recently to be a calcium-activated Cl- channel (CaCC). CaCCs perform important functions in cell physiology, including regulation of epithelial secretion, cardiac and neuronal excitability, and smooth muscle contraction. CaCC modulators are of potential utility for treatment of hypertension, diarrhea, and cystic fibrosis. Screening of drug and natural product collections identified tannic acid as an inhibitor of TMEM16A, with IC50 similar to 6 mu M and similar to 100% inhibition at higher concentrations. Tannic acid inhibited CaCCs in multiple cell types but did not affect CFTR Cl- channels. Structure-activity analysis indicated the requirement of gallic or digallic acid substituents on a macromolecular scaffold (gallotannins), as are present in green tea and red wine. Other polyphenolic components of teas and wines, including epicatechin, catechin, and malvidin-3-glucoside, poorly inhibited CaCCs. Remarkably, a 1000-fold dilution of red wine and 100-fold dilution of green tea inhibited CaCCs by >50%. Tannic acid, red wine, and green tea inhibited arterial smooth muscle contraction and intestinal Cl- secretion. Gallotannins are thus potent CaCC inhibitors whose biological activity provides a potential molecular basis for the cardioprotective and antisecretory benefits of red wine and green tea.-Namkung, W., Thiagarajah, J. R., Phuan, P.-W., Verkman, A. S. Inhibition of Ca2+-activated Cl- channels by gallotannins as a possible molecular basis for health benefits of red wine and green tea. FASEB J. 24, 4178-4186 (2010). www.fasebj.org	[Verkman, A. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu			U.S. National Institutes of Health [HL73856, DK72517, DK86125, DK35124, EB00415, EY13574]; Cystic Fibrosis Foundation; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, P30DK072517, R01DK035124, RC1DK086125] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants HL73856, DK72517, DK86125, DK35124, EB00415, and EY13574, and Research Development Program and Drug Discovery grants from the Cystic Fibrosis Foundation.	Actis-Goretta L, 2006, J AGR FOOD CHEM, V54, P229, DOI 10.1021/jf052263o; Aviram M, 2002, ANN NY ACAD SCI, V957, P146, DOI 10.1111/j.1749-6632.2002.tb02913.x; Ball JM, 1996, SCIENCE, V272, P101, DOI 10.1126/science.272.5258.101; Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518; Cordova AC, 2005, J AM COLL SURGEONS, V200, P428, DOI 10.1016/j.jamcollsurg.2004.10.030; Criddle DN, 1996, BRIT J PHARMACOL, V118, P1065, DOI 10.1111/j.1476-5381.1996.tb15507.x; Crozier A, 2009, NAT PROD REP, V26, P1001, DOI 10.1039/b802662a; DROOGMANS G, 1991, J PHYSIOL-LONDON, V440, P623, DOI 10.1113/jphysiol.1991.sp018728; Dufresne CJ, 2001, J NUTR BIOCHEM, V12, P404, DOI 10.1016/S0955-2863(01)00155-3; Eggermont Jan, 2004, Proc Am Thorac Soc, V1, P22, DOI 10.1513/pats.2306010; FITZPATRICK DF, 1993, AM J PHYSIOL, V265, pH774; Flesch M, 1998, AM J PHYSIOL-HEART C, V275, pH1183, DOI 10.1152/ajpheart.1998.275.4.H1183; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; Galietta LJV, 2009, BIOPHYS J, V97, P3047, DOI 10.1016/j.bpj.2009.09.024; Gomez-Pinilla PJ, 2009, AM J PHYSIOL-GASTR L, V296, pG1370, DOI 10.1152/ajpgi.00074.2009; Hartzell HC, 2009, J PHYSIOL-LONDON, V587, P2127, DOI 10.1113/jphysiol.2008.163709; Huang F, 2009, P NATL ACAD SCI USA, V106, P21413, DOI 10.1073/pnas.0911935106; Kunzelmann K, 2009, CELL CALCIUM, V46, P233, DOI 10.1016/j.ceca.2009.09.003; Loewen ME, 2005, PHYSIOL REV, V85, P1061, DOI 10.1152/physrev.00016.2004; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; MAXWELL S, 1994, LANCET, V344, P193, DOI 10.1016/S0140-6736(94)92795-2; Moore RJ, 2009, BRIT J NUTR, V102, P1790, DOI 10.1017/S0007114509991218; Morris AP, 1999, AM J PHYSIOL-GASTR L, V277, pG431, DOI 10.1152/ajpgi.1999.277.2.G431; Namkung W, 2009, J BIOL CHEM, V284, P15916, DOI 10.1074/jbc.M808021200; Nelson MT, 1997, J PHYSIOL-LONDON, V502, P259, DOI 10.1111/j.1469-7793.1997.259bk.x; Ousingsawat J, 2009, J BIOL CHEM, V284, P28698, DOI 10.1074/jbc.M109.012120; Palombo EA, 2006, PHYTOTHER RES, V20, P717, DOI 10.1002/ptr.1907; POWELL DW, 1980, SECRETORY DIARRHEA, P187; Rock JR, 2008, DEV BIOL, V321, P141, DOI 10.1016/j.ydbio.2008.06.009; Rock JR, 2009, J BIOL CHEM, V284, P14875, DOI 10.1074/jbc.C109.000869; Rolfe VE, 1997, J PHYSIOL-LONDON, V503, P347, DOI 10.1111/j.1469-7793.1997.347bh.x; Sayer B, 2002, BRIT J PHARMACOL, V135, P1794, DOI 10.1038/sj.bjp.0704633; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096; Schroeder BC, 2008, CELL, V134, P1019, DOI 10.1016/j.cell.2008.09.003; Sumpio BE, 2006, J AM COLL SURGEONS, V202, P813, DOI 10.1016/j.jamcollsurg.2006.01.018; Verkman AS, 2009, NAT REV DRUG DISCOV, V8, P153, DOI 10.1038/nrd2780; Waterhouse AL, 2002, ANN NY ACAD SCI, V957, P21, DOI 10.1111/j.1749-6632.2002.tb02903.x; Yang CS, 2008, MOL NUTR FOOD RES, V52, pS139, DOI 10.1002/mnfr.200700234; Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313	40	153	162	2	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4178	4186		10.1096/fj.10-160648	http://dx.doi.org/10.1096/fj.10-160648			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20581223	Green Published			2022-12-28	WOS:000283861100006
J	Stenger, C; Hanse, M; Pratte, D; Mbala, ML; Akbar, S; Koziel, V; Escanye, MC; Kriem, B; Malaplate-Armand, C; Olivier, JL; Oster, T; Pillot, T; Yen, FT				Stenger, Christophe; Hanse, Marine; Pratte, Dagmar; Mbala, Marie-Ludvine; Akbar, Samina; Koziel, Violette; Escanye, Marie-Christine; Kriem, Badreddine; Malaplate-Armand, Catherine; Olivier, Jean-Luc; Oster, Thierry; Pillot, Thierry; Yen, Frances T.			Up-regulation of hepatic lipolysis stimulated lipoprotein receptor by leptin: a potential lever for controlling lipid clearance during the postprandial phase	FASEB JOURNAL			English	Article						leptin receptor; liver; adipose tissue; peripheral leptin resistance	TRIGLYCERIDE-RICH LIPOPROTEINS; CENTRAL-NERVOUS-SYSTEM; ACTIVATED PROTEIN-KINASE; WEIGHT-GAIN; MICE; OBESE; METABOLISM; EXPRESSION; LIPEMIA; LIVER	As a hepatic receptor for triglyceriderich lipoproteins, the lipolysis-stimulated lipoprotein receptor (LSR) may be involved in the dynamics of lipid distribution between the liver and peripheral tissues. Here, we explore the potential role of leptin in regulating LSR. At physiological concentrations (1-10 ng/ml), leptin increased LSR protein and mRNA levels in Hepa1-6 cells through an ERK1/2-dependent and alpha-amanitin-sensitive pathway. In vivo, leptin treatment of C57BL6/Rj mice (1 mu g 2 x /d, 8 d) led to a significant increase in hepatic LSR mRNA and protein, decreased liver triglycerides and increased VLDL secretion as compared to controls. LSR+/- mice with elevated postprandial lipemia placed on a high-fat (60% kcal) diet exhibited accelerated weight gain and increased fat mass as compared to controls. While plasma leptin levels were increased 3-fold, hepatic leptin receptor protein levels and phosphorylation of ERK1/2 were significantly reduced. Therefore, leptin is an important regulator of LSR protein levels providing the means for the control of hepatic uptake of lipids during the postprandial phase. However, this may no longer be functional in LSR+/- mice placed under a chronic dietary fat load, suggesting that this animal model could be useful for the study of molecular mechanisms involved in peripheral leptin resistance.-Stenger, C., Hanse, M., Pratte, D., Mbala, M.-L., Akbar, S., Koziel, V., Escanye, M.-C., Kriem, B., Malaplate-Armand, C., Olivier, J.-L., Oster, T., Pillot, T., Yen, F. T. Upregulation of hepatic lipolysis stimulated lipoprotein receptor by leptin: a potential lever for controlling lipid clearance during the postprandial phase. FASEB J. 24, 4218-4228 (2010). www.fasebj.org	[Stenger, Christophe; Hanse, Marine; Pratte, Dagmar; Mbala, Marie-Ludvine; Akbar, Samina; Koziel, Violette; Escanye, Marie-Christine; Kriem, Badreddine; Malaplate-Armand, Catherine; Olivier, Jean-Luc; Oster, Thierry; Pillot, Thierry; Yen, Frances T.] Nancy Univ, INPL, ENSAIA, ENSALA, F-54501 Vandoeuvre Les Nancy, France; [Escanye, Marie-Christine; Malaplate-Armand, Catherine; Olivier, Jean-Luc] CHU, Dept Clin Biochem, Nancy, France; [Pillot, Thierry] Univ Paul Verlaine, UFR SciFA, Metz, France	Universite de Lorraine; CHU de Nancy; Universite de Lorraine	Yen, FT (corresponding author), Nancy Univ, INPL, ENSAIA, ENSALA, 2 Ave Foret Haye, F-54501 Vandoeuvre Les Nancy, France.	frances.yenpotin@ensaia.inpl-nancy.fr	Olivier, Jean luc/AAQ-2721-2021; Yen, Frances T/G-9175-2014	Yen, Frances T/0000-0001-8740-4304	Region Lorraine and Nancy University-Institut National Polytechnique de Lorraine; Ministry of Research and Higher Education; French Ministry of Higher Education and Research, Nancy University-INPL; Council for the Lorraine Region; Nancy Commune	Region Lorraine and Nancy University-Institut National Polytechnique de Lorraine(Region Grand-Est); Ministry of Research and Higher Education(Ministry of Research and Technology of the Republic of Indonesia (RISTEK)); French Ministry of Higher Education and Research, Nancy University-INPL; Council for the Lorraine Region(Region Grand-Est); Nancy Commune	C.S. and M.H. contributed equally to this work. C.S. received funding from the Region Lorraine and Nancy University-Institut National Polytechnique de Lorraine [Bonus Qualite Recherche (BQR)], and M.H. received funding from the Ministry of Research and Higher Education (thesis fellowship). This work was funded in part by the French Ministry of Higher Education and Research, Nancy University-INPL (BQR grant), and grants from local government agencies, including the Council for the Lorraine Region and the Nancy Commune.	ATTIE AD, 1982, HEPATOLOGY, V2, P269; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Boquist S, 1999, CIRCULATION, V100, P723, DOI 10.1161/01.CIR.100.7.723; Butler AA, 2010, DIABETES, V59, P323, DOI 10.2337/db09-1471; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Cohen P, 2005, J BIOL CHEM, V280, P10034, DOI 10.1074/jbc.M413684200; Couillard C, 1998, DIABETES, V47, P953, DOI 10.2337/diabetes.47.6.953; Cui H, 2006, FASEB J, V20, P2654, DOI 10.1096/fj.06-5989fje; DONAHOO WT, 2010, METABOLISM, DOI DOI 10.1016/J.METABOL.2010.03.01; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Garza JC, 2008, J BIOL CHEM, V283, P18238, DOI 10.1074/jbc.M800053200; GROOT PHE, 1991, ARTERIOSCLER THROMB, V11, P653, DOI 10.1161/01.ATV.11.3.653; Guerci B, 2000, INT J OBESITY, V24, P468, DOI 10.1038/sj.ijo.0801181; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; Irigaray P, 2006, FEBS J, V273, P1362, DOI 10.1111/j.1742-4658.2006.05159.x; Jiang L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006884; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Leshan RL, 2006, OBESITY, V14, P208, DOI 10.1038/oby.2006.310; LEWIS GF, 1990, J CLIN ENDOCR METAB, V71, P1041, DOI 10.1210/jcem-71-4-1041; MacArthur JM, 2007, J CLIN INVEST, V117, P153, DOI 10.1172/JCI29154; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mahley RW, 2007, J CLIN INVEST, V117, P94, DOI 10.1172/JCI30889; Mekki N, 1999, J CLIN ENDOCR METAB, V84, P184, DOI 10.1210/jc.84.1.184; Morioka T, 2007, J CLIN INVEST, V117, P2860, DOI 10.1172/JCI30910; Narvekar P, 2009, DIABETES, V58, P1040, DOI 10.2337/db08-1184; Papathanassoglou E, 2006, J IMMUNOL, V176, P7745, DOI 10.4049/jimmunol.176.12.7745; SCHOTZ MC, 1957, AM J PHYSIOL, V188, P399, DOI 10.1152/ajplegacy.1957.188.2.399; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Signore AP, 2008, J NEUROCHEM, V106, P1977, DOI 10.1111/j.1471-4159.2008.05457.x; Uotani S, 2006, BIOCHEM BIOPH RES CO, V351, P171, DOI 10.1016/j.bbrc.2006.10.015; Yasari S, 2009, MOL CELL BIOCHEM, V324, P13, DOI 10.1007/s11010-008-9979-y; Yen FT, 2008, J BIOL CHEM, V283, P25650, DOI 10.1074/jbc.M801027200; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	35	24	26	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2010	24	11					4218	4228		10.1096/fj.10-160440	http://dx.doi.org/10.1096/fj.10-160440			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20647547				2022-12-28	WOS:000283861100010
J	Wexler-Cohen, Y; Ashkenazi, A; Viard, M; Blumenthal, R; Shai, Y				Wexler-Cohen, Yael; Ashkenazi, Avraham; Viard, Mathias; Blumenthal, Robert; Shai, Yechiel			Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain	FASEB JOURNAL			English	Article						membrane fusion; HIV-1 entry inhibitor; peptide-membrane interaction; viral envelope protein	TRIMERIC COILED-COIL; IMMUNODEFICIENCY-VIRUS; POTENT INHIBITORS; CORE STRUCTURE; ENTRY; TYPE-1; SURFACE; DESIGN; REGION; STABILIZATION	The interactions between the N- and C-terminal heptad repeat (NHR and CHR) regions of the human immunodeficiency virus (HIV-1) glycoprotein gp41 create a structure comprising a 6-helix bundle (SHB). A sequence in the SHB named the "pocket" is crucial for the SHB's stability and for the fusion inhibitory activity of 36-residue NHR peptide N36. We report that a short 27-residue peptide, N27, which lacks the pocket sequence, exhibits potent inhibitory activity in both cell-cell and virus-cell fusion assays when fatty acids were conjugated to its N but not C terminus. Furthermore, mutations in the positions that prevent interaction with the CHR but not with the NHR resulted in a dramatic reduction in N27 activity. These data support a mechanism in which N27 mainly targets the CHR rather than the internal NHR coiled-coil, reveal the N-terminal edge of the endogenous core structure in situ and hence complement our recent findings of the C-terminal edge of the core, and provide a new approach for designing short inhibitors from the NHR region of other lentiviruses due to similarities in their envelope proteins.-Wexler-Cohen, Y., Ashkenazi, A., Viard, M., Blumenthal, R., Shai, Y. Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. FASEB J. 24, 4196-4202 (2010). www.fasebj.org	[Wexler-Cohen, Yael; Ashkenazi, Avraham; Shai, Yechiel] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; [Viard, Mathias; Blumenthal, Robert] NCI, Nanobiol Program, Ctr Canc Res, Frederick, MD 21701 USA; [Viard, Mathias] SAIC Frederick Inc, Basic Res Program, NCI Frederick, Frederick, MD USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	yechiel.shai@weizmann.ac.il		Ashkenazi, Avraham/0000-0002-1253-497X	Israel Science Foundation; National Cancer Institute, NIH [HHSN26120080001E]; NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC008303] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Batya Zarmi for her valuable help with peptide purification, and Dr. Ayala Sharp and Eitan Ariel and the staff of the flow cytometry unit at the Weizmann Institute of Science for their valuable technical assistance and advice. This study was supported by the Israel Science Foundation and has been funded in part with federal funds from the National Cancer Institute, NIH, under contract HHSN26120080001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. This research was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Alfsen A, 2005, MOL BIOL CELL, V16, P4267, DOI 10.1091/mbc.E05-03-0192; Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200; Bianchi E, 2005, P NATL ACAD SCI USA, V102, P12903, DOI 10.1073/pnas.0502449102; Brugger B, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-70; Burton A, 2003, LANCET INFECT DIS, V3, P260, DOI 10.1016/S1473-3099(03)00620-0; Cao J, 1996, J VIROL, V70, P1340, DOI 10.1128/JVI.70.3.1340-1354.1996; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455; Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/0022-1317-83-8-1809; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Dimitrov AS, 2003, BIOCHEMISTRY-US, V42, P14150, DOI 10.1021/bi035154g; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; He YX, 2008, J VIROL, V82, P6349, DOI 10.1128/JVI.00319-08; Kilgore NR, 2003, J VIROL, V77, P7669, DOI 10.1128/JVI.77.13.7669-7672.2003; Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200; Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200; Melikyan GB, 2006, J VIROL, V80, P3249, DOI 10.1128/JVI.80.7.3249-3258.2006; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; Noah E, 2008, BIOCHEMISTRY-US, V47, P6782, DOI 10.1021/bi7023139; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Sollner TH, 2004, CURR OPIN CELL BIOL, V16, P429, DOI 10.1016/j.ceb.2004.06.015; Suntoke TR, 2005, J BIOL CHEM, V280, P19852, DOI 10.1074/jbc.M502196200; WEISS A, 1984, J IMMUNOL, V133, P123; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com; Wexler-Cohen Y, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000509; White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI [10.1080/10409230802058320, 10.1080/10409230802058320 ]; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; Yang XZ, 2006, J VIROL, V80, P4388, DOI 10.1128/JVI.80.9.4388-4395.2006; Yu H, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-93; Zhang CWH, 2001, J BIOL CHEM, V276, P39577, DOI 10.1074/jbc.M107147200	37	27	28	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4196	4202		10.1096/fj.09-151704	http://dx.doi.org/10.1096/fj.09-151704			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20605950	Green Published			2022-12-28	WOS:000283861100008
J	Arbones-Mainar, JM; Johnson, LA; Altenburg, MK; Kim, HS; Maeda, N				Arbones-Mainar, Jose M.; Johnson, Lance A.; Altenburg, Michael K.; Kim, Hyung-Suk; Maeda, Nobuyo			Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4	FASEB JOURNAL			English	Article						NAFLD; apoE; fatty liver; adipogenesis; Western-type diet; insulin resistance	E TYPE-4 ALLELE; FATTY LIVER; ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; ADIPOSE-TISSUE; E POLYMORPHISM; TARGET GENES; RECEPTOR; APOE; GAMMA	Thiazolidinediones (TZDs) are insulin sensitizers used to treat patients with insulin resistance. To assess potential gene-drug interactions, mice expressing human apolipoprotein E3 or E4 (APOE3 or APOE4) were fed a Western-type high-fat diet for 12 wk, at which time they developed similarly impaired glucose tolerance. Supplementing the diet with rosiglitazone (1.5 mg/g body weight) for an additional 4 wk improved plasma lipid profiles in both APOE3 and APOE4 mice. However, glucose tolerance improved only in APOE3 mice. Induction of adipogenesis and lipogenesis was severely blunted in adipose tissues, but not in the livers, of APOE4 mice. Consequently, lipids were channeled to the liver, causing marked steatosis in these mice. Impaired glucose tolerance was not a prerequisite for this adverse effect, and long-term treatment with rosiglitazone altered liver enzymes and caused hepatic fibrosis in APOE4 mice. Finally, TZDs failed to stimulate PPAR gamma activation and adipocyte differentiation in preadipocytes and embryonic fibroblasts isolated from APOE4 mice compared to those from APOE3 mice. We conclude that the effects of TZDs are APOE isoform dependent, and that the metabolic damage observed in APOE4 mice is rooted in an impaired activation of the adipogenic program in the adipose tissues expressing APOE4.-Arbones-Mainar, J. M., Johnson, L. A., Altenburg, M. K., Kim, H.-S., Maeda, N. Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4. FASEB J. 24, 3809-3818 (2010). www.fasebj.org	[Arbones-Mainar, Jose M.; Johnson, Lance A.; Altenburg, Michael K.; Kim, Hyung-Suk; Maeda, Nobuyo] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Maeda, N (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, 701 Brinkhous Bullitt Bldg, Chapel Hill, NC 27599 USA.	nobuyo@med.unc.edu	Arbones-Mainar, Jose M/AGL-8624-2022	Arbones-Mainar, Jose M/0000-0002-8982-3737; Johnson, Lance/0000-0003-0134-7586	U.S. National Institute of Health [HL42630, HL87946]; Ministerio de Educacion y Ciencia (Spain); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042630, U01HL087946, R37HL042630] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministerio de Educacion y Ciencia (Spain)(Spanish Government); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by U.S. National Institute of Health grants HL42630 and HL87946. J.M.A.-M. was partially supported by a postdoctoral fellowship from the Ministerio de Educacion y Ciencia (Spain). The authors thank Marcus McNair, Anna Garcia, and Jennifer Wilder for their assistance and Prof. Jesus Osada for his critical reading of this work.	Altenburg M, 2008, ARTERIOSCL THROM VAS, V28, P1104, DOI 10.1161/ATVBAHA.108.164863; Arbones-Mainar JM, 2008, INT J OBESITY, V32, P1595, DOI 10.1038/ijo.2008.143; Arbones-Mainar JM, 2006, J NUTR, V136, P353, DOI 10.1093/jn/136.2.353; Bazin R, 2000, METH MOL B, V155, P121; Bennet AM, 2007, JAMA-J AM MED ASSOC, V298, P1300, DOI 10.1001/jama.298.11.1300; Bogacka I, 2004, DIABETES CARE, V27, P1660, DOI 10.2337/diacare.27.7.1660; Cardona F, 2006, CLIN CHEM, V52, P1920, DOI 10.1373/clinchem.2006.069690; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Conner DA, 2001, CURR PROTOC MOL BIOL; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Elosua R, 2003, OBES RES, V11, P1502, DOI 10.1038/oby.2003.201; Garcia-Ruiz I, 2007, HEPATOLOGY, V46, P414, DOI 10.1002/hep.21687; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Huang ZH, 2006, DIABETES, V55, P3394, DOI 10.2337/db06-0354; Huang ZH, 2009, AM J PHYSIOL-ENDOC M, V296, pE1110, DOI 10.1152/ajpendo.90964.2008; Im SS, 2005, DIABETES, V54, P1684, DOI 10.2337/diabetes.54.6.1684; Johnson L, 2008, ARTERIOSCL THROM VAS, V28, pE95; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; Malloy SI, 2004, ARTERIOSCL THROM VAS, V24, P91, DOI 10.1161/01.ATV.0000094963.07902.FB; Pagano C, 2005, EUR J ENDOCRINOL, V152, P113, DOI 10.1530/eje.1.01821; Pendse AA, 2009, J LIPID RES, V50, pS178, DOI 10.1194/jlr.R800070-JLR200; Peng DQ, 2003, INT J CARDIOL, V92, P257, DOI 10.1016/S0167-5273(03)00101-3; Ranganathan G, 2006, J LIPID RES, V47, P2444, DOI 10.1194/jlr.M600248-JLR200; Risner ME, 2006, PHARMACOGENOMICS J, V6, P246, DOI 10.1038/sj.tpj.6500369; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Sima A, 2007, CLIN CHEM LAB MED, V45, P1149, DOI 10.1515/CCLM.2007.258; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; SMITH GS, 1992, ARCH NEUROL-CHICAGO, V49, P1142, DOI 10.1001/archneur.1992.00530350056020; Westerbacka J, 2007, DIABETES, V56, P2759, DOI 10.2337/db07-0156; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Ye JM, 2004, DIABETOLOGIA, V47, P1306, DOI 10.1007/s00125-004-1436-1; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yue L, 2009, J BIOL CHEM, V284, P10453, DOI 10.1074/jbc.M808482200; Yue LL, 2004, J BIOL CHEM, V279, P47626, DOI 10.1074/jbc.M408461200	37	23	23	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3809	3818		10.1096/fj.10-159517	http://dx.doi.org/10.1096/fj.10-159517			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20501792	Green Published			2022-12-28	WOS:000285005900019
J	Chastain, PD; Nakamura, J; Rao, SB; Chu, HT; Ibrahim, JG; Swenberg, JA; Kaufman, DG				Chastain, Paul D., II; Nakamura, Jun; Rao, Shangbang; Chu, Haitao; Ibrahim, Joseph G.; Swenberg, James A.; Kaufman, David G.			Abasic sites preferentially form at regions undergoing DNA replication	FASEB JOURNAL			English	Article						DNA damage; apurinic/apyrimidinic sites; oxidative stress; hydrogen peroxide; DNA fiber immunostaining	OXIDATIVE STRESS; HUMAN-CELLS; S-PHASE; MACULAR DEGENERATION; PARKINSONS-DISEASE; IONIZING-RADIATION; MITOCHONDRIAL-DNA; DAMAGE CLUSTERS; ANTIOXIDANTS; CATARACTS	We investigated whether apurinic/apyrimidinic (AP/abasic) sites were more frequent in regions of DNA replication in cells and whether their number increased during oxidative stress. DNA fiber spreading and fluorescent immunostaining were used to detect areas of DNA replication and sites of AP lesions in extended DNA fibers. The distribution of AP sites was determined in DNA fibers from vertebrate cells maintained under normal culture conditions or stressed with exogenous H(2)O(2). AP lesions per unit length were enumerated in bulk DNA or at replication sites. The background density of AP sites in DNA fibers was 5.4 AP sites/10(6) nt, while newly replicated DNA contained 12.9 AP sites/10(6) nt. In cells exposed to 20 mu M H(2)O(2), AP sites in newly replicated DNA increased to 20.8/10(6) nt. Determinations of AP site density in bulk DNA by fiber analysis or standard slot blot assays agreed to within 10%. Our findings show that the fiber assay not only accurately determines the frequency of AP sites but also shows their distribution. They also reveal that there is increased susceptibility to oxidative damage in DNA regions undergoing replication, which may explain the previously observed clustering of AP sites.-Chastain II, P. D., Nakamura, J., Rao, S., Chu, H., Ibrahim, J. G., Swenberg, J. A., Kaufman, D. G. Abasic sites preferentially form at regions undergoing DNA replication. FASEB J. 24, 3674-3680 (2010). www.fasebj.org	[Chastain, Paul D., II; Swenberg, James A.; Kaufman, David G.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Nakamura, Jun; Swenberg, James A.] Univ N Carolina, Dept Environm Sci & Engn, Sch Publ Hlth, Chapel Hill, NC 27599 USA; [Rao, Shangbang; Chu, Haitao; Ibrahim, Joseph G.; Swenberg, James A.; Kaufman, David G.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Rao, Shangbang; Chu, Haitao; Ibrahim, Joseph G.] Univ N Carolina, Dept Biostat, Sch Publ Hlth, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Chastain, PD (corresponding author), Univ N Carolina, Sch Med, Dept Pathol & Lab Med, 620 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.	pchastai@med.unc.edu	Chu, Haitao/J-7576-2012; Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788; Nakamura, Jun/0000-0002-1756-7199; Chu, Haitao/0000-0003-0932-598X	U.S. National Institutes of Health [R01-CA084493, R21-CA125337];  [P30-ES10126];  [P42-ES05948];  [T32-ES07017]; NATIONAL CANCER INSTITUTE [R21CA125337, R01CA084493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, T32ES007017, P42ES005948] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by U.S. National Institutes of Health grants R01-CA084493 and R21-CA125337 to D.G.K.; J.N. and J.A.S. were supported by grants P30-ES10126 and P42-ES05948; P.D.C. was also supported by grants T32-ES07017 and P42-ES05948. The authors have no conflicts of interest or financial disclosures to report.	Alexander R W, 1998, Trans Am Clin Climatol Assoc, V109, P129; Barber SC, 2010, FREE RADICAL BIO MED, V48, P629, DOI 10.1016/j.freeradbiomed.2009.11.018; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bennett P, 2008, FREE RADICAL BIO MED, V45, P1352, DOI 10.1016/j.freeradbiomed.2008.08.007; Bennett PV, 2005, FREE RADICAL BIO MED, V39, P832, DOI 10.1016/j.freeradbiomed.2005.05.008; Berthoud VM, 2009, ANTIOXID REDOX SIGN, V11, P339, DOI 10.1089/ars.2008.2119; Bozner P, 1997, J NEUROPATH EXP NEUR, V56, P1356, DOI 10.1097/00005072-199712000-00010; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Chastain PD, 2006, FASEB J, V20, P2612, DOI 10.1096/fj.06-6145fje; Chastain PD, 2006, CELL CYCLE, V5, P2160, DOI 10.4161/cc.5.18.3236; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; De Rosa S, 2010, CURR VASC PHARMACOL, V8, P259; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fiorillo C, 1998, CLIN CHEM LAB MED, V36, P149, DOI 10.1515/CCLM.1998.028; Frum RA, 2008, CELL CYCLE, V7, P1440, DOI 10.4161/cc.7.10.5879; Frum RA, 2009, CELL CYCLE, V8, P3133, DOI 10.4161/cc.8.19.9682; Georgakilas AG, 2002, NUCLEIC ACIDS RES, V30, P2800, DOI 10.1093/nar/gkf393; Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131; Herrick J, 1999, BIOCHIMIE, V81, P859, DOI 10.1016/S0300-9084(00)87170-9; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lebofsky Ronald, 2003, Briefings in Functional Genomics & Proteomics, V1, P385, DOI 10.1093/bfgp/1.4.385; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Matsuzaki Y, 2002, NUCLEIC ACIDS RES, V30, P3273, DOI 10.1093/nar/gkf440; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Miller RL, 2009, NEUROCHEM RES, V34, P55, DOI 10.1007/s11064-008-9656-2; Misra MK, 2009, MED SCI MONITOR, V15, pRA209; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; Multhaup G, 1997, BIOCHEM PHARMACOL, V54, P533, DOI 10.1016/S0006-2952(97)00062-2; Nakamura J, 1999, CANCER RES, V59, P2522; Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045; Nowsheen S, 2009, MUTAT RES-GEN TOX EN, V674, P131, DOI 10.1016/j.mrgentox.2008.09.010; Pastukh V, 2007, FREE RADICAL BIO MED, V43, P1616, DOI 10.1016/j.freeradbiomed.2007.08.027; PAULES RS, 1988, P NATL ACAD SCI USA, V85, P2176, DOI 10.1073/pnas.85.7.2176; Plafker SM, 2010, ADV EXP MED BIOL, V664, P447, DOI 10.1007/978-1-4419-1399-9_51; Radunovic A, 1997, NEUROSCI LETT, V239, P105, DOI 10.1016/S0304-3940(97)00905-1; Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008; Scapagnini Giovanni, 2010, Front Biosci (Schol Ed), V2, P616; Singh Uma, 2006, Pathophysiology, V13, P129, DOI 10.1016/j.pathophys.2006.05.002; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Sutherland BM, 2003, FREE RADICAL BIO MED, V35, P495, DOI 10.1016/S0891-5849(03)00327-7; Tian KG, 2002, DNA REPAIR, V1, P1039, DOI 10.1016/S1568-7864(02)00163-5; TISSIE G, 1988, OPHTHALMIC RES, V20, P27, DOI 10.1159/000266252; VARMA SD, 1995, CRIT REV FOOD SCI, V35, P111, DOI 10.1080/10408399509527691; VARMA SD, 1995, J OCUL PHARMACOL TH, V11, P543, DOI 10.1089/jop.1995.11.543; VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5; Yang N, 2004, DNA REPAIR, V3, P1323, DOI 10.1016/j.dnarep.2004.04.014	50	33	34	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2010	24	10					3674	3680		10.1096/fj.09-145276	http://dx.doi.org/10.1096/fj.09-145276			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20511393	Green Published			2022-12-28	WOS:000285005900008
J	Gluenz, E; Hoog, JL; Smith, AE; Dawe, HR; Shaw, MK; Gull, K				Gluenz, Eva; Hoeoeg, Johanna L.; Smith, Amy E.; Dawe, Helen R.; Shaw, Michael K.; Gull, Keith			Beyond 9+0: noncanonical axoneme structures characterize sensory cilia from protists to humans	FASEB JOURNAL			English	Article						signaling; host-pathogen interaction; primary cilium; electron microscopy	CLASS-II MOLECULES; INTRAFLAGELLAR TRANSPORT; LEISHMANIA-AMAZONENSIS; FINE-STRUCTURE; ULTRASTRUCTURE; AMASTIGOTES; FLAGELLUM; NEURONS; RAT	The intracellular amastigote stages of parasites such as Leishmania are often referred to as aflagellate. They do, however, possess a short axoneme of cryptic function. Here, our examination of the structure of this axoneme leads to a testable hypothesis of its role in the cell biology of pathogenicity. We show a striking similarity between the microtubule axoneme structure of the Leishmania mexicana parasite infecting a macrophage and vertebrate primary cilia. In both, the 9-fold microtubule doublet symmetry is broken by the incursion of one or more microtubule doublets into the axoneme core, giving rise to an architecture that we term here the 9v (variable) axoneme. Three-dimensional reconstructions revealed that no particular doublet initiated the symmetry break, and moreover it often involved 2 doublets. The tip of the L. mexicana flagellum was frequently intimately associated with the macrophage vacuole membrane. We propose that the main function of the amastigote flagellum is to act as a sensory organelle with important functions in host-parasite interactions and signaling in the intracellular stage of the L. mexicana life cycle.-Gluenz, E., Hoog, J. L., Smith, A. E., Dawe, H. R., Shaw, M. K., Gull, K. Beyond 9 + 0: noncanonical axoneme structures characterize sensory cilia from protists to humans. FASEB J. 24, 3117-3121 (2010). www.fasebj.org	[Gluenz, Eva; Hoeoeg, Johanna L.; Smith, Amy E.; Dawe, Helen R.; Shaw, Michael K.; Gull, Keith] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Hoeoeg, Johanna L.] Univ Colorado, Boulder Lab Electron Microscopy Cells 3D, Dept MCD Biol, Boulder, CO 80309 USA	University of Oxford; University of Colorado System; University of Colorado Boulder	Gull, K (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	keith.gull@path.ox.ac.uk		Hoog, Johanna/0000-0003-2162-3816; Gluenz, Eva/0000-0003-4346-8896	Wellcome Trust; Beit Memorial Fellowships for Medical Research; Jackson Scholarship Fund; EMBO long-term fellowship; E. P. Abraham Trust; National Institutes of Health, (University of Colorado, Boulder, CO, USA) [RR00592]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000592] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); Beit Memorial Fellowships for Medical Research; Jackson Scholarship Fund; EMBO long-term fellowship(European Molecular Biology Organization (EMBO)); E. P. Abraham Trust; National Institutes of Health, (University of Colorado, Boulder, CO, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dick McIntosh for comments on the manuscript and David Vaux (University of Oxford, Oxford, UK) for the gift of J774 macrophages. This work was funded by the Wellcome Trust, the Beit Memorial Fellowships for Medical Research, the Jackson Scholarship Fund (Merton College Oxford, to A. E. S.), an EMBO long-term fellowship (to J.L.H.), and the E. P. Abraham Trust. K. G. held a Wellcome Trust Principal Research Fellowship, H. R. D. is a Beit Memorial Fellow, and J.L.H. is a Sir Henry Wellcome Fellow. The Boulder Laboratory for 3D Electron Microscopy of Cells is supported by National Institutes of Health Biotechnology grant RR00592 to A. Hoenger (University of Colorado, Boulder, CO, USA).	ALEXANDER J, 1978, T ROY SOC TROP MED H, V72, P345, DOI 10.1016/0035-9203(78)90124-4; ALLEN RA, 1965, J ULTRA MOL STRUCT R, V12, P730, DOI 10.1016/S0022-5320(65)80058-2; Baldari CT, 2010, CURR OPIN CELL BIOL, V22, P75, DOI 10.1016/j.ceb.2009.10.010; BRETONGORIUS J, 1967, NOUV REV FR HEMATOL, V7, P79; Castro R, 2006, J PARASITOL, V92, P1162, DOI 10.1645/GE-841R.1; CHANG KP, 1980, SCIENCE, V209, P1240, DOI 10.1126/science.7403880; DAHL HA, 1963, Z ZELLFORSCH MIK ANA, V60, P369, DOI 10.1007/BF00336612; Dawe HR, 2005, J CELL SCI, V118, P5421, DOI 10.1242/jcs.02659; Evans JE, 2006, J CELL BIOL, V172, P663, DOI 10.1083/jcb.200509115; Gadelha C, 2006, J CELL SCI, V119, P2405, DOI 10.1242/jcs.02969; Gerdes JM, 2009, CELL, V137, P32, DOI 10.1016/j.cell.2009.03.023; Gull K, 2009, PHAGOCYTE-PATHOGEN INTERACTIONS: MACROPHAGES AND THE HOST RESPONSE TO INFECTION, P453; HENTZER B, 1977, ACTA PATH MICRO IM B, V85, P153; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; LANG T, 1994, J CELL SCI, V107, P69; LEAO SD, 1995, J CELL SCI, V108, P3219; MORAN DT, 1982, J NEUROCYTOL, V11, P721, DOI 10.1007/BF01153516; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Scholey JM, 2006, CELL, V125, P439, DOI 10.1016/j.cell.2006.04.013; Shah AS, 2009, SCIENCE, V325, P1131, DOI 10.1126/science.1173869; SIMPSON CF, 1982, AM J VET RES, V43, P1684; SOLTER KM, 1977, NATURE, V265, P444, DOI 10.1038/265444a0	23	69	71	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3117	3121		10.1096/fj.09-151381	http://dx.doi.org/10.1096/fj.09-151381			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20371625	Green Published			2022-12-28	WOS:000281446400002
J	Maki, N; Suetsugu-Maki, R; Sano, S; Nakamura, K; Nishimura, O; Tarui, H; Del Rio-Tsonis, K; Ohsumi, K; Agata, K; Tsonis, PA				Maki, Nobuyasu; Suetsugu-Maki, Rinako; Sano, Shozo; Nakamura, Kenta; Nishimura, Osamu; Tarui, Hiroshi; Del Rio-Tsonis, Katia; Ohsumi, Keita; Agata, Kiyokazu; Tsonis, Panagiotis A.			Oocyte-type linker histone B4 is required for transdifferentiation of somatic cells in vivo	FASEB JOURNAL			English	Article						newt; lens regeneration; histone H1; gamma-crystallin	NUCLEAR TRANSFER; CRYSTALLIN GENE; SEA-URCHIN; H1; DIFFERENTIATION; REGENERATION; REPLACEMENT; ZEBRAFISH; VARIANTS; DYNAMICS	The ability to reprogram in vivo a somatic cell after differentiation is quite limited. One of the most impressive examples of such a process is transdifferentiation of pigmented epithelial cells (PECs) to lens cells during lens regeneration in newts. However, very little is known of the molecular events that allow newt cells to transdifferentiate. Histone B4 is an oocyte-type linker histone that replaces the somatic-type linker histone H1 during reprogramming mediated by somatic cell nuclear transfer (SCNT). We found that B4 is expressed and required during transdifferentiation of PECs. Knocking down of B4 decreased proliferation and increased apoptosis, which resulted in considerable smaller lens. Furthermore, B4 knockdown altered gene expression of key genes of lens differentiation and nearly abolished expression of gamma-crystallin. These data are the first to show expression of oocyte-type linker histone in somatic cells and its requirement in newt lens transdifferentiation and suggest that transdifferentiation in newts might share common strategies with reprogramming after SCNT.-Maki, N., Suetsugu-Maki, R., Sano, S., Nakamura, K., Nishimura, O., Tarui, H., Del Rio-Tsonis, K., Ohsumi, K., Agata, K., Tsonis, P. A. Oocyte-type linker histone B4 is required for transdifferentiation of somatic cells in vivo. FASEB J. 24, 3462-3467 (2010). www.fasebj.org	[Maki, Nobuyasu; Suetsugu-Maki, Rinako; Nakamura, Kenta; Tsonis, Panagiotis A.] Univ Dayton, Dept Biol, Dayton, OH 45469 USA; [Maki, Nobuyasu; Suetsugu-Maki, Rinako; Nakamura, Kenta; Tsonis, Panagiotis A.] Univ Dayton, Ctr Tissue Regenerat & Engn Dayton, Dayton, OH 45469 USA; [Maki, Nobuyasu; Sano, Shozo; Tarui, Hiroshi; Agata, Kiyokazu] RIKEN, Ctr Dev Biol, Kobe, Hyogo, Japan; [Nishimura, Osamu; Agata, Kiyokazu] Kyoto Univ, Dept Biophys, Kyoto, Japan; [Del Rio-Tsonis, Katia] Miami Univ, Dept Zool, Oxford, OH 45056 USA; [Ohsumi, Keita] Nagoya Univ, Div Biol Sci, Nagoya, Aichi 4648601, Japan	University of Dayton; University of Dayton; RIKEN; Kyoto University; University System of Ohio; Miami University; Nagoya University	Maki, N (corresponding author), Univ Dayton, Dept Biol, 300 Coll Pk,SC46, Dayton, OH 45469 USA.	makinobu@notes.udayton.edu; panagiotis.tsonis@notes.udayton.edu	Nishimura, Osamu/AAC-1236-2020	Nishimura, Osamu/0000-0003-1969-2580; Agata, Kiyokazu/0000-0002-5195-2576	KAKENHI grant [17657068]; Naito Foundation; Japan Ministry of Education, Culture, Sports, Science, and Technology [17GS0318]; U.S. National Institutes of Health [EY10540]; NATIONAL EYE INSTITUTE [R01EY010540] Funding Source: NIH RePORTER	KAKENHI grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Naito Foundation(Naito Memorial Foundation); Japan Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank Y. Tanabe, and J. Hayashi for EST analysis. The authors are grateful to K. Ura for a helpful discussion. This work was supported by a KAKENHI grant (17657068) to N.M.; by the Naito Foundation and the Project for Realization of Regenerative Medicine as well as a Grant-in-Aid for Creative Research from the Japan Ministry of Education, Culture, Sports, Science, and Technology (17GS0318) to K. A., and by a U. S. National Institutes of Health grant (EY10540) to P. A. T.	ABE SI, 1977, DEV GROWTH DIFFER, V19, P309; Becker M, 2005, MOL BIOL CELL, V16, P3887, DOI 10.1091/mbc.E05-04-0350; CHO HS, 1994, GENE, V143, P233; CVEKL A, 1995, MOL CELL BIOL, V15, P653; EGUCHI G, 1973, P NATL ACAD SCI USA, V70, P1495, DOI 10.1073/pnas.70.5.1495; Gao SR, 2004, DEV BIOL, V266, P62, DOI 10.1016/j.ydbio.2003.10.003; Godde JS, 2009, INT J DEV BIOL, V53, P215, DOI 10.1387/ijdb.082644jg; Lee H, 2004, SCIENCE, V304, P1675, DOI 10.1126/science.1098096; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Maki N, 2007, DEV DYNAM, V236, P941, DOI 10.1002/dvdy.21027; Mandl B, 1997, MOL CELL BIOL, V17, P1189, DOI 10.1128/MCB.17.3.1189; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; McGraw S, 2006, MOL REPROD DEV, V73, P692, DOI 10.1002/mrd.20448; Morcos PA, 2008, BIOTECHNIQUES, V45, P613, DOI 10.2144/000113005; Muller K, 2002, MECH DEVELOP, V117, P253, DOI 10.1016/S0925-4773(02)00174-0; NEELIN JM, 1964, CAN J BIOCHEM PHYS, V42, P1743, DOI 10.1139/o64-185; Saeki H, 2005, P NATL ACAD SCI USA, V102, P5697, DOI 10.1073/pnas.0409824102; Tanaka M, 2005, BIOL REPROD, V72, P135, DOI 10.1095/biolreprod.104.032474; Tanaka M, 2001, DEVELOPMENT, V128, P655; Teranishi T, 2004, DEV BIOL, V266, P76, DOI 10.1016/j.ydbio.2003.10.004; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Wade PA, 2002, EUR J BIOCHEM, V269, P2284, DOI 10.1046/j.1432-1033.2002.02887.x; Wibrand K, 2002, MECH DEVELOP, V117, P249, DOI 10.1016/S0925-4773(02)00173-9; Yoshida T, 2002, GENES CELLS, V7, P693, DOI 10.1046/j.1365-2443.2002.00548.x	24	36	38	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3462	3467		10.1096/fj.10-159285	http://dx.doi.org/10.1096/fj.10-159285			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20460584	Green Published			2022-12-28	WOS:000281446400033
J	Anelli, V; Gault, CR; Snider, AJ; Obeid, LM				Anelli, Viviana; Gault, Christopher R.; Snider, Ashley J.; Obeid, Lina M.			Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro	FASEB JOURNAL			English	Article							ENDOTHELIAL GROWTH-FACTOR; SIGNALING PATHWAYS; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; EXTRACELLULAR RELEASE; MASS-SPECTROMETRY; POOR SURVIVAL; G-PROTEIN; VEGF-C; 1-PHOSPHATE	Sphingosine-1-phosphate (S1P) is an important bioactive sphingolipid involved in angiogenesis and lymphangiogenesis, 2 important processes that influence the growth, survival, and spread of tumors. S1P acts as an extracellular mediator through binding to 5 highly specific S1P receptors, S1P(1-5). Sphingosine kinase-1 (SK1), one of 2 known sphingosine kinase enzymes responsible for S1P production, appears to be overexpressed in many tumors. Although a role for S1P in angiogenesis and lymphangiogenesis has been established, it is unclear whether S1P secreted from cancer cells has a paracrine function in a tumor environment. Here we investigated whether modulation of cellular SK1 could initiate a paracrine angiogenic and lymphangiogenic switch. We found that SK1 overexpression in HEK cells or its down-regulation in glioma or breast cancer cells modulated extracellular S1P levels accordingly, which in turn increased or decreased both migration and tube formation in cocultured vascular or lymphatic endothelial cells. In contrast, down-regulation of sphingosine kinase 2 in both glioma and breast cancer cells had no appreciable effect on cellular or secreted S1P levels. In addition, vascular endothelial growth factors VEGF and VEGF-C down-regulation in cancer cells appeared insufficient to block the angiogenic and lymphangiogenic switch triggered by these cells. Moreover, S1P initiated endothelial cell sprouting in 3-dimensional collagen matrices, which is representative of a multistep angiogenic process. Our data collectively demonstrate for the first time that SK1 plays an essential role in regulating in vitro paracrine angiogenesis and lymphangiogenesis.-Anelli, V., Gault, C. R., Snider, A.J., Obeid, L. M. Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro. FASEB J. 24, 2727-2738 (2010). www.fasebj.org	[Obeid, Lina M.] Med Univ S Carolina, Div Gen Internal Med Geriatr, Dept Med, Charleston, SC 29425 USA; [Anelli, Viviana; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Anelli, Viviana] Univ Milan, Dept Med Chem Biochem & Biotechnol, Milan, Italy; [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; University of Milan; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Div Gen Internal Med Geriatr, Dept Med, MSC 779, Charleston, SC 29425 USA.	obeidl@musc.edu		ANELLI, Viviana Vittoria/0000-0003-1964-3252; obeid, lina/0000-0002-0734-0847	National Institutes of Health [NIH/NIGMS GM062887, NIH/NCI CA097132, NIH/P20 RR17677]; Hollings Cancer Center [P30-CA-56036]; NATIONAL CANCER INSTITUTE [P30CA056036, P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hollings Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Kathy Wiita-Fisk for administrative assistance. The authors also thank the Lipidomics Core at the Medical University of South Carolina. Grant support came from National Institutes of Health grants NIH/NIGMS GM062887 (L.M.O.), NIH/NCI CA097132 (L.M.O.), NIH/P20 RR17677 for the Centers of Biomedical Research Excellence (COBRE) Lipidomics Core, and Hollings Cancer Center core grant P30-CA-56036 for the Microscopy Core.	Alvarez SE, 2007, TRENDS ENDOCRIN MET, V18, P300, DOI 10.1016/j.tem.2007.07.005; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Anelli V, 2005, J NEUROCHEM, V92, P1204, DOI 10.1111/j.1471-4159.2004.02955.x; Anelli V, 2008, J BIOL CHEM, V283, P3365, DOI 10.1074/jbc.M708241200; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Chae SS, 2004, J CLIN INVEST, V114, P1082, DOI 10.1172/JCI200422716; English DK, 1999, J HEMATOTHER, V8, P1, DOI 10.1089/106161299320514; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Joukov V, 1996, EMBO J, V15, P290; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Lee YM, 2007, PROSTAG OTH LIPID M, V84, P154, DOI 10.1016/j.prostaglandins.2007.08.001; Li W, 2009, CLIN CANCER RES, V15, P1393, DOI 10.1158/1078-0432.CCR-08-1158; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Nakatsu Martin N, 2007, J Vis Exp, P186, DOI 10.3791/186; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Rossant J, 2002, ANNU REV CELL DEV BI, V18, P541, DOI 10.1146/annurev.cellbio.18.012502.105825; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Spassieva S, 2007, METHOD ENZYMOL, V434, P233, DOI 10.1016/S0076-6879(07)34012-3; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Vadas M, 2008, BBA-MOL CELL BIOL L, V1781, P442, DOI 10.1016/j.bbalip.2008.06.007; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845; Venkataraman K, 2006, BIOCHEM J, V397, P461, DOI 10.1042/BJ20060251; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; Yoon CM, 2008, BLOOD, V112, P1129, DOI 10.1182/blood-2007-11-125203; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	39	72	74	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2727	2738		10.1096/fj.09-150540	http://dx.doi.org/10.1096/fj.09-150540			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20335228	Green Published			2022-12-28	WOS:000285005400014
J	Mannes, AM; Seiler, A; Bosello, V; Maiorino, M; Conrad, M				Mannes, Alexander M.; Seiler, Alexander; Bosello, Valentina; Maiorino, Matilde; Conrad, Marcus			Cysteine mutant of mammalian GPx4 rescues cell death induced by disruption of the wild-type selenoenzyme	FASEB JOURNAL			English	Article						PHGPx; apoptosis; proliferation; redox regulation; selenocysteine	HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; THIOREDOXIN REDUCTASE; TARGETED DISRUPTION; OXIDATIVE DAMAGE; MOUSE; MECHANISMS; GENE; PEROXIREDOXINS; PURIFICATION; SPECIFICITY	Selenoproteins are expressed in many organisms, including bacteria, insects, fish, and mammals. Yet, it has remained obscure why some organisms rely on selenoproteins while others, like yeast and plants, express Cys-containing homologues. This study addressed the possible advantage of selenocysteine (Sec) vs. Cys in the essential selenoprotein glutathione peroxidase 4 (GPx4), using 4-hydroxy-tamoxifen-inducible Cre-excision of loxP-flanked GPx4 alleles in murine cells. Previously, it was shown that GPx4 disruption caused rapid cell death, which was prevented by alpha-tocopherol. Results presented herein demonstrate that the expression of wild-type (WT) GPx4 and its Sec/Cys (U46C) mutant rescued cell death of GPx4(-/-) cells, whereas the Sec/Ser (U46S) mutant failed. Notably, the specific activity of U46C was decreased by similar to 90% and was indistinguishable from U46S-expressing and mock-transfected cells. Hence, the U46C mutant prevented apoptosis despite hardly measurable in vitro activity. Doxycycline-inducible expression revealed that minute amounts of either U46C or WT GPx4 prevented cell death, albeit WT GPx4 was more efficient. Interestingly, at the same expression level, proliferation was promoted in U46C-expressing cells but attenuated in WT-expressing cells. In summary, both catalytic efficiency and the expression level of GPx4 control the balance between cell survival and proliferation.-Mannes, A. M., Seiler, A., Bosello, V., Maiorino, M., Conrad, M. Cysteine mutant of mammalian GPx4 rescues cell death induced by disruption of the wild-type selenoenzyme. FASEB J. 25, 2135-2144 (2011). www.fasebj.org	[Conrad, Marcus] Helmholtz Zentrum Munchen, Inst Dev Genet, D-85764 Neuherberg, Germany; [Mannes, Alexander M.; Seiler, Alexander; Conrad, Marcus] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Clin Mol Biol & Tumor Genet, Munich, Germany; [Bosello, Valentina; Maiorino, Matilde] Univ Padua, Dept Biol Chem, Padua, Italy; [Conrad, Marcus] German Ctr Neurodegenerat Dis, DZNE, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Padua; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE)	Conrad, M (corresponding author), Helmholtz Zentrum Munchen, Inst Dev Genet, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.	marcus.conrad@helmholtz-muenchen.de	Conrad, Marcus/E-8792-2015	Conrad, Marcus/0000-0003-1140-5612; bosello travain, valentina/0000-0003-4659-1873	Deutsche Forschungsgemeinschaft (DFG) [CO 291/2-3, SPP1190]; Universita' di Padova Progetto di Ateneo [CPDA087343/08]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Universita' di Padova Progetto di Ateneo	The authors thank Georg W. Bornkamm and Fulvio Ursini for fruitful discussions and Heidi Forster for excellent technical assistance. The authors are grateful to Drs. Rob Chapman and Simon Laws for critically reading the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) CO 291/2-3 (to M. C.), by the DFG-Priority Programme SPP1190 (to M. C.), and by Universita' di Padova Progetto di Ateneo CPDA087343/08 (to M.M.).	Allmang C, 2009, BBA-GEN SUBJECTS, V1790, P1415, DOI 10.1016/j.bbagen.2009.03.003; Arner ESJ, 2010, EXP CELL RES, V316, P1296, DOI 10.1016/j.yexcr.2010.02.032; Bornkamm GW, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni137; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Chen K, 2008, J CELL BIOL, V181, P1129, DOI 10.1083/jcb.200709049; Conrad M, 2005, MOL CELL BIOL, V25, P7637, DOI 10.1128/MCB.25.17.7637-7644.2005; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Conrad M, 2010, P NATL ACAD SCI USA, V107, P15774, DOI 10.1073/pnas.1007909107; Conrad M, 2010, ANTIOXID REDOX SIGN, V12, P851, DOI 10.1089/ars.2009.2912; Conrad M, 2009, BBA-GEN SUBJECTS, V1790, P1575, DOI 10.1016/j.bbagen.2009.05.001; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; Fomenko DE, 2008, MOL CELLS, V26, P228; Gloeckner CJ, 2007, PROTEOMICS, V7, P4228, DOI 10.1002/pmic.200700038; Hall A, 2009, FEBS J, V276, P2469, DOI 10.1111/j.1742-4658.2009.06985.x; Handy DE, 2009, J BIOL CHEM, V284, P11913, DOI 10.1074/jbc.M900392200; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hondal RJ, 2011, AMINO ACIDS, V41, P73, DOI 10.1007/s00726-010-0494-6; Imai H, 2003, BIOCHEM BIOPH RES CO, V305, P278, DOI 10.1016/S0006-291X(03)00734-4; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Kim IY, 1997, P NATL ACAD SCI USA, V94, P418, DOI 10.1073/pnas.94.2.418; Liang HY, 2009, J BIOL CHEM, V284, P30836, DOI 10.1074/jbc.M109.032839; Loscalzo J, 2008, CELL METAB, V8, P182, DOI 10.1016/j.cmet.2008.08.004; Lu J, 2009, FASEB J, V23, P2394, DOI 10.1096/fj.08-127662; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; Maiorino M, 2007, J MOL BIOL, V365, P1033, DOI 10.1016/j.jmb.2006.10.033; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; Schneider M, 2009, FASEB J, V23, P3233, DOI 10.1096/fj.09-132795; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; THOMAS JP, 1990, J BIOL CHEM, V265, P454; Toppo S, 2008, ANTIOXID REDOX SIGN, V10, P1501, DOI 10.1089/ars.2008.2057; Toppo S, 2009, BBA-GEN SUBJECTS, V1790, P1486, DOI 10.1016/j.bbagen.2009.04.007; Tosatto SCE, 2008, ANTIOXID REDOX SIGN, V10, P1515, DOI 10.1089/ars.2008.2055; Trujillo M, 2006, J BIOL CHEM, V281, P20555, DOI 10.1074/jbc.M601008200; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6	39	30	30	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2135	2144		10.1096/fj.10-177147	http://dx.doi.org/10.1096/fj.10-177147			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21402720				2022-12-28	WOS:000292242200006
J	Angiolini, E; Coan, PM; Sandovici, I; Iwajomo, OH; Peck, G; Burton, GJ; Sibley, CP; Reik, W; Fowden, AL; Constancia, M				Angiolini, Emily; Coan, Phillip M.; Sandovici, Ionel; Iwajomo, O. H.; Peck, Gerrard; Burton, Graham J.; Sibley, Colin P.; Reik, Wolf; Fowden, Abigail L.; Constancia, Miguel			Developmental adaptations to increased fetal nutrient demand in mouse genetic models of Igf2-mediated overgrowth	FASEB JOURNAL			English	Article						genomic imprinting; insulin-like growth factor; H19; placenta	BECKWITH-WIEDEMANN; PLACENTAL EFFICIENCY; IGF-II; TRANSPORT; INSULIN; GROWTH; DELETION; OBESITY; REGION; MICE	The healthy development of the fetus depends on an optimal balance between fetal genetic drive for growth and the maternal ability to provide nutrients through the placenta. Nothing is known about fetal-placental signaling in response to increased fetal demand in the situation of overgrowth. Here, we examined this question using the H19(Delta 13) mouse model, shown previously to result in elevated levels of Igf2. Fetal and placental weights in H19(Delta 13) were increased by 23% and 45%, respectively, at E19, when compared with wild-type mice. Unexpectedly, we found that disproportionately large H19(Delta 13) placentas transport 20-35% less (per gram placenta) glucose and system A amino acids and have similar reductions in passive permeability, despite a significantly greater surface area for nutrient exchange and theoretical diffusion capacity compared with wild-type mice. Expression of key transporter genes Slc2a3 and Slc38a4 was reduced by similar to 20%. Decreasing the overgrowth of the H19(Delta 13) placenta by genetically reducing levels of Igf2P0 resulted in up-regulation of system A activity and maintenance of fetal overgrowth. Our results provide direct evidence that large placentas can modify their nutrient transfer capacity to regulate fetal nutrient acquisition. Our findings are indicative of fetal-placental signaling mechanisms that limit total demand for maternal nutrients.-Angiolini, E., Coan, P.M., Sandovici, I., Iwajomo, O.H., Peck, G., Burton, G.J., Sibley, C.P., Reik, W., Fowden, A.L., Constancia, M. Developmental adaptations to increased fetal nutrient demand in mouse genetic models of Igf2-mediated overgrowth. FASEB J. 25, 1737-1745 (2011). www.fasebj.org	[Angiolini, Emily; Sandovici, Ionel; Peck, Gerrard; Constancia, Miguel] Univ Cambridge, Dept Obstet & Gynaecol, Metab Res Labs, Cambridge CB2 0SW, England; [Coan, Phillip M.; Sandovici, Ionel; Burton, Graham J.; Reik, Wolf; Fowden, Abigail L.; Constancia, Miguel] Univ Cambridge, Dept Physiol Dev & Neurosci, Ctr Trophoblast Res, Cambridge CB2 0SW, England; [Angiolini, Emily; Iwajomo, O. H.; Reik, Wolf] Babraham Inst, Lab Dev Genet & Imprinting, Cambridge, England; [Angiolini, Emily; Sandovici, Ionel; Peck, Gerrard; Constancia, Miguel] Cambridge Biomed Res Ctr, Natl Inst Hlth Res, Cambridge, England; [Sibley, Colin P.] Univ Manchester, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Maternal & Fetal Hlth Res Ctr,Sch Biomed, Manchester M13 0JH, Lancs, England	University of Cambridge; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge; University of Manchester	Constancia, M (corresponding author), Univ Cambridge, Dept Obstet & Gynaecol, Metab Res Labs, Rosie Hosp, Robinson Way, Cambridge CB2 0SW, England.	jmasmc2@cam.ac.uk	Coan, P. M./ABA-1971-2020; Constancia, Miguel/F-6654-2013; Coan, P. M./AFQ-3665-2022; Reik, Wolf/I-6794-2012; sandovici, Ionel/H-3505-2019	Coan, P. M./0000-0001-6158-380X; Coan, P. M./0000-0001-6158-380X; sandovici, Ionel/0000-0001-5674-4269; Reik, Wolf/0000-0003-0216-9881; Constancia, Miguel/0000-0002-8976-1679	Biotechnology and Biological Sciences Research Council; FP6 Epigenome Network of Excellence; Medical Research Council Center for Obesity and Related Metabolic Disorders; Biotechnology and Biological Sciences Research Council [BBS/E/B/0000S119, BB/B50118X/2, S18929, BB/B50118X/1, BB/C513626/1] Funding Source: researchfish; Medical Research Council [G0700760, G0600717B] Funding Source: researchfish; MRC [G0700760] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); FP6 Epigenome Network of Excellence; Medical Research Council Center for Obesity and Related Metabolic Disorders(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Paul Smith for technical help with the placental transfer assays, E. Walters and Anne Segonds-Pichon for help with the statistical analyses, and Prof. Anne Ferguson-Smith for advice and discussions. This work was supported by grants from the Biotechnology and Biological Sciences Research Council, FP6 Epigenome Network of Excellence, and the Medical Research Council Center for Obesity and Related Metabolic Disorders.	Angiolini E, 2006, PLACENTA, V27, pS98, DOI 10.1016/j.placenta.2005.12.008; Atkinson DE, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P2787; Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808; Choufani S, 2010, AM J MED GENET C, V154C, P343, DOI 10.1002/ajmg.c.30267; Coan PM, 2008, J PHYSIOL-LONDON, V586, P4567, DOI 10.1113/jphysiol.2008.156133; Coan PM, 2004, BIOL REPROD, V70, P1806, DOI 10.1095/biolreprod.103.024166; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Constancia M, 2005, P NATL ACAD SCI USA, V102, P19219, DOI 10.1073/pnas.0504468103; Constancia M, 2004, NATURE, V432, P53, DOI 10.1038/432053a; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; Dilworth MR, 2010, P NATL ACAD SCI USA, V107, P3894, DOI 10.1073/pnas.0911710107; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Esquiliano DR, 2009, PLACENTA, V30, P693, DOI 10.1016/j.placenta.2009.05.004; Fowden AL, 2009, J PHYSIOL-LONDON, V587, P3459, DOI 10.1113/jphysiol.2009.173013; Fowden AL, 2006, J PHYSIOL-LONDON, V572, P5, DOI 10.1113/jphysiol.2005.104141; Gicquel C, 2006, HORM RES, V65, P28, DOI 10.1159/000091503; Jansson T, 2006, PLACENTA, V27, pS109, DOI 10.1016/j.placenta.2006.01.017; Jansson T, 2006, PLACENTA, V27, pS91, DOI 10.1016/j.placenta.2005.11.010; Jansson T, 2002, DIABETES, V51, P2214, DOI 10.2337/diabetes.51.7.2214; Jansson T, 2007, CLIN SCI, V113, P1, DOI 10.1042/CS20060339; Jones HN, 2009, FASEB J, V23, P271, DOI 10.1096/fj.08-116889; Kawahara M, 2010, J REPROD DEVELOP, V56, P79, DOI 10.1262/jrd.09-140A; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; Reik W, 2003, J PHYSIOL-LONDON, V547, P35, DOI 10.1113/jphysiol.2002.033274; SCHRODER HJ, 1995, EUR J OBSTET GYN R B, V63, P81, DOI 10.1016/0301-2115(95)02206-M; Seidell JC, 2000, BRIT J NUTR, V83, pS5, DOI 10.1017/S000711450000088X; Simeoni U, 2009, SEMIN FETAL NEONAT M, V14, P119, DOI 10.1016/j.siny.2009.01.002; Stotland NE, 2004, INT J GYNECOL OBSTET, V87, P220, DOI 10.1016/j.ijgo.2004.08.010; Tycko B, 2002, J CELL PHYSIOL, V192, P245, DOI 10.1002/jcp.10129; WENG EY, 1995, AM J MED GENET, V56, P366, DOI 10.1002/ajmg.1320560405; Zhang J, 2008, AM J OBSTET GYNECOL, V199, pS51, DOI 10.1016/j.ajog.2008.09.161	34	49	49	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1737	1745		10.1096/fj.10-175273	http://dx.doi.org/10.1096/fj.10-175273			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21282203				2022-12-28	WOS:000290023800029
J	Bahney, CS; Hsu, CW; Yoo, JU; West, JL; Johnstone, B				Bahney, Chelsea S.; Hsu, Chih-Wei; Yoo, Jung U.; West, Jennifer L.; Johnstone, Brian			A bioresponsive hydrogel tuned to chondrogenesis of human mesenchymal stem cells	FASEB JOURNAL			English	Article						biodegradable scaffold; cartilage tissue engineering; matrix metalloproteinase; poly(ethylene glycol) diacrylate; matrilysin	HYALURONIC-ACID HYDROGELS; IN-VITRO CHONDROGENESIS; POLY(ETHYLENE GLYCOL); EXTRACELLULAR-MATRIX; ARTICULAR-CARTILAGE; CONTROLLED DIFFERENTIATION; TISSUE REGENERATION; AMINO PROPEPTIDE; DEGRADATION; MATRILYSIN	Cartilage tissue engineering aims to replace damaged or diseased tissue with a functional regenerate that restores joint function. Scaffolds are used to deliver cells and facilitate tissue development, but they can also interfere with the structural assembly of the cartilage matrix. Biodegradable scaffolds have been proposed as a means to improve matrix deposition and the biomechanical properties of neocartilage. The challenge is designing scaffolds with appropriate degradation rates, ideally such that scaffold degradation is proportional to matrix deposition. In this study, we developed a bioresponsive hydrogel with cell-mediated degradation aligned to the chondrogenic differentiation of human mesenchymal stem cells (hMSCs). We identified matrix metalloproteinase 7 (MMP7) as an enzyme with a temporal expression pattern that corresponded with cartilage development. By embedding MMP7 peptide substrates within a poly(ethylene glycol) diacrylate backbone, we built MMP7-sensitive hydrogels with distinct degradation rates. When MMP7-sensitive scaffolds were compared with nondegradable scaffolds in vitro, photoencapsulated hMSCs produced neocartilage constructs with more extensive collagenous matrices, as demonstrated through immunohistochemistry and biochemical quantification of matrix molecules. Furthermore, these changes translated into an increased dynamic compressive modulus. This work presents a practical strategy for designing biomaterials uniquely tuned to individual biological processes.-Bahney, C. S., Hsu, C.-W., Yoo, J. U., West, J. L., Johnstone, B. A bioresponsive hydrogel tuned to chondrogenesis of human mesenchymal stem cells. FASEB J. 25, 1486-1496 (2011). www.fasebj.org	[Bahney, Chelsea S.; Yoo, Jung U.; Johnstone, Brian] Oregon Hlth & Sci Univ, Dept Orthopaed & Rehabil, Portland, OR 97239 USA; [Bahney, Chelsea S.; Johnstone, Brian] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA; [Hsu, Chih-Wei; West, Jennifer L.] Rice Univ, Dept Bioengn, Houston, TX USA	Oregon Health & Science University; Oregon Health & Science University; Rice University	Johnstone, B (corresponding author), Oregon Hlth & Sci Univ, Dept Orthopaed & Rehabil, 3181 SW Sam Jackson Rd,OP31, Portland, OR 97239 USA.	johnstob@ohsu.edu	Hsu, Chih-Wei/ABI-1472-2020; West, Jennifer L/A-4582-2008	Hsu, Chih-Wei/0000-0002-9591-9567; West, Jennifer L/0000-0001-8550-2875	Gerlinger Endowment (Oregon Health and Science University); National Football League Charities; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM071338] Funding Source: NIH RePORTER	Gerlinger Endowment (Oregon Health and Science University); National Football League Charities; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Hans Peter Bachinger and Jessica Hacker (Shriners Hospital, Portland, OR, USA) for synthesizing the peptides used to build the bioresponsive hydrogels; Drs. Trevor Lujan and Michael Bottlang (Legacy Biomechanics Laboratory, Portland, OR, USA) for assistance with mechanical testing; Dr. Ronen Schweitzer (Oregon Health and Science University) for providing embryonic mouse limbs for immunohistochemical staining; and Drs. Bob Hart and Alex Ching (Oregon Health and Science University) for providing bone marrow aspirates following patient consent. Research was supported in part by grants from the Gerlinger Endowment (Oregon Health and Science University) and the National Football League Charities. The authors declare the following conflict of interest: the process for in vitro chondrogenesis of MSCs was patented by B.J. and J.U.Y and licensed to Osiris Therapeutics, Inc. (Columbia, MD, USA).	Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269; Bryant S J, 1999, Biomed Sci Instrum, V35, P309; Bryant SJ, 2000, J BIOMAT SCI-POLYM E, V11, P439, DOI 10.1163/156856200743805; Bryant SJ, 2004, ANN BIOMED ENG, V32, P407, DOI 10.1023/B:ABME.0000017535.00602.ca; Bryant SJ, 2003, J BIOMED MATER RES A, V67A, P1430, DOI 10.1002/jbm.a.20003; Bryant SJ, 2002, J BIOMED MATER RES, V59, P63, DOI 10.1002/jbm.1217; Bryant SJ, 2003, J BIOMED MATER RES A, V64A, P70, DOI 10.1002/jbm.a.10319; Burns JW, 2009, NAT MATER, V8, P441, DOI 10.1038/nmat2462; Buxton AN, 2007, TISSUE ENG, V13, P2549, DOI 10.1089/ten.2007.0075; Carter DR, 2004, CLIN ORTHOP RELAT R, pS69, DOI 10.1097/01.blo.0000144970.05107.7e; Chung C, 2009, BIOMATERIALS, V30, P4287, DOI 10.1016/j.biomaterials.2009.04.040; Colige A, 2005, J BIOL CHEM, V280, P34397, DOI 10.1074/jbc.M506458200; Dickhut A, 2009, J CELL PHYSIOL, V219, P219, DOI 10.1002/jcp.21673; Djouad F, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2153; Erickson IE, 2009, OSTEOARTHR CARTILAGE, V17, P1639, DOI 10.1016/j.joca.2009.07.003; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Fingleton B, 2007, HYBRIDOMA, V26, P22, DOI 10.1089/hyb.2006.028; Fingleton BM, 1999, APMIS, V107, P102, DOI 10.1111/j.1699-0463.1999.tb01532.x; Flannery CR, 2006, FRONT BIOSCI-LANDMRK, V11, P544, DOI 10.2741/1818; Fukui N, 2002, J BIOL CHEM, V277, P2193, DOI 10.1074/jbc.M105485200; Graham N B, 1998, Med Device Technol, V9, P22; Graham N B, 1998, Med Device Technol, V9, P18; Huebsch N, 2009, NATURE, V462, P426, DOI 10.1038/nature08601; Hung CT, 2004, ANN BIOMED ENG, V32, P35, DOI 10.1023/B:ABME.0000007789.99565.42; Hwang NS, 2008, ADV DRUG DELIVER REV, V60, P199, DOI 10.1016/j.addr.2007.08.036; Hwang NS, 2006, TISSUE ENG, V12, P2695, DOI 10.1089/ten.2006.12.2695; Hwang NS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002498; Hwang NS, 2008, P NATL ACAD SCI USA, V105, P20641, DOI 10.1073/pnas.0809680106; Ifkovits JL, 2007, TISSUE ENG, V13, P2369, DOI 10.1089/ten.2007.0093; Ii M, 2006, EXP BIOL MED, V231, P20; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Johnstone B., 2006, CELL SOURCES CARTILA; Kisiday JD, 2004, J BIOMECH, V37, P595, DOI 10.1016/j.jbiomech.2003.10.005; Kloxin AM, 2009, SCIENCE, V324, P59, DOI 10.1126/science.1169494; Lujan TJ, 2009, J APPL PHYSIOL, V106, P423, DOI 10.1152/japplphysiol.90748.2008; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Lutolf MP, 2003, P NATL ACAD SCI USA, V100, P5413, DOI 10.1073/pnas.0737381100; Malemud CJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1702, DOI 10.2741/1916; Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142-9612(00)00196-4; Martens PJ, 2003, BIOMACROMOLECULES, V4, P283, DOI 10.1021/bm025666v; Nakamura M, 2005, BIOCHEM BIOPH RES CO, V333, P1011, DOI 10.1016/j.bbrc.2005.06.010; Nguyen KT, 2002, BIOMATERIALS, V23, P4307, DOI 10.1016/S0142-9612(02)00175-8; Nicodemus GD, 2008, TISSUE ENG PT B-REV, V14, P149, DOI 10.1089/ten.teb.2007.0332; Park S, 2006, J BIOMECH ENG-T ASME, V128, P623, DOI 10.1115/1.2206201; Park Y, 2004, TISSUE ENG, V10, P515, DOI 10.1089/107632704323061870; Pelttari K, 2006, ARTHRITIS RHEUM-US, V54, P3254, DOI 10.1002/art.22136; Pelttari K, 2008, INJURY, V39, pS58, DOI 10.1016/j.injury.2008.01.038; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Ra HJ, 2009, J BIOL CHEM, V284, P27924, DOI 10.1074/jbc.M109.035147; Rawlings ND, 2008, NUCLEIC ACIDS RES, V36, pD320, DOI 10.1093/nar/gkm954; Rice MA, 2004, J BIOMED MATER RES A, V70A, P560, DOI 10.1002/jbm.a.30106; Rice MA, 2007, TISSUE ENG, V13, P683, DOI 10.1089/ten.2006.0142; Sahoo S, 2008, BIOMACROMOLECULES, V9, P1088, DOI 10.1021/bm800051m; Salinas CN, 2008, BIOMATERIALS, V29, P2370, DOI 10.1016/j.biomaterials.2008.01.035; Salinas CN, 2009, J BIOMED MATER RES A, V90A, P456, DOI 10.1002/jbm.a.32112; Scherer RL, 2008, MOL IMAGING, V7, P118, DOI 10.2310/7290.2008.00010; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Temenoff JS, 2000, BIOMATERIALS, V21, P431, DOI 10.1016/S0142-9612(99)00213-6; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Ulijn RV, 2007, MATER TODAY, V10, P40, DOI 10.1016/S1369-7021(07)70049-4; Varghese S, 2008, MATRIX BIOL, V27, P12, DOI 10.1016/j.matbio.2007.07.002; Vinatier C, 2009, TRENDS BIOTECHNOL, V27, P307, DOI 10.1016/j.tibtech.2009.02.005; Wang FQ, 2005, INT J CANCER, V114, P19, DOI 10.1002/ijc.20697; Wang WS, 2006, CELL MOL LIFE SCI, V63, P663, DOI 10.1007/s00018-005-5425-4; West JL, 1999, MACROMOLECULES, V32, P241, DOI 10.1021/ma981296k; Williams CG, 2005, BIOMATERIALS, V26, P1211, DOI 10.1016/j.biomaterials.2004.04.024; Williams DF, 2009, BIOMATERIALS, V30, P5897, DOI 10.1016/j.biomaterials.2009.07.027; Wong M, 2003, BONE, V33, P1, DOI 10.1016/S8756-3282(03)00083-8; Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623-199812000-00004; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	70	91	98	5	56	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1486	1496		10.1096/fj.10-165514	http://dx.doi.org/10.1096/fj.10-165514			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21282205	Green Published			2022-12-28	WOS:000290023800007
J	Zhang, LP; Rajan, V; Lin, E; Hu, ZY; Han, HQ; Zhou, XL; Song, YP; Min, HS; Wang, XN; Du, J; Mitch, WE				Zhang, Liping; Rajan, Vik; Lin, Eugene; Hu, Zhaoyong; Han, H. Q.; Zhou, Xiaolan; Song, Yanping; Min, Hosung; Wang, Xiaonan; Du, Jie; Mitch, William E.			Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease	FASEB JOURNAL			English	Article						inflammatory cytokines; muscle protein synthesis; muscle protein degradation; muscle wasting	UBIQUITIN-PROTEASOME PATHWAY; FOXO TRANSCRIPTION FACTORS; KAPPA-B KINASE; SKELETAL-MUSCLE; INSULIN-RESISTANCE; PROTEIN-DEGRADATION; MUSCULAR-DYSTROPHY; EXPRESSION; GENE; ACTIVATION	Chronic kidney disease (CKD) and several other catabolic conditions are characterized by increased circulating inflammatory cytokines, defects in IGF-1 signaling, abnormal muscle protein metabolism, and progressive muscle atrophy. In these conditions, no reliable treatments successfully block the development of muscle atrophy. In mice with CKD, we found a 2- to 3-fold increase in myostatin expression in muscle. Its pharmacological inhibition by subcutaneous injections of an anti-myostatin peptibody into CKD mice (IC(50) similar to 1.2 nM) reversed the loss of body weight (approximate to 5-7% increase in body mass) and muscle mass (similar to 10% increase in muscle mass) and suppressed circulating inflammatory cytokines vs. results from CKD mice injected with PBS. Pharmacological myostatin inhibition also decreased the rate of protein degradation (16.38 +/- 1.29%; P < 0.05), increased protein synthesis in extensor digitorum longus muscles (13.21 +/- 1.09%; P < 0.05), markedly enhanced satellite cell function, and improved IGF-1 intracellular signaling. In cultured muscle cells, TNF-alpha increased myostatin expression via a NF-kappa B-dependent pathway, whereas muscle cells exposed to myostatin stimulated IL-6 production via p38 MAPK and MEK1 pathways. Because IL-6 stimulates muscle protein breakdown, we conclude that CKD increases myostatin through cytokine-activated pathways, leading to muscle atrophy. Myostatin antagonism might become a therapeutic strategy for improving muscle growth in CKD and other conditions with similar characteristics.-Zhang, L., Rajan, V., Lin, E., Hu, Z., Han, H. Q., Zhou, X., Song, Y., Min, H., Wang, X., Du, J., Mitch, W. E. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 25, 1653-1663 (2011). www.fasebj.org	[Zhang, Liping; Rajan, Vik; Lin, Eugene; Hu, Zhaoyong; Du, Jie; Mitch, William E.] Baylor Coll Med, Div Nephrol, Houston, TX 77030 USA; [Han, H. Q.; Zhou, Xiaolan; Song, Yanping; Min, Hosung] Amgen Inc, Metab Disorders Dept, Thousand Oaks, CA USA; [Wang, Xiaonan] Emory Univ, Div Renal, Atlanta, GA 30322 USA	Baylor College of Medicine; Amgen; Emory University	Mitch, WE (corresponding author), Baylor Coll Med, Div Nephrol, M-S BCM 395,1 Baylor Plaza,ABBR R705, Houston, TX 77030 USA.	mitch@bcm.edu		Lin, Eugene/0000-0002-3559-5134	Satellite Healthcare; American Diabetes Association [1-11-BS-194]; National Institutes of Health [R37-DK37175, R01-DK62828, P50-DK64233]; Amgen Inc.; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062828, P50DK064233, R37DK037175] Funding Source: NIH RePORTER	Satellite Healthcare; American Diabetes Association(American Diabetes Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amgen Inc.(Amgen); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Huiling Wang and Limei Ran for their assistance with care of mice with CKD. This study was sponsored by Satellite Healthcare (L.Z.), the American Diabetes Association (1-11-BS-194; L.Z.), the National Institutes of Health (grants R37-DK37175, R01-DK62828, and P50-DK64233), and a grant from Dr. and Mrs. Harold Selzman. Portions of these experiments were supported by a grant from Amgen Inc. L.Z., V. R., E. L., Z.H., X. W., J.D., and W. E. M declare no conflicts of interest. H. Q. H., X.Z., Y.S., and H. M. are current or former employees of Amgen Inc.	Bailey JL, 2006, J AM SOC NEPHROL, V17, P1388, DOI 10.1681/ASN.2004100842; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; Bartoli M, 2007, GENE THER, V14, P733, DOI 10.1038/sj.gt.3302928; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Bogdanovich S, 2005, FASEB J, V19, P543, DOI 10.1096/fj.04-2796com; Brunskill NJ, 1998, J CLIN INVEST, V101, P2140, DOI 10.1172/JCI1923; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Girgenrath S, 2005, MUSCLE NERVE, V31, P34, DOI 10.1002/mus.20175; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; HASSELGREN PO, 1987, ARCH SURG-CHICAGO, V122, P228; Hu Zhaoyong, 2009, J Clin Invest, V119, P3059, DOI 10.1172/JCI38770; Lalani R, 2000, J ENDOCRINOL, V167, P417, DOI 10.1677/joe.0.1670417; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1; Ma K, 2001, AM J PHYSIOL-ENDOC M, V281, pE1128, DOI 10.1152/ajpendo.2001.281.6.E1128; MAY RC, 1987, J CLIN INVEST, V79, P1099, DOI 10.1172/JCI112924; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McFarlane C, 2006, J CELL PHYSIOL, V209, P501, DOI 10.1002/jcp.20757; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Philip B, 2005, CELL SIGNAL, V17, P365, DOI 10.1016/j.cellsig.2004.08.003; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; SHORTREED K, 2008, SKELETAL MUSCLE DAMA, P77; Stenvinkel P, 2005, KIDNEY INT, V67, P1216, DOI 10.1111/j.1523-1755.2005.00200.x; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sumner CJ, 2009, HUM MOL GENET, V18, P3145, DOI 10.1093/hmg/ddp253; Wagner KR, 2008, ANN NEUROL, V63, P561, DOI 10.1002/ana.21338; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Wang XH, 2010, J BIOL CHEM, V285, P3527; Welle S, 2006, AM J PHYSIOL-ENDOC M, V290, pE409, DOI 10.1152/ajpendo.00433.2005; Wilkes JJ, 2009, DIABETES, V58, P1133, DOI 10.2337/db08-0245; Zachwieja J J, 1999, J Gravit Physiol, V6, P11; Zhang LP, 2010, J AM SOC NEPHROL, V21, P419, DOI 10.1681/ASN.2009060571; Zhang LP, 2009, J AM SOC NEPHROL, V20, P604, DOI 10.1681/ASN.2008060628; Zhang LP, 2005, CANCER RES, V65, P457; Zhang LP, 2005, CIRC RES, V97, P975, DOI 10.1161/01.RES.0000190589.52286.41; Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	46	201	211	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1653	1663		10.1096/fj.10-176917	http://dx.doi.org/10.1096/fj.10-176917			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21282204	Green Published			2022-12-28	WOS:000290023800022
J	Garland, RC; Sun, DW; Zandi, S; Xie, F; Faez, S; Tayyari, F; Frimmel, SAF; Schering, A; Nakao, S; Hafezi-Moghadam, A				Garland, Rebecca C.; Sun, Dawei; Zandi, Souska; Xie, Fang; Faez, Sepideh; Tayyari, Faryan; Frimmel, Sonja A. F.; Schering, Alexander; Nakao, Shintaro; Hafezi-Moghadam, Ali			Noninvasive molecular imaging reveals role of PAF in leukocyte-endothelial interaction in LPS-induced ocular vascular injury	FASEB JOURNAL			English	Article						platelet-activating factor; leukocyte recruitment; endotoxin-induced uveitis; P-selectin glycoprotein ligand-1; ginkgolide B; WEB 2086	PLATELET-ACTIVATING-FACTOR; ENDOTOXIN-INDUCED UVEITIS; SELECTIN GLYCOPROTEIN LIGAND-1; ROLLING IN-VIVO; P-SELECTIN; FACTOR-ACETYLHYDROLASE; HUMAN NEUTROPHILS; FACTOR RECEPTOR; UP-REGULATION; PLASMA	Uveitis is a systemic immune disease and a common cause of blindness. The eye is an ideal organ for light-based imaging of molecular events underlying vascular and immune diseases. The phospholipid platelet-activating factor (PAF) is an important mediator of inflammation, the action of which in endothelial and immune cells in vivo is not well understood. The purpose of this study was to investigate the role of PAF in endothelial injury in uveitis. Here, we use our recently introduced in vivo molecular imaging approach in combination with the PAF inhibitors WEB 2086 (WEB) and ginkgolide B (GB). The differential inhibitory effects of WEB and GB in reducing LPS-induced endothelial injury in the choroid indicate an important role for PAF-like lipids, which might not require the PAF receptor for their signaling. P-selectin glycoprotein ligand-1-mediated rolling of mouse leukocytes on immobilized P-selectin in our autoperfused microflow chamber assay revealed a significant reduction in rolling velocity on the cells' contact with PAF. Rolling cells that came in contact with PAF rapidly assumed morphological signs of cell activation, indicating that activation during rolling does not require integrins. Our results show a key role for PAF in mediating endothelial and leukocyte activation in acute ocular inflammation. Our in vivo molecular imaging provides a detailed view of cellular and molecular events in the complex physiological setting.-Garland, R. C., Sun, D., Zandi, S., Xie, F., Faez, S., Tayyari, F., Frimmel, S. A. F., Schering, A., Nakao, S., Hafezi-Moghadam, A. Noninvasive molecular imaging reveals role of PAF in leukocyte-endothelial interaction in LPS-induced ocular vascular injury. FASEB J. 25, 1284-1294 (2011). www.fasebj.org	[Garland, Rebecca C.; Sun, Dawei; Zandi, Souska; Xie, Fang; Schering, Alexander; Hafezi-Moghadam, Ali] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Funct & Mol Imaging, Boston, MA 02115 USA; [Garland, Rebecca C.; Sun, Dawei; Zandi, Souska; Xie, Fang; Schering, Alexander; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Garland, Rebecca C.; Sun, Dawei; Zandi, Souska; Xie, Fang; Faez, Sepideh; Tayyari, Faryan; Frimmel, Sonja A. F.; Schering, Alexander; Nakao, Shintaro; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; [Garland, Rebecca C.; Sun, Dawei; Zandi, Souska; Xie, Fang; Faez, Sepideh; Tayyari, Faryan; Frimmel, Sonja A. F.; Schering, Alexander; Nakao, Shintaro; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA; [Sun, Dawei] Harbin Med Coll, Affiliated Hosp 2, Dept Ophthalmol, Harbin, Peoples R China	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary; Harbin Medical University	Hafezi-Moghadam, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Funct & Mol Imaging, 221 Longwood Ave,3rd Floor, Boston, MA 02115 USA.	ahm@bwh.harvard.edu	Tayyari, Faryan/AAS-9020-2020	Zandi, Souska/0000-0001-9351-4278; Hafezi-Moghadam, Ali/0000-0002-5336-0697	U.S. National Institutes of Health [AI-050775]; American Health Assistance Foundation; Malaysian Palm Oil Board; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Health Assistance Foundation(BrightFocus Foundation); Malaysian Palm Oil Board; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Research-grade YSPSL (recombinant soluble P-selectin glycoprotein ligand IgG fusion protein rPSGL-Ig) was a kind gift of Y's Therapeutics (San Bruno, CA, USA). This work was supported by U.S. National Institutes of Health grant AI-050775, the American Health Assistance Foundation, and the Malaysian Palm Oil Board.	Almulki L, 2009, FASEB J, V23, P929, DOI 10.1096/fj.08-118760; Davenpeck KL, 2000, J IMMUNOL, V165, P2764, DOI 10.4049/jimmunol.165.5.2764; Devine L, 1996, IMMUNOLOGY, V88, P456, DOI 10.1046/j.1365-2567.1996.d01-666.x; Gardner AA, 2008, J BIOL CHEM, V283, P17099, DOI 10.1074/jbc.M802394200; Gelb MH, 2000, BBA-MOL CELL BIOL L, V1488, P20, DOI 10.1016/S1388-1981(00)00106-2; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Hafezi-Moghadam A, 2007, FASEB J, V21, P464, DOI 10.1096/fj.06-6390com; Hafezi-Moghadam A, 2004, AM J PHYSIOL-CELL PH, V286, pC876, DOI 10.1152/ajpcell.00500.2003; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Howard KM, 2000, J BIOL CHEM, V275, P19891, DOI 10.1074/jbc.M001462200; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Jeong YI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006503; Maliba R, 2008, J LEUKOCYTE BIOL, V83, P352, DOI 10.1189/jlb.0107056; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Miyahara S, 2008, FASEB J, V22, P1973, DOI 10.1096/fj.07-096891; Miyamoto K, 1996, INVEST OPHTH VIS SCI, V37, P2708; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; NUNEZ D, 1986, EUR J PHARMACOL, V123, P197, DOI 10.1016/0014-2999(86)90660-6; ODONNELL SR, 1988, BRIT J PHARMACOL, V94, P437, DOI 10.1111/j.1476-5381.1988.tb11545.x; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Proudfoot JM, 2009, J LIPID RES, V50, P716, DOI 10.1194/jlr.M800607-JLR200; Rollin S, 2004, BLOOD, V103, P3789, DOI 10.1182/blood-2003-07-2272; ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0; Schmidt H, 1996, J SURG RES, V60, P29, DOI 10.1006/jsre.1996.0006; Seo HS, 2006, CLIN VACCINE IMMUNOL, V13, P452, DOI 10.1128/CVI.13.4.452-458.2006; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; STEWART AG, 1988, BRIT J PHARMACOL, V94, P1225, DOI 10.1111/j.1476-5381.1988.tb11642.x; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Sun DW, 2010, FASEB J, V24, P1532, DOI 10.1096/fj.09-148981; SuttorpSchulten MSA, 1996, BRIT J OPHTHALMOL, V80, P844, DOI 10.1136/bjo.80.9.844; Suzuma K, 1997, INVEST OPHTH VIS SCI, V38, P1610; Tellis CC, 2009, BBA-MOL CELL BIOL L, V1791, P327, DOI 10.1016/j.bbalip.2009.02.015; Xie F, 2010, AM J PATHOL, V177, P39, DOI 10.2353/ajpath.2010.100007; YUE TL, 1991, J LIPID MEDIATOR, V3, P13	36	19	21	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1284	1294		10.1096/fj.10-160051	http://dx.doi.org/10.1096/fj.10-160051			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21257713	Green Published			2022-12-28	WOS:000288982800017
J	Tian, YM; Kongsuphol, P; Hug, M; Ousingsawat, J; Witzgall, R; Schreiber, R; Kunzelmann, K				Tian, Yuemin; Kongsuphol, Patthara; Hug, Martin; Ousingsawat, Jiraporn; Witzgall, Ralph; Schreiber, Rainer; Kunzelmann, Karl			Calmodulin-dependent activation of the epithelial calcium-dependent chloride channel TMEM16A	FASEB JOURNAL			English	Article						Ca2+ -activated Cl- channels; anoctamin 1; exocytosis; SK4; 1-EBIO; cystic fibrosis	CA2+-ACTIVATED K+ CHANNEL; STIMULATES CL-SECRETION; INTERMEDIATE-CONDUCTANCE; SMOOTH-MUSCLE; INTERSTITIAL-CELLS; CYSTIC-FIBROSIS; PROTEIN-KINASE; CA CHANNEL; EXPRESSION; BENZIMIDAZOLONES	TMEM16A (anoctamin 1, Ano1), a member of a family of 10 homologous proteins, has been shown to form an essential component of Ca2+ -activated Cl- channels. TMEM16A-null mice exhibit severe defects in epithelial transport along with tracheomalacia and death within 1 mo after birth. Despite its outstanding physiological significance, the mechanisms for activation of TMEM16A remain obscure. TMEM16A is activated on increase in intracellular Ca2+, but it is unclear whether Ca2+ binds directly to the channel or whether additional components are required. We demonstrate that TMEM16A is strictly membrane localized and requires cytoskeletal interactions to be fully activated. Despite the need for cytosolic ATP for full activation, phosphorylation by protein kinases is not required. In contrast, the Ca2+ binding protein calmodulin appears indispensable and interacts physically with TMEM16A. Openers of small-and intermediate-conductance Ca2+ -activated potassium channels known to interact with calmodulin, such as 1-EBIO, DCEBIO, or riluzole, also activated TMEM16A. These results reinforce the use of these compounds for activation of electrolyte secretion in diseases such as cystic fibrosis.-Tian, Y., Kongsuphol, P., Hug, M., Ousingsawat, J., Witzgall, R., Schreiber, R., Kunzelmann, K. Calmodulin-dependent activation of the epithelial calcium-dependent chloride channel TMEM16A. FASEB J. 25, 1058-1068 (2011). www.fasebj.org	[Tian, Yuemin; Kongsuphol, Patthara; Ousingsawat, Jiraporn; Schreiber, Rainer; Kunzelmann, Karl] Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany; [Hug, Martin] Apotheke Univ Klin Freiburg, Freiburg, Germany; [Witzgall, Ralph] Univ Regensburg, Inst Anat, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	karl.kunzelmann@vkl.uni-regensburg.de	Tian, Yuemin/AAE-8827-2021	Witzgall, Ralph/0000-0002-5283-4846; Kunzelmann, Karl/0000-0002-4583-7037	Deutsche Forschungsgemeinschaft (DFG) [SFB699 A7]; German Mukoviszidose eV; EU [EU-FP6-2005-LH-037365]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Mukoviszidose eV; EU(European Commission)	This study was supported by the Deutsche Forschungsgemeinschaft (DFG SFB699 A7), German Mukoviszidose eV, and the EU TargetScreen2 project (EU-FP6-2005-LH-037365). The authors thank Christine Meese and Karin Schadendorf for their excellent technical support in performing the ReAsH analysis of TMEM16A. The authors thank Hoechst/Aventis for providing the benzimidazolinone compound S0011198.	Almaca J, 2009, J BIOL CHEM, V284, P28571, DOI 10.1074/jbc.M109.010074; Alvarez LJ, 2005, AM J PHYSIOL-CELL PH, V289, pC138, DOI 10.1152/ajpcell.00190.2004; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Balla T, 2009, PHYSIOLOGY, V24, P231, DOI 10.1152/physiol.00014.2009; Boucher RC, 2007, J INTERN MED, V261, P5, DOI 10.1111/j.1365-2796.2006.01744.x; Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518; CHAN HC, 1994, J BIOL CHEM, V269, P32464; Chorna NE, 2007, J CELL PHYSIOL, V211, P410, DOI 10.1002/jcp.20946; De la Fuente R, 2008, MOL PHARMACOL, V73, P758, DOI 10.1124/mol.107.043208; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Eggermont Jan, 2004, Proc Am Thorac Soc, V1, P22, DOI 10.1513/pats.2306010; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Ferrera L, 2009, J BIOL CHEM, V284, P33360, DOI 10.1074/jbc.M109.046607; Galietta LJV, 2009, BIOPHYS J, V97, P3047, DOI 10.1016/j.bpj.2009.09.024; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; Gomez-Pinilla PJ, 2009, AM J PHYSIOL-GASTR L, V296, pG1370, DOI 10.1152/ajpgi.00074.2009; Greenwood IA, 2001, J PHYSIOL-LONDON, V534, P395, DOI 10.1111/j.1469-7793.2001.00395.x; Hamilton KL, 2006, AM J PHYSIOL-CELL PH, V290, pC152, DOI 10.1152/ajpcell.00187.2005; Hamilton KL, 1999, PFLUG ARCH EUR J PHY, V439, P158, DOI 10.1007/s004240051140; Hartzell C, 2005, ANNU REV PHYSIOL, V67, P719, DOI 10.1146/annurev.physiol.67.032003.154341; Ho MWY, 2001, J BIOL CHEM, V276, P18673, DOI 10.1074/jbc.M101128200; Huang F, 2009, P NATL ACAD SCI USA, V106, P21413, DOI 10.1073/pnas.0911935106; HUG T, 1995, PFLUG ARCH EUR J PHY, V429, P682, DOI 10.1007/BF00373989; Hwang SJ, 2009, J PHYSIOL-LONDON, V587, P4887, DOI 10.1113/jphysiol.2009.176198; Jensen BS, 2001, CURR DRUG TARGETS, V2, P401, DOI 10.2174/1389450013348173; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; KOLB HA, 1990, REV PHYSIOL BIOCH P, V115, P51; Kunzelmann Karl, 2003, Am J Respir Med, V2, P299; Kunzelmann K, 2009, CELL CALCIUM, V46, P233, DOI 10.1016/j.ceca.2009.09.003; Lee RJ, 2010, AM J PHYSIOL-LUNG C, V298, pL210, DOI 10.1152/ajplung.00342.2009; Liu BY, 2010, J CLIN INVEST, V120, P1240, DOI 10.1172/JCI41084; Maruyama Y, 1996, J PHYSIOL-LONDON, V492, P807, DOI 10.1113/jphysiol.1996.sp021347; Mazzochi C, 2006, AM J PHYSIOL-RENAL, V291, pF1113, DOI 10.1152/ajprenal.00195.2006; Ousingsawat J, 2009, J BIOL CHEM, V284, P28698, DOI 10.1074/jbc.M109.012120; Pedarzani P, 2001, J BIOL CHEM, V276, P9762, DOI 10.1074/jbc.M010001200; Pedersen KA, 1999, BBA-BIOMEMBRANES, V1420, P231, DOI 10.1016/S0005-2736(99)00110-8; Petersen OH, 2008, ANNU REV PHYSIOL, V70, P273, DOI 10.1146/annurev.physiol.70.113006.100618; Preston P, 2010, J BIOL CHEM, V285, P7165, DOI 10.1074/jbc.M109.047829; Rock JR, 2008, DEV BIOL, V321, P141, DOI 10.1016/j.ydbio.2008.06.009; Rock JR, 2009, J BIOL CHEM, V284, P14875, DOI 10.1074/jbc.C109.000869; Romanenko VG, 2010, J BIOL CHEM, V285, P12990, DOI 10.1074/jbc.M109.068544; Saleh SN, 2007, J PHARMACOL EXP THER, V321, P1075, DOI 10.1124/jpet.106.118786; Sankaranarayanan A, 2009, MOL PHARMACOL, V75, P281, DOI 10.1124/mol.108.051425; Schreiber R, 2010, J BIOL CHEM, V285, P7838, DOI 10.1074/jbc.M109.065367; Schroeder BC, 2008, CELL, V134, P1019, DOI 10.1016/j.cell.2008.09.003; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Skals M, 2010, J BIOL CHEM, V285, P15557, DOI 10.1074/jbc.M109.082578; Strobaek D, 2004, BBA-BIOMEMBRANES, V1665, P1, DOI 10.1016/j.bbamem.2004.07.006; Syme CA, 2000, AM J PHYSIOL-CELL PH, V278, pC570, DOI 10.1152/ajpcell.2000.278.3.C570; Thelin WR, 2007, J CLIN INVEST, V117, P364, DOI 10.1172/JCI30376; von Hahn T, 2001, CELL PHYSIOL BIOCHEM, V11, P219, DOI 10.1159/000051936; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; Wang YX, 1997, P NATL ACAD SCI USA, V94, P14918, DOI 10.1073/pnas.94.26.14918; Warth R, 1999, PFLUG ARCH EUR J PHY, V438, P437, DOI 10.1007/s004240051059; Wiwchar M, 2009, BRIT J PHARMACOL, V158, P1356, DOI 10.1111/j.1476-5381.2009.00405.x; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313	59	112	116	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1058	1068		10.1096/fj.10-166884	http://dx.doi.org/10.1096/fj.10-166884			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21115851				2022-12-28	WOS:000287806200025
J	Veyrac, A; Bakker, J				Veyrac, Alexandra; Bakker, Julie			Postnatal and adult exposure to estradiol differentially influences adult neurogenesis in the main and accessory olfactory bulb of female mice	FASEB JOURNAL			English	Article						aromatase-knockout mice; neuronal survival; functional integration	NEWLY-GENERATED NEURONS; EXPERIENCE-DEPENDENT SURVIVAL; DENTATE GYRUS; CELL-PROLIFERATION; SEXUAL-DIFFERENTIATION; GRANULE NEURONS; NEWBORN NEURONS; MEADOW VOLES; CYP19 GENE; STIMULATED NEUROGENESIS	Neurons incorporated into the adult main olfactory bulb (MOB) and accessory olfactory bulb (AOB) derive from the subventricular zone (SVZ). Despite some recent studies on the role of olfactory neurogenesis in sociosexual behaviors mediated by hormones, data on the implication of estrogens are still lacking. Taking advantage of female aromatase-knockout (ArKO) mice, which are unable to produce estradiol across their life span, we investigated the role of estradiol exposure during early postnatal and adult periods on adult neurogenesis in the MOB and AOB. We found that proliferation of progenitor cells in the adult female SVZ was not influenced by estradiol. However, whereas adult exposure to estradiol influences the turnover of MOB newborn neurons, the survival of those in the AOB depends on exposure to estradiol during the early postnatal period. Finally, based on their expression of Zif268, we showed that newborn neurons in the MOB responded to sociosexual odors, albeit to a lesser extent in ArKO females, suggesting a contribution of estradiol during the early postnatal period to this response. Together, these results suggest that the survival and functional integration of newborn neurons in the adult female MOB and AOB are differentially influenced by estrogens from the early postnatal period to adulthood.-Veyrac, A., Bakker, J. Postnatal and adult exposure to estradiol differentially influences adult neurogenesis in the main and accessory olfactory bulb of female mice. FASEB J. 25, 1048-1057 (2011). www.fasebj.org	[Veyrac, Alexandra; Bakker, Julie] Univ Liege, Grp Interdisciplinaire Genoproteom Appl GIGA Neur, B-4000 Liege, Belgium	University of Liege	Bakker, J (corresponding author), Univ Liege, Grp Interdisciplinaire Genoproteom Appl GIGA Neur, Ave Lhop 1,B36, B-4000 Liege, Belgium.	jbakker@ulg.ac.be	Veyrac, Alexandra/G-8313-2017	VEYRAC, Alexandra/0000-0002-8063-4016	U.S. National Institutes of Health [HD-044897]; University of Liege [C-06/89]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044897] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Liege(University of Liege); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors thank Drs. Michael Baum, Serge Laroche, and Silvia DeMarchis for comments on an earlier version of the manuscript; Marie Tsampalas for technical assistance; and Frederic Levy and Matthieu Keller for using the Mercator software. This work was supported by U.S. National Institutes of Health grant HD-044897 and grants from the University of Liege (C-06/89 to J.B. and A.V.). J.B. is a research associate at the Fonds National de la Recherche Scientifique.	Alonso M, 2006, J NEUROSCI, V26, P10508, DOI 10.1523/JNEUROSCI.2633-06.2006; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Bakker J, 2002, HORM BEHAV, V42, P158, DOI 10.1006/hbeh.2002.1805; Bakker J, 2003, J NEUROENDOCRINOL, V15, P615, DOI 10.1046/j.1365-2826.2003.01036.x; Bakker J, 2002, J NEUROSCI, V22, P9104; Bakker J, 2008, FRONT NEUROENDOCRIN, V29, P1, DOI 10.1016/j.yfrne.2007.06.001; Banasr M, 2001, EUR J NEUROSCI, V14, P1417, DOI 10.1046/j.0953-816x.2001.01763.x; Belluzzi O, 2003, J NEUROSCI, V23, P10411; Boehm U, 2005, CELL, V123, P683, DOI 10.1016/j.cell.2005.09.027; Britt KL, 2001, J STEROID BIOCHEM, V79, P181, DOI 10.1016/S0960-0760(01)00158-3; Brock O, 2010, NEUROSCIENCE, V166, P368, DOI 10.1016/j.neuroscience.2009.12.050; Carleton A, 2003, NAT NEUROSCI, V6, P507, DOI 10.1038/nn1048; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; Galea LAM, 1999, NEUROSCIENCE, V89, P955, DOI 10.1016/S0306-4522(98)00345-5; Galea LAM, 2008, BRAIN RES REV, V57, P332, DOI 10.1016/j.brainresrev.2007.05.008; Giachino C, 2005, J NEUROSCI, V25, P10105, DOI 10.1523/JNEUROSCI.3512-05.2005; Guerin D, 2009, NEUROBIOL AGING, V30, P272, DOI 10.1016/j.neurobiolaging.2007.05.020; Honda S, 1998, BIOCHEM BIOPH RES CO, V252, P445, DOI 10.1006/bbrc.1998.9672; HOWARD C, 1998, UNBIASED STEREOLOGY, P41; Hoyk Z, 2006, NEUROSCIENCE, V141, P1919, DOI 10.1016/j.neuroscience.2006.05.053; Huang LY, 2002, HORM BEHAV, V41, P343, DOI 10.1006/hbeh.2002.1767; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Keller M, 2006, EUR J NEUROSCI, V23, P521, DOI 10.1111/j.1460-9568.2005.04589.x; Keller M, 2009, BEHAV BRAIN RES, V200, P268, DOI 10.1016/j.bbr.2009.01.020; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Knapska E, 2004, PROG NEUROBIOL, V74, P183, DOI 10.1016/j.pneurobio.2004.05.007; Kowase T, 2007, ENDOCRINOLOGY, V148, P6083, DOI 10.1210/en.2007-0407; Larsen CM, 2008, HORM BEHAV, V53, P509, DOI 10.1016/j.yhbeh.2007.11.020; LARSEN CM, ENDOCRINOLOGY, V151, P3805; Lawson MA, 2007, MOL ENDOCRINOL, V21, P1175, DOI 10.1210/me.2006-0392; Lemasson M, 2005, J NEUROSCI, V25, P6816, DOI 10.1523/JNEUROSCI.1114-05.2005; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Magavi SSP, 2005, J NEUROSCI, V25, P10729, DOI 10.1523/JNEUROSCI.2250-05.2005; Mak GK, 2007, NAT NEUROSCI, V10, P1003, DOI 10.1038/nn1928; Mak GK, 2010, NAT NEUROSCI, V13, P753, DOI 10.1038/nn.2550; Mandairon N, 2006, EUR J NEUROSCI, V24, P3578, DOI 10.1111/j.1460-9568.2006.05235.x; MANNAN MA, 1991, J ENDOCRINOL, V130, P101, DOI 10.1677/joe.0.1300101; Martel KL, 2007, EUR J NEUROSCI, V26, P463, DOI 10.1111/j.1460-9568.2007.05651.x; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mouret A, 2008, J NEUROSCI, V28, P11511, DOI 10.1523/JNEUROSCI.2954-08.2008; Mouret A, 2009, J NEUROSCI, V29, P12302, DOI 10.1523/JNEUROSCI.3383-09.2009; Nissant A, 2009, NAT NEUROSCI, V12, P728, DOI 10.1038/nn.2298; Oboti L, 2009, EUR J NEUROSCI, V29, P679, DOI 10.1111/j.1460-9568.2009.06614.x; Ormerod BK, 2003, J NEUROBIOL, V55, P247, DOI 10.1002/neu.10181; Ormerod BK, 2004, NEUROSCIENCE, V128, P645, DOI 10.1016/j.neuroscience.2004.06.039; Ormerod BK, 2001, NEUROSCIENCE, V102, P369, DOI 10.1016/S0306-4522(00)00474-7; Petreanu L, 2002, J NEUROSCI, V22, P6106; Pierman S, 2008, EUR J NEUROSCI, V27, P423, DOI 10.1111/j.1460-9568.2007.06016.x; Quadros PS, 2002, ENDOCRINOLOGY, V143, P3727, DOI 10.1210/en.2002-211438; Quadros PS, 2002, J NEUROBIOL, V51, P24, DOI 10.1002/neu.10040; Rochefort C, 2002, J NEUROSCI, V22, P2679, DOI 10.1523/JNEUROSCI.22-07-02679.2002; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Shingo T, 2003, SCIENCE, V299, P117, DOI 10.1126/science.1076647; Slade JP, 2000, J NEUROENDOCRINOL, V12, P671; Smith MT, 2001, HORM BEHAV, V39, P11, DOI 10.1006/hbeh.2000.1630; Spencer JL, 2008, FRONT NEUROENDOCRIN, V29, P219, DOI 10.1016/j.yfrne.2007.08.006; SULTAN S, FASEB J, V24, P2355; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; Tanapat P, 2005, J COMP NEUROL, V481, P252, DOI 10.1002/cne.20385; Toda K, 2001, J ENDOCRINOL, V170, P99, DOI 10.1677/joe.0.1700099; Veyrac A, 2009, NEUROPSYCHOPHARMACOL, V34, P786, DOI 10.1038/npp.2008.191; Winner B, 2002, EUR J NEUROSCI, V16, P1681, DOI 10.1046/j.1460-9568.2002.02238.x; Yamaguchi M, 2005, P NATL ACAD SCI USA, V102, P9697, DOI 10.1073/pnas.0406082102; Yoon HY, 2005, CELL, V123, P669, DOI 10.1016/j.cell.2005.08.039; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	68	31	31	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1048	1057		10.1096/fj.10-172635	http://dx.doi.org/10.1096/fj.10-172635			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21148416	Green Published, Green Submitted			2022-12-28	WOS:000287806200024
J	Yamada, T; Tani, Y; Nakanishi, H; Taguchi, R; Arita, M; Arai, H				Yamada, Tomohiro; Tani, Yukako; Nakanishi, Hiroki; Taguchi, Ryo; Arita, Makoto; Arai, Hiroyuki			Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice	FASEB JOURNAL			English	Article						anti-inflammation; lipid mediator; lipoxygenase; metabolomics; protectin	DOCOSAHEXAENOIC ACID; LIPID MEDIATORS; INFLAMMATION; PROGRAMS; CELLS; IL-5	Acute inflammation in healthy individuals is self-limiting and has an active termination program. The mechanisms by which acute inflammation is resolved are of interest. In murine zymosan-induced peritonitis, we found that eosinophils are recruited to the inflamed loci during the resolution phase of acute inflammation. In vivo depletion of eosinophils caused a resolution deficit, namely impaired lymphatic drainage with reduced appearance of phagocytes carrying engulfed zymosan in the draining lymph node, and sustained numbers of polymorphonuclear leukocytes in inflamed tissues. Liquid chromatography-tandem mass spectrometry-based lipidomics of the resolving exudates revealed that locally activated eosinophils in the resolution phase produced proresolving mediators, including protectin D1 (PD1) from docosahexaenoic acid. The resolution deficit caused by eosinophil depletion was rescued by eosinophil restoration or the administration of PD1. Eosinophils deficient in 12/15-lipoxygenase could not rescue the resolution phenotype. The present results indicate that mouse eosinophils and eosinophil-derived lipid mediators, including PD1, have a role in promoting the resolution of acute inflammation, expanding the roles of eosinophils in host defense and resolution.-Yamada, T., Tani, Y., Nakanishi, H., Taguchi, R., Arita, M., Arai, H. Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice. FASEB J. 25, 561-568 (2011). www.fasebj.org	[Arita, Makoto] Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; [Nakanishi, Hiroki; Taguchi, Ryo] Univ Tokyo, Dept Metabolome, Grad Sch Med, Tokyo 1130033, Japan; [Taguchi, Ryo; Arai, Hiroyuki] Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Saitama, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Arita, M (corresponding author), Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	marita@mol.f.u-tokyo.ac.jp		Nakanishi, Hiroki/0000-0002-5108-1598; Arita, Makoto/0000-0001-9902-0463	Japan Science and Technology Agency; Core Research for Evolutional Science and Technology (CREST); Astella Foundation for Research on Metabolic Disorders	Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); Core Research for Evolutional Science and Technology (CREST)(Core Research for Evolutional Science and Technology (CREST)); Astella Foundation for Research on Metabolic Disorders	These studies were supported by the Japan Science and Technology Agency, Precursory Research for Embryonic Science and Technology (PRESTO; to M.A.) and Core Research for Evolutional Science and Technology (CREST; to H.A. and R.T), and a grant from the Astella Foundation for Research on Metabolic Disorders (to M.A.). The authors thank Dr. Kiyoshi Takatsu (University of Toyama, Toyama, Japan) for kindly providing IL-5 transgenic mice. The authors thank M. Kamiyama and M. Kamio for technical assistance with lipid extraction and sample preparation for LC-MS/MS, and S. Ishikawa and staff for animal care.	Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131; Bellingan GJ, 1996, J IMMUNOL, V157, P2577; Blaho VA, 2009, J BIOL CHEM, V284, P21599, DOI 10.1074/jbc.M109.003822; Cotran R. S., 1999, ROBBINS PATHOLOGIC B, V6th; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Jacobsen EA, 2007, J ALLERGY CLIN IMMUN, V119, P1313, DOI 10.1016/j.jaci.2007.03.043; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Takatsu K, 2008, CURR OPIN IMMUNOL, V20, P288, DOI 10.1016/j.coi.2008.04.001; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	20	102	103	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					561	568		10.1096/fj.10-170027	http://dx.doi.org/10.1096/fj.10-170027			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20959515				2022-12-28	WOS:000286724800014
J	Camm, EJ; Martin-Gronert, MS; Wright, NL; Hansell, JA; Ozanne, SE; Giussani, DA				Camm, E. J.; Martin-Gronert, M. S.; Wright, N. L.; Hansell, J. A.; Ozanne, S. E.; Giussani, D. A.			Prenatal hypoxia independent of undernutrition promotes molecular markers of insulin resistance in adult offspring	FASEB JOURNAL			English	Article						IUGR; insulin-signaling proteins; type 2 diabetes	PROTEIN-KINASE-C; LOW-BIRTH-WEIGHT; FREE FATTY-ACIDS; NUTRIENT RESTRICTION; GROWTH-RETARDATION; GLUCOSE-TRANSPORT; 3-KINASE ACTIVITY; SKELETAL-MUSCLE; DIABETIC OB/OB; HIGH-ALTITUDE	Molecular mechanisms predisposing people to insulin resistance are starting to emerge. Altered insulin signaling for hepatic gluconeogenesis and muscle glucose uptake is thought to play a central role. Development under suboptimal conditions is also known to increase the risk of insulin resistance in adulthood. However, the partial contributions of reduced oxygen vs. nutrient delivery to the fetus, two common adverse conditions in utero, to developmental programming of insulin resistance remain unknown. The aim of this study was to determine the effects of developmental hypoxia or undernutrition on the expression of insulin-signaling proteins in liver and skeletal muscle in adult rat offspring. We show that the expression of hepatic phospho-Akt and muscle Akt2 were significantly reduced in offspring of hypoxic, relative to offspring from normoxic or undernourished, pregnancies. Hepatic Akt-1, Akt-2, and PKC zeta protein expression was reduced in offspring from both hypoxic and undernourished pregnancies. Muscle GLUT4 expression was decreased in undernourished, and further decreased in hypoxic, offspring. These findings link prenatal hypoxia to down-regulation of components of hepatic and muscle Akt expression in adult offspring. Akt may represent a pharmaceutical target for clinical intervention against the developmental programming of metabolic disease resulting from prenatal hypoxia.-Camm, E. J., Martin-Gronert, M. S., Wright, N. L., Hansell, J. A., Ozanne, S. E., Giussani, D. A. Prenatal hypoxia independent of undernutrition promotes molecular markers of insulin resistance in adult offspring. FASEB J. 25, 420-427 (2011). www.fasebj.org	[Camm, E. J.; Wright, N. L.; Hansell, J. A.; Giussani, D. A.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England; [Martin-Gronert, M. S.; Ozanne, S. E.] Univ Cambridge, Addenbrookes Hosp, Metab Res Labs, Inst Metab Sci, Cambridge CB2 3EG, England	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Giussani, DA (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England.	dag26@cam.ac.uk		Ozanne, Susan/0000-0001-8753-5144; Giussani, Dino/0000-0002-1308-1204	British Heart Foundation; Medical Research Council Centre for Obesity and Related Metabolic Disorders (MRC-CORD); Royal Society; British Heart Foundation [FS/09/029/27902] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); Medical Research Council Centre for Obesity and Related Metabolic Disorders (MRC-CORD)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Royal Society(Royal Society of London); British Heart Foundation(British Heart Foundation)	This work was supported by the British Heart Foundation and the Medical Research Council Centre for Obesity and Related Metabolic Disorders (MRC-CORD). S.E.O. is a British Heart Foundation Senior Fellow. D. A. G. is a Royal Society Wolfson Research Merit Award Holder.	Bandyopadhyay GK, 2005, DIABETES, V54, P2351, DOI 10.2337/diabetes.54.8.2351; Barker DJP, 2009, ANN HUM BIOL, V36, P445, DOI 10.1080/03014460902980295; BARKER DJP, 1988, BRIT MED J, V297, P134, DOI 10.1136/bmj.297.6641.134-b; Baschat AA, 2004, SEMIN PERINATOL, V28, P67, DOI 10.1053/j.semperi.2003.10.014; Boden G, 2001, Endocr Pract, V7, P44; Byrne CD, 2000, J CLIN PATHOL, V53, P822, DOI 10.1136/jcp.53.11.822; Camm EJ, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.046; Campbell ME, 2005, PEDIATR RES, V58, P840, DOI 10.1203/01.PDR.0000181376.83137.ED; CHANG JHT, 1984, BIOL NEONATE, V46, P10; Cheema KK, 2005, BRIT J NUTR, V93, P471, DOI 10.1079/BJN20041392; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cianfarani S, 1999, ARCH DIS CHILD-FETAL, V81, pF71, DOI 10.1136/fn.81.1.F71; DEGRAUW TJ, 1986, BIOL NEONATE, V49, P85, DOI 10.1159/000242515; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Farese RV, 2005, EXP BIOL MED, V230, P593; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; Giussani DA, 2001, PEDIATR RES, V49, P490, DOI 10.1203/00006450-200104000-00009; Giussani DA, 2007, J PHYSIOL-LONDON, V585, P911, DOI 10.1113/jphysiol.2007.141572; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; HASS JD, 1980, HUM BIOL, V52, P459; Jensen CB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003738; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim JK, 2004, J CLIN INVEST, V114, P823, DOI 10.1172/JCI200422230; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Kim YB, 2003, DIABETES, V52, pA281; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Li GH, 2003, J SOC GYNECOL INVEST, V10, P265, DOI 10.1016/S1071-5576(03)00074-1; LICHTY JA, 1957, AMA J DIS CHILD, V93, P666, DOI 10.1001/archpedi.1957.02060040668009; Martin-Gronert MS, 2007, J INTERN MED, V261, P437, DOI 10.1111/j.1365-2796.2007.01800.x; McClung J., 1969, EFFECTS HIGH ALTITUD; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; Moore LG, 1998, YEARB PHYS ANTHROPOL, V41, P25; Neerhof MG, 2008, SEMIN PERINATOL, V32, P201, DOI 10.1053/j.semperi.2007.11.002; Ozaki T, 2001, J PHYSIOL-LONDON, V530, P141, DOI 10.1111/j.1469-7793.2001.0141m.x; Ozanne SE, 2006, DIABETOLOGIA, V49, P2993, DOI 10.1007/s00125-006-0466-2; Ozanne SE, 2005, DIABETOLOGIA, V48, P547, DOI 10.1007/s00125-005-1669-7; Park E, 2007, J ENDOCRINOL, V195, P323, DOI 10.1677/JOE-07-0005; Peyronnet J, 2002, PFLUG ARCH EUR J PHY, V443, P858, DOI 10.1007/s00424-001-0766-9; Roberts JM, 2005, HYPERTENSION, V46, P1243, DOI 10.1161/01.HYP.0000188408.49896.c5; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Rueda-Clausen CF, 2009, CARDIOVASC RES, V81, P713, DOI 10.1093/cvr/cvn341; Salinas CE, 2010, J DEV ORIG HLTH DIS, V1, P60, DOI 10.1017/S2040174409990043; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Standaert ML, 2004, J BIOL CHEM, V279, P24929, DOI 10.1074/jbc.M402440200; Williams SJ, 2005, AM J PHYSIOL-REG I, V288, pR360, DOI 10.1152/ajpregu.00178.2004; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zamudio S, 2007, FRONT BIOSCI-LANDMRK, V12, P2967, DOI 10.2741/2286; Zick Y, 2004, BIOCHEM SOC T, V32, P812, DOI 10.1042/BST0320812	52	57	58	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					420	427		10.1096/fj.10-158188	http://dx.doi.org/10.1096/fj.10-158188			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20923964				2022-12-28	WOS:000285869500038
J	Yan, HD; Deshpande, DA; Misior, AM; Miles, MC; Saxena, H; Riemer, EC; Pascual, RM; Panettieri, RA; Penn, RB				Yan, Huandong; Deshpande, Deepak A.; Misior, Anna M.; Miles, Matthew C.; Saxena, Himansh; Riemer, Ellen C.; Pascual, Rodolfo M.; Panettieri, Reynold A.; Penn, Raymond B.			Anti-mitogenic effects of beta-agonists and PGE(2) on airway smooth muscle are PKA dependent	FASEB JOURNAL			English	Article						airway remodeling; asthma; cell proliferation; cyclic AMP; G protein-coupled receptor	PROTEIN-COUPLED RECEPTORS; CELL-PROLIFERATION; HUMAN BETA(2)-ADRENOCEPTOR; KINASE-A; CAMP; DESENSITIZATION; INHIBITION; MECHANISMS; PHOSPHORYLATION; ACTIVATION	Inhaled beta-agonists are effective airway smooth muscle (ASM)-relaxing agents that help reverse bronchoconstriction in asthma, but their ability to affect the aberrant ASM growth that also occurs with asthma is poorly understood. beta-Agonists exhibit PKA-dependent antimitogenic effects in several cell types. However, recent studies suggest that Epac, and not PKA, mediates the antimitogenic effect of cAMP in both ASM and fibroblasts. This study aims to clarify the role of PKA in mediating the effect of G(s)-coupled receptors on human ASM growth. Pretreatment of ASM cultures with beta-agonists albuterol, isoproterenol, or salmeterol (100 nM to 10 mu M) caused a significant (similar to 25-30%) inhibition of EGF-stimulated ASM thymidine incorporation and cell proliferation, whereas a much greater inhibition was observed from pretreatment with PGE(2) (75-80%). However, all agents were ineffective in cells expressing GFP chimeras of either PKI (a PKA inhibitor) or a mutant PKA regulatory subunit relative to the control cells expressing GFP. The antimitogenic efficacy of PGE(2) in inhibiting control cultures was associated with greater ability to stimulate sustained PKA activation and greater inhibition of late-phase promitogenic p42/p44 and PI3K activities. These findings suggest that therapeutic approaches enabling superior PKA activation in ASM will be most efficacious in deterring ASM growth.-Yan, H., Deshpande, D. A., Misior, A. M., Miles, M. C., Saxena, H., Riemer, E. C., Pascual, R. M., Panettieri, R. A., Penn. R. B. Anti-mitogenic effects of beta-agonists and PGE2 on airway smooth muscle are PKA dependent. FASEB J. 25, 389-397 (2011). www.fasebj.org	[Yan, Huandong; Deshpande, Deepak A.; Saxena, Himansh; Penn, Raymond B.] Univ Maryland, Sch Med, Dept Med, Cardiopulm Genom Program, Baltimore, MD 21201 USA; [Misior, Anna M.; Miles, Matthew C.; Pascual, Rodolfo M.] Wake Forest Univ Hlth Sci, Ctr Human Genom, Winston Salem, NC USA; [Misior, Anna M.; Miles, Matthew C.; Pascual, Rodolfo M.] Wake Forest Univ Hlth Sci, Dept Internal Med, Winston Salem, NC USA; [Riemer, Ellen C.] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA; [Panettieri, Reynold A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University System of Maryland; University of Maryland Baltimore; Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; Medical University of South Carolina; University of Pennsylvania	Penn, RB (corresponding author), Univ Maryland, Sch Med, Dept Med, Cardiopulm Genom Program, 20 Penn St,HSF II Rm 147, Baltimore, MD 21201 USA.	rpenn@medicine.umaryland.edu	panettieri, reynold/AAG-9485-2019	Miles, Matthew/0000-0003-4768-385X	National Institutes of Health Heart, Lung, and Blood Institute [HL58506, HL087560]; GlaxoSmithKline; Interdisciplinary Training Program in Muscle Biology [AR007592]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058506, R01HL058506, K99HL087560, R00HL087560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG041265] Funding Source: NIH RePORTER	National Institutes of Health Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); GlaxoSmithKline(GlaxoSmithKline); Interdisciplinary Training Program in Muscle Biology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded by National Institutes of Health Heart, Lung, and Blood Institute grants HL58506 (R.B.P.) and HL087560 (D.A.D.), and an independent investigator grant from GlaxoSmithKline (R.B.P.). M.C.M is a trainee in the Tinsley R. Harrison Translational Research Training Program. H.S. is supported by the Interdisciplinary Training Program in Muscle Biology training grant AR007592.	Baker JG, 2003, MOL PHARMACOL, V64, P1357, DOI 10.1124/mol.64.6.1357; Billington CK, 2005, BIOCHEMISTRY-US, V44, P14595, DOI 10.1021/bi0510734; BUTT E, 1994, J BIOL CHEM, V269, P14509; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; Deshpande DA, 2008, FASEB J, V22, P2134, DOI 10.1096/fj.07-102459; Deshpande DA, 2006, CELL SIGNAL, V18, P2105, DOI 10.1016/j.cellsig.2006.04.008; Gosens R, 2003, AM J RESP CELL MOL, V28, P257, DOI 10.1165/rcmb.2002-0128OC; Grandoch M, 2009, BRIT J PHARMACOL, V159, P265; Guo MH, 2005, BIOCHEMISTRY-US, V44, P13771, DOI 10.1021/bi051255y; Haag S, 2008, N-S ARCH PHARMACOL, V378, P617, DOI 10.1007/s00210-008-0334-3; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Huang SK, 2008, AM J RESP CELL MOL, V39, P482, DOI 10.1165/rcmb.2008-0080OC; January B, 1998, BRIT J PHARMACOL, V123, P701, DOI 10.1038/sj.bjp.0701658; Kassel KM, 2008, AM J PHYSIOL-LUNG C, V294, pL131, DOI 10.1152/ajplung.00381.2007; Kong KC, 2008, BIOCHEMISTRY-US, V47, P9279, DOI 10.1021/bi801056w; Kong KC, 2006, FASEB J, V20, P1558, DOI 10.1096/fj.05-5622fje; Krymskaya VP, 2000, AM J RESP CELL MOL, V23, P546, DOI 10.1165/ajrcmb.23.4.4115; Misior AM, 2008, MOL PHARMACOL, V73, P566, DOI 10.1124/mol.107.040519; Misior AM, 2009, AM J RESP CELL MOL, V41, P24, DOI 10.1165/rcmb.2008-0266OC; NOVERAL JP, 1994, AM J PHYSIOL, V267, pL291, DOI 10.1152/ajplung.1994.267.3.L291; Orsini MJ, 1999, AM J PHYSIOL-LUNG C, V277, pL479, DOI 10.1152/ajplung.1999.277.3.L479; Penn RB, 2008, N-S ARCH PHARMACOL, V378, P149, DOI 10.1007/s00210-008-0263-1; Penn RB, 1998, AM J RESP CELL MOL, V19, P338, DOI 10.1165/ajrcmb.19.2.3025; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; Roscioni SS, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-88; Spicuzza L, 2001, BRIT J PHARMACOL, V133, P1201, DOI 10.1038/sj.bjp.0704213; Stewart AG, 1999, MOL PHARMACOL, V56, P1079, DOI 10.1124/mol.56.5.1079; Stewart AG, 1997, BRIT J PHARMACOL, V121, P361, DOI 10.1038/sj.bjp.0701128; TOMLINSON PR, 1995, BIOCHEM PHARMACOL, V49, P1809, DOI 10.1016/0006-2952(94)00532-Q; WALSH DA, 1971, J BIOL CHEM, V246, P1977	30	49	51	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2011	25	1					389	397		10.1096/fj.10-164798	http://dx.doi.org/10.1096/fj.10-164798			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20805374	Green Published			2022-12-28	WOS:000285869500035
J	Yang, LM; Blount, P				Yang, Li-Min; Blount, Paul			Manipulating the permeation of charged compounds through the MscL nanovalve	FASEB JOURNAL			English	Article						osmoregulation; drug-release device; ionic preference; ionic selectivity	MECHANOSENSITIVE CHANNEL MSCL; ESCHERICHIA-COLI-CELLS; ION-CHANNEL; MYCOBACTERIUM-TUBERCULOSIS; OSMOTIC DOWNSHOCK; STEALTH LIPOSOMES; SINGLE RESIDUE; SENSORY VALVE; PROTEIN; MEMBRANE	MscL is a bacterial mechanosensor that serves as a biological emergency release valve, releasing cytoplasmic solutes to the environment on osmotic downshock. Previous studies have recognized that this channel has properties that make it ideal for use as a triggered nanovalve for vesicular-based targeted drug-release devices. One can even change the modality of the sensor. Briefly, the introduction of charges into the MscL pore lumen gates the channel in the absence of membrane tension; thus, by inserting compounds that acquire a charge on exposure to an alternative stimulus, such as light or pH, into the pore of the channel, controllable nanoswitches that detect these alternative modalities have been engineered. However, a charge in the pore lumen could not only encourage actuation of the nanopore but also have a significant influence on the permeation of large charged compounds, which would thus have important implications for the efficiency of drug-release devices. In this study, we used in vivo and electrophysiological approaches to demonstrate that the introduction of a charge into pore lumen of MscL does indeed influence the permeation of charged molecules. These effects were more drastic for larger compounds and, surprisingly, were related to the orientation of the MscL channel in the membrane.-Yang, L-M, Blount, P. Manipulating the permeation of charged compounds through the MscL nanovalve. FASEB J. 25, 428-434 (2011). www.fasebj.org	[Yang, Li-Min; Blount, Paul] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Blount, P (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	paul.blount@utsouthwestern.edu			Cancer Prevention and Research Institute of Texas (CPRIT) [RP100146]; Welch Foundation [I-1420]; U.S. National Aeronautics and Space Administration [NNH08ZTT003N NRA]; U.S. National Institutes of Health [GM61028]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas (CPRIT); Welch Foundation(The Welch Foundation); U.S. National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs. Zoltan Kovacs, Irene Iscla, and Yuezhou Li for many helpful discussions and critical reading of the manuscript. This work was supported by grant RP100146 from the Cancer Prevention and Research Institute of Texas (CPRIT; http://www.cprit.state.tx.us), grant I-1420 of the Welch Foundation, grant NNH08ZTT003N NRA from the U.S. National Aeronautics and Space Administration, and grant GM61028 and its supplement from the U.S. National Institutes of Health.	Ajouz B, 1998, J BIOL CHEM, V273, P26670, DOI 10.1074/jbc.273.41.26670; Ajouz B, 1998, BIOPHYS J, V74, pA238; Bartlett JL, 2006, BIOPHYS J, V91, P3684, DOI 10.1529/biophysj.106.088062; Bartlett JL, 2004, P NATL ACAD SCI USA, V101, P10161, DOI 10.1073/pnas.0402040101; Berrier C, 2004, BIOCHEMISTRY-US, V43, P12585, DOI 10.1021/bi049049y; Berrier C, 2000, J BACTERIOL, V182, P248, DOI 10.1128/JB.182.1.248-251.2000; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Blount P, 1999, Methods Enzymol, V294, P458; Blount P, 1996, BIOL CELL, V87, P1, DOI 10.1016/S0248-4900(97)89832-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Clayton D, 2004, P NATL ACAD SCI USA, V101, P4764, DOI 10.1073/pnas.0305693101; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; Ewis HE, 2005, FEMS MICROBIOL LETT, V253, P295, DOI 10.1016/j.femsle.2005.09.046; Gabizon AA, 2001, CLIN CANCER RES, V7, P223; Immordino ML, 2006, INT J NANOMED, V1, P297; Kocer A, 2005, SCIENCE, V309, P755, DOI 10.1126/science.1114760; Kocer A, 2007, NAT PROTOC, V2, P1426, DOI 10.1038/nprot.2007.196; Kocer A, 2006, ANGEW CHEM INT EDIT, V45, P3126, DOI 10.1002/anie.200503403; Kocer-Sagiroglu A, 2005, J CONTROL RELEASE, V101, P374; Kumanovics A, 2002, FASEB J, V16, P1623, DOI 10.1096/fj.02-0238hyp; Levin G, 2004, BIOPHYS J, V86, P2862, DOI 10.1016/S0006-3495(04)74338-6; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Masuko T, 2005, ANAL BIOCHEM, V339, P69, DOI 10.1016/j.ab.2004.12.001; Moe PC, 2000, J BIOL CHEM, V275, P31121, DOI 10.1074/jbc.M002971200; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; NAKAJIMA H, 1979, J BIOCHEM-TOKYO, V85, P303, DOI 10.1093/oxfordjournals.jbchem.a132325; Nakatani K, 2007, LANGMUIR, V23, P7170, DOI 10.1021/la7002723; OGAHARA T, 1995, J BACTERIOL, V177, P5987, DOI 10.1128/jb.177.20.5987-5990.1995; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Powl AM, 2008, BIOCHEMISTRY-US, V47, P4317, DOI 10.1021/bi702409t; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2; Yoshimura K, 2001, BIOPHYS J, V80, P2198, DOI 10.1016/S0006-3495(01)76192-9	38	11	12	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					428	434		10.1096/fj.10-170076	http://dx.doi.org/10.1096/fj.10-170076			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20930114	Green Published			2022-12-28	WOS:000285869500039
J	Zhou, YY; Shaw, N; Li, Y; Zhao, Y; Zhang, RG; Liu, ZJ				Zhou, Yangyan; Shaw, Neil; Li, Yang; Zhao, Yu; Zhang, Rongguang; Liu, Zhi-Jie			Structure-function analysis of human l-prostaglandin D synthase bound with fatty acid molecules	FASEB JOURNAL			English	Article						allergy; arachidonic acid; lipocalin	CEREBROSPINAL-FLUID; ARACHIDONIC-ACID; BETA-TRACE; BINDING; DISEASES; PROTEIN; CLONING; INFLAMMATION; REFINEMENT; EXPRESSION	Human prostaglandin D synthase (L-PGDS) is a lipocalin-type enzyme involved in the metabolism of arachidonic acid and plays a key role in the regulation of sleep, allergy, pain sensation, and the development of male reproductive organs. Here, using a combination of crystallographic, biochemical, mutagenesis, and kinetic studies, we have gained insights into the mode of ligand binding by human L-PGDS and have identified residues involved in catalysis. Interestingly, structural evidence reveals that 2 molecules of fatty acids, one molecule each of oleic and palmitoleic acid, bind inside the beta barrel. The oleic acid is buried and binds in a highly basic patch in proximity to the catalytically critical Cys65, mimicking the binding of prostaglandin H-2. The palmitoleic acid sits in a relatively neutral region with very few interactions with the protein. Mutating Met64, Leu79, Phe83, or Leu131 to alanine reduced the catalytic efficiency by almost 10-fold, while K59A and Y149A mutations enhanced the catalytic efficiency by >2-fold. Met64 seems to function as a kinetic clamp, pushing the thiol group of Cys65 close to the site of nucleophilic attack during catalysis.-Zhou, Y., Shaw, N., Li, Y., Zhao, Y., Zhang, R., Liu, Z.-J. Structure-function analysis of human l-prostaglandin D synthase bound with fatty acid molecules. FASEB J. 24, 4668-4677 (2010). www.fasebj.org	[Zhou, Yangyan; Shaw, Neil; Li, Yang; Zhao, Yu; Zhang, Rongguang; Liu, Zhi-Jie] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; [Zhou, Yangyan] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Liu, ZJ (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	zjliu@ibp.ac.cn	Liu, Zhi-Jie/A-3946-2012; Li, Yang/M-1246-2013; Li, Yang/G-3685-2011	Liu, Zhi-Jie/0000-0001-7279-2893; Shaw, Neil/0000-0003-2722-9967	Ministry of Science and Technology of China [2006AA02A316, 2009DFB30310, 2006CB910901]; National Natural Science Foundation of China [30670427, 30721003]; Ministry of Health of China [2008ZX10404]; CAS [KSCX2-YW-R-127, INFO-115-D01-2009, 2010Y1SA1]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Health of China; CAS(Chinese Academy of Sciences)	This work was funded by the Ministry of Science and Technology of China (grants 2006AA02A316, 2009DFB30310, and 2006CB910901), the National Natural Science Foundation of China (grants 30670427 and 30721003), the Ministry of Health of China (grant 2008ZX10404), a CAS research grant (KSCX2-YW-R-127 and INFO-115-D01-2009), and a CAS fellowship for young international scientists (grant 2010Y1SA1) awarded to N.S. Crystallographic data were collected at beamline BL17U1 of the SSRF (Shanghai, China).	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beuckmann CT, 1999, BIOCHEMISTRY-US, V38, P8006, DOI 10.1021/bi990261p; Breustedt DA, 2009, ACTA CRYSTALLOGR D, V65, P1118, DOI 10.1107/S0907444909031011; Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S; Darios F, 2006, NATURE, V440, P813, DOI 10.1038/nature04598; Das UN, 2006, CURR PHARM BIOTECHNO, V7, P467, DOI 10.2174/138920106779116856; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fujimori K, 2006, GENE, V375, P14, DOI 10.1016/j.gene.2006.01.037; Hansson SF, 2009, J ALZHEIMERS DIS, V16, P389, DOI 10.3233/JAD-2009-0966; HOFFMANN A, 1993, J NEUROCHEM, V61, P451; Irikura D, 2003, J BIOCHEM, V133, P29, DOI 10.1093/jb/mvg006; Kaiser E, 1999, CRIT REV CL LAB SCI, V36, P65, DOI 10.1080/10408369991239187; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Kumasaka T, 2009, J BIOL CHEM, V284, P22344, DOI 10.1074/jbc.M109.018341; Malki S, 2005, EMBO J, V24, P1798, DOI 10.1038/sj.emboj.7600660; Mohri I, 2006, J NEUROCHEM, V97, P641, DOI 10.1111/j.1471-4159.2006.03753.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; PHINNEY SD, 1990, AM J CLIN NUTR, V51, P385, DOI 10.1093/ajcn/51.3.385; Qu WM, 2006, P NATL ACAD SCI USA, V103, P17949, DOI 10.1073/pnas.0608581103; Salomon RG, 2000, TRENDS CARDIOVAS MED, V10, P53, DOI 10.1016/S1050-1738(00)00040-2; Shimamoto S, 2007, J BIOL CHEM, V282, P31373, DOI 10.1074/jbc.M700123200; Stols L, 2002, PROTEIN EXPRES PURIF, V25, P8, DOI 10.1006/prep.2001.1603; Tanaka T, 1997, J BIOL CHEM, V272, P15789, DOI 10.1074/jbc.272.25.15789; Terwilliger TC, 2008, ACTA CRYSTALLOGR D, V64, P61, DOI 10.1107/S090744490705024X; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; Urade Y, 2000, BBA-PROTEIN STRUCT M, V1482, P259, DOI 10.1016/S0167-4838(00)00161-8; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang ZJ, 2006, CHEM-BIOL INTERACT, V163, P207, DOI 10.1016/j.cbi.2006.08.005	33	37	41	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4668	4677		10.1096/fj.10-164863	http://dx.doi.org/10.1096/fj.10-164863			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20667974				2022-12-28	WOS:000284824400008
J	Kim, MJ; Chae, SS; Koh, YH; Lee, SK; Jo, SA				Kim, Min-Ju; Chae, San Sook; Koh, Young Ho; Lee, Suk Kyung; Jo, Sangmee Ahn			Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain	FASEB JOURNAL			English	Article						Alzheimer's disease; peptidase; amyloid-beta; oligomer	LINKED ACIDIC DIPEPTIDASE; ALZHEIMERS-DISEASE; BETA-PROTEIN; N-ACETYLASPARTYLGLUTAMATE; MEMBRANE ANTIGEN; CEREBROSPINAL-FLUID; MASS-SPECTROMETRY; PROSTATE-CANCER; HYPOTHESIS; INHIBITION	Proteolytic processing of amyloid peptides (A beta s) is one important mechanism that controls the brain A beta level. Although several A beta-degrading enzymes were identified, evidence has suggested the presence of other peptidases. Here, we report a novel function of glutamate carboxypeptidase II (GCPII) in A beta degradation in brain, which is a peptidase involved in N-acetylaspartylglutamate cleavage, folate metabolism, and prostate tumorigenesis. Maldi-Tof/MS analysis showed that recombinant human GCPII cleaved the A beta 1-40 and A beta 1-42 monomers at their C-termini, producing smaller fragments, and A beta 1-14 that lacked aggregation property and cellular toxicity. GCPII also degrades soluble oligomers and fibrils and can reduce the endogenous plaque size in brain sections obtained from amyloid precursor protein (APP) Swedish/presinilin (PS)-1 Delta E9 transgenic mice. Overexpression of GCPII in either HEK293-APP Swedish cells or primary neurons and glial cells reduced the levels of secreted or exogenously supplemented A beta s and reduced A beta-induced neurotoxicity, suggesting the biological significance of GCPII-mediated A beta cleavage. Moreover, treatment of 8-mo-old transgenic mice for 1 mo with 2-(phosphonomethyl)-pentanedioic acid (10 mg/kg, intraperitoneally), a specific GCPII inhibitor, increased cerebral A beta content. These results suggest an important physiological role for GCPII in A beta clearance in brain and provide the evidence that dysregulation of GCPII is involved in Alzheimer's disease pathology.-Kim, M.-J., Chae, S. S., Koh, Y. H., Lee, S. K., Jo, S. A. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain. FASEB J. 24, 4491-4502 (2010). www.fasebj.org	[Kim, Min-Ju; Chae, San Sook; Koh, Young Ho; Lee, Suk Kyung; Jo, Sangmee Ahn] Korea Ctr Dis Control & Prevent, Div Brain Dis, Ctr Biomed Sci, Natl Inst Hlth, Seoul 122701, South Korea	Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science	Jo, SA (corresponding author), Korea Ctr Dis Control & Prevent, Div Brain Dis, Ctr Biomed Sci, Natl Inst Hlth, Seoul 122701, South Korea.	sangmeeaj@nih.go.kr			National Institute of Health, Korea [4845-300-210]	National Institute of Health, Korea	The authors thank Dr. Jeewoo Lee (Seoul National University, Seoul, Korea) for providing the PMPA for the study. The authors also thank Drs. J. T. Coyle, I. Jo, and K. Ahn for their critical reading and valuable comments of the manuscript, and Dr. S.Y. Suh for her preliminary work. This study was supported by an intramural research fund from the National Institute of Health (4845-300-210), Korea.	Anderson MO, 2007, BIOORGAN MED CHEM, V15, P6678, DOI 10.1016/j.bmc.2007.08.006; Bacich DJ, 2002, J NEUROCHEM, V83, P20, DOI 10.1046/j.1471-4159.2002.01117.x; Barinka C, 2008, J MOL BIOL, V376, P1438, DOI 10.1016/j.jmb.2007.12.066; Bennett RG, 2000, J BIOL CHEM, V275, P36621, DOI 10.1074/jbc.M006170200; Berger UV, 1999, J COMP NEUROL, V415, P52, DOI 10.1002/(SICI)1096-9861(19991206)415:1<52::AID-CNE4>3.0.CO;2-K; Borreguero JM, 2005, P NATL ACAD SCI USA, V102, P6015, DOI 10.1073/pnas.0502006102; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; Chang SS, 1999, MOL UROL, V3, P313; Chen YR, 2006, J BIOL CHEM, V281, P24414, DOI 10.1074/jbc.M602363200; Chopra M, 2009, J PHARMACOL EXP THER, V330, P212, DOI 10.1124/jpet.109.152553; Devlin AM, 2000, HUM MOL GENET, V9, P2837, DOI 10.1093/hmg/9.19.2837; Fricker AC, 2009, NEUROPHARMACOLOGY, V56, P1060, DOI 10.1016/j.neuropharm.2009.03.002; Ghadge GD, 2003, P NATL ACAD SCI USA, V100, P9554, DOI 10.1073/pnas.1530168100; Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017; Hlouchova K, 2007, J NEUROCHEM, V101, P682, DOI 10.1111/j.1471-4159.2006.04341.x; Jo C, 2005, BBA-MOL CELL RES, V1743, P187, DOI 10.1016/j.bbamcr.2004.11.002; Kim J, 2007, J NUTR, V137, P2093, DOI 10.1093/jn/137.9.2093; Kim MJ, 2007, EXP MOL MED, V39, P14, DOI 10.1038/emm.2007.3; Larner AJ, 1999, NEUROBIOL AGING, V20, P65; Lazo ND, 2005, PROTEIN SCI, V14, P1581, DOI 10.1110/ps.041292205; Leissring Malcolm A., 2006, Current Alzheimer Research, V3, P431, DOI 10.2174/156720506779025206; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Liao MQ, 2007, FEBS LETT, V581, P1161, DOI 10.1016/j.febslet.2007.02.026; Mesters JR, 2006, EMBO J, V25, P1375, DOI 10.1038/sj.emboj.7600969; Michaud A, 1997, MOL PHARMACOL, V51, P1070, DOI 10.1124/mol.51.6.1070; Mueller-Steiner S, 2006, NEURON, V51, P703, DOI 10.1016/j.neuron.2006.07.027; Nourhashemi F, 2000, AM J CLIN NUTR, V71, p643S; Ogawa T, 2005, J NEUROCHEM, V95, P1156, DOI 10.1111/j.1471-4159.2005.03436.x; Orning L, 1999, ARCH BIOCHEM BIOPHYS, V368, P131, DOI 10.1006/abbi.1999.1289; Passani LA, 1997, MOL CHEM NEUROPATHOL, V31, P97, DOI 10.1007/BF02815236; Peng XQ, 2010, EUR J PHARMACOL, V627, P156, DOI 10.1016/j.ejphar.2009.10.062; Portelius E, 2006, J PROTEOME RES, V5, P1010, DOI 10.1021/pr050475v; Portelius E, 2007, J PROTEOME RES, V6, P4433, DOI 10.1021/pr0703627; Qiu WQ, 2006, NEUROBIOL AGING, V27, P190, DOI 10.1016/j.neurobiolaging.2005.01.004; Rajasekaran AK, 2005, AM J PHYSIOL-CELL PH, V288, pC975, DOI 10.1152/ajpcell.00506.2004; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shea TB, 2002, J ALZHEIMERS DIS, V4, P261, DOI 10.3233/JAD-2002-4401; Skidgel RA, 2004, PEPTIDES, V25, P521, DOI 10.1016/j.peptides.2003.12.010; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tsai G, 2003, SYNAPSE, V50, P285, DOI 10.1002/syn.10263; Tsukamoto T, 2007, DRUG DISCOV TODAY, V12, P767, DOI 10.1016/j.drudis.2007.07.010; Xi ZX, 2010, NEUROPHARMACOLOGY, V58, P304, DOI 10.1016/j.neuropharm.2009.06.016; Yan P, 2006, J BIOL CHEM, V281, P24566, DOI 10.1074/jbc.M602440200; Yu LP, 2009, BIOCHEMISTRY-US, V48, P1870, DOI 10.1021/bi802046n; Zhou J, 2005, NAT REV DRUG DISCOV, V4, P1015, DOI 10.1038/nrd1903	47	24	24	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4491	4502		10.1096/fj.09-148825	http://dx.doi.org/10.1096/fj.09-148825			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20624932				2022-12-28	WOS:000283861100034
J	Tarantino, C; Paolella, G; Cozzuto, L; Minopoli, G; Pastore, L; Parisi, S; Russo, T				Tarantino, Carolina; Paolella, Gaetana; Cozzuto, Luca; Minopoli, Giuseppina; Pastore, Lucio; Parisi, Silvia; Russo, Tommaso			miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells	FASEB JOURNAL			English	Article						pluripotency; Sirt1; Smarca5; Jarid1b	SELF-RENEWAL; MICRORNAS; EXPRESSION; NANOG; PLURIPOTENCY; MIR-34A; CANCER; BIOGENESIS; OCT4; GENE	MicroRNAs (miRNAs) play an important role in proper function and differentiation of mouse embryonic stem cells (ESCs). We performed a systematic comparison of miRNA expression in undifferentiated vs. differentiating ESCs. We report that 138 miRNAs are increased on the induction of differentiation. We compared the entire list of candidate mRNA targets of up-regulated miRNAs with that of mRNA down-regulated in ESCs on induction of differentiation. Among the candidate targets emerging from this analysis, we found three genes, Smarca5, Jarid1b, and Sirt1, previously demonstrated to be involved in sustaining the undifferentiated phenotype in ESCs. On this basis, we first demonstrated that Smarca5 is a direct target of miR-100, Jarid1b of miR-137, and we also confirmed previously published data demonstrating that Sirt1 is a direct target of miR-34a in a different context. The suppression of these three miRNAs by anti-miRs caused the block of ESC differentiation induced by LIF withdrawal. On the other hand, the overexpression of the three miRNAs resulted in an altered expression of differentiation markers. These results demonstrate that miR-34a, miR-100, and miR-137 are required for proper differentiation of mouse ESCs, and that they function in part by targeting Sirt1, Smarca5, and Jarid1b mRNAs.-Tarantino, C., Paolella, G., Cozzuto, L., Minopoli, G., Pastore, L., Parisi, S., Russo, T. miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells. FASEB J. 24, 3255-3263 (2010). www.fasebj.org	[Tarantino, Carolina; Paolella, Gaetana; Cozzuto, Luca; Minopoli, Giuseppina; Pastore, Lucio; Parisi, Silvia; Russo, Tommaso] Ceinge Biotecnol Avanzate, I-80145 Naples, Italy; [Tarantino, Carolina; Parisi, Silvia] SEMM, Milan, Italy; [Paolella, Gaetana; Minopoli, Giuseppina; Pastore, Lucio; Russo, Tommaso] Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Naples, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II	Parisi, S (corresponding author), Ceinge Biotecnol Avanzate, Via Comunale Margherita 452, I-80145 Naples, Italy.	parisi@ceinge.unina.it; tommaso.russo@unina.it	Pastore, Lucio/AAF-3487-2019; Pastore, Lucio/F-4668-2010; Cozzuto, Luca/K-5385-2015; Russo, Tommaso/K-1331-2016	Pastore, Lucio/0000-0001-6894-9317; Cozzuto, Luca/0000-0003-3194-8892; Russo, Tommaso/0000-0003-4426-0106; PAOLELLA, Gaetana/0000-0003-2188-3829; Tarantino, Carolina/0000-0003-2470-3803	EC-Sirocco Consortium; Associazione Italiana Ricerca sul Cancro (AIRC); Italian Ministry of Health-Ricerca Finalizzata	EC-Sirocco Consortium; Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health-Ricerca Finalizzata(Ministry of Health, Italy)	This work was supported by grants from EC-Sirocco Consortium, Associazione Italiana Ricerca sul Cancro (AIRC), and the Italian Ministry of Health-Ricerca Finalizzata 2007.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calabrese JM, 2007, P NATL ACAD SCI USA, V104, P18097, DOI 10.1073/pnas.0709193104; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Ciaudo C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000620; Dey BK, 2008, MOL CELL BIOL, V28, P5312, DOI 10.1128/MCB.00128-08; Dressel R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002622; Han MK, 2008, CELL STEM CELL, V2, P241, DOI 10.1016/j.stem.2008.01.002; Hashimi ST, 2009, BLOOD, V114, P404, DOI 10.1182/blood-2008-09-179150; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kato M, 2008, BIOL CELL, V100, P71, DOI 10.1042/BC20070078; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Krichevsky AM, 2006, STEM CELLS, V24, P857, DOI 10.1634/stemcells.2005-0441; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; Li XK, 2008, STEM CELLS DEV, V17, P1043, DOI 10.1089/scd.2008.0036; Lin CH, 2009, EMBO J, V28, P3157, DOI 10.1038/emboj.2009.254; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Parisi S, 2008, J CELL SCI, V121, P2629, DOI 10.1242/jcs.027599; Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Sampath P, 2008, CELL STEM CELL, V2, P448, DOI 10.1016/j.stem.2008.03.013; Seward DJ, 2007, NAT STRUCT MOL BIOL, V14, P240, DOI 10.1038/nsmb1200; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391; Stopka T, 2003, P NATL ACAD SCI USA, V100, P14097, DOI 10.1073/pnas.2336105100; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Ziegelbauer JM, 2009, NAT GENET, V41, P130, DOI 10.1038/ng.266	44	103	108	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3255	3263		10.1096/fj.09-152207	http://dx.doi.org/10.1096/fj.09-152207			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20439489				2022-12-28	WOS:000281446400014
J	Knubel, CP; Martinez, FF; Fretes, RE; Lujan, CD; Theumer, MG; Cervi, L; Motran, CC				Paola Knubel, Carolina; Fabian Martinez, Fernando; Fretes, Ricardo E.; Diaz Lujan, Cintia; Gustavo Theumer, Martin; Cervi, Laura; Cristina Motran, Claudia			Indoleamine 2,3-dioxigenase (IDO) is critical for host resistance against Trypanosoma cruzi	FASEB JOURNAL			English	Article						Infection; parasites; immunomodulation; kynurenines	NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE SYNTHASE; T-CELL PROLIFERATION; INTERFERON-GAMMA; TRYPTOPHAN CATABOLISM; DENDRITIC CELLS; HUMAN-FIBROBLASTS; INTRACELLULAR PATHOGENS; ALTERNATIVE ACTIVATION; TOXOPLASMA-GONDII	Indoleamine 2,3-dioxigenase (IDO) is an inflammatory cytokine-inducible rate-limiting enzyme of the tryptophan (Trp) catabolism, which is involved in the inhibition of intracellular pathogen replication as well as in immunomodulation. Here we demonstrated the effect of IDO-dependent Trp catabolism on Trypanosoma cruzi resistance to acute infection. Infection with T. cruzi resulted in the systemic activation of IDO. The blocking of IDO activity in vivo impaired resistance to the infection and exacerbated the parasite load and infection-associated pathology. In addition, IDO activity was critical to controlling the parasite's replication in macrophages (Mos), despite the high production of nitric oxide produced by IDO-blocked T. cruzi-infected Mos. Analysis of the mechanisms by which IDO controls the parasite replication revealed that T. cruzi amastigotes were sensitive to L-kynurenine downstream metabolites 3-hydroxykynurenine (3-HK) and 3-hydroxyanthranilic acid, while 3-HK also affected the trypomastigote stage. Finally, 3-HK treatment of mice acutely infected with T. cruzi was able to control the parasite and to improve the survival of lethally infected mice. During infection, IDO played a critical role in host defense against T. cruzi; therefore, the intervention of IDO pathway could be useful as a novel antitrypanosomatid therapeutic strategy.-Knubel, C. P., Martinez, F. F., Fretes, R. E., Diaz Lujan, C., Theumer, M. G., Cervi, L., Motran, C. C. Indoleamine 2,3-dioxigenase (IDO) is critical for host resistance against Trypanosoma cruzi. FASEB J. 24, 2689-2701 (2010). www.fasebj.org	[Paola Knubel, Carolina; Fabian Martinez, Fernando; Gustavo Theumer, Martin; Cervi, Laura; Cristina Motran, Claudia] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Ctr Invest Bioquim Clin & Inmunol CIBICI CONICET, RA-5000 Cordoba, Argentina; [Fretes, Ricardo E.; Diaz Lujan, Cintia] Univ Nacl Cordoba, Fac Med, Inst Biol Celular, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; National University of Cordoba	Motran, CC (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Ctr Invest Bioquim Clin & Inmunol CIBICI CONICET, Ciudad Univ, RA-5000 Cordoba, Argentina.	cmotran@fcq.unc.edu.ar	Motran, Claudia/U-9106-2019	Motran, Claudia/0000-0002-8088-3901	Agencia Nacional de Promocion Cientifica y Tecnica [PICT 25511]; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) of Argentina; Ministerio de Ciencia y Tecnologia de la Provincia de Cordoba; Secretaria de Ciencia y Tecnica-Universidad Nacional de Cordoba	Agencia Nacional de Promocion Cientifica y Tecnica(ANPCyT); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) of Argentina(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Ministerio de Ciencia y Tecnologia de la Provincia de Cordoba(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Secretaria de Ciencia y Tecnica-Universidad Nacional de Cordoba(Secretaria de Ciencia y Tecnologia (SECYT))	C.P.K. thanks Agencia Nacional de Promocion Cientifica y Tecnica, and F. F. M. thanks the Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) of Argentina for the fellowships granted. C.C.M., L.C., and M.G.T. are members of the Scientific Career of CONICET of Argentina. The authors are grateful to Cecilia Sampedro and Carlos Mas [Centro de Investigaciones en Quimica Biologica de Cordoba (CIQUIBIC)-CONICET] for assistance with video microscopy. The authors thank Eva Acosta Rodriguez for critical reading of the manuscript and native speaker Dr. Paul Hobson, who revised the manuscript. This work was supported by grants from CONICET of Argentina, Agencia Nacional de Promocion Cientifica y Tecnica (PICT 25511), Ministerio de Ciencia y Tecnologia de la Provincia de Cordoba, and Secretaria de Ciencia y Tecnica-Universidad Nacional de Cordoba (grants to C.M.). The funding bodies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no competing interests.	Adams O, 2004, J VIROL, V78, P2632, DOI 10.1128/JVI.78.5.2632-2636.2004; BLASI E, 1993, ANTIMICROB AGENTS CH, V37, P2422, DOI 10.1128/AAC.37.11.2422; BYRNE GI, 1986, INFECT IMMUN, V53, P347, DOI 10.1128/IAI.53.2.347-351.1986; Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711; Ceravolo IP, 1999, INFECT IMMUN, V67, P2233; Collazo CM, 2001, J EXP MED, V194, P181, DOI 10.1084/jem.194.2.181; Cummings KL, 2004, INFECT IMMUN, V72, P4081, DOI 10.1128/IAI.72.7.4081-4089.2004; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006; GUPTA SL, 1994, INFECT IMMUN, V62, P2277, DOI 10.1128/IAI.62.6.2277-2284.1994; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; Hill M, 2007, EUR J IMMUNOL, V37, P3054, DOI 10.1002/eji.200636704; Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426; Hwang SL, 2005, CELL RES, V15, P167, DOI 10.1038/sj.cr.7290282; Koga R, 2006, J IMMUNOL, V177, P7059, DOI 10.4049/jimmunol.177.10.7059; Kudo Y, 2000, BBA-MOL BASIS DIS, V1500, P119, DOI 10.1016/S0925-4439(99)00096-4; Lieberman LA, 2004, J IMMUNOL, V172, P457, DOI 10.4049/jimmunol.172.1.457; MacKenzie CR, 1998, J INFECT DIS, V178, P875, DOI 10.1086/515347; Mellor A, 2005, BIOCHEM BIOPH RES CO, V338, P20, DOI 10.1016/j.bbrc.2005.08.232; Mellor AL, 2004, INT IMMUNOL, V16, P1391, DOI 10.1093/intimm/dxh140; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mellor AL, 2002, J IMMUNOL, V168, P3771, DOI 10.4049/jimmunol.168.8.3771; Motran CC, 2002, J LEUKOCYTE BIOL, V72, P512; Motran CC, 1998, EXP PARASITOL, V88, P223, DOI 10.1006/expr.1998.4255; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; ORTIZORTIZ L, 1976, INT ARCH ALLER A IMM, V50, P232, DOI 10.1159/000231501; PETRAY P, 1995, IMMUNOL LETT, V47, P121, DOI 10.1016/0165-2478(95)00083-H; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; Roggero E, 2002, CLIN EXP IMMUNOL, V128, P421, DOI 10.1046/j.1365-2249.2002.01874.x; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; Sekkai D, 1997, ARCH BIOCHEM BIOPHYS, V340, P117, DOI 10.1006/abbi.1997.9913; Shoda LKM, 2001, INFECT IMMUN, V69, P2162, DOI 10.1128/IAI.69.4.2162-2171.2001; SILVA JS, 1995, INFECT IMMUN, V63, P4862, DOI 10.1128/IAI.63.12.4862-4867.1995; Sosa-Estani S, 2006, CURR OPIN INFECT DIS, V19, P583, DOI 10.1097/01.qco.0000247592.21295.a5; Stempin C, 2002, J LEUKOCYTE BIOL, V72, P727; Sulsen VP, 2008, ANTIMICROB AGENTS CH, V52, P2415, DOI 10.1128/AAC.01630-07; TANOWITZ HB, 1992, CLIN MICROBIOL REV, V5, P400, DOI 10.1128/CMR.5.4.400-419.1992; Taylor GA, 2000, P NATL ACAD SCI USA, V97, P751, DOI 10.1073/pnas.97.2.751; Taylor GA, 2007, MICROBES INFECT, V9, P1644, DOI 10.1016/j.micinf.2007.09.004; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; VESPA GNR, 1994, INFECT IMMUN, V62, P5177, DOI 10.1128/IAI.62.11.5177-5182.1994; Vincendeau P, 1999, ADV EXP MED BIOL, V467, P525; Widner B, 1997, CLIN CHEM, V43, P2424; Zuniga E, 2000, CLIN EXP IMMUNOL, V119, P507, DOI 10.1046/j.1365-2249.2000.01150.x	47	42	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2689	2701		10.1096/fj.09-150920	http://dx.doi.org/10.1096/fj.09-150920			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20233946				2022-12-28	WOS:000285005400011
J	Theodoropoulou, S; Kolovou, PE; Morizane, Y; Kayama, M; Nicolaou, F; Miller, JW; Gragoudas, E; Ksander, BR; Vavvas, DG				Theodoropoulou, Sofia; Kolovou, Paraskevi E.; Morizane, Yuki; Kayama, Maki; Nicolaou, Fotini; Miller, Joan W.; Gragoudas, Evangelos; Ksander, Bruce R.; Vavvas, Demetrios G.			Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase	FASEB JOURNAL			English	Article						cancer; energy; metabolism; eye; intraocular tumors	RIBOSIDE INDUCES APOPTOSIS; PROTEIN-KINASE; BILATERAL RETINOBLASTOMA; ENERGY STATUS; KEY SENSOR; CANCER; GROWTH; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE-1-BETA-D-RIBOFURANOSIDE; CHEMOREDUCTION; CHEMOTHERAPY	5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR), an analog of AMP, is widely used as an activator of AMP-kinase (AMPK), a protein that regulates the responses of the cell to energy change. We studied the effects of AICAR on the growth of retinoblastoma cell lines (Y79, WERI, and RB143). AICAR inhibited Rb cell growth, induced apoptosis and S-phase cell cycle arrest, and led to activation of AMPK. These effects were abolished by treatment with dypiridamole, an inhibitor that blocks entrance of AICAR into cells. Treatment with the adenosine kinase inhibitor 5-iodotubericidin to inhibit the conversion of AICAR to ZMP (the direct activator of AMPK) reversed most of the growth-inhibiting effects of AICAR, indicating that some of the antiproliferative effects of AICAR are mediated through AMPK activation. In addition, AICAR treatment was associated with inhibition of the mammalian target of rapamycin pathway, decreased phosphorylation of ribosomal protein-S6 and 4E-BP1, down-regulation of cyclins A and E, and decreased expression of p21. Our results indicate that AICAR-induced activation of AMPK inhibits retinoblastoma cell growth. This is one of the first descriptions of a nonchemotherapeutic drug with low toxicity that may be effective in treating Rb patients.-Theodoropoulou, S., Kolovou, P. E., Morizane, Y., Kayama, M., Nicolaou, F., Miller, J. W., Gragoudas, E., Ksander, B. R., Vavvas, D. G. Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J. 24, 2620-2630 (2010). www.fasebj.org	[Theodoropoulou, Sofia; Morizane, Yuki; Kayama, Maki; Miller, Joan W.; Gragoudas, Evangelos; Vavvas, Demetrios G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab,Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA; [Kolovou, Paraskevi E.; Ksander, Bruce R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; [Nicolaou, Fotini] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Surg Labs, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts General Hospital; Schepens Eye Research Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital	Vavvas, DG (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab,Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA.	demetrios_vavvas@meei.harvard.edu		Miller, Joan/0000-0003-2046-3996; Vavvas, Demetrios/0000-0002-8622-6478; Theodoropoulou, Sofia/0000-0003-3038-5354	Onassis Foundation; Massachusetts Lions Eye Research Fund; Research to Prevent Blindness; U.S. National Institutes of Health [NIH EY009294]; NATIONAL EYE INSTITUTE [R01EY009294] Funding Source: NIH RePORTER	Onassis Foundation; Massachusetts Lions Eye Research Fund; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	D.G.V. was supported by an Onassis Foundation Scholars grant, the Massachusetts Lions Eye Research Fund, and Research to Prevent Blindness. B.R.K. was supported by U.S. National Institutes of Health grant NIH EY009294.	Baumann P, 2007, EXP CELL RES, V313, P3592, DOI 10.1016/j.yexcr.2007.06.020; Benz MS, 2000, ARCH OPHTHALMOL-CHIC, V118, P577; Broaddus E, 2009, BRIT J OPHTHALMOL, V93, P24, DOI 10.1136/bjo.2008.143842; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Garcia-Gil M, 2003, NEUROSCIENCE, V117, P811, DOI 10.1016/S0306-4522(02)00836-9; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; GURNEY J, 2003, CANC INFANTS; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Ido Y, 2002, DIABETES, V51, P159, DOI 10.2337/diabetes.51.1.159; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Lopez JM, 2003, BIOCHEM J, V370, P1027, DOI 10.1042/BJ20021053; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; MacPherson D, 2007, EMBO J, V26, P784, DOI 10.1038/sj.emboj.7601515; Nakanishi C, 2004, ONCOLOGY-BASEL, V67, P476, DOI 10.1159/000082933; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Nishimura S, 2001, J CLIN ONCOL, V19, P4182, DOI 10.1200/JCO.2001.19.21.4182; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; ROARTY JD, 1988, OPHTHALMOLOGY, V95, P1583; Robert G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007889; Rodriguez-Galindo C, 2003, OPHTHALMOLOGY, V110, P1237, DOI 10.1016/S0161-6420(03)00258-6; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633; Schefler AC, 2007, OPHTHALMOLOGY, V114, P162, DOI 10.1016/j.ophtha.2006.06.042; Sengupta TK, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-46; Shields Carol L, 2008, Semin Ophthalmol, V23, P324, DOI 10.1080/08820530802506029; Shields CL, 2009, OPHTHALMOLOGY, V116, P544, DOI 10.1016/j.ophtha.2008.10.014; Shields CL, 2009, ARCH OPHTHALMOL-CHIC, V127, P282, DOI 10.1001/archophthalmol.2008.626; Shields CL, 2003, ARCH OPHTHALMOL-CHIC, V121, P1571, DOI 10.1001/archopht.121.11.1571; Shields CL, 2002, ARCH OPHTHALMOL-CHIC, V120, P460; Su RY, 2007, MOL CANCER THER, V6, P1562, DOI 10.1158/1535-7163.MCT-06-0800; Sussman DA, 2003, ARCH OPHTHALMOL-CHIC, V121, P979, DOI 10.1001/archopht.121.7.979; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200; YOUNG J, 2003, RETINOBLASTOMA; Zang Y, 2009, J BIOL CHEM, V284, P6175, DOI 10.1074/jbc.M806887200; Zhang JK, 2004, CELL CYCLE, V3, P952	44	30	32	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2620	2630		10.1096/fj.09-152546	http://dx.doi.org/10.1096/fj.09-152546			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371623	Green Published			2022-12-28	WOS:000285005400004
J	Torri, F; Akelai, A; Lupoli, S; Sironi, M; Amann-Zalcenstein, D; Fumagalli, M; Dal Fiume, C; Ben-Asher, E; Kanyas, K; Cagliani, R; Cozzi, P; Trombetti, G; Lievers, LS; Salvi, E; Orro, A; Beckmann, JS; Lancet, D; Kohn, Y; Milanesi, L; Ebstein, RB; Lerer, B; Macciardi, F				Torri, Federica; Akelai, Anna; Lupoli, Sara; Sironi, Manuela; Amann-Zalcenstein, Daniela; Fumagalli, Matteo; Dal Fiume, Chiara; Ben-Asher, Edna; Kanyas, Kyra; Cagliani, Rachele; Cozzi, Paolo; Trombetti, Gabriele; Lievers, Luisa Strik; Salvi, Erika; Orro, Alessandro; Beckmann, Jacques S.; Lancet, Doron; Kohn, Yoav; Milanesi, Luciano; Ebstein, Richard B.; Lerer, Bernard; Macciardi, Fabio			Fine mapping of AHI1 as a schizophrenia susceptibility gene: from association to evolutionary evidence	FASEB JOURNAL			English	Article						AHI1 association studies; positive selection	GENOME-WIDE ASSOCIATION; BIPOLAR DISORDER; NEUROTROPHIC FACTOR; JOUBERT-SYNDROME; DIAGNOSTIC CRITERIA; NATIONAL-INSTITUTE; LINKAGE ANALYSIS; CHROMOSOME 6Q23; BRAIN; LOCUS	In previous studies, we identified a locus for schizophrenia on 6q23.3 and proposed the Abelson helper integration site 1 (AHI1) as the candidate gene. AHI1 is expressed in the brain and plays a key role in neurodevelopment, is involved in Joubert syndrome, and has been recently associated with autism. The neurodevelopmental role of AHI1 fits with etiological hypotheses of schizophrenia. To definitively confirm our hypothesis, we searched for associations using a dense map of the region. Our strongest findings lay within the AHI1 gene: single-nucleotide polymorphisms rs11154801 and rs7759971 showed significant associations (P=6.23E-06; P=0.84E-06) and haplotypes gave P values in the 10E-8 to 10E-10 range. The second highest significant region maps close to AHI1 and includes the intergenic region between BC040979 and PDE7B (rs2038549 at P=9.70E-06 and rs1475069 at P=6.97E-06), and PDE7B and MAP7. Using a sample of Palestinian Arab families to confirm these findings, we found isolated signals. While these results did not retain their significance after correction for multiple testing, the joint analysis across the 2 samples supports the role of AHI1, despite the presence of heterogeneity. Given the hypothesis of positive selection of schizophrenia genes, we resequenced a 11 kb region within AHI1 in ethnically defined populations and found evidence for a selective sweep. Network analysis indicates 2 haplotype clades, with schizophrenia-susceptibility haplotypes clustering within the major clade. In conclusion, our data support the role of AHI1 as a susceptibility gene for schizophrenia and confirm it has been subjected to positive selection, also shedding light on new possible candidate genes, MAP7 and PDE7B.-Torri, F., Akelai, A., Lupoli, S., Sironi, M., Amann-Zalcenstein, D., Fumagalli, M., Dal Fiume, C., BenAsher, E., Kanyas, K., Cagliani, R., Cozzi, P., Trombetti, G., Lievers, L. S., Salvi, E., Orro, A., Beckmann, J. S., Lancet, D., Kohn, Y., Milanesi, L., Ebstein, R. B., Lerer, B., Macciardi, F. Fine mapping of AHI1 as a schizophrenia susceptibility gene: from association to evolutionary evidence. FASEB J. 24, 3066 -3082 (2010). www.fasebj.org	[Macciardi, Fabio] Univ Milan, Sch Med, Dept Sci & Biomed Technol, Fondaz Filarete,Genom & Bioinformat Unit, I-20090 Milan, Italy; [Torri, Federica; Lievers, Luisa Strik; Salvi, Erika] Univ Milan, Dept Med Surg & Dent, San Paolo Hosp, I-20090 Milan, Italy; [Lupoli, Sara] Ist Sci San Raffaele, INSPE, I-20132 Milan, Italy; [Sironi, Manuela; Fumagalli, Matteo; Cagliani, Rachele] Ist Ricovero & Cura Carattere Sci E Medea, Inst Sci, Parini, Italy; [Fumagalli, Matteo] Politecn Milan, Dept Bioengn, I-20133 Milan, Italy; [Orro, Alessandro] CILEA Consortium, Milan, Italy; [Cozzi, Paolo; Trombetti, Gabriele; Orro, Alessandro; Milanesi, Luciano] CNR, Inst Biomed Technol, I-20133 Milan, Italy; [Akelai, Anna; Kanyas, Kyra; Kohn, Yoav; Lerer, Bernard] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel; [Ben-Asher, Edna; Beckmann, Jacques S.] CHU Vaudois, CH-1011 Lausanne, Switzerland; [Ben-Asher, Edna; Beckmann, Jacques S.] Univ Lausanne, Lausanne, Switzerland; [Amann-Zalcenstein, Daniela; Lancet, Doron] Weizmann Inst Sci, IL-76100 Rehovot, Israel; [Ebstein, Richard B.] Herzog Hosp, Jerusalem, Israel; [Macciardi, Fabio] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA	University of Milan; San Paolo-Polo Universitaria Hospital; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Eugenio Medea; Polytechnic University of Milan; CINECA, Italy; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Hebrew University of Jerusalem; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Weizmann Institute of Science; Hebrew University of Jerusalem; Herzog Medical Center; University of California System; University of California Irvine	Macciardi, F (corresponding author), Univ Milan, Sch Med, Dept Sci & Biomed Technol, Fondaz Filarete,Genom & Bioinformat Unit, Via F Lli Cervi 93, I-20090 Milan, Italy.	fabio.macciardi@unimi.it	Salvi, Erika/C-1033-2015; Beckmann, Jacques S/A-9772-2008; Orro, Alessandro/ABA-3542-2020; Sironi, manuela/K-5633-2016; Milanesi, Luciano/AAE-7230-2019; Cagliani, Rachele/K-4545-2016; Salvi, Erika/AAA-1415-2019; Fumagalli, Matteo/H-6448-2019; Cozzi, Paolo/AFM-1008-2022; Macciardi, Fabio/N-3768-2014	Salvi, Erika/0000-0002-2724-2291; Beckmann, Jacques S/0000-0002-9741-1900; Sironi, manuela/0000-0002-2267-5266; Milanesi, Luciano/0000-0002-1201-3939; Cagliani, Rachele/0000-0003-2670-3532; Salvi, Erika/0000-0002-2724-2291; Fumagalli, Matteo/0000-0002-4084-2953; Macciardi, Fabio/0000-0003-0537-4266; Trombetti, Gabriele/0000-0001-7604-9351; Ebstein, Richard/0000-0002-3626-541X; Cozzi, Paolo/0000-0003-0388-6874	FIRB Italia-Israele [RBIN04SWHR]; Doctorate School of Molecular Medicine, University of Milan, POCEMON [FP7-ICT-2007-216088]; Hypergenes [Health-F4-2007-201550]; InGenious HyperCare [LSHM-CT-2006-037093]; Israel Science Foundation (Israel Academy of Sciences) [348/09]	FIRB Italia-Israele; Doctorate School of Molecular Medicine, University of Milan, POCEMON; Hypergenes; InGenious HyperCare(European Commission); Israel Science Foundation (Israel Academy of Sciences)(Israel Science Foundation)	The study was conceived and designed by F.M., B.L., and D.A. The DNA samples were prepared by D.A. and A.A. and genotyped by F.T. and C.D.F. Analyses were performed by F.T., S.L., M.S., M.F., and A.A. C.B. supervised the genotyping and F.M. the analysis. The manuscript was written by F.T. with contributions from F.M., M.S., L.S.L., J.S.B., and B.L. All authors read and approved the manuscript. The authors thank Dr. Adnan Hamdan for assistance in recruitment and Alexandra Slonimsky for assistance with preparation of DNA samples. This work was supported by FIRB Italia-Israele (RBIN04SWHR), a fellowship of the Doctorate School of Molecular Medicine, University of Milan, POCEMON (FP7-ICT-2007-216088), Hypergenes (Health-F4-2007-201550), InGenious HyperCare (LSHM-CT-2006-037093), and the Israel Science Foundation (Israel Academy of Sciences, grant 348/09).	Allen NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171; Alvarez Retuerto AI, 2008, HUM MOL GENET, V17, P3887, DOI 10.1093/hmg/ddn291; Amann-Zalcenstein D, 2006, EUR J HUM GENET, V14, P1111, DOI 10.1038/sj.ejhg.5201675; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Andrieux A, 2002, GENE DEV, V16, P2350, DOI 10.1101/gad.223302; Badner JA, 2002, MOL PSYCHIATR, V7, P405, DOI 10.1038/sj.mp.4001012; Bailer U, 2002, BIOL PSYCHIAT, V52, P40, DOI 10.1016/S0006-3223(02)01320-3; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; BARON M, 1994, PSYCHIATR GENET, V4, P43, DOI 10.1097/00041444-199421000-00007; Barreiro LB, 2008, NAT GENET, V40, P340, DOI 10.1038/ng.78; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bleuler E., 1911, HDB PSYCHIAT; Bosc C, 2003, BIOCHEMISTRY-US, V42, P12125, DOI 10.1021/bi0352163; Cao QH, 1997, GENOMICS, V43, P1, DOI 10.1006/geno.1997.4815; Carrera N, 2009, AM J MED GENET B, V150B, P369, DOI 10.1002/ajmg.b.30823; Crespi B, 2007, P ROY SOC B-BIOL SCI, V274, P2801, DOI 10.1098/rspb.2007.0876; Crow TJ, 2008, SCHIZOPHR RES, V102, P31, DOI 10.1016/j.schres.2008.03.010; Crow TJ, 1997, SCHIZOPHR RES, V28, P127, DOI 10.1016/S0920-9964(97)00110-2; Dick DM, 2003, AM J HUM GENET, V73, P107, DOI 10.1086/376562; Doering JE, 2008, J COMP NEUROL, V511, P238, DOI 10.1002/cne.21824; Duan JB, 2004, AM J HUM GENET, V75, P624, DOI 10.1086/424887; Durany N, 2001, SCHIZOPHR RES, V52, P79, DOI 10.1016/S0920-9964(00)00084-0; EWENS WJ, 1995, AM J HUM GENET, V57, P455; Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003; Fan JB, 2006, NAT REV GENET, V7, P632, DOI 10.1038/nrg1901; Fay JC, 2000, GENETICS, V155, P1405; Ferland RJ, 2004, NAT GENET, V36, P1008, DOI 10.1038/ng1419; First MB, 1996, PSYCHIAT CLIN N AM, V19, P29, DOI 10.1016/S0193-953X(05)70271-9; Frantseva MV, 2008, CEREB CORTEX, V18, P990, DOI 10.1093/cercor/bhm151; FU YX, 1993, GENETICS, V133, P693; Fumagalli M, 2009, GENOME RES, V19, P199, DOI 10.1101/gr.082768.108; Gorski JA, 2003, J NEUROSCI, V23, P6856; GRIFFITHS RC, 1994, PHILOS T ROY SOC B, V344, P403, DOI 10.1098/rstb.1994.0079; GRIFFITHS RC, 1995, MATH BIOSCI, V127, P77, DOI 10.1016/0025-5564(94)00044-Z; Harrison PJ, 2003, LANCET, V361, P417, DOI 10.1016/S0140-6736(03)12379-3; Hashimoto T, 2005, J NEUROSCI, V25, P372, DOI 10.1523/JNEUROSCI.4035-04.2005; Hirayasu Y, 2007, NEUROPATHOLOGY, V27, P601, DOI 10.1111/j.1440-1789.2007.00827.x; Horrobin DF, 1998, MED HYPOTHESES, V50, P269, DOI 10.1016/S0306-9877(98)90000-7; HUDSON RR, 1987, GENETICS, V116, P153; HUXLEY J, 1964, NATURE, V204, P220, DOI 10.1038/204220a0; Ingason A, 2007, EUR J HUM GENET, V15, P988, DOI 10.1038/sj.ejhg.5201848; Jaber L, 2000, CLIN GENET, V58, P106, DOI 10.1034/j.1399-0004.2000.580203.x; JABER L, 1994, ARCH PEDIAT ADOL MED, V148, P412, DOI 10.1001/archpedi.1994.02170040078013; Jensen JD, 2008, MOL BIOL EVOL, V25, P438, DOI 10.1093/molbev/msm273; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Jiang XY, 2002, J VIROL, V76, P9046, DOI 10.1128/JVI.76.18.9046-9059.2002; Kaufmann CA, 1998, AM J MED GENET, V81, P282, DOI 10.1002/(SICI)1096-8628(19980710)81:4<282::AID-AJMG2>3.0.CO;2-W; Keller MC, 2006, BEHAV BRAIN SCI, V29, P385, DOI 10.1017/S0140525X06009095; Khaitovich P, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-8-r124; Kirov G, 2009, MOL PSYCHIATR, V14, P796, DOI 10.1038/mp.2008.33; Kohn Y, 2005, MOL PSYCHIATR, V10, P1062, DOI 10.1038/sj.mp.4001738; Kohn Y, 2002, ISR J PSYCHIATR REL, V39, P240; Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563; Langlois MR, 1996, CLIN CHEM, V42, P1589; Lencz T, 2007, MOL PSYCHIATR, V12, P572, DOI 10.1038/sj.mp.4001983; Lerer B, 2003, MOL PSYCHIATR, V8, P488, DOI 10.1038/sj.mp.4001322; Levi A, 2005, EUR J HUM GENET, V13, P763, DOI 10.1038/sj.ejhg.5201406; Levinson DF, 2000, AM J HUM GENET, V67, P652, DOI 10.1086/303041; Lewis CM, 2003, AM J HUM GENET, V73, P34, DOI 10.1086/376549; Lichtermann D, 2000, EUR ARCH PSY CLIN N, V250, P304, DOI 10.1007/s004060070005; Lindholm E, 2001, AM J HUM GENET, V69, P96, DOI 10.1086/321288; Lisman JE, 2008, TRENDS NEUROSCI, V31, P234, DOI 10.1016/j.tins.2008.02.005; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martinez M, 1999, AM J MED GENET, V88, P337, DOI 10.1002/(SICI)1096-8628(19990820)88:4<337::AID-AJMG9>3.3.CO;2-1; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; MCGUE M, 1989, ARCH GEN PSYCHIAT, V46, P478; MCGUFFIN P, 1994, BRIT J PSYCHIAT, V164, P593, DOI 10.1192/bjp.164.5.593; McInnis MG, 2003, BIOL PSYCHIAT, V54, P1265, DOI 10.1016/j.biopsych.2003.08.001; Middleton FA, 2004, AM J HUM GENET, V74, P886, DOI 10.1086/420775; Morris JA, 2003, HUM MOL GENET, V12, P1591, DOI 10.1093/hmg/ddg162; Muglia P, 2003, MOL PSYCHIATR, V8, P146, DOI 10.1038/sj.mp.4001221; Need AC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000373; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; Ng MYM, 2009, MOL PSYCHIATR, V14, P774, DOI 10.1038/mp.2008.135; Nielsen R, 2007, NAT REV GENET, V8, P857, DOI 10.1038/nrg2187; O'Donovan MC, 2008, NAT GENET, V40, P1053, DOI 10.1038/ng.201; OCKLEFORD CD, 1987, J CELL SCI, V87, P27; Owen MJ, 2002, PSYCHIAT GENETICS GE, P247; Ozonoff S, 1999, J CHILD NEUROL, V14, P636, DOI 10.1177/088307389901401003; Parisi MA, 2007, EUR J HUM GENET, V15, P511, DOI 10.1038/sj.ejhg.5201648; Perez-Torres S, 2003, EXP NEUROL, V182, P322, DOI 10.1016/S0014-4886(03)00042-6; Potkin SG, 2009, MOL PSYCHIATR, V14, P416, DOI 10.1038/mp.2008.127; Potkin SG, 2009, SCHIZOPHRENIA BULL, V35, P96, DOI 10.1093/schbul/sbn155; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Rapoport JL, 2005, MOL PSYCHIATR, V10, P434, DOI 10.1038/sj.mp.4001642; Riley BP, 2000, AM J MED GENET, V97, P23, DOI 10.1002/(SICI)1096-8628(200021)97:1<23::AID-AJMG5>3.0.CO;2-K; Sasaki T, 2000, BIOCHEM BIOPH RES CO, V271, P575, DOI 10.1006/bbrc.2000.2661; Schaffner SF, 2005, GENOME RES, V15, P1576, DOI 10.1101/gr.3709305; Sheng G, 2008, J CLIN INVEST, V118, P2785, DOI 10.1172/JCI35339; Shi JX, 2009, NATURE, V460, P753, DOI 10.1038/nature08192; Shifman S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040028; SHINODA K, 1993, J COMP NEUROL, V329, P1, DOI 10.1002/cne.903290102; Spampinato MV, 2008, AM J MED GENET A, V146A, P1389, DOI 10.1002/ajmg.a.32282; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; Steemers Frank J., 2007, Biotechnology Journal, V2, P41, DOI 10.1002/biot.200600213; STEEN KV, 2005, HUM GENOMICS, V2, P67; Stefansson H, 2008, NATURE, V455, P232, DOI 10.1038/nature07229; Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sullivan PF, 2008, MOL PSYCHIATR, V13, P570, DOI 10.1038/mp.2008.25; TAJIMA F, 1989, GENETICS, V123, P585; Thornton K, 2003, BIOINFORMATICS, V19, P2325, DOI 10.1093/bioinformatics/btg316; Valente EM, 2006, ANN NEUROL, V59, P527, DOI 10.1002/ana.20749; Walsh T, 2008, SCIENCE, V320, P539, DOI 10.1126/science.1155174; Wang E, 2004, AM J HUM GENET, V74, P931, DOI 10.1086/420854; Wang N, 2002, AM J HUM GENET, V71, P1227, DOI 10.1086/344398; WATTERSON GA, 1978, GENETICS, V88, P405; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; Weir B.S., 1996, GENETIC DATA ANAL; White T, 2008, SCHIZOPHRENIA BULL, V34, P18, DOI 10.1093/schbul/sbm110; Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864; Williams NM, 2003, AM J HUM GENET, V73, P1355, DOI 10.1086/380206; Wittke-Thompson JK, 2005, AM J HUM GENET, V76, P967, DOI 10.1086/430507; Wright SI, 2004, GENETICS, V168, P1071, DOI 10.1534/genetics.104.026500; Xu B, 2008, NAT GENET, V40, P880, DOI 10.1038/ng.162; Yu FL, 2009, HUM MOL GENET, V18, P4853, DOI 10.1093/hmg/ddp457; Zeng K, 2007, MOL BIOL EVOL, V24, P1562, DOI 10.1093/molbev/msm078; Zhai WW, 2009, MOL BIOL EVOL, V26, P273, DOI 10.1093/molbev/msn231	124	30	30	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					3066	3082		10.1096/fj.09-152611	http://dx.doi.org/10.1096/fj.09-152611			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371615	Green Submitted			2022-12-28	WOS:000285005400043
J	Formenti, F; Beer, PA; Croft, QPP; Dorrington, KL; Gale, DP; Lappin, TRJ; Lucas, GS; Maher, ER; Maxwell, PH; McMullin, MF; O'Connor, DF; Percy, MJ; Pugh, CW; Ratcliffe, PJ; Smith, TG; Talbot, NP; Robbins, PA				Formenti, Federico; Beer, Philip A.; Croft, Quentin P. P.; Dorrington, Keith L.; Gale, Daniel P.; Lappin, Terence R. J.; Lucas, Guy S.; Maher, Eamonn R.; Maxwell, Patrick H.; McMullin, Mary F.; O'Connor, David F.; Percy, Melanie J.; Pugh, Christopher W.; Ratcliffe, Peter J.; Smith, Thomas G.; Talbot, Nick P.; Robbins, Peter A.			Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2 alpha gain-of-function mutation	FASEB JOURNAL			English	Article						pulmonary hypertension; ventilation; metabolism; polycythemia	PULMONARY-ARTERY PRESSURE; DOPPLER-ECHOCARDIOGRAPHY; TUMOR-SUPPRESSOR; CARDIAC-OUTPUT; NONINVASIVE ESTIMATION; PROLYL HYDROXYLASES; SYSTOLIC PRESSURE; PROTEIN; GENE; ALPHA	The hypoxia-inducible factors (HIFs; isoforms HIF-1 alpha, HIF-2 alpha, HIF-3 alpha) mediate many responses to hypoxia. Their regulation is principally by oxygen-dependent degradation, which is initiated by hydroxylation of specific proline residues followed by binding of von Hippel-Lindau (VHL) protein. Chuvash polycythemia is a disorder with elevated HIF. It arises through germline homozygosity for hypomorphic VHL alleles and has a phenotype of hematological, cardiopulmonary, and metabolic abnormalities. This study explores the phenotype of two other HIF pathway diseases: classic VHL disease and HIF-2 alpha gain-of-function mutation. No cardiopulmonary abnormalities were detected in classic VHL disease. HIF-2 alpha gain-of-function mutations were associated with pulmonary hypertension, increased cardiac output, increased heart rate, and increased pulmonary ventilation relative to metabolism. Comparison of the HIF-2 alpha gain-of-function responses with data from studies of Chuvash polycythemia suggested that other aspects of the Chuvash phenotype were diminished or absent. In classic VHL disease, patients are germline heterozygous for mutations in VHL, and the present results suggest that a single wild-type allele for VHL is sufficient to maintain normal cardiopulmonary function. The HIF-2 alpha gain-of-function phenotype may be more limited than the Chuvash phenotype either because HIF-1 alpha is not elevated in the former condition, or because other HIF-independent functions of VHL are perturbed in Chuvash polycythemia.-Formenti, F., Beer, P. A., Croft, Q. P. P., Dorrington, K. L., Gale, D. P., Lappin, T. R. J., Lucas, G. S., Maher, E. R., Maxwell, P. H., McMullin, M. F., O'Connor, D. F., Percy, M. J., Pugh, C. W., Ratcliffe, P. J., Smith, T. G., Talbot, N. P., Robbins, P. A. Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2 alpha gain-of-function mutation. FASEB J. 25, 2001-2011 (2011). www.fasebj.org	[Formenti, Federico; Croft, Quentin P. P.; Dorrington, Keith L.; O'Connor, David F.; Smith, Thomas G.; Talbot, Nick P.; Robbins, Peter A.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Pugh, Christopher W.; Ratcliffe, Peter J.] Univ Oxford, Nuffield Dept Clin Med, Oxford OX1 3PT, England; [Beer, Philip A.] Univ Cambridge, Cambridge, England; [Beer, Philip A.] Addenbrookes Hosp, Dept Haematol, Cambridge CB2 2QQ, England; [Gale, Daniel P.; Maxwell, Patrick H.] UCL, Div Med, Rayne Inst, London, England; [Lappin, Terence R. J.] Queens Univ, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [McMullin, Mary F.; Percy, Melanie J.] Queens Univ, Belfast City Hosp, Dept Haematol, Belfast, Antrim, North Ireland; [Lucas, Guy S.] Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England; [Maher, Eamonn R.] Univ Birmingham, Ctr Rare Dis & Personalised Med, Sch Clin & Expt Med, Birmingham, W Midlands, England	University of Oxford; University of Oxford; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; King's College London; University College London; Belfast City Hospital; Queens University Belfast; Belfast City Hospital; Queens University Belfast; University of Manchester; University of Birmingham	Formenti, F (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Parks Rd, Oxford OX1 3PT, England.	federico.formenti@dpag.ox.ac.uk; peter.robbins@dpag.ox.ac.uk	Maxwell, Patrick H/C-5557-2008; MAHER, EAMONN R/A-9507-2008; Gale, Daniel/D-5594-2013; McMullin, Mary Frances/AAG-6078-2021; McMullin, Mary F/AAF-6472-2020; Formenti, Federico/F-3501-2012; Robbins, Peter/C-7846-2016	Maxwell, Patrick H/0000-0002-0338-2679; MAHER, EAMONN R/0000-0002-6226-6918; Gale, Daniel/0000-0002-9170-1579; McMullin, Mary Frances/0000-0002-0773-0204; Formenti, Federico/0000-0003-4289-0761; Robbins, Peter/0000-0002-4975-0609; Smith, Thomas/0000-0002-5197-5030; Pugh, Chris/0000-0002-5170-1662; Ratcliffe, Peter/0000-0002-2853-806X; Beer, Philip/0000-0003-3056-5419; Talbot, Nick/0000-0002-9186-8950	University College Oxford; Department of Physiology, Anatomy, and Genetics; University of Oxford, Oxford, UK; Wellcome Trust [075876]; Dunhill Medical Trust; Royal Society [TG092416]; NIHR Cambridge Biomedical Research Centre, Cambridge, UK; British Heart Foundation [RG/11/1/28684] Funding Source: researchfish; National Institute for Health Research [NF-SI-0507-10315] Funding Source: researchfish	University College Oxford; Department of Physiology, Anatomy, and Genetics; University of Oxford, Oxford, UK; Wellcome Trust(Wellcome Trust); Dunhill Medical Trust(Dunhill Medical Trust); Royal Society(Royal Society of London); NIHR Cambridge Biomedical Research Centre, Cambridge, UK(National Institute for Health Research (NIHR)); British Heart Foundation(British Heart Foundation); National Institute for Health Research(National Institute for Health Research (NIHR))	The authors thank the patients and volunteers who took part in the studies. F.F. was funded by a University College Oxford postdoctoral research scholarship and by the Fell Fund from the Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, UK. This work was supported by the Wellcome Trust (grant 075876 to P.A.R.), by the Dunhill Medical Trust (to K.L.D.), by the Royal Society (grant TG092416 to F.F.), and by the NIHR Cambridge Biomedical Research Centre, Cambridge, UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. F.F., P.A.B., Q.P.P.C., K.L.D., D.P.G., T.R.J.L., G.S.L., E.R.M., P.H.M., M.F.M., D.F.O., M.J.P., C.W.P., P.J.R., T.G.S., N.P.T., and P.A.R. agree with the manuscript's results and conclusions; F.F., C.W.P., and P.A.R. designed the experiments and the study; F.F. analyzed the data; F.F., Q.P.P.C., K.L.D., D.F.O., T.G.S., and N.P.T. collected data and conducted experiments for the study; F.F., P.A.B., D.P.G., T.R.J.L., G.S.L., E.R.M., P.H.M., M.F.M., M.J.P., T.G.S., and P.A.R. enrolled patients; F.F., P.J.R., and P.A.R. wrote the manuscript; K.L.D. and P.A.R. supervised and obtained funding. P.J.R., P.H.M., and C.W.P. are scientific cofounders of, and hold equity in, ReOx Ltd, a university spinoff company that is seeking to make HIF hydroxylase inhibitors. The other authors declare no competing financial interests.	Allemann Y, 2000, AM J PHYSIOL-HEART C, V279, pH2013, DOI 10.1152/ajpheart.2000.279.4.H2013; Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bushuev VI, 2006, HAEMATOLOGICA, V91, P744; Chemla D, 2004, CHEST, V126, P1313, DOI 10.1378/chest.126.4.1313; CHRISTIE J, 1987, CIRCULATION, V76, P539, DOI 10.1161/01.CIR.76.3.539; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; ERIKSEN M, 1990, MED BIOL ENG COMPUT, V28, P555, DOI 10.1007/BF02442607; Formenti F, 2010, P NATL ACAD SCI USA, V107, P12722, DOI 10.1073/pnas.1002339107; Frew IJ, 2007, CURR OPIN CELL BIOL, V19, P685, DOI 10.1016/j.ceb.2007.10.001; Gale DP, 2008, BLOOD, V112, P919, DOI 10.1182/blood-2008-04-153718; Gordeuk VR, 2006, SEMIN THROMB HEMOST, V32, P289, DOI 10.1055/s-2006-939441; Gordeuk VR, 2004, BLOOD, V103, P3924, DOI 10.1182/blood-2003-07-2535; GROVES BM, 1987, J APPL PHYSIOL, V63, P521, DOI 10.1152/jappl.1987.63.2.521; Grunig E, 2000, J AM COLL CARDIOL, V35, P980, DOI 10.1016/S0735-1097(99)00633-6; Hickey MM, 2010, J CLIN INVEST, V120, P827, DOI 10.1172/JCI36362; HOWSON MG, 1986, J PHYSIOL-LONDON, V382, pP12; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Martini M, 2008, HAEMATOL-HEMATOL J, V93, P1068, DOI 10.3324/haematol.13210; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PEACOCK AJ, 1990, RESP MED, V84, P335, DOI 10.1016/S0954-6111(08)80063-7; Percy MJ, 2008, BLOOD, V111, P5400, DOI 10.1182/blood-2008-02-137703; Percy MJ, 2008, NEW ENGL J MED, V358, P162, DOI 10.1056/NEJMoa073123; Prowse AH, 1997, AM J HUM GENET, V60, P765; ROBBINS PA, 1982, J APPL PHYSIOL, V52, P1353, DOI 10.1152/jappl.1982.52.5.1353; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389; Sergeyeva A, 1997, BLOOD, V89, P2148, DOI 10.1182/blood.V89.6.2148; SKJAERPE T, 1986, EUR HEART J, V7, P704, DOI 10.1093/oxfordjournals.eurheartj.a062126; Smith TG, 2006, PLOS MED, V3, P1178, DOI 10.1371/journal.pmed.0030290; Smith TG, 2009, JAMA-J AM MED ASSOC, V302, P1444, DOI 10.1001/jama.2009.1404; Sugawara J, 2003, ACTA PHYSIOL SCAND, V179, P361, DOI 10.1046/j.0001-6772.2003.01211.x; Walmsley SR, 2006, BLOOD, V108, P3176, DOI 10.1182/blood-2006-04-018796; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wasserman K, 2005, PRINCIPLES EXERCISE; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657	51	70	70	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					2001	2011		10.1096/fj.10-177378	http://dx.doi.org/10.1096/fj.10-177378			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21389259	Green Published, hybrid			2022-12-28	WOS:000291023800022
J	Gherghe, CM; Duan, JZ; Gong, JC; Rojas, M; Klauber-Demore, N; Majesky, M; Deb, A				Gherghe, Costin M.; Duan, Jinzhu; Gong, Jucheng; Rojas, Mauricio; Klauber-Demore, Nancy; Majesky, Mark; Deb, Arjun			Wnt1 is a proangiogenic molecule, enhances human endothelial progenitor function, and increases blood flow to ischemic limbs in a HGF-dependent manner	FASEB JOURNAL			English	Article						angiogenesis; vascular progenitor; paracrine	GENE-THERAPY; CELLS; INHIBITION; MECHANISMS	Human endothelial progenitor cells (hEPCs) participate in neovascularization of ischemic tissues. Function and number of hEPCs decline in patients with cardiovascular disease, and therapeutic strategies to enhance hEPC function remain an important field of investigation. The Wnt signaling system, comprising 19 lipophilic proteins, regulates vascular patterning in the developing embryo. However, the effects of Wnts on hEPCs and the adult vasculature remain unclear. We demonstrate here that Wnt1 is expressed in a subset of endothelial cells lining the murine embryonic dorsal aorta and is reactivated in malignant angiosarcoma, suggesting a strong association of Wnt1 with angiogenesis. We investigate the effects of Wnt1 in enhancing hEPC function and blood flow to ischemic tissues and show that Wnt1 enhances the proliferative and angiogenic functions of hEPCs in a hepatocyte growth factor (HGF)-dependent manner. Injection of Wnt1-expressing hEPCs increases blood flow and capillary density in murine ischemic hindlimbs. Furthermore, injection of Wnt1 protein alone similarly increases blood flow and capillary density in ischemic hindlimbs, and this effect is associated with increased HGF expression in ischemic muscle. These findings demonstrate that Wnt1, a marker of neural crest cells and hitherto unknown angiogenic function, is a novel angiogenic protein that is expressed in developing endothelial cells, exerts salutary effects on postnatal hEPCs, and can be therapeutically deployed to increase blood flow and angiogenesis in ischemic tissues.-Gherghe, C. M., Duan, J., Gong, J., Rojas, M., Klauber-Demore, N., Majesky, M., Deb, A. Wnt1 is a proangiogenic molecule, enhances human endothelial progenitor function, and increases blood flow to ischemic limbs in a HGF-dependent manner. FASEB J. 25, 1836-1843 (2011). www.fasebj.org	[Gherghe, Costin M.; Duan, Jinzhu; Gong, Jucheng; Rojas, Mauricio; Deb, Arjun] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; [Gherghe, Costin M.; Duan, Jinzhu; Gong, Jucheng; Deb, Arjun] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; [Klauber-Demore, Nancy] Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA; [Gherghe, Costin M.; Duan, Jinzhu; Gong, Jucheng; Rojas, Mauricio; Klauber-Demore, Nancy; Deb, Arjun] Univ N Carolina, UNC McAllister Heart Inst, Chapel Hill, NC 27599 USA; [Gherghe, Costin M.; Duan, Jinzhu; Gong, Jucheng; Klauber-Demore, Nancy; Deb, Arjun] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Majesky, Mark] Univ Washington, Sch Med, Dept Pediat, Div Cardiol,Seattle Childrens Res Inst, Seattle, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Seattle Children's Hospital; University of Washington; University of Washington Seattle	Deb, A (corresponding author), Univ N Carolina, Dept Med, 3212B MBRB,Campus Box 7126,111 Mason Farm Rd, Chapel Hill, NC 27599 USA.	arjundeb@med.unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022		National Institutes of Health; Ellison Medical Foundation; NATIONAL CANCER INSTITUTE [R01CA142657] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL102190, R00HL088317, R01HL093594] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank the Mouse Histology Core (Virus and Flow Cytometry Core, University of North Carolina-Chapel Hill) for assistance with techniques. The authors thank Jackie Kylander and Taylor Kopple (Mouse Cardiovascular Core, University of North Carolina-Chapel Hill) for assistance with laser-Doppler scanning and Dr. Gobinda Sarkar (Mayo Clinic, Rochester, MN, USA) for critique of the manuscript. This work was supported by grants from the National Institutes of Health and Ellison Medical Foundation to A.D.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Becker GJ, 2002, J VASC INTERV RADIOL, V13, P7, DOI 10.1016/S1051-0443(07)60002-5; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Deb A, 2010, CIRCULATION, V121, P850, DOI 10.1161/CIR.0b013e3181d4c360; Dudek AZ, 2007, BRIT J CANCER, V97, P513, DOI 10.1038/sj.bjc.6603883; Dzau VJ, 2005, HYPERTENSION, V46, P7, DOI 10.1161/01.HYP.0000168923.92885.f7; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Kusano KF, 2005, NAT MED, V11, P1197, DOI 10.1038/nm1313; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; MASCKAUCHAN HTN, 2005, ANGIOGENESIS, V8, P43; Matsui H, 2007, STEM CELLS, V25, P2660, DOI 10.1634/stemcells.2006-0699; Monkley SJ, 1996, DEVELOPMENT, V122, P3343; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; Ono K, 1997, CIRCULATION, V95, P2552, DOI 10.1161/01.CIR.95.11.2552; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; You L, 2004, CANCER RES, V64, P3474, DOI 10.1158/0008-5472.CAN-04-0115; Zerlin M, 2008, ANGIOGENESIS, V11, P63, DOI 10.1007/s10456-008-9095-3	24	27	30	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1836	1843		10.1096/fj.10-172981	http://dx.doi.org/10.1096/fj.10-172981			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21321190	Green Published			2022-12-28	WOS:000291023800007
J	Gildea, DE; Luetkemeier, ES; Bao, XZ; Loftus, SK; Mackem, S; Yang, YZ; Pavan, WJ; Biesecker, LG				Gildea, Derek E.; Luetkemeier, Erin S.; Bao, Xiaozhong; Loftus, Stacie K.; Mackem, Susan; Yang, Yingzi; Pavan, William J.; Biesecker, Leslie G.			The pleiotropic mouse phenotype extra-toes spotting is caused by translation initiation factor Eif3c mutations and is associated with disrupted sonic hedgehog signaling	FASEB JOURNAL			English	Article						development; polydactyly; positional cloning; GLI3 processing	GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; DEVELOPING NEURAL-TUBE; LIMB DEVELOPMENT; POLARIZING ACTIVITY; FEEDBACK LOOP; IN-VIVO; GLI3; GENE; EXPRESSION; DELETION	Polydactyly is a common malformation and can be an isolated anomaly or part of a pleiotropic syndrome. The elucidation of the mutated genes that cause polydactyly provides insight into limb development pathways. The extra-toes spotting (Xs) mouse phenotype manifests anterior polydactyly, predominantly in the forelimbs, with ventral hypopigmenation. The mapping of Xs(J) to chromosome 7 was confirmed, and the interval was narrowed to 322 kb using intersubspecific crosses. Two mutations were identified in eukaryotic translation initiation factor 3 subunit C (Eif3c). An Eif3c c.907C > T mutation (p.Arg303X) was identified in Xs(J), and a c.1702_1758del mutation (p.Leu568_Leu586del) was identified in extra-toes spotting-like (Xsl), an allele of Xs(J). The effect of the Xs(J) mutation on the SHH/GLI3 pathway was analyzed by in situ hybridization analysis, and we show that Xs mouse embryos have ectopic Shh and Ptch1 expression in the anterior limb. In addition, anterior limb buds show aberrant Gli3 processing, consistent with perturbed SHH/GLI3 signaling. Based on the occurrence of Eif3c mutations in 2 Xs lines and haploinsufficiency of the Xs(J) allele, we conclude that the Xs phenotype is caused by a mutation in Eif3c, a component of the translation initiation complex, and that the phenotype is associated with aberrant SHH/GLI3 signaling.-Gildea, D. E., Luetkemeier, E. S., Bao, X., Loftus, S. K., Mackem, S., Yang, Y., Pavan, W. J., Biesecker, L. G. The pleiotropic mouse phenotype extra-toes spotting is caused by translation initiation factor Eif3c mutations and is associated with disrupted sonic hedgehog signaling. FASEB J. 25, 1596-1605 (2011). www.fasebj.org	[Gildea, Derek E.; Luetkemeier, Erin S.; Loftus, Stacie K.; Yang, Yingzi; Pavan, William J.; Biesecker, Leslie G.] NHGRI, NIH, Bethesda, MD 20892 USA; [Gildea, Derek E.] George Washington Univ, Inst Biomed Sci, Washington, DC USA; [Bao, Xiaozhong; Mackem, Susan] NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Biesecker, LG (corresponding author), NHGRI, NIH, Bldg 49,Rm 4A56, Bethesda, MD 20892 USA.	leslieb@helix.nih.gov		Loftus, Stacie/0000-0002-1958-4689; Pavan, William/0000-0001-8281-5120	National Human Genome Research Institute; National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIABC011118] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200328, ZIAHG000070] Funding Source: NIH RePORTER	National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	The authors thank Arturo Incao, Marjorie Lindhurst, and Julie Nadel for assistance with animal husbandry. The authors also thank Julia Fekecs for help with generating figures. This research was supported by the Intramural Research Programs of the National Human Genome Research Institute and the National Cancer Institute. Information on Xsl can be found online (http://mousemutant.jax.org/articles/mmrmutantxsl.html).	Aoto K, 2002, DEV BIOL, V251, P320, DOI 10.1006/dbio.2002.0811; Barkic M, 2009, MOL CELL BIOL, V29, P2489, DOI 10.1128/MCB.01588-08; Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; Chen YT, 2004, DEVELOPMENT, V131, P2339, DOI 10.1242/dev.01115; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hinnebusch AG, 2006, TRENDS BIOCHEM SCI, V31, P553, DOI 10.1016/j.tibs.2006.08.005; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; JOHNSON DR, 1967, J EMBRYOL EXP MORPH, V17, P543; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; KO V, 1998, GENOMICS APPROACH ST; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loftus SK, 2002, P NATL ACAD SCI USA, V99, P4471, DOI 10.1073/pnas.072087599; LYON MF, 1989, MOUSE NEWS LETT, V83, P158; Mackem S, 1999, CELL TISSUE RES, V296, P27, DOI 10.1007/s004410051263; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Masutani M, 2007, EMBO J, V26, P3373, DOI 10.1038/sj.emboj.7601765; MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645; Maynard TM, 2002, MAMM GENOME, V13, P58, DOI 10.1007/s00335-001-2115-X; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; O'Rourke MP, 2002, DEV BIOL, V248, P143, DOI 10.1006/dbio.2002.0730; Oliver ER, 2004, DEVELOPMENT, V131, P3907, DOI 10.1242/dev.01268; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SAMPLES RM, 2006, MGI DIRECT DATA SUBM, P6090; Schultz RM, 2002, HUM REPROD UPDATE, V8, P323, DOI 10.1093/humupd/8.4.323; Shin SH, 1999, P NATL ACAD SCI USA, V96, P2880, DOI 10.1073/pnas.96.6.2880; Southard J., 1977, MOUSE NEWS LETT, V56, P40; Valasek L, 2003, GENE DEV, V17, P786, DOI 10.1101/gad.1065403; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; VORTKAMP A, 1992, MAMM GENOME, V3, P461, DOI 10.1007/BF00356157; WINTER RM, 1988, AM J MED GENET, V31, P793, DOI 10.1002/ajmg.1320310411; Yang Y, 1998, DEVELOPMENT, V125, P3123; Zakany J, 2004, SCIENCE, V304, P1669, DOI 10.1126/science.1096049	37	9	9	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1596	1605		10.1096/fj.10-169771	http://dx.doi.org/10.1096/fj.10-169771			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21292980	Green Published			2022-12-28	WOS:000290023800017
J	Ferraz-de-Souza, B; Lin, L; Shah, S; Jina, N; Hubank, M; Dattani, MT; Achermann, JC				Ferraz-de-Souza, Bruno; Lin, Lin; Shah, Sonia; Jina, Nipurna; Hubank, Mike; Dattani, Mehul T.; Achermann, John C.			ChIP-on-chip analysis reveals angiopoietin 2 (Ang2, ANGPT2) as a novel target of steroidogenic factor-1 (SF-1, NR5A1) in the human adrenal gland	FASEB JOURNAL			English	Article						adrenal development; adrenal tumorigenesis; transcriptional regulation; angiogenesis; NCI-H295R adrenocortical cells	ADRENOCORTICAL TUMORS; NUCLEAR RECEPTOR; GENE-EXPRESSION; TRANSCRIPTION; MUTATION; BINDING; PROMOTER; DIFFERENTIATION; AMPLIFICATION; ANGIOGENESIS	The nuclear receptor steroidogenic factor-1 (SF-1, NR5A1) is a key regulator of adrenal and gonadal biology. Disruption of SF-1 can lead to disorders of adrenal development, while increased SF-1 dosage has been associated with adrenocortical tumorigenesis. We aimed to identify a novel subset of SF-1 target genes in the adrenal by using chromatin immunoprecipitation (ChIP) microarrays (ChIP-on-chip) combined with systems analysis. SF-1 ChIP-on-chip was performed in NCI-H295R human adrenocortical cells using promoter tiling arrays, leading to the identification of 445 gene loci where SF-1-binding regions were located from 10 kb upstream to 3 kb downstream of a transcriptional start. Network analysis of genes identified as putative SF-1 targets revealed enrichment for angiogenic process networks. A 1.1-kb SF-1-binding region was identified in the angiopoietin 2 (Ang2, ANGPT2) promoter in a highly repetitive region, and SF-1-dependent activation was confirmed in luciferase assays. Angiogenesis is paramount in adrenal development and tumorigenesis, but until now a direct link between SF-1 and vascular remodeling has not been established. We have identified Ang2 as a potentially important novel target of SF-1 in the adrenal gland, indicating that regulation of angiogenesis might be an important additional mechanism by which SF-1 exerts its actions in the adrenal gland.-Ferraz-de-Souza, B., Lin, L., Shah, S., Jina, N., Hubank, M., Dattani, M. T., Achermann, J. C. ChIP-on-chip analysis reveals angiopoietin 2 (Ang2, ANGPT2) as a novel target of steroidogenic factor-1 (SF-1, NR5A1) in the human adrenal gland. FASEB J. 25, 1166-1175 (2011). www.fasebj.org	[Ferraz-de-Souza, Bruno; Lin, Lin; Dattani, Mehul T.; Achermann, John C.] UCL, UCL Inst Child Hlth, Dev Endocrinol Res Grp, London WC1N 1EH, England; [Jina, Nipurna; Hubank, Mike] UCL, UCL Genom, London WC1N 1EH, England; [Shah, Sonia] Univ London, Bloomsbury Ctr Bioinformat, London, England	University of London; University College London; University of London; University College London; University of London	Achermann, JC (corresponding author), UCL, UCL Inst Child Hlth, Dev Endocrinol Res Grp, 30 Guilford St, London WC1N 1EH, England.	j.achermann@ich.ucl.ac.uk	Achermann, John/C-5476-2008; Ferraz-de-Souza, Bruno/G-1069-2010; Hubank, Michael JF/C-1837-2008; Achermann, John/N-2906-2019; Shah, Sonia/N-7547-2013	Achermann, John/0000-0001-8787-6272; Ferraz-de-Souza, Bruno/0000-0003-4863-2544; Hubank, Michael JF/0000-0002-2901-0742; Achermann, John/0000-0001-8787-6272; Shah, Sonia/0000-0001-5860-4526	Medical Research Council/Wellcome Trust [G0700089, 082557]; Capes/Brazil [4798066]; Wellcome Trust [079666]; MRC [G0700089, G9900837] Funding Source: UKRI; Medical Research Council [G9900837, G0700089] Funding Source: researchfish	Medical Research Council/Wellcome Trust(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)Wellcome Trust); Capes/Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors are grateful to Rahul Parnaik for performing immunohistochemical studies. The authors thank P. S. H. Soon for making the supplemental material to ref. 32 available, Jacky Pallas and Catherine Risebro for useful discussions, and J. Larry Jameson (Northwestern University, Chicago, IL, USA) and Ronald Evans (Salk Institute, San Diego, CA, USA) for plasmids. Human fetal tissue was provided by the Medical Research Council/Wellcome Trust-funded Human Developmental Biology Resource (http://www.hdbr.org) (MRC G0700089; The Wellcome Trust 082557), with technical assistance from Dianne Gerrelli. This work was supported by a Capes scholarship (4798066, Capes/Brazil) to B.F.-D. and a Wellcome Trust Senior Research Fellowship in Clinical Science (079666) to J. C. A. The array data have been submitted to the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under series accession no. GSE26144.	Achermann JC, 1999, NAT GENET, V22, P125, DOI 10.1038/9629; Achermann JC, 2002, J CLIN ENDOCR METAB, V87, P1829, DOI 10.1210/jc.87.4.1829; Almeida MQ, 2010, J CLIN ENDOCR METAB, V95, P1458, DOI 10.1210/jc.2009-2040; Bach F, 2007, EJSO-EUR J SURG ONC, V33, P7, DOI 10.1016/j.ejso.2006.07.015; Biason-Lauber A, 2000, AM J HUM GENET, V67, P1563, DOI 10.1086/316893; Bland ML, 2004, MOL ENDOCRINOL, V18, P941, DOI 10.1210/me.2003-0333; Bland ML, 2000, P NATL ACAD SCI USA, V97, P14488, DOI 10.1073/pnas.97.26.14488; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Doghman M, 2007, MOL ENDOCRINOL, V21, P2968, DOI 10.1210/me.2007-0120; Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P101, DOI 10.1210/er.19.2.101; Ferraz-de-Souza B, 2011, MOL CELL ENDOCRINOL, V336, P198, DOI 10.1016/j.mce.2010.11.006; Ferraz-De-Souza B, 2009, J CLIN ENDOCR METAB, V94, P678, DOI 10.1210/jc.2008-1064; Figueiredo BC, 2005, J CLIN ENDOCR METAB, V90, P615, DOI 10.1210/jc.2004-0942; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; Gizard F, 2002, J BIOL CHEM, V277, P39144, DOI 10.1074/jbc.M205786200; Goto M, 2006, J CLIN INVEST, V116, P953, DOI 10.1172/JCI25091; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; Gudmundsson J, 2009, NAT GENET, V41, P460, DOI 10.1038/ng.339; Guo IC, 2007, J BIOMED SCI, V14, P509, DOI 10.1007/s11373-007-9177-z; Hu MC, 2001, MOL ENDOCRINOL, V15, P812, DOI 10.1210/me.15.5.812; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; Ishimoto H, 2006, J CLIN ENDOCR METAB, V91, P1909, DOI 10.1210/jc.2005-2252; Ishimoto H, 2008, J CLIN ENDOCR METAB, V93, P2402, DOI 10.1210/jc.2007-2509; Ito M, 2000, J BIOL CHEM, V275, P31708, DOI 10.1074/jbc.M002892200; Ji HK, 2005, BIOINFORMATICS, V21, P3629, DOI 10.1093/bioinformatics/bti593; Ji HK, 2008, NAT BIOTECHNOL, V26, P1293, DOI 10.1038/nbt.1505; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; Krude H, 2002, J CLIN INVEST, V109, P475, DOI 10.1172/JC1200214341; Lalli E, 2010, J MOL ENDOCRINOL, V44, P301, DOI 10.1677/JME-09-0143; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Nicol JW, 2009, BIOINFORMATICS, V25, P2730, DOI 10.1093/bioinformatics/btp472; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Ramayya MS, 1997, J CLIN ENDOCR METAB, V82, P1799, DOI 10.1210/jc.82.6.1799; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Sbiera S, 2010, J CLIN ENDOCR METAB, V95, pE161, DOI 10.1210/jc.2010-0653; Schimmer BP, 2010, MOL ENDOCRINOL, V24, P1322, DOI 10.1210/me.2009-0519; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; Soon PSH, 2009, ENDOCR-RELAT CANCER, V16, P573, DOI 10.1677/ERC-08-0237; SUNTHORNTHEPVARAKUL T, 1995, NEW ENGL J MED, V332, P155, DOI 10.1056/NEJM199501193320305; Untergasser A, 2007, NUCLEIC ACIDS RES, V35, pW71, DOI 10.1093/nar/gkm306; Val P, 2007, DEVELOPMENT, V134, P2349, DOI 10.1242/dev.004390; West AN, 2007, CANCER RES, V67, P600, DOI 10.1158/0008-5472.CAN-06-3767; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zhao Y, 2010, ARTERIOSCL THROM VAS, V30, P1535, DOI 10.1161/ATVBAHA.109.191163	49	21	22	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1166	1175		10.1096/fj.10-170522	http://dx.doi.org/10.1096/fj.10-170522			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21163858	Green Published, hybrid			2022-12-28	WOS:000288982800006
J	Siddiqui, IA; Asim, M; Hafeez, BB; Adhami, VM; Tarapore, RS; Mukhtar, H				Siddiqui, Imtiaz A.; Asim, Mohammad; Hafeez, Bilal B.; Adhami, Vaqar M.; Tarapore, Rohinton S.; Mukhtar, Hasan			Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer	FASEB JOURNAL			English	Article						androgen antagonist; androgen receptor signaling; androgen-regulated miRNA; hormone-refractory prostate cancer	NF-KAPPA-B; MICRORNA EXPRESSION; GROWTH-INHIBITION; MESSENGER-RNA; TUMOR-GROWTH; IN-VITRO; APOPTOSIS; CELLS; INDUCTION; EPIGALLOCATECHIN-3-GALLATE	Androgen deprivation therapy is the major treatment for advanced prostate cancer (PCa). However, it is a temporary remission, and the patients almost inevitably develop hormone refractory prostate cancer (HRPC). HRPC is almost incurable, although most HRPC cells still express androgen receptor (AR) and depend on the AR for growth, making AR a prime drug target. Here, we provide evidence that epigallocatechin-3-gallate (EGCG), the major polyphenol in green tea, is a direct antagonist of androgen action. In silico modeling and FRET-based competition assay showed that EGCG physically interacts with the ligand-binding domain of AR by replacing a high-affinity labeled ligand (IC50 0.4 mu M). The functional consequence of this interaction was a decrease in AR-mediated transcriptional activation, which was due to EGCG mediated inhibition of interdomain N-C termini interaction of AR. Treatment with EGCG also repressed the transcriptional activation by a hotspot mutant AR (T877A) expressed ectopically as well as the endogenous AR mutant. As the physiological consequence of AR antagonism, EGCG repressed R1881-induced PCa cell growth. In a xenograft model, EGCG was found to inhibit AR nuclear translocation and protein expression. We also observed a significant down-regulation of androgen-regulated miRNA-21 and up-regulation of a tumor suppressor, miRNA-330, in tumors of mice treated with EGCG. Taken together, we provide evidence that EGCG functionally antagonizes androgen action at multiple levels, resulting in inhibition of PCa growth.-Siddiqui, I. A., Asim, M., Hafeez, B. B., Adhami, V. M., Tarapore, R. S., Mukhtar, H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J. 25, 1198-1207 (2011). www.fasebj.org	[Mukhtar, Hasan] Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, B-25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Adhami, Vaqar/AAY-2837-2020; Tarapore, Rohinton/J-8300-2012	Adhami, Vaqar/0000-0002-2048-4570; 	U.S. Public Health Service [RO1CA78809, RO1CA101039, RO1CA120451]; U.S. National Institutes of Health [T32 AR 055893]; NATIONAL CANCER INSTITUTE [R01CA078809, R01CA101039, R01CA120451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR055893] Funding Source: NIH RePORTER	U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Drs. Aria Baniahmad (University of Jena, Jena, Germany), Albert Brinkmann (University of Rotterdam, Rotterdam, The Netherlands), and Zafar Nawaz (University of Miami, Miami, FL, USA) for providing plasmids used in this study. The authors thank Drs. George Thalman (Institute for Surgical Technology and Biomechanics, Bern University, Bern, Switzerland) and Randall Tibbetts (University of Wisconsin, Madison, WI, USA) for providing C4-2 and CV1 cells, respectively. The authors thank Dr. Kenneth Satyshur (Department of Bacteriology, University of Wisconsin, Madison, WI, USA) for help with in silico studies. This work was supported by U.S. Public Health Service grants RO1CA78809, RO1CA101039, and RO1CA120451 to H. M. I. A. S. was supported by U.S. National Institutes of Health grant T32 AR 055893.	Adhami VM, 2007, CLIN CANCER RES, V13, P1611, DOI 10.1158/1078-0432.CCR-06-2269; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Asim M, 2008, ONCOGENE, V27, P3596, DOI 10.1038/sj.onc.1211016; Bettuzzi S, 2006, CANCER RES, V66, P1234, DOI 10.1158/0008-5472.CAN-05-1145; Blot WJ, 1996, EUR J CANCER PREV, V5, P425; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Brusselmans K, 2003, INT J CANCER, V106, P856, DOI 10.1002/ijc.11317; Cantin L, 2007, J BIOL CHEM, V282, P30910, DOI 10.1074/jbc.M705524200; Centenera MM, 2008, MOL ENDOCRINOL, V22, P2373, DOI 10.1210/me.2008-0017; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen S, 1998, MOL ENDOCRINOL, V12, P1558, DOI 10.1210/me.12.10.1558; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Chuu CP, 2009, CANCER LETT, V275, P86, DOI 10.1016/j.canlet.2008.10.001; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Gupta S, 1999, CANCER RES, V59, P2115; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Hastak K, 2003, ONCOGENE, V22, P4851, DOI 10.1038/sj.onc.1206708; Henshall SM, 2001, CANCER RES, V61, P423; Hsu CL, 2005, MOL ENDOCRINOL, V19, P350, DOI 10.1210/me.2004-0190; Hyytinen ER, 2002, LAB INVEST, V82, P1591, DOI 10.1097/01.LAB.0000038924.67707.75; Isaacs JT, 2000, JNCI-J NATL CANCER I, V92, P1367, DOI 10.1093/jnci/92.17.1367; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Khan N, 2008, CANCER RES, V68, P8555, DOI 10.1158/0008-5472.CAN-08-0240; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Lee KH, 2009, ONCOGENE, V28, P3360, DOI 10.1038/onc.2009.192; LIAO SS, 1995, BIOCHEM BIOPH RES CO, V214, P833, DOI 10.1006/bbrc.1995.2362; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; McLarty J, 2009, CANCER PREV RES, V2, P673, DOI 10.1158/1940-6207.CAPR-08-0167; Morrissey C, 2007, INT J UROL, V14, P545, DOI 10.1111/j.1442-2042.2007.01774.x; Naftalin RJ, 2003, BRIT J PHARMACOL, V140, P487, DOI 10.1038/sj.bjp.0705460; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Ozers MS, 2007, BIOCHEMISTRY-US, V46, P683, DOI 10.1021/bi061321b; Paschka AG, 1998, CANCER LETT, V130, P1, DOI 10.1016/S0304-3835(98)00084-6; Perry JE, 1996, PROSTATE, P79; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Ren FG, 2000, ONCOGENE, V19, P1924, DOI 10.1038/sj.onc.1203511; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Ricciardelli C, 2005, PROSTATE, V63, P19, DOI 10.1002/pros.20154; RUIZEVELD D, 1994, AM J PATHOL, V144, P735; Siddiqui IA, 2008, ONCOGENE, V27, P2055, DOI 10.1038/sj.onc.1210840; Siddiqui IA, 2006, CARCINOGENESIS, V27, P833, DOI 10.1093/carcin/bgi323; Siddiqui IA, 2008, PHARM RES-DORDR, V25, P2135, DOI 10.1007/s11095-008-9553-z; Stuart EC, 2006, LIFE SCI, V79, P2329, DOI 10.1016/j.lfs.2006.07.036; Taplin ME, 1999, CANCER RES, V59, P2511; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040; WONG CI, 1993, J BIOL CHEM, V268, P19004; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; Zhu WH, 2010, AM J THER, V17, P176, DOI 10.1097/MJT.0b013e3181c6c0b2	57	155	164	0	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1198	1207		10.1096/fj.10-167924	http://dx.doi.org/10.1096/fj.10-167924			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21177307	Green Published			2022-12-28	WOS:000288982800009
J	Westerlund, M; Behbahani, H; Gellhaar, S; Forsell, C; Belin, AC; Anvret, A; Zettergren, A; Nissbrandt, H; Lind, C; Sydow, O; Graff, C; Olson, L; Ankarcrona, M; Galter, D				Westerlund, Marie; Behbahani, Homira; Gellhaar, Sandra; Forsell, Charlotte; Belin, Andrea Carmine; Anvret, Anna; Zettergren, Anna; Nissbrandt, Hans; Lind, Charlotta; Sydow, Olof; Graff, Caroline; Olson, Lars; Ankarcrona, Maria; Galter, Dagmar			Altered enzymatic activity and allele frequency of OMI/HTRA2 in Alzheimer's disease	FASEB JOURNAL			English	Article						postmortem tissue; PRSS25; Western blot; in situ hybridization; protease assay	CEREBRAL AMYLOID ANGIOPATHY; SERINE-PROTEASE; PARKINSONS-DISEASE; CELL-DEATH; HUMAN HTRA2; BETA; DEGRADATION; NEPRILYSIN; INHIBITOR; APOPTOSIS	The serine-protease OMI/HTRA2, required for several cellular processes, including mitochondrial function, autophagy, chaperone activity, and apoptosis, has been implicated in the pathogenesis of both Alzheimer's disease (AD) and Parkinson's disease (PD). Western blot quantification of OMI/HTRA2 in frontal cortex of patients with AD (n=10) and control subjects (n=10) in two separate materials indicated reduced processed (active, 35 kDa) OMI/HTRA2 levels, whereas unprocessed (50 kDa) enzyme levels were not significantly different between the groups. Interestingly, the specific protease activity of OMI/HTRA2 was found to be significantly increased in patients with AD (n=10) compared to matched control subjects (n=10) in frontal cortex in two separate materials. Comparison of OMI/HTRA2 mRNA levels in frontal cortex and hippocampus, two brain areas particularly affected by AD, indicated similar levels in patients with AD (n=10) and matched control subjects (n=10). In addition, we analyzed the occurrence of the OMI/HTRA2 variants A141S and G399S in Swedish case-control materials for AD and PD and found a weak association of A141S with AD, but not with PD. In conclusion, our genetic, histological, and biochemical findings give further support to an involvement of OMI/HTRA2 in the pathology of AD; however, further studies are needed to clarify the role of this gene in neurodegeneration.-Westerlund, M., Behbahani, H., Gellhaar, S., Forsell, C., Carmine Belin, A., Anvret, A., Zettergren, A., Nissbrandt, H., Lind, C., Sydow, O., Graff, C., Olson, L., Ankarcrona, M., Galter, D. Altered enzymatic activity and allele frequency of OMI/HTRA2 in Alzheimer's disease. FASEB J. 25, 1345-1352 (2011). www.fasebj.org	[Westerlund, Marie; Gellhaar, Sandra; Belin, Andrea Carmine; Anvret, Anna; Olson, Lars; Galter, Dagmar] Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; [Behbahani, Homira; Forsell, Charlotte; Ankarcrona, Maria] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Sumitomo Pharma Alzheimer Ctr, S-17177 Stockholm, Sweden; [Behbahani, Homira; Forsell, Charlotte; Graff, Caroline; Ankarcrona, Maria] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Alzheimer Dis Res Ctr, S-17177 Stockholm, Sweden; [Zettergren, Anna; Nissbrandt, Hans] Gothenburg Univ, Sahlgrenska Acad, Dept Pharmacol, Gothenburg, Sweden; [Lind, Charlotta; Sydow, Olof] Karolinska Univ Hosp, Dept Clin Neurosci, Stockholm, Sweden; [Graff, Caroline] Karolinska Univ Hosp, Dept Geriatr Med, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Gothenburg; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Galter, D (corresponding author), Karolinska Inst, Dept Neurosci, Retzius Vag 8,B2 4, S-17177 Stockholm, Sweden.	dagmar.galter@ki.se	Galter, Dagmar/C-4826-2011; Belin, Andrea Carmine/AAV-9933-2021; graff, caroline/A-2545-2009	Galter, Dagmar/0000-0001-6485-6244; Belin, Andrea Carmine/0000-0001-6668-3172; Sydow, Olof/0000-0001-7798-8297; Graff, Caroline/0000-0002-9949-2951; Ankarcrona, Maria/0000-0002-7022-3694	U.S. Public Health Service [PHS/R 24-MH 068855]; Swedish Brain Power; Swedish Research Council; Swedish Parkinson Foundation; Swedish Brain Foundation; Dainippon Sumitomo Pharma (Osaka, Japan); Karolinska Institutet; NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH068855] Funding Source: NIH RePORTER	U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Swedish Brain Power; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Parkinson Foundation; Swedish Brain Foundation; Dainippon Sumitomo Pharma (Osaka, Japan); Karolinska Institutet(Karolinska Institutet); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank Karin Lundstromer, Karin Pernold, Eva Lindqvist, and Ann-Christin Thelander for excellent technical assistance and Prof. Laura Fratiglioni (Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden) for providing control samples from the SNAC-K project. The NBB (Amsterdam, the Netherlands) and the BBKI (Stockholm, Sweden) provided human brain samples from patients and control subjects. Brain tissue was also provided by the HBTRC (Belmont, MA, USA), which is supported in part by U.S. Public Health Service grant PHS/R 24-MH 068855. The authors also thank Dr. Miguel L. Martins (Cell Death Regulation Laboratory, MRC Toxicology Unit, Leicester, UK) for the kind gift of the S276C mutant Omi/HtrA2 protein. This study was supported by research grants from Swedish Brain Power, the Swedish Research Council, the Swedish Parkinson Foundation, the Swedish Brain Foundation, Dainippon Sumitomo Pharma (Osaka, Japan), and Karolinska Institutet Funds.	Alnemri ES, 2007, NAT CELL BIOL, V9, P1227, DOI 10.1038/ncb1107-1227; Behbahani H, 2010, NEUROCHEM INT, V57, P668, DOI 10.1016/j.neuint.2010.08.004; Belin AC, 2007, NEUROSCI LETT, V420, P257, DOI 10.1016/j.neulet.2007.05.010; Bogaerts V, 2008, HUM MUTAT, V29, P832, DOI 10.1002/humu.20713; Carpentier M, 2002, J NEUROPATH EXP NEUR, V61, P849, DOI 10.1093/jnen/61.10.849; Dagda RK, 2009, J BIOENERG BIOMEMBR, V41, P473, DOI 10.1007/s10863-009-9255-1; Galter D, 2003, NEUROBIOL DIS, V14, P637, DOI 10.1016/j.nbd.2003.09.001; Galter D, 2007, PHYSIOL BEHAV, V92, P46, DOI 10.1016/j.physbeh.2007.05.046; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Gupta S, 2004, J BIOL CHEM, V279, P45844, DOI 10.1074/jbc.M404940200; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Huttunen HJ, 2007, J BIOL CHEM, V282, P28285, DOI 10.1074/jbc.M702951200; JONES JM, 1993, GENOMICS, V16, P669, DOI 10.1006/geno.1993.1246; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kawamoto Y, 2010, NEUROREPORT, V21, P1121, DOI 10.1097/WNR.0b013e328340a731; Kieper N, 2010, EXP CELL RES, V316, P1213, DOI 10.1016/j.yexcr.2010.01.005; Kooistra J, 2009, J ALZHEIMERS DIS, V17, P281, DOI 10.3233/JAD-2009-1037; Kruger R, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2009.11.021; Li B, 2010, CELL DEATH DIFFER, V17, P1773, DOI 10.1038/cdd.2010.55; Liu ML, 2009, J CELL SCI, V122, P1917, DOI 10.1242/jcs.042226; Liu ML, 2005, MOL CELLS, V20, P83; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; Miners JS, 2006, J NEUROPATH EXP NEUR, V65, P1012, DOI 10.1097/01.jnen.0000240463.87886.9a; Miners JS, 2009, J NEUROPATH EXP NEUR, V68, P902, DOI 10.1097/NEN.0b013e3181afe475; Park HJ, 2004, NEUROSCI LETT, V357, P63, DOI 10.1016/j.neulet.2003.11.068; Plun-Favreau H, 2007, NAT CELL BIOL, V9, P1243, DOI 10.1038/ncb1644; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; Ross OA, 2008, PARKINSONISM RELAT D, V14, P539, DOI 10.1016/j.parkreldis.2008.08.003; Seong YM, 2004, J BIOL CHEM, V279, P37588, DOI 10.1074/jbc.M401408200; Simon-Sanchez J, 2008, HUM MOL GENET, V17, P1988, DOI 10.1093/hmg/ddn096; Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Vande Walle L, 2008, CELL DEATH DIFFER, V15, P453, DOI 10.1038/sj.cdd.4402291; Vande Walle L, 2010, CELL RES, V20, P421, DOI 10.1038/cr.2010.18; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200	36	22	27	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1345	1352		10.1096/fj.10-163402	http://dx.doi.org/10.1096/fj.10-163402			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21163861	Green Published			2022-12-28	WOS:000288982800023
J	Lahav, T; Sivam, D; Volpin, H; Ronen, M; Tsigankov, P; Green, A; Holland, N; Kuzyk, M; Borchers, C; Zilberstein, D; Myler, PJ				Lahav, T.; Sivam, D.; Volpin, H.; Ronen, M.; Tsigankov, P.; Green, A.; Holland, N.; Kuzyk, M.; Borchers, C.; Zilberstein, D.; Myler, P. J.			Multiple levels of gene regulation mediate differentiation of the intracellular pathogen Leishmania	FASEB JOURNAL			English	Article						gene expression; development; microarray; proteomics	INFECTED MACROPHAGES; AXENIC AMASTIGOTES; GLOBAL ANALYSIS; LIFE-CYCLE; EXPRESSION; DONOVANI; PARASITE; TRANSCRIPTOME; INHIBITION; VACUOLES	For many years, mRNA abundance has been used as the surrogate measure of gene expression in biological systems. However, recent genome-scale analyses in both bacteria and eukaryotes have revealed that mRNA levels correlate with steady-state protein abundance for only 50-70% of genes, indicating that translation and post-translation processes also play important roles in determining gene expression. What is not yet clear is whether dynamic processes such as cell cycle progression, differentiation, or response to environmental changes change the relationship between mRNA and protein abundance. Here, we describe a systems approach to interrogate promastigote-to-amastigote differentiation in the obligatory intracellular parasitic protozoan Leishmania donovani. Our results indicate that regulation of mRNA levels plays a major role early in the differentiation process, while translation and post-translational regulation are more important in the latter part. In addition, it appears that the differentiation signal causes a transient global increase in the rate of protein synthesis, which is subsequently down-regulated by phosphorylation of alpha-subunit of translation initiation factor 2. Thus, Leishmania dynamically changes the relationship between mRNA and protein abundance as it adapts to new environmental circumstances. It is likely that similar mechanisms play a more important role than previously recognized in regulation of gene expression in other organisms.-Lahav, T., Sivam, D., Volpin, H., Ronen, M., Tsigankov, P., Green, A., Holland, N., Kuzyk, M., Borchers, C., Zilberstein, D., Myler, P. J. Multiple levels of gene regulation mediate differentiation of the intracellular pathogen Leishmania. FASEB J. 25, 515-525 (2011). www.fasebj.org	[Lahav, T.; Ronen, M.; Tsigankov, P.; Holland, N.; Zilberstein, D.] Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel; [Sivam, D.; Green, A.; Myler, P. J.] Seattle Biomed Res Inst, Seattle, WA 98109 USA; [Sivam, D.; Myler, P. J.] Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA; [Myler, P. J.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Volpin, H.] Keygene NV, Wageningen, Netherlands; [Kuzyk, M.; Borchers, C.] Univ Victoria, Prote Ctr, Victoria, BC, Canada	Technion Israel Institute of Technology; Center for Infectious Disease Research; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Keygene N.V.; University of Victoria	Zilberstein, D (corresponding author), Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel.	danz@tx.technion.ac.il	BORCHERS, Christoph/U-5964-2019; Myler, Peter John/AAR-9535-2021	Myler, Peter/0000-0002-0056-0513	U.S.-Israel Binational Foundation [2003237]; Israel Ministry of Health Chief Scientist Foundation [33928]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047234] Funding Source: NIH RePORTER	U.S.-Israel Binational Foundation(US-Israel Binational Science Foundation); Israel Ministry of Health Chief Scientist Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Dr. Roni Koren, Adele Goldman, and Gur Sevillya for experimental aid, Drs. Dan Cassel and Marilyn Parsons for critical discussions, and Dr. Yoav Arava for his help with polysome analyses. This work was supported by U.S.-Israel Binational Foundation grant 2003237 and by Israel Ministry of Health Chief Scientist Foundation grant 33928.	Akopyants NS, 2004, MOL BIOCHEM PARASIT, V136, P71, DOI 10.1016/j.molbiopara.2004.03.002; ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; Almeida R, 2004, MOL BIOCHEM PARASIT, V136, P87, DOI 10.1016/j.molbiopara.2004.03.004; ANTOINE JC, 1990, INFECT IMMUN, V58, P779, DOI 10.1128/IAI.58.3.779-787.1990; Barak E, 2005, MOL BIOCHEM PARASIT, V141, P99, DOI 10.1016/j.molbiopara.2005.02.004; BATES PA, 1994, EXP PARASITOL, V79, P215, DOI 10.1006/expr.1994.1084; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Burchmore RJS, 2001, INT J PARASITOL, V31, P1311, DOI 10.1016/S0020-7519(01)00259-4; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; Chaussee MA, 2008, ARCH MICROBIOL, V189, P27, DOI 10.1007/s00203-007-0290-1; Clayton C, 2007, MOL BIOCHEM PARASIT, V156, P93, DOI 10.1016/j.molbiopara.2007.07.007; Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011; DESCOTEAUX A, 1992, J IMMUNOL, V149, P3008; Desjardins M, 1997, J EXP MED, V185, P2061, DOI 10.1084/jem.185.12.2061; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Garcia-Martinez J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r222; Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117; Haile S, 2007, CURR OPIN MICROBIOL, V10, P569, DOI 10.1016/j.mib.2007.10.001; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; LANG T, 1994, J CELL SCI, V107, P2137; Le Roch KG, 2004, GENOME RES, V14, P2308, DOI 10.1101/gr.2523904; Leifso K, 2007, MOL BIOCHEM PARASIT, V152, P35, DOI 10.1016/j.molbiopara.2006.11.009; Lu P, 2007, NAT BIOTECHNOL, V25, P117, DOI 10.1038/nbt1270; Martinez-Calvillo S, 2003, MOL CELL, V11, P1291, DOI 10.1016/S1097-2765(03)00143-6; Melamed D, 2008, RNA, V14, P1337, DOI 10.1261/rna.864908; Moraes MCS, 2007, EUKARYOT CELL, V6, P1979, DOI 10.1128/EC.00249-07; Rosenzweig D, 2008, FASEB J, V22, P590, DOI 10.1096/fj.07-9254com; Saar Y, 1998, MOL BIOCHEM PARASIT, V95, P9, DOI 10.1016/S0166-6851(98)00062-0; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saxena A, 2007, MOL BIOCHEM PARASIT, V152, P53, DOI 10.1016/j.molbiopara.2006.11.011; Schmidt MW, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100117; Siegel TN, 2009, GENE DEV, V23, P1063, DOI 10.1101/gad.1790409; Soukas A, 2000, GENE DEV, V14, P963; Swanson MS, 2002, TRAFFIC, V3, P170, DOI 10.1034/j.1600-0854.2002.030302.x; Thomas S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-152; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Worthey EA, 2003, NUCLEIC ACIDS RES, V31, P4201, DOI 10.1093/nar/gkg469; Zilberstein Dan, 2008, P107	43	111	112	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					515	525		10.1096/fj.10-157529	http://dx.doi.org/10.1096/fj.10-157529			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20952481	Green Published			2022-12-28	WOS:000286724800010
J	Wu, H; Lin, YY; Li, WG; Sun, Z; Gao, WW; Zhang, HP; Xie, L; Jiang, FQ; Qin, B; Yan, TD; Chen, LQ; Zhao, Y; Cao, XH; Wu, Y; Lin, BZ; Zhou, H; Wong, AST; Zhang, XK; Zeng, JZ				Wu, Hua; Lin, Yayu; Li, Wengang; Sun, Zhe; Gao, Weiwei; Zhang, Haiping; Xie, Lei; Jiang, Fuquan; Qin, Bin; Yan, Tingdong; Chen, Liqun; Zhao, Yi; Cao, Xihua; Wu, Yin; Lin, Bingzhen; Zhou, Hu; Wong, Alice Sze-Tsai; Zhang, Xiao-Kun; Zeng, Jin-Zhang			Regulation of Nur77 expression by beta-catenin and its mitogenic effect in colon cancer cells	FASEB JOURNAL			English	Article						AP-1; PI3K; JNK; bile acid	ORPHAN RECEPTOR GENE; NERVE GROWTH-FACTOR; HUMAN COLORECTAL-CANCER; ABERRANT CRYPT FOCI; STEROID-RECEPTOR; BILE-ACIDS; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAYS; TUMOR-GROWTH; RAT COLON	The orphan nuclear receptor Nur77 is an immediate-early response gene whose expression is rapidly induced by various extracellular stimuli. The aims of this study were to study the role of Nur77 expression in the growth and survival of colon cancer cells and the mechanism by which Nur77 expression was regulated. We showed that levels of Nur77 were elevated in a majority of human colon tumors (9/12) compared to their nontumorous tissues and that Nur77 expression could be strongly induced by different colonic carcinogens including deoxycholic acid (DCA). DCA-induced Nur77 expression resulted in up-regulation of antiapoptotic BRE and angiogenic VEGF, and it enhanced the growth, colony formation, and migration of colon cancer cells. In studying the mechanism by which Nur77 was regulated in colon cancer cells, we found that beta-catenin was involved in induction of Nur77 expression through its activation of the transcriptional activity of AP-1 (c-Fos/c-Jun) that bound to and transactivated the Nur77 promoter. Together, our results demonstrate that Nur77 acts to promote the growth and survival of colon cancer cells and serves as an important mediator of the Wnt/beta-catenin and AP-1 signaling pathways.-Wu, H., Lin, Y., Li, W., Sun, Z., Gao, W., Zhang, H., Xie, L., Jiang, F., Qin, B., Yan, T., Chen, L., Zhao, Y., Cao, X., Wu, Y., Lin, B., Zhou, H., Wong, A.S.-T., Zhang, X.-K., Zeng, J.-Z. Regulation of Nur77 expression by beta-catenin and its mitogenic effect in colon cancer cells. FASEB J. 25, 192-205 (2011). www.fasebj.org	[Zeng, Jin-Zhang] Xiamen Univ, Inst Biomed Res, Ctr Canc, Xiamen 361005, Peoples R China; [Li, Wengang; Zhang, Haiping] Xiamen Univ, Hosp Xiamen 1, Xiamen 361005, Peoples R China; [Cao, Xihua; Wu, Yin; Lin, Bingzhen; Zhou, Hu; Zhang, Xiao-Kun] Sanford Burnham Med Res Inst, Ctr Canc, La Jolla, CA USA; [Wong, Alice Sze-Tsai] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China	Xiamen University; Xiamen University; Sanford Burnham Prebys Medical Discovery Institute; University of Hong Kong	Zeng, JZ (corresponding author), Xiamen Univ, Inst Biomed Res, Ctr Canc, Xiamen 361005, Peoples R China.	xzhang@burnham.org; jzzeng@xmu.edu.cn	Zeng, JZ/G-3377-2010; Wu, Hua/W-4204-2019; Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475	863 Program [2007AA09Z404]; National Natural Science Foundation of China (NSFC) [30971445]; Key Science and Technology Planning Project [2007I0023]; Natural Science Foundation of Fujian Province, China [2009J01198]; NSFC/Hong Kong Research Grants Council (RGC) [30931160431]; U.S. National Institutes of Health [CA109345, CA140980, GM089927]; U.S. Army Medical Research and Material Command [PCRPW81XWH-08-1-0478]; Natural Science Foundation of Fujian Province [2008Y0062];  [N_HKU 735/09]; NATIONAL CANCER INSTITUTE [R01CA140980, R01CA109345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089927] Funding Source: NIH RePORTER	863 Program(National High Technology Research and Development Program of China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Key Science and Technology Planning Project; Natural Science Foundation of Fujian Province, China(Natural Science Foundation of Fujian Province); NSFC/Hong Kong Research Grants Council (RGC)(Hong Kong Research Grants CouncilNational Natural Science Foundation of China (NSFC)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was in part supported by grants to J.-Z.Z. from the 863 Program (2007AA09Z404), the National Natural Science Foundation of China (NSFC; 30971445), the Key Science and Technology Planning Project (2007I0023), the Natural Science Foundation of Fujian Province, China (2009J01198), and the NSFC/Hong Kong Research Grants Council (RGC; 30931160431), a grant to A.S.-T.W. (N_HKU 735/09), and grants to X.Z. from the U.S. National Institutes of Health (CA109345, CA140980, GM089927), the U.S. Army Medical Research and Material Command (PCRPW81XWH-08-1-0478), and the Natural Science Foundation of Fujian Province (2008Y0062). The authors declare no conflicts of interest.	Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blum CA, 2001, CARCINOGENESIS, V22, P315, DOI 10.1093/carcin/22.2.315; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Chen YL, 2008, MOL PHARMACOL, V74, P1046, DOI 10.1124/mol.107.044800; Chiu BCH, 2003, CANCER EPIDEM BIOMAR, V12, P201; Cho SD, 2007, CANCER RES, V67, P674, DOI 10.1158/0008-5472.CAN-06-2907; Cho SD, 2010, MOL PHARMACOL, V77, P396, DOI 10.1124/mol.109.061143; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Debruyne PR, 2002, ONCOGENE, V21, P6740, DOI 10.1038/sj.onc.1205729; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Flynn C, 2007, MOL CARCINOGEN, V46, P60, DOI 10.1002/mc.20253; Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050; Hashizume H, 2010, CANCER RES, V70, P2213, DOI 10.1158/0008-5472.CAN-09-1977; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Hirose Y, 2003, CARCINOGENESIS, V24, P107, DOI 10.1093/carcin/24.1.107; Hlubek F, 2001, CANCER RES, V61, P8089; Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200; Ikari A, 2010, J CELL PHYSIOL, V222, P481, DOI 10.1002/jcp.21988; IMRAY CHE, 1992, GUT, V33, P1239, DOI 10.1136/gut.33.9.1239; Inaoka Y, 2008, MOL REPROD DEV, V75, P931, DOI 10.1002/mrd.20788; Jaeschke A, 2006, MOL CELL, V23, P899, DOI 10.1016/j.molcel.2006.07.028; Jean-Louis S, 2006, J BIOL CHEM, V281, P14948, DOI 10.1074/jbc.M506710200; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Lee MO, 2001, BIOCHEM BIOPH RES CO, V288, P1162, DOI 10.1006/bbrc.2001.5910; Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lin CX, 2001, CANCER LETT, V169, P121, DOI 10.1016/S0304-3835(01)00525-0; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu J, 2008, CANCER RES, V68, P8871, DOI 10.1158/0008-5472.CAN-08-1972; Liu JJ, 2010, CANCER RES, V70, P3628, DOI 10.1158/0008-5472.CAN-09-3160; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mai V, 2003, CANCER RES, V63, P1752; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Mimori-Kiyosue Y, 2001, J CELL BIOL, V154, P1105, DOI 10.1083/jcb.200106113; Pai R, 2004, MOL BIOL CELL, V15, P2156, DOI 10.1091/mbc.E03-12-0894; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Raufman JP, 2008, J CELL PHYSIOL, V215, P538, DOI 10.1002/jcp.21332; Saadeddin A, 2009, MOL CANCER RES, V7, P1189, DOI 10.1158/1541-7786.MCR-09-0027; Silvers AL, 2003, NEOPLASIA, V5, P319, DOI 10.1016/S1476-5586(03)80025-8; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Thompson J, 2008, J EXP MED, V205, P1029, DOI 10.1084/jem.20080101; Toualbi K, 2007, ONCOGENE, V26, P3492, DOI 10.1038/sj.onc.1210133; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; UEMURA H, 1995, J BIOL CHEM, V270, P5427, DOI 10.1074/jbc.270.10.5427; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; Wilson AJ, 2003, CANCER RES, V63, P5401; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; Zeng Jin-Zhang, 2007, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V6, P315, DOI 10.2174/187152307783220022; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhang XK, 2007, EXPERT OPIN THER TAR, V11, P69, DOI 10.1517/14728222.11.1.69	63	90	93	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					192	205		10.1096/fj.10-166462	http://dx.doi.org/10.1096/fj.10-166462			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20847229	Green Published			2022-12-28	WOS:000285869500018
J	Mays, CE; Ryou, C				Mays, Charles E.; Ryou, Chongsuk			Plasminogen stimulates propagation of protease-resistant prion protein in vitro	FASEB JOURNAL			English	Article						cofactor; prion replication; protein misfolding	CYCLIC AMPLIFICATION; PRP ACCUMULATION; BINDING; CONVERSION; CELLS; MICE; ACTIVATION; GENERATION; COMPONENTS; THROMBOSIS	To clarify the role of plasminogen as a cofactor for prion propagation, we conducted functional assays using a cell-free prion protein (PrP) conversion assay termed protein misfolding cyclic amplification (PMCA) and prion-infected cell lines. Here, we report that plasminogen stimulates propagation of the protease-resistant scrapie PrP (PrPSc). Compared to control PMCA conducted without plasminogen, addition of plasminogen in PMCA using wild-type brain material significantly increased PrP conversion, with an EC50 = similar to 56 nM. PrP conversion in PMCA was substantially less efficient with plasminogen-deficient brain material than with wild-type material. The activity stimulating PrP conversion was specific for plasminogen and conserved in its kringle domains. Such activity was abrogated by modification of plasminogen structure and interference of PrP-plasminogen interaction. Kinetic analysis of PrPSc generation demonstrated that the presence of plasminogen in PMCA enhanced the PrPSc production rate to similar to 0.97U/mu l/h and reduced turnover time to similar to 1 h compared to those (similar to 0.4 U/mu l/h and similar to 2.5 h) obtained without supplementation. Furthermore, as observed in PMCA, plasminogen and kringles promoted PrPSc propagation in ScN2a and Elk 21(+) cells. Our results demonstrate that plasminogen functions in stimulating conversion processes and represents the first cellular protein cofactor that enhances the hypothetical mechanism of prion propagation.-Mays, C. E., Ryou, C. Plasminogen stimulates propagation of protease-resistant prion protein in vitro. FASEB J. 24, 5102-5112 (2010). www.fasebj.org	Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Ryou, C (corresponding author), 800 Rose St,HSRB 326, Lexington, KY 40536 USA.	cryou2@email.uky.edu			Sanders-Brown Center on Aging and College of Medicine, University of Kentucky	Sanders-Brown Center on Aging and College of Medicine, University of Kentucky	The authors thank Glenn Telling (University of Kentucky) for constructive discussion as well as for sharing experimental reagents and equipment. The authors are grateful to Jay Degen (Children's Hospital Research Foundation, Cincinnati, OH, USA) and Stanley Prusiner (University of California, San Francisco, CA, USA) for providing reagents. The authors also thank Paula Thomason for editing the manuscript. This work was supported in part by funds from the Sanders-Brown Center on Aging and College of Medicine, University of Kentucky.	Atarashi R, 2008, NAT METHODS, V5, P211, DOI 10.1038/nmeth0308-211; Atarashi R, 2007, NAT METHODS, V4, P645, DOI 10.1038/NMETH1066; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Bian JF, 2010, J VIROL, V84, P8322, DOI 10.1128/JVI.00633-10; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Castellino FJ, 2005, THROMB HAEMOSTASIS, V93, P647, DOI 10.1160/TH04-12-0842; Castellino FJ, 1997, CIBA F SYMP, V212, P46; CAUGHEY B, 1994, PHILOS T R SOC B, V343, P399, DOI 10.1098/rstb.1994.0035; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CEDERHOLMWILLIAMS SA, 1981, J CLIN PATHOL, V34, P979, DOI 10.1136/jcp.34.9.979; Christen B, 2009, J MOL BIOL, V389, P833, DOI 10.1016/j.jmb.2009.04.040; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Colby DW, 2007, P NATL ACAD SCI USA, V104, P20914, DOI 10.1073/pnas.0710152105; Colby DW, 2009, P NATL ACAD SCI USA, V106, P20417, DOI 10.1073/pnas.0910350106; Cuccioloni M, 2005, PROTEINS, V58, P728, DOI 10.1002/prot.20346; Dandoy-Dron F, 2006, NEUROSCI LETT, V405, P181, DOI 10.1016/j.neulet.2006.05.066; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Degen JL, 2001, ANN NY ACAD SCI, V936, P276; Deleault NR, 2007, P NATL ACAD SCI USA, V104, P9741, DOI 10.1073/pnas.0702662104; Deleault NR, 2005, J BIOL CHEM, V280, P26873, DOI 10.1074/jbc.M503973200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Ellis V, 2002, BIOCHEMISTRY-US, V41, P6891, DOI 10.1021/bi025676g; Epple G, 2004, J THROMB HAEMOST, V2, P962, DOI 10.1111/j.1538-7836.2004.00675.x; Epple G, 2004, THROMB HAEMOSTASIS, V91, P465, DOI 10.1160/TH03-06-0382; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kim Y, 2009, ANTIVIR RES, V84, P185, DOI 10.1016/j.antiviral.2009.09.002; Kim Y, 2009, MOL CELL BIOCHEM, V328, P177, DOI 10.1007/s11010-009-0087-4; KIMBERLIN RH, 1986, ANTIMICROB AGENTS CH, V30, P409, DOI 10.1128/AAC.30.3.409; Kornblatt JA, 2004, CELL MOL BIOL, V50, P387; Kornblatt JA, 2003, BIOCHEM BIOPH RES CO, V305, P518, DOI 10.1016/S0006-291X(03)00804-0; Kornblatt JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006196; Ledesma MD, 2000, EMBO REP, V1, P530; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lucassen R, 2003, BIOCHEMISTRY-US, V42, P4127, DOI 10.1021/bi027218d; Maissen M, 2001, LANCET, V357, P2026, DOI 10.1016/S0140-6736(00)05110-2; Mays CE, 2008, BRAIN RES, V1208, P170, DOI 10.1016/j.brainres.2008.02.103; Mays CE, 2009, BIOCHEM BIOPH RES CO, V388, P306, DOI 10.1016/j.bbrc.2009.07.163; Negredo C, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-43; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Praus M, 2003, THROMB HAEMOSTASIS, V89, P812, DOI 10.1055/s-0037-1613466; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Ryou C, 2003, J MOL BIOL, V329, P323, DOI 10.1016/S0022-2836(03)00342-5; Ryou C, 2007, J MICROBIOL BIOTECHN, V17, P1059; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Salmona M, 2005, J VIROL, V79, P11225, DOI 10.1128/JVI.79.17.11225-11230.2005; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; Shaked Y, 2002, J NEUROCHEM, V82, P1, DOI 10.1046/j.1471-4159.2002.00995.x; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Wang F, 2010, SCIENCE, V327, P1132, DOI 10.1126/science.1183748; WHITELAW A, 1995, ACTA PAEDIATR, V84, P933, DOI 10.1111/j.1651-2227.1995.tb13795.x; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Xanthopoulos K, 2005, NEUROBIOL DIS, V20, P519, DOI 10.1016/j.nbd.2005.04.008; Zerr I, 2004, NEUROSCI LETT, V371, P163, DOI 10.1016/j.neulet.2004.08.063; Zhang L, 2002, THROMB HAEMOSTASIS, V87, P493; Zulianello L, 2000, J VIROL, V74, P4351, DOI 10.1128/JVI.74.9.4351-4360.2000	65	27	31	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5102	5112		10.1096/fj.10-163600	http://dx.doi.org/10.1096/fj.10-163600			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20732953				2022-12-28	WOS:000284824400048
J	Budding, AE; Grasman, ME; Lin, F; Bogaards, JA; Soeltan-Kaersenhout, DJ; Vandenbroucke-Grauls, CMJE; van Bodegraven, AA; Savelkoul, PHM				Budding, A. E.; Grasman, M. E.; Lin, F.; Bogaards, J. A.; Soeltan-Kaersenhout, D. J.; Vandenbroucke-Grauls, C. M. J. E.; van Bodegraven, A. A.; Savelkoul, P. H. M.			IS-pro: high-throughput molecular fingerprinting of the intestinal microbiota	FASEB JOURNAL			English	Article						profiling; 16S-23S IS region; complex microbial communities; gut bacteria; phylum sorting	16S RIBOSOMAL-RNA; FRAGMENT-LENGTH-POLYMORPHISM; INTERGENIC SPACER ANALYSIS; BACTERIAL COMMUNITIES; DIVERSITY; DISEASE; REPRODUCIBILITY; IDENTIFICATION; INDEXES; CLONING	The human intestinal microbiota is known to play an important role in human health and disease, and with the advent of novel molecular techniques, disease-specific variations in its composition have been found. However, analysis of the intestinal microbiota has not yet been applicable in large-scale clinical research or routine diagnostics because of the complex and expensive nature of the techniques needed. Here, we describe a new PCR-based profiling technique for high-throughput analysis of the human intestinal microbiota, which we have termed IS-pro. This technique combines bacterial species differentiation by the length of the 16S-23S rDNA interspace region with instant taxonomic classification by phylum-specific fluorescent labeling of PCR primers. We validated IS-pro in silico, in vitro, and in vivo, on human colonic biopsies and feces, and introduced a standardized protocol for data analysis. IS-pro is easy to implement in general clinical microbiological laboratories with access to capillary gel electrophoresis, and the high-throughput nature of the test makes analysis of large numbers of samples feasible. This combination renders IS-pro ideally suited for use in clinical research and routine diagnostics.-Budding, A. E., Grasman, M. E., Lin, F., Bogaards, J. A., Soeltan-Kaersenhout, D. J., Vandenbroucke-Grauls, C. M. J. E., van Bodegraven, A. A., Savelkoul, P. H. M. IS-pro: high-throughput molecular fingerprinting of the intestinal microbiota. FASEB J. 24, 4556-4564 (2010). www.fasebj.org	[Budding, A. E.; Lin, F.; Soeltan-Kaersenhout, D. J.; Vandenbroucke-Grauls, C. M. J. E.; Savelkoul, P. H. M.] Vrije Univ Amsterdam Med Ctr, Dept Med Microbiol & Infect Control, NL-1007 MB Amsterdam, Netherlands; [Grasman, M. E.; van Bodegraven, A. A.] Vrije Univ Amsterdam Med Ctr, Dept Gastroenterol & Hepatol, NL-1007 MB Amsterdam, Netherlands; [Bogaards, J. A.] Vrije Univ Amsterdam Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Budding, AE (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Med Microbiol & Infect Control, POB 7057, NL-1007 MB Amsterdam, Netherlands.	d.budding@vumc.nl	van Bodegraven, Ad/ABG-4367-2020; Vandenbroucke-Grauls, Christina/AAO-7953-2020; van Bodegraven, Ad A/L-3180-2013	Vandenbroucke-Grauls, Christina/0000-0003-2074-1597; Budding, Andries/0000-0001-5128-5411; Bogaards, Johannes/0000-0002-3389-5141				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Blackwood CB, 2007, APPL ENVIRON MICROB, V73, P5276, DOI 10.1128/AEM.00514-07; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Dunbar J, 2001, APPL ENVIRON MICROB, V67, P190, DOI 10.1128/AEM.67.1.190-197.2001; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Engebretson JJ, 2003, APPL ENVIRON MICROB, V69, P4823, DOI 10.1128/AEM.69.8.4823-4829.2003; Fisher MM, 1999, APPL ENVIRON MICROB, V65, P4630; Fisher MM, 2000, MICROBIAL ECOL, V40, P125, DOI 10.1007/s002480000049; FOX GE, 1992, INT J SYST BACTERIOL, V42, P166, DOI 10.1099/00207713-42-1-166; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Guasp C, 2000, INT J SYST EVOL MICR, V50, P1629, DOI 10.1099/00207713-50-4-1629; Gurtler V, 1996, MICROBIOL-SGM, V142, P3, DOI 10.1099/13500872-142-1-3; Hoffmann M, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-90; Hold GL, 2002, FEMS MICROBIOL ECOL, V39, P33, DOI 10.1111/j.1574-6941.2002.tb00904.x; HUNTER PR, 1990, J CLIN MICROBIOL, V28, P1903, DOI 10.1128/JCM.28.9.1903-1905.1990; JENSEN MA, 1993, APPL ENVIRON MICROB, V59, P945, DOI 10.1128/AEM.59.4.945-952.1993; Leuko S, 2007, EXTREMOPHILES, V11, P203, DOI 10.1007/s00792-006-0028-z; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Manichanh C, 2006, GUT, V55, P205, DOI 10.1136/gut.2005.073817; Nesme X, 2004, MOL MICROBIAL ECOLOG, P671; Niers L, 2009, ALLERGY, V64, P1349, DOI 10.1111/j.1398-9995.2009.02021.x; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; PETERSON C, 2007, J VIS EXP, V2, P164; Ranjard L, 2001, APPL ENVIRON MICROB, V67, P4479, DOI 10.1128/AEM.67.10.4479-4487.2001; Ren DW, 2011, INT J SYST EVOL MICR, V61, P580, DOI 10.1099/ijs.0.023143-0; Schneider T, 2008, LANCET INFECT DIS, V8, P179, DOI 10.1016/S1473-3099(08)70042-2; Stewart FJ, 2007, J MOL EVOL, V65, P44, DOI 10.1007/s00239-006-0235-3; Wang M, 2005, FEMS MICROBIOL ECOL, V54, P219, DOI 10.1016/j.femsec.2005.03.012; Wilton SD, 1997, BIOTECHNIQUES, V22, P642, DOI 10.2144/97224bm14; Zoetendal EG, 2002, APPL ENVIRON MICROB, V68, P3401, DOI 10.1128/AEM.68.7.3401-3407.2002; Zoetendal EG, 1998, APPL ENVIRON MICROB, V64, P3854	31	70	73	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2010	24	11					4556	4564		10.1096/fj.10-156190	http://dx.doi.org/10.1096/fj.10-156190			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20643909				2022-12-28	WOS:000283861100040
J	Menezes, K; de Menezes, JRL; Nascimento, MA; Santos, RD; Coelho-Sampaio, T				Menezes, Karla; Lacerda de Menezes, Joao Ricardo; Nascimento, Marcos Assis; Santos, Raphael de Siqueira; Coelho-Sampaio, Tatiana			Polylaminin, a polymeric form of laminin, promotes regeneration after spinal cord injury	FASEB JOURNAL			English	Article						CNS regeneration; neuroprotection; protein polymerization	NECROSIS-FACTOR-ALPHA; BASEMENT-MEMBRANE; FUNCTIONAL RECOVERY; AXON REGENERATION; CNS; ADULT; INFLAMMATION; TRANSECTION; STRATEGIES; MATRICES	Regeneration of spinal cord injury (SCI) is a major topic of biomedical research. Laminin is an extracellular matrix protein implicated in neural development and regeneration, but despite that, there are no reports of exogenous laminin contributing to improve the outcome of experimental SCI. Here we investigated whether a biomimetic polymer of laminin assembled on pH acidification, henceforth called polylaminin, could be used to treat SCI in rats. Acute local injection of polylaminin, but not of nonpolymerized laminin, improved motor function after thoracic compression, partial or complete transection. In the latter case, the BBB score for open field locomotion 8 wk after lesion increased from 4.2 +/- 0.48 to 8.8 +/- 1.14 in animals treated with polylaminin of human origin. Accordingly, neurons retrogradely labeled from the sublesion stump were detected in the spinal cord and brain stem, indicating regrowth of short and long fibers across a complete transection. Polylaminin also played an unsuspected anti-inflammatory role, which underlies the early onset of its positive effects on locomotion from the first week after treatment. The beneficial effects of polylaminin were not observed in animals treated with the nonpolymerized protein or vehicle only. We propose that polylaminin is a promising therapeutic agent to treat human SCI.-Menezes, K., Menezes, J. R. L., Nascimento, M. A., Siqueira Santos, R., Coelho-Sampaio, T. Polylaminin, a polymeric form of laminin, promotes regeneration after spinal cord injury. FASEB J. 24, 4513-4522 (2010). www.fasebj.org	[Coelho-Sampaio, Tatiana] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Ctr Ciencias Saude, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Coelho-Sampaio, T (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Ctr Ciencias Saude, Sala B1-011, BR-21941590 Rio De Janeiro, Brazil.	tcsampaio@histo.ufrj.br	Menezes, João R. L./D-5668-2012	Assis Nascimento, Marcos/0000-0002-9830-9801	Brazilian National Research Council (CNPq); State of Rio de Janeiro Research Agency (FAPERJ)	Brazilian National Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); State of Rio de Janeiro Research Agency (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	The authors thank the excellent technical assistance of Ian Machado de Freitas. This work was supported by grants from the Brazilian National Research Council (CNPq) and from the State of Rio de Janeiro Research Agency (FAPERJ).	Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BERNSTEIN JJ, 1985, BRAIN RES, V327, P135, DOI 10.1016/0006-8993(85)91507-0; Brechtel K, 2006, SPINAL CORD, V44, P605, DOI 10.1038/sj.sc.3101894; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Bunge MB, 2008, J SPINAL CORD MED, V31, P262, DOI 10.1080/10790268.2008.11760720; Cai ZW, 2003, BRAIN RES, V975, P37, DOI 10.1016/S0006-8993(03)02545-9; Courtine G, 2008, NAT MED, V14, P69, DOI 10.1038/nm1682; Coutts M, 2008, EXP NEUROL, V209, P368, DOI 10.1016/j.expneurol.2007.09.002; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Durbeej M, 2010, CELL TISSUE RES, V339, P259, DOI 10.1007/s00441-009-0838-2; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; Freire E, 2004, J CELL SCI, V117, P4067, DOI 10.1242/jcs.01276; Freire E, 2002, J CELL SCI, V115, P4867, DOI 10.1242/jcs.00173; Freire E, 2000, J BIOL CHEM, V275, P817, DOI 10.1074/jbc.275.2.817; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; Grimpe B, 2002, J NEUROSCI, V22, P3144, DOI 10.1523/JNEUROSCI.22-08-03144.2002; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; LIESI P, 1985, EMBO J, V4, P2505, DOI 10.1002/j.1460-2075.1985.tb03963.x; LuckenbillEdds L, 1997, BRAIN RES REV, V23, P1, DOI 10.1016/S0165-0173(96)00013-6; Meiners S, 2003, MOL NEUROBIOL, V27, P177, DOI 10.1385/MN:27:2:177; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Barroso MMS, 2008, J BIOL CHEM, V283, P11714, DOI 10.1074/jbc.M709301200; Scheele S, 2007, J MOL MED, V85, P825, DOI 10.1007/s00109-007-0182-5; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Tsiper MV, 2002, J CELL SCI, V115, P1005; Tysseling-Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143-08.2008; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; Verma P, 2008, NEUROREHAB NEURAL RE, V22, P429, DOI 10.1177/1545968307313500; Wiksten M, 2004, J NEUROSCI RES, V78, P403, DOI 10.1002/jnr.20159; Wondimu Z, 2006, MATRIX BIOL, V25, P89, DOI 10.1016/j.matbio.2005.10.001; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	43	28	31	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4513	4522		10.1096/fj.10-157628	http://dx.doi.org/10.1096/fj.10-157628			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20643907				2022-12-28	WOS:000283861100036
J	Murphy, KT; Koopman, R; Naim, T; Leger, B; Trieu, J; Ibebunjo, C; Lynch, GS				Murphy, Kate T.; Koopman, Rene; Naim, Timur; Leger, Bertrand; Trieu, Jennifer; Ibebunjo, Chikwendu; Lynch, Gordon S.			Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function	FASEB JOURNAL			English	Article						aging; muscle hypertrophy; muscle atrophy; TGF-beta	CONTRACTION-INDUCED INJURY; DYSTROPHIC MDX MICE; MUSCULAR-DYSTROPHY; RESISTANCE EXERCISE; GENE-EXPRESSION; MESSENGER-RNA; SARCOPENIA; AGE; GROWTH; PROTEIN	Sarcopenia is the progressive loss of skeletal muscle mass and function with advancing age, leading to reduced mobility and quality of life. We tested the hypothesis that antibody-directed myostatin inhibition would attenuate the decline in mass and function of muscles of aged mice and that apoptosis would be reduced. Eighteen-month-old C57BL/6 mice were treated for 14 wk with a once-weekly injection of saline (control, n=9) or a mouse chimera of anti-human myostatin antibody (PF-354, 10 mg/kg; n=12). PF-354 prevented the age-related reduction in body mass and increased soleus, gastrocnemius, and quadriceps muscle mass (P<0.05). PF-354 increased fiber cross-sectional area by 12% and enhanced maximum in situ force of tibialis anterior (TA) muscles by 35% (P<0.05). PF-354 increased the proportion of type IIa fibers by 114% (P<0.01) and enhanced activity of oxidative enzymes (SDH) by 39% (P<0.01). PF-354 reduced markers of apoptosis in TA muscle cross-sections by 56% (P<0.03) and reduced caspase3 mRNA by 65% (P<0.04). Antibody-directed myostatin inhibition attenuated the decline in mass and function of muscles of aging mice, in part, by reducing apoptosis. These observations identify novel roles for myostatin in regulation of muscle mass and highlight the therapeutic potential of antibody-directed myostatin inhibition for sarcopenia.-Murphy, K. T., Koopman, R., Naim, T., Leger, B., Trieu, J., Ibebunjo, C. Lynch, G. S. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J. 24, 4433-4442 (2010). www.fasebj.org	[Murphy, Kate T.; Koopman, Rene; Naim, Timur; Leger, Bertrand; Trieu, Jennifer; Lynch, Gordon S.] Univ Melbourne, Dept Physiol, Basic & Clin Myol Lab, Melbourne, Vic 3010, Australia; [Ibebunjo, Chikwendu] Pfizer Global Res & Dev, Groton, CT USA	University of Melbourne; Pfizer	Lynch, GS (corresponding author), Univ Melbourne, Dept Physiol, Basic & Clin Myol Lab, Melbourne, Vic 3010, Australia.	gsl@unimelb.edu.au	Léger, Bertrand/AAK-4356-2020; Lynch, Gordon/G-9553-2015; Ibebunjo, Chikwendu/AAP-8881-2021	Lynch, Gordon/0000-0001-9220-9810; Murphy, Kate/0000-0003-1993-4367; Leger, Bertrand/0000-0003-2782-1442	Pfizer Global Research and Development (USA); Australian Association of Gerontology; National Health and Medical Research Council (NHMRC); Netherlands Organization for Scientific Research (NWO); Swiss National Fund	Pfizer Global Research and Development (USA)(Pfizer); Australian Association of Gerontology; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Swiss National Fund(Swiss National Science Foundation (SNSF))	This study was supported by research grants from Pfizer Global Research and Development (USA) and the Australian Association of Gerontology. K.T.M. is supported by a Biomedical Australian Fellowship from the National Health and Medical Research Council (NHMRC). R.K. was supported by a Rubicon Research Fellowship from the Netherlands Organization for Scientific Research (NWO). B.L. is supported by a Fellowship from the Swiss National Fund. C.I. helped design the experiments, assisted in data analysis, and contributed to the writing and editing of the manuscript. The authors declare no conflicts of interest.	Amirouche A, 2009, ENDOCRINOLOGY, V150, P286, DOI 10.1210/en.2008-0959; Amthor H, 2007, P NATL ACAD SCI USA, V104, P1835, DOI 10.1073/pnas.0604893104; BLANCO CE, 1988, HISTOCHEM J, V20, P230, DOI 10.1007/BF01747468; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Bogdanovich S, 2005, FASEB J, V19, P543, DOI 10.1096/fj.04-2796com; BURKHOLDER TJ, 1994, J MORPHOL, V221, P177, DOI 10.1002/jmor.1052210207; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; Chelh I, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-196; Cohn RD, 2007, NEUROMUSCULAR DISORD, V17, P290, DOI 10.1016/j.nmd.2007.01.011; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dellorusso C, 2001, J MUSCLE RES CELL M, V22, P467, DOI 10.1023/A:1014587918367; Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001; Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003; FAULKNER JA, 1995, J GERONTOL A-BIOL, V50, P124; Faulkner JA, 2007, CLIN EXP PHARMACOL P, V34, P1091, DOI 10.1111/j.1440-1681.2007.04752.x; Garcia-Roves PM, 2006, AM J PHYSIOL-ENDOC M, V290, pE1172, DOI 10.1152/ajpendo.00633.2005; Girgenrath S, 2005, MUSCLE NERVE, V31, P34, DOI 10.1002/mus.20175; Harcourt LJ, 2005, AM J PATHOL, V166, P1131, DOI 10.1016/S0002-9440(10)62333-4; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407; Koopman R, 2006, EUR J APPL PHYSIOL, V96, P525, DOI 10.1007/s00421-005-0118-0; Koopman R, 2006, AM J PHYSIOL-ENDOC M, V290, pE1245, DOI 10.1152/ajpendo.00530.2005; Kovacheva EL, 2010, ENDOCRINOLOGY, V151, P628, DOI 10.1210/en.2009-1177; LeBrasseur NK, 2009, J GERONTOL A-BIOL, V64, P940, DOI 10.1093/gerona/glp068; Leeuwenburgh C, 2005, AM J PHYSIOL-REG I, V288, pR1288, DOI 10.1152/ajpregu.00576.2004; Liu CM, 2008, GENE THER, V15, P155, DOI 10.1038/sj.gt.3303016; Lundby C, 2005, EUR J APPL PHYSIOL, V95, P351, DOI 10.1007/s00421-005-0022-7; Lynch GS, 2008, EXPERT OPIN EMERG DR, V13, P655, DOI [10.1517/14728210802544476, 10.1517/14728210802544476 ]; Lynch GS, 2004, CLIN EXP PHARMACOL P, V31, P557, DOI 10.1111/j.1440-1681.2004.04026.x; Lynch GS, 2004, INTERN MED J, V34, P294, DOI 10.1111/j.1444-0903.2004.00568.x; Lynch GS, 2001, J PHYSIOL-LONDON, V535, P591, DOI 10.1111/j.1469-7793.2001.00591.x; Marzetti E, 2008, MECH AGEING DEV, V129, P542, DOI 10.1016/j.mad.2008.05.005; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McFarlane C, 2006, J CELL PHYSIOL, V209, P501, DOI 10.1002/jcp.20757; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Morissette MR, 2009, AGING CELL, V8, P573, DOI 10.1111/j.1474-9726.2009.00508.x; Murphy KT, 2010, AM J PATHOL, V176, P2425, DOI 10.2353/ajpath.2010.090932; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; Roubenoff R, 1998, J CLIN ENDOCR METAB, V83, P1502, DOI 10.1210/jc.83.5.1502; Ryall JG, 2008, AM J PHYSIOL-HEART C, V294, pH2587, DOI 10.1152/ajpheart.00985.2007; Sartori R, 2009, AM J PHYSIOL-CELL PH, V296, pC1248, DOI 10.1152/ajpcell.00104.2009; Schertzer JD, 2007, AM J PATHOL, V171, P1180, DOI 10.2353/ajpath.2007.070292; Schertzer JD, 2006, AM J PHYSIOL-ENDOC M, V291, pE499, DOI 10.1152/ajpendo.00101.2006; Short KR, 2005, J APPL PHYSIOL, V99, P95, DOI 10.1152/japplphysiol.00129.2005; Siriett V, 2007, MOL THER, V15, P1463, DOI 10.1038/sj.mt.6300182; Siriett V, 2006, J CELL PHYSIOL, V209, P866, DOI 10.1002/jcp.20778; Siu PM, 2009, MED SCI SPORT EXER, V41, P1876, DOI 10.1249/MSS.0b013e3181a6470b; Steelman CA, 2006, FASEB J, V20, P580, DOI 10.1096/fj.05-5125fje; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; Welle S, 2009, AM J PHYSIOL-ENDOC M, V296, pE567, DOI 10.1152/ajpendo.90862.2008; Yarasheski K E, 2002, J Nutr Health Aging, V6, P343; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	54	91	99	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2010	24	11					4433	4442		10.1096/fj.10-159608	http://dx.doi.org/10.1096/fj.10-159608			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20624929				2022-12-28	WOS:000283861100029
J	Quinzii, CM; Lopez, LC; Gilkerson, RW; Dorado, B; Coku, J; Naini, AB; Lagier-Tourenne, C; Schuelke, M; Salviati, L; Carrozzo, R; Santorelli, F; Rahman, S; Tazir, M; Koenig, M; DiMauro, S; Hirano, M				Quinzii, Catarina M.; Lopez, Luis C.; Gilkerson, Robert W.; Dorado, Beatriz; Coku, Jorida; Naini, Ali B.; Lagier-Tourenne, Clotilde; Schuelke, Markus; Salviati, Leonardo; Carrozzo, Rosalba; Santorelli, Filippo; Rahman, Shamima; Tazir, Meriem; Koenig, Michel; DiMauro, Salvatore; Hirano, Michio			Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ(10) deficiency	FASEB JOURNAL			English	Article						mitochondria; respiratory chain; ATP; ubiquinone; mitochondrial disease	COENZYME Q(10); BIOSYNTHESIS; MITOCHONDRIA; NEPHROPATHY; DEGRADATION; METABOLISM; RESISTANCE; MUTATIONS; DEFECTS; ND5	Coenzyme Q(10) (CoQ(10)) is essential for electron transport in the mitochondrial respiratory chain and antioxidant defense. The relative importance of respiratory chain defects, ROS production, and apoptosis in the pathogenesis of CoQ(10) deficiency is unknown. We determined previously that severe CoQ(10) deficiency in cultured skin fibroblasts harboring COQ2 and PDSS2 mutations produces divergent alterations of bioenergetics and oxidative stress. Here, to better understand the pathogenesis of CoQ(10) deficiency, we have characterized the effects of varying severities of CoQ(10) deficiency on ROS production and mitochondrial bioenergetics in cells harboring genetic defects of CoQ(10) biosynthesis. Levels of CoQ(10) seem to correlate with ROS production; 10-15% and >60% residual CoQ(10) are not associated with significant ROS production, whereas 30-50% residual CoQ(10) is accompanied by increased ROS production and cell death. Our results confirm that varying degrees of CoQ(10) deficiency cause variable defects of ATP synthesis and oxidative stress. These findings may lead to more rational therapeutic strategies for CoQ(10) deficiency.-Quinzii, C. M., Lopez, L. C., Gilkerson, R. W., Dorado, B., Coku, J., Naini, A. B., Lagier-Tourenne, C., Schuelke, M., Salviati, L., Carrozzo, R., Santorelli, F., Rahman, S., Tazir, M., Koenig, M., DiMauro, S., Hirano, M. Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ(10) deficiency. FASEB J. 24, 3733-3743 (2010). www.fasebj.org	[Quinzii, Catarina M.; Lopez, Luis C.; Gilkerson, Robert W.; Dorado, Beatriz; Coku, Jorida; Naini, Ali B.; DiMauro, Salvatore; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA; [Lagier-Tourenne, Clotilde; Koenig, Michel] Univ Strasbourg, Inst Genet & Mol & Cellular Biol, CNRS, INSERM, Illrirch, France; [Schuelke, Markus] Charite Virchow Univ Hosp, Dept Neuropediat, Berlin, Germany; [Salviati, Leonardo] Univ Padua, Dept Pediat, Serv Genet Clin & Epidemiol, Padua, Italy; [Carrozzo, Rosalba; Santorelli, Filippo] Bambi Gesu Childrens Hosp, Ist Ricovero & Cura Carattere Sci, Rome, Italy; [Rahman, Shamima] UCL, Mitochondrial Res Grp, Clin & Mol Genet Unit, Inst Child Hlth, London, England; [Tazir, Meriem] Ctr Hosp Univ Mustapha, Serv Neurol, Algiers, Algeria	Columbia University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Padua; IRCCS Bambino Gesu; University of London; University College London	Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 630 W 168th St,P&S 4-423, New York, NY 10032 USA.	mh29@columbia.edu	Lopez, Luis Carlos/AAP-9411-2020; Lopez, Luis Carlos/L-5129-2014; Salviati, Leonardo/L-1007-2016; Rahman, Shamima/C-5232-2008; Santorelli, Filippo M/ABE-5124-2020; Carrozzo, Rosalba/A-2808-2014; lagier-Tourenne, Clotilde/ABE-6303-2020; Rahman, Shamima/M-7904-2019	Lopez, Luis Carlos/0000-0003-3355-0298; Lopez, Luis Carlos/0000-0003-3355-0298; Salviati, Leonardo/0000-0001-5642-9963; Rahman, Shamima/0000-0003-2088-730X; Santorelli, Filippo M/0000-0002-1359-9062; Carrozzo, Rosalba/0000-0002-3327-4054; lagier-Tourenne, Clotilde/0000-0002-3058-8322; Schuelke, Markus/0000-0003-2824-3891; Dorado, Beatriz/0000-0002-1958-4558	U.S. National Institutes of Health (NIH) [HD32062]; NIH [NS11786]; Muscular Dystrophy Association; Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF); Ministerio de Educacion y Ciencia, Spain; Telethon [GGP09207]; MRC [G0200335] Funding Source: UKRI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062, R01HD057543] Funding Source: NIH RePORTER; Medical Research Council [G0200335] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [V1220] Funding Source: researchfish	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF); Ministerio de Educacion y Ciencia, Spain(Spanish Government); Telethon(Fondazione Telethon); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Great Ormond Street Hospital Childrens Charity	This work was supported by U.S. National Institutes of Health (NIH) grant HD32062. M.H. is also supported by grants from the NIH (NS11786), the Muscular Dystrophy Association, and the Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF). C.M.Q. was supported by the Muscular Dystrophy Association. L.C.L. was supported by a postdoctoral fellowship from the Ministerio de Educacion y Ciencia, Spain. L.S. is supported by Telethon grant GGP09207.	Abramov AY, 2010, BRAIN, V133, P797, DOI 10.1093/brain/awq015; Baracca A, 2007, BBA-BIOENERGETICS, V1767, P913, DOI 10.1016/j.bbabio.2007.05.005; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Bentinger M, 2007, MITOCHONDRION, V7, pS41, DOI 10.1016/j.mito.2007.02.006; Blanchard-Fillion B, 2006, J NEUROSCI, V26, P6124, DOI 10.1523/JNEUROSCI.1038-06.2006; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Diomedi-Camassei F, 2007, J AM SOC NEPHROL, V18, P2773, DOI 10.1681/ASN.2006080833; Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018; Geromel V, 2001, FREE RADICAL RES, V35, P11, DOI 10.1080/10715760100300551; Gilkerson RW, 2000, FEBS LETT, V474, P1, DOI 10.1016/S0014-5793(00)01527-1; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Johnson A, 2005, J BIOL CHEM, V280, P31397, DOI 10.1074/jbc.M503277200; Kawamukai M, 2009, BIOTECHNOL APPL BIOC, V53, P217, DOI 10.1042/BA20090035; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krysko DV, 2008, METHOD ENZYMOL, V442, P307, DOI [10.1016/S0070-6879(08)01416-X, 10.1016/S0076-6879(08)01416-X]; Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024; Lee MS, 2004, ANN NY ACAD SCI, V1011, P146, DOI 10.1196/annals.1293.015; Lopez LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023; Lopez-Martin JM, 2007, HUM MOL GENET, V16, P1091, DOI 10.1093/hmg/ddm058; McKenzie M, 2007, J BIOL CHEM, V282, P36845, DOI 10.1074/jbc.M704158200; Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010; Oka S, 2008, EMBO J, V27, P421, DOI 10.1038/sj.emboj.7601975; Park SY, 2004, J BIOL CHEM, V279, P7512, DOI 10.1074/jbc.M307677200; Peng M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000061; Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092; Quinzii CM, 2008, BIOFACTORS, V32, P113, DOI 10.1002/biof.5520320113; Quinzii CM, 2008, FASEB J, V22, P1874, DOI 10.1096/fj.07-100149; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; Rodriguez-Hernandez A, 2009, AUTOPHAGY, V5, P19, DOI 10.4161/auto.5.1.7174; Saiki R, 2008, AM J PHYSIOL-RENAL, V295, pF1535, DOI 10.1152/ajprenal.90445.2008; Shokolenko I, 2009, NUCLEIC ACIDS RES, V37, P2539, DOI 10.1093/nar/gkp100; Tauche A, 2008, FEMS YEAST RES, V8, P1263, DOI 10.1111/j.1567-1364.2008.00436.x; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012	33	112	116	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3733	3743		10.1096/fj.09-152728	http://dx.doi.org/10.1096/fj.09-152728			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20495179	Green Published, Green Submitted			2022-12-28	WOS:000285005900013
J	Yu, J; Peng, H; Ruan, Q; Fatima, A; Getsios, S; Lavker, RM				Yu, Jia; Peng, Han; Ruan, Qing; Fatima, Anees; Getsios, Spiro; Lavker, Robert M.			MicroRNA-205 promotes keratinocyte migration via the lipid phosphatase SHIP2	FASEB JOURNAL			English	Article						cell signaling; cell survival; corneal epithelium; epidermis	BREAST-CANCER METASTASIS; CELL-MIGRATION; ERM PROTEINS; ACTIN DYNAMICS; TYROSINE PHOSPHORYLATION; 5'-INOSITOL PHOSPHATASE; MESENCHYMAL TRANSITION; DOWN-REGULATION; HUMAN PROSTATE; MAMMALIAN EYE	microRNA-205 (miR-205) and miR-184 coordinately regulate the lipid phosphatase SHIP2 for Akt survival signaling in keratinocytes. As the PI3K-Akt pathway has also been implicated in regulating the actin cytoskeleton and cell motility, we investigated the role that these 2 miRNAs play in keratinocyte migration. We used antagomirs (antago) to reduce the levels of miR-205 and miR-184 in primary human epidermal keratinocytes (HEKs) and corneal epithelial keratinocytes (HCEKs) as well as direct SHIP2 silencing using siRNA oligos. Treatment of HEKs and HCEKs with antago-205 increased SHIP2 levels and impaired the ability of these cells to seal linear scratch wounds compared with untreated or irrelevant-antago treatments. In contrast, AKT signaling was enhanced and wounds sealed faster in HCEKs where miR-184 was suppressed, enabling miR-205 to inhibit SHIP2. Similar increases in migration were observed following direct SHIP2 silencing in HEKs. Furthermore, down-regulation of miR-205 resulted in an increase in Rho-ROCKI activity, phosphorylation of the actin severing protein cofilin, and a corresponding diminution of filamentous actin. The connection among miR-205, RhoA-ROCKI-cofilin inactivation, and the actin cytoskeleton represents a novel post-translational mechanism for the regulation of normal human keratinocyte migration.-Yu, J., Peng, H., Ruan, Q., Fatima, A., Getsios, S., Lavker, R. M. MicroRNA-205 promotes keratinocyte migration via the lipid phosphatase SHIP2. FASEB J. 24, 3950-3959 (2010). www.fasebj.org	[Yu, Jia; Peng, Han; Ruan, Qing; Fatima, Anees; Getsios, Spiro; Lavker, Robert M.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Lavker, RM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, 303 E Chicago Ave,Ward 9-124, Chicago, IL 60611 USA.	r-lavker@northwestern.edu	Peng, Han/I-1922-2012	Peng, Han/0000-0002-1105-8254; fatima, anees/0000-0003-3329-2284; Yu, Jia/0000-0003-3499-5133	NIH [EY017536, EY019463]; U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [P30AR057216]; Dermatology Foundation; NATIONAL EYE INSTITUTE [R01EY019463, R21EY017536] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057216] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Dermatology Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank members of the laboratory of Kathleen Green for input and advice, in particular Adi Dubash for assistance in determining the status of activated Rho. The authors thank Nihal Kaplan for critical reading of the manuscript and helpful discussions. Primary epidermal keratinocyte cultures were obtained from the Northwestern University Skin Disease Research Center Keratinocyte Core Facility with support from the U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant P30AR057216. This research is supported by NIH grants EY017536 and EY019463 (R.M.L.) and a Dermatology Foundation Career Development Award (S.G.).	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Darmellah A, 2009, CARDIOVASC RES, V81, P294, DOI 10.1093/cvr/cvn320; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hao JJ, 2009, J CELL BIOL, V184, P451, DOI 10.1083/jcb.200807047; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Atsuko H, 2007, J MUSCLE RES CELL M, V28, P183, DOI 10.1007/s10974-007-9117-6; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jiang JM, 2005, NUCLEIC ACIDS RES, V33, P5394, DOI 10.1093/nar/gki863; Kakinuma N, 2008, J CELL BIOL, V181, P537, DOI 10.1083/jcb.200707022; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lampugnani MG, 1999, METH MOL B, V96, P177; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lavker Robert M., 2009, Human Genomics, V3, P332; Le Clainche C, 2008, PHYSIOL REV, V88, P489, DOI 10.1152/physrev.00021.2007; Lebanony D, 2009, J CLIN ONCOL, V27, P2030, DOI 10.1200/JCO.2008.19.4134; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Lim MA, 2004, ONCOGENE, V23, P9348, DOI 10.1038/sj.onc.1208147; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Lu L, 2001, EXP BIOL MED, V226, P653, DOI 10.1177/153537020222600711; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Prag S, 2007, MOL BIOL CELL, V18, P2935, DOI 10.1091/mbc.E06-11-1031; Prasad N, 2002, J CELL SCI, V115, P3807, DOI 10.1242/jcs.00070; Prasad NK, 2009, INT J ONCOL, V34, P97, DOI 10.3892/ijo_00000133; Prasad NK, 2005, J BIOL CHEM, V280, P13129, DOI 10.1074/jbc.M410289200; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; RAJA SK, 2007, FRONT BIOSCI, V12, P2849, DOI DOI 10.2741/2277; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Ryan D, 2006, MOL VIS, V12, P1175; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sharrard RM, 2007, CELL SIGNAL, V19, P129, DOI 10.1016/j.cellsig.2006.05.029; Shi Q, 2003, MOL BIOL CELL, V14, P4306, DOI 10.1091/mbc.E03-01-0046; Song HS, 2009, BIOCHEM BIOPH RES CO, V388, P400, DOI 10.1016/j.bbrc.2009.08.020; Stepp MA, 2007, J CELL SCI, V120, P2851, DOI 10.1242/jcs.03480; Taboubi S, 2007, FASEB J, V21, P4047, DOI 10.1096/fj.06-7476com; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Tran N, 2007, BIOCHEM BIOPH RES CO, V358, P12, DOI 10.1016/j.bbrc.2007.03.201; Trinkaus-Randall V, 2000, J CELL PHYSIOL, V184, P385, DOI 10.1002/1097-4652(200009)184:3<385::AID-JCP14>3.0.CO;2-7; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Vandermoere F, 2007, MOL CELL PROTEOMICS, V6, P114, DOI 10.1074/mcp.M600335-MCP200; Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115; Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; Yu J, 2008, P NATL ACAD SCI USA, V105, P19300, DOI 10.1073/pnas.0803992105; Yurko MA, 2001, J CELL PHYSIOL, V188, P24, DOI 10.1002/jcp.1093	69	119	131	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3950	3959		10.1096/fj.10-157404	http://dx.doi.org/10.1096/fj.10-157404			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20530248	Green Published			2022-12-28	WOS:000285005900032
J	Cuong, CT; Vohradsky, J				Cuong Chieu To; Vohradsky, Jiri			Measurement variation determines the gene network topology reconstructed from experimental data: a case study of the yeast cyclin network	FASEB JOURNAL			English	Article						numerical modeling; genetic programming	CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; REGULATORY NETWORKS; TRANSCRIPTIONAL RESPONSE; EXPRESSION DATA; MICROARRAY; MODEL; INFERENCE; TARGETS; GENOME	Inference of the topology of gene regulatory networks from experimental data is one of the primary challenges of systems biology. In an example of a genetic network of cyclins in the yeast cell cycle, we analyzed static genome-wide location data together with microarray kinetic measurements using a recurrent neural network-based model of gene expression and a newly developed, unbiased algorithm based on evolutionary programming principles. The modeling and simulation of gene expression dynamics identified cyclin genetic networks that were active during the cell cycle. We document that because there is inherent experimental variation, it is not possible to identify a single genetic network, only a set of equivalent networks with the same probability of occurrence. Analysis of these networks showed that each target gene was controlled by only a few regulators and that the control was robust. These results led to the reformulation of the cyclin genetic network in the yeast cell cycle as previously published. The analysis shows that with the methodologies that are currently available, it is not possible to predict only one genetic network; rather, we must work with the hypothesis of multiple, equivalent networks. Chromatin immunoprecipitation (ChIP)-on-chip experiments are not sufficient to predict the functional networks that are active during an investigated process. Such predictions must be considered as only potential, and their actual realization during particular cellular processes must be identified by incorporating both kinetic and other types of data.-To, C. C., Vohradsky, J. Measurement variation determines the gene network topology reconstructed from experimental data: a case study of the yeast cyclin network. FASEB J. 24, 3468-3478 (2010). www.fasebj.org	[Vohradsky, Jiri] Acad Sci Czech Republ, Inst Microbiol, Lab Bioinformat, CR-14220 Prague, Czech Republic; [Cuong Chieu To] Saigon Inst Technol, Saigon, Vietnam	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Vohradsky, J (corresponding author), Acad Sci Czech Republ, Inst Microbiol, Lab Bioinformat, Videnska 1083, CR-14220 Prague, Czech Republic.	vohr@biomed.cas.cz			Czech Science Foundation [310/07/1009]; Institutional Research Concept [AV0Z50200510]; EC [LSHM-CT-2004-005224]	Czech Science Foundation(Grant Agency of the Czech Republic); Institutional Research Concept; EC(European CommissionEuropean Commission Joint Research Centre)	This work was supported by grants from the Czech Science Foundation (310/07/1009), the Institutional Research Concept (AV0Z50200510), and the EC Integrated Project Actino-GEN (LSHM-CT-2004-005224).	Bahler J, 2005, ANNU REV GENET, V39, P69, DOI 10.1146/annurev.genet.39.110304.095808; Bar-Joseph Z, 2004, BIOINFORMATICS, V20, P2493, DOI 10.1093/bioinformatics/bth283; Barenco M, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-r25; Barenco M, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.84; Cantu-Paz E., 2001, EFFICIENT ACCURATE P, P33, DOI [10.1007/978-1-4615-4369-5, DOI 10.1007/978-1-4615-4369-5]; D'haeseleer P, 2000, BIOINFORMATICS, V16, P707, DOI 10.1093/bioinformatics/16.8.707; De Jong H, 2002, J COMPUT BIOL, V9, P67, DOI 10.1089/10665270252833208; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hart CE, 2006, PLOS COMPUT BIOL, V2, P1592, DOI 10.1371/journal.pcbi.0020169; Hasty J, 2001, NAT REV GENET, V2, P268, DOI 10.1038/35066056; Hollenhorst PC, 2001, GENE DEV, V15, P2445, DOI 10.1101/gad.906201; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Khanin R, 2006, P NATL ACAD SCI USA, V103, P18592, DOI 10.1073/pnas.0603390103; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lee WP, 2009, BRIEF BIOINFORM, V10, P408, DOI 10.1093/bib/bbp028; Li H, 2008, BIOINFORMATICS, V24, P1874, DOI 10.1093/bioinformatics/btn332; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Pramila T, 2006, GENE DEV, V20, P2266, DOI 10.1101/gad.1450606; Sabatti C, 2006, BIOINFORMATICS, V22, P739, DOI 10.1093/bioinformatics/btk017; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; van Someren E P, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P355; Veitia RA, 2003, BIOL REV, V78, P149, DOI 10.1017/S1464793102006036; Vohradsky J, 2001, FASEB J, V15, P846, DOI 10.1096/fj.00-0361com; Vohradsky J, 2001, J BIOL CHEM, V276, P36168, DOI 10.1074/jbc.M104391200; Vu TT, 2007, NUCLEIC ACIDS RES, V35, P279, DOI 10.1093/nar/gkl1001; Vu TT, 2009, GENOMICS, V93, P426, DOI 10.1016/j.ygeno.2009.01.006; Wang RS, 2007, MOL CELLS, V24, P307; Wang Y, 2006, BIOINFORMATICS, V22, P2413, DOI 10.1093/bioinformatics/btl396	31	7	7	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3468	3478		10.1096/fj.10-160515	http://dx.doi.org/10.1096/fj.10-160515			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20511392				2022-12-28	WOS:000281446400034
J	Hashidate, T; Murakami, N; Nakagawa, M; Ichikawa, M; Kurokawa, M; Shimizu, T; Nakamura, M				Hashidate, Tomomi; Murakami, Naoka; Nakagawa, Masahiro; Ichikawa, Motoshi; Kurokawa, Mineo; Shimizu, Takao; Nakamura, Motonao			AML1 enhances the expression of leukotriene B-4 type-1 receptor in leukocytes	FASEB JOURNAL			English	Article						G-protein-coupled receptor; BLT1	HISTONE DEACETYLASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; RETINOIC ACID; CELL-DIFFERENTIATION; T-CELLS; AIRWAY HYPERRESPONSIVENESS; TRANSCRIPTION FACTORS; ADULT HEMATOPOIESIS; GENE-EXPRESSION; HL-60 CELLS	Leukotriene B-4 type-1 receptor (BLT1), which plays a role in various inflammatory diseases, is exclusively expressed in peripheral leukocytes, which suggests that its expression is stringently regulated. However, the precise mechanism of BLT1 expression is not fully understood. Here we report that acute myeloid leukemia 1 (AML1/Runx1) is involved in the enhancement of BLT1 expression in leukocytes. In retinoic acid (RA)-stimulated human promyelocytic leukemia (HL-60) cells, the transcription of the BLT1 gene was found to be significantly activated. RA did not directly modulate the BLT1 promoter, suggesting enhancers in other loci. DNase I-hypersensitivity analyses revealed an activated region, termed AE-BLex, at the intron-I: exon-II boundary. AE-BLex acts as an enhancer for the BLT1 promoter and possesses 2 AML1 recognition sites. The importance of AML1 was determined using electrophoretic mobility shift assays, reporter assays, and knockdown experiments. We demonstrated that the enhancement of BLT1 expression during the RA-induced differentiation of HL-60 cells is due to a loosening of the chromatin structure around AE-BLex, which leads to the incremental binding of AML1. The AML1/AE-BLex complex was confirmed in other BLT1-expressing leukemia cell lines and human peripheral leukocytes. Thus, AML1 enhances BLT1 expression by binding to AE-BLex, which is accessible in leukocytes.-Hashidate, T., Murakami, N., Nakagawa, M., Ichikawa, M., Kurokawa, M., Shimizu, T., Nakamura, M. AML1 enhances the expression of leukotriene B-4 type-1 receptor in leukocytes. FASEB J. 24, 3500-3510 (2010). www.fasebj.org	[Nakamura, Motonao] Univ Tokyo, Dept Biochem & Mol Biol, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; [Nakagawa, Masahiro; Ichikawa, Motoshi; Kurokawa, Mineo] Univ Tokyo, Fac Med, Dept Hematol & Oncol, Tokyo 1130033, Japan; [Shimizu, Takao; Nakamura, Motonao] Univ Tokyo, Ctr NanoBio Integrat, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Nakamura, M (corresponding author), Univ Tokyo, Dept Biochem & Mol Biol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	moto-nakamura@umin.net	Shimizu, Takao/AAV-7052-2021	Nakagawa, Masahiro/0000-0002-6420-2555; Ichikawa, Motoshi/0000-0001-6497-0848	Ministry of Education, Culture, Sports, Science, and Technology of Japan; Japan Society for the Promotion of Science; Ministry of Health, Labor, and Welfare; Grants-in-Aid for Scientific Research [19679004, 22790901] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Drs. S. Ishii, Y. Kita, H. Shindou, and all laboratory members for their constructive comments. The authors are also grateful to Dr. T. Yokomizo (Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University) for discussions. This work was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to M.N. and T. S.), and a Global COE program (University of Tokyo) from the Japan Society for the Promotion of Science (to T. S.). M. K. was supported in part by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science, and by Health and Labor Science Research grants from the Ministry of Health, Labor, and Welfare. T. H. was supported by research fellowships for young scientists from the Japan Society for the Promotion of Science.	BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; Chen M, 2006, J EXP MED, V203, P837, DOI 10.1084/jem.20052371; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; Egawa T, 2007, J EXP MED, V204, P1945, DOI 10.1084/jem.20070133; Ferrara FF, 2001, CANCER RES, V61, P2; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Friedman AD, 2007, ONCOGENE, V26, P6816, DOI 10.1038/sj.onc.1210764; GOETZL EJ, 1981, J EXP MED, V153, P482, DOI 10.1084/jem.153.2.482; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; Huang G, 2008, NAT GENET, V40, P51, DOI 10.1038/ng.2007.7; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Kato K, 2000, J EXP MED, V192, P413, DOI 10.1084/jem.192.3.413; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komine O, 2003, J EXP MED, V198, P51, DOI 10.1084/jem.20021200; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LUBBERT M, 1991, BLOOD, V78, P345; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Merzvinskyte R, 2006, ANN NY ACAD SCI, V1091, P356, DOI 10.1196/annals.1378.080; MICHAELIS L, 1903, Z KREBSFORSCH, V1, P105; Miyahara N, 2005, J IMMUNOL, V174, P4979, DOI 10.4049/jimmunol.174.8.4979; Murakami N, 2009, GENES CELLS, V14, P1441, DOI 10.1111/j.1365-2443.2009.01360.x; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Obinata H, 2003, BIOCHEM BIOPH RES CO, V309, P114, DOI 10.1016/S0006-291X(03)01554-7; Ohnishi Hiroshi, 2008, Allergol Int, V57, P291, DOI 10.2332/allergolint.08-RAI-0019; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Puig-Kroger A, 2003, BLOOD, V102, P3252, DOI 10.1182/blood-2003-02-0618; Savickiene J, 2006, EUR J PHARMACOL, V549, P9, DOI 10.1016/j.ejphar.2006.08.010; Savickiene J, 2009, ANN NY ACAD SCI, V1171, P321, DOI 10.1111/j.1749-6632.2009.04718.x; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Stankova J, 2002, J IMMUNOL, V168, P3570, DOI 10.4049/jimmunol.168.7.3570; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217; Wu JB, 2009, J BIOL CHEM, V284, P16723, DOI 10.1074/jbc.M901779200; YEN A, 1985, LEUKEMIA RES, V9, P51, DOI 10.1016/0145-2126(85)90021-9; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	48	9	9	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3500	3510		10.1096/fj.10-156844	http://dx.doi.org/10.1096/fj.10-156844			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20395453				2022-12-28	WOS:000281446400037
J	Hmila, I; Saerens, D; Ben Abderrazek, R; Vincke, C; Abidi, N; Benlasfar, Z; Govaert, J; El Ayeb, M; Bouhaouala-Zahar, B; Muyldermans, S				Hmila, Issam; Saerens, Dirk; Ben Abderrazek, Rahma; Vincke, Cecile; Abidi, Naima; Benlasfar, Zakaria; Govaert, Jochen; El Ayeb, Mohamed; Bouhaouala-Zahar, Balkiss; Muyldermans, Serge			A bispecific nanobody to provide full protection against lethal scorpion envenoming	FASEB JOURNAL			English	Article							ANDROCTONUS-AUSTRALIS-HECTOR; HEAVY-CHAIN ANTIBODIES; SINGLE-DOMAIN ANTIBODIES; ANTIVENOM IMMUNOTHERAPY; MONOCLONAL-ANTIBODIES; FUNCTIONAL-EVALUATION; ANTIGEN-BINDING; ALPHA-TOXIN; VENOM; NEUROTOXIN	Envenoming following scorpion sting is a common emergency in many parts of the world. Our aim was to ameliorate the current 100-kDa horse plasma antivenom serum (PAS)-derived Fab(2)' to more quickly reach the highly diffusible scorpion toxins (7 kDa). We immunized dromedaries with toxins from Androctonus australis hector (Aah) scorpions and cloned the single-domain antibody fragments or nanobodies (15 kDa) from their B cells. Nanobodies against AahI' toxin (with AahII the most toxic compound of the venom) were retrieved from the libraries, and their AahI'-toxin neutralization was monitored in mice. Remarkably, the NbAahI'F12 fully protected mice against 100 LD50 of AahI' administered intracerebroventricularly. Moreover, where PAS failed completely to neutralize 2 LD50 of crude venom injected subcutaneously, the designed bispecific NbF12-10 against AahI'/AahII toxins succeeded in neutralizing 5 LD50. Finally, in a challenge assay in which mice were subcutaneously injected with a lethal dose of scorpion venom, the subsequent intravenous injection of 85 mu g of NbF12-10 protected all mice, even if the whole procedure was repeated 3 times. Furthermore, the NbF12-10 remained fully protective when mice with severe signs of envenoming were treated a few minutes before the untreated mice died.-Hmila, I., Saerens, D., Ben Abderrazek, R., Vincke, C., Abidi, N., Benlasfar, Z., Govaert, J., El Ayeb, M., Bouhaouala-Zahar, B., Muyldermans, S. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J. 24, 3479-3489 (2010). www.fasebj.org	[Hmila, Issam; Ben Abderrazek, Rahma; Abidi, Naima; El Ayeb, Mohamed; Bouhaouala-Zahar, Balkiss] Inst Pasteur, Lab Venins & Toxines, Tunis 1002, Tunisia; [Benlasfar, Zakaria] Inst Pasteur, Serv Unites Anim, Tunis 1002, Tunisia; [Saerens, Dirk; Vincke, Cecile; Govaert, Jochen; Muyldermans, Serge] Vrije Univ Brussel VIB, Cellular & Mol Immunol Lab, B-1050 Brussels, Belgium; [Saerens, Dirk; Vincke, Cecile; Govaert, Jochen; Muyldermans, Serge] Vrije Univ Brussel VIB, Dept Cellular & Mol Interact, B-1050 Brussels, Belgium; [Bouhaouala-Zahar, Balkiss] Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia	Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Universite de Tunis-El-Manar; Faculte de Medecine de Tunis (FMT)	Bouhaouala-Zahar, B (corresponding author), Inst Pasteur, Lab Venins & Toxines, 13 Pl Pasteur,BP 74, Tunis 1002, Tunisia.	balkiss.bouhaouala@pasteur.rns.tn	Muyldermans, Serge/AAC-7374-2019; Saerens, Dirk/B-9162-2008; Muyldermans, Serge V/C-6418-2016; Vincke, Cecile/C-6590-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575; Saerens, Dirk/0000-0001-8894-8039; BOUHAOUALA-ZAHAR, Balkiss/0000-0003-3147-245X; Vincke, Cecile/0000-0003-0681-7444	International Foundation for Science (IFS) [F/2762-2]; NATO project [sfp981865]; Pasteur Institute, Ministry of Health and Research and Development [Tox10]	International Foundation for Science (IFS)(International Foundation for Science); NATO project(NATO (North Atlantic Treaty Organisation)); Pasteur Institute, Ministry of Health and Research and Development	The authors thank Professor Hechmi Louzir, General Director of Pasteur Institute, for constant encouragements. The authors thank Ms. T. Chagour and Ms. E. Ghribi for technical assistance on toxin purifications and neutralization assays, respectively. The authors thank Dr. A. Meddeb-Garnaoui for help on lymphocyte extraction, and Dr. H. Dabbek (Centre regional de production animaliere de Kebili) for his invaluable help on dromedary immunization. The authors greatly appreciate the gift of the rabbit anti-AahI' and anti-AahII sera from Dr. C. Devaux (Institut Jean Roche, Marseille, France). This work was partially supported by grants from the International Foundation for Science (IFS; F/2762-2), NATO project sfp981865, and by the Pasteur Institute, Ministry of Health and Research and Development (Tox10).	Abroug F, 1999, LANCET, V354, P906, DOI 10.1016/S0140-6736(98)12083-4; Aubrey N, 2004, TOXICON, V43, P233, DOI 10.1016/j.toxicon.2003.11.024; Aubrey N, 2003, CELL MOL LIFE SCI, V60, P617, DOI 10.1007/s000180300053; BAHRAOUI E, 1988, J IMMUNOL, V141, P214; Ben Abderrazek R, 2009, BIOCHEM J, V424, P263, DOI 10.1042/BJ20090697; BouhaoualaZahar B, 1996, EUR J BIOCHEM, V238, P653, DOI 10.1111/j.1432-1033.1996.0653w.x; Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021; Chippaux JP, 1998, TOXICON, V36, P1503, DOI 10.1016/S0041-0101(98)00140-8; Clot-Faybesse O, 1999, FEBS LETT, V458, P313, DOI 10.1016/S0014-5793(99)01179-5; Conrath K, 2005, J MOL BIOL, V350, P112, DOI 10.1016/j.jmb.2005.04.050; Conrath KE, 2003, DEV COMP IMMUNOL, V27, P87, DOI 10.1016/S0145-305X(02)00071-X; Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200; De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103; Devaux C, 2001, EUR J BIOCHEM, V268, P694, DOI 10.1046/j.1432-1327.2001.01923.x; ELAYEB M, 1985, TOXICON, V23, P755, DOI 10.1016/0041-0101(85)90005-4; ELAYEB M, 1986, BIOCHEMISTRY-US, V25, P6671, DOI 10.1021/bi00369a052; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; GRANIER C, 1989, MOL IMMUNOL, V26, P503, DOI 10.1016/0161-5890(89)90001-1; Hmila I, 2008, MOL IMMUNOL, V45, P3847, DOI 10.1016/j.molimm.2008.04.011; Ismail M, 1998, TOXICON, V36, P1523, DOI 10.1016/S0041-0101(98)00144-5; Juste M, 2007, CELL MOL LIFE SCI, V64, P206, DOI 10.1007/s00018-006-6401-3; Krifi MN, 2005, TOXICON, V45, P187, DOI 10.1016/j.toxicon.2004.10.007; Krifi MN, 2001, TOXICON, V39, P1317, DOI 10.1016/S0041-0101(01)00083-6; Meddeb-Mouelhi F, 2003, TOXICON, V42, P785, DOI 10.1016/j.toxicon.2003.10.021; Miranda F., 1970, EUR J BIOCHEM, V16, P279; Mousli M, 1999, FEBS LETT, V442, P183, DOI 10.1016/S0014-5793(98)01647-0; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; PACE CM, 1997, PROTEIN STRUCTURE PR, P297; Presta LG, 2006, ADV DRUG DELIVER REV, V58, P640, DOI 10.1016/j.addr.2006.01.026; Saerens D, 2004, J BIOL CHEM, V279, P51965, DOI 10.1074/jbc.M409292200; Saerens D, 2008, CURR OPIN PHARMACOL, V8, P600, DOI 10.1016/j.coph.2008.07.006; Vincke C, 2009, J BIOL CHEM, V284, P3273, DOI 10.1074/jbc.M806889200	32	75	85	3	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3479	3489		10.1096/fj.09-148213	http://dx.doi.org/10.1096/fj.09-148213			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20410443				2022-12-28	WOS:000281446400035
J	Mohamed, JS; Lopez, MA; Cox, GA; Boriek, AM				Mohamed, Junaith S.; Lopez, Michael A.; Cox, Gregory A.; Boriek, Aladin M.			Anisotropic regulation of Ankrd2 gene expression in skeletal muscle by mechanical stretch	FASEB JOURNAL			English	Article						diaphragm; NF-kappa B; AP-1; mdm mice; mechanotransduction	NF-KAPPA-B; MUSCULAR-DYSTROPHY; FIBER ARCHITECTURE; ECCENTRIC CONTRACTIONS; MAP KINASES; PROTEIN; TITIN; STRESS; ACTIVATION; PATHWAYS	The diaphragm muscles in vivo are subjected to mechanical forces both in the direction of the muscle fibers and in the direction transverse to the fibers. However, the effect of directional mechanical forces in skeletal muscle gene regulation is completely unknown. Here, we identified that stretch in the longitudinal and transverse directions to the diaphragm muscle fibers up-regulated Ankrd2 gene expression by two distinct signaling pathways in wild-type (WT) and mdm, a mouse model of muscular dystrophy with early-onset of progressive muscle-wasting. Stretch in the longitudinal direction activated both NF-kappa B and AP-1 transcription factors, whereas stretch in the transverse direction activated only AP-1 transcription factor. Interestingly, longitudinal stretch activated Ankrd2 promoter only by NF-kappa B, whereas transverse stretch activated Ankrd2 promoter by AP-1. Moreover, we found that longitudinal stretch activated Akt, which up-regulated Ankrd2 expression through NF-kappa B. However, transverse stretch activated Ras-GTP, Raf-1, and Erk1/2 proteins, which up-regulated Ankrd2 expression through AP-1. Surprisingly, the stretch-activated NF-kappa B and AP-1 signaling pathways was not involved in Ankrd2 regulation at the basal level, which was high in the mdm mouse diaphragm. Taken together, our data show the anisotropic regulation of Ankrd2 gene expression in the diaphragm muscles of WT and mdm mice via two distinct mechanosensitive signaling pathways.-Mohamed, J. S., Lopez, M. A., Cox, G. A., Boriek, A. M. Anisotropic regulation of Ankrd2 gene expression in skeletal muscle by mechanical stretch. FASEB J. 24, 3330-3340 (2010). www.fasebj.org	[Mohamed, Junaith S.; Lopez, Michael A.; Boriek, Aladin M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Cox, Gregory A.] Jackson Lab, Bar Harbor, ME 04609 USA	Baylor College of Medicine; Jackson Laboratory	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	boriek@bcm.tmc.edu	Mohamed, Junaith/AAC-4050-2020; Lopez, Michael A./AAT-2145-2021	Lopez, Michael A./0000-0002-3029-0761	National Heart, Lung and Blood Institute [HL-63134]; National Science Foundation [CBET-0650686]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063134] Funding Source: NIH RePORTER	National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Science Foundation(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	National Heart, Lung and Blood Institute grant HL-63134 and National Science Foundation grant CBET-0650686 supported this work.	BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barash IA, 2004, AM J PHYSIOL-CELL PH, V286, pC355, DOI 10.1152/ajpcell.00211.2003; Bean C, 2005, J MOL BIOL, V349, P349, DOI 10.1016/j.jmb.2005.03.063; Bean C, 2008, BBA-MOL CELL RES, V1783, P1023, DOI 10.1016/j.bbamcr.2008.01.027; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Boriek AM, 2000, J APPL PHYSIOL, V89, P2187, DOI 10.1152/jappl.2000.89.6.2187; Boriek AM, 2002, J APPL PHYSIOL, V92, P725, DOI 10.1152/jappl.2002.92.2.725; Boriek AM, 2001, AM J PHYSIOL-REG I, V280, pR156, DOI 10.1152/ajpregu.2001.280.1.R156; Boriek AM, 1998, J APPL PHYSIOL, V84, P318; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHARU D, 2006, J CELL PHYSL, V208, P575; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GOLDSPINK G, 1992, AM J PHYSIOL, V262, pR356, DOI 10.1152/ajpregu.1992.262.3.R356; Granzier HL, 2004, CIRC RES, V94, P284, DOI 10.1161/01.RES.0000117769.88862.F8; Hackman P, 2002, AM J HUM GENET, V71, P492, DOI 10.1086/342380; Haravuori H, 2001, NEUROLOGY, V56, P869, DOI 10.1212/WNL.56.7.869; Hentzen ER, 2006, J PHYSIOL-LONDON, V570, P157, DOI 10.1113/jphysiol.2005.093005; Ishiguro N, 2002, AM J PATHOL, V160, P1767, DOI 10.1016/S0002-9440(10)61123-6; Kemp TJ, 2000, GENOMICS, V66, P229, DOI 10.1006/geno.2000.6213; Kojic S, 2004, J MOL BIOL, V339, P313, DOI 10.1016/j.jmb.2004.03.071; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463; Lehti TM, 2007, J MUSCLE RES CELL M, V28, P39, DOI 10.1007/s10974-007-9102-0; Lopez MA, 2008, AM J PHYSIOL-CELL PH, V295, pC1092, DOI 10.1152/ajpcell.16.2008; MARGULIES SS, 1994, J APPL PHYSIOL, V76, P2070, DOI 10.1152/jappl.1994.76.5.2070; Mckoy G, 2005, J APPL PHYSIOL, V98, P2337, DOI 10.1152/japplphysiol.01046.2004; Miller MK, 2003, J MOL BIOL, V333, P951, DOI 10.1016/j.jmb.2003.09.012; Moriyama M, 2001, BIOCHEM BIOPH RES CO, V285, P715, DOI 10.1006/bbrc.2001.5216; Pardo PS, 2008, AM J PHYSIOL-CELL PH, V294, pC1056, DOI 10.1152/ajpcell.00270.2007; Patel ND, 2003, AM J PHYSIOL-CELL PH, V284, pC962, DOI 10.1152/ajpcell.00326.2002; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Puchner EM, 2008, P NATL ACAD SCI USA, V105, P13385, DOI 10.1073/pnas.0805034105; Roy R R, 1991, Exerc Sport Sci Rev, V19, P269; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schramek H, 2002, NEWS PHYSIOL SCI, V17, P62, DOI 10.1152/nips.01365.2001; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Tskhovrebova L, 2003, NAT REV MOL CELL BIO, V4, P679, DOI 10.1038/nrm1198; Tsukamoto Y, 2002, LAB INVEST, V82, P645, DOI 10.1038/labinvest.3780459; Yokoyama T, 2007, J CELL BIOL, V177, P781, DOI 10.1083/jcb.200703195	47	26	26	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3330	3340		10.1096/fj.10-158386	http://dx.doi.org/10.1096/fj.10-158386			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20442316	Green Published			2022-12-28	WOS:000281446400021
J	Zingaretti, C; Falugi, F; Nardi-Dei, V; Pietrocola, G; Mariani, M; Liberatori, S; Gallotta, M; Tontini, M; Tani, C; Speziale, P; Grandi, G; Margarit, I				Zingaretti, Chiara; Falugi, Fabiana; Nardi-Dei, Vincenzo; Pietrocola, Giampiero; Mariani, Massimo; Liberatori, Sabrina; Gallotta, Marilena; Tontini, Marta; Tani, Chiara; Speziale, Pietro; Grandi, Guido; Margarit, Immaculada			Streptococcus pyogenes SpyCEP: a chemokine-inactivating protease with unique structural and biochemical features	FASEB JOURNAL			English	Article						group A Streptococcus; IL-8 cleavage; serine protease; ScpC	INVASIVE DISEASE; C5A PEPTIDASE; CLEAVAGE; SURFACE; IDENTIFICATION; DEGRADATION; RESISTANCE; PROTEINS; VACCINE; SCPC	SpyCEP is a 170-kDa multidomain serine protease expressed on the surface of the human pathogen Streptococcus pyogenes, which plays an important role in infection by catalyzing cleavage and inactivation of the neutrophil chemoatractant interleukin-8. In this study, we investigated the biochemical features and maturation process of SpyCEP, starting from a recombinant form of the protease expressed and purified from Escherichia coli. We show that active recombinant SpyCEP differs from other bacterial proteases in that it is constituted by 2 noncovalently linked fragments derived from autocatalytic processing, an N-terminal fragment of 210 aa bearing one of the 3 catalytic triad residues, and a 1369-residue C-terminal polypeptide containing the remaining 2 catalytic amino acids. The same type of organization is present in the enzyme obtained from S. pyogenes. Furthermore, N-terminal SpyCEP is not involved in the folding of the mature enzyme. The 2 protease fragments were separately expressed in E. coli as soluble polypeptides that, when combined, reconstituted a fully active enzyme complex. Therefore, SpyCEP appears to possess a completely new structural architecture that has not been described so far for other microbial proteases.-Zingaretti, C., Falugi, F., Nardi-Dei, V., Pietrocola, G., Mariani, M., Liberatori, S., Gallotta, M., Tontini, M., Tani, C., Speziale, P., Grandi, G., Margarit, I. Streptococcus pyogenes SpyCEP: a chemokine-inactivating protease with unique structural and biochemical features. FASEB J. 24, 2839-2848 (2010). www.fasebj.org	[Zingaretti, Chiara; Falugi, Fabiana; Nardi-Dei, Vincenzo; Mariani, Massimo; Liberatori, Sabrina; Gallotta, Marilena; Tontini, Marta; Tani, Chiara; Grandi, Guido; Margarit, Immaculada] Novartis Vaccines & Diagnost, Siena, Italy; [Zingaretti, Chiara] Ist Nazl Genet Mol, Milan, Italy; [Pietrocola, Giampiero; Speziale, Pietro] Univ Pavia, Dept Biochem, I-27100 Pavia, Italy	Novartis; University of Pavia	Margarit, I (corresponding author), Novartis Vaccines, Via Fiorentina 1, I-53100 Siena, Italy.	immaculada.margarit_y_ros@novartis.com	Liberatori, Sabrina/GYU-1878-2022	PIETROCOLA, GIAMPIERO/0000-0002-7069-8155; Grandi, Guido/0000-0001-9724-2185; Liberatori, Sabrina/0000-0003-3524-0429				Anderson ET, 2002, EUR J BIOCHEM, V269, P4839, DOI 10.1046/j.1432-1033.2002.03183.x; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Brown CK, 2005, P NATL ACAD SCI USA, V102, P18391, DOI 10.1073/pnas.0504954102; Buccato S, 2006, J INFECT DIS, V194, P331, DOI 10.1086/505433; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Chhatwal GS, 2005, TRENDS MOL MED, V11, P152, DOI 10.1016/j.molmed.2005.02.001; Doran JD, 1999, EUR J BIOCHEM, V263, P145, DOI 10.1046/j.1432-1327.1999.00473.x; Edwards RJ, 2005, J INFECT DIS, V192, P783, DOI 10.1086/432485; Framson PE, 1997, APPL ENVIRON MICROB, V63, P3539, DOI 10.1128/AEM.63.9.3539-3547.1997; Fritzer A, 2009, BIOCHEM J, V422, P533, DOI 10.1042/BJ20090278; Harris TO, 2003, J CLIN INVEST, V111, P61, DOI 10.1172/JCI200316270; Hidalgo-Grass C, 2004, LANCET, V363, P696, DOI 10.1016/S0140-6736(04)15643-2; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Khan AR, 1998, PROTEIN SCI, V7, P815; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Manetti AGO, 2007, MOL MICROBIOL, V64, P968, DOI 10.1111/j.1365-2958.2007.05704.x; PEREZCASAL J, 1993, MOL MICROBIOL, V8, P809, DOI 10.1111/j.1365-2958.1993.tb01628.x; Rasmussen M, 2002, MOL MICROBIOL, V43, P537, DOI 10.1046/j.1365-2958.2002.02766.x; Rodriguez-Ortega MJ, 2006, NAT BIOTECHNOL, V24, P191, DOI 10.1038/nbt1179; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; Siezen RJ, 1999, ANTON LEEUW INT J G, V76, P139, DOI 10.1023/A:1002036906922; Sjolinder H, 2008, INFECT IMMUN, V76, P3959, DOI 10.1128/IAI.00128-08; Sumby P, 2008, INFECT IMMUN, V76, P978, DOI 10.1128/IAI.01354-07; Turner CE, 2009, VACCINE, V27, P4923, DOI 10.1016/j.vaccine.2009.06.042; Zinkernagel AS, 2008, CELL HOST MICROBE, V4, P170, DOI 10.1016/j.chom.2008.07.002	26	30	30	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2839	2848		10.1096/fj.09-145631	http://dx.doi.org/10.1096/fj.09-145631			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20339024				2022-12-28	WOS:000285005400024
J	Marassio, G; Prange, T; David, HN; Santos, JSDO; Gabison, L; Delcroix, N; Abraini, JH; Colloc'h, N				Marassio, Guillaume; Prange, Thierry; David, Helene N.; Santos, Jana Sopkova-de Oliveira; Gabison, Laure; Delcroix, Nicolas; Abraini, Jacques H.; Colloc'h, Nathalie			Pressure-response analysis of anesthetic gases xenon and nitrous oxide on urate oxidase: a crystallographic study	FASEB JOURNAL			English	Article						inert gas; neuroprotection; hydrophobic cavity; enzymatic activity; dose response	NMDA ANTAGONIST; BINDING; MODEL; DRUG; SITE; NEUROTOXICITY; ISOFLURANE; INHIBITOR; MECHANISM; CHANNELS	The remarkably safe anesthetics xenon (Xe) and, to lesser extent, nitrous oxide (N2O) possess neuroprotective properties in preclinical studies. To investigate the mechanisms of pharmacological action of these gases, which are still poorly known, we performed both crystallography under a large range of gas pressure and biochemical studies on urate oxidase, a prototype of globular gas-binding proteins whose activity is modulated by inert gases. We show that Xe and N2O bind to, compete for, and expand the volume of a hydrophobic cavity located just behind the active site of urate oxidase and further inhibit urate oxidase enzymatic activity. By demonstrating a significant relationship between the binding and biochemical effects of Xe and N2O, given alone or in combination, these data from structure to function highlight the mechanisms by which chemically and metabolically inert gases can alter protein function and produce their pharmacological effects. Interestingly, the effects of a Xe:N2O equimolar mixture were found to be equivalent to those of Xe alone, thereby suggesting that gas mixtures containing Xe and N2O could be an alternative and efficient neuroprotective strategy to Xe alone, whose widespread clinical use is limited due to the cost of production and availability of this gas.-Marassio, G., Prange, T., David, H. N., Sopkova-de Oliveira Santos, J., Gabison, L., Delcroix, N., Abraini, J. H., Colloc'h, N. Pressure-response analysis of anesthetic gases xenon and nitrous oxide on urate oxidase: a crystallographic study. FASEB J. 25, 2266-2275 (2011). www.fasebj.org	[Colloc'h, Nathalie] UCBN, CNRS, Ctr Cyceron, ERTi 1083,CINAPS,UMR 6232, F-14074 Caen, France; [Prange, Thierry; Gabison, Laure] Univ Paris 05, CNRS, Fac Pharm, LCRB,UMR 8015, Paris, France; [Santos, Jana Sopkova-de Oliveira] UCBN, EA, CERMN, Caen, France; [Abraini, Jacques H.] Univ Laval Robert Giffard, Ctr Rech, Quebec City, PQ, Canada	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Universite de Caen Normandie; Laval University	Colloc'h, N (corresponding author), UCBN, CNRS, Ctr Cyceron, ERTi 1083,CINAPS,UMR 6232, Blvd Becquerel, F-14074 Caen, France.	colloch@cyceron.fr	Colloc'h, Nathalie/L-1570-2015; Sopkova-de Oliveira, Jana/L-2891-2015; Prangé, Thierry/AAA-4009-2022; Santos, Jana Sopkova-de Oliveira/M-6115-2019	Prangé, Thierry/0000-0002-7129-7396; Santos, Jana Sopkova-de Oliveira/0000-0002-4829-8120	Centre National de la Recherche Scientifique; Universite de Caen-Basse-Normandie; Universite Paris Descartes; Direction Generale de l'Armement (DGA); Ministere de l'Education et de la Recherche; Conseil Regional de Basse-Normandie	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Universite de Caen-Basse-Normandie; Universite Paris Descartes; Direction Generale de l'Armement (DGA); Ministere de l'Education et de la Recherche; Conseil Regional de Basse-Normandie(Region Normandie)	The authors gratefully thank Bertrand Castro and Mohamed El Hajji (Sanofi-Aventis, Montpellier, France) for supplying UOX. The authors also thank Martin Walsh, Hassan Belrhali, and other members of the staff of the BM14 beamline, Gavin Fox and other members of the staff of the BM16 beamline, and Michel Pirocchi and other members of the staff of the BM30A beamline at the European Synchrotron Radiation Facility (Grenoble, France) for access and advice during data collection. This research was supported by the Centre National de la Recherche Scientifique, the Universite de Caen-Basse-Normandie, the Universite Paris Descartes, and the Direction Generale de l'Armement (DGA). G. M. and L. G. were supported by a grant from the Ministere de l'Education et de la Recherche. H.N.D. was supported by a grant from the Conseil Regional de Basse-Normandie. J.H.A. is coinventor with no financial interest of the patent "Inhalable gaseous medicament based on xenon and nitrous oxide" (owner: Air Liquide Sante International).	Abraini JH, 2005, ANN NY ACAD SCI, V1053, P289, DOI 10.1196/annals.1344.025; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Cattano D, 2008, NEUROSCI LETT, V440, P217, DOI 10.1016/j.neulet.2008.05.086; Colloc'h N, 2007, BIOPHYS J, V92, P217, DOI 10.1529/biophysj.106.093807; Colloch N, 1997, NAT STRUCT BIOL, V4, P947, DOI 10.1038/nsb1197-947; CULLEN SC, 1951, SCIENCE, V113, P580, DOI 10.1126/science.113.2942.580; David HN, 2008, FASEB J, V22, P1275, DOI 10.1096/fj.07-9420com; David HN, 2010, J CEREBR BLOOD F MET, V30, P718, DOI 10.1038/jcbfm.2009.275; David HN, 2003, J CEREBR BLOOD F MET, V23, P1168, DOI 10.1097/01.WCB.0000087342.31689.18; DeLano W.L, PYMOL MOL GRAPHICS S; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Dinse A, 2005, BRIT J ANAESTH, V94, P479, DOI 10.1093/bja/aei080; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DYCK PJ, 1980, ANESTHESIOLOGY, V53, P205, DOI 10.1097/00000542-198009000-00005; Eckenhoff R G, 2001, Mol Interv, V1, P258; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FENSTER M N, 1951, J Med Soc N J, V48, P281; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Girard E, 2010, BIOPHYS J, V98, P2365, DOI 10.1016/j.bpj.2010.01.058; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Haelewyn B, 2008, CRIT CARE MED, V36, P2651, DOI 10.1097/CCM.0b013e318183f646; Hayakawa N, 2008, J MOL BIOL, V384, P812, DOI 10.1016/j.jmb.2008.09.075; Homi HM, 2003, ANESTHESIOLOGY, V99, P876, DOI 10.1097/00000542-200310000-00020; Hopkins PM, 2005, BEST PRACT RES-CLIN, V19, P381, DOI 10.1016/j.bpa.2005.03.002; Hubbard SJ, 1996, J MOL BIOL, V261, P289, DOI 10.1006/jmbi.1996.0460; Jevtovic-Todorovic V, 1998, NAT MED, V4, P460, DOI 10.1038/nm0498-460; Johansson JS, 2005, FEBS J, V272, P573, DOI 10.1111/j.1742-4658.2004.04500.x; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Luo Y, 2008, ANESTHESIOLOGY, V109, P782, DOI 10.1097/ALN.0b013e3181895f88; Ma DQ, 2003, ANESTHESIOLOGY, V98, P690, DOI 10.1097/00000542-200303000-00017; Miller KW, 2002, BRIT J ANAESTH, V89, P17, DOI 10.1093/bja/aef167; Moschetti T, 2009, BIOPHYS J, V97, P1700, DOI 10.1016/j.bpj.2009.05.059; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Olia AS, 2009, PROTEIN SCI, V18, P537, DOI 10.1002/pro.53; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prange T, 1998, PROTEINS, V30, P61, DOI 10.1002/(SICI)1097-0134(19980101)30:1<61::AID-PROT6>3.0.CO;2-N; SCHILTZ M, 1995, STRUCTURE, V3, P309, DOI 10.1016/S0969-2126(01)00161-7; SCHILTZ M, 1994, J APPL CRYSTALLOGR, V27, P950, DOI 10.1107/S0021889894005923; Sonner JM, 2005, MOL PHARMACOL, V68, P61, DOI 10.1124/mol.104.009936; Vedula LS, 2009, J BIOL CHEM, V284, P24176, DOI 10.1074/jbc.M109.017814; Voges D, 1995, ADV ENZYMOL RAMB, V71, P209; Yamakura T, 2000, ANESTHESIOLOGY, V93, P1095, DOI 10.1097/00000542-200010000-00034; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	49	27	27	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2266	2275		10.1096/fj.11-183046	http://dx.doi.org/10.1096/fj.11-183046			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21421845				2022-12-28	WOS:000292242200018
J	Shan, S; Chen, XH; Liu, T; Zhao, HC; Rao, ZH; Lou, ZY				Shan, Shan; Chen, Xuehui; Liu, Ting; Zhao, Hanchao; Rao, Zihe; Lou, Zhiyong			Crystal structure of 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE) from Mycobacterium tuberculosis	FASEB JOURNAL			English	Article						mechanism; drug discovery	NON-MEVALONATE PATHWAY; ISOPRENOID BIOSYNTHESIS; MECHANISM; ENZYMES; TARGET	Isoprenoid precursors, which are a large group of natural products and play key roles in many biological pathways, can only be biosynthesized by the 2-C-methyl-D-erythritol 4-phosphate pathway in Mycobacterium tuberculosis. The 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE), which is an essential enzyme in the isoprenoid precursor biosynthesis pathway, catalyzes ATP-dependent phosphorylation of 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) to 4-diphosphocytidyl-2C-methyl-D-erythritol-2-phosphate and plays a crucial role in M. tuberculosis survival. Therefore, IspE is characterized as an attractive and potential target for antimicrobial drug discovery. However, no experimental structure of M. tuberculosis IspE has been reported, which has hindered our understanding of its structural details and mechanism of action. Here, we report the expression and purification of fully active full-length M. tuberculosis IspE and solve the high-resolution crystal structures of IspE alone and in complex with either the substrate CDP-ME or nonhydrolyzable ATP analog or ADP. The structures present a characteristic galactose/homoserine/mevalonate/phosphomevalonate kinase superfamily alpha/beta-fold with a catalytic center located in a cleft between 2 domains and display clear substrate and ATP binding pockets. Our results also indicate distinct differences in ligand binding of M. tuberculosis IspE with other reported IspEs. Combined with the results of mutagenesis and enzymatic studies, our results provide useful information on the structural basis of IspE for future anti-M. tuberculosis drug discovery targeting this kinase.-Shan, S. Chen, X., Liu, T., Zhao, H., Rao, Z., Lou, Z. Crystal structure of 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE) from Mycobacterium tuberculosis. FASEB J. 25, 1577-1584 (2011). www.fasebj.org	[Shan, Shan; Zhao, Hanchao; Rao, Zihe; Lou, Zhiyong] Tsinghua Univ, Struct Biol Lab, Beijing 100084, Peoples R China; [Shan, Shan; Zhao, Hanchao; Rao, Zihe; Lou, Zhiyong] Tsinghua Univ, MOE Lab Prot Sci, Beijing 100084, Peoples R China; [Chen, Xuehui; Rao, Zihe] Chinese Acad Sci, Inst Biophys, Natl Lab Macromol, Beijing 100080, Peoples R China; [Liu, Ting; Rao, Zihe; Lou, Zhiyong] Tianjin Joint Acad Biotechnol & Med, High Throughput Mol Drug Discovery Ctr, Tianjin, Peoples R China	Tsinghua University; Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Lou, ZY (corresponding author), Tsinghua Univ, Struct Biol Lab, New Life Sci Bldg, Beijing 100084, Peoples R China.	louzy@xtal.tsinghua.edu.cn	Rao, Zihe/HCH-6944-2022	Zhao, Hanchao/0000-0002-4121-2435	National Natural Science Foundation of China [30870486, 30770516, 30730022]; 973 Project [2007CB914304, 2010CB530100]; National Major Projects [2009ZX09311-001, 2009ZX10004-304]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 Project(National Basic Research Program of China); National Major Projects	This work was supported by the National Natural Science Foundation of China (grants 30870486, 30770516, and 30730022), the 973 Project (grants 2007CB914304 and 2010CB530100), and the National Major Projects (grants 2009ZX09311-001 and 2009ZX10004-304).	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bernal C, 2005, ANAL BIOCHEM, V340, P245, DOI 10.1016/j.ab.2005.01.055; Bonanno JB, 2001, P NATL ACAD SCI USA, V98, P12896, DOI 10.1073/pnas.181466998; Brennan PJ, 2007, CURR TOP MED CHEM, V7, P475, DOI 10.2174/156802607780059763; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; Comas I, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000600; de Ruyck J, 2008, CURR PROTEIN PEPT SC, V9, P117; DeLano W.L, PYMOL MOL GRAPHICS S; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Eisenreich W, 2004, CELL MOL LIFE SCI, V61, P1401, DOI 10.1007/s00018-004-3381-z; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eoh H, 2009, CHEM BIOL, V16, P1230, DOI 10.1016/j.chembiol.2009.10.014; Eoh H, 2009, TUBERCULOSIS, V89, P1, DOI 10.1016/j.tube.2008.07.004; Fritz G, 2009, CURR CANCER DRUG TAR, V9, P626, DOI 10.2174/156800909789057033; Gershenzon J, 2007, NAT CHEM BIOL, V3, P408, DOI 10.1038/nchembio.2007.5; Hasan S, 2006, PLOS COMPUT BIOL, V2, P539, DOI 10.1371/journal.pcbi.0020061; Holm L, 1996, METHOD ENZYMOL, V266, P653; Jirage Dayadevi, 2010, Infectious Disorders - Drug Targets, V10, P134; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; [李爱华 Li Aihua], 2010, [生物物理学报, Acta Biophysica Sinica], V26, P680; Lou ZY, 2010, PROTEIN CELL, V1, P435, DOI 10.1007/s13238-010-0057-3; [马万顺 Ma Wanshun], 2010, [生物物理学报, Acta Biophysica Sinica], V26, P638; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Miallau L, 2003, P NATL ACAD SCI USA, V100, P9173, DOI 10.1073/pnas.1533425100; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; Missinou MA, 2002, LANCET, V360, P1941, DOI 10.1016/S0140-6736(02)11860-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rodriguez-Concepion M, 2004, CURR PHARM DESIGN, V10, P2391, DOI 10.2174/1381612043384006; Rohdich F, 2001, CURR OPIN CHEM BIOL, V5, P535, DOI 10.1016/S1367-5931(00)00240-4; Rohmer M, 1998, PROG DRUG RES, V50, P135; Sgraja T, 2008, FEBS J, V275, P2779, DOI 10.1111/j.1742-4658.2008.06418.x; Testa C. A., 2003, Current Pharmaceutical Biotechnology, V4, P248, DOI 10.2174/1389201033489784; Tuteja N, 2004, EUR J BIOCHEM, V271, P1849, DOI 10.1111/j.1432-1033.2004.04094.x; Wada T, 2003, J BIOL CHEM, V278, P30022, DOI 10.1074/jbc.M304339200; [张淑妍 ZHANG Shuyan], 2010, [生物物理学报, Acta Biophysica Sinica], V26, P97; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	39	16	16	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1577	1584		10.1096/fj.10-175786	http://dx.doi.org/10.1096/fj.10-175786			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21282208				2022-12-28	WOS:000290023800015
J	Valente, P; Fernandez-Carvajal, A; Camprubi-Robles, M; Gomis, A; Quirce, S; Viana, F; Fernandez-Ballester, G; Gonzalez-Ros, JM; Belmonte, C; Planells-Cases, R; Ferrer-Montiel, A				Valente, Pierluigi; Fernandez-Carvajal, Asia; Camprubi-Robles, Maria; Gomis, Ana; Quirce, Susana; Viana, Felix; Fernandez-Ballester, Gregorio; Gonzalez-Ros, Jose M.; Belmonte, Carlos; Planells-Cases, Rosa; Ferrer-Montiel, Antonio			Membrane-tethered peptides patterned after the TRP domain (TRPducins) selectively inhibit TRPV1 channel activity	FASEB JOURNAL			English	Article						pain; ionotropic receptors; pepducin; analgesia; inflammation	RECEPTOR POTENTIAL CHANNELS; VANILLOID RECEPTOR; CAPSAICIN RECEPTOR; SENSORY NEURONS; IN-VIVO; PAIN; THERMOSENSATION; IDENTIFICATION; DETERMINANTS; NOCICEPTION	The transient receptor potential vanilloid 1 (TRPV1) channel is a thermosensory receptor implicated in diverse physiological and pathological processes. The TRP domain, a highly conserved region in the C terminus adjacent to the internal channel gate, is critical for subunit tetramerization and channel gating. Here, we show that cell-penetrating, membrane-anchored peptides patterned after this protein domain are moderate and selective TRPV1 antagonists both in vitro and in vivo, blocking receptor activity in intact rat primary sensory neurons and their peripheral axons with mean decline time of 30 min. The most potent lipopeptide, TRP-p5, blocked all modes of TRPV1 gating with micromolar efficacy (IC50 < 10 mu M), without significantly affecting other thermoTRP channels. In contrast, its retrosequence or the corresponding sequences of other TRPV channels did not alter TRPV1 channel activity (IC50 > 100 mu M). TRP-p5 did not affect the capsaicin sensitivity of the vanilloid receptor. Our data suggest that TRP-p5 interferes with protein-protein interactions at the level of the TRP domain that are essential for the "conformational" change that leads to gate opening. Therefore, these palmitoylated peptides, which we termed TRPducins, are noncompetitive, voltage-independent, sequence-specific TRPV1 blockers. Our findings indicate that TRPducin-like peptides may embody a novel molecular strategy that can be exploited to generate a selective pharmacological arsenal for the TRP superfamily of ion channels.-Valente, P., Fernandez-Carvajal, A., Camprubi-Robles, M., Gomis, A., Quirce, S., Viana, F., Fernandez-Ballester, G., Gonzalez-Ros, J. M., Belmonte, C., Planells-Cases, R., Ferrer-Montiel, A. Membrane-tethered peptides patterned after the TRP domain (TRPducins) selectively inhibit TRPV1 channel activity. FASEB J. 25, 1628-1640 (2011). www.fasebj.org	[Valente, Pierluigi; Fernandez-Carvajal, Asia; Camprubi-Robles, Maria; Fernandez-Ballester, Gregorio; Gonzalez-Ros, Jose M.; Ferrer-Montiel, Antonio] Univ Miguel Hernandez, Inst Biol Mol & Celular, Elche 03202, Alicante, Spain; [Gomis, Ana; Quirce, Susana; Viana, Felix; Belmonte, Carlos] Univ Miguel Hernandez, CSIC, Inst Neurociencias, Elche 03202, Alicante, Spain; [Planells-Cases, Rosa] Ctr Invest Principe Felipe, Valencia, Spain	Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Prince Felipe Research Center	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Av Univ S-N, Elche 03202, Alicante, Spain.	aferrer@umh.es	Viana, Felix/U-8533-2017; Valente, Pierluigi/AAF-2802-2021; Ferrer-Montiel, Antonio/C-3072-2015; Gomis, Ana/S-1854-2017; Carvajal, Asia Fernandez/G-8877-2015	Viana, Felix/0000-0003-1439-949X; Ferrer-Montiel, Antonio/0000-0002-2973-6607; Gomis, Ana/0000-0003-4651-7673; Gonzalez Ros, Jose Manuel/0000-0002-4804-6855; Fernandez-Carvajal, Asia/0000-0003-2741-1427	Spain Ministry of Science and Innovation [BFU2009-08346, BFU2008-0062, SAF2007-63193, BFU2009-07835, BFU2007-61855, BFU2008-04425]; Consolider-Ingenio [CSD2008-00005, CSD2007-00002]; la Generalitat Valenciana [Prometeo/2010/046]; Consejo Superior de Investigaciones Cientificas [2009-20I098]	Spain Ministry of Science and Innovation(Spanish Government); Consolider-Ingenio(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); la Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)); Consejo Superior de Investigaciones Cientificas	The authors thank David Julius (University of California, San Francisco, USA) for providing rat TRPV1 cDNA, Ramon Latorre (Centro de Neurociencias de Valparaiso, Valparaiso, Chile) for rat HEK-TRPM8 cells, Ardem Patapoutian (Institute for Childhood and Neglected Diseases, La Jolla, CA, USA) for mouse CHO-TRPA1 cells, Johanna Lilja and Anna Forsby (University of Stockholm, Stockholm, Sweden) for rat SH-SY5Y-TRPV1 cells, and Ainara Lopez for testing the acetylated TRP-p5 peptide. This work was supported by Spain Ministry of Science and Innovation grants BFU2009-08346 to A. F.-M., BFU2008-0062 to J.M.G.R., SAF2007-63193 to R. P.-C., BFU2009-07835 to A. G., BFU2007-61855 to F. V., and BFU2008-04425 to C. B.; Consolider-Ingenio 2010 CSD2008-00005 to A. F.-M., J.M.G.-R., and R. P.-C., and CSD2007-00002 to A. G., F. V., and C. B.; la Generalitat Valenciana Prometeo/2010/046 to A. F.-M., F. V., and C. B.; and Intramural (Consejo Superior de Investigaciones Cientificas) Ref. 2009-20I098 to A. G. Author contributions: P. V., A. F.-C., S. Q., A. G., and M. C. performed the experiments; G.F.-B. carried out the molecular modeling; F. V., J.M., G. R, C. B., and R. P. contributed to discussion, data analysis, and writing of the paper; and A. F.-M. designed the experiments, analyzed the data, and wrote the paper.	Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Bautista DM, 2005, P NATL ACAD SCI USA, V102, P12248, DOI 10.1073/pnas.0505356102; Blanes-Mira C, 2004, J NEUROCHEM, V88, P124, DOI 10.1046/j.1471-4159.2003.02133.x; Brauchi S, 2006, J NEUROSCI, V26, P4835, DOI 10.1523/JNEUROSCI.5080-05.2006; Brauchi S, 2007, P NATL ACAD SCI USA, V104, P10246, DOI 10.1073/pnas.0703420104; Camprubi-Robles M, 2009, FASEB J, V23, P3722, DOI 10.1096/fj.09-134346; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Choveau FS, 2011, J BIOL CHEM, V286, P707, DOI 10.1074/jbc.M110.146324; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Cortright DN, 2009, CURR PHARM DESIGN, V15, P1736, DOI 10.2174/138161209788186308; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Fajardo O, 2008, J NEUROSCI, V28, P7863, DOI 10.1523/JNEUROSCI.1696-08.2008; Fajardo O, 2008, CHANNELS, V2, P429, DOI 10.4161/chan.2.6.7126; Fernandez-Ballester G, 2008, J MEMBRANE BIOL, V223, P161, DOI 10.1007/s00232-008-9123-7; Garcia-Martinez C, 2002, P NATL ACAD SCI USA, V99, P2374, DOI 10.1073/pnas.022285899; Garcia-Martinez C, 2006, J PAIN, V7, P735, DOI 10.1016/j.jpain.2006.03.008; Garcia-Sanz N, 2004, J NEUROSCI, V24, P5307, DOI 10.1523/JNEUROSCI.0202-04.2004; Garcia-Sanz N, 2007, J NEUROSCI, V27, P11641, DOI 10.1523/JNEUROSCI.2457-07.2007; Gavva NR, 2008, PAIN, V136, P202, DOI 10.1016/j.pain.2008.01.024; Gomis A, 2004, ARTHRITIS RHEUM-US, V50, P314, DOI 10.1002/art.11421; Gomis A, 2007, PAIN, V130, P126, DOI 10.1016/j.pain.2006.11.012; Karashima Y, 2009, P NATL ACAD SCI USA, V106, P1273, DOI 10.1073/pnas.0808487106; Khairatkar-Joshi N, 2009, TRENDS MOL MED, V15, P14, DOI 10.1016/j.molmed.2008.11.004; Kuliopulos A, 2003, LIFE SCI, V74, P255, DOI 10.1016/j.lfs.2003.09.012; Latorre R, 2007, CELL CALCIUM, V42, P427, DOI 10.1016/j.ceca.2007.04.004; Lilja J, 2007, J NEUROSCI RES, V85, P1413, DOI 10.1002/jnr.21255; McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104; Meseguer V, 2008, J NEUROSCI, V28, P576, DOI 10.1523/JNEUROSCI.4772-07.2008; Messeguer A, 2006, CURR NEUROPHARMACOL, V4, P1, DOI 10.2174/157015906775202995; Montell C, 2007, CURR BIOL, V17, pR885, DOI 10.1016/j.cub.2007.08.016; Petho G, 2004, PAIN, V109, P284, DOI 10.1016/j.pain.2004.01.038; Salazar H, 2009, NAT STRUCT MOL BIOL, V16, P704, DOI 10.1038/nsmb.1633; Sherkheli MA, 2008, PAK J PHARM SCI, V21, P370; Siemens J, 2006, NATURE, V444, P208, DOI 10.1038/nature05285; Valente P, 2008, FASEB J, V22, P3298, DOI 10.1096/fj.08-107425; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Vennekens R, 2008, CURR PHARM DESIGN, V14, P18; Viana F, 2009, EXPERT OPIN THER PAT, V19, P1787, DOI 10.1517/13543770903393771; Yang E, 2009, CANCER RES, V69, P6223, DOI 10.1158/0008-5472.CAN-09-0187; Yao J, 2009, PLOS BIOL, V7, P350, DOI 10.1371/journal.pbio.1000046; Zhang XM, 2008, NEURON, V59, P450, DOI 10.1016/j.neuron.2008.05.015	42	28	29	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1628	1640		10.1096/fj.10-174433	http://dx.doi.org/10.1096/fj.10-174433			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21307333	Green Submitted			2022-12-28	WOS:000290023800020
J	Grubb, DR; Iliades, P; Cooley, N; Yu, YL; Luo, JT; Filtz, TM; Woodcock, EA				Grubb, David R.; Iliades, Peter; Cooley, Nicola; Yu, Yen Lin; Luo, Jieting; Filtz, Theresa M.; Woodcock, Elizabeth A.			Phospholipase C beta 1b associates with a Shank3 complex at the cardiac sarcolemma	FASEB JOURNAL			English	Article						compartmentalized signaling; alpha-fodrin; light membrane rafts; proline-rich domain; SH3 domain	NEONATAL-RAT CARDIOMYOCYTES; SCAFFOLDING PROTEIN SHANK3; B-SPLICE VARIANT; POSTSYNAPTIC DENSITY; PARATHYROID-HORMONE; C-BETA; RECEPTOR; FAMILY; MUTATIONS; DOMAIN	Activation of the heterotrimeric G protein Gq causes cardiomyocyte hypertrophy in vivo and in cell models. Our previous studies have shown that responses to activated Gq in cardiomyocytes are mediated exclusively by phospholipase C beta 1b (PLC beta 1b), because only this PLC beta subtype localizes at the cardiac sarcolemma. In the current study, we investigated the proteins involved in targeting PLC beta 1b to the sarcolemma in neonatal rat cardiomyocytes. PLC beta 1b, but not PLC beta 1a, coimmunoprecipitated with the high-MW scaffolding protein SH3 and ankyrin repeat protein 3 (Shank3), as well as the known Shank3-interacting protein alpha-fodrin. The 32-aa splice-variant-specific C-terminal tail of PLC beta 1b also associated with Shank3 and alpha-fodrin, indicating that PLC beta 1b binds via the C-terminal sequence. Shank3 colocalized with PLC beta 1b at the sarcolemma, and both proteins were enriched in the light membrane fractions. Knockdown of Shank3 using siRNA reduced PLC activation and downstream hypertrophic responses, demonstrating the importance of sarcolemmal localization for PLC signaling. These data indicate that PLC beta 1b associates with a Shank3 complex at the cardiac sarcolemma via its splice-variant-specific C-terminal tail. Sarcolemmmal localization is central to PLC activation and subsequent downstream signaling following Gq-coupled receptor activation.-Grubb, D. R., Iliades, P., Cooley, N., Yu, Y. L., Luo, J., Filtz, T. M., Woodcock, E. A. Phospholipase C beta 1b associates with a Shank3 complex at the cardiac sarcolemma. FASEB J. 25, 1040-1047 (2011). www.fasebj.org	[Grubb, David R.; Iliades, Peter; Cooley, Nicola; Yu, Yen Lin; Luo, Jieting; Woodcock, Elizabeth A.] Baker Int Diabet Inst IDI, Heart & Diabet Inst, Melbourne, Vic 3004, Australia; [Filtz, Theresa M.] Oregon State Univ, Dept Pharmaceut Sci, Corvallis, OR 97331 USA	Oregon State University	Woodcock, EA (corresponding author), Baker Int Diabet Inst IDI, Heart & Diabet Inst, 75 Commercial Rd, Melbourne, Vic 3004, Australia.	liz.woodcock@bakeridi.edu.au		Filtz, Theresa/0000-0002-5348-1114	National Health and Medical Research Council (NHMRC) of Australia [526621, 526623]; Australian National Heart Foundation [GM08-3695]	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian National Heart Foundation(National Heart Foundation of Australia)	This work was supported by grants in aid from the National Health and Medical Research Council (NHMRC) of Australia (526621 and 526623), as well as the Australian National Heart Foundation (GM08-3695). E.A.W. is a Principal Research Fellow of the NHMRC (586621).	Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Arthur JF, 2001, J BIOL CHEM, V276, P37341, DOI 10.1074/jbc.M106572200; BAHK YY, 1994, J BIOL CHEM, V269, P8240; Beri S, 2007, J NEUROCHEM, V101, P1380, DOI 10.1111/j.1471-4159.2007.04539.x; Bertaso F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009755; Bockers TM, 2001, J BIOL CHEM, V276, P40104, DOI 10.1074/jbc.M102454200; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Cai Y, 2005, ONCOGENE, V24, P4293, DOI 10.1038/sj.onc.1208593; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933; Filtz TM, 2009, FASEB J, V23, P3564, DOI 10.1096/fj.09-133983; Gauthier J, 2010, P NATL ACAD SCI USA, V107, P7863, DOI 10.1073/pnas.0906232107; Grubb DR, 2008, FASEB J, V22, P2768, DOI 10.1096/fj.07-102558; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Hwang JI, 2005, J BIOL CHEM, V280, P12467, DOI 10.1074/jbc.M410740200; Kaneko T, 2008, FRONT BIOSCI-LANDMRK, V13, P4938, DOI 10.2741/3053; Kreienkamp H-J., 2008, V186, P365, DOI 10.1007/978-3-540-72843-6_15; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Mahon MJ, 2004, J BIOL CHEM, V279, P23550, DOI 10.1074/jbc.M313229200; Moessner R, 2007, AM J HUM GENET, V81, P1289, DOI 10.1086/522590; Morris JB, 2006, J MOL CELL CARDIOL, V41, P17, DOI 10.1016/j.yjmcc.2006.03.011; Olson PA, 2005, J NEUROSCI, V25, P1050, DOI 10.1523/JNEUROSCI.3327-04.2005; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pham TM, 2003, J MOL CELL CARDIOL, V35, P287, DOI 10.1016/S0022-2828(03)00009-9; Saavedra MV, 2008, NEUROREPORT, V19, P1123, DOI 10.1097/WNR.0b013e3283086797; Schlundt A, 2009, MOL CELL PROTEOMICS, V8, P2474, DOI 10.1074/mcp.M800337-MCP200; Schotten U, 2003, PROG BIOPHYS MOL BIO, V82, P151, DOI 10.1016/S0079-6107(03)00012-9; Schuetz G, 2004, J CELL BIOL, V167, P945, DOI 10.1083/jcb.200404108; Sheng M, 2000, J CELL SCI, V113, P1851; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Sun C, 2005, J PEPT RES, V65, P411, DOI 10.1111/j.1399-3011.2005.00240.x; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Woodcock EA, 2009, J MOL CELL CARDIOL, V47, P676, DOI 10.1016/j.yjmcc.2009.08.020; Zhang W, 2006, J BIOL CHEM, V281, P5811, DOI 10.1074/jbc.M507871200	36	22	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1040	1047		10.1096/fj.10-171470	http://dx.doi.org/10.1096/fj.10-171470			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21148417				2022-12-28	WOS:000287806200023
J	Jin, DZ; Guo, H; Bu, SY; Zhang, YY; Hannaford, J; Mashek, DG; Chen, XL				Jin, Daozhong; Guo, Hong; Bu, So Young; Zhang, Yuanyuan; Hannaford, Jennifer; Mashek, Douglas G.; Chen, Xiaoli			Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure	FASEB JOURNAL			English	Article						rosiglitazone; brown adipose tissue; thermogenesis; insulin sensitization	BROWN ADIPOCYTE DIFFERENTIATION; INDUCED INSULIN-RESISTANCE; TYPE-2 DIABETIC-PATIENTS; ADIPOSE-TISSUE; THIAZOLIDINEDIONES; ROSIGLITAZONE; PIOGLITAZONE; OBESITY; FAT; GLYCERONEOGENESIS	We have previously identified lipocalin 2 (Lcn2) as a cytokine playing a critical role in the regulation of body fat mass, lipid metabolism, and insulin resistance. Lcn2 deficiency reduces PPAR gamma gene expression in adipocytes. In this study, we investigated the role of Lcn2 in PPAR gamma activation and function via assessing the insulin sensitization and fatty acid (FA) homeostasis of PPAR gamma agonist in high-fat diet (HFD)-induced obesity in Lcn2(-/-) mice. We found that rosiglitazone (Rosi) significantly improved insulin sensitivity in Lcn2(-/-) mice as effectively as in wild-type (WT) mice; unfed-state levels of blood glucose, free FAs, and triglycerides (TGs) were significantly reduced after a 25-d treatment of Rosi in Lcn2(-/-) mice. However, Rosi action on fat deposition and FA homeostasis was altered; Rosi-induced body weight and subcutaneous fat gain and liver lipid accumulation were markedly lessened in Lcn2(-/-) mice. The results of in vivo metabolic labeling showed that Rosi markedly reduced de novo lipogenesis in adipose tissue of Lcn2(-/-) mice. In brown adipose tissue (BAT), the expression of the genes functioning in TG hydrolysis and mitochondrial oxidation was up-regulated more in Lcn2(-/-) than in WT mice. Most strikingly, Rosi stimulated significantly higher levels of uncoupling protein-1 expression in BAT, and completely rescued cold intolerance in Lcn2(-/-) mice. We demonstrate that Lcn2 is a critical selective modulator of PPAR gamma activation and function in lipid homeostasis and energy expenditure.-Jin, D., Guo, H., Bu, Y. S., Zhang, Y., Hannaford, J., Mashek, D. G., Chen, X. Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure. FASEB J. 25, 754-764 (2011). www.fasebj.org	[Jin, Daozhong; Guo, Hong; Bu, So Young; Zhang, Yuanyuan; Hannaford, Jennifer; Mashek, Douglas G.; Chen, Xiaoli] Univ Minnesota Twin Cities, Dept Food Sci & Nutr, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Chen, XL (corresponding author), Univ Minnesota Twin Cities, Dept Food Sci & Nutr, St Paul, MN 55108 USA.	xlchen@umn.edu	Mashek, Douglas/ABD-6844-2021; Zhang, Yuanyuan/M-9602-2014	Zhang, Yuanyuan/0000-0002-5894-5387; Mashek, Douglas/0000-0001-7033-3386	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK080743]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080743] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The project described was supported by grant R01DK080743 (to X. C.) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK or the National Institutes of Health. The authors thank Wendy Wright for assistance in mouse breeding and colony maintenance and Dr. David A. Bernlohr (Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota) for providing the critical comments on the manuscript.	Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P1, DOI 10.1016/S0167-4838(00)00137-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boden G, 2005, DIABETES, V54, P880, DOI 10.2337/diabetes.54.3.880; Burkey BF, 2000, METABOLISM, V49, P1301, DOI 10.1053/meta.2000.9524; Cadoudal T, 2007, DIABETOLOGIA, V50, P666, DOI 10.1007/s00125-006-0560-5; Camirand A, 1998, ENDOCRINOLOGY, V139, P428, DOI 10.1210/en.139.1.428; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; DIETSCHY JM, 1984, J LIPID RES, V25, P1469; Fukui Y, 2000, DIABETES, V49, P759, DOI 10.2337/diabetes.49.5.759; Gastaldelli A, 2006, J CLIN ENDOCR METAB, V91, P806, DOI 10.1210/jc.2005-1159; Gregoire FM, 2009, MOL ENDOCRINOL, V23, P975, DOI 10.1210/me.2008-0473; Guan YF, 2005, NAT MED, V11, P861, DOI 10.1038/nm1278; Guo H, 2010, DIABETES, V59, pA370; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Kohlroser J, 2000, AM J GASTROENTEROL, V95, P272; Koliwad SK, 2010, J CLIN INVEST, V120, P756, DOI 10.1172/JCI36066; Kramer D, 2001, METABOLISM, V50, P1294, DOI 10.1053/meta.2001.27202; Laplante M, 2006, DIABETES, V55, P2771, DOI 10.2337/db06-0551; Lessard SJ, 2007, DIABETES, V56, P1856, DOI 10.2337/db06-1065; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Matsuda J, 1998, DIABETES, V47, pA431; Miyazaki Y, 2001, DIABETES CARE, V24, P710, DOI 10.2337/diacare.24.4.710; Miyazaki Y, 2001, DIABETOLOGIA, V44, pA37; Mori Y, 1999, DIABETES CARE, V22, P908, DOI 10.2337/diacare.22.6.908; Rabelo R, 1997, ENDOCRINOLOGY, V138, P5325, DOI 10.1210/en.138.12.5325; Ranganathan G, 2006, J LIPID RES, V47, P2444, DOI 10.1194/jlr.M600248-JLR200; Reginato MJ, 1998, J BIOL CHEM, V273, P32679, DOI 10.1074/jbc.273.49.32679; Rennings AJM, 2006, DIABETES CARE, V29, P581, DOI 10.2337/diacare.29.03.06.dc05-01467; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Smith SR, 2005, METABOLISM, V54, P24, DOI 10.1016/j.metabol.2004.07.008; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; Tan BK, 2009, DIABETES CARE, V32, P129, DOI 10.2337/dc08-1236; Tordjman J, 2003, J BIOL CHEM, V278, P18785, DOI 10.1074/jbc.M206999200; WEBER TM, 1988, INSULIN RECEPTOR; Xiang CC, 2007, DIABETOLOGIA, V50, P1070, DOI 10.1007/s00125-007-0626-z; Yan QW, 2007, DIABETES, V56, P2533, DOI 10.2337/db07-0007; Zhang JH, 2008, MOL ENDOCRINOL, V22, P1416, DOI 10.1210/me.2007-0420	38	66	68	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					754	764		10.1096/fj.10-165175	http://dx.doi.org/10.1096/fj.10-165175			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20974668	Green Published			2022-12-28	WOS:000286724800032
J	Maldonado-Perez, D; Golightly, E; Denison, FC; Jabbour, HN; Norman, JE				Maldonado-Perez, David; Golightly, Ellen; Denison, Fiona C.; Jabbour, Henry N.; Norman, Jane E.			A role for lipoxin A(4) as anti-inflammatory and proresolution mediator in human parturition	FASEB JOURNAL			English	Article						labor; lipoxin receptor; myometrium; inflammation; proinflammatory cytokines	GENE-EXPRESSION; LIPID MEDIATORS; FETAL MEMBRANES; HUMAN-PREGNANCY; PRETERM LABOR; KAPPA-B; INFLAMMATION; MYOMETRIUM; LEUKOCYTES; RECEPTOR	The purpose of this study was to investigate the role of lipoxin A(4), an anti-inflammatory and proresolution modulator, during human parturition. We measured serum levels of lipoxin A(4) and myometrial protein release using ELISA, quantified lipoxin receptor (FPR2/ALX) mRNA expression using qRT-PCR, and localized protein expression using immuno-histochemstry in myometrial biopsies from pregnant women. In addition, we compared the effects of lipoxin A(4) (100 nM) with vehicle on basal and LPS-stimulated expression of proinflammatory cytokines from samples of myometrium from pregnant women. Mean +/- SE circulating level of lipoxin A(4) was 5.89 +/- 0.63 nM at 24-wk gestation, with a further modest increase during pregnancy (P<0.05), but no differences in gestation matched women before and after labor (P>0.05). Levels of lipoxin A(4) in nonpregnant women were 0.48 +/- 0.04 nM, significantly lower than in pregnant women (P<0.001). FPR2/ALX localized to myocytes and neutrophils, with a 9-fold increase in mRNA expression in labor (P<0.001). Lipoxin A(4) significantly reduced LPS-induced but not basal expression of the proinflammatory cytokines IL-6 and IL-8 in cultured myometrium (P<0.05), compared to vehicle-treated controls. We demonstrate for the first time a potential role for lipoxin A(4) and its receptor in the resolution of the inflammatory events of both physiological and pathological labor.-Maldonado-Perez, D., Golightly, E., Denison, F. C., Jabbour, H. N., Norman, J. E. A role for lipoxin A(4) as anti-inflammatory and proresolution mediator in human parturition. FASEB J. 25, 569-575 (2011). www.fasebj.org	[Norman, Jane E.] Univ Edinburgh, Div Reprod & Dev Sci, Ctr Reprod Biol, Edinburgh EH16 4TJ, Midlothian, Scotland; [Jabbour, Henry N.] Queens Med Res Inst, MRC, Human Reprod Sci Unit, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Norman, JE (corresponding author), Univ Edinburgh, Div Reprod & Dev Sci, Ctr Reprod Biol, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	jane.norman@ed.ac.uk	Norman, Jane/B-2347-2010	Norman, Jane/0000-0001-6031-6953; Denison, Fiona/0000-0003-0371-2014	Piggy Bank Kids; Medical Research Council [MC_U127684438, G1002033] Funding Source: researchfish; MRC [G1002033, MC_U127684438] Funding Source: UKRI	Piggy Bank Kids; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Zillah Jones for her help in collecting tissue samples, Linnea Anderson for help in sample preparation, and Ryan Wong for technical support. This work was supported by Piggy Bank Kids.	Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; Decker Y, 2009, AM J PHYSIOL-CELL PH, V296, pC1420, DOI 10.1152/ajpcell.00380.2008; Evans J, 2008, ENDOCRINOLOGY, V149, P2877, DOI 10.1210/en.2007-1633; Haddad R, 2006, AM J OBSTET GYNECOL, V195, P822, DOI 10.1016/j.ajog.2006.06.053; Jabbour HN, 2009, REPRODUCTION, V138, P903, DOI 10.1530/REP-09-0247; Jozsef L, 2002, P NATL ACAD SCI USA, V99, P13266, DOI 10.1073/pnas.202296999; Lirussi F, 2008, BIOL REPROD, V78, P497, DOI 10.1095/biolreprod.107.064444; Maderna P, 2010, FASEB J, V24, P4240, DOI 10.1096/fj.10-159913; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Osman I, 2003, MOL HUM REPROD, V9, P41, DOI 10.1093/molehr/gag001; Pirianov G, 2009, ENDOCRINOLOGY, V150, P699, DOI 10.1210/en.2008-1178; Reville K, 2006, J IMMUNOL, V176, P1878, DOI 10.4049/jimmunol.176.3.1878; ROMERO R, 1992, AM J OBSTET GYNECOL, V167, P1041, DOI 10.1016/S0002-9378(12)80035-4; Romero R, 2007, SEMIN REPROD MED, V25, P21, DOI 10.1055/s-2006-956773; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Sehringer B, 2000, J CLIN ENDOCR METAB, V85, P4859, DOI 10.1210/jc.85.12.4859; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002; Smith GCS, 2001, MOL HUM REPROD, V7, P587, DOI 10.1093/molehr/7.6.587; Starosta V, 2008, J IMMUNOL, V181, P8688, DOI 10.4049/jimmunol.181.12.8688; Telfer JF, 1997, HUM REPROD, V12, P2306, DOI 10.1093/humrep/12.10.2306; Terrone DA, 2001, OBSTET GYNECOL, V98, P476, DOI 10.1016/S0029-7844(01)01424-7; Thomson AJ, 1999, HUM REPROD, V14, P229, DOI 10.1093/humrep/14.1.229; Wu SH, 2008, INFLAMM RES, V57, P430, DOI 10.1007/s00011-008-7147-1; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Yuan M, 2009, MOL HUM REPROD, V15, P713, DOI 10.1093/molehr/gap054	26	37	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2011	25	2					569	575		10.1096/fj.10-170340	http://dx.doi.org/10.1096/fj.10-170340			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20959513				2022-12-28	WOS:000286724800015
J	Schaefer, JS; Klein, JR				Schaefer, Jeremy S.; Klein, John R.			Immunological regulation of metabolism-a novel quintessential role for the immune system in health and disease	FASEB JOURNAL			English	Article						immune-endocrine; infection; innate immunity; thyroid	THYROID-STIMULATING HORMONE; T-CELL DEVELOPMENT; BONE-MARROW-CELLS; VIRUS-INFECTION; BETA-SUBUNIT; DENDRITIC CELLS; THYROTROPIN; TSH; INVOLVEMENT; DYSFUNCTION	The hypothalamus-pituitary-thyroid (HPT) axis is an integrated hormone network that is essential for maintaining metabolic homeostasis. It has long been known that thyroid stimulating hormone (TSH), a central component of the HPT axis, can be made by cells of the immune system; however, the role of immune system TSH remains enigmatic and most studies have viewed it as a cytokine used to regulate immune function. Recent studies now indicate that immune system-derived TSH, in particular, a splice variant of TSH beta that is preferentially made by cells of the immune system, is produced by a subset of hematopoietic cells that traffic to the thyroid. On the basis of these and other findings, we propose the novel hypothesis that the immune system is an active participant in the regulation of basal metabolism. We further speculate that this process plays a critical role during acute and chronic infections and that it contributes to a wide range of chronic inflammatory conditions with links to thyroid dysregulation. This hypothesis, which is amenable to empirical analysis, defines a previously unknown role for the immune system in health and disease, and it provides a dynamic connection between immune-endocrine interactions at the organismic level.-Schaefer, J. S., Klein, J. R. Immunological regulation of metabolism-a novel quintessential role for the immune system in health and disease. FASEB J. 25, 29-34 (2011). www.fasebj.org	[Schaefer, Jeremy S.; Klein, John R.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost Sci, Dent Branch, Houston, TX 77054 USA	University of Texas System; University of Texas Health Science Center Houston	Klein, JR (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Diagnost Sci, Dent Branch, BBSB,Rm 5813,1941 East Rd, Houston, TX 77054 USA.	john.r.klein@uth.tmc.edu			National Institutes of Health [DK035566]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK035566, R01DK035566] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grant DK035566. The authors are grateful to Dina Montufar-Solis for expert technical assistance.	Bagriacik EU, 2001, CELL IMMUNOL, V212, P92, DOI 10.1006/cimm.2001.1846; Bagriacik EU, 2000, J IMMUNOL, V164, P6158, DOI 10.4049/jimmunol.164.12.6158; BIANCHI GP, 1995, ITAL J GASTROENTEROL, V27, P291; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V125, P30, DOI 10.1016/S0006-291X(84)80329-0; Camargo R, 2001, THYROID, V11, P981, DOI 10.1089/105072501753211073; Campos-Rodriguez R, 2006, INFECT IMMUN, V74, P1883, DOI 10.1128/IAI.74.3.1883-1889.2006; Collins J, 2002, EUR J NUCL MED MOL I, V29, pS417, DOI 10.1007/s00259-002-0848-8; Costa LP, 2009, J AUTOIMMUN, V33, P121, DOI 10.1016/j.jaut.2009.04.001; Dall'Asta C, 2010, OBESITY, V18, P854, DOI 10.1038/oby.2009.320; Douglas R. S., J CLIN ENDOCRINOL ME, V95, P430; Eldar-Geva T, 2007, GYNECOL ENDOCRINOL, V23, P332, DOI 10.1080/09513590701267651; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Gul U, 2009, EUR J DERMATOL, V19, P221, DOI 10.1684/ejd.2009.0632; HARBOUR DV, 1989, MOL CELL ENDOCRINOL, V64, P229, DOI 10.1016/0303-7207(89)90150-0; HARBOUR DV, 1991, CIRC SHOCK, V35, P181; Klein JR, 2004, J EXP BIOL, V207, P55, DOI 10.1242/jeb.00710; KRUGER TE, 1986, J IMMUNOL, V137, P197; KRUGER TE, 1989, J IMMUNOL, V142, P744; Laghi F, 2009, EUR RESPIR J, V34, P975, DOI 10.1183/09031936.00103708; Lodha R, 2007, ACTA PAEDIATR, V96, P406, DOI 10.1111/j.1651-2227.2007.00135.x; Mader R, 2007, CLIN RHEUMATOL, V26, P1891, DOI 10.1007/s10067-007-0602-5; Maksymowych WP, 2009, CLIN EXP RHEUMATOL, V27, pS20; Manzolli S, 1999, J ALLERGY CLIN IMMUN, V104, P595, DOI 10.1016/S0091-6749(99)70329-5; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; Mazziotti G, 2010, BONE, V46, P747, DOI 10.1016/j.bone.2009.10.031; Mooij P, 1992, Thyroidology, V4, P45; Nolan K A, 1992, Clin Geriatr Med, V8, P19; Salmaso C, 2002, ANN NY ACAD SCI, V966, P496, DOI 10.1111/j.1749-6632.2002.tb04253.x; Schaefer JS, 2009, GEN COMP ENDOCR, V162, P241, DOI 10.1016/j.ygcen.2009.04.006; Scofield VL, 2005, IMMUNOL LETT, V99, P36, DOI 10.1016/j.imlet.2004.12.010; Silveira MG, 2009, LIVER INT, V29, P1094, DOI 10.1111/j.1478-3231.2009.02003.x; SMITH EM, 1983, P NATL ACAD SCI-BIOL, V80, P6010, DOI 10.1073/pnas.80.19.6010; Suzuki C, 2009, ENDOCRINOLOGY, V150, P2237, DOI 10.1210/en.2008-0823; Vaccaro M, 2002, THYROID, V12, P1147, DOI 10.1089/105072502321085261; Varghese S, 2008, J CELL BIOCHEM, V105, P271, DOI 10.1002/jcb.21825; Vincent BH, 2009, GENES IMMUN, V10, P18, DOI 10.1038/gene.2008.69; Wang HC, 2003, BLOOD, V101, P119, DOI 10.1182/blood-2002-02-0544; WANG J, 1994, SCIENCE, V265, P1860, DOI 10.1126/science.8091211; Wang J, 1997, SCIENCE, V275, P1937, DOI 10.1126/science.275.5308.1937; WANG J, 1995, CELL IMMUNOL, V161, P299, DOI 10.1006/cimm.1995.1040; Whetsell M, 1999, CELL IMMUNOL, V192, P159, DOI 10.1006/cimm.1998.1444	41	18	19	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					29	34		10.1096/fj.10-168203	http://dx.doi.org/10.1096/fj.10-168203			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20826543	Green Published			2022-12-28	WOS:000285869500003
J	Wool, GD; Cabana, VG; Lukens, J; Shaw, PX; Binder, CJ; Witztum, JL; Reardon, CA; Getz, GS				Wool, Geoffrey D.; Cabana, Veneracion G.; Lukens, John; Shaw, Peter X.; Binder, Christoph J.; Witztum, Joseph L.; Reardon, Catherine A.; Getz, Godfrey S.			4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice	FASEB JOURNAL			English	Article						mimetic; apoA-I; oxidation; innate immunity; E06/T15	I-MIMETIC PEPTIDE; HIGH-DENSITY-LIPOPROTEIN; REVERSE CHOLESTEROL TRANSPORT; OXIDATION-SPECIFIC EPITOPES; A-I; OXIDIZED LDL; APOA-I; DEFICIENT MICE; HDL; D-4F	Our objective was to contrast the effect of apolipoprotein (apo) A-I mimetic peptides, such as 4F and 4F-Pro-4F (Pro), on nascent and mature atherosclerotic lesions and on levels of antibodies against oxidation-specific epitopes. Chow-fed apoE(-/-) mice were injected intraperitoneally with either the 4F peptide or a tandem helix apoA-I mimetic peptide (Pro) every other day. Mice treated with 4F, but not Pro, for 4 wk starting at 10 wk of age showed a dramatic decrease in atherosclerosis at 2 arterial sites. However, neither peptide was effective in mice treated for 8 wk starting at 20 wk of age; lesions were larger and more mature at this time point. Peptide treatment caused increased production of antibodies against oxidation-specific epitopes, including a disproportionate induction of the IgM natural antibody (NAb) E06/T15 to oxidized phospholipids. In summary, 4F, but not the tandem peptide Pro, effectively inhibited early atherogenesis but was ineffective against more mature lesions. Two different apoA-I mimetic peptides increased titers of natural antibodies against oxidation-specific epitopes.-Wool, G. D., Cabana, V. G., Lukens, J., Shaw, P. X., Binder, C. J., Witztum, J. L., Reardon, C. A., Getz, G. S. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J. 25, 290-300 (2011). www.fasebj.org	[Wool, Geoffrey D.; Cabana, Veneracion G.; Lukens, John; Reardon, Catherine A.; Getz, Godfrey S.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Shaw, Peter X.; Witztum, Joseph L.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Binder, Christoph J.] Austrian Acad Sci, CeMM, A-1010 Vienna, Austria; [Binder, Christoph J.] Med Univ Vienna, Dept Lab Med, Vienna, Austria	University of Chicago; University of California System; University of California San Diego; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna	Getz, GS (corresponding author), 5841 S Maryland Ave,MC1089, Chicago, IL 60637 USA.	g-getz@uchicago.edu		Binder, Christoph J./0000-0001-8313-7050; Wool, Geoffrey/0000-0002-3335-2905	U.S. National Institutes of Health/National Heart, Lung, and Blood Institute [HL68661]; Foundation Leducq; National Institute of Child Health and Human Development [HD007009]; Francis L. Lederer Foundation; American Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068661] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Foundation Leducq(Leducq Foundation); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Francis L. Lederer Foundation; American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the U.S. National Institutes of Health/National Heart, Lung, and Blood Institute (HL68661 to GSG) and the Foundation Leducq (to G.S.G., C.J.B., and J.L.W.). G.D.W. has received support from the National Institute of Child Health and Human Development (HD007009 Graduate Training in Growth and Development), the Francis L. Lederer Foundation Scholarship Fund, and an American Heart Association predoctoral fellowship. J.L.W. is named as inventor in patents and patent applications from the University of California-San Diego for the potential commercial use of antibodies to oxidized LDL.	Barral P, 2008, P NATL ACAD SCI USA, V105, P8345, DOI 10.1073/pnas.0802968105; Binder CJ, 2004, J CLIN INVEST, V114, P427, DOI 10.1172/jci200420479; Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876; Bloedon LT, 2008, J LIPID RES, V49, P1344, DOI 10.1194/jlr.P800003-JLR200; Cabana VG, 1996, J LIPID RES, V37, P2662; Caligiuri G, 2007, J AM COLL CARDIOL, V50, P540, DOI 10.1016/j.jacc.2006.11.054; Carnemolla R, 2008, J BIOL CHEM, V283, P15779, DOI 10.1074/jbc.M710244200; Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x; Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800; DANNER D, 1985, P NATL ACAD SCI USA, V82, P8658, DOI 10.1073/pnas.82.24.8658; Duffy D, 2009, NAT REV CARDIOL, V6, P455, DOI 10.1038/nrcardio.2009.94; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; Garber DW, 2001, J LIPID RES, V42, P545; Getz GS, 2009, CURR OPIN LIPIDOL, V20, P171, DOI 10.1097/MOL.0b013e32832ac051; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Kontush A, 2006, PHARMACOL REV, V58, P342, DOI 10.1124/pr.58.3.1; Li XJ, 2004, CIRCULATION, V110, P1701, DOI 10.1161/01.CIR.0000142857.79401.69; Nanjee MN, 2001, J LIPID RES, V42, P1586; Navab M, 2000, J LIPID RES, V41, P1481; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1426, DOI 10.1161/01.ATV.0000167412.98221.1a; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1325, DOI 10.1161/01.ATV.0000165694.39518.95; Navab M, 2004, CIRCULATION, V109, P3215, DOI 10.1161/01.CIR.0000134275.90823.87; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; Navab M, 2010, ARTERIOSCL THROM VAS, V30, P164, DOI 10.1161/ATVBAHA.109.187518; Ou JS, 2005, CIRC RES, V97, P1190, DOI 10.1161/01.RES.0000190634.60042.cb; PALINSKI W, 1995, P NATL ACAD SCI USA, V92, P821, DOI 10.1073/pnas.92.3.821; Rader DJ, 2009, J LIPID RES, V50, pS189, DOI 10.1194/jlr.R800088-JLR200; Reardon CA, 2001, ARTERIOSCL THROM VAS, V21, P1011, DOI 10.1161/01.ATV.21.6.1011; Ross DA, 1998, IMMUNOL REV, V166, P143, DOI 10.1111/j.1600-065X.1998.tb01259.x; Salio M, 2010, CURR OPIN IMMUNOL, V22, P81, DOI 10.1016/j.coi.2009.12.008; Shao B, 2009, J LIPID RES, V50, P599, DOI 10.1194/jlr.E900001-JLR200; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Tsimikas S, 2001, ARTERIOSCL THROM VAS, V21, P95, DOI 10.1161/01.ATV.21.1.95; Van Lenten BJ, 2008, J LIPID RES, V49, P2302, DOI 10.1194/jlr.M800075-JLR200; Van Lenten BJ, 2007, J LIPID RES, V48, P2344, DOI 10.1194/jlr.M700138-JLR200; VanderLaan PA, 2004, ARTERIOSCL THROM VAS, V24, P12, DOI 10.1161/01.ATV.0000105054.43931.f0; VanderLaan PA, 2007, AM J PATHOL, V170, P1100, DOI 10.2353/ajpath.2007.060188; Wool GD, 2008, J LIPID RES, V49, P1268, DOI 10.1194/jlr.M700552-JLR200; Wool GD, 2009, J LIPID RES, V50, P1889, DOI 10.1194/jlr.M900151-JLR200	40	33	33	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					290	300		10.1096/fj.10-165670	http://dx.doi.org/10.1096/fj.10-165670			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20876212	Green Published			2022-12-28	WOS:000285869500026
J	Butler, JA; Ventura, N; Johnson, TE; Rea, SL				Butler, Jeffrey A.; Ventura, Natascia; Johnson, Thomas E.; Rea, Shane L.			Long-lived mitochondrial (Mit) mutants of Caenorhabditis elegans utilize a novel metabolism	FASEB JOURNAL			English	Article						aging; metabolomics; isp-1; mev-1; hif-1	SYSTEMATIC RNAI SCREEN; LIFE-SPAN; C-ELEGANS; HYPOXIA; STRESS; MODEL; INTERFERENCE; ANAEROBIOSIS; RESTRICTION; MUTATIONS	The Caenorhabditis elegans mitochondrial (Mit) mutants have disrupted mitochondrial electron transport chain (ETC) functionality, yet, surprisingly, they are long lived. We have previously proposed that Mit mutants supplement their energy needs by exploiting alternate energy production pathways normally used by wild-type animals only when exposed to hypoxic conditions. We have also proposed that longevity in the Mit mutants arises as a property of their new metabolic state. If longevity does arise as a function of metabolic state, we would expect to find a common metabolic signature among these animals. To test these predictions, we established a novel approach monitoring the C. elegans exometabolism as a surrogate marker for internal metabolic events. Using HPLC-ultraviolet-based metabolomics and multivariate analyses, we show that long-lived clk-1(qm30) and isp-1(qm150) Mit mutants have a common metabolic profile that is distinct from that of aerobically cultured wild-type animals and, unexpectedly, wild-type animals cultured under severe oxygen deprivation. Moreover, we show that 2 short-lived mitochondrial ETC mutants, mev-1(kn1) and ucr-2.3(pk732), also share a common metabolic signature that is unique. We show that removal of soluble fumarate reductase unexpectedly increases health span in several genetically defined Mit mutants, identifying at least 1 alternate energy production pathway, malate dismutation, that is operative in these animals. Our study suggests long-lived, genetically specified Mit mutants employ a novel metabolism and that life span may well arise as a function of metabolic state.-Butler, J. A., Ventura, N., Johnson, T. E., Rea, S. L. Long-lived mitochondrial (Mit) mutants of Caenorhabditis elegans utilize a novel metabolism. FASEB J. 24, 4977-4988 (2010). www.fasebj.org	[Butler, Jeffrey A.; Rea, Shane L.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA; [Butler, Jeffrey A.; Rea, Shane L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA; [Butler, Jeffrey A.; Johnson, Thomas E.; Rea, Shane L.] Univ Colorado, Inst Behav Genet, Dept Integrat Physiol, Boulder, CO 80309 USA; [Ventura, Natascia] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Colorado System; University of Colorado Boulder; University of Rome Tor Vergata	Rea, SL (corresponding author), 15355 Lambda Dr,STCBM Bldg,Rm 2-200-04,Texas Res, San Antonio, TX 78245 USA.	reas3@uthscsa.edu	Ventura, Natascia/ABF-4279-2020; Rea, Shane/F-4073-2014	ventura, natascia/0000-0001-8718-4321; /0000-0001-7147-8237	National Institute on Aging; Polis Foundation; Ellison Medical Foundation; National Ataxia Foundation	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Polis Foundation; Ellison Medical Foundation(Lawrence Ellison Foundation); National Ataxia Foundation	The authors thank Elizabeth Glasser, Justin Springett, Yvonne Penrod, and William Swan for technical assistance. The authors also thank Milena Girotti, Shylesh Bhaskaran, and Chris Link for critically reading the manuscript, as well as the anonymous reviewer who provided insightful feedback. Financial support was provided by the National Institute on Aging (to T.E.J. and S. L. R.), the Polis Foundation (to T.E.J. and S. L. R.), the Ellison Medical Foundation (to T.E.J. and S. L. R.), and the National Ataxia Foundation (to N.V.). The nematode strain GR1371 was provided by the Caenorhabditis Genetics Centre (University of Minnesota, Minneapolis, MN, USA). NL1832 was a gift from Ron Plasterk (Utrecht University, Utrecht, Holland).	Anderson LL, 2009, SCIENCE, V323, P630, DOI 10.1126/science.1166175; Burgess J, 2003, J BIOL CHEM, V278, P49555, DOI 10.1074/jbc.M308507200; Chen D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000486; Cristina D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000450; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dingley S, 2010, MITOCHONDRION, V10, P125, DOI 10.1016/j.mito.2009.11.003; Dong MQ, 2007, SCIENCE, V317, P660, DOI 10.1126/science.1139952; Enomoto K, 2002, FEMS MICROBIOL LETT, V215, P103; Falk MJ, 2008, MOL GENET METAB, V93, P388, DOI 10.1016/j.ymgme.2007.11.007; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Foll RL, 1999, COMP BIOCHEM PHYS B, V124, P269, DOI 10.1016/S0305-0491(99)00130-3; Fuchs S, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-14; Ghafouri S, 2007, NEMATOLOGY, V9, P87, DOI 10.1163/156854107779969718; Greer EL, 2009, AGING CELL, V8, P113, DOI 10.1111/j.1474-9726.2009.00459.x; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Hartman PS, 2001, MECH AGEING DEV, V122, P1187, DOI 10.1016/S0047-6374(01)00259-7; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Jazwinski SM, 2005, GENE, V354, P22, DOI 10.1016/j.gene.2005.03.040; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; LI WB, 1993, BIOCHEMISTRY-US, V32, P1833, DOI 10.1021/bi00058a018; Link CD, 2002, METHOD ENZYMOL, V353, P497; Mehta R, 2009, SCIENCE, V324, P1196, DOI 10.1126/science.1173507; Mendenhall AR, 2006, GENETICS, V174, P1173, DOI 10.1534/genetics.106.061390; Mendenhall AR, 2009, PHYSIOL GENOMICS, V36, P167, DOI 10.1152/physiolgenomics.90278.2008; Mo ML, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-37; Nomura H, 2006, J BIOCHEM, V139, P967, DOI 10.1093/jb/mvj114; Powell-Coffman JA, 2010, TRENDS ENDOCRIN MET, V21, P435, DOI 10.1016/j.tem.2010.02.006; Rea S, 2003, DEV CELL, V5, P197, DOI 10.1016/S1534-5807(03)00242-9; Rea S, 2001, FEBS LETT, V509, P389, DOI 10.1016/S0014-5793(01)03099-X; Rea SL, 2007, PLOS BIOL, V5, P2312, DOI 10.1371/journal.pbio.0050259; Rea SL, 2005, EXP GERONTOL, V40, P841, DOI 10.1016/j.exger.2005.06.015; Rea SL, 2005, NAT GENET, V37, P894, DOI 10.1038/ng1608; REA SL, 2010, DEV DISABIL IN PRESS; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Scott BA, 2002, SCIENCE, V296, P2388, DOI 10.1126/science.1072302; Senoo-Matsuda N, 2003, J BIOL CHEM, V278, P22031, DOI 10.1074/jbc.M211377200; Shen C, 2005, J BIOL CHEM, V280, P20580, DOI 10.1074/jbc.M501894200; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Van Voorhies WA, 2000, J EXP BIOL, V203, P2467; Vastenhouw NL, 2003, CURR BIOL, V13, P1311, DOI 10.1016/s0960-9822(03)00539-6; Ventura Natascia, 2007, Biotechnology Journal, V2, P584, DOI 10.1002/biot.200600248; Ventura N, 2006, EXP GERONTOL, V41, P974, DOI 10.1016/j.exger.2006.06.060; Ventura N, 2009, AGING CELL, V8, P380, DOI 10.1111/j.1474-9726.2009.00482.x; WONG A, 1995, GENETICS, V139, P1247; Wood WB, 1988, NEMATODE CAENORHABDI; Yang W, 2010, AGING CELL, V9, P433, DOI 10.1111/j.1474-9726.2010.00571.x; Zhang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006348	54	54	54	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4977	4988		10.1096/fj.10-162941	http://dx.doi.org/10.1096/fj.10-162941			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20732954	Green Published			2022-12-28	WOS:000284824400036
J	Brenkman, AB; van den Broek, NJF; de Keizer, PLJ; van Gent, DC; Burgering, BMT				Brenkman, Arjan B.; van den Broek, Niels J. F.; de Keizer, Peter L. J.; van Gent, Dik C.; Burgering, Boudewijn M. T.			The DNA damage repair protein Ku70 interacts with FOXO4 to coordinate a conserved cellular stress response	FASEB JOURNAL			English	Article						oxidative stress; p27(kip1); aging	FORKHEAD TRANSCRIPTION FACTOR; STRAND BREAK REPAIR; LIFE-SPAN; V(D)J RECOMBINATION; CAENORHABDITIS-ELEGANS; TUMOR SUPPRESSORS; OXIDATIVE STRESS; FACTOR AFX; KINASE-B; KU80	In this study, we searched for proteins regulating the tumor suppressor and life-span regulator FOXO4. Through an unbiased tandem-affinity purification strategy combined with mass spectrometry, we identified the heterodimer Ku70/Ku80 (Ku), a DNA double-strand break repair component. Using biochemical interaction studies, we found Ku70 to be necessary and sufficient for the interaction. FOXO4 mediates its tumor-suppressive function in part through transcriptional regulation of the cell cycle arrest p27(kip1) gene. Immunoblotting, luciferase reporter assays, and flow cytometry showed that Ku70 inhibited FOXO4-mediated p27(kip1) transcription and cell cycle arrest induction by >40%. In contrast, Ku70 RNAi but not control RNAi significantly increased p27(kip1) transcription. In addition, in contrast to wild-type mouse embryonic stem (ES) cells, Ku70(-/-) ES cells showed significantly increased FOXO activity, which was rescued by Ku70 reexpression. Immunofluorescence studies demonstrated that Ku70 sequestered FOXO4 in the nucleus. Interestingly, the Ku70-FOXO4 interaction stoichiometry followed a nonlinear dose-response curve by hydrogen peroxide-generated oxidative stress. Low levels of oxidative stress increased interaction stoichiometry up to 75%, peaking at 50 mu M, after which dissociation occurred. Because the Ku70 ortholog in the roundworm Caenorhabditis elegans was shown to regulate life span involving C. elegans FOXO, our findings suggest a conserved critical Ku70 role for FOXO function toward coordination of a survival program, regulated by the magnitude of oxidative damage.-Brenkman, A. B., van den Broek, N. J. F., de Keizer, P. L. J., van Gent, D. C., Burgering, B. M. T. The DNA damage repair protein Ku70 interacts with FOXO4 to coordinate a conserved cellular stress response. FASEB J. 24, 4271-4280 (2010). www.fasebj.org	[Brenkman, Arjan B.; van den Broek, Niels J. F.] Univ Med Ctr Utrecht, Dept Metab & Endocrine Dis, NL-3584 EA Utrecht, Netherlands; [Brenkman, Arjan B.; van den Broek, Niels J. F.; de Keizer, Peter L. J.; Burgering, Boudewijn M. T.] Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 EA Utrecht, Netherlands; [Brenkman, Arjan B.; van den Broek, Niels J. F.; de Keizer, Peter L. J.; Burgering, Boudewijn M. T.] Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 EA Utrecht, Netherlands; [Brenkman, Arjan B.; van den Broek, Niels J. F.] Netherlands Metabol Ctr, Utrecht, Netherlands; [van Gent, Dik C.] Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Cell Biol & Genet, Rotterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC	Brenkman, AB (corresponding author), Univ Med Ctr Utrecht, Dept Metab & Endocrine Dis, Lundlaan 6, NL-3584 EA Utrecht, Netherlands.	a.b.brenkman@umcutrecht.nl	de+Keizer, Peter/AAD-5320-2020	de+Keizer, Peter/0000-0002-6948-925X; van Gent, Dik C./0000-0003-1473-8148	European Commission [LSHC-CT-2004-503438]; Netherlands Organization for Scientific Research	European Commission(European CommissionEuropean Commission Joint Research Centre); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	A.B.B. was supported by the European Commission Transfog Consortium (LSHC-CT-2004-503438). P.L.J.D. was supported by a Netherlands Organization for Scientific Research grant to B.M.T.B. The authors thank Dr. W. W. M. Pijnappel for his help in culturing ES cells, and Dr. R. van Gent, Dr. K. Mulder, and Dr. E. Kalkhoven for their helpful discussion and critical reading of this manuscript. The authors declare no conflicts of interest.	BLIER PR, 1993, J BIOL CHEM, V268, P7594; Brenkman AB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002819; Brenkman AB, 2008, CANCER RES, V68, P7597, DOI 10.1158/0008-5472.CAN-08-1059; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Brunet A, 2007, NAT GENET, V39, P1306, DOI 10.1038/ng1107-1306; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Fiaschi T, 2006, J BIOL CHEM, V281, P22983, DOI 10.1074/jbc.M603040200; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Holcomb VB, 2007, MECH AGEING DEV, V128, P601, DOI 10.1016/j.mad.2007.08.006; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Lei H, 2009, MOL CANCER RES, V7, P1294, DOI 10.1158/1541-7786.MCR-08-0531; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Li H, 2009, ONCOGENE, V28, P1875, DOI 10.1038/onc.2009.57; Li H, 2007, MOL CELL BIOL, V27, P8205, DOI 10.1128/MCB.00785-07; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; McColl G, 2005, FASEB J, V19, P1716, DOI 10.1096/fj.04-2447fje; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Schumacher B, 2008, TRENDS GENET, V24, P77, DOI 10.1016/j.tig.2007.11.004; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; van Gent DC, 2007, ONCOGENE, V26, P7731, DOI 10.1038/sj.onc.1210871; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; Wolff S, 2006, EXP GERONTOL, V41, P894, DOI 10.1016/j.exger.2006.06.054; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451; Yamagata K, 2008, MOL CELL, V32, P221, DOI 10.1016/j.molcel.2008.09.013; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	48	30	30	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2010	24	11					4271	4280		10.1096/fj.10-158717	http://dx.doi.org/10.1096/fj.10-158717			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20570964				2022-12-28	WOS:000283861100015
J	Adinolfi, E; Cirillo, M; Woltersdorf, R; Falzoni, S; Chiozzi, P; Pellegatti, P; Callegari, MG; Sandona, D; Markwardt, F; Schmalzing, G; Di Virgilio, F				Adinolfi, Elena; Cirillo, Maria; Woltersdorf, Ronja; Falzoni, Simonetta; Chiozzi, Paola; Pellegatti, Patrizia; Callegari, Maria Giulia; Sandona, Doriana; Markwardt, Fritz; Schmalzing, Guenther; Di Virgilio, Francesco			Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor	FASEB JOURNAL			English	Article						extracellular ATP; purinergic receptors; cell growth; ion channels	P2X(7) ATP RECEPTOR; EXTRACELLULAR ATP; PLASMA-MEMBRANE; MOLECULAR PHYSIOLOGY; P-2Z RECEPTOR; CELLS; CHANNEL; PROLIFERATION; EXPRESSION; LYMPHOCYTES	P2X7 is the largest member of the P2X subfamily of purinergic receptors. A typical feature is the carboxyl tail, which allows formation of a large pore. Recently a naturally occurring truncated P2X7 splice variant, isoform B (P2X7B), has been identified. Here we show that P2X7B expression in HEK293 cells, a cell type lacking endogenous P2X receptors, mediated ATP-stimulated channel activity but not plasma membrane permeabilization, raised endoplasmic reticulum Ca(2+) content, activated the transcription factor NFATc1, increased the cellular ATP content, and stimulated growth. In addition, P2X7B-transfected HEK293 cells (HEK293-P2X7B), like most tumor cells, showed strong soft agar-infiltrating ability. When coexpressed with full-length P2X7 (P2X7A), P2X7B coassembled with P2X7A into a heterotrimer and potentiated all known responses mediated by this latter receptor. P2X7B mRNA was found to be widely distributed in human tissues, especially in the immune and nervous systems, and to a much higher level than P2X7A. Finally, P2X7B expression was increased on mitogenic stimulation of peripheral blood lymphocyte. Altogether, these data show that P2X7B is widely expressed in several human tissues, modulates P2X7A functions, participates in the control of cell growth, and may help understand the role of the P2X7 receptor in the control of normal and cancer cell proliferation.-Adinolfi, E., Cirillo, M., Woltersdorf, R., Falzoni, S., Chiozzi, P., Pellegatti, P., Callegari, M. G., Sandona, D., Markwardt, F., Schmalzing, G., Di Virgilio, F. Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J. 24, 3393-3404 (2010). www.fasebj.org	[Adinolfi, Elena; Cirillo, Maria; Falzoni, Simonetta; Chiozzi, Paola; Pellegatti, Patrizia; Callegari, Maria Giulia; Di Virgilio, Francesco] Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy; [Woltersdorf, Ronja; Schmalzing, Guenther] Rhein Westfal TH Aachen, Dept Mol Pharmacol, Aachen, Germany; [Sandona, Doriana] Univ Padua, Dept Biomed Sci, Padua, Italy; [Markwardt, Fritz] Univ Halle Wittenberg, Julius Bernstein Inst Physiol, Halle, Germany	University of Ferrara; RWTH Aachen University; University of Padua; Martin Luther University Halle Wittenberg	Di Virgilio, F (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Interdisciplinary Ctr Study Inflammat, Via L Borsari 46, I-44100 Ferrara, Italy.	fdv@unife.it	Markwardt, Fritz/F-7693-2013; Adinolfi, Elena/F-9169-2010; Pellegatti, Patrizia/A-1891-2011; DI VIRGILIO, Francesco/O-4634-2019; Di Virgilio, Francesco/J-3754-2018; sandona, dorianna/AAB-9480-2020	Markwardt, Fritz/0000-0001-6761-2923; Adinolfi, Elena/0000-0001-8129-9929; DI VIRGILIO, Francesco/0000-0003-3566-1362; Di Virgilio, Francesco/0000-0003-3566-1362; Falzoni, Simonetta/0000-0002-6594-0357; Chiozzi, Paola/0000-0003-4952-334X	Italian Association for Cancer Research [IG 5354]; Telethon of Italy [GGP06070]; Italian Space Agency (ASI-OSMA); Commission of European Communities [HEALTH-F2-2007-202231]; Regione Emilia Romagna; University of Ferrara; Deutsche Forschungsgemeinschaft [Schm536/9-1, Ma1581/15-1]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Telethon of Italy(Fondazione Telethon); Italian Space Agency (ASI-OSMA)(Agenzia Spaziale Italiana (ASI)); Commission of European Communities(European Commission); Regione Emilia Romagna(Regione Emilia Romagna); University of Ferrara; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This research was supported by grants from the Italian Association for Cancer Research (IG 5354), Telethon of Italy (GGP06070), the Italian Space Agency (ASI-OSMA), the Commission of European Communities (7th Framework Program HEALTH-F2-2007-202231), the Regione Emilia Romagna (Research Programs "Innovative Approaches to the Diagnosis of Inflammatory Diseases" and "Monitor"), the Young Researchers Project of the University of Ferrara (to E. A.), the Deutsche Forschungsgemeinschaft (Schm536/9-1 to G. S. and Ma1581/15-1 to F. M.), and institutional funds from the University of Ferrara. F. D. V. acts as consultant to Cordex Pharma Inc. and Affectis Pharma AG, biotech companies involved in the development of ATP-based drugs.	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2003, J BIOL CHEM, V278, P37344, DOI 10.1074/jbc.M301508200; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Aschrafi A, 2004, J MOL BIOL, V342, P333, DOI 10.1016/j.jmb.2004.06.092; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; Becker D, 2008, J BIOL CHEM, V283, P25725, DOI 10.1074/jbc.M803855200; Bianco F, 2006, J NEUROCHEM, V99, P745, DOI 10.1111/j.1471-4159.2006.04101.x; Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5; Cheewatrakoolpong B, 2005, BIOCHEM BIOPH RES CO, V332, P17, DOI 10.1016/j.bbrc.2005.04.087; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302-009-9145-3; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; Duckwitz W, 2006, J BIOL CHEM, V281, P39561, DOI 10.1074/jbc.M606113200; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Feng YH, 2006, J BIOL CHEM, V281, P17228, DOI 10.1074/jbc.M602999200; Ferrari D, 2007, BRIT J PHARMACOL, V150, P445, DOI 10.1038/sj.bjp.0706994; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; Kawate T, 2009, NATURE, V460, P592, DOI 10.1038/nature08198; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; la Sala A, 2003, J LEUKOCYTE BIOL, V73, P339, DOI 10.1189/jlb.0802418; Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Morelli A, 2003, MOL BIOL CELL, V14, P2655, DOI 10.1091/mbc.02-04-0061; Morgenstern B, 2004, NUCLEIC ACIDS RES, V32, pW33, DOI 10.1093/nar/gkh373; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05-03-0222; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Surprenant A, 2009, ANNU REV PHYSIOL, V71, P333, DOI 10.1146/annurev.physiol.70.113006.100630	38	180	181	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3393	3404		10.1096/fj.09-153601	http://dx.doi.org/10.1096/fj.09-153601			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20453110				2022-12-28	WOS:000281446400027
J	Hu, MC; Shi, MJ; Zhang, JN; Pastor, J; Nakatani, T; Lanske, B; Razzaque, MS; Rosenblatt, KP; Baum, MG; Kuro-o, M; Moe, OW				Hu, Ming Chang; Shi, Mingjun; Zhang, Jianning; Pastor, Johanne; Nakatani, Teruyo; Lanske, Beate; Razzaque, M. Shawkat; Rosenblatt, Kevin P.; Baum, Michel G.; Kuro-o, Makoto; Moe, Orson W.			Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule	FASEB JOURNAL			English	Article						renal brush border membrane; FGF23; NaPi-2a; beta-glucuronidase; proteolytic degradation	TRANSCRIPTS ENCODING MEMBRANE; FIBROBLAST GROWTH FACTOR-23; BONE-MINERAL DENSITY; NA/P-I COTRANSPORTER; HORMONE KLOTHO; TRPV5 CHANNEL; ALPHA-KLOTHO; NAPI-IIA; P-I; GENE	Klotho has profound effects on phosphate metabolism, but the mechanisms of how Klotho affects phosphate homeostasis is unknown. We detected Klotho in the proximal tubule cell, brush border, and urinary lumen, where phosphate homeostasis resides. Increasing Klotho in the kidney and urine chronically by transgenic overexpression or acutely by intravenous infusion caused hypophosphatemia, phosphaturia from decreased proximal phosphate reabsorption, and decreased activity and protein of the principal renal phosphate transporter NaPi-2a. The phosphaturic effect was present in FGF23-null mice, indicating a direct action distinct from Klotho's known role as a coreceptor for FGF23. Direct inhibition of NaPi-2a by Klotho was confirmed in cultured cells and in cell-free membrane vesicles characterized by acute inhibition of transport activity followed by decreased cell surface protein. Transport inhibition can be mimicked by recombinant beta-glucuronidase and is associated with proteolytic degradation and reduced surface NaPi-2a. The inhibitory effect of Klotho on NaPi-2a was blocked by beta-glucuronidase inhibitor but not by protease inhibitor. Klotho is a novel phosphaturic substance that acts as an enzyme in the proximal tubule urinary lumen by modifying glycans, which cause decreased transporter activity, followed by proteolytic degradation and possibly internalization of NaPi-2a from the apical membrane.-Hu, M. C., Shi, M., Zhang, J., Pastor, J., Nakatani, T., Lanske, B., Shawkat Razzaque, M., Rosenblatt, K. P., Baum, M. G., Kuro-o, M., Moe, O. W. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 24, 3438-3450 (2010). www.fasebj.org	[Hu, Ming Chang; Shi, Mingjun; Kuro-o, Makoto; Moe, Orson W.] Univ Texas SW Med Ctr Dallas, Charles & Jane Pak Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA; [Hu, Ming Chang; Zhang, Jianning; Baum, Michel G.; Moe, Orson W.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Hu, Ming Chang; Baum, Michel G.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Pastor, Johanne; Rosenblatt, Kevin P.; Kuro-o, Makoto] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Moe, Orson W.] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; [Nakatani, Teruyo; Lanske, Beate; Razzaque, M. Shawkat] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard School of Dental Medicine	Moe, OW (corresponding author), Univ Texas SW Med Ctr Dallas, Charles & Jane Pak Ctr Mineral Metab & Clin Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	orson.moe@utsouthwestern.edu	Razzaque, Mohammed S./K-4282-2019	Lanske, Beate/0000-0003-4638-804X	Simmons Family Foundation; National Institutes of Health [AG19712, AG25326, DK067158, DK41612, DK-48482, DK-20543, P30-DK-079328]; American Heart Association [0865235F]; Eisai Research Fund; Ellison Medical Foundation; Ted Nash Long Life Foundation; Charles and Jane Pak Center of Mineral Metabolism and Clinical Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041612, R01DK067158, R01DK048482, R29DK048482, P30DK079328, P01DK020543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019712, R01AG025326] Funding Source: NIH RePORTER	Simmons Family Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Eisai Research Fund; Ellison Medical Foundation(Lawrence Ellison Foundation); Ted Nash Long Life Foundation; Charles and Jane Pak Center of Mineral Metabolism and Clinical Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was primarily supported by the Simmons Family Foundation. The authors also received support from the National Institutes of Health (AG19712, AG25326, DK067158, DK41612, DK-48482, DK-20543, and P30-DK-079328), the American Heart Association (0865235F), the Eisai Research Fund, the Ellison Medical Foundation, the Ted Nash Long Life Foundation, and a Seed Grant from the Charles and Jane Pak Center of Mineral Metabolism and Clinical Research. Authors are grateful to Dr. O Bonny for valuable suggestions and discussions and to Drs. J. Biber and H. Murer (Institute of Physiology, University of Zurich, Zurich, Switzerland) for antisera against rat NaPi-2a.	Allred AJ, 2000, AM J PHYSIOL-RENAL, V279, pF841, DOI 10.1152/ajprenal.2000.279.5.F841; ARAR M, 1995, AM J PHYSIOL-RENAL, V268, pF309, DOI 10.1152/ajprenal.1995.268.2.F309; Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299; Bacic D, 2005, AM J PHYSIOL-RENAL, V288, pF740, DOI 10.1152/ajprenal.00380.2004; Baum M, 2005, KIDNEY INT, V68, P1148, DOI 10.1111/j.1523-1755.2005.00506.x; Baum M, 2005, AM J PHYSIOL-RENAL, V288, pF363, DOI 10.1152/ajprenal.00217.2004; Baum M, 2003, P NATL ACAD SCI USA, V100, P11098, DOI 10.1073/pnas.1834060100; Ben-Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409; Biber J, 1996, KIDNEY INT, V49, P981, DOI 10.1038/ki.1996.139; Brownstein CA, 2008, P NATL ACAD SCI USA, V105, P3455, DOI 10.1073/pnas.0712361105; Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105; Cha SK, 2009, MOL PHARMACOL, V76, P38, DOI 10.1124/mol.109.055780; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Diepens RJW, 2004, AM J PHYSIOL-RENAL, V286, pF483, DOI 10.1152/ajprenal.00231.2003; Friedman DJ, 2009, J BONE MINER RES, V24, P1847, DOI [10.1359/JBMR.090516, 10.1359/jbmr.090516]; Fuster DG, 2008, J AM SOC NEPHROL, V19, P1547, DOI 10.1681/ASN.2007111245; Girardi ACC, 2004, AM J PHYSIOL-CELL PH, V287, pC1238, DOI 10.1152/ajpcell.00186.2004; Goetz R, 2010, P NATL ACAD SCI USA, V107, P407, DOI 10.1073/pnas.0902006107; Green J, 2001, KIDNEY INT, V60, P1182, DOI 10.1046/j.1523-1755.2001.0600031182.x; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; HAYES G, 1994, J BIOL CHEM, V269, P24143; Hilfiker H, 1998, P NATL ACAD SCI USA, V95, P14564, DOI 10.1073/pnas.95.24.14564; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Ichikawa S, 2007, J CLIN INVEST, V117, P2684, DOI 10.1172/JCI31330; Imura A, 2007, SCIENCE, V316, P1615, DOI 10.1126/science.1135901; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kawano KI, 2002, J BONE MINER RES, V17, P1744, DOI 10.1359/jbmr.2002.17.10.1744; Khundmiri SJ, 2005, BBA-BIOMEMBRANES, V1716, P19, DOI 10.1016/j.bbamem.2005.08.009; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lanske B, 2007, AGEING RES REV, V6, P73, DOI 10.1016/j.arr.2007.02.002; Leung JC, 2005, HORM METAB RES, V37, P265, DOI 10.1055/s-2005-870096; LEVI M, 1991, AM J PHYSIOL, V261, pF767, DOI 10.1152/ajprenal.1991.261.5.F767; LEVINE DZ, 1971, AM J PHYSIOL, V221, P1164, DOI 10.1152/ajplegacy.1971.221.4.1164; Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91; Madjdpour C, 2004, PFLUG ARCH EUR J PHY, V448, P402, DOI 10.1007/s00424-004-1253-x; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Mizuno I, 2001, LIFE SCI, V68, P2917, DOI 10.1016/S0024-3205(01)01092-X; Moe OW, 2009, AM J PHYSIOL-RENAL, V296, pF689, DOI 10.1152/ajprenal.00007.2009; Murer H, 1996, ANNU REV PHYSIOL, V58, P607, DOI 10.1146/annurev.physiol.58.1.607; Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08-114397; Nolan VG, 2006, BRIT J HAEMATOL, V133, P570, DOI 10.1111/j.1365-2141.2006.06074.x; Nolan VG, 2005, BRIT J HAEMATOL, V128, P266, DOI 10.1111/j.1365-2141.2004.05295.x; Ogbureke KUE, 2005, KIDNEY INT, V68, P155, DOI 10.1111/j.1523-1755.2005.00389.x; Ohtsubo K, 2005, CELL, V123, P1307, DOI 10.1016/j.cell.2005.09.041; Ohyama Y, 1998, BIOCHEM BIOPH RES CO, V251, P920, DOI 10.1006/bbrc.1998.9576; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; PREISIG PA, 1987, J CLIN INVEST, V80, P970, DOI 10.1172/JCI113190; Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05-5432fje; Rhee EJ, 2006, J ENDOCRINOL INVEST, V29, P613, DOI 10.1007/BF03344160; Riancho JA, 2007, BIOGERONTOLOGY, V8, P121, DOI 10.1007/s10522-006-9039-5; Roseman S, 2001, J BIOL CHEM, V276, P41527, DOI 10.1074/jbc.R100053200; SCHNERMANN J, 1971, PFLUG ARCH EUR J PHY, V329, P307, DOI 10.1007/BF00588002; Segawa H, 2007, AM J PHYSIOL-RENAL, V292, pF769, DOI 10.1152/ajprenal.00248.2006; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Shiraki-Iida T, 2000, J GENE MED, V2, P233, DOI 10.1002/1521-2254(200007/08)2:4<233::AID-JGM110>3.0.CO;2-5; Shiraki-Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014-5793(98)00127-6; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; Tohyama O, 2004, J BIOL CHEM, V279, P9777, DOI 10.1074/jbc.M312392200; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003-0048; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Villa-Bellosta R, 2009, AM J PHYSIOL-RENAL, V296, pF691, DOI 10.1152/ajprenal.90623.2008; Virkki LV, 2007, AM J PHYSIOL-RENAL, V293, pF643, DOI 10.1152/ajprenal.00228.2007; Xiao YS, 1997, BIOCHEM J, V323, P401, DOI 10.1042/bj3230401; Yamada Y, 2005, J MOL MED, V83, P50, DOI 10.1007/s00109-004-0578-4; Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200; Yu XJ, 2005, CYTOKINE GROWTH F R, V16, P221, DOI 10.1016/j.cytogfr.2005.01.002; Zhang F, 2007, OSTEOARTHR CARTILAGE, V15, P624, DOI 10.1016/j.joca.2006.12.002	71	418	438	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3438	3450		10.1096/fj.10-154765	http://dx.doi.org/10.1096/fj.10-154765			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20466874	Green Published			2022-12-28	WOS:000281446400031
J	Ho, PC; Chang, KC; Chuang, YS; Wei, LN				Ho, Ping-Chih; Chang, Kun-Che; Chuang, Ya-Shan; Wei, Li-Na			Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production	FASEB JOURNAL			English	Article						3 '-UTR; simvastatin; high-fat diet; sepsis; NF-kappa B	REPRESSIVE ACTIVITY; COREPRESSOR RIP140; GENE-EXPRESSION; MOLECULAR INTERACTION; METABOLIC DISEASES; KAPPA-B; NUCLEAR; PHOSPHORYLATION; MIR-33; DIET	Receptor interacting protein 140 (RIP140) is a nuclear receptor coregulator that affects a wide spectrum of biological processes. It is unclear whether and how the expression level of RIP140 can be modulated and whether RIP140 is involved in inflammatory diseases. Here, we examine how intracellular cholesterol regulates RIP140 expression, and we evaluate the effect of RIP140 expression on macrophage proinflammatory potential. Macrophages treated with modified low-density lipoprotein express higher RIP140 mRNA and protein levels. Consistently, simvastatin reduces RIP140 levels, which can be reversed by mevalonate. Moreover, a high-fat diet elevates RIP140 but lowers miR-33 levels in peritoneal macrophages, and increases the production of IL-1 beta and TNF-alpha in macrophages. Mechanistically, miR-33 targets RIP140 mRNA by recognizing its target located in a highly conserved sequence of the 3'-untranslated region (3'-UTR) of RIP140 mRNA. Consequentially, miR-33 reduces RIP140 coactivator activity for NF-kappa B, which is supported by the reduction in NF-kappa B reporter activity and the inflammatory potential in macrophages. This study uncovers a cholesterol-miR-33-RIP140 regulatory pathway that modulates the proinflammatory potential in macrophages in response to an alteration in the intracellular cholesterol status, and identifies RIP140 as a direct target of miR-33 that mediates simvastatin-triggered anti-inflammation.-Ho, P.-C.; Chang, K.-C., Chuang, Y.-S., Wei, L.-N. Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production. FASEB J. 25, 1758-1766 (2011). www.fasebj.org	[Ho, Ping-Chih; Chang, Kun-Che; Chuang, Ya-Shan; Wei, Li-Na] Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	weixx009@umn.edu		Chang, Kun-Che/0000-0002-0871-5612; Ho, Ping-Chih/0000-0003-3078-3774	U.S. National Institutes of Health [DK60521, DK060521-07S1, DK54733, DK054733-09S1, DA11190, K02-DA13926]; American Heart Association; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060521, R01DK054733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011190, K02DA013926, P50DA011806] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Y.-C. Tsui for help with the septic shock model and animal handling. The authors also thank F.A. Beyan and A. Smith for technical help. This study was supported in part by U.S. National Institutes of Health grants DK60521, DK060521-07S1, DK54733, DK054733-09S1, DA11190, and K02-DA13926; a Distinguished McKnight University Professorship (L.-N.W.); and an American Heart Association predoctoral fellowship (P.-C.H.).	CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chang M, 2009, NAT IMMUNOL, V10, P1089, DOI 10.1038/ni.1777; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen YX, 2004, MOL CELL ENDOCRINOL, V226, P43, DOI 10.1016/j.mce.2004.07.001; Chen YX, 2002, MOL ENDOCRINOL, V16, P2528, DOI 10.1210/me.2002-0124; Christian M, 2005, MOL CELL BIOL, V25, P9383, DOI 10.1128/MCB.25.21.9383-9391.2005; El Gazzar M, 2010, J BIOL CHEM, V285, P20940, DOI 10.1074/jbc.M110.115063; Fritah A, 2010, AM J PHYSIOL-ENDOC M, V299, pE335, DOI 10.1152/ajpendo.00243.2010; Gao F, 2008, BRIT J ANAESTH, V100, P288, DOI 10.1093/bja/aem406; Gerin I, 2010, J BIOL CHEM, V285, P33652, DOI 10.1074/jbc.M110.152090; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gupta P, 2005, MOL CELL PROTEOMICS, V4, P1776, DOI 10.1074/mcp.M500236-MCP200; Gupta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002658; Hernandez-Presa MA, 2003, CARDIOVASC RES, V57, P168, DOI 10.1016/S0008-6363(02)00619-3; Ho PC, 2008, CELL SIGNAL, V20, P1911, DOI 10.1016/j.cellsig.2008.07.001; Ho PC, 2009, CELL METAB, V10, P516, DOI 10.1016/j.cmet.2009.09.012; Horie T, 2010, P NATL ACAD SCI USA, V107, P17321, DOI 10.1073/pnas.1008499107; Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449; Huq MDM, 2007, NAT CHEM BIOL, V3, P161, DOI 10.1038/nchembio861; Huq MDM, 2006, EMBO J, V25, P5094, DOI 10.1038/sj.emboj.7601389; Huq MDM, 2009, J PROTEOME RES, V8, P1156, DOI 10.1021/pr800569c; Huq MDM, 2005, PROTEOMICS, V5, P2157, DOI 10.1002/pmic.200401090; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Lefevre L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012828; Leonardsson G, 2004, P NATL ACAD SCI USA, V101, P8437, DOI 10.1073/pnas.0401013101; Marquart TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/pnas.1005191107; Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399; Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123; Naura AS, 2009, LAB INVEST, V89, P1243, DOI 10.1038/labinvest.2009.98; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Park SW, 2005, MOL CELL PROTEOMICS, V4, P300, DOI 10.1074/mcp.M400195-MCP200; Powelka AM, 2006, J CLIN INVEST, V116, P125, DOI 10.1172/JCI26040; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; REDMOND HP, 1991, ANN SURG, V214, P502, DOI 10.1097/00000658-199110000-00014; Rivera Chantal A., 2010, BMC Physiology, V10, P20, DOI 10.1186/1472-6793-10-20; Russell JA, 2006, NEW ENGL J MED, V355, P1699, DOI 10.1056/NEJMra043632; Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23; Strandberg L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007605; Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Tsai NP, 2009, BIOCHEM J, V424, P411, DOI 10.1042/BJ20090915; Vachharajani Vidula, 2006, J Intensive Care Med, V21, P287, DOI 10.1177/0885066606290670; White R, 2000, NAT MED, V6, P1368, DOI 10.1038/82183; White R, 2008, FEBS LETT, V582, P39, DOI 10.1016/j.febslet.2007.11.017; Yvan-Charvet L, 2008, CIRCULATION, V118, P1837, DOI 10.1161/CIRCULATIONAHA.108.793869; Yvan-Charvet L, 2010, ARTERIOSCL THROM VAS, V30, P139, DOI 10.1161/ATVBAHA.108.179283; Zschiedrich I, 2008, BLOOD, V112, P264, DOI 10.1182/blood-2007-11-121699	50	62	69	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1758	1766		10.1096/fj.10-179267	http://dx.doi.org/10.1096/fj.10-179267			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21285396	Green Published			2022-12-28	WOS:000290023800031
J	Esser, J; Gehrmann, U; Salvado, MD; Wetterholm, A; Haeggstrom, JZ; Samuelsson, B; Gabrielsson, S; Scheynius, A; Radmark, O				Esser, Julia; Gehrmann, Ulf; Salvado, M. Dolores; Wetterholm, Anders; Haeggstrom, Jesper Z.; Samuelsson, Bengt; Gabrielsson, Susanne; Scheynius, Annika; Radmark, Olof			Zymosan suppresses leukotriene C-4 synthase activity in differentiating monocytes: antagonism by aspirin and protein kinase inhibitors	FASEB JOURNAL			English	Article						acetylsalicylic acid; eicosanoids; macrophages; Toll-like receptor 2	REGULATES 5-LIPOXYGENASE ACTIVITY; COLONY-STIMULATING FACTOR; GROWTH-FACTOR-BETA; TRANSCELLULAR BIOSYNTHESIS; CYSTEINYL-LEUKOTRIENES; DENDRITIC CELLS; IN-VIVO; PERITONEAL-MACROPHAGES; EICOSANOID GENERATION; PHOSPHOLIPASE A(2)	Cysteinyl leukotrienes (cysLTs) are potent proinflammatory mediators with particular relevance for asthma. However, control of cysLT biosynthesis in the time period after onset of acute inflammation has not been extensively studied. As a model for later phases of inflammation, we investigated regulation of leukotriene (LT) C-4 synthase (LTC4S) in differentiating monocytes, exposed for several days to fungal zymosan. Incubations with LTA(4) revealed 20-fold increased LTC4S activity during differentiation of monocytic Mono Mac 6 (MM6) cells, which was reduced by 80% in the presence of zymosan (25 mu g/ml, 96 h). Zymosan (48 h) similarly attenuated LTC4S activity of primary human monocyte-derived macrophages and dendritic cells. Several findings indicate phosphoregulation of LTC4S: increased activity during MM6 cell differentiation correlated with reduced phosphorylation of 70-kDa ribosomal protein S6 kinase (p70S6K), which could phosphorylate purified LTC4S; the p70S6K inhibitor rapamycin (20 nM) doubled LTC4S activity of undifferentiated MM6 cells, and protein kinase A and C inhibitors (H-89, CGP-53353, and staurosporine) reversed the zymosan-induced suppression of LTC4S activity. Finally, zymosan (48 h) up-regulated PGE(2) biosynthesis, and aspirin (10 mu M) or prostaglandin E-2 (PGE(2)) receptor antagonists counteracted the zymosan effect. Our results suggest a late PGE(2)-mediated phosphoregulation of LTC4S during microbial exposure, which may contribute to resolution of inflammation, with implications for aspirin hypersensitivity.-Esser, J., Gehrmann, U., Salvado, M. D., Wetterholm, A., Haeggstrom, J. Z., Samuelsson, B., Gabrielsson, S., Scheynius, A., Radmark, O. Zymosan suppresses leukotriene C-4 synthase activity in differentiating monocytes: antagonism by aspirin and protein kinase inhibitors. FASEB J. 25, 1417-1427 (2011). www.fasebj.org	[Esser, Julia; Salvado, M. Dolores; Wetterholm, Anders; Haeggstrom, Jesper Z.; Samuelsson, Bengt; Radmark, Olof] Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden; [Gehrmann, Ulf; Gabrielsson, Susanne; Scheynius, Annika] Karolinska Inst, Clin Allergy Res Unit, Dept Med Solna, S-17177 Stockholm, Sweden; [Gehrmann, Ulf; Gabrielsson, Susanne; Scheynius, Annika] Univ Hosp Solna, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Radmark, O (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden.	olof.radmark@ki.se	Gabrielsson, S./E-4145-2014; Sobrido, Maria/D-6697-2016	Gabrielsson, S./0000-0003-1771-1346; Sobrido, Maria/0000-0003-2060-4410; Esser-von Bieren, Julia/0000-0003-1898-9382	Swedish Research Council; European Union [FP7-Health-201668]; Vardal Foundation; Centre for Allergy Research at Karolinska Institutet; Vinnova consortium [2007-01999]; Swedish Asthma and Allergy Association's Research Foundation; Cancer and Allergy Foundation; Swedish Heart-Lung Foundation; Karolinska Institutet	Swedish Research Council(Swedish Research CouncilEuropean Commission); European Union(European Commission); Vardal Foundation; Centre for Allergy Research at Karolinska Institutet(Karolinska Institutet); Vinnova consortium(Vinnova); Swedish Asthma and Allergy Association's Research Foundation; Cancer and Allergy Foundation; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Karolinska Institutet(Karolinska Institutet)	The authors thank Gudrun Tibbelin (Karolinska Institutet, Stockholm, Sweden) for providing purified LTC<INF>4</INF>S. This work was supported by grants from the Swedish Research Council, European Union (FP7-Health-201668), the Vardal Foundation, the Centre for Allergy Research at Karolinska Institutet, the Vinnova consortium (2007-01999), the Swedish Asthma and Allergy Association's Research Foundation, the Cancer and Allergy Foundation, and the Swedish Heart-Lung Foundation and by Karolinska Institutet. The authors have no conflicting financial interests.	ALI A, 1994, J IMMUNOL, V153, P776; Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Brock TG, 2003, PROSTAG OTH LIPID M, V71, P131, DOI 10.1016/S1098-8823(03)00036-4; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; Buentke E, 2001, CLIN EXP ALLERGY, V31, P1583, DOI 10.1046/j.1365-2222.2001.01199.x; COFFEY M, J LIPID MEDIAT, V6, P43; CZOP JK, 1985, P NATL ACAD SCI USA, V82, P2751, DOI 10.1073/pnas.82.9.2751; DAHLEN SE, 1986, RESPIRATION, V50, P22, DOI 10.1159/000195097; Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039; Farooque SP, 2009, ANNU REV PHYSIOL, V71, P465, DOI 10.1146/annurev.physiol.010908.163114; FAULER J, 1994, ARTHRITIS RHEUM-US, V37, P93, DOI 10.1002/art.1780370114; Fernandez-Boyanapalli R, 2010, BLOOD, V116, P4512, DOI 10.1182/blood-2010-02-272005; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; Gaber F, 2008, THORAX, V63, P1076, DOI 10.1136/thx.2008.101196; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Goodridge Helen S., 2008, V183, P87; Gupta N, 1999, FEBS LETT, V449, P66, DOI 10.1016/S0014-5793(99)00397-X; Hackstein H, 2001, J IMMUNOL, V166, P7053, DOI 10.4049/jimmunol.166.12.7053; Hallstrand TS, 2010, CURR OPIN ALLERGY CL, V10, P60, DOI 10.1097/ACI.0b013e32833489c3; HAM EA, 1983, P NATL ACAD SCI-BIOL, V80, P4349, DOI 10.1073/pnas.80.14.4349; Harizi H, 2003, J IMMUNOL, V170, P139, DOI 10.4049/jimmunol.170.1.139; Harizi H, 2011, IMMUNOL CELL BIOL, V89, P275, DOI 10.1038/icb.2010.94; Heberden C, 1998, GEN PHARMACOL-VASC S, V30, P145, DOI 10.1016/S0306-3623(97)00271-1; KARGMAN S, 1994, MOL PHARMACOL, V45, P1043; Kikawada E, 2007, BLOOD, V110, P561, DOI 10.1182/blood-2006-10-052258; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; Lindner SC, 2009, J LEUKOCYTE BIOL, V86, P389, DOI 10.1189/jlb.1008591; Martelli AM, 2010, HISTOL HISTOPATHOL, V25, P669, DOI 10.14670/HH-25.669; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Medeiros AI, 2009, J EXP MED, V206, P61, DOI 10.1084/jem.20082058; Moreira LO, 2008, CELL MICROBIOL, V10, P2067, DOI 10.1111/j.1462-5822.2008.01189.x; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Ohira T, 2010, J BIOL CHEM, V285, P3451, DOI 10.1074/jbc.M109.044131; Olynych TJ, 2006, J ALLERGY CLIN IMMUN, V118, P837, DOI 10.1016/j.jaci.2006.06.008; Peiretti F, 2001, J BIOL CHEM, V276, P32214, DOI 10.1074/jbc.M103357200; Peters-Golden M, 2005, J IMMUNOL, V174, P589, DOI 10.4049/jimmunol.174.2.589; Planaguma A, 2002, FASEB J, V16, P1937, DOI 10.1096/fj.02-0224fje; Riddick CA, 1999, J IMMUNOL, V162, P1101; Rouzer CA, 2006, BIOCHEM J, V399, P91, DOI 10.1042/BJ20060615; Sala A, 1997, J PHYSIOL PHARMACOL, V48, P665; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Schaloske RH, 2005, BBA-MOL CELL BIOL L, V1687, P64, DOI 10.1016/j.bbalip.2004.11.005; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Sjolinder M, 1995, FEBS LETT, V377, P87, DOI 10.1016/0014-5793(95)01303-2; Snelgrove RJ, 2010, SCIENCE, V330, P90, DOI 10.1126/science.1190594; STEINHILBER D, 1993, P NATL ACAD SCI USA, V90, P5984, DOI 10.1073/pnas.90.13.5984; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Suram S, 2006, J BIOL CHEM, V281, P5506, DOI 10.1074/jbc.M509824200; Thivierge M, 2009, J IMMUNOL, V183, P6778, DOI 10.4049/jimmunol.0901800; TORNHAMRE S, 1995, EUR J BIOCHEM, V234, P513, DOI 10.1111/j.1432-1033.1995.513_b.x; Underhill DM, 2003, J ENDOTOXIN RES, V9, P176, DOI 10.1179/096805103125001586; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; Weichhart T, 2009, TRENDS IMMUNOL, V30, P218, DOI 10.1016/j.it.2009.02.002; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; Wetterholm A, 2008, PROTEIN EXPRES PURIF, V60, P1, DOI 10.1016/j.pep.2008.03.005; WILLIAMS JD, 1985, J IMMUNOL, V134, P2624; Yanaba K, 2009, J IMMUNOL, V182, P7459, DOI 10.4049/jimmunol.0900270; Zarini S, 2009, P NATL ACAD SCI USA, V106, P8296, DOI 10.1073/pnas.0903851106; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	62	18	18	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1417	1427		10.1096/fj.10-175828	http://dx.doi.org/10.1096/fj.10-175828			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21228223				2022-12-28	WOS:000288982800030
J	Avdic, V; Zhang, P; Lanouette, S; Voronova, A; Skerjanc, I; Couture, JF				Avdic, Vanja; Zhang, Pamela; Lanouette, Sylvain; Voronova, Anastassia; Skerjanc, Ilona; Couture, Jean-Francois			Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3-based peptide mimetic	FASEB JOURNAL			English	Article						epigenetics; chromatin biology; nucleosomes; SET1 family of methyltransferases	MIXED LINEAGE LEUKEMIA; STRUCTURAL BASIS; MOLECULAR RECOGNITION; LYSINE METHYLATION; PROTEIN WDR5; CORE COMPLEX; HOX GENES; H3; DOMAIN; CELLS	The SET1 family of methyltransferases carries out the bulk of histone H3 Lys-4 methylation in vivo. One of the common features of this family is the regulation of their methyltransferase activity by a tripartite complex composed of WDR5, RbBP5, and Ash2L. To selectively probe the role of the SET1 family of methyltransferases, we have developed a library of histone H3 peptide mimetics and report herein the characterization of an N alpha acetylated form of histone H3 peptide (N alpha H3). Binding and inhibition studies reveal that the addition of an acetyl moiety to the N terminus of histone H3 significantly enhances its binding to WDR5 and prevents the stimulation of MLL1 methyltransferase activity by the WDR5-RbBP5-Ash2L complex. The crystal structure of N alpha H3 in complex with WDR5 reveals that a high-affinity hydrophobic pocket accommodates the binding of the acetyl moiety. These results provide the structural basis to control WDR5-RbBP5-Ash2L-MLL1 activity and a tool to manipulate stem cell differentiation programs.-Avdic, V., Zhang, P., Lanouette, S., Voronova, A., Skerjanc, I., Couture, J.-F. Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3-based peptide mimetic. FASEB J. 25, 960-967 (2011). www.fasebj.org	[Avdic, Vanja; Zhang, Pamela; Lanouette, Sylvain; Couture, Jean-Francois] Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON K1H 8M5, Canada; [Avdic, Vanja; Zhang, Pamela; Lanouette, Sylvain; Voronova, Anastassia; Skerjanc, Ilona; Couture, Jean-Francois] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa	Couture, JF (corresponding author), Univ Ottawa, Ottawa Inst Syst Biol, 451 Smyth Rd,Roger Guindon Hall, Ottawa, ON K1H 8M5, Canada.	jean-francois.couture@uottawa.ca	Voronova, Anastassia/GLR-8891-2022; Skerjanc, Ilona/AAN-3318-2020	Voronova, Anastassia/0000-0001-7504-1905	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The authors thank Dr. Alexandre Blais for reviewing this manuscript. This work was supported by a Canadian Institutes of Health Research grant to J.-F.C. J.-F.C. holds a Canadian Research Chair in Structural Biology and Epigenetics. The coordinates for the WDR5-NaH3 complex have been deposited in the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank under accession number 3PSL.pdb.	Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Chonghaile TN, 2008, ONCOGENE, V27, pS149, DOI 10.1038/onc.2009.52; Cosgrove MS, 2010, FEBS J, V277, P1832, DOI 10.1111/j.1742-4658.2010.07609.x; Couture JF, 2006, CURR OPIN STRUC BIOL, V16, P753, DOI 10.1016/j.sbi.2006.10.002; Couture JF, 2007, NAT STRUCT MOL BIOL, V14, P689, DOI 10.1038/nsmb1273; Couture JF, 2006, NAT STRUCT MOL BIOL, V13, P698, DOI 10.1038/nsmb1116; Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615; Dai Y, 2010, CLIN EXP RHEUMATOL, V28, P158; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gao JM, 2009, NAT STRUCT MOL BIOL, V16, P684, DOI 10.1038/nsmb.1610; Greer EL, 2010, NATURE, V466, P383, DOI 10.1038/nature09195; Han ZF, 2006, MOL CELL, V22, P137, DOI 10.1016/j.molcel.2006.03.018; Karatas H, 2010, J MED CHEM, V53, P5179, DOI 10.1021/jm100139b; Lim DA, 2009, NATURE, V458, P529, DOI 10.1038/nature07726; Martens JHA, 2010, FEBS LETT, V584, P2662, DOI 10.1016/j.febslet.2010.04.002; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; McKinnell IW, 2008, NAT CELL BIOL, V10, P77, DOI 10.1038/ncb1671; Mendez AJ, 2010, CURR OPIN ENDOCRINOL, V17, P171, DOI 10.1097/MED.0b013e3283373cb5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel A, 2008, J BIOL CHEM, V283, P32162, DOI 10.1074/jbc.M806317200; Patel A, 2008, J BIOL CHEM, V283, P32158, DOI 10.1074/jbc.C800164200; Patel A, 2009, J BIOL CHEM, V284, P24242, DOI 10.1074/jbc.M109.014498; Popovic R, 2005, J CELL BIOCHEM, V95, P234, DOI 10.1002/jcb.20430; Probst AV, 2009, NAT REV MOL CELL BIO, V10, P192, DOI 10.1038/nrm2640; Rampalli S, 2007, NAT STRUCT MOL BIOL, V14, P1150, DOI 10.1038/nsmb1316; Ruthenburg AJ, 2006, NAT STRUCT MOL BIOL, V13, P704, DOI 10.1038/nsmb1119; Schuetz A, 2006, EMBO J, V25, P4245, DOI 10.1038/sj.emboj.7601316; Song JJ, 2008, J BIOL CHEM, V283, P35258, DOI 10.1074/jbc.M806900200; Southall SM, 2009, MOL CELL, V33, P181, DOI 10.1016/j.molcel.2008.12.029; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; Yang HB, 2009, BIOCHEM CELL BIOL, V87, P151, DOI 10.1139/O08-131; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	36	13	13	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					960	967		10.1096/fj.10-171959	http://dx.doi.org/10.1096/fj.10-171959			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21135039				2022-12-28	WOS:000287806200016
J	Doyle, A; Zhang, GH; Fattah, EAA; Eissa, NT; Li, YP				Doyle, Alexander; Zhang, Guohua; Fattah, Elmoataz A. Abdel; Eissa, N. Tony; Li, Yi-Ping			Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways	FASEB JOURNAL			English	Article						autophagosomes; atrogin-1/MAFbx; p38 MAPK; 3-methyladenine; lactacystin	NECROSIS-FACTOR-ALPHA; RAT SKELETAL-MUSCLE; PROTEIN-DEGRADATION; SIGNALING PATHWAY; MESSENGER-RNAS; AMINO-ACIDS; TNF-ALPHA; KAPPA-B; EXPRESSION; SEPSIS	Cachectic muscle wasting is a frequent complication of many inflammatory conditions, due primarily to excessive muscle catabolism. However, the pathogenesis and intervention strategies against it remain to be established. Here, we tested the hypothesis that Toll-like receptor 4 (TLR4) is a master regulator of inflammatory muscle catabolism. We demonstrate that TLR4 activation by lipopolysaccharide (LPS) induces C2C12 myotube atrophy via up-regulating autophagosome formation and the expression of ubiquitin ligase atrogin-1/MAFbx and MuRF1. TLR4-mediated activation of p38 MAPK is necessary and sufficient for the up-regulation of atrogin1/MAFbx and autophagosomes, resulting in myotube atrophy. Similarly, LPS up-regulates muscle autophagosome formation and ubiquitin ligase expression in mice. Importantly, autophagy inhibitor 3-methyladenine completely abolishes LPS-induced muscle proteolysis, while proteasome inhibitor lactacystin partially blocks it. Furthermore, TLR4 knockout or p38 MAPK inhibition abolishes LPS-induced muscle proteolysis. Thus, TLR4 mediates LPS-induced muscle catabolism via coordinate activation of the ubiquitin-proteasome and the autophagy-lysosomal pathways.-Doyle, A., Zhang, G., Abdel Fattah, E. A., Eissa, N. T., Li, Y.-P. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J. 25, 99-110 (2011). www.fasebj.org	[Doyle, Alexander; Zhang, Guohua; Li, Yi-Ping] Univ Texas Houston, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Fattah, Elmoataz A. Abdel; Eissa, N. Tony] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine	Li, YP (corresponding author), Univ Texas Houston, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.	yi-ping.li@uth.tmc.edu	Zhang, Guohua/AFR-1220-2022; Li, Yi-Ping/ABF-9245-2020		National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR052511]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052511] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by a National Institute of Arthritis and Musculoskeletal and Skin Diseases R01 grant to Y.-P.L. (AR052511). The authors thank S. Akira (Osaka University, Oskaka, Japan) for sharing the TLR4 <SUP>/</SUP> mice, and J. Han (Scripps Research Institute, La Jolla, CA, USA) for sharing the adenovirus construct of MKK6bE.	Al-Attas OS, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-20; Argiles JM, 2000, EUR CYTOKINE NETW, V11, P552; Baltgalvis KA, 2009, PFLUG ARCH EUR J PHY, V457, P989, DOI 10.1007/s00424-008-0574-6; Bechet D, 2005, INT J BIOCHEM CELL B, V37, P2098, DOI 10.1016/j.biocel.2005.02.029; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Boyd JH, 2006, INFECT IMMUN, V74, P6829, DOI 10.1128/IAI.00286-06; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Dehoux MJM, 2003, FEBS LETT, V544, P214, DOI 10.1016/S0014-5793(03)00505-2; Doan HQ, 2009, ANTICANCER RES, V29, P2473; Ehrchen JM, 2009, J LEUKOCYTE BIOL, V86, P557, DOI 10.1189/jlb.1008647; Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013; FULKS RM, 1975, J BIOL CHEM, V250, P290; GOLDBERG RM, 1995, J CLIN ONCOL, V13, P2856, DOI 10.1200/JCO.1995.13.11.2856; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Han DM, 2007, INT J LAB HEMATOL, V29, P185, DOI 10.1111/j.1751-553X.2006.00839.x; HASSELGREN PO, 1986, ARCH SURG-CHICAGO, V121, P918; HASSELGREN PO, 1989, METABOLISM, V38, P634, DOI 10.1016/0026-0495(89)90100-5; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Jin BW, 2007, J CELL BIOCHEM, V100, P960, DOI 10.1002/jcb.21060; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Lang CH, 2003, SHOCK, V19, P538, DOI 10.1097/01.shk.0000055237.25446.80; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Li W, 2009, AM J PHYSIOL-CELL PH, V297, pC706, DOI 10.1152/ajpcell.00626.2008; Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC370, DOI 10.1152/ajpcell.00453.2002; Liu KH, 2008, SURGERY, V143, P375, DOI 10.1016/j.surg.2007.09.035; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; Menconi M, 2008, J CELL BIOCHEM, V105, P353, DOI 10.1002/jcb.21833; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Moylan JS, 2008, AM J PHYSIOL-CELL PH, V295, pC986, DOI 10.1152/ajpcell.00041.2008; Moylan JS, 2007, MUSCLE NERVE, V35, P411, DOI 10.1002/mus.20743; Niebauer J, 1999, LANCET, V353, P1838, DOI 10.1016/S0140-6736(98)09286-1; ROSENBLATT S, 1983, ARCH SURG-CHICAGO, V118, P167; Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Takeda K, 2001, JPN J INFECT DIS, V54, P209; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Thomas M, 2005, P NATL ACAD SCI USA, V102, P5679, DOI 10.1073/pnas.0502067102; Tiao G, 1997, J CLIN INVEST, V99, P163, DOI 10.1172/JCI119143; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Vary T C, 1998, Curr Opin Clin Nutr Metab Care, V1, P217, DOI 10.1097/00075197-199803000-00013; WAALKES TP, 1957, J LAB CLIN MED, V50, P733; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2; Xu Y, 2008, AUTOPHAGY, V4, P110, DOI 10.4161/auto.5225; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Zhao JH, 2008, AUTOPHAGY, V4, P378, DOI 10.4161/auto.5633; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	57	167	178	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					99	110		10.1096/fj.10-164152	http://dx.doi.org/10.1096/fj.10-164152			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20826541	Green Published			2022-12-28	WOS:000285869500010
J	Eunju, O; Lee, BH; Ahn, HY; Shin, JC; Kim, HK; Kim, M; Park, IY; Park, YG; Joe, YA				Eunju, O.; Lee, Byung Hun; Ahn, Hyun-Young; Shin, Jong-Chul; Kim, Hyun-Kyung; Kim, Myungshin; Park, In-Yang; Park, Yong-Gyu; Joe, Young Ae			Efficient nonadhesive ex vivo expansion of early endothelial progenitor cells derived from CD34(+) human cord blood fraction for effective therapeutic vascularization	FASEB JOURNAL			English	Article						ex vivo expansion; ischemia; neovascularization	HEMATOPOIETIC STEM-CELLS; FIBROBLAST-GROWTH-FACTOR; MYOCARDIAL-INFARCTION; MONONUCLEAR-CELLS; TRANSPLANTATION; NEOVASCULARIZATION; ANGIOGENESIS; SENESCENCE; RECOVERY; POTENCY	Endothelial progenitor cells (EPCs) have been shown to have therapeutic potential in ischemic disease. However, the number of EPCs for cell therapy is limited. In this study, instead of the typical adherent culture method, we investigated a more efficient, clinically applicable nonadhesive expansion method for early EPCs using cord blood-derived cells to overcome rapid cellular senescence. After a suspension culture of isolated CD34(+) cells in serum-free medium containing each cytokine combination was maintained for 9 d, the number of expanded functional EPCs was assessed by an adherent culture assay. Compared to mononuclear cells, the CD34(+) fraction was superior in its expansion of functional EPCs that could differentiate into acLDL/UEA-1(+) cells without significant cellular senescence, whereas the CD34(-) fraction showed no EPC expansion. Among the cytokine combinations tested for the CD34(+) fraction, a combination (SFIb) consisting of stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand, interleukin-3, and basic fibroblast growth factor resulted in a reproducible 64- to 1468-fold EPC expansion from various cord blood origins. Interestingly, the SFIb combination displayed markedly increased EPC expansion (2.43-fold), with a higher percentage of CD34(+) cells (2.17-fold), undifferentiated blasts (2.38-fold) and CXCR4(+) cells (1.68-fold) compared to another cytokine combination (SCF, thrombopoietin, and granulocyte colony-stimulating factor), although the two cytokine combinations had a similar level of total mononucleated cell expansion (similar to 10% difference). Accordingly, the cells expanded in the SFIb combination were more effective in recovery of blood flow and neovascularization in hind-limb ischemia in vivo. Taken together, these results suggest that the nonadhesive serum-free culture conditions of the CD34(+) fraction provide an effective EPC expansion method for cell therapy, and an expansion condition leading to high percentages of CD34(+) cells and blasts is likely important in EPC expansion.-O, E., Lee, B. H., Ahn, H.-Y., Shin, J.-C., Kim, H.-Y., Kim, M., Park, I. Y., Park, Y.-G., Joe, Y. A. Efficient nonadhesive ex vivo expansion of early endothelial progenitor cells derived from CD34(+) human cord blood fraction for effective therapeutic vascularization. FASEB J. 25, 159-169 (2011). www.fasebj.org	[Joe, Young Ae] Catholic Univ Korea, Canc Res Inst, Coll Med, Seocho Ku, Seoul 137701, South Korea; [Eunju, O.; Lee, Byung Hun; Kim, Hyun-Kyung; Joe, Young Ae] Catholic Univ Korea, Dept Biomed Sci, Seoul 137701, South Korea; [Ahn, Hyun-Young; Shin, Jong-Chul; Park, In-Yang] Catholic Univ Korea, Dept Obstet & Gynecol, Div Maternal Fetal Med, Seoul 137701, South Korea; [Kim, Myungshin] Catholic Univ Korea, Dept Lab Med, Seoul 137701, South Korea; [Park, Yong-Gyu] Catholic Univ Korea, Dept Biostat, Coll Med, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Joe, YA (corresponding author), Catholic Univ Korea, Canc Res Inst, Coll Med, Seocho Ku, Banpo Dong 505, Seoul 137701, South Korea.	youngjoe@catholic.ac.kr	Kim, Myungshin/AAK-1544-2021; Kim, Myungshin/AAP-9262-2020	Kim, Myungshin/0000-0001-8632-0168; Kim, Myungshin/0000-0001-8632-0168	Ministry of Education, Science and Technology [2006-2004327, 2009-0084059]; Catholic Institute of Cell Therapy Basic Science Programs Foundation [2006005051]	Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Catholic Institute of Cell Therapy Basic Science Programs Foundation	The authors thank Hyo-Eun Park for technical support and helpful advice on animal experiments. This research was supported mainly by the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (2006-2004327, 2009-0084059) and, in part, by the Catholic Institute of Cell Therapy Basic Science Programs Foundation, program year 2006 (2006005051).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2003, CIRC RES, V92, P1049, DOI 10.1161/01.RES.0000070067.64040.7C; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Burger PE, 2002, BLOOD, V100, P3527, DOI 10.1182/blood.V100.10.3527; Chavakis E, 2010, CIRCULATION, V121, P325, DOI 10.1161/CIRCULATIONAHA.109.901405; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; Dimmeler S, 2008, CIRC RES, V102, P1319, DOI 10.1161/CIRCRESAHA.108.175943; Dimmeler S, 2008, ARTERIOSCL THROM VAS, V28, P208, DOI 10.1161/ATVBAHA.107.155317; Friedrich EB, 2006, CIRC RES, V98, pE20, DOI 10.1161/01.RES.0000205765.28940.93; Gehling UM, 2000, BLOOD, V95, P3106; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Harraz M, 2001, STEM CELLS, V19, P304, DOI 10.1634/stemcells.19-4-304; Hendrikx M, 2006, CIRCULATION, V114, pI101, DOI 10.1161/CIRCULATIONAHA.105.000505; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hofmann M, 2005, CIRCULATION, V111, P2198, DOI 10.1161/01.CIR.0000163546.27639.AA; Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06; Iba O, 2002, CIRCULATION, V106, P2019, DOI 10.1161/01.CIR.0000031332.45480.79; Ishikawa M, 2004, STEM CELLS DEV, V13, P344, DOI 10.1089/1547328041797435; Kashiwakura I, 2005, LEUKEMIA LYMPHOMA, V46, P329, DOI 10.1080/10428190400019958; Kawamoto A, 2007, CATHETER CARDIO INTE, V70, P477, DOI 10.1002/ccd.21292; Kawamoto A, 2006, CIRCULATION, V114, P2163, DOI 10.1161/CIRCULATIONAHA.106.644518; Kovacic JC, 2008, TRENDS CARDIOVAS MED, V18, P45, DOI 10.1016/j.tcm.2007.12.002; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Piacibello W, 2005, FOLIA HISTOCHEM CYTO, V43, P197; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Schmeisser A, 2001, CARDIOVASC RES, V49, P671, DOI 10.1016/S0008-6363(00)00270-4; Sekiguchi H, 2009, J CELL PHYSIOL, V219, P235, DOI 10.1002/jcp.21672; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Ueda T, 2001, INT J HEMATOL, V73, P457, DOI 10.1007/BF02994007; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Urbich C, 2003, CIRCULATION, V108, P2511, DOI 10.1161/01.CIR.0000096483.29777.50; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Zhang L, 2006, EUR J HAEMATOL, V76, P1, DOI 10.1111/j.1600-0609.2005.00579.x	36	30	33	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					159	169		10.1096/fj.10-162040	http://dx.doi.org/10.1096/fj.10-162040			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20852063				2022-12-28	WOS:000285869500015
J	Jones, GW; Stumhofer, JS; Foster, T; Twohig, JP; Hertzog, P; Topley, N; Williams, AS; Hunter, CA; Jenkins, BJ; Wang, ECY; Jones, SA				Jones, Gareth W.; Stumhofer, Jason S.; Foster, Tom; Twohig, Jason P.; Hertzog, Paul; Topley, Nicholas; Williams, Anwen S.; Hunter, Christopher A.; Jenkins, Brendan J.; Wang, Eddie C. Y.; Jones, Simon A.			Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation	FASEB JOURNAL			English	Article						cytokine; T-cell regulation; inflammation	TGF-BETA; AUTOIMMUNE INFLAMMATION; RHEUMATOID-ARTHRITIS; HELPER-CELLS; FAMILY-MEMBERS; CUTTING EDGE; RECEPTOR DR3; ROR-GAMMA; IN-VIVO; APOPTOSIS	Tumor necrosis factor (TNF)-like cytokine (TL1A) is a T-cell costimulator that bolsters cytokine-induced activation through death receptor 3 (DR3). To explore the relationship between T-cell activation and TL1A responsiveness, flow cytometry profiled DR3 expression in resting and activated T cells. In human CD4(+) T cells, DR3 was induced rapidly following activation and expressed prominently by interleukin (IL)-17-secreting T cells (Th17). Splenic T cells from wild-type and DR3-deficient mice showed that TL1A activation of DR3 inhibits Th17 generation (81 +/- 2.6% at 100 ng/ml TL1A) from naive T cells. This response was not associated with suppression of T-cell proliferation. Using neutralizing antibodies or T cells derived from genetically modified mice, TL1A inhibition of Th17 development was found to be independent of IL-2, IL-27, gamma IFN, IFNAR1, and STAT1. Under suboptimal TCR activation, TL1A continued to block IL-17A secretion, however, the reduced threshold of TCR engagement was now linked with an increase in TL1A-driven proliferation. In contrast, fully committed Th17 cells displayed an altered TL1A responsiveness and in the absence of TCR costimulation supported the maintenance of T cell IL-17A expression. Consequently, TL1A orchestrates unique outcomes in naive and effector T-helper cells, which may affect the proliferation, differentiation and maintenance of Th17 cells in peripheral compartments and inflamed tissues.-Jones, G. W., Stumhofer, J. S., Foster, T., Twohig, J. P., Hertzog, P., Topley, N., Williams, A. S., Hunter, C. A., Jenkins, B. J., Wang, E. C. Y., Jones, S. A. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J. 25, 409-419 (2011). www.fasebj.org	[Jones, Gareth W.; Foster, Tom; Twohig, Jason P.; Topley, Nicholas; Wang, Eddie C. Y.; Jones, Simon A.] Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff CF14 4XN, S Glam, Wales; [Williams, Anwen S.] Cardiff Univ, Sch Med, Dept Rheumatol, Cardiff CF14 4XN, S Glam, Wales; [Jones, Gareth W.; Hertzog, Paul; Jenkins, Brendan J.] Monash Univ, Monash Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia; [Stumhofer, Jason S.; Hunter, Christopher A.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	Cardiff University; Cardiff University; Monash University; University of Pennsylvania	Jones, SA (corresponding author), Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	jonessa@cf.ac.uk	Hertzog, Paul J/I-7053-2013; Hertzog, Paul J/G-6734-2013; jenkins, brendan/J-7854-2012; Jones, Simon Arnett/Q-7017-2018	Hertzog, Paul J/0000-0002-1373-8472; Hertzog, Paul J/0000-0002-1373-8472; Jones, Gareth/0000-0002-0125-4841; Jenkins, Brendan/0000-0002-7552-4656; Jones, Simon Arnett/0000-0001-7297-9711; Wang, Eddie/0000-0002-2243-4964	Arthritis Research UK [18286, ARC19234]; Medical Research Council [G0300180, G0901119]; Wellcome Trust; National Institutes of Health [AI42334]; Mari Lowe Centre; MRC [G0300180, G0901119] Funding Source: UKRI; Versus Arthritis [18286] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042334] Funding Source: NIH RePORTER	Arthritis Research UK(Versus Arthritis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mari Lowe Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Versus Arthritis(Versus Arthritis); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded through grant support provided by Arthritis Research UK (project grant 18286 to S.A.J.; traveling fellowship ARC19234 to G.J.), the Medical Research Council (grants G0300180 and G0901119 to E.W.), the Wellcome Trust, the National Institutes of Health (grant AI42334 to C.H.), and the Mari Lowe Centre (to C.H.). The authors also acknowledge the help and advice provided by Drs. Philip Taylor and Awen Gallimore.	Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Bamias G, 2003, J IMMUNOL, V171, P4868, DOI 10.4049/jimmunol.171.9.4868; Bamias G, 2008, CLIN IMMUNOL, V129, P249, DOI 10.1016/j.clim.2008.07.014; Bamias G, 2006, P NATL ACAD SCI USA, V103, P8441, DOI 10.1073/pnas.0510903103; Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Borysenko CW, 2006, J CELL PHYSIOL, V209, P1021, DOI 10.1002/jcp.20812; Briso EM, 2008, J IMMUNOL, V180, P7102, DOI 10.4049/jimmunol.180.11.7102; Bull MJ, 2008, J EXP MED, V205, P2457, DOI 10.1084/jem.20072378; Cassatella MA, 2007, J IMMUNOL, V178, P7325, DOI 10.4049/jimmunol.178.11.7325; Cejas PJ, 2010, BLOOD, V115, P4750, DOI 10.1182/blood-2009-09-242768; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Curnow SJ, 2004, J IMMUNOL, V173, P5290, DOI 10.4049/jimmunol.173.8.5290; Davidson TS, 2007, J IMMUNOL, V178, P4022, DOI 10.4049/jimmunol.178.7.4022; Gonzalez LC, 2005, P NATL ACAD SCI USA, V102, P1116, DOI 10.1073/pnas.0409071102; Guo BC, 2008, J CLIN INVEST, V118, P1680, DOI 10.1172/JCI33342; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JCI200215841; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jones GW, 2010, J IMMUNOL, V184, P2130, DOI 10.4049/jimmunol.0901528; Kikly K, 2006, CURR OPIN IMMUNOL, V18, P670, DOI 10.1016/j.coi.2006.09.008; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; Meylan F, 2008, IMMUNITY, V29, P79, DOI 10.1016/j.immuni.2008.04.021; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Neufert C, 2007, EUR J IMMUNOL, V37, P1809, DOI 10.1002/eji.200636896; Papadakis KA, 2004, FASEB J, V18, pA465; Pappu BP, 2008, J EXP MED, V205, P1049, DOI 10.1084/jem.20071364; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Prehn JL, 2007, J IMMUNOL, V178, P4033, DOI 10.4049/jimmunol.178.7.4033; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; Takami N, 2006, ARTHRITIS RHEUM-US, V54, P779, DOI 10.1002/art.21637; Takedatsu H, 2008, GASTROENTEROLOGY, V135, P552, DOI 10.1053/j.gastro.2008.04.037; Teague TK, 1997, J IMMUNOL, V158, P5791; Teague TK, 2000, J EXP MED, V191, P915, DOI 10.1084/jem.191.6.915; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wang ECY, 2001, MOL CELL BIOL, V21, P3451, DOI 10.1128/MCB.21.10.3451-3461.2001; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wen L, 2003, J BIOL CHEM, V278, P39251, DOI 10.1074/jbc.M305833200; Xiao QL, 2005, BIOCHEM J, V388, P913, DOI 10.1042/BJ20041739; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Zehntner SP, 2007, J IMMUNOL, V179, P7553, DOI 10.4049/jimmunol.179.11.7553; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	52	39	46	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					409	419		10.1096/fj.10-166843	http://dx.doi.org/10.1096/fj.10-166843			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20826539	Green Published, Green Accepted			2022-12-28	WOS:000285869500037
J	Lao, QZ; Kobrinsky, E; Liu, Z; Soldatov, NM				Lao, Qi Zong; Kobrinsky, Evgeny; Liu, Zhuo; Soldatov, Nikolai M.			Oligomerization of Ca-v beta subunits is an essential correlate of Ca2+ channel activity	FASEB JOURNAL			English	Article						protein-protein interaction; high-order protein complexes; calcium channel regulation; calcium signaling	GATED CALCIUM-CHANNELS; ALKALINE-PHOSPHATASE; HEART; MODULATION; EXPRESSION; COMPLEX; HETEROGENEITY; MECHANISM; MODULE	Voltage-gated calcium channels conduct Ca2+ ions in response to membrane depolarization. The resulting transient increase in cytoplasmic free calcium concentration is a critical trigger for the initiation of such vital responses as muscle contraction and transcription. L-type Ca(v)1.2 calcium channels are complexes of the pore-forming alpha(1C) subunit associated with cytosolic Ca-v beta subunits. All major Ca-v beta s share a highly homologous membrane associated guanylate kinaselike (MAGUK) domain that binds to alpha(1C) at the alpha-interaction domain (AID), a short motif in the linker between transmembrane repeats I and II. In this study we show that Ca-v beta subunits form multimolecular homoand heterooligomeric complexes in human vascular smooth muscle cells expressing native calcium channels and in Cos7 cells expressing recombinant Ca(v)1.2 channel subunits. Ca-v beta s oligomerize at the alpha(1C) subunits residing in the plasma membrane and bind to the AID. However, Ca-v beta oligomerization occurs independently on the association with alpha(1C). Molecular structures responsible for Ca-v beta oligomerization reside in 3 regions of the guanylate kinase subdomain of MAGUK. An augmentation of Ca-v beta homooligomerization significantly increases the calcium current density, while heterooligomerization may also change the voltagedependence and inactivation kinetics of the channel. Thus, oligomerization of Ca-v beta subunits represents a novel and essential aspect of calcium channel regulation.-Lao, Q. Z., Kobrinsky, E., Liu, Z., Soldatov, N. M. Oligomerization of Ca-v beta subunits is an essential correlate of Ca2+ channel activity. FASEB J. 24, 5013-5023 (2010). www. fasebj. org	[Lao, Qi Zong; Kobrinsky, Evgeny; Liu, Zhuo; Soldatov, Nikolai M.] NIA, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Soldatov, NM (corresponding author), Humgenex Inc, 3105 Starner Court, Kensington, MD 20895 USA.	soldatovn.humgenex@verizon.net			National Institute on Aging [Z01 AG000294-08]; NATIONAL INSTITUTE ON AGING [Z01AG000294] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the National Institute on Aging Intramural Research Program (Z01 AG000294-08 to N.M.S.).	AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; Canti C, 2001, BIOPHYS J, V81, P1439, DOI 10.1016/S0006-3495(01)75799-2; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen XW, 2005, CIRC RES, V97, P1009, DOI 10.1161/01.RES.0000189270.72915.D1; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Gonzalez-Gutierrez G, 2008, P NATL ACAD SCI USA, V105, P14198, DOI 10.1073/pnas.0806558105; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hullin R, 1999, CIRCULATION, V100, P155, DOI 10.1161/01.CIR.100.2.155; Hullin R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000292; Kobrinsky E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005587; Koushik SV, 2006, BIOPHYS J, V91, pL99, DOI 10.1529/biophysj.106.096206; Lao QZ, 2008, J BIOL CHEM, V283, P15577, DOI 10.1074/jbc.M802035200; Levy D, 2009, NAT GENET, V41, P677, DOI 10.1038/ng.384; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; McGee AW, 2004, NEURON, V42, P89, DOI 10.1016/S0896-6273(04)00149-7; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; Miriyala J, 2008, CIRC RES, V102, pE54, DOI 10.1161/CIRCRESAHA.108.171736; Navedo MF, 2010, CIRC RES, V106, P748, DOI 10.1161/CIRCRESAHA.109.213363; Navedo MF, 2005, P NATL ACAD SCI USA, V102, P11112, DOI 10.1073/pnas.0500360102; Neely A, 2004, J BIOL CHEM, V279, P21689, DOI 10.1074/jbc.M312675200; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Page KM, 2010, J BIOL CHEM, V285, P835, DOI 10.1074/jbc.M109.065045; POWERS PA, 1992, J BIOL CHEM, V267, P22967; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Ravindran A, 2008, P NATL ACAD SCI USA, V105, P8154, DOI 10.1073/pnas.0711624105; Swamy Mahima, 2006, Sci STKE, V2006, ppl4, DOI 10.1126/stke.3452006pl4; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Walsh CP, 2009, J BIOL CHEM, V284, P22310, DOI 10.1074/jbc.M109.017152; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62; Yasuda T, 2004, J GEN PHYSIOL, V123, P401, DOI 10.1085/jgp.200308967; YEH MF, 1976, J BIOL CHEM, V251, P3134; Zhang R, 2005, FASEB J, V19, P1153, DOI 10.1096/fj.04-3283fje	40	15	15	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5013	5023		10.1096/fj.10-165381	http://dx.doi.org/10.1096/fj.10-165381			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20732952	Green Published			2022-12-28	WOS:000284824400039
J	Panici, JA; Harper, JM; Miller, RA; Bartke, A; Spong, A; Masternak, MM				Panici, Jacob A.; Harper, James M.; Miller, Richard A.; Bartke, Andrzej; Spong, Adam; Masternak, Michal M.			Early life growth hormone treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice	FASEB JOURNAL			English	Article						Ames dwarf; aging; stress resistance	AMES DWARF MICE; INSULIN SENSITIVITY; MULTIPLE FORMS; SPAN; MEN; FIBROBLASTS; PARAMETERS; FERTILITY; RECEPTOR; DISEASE	Hypopituitary Ames dwarf mice were injected either with growth hormone (GH) or thyroxine for a 6-wk period to see whether this intervention would reverse their long life span or the resistance of their cells to lethal stresses. Ames dwarf mice survived 987 +/- 24 d (median), longer than nonmutant control mice (664 +/- 48), but GH-injected dwarf mice did not differ from controls (707 +/- 9). Fibroblast cells from Ames dwarf mice were more resistant to cadmium than cells from nonmutant controls (LD50 values of 9.98 +/- 1.7 and 3.9 +/- 0.8, respectively), but GH injections into Ames dwarf mice restored the normal level of cadmium resistance (LD50 = 5.8 +/- 0.9). Similar restoration of normal resistance was observed for fibroblasts exposed to paraquat, methyl methanesulfonate, and rotenone (P<0.05 in each case for contrast of GH-treated vs. untreated dwarf mice; P<0.05 for dwarf vs. nonmutant control mice.) T4 injections into Ames dwarf mice, in contrast, did not restore normal life span. We conclude that the remarkable life-span extension of Ames dwarf mice, and the stress resistance of cells from these mice, depends on low levels of GH exposure in juvenile and very young adult mice.-Panici, J. A., Harper, J. M., Miller, R. A., Bartke, A., Spong, A., Masternak, M. M. Early life growth hormone treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice. FASEB J. 24, 5073-5079 (2010). www.fasebj.org	[Masternak, Michal M.] So Illinois Univ, Sch Med, Dept Internal Med, Div Geriatr Med, Springfield, IL 62794 USA; [Harper, James M.; Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Harper, James M.; Miller, Richard A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA; [Miller, Richard A.] Ann Arbor Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA; [Masternak, Michal M.] Polish Acad Sci, Inst Human Genet, PL-60479 Poznan, Poland	Southern Illinois University System; Southern Illinois University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; Polish Academy of Sciences; Institute of Human Genetics of the Polish Academy of Sciences	Masternak, MM (corresponding author), So Illinois Univ, Sch Med, Dept Internal Med, Div Geriatr Med, 801 N Rutledge,Rm 4389,POB 19628, Springfield, IL 62794 USA.	mmasternak@siumed.edu	Bartke, Andzej/D-6640-2017	Bartke, Andzej/0000-0002-2569-557X; Harper, James/0000-0003-0765-8828	Ellison Medical Foundation, National Institute on Aging [AG031736, AG019899, AG023122]; NATIONAL INSTITUTE ON AGING [P01AG031736, R01AG019899, U19AG023122] Funding Source: NIH RePORTER	Ellison Medical Foundation, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)Lawrence Ellison Foundation); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by The Ellison Medical Foundation, National Institute on Aging grants AG031736, AG019899, and AG023122.	BARTKE A, 1965, J REPROD FERTIL, V10, P93, DOI 10.1530/jrf.0.0100093; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Blackman MB, 2002, JAMA-J AM MED ASSOC, V288, P2282, DOI 10.1001/jama.288.18.2282; Bonkowski MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004567; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Conover CA, 2007, AGING CELL, V6, P727, DOI 10.1111/j.1474-9726.2007.00328.x; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; Csiszar A, 2008, AM J PHYSIOL-HEART C, V295, pH475, DOI 10.1152/ajpheart.00644.2008; Dominici FP, 2002, J ENDOCRINOL, V173, P81, DOI 10.1677/joe.0.1730081; Harper JM, 2007, AGING CELL, V6, P1, DOI 10.1111/j.1474-9726.2006.00255.x; Ikeno Y, 2003, J GERONTOL A-BIOL, V58, P291; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; Kinney BA, 2001, HORM BEHAV, V39, P277, DOI 10.1006/hbeh.2001.1654; Lange KHW, 2002, J CLIN ENDOCR METAB, V87, P513, DOI 10.1210/jc.87.2.513; Leiser SF, 2006, MECH AGEING DEV, V127, P821, DOI 10.1016/j.mad.2006.08.003; Leiser SF, 2010, MOL CELL BIOL, V30, P871, DOI 10.1128/MCB.01145-09; Liu H, 2007, ANN INTERN MED, V146, P104, DOI 10.7326/0003-4819-146-2-200701160-00005; Louis A, 2010, J GERONTOL A-BIOL, V65, P344, DOI 10.1093/gerona/glq018; Masternak MM, 2010, J GERONTOL A-BIOL, V65, P24, DOI 10.1093/gerona/glp172; Masternak MM, 2009, J GERONTOL A-BIOL, V64, P516, DOI 10.1093/gerona/glp024; Masternak MM, 2004, J GERONTOL A-BIOL, V59, P784; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Papadakis Maxine A., 1996, Wound Repair and Regeneration, V4, P421, DOI 10.1046/j.1524-475X.1996.40405.x; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; Salmon AB, 2005, AM J PHYSIOL-ENDOC M, V289, pE23, DOI 10.1152/ajpendo.00575.2004; Salmon AB, 2008, J GERONTOL A-BIOL, V63, P232, DOI 10.1093/gerona/63.3.232; Sonntag WE, 2005, ENDOCRINOLOGY, V146, P2920, DOI 10.1210/en.2005-0058; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Vergara M, 2004, J GERONTOL A-BIOL, V59, P1244, DOI 10.1093/gerona/59.12.1244	31	108	108	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5073	5079		10.1096/fj.10-163253	http://dx.doi.org/10.1096/fj.10-163253			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20720157	Green Submitted, Green Published			2022-12-28	WOS:000284824400045
J	Kalujnaia, S; Mcvee, J; Kasciukovic, T; Stewart, AJ; Cramb, G				Kalujnaia, Svetlana; McVee, Jill; Kasciukovic, Taciana; Stewart, Alan J.; Cramb, Gordon			A role for inositol monophosphatase 1 (IMPA1) in salinity adaptation in the euryhaline eel (Anguilla anguilla)	FASEB JOURNAL			English	Article						European eel; teleost; osmolyte; chondrocyte; osmoregulation	EUROPEAN EEL; MYOINOSITOL MONOPHOSPHATASE; ORGANIC OSMOLYTES; OSMOREGULATORY TISSUES; SENSITIVE ENZYME; ATLANTIC SALMON; MESSENGER-RNA; FISH GILL; EXPRESSION; LITHIUM	This study investigated the expression and tissue distribution of inositol monophosphatase (IMPA1) and characterized its role in salinity adaptation in the eel. The coding sequence of eel IMPA1 was determined and confirmed to be orthologous to the mammalian gene/enzyme by phylogenetic analysis and structural modeling. Quantitative real-time PCR and Western blot techniques indicated up to 17-fold increases in mRNA expression and 2-fold increases in protein abundance in major osmoregulatory tissues following transfer of fish to seawater (SW). This was accompanied by up to 5-fold increases in enzyme activity, and 1.8- and 3-fold increases in inositol contents within the gill and kidney, respectively. Immunohistological studies revealed that IMPA1 protein expression predominated in SW-acclimated fish within basal epithelial/epidermal layers of the gill, esophagus, intestine, skin, and fins. SW transfer also induced a 10-fold increase in inositol content in the fin. IMPA1 immunoreactivity was also identified in chondrocytes within the cartilagenous matrix of the gills and fins, as well as in clusters of interstitial cells surrounding the kidney tubules. The observed increases in expression of IMPA1 highlight a protective role for inositol within various eel tissues following SW acclimation. This constitutes an adaptive mechanism in teleost fish naturally exposed to hypertonic environments.-Kalujnaia, S., McVee, J., Kasciukovic, T., Stewart, A. J., Cramb, G. A role for inositol monophosphatase 1 (IMPA1) in salinity adaptation in the euryhaline eel (Anguilla anguilla). FASEB J. 24, 3981-3991 (2010). www.fasebj.org	[Kalujnaia, Svetlana; McVee, Jill; Kasciukovic, Taciana; Stewart, Alan J.; Cramb, Gordon] Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland	University of St Andrews	Cramb, G (corresponding author), Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland.	gc@st-andrews.ac.uk	Stewart, Alan J/B-6569-2008	Stewart, Alan J/0000-0003-4580-1840	Natural Environment Research Council [NE/E015514, NE/F001401]; NERC [NE/E015514/1, NE/F001401/1] Funding Source: UKRI; Natural Environment Research Council [NE/F001401/1, NE/E015514/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	The authors thank Caroline J. Osborne and Brian Powell for technical support. The work was supported by project grants from the Natural Environment Research Council (NE/E015514 and NE/F001401).	Alcazar-Roman AR, 2008, CHROMOSOMA, V117, P1, DOI 10.1007/s00412-007-0126-4; Alfieri RR, 2007, PFLUG ARCH EUR J PHY, V454, P173, DOI 10.1007/s00424-006-0195-x; Amlund H, 2004, COMP BIOCHEM PHYS C, V138, P507, DOI 10.1016/j.cca.2004.08.010; Aoki M, 2003, J EXP BIOL, V206, P3495, DOI 10.1242/jeb.00579; Ashizawa N, 2000, J BIOCHEM BIOPH METH, V44, P89, DOI 10.1016/S0165-022X(00)00069-5; ATACK JR, 1995, FEBS LETT, V361, P1, DOI 10.1016/0014-5793(95)00063-F; Beck F X, 1992, Curr Opin Nephrol Hypertens, V1, P43, DOI 10.1097/00041552-199210000-00007; Beck FX, 2006, CONTRIB NEPHROL, V152, P181, DOI 10.1159/000096323; Bissonnette P, 2008, AM J PHYSIOL-CELL PH, V295, pC791, DOI 10.1152/ajpcell.00390.2007; Burg MB, 2008, J BIOL CHEM, V283, P7309, DOI 10.1074/jbc.R700042200; Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006; Campanella JJ, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-29; Evans DH, 2005, PHYSIOL REV, V85, P97, DOI 10.1152/physrev.00050.2003; Evans TG, 2008, J EXP BIOL, V211, P3636, DOI 10.1242/jeb.022160; Farnum CE, 2002, BONE, V30, P574, DOI 10.1016/S8756-3282(01)00710-4; Fiess JC, 2007, COMP BIOCHEM PHYS A, V146, P252, DOI 10.1016/j.cbpa.2006.10.027; Gill R, 2005, ACTA CRYSTALLOGR D, V61, P545, DOI 10.1107/S0907444905004038; HALL AC, 1995, J PHYSIOL-LONDON, V484, P755, DOI 10.1113/jphysiol.1995.sp020701; Hazon N, 2003, COMP BIOCHEM PHYS B, V136, P685, DOI 10.1016/S1096-4959(03)00280-X; Kalujnaia S, 2009, ANN NY ACAD SCI, V1163, P433, DOI 10.1111/j.1749-6632.2009.04457.x; Kalujnaia S, 2009, GEN COMP ENDOCR, V161, P103, DOI 10.1016/j.ygcen.2008.11.005; Kalujnaia S, 2007, PHYSIOL GENOMICS, V31, P385, DOI 10.1152/physiolgenomics.00059.2007; Kalujnaia S, 2010, FASEB J, V24; Kiefer Florian, 2009, Nucleic Acids Res, V37, pD387, DOI 10.1093/nar/gkn750; Lignot JH, 2002, J EXP BIOL, V205, P2653; Lopez F, 1999, MOL MICROBIOL, V31, P1255, DOI 10.1046/j.1365-2958.1999.01267.x; Lopez-Coronado JM, 1999, J BIOL CHEM, V274, P16034, DOI 10.1074/jbc.274.23.16034; Lyng MB, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-20; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; Marshall William S., 2006, P177; Martinez AS, 2005, AM J PHYSIOL-REG I, V288, pR1733, DOI 10.1152/ajpregu.00747.2004; McCormick SD, 2003, J EXP BIOL, V206, P4575, DOI 10.1242/jeb.00711; McDonald MD, 2006, J MEMBRANE BIOL, V212, P93, DOI 10.1007/s00232-006-0869-5; Michell RH, 2008, NAT REV MOL CELL BIO, V9, P151, DOI 10.1038/nrm2334; Ohnishi T, 2007, J BIOL CHEM, V282, P637, DOI 10.1074/jbc.M604474200; OLSON KR, 1991, J ELECTRON MICR TECH, V19, P389, DOI 10.1002/jemt.1060190402; Roberts SJ, 2004, BIOCHEM J, V382, P59, DOI 10.1042/BJ20040511; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKAGUCHI H, 1993, AM J PHYSIOL, V265, pR474, DOI 10.1152/ajpregu.1993.265.2.R474; Takeuchi K, 2000, BBA-BIOMEMBRANES, V1464, P219, DOI 10.1016/S0005-2736(00)00158-9; TIERNEY ML, 1995, GEN COMP ENDOCR, V100, P39, DOI 10.1006/gcen.1995.1130; Tipsmark CK, 2010, J EXP BIOL, V213, P368, DOI 10.1242/jeb.034785; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P8916, DOI 10.1073/pnas.92.19.8916; Weltzien FA, 2006, ENDOCRINOLOGY, V147, P2964, DOI 10.1210/en.2005-1477; YAMAUCHI A, 1994, J AM SOC NEPHROL, V5, P62; Yancey PH, 2005, J EXP BIOL, V208, P2819, DOI 10.1242/jeb.01730; YORK JD, 1994, BIOCHEMISTRY-US, V33, P13164, DOI 10.1021/bi00249a002	47	22	23	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3981	3991		10.1096/fj.10-161000	http://dx.doi.org/10.1096/fj.10-161000			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20547660				2022-12-28	WOS:000285005900035
J	Rao, PK; Missiaglia, E; Shields, L; Hyde, G; Yuan, BB; Shepherd, CJ; Shipley, J; Lodish, HF				Rao, Prakash K.; Missiaglia, Edoardo; Shields, Lauren; Hyde, Greg; Yuan, Bingbing; Shepherd, Christopher J.; Shipley, Janet; Lodish, Harvey F.			Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells	FASEB JOURNAL			English	Article						microRNA; muscle; tumor	MUSCLE-SPECIFIC MICRORNA; SKELETAL-MUSCLE; EXPRESSION SIGNATURE; GENE-EXPRESSION; IDENTIFICATION; TARGET; MYOGENESIS; INDUCE; MYOD	Rhabdomyosarcoma is the most common soft tissue sarcoma in the pediatric population. As this tumor has an undifferentiated myogenic phenotype, agents that promote differentiation hold particular promise as part of a novel therapeutic approach to combat this type of cancer. In this report, we focus on the contribution of two microRNAs (miRNAs) in rhabdomyosarcomas. Levels of miR-1 and miR-133a are drastically reduced in representative cell lines from each major rhabdomyosarcoma subtype (embryonal and alveolar). Introduction of miR-1 and miR-133a into an embryonal rhabdomyosarcoma-derived cell line is cytostatic, thereby suggesting a tumor suppressor-like role for these myogenic miRNAs. Transcriptional profiling of cells after miR-1 and miR-133a expression reveals that miR-1 (but not miR-133a) exerts a strong promyogenic influence on these poorly differentiated tumor cells. We identify mRNAs that are down-regulated by these miRNAs and propose roles for miR-1 and miR-133a in repressing isoforms of genes that are normally not expressed in muscle. Finally, we show that mRNA targets of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas, suggesting a causative role for these miRNAs in the development of rhabdomyosarcomas. More important, these results point to the promise of enhancing rhabdomyosarcoma therapy using miRNAs as agents that mediate cytostasis and promote muscle differentiation.-Rao, P. K., Missiaglia, E., Shields, L., Hyde, G., Yuan, B., Shepherd, C. J., Shipley, J., Lodish, H. F. Distinct roles for Mir-1 and Mir-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J. 24, 3427-3437 (2010). www.fasebj.org	[Rao, Prakash K.; Shields, Lauren; Hyde, Greg; Yuan, Bingbing; Lodish, Harvey F.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Missiaglia, Edoardo; Shepherd, Christopher J.; Shipley, Janet] Inst Canc Res, Mol Cytogenet Team, Sutton, Surrey, England; [Shields, Lauren; Lodish, Harvey F.] MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of London; Institute of Cancer Research - UK; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu		missiaglia, edoardo/0000-0001-9221-0117; Shipley, Janet/0000-0001-6748-8678	National Institutes of Health [R01 DK068348]; Chris Lucas Trust; Cancer Research UK [C5066/A9541]; Muscular Dystrophy Association (MDA) [3882]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068348] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chris Lucas Trust; Cancer Research UK(Cancer Research UK); Muscular Dystrophy Association (MDA)(Muscular Dystrophy Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Work in H. F. L.'s laboratory was supported by National Institutes of Health grant R01 DK068348, and work in J.S.'s laboratory was supported by the Chris Lucas Trust and by Cancer Research UK (C5066/A9541). P. K. R. was supported by the Muscular Dystrophy Association (MDA grant 3882) and thanks members of the H. F. L. and David Bartel (Whitehead Institute for Biomedical Research, Cambridge, MA, USA) laboratories for their insightful comments.	Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; Carey KA, 2006, PATHOL INT, V56, P246, DOI 10.1111/j.1440-1827.2006.01958.x; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; HORN RC, 1958, CANCER, V11, P181, DOI 10.1002/1097-0142(195801/02)11:1<181::AID-CNCR2820110130>3.0.CO;2-I; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu N, 2007, P NATL ACAD SCI USA, V104, P20844, DOI 10.1073/pnas.0710558105; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Mishima Y, 2009, GENE DEV, V23, P619, DOI 10.1101/gad.1760209; Missiaglia E, 2009, GENE CHROMOSOME CANC, V48, P455, DOI 10.1002/gcc.20655; Morotti RA, 2006, AM J SURG PATHOL, V30, P962, DOI 10.1097/00000478-200608000-00005; O'Rourke JR, 2007, DEV BIOL, V311, P359, DOI 10.1016/j.ydbio.2007.08.032; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Subramanian S, 2008, ONCOGENE, V27, P2015, DOI 10.1038/sj.onc.1210836; Tang HB, 2009, MOL BIOL CELL, V20, P1120, DOI 10.1091/mbc.E08-07-0759; Taniguchi E, 2008, ONCOGENE, V27, P6550, DOI 10.1038/onc.2008.255; Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	39	108	112	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3427	3437		10.1096/fj.09-150698	http://dx.doi.org/10.1096/fj.09-150698			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20466878	Green Published			2022-12-28	WOS:000281446400030
J	Unsworth, H; Raguz, S; Edwards, HJ; Higgins, CF; Yague, E				Unsworth, H.; Raguz, S.; Edwards, H. J.; Higgins, C. F.; Yaguee, E.			mRNA escape from stress granule sequestration is dictated by localization to the endoplasmic reticulum	FASEB JOURNAL			English	Article						membrane proteins; RNA localization; drug resistance; P-glycoprotein; TIA-1	P-GLYCOPROTEIN; TRANSLATION; PROTEINS; CELLS; MEMBRANE; BINDING; CANCER; COMPARTMENT; EXPRESSION; INITIATION	In mammalian cells, cytotoxic stress triggers several signaling cascades that converge in the phosphorylation of translation initiation factor 2 alpha, shuttling of nuclear RNA-binding proteins such as TIA-1 to the cytoplasm, and aggregation of most cellular mRNAs into TIA-1-containing stress granules (SGs). As a result, protein synthesis is greatly impaired. Here we describe different dynamics of endogenous transcripts according to their cellular location, in response to stress. While cytosolic mRNAs aggregate into SGs, endoplasmic reticulum (ER) -bound transcripts escape sequestration. This has been specifically demonstrated using the multidrug resistance transporter gene (MDR1) as a model and showing that chimeric RNA constructs can be directed to the cytosol or tethered to the ER depending on the nature of the chimera, in response to stress. In addition, polysome profile analyses indicate that, on stress, ribosomes do not disengage from ER-associated transcripts (puromycin insensitive) and recover their translation status faster than SG-targeted cytosolic mRNAs once the stress is lifted. These findings have important implications for cell survival given that many membrane proteins, which are translated at the ER, have important roles in detoxification.-Unsworth, H., Raguz, S., Edwards, H. J., Higgins, C. F., Yague, E. mRNA escape from stress granule sequestration is dictated by localization to the endoplasmic reticulum. FASEB J. 24, 3370-3380 (2010). www.fasebj.org	[Yaguee, E.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London W12 0NN, England; [Unsworth, H.; Raguz, S.; Edwards, H. J.; Higgins, C. F.; Yaguee, E.] MRC, Ctr Clin Sci, London, England	Imperial College London	Yague, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	ernesto.yague@imperial.ac.uk			UK Medical Research Council (MRC); MRC	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Tristan Rodriguez for his advice on FISH hybridization techniques, Ana Pombo and Sheila Quingchun Xie for their advice on confocal microscopy, and Anne Willis, Christopher Proud, Michael Clemens, Jeremy Brown, and John E. Hesketh for their helpful comments at various stages of the project. This work was funded by the UK Medical Research Council (MRC). H.U. was the recipient of an MRC Career Development Fellowship. The authors declare no conflict of interest.	Anderson P, 2002, J CELL SCI, V115, P3227; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; Anthony V, 2002, CURR PROTEIN PEPT SC, V3, P485, DOI 10.2174/1389203023380503; Blott EJ, 1999, EMBO J, V18, P6800, DOI 10.1093/emboj/18.23.6800; BONIFACINO JS, 1998, CURRENT PROTOCOLS MO; Borgese N, 2007, CURR OPIN CELL BIOL, V19, P368, DOI 10.1016/j.ceb.2007.04.019; Callaghan R, 2008, J CLIN PHARMACOL, V48, P365, DOI 10.1177/0091270007311568; de Silanes IL, 2005, MOL CELL BIOL, V25, P9520, DOI 10.1128/MCB.25.21.9520-9531.2005; Egea PF, 2005, CURR OPIN STRUC BIOL, V15, P213, DOI 10.1016/j.sbi.2005.03.007; Eulalio A, 2007, NAT REV MOL CELL BIO, V8, P9, DOI 10.1038/nrm2080; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Heinrich SU, 2003, EMBO J, V22, P3654, DOI 10.1093/emboj/cdg346; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Kostenko EV, 2000, FEBS LETT, V475, P181, DOI 10.1016/S0014-5793(00)01650-1; Lerner RS, 2006, RNA, V12, P775, DOI 10.1261/rna.2318906; Lerner RS, 2003, RNA, V9, P1123, DOI 10.1261/rna.5610403; Liscovitch M, 2007, CANCER LETT, V245, P350, DOI 10.1016/j.canlet.2006.01.013; Marnbula SS, 2007, METHODS, V43, P168, DOI 10.1016/j.ymeth.2007.06.009; Modok S, 2006, CURR OPIN PHARMACOL, V6, P350, DOI 10.1016/j.coph.2006.01.009; Nicchitta CV, 2005, BIOCHEM CELL BIOL, V83, P687, DOI 10.1139/O05-147; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Raguz S, 2008, INT J CANCER, V122, P1058, DOI 10.1002/ijc.23149; Randle RA, 2007, BIOCHEM J, V406, P445, DOI 10.1042/BJ20070235; Sivan G, 2007, MOL CELL BIOL, V27, P6639, DOI 10.1128/MCB.00798-07; SKACH WR, 1993, J BIOL CHEM, V268, P23552; Stephens SB, 2005, MOL BIOL CELL, V16, P5819, DOI 10.1091/mbc.E05-07-0685; Stohr N, 2006, J CELL BIOL, V175, P527, DOI 10.1083/jcb.200608071; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Thermann R, 2007, NATURE, V447, P875, DOI 10.1038/nature05878; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Yague E, 2003, J BIOL CHEM, V278, P10344, DOI 10.1074/jbc.M211093200; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709	34	49	51	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3370	3380		10.1096/fj.09-151142	http://dx.doi.org/10.1096/fj.09-151142			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20453113	Green Submitted			2022-12-28	WOS:000281446400025
J	Huster, M; Frei, E; Hofmann, F; Wegener, JW				Huster, Maria; Frei, Eva; Hofmann, Franz; Wegener, Joerg W.			A complex of Ca(V)1.2/PKC is involved in muscarinic signaling in smooth muscle	FASEB JOURNAL			English	Article						micturition; contraction; urinary bladder; phospholipase D	PROTEIN-KINASE-C; RAT URINARY-BLADDER; CARBACHOL-INDUCED CONTRACTION; CALCIUM-CHANNELS; GUINEA-PIG; CA2+ CHANNELS; TRANSDUCTION PATHWAYS; MYOSIN PHOSPHATASE; DETRUSOR MUSCLE; XENOPUS OOCYTES	Here we present functional and biochemical evidence for a Ca2+ channel (Ca(V)1.2)/protein kinase C (PKC) signaling complex being a key player in muscarinic regulation of urinary bladder smooth muscle. Muscarinic stimulation induced Ca2+ signals and concomitant contractions in detrusor muscle from mice that were dependent on functional Ca2+ channels. These signals were still present in muscles being depolarized by 85 mM extracellular K+. Muscarinic-induced contractions were reduced by a PKC inhibitor [bisindolylmaleimide I (BIM-I)] and a phospholipase D (PLD) inhibitor (1-butanol). A phorbol ester (PDBu) enlarged muscarinic-induced Ca2+ signals and contractions. The effects of BIM-I and PDBu were inhibited by isradipine and/or absent in muscles from Ca(V)1.2-deficient mice. Both carbachol and PDBu increased Ca(V)1.2 channel currents in isolated bladder myocytes. Blue native-PAGE electrophoresis revealed that Ca(V)1.2, PKC, and PLD are closely associated in muscles being previously stimulated by carbachol. Immunoprecipitation using anti-Ca(V)1.2 followed by Western blotting demonstrated that Ca(V)1.2 and PKC are coupled in stimulated muscles from wild-type mice. Autoradiography on immunoprecipitates showed that Ca(V)1.2 is a substrate for PKC-mediated phosphorylation. These findings suggest that a signaling complex consisting of Ca(V)1.2, PKC, and, probably, PLD controls muscarinic-mediated phasic contraction of urinary bladder smooth muscle.-Huster, M., Frei, E., Hofmann, F., Wegener, J.W. A complex of Ca(V)1.2/PKC is involved in muscarinic signaling in smooth muscle. FASEB J. 24, 2651-2659 (2010). www.fasebj.org	[Huster, Maria; Frei, Eva; Hofmann, Franz; Wegener, Joerg W.] Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Wegener, JW (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	wegener@ipt.med.tu-muenchen.de		Wegener, Jorg/0000-0002-8129-1537	Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This study was supported by the Deutsche Forschungsgemeinschaft. The authors thank Lucia Koblitz for excellent technical assistance.	Albert AP, 2005, J PHYSIOL-LONDON, V566, P769, DOI 10.1113/jphysiol.2005.090852; An JY, 2002, BRIT J PHARMACOL, V137, P1001, DOI 10.1038/sj.bjp.0704954; Andersson KE, 2004, PHYSIOL REV, V84, P935, DOI 10.1152/physrev.00038.2003; Balijepalli RC, 2006, P NATL ACAD SCI USA, V103, P7500, DOI 10.1073/pnas.0503465103; BO X, 1990, BRIT J PHARMACOL, V101, P494, DOI 10.1111/j.1476-5381.1990.tb12736.x; Callaghan B, 2004, CIRC RES, V94, P626, DOI 10.1161/01.RES.0000118248.17466.B7; Chang S, 2009, LAB INVEST, V89, P823, DOI 10.1038/labinvest.2009.38; CREED KE, 1983, J PHYSIOL-LONDON, V338, P149, DOI 10.1113/jphysiol.1983.sp014666; Durlu-Kandilci NT, 2006, BRIT J PHARMACOL, V148, P376, DOI 10.1038/sj.bjp.0706723; Ekman M, 2009, BJU INT, V104, P690, DOI 10.1111/j.1464-410X.2009.08576.x; Ekman M, 2009, BJU INT, V103, P90, DOI 10.1111/j.1464-410X.2008.07935.x; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; Fleichman M, 2004, J PHARMACOL EXP THER, V308, P54, DOI 10.1124/jpet.103.058255; FOVAEUS M, 1987, J UROLOGY, V137, P798, DOI 10.1016/S0022-5347(17)44214-5; Frazier EP, 2008, N-S ARCH PHARMACOL, V377, P449, DOI 10.1007/s00210-007-0208-0; Frazier EP, 2007, J PHARMACOL EXP THER, V322, P998, DOI 10.1124/jpet.107.125393; Frei E, 2009, EUR J PHARMACOL, V610, P106, DOI 10.1016/j.ejphar.2009.03.036; FUJII K, 1988, J PHYSIOL-LONDON, V404, P39, DOI 10.1113/jphysiol.1988.sp017277; Gerthoffer WT, 2005, AM J PHYSIOL-GASTR L, V288, pG849, DOI 10.1152/ajpgi.00530.2004; IACOVOU JW, 1990, J UROLOGY, V144, P775, DOI 10.1016/S0022-5347(17)39590-3; Kajioka S, 2002, EUR J PHARMACOL, V443, P19, DOI 10.1016/S0014-2999(02)01593-5; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Koller A, 2003, BIOCHEM BIOPH RES CO, V300, P155, DOI 10.1016/S0006-291X(02)02799-7; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; Lai HH, 2004, NEUROCHEM INT, V45, P1185, DOI 10.1016/j.neuint.2004.06.016; Lemke T, 2008, J BIOL CHEM, V283, P34738, DOI 10.1074/jbc.M804981200; Lin MJ, 1998, N-S ARCH PHARMACOL, V357, P553, DOI 10.1007/PL00005207; Liu XR, 2001, GASTROENTEROLOGY, V120, P480, DOI 10.1053/gast.2001.21167; Ludwig A, 1997, J NEUROSCI, V17, P1339; Matsui M, 2000, P NATL ACAD SCI USA, V97, P9579, DOI 10.1073/pnas.97.17.9579; MUNRO DD, 1994, CELL CALCIUM, V15, P369, DOI 10.1016/0143-4160(94)90012-4; Murthy KS, 2006, ANNU REV PHYSIOL, V68, P345, DOI 10.1146/annurev.physiol.68.040504.094707; NAKAYAMA S, 1993, BRIT J PHARMACOL, V110, P317, DOI 10.1111/j.1476-5381.1993.tb13811.x; NELSON MT, 1988, NATURE, V336, P382, DOI 10.1038/336382a0; O-Uchi J, 2005, P NATL ACAD SCI USA, V102, P9400, DOI 10.1073/pnas.0503569102; Ratz PH, 2002, BRIT J PHARMACOL, V137, P983, DOI 10.1038/sj.bjp.0704952; Rivera L, 2006, BJU INT, V98, P868, DOI 10.1111/j.1464-410X.2006.06431.x; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; Salamanca DA, 2005, BIOCHEM PHARMACOL, V70, P1537, DOI 10.1016/j.bcp.2005.07.017; Schneider T, 2004, J PHARMACOL EXP THER, V309, P1148, DOI 10.1124/jpet.103.063735; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; SINGERLAHAT D, 1992, FEBS LETT, V306, P113, DOI 10.1016/0014-5793(92)80980-U; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Wegener JW, 2004, FASEB J, V18, P1159, DOI 10.1096/fj.04-1516fje; Weiss S, 2004, J BIOL CHEM, V279, P12503, DOI 10.1074/jbc.M310196200; Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62; Woodsome TP, 2001, J PHYSIOL-LONDON, V535, P553, DOI 10.1111/j.1469-7793.2001.t01-1-00553.x; Wuest M, 2007, EUR J PHARMACOL, V565, P180, DOI 10.1016/j.ejphar.2007.02.046; Yang L, 2005, J BIOL CHEM, V280, P207, DOI 10.1074/jbc.M410509200; Yang L, 2009, BIOCHEMISTRY-US, V48, P6674, DOI 10.1021/bi900322a; YOSHINO M, 1995, EXP PHYSIOL, V80, P575, DOI 10.1113/expphysiol.1995.sp003868	52	19	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2010	24	8					2651	2659		10.1096/fj.09-149856	http://dx.doi.org/10.1096/fj.09-149856			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371628				2022-12-28	WOS:000285005400007
J	Lui, JC; Forcinito, P; Chang, M; Chen, WP; Barnes, KM; Baron, J				Lui, Julian C.; Forcinito, Patricia; Chang, Maria; Chen, Weiping; Barnes, Kevin M.; Baron, Jeffrey			Coordinated postnatal down-regulation of multiple growth-promoting genes: evidence for a genetic program limiting organ growth	FASEB JOURNAL			English	Article						organ size; microarray; histone modification; proliferation	HUMAN GENOME; CELLULAR MEMORY; SOMATIC GROWTH; GROUP PROTEINS; FETAL-RAT; LIVER; SIZE; POLYCOMB; DIFFERENTIATION; TRANSPLANTS	Children grow, but adults do not. The cessation of growth in multiple organs is the end result of a progressive decline in cell proliferation beginning in early life. The mechanisms responsible for this growth deceleration are largely unknown. Using expression microarray and real-time PCR, we identified a common program of gene expression in lung, kidney, and liver during growth deceleration in juvenile rats. Gene ontology analyses and siRNA-mediated knockdown in vitro indicated that many of the down-regulated genes are growth promoting. Down-regulated genes in the program showed declining histone H3K4 trimethylation with age, implicating underlying epigenetic mechanisms. To investigate the physiological processes driving the genetic program, a tryptophan-deficient diet was used to temporarily inhibit juvenile growth in newborn rats for 4 wk. Afterward, microarray analysis showed that the genetic program had been delayed, implying that it is driven by body growth itself rather than age. Taken together, the findings suggest that growth in early life induces progressive down-regulation of a large set of proliferation-stimulating genes, causing organ growth to slow and eventually cease.-Lui, J. C., Forcinito, P., Chang, M., Chen, W., Barnes, K. M., Baron, J. Coordinated postnatal down-regulation of multiple growth-promoting genes: evidence for a genetic program limiting organ growth. FASEB J. 24, 3083-3092 (2010). www.fasebj.org	[Lui, Julian C.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Dev Endocrinol Branch, Program Dev Endocrinol & Genet, NIH,CRC, Bethesda, MD 20892 USA; [Chen, Weiping] NIDDKD, Microarray Core Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lui, JC (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Dev Endocrinol Branch, Program Dev Endocrinol & Genet, NIH,CRC, Room 1-3330,10 Ctr Dr,MSC-1103, Bethesda, MD 20892 USA.	luichunk@mail.nih.gov	Lui, Julian/E-2253-2012; Chen, Wei/GZK-7348-2022	Lui, Julian/0000-0002-0611-4901; Forcinito, Patricia/0000-0001-9754-9881	Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000640] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.	Bantignies F, 2006, CURR OPIN CELL BIOL, V18, P275, DOI 10.1016/j.ceb.2006.04.003; Barreyro FJ, 2007, J BIOL CHEM, V282, P27141, DOI 10.1074/jbc.M704391200; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; Chang M, 2008, PEDIATR RES, V64, P240, DOI 10.1203/PDR.0b013e318180e47a; COOKE PS, 1986, BIOL NEONATE, V49, P211; El Khattabi I, 2003, AM J PHYSIOL-ENDOC M, V285, pE991, DOI 10.1152/ajpendo.00037.2003; Finkielstain GP, 2009, ENDOCRINOLOGY, V150, P1791, DOI 10.1210/en.2008-0868; Gomer RH, 2001, NAT REV MOL CELL BIO, V2, P48, DOI 10.1038/35048058; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; KAM I, 1987, HEPATOLOGY, V7, P362, DOI 10.1002/hep.1840070225; Kennedy D, 2005, SCIENCE, V309, P75, DOI 10.1126/science.309.5731.75; Koch CM, 2007, GENOME RES, V17, P691, DOI 10.1101/gr.5704207; Lee S, 2008, MOL ENDOCRINOL, V22, P1312, DOI 10.1210/me.2008-0012; Lui JC, 2008, AM J PHYSIOL-REG I, V295, pR189, DOI 10.1152/ajpregu.00182.2008; McKinnell IW, 2008, NAT CELL BIOL, V10, P77, DOI 10.1038/ncb1671; Narayanan A, 2007, P NATL ACAD SCI USA, V104, P10835, DOI 10.1073/pnas.0704351104; O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200; Orozco-Suarez S, 2003, INT J DEV NEUROSCI, V21, P13, DOI 10.1016/S0736-5748(02)00124-7; Pape L, 2006, NEPHROL DIAL TRANSPL, V21, P2596, DOI 10.1093/ndt/gfl119; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; ROSE SR, 1991, J CLIN ENDOCR METAB, V73, P428, DOI 10.1210/jcem-73-2-428; Sakai Y, 2002, CELL TRANSPLANT, V11, P435; Schafer R, 2006, ARTIF ORGANS, V30, P130, DOI 10.1111/j.1525-1594.2006.00199.x; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; SEGALL PE, 1976, MECH AGEING DEV, V5, P109, DOI 10.1016/0047-6374(76)90012-9; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688; Stanger BZ, 2007, NATURE, V445, P886, DOI 10.1038/nature05537; Sutter NB, 2007, SCIENCE, V316, P112, DOI 10.1126/science.1137045; Watanabe N, 2007, HEPATOLOGY, V45, P1240, DOI 10.1002/hep.21539; WINICK M, 1965, DEV BIOL, V12, P451, DOI 10.1016/0012-1606(65)90009-6; Yan CH, 2006, MOL CELL BIOL, V26, P6357, DOI 10.1128/MCB.00311-06; Yao M, 2007, ENDOCRINOLOGY, V148, P2518, DOI 10.1210/en.2006-1413; ZAPF J, 1981, J CLIN INVEST, V68, P1321, DOI 10.1172/JCI110379	36	40	41	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2010	24	8					3083	3092		10.1096/fj.09-152835	http://dx.doi.org/10.1096/fj.09-152835			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371622	Green Published			2022-12-28	WOS:000285005400044
J	Nguyen, A; Rauch, TA; Pfeifer, GP; Hu, VW				Nguyen, AnhThu; Rauch, Tibor A.; Pfeifer, Gerd P.; Hu, Valerie W.			Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain	FASEB JOURNAL			English	Article						DNA methylation; brain expression; BLC-2 gene expression; CpG island microarrays; immunohistochemistry	NUCLEAR RECEPTOR; DNA METHYLATION; ALPHA; EXPRESSION; EXPLORATION; MECHANISMS; DYSREGULATION; CEREBELLUM; MUTATIONS; CHILDREN	Autism is currently considered a multigene disorder with epigenetic influences. To investigate the contribution of DNA methylation to autism spectrum disorders, we have recently completed large-scale methylation profiling by CpG island microarray analysis of lymphoblastoid cell lines derived from monozygotic twins discordant for diagnosis of autism and their nonautistic siblings. Methylation profiling revealed many candidate genes differentially methylated between discordant MZ twins as well as between both twins and nonautistic siblings. Bioinformatics analysis of the differentially methylated genes demonstrated enrichment for high-level functions including gene transcription, nervous system development, cell death/survival, and other biological processes implicated in autism. The methylation status of 2 of these candidate genes, BCL-2 and retinoic acid-related orphan receptor alpha (RORA), was further confirmed by bisulfite sequencing and methylation-specific PCR, respectively. Immunohistochemical analyses of tissue arrays containing slices of the cerebellum and frontal cortex of autistic and age-and sex-matched control subjects revealed decreased expression of RORA and BCL-2 proteins in the autistic brain. Our data thus confirm the role of epigenetic regulation of gene expression via differential DNA methylation in idiopathic autism, and furthermore link molecular changes in a peripheral cell model with brain pathobiology in autism.-Nguyen, A., Rauch, T. A., Pfeifer, G. P., Hu, V. W. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. FASEB J. 24, 3036-3051 (2010). www.fasebj.org	[Nguyen, AnhThu; Hu, Valerie W.] George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Rauch, Tibor A.; Pfeifer, Gerd P.] City Hope Natl Med Ctr, Dept Canc Biol, Duarte, CA USA	George Washington University; City of Hope	Hu, VW (corresponding author), George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, 2300 Eye St NW, Washington, DC 20037 USA.	bcmvwh@gwumc.edu		Hu, Valerie/0000-0002-3357-0777	Autistic Speaks [2381]; U.S. National Institutes of Health [R21 MH073393]; National Institute of Mental Health [1U24MH081810]; NATIONAL INSTITUTE OF MENTAL HEALTH [U24MH081810, R21MH073393] Funding Source: NIH RePORTER	Autistic Speaks; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by a grant from Autistic Speaks (2381 to V.W.H.) and, in part, by U.S. National Institutes of Health grant R21 MH073393 (V.W.H.). The authors are grateful to Dr. Anastas Popratiloff (Director, Center for Microscopy and Image Analysis at George Washington University Medical Center) for his assistance with microscopy. The authors also thank Dr. Charles Eberhart (Johns Hopkins University, Baltimore, MD, USA) and Dr. Janine LaSalle (University of California, Davis, CA, USA) for making the brain tissue arrays available to us through the Autism Tissue Program, and the families of the donors for their invaluable gift to autism research. The authors gratefully acknowledge the resources (both LCL and phenotypic data) provided by the Autism Genetic Resource Exchange (AGRE) Consortium and the participating AGRE families. AGRE is a program of Autism Speaks and is supported, in part, by grant 1U24MH081810 from the National Institute of Mental Health to Clara M. Lajonchere (PI). The AGRE Consortium: Dan Geschwind, M.D., Ph.D., University of California-Los Angeles (UCLA), Los Angeles, CA, USA; Maja Bucan, Ph.D., University of Pennsylvania, Philadelphia, PA, USA; W. Ted Brown, M.D., Ph.D., F.A.C.M.G., New York State Institute for Basic Research in Developmental Disabilities, Long Island, NY, USA; Rita M. Cantor, Ph.D., UCLA School of Medicine, Los Angeles, CA, USA; John N. Constantino, M.D., Washington University School of Medicine, St. Louis, MO, USA; T. Conrad Gilliam, Ph.D., University of Chicago, Chicago, IL, USA; Martha Herbert, M.D., Ph.D., Harvard Medical School, Boston, MA, USA; Clara Lajonchere, Ph.D., Cure Autism Now, Los Angeles, CA, USA; David H. Ledbetter, Ph.D., Emory University, Atlanta, GA, USA; Christa Lese-Martin, Ph.D., Emory University, Atlanta, GA, USA; Janet Miller, J.D., Ph.D., Cure Autism Now, Los Angeles, CA, USA; Stanley F. Nelson, M.D., UCLA School of Medicine, Los Angeles, CA, USA; Gerard D. Schellenberg, Ph.D., University of Washington, Seattle, WA, USA; Carol A. Samango-Sprouse, Ed.D., George Washington University, Washington, DC, USA; Sarah Spence, M.D., Ph.D., UCLA, Los Angeles, CA, USA; Matthew State, M.D., Ph.D., Yale University, New Haven, CT, USA; Rudolph E. Tanzi, Ph.D., Massachusetts General Hospital, Boston, MA, USA. The authors' contributions are as follows: A.N. performed all of the experiments in this study and cowrote the manuscript in partial fulfillment of the requirements for the master's degree in biochemistry at George Washington University; T.A.R. and G.P.P. generously provided the purified GST-tagged MBD2b and His-tagged MBD3L1 proteins as well as advice on the MIRA procedures; V.W.H. conceived and designed the study, provided overall supervision, and wrote the manuscript.	Abdolmaleky HM, 2008, PHARMACOGENOMICS, V9, P1809, DOI 10.2217/14622416.9.12.1809; Akashi M, 2005, NAT STRUCT MOL BIOL, V12, P441, DOI 10.1038/nsmb925; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; Baron CA, 2006, J AUTISM DEV DISORD, V36, P973, DOI 10.1007/s10803-006-0134-x; Beaudet AL, 2007, NAT MED, V13, P534, DOI 10.1038/nm0507-534; Boukhtouche F, 2006, J NEUROCHEM, V96, P1778, DOI 10.1111/j.1471-4159.2006.03708.x; Boukhtouche F, 2006, CEREBELLUM, V5, P97, DOI 10.1080/14734220600750184; Bourgeron T, 2007, COLD SPRING HARB SYM, V72, P645, DOI 10.1101/sqb.2007.72.020; Casanova MF, 2006, NEUROSCIENTIST, V12, P435, DOI 10.1177/1073858406290375; Champagne FA, 2008, FRONT NEUROENDOCRIN, V29, P386, DOI 10.1016/j.yfrne.2008.03.003; Chauhan Abha, 2006, Pathophysiology, V13, P171, DOI 10.1016/j.pathophys.2006.05.007; Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684; Cohly HHP, 2005, INT REV NEUROBIOL, V71, P317, DOI 10.1016/S0074-7742(05)71013-8; Davies W, 2001, ANN MED, V33, P428, DOI 10.3109/07853890108995956; Doulazmi M, 1999, J COMP NEUROL, V411, P267; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; Eberhart CG, 2006, J AUTISM DEV DISORD, V36, P1131, DOI 10.1007/s10803-006-0135-9; Enstrom AM, 2009, BRAIN BEHAV IMMUN, V23, P124, DOI 10.1016/j.bbi.2008.08.001; Fatemi SH, 2001, J AUTISM DEV DISORD, V31, P529, DOI 10.1023/A:1013234708757; Fatemi SH, 2001, SYNAPSE, V42, P281, DOI 10.1002/syn.10002; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; FOLSTEIN S, 1977, J CHILD PSYCHOL PSYC, V18, P297, DOI 10.1111/j.1469-7610.1977.tb00443.x; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, GENOMICS, V28, P596, DOI 10.1006/geno.1995.1197; Gold DA, 2003, NEURON, V40, P1119, DOI 10.1016/S0896-6273(03)00769-4; Gold DA, 2007, BRAIN RES, V1140, P19, DOI 10.1016/j.brainres.2005.11.080; GOODALL G, 1987, BEHAV NEURAL BIOL, V47, P307, DOI 10.1016/S0163-1047(87)90422-5; Gregg JP, 2008, GENOMICS, V91, P22, DOI 10.1016/j.ygeno.2007.09.003; Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62; Hadj-Sahraoui N, 2001, DEV BRAIN RES, V126, P201, DOI 10.1016/S0165-3806(01)00095-5; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Hogart A, 2007, HUM MOL GENET, V16, P691, DOI 10.1093/hmg/ddm014; Hu VW, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-118; Hu VW, 2009, AUTISM RES, V2, P78, DOI 10.1002/aur.73; Hu VW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005775; Jarvis CI, 2002, MOL CELL ENDOCRINOL, V186, P1, DOI 10.1016/S0303-7207(01)00668-2; Kaminsky Z, 2006, ANN MED, V38, P530, DOI 10.1080/07853890600989211; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Lalonde R, 2008, NEUROBIOL LEARN MEM, V90, P472, DOI 10.1016/j.nlm.2008.05.004; LALONDE R, 1988, BEHAV BRAIN RES, V27, P273, DOI 10.1016/0166-4328(88)90124-6; LALONDE R, 1987, PHYSIOL BEHAV, V41, P115, DOI 10.1016/0031-9384(87)90139-9; LALONDE R, 1987, J NEUROGENET, V4, P285, DOI 10.3109/01677068709102349; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; Loat CS, 2008, GENES BRAIN BEHAV, V7, P754, DOI 10.1111/j.1601-183X.2008.00414.x; Lopez-Rangel E, 2006, CLIN GENET, V69, P21, DOI 10.1111/j.1399-0004.2006.00543a.x; Mehler MF, 2006, J PHYSIOL-LONDON, V575, P333, DOI 10.1113/jphysiol.2006.113191; Melke J, 2008, MOL PSYCHIATR, V13, P90, DOI 10.1038/sj.mp.4002016; Nagarajan Raman P, 2006, Epigenetics, V1, pe1; Nakayama Atsuo, 2006, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V26, P209; Nicholas B, 2007, MOL PSYCHIATR, V12, P581, DOI 10.1038/sj.mp.4001953; Nishimura Y, 2007, HUM MOL GENET, V16, P1682, DOI 10.1093/hmg/ddm116; Palmen SJMC, 2004, BRAIN, V127, P2572, DOI 10.1093/brain/awh287; Pardo CA, 2006, INT REV PSYCHIATR, V17, P485, DOI 10.1080/02646830500381930; Polleux F, 2004, MENT RETARD DEV D R, V10, P303, DOI 10.1002/mrdd.20044; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Rauch T, 2006, CANCER RES, V66, P7939, DOI 10.1158/0008-5472.CAN-06-1888; Schanen NC, 2006, HUM MOL GENET, V15, pR138, DOI 10.1093/hmg/ddl213; SIEGEL B, 1991, PSYCHIAT CLIN N AM, V14, P53; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van den Veyver IB, 2001, BRAIN DEV-JPN, V23, pS147, DOI 10.1016/S0387-7604(01)00376-X; van Vliet J, 2007, CELL MOL LIFE SCI, V64, P1531, DOI 10.1007/s00018-007-6526-z; VOLKMAR FR, 1994, AM J PSYCHIAT, V151, P1361; Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x	64	242	250	0	34	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					3036	3051		10.1096/fj.10-154484	http://dx.doi.org/10.1096/fj.10-154484			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20375269	Green Published			2022-12-28	WOS:000285005400041
J	Pan, H; Myerson, JW; Ivashyna, O; Soman, NR; Marsh, JN; Hood, JL; Lanza, GM; Schlesinger, PH; Wickline, SA				Pan, Hua; Myerson, Jacob W.; Ivashyna, Olena; Soman, Neelesh R.; Marsh, Jon N.; Hood, Joshua L.; Lanza, Gregory M.; Schlesinger, Paul H.; Wickline, Samuel A.			Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures	FASEB JOURNAL			English	Article						molecular imaging; targeted drug delivery; biomarker; nanoparticles; liposome	ADHESION MOLECULES; MELITTIN; ANGIOGENESIS; BINDING; MICROPARTICLES; KINETICS; DELIVERY	Current strategies for deploying synthetic nanocarriers involve the creation of agents that incorporate targeting ligands, imaging agents, and/or therapeutic drugs into particles as an integral part of the formulation process. Here we report the development of an amphipathic peptide linker that enables postformulation editing of payloads without the need for reformulation to achieve multiplexing capability for lipidic nanocarriers. To exemplify the flexibility of this peptide linker strategy, 3 applications were demonstrated: converting nontargeted nanoparticles into targeting vehicles; adding cargo to preformulated targeted nanoparticles for in vivo site-specific delivery; and labeling living cells for in vivo tracking. This strategy is expected to enhance the clinical application of molecular imaging and/or targeted therapeutic agents by offering extended flexibility for multiplexing targeting ligands and/or drug payloads that can be selected after base nanocarrier formulation.-Pan, H., Myerson, J. W., Ivashyna, O., Soman, N. R., Marsh, J. N., Hood, J. L., Lanza, G. M., Schlesinger, P. H., Wickline, S. A.. Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures. FASEB J. 24, 2928-2937 (2010). www.fasebj.org	[Wickline, Samuel A.] Washington Univ, Sch Med, C TRAIN, Dept Med, St Louis, MO 63108 USA; [Myerson, Jacob W.; Soman, Neelesh R.; Lanza, Gregory M.; Wickline, Samuel A.] Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO 63108 USA; [Ivashyna, Olena; Schlesinger, Paul H.; Wickline, Samuel A.] Washington Univ, Sch Med, Dept Mol & Cell Biol, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Wickline, SA (corresponding author), Washington Univ, Sch Med, C TRAIN, Dept Med, 4320 Forest Pk Ave,Suite 101,Campus Box 8215, St Louis, MO 63108 USA.	wicklines@aol.com	Hood, Joshua L./I-9797-2019; Pan, Hua/C-7662-2011; Schlesinger, Paul H/C-6049-2012	Hood, Joshua L./0000-0003-3998-4118; 	National Institutes of Health [HL073646, CA119342]; NATIONAL CANCER INSTITUTE [U54CA119342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056223] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Stacy J. Allen, Michael J. Scott, and Xiaoxia Yang for critical support with the animal study, Eric T. Christenson for helpful discussions, Ralph Fuhrhop for the PFC nanoparticle formulation, and Huiying Zhang for assisting with the histological analysis. This work was supported by National Institutes of Health grants HL073646 and CA119342 to S.A.W.	ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303, DOI 10.1039/dc9868100303; BAZZO R, 1988, EUR J BIOCHEM, V173, P139, DOI 10.1111/j.1432-1033.1988.tb13977.x; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; BLONDELLE SE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P331, DOI 10.1016/0167-4838(93)90024-L; Cai WB, 2008, J NUCL MED, V49, p113S, DOI 10.2967/jnumed.107.045922; DAWSON CR, 1978, BIOCHIM BIOPHYS ACTA, V510, P75, DOI 10.1016/0005-2736(78)90131-1; DEGRADO WF, 1982, BIOPHYS J, V37, P329, DOI 10.1016/S0006-3495(82)84681-X; DEMPSEY CE, 1991, FEBS LETT, V281, P240, DOI 10.1016/0014-5793(91)80402-O; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; GEVOD VS, 1984, BIOPHYS J, V45, P1079, DOI 10.1016/S0006-3495(84)84255-1; Hartge Martin M, 2007, Diab Vasc Dis Res, V4, P84; Kelly KA, 2006, MOL IMAGING BIOL, V8, P201, DOI 10.1007/s11307-006-0043-6; Klocek G, 2009, BIOCHEMISTRY-US, V48, P2586, DOI 10.1021/bi802127h; Lanza GM, 2005, CURR TOP DEV BIOL, V70, P57, DOI 10.1016/S0070-2153(05)70003-X; Li D, 2007, J BIOMAT SCI-POLYM E, V18, P545, DOI 10.1163/156856207780852532; McAteer MA, 2008, ARTERIOSCL THROM VAS, V28, P77, DOI 10.1161/ATVBAHA.107.145466; McAteer MA, 2007, NAT MED, V13, P1253, DOI 10.1038/nm1631; MOLLAY C, 1973, BIOCHIM BIOPHYS ACTA, V316, P196, DOI 10.1016/0005-2760(73)90009-X; Morawski AM, 2004, MAGN RESON MED, V52, P1255, DOI 10.1002/mrm.20287; Namiki Y, 2009, NAT NANOTECHNOL, V4, P598, DOI [10.1038/NNANO.2009.202, 10.1038/nnano.2009.202]; Rapoport M, 2009, EXPERT OPIN DRUG DEL, V6, P453, DOI [10.1517/17425240902887029, 10.1517/17425240902887029 ]; Rex S, 2000, BIOPHYS CHEM, V85, P209, DOI 10.1016/S0301-4622(00)00121-6; Rivett DE, 1996, BIOCHEM J, V316, P525, DOI 10.1042/bj3160525; Schmieder AH, 2005, MAGN RESON MED, V53, P621, DOI 10.1002/mrm.20391; SESSA G, 1969, J BIOL CHEM, V244, P3575; Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r; Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842; STROM R, 1978, FEBS LETT, V96, P45, DOI 10.1016/0014-5793(78)81059-X; Toraya S, 2004, BIOPHYS J, V87, P3323, DOI 10.1529/biophysj.104.046102; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; Waters EA, 2008, MAGN RESON MED, V60, P1232, DOI 10.1002/mrm.21794; WEISSMANN G, 1969, BIOCHEM PHARMACOL, V18, P1771, DOI 10.1016/0006-2952(69)90167-1; WERKMEISTER JA, 1993, BIOCHIM BIOPHYS ACTA, V1157, P50, DOI 10.1016/0304-4165(93)90077-L; Willmann JK, 2008, RADIOLOGY, V248, P936, DOI 10.1148/radiol.2483072231; Winter PM, 2006, ARTERIOSCL THROM VAS, V26, P2103, DOI 10.1161/01.ATV.0000235724.11299.76; Wu TC, 2007, CANCER RES, V67, P6003, DOI 10.1158/0008-5472.CAN-07-1543	38	28	35	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2928	2937		10.1096/fj.09-153130	http://dx.doi.org/10.1096/fj.09-153130			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20335225	Green Published			2022-12-28	WOS:000285005400032
J	Ong, ZY; Muhlhausler, BS				Ong, Z. Y.; Muhlhausler, B. S.			Maternal "junk-food" feeding of rat dams alters food choices and development of the mesolimbic reward pathway in the offspring	FASEB JOURNAL			English	Article						nutrition; programming	HIGH-FAT DIET; HYPOTHALAMIC NEURONS; DOPAMINE TRANSPORTER; OPIOID RECEPTOR; GENE-EXPRESSION; NEUROPEPTIDE-Y; OBESITY; PREGNANCY; TERM; LACTATION	Individuals exposed to high-fat, high-sugar diets before birth have an increased risk of obesity in later life. Recent studies have shown that these offspring exhibit increased preference for fat, leading to suggestions that perinatal exposure to high-fat, high-sugar foods results in permanent changes within the central reward system that increase the subsequent drive to overconsume palatable foods. The present study has determined the effect of a maternal "junk-food" diet on the expression of key components of the mesolimbic reward pathway in the offspring of rat dams at 6 wk and 3 mo of age. We show that offspring of junk-food-fed (JF) dams exhibit higher fat intake from weaning until at least 3 mo of age (males: 16 +/- 0.6 vs. 11 +/- 0.8 g/kg/d; females: 19 +/- 1.3 vs. 13 +/- 0.4 g/kg/d; P < 0.01). mRNA expression of mu-opioid receptor (Mu) was 1.6-fold higher (P < 0.01) and dopamine active transporter (DAT) was 2-fold lower (P < 0.05) in JF offspring at 6 wk of age. By 3 mo, these differences were reversed, and Mu mRNA expression was 2.8-fold lower (P < 0.01) and DAT mRNA expression was 1.9-fold higher (P < 0.01) in the JF offspring. These findings suggest that perinatal exposure to high-fat, high-sugar diets results in altered development of the central reward system, resulting in increased fat intake and altered response of the reward system to excessive junk-food intake in postnatal life.-Ong, Z. Y., Muhlhausler, B. S. Maternal "junk-food" feeding of rat dams alters food choices and development of the mesolimbic reward pathway in the offspring. FASEB J. 25, 2167-2179 (2011). www.fasebj.org	[Muhlhausler, B. S.] Univ Adelaide, Sch Agr Food & Wine, FOODplus Res Ctr, Adelaide, SA 5064, Australia; [Ong, Z. Y.; Muhlhausler, B. S.] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia	University of Adelaide; University of South Australia	Muhlhausler, BS (corresponding author), Univ Adelaide, Sch Agr Food & Wine, FOODplus Res Ctr, Adelaide, SA 5064, Australia.	beverly.muhlhausler@adelaide.edu.au	Ong, Zhi Yi/AFP-0699-2022	Ong, Zhi Yi/0000-0002-8300-6955; Muhlhausler, Beverly/0000-0002-9021-6790	Clive and Vera Ramaciotti Establishment Grant; National Health and Medical Research Council of Australia; University of South Australia	Clive and Vera Ramaciotti Establishment Grant; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of South Australia	This work was supported by a Clive and Vera Ramaciotti Establishment Grant (awarded to B. M). B. M. is supported by a Peter Doherty Training Fellowship from the National Health and Medical Research Council of Australia. Z.Y. is supported by a President's Scholarship from the University of South Australia. The authors acknowledge the expert assistance of Jayne Skinner, David Phuong, and Lauren Astill with animal protocols. The authors also thank John Carragher for editorial assistance.	Antonopoulos J, 2002, NEUROSCIENCE, V110, P245, DOI 10.1016/S0306-4522(01)00575-9; Barnes MJ, 2006, PEPTIDES, V27, P3292, DOI 10.1016/j.peptides.2006.08.008; Bayol SA, 2007, BRIT J NUTR, V98, P843, DOI 10.1017/S0007114507812037; Bellinger L, 2004, BRIT J NUTR, V92, P513, DOI 10.1079/BJN20041224; Berthoud HR, 2006, OBESITY, V14, P197; Bhasin KKS, 2009, DIABETES, V58, P559, DOI 10.2337/db07-1530; Bhattacharya S, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-168; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Brand-Miller JC, 2002, AM J CLIN NUTR, V76, p281S, DOI 10.1093/ajcn/76.1.281S; Brion MJA, 2010, AM J CLIN NUTR, V91, P748, DOI 10.3945/ajcn.2009.28623; Catalano PM, 2006, BJOG-INT J OBSTET GY, V113, P1126, DOI 10.1111/j.1471-0528.2006.00989.x; Catalano PM, 2007, OBSTET GYNECOL, V109, P419, DOI 10.1097/01.AOG.0000253311.44696.85; CERRUTI C, 1994, MOL BRAIN RES, V22, P132, DOI 10.1016/0169-328X(94)90040-X; Cripps RL, 2009, CLIN SCI, V117, P85, DOI 10.1042/CS20080393; Davidowa H, 2003, EUR J NEUROSCI, V18, P613, DOI 10.1046/j.1460-9568.2003.02789.x; Erlanson-Albertsson C, 2005, BASIC CLIN PHARMACOL, V97, P61, DOI 10.1111/j.1742-7843.2005.pto_179.x; Ferezou-Viala J, 2007, AM J PHYSIOL-REG I, V293, pR1056, DOI 10.1152/ajpregu.00117.2007; Fulton S, 2006, NEURON, V51, P811, DOI 10.1016/j.neuron.2006.09.006; Fulton S, 2010, FRONT NEUROENDOCRIN, V31, P85, DOI 10.1016/j.yfrne.2009.10.003; Geiger BM, 2009, NEUROSCIENCE, V159, P1193, DOI 10.1016/j.neuroscience.2009.02.007; Gluckman Peter D, 2004, Semin Fetal Neonatal Med, V9, P419, DOI 10.1016/j.siny.2004.03.001; Gorski JN, 2006, AM J PHYSIOL-REG I, V291, pR768, DOI 10.1152/ajpregu.00138.2006; Grove KL, 2003, PHYSIOL BEHAV, V79, P47, DOI 10.1016/S0031-9384(03)00104-5; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Hommel JD, 2006, NEURON, V51, P801, DOI 10.1016/j.neuron.2006.08.023; Howie GJ, 2009, J PHYSIOL-LONDON, V587, P905, DOI 10.1113/jphysiol.2008.163477; Johnson PM, 2010, NAT NEUROSCI, V13, P635, DOI 10.1038/nn.2519; KALSBEEK A, 1988, J COMP NEUROL, V269, P58, DOI 10.1002/cne.902690105; Kelley AE, 2005, PHYSIOL BEHAV, V86, P773, DOI 10.1016/j.physbeh.2005.08.066; Kirk SL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005870; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; Mennella JA, 2009, ADV EXP MED BIOL, V639, P113, DOI 10.1007/978-1-4020-8749-3_9; Mennella JA, 2002, EARLY HUM DEV, V68, P71, DOI 10.1016/S0378-3782(02)00008-7; Muhlhausler BS, 2006, FASEB J, V20, P1257, DOI 10.1096/fj.05-5241fje; Naef L, 2008, PSYCHOPHARMACOLOGY, V197, P83, DOI 10.1007/s00213-007-1008-4; Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578; Nommsen-Rivers LA, 2010, AM J CLIN NUTR, V92, P574, DOI 10.3945/ajcn.2010.29192; Rajasingam D, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.10.047; ROLLS BA, 1986, PHYSIOL BEHAV, V38, P185, DOI 10.1016/0031-9384(86)90153-8; ROLLS BJ, 1982, PHYSIOL BEHAV, V28, P393, DOI 10.1016/0031-9384(82)90130-5; Silverman BL, 1998, DIABETES CARE, V21, pB142; Svingos AL, 1999, SYNAPSE, V34, P1; Teegarden SL, 2009, NEUROSCIENCE, V162, P924, DOI 10.1016/j.neuroscience.2009.05.029; Teegarden SL, 2007, BIOL PSYCHIAT, V61, P1021, DOI 10.1016/j.biopsych.2006.09.032; Trottier G, 1998, ENDOCRINOLOGY, V139, P3704, DOI 10.1210/en.139.9.3704; Van den Heuvel DMA, 2008, PROG NEUROBIOL, V85, P75, DOI 10.1016/j.pneurobio.2008.01.003; Velkoska E, 2005, AM J PHYSIOL-ENDOC M, V288, pE1236, DOI 10.1152/ajpendo.00505.2004; Vigano D, 2003, NEUROSCIENCE, V117, P921, DOI 10.1016/S0306-4522(02)00825-4; Vucetic Z, 2010, ENDOCRINOLOGY, V151, P4756, DOI 10.1210/en.2010-0505; Walker CD, 2008, ANN NY ACAD SCI, V1144, P189, DOI 10.1196/annals.1418.023; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982	52	167	171	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2167	2179		10.1096/fj.10-178392	http://dx.doi.org/10.1096/fj.10-178392			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21427213	Green Published			2022-12-28	WOS:000292242200009
J	Ochala, J; Lehtokari, VL; Iwamoto, H; Li, MS; Feng, HZ; Jin, JP; Yagi, N; Wallgren-Pettersson, C; Penisson-Besnier, I; Larsson, L				Ochala, Julien; Lehtokari, Vilma-Lotta; Iwamoto, Hiroyuki; Li, Meishan; Feng, Han-Zhong; Jin, Jian-Ping; Yagi, Naoto; Wallgren-Pettersson, Carina; Penisson-Besnier, Isabelle; Larsson, Lars			Disrupted myosin cross-bridge cycling kinetics triggers muscle weakness in nebulin-related myopathy	FASEB JOURNAL			English	Article						congenital myopathy; tropomyosin activation	X-RAY-DIFFRACTION; FILAMENT REGULATORY PROTEINS; VITRO MOTILITY ASSAY; SKELETAL-MUSCLE; NEMALINE MYOPATHY; SHORTENING VELOCITY; CALCIUM ACTIVATION; STRUCTURAL-CHANGES; SARCOMERE LENGTH; FORCE GENERATION	Nebulin is a giant protein expressed at high levels in skeletal muscle. Mutations in the nebulin gene (NEB) lead to muscle weakness and various congenital myopathies. Despite increasing clinical and scientific interest, the pathogenesis of weakness remains unknown. The present study, therefore, aims at unraveling the underlying molecular mechanisms. Hence, we recorded and analyzed the mechanics as well as the X-ray diffraction patterns of human membrane-permeabilized single muscle fibers expressing nebulin mutations. Results demonstrated that, during contraction, the cycling rate of myosin heads attaching to actin is dramatically perturbed, causing a reduction in the fraction of myosin-actin interactions in the strong binding state. This phenomenon prevents complete thin-filament activation, more especially proper and full tropomyosin movement, further limiting additional binding of myosin cross-bridges. At the cell level, this reduces the force-generating capacity and, overall, provokes muscle weakness. To reverse such a negative cascade of events, future potential therapeutic interventions should, therefore, focus on the triggering component, the altered myosin cross-bridge cycling kinetics.-Ochala, J., Lehtokari, V.-L., Iwamoto, H., Li, M., Feng, H.-Z., Jin, J. P., Yagi, N., Wallgren-Pettersson, C. Penisson-Besnier, I., Larsson, L. Disrupted myosin cross-bridge cycling kinetics triggers muscle weakness in nebulin-related myopathy. FASEB J. 25, 1903-1913 (2011). www.fasebj.org	[Ochala, Julien; Li, Meishan; Larsson, Lars] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Lehtokari, Vilma-Lotta; Wallgren-Pettersson, Carina] Univ Helsinki, Dept Med Genet, Helsinki, Finland; [Lehtokari, Vilma-Lotta; Wallgren-Pettersson, Carina] Univ Helsinki, Folkhalsan Inst Genet, Haartman Inst, Helsinki, Finland; [Iwamoto, Hiroyuki; Yagi, Naoto] Japan Synchrotron Radiat Res Inst, Hyogo, Japan; [Feng, Han-Zhong; Jin, Jian-Ping] Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; [Penisson-Besnier, Isabelle] Ctr Hosp Univ Angers, Ctr Reference Malad Neuromusculaires, Dept Neurol, Angers, France; [Larsson, Lars] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA	Uppsala University; University of Helsinki; University of Helsinki; Japan Synchrotron Radiation Research Institute; Wayne State University; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ochala, J (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Entrance 85,3rd Floor, SE-75185 Uppsala, Sweden.	julien.ochala@neuro.uu.se	Ochala, Julien/K-4120-2017; Jin, Jian-Ping/AAD-1149-2020; Larsson, Lars/AAY-1347-2021	Ochala, Julien/0000-0002-6358-2920; Lehtokari, Vilma-Lotta/0000-0002-8276-0972; Jin, JP/0000-0001-9932-1063; Larsson, Lars/0000-0003-3722-035X	Swedish Research Council [8651]; Association Francaise contre les Myopathies; Tore Nilson Stiftelse; Stiftelsen Apotekare Hedbergs Fond for Medicinsk Forskning; Rektors Resebidrag fran Wallenbergstiftelsen; U.S. National Institutes of Health [AR-048816]; Academy of Finland; Sigrid Juselius Foundation; Finska Lakaresallskapet; Medicinska Understodsforeningen Liv och Halsa; Swedish Cancer Foundation; European Commission [CT-223756]; King Gustaf V and Queen Victoria's Foundation; Thureus Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048816] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Tore Nilson Stiftelse; Stiftelsen Apotekare Hedbergs Fond for Medicinsk Forskning; Rektors Resebidrag fran Wallenbergstiftelsen; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finska Lakaresallskapet; Medicinska Understodsforeningen Liv och Halsa; Swedish Cancer Foundation; European Commission(European CommissionEuropean Commission Joint Research Centre); King Gustaf V and Queen Victoria's Foundation; Thureus Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Dr. P. Marcorelles for the electron microscopy study and Y. Hedstrom, C. Dumez, and I. Viau for excellent technical assistance. The authors also thank Dr. K. Pelin for helpful comments on the manuscript. X-ray experiments were performed under the approval of the SPring-8 Proposal Review Committee (2009B1918). This study was supported by grants from the Swedish Research Council, Association Francaise contre les Myopathies, Tore Nilson Stiftelse, Stiftelsen Apotekare Hedbergs Fond for Medicinsk Forskning, and Rektors Resebidrag fran Wallenbergstiftelsen to J.O.; the U.S. National Institutes of Health (AR-048816) to J.-P.J.; the Academy of Finland, Association Francaise contre les Myopathies, Sigrid Juselius Foundation, Finska Lakaresallskapet, and Medicinska Understodsforeningen Liv och Halsa to C.W.-P.; and the Swedish Research Council (8651), Association Francaise contre les Myopathies, Swedish Cancer Foundation, European Commission (MyoAge, Fp7 CT-223756), King Gustaf V and Queen Victoria's Foundation, and Thureus Foundation to L.L.	Bang ML, 2009, FASEB J, V23, P4117, DOI 10.1096/fj.09-137729; BRENNER B, 1986, P NATL ACAD SCI USA, V83, P3542, DOI 10.1073/pnas.83.10.3542; Castillo A, 2009, BIOPHYS J, V96, P1856, DOI 10.1016/j.bpj.2008.10.053; Chandra M, 2009, J BIOL CHEM, V284, P30889, DOI 10.1074/jbc.M109.049718; EDMAN KAP, 1979, J PHYSIOL-LONDON, V291, P143, DOI 10.1113/jphysiol.1979.sp012804; Frontera WR, 1997, MUSCLE NERVE, V20, P948, DOI 10.1002/(SICI)1097-4598(199708)20:8<948::AID-MUS3>3.0.CO;2-6; Gokhin DS, 2009, AM J PHYSIOL-CELL PH, V296, pC1123, DOI 10.1152/ajpcell.00503.2008; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Hook P, 1999, J PHYSIOL-LONDON, V520, P463, DOI 10.1111/j.1469-7793.1999.00463.x; Hook P, 2000, J MUSCLE RES CELL M, V21, P357, DOI 10.1023/A:1005614212575; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY HE, 1973, COLD SPRING HARB SYM, V37, P361, DOI 10.1101/SQB.1973.037.01.046; Iwamoto H, 2003, BIOPHYS J, V85, P2492, DOI 10.1016/S0006-3495(03)74672-4; Iwamoto H, 2002, J MOL BIOL, V317, P707, DOI 10.1006/jmbi.2002.5449; Iwamoto H, 2001, J MOL BIOL, V305, P863, DOI 10.1006/jmbi.2000.4334; Iwamoto H, 2009, J MOL BIOL, V390, P99, DOI 10.1016/j.jmb.2009.05.002; JIN JP, 1995, J BIOL CHEM, V270, P6908; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; Lehman W, 2008, ADV EXP MED BIOL, V644, P95; Lehtokari VL, 2006, HUM MUTAT, V27, P946, DOI 10.1002/humu.20370; Martyn DA, 2007, BIOPHYS J, V92, P4379, DOI 10.1529/biophysj.106.096768; MCDONALD KS, 1995, J APPL PHYSIOL, V79, P1796, DOI 10.1152/jappl.1995.79.5.1796; MOSS RL, 1979, J PHYSIOL-LONDON, V292, P177, DOI 10.1113/jphysiol.1979.sp012845; OCHALA J, P NATL ACAD SCI US, V107, P9807; Ochala J, 2008, J MOL MED-JMM, V86, P1197, DOI 10.1007/s00109-008-0380-9; Ogut O, 2003, J BIOL CHEM, V278, P3089, DOI 10.1074/jbc.M205853200; Ottenheijm CAC, 2010, J STRUCT BIOL, V170, P334, DOI 10.1016/j.jsb.2009.11.013; Ottenheijm CAC, 2009, HUM MOL GENET, V18, P2359, DOI 10.1093/hmg/ddp168; Pappas C. T., J CELL BIOL, V189, P859; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; Penisson-Besnier I, 2007, NEUROMUSCULAR DISORD, V17, P330, DOI 10.1016/j.nmd.2007.01.017; Regnier M, 1998, BIOPHYS J, V74, P2005, DOI 10.1016/S0006-3495(98)77907-X; Reiser PJ, 2006, ARCH BIOCHEM BIOPHYS, V456, P112, DOI 10.1016/j.abb.2006.06.013; Romero NB, 2009, NEUROLOGY, V73, P1159, DOI 10.1212/WNL.0b013e3181bacf45; Root DD, 2001, BIOCHEMISTRY-US, V40, P1171, DOI 10.1021/bi0015010; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; Solaro RJ, 2009, IDRUGS, V12, P243; Thedinga E, 1999, J MUSCLE RES CELL M, V20, P785, DOI 10.1023/A:1005658825375; TONINO P, J CELL SCI, V123, P384; Wakayama J, 2004, BIOPHYS J, V87, P430, DOI 10.1529/biophysj.103.035063; Wallgren-Pettersson C, 2007, BRAIN, V130, P1465, DOI 10.1093/brain/awm094; Wang K, 1996, J BIOL CHEM, V271, P4304; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; Wang K, 1996, ADV BIOPHYS, V33, P123; Yagi N, 2003, BIOPHYS J, V84, P1093, DOI 10.1016/S0006-3495(03)74925-X	45	39	39	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2011	25	6					1903	1913		10.1096/fj.10-176727	http://dx.doi.org/10.1096/fj.10-176727			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21350120	Green Published			2022-12-28	WOS:000291023800014
J	Grewal, JS; Pilgrim, MJ; Grewal, S; Kasman, L; Werner, P; Bruorton, ME; London, SD; London, L				Grewal, Jasvir S.; Pilgrim, Mark J.; Grewal, Suman; Kasman, Laura; Werner, Phillip; Bruorton, Mary E.; London, Steven D.; London, Lucille			Salivary glands act as mucosal inductive sites via the formation of ectopic germinal centers after site-restricted MCMV infection	FASEB JOURNAL			English	Article						mucosal immunity; viral immunity	CLASS SWITCH RECOMBINATION; SJOGRENS-SYNDROME PATIENTS; B-CELLS; T-CELL; STREPTOCOCCUS-MUTANS; LYMPHOID NEOGENESIS; IMMUNOGLOBULIN-A; DIFFERENTIAL EXPRESSION; AUTOANTIBODY PRODUCTION; MONOCLONAL-ANTIBODIES	We investigated the hypothesis that salivary gland inoculation stimulates formation of ectopic germinal centers (GCs), transforming the gland into a mucosal inductive site. Intraglandular infection of mice with murine cytomegalovirus (MCMV; control: UV-inactivated MCMV) induces salivary gland ectopic follicles comprising cognate interactions between CD4(+) and B220(+) lymphocytes, IgM(+) and isotype-switched IgG(+) and IgA(+) B cells, antigen presenting cells, and follicular dendritic cells. B cells coexpressed the GC markers GCT (57%) and GL7 (52%), and bound the lectin peanut agglutinin. Lymphoid follicles were characterized by a 2- to 3-fold increase in mRNA for CXCL13 (lymphoid neogenesis), syndecan-1 (plasma cells), Blimp-1 (plasma cell development/differentiation), and a 2- to 6-fold increase for activation-induced cytidine deaminase, PAX5, and the nonexcised rearranged DNA of an IgA class-switch event, supporting somatic hypermutation and class-switch recombination within the salivary follicles. Intraglandular inoculation also provided protection against a systemic MCMV challenge, as evidenced by decreased viral titers (10(5) plaque-forming units to undetectable), and restoration of normal salivary flow rates from a 6-fold decrease. Therefore, these features suggest that the salivary gland participates in oral mucosal immunity via generation of ectopic GCs, which function as ectopic mucosal inductive sites.-Grewal, J. S., Pilgrim, M. J., Grewal, S., Kasman, L., Werner, P., Bruorton, M. E., London, S. D., London, L. Salivary glands act as mucosal inductive sites via the formation of ectopic germinal centers after site-restricted MCMV infection. FASEB J. 25, 1680-1696 (2011). www.fasebj.org	[Grewal, Jasvir S.; Grewal, Suman; London, Steven D.; London, Lucille] SUNY Stony Brook, Sch Dent Med, Dept Oral Biol & Pathol, Stony Brook, NY 11794 USA; [Pilgrim, Mark J.; Kasman, Laura; Werner, Phillip; Bruorton, Mary E.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Werner, Phillip] Med Univ S Carolina, Coll Dent Med, Charleston, SC 29425 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Medical University of South Carolina; Medical University of South Carolina	London, L (corresponding author), SUNY Stony Brook, Sch Dent Med, Dept Oral Biol & Pathol, 231 Dutchess Hall, Stony Brook, NY 11794 USA.	lucille.london@stonybrook.edu	Kasman, Laura/AAF-3536-2021	Kasman, Laura/0000-0002-8661-2918	MUSC; U.S. National Institutes of Health/National Institute of Dental and Craniofacial [1R01 DE016652]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016652] Funding Source: NIH RePORTER	MUSC; U.S. National Institutes of Health/National Institute of Dental and Craniofacial(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank Dr. S. Crowe for early work on the BrdU assay; Rick Peppler and the Medical University of South Carolina (MUSC) Hollings Cancer Center and Stony Brook University Research Flow Cytometry Core Facility; Dr. Margaret Kelly for her assistance with confocal microscopy; Dr. Jeffrey Reitzel for his assistance with the ELISPOT assay; and the Hollings Cancer Center Molecular Imaging Center. This work was supported by the MUSC Institutional Research Funds and U.S. National Institutes of Health/National Institute of Dental and Craniofacial Research grant 1R01 DE016652 (S. D. L.). The authors declare no conflicting financial or commercial interests.	Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Aloisi F, 2006, NAT REV IMMUNOL, V6, P205, DOI 10.1038/nri1786; Amft N, 2001, SCAND J IMMUNOL, V54, P62, DOI 10.1046/j.1365-3083.2001.00970.x; Angelin-Duclos C, 2000, J IMMUNOL, V165, P5462, DOI 10.4049/jimmunol.165.10.5462; Armengol MP, 2001, AM J PATHOL, V159, P861, DOI 10.1016/S0002-9440(10)61762-2; Armengol MP, 2003, J IMMUNOL, V170, P6320, DOI 10.4049/jimmunol.170.12.6320; Bharhani MS, 2007, INT IMMUNOL, V19, P567, DOI 10.1093/intimm/dxm022; Bharhani MS, 2005, J IMMUNOL, V174, P3580, DOI 10.4049/jimmunol.174.6.3580; Bombardieri M, 2007, J IMMUNOL, V179, P4929, DOI 10.4049/jimmunol.179.7.4929; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001; Butcher EC, 2005, J IMMUNOL, V175, P1363; Carragher DM, 2008, SEMIN IMMUNOL, V20, P26, DOI 10.1016/j.smim.2007.12.004; CEBRA JJ, 1989, IMMUNOL INVEST, V18, P545, DOI 10.3109/08820138909112262; Cervenak L, 2001, IMMUNOL LETT, V78, P89, DOI 10.1016/S0165-2478(01)00239-5; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Cozine CL, 2005, CURR OPIN IMMUNOL, V17, P298, DOI 10.1016/j.coi.2005.04.007; DELVAL M, 1988, J VIROL, V62, P3965, DOI 10.1128/JVI.62.11.3965-3972.1988; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; EIDT S, 1993, J CLIN PATHOL, V46, P832, DOI 10.1136/jcp.46.9.832; FARRELL HE, 1990, J GEN VIROL, V71, P655, DOI 10.1099/0022-1317-71-3-655; Fernandez JA, 1999, VIROLOGY, V255, P40, DOI 10.1006/viro.1998.9575; FRENI MA, 1995, HEPATOLOGY, V22, P389, DOI 10.1002/hep.1840220203; GENCO RJ, 1969, NATURE, V221, P679, DOI 10.1038/221679a0; Hansen A, 2005, ARTHRITIS RHEUM-US, V52, P2109, DOI 10.1002/art.21129; Hansen A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2210; Hjelmstrom P, 2001, J LEUKOCYTE BIOL, V69, P331; Holtappels R, 2001, J VIROL, V75, P6584, DOI 10.1128/JVI.75.14.6584-6600.2001; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Inoue H, 1999, ORAL MICROBIOL IMMUN, V14, P21, DOI 10.1034/j.1399-302X.1999.140102.x; Jonsson MV, 2008, J ORAL PATHOL MED, V37, P515, DOI 10.1111/j.1600-0714.2008.00674.x; Jonsson MV, 2005, J CLIN IMMUNOL, V25, P189, DOI 10.1007/s10875-005-4091-5; Kagami H, 1998, HUM GENE THER, V9, P305, DOI 10.1089/hum.1998.9.3-305; Kallies A, 2004, J EXP MED, V200, P967, DOI 10.1084/jem.20040973; Kasman LM, 2009, ORAL DIS, V15, P587, DOI 10.1111/j.1601-0825.2009.01600.x; Kawabata S, 1999, INFECT IMMUN, V67, P5863, DOI 10.1128/IAI.67.11.5863-5868.1999; Kinoshita K, 2001, P NATL ACAD SCI USA, V98, P12620, DOI 10.1073/pnas.221454398; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; LASZLO G, 1993, J IMMUNOL, V150, P5252; Le Pottier L, 2009, J IMMUNOL, V182, P3540, DOI 10.4049/jimmunol.0803588; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Lindroth K, 2007, IMMUNOL LETT, V113, P70, DOI 10.1016/j.imlet.2007.07.018; LONDON SD, 1990, J IMMUNOL, V144, P3187; LONDON SD, 1987, J EXP MED, V165, P830, DOI 10.1084/jem.165.3.830; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; Maglione PJ, 2007, J IMMUNOL, V178, P7222, DOI 10.4049/jimmunol.178.11.7222; Mason KL, 2008, ADV EXP MED BIOL, V635, P1, DOI 10.1007/978-0-387-09550-9_1; Mazzucchelli L, 1999, J CLIN INVEST, V104, pR49, DOI 10.1172/JCI7830; MCGHEE JR, 1975, J IMMUNOL, V114, P300; MEGA J, 1995, ADV EXP MED BIOL, V371, P1103; Murakami J, 1999, HEPATOLOGY, V30, P143, DOI 10.1002/hep.510300107; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Murasawa M, 2002, EUR J IMMUNOL, V32, P291, DOI 10.1002/1521-4141(200201)32:1<291::AID-IMMU291>3.0.CO;2-L; Naito Y, 2007, MOL CELL BIOL, V27, P3008, DOI 10.1128/MCB.02047-06; Nakamura H, 1999, LAB INVEST, V79, P261; Pilgrim MJ, 2007, EXP MOL PATHOL, V82, P269, DOI 10.1016/j.yexmp.2006.12.010; PLATT FM, 1992, CELL IMMUNOL, V143, P449, DOI 10.1016/0008-8749(92)90039-R; Reksten TR, 2009, RHEUMATOLOGY, V48, P1102, DOI 10.1093/rheumatology/kep149; RUSSELL MW, 1991, INFECT IMMUN, V59, P4061, DOI 10.1128/IAI.59.11.4061-4070.1991; Salomonsson S, 2003, ARTHRITIS RHEUM-US, V48, P3187, DOI 10.1002/art.11311; Salomonsson S, 2002, SCAND J IMMUNOL, V55, P336, DOI 10.1046/j.1365-3083.2002.01058.x; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; Sankar V, 2002, ORAL DIS, V8, P275, DOI 10.1034/j.1601-0825.2002.02856.x; Scalzo AA, 2007, IMMUNOL CELL BIOL, V85, P46, DOI 10.1038/sj.icb.7100013; Seo KY, 2010, J IMMUNOL, V185, P3610, DOI 10.4049/jimmunol.1000680; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Smith DJ, 1997, INFECT IMMUN, V65, P4424, DOI 10.1128/IAI.65.11.4424-4430.1997; Smith DJ, 1996, INFECT IMMUN, V64, P3069, DOI 10.1128/IAI.64.8.3069-3073.1996; STARR SE, 1977, INFECT IMMUN, V17, P458, DOI 10.1128/IAI.17.2.458-462.1977; Stott DI, 1998, J CLIN INVEST, V102, P938, DOI 10.1172/JCI3234; Szodoray P, 2005, SCAND J IMMUNOL, V62, P421, DOI 10.1111/j.1365-3083.2005.01688.x; Szodoray P, 2005, CLIN IMMUNOL, V117, P168, DOI 10.1016/j.clim.2005.06.016; Takahashi I, 2009, CURR OPIN IMMUNOL, V21, P352, DOI 10.1016/j.coi.2009.04.002; Tarlinton D, 2008, CURR OPIN IMMUNOL, V20, P162, DOI 10.1016/j.coi.2008.03.016; TAUBMAN MA, 1974, INFECT IMMUN, V9, P1079, DOI 10.1128/IAI.9.6.1079-1091.1974; TAUBMAN MA, 1971, IMMUNOCHEMISTRY, V8, P1137, DOI 10.1016/0019-2791(71)90392-2; TAUBMAN MA, 1973, COMP IMMUNOLOGY ORAL, P138; Thaunat O, 2006, TRENDS IMMUNOL, V27, P441, DOI 10.1016/j.it.2006.08.003; Tucker SN, 2004, VACCINE, V22, P2500, DOI 10.1016/j.vaccine.2003.12.034; Tucker SN, 2003, MOL THER, V8, P392, DOI 10.1016/S1525-0016(03)00180-1; Weyand CM, 2001, AM J PATHOL, V159, P787, DOI 10.1016/S0002-9440(10)61751-8; Xanthou G, 1999, CLIN EXP IMMUNOL, V118, P154; Xanthou G, 2001, ARTHRITIS RHEUM-US, V44, P408; Ye M, 2002, J VIROL, V76, P2100, DOI 10.1128/jvi.76.5.2100-2112.2002	85	20	20	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1680	1696		10.1096/fj.10-174656	http://dx.doi.org/10.1096/fj.10-174656			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21307334	Green Published			2022-12-28	WOS:000290023800024
J	Camarota, LM; Woollett, LA; Howles, PN				Camarota, Lisa M.; Woollett, Laura A.; Howles, Philip N.			Reverse cholesterol transport is elevated in carboxyl ester lipase-knockout mice	FASEB JOURNAL			English	Article						HDL metabolism; bile; fecal sterols; liver; macrophage	SCAVENGER RECEPTOR BI; APOLIPOPROTEIN-A-I; TRANSFER PROTEIN-INHIBITION; LOW-DENSITY-LIPOPROTEIN; SELECTIVE UPTAKE; SR-BI; STEROL EXCRETION; ACID SYNTHESIS; OVEREXPRESSION; MACROPHAGES	Mechanisms to increase reverse cholesterol transport (RCT) and biliary sterol disposal are currently sought to prevent atherosclerosis. Previous work with HepG2 cells and primary hepatocytes showed that carboxyl ester lipase (CEL), a broad-spectrum lipase secreted by pancreas and liver, plays an important role in hydrolysis of high-density lipoprotein (HDL) cholesteryl esters (CEs) after selective uptake by hepatocytes. The effect of CEL on RCT of HDL cholesterol was assessed by measuring biliary and fecal disposal of radiolabeled HDL-CE in control and Cel(-/-) mice. Radiolabeled CE was increased 3-fold in hepatic bile of Cel(-/-) mice, and the mass of CE in gall bladder bile was elevated. Total radiolabeled transport from plasma to hepatic bile was more rapid in Cel(-/-) mice. Fecal disposal of radiolabel from HDL-CE, as well as total sterol mass, was markedly elevated for Cel(-/-) mice, primarily due to more CE. RCT of macrophage CE was also increased in Cel(-/-) mice, as measured by excretion of radiolabel from injected J774 cells. Increased sterol loss was compensated by increased cholesterol synthesis in Cel(-/-) mice. Together, the data demonstrate significantly increased RCT in the absence of CEL and suggest a novel mechanism by which to manipulate plasma cholesterol flux.-Camarota, L. M., Woollett, L. A., Howles, P. N. Reverse cholesterol transport is elevated in carboxyl ester lipase-knockout mice. FASEB J. 25, 1370-1377 (2011). www.fasebj.org	[Camarota, Lisa M.; Woollett, Laura A.; Howles, Philip N.] Univ Cincinnati, Dept Pathol, Metab Dis Inst, Coll Med, Cincinnati, OH 45237 USA	University System of Ohio; University of Cincinnati	Howles, PN (corresponding author), Univ Cincinnati, Dept Pathol, Metab Dis Inst, Coll Med, 2120 E Galbraith Rd, Cincinnati, OH 45237 USA.	philip.howles@uc.edu			National Institutes of Health [R01 HL078900]; American Heart Association [AHA SW-97-16-B]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078900] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Ronald Jandacek (University of Cincinnati College of Medicine) for the generous use of the OX700 Biological Oxidizer to measure radiolabeled bile acids in feces, Katie Burke for technical assistance with sterol synthesis assays, and Dr. David Y. Hui for many helpful discussions. This work was supported by grants from the National Institutes of Health (R01 HL078900) and the American Heart Association (AHA SW-97-16-B). Some of the data in this manuscript were previously published in abstract form (45).	Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Bengtsson-Ellmark SH, 2004, EUR J HUM GENET, V12, P627, DOI 10.1038/sj.ejhg.5201204; BRODTEPPLEY J, 1995, BBA-MOL BASIS DIS, V1272, P69, DOI 10.1016/0925-4439(95)00083-G; Brousseau ME, 2005, ARTERIOSCL THROM VAS, V25, P1057, DOI 10.1161/01.ATV.0000161928.16334.dd; Brown JM, 2008, J BIOL CHEM, V283, P10522, DOI 10.1074/jbc.M707659200; Camarota LM, 2004, J BIOL CHEM, V279, P27599, DOI 10.1074/jbc.M402946200; CUTCHEL M, 2006, CIRCULATION, V113, P2548; Forrester JS, 2005, CIRCULATION, V111, P1847, DOI 10.1161/01.CIR.0000160860.36911.BD; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; Getz GS, 2009, CURR OPIN LIPIDOL, V20, P171, DOI 10.1097/MOL.0b013e32832ac051; Ghosh S, 1998, AM J PHYSIOL-GASTR L, V274, pG662, DOI 10.1152/ajpgi.1998.274.4.G662; Harder CJ, 2007, J BIOL CHEM, V282, P1445, DOI 10.1074/jbc.M604627200; Harder CJ, 2006, J LIPID RES, V47, P492, DOI 10.1194/jlr.M500444-JLR200; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; Howles P., 2001, INTESTINAL LIPID MET, P119; Howles P, 2008, ARTERIOSCL THROM VAS, V28, pE61; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; Huang ZH, 2003, BIOCHEMISTRY-US, V42, P3949, DOI 10.1021/bi0269207; Huggins KW, 2003, J BIOL CHEM, V278, P42899, DOI 10.1074/jbc.M303422200; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; Mizoguchi T, 2004, J LIPID RES, V45, P396, DOI 10.1194/jlr.D300024-JLR200; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; PIETERS MN, 1991, BIOCHEM J, V280, P359, DOI 10.1042/bj2800359; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Post SM, 2003, ARTERIOSCL THROM VAS, V23, P892, DOI 10.1161/01.ATV.0000067702.22390.20; Sabol SL, 2005, J LIPID RES, V46, P2151, DOI 10.1194/jlr.M500080-JLR200; SCHEIBNER J, 1994, J LIPID RES, V35, P690; Schwarz M, 1998, J LIPID RES, V39, P1833; Sehayek E, 2003, J LIPID RES, V44, P1605, DOI 10.1194/jlr.M200488-JLR200; SEWELL RB, 1983, J LIPID RES, V24, P391; Tchoua U, 2008, CARDIOVASC RES, V77, P732, DOI 10.1093/cvr/cvm087; van der Velde AE, 2008, AM J PHYSIOL-GASTR L, V295, pG203, DOI 10.1152/ajpgi.90231.2008; Van der Velde AE, 2007, GASTROENTEROLOGY, V133, P967, DOI 10.1053/j.gastro.2007.06.019; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Weng W, 1999, BIOCHEMISTRY-US, V38, P4143, DOI 10.1021/bi981679a; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Zhang YZ, 2003, CIRCULATION, V108, P661, DOI 10.1161/01.CIR.0000086981.09834.E0; Zhao B, 2005, PHYSIOL GENOMICS, V23, P304, DOI 10.1152/physiolgenomics.00187.2005; Zhao B, 2008, J LIPID RES, V49, P2212, DOI 10.1194/jlr.M800277-JLR200; Zhao B, 2007, AM J PHYSIOL-CELL PH, V292, pC405, DOI 10.1152/ajpcell.00306.2006	45	10	13	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1370	1377		10.1096/fj.10-169680	http://dx.doi.org/10.1096/fj.10-169680			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21212359	Green Published			2022-12-28	WOS:000288982800026
J	Lusso, P; Vangelista, L; Cimbro, R; Secchi, M; Sironi, F; Longhi, R; Faiella, M; Maglio, O; Pavone, V				Lusso, Paolo; Vangelista, Luca; Cimbro, Raffaello; Secchi, Massimiliano; Sironi, Francesca; Longhi, Renato; Faiella, Marina; Maglio, Ornella; Pavone, Vincenzo			Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity	FASEB JOURNAL			English	Article						chemokines; viral receptors; CCR5; AIDS; antivirals; rational design	IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-STRUCTURE PREDICTION; NUCLEIC-ACIDS; HIV-1 INFECTION; FORCE-FIELD; CELL FUSION; CHEMOKINE; CCR5; SPECTROSCOPY; ANTAGONIST	The chemokine receptor CCR5 is utilized as a critical coreceptor by most primary HIV-1 strains. While the lack of structural information on CCR5 has hampered the rational design of specific inhibitors, mimetics of the chemokines that naturally bind CCR5 can be molecularly engineered. We used a structure-guided approach to design peptide mimetics of the N-loop and beta 1-strand regions of regulated on activation normal T-cell-expressed and secreted (RANTES)/CCL5, which contain the primary molecular determinants of HIV-1 blockade. Rational modifications were sequentially introduced into the N-loop/beta 1-strand sequence, leading to the generation of mimetics with potent activity against a broad spectrum of CCR5-specific HIV-1 isolates (IC(50) range: 104-640 nM) but lacking activity against CXCR4-specific HIV-1 isolates. Functional enhancement was initially achieved with the stabilization of the N loop in the beta-extended conformation adopted in full-length RANTES, as confirmed by nuclear magnetic resonance (NMR) analysis. However, the most dramatic increase in antiviral potency resulted from the engraftment of an in silico-optimized linker segment designed using de novo structure-prediction algorithms to stabilize the C-terminal alpha-helix and experimentally validated by NMR. Our mimetics exerted CCR5-antagonistic effects, demonstrating that the antiviral and proinflammatory functions of RANTES can be uncoupled. RANTES peptide mimetics provide new leads for the development of safe and effective HIV-1 entry inhibitors.-Lusso, P., Vangelista, L., Cimbro, R., Secchi, M., Sironi, F., Longhi, R., Faiella, M., Maglio, O., Pavone, V. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J. 25, 1230-1243 (2011). www.fasebj.org	[Lusso, Paolo; Vangelista, Luca; Cimbro, Raffaello; Secchi, Massimiliano; Sironi, Francesca] Ist Sci San Raffaele, Dept Biol & Technol Res DIBIT, Unit Human Virol, I-20132 Milan, Italy; [Lusso, Paolo] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy; [Longhi, Renato] CNR, ICRM, I-20133 Milan, Italy; [Faiella, Marina; Maglio, Ornella; Pavone, Vincenzo] Univ Naples Federico 2, Dept Chem, Naples, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Cagliari; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); University of Naples Federico II	Lusso, P (corresponding author), NIAID, Immunoregulat Lab, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	plusso@niaid.nih.gov	Secchi, Massimiliano/AAN-5461-2020; Pavone, Vincenzo/D-1688-2011; Maglio, Ornella/F-1162-2016; Sironi, Francesca/ABH-7705-2020	Secchi, Massimiliano/0000-0002-4570-1885; Pavone, Vincenzo/0000-0001-6432-0802; Maglio, Ornella/0000-0002-7829-1907; Sironi, Francesca/0000-0003-0908-6683; Cimbro, Raffaello/0000-0002-6251-5160; Vangelista, Luca/0000-0003-0764-5031	Istituto Superiore di Sanita (ISS)-AIDS Project, Rome; European Microbicides Project (EMPRO); EU, Brussels	Istituto Superiore di Sanita (ISS)-AIDS Project, Rome; European Microbicides Project (EMPRO); EU, Brussels	The authors thank Paolo Sarmientos for helpful discussion and peptide synthesis, Luca DeGioia and Stephan Grzesiek for critical reading of the manuscript, Gabriella Scarlatti (DIBIT-HSR, Milan, Italy) for providing pediatric HIV-1 isolates, Monica Tolazzi for performing virologic assays, and the NIH AIDS Research and Reference Reagent Program (Rockville, MD, USA) for providing primary HIV-1 isolates. This work was supported in part by the Istituto Superiore di Sanita (ISS)-AIDS Project, Rome; the European Microbicides Project (EMPRO); and Combined Highly Active Anti-Retroviral Microbicides (CHAARM), EU, Brussels. The authors declare no competing financial interests.	BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bradley P, 2005, PROTEINS, V61, P128, DOI 10.1002/prot.20729; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; Cooper DA, 2004, LANCET INFECT DIS, V4, P426, DOI 10.1016/S1473-3099(04)01058-8; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; GRIESINGER C, 1987, J MAGN RESON, V75, P261, DOI 10.1016/0022-2364(87)90035-7; Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; He YX, 2008, J BIOL CHEM, V283, P11126, DOI 10.1074/jbc.M800200200; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Keller R., 2004, COMPUTER AIDED RESON, V1; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; Lederman MM, 2006, JAMA-J AM MED ASSOC, V296, P815, DOI 10.1001/jama.296.7.815; Lusso P, 2006, EMBO J, V25, P447, DOI 10.1038/sj.emboj.7600947; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; Meanwell NA, 2007, CURR OPIN INVEST DR, V8, P669; METROPOLIS N, 1949, J AM STAT ASSOC, V44, P335, DOI 10.2307/2280232; Nardese V, 2001, NAT STRUCT BIOL, V8, P611, DOI 10.1038/89653; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Pavone V, 1996, BIOPOLYMERS, V38, P705, DOI 10.1002/(SICI)1097-0282(199606)38:6<705::AID-BIP3>3.3.CO;2-O; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Rek A, 2009, BBA-PROTEINS PROTEOM, V1794, P577, DOI 10.1016/j.bbapap.2009.01.001; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; Shaw JP, 2004, STRUCTURE, V12, P2081, DOI 10.1016/j.str.2004.08.014; Simons KT, 1999, PROTEINS, P171; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398; Strizki JM, 2005, ANTIMICROB AGENTS CH, V49, P4911, DOI 10.1128/AAC.49.12.4911-4919.2005; Vangelista L, 2006, BIOCHEM BIOPH RES CO, V351, P664, DOI 10.1016/j.bbrc.2006.10.090; Watson C, 2005, MOL PHARMACOL, V67, P1268, DOI 10.1124/mol.104.008565; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Wilken J, 1999, CHEM BIOL, V6, P43, DOI 10.1016/S1074-5521(99)80019-2; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wuthrich K., 1986, NMR PROTEINS NUCL AC	40	18	19	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2011	25	4					1230	1243		10.1096/fj.10-167627	http://dx.doi.org/10.1096/fj.10-167627			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21199933	Green Published			2022-12-28	WOS:000288982800012
J	Sestito, R; Madonna, S; Scarponi, C; Cianfarani, F; Failla, CM; Cavani, A; Girolomoni, G; Albanesi, C				Sestito, Rosanna; Madonna, Stefania; Scarponi, Claudia; Cianfarani, Francesca; Failla, Cristina M.; Cavani, Andrea; Girolomoni, Giampiero; Albanesi, Cristina			STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation	FASEB JOURNAL			English	Article						class III histone deacetylase (HDAC); post-translational modification; psoriasis; skin inflammation; IFN-gamma	T-CELL; SKIN INFLAMMATION; INTERFERON-GAMMA; PSORIATIC SKIN; INTERLEUKIN 22; DIFFERENTIATION; ACTIVATION; IDENTIFICATION; EXPRESSION; CYTOKINE	IL-22 has a pathogenetic role in psoriasis, where it is responsible for the altered proliferation and differentiation of keratinocytes and induces inflammatory molecules. The IL-22-induced effects are mediated by STAT3, whose activity is proportional to acetylation in lysine (Lys)685 and phosphorylation in tyrosine (Tyr)705. Lys 685 acetylation of STAT3 is inhibited by sirtuin (SIRT)1, a class III deacetylase promoting keratinocyte differentiation. Due to the opposite effects of IL-22 and SIRT1, we investigated whether IL-22-induced effects in keratinocytes could be regulated by SIRT1 through control of STAT3. We found that SIRT1 opposes the IL-22-induced STAT3 activity by deacetylating STAT3 and reducing STAT3 Tyr705 phosphorylation. By controlling STAT3, SIRT1 also influences the IL-22-induced expression of molecules involved in proliferation and inflammation as well as proliferation and migration processes in cultured keratinocytes. Although SIRT1 levels were similar in keratinocytes of healthy individuals and patients with psoriasis, they were reduced in psoriatic skin lesions, with the lymphokine IFN-gamma inhibiting SIRT1 expression. Concomitantly, IFN-gamma enhanced basal acetylation of STAT3 and its phosphorylation induced by IL-22. In conclusion, STAT3-dependent IL-22 signaling and effects in keratinocytes are negatively regulated by SIRT1. In skin affected by psoriasis, SIRT1 is down-regulated by IFN-gamma, which thus renders psoriatic keratinocytes more prone to respond to IL-22.-Sestito, R., Madonna, S., Scarponi, C., Cianfarani, F., Failla, C. M., Cavani, A., Girolomoni, G., Albanesi, C. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J. 25, 916-927 (2011). www.fasebj.org	[Sestito, Rosanna; Madonna, Stefania; Scarponi, Claudia; Cavani, Andrea; Albanesi, Cristina] IDI, IRCCS, Expt Immunol Lab, I-00167 Rome, Italy; [Cianfarani, Francesca; Failla, Cristina M.] IDI, IRCCS, Mol & Cell Biol Lab, I-00167 Rome, Italy; [Sestito, Rosanna; Girolomoni, Giampiero] Univ Verona, Dept Med, I-37100 Verona, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Verona	Albanesi, C (corresponding author), IDI, IRCCS, Expt Immunol Lab, Via Monti Creta 104, I-00167 Rome, Italy.	c.albanesi@idi.it	Sestito, Rosanna/K-2361-2018; Madonna, stefania/AAC-3381-2022; GIROLOMONI, Giampiero/AAC-3405-2022; Failla, Cristina M./AAA-2881-2019; Albanesi, Cristina/K-4699-2016	Sestito, Rosanna/0000-0001-5460-2777; Albanesi, Cristina/0000-0002-7537-6833; Cianfarani, Francesca/0000-0001-7859-2913; Failla, Cristina/0000-0001-5991-8914				BATACSORGO Z, 1993, J EXP MED, V178, P1271, DOI 10.1084/jem.178.4.1271; Blander G, 2009, J INVEST DERMATOL, V129, P41, DOI 10.1038/jid.2008.179; Boniface K, 2007, CLIN EXP IMMUNOL, V150, P407, DOI 10.1111/j.1365-2249.2007.03511.x; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Feige JN, 2008, CURR OPIN CELL BIOL, V20, P303, DOI 10.1016/j.ceb.2008.03.012; FIERLBECK G, 1990, ARCH DERMATOL, V126, P351, DOI 10.1001/archderm.126.3.351; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Genovese C, 2006, ONCOGENE, V25, P5201, DOI 10.1038/sj.onc.1209652; Guilloteau K, 2010, J IMMUNOL, V184, P5263, DOI 10.4049/jimmunol.0902464; HANCOCK GE, 1988, J EXP MED, V168, P1395, DOI 10.1084/jem.168.4.1395; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; Lejeune D, 2002, J BIOL CHEM, V277, P33676, DOI 10.1074/jbc.M204204200; Madonna S, 2008, FASEB J, V22, P3287, DOI 10.1096/fj.08-106831; Miyoshi K, 2011, J INVEST DERMATOL, V131, P108, DOI 10.1038/jid.2010.255; Nie YZ, 2009, NAT CELL BIOL, V11, P492, DOI 10.1038/ncb1857; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Sano S, 2008, J DERMATOL SCI, V50, P1, DOI 10.1016/j.jdermsci.2007.05.016; SCHEYNIUS A, 1992, J INVEST DERMATOL, V98, P255, DOI 10.1111/1523-1747.ep12556086; Spolski R, 2009, EUR J IMMUNOL, V39, P658, DOI 10.1002/eji.200839066; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, CYTOKINE GROWTH F R, V17, P367, DOI 10.1016/j.cytogfr.2006.09.001; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhu BM, 2008, J INVEST DERMATOL, V128, P1821, DOI 10.1038/sj.jid.5701224	35	109	116	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					916	927		10.1096/fj.10-172288	http://dx.doi.org/10.1096/fj.10-172288			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21098725				2022-12-28	WOS:000287806200012
J	Aranda, S; Laguna, A; de la Luna, S				Aranda, Sergi; Laguna, Ariadna; de la Luna, Susana			DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles	FASEB JOURNAL			English	Review						cell differentiation; cell survival; endocytosis; phosphorylation	TO-EMBRYO TRANSITION; PHOSPHORYLATION-REGULATED KINASE; DOWN-SYNDROME; TRANSCRIPTION FACTOR; CELL-DIVISION; TYROSINE-PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; INHIBITS PROLIFERATION; APOPTOTIC RESPONSE	Dual-specificity tyrosine-regulated kinases (DYRKs) comprise a family of protein kinases within the CMGC group of the eukaryotic kinome. Members of the DYRK family are found in 4 (animalia, plantae, fungi, and protista) of the 5 main taxa or kingdoms, and all DYRK proteins studied to date share common structural, biochemical, and functional properties with their ancestors in yeast. Recent work on DYRK proteins indicates that they participate in several signaling pathways critical for developmental processes and cell homeostasis. In this review, we focus on the DYRK family of proteins from an evolutionary, biochemical, and functional point of view and discuss the most recent, relevant, and controversial contributions to the study of these kinases.-Aranda, S., Laguna, A., de la Luna, S. DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles. FASEB J. 25, 449-462 (2011). www.fasebj.org	[Aranda, Sergi; Laguna, Ariadna; de la Luna, Susana] Univ Pompeu Fabra, Ctr Genom Regulat, Barcelona, Spain; [Aranda, Sergi; Laguna, Ariadna; de la Luna, Susana] Ctr Invest Biomed Red Enfermedades Raras, Barcelona, Spain; [de la Luna, Susana] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; ICREA	de la Luna, S (corresponding author), Ctr Genom Regulat CRG, Dr Aiguader 88, Barcelona 08003, Spain.	susana.luna@crg.es	Aranda, Sergi/K-1211-2015; de la Luna, Susana/E-9553-2015; Aranda, Sergi/X-9658-2019; Laguna, Ariadna/F-9561-2016	Aranda, Sergi/0000-0003-3853-430X; de la Luna, Susana/0000-0001-7765-916X; Aranda, Sergi/0000-0003-3853-430X; Laguna, Ariadna/0000-0002-9732-6677	Spanish Ministry of Science and Innovation [BFU2007-61043/BMC]; AGAUR [2009SGR1464]; EC; Foundation Jerome Lejeune; ICREA Funding Source: Custom	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); EC(European CommissionEuropean Commission Joint Research Centre); Foundation Jerome Lejeune; ICREA(ICREA)	The authors thank all of the members of the M. L. Arbones (Center for Genomic Regulation, Barcelona, Spain) and S.L. groups for helpful comments and discussion. S.A. and A.L. were FI predoctoral fellows [Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, Barcelona, Spain]. S.L.'s group is supported by the Spanish Ministry of Science and Innovation (BFU2007-61043/BMC), AGAUR (2009SGR1464), EC AnEUploidy grant, and Foundation Jerome Lejeune. The authors apologize to any DYRK community members in the event that their published work has not been included in the reference list or in references associated with the supplemental tables.	Adayev T, 2007, BIOCHEMISTRY-US, V46, P7614, DOI 10.1021/bi700251n; Adayev T, 2006, BIOCHEMISTRY-US, V45, P12011, DOI 10.1021/bi060632j; Alvarez M, 2003, J CELL SCI, V116, P3099, DOI 10.1242/jcs.00618; Alvarez M, 2007, MOL BIOL CELL, V18, P1167, DOI 10.1091/mbc.E06-08-0668; Aranda S, 2008, MOL CELL BIOL, V28, P5899, DOI 10.1128/MCB.00394-08; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356; Bahler J, 2001, EMBO J, V20, P1064, DOI 10.1093/emboj/20.5.1064; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Benavides-Piccione R, 2005, NEUROBIOL DIS, V20, P115, DOI 10.1016/j.nbd.2005.02.004; Bogacheva O, 2008, J BIOL CHEM, V283, P36665, DOI 10.1074/jbc.M807844200; Buratti E, 2010, FEBS J, V277, P2268, DOI 10.1111/j.1742-4658.2010.07643.x; Campbell LE, 2002, FEBS LETT, V510, P31, DOI 10.1016/S0014-5793(01)03221-5; Canzonetta C, 2008, AM J HUM GENET, V83, P388, DOI 10.1016/j.ajhg.2008.08.012; Celton-Morizur S, 2006, J CELL SCI, V119, P4710, DOI 10.1242/jcs.03261; Chang HS, 2007, INT J CANCER, V120, P2377, DOI 10.1002/ijc.22573; Cheng KCC, 2009, CELL, V139, P560, DOI 10.1016/j.cell.2009.08.047; Deng XB, 2005, J BIOL CHEM, V280, P4894, DOI 10.1074/jbc.M411894200; Deng XB, 2004, J BIOL CHEM, V279, P22498, DOI 10.1074/jbc.M400479200; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Deng XB, 2009, CANCER RES, V69, P3317, DOI 10.1158/0008-5472.CAN-08-2903; Ferron SR, 2010, CELL STEM CELL, V7, P367, DOI 10.1016/j.stem.2010.06.021; Fotaki V, 2002, MOL CELL BIOL, V22, P6636, DOI 10.1128/MCB.22.18.6636-6647.2002; Friedman E, 2007, J CELL BIOCHEM, V102, P274, DOI 10.1002/jcb.21451; Gao JC, 2009, CANCER BIOL THER, V8, P1678; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; Gockler N, 2009, FEBS J, V276, P6324, DOI 10.1111/j.1742-4658.2009.07346.x; Guo XM, 2010, J BIOL CHEM, V285, P13223, DOI 10.1074/jbc.M110.102574; Guven-Ozkan T, 2008, CELL, V135, P149, DOI 10.1016/j.cell.2008.07.040; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; Hammerle B, 2003, EUR J NEUROSCI, V17, P2277, DOI 10.1046/j.1460-9568.2003.02665.x; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Janumyan Y, 2008, J BIOL CHEM, V283, P34108, DOI 10.1074/jbc.M806294200; Kang JE, 2005, J NEUROSCI RES, V81, P62, DOI 10.1002/jnr.20534; Kannan N, 2004, PROTEIN SCI, V13, P2059, DOI 10.1110/ps.04637904; Kassis S, 2000, BIOCHEM J, V348, P263, DOI 10.1042/0264-6021:3480263; Kelly PA, 2005, MOL BIOL CELL, V16, P3562, DOI 10.1091/mbc.E04-12-1085; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim D, 2004, BIOCHEM BIOPH RES CO, V323, P499, DOI 10.1016/j.bbrc.2004.08.102; Kim MY, 2006, P NATL ACAD SCI USA, V103, P13074, DOI 10.1073/pnas.0601915103; Kinstrie R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000579; Kuhn C, 2009, J BIOL CHEM, V284, P17320, DOI 10.1074/jbc.M109.006759; Laguna A, 2008, DEV CELL, V15, P841, DOI 10.1016/j.devcel.2008.10.014; Lauth M, 2010, NAT STRUCT MOL BIOL, V17, P718, DOI 10.1038/nsmb.1833; Leder S, 2003, BIOCHEM J, V372, P881, DOI 10.1042/BJ20030182; Lee K, 2000, CANCER RES, V60, P3631; Lee Y, 2009, J BIOL CHEM, V284, P33343, DOI 10.1074/jbc.M109.042234; Lepagnol-Bestel AM, 2009, HUM MOL GENET, V18, P1405, DOI 10.1093/hmg/ddp047; Li D, 2010, J BIOL CHEM, V285, P35374, DOI 10.1074/jbc.M110.148445; Li K, 2002, J BIOL CHEM, V277, P47052, DOI 10.1074/jbc.M205374200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Lochhead PA, 2005, CELL, V121, P925, DOI 10.1016/j.cell.2005.03.034; Lochhead PA, 2003, BIOCHEM J, V374, P381, DOI 10.1042/BJ20030500; Lord KA, 2000, BLOOD, V95, P2838, DOI 10.1182/blood.V95.9.2838.009k29_2838_2846; Maddika S, 2009, NAT CELL BIOL, V11, P409, DOI 10.1038/ncb1848; Maenz B, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-30; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Marti E, 2003, BRAIN RES, V964, P250, DOI 10.1016/S0006-8993(02)04069-6; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Martin SG, 2009, NATURE, V459, P852, DOI 10.1038/nature08054; Mercer SE, 2005, J BIOL CHEM, V280, P25788, DOI 10.1074/jbc.M413594200; Moller RS, 2008, AM J HUM GENET, V82, P1165, DOI 10.1016/j.ajhg.2008.03.001; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; Moseley JB, 2009, NATURE, V459, P857, DOI 10.1038/nature08074; Murakami Noriko, 2009, Biochemistry, V48, P9297, DOI 10.1021/bi9010557; Nishi Y, 2005, DEV BIOL, V288, P139, DOI 10.1016/j.ydbio.2005.09.053; Nishi Y, 2008, DEVELOPMENT, V135, P687, DOI 10.1242/dev.013425; Padte NN, 2006, CURR BIOL, V16, P2480, DOI 10.1016/j.cub.2006.11.024; Pang KM, 2004, DEV BIOL, V265, P127, DOI 10.1016/j.ydbio.2003.09.024; Park J, 2010, J BIOL CHEM, V285, P31895, DOI 10.1074/jbc.M110.147520; Park J, 2009, CELL MOL LIFE SCI, V66, P3235, DOI 10.1007/s00018-009-0123-2; Parry JM, 2009, CURR BIOL, V19, P1752, DOI 10.1016/j.cub.2009.09.015; Pelkmans L, 2005, NATURE, V436, P128, DOI 10.1038/nature03866; Pelkmans L, 2005, NATURE, V3571, P1; Pellettieri J, 2003, DEV CELL, V5, P451, DOI 10.1016/S1534-5807(03)00231-4; Quintin S, 2003, EMBO REP, V4, P1175, DOI 10.1038/sj.embor.7400029; Raaf L, 2010, INT J CARDIOL, V145, P306, DOI 10.1016/j.ijcard.2009.10.043; Raich WB, 2003, GENETICS, V163, P571; Ryoo SR, 2007, J BIOL CHEM, V282, P34850, DOI 10.1074/jbc.M707358200; Sacher F, 2007, MOL CELL ENDOCRINOL, V267, P80, DOI 10.1016/j.mce.2006.12.041; Scales TME, 2009, J CELL SCI, V122, P2424, DOI 10.1242/jcs.040162; Seifert A, 2009, CELL SIGNAL, V21, P1626, DOI 10.1016/j.cellsig.2009.06.009; Seifert A, 2008, FEBS J, V275, P6268, DOI 10.1111/j.1742-4658.2008.06751.x; Shi JH, 2008, J BIOL CHEM, V283, P28660, DOI 10.1074/jbc.M802645200; Shirayama M, 2006, CURR BIOL, V16, P47, DOI 10.1016/j.cub.2005.11.070; Sitz JH, 2004, MOL CELL BIOL, V24, P5821, DOI 10.1128/MCB.24.13.5821-5834.2004; Souza GM, 1998, DEVELOPMENT, V125, P2291; Stitzel ML, 2007, CURR BIOL, V17, P1545, DOI 10.1016/j.cub.2007.08.049; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Taira N, 2010, J BIOL CHEM, V285, P4909, DOI 10.1074/jbc.M109.042341; Taminato A, 2002, MOL BIOL CELL, V13, P2266, DOI 10.1091/mbc.01-11-0555; Tatebe H, 2008, CURR BIOL, V18, P322, DOI 10.1016/j.cub.2008.02.005; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Varjosalo M, 2008, CELL, V133, P537, DOI 10.1016/j.cell.2008.02.047; Wegiel J, 2004, BRAIN RES, V1010, P69, DOI 10.1016/j.brainres.2004.03.008; Yabut O, 2010, J NEUROSCI, V30, P4004, DOI 10.1523/JNEUROSCI.4711-09.2010; Yamashita SI, 2009, ANTICANCER RES, V29, P2753; Zhang DY, 2005, GENOMICS, V85, P117, DOI 10.1016/j.ygeno.2004.08.021; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	103	205	210	3	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					449	462		10.1096/fj.10-165837	http://dx.doi.org/10.1096/fj.10-165837			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21048044				2022-12-28	WOS:000286724800004
J	Qin, XH; Tan, Y; Wang, LL; Wang, ZF; Wang, BF; Wen, X; Yang, GF; Xi, Z; Shen, YQ				Qin, Xiaohong; Tan, Ying; Wang, Lele; Wang, Zhifang; Wang, Baifan; Wen, Xin; Yang, Guangfu; Xi, Zhen; Shen, Yuequan			Structural insight into human variegate porphyria disease	FASEB JOURNAL			English	Article						protoporphyrinogen IX oxidase; mitochondrial inner membrane protein; VP-causing mutations; FAD-containing enzyme	PROTOPORPHYRINOGEN OXIDASE GENE; CRYSTAL-STRUCTURE; TERMINAL STEPS; IX OXIDASE; HEME; MUTATIONS; ENZYME; IDENTIFICATION; EXPRESSION; PROTEINS	Human protoporphyrinogen IX oxidase (hPPO), a mitochondrial inner membrane protein, converts protoporphyrinogen IX to protoporphyrin IX in the heme biosynthetic pathway. Mutations in the hPPO gene cause the inherited human disease variegate porphyria (VP). In this study, we report the crystal structure of hPPO in complex with the coenzyme flavin adenine dinucleotide (FAD) and the inhibitor acifluorfen at a resolution of 1.9 angstrom. The structural and biochemical analyses revealed the molecular details of FAD and acifluorfen binding to hPPO as well as the interactions of the substrate with hPPO. Structural analysis and gel chromatography indicated that hPPO is a monomer rather than a homodimer in vitro. The founder-effect mutation R59W in VP patients is most likely caused by a severe electrostatic hindrance in the hydrophilic binding pocket involving the bulky, hydrophobic indolyl ring of the tryptophan. Forty-seven VP-causing mutations were purified by chromatography and kinetically characterized in vitro. The effect of each mutation was demonstrated in the high-resolution crystal structure.-Qin, X., Tan, Y., Wang, L., Wang, Z., Wang, B., Wen, X., Yang, G., Xi, Z., Shen, Y. Structural insight into human variegate porphyria disease. FASEB J. 25, 653-664 (2011). www.fasebj.org	[Qin, Xiaohong; Wang, Lele; Shen, Yuequan] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China; [Tan, Ying; Wang, Zhifang; Wang, Baifan; Wen, Xin; Xi, Zhen] Nankai Univ, State Key Lab Elementoorgan Chem, Dept Biol Chem, Coll Chem, Tianjin 300071, Peoples R China; [Tan, Ying; Yang, Guangfu] Cent China Normal Univ, Key Lab Pesticide & Chem Biol, Minist Educ, Coll Chem, Wuhan, Peoples R China	Nankai University; Nankai University; Central China Normal University	Shen, YQ (corresponding author), Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China.	zhenxi@nankai.edu.cn; yuequan74@yahoo.com	Wang, Baifan/J-3491-2014; Shen, Yuequan/C-8950-2013; TAN, YING/AAT-4671-2020	Wang, Baifan/0000-0003-0887-5795; Shen, Yuequan/0000-0002-3775-0900; TAN, YING/0000-0003-2957-0165	Ministry of Science and Technology [2007CB914301, 2009CB825504, 2006AA02A319, 2010CB126102, 2008DFA30770]; Tianjin Basic Research program [08QTPTJC28200, 08SYSYTC00200]; National Science Foundation of China [30940015, 20932005, 90713011, 30770428]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Tianjin Basic Research program; National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the Ministry of Science and Technology (2007CB914301, 2009CB825504, 2006AA02A319, 2010CB126102, and 2008DFA30770), the Tianjin Basic Research program (08QTPTJC28200 and 08SYSYTC00200), and the National Science Foundation of China (30940015, 20932005, 90713011, and 30770428). The authors are grateful to the staff at beamline BL-17U1 in the Shanghai Synchrotron Radiation Facility and beamline 3W1A in the Beijing Synchrotron Radiation Facility for excellent technical assistance during data collection. The atomic coordinates and structure factors for the structure of hPPO in complex with acifluorfen have been deposited in the PDB (accession code 3NKS).	Bonnin A, 2009, J INHERIT METAB DIS, V32, pS59, DOI 10.1007/s10545-009-1059-2; BRENNER DA, 1980, NEW ENGL J MED, V302, P765, DOI 10.1056/NEJM198004033021401; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi EJ, 2006, PROTEIN ENG DES SEL, V19, P285, DOI 10.1093/protein/gzl007; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Corradi HR, 2006, J BIOL CHEM, V281, P38625, DOI 10.1074/jbc.M606640200; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; Dailey TA, 1998, J BIOL CHEM, V273, P13658, DOI 10.1074/jbc.273.22.13658; Dailey TA, 1996, PROTEIN SCI, V5, P98; DEYBACH JC, 1985, EUR J BIOCHEM, V149, P431, DOI 10.1111/j.1432-1033.1985.tb08943.x; Deybach JC, 1996, HUM MOL GENET, V5, P407, DOI 10.1093/hmg/5.3.407; Di Pierro E, 2009, CELL MOL BIOL, V55, P79, DOI 10.1170/T856; Elder GH, 1997, LANCET, V349, P1613, DOI 10.1016/S0140-6736(96)09070-8; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FERREIRA GC, 1988, J BIOL CHEM, V263, P3835; Gill R, 2009, BIOCHEM J, V420, P17, DOI 10.1042/BJ20082077; Heinemann IU, 2008, ARCH BIOCHEM BIOPHYS, V474, P238, DOI 10.1016/j.abb.2008.02.015; Heinemann IU, 2007, BIOCHEM J, V402, P575, DOI 10.1042/BJ20061321; Hunte C., 2003, MEMBRANE PROTEIN PUR; Ilc G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011715; Kauppinen R, 2005, LANCET, V365, P241; Koch M, 2004, EMBO J, V23, P1720, DOI 10.1038/sj.emboj.7600189; Kunji ERS, 2008, METHODS, V46, P62, DOI 10.1016/j.ymeth.2008.10.020; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee DS, 2005, P NATL ACAD SCI USA, V102, P14232, DOI 10.1073/pnas.0506557102; MAIRE ML, 2008, NAT PROTOC, V3, P1782; Maneli MH, 2003, BBA-PROTEINS PROTEOM, V1650, P10, DOI 10.1016/S1570-9639(03)00186-9; Mathews MAA, 2001, EMBO J, V20, P5832, DOI 10.1093/emboj/20.21.5832; McCoy AJ, 2007, ACTA CRYSTALLOGR D, V63, P32, DOI 10.1107/S0907444906045975; Meissner PN, 1996, NAT GENET, V13, P95, DOI 10.1038/ng0596-95; Morgan RR, 2002, CELL MOL BIOL, V48, P79; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MORTIER WJ, 1985, J AM CHEM SOC, V107, P829, DOI 10.1021/ja00290a017; NISHIMURA K, 1995, J BIOL CHEM, V270, P8076, DOI 10.1074/jbc.270.14.8076; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PROULX KL, 1993, PROTEIN SCI, V2, P1092, DOI 10.1002/pro.5560020703; Puy H, 1996, BIOCHEM BIOPH RES CO, V226, P226, DOI 10.1006/bbrc.1996.1337; Puy H, 2010, LANCET, V375, P924, DOI 10.1016/S0140-6736(09)61925-5; Qin XH, 2010, J STRUCT BIOL, V170, P76, DOI 10.1016/j.jsb.2009.11.012; ROBERTS AG, 1995, HUM MOL GENET, V4, P2387, DOI 10.1093/hmg/4.12.2387; Rossetti MV, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-54; Sassa S, 2006, BRIT J HAEMATOL, V135, P281, DOI 10.1111/j.1365-2141.2006.06289.x; Schneider-Yin X, 2009, SWISS MED WKLY, V139, P198, DOI smw-12496; Shepherd M, 2005, ANAL BIOCHEM, V344, P115, DOI 10.1016/j.ab.2005.06.012; Song GJ, 2009, FASEB J, V23, P396, DOI 10.1096/fj.08-115469; Sun L, 2009, AMINO ACIDS, V37, P523, DOI 10.1007/s00726-009-0256-5; Warnich L, 1996, HUM MOL GENET, V5, P981, DOI 10.1093/hmg/5.7.981; Whitby FG, 1998, EMBO J, V17, P2463, DOI 10.1093/emboj/17.9.2463; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Wu CK, 2001, NAT STRUCT BIOL, V8, P156, DOI 10.1038/84152	51	46	49	0	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					653	664		10.1096/fj.10-170811	http://dx.doi.org/10.1096/fj.10-170811			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21048046				2022-12-28	WOS:000286724800023
J	Wang, XQ; Hawkins, BT; Miller, DS				Wang, Xueqian; Hawkins, Brian T.; Miller, David S.			Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier	FASEB JOURNAL			English	Article						P-glycoprotein; multidrug resistance-associated protein 2; breast cancer resistance protein; dioxin; brain capillaries	CANCER RESISTANCE PROTEIN; P-GLYCOPROTEIN; IN-VITRO; DNA-BINDING; ALPHA-NAPHTHOFLAVONE; DRUG TRANSPORTER; ABC TRANSPORTERS; CYTOCHROMES P450; DIOXIN RECEPTOR; AH RECEPTOR	Many widespread and persistent organic pollutants, e.g., 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), activate the aryl hydrocarbon receptor (AhR), causing it to translocate to the cell nucleus, where it transactivates target genes. AhR's ability to target the blood-brain barrier is essentially unexplored. We show here that exposing isolated rat brain capillaries to 0.05-0.5 nM TCDD roughly doubled transport activity and protein expression of P-glycoprotein, an ATP-driven drug efflux pump and a critical determinant of drug entry into the CNS. These effects were abolished by actinomycin D or cycloheximide or by the AhR antagonists resveratrol and alpha-naphthoflavone. Brain capillaries from TCDD-dosed rats (1-5 mu g/kg, i.p.) exhibited increased transport activity and protein expression of 3 xenobiotic efflux pumps, P-glycoprotein, multidrug resistance-associated protein 2, and breast cancer resistance polypeptide, as well as expression of Cyp1a1 and Cyp1b1, both AhR target genes. Consistent with increased P-glycoprotein expression in capillaries from TCDD-dosed rats, in situ brain perfusion indicated significantly reduced brain accumulation of verapamil, a P-glycoprotein substrate. These findings suggest a new paradigm for the field of environmental toxicology: toxicants acting through AhR to target xenobiotic efflux transporters at the blood-brain barrier and thus reduce brain accumulation of CNS-acting therapeutic drugs.-Wang, X., Hawkins, B. T., Miller, D. S. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J. 25, 644-652 (2011). www.fasebj.org	[Wang, Xueqian; Hawkins, Brian T.; Miller, David S.] NIEHS, Lab Toxicol & Pharmacol, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Miller, DS (corresponding author), NIEHS, Lab Toxicol & Pharmacol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	miller@niehs.nih.gov		Hawkins, Brian/0000-0001-6719-5402	National Institute of Environmental Health Sciences, National Institutes of Health	National Institute of Environmental Health Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Agarwal S, 2010, J PHARMACOL EXP THER, V334, P147, DOI 10.1124/jpet.110.167601; Allen JD, 2002, MOL CANCER THER, V1, P417; Bauer B, 2008, J CEREBR BLOOD F MET, V28, P1222, DOI 10.1038/jcbfm.2008.16; Bauer B, 2006, MOL PHARMACOL, V70, P1212, DOI 10.1124/mol.106.023796; Bertazzi PA, 1998, ENVIRON HEALTH PERSP, V106, P625, DOI 10.2307/3433813; Casper RF, 1999, MOL PHARMACOL, V56, P784; Chen Y, 2009, J PHARMACOL EXP THER, V330, P956, DOI 10.1124/jpet.109.154781; Collins LL, 2008, TOXICOL SCI, V103, P125, DOI 10.1093/toxsci/kfn017; Dagenais C, 2001, PHARMACEUT RES, V18, P957, DOI 10.1023/A:1010984110732; Dauchy S, 2009, BIOCHEM PHARMACOL, V77, P897, DOI 10.1016/j.bcp.2008.11.001; Dauchy S, 2008, J NEUROCHEM, V107, P1518, DOI 10.1111/j.1471-4159.2008.05720.x; de Klerk OL, 2010, J PSYCHOPHARMACOL, V24, P1237, DOI 10.1177/0269881109349840; Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200; Drahushuk AT, 1996, TOXICOL APPL PHARM, V140, P393, DOI 10.1006/taap.1996.0236; Filbrandt CR, 2004, NEUROTOXICOLOGY, V25, P605, DOI 10.1016/j.neuro.2003.08.007; GASIEWICZ TA, 1987, J BIOL CHEM, V262, P2116; Geyer J, 2009, J VET PHARMACOL THER, V32, P87, DOI 10.1111/j.1365-2885.2008.01007.x; Granberg L, 2003, DRUG METAB DISPOS, V31, P259, DOI 10.1124/dmd.31.3.259; Han Y, 2006, BIOL PHARM BULL, V29, P1032, DOI 10.1248/bpb.29.1032; Harrigan JA, 2006, TOXICOL IN VITRO, V20, P426, DOI 10.1016/j.tiv.2005.08.015; HARTZ AM, MOL PHARM, V77, P715; Hartz AMS, 2004, MOL PHARMACOL, V66, P387, DOI 10.1124/mol.104.001503; Hawkins BT, 2010, J NEUROSCI, V30, P1417, DOI 10.1523/JNEUROSCI.5103-09.2010; Hong SJ, 1998, TOXICOL APPL PHARM, V148, P7, DOI 10.1006/taap.1997.8317; Jigorel E, 2006, DRUG METAB DISPOS, V34, P1756, DOI 10.1124/dmd.106.010033; Johnson DR, 2002, TOXICOL SCI, V67, P182, DOI 10.1093/toxsci/67.2.182; Joiakim A, 2003, DRUG METAB DISPOS, V31, P1279, DOI 10.1124/dmd.31.11.1279; Kainu T, 1995, NEUROREPORT, V6, P2557, DOI 10.1097/00001756-199512150-00026; Klaassen CD, PHARM REV, V62, P1; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Mandal PK, 2005, J COMP PHYSIOL B, V175, P221, DOI 10.1007/s00360-005-0483-3; Mathieu MC, 2001, J BIOL CHEM, V276, P4819, DOI 10.1074/jbc.M008495200; Miller DS, 2010, TRENDS PHARMACOL SCI, V31, P246, DOI 10.1016/j.tips.2010.03.003; Miller DS, 2000, MOL PHARMACOL, V58, P1357, DOI 10.1124/mol.58.6.1357; Minsavage GD, 2004, J BIOL CHEM, V279, P20582, DOI 10.1074/jbc.M312977200; Nayyar T, 2002, EXP TOXICOL PATHOL, V53, P461, DOI 10.1078/0940-2993-00219; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Noguchi K, 2009, ADV DRUG DELIVER REV, V61, P26, DOI 10.1016/j.addr.2008.07.003; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rigor RR, 2010, J CEREBR BLOOD F MET, V30, P1373, DOI 10.1038/jcbfm.2010.21; SANTOSTEFANO M, 1993, MOL PHARMACOL, V43, P200; SCHRAMM U, 1995, AM J PHYSIOL-RENAL, V268, pF46, DOI 10.1152/ajprenal.1995.268.1.F46; Seelbach M, 2010, ENVIRON HEALTH PERSP, V118, P479, DOI 10.1289/ehp.0901334; Shukla S, 2009, PHARM RES-DORDR, V26, P480, DOI 10.1007/s11095-008-9735-8; Smith Quentin R, 2003, Methods Mol Med, V89, P209; Wang XQ, 2010, MOL PHARMACOL, V78, P376, DOI 10.1124/mol.110.063685; White SS, 2009, J ENVIRON SCI HEAL C, V27, P197, DOI 10.1080/10590500903310047; WILHELMSSON A, 1994, J BIOL CHEM, V269, P19028; Zhou SF, 2008, CURR MED CHEM, V15, P1981, DOI 10.2174/092986708785132870	50	78	80	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					644	652		10.1096/fj.10-169227	http://dx.doi.org/10.1096/fj.10-169227			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21048045	Green Published			2022-12-28	WOS:000286724800022
J	Curril, IM; Koide, M; Yang, CH; Segal, A; Wellman, GC; Spees, JL				Curril, Ingrid M.; Koide, Masayo; Yang, Calvin H.; Segal, Alan; Wellman, George C.; Spees, Jeffrey L.			Incomplete reprogramming after fusion of human multipotent stromal cells and bronchial epithelial cells	FASEB JOURNAL			English	Article						cell fusion; progenitor cell; CFTR; ENaC	HEMATOPOIETIC STEM-CELLS; MARROW-DERIVED CELLS; PURKINJE NEURONS; SKELETAL-MUSCLE; CHANNEL; HETEROKARYONS; PLASTICITY; REPAIR; FUSE; LUNG	Bone marrow-derived progenitor cells can fuse with cells of several different tissues, including lung, especially following injury. Despite many reports of cell fusion, few studies have examined the function of the resulting hybrid cells. We cocultured human multipotent stromal cells (hMSCs) and normal human bronchial epithelial cells (NHBEs) and observed the formation of hMSC/NHBE heterokaryons. The heterokaryons expressed several proteins characteristic of epithelial cells, such as keratin and occludin. Hybrid cells also expressed the mRNAs and proteins for 2 important ion channels that maintain bronchial and alveolar fluid balance: the cystic fibrosis transmembrane conductance regulator (CFTR) and the amiloride-sensitive epithelial Na+ channel (ENaC). By immunocytochemistry, CFTR was expressed in many hybrid cells but was absent or low in others. Whole-cell patch-clamp recordings demonstrated a glibenclamide-sensitive current in the presence of barium chloride, consistent with functional CFTR channels, in control NHBEs and hMSC/NHBE heterokaryons. Total cell capacitance measurements showed that the membrane surface area of heterokaryons was similar to that of NHBEs. Heterokaryons expressed the alpha- and gamma-ENaC subunits but did not express the beta-ENaC subunit, indicating the inability to form a complete ENaC channel. In addition, hybrid cells formed by the fusion of hMSCs with immortalized bronchial cells that expressed CFTR Delta F508 did not lead to reprogramming of the hMSC nucleus and expression of wild-type CFTR mRNA. Our data show that reprogramming can be incomplete following fusion of adult progenitor cells and somatic cells and may lead to altered cell function.-Curril, I. M., Koide, M., Yang, C. H., Segal, A., Wellman, G. C., Spees, J. L. Incomplete reprogramming after fusion of human multipotent stromal cells and bronchial epithelial cells. FASEB J. 24, 4856-4864 (2010). www.fasebj.org	[Segal, Alan; Spees, Jeffrey L.] Univ Vermont, Dept Med, Colchester, VT 05446 USA; [Curril, Ingrid M.; Spees, Jeffrey L.] Vermont Lung Ctr, Burlington, VT USA; [Curril, Ingrid M.; Spees, Jeffrey L.] Cell & Mol Biol Program, Burlington, VT USA; [Koide, Masayo; Wellman, George C.] Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Spees, JL (corresponding author), Univ Vermont, Dept Med, 208 S Pk Dr,Ste 2, Colchester, VT 05446 USA.	jeffrey.spees@uvm.edu			U.S. National Institutes of Health/National Heart, Lung, and Blood Institute [R01-HL-085210]; National Center for Research Resources Centers of Biomedical Research Excellence [P20 RR-155557]; Vermont Lung Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085210] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Research Resources Centers of Biomedical Research Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Vermont Lung Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Colette Charland (University of Vermont) for technical assistance with FACS. The authors thank Dr. Darwin Prockop (Texas A&M University Health Science Center, Temple, TX, USA) for providing hMSCs. The CFT1 cell line was created by Dr. James Yankaskas (University of North Carolina, Chapel Hill, NC, USA). The authors thank Dr. Albert Van der Vliet (University of Vermont) for providing and assistance with the CFTR delta F508 cell line and Dr. Alexander Aronshtam (University of Vermont) for help with DNA sequence analysis. This work was supported in part by U.S. National Institutes of Health/National Heart, Lung, and Blood Institute grant R01-HL-085210 (to J.L.S.) and National Center for Research Resources Centers of Biomedical Research Excellence grant P20 RR-155557 (Vermont Lung Center, Charles Irvin, principal investigator). I.C. was supported by the Vermont Lung Center T32 Pulmonary Training Program.	Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Bae JS, 2007, STEM CELLS, V25, P1307, DOI 10.1634/stemcells.2006-0561; Bae JS, 2005, HUM GENE THER, V16, P1006, DOI 10.1089/hum.2005.16.1006; Caci E, 2009, AM J RESP CELL MOL, V40, P211, DOI 10.1165/rcmb.2007-0456OC; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Doyonnas R, 2004, P NATL ACAD SCI USA, V101, P13507, DOI 10.1073/pnas.0405361101; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Herzog ED, 2007, FASEB J, V21, pA144; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; Kang CS, 2009, AM J PHYSIOL-HEART C, V296, pH1949, DOI 10.1152/ajpheart.00903.2008; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Melin P, 2007, BBA-BIOMEMBRANES, V1768, P2438, DOI 10.1016/j.bbamem.2007.05.013; MOODY WJ, 1983, P NATL ACAD SCI-BIOL, V80, P3096, DOI 10.1073/pnas.80.10.3096; Nygren JM, 2008, NAT CELL BIOL, V10, P584, DOI 10.1038/ncb1721; Palermo A, 2009, FASEB J, V23, P1431, DOI 10.1096/fj.08-122903; Randrianarison N, 2008, AM J PHYSIOL-LUNG C, V294, pL409, DOI 10.1152/ajplung.00307.2007; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Spees JL, 2008, FASEB J, V22, P1226, DOI 10.1096/fj.07-8076com; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Wiersema A, 2008, STEM CELL RES, V1, P150, DOI 10.1016/j.scr.2008.02.001; Zhang F, 2007, P NATL ACAD SCI USA, V104, P4395, DOI 10.1073/pnas.0700181104	27	4	4	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4856	4864		10.1096/fj.09-152991	http://dx.doi.org/10.1096/fj.09-152991			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20724526	Green Published			2022-12-28	WOS:000284824400025
J	Noujaim, SF; Stuckey, JA; Ponce-Balbuena, D; Ferrer-Villada, T; Lopez-Izquierdo, A; Pandit, S; Calvo, CJ; Grzeda, KR; Berenfeld, O; Chapula, JAS; Jalife, J				Noujaim, Sami F.; Stuckey, Jeanne A.; Ponce-Balbuena, Daniela; Ferrer-Villada, Tania; Lopez-Izquierdo, Angelica; Pandit, Sandeep; Calvo, Conrado J.; Grzeda, Krzysztof R.; Berenfeld, Omer; Sanchez Chapula, Jose A.; Jalife, Jose			Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets	FASEB JOURNAL			English	Article						chloroquine; fibrillation; I-K1; I-KATP; I-KACh	ATRIAL-FIBRILLATION; CLINICAL CHARACTERIZATION; FUNCTIONAL REENTRY; CURRENT I-K1; CHLOROQUINE; MUTATION; KIR2.1; MECHANISM; CURRENTS; SYSTEM	Atrial and ventricular tachyarrhythmias can be perpetuated by up-regulation of inward rectifier potassium channels. Thus, it may be beneficial to block inward rectifier channels under conditions in which their function becomes arrhythmogenic (e.g., inherited gain-of-function mutation channelopathies, ischemia, and chronic and vagally mediated atrial fibrillation). We hypothesize that the antimalarial quinoline chloroquine exerts potent antiarrhythmic effects by interacting with the cytoplasmic domains of Kir2.1 (I-K1), Kir3.1 (I-KACh), or Kir6.2 (I-KATP) and reducing inward rectifier potassium currents. In isolated hearts of three different mammalian species, intracoronary chloroquine perfusion reduced fibrillatory frequency (atrial or ventricular), and effectively terminated the arrhythmia with resumption of sinus rhythm. In patch-clamp experiments chloroquine blocked I-K1, I-KACh, and I-KATP. Comparative molecular modeling and ligand docking of chloroquine in the intracellular domains of Kir2.1, Kir3.1, and Kir6.2 suggested that chloroquine blocks or reduces potassium flow by interacting with negatively charged amino acids facing the ion permeation vestibule of the channel in question. These results open a novel path toward discovering antiarrhythmic pharma-cophores that target specific residues of the cytoplasmic domain of inward rectifier potassium channels.-Noujaim, S. F., Stuckey, J. A., Ponce-Balbuena, D., Ferrer-Villada, T., Lopez-Izquierdo, A., Pandit, S., Calvo, C. J., Grzeda, K. R., Berenfeld, O., Sanchez Chapula, J. A., Jalife, J. Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets. FASEB J. 24, 4302-4312 (2010). www.fasebj.org	[Noujaim, Sami F.; Pandit, Sandeep; Calvo, Conrado J.; Grzeda, Krzysztof R.; Berenfeld, Omer; Jalife, Jose] Univ Michigan, Ctr Arrhythmia Res, Ann Arbor, MI 48108 USA; [Stuckey, Jeanne A.] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48108 USA; [Ponce-Balbuena, Daniela; Ferrer-Villada, Tania; Lopez-Izquierdo, Angelica; Sanchez Chapula, Jose A.] Univ Colima, Unidad Invest Carlos Mendez, Ctr Univ Invest Biomed, Colima, Mexico	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Universidad de Colima	Jalife, J (corresponding author), Univ Michigan, Ctr Arrhythmia Res, 5025 Venture Dr, Ann Arbor, MI 48108 USA.	jjalife@umich.edu	Lopez Izquierdo, Angelica/B-4445-2013; Jalife, Jose/L-4833-2015; Lopez-Izquierdo, Angelica/AAD-7355-2021; Jalife, Jose/AAJ-9156-2021; LOPEZ-IZQUIERDO, ANGELICA/R-6018-2019; Calvo, Conrado/H-8348-2016; Lopez-Izquierdo, Angelica/B-9404-2016	Jalife, Jose/0000-0003-0080-3500; Lopez-Izquierdo, Angelica/0000-0002-2620-7750; Jalife, Jose/0000-0003-0080-3500; Calvo, Conrado/0000-0002-1700-4863; Berenfeld, Omer/0000-0001-9532-7871	National Heart, Lung, and Blood Institute [P01-HL039707, P01-HL087226, R01-HL080159, R01 HL60843]; Leducq Foundation; American Heart Association (AHA); University of Michigan Center for Structural Biology; Secretaria de Educacion Publica-Consejo Nacional de Ciencia y Tecnologia, Mexico [CB-2008-01-105941]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL039707, R01HL080159, R01HL060843, P01HL087226] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Leducq Foundation(Leducq Foundation); American Heart Association (AHA)(American Heart Association); University of Michigan Center for Structural Biology(University of Michigan System); Secretaria de Educacion Publica-Consejo Nacional de Ciencia y Tecnologia, Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study is supported by National Heart, Lung, and Blood Institute grants P01-HL039707, P01-HL087226, R01-HL080159, and R01 HL60843; the Leducq Foundation, (J.J.), an American Heart Association (AHA) Scientist Development Grant (S.P.); an AHA Postdoctoral Fellowship (S.F.N.); the University of Michigan Center for Structural Biology; and Secretaria de Educacion Publica-Consejo Nacional de Ciencia y Tecnologia, Mexico, grant CB-2008-01-105941 (J.A.S.C.). The authors thank Elliot Wang and Drs. Steven R. Ennis and Jerome Kalifa for technical assistance and useful discussions.	Atienza F, 2006, CIRCULATION, V114, P2434, DOI 10.1161/CIRCULATIONAHA.106.633735; Avina-Zubieta JA, 1998, ANN RHEUM DIS, V57, P582, DOI 10.1136/ard.57.10.582; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beckstein O, 2004, PHYS BIOL, V1, P42, DOI 10.1088/1478-3967/1/1/005; Benavides-Haro DE, 2000, N-S ARCH PHARMACOL, V361, P311, DOI 10.1007/s002109900185; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURRELL ZL, 1958, NEW ENGL J MED, V258, P798, DOI 10.1056/NEJM195804172581608; Dhamoon AS, 2005, HEART RHYTHM, V2, P316, DOI 10.1016/j.hrthm.2004.11.012; Dobrev D, 2002, CARDIOVASC RES, V54, P397, DOI 10.1016/S0008-6363(01)00555-7; Ehrlich JR, 2008, J CARDIOVASC PHARM, V52, P129, DOI 10.1097/FJC.0b013e31816c4325; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fujita A, 2000, PHARMACOL THERAPEUT, V85, P39, DOI 10.1016/S0163-7258(99)00050-9; GRAY RA, 1995, CIRCULATION, V91, P2454, DOI 10.1161/01.CIR.91.9.2454; Gribble FM, 2000, BRIT J PHARMACOL, V131, P756, DOI 10.1038/sj.bjp.0703638; Haissaguerre M, 2009, J CARDIOVASC ELECTR, V20, P93, DOI 10.1111/j.1540-8167.2008.01326.x; Hibino H, 2010, PHYSIOL REV, V90, P291, DOI 10.1152/physrev.00021.2009; KUJANIK S, 2007, ACTA MED MARTINIANA, V7, P3; Logothetis DE, 2007, PFLUG ARCH EUR J PHY, V455, P83, DOI 10.1007/s00424-007-0276-5; Lu CW, 2006, J MED GENET, V43, DOI 10.1136/jmg.2006.040816; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mzayek Fawaz, 2007, PLoS Clin Trials, V2, pe6, DOI 10.1371/journal.pctr.0020006; Noujaim SF, 2007, J PHYSIOL-LONDON, V578, P315, DOI 10.1113/jphysiol.2006.121475; Pandit SV, 2005, BIOPHYS J, V88, P3806, DOI 10.1529/biophysj.105.060459; Pegan S, 2005, NAT NEUROSCI, V8, P279, DOI 10.1038/nn1411; Peters S, 2007, EUROPACE, V9, P162, DOI 10.1093/europace/eul188; Ponce-Balbuena D, 2009, J PHARMACOL EXP THER, V331, P563, DOI 10.1124/jpet.109.156075; Priori SG, 2005, CIRC RES, V96, P800, DOI 10.1161/01.RES.0000162101.76263.8c; Priori SG, 2004, ANN NY ACAD SCI, V1015, P96, DOI 10.1196/annals.1302.008; Rodriguez-Menchaca AA, 2008, P NATL ACAD SCI USA, V105, P1364, DOI 10.1073/pnas.0708153105; Saksena S, 2001, PACE, V24, P1435, DOI 10.1046/j.1460-9592.2001.01435.x; Samie FH, 2001, CIRC RES, V89, P1216, DOI 10.1161/hh2401.100818; Sanchez-Capula JA, 2001, J PHARMACOL EXP THER, V297, P437; Sarmast F, 2003, CARDIOVASC RES, V59, P863, DOI 10.1016/S0008-6363(03)00540-6; Sowunmi A, 1999, T ROY SOC TROP MED H, V93, P78, DOI 10.1016/S0035-9203(99)90189-X; Tie H, 2000, BRIT J PHARMACOL, V130, P1967, DOI 10.1038/sj.bjp.0703470; Tristani-Firouzi M, 2002, J CLIN INVEST, V110, P381, DOI 10.1172/JCI200215183; Uchida T, 1999, CIRCULATION, V99, P704, DOI 10.1161/01.CIR.99.5.704; Varro A, 2004, CURR MED CHEM, V11, P1, DOI 10.2174/0929867043456296; Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD222, DOI 10.1093/nar/gkm800; Xia M, 2005, BIOCHEM BIOPH RES CO, V332, P1012, DOI 10.1016/j.bbrc.2005.05.054; Zhang L, 2005, CIRCULATION, V111, pE222	42	43	45	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4302	4312		10.1096/fj.10-163246	http://dx.doi.org/10.1096/fj.10-163246			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20585026	Green Submitted, Green Published			2022-12-28	WOS:000283861100018
J	Huichalaf, C; Sakai, K; Jin, BW; Jones, K; Wang, GL; Schoser, B; Schneider-Gold, C; Sarkar, P; Pereira-Smith, OM; Timchenko, N; Timchenko, L				Huichalaf, Claudia; Sakai, Keiko; Jin, Bingwen; Jones, Karlie; Wang, Guo-Li; Schoser, Benedikt; Schneider-Gold, Christiane; Sarkar, Partha; Pereira-Smith, Olivia M.; Timchenko, Nikolai; Timchenko, Lubov			Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1) cells	FASEB JOURNAL			English	Article						PKR; CUG-binding protein; CUGBP1; MRG15/MORF	BINDING PROTEIN-BETA; EXPANDED CTG REPEATS; TRIPLET REPEAT; MESSENGER-RNA; INCREASES TRANSLATION; OXIDATIVE STRESS; MOLECULAR-BASIS; REGION; DIFFERENTIATION; EXPRESSION	The purpose of this study was to investigate the role of the mutant CUGn RNA in the induction of stress in type 1 myotonic dystrophy (DM1) cells and in the stress-mediated inhibition of protein translation in DM1. To achieve our goals, we performed HPLC-based purification of stress granules (SGs), immunoanalysis of SGs with stress markers TIA-1, CUGBP1, and ph-eIF2, site-specific mutagenesis, and examinations of RNA-protein and protein-protein interactions in myoblasts from control and DM1 patients. The cause-and-effect relationships were addressed in stable cells expressing mutant CUG repeats. We found that the mutant CUGn RNA induces formation of SGs through the increase of the double-stranded RNA-dependent protein kinase (PKR) and following inactivation of eIF2 alpha, one of the substrates of PKR. We show that SGs trap mRNA coding for the DNA repair and remodeling factor MRG15 (MORF4L1), translation of which is regulated by CUGBP1. As the result of the trapping, the levels of MRG15 are reduced in DM1 cells and in CUG-expressing cells. These data show that CUG repeats cause stress in DM1 through the PKR-ph-eIF2 alpha pathway inhibiting translation of certain mRNAs, such as MRG15 mRNA. The repression of protein translation by stress might contribute to the progressive muscle loss in DM1.-Huichalaf, C., Sakai, K., Jin, B., Jones, K., Wang, G.-L., Schoser, B., Schneider-Gold, C., Sarkar, P., Pereira-Smith, O. M., Timchenko, N., Lubov, T. Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1) cells. FASEB J. 24, 3706-3719 (2010). www.fasebj.org	[Huichalaf, Claudia; Sakai, Keiko; Jin, Bingwen; Jones, Karlie; Timchenko, Lubov] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Wang, Guo-Li; Timchenko, Nikolai] Baylor Coll Med, Dept Pathol & Immunol, Huffington Ctr Aging, Houston, TX 77030 USA; [Schoser, Benedikt] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany; [Schneider-Gold, Christiane] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-4630 Bochum, Germany; [Sarkar, Partha] Univ Houston, Texas Med Branch, Galveston, TX USA; [Pereira-Smith, Olivia M.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	Baylor College of Medicine; Baylor College of Medicine; University of Munich; Ruhr University Bochum; University of Houston System; University of Houston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Health San Antonio	Timchenko, L (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Room T424,1 Baylor Plaza, Houston, TX 77030 USA.	lubovt@bcm.tmc.edu	Schoser, Benedikt/AAH-6286-2020	Schneider-Gold, Christiane/0000-0002-9232-201X; Schoser, Benedikt/0000-0002-2757-8131	National Institutes of Health [AR052791, AR044387, AR044387-ARRA, NS063298, GM55188, CA100070, AG025477, AG032134]; Deutsche Gesellschaft fur Muskelkranke, Freiburg, Germany; German Ministry of Education and Research (BMBF, Bonn, Germany) [MD-NET/01GM0601]; EC [01/2003-03/2006]; NATIONAL CANCER INSTITUTE [R01CA100070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044387, R01AR052791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS063298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025477, R01AG032134] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Gesellschaft fur Muskelkranke, Freiburg, Germany; German Ministry of Education and Research (BMBF, Bonn, Germany)(Federal Ministry of Education & Research (BMBF)); EC(European CommissionEuropean Commission Joint Research Centre); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institutes of Health grants AR052791, AR044387, AR044387-ARRA, NS063298 (to L.T.T.), GM55188, CA100070, AG025477 (to N.A.T.), and AG032134 (to O.M.P.-S.). B.S. has received research support from the Deutsche Gesellschaft fur Muskelkranke, Freiburg, Germany; he is a member of the German Muscular Dystrophy Network (MD-NET/01GM0601) funded by the German Ministry of Education and Research (BMBF, Bonn, Germany). MD-NET is a partner of TREAT-NMD (EC, 6th FP, proposal 036825). The authors thank the Muscle Tissue Culture Collection (MTCC) for providing the samples. MTCC is a partner of the EuroBioBank Network, established in 2001 thanks to EC funding (01/2003-03/2006).	Anderson P, 2002, CELL STRESS CHAPERON, V7, P213, DOI 10.1379/1466-1268(2002)007<0213:VSTROE>2.0.CO;2; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; ARCHRAFI A, 2005, P NATL ACAD SCI USA, V102, P2180; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Fujimura K, 2008, EXP CELL RES, V314, P543, DOI 10.1016/j.yexcr.2007.10.024; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper PS, 2001, MYOTONIC DYSTROPHY; Ho TH, 2005, HUM MOL GENET, V14, P1539, DOI 10.1093/hmg/ddi162; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Ikezoe K, 2007, ACTA NEUROPATHOL, V114, P527, DOI 10.1007/s00401-007-0267-9; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Kuyumcu-Martinez NM, 2007, MOL CELL, V28, P68, DOI 10.1016/j.molcel.2007.07.027; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Mahadevan MS, 2006, NAT GENET, V38, P1066, DOI 10.1038/ng1857; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Moraes KCM, 2006, RNA, V12, P1084, DOI 10.1261/rna.59606; Onishi H, 2008, J NEUROSCI RES, V86, P1994, DOI 10.1002/jnr.21655; Ordway JM, 1996, BIOTECHNIQUES, V21, P609; Orengo JP, 2008, P NATL ACAD SCI USA, V105, P2646, DOI 10.1073/pnas.0708519105; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; Pardo PS, 2002, J BIOL CHEM, V277, P50860, DOI 10.1074/jbc.M203839200; Pena AAN, 2007, ANN NY ACAD SCI, V1100, P299, DOI 10.1196/annals.1395.031; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Salisbury E, 2008, EXP CELL RES, V314, P2266, DOI 10.1016/j.yexcr.2008.04.018; Salisbury E, 2009, AM J PATHOL, V175, P748, DOI 10.2353/ajpath.2009.090047; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; Seznec H, 2001, HUM MOL GENET, V10, P2717, DOI 10.1093/hmg/10.23.2717; Tian B, 2000, RNA, V6, P79, DOI 10.1017/S1355838200991544; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Timchenko LT, 2006, J BIOL CHEM, V281, P32806, DOI 10.1074/jbc.M605701200; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 2005, J BIOL CHEM, V280, P20549, DOI 10.1074/jbc.M409563200; Timchenko NA, 2004, J BIOL CHEM, V279, P13129, DOI 10.1074/jbc.M312923200; Timchenko NA, 2001, J BIOL CHEM, V276, P7820, DOI 10.1074/jbc.M005960200; Timchenko NA, 2001, MOL CELL BIOL, V21, P6927, DOI 10.1128/MCB.21.20.6927-6938.2001; Toscano A, 2005, FREE RADICAL RES, V39, P771, DOI 10.1080/10715760500138932; Usuki F, 2000, BIOCHEM BIOPH RES CO, V267, P739, DOI 10.1006/bbrc.1999.2026; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510; Woeller CF, 2007, J BIOL CHEM, V282, P29927, DOI 10.1074/jbc.M706264200	48	69	69	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3706	3719		10.1096/fj.09-151159	http://dx.doi.org/10.1096/fj.09-151159			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20479119	Green Published			2022-12-28	WOS:000285005900011
J	Kriehuber, T; Rattei, T; Weinmaier, T; Bepperling, A; Haslbeck, M; Buchner, J				Kriehuber, Thomas; Rattei, Thomas; Weinmaier, Thomas; Bepperling, Alexander; Haslbeck, Martin; Buchner, Johannes			Independent evolution of the core domain and its flanking sequences in small heat shock proteins	FASEB JOURNAL			English	Article						alpha-crystallin; protein folding; Hsp20; protein evolution	ALPHA-CRYSTALLIN; MOLECULAR CHAPERONES; MULTIDOMAIN PROTEINS; UNFOLDING PROTEINS; SUBUNIT EXCHANGE; STRESS-PROTEINS; FAMILY; HSP25; DIVERSITY; GENOMES	Small heat shock proteins (sHsps) are molecular chaperones involved in maintaining protein homeostasis; they have also been implicated in protein folding diseases and in cancer. In this protein family, a conserved core domain, the so-called alpha-crystallin or Hsp20 domain, is flanked by highly variable, nonconserved sequences that are essential for chaperone function. Analysis of 8714 sHsps revealed a broad variation of primary sequences within the superfamily as well as phyla-dependent differences. Significant variations were found in the number of sHsps per genome, their amino acid composition, and the length distribution of the different sequence parts. Reconstruction of the evolutionary tree for the sHsp superfamily shows that the flanking regions fall into several subgroups, indicating that they were remodeled several times in parallel but independent of the evolution of the alpha-crystallin domain. The evolutionary history of sHsps is thus set apart from that of other protein families in that two exon boundary-independent strategies are combined: the evolution of the conserved alpha-crystallin domain and the independent evolution of the N- and C-terminal sequences. This scenario allows for increased variability in specific small parts of the protein and thus promotes functional and structural differentiation of sHsps, which is not reflected in the general evolutionary tree of species.-Kriehuber, T., Rattei, T., Weinmaier, T., Bepperling, A., Haslbeck, M., Buchner, J. Independent evolution of the core domain and its flanking sequences in small heat shock proteins. FASEB J. 24, 3633-3642 (2010). www.fasebj.org	[Kriehuber, Thomas; Bepperling, Alexander; Haslbeck, Martin; Buchner, Johannes] Tech Univ Munich, Dept Chem, D-85747 Garching, Germany; [Kriehuber, Thomas; Bepperling, Alexander; Haslbeck, Martin; Buchner, Johannes] Tech Univ Munich, Munich Ctr Integrated Prot Sci, D-85747 Garching, Germany; [Rattei, Thomas; Weinmaier, Thomas] Tech Univ Munich, Dept Genome Oriented Bioinformat, Wissensch Zentrum Weihenstephan, D-8050 Freising Weihenstephan, Germany	Technical University of Munich; Technical University of Munich; Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Dept Chem, Lichtenbergstr 4, D-85747 Garching, Germany.	t.rattei@wzw.tum.de; johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010; Rattei, Thomas/F-1366-2011; Weinmaier, Thomas/K-5780-2013; Haslbeck, Martin/A-4413-2013	Rattei, Thomas/0000-0002-0592-7791; Weinmaier, Thomas/0000-0002-9552-3220; Buchner, Johannes/0000-0003-1282-7737	Deutsche Forschungsgemeinschaft [SFB594]; Fonds der Chemischen Industrie	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission)	This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB594 to J.B. and M.H.). T.K. was supported by a fellowship from the Fonds der Chemischen Industrie.	ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; Bellyei S, 2007, EUR J CELL BIOL, V86, P161, DOI 10.1016/j.ejcb.2006.12.004; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Candido E Peter M, 2002, Prog Mol Subcell Biol, V28, P61; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chang Hung-Chun, 2007, Cell, V128, P212; Chen J, 2010, J MOL BIOL, V398, P122, DOI 10.1016/j.jmb.2010.02.022; Dayhoff M, 1978, ATLAS PROTEIN SEQ ST, P345; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1998, ANAL BIOCHEM, V259, P218, DOI 10.1006/abio.1998.2630; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FELSENSTEIN J, 2005, PHYLIP PHYLOGENS INF; Finn RD, 2008, NUCLEIC ACIDS RES, V36, pD281, DOI 10.1093/nar/gkm960; Fontaine JM, 2003, CELL STRESS CHAPERON, V8, P62, DOI 10.1379/1466-1268(2003)8<62:TSODFP>2.0.CO;2; Franck E, 2004, J MOL EVOL, V59, P792, DOI 10.1007/s00239-004-0013-z; Franzmann TM, 2005, J MOL BIOL, V350, P1083, DOI 10.1016/j.jmb.2005.05.034; Han JH, 2007, NAT REV MOL CELL BIO, V8, P319, DOI 10.1038/nrm2144; Haslbeck M, 2004, J MOL BIOL, V343, P445, DOI 10.1016/j.jmb.2004.08.048; Haslbeck M, 2005, NAT STRUCT MOL BIOL, V12, P842, DOI 10.1038/nsmb993; Haslbeck M, 2004, EMBO J, V23, P638, DOI 10.1038/sj.emboj.7600080; Hayes D, 2009, J BIOL CHEM, V284, P18801, DOI 10.1074/jbc.M109.011353; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kannan N, 2007, PLOS BIOL, V5, P467, DOI 10.1371/journal.pbio.0050017; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; Kappe G, 2010, CELL STRESS CHAPERON, V15, P457, DOI 10.1007/s12192-009-0155-4; Kappe Guido, 2002, Prog Mol Subcell Biol, V28, P1; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kokke BPA, 1998, FEBS LETT, V433, P228, DOI 10.1016/S0014-5793(98)00917-X; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Letunic I, 2007, BIOINFORMATICS, V23, P127, DOI 10.1093/bioinformatics/btl529; Lindner RA, 2000, EUR J BIOCHEM, V267, P1923, DOI 10.1046/j.1432-1327.2000.01188.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Mchaourab HS, 2009, BIOCHEMISTRY-US, V48, P3828, DOI 10.1021/bi900212j; Moorhead GBG, 2009, BIOCHEM J, V417, P401, DOI 10.1042/BJ20081986; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Perlman SJ, 2006, P ROY SOC B-BIOL SCI, V273, P2097, DOI 10.1098/rspb.2006.3541; Peschek J, 2009, P NATL ACAD SCI USA, V106, P13272, DOI 10.1073/pnas.0902651106; PLESOFSKYVIG N, 1992, J MOL EVOL, V35, P537, DOI 10.1007/BF00160214; *R DEV COR TEAM, 2005, R LANG ENV STAT COMP; Ramelot TA, 2009, PROTEINS, V75, P147, DOI 10.1002/prot.22229; Rattei T, 2008, NUCLEIC ACIDS RES, V36, pD289, DOI 10.1093/nar/gkm963; Sakano D, 2006, BIOSCI BIOTECH BIOCH, V70, P2443, DOI 10.1271/bbb.60176; Sayers EW, 2009, NUCLEIC ACIDS RES, V37, pD5, DOI 10.1093/nar/gkp967; Scharf KD, 2001, CELL STRESS CHAPERON, V6, P225, DOI 10.1379/1466-1268(2001)006<0225:TEFOAT>2.0.CO;2; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Stromer T, 2004, J BIOL CHEM, V279, P11222, DOI 10.1074/jbc.M310149200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Sun Y, 2005, FEBS J, V272, P2613, DOI 10.1111/j.1742-4658.2005.04708.x; Tang Yun-Chi, 2007, Cell, V128, P412; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Ventura M, 2007, APPL ENVIRON MICROB, V73, P4695, DOI 10.1128/AEM.02496-06; Vogel C, 2004, CURR OPIN STRUC BIOL, V14, P208, DOI 10.1016/j.sbi.2004.03.011; Vos MJ, 2008, BIOCHEMISTRY-US, V47, P7001, DOI 10.1021/bi800639z; Walter MC, 2009, NUCLEIC ACIDS RES, V37, pD408, DOI 10.1093/nar/gkn749; Walter S, 2002, ANGEW CHEM INT EDIT, V41, P1098, DOI 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9; Waters ER, 2008, CELL STRESS CHAPERON, V13, P127, DOI 10.1007/s12192-008-0023-7; Waters ER, 2007, J MOL EVOL, V65, P162, DOI 10.1007/s00239-006-0223-7; WATERS ER, 1995, GENETICS, V141, P785; Waters ER, 1999, MOL BIOL EVOL, V16, P127, DOI 10.1093/oxfordjournals.molbev.a026033; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325	70	175	185	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3633	3642		10.1096/fj.10-156992	http://dx.doi.org/10.1096/fj.10-156992			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20501794				2022-12-28	WOS:000285005900004
J	Lantier, L; Mounier, R; Leclerc, J; Pende, M; Foretz, M; Viollet, B				Lantier, Louise; Mounier, Remi; Leclerc, Jocelyne; Pende, Mario; Foretz, Marc; Viollet, Benoit			Coordinated maintenance of muscle cell size control by AMP-activated protein kinase	FASEB JOURNAL			English	Article						muscle protein synthesis pathway; mTOR-p70S6K signaling; knockout mice	TWITCH SKELETAL-MUSCLE; MAMMALIAN TARGET; METABOLIC-RESPONSE; S6 KINASE; HYPERTROPHY; MTOR; GROWTH; PHOSPHORYLATION; ATROPHY; PATHWAY	Skeletal muscle mass is regulated by signaling pathways that govern protein synthesis and cell proliferation, and the mammalian target of rapamycin (mTOR) plays a key role in these processes. Recent studies suggested the crucial role of AMP-activated protein kinase (AMPK) in the inhibition of protein synthesis and cell growth. Here, we address the role of AMPK in the regulation of muscle cell size in vitro and in vivo. The size of AMPK-deficient myotubes was 1.5-fold higher than for controls. A marked increase in p70S6K Thr(389) and rpS6 Ser-235/236 phosphorylation was observed concomitantly with an up-regulation of protein synthesis rate. Treatment with rapamycin prevented p70S6K phosphorylation and rescued cell size control in AMPK-deficient cells. Importantly, myotubes lacking AMPK were resistant to further cell size increase beyond AMPK deletion alone, as MyrAkt-induced hypertrophy was absent in these cells. Moreover, in skeletal muscle-specific deficient AMPK alpha 1/alpha 2 KO mice, soleus muscle showed a higher mass with myofibers of larger size and was associated with increased p70S6K and rpS6 phosphorylation. Our results uncover the role of AMPK in the maintenance of muscle cell size control and highlight the crosstalk between AMPK and mTOR/p70S6K signaling pathways coordinating a metabolic checkpoint on cell growth.-Lantier, L., Mounier, R., Leclerc, J., Pende, M., Foretz, M., Viollet, B. Coordinated maintenance of muscle cell size control by AMP-activated protein kinase. FASEB J. 24, 3555-3561 (2010). www.fasebj.org	[Viollet, Benoit] INSERM, Inst Cochin, Dept Endocrinol Metab & Canc, U1016, F-75014 Paris, France; [Lantier, Louise; Mounier, Remi; Leclerc, Jocelyne; Foretz, Marc; Viollet, Benoit] Univ Paris 05, Inst Cochin, CNRS, UMR 8104, Paris, France; [Pende, Mario] INSERM, U845, Paris, France; [Pende, Mario] Univ Paris 05, UMRS 845, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Viollet, B (corresponding author), INSERM, Inst Cochin, Dept Endocrinol Metab & Canc, U1016, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	benoit.viollet@inserm.fr	Pende, Mario/AFR-1348-2022; Viollet, Benoit/N-2397-2019; FORETZ, Marc/O-7334-2017; Viollet, Benoit/O-6927-2017	Pende, Mario/0000-0002-7864-8937; Viollet, Benoit/0000-0002-0121-0224; FORETZ, Marc/0000-0001-7017-9032; Viollet, Benoit/0000-0002-0121-0224	European Commission [LSHM-CT-2004-005272]; Agence Nationale pour la Recherche [PHYSIO 2006 R06428KS]; Association Francaise contre les Myopathies [14138]	European Commission(European CommissionEuropean Commission Joint Research Centre); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies)	The authors thank Judith Melki (INSERM U788, Le Kremlin Bicetre, France) for kindly supplying the HSA-Cre transgenic mice for breeding, Kei Sakamoto (University of Dundee, Dundee, UK) for the kind gift of A-769662, and Grahame Hardie (University of Dundee) for providing anti-AMPK alpha 1 and alpha 2 antibodies. The authors are indebted to Dr. Luc Bertrand for the protein synthesis protocol. The authors also thank Athanassia Sotiropoulos for helpful and fruitful discussions. This work was supported by the European Commission integrated project (LSHM-CT-2004-005272), Agence Nationale pour la Recherche (PHYSIO 2006 R06428KS), and Association Francaise contre les Myopathies (grant 14138).	Aguilar V, 2007, CELL METAB, V5, P476, DOI 10.1016/j.cmet.2007.05.006; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Chan AYM, 2008, J BIOL CHEM, V283, P24194, DOI 10.1074/jbc.M802869200; Chan AYM, 2004, J BIOL CHEM, V279, P32771, DOI 10.1074/jbc.M403528200; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Dreyer HC, 2006, J PHYSIOL-LONDON, V576, P613, DOI 10.1113/jphysiol.2006.113175; Glass DJ, 2005, INT J BIOCHEM CELL B, V37, P1974, DOI 10.1016/j.biocel.2005.04.018; Gordon SE, 2008, EXERC SPORT SCI REV, V36, P179, DOI 10.1097/JES.0b013e3181877e13; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2008, MOL CELL, V30, P263, DOI 10.1016/j.molcel.2008.04.012; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Klein DK, 2007, AM J PHYSIOL-ENDOC M, V293, pE1242, DOI 10.1152/ajpendo.00382.2007; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; Lee-Young RS, 2009, J BIOL CHEM, V284, P23925, DOI 10.1074/jbc.M109.021048; Mcgee SL, 2008, J PHYSIOL-LONDON, V586, P1731, DOI 10.1113/jphysiol.2007.143685; Miniou P, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.19.e27; Mounier R, 2009, FASEB J, V23, P2264, DOI 10.1096/fj.08-119057; Nakashima K, 2007, BIOSCI BIOTECH BIOCH, V71, P1650, DOI 10.1271/bbb.70057; Nystrom GJ, 2008, INT J CLIN EXP MED, V1, P50; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Thomson DM, 2008, J APPL PHYSIOL, V104, P625, DOI 10.1152/japplphysiol.00915.2007; Thomson DM, 2005, J APPL PHYSIOL, V98, P557, DOI 10.1152/japplphysiol.00811.2004; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zarrinpashneh E, 2006, AM J PHYSIOL-HEART C, V291, pH2875, DOI 10.1152/ajpheart.01032.2005; Zhang P, 2008, HYPERTENSION, V52, P918, DOI 10.1161/HYPERTENSIONAHA.108.114702; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	40	78	83	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3555	3561		10.1096/fj.10-155994	http://dx.doi.org/10.1096/fj.10-155994			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20460585	Green Submitted			2022-12-28	WOS:000281446400042
J	Cozzi, R; Malito, E; Nuccitelli, A; D'Onofrio, M; Martinelli, M; Ferlenghi, I; Grandi, G; Telford, JL; Maione, D; Rinaudo, CD				Cozzi, Roberta; Malito, Enrico; Nuccitelli, Annalisa; D'Onofrio, Mariapina; Martinelli, Manuele; Ferlenghi, Ilaria; Grandi, Guido; Telford, John L.; Maione, Domenico; Rinaudo, C. Daniela			Structure analysis and site-directed mutagenesis of defined key residues and motives for pilus-related sortase C1 in group B Streptococcus	FASEB JOURNAL			English	Article						pilus islands; pilus polymerization; backbone protein; ancillary proteins; in vivo complementation mutagenesis	STAPHYLOCOCCUS-AUREUS; CELL-WALL; CRYSTAL-STRUCTURES; PROTEIN; TRANSPEPTIDASE; VACCINE; IDENTIFICATION; COLONIZATION	In group B Streptococcus (GBS), 3 structurally distinct types of pili have been discovered as potential virulence factors and vaccine candidates. The pilus-forming proteins are assembled into high-molecular-weight polymers via a transpeptidation mechanism mediated by specific class C sortases. Using a multidisciplinary approach including bioinformatics, structural and biochemical studies, and in vivo mutagenesis, we performed a broad characterization of GBS sortase C1 of pilus island 2a. The high-resolution X-ray structure of the enzyme revealed that the active site, into the beta-barrel core of the enzyme, is made of the catalytic triad His157-Cys219-Arg228 and covered by a loop, known as the "lid." We show that the catalytic triad and the predicted N- and C-terminal transmembrane regions are required for the enzyme activity. Interestingly, by in vivo complementation mutagenesis studies, we found that the deletion of the entire lid loop or mutations in specific lid key residues had no effect on catalytic activity of the enzyme. In addition, kinetic characterizations of recombinant enzymes indicate that the lid mutants can still recognize and cleave the substrate-mimicking peptide at least as well as the wild-type protein.-Cozzi, R., Malito, E., Nuccitelli, A., D'Onofrio, M., Martinelli, M., Ferlenghi, I., Grandi, G., Telford, J. L., Maione, D., Rinaudo, C. D. Structure analysis and site-directed mutagenesis of defined key residues and motives for pilus-related sortase C1 in group B Streptococcus. FASEB J. 25, 1874-1886 (2011). www.fasebj.org	[Cozzi, Roberta; Malito, Enrico; Nuccitelli, Annalisa; Martinelli, Manuele; Ferlenghi, Ilaria; Grandi, Guido; Telford, John L.; Maione, Domenico; Rinaudo, C. Daniela] Novartis Vaccines & Diagnost, Siena, Italy; [Malito, Enrico] Novartis Res Fdn, Genom Inst, San Diego, CA USA; [D'Onofrio, Mariapina] Univ Verona, Dept Biotechnol, I-37100 Verona, Italy	Novartis; Novartis; University of Verona	Maione, D (corresponding author), Novartis Vaccines, Via Fiorentina 1, I-53100 Siena, Italy.	domenico.maione@novartis.com	Telford, John Laird/ABG-8144-2020	Grandi, Guido/0000-0001-9724-2185; martinelli, manuele/0000-0002-9371-076X; D'ONOFRIO, Mariapina/0000-0002-8699-0847	University of Bologna (Bologna, Italy)	University of Bologna (Bologna, Italy)	The authors are grateful to Glen Spraggon (Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA) and to Matthew Bottomley (Novartis Vaccines, Siena, Italy) for valuable discussions and critical review of the manuscript. The authors thank Prof. Tom Alber (University of California, Berkeley, CA, USA) for fruitful discussion of the sortase enzyme structures. The authors thank Roberto Rosini (Novartis Vaccines) for providing the GBS KO strain 515 Delta(SrtC1 + SrtC2). R.C. is the recipient of a Novartis fellowship from the Ph.D. program in Cellular, Molecular and Industrial Biology of the University of Bologna (Bologna, Italy).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brandl M, 2001, J MOL BIOL, V307, P357, DOI 10.1006/jmbi.2000.4473; Buccato S, 2006, J INFECT DIS, V194, P331, DOI 10.1086/505433; DeLano W.L, PYMOL MOL GRAPHICS S; Dramsi S, 2005, RES MICROBIOL, V156, P289, DOI 10.1016/j.resmic.2004.10.011; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Guttilla IK, 2009, J BACTERIOL, V191, P5603, DOI 10.1128/JB.00627-09; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Huang XY, 2003, BIOCHEMISTRY-US, V42, P11307, DOI 10.1021/bi034391g; Hung TT, 2004, MOL MICROBIOL, V53, P251, DOI 10.1111/j.1365-2958.2004.04117.x; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; Johri AK, 2006, NAT REV MICROBIOL, V4, P932, DOI 10.1038/nrmicro1552; Kling DE, 1999, BIOTECHNIQUES, V27, P24, DOI 10.2144/99271bm03; Klock Heath E., 2009, V498, P91, DOI 10.1007/978-1-59745-196-3_6; Lalioui L, 2005, INFECT IMMUN, V73, P3342, DOI 10.1128/IAI.73.6.3342-3350.2005; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lauer P, 2005, SCIENCE, V309, P105, DOI 10.1126/science.1111563; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Mandlik A, 2008, TRENDS MICROBIOL, V16, P33, DOI 10.1016/j.tim.2007.10.010; Manzano C, 2009, BIOCHEMISTRY-US, V48, P10549, DOI 10.1021/bi901261y; Manzano C, 2008, STRUCTURE, V16, P1838, DOI 10.1016/j.str.2008.10.007; Margarit I, 2009, J INFECT DIS, V199, P108, DOI 10.1086/595564; Marraffini LA, 2006, MICROBIOL MOL BIOL R, V70, P192, DOI 10.1128/MMBR.70.1.192-221.2006; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Naik MT, 2006, J BIOL CHEM, V281, P1817, DOI 10.1074/jbc.M506123200; Nakata M, 2009, INFECT IMMUN, V77, P32, DOI 10.1128/IAI.00772-08; Neiers F, 2009, J MOL BIOL, V393, P704, DOI 10.1016/j.jmb.2009.08.058; Nobbs AH, 2008, INFECT IMMUN, V76, P3550, DOI 10.1128/IAI.01613-07; Otwinowski Z, 2003, ACTA CRYSTALLOGR A, V59, P228, DOI 10.1107/S0108767303005488; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; Rinaudo CD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009216; Rosini R, 2006, MOL MICROBIOL, V61, P126, DOI 10.1111/j.1365-2958.2006.05225.x; Telford JL, 2006, NAT REV MICROBIOL, V4, P509, DOI 10.1038/nrmicro1443; Ton-That H, 2004, BBA-MOL CELL RES, V1694, P269, DOI 10.1016/j.bbamcr.2004.04.014; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; van Stipdonk MJB, 2009, CANCER RES, V69, P7784, DOI 10.1158/0008-5472.CAN-09-1724; VIGUERA AR, 1995, BIOCHEMISTRY-US, V34, P8771, DOI 10.1021/bi00027a028; WEINER EM, J BIOL CHEM; WIRTH R, 1986, J BACTERIOL, V165, P831, DOI 10.1128/jb.165.3.831-836.1986; Zong YN, 2004, J BIOL CHEM, V279, P31383, DOI 10.1074/jbc.M401374200; Zong YN, 2004, STRUCTURE, V12, P105, DOI 10.1016/j.str.2003.11.021	43	25	25	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1874	1886		10.1096/fj.10-174797	http://dx.doi.org/10.1096/fj.10-174797			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21357525				2022-12-28	WOS:000291023800011
J	Mackey, AL; Brandstetter, S; Schjerling, P; Bojsen-Moller, J; Qvortrup, K; Pedersen, MM; Doessing, S; Kjaer, M; Magnusson, SP; Langberg, H				Mackey, Abigail L.; Brandstetter, Simon; Schjerling, Peter; Bojsen-Moller, Jens; Qvortrup, Klaus; Pedersen, Mette M.; Doessing, Simon; Kjaer, Michael; Magnusson, S. Peter; Langberg, Henning			Sequenced response of extracellular matrix deadhesion and fibrotic regulators after muscle damage is involved in protection against future injury in human skeletal muscle	FASEB JOURNAL			English	Article						insulin-like growth factor-1; satellite cells; collagen; tenascin C; repeated bout effect	ECCENTRIC EXERCISE; IGF-I; CONNECTIVE-TISSUE; GENE-EXPRESSION; SATELLITE CELL; LENGTHENING CONTRACTIONS; MATRICELLULAR PROTEINS; RESISTANCE EXERCISE; SINGLE BOUT; TENASCIN-C	The purpose of this study was to test the hypothesis that remodeling of skeletal muscle extracellular matrix (ECM) is involved in protecting human muscle against injury. Biopsies were obtained from medial gastrocnemius muscles after a single bout of electrical stimulation (B) or a repeated bout (RB) 30 d later, or 30 d after a single stimulation bout (RBc). A muscle biopsy was collected from the control leg for comparison with the stimulated leg. Satellite cell content, tenascin C, and muscle regeneration were assessed by immunohistochemistry; real-time PCR was used to measure mRNA levels of collagens, laminins, heat-shock proteins (HSPs), inflammation, and related growth factors. The large responses of HSPs, CCL2, and tenascin C detected 48 h after a single bout were attenuated in the RB trial, indicative of protection against injury. Satellite cell content and 12 target genes, including IGF-1, were elevated 30 d after a single bout. Among those displaying the greatest difference vs. control muscle, ECM laminin-beta 1 and collagen types I and III were elevated similar to 6- to 9-fold (P<0.001). The findings indicate that the sequenced events of load-induced early deadhesion and later strengthening of skeletal muscle ECM play a role in protecting human muscle against future injury.-Mackey, A. L., Brandstetter, S., Schjerling, P., Bojsen-Moller, J., Qvortrup, K., Pedersen, M. M., Doessing, S. Kjaer, M., Magnusson, S. P., Langberg, H. Sequenced response of extracellular matrix deadhesion and fibrotic regulators after muscle damage is involved in protection against future injury in human skeletal muscle. FASEB J. 25, 1943-1959 (2011). www.fasebj.org	[Mackey, Abigail L.; Brandstetter, Simon; Schjerling, Peter; Bojsen-Moller, Jens; Pedersen, Mette M.; Doessing, Simon; Kjaer, Michael; Magnusson, S. Peter; Langberg, Henning] Bispebjerg Hosp, Inst Sports Med, Dept Orthopaed Surg M, DK-2400 Copenhagen NV, Denmark; [Mackey, Abigail L.; Brandstetter, Simon; Schjerling, Peter; Bojsen-Moller, Jens; Pedersen, Mette M.; Doessing, Simon; Kjaer, Michael; Magnusson, S. Peter; Langberg, Henning] Univ Copenhagen, Ctr Healthy Aging, Fac Hlth Sci, DK-1168 Copenhagen, Denmark; [Qvortrup, Klaus] Univ Copenhagen, Dept Biomed Sci, Panum Inst, DK-1168 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; University of Copenhagen	Mackey, AL (corresponding author), Bispebjerg Hosp, Inst Sports Med, Dept Orthopaed Surg M, Bldg 8,1st Floor,Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.	abigail.mackey@gmail.com	Magnusson, S. Peter/AAD-5903-2022; Schjerling, Peter/F-6194-2011; Magnusson, Peter/AAN-1631-2020; Mackey, Abigail/D-1060-2009; Kjaer, Michael/W-6842-2019; Pedersen, Mette Merete/H-2947-2019	Magnusson, S. Peter/0000-0002-4308-5484; Schjerling, Peter/0000-0001-7138-3211; Mackey, Abigail/0000-0002-2017-4580; Kjaer, Michael/0000-0002-4582-8755; Brandstetter, Susanne/0000-0002-7021-8895; Langberg, Henning/0000-0001-8454-6534; Qvortrup, Klaus/0000-0001-8811-0260; bojsen-moller, jens/0000-0001-6737-446X	Nordea Foundation; Danish Agency for Science Technology and Innovation (Medical Research Council); Danish Rheumatism Association [R74-A1088]; Lundbeck Foundation	Nordea Foundation; Danish Agency for Science Technology and Innovation (Medical Research Council)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Rheumatism Association; Lundbeck Foundation(Lundbeckfonden)	Casper Mortensen and Christine Bodilsen are gratefully acknowledged for help with recruiting subjects and collecting data. The excellent technical assistance involved in taking the blood samples and preparing the muscle biopsies (Camilla Hansen) and the preparation of samples for electron microscopy (Mary-Ann Gleie) is warmly acknowledged. The F1.652, A4.951, and A4.74 antibodies developed by Helen M. Blau were obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA, USA), developed under the auspices of the U.S. National Institute of Child Health and Human Development and maintained by the Department of Biological Sciences, University of Iowa. Funding is gratefully acknowledged from the Nordea Foundation (Healthy Aging grant), the Danish Agency for Science Technology and Innovation (Medical Research Council), the Danish Rheumatism Association (R74-A1088), and the Lundbeck Foundation.	Aldayel A, 2010, EUR J APPL PHYSIOL, V108, P709, DOI 10.1007/s00421-009-1278-0; Alexakis C, 2007, AM J PHYSIOL-CELL PH, V293, pC661, DOI 10.1152/ajpcell.00061.2007; Bamman MM, 2007, J APPL PHYSIOL, V102, P2232, DOI 10.1152/japplphysiol.00024.2007; Barber RD, 2005, PHYSIOL GENOMICS, V21, P389, DOI 10.1152/physiolgenomics.00025.2005; Barton ER, 2010, J APPL PHYSIOL, V108, P1069, DOI 10.1152/japplphysiol.01308.2009; BISCHOFF R, 1990, DEVELOPMENT, V109, P943; Chen CC, 2009, INT J BIOCHEM CELL B, V41, P771, DOI 10.1016/j.biocel.2008.07.025; CLARKSON PM, 1987, CLIN SCI, V73, P383, DOI 10.1042/cs0730383; Crameri RM, 2007, J PHYSIOL-LONDON, V583, P365, DOI 10.1113/jphysiol.2007.128827; Crameri RM, 2004, MATRIX BIOL, V23, P259, DOI 10.1016/j.matbio.2004.05.009; Eriksson A, 2006, HISTOCHEM CELL BIOL, V126, P409, DOI 10.1007/s00418-006-0176-3; Fluck M, 2000, J CELL SCI, V113, P3583; Fluck M, 2008, P NATL ACAD SCI USA, V105, P13662, DOI 10.1073/pnas.0805365105; FUKUNAGA T, 1992, J ORTHOPAED RES, V10, P926, DOI 10.1002/jor.1100100623; Gullberg G, 1999, CELL MOL LIFE SCI, V56, P442, DOI 10.1007/PL00000616; Haddad F, 2002, J APPL PHYSIOL, V93, P394, DOI 10.1152/japplphysiol.01153.2001; Hameed M, 2003, J PHYSIOL-LONDON, V547, P247, DOI 10.1113/jphysiol.2002.032136; Heinemeier KM, 2007, J APPL PHYSIOL, V102, P573, DOI 10.1152/japplphysiol.00866.2006; HIKIDA RS, 1983, J NEUROL SCI, V59, P185, DOI 10.1016/0022-510X(83)90037-0; Hill M, 2003, J ANAT, V203, P89, DOI 10.1046/j.1469-7580.2003.00195.x; Hubal MJ, 2008, AM J PHYSIOL-REG I, V294, pR1628, DOI 10.1152/ajpregu.00853.2007; JONES DA, 1986, J PHYSIOL-LONDON, V375, P435, DOI 10.1113/jphysiol.1986.sp016126; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kalliokoski KK, 2007, CLIN PHYSIOL FUNCT I, V27, P239, DOI 10.1111/j.1475-097X.2007.00744.x; Kjaer M, 2004, PHYSIOL REV, V84, P649, DOI 10.1152/physrev.00031.2003; Kuang S, 2008, CELL STEM CELL, V2, P22, DOI 10.1016/j.stem.2007.12.012; LAPIER TK, 1995, J APPL PHYSIOL, V78, P1065, DOI 10.1152/jappl.1995.78.3.1065; Lapointe BM, 2002, AM J PHYSIOL-REG I, V282, pR323, DOI 10.1152/ajpregu.00339.2001; Lu HY, 2011, FASEB J, V25, P358, DOI 10.1096/fj.10-171579; Mackey AL, 2008, J APPL PHYSIOL, V105, P1620, DOI 10.1152/japplphysiol.90952.2008; Mackey AL, 2010, J APPL PHYSIOL, V109, P1920, DOI 10.1152/japplphysiol.00789.2010; Mackey AL, 2009, MUSCLE NERVE, V40, P455, DOI 10.1002/mus.21369; Mackey AL, 2005, SCAND J MED SCI SPOR, V15, P402, DOI 10.1111/j.1600-0838.2005.00449.x; Mackey AL, 2004, J APPL PHYSIOL, V97, P197, DOI 10.1152/japplphysiol.01174.2003; McHugh MP, 2003, SCAND J MED SCI SPOR, V13, P88, DOI 10.1034/j.1600-0838.2003.02477.x; McKay BR, 2008, J PHYSIOL-LONDON, V586, P5549, DOI 10.1113/jphysiol.2008.160176; MIKKELSEN UR, 2010, SCAND J MED SCI SPOR, DOI DOI 10.1111/J.1600-0838.2010.01170.X; Miller BF, 2005, J PHYSIOL-LONDON, V567, P1021, DOI 10.1113/jphysiol.2005.093690; Murase S, 2010, J NEUROSCI, V30, P3752, DOI 10.1523/JNEUROSCI.3803-09.2010; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nosaka K, 2001, MED SCI SPORT EXER, V33, P1490, DOI 10.1097/00005768-200109000-00011; Paulsen G, 2009, J APPL PHYSIOL, V107, P570, DOI 10.1152/japplphysiol.00209.2009; Pelosi L, 2007, FASEB J, V21, P1393, DOI 10.1096/fj.06-7690com; POSTLETHWAITE AE, 1976, J EXP MED, V143, P1299, DOI 10.1084/jem.143.6.1299; ROUND JM, 1987, J NEUROL SCI, V82, P1, DOI 10.1016/0022-510X(87)90002-5; Sarasa-Renedo A, 2005, SCAND J MED SCI SPOR, V15, P223, DOI 10.1111/j.1600-0838.2005.00461.x; SUOMINEN H, 1975, EUR J APPL PHYSIOL O, V34, P249, DOI 10.1007/BF00999938; Thompson HS, 2002, ACTA PHYSIOL SCAND, V174, P47, DOI 10.1046/j.1365-201x.2002.00922.x; Vissing K, 2004, FASEB J, V18, P94, DOI 10.1096/fj.04-2084fje; Vissing K, 2009, ACTA PHYSIOL, V196, P283, DOI 10.1111/j.1748-1716.2008.01940.x; Yang SY, 1996, J MUSCLE RES CELL M, V17, P487, DOI 10.1007/BF00123364; Yang SY, 2002, FEBS LETT, V522, P156, DOI 10.1016/S0014-5793(02)02918-6	52	126	130	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1943	1959		10.1096/fj.10-176487	http://dx.doi.org/10.1096/fj.10-176487			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21368102	Green Published			2022-12-28	WOS:000291023800018
J	Cerf, E; Gustot, A; Goormaghtigh, E; Ruysschaert, JM; Raussens, V				Cerf, Emilie; Gustot, Adelin; Goormaghtigh, Erik; Ruysschaert, Jean-Marie; Raussens, Vincent			High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer's disease	FASEB JOURNAL			English	Article						amyloid cascade; infrared spectroscopy; mechanism of apoE pathogenicity	TRANSFORM INFRARED-SPECTROSCOPY; IMPAIR SYNAPTIC PLASTICITY; GENOME-WIDE ASSOCIATION; CHAIN PLEATED SHEET; AMIDE-ONE VIBRATION; RESONANCE INTERACTION; IDENTIFIES VARIANTS; TRANSGENIC MICE; THIOFLAVIN-T; PROTEIN	Nowadays, the emerging role of amyloid-beta peptide (A beta) oligomers in Alzheimer's disease (AD) is widely accepted, putting aside the old idea that fibrils are the primary entities responsible for the onset of the disease. Besides, carrying the E4 isoform of apolipoprotein E (apoE) represents the highest risk of developing AD. Nevertheless, the involvement of apoE4 in AD remains confusing. The goal of this study was to bring new insights into the role of apoE4 in A beta aggregation. We used infrared spectroscopy, thioflavin T fluorescence, and Western blots to evaluate the influence of apoE isoforms on A beta aggregation in vitro. Comparing A beta controls with A beta incubated either with the apoE3 or apoE4 isoform, we report a 30% reduction of the A beta fibrillar content, whereas the oligomeric content is 2 times higher on incubation with the pathological isoform apoE4. ApoE4 would bind and block A beta in its oligomeric conformation, inhibiting further formation of less toxic fibrillar forms of A beta. While previous studies mostly correlated E4 with fibrils, our report underlines a link between apoE4 and A beta oligomers and therefore reconciles apoE4 with the new amyloid cascade hypothesis. Our observations suggest that apoE4 strongly stabilizes A beta oligomers, the pathological species responsible for Alzheimer's disease.-Cerf, E., Gustot, A., Goormaghtigh, E., Ruysschaert, J.-M., Raussens, V. High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J. 25, 1585-1595 (2011). www.fasebj.org	[Cerf, Emilie; Gustot, Adelin; Goormaghtigh, Erik; Ruysschaert, Jean-Marie; Raussens, Vincent] Univ Libre Brussels, Ctr Struct Biol & Bioinformat, B-1050 Brussels, Belgium	Universite Libre de Bruxelles	Raussens, V (corresponding author), Univ Libre Brussels, Ctr Struct Biol & Bioinformat, Blvd Triomphe CP206-2, B-1050 Brussels, Belgium.	vrauss@ulb.ac.be		Goormaghtigh, Erik/0000-0002-2071-2262				Bailey RW, 2001, BIOCHEMISTRY-US, V40, P11828, DOI 10.1021/bi010135x; Bales KR, 2009, J NEUROSCI, V29, P6771, DOI 10.1523/JNEUROSCI.0887-09.2009; Baumann MH, 2000, BIOCHEM J, V349, P77, DOI 10.1042/0264-6021:3490077; Biancalana M, 2010, BBA-PROTEINS PROTEOM, V1804, P1405, DOI 10.1016/j.bbapap.2010.04.001; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; Cerf E, 2010, SPECTROSC-INT J, V24, P245, DOI 10.1155/2010/916373; Cerf E, 2009, BIOCHEM J, V421, P415, DOI 10.1042/BJ20090379; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P627, DOI 10.1002/bip.1976.360150403; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P607, DOI 10.1002/bip.1976.360150402; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Dolev I, 2004, P NATL ACAD SCI USA, V101, P13909, DOI 10.1073/pnas.0404458101; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GOORMAGHTIGH E, 1994, SPECTROCHIM ACTA A, V50, P2137; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; Goormaghtigh E., 2009, ADV BIOMED SPECTROSC, V2, P104; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440; Huang YD, 2006, NEUROLOGY, V66, pS79, DOI 10.1212/01.wnl.0000192102.41141.9e; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Luo JH, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000663; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Nielsen HM, 2010, GLIA, V58, P1235, DOI 10.1002/glia.21004; Nuutinen T, 2009, BRAIN RES REV, V61, P89, DOI 10.1016/j.brainresrev.2009.05.007; Oberg KA, 2004, EUR J BIOCHEM, V271, P2937, DOI 10.1111/j.1432-1033.2004.04220.x; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Reiman EM, 2009, P NATL ACAD SCI USA, V106, P6820, DOI 10.1073/pnas.0900345106; Sakono M, 2010, FEBS J, V277, P1348, DOI 10.1111/j.1742-4658.2010.07568.x; Sarroukh R, 2011, CELL MOL LIFE SCI, V68, P1429, DOI 10.1007/s00018-010-0529-x; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Selkoe DJ, 2008, BEHAV BRAIN RES, V192, P106, DOI 10.1016/j.bbr.2008.02.016; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Stratman NC, 2005, CHEM PHYS LIPIDS, V137, P52, DOI 10.1016/j.chemphyslip.2005.06.005; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Townsend M, 2006, J PHYSIOL-LONDON, V572, P477, DOI 10.1113/jphysiol.2005.103754; Wellnitz S, 2005, J NEUROCHEM, V94, P1351, DOI 10.1111/j.1471-4159.2005.03295.x; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Wood SJ, 1996, BIOCHEMISTRY-US, V35, P12623, DOI 10.1021/bi961074j; Zhong N, 2008, ALZHEIMERS DEMENT, V4, P179, DOI 10.1016/j.jalz.2008.01.006; Zhong N, 2009, J BIOL CHEM, V284, P27273, DOI 10.1074/jbc.M109.014464; Zhong N, 2009, J BIOL CHEM, V284, P6027, DOI 10.1074/jbc.R800009200	55	71	74	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1585	1595		10.1096/fj.10-175976	http://dx.doi.org/10.1096/fj.10-175976			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21266538				2022-12-28	WOS:000290023800016
J	Kim, YK; Wassef, L; Chung, S; Jiang, HF; Wyss, A; Blaner, WS; Quadro, L				Kim, Youn-Kyung; Wassef, Lesley; Chung, Stacey; Jiang, Hongfeng; Wyss, Adrian; Blaner, William S.; Quadro, Loredana			beta-Carotene and its cleavage enzyme beta-carotene-15,15 '-oxygenase (CMOI) affect retinoid metabolism in developing tissues	FASEB JOURNAL			English	Article						provitamin A; lecithin:retinol acyltransferase; LRAT; embryonic vitamin A deficiency	VITAMIN-A; EMBRYONIC-DEVELOPMENT; ACYLTRANSFERASE LRAT; ENDOGENOUS RETINOIDS; PROVITAMIN-A; ACID; LECITHIN; MOUSE; MICE; IDENTIFICATION	The mammalian embryo relies on maternal circulating retinoids (vitamin A derivatives) for development. beta-Carotene is the major human dietary provitamin A. beta-Carotene-15,15'-oxygenase (CMOI) has been proposed as the main enzyme generating retinoid from beta-carotene in vivo. CMOI is expressed in embryonic tissues, suggesting that beta-carotene provides retinoids locally during development. We performed loss of CMOI function studies in mice lacking retinol-binding protein (RBP), an established model of embryonic vitamin A deficiency (VAD). We show that, unexpectedly, lack of CMOI in the developing tissues further exacerbates the severity of VAD and thus the embryonic malformations of RBP(-/-) mice. Since beta-carotene was not present in any of the mouse diets, we unveiled a novel action of CMOI independent from its beta-carotene cleavage activity. We also show for the first time that CMOI exerts an additional function on retinoid metabolism by influencing retinyl ester formation via modulation of lecithin: retinol acyltransferase (LRAT) activity, at least in developing tissues. Finally, we demonstrate unequivocally that beta-carotene can serve as an alternative vitamin A source for the in situ synthesis of retinoids in developing tissues by the action of CMOI.-Kim, Y.-K., Wassef, L., Chung, S., Jiang, H., Wyss, A., Blaner, W. S., Quadro, L. beta-Carotene and its cleavage enzyme beta-carotene-15,15'-oxygenase (CMOI) affect retinoid metabolism in developing tissues. FASEB J. 25, 1641-1652 (2011). www.fasebj.org	[Kim, Youn-Kyung; Wassef, Lesley; Chung, Stacey; Quadro, Loredana] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA; [Kim, Youn-Kyung; Wassef, Lesley; Chung, Stacey; Quadro, Loredana] Rutgers State Univ, Rutgers Ctr Lipid Res, New Brunswick, NJ 08901 USA; [Jiang, Hongfeng; Blaner, William S.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA; [Wyss, Adrian] DSM Nutr Prod, Basel, Switzerland	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Columbia University; DSM NV	Quadro, L (corresponding author), Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA.	quadro@aesop.rutgers.edu	jiang, hongfeng/I-6188-2013		U.S. National Institutes of Health (NIH) [R01HD057493, R01HD057493-02S1]; U.S. Department of Agriculture Cooperative State Research, Education, and Extension Service, Bioactive Food Components for Optimal Health [2006-35200-16580]; NIH [R01DK079221, RC2AA019413]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK079221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [RC2AA019413] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Agriculture Cooperative State Research, Education, and Extension Service, Bioactive Food Components for Optimal Health(United States Department of Agriculture (USDA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by grants R01HD057493 and R01HD057493-02S1 from the U.S. National Institutes of Health (NIH) and partially by National Research Initiative grant 2006-35200-16580 from the U.S. Department of Agriculture Cooperative State Research, Education, and Extension Service, Bioactive Food Components for Optimal Health (31.0) Program to L. Q. In addition, W. S. B. and H. J were supported by grants R01DK079221 and RC2AA019413 from NIH.	Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; Dimenstein R, 1996, BIOL NEONATE, V69, P230, DOI 10.1159/000244315; Engelking LJ, 2006, J CLIN INVEST, V116, P2356, DOI 10.1172/JCI28988; ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x; Fortuna VA, 2001, J NUTR BIOCHEM, V12, P610, DOI 10.1016/S0955-2863(01)00179-6; Glise D, 1998, IN VIVO, V12, P447; Hessel S, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706763200; Kane MA, 2010, METHODS MOL BIOL, V652, P1, DOI 10.1007/978-1-60327-325-1_1; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Kim YK, 2008, J BIOL CHEM, V283, P5611, DOI 10.1074/jbc.M708885200; Kim YK, 2010, METHODS MOL BIOL, V652, P263, DOI 10.1007/978-1-60327-325-1_15; Kiser PD, 2010, PROG RETIN EYE RES, V29, P428, DOI 10.1016/j.preteyeres.2010.03.002; Lampert JM, 2003, DEVELOPMENT, V130, P2173, DOI 10.1242/dev.00437; Lindqvist A, 2007, J NUTR, V137, P2346, DOI 10.1093/jn/137.11.2346; Marceau G, 2007, VITAM HORM, V75, P97, DOI 10.1016/S0083-6729(06)75004-X; Mark Manuel, 2009, Nucl Recept Signal, V7, pe002, DOI 10.1621/nrs.07002; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; Niederreither K, 2002, P NATL ACAD SCI USA, V99, P16111, DOI 10.1073/pnas.252626599; O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; Pasqualetti M, 2001, NAT GENET, V29, P34, DOI 10.1038/ng702; Quadro L, 2005, ENDOCRINOLOGY, V146, P4479, DOI 10.1210/en.2005-0158; Quadro L, 2004, AM J PHYSIOL-ENDOC M, V286, pE844, DOI 10.1152/ajpendo.00556.2003; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Ross AC, 2010, METHODS MOL BIOL, V652, P295, DOI 10.1007/978-1-60327-325-1_17; Scaife AR, 2006, BRIT J NUTR, V95, P771, DOI 10.1079/BJN20051718; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9647, DOI 10.1021/bi00451a016; Shmarakov I, 2010, ARCH BIOCHEM BIOPHYS, V504, P3, DOI 10.1016/j.abb.2010.05.010; Ulven SM, 2000, DEV BIOL, V220, P379, DOI 10.1006/dbio.2000.9634; van Helden YGJ, 2010, CELL MOL LIFE SCI, V67, P2039, DOI 10.1007/s00018-010-0341-7; VOGEL S, 1999, HANDB EXP PHARM, V139, P31; von Lintig J, 2005, BBA-MOL BASIS DIS, V1740, P122, DOI 10.1016/j.bbadis.2004.11.010; von Lintig J, 2010, ANNU REV NUTR, V30, P35, DOI 10.1146/annurev-nutr-080508-141027; von Lintig J, 2010, TRENDS BIOCHEM SCI, V35, P400, DOI 10.1016/j.tibs.2010.01.005; Wang XD, 1996, J BIOL CHEM, V271, P26490, DOI 10.1074/jbc.271.43.26490; WANG XD, 1992, ARCH BIOCHEM BIOPHYS, V293, P298, DOI 10.1016/0003-9861(92)90399-H; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834; Yeum KJ, 1998, J AM COLL NUTR, V17, P442, DOI 10.1080/07315724.1998.10718791; Zolfaghari R, 2000, J LIPID RES, V41, P2024	42	48	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1641	1652		10.1096/fj.10-175448	http://dx.doi.org/10.1096/fj.10-175448			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21285397	Green Published			2022-12-28	WOS:000290023800021
J	Kobrinsky, E; Duong, SQ; Sheydina, A; Soldatov, NM				Kobrinsky, Evgeny; Duong, Son Q.; Sheydina, Anna; Soldatov, Nikolai M.			Microdomain organization and frequency-dependence of CREB-dependent transcriptional signaling in heart cells	FASEB JOURNAL			English	Article						cardiac myocytes; wavelet transform analysis; Ca(v)1.2 calcium channel; FRET microscopy; patch clamp	ELEMENT-BINDING PROTEIN; TARGET GENE ACTIVATION; CARDIAC MEMORY; CALCIUM OSCILLATIONS; PHOSPHORYLATION; EXPRESSION; CHANNEL; CAMP; SPECIFICITY; HYPERTROPHY	Voltage-gated Ca(v)1.2 calcium channels couple membrane depolarization to cAMP response-element-binding protein (CREB)-dependent transcriptional activation. To investigate the spatial and temporal organization of CREB-dependent transcriptional nuclear microdomains, we combined perforated patch-clamp technique and FRET microscopy for monitoring CREB and CREB-binding protein interaction in the nuclei of live cells. The experimental approach to the quantitative assessment of CREB-dependent transcriptional signaling evoked by cAMP-and Ca(v)1.2-dependent mechanisms was devised in COS1 cells expressing recombinant Ca(v)1.2 calcium channels. Using continuous 2-dimensional wavelet transform and time series analyses, we found that nuclear CREB-dependent transcriptional signaling is organized differentially in spatially and temporally separated microdomains of 4 distinct types. In rat neonatal cardiomyocytes, CREB-dependent transcription is mediated by the cAMP-initiated CaMKII-sensitive and Ca(v)1.2-initiated CaMKII-insensitive mechanisms. The latter microdomains show a tendency to exhibit periodic behavior correlated with spontaneous contraction of myocytes suggestive of frequency-dependent CREB-dependent transcriptional regulation in the heart.-Kobrinsky, E., Duong, S. Q., Sheydina, A., Soldatov, N. M. Microdomain organization and frequency-dependence of CREB-dependent transcriptional signaling in heart cells. FASEB J. 25, 1544-1555 (2011). www.fasebj.org	[Kobrinsky, Evgeny; Duong, Son Q.; Sheydina, Anna; Soldatov, Nikolai M.] NIA, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Soldatov, NM (corresponding author), Humgenex Inc, 3105 Starner Ct, Kensington, MD 20895 USA.	soldatovn.humgenex@verizon.net			National Institute on Aging [Z01 AG000294-08]	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by the National Institute on Aging Intramural Research Program (Z01 AG000294-08 to NMS). The authors thank Dr. Mark R. Montminy (The Salk Institute for Biological Studies, La Jolla, CA, USA) for providing KID and KIX constructs and Dr. Kenneth R. Boheler (National Institute on Aging, U.S. National Institutes of Health, Baltimore, MD, USA) for providing rat cardiac myocytes.	Ashall L, 2009, SCIENCE, V324, P242, DOI 10.1126/science.1164860; Barbado M, 2009, BBA-MOL CELL RES, V1793, P1096, DOI 10.1016/j.bbamcr.2009.02.004; Bers DM, 2008, ANNU REV PHYSIOL, V70, P23, DOI 10.1146/annurev.physiol.70.113006.100455; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Cai L, 2008, NATURE, V455, P485, DOI 10.1038/nature07292; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colella M, 2008, P NATL ACAD SCI USA, V105, P2859, DOI 10.1073/pnas.0712316105; Cook PR, 2010, J MOL BIOL, V395, P1, DOI 10.1016/j.jmb.2009.10.031; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FAY FS, 1973, P NATL ACAD SCI USA, V70, P641, DOI 10.1073/pnas.70.3.641; Feng J, 2008, CARDIOVASC RES, V78, P98, DOI 10.1093/cvr/cvn016; Flavell SW, 2008, ANNU REV NEUROSCI, V31, P563, DOI 10.1146/annurev.neuro.31.060407.125631; Gerlach AC, 2000, J BIOL CHEM, V275, P585, DOI 10.1074/jbc.275.1.585; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Grinsted A, 2004, NONLINEAR PROC GEOPH, V11, P561, DOI 10.5194/npg-11-561-2004; GRINSTED A, 2009, CROSSWAVELET COHEREN; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Ichiki T, 2006, ARTERIOSCL THROM VAS, V26, P449, DOI 10.1161/01.ATV.0000196747.79349.d1; JACQUES L, 2007, YET ANOTHER WAVELET; Klevecz RR, 2007, COLD SPRING HARB SYM, V72, P421, DOI 10.1101/sqb.2007.72.040; Kobayashi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.281pe47; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Kobrinsky E, 2005, BIOPHYS J, V88, P3625, DOI 10.1529/biophysj.104.054056; Kobrinsky E, 2003, J BIOL CHEM, V278, P5021, DOI 10.1074/jbc.M211254200; Kobrinsky E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005587; Koch M, 2003, J NEUROCHEM, V85, P170, DOI 10.1046/j.1471-4159.2003.01651.x; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Li GW, 2009, FEBS LETT, V583, P3979, DOI 10.1016/j.febslet.2009.11.035; Lieser SA, 2005, BBA-PROTEINS PROTEOM, V1754, P191, DOI 10.1016/j.bbapap.2005.07.024; Mager DE, 2007, BIOPHYS J, V93, P2900, DOI 10.1529/biophysj.106.102582; Maltsev VA, 1998, CIRCULATION, V98, P2545, DOI 10.1161/01.CIR.98.23.2545; MANDERS EMM, 1992, J CELL SCI, V103, P857; Marais E, 2008, CARDIOVASC DRUG THER, V22, P3, DOI 10.1007/s10557-007-6078-3; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Ozgen N, 2009, HEART RHYTHM, V6, P564, DOI 10.1016/j.hrthm.2009.01.008; Parker D, 1996, MOL CELL BIOL, V16, P694; Patberg KW, 2003, CIRC RES, V93, pE87, DOI 10.1161/01.RES.0000099505.81736.E7; Plotnikov AN, 2003, CIRCULATION, V107, P2844, DOI 10.1161/01.CIR.0000068376.88600.41; Ravindran A, 2008, P NATL ACAD SCI USA, V105, P8154, DOI 10.1073/pnas.0711624105; Rosen MR, 2006, J PHYSIOL-LONDON, V570, P209, DOI 10.1113/jphysiol.2005.097873; Salazar C, 2008, BIOPHYS J, V94, P1203, DOI 10.1529/biophysj.107.113084; Santana LF, 2008, CIRC RES, V103, P681, DOI 10.1161/CIRCRESAHA.108.185090; Satin J, 2008, STEM CELLS, V26, P1961, DOI 10.1634/stemcells.2007-0591; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Stricker J, 2008, NATURE, V456, P516, DOI 10.1038/nature07389; Sutherland H, 2009, NAT REV GENET, V10, P457, DOI 10.1038/nrg2592; Sviridov AP, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2400248; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Torrence C, 1999, J CLIMATE, V12, P2679, DOI 10.1175/1520-0442(1999)012<2679:ICITEM>2.0.CO;2; Trinkle-Mulcahy L, 2008, FEBS LETT, V582, P1960, DOI 10.1016/j.febslet.2008.04.029; Wheeler DG, 2008, J CELL BIOL, V183, P849, DOI 10.1083/jcb.200805048; Yang HT, 2002, P NATL ACAD SCI USA, V99, P9225, DOI 10.1073/pnas.142651999; YONEMOCHI H, 1990, CIRCULATION, V81, P1401, DOI 10.1161/01.CIR.81.4.1401; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034	60	13	14	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1544	1555		10.1096/fj.10-176198	http://dx.doi.org/10.1096/fj.10-176198			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21248242	Green Published			2022-12-28	WOS:000290023800012
J	Vanhees, K; Coort, S; Ruijters, EJB; Godschalk, RWL; van Schooten, FJ; van Doorn-Khosrovani, SBV				Vanhees, Kimberly; Coort, Susan; Ruijters, Erik J. B.; Godschalk, Roger W. L.; van Schooten, Frederik J.; van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk			Epigenetics: prenatal exposure to genistein leaves a permanent signature on the hematopoietic lineage	FASEB JOURNAL			English	Article						flavonoid; in utero exposure; DNA methylation; gene expression; hematopoiesis	ARYL-HYDROCARBON RECEPTOR; STEM-CELL QUIESCENCE; BCL-X-L; MOLECULAR-IDENTIFICATION; MEGALOBLASTIC-ANEMIA; EXPRESSION; DIETARY; MICE; PROTEIN; PROGENITORS	Recent studies demonstrate that maternal diet during pregnancy results in long-lasting effects on the progeny. Supplementation of maternal diet with genistein, a phytoestrogen ubiquitous in the daily diet, altered coat color of agouti mice due to epigenetic changes. We studied hematopoiesis of mice prenatally exposed to genistein (270 mg/kg feed) compared with that of mice prenatally exposed to phytoestrogen-poor feed and observed a significant increase in granulopoiesis, erythropoiesis, and mild macrocytosis at the adult age of 12 wk. Genistein exposure was associated with hypermethylation of certain repetitive elements, which coincided with a significant down-regulation of estrogen-responsive genes and genes involved in hematopoiesis in bone marrow cells of genistein-exposed mice, as assessed by microarray technology. Although genistein exposure did not affect global methylation in fetal liver of fetuses at embryonic day 14.5, it accelerated the switch from primitive to definitive erythroid lineage. Taken together, our data demonstrate that prenatal exposure to genistein affects fetal erythropoiesis and exerts lifelong alterations in gene expression and DNA methylation of hematopoietic cells.-Vanhees, K., Coort, S., Ruitjers, E. J. B., Godschalk, R. W. L., van Schooten, F. J., Barjesteh van Waalwijk van Doorn-Khosrovani, S. Epigenetics: prenatal exposure to genistein leaves a permanent signature on the hematopoietic lineage. FASEB J. 25, 797-807 (2011). www.fasebj.org	[Vanhees, Kimberly; Ruijters, Erik J. B.; Godschalk, Roger W. L.; van Schooten, Frederik J.; van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk] Maastricht Univ, Dept Hlth Risk Anal & Toxicol, Nutr & Toxicol Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands; [Coort, Susan] Maastricht Univ, Dept Bioinformat, Bioinformat Grp, Cardiovasc Res Inst Maastrict CARIM, NL-6200 MD Maastricht, Netherlands; [Coort, Susan] Maastricht Univ, Tech Univ BiGCaT, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University	Vanhees, K (corresponding author), Maastricht Univ, Dept Hlth Risk Anal & Toxicol, Res Inst NUTRIM, POB 616, NL-6200 MD Maastricht, Netherlands.	kimberly.vanhees@maastrichtuniversity.nl	Coort, Susan/ABF-1021-2021	Coort, Susan/0000-0003-1224-9690	American Institute for Cancer Research [06A031]	American Institute for Cancer Research	This work was supported by grant 06A031 from the American Institute for Cancer Research. The authors sincerely thank Igor Pogribny and his laboratory staff (National Center for Toxicological Research) for their valuable support in setting up the DNA methylation assay and Ralph Gottschalk for the assistance during the microarray experiment. All of the authors declare no conflicts of interest.	Adlercreutz H, 1999, AM J OBSTET GYNECOL, V180, P737, DOI 10.1016/S0002-9378(99)70281-4; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Aslinia F, 2006, CLIN MED RES, V4, P236, DOI 10.3121/cmr.4.3.236; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; COWARD L, 1993, J AGR FOOD CHEM, V41, P1961, DOI 10.1021/jf00035a027; DAVIES KA, 1989, TRENDS GENET, V5, P222, DOI 10.1016/0168-9525(89)90086-3; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gaj S, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-360; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Hanspal M, 1998, BLOOD, V92, P2940, DOI 10.1182/blood.V92.8.2940.420k31_2940_2950; He H, 2009, PHYTOTHER RES, V23, P868, DOI 10.1002/ptr.2715; Hertrampf T, 2009, TOXICOL LETT, V184, P198, DOI 10.1016/j.toxlet.2008.11.006; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; KAUSHANSKY K, 1995, J CLIN INVEST, V96, P1683, DOI 10.1172/JCI118210; Keel SB, 2008, SCIENCE, V319, P825, DOI 10.1126/science.1151133; Kincade PW, 2006, NAT IMMUNOL, V7, P701, DOI 10.1038/ni0706-701; Kingsley PD, 2006, BLOOD, V107, P1665, DOI 10.1182/blood-2005-08-3097; Klausen P, 2004, J LEUKOCYTE BIOL, V75, P569, DOI 10.1189/jlb.1003474; Klein SL, 2002, MOL MED, V8, P742, DOI 10.1007/BF03402038; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Miodini P, 1999, BRIT J CANCER, V80, P1150, DOI 10.1038/sj.bjc.6690479; Moller FJ, 2009, J STEROID BIOCHEM, V113, P296, DOI 10.1016/j.jsbmb.2009.01.016; O'Donnell LC, 2002, J LEUKOCYTE BIOL, V72, P478; Ohta R, 2009, EXP ANIM TOKYO, V58, P471, DOI 10.1538/expanim.58.471; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Pellegrino CM, 1998, BLOOD CELL MOL DIS, V24, P31, DOI 10.1006/bcmd.1998.0168; Percy MJ, 2006, P NATL ACAD SCI USA, V103, P654, DOI 10.1073/pnas.0508423103; Pogribny IP, 2006, CARCINOGENESIS, V27, P1180, DOI 10.1093/carcin/bgi364; Pogribny IP, 2008, BRAIN RES, V1237, P25, DOI 10.1016/j.brainres.2008.07.077; Quigley JG, 2004, CELL, V118, P757, DOI 10.1016/j.cell.2004.08.014; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; SCOTT JM, 1980, CLIN HAEMATOL, V9, P587; SHALABY MR, 1995, CLIN IMMUNOL IMMUNOP, V74, P185, DOI 10.1006/clin.1995.1027; Singh KP, 2009, BIOCHEM PHARMACOL, V77, P577, DOI 10.1016/j.bcp.2008.10.001; Singh KP, 2009, CARCINOGENESIS, V30, P11, DOI 10.1093/carcin/bgn224; Skibola CF, 2000, FREE RADICAL BIO MED, V29, P375, DOI 10.1016/S0891-5849(00)00304-X; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Takakuwa Y, 2001, CURR OPIN HEMATOL, V8, P80, DOI 10.1097/00062752-200103000-00004; Tam BYY, 2006, NAT MED, V12, P793, DOI 10.1038/nm1428; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tanaka J, 2007, MOL CELL ENDOCRINOL, V272, P38, DOI 10.1016/j.mce.2007.04.008; TAURO GP, 1976, NEW ENGL J MED, V294, P466, DOI 10.1056/NEJM197602262940903; Tsantes AE, 2006, ANTIOXID REDOX SIGN, V8, P1205, DOI 10.1089/ars.2006.8.1205; van Doorn-Khosrovani SBV, 2007, CARCINOGENESIS, V28, P1703, DOI 10.1093/carcin/bgm102; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Williams WP, 2004, VIROLOGY, V327, P233, DOI 10.1016/j.virol.2004.06.040; Yasuda T, 2004, J EXP MED, V200, P1681, DOI 10.1084/jem.20041247; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322	60	64	67	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					797	807		10.1096/fj.10-172155	http://dx.doi.org/10.1096/fj.10-172155			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21048042				2022-12-28	WOS:000286724800037
J	Vingtdeux, V; Chandakkar, P; Zhao, HT; d'Abramo, C; Davies, P; Marambaud, P				Vingtdeux, Valerie; Chandakkar, Pallavi; Zhao, Haitian; d'Abramo, Cristina; Davies, Peter; Marambaud, Philippe			Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-beta peptide degradation	FASEB JOURNAL			English	Article						Alzheimer's disease; mTOR; resveratrol; raptor; p62	PROTEIN-KINASE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; RESVERATROL; MTOR; MECHANISMS; EXPRESSION; RAPAMYCIN; PATHWAY; CELLS	AMP-activated protein kinase (AMPK) is a metabolic sensor involved in intracellular energy metabolism through the control of several homeostatic mechanisms, which include autophagy and protein degradation. Recently, we reported that AMPK activation by resveratrol promotes autophagy-dependent degradation of the amyloid-beta (A beta) peptides, the core components of the cerebral senile plaques in Alzheimer's disease. To identify more potent enhancers of A beta degradation, we screened a library of synthetic small molecules selected for their structural similarities with resveratrol. Here, we report the identification of a series of structurally related molecules, the RSVA series, which inhibited A beta accumulation in cell lines nearly 40 times more potently than did resveratrol. Two of these molecules, RSVA314 and RSVA405, were further characterized and were found to facilitate CaMKK beta-dependent activation of AMPK, to inhibit mTOR (mammalian target of rapamycin), and to promote autophagy to increase A beta degradation by the lysosomal system (apparent EC50 similar to 1 mu M). This work identifies the RSVA compounds as promising lead molecules for the development of a new class of AMPK activating drugs controlling mTOR signaling, autophagy, and A beta clearance.-Vingtdeux, V., Chandakkar, P., Zhao, H., d'Abramo, C., Davies, P., Marambaud, P. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-beta peptide degradation. FASEB J. 25, 219-231 (2011). www.fasebj.org	[Vingtdeux, Valerie; Chandakkar, Pallavi; Zhao, Haitian; d'Abramo, Cristina; Davies, Peter; Marambaud, Philippe] N Shore Long Isl Jewish Med Ctr, Litwin Zucker Res Ctr Study Alzheimers Dis, Feinstein Inst Med Res, Manhasset, NY 11030 USA; [Davies, Peter; Marambaud, Philippe] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA	Northwell Health; Yeshiva University; Albert Einstein College of Medicine	Marambaud, P (corresponding author), N Shore Long Isl Jewish Med Ctr, Litwin Zucker Res Ctr Study Alzheimers Dis, Feinstein Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.	philippe.marambaud@einstein.yu.edu	Vingtdeux, Valerie/C-2463-2012	Vingtdeux, Valerie/0000-0003-4550-503X; Marambaud, Philippe/0000-0002-8983-1497; Davies, Peter/0000-0002-8015-1997	Weill Medical College of Cornell University, New York, NY, USA [UL1-RR024996]; National Institutes of Health, National Center for Complementary and Alternative Medicine [PO1 AT004511]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [P01AT004511] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG022102] Funding Source: NIH RePORTER	Weill Medical College of Cornell University, New York, NY, USA; National Institutes of Health, National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)NIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Gopal Thinakaran (University of Chicago, Chicago, IL, USA), Dr. Luciano D'Adamio (Albert Einstein College of Medicine, Bronx, NY, USA), Dr. Luc Buee (INSERM U815, Centre Jean Pierre Aubert, Lille, France), and Dr. David Carling (Medical Research Council Clinical Sciences Centre, Imperial College, London, UK) for kindly providing cell lines and cDNA. This work was supported in part by the Institutional Clinical and Translational Science Award UL1-RR024996 (Weill Medical College of Cornell University, New York, NY, USA; Clinical and Translational Science Center Pilot Award to P. M.) and National Institutes of Health grant PO1 AT004511 (National Center for Complementary and Alternative Medicine Project 2 to P. M.).	Caccamo A, 2010, J BIOL CHEM, V285, P13107, DOI 10.1074/jbc.M110.100420; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Carling D, 2008, INT J OBESITY, V32, pS55, DOI 10.1038/ijo.2008.124; Chan EY, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.284pe51; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Fogarty S, 2010, BIOCHEM J, V426, P109, DOI 10.1042/BJ20091372; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001; Hidvegi T, 2010, SCIENCE, V329, P229, DOI 10.1126/science.1190354; Hung SY, 2009, AUTOPHAGY, V5, P502, DOI 10.4161/auto.5.4.8096; Jaeger PA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011102; Jaeger PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-16; Karuppagounder SS, 2009, NEUROCHEM INT, V54, P111, DOI 10.1016/j.neuint.2008.10.008; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008; Li J, 2010, J CEREBR BLOOD F MET, V30, P480, DOI 10.1038/jcbfm.2009.255; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Marambaud P, 2005, GENES BRAIN BEHAV, V4, P134, DOI 10.1111/j.1601-183X.2005.00086.x; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Martinez-Vicente M, 2010, NAT NEUROSCI, V13, P567, DOI 10.1038/nn.2528; Meijer AJ, 2007, AUTOPHAGY, V3, P238, DOI 10.4161/auto.3710; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nath N, 2009, J IMMUNOL, V182, P8005, DOI 10.4049/jimmunol.0803563; Nixon RA, 2008, AUTOPHAGY, V4, P590, DOI 10.4161/auto.6259; Nixon RA, 2007, J CELL SCI, V120, P4081, DOI 10.1242/jcs.019265; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; Poels J, 2009, BIOESSAYS, V31, P944, DOI 10.1002/bies.200900003; Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Ronnett GV, 2009, J NEUROCHEM, V109, P17, DOI 10.1111/j.1471-4159.2009.05916.x; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sanyal S, 2002, NATURE, V416, P870, DOI 10.1038/416870a; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; She QB, 2001, CANCER RES, V61, P1604; Spilman P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009979; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Sudarsanam S, 2010, CURR OPIN DRUG DISC, V13, P31; Thomson DM, 2008, J APPL PHYSIOL, V104, P429, DOI 10.1152/japplphysiol.00900.2007; Tyagi A, 2005, CARCINOGENESIS, V26, P1978, DOI 10.1093/carcin/bgi165; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482; Vingtdeux V, 2007, J BIOL CHEM, V282, P18197, DOI 10.1074/jbc.M609475200; Vingtdeux V, 2010, J BIOL CHEM, V285, P9100, DOI 10.1074/jbc.M109.060061; Vingtdeux V, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S6; Viollet B, 2009, FRONT BIOSCI-LANDMRK, V14, P3380, DOI 10.2741/3460; Wang ZR, 2006, BIOCHEM BIOPH RES CO, V346, P367, DOI 10.1016/j.bbrc.2006.05.156; Wilquet V, 2004, CURR OPIN NEUROBIOL, V14, P582, DOI 10.1016/j.conb.2004.08.001; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; Zhao Haitian, 2008, BMC Res Notes, V1, P38, DOI 10.1186/1756-0500-1-38; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zorn JA, 2010, NAT CHEM BIOL, V6, P179, DOI 10.1038/NCHEMBIO.318	60	177	189	0	43	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					219	231		10.1096/fj.10-167361	http://dx.doi.org/10.1096/fj.10-167361			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20852062	Green Published			2022-12-28	WOS:000285869500020
J	Patel, HB; Bombardieri, M; Sampaio, ALF; D'Acquisto, F; Gray, M; Grieco, P; Getting, SJ; Pitzalis, C; Perretti, M				Patel, Hetal B.; Bombardieri, Michele; Sampaio, Andre L. F.; D'Acquisto, Fulvio; Gray, Mohini; Grieco, Paolo; Getting, Stephen J.; Pitzalis, Costantino; Perretti, Mauro			Anti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis	FASEB JOURNAL			English	Article						G-protein-coupled receptor; melanocortins; bone erosion; osteoclasts; cytokines	MELANOCYTE-STIMULATING HORMONE; MAST-CELLS; OSTEOCLAST DIFFERENTIATION; INFLAMMATORY ARTHRITIS; RHEUMATOID-ARTHRITIS; PRECURSOR PROTEASES; ALPHA-MSH; EXPRESSION; RESOLUTION; DISEASE	The development of biological therapies has improved management of rheumatoid arthritis. However, costs and unresponsiveness to therapy in a sizeable proportion of patients limit their use, making it imperative to identify new targets for drug development programs. Here we investigated the melanocortin-receptor type 3 (MC3) pathway. Gene-deficient mice were subjected to a model of serum-transfer-induced arthritis and joints analyzed for gene expression (cytokines, MCs) and morphology. Pharmacological analyses were also conducted in this model. Osteoclastogenesis was studied from bone marrow cells. Mc(3)(-/-) mice displayed an exacerbated inflammatory arthritis, associated with prominent bone erosion and higher articular expression of Rankl. Osteoclastogenesis studied from Mc(3)(-/-) bone marrow cells revealed a higher degree of responsiveness to Rankl, linked to prolonged NF-kappa B activation compared to wild types. Up-regulation of a discrete set of inflammatory genes, including Il-1 beta, Il-6, and Nos2, was measured in Mc(3)(-/-) mice, and a marked up-regulation of joint Mc(3) accompanied arthritis resolution in wild-type mice. Administration of an MC3 agonist, D[Trp8]-gamma-MSH, attenuated disease incidence and severity in wild-type but not Mc(3)(-/)- mice. Overall, these findings identify MC3-mediated signaling as a beneficial pathway in experimental arthritis; hence this receptor is a novel target for the development of therapeutics for arthritis.-Patel, H. B., Bombardieri, M., Sampaio, A. L. F., D'Acquisto, F., Gray, M., Grieco, P., Getting, S. J., Pitzalis, C., Perretti, M. Anti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. FASEB J. 24, 4835-4843 (2010). www.fasebj.org	[Patel, Hetal B.; Bombardieri, Michele; Sampaio, Andre L. F.; D'Acquisto, Fulvio; Pitzalis, Costantino; Perretti, Mauro] Queen Mary Univ, Barts & London Sch Med, William Harvey Res Inst, London EC1M 6BQ, England; [Gray, Mohini] Univ Edinburgh, Med Res Council Ctr Inflammat, Edinburgh, Midlothian, Scotland; [Grieco, Paolo] Univ Naples Federico 2, Dept Pharmaceut Chem & Toxicol, Naples, Italy; [Getting, Stephen J.] Univ Westminster, London W1R 8AL, England	University of London; Queen Mary University London; University of Edinburgh; University of Naples Federico II; University of Westminster	Perretti, M (corresponding author), Queen Mary Univ, Barts & London Sch Med, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	m.perretti@qmul.ac.uk	D'Acquisto, Fulvio/E-7204-2018; Grieco, Paolo/AAB-9034-2019	D'Acquisto, Fulvio/0000-0002-4513-1608; Grieco, Paolo/0000-0002-6854-8123; Pitzalis, Costantino/0000-0003-1326-5051	Arthritis Research UK [17299, 18049]; UK National Institute of Health Research; Medical Research Council [G9900991B] Funding Source: researchfish	Arthritis Research UK(Versus Arthritis); UK National Institute of Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Drs. Mike Seed and Alessandra Marrelli and Anthony Huggins for assistance with histology, TRAP staining, and EMSA analyses, respectively. M.P. declares a collaborative project on novel melanocortins with Action Pharma A/S (Copenhagen, Denmark). P.G. owns a patent on the synthesis of the MC3 agonist used in this study. C.P. and M.P. share senior authorship. The study was funded by Arthritis Research UK (grants 17299 and 18049). This work forms part of the research themes contributing to the translational research portfolio of Barts and the London Cardiovascular Biomedical Research Unit, which is supported and funded by the UK National Institute of Health Research.	Adachi S, 1999, J IMMUNOL, V163, P3363; Alexander SPH, 2009, BRIT J PHARMACOL, V158, pS1, DOI 10.1111/j.1476-5381.2009.00499.x; Artuc M, 2006, J INVEST DERMATOL, V126, P1976, DOI 10.1038/sj.jid.5700318; Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Brzoska T, 2008, ENDOCR REV, V29, P581, DOI 10.1210/er.2007-0027; Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1; Ceriani Giuliana, 1994, Neuroimmunomodulation, V1, P28, DOI 10.1159/000097087; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526; Gantz I, 2003, AM J PHYSIOL-ENDOC M, V284, pE468, DOI 10.1152/ajpendo.00434.2002; Getting SJ, 2001, J LEUKOCYTE BIOL, V69, P98; Getting SJ, 2006, FASEB J, V20, P2234, DOI 10.1096/fj.06-6339com; Getting SJ, 2006, PHARMACOL THERAPEUT, V111, P1, DOI 10.1016/j.pharmthera.2005.06.022; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gonzalez-Rey E, 2007, NAT REV IMMUNOL, V7, P52, DOI 10.1038/nri1984; Grassel S, 2009, ARTHRITIS RHEUM-US, V60, P3017, DOI 10.1002/art.24846; Grieco P, 2000, J MED CHEM, V43, P4998, DOI 10.1021/jm000211e; GUTMAN AB, 1950, AM J MED, V9, P24, DOI 10.1016/0002-9343(50)90004-0; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; Huggins A, 2009, FASEB J, V23, P985, DOI 10.1096/fj.08-119040; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Kronke G, 2009, J IMMUNOL, V183, P3383, DOI 10.4049/jimmunol.0900327; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Leoni G, 2008, FASEB J, V22, P4228, DOI 10.1096/fj.08-113886; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697; Matsumoto I, 2002, NAT IMMUNOL, V3, P360, DOI 10.1038/ni772; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; RITTER J, 1994, J RHEUMATOL, V21, P696; Ruschpler P, 2003, ARTHRITIS RES THER, V5, pR241, DOI 10.1186/ar783; Schaller M, 2001, NAT IMMUNOL, V2, P746, DOI 10.1038/90696; Schlesinger N, 2008, DRUGS, V68, P407, DOI 10.2165/00003495-200868040-00002; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Solomon S, 2005, EUR J IMMUNOL, V35, P3064, DOI 10.1002/eji.200526167; STAR RA, 1995, P NATL ACAD SCI USA, V92, P8016, DOI 10.1073/pnas.92.17.8016; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tolar J, 2004, NEW ENGL J MED, V350, P735, DOI 10.1056/NEJM200402123500723; Zhong Q, 2005, BONE, V36, P820, DOI 10.1016/j.bone.2005.01.020; Zhou HF, 2009, FASEB J, V23, P2978, DOI 10.1096/fj.09-129874	46	40	41	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4835	4843		10.1096/fj.10-167759	http://dx.doi.org/10.1096/fj.10-167759			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20702773				2022-12-28	WOS:000284824400023
J	Maderna, P; Cottell, DC; Toivonen, T; Dufton, N; Dalli, J; Perretti, M; Godson, C				Maderna, Paola; Cottell, David C.; Toivonen, Tiina; Dufton, Neil; Dalli, Jesmond; Perretti, Mauro; Godson, Catherine			FPR2/ALX receptor expression and internalization are critical for lipoxin A(4) and annexin-derived peptide-stimulated phagocytosis	FASEB JOURNAL			English	Article						resolution; inflammation	ASPIRIN-TRIGGERED LIPOXINS; LEUCYL-L-PHENYLALANINE; APOPTOTIC CELLS; HUMAN-NEUTROPHILS; LIPID MEDIATORS; STABLE ANALOGS; IN-VIVO; INFLAMMATION; RESOLUTION; MACROPHAGES	Lipoxins (LXs) are endogenously produced eicosanoids with well-described anti-inflammatory and proresolution activities, stimulating nonphlogistic phagocytosis of apoptotic cells by macrophages. LXA(4) and the glucocorticoid-derived annexin A1 peptide (Ac2-26) bind to a common G-protein-coupled receptor, termed FPR2/ALX. However, direct evidence of the involvement of FPR2/ALX in the anti-inflammatory and proresolution activity of LXA(4) is still to be investigated. Here we describe FPR2/ALX trafficking in response to LXA(4) and Ac2-26 stimulation. We have transfected cells with HA-tagged FPR2/ALX and studied receptor trafficking in unstimulated, LXA(4) (1-10 nM)- and Ac2-26 (30 mu M)-treated cells using multiple approaches that include immunofluorescent confocal microscopy, immuno-gold labeling of cryosections, and ELISA and investigated receptor trafficking in agonist-stimulated phagocytosis. We conclude that PKC-dependent internalization of FPR2/ALX is required for phagocytosis. Using bone marrow-derived macrophages (BMDMs) from mice in which the FPR2/ALX ortholog Fpr2 had been deleted, we observed the nonredundant function for this receptor in LXA(4) and Ac2-26 stimulated phagocytosis of apoptotic neutrophils. LXA(4) stimulated phagocytosis 1.7-fold above basal (P<0.001) by BMDMs from wild-type mice, whereas no effect was found on BMDMs from Fpr2(-/-) mice. Similarly, Ac2-26 stimulates phagocytosis by BMDMs from wild-type mice 1.5-fold above basal (P<0.05). However, Ac2-26 failed to stimulate phagocytosis by BMDMs isolated from Fpr2(-/-) mice relative to vehicle. These data reveal novel and complex mechanisms of the FPR2/ALX receptor trafficking and functionality in the resolution of inflammation.-Maderna, P., Cottell, D. C., Toivonen, T., Dufton, N., Dalli, J., Perretti, M., Godson, C. FPR2/ALX receptor expression and internalization are critical for lipoxin A(4) and annexin-derived peptide-stimulated phagocytosis. FASEB J. 24, 4240-4249 (2010). www.fasebj.org	[Godson, Catherine] Univ Coll Dublin, UCD Diabet Res Ctr, Conway Inst, UCD Sch Med & Med Sci, Dublin 4, Ireland; [Cottell, David C.; Toivonen, Tiina] Univ Coll Dublin, Electron Microscopy Lab, UCD Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; [Dufton, Neil; Dalli, Jesmond; Perretti, Mauro] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med, London, England	University College Dublin; University College Dublin; University of London; Queen Mary University London	Godson, C (corresponding author), Univ Coll Dublin, UCD Diabet Res Ctr, Conway Inst, UCD Sch Med & Med Sci, Dublin 4, Ireland.	catherine.godson@ucd.ie	Dufton, Neil P/AAI-9571-2020	Dufton, Neil P/0000-0002-6283-9210; Godson, Catherine/0000-0003-0655-1041; Dalli, Jesmond/0000-0001-6328-3640	UCD; Health Research Board, Ireland; Science Foundation Ireland; EU [LSHM-CT-2004-00503]; Programme for Research in Third Level Institutions (PRTLI); Wellcome Trust [086867/Z/08]	UCD; Health Research Board, Ireland; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); EU(European Commission); Programme for Research in Third Level Institutions (PRTLI); Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank Prof. Gareth Griffiths (University of Oslo, Oslo, Norway) for the helpful discussion. This work was supported by UCD Seed Funding (P.M., D.C.C.), Health Research Board, Ireland (C.G.), Science Foundation Ireland (C.G.), the EU FP6 EICOSANOX programme LSHM-CT-2004-00503 (P.M. and C.G.) and funded under the Programme for Research in Third Level Institutions (PRTLI), administered by the Higher Education Authority (P.M., D.C.C., T.T., C.G.). The support of the Wellcome Trust (086867/Z/08; M.P.) is also acknowledged.	BRANDENBURG LO, J NEUROCHEM, V113, P749; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 2005, PROSTAG LEUKOTR ESS, V73, P163, DOI 10.1016/j.plefa.2005.05.003; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Christophe T, 2001, J BIOL CHEM, V276, P21585, DOI 10.1074/jbc.M007769200; COLGAN SP, 1993, J CLIN INVEST, V92, P75, DOI 10.1172/JCI116601; DUFTON N, J IMMUNOL, V184, P2611; Ernst S, 2004, CELL MOL LIFE SCI, V61, P1684, DOI 10.1007/s00018-004-4116-x; Filep JG, 1999, BLOOD, V94, P4132, DOI 10.1182/blood.V94.12.4132.424k25_4132_4142; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; FIORE S, 1992, J BIOL CHEM, V267, P16168; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Gray M, 2007, P NATL ACAD SCI USA, V104, P14080, DOI 10.1073/pnas.0700326104; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; Huet E, 2007, CELL SIGNAL, V19, P1939, DOI 10.1016/j.cellsig.2007.05.006; Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; LEE TH, 1989, CLIN SCI, V77, P195, DOI 10.1042/cs0770195; Lim LHK, 2007, FASEB J, V21, P968, DOI 10.1096/fj.06-7464rev; Maderna P, 2003, BBA-MOL BASIS DIS, V1639, P141, DOI 10.1016/j.bbadis.2003.09.004; Maderna P, 2005, PROSTAG LEUKOTR ESS, V73, P179, DOI 10.1016/j.plefa.2005.05.004; Maderna P, 2005, J IMMUNOL, V174, P3727, DOI 10.4049/jimmunol.174.6.3727; Maderna P, 2002, AM J PATHOL, V160, P2275, DOI 10.1016/S0002-9440(10)61175-3; Maderna P, 2009, BRIT J PHARMACOL, V158, P947, DOI 10.1111/j.1476-5381.2009.00386.x; McMahon B, 2004, AM J PHYSIOL-RENAL, V286, pF189, DOI 10.1152/ajprenal.00224.2003; Mitchell D, 2007, J BIOL CHEM, V282, P15606, DOI 10.1074/jbc.M611004200; Mitchell S, 2002, J AM SOC NEPHROL, V13, P2497, DOI 10.1097/01.ASN.0000032417.73640.72; O'Sullivan TP, 2007, J MED CHEM, V50, P5894, DOI 10.1021/jm060270d; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Papayianni A, 1996, J IMMUNOL, V156, P2264; PAPAYIANNI A, 1995, KIDNEY INT, V47, P1295, DOI 10.1038/ki.1995.184; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Perretti M, 2003, TRENDS PHARMACOL SCI, V24, P574, DOI 10.1016/j.tips.2003.09.010; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Perretti M, 2004, J LEUKOCYTE BIOL, V76, P25, DOI 10.1189/jlb.1103552; PERRETTI M, 1995, BIOCHEM PHARMACOL, V50, P1037, DOI 10.1016/0006-2952(95)00238-U; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Reville K, 2006, J IMMUNOL, V176, P1878, DOI 10.4049/jimmunol.176.3.1878; Romano M, 2007, THESCIENTIFICWORLDJO, V7, P1393, DOI 10.1100/tsw.2007.186; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Scannell M, 2007, J IMMUNOL, V178, P4595, DOI 10.4049/jimmunol.178.7.4595; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880; Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; SOYOMBO O, 1994, ALLERGY, V49, P230, DOI 10.1111/j.1398-9995.1994.tb02654.x; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578	52	133	147	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4240	4249		10.1096/fj.10-159913	http://dx.doi.org/10.1096/fj.10-159913			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20570963	Green Accepted			2022-12-28	WOS:000283861100012
J	Yang, L; Zhao, LY; Gan, ZJ; He, ZX; Xu, JY; Gao, XA; Wang, XR; Han, WP; Chen, LY; Xu, T; Li, WJ; Liu, Y				Yang, Liu; Zhao, Liyun; Gan, Zhenji; He, Zixuan; Xu, Jingyue; Gao, Xiang; Wang, Xiaorui; Han, Weiping; Chen, Liangyi; Xu, Tao; Li, Wenjun; Liu, Yong			Deficiency in RNA editing enzyme ADAR2 impairs regulated exocytosis	FASEB JOURNAL			English	Article						GSIS; adenosine deaminase; pancreatic beta cells; PC12 cells	PANCREATIC BETA-CELLS; SENSITIVE K+ CHANNEL; NEURONAL SNARE COMPLEX; INSULIN-SECRETION; ADENOSINE-DEAMINASE; GRANULE EXOCYTOSIS; RECEPTOR CHANNELS; RAT-BRAIN; GLUTAMATE; EXPRESSION	Mammalian RNA editing catalyzed by adenosine deaminases acting on RNA (ADARs) ADAR1 and ADAR2 plays pivotal roles in the brain through functional modifications of neurotransmitter receptors and ion channels. We have demonstrated previously that RNA editing by ADAR2 is regulated metabolically in pancreatic beta cells. To investigate the cellular functions of ADAR2 in professional secretory cells, we studied the effects of ADAR2 knockdown on regulated exocytosis. Selective knockdown of ADAR2 expression markedly impaired glucose-stimulated insulin secretion in the rat insulinoma INS-1 cells and primary pancreatic islets and significantly diminished KC1-stimulated secretion of exogenous human growth hormone or endogenous chromogranin B protein in the rat adrenal pheochromocytoma PC12 cells. Notably, restored overexpression of catalytically active but not editing-deficient mutant ADAR2 could rescue the impairment in stimulated secretion from ADAR2 knockdown cells. Moreover, ADAR2 suppression significantly attenuated Ca2(+) -evoked membrane capacitance increases and appreciably reduced the number of membrane-docked insulin granules in INS-1 cells. Interestingly, the secretory defects resulting from ADAR2 deficiency were coupled to decreased expression of Munc18-1 and synaptotagmin-7, two key molecules in the regulation of vesicle exocytosis. Thus, these findings reveal an important aspect of ADAR2 actions in regulated exocytosis, implicating RNA editing in the control of cellular secretory machinery.-Yang, L., Zhao, L., Gan, Z., He, Z., Xu, J., Gao, X., Wang, X., Han, W., Chen, L., Xu, T., Li, W., Liu, Y. Deficiency in RNA editing enzyme ADAR2 impairs regulated exocytosis. FASEB J. 24, 3720-3732 (2010). www.fasebj.org	[Yang, Liu; Zhao, Liyun; Gan, Zhenji; Li, Wenjun; Liu, Yong] Chinese Acad Sci, Inst Nutr Sci, Shanghai Inst Biol Sci, Key Lab Nutr & Metab, Shanghai 200031, Peoples R China; [He, Zixuan; Chen, Liangyi; Xu, Tao] Chinese Acad Sci, Inst Biophys, Beijing 100080, Peoples R China; [Xu, Jingyue; Gao, Xiang] Nanjing Univ, Model Anim Res Ctr, Nanjing 210008, Peoples R China; [Wang, Xiaorui; Han, Weiping] ASTAR, Singapore Bioimaging Consortium, Singapore, Singapore	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Nanjing University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Bioengineering & Bioimaging (IBB); A*STAR - Singapore Bioimaging Consortium (SBIC)	Li, WJ (corresponding author), Chinese Acad Sci, Inst Nutr Sci, Shanghai Inst Biol Sci, Key Lab Nutr & Metab, Shanghai 200031, Peoples R China.	wjli@sibs.ac.cn; liuy@sibs.ac.cn	Chen, Liangyi/F-1352-2010; he, zixuan/ADY-7938-2022	Chen, Liangyi/0000-0003-1270-7321; LIU, YONG/0000-0001-7771-4181; Gan, Zhenji/0000-0001-5940-207X	China National Natural Science Foundation [30830033, 90713027, 30988002]; Ministry of Science and Technology [2006CB503900, 2007CB947100, 2006BAI23B00]; Chinese Academy of Sciences [KSCX1-YW-02, KSCX2-YW-R-115, SIBS2008006]; Science and Technology Commission of Shanghai Municipality [10XD1406400]; A*STAR Biomedical Research Council	China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Chinese Academy of Sciences(Chinese Academy of Sciences); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); A*STAR Biomedical Research Council(Agency for Science Technology & Research (A*STAR))	The authors thank Dr. Philippe A. Halban (University of Geneva, Geneva, Switzerland) and Dr. Romano Regazzi (University of Lausanne, Lausanne, Switzerland) for kindly providing the hGH expression plasmid; and Dr. Charles E. Samuel (University of California, Santa Barbara, CA, USA), Dr. Liangyou Rui (University of Michigan, Ann Arbor, MI, USA) and Dr. Zheng-gang Liu (National Cancer Institute, U.S. National Institutes of Health) for critical reading of the manuscript. This work was supported by grants from the China National Natural Science Foundation (30830033, 90713027, and 30988002), the Ministry of Science and Technology (973 Programs 2006CB503900, 2007CB947100 and 2006BAI23B00), the Chinese Academy of Sciences (Knowledge Innovation programs KSCX1-YW-02 and KSCX2-YW-R-115, and CS program SIBS2008006), the Science and Technology Commission of Shanghai Municipality (10XD1406400), and the A*STAR Biomedical Research Council to Y.L., W.J.L., X.G., and W.H. The authors declare no conflicts of interest.	Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Bhalla T, 2004, NAT STRUCT MOL BIOL, V11, P950, DOI 10.1038/nsmb825; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bratanova-Tochkova TK, 2002, DIABETES, V51, pS83, DOI 10.2337/diabetes.51.2007.S83; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Cai HJ, 2008, P NATL ACAD SCI USA, V105, P19538, DOI 10.1073/pnas.0810232105; Deak F, 2009, J CELL BIOL, V184, P751, DOI 10.1083/jcb.200812026; Desterro JMP, 2003, J CELL SCI, V116, P1805, DOI 10.1242/jcs.00371; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; FEHMANN HC, 1990, FEBS LETT, V262, P279, DOI 10.1016/0014-5793(90)80210-A; Gan ZJ, 2006, J BIOL CHEM, V281, P33386, DOI 10.1074/jbc.M604484200; Gauthier BR, 2008, FASEB J, V22, P194, DOI 10.1096/fj.07-8333com; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Gerber SH, 2008, SCIENCE, V321, P1507, DOI 10.1126/science.1163174; Gustavsson N, 2008, P NATL ACAD SCI USA, V105, P3992, DOI 10.1073/pnas.0711700105; Gustavsson N, 2009, J PHYSIOL-LONDON, V587, P1169, DOI 10.1113/jphysiol.2008.168005; Gut A, 2001, J CELL SCI, V114, P1709; Hayashi M, 2003, J BIOL CHEM, V278, P1966, DOI 10.1074/jbc.M206758200; Heale BSE, 2009, EMBO J, V28, P3145, DOI 10.1038/emboj.2009.244; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hoopengardner B, 2003, SCIENCE, V301, P832, DOI 10.1126/science.1086763; Hui EF, 2009, CELL, V138, P709, DOI 10.1016/j.cell.2009.05.049; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; Kang LJ, 2006, CELL METAB, V3, P463, DOI 10.1016/j.cmet.2006.04.012; Kanno T, 2004, METHODS, V33, P302, DOI 10.1016/j.ymeth.2004.01.003; Kawahara Y, 2007, SCIENCE, V315, P1137, DOI 10.1126/science.1138050; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Komatsu M, 2001, ENDOCR J, V48, P275, DOI 10.1507/endocrj.48.275; Koster JC, 2005, DIABETES, V54, P3065, DOI 10.2337/diabetes.54.11.3065; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Levin BE, 1999, AM J PHYSIOL-REG I, V276, pR1223; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Ma GQ, 2008, TRAFFIC, V9, P2165, DOI 10.1111/j.1600-0854.2008.00836.x; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Martens S, 2008, NAT REV MOL CELL BIO, V9, P543, DOI 10.1038/nrm2417; McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Olofsson CS, 2002, PFLUG ARCH EUR J PHY, V444, P43, DOI 10.1007/s00424-002-0781-5; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Seeburg PH, 2002, NEURON, V35, P17, DOI 10.1016/S0896-6273(02)00760-2; Shen JS, 2007, CELL, V128, P183, DOI 10.1016/j.cell.2006.12.016; Singh M, 2007, J BIOL CHEM, V282, P22448, DOI 10.1074/jbc.M700265200; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Stein A, 2009, NATURE, V460, P525, DOI 10.1038/nature08156; Tareste D, 2008, P NATL ACAD SCI USA, V105, P2380, DOI 10.1073/pnas.0712125105; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Tomas A, 2008, TRAFFIC, V9, P813, DOI 10.1111/j.1600-0854.2008.00709.x; Toonen RFG, 2006, P NATL ACAD SCI USA, V103, P18332, DOI 10.1073/pnas.0608507103; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041	62	18	20	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3720	3732		10.1096/fj.09-152363	http://dx.doi.org/10.1096/fj.09-152363			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20501795				2022-12-28	WOS:000285005900012
J	Ofek, P; Fischer, W; Calderon, M; Haag, R; Satchi-Fainaro, R				Ofek, Paula; Fischer, Wiebke; Calderon, Marcelo; Haag, Rainer; Satchi-Fainaro, Ronit			In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers	FASEB JOURNAL			English	Article						angiogenesis; polymer therapeutics; dendrimers; luciferase; glioblastoma; noninvasive intravital imaging	MACROMOLECULAR THERAPEUTICS; DIVALENT PEPTIDE; CATIONIC LIPIDS; GENE; CONJUGATE; ACCUMULATION; EXPRESSION; LIPOSOMES; CHLORIDE; CELLS	New targets for RNA interference (RNAi)based cancer therapy are constantly emerging from the increasing knowledge on key molecular pathways that are paramount for carcinogenesis. Nevertheless, in vivo delivery of small interfering RNA (siRNA) remains a crucial challenge for therapeutic success. siRNAs on their own are not taken up by most mammalian cells in a way that preserves their activity. Moreover, when applied in vivo, siRNA-based approaches are all limited by poor penetration into the target tissue and low silencing efficiency. To circumvent these limitations, we have developed novel polymerized polyglycerol-based dendrimer core shell structures to deliver siRNA to tumors in vivo. These cationic dendrimers can strongly improve the stability of the siRNA, its intracellular trafficking, its silencing efficacy, and its accumulation in the tumor environment owing to the enhanced permeability and retention effect. Here, we show that our dendritic nanocarriers exhibited low cytotoxicity and high efficacy in delivering active siRNA into cells. With use of human glioblastoma and murine mammary adenocarcinoma cell lines as model systems, these siRNA-dendrimer polyplexes silenced the luciferase gene, ectopically overexpressed in these cells. Importantly, significant gene silencing was accomplished in vivo within 24 h of treatment with our luciferase siRNA-nanocarrier polyplexes, as measured by noninvasive intravital bioluminescence imaging. Moreover, our siRNA-nanocarriers show very low levels of toxicity as no significant weight loss was observed after intravenous administration of the polyplexes. We show a proof of concept for siRNA delivery in vivo using a luciferase-based model. We predict that in vivo silencing of important cell growth and angiogenesis regulator genes in a selective manner will justify this approach as a successful anticancer therapy.-Ofek, P., Fischer, W., Calderon, M., Haag, R., Satchi-Fainaro, R. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J. 24, 3122-3134 (2010). www.fasebj.org	[Ofek, Paula; Satchi-Fainaro, Ronit] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; [Fischer, Wiebke; Calderon, Marcelo; Haag, Rainer] Free Univ Berlin, Inst Chem & Biochem, D-1000 Berlin, Germany	Tel Aviv University; Sackler Faculty of Medicine; Free University of Berlin	Satchi-Fainaro, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	ronitsf@post.tau.ac.il	Satchi-Fainaro, Ronit/F-9137-2011; Calderon, Marcelo/A-3594-2013	Satchi-Fainaro, Ronit/0000-0002-7360-7837; Calderon, Marcelo/0000-0002-2734-9742; Ofek, Paula/0000-0002-8516-1107; Calderon, Marcelo/0000-0002-3108-3852	Israel Science Foundation [1300/06]; Marguerite Stolz Research Fellowship; Adams Super Center for Brain Studies; German Ministry of Science	Israel Science Foundation(Israel Science Foundation); Marguerite Stolz Research Fellowship; Adams Super Center for Brain Studies; German Ministry of Science	The authors thank Leonid Mitelman (Interdepartmental Core Facility at the Sackler School of Medicine) for his excellent assistance with the confocal laser scanning microscope. The authors thank Professor Ronit Sagi-Eisenberg for insightful discussion on endocytosis and Andrea Schulz for AFM measurements. The authors also thank Merkel Technologies Ltd. and David Merkel Golan for his kind assistance using the ImageStream multispectral imaging flow cytometer. This research was supported by the Israel Science Foundation (grant 1300/06), the Marguerite Stolz Research Fellowship Fund for Outstanding Junior Faculty, and the Adams Super Center for Brain Studies. R. H. is grateful to the German Ministry of Science for a NanoFuture award.	Behlke MA, 2006, MOL THER, V13, P644, DOI 10.1016/j.ymthe.2006.01.001; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839; CAIN BF, 1978, J MED CHEM, V21, P658, DOI 10.1021/jm00205a013; Calderon M, 2010, ADV MATER, V22, P190, DOI 10.1002/adma.200902144; CARRASCO L, 1994, FEBS LETT, V350, P151, DOI 10.1016/0014-5793(94)00780-2; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P2705, DOI 10.1093/nar/gkg393; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DIJKSTRA J, 1984, BIOCHIM BIOPHYS ACTA, V804, P58, DOI 10.1016/0167-4889(84)90099-5; DUNCAN R, 1994, J DRUG TARGET, V2, P341, DOI 10.3109/10611869409015915; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Firon M, 2000, ONCOGENE, V19, P2386, DOI 10.1038/sj.onc.1203557; FU YX, 1990, CANCER RES, V50, P227; Gary DJ, 2007, J CONTROL RELEASE, V121, P64, DOI 10.1016/j.jconrel.2007.05.021; Geall AJ, 2000, J PHARMACEUT BIOMED, V22, P849, DOI 10.1016/S0731-7085(00)00250-8; Grimm D, 2007, J CLIN INVEST, V117, P3633, DOI 10.1172/JCI34129; Guillot-Nieckowski M, 2007, LANGMUIR, V23, P737, DOI 10.1021/la0624891; Haag R, 2006, ANGEW CHEM INT EDIT, V45, P1198, DOI 10.1002/anie.200502113; HAAG R, 2004, Patent No. 10211664; HARD T, 1988, EUR BIOPHYS J BIOPHY, V16, P231, DOI 10.1007/BF00261265; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Karmali PP, 2007, MED RES REV, V27, P696, DOI 10.1002/med.20090; Kramer M, 2005, MACROMOLECULES, V38, P8308, DOI 10.1021/ma0510791; Kramer M, 2004, CHEMBIOCHEM, V5, P1081, DOI 10.1002/cbic.200300905; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Martin B, 2005, CURR PHARM DESIGN, V11, P375, DOI 10.2174/1381612053382133; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Melnikov S, 2009, CELL SIGNAL, V21, P1607, DOI 10.1016/j.cellsig.2009.06.007; Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133; Misinzo G, 2008, J VIROL, V82, P1128, DOI 10.1128/JVI.01229-07; Oh YK, 2009, ADV DRUG DELIVER REV, V61, P850, DOI 10.1016/j.addr.2009.04.018; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Roller S, 2005, MOL DIVERS, V9, P305, DOI 10.1007/s11030-005-8117-y; Ryppa C, 2008, BIOCONJUGATE CHEM, V19, P1414, DOI 10.1021/bc800117r; Ryppa C, 2009, INT J PHARMACEUT, V368, P89, DOI 10.1016/j.ijpharm.2008.09.055; Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140; Segal E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005233; Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200; Sunder A, 1999, MACROMOLECULES, V32, P4240, DOI 10.1021/ma990090w; Sunder A, 2000, MACROMOLECULES, V33, P253, DOI 10.1021/ma9915881; Takakura Y, 2002, J DRUG TARGET, V10, P99, DOI 10.1080/10611860290016694; Welsh DJ, 2009, ANGEW CHEM INT EDIT, V48, P4047, DOI 10.1002/anie.200900401	48	103	108	1	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3122	3134		10.1096/fj.09-149641	http://dx.doi.org/10.1096/fj.09-149641			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20385622				2022-12-28	WOS:000281446400003
J	Urs, S; Venkatesh, D; Tang, YF; Henderson, T; Yang, XH; Friesel, RE; Rosen, CJ; Liaw, L				Urs, Sumithra; Venkatesh, Deepak; Tang, Yuefeng; Henderson, Terry; Yang, Xuehui; Friesel, Robert E.; Rosen, Clifford J.; Liaw, Lucy			Sprouty1 is a critical regulatory switch of mesenchymal stem cell lineage allocation	FASEB JOURNAL			English	Article						adipocyte; osteoblast; growth factor signaling; body fat; bone mass	PPAR-GAMMA; INSULIN-RESISTANCE; DIFFERENTIATION; TAZ; BONE; FAT; ACTIVATION; MUSCLE; PREADIPOCYTES; LIPODYSTROPHY	Development of bone and adipose tissue are linked processes arising from a common progenitor cell, but having an inverse relationship in disease conditions such as osteoporosis. Cellular differentiation of both tissues relies on growth factor cues, and we focus this study on Sprouty1 (Spry1), an inhibitor of growth factor signaling. We tested whether Spry1 can modify the development of fat cells through its activity in regulating growth factors known to be important for adipogenesis. We utilized conditional expression and genetic-null mouse models of Spry1 in adipocytes using the fatty acid binding promoter (aP2). Conditional deletion of Spry1 results in 10% increased body fat and decreased bone mass. This phenotype was rescued on Spry1 expression, which results in decreased body fat and increased bone mass. Ex vivo bone marrow experiments indicate Spry1 in bone marrow and adipose progenitor cells favors differentiation of osteoblasts at the expense of adipocytes by suppressing CEBP-beta and PPAR gamma while up regulating TAZ. Age and gender-matched littermates expressing only Cre recombinase were used as controls. Spry1 is a critical regulator of adipocyte differentiation and mesenchymal stem cell (MSC) lineage allocation, potentially acting through regulation of CEBP-beta and TAZ.-Urs, S., Venkatesh, D., Tang, Y., Henderson, T., Yang, X., Friesel, R. E., Rosen, C. J., Liaw, L. Sprouty1 is a critical regulatory switch of mesenchymal stem cell lineage allocation. FASEB J. 24, 3264-3273 (2010). www.fasebj.org	[Urs, Sumithra; Venkatesh, Deepak; Tang, Yuefeng; Henderson, Terry; Yang, Xuehui; Friesel, Robert E.; Rosen, Clifford J.; Liaw, Lucy] Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA	Maine Medical Center	Liaw, L (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	liawl@mmc.org	Pillay, Nischalan/F-9536-2012; Tang, Yuefeng/J-9770-2012		U.S. National Institutes of Health (NIH) [R01HL070865, AR54604, DK73871, P20RR1555]; NIH [P20RR1555]; National Center for Research Resources;  [P20RR181789]; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR001555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073871] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors gratefully acknowledge the support of their histopathology core (K. Carrier and V. Lindner), mouse transgenic core (A. Harrington), animal facility personnel, and clinical and translational research laboratory services (P. Le and C.J.R.). This work was supported by U.S. National Institutes of Health (NIH) grants R01HL070865 (to L. L.), AR54604 (to C.J.R.), DK73871 (to R. E. F.) and P20RR1555 (PI: R. E. F.). The Histopathology Core Facility was supported by P20RR181789 (PI: D. Wojchowski), and the Mouse Transgenic Facility was supported by NIH grant P20RR1555 (PI: R. E. F.), both from the National Center for Research Resources.	Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Bays Harold E, 2008, Expert Rev Cardiovasc Ther, V6, P343, DOI 10.1586/14779072.6.3.343; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Duan SZ, 2007, J CLIN INVEST, V117, P812, DOI 10.1172/JCI28859; Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c; Eda H, 2008, BIOCHEM BIOPH RES CO, V366, P471, DOI 10.1016/j.bbrc.2007.11.140; Guy GR, 2009, J ENDOCRINOL, V203, P191, DOI 10.1677/JOE-09-0110; Havrda MC, 2006, THROMB HAEMOSTASIS, V96, P361, DOI 10.1160/TH06-04-0224; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hibuse T, 2005, P NATL ACAD SCI USA, V102, P10993, DOI 10.1073/pnas.0503291102; Hong D, 2009, J STEROID BIOCHEM, V116, P86, DOI 10.1016/j.jsbmb.2009.05.007; Hong JH, 2006, CELL CYCLE, V5, P176, DOI 10.4161/cc.5.2.2362; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Hughess FJ, 1998, METHODS BONE BIOL, P1; Kakudo N, 2007, BIOCHEM BIOPH RES CO, V359, P239, DOI 10.1016/j.bbrc.2007.05.070; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Koutnikova H, 2003, P NATL ACAD SCI USA, V100, P14457, DOI 10.1073/pnas.2336090100; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Lin YF, 2008, CELL PROLIFERAT, V41, P803, DOI 10.1111/j.1365-2184.2008.00542.x; Medina-Gomez G, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030064; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Moyers JS, 2007, J CELL PHYSIOL, V210, P1, DOI 10.1002/jcp.20847; Newell FS, 2006, FASEB J, V20, P2615, DOI 10.1096/fj.05-5710fje; Novakofski J, 2004, J ANIM SCI, V82, P905; Rodriguez JP, 2008, CURR STEM CELL RES T, V3, P208, DOI 10.2174/157488808785740325; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Rosen CJ, 2009, AM J MED, V122, P409, DOI 10.1016/j.amjmed.2008.11.027; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Urs S, 2006, TRANSGENIC RES, V15, P647, DOI 10.1007/s11248-006-9000-z; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Widberg CH, 2009, AM J PHYSIOL-ENDOC M, V296, pE121, DOI 10.1152/ajpendo.90602.2008; Yang XH, 2008, DEV BIOL, V321, P64, DOI 10.1016/j.ydbio.2008.05.555	34	40	42	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3264	3273		10.1096/fj.10-155127	http://dx.doi.org/10.1096/fj.10-155127			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20410440	Green Published			2022-12-28	WOS:000281446400015
J	Cudaback, E; Li, XW; Montine, KS; Montine, TJ; Keene, CD				Cudaback, Eiron; Li, Xianwu; Montine, Kathleen S.; Montine, Thomas J.; Keene, C. Dirk			Apolipoprotein E isoform-dependent microglia migration	FASEB JOURNAL			English	Article						C5a; ATP; ERK; receptor associated protein; targeted replacement	GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; LIPOPROTEIN RECEPTOR; TARGETED REPLACEMENT; NERVOUS-SYSTEM; SENILE PLAQUES; APOE GENOTYPE; MOUSE MODEL; E GENE; ACTIVATION	Complement component C5a and ATP are potent effectors of microglial movement and are increased in diverse neurodegenerative diseases and at sites of injury. Apolipoprotein E (apoE) influences microglial function, and different human apoE isoforms confer variable risk for development of neurodegenerative disorders, especially Alzheimer's disease. The purpose of this investigation was to test the hypothesis that mouse apoE and human apoE isoforms influence microglial migration. Using primary wild-type and apoE-deficient microglia, we show that C5a- and ATP-stimulated chemotaxis are largely apoE-dependent processes with different molecular bases. Although the C5a-dependent chemotaxis of wild-type microglia was completely blocked by receptor-associated protein (RAP), suggesting apoE receptor involvement, ATP-stimulated migration was unaffected by RAP but was associated with differential ERK phosphorylation. Studies using primary microglia derived from targeted replacement mice "humanized" for the coding exons (protein isoform) of human epsilon 2 (apoE2), epsilon 3 (apoE3), or epsilon 4 (apoE4) allele of APOE revealed that primary mouse microglia expressing apoE4 or apoE2 exhibited significantly reduced C5a- and ATP-stimulated migration compared with microglia expressing human apoE3. This study, for the first time, demonstrates apoE dependence and apoE isoform-specific modulation of microglial migration in response to distinct chemotactic stimuli commonly associated with neurodegenerative disease.-Cudaback, E., Li, X., Montine, K. S., Montine, T. J., Keene, C. D. Apolipoprotein E isoform-dependent microglia migration. FASEB J. 25, 2082-2091 (2011). www.fasebj.org	[Keene, C. Dirk] Univ Washington, Harborview Med Ctr, Dept Pathol, Div Neuropathol, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Keene, CD (corresponding author), Univ Washington, Harborview Med Ctr, Dept Pathol, Div Neuropathol, Box 359645,325 9th Ave, Seattle, WA 98104 USA.	cdkeene@uw.edu	Keene, Christopher D/N-1806-2015	Keene, Christopher/0000-0002-5291-1469; Montine, Kathleen/0000-0003-2110-8363	U.S. National Institutes of Health [AG05136, ES16754, 5T32 AG000258]; Nancy and Buster Alvord Endowment; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005136, T32AG000258] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nancy and Buster Alvord Endowment; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr. Yue Yang, Meilany Wijaya, Amy Look, and Lisa Keene for technical assistance and Carol Arnold for managerial support. We also thank Dr. Nobuyo Maeda for the generous gift of apoE2-, apoE3-, and apoE4-targeted replacement mice. This work was supported by U.S. National Institutes of Health grants AG05136 and ES16754 as well as 5T32 AG000258 (Dr. Suzanne Craft) and the Nancy and Buster Alvord Endowment.	Ager RR, 2010, J NEUROCHEM, V113, P389, DOI 10.1111/j.1471-4159.2010.06595.x; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Beecham GW, 2009, AM J HUM GENET, V84, P35, DOI 10.1016/j.ajhg.2008.12.008; Belinson H, 2009, J NEURAL TRANSM, V116, P1427, DOI 10.1007/s00702-009-0218-9; Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431; Calvo M, 2010, J NEUROSCI, V30, P5437, DOI 10.1523/JNEUROSCI.5169-09.2010; Choi MS, 2010, ARCH PHARM RES, V33, P257, DOI 10.1007/s12272-010-0211-8; Christie RH, 1996, AM J PATHOL, V148, P399; Cimino PJ, 2009, AM J PATHOL, V175, P1622, DOI 10.2353/ajpath.2009.090443; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DEGRELL I, 1988, ARCH GERONTOL GERIAT, V7, P173, DOI 10.1016/0167-4943(88)90029-5; Egensperger R, 1998, BRAIN PATHOL, V8, P439; Egger M, 2008, EUR J PHARMACOL, V598, P104, DOI 10.1016/j.ejphar.2008.09.016; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Fonseca MI, 2009, J IMMUNOL, V183, P1375, DOI 10.4049/jimmunol.0901005; Garrett MC, 2009, BRAIN RES, V1298, P171, DOI 10.1016/j.brainres.2009.04.047; Gyoneva S, 2009, PARKINSONISM RELAT D, V15, pS195, DOI 10.1016/S1353-8020(09)70813-2; Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hickman SE, 2010, CNS NEUROL DISORD-DR, V9, P168, DOI 10.2174/187152710791011982; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Horvath RJ, 2009, J NEUROSCI, V29, P998, DOI 10.1523/JNEUROSCI.4595-08.2009; HOWELL OW, J NEUROPATHOL EXP NE, V69, P1017; Inoue K, 2008, CELL MOL LIFE SCI, V65, P3074, DOI 10.1007/s00018-008-8210-3; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Irino Y, 2008, J NEUROSCI RES, V86, P1511, DOI 10.1002/jnr.21610; JAKOB A, 2010, J NEUROINFLAMM, V221, P46; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Keene CD, 2010, AM J PATHOL, V177, P346, DOI 10.2353/ajpath.2010.090840; Kim GH, 2008, NEUROSURGERY, V63, P122, DOI 10.1227/01.NEU.0000335079.70222.8D; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Kurpius D, 2007, GLIA, V55, P873, DOI 10.1002/glia.20509; Lambert C, 2010, BRAIN BEHAV IMMUN, V24, P1241, DOI 10.1016/j.bbi.2010.02.010; LEE CY, J NEURAL TRANSM, V117, P949; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Maezawa I, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-21; Maezawa I, 2006, FASEB J, V20, P797, DOI 10.1096/fj.05-5423fje; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Malm TM, 2008, GLIA, V56, P1767, DOI 10.1002/glia.20726; Marzolo MP, 2000, J NEUROSCI RES, V60, P401, DOI 10.1002/(SICI)1097-4547(20000501)60:3<401::AID-JNR15>3.3.CO;2-C; MCGEER PL, 1989, NEUROSCI LETT, V107, P341, DOI 10.1016/0304-3940(89)90843-4; Miller AM, 2009, GLIA, V57, P875, DOI 10.1002/glia.20813; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; Peri F, 2008, CELL, V133, P916, DOI 10.1016/j.cell.2008.04.037; Pocivavsek A, 2009, GLIA, V57, P444, DOI 10.1002/glia.20772; SAMUELS SE, J GEN PHYSL, V136, P425; Sanz JM, 2009, J IMMUNOL, V182, P4378, DOI 10.4049/jimmunol.0803612; Seabrook TJ, 2006, GLIA, V53, P776, DOI 10.1002/glia.20338; Seshadri S, JAMA, V303, P1832; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Valazquez P, 1997, NAT MED, V3, P77, DOI 10.1038/nm0197-77; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Venneti S, 2009, J NEUROIMMUNE PHARM, V4, P227, DOI 10.1007/s11481-008-9142-2; WANG Y, J NEUROINFLAMMATION, V7, P24; Ward PA, 2009, J MOL MED, V87, P375, DOI 10.1007/s00109-009-0442-7; Woodruff TM, 2010, NEUROMOL MED, V12, P179, DOI 10.1007/s12017-009-8085-y; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhang C, 2009, AM J PATHOL, V174, P586, DOI 10.2353/ajpath.2009.080661	67	36	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					2082	2091		10.1096/fj.10-176891	http://dx.doi.org/10.1096/fj.10-176891			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21385991	Green Published, Bronze			2022-12-28	WOS:000291023800030
J	Barroso-delJesus, A; Lucena-Aguilar, G; Sanchez, L; Ligero, G; Gutierrez-Aranda, I; Menendez, P				Barroso-delJesus, Alicia; Lucena-Aguilar, Gema; Sanchez, Laura; Ligero, Gertrudis; Gutierrez-Aranda, Ivan; Menendez, Pablo			The Nodal inhibitor Lefty is negatively modulated by the microRNA miR-302 in human embryonic stem cells	FASEB JOURNAL			English	Article						hESC; TGF beta/Nodal pathway; self-renewal	CD34(+); QUALITY; TRANSPLANTATION; MAINTENANCE; DERIVATION; DISCOVERY; REVEALS; DICER; IGF; P53	MicroRNAs (miRNAs) have been shown to be important in early development and maintenance of human embryonic stem cells (hESCs). The miRNA miR-302-367 is specifically expressed in hESCs, and its expression decays on differentiation. We previously identified the structure of the gene coding for the human miR-302-367 cluster and characterized its promoter. The promoter activity was functionally validated in hESCs, opening up new avenues to further investigate how these miRNA molecules fit in the complex molecular network conferring "stemness" properties to hESCs. The physiological roles of specific miRNA-mRNA interactions remain largely unknown. Here, we investigated putative miR-302-367 mRNA targets in hESCs, potentially relevant for ESC biology. We found that the Nodal inhibitors Lefty1 and Lefty2 are post-transcriptionally targeted by miR-302s in hESCs. Functional analyses indicate that miR-302s negatively modulate the level of lefties, and become upstream regulators of the TGF beta/Nodal pathway, functioning via Smad-2/3 signaling. Overexpression of the miR-302-367 cluster in hESCs causes a delay in early hESC differentiation, as measured by enhanced levels of ESC-specific transcription factors, coupled to a faster teratoma formation in mice transplanted with miR-302-367-expressing hESCs and a concomitant impairment of germ layer specification, displaying robust decreased levels of early mesodermal, endodermal, and ectodermal specific markers. These findings suggest that Lefty is negatively modulated by miR-302s in hESCs, which plays an important role in maintaining the balance between pluripotency and germ layer specification.-Barroso-delJesus, A., Lucena-Aguilar, G., Sanchez, L., Ligero, G., Gutierrez-Aranda, I., Menendez, P. The Nodal inhibitor Lefty is negatively modulated by the microRNA miR-302 in human embryonic stem cells. FASEB J. 25, 1497-1508 (2011). www.fasebj.org	[Barroso-delJesus, Alicia] CSIC, Genom Facil, Inst Parasitol & Biomed Lopez Neyra, Armilla 18100, Granada, Spain; [Barroso-delJesus, Alicia; Lucena-Aguilar, Gema; Sanchez, Laura; Ligero, Gertrudis; Gutierrez-Aranda, Ivan; Menendez, Pablo] Univ Granada, Consejeria Salud, Ctr Invest Biomed, Andalusian Stem Cell Bank, Armilla, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Granada	Barroso-delJesus, A (corresponding author), CSIC, Genom Facil, Inst Parasitol & Biomed Lopez Neyra, Avda Conocimiento, Armilla 18100, Granada, Spain.	abarroso@ipb.csic.es; pablo.menendez@juntadeandalucia.es	Bujan, Pablo Menendez/W-3736-2017	Bujan, Pablo Menendez/0000-0001-9372-1007; SANCHEZ CONTRERAS, LAURA/0000-0003-2243-6166; Barroso-delJesus, Alicia/0000-0001-8558-0056; Ligero Martin, Gertrudis/0000-0002-5559-0664	Consejeria de Salud [0004/2005, 0030/2006]; Consejeria de Innovacion de la Junta de Andalucia [P08-CTS-3678]; Spanish Ministry of Health (FIS/FEDER) [PI070026, PI100449]; Ministerio de Ciencia e Innovacion [PLE-2009-0111]	Consejeria de Salud; Consejeria de Innovacion de la Junta de Andalucia(Junta de Andalucia); Spanish Ministry of Health (FIS/FEDER)(Instituto de Salud Carlos IIISpanish GovernmentEuropean Commission); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	This work was funded by the Consejeria de Salud (grants 0004/2005 to A.B.-D. and 0030/2006 to P. M.) and Consejeria de Innovacion de la Junta de Andalucia (grant P08-CTS-3678 to P. M.), the Spanish Ministry of Health (FIS/FEDER PI070026 and PI100449 to P. M.) and the Ministerio de Ciencia e Innovacion (PLE-2009-0111 to P. M.). The authors thank members of the BACM for their technical support and critical insights. The authors especially thank Dr. Cristina Romero-Lopez for her help in the construction of plvx-302-367 vector and for scientific discussions. The authors are also indebted to Prof. Outi Hovatta (Karolinska Institute, Stockholm, Sweden), Profs. A. Rosa and A. H. Brivanlou (Rockefeller University, New York, NY, USA), and Dr. Alfredo Berzal Herranz (Instituto de Parasitologia y Biomedicina Lopez-Neyra, Granada, Spain) for providing key reagents. The authors declare no conflicts of interest. A.B.-D. designed and performed the experiments, analyzed and interpreted the data, and wrote the paper. G.L.-A., L. S., G. L., and I.G.-A. performed experiments and analyzed the data. P. M. analyzed and interpreted the data and wrote the paper.	Allegrucci C, 2007, HUM REPROD UPDATE, V13, P103, DOI 10.1093/humupd/dml041; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bar M, 2008, STEM CELLS, V26, P2496, DOI 10.1634/stemcells.2008-0356; Barroso-delJesus A, 2008, MOL CELL BIOL, V28, P6609, DOI 10.1128/MCB.00398-08; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Branford WW, 2002, CURR BIOL, V12, P2136, DOI 10.1016/S0960-9822(02)01360-X; Bueno C, 2010, CYTOTHERAPY, V12, P45, DOI 10.3109/14653240903377052; Bueno C, 2009, CARCINOGENESIS, V30, P1628, DOI 10.1093/carcin/bgp169; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Calvanese V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003294; Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08; Catalina P, 2009, LEUKEMIA RES, V33, P980, DOI 10.1016/j.leukres.2008.08.028; Catalina P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-76; Choi WY, 2007, SCIENCE, V318, P271, DOI 10.1126/science.1147535; Cobo F, 2008, CLONING STEM CELLS, V10, P65, DOI 10.1089/clo.2007.0020; Cortes JL, 2008, STEM CELLS DEV, V17, P255, DOI 10.1089/scd.2007.0157; Cortes JL, 2009, HUM REPROD, V24, P1844, DOI 10.1093/humrep/dep107; Dvash T, 2007, STEM CELLS, V25, P465, DOI 10.1634/stemcells.2006-0179; Feldman B, 2002, CURR BIOL, V12, P2129, DOI 10.1016/S0960-9822(02)01361-1; Gratama JW, 2000, J IMMUNOL METHODS, V239, P13, DOI 10.1016/S0022-1759(00)00154-X; Gutierrez-Aranda I, 2010, STEM CELLS, V28, P1568, DOI 10.1002/stem.471; Hatfield SD, 2005, NATURE, V435, P974, DOI 10.1038/nature03816; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Jesus ABD, 2009, CELL CYCLE, V8, P394; Judson RL, 2009, NAT BIOTECHNOL, V27, P459, DOI 10.1038/nbt.1535; Lakshmipathy U, 2007, STEM CELLS DEV, V16, P1003, DOI 10.1089/scd.2007.0026; Laurent LC, 2008, STEM CELLS, V26, P1506, DOI 10.1634/stemcells.2007-1081; Laurent LC, 2008, J CELL MOL MED, V12, P2181, DOI 10.1111/j.1582-4934.2008.00513.x; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Menendez P, 2004, MOL THER, V10, P1109, DOI 10.1016/j.ymthe.2004.08.016; Menendez P, 1998, CYTOMETRY, V34, P264, DOI 10.1002/(SICI)1097-0320(19981215)34:6<264::AID-CYTO4>3.0.CO;2-P; Menendez P, 2002, BRIT J HAEMATOL, V119, P135, DOI 10.1046/j.1365-2141.2002.03794.x; Menendez P, 2005, STEM CELL REV, V1, P151, DOI 10.1385/SCR:1:2:151; Montes R, 2009, CELL RES, V19, P698, DOI 10.1038/cr.2009.35; Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Ramos-Mejia V, 2010, MOL THER, V18, P2173, DOI 10.1038/mt.2010.179; Rodriguez R, 2009, NEOPLASIA, V11, P397, DOI 10.1593/neo.81620; Rosa A, 2009, DEV CELL, V16, P517, DOI 10.1016/j.devcel.2009.02.007; Rubio R, 2010, CANCER RES, V70, P4185, DOI 10.1158/0008-5472.CAN-09-4640; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Shojaei F, 2008, EXP HEMATOL, V36, P1436, DOI 10.1016/j.exphem.2008.06.001; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Tabibzadeh S, 2006, STEM CELLS, V24, P1998, DOI 10.1634/stemcells.2006-0075; Tavakoli T, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-44; Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553	52	74	78	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1497	1508		10.1096/fj.10-172221	http://dx.doi.org/10.1096/fj.10-172221			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21266536				2022-12-28	WOS:000290023800008
J	Miller, G; Matthews, SP; Reinheckel, T; Fleming, S; Watts, C				Miller, Gail; Matthews, Stephen P.; Reinheckel, Thomas; Fleming, Stewart; Watts, Colin			Asparagine endopeptidase is required for normal kidney physiology and homeostasis	FASEB JOURNAL			English	Article						legumain; lysosome; proteolysis; kidney proximal tubule; EGF receptor	GROWTH-FACTOR RECEPTOR; CATHEPSIN-L; ANTIGEN PRESENTATION; LYSOSOMAL CYSTEINE; MAMMALIAN LEGUMAIN; DEGRADATION; PROLIFERATION; PROGELATINASE; ACTIVATION; EXPRESSION	Although protein recapture and catabolism is known as a key function of kidney proximal tubular cells (PTCs), to date, no single protease has been shown to be required. Asparagine endopeptidase (AEP) is an unusually specific endosomal and lysosomal cysteine protease, expressed at high levels in the PTCs of the mammalian kidney. We report that mice lacking AEP accumulate a discrete set of proteins in their PTC endosomes and lysosomes, which indicates a defect in the normal catabolism of proteins captured from the filtrate. Moreover, the mice develop progressive kidney pathology, including hyperplasia of PTCs, interstitial fibrosis, development of glomerular cysts, and renal pelvis dilation. By 6 mo of age, the glomerular filtration rate in AEP-null mice dropped by almost a factor of 2, and the mice developed proteinuria. We also show that EGF receptor levels are significantly higher in AEP-null PTCs, which likely explains the hyperplasia, and we show that chemical inhibition of AEP activity suppresses down-regulation of the EGF receptor in vitro. Thus, AEP is required for normal protein catabolism by PTCs, and its loss induces proliferative and other abnormalities in the murine kidney, at least in part through defective regulation of the EGF receptor.-Miller, G., Matthews, S. P., Reinheckel, R., Fleming, S., Watts, C. Asparagine endopeptidase is required for normal kidney physiology and homeostasis. FASEB J. 25, 1606-1617 (2011). www.fasebj.org	[Miller, Gail; Matthews, Stephen P.; Watts, Colin] Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; [Fleming, Stewart] Univ Dundee, Ninewells Hosp, Dept Mol Pathol, Dundee DD1 5EH, Scotland; [Reinheckel, Thomas] Univ Freiburg, Inst Mol Med & Zellforsch, Freiburg, Germany	University of Dundee; University of Dundee; University of Freiburg	Watts, C (corresponding author), Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.	c.watts@dundee.ac.uk	Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Watts, Colin/0000-0001-6183-2087; Matthews, Stephen/0000-0003-3556-962X	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank Kathe Young, Calum Thomson, and John James for performing immunohistochemistry, histology staining, and electron microscopy. The authors thank Alan Prescott and John Lucocq for assistance and advice on fluorescence and electron microscopy. The authors thank Kenneth Beattie and Douglas Lamont for peptide mass fingerprinting and Doreen Keane and Keith Burling (Core Biochemical Assay Laboratory, Addenbrooke's Hospital, Cambridge, UK) for technical assistance. This work was supported by a Wellcome Trust program grant to C. W.	Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Chan CB, 2009, P NATL ACAD SCI USA, V106, P468, DOI 10.1073/pnas.0809824105; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Christensen EI, 2002, NAT REV MOL CELL BIO, V3, P258, DOI 10.1038/nrm778; Costantino CM, 2008, J IMMUNOL, V180, P2876, DOI 10.4049/jimmunol.180.5.2876; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Faul C, 2008, NAT MED, V14, P931, DOI 10.1038/nm.1857; Kawashima A, 1998, KIDNEY INT, V54, P275, DOI 10.1046/j.1523-1755.1998.00958.x; Khoudoli G.A., 2004, PROTEOME SCI, V2, P6, DOI DOI 10.1186/1477-5956-2-6; KOLDOVSKY O, 1971, BIOCHEM J, V125, P697, DOI 10.1042/bj1250697; Liu C, 2003, CANCER RES, V63, P2957; Liu ZX, 2008, MOL CELL, V29, P665, DOI 10.1016/j.molcel.2008.02.017; Loak K, 2003, BIOL CHEM, V384, P1239, DOI 10.1515/BC.2003.136; Maehr R, 2005, J IMMUNOL, V174, P7066, DOI 10.4049/jimmunol.174.11.7066; Manoury B, 2003, IMMUNITY, V18, P489, DOI 10.1016/S1074-7613(03)00085-2; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; Matthews SP, 2010, J IMMUNOL, V184, P2423, DOI 10.4049/jimmunol.0901486; Mattock KL, 2010, ATHEROSCLEROSIS, V208, P83, DOI 10.1016/j.atherosclerosis.2009.07.022; Moch H, 1997, HUM PATHOL, V28, P1255; Morita Y, 2007, FEBS LETT, V581, P1417, DOI 10.1016/j.febslet.2007.02.064; Moss CX, 2007, EMBO J, V26, P2137, DOI 10.1038/sj.emboj.7601660; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Patel N, 2009, J CLIN INVEST, V119, P1964, DOI 10.1172/JCI37977; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Sarandeses CS, 2003, J BIOL CHEM, V278, P13286, DOI 10.1074/jbc.M213005200; Sepulveda FE, 2009, IMMUNITY, V31, P737, DOI 10.1016/j.immuni.2009.09.013; Sever S, 2007, J CLIN INVEST, V117, P2095, DOI 10.1172/JCI32022; Shirahama-Noda K, 2003, J BIOL CHEM, V278, P33194, DOI 10.1074/jbc.M302742200; STOCKLIN E, 1993, J CELL BIOL, V122, P199, DOI 10.1083/jcb.122.1.199; Tagboto S, 2007, BMC CLIN PATHOL, V7, DOI 10.1186/1472-6890-7-5; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; TERZI F, 2007, DRUG DISC TODAY DIS, V4, P47; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Watts C, 2005, IMMUNOL REV, V207, P218, DOI 10.1111/j.0105-2896.2005.00312.x; Watts C, 2003, BIOCHEM SOC SYMP, V70, P31, DOI 10.1042/bss0700031; Watts C, 2001, CURR OPIN IMMUNOL, V13, P26, DOI 10.1016/S0952-7915(00)00177-1; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119	41	53	55	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1606	1617		10.1096/fj.10-172312	http://dx.doi.org/10.1096/fj.10-172312			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21292981				2022-12-28	WOS:000290023800018
J	Metzele, R; Alt, C; Bai, XW; Yan, YS; Zhang, Z; Pan, ZZ; Coleman, M; Vykoukal, J; Song, YH; Alt, E				Metzele, Roxana; Alt, Christopher; Bai, Xiaowen; Yan, Yasheng; Zhang, Zhi; Pan, Zhizhong; Coleman, Michael; Vykoukal, Jody; Song, Yao-Hua; Alt, Eckhard			Human adipose tissue-derived stem cells exhibit proliferation potential and spontaneous rhythmic contraction after fusion with neonatal rat cardiomyocytes	FASEB JOURNAL			English	Article						differentiation; action potential	MYOCARDIAL-INFARCTION; PROGENITOR CELLS; CARDIAC-FUNCTION; SKELETAL-MUSCLE; DIFFERENTIATION; TRANSPLANTATION; VIRUS	Various types of stem cells have been shown to have beneficial effects on cardiac function. It is still debated whether fusion of injected stem cells with local resident cardiomyocytes is one of the mechanisms. To better understand the role of fusion in stem cell-based myocardial regeneration, the present study was designed to investigate the fate of human adipose tissue-derived stem cells (hASCs) fused with neonatal rat cardiomyocytes in vitro. hASCs labeled with the green fluorescent probe Vybrant DiO were cocultured with neonatal rat cardiomyocytes labeled with the red fluorescent probe Vybrant DiI and then treated with fusion-inducing hemagglutinating virus of Japan (HVJ). Cells that incorporated both red and green fluorescent signals were considered to be hASCs that had fused with rat cardiomyocytes. Fusion efficiency was 19.86 +/- 4.84% at 5 d after treatment with HVJ. Most fused cells displayed cardiomyocyte-like morphology and exhibited spontaneous rhythmic contraction. Both immunofluorescence staining and lentiviral vector labeling showed that fused cells contained separate rat cardiomyocyte and hASC nuclei. Immunofluorescence staining assays demonstrated that human nuclei in fused cells still expressed the proliferation marker Ki67. In addition, hASCs fused with rat cardiomyocytes were positive for troponin I. Whole-cell voltage-clamp analysis demonstrated action potentials in beating fused cells. RT-PCR analysis using rat-or human-specific myosin heavy chain primers revealed that the myosin heavy-chain expression in fused cells was derived from rat cardiomyocytes. Real-time PCR identified expression of human troponin T in fused cells and the presence of rat cardiomyocytes induced a cardiomyogenic protein expression of troponin T in human ASCs. This study illustrates that hASCs exhibit both stem cell (proliferation) and cardiomyocyte properties (action potential and spontaneous rhythmic beating) after fusion with rat cardiomyocytes, supporting the theory that fusion, even if artificially induced in our study, could indeed be a mechanism for cardiomyocyte renewal in the heart.-Metzele, R., Alt, C., Bai, X., Yan, Y., Zhang, Z., Pan, Z., Coleman, M., Vykoukal, J., Song, Y.-H., Alt, E. Human adipose tissue-derived stem cells exhibit proliferation potential and spontaneous rhythmic con-traction after fusion with neonatal rat cardiomyocytes. FASEB J. 25, 830-839 (2011). www.fasebj.org	[Alt, Eckhard] Univ Texas MD Anderson Canc Ctr, Interdisciplinary Stem Cell Lab, Unit 951, Dept Mol Pathol, Houston, TX 77030 USA; [Zhang, Zhi; Pan, Zhizhong] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol, Houston, TX 77030 USA; [Coleman, Michael] InGeneron Inc, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Alt, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Interdisciplinary Stem Cell Lab, Unit 951, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ealtmd@aol.com			Alliance of Cardiovascular Researchers [543102]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA023069, R01DA027541] Funding Source: NIH RePORTER	Alliance of Cardiovascular Researchers; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Sebastian Gehmert, Sanga Gehmert, Grace Wu, Martha French, and Cynthia Austin for their excellent technical assistance. This work was supported by the Alliance of Cardiovascular Researchers, grant 543102 (to E.A.).	Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bai XW, 2007, AM J PHYSIOL-CELL PH, V293, pC1539, DOI 10.1152/ajpcell.00089.2007; Cai LY, 2009, STEM CELLS, V27, P230, DOI 10.1634/stemcells.2008-0273; Dawn B, 2008, STEM CELLS, V26, P1646, DOI 10.1634/stemcells.2007-0715; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Farahmand P, 2008, CIRCULATION, V118, pS130, DOI 10.1161/CIRCULATIONAHA.107.757617; Gimble JM, 2003, CYTOTHERAPY, V5, P362, DOI 10.1080/14653240310003026; Ishikawa F, 2006, FASEB J, V20, P950, DOI 10.1096/fj.05-4863fje; KIM J, 1987, J MEMBRANE BIOL, V97, P241, DOI 10.1007/BF01869226; Lapidos KA, 2004, J CLIN INVEST, V114, P1577, DOI 10.1172/JCI200423071; Mochizuki H, 1998, J VIROL, V72, P8873, DOI 10.1128/JVI.72.11.8873-8883.1998; Noiseux N, 2006, MOL THER, V14, P840, DOI 10.1016/j.ymthe.2006.05.016; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oedayrajsingh-Varma MJ, 2006, CYTOTHERAPY, V8, P166, DOI 10.1080/14653240600621125; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Planat-Benard V, 2004, CIRC RES, V94, P223, DOI 10.1161/01.RES.0000109792.43271.47; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Rota M, 2007, P NATL ACAD SCI USA, V104, P17783, DOI 10.1073/pnas.0706406104; Stamm C, 2004, THORAC CARDIOV SURG, V52, P152, DOI 10.1055/s-2004-817981; Valina C, 2007, EUR HEART J, V28, P2667, DOI 10.1093/eurheartj/ehm426; Zhang S, 2007, CIRC RES, V100, P693, DOI 10.1161/01.RES.0000260803.98329.1c	22	32	34	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					830	839		10.1096/fj.09-153221	http://dx.doi.org/10.1096/fj.09-153221			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21059751	Green Published			2022-12-28	WOS:000287806200004
J	Lu, YB; Iandiev, I; Hollborn, M; Korber, N; Ulbricht, E; Hirrlinger, PG; Pannicke, T; Wei, EQ; Bringmann, A; Wolburg, H; Wilhelmsson, U; Pekny, M; Wiedemann, P; Reichenbach, A; Kas, JA				Lu, Yun-Bi; Iandiev, Ianors; Hollborn, Margrit; Koerber, Nicole; Ulbricht, Elke; Hirrlinger, Petra G.; Pannicke, Thomas; Wei, Er-Qing; Bringmann, Andreas; Wolburg, Hartwig; Wilhelmsson, Ulrika; Pekny, Milos; Wiedemann, Peter; Reichenbach, Andreas; Kaes, Josef A.			Reactive glial cells: increased stiffness correlates with increased intermediate filament expression	FASEB JOURNAL			English	Article						biomechanics; elasticity; viscosity; retina; reactive gliosis	FIBRILLARY ACIDIC PROTEIN; MULLER CELLS; VISCOELASTIC PROPERTIES; RAT RETINA; INJURY; MICE; ASTROCYTES; VIMENTIN; BRAIN; REGENERATION	Increased stiffness of reactive glial cells may impede neurite growth and contribute to the poor regenerative capabilities of the mammalian central nervous system. We induced reactive gliosis in rodent retina by ischemia-reperfusion and assessed intermediate filament (IF) expression and the viscoelastic properties of dissociated single glial cells in wild-type mice, mice lacking glial fibrillary acidic protein and vimentin (GFAP(-/-)Vim(-/-)) in which glial cells are consequently devoid of IFs, and normal Long-Evans rats. In response to ischemia-reperfusion, glial cells stiffened significantly in wild-type mice and rats but were unchanged in GFAP(-/-)Vim(-/-) mice. Cell stiffness (elastic modulus) correlated with the density of IFs. These results support the hypothesis that rigid glial scars impair nerve regeneration and that IFs are important determinants of cellular viscoelasticity in reactive glia. Thus, therapeutic suppression of IF up-regulation in reactive glial cells may facilitate neuroregeneration.-Lu, Y.-B., Iandiev, I., Hollborn, M., Korber, N., Ulbricht, E., Hirrlinger, P. G., Pannicke, T., Wei, E.-Q., Bringmann, A., Wolburg, H., Wilhelmsson, U., Pekny, M., Wiedemann, P., Reichenbach, A., Kas, J. A. Reactive glial cells: increased stiffness correlates with increased intermediate filament expression. FASEB J. 25, 624-631 (2011). www.fasebj.org	[Lu, Yun-Bi; Koerber, Nicole; Ulbricht, Elke; Hirrlinger, Petra G.; Pannicke, Thomas; Reichenbach, Andreas] Univ Leipzig, Paul Flechsig Inst Brain Res, D-04109 Leipzig, Germany; [Lu, Yun-Bi; Kaes, Josef A.] Univ Leipzig, Div Soft Matter Phys, Dept Phys, D-04109 Leipzig, Germany; [Iandiev, Ianors; Hollborn, Margrit; Bringmann, Andreas; Wiedemann, Peter] Univ Leipzig, Dept Ophthalmol, D-04109 Leipzig, Germany; [Lu, Yun-Bi; Wei, Er-Qing] Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310003, Zhejiang, Peoples R China; [Koerber, Nicole] Translat Ctr Regenerat Med, Leipzig, Germany; [Wolburg, Hartwig] Univ Tubingen, Inst Pathol, D-7400 Tubingen, Germany; [Wilhelmsson, Ulrika; Pekny, Milos] Univ Gothenburg, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden	Leipzig University; Leipzig University; Leipzig University; Zhejiang University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Gothenburg	Reichenbach, A (corresponding author), Univ Leipzig, Paul Flechsig Inst Brain Res, D-04109 Leipzig, Germany.	reia@medizin.uni-leipzig.de	Körber, Nicole/A-5118-2017; Reichenbach, Andreas/B-2510-2017; Pannicke, Thomas/A-5078-2017	Pannicke, Thomas/0000-0001-7435-9540; Wilhelmsson, Ulrika/0000-0003-3227-2687; Kas, Josef A./0000-0003-3158-2480	Deutsche Forschungsgemeinschaft; National Natural Science Foundation of China [30700150]; Deutscher Akademischer Austauschdienst; Zhejiang Provincial Natural Science Foundation of China [Y2080105]; Translational Center for Regenerative Medicine; Center for Biotechnology and Biomedicine (BBZ) at the University of Leipzig; Swedish Medical Research Council [11548]; Torsten and Ragnar Soderberg Foundations; LUA/ALF Goteborg, Hjarnfonden; Frimurare Foundation; Amlov's Foundation;  [SPP1172]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Deutscher Akademischer Austauschdienst(Deutscher Akademischer Austausch Dienst (DAAD)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); Translational Center for Regenerative Medicine; Center for Biotechnology and Biomedicine (BBZ) at the University of Leipzig; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Torsten and Ragnar Soderberg Foundations; LUA/ALF Goteborg, Hjarnfonden; Frimurare Foundation; Amlov's Foundation; 	This study was supported by grants from the Deutsche Forschungsgemeinschaft: Research Training School Inter-Neuro and BuildMoNa to A.R. and J.K. and SPP1172 to A.R.; the National Natural Science Foundation of China (grant 30700150) to Y.-B.L.; the Deutscher Akademischer Austauschdienst to Y.-B.L.; the Zhejiang Provincial Natural Science Foundation of China (grant Y2080105) to Y.-B.L; the Translational Center for Regenerative Medicine to N.K.; the Center for Biotechnology and Biomedicine (BBZ) at the University of Leipzig to A.R. and J.K.; and the Swedish Medical Research Council (project 11548), the Torsten and Ragnar Soderberg Foundations, LUA/ALF Goteborg, Hjarnfonden, the Frimurare Foundation, and Amlov's Foundation to U.W. and M.P. The authors thank Gabi Frommer-Kastle for expert help with electron microscopy and Jens Grosche for preparing Fig. 1.	Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BIGNAMI A, 1979, EXP EYE RES, V28, P63; Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Franze K, 2007, P NATL ACAD SCI USA, V104, P8287, DOI 10.1073/pnas.0611180104; Franze K, 2009, BIOPHYS J, V97, P1883, DOI 10.1016/j.bpj.2009.07.033; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Koehler RC, 2009, TRENDS NEUROSCI, V32, P160, DOI 10.1016/j.tins.2008.11.005; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Lundkvist A, 2004, J CELL SCI, V117, P3481, DOI 10.1242/jcs.01221; Mahaffy RE, 2000, PHYS REV LETT, V85, P880, DOI 10.1103/PhysRevLett.85.880; Mahaffy RE, 2004, BIOPHYS J, V86, P1777, DOI 10.1016/S0006-3495(04)74245-9; Miller G, 2005, SCIENCE, V308, P778, DOI 10.1126/science.308.5723.778; Miller WJ, 2009, J NEUROTRAUM, V26, P789, DOI [10.1089/neu.2008.0727, 10.1089/neu.2008-0727]; Mitz SA, 2009, NEUROSCIENCE, V163, P552, DOI 10.1016/j.neuroscience.2009.06.058; Pannicke T, 2004, MOL CELL NEUROSCI, V26, P493, DOI 10.1016/j.mcn.2004.04.005; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 2004, TRENDS NEUROSCI, V27, P243, DOI 10.1016/j.tins.2004.01.012; Pellerin L, 2008, CURR OPIN CLIN NUTR, V11, P701, DOI 10.1097/MCO.0b013e328312c368; Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001; REICHENBACH A, 1988, Z MIKROSK ANAT FORSC, V102, P721; Reichenbach A, 2008, SCIENCE, V322, P693, DOI 10.1126/science.1166197; Schiwy N, 2009, EUR J NEUROSCI, V30, P1544, DOI 10.1111/j.1460-9568.2009.06929.x; STEFANSSON E, 1988, INVEST OPHTH VIS SCI, V29, P1050; Teixeira AI, 2009, BIOMATERIALS, V30, P4567, DOI 10.1016/j.biomaterials.2009.05.013; Widestrand A, 2007, STEM CELLS, V25, P2619, DOI 10.1634/stemcells.2007-0122; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103	33	120	124	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					624	631		10.1096/fj.10-163790	http://dx.doi.org/10.1096/fj.10-163790			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20974670				2022-12-28	WOS:000286724800020
J	Chang, Y; de Nadai, P; Azzaoui, I; Morales, O; Delhem, N; Vorng, H; Tomavo, S; Yahia, SA; Zhang, GZ; Wallaert, B; Chenivesse, C; Tsicopoulos, A				Chang, Ying; de Nadai, Patricia; Azzaoui, Imane; Morales, Olivier; Delhem, Nadira; Vorng, Han; Tomavo, Stanislas; Yahia, Saliha Ait; Zhang, Guizhen; Wallaert, Benoit; Chenivesse, Cecile; Tsicopoulos, Anne			The chemokine CCL18 generates adaptive regulatory T cells from memory CD4(+) T cells of healthy but not allergic subjects	FASEB JOURNAL			English	Article						polarization; tolerance; allergy	ACTIVATION IN-VITRO; GROWTH-FACTOR-BETA; DENDRITIC CELLS; ATOPIC-DERMATITIS; FOXP3 EXPRESSION; TGF-BETA; SUBSETS; CD25(+); CTLA-4; DIFFERENTIATION	The purpose of this study was to assess the direct effect of CCL18, a chemokine elevated in allergic diseases and induced by Th2 cytokines, on the polarization of human CD4(+) T cells. Purified human T cells from healthy subjects were pretreated or not with CCL18, and evaluated for cytokine production. CCL18-pretreated memory but not naive CD4(+) T cells exhibited an increased production of IL-10 (12.3 +/- 2.6 vs. 5.6 +/- 0.9 ng/ml for medium) and TGF-beta 1 but not IL-4, IFN-gamma, and IL-17 compared with control cells. Pretreatment of highly purified CD4(+) CD25(-) memory T cells with CCL18 led to their conversion to CD4(+) CD25(-) Foxp3(+) regulatory T cells able to inhibit the proliferation of CD4(+) CD25(-) effector T cells by both cytokine and cell contact-dependent mechanisms. However, this regulatory effect of CCL18 was lost when T cells originated from allergic subjects in relation with a decreased binding of CCL18 to these cells [0.7 +/- 0.3 mean fluorescence intensity (MFI)] as compared to those from healthy subjects (6.0 +/- 1.7 MFI). This study is the first to define a chemokine that generates adaptive regulatory T cells from CD4(+) CD25(-) memory T cells. This mechanism appears defective in allergic patients and may underlie the decreased tolerance observed in allergic diseases.-Chang, Y., de Nadai, P., Azzaoui, I., Morales, O., Delhem, N., Vorng, H., Tomavo, S., Ait Yahia, S., Zhang, G., Wallaert, B., Chenivesse, C., Tsicopoulos, A. The chemokine CCL18 generates adaptive regulatory Tcells from memory CD4(+) Tcells of healthy but not allergic subjects. FASEB J. 24, 5063-5072 (2010). www.fasebj.org	[Chang, Ying; de Nadai, Patricia; Azzaoui, Imane; Vorng, Han; Tomavo, Stanislas; Yahia, Saliha Ait; Wallaert, Benoit; Chenivesse, Cecile; Tsicopoulos, Anne] Inst Pasteur, Ctr Infect & Immun Lille, F-59019 Lille, France; [Chang, Ying; de Nadai, Patricia; Azzaoui, Imane; Vorng, Han; Tomavo, Stanislas; Yahia, Saliha Ait; Wallaert, Benoit; Chenivesse, Cecile; Tsicopoulos, Anne] Inst Natl Sante & Rech Med, Lille, France; [Chang, Ying; de Nadai, Patricia; Azzaoui, Imane; Vorng, Han; Tomavo, Stanislas; Yahia, Saliha Ait; Wallaert, Benoit; Chenivesse, Cecile; Tsicopoulos, Anne] CNRS, UMR 8204, Lille, France; [Chang, Ying; de Nadai, Patricia; Azzaoui, Imane; Vorng, Han; Tomavo, Stanislas; Yahia, Saliha Ait; Wallaert, Benoit; Chenivesse, Cecile; Tsicopoulos, Anne] Univ Lille Nord France, Lille, France; [Delhem, Nadira; Zhang, Guizhen] China Japan Union Hosp, Cent Res Dept, Changchun, Peoples R China; [Morales, Olivier] CNRS, Inst Biol, UMR 8161, Lille, France; [Wallaert, Benoit; Chenivesse, Cecile; Tsicopoulos, Anne] Clin Malad Resp, Lille, France; [Wallaert, Benoit; Chenivesse, Cecile; Tsicopoulos, Anne] Ctr Hosp Reg & Univ Lille, F-59037 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Jilin University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille	Tsicopoulos, A (corresponding author), Inst Pasteur, Ctr Infect & Immun Lille, 1 Rue Prof Calmette,BP 245, F-59019 Lille, France.	anne.tsicopoulos@pasteur-lille.fr	Tsicopoulos, Anne/C-2260-2019; Chang, Ying/I-1362-2012; MORALES, Olivier/AAR-5337-2020; SALIHA, AIT YAHIA/B-8269-2018; Pope, Janet/G-3342-2011	Tsicopoulos, Anne/0000-0002-1579-2763; SALIHA, AIT YAHIA/0000-0003-1108-4222; Pope, Janet/0000-0003-1479-5302; Azzaoui, Imane/0000-0001-5603-6780; de NADAI, Patricia/0000-0001-6084-7447; MORALES, Olivier/0000-0002-2135-3265	Institut National de la Sante et de la Recherche Medicale and Societe Francaise d'Allergologie	Institut National de la Sante et de la Recherche Medicale and Societe Francaise d'Allergologie	This work was supported by grants from Institut National de la Sante et de la Recherche Medicale and Societe Francaise d'Allergologie.	Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Allakhverdi Z, 2006, J ALLERGY CLIN IMMUN, V118, P1342, DOI 10.1016/j.jaci.2006.07.034; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Birebent B, 2004, EUR J IMMUNOL, V34, P3485, DOI 10.1002/eji.200324632; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Braun MC, 2000, J IMMUNOL, V164, P3009, DOI 10.4049/jimmunol.164.6.3009; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; Callebaut I, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-100; Cappello P, 2006, J IMMUNOL, V177, P6143, DOI 10.4049/jimmunol.177.9.6143; Chang TLY, 2002, J VIROL, V76, P2245, DOI 10.1128/JVI.76.5.2245-2254.2002; De Nadai P, 2006, J IMMUNOL, V176, P6286, DOI 10.4049/jimmunol.176.10.6286; Fisson S, 2003, J EXP MED, V198, P737, DOI 10.1084/jem.20030686; Gilet J, 2009, J INVEST DERMATOL, V129, P879, DOI 10.1038/jid.2008.333; Grimbert P, 2006, J IMMUNOL, V177, P3534, DOI 10.4049/jimmunol.177.6.3534; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Hieshima K, 1997, J IMMUNOL, V159, P1140; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Karpus WJ, 1997, J IMMUNOL, V158, P4129; Kodelja V, 1998, J IMMUNOL, V160, P1411; Le YY, 2004, CELL MOL IMMUNOL, V1, P95; Lehmann J, 2002, P NATL ACAD SCI USA, V99, P13031, DOI 10.1073/pnas.192162899; Li MO, 2008, IMMUNITY, V28, P468, DOI 10.1016/j.immuni.2008.03.003; Lindhout E, 2001, J IMMUNOL, V166, P3284, DOI 10.4049/jimmunol.166.5.3284; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Marsland BJ, 2005, IMMUNITY, V22, P493, DOI 10.1016/j.immuni.2005.02.010; Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003; Molon B, 2005, NAT IMMUNOL, V6, P465, DOI 10.1038/ni1191; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Nanki T, 2000, J IMMUNOL, V164, P5010, DOI 10.4049/jimmunol.164.10.5010; Niedbala W, 2007, P NATL ACAD SCI USA, V104, P15478, DOI 10.1073/pnas.0703725104; Oflazoglu E, 2008, EUR J DERMATOL, V18, P41; Pyzik M, 2007, J LEUKOCYTE BIOL, V82, P335, DOI 10.1189/jlb.1006644; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sallusto F, 2008, NAT IMMUNOL, V9, P949, DOI 10.1038/ni.f.214; Schutyser E, 2005, J LEUKOCYTE BIOL, V78, P14, DOI 10.1189/jlb.1204712; SEMNANI RT, 1994, J EXP MED, V180, P2125, DOI 10.1084/jem.180.6.2125; Shang LM, 2008, GASTROENTEROLOGY, V135, P529, DOI 10.1053/j.gastro.2008.04.020; Takahashi T, 1998, INT IMMUNOL, V10, P1969, DOI 10.1093/intimm/10.12.1969; Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143; Tasaki Y, 1999, GENOMICS, V55, P353, DOI 10.1006/geno.1998.5670; Taub DD, 1996, J IMMUNOL, V156, P2095; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Vissers JLM, 2001, J LEUKOCYTE BIOL, V69, P785; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Vulcano M, 2003, J IMMUNOL, V170, P3843, DOI 10.4049/jimmunol.170.7.3843; Walker LSK, 2003, J EXP MED, V198, P249, DOI 10.1084/jem.20030315; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wimmer A, 2006, BLOOD, V108, P3722, DOI 10.1182/blood-2006-04-014399; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Zheng SG, 2006, J IMMUNOL, V176, P3321, DOI 10.4049/jimmunol.176.6.3321; Zlotnik A, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-12-243	54	34	36	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2010	24	12					5063	5072		10.1096/fj.10-162560	http://dx.doi.org/10.1096/fj.10-162560			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20702776				2022-12-28	WOS:000284824400044
J	Neumann, J; Schaale, K; Farhat, K; Endermann, T; Ulmer, AJ; Ehlers, S; Reiling, N				Neumann, Jan; Schaale, Kolja; Farhat, Katja; Endermann, Tobias; Ulmer, Artur J.; Ehlers, Stefan; Reiling, Norbert			Frizzled1 is a marker of inflammatory macrophages, and its ligand Wnt3a is involved in reprogramming Mycobacterium tuberculosis-infected macrophages	FASEB JOURNAL			English	Article						innate immunity; Wnt signaling; inflammation	TOLL-LIKE RECEPTORS; BETA-CATENIN; SIGNALING PATHWAY; EPITHELIAL-CELLS; IN-VIVO; EXPRESSION; PROTEIN; ALPHA; RECOGNITION; DISEASE	Wnt/Frizzled signaling, essential for embryonic development, has also recently been implicated in the modulation of inflammatory processes. In the current study, we observed a reciprocal regulation of the Toll-like receptor (TLR)/nuclear factor-kappa B (NF-kappa B) and the Wnt/beta-catenin pathway after aerosol infection of mice with Mycobacterium tuberculosis: whereas proinflammatory mediators were substantially increased, beta-catenin signaling was significantly reduced. A systematic screen of Fzd homologs in infected mice identified Fzd1 mRNA to be significantly up-regulated during the course of infection. In vitro infection of murine macrophages led to a strong induction of Fzd1 that was dependent on TLRs, the myeloid differentiation response gene 88 (MyD88), and a functional NF-kappa B pathway. Flow cytometry demonstrated an elevated Fzd1 expression on macrophages in response to M. tuberculosis that was synergistically enhanced in the presence of IFN-gamma. Addition of the Fzd1 ligand Wnt3a induced Wnt/beta-catenin signaling in murine macrophages that was inhibited in the presence of a soluble Fzd1/Fc fusion protein. Furthermore, Wnt3a reduced TNF release, suggesting that Wnt3a promotes anti-inflammatory functions in murine macrophages. The current data support the notion that evolutionarily conserved Wnt/Fzd signaling is involved in balancing the inflammatory response to microbial stimulation of innate immune cells of vertebrate origin.-Neumann, J., Schaale, K., Farhat, K., Endermann, T., Ulmer, A. J., Ehlers, S., Reiling, N. Frizzled1 is a marker of inflammatory macrophages, and its ligand Wnt3a is involved in reprogramming Mycobacterium tuberculosis-infected macrophages. FASEB J. 24, 4599-4612 (2010). www.fasebj.org	[Neumann, Jan; Schaale, Kolja; Endermann, Tobias; Reiling, Norbert] Leibniz Ctr Med & Biosci, Div Microbial Interface Biol, Res Ctr Borstel, D-23845 Borstel, Germany; [Farhat, Katja; Ulmer, Artur J.] Leibniz Ctr Med & Biosci, Div Cellular Immunol, Res Ctr Borstel, D-23845 Borstel, Germany; [Ehlers, Stefan] Univ Kiel, Kiel, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel; University of Kiel	Reiling, N (corresponding author), Leibniz Ctr Med & Biosci, Div Microbial Interface Biol, Res Ctr Borstel, Pk Allee 22, D-23845 Borstel, Germany.	nreiling@fz-borstel.de	Schaale, Kolja/J-1587-2014; Ehlers, Stefan/B-4075-2010; Reiling, Norbert/D-6796-2013	Schaale, Kolja/0000-0002-4768-4652; Reiling, Norbert/0000-0001-6673-4291	Deutsche Forschungsgemeinschaft [SFB 415-C7, EXC306]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported in part by Deutsche Forschungsgemeinschaft grants SFB 415-C7 and EXC306 to N.R. and S.E. The authors declare that they have no conflicting financial interests. The authors gratefully acknowledge K. Kopp, K. Seeger, S. Kroger, and L. Dost for expert technical assistance.	Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Blumenthal A, 2006, BLOOD, V108, P965, DOI 10.1182/blood-2005-12-5046; Carayol N, 2002, AM J RESP CELL MOL, V26, P341, DOI 10.1165/ajrcmb.26.3.4684; Chacon MA, 2008, J CELL PHYSIOL, V217, P215, DOI 10.1002/jcp.21497; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Deutseher E, 2007, DEV BIOL, V307, P227, DOI 10.1016/j.ydbio.2007.04.036; Duan YL, 2007, LAB INVEST, V87, P613, DOI 10.1038/labinvest.3700545; Farhat K, 2008, J LEUKOCYTE BIOL, V83, P692, DOI 10.1189/jlb.0807586; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh M, 2002, ENDOCRINOLOGY, V143, P898, DOI 10.1210/en.143.3.898; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Konigshoff M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002142; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Krutzik PO, 2003, CYTOM PART A, V55A, P61, DOI 10.1002/cyto.a.10072; Lattin Jane E, 2008, Immunome Res, V4, P5, DOI 10.1186/1745-7580-4-5; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Mazzon E, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-75; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Milovanovic T, 2004, INT J ONCOL, V25, P1337; Mucenski ML, 2005, AM J PHYSIOL-LUNG C, V289, pL971, DOI 10.1152/ajplung.00172.2005; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; Pereira C, 2008, ARTERIOSCL THROM VAS, V28, P504, DOI 10.1161/ATVBAHA.107.157438; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Qureshi ST, 2003, GENES IMMUN, V4, P87, DOI 10.1038/sj.gene.6363937; Reiling N, 2001, IMMUNOBIOLOGY, V204, P558, DOI 10.1078/0171-2985-00093; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Reiling N, 2001, J IMMUNOL, V167, P3339, DOI 10.4049/jimmunol.167.6.3339; Roman-Roman S, 2004, J BIOL CHEM, V279, P5725, DOI 10.1074/jbc.M309233200; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Sen M, 2008, J IMMUNOL, V181, P4441, DOI 10.4049/jimmunol.181.7.4441; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Stenger S, 2002, CURR OPIN IMMUNOL, V14, P452, DOI 10.1016/S0952-7915(02)00355-2; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tickenbrock L, 2006, J LEUKOCYTE BIOL, V79, P1306, DOI 10.1189/jlb.0905539; Wang ZS, 2005, MOL CELL BIOL, V25, P5022, DOI 10.1128/MCB.25.12.5022-5030.2005; Willems E, 2008, ANAL BIOCHEM, V379, P127, DOI 10.1016/j.ab.2008.04.036; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Zhang Y, 2008, NAT GENET, V40, P862, DOI 10.1038/ng.157	53	100	107	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2010	24	11					4599	4612		10.1096/fj.10-160994	http://dx.doi.org/10.1096/fj.10-160994			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20667980				2022-12-28	WOS:000283861100044
J	Azzi, J; Tang, L; Moore, R; Tong, R; El Haddad, N; Akiyoshi, T; Mfarrej, B; Yang, SM; Jurewicz, M; Ichimura, T; Lindeman, N; Cheng, JJ; Abdi, R				Azzi, Jamil; Tang, Li; Moore, Robert; Tong, Rong; El Haddad, Najib; Akiyoshi, Takurin; Mfarrej, Bechara; Yang, Sunmi; Jurewicz, Mollie; Ichimura, Takaharu; Lindeman, Neal; Cheng, Jianjun; Abdi, Reza			Polylactide-cyclosporin A nanoparticles for targeted immunosuppression	FASEB JOURNAL			English	Article						CsA toxicity; dendritic cells; targeted delivery	DENDRITIC CELLS; DRUG-DELIVERY; BIODEGRADABLE NANOPARTICLES; FORMULATION; POLYMERIZATION; BIODISTRIBUTION; TRANSPLANTATION; LACTIDE	Polymeric nanoparticles (NPs), prepared via coprecipitation of drugs and polymers, are promising drug delivery vehicles for treating diseases with improved efficacy and reduced toxicity. Here, we report an unprecedented strategy for preparing polylactide-cyclosporine A (PLA-CsA) NPs (termed CsA-NPs) through CsA-initiated ring-opening polymerization of lactide (LA) followed by nanoprecipitation. The resulting CsA-NPs have sub-100 nm sizes and narrow particle size distributions, and release CsA in a sustained manner without a "burst"-release effect. Both free CsA and CsA-NPs displayed comparable suppression of T-cell proliferation and production of inflammatory cytokines in various T-cell assays in a dose-dependent manner. The IC50 values for CsA and CsA-NPs were 27.5 and 72.0 ng/ml, respectively. As lymph nodes are the main loci for T-cell activation, we coupled dendritic cells (DCs) with CsA-NPs and successfully delivered CsA selectively to the lymph nodes. Our studies indicated that CsA-NPs could be internalized in the DCs with a sustained release of CsA to the culture medium, suppressing alloreactive T-cell proliferation. Allogeneic DCs loaded with CsA-NPs were able to migrate to the draining lymph nodes where the T-cell priming was significantly reduced without any systemic release. This innovative nanoparticulate CsA delivery technology constitutes a strong basis for future targeted delivery of immunosuppressive drugs with improved efficiency and reduced toxicity.-Azzi, J., Tang, L., Tong, R., El Haddad, N., Akiyoshi, T., Mfarrej, B., Moore, R., Yang, S., Jurewicz, M., Ichimura, T., Lindeman, N., Cheng, J., Abdi, R. Polylactide-cyclosporin A nanoparticles for targeted immunosuppression. FASEB J. 24, 3927-3938 (2010). www.fasebj.org	[Azzi, Jamil; Moore, Robert; El Haddad, Najib; Akiyoshi, Takurin; Mfarrej, Bechara; Yang, Sunmi; Jurewicz, Mollie; Ichimura, Takaharu; Abdi, Reza] Brigham & Womens Hosp, Transplantat Res Ctr, Div Renal, Boston, MA 02115 USA; [Lindeman, Neal] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Azzi, Jamil; Moore, Robert; El Haddad, Najib; Akiyoshi, Takurin; Mfarrej, Bechara; Yang, Sunmi; Jurewicz, Mollie; Abdi, Reza] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA; [Tang, Li; Tong, Rong; Cheng, Jianjun] Univ Illinois, Dept Mat Sci & Engn, Urbana, IL 61801 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Illinois System; University of Illinois Urbana-Champaign	Abdi, R (corresponding author), Brigham & Womens Hosp, Transplant Res Ctr, 221 Longwood Ave, Boston, MA 02115 USA.	jianjunc@illinois.edu; rabdi@rics.bwh.harvard.edu	Mfarrej, Bechara/AAE-9616-2021; Tang, Li/A-6844-2013; Tong, Rong/A-4100-2013; Cheng, Jianjun/AAF-4301-2019	Mfarrej, Bechara/0000-0002-8361-5240; Tong, Rong/0000-0002-2034-9272; Cheng, Jianjun/0000-0003-2561-9291; Jurewicz, Mollie/0000-0001-8482-3060; Tang, Li/0000-0002-6393-982X	National Kidney Foundation; Roche Organ Transplantation Research Foundation; Juvenile Diabetes Research Foundation; John Merrill Transplant Scholar grant; National Science Foundation [DMR-0748834]; U.S. National Institutes of Health [1R21CA139329-01, 1R21EB009486-01]; Siteman Center for Cancer Nanotechnology Excellence (SCCNE; Washington University, St. Louis, MO, USA); Prostate Cancer Foundation; Center for Nanoscale Science and Technology (CNST; University of Illinois at Urbana-Champaign); NATIONAL CANCER INSTITUTE [R21CA139329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB009486] Funding Source: NIH RePORTER	National Kidney Foundation; Roche Organ Transplantation Research Foundation; Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); John Merrill Transplant Scholar grant; National Science Foundation(National Science Foundation (NSF)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Siteman Center for Cancer Nanotechnology Excellence (SCCNE; Washington University, St. Louis, MO, USA); Prostate Cancer Foundation; Center for Nanoscale Science and Technology (CNST; University of Illinois at Urbana-Champaign); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	The authors thank Elizabeth Glidden for her assistance in measuring CsA. This work was supported by a National Kidney Foundation clinical scientist award, a Roche Organ Transplantation Research Foundation grant, a Juvenile Diabetes Research Foundation regular grant, a John Merrill Transplant Scholar grant (to R.A.), National Science Foundation Career Program grant DMR-0748834 (to J.C.), U.S. National Institutes of Health grants 1R21CA139329-01 and 1R21EB009486-01(to J.C.), the Siteman Center for Cancer Nanotechnology Excellence (SCCNE; Washington University, St. Louis, MO, USA), the Center for Nanoscale Science and Technology (CNST; University of Illinois at Urbana-Champaign; to J.C.), and a Prostate Cancer Foundation Competitive Award Program grant (to J.C.).	Abdi R, 2002, DIABETES, V51, P2489, DOI 10.2337/diabetes.51.8.2489; Alvarez-Lorenzo C, 2008, MINI-REV MED CHEM, V8, P1065, DOI 10.2174/138955708785909952; Caliceti P, 2003, ADV DRUG DELIVER REV, V55, P1261, DOI 10.1016/S0169-409X(03)00108-X; Chamberlain BM, 2001, J AM CHEM SOC, V123, P3229, DOI 10.1021/ja003851f; Chaney EJ, 2010, MOL IMAGING, V9, P153, DOI 10.2310/7290.2010.00012; Chapman JR, 2006, NEPHROL DIAL TRANSPL, V21, P2060, DOI 10.1093/ndt/gfl219; Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047; Fahmy TM, 2007, NANOMED-NANOTECHNOL, V3, P75, DOI 10.1016/j.nano.2006.11.010; Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103; Fiorina P, 2008, TRANSPLANTATION, V85, P1030, DOI 10.1097/TP.0b013e31816843a0; Galindo-Rodriguez S, 2004, PHARM RES-DORDR, V21, P1428, DOI 10.1023/B:PHAM.0000036917.75634.be; Giannoukakis N, 2008, PEDIATR DIABETES, V9, P4, DOI 10.1111/j.1399-5448.2008.00401.x; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; Izawa A, 2007, J AM SOC NEPHROL, V18, P2929, DOI 10.1681/ASN.2006111261; Kaplan B, 2004, J AM SOC NEPHROL, V15, P3270, DOI 10.1097/01.ASN.0000146569.59482.8C; Lohr J, 2006, J EXP MED, V203, P2785, DOI 10.1084/jem.20061341; Matsumura Y, 2004, BRIT J CANCER, V91, P1775, DOI 10.1038/sj.bjc.6602204; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Musumeci T, 2006, INT J PHARMACEUT, V325, P172, DOI 10.1016/j.ijpharm.2006.06.023; Neto AB, 1999, TRANSPLANT INT, V12, P208, DOI 10.1111/j.1432-2277.1999.tb00608.x; Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4; Sakuma S, 2001, INT IMMUNOPHARMACOL, V1, P749, DOI 10.1016/S1567-5769(01)00008-X; Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/s0168-3659(00)00339-4; Tong R, 2008, ANGEW CHEM INT EDIT, V47, P4830, DOI 10.1002/anie.200800491; Tong R, 2007, POLYM REV, V47, P345, DOI 10.1080/15583720701455079; Tong R, 2010, BIOMATERIALS, V31, P3043, DOI 10.1016/j.biomaterials.2010.01.009; Tong R, 2010, BIOCONJUGATE CHEM, V21, P111, DOI 10.1021/bc900356g; Tong R, 2009, J AM CHEM SOC, V131, P4744, DOI 10.1021/ja8084675; Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07; Wong WC, 2005, TRANSPLANTATION, V80, P289, DOI 10.1097/01.tp.0000168436.76784.45; Xu MQ, 2004, WORLD J GASTROENTERO, V10, P2361; Yuan XL, 2008, J EXP MED, V205, P3133, DOI 10.1084/jem.20081937	32	66	78	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3927	3938		10.1096/fj.10-154690	http://dx.doi.org/10.1096/fj.10-154690			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20547662	Green Published			2022-12-28	WOS:000285005900030
J	Durham, WJ; Casperson, SL; Dillon, EL; Keske, MA; Paddon-Jones, D; Sanford, AP; Hickner, RC; Grady, JJ; Sheffield-Moore, M				Durham, William J.; Casperson, Shanon L.; Dillon, Edgar L.; Keske, Michelle A.; Paddon-Jones, Douglas; Sanford, Arthur P.; Hickner, Robert C.; Grady, James J.; Sheffield-Moore, Melinda			Age-related anabolic resistance after endurance-type exercise in healthy humans	FASEB JOURNAL			English	Article						amino acids; blood flow; microdialysis ethanol; contrast-enhanced ultrasound; microcirculation	MUSCLE PROTEIN-SYNTHESIS; NUTRITIVE BLOOD-FLOW; HUMAN SKELETAL-MUSCLE; AMINO-ACID-TRANSPORT; INSULIN-RESISTANCE; ADIPOSE-TISSUE; MICROVASCULAR RECRUITMENT; DIETARY REQUIREMENTS; ETHANOL TECHNIQUE; REDOX STATE	Age-related skeletal muscle loss is thought to stem from suboptimal nutrition and resistance to anabolic stimuli. Impaired microcirculatory (nutritive) blood flow may contribute to anabolic resistance by reducing delivery of amino acids to skeletal muscle. In this study, we employed contrast-enhanced ultrasound, microdialysis sampling of skeletal muscle interstitium, and stable isotope methodology, to assess hemodynamic and metabolic responses of older individuals to endurance type (walking) exercise during controlled amino acid provision. We hypothesized that older individuals would exhibit reduced microcirculatory blood flow, interstitial amino acid concentrations, and amino acid transport when compared with younger controls. We report for the first time that aging induces anabolic resistance following endurance exercise, manifested as reduced (by similar to 40%) efficiency of muscle protein synthesis. Despite lower (by similar to 40-45%) microcirculatory flow in the older than in the younger participants, circulating and interstitial amino acid concentrations and phenylalanine transport into skeletal muscle were all equal or higher in older individuals than in the young, comprehensively refuting our hypothesis that amino acid availability limits postexercise anabolism in older individuals. Our data point to alternative mediators of age-related anabolic resistance and importantly suggest correction of these impairments may reduce requirements for, and increase the efficacy of, dietary protein in older individuals. Durham, W. J., Casperson, S. L., Dillon, E. L., Keske, M. A., Paddon-Jones, D., Sanford, A. P., Hickner, R. C., Grady, J. J., Sheffield-Moore, M. Age-related anabolic resistance after endurance-type exercise in healthy humans. FASEB J. 24, 4117-4127 (2010). www.fasebj.org	[Durham, William J.; Casperson, Shanon L.; Dillon, Edgar L.; Paddon-Jones, Douglas; Sheffield-Moore, Melinda] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA; [Paddon-Jones, Douglas] Univ Texas Med Branch, Dept Phys Therapy, Galveston, TX 77555 USA; [Sanford, Arthur P.] Univ Texas Med Branch, Dept Surg, Galveston, TX 77555 USA; [Grady, James J.] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Hickner, Robert C.] E Carolina Univ, Human Performance Lab, Greenville, NC 27858 USA; [Keske, Michelle A.] Univ Tasmania, Menzies Res Inst, Hobart, Tas, Australia	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of North Carolina; East Carolina University; University of Tasmania; Menzies Institute for Medical Research	Sheffield-Moore, M (corresponding author), Univ Texas Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.	melmoore@utmb.edu	Casperson, Shanon L/AAY-3904-2021; Casperson, Shanon L/AAW-6512-2021; /B-2495-2008; Sheffield-Moore, Melinda/A-9794-2016	Casperson, Shanon L/0000-0002-6954-9523; /0000-0002-0513-5399; Sheffield-Moore, Melinda/0000-0001-6579-4655; hickner, Robert/0000-0002-2683-1617; Keske, Michelle/0000-0003-4214-7628; Paddon-Jones, Douglas/0000-0002-3762-5130	National Institutes of Health/National Institute on Aging [R01 AG21539, R21 AG19209]; Claude D. Pepper Older Americans Independence Center [P30 AG024832]; National Center for Research Resources, National Institutes of Health, U.S. Public Health Service [M01 RR 00073]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG019209, P30AG024832, R01AG021539] Funding Source: NIH RePORTER	National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Claude D. Pepper Older Americans Independence Center; National Center for Research Resources, National Institutes of Health, U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank the study volunteers, General Clinical Research Center (GCRC) nurses, and the Sealy Center on Aging recruitment coordinators, Sue Minello and Roxana Hirst. The authors thank Chuan Hong for assistance with the statistical analysis. The authors thank the Biomolecular Resource Facility and the University of Texas Medical Branch (UTMB) Protein Chemistry Lab for assistance with plasma and interstitial amino acid analysis. This research was supported by National Institutes of Health/National Institute on Aging grants R01 AG21539 (M.S.-M.) and R21 AG19209 (R.H.) and Claude D. Pepper Older Americans Independence Center grant P30 AG024832 (J.G.). The authors thank Bristol-Myers Squibb (New York, NY, USA) for providing the Definity contrast agent for this study. Studies were conducted at the GCRC, UTMB at Galveston, funded by grant M01 RR 00073 from the National Center for Research Resources, National Institutes of Health, U.S. Public Health Service.	Adams F, 2005, HORM METAB RES, V37, P68, DOI 10.1055/s-2005-861156; Alway SE, 2008, EXERC SPORT SCI REV, V36, P51, DOI 10.1097/JES.0b013e318168e9dc; Atherton PJ, 2005, FASEB J, V19, P786, DOI 10.1096/fj.04-2179fje; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; BAUMANN PQ, 1994, AM J PHYSIOL, V267, pE203, DOI 10.1152/ajpendo.1994.267.2.E203; Bergman RN, 1997, RECENT PROG HORM RES, V52, P359; BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693; BIOLO G, 1995, AM J PHYSIOL-ENDOC M, V268, pE75, DOI 10.1152/ajpendo.1995.268.1.E75; Bodine SC, 2006, MED SCI SPORT EXER, V38, P1950, DOI 10.1249/01.mss.0000233797.24035.35; Bohe J, 2003, J PHYSIOL-LONDON, V552, P315, DOI 10.1113/jphysiol.2003.050674; Bohe J, 2001, J PHYSIOL-LONDON, V532, P575, DOI 10.1111/j.1469-7793.2001.0575f.x; Borsheim E, 2006, AM J PHYSIOL-ENDOC M, V290, pE643, DOI 10.1152/ajpendo.00267.2005; CAMERA DM, 2010, MED SCI SPORTS EXERC; CARRARO F, 1990, AM J PHYSIOL, V259, pE470, DOI 10.1152/ajpendo.1990.259.4.E470; Clark MG, 2008, AM J PHYSIOL-ENDOC M, V295, pE732, DOI 10.1152/ajpendo.90477.2008; Clark MG, 2006, CURR OPIN CLIN NUTR, V9, P185, DOI 10.1097/01.mco.0000222097.90890.c2; Clerk LH, 2006, DIABETES, V55, P1436, DOI 10.2337/db05-1373; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Drummond MJ, 2008, J APPL PHYSIOL, V104, P1452, DOI 10.1152/japplphysiol.00021.2008; Drummond MJ, 2009, J APPL PHYSIOL, V106, P1374, DOI 10.1152/japplphysiol.91397.2008; Fischer LM, 2007, AM J CLIN NUTR, V85, P1275; Fujita S, 2007, DIABETES, V56, P1615, DOI 10.2337/db06-1566; Gore DC, 2007, AM J PHYSIOL-ENDOC M, V292, pE319, DOI 10.1152/ajpendo.00399.2005; Graham TE, 1998, MED SCI SPORT EXER, V30, P34, DOI 10.1097/00005768-199801000-00006; Hack V, 1997, FASEB J, V11, P84, DOI 10.1096/fasebj.11.1.9034170; Hack V, 1998, BLOOD, V92, P59, DOI 10.1182/blood.V92.1.59.413a05_59_67; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hasten DL, 2000, AM J PHYSIOL-ENDOC M, V278, pE620, DOI 10.1152/ajpendo.2000.278.4.E620; Hellsten Y, 1999, J PHYSIOL-LONDON, V520, P909, DOI 10.1111/j.1469-7793.1999.00909.x; HICKNER RC, 1992, ACTA PHYSIOL SCAND, V146, P87, DOI 10.1111/j.1748-1716.1992.tb09396.x; Hickner RC, 2003, J GERONTOL A-BIOL, V58, P20; HICKNER RC, 1995, J APPL PHYSIOL, V79, P638, DOI 10.1152/jappl.1995.79.2.638; Hickner RC, 1997, AM J PHYSIOL-HEART C, V273, pH405, DOI 10.1152/ajpheart.1997.273.1.H405; Hildebrandt W, 2002, MECH AGEING DEV, V123, P1269, DOI 10.1016/S0047-6374(02)00013-1; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; Hood DA, 2009, APPL PHYSIOL NUTR ME, V34, P465, DOI 10.1139/H09-045; Jackson MJ, 2008, IUBMB LIFE, V60, P497, DOI 10.1002/iub.72; Johnston APW, 2008, APPL PHYSIOL NUTR ME, V33, P191, DOI 10.1139/H07-141; Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7; JORFELDT L, 1971, CLIN SCI, V41, P459, DOI 10.1042/cs0410459; Kumar V, 2009, J APPL PHYSIOL, V106, P2026, DOI 10.1152/japplphysiol.91481.2008; Lee R, 2010, ANAL CHEM, V82, P2959, DOI 10.1021/ac9029746; LEWIS SEM, 1984, BIOCHEM J, V217, P517, DOI 10.1042/bj2170517; McBride T, 2000, MECH AGEING DEV, V115, P127, DOI 10.1016/S0047-6374(00)00111-1; McIver KL, 2006, PAIN, V120, P161, DOI 10.1016/j.pain.2005.10.032; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Miller BF, 2005, J PHYSIOL-LONDON, V567, P1021, DOI 10.1113/jphysiol.2005.093690; Miller S, 2004, AM J PHYSIOL-ENDOC M, V287, pE136, DOI 10.1152/ajpendo.00092.2004; Miyazaki M, 2009, J APPL PHYSIOL, V106, P1367, DOI 10.1152/japplphysiol.91355.2008; Newman JMB, 2001, AM J PHYSIOL-HEART C, V281, pH2731, DOI 10.1152/ajpheart.2001.281.6.H2731; Paddon-Jones D, 2008, AM J CLIN NUTR, V87, p1558S, DOI 10.1093/ajcn/87.5.1558S; Pikosky MA, 2006, J NUTR, V136, P379, DOI 10.1093/jn/136.2.379; PLUSKAL MG, 1984, J GERONTOL, V39, P385, DOI 10.1093/geronj/39.4.385; Rasmussen BB, 2006, FASEB J, V20, P768, DOI 10.1096/fj.05-4607fje; Reid MB, 2002, ANN NY ACAD SCI, V959, P108, DOI 10.1111/j.1749-6632.2002.tb02087.x; Rennie MJ, 2009, APPL PHYSIOL NUTR ME, V34, P377, DOI 10.1139/H09-012; Roberts JL, 2005, J PHYSIOL-LONDON, V563, P213, DOI 10.1113/jphysiol.2003.056531; SAS Institute, 2008, SAS STAT US GUID; Schiffelers SLH, 2003, INT J OBESITY, V27, P227, DOI 10.1038/sj.ijo.802230; Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221; Sheffield-Moore M, 2004, AM J PHYSIOL-ENDOC M, V287, pE513, DOI 10.1152/ajpendo.00334.2003; Sheffield-Moore M, 1999, J CLIN ENDOCR METAB, V84, P2705, DOI 10.1210/jc.84.8.2705; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Short KR, 2004, AM J PHYSIOL-ENDOC M, V286, pE92, DOI 10.1152/ajpendo.00366.2003; Symons TB, 2007, AM J CLIN NUTR, V86, P451, DOI 10.1093/ajcn/86.2.451; Symons TB, 2009, J AM DIET ASSOC, V109, P1582, DOI 10.1016/j.jada.2009.06.369; Thomson DM, 2009, J PHYSIOL-LONDON, V587, P2077, DOI 10.1113/jphysiol.2008.166512; Tipton KD, 2008, ESSAYS BIOCHEM, V44, P85, DOI 10.1042/BSE0440085; Van Pelt RE, 2006, OBESITY, V14, P2163, DOI 10.1038/oby.2006.253; VANHALL G, 1995, J PHYSIOL-LONDON, V489, P251, DOI 10.1113/jphysiol.1995.sp021047; Vary TC, 2007, J NUTR, V137, P1835, DOI 10.1093/jn/137.8.1835; Vincent MA, 2004, DIABETES, V53, P1418, DOI 10.2337/diabetes.53.6.1418; Vincent MA, 2006, AM J PHYSIOL-ENDOC M, V290, pE1191, DOI 10.1152/ajpendo.00497.2005; Volpi E, 2001, JAMA-J AM MED ASSOC, V286, P1206, DOI 10.1001/jama.286.10.1206; Volpi E, 2000, J CLIN ENDOCR METAB, V85, P4481, DOI 10.1210/jc.85.12.4481; Volpi E, 1999, AM J PHYSIOL-ENDOC M, V277, pE513, DOI 10.1152/ajpendo.1999.277.3.E513; Wei K, 1998, CIRCULATION, V97, P473; WELLE S, 1995, AM J PHYSIOL-ENDOC M, V268, pE422, DOI 10.1152/ajpendo.1995.268.3.E422; Wilkinson SB, 2008, J PHYSIOL-LONDON, V586, P3701, DOI 10.1113/jphysiol.2008.153916; Williamson JR, 1996, J APPL PHYSIOL, V80, P747, DOI 10.1152/jappl.1996.80.3.747; Wolfe RR, 1992, RADIOACTIVE STABLE I; Yarasheski KE, 1999, AM J PHYSIOL-ENDOC M, V277, pE118, DOI 10.1152/ajpendo.1999.277.1.E118; YARASHESKI KE, 1993, AM J PHYSIOL, V265, pE210, DOI 10.1152/ajpendo.1993.265.2.E210; YOUNG VR, 1978, FED PROC, V37, P2291; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156	86	64	65	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					4117	4127		10.1096/fj.09-150177	http://dx.doi.org/10.1096/fj.09-150177			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20547663	Green Published			2022-12-28	WOS:000285005900046
J	Chakroun, N; Prigent, S; Dreiss, CA; Noinville, S; Chapuis, C; Fraternali, F; Rezaei, H				Chakroun, Nesrine; Prigent, Stephanie; Dreiss, Cecile A.; Noinville, Sylvie; Chapuis, Celine; Fraternali, Franca; Rezaei, Human			The oligomerization properties of prion protein are restricted to the H2H3 domain	FASEB JOURNAL			English	Article						polymerization pathway; beta-hairpin; intermediate; strain	MOLECULAR-DYNAMICS SIMULATIONS; PARTICLE MESH EWALD; CONFORMATIONAL TRANSITION; SCRAPIE; CONVERSION; DISEASE; PROPAGATION; PARALLEL; MUTATION; SYSTEMS	The propensity of the prion protein (PrP) to adopt different structures is a clue to its pathological behavior. The determination of the region involved in the PrPC to PrPSc conversion is fundamental for the understanding of the mechanisms underlying this process at the molecular level. In this paper, the polymerization of the helical H2H3 domain of ovine PrP (OvPrP) was compared to the full-length construct (using chromatography and light scattering). We show that the oligomerization patterns are identical, although the H2H3 domain has a higher polymerization rate. Furthermore, the depolymerization kinetics of purified H2H3 oligomers compared to those purified from the full-length PrP reveal that regions outside H2H3 do not significantly contribute to the oligomerization process. By combining rational mutagenesis and molecular dynamics to investigate the early stages of H2H3 oligomerization, we observe a conformationally stable beta-sheet structure that we propose as a possible nucleus for oligomerization; we also show that single point mutations in H2 and H3 present structural polymorphisms and oligomerization properties that could constitute the basis of species or strain variability.-Chakroun, N., Prigent, S., Dreiss, C. A., Noinville, S., Chapuis, C., Fraternali, F., Rezaei, H. The oligomerization properties of prion protein are restricted to the H2H3 domain. FASEB J. 24, 3222-3231 (2010). www.fasebj.org	[Chakroun, Nesrine; Prigent, Stephanie; Noinville, Sylvie; Chapuis, Celine; Rezaei, Human] INRA, Equipe Biol Physicochim Prions, F-78352 Jouy En Josas, France; [Chakroun, Nesrine; Fraternali, Franca] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Chakroun, Nesrine; Dreiss, Cecile A.] Kings Coll London, Div Pharmaceut Sci, London SE1 1UL, England	INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of London; King's College London; University of London; King's College London	Rezaei, H (corresponding author), INRA, Equipe Biol Physicochim Prions, F-78352 Jouy En Josas, France.	franca.fraternali@kcl.ac.uk; rezaei@jouy.inra.fr	Fraternali, Franca/C-8912-2009; Noinville, Sylvie/S-8318-2019; Noinville, Sylvie/B-1086-2009; Fraternali, Franca/D-4410-2011	Fraternali, Franca/0000-0002-3143-6574; Noinville, Sylvie/0000-0002-8320-9488; 	French National Institute of Agronomic Research (INRA); Alliance Biosecure; Royal Society	French National Institute of Agronomic Research (INRA); Alliance Biosecure; Royal Society(Royal Society of London)	Financial support for this work was provided by the French National Institute of Agronomic Research (INRA) including INRA-Package, Alliance Biosecure, and the Royal Society (travel expenses). The authors acknowledge EPSRC/Diamond Light Source for the provision of a CASE studentship (N.C.). The authors thank Annalisa Pastore and Jens Kleinjung for their advice and suggestions. The authors also thank G. van der Rest for access to MS facilities and interest in this work. H. R., F. F., and C. A. D. designed the research plan with the contribution of S. P. and N.C.; H. R., S. P., C. C., and S.N. performed the kinetic experiments, oligomer purification, mutant design, and in vitro data analysis; F. F., N.C., and C. A. D. performed the MD analysis; H. R., S. P., and D. S. designed and constructed the MWSLS device. All authors contributed to writing the paper.	Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658, DOI 10.1007/978-94-015-7658]; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Blinov N, 2009, BIOCHEMISTRY-US, V48, P1488, DOI 10.1021/bi802043h; CHEATHAM TE, 1995, J AM CHEM SOC, V117, P4193, DOI 10.1021/ja00119a045; Chebaro Y, 2009, J PHYS CHEM B, V113, P6942, DOI 10.1021/jp900334s; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Cobb NJ, 2007, P NATL ACAD SCI USA, V104, P18946, DOI 10.1073/pnas.0706522104; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; De Simone A, 2005, P NATL ACAD SCI USA, V102, P7535, DOI 10.1073/pnas.0501748102; De Simone A, 2007, BIOPHYS J, V93, P1284, DOI 10.1529/biophysj.107.108613; Eghiaian F, 2007, P NATL ACAD SCI USA, V104, P7414, DOI 10.1073/pnas.0607745104; Esler WP, 2000, BIOCHEMISTRY-US, V39, P6288, DOI 10.1021/bi992933h; Ferreiro E, 2008, J NEUROCHEM, V104, P766, DOI 10.1111/j.1471-4159.2007.05048.x; Fioriti L, 2005, MOL CELL NEUROSCI, V28, P165, DOI 10.1016/j.mcn.2004.09.006; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Gu W, 2003, BIOPHYS CHEM, V104, P79, DOI 10.1016/S0301-4622(02)00340-X; Haire LF, 2004, J MOL BIOL, V336, P1175, DOI 10.1016/j.jmb.2003.12.059; Kundu B, 2003, P NATL ACAD SCI USA, V100, P12069, DOI 10.1073/pnas.2033281100; Langella E, 2004, BIOPHYS J, V87, P3623, DOI [10.1529/biophysj.104.043448, 10.1529/biophysj.104.043449]; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; Lu BY, 2002, BIOCHEM J, V364, P81, DOI 10.1042/bj3640081; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rezaei H, 2005, J MOL BIOL, V347, P665, DOI 10.1016/j.jmb.2005.01.043; Rezaei H, 2000, EUR J BIOCHEM, V267, P2833, DOI 10.1046/j.1432-1033.2000.01347.x; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Simoneau S, 2007, PLOS PATHOG, V3, P1175, DOI 10.1371/journal.ppat.0030125; Sokolowski F, 2003, J BIOL CHEM, V278, P40481, DOI 10.1074/jbc.M304391200; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; VANGUNSTEREN WF, 1984, J MOL BIOL, V176, P559, DOI 10.1016/0022-2836(84)90177-3; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499	39	69	69	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3222	3231		10.1096/fj.09-153924	http://dx.doi.org/10.1096/fj.09-153924			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20410442				2022-12-28	WOS:000281446400011
J	Talens, RP; Boomsma, DI; Tobi, EW; Kremer, D; Jukema, JW; Willemsen, G; Putter, H; Slagboom, PE; Heijmans, BT				Talens, Rudolf P.; Boomsma, Dorret I.; Tobi, Elmar W.; Kremer, Dennis; Jukema, J. Wouter; Willemsen, Gonneke; Putter, Hein; Slagboom, P. Eline; Heijmans, Bastiaan T.			Variation, patterns, and temporal stability of DNA methylation: considerations for epigenetic epidemiology	FASEB JOURNAL			English	Article						epigenome; biobank; human studies; complex disease	MASS-SPECTROMETRY; COLORECTAL-CANCER; GENE-EXPRESSION; EPIGENOME; LOCUS; TWINS; ASSOCIATION; UPSTREAM; IMPRINTS; FAMILIES	The prospect of finding epigenetic risk factors for complex diseases would be greatly enhanced if DNA from existing biobanks, which is generally extracted from whole blood, could be used to perform epigenetic association studies. We characterized features of DNA methylation at 16 candidate loci, 8 of which were imprinted, in DNA samples from the Netherlands Twin Register biobank. Except for un-methylated or fully methylated sites, CpG methylation varied considerably in a sample of 30 unrelated individuals. This variation remained after accounting for the cellular heterogeneity of blood. Methylation of CpG sites was correlated within loci and, for 4 imprinted loci, across chromosomes. In 34 additional individuals, we investigated the DNA methylation of 8 representative loci in 2 longitudinal blood and 2 longitudinal buccal cell samples (follow-up 11-20 and 2-8 yr, respectively). Five of 8 loci were stable over time (rho > 0.75) in both tissues, indicating that prospective epigenetic studies may be possible. For 4 loci, the DNA methylation in blood (mesoderm) correlated with that in the buccal cells (ectoderm) (rho > 0.75). Our data suggest that epigenetic studies on complex diseases may be feasible for a proportion of genomic loci provided that they are carefully designed.-Talens, R. P., Boomsma, D. I., Tobi, E. W., Kremer, D., Jukema, J. W., Willemsen, G., Putter, H., Slagboom, P. E., Heijmans, B. T. Variation, patterns, and temporal stability of DNA methylation: considerations for epigenetic epidemiology. FASEB J. 24, 3135-3144 (2010). www.fasebj.org	[Talens, Rudolf P.; Tobi, Elmar W.; Kremer, Dennis; Slagboom, P. Eline; Heijmans, Bastiaan T.] Leiden Univ, Med Ctr, Dept Mol Epidemiol, NL-2300 RC Leiden, Netherlands; [Jukema, J. Wouter] Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; [Putter, Hein] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands; [Boomsma, Dorret I.; Willemsen, Gonneke] Vrije Univ Amsterdam, Dept Biol Psychol, Amsterdam, Netherlands; [Slagboom, P. Eline; Heijmans, Bastiaan T.] Netherlands Consortium Healthy Ageing, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Heijmans, BT (corresponding author), Leiden Univ, Med Ctr, Dept Mol Epidemiol, Postal Zone S-05-P,POB 9600, NL-2300 RC Leiden, Netherlands.	b.t.heijmans@lumc.nl	Tobi, Elmar W/C-1834-2014; Jukema, J. Wouter/ABD-6503-2021; Slagboom, P. Eline/R-4790-2016; Boomsma, Dorret I/AAX-4470-2020; Putter, Hein/C-2244-2018	Tobi, Elmar W/0000-0002-1378-3687; Jukema, J. Wouter/0000-0002-3246-8359; Slagboom, P. Eline/0000-0002-2875-4723; Putter, Hein/0000-0001-5395-1422; Willemsen, Gonneke/0000-0003-3755-0236	Netherlands Heart Foundation [NHS2006B083]; Netherlands Organization for Scientific Research (NWO); Twin-family database for behavior genomics studies [480-04-004, 911-03-016]; Spinozapremie [SPI 56-464-14192]; Centre for Medical Systems Biology (CMSB); Centre for Neurogenomics and Cognitive Research (CNCR-VU); Genome-wide analyses of European twin and population cohorts [EU/QLRT-2001-01254]; European Union [FP6 036894]; NGI/NWO [050 60 810]	Netherlands Heart Foundation(Netherlands Heart Foundation); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Twin-family database for behavior genomics studies; Spinozapremie; Centre for Medical Systems Biology (CMSB); Centre for Neurogenomics and Cognitive Research (CNCR-VU); Genome-wide analyses of European twin and population cohorts; European Union(European Commission); NGI/NWO(Netherlands Organization for Scientific Research (NWO))	The authors thank Dr. L. H. Lumey (Mailman School of Public Health, Columbia University, New York, NY, USA), for access to the Dutch Hunger Winter Family Study samples used in our analysis. This work was supported by grants from the Netherlands Heart Foundation (NHS2006B083); the Netherlands Organization for Scientific Research (NWO); the twin-family database for behavior genomics studies (480-04-004, 911-03-016); Spinozapremie (SPI 56-464-14192); the Centre for Medical Systems Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI) and the Centre for Neurogenomics and Cognitive Research (CNCR-VU); genome-wide analyses of European twin and population cohorts (EU/QLRT-2001-01254); the European Union-funded Network of Excellence LifeSpan (FP6 036894); and the NGI/NWO-funded Netherlands Consortium for Healthy Ageing (050 60 810).	Adkins RM, 2007, PEDIATR RES, V62, P451, DOI 10.1203/PDR.0b013e3181425841; Ally MS, 2009, CANCER EPIDEM BIOMAR, V18, P922, DOI 10.1158/1055-9965.EPI-08-0703; Altman D.G., 1991, PRACTICAL STAT MED R; Arnaud P, 2003, HUM MOL GENET, V12, P1005, DOI 10.1093/hmg/ddg110; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Bock C, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn122; Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003; Boomsma DI, 2008, EUR J HUM GENET, V16, P335, DOI 10.1038/sj.ejhg.5201979; Boomsma DI, 2006, TWIN RES HUM GENET, V9, P849, DOI 10.1375/183242706779462426; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dong J, 2007, J IMMUNOL, V179, P2389, DOI 10.4049/jimmunol.179.4.2389; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105; El-Maarri O, 2007, HUM GENET, V122, P505, DOI 10.1007/s00439-007-0430-3; Feinberg AP, 2008, JAMA-J AM MED ASSOC, V299, P1345, DOI 10.1001/jama.299.11.1345; Foley DL, 2009, AM J EPIDEMIOL, V169, P389, DOI 10.1093/aje/kwn380; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Hayward BE, 2000, HUM MOL GENET, V9, P835, DOI 10.1093/hmg/9.5.835; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Heijmans BT, 2007, HUM MOL GENET, V16, P547, DOI 10.1093/hmg/ddm010; Heijmans BT, 2009, EPIGENETICS-US, V4, P526, DOI 10.4161/epi.4.8.10265; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kouzarides T, 2007, CELL, V128, P802, DOI 10.1016/j.cell.2007.02.018; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Lumey LH, 2007, INT J EPIDEMIOL, V36, P1196, DOI 10.1093/ije/dym126; Martin GM, 2005, P NATL ACAD SCI USA, V102, P10413, DOI 10.1073/pnas.0504743102; McGill BE, 2006, P NATL ACAD SCI USA, V103, P18267, DOI 10.1073/pnas.0608702103; Medstrand P, 2001, J BIOL CHEM, V276, P1896, DOI 10.1074/jbc.M006557200; Melzner I, 2002, J BIOL CHEM, V277, P45420, DOI 10.1074/jbc.M208511200; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; Petronis A, 2001, TRENDS GENET, V17, P142, DOI 10.1016/S0168-9525(00)02213-7; Pons D, 2009, EUR HEART J, V30, P266, DOI 10.1093/eurheartj/ehn603; Probst MCO, 2004, ATHEROSCLEROSIS, V175, P269, DOI 10.1016/j.atherosclerosis.2004.02.019; Rakyan VK, 2004, PLOS BIOL, V2, P2170, DOI 10.1371/journal.pbio.0020405; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; Rosa AL, 2005, CHROMOSOME RES, V13, P809, DOI 10.1007/s10577-005-1015-4; Sandovici I, 2003, HUM MOL GENET, V12, P1569, DOI 10.1093/hmg/ddg167; Shen LL, 2007, CURR OPIN CLIN NUTR, V10, P576, DOI 10.1097/MCO.0b013e3282bf6f43; Smith ZD, 2009, METHODS, V48, P226, DOI 10.1016/j.ymeth.2009.05.003; Stanssens P, 2004, GENOME RES, V14, P126; Sullivan KE, 2007, MOL CELL BIOL, V27, P5147, DOI 10.1128/MCB.02429-06; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382; Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353; Turunen MP, 2009, BBA-GEN SUBJECTS, V1790, P886, DOI 10.1016/j.bbagen.2009.02.008; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; West B. T., 2006, LINEAR MIXED MODELS, P180	62	235	238	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3135	3144		10.1096/fj.09-150490	http://dx.doi.org/10.1096/fj.09-150490			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20385621				2022-12-28	WOS:000281446400004
J	Chen, NC; Yang, F; Capecci, LM; Gu, ZY; Schafer, AI; Durante, W; Yang, XF; Wang, H				Chen, Natalie C.; Yang, Fan; Capecci, Louis M.; Gu, Ziyu; Schafer, Andrew I.; Durante, William; Yang, Xiao-Feng; Wang, Hong			Regulation of homocysteine metabolism and methylation in human and mouse tissues	FASEB JOURNAL			English	Article						gene expression; homocysteine metabolism; methylation	CYSTATHIONINE BETA-SYNTHASE; S-ADENOSYLHOMOCYSTEINE HYDROLASE; GLYCINE N-METHYLTRANSFERASE; ENDOTHELIAL-CELL GROWTH; PLASMA HOMOCYSTEINE; DNA METHYLATION; KNOCKOUT MOUSE; MICE DEFICIENT; FOLIC-ACID; LIVER	Hyperhomocysteinemia is an independent risk factor for cardiovascular disease. Homocysteine (Hcy) metabolism involves multiple enzymes; however, tissue Hcy metabolism and its relevance to methylation remain unknown. Here, we established gene expression profiles of 8 Hcy metabolic and 12 methylation enzymes in 20 human and 19 mouse tissues through bioinformatic analysis using expression sequence tag clone counts in tissue cDNA libraries. We analyzed correlations between gene expression, Hcy, S-adenosylhomocysteine (SAH), and S-adenosylmethionine (SAM) levels, and SAM/SAH ratios in mouse tissues. Hcy metabolic and methylation enzymes were classified into two types. The expression of Type 1 enzymes positively correlated with tissue Hcy and SAH levels. These include cystathionine beta-synthase, cystathionine-gamma-lyase, paraxonase 1, 5,10-methylenetetrahydrofolate reductase, betaine: homocysteine methyltransferase, methionine adenosyltransferase, phosphatidylethanolamine N-methyltransferases and glycine N-methyltransferase. Type 2 enzyme expressions correlate with neither tissue Hcy nor SAH levels. These include SAH hydrolase, methionyl-tRNA synthase, 5-methyltetrahydrofolate:Hcy methyltransferase, S-adenosylmethionine decarboxylase, DNA methyltransferase 1/3a, isoprenylcysteine carboxyl methyltransferases, and histone-lysine N-methyltransferase. SAH is the only Hcy metabolite significantly correlated with Hcy levels and methylation enzyme expression. We established equations expressing combined effects of methylation enzymes on tissue SAH, SAM, and SAM/SAH ratios. Our study is the first to provide panoramic tissue gene expression profiles and mathematical models of tissue methylation regulation.-Chen, N. C., Yang, F., Capecci, L. M., Gu, Z., Schafer, A. I., Durante, W., Yang, X.-F., Wang, H. Regulation of homocysteine metabolism and methylation in human and mouse tissues. FASEB J. 24, 2804-2817 (2010). www.fasebj.org	[Wang, Hong] Temple Univ, Sch Med, Dept Pharmacol, MRB, Philadelphia, PA 19140 USA; [Yang, Xiao-Feng; Wang, Hong] Temple Univ, Sch Med, Cardiovasc Res Ctr, Philadelphia, PA 19140 USA; [Wang, Hong] Temple Univ, Sch Med, Thrombosis Res Ctr, Philadelphia, PA 19140 USA; [Schafer, Andrew I.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Durante, William] Univ Missouri, Dept Med Pharmacol & Physiol, Columbia, MO USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Cornell University; University of Missouri System; University of Missouri Columbia	Wang, H (corresponding author), Temple Univ, Sch Med, Dept Pharmacol, MRB, 3420 N Broad St, Philadelphia, PA 19140 USA.	xfyang@temple.edu; hongw@temple.edu			NIH [HL67033, HL82774, HL77288, HL094451, HL74966]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077288, R01HL094451, R01HL074966, R01HL067033, R01HL082774] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in part, by NIH grants HL67033, HL82774, and HL77288 (H.W.), HL094451 (X.F.Y.), and HL74966 (W.D.).	Barak AJ, 1996, ALCOHOL, V13, P395, DOI 10.1016/0741-8329(96)00030-4; Bazzano LA, 2009, AM J MED SCI, V338, P48, DOI 10.1097/MAJ.0b013e3181aaefd6; Bogdarina I, 2007, CIRC RES, V100, P520, DOI 10.1161/01.RES.0000258855.60637.58; Caudill MA, 2001, J NUTR, V131, P2811, DOI 10.1093/jn/131.11.2811; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Choumenkovitch SF, 2002, J NUTR, V132, P2157, DOI 10.1093/jn/132.8.2157; Collinsova M, 2006, J NUTR, V136, P1493, DOI 10.1093/jn/136.6.1493; COX R, 1977, BIOCHIM BIOPHYS ACTA, V474, P493, DOI 10.1016/0005-2787(77)90070-3; De Franchis R, 1998, EUR J PEDIATR, V157, pS67, DOI 10.1007/PL00014309; DEGUCHI T, 1971, J BIOL CHEM, V246, P3175; Devlin AM, 2004, BLOOD, V103, P2624, DOI 10.1182/blood-2003-09-3078; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102; HELLAND S, 1983, CANCER RES, V43, P1847; HELLAND S, 1983, CANCER RES, V43, P4142; HOFFMAN DR, 1981, LIPIDS, V16, P561, DOI 10.1007/BF02534900; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Igolnikov AC, 2006, J HEPATOL, V44, P586, DOI 10.1016/j.jhep.2005.08.026; Jacobs RL, 2001, J BIOL CHEM, V276, P43740, DOI 10.1074/jbc.M107553200; Jacobsen DW, 1998, CLIN CHEM, V44, P1833; Jamaluddin MS, 2007, CLIN CHEM LAB MED, V45, P1660, DOI 10.1515/CCLM.2007.350; Jamaluddin MS, 2007, BLOOD, V110, P3648, DOI 10.1182/blood-2007-06-096701; James SJ, 2002, J NUTR, V132, p2361S, DOI 10.1093/jn/132.8.2361S; KERR SJ, 1972, J BIOL CHEM, V247, P4248; Kharbanda KK, 2009, SEMIN LIVER DIS, V29, P155, DOI 10.1055/s-0029-1214371; Lee ME, 1999, TRENDS CARDIOVAS MED, V9, P49, DOI 10.1016/S1050-1738(99)00002-X; Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X; Luka Z, 2006, TRANSGENIC RES, V15, P393, DOI 10.1007/s11248-006-0008-1; Mager A, 2009, AM J CARDIOL, V104, P745, DOI 10.1016/j.amjcard.2009.05.011; Maron BA, 2009, ANNU REV MED, V60, P39, DOI 10.1146/annurev.med.60.041807.123308; Matthews RG, 2007, CLIN CHEM LAB MED, V45, P1700, DOI 10.1515/CCLM.2007.324; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; Meigs JB, 2001, DIABETES CARE, V24, P1403, DOI 10.2337/diacare.24.8.1403; Nieman KM, 2004, J BIOL CHEM, V279, P45708, DOI 10.1074/jbc.M408664200; Park JH, 2008, J CLIN INVEST, V118, P2316, DOI [10.1172/JC133655, 10.1172/JCI33655]; PERNA AF, 1993, J CLIN INVEST, V91, P2497; PERNA AF, 1995, KIDNEY INT, V47, P247, DOI 10.1038/ki.1995.31; Perna AF, 1997, J AM SOC NEPHROL, V8, pA1148; Pontius JU, 2003, NCBI HDB, V1, P1; Qi ZX, 2003, GENET MED, V5, P458, DOI 10.1097/01.GIM.0000095001.12570.A8; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Song YQ, 2009, DIABETES, V58, P1921, DOI 10.2337/db09-0087; Stead LM, 2000, BIOCHEM J, V350, P685, DOI 10.1042/0264-6021:3500685; SVARDAL A, 1986, J BIOL CHEM, V261, P3156; Tessari P, 2005, DIABETES, V54, pA326; UELAND PM, 1984, J BIOL CHEM, V259, P2360; Wang H, 2002, BLOOD, V99, P939; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380; Wang LQ, 2005, HUM MOL GENET, V14, P2201, DOI 10.1093/hmg/ddi224; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Xiong ZY, 2009, ATHEROSCLEROSIS, V203, P401, DOI 10.1016/j.atherosclerosis.2008.07.041; Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667; YEO EJ, 1994, P NATL ACAD SCI USA, V91, P210, DOI 10.1073/pnas.91.1.210; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; Yin Y, 2009, INT J IMMUNOPATH PH, V22, P311, DOI 10.1177/039463200902200208	55	114	122	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2804	2817		10.1096/fj.09-143651	http://dx.doi.org/10.1096/fj.09-143651			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20305127	Green Published			2022-12-28	WOS:000285005400021
J	Liang, LM; Liu, SQ; Yang, JK; Meng, ZH; Lei, LP; Zhang, KQ				Liang, Lianming; Liu, Shuqun; Yang, Jinkui; Meng, Zhaohui; Lei, Liping; Zhang, Keqin			Comparison of homology models and crystal structures of cuticle-degrading proteases from nematophagous fungi: structural basis of nematicidal activity	FASEB JOURNAL			English	Article						disulfide bridge; structural flexibility; electrostatic surface potential	NEMATODE-TRAPPING FUNGUS; EXTRACELLULAR SERINE-PROTEASE; MOLECULAR-DYNAMICS; CAENORHABDITIS-ELEGANS; PURIFICATION; SIMULATION; SUBTILISIN; STABILITY; INFECTION; ENZYMES	Cuticle-degrading proteases secreted by nematophagous fungi can degrade nematode cuticle during infection. Alkaline proteases from nematode-parasitic fungi show stronger nematicidal activity in vitro than neutral proteases from nematode-trapping fungi. Sequence alignment of these proteases revealed that the active-site residues were much conserved. Disulfide bridges in alkaline proteases not only contribute to the thermal stability of enzyme structure but also increase the flexibility of S1 and S4 pockets located at the substrate-binding site. Molecular electrostatic potential surfaces of these proteases change gradually from negative to positive while arranging in the order from neutral to alkaline proteases, possibly contributing to the distinct extent of substrate (nematode cuticle) attraction by proteases. The differences in flexibility of substrate-binding site and in electrostatic surface potential distribution between neutral and alkaline cuticle-degrading proteases are associated with the changes of their catalytic activities and nematicidal activities with fungal species. Our results indicate that nematode-parasitic and nematode-trapping fungi have evolved for distinct adaptation under selective pressure.-Liang, L., Liu, S., Yang, J., Meng, Z., Lei, L., Zhang, K. Comparison of homology models and crystal structures of cuticle-degrading proteases from nematophagous fungi: structural basis of nematicidal activity. FASEB J. 25, 1894-1902 (2011). www.fasebj.org	[Liang, Lianming; Liu, Shuqun; Yang, Jinkui; Meng, Zhaohui; Zhang, Keqin] Yunnan Univ, Lab Conservat & Utilizat Bioresources, Kunming 650091, Peoples R China; [Liang, Lianming; Liu, Shuqun; Yang, Jinkui; Meng, Zhaohui; Zhang, Keqin] Yunnan Univ, Key Lab Microbial Resources, Minist Educ, Kunming 650091, Peoples R China; [Meng, Zhaohui] Kunming Med Univ, Mol Cardiol Lab, Dept Cardiol, Affiliated Hosp 1, Kunming, Peoples R China; [Lei, Liping] Tobacco Agr Sci Inst Yunnan Prov, Yuxi, Peoples R China	Yunnan University; Yunnan University; Kunming Medical University; China National Tobacco Corporation	Zhang, KQ (corresponding author), Yunnan Univ, Lab Conservat & Utilizat Bioresources, Kunming 650091, Peoples R China.	kqzhang111@yahoo.com.cn	Liang, Lian-Ming/AAL-3861-2021; zhang, ke/AAH-8217-2019	Yang, Jinkui/0000-0002-3106-2189	National Basic Research Program of China [2007CB411600]; National Natural Science Foundation of China [30630003, 30860011, 30960229, 30660107]; Department of Science and Technology of Yunnan Province [2007PY-22, 2007C007Z, 2009CI052]; Yunnan Branch of China Tobacco Industrial Corporation [2010YN17]; Yunnan University [2010C02Z]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science and Technology of Yunnan Province; Yunnan Branch of China Tobacco Industrial Corporation; Yunnan University	The authors thank Dr. Jianping Xu (McMaster University, Hamilton, ON, Canada) for help and advice in this experiment and the High Performance Computer Center of Yunnan University for computational support. This work was jointly funded by the National Basic Research Program of China (approval 2007CB411600); projects from the National Natural Science Foundation of China (approvals 30630003, 30860011, 30960229, and 30660107); the Department of Science and Technology of Yunnan Province (approvals 2007PY-22, 2007C007Z, and 2009CI052); the Yunnan Branch of China Tobacco Industrial Corporation (grant 2010YN17); and Yunnan University (grant 2010C02Z).	Ahman J, 2002, APPL ENVIRON MICROB, V68, P3408, DOI 10.1128/AEM.68.7.3408-3415.2002; Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658, DOI 10.1007/978-94-015-7658]; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; COX GN, 1981, J CELL BIOL, V90, P7, DOI 10.1083/jcb.90.1.7; Dong LQ, 2007, NEMATOLOGY, V9, P743, DOI 10.1163/156854107782024802; FERSHT AR, 1993, CURR OPIN STRUC BIOL, V3, P75, DOI 10.1016/0959-440X(93)90205-Y; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; HIMMELHOCH S, 1978, EXP PARASITOL, V45, P208, DOI 10.1016/0014-4894(78)90061-9; Huang XW, 2004, RES MICROBIOL, V155, P811, DOI 10.1016/j.resmic.2004.07.003; JOSHI L, 1995, FEMS MICROBIOL LETT, V125, P211, DOI 10.1111/j.1574-6968.1995.tb07360.x; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 2006, PROCESS BIOCHEM, V41, P925, DOI 10.1016/j.procbio.2005.10.006; Li J, 2010, BMC EVOL BIOL, V10, DOI [10.1186/1471-2148-10-68, 10.1186/1471-2407-10-354]; Liang LM, 2010, FASEB J, V24, P1391, DOI 10.1096/fj.09-136408; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Liu SQ, 2010, J MOL MODEL, V16, P17, DOI 10.1007/s00894-009-0518-x; Liu SQ, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-33; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; Morton CO, 2003, MYCOL RES, V107, P38, DOI 10.1017/S0953756202007050; MURRELL KD, 1983, EXP PARASITOL, V55, P331, DOI 10.1016/0014-4894(83)90030-9; Sakaguchi M, 2008, J BIOCHEM, V143, P625, DOI 10.1093/jb/mvn007; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SEGERS R, 1994, MICROBIOL-SGM, V140, P2715, DOI 10.1099/00221287-140-10-2715; STLEGER RJ, 1987, ARCH BIOCHEM BIOPHYS, V253, P221, DOI 10.1016/0003-9861(87)90655-2; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tao Y, 2010, J BIOMOL STRUCT DYN, V28, P143, DOI 10.1080/073911010010524953; TIRONI IG, 1995, J CHEM PHYS, V102, P5451, DOI 10.1063/1.469273; TUNLID A, 1994, MICROBIOL-UK, V140, P1687, DOI 10.1099/13500872-140-7-1687; Yang JK, 2007, APPL MICROBIOL BIOT, V75, P21, DOI 10.1007/s00253-007-0881-4; Yang JK, 2005, BIOTECHNOL LETT, V27, P1123, DOI 10.1007/s10529-005-8461-0; Zhao ML, 2004, MYCOLOGIA, V96, P16, DOI 10.2307/3761982	36	20	25	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1894	1902		10.1096/fj.10-175653	http://dx.doi.org/10.1096/fj.10-175653			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21350115				2022-12-28	WOS:000291023800013
J	Blume, M; Hliscs, M; Rodriguez-Contreras, D; Sanchez, M; Landfear, S; Lucius, R; Matuschewski, K; Gupta, N				Blume, Martin; Hliscs, Marion; Rodriguez-Contreras, Dayana; Sanchez, Marco; Landfear, Scott; Lucius, Richard; Matuschewski, Kai; Gupta, Nishith			A constitutive pan-hexose permease for the Plasmodium life cycle and transgenic models for screening of antimalarial sugar analogs	FASEB JOURNAL			English	Article						sugar transport; metabolic drug target; high-throughput screening	FALCIPARUM-INFECTED ERYTHROCYTES; MALARIA PARASITES; GLUCOSE TRANSPORTERS; EXPRESSION SYSTEM; TOXOPLASMA-GONDII; METABOLISM; VALIDATION; BERGHEI; GROWTH; YEAST	Glucose is considered essential for erythrocytic stages of the malaria parasite, Plasmodium falciparum. Importance of sugar and its permease for hepatic and sexual stages of Plasmodium, however, remains elusive. Moreover, increasing global resistance to current antimalarials necessitates the search for novel drugs. Here, we reveal that hexose transporter 1 (HT1) of Plasmodium berghei can transport glucose (K-m similar to 87 mu M), mannose (K-i similar to 93 mu M), fructose (K-i similar to 0.54 mM), and galactose (K-i similar to 5 mM) in Leishmania mexicana mutant and Xenopus laevis; and, therefore, is functionally equivalent to HT1 of P. falciparum (Glc, K-m similar to 175 mu M; Man, K-i similar to 276 mu M; Fru, K-i similar to 1.25 mM; Gal, K-i similar to 5.86 mM). Notably, a glucose analog, C3361, attenuated hepatic (IC50 similar to 15 mu M) and ookinete development of P. berghei. The PbHT1 could be ablated during intraerythrocytic stages only by concurrent complementation with PbHT1-HA or PfHT1. Together; these results signify that PbHT1 and glucose are required for the entire life cycle of P. berghei. Accordingly, PbHT1 is expressed in the plasma membrane during all parasite stages. To permit a high-throughput screening of PfHT1 inhibitors and their subsequent in vivo assessment, we have generated Saccharomyces cerevisiae mutant expressing codon-optimized PfHT1, and a PfHT1-dependent Delta pbht1 parasite strain. This work provides a platform to facilitate the development of drugs against malaria, and it suggests a disease-control aspect by reducing parasite transmission.-Blume, M., Hliscs, M., Rodriguez-Contreras, D., Sanchez, M., Landfear, S., Lucius, R., Matuschewski, K., Gupta, N. A constitutive pan-hexose permease for the Plasmodium life cycle and transgenic models for screening of antimalarial sugar analogs. FASEB J. 25, 1218-1229 (2011). www.fasebj.org	[Blume, Martin; Lucius, Richard; Gupta, Nishith] Humboldt Univ, Dept Mol Parasitol, Berlin, Germany; [Hliscs, Marion; Matuschewski, Kai] Max Planck Inst Infect Biol, Parasitol Unit, Berlin, Germany; [Rodriguez-Contreras, Dayana; Sanchez, Marco; Landfear, Scott] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Humboldt University of Berlin; Max Planck Society; Oregon Health & Science University	Gupta, N (corresponding author), Humboldt Univ, Dept Mol Parasitol, Philippstr 13,House 14, Berlin, Germany.	gupta.nishith@staff.hu-berlin.de		Matuschewski, Kai/0000-0001-6147-8591; Blume, Martin/0000-0002-6894-3000; Gupta, Nishith/0000-0003-1452-5126; Landfear, Scott/0000-0002-1643-6664	Helmholtz Foundation (Germany); German Research Foundation [SFB618/C7]; U.S. National Institutes of Health [AI25920]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER	Helmholtz Foundation (Germany)(Helmholtz Association); German Research Foundation(German Research Foundation (DFG)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Grit Meusel (Humboldt University, Berlin, Germany) for her technical assistance. The doctoral research of M. B. is supported by the Helmholtz Foundation (Germany). This work was also supported by an intramural research grant to K. M., German Research Foundation grant SFB618/C7 to N.G. and R. L., and U.S. National Institutes of Health grant AI25920 to S. L. The NCBI database accession numbers of the nucleotide/protein sequences derived from this research are as follows: PbHT1, HM156735; PfHT1-Synthetic, HM161875; and EtHT1, HM161877.	Blume M, 2009, P NATL ACAD SCI USA, V106, P12998, DOI 10.1073/pnas.0903831106; Burchmore RJS, 2003, P NATL ACAD SCI USA, V100, P3901, DOI 10.1073/pnas.0630165100; Daily JP, 2007, NATURE, V450, P1091, DOI 10.1038/nature06311; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; Dondorp AM, 2010, NAT REV MICROBIOL, V8, P272, DOI 10.1038/nrmicro2331; Feistel T, 2008, MOL BIOCHEM PARASIT, V162, P71, DOI 10.1016/j.molbiopara.2008.07.005; Friesen J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001058; FRY M, 1991, PARASITOLOGY, V102, P17, DOI 10.1017/S0031182000060297; Gowda DC, 1997, J BIOL CHEM, V272, P6428, DOI 10.1074/jbc.272.10.6428; Gupta N, 2005, J BIOL CHEM, V280, P16345, DOI 10.1074/jbc.M501523200; Janse CJ, 2006, MOL BIOCHEM PARASIT, V145, P60, DOI 10.1016/j.molbiopara.2005.09.007; Joet T, 2003, P NATL ACAD SCI USA, V100, P7476, DOI 10.1073/pnas.1330865100; Kirk K, 1996, MOL BIOCHEM PARASIT, V82, P195, DOI 10.1016/0166-6851(96)02734-X; Lasonder E, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000195; Lim L, 2010, FEBS LETT, V584, P549, DOI 10.1016/j.febslet.2009.11.097; Olszewski KL, 2010, NATURE, V466, P774, DOI 10.1038/nature09301; ROTH EF, 1988, BLOOD, V72, P1922; ROTH EF, 1987, J BIOL CHEM, V262, P15678; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Sanchez MA, 2004, MOL MEMBR BIOL, V21, P11, DOI 10.1080/0968768031000140845; Schuster FL, 2002, CLIN MICROBIOL REV, V15, P355, DOI 10.1128/CMR.15.3.355-364.2002; Seeber F, 2008, TRENDS PARASITOL, V24, P468, DOI 10.1016/j.pt.2008.07.004; Seyfang A, 2000, J BIOL CHEM, V275, P5687, DOI 10.1074/jbc.275.8.5687; Siden-Kiamos I, 2000, J CELL SCI, V113, P3419; Slavic K, 2010, MOL MICROBIOL, V75, P1402, DOI 10.1111/j.1365-2958.2010.07060.x; TSUJI M, 1994, PARASITOL RES, V80, P16, DOI 10.1007/BF00932618; Vaidya AB, 2009, ANNU REV MICROBIOL, V63, P249, DOI 10.1146/annurev.micro.091208.073424; van Dooren GG, 2006, FEMS MICROBIOL REV, V30, P596, DOI 10.1111/j.1574-6976.2006.00027.x; VANDERJAGT DL, 1990, MOL BIOCHEM PARASIT, V42, P277, DOI 10.1016/0166-6851(90)90171-H; Wieczorke R, 2003, CELL PHYSIOL BIOCHEM, V13, P123, DOI 10.1159/000071863; Wieczorke R, 1999, FEBS LETT, V464, P123, DOI 10.1016/S0014-5793(99)01698-1; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; Woodrow CJ, 2000, P NATL ACAD SCI USA, V97, P9931, DOI 10.1073/pnas.170153097; Youk H, 2009, NATURE, V462, P875, DOI 10.1038/nature08653	34	32	32	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2011	25	4					1218	1229		10.1096/fj.10-173278	http://dx.doi.org/10.1096/fj.10-173278			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21169382	Green Published			2022-12-28	WOS:000288982800011
J	Liu, X; Zhao, DZ; James, L; Li, JA; Zeng, HY				Liu, Xin; Zhao, Dezheng; James, Lauralee; Li, Jian; Zeng, Huiyan			Requirement of the nuclear localization of transcription enhancer factor 3 for proliferation, migration, tube formation, and angiogenesis induced by vascular endothelial growth factor	FASEB JOURNAL			English	Article						TEF3; VEGF; DSCR1	VEGF-A; RTEF-1; TISSUES; CLONING; FAMILY; MUSCLE; CELLS	Transcription enhancer factor 3 (TEF3) is known to regulate the expression of muscle-specific genes and to play important roles in muscle development and diseases. However, little is known about its role in vascular endothelial growth factor (VEGF)induced angiogenesis. Most recently, we discovered a novel function of TEF3, in which TEF3 is required for the up-regulation of a proangiogenic factor, Down syndrome candidate region 1 isoform 1L (DSCR1-1L), induced by VEGF-A(165) in endothelial cells. Overexpression of TEF3 isoform 1 (TEF3-1) is sufficient to induce DSCR1-1L expression. Here, we report that knocking down the expression of TEF3 almost completely inhibits VEGF-A(165)-induced proliferation, migration, tube formation, formation of F-actin stress fiber, and in vivo Matrigel angiogenesis. This inhibition cannot be rescued by DSCR1-1L overexpression. Further, overexpression of TEF3-1, but not its nuclear localization signal-deletion mutant (TEF3-Delta NLS), induces human umbilical vein endothelial cell proliferation, migration, tube formation, and formation of F-actin stress fiber, even in the absence of VEGF-A(165) stimulation, which is partially inhibited by DSCR1-1L silencing. Our data demonstrate that TEF3, mainly its nuclear localization, is required for VEGF-A(165)-induced endothelial proliferation, migration, tube formation, and in vivo Matrigel angiogenesis.-Liu, X., Zhao, D., James, L., Li, J., Zeng, H. Requirement of the nuclear localization of transcription enhancer factor 3 for proliferation, migration, tube formation, and angiogenesis induced by vascular endothelial growth factor. FASEB J. 25, 1188-1197 (2011). www.fasebj.org	[Zeng, Huiyan] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; [Zhao, Dezheng] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; [James, Lauralee; Zeng, Huiyan] Beth Israel Deaconess Med Ctr, Mol & Vasc Med Div, Boston, MA 02215 USA; [Li, Jian] Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiol, Boston, MA 02215 USA; [Zhao, Dezheng; James, Lauralee; Zeng, Huiyan] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Zeng, HY (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave Res N,RN270F, Boston, MA 02215 USA.	hzeng@bidmc.harvard.edu	LI, RUIJIAN/GYJ-0470-2022		American Cancer Society [RSG-05-118-01-CSM]	American Cancer Society(American Cancer Society)	This work was supported by American Cancer Society grant RSG-05-118-01-CSM.	Chen HH, 2004, CIRCULATION, V110, P2980, DOI 10.1161/01.CIR.0000146902.84099.26; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; Folkman J, 1997, EXS, V79, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Hayashi K, 1996, MOL CELL ENDOCRINOL, V123, P205, DOI 10.1016/S0303-7207(96)03909-3; Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100; Liu X, 2008, J BIOL CHEM, V283, P34159, DOI 10.1074/jbc.M806338200; Nagy JA, 2006, LAB INVEST, V86, P767, DOI 10.1038/labinvest.3700436; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Qin LL, 2006, MOL CANCER RES, V4, P811, DOI 10.1158/1541-7786.MCR-06-0126; Ryeom S, 2008, CANCER CELL, V13, P420, DOI 10.1016/j.ccr.2008.02.018; Shie JL, 2004, J BIOL CHEM, V279, P25010, DOI 10.1074/jbc.M403103200; Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Yagi R, 2007, DEVELOPMENT, V134, P3827, DOI 10.1242/dev.010223; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	19	18	18	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1188	1197		10.1096/fj.10-167619	http://dx.doi.org/10.1096/fj.10-167619			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21169383				2022-12-28	WOS:000288982800008
J	Kaspar, JW; Jaiswal, AK				Kaspar, James W.; Jaiswal, Anil K.			Tyrosine phosphorylation controls nuclear export of Fyn, allowing Nrf2 activation of cytoprotective gene expression	FASEB JOURNAL			English	Article						INrf2; Keap1; oxidative stress; cytoprotective gene induction; cellular protection; cell survival	PROTEIN-KINASE-C; NF-E2-RELATED FACTOR-2; OXIDOREDUCTASE-1 GENE; SRC FAMILY; TRANSCRIPTION; DEGRADATION; CANCER; SIGNAL; ALPHA; KEAP1	Fyn, an Src kinase family member, acts as a negative regulator of NF-E2-related factor 2 (Nrf2). Under stressful conditions, Nrf2 translocates into the nucleus and binds to the antioxidant response element (ARE), activating defensive gene expression. Once Nrf2 completes activation, Fyn phosphorylates tyrosine 568 of Nrf2, resulting in the nuclear export and degradation of Nrf2. The present studies demonstrate that within 0.5 h of antioxidant treatment in human hepatoblastoma (HepG2) cells, Fyn exports out of the nucleus, allowing Nrf2 unimpeded movement to the ARE. Mutation of tyrosine 213 of Fyn stymied nuclear export, suggesting that tyrosine phosphorylation controls nuclear export. Mass spectrometry confirmed tyrosine 213 as the site of phosphorylation. ChIP and real-time PCR assays revealed that FynY213A mutant caused decreased binding of Nrf2 to the promoter of defensive gene NAD(P) H: quinone oxidoreductase 1 (NQO1) and decreased NQO1 expression by 5-fold (P < 0.0001) compared to wild-type Fyn. In addition, a putative nuclear export signal (NES) was identified, and mutation of it also inhibited nuclear export of Fyn. Furthermore, FynY213A caused an increased susceptibility to cell death following treatment with etoposide in mouse hepatoma (Hepa-1) cells. The preinduction regulation of Nrf2 is controlled by the nuclear export of Fyn, allowing for activation of defensive gene expression.-Kaspar, J. W., Jaiswal, A. K. Tyrosine phosphorylation controls nuclear export of Fyn, allowing Nrf2 activation of cytoprotective gene expression. FASEB J. 25, 1076-1087 (2011). www.fasebj.org	[Kaspar, James W.; Jaiswal, Anil K.] Univ Maryland, Dept Pharmacol & Expt Therapeut, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Jaiswal, AK (corresponding author), Univ Maryland, Dept Pharmacol & Expt Therapeut, Sch Med, 655 W Baltimore St, Baltimore, MD 21201 USA.	ajaiswal@som.umaryland.edu			U.S. National Institutes of Health [RO1 GM047466]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This investigation was supported by U.S. National Institutes of Health grant RO1 GM047466. The authors thank Dr. Suresh K. Niture (University of Maryland School of Medicine, Baltimore, MD, USA) for helpful suggestions.	Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Bromberg KD, 2003, J BIOL CHEM, V278, P7406, DOI 10.1074/jbc.M212056200; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gao Y, 2009, J BIOL CHEM, V284, P7114, DOI 10.1074/jbc.M804801200; Hirota A, 2005, J INVEST DERMATOL, V124, P825, DOI 10.1111/j.0022-202X.2005.23670.x; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200; Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200; Kaabeche K, 2004, J BIOL CHEM, V279, P36259, DOI 10.1074/jbc.M402469200; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kannan S, 2006, CANCER RES, V66, P8421, DOI 10.1158/0008-5472.CAN-06-1181; Kaspar JW, 2010, J BIOL CHEM, V285, P21349, DOI 10.1074/jbc.M110.121863; Kaspar JW, 2010, J BIOL CHEM, V285, P153, DOI 10.1074/jbc.M109.040022; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; KIKUKO I, 2008, EXP CELL RES, V314, P3392; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Mayer BJ, 1997, CURR BIOL, V7, pR295, DOI 10.1016/S0960-9822(06)00141-2; Niture SK, 2009, J BIOL CHEM, V284, P13856, DOI 10.1074/jbc.M808084200; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2; Sanguinetti AR, 2003, BIOCHEM J, V376, P159, DOI 10.1042/BJ20030336; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Strachan GD, 2005, BIOCHEM BIOPH RES CO, V336, P490, DOI 10.1016/j.bbrc.2005.08.127; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095	32	70	72	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1076	1087		10.1096/fj.10-171553	http://dx.doi.org/10.1096/fj.10-171553			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21097520	Green Published			2022-12-28	WOS:000287806200027
J	Li, J; Powell, SR; Wang, XJ				Li, Jie; Powell, Saul R.; Wang, Xuejun			Enhancement of proteasome function by PA28 alpha overexpression protects against oxidative stress	FASEB JOURNAL			English	Article						proteasome activator 28; green fluorescence protein; apoptosis; oxidized proteins; cell culture	PROTEOLYTIC FUNCTION; 26S PROTEASOME; DEGRADATION SIGNALS; INTERFERON-GAMMA; 20S PROTEASOMES; QUALITY-CONTROL; ACTIVATOR PA28; MICE LACKING; SYSTEM; REG	The principal function of the proteasome is targeted degradation of intracellular proteins. Proteasome dysfunction has been observed in experimental cardiomyopathies and implicated in human congestive heart failure. Measures to enhance proteasome proteolytic function are currently lacking but would be beneficial in testing the pathogenic role of proteasome dysfunction and could have significant therapeutic potential. The association of proteasome activator 28 (PA28) with the 20S proteasome may play a role in antigen processing. It is unclear, however, whether the PA28 plays any important role outside of antigen presentation, although up-regulation of PA28 has been observed in certain types of cardiomyopathy. Here, we show that PA28 alpha overexpression (PA28 alpha OE) stabilized PA28 beta, increased 11S proteasomes, and enhanced the degradation of a previously validated proteasome surrogate substrate (GFPu) in cultured neonatal rat cardiomyocytes. PA28 alpha OE significantly attenuated H2O2-induced increases in the protein carbonyls and markedly suppressed apoptosis in cultured cardiomyocytes under basal conditions or when stressed by H2O2. We conclude that PA28 alpha OE is sufficient to up-regulate 11S proteasomes, enhance proteasome-mediated removal of misfolded and oxidized proteins, and protect against oxidative stress in cardiomyocytes, providing a highly sought means to increase proteasomal degradation of abnormal cellular proteins.-Li, J., Powell, S. R., Wang, X. Enhancement of proteasome function by PA28 alpha overexpression protects against oxidative stress. FASEB J. 25, 883-893 (2011). www.fasebj.org	[Li, Jie; Wang, Xuejun] Univ S Dakota, Sanford Sch Med, Div Basic Biomed Sci, Vermillion, SD 57069 USA; [Li, Jie; Wang, Xuejun] Univ S Dakota, Sanford Sch Med, Cardiovasc Res Inst, Vermillion, SD 57069 USA; [Powell, Saul R.] Feinstein Inst Med Res, Cardiac Metab Lab, Manhasset, NY USA	University of South Dakota; University of South Dakota; Northwell Health	Wang, XJ (corresponding author), Univ S Dakota, Sanford Sch Med, Div Basic Biomed Sci, 414 E Clark St,Lee Med Bldg, Vermillion, SD 57069 USA.	xuejun.wang@usd.edu	Wang, Xuejun/AAT-9490-2021; Wang, Xuejun/K-8874-2013	Wang, Xuejun/0000-0001-9267-1343; Wang, Xuejun/0000-0001-9267-1343; LI, JIE/0000-0003-3902-642X	U.S. National Institutes of Health [R01HL072166, R01HL085629, R01HL068936]; American Heart Association [0740025N]; University of South Dakota; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068936, R01HL085629, R01HL072166] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); University of South Dakota; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Huabo Su for stimulating discussion over this manuscript and Ms. Kathleen Horak for technical assistance in creating Ad-PA28 alpha and Ad-PA28 beta. X.W. is an established investigator of the American Heart Association. This work was supported, in part, by U.S. National Institutes of Health grants R01HL072166 and R01HL085629 (to X.W.) and R01HL068936 (to S.R.P. and X.W.) and American Heart Association grant 0740025N (to X.W.), as well as by the Physician Scientist Program of the University of South Dakota.	Bahrudin U, 2008, J MOL BIOL, V384, P896, DOI 10.1016/j.jmb.2008.09.070; Barton LF, 2004, J IMMUNOL, V172, P3948, DOI 10.4049/jimmunol.172.6.3948; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Cascio P, 2005, METHOD ENZYMOL, V398, P336, DOI 10.1016/S0076-6879(05)98028-2; Cascio P, 2002, EMBO J, V21, P2636, DOI 10.1093/emboj/21.11.2636; Chen JZ, 2009, CELL IMMUNOL, V254, P85, DOI 10.1016/j.cellimm.2008.09.001; Chen QH, 2005, CIRC RES, V97, P1018, DOI 10.1161/01.RES.0000189262.92896.0b; Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022; Divald A, 2010, CIRC RES, V106, P1829, DOI 10.1161/CIRCRESAHA.110.219485; Dong X, 2004, AM J PHYSIOL-HEART C, V287, pH1417, DOI 10.1152/ajpheart.01233.2003; Drews O, 2007, MOL CELL PROTEOMICS, V6, P2021, DOI 10.1074/mcp.M700187-MCP200; Ferrington DA, 2005, FASEB J, V19, P664, DOI 10.1096/fj.04-2578fje; Gilon T, 2000, MOL CELL BIOL, V20, P7214, DOI 10.1128/MCB.20.19.7214-7219.2000; Gomes AV, 2006, CIRC RES, V99, P362, DOI 10.1161/01.RES.0000237386.98506.f7; Gomes AV, 2009, MOL CELL PROTEOMICS, V8, P302, DOI 10.1074/mcp.M800058-MCP200; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Herrmann J, 2007, CIRC RES, V101, P865, DOI 10.1161/CIRCRESAHA.107.152959; Huang HB, 2010, CELL RES, V20, P1372, DOI 10.1038/cr.2010.123; Husom AD, 2004, ARCH BIOCHEM BIOPHYS, V421, P67, DOI 10.1016/j.abb.2003.10.010; Imai J, 2003, EMBO J, V22, P3557, DOI 10.1093/emboj/cdg349; Kloetzel PM, 1999, BIOL CHEM, V380, P293, DOI 10.1515/BC.1999.040; Kloss A, 2010, CARDIOVASC RES, V85, P367, DOI 10.1093/cvr/cvp217; Kumarapeli ARK, 2005, FASEB J, V19, P2051, DOI 10.1096/fj.05-3973fje; Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Liu J, 2006, FASEB J, V20, pA966; Liu JB, 2006, J MOL CELL CARDIOL, V40, P451, DOI 10.1016/j.yjmcc.2005.12.011; Lu HJ, 2008, MOL CELL PROTEOMICS, V7, P2073, DOI 10.1074/mcp.M800064-MCP200; Lu XH, 2001, ARCH BIOCHEM BIOPHYS, V387, P163, DOI 10.1006/abbi.2001.2270; Mearini G, 2008, BBA-MOL BASIS DIS, V1782, P749, DOI 10.1016/j.bbadis.2008.06.009; Minami Y, 2000, J BIOL CHEM, V275, P9055, DOI 10.1074/jbc.275.12.9055; Murata S, 1999, J BIOL CHEM, V274, P38211, DOI 10.1074/jbc.274.53.38211; Murata S, 2001, EMBO J, V20, P5898, DOI 10.1093/emboj/20.21.5898; Patterson C, 2007, CIRCULATION, V115, P1456, DOI 10.1161/CIRCULATIONAHA.106.649863; Powell SR, 2008, J MOL CELL CARDIOL, V44, P618, DOI 10.1016/j.yjmcc.2007.12.009; Powell SR, 2007, J MOL CELL CARDIOL, V42, P265, DOI 10.1016/j.yjmcc.2006.10.010; Powell SR, 2006, AM J PHYSIOL-HEART C, V291, pH1, DOI 10.1152/ajpheart.00062.2006; Predmore JM, 2010, CIRCULATION, V121, P997, DOI 10.1161/CIRCULATIONAHA.109.904557; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; Salomons FA, 2009, MOL CELL BIOL, V29, P1774, DOI 10.1128/MCB.01485-08; Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101; Sarikas A, 2005, CARDIOVASC RES, V66, P33, DOI 10.1016/j.cardiores.2005.01.004; Schwartzbauer G, 2001, J BIOL CHEM, V276, P35786, DOI 10.1074/jbc.M102479200; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; Stohwasser R, 2000, EUR J BIOCHEM, V267, P6221, DOI 10.1046/j.1432-1327.2000.01706.x; Su HB, 2010, CARDIOVASC RES, V85, P253, DOI 10.1093/cvr/cvp287; Su HB, 2009, INT J BIOCHEM CELL B, V41, P615, DOI 10.1016/j.biocel.2008.07.008; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Tang MX, 2010, CARDIOVASC RES, V88, P424, DOI 10.1093/cvr/cvq217; Tannous P, 2008, CIRCULATION, V117, P3070, DOI 10.1161/CIRCULATIONAHA.107.763870; Wang XJ, 2008, J MOL CELL CARDIOL, V45, P11, DOI 10.1016/j.yjmcc.2008.03.025; Wang XJ, 2006, CIRC RES, V99, P1315, DOI 10.1161/01.RES.0000252342.61447.a2; Weekes J, 2003, PROTEOMICS, V3, P208, DOI 10.1002/pmic.200390029; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Whittier JE, 2004, J BIOL CHEM, V279, P46135, DOI 10.1074/jbc.M406048200; Yamano T, 2002, J EXP MED, V196, P185, DOI 10.1084/jem.20011922; Young GW, 2008, TRENDS CARDIOVAS MED, V18, P93, DOI 10.1016/j.tcm.2008.01.004; Zhang ZG, 1999, BIOCHEMISTRY-US, V38, P5651, DOI 10.1021/bi990056+; Zong C, 2006, CIRC RES, V99, P372, DOI 10.1161/01.RES.0000237389.40000.02	60	107	107	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					883	893		10.1096/fj.10-160895	http://dx.doi.org/10.1096/fj.10-160895			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21098724	Green Published			2022-12-28	WOS:000287806200009
J	Chakravarthy, H; Ormsbee, BD; Mallanna, SK; Rizzino, A				Chakravarthy, Harini; Ormsbee, Briana D.; Mallanna, Sunil K.; Rizzino, Angie			Rapid activation of the bivalent gene Sox21 requires displacement of multiple layers of gene-silencing machinery	FASEB JOURNAL			English	Article						H3K4me3; H3K27me3; PRC; HDAC; Sox2	EMBRYONIC STEM-CELLS; POLYCOMB-REPRESSIVE COMPLEX-2; SOX2-OCT-3/4 TARGET GENES; RNA-POLYMERASE-II; GROUP PROTEIN EED; HISTONE H3; TRANSCRIPTIONAL REPRESSION; DEVELOPMENTAL REGULATORS; MOUSE DEVELOPMENT; CARCINOMA-CELLS	The rapid formation of numerous tissues during development is highly dependent on the swift activation of key developmental regulators. Recent studies indicate that many key regulatory genes are repressed in embryonic stem cells (ESCs), yet poised for rapid activation due to the presence of both activating (H3K4 trimethylation) and repressive (H3K27 trimethylation) histone modifications (bivalent genes). However, little is known about bivalent gene regulation. In this study, we investigated the regulation of the bivalent gene Sox21, which is activated rapidly when ESCs differentiate in response to increases in Sox2. Chromatin immunoprecipitation demonstrated that prior to differentiation, the Sox21 gene is bound by a complex array of repressive and activating transcriptional machinery. Upon activation, all identified repressive machinery and histone modifications associated with the gene are lost, but the activating modifications and transcriptional machinery are retained. Notably, these changes do not occur when ESCs differentiate in response to retinoic acid. Moreover, ESCs lacking a functional PRC2 complex fail to activate this gene, apparently due to its association with other repressive complexes. Together, these findings suggest that bivalent genes, such as Sox21, are silenced by a complex set of redundant repressive machinery, which exit rapidly in response to appropriate differentiation signals.-Chakravarthy, H., Ormsbee, B. D., Mallanna, S. K., Rizzino, A. Rapid activation of the bivalent gene Sox21 requires displacement of multiple layers of gene-silencing machinery. FASEB J. 25, 206-218 (2011). www.fasebj.org	[Chakravarthy, Harini; Ormsbee, Briana D.; Mallanna, Sunil K.; Rizzino, Angie] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Chakravarthy, Harini; Rizzino, Angie] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA.	arizzino@unmc.edu			National Institute of General Medicinal Sciences [GM 080751]; National Cancer Institute [CA009476, CA36727]; NATIONAL CANCER INSTITUTE [T32CA009476, P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080751] Funding Source: NIH RePORTER	National Institute of General Medicinal Sciences; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Terry Magnuson (University of North Carolina, Chapel Hill, NC, USA) for the gift of Eed-null ESCs, and Heather Rizzino for editorial assistance. This work was supported by a grant from the National Institute of General Medicinal Sciences (GM 080751). B.D.O. was supported in part by a Cancer Biology Training Grant from the National Cancer Institute (CA009476). Core facilities of the University of Nebraska Medical Center Eppley Cancer Center were supported in part by a Cancer Center Support Grant from the National Cancer Institute (CA36727).	Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Baltus GA, 2009, J BIOL CHEM, V284, P6998, DOI 10.1074/jbc.M807670200; Bernadt CT, 2005, GENE EXPRESSION, V12, P193, DOI 10.3727/000000005783992052; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Boer B, 2007, NUCLEIC ACIDS RES, V35, P1773, DOI 10.1093/nar/gkm059; Boer B, 2006, J CELL PHYSIOL, V208, P97, DOI 10.1002/jcp.20635; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chakravarthy H., 2010, TFE; Chakravarthy H, 2008, J CELL PHYSIOL, V216, P651, DOI 10.1002/jcp.21440; Chamberlain SJ, 2008, STEM CELLS, V26, P1496, DOI 10.1634/stemcells.2008-0102; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Duncan EM, 2008, CELL, V135, P284, DOI 10.1016/j.cell.2008.09.055; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Gontan C, 2009, J CELL BIOL, V185, P27, DOI 10.1083/jcb.200810106; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Kopp JL, 2008, STEM CELLS, V26, P903, DOI 10.1634/stemcells.2007-0951; Lee ER, 2007, STEM CELLS, V25, P2191, DOI 10.1634/stemcells.2007-0203; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736; Mallanna SK, 2010, STEM CELLS, V28, P1715, DOI 10.1002/stem.494; Mallanna SK, 2008, MOL REPROD DEV, V75, P1247, DOI 10.1002/mrd.20871; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Montgomery ND, 2007, J MOL BIOL, V374, P1145, DOI 10.1016/j.jmb.2007.10.040; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Nakatake Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008; Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06; Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Sandberg M, 2005, NAT NEUROSCI, V8, P995, DOI 10.1038/nn1493; Schoeftner S, 2006, EMBO J, V25, P3110, DOI 10.1038/sj.emboj.7601187; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Stock JK, 2007, NAT CELL BIOL, V9, P1428, DOI 10.1038/ncb1663; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; van den Boom V, 2007, J CELL BIOL, V178, P913, DOI 10.1083/jcb.200702058; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	48	19	19	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					206	218		10.1096/fj.10-166926	http://dx.doi.org/10.1096/fj.10-166926			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20876214	Green Published			2022-12-28	WOS:000285869500019
J	Lu, HY; Huang, DP; Saederup, N; Charo, IF; Ransohoff, RM; Zhou, L				Lu, Haiyan; Huang, Danping; Saederup, Noah; Charo, Israel F.; Ransohoff, Richard M.; Zhou, Lan			Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury	FASEB JOURNAL			English	Article						chemokine; chemokine receptor; inflammation; IGF-I; skeletal muscle regeneration	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CHEMOKINE RECEPTOR 2; MDX MICE; IGF-I; CELL ACTIVATION; BONE-MARROW; REGENERATION; EXPRESSION; MONOCYTES; INFLAMMATION	CC chemokine receptor 2 (CCR2) is essential to acute skeletal muscle injury repair. We studied the subpopulation of inflammatory cells recruited via CCR2 signaling and their cellular functions with respect to muscle regeneration. Mobilization of monocytes/macrophages (MOs/MPs), but not lymphocytes or neutrophils, was impaired from bone marrow to blood and from blood to injured muscle in Ccr2(-/-) mice. While the Ly-6C(+) but not the Ly-6C(-) subset of MOs/MPs was significantly reduced in blood, both subsets were drastically reduced in injured muscle of Ccr2(-/-) mice. Expression of insulin-like growth factor-1 (IGF-I) was markedly up-regulated in injured muscle of wild-type but not Ccr2(-/-) mice. IGF-I was strongly expressed by macrophages within injured muscle, more prominently by the Ly-6C(-) subset. A single injection of IGF-I, but not PBS, into injured muscle to replace IGF-I remarkably improved muscle regeneration in Ccr2(-/-) mice. CCR2 was not detected in myogenic cells or capillary endothelial cells in injured muscle to suggest its direct involvement in muscle regeneration or angiogenesis. We conclude that CCR2 is essential to acute skeletal muscle injury repair primarily by recruiting Ly-6C(+) MOs/MPs. Within injured muscle, these cells conduct phagocytosis, contribute to accumulation of intramuscular Ly-6C(-) macrophages, and produce a high level of IGF-I to promote muscle regeneration.-Lu, H., Huang, D., Saederupm, N., Charo, I. F., Ransohoff, R. M., Zhou, L. Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury. FASEB J. 25, 358-369 (2011). www.fasebj.org	[Lu, Haiyan; Huang, Danping; Ransohoff, Richard M.; Zhou, Lan] Cleveland Clin, Neuroinflammat Res Ctr, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; [Ransohoff, Richard M.; Zhou, Lan] Cleveland Clin, Neurol Inst, Dept Neurol, Cleveland, OH 44195 USA; [Saederup, Noah; Charo, Israel F.] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA; [Saederup, Noah; Charo, Israel F.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Zhou, L (corresponding author), Cleveland Clin, Neuroinflammat Res Ctr, Dept Neurosci, Lerner Res Inst, 9500 Euclid Ave,S90, Cleveland, OH 44195 USA.	zhoul2@ccf.org			U.S. National Institutes of Health [K08 NS049346, 91682, K24 51400]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS049346] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study is supported by U.S. National Institutes of Health grants K08 NS049346 (to L.Z.), MDA#91682 (to L.Z.), and K24 51400 (to R.M.R.). The authors thank Drs. Liping Liu and Georgiana Cheng and the Flow Cytometry Core of the Cleveland Clinic for superb technical support.	ALLEN RE, 1989, J CELL PHYSIOL, V138, P311, DOI 10.1002/jcp.1041380213; Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Bartoli C, 2001, ACTA NEUROPATHOL, V102, P385; BISCHOFF R, 1994, DEV DYNAM, V201, P41, DOI 10.1002/aja.1002010105; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Cantini M, 2002, NEUROL SCI, V23, P189, DOI 10.1007/s100720200060; Cardona AE, 2008, BLOOD, V112, P256, DOI 10.1182/blood-2007-10-118497; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Contreras-Shannon V, 2007, AM J PHYSIOL-CELL PH, V292, pC953, DOI 10.1152/ajpcell.00154.2006; Dumont N, 2010, AM J PATHOL, V176, P2228, DOI 10.2353/ajpath.2010.090884; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hayashi S, 2004, HISTOCHEM CELL BIOL, V122, P427, DOI 10.1007/s00418-004-0704-y; Heinemeier KM, 2009, J APPL PHYSIOL, V106, P178, DOI 10.1152/japplphysiol.91092.2008; Hill M, 2003, J PHYSIOL-LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832; Huang P, 2009, FASEB J, V23, P2539, DOI 10.1096/fj.09-129833; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Kurek JB, 1997, MUSCLE NERVE, V20, P815; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Layland J, 2005, FASEB J, V19, P1137, DOI 10.1096/fj.04-2519fje; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Menetrey J, 2000, J BONE JOINT SURG BR, V82B, P131, DOI 10.1302/0301-620X.82B1.8954; Miller KJ, 2000, AM J PHYSIOL-CELL PH, V278, pC174, DOI 10.1152/ajpcell.2000.278.1.C174; Musaro A, 2005, ARCH ITAL BIOL, V143, P243; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Ochoa O, 2007, AM J PHYSIOL-REG I, V293, pR651, DOI 10.1152/ajpregu.00069.2007; Pelosi L, 2007, FASEB J, V21, P1393, DOI 10.1096/fj.06-7690com; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Quinones MP, 2004, J CLIN INVEST, V113, P856, DOI 10.1172/JCI200420126; ROBERTSON TA, 1993, EXP CELL RES, V207, P321, DOI 10.1006/excr.1993.1199; Sacco A, 2005, J CELL BIOL, V171, P483, DOI 10.1083/jcb.200506123; Saederup N., 2010, PLOS ONE IN PRESS; Summan M, 2006, AM J PHYSIOL-REG I, V290, pR1488, DOI 10.1152/ajpregu.00465.2005; Sun DX, 2009, FASEB J, V23, P382, DOI 10.1096/fj.07-095901; Tang G, 2004, J VASC SURG, V40, P786, DOI 10.1016/j.jvs.2004.07.012; Tidball JG, 2007, J PHYSIOL-LONDON, V578, P327, DOI 10.1113/jphysiol.2006.118265; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Vetrone SA, 2009, J CLIN INVEST, V119, P1583, DOI 10.1172/JCI37662; Wagatsuma A, 2007, MOL CELL BIOCHEM, V298, P151, DOI 10.1007/s11010-006-9361-x; Xia MD, 2009, EXPERT OPIN THER PAT, V19, P295, DOI 10.1517/13543770902755129; Yahiaoui L, 2008, J PHYSIOL-LONDON, V586, P3991, DOI 10.1113/jphysiol.2008.152090; Zhou L, 2006, NEUROMUSCULAR DISORD, V16, P32, DOI 10.1016/j.nmd.2005.09.009; Zhou L, 2008, J NEUROL SCI, V264, P106, DOI 10.1016/j.jns.2007.08.029	52	186	191	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					358	369		10.1096/fj.10-171579	http://dx.doi.org/10.1096/fj.10-171579			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20889618	Green Published			2022-12-28	WOS:000285869500032
J	Koeberle, A; Shindou, H; Harayama, T; Shimizu, T				Koeberle, Andreas; Shindou, Hideo; Harayama, Takeshi; Shimizu, Takao			Role of lysophosphatidic acid acyltransferase 3 for the supply of highly polyunsaturated fatty acids in TM4 Sertoli cells	FASEB JOURNAL			English	Article						1-acylglycerol-3-phosphate-O-acyltransferase; phosphatidylcholine; phosphatidic acid; testis	RAT SERTOLI; LIPID-COMPOSITION; DOCOSAHEXAENOIC ACID; GERMINAL CELLS; METABOLISM; TESTIS; EXPRESSION; CLONING; PHARMACOKINETICS; BIOSYNTHESIS	Sertoli cells supply germ cells with nutrients, including highly polyunsaturated fatty acids (hPUFAs), which are essential for testicular function. We have previously reported high expression of lysophosphatidic acid acyltransferase (LPAAT)3 in mature mouse testis and suggested an arachidonoyl-transferase activity to LPA. To investigate the role of LPAAT3 in the storage and release of PUFAs, TM4 Sertoli cells were stably transfected with LPAAT3-small hairpin (sh) RNA. Arachidonoyl-, eicosapentaenoyl-, and docosapentaenoyl-containing phosphatidylcholine (PC) and linoleoyl-containing phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidylglycerol were significantly decreased as determined by liquid chromatography coupled to electrospray ionization mass spectrometry. Expression of murine LPAAT3 in Chinese hamster ovary (CHO)-K1 cells had essentially an opposite effect. The level of polyunsaturated PC correlated with cellular levels of free docosapentaenoic acid and eicosapentaenoic acid in TM4 and CHO-K1 cells, respectively. Activity assays using microsomal preparations as a source of LPAAT3 revealed an excessive PA synthesis from LPA acceptors for docosahexaenoyl-, arachidonoyl- and less pronounced for linoleoylCoA. Wepropose that the efficient incorporation of hPUFAs into PA-the precursor of several phospholipids, including PC-and the selective increase of the polyunsaturated PC pool in TM4 Sertoli cells might be required for the controlled release of hPUFAs and their supply to germ cells.-Koeberle, A., Shindou, H., Harayama, T., Shimizu, T. Role of lysophosphatidic acid acyltransferase 3 for the supply of highly polyunsaturated fatty acids in TM4 Sertoli cells. FASEB J. 24, 4929-4938 (2010). www.fasebj.org	[Shindou, Hideo] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Shindou, H (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan.	hshindou-tky@umin.ac.jp	Shimizu, Takao/AAV-7052-2021; Harayama, Takeshi/AAD-8852-2022; Koeberle, Andreas/ABB-2356-2020	Harayama, Takeshi/0000-0003-2255-4197; Koeberle, Andreas/0000-0001-6269-5088	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan; Japan Society for Promotion of Sciences; Center for NanoBio Integration at The University of Tokyo; Ministry of Health, Labour; Uehara Memorial Foundation; Cell Science Research Foundation; Japan Society for the Promotion of Science for Young Scientists; Takeda Science Foundation	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for Promotion of Sciences(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Center for NanoBio Integration at The University of Tokyo; Ministry of Health, Labour; Uehara Memorial Foundation(Uehara Memorial Foundation); Cell Science Research Foundation(Cell Science Research Foundation, Japan); Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF))	The authors thank Dr. J.-I. Miyazaki (Osaka University) for supplying the expression vector pCXN2. This work was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (T. S.) and a Global COE Program (The University of Tokyo) from the Japan Society for Promotion of Sciences (T. S.). T. S. and H. S. were supported by the Center for NanoBio Integration at The University of Tokyo. H. S. was supported by Health and Labour Sciences research grants (Research on Allergic Disease and Immunology) of the Ministry of Health, Labour; a Grant-in-Aid for Young Scientists (B) from the MEXT of Japan; and the Uehara Memorial Foundation and the Cell Science Research Foundation. T. H. was supported by research fellowships of the Japan Society for the Promotion of Science for Young Scientists. A. K. received a stipend from the Takeda Science Foundation.	BECKMAN JK, 1980, LIPIDS, V15, P389, DOI 10.1007/BF02534061; BECKMAN JK, 1979, LIPIDS, V14, P262, DOI 10.1007/BF02533912; BIERI JG, 1965, COMP BIOCHEM PHYSIOL, V15, P275, DOI 10.1016/0010-406X(65)90131-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CONIGLIO JG, 1975, BIOL REPROD, V12, P255, DOI 10.1095/biolreprod12.2.255; Connor WE, 1998, J LIPID RES, V39, P1404; DAVIS JT, 1966, BIOCHEM J, V98, P342, DOI 10.1042/bj0980342; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; FISHER DM, 1983, BIOCHIM BIOPHYS ACTA, V751, P27, DOI 10.1016/0005-2760(83)90253-9; GROGAN WM, 1982, LIPIDS, V17, P605, DOI 10.1007/BF02535366; Henneberry AL, 2000, J BIOL CHEM, V275, P29808, DOI 10.1074/jbc.M005786200; Huyghe S, 2006, ENDOCRINOLOGY, V147, P2228, DOI 10.1210/en.2005-1571; HUYNH S, 1991, COMP BIOCHEM PHYS B, V99, P265, DOI 10.1016/0305-0491(91)90039-G; Knudsen J, 2000, J NUTR, V130, p294S, DOI 10.1093/jn/130.2.294S; LACY D, 1962, BRIT MED BULL, V18, P205, DOI 10.1093/oxfordjournals.bmb.a069979; Lin DS, 2004, J LIPID RES, V45, P529, DOI 10.1194/jlr.M300374-JLR200; LYNCH KM, 1951, ENDOCRINOLOGY, V49, P8, DOI 10.1210/endo-49-1-8; MARSEN TA, 1992, PROSTAG LEUKOTR ESS, V46, P191, DOI 10.1016/0952-3278(92)90069-U; NISSEN HP, 1983, ANDROLOGIA, V15, P264; Ogiso H, 2008, ANAL BIOCHEM, V375, P124, DOI 10.1016/j.ab.2007.12.027; ORTH JM, 1988, ENDOCRINOLOGY, V122, P787, DOI 10.1210/endo-122-3-787; OULHAJ H, 1992, COMP BIOCHEM PHYS B, V102, P897, DOI 10.1016/0305-0491(92)90099-D; Petersen C, 2006, HORM RES, V66, P153, DOI 10.1159/000094142; Retterstol K, 2001, LIPIDS, V36, P601, DOI 10.1007/s11745-001-0763-z; Retterstol K, 2001, REPRODUCTION, V121, P881, DOI 10.1530/reprod/121.6.881; ROBERT J, 1977, BIOCHIMIE, V59, P417, DOI 10.1016/S0300-9084(77)80318-0; Roqueta-Rivera M, 2010, J LIPID RES, V51, P360, DOI 10.1194/jlr.M001180; Rusca A, 2009, EUR J CLIN PHARMACOL, V65, P503, DOI 10.1007/s00228-008-0605-4; Saether T, 2003, BIOL REPROD, V69, P117, DOI 10.1095/biolreprod.102.014035; Schmidt JA, 2009, J CELL BIOL, V186, P211, DOI 10.1083/jcb.200904147; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Shindou H, 2009, J BIOL CHEM, V284, P1, DOI 10.1074/jbc.R800046200; Stamps AC, 1997, BIOCHEM J, V326, P455, DOI 10.1042/bj3260455; Stoffel W, 2008, EMBO J, V27, P2281, DOI 10.1038/emboj.2008.156; Stroud CK, 2009, J LIPID RES, V50, P1870, DOI 10.1194/jlr.M900039-JLR200; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; Yuki K, 2009, J LIPID RES, V50, P860, DOI 10.1194/jlr.M800468-JLR200	38	30	30	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4929	4938		10.1096/fj.10-162818	http://dx.doi.org/10.1096/fj.10-162818			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20705908				2022-12-28	WOS:000284824400031
J	Lee, VHY; Lee, LTO; Chu, JYS; Lam, IPY; Siu, FKY; Vaudry, H; Chow, BKC				Lee, Vien H. Y.; Lee, Leo T. O.; Chu, Jessica Y. S.; Lam, Ian P. Y.; Siu, Francis K. Y.; Vaudry, Hubert; Chow, Billy K. C.			An indispensable role of secretin in mediating the osmoregulatory functions of angiotensin II	FASEB JOURNAL			English	Article						fluid homeostasis; secretin receptor-deficient mice; circumventricular organs; vasopressin	RECEPTOR SUBTYPES; LAMINA TERMINALIS; FOS EXPRESSION; VASOPRESSIN; MICE; WATER; THIRST; BRAIN; APPETITE; RELEASE	Fluid balance is critical to life and hence is tightly controlled in the body. Angiotensin II (ANGII), one of the most important components of this regulatory system, is recognized as a dipsogenic hormone that stimulates vasopressin (VP) expression and release. However, detailed mechanisms regarding how ANGII brings about these changes are not fully understood. In the present study, we show initially that the osmoregulatory functions of secretin (SCT) in the brain are similar to those of ANGII in mice and, more important, we discovered the role of SCT as the link between ANGII and its downstream effects. This was substantiated by the use of two knockout mice, SCTR-/- and SCT-/-, in which we show the absence of an intact SCT/secretin receptor (SCTR) axis resulted in an abolishment or much reduced ANGII osmoregulatory functions. By immunohistochemical staining and in situ hybridization, the proteins and transcripts of SCT and its receptor are found in the paraventricular nucleus (PVN) and lamina terminalis. We propose that SCT produced in the circumventricular organs is transported and released in the PVN to stimulate vasopressin expression and release. In summary, our findings identify SCT and SCTR as novel elements of the ANGII osmoregulatory pathway in maintaining fluid balance in the body.-Lee, V. H. Y., Lee, L. T. O., Chu, J. Y. S., Lam, I. P. Y., Siu, F. K. Y, Vaudry, H., Chow, B. K. C. An indispensable role of secretin in mediating the osmoregulatory functions of angiotensin II. FASEB J. 24, 5024-5032 (2010). www.fasebj.org	[Lee, Vien H. Y.; Lee, Leo T. O.; Chu, Jessica Y. S.; Lam, Ian P. Y.; Siu, Francis K. Y.; Chow, Billy K. C.] Univ Hong Kong, Sch Biol Sci, Pokfulam, Hong Kong, Peoples R China; [Vaudry, Hubert] Univ Rouen, Inst Natl Sante & Rech Med, Mont St Aignan, France	University of Hong Kong; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Chow, BKC (corresponding author), Univ Hong Kong, Sch Biol Sci, Pokfulam, Hong Kong, Peoples R China.	bkcc@hkusua.hku.hk	Lee, Leo T.O./AAB-1581-2021; Chow, Billy/D-3064-2009	Chow, Billy/0000-0003-3390-0307; /0000-0003-2167-6926	Hong Kong Research Grants Council [GRF7686/08, GRF738/09]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	The authors thank Prof. Cheah K. S. (University of Hong Kong; supported by HKU 02/02C) for the development of the SCT<SUP>-/-</SUP> mice, Prof. Chung S. K. (University of Hong Kong) for the development of SCTR<SUP>-/-</SUP> mice, and Dr. Neal Copeland (National Cancer Institute, Frederick, MD, USA) for providing the bacterial recombination cells and vectors. This study was supported by the Hong Kong Research Grants Council (GRF7686/08 to L.T.O.L. and GRF738/09 to B.K.C.C.).	Bolbecker AR, 2009, AM J PSYCHIAT, V166, P460, DOI 10.1176/appi.ajp.2008.08040597; Chen YF, 2003, BRAIN RES, V965, P35, DOI 10.1016/S0006-8993(02)04059-3; Cheng CYY, 2009, J MOL ENDOCRINOL, V43, P81, DOI 10.1677/JME-08-0123; Chu JYS, 2007, MOL CELL BIOL, V27, P2499, DOI 10.1128/MCB.01088-06; Chu JYS, 2009, P NATL ACAD SCI USA, V106, P15961, DOI 10.1073/pnas.0903695106; Crews EC, 2005, AM J PHYSIOL-REG I, V288, pR638, DOI 10.1152/ajpregu.00525.2004; DENTON DA, 1990, AM J PHYSIOL, V259, pR729, DOI 10.1152/ajpregu.1990.259.4.R729; Ferguson AV, 2001, EXP BIOL MED, V226, P85, DOI 10.1177/153537020122600205; Han L, 1996, BRAIN RES, V708, P45, DOI 10.1016/0006-8993(95)01326-1; HEALY DP, 1984, HYPERTENSION, V6, pI130, DOI 10.1161/01.HYP.6.2_Pt_2.I130; JOHNSON AD, 1993, FASEB J, V7, pA1055; Johnson AK, 1996, CLIN EXP PHARMACOL P, V23, P183, DOI 10.1111/j.1440-1681.1996.tb02594.x; Lauand F, 2007, NEUROSCIENCE, V147, P247, DOI 10.1016/j.neuroscience.2007.04.021; Lee SMY, 2005, NEUROSCIENCE, V134, P377, DOI 10.1016/j.neuroscience.2005.04.009; Li XC, 2009, KIDNEY INT, V76, P169, DOI 10.1038/ki.2009.134; LIND RW, 1984, PHYSIOL BEHAV, V32, P69; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lochard N, 2003, J BIOL CHEM, V278, P2184, DOI 10.1074/jbc.M209933200; MACGREGOR DP, 1995, BRAIN RES, V675, P231, DOI 10.1016/0006-8993(95)00076-3; MAHON JM, 1995, NEUROSCIENCE, V69, P199, DOI 10.1016/0306-4522(95)00238-E; McKinley MJ, 2008, AM J PHYSIOL-REG I, V294, pR1533, DOI 10.1152/ajpregu.00848.2007; McKinley MJ, 2004, J NEUROENDOCRINOL, V16, P340, DOI 10.1111/j.0953-8194.2004.01184.x; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Sitniewska EM, 2002, REGUL PEPTIDES, V105, P163, DOI 10.1016/S0167-0115(02)00018-6; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Wilson WL, 2005, BRAIN RES, V1060, P108, DOI 10.1016/j.brainres.2005.08.032; Yung WH, 2001, J NEUROSCI, V21, P7063, DOI 10.1523/JNEUROSCI.21-18-07063.2001	27	36	36	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5024	5032		10.1096/fj.10-165399	http://dx.doi.org/10.1096/fj.10-165399			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20739612	Green Published			2022-12-28	WOS:000284824400040
J	Cala, O; Pinaud, N; Simon, C; Fouquet, E; Laguerre, M; Dufourc, EJ; Pianet, I				Cala, Olivier; Pinaud, Noel; Simon, Cecile; Fouquet, Eric; Laguerre, Michel; Dufourc, Erick J.; Pianet, Isabelle			NMR and molecular modeling of wine tannins binding to saliva proteins: revisiting astringency from molecular and colloidal prospects	FASEB JOURNAL			English	Article						procyanidins; proline-rich-proteins; DOSY NMR; STD NMR; molecular dynamics; hydrophilic interactions; hydrophobic interactions	PROLINE-RICH PROTEIN; PROCYANIDIN DIMERS; CONDENSED TANNINS; DIFFUSION NMR; SPECTROSCOPY; PRECIPITATION; BITTERNESS; WATER; ACETYLCHOLINE; POLYPHENOLS	In organoleptic science, the association of tannins to saliva proteins leads to the poorly understood phenomenon of astringency. To decipher this interaction at molecular and colloidal levels, the binding of 4 procyanidin dimers (B1-4) and 1 trimer (C2) to a human saliva proline-rich peptide, IB7(14), was studied. Interactions have been characterized by measuring dissociation constants, sizes of complexes, number, and nature of binding sites using NMR (chemical shift variations, diffusion-ordered spectroscopy, and saturation transfer diffusion). The binding sites were identified using molecular mechanics, and the hydrophilic/hydrophobic nature of the interactions was resolved by calculating the molecular lipophilicity potential within the complexes. The following comprehensive scheme can be proposed: 1) below the tannin critical micelle concentration (CMC), interaction is specific, and the procyanidin anchorage always occurs on the same three IB7(14) sites. The tannin 3-dimensional structure plays a key role in the binding force and in the tannin's ability to act as a bidentate ligand: tannins adopting an extended conformation exhibit higher affinity toward protein and initiate the formation of a network. 2) Above the CMC, after the first specific hydrophilic interaction has taken place, a random hydrophobic stacking occurs between tannins and proteins. The whole process is discussed in the general frame of wine tannins eliciting astringency.-Cala, O., Pinaud, N., Simon, C., Fouquet, E., Laguerre, M., Dufourc, E. J., Pianet, I. NMR and molecular modeling of wine tannins binding to saliva proteins: revisiting astringency from molecular and colloidal prospects. FASEB J. 24, 4281-4290 (2010). www.fasebj.org	[Pinaud, Noel; Fouquet, Eric; Pianet, Isabelle] Univ Bordeaux, Inst Mol Sci, CESAMO, Talence, France; [Cala, Olivier; Simon, Cecile; Laguerre, Michel; Dufourc, Erick J.] Univ Bordeaux, Pessac, France	UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Pianet, I (corresponding author), Univ Bordeaux 1, Inst Mol Sci, UMR 5255, CNRS,CESAMO, 351 Cours Liberat, F-33405 Talence, France.	i.pianet@ism.u-bordeaux1.fr	Cala, Olivier/AAE-8065-2019; DUFOURC, Erick Joel/AAA-4992-2020	Cala, Olivier/0000-0003-3579-0973; DUFOURC, Erick Joel/0000-0002-8221-9326; Pinaud, Noel/0000-0001-7646-5312; FOUQUET, ERIC/0000-0002-2081-8155	Conseil Interprofessionnel de Bordeaux (CIVB, Bordeaux, France); Region Aquitaine; Centre National de la Recherche Scientifique (CNRS); Universite de Bordeaux; European Union	Conseil Interprofessionnel de Bordeaux (CIVB, Bordeaux, France); Region Aquitaine(Region Nouvelle-Aquitaine); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Universite de Bordeaux; European Union(European Commission)	This work was supported by the Conseil Interprofessionnel de Bordeaux (CIVB, Bordeaux, France), the Region Aquitaine, the Centre National de la Recherche Scientifique (CNRS), the Universite de Bordeaux, and the European Union, which helps the Conseil Regional d'Aquitaine.	ARNOLD RA, 1980, J AGR FOOD CHEM, V28, P675, DOI 10.1021/jf60229a026; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Baxter NJ, 1996, J CHEM SOC FARADAY T, V92, P231, DOI 10.1039/ft9969200231; Baxter NJ, 1997, BIOCHEMISTRY-US, V36, P5566, DOI 10.1021/bi9700328; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Boisselier E, 2008, CHEM-EUR J, V14, P5577, DOI 10.1002/chem.200701607; CARTEAU D, 2007, CR CHIM, V11, P493; Carteau D, 2007, LANGMUIR, V23, P3561, DOI 10.1021/la062339q; Carvalho E, 2006, J AGR FOOD CHEM, V54, P8936, DOI 10.1021/jf061835h; Charlton AJ, 2002, J AGR FOOD CHEM, V50, P1593, DOI 10.1021/jf010897z; Charlton AJ, 1996, FEBS LETT, V382, P289, DOI 10.1016/0014-5793(96)00186-X; Chung KT, 1998, TRENDS FOOD SCI TECH, V9, P168, DOI 10.1016/S0924-2244(98)00028-4; Cohen Y, 2005, ANGEW CHEM INT EDIT, V44, P520, DOI 10.1002/anie.200300637; Corder R, 2006, NATURE, V444, P566, DOI 10.1038/444566a; DARDEN TA, 1993, ENVIRON HEALTH PERSP, V101, P410, DOI 10.2307/3431897; Duluard S, 2008, J RAMAN SPECTROSC, V39, P627, DOI 10.1002/jrs.1896; Fabre S, 2010, CR CHIM, V13, P561, DOI 10.1016/j.crci.2009.11.007; Gawel R., 1998, AUST J GRAPE WINE R, V4, P74, DOI DOI 10.1111/J.1755-0238.1998.TB00137.X; HAGERMAN AE, 1981, J BIOL CHEM, V256, P4494; Hagerman AE, 1998, J AGR FOOD CHEM, V46, P2590, DOI 10.1021/jf971097k; JOSLYN M. A., 1964, ADVANCE FOOD RES, V13, P179; Kallithraka S, 2001, J SCI FOOD AGR, V81, P261, DOI 10.1002/1097-0010(20010115)81:2<261::AID-JSFA804>3.0.CO;2-T; Kawamoto H, 1996, PHYTOCHEMISTRY, V41, P1427, DOI 10.1016/0031-9422(95)00728-8; LEA AGH, 1978, J SCI FOOD AGR, V29, P478, DOI 10.1002/jsfa.2740290512; LeSolleu H, 1997, J LIPID MEDIAT CELL, V16, P75; LUCK G, 1994, PHYTOCHEMISTRY, V37, P357, DOI 10.1016/0031-9422(94)85061-5; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; MURRAY NJ, 1994, EUR J BIOCHEM, V219, P923, DOI 10.1111/j.1432-1033.1994.tb18574.x; Ornelas C, 2007, CHEM COMMUN, P5093, DOI 10.1039/b710391c; Pascal C, 2008, J AGR FOOD CHEM, V56, P6724, DOI 10.1021/jf800790d; Pascal C, 2007, J AGR FOOD CHEM, V55, P4895, DOI 10.1021/jf0704108; Peleg H, 1999, J SCI FOOD AGR, V79, P1123, DOI 10.1002/(SICI)1097-0010(199906)79:8<1123::AID-JSFA336>3.3.CO;2-4; Pianet I, 2008, LANGMUIR, V24, P11027, DOI 10.1021/la8015904; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Schwarz B, 2008, EUR FOOD RES TECHNOL, V227, P1693, DOI 10.1007/s00217-008-0895-x; Simon C, 2003, BIOCHEMISTRY-US, V42, P10385, DOI 10.1021/bi034354p; Simon C, 2003, J PEPT SCI, V9, P125, DOI 10.1002/psc.438; Singleton V. L., 1976, In 'Phenolic, sulfur, and nitrogen compounds in food flavors' [see FSTA (1977) 9 5T271]., P47; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; SWAIN T, 1962, COMP BIOCH, V3, P755; Tarascou I, 2006, EUR J ORG CHEM, V2006, P5367, DOI 10.1002/ejoc.200600668; Tarascou I, 2007, MAGN RESON CHEM, V45, P157, DOI 10.1002/mrc.1938; Tarascou I, 2006, MAGN RESON CHEM, V44, P868, DOI 10.1002/mrc.1867; VANGUNSTEREN WF, 1987, GROMOS 97 MANUAL; Vidal S, 2003, J SCI FOOD AGR, V83, P564, DOI 10.1002/jsfa.1394	46	87	89	1	96	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4281	4290		10.1096/fj.10-158741	http://dx.doi.org/10.1096/fj.10-158741			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20605948				2022-12-28	WOS:000283861100016
J	Schaedler, TA; van Veen, HW				Schaedler, Theresia A.; van Veen, Hendrik W.			A flexible cation binding site in the multidrug major facilitator superfamily transporter LmrP is associated with variable proton coupling	FASEB JOURNAL			English	Article						multidrug resistance; secondary-active transport; ligand binding; coupling stoichiometry	ESCHERICHIA-COLI; ABC TRANSPORTER; LACTOCOCCUS-LACTIS; LIGAND-BINDING; RESISTANCE; MECHANISM; RECOGNITION; PROTEINS; BACTERIA; EMRE	The multidrug major facilitator superfamily transporter LmrP from Lactococcus lactis mediates protonmotive-force dependent efflux of amphiphilic ligands from the cell. We compared the role of membrane-embedded carboxylates in transport and binding of divalent cationic propidium and monovalent cationic ethidium. D235N, E327Q, and D142N replacements each resulted in loss of electrogenicity in the propidium efflux reaction, pointing to electrogenic 3H(+)/propidium2(+) antiport. During ethidium efflux, single D142N and D235N replacements resulted in apparent loss of electrogenicity, whereas the E327Q substitution did not affect the energetics, consistent with electrogenic 2H(+)/ethidium(+) antiport. Different roles of carboxylates were also observed in fluorescence anisotropy-based ligand-binding assays. Whereas D235 and E327 were both involved in propidium binding, the loss of one of these carboxylates could be compensated for by the other in ethidium binding. The D142N replacement did not affect the binding of either ligand. These data point to the presence of a dedicated proton binding site containing D142, and a flexible proton/ligand binding site containing D235 and E327, the contributions to proton and ligand binding of which depend on the chemical structure of the bound ligand. Our findings provide the first evidence that multidrug transport by secondary-active transporters can be associated with variable ion coupling.-Schaedler, T. A., van Veen, H. W. A flexible cation binding site in the multidrug major facilitator superfamily transporter LmrP is associated with variable proton coupling. FASEB J. 24, 3653-3661(2010). www.fasebj.org	[Schaedler, Theresia A.; van Veen, Hendrik W.] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	van Veen, HW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	hwv20@cam.ac.uk	van Veen, Hendrik W./A-4162-2008	van Veen, Hendrik W./0000-0002-9658-8077; Schaedler, Theresia/0000-0002-7247-4091	Cambridge European Trusts; Pembroke College; Kurt Hahn Trust	Cambridge European Trusts; Pembroke College; Kurt Hahn Trust	The authors thank Prof. Peter Henderson (Institute of membrane and Systems Biology, University of Leeds, Leeds, UK) for the gift of GalP vesicles. Theresia Schaedler is a recipient of awards from the Cambridge European Trusts, Pembroke College, and Kurt Hahn Trust.	Adam Y, 2007, P NATL ACAD SCI USA, V104, P17989, DOI 10.1073/pnas.0704425104; Adler J, 2004, BIOCHEMISTRY-US, V43, P518, DOI 10.1021/bi035485t; Balakrishnan L, 2004, J BIOL CHEM, V279, P11273, DOI 10.1074/jbc.M308494200; Bapna A, 2007, J MOL MICROB BIOTECH, V12, P197, DOI 10.1159/000099641; Bolhuis H, 1996, J BIOL CHEM, V271, P24123, DOI 10.1074/jbc.271.39.24123; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Guan L, 2006, ANNU REV BIOPH BIOM, V35, P67, DOI 10.1146/annurev.biophys.35.040405.102005; Gutmann DAP, 2010, TRENDS BIOCHEM SCI, V35, P36, DOI 10.1016/j.tibs.2009.07.009; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; KASHKET ER, 1980, J BACTERIOL, V143, P128, DOI 10.1128/JB.143.1.128-134.1980; Law CJ, 2008, ANNU REV MICROBIOL, V62, P289, DOI 10.1146/annurev.micro.61.080706.093329; Lewinson O, 2003, P NATL ACAD SCI USA, V100, P1667, DOI 10.1073/pnas.0435544100; Mazurkiewicz P, 2004, BBA-BIOENERGETICS, V1658, P252, DOI 10.1016/j.bbabio.2004.06.004; McKeegan KS, 2003, TRENDS MICROBIOL, V11, P21, DOI 10.1016/S0966-842X(02)00010-0; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Nikaido H, 2009, ANNU REV BIOCHEM, V78, P119, DOI 10.1146/annurev.biochem.78.082907.145923; Novo D, 1999, CYTOMETRY, V35, P55, DOI 10.1002/(SICI)1097-0320(19990101)35:1<55::AID-CYTO8>3.0.CO;2-2; Peters KM, 2008, BIOCHEMISTRY-US, V47, P8122, DOI 10.1021/bi8008246; Piddock LJV, 2006, NAT REV MICROBIOL, V4, P629, DOI 10.1038/nrmicro1464; Putman M, 2001, MICROBIOL-SGM, V147, P2873, DOI 10.1099/00221287-147-10-2873; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Rotem D, 2004, J BIOL CHEM, V279, P48787, DOI 10.1074/jbc.M408187200; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; Schuldiner S, 2009, BBA-PROTEINS PROTEOM, V1794, P748, DOI 10.1016/j.bbapap.2008.12.018; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Shilling R, 2005, FASEB J, V19, P1698, DOI 10.1096/fj.04-3558fje; Sigal N, 2009, J BIOL CHEM, V284, P6966, DOI 10.1074/jbc.M808877200; Tamura N, 2003, CURR OPIN CHEM BIOL, V7, P570, DOI 10.1016/j.cbpa.2003.08.014; TENBRINK B, 1982, J BACTERIOL, V152, P682; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; Velamakanni S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006137; Venter H, 2003, NATURE, V426, P866, DOI 10.1038/nature02173; Venter H, 2008, BIOCHEM PHARMACOL, V75, P866, DOI 10.1016/j.bcp.2007.10.022; Ward A, 2000, PRACT APPROACH SER, P141; Woebking B, 2008, BIOCHEMISTRY-US, V47, P10904, DOI 10.1021/bi800778d; Wohlfahrt G, 2003, BIOCHEMISTRY-US, V42, P10095, DOI 10.1021/bi034954o	37	35	36	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3653	3661		10.1096/fj.10-156927	http://dx.doi.org/10.1096/fj.10-156927			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20472749				2022-12-28	WOS:000285005900006
J	Gautier, T; Paul, C; Deckert, V; Desrumaux, C; Klein, A; Labbe, J; Le Guern, N; Athias, A; Monier, S; Hammann, A; Bettaieb, A; Jeannin, JF; Lagrost, L				Gautier, Thomas; Paul, Catherine; Deckert, Valerie; Desrumaux, Catherine; Klein, Alexis; Labbe, Jerome; Le Guern, Naig; Athias, Anne; Monier, Serge; Hammann, Arlette; Bettaieb, Ali; Jeannin, Jean-Francois; Lagrost, Laurent			Innate immune response triggered by triacyl lipid A is dependent on phospholipid transfer protein (PLTP) gene expression	FASEB JOURNAL			English	Article						lipopolysaccharide; inflammation; lipoprotein; lipid transfer protein; cancer	LIPOPOLYSACCHARIDE-BINDING PROTEIN; CELL-BOUND LPS; HIGH-DENSITY; BACTERIAL LIPOPOLYSACCHARIDE; MACROPHAGE ACTIVATION; AGGREGATION BEHAVIOR; PLASMA-LIPOPROTEINS; BIOLOGICAL-ACTIVITY; COLON-CANCER; ENDOTOXIN	Hexaacyl lipopolysaccharide (LPS) aggregates in aqueous media, but its partially deacylated lipid A moiety forms monomers with weaker toxicity. Because plasma phospholipid transfer protein (PLTP) transfers hexaacyl LPS, its impact on metabolism and biological activity of triacyl lipid A in mice was addressed. Triacyl lipid A bound readily to plasma high-density lipoproteins (HDLs) when active PLTP was expressed [HDL-associated lipid A after 4.5 h: 59.1 +/- 16.0% of total in wild-type (WT) vs. 32.5 +/- 10.3% in PLTP-deficient mice, P<0.05]. In the opposite to hexaacyl LPS, plasma residence time of lipid A was extended by PLTP, and proinflammatory cytokines were produced in higher amounts in WT than PLTP-/- mice (remaining lipid A after 8 h: 53 +/- 12 vs. 35 +/- 7%, and IL6 concentration after 4.5 h: 45.5 +/- 5.9 vs. 14.6 +/- 7.8 ng/ml, respectively; P<0.05 in all cases). After 1 wk, onset of B16-induced melanoma was observed in only 30% of lipid A-treated WT mice, whereas >80% of the untreated WT, untreated PLTP-deficient, or lipid A-treated PLTP-deficient animals bore tumors (P<0.05 in all cases). It is concluded that PLTP is essential in mediating the association of triacyl lipid A with lipoproteins, leading to extension of its residence time and to magnification of its proinflammatory and anticancer properties.-Gautier, T., Paul, C., Deckert, V., Desrumaux, C., Klein, A., Labbe, J., Le Guern, N., Athias, A., Monier, S., Hammann, A., Bettaieb, A., Jeannin, J.-F., Lagrost, L. Innate immune response triggered by triacyl lipid A is dependent on phospholipid transfer protein (PLTP) gene expression. FASEB J. 24, 3544-3554 (2010). www.fasebj.org	[Lagrost, Laurent] Univ Bourgogne, Fac Med, Ctr Rech, INSERM,UMR866, F-21079 Dijon, France; [Paul, Catherine; Labbe, Jerome; Bettaieb, Ali; Jeannin, Jean-Francois] EPHE, Lab Immunol & Immunotherapie Canc, Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Bourgogne	Lagrost, L (corresponding author), Univ Bourgogne, Fac Med, Ctr Rech, INSERM,UMR866, 7 Blvd Jeanne dArc,BP87900, F-21079 Dijon, France.	laurent.lagrost@u-bourgogne.fr	Paul, Catherine/F-8376-2019; Desrumaux, Catherine/O-1925-2018; Gautier, Thomas/Q-5371-2018	Gautier, Thomas/0000-0003-1119-7382; DECKERT, Valerie/0000-0001-5728-1710; Paul, Catherine/0000-0002-7657-5535; Bettaieb, Ali/0000-0002-6018-9592	Universite de Bourgogne; Conseil Regional de Bourgogne; INSERM (Institut National de la Sante et de la Recherche Medicale); ANR (Agence Nationale de la Recherche); Fondation pour la Recherche Medicale (FRM)	Universite de Bourgogne; Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); INSERM (Institut National de la Sante et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); ANR (Agence Nationale de la Recherche)(French National Research Agency (ANR)); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	The authors thank Philip Bastable for manuscript editing. This work was supported by grants from the Universite de Bourgogne, the Conseil Regional de Bourgogne, INSERM (Institut National de la Sante et de la Recherche Medicale), the ANR (Agence Nationale de la Recherche), and the Fondation pour la Recherche Medicale (FRM).	Bergstrand A, 2006, COLLOID SURFACE B, V53, P9, DOI 10.1016/j.colsurfb.2006.06.007; Brandenburg K, 2002, EUR J BIOCHEM, V269, P5972, DOI 10.1046/j.1432-1033.2002.03333.x; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; Brandenburg K, 2000, EUR J BIOCHEM, V267, P3370, DOI 10.1046/j.1432-1327.2000.01370.x; BUCHWALD H, 1992, LANCET, V339, P1154, DOI 10.1016/0140-6736(92)90744-N; Buchau AS, 2010, J IMMUNOL, V184, P369, DOI 10.4049/jimmunol.0902110; Cai L, 2008, J CLIN INVEST, V118, P364, DOI 10.1172/JCI31539; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Cockerill GW, 2001, CIRCULATION, V103, P108; D'Agostini C, 2005, INT IMMUNOPHARMACOL, V5, P1205, DOI 10.1016/j.intimp.2005.02.013; Garay RP, 2007, EUR J PHARMACOL, V563, P1, DOI 10.1016/j.ejphar.2007.02.018; Gautier T, 2008, J BIOL CHEM, V283, P18702, DOI 10.1074/jbc.M802802200; Guyard-Dangremont V, 1998, COMP BIOCHEM PHYS B, V120, P517, DOI 10.1016/S0305-0491(98)10038-X; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; Hyka N, 2001, BLOOD, V97, P2381, DOI 10.1182/blood.V97.8.2381; JEANNIN JF, 1991, GASTROENTEROLOGY, V101, P726, DOI 10.1016/0016-5085(91)90532-P; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Kitchens RL, 1999, J BIOL CHEM, V274, P34116, DOI 10.1074/jbc.274.48.34116; Kitchens RL, 2001, J CLIN INVEST, V108, P485, DOI 10.1172/JCI200113139; Klimp AH, 2002, CRIT REV ONCOL HEMAT, V44, P143, DOI 10.1016/S1040-8428(01)00203-7; Koch PJ, 1999, J COLLOID INTERF SCI, V213, P557, DOI 10.1006/jcis.1999.6137; Lakomy D, 2009, ARTERIOSCL THROM VAS, V29, P1923, DOI 10.1161/ATVBAHA.109.193201; Levels JHM, 2005, INFECT IMMUN, V73, P2321, DOI 10.1128/IAI.73.4.2321-2326.2005; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; NISHIJIMA M, 1985, P NATL ACAD SCI USA, V82, P282, DOI 10.1073/pnas.82.2.282; OLSSON NO, 1982, ANN INST PASTEUR IMM, VD133, P245; Onier N, 1999, CLIN EXP METASTAS, V17, P299, DOI 10.1023/A:1006663017149; Salmon AHJ, 2009, CURR OPIN NEPHROL HY, V18, P197, DOI 10.1097/MNH.0b013e328329f837; Sasaki H, 2008, BIOPHYS J, V95, P986, DOI 10.1529/biophysj.108.129197; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; SHNYRA A, 1993, INFECT IMMUN, V61, P5351, DOI 10.1128/IAI.61.12.5351-5360.1993; Sprong T, 2004, J LIPID RES, V45, P742, DOI 10.1194/jlr.M300453-JLR200; Szponar B, 2003, CLIN CHEM, V49, P1149, DOI 10.1373/49.7.1149; Thompson PA, 2003, J BIOL CHEM, V278, P28367, DOI 10.1074/jbc.M302921200; Tzotzas T, 2009, OBES REV, V10, P403, DOI 10.1111/j.1467-789X.2009.00586.x; ULEVITCH RJ, 1981, J CLIN INVEST, V67, P827, DOI 10.1172/JCI110100; Van Lenten BJ, 2001, CIRCULATION, V103, P2283; VANLENTEN BJ, 1986, P NATL ACAD SCI USA, V83, P2704; Vesy CJ, 2000, INFECT IMMUN, V68, P2410, DOI 10.1128/IAI.68.5.2410-2417.2000; Vikstedt R, 2007, ARTERIOSCL THROM VAS, V27, P578, DOI 10.1161/01.ATV.0000254815.49414.be; Vreugdenhil ACE, 2001, J CLIN INVEST, V107, P225, DOI 10.1172/JCI10832; Wendel M, 2007, INTENS CARE MED, V33, P25, DOI 10.1007/s00134-006-0433-x	43	9	9	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3544	3554		10.1096/fj.09-152876	http://dx.doi.org/10.1096/fj.09-152876			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20418497				2022-12-28	WOS:000281446400041
J	Besaratinia, A; Pfeifer, GP				Besaratinia, Ahmad; Pfeifer, Gerd P.			Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing	FASEB JOURNAL			English	Review						cancer; etiology; mutation; tumor suppressor gene	HUMAN CANCER HAZARD; ARISTOLOCHIC ACID; DNA-DAMAGE; TUMOR-SUPPRESSOR; LUNG-CANCER; SKIN-CANCER; POLLUTANT 3-NITROBENZANTHRONE; HEPATOCELLULAR-CARCINOMA; MOLECULAR EPIDEMIOLOGY; MUTAGENIC SPECIFICITY	Tumor-driving mutations in the TP53 gene occur frequently in human cancers. These inactivating mutations arise predominantly from a single-point mutation in the DNA-binding domain of this tumor suppressor gene (i.e., exons 4-9). The human p53 knock-in (Hupki) mouse model was constructed using gene-targeting technology to create a mouse strain that harbors human wild-type TP53 DNA sequences in both copies of the mouse TP53 gene. Replacement of exons 4-9 of the endogenous mouse TP53 alleles in the Hupki mouse with the homologous normal human TP53 gene sequences has offered a humanized replica of the TP53 gene in a murine genetic environment. The Hupki mouse model system has proven to be an invaluable research tool for studying the underlying mechanisms of human TP53 mutagenesis. The utility of the Hupki mouse model system for exploring carcinogen-induced TP53 mutagenesis has been demonstrated in both in vivo animal experiments and in vitro cell culture experiments. Here, we highlight applications of the Hupki mouse model system for investigating mutagenesis induced by a variety of environmental carcinogens, including sunlight ultraviolet radiation, benzo[a] pyrene (a tobacco smoke-derived carcinogen), 3-nitrobenzanthrone (an urban air pollutant), aristolochic acid (a component of Chinese herbal medicine), and aflatoxin B1 (a food contaminant). We summarize the salient findings of the respective studies and discuss their relevance to human cancer etiology.-Besaratinia, A., Pfeifer, G. P. Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. FASEB J. 24, 2612-2619 (2010). www.fasebj.org	[Besaratinia, Ahmad; Pfeifer, Gerd P.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Besaratinia, A (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	ania@coh.org		Besaratinia, Ahmad/0000-0001-7231-228X	University of California [18KT-0040]; National Cancer Institute [R01CA084469]; NATIONAL CANCER INSTITUTE [R01CA084469] Funding Source: NIH RePORTER	University of California(University of California System); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the University of California Tobacco Related Disease Research Program (18KT-0040 to A.B.) and the National Cancer Institute (R01CA084469 to G.P.P.).	Albertini RJ, 2001, MUTAT RES-REV MUTAT, V489, P1, DOI 10.1016/S1383-5742(01)00064-3; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Arlt VM, 2005, MUTAGENESIS, V20, P399, DOI 10.1093/mutage/gei057; Arlt VM, 2004, ENVIRON MOL MUTAGEN, V43, P186, DOI 10.1002/em.20014; Arlt VM, 2002, MUTAGENESIS, V17, P265, DOI 10.1093/mutage/17.4.265; Besaratinia A, 2008, HUM MUTAT, V29, P983, DOI 10.1002/humu.20802; Besaratinia A, 2008, LANCET ONCOL, V9, P657, DOI 10.1016/S1470-2045(08)70172-4; Besaratinia A, 2006, CARCINOGENESIS, V27, P1526, DOI 10.1093/carcin/bgi311; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Carbone Michele, 2004, Cancer Res, V64, P5518, DOI 10.1158/0008-5472.CAN-04-0255; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; Feldmeyer N, 2006, MUTAT RES-GEN TOX EN, V608, P163, DOI 10.1016/j.mrgentox.2006.02.017; Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57; Fronza G, 2000, MUTAT RES-REV MUTAT, V462, P293, DOI 10.1016/S1383-5742(00)00011-9; GEE P, 1994, P NATL ACAD SCI USA, V91, P11606, DOI 10.1073/pnas.91.24.11606; GILMAN P, 2002, EPA600890057F NAT CT; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grollman AP, 2007, P NATL ACAD SCI USA, V104, P12129, DOI 10.1073/pnas.0701248104; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hashimoto AH, 2007, ENVIRON MOL MUTAGEN, V48, P682, DOI 10.1002/em.20335; Hergenhahn M, 2004, CELL CYCLE, V3, P738; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Hussain SP, 2007, ONCOGENE, V26, P2166, DOI 10.1038/sj.onc.1210279; Hussain S P, 2000, Ann N Y Acad Sci, V919, P79; Hussain SP, 1998, CANCER RES, V58, P4023; Jaworski M, 2005, CARCINOGENESIS, V26, P1829, DOI 10.1093/carcin/bgi142; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kohara A, 2002, MUTAT RES-GEN TOX EN, V515, P63, DOI 10.1016/S1383-5718(01)00350-3; Lambert LB, 2005, MUTAT RES-REV MUTAT, V590, P1, DOI 10.1016/j.mrrev.2005.04.002; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Liu ZP, 2004, P NATL ACAD SCI USA, V101, P2963, DOI 10.1073/pnas.0308607101; Lord GM, 2004, AM J KIDNEY DIS, V43, DOI 10.1053/j.ajkd.2003.11.024; Lord GM, 2001, LANCET, V358, P1515, DOI 10.1016/S0140-6736(01)06576-X; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Luo JL, 2001, CANCER RES, V61, P8158; Mardis ER, 2009, HUM MOL GENET, V18, pR163, DOI 10.1093/hmg/ddp396; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Morozova O, 2008, GENOMICS, V92, P255, DOI 10.1016/j.ygeno.2008.07.001; Mortelmans K, 2000, MUTAT RES-FUND MOL M, V455, P29, DOI 10.1016/S0027-5107(00)00064-6; Nedelko T, 2009, INT J CANCER, V124, P987, DOI 10.1002/ijc.24006; Nishida H, 2008, MUTAT RES-GEN TOX EN, V654, P82, DOI 10.1016/j.mrgentox.2008.05.004; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier Magali, 2004, IARC Sci Publ, P247; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; PFAU W, 1990, CARCINOGENESIS, V11, P313, DOI 10.1093/carcin/11.2.313; Pfeifer GP, 2009, HUM GENET, V125, P493, DOI 10.1007/s00439-009-0657-2; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Reinbold M, 2008, ONCOGENE, V27, P2788, DOI 10.1038/sj.onc.1210932; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smardova J, 2005, DIFFERENTIATION, V73, P261, DOI 10.1111/j.1432-0436.2005.00028.x; Thilly WG, 2003, NAT GENET, V34, P255, DOI 10.1038/ng1205; Tong WM, 2006, INT J CANCER, V119, P745, DOI 10.1002/ijc.21890; Toyooka S, 2003, HUM MUTAT, V21, P229, DOI 10.1002/humu.10177; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; vom Brocke J, 2006, CARCINOGENESIS, V27, P2141, DOI 10.1093/carcin/bg1101; vom Brocke J, 2009, MUTAGENESIS, V24, P17, DOI 10.1093/mutage/gen049; Whibley C, 2010, J BIOL CHEM, V285, P11326, DOI 10.1074/jbc.M109.064444; Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	78	26	26	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2612	2619		10.1096/fj.10-157263	http://dx.doi.org/10.1096/fj.10-157263			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371617	Green Submitted, Green Published			2022-12-28	WOS:000285005400003
J	Shi, H; Boadu, E; Mercan, F; Le, AM; Flach, RJR; Zhang, L; Tyner, KJ; Olwin, BB; Bennett, AM				Shi, Hao; Boadu, Emmanuel; Mercan, Fatih; Le, Annie M.; Flach, Rachel J. Roth; Zhang, Lei; Tyner, Kristina J.; Olwin, Bradley B.; Bennett, Anton M.			MAP kinase phosphatase-1 deficiency impairs skeletal muscle regeneration and exacerbates muscular dystrophy	FASEB JOURNAL			English	Article						myogenesis; muscle damage; MAPK; protein tyrosine phosphatase; muscle stem cells	INNATE IMMUNE-RESPONSES; DISTINCT SIGNALING PATHWAYS; FIBROBLAST-GROWTH-FACTOR; SATELLITE CELLS; MYOBLAST PROLIFERATION; DIFFERENTIATION; MYOGENESIS; MICE; P38; MKP-1	In skeletal muscle, the mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) is a critical negative regulator of the MAPKs. Since the MAPKs have been reported to be both positive and negative for myogenesis, the physiological role of MKP-1 in skeletal muscle repair and regeneration has remained unclear. Here, we show that MKP-1 plays an essential role in adult regenerative myogenesis. In a cardiotoxin-induced muscle injury model, lack of MKP-1 impaired muscle regeneration. In mdx mice, MKP-1 deficiency reduced body weight, muscle mass, and muscle fiber cross-sectional area. In addition, MKP-1-deficient muscles exhibit exacerbated myopathy accompanied by increased inflammation. Lack of MKP-1 compromised myoblast proliferation and induced precocious differentiation, phenotypes that were rescued by pharmacological inhibition of p38 alpha/beta MAPK. MKP-1 coordinates both myoblast proliferation and differentiation. Mechanistically, MyoD bound to the MKP-1 promoter and activated MKP-1 expression in proliferating myoblasts. Later, during myogenesis, MyoD uncoupled from the MKP-1 promoter leading to the down-regulation of MKP-1 and facilitation of promyogenic p38 alpha/beta MAPK signaling. Hence, MKP-1 plays a critical role in muscle stem cells and in the immune response to coordinate muscle repair and regeneration.-Shi, H., Boadu, E., Mercan, F., Le, A. M., Roth Flach, R. J., Zhang, L., Tyner, K. J., Olwin, B. B., Bennett, A. M. MAP kinase phosphatase-1 deficiency impairs skeletal muscle regeneration and exacerbates muscular dystrophy. FASEB J. 24, 2985-2997 (2010). www.fasebj.org	[Shi, Hao; Boadu, Emmanuel; Mercan, Fatih; Le, Annie M.; Flach, Rachel J. Roth; Zhang, Lei; Bennett, Anton M.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; [Tyner, Kristina J.; Olwin, Bradley B.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Yale University; University of Colorado System; University of Colorado Boulder	Bennett, AM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, SHM B226D,333 Cedar St, New Haven, CT 06520 USA.	anton.bennett@yale.edu	Olwin, Bradley B/A-1333-2014	Bennett, Anton/0000-0001-5187-7599	National Institutes of Health [AR46504, AR039467]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039467, R01AR046504, R01AR039467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK057751] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grants AR46504 to A.M.B. and AR039467 to B.B.O.	Amalfitano A, 1996, MUSCLE NERVE, V19, P1549, DOI 10.1002/(SICI)1097-4598(199612)19:12<1549::AID-MUS4>3.0.CO;2-A; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Boutros T, 2008, PHARMACOL REV, V60, P261, DOI 10.1124/pr.107.00106; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chi H, 2007, J ORGAN DYSFUNCT, V3, P72; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; CLARKE MSF, 1993, J CELL SCI, V106, P121; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davies KE, 2006, NAT REV MOL CELL BIO, V7, P762, DOI 10.1038/nrm2024; Fornaro M, 2006, J CELL BIOL, V175, P87, DOI 10.1083/jcb.200602029; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Hammer M, 2006, J EXP MED, V203, P15, DOI 10.1084/jem.20051753; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Jones NC, 2005, J CELL BIOL, V169, P105, DOI 10.1083/jcb.200408066; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Khurana A, 2004, J MUSCLE RES CELL M, V25, P645, DOI 10.1007/s10974-004-7099-1; Kondoh K, 2007, J BIOL CHEM, V282, P3058, DOI 10.1074/jbc.M607630200; KWAK SP, 1994, J BIOL CHEM, V269, P3569; Laird DJ, 2008, CELL, V132, P612, DOI 10.1016/j.cell.2008.01.041; Meriane M, 2002, BIOL CELL, V94, P535, DOI 10.1016/S0248-4900(02)00023-0; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Perdiguero E, 2007, EMBO J, V26, P1245, DOI 10.1038/sj.emboj.7601587; Roth RJ, 2009, J CLIN INVEST, V119, P3817, DOI 10.1172/JCI39054; Ruiz-Bonilla V, 2008, CELL CYCLE, V7, P2208, DOI 10.4161/cc.7.14.6273; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Shi H, 2008, FASEB J, V22, P2990, DOI 10.1096/fj.07-097600; Shi H, 2009, AM J PHYSIOL-CELL PH, V296, pC1040, DOI 10.1152/ajpcell.00475.2008; Tatsumi R, 2002, MOL BIOL CELL, V13, P2909, DOI 10.1091/mbc.E02-01-0062; Tidball JG, 2005, CURR OPIN RHEUMATOL, V17, P707, DOI 10.1097/01.bor.0000179948.65895.1a; Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Wu JJ, 2006, CELL METAB, V4, P61, DOI 10.1016/j.cmet.2006.05.010; Wu JJ, 2005, J BIOL CHEM, V280, P16461, DOI 10.1074/jbc.M501762200; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794	41	38	39	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2985	2997		10.1096/fj.09-150045	http://dx.doi.org/10.1096/fj.09-150045			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371627	Green Published			2022-12-28	WOS:000285005400037
J	Hatzirodos, N; Bayne, RA; Irving-Rodgers, HF; Hummitzsch, K; Sabatier, L; Lee, S; Bonner, W; Gibson, MA; Rainey, WE; Carr, BR; Mason, HD; Reinhardt, DP; Anderson, RA; Rodgers, RJ				Hatzirodos, Nicholas; Bayne, Rosemary A.; Irving-Rodgers, Helen F.; Hummitzsch, Katja; Sabatier, Laetitia; Lee, Sam; Bonner, Wendy; Gibson, Mark A.; Rainey, William E.; Carr, Bruce R.; Mason, Helen D.; Reinhardt, Dieter P.; Anderson, Richard A.; Rodgers, Raymond J.			Linkage of regulators of TGF-beta activity in the fetal ovary to polycystic ovary syndrome	FASEB JOURNAL			English	Article						latent transforming growth factor-beta binding protein; fibrillin	TRANSFORMING-GROWTH-FACTOR; EXTRACELLULAR-MATRIX; MESSENGER-RNA; INSULIN-RESISTANCE; GENE-EXPRESSION; SEX STEROIDS; THECA CELLS; PROTEIN; FIBRILLIN-3; WOMEN	Although not often discussed, the ovaries of women with polycystic ovary syndrome (PCOS) show all the hallmarks of increased TGF-beta activity, with increased amounts of fibrous tissue and collagen in the ovarian capsule or tunica albuginea and ovarian stroma. Recent studies suggest that PCOS could have fetal origins. Genetic studies of PCOS have also found linkage with a microsatellite located in intron 55 of the extracellular matrix protein fibrillin 3. Fibrillins regulate TGF-beta bioactivity in tissues by binding latent TGF-beta binding proteins. We therefore examined expression of fibrillins 1-3, latent TGF-beta binding proteins 1-4, and TGF-beta 1-3 in bovine and human fetal ovaries at different stages of gestation and in adult ovaries. We also immunolocalized fibrillins 1 and 3. The results indicate that TGF-beta pathways operate during ovarian fetal development, but most important, we show fibrillin 3 is present in the stromal compartments of fetal ovaries and is highly expressed at a critical stage early in developing human and bovine fetal ovaries when stroma is expanding and follicles are forming. These changes in expression of fibrillin 3 in the fetal ovary could lead to a predisposition to develop PCOS in later life.-Hatzirodos, N., Bayne, R. A., Irving-Rodgers, H. F., Hummitzsch, K., Sabatier, L., Lee, S., Bonner, W., Gibson, M. A., Rainey, W. E., Carr, B. R., Mason, H. D., Reinhardt, D. P., Anderson, R. A., Rodgers, R. J. Linkage of regulators of TGF-beta activity in the fetal ovary to polycystic ovary syndrome. FASEB J. 25, 2256-2265 (2011). www.fasebj.org	[Hatzirodos, Nicholas; Irving-Rodgers, Helen F.; Hummitzsch, Katja; Lee, Sam; Bonner, Wendy; Rodgers, Raymond J.] Univ Adelaide, Robinson Inst, Discipline Obstet & Gynaecol, Res Ctr Reprod Hlth, Adelaide, SA 5005, Australia; [Gibson, Mark A.] Univ Adelaide, Sch Med Sci, Discipline Pathol, Adelaide, SA 5005, Australia; [Bayne, Rosemary A.] Univ Edinburgh, Ctr Reprod Biol, Med Res Council Human Reprod Sci Unit, Edinburgh EH3 9EW, Midlothian, Scotland; [Anderson, Richard A.] Univ Edinburgh, Ctr Reprod Biol, Div Reprod & Dev Sci, Edinburgh EH3 9EW, Midlothian, Scotland; [Sabatier, Laetitia] McGill Univ, Fac Med, Dept Anat & Cell Biol, Montreal, PQ, Canada; [Reinhardt, Dieter P.] McGill Univ, Fac Dent, Montreal, PQ, Canada; [Rainey, William E.] Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA; [Carr, Bruce R.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Dallas, TX 75390 USA; [Mason, Helen D.] St Georges Univ London, Div Basic Med Sci, London, England	Robinson Research Institute; University of Adelaide; University of Adelaide; University of Edinburgh; University of Edinburgh; McGill University; McGill University; University System of Georgia; Augusta University; University of Texas System; University of Texas Southwestern Medical Center Dallas; St Georges University London	Rodgers, RJ (corresponding author), Univ Adelaide, Robinson Inst, Discipline Obstet & Gynaecol, Res Ctr Reprod Hlth, Adelaide, SA 5005, Australia.	ray.rodgers@adelaide.edu.au	Rodgers, Raymond J/C-3476-2009; Reinhardt, Dieter P/A-3102-2008; Hummitzsch, Katja/K-6940-2013	Reinhardt, Dieter P/0000-0001-6535-9872; Hummitzsch, Katja/0000-0001-5023-2668; Bayne, Rosemary (Rosey)/0000-0001-5820-6050	National Health and Medical Research Council of Australia; University of Adelaide; Clive and Vera Ramaciotti Foundation; Wellcome Trust; National Institute of Health; Medical Research Council UK; MRC [G1100357, G1002033, G0700916] Funding Source: UKRI; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043140] Funding Source: NIH RePORTER; Medical Research Council [G1100357, G0700916, G1002033] Funding Source: researchfish	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of Adelaide; Clive and Vera Ramaciotti Foundation; Wellcome Trust(Wellcome TrustEuropean Commission); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Mr. Thomas Sullivan for assistance with the statistical analyses and T&R Pastoral for donation of bovine ovaries. Funding to support this research was obtained from the National Health and Medical Research Council of Australia, the University of Adelaide, the Clive and Vera Ramaciotti Foundation, the Wellcome Trust, the National Institute of Health, and the Medical Research Council UK. N.H., H.F.I-R., K.H., S.L., W.B., M.A.G., and R.J.R. planned the experiments, conducted RT-PCR, immunohistochemistry, and statistical analysis, and wrote the manuscript. R. A. B. and R. A. A. conducted RT-PCR and provided human fetal ovarian samples and reviewed the manuscript. W. E. R., B. R. C., and H. D. M. provided human adult ovarian samples and RNA and reviewed the manuscript. L. S. and D. P. R. expressed recombinant fibrillins, made antisera to FBN3 and adsorbed it against FBN2, established methods for immuno-staining, and reviewed the manuscript.	Abbott DH, 2005, HUM REPROD UPDATE, V11, P357, DOI 10.1093/humupd/dmi013; Amato P, 2004, BEST PRACT RES CL OB, V18, P707, DOI 10.1016/j.bpobgyn.2004.05.002; Azziz R, 2005, J CLIN ENDOCR METAB, V90, P4650, DOI 10.1210/jc.2005-0628; BARNES RB, 1994, J CLIN ENDOCR METAB, V79, P1328, DOI 10.1210/jcem.79.5.7962325; Bottinger EP, 2007, SEMIN NEPHROL, V27, P309, DOI 10.1016/j.semnephrol.2007.02.009; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; Christner PJ, 2006, AMINO ACIDS, V30, P445, DOI 10.1007/s00726-005-0265-y; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; Coutts SM, 2008, DEV BIOL, V314, P189, DOI 10.1016/j.ydbio.2007.11.026; Diamanti-Kandarakis E, 2006, ENDOCRINE, V30, P19, DOI 10.1385/ENDO:30:1:19; Forsdike RA, 2007, J ENDOCRINOL, V192, P421, DOI 10.1677/joe.1.07097; Friel A, 2002, INT J ANDROL, V25, P59, DOI 10.1046/j.1365-2605.2002.00326.x; Govinden R, 2003, PHARMACOL THERAPEUT, V98, P257, DOI 10.1016/S0163-7258(03)00035-4; HAGUE WM, 1990, CLIN ENDOCRINOL, V33, P501, DOI 10.1111/j.1365-2265.1990.tb03887.x; Hetzel M, 2005, LUNG, V183, P225, DOI 10.1007/s00408-004-2534-z; Hirani R, 2007, MATRIX BIOL, V26, P213, DOI 10.1016/j.matbio.2006.12.006; Hughesdon P E, 1982, Obstet Gynecol Surv, V37, P59, DOI 10.1097/00006254-198202000-00001; Jordan CD, 2010, J HISTOCHEM CYTOCHEM, V58, P903, DOI 10.1369/jhc.2010.956615; Kenney MC, 2003, EXP EYE RES, V77, P537, DOI 10.1016/S0014-4835(03)00218-5; Khan R, 2006, IMMUNOLOGY, V118, P10, DOI 10.1111/j.1365-2567.2006.02336.x; Kielty CM, 2002, J CELL SCI, V115, P2817; Kisseleva T, 2007, J GASTROEN HEPATOL, V22, pS73, DOI 10.1111/j.1440-1746.2006.04658.x; LeClair R, 2007, TRENDS CARDIOVAS MED, V17, P202, DOI 10.1016/j.tcm.2007.05.004; Legro RS, 2002, J CLIN ENDOCR METAB, V87, P2128, DOI 10.1210/jc.87.5.2128; MASON HD, 1994, J CLIN ENDOCR METAB, V79, P1355, DOI 10.1210/jc.79.5.1355; Natoli AK, 2005, HYPERTENSION, V46, P1129, DOI 10.1161/01.HYP.0000187016.06549.96; Nelson VL, 1999, MOL ENDOCRINOL, V13, P946, DOI 10.1210/me.13.6.946; Nelson VL, 2001, J CLIN ENDOCR METAB, V86, P5925, DOI 10.1210/jc.86.12.5925; Norman RJ, 2007, LANCET, V370, P685, DOI 10.1016/S0140-6736(07)61345-2; Padmanabhan V, 2009, J CLIN ENDOCR METAB, V94, P1883, DOI 10.1210/jc.2009-0492; Prodoehl MJ, 2009, MOL HUM REPROD, V15, P829, DOI 10.1093/molehr/gap072; Prodoehl MJ, 2009, MOL CELL ENDOCRINOL, V307, P133, DOI 10.1016/j.mce.2009.03.002; Prud'homme GJ, 2007, LAB INVEST, V87, P1077, DOI 10.1038/labinvest.3700669; Ramirez F, 1999, INT J BIOCHEM CELL B, V31, P255, DOI 10.1016/S1357-2725(98)00109-5; Russe I, 1983, Bibl Anat, V24, P77; Sabatier L, 2010, MATRIX BIOL, V21, P21; Samuel CS, 2003, ARCH BIOCHEM BIOPHYS, V411, P47, DOI 10.1016/S0003-9861(02)00710-5; Son ED, 2005, J INVEST DERMATOL, V124, P1149, DOI 10.1111/j.0022-202X.2005.23736.x; Stewart DR, 2006, J CLIN ENDOCR METAB, V91, P4112, DOI 10.1210/jc.2006-0951; Sullivan TM, 2009, REPROD FERT DEVELOP, V21, P773, DOI 10.1071/RD09004; Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008; Urbanek M, 1999, P NATL ACAD SCI USA, V96, P8573, DOI 10.1073/pnas.96.15.8573; Urbanek M, 2007, J CLIN ENDOCR METAB, V92, P4191, DOI 10.1210/jc.2007-0761; Veiga-Lopez A, 2008, BIOL REPROD, V78, P636, DOI 10.1095/biolreprod.107.065904; Verrecchia F, 2004, CELL SIGNAL, V16, P873, DOI 10.1016/j.cellsig.2004.02.007; Webber LJ, 2003, LANCET, V362, P1017, DOI 10.1016/S0140-6736(03)14410-8; Wen Y, 2006, HUM REPROD, V21, P1266, DOI 10.1093/humrep/dei485; Yildiz BO, 2003, J CLIN ENDOCR METAB, V88, P2031, DOI 10.1210/jc.2002-021499	48	62	63	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2256	2265		10.1096/fj.11-181099	http://dx.doi.org/10.1096/fj.11-181099			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21411746	Green Published			2022-12-28	WOS:000292242200017
J	Henry, J; Hsu, CY; Haftek, M; Nachat, R; de Koning, HD; Gardinal-Galera, I; Hitomi, K; Balica, S; Jean-Decoster, C; Schmitt, AM; Paul, C; Serre, G; Simon, M				Henry, Julie; Hsu, Chiung-Yueh; Haftek, Marek; Nachat, Rachida; de Koning, Heleen D.; Gardinal-Galera, Isabelle; Hitomi, Kiyotaka; Balica, Stefana; Jean-Decoster, Catherine; Schmitt, Anne-Marie; Paul, Carle; Serre, Guy; Simon, Michel			Hornerin is a component of the epidermal cornified cell envelopes	FASEB JOURNAL			English	Article						atopic dermatitis; skin; keratinocytes; transglutaminase; terminal differentiation; corneocytes	BARRIER DYSFUNCTION; ATOPIC-DERMATITIS; FILAGGRIN; EXPRESSION; PROTEIN; IDENTIFICATION; PROFILAGGRIN; INVOLUCRIN; EPITHELIA; MOUSE	A single-nucleotide polymorphism within the gene encoding hornerin (HRNR) has recently been linked with atopic dermatitis (AD) susceptibility. HRNR shares features with filaggrin, a key protein for keratinocyte differentiation, but conflicting reports have been published concerning its expression in the epidermis, and its role is still unknown. To analyze HRNR expression and function in the epidermis, anti-HRNR antibodies were produced and used in Western blot analysis and immunohistochemical, confocal, and immunoelectron microscopy analyses of human skin and of cornified cell envelopes purified from plantar stratum corneum. We also tested whether HRNR was a substrate of transglutaminases. In the epidermis, HRNR was detected at the periphery of keratohyalin granules in the upper granular layer and at the corneocyte periphery in the whole cornified layer. Detected in Western blot analysis as numerous bands, HRNR was relatively insoluble and only extracted from epidermis with urea and/or reducing agents. The presence of HRNR in the purified envelopes was confirmed by immunoelectron microscopy and by Western blot analysis after V8-protease digestion. HRNR was shown to be a substrate of transglutaminase 3. These data demonstrate that HRNR is a component of cornified cell envelopes of human epidermis. Its reduced expression in AD may contribute to the epidermal barrier defect observed in the disease.-Henry, J., Hsu, C.-Y., Haftek, M., Nachat, R., de Koning, H. D., Gardinal-Galera, I., Hitomi, K., Balica, S., Jean-Decoster, C., Schmitt, A.-M., Paul, C., Serre, G., Simon, M. Hornerin is a component of the epidermal cornified cell envelopes. FASEB J. 25, 1567-1576 (2011). www.fasebj.org	[Henry, Julie; Hsu, Chiung-Yueh; Nachat, Rachida; Gardinal-Galera, Isabelle; Paul, Carle; Serre, Guy; Simon, Michel] Univ Toulouse 3, Inst Federatif Rech 150, INSERM, Ctr Hosp Univ,CNRS,UMR5165, F-31062 Toulouse, France; [Haftek, Marek] Univ Lyon 1, EA4169, F-69365 Lyon, France; [de Koning, Heleen D.] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, NL-6525 ED Nijmegen, Netherlands; [Gardinal-Galera, Isabelle; Balica, Stefana; Paul, Carle] Toulouse Univ Hosp, Dept Dermatol, Toulouse, France; [Hitomi, Kiyotaka] Nagoya Univ, Grad Sch Bioagr Sci, Naboya, Japan; [Jean-Decoster, Catherine; Schmitt, Anne-Marie] Pierre Fabre Dermo Cosmet, Ctr Europeen Rech Peau & Epitheliums Revetement, Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Radboud University Nijmegen; CHU de Toulouse; Nagoya University	Simon, M (corresponding author), CHU Purpan, CNRS, UPS UMR5165, Pl Dr Baylac TSA40031, F-31059 Toulouse 9, France.	michel.simon@udear.cnrs.fr	Simon, Michel/B-7308-2011; de Koning, Heleen/A-5374-2011	Simon, Michel/0000-0003-3655-6329; Paul, Carle/0000-0003-0165-5263; Nachat Kappes, Rachida/0000-0001-7523-3560; HSU, Chiung-Yueh/0000-0002-4671-0919	Centre National de la Recherche Scientifique (CNRS), Toulouse III University, Pierre-Fabre Research Institute; French Society for Dermatological Research (SRD); Toulouse University Hospital [action BM0903]; INSERM; Fondation pour la Dermatite Atopique	Centre National de la Recherche Scientifique (CNRS), Toulouse III University, Pierre-Fabre Research Institute(Centre National de la Recherche Scientifique (CNRS)); French Society for Dermatological Research (SRD); Toulouse University Hospital; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Fondation pour la Dermatite Atopique(Fondation pour la Recherche Medicale)	The authors thank Prof. Jean-Pierre Chavoin (Plastic Surgery Department, Hospital of Toulouse, Toulouse, France) and Prof. Nam-ho Huh (Okayama University Medical School, Okayama, Japan) for the human skin samples, Renan Destrade for his technical assistance, and Sophie Allard from the confocal microscopy facility [Institut National de la Sante et de la Recherche Medicale (INSERM), IFR150, Toulouse]. Electron microscopy specimens were observed at Centre de Microscopie Electronique Appliquee a la Biologie et la Geologie (CMEABG; University of Lyon, Lyon, France). This work was supported by grants from Centre National de la Recherche Scientifique (CNRS), Toulouse III University, Pierre-Fabre Research Institute, and the French Society for Dermatological Research (SRD), and by the European COST program SKINBAD (action BM0903), Toulouse University Hospital, and INSERM. I. G.-G. was supported by the Fondation pour la Dermatite Atopique. The authors are indebted to all the patients who participated in this study.	Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; DALE BA, 1979, J INVEST DERMATOL, V72, P257, DOI 10.1111/1523-1747.ep12531715; de Koning HD, 2010, J INVEST DERMATOL, V130, P2611, DOI 10.1038/jid.2010.196; Ekanayake-Mudiyanselage S, 1998, J INVEST DERMATOL, V111, P517, DOI 10.1046/j.1523-1747.1998.00318.x; Elias P M, 1999, Am J Contact Dermat, V10, P119, DOI 10.1016/S1046-199X(99)90054-4; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Galliano MF, 2006, J BIOL CHEM, V281, P5780, DOI 10.1074/jbc.M508017200; Girbal-Neuhauser E, 1999, J IMMUNOL, V162, P585; Guerrin M, 2003, BIOCHEM J, V370, P167, DOI 10.1042/BJ20020870; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hitomi K, 2000, BIOSCI BIOTECH BIOCH, V64, P2128, DOI 10.1271/bbb.64.2128; LYNLEY AM, 1983, BIOCHIM BIOPHYS ACTA, V744, P28, DOI 10.1016/0167-4838(83)90336-9; Makino T, 2003, J HISTOCHEM CYTOCHEM, V51, P485, DOI 10.1177/002215540305100410; Makino T, 2001, J BIOL CHEM, V276, P47445, DOI 10.1074/jbc.M107512200; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Nachat R, 2005, J INVEST DERMATOL, V124, P384, DOI 10.1111/j.0022-202X.2004.23568.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Presland R. B., 2006, SKIN BARRIER, P111; Rawlings A.V., 2004, DERMATOL THER S1, V17, P43, DOI [10.1111/j.1396-0296.2004.04s1005.x, DOI 10.1111/J.1396-0296.2004.04S1005.X]; RICHARDS S, 1988, BIOCHEM J, V253, P153, DOI 10.1042/bj2530153; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Ruse M, 2001, BIOCHEMISTRY-US, V40, P3167, DOI 10.1021/bi0019747; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; SIMON M, 1995, J INVEST DERMATOL, V105, P432, DOI 10.1111/1523-1747.ep12321148; Simon M, 1996, BIOCHEM J, V317, P173, DOI 10.1042/bj3170173; Simon M, 1997, J BIOL CHEM, V272, P31770, DOI 10.1074/jbc.272.50.31770; SMITH SA, 1986, J INVEST DERMATOL, V86, P168, DOI 10.1111/1523-1747.ep12284213; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Taieb A, 1999, CONTACT DERMATITIS, V41, P177, DOI 10.1111/j.1600-0536.1999.tb06125.x; Takaishi M, 2005, J BIOL CHEM, V280, P4696, DOI 10.1074/jbc.M409026200; Torma H, 2008, J INVEST DERMATOL, V128, P1212, DOI 10.1038/sj.jid.5701170; Wu ZH, 2009, J INVEST DERMATOL, V129, P1446, DOI 10.1038/jid.2008.370; Wu ZH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005227	36	64	65	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1567	1576		10.1096/fj.10-168658	http://dx.doi.org/10.1096/fj.10-168658			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21282207				2022-12-28	WOS:000290023800014
J	Wan, M; Godson, C; Guiry, PJ; Agerberth, B; Haeggstrom, JZ				Wan, Min; Godson, Catherine; Guiry, Patrick J.; Agerberth, Birgitta; Haeggstrom, Jesper Z.			Leukotriene B-4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A(4) and resolvin E1	FASEB JOURNAL			English	Article						cathelicidin; eicosanoid; inflammation; resolution	CYTOSOLIC PHOSPHOLIPASE A(2); GROWTH-FACTOR RECEPTOR; CATHELICIDIN PEPTIDE; ARACHIDONIC-ACID; B-4 RECEPTOR; ACTIVATION; EXPRESSION; LIGAND; INFLAMMATION; NEUTROPHILS	In humans, the antimicrobial peptide LL-37 and leukotriene B-4 (LTB4) are important proinflammatory mediators, whereas lipoxin A(4) (LXA(4)) and resolvin E1 (RvE1) possess anti-inflammatory, proresolving properties. Previously, we reported that LTB4 triggers LL-37 release from human neutrophils (PMNs) and, conversely, that LL-37 promotes LTB4 production from these cells. Here we show that this effect of LL-37 is mediated via the GPCR FPR2/ALX. LL-37 (5-30 mu g/ml) induces intracellular calcium mobilization in a dose-dependent manner, and the signal transduction leading to LTB4 release involves p38 MAP kinase and phosphorylation of cPLA(2). LXA(4), an endogenous lipid ligand of FPR2/ALX, and a stable LXA(4) analog [benzo-LXA(4)] were ineffective as stimuli at the concentrations of 0.1-10 nM for LTB4 release from PMNs. Likewise, the BLT1 ligand RvE1, a derivative of eicosapentaenoic acid, inhibited LTB4-induced LL-37 production from PMNs at 1-100 nM, whereas chemerin, a peptide ligand of the RvE1 receptor ChemR23, failed to block LTB4-induced LL-37 release at the same concentrations. Hence, in human neutrophils, binding of LL-37 to FPR2/ALX promotes LTB4 production, which can bind to BLT1 and elicit further LL-37 release. This proinflammatory circuit might be inhibited by LXA(4) and RvE1 acting at FPR2/ALX and BLT1, respectively, leading to dampened mediator release.-Wan, M., Godson, C., Guiry, P. J., Agerberth, B., Haeggstrom, J. Z. Leukotriene B-4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A(4) and resolvin E1. FASEB J. 25, 1697-1705 (2011). www.fasebj.org	[Wan, Min; Haeggstrom, Jesper Z.] Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; [Agerberth, Birgitta] Karolinska Inst, Div Physiol Chem 1, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; [Godson, Catherine] Univ Coll Dublin, UCD Conway Inst, UCD Diabet Res Ctr, Dublin 2, Ireland; [Godson, Catherine] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland; [Guiry, Patrick J.] Univ Coll Dublin, UCD Sch Chem & Chem Biol, Ctr Synth & Chem Biol, Dublin 2, Ireland	Karolinska Institutet; Karolinska Institutet; University College Dublin; University College Dublin; University College Dublin	Haeggstrom, JZ (corresponding author), Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	jesper.haeggstrom@ki.se		Godson, Catherine/0000-0003-0655-1041	Swedish Research Council [10350, 11217, 20854, CERIC]; EC [005033, 201668]; Swedish Foundation for Strategic Research; Torsten and Ragnar Soderbergs Foundations; Enterprise Ireland; Science Foundation Ireland; Vallee Foundation; Karolinska Institutet	Swedish Research Council(Swedish Research CouncilEuropean Commission); EC(European CommissionEuropean Commission Joint Research Centre); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Torsten and Ragnar Soderbergs Foundations; Enterprise Ireland; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Vallee Foundation; Karolinska Institutet(Karolinska Institutet)	This study was supported by the Swedish Research Council (10350, 11217, 20854, Linneus grant CERIC); Chronic Inflammation-Diagnosis and Therapy (CIDaT), EC FP6 and FP7 funding (005033, 201668); the Swedish Foundation for Strategic Research; the Torsten and Ragnar Soderbergs Foundations; Enterprise Ireland; and Science Foundation Ireland. J.Z.H. was supported by the Vallee Foundation and a Distinguished Professor Award from Karolinska Institutet. The authors report no conflicts of interest.	Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Arita M, 2007, J IMMUNOL, V178, P3912, DOI 10.4049/jimmunol.178.6.3912; Barnea G, 2008, P NATL ACAD SCI USA, V105, P64, DOI 10.1073/pnas.0710487105; Bonnans C, 2002, AM J RESP CRIT CARE, V165, P1531, DOI 10.1164/rccm.200201-053OC; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Edfeldt K, 2006, ARTERIOSCL THROM VAS, V26, P1551, DOI 10.1161/01.ATV.0000223901.08459.57; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Fierro IM, 2003, J IMMUNOL, V170, P2688, DOI 10.4049/jimmunol.170.5.2688; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; HAWTHORNE AB, 1992, GUT, V33, P513, DOI 10.1136/gut.33.4.513; Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041; Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Le YY, 2000, IMMUNOL REV, V177, P185, DOI 10.1034/j.1600-065X.2000.17704.x; Lee HY, 2006, BIOCHEM PHARMACOL, V72, P860, DOI 10.1016/j.bcp.2006.06.022; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; Maderna P, 2010, FASEB J, V24, P4240, DOI 10.1096/fj.10-159913; Mitchell D, 2004, AM J PATHOL, V164, P937, DOI 10.1016/S0002-9440(10)63181-1; Mitchell D, 2007, J BIOL CHEM, V282, P15606, DOI 10.1074/jbc.M611004200; Mookherjee N, 2009, J IMMUNOL, V183, P2688, DOI 10.4049/jimmunol.0802586; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagaoka I, 2006, J IMMUNOL, V176, P3044, DOI 10.4049/jimmunol.176.5.3044; Nijnik A, 2009, CURR OPIN HEMATOL, V16, P41, DOI 10.1097/MOH.0b013e32831ac517; O'Sullivan TP, 2007, J MED CHEM, V50, P5894, DOI 10.1021/jm060270d; Peters-Golden M, 2005, J IMMUNOL, V174, P589, DOI 10.4049/jimmunol.174.2.589; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Planaguma A, 2008, AM J RESP CRIT CARE, V178, P574, DOI 10.1164/rccm.200801-061OC; Pouliot M, 2000, BIOCHEMISTRY-US, V39, P4761, DOI 10.1021/bi992551b; Qiu H, 2006, P NATL ACAD SCI USA, V103, P8161, DOI 10.1073/pnas.0602414103; Schauber J, 2006, EUR J GASTROEN HEPAT, V18, P615, DOI 10.1097/00042737-200606000-00007; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; Wan M, 2007, FASEB J, V21, P2897, DOI 10.1096/fj.06-7974com; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Wittamer V, 2004, J BIOL CHEM, V279, P9956, DOI 10.1074/jbc.M313016200; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Zabel BA, 2008, J EXP MED, V205, P2207, DOI 10.1084/jem.20080300; Zhang ZF, 2009, EUR J IMMUNOL, V39, P3181, DOI 10.1002/eji.200939496	55	64	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1697	1705		10.1096/fj.10-175687	http://dx.doi.org/10.1096/fj.10-175687			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21307335				2022-12-28	WOS:000290023800025
J	Scarpato, R; Verola, C; Fabiani, B; Bianchi, V; Saggese, G; Federico, G				Scarpato, Roberto; Verola, Carmela; Fabiani, Barbara; Bianchi, Vanessa; Saggese, Giuseppe; Federico, Giovanni			Nuclear damage in peripheral lymphocytes of obese and overweight Italian children as evaluated by the gamma-H2AX focus assay and micronucleus test	FASEB JOURNAL			English	Article						DNA double-strand break; chromosome damage; childhood obesity	DOUBLE-STRAND BREAKS; HISTONE H2AX PHOSPHORYLATION; BODY-MASS INDEX; BLOOD-LYMPHOCYTES; DNA-DAMAGE; CHILDHOOD OBESITY; CYTOGENETIC DAMAGE; CHROMOSOME-DAMAGE; DISEASE PATIENTS; THYROID-CANCER	Childhood obesity, often characterized by a chronic low-grade inflammation, has been associated with an increased risk of developing some types of cancer later in life. Nuclear gamma-H2AX foci represent the first detectable response of cells to DNA tumorigenesis lesions, such as the double-strand breaks (DSBs). An excess of micronucleated peripheral lymphocytes was found in subjects with cancer or inflammatation-based diseases. We set out to investigate the expression of genome damage, from DNA lesions to chromosome mutations (micronuclei), in overweight and obese children. Using the gamma-H2AX focus assay and micronucleus (MN) test, we analyzed peripheral lymphocytes from 119 Italian children classified as normal weight (n=38), overweight (n=20), or obese (n=61). Cultures treated with bleomycin (BLM) were also set up for each child in both assays to check functioning of the apparatus that ensures DNA integrity. We measured serum TNF-alpha, IL-6, and C-reactive protein (CRP) as markers of inflammation. Overweight and obese children had significantly higher levels of H2AX phosphorylation (0.0191 +/- 0.0039 and 0.0274 +/- 0.0029 gamma-H2AXF/n) and increased MN frequencies (2.30 +/- 0.25 and 2.45 +/- 0.22%) than normal-weight children (0.0034 +/- 0.0006 gamma-H2AXF/n, and 0.92 +/- 0.12% MN), while all subjects responded to BLM induction, irrespective of their weight status. The fold increase of spontaneous MN frequencies in overweight and obese subjects was 2.5 and 2.7, respectively, well below the corresponding increase in the gamma-H2AX foci 5.6- and 8.0-fold, respectively). IL-6 and CRP mean values were significantly higher in obese and overweight children than in controls. Here, we demonstrated that peripheral cells of overweight and obese children showed increased levels of DSBs, which were not completely repaired as part of them has been converted into micronuclei. Characterization of childhood obesity inflammation could be implemented using molecular markers of genome damage.-Scarpato, R., Verola, C., Fabiani, B., Bianchi, V., Saggese, G., Federico, G. Nuclear damage in peripheral lymphocytes of obese and overweight Italian children as evaluated by the gamma-H2AX focus assay and micronucleus test. FASEB J. 25, 685-693 (2011). www.fasebj.org	[Scarpato, Roberto; Verola, Carmela; Fabiani, Barbara] Univ Pisa, Dipartimento Biol, Unita Genet Mutagenesi & Epidemiol Ambientale, I-56100 Pisa, Italy; [Bianchi, Vanessa; Saggese, Giuseppe; Federico, Giovanni] Univ Pisana, Azienda Osped, Dipartimento Materno Infantile, Sez Endocrinol & Diabetol Pediat, Pisa, Italy	University of Pisa; University of Pisa; Azienda Ospedaliero Universitaria Pisana	Scarpato, R (corresponding author), Univ Pisa, Dipartimento Biol, Unita Genet Mutagenesi & Epidemiol Ambientale, Via Derna 1, I-56100 Pisa, Italy.	rscarpato@biologia.unipi.it	Scarpato, Roberto/K-8987-2016		Italian Ministry of Education, University and Research	Italian Ministry of Education, University and Research(Ministry of Education, Universities and Research (MIUR))	This work has been partially funded by the Italian Ministry of Education, University and Research (PRIN). The authors acknowledge the technical support of Dr. Lisa Fiore (Laboratorio di Endocrinologia Pediatrica, Sezione di Endocrinologia e Diabetologia Pediatrica, Dipartimento Materno-Infantile, Azienda Ospedaliero-Universitaria Pisana) for blood sample preparation and of Dr. Maria Rita Metelli (Dipartimento di Medicina di Laboratorio e Diagnostica Molecolare, Azienda Ospedaliero-Universitaria Pisana) for TNF-alpha, CRP, and IL-6 assays.	Ahima RS, 2009, NAT MED, V15, P996, DOI 10.1038/nm0909-996; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Beels L, 2009, CIRCULATION, V120, P1903, DOI 10.1161/CIRCULATIONAHA.109.880385; Biro FM, 2010, AM J CLIN NUTR, V91, p1499S, DOI 10.3945/ajcn.2010.28701B; Bonassi S, 2007, CARCINOGENESIS, V28, P625, DOI 10.1093/carcin/bgl177; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Cizmecioglu FM, 2009, EXP CLIN ENDOCR DIAB, V117, P622, DOI 10.1055/s-0028-1112151; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Dardano A, 2007, J CLIN ENDOCR METAB, V92, P4286, DOI 10.1210/jc.2007-0597; Emerit I, 1997, DERMATOLOGY, V194, P140, DOI 10.1159/000246083; Emerit I, 1997, MUTAT RES-FUND MOL M, V373, P47, DOI 10.1016/S0027-5107(96)00187-X; Federico G, 2008, EUR J NUCL MED MOL I, V35, P2113, DOI 10.1007/s00259-008-0867-1; Fenech M, 2003, MUTAT RES-GEN TOX EN, V534, P45, DOI 10.1016/S1383-5718(02)00248-6; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Gutierrez S, 1999, EUR J NUCL MED, V26, P1589, DOI 10.1007/s002590050499; Heitmann BL, 2009, NUTR REV, V67, pS89, DOI 10.1111/j.1753-4887.2009.00167.x; Hoelzl C, 2005, J Physiol Pharmacol, V56 Suppl 2, P49; Holland N, 2007, PEDIATR RES, V61, P209, DOI 10.1203/pdr.0b013e31802d77c7; *IT MIN HLTH I SUP, 2008, EP OB SCH CHILDR IT; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Kapka L, 2007, MUTAGENESIS, V22, P201, DOI 10.1093/mutage/gem004; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Kuefner MA, 2009, INVEST RADIOL, V44, P440, DOI 10.1097/RLI.0b013e3181a654a5; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; Maffeis C, 2008, J CLIN ENDOCR METAB, V93, P2122, DOI 10.1210/jc.2007-2089; Maffeis C, 2007, NUTR METAB CARDIOVAS, V17, P394, DOI 10.1016/j.numecd.2006.08.006; Martinez-Perez L M, 2007, Prague Med Rep, V108, P248; Mateuca R, 2006, BIOCHIMIE, V88, P1515, DOI 10.1016/j.biochi.2006.07.004; Migliore L, 2002, NEUROLOGY, V58, P1809, DOI 10.1212/WNL.58.12.1809; Moran LJ, 2008, MUTAT RES-FUND MOL M, V639, P55, DOI 10.1016/j.mrfmmm.2007.11.007; Negre-Salvayre A, 2009, ANTIOXID REDOX SIGN, V11, P3071, DOI [10.1089/ars.2009.2484, 10.1089/ARS.2009.2484]; Neri M, 2005, ENVIRON HEALTH PERSP, V113, P1226, DOI 10.1289/ehp.7806; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Park J, 2007, DIABETES RES CLIN PR, V77, pS11, DOI 10.1016/j.diabres.2007.01.037; Pernice F, 2006, EUR J PHARMACOL, V532, P223, DOI 10.1016/j.ejphar.2006.01.003; Porciello G, 2003, J RHEUMATOL, V30, P1244; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Retnakaran R, 2006, DIABETES OBES METAB, V8, P483, DOI 10.1111/j.1463-1326.2005.00533.x; Riches LC, 2008, MUTAGENESIS, V23, P331, DOI 10.1093/mutage/gen039; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Sak A, 2007, INT J RADIAT BIOL, V83, P639, DOI 10.1080/09553000701596118; Sander Miriam, 2008, Mol Carcinog, V47, P707, DOI 10.1002/mc.20214; Sbarbati A, 2006, PEDIATRICS, V117, P220, DOI 10.1542/peds.2004-2854; Scarpato R, 2009, EUR J CLIN INVEST, V39, P1091, DOI 10.1111/j.1365-2362.2009.02214.x; Shalitin S, 2009, HORM RES, V72, P287, DOI 10.1159/000245931; Skinner AC, 2010, PEDIATRICS, V125, pE801, DOI 10.1542/peds.2009-2182; Skinner AC, 2009, PEDIATRICS, V124, pE905, DOI 10.1542/peds.2009-0179; Takahashi A, 2005, CANCER LETT, V229, P171, DOI 10.1016/j.canlet.2005.07.016; Tanaka T, 2007, CELL PROLIFERAT, V40, P1; Tucker JD, 2009, MUTAT RES-GEN TOX EN, V677, P53, DOI 10.1016/j.mrgentox.2009.05.005; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Watters GP, 2009, MUTAT RES-GEN TOX EN, V679, P50, DOI 10.1016/j.mrgentox.2009.07.007; Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Wu XF, 2007, CANCER RES, V67, P3493, DOI 10.1158/0008-5472.CAN-06-4137; Wuttke K, 1996, INT J RADIAT BIOL, V69, P259, DOI 10.1080/095530096146101; Yan B, 2009, METHODS MOL BIOL, V512, P15, DOI 10.1007/978-1-60327-530-9_2	60	67	68	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2011	25	2					685	693		10.1096/fj.10-168427	http://dx.doi.org/10.1096/fj.10-168427			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21068397				2022-12-28	WOS:000286724800026
J	Strater, N; Marek, S; Kuettner, EB; Kloos, M; Keim, A; Bruser, A; Kirchberger, J; Schoneberg, T				Straeter, Norbert; Marek, Sascha; Kuettner, E. Bartholomeus; Kloos, Marco; Keim, Antje; Brueser, Antje; Kirchberger, Juergen; Schoeneberg, Torsten			Molecular architecture and structural basis of allosteric regulation of eukaryotic phosphofructokinases	FASEB JOURNAL			English	Article						metabolism; protein crystallography; structural biology	CATECHOL-O-METHYLTRANSFERASE; YEAST PHOSPHOFRUCTOKINASE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; MUSCLE PHOSPHOFRUCTOKINASE; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; PICHIA-PASTORIS; BACILLUS-STEAROTHERMOPHILUS; FRUCTOSE 2,6-BISPHOSPHATE	Eukaryotic ATP-dependent 6-phosphofructokinases (Pfks) differ from their bacterial counterparts in a much more complex structural organization and allosteric regulation. Pichia pastoris Pfk (PpPfk) is, with similar to 1 MDa, the most complex and probably largest eukaryotic Pfk. We have determined the crystal structure of full-length PpPfk to 3.05 angstrom resolution in the T state. PpPfk forms a (alpha beta gamma)(4) dodecamer of D(2) symmetry with dimensions of 161 x 157 x 233 angstrom mainly via interactions of the alpha chains. The N-terminal domains of the alpha and beta chains have folds that are distantly related to glyoxalase I, but the active sites are no longer functional. Interestingly, these domains located at the 2 distal ends of this protein along the long 2-fold axis form a (alpha beta)(2) dimer as does the core Pfk domains; however, the domains are swapped across the tetramerization interface. In PpPfk, the unique gamma subunit participates in oligomerization of the alpha beta chains. This modulator protein was acquired from an ancient S-adenosylmethionine-dependent methyltransferase. The identification of novel ATP binding sites, which do not correspond to the bacterial catalytic or effector binding sites, point to marked structural and functional differences between bacterial and eukaryotic Pfks.-Strater, N., Marek, S., Kuettner, E. B., Kloos, M., Keim, A., Bruser, A., Kirchberger, J., Schoneberg, T. Molecular architecture and structural basis of allosteric regulation of eukaryotic phosphofructokinases. FASEB J. 25, 89-98 (2011). www.fasebj.org	[Straeter, Norbert; Marek, Sascha; Kuettner, E. Bartholomeus; Kloos, Marco; Keim, Antje] Univ Leipzig, Inst Bioanalyt Chem, Ctr Biotechnol & Biomed, D-04103 Leipzig, Germany; [Brueser, Antje; Kirchberger, Juergen; Schoeneberg, Torsten] Univ Leipzig, Inst Biochem, Fac Med, D-04103 Leipzig, Germany	Leipzig University; Leipzig University	Strater, N (corresponding author), Univ Leipzig, Inst Bioanalyt Chem, Ctr Biotechnol & Biomed, Deutsch Pl 5, D-04103 Leipzig, Germany.	strater@bbz.uni-leipzig.de; schoberg@medizin.uni-leipzig.de	Strater, Norbert/P-4856-2018	Strater, Norbert/0000-0002-2001-0500	Deutsche Forschungsgemeinschaft [SFB 610]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The Deutsche Forschungsgemeinschaft is acknowledged for funding (SFB 610). The authors thank the Joint Berlin MX-Laboratory at BESSY II, the European Synchrotron Radiation Facility (Grenoble, France), and the European Molecular Biology Laboratory Hamburg Outstation at Deutsches Elektronen-Synchrotron (Hamburg, Germany) for beam time and assistance during synchrotron data collection, as well as the Helmholtz Zentrum Berlin for traveling support. The authors also thank Anja Hutschenreuther for performing measurements of glyoxalase I activity of PpPfk.	Albuquerque CP, 2008, MOL CELL PROTEOMICS, V7, P1389, DOI 10.1074/mcp.M700468-MCP200; ARVANITIDIS A, 1994, J BIOL CHEM, V269, P8911; Barcena M, 2007, J STRUCT BIOL, V159, P135, DOI 10.1016/j.jsb.2007.03.004; Benjamin S, 2007, J STRUCT BIOL, V159, P498, DOI 10.1016/j.jsb.2007.06.001; Benjamin S, 2009, J STRUCT BIOL, V168, P345, DOI 10.1016/j.jsb.2009.06.014; Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; Cameron AD, 1999, BIOCHEMISTRY-US, V38, P13480, DOI 10.1021/bi990696c; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Edelmann A, 2002, YEAST, V19, P949, DOI 10.1002/yea.889; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; Ferreras C, 2009, J BIOL CHEM, V284, P9124, DOI 10.1074/jbc.M807737200; Fillgrove KL, 2007, BIOCHEMISTRY-US, V46, P8110, DOI 10.1021/bi700625p; FREYER R, 1977, THESIS U LEIPZIG GER; HEINISCH J, 1989, GENE, V78, P309; Heinisch JJ, 1996, J BIOL CHEM, V271, P15928, DOI 10.1074/jbc.271.27.15928; Hollenbach M, 2008, BIOCHEM PHARMACOL, V76, P631, DOI 10.1016/j.bcp.2008.06.006; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Kemp RG, 2002, BIOCHEMISTRY-US, V41, P9426, DOI 10.1021/bi020110d; Kirchberger J, 2002, YEAST, V19, P933, DOI 10.1002/yea.885; KOPPERSCHLAGER G, 1993, EUR J BIOCHEM, V217, P527, DOI 10.1111/j.1432-1033.1993.tb18273.x; Kricke J, 1999, INT J BIOL MACROMOL, V24, P27, DOI 10.1016/S0141-8130(98)00063-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li YL, 1999, BIOCHEMISTRY-US, V38, P16407, DOI 10.1021/bi991761l; Martinez-Costa OH, 2007, FEBS LETT, V581, P3033, DOI 10.1016/j.febslet.2007.05.059; Martinez-Oyanedel J, 2007, J MOL BIOL, V366, P1185, DOI 10.1016/j.jmb.2006.10.019; Mcnae IW, 2009, J MOL BIOL, V385, P1519, DOI 10.1016/j.jmb.2008.11.047; NISSLER K, 1985, BIOMED BIOCHIM ACTA, V44, P251; Obmolova G, 1998, ACTA CRYSTALLOGR D, V54, P96, DOI 10.1107/S0907444997007555; Palma PN, 2006, MOL PHARMACOL, V70, P143, DOI 10.1124/mol.106.023119; Paricharttanakul NM, 2005, BIOCHEMISTRY-US, V44, P15280, DOI 10.1021/bi051283g; PARMEGGIANI A, 1966, J BIOL CHEM, V241, P4625; PLIETZ P, 1978, FEBS LETT, V91, P230, DOI 10.1016/0014-5793(78)81179-X; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; Rais B, 2000, BBA-PROTEIN STRUCT M, V1479, P303, DOI 10.1016/S0167-4838(00)00047-9; Riley-Lovingshimer MR, 2002, BIOCHEMISTRY-US, V41, P12967, DOI 10.1021/bi0263412; ROBERTS SJ, 1987, BIOCHEMISTRY-US, V26, P3437, DOI 10.1021/bi00386a028; Rodicio R, 2000, J BIOL CHEM, V275, P40952, DOI 10.1074/jbc.M007131200; Ruiz T, 2003, J STRUCT BIOL, V143, P124, DOI 10.1016/S1047-8477(03)00140-0; Ruiz T, 2001, J STRUCT BIOL, V136, P167, DOI 10.1006/jsbi.2002.4440; Rutherford K, 2008, J MOL BIOL, V380, P120, DOI 10.1016/j.jmb.2008.04.040; RYPNIEWSKI WR, 1989, J MOL BIOL, V207, P805, DOI 10.1016/0022-2836(89)90246-5; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Smolka MB, 2007, P NATL ACAD SCI USA, V104, P10364, DOI 10.1073/pnas.0701622104; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; Tanneberger K, 2007, J BIOL CHEM, V282, P23687, DOI 10.1074/jbc.M611547200; TELFORD JN, 1975, P NATL ACAD SCI USA, V72, P3054, DOI 10.1073/pnas.72.8.3054; TIJANE MN, 1979, FEBS LETT, V105, P249, DOI 10.1016/0014-5793(79)80622-5; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2	52	15	18	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2011	25	1					89	98		10.1096/fj.10-163865	http://dx.doi.org/10.1096/fj.10-163865			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20833871				2022-12-28	WOS:000285869500009
J	Sun, LY; Bokov, AF; Richardson, A; Miller, RA				Sun, Liou Y.; Bokov, Alex F.; Richardson, Arlan; Miller, Richard A.			Hepatic response to oxidative injury in long-lived Ames dwarf mice	FASEB JOURNAL			English	Article						ERK; Nrf2; aging; stress	GENE-EXPRESSION PROFILE; LIFE-SPAN; STRESS RESISTANCE; TRANSCRIPTION FACTOR; CELL-SURVIVAL; MUTANT MICE; BCL2 FAMILY; MAP KINASE; GROWTH; ACTIVATION	Multiple stress resistance pathways were evaluated in the liver of Ames dwarf mice before and after exposure to the oxidative toxin diquat, seeking clues to the exceptional longevity conferred by this mutation. Before diquat treatment, Ames dwarf mice, compared with nonmutant littermate controls, had 2- to 6-fold higher levels of expression of mRNAs for immediate early genes and 2- to 5-fold higher levels of mRNAs for genes dependent on the transcription factor Nrf2. Diquat led to a 2-fold increase in phosphorylation of the stress kinase ERK in control (but not Ames dwarf) mice and to a 50% increase in phosphorylation of the kinase JNK2 in Ames dwarf (but not control) mice. Diquat induction of Nrf2 protein was higher in dwarf mice than in controls. Of 6 Nrf2-responsive genes evaluated, 4 (HMOX, NQO-1, MT-1, and MT-2) remained 2- to 10-fold lower in control than in dwarf liver after diquat, and the other 2 (GCLM and TXNRD) reached levels already seen in dwarf liver at baseline. Thus, livers of Ames dwarf mice differ systematically from controls in multiple stress resistance pathways before and after exposure to diquat, suggesting mechanisms for stress resistance and extended longevity in Ames dwarf mice.-Sun, L. Y., Bokov, A. F., Richardson, A., Miller, R. A. Hepatic response to oxidative injury in long-lived Ames dwarf mice. FASEB J. 25, 398-408 (2011). www.fasebj.org	[Sun, Liou Y.; Miller, Richard A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA; [Sun, Liou Y.; Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Miller, Richard A.] Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA; [Bokov, Alex F.; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Bokov, Alex F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Miller, RA (corresponding author), Univ Michigan, Geriatr Ctr, Rm 3001,BSRB Box 2200,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	millerr@umich.edu			National Institute on Aging [AG-031736, AG-024824, AG-013283, AG-021890]; San Antonio Nathan Shock Aging Center [1P30-AG-13319]; NATIONAL INSTITUTE ON AGING [T32AG021890, P30AG013283, P30AG024824, P01AG031736, P30AG013319] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); San Antonio Nathan Shock Aging Center; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institute on Aging grants AG-031736, AG-024824, and AG-013283 (to R.A.M.); AG-021890 (to A.F.B.); and San Antonio Nathan Shock Aging Center 1P30-AG-13319 (to A.R.). The authors thank Marian Sabia and Vivian Diaz for assistance.	Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Amador-Noguez D, 2004, AGING CELL, V3, P423, DOI 10.1111/j.1474-9728.2004.00125.x; Bartke A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/en.2005-0411; Beidelschies MA, 2008, J CELL PHYSIOL, V217, P652, DOI 10.1002/jcp.21539; Bianchet MA, 2008, VITAM HORM, V78, P63, DOI 10.1016/S0083-6729(07)00004-0; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Bokov AF, 2009, J GERONTOL A-BIOL, V64, P819, DOI 10.1093/gerona/glp052; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Cabodi S, 2009, J CELL PHYSIOL, V218, P294, DOI 10.1002/jcp.21603; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; Dickinson DA, 2004, FREE RADICAL BIO MED, V37, P1152, DOI 10.1016/j.freeradbiomed.2004.06.011; FARRINGTON JA, 1973, BIOCHIM BIOPHYS ACTA, V314, P372, DOI 10.1016/0005-2728(73)90121-7; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Harper JM, 2006, MECH AGEING DEV, V127, P687, DOI 10.1016/j.mad.2006.04.002; Hsieh CC, 2009, AGING-US, V1, P784, DOI 10.18632/aging.100077; Ikeno Y, 2003, J GERONTOL A-BIOL, V58, P291; Jones GM, 2000, J TOXICOL-CLIN TOXIC, V38, P123, DOI 10.1081/CLT-100100926; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kennedy MA, 2003, EXP GERONTOL, V38, P997, DOI 10.1016/S0531-5565(03)00164-5; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kinney BA, 2001, HORM BEHAV, V39, P277, DOI 10.1006/hbeh.2001.1654; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Korb A, 2006, ARTHRITIS RHEUM, V54, P2745, DOI 10.1002/art.22080; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Legos JJ, 2001, BRAIN RES, V892, P70, DOI 10.1016/S0006-8993(00)03228-5; Leiser SF, 2010, MOL CELL BIOL, V30, P871, DOI 10.1128/MCB.01145-09; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Li J, 2004, EXP GERONTOL, V39, P735, DOI 10.1016/j.exger.2004.02.008; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Lithgow G. J., 2008, MOL BIOL AGING; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Maynard SP, 2006, AGING CELL, V5, P89, DOI 10.1111/j.1474-9726.2006.00187.x; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meyer Y, 2009, ANNU REV GENET, V43, P335, DOI 10.1146/annurev-genet-102108-134201; Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x; Miller RA, 2009, J GERONTOL A-BIOL, V64, P179, DOI 10.1093/gerona/gln072; Morse D, 2009, FREE RADICAL BIO MED, V47, P1, DOI 10.1016/j.freeradbiomed.2009.04.007; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Oppermann U, 2007, ANNU REV PHARMACOL, V47, P293, DOI 10.1146/annurev.pharmtox.47.120505.105316; ORENTREICH N, 1993, J NUTR, V123, P269; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pearson KJ, 2008, P NATL ACAD SCI USA, V105, P2325, DOI 10.1073/pnas.0712162105; Piantadosi CA, 2008, FREE RADICAL BIO MED, V45, P562, DOI 10.1016/j.freeradbiomed.2008.05.013; Rabkin SW, 2009, J HEART VALVE DIS, V18, P653; Salmon AB, 2005, AM J PHYSIOL-ENDOC M, V289, pE23, DOI 10.1152/ajpendo.00575.2004; Salmon AB, 2008, J GERONTOL A-BIOL, V63, P219, DOI 10.1093/gerona/63.3.219; Sierra F, 2006, J GERONTOL A-BIOL, V61, P557, DOI 10.1093/gerona/61.6.557; Song BB, 2008, J CLIN INVEST, V118, P3378, DOI 10.1172/JCI34587; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Sun LY, 2006, ENDOCRINOLOGY, V147, P5480, DOI 10.1210/en.2006-0586; Sun LY, 2009, FREE RADICAL BIO MED, V47, P1753, DOI 10.1016/j.freeradbiomed.2009.09.021; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Sykiotis GP, 2008, DEV CELL, V14, P76, DOI 10.1016/j.devcel.2007.12.002; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Torres F, 2010, MOL CARCINOGEN, V49, P464, DOI 10.1002/mc.20619; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987	68	27	27	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					398	408		10.1096/fj.10-164376	http://dx.doi.org/10.1096/fj.10-164376			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20826540	Green Published, Green Submitted			2022-12-28	WOS:000285869500036
J	Volz, T; Nega, M; Buschmann, J; Kaesler, S; Guenova, E; Peschel, A; Rocken, M; Gotz, F; Biedermann, T				Volz, Thomas; Nega, Mulugeta; Buschmann, Julia; Kaesler, Susanne; Guenova, Emmanuella; Peschel, Andreas; Roecken, Martin; Goetz, Friedrich; Biedermann, Tilo			Natural Staphylococcus aureus-derived peptidoglycan fragments activate NOD2 and act as potent costimulators of the innate immune system exclusively in the presence of TLR signals	FASEB JOURNAL			English	Article						innate immunity; dendritic cells; atopic dermatitis; Th1 cells; Th17 cells	BACTERIAL CELL-WALLS; LIPOTEICHOIC ACID; DENDRITIC CELLS; O-ACETYLTRANSFERASE; LYSOZYME RESISTANCE; RECOGNITION; LIPOPROTEINS; INFECTIONS; RECEPTORS; RESPONSES	Innate immune sensing of Staphylococcus aureus unravels basic mechanisms leading to either effective antibacterial immune responses or harmful inflammation. The nature and properties of S. aureus-derived pathogen-associated molecular pattern (PAMPs) are still not completely understood. We investigated the innate immune sensing of peptidoglycan (PGN) structures and subsequent immune consequences. Macromolecular PGN (PGN(polymer)) preparations activated NF-kappa B through human Toll-like receptors 2 (TLR2), as shown by luciferase reporter assays, and induced murine dendritic cell (DC) maturation and cytokine production. In contrast, PGN(polymer) from lgt-mutant S. aureus failed to stimulate human TLR2, demonstrating that lipoproteins within the macromolecular structures of PGN(polymer), but not PGN itself, activate TLR2. Thus, HPLC-purified monomeric PGN (PGN(monomer)) structures were investigated. Strikingly, PGN(monomer) completely lacked NF-kappa B activation, lacked TLR2 activity, and failed to functionally activate murine DCs. However, PGN(monomer) in concert with various TLR ligands most effectively stimulated DCs to up-regulate IL-12p70 and IL-23 by >= 3- to 5-fold. Consequently, DCs coactivated by PGN(monomer) markedly up-regulated Th1 and Th17 while suppressing Th2 cell priming. Notably, PGN(monomer) failed to coactivate NOD2(-/-) DCs. This demonstrates that PGN(monomer) is a natural ligand of NOD2, which was previously only demonstrated for synthetic compounds like muramyl dipeptide. Interestingly, murine DCs lacking TLR2 remained mute in response to the combinative immune sensing of S. aureus-derived PAMPs, including PGN(monomer), providing for the first time an explanation of why S. aureus can colonize the nasal mucosa in the absence of inflammation. This is very likely based on the lack of TLR2 expression in mucosal epithelial cells under normal conditions, which determines the unresponsiveness to S. aureus PAMPs.-Volz, T., Nega, M., Buschmann, J., Kaesler, S., Guenova, E., Peschel, A., Rocken, M., Gotz, F., Biedermann, T. Natural Staphylococcus aureus-derived peptidoglycan fragments activate NOD2 and act as potent costimulator of the innate immune system exclusively in the presence of TLR signals. FASEB J. 24, 4089-4102 (2010). www.fasebj.org	[Volz, Thomas; Kaesler, Susanne; Guenova, Emmanuella; Roecken, Martin; Biedermann, Tilo] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany; [Nega, Mulugeta; Buschmann, Julia; Goetz, Friedrich] Univ Tubingen, Dept Microbial Genet, D-72076 Tubingen, Germany; [Peschel, Andreas] Univ Tubingen, Dept Med Microbiol & Hyg, Cellular & Mol Microbiol Sect, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Biedermann, T (corresponding author), Univ Tubingen, Dept Dermatol, Liebermeisterstr 25, D-72076 Tubingen, Germany.	friedrich.goetz@uni-tuebingen.de; tilo.biedermann@med.uni-tuebingen.de	Guenova, Emmanuella/G-7441-2017	Guenova, Emmanuella/0000-0001-5478-8735; Rocken, Martin/0000-0003-3795-7001; Biedermann, Tilo/0000-0002-5352-5105	Deutsche Forschungsgemeinschaft [DFG Bi 696/3-3, DFG Bi 696/5-1, SFB 685 A6, SFB 766]; Landesstiftung Baden-Wurttemberg [P-LS-AL2/4]; IZKF-Verbundprojekt [1596-0-0]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Landesstiftung Baden-Wurttemberg; IZKF-Verbundprojekt	This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG Bi 696/3-3; DFG Bi 696/5-1, SFB 685 A6 and SFB 766), Landesstiftung Baden-Wurttemberg (P-LS-AL2/4), IZKF-Verbundprojekt 1596-0-0, and the IZKF-FACS core facility. The authors thank Jennifer Rottenberger, Regine Stemmler, Ulrike Schmidt, and Sandra Schmitz for technical assistance. The authors acknowledge the expert technical assistance of Cornelia Grimmel from the FACS core facility of the interdisciplinary center for clinical research of the University Hospital of Tubingen.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Asong J, 2009, J BIOL CHEM, V284, P8634, DOI 10.1074/jbc.M806633200; Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1084/jem.20051782; Baker BS, 2006, CLIN EXP IMMUNOL, V144, P1, DOI 10.1111/j.1365-2249.2005.02980.x; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bera A, 2005, MOL MICROBIOL, V55, P778, DOI 10.1111/j.1365-2958.2004.04446.x; Bera A, 2006, INFECT IMMUN, V74, P4598, DOI 10.1128/IAI.00301-06; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Biedermann T, 2006, ACTA DERM-VENEREOL, V86, P99, DOI 10.2340/00015555-047; Biedermann T, 2004, J INVEST DERM SYMP P, V9, P5, DOI 10.1111/j.1087-0024.2004.00829.x; Bowler PG, 2001, CLIN MICROBIOL REV, V14, P244, DOI 10.1128/CMR.14.2.244-269.2001; Coombes JL, 2008, NAT REV IMMUNOL, V8, P435, DOI 10.1038/nri2335; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11255; Dziarski R, 2005, J ENDOTOXIN RES, V11, P304, DOI 10.1179/096805105X67256; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; GILPIN RW, 1974, J BACTERIOL, V119, P672, DOI 10.1128/JB.119.3.672-676.1974; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Hashimoto M, 2006, J IMMUNOL, V177, P3162, DOI 10.4049/jimmunol.177.5.3162; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; IORDANESCU S, 1976, J GEN MICROBIOL, V96, P277, DOI 10.1099/00221287-96-2-277; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; KLUYTMANS JAJW, 1995, J INFECT DIS, V171, P216, DOI 10.1093/infdis/171.1.216; Kraus D, 2007, INFECT IMMUN, V75, P2084, DOI 10.1128/IAI.01576-06; Kurokawa K, 2009, J BIOL CHEM, V284, P8406, DOI 10.1074/jbc.M809618200; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Magalhaes JG, 2008, J IMMUNOL, V181, P7925, DOI 10.4049/jimmunol.181.11.7925; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Roll A, 2004, CURR OPIN ALLERGY CL, V4, P373, DOI 10.1097/00130832-200410000-00008; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schmaler M, 2009, J IMMUNOL, V182, P7110, DOI 10.4049/jimmunol.0804292; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Sousa CRE, 2004, CURR OPIN IMMUNOL, V16, P21, DOI 10.1016/j.coi.2003.11.007; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Stoll H, 2005, INFECT IMMUN, V73, P2411, DOI 10.1128/IAI.73.4.2411-2423.2005; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Traub S, 2006, J ENDOTOXIN RES, V12, P69, DOI 10.1179/096805106X89044; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; van Langevelde P, 1998, ANTIMICROB AGENTS CH, V42, P3073, DOI 10.1128/AAC.42.12.3073; Wang JE, 2003, SHOCK, V20, P402, DOI 10.1097/01.shk.0000092268.01859.0d; Weindl G, 2007, J CLIN INVEST, V117, P3664, DOI 10.1172/JCI28115; WONG W, 1974, J BACTERIOL, V120, P837, DOI 10.1128/JB.120.2.837-843.1974; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	58	84	86	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					4089	4102		10.1096/fj.09-151001	http://dx.doi.org/10.1096/fj.09-151001			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20522786				2022-12-28	WOS:000285005900044
J	Caito, S; Rajendrasozhan, S; Cook, S; Chung, S; Yao, HW; Friedman, AE; Brookes, PS; Rahman, I				Caito, Samuel; Rajendrasozhan, Saravanan; Cook, Suzanne; Chung, Sangwoon; Yao, Hongwei; Friedman, Alan E.; Brookes, Paul S.; Rahman, Irfan			SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress	FASEB JOURNAL			English	Article						sirtuins; aldehydes; epithelium; cigarette smoke inflammation	NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; ALVEOLAR EPITHELIAL-CELLS; INDUCED OXIDATIVE STRESS; FREE-RADICAL CHEMISTRY; PROTEIN-KINASE CK2; CIGARETTE-SMOKE; INFLAMMATORY RESPONSES; CYTOKINE RELEASE; GENE-EXPRESSION	Sirtuin1 (SIRT1) deacetylase levels are decreased in chronic inflammatory conditions and aging where oxidative stress occurs. We determined the mechanism of SIRT1 redox post-translational modifications leading to its degradation. Human lung epithelial cells exposed to hydrogen peroxide (150-250 mu M), aldehyde-acrolein (10-30 mu M), and cigarette smoke extract (CSE; 0.1-1.5%) in the presence of intracellular glutathione-modulating agents at 1-24 h, and oxidative post-translational modifications were assayed in cells, as well as in lungs of mice lacking and overexpressing glutaredoxin-1 (Glrx1), and wild-type (WT) mice in response to cigarette smoke (CS). CSE and aldehydes dose and time dependently decreased SIRT1 protein levels, with EC50 of 1% for CSE and 30 mu M for acrolein at 6 h, and > 80% inhibition at 24 h with CSE, which was regulated by modulation of intracellular thiol status of the cells. CS decreased the lung levels of SIRT1 in WT mice, which was enhanced by deficiency of Glrx1 and prevented by overexpression of Glrx1. Oxidants, aldehydes, and CS induced carbonyl modifications on SIRT1 on cysteine residues concomitant with decreased SIRT1 activity. Proteomics studies revealed alkylation of cysteine residue on SIRT1. Our data suggest that oxidants/aldehydes covalently modify SIRT1, decreasing enzymatic activity and marking the protein for proteasomal degradation, which has implications in inflammatory conditions.-Caito, S., Rajendrasozhan, S., Cook, S., Chung, S., Yao, H., Friedman, A. E., Brookes, P. S., Rahman, I. SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. FASEB J. 24, 3145-3159 (2010). www.fasebj.org	[Caito, Samuel; Rajendrasozhan, Saravanan; Cook, Suzanne; Chung, Sangwoon; Yao, Hongwei; Friedman, Alan E.; Rahman, Irfan] Univ Rochester, Med Ctr, Dept Environm Med, Lung Biol & Dis Program, Rochester, NY 14642 USA; [Brookes, Paul S.] Univ Rochester, Med Ctr, Dept Anesthesiol, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Rahman, I (corresponding author), Univ Rochester, Med Ctr, Dept Environm Med, Lung Biol & Dis Program, 601 Elmwood Ave,Box 850, Rochester, NY 14642 USA.	irfan_rahman@urmc.rochester.edu	Friedman, Alan/Q-4858-2018; Yao, Hongwei/G-6444-2010; Rajendrasozhan, Saravanan/ABC-5213-2020	Friedman, Alan/0000-0002-4764-8168; Rajendrasozhan, Saravanan/0000-0002-4234-9417; Brookes, Paul/0000-0002-8639-8413	U.S. National Institutes of Health [1R01-HL092842, R01-HL085613, 1R01HL097751-01]; National Institute of Environmental Health Sciences Center [ES01247]; Toxicology Training Program [T32-ES07026]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085613, R01HL092842, R01HL097751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247, T32ES007026] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Toxicology Training Program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by U.S. National Institutes of Health grants 1R01-HL092842, R01-HL085613, and 1R01HL097751-01; National Institute of Environmental Health Sciences Center grant ES01247; and Toxicology Training Program grant T32-ES07026. The authors thank Dr. Se-Ran Yang for her technical assistance. The authors also thank Dr. Ye-Shih Ho (Institute of Environmental Health Sciences and Department of Biochemistry and Molecular Biology, Wayne State University, Detroit, MI, USA) for providing Glrx1-KO and Glrx1-Tg mice. None of the authors have any ethical conflicts of interest for publication of this manuscript.	Adenuga D, 2009, AM J RESP CELL MOL, V40, P464, DOI 10.1165/rcmb.2008-0255OC; Alcendor RR, 2007, CIRC RES, V100, P1512, DOI 10.1161/01.RES.0000267723.65696.4a; Baur JA, 2010, BBA-PROTEINS PROTEOM, V1804, P1626, DOI 10.1016/j.bbapap.2009.10.025; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Caito S, 2008, ANTIOXID REDOX SIGN, V10, P253, DOI 10.1089/ars.2007.1889; Carbone DL, 2004, FREE RADICAL BIO MED, V37, P1430, DOI 10.1016/j.freeradbiomed.2004.07.016; CARP H, 1978, AM REV RESPIR DIS, V118, P617; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Csiszar A, 2008, AM J PHYSIOL-HEART C, V294, pH2721, DOI 10.1152/ajpheart.00235.2008; Edirisinghe I, 2008, FASEB J, V22, P2297, DOI 10.1096/fj.07-099481; EISERICH JP, 1995, AM J CLIN NUTR, V62, P1490, DOI 10.1093/ajcn/62.6.1490S; Elliott PJ, 2008, CURR OPIN INVEST DR, V9, P371; Ford J, 2008, CELL CYCLE, V7, P3091, DOI 10.4161/cc.7.19.6799; Fratelli M, 2005, P NATL ACAD SCI USA, V102, P13998, DOI 10.1073/pnas.0504398102; Fujioka K, 2006, ENVIRON TOXICOL, V21, P47, DOI 10.1002/tox.20153; Furukawa A, 2007, CELL PHYSIOL BIOCHEM, V20, P45, DOI 10.1159/000104152; Gallogly MM, 2007, CURR OPIN PHARMACOL, V7, P381, DOI 10.1016/j.coph.2007.06.003; Ghezzi P, 2003, PROTEOMICS, V3, P1145, DOI 10.1002/pmic.200300435; Grimsrud PA, 2008, J BIOL CHEM, V283, P21837, DOI 10.1074/jbc.R700019200; Grune T, 2003, BIOCHEM BIOPH RES CO, V305, P709, DOI 10.1016/S0006-291X(03)00809-X; Hisahara S, 2008, P NATL ACAD SCI USA, V105, P15599, DOI 10.1073/pnas.0800612105; Ho YS, 2007, FREE RADICAL BIO MED, V43, P1299, DOI 10.1016/j.freeradbiomed.2007.07.025; Hong EH, 2010, J BIOL CHEM, V285, P1283, DOI 10.1074/jbc.M109.058628; Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091; Kang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006611; Karrasch S, 2008, RESP MED, V102, P1215, DOI 10.1016/j.rmed.2008.04.013; Kodama M, 1997, ANTICANCER RES, V17, P433; Kode A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-132; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MARKLUND S, 1976, J BIOL CHEM, V251, P7504; Mercer BA, 2004, J BIOL CHEM, V279, P17690, DOI 10.1074/jbc.M313842200; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Mulier B, 1998, EUR RESPIR J, V11, P384, DOI 10.1183/09031936.98.11020384; Murtaza I, 2008, J BIOL CHEM, V283, P5996, DOI 10.1074/jbc.M706466200; Nakamaru Y, 2009, FASEB J, V23, P2810, DOI 10.1096/fj.08-125468; Nystrom T, 2005, EMBO J, V24, P1311, DOI 10.1038/sj.emboj.7600599; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Ota H, 2008, ARTERIOSCL THROM VAS, V28, P1634, DOI 10.1161/ATVBAHA.108.164368; Ottenheijm CAC, 2006, AM J RESP CRIT CARE, V174, P997, DOI 10.1164/rccm.200605-721OC; Pantano C, 2006, ANTIOXID REDOX SIGN, V8, P1791, DOI 10.1089/ars.2006.8.1791; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067, DOI 10.1152/ajplung.1999.277.6.L1067; Rajendrasozhan S, 2008, AM J RESP CRIT CARE, V177, P861, DOI 10.1164/rccm.200708-1269OC; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Salminen A, 2008, CELL MOL LIFE SCI, V65, P1049, DOI 10.1007/s00018-008-7461-3; Sanders BD, 2010, BBA-PROTEINS PROTEOM, V1804, P1604, DOI 10.1016/j.bbapap.2009.09.009; Sasaki T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004020; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Sayre LM, 2006, DRUG METAB REV, V38, P651, DOI 10.1080/03602530600959508; Shen Z, 2009, AM J PHYSIOL-GASTR L, V296, pG1047, DOI 10.1152/ajpgi.00016.2009; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; Thatcher TH, 2007, AM J PATHOL, V170, P855, DOI 10.2353/ajpath.2007.060391; Tsuji T, 2004, AM J RESP CELL MOL, V31, P643, DOI 10.1165/rcmb.2003-0290OC; Tsuji T, 2006, AM J RESP CRIT CARE, V174, P886, DOI 10.1164/rccm.200509-1374OC; Tuder RM, 2006, AM J RESP CRIT CARE, V174, P490, DOI 10.1164/rccm.200607-924ED; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Vogelmeier C, 2007, AM J RESP CRIT CARE, V175, P1217, DOI 10.1164/rccm.200703-513ED; Westphal CH, 2007, TRENDS BIOCHEM SCI, V32, P555, DOI 10.1016/j.tibs.2007.09.008; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200; Yang SR, 2007, AM J PHYSIOL-LUNG C, V292, pL567, DOI 10.1152/ajplung.00308.2006; Yao HW, 2008, AM J PHYSIOL-LUNG C, V294, pL1174, DOI 10.1152/ajplung.00439.2007; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Ying J, 2007, FREE RADICAL BIO MED, V43, P1099, DOI 10.1016/j.freeradbiomed.2007.07.014; Zhang T, 2010, BBA-PROTEINS PROTEOM, V1804, P1666, DOI 10.1016/j.bbapap.2009.10.022; Zschoernig B, 2009, BIOCHEM BIOPH RES CO, V381, P372, DOI 10.1016/j.bbrc.2009.02.085	77	224	235	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3145	3159		10.1096/fj.09-151308	http://dx.doi.org/10.1096/fj.09-151308			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20385619	Green Published			2022-12-28	WOS:000281446400005
J	Cioffi, F; Zambad, SP; Chhipa, L; Senese, R; Busiello, RA; Tuli, D; Munshi, S; Moreno, M; Lombardi, A; Gupta, RC; Chauthaiwale, V; Dutt, C; de Lange, P; Silvestri, E; Lanni, A; Goglia, F				Cioffi, Federica; Zambad, Shitalkumar P.; Chhipa, Laxmikant; Senese, Rosalba; Busiello, Rosa Anna; Tuli, Davinder; Munshi, Siralee; Moreno, Maria; Lombardi, Assunta; Gupta, Ramesh C.; Chauthaiwale, Vijay; Dutt, Chaitanya; de Lange, Pieter; Silvestri, Elena; Lanni, Antonia; Goglia, Fernando			TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet	FASEB JOURNAL			English	Article						thyroid hormones; hepatic steatosis; mitochondria	METABOLIC SYNDROME; IN-VITRO; 3,5-DIIODO-L-THYRONINE; COA; OBESITY; HEART; DIIODOTHYRONINES; GLUCOSE; TISSUES; HUMANS	Chronic overnutrition and modern life-styles are causing a worldwide epidemic of obesity and associated comorbidities, which is creating a demand to identify underlying biological mechanisms and to devise effective treatments. In rats receiving a high-fat diet (HFD), we analyzed the effects of a 4-wk administration of a novel functional analog of iodothyronines, TRC150094 (TRC). HFD-TRC rats exhibited increased energy expenditure (+24% vs. HFD rats; P<0.05) and body weight (BW) gain comparable to that of standard chow-fed (N) rats [N, HFD, and HFD-TRC rats, +97 g, +140 g (P<0.05 vs. N), and +98 g (P<0.05 vs. HFD)]. HFD-TRC rats had significantly less visceral adipose tissue (vs. HFD rats) and exhibited altered metabolism in two major tissues that are very active metabolically. In liver, mitochondrial fatty acid import and oxidation were increased (+56 and +32%, respectively; P<0.05 vs. HFD rats), and consequently the hepatic triglyceride content was lower (-35%; P<0.05 vs. HFD rats). These effects were independent of the AMP-activated protein kinase-acetyl CoA-carboxylase-malonyl CoA pathway but involved sirtuin 1 activation. In skeletal muscle, TRC induced a fiber shift toward the oxidative type in tibialis anterior muscle, increasing its capacity to oxidize fatty acids. HFD-TRC rats had lower (vs. HFD rats) plasma cholesterol and triglyceride concentrations. If reproduced in humans, these results will open interesting possibilities regarding the counteraction of metabolic dysfunction associated with ectopic/visceral fat accumulation.-Cioffi, F., Zambad, S. P., Chhipa, L., Senese, R., Busiello, R. A., Tuli, D., Munshi, S., Moreno, M., Lombardi, A., Gupta, R. C., Chauthaiwale, V., Dutt, C., de Lange, P., Silvestri, E., Lanni, A., Goglia, F. TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet. FASEB J. 24, 3451-3461 (2010). www.fasebj.org	[Moreno, Maria; Silvestri, Elena; Goglia, Fernando] Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; [Cioffi, Federica; Senese, Rosalba; de Lange, Pieter; Lanni, Antonia] Univ Naples 2, Dipartimento Sci Vita, Caserta, Italy; [Zambad, Shitalkumar P.] Torrent Pharmaceut Ltd, Dept Pharmacol, Ahmadabad, Gujarat, India; [Chhipa, Laxmikant; Tuli, Davinder; Gupta, Ramesh C.] Torrent Pharmaceut Ltd, Med Drug Discovery, Ahmadabad, Gujarat, India; [Munshi, Siralee] Torrent Pharmaceut Ltd, Cellular & Mol Biol, Ahmadabad, Gujarat, India; [Chauthaiwale, Vijay] Torrent Pharmaceut Ltd, Discovery Res, Ahmadabad, Gujarat, India; [Dutt, Chaitanya] Torrent Pharmaceut Ltd, Clin Res, Torrent Res Ctr, Ahmadabad, Gujarat, India; [Busiello, Rosa Anna; Lombardi, Assunta] Univ Naples Federico 2, Dipartimento Biol, Naples, Italy	University of Sannio; Universita della Campania Vanvitelli; University of Naples Federico II	Goglia, F (corresponding author), Univ Sannio, Dipartimento Sci Biol & Ambientali, Via Port Arsa 11, I-82100 Benevento, Italy.	goglia@unisannio.it	Zambad, Shitalkumar/AIF-1927-2022; cioffi, federica/AAB-8161-2019; de Lange, Pieter/GXA-3052-2022	Zambad, Shitalkumar/0000-0002-4085-8613; cioffi, federica/0000-0002-1530-8556; SENESE, Rosalba/0000-0003-1571-0980; GOGLIA, Fernando/0000-0003-0468-9645; MORENO, Maria/0000-0002-6218-5501; Silvestri, Elena/0000-0002-0592-9033	Torrent Pharmaceuticals Ltd. (Ahmedabad, Gujarat, India)	Torrent Pharmaceuticals Ltd. (Ahmedabad, Gujarat, India)	The authors thank Dr. Onorato Goglia (Azienda Ospedaliera Rummo-Benevento) for performing cholesterol and triglycerides assays. This study was funded by Torrent Pharmaceuticals Ltd. (Ahmedabad, Gujarat, India). TRC150094 is a molecule patented under a patent owned by Torrent Pharmaceuticals Ltd. S.P.Z., L. C., D. T., S. M., R. C. G., V. C., and C. D. are employees of Torrent Pharmaceuticals Ltd. No other potential conflict of interest relevant to this article was reported.	Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198; Ball SG, 1997, J MOL ENDOCRINOL, V19, P137, DOI 10.1677/jme.0.0190137; Berkenstam A, 2008, P NATL ACAD SCI USA, V105, P663, DOI 10.1073/pnas.0705286104; BOSHOUWERS FMG, 1983, BRIT POULTRY SCI, V24, P273, DOI 10.1080/00071668308416739; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; Chen K, 2008, DIABETES VASC DIS RE, V5, P96, DOI 10.3132/dvdr.2008.016; Cooper DS, 2003, LANCET, V362, P459, DOI 10.1016/S0140-6736(03)14073-1; de Simone G, 2007, DIABETES CARE, V30, P1851, DOI 10.2337/dc06-2152; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Enas Enas A, 2007, J Cardiometab Syndr, V2, P267, DOI 10.1111/j.1559-4564.2007.07392.x; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; FOLCH J, 1957, J BIOL CHEM, V226, P497; HICKEY MS, 1995, AM J PHYSIOL-ENDOC M, V268, pE453, DOI 10.1152/ajpendo.1995.268.3.E453; Krotkiewski M, 2002, EUR J PHARMACOL, V440, P85, DOI 10.1016/S0014-2999(02)01420-6; Ladenson PW, 2010, NEW ENGL J MED, V362, P906, DOI 10.1056/NEJMoa0905633; Lanni A, 2005, FASEB J, V19, DOI 10.1096/fj.05.3977fje; LANNI A, 1992, MOL CELL ENDOCRINOL, V86, P143, DOI 10.1016/0303-7207(92)90138-V; Lanni A, 1996, J PHYSIOL-LONDON, V494, P831, DOI 10.1113/jphysiol.1996.sp021536; Lombardi A, 2009, AM J PHYSIOL-ENDOC M, V296, pE497, DOI 10.1152/ajpendo.90642.2008; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; Mollica MP, 2009, J HEPATOL, V51, P363, DOI 10.1016/j.jhep.2009.03.023; Moreno M, 1997, J PHYSIOL-LONDON, V505, P529, DOI 10.1111/j.1469-7793.1997.529bb.x; Moreno M, 2008, THYROID, V18, P239, DOI 10.1089/thy.2007.0248; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Tanner CJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE1191, DOI 10.1152/ajpendo.00416.2001; Yu J, 2009, ANN NY ACAD SCI, V1173, P10	31	34	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3451	3461		10.1096/fj.10-157115	http://dx.doi.org/10.1096/fj.10-157115			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20453112				2022-12-28	WOS:000281446400032
J	Zhao, M; Valamanesh, F; Celerier, I; Savoldelli, M; Jonet, L; Jeanny, JC; Jaisser, F; Farman, N; Behar-Cohen, F				Zhao, Min; Valamanesh, Fatemeh; Celerier, Isabelle; Savoldelli, Michele; Jonet, Laurent; Jeanny, Jean-Claude; Jaisser, Frederic; Farman, Nicolette; Behar-Cohen, Francine			The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells	FASEB JOURNAL			English	Article						mineralocorticoid receptor; glucocorticoids; aquaporin 4; Kir 4.1 potassium channel; ENaC sodium channel	INTRAVITREAL TRIAMCINOLONE ACETONIDE; EPITHELIAL SODIUM-CHANNEL; CARDIOVASCULAR-DISEASE; RECEPTOR; EXPRESSION; RETINA; RAT; MICE; AQUAPORIN-4; DISRUPTION	Glucocorticoids reduce diabetic macular edema, but the mechanisms underlying glucocorticoid effects are imperfectly elucidated. Glucocorticoids may bind to glucocorticoid (GR) and mineralocorticoid (MR) receptors. We hypothesize that MR activation may influence retinal hydration. The effect of the MR agonist aldosterone (24 h) on ion/water channel expression (real-time PCR, Western blot, immunofluorescence) was investigated on cultured retinal Muller glial cells (RMGs, which contribute to fluid homeostasis in the retina), in Lewis rat retinal explants, and in retinas from aldosterone-injected eyes. We evidenced cell-specific expression of MR, GR, and 11-beta-hydroxysteroid dehydrogenase type II. Aldosterone significantly enhances expression of sodium and potassium channels ENaC-alpha (6.5-fold) and Kir4.1 (1.9-fold) through MR and GR occupancy, whereas aquaporin 4 (AQP4, 2.9-fold) up-regulation is MR-selective. Aldosterone intravitreous injection induces retinal swelling (24% increase compared to sham-injected eyes) and activation of RMGs. It promotes additional localization of Kir4.1 and AQP4 toward apical microvilli of RMGs. Our results highlight the mineralocorticoid-sensitivity of the neuroretina and show that aldosterone controls hydration of the healthy retina through regulation of ion/water channels expression in RMGs. These results provide a rationale for future investigations of abnormal MR signaling in the pathological retina.-Zhao, M., Valamanesh, F., Celerier, I., Savoldelli, M., Jonet, L., Jeanny, J.-C., Jaisser, F., Farman, N., Behar-Cohen, F. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells. FASEB J. 24, 3405-3415 (2010). www.fasebj.org	[Zhao, Min; Valamanesh, Fatemeh; Jonet, Laurent; Jeanny, Jean-Claude; Behar-Cohen, Francine] Univ Paris 05, INSERM, Ctr Rech Cordeliers, U872,Team 17, F-75006 Paris, France; [Valamanesh, Fatemeh] Fdn Adolphe De Rothschild, Paris, France; [Savoldelli, Michele] Univ Paris 05, Hotel Dieu Univ Hosp, F-75006 Paris, France; [Celerier, Isabelle; Jaisser, Frederic; Farman, Nicolette] Univ Paris 06, INSERM, Ctr Rech Cordeliers, U872,Team 1, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Behar-Cohen, F (corresponding author), Univ Paris 05, INSERM, Ctr Rech Cordeliers, U872,Team 17, 15 Rue Ecole Med, F-75006 Paris, France.	francine.behar@gmail.com	Zhao, Min/AAX-7664-2020; Jaisser, Frederic/P-4287-2017	Zhao, Min/0000-0002-5418-7275; Jaisser, Frederic/0000-0001-9051-1901	Fondation Rothschild; Ministere de la Recherche; INSERM; Union National des Aveugles et Deficients Visuels (UNADEV) funds	Fondation Rothschild; Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Union National des Aveugles et Deficients Visuels (UNADEV) funds	The authors thank Christophe Klein of the Research Center of Cordeliers for his help in confocal microscopy and Astrid Limb (University College London, London, UK) for providing the human RMG cell line. M.Z. and F. V. were supported by the Fondation Rothschild. I. C. is the recipient of a Ph.D. grant from the Ministere de la Recherche. This work has been supported by INSERM and Union National des Aveugles et Deficients Visuels (UNADEV) funds.	Baath J, 2007, J OCUL PHARMACOL TH, V23, P304, DOI 10.1089/jop.2006.125; Berger S, 1998, P NATL ACAD SCI USA, V95, P9424, DOI 10.1073/pnas.95.16.9424; Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008; Bhalla V, 2006, AM J PHYSIOL-RENAL, V291, pF714, DOI 10.1152/ajprenal.00061.2006; Boulkroun S, 2002, J BIOL CHEM, V277, P31506, DOI 10.1074/jbc.M200272200; Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003; Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001; Brockway LM, 2002, AM J PHYSIOL-CELL PH, V283, pC126, DOI 10.1152/ajpcell.00457.2001; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DEKOZAK Y, 1994, J NEUROIMMUNOL, V55, P1, DOI 10.1016/0165-5728(94)90141-4; DeRijk RH, 2008, EUR J PHARMACOL, V583, P303, DOI 10.1016/j.ejphar.2007.11.072; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; Farman N, 2001, AM J PHYSIOL-RENAL, V280, pF181, DOI 10.1152/ajprenal.2001.280.2.F181; Farman N, 2010, EXP DERMATOL, V19, P100, DOI 10.1111/j.1600-0625.2009.01011.x; Fiebeler A, 2007, CURR OPIN NEPHROL HY, V16, P134; Funder JW, 2007, AM J CARDIOVASC DRUG, V7, P151, DOI 10.2165/00129784-200707030-00001; Gaeggeler HP, 2005, J AM SOC NEPHROL, V16, P878, DOI 10.1681/ASN.2004121110; Golestaneh N, 2001, GLIA, V33, P160, DOI 10.1002/1098-1136(200102)33:2<160::AID-GLIA1015>3.0.CO;2-4; Goodyear MJ, 2009, VISUAL NEUROSCI, V26, P159, DOI 10.1017/S0952523809090038; Guo C, 2006, ENDOCRINOLOGY, V147, P5363, DOI 10.1210/en.2006-0944; Iandiev L, 2008, NEUROSCI LETT, V434, P317, DOI 10.1016/j.neulet.2008.02.026; Joels M, 2008, TRENDS NEUROSCI, V31, P1, DOI 10.1016/j.tins.2007.10.005; Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004; Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195; Kofuji P, 2000, J NEUROSCI, V20, P5733, DOI 10.1523/JNEUROSCI.20-15-05733.2000; Leopold JA, 2007, NAT MED, V13, P189, DOI 10.1038/nm1545; Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864; Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037; Mirshahi M, 1996, BIOCHEM BIOPH RES CO, V219, P150, DOI 10.1006/bbrc.1996.0197; MOSCONA AA, 1967, SCIENCE, V158, P496, DOI 10.1126/science.158.3800.496; Ouvrard-Pascaud A, 2005, CIRCULATION, V111, P3025, DOI 10.1161/CIRCULATIONAHA.104.503706; Pascual-Le Tallec L, 2005, MOL ENDOCRINOL, V19, P2211, DOI 10.1210/me.2005-0089; Pippal JB, 2008, J MOL ENDOCRINOL, V41, P405, DOI 10.1677/JME-08-0093; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Revollo JR, 2009, ANN NY ACAD SCI, V1179, P167, DOI 10.1111/j.1749-6632.2009.04986.x; Rickard AJ, 2009, J MOL ENDOCRINOL, V42, P449, DOI 10.1677/JME-08-0144; Rozeboom AM, 2007, P NATL ACAD SCI USA, V104, P4688, DOI 10.1073/pnas.0606067104; Ruiz-Ederra J, 2007, J BIOL CHEM, V282, P21866, DOI 10.1074/jbc.M703236200; Valamanesh F, 2007, MOL VIS, V13, P1746; Verkman AS, 2008, PROG RETIN EYE RES, V27, P420, DOI 10.1016/j.preteyeres.2008.04.001; Viengchareun Say, 2007, Nucl Recept Signal, V5, pe012, DOI 10.1621/nrs.05012; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; Zennaro MC, 2009, TRENDS ENDOCRIN MET, V20, P444, DOI 10.1016/j.tem.2009.05.006	43	104	110	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3405	3415		10.1096/fj.09-154344	http://dx.doi.org/10.1096/fj.09-154344			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20466875				2022-12-28	WOS:000281446400028
J	Audet, M; Lagace, M; Silversides, DW; Bouvier, M				Audet, Martin; Lagace, Monique; Silversides, David W.; Bouvier, Michel			Protein-protein interactions monitored in cells from transgenic mice using bioluminescence resonance energy transfer	FASEB JOURNAL			English	Article						beta-arrestin2; beta 2-adrenergic receptor; Renilla luciferase; green fluorescent protein	BETA-ADRENERGIC RECEPTORS; LIVING CELLS; BETA-2-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; TRANSFER BRET; LIVE CELLS; CONFORMATIONAL-CHANGES; GENE-EXPRESSION; LEYDIG-CELLS; RAT TESTIS	Monitoring the dynamics of protein-protein interactions in their natural environment remains a challenge. Resonance energy transfer approaches represent a promising avenue to directly probe these interactions in real time. The present study aims at establishing a proof of principle that bioluminescence resonance energy transfer (BRET) can be used to study the regulation of protein-protein interaction in cells from transgenic animals. A transgenic mouse line coexpressing the beta(2)-adrenergic receptor fused to Renilla luciferase (beta(2)AR-Rluc) and beta arrestin-2 fused to a green fluorescent protein (GFP2-beta arr2) was generated. The fusion proteins were found to be functional in the transgenic animals and the beta(2)AR-Rluc maintained pharmacological properties, comparable to that of the native receptor. Sufficiently high luminescence signal was generated to allow detection of BRET in testis cells where the beta(2)AR-Rluc transgene was expressed at levels significantly higher than that of the endogenous receptor in this tissue but remain within physiological range when compared with other beta(2)AR-expressing tissues. Stimulation with a beta-adrenergic agonist led to a significant dose-and time-dependent increase in BRET, which reflected ligand-promoted recruitment of beta arr2 to the receptor. Our study demonstrates that BRET can be used to monitor the dynamic regulation of protein-protein interactions in cells derived from transgenic mice.-Audet, M., Lagace, M., Silversides, D. W., Bouvier, M. Protein-protein interactions monitored in cells from transgenic mice using bioluminescence resonance energy transfer. FASEB J. 24, 2829-2838 (2010). www.fasebj.org	[Audet, Martin; Lagace, Monique; Bouvier, Michel] Univ Montreal, Dept Biochem, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; [Audet, Martin; Lagace, Monique; Bouvier, Michel] Univ Montreal, Grp Rech Univ Med, Montreal, PQ H3C 3J7, Canada; [Silversides, David W.] Univ Montreal, Fac Med Vet, Dept Vet Biomed, Ctr Rech Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Bouvier, M (corresponding author), CP 6128 Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	michel.bouvier@umontreal.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100	Canadian Institute for Health Research (CIHR) [GOP-48289]; CIHR/Canadian Hypertension Society/Pfizer; Fonds de la Recherche en Sante du Quebec	Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR/Canadian Hypertension Society/Pfizer(Canadian Institutes of Health Research (CIHR)Pfizer); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec)	The authors thank Drs. Mounia Azzi, Patricia Rene, Louis Gaboury, and Fadi Hamdan for their assistance in the development of some of the methods, as well as Marc Palardy, Celine Forget, and Diana Raiwet for their roles in the vector design, construction, generation of transgenic mouse lines, Southern blot analysis, and animal colony maintenance. The authors are also grateful to Dr. Hiroyuki Kobayashi for his critical reading of the manuscript. This work was supported by grants of the Canadian Institute for Health Research (CIHR) to M.B. and D.W.S. (GOP-48289). M.A. held studentships from the CIHR/Canadian Hypertension Society/Pfizer joint program and the Fonds de la Recherche en Sante du Quebec. M.B. holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology.	Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Azzi M, 2001, MOL PHARMACOL, V60, P999, DOI 10.1124/mol.60.5.999; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; BREUILLER M, 1988, BIOCHEM BIOPH RES CO, V151, P1454, DOI 10.1016/S0006-291X(88)80525-4; Calebiro D, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000172; Charest PG, 2005, EMBO REP, V6, P334, DOI 10.1038/sj.embor.7400373; Coulon V, 2008, BIOPHYS J, V94, P1001, DOI 10.1529/biophysj.107.117275; David M, 2006, CELL SIGNAL, V18, P2172, DOI 10.1016/j.cellsig.2006.05.014; De A, 2005, FASEB J, V19, P2017, DOI 10.1096/fj.05-4628fje; De A, 2009, FASEB J, V23, P2702, DOI 10.1096/fj.08-118919; Drake MT, 2008, J BIOL CHEM, V283, P5669, DOI 10.1074/jbc.M708118200; Ducros M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004418; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gunnarsson D, 2007, TOXICOL LETT, V168, P51, DOI 10.1016/j.toxlet.2006.10.015; Hamdan FF, 2007, J BIOL CHEM, V282, P29089, DOI 10.1074/jbc.M700577200; Hamdan FF, 2005, J BIOMOL SCREEN, V10, P463, DOI 10.1177/1087057105275344; HAMDAN FF, 2006, CURR PROTOC NEUROSCI; Hanyaloglu AC, 2008, ANNU REV PHARMACOL, V48, P537, DOI 10.1146/annurev.pharmtox.48.113006.094830; Hara M, 2004, AM J PHYSIOL-CELL PH, V287, pC932, DOI 10.1152/ajpcell.00151.2004; Hasbi A, 2004, MOL ENDOCRINOL, V18, P1277, DOI 10.1210/me.2003-0440; HEDGER MP, 1987, ENDOCRINOLOGY, V121, P1824, DOI 10.1210/endo-121-5-1824; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Kocan M, 2008, J BIOMOL SCREEN, V13, P888, DOI 10.1177/1087057108324032; Lissandron V, 2007, CELL SIGNAL, V19, P2296, DOI 10.1016/j.cellsig.2007.07.004; METHOT D, 1995, NUCLEIC ACIDS RES, V23, P4551, DOI 10.1093/nar/23.22.4551; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Nikolaev VO, 2006, CIRC RES, V99, P1084, DOI 10.1161/01.RES.0000250046.69918.d5; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Pfleger KDG, 2006, NAT METHODS, V3, P165, DOI 10.1038/nmeth841; Prasad SVN, 2002, J CELL BIOL, V158, P563, DOI 10.1083/jcb.200202113; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Swenson ES, 2007, STEM CELLS, V25, P2593, DOI 10.1634/stemcells.2007-0241; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TOLSZCZUK M, 1988, J ANDROL, V9, P172; Triposkiadis F, 2009, J AM COLL CARDIOL, V54, P1747, DOI 10.1016/j.jacc.2009.05.015; Wier WG, 2008, J PHYSIOL-LONDON, V586, P2437, DOI 10.1113/jphysiol.2008.151522; Xia ZY, 2009, CURR OPIN BIOTECH, V20, P37, DOI 10.1016/j.copbio.2009.01.001; Xie Y, 2008, AM J PHYSIOL-CELL PH, V295, pC388, DOI 10.1152/ajpcell.00178.2008; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	42	21	21	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2829	2838		10.1096/fj.09-144816	http://dx.doi.org/10.1096/fj.09-144816			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20335229				2022-12-28	WOS:000285005400023
J	Fuster, JJ; Gonzalez, JM; Edo, MD; Viana, R; Boya, P; Cervera, J; Verges, M; Rivera, J; Andres, V				Fuster, Jose J.; Gonzalez, Jose M.; Edo, Maria D.; Viana, Rosa; Boya, Patricia; Cervera, Javier; Verges, Marcel; Rivera, Jose; Andres, Vicente			Tumor suppressor p27(Kip1) undergoes endolysosomal degradation through its interaction with sorting nexin 6	FASEB JOURNAL			English	Article						SNX6; proteolysis; endosome; lysosome; cell cycle	CDK INHIBITOR P27; CELL-CYCLE ARREST; C-FOS; DOWN-REGULATION; EGF RECEPTOR; MICE LACKING; LAMIN A/C; S PHASE; MIGRATION; GROWTH	A large body of evidence supports the hypothesis that proteasomal degradation of the growth suppressor p27(Kip1) (p27) facilitates mammalian cell cycle progression. However, very few studies have addressed the possibility of proteasome-independent mechanisms of p27 proteolysis. Here we provide evidence for a novel pathway of p27 degradation via the lysosome that is mediated by its interaction with the endosomal protein sorting nexin 6 (SNX6), a member of the sorting nexin family of vesicular trafficking regulators. p27 and SNX6 interact in vitro and in vivo in mammalian cells, partially colocalize in endosomes, and are present in purified endosomal fractions. Gain-and loss-of-function studies revealed that SNX6 induces endosomal accumulation of p27. Moreover, p27 is detected in lysosomes and inhibition of lysosome-dependent proteolysis impairs serum-mediated down-regulation of p27 in a SNX6-dependent manner. To validate the localization of p27 in these organelles, we analyzed several cell lines using two different anti-p27 antibodies, several organelle-specific markers [e.g., early endosome antigen 1, lysosomal-associated membrane protein (LAMP) 1, LAMP2, and LysoTracker], and overexpression of fluorescent p27 and SNX6. Remarkably, silencing of SNX6 attenuates p27 down-regulation in the G(1) phase of the mitotic cell cycle and delays cell cycle progression. We therefore conclude that, in addition to the proteasome-dependent pathway, SNX6-mediated endolysosomal degradation of p27 also contributes to cell cycle progression in mammalian cells.-Fuster, J. J., Gonzalez, J. M., Edo, M. D., Viana, R., Boya, P., Cervera, J., Verges, M., Rivera, J., Andres, V. Tumor suppressor p27(Kip1) undergoes endolysosomal degradation through its interaction with sorting nexin 6. FASEB J. 24, 2998-3009 (2010). www.fasebj.org	[Fuster, Jose J.; Rivera, Jose; Andres, Vicente] CNIC, Lab Mol & Genet Cardiovasc Pathophysiol, Dept Atherothrombosis & Cardiovasc Imaging, Madrid 28029, Spain; [Fuster, Jose J.; Gonzalez, Jose M.; Edo, Maria D.; Viana, Rosa; Andres, Vicente] CSIC, Inst Biomed Valencia, Lab Vasc Biol, Dept Mol & Cellular Pathol & Therapy, Valencia, Spain; [Boya, Patricia] CSIC, Ctr Invest Biol, Dept Cellular & Mol Physiopathol, Dev Differentiat & Degenerat Lab, Madrid, Spain; [Cervera, Javier] Ctr Invest Principe Felipe, Mol Recognit Lab, Valencia, Spain; [Verges, Marcel] Ctr Invest Principe Felipe, Lab Epithelial Cell Biol, Valencia, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Prince Felipe Research Center; Prince Felipe Research Center	Andres, V (corresponding author), CNIC, Lab Mol & Genet Cardiovasc Pathophysiol, Dept Atherothrombosis & Cardiovasc Imaging, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	vandres@cnic.es	Andres, Vicente/I-6440-2014; Fuster, José J/D-3685-2011; Rivera-Torres, José/P-2793-2015; Viana, Rosa/L-1922-2014; Gonzalez-Granado, Jose M/A-2952-2015; Verges, Marcel/L-5784-2014; Boya, Patricia/P-8345-2019; Boya, Patricia/K-2911-2014	Andres, Vicente/0000-0002-0125-7209; Fuster, José J/0000-0002-5970-629X; Rivera-Torres, José/0000-0003-0365-9604; Viana, Rosa/0000-0002-0036-0669; Gonzalez-Granado, Jose M/0000-0002-1177-869X; Verges, Marcel/0000-0002-2606-223X; Boya, Patricia/0000-0003-3045-951X; Boya, Patricia/0000-0003-3045-951X	Spanish Ministry of Science and Innovation (MICINN); European Regional Development Fund [SAF2004-3057, SAF2007-62110]; Instituto de Salud Carlos III (ISCIII) [RD06/0014/0021]; Fundacion Ramon Areces; European Social Fund; Pro-CNIC Foundation	Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Regional Development Fund(European Commission); Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission); Fundacion Ramon Areces; European Social Fund(European Social Fund (ESF)); Pro-CNIC Foundation	The authors thank M. A. Ibanez for help with the preparation and analysis of endosomal fractions, M. J. Andres-Manzano for help preparing the figures, and colleagues who generously provided reagents (Bruno Amati, European Institute of Oncology, Milan, Italy; Jun-ya Kato, Institute of Science and Technology, Nara, Japan; Jennifer Lippincott-Schwartz, NIH, Bethesda, MD, USA; W. Tony Parks, University of Washington, Seattle, WA, USA; Bert Vogelstein, Johns Hopkins University, Baltimore, MD, USA; Gabriel Gil, IMIM, Barcelona, Spain; Pascual Sanz, IBV-CSIC, Valencia, Spain; and Michael Clague, University of Liverpool, Liverpool, UK). This work was supported by grants to V.A. from the Spanish Ministry of Science and Innovation (MICINN) and the European Regional Development Fund (grants SAF2004-3057 and SAF2007-62110), Instituto de Salud Carlos III (ISCIII; grant RD06/0014/0021, RECAVA), and Fundacion Ramon Areces. J.M.G. was supported by ISCIII, and J.J.F. by the CSIC-I3P predoctoral fellowship program cosponsored by the European Social Fund. The CNIC is supported by the MICINN and the Pro-CNIC Foundation.	Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; BIN Z, 2006, P NATL ACAD SCI USA, V103, P16776; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bonifacino JS, 2008, CURR OPIN CELL BIOL, V20, P427, DOI 10.1016/j.ceb.2008.03.009; BORRIELLO A, 2007, CELL CYCLE, V6, P9; Carlton J, 2005, TRAFFIC, V6, P75, DOI 10.1111/j.1600-0854.2005.00260.x; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cavet ME, 2008, FASEB J, V22, P3607, DOI 10.1096/fj.07-094086; Chastagner P, 2006, EMBO REP, V7, P1147, DOI 10.1038/sj.embor.7400822; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Choi JH, 2004, J CELL SCI, V117, P4209, DOI 10.1242/jcs.01233; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Cullen PJ, 2008, NAT REV MOL CELL BIO, V9, P574, DOI 10.1038/nrm2427; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Derby MC, 2007, INT REV CYTOL, V261, P47, DOI 10.1016/S0074-7696(07)61002-X; Diez-Juan A, 2004, BLOOD, V103, P158, DOI 10.1182/blood-2003-07-2319; Diez-Juan A, 2003, CIRC RES, V92, P402, DOI 10.1161/01.RES.0000059306.71961.ED; Diez-Juan A, 2001, FASEB J, V15, P1989, DOI 10.1096/fj.01-0130com; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Goukassian D, 2001, FASEB J, V15, P1877, DOI 10.1096/fj.01-0065com; Gullapalli A, 2006, MOL BIOL CELL, V17, P1228, DOI 10.1091/mbc.E05-09-0899; HIROKI A, 2006, J NEUROCHEM, V99, P733; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Ivorra' C, 2006, GENE DEV, V20, P307, DOI 10.1101/gad.349506; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Gonzalez JM, 2008, J CELL BIOL, V183, P653, DOI 10.1083/jcb.200805049; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Moeller SJ, 2003, MOL CELL BIOL, V23, P3735, DOI 10.1128/MCB.23.11.3735-3752.2003; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Pritsker M, 2006, P NATL ACAD SCI USA, V103, P6946, DOI 10.1073/pnas.0509861103; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sugiyama Y, 2001, J BIOL CHEM, V276, P12084, DOI 10.1074/jbc.M010811200; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Verges M, 2007, FRONT BIOSCI-LANDMRK, V12, P3825, DOI 10.2741/2355; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Wassmer T, 2007, J CELL SCI, V120, P45, DOI 10.1242/jcs.03302; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	59	25	27	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2010	24	8					2998	3009		10.1096/fj.09-138255	http://dx.doi.org/10.1096/fj.09-138255			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20228253	Green Submitted			2022-12-28	WOS:000285005400038
J	Feng, ZH; Zhang, C; Kang, HJ; Sun, Y; Wang, HJ; Naqvi, A; Frank, AK; Rosenwaks, Z; Murphy, ME; Levine, AJ; Hu, WW				Feng, Zhaohui; Zhang, Cen; Kang, Hey-Joo; Sun, Yvonne; Wang, Haijian; Naqvi, Asad; Frank, Amanda K.; Rosenwaks, Zev; Murphy, Maureen E.; Levine, Arnold J.; Hu, Wenwei			Regulation of female reproduction by p53 and its family members	FASEB JOURNAL			English	Article						implantation; leukemia inhibitory factor; single nucleotide polymorphism; p63; p73	LEUKEMIA INHIBITORY FACTOR; ESTROGEN-RECEPTOR; TUMOR-FORMATION; PATHWAY; MOUSE; IMPLANTATION; POLYMORPHISM; EXPRESSION; HUMANS; CELLS	Tumor suppressor p53 is crucial for embryonic implantation through transcriptional up-regulation of uterine leukemia inhibitory factor (LIF). This article reports that p53 and estrogen receptor alpha were activated in endometrial tissues during implantation to coordinately regulate LIF production. By using human p53 knockin (Hupki) mice carrying a single nucleotide polymorphism (SNP) at codon 72 (arginine/proline), the arginine allele was demonstrated to produce higher uterine LIF levels during implantation than the proline allele. In humans, the diversity of haplotypes of the p53 gene has decreased during evolution, because the arginine allele, existing in only a subset of haplotypes, is under positive selection. This observation is consistent with previous results showing that the proline allele is enriched in patients undergoing in vitro fertilization (IVF). Studies with p63- and p73-knockout mice have demonstrated the involvement of p63 and p73 in female reproduction and their roles in egg formation and apoptosis (p63) and spindle checkpoint (p73) in female mice. Here, the role of p63 and p73 in human reproduction was investigated. Selected alleles of SNPs in p63 and p73 genes were enriched in IVF patients. These findings demonstrate that the p53 family members are involved in several steps to regulate female reproduction in mice and humans.-Feng, Z., Zhang, C., Kang, H.-J., Sun, Y., Wang, H., Naqvi, A., Frank, A. K., Rosenwaks, Z., Murphy, M. E., Levine, A. J., Hu, W. Regulation of female reproduction by p53 and its family members. FASEB J. 25, 2245-2255 (2011). www.fasebj.org	[Wang, Haijian; Naqvi, Asad; Levine, Arnold J.] Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; [Feng, Zhaohui; Zhang, Cen; Sun, Yvonne; Levine, Arnold J.; Hu, Wenwei] Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ USA; [Kang, Hey-Joo; Rosenwaks, Zev] Weill Cornell Med Coll, Ctr Reprod Med & Infertil, New York, NY USA; [Frank, Amanda K.; Murphy, Maureen E.] Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Cornell University; Fox Chase Cancer Center	Levine, AJ (corresponding author), Inst Adv Study, Sch Nat Sci, Einstein Dr, Princeton, NJ 08540 USA.	alevine@ias.edu; huw1@umdnj.edu		Murphy, Maureen/0000-0001-7644-7296	U.S. National Institutes of Health [1P30-CA147892-01]; NATIONAL CANCER INSTITUTE [P30CA147892, R01CA102184] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by U.S. National Institutes of Health grant 1P30-CA147892-01 (to W.H. and A.J.L.).	Aghajanova L, 2004, ANN NY ACAD SCI, V1034, P176, DOI 10.1196/annals.1335.020; Atwal GS, 2007, P NATL ACAD SCI USA, V104, P4524, DOI 10.1073/pnas.0610998104; Atwal GS, 2009, P NATL ACAD SCI USA, V106, P10236, DOI 10.1073/pnas.0901298106; BELYI VA, COLD SPRING HARB PER, V2; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Chen JR, 2000, ENDOCRINOLOGY, V141, P4365, DOI 10.1210/en.141.12.4365; Cheng Jr-Gang, 2002, Rev Endocr Metab Disord, V3, P119, DOI 10.1023/A:1015402811650; DOTSCH V, COLD SPRING HARB PER, V2; Fels DR, 2005, TRENDS BIOCHEM SCI, V30, P426, DOI 10.1016/j.tibs.2005.06.009; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Hirota Y, 2010, J CLIN INVEST, V120, P803, DOI 10.1172/JCI40051; Hu WW, 2007, NATURE, V450, P721, DOI 10.1038/nature05993; Hu WW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001073; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Jeong BS, 2010, FASEB J, V24, P1347, DOI 10.1096/fj.09-146001; Kang HJ, 2009, P NATL ACAD SCI USA, V106, P9761, DOI 10.1073/pnas.0904280106; Kurita T, 2005, MECH DEVELOP, V122, P1043, DOI 10.1016/j.mod.2005.04.008; Laird SM, 1997, HUM REPROD, V12, P569; LANE D, COLD SPRING HARB PER, V2; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZP, 2004, P NATL ACAD SCI USA, V101, P2963, DOI 10.1073/pnas.0308607101; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Mikolajczyk M, 2007, AM J REPROD IMMUNOL, V58, P65, DOI 10.1111/j.1600-0897.2007.00492.x; Murphy ME, 2006, CELL DEATH DIFFER, V13, P916, DOI 10.1038/sj.cdd.4401907; Reinbold M, 2008, ONCOGENE, V27, P2788, DOI 10.1038/sj.onc.1210932; Robertson SA, 1996, BIOL REPROD, V54, P183, DOI 10.1095/biolreprod54.1.183; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; TRANQUILLI AL, MED HYPOTHESES, V75, P38; Vernole P, 2009, CELL CYCLE, V8, P421, DOI 10.4161/cc.8.3.7623; YAMASHITA S, 1990, ENDOCRINOLOGY, V127, P2456, DOI 10.1210/endo-127-5-2456	37	61	66	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2245	2255		10.1096/fj.10-180166	http://dx.doi.org/10.1096/fj.10-180166			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21402718	Green Published, Bronze			2022-12-28	WOS:000292242200016
J	Xu, J; Zhu, DH; He, SK; Spee, C; Ryan, SJ; Hinton, DR				Xu, Jing; Zhu, Danhong; He, Shikun; Spee, Christine; Ryan, Stephen J.; Hinton, David R.			Transcriptional regulation of bone morphogenetic protein 4 by tumor necrosis factor and its relationship with age-related macular degeneration	FASEB JOURNAL			English	Article						choroidal neovascularization; CNV; c-Jun NH(2)-terminal kinase; JNK; specificity protein 1; Sp1; phosphorylation	INDUCED CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; TNF-ALPHA; SP1 PHOSPHORYLATION; GENE-TRANSCRIPTION; SIGNALING PATHWAY; MOUSE EMBRYO; EXPRESSION; BMP4	Bone morphogenetic protein-4 (BMP4) may be involved in the molecular switch that determines which late form of age-related macular degeneration (AMD) an individual develops. BMP4 expression is high in retinal pigment epithelium (RPE) cells in late, dry AMD patients, while BMP4 expression is low in the wet form of the disease, characterized by choroidal neovascularization (CNV). Here, we sought to determine the mechanism by which BMP4 is down-regulated in CNV. BMP4 expression was decreased within laser-induced CNV lesions in mice at a time when tumor necrosis factor (TNF) expression was high (7 d postlaser) and was reexpressed in RPE when TNF levels declined (14 d postlaser). We found that TNF, an important angiogenic stimulus, significantly down-regulates BMP4 expression in cultured human fetal RPE cells, ARPE-19 cells, and RPE cells in murine posterior eye cup explants. We identified two specificity protein 1 (Sp1) binding sites in the BMP4 promoter that are required for basal expression of BMP4 and its down-regulation by TNF. Through c-Jun NH(2)-terminal kinase (JNK) activation, TNF modulates Sp1 phosphorylation, thus decreasing its affinity to the BMP4 promoter. The down-regulation of BMP4 expression by TNF in CNV and mechanisms established might be useful for defining novel targets for AMD therapy.-Xu, J., Zhu, D., He, S., Spee, C., Ryan, S. J., Hinton, D. R. Transcriptional regulation of bone morphogenetic protein 4 by tumor necrosis factor and its relationship with age-related macular degeneration. FASEB J. 25, 2221-2233 (2011). www.fasebj.org	[Xu, Jing] Univ So Calif, Keck Sch Med, Grad Program Neurosci, Los Angeles, CA 90089 USA; [He, Shikun; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA; [Zhu, Danhong; He, Shikun; Spee, Christine; Ryan, Stephen J.; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA; [Xu, Jing; Zhu, Danhong; He, Shikun; Spee, Christine; Ryan, Stephen J.; Hinton, David R.] Doheny Eye Inst, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; Doheny Eye Institute	Hinton, DR (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol & Ophthalmol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90089 USA.	dhinton@hsc.usc.edu			U.S. National Institutes of Health [EY01545, EY03040]; Arnold and Mabel Beckman Foundation; Research to Prevent Blindness Inc. (New York, NY, USA); NATIONAL EYE INSTITUTE [R01EY001545] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arnold and Mabel Beckman Foundation; Research to Prevent Blindness Inc. (New York, NY, USA)(Research to Prevent Blindness (RPB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank Dr. Ram Kannan, Dr. Jeannie Chen, and Dr. Harold Kochounian for discussion and comments on this manuscript. The authors thank Ernesto Barron and Eric Barron for assistance with figure preparation. This research was supported by U.S. National Institutes of Health grants EY01545 and EY03040, the Arnold and Mabel Beckman Foundation, and an unrestricted grant to the Department of Ophthalmology from Research to Prevent Blindness Inc. (New York, NY, USA).	Afonso V, 2006, FREE RADICAL BIO MED, V41, P709, DOI 10.1016/j.freeradbiomed.2006.05.014; An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j; An EY, 2008, MOL VIS, V14, P2292; Anderson HDI, 2004, J BIOL CHEM, V279, P963, DOI 10.1074/jbc.M309552200; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bakrania P, 2008, AM J HUM GENET, V82, P304, DOI 10.1016/j.ajhg.2007.09.023; Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216; Bilsland AE, 2006, CANCER RES, V66, P1363, DOI 10.1158/0008-5472.CAN-05-1941; Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200; Bramlage CP, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1923; Chang B, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-18; Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chu SJ, 2005, GENE, V348, P1, DOI 10.1016/j.gene.2005.01.013; Chuang JY, 2008, MOL BIOL CELL, V19, P1139, DOI 10.1091/mbc.E07-09-0881; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104; de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326; Denson LA, 2001, J CLIN INVEST, V107, P1451, DOI 10.1172/JCI10994; Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; FOJAS DB, 2001, EMBO J, V20, P5737; Furuta Y, 1998, GENE DEV, V12, P3764, DOI 10.1101/gad.12.23.3764; Garcia-Layana A, 2009, OPHTHALMIC RES, V42, P205, DOI 10.1159/000232946; Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724; Hangai M, 2006, J NEUROIMMUNOL, V171, P45, DOI 10.1016/j.jneuroim.2005.09.018; Hangai M, 2001, INVEST OPHTH VIS SCI, V42, P1617; Higuchi H, 2004, J BIOL CHEM, V279, P51, DOI 10.1074/jbc.M309476200; Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3; Horiguchi M, 2000, CYTOKINE, V12, P526, DOI 10.1006/cyto.1999.0577; Huang J, 2009, DEVELOPMENT, V136, P1741, DOI 10.1242/dev.034082; Jin M, 2004, INVEST OPHTH VIS SCI, V45, P323, DOI 10.1167/iovs.03-0355; Kane R, 2008, MOL VIS, V14, P1138; Kiyono M, 2006, ONCOGENE, V25, P7131, DOI 10.1038/sj.onc.1209700; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; Koga T, 2007, AM J PHYSIOL-LUNG C, V293, pL693, DOI 10.1152/ajplung.00491.2006; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; LEE JJ, ONCOGENE, V29, P561; Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058; Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Muller F, 2007, DEVELOPMENT, V134, P3483, DOI 10.1242/dev.02884; Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891; Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221; Park KM, 2009, J BIOL CHEM, V284, P27557, DOI 10.1074/jbc.M109.034504; Plikus MV, 2008, NATURE, V451, P340, DOI 10.1038/nature06457; Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0; Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007; Shimizu T, 1998, BONE, V23, P127, DOI 10.1016/S8756-3282(98)00086-6; Singhatanadgit W, 2006, INT J BIOCHEM CELL B, V38, P1794, DOI 10.1016/j.biocel.2006.05.005; Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33; Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667; Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08; Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004; Thompson DL, 2003, MOL CELL BIOL, V23, P2277, DOI 10.1128/MCB.23.7.2277-2286.2003; Trousse F, 2001, J NEUROSCI, V21, P1292; vandenWijngaard A, 1996, BIOCHEM BIOPH RES CO, V219, P789, DOI 10.1006/bbrc.1996.0312; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Weaver M, 2000, DEVELOPMENT, V127, P2695; Weston CR, 2003, GENE DEV, V17, P1271, DOI 10.1101/gad.1087303; Wordinger RJ, 2007, EXP BIOL MED, V232, P979, DOI 10.3181/0510-MR-345; Yang P, 2005, INVEST OPHTH VIS SCI, V46, P1755, DOI 10.1167/iovs.04-1039; Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078; Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030; Zhu NL, 2007, GENE, V393, P70, DOI 10.1016/j.gene.2007.01.016	68	17	19	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2221	2233		10.1096/fj.10-178350	http://dx.doi.org/10.1096/fj.10-178350			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21411747	Green Published			2022-12-28	WOS:000292242200014
J	Marazziti, D; Di Pietro, C; Mandillo, S; Golini, E; Matteoni, R; Tocchini-Valentini, GP				Marazziti, Daniela; Di Pietro, Chiara; Mandillo, Silvia; Golini, Elisabetta; Matteoni, Rafaele; Tocchini-Valentini, Glauco P.			Absence of the GPR37/PAEL receptor impairs striatal Akt and ERK2 phosphorylation, Delta FosB expression, and conditioned place preference to amphetamine and cocaine	FASEB JOURNAL			English	Article						DA; DAT; D1 receptor; D2 receptor; cellular signaling pathways	SIGNAL-REGULATED KINASE; COUPLED PEPTIDE RECEPTOR; DOPAMINE TRANSPORTER; GENE-EXPRESSION; INCREASES PHOSPHORYLATION; MONOAMINE TRANSPORTERS; MOLECULAR-MECHANISMS; RAT STRIATUM; MICE LACKING; C-FOS	The orphan G-protein-coupled receptor 37 (GPR37) colocalizes with the dopamine (DA) transporter (DAT) in mouse nigrostriatal presynaptic membranes, and its genetic ablation in homozygous null-mutant (GPR37-KO) mice provokes the marked increase of plasma membrane expression of DAT, alteration of psychostimulant-induced locomotor activity, and reduction of catalepsy induced by DA-receptor antagonists. We report that extracts from GPR37-KO mice displayed biochemical alterations of the nigrostriatal signaling pathways mediated by D1 and D2 dopaminergic receptors. Null-mutant mice showed an increase of the basal phosphorylation level of the D2-regulated Akt kinase. The basal phosphorylation of the D1-activated ERK2 kinase was not altered, but acute treatments with amphetamine or cocaine failed to produce its specific increase, as detected in samples from wild-type littermates. Furthermore, the chronic administration of cocaine to GPR37-KO mice did not increase the expression of the Delta FosB transcription factor isoforms. Consistently, behavioral analysis showed that null-mutant animals did not respond to the incentive properties of amphetamine or cocaine, in conditioned place preference tests. Thus, the lack of GPR37 affects both ERK2- and Akt-mediated striatal signaling pathways, impairing the biochemical and behavioral responses typically induced by acute and chronic administration of psychostimulant drugs.-Marazziti, D., Di Pietro, C., Mandillo, S., Golini, E., Matteoni, R., and Tocchini-Valentini, G. P. Absence of the GPR37/PAEL receptor impairs striatal Akt and ERK2 phosphorylation, Delta FosB expression, and conditioned place preference to amphetamine and cocaine. FASEB J. 25, 2071-2081 (2011). www.fasebj.org	[Marazziti, Daniela; Di Pietro, Chiara; Mandillo, Silvia; Golini, Elisabetta; Matteoni, Rafaele; Tocchini-Valentini, Glauco P.] CNR, Ist Biol Cellulare, I-00015 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR)	Tocchini-Valentini, GP (corresponding author), CNR, Ist Biol Cellulare, Campus A Buzzati Traverso,Via E Ramarini 32, I-00015 Rome, Italy.	gtocchini@ibc.cnr.it	Mandillo, Silvia/E-6503-2019; Golini, Elisabetta/AAX-2849-2020; Daniela, Marazziti/AAC-1062-2022; Di Pietro, Chiara/AAA-7161-2021; Mandillo, Silvia/AAW-1363-2020	Mandillo, Silvia/0000-0002-4869-0974; Daniela, Marazziti/0000-0002-1582-9271; MATTEONI, RAFAELE/0000-0002-0314-5948; DI PIETRO, CHIARA/0000-0002-2680-1821	Italian Ministry of Research	Italian Ministry of Research(Ministry of Education, Universities and Research (MIUR))	The authors are grateful to C. Gross and G. Di Segni for critical reading of the manuscript. The authors greatly thank G. Di Franco, G. D'Erasmo, and A. Ventrera for excellent technical assistance; A. Ferrara and T. Cuccurullo for secretarial work. This study was supported by Italian Ministry of Research grants (FIRB-Internazionale G. Armenise Harvard Foundation 2005, FIRB-Idee Progettuali 2005, PRIN-Cofin. 2007), and EU-Framework Programmes 6 and 7 (EURASNET, EUMODIC, and PHENOSCALE contracts).	Beaulieu JM, 2007, J NEUROSCI, V27, P881, DOI 10.1523/JNEUROSCI.5074-06.2007; Beaulieu JM, 2006, J BIOL CHEM, V281, P32072, DOI 10.1074/jbc.M606062200; Beaulieu JM, 2009, ANNU REV PHARMACOL, V49, P327, DOI 10.1146/annurev.pharmtox.011008.145634; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Berhow MT, 1996, J NEUROSCI, V16, P4707; Borgkvist A, 2007, NEUROPSYCHOPHARMACOL, V32, P1995, DOI 10.1038/sj.npp.1301321; Bozzi Y, 2006, TRENDS NEUROSCI, V29, P167, DOI 10.1016/j.tins.2006.01.002; Budygin EA, 2004, P NATL ACAD SCI USA, V101, P7781, DOI 10.1073/pnas.0401418101; Cabib S, 1996, PSYCHOPHARMACOLOGY, V125, P92, DOI 10.1007/BF02247398; Carlsson A, 2001, SCIENCE, V294, P1021, DOI 10.1126/science.1066969; Chen J, 2004, J BIOL CHEM, V279, P39317, DOI 10.1074/jbc.M403891200; Choe ES, 2002, NEUROPSYCHOPHARMACOL, V27, P565; Dunham JH, 2009, BIOCHEMISTRY-US, V48, P10286, DOI 10.1021/bi9013775; Gainetdinov RR, 2002, TRENDS PHARMACOL SCI, V23, P367, DOI 10.1016/S0165-6147(02)02044-8; Gainetdinov RR, 2003, ANNU REV PHARMACOL, V43, P261, DOI 10.1146/annurev.pharmtox.43.050802.112309; Ghisi V, 2009, CELL SIGNAL, V21, P87, DOI 10.1016/j.cellsig.2008.09.011; Girault JA, 2007, CURR OPIN PHARMACOL, V7, P77, DOI 10.1016/j.coph.2006.08.012; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; Hall FS, 2009, NEUROSCIENCE, V162, P870, DOI 10.1016/j.neuroscience.2009.05.058; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOPE B, 1992, P NATL ACAD SCI USA, V89, P5764, DOI 10.1073/pnas.89.13.5764; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2007, NEUROSCI RES, V59, P413, DOI 10.1016/j.neures.2007.08.005; Jenab S, 2005, MOL BRAIN RES, V142, P134, DOI 10.1016/j.molbrainres.2005.08.015; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; Marazziti D, 2004, P NATL ACAD SCI USA, V101, P10189, DOI 10.1073/pnas.0403661101; Marazziti D, 1998, GENOMICS, V53, P315, DOI 10.1006/geno.1998.5433; Marazziti D, 1997, GENOMICS, V45, P68, DOI 10.1006/geno.1997.4900; Marazziti D, 2007, P NATL ACAD SCI USA, V104, P9846, DOI 10.1073/pnas.0703368104; Masson J, 1999, PHARMACOL REV, V51, P439; Mateo Y, 2004, P NATL ACAD SCI USA, V101, P372, DOI 10.1073/pnas.0207805101; McClung CA, 2004, MOL BRAIN RES, V132, P146, DOI 10.1016/j.molbrainres.2004.05.014; McGinty JF, 2008, J NEUROCHEM, V104, P1440, DOI 10.1111/j.1471-4159.2008.05240.x; Medvedev IO, 2005, PSYCHOPHARMACOLOGY, V180, P408, DOI 10.1007/s00213-005-2173-y; Moratalla R, 1996, NEURON, V17, P147, DOI 10.1016/S0896-6273(00)80288-3; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nestler EJ, 1997, CURR OPIN NEUROBIOL, V7, P713, DOI 10.1016/S0959-4388(97)80094-3; Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; Nye HE, 1995, J PHARMACOL EXP THER, V275, P1671; Pavon N, 2006, BIOL PSYCHIAT, V59, P64, DOI 10.1016/j.biopsych.2005.05.044; Pich EM, 1997, SCIENCE, V275, P83; Salahpour A, 2008, P NATL ACAD SCI USA, V105, P4405, DOI 10.1073/pnas.0707646105; SCHECHTER MD, 1993, NEUROSCI BIOBEHAV R, V17, P21, DOI 10.1016/S0149-7634(05)80228-3; Shi XD, 2007, J NEUROCHEM, V103, P706, DOI 10.1111/j.1471-4159.2007.04760.x; Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298; Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699; Sotnikova TD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013452; Surmeier DJ, 2007, TRENDS NEUROSCI, V30, P228, DOI 10.1016/j.tins.2007.03.008; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Uhl GR, 1996, CURR BIOL, V6, P935, DOI 10.1016/S0960-9822(02)00630-9; Usiello A, 2000, NATURE, V408, P199, DOI 10.1038/35041572; Valjent E, 2000, J NEUROSCI, V20, P8701; Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102; Valjent E, 2004, EUR J NEUROSCI, V19, P1826, DOI 10.1111/j.1460-9568.2004.03278.x; Wang CH, 2005, J NEUROCHEM, V93, P899, DOI 10.1111/j.1471-4159.2005.03055.x; Xie ZH, 2009, BIOCHEM PHARMACOL, V78, P1095, DOI 10.1016/j.bcp.2009.05.031; Zhang L, 2004, J NEUROSCI, V24, P3344, DOI 10.1523/JNEUROSCI.0060-04.2004	63	18	23	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					2071	2081		10.1096/fj.10-175737	http://dx.doi.org/10.1096/fj.10-175737			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21372109				2022-12-28	WOS:000291023800029
J	Qiu, P; Wheater, MK; Qiu, Y; Sosne, G				Qiu, Ping; Wheater, Michelle Kurpakus; Qiu, Yue; Sosne, Gabriel			Thymosin beta(4) inhibits TNF-alpha-induced NF-kappa B activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK	FASEB JOURNAL			English	Article						cornea; actin; inflammation; cytokine; chemokine; focal adhesion	RELA/P65 NUCLEAR TRANSLOCATION; INFLAMMATORY MEDIATORS; ACTIN; BETA-4; CORNEAL; APOPTOSIS; BINDING; TRANSCRIPTION; PROTEIN; CELLS	The mechanisms by which thymosin beta 4 (T beta(4)) regulates the inflammatory response to injury are poorly understood. Previously, we demonstrated that ectopic T beta(4) treatment inhibits injury-induced proinflammatory cytokine and chemokine production. We have also shown that T beta(4) suppresses TNF-alpha-mediated NF-kappa B activation. Herein, we present novel evidence that T beta(4) directly targets the NF-kappa B RelA/p65 subunit. We find that enforced expression of T beta(4) interferes with TNF-alpha-mediated NF-kappa B activation, as well as downstream IL-8 gene transcription. These activities are independent of the G-actin-binding properties of T beta(4). T beta(4) blocks RelA/p65 nuclear translocation and targeting to the cognate kappa B site in the proximal region of the IL-8 gene promoter. T beta(4) also inhibits the sensitizing effects of its intracellular binding partners, PINCH-1 and ILK, on NF-kappa B activity after TNF-alpha stimulation. The identification of a functional regulatory role by T beta(4) and the focal adhesion proteins PINCH- 1 and ILK on NF-kappa B activity in this study opens a new window for scientific exploration of how T beta(4) modulates inflammation. In addition, the results of this study serve as a foundation for developing T beta(4) as a new anti-inflammatory therapy.-Qiu, P., Kurpakus Wheater, M., Qiu, Y., Sosne, G. Thymosin beta(4) inhibits TNF-alpha-induced NF-kappa B activation, IL-8 expression, and the sensitizing effects by its partners PINCH- 1 and ILK. FASEB J. 25, 1815-1826 (2011). www.fasebj.org	[Sosne, Gabriel] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Qiu, Ping; Qiu, Yue] Wayne State Univ, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI USA; [Wheater, Michelle Kurpakus] Univ Detroit, Dept Biomed & Diagnost Sci, Mercy Sch Dent, Detroit, MI 48221 USA	Wayne State University; Wayne State University; University of Detroit Mercy	Sosne, G (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield Ave,8314 Scott Hall, Detroit, MI 48201 USA.	gsosne@med.wayne.edu			U.S. National Institutes of Health [KO88EY13412]; Department of Anatomy and Cell Biology [P30EY04068]; Sinai Guild; Midwest Eye Banks and Transplantation Center; U.S. Army Medical Research Institute of Chemical Defense [W81XWH-09-P-0412]; Research to Prevent Blindness (New York, NY, USA); NATIONAL EYE INSTITUTE [P30EY004068, K08EY013412] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Anatomy and Cell Biology; Sinai Guild; Midwest Eye Banks and Transplantation Center; U.S. Army Medical Research Institute of Chemical Defense; Research to Prevent Blindness (New York, NY, USA)(Research to Prevent Blindness (RPB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank Dr. Hynda K. Kleinman for the critical reading of the manuscript and Dr. Linda D. Hazlett for her kind support. The authors are grateful to Dr. Chuanyue Wu (University of Pittsburgh, Pittsburgh, PA, USA) and Dr. Czeslaw S. Cierniewski (Nencki Institute of Experimental Biology, Warsaw, Poland) for supplying plasmids. The authors thank F. Zhang for technical support in manuscript preparation. This work was supported in part by grants from the U.S. National Institutes of Health (KO88EY13412) to G.S., the Department of Anatomy and Cell Biology (Core Vision grant P30EY04068), the Sinai Guild to G.S., the Midwest Eye Banks and Transplantation Center to G.S. and P.Q., and the U.S. Army Medical Research Institute of Chemical Defense (W81XWH-09-P-0412) to G.S. G.S. is a the recipient of a Physician Scientist Award from Research to Prevent Blindness (New York, NY, USA). G.S. is a nonsalaried medical and scientific board advisor to RegeneRx Biopharmaceuticals, Inc. (Rockville, MD, USA), which supplied the T beta<INF>4</INF>. The other authors declare no conflicting financial interests.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Babakov VN, 2008, EXP CELL RES, V314, P1030, DOI 10.1016/j.yexcr.2007.12.001; Badamchian M, 2003, INT IMMUNOPHARMACOL, V3, P1225, DOI 10.1016/S1567-5769(03)00024-9; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Bednarek R, 2008, J BIOL CHEM, V283, P1534, DOI 10.1074/jbc.M707539200; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Bock-Marquette I, 2009, J MOL CELL CARDIOL, V46, P728, DOI 10.1016/j.yjmcc.2009.01.017; Bodendorf S, 2007, ANN NY ACAD SCI, V1112, P418, DOI 10.1196/annals.1415.023; Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; Brieger A, 2007, BIOCHEM BIOPH RES CO, V364, P731, DOI 10.1016/j.bbrc.2007.10.010; Cha HJ, 2003, J NATL CANCER I, V95, P1674, DOI 10.1093/jnci/djg100; Choi SY, 2007, BIOCHEM BIOPH RES CO, V362, P587, DOI 10.1016/j.bbrc.2007.08.031; Cuschieri J, 2003, SHOCK, V19, P433, DOI 10.1097/01.shk.0000051762.08171.ea; Dougherty GW, 2008, EUR J CELL BIOL, V87, P721, DOI 10.1016/j.ejcb.2008.02.011; Fan Y, 2009, DEV CELL, V16, P661, DOI 10.1016/j.devcel.2009.03.009; Fazal F, 2007, J BIOL CHEM, V282, P3940, DOI 10.1074/jbc.M608074200; Fazal F, 2009, J BIOL CHEM, V284, P21047, DOI 10.1074/jbc.M109.016444; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Goldstein AL, 2005, TRENDS MOL MED, V11, P421, DOI 10.1016/j.molmed.2005.07.004; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; HANNAPPEL E, 1987, J CHROMATOGR, V397, P279, DOI 10.1016/S0021-9673(01)85010-X; HEINTZ D, 1994, EUR J BIOCHEM, V223, P345, DOI 10.1111/j.1432-1033.1994.tb19000.x; Higashitsuji H, 2007, BIOCHEM BIOPH RES CO, V363, P879, DOI 10.1016/j.bbrc.2007.09.072; Hinkel R, 2008, CIRCULATION, V117, P2232, DOI 10.1161/CIRCULATIONAHA.107.758904; Hsiao HL, 2006, CARCINOGENESIS, V27, P936, DOI 10.1093/carcin/bgi316; Huang CM, 2006, PROTEOMICS, V6, P5805, DOI 10.1002/pmic.200600163; Huang JY, 2004, EXP CELL RES, V298, P133, DOI 10.1016/j.yexcr.2004.04.019; Huff T, 2004, J CELL SCI, V117, P5333, DOI 10.1242/jcs.01404; Inzitari R, 2009, J SEP SCI, V32, P57, DOI 10.1002/jssc.200800496; KUNSCH C, 1994, J IMMUNOL, V153, P153; Kupatt C, 2008, TRENDS CARDIOVAS MED, V18, P205, DOI 10.1016/j.tcm.2008.10.002; Kustermans G, 2008, BIOCHEM PHARMACOL, V76, P1214, DOI 10.1016/j.bcp.2008.08.017; Lee HR, 2009, IMMUNOL LETT, V123, P72, DOI 10.1016/j.imlet.2009.02.008; Lee SJ, 2008, FEBS LETT, V582, P2161, DOI 10.1016/j.febslet.2008.03.058; Leeanansaksiri W, 2004, CHEM BIODIVERS, V1, P1091, DOI 10.1002/cbdv.200490081; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Liu L, 2009, FEBS J, V276, P1459, DOI 10.1111/j.1742-4658.2009.06888.x; LOW TLK, 1982, J BIOL CHEM, V257, P1000; Marx J, 2007, SCIENCE, V316, P682, DOI 10.1126/science.316.5825.682; Miralles F, 2006, CURR OPIN CELL BIOL, V18, P261, DOI 10.1016/j.ceb.2006.04.009; Moon HS, 2006, EXP CELL RES, V312, P3425, DOI 10.1016/j.yexcr.2006.07.021; Nemeth ZH, 2004, J CELL PHYSIOL, V200, P71, DOI 10.1002/jcp.10477; Nummela P, 2006, CANCER RES, V66, P701, DOI 10.1158/0008-5472.CAN-05-2421; Oh SY, 2006, EXP CELL RES, V312, P1651, DOI 10.1016/j.yexcr.2006.01.030; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Philp D, 2003, FASEB J, V17, P2103, DOI 10.1096/fj.03-0121fje; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Qiu P, 2002, MAMM GENOME, V13, P327, DOI 10.1007/s00335-001-2141-8; Qiu P, 2007, J CELL PHYSIOL, V212, P165, DOI 10.1002/jcp.21012; Renner F, 2009, TRENDS BIOCHEM SCI, V34, P128, DOI 10.1016/j.tibs.2008.12.003; Reti R, 2008, EUR J ORAL SCI, V116, P424, DOI 10.1111/j.1600-0722.2008.00569.x; Romeo GR, 2007, CIRC RES, V101, P357, DOI 10.1161/CIRCRESAHA.107.151399; Rossenu S, 2003, J BIOL CHEM, V278, P16642, DOI 10.1074/jbc.M208311200; Schillaci D, 2010, J APPL MICROBIOL, V108, P17, DOI 10.1111/j.1365-2672.2009.04394.x; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Sharma SM, 2009, OCUL IMMUNOL INFLAMM, V17, P403, DOI 10.3109/09273940903072443; Singh K, 2009, J BIOL CHEM, V284, P1267, DOI 10.1074/jbc.M801088200; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Sosne G, 2005, INVEST OPHTH VIS SCI, V46, P2388, DOI 10.1167/iovs.04-1368; Sosne G, 2004, INVEST OPHTH VIS SCI, V45, P1095, DOI 10.1167/iovs.03-1002; Sosne G, 2001, EXP EYE RES, V72, P605, DOI 10.1006/exer.2000.0985; Sosne G, 2007, EXP EYE RES, V84, P663, DOI 10.1016/j.exer.2006.12.004; Sosne G, 2006, EXP EYE RES, V83, P502, DOI 10.1016/j.exer.2006.02.001; Sosne G, 2010, FASEB J, V24, P2144, DOI 10.1096/fj.09-142307; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464; Tang YQ, 2002, INFECT IMMUN, V70, P6524, DOI 10.1128/IAI.70.12.6524-6533.2002; Tapp H, 2009, BIOTECH HISTOCHEM, V84, P287, DOI 10.3109/10520290903116884; Trubiani O, 2000, HISTOCHEM CELL BIOL, V113, P369; Truhlar SME, 2006, P NATL ACAD SCI USA, V103, P18951, DOI 10.1073/pnas.0605794103; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Yang H, 2008, NEUROCHEM RES, V33, P2269, DOI 10.1007/s11064-008-9712-y; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; Young JD, 1999, NAT MED, V5, P1424; Zhang HFM, 2006, AM J PHYSIOL-CELL PH, V290, pC1310, DOI 10.1152/ajpcell.00450.2005	79	74	77	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1815	1826		10.1096/fj.10-167940	http://dx.doi.org/10.1096/fj.10-167940			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21343177	Green Published			2022-12-28	WOS:000291023800005
J	Kim, HJ; Miron, VE; Dukala, D; Proia, RL; Ludwin, SK; Traka, M; Antel, JP; Soliven, B				Kim, Hye Jung; Miron, Veronique E.; Dukala, Danuta; Proia, Richard L.; Ludwin, Samuel K.; Traka, Maria; Antel, Jack P.; Soliven, Betty			Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model	FASEB JOURNAL			English	Article						FTY720; fingolimod; oligodendrocytes; multiple sclerosis; demyelination; remyelination	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MATURE OLIGODENDROCYTE APOPTOSIS; IMMUNOMODULATORY DRUG FTY720; RELAPSING MULTIPLE-SCLEROSIS; PROTEIN-COUPLED RECEPTORS; PRIMARY DEMYELINATION; SIGNAL-TRANSDUCTION; ORAL FINGOLIMOD; GENE-EXPRESSION	Fingolimod (FTY720) is a sphingosine 1-phosphate (S1P) receptor modulator that regulates lymphocyte trafficking and exerts pleiotropic actions on oligodendrocytes (OLGs) and other neural cells. The purpose of this study was to investigate the role of S1P receptors in a non-T-cell model of demyelination, the cuprizone (cupr) model in C57BL/6 mice. Treatment with FTY720 (1 mg/kg) led to attenuated injury to OLGs, myelin, and axons in the corpus callosum (percentage of myelinated fibers was 44.7% in cupr-water and 63% in cupr-FTY720). Reactive astrogliosis and microgliosis were ameliorated when FTY720 was given from d 1, but astrogliosis was augmented when FTY720 was given from wk 4-9. FTY720 did not promote remyelination in this model. The protective effect of FTY720 was associated with decreased interleukin-1 beta and CCL2 transcripts in the corpus callosum, as well as altered S1P1 expression. Targeted deletion of S1P1 in OLG lineage cells did not lead to obvious clinical phenotype, but resulted in subtle abnormalities in myelin and an increased susceptibility to cupr-induced demyelination. We conclude that S1P receptors expressed by neuroglia are involved in regulating the response to injury, and CNS effects of FTY720 could contribute to its favorable therapeutic response in multiple sclerosis.-Kim, H. J., Miron, V. E., Dukala, D., Proia, R. L., Ludwin, S. K., Traka, M., Antel, J. P., Soliven, B. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J. 25, 1509-1518 (2011). www.fasebj.org	[Kim, Hye Jung; Dukala, Danuta; Traka, Maria; Soliven, Betty] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; [Miron, Veronique E.; Antel, Jack P.] McGill Univ, Dept Neuroimmunol, Montreal, PQ, Canada; [Proia, Richard L.] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA; [Ludwin, Samuel K.] Queens Univ, Dept Neuropathol, Kingston, ON, Canada	University of Chicago; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Queens University - Canada	Soliven, B (corresponding author), Univ Chicago, Dept Neurol MC2030, 5841 S Maryland Ave, Chicago, IL 60637 USA.	bsoliven@neurology.bsd.uchicago.edu	Traka, Maria/U-2176-2019; Miron, Veronique E./H-4280-2019; Proia, Richard L/A-7908-2012	Miron, Veronique E./0000-0003-1738-0647; antel, jack/0000-0002-5148-0636; Proia, Richard/0000-0003-0456-1270	U.S. National Institute of Neurological Disorders and Stroke [R21 NS049014]; National MS Society [RG3951A7/1, TR3762-A-1]; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; MS Society of Canada; Novartis; Canadian Institutes of Health; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056015, ZIADK056018, ZIADK056016, ZIADK056014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS049014] Funding Source: NIH RePORTER	U.S. National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National MS Society(National Multiple Sclerosis Society); National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MS Society of Canada; Novartis(Novartis); Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. B. Popko, Dr. N. Turgut, Dr. T. Johnson, and B. Durafourt for their assistance or advice in some experiments. This work was supported by the U.S. National Institute of Neurological Disorders and Stroke (R21 NS049014), the National MS Society (RG3951A7/1), and a gift from M. P. Miller (B. S.); the Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (R. L. P.); the National MS Society (TR3762-A-1), a grant from the MS Society of Canada, and a grant from Novartis (J.P.A.); and a Canadian Institutes of Health Research studentship (V. E. M.).	Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Bacia A, 2004, GLIA, V48, P156, DOI 10.1002/glia.20067; Balatoni B, 2007, BRAIN RES BULL, V74, P307, DOI 10.1016/j.brainresbull.2007.06.023; Bassi R, 2006, GLIA, V53, P621, DOI 10.1002/glia.20324; Biancotti JC, 2008, NEUROCHEM RES, V33, P2615, DOI 10.1007/s11064-008-9792-8; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Choi JW, 2011, P NATL ACAD SCI USA, V108, P751, DOI 10.1073/pnas.1014154108; Coelho RP, 2007, J PHARMACOL EXP THER, V323, P626, DOI 10.1124/jpet.107.123927; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Crawford DK, 2009, NEUROSCIENCE, V164, P1407, DOI 10.1016/j.neuroscience.2009.09.069; Foster CA, 2007, J PHARMACOL EXP THER, V323, P469, DOI 10.1124/jpet.107.127183; Fujino M, 2003, J PHARMACOL EXP THER, V305, P70, DOI 10.1124/jpet.102.045658; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Harsan LA, 2008, J NEUROSCI, V28, P14189, DOI 10.1523/JNEUROSCI.4453-08.2008; Hida H, 1999, J NEUROSCI, V19, P7458, DOI 10.1523/JNEUROSCI.19-17-07458.1999; Hiremath MM, 2008, J NEUROIMMUNOL, V203, P23, DOI 10.1016/j.jneuroim.2008.06.034; Hiremath MM, 1998, J NEUROIMMUNOL, V92, P38, DOI 10.1016/S0165-5728(98)00168-4; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Jaillard C, 2005, J NEUROSCI, V25, P1459, DOI 10.1523/JNEUROSCI.4645-04.2005; Jung CG, 2007, GLIA, V55, P1656, DOI 10.1002/glia.20576; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Kim HJ, 2009, J NEUROIMMUNOL, V214, P93, DOI 10.1016/j.jneuroim.2009.07.006; KOMOLY S, 1992, P NATL ACAD SCI USA, V89, P1894, DOI 10.1073/pnas.89.5.1894; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lee KD, 2009, J NEUROTRAUM, V26, P2335, DOI 10.1089/neu.2008.0840; Lindner M, 2008, NEUROPATH APPL NEURO, V34, P105, DOI 10.1111/j.1365-2990.2007.00879.x; Lindner M, 2009, NEUROSCI LETT, V453, P120, DOI 10.1016/j.neulet.2009.02.004; LUDWIN SK, 1978, LAB INVEST, V39, P597; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mason JL, 2000, J NEUROSCI RES, V61, P251, DOI 10.1002/1097-4547(20000801)61:3<251::AID-JNR3>3.0.CO;2-W; Mason JL, 2000, J NEUROSCI, V20, P5703, DOI 10.1523/JNEUROSCI.20-15-05703.2000; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; Miron VE, 2008, AM J PATHOL, V173, P1143, DOI 10.2353/ajpath.2008.080478; Miron VE, 2010, AM J PATHOL, V176, P2682, DOI 10.2353/ajpath.2010.091234; Morell P, 1998, MOL CELL NEUROSCI, V12, P220, DOI 10.1006/mcne.1998.0715; Mullershausen F, 2007, J NEUROCHEM, V102, P1151, DOI 10.1111/j.1471-4159.2007.04629.x; Mullershausen F, 2009, NAT CHEM BIOL, V5, P428, DOI 10.1038/nchembio.173; NAYAK D, NEUROSCIENCE, V166, P132; Novgorodov AS, 2007, FASEB J, V21, P1503, DOI 10.1096/fj.06-7420com; Oo ML, 2007, J BIOL CHEM, V282, P9082, DOI 10.1074/jbc.M610318200; Pebay A, 2001, EUR J NEUROSCI, V13, P2067, DOI 10.1046/j.0953-816x.2001.01585.x; Rao TS, 2003, BRAIN RES, V990, P182, DOI 10.1016/S0006-8993(03)03527-3; Remington LT, 2007, AM J PATHOL, V170, P1713, DOI 10.2353/ajpath.2007.060783; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; Sidman R.L., 1999, HIGH RESOLUTION MOUS; Soliven B, 2003, AM J PHYSIOL-CELL PH, V284, pC85, DOI 10.1152/ajpcell.00145.2002; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Tham CS, 2003, INT J DEV NEUROSCI, V21, P431, DOI 10.1016/j.ijdevneu.2003.09.003; Van Doorn R, 2010, GLIA, V58, P1465, DOI 10.1002/glia.21021; Vana AC, 2007, J NEUROPATH EXP NEUR, V66, P975, DOI 10.1097/NEN.0b013e3181587d46; Veto S, 2010, BRAIN, V133, P822, DOI 10.1093/brain/awp337; Webb M, 2004, J NEUROIMMUNOL, V153, P108, DOI 10.1016/j.jneuroim.2004.04.015; Wei SH, 2005, NAT IMMUNOL, V6, P1228, DOI 10.1038/ni1269; Woodruff RH, 2004, MOL CELL NEUROSCI, V25, P252, DOI 10.1016/j.mcn.2003.10.014; Wu YP, 2008, HUM MOL GENET, V17, P2257, DOI 10.1093/hmg/ddn126; Yamagata K, 2003, GLIA, V41, P199, DOI 10.1002/glia.10180; Yu NC, 2004, GLIA, V45, P17, DOI 10.1002/glia.10297	61	80	81	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1509	1518		10.1096/fj.10-173203	http://dx.doi.org/10.1096/fj.10-173203			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21248243	Green Published			2022-12-28	WOS:000290023800009
J	Good, CH; Hoffman, AF; Hoffer, BJ; Chefer, VI; Shippenberg, TS; Backman, CM; Larsson, NG; Olson, L; Gellhaar, S; Galter, D; Lupica, CR				Good, Cameron H.; Hoffman, Alexander F.; Hoffer, Barry J.; Chefer, Vladimir I.; Shippenberg, Toni S.; Baeckman, Cristina M.; Larsson, Nils-Goeran; Olson, Lars; Gellhaar, Sandra; Galter, Dagmar; Lupica, Carl R.			Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease	FASEB JOURNAL			English	Article						dopamine; patch clamp; striatum; substantia nigra pars compacta	ACTIVATED CATION CURRENT; SUBSTANTIA-NIGRA NEURONS; MIDBRAIN DOPAMINERGIC-NEURONS; CURRENT I-H; NUCLEUS-ACCUMBENS; PHYSIOLOGICAL-FUNCTION; DNA DELETIONS; HCN CHANNELS; RAT; MICRODIALYSIS	Parkinson's disease (PD) involves progressive loss of nigrostriatal dopamine (DA) neurons over an extended period of time. Mitochondrial damage may lead to PD, and neurotoxins affecting mitochondria are widely used to produce degeneration of the nigrostriatal circuitry. Deletion of the mitochondrial transcription factor A gene (Tfam) in C57BL6 mouse DA neurons leads to a slowly progressing parkinsonian phenotype in which motor impairment is first observed at similar to 12 wk of age. L-DOPA treatment improves motor dysfunction in these "MitoPark" mice, but this declines when DA neuron loss is more complete. To investigate early neurobiological events potentially contributing to PD, we compared the neurochemical and electrophysiological properties of the nigrostriatal circuit in behaviorally asymptomatic 6- to 8-wk-old MitoPark mice and age-matched control littermates. Release, but not uptake of DA, was impaired in MitoPark mouse striatal brain slices, and nigral DA neurons lacked characteristic pacemaker activity compared with control mice. Also, hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channel function was reduced in MitoPark DA neurons, although HCN messenger RNA was unchanged. This study demonstrates altered nigrostriatal function that precedes behavioral parkinsonian symptoms in this genetic PD model. A full understanding of these presymptomatic cellular properties may lead to more effective early treatments of PD.-Good, C. H., Hoffman, A. F., Hoffer, B. J., Chefer, V. I., Shippenberg, T. S., Backman, C. M., Larsson, N.-G., Olson, L., Gellhaar, S., Galter, D., Lupica, C. R. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB J. 25, 1333-1344 (2011). www.fasebj.org	[Good, Cameron H.; Hoffman, Alexander F.; Lupica, Carl R.] NIDA, NIH, IRP, Electrophys Res Sect,US Dept Hlth & Human Serv, Baltimore, MD 21224 USA; [Good, Cameron H.; Hoffman, Alexander F.; Hoffer, Barry J.; Baeckman, Cristina M.; Lupica, Carl R.] NIDA, Cellular Neurobiol Branch, Intramural Res Program, NIH,US Dept Hlth & Human Serv, Baltimore, MD 21224 USA; [Chefer, Vladimir I.; Shippenberg, Toni S.] NIDA, Behav Neurosci Res Branch, Integrat Neurosci Sect, Intramural Res Program,NIH,US Dept Hlth & Human, Baltimore, MD 21224 USA; [Larsson, Nils-Goeran] Max Planck Inst Biol Ageing, Cologne, Germany; [Olson, Lars; Gellhaar, Sandra; Galter, Dagmar] Karolinska Inst Stockholm, Dept Neurosci, Stockholm, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); Max Planck Society; Karolinska Institutet	Lupica, CR (corresponding author), NIDA, NIH, IRP, Electrophys Res Sect,US Dept Hlth & Human Serv, 333 Cassell Dr, Baltimore, MD 21224 USA.	clupica@mail.nih.gov	Larsson, Nils-Göran/GVS-5578-2022; Hoffman, Alex/H-3035-2012; Galter, Dagmar/C-4826-2011; backman, cristina/C-1276-2013; Hoffman, Alex/AIF-4544-2022; Lupica, Carl/AAY-3193-2021	Larsson, Nils-Göran/0000-0001-5100-996X; Hoffman, Alex/0000-0002-2676-0628; Galter, Dagmar/0000-0001-6485-6244; Hoffman, Alex/0000-0002-2676-0628; Lupica, Carl/0000-0002-5375-3263	U.S. National Institutes of Health, the National Institute on Drug Abuse; Swedish Research Council; Swedish Brain Foundation; Hallsten's Foundation; Swedish Parkinson's Foundation; Swedish Brain Power; Michael J. Fox Foundation; Karolinska Institute; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000588, ZIADA000519, ZIADA000518, ZIADA000560, ZIADA000516, ZIADA000517, ZIADA000538] Funding Source: NIH RePORTER	U.S. National Institutes of Health, the National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Brain Foundation; Hallsten's Foundation; Swedish Parkinson's Foundation; Swedish Brain Power; Michael J. Fox Foundation; Karolinska Institute(Karolinska Institutet); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work supported by the U.S. National Institutes of Health, the National Institute on Drug Abuse Intramural Research Program, the Swedish Research Council, the Swedish Brain Foundation, Hallsten's Foundation, the Swedish Parkinson's Foundation, Swedish Brain Power, the Michael J. Fox Foundation, and the Karolinska Institute. N.-G. L. and L.O. are co-owners of a company owning commercial rights to the MitoPark mice.	AGID Y, 1991, LANCET, V337, P1321, DOI 10.1016/0140-6736(91)92989-F; Backman CM, 2006, GENESIS, V44, P383, DOI 10.1002/dvg.20228; Beal MF, 2010, NATURE, V466, pS8, DOI 10.1038/466S8a; Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; Bonci A, 1998, J NEUROSCI, V18, P6693; CASTANEDA E, 1990, J NEUROSCI, V10, P1847; Chefer VI, 2006, J NEUROSCI METH, V155, P187, DOI 10.1016/j.jneumeth.2005.12.018; Chen YH, 2008, FASEB J, V22, P261, DOI 10.1096/fj.07-8797com; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2010, NEURON, V66, P646, DOI 10.1016/j.neuron.2010.04.034; Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103; FRANKLIN KBJ, 1997, MOUSE BRAIN STEREOTA, pR22; Galter D, 2010, GENES BRAIN BEHAV, V9, P173, DOI 10.1111/j.1601-183X.2009.00542.x; Garris PA, 1997, BRAIN RES, V753, P225, DOI 10.1016/S0006-8993(97)00003-6; GRACE AA, 1983, NEUROSCIENCE, V10, P301, DOI 10.1016/0306-4522(83)90135-5; Guatteo E, 2005, NEUROTOXICOLOGY, V26, P857, DOI 10.1016/j.neuro.2005.01.013; Harris NC, 1995, J NEUROPHYSIOL, V74, P2366, DOI 10.1152/jn.1995.74.6.2366; Heien MLAV, 2005, P NATL ACAD SCI USA, V102, P10023, DOI 10.1073/pnas.0504657102; HOLLERMAN JR, 1990, BRAIN RES, V533, P203, DOI 10.1016/0006-8993(90)91341-D; Hyland BI, 2002, NEUROSCIENCE, V114, P475, DOI 10.1016/S0306-4522(02)00267-1; JIANG ZG, 1993, J PHYSIOL-LONDON, V462, P753, DOI 10.1113/jphysiol.1993.sp019580; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; JUSTICE JB, 1993, J NEUROSCI METH, V48, P263, DOI 10.1016/0165-0270(93)90097-B; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LEENDERS KL, 1990, ARCH NEUROL-CHICAGO, V47, P1290, DOI 10.1001/archneur.1990.00530120034007; Li X, 2009, PSYCHOPHARMACOLOGY, V204, P1, DOI 10.1007/s00213-008-1432-0; Maccaferri G, 1996, J PHYSIOL-LONDON, V497, P119, DOI 10.1113/jphysiol.1996.sp021754; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; MERCURI NB, 1994, NEUROSCIENCE, V63, P757, DOI 10.1016/0306-4522(94)90520-7; MERCURI NB, 1994, J NEUROPHYSIOL, V71, P1165, DOI 10.1152/jn.1994.71.3.1165; MERCURI NB, 1995, EUR J NEUROSCI, V7, P462, DOI 10.1111/j.1460-9568.1995.tb00342.x; MIZUNO Y, 1987, J NEUROCHEM, V48, P1787, DOI 10.1111/j.1471-4159.1987.tb05737.x; PARSONS LH, 1991, J NEUROSCI METH, V40, P139, DOI 10.1016/0165-0270(91)90063-6; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Sabeti J, 2002, J NEUROSCI METH, V121, P41, DOI 10.1016/S0165-0270(02)00229-7; Schultz W, 2007, ANNU REV NEUROSCI, V30, P259, DOI 10.1146/annurev.neuro.28.061604.135722; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Smeyne RJ, 2005, MOL BRAIN RES, V134, P57, DOI 10.1016/j.molbrainres.2004.09.017; SMITH AD, 1994, J NEUROSCI METH, V54, P75, DOI 10.1016/0165-0270(94)90161-9; Sombers LA, 2009, J NEUROSCI, V29, P1735, DOI 10.1523/JNEUROSCI.5562-08.2009; STACHOWIAK MK, 1987, J NEUROSCI, V7, P1648; Svoboda KR, 1998, J NEUROSCI, V18, P7084; Terzioglu M, 2008, FEBS J, V275, P1384, DOI 10.1111/j.1742-4658.2008.06302.x; Wahl-Schott C, 2009, CELL MOL LIFE SCI, V66, P470, DOI 10.1007/s00018-008-8525-0; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Watabe M, 2008, MOL PHARMACOL, V74, P933, DOI 10.1124/mol.108.048546; Watts AE, 1996, J NEUROPHYSIOL, V76, P2262, DOI 10.1152/jn.1996.76.4.2262; Westerlund M, 2010, PROG NEUROBIOL, V90, P146, DOI 10.1016/j.pneurobio.2009.11.001; ZIGMOND MJ, 1973, SCIENCE, V182, P717, DOI 10.1126/science.182.4113.717; ZIGMOND MJ, 1989, MOL CHEM NEUROPATHOL, V10, P185, DOI 10.1007/BF03159728; ZIGMOND MJ, 1990, TRENDS NEUROSCI, V13, P290, DOI 10.1016/0166-2236(90)90112-N	57	84	85	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1333	1344		10.1096/fj.10-173625	http://dx.doi.org/10.1096/fj.10-173625			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21233488	Green Published			2022-12-28	WOS:000288982800022
J	Hancock, CR; Han, DH; Higashida, K; Kim, SH; Holloszy, JO				Hancock, Chad R.; Han, Dong-Ho; Higashida, Kazuhiko; Kim, Sang Hyun; Holloszy, John O.			Does calorie restriction induce mitochondrial biogenesis? A reevaluation	FASEB JOURNAL			English	Article						aging; citrate synthase; cytochrome c; PGC-1 alpha	TRANSCRIPTIONAL COACTIVATOR PGC-1; RAT SKELETAL-MUSCLE; OXIDATIVE DAMAGE; GLUCOSE-TRANSPORT; GENE-EXPRESSION; PPAR-DELTA; AGE; METABOLISM; SARCOPENIA; INCREASE	It has been reported that 30% calorie restriction (CR) for 3 mo results in large increases in mitochondrial biogenesis in heart, brain, liver, and adipose tissue, with concomitant increases in respiration and ATP synthesis. We found these results surprising, and performed this study to determine whether 30% CR does induce an increase in mitochondria in heart, brain, liver, adipose tissue, and/or skeletal muscle. To this end, we measured the levels of a range of mitochondrial proteins, and mRNAs. With the exception of long-chain acyl-CoA dehydrogenase protein level, which was increased similar to 60% in adipose tissue, none of the mitochondrial proteins or mRNAs that we measured were increased in rats subjected to 30% CR for 14 wk. There was also no increase in citrate synthase activity. Because it is not possible to have an increase in mitochondria without any increase in key mitochondrial proteins, we conclude that 30% CR does not induce an increase in mitochondria in heart, brain, liver, adipose tissue, or skeletal muscle in laboratory rodents.-Hancock, C. R., Han, D.-H., Higashida, K., Kim, S. H., Holloszy, J. O. Does calorie restriction induce mitochondrial biogenesis? A reevaluation. FASEB J. 25, 785-791 (2011). www.fasebj.org	[Hancock, Chad R.; Han, Dong-Ho; Higashida, Kazuhiko; Kim, Sang Hyun; Holloszy, John O.] Washington Univ, Sch Med, Div Geriatr & Nutr Sci, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Div Geriatr & Nutr Sci, Dept Med, 4566 Scott Ave,Campus Box 8113, St Louis, MO 63110 USA.	jhollosz@dom.wustl.edu	Hancock, Chad R./X-4803-2018	Hancock, Chad R./0000-0002-1578-5301	U.S. National Institutes of Health [AG00425]; American Diabetes Association; Individual National Research Service Award [DK076410]; Japan Society for the Promotion of Science; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK076410, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG000425, R37AG000425, Z01AG000425, R01AG000425] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); Individual National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Iheoma Nwaogu and Jamie Votava for their technical assistance. This research was supported by U.S. National Institutes of Health grant AG00425. C. R. H. was supported by an American Diabetes Association-based post-doctoral fellowship initially and then by Individual National Research Service Award DK076410. K. H. was supported by a Research Fellow of the Japan Society for the Promotion of Science grant.	Baar K, 2003, FASEB J, V17, P1666, DOI 10.1096/fj.03-0049com; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Baker DJ, 2006, J GERONTOL A-BIOL, V61, P675, DOI 10.1093/gerona/61.7.675; Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343; Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; BOOTH FW, 1997, HDB PHYSL 12, P1075; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; CARTIER LJ, 1986, J BIOL CHEM, V261, P3827; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; CONSTABLE SH, 1987, AM J PHYSIOL, V253, pC316, DOI 10.1152/ajpcell.1987.253.2.C316; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Garcia-Roves P, 2007, P NATL ACAD SCI USA, V104, P10709, DOI 10.1073/pnas.0704024104; Guarente L, 2008, CELL, V132, P171, DOI 10.1016/j.cell.2008.01.007; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Huang JH, 2009, IUBMB LIFE, V61, P201, DOI 10.1002/iub.164; Judge S, 2007, AM J PHYSIOL-CELL PH, V292, pC1983, DOI 10.1152/ajpcell.00285.2006; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CM, 1998, ANN NY ACAD SCI, V854, P182, DOI 10.1111/j.1749-6632.1998.tb09901.x; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marzetti E, 2010, BBA-GEN SUBJECTS, V1800, P235, DOI 10.1016/j.bbagen.2009.05.007; Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; McKiernan SH, 2007, AM J PHYSIOL-RENAL, V292, pF1751, DOI 10.1152/ajprenal.00307.2006; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Mulligan JD, 2008, EXP GERONTOL, V43, P146, DOI 10.1016/j.exger.2007.10.011; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Otani K, 2004, J BIOL CHEM, V279, P20915, DOI 10.1074/jbc.M400213200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rabol R, 2009, METABOLISM, V58, P1145, DOI 10.1016/j.metabol.2009.03.014; Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; Taffet GE, 1997, J GERONTOL A-BIOL, V52, pB285, DOI 10.1093/gerona/52A.6.B285; Terada S, 2006, AM J PHYSIOL-ENDOC M, V290, pE607, DOI 10.1152/ajpendo.00430.2005; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Ward WF, 2005, J GERONTOL A-BIOL, V60, P847, DOI 10.1093/gerona/60.7.847; WINDER WW, 1979, AM J PHYSIOL, V236, pC132, DOI 10.1152/ajpcell.1979.236.3.C132	45	101	104	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					785	791		10.1096/fj.10-170415	http://dx.doi.org/10.1096/fj.10-170415			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21048043	Green Published			2022-12-28	WOS:000286724800035
J	Roepke, TK; King, EC; Purtell, K; Kanda, VA; Lerner, DJ; Abbott, GW				Roepke, Torsten K.; King, Elizabeth C.; Purtell, Kerry; Kanda, Vikram A.; Lerner, Daniel J.; Abbott, Geoffrey W.			Genetic dissection reveals unexpected influence of beta subunits on KCNQ1 K+ channel polarized trafficking in vivo	FASEB JOURNAL			English	Article						gastric acid; MiRP1; potassium channel	GASTRIC-ACID-SECRETION; POTASSIUM CHANNEL; PARIETAL-CELLS; MDCK CELLS; GASTROINTESTINAL EPITHELIA; MEMBRANE; LOCALIZATION; DISRUPTION; REPOLARIZATION; MECHANISM	Targeted deletion of the Kcne2 potassium channel beta subunit gene ablates gastric acid secretion and predisposes to gastric neoplasia in mice. Here, we discovered that Kcne2 deletion basolaterally reroutes the Kcnq1 alpha subunit in vivo in parietal cells (PCs), in which the normally apical location of the Kcnq1-Kcne2 channel facilitates its essential role in gastric acid secretion. Quantitative RT-PCR and Western blotting revealed that Kcne2 deletion remodeled fundic Kcne3 (2.9 +/- 0.8-fold mRNA increase, n = 10; 5.3 +/- 0.4-fold protein increase, n=7) but not Kcne1, 4, or 5, and resulted in basolateral Kcnq1-Kcne3 complex formation in Kcne2(-/-) PCs. Concomitant targeted deletion of Kcne3 (creating Kcne2(-/-) Kcne3(-/-) mice) restored PC apical Kcnq1 localization without Kcne1, 4, or 5 remodeling (assessed by quantitative RT-PCR; n = 5-10), indicating Kcne3 actively, basolaterally rerouted Kcnq1 in Kcne2(-/-) PCs. Despite this, Kcne3 deletion exacerbated gastric hyperplasia in Kcne2(-/-) mice, and both hypochlorhydria and hyperplasia in Kcne2(-/-) mice, suggesting that Kcne3 up-regulation was beneficial in Kcne2-depleted PCs. The findings reveal, in vivo, Kcne-dependent alpha subunit polarized trafficking and the existence and consequences of potassium channel beta subunit remodeling.-Roepke, T. K., King, E. C., Purtell, K., Kanda, V. A., Lerner, D. J., Abbott, G. W. Genetic dissection reveals unexpected influence of beta subunits on KCNQ1K K+ channel polarized trafficking in vivo. FASEB J. 25, 727-736 (2011). www.fasebj.org	[Roepke, Torsten K.; King, Elizabeth C.; Purtell, Kerry; Kanda, Vikram A.; Abbott, Geoffrey W.] Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA; [Roepke, Torsten K.; Lerner, Daniel J.; Abbott, Geoffrey W.] Cornell Univ, Dept Med, Weill Med Coll, New York, NY 10021 USA	Cornell University; Cornell University	Abbott, GW (corresponding author), Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA.	gwa2001@med.cornell.edu		Abbott, Geoffrey/0000-0003-4552-496X	National Institutes of Health (NIH) [R01 HL079275, T32GM073546]; American Heart Association [0855756D]; Irma T. Hirschl Career Scientist Award; National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM073546] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Irma T. Hirschl Career Scientist Award; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors are grateful for expert technical assistance from S. Backovic, L. Cohen-Gould (Director of the Electron Microscopy and Histology Core Facility at Weill Cornell Medical College), M. S. Jiao, the Molecular Cytology Core Facility of Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute Mouse Genetics Core Facility, and Rockefeller University Transgenic Mouse Facility. G. W. A. is thankful for support from the National Heart, Lung, and Blood Institute; the National Institutes of Health (NIH; R01 HL079275); the American Heart Association (grant-in-aid 0855756D); and an Irma T. Hirschl Career Scientist Award. K. P. is supported by an NIH predoctoral training grant (T32GM073546).	Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Clancy SM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006330; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; Duffield A, 2004, TRAFFIC, V5, P449, DOI 10.1111/j.1398-9219.2004.00192.x; Fujita A, 2002, J PHYSIOL-LONDON, V540, P85, DOI 10.1113/jphysiol.2001.013439; Heitzmann D, 2004, J PHYSIOL-LONDON, V561, P547, DOI 10.1113/jphysiol.2004.075168; Heitzmann D, 2008, PHYSIOL REV, V88, P1119, DOI 10.1152/physrev.00020.2007; Jespersen T, 2004, J CELL SCI, V117, P4517, DOI 10.1242/jcs.01318; Kaufhold MA, 2008, GASTROENTEROLOGY, V134, P1058, DOI 10.1053/j.gastro.2008.01.033; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Malinowska DH, 2004, AM J PHYSIOL-CELL PH, V286, pC495, DOI 10.1152/ajpcell.00386.2003; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; McDaniel N, 2005, AM J PHYSIOL-GASTR L, V289, pG550, DOI 10.1152/ajpgi.00095.2005; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; OKADA Y, 1984, J PHYSIOL-LONDON, V354, P109, DOI 10.1113/jphysiol.1984.sp015366; Panaghie G, 2007, J GEN PHYSIOL, V129, P121, DOI 10.1085/jgp.200609612; Porcello DM, 2002, J NEUROPHYSIOL, V87, P1303, DOI 10.1152/jn.00556.2001; Preston P, 2010, J BIOL CHEM, V285, P7165, DOI 10.1074/jbc.M109.047829; Roepke TK, 2008, FASEB J, V22, P3648, DOI 10.1096/fj.08-110171; Roepke TK, 2006, J BIOL CHEM, V281, P23740, DOI 10.1074/jbc.M604155200; Roepke TK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011451; Roepke TK, 2009, NAT MED, V15, P1186, DOI 10.1038/nm.2029; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Spandidos A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-633; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Vallon V, 2005, P NATL ACAD SCI USA, V102, P17864, DOI 10.1073/pnas.0505860102	31	25	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2011	25	2					727	736		10.1096/fj.10-173682	http://dx.doi.org/10.1096/fj.10-173682			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21084694	Green Published			2022-12-28	WOS:000286724800030
J	Livne, L; Epand, RF; Papahadjopoulos-Sternberg, B; Epand, RM; Mor, A				Livne, L.; Epand, R. F.; Papahadjopoulos-Sternberg, B.; Epand, R. M.; Mor, A.			OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria	FASEB JOURNAL			English	Article						host defense peptides; slow drug release; systemic therapy	PROTEOLIPOSOME-DERIVED COCHLEATE; DERMASEPTIN S4 DERIVATIVES; ACYL-LYSINE OLIGOMERS; ANTIMICROBIAL PEPTIDES; ANTIBACTERIAL PROPERTIES; ESCHERICHIA-COLI; LYSYL OLIGOMER; AMPHOTERICIN-B; DRUG-DELIVERY; RAT MODELS	Antibiotic resistance has become a worldwide medical problem. To find new ways of overcoming this phenomenon, we investigated the role of the membrane-active oligo-acyl-lysyl (OAK) sequence C12K-7 alpha 8, in combination with essentially ineffective antibiotics. Determination of minimal inhibitory concentration (MIC) against gram-negative multidrug-resistant strains of Escherichia coli revealed combinations with sub-MIC OAK levels that acted synergistically with several antibiotics, thus lowering their MICs by several orders of magnitude. To shed light into the molecular basis for this synergism, we used both mutant strains and biochemical assays. Our results suggest that bacterial sensitization to antibiotics was derived mainly from the OAK's capacity to overcome the efflux-enhanced resistance mechanism, by promoting backdoor entry of otherwise excluded antibiotics. To facilitate simultaneous delivery of the pooled drugs to an infection site, we developed a novel OAK-based cochleate system with demonstrable stability in whole blood. To assess the potential therapeutic use of such cochleates, we performed preliminary experiments that imitate systemic treatment of neutropenic mice infected with lethal inoculums of multidrug resistance E. coli. Single-dose administration of erythromycin coencapsulated in OAK-based cochleates has decreased drug toxicity and increased therapeutic efficacy in a dose-dependent manner. Collectively, our findings suggest a potentially useful approach for fighting efflux-enhanced resistance mechanisms.-Livne, L., Epand, R. F., Papahadjopoulos-Sternberg, B., Epand, R. M., Mor, A. OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria. FASEB J. 24, 5092-5101 (2010). www.fasebj.org	[Livne, L.; Mor, A.] Technion Israel Inst Technol, Dept Biotechnol & Food Engn, Haifa, Israel; [Epand, R. F.; Epand, R. M.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada; [Papahadjopoulos-Sternberg, B.] NanoAnalyt Lab, San Francisco, CA USA	Technion Israel Institute of Technology; McMaster University	Mor, A (corresponding author), Technion Israel Inst Technol, Dept Biotechnol & Food Engn, Haifa, Israel.	amor@tx.technion.ac.il	, Richard/R-2316-2019	, Richard/0000-0002-9602-9558	Israel Science Foundation [283/08]; Canadian Institutes of Health Research [MOP 86608]	Israel Science Foundation(Israel Science Foundation); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This research was supported by the Israel Science Foundation (grant 283/08) and by grant MOP 86608 from the Canadian Institutes of Health Research.	Acar JF, 2000, MED CLIN N AM, V84, P1391, DOI 10.1016/S0025-7125(05)70294-7; Anantharaman A, 2010, ANTIMICROB AGENTS CH, V54, P1693, DOI 10.1128/AAC.01231-09; Auerbach T, 2010, P NATL ACAD SCI USA, V107, P1983, DOI 10.1073/pnas.0914100107; Bohnert HA, 2005, ANTIMICROB AGENTS CH, V49, P849, DOI 10.1128/AAC.49.2.849-852.2005; Boor KJ, 2006, PLOS BIOL, V4, P18, DOI 10.1371/journal.pbio.0040023; Bracho G, 2006, VACCINE, V24, pS30, DOI 10.1016/j.vaccine.2005.01.108; Bradshaw JP, 2003, BIODRUGS, V17, P233, DOI 10.2165/00063030-200317040-00002; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Cassell GH, 1997, FEMS IMMUNOL MED MIC, V18, P271, DOI 10.1016/S0928-8244(97)00057-6; Cirioni O, 2008, J ANTIMICROB CHEMOTH, V62, P1332, DOI 10.1093/jac/dkn393; Cirioni O, 2007, CRIT CARE MED, V35, P1717, DOI 10.1097/01.CCM.0000266685.25436.03; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P1433, DOI 10.1086/375081; DARVEAU RP, 1991, ANTIMICROB AGENTS CH, V35, P1153, DOI 10.1128/AAC.35.6.1153; del Campo J, 2006, VACCINE, V24, pS50, DOI 10.1016/j.vaccine.2005.01.119; del Campo J, 2009, METHODS, V49, P301, DOI 10.1016/j.ymeth.2009.03.025; Delmas G, 2002, ANTIMICROB AGENTS CH, V46, P2704, DOI 10.1128/AAC.46.8.2704-2707.2002; Dzidic S, 2008, FOOD TECHNOL BIOTECH, V46, P11; Epand RF, 2009, BIOPHYS J, V97, P2250, DOI 10.1016/j.bpj.2009.08.006; Epand RM, 2008, DRUG NEWS PERSPECT, V21, P307, DOI 10.1358/dnp.2008.21.6.1246829; Epand RM, 2008, J AM CHEM SOC, V130, P14346, DOI 10.1021/ja8062327; Giacometti A, 2000, DIAGN MICR INFEC DIS, V38, P115, DOI 10.1016/S0732-8893(00)00175-9; Gordon YJ, 2005, CURR EYE RES, V30, P505, DOI 10.1080/02713680590968637; Gould-Fogerite S, 1998, ADV DRUG DELIVER REV, V32, P273, DOI 10.1016/S0169-409X(98)00014-3; Gunn JS, 2008, TRENDS MICROBIOL, V16, P284, DOI 10.1016/j.tim.2008.03.007; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Hardman J. G., 1996, GOODMAN GILMANS PHAR; Held-Kuznetsov V, 2009, FASEB J, V23, P4299, DOI 10.1096/fj.09-136358; HOBEN HJ, 1982, APPL ENVIRON MICROB, V44, P1246, DOI 10.1128/AEM.44.5.1246-1247.1982; Jana S, 2006, APPL MICROBIOL BIOT, V70, P140, DOI 10.1007/s00253-005-0279-0; Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05; LEVY O, 1994, J CLIN INVEST, V94, P672, DOI 10.1172/JCI117384; Lewis JS, 2007, ANTIMICROB AGENTS CH, V51, P4015, DOI 10.1128/AAC.00576-07; Livne L, 2009, CHEM BIOL, V16, P1250, DOI 10.1016/j.chembiol.2009.11.012; LORENZEN A, 1993, ANAL BIOCHEM, V214, P346, DOI 10.1006/abio.1993.1504; Manges AR, 2001, NEW ENGL J MED, V345, P1007, DOI 10.1056/NEJMoa011265; Marr AK, 2006, CURR OPIN PHARMACOL, V6, P468, DOI 10.1016/j.coph.2006.04.006; Miclea RD, 2007, BBA-BIOMEMBRANES, V1768, P2890, DOI 10.1016/j.bbamem.2007.08.001; Minahk CJ, 2004, J ANTIMICROB CHEMOTH, V53, P240, DOI 10.1093/jac/dkh079; Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X; MOR A, 1994, J BIOL CHEM, V269, P31635; Navon-Venezia S, 2002, ANTIMICROB AGENTS CH, V46, P689, DOI 10.1128/AAC.46.3.689-694.2002; Otto M, 2009, CONTRIB MICROBIOL, V16, P136, DOI 10.1159/000219377; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; PARASASSI T, 1994, BIOPHYS J, V66, P763, DOI 10.1016/S0006-3495(94)80852-5; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; Parisien A, 2008, J APPL MICROBIOL, V104, P1, DOI 10.1111/j.1365-2672.2007.03498.x; Perez O, 2006, VACCINE, V24, pS1, DOI 10.1016/j.vaccine.2005.01.100; Perez O, 2004, IMMUNOL CELL BIOL, V82, P603, DOI 10.1111/j.1440-1711.2004.01293.x; Radzishevsky I, 2007, ANTIMICROB AGENTS CH, V51, P1753, DOI 10.1128/AAC.01288-06; Radzishevsky IS, 2008, CHEM BIOL, V15, P354, DOI 10.1016/j.chembiol.2008.03.006; Radzishevsky IS, 2007, NAT BIOTECHNOL, V25, P657, DOI 10.1038/nbt1309; Ramani K, 2003, BBA-BIOMEMBRANES, V1618, P67, DOI 10.1016/j.bbamem.2003.10.009; Rhodius VA, 2006, PLOS BIOL, V4, P43, DOI 10.1371/journal.pbio.0040002; Rice LB, 2009, CURR OPIN MICROBIOL, V12, P476, DOI 10.1016/j.mib.2009.08.001; Rotem S, 2008, FASEB J, V22, P2652, DOI 10.1096/fj.07-105015; Rotem S, 2009, BBA-BIOMEMBRANES, V1788, P1582, DOI 10.1016/j.bbamem.2008.10.020; Rydlo T, 2006, ANTIMICROB AGENTS CH, V50, P490, DOI 10.1128/AAC.50.2.490-497.2006; Santangelo R, 2000, ANTIMICROB AGENTS CH, V44, P2356, DOI 10.1128/AAC.44.9.2356-2360.2000; Sarig H, 2010, FASEB J, V24, P1904, DOI 10.1096/fj.09-149427; Scott RW, 2008, CURR OPIN BIOTECH, V19, P620, DOI 10.1016/j.copbio.2008.10.013; Spellberg B, 2008, CLIN INFECT DIS, V46, P155, DOI 10.1086/524891; Steenbergen JN, 2009, J ANTIMICROB CHEMOTH, V64, P1130, DOI 10.1093/jac/dkp346; STERNBERG B, 1996, LIPOSOMES MODEL MEMB, V4; Syed UM, 2008, INT J PHARMACEUT, V363, P118, DOI 10.1016/j.ijpharm.2008.06.026; Ulvatne H, 2001, J ANTIMICROB CHEMOTH, V48, P203, DOI 10.1093/jac/48.2.203; Vaara M, 2008, ANTIMICROB AGENTS CH, V52, P3229, DOI 10.1128/AAC.00405-08; Walker SA, 1997, NATURE, V387, P61, DOI 10.1038/387061a0; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Wright GD, 2003, CURR OPIN CHEM BIOL, V7, P563, DOI 10.1016/j.cbpa.2003.08.004; Wu GQ, 2009, CURR MICROBIOL, V59, P147, DOI 10.1007/s00284-009-9410-2; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Yonath A, 2005, ANNU REV BIOCHEM, V74, P649, DOI 10.1146/annurev.biochem.74.082803.133130; Zaknoon F, 2009, ANTIMICROB AGENTS CH, V53, P3422, DOI 10.1128/AAC.00010-09; Zarif L, 2005, METHOD ENZYMOL, V391, P314, DOI 10.1016/S0076-6879(05)91018-5; Zarif L, 2002, J CONTROL RELEASE, V81, P7, DOI 10.1016/S0168-3659(02)00010-X; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	76	31	32	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5092	5101		10.1096/fj.10-167809	http://dx.doi.org/10.1096/fj.10-167809			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20720156				2022-12-28	WOS:000284824400047
J	Acharjee, S; Noorbakhsh, F; Stemkowski, PL; Olechowski, C; Cohen, EA; Ballanyi, K; Kerr, B; Pardo, C; Smith, PA; Power, C				Acharjee, Shaona; Noorbakhsh, Farshid; Stemkowski, Patrick L.; Olechowski, Camille; Cohen, Eric A.; Ballanyi, Klaus; Kerr, Bradley; Pardo, Carlos; Smith, Peter A.; Power, Christopher			HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain	FASEB JOURNAL			English	Article						dorsal root ganglion; electrophysiology; calcium imaging; interferon-alpha	DORSAL ROOT-GANGLIA; SENSORY NEURONS; VPR PROTEIN; AXONAL POLYNEUROPATHY; CHANNEL CURRENTS; INTERFERON-ALPHA; RAT; REGENERATION; EXPRESSION; K+	Painful peripheral neuropathy has become the principal neurological disorder in HIV/AIDS patients. Herein, we investigated the effects of a cytotoxic HIV-1 accessory protein, viral protein R (Vpr), on the peripheral nervous system (PNS). Host and viral gene expression was investigated in peripheral nerves from HIV-infected individuals and in HIV-infected human dorsal root ganglion (DRG) cultures by RT-PCR and immunocytochemistry. Cytosolic calcium ([Ca2+]) fluxes and neuronal membrane responses were analyzed in cultured DRGs. Neurobehavioral responses and cytokine levels were assessed in a transgenic mouse model in which the vpr transgene was expressed in an immunodeficient background (vpr/RAG1(-/-)). Vpr transcripts and proteins were detected in peripheral nerves and DRGs from HIV-infected patients. Exposure of rat or human cultured DRG neurons to Vpr rapidly increased [Ca2+] and action potential frequency while increasing input resistance. HIV infection of human DRG cultures caused neurite retraction (P<0.05), accompanied by induction of interferon-alpha (IFN-alpha) transcripts (P<0.05). vpr/RAG1(-/-) mice expressed Vpr together with increased IFN-alpha (P<0.05) in the PNS and also exhibited mechanical allodynia, unlike their vpr/RAG1(-/-) littermates (P<0.05). Herein, Vpr caused DRG neuronal damage, likely through cytosolic calcium activation and cytokine perturbation, highlighting Vpr's contribution to HIV-associated peripheral neuropathy and ensuing neuropathic pain.-Acharjee, S., Noorbakhsh, S., Stemkowski, P. L., Olechowski, C., Cohen, E. A., Ballanyi, K., Kerr, B., Pardo, C., Smith, P. A., Power, C. HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain. FASEB J. 24, 4343-4353 (2010). www.fasebj.org	[Power, Christopher] Univ Alberta, Dept Med, Heritage Med Res Ctr 6, Edmonton, AB T6G 2S2, Canada; [Power, Christopher] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada; [Ballanyi, Klaus] Univ Alberta, Dept Physiol, Edmonton, AB T6G 2S2, Canada; [Stemkowski, Patrick L.; Olechowski, Camille; Ballanyi, Klaus; Kerr, Bradley; Smith, Peter A.] Univ Alberta, Ctr Neurosci, Edmonton, AB T6G 2S2, Canada; [Smith, Peter A.] Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2S2, Canada; [Kerr, Bradley] Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB T6G 2S2, Canada; [Cohen, Eric A.] Univ Montreal, Inst Rech Clin Montreal, Montreal, PQ, Canada; [Cohen, Eric A.] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada; [Pardo, Carlos] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Johns Hopkins University	Power, C (corresponding author), Univ Alberta, Dept Med, Heritage Med Res Ctr 6, Edmonton, AB T6G 2S2, Canada.	chris.power@ualberta.ca	Power, Christopher/C-7181-2013; Pardo, Carlos A./A-5192-2008	Pardo, Carlos A./0000-0002-4128-5335; Power, Christopher/0000-0002-5131-9711	Alberta Heritage Foundation for Medical Research (AHFMR); Canadian Institutes for Health Research (CIHR); Canada Research Chairs (Tier 1) in Retrovirology and Neurological Infection and Immunity; Multiple Sclerosis Society of Canada	Alberta Heritage Foundation for Medical Research (AHFMR)(Alberta Heritage Foundation for Medical Research); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canada Research Chairs (Tier 1) in Retrovirology and Neurological Infection and Immunity(Canada Research Chairs); Multiple Sclerosis Society of Canada	The authors thank Araya Ruangkittisakul for technical assistance and Dr. Yu Zhu for helpful discussions. F.N. holds fellowships from the Alberta Heritage Foundation for Medical Research (AHFMR) and the Canadian Institutes for Health Research (CIHR). E.C. and C.P. hold Canada Research Chairs (Tier 1) in Retrovirology and Neurological Infection and Immunity, respectively. B.K. holds a Don Paty Career Award from the Multiple Sclerosis Society of Canada. K.B. is an AHFMR Scientist, and C.P. is an AHFMR Senior Scholar. These studies were supported by the CIHR.	Abdulla FA, 2002, J NEUROPHYSIOL, V88, P2518, DOI 10.1152/jn.00913.2001; Abdulla FA, 2001, J NEUROPHYSIOL, V85, P644, DOI 10.1152/jn.2001.85.2.644; ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Alier KA, 2008, J PHARMACOL EXP THER, V324, P224, DOI 10.1124/jpet.107.129171; BERNSEN PLJA, 1985, LANCET, V1, P50; Bruce-Keller AJ, 2003, J NEUROSCI, V23, P8417; Cherry CL, 2009, NEUROLOGY, V73, P315, DOI 10.1212/WNL.0b013e3181af7a22; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CHRISTOPHER P, 2003, ANN NEUROL, V53, P731; Dickie P, 2004, VIROLOGY, V322, P69, DOI 10.1016/j.virol.2004.01.026; Emir S, 1999, PEDIATR HEMAT ONCOL, V16, P557, DOI 10.1080/088800199276868; Gold MS, 1996, J NEUROPHYSIOL, V75, P2629, DOI 10.1152/jn.1996.75.6.2629; Gonzalez-Duarte Alejandra, 2007, Curr HIV/AIDS Rep, V4, P114, DOI 10.1007/s11904-007-0017-6; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Huang MB, 2000, J NEUROVIROL, V6, P202, DOI 10.3109/13550280009015823; JACOBS JM, 1976, J NEUROL SCI, V29, P95, DOI 10.1016/0022-510X(76)90083-6; Jolivalt CG, 2008, EUR J PAIN, V12, P76, DOI 10.1016/j.ejpain.2007.03.008; Jones G, 2005, VIROLOGY, V334, P178, DOI 10.1016/j.virol.2005.01.027; Jones GJ, 2007, J NEUROSCI, V27, P3703, DOI 10.1523/JNEUROSCI.5522-06.2007; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Keswani SC, 2006, J NEUROSCI, V26, P10299, DOI 10.1523/JNEUROSCI.3135-06.2006; Keswani SC, 2002, AIDS, V16, P2105, DOI 10.1097/00002030-200211080-00002; Le Rouzic E, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-11; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Linley JE, 2008, J NEUROSCI, V28, P11240, DOI 10.1523/JNEUROSCI.2297-08.2008; Lu VB, 2009, J PHYSIOL-LONDON, V587, P1013, DOI 10.1113/jphysiol.2008.166306; MARRION NV, 1991, NEURON, V6, P533, DOI 10.1016/0896-6273(91)90056-6; McArthur JC, 2005, LANCET NEUROL, V4, P543, DOI 10.1016/S1474-4422(05)70165-4; NEGORO K, 1994, MUSCLE NERVE, V17, P1351; Nitahara-Kasahara Y, 2007, J VIROL, V81, P5284, DOI 10.1128/JVI.01928-06; Noorbakhsh F, 2005, J IMMUNOL, V174, P7320, DOI 10.4049/jimmunol.174.11.7320; Okamoto K, 2001, EXP NEUROL, V169, P386, DOI 10.1006/exnr.2001.7677; Olechowski CJ, 2009, PAIN, V141, P156, DOI 10.1016/j.pain.2008.11.002; Pandya R, 2005, CAN J NEUROL SCI, V32, P201, DOI 10.1017/S0317167100003978; Pardo CA, 2001, J PERIPHER NERV SYST, V6, P21, DOI 10.1046/j.1529-8027.2001.006001021.x; Passmore GM, 2003, J NEUROSCI, V23, P7227, DOI 10.1523/JNEUROSCI.23-18-07227.2003; Piller SC, 1999, J VIROL, V73, P4230, DOI 10.1128/JVI.73.5.4230-4238.1999; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; Piller SC, 1998, P NATL ACAD SCI USA, V95, P4595, DOI 10.1073/pnas.95.8.4595; RANCE NE, 1988, NEUROLOGY, V38, P265, DOI 10.1212/WNL.38.2.265; Rho MB, 1995, BRAIN BEHAV IMMUN, V9, P366, DOI 10.1006/brbi.1995.1034; Ruangkittisakul A, 2006, J NEUROSCI, V26, P11870, DOI 10.1523/JNEUROSCI.3357-06.2006; Rutkove SB, 1997, ARCH NEUROL-CHICAGO, V54, P907, DOI 10.1001/archneur.1997.00550190093020; Sas AR, 2009, J NEUROSCI, V29, P3948, DOI 10.1523/JNEUROSCI.5595-08.2009; Smyth K, 2007, HIV MED, V8, P367, DOI 10.1111/j.1468-1293.2007.00478.x; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Vallejo R, 2010, PAIN PRACT, V10, P167, DOI 10.1111/j.1533-2500.2010.00367.x; WALL PD, 1983, PAIN, V17, P321, DOI 10.1016/0304-3959(83)90164-1; WALTER GB, 1998, MUSCLE NERVE, V21, P1188; White FA, 2009, MOL INTERV, V9, P188, DOI 10.1124/mi.9.4.7; Zhong J, 1999, J NEUROSCI, V19, P4305; Zhu Y, 2009, FASEB J, V23, P2928, DOI 10.1096/fj.08-128819	54	41	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4343	4353		10.1096/fj.10-162313	http://dx.doi.org/10.1096/fj.10-162313			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20628092				2022-12-28	WOS:000283861100022
J	Akhmedov, D; Braun, M; Mataki, C; Park, KS; Pozzan, T; Schoonjans, K; Rorsman, P; Wollheim, CB; Wiederkehr, A				Akhmedov, Dmitry; Braun, Matthias; Mataki, Chikage; Park, Kyu-Sang; Pozzan, Tullio; Schoonjans, Kristina; Rorsman, Patrik; Wollheim, Claes B.; Wiederkehr, Andreas			Mitochondrial matrix pH controls oxidative phosphorylation and metabolism-secretion coupling in INS-1E clonal beta cells	FASEB JOURNAL			English	Article						ATP; insulin; respiration; mtAlpHi/YC3.6	STIMULATED INSULIN-SECRETION; GLUCOSE-INDUCED CHANGES; RAT PANCREATIC-ISLETS; FLUORESCENT PROTEINS; ATP; CALCIUM; INTRAMITOCHONDRIAL; RELEASE; ATP/ADP; ADP	Glucose-evoked mitochondrial signals augment ATP synthesis in the pancreatic beta cell. This activation of energy metabolism increases the cytosolic ATP/ADP ratio, which stimulates plasma membrane electrical activity and insulin granule exocytosis. We have recently demonstrated that matrix pH increases during nutrient stimulation of the pancreatic beta cell. Here, we have tested whether mitochondrial matrix pH controls oxidative phosphorylation and metabolism-secretion coupling in the rat beta-cell line INS-1E. Acidification of the mitochondrial matrix pH by nigericin blunted nutrient-dependent respiratory and ATP responses (continuously monitored in intact cells). Using electrophysiology and single cell imaging, we find that the associated defects in energy metabolism suppress glucose-stimulated plasma membrane electrical activity and cytosolic calcium transients. The same parameters were unaffected after direct stimulation of electrical activity with tolbutamide, which bypasses mitochondrial function. Furthermore, lowered matrix pH strongly inhibited sustained, but not first-phase, insulin secretion. Our results demonstrate that the matrix pH exerts a control function on oxidative phosphorylation in intact cells and that this mode of regulation is of physiological relevance for the generation of downstream signals leading to insulin granule exocytosis. We propose that matrix pH serves a novel signaling role in sustained cell activation.-Akhmedov, D., Braun, M., Mataki, C., Park, K.-S., Pozzan, T., Schoonjans, K., Rorsman, P., Wollheim, C. B., Wiederkehr, A. Mitochondrial matrix pH controls oxidative phosphorylation and metabolism-secretion coupling in INS-1E clonal beta cells. FASEB J. 24, 4613-4626 (2010). www.fasebj.org	[Wiederkehr, Andreas] Univ Geneva, Dept Cell Physiol & Metab, Univ Med Ctr, CH-1211 Geneva 4, Switzerland; [Braun, Matthias; Rorsman, Patrik] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England; [Mataki, Chikage; Schoonjans, Kristina] Ecole Polytech Fed Lausanne, Lab Integrat Syst & Physiol, Lausanne, Switzerland; [Park, Kyu-Sang] Yonsei Univ, Dept Physiol, Wonju Coll Med, Wonju, South Korea; [Pozzan, Tullio] Univ Padua, Dept Biomed Sci, Padua, Italy; [Pozzan, Tullio] CNR, Inst Neurosci, Padua, Italy	University of Geneva; University of Oxford; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Yonsei University; University of Padua; Consiglio Nazionale delle Ricerche (CNR)	Wiederkehr, A (corresponding author), Univ Geneva, Dept Cell Physiol & Metab, Univ Med Ctr, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	andreas.wiederkehr@unige.ch	Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767; Schoonjans, Kristina/0000-0003-1247-4265; Park, Kyu-Sang/0000-0003-0322-9807	Swiss National Foundation [310000-116750/1]; Ecole Polytechnique Federale de Lausanne; EuroDia [LSHM-CT-2006-518153]; European Community; Wellcome Trust; UK Medical Research Council	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Ecole Polytechnique Federale de Lausanne; EuroDia; European Community(European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Nicole Aebischer, Dale Brighouse, Olivier Dupont, Elodie Husi, and Danielle Nappey for expert technical assistance. The authors gratefully acknowledge the continued support by the Swiss National Foundation (310000-116750/1); the Ecole Polytechnique Federale de Lausanne; EuroDia (LSHM-CT-2006-518153), a European Community-funded project under framework program 6; the Wellcome Trust; and the UK Medical Research Council.	Abad MFC, 2004, J BIOL CHEM, V279, P11521, DOI 10.1074/jbc.M306766200; Balaban RS, 2009, BBA-BIOENERGETICS, V1787, P1334, DOI 10.1016/j.bbabio.2009.05.011; Das AM, 2003, MOL GENET METAB, V79, P71, DOI 10.1016/S1096-7192(03)00069-6; Detimary P, 1996, ENDOCRINOLOGY, V137, P4671, DOI 10.1210/en.137.11.4671; Doliba NM, 2007, AM J PHYSIOL-ENDOC M, V292, pE1507, DOI 10.1152/ajpendo.00282.2006; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; Fransson U, 2006, DIABETOLOGIA, V49, P1578, DOI 10.1007/s00125-006-0263-y; Gauthier BR, 2009, CELL METAB, V10, P110, DOI 10.1016/j.cmet.2009.07.002; GREENBAUM NL, 1985, J BIOL CHEM, V260, P873; Henquin JC, 2009, DIABETOLOGIA, V52, P739, DOI 10.1007/s00125-009-1314-y; HUTTON JC, 1980, DIABETOLOGIA, V18, P395; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Jensen MV, 2008, AM J PHYSIOL-ENDOC M, V295, pE1287, DOI 10.1152/ajpendo.90604.2008; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Morgan A, 2005, BIOCHEM SOC T, V33, P1341, DOI 10.1042/BST0331341; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Nicholls DG, 2008, BBA-BIOENERGETICS, V1777, P550, DOI 10.1016/j.bbabio.2008.03.014; Nicholls DG, 2006, J BIOL CHEM, V281, P14864, DOI 10.1074/jbc.M510916200; OHTA M, 1990, J BIOL CHEM, V265, P17525; Ortsater H, 2002, PFLUG ARCH EUR J PHY, V444, P506, DOI 10.1007/s00424-002-0842-9; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Park KS, 2008, J BIOL CHEM, V283, P33347, DOI 10.1074/jbc.M806251200; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; SCHULTZ V, 1993, ANAL BIOCHEM, V215, P302, DOI 10.1006/abio.1993.1591; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Sweet IR, 2004, DIABETES, V53, P401, DOI 10.2337/diabetes.53.2.401; Wiederkehr A, 2008, CELL CALCIUM, V44, P64, DOI 10.1016/j.ceca.2007.11.004; Wiederkehr A, 2009, EMBO J, V28, P417, DOI 10.1038/emboj.2008.302	32	49	50	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4613	4626		10.1096/fj.10-162222	http://dx.doi.org/10.1096/fj.10-162222			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20647546	Green Published			2022-12-28	WOS:000283861100045
J	Busco, G; Cardone, RA; Greco, MR; Bellizzi, A; Colella, M; Antelmi, E; Mancini, MT; Dell'Aquila, ME; Casavola, V; Paradiso, A; Reshkin, SJ				Busco, Giovanni; Cardone, Rosa A.; Greco, Maria R.; Bellizzi, Antonia; Colella, Matilde; Antelmi, Ester; Mancini, Maria T.; Dell'Aquila, Maria E.; Casavola, Valeria; Paradiso, Angelo; Reshkin, Stephan J.			NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space	FASEB JOURNAL			English	Article						metastasis; pHe; MDA-MB-231; breast cancer	CANCER-CELL INVASION; EXTRACELLULAR-MATRIX DEGRADATION; BREAST-TUMOR CELLS; H EXCHANGER NHE1; NA+/H+ EXCHANGER; MELANOMA-CELLS; CATHEPSIN-B; PERICELLULAR PROTEOLYSIS; PH; METASTASIS	Extracellular matrix (ECM) degradation is a critical process in tumor cell invasion and requires membrane and released proteases focalized at membrane structures called invadopodia. While extracellular acidification is important in driving tumor invasion, the structure/function mechanisms underlying this regulation are still unknown. Invadopodia are similar in structure and function to osteoclast podosomes responsible for bone degradation, and extracellular acidification is central to podosome action, suggesting that it could also be for invadopodial function. Here, utilizing a novel system for in situ zymography in native matrices, we show that the Na+/H+ exchanger (NHE1) and NHE1-generated extracellular acidification are localized at and necessary for invadopodial-dependent ECM degradation, thereby promoting tumor invasion. Stimulation with EGF increased both NHE1-dependent proton secretion and ECM degradation. Manipulation of the NHE1 expression by RNA interference or activity via either transport-deficient mutation or the specific inhibitor cariporide confirmed that NHE1 expression and activity are required for invadopodia-mediated ECM degradation. Taken together, our data show a concordance among NHE1 localization, the generation of a well-defined acidic extracellular pH in the nanospace surrounding invadopodia, and matrix-degrading activity at invadopodia of human malignant breast carcinoma cells, providing a structural basis for the role of NHE1 in invasion and identifying NHE1 as a strategic target for therapeutic intervention.-Busco, G., Cardone, R. A., Greco, M. R., Bellizzi, A., Colella, M., Antelmi, E., Mancini, M. T., Dell'Aquila, M. E., Casavola, V., Paradiso, A., Reshkin, S. J. NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. FASEB J. 24, 3903-3915 (2010). www.fasebj.org	[Busco, Giovanni; Cardone, Rosa A.; Greco, Maria R.; Colella, Matilde; Antelmi, Ester; Mancini, Maria T.; Casavola, Valeria; Reshkin, Stephan J.] Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy; [Dell'Aquila, Maria E.] Univ Bari, Dept Anim Prod, I-70126 Bari, Italy; [Bellizzi, Antonia; Paradiso, Angelo] Natl Canc Inst Giovanni Paolo II, Clin Expt Oncol Lab, Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; IRCCS Istituto Tumori Bari Giovanni Paolo II	Reshkin, SJ (corresponding author), Univ Bari, Dept Gen & Environm Physiol, Via Amendola 165-A, I-70126 Bari, Italy.	reshkin@biologia.uniba.it	Antelmi, Elena/K-3252-2018; paradiso, angelo V/J-9457-2018; Colella, Matilde/G-9246-2011; Busco, Giovanni/F-2711-2018; Reshkin, Stephan/AAI-6680-2020	Colella, Matilde/0000-0002-9584-7030; Busco, Giovanni/0000-0001-6859-9468; Reshkin, Stephan/0000-0001-9757-5908; GRECO, Maria Raffaella/0000-0001-7454-8990; CASAVOLA, Valeria/0000-0003-4471-4948; Antelmi, Elena/0000-0003-1739-6139; Dell'Aquila, Maria Elena/0000-0003-3629-7005; Antelmi, Ester/0000-0003-0685-4827	Italian Association for Cancer Research [5167]	Italian Association for Cancer Research	The authors thank the Italian Association for Cancer Research (grant 5167) for supporting this work. The authors' laboratory is part of the Italian network Istituto Nazionale Biostrutture e Biosistemi. The authors thank Prof. Diane Barber (University of California, San Francisco, CA, USA) for kindly supplying the construct containing the ion transport dead E226I-NHE1 mutant and Sanofi-Aventis (Paris, France) for supplying cariporide (HOE642). The authors also thank Dr. Roberto Buccione (Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy) for teaching the basics of the invadopodia isolation technique.	Albini A, 2004, INT J DEV BIOL, V48, P563, DOI 10.1387/ijdb.041822aa; Alexander NR, 2008, CURR BIOL, V18, P1295, DOI 10.1016/j.cub.2008.07.090; Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Briozzo P, 1998, STRUCTURE, V6, P1517, DOI 10.1016/S0969-2126(98)00150-6; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; Caldieri G, 2009, INT REV CEL MOL BIO, V275, P1, DOI 10.1016/S1937-6448(09)75001-4; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan KT, 2009, J CELL BIOL, V185, P357, DOI 10.1083/jcb.200809110; Chen WT, 2008, J CHIN MED ASSOC, V71, P128, DOI 10.1016/S1726-4901(08)70004-2; Chen WT, 2003, CANCER METAST REV, V22, P259, DOI 10.1023/A:1023055600919; Chiang YH, 2008, J CELL PHYSIOL, V214, P810, DOI 10.1002/jcp.21277; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Cortesio CL, 2008, J CELL BIOL, V180, P957, DOI 10.1083/jcb.200708048; Demou ZN, 2005, CANCER RES, V65, P5674, DOI 10.1158/0008-5472.CAN-04-1682; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Duffy MJ, 2008, J PATHOL, V214, P283, DOI 10.1002/path.2282; Enderling H, 2008, BIOPHYS J, V95, P2203, DOI 10.1529/biophysj.108.133199; Frederiks WM, 2004, J HISTOCHEM CYTOCHEM, V52, P711, DOI 10.1369/jhc.4R6251.2004; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Gatenby RA, 2006, INT J EPIDEMIOL, V35, P1165, DOI 10.1093/ije/dyl192; Giusti I, 2008, NEOPLASIA, V10, P481, DOI 10.1593/neo.08178; GOLDHABER P, 1987, AM J PHYSIOL, V253, pE90, DOI 10.1152/ajpendo.1987.253.1.E90; Huang WC, 2008, CURR BIOL, V18, P781, DOI 10.1016/j.cub.2008.04.049; KATO Y, 1992, J BIOL CHEM, V267, P11424; Kindzelskii AL, 2004, HISTOCHEM CELL BIOL, V121, P299, DOI 10.1007/s00418-004-0639-3; Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102; Kraus M, 1996, TUMOR BIOL, V17, P133, DOI 10.1159/000217977; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Lizarraga F, 2009, CANCER RES, V69, P2792, DOI 10.1158/0008-5472.CAN-08-3709; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Lunt SJ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-2; Makale M, 2008, METHOD ENZYMOL, V444, P175, DOI 10.1016/S0076-6879(08)02808-5; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; McNiven MA, 2004, FRONT BIOSCI-LANDMRK, V9, P1944, DOI 10.2741/1348; Moellering RE, 2008, CLIN EXP METASTAS, V25, P411, DOI 10.1007/s10585-008-9145-7; MONTCOURRIER P, 1994, J CELL SCI, V107, P2381; Pereverzev A, 2008, BONE, V42, P150, DOI 10.1016/j.bone.2007.08.044; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rofstad EK, 2000, INT J RADIAT BIOL, V76, P589, DOI 10.1080/095530000138259; Rofstad EK, 2003, CANCER RES, V63, P4055; ROZHIN J, 1994, CANCER RES, V54, P6517; Sabe H, 2003, J BIOCHEM, V134, P485, DOI 10.1093/jb/mvg181; Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195; Sameni M, 2000, NEOPLASIA, V2, P496, DOI 10.1038/sj.neo.7900116; SCHLAPPACK OK, 1991, BRIT J CANCER, V64, P663, DOI 10.1038/bjc.1991.378; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Stock C, 2007, CELL PHYSIOL BIOCHEM, V20, P679, DOI 10.1159/000107550; Stock C, 2009, PFLUG ARCH EUR J PHY, V458, P981, DOI 10.1007/s00424-009-0677-8; Stylli SS, 2008, J CLIN NEUROSCI, V15, P725, DOI 10.1016/j.jocn.2008.03.003; Taves J, 2008, ARCH BIOCHEM BIOPHYS, V477, P60, DOI 10.1016/j.abb.2008.05.007; Vader D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005902; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Wolf K, 2005, BIOCHIMIE, V87, P315, DOI 10.1016/j.biochi.2004.10.016; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076	64	166	167	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3903	3915		10.1096/fj.09-149518	http://dx.doi.org/10.1096/fj.09-149518			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20547664	Green Submitted			2022-12-28	WOS:000285005900028
J	Bryan, BA; Dennstedt, E; Mitchell, DC; Walshe, TE; Noma, K; Loureiro, R; Saint-Geniez, M; Campaigniac, JP; Liao, JK; D'Amore, PA				Bryan, Brad A.; Dennstedt, Emily; Mitchell, Dianne C.; Walshe, Tony E.; Noma, Kensuke; Loureiro, Robyn; Saint-Geniez, Magali; Campaigniac, Jean-Paul; Liao, James K.; D'Amore, Patricia A.			RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis	FASEB JOURNAL			English	Article						endothelial cells; Y-27632; Rho kinase; GTPase; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; VENTRAL BODY-WALL; CELL-MIGRATION; ROCK-I; RHO-KINASE; GTPASE RHO; PROTEIN; ACTIVATION; EXPRESSION; PHOSPHORYLATION	The small GTPase RhoA and its downstream effectors, ROCK1 and ROCK2, regulate a number of cellular processes, including cell motility, proliferation, survival, and permeability. Pharmacological inhibitors of the Rho pathway reportedly block angiogenesis; however, the molecular details of this inhibition are largely unknown. We demonstrate that vascular endothelial growth factor-A (VEGF) rapidly induces RhoA activation in endothelial cells (ECs). Moreover, the pharmacological inhibition of ROCK1/2 using 10 mu M Y-27632 (the IC50 for this compound in ECs) strongly disrupts vasculogenesis in pluripotent embryonic stem cell cultures, VEGF-mediated regenerative angiogenesis in ex vivo retinal explants, and VEGF-mediated in vitro EC tube formation. Furthermore, using small interfering RNA knockdown and mouse heterozygote knockouts of ROCK1 and ROCK2, we provide data indicating that VEGF-driven angiogenesis is largely mediated through ROCK2. These data demonstrate that Rho/ROCK signaling is an important mediator in a number of angiogenic processes, including EC migration, survival, and cell permeability, and suggest that Rho/ROCK inhibition may prove useful for the treatment of angiogenesis-related disorders.-Bryan, B. A., Dennstedt, E., Mitchell, D. C., Walshe, T. E., Noma, K., Loureiro, R., Saint-Geniez, M., Campaigniac, J.-P., Liao, J. K., D'Amore, P. A. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 24, 3186 -3195 (2010). www.fasebj.org	[Bryan, Brad A.; Mitchell, Dianne C.; Walshe, Tony E.; Loureiro, Robyn; Saint-Geniez, Magali; D'Amore, Patricia A.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; [Bryan, Brad A.; Mitchell, Dianne C.; Walshe, Tony E.; Loureiro, Robyn; Saint-Geniez, Magali; D'Amore, Patricia A.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA; [Bryan, Brad A.; Mitchell, Dianne C.; Walshe, Tony E.; Loureiro, Robyn; Saint-Geniez, Magali; D'Amore, Patricia A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA; [Bryan, Brad A.; Dennstedt, Emily; Campaigniac, Jean-Paul] Worcester State Coll, Dept Biol, Worcester, MA USA; [Noma, Kensuke; Liao, James K.] Brigham & Womens Hosp, Vasc Med Res Unit, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts System of Public Higher Education; Worcester State University; Harvard University; Brigham & Women's Hospital	D'Amore, PA (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	damore@schepens.harvard.edu	SAINT-GENIEZ, MAGALI/P-3509-2019; D'Amore, Patricia A/G-5660-2017; Walshe, Tony/AAJ-8833-2020	SAINT-GENIEZ, MAGALI/0000-0001-9897-138X; D'Amore, Patricia A/0000-0001-9652-8974; 	U.S. National Institutes of Health [EY-05318, EY-015435, CA-45548, HL-052233, HL-098931]; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005318, R01EY015435] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL098931, R01HL080187, R01HL052233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070001] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by U.S. National Institutes of Health grants EY-05318, EY-015435, and CA-45548 to P. A. D; HL-052233 to J.K.L.; and HL-098931 to B. A. B. P. A. D is a Research to Prevent Blindness Senior Scientific Investigator. The authors thank Dr. M. Liu (Texas A&M University Health Science Center, Houston, TX, USA) for the use of the Rhotekin-GST expression plasmid.	Abecassis I, 2003, EXP CELL RES, V291, P363, DOI 10.1016/j.yexcr.2003.08.006; Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Bryan BA, 2007, CELL MOL LIFE SCI, V64, P2053, DOI 10.1007/s00018-007-7008-z; Bryan BA, 2005, CELL MOL LIFE SCI, V62, P1547, DOI 10.1007/s00018-005-5029-z; Bryan BA, 2008, MOL BIOL CELL, V19, P994, DOI 10.1091/mbc.E07-09-0856; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Cleaver O, 1998, DEVELOPMENT, V125, P3905; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Croft DR, 2006, MOL CELL BIOL, V26, P4612, DOI 10.1128/MCB.02061-05; Darland D. C., 2001, Angiogenesis, V4, P11, DOI 10.1023/A:1016611824696; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Ghosh K, 2008, P NATL ACAD SCI USA, V105, P11305, DOI 10.1073/pnas.0800835105; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538-7836.2006.02259.x; Hata Y, 2008, JPN J OPHTHALMOL, V52, P16, DOI 10.1007/s10384-007-0487-5; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029; Im E, 2007, J BIOL CHEM, V282, P29122, DOI 10.1074/jbc.M702637200; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; JIMENEZ B, 1995, ONCOGENE, V10, P811; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kaneko T, 2000, BIOCHEM BIOPH RES CO, V273, P110, DOI 10.1006/bbrc.2000.2901; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 2009, AM J PHYSIOL-HEART C, V296, pH893, DOI 10.1152/ajpheart.01038.2008; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; McLaughlin AP, 2001, AM J PHYSIOL-CELL PH, V281, pC1448, DOI 10.1152/ajpcell.2001.281.5.C1448; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Ng YS, 2004, LAB INVEST, V84, P1209, DOI 10.1038/labinvest.3700150; Noma K, 2008, J CLIN INVEST, V118, P1632, DOI 10.1172/JCI29226; Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C; Petrache I, 2003, BIOCHEM BIOPH RES CO, V306, P244, DOI 10.1016/S0006-291X(03)00945-8; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ramsauer M, 2007, J CELL SCI, V120, P1810, DOI 10.1242/jcs.003533; RATAJSKA A, 1995, DEV DYNAM, V203, P399, DOI 10.1002/aja.1002030403; Rikitake Y, 2005, CIRCULATION, V112, P2959, DOI 10.1161/CIRCULATIONAHA.105.584623; Rikitake Y, 2005, STROKE, V36, P2251, DOI 10.1161/01.STR.0000181077.84981.11; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shimizu Y, 2005, J CELL BIOL, V168, P941, DOI 10.1083/jcb.200411179; Thumkeo D, 2005, GENES CELLS, V10, P825, DOI 10.1111/j.1365-2443.2005.00882.x; Thumkeo D, 2003, MOL CELL BIOL, V23, P5043, DOI 10.1128/MCB.23.14.5043-5055.2003; Titus B, 2005, CRIT REV EUKAR GENE, V15, P103, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.20; Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014-5793(01)02337-7; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; Watanabe T, 2005, TRENDS CELL BIOL, V15, P76, DOI 10.1016/j.tcb.2004.12.006; Wei L, 2001, DEVELOPMENT, V128, P2953; Yin LM, 2007, MOL CANCER THER, V6, P1517, DOI 10.1158/1535-7163.MCT-06-0689; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zeng LX, 2005, FASEB J, V19, P1845, DOI 10.1096/fj.05-4240fje; Zhang YM, 2006, FASEB J, V20, P916, DOI 10.1096/fj.05-5129com; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638	64	186	196	2	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3186	3195		10.1096/fj.09-145102	http://dx.doi.org/10.1096/fj.09-145102			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20400538	Green Published			2022-12-28	WOS:000281446400008
J	Cardenas, C; Juretic, N; Bevilacqua, JA; Garcia, IE; Figueroa, R; Hartley, R; Taratuto, AL; Gejman, R; Riveros, N; Molgo, J; Jaimovich, E				Cardenas, Cesar; Juretic, Nevenka; Bevilacqua, Jorge A.; Garcia, Isaac E.; Figueroa, Reinaldo; Hartley, Ricardo; Taratuto, Ana L.; Gejman, Roger; Riveros, Nora; Molgo, Jordi; Jaimovich, Enrique			Abnormal distribution of inositol 1,4,5-trisphosphate receptors in human muscle can be related to altered calcium signals and gene expression in Duchenne dystrophy-derived cells	FASEB JOURNAL			English	Article						skeletal muscle; excitation-transcription coupling; dystrophin; muscle plasticity; myofiber types	ELEMENT-BINDING PROTEIN; SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; CA2+ TRANSIENTS; UP-REGULATION; MEMBRANE DEPOLARIZATION; CARDIAC MYOCYTES; SATELLITE CELLS; IP3 RECEPTORS; MDX MUSCLE	Inositol 1,4,5-trisphosphate (IP3) receptors (IP(3)Rs) drive calcium signals involved in skeletal muscle excitation-transcription coupling and plasticity; IP3R subtype distribution and downstream events evoked by their activation have not been studied in human muscle nor has their possible alteration in Duchenne muscular dystrophy (DMD). We studied the expression and localization of IP3R subtypes in normal and DMD human muscle and in normal (RCMH) and dystrophic (RCDMD) human muscle cell lines. In normal muscle, both type 1 IP(3)Rs (IP(3)R1) and type 2 IP(3)Rs (IP(3)R2) show a higher expression in type II fibers, whereas type 3 IP(3)Rs (IP(3)R3) show uniform distribution. In DMD biopsies, all fibers display a homogeneous IP(3)R2 label, whereas 24 +/- 7% of type II fibers have lost the IP(3)R1 label. RCDMD cells show 5-fold overexpression of IP(3)R2 and down-regulation of IP(3)R3 compared with RCMH cells. A tetanic stimulus induces IP3-dependent slow Ca2+ transients significantly larger and faster in RCDMD cells than in RCMH cells as well as significant ERK1/2 phosphorylation in normal but not in dystrophic cells. Excitation-driven gene expression was different among cell lines; 44 common genes were repressed in RCMH cells and expressed in RCDMD cells or vice versa. IP3-dependent Ca2+ release may play a significant role in DMD pathophysiology.-Cardenas, C., Juretic, N., Bevilacqua, J. A., Garcia, I. E., Figueroa, R., Hartley, R., Taratuto, A. L., Gejman, R., Riveros, N., Molgo, J., Jaimovich, E. Abnormal distribution of inositol 1,4,5-trisphosphate receptors in human muscle can be related to altered calcium signals and gene expression in Duchenne dystrophy-derived cells. FASEB J. 24, 3210-3221 (2010). www.fasebj.org	[Cardenas, Cesar; Juretic, Nevenka; Bevilacqua, Jorge A.; Garcia, Isaac E.; Figueroa, Reinaldo; Hartley, Ricardo; Riveros, Nora; Jaimovich, Enrique] Univ Chile, Inst Ciencias Biomed, Ctr Estudios Mol Celula, Fac Med, Santiago 1027 7, Chile; [Bevilacqua, Jorge A.] Univ Chile, Inst Ciencias Biomed, Programa Anat & Biol Desarrollo, Fac Med, Santiago 7, Chile; [Cardenas, Cesar; Molgo, Jordi] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; [Bevilacqua, Jorge A.] Univ Chile, Hosp Clin, Dept Neurol & Neurocirugia, Independencia, Chile; [Taratuto, Ana L.] FLENI, Inst Invest Neurol, Dept Neuropatol, Buenos Aires, DF, Argentina; [Gejman, Roger] Pontificia Univ Catolica Chile, Fac Med, Dept Anat Patol, Santiago, Chile; CNRS, Inst Neurobiol Alfred Fessard, FRC2118, Lab Neurobiol Cellulaire & Mol,UPR9040, Gif Sur Yvette, France	Universidad de Chile; Universidad de Chile; University of Pennsylvania; Universidad de Chile; Pontificia Universidad Catolica de Chile; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Jaimovich, E (corresponding author), Univ Chile, Inst Ciencias Biomed, Ctr Estudios Mol Celula, Fac Med, Santiago 1027 7, Chile.	ejaimovi@med.uchile.cl	Figueroa Contreras, Reinaldo/GXF-6114-2022; Jaimovich, Enrique/AAY-7632-2020; Bevilacqua, Jorge A./I-3113-2013; Juretic, Nevenka/N-6973-2018	Figueroa Contreras, Reinaldo/0000-0002-7718-0201; Bevilacqua, Jorge A./0000-0002-0525-9308; Juretic, Nevenka/0000-0003-1098-435X; Hartley, Ricardo/0000-0001-5058-9309	Fondo de Investigacion Avanzada en Areas Prioritarias (FONDAP) [15010006]; Fondo Nacional de Investigacion Cientifica y Tecnologica [1080120]; ECOS Sud-CONICYT exchange program [C03S02]; Proyecto OAIC [OAIC 106-05]; Hospital Clinico Universidad de Chile; Association Francaise Contre les Myopathies; FONDAP; AFM at Laboratoire de Neurobiologie Cellulaire et Moleculaire (France); Programa Bicentenario de Ciencia y Tecnologia [PSD24]	Fondo de Investigacion Avanzada en Areas Prioritarias (FONDAP)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDAP); Fondo Nacional de Investigacion Cientifica y Tecnologica(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); ECOS Sud-CONICYT exchange program; Proyecto OAIC; Hospital Clinico Universidad de Chile; Association Francaise Contre les Myopathies(Association Francaise contre les Myopathies); FONDAP; AFM at Laboratoire de Neurobiologie Cellulaire et Moleculaire (France); Programa Bicentenario de Ciencia y Tecnologia	The authors are grateful to Monica Silva for culture preparations and to Dr. Ulises Urzua for microarray laboratory facilities. The authors thank Dr. Marcos Ganga (Department of Traumatology, Hospital Clinico Universidad de Chile, Independencia, Chile) and Drs. Christian Bermudez and Ernesto Larrain (Department of Cardiology, Hospital Clinico Universidad de Chile) for their collaboration in obtaining normal tissue samples. This work was supported by Fondo de Investigacion Avanzada en Areas Prioritarias (FONDAP; grant 15010006) and Fondo Nacional de Investigacion Cientifica y Tecnologica (grant 1080120 to E.J.), ECOS Sud-CONICYT exchange program (C03S02), Proyecto OAIC (OAIC 106-05), Hospital Clinico Universidad de Chile (J.A.B. and C. C.), and the Association Francaise Contre les Myopathies (AFM) (J.M.). C. C. was supported by a postdoctoral fellowship from FONDAP and by a short-term fellowship from AFM at Laboratoire de Neurobiologie Cellulaire et Moleculaire (France). N.J. was supported by a postdoctoral fellowship from project PSD24, Programa Bicentenario de Ciencia y Tecnologia.	Alderton JM, 2000, TRENDS CARDIOVAS MED, V10, P268, DOI 10.1016/S1050-1738(00)00075-X; Araya R, 2003, J GEN PHYSIOL, V121, P3, DOI 10.1085/jgp.20028671; Balghi H, 2006, J GEN PHYSIOL, V127, P171, DOI 10.1085/jgp.200509456; Balghi H, 2006, J GEN PHYSIOL, V128, P219, DOI 10.1085/jgp.200609559; Basset O, 2004, J BIOL CHEM, V279, P47092, DOI 10.1074/jbc.M405054200; Batchelor CL, 2006, TRENDS CELL BIOL, V16, P198, DOI 10.1016/j.tcb.2006.02.001; Buvinic S, 2009, J BIOL CHEM, V284, P34490, DOI 10.1074/jbc.M109.057315; Canto C, 2006, J BIOL CHEM, V281, P21690, DOI 10.1074/jbc.M600475200; Cardenas C, 2005, J CELL SCI, V118, P3131, DOI 10.1242/jcs.02446; Cardenas C, 2004, J BIOL CHEM, V279, P39122, DOI 10.1074/jbc.M401044200; Carrasco MA, 2003, AM J PHYSIOL-CELL PH, V284, pC1438, DOI 10.1152/ajpcell.00117.2002; CAVIEDES R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P247, DOI 10.1016/0167-4889(92)90183-C; CAVIEDES R, 1994, MUSCLE NERVE, V17, P1021, DOI 10.1002/mus.880170909; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Culligan K, 2002, J APPL PHYSIOL, V92, P435, DOI 10.1152/japplphysiol.00903.2001; Deval E, 2002, NEUROMUSCULAR DISORD, V12, P665, DOI 10.1016/S0960-8966(02)00022-6; Dominov JA, 1996, DEV GENET, V19, P108, DOI 10.1002/(SICI)1520-6408(1996)19:2<108::AID-DVG2>3.0.CO;2-D; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; Eltit JM, 2006, J BIOL CHEM, V281, P12143, DOI 10.1074/jbc.M511218200; Eltit JM, 2004, BIOPHYS J, V86, P3042, DOI 10.1016/S0006-3495(04)74353-2; Froemming GR, 2000, BBA-BIOMEMBRANES, V1466, P151, DOI 10.1016/S0005-2736(00)00195-4; Gailly P, 2002, BBA-PROTEINS PROTEOM, V1600, P38, DOI 10.1016/S1570-9639(02)00442-9; Gillis JM, 1999, J MUSCLE RES CELL M, V20, P605, DOI 10.1023/A:1005545325254; Haslett JN, 2003, NEUROGENETICS, V4, P163, DOI 10.1007/s10048-003-0148-x; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Herrero J, 2004, NUCLEIC ACIDS RES, V32, pW485, DOI 10.1093/nar/gkh421; Hirata M, 2007, ACTA NEUROPATHOL, V113, P451, DOI 10.1007/s00401-007-0198-5; Ibarra C, 2004, J BIOL CHEM, V279, P7554, DOI 10.1074/jbc.M311604200; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; JAIMOVICH E, 1994, CELL CALCIUM, V15, P356, DOI 10.1016/0143-4160(94)90011-6; Jaimovich E, 2000, AM J PHYSIOL-CELL PH, V278, pC998, DOI 10.1152/ajpcell.2000.278.5.C998; Jordan T, 2005, J CELL SCI, V118, P2295, DOI 10.1242/jcs.02341; Jorquera G, 2009, AM J PHYSIOL-CELL PH, V297, pC581, DOI 10.1152/ajpcell.00167.2009; Juretic N, 2006, AM J PHYSIOL-CELL PH, V290, pC1428, DOI 10.1152/ajpcell.00449.2005; Juretic N, 2007, J CELL PHYSIOL, V210, P819, DOI 10.1002/jcp.20902; Kasri NN, 2006, CELL CALCIUM, V40, P41, DOI 10.1016/j.ceca.2006.03.005; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Krag TOB, 2004, P NATL ACAD SCI USA, V101, P13856, DOI 10.1073/pnas.0405972101; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; Laflamme K, 2002, J CELL BIOCHEM, V85, P219, DOI 10.1002/jcb.10124; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; Lebrasseur NK, 2003, AM J PHYSIOL-CELL PH, V284, pC1149, DOI 10.1152/ajpcell.00487.2002; Liberona JL, 1998, MUSCLE NERVE, V21, P902, DOI 10.1002/(SICI)1097-4598(199807)21:7<902::AID-MUS8>3.0.CO;2-A; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; MOSCHELLA MC, 1995, J MUSCLE RES CELL M, V16, P390, DOI 10.1007/BF00114504; Nakamura A, 2005, BBA-MOL BASIS DIS, V1740, P326, DOI 10.1016/j.bbadis.2004.12.003; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Noguchi S, 2003, HUM MOL GENET, V12, P595, DOI 10.1093/hmg/ddg065; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Powell JA, 2003, J NEUROSCI, V23, P8185; Powell JA, 2001, J CELL SCI, V114, P3673; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; Salanova M, 2008, HISTOCHEM CELL BIOL, V130, P105, DOI 10.1007/s00418-008-0399-6; Tasker PN, 1999, CIRC RES, V84, P536, DOI 10.1161/01.RES.84.5.536; Turk R, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-98; TURNER PR, 1993, J MEMBRANE BIOL, V133, P243; Vaquerizas JM, 2004, BIOINFORMATICS, V20, P3656, DOI 10.1093/bioinformatics/bth401	59	18	18	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3210	3221		10.1096/fj.09-152017	http://dx.doi.org/10.1096/fj.09-152017			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20395455				2022-12-28	WOS:000281446400010
J	Gibbs, PEM; Miralem, T; Maines, MD				Gibbs, Peter E. M.; Miralem, Tihomir; Maines, Mahin D.			Characterization of the human biliverdin reductase gene structure and regulatory elements: promoter activity is enhanced by hypoxia and suppressed by TNF-alpha-activated NF-kappa B	FASEB JOURNAL			English	Article						oxidative stress; antioxidants; bile pigments; cytokines; heme oxygenase; HIF-1	HEME OXYGENASE-1 GENE; TRANSCRIPTION FACTORS; RAT-LIVER; SIGNAL-TRANSDUCTION; MEDIATED INDUCTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; OXIDATIVE STRESS; CARBON-MONOXIDE; BINDING-SITES	hBVR is a Ser/Thr/Tyr kinase/scaffold protein/transcription factor/intracellular transporter of regulators. hBVR is an upstream activator of the insulin/IGF-1/MAPK/PI3K signaling pathway, and of NF-kappa B. As a reductase, it converts biliverdin to the antioxidant, bilirubin. hBVR gene has 8 exons; exon 1 is not translated. We report the characterization of hBVR promoter and its negative and positive regulation, respectively, by TNF-alpha and hypoxia. The 5' end of exon 1 was defined by primer extension analyses; deletion of an inhibitor sequence 350-425 bp upstream of this exon enhanced the promoter activity. One of two NF-kappa B binding sites in the 836-bp promoter was functional; the P65 subunit of NF-kappa B and TNF-alpha acted as inhibitors. On the basis of EMSA and ChIP assays, TNF-alpha treatment increases binding of NF-kappa B to its regulatory element. Overexpression of I kappa B increased hBVR mRNA. Biliverdin, but not bilirubin, was as effective as TNF-alpha in inhibiting hBVR promoter activity. Only one of 4 hypoxia responsive elements (HREs) bound to HIF-1 alpha and ARNT expressed in HEK293A cells. An abasic site was introduced at the 3' G of the HRE. This element bound HIF-1 in the gel shift and in in-cell luciferase assays. hBVR was detected in the nucleus at 1, 2, and 4 h after hypoxia (1% O-2), at which times its kinase and reductase activities were increased. Because hypoxia positively influences hBVR promoter and phosphorylation and TNF-alpha activated NF-kappa B inhibits the promoter, while biliverdin inhibits both NF-kappa B activity and hBVR promoter, we propose a regulatory mechanism for NF-kappa B by hypoxia and TNF-alpha centered on hBVR/biliverdin.-Gibbs, P. E. M., Miralem, T., Maines, M. D. Characterization of the human biliverdin reductase gene structure and regulatory elements: promoter activity is enhanced by hypoxia and suppressed by TNF-alpha-activated NF-kappa B. FASEB J. 24, 3239-3254 (2010). www.fasebj.org	[Gibbs, Peter E. M.; Miralem, Tihomir; Maines, Mahin D.] Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Maines, MD (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	mahin_maines@urmc.rochester.edu	Miralem, Tihomir/F-7576-2013	Miralem, Tihomir/0000-0001-7705-0442	NIEHS NIH HHS [R01 ES004066-26, R01 ES004066, R01 ES012187, R01 ES012187-08] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012187, R01ES004066] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Ahmad Z, 2002, J BIOL CHEM, V277, P9226, DOI 10.1074/jbc.M108239200; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1992, J BIOL CHEM, V267, P21894; AUST SD, 1982, FREE RADICALS BIOL, V5, P1; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.20; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ehrismann D, 2007, BIOCHEM J, V401, P227, DOI 10.1042/BJ20061151; EWING JF, 1995, BRAIN RES, V672, P29, DOI 10.1016/0006-8993(94)01290-X; EWING JF, 1993, J NEUROCHEM, V61, P1015, DOI 10.1111/j.1471-4159.1993.tb03615.x; Florczyk UM, 2008, PHARMACOL REP, V60, P38; Gibbs PEM, 2007, INT J CANCER, V121, P2567, DOI 10.1002/ijc.22978; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HUANG TJ, 1989, ARCH BIOCHEM BIOPHYS, V270, P513, DOI 10.1016/0003-9861(89)90533-X; Immenschuh S, 2006, HISTOL HISTOPATHOL, V21, P679, DOI 10.14670/HH-21.679; Jozkowicz A, 2004, BIOCHEM BIOPH RES CO, V314, P31, DOI 10.1016/j.bbrc.2003.12.059; Kapitulnik J, 2004, MOL PHARMACOL, V66, P773, DOI 10.1124/mol.104.002832; Kapitulnik J, 2009, TRENDS PHARMACOL SCI, V30, P129, DOI 10.1016/j.tips.2008.12.003; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kikuchi A, 2001, NAT STRUCT BIOL, V8, P221, DOI 10.1038/84955; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; Lee PJ, 2003, FREE RADICAL BIO MED, V35, P341, DOI 10.1016/S0891-5849(03)00279-X; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; Lehmann E, 2010, HEPATOLOGY, V51, P398, DOI 10.1002/hep.23339; Lerner-Marmarosh N, 2005, P NATL ACAD SCI USA, V102, P7109, DOI 10.1073/pnas.0502173102; Lerner-Marmarosh N, 2008, P NATL ACAD SCI USA, V105, P6870, DOI 10.1073/pnas.0800750105; Lerner-Marmarosh N, 2007, FASEB J, V21, P3949, DOI 10.1096/fj.07-8544com; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Maghzal GJ, 2009, J BIOL CHEM, V284, P29251, DOI 10.1074/jbc.M109.037119; Maines MD, 2007, J BIOL CHEM, V282, P8110, DOI 10.1074/jbc.M513427200; Maines MD, 2005, PHYSIOLOGY, V20, P382, DOI 10.1152/physiol.00029.2005; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; Maines MD, 1999, J UROLOGY, V162, P1467, DOI 10.1016/S0022-5347(05)68342-5; Maines MD, 2001, J PHARMACOL EXP THER, V296, P1091; MAINES MD, 1986, J BIOL CHEM, V261, P411; Mancuso C, 2006, ANTIOXID REDOX SIGN, V8, P487, DOI 10.1089/ars.2006.8.487; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MCCOUBREY WK, 1995, GENE, V160, P235, DOI 10.1016/0378-1119(95)00112-J; McDonagh AF, 2001, NAT STRUCT BIOL, V8, P198, DOI 10.1038/84915; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Michel G, 2002, BBA-GENE STRUCT EXPR, V1578, P73, DOI 10.1016/S0167-4781(02)00484-0; Miralem T, 2005, J BIOL CHEM, V280, P17084, DOI 10.1074/jbc.M413121200; Miralem T, 2010, J BIOL CHEM, V285, P12551, DOI 10.1074/jbc.M109.032771; Nakao A, 2005, AM J TRANSPLANT, V5, P282, DOI 10.1111/j.1600-6143.2004.00695.x; Nakao A, 2004, GASTROENTEROLOGY, V127, P595, DOI 10.1053/j.gastro.2004.05.059; Ovcharenko I, 2004, GENOME RES, V14, P472, DOI 10.1101/gr.2129504; Ozgenc AI, 2005, J BACTERIOL, V187, P1974, DOI 10.1128/JB.187.6.1974-1984.2005; Alok SP, 2007, J MOL CELL CARDIOL, V43, P580, DOI 10.1016/j.yjmcc.2007.08.003; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pastukh V, 2007, FREE RADICAL BIO MED, V43, P1616, DOI 10.1016/j.freeradbiomed.2007.08.027; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Ryter SW, 2007, AM J RESP CELL MOL, V36, P175, DOI 10.1165/rcmb.2006-0333TR; Ryter SW, 2005, ANTIOXID REDOX SIGN, V7, P80, DOI 10.1089/ars.2005.7.80; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Sedlak TW, 2009, P NATL ACAD SCI USA, V106, P5171, DOI 10.1073/pnas.0813132106; Sinal CJ, 1997, MOL PHARMACOL, V52, P590, DOI 10.1124/mol.52.4.590; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; Thomas JW, 2003, MAMM GENOME, V14, P673, DOI 10.1007/s00335-003-2300-1; Tongers J, 2004, CARDIOVASC RES, V63, P545, DOI 10.1016/j.cardiores.2004.04.015; Tudor C, 2008, BIOCHEM J, V413, P405, DOI 10.1042/BJ20080018; Wegiel B, 2009, J BIOL CHEM, V284, P21369, DOI 10.1074/jbc.M109.027433; Whitby FG, 2002, J MOL BIOL, V319, P1199, DOI 10.1016/S0022-2836(02)00383-2; Wright MM, 2009, BIOCHEM J, V422, P353, DOI 10.1042/BJ20090339; Zeng R, 2008, J AM SOC NEPHROL, V19, P380, DOI 10.1681/ASN.2006111194; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Ziel KA, 2005, FASEB J, V19, P387, DOI 10.1096/fj.04-2805com	74	20	21	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3239	3254		10.1096/fj.09-144592	http://dx.doi.org/10.1096/fj.09-144592			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20410444	Green Published			2022-12-28	WOS:000281446400013
J	Jeong, H; Bae, S; An, SY; Byun, MR; Hwang, JH; Yaffe, MB; Hong, JH; Hwang, ES				Jeong, Hana; Bae, Sujung; An, Su Yeon; Byun, Mi Ran; Hwang, Jun-Ha; Yaffe, Michael B.; Hong, Jeong-Ho; Hwang, Eun Sook			TAZ as a novel enhancer of MyoD-mediated myogenic differentiation	FASEB JOURNAL			English	Article						myogenin; myoblast; mesenchymal stem cells; MCK	MUSCLE SATELLITE CELLS; MESENCHYMAL STEM-CELLS; HELIX-LOOP-HELIX; MOUSE SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; WW DOMAIN; HISTONE DEACETYLASES; TEMPORAL EXPRESSION; GENE-EXPRESSION; PROTEINS	Myoblast differentiation is indispensable for skeletal muscle formation and is governed by the precisely coordinated regulation of a series of transcription factors, including MyoD and myogenin, and transcriptional coregulators. TAZ (transcriptional coactivator with PDZ-binding motif) has been characterized as a modulator of mesenchymal stem cell differentiation into osteoblasts and adipocytes through its regulation of lineage-specific master transcription factors. In this study, we investigated whether TAZ affects myoblast differentiation, which is one of the differentiated lineages of mesenchymal stem cells. Ectopic overexpression of TAZ in myoblasts increases myogenic gene expression in a MyoD-dependent manner and hastens myofiber formation, whereas TAZ knockdown delays myogenic differentiation. In addition, enforced coexpression of TAZ and MyoD in fibroblasts accelerates MyoD-induced myogenic differentiation. TAZ physically interacts with MyoD through the WW domain and activates MyoD-dependent gene transcription. TAZ additionally enhances the interaction of MyoD with the myogenin gene promoter. These results strongly suggest that TAZ functions as a novel transcriptional modulator of myogenic differentiation by promoting MyoD-mediated myogenic gene expression.-Jeong, H., Bae, S., An, S. Y., Byun, M. R., Hwang, J.-H., Yaffe, M. B., Hong, J.-H., Hwang, E. S. TAZ as a novel enhancer of MyoD-mediated myogenic differentiation. FASEB J. 24, 3310-3320 (2010). www.fasebj.org	[Jeong, Hana; Bae, Sujung; An, Su Yeon; Hong, Jeong-Ho; Hwang, Eun Sook] Ewha Womans Univ, Coll Pharm, Div Life & Pharmaceut Sci, Seoul 120750, South Korea; [Jeong, Hana; Bae, Sujung; An, Su Yeon; Hong, Jeong-Ho; Hwang, Eun Sook] Ewha Womans Univ, Ctr Cell Signaling & Drug Discovery Res, Seoul 120750, South Korea; [Byun, Mi Ran; Hwang, Jun-Ha] Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; [Yaffe, Michael B.] MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Ewha Womans University; Ewha Womans University; Korea University; Massachusetts Institute of Technology (MIT)	Hwang, ES (corresponding author), Ewha Womans Univ, Coll Pharm, Div Life & Pharmaceut Sci, Sci Bldg C206,11-1 Daehyun Dong, Seoul 120750, South Korea.	jh_hong@korea.ac.kr; eshwang@ewha.ac.kr			Ministry of Education, Science, and Technology (MEST) [2009-0073324, R01-2007-000-11173-0, R15-2006-020]; MEST [M10748000286-07N4800-28610]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	Ministry of Education, Science, and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Dr. Andrew B. Lassar (Harvard University, Boston, MA, USA) for generous gifts of MCK-Luc, myogenin-Luc, MyoD, and myogenin expression plasmids. The authors also thank Dr. Thomas Benjamin (Harvard University) for sharing TAZ KO MEFs. This work was supported by the Basic Science Research Program (2009-0073324 to E. S. H., R01-2007-000-11173-0 to J.H.H.) and the National Core Research Center program (R15-2006-020 to E. S. H.) funded by the Ministry of Education, Science, and Technology (MEST) and also supported by a grant from the Research Program for New Drug Target Discovery (M10748000286-07N4800-28610 to J.H.H.) funded by MEST. The authors declare that they have no conflict of interest.	Arnold HH, 2000, CURR TOP DEV BIOL, V48, P129; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; BISCHOFF R, 1990, DEVELOPMENT, V109, P943; BISCHOFF R, 1994, DEV DYNAM, V201, P41, DOI 10.1002/aja.1002010105; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Cooper RN, 1999, J CELL SCI, V112, P2895; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; De Bari C, 2003, J CELL BIOL, V160, P909, DOI 10.1083/jcb.200212064; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; Di Palma T, 2009, EXP CELL RES, V315, P162, DOI 10.1016/j.yexcr.2008.10.016; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Huard J, 2002, J BONE JOINT SURG AM, V84A, P822, DOI 10.2106/00004623-200205000-00022; Jeon ES, 2006, J CELL SCI, V119, P4994, DOI 10.1242/jcs.03281; Jung H, 2009, BIOCHEM PHARMACOL, V78, P1323, DOI 10.1016/j.bcp.2009.07.001; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kang HS, 2009, MOL CELL BIOL, V29, P2556, DOI 10.1128/MCB.01620-08; KARPATI G, 1982, MUSCLE NERVE, V5, P369, DOI 10.1002/mus.880050506; Kim MR, 2009, STEM CELLS, V27, P191, DOI 10.1634/stemcells.2008-0363; Kitagawa M, 2007, BIOCHEM BIOPH RES CO, V361, P1022, DOI 10.1016/j.bbrc.2007.07.129; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Le Grand F, 2007, CURR OPIN CELL BIOL, V19, P628, DOI 10.1016/j.ceb.2007.09.012; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434; Makita R, 2008, AM J PHYSIOL-RENAL, V294, pF542, DOI 10.1152/ajprenal.00201.2007; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MCGEACHIE JK, 1987, CELL TISSUE RES, V248, P125, DOI 10.1007/BF01239972; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Murakami M, 2006, BIOCHEM BIOPH RES CO, V339, P533, DOI 10.1016/j.bbrc.2005.10.214; Murakami M, 2005, P NATL ACAD SCI USA, V102, P18034, DOI 10.1073/pnas.0509109102; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; PRICE HM, 1964, LAB INVEST, V13, P1264; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; SMITH CK, 1994, J CELL PHYSIOL, V159, P379, DOI 10.1002/jcp.1041590222; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Tan MY, 2009, BIOMATERIALS, V30, P3234, DOI 10.1016/j.biomaterials.2009.02.013; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Warren GL, 2007, J PHYSIOL-LONDON, V582, P825, DOI 10.1113/jphysiol.2007.132373; YABLONKAREUVENI Z, 1994, DEV BIOL, V164, P588, DOI 10.1006/dbio.1994.1226; Yoon YS, 2005, BIOL CELL, V97, P253, DOI 10.1042/BC20040099; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	64	80	84	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3310	3320		10.1096/fj.09-151324	http://dx.doi.org/10.1096/fj.09-151324			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20466877				2022-12-28	WOS:000281446400019
J	Kiyota, T; Okuyama, S; Swan, RJ; Jacobsen, MT; Gendelman, HE; Ikezu, T				Kiyota, Tomomi; Okuyama, Satoshi; Swan, Russell J.; Jacobsen, Michael T.; Gendelman, Howard E.; Ikezu, Tsuneya			CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice	FASEB JOURNAL			English	Article						IL-4; AAV therapy; memory formation; neurogenesis; NMDA receptor	AMYLOID-PRECURSOR-PROTEIN; PASSIVE IMMUNOTHERAPY; SYNAPTIC PLASTICITY; MEMORY DEFICITS; IN-VITRO; A-BETA; IL-4; ACTIVATION; CELLS; PATHOLOGY	Cytokines play an emerging role as neurotransmitters, neuromodulators, and neurohormones in the brain. This paradigm shift in cytokine function offers a new framework to understand their roles in ameliorating neurodegenerative disorders, such as Alzheimer's disease (AD). Molecular adjuvant therapy of AD animal models with glatiramer acetate induces antiinflammatory responses and therapeutic effects. Although these effects are potentially mediated through antiinflammatory cytokine signaling, the exact molecular identities and pathways are poorly understood. Here, we show that virus-mediated expression of the mouse interleukin (IL)-4 gene in beta-amyloid precursor protein + presenilin-1 (APP + PS1) bigenic mice attenuates AD pathogenesis. Introduction of an adeno-associated viral (AAV) vector encoding IL-4 into the hippocampus resulted in sustained expression of IL-4, reduced astro/microgliosis, amyloid-beta peptide (A beta) oligomerization and deposition, and enhanced neurogenesis. Moreover, increased levels of IL-4 improved spatial learning, promoted phosphorylation of N-methyl-D-aspartate receptor subunit 2B at Tyr 1472, and enhanced its cell surface retention both in vivo and in vitro. Our data suggest that neuronal anti-inflammatory cytokine signaling may be a potential alternative target for non-A beta-mediated treatment of AD.-Kiyota, T., Okuyama, S., Swan, R. J., Jacobsen, M. T., Gendelman, H. E., Ikezu, T. CNS expression of anti-inflammatory cytokine interleukin- 4 attenuates Alzheimer's disease-like pathogenesis in APP + PS1 bigenic mice. FASEB J. FASEB J. 24, 3093-3102 (2010). www.fasebj.org	[Kiyota, Tomomi; Okuyama, Satoshi; Swan, Russell J.; Jacobsen, Michael T.; Gendelman, Howard E.; Ikezu, Tsuneya] Univ Nebraska Med Ctr, Ctr Neurodegenerat Disorders, Omaha, NE USA; [Kiyota, Tomomi; Swan, Russell J.; Jacobsen, Michael T.; Gendelman, Howard E.; Ikezu, Tsuneya] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA; [Okuyama, Satoshi; Ikezu, Tsuneya] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Ikezu, T (corresponding author), 985930 Nebraska Med Ctr, Omaha, NE 68198 USA.	tikezu@unmc.edu		Ikezu, Tsuneya/0000-0002-3979-8596	Vada Kinman Oldfield Alzheimer's Research Fund; UNMC; NIH [P01 NS043985, R01 MH083523, R21 AG032600]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH083523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS043985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG032600] Funding Source: NIH RePORTER	Vada Kinman Oldfield Alzheimer's Research Fund; UNMC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Karen Hsiao-Ashe (University of Minnesota, Minneapolis, MN, USA) for providing Tg2576 mice; Dr. Karen Duff (Columbia University, New York, NY, USA) for providing M146L PS1 mice; Dr. Dave Morgan (University of South Florida, Tampa, FL, USA) for RAWM test training and consultation; Dr. Ronald Klein (Louisiana State University, Shreveport, LA, USA) for pGFP plasmid; the University of Pennsylvania Gene Therapy Program for recombinant AAV1 vectors; Dr. Sylvain Lesne (University of Minnesota, Minneapolis, MN, USA) for the A beta oligomer immunoblotting protocol; and Tim Smith, Scott Andrews, and Meg Marquardt for editing of the manuscript. This work is supported by the Vada Kinman Oldfield Alzheimer's Research Fund (T.K., T.I.); UNMC Brain Bank Core Fund (T.I.); and NIH grants P01 NS043985 (H.E.G., T.I.), R01 MH083523 (T.I.), and R21 AG032600 (T.I.).	Adao-Novaes J, 2009, J NEUROSCI RES, V87, P2167, DOI 10.1002/jnr.22026; Aharoni R, 2002, J NEUROIMMUNOL, V126, P58, DOI 10.1016/S0165-5728(02)00053-X; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Birmingham K, 2002, NAT MED, V8, P199, DOI 10.1038/nm0302-199b; Braithwaite SP, 2006, TRENDS NEUROSCI, V29, P452, DOI 10.1016/j.tins.2006.06.007; Brody DL, 2008, ANNU REV NEUROSCI, V31, P175, DOI 10.1146/annurev.neuro.31.060407.125529; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103; Chafekar SM, 2007, ANTIOXID REDOX SIGN, V9, P2245, DOI 10.1089/ars.2007.1797; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; DaSilva KA, 2006, NEUROBIOL DIS, V23, P433, DOI 10.1016/j.nbd.2006.03.013; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Farfara D, 2008, J CELL MOL MED, V12, P762, DOI 10.1111/j.1582-4934.2008.00314.x; Frazer ME, 2008, MOL THER, V16, P845, DOI 10.1038/mt.2008.39; Frenkel D, 2005, CLIN IMMUNOL, V115, pS24; He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; HOWARD M, 1992, J CLIN IMMUNOL, V12, P239, DOI 10.1007/BF00918147; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Ip WK, 2006, CLIN EXP IMMUNOL, V145, P162, DOI 10.1111/j.1365-2249.2006.03085.x; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; Kiyota T, 2009, MOL THER, V17, P803, DOI 10.1038/mt.2009.44; Klein RL, 2002, EXP NEUROL, V176, P66, DOI 10.1006/exnr.2002.7942; Knowles JK, 2009, J NEUROSCI, V29, P10627, DOI 10.1523/JNEUROSCI.0620-09.2009; Koeberle PD, 2004, NEUROSCIENCE, V125, P903, DOI 10.1016/S0306-4522(03)00398-1; Lalani I, 1997, ANN ALLERG ASTHMA IM, V79, P469, DOI 10.1016/S1081-1206(10)63052-9; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lin SJ, 2007, APOPTOSIS, V12, P1659, DOI 10.1007/s10495-007-0085-5; Lyons A, 2007, J NEUROSCI, V27, P8309, DOI 10.1523/JNEUROSCI.1781-07.2007; Lyons A, 2007, J NEUROCHEM, V101, P771, DOI 10.1111/j.1471-4159.2006.04370.x; Maher FO, 2005, NEUROBIOL AGING, V26, P717, DOI 10.1016/j.neurobiolaging.2004.07.002; Marques CP, 2004, GLIA, V47, P358, DOI 10.1002/glia.20045; Molina-Holgado E, 2002, J NEUROCHEM, V81, P1242, DOI 10.1046/j.1471-4159.2002.00925.x; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murata T, 1996, J IMMUNOL, V156, P2972; Opal SM, 1998, CLIN INFECT DIS, V27, P1497, DOI 10.1086/515032; Paul S, 2000, J NEUROSCI, V20, P5630, DOI 10.1523/JNEUROSCI.20-15-05630.2000; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Sayeski PP, 1999, J BIOL CHEM, V274, P33131, DOI 10.1074/jbc.274.46.33131; Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shimizu E, 2008, J IMMUNOL, V181, P6503, DOI 10.4049/jimmunol.181.9.6503; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Stern JNH, 2008, P NATL ACAD SCI USA, V105, P5172, DOI 10.1073/pnas.0712131105; Szczepanik AM, 2001, J NEUROIMMUNOL, V113, P49, DOI 10.1016/S0165-5728(00)00404-5; Tan J, 2002, NAT NEUROSCI, V5, P1288, DOI 10.1038/nn968; Tesseur I, 2006, J CLIN INVEST, V116, P3060, DOI 10.1172/JCI27341; Vincent AM, 2004, NEUROBIOL DIS, V16, P407, DOI 10.1016/j.nbd.2004.03.001; Vlad SC, 2008, NEUROLOGY, V70, P1672, DOI 10.1212/01.wnl.0000311269.57716.63; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Weiner HL, 2006, NAT REV IMMUNOL, V6, P404, DOI 10.1038/nri1843; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Yamamoto M, 2005, AM J PATHOL, V166, P1475, DOI 10.1016/S0002-9440(10)62364-4; Yamamoto M, 2008, J IMMUNOL, V181, P3877, DOI 10.4049/jimmunol.181.6.3877; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378	60	148	154	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					3093	3102		10.1096/fj.10-155317	http://dx.doi.org/10.1096/fj.10-155317			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371618	Green Published			2022-12-28	WOS:000285005400045
J	Koga, H; Kaushik, S; Cuervo, AM				Koga, Hiroshi; Kaushik, Susmita; Cuervo, Ana Maria			Altered lipid content inhibits autophagic vesicular fusion	FASEB JOURNAL			English	Article						lysosomes; membrane fusion; proteolysis	RAT-LIVER LYSOSOMES; SELECTIVE UPTAKE; IN-VITRO; DEGRADATION; PROTEINS; CARDIOMYOPATHY; RECONSTITUTION; MACROAUTOPHAGY; MATURATION; DEPENDENCE	The autophagic/lysosomal system includes a variety of vesicular compartments that undergo dynamic fusion events. However, the characteristics and factors modulating these interactions remain, for the most part, unknown. To gain insights on the properties that govern lysosomal fusion events, we have established an in vitro fusion assay using different lysosomal/autophagic compartments isolated from mouse liver. We have found that autophagosome/lysosome fusion is a temperaturedependent process (fusion increment of 0.2 +/- 0.01%/degrees C), which requires ATP (1-3 mM), GTP (1-2 mM), Ca2+ (0.2-2 mM), and an acidic lysosomal pH (pH 5.2). Furthermore, changes in membrane lipid composition, induced either in vitro, by treatment with 25 mM methyl-beta-cyclodextrin, or in vivo, by subjecting animals to a high-fat-diet challenge (60% kcal in fat) reduce autophagosome/lysosome fusion up to 70% of that observed in untreated fractions or from animals under a normal regular diet. These findings reveal a novel role for lipids in autophagic fusion and provide a mechanism for the reduced macroautophagic rates observed during exposure to a chronic lipid challenge. Changes in the intracellular lipid content (i.e., metabolic disorders) may thus have pronounced effects on the fusion step of macroautophagy and affect the overall activity of this intracellular proteolytic pathway.-Koga, H., Kaushik, S., Cuervo, A. M. Altered lipid content inhibits autophagic vesicular fusion. FASEB J. 24, 3052-3065 (2010). www.fasebj.org	[Koga, Hiroshi; Kaushik, Susmita; Cuervo, Ana Maria] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; [Cuervo, Ana Maria] Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Cuervo, AM (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, Chanin Bldg Rm 504,1300 Morris Pk Ave, Bronx, NY 10461 USA.	ana-maria.cuervo@einstein.yu.edu	Kaushik, Susmita/GVS-3186-2022	Kaushik, Susmita/0000-0002-6096-5387; Cuervo, Ana Maria/0000-0002-0771-700X	National Institutes of Health [AG031782, AG021904, DK041918]; NIN/NIA [T32AG023475]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG023475, P01AG031782, R01AG021904, R37AG021904] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIN/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are grateful to Samantha J. Orenstein and Dr. Fernando Macian for their insights and critical revision of this manuscript, and to Drs. Mark J. Czaja, Allan W. Wolkoff, and John W. Murray (Albert Einstein College of Medicine, Bronx, NY, USA) for providing us with valuable reagents. This work was supported by National Institutes of Health grants AG031782, AG021904, and DK041918. S.K. is supported by NIN/NIA T32AG023475.	AUTERI JS, 1983, J CELL PHYSIOL, V115, P167, DOI 10.1002/jcp.1041150210; BAKER L, 1990, DIABETOLOGIA, V33, P593, DOI 10.1007/BF00400202; Bananis E, 2003, J CELL SCI, V116, P2749, DOI 10.1242/jcs.00478; Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606; CUERVO AM, 1995, EUR J BIOCHEM, V227, P792, DOI 10.1111/j.1432-1033.1995.tb20203.x; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Deng D, 2009, BBA-BIOMEMBRANES, V1788, P470, DOI 10.1016/j.bbamem.2008.11.018; Deretic V, 2008, FUTURE MICROBIOL, V3, P517, DOI 10.2217/17460913.3.5.517; Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114; Gao WT, 2008, AUTOPHAGY, V4, P754, DOI 10.4161/auto.6360; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; GORDON PB, 1993, J BIOL CHEM, V268, P26107; Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511; Iwai-Kanai E, 2008, AUTOPHAGY, V4, P322, DOI 10.4161/auto.5603; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Kaushik S, 2006, EMBO J, V25, P3921, DOI 10.1038/sj.emboj.7601283; Kawai A, 2007, AUTOPHAGY, V3, P154, DOI 10.4161/auto.3634; Lindblom G, 2009, BBA-BIOMEMBRANES, V1788, P234, DOI 10.1016/j.bbamem.2008.08.016; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; MARZELLA L, 1982, J CELL BIOL, V93, P144, DOI 10.1083/jcb.93.1.144; Massey AC, 2008, AUTOPHAGY, V4, P442, DOI 10.4161/auto.5654; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; Morvan J, 2009, AUTOPHAGY, V5, P676, DOI 10.4161/auto.5.5.8378; Mouritsen OG, 2004, LIPIDS, V39, P1101, DOI 10.1007/s11745-004-1336-x; Murray John W, 2007, Methods Mol Biol, V392, P143; Murray JW, 2003, ADV DRUG DELIVER REV, V55, P1385, DOI 10.1016/j.addr.2003.07.008; Murray JW, 2000, MOL BIOL CELL, V11, P419, DOI 10.1091/mbc.11.2.419; Nara A, 2002, CELL STRUCT FUNCT, V27, P29, DOI 10.1247/csf.27.29; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Overbye A, 2007, AUTOPHAGY, V3, P300, DOI 10.4161/auto.3910; Singh R, 2009, HEPATOLOGY, V49, P87, DOI 10.1002/hep.22578; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Wang YJ, 2004, J BIOL CHEM, V279, P31089, DOI 10.1074/jbc.M404170200; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WILSCHUT J, 1985, BIOCHEMISTRY-US, V24, P8, DOI 10.1021/bi00322a002; Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082; Zhang C, 2008, NAT MED, V14, P959, DOI 10.1038/nm.1851	47	315	324	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					3052	3065		10.1096/fj.09-144519	http://dx.doi.org/10.1096/fj.09-144519			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20375270	Green Published			2022-12-28	WOS:000285005400042
J	Xi, JY; Khalil, M; Shishechian, N; Hannes, T; Pfannkuche, K; Liang, HM; Fatima, A; Haustein, M; Suhr, F; Bloch, W; Reppel, M; Saric, T; Wernig, M; Janisch, R; Brockmeier, K; Hescheler, J; Pillekamp, F				Xi, Jiaoya; Khalil, Markus; Shishechian, Nava; Hannes, Tobias; Pfannkuche, Kurt; Liang, Huamin; Fatima, Azra; Haustein, Moritz; Suhr, Frank; Bloch, Wilhelm; Reppel, Michael; Saric, Tomo; Wernig, Marius; Jaenisch, Rudolf; Brockmeier, Konrad; Hescheler, Juergen; Pillekamp, Frank			Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells	FASEB JOURNAL			English	Article						mESC-CMs; miPS-CMs; cardiac tissue; sarcoplasmic reticulum; physiology	FORCE-FREQUENCY-RELATIONSHIP; FUNCTIONAL-PROPERTIES; CARDIAC MYOCYTES; SARCOPLASMIC-RETICULUM; HEART; MYOCARDIUM; CARDIOMYOGENESIS; FIBROBLASTS; EXPRESSION; MODEL	Cardiomyocytes generated from embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells are suggested for repopulation of destroyed myocardium. Because contractile properties are crucial for functional regeneration, we compared cardiomyocytes differentiated from ES cells (ESC-CMs) and iPS cells (iPS-CMs). Native myocardium served as control. Murine ESCs or iPS cells were differentiated 11 d in vitro and cocultured 5-7 d with irreversibly injured myocardial tissue slices. Vital embryonic ventricular tissue slices of similar age served for comparison. Force-frequency relationship (FFR), effects of Ca2+, Ni2+, nifedipine, ryanodine, beta-adrenergic, and muscarinic modulation were studied during loaded contractions. FFR was negative for ESC-CMs and iPS-CMs. FFR was positive for embryonic tissue and turned negative after treatment with ryanodine. In all groups, force of contraction and relaxation time increased with the concentration of Ca2+ and decreased with nifedipine. Force was reduced by Ni2+. Isoproterenol (1 mu M) increased the force most pronounced in embryonic tissue (207 +/- 31%, n=7; ESC-CMs: 123 +/- 5%, n=4; iPS-CMs: 120 +/- 4%, n=8). EC50 values were similar. Contractile properties of iPS-CMs and ESC-CMs were similar, but they were significantly different from ventricular tissue of comparable age. The results indicate immaturity of the sarcoplasmic reticulum and the beta-adrenergic response of iPS-CMs and ESC-CMs.-Xi, J., Khalil, M., Shishechian, N., Hannes, T., Pfannkuche, K., Liang, H., Fatima, A., Haustein, M., Suhr, F., Bloch, W., Reppel, M., Saric, T., Wernig, M., Jaenisch, R., Brockmeier, K., Hescheler, J., Pillekamp, F. Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J. 24, 2739-2751 (2010). www.fasebj.org	[Pillekamp, Frank] Univ Dusseldorf, Dept Paediat Cardiol, Childrens Hosp, D-40225 Dusseldorf, Germany; [Xi, Jiaoya; Khalil, Markus; Pfannkuche, Kurt; Liang, Huamin; Fatima, Azra; Haustein, Moritz; Reppel, Michael; Saric, Tomo; Hescheler, Juergen; Pillekamp, Frank] Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; [Khalil, Markus; Shishechian, Nava; Hannes, Tobias; Brockmeier, Konrad] Univ Cologne, Dept Pediat Cardiol, D-50931 Cologne, Germany; [Saric, Tomo; Hescheler, Juergen] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; [Xi, Jiaoya; Liang, Huamin] Huazhong Univ Sci & Technol, Tongji Med Coll, German Chinese Stem Cell Ctr, Wuhan 430074, Hubei, Peoples R China; [Suhr, Frank; Bloch, Wilhelm] German Sport Univ Cologne, Dept Mol & Cellular Sports Med, Cologne, Germany; [Xi, Jiaoya; Liang, Huamin] Huazhong Univ Sci & Technol, Dept Physiol, Wuhan 430074, Hubei, Peoples R China; [Reppel, Michael] Med Univ Lubeck, Dept Cardiol, D-23538 Lubeck, Germany; [Wernig, Marius] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA USA; [Jaenisch, Rudolf] MIT, Dept Biol, Cambridge, MA USA; [Jaenisch, Rudolf] MIT, Whitehead Inst Biomed Res, Cambridge, MA USA	Heinrich Heine University Dusseldorf; University of Cologne; University of Cologne; University of Cologne; Huazhong University of Science & Technology; German Sport University Cologne; Huazhong University of Science & Technology; University of Lubeck; Stanford University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Pillekamp, F (corresponding author), Univ Dusseldorf, Dept Paediat Cardiol, Childrens Hosp, Moorenstr 5, D-40225 Dusseldorf, Germany.	j.hescheler@uni-koeln.de; frank.pillekamp@med.uni-duesseldorf.de	Suhr, Frank/AAU-5080-2021; Saric, Tomo/B-3415-2015; Khalil, Markus/AFS-7292-2022	Saric, Tomo/0000-0001-8344-1095; Khalil, Markus/0000-0001-8897-7200; Hannes, Tobias/0000-0002-8550-2282; Suhr, Frank/0000-0002-9013-3944; Pfannkuche, Kurt Paul/0000-0002-4284-774X	Imhoff-Stiftung; Koln Fortune [154/2007]; Bundesministerium fur Bildung und Forschung [01GN0947]	Imhoff-Stiftung; Koln Fortune; Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF))	This work was supported by the Imhoff-Stiftung (F.P.), Koln Fortune (T.H., grant 154/2007), and the Bundesministerium fur Bildung und Forschung (T.S., grant 01GN0947). The authors thank Annette Koster, Susan Rohani, and Rebecca Dieterich for excellent technical support and Mrs. Wood for the secretarial assistance. Authors' contributions are as follows: J.X.: collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript. M.K.: administrative support, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript. N.S.: collection and assembly of data, data analysis and interpretation, final approval of manuscript. T.H.: data analysis and interpretation, final approval of manuscript. K.P.: provision of study material (iPS cell line), final approval of manuscript. H.L.: provision of study material (iPS cell line), final approval of manuscript. A.F.: provision of study material (iPS cell line), final approval of manuscript. M.H.: collection and assembly of data, data analysis and interpretation, final approval of manuscript. W.B.: collection and assembly of data, data analysis and interpretation, final approval of manuscript. F.S.: Collection and assembly of data, data analysis and interpretation, final approval of manuscript. M.R.: Final approval of manuscript. T.S.: provision of study material (iPS cell line), final approval of manuscript. M.W.: provision of study material (iPS cell line), final approval of manuscript. R.J.: provision of study material (iPS cell line), final approval of manuscript. K.B.: administrative support, manuscript writing, final approval of manuscript. J.H.: administrative support, data analysis and interpretation, manuscript writing, final approval of manuscript. F.P.: conception and design, financial support, administrative support, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript.	Amabile G, 2009, TRENDS MOL MED, V15, P59, DOI 10.1016/j.molmed.2008.12.003; Baharvand H, 2006, CELL BIOL INT, V30, P800, DOI 10.1016/j.cellbi.2006.06.002; Chen Y, 2009, BIOL CELL, V101, P335, DOI 10.1042/BC20080108; Chien KR, 2008, SCIENCE, V322, P1494, DOI 10.1126/science.1163267; Davia K, 1998, BASIC RES CARDIOL, V93, P33; Delbridge LMD, 1997, J MOL CELL CARDIOL, V29, P11, DOI 10.1006/jmcc.1996.0247; Dolnikov K, 2006, STEM CELLS, V24, P236, DOI 10.1634/stemcells.2005-0036; Endoh M, 2004, EUR J PHARMACOL, V500, P73, DOI 10.1016/j.ejphar.2004.07.013; Endoh M, 2006, J PHARMACOL SCI, V100, P525, DOI 10.1254/jphs.CPJ06009X; Engler AJ, 2008, J CELL SCI, V121, P3794, DOI 10.1242/jcs.029678; Halbach M, 2007, CIRC RES, V101, P484, DOI 10.1161/CIRCRESAHA.107.153643; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Koban MU, 1998, CARDIOVASC RES, V37, P405, DOI 10.1016/S0008-6363(97)00276-9; Kolossov E, 2005, FASEB J, V19, P577, DOI 10.1096/fj.03-1451fje; Kolossov E, 2006, J EXP MED, V203, P2315, DOI 10.1084/jem.20061469; Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327; Lee JH, 1999, J NEUROSCI, V19, P1912; Liu J, 2009, AM J PHYSIOL-CELL PH, V297, pC152, DOI 10.1152/ajpcell.00060.2009; Mauritz C, 2008, CIRCULATION, V118, P507, DOI 10.1161/CIRCULATIONAHA.108.778795; Moorman AFM, 2000, DEV BIOL, V223, P279, DOI 10.1006/dbio.2000.9752; Moorman AFM, 2007, PHILOS T R SOC B, V362, P1257, DOI 10.1098/rstb.2007.2113; Murry CE, 2005, CIRCULATION, V112, P3174, DOI 10.1161/CIRCULATIONAHA.105.546218; Papp S, 2009, STEM CELLS, V27, P1507, DOI 10.1002/stem.85; Parilak LD, 2009, CAN J PHYSIOL PHARM, V87, P69, DOI 10.1139/Y08-087; Pfannkuche K, 2009, CELL PHYSIOL BIOCHEM, V24, P73, DOI 10.1159/000227815; Pillekamp F, 2005, CELL PHYSIOL BIOCHEM, V16, P127, DOI 10.1159/000087739; Pillekamp F, 2007, CELL PHYSIOL BIOCHEM, V20, P837, DOI 10.1159/000110443; Pillekamp F, 2007, STEM CELLS, V25, P174, DOI 10.1634/stemcells.2006-0094; Schenke-Layland K, 2008, STEM CELLS, V26, P1537, DOI 10.1634/stemcells.2008-0033; Shimko VF, 2008, TISSUE ENG PT A, V14, P49, DOI 10.1089/ten.a.2007.0092; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tran TH, 2009, STEM CELLS, V27, P1869, DOI 10.1002/stem.95; Weisel KC, 2010, STEM CELLS DEV, V19, P745, DOI 10.1089/scd.2008.0356; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wiegerinck RF, 2009, PEDIATR RES, V65, P414, DOI 10.1203/PDR.0b013e318199093c; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Zhang JH, 2009, CIRC RES, V104, pE30, DOI 10.1161/CIRCRESAHA.108.192237; Zhao W, 2004, J MOL CELL CARDIOL, V37, P607, DOI 10.1016/j.yjmcc.2004.05.013	40	77	78	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2739	2751		10.1096/fj.09-145177	http://dx.doi.org/10.1096/fj.09-145177			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371616				2022-12-28	WOS:000285005400015
J	Sultan, S; Mandairon, N; Kermen, F; Garcia, S; Sacquet, J; Didier, A				Sultan, S.; Mandairon, N.; Kermen, F.; Garcia, S.; Sacquet, J.; Didier, A.			Learning-dependent neurogenesis in the olfactory bulb determines long-term olfactory memory	FASEB JOURNAL			English	Article						plasticity; associative learning; Zif268	D-CYCLOSERINE; ADULT NEUROGENESIS; ODOR RECOGNITION; MAMMALIAN BRAIN; GRANULE CELL; NEURONS; DISCRIMINATION; PLASTICITY; EXPERIENCE; INCREASES	Inhibitory interneurons of the olfactory bulb are subjected to permanent adult neurogenesis. Their number is modulated by learning, suggesting that they could play a role in plastic changes of the bulbar network associated with olfactory memory. Adult male C57BL/6 mice were trained in an associative olfactory task, and we analyzed long-term retention of the task 5, 30, and 90 d post-training. In parallel, we assessed the fate of these newborn cells, mapped their distribution in the olfactory bulb and measured their functional implication using the immediate early gene Zif268. In a second set of experiments, we pharmacologically modulated glutamatergic transmission and using the same behavioral task assessed the consequences on memory retention and neurogenesis. Finally, by local infusion of an antimitotic drug, we selectively blocked neurogenesis during acquisition of the task and looked at the effects on memory retention. First we demonstrated that retrieval of an associative olfactory task recruits the newborn neurons in odor-specific areas of the olfactory bulb selected to survive during acquisition of the task and that it does this in a manner that depends on the strength of learning. We then demonstrated that acquisition is not dependent on neurogenesis if long-term retention of the task is abolished by blocking neurogenesis. Adult-born neurons are thus involved in changes in the neural representation of an odor; this underlies long-term olfactory memory as the strength of learning is linked to the duration of this memory. Neurogenesis thus plays a crucial role in long-term olfactory memory.-Sultan, S., Mandairon, N., Kermen, F., Garcia, S., Sacquet, J., Didier, A. Learning-dependent neurogenesis in the olfactory bulb determines long-term olfactory memory. FASEB J. 24, 2355-2363 (2010). www.fasebj.org	[Didier, A.] Univ Lyon 1, F-69007 Lyon, France; Ctr Natl Rech Sci, Unite Mixte Rech 5020, F-69007 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS)	Didier, A (corresponding author), Univ Lyon 1, F-69007 Lyon, France.	didier@olfac.univ-lyon1.fr	Mandairon, Nathalie/H-4439-2017; DIDIER, Anne/H-4413-2017	Mandairon, Nathalie/0000-0001-7935-5215; DIDIER, Anne/0000-0003-3118-9961; GARCIA, Samuel/0000-0001-6389-9779; KERMEN, Florence/0000-0002-2247-9636	Centre National de la Recherche Scientifique et Universite Lyon 1; French Ministry of Research and Technology; Region Rhone-Alpes	Centre National de la Recherche Scientifique et Universite Lyon 1(Centre National de la Recherche Scientifique (CNRS)); French Ministry of Research and Technology; Region Rhone-Alpes(Region Auvergne-Rhone-Alpes)	The authors thank Dr. M. Richard for her helpful comments on the manuscript. This work was supported by the Centre National de la Recherche Scientifique et Universite Lyon 1, the French Ministry of Research and Technology (doctoral fellowship to S. S.) and the Region Rhone-Alpes.	Alonso M, 2006, J NEUROSCI, V26, P10508, DOI 10.1523/JNEUROSCI.2633-06.2006; Bruel-Jungerman E, 2006, J NEUROSCI, V26, P5888, DOI 10.1523/JNEUROSCI.0782-06.2006; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; Buonviso N, 2000, NEUROSCIENCE, V95, P325; Burton S, 2000, J NEUROSCI, V20, P5468, DOI 10.1523/JNEUROSCI.20-14-05468.2000; Busto GU, 2009, EUR J NEUROSCI, V29, P1431, DOI 10.1111/j.1460-9568.2009.06689.x; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; FREEMAN WJ, 1982, PSYCHOPHYSIOLOGY, V19, P44, DOI 10.1111/j.1469-8986.1982.tb02598.x; Golden GJ, 2007, PHARMACOL BIOCHEM BE, V86, P587, DOI 10.1016/j.pbb.2007.02.004; Griesbach GS, 1998, BEHAV BRAIN RES, V97, P29, DOI 10.1016/S0166-4328(98)00015-1; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Jonasson Z, 2004, HIPPOCAMPUS, V14, P28, DOI 10.1002/hipo.10146; Kaut KP, 2001, COGN AFFECT BEHAV NE, V1, P270, DOI 10.3758/CABN.1.3.270; Kaut KP, 2003, BEHAV NEUROSCI, V117, P304, DOI 10.1037/0735-7044.117.2.304; Kay LM, 1999, NAT NEUROSCI, V2, P1003, DOI 10.1038/14801; Knapska E, 2004, PROG NEUROBIOL, V74, P183, DOI 10.1016/j.pneurobio.2004.05.007; Lazarini F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007017; Leon M, 2003, BRAIN RES REV, V42, P23, DOI 10.1016/S0165-0173(03)00142-5; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Magavi SSP, 2005, J NEUROSCI, V25, P10729, DOI 10.1523/JNEUROSCI.2250-05.2005; Mandairon N, 2006, NEUROSCIENCE, V141, P443, DOI 10.1016/j.neuroscience.2006.03.066; Mandairon N, 2008, NEUROBIOL LEARN MEM, V90, P178, DOI 10.1016/j.nlm.2008.02.008; Mandairon N, 2006, EUR J NEUROSCI, V24, P3578, DOI 10.1111/j.1460-9568.2006.05235.x; Mandairon N, 2009, J NEUROSCI METH, V180, P296, DOI 10.1016/j.jneumeth.2009.04.008; Martin C, 2006, EUR J NEUROSCI, V23, P1801, DOI 10.1111/j.1460-9568.2006.04711.x; Martin C, 2004, J NEUROSCI, V24, P389, DOI 10.1523/JNEUROSCI.3433-03.2004; Mombaerts P, 2004, CURR OPIN NEUROBIOL, V14, P31, DOI 10.1016/j.conb.2004.01.014; Moreno MM, 2009, P NATL ACAD SCI USA, V106, P17980, DOI 10.1073/pnas.0907063106; Mouly AM, 2001, NEUROSCIENCE, V102, P11, DOI 10.1016/S0306-4522(00)00476-0; Mouret A, 2008, J NEUROSCI, V28, P11511, DOI 10.1523/JNEUROSCI.2954-08.2008; Nissant A, 2009, NAT NEUROSCI, V12, P728, DOI 10.1038/nn.2298; Nunnink M, 2007, PHARMACOL BIOCHEM BE, V87, P321, DOI 10.1016/j.pbb.2007.05.006; Rochefort C, 2002, J NEUROSCI, V22, P2679, DOI 10.1523/JNEUROSCI.22-07-02679.2002; Sheinin A, 2001, NEUROPHARMACOLOGY, V41, P151, DOI 10.1016/S0028-3908(01)00073-9; Shepherd GM, 2007, BRAIN RES REV, V55, P373, DOI 10.1016/j.brainresrev.2007.03.005; Weber M, 2007, NEUROBIOL LEARN MEM, V87, P476, DOI 10.1016/j.nlm.2006.12.010	37	116	119	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2355	2363		10.1096/fj.09-151456	http://dx.doi.org/10.1096/fj.09-151456			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20215526				2022-12-28	WOS:000279343600022
J	Witte, F; Bernatik, O; Kirchner, K; Masek, J; Mahl, A; Krejci, P; Mundlos, S; Schambony, A; Bryja, V; Stricker, S				Witte, Florian; Bernatik, Ondrej; Kirchner, Katharina; Masek, Jan; Mahl, Annika; Krejci, Pavel; Mundlos, Stefan; Schambony, Alexandra; Bryja, Vitezslav; Stricker, Sigmar			Negative regulation of Wnt signaling mediated by CK1-phosphorylated Dishevelled via Ror2	FASEB JOURNAL			English	Article						Wnt/beta-catenin signaling; casein kinase; Wnt5a; Xenopus	RECEPTOR TYROSINE KINASE; BETA-ARRESTIN; PHOSPHORYLATION; DIFFERENTIATION; LOCALIZATION; BRANCHES; PATHWAY	Dishevelled (Dv1) is a multifunctional effector of different Wnt cascades. Both canonical Wnt3a and noncanonical Wnt5a stimulate casein-kinase-1 (CK1) -mediated phosphorylation of Dv1, visualized as electrophoretic mobility shift [phosphorylated and shifted Dv1 (ps-Dv1)]. However, the role of this phosphorylation remains obscure. Here we report the functional interaction of ps-Dv1 with the receptor tyrosine kinase Ror2, which is an alternative Wnt receptor and is able to inhibit canonical Wnt signaling. We demonstrate interaction between Ror2 and ps-Dv1 at the cell membrane after Wnt3a or Wnt5a stimulus dependent on CK1. Ps-Dv1 interacts with the C-terminal proline-serine-threonine-rich domain of Ror2, which is required for efficient inhibition of canonical Wnt signaling. We further show that the Dv1 C terminus, which seems to be exposed in ps-Dv1 and efficiently binds Ror2, is an intrinsic negative regulator of the canonical Wnt pathway downstream of beta-catenin. The Dv1 C terminus is necessary and sufficient to inhibit canonical Wnt/beta-catenin signaling, which is dependent on the presence of Ror2. Furthermore, both the Dv1 C terminus and CK1 epsilon can inhibit the Wnt5a/Ror2/ATF2 pathway in mammalian cells and Xenopus explant cultures. This suggests that phosphorylation of Dv1 triggers negative feedback regulation for different branches of Wnt signaling in a Ror2-dependent manner.-Witte, F., Bernatik, O., Kirchner, K., Masek, J., Mahl, A., Krejci, P., Mundlos, S., Schambony, A., Bryja, V., Stricker, S. Negative regulation of Wnt signaling mediated by CK1-phosphorylated Dishevelled via Ror2. FASEB J. 24, 2417-2426 (2010). www.fasebj.org	[Witte, Florian; Mahl, Annika; Mundlos, Stefan; Stricker, Sigmar] Max Planck Inst Mol Genet, Dev & Dis Grp, D-14195 Berlin, Germany; [Witte, Florian; Mahl, Annika; Mundlos, Stefan; Stricker, Sigmar] Charite, Inst Med Genet, D-13353 Berlin, Germany; [Witte, Florian; Mahl, Annika] Free Univ Berlin, Inst Chem Biochem, D-1000 Berlin, Germany; [Bernatik, Ondrej; Masek, Jan; Krejci, Pavel; Bryja, Vitezslav] Masaryk Univ, Fac Sci, Inst Expt Biol, CS-61137 Brno, Czech Republic; [Bernatik, Ondrej; Masek, Jan; Krejci, Pavel; Bryja, Vitezslav] Acad Sci Czech Republ, Inst Biophys, Dept Cytokinet, CS-61265 Brno, Czech Republic; [Kirchner, Katharina; Schambony, Alexandra] Univ Erlangen Nurnberg, Dept Biol, Dev Biol Unit, Erlangen, Germany	Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Masaryk University Brno; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; University of Erlangen Nuremberg	Stricker, S (corresponding author), Max Planck Inst Mol Genet, Dev & Dis Grp, Ihnestr 73, D-14195 Berlin, Germany.	bryja@sci.muni.cz; strick_s@molgen.mpg.de	Krejčí, Pavel/I-4285-2014; Masek, Jan/I-9029-2014; Bryja, Vít?zslav/H-1925-2014; Stricker, Sigmar/B-9169-2009; Mundlos, Stefan/ABH-9585-2020; Mašek, Jan/N-3169-2019; Bryja, Vítězslav/P-4217-2019	Bryja, Vít?zslav/0000-0002-9136-5085; Stricker, Sigmar/0000-0002-7174-5363; Mašek, Jan/0000-0003-2904-3808; Bryja, Vítězslav/0000-0002-9136-5085; Mundlos, Stefan/0000-0002-9788-3166; Krejci, Pavel/0000-0003-0618-9134; Schambony, Alexandra/0000-0001-8771-5487; Bernatik, Ondrej/0000-0002-2188-332X	Deutsche Forschungsgemeinschaft (DFG) [SFB 577, SCHA965/2-3, 6-1]; Ministry of Education, Youth and Sports of the Czech Republic [MSM0021622430]; Academy of Sciences of the Czech Republic [KJB501630801, AVOZ50040507, AVOZ50040702]; Czech Science Foundation [204/09/H058, 204/09/0498, 204/09/J030]; EMBO; Berlin-Brandenburg School for Regenerative Therapies (BSRT)	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Ministry of Education, Youth and Sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Academy of Sciences of the Czech Republic(Czech Academy of Sciences); Czech Science Foundation(Grant Agency of the Czech Republic); EMBO(European Molecular Biology Organization (EMBO)); Berlin-Brandenburg School for Regenerative Therapies (BSRT)	The authors thank Kathrin Seidel for excellent technical assistance. This work was funded by grants from the Deutsche Forschungsgemeinschaft (DFG) to S.S. and S.M. (SFB 577) and to A.S. (SCHA965/2-3 and 6-1). V.B. is supported by MSM0021622430 (Ministry of Education, Youth and Sports of the Czech Republic), KJB501630801, AVOZ50040507, AVOZ50040702 (Academy of Sciences of the Czech Republic), 204/09/H058, 204/09/0498, 204/09/J030 (Czech Science Foundation), and an EMBO installation grant. A.M. is supported by the Berlin-Brandenburg School for Regenerative Therapies (BSRT).	Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Billiard J, 2005, MOL ENDOCRINOL, V19, P90, DOI 10.1210/me.2004-0153; Bryja V, 2007, J CELL SCI, V120, P586, DOI 10.1242/jcs.03368; Bryja V, 2007, P NATL ACAD SCI USA, V104, P6690, DOI 10.1073/pnas.0611356104; Bryja V, 2008, EMBO REP, V9, P1244, DOI 10.1038/embor.2008.193; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Green JL, 2007, DEVELOPMENT, V134, P4053, DOI 10.1242/dev.005363; Hikasa H, 2002, DEVELOPMENT, V129, P5227; Hollemann T, 1999, ADV MOLEC BIOL, P279; Kani S, 2004, J BIOL CHEM, V279, P50102, DOI 10.1074/jbc.M409039200; Kibardin A, 2006, DEVELOPMENT, V133, P2845, DOI 10.1242/dev.02445; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Liu Y, 2007, MOL ENDOCRINOL, V21, P3050, DOI 10.1210/me.2007-0323; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Ossipova O, 2005, DEV CELL, V8, P829, DOI 10.1016/j.devcel.2005.04.011; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Sammar M, 2004, GENES CELLS, V9, P1227, DOI 10.1111/j.1365-2443.2004.00799.x; Schambony A, 2007, DEV CELL, V12, P779, DOI 10.1016/j.devcel.2007.02.016; Schulte G, 2005, J NEUROCHEM, V92, P1550, DOI 10.1111/j.1471-4159.2004.03022.x; Schwabe GC, 2000, AM J HUM GENET, V67, P822, DOI 10.1086/303084; Schwarz-Romond T, 2007, NAT STRUCT MOL BIOL, V14, P484, DOI 10.1038/nsmb1247; Schwarzer W, 2009, HUM MOL GENET, V18, P4013, DOI 10.1093/hmg/ddp345; Semenov MV, 2007, CELL, V131, DOI 10.1016/j.cell.2007.12.011; Sun H, 2001, IEEE ASME INT C ADV, P636, DOI 10.1109/AIM.2001.936541; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Wallingford JB, 2005, DEVELOPMENT, V132, P4421, DOI 10.1242/dev.02068; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Winkel A, 2008, CELL SIGNAL, V20, P2134, DOI 10.1016/j.cellsig.2008.08.009; Yamamoto H, 2007, GENES CELLS, V12, P1215, DOI 10.1111/j.1365-2443.2007.01128.x	39	56	56	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2417	2426		10.1096/fj.09-150615	http://dx.doi.org/10.1096/fj.09-150615			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20215527	Bronze			2022-12-28	WOS:000279343600028
J	Ripps, H				Ripps, Harris			Light to sight: milestones in phototransduction	FASEB JOURNAL			English	Editorial Material							ROD OUTER SEGMENT; GMP-SENSITIVE CONDUCTANCE; CYCLIC-GMP; PLASMA-MEMBRANE; RETINAL RODS; CALCIUM; PHOTORECEPTORS; CONES; TRANSDUCTION; EXCITATION		[Ripps, Harris] Marine Biol Lab, Woods Hole, MA 02543 USA; [Ripps, Harris] Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci, Chicago, IL USA; [Ripps, Harris] Univ Illinois, Coll Med, Dept Anat & Cell Biol, Chicago, IL USA; [Ripps, Harris] Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL USA	Marine Biological Laboratory - Woods Hole; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ripps, H (corresponding author), Marine Biol Lab, 7 MBL St, Woods Hole, MA 02543 USA.	harrripp@uic.edu						BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BITENSKY MW, 1971, P NATL ACAD SCI USA, V68, P561, DOI 10.1073/pnas.68.3.561; BITENSKY MW, 1973, LIFE SCI, V13, P1451, DOI 10.1016/0024-3205(73)90133-1; BOLSOVER SR, 1985, J PHYSIOL-LONDON, V364, P381, DOI 10.1113/jphysiol.1985.sp015751; COHEN AI, 1965, ANAT REC, V152, P63, DOI 10.1002/ar.1091520108; DOWLING JE, 1973, NATURE, V242, P101, DOI 10.1038/242101a0; FATT P, 1982, FEBS LETT, V149, P159, DOI 10.1016/0014-5793(82)81093-4; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FESENKO EE, 1986, BIOCHIM BIOPHYS ACTA, V856, P661, DOI 10.1016/0005-2736(86)90162-8; GEORGE JS, 1983, NATURE, V303, P344, DOI 10.1038/303344a0; GOLD GH, 1986, P NATL ACAD SCI USA, V83, P1150, DOI 10.1073/pnas.83.4.1150; HAGINS WA, 1974, EXP EYE RES, V18, P299, DOI 10.1016/0014-4835(74)90157-2; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj; Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849; MARKS WB, 1965, J PHYSIOL-LONDON, V178, P14, DOI 10.1113/jphysiol.1965.sp007611; MILLER WH, 1982, J GEN PHYSIOL, V80, P103, DOI 10.1085/jgp.80.1.103; MILLER WH, 1973, EXP EYE RES, V16, P357, DOI 10.1016/0014-4835(73)90129-2; NICOL GD, 1978, P NATL ACAD SCI USA, V75, P5217, DOI 10.1073/pnas.75.10.5217; NICOL GD, 1987, J GEN PHYSIOL, V89, P297, DOI 10.1085/jgp.89.2.297; PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Ripps H, 2008, FASEB J, V22, P4038, DOI 10.1096/fj.08-1202ufm; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHNAPF JL, 1987, SCI AM, V256, P40, DOI 10.1038/scientificamerican0487-40; SCHRODER WH, 1984, NATURE, V309, P268, DOI 10.1038/309268a0; SVAETICHIN G, 1956, ACTA PHYSL SCAND S, V134, P17; SZUTS EZ, 1977, BIOCHIM BIOPHYS ACTA, V468, P194, DOI 10.1016/0005-2736(77)90114-6; TOMITA T, 1967, VISION RES, V7, P519, DOI 10.1016/0042-6989(67)90061-2; TOMITA TSUNEO, 1959, JAPANESE JOUR PHYSIOL, V9, P63; TRIFONOV Y A, 1971, Neirofiziologiya, V3, P89; WERBLIN FS, 1969, J NEUROPHYSIOL, V32, P339, DOI 10.1152/jn.1969.32.3.339; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0; YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61	36	9	10	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					970	975		10.1096/fj.10-0402ufm	http://dx.doi.org/10.1096/fj.10-0402ufm			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	20356909				2022-12-28	WOS:000276462300003
J	Maingat, F; Halloran, B; Acharjee, S; van Marle, G; Church, D; Gill, MJ; Uwiera, RRE; Cohen, EA; Meddings, J; Madsen, K; Power, C				Maingat, Ferdinand; Halloran, Brendan; Acharjee, Shaona; van Marle, Guido; Church, Deirdre; Gill, M. John; Uwiera, Richard R. E.; Cohen, Eric A.; Meddings, Jon; Madsen, Karen; Power, Christopher			Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress	FASEB JOURNAL			English	Article						ER stress; HIV; FIV; gut; lentivirus; disease	IMMUNODEFICIENCY-VIRUS-INFECTION; UNFOLDED PROTEIN RESPONSE; LENTIVIRUS INFECTION; HIV-INFECTION; NEURONAL INJURY; INNATE IMMUNITY; FIV INFECTION; ACTIVATION; NEUROVIRULENCE; APOPTOSIS	Immunosuppressive lentivirus infections, including human, simian, and feline immunodeficiency viruses (HIV, SIV, and FIV, respectively), cause the acquired immunodeficiency syndrome (AIDS), frequently associated with AIDS enteropathy. Herein, we investigated the extent to which lentivirus infections affected mucosal integrity and intestinal permeability in conjunction with immune responses and activation of endoplasmic reticulum (ER) stress pathways. Duodenal biopsies from individuals with HIV/AIDS exhibited induction of IL-1 beta, CD3 epsilon, HLA-DRA, spliced XBP-1(Xbp-1s), and CHOP expression compared to uninfected persons (P < 0.05). Gut epithelial cells exposed to HIV-1 Vpr demonstrated elevated TNF-alpha, IL-1 beta, spliced Xbp-1s, and CHOP expression (P < 0.05) together with calcium activation and disruption of epithelial cell monolayer permeability. In addition to reduced blood CD4(+) T lymphocyte levels, viral loads in the gut and plasma were high in FIV-infected animals (P < 0.05). FIV-infected animals also exhibited a failure to gain weight and increased lactulose/mannitol ratios compared with uninfected animals (P < 0.05). Proinflammatory and ER stress gene expression were activated in the ileum of FIV-infected animals (P < 0.05), accompanied by intestinal epithelial damage with loss of epithelial cells and leukocyte infiltration of the lamina propria. Lentivirus infections cause gut inflammation and ensuing damage to intestinal epithelial cells, likely through induction of ER stress pathways, resulting in disruption of gut functional integrity.-Maingat, F., Halloran, B., Acharjee, S., van Marle, G., Church, D., Gill, M. J., Uwiera, R. R. E., Cohen, E. A., Meddings, J., Madsen, K., Power, C. Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. FASEB J. 25, 2211-2220 (2011). www.fasebj.org	[Maingat, Ferdinand; Halloran, Brendan; Acharjee, Shaona; Meddings, Jon; Madsen, Karen; Power, Christopher] Univ Alberta, Dept Med, Heritage Med Res Ctr 6 11, Edmonton, AB T6G 2S2, Canada; [Uwiera, Richard R. E.] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB T6G 2S2, Canada; [van Marle, Guido; Gill, M. John; Power, Christopher] Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB, Canada; [Church, Deirdre] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Cohen, Eric A.] Univ Montreal, Dept Microbiol & Infect Dis, Montreal, PQ, Canada	University of Alberta; University of Alberta; University of Calgary; University of Calgary; Universite de Montreal	Power, C (corresponding author), Univ Alberta, Dept Med, Heritage Med Res Ctr 6 11, Edmonton, AB T6G 2S2, Canada.	chris.power@ualberta.ca	Power, Christopher/C-7181-2013; Madsen, Karen L/H-5898-2011; Dodsley, Maria/G-7083-2016; Gill, Michael John/G-7083-2016	Dodsley, Maria/0000-0001-7587-558X; Gill, Michael John/0000-0002-8546-8790; Power, Christopher/0000-0002-5131-9711; van Marle, Guido/0000-0002-5148-6229	Alberta Heritage Foundation for Medical Research; Canadian Institutes of Health Research; U.S. National Institutes of Health (National Institute for Mental Health)	Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); U.S. National Institutes of Health (National Institute for Mental Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank Naomi Hotte, Claire Arrieta, and Amber Paul for their technical assistance and the staff in the University of Alberta Health Sciences Laboratory Animal Services for their support and assistance. E. A. C. and C. P. hold Canada Research Chairs (CRCs; tier 1) in Human Retrovirology and Neurological Infection and Immunity, respectively. C. P. holds an Alberta Heritage Foundation for Medical Research senior scholarship. These studies were supported by the Canadian Institutes of Health Research (C. P., K. M.) and the U.S. National Institutes of Health (National Institute for Mental Health; C. P.). None of the authors have commercial interests or activities related to the contents of the present manuscript.	Batman PA, 2007, AIDS, V21, P433, DOI 10.1097/QAD.0b013e3280142ee8; Boven LA, 2007, J NEUROVIROL, V13, P173, DOI 10.1080/13550280701258399; Brenchley JM, 2008, MUCOSAL IMMUNOL, V1, P23, DOI 10.1038/mi.2007.1; Brenchley JM, 2008, CURR OPIN HIV AIDS, V3, P356, DOI 10.1097/COH.0b013e3282f9ae9c; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; Dandekar Satya, 2007, Curr HIV/AIDS Rep, V4, P10, DOI 10.1007/s11904-007-0002-0; Elder JH, 2008, VET IMMUNOL IMMUNOP, V123, P3, DOI 10.1016/j.vetimm.2008.01.007; Gargalovic PS, 2006, ARTERIOSCL THROM VAS, V26, P2490, DOI 10.1161/01.ATV.0000242903.41158.a1; Gemeniano MC, 2004, VIROLOGY, V325, P167, DOI 10.1016/j.virol.2004.05.007; GILL MJ, 1992, AIDS, V6, P553, DOI 10.1097/00002030-199206000-00005; Ishihara T, 2010, BIOCHEM PHARMACOL, V79, P1622, DOI 10.1016/j.bcp.2010.01.030; Johnston JB, 2002, J NEUROVIROL, V8, P420, DOI 10.1080/13550280260422721; Kaser A, 2010, MUCOSAL IMMUNOL, V3, P11, DOI 10.1038/mi.2009.122; Kaser A, 2009, SEMIN IMMUNOL, V21, P156, DOI 10.1016/j.smim.2009.01.001; Kennedy JM, 2004, AIDS, V18, P1241, DOI 10.1097/00002030-200406180-00002; Kotler DP, 2005, AIDS, V19, P107, DOI 10.1097/00002030-200501280-00002; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; Li QS, 2008, J INFECT DIS, V197, P420, DOI 10.1086/525046; Maingat F, 2010, J IMMUNOL, V184, P1566, DOI 10.4049/jimmunol.0902575; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Meddings JB, 1998, GASTROENTEROLOGY, V114, P83, DOI 10.1016/S0016-5085(98)70636-5; Mogensen TH, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-54; Orandle MS, 2007, J VIROL, V81, P6265, DOI 10.1128/JVI.02671-06; Planelles V, 2009, CURR TOP MICROBIOL, V339, P177, DOI 10.1007/978-3-642-02175-6_9; Power C, 1998, J VIROL, V72, P9109, DOI 10.1128/JVI.72.11.9109-9115.1998; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Sankaran S, 2008, J VIROL, V82, P538, DOI 10.1128/JVI.01449-07; Shacklett BL, 2000, VIROLOGY, V270, P317, DOI 10.1006/viro.2000.0299; Snyder A, 2010, AIDS, V24, P1107, DOI 10.1097/QAD.0b013e328337b0ab; Tsutsui S, 2008, FASEB J, V22, P786, DOI 10.1096/fj.07-9002com; Willett BJ, 1997, IMMUNOL TODAY, V18, P182, DOI 10.1016/S0167-5699(97)84665-8; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhu Y, 2005, J IMMUNOL, V175, P1118, DOI 10.4049/jimmunol.175.2.1118; Zhu Y, 2009, FASEB J, V23, P2928, DOI 10.1096/fj.08-128819; Zink MC, 2006, CURR HIV RES, V4, P293	35	34	35	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2211	2220		10.1096/fj.10-175992	http://dx.doi.org/10.1096/fj.10-175992			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21427211	Green Published			2022-12-28	WOS:000292242200013
J	Eylenstein, A; Gehring, EM; Heise, N; Shumilina, E; Schmidt, S; Szteyn, K; Munzer, P; Nurbaeva, MK; Eichenmuller, M; Tyan, L; Regel, I; Foller, M; Kuhl, D; Soboloff, J; Penner, R; Lang, F				Eylenstein, Anja; Gehring, Eva-Maria; Heise, Nicole; Shumilina, Ekaterina; Schmidt, Sebastian; Szteyn, Kalina; Muenzer, Patrick; Nurbaeva, Meerim K.; Eichenmueller, Melanie; Tyan, Leonid; Regel, Ivonne; Foeller, Michael; Kuhl, Dietmar; Soboloff, Jonathan; Penner, Reinhold; Lang, Florian			Stimulation of Ca2+-channel Orai1/STIM1 by serum- and glucocorticoid-inducible kinase 1 (SGK1)	FASEB JOURNAL			English	Article						CRAC; store-operated calcium channel; SOCE; degranulation; migration	REGULATING FACTOR NHERF2; CA2+ CHANNEL TRPV5; INTRACELLULAR CALCIUM; CRAC CHANNEL; PROTEIN-KINASE; UP-REGULATION; PORE SUBUNIT; ION CHANNELS; MICE LACKING; STORE	Ca2+ signaling includes store-operated Ca2+ entry (SOCE) following depletion of endoplasmic reticulum (ER) Ca2+ stores. On store depletion, the ER Ca2+ sensor STIM1 activates Orai1, the pore-forming unit of Ca2+-release-activated Ca2+ (CRAC) channels. Here, we show that Orai1 is regulated by serum-and glucocorticoid-inducible kinase 1 (SGK1), a growth factor-regulated kinase. Membrane Orai1 protein abundance, I-CRAC, and SOCE in human embryonic kidney (HEK293) cells stably expressing Orai1 and transfected with STIM1 were each significantly enhanced by coexpression of constitutively active (S422D)SGK1 (by+81, +378, and +136%, respectively) but not by inactive (K127N)SGK1. Coexpression of the ubiquitin ligase Nedd4-2, an established negatively regulated SGK1 target, down-regulated SOCE (by -48%) and I-CRAC (by -60%), an effect reversed by expression of (S422D)SGK1 (by + 175 and +173%, respectively). Orai1 protein abundance and SOCE were significantly lower in mast cells from SGK1-knockout (sgk1(-/-)) mice (by -37% and -52%, respectively) than in mast cells from wild-type (sgk1(+/+)) littermates. Activation of SOCE by sarcoplasmic/endoplasmic reticulum Ca2+-ATPase-inhibitor thapsigargin (2 mu M) stimulated migration, an effect significantly higher (by +306%) in (S422D)SGK1-expressing than in (K127N)SGK1-expressing HEK293 cells, and also significantly higher (by + 108%) in sgk1(+/+) than in sgk1(-/-) mast cells. SGK1 is thus a novel key player in the regulation of SOCE.-Eylenstein, A., Gehring, E.-M., Heise, N., Shumilina, E., Schmidt, S., Szteyn, K., Munzer, P., Nurbaeva, M. K., Eichenmuller, M., Tyan, L., Regel, I., Foller, M., Kuhl, D., Soboloff, J., Penner, R., Lang, R. Stimulation of Ca2+-channel Orai1/STIM1 by serum-and glucocorticoid-inducible kinase 1 (SGK1). FASEB J. 25, 2012-2021 (2011). www.fasebj.org	[Eylenstein, Anja; Gehring, Eva-Maria; Heise, Nicole; Shumilina, Ekaterina; Schmidt, Sebastian; Szteyn, Kalina; Muenzer, Patrick; Nurbaeva, Meerim K.; Eichenmueller, Melanie; Tyan, Leonid; Regel, Ivonne; Foeller, Michael; Lang, Florian] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; [Kuhl, Dietmar] Univ Med Ctr Hamburg Eppendorf UKE, Ctr Mol Neurobiol ZMNH, Inst Mol & Cellular Cognit IMCC, Hamburg, Germany; [Soboloff, Jonathan] Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19122 USA; [Penner, Reinhold] Univ Hawaii, Ctr Biomed Res, Queens Med Ctr, Honolulu, HI 96822 USA	Eberhard Karls University of Tubingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; The Queen's Medical Center; University of Hawaii System	Lang, F (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	Regel, Ivonne/AFS-1831-2022; Soboloff, Jonathan/I-6995-2012; Kuhl, Dietmar/A-4689-2009	Soboloff, Jonathan/0000-0001-5192-1297; Kuhl, Dietmar/0000-0002-4772-6701; Munzer, Patrick/0000-0001-5357-038X; Penner, Reinhold/0000-0002-5366-1537	Deutsche Forschungsgemeinschaft [GK 1302, SFB 773]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM097335] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors acknowledge the technical assistance of E. Faber and the preparation of the manuscript by T. Loch and L. Subasic. This study was supported by the Deutsche Forschungsgemeinschaft (GK 1302, SFB 773).	Amato R, 2009, J MOL MED, V87, P1221, DOI 10.1007/s00109-009-0525-5; Baba Y, 2008, NAT IMMUNOL, V9, P81, DOI 10.1038/ni1546; Baryshnikov SG, 2009, AM J PHYSIOL-CELL PH, V297, pC1103, DOI 10.1152/ajpcell.00283.2009; Becchetti A, 2010, ADV EXP MED BIOL, V674, P107; Berra-Romani R, 2008, AM J PHYSIOL-CELL PH, V295, pC779, DOI 10.1152/ajpcell.00173.2008; Bhalla V, 2005, MOL ENDOCRINOL, V19, P3073, DOI 10.1210/me.2005-0193; Bhalla V, 2006, AM J PHYSIOL-RENAL, V291, pF714, DOI 10.1152/ajprenal.00061.2006; Bird GS, 2008, METHODS, V46, P204, DOI 10.1016/j.ymeth.2008.09.009; Boehmer C, 2007, FEBS LETT, V581, P5586, DOI 10.1016/j.febslet.2007.11.006; Boehmer C, 2008, CELL PHYSIOL BIOCHEM, V22, P591, DOI 10.1159/000185543; Bogeski I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000672; Bradding P, 2009, BRIT J PHARMACOL, V157, P1330, DOI 10.1111/j.1476-5381.2009.00362.x; Burgoyne RD, 2007, NAT REV NEUROSCI, V8, P182, DOI 10.1038/nrn2093; Cahalan MD, 2007, CELL CALCIUM, V42, P133, DOI 10.1016/j.ceca.2007.03.002; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dehner M, 2008, J BIOL CHEM, V283, P19201, DOI 10.1074/jbc.M710366200; Dietrich A, 2010, THROMB HAEMOSTASIS, V103, P262, DOI 10.1160/TH09-08-0517; Embark HM, 2004, CELL PHYSIOL BIOCHEM, V14, P203, DOI 10.1159/000080329; Faouzi M, 2011, J CELL PHYSIOL, V226, P542, DOI 10.1002/jcp.22363; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Imai S, 2003, LIFE SCI, V72, P2199, DOI 10.1016/S0024-3205(03)00092-4; Ji W, 2008, P NATL ACAD SCI USA, V105, P13668, DOI 10.1073/pnas.0806499105; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Klaus F, 2008, J PHYSIOL-LONDON, V586, P1539, DOI 10.1113/jphysiol.2007.146191; Klingel K, 2000, AM J PHYSIOL-GASTR L, V279, pG998, DOI 10.1152/ajpgi.2000.279.5.G998; Krueger B, 2009, CELL PHYSIOL BIOCHEM, V24, P605, DOI 10.1159/000257516; Lang F, 2000, P NATL ACAD SCI USA, V97, P8157, DOI 10.1073/pnas.97.14.8157; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Lang F, 2010, INT J BIOCHEM CELL B, V42, P1571, DOI 10.1016/j.biocel.2010.05.016; Lang F, 2009, CURR OPIN NEPHROL HY, V18, P439, DOI 10.1097/MNH.0b013e32832f125e; Laufer J, 2009, CELL PHYSIOL BIOCHEM, V23, P25, DOI 10.1159/000204077; Liang XB, 2008, J BIOL CHEM, V283, P27418, DOI 10.1074/jbc.M803687200; Liang XB, 2006, J BIOL CHEM, V281, P16323, DOI 10.1074/jbc.M601360200; Liao Y, 2007, P NATL ACAD SCI USA, V104, P4682, DOI 10.1073/pnas.0611692104; Liao YY, 2009, P NATL ACAD SCI USA, V106, P3202, DOI 10.1073/pnas.0813346106; Lioudyno MI, 2008, P NATL ACAD SCI USA, V105, P2011, DOI 10.1073/pnas.0706122105; Mignen O, 2008, J PHYSIOL-LONDON, V586, P419, DOI 10.1113/jphysiol.2007.147249; Nagaki K, 2006, BIOCHEMISTRY-US, V45, P6733, DOI 10.1021/bi052640q; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Palmada M, 2005, CELL PHYSIOL BIOCHEM, V15, P175, DOI 10.1159/000083650; Pani B, 2009, CELL CALCIUM, V45, P625, DOI 10.1016/j.ceca.2009.02.009; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peel SE, 2008, AM J RESP CELL MOL, V38, P744, DOI 10.1165/rcmb.2007-0395OC; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Penna A, 2008, NATURE, V456, P116, DOI 10.1038/nature07338; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Putney JW, 2007, J CELL SCI, V120, P1959, DOI 10.1242/jcs.03462; Rajamanickam J, 2007, J NEUROCHEM, V102, P858, DOI 10.1111/j.1471-4159.2007.04585.x; Roberts-Thomson SJ, 2010, PHARMACOL THERAPEUT, V127, P121, DOI 10.1016/j.pharmthera.2010.04.016; Robinson LJ, 2010, ANN NY ACAD SCI, V1192, P351, DOI 10.1111/j.1749-6632.2009.05219.x; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Rotte A, 2009, CELL PHYSIOL BIOCHEM, V23, P133, DOI 10.1159/000204102; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Salter RD, 2009, IMMUNOL REV, V231, P278, DOI 10.1111/j.1600-065X.2009.00806.x; Schaff UY, 2010, BLOOD, V115, P657, DOI 10.1182/blood-2009-05-224659; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047; Shin DM, 2008, NAT CELL BIOL, V10, P639, DOI 10.1038/ncb0608-639; Shumilina E, 2008, J IMMUNOL, V180, P8040, DOI 10.4049/jimmunol.180.12.8040; Shumilina E, 2010, CELL PHYSIOL BIOCHEM, V26, P699, DOI 10.1159/000322337; Shuttleworth TJ, 2009, CELL CALCIUM, V45, P602, DOI 10.1016/j.ceca.2009.02.001; Smyth JT, 2009, NAT CELL BIOL, V11, P1465, DOI 10.1038/ncb1995; Snyder PM, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.279pe41; Sobiesiak M, 2009, J IMMUNOL, V183, P4395, DOI 10.4049/jimmunol.0803017; Sopjani M, 2010, J MEMBRANE BIOL, V233, P35, DOI 10.1007/s00232-009-9222-0; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Taruno A, 2008, AM J PHYSIOL-RENAL, V294, pF177, DOI 10.1152/ajprenal.00250.2007; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Wang K, 2010, CELL PHYSIOL BIOCHEM, V25, P271, DOI 10.1159/000276561; Woodard GE, 2010, J BIOL CHEM, V285, P8045, DOI 10.1074/jbc.M109.033605; Wulff P, 2002, J CLIN INVEST, V110, P1263, DOI 10.1172/JCI200215696; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhou YD, 2009, J BIOL CHEM, V284, P19164, DOI 10.1074/jbc.C109.010900	79	76	78	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					2012	2021		10.1096/fj.10-178210	http://dx.doi.org/10.1096/fj.10-178210			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21385992	Green Published			2022-12-28	WOS:000291023800023
J	Hilberath, JN; Carlo, T; Pfeffer, MA; Croze, RH; Hastrup, F; Levy, BD				Hilberath, Jan N.; Carlo, Troy; Pfeffer, Michael A.; Croze, Roxanne H.; Hastrup, Frantz; Levy, Bruce D.			Resolution of Toll-like receptor 4-mediated acute lung injury is linked to eicosanoids and suppressor of cytokine signaling 3	FASEB JOURNAL			English	Article						inflammation; lung elastance; vascular permeability; lipid mediators; macrophages	INFLAMMATION; MACROPHAGES; MICE; IDENTIFICATION; ASPIRATION; RESPONSES; PROTEINS; DELIVERY; PATHWAY; STRESS	The purpose of this study was to investigate roles for Toll-like receptor 4 (TLR4) in host responses to sterile tissue injury. Hydrochloric acid was instilled into the left mainstem bronchus of TLR4-defective (both C3H/HeJ and congenic C. C3-Tlr4(Lps-d)/J) and control mice to initiate mild, self-limited acute lung injury (ALI). Outcome measures included respiratory mechanics, barrier integrity, leukocyte accumulation, and levels of select soluble mediators. TLR4-defective mice were more resistant to ALI, with significantly decreased perturbations in lung elastance and resistance, resulting in faster resolution of these parameters [resolution interval (R-i); similar to 6 vs. 12 h]. Vascular permeability changes and oxidative stress were also decreased in injured HeJ mice. These TLR4-defective mice paradoxically displayed increased lung neutrophils [(HeJ) 24 x 10(3) vs. (control) 13 x 10(3) cells/bronchoalveolar lavage]. Proresolving mechanisms for TLR4-defective animals included decreased eicosanoid biosynthesis, including cysteinyl leukotrienes (80% mean decrease) that mediated CysLT1 receptor-dependent vascular permeability changes; and induction of lung suppressor of cytokine signaling 3 (SOCS3) expression that decreased TLR4-driven oxidative stress. Together, these findings indicate pivotal roles for TLR4 in promoting sterile ALI and suggest downstream provocative roles for cysteinyl leukotrienes and protective roles for SOCS3 in the intensity and duration of host responses to ALI.-Hilberath, J N., Carlo, T., Pfeffer, M. A., Croze, R. H., Hastrup, F., Levy, B. D. Resolution of Toll-like receptor 4-mediated acute lung injury is linked to eicosanoids and suppressor of cytokine signaling 3. FASEB J. 25, 1827-1835 (2011). www.fasebj.org	[Levy, Bruce D.] Brigham & Womens Hosp, Harvard Inst Med, Div Pulm & Crit Care Med, Dept Internal Med, Boston, MA 02115 USA; [Hilberath, Jan N.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Hilberath, Jan N.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Levy, BD (corresponding author), Brigham & Womens Hosp, Harvard Inst Med, Div Pulm & Crit Care Med, Dept Internal Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	blevy@partners.org		Hilberath, Jan N./0000-0002-0799-2941	National Institutes of Health [HL068669, HL090927]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090927, R01HL068669] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors acknowledge Bonna Ith for expert help with histology, and Anton Serhan for assistance with the transfection experiments. This study was supported by departmental funds (J.N.H.) and National Institutes of Health grants HL068669 and HL090927 (B.D.L.). B.D.L. is a coinventor on patents on the use of lipoxins in lung disease that are assigned to Brigham and Women's Hospital, which have been licensed for clinical development.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bonnans C, 2006, AM J PATHOL, V168, P1064, DOI 10.2353/ajpath.2006.051056; Bystrom J, 2008, BLOOD, V112, P4117, DOI 10.1182/blood-2007-12-129767; Carpenter CT, 1998, CHEST, V114, P1653, DOI 10.1378/chest.114.6.1653; Cavassani KA, 2008, J EXP MED, V205, P2609, DOI 10.1084/jem.20081370; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Fang M, 2005, CELL MOL IMMUNOL, V2, P373; Frank JA, 2006, AM J PHYSIOL-LUNG C, V291, pL1191, DOI 10.1152/ajplung.00055.2006; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Fukunaga K, 2005, J IMMUNOL, V174, P5033, DOI 10.4049/jimmunol.174.8.5033; Gao HW, 2006, J IMMUNOL, V177, P612, DOI 10.4049/jimmunol.177.1.612; Garantziotis S, 2010, AM J RESP CRIT CARE, V181, P666, DOI 10.1164/rccm.200903-0381OC; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043; Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269; Keller M, 2006, FASEB J, V20, P702, DOI 10.1096/fj.05-4075fje; Levy BD, 2007, FASEB J, V21, P3877, DOI 10.1096/fj.07-8653com; Liu X, 2008, MOL IMMUNOL, V45, P1405, DOI 10.1016/j.molimm.2007.08.018; Ma SF, 2005, AM J PHYSIOL-LUNG C, V289, pL468, DOI 10.1152/ajplung.00109.2005; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Peddibhotla S, 2009, P NATL ACAD SCI USA, V106, P5159, DOI 10.1073/pnas.0806671106; Planaguma A, 2010, MUCOSAL IMMUNOL, V3, P270, DOI 10.1038/mi.2009.141; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Ramirez Cruz Nora E, 2004, Rev Alerg Mex, V51, P210; Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004; Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683; Rovati GE, 2007, THESCIENTIFICWORLDJO, V7, P1375, DOI 10.1100/tsw.2007.185; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2000, NAT IMMUNOL, V1, P13, DOI 10.1038/76865; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; UDAKA K, 1970, P SOC EXP BIOL MED, V133, P1384; VOGEL SN, 1994, INFECT IMMUN, V62, P4454, DOI 10.1128/IAI.62.10.4454-4459.1994; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Yoshimura Akihiko, 2009, Keio Journal of Medicine, V58, P73; Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499	47	26	34	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1827	1835		10.1096/fj.10-169896	http://dx.doi.org/10.1096/fj.10-169896			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21321188	Green Published			2022-12-28	WOS:000291023800006
J	Tirino, V; Desiderio, V; Paino, F; De Rosa, A; Papaccio, F; Fazioli, F; Pirozzi, G; Papaccio, G				Tirino, Virginia; Desiderio, Vincenzo; Paino, Francesca; De Rosa, Alfredo; Papaccio, Federica; Fazioli, Flavio; Pirozzi, Giuseppe; Papaccio, Gianpaolo			Human primary bone sarcomas contain CD133(+) cancer stem cells displaying high tumorigenicity in vivo	FASEB JOURNAL			English	Article						tumor-initiating cells; sarcospheres; osteosarcoma; chondrosarcoma	SIDE POPULATION CELLS; INITIATING CELLS; OSTEOSARCOMA; IDENTIFICATION; BIOLOGY; TUMORS; DIFFERENTIATION; EXPRESSION; CARCINOMA; EXPANSION	This study aimed to identify, isolate, and characterize cancer stem cells from human primary sarcomas. We performed cytometric analyses for stemness and differentiation antigens, including CD29, CD34, CD44, CD90, CD117, and CD133, on 21 human primary sarcomas on the day of surgery. From sarcoma biopsies, we obtained 2 chondrosarcoma-stabilized cell lines and 2 osteosarcoma stabilized cell lines, on which sphere formation, side population profile, stemness gene expression, and in vivo and in vitro assays were performed. All samples expressed the CD133, CD44, and CD29 markers. Therefore, we selected a CD133(+) subpopulation from stabilized cell lines that displayed the capacity to grow as sarcospheres able to initiate and sustain tumor growth in nonobese diabetic/severe combined (NOD/SCID) mice, to express stemness genes, including OCT3/4, Nanog, Sox2, and Nestin, and to differentiate into mesenchymal lineages, such as osteoblasts and adipocytes. Our findings show the existence of cancer stem cells in human primary bone sarcomas and highlight CD133 as a pivotal marker for identification of these cells. This may be of primary importance in the development of new therapeutic strategies and new prognostic procedures against these highly aggressive and metastatic tumors.-Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., Fazioli, F., Pirozzi, G., Papaccio, G. Human primary bone sarcomas contain CD133(+) cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 25, 2022-2030 (2011). www.fasebj.org	[Papaccio, Gianpaolo] Univ Naples 2, Dept Expt Med, Sect Histol & Embryol, I-80138 Naples, Italy; [De Rosa, Alfredo] Univ Naples 2, Dept Odontostomatol & Maxillofacial Surg, I-80138 Naples, Italy; [Pirozzi, Giuseppe] Natl Canc Inst, Dept Expt Oncol, Naples, Italy; [Fazioli, Flavio] Natl Canc Inst, Dept Surg Oncol, Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Papaccio, G (corresponding author), Univ Naples 2, Dept Expt Med, Sect Histol & Embryol, 5 Via L Armanni, I-80138 Naples, Italy.	gianpaolo.papaccio@unina2.it	desiderio, vincenzo/K-4244-2018; paino, francesca/AAC-8150-2019; Papaccio, Gianpaolo/B-7150-2014	paino, francesca/0000-0002-3186-1888; Papaccio, Federica/0000-0002-0302-8696; FAZIOLI, FLAVIO/0000-0002-4308-1192; desiderio, vincenzo/0000-0003-1819-6083; Papaccio, Gianpaolo/0000-0002-4014-5306; Tirino, Virginia/0000-0003-2731-5718	SIRIO-FIRB [06, RBIP06FH7J_006]	SIRIO-FIRB	The authors kindly thank Dr. Maria Vincenza Carriero (National Cancer Institute, Naples, Italy) for supplying the BS15 cell line and thank Biogem Scarl (Ariano Irpino, Italy) for use of the Animal Model facility. The authors kindly thank Dr. Rachel Sammons (University of Birmingham School of Dentistry, Birmingham, UK) for English editing. This study is supported by SIRIO-FIRB 2007/2009 grant 06 n. RBIP06FH7J_006 to G.P. The authors declare no competing financial interests.	ADHIKARI AS, CANC RES, V70, P4602; Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; ARAKI N, 1991, CLIN ORTHOP RELAT R, P271; Bussolati B, 2008, FASEB J, V22, P3696, DOI 10.1096/fj.08-102590; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Deleyrolle Loic P., 2009, V549, P91, DOI 10.1007/978-1-60327-931-4_7; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Fukuda K, 2009, INT J ONCOL, V34, P1201, DOI 10.3892/ijo_00000248; Gatta G, 2005, J CLIN ONCOL, V23, P3742, DOI 10.1200/JCO.2005.00.554; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Hadnagy A, 2006, EXP CELL RES, V312, P3701, DOI 10.1016/j.yexcr.2006.08.030; Hirschmann-Jax C, 2005, CELL CYCLE, V4, P203; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Hu C, 2008, CARCINOGENESIS, V29, P2289, DOI 10.1093/carcin/bgn223; JEFFREE GM, 1975, BRIT J CANCER, V32, P87, DOI 10.1038/bjc.1975.136; Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9-4-422; Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Murase M, 2009, BRIT J CANCER, V101, P1425, DOI 10.1038/sj.bjc.6605330; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Olstad OK, 2003, ANTICANCER RES, V23, P2201; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Suva ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008-5472.CAN-08-2242; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tang C, 2007, ANN ACAD MED SINGAP, V36, P352; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Tirino V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003469; Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20; Veselska R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-300; Yin SY, 2007, INT J CANCER, V120, P1444, DOI 10.1002/ijc.22476	42	154	164	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					2022	2030		10.1096/fj.10-179036	http://dx.doi.org/10.1096/fj.10-179036			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21385990				2022-12-28	WOS:000291023800024
J	Dhondt, J; Peeraer, E; Verheyen, A; Nuydens, R; Buysschaert, I; Poesen, K; Van Geyte, K; Beerens, M; Shibuya, M; Haigh, JJ; Meert, T; Carmeliet, P; Lambrechts, D				Dhondt, Joke; Peeraer, Eve; Verheyen, An; Nuydens, Rony; Buysschaert, Ian; Poesen, Koen; Van Geyte, Katie; Beerens, Manu; Shibuya, Masabumi; Haigh, Jody J.; Meert, Theo; Carmeliet, Peter; Lambrechts, Diether			Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons	FASEB JOURNAL			English	Article						neurovascular link; distal neuropathy	ENDOTHELIAL GROWTH-FACTOR; INDUCED PERIPHERAL NEUROPATHY; DIABETIC-NEUROPATHY; GENE-TRANSFER; ANGIOGENESIS; INJURY; NERVE; EXPRESSION; CANCER; CELLS	Even though VEGF-B is a homologue of the potent angiogenic factor VEGF, its angiogenic activities have been controversial. Intrigued by findings that VEGF-B may also affect neuronal cells, we assessed the neuroprotective and vasculoprotective effects of VEGF-B in the skin, in which vessels and nerves are functionally intertwined. Although VEGF-B and its FLT1 receptor were prominently expressed in dorsal root ganglion (DRG) neurons innervating the hindlimb skin, they were not essential for nerve function or vascularization of the skin. However, primary DRG cultures lacking VEGF-B or FLT1 exhibited increased neuronal stress and were more susceptible to paclitaxel-induced cell death. Concomitantly, mice lacking VEGF-B or a functional FLT1 developed more retrograde degeneration of sensory neurons in a model of distal neuropathy. On the other hand, the addition of the VEGF-B isoform, VEGF-B(186), to DRG cultures antagonized neuronal stress, maintained the mitochondrial membrane potential and stimulated neuronal survival. Mice overexpressing VEGF-B(186) or FLT1 selectively in neurons were protected against the distal neuropathy, whereas exogenous VEGF-B(186), either delivered by gene transfer or as a recombinant factor, was protective by directly affecting sensory neurons and not the surrounding vasculature. Overall, this indicates that VEGF-B, instead of acting as an angiogenic factor, exerts direct neuroprotective effects through FLT1. These findings also suggest a clinically relevant role for VEGF-B in preventing distal neuropathies.-Dhondt, J., Peeraer, E., Verheyen, A., Nuydens, R., Buysschaert, I., Poesen, K., Van Geyte, K., Beerens, M., Shibuya, M., Haigh, J. J., Meert, T., Carmeliet, P., Lambrechts, D. Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons. FASEB J. 25, 1461-1473 (2011). www.fasebj.org	[Lambrechts, Diether] Katholieke Univ Leuven, Vesalius Res Ctr, Flanders Inst Biotechnol, B-3000 Louvain, Belgium; [Dhondt, Joke; Verheyen, An; Buysschaert, Ian; Poesen, Koen; Van Geyte, Katie; Beerens, Manu; Carmeliet, Peter; Lambrechts, Diether] VIB, Vesalius Res Ctr, Louvain, Belgium; [Peeraer, Eve; Verheyen, An; Nuydens, Rony; Meert, Theo] Johnson & Johnson Pharmaceut Res & Dev, Dept Neurosci, Beerse, Belgium; [Peeraer, Eve] Univ Hasselt, Biomed Res Inst, Diepenbeek, Belgium; [Shibuya, Masabumi] Tokyo Med & Dent Univ, Dept Mol Oncol, Tokyo, Japan; [Haigh, Jody J.] VIB, Dept Mol Biomed Res, Vasc Cell Biol Unit, Ghent, Belgium; [Haigh, Jody J.] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); Johnson & Johnson; Janssen Pharmaceuticals; Hasselt University; Tokyo Medical & Dental University (TMDU); Flanders Institute for Biotechnology (VIB); Ghent University	Lambrechts, D (corresponding author), Katholieke Univ Leuven, Vesalius Res Ctr, Flanders Inst Biotechnol, Campus Gasthuisberg,Herestr 49,Box 912, B-3000 Louvain, Belgium.	diether.lambrechts@vib-kuleuven.be	Verdrengh, Evelien/H-4571-2012; Lambrechts, Diether/AAJ-3167-2020; Carmeliet, Peter/AAQ-5140-2020; Poesen, Koen/B-3759-2013	Lambrechts, Diether/0000-0002-3429-302X; Carmeliet, Peter/0000-0001-7961-1821; haigh, jody/0000-0002-7319-8922; Beerens, Manu/0000-0002-7398-7761	Research Foundation Flanders, Belgium; Institute for the Promotion of Innovation by Science and Technology in Flanders; Geneeskundige stichting Koningin Elisabeth; Muscular Dystrophy Association; governmental Institute for Science and Technology (IWT) for the promotion of research; Katholieke Universiteit Leuven; Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium	Research Foundation Flanders, Belgium(FWO); Institute for the Promotion of Innovation by Science and Technology in Flanders(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Geneeskundige stichting Koningin Elisabeth; Muscular Dystrophy Association(Muscular Dystrophy Association); governmental Institute for Science and Technology (IWT) for the promotion of research(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Katholieke Universiteit Leuven(KU Leuven); Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium(Johnson & JohnsonJohnson & Johnson USA)	D. L. is supported by the Research Foundation Flanders, Belgium; J.D. and K. P. are supported by the Institute for the Promotion of Innovation by Science and Technology in Flanders. P. C. is supported by grants from the Geneeskundige stichting Koningin Elisabeth, and by the Muscular Dystrophy Association. This project is partly funded by a research and development grant of the governmental Institute for Science and Technology (IWT) for the promotion of research between universities (D. L., Katholieke Universiteit Leuven) and industry (T. M. and R.N., Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium).	Argyriou AA, 2008, CRIT REV ONCOL HEMAT, V66, P218, DOI 10.1016/j.critrevonc.2008.01.008; Bennett CL, 2008, JAMA-J AM MED ASSOC, V299, P914, DOI 10.1001/jama.299.8.914; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; De Almodovar CR, 2009, PHYSIOL REV, V89, P607, DOI 10.1152/physrev.00031.2008; Falk T, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-49; George SHL, 2007, P NATL ACAD SCI USA, V104, P4455, DOI 10.1073/pnas.0609277104; HAGBERG CE, NATURE, V464, P917; Kanda M, 2008, J SURG ONCOL, V98, P190, DOI 10.1002/jso.21095; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kirchmair R, 2005, CIRCULATION, V111, P2662, DOI 10.1161/CIRCULATIONAHA.104.470849; Kirchmair R, 2007, MOL THER, V15, P69, DOI 10.1038/sj.mt.6300019; Lahteenvuo JE, 2009, CIRCULATION, V119, P845, DOI 10.1161/CIRCULATIONAHA.108.816454; Li X, 2008, ARTERIOSCL THROM VAS, V28, P1614, DOI 10.1161/ATVBAHA.107.158725; Li Y, 2008, J CLIN INVEST, V118, P913, DOI 10.1172/JCI33673; Lipton SA, 2004, NEW ENGL J MED, V350, P2516, DOI 10.1056/NEJMcibr041121; Mould AW, 2003, ARTHRITIS RHEUM-US, V48, P2660, DOI 10.1002/art.11232; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Peters CM, 2007, EXP NEUROL, V203, P42, DOI 10.1016/j.expneurol.2006.07.022; Poesen K, 2008, J NEUROSCI, V28, P10451, DOI 10.1523/JNEUROSCI.1092-08.2008; Popovici C, 2002, NEUROSCI LETT, V329, P116, DOI 10.1016/S0304-3940(02)00595-5; Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; Shu XQ, 1999, P NATL ACAD SCI USA, V96, P7693, DOI 10.1073/pnas.96.14.7693; Silvestre JS, 2003, CIRC RES, V93, P114, DOI 10.1161/01.RES.0000081594.21764.44; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sun YJ, 2004, J CEREBR BLOOD F MET, V24, P1146, DOI 10.1097/01.WCB.0000134477.38980.38; Tschachler E, 2004, J INVEST DERMATOL, V122, P177, DOI 10.1046/j.0022-202X.2003.22102.x; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; Valable S, 2003, FASEB J, V17, P443, DOI 10.1096/fj.02-0372fje; Wilson K, 2006, INT J NEUROPROT NEUR, V3, P31; Zacchigna S, 2008, NAT REV NEUROSCI, V9, P169, DOI 10.1038/nrn2336; ZENTILIN L, FASEB J, V24, P1467	36	38	40	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1461	1473		10.1096/fj.10-170944	http://dx.doi.org/10.1096/fj.10-170944			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21248239	Bronze, Green Published			2022-12-28	WOS:000290023800005
J	Cao, XM; Pobezinskaya, YL; Morgan, MJ; Liu, ZG				Cao, Xiumei; Pobezinskaya, Yelena L.; Morgan, Michael J.; Liu, Zheng-gang			The role of TRADD in TRAIL-induced apoptosis and signaling	FASEB JOURNAL			English	Article						MEF; FADD; RIP1; DR5	NF-KAPPA-B; FADD-DEPENDENT APOPTOSIS; DEATH-DOMAIN KINASE; INDUCED ACTIVATION; RECEPTORS 1; PATHWAY; CASPASE-8; LIGAND; CELLS; RIP	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily. TRAIL is promising for anticancer therapy because it induces apoptosis in cancer cells with little or no toxicity to normal cells; hence, TRAIL-receptor agonists are currently undergoing clinical trials for cancer treatment. However, many molecular signaling mechanisms in TRAIL signaling are not completely characterized. The functions of adaptor proteins, including TNF-receptor-associated death domain protein (TRADD) and receptor-interacting protein-1 (RIP1) in TRAIL signaling have been controversial. We demonstrate that while wild-type mouse embryonic fibroblasts (MEFs) are completely resistant to TRAIL-induced apoptosis, MEFs derived from Tradd(-/-) mice are hypersensitive to TRAIL (IC50 similar to 0.5 nM rmTRAIL, 24 h), an effect also seen in primary keratinocytes treated with TRAIL/CHX. Restoration of TRADD in Tradd(-/-) MEFs restores TRAIL resistance, indicating that TRADD plays a survival role in TRAIL signaling. We show that TRADD is recruited to the TRAIL-receptor complex, and RIP1 recruitment is mediated by TRADD. While early activation of the MAP kinase ERK is deficient in Tradd(-/-) cells, the main mechanism for enhanced TRAIL sensitivity is likely due to increased recruitment of FADD to the receptor complex, indicating that TRADD may limit FADD binding within the receptor complex and also mediate RIP1-dependent nonapoptotic signaling events, thus reducing caspase activation and subsequent apoptosis. These novel findings have potential implications for cancer therapy using TRAIL-receptor agonists.-Cao, X., Pobezinskaya, Y. L., Morgan, M. J., Liu, Z. The role of TRADD in TRAIL-induced apoptosis and signaling. FASEB J. 25, 1353-1358 (2011). www.fasebj.org	[Cao, Xiumei; Pobezinskaya, Yelena L.; Morgan, Michael J.; Liu, Zheng-gang] NCI, Cell & Canc Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, ZG (corresponding author), NCI, Cell & Canc Biol Branch, Ctr Canc Res, 37 Convent Dr,Rm 1130, Bethesda, MD 20892 USA.	zgliu@helix.nih.gov			Center for Cancer Research, National Cancer Institute, NIH; NATIONAL CANCER INSTITUTE [ZIASC010376] Funding Source: NIH RePORTER	Center for Cancer Research, National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank S. Lipkowitz (U.S. NIH, Bethesda, MD, USA) for GST-rhTRAIL and Jianke Zhang (Thomas Jefferson University, Philadelphia, PA, USA) for the mouse FADD antibody. This work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH.	Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jin ZY, 2006, MOL CELL BIOL, V26, P8136, DOI 10.1128/MCB.00257-06; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Pobezinskaya YL, 2008, NAT IMMUNOL, V9, P1047, DOI 10.1038/ni.1639; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Song JJ, 2008, CELL SIGNAL, V20, P892, DOI 10.1016/j.cellsig.2008.01.001; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Tang WH, 2009, CELL RES, V19, P758, DOI 10.1038/cr.2009.57; Tang WH, 2009, FEBS J, V276, P581, DOI 10.1111/j.1742-4658.2008.06809.x; Thomas LR, 2004, J BIOL CHEM, V279, P32780, DOI 10.1074/jbc.M401680200; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Verbrugge I, 2008, ONCOGENE, V27, P574, DOI 10.1038/sj.onc.1210696	23	32	35	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1353	1358		10.1096/fj.10-170480	http://dx.doi.org/10.1096/fj.10-170480			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21187341	Green Published			2022-12-28	WOS:000288982800024
J	Franco, HL; Dai, D; Lee, KY; Rubel, CA; Roop, D; Boerboom, D; Jeong, JW; Lydon, JP; Bagchi, IC; Bagchi, MK; DeMayo, FJ				Franco, Heather L.; Dai, Daisy; Lee, Kevin Y.; Rubel, Cory A.; Roop, Dennis; Boerboom, Derek; Jeong, Jae-Wook; Lydon, John P.; Bagchi, Indrani C.; Bagchi, Milan K.; DeMayo, Francesco J.			WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse	FASEB JOURNAL			English	Article						p63; estrogen; Bmp2; Foxo1	LEUKEMIA INHIBITORY FACTOR; BETA-CATENIN; TARGET GENES; UTERUS; EXPRESSION; BLASTOCYST; ESTROGEN; MICE; DIETHYLSTILBESTROL; ACTIVATION	WNT4, a member of the Wnt family of ligands, is critical for the development of the female reproductive tract. Analysis of Wnt4 expression in the adult uterus during pregnancy indicates that it may play a role in the regulation of endometrial stromal cell proliferation, survival, and differentiation, which is required to support the developing embryo. To investigate the role of Wnt4 in adult uterine physiology, conditional ablation of Wnt4 using the PRcre mouse model was accomplished. Ablation of Wnt4 rendered female mice subfertile due to a defect in embryo implantation and subsequent defects in endometrial stromal cell survival, differentiation, and responsiveness to progesterone signaling. In addition to altered stromal cell function, the uteri of PRcre/+ Wnt4(f/f) (Wnt4(d/d)) mice displayed altered epithelial differentiation characterized by a reduction in the number of uterine glands and the emergence of a p63-positive basal cell layer beneath the columnar luminal epithelial cells. The altered epithelial cell phenotype was further escalated by chronic estrogen treatment, which caused squamous cell metaplasia of the uterine epithelium in the Wnt4(d/d) mice. Thus, WNT4 is a critical regulator not only of proper postnatal uterine development, but also embryo implantation and decidualization.-Franco, H. L., Dai, D., Lee, K. Y., Rubel, C. S., Roop, D., Boerboom, D., Jeong, J.-W., Lydon, J.-P., Bagchi, I. C., Bagchi, M. K., DeMayo, F. J. WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse. FASEB J. 25, 1176-1187 (2011). www.fasebj.org	[Franco, Heather L.; Lee, Kevin Y.; Rubel, Cory A.; Jeong, Jae-Wook; Lydon, John P.; DeMayo, Francesco J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Dai, Daisy; DeMayo, Francesco J.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Roop, Dennis] Univ Colorado, Dept Dermatol, Aurora, CO USA; [Roop, Dennis] Univ Colorado, Charles C Gates Ctr Regenerat Med & Stem Cell Bio, Aurora, CO USA; [Boerboom, Derek] Univ Montreal, Dept Biomed Vet, St Hyacinthe, PQ, Canada; [Bagchi, Indrani C.] Univ Illinois, Dept Vet Biosci, Urbana, IL USA; [Bagchi, Milan K.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL USA	Baylor College of Medicine; Baylor College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Universite de Montreal; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	DeMayo, FJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	fdemayo@bcm.tmc.edu	DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336; Lee, Kevin/0000-0002-1528-7417	U.S. National Institutes of Health (NIH) [R01HD042311, R01HD057873, R01CA77530]; Canadian Institutes of Health Research; Reproductive Biology Training Grant [5T32HD07165]; Baylor Research Advocates for Student Scientists; Winterman Foundation; Houston Livestock Show and Rodeo Scholarship Fund; Eunice Kennedy Shriver National Institute of Child Health and Human Development/NIH [U54HD0077495, U54HD055787, U54HD28934]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057873, U54HD028934, T32HD007165, U54HD055787, R01HD042311] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA077530] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Reproductive Biology Training Grant; Baylor Research Advocates for Student Scientists; Winterman Foundation; Houston Livestock Show and Rodeo Scholarship Fund; Eunice Kennedy Shriver National Institute of Child Health and Human Development/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Joanne S. Richards for assistance with the Wnt4<SUP>f/f</SUP> mice; Sungnam Cho, Jie Yang, and Bryan Ngo for technical assistance; and Sophia Y. Tsai and Janet DeMayo for manuscript preparation. This work was supported by U.S. National Institutes of Health (NIH) grants R01HD042311 (to F.J.D.), R01HD057873 (to J.W.J.), and R01CA77530 (to J.P.L.); an operating grant from the Canadian Institutes of Health Research (to D. B.); Reproductive Biology Training Grant 5T32HD07165 and a scholarship from Baylor Research Advocates for Student Scientists, supported in part by the Winterman Foundation and the Houston Livestock Show and Rodeo Scholarship Fund (to H. L. F.); and Eunice Kennedy Shriver National Institute of Child Health and Human Development/NIH grants U54HD0077495 (to F.J.D.), U54HD055787 (to I. C. B., M. K. B., and F.J.D.), and U54HD28934 (to the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core) through a cooperative agreement as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research.	Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Arango NA, 2005, DEV BIOL, V288, P276, DOI 10.1016/j.ydbio.2005.09.045; Besnard V, 2004, GENE EXPR PATTERNS, V5, P193, DOI 10.1016/j.modgep.2004.08.006; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; Boyer A, 2010, FASEB J, V24, P3010, DOI 10.1096/fj.09-145789; Brasted M, 2003, BIOL REPROD, V69, P1273, DOI 10.1095/biolreprod.103.016550; Brosens JJ, 2006, J MOL ENDOCRINOL, V36, P389, DOI 10.1677/jme.1.02060; Chen JR, 2000, ENDOCRINOLOGY, V141, P4365, DOI 10.1210/en.141.12.4365; Chen XM, 2009, REPRODUCTION, V138, P351, DOI 10.1530/REP-09-0090; Cheng JG, 2003, BIOL REPROD, V68, P401, DOI 10.1095/biolreprod.102.009589; Couse JF, 2001, DEV BIOL, V238, P224, DOI 10.1006/dbio.2001.0413; Daikoku T, 2004, MOL ENDOCRINOL, V18, P1238, DOI 10.1210/me.2003-0403; FINN CA, 1972, BIOL REPROD, V7, P82, DOI 10.1093/biolreprod/7.1.82; Franco HL, 2008, SEMIN CELL DEV BIOL, V19, P178, DOI 10.1016/j.semcdb.2007.12.001; Goldberg JM, 1999, FERTIL STERIL, V72, P1, DOI 10.1016/S0015-0282(99)00153-3; Gray CA, 2002, REPRODUCTION, V124, P289, DOI 10.1530/rep.0.1240289; Grinius L, 2006, J ENDOCRINOL, V189, P179, DOI 10.1677/joe.1.06451; Hamatani T, 2004, P NATL ACAD SCI USA, V101, P10326, DOI 10.1073/pnas.0402597101; Hayashi K, 2009, BIOL REPROD, V80, P989, DOI 10.1095/biolreprod.108.075416; Hou XN, 2004, MOL ENDOCRINOL, V18, P3035, DOI 10.1210/me.2004-0259; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Jeong JW, 2009, ONCOGENE, V28, P31, DOI 10.1038/onc.2008.363; Jeong JW, 2010, BIOL REPROD, V83, P396, DOI 10.1095/biolreprod.109.083154; Katayama S, 2006, TOXICOL SCI, V91, P419, DOI 10.1093/toxsci/kfj167; Kimber SJ, 2005, REPRODUCTION, V130, P131, DOI 10.1530/rep.1.00304; Koster MI, 2007, ANNU REV CELL DEV BI, V23, P93, DOI 10.1146/annurev.cellbio.23.090506.123357; Labied S, 2006, MOL ENDOCRINOL, V20, P35, DOI 10.1210/me.2005-0275; Lee KY, 2007, MOL CELL BIOL, V27, P5468, DOI 10.1128/MCB.00342-07; Lee KY, 2004, REPRODUCTION, V128, P679, DOI 10.1530/rep.1.00340; Li J, 2005, BIOL REPROD, V72, P700, DOI 10.1095/biolreprod.104.033837; Li QX, 2007, J BIOL CHEM, V282, P31725, DOI 10.1074/jbc.M704723200; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Mendivil A, 2009, CANCER CONTROL, V16, P46, DOI 10.1177/107327480901600107; Mericskay M, 2004, DEVELOPMENT, V131, P2061, DOI 10.1242/dev.01090; Miller C, 1998, DEVELOPMENT, V125, P3201; Mohamed OA, 2005, P NATL ACAD SCI USA, V102, P8579, DOI 10.1073/pnas.0500612102; Nagy A., 2003, MANIPULATING MOUSE E; Osada M, 2006, BIOCHEM BIOPH RES CO, V339, P1120, DOI 10.1016/j.bbrc.2005.11.118; Sassoon D, 1999, MOL CELL ENDOCRINOL, V158, P1, DOI 10.1016/S0303-7207(99)00170-7; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Tranguch S, 2005, P NATL ACAD SCI USA, V102, P14326, DOI 10.1073/pnas.0505775102; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Wang HB, 2006, NAT REV GENET, V7, P185, DOI 10.1038/nrg1808; Xie HR, 2008, DEVELOPMENT, V135, P717, DOI 10.1242/dev.015339; Xu XB, 2007, HUM REPROD, V22, P3184, DOI 10.1093/humrep/dem312; Yang ZC, 2006, MOL ENDOCRINOL, V20, P2682, DOI 10.1210/me.2006-0024	48	187	200	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1176	1187		10.1096/fj.10-175349	http://dx.doi.org/10.1096/fj.10-175349			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21163860	Green Published			2022-12-28	WOS:000288982800007
J	Lie, PPY; Cheng, CY; Mruk, DD				Lie, Pearl P. Y.; Cheng, C. Yan; Mruk, Dolores D.			Interleukin-1 alpha is a regulator of the blood-testis barrier	FASEB JOURNAL			English	Article						Sertoli cell; actin; cytokine; spermatogenesis; seminiferous epithelial cycle	ANCHORING JUNCTION DYNAMICS; GERM CELL-INTERACTIONS; NECROSIS-FACTOR-ALPHA; SEMINIFEROUS EPITHELIUM; TISSUE INHIBITOR; SERTOLI; PROTEIN; TIGHT; METALLOPROTEASES-1; SPERMATOGENESIS	Throughout spermatogenesis, the Sertoli cell blood-testis barrier (BTB) is strictly regulated by cytokines, which mediate its timely restructuring, thereby allowing spermatocytes to enter the adluminal compartment of the seminiferous epithelium for development into spermatozoa. The aim herein was to investigate whether germ cells play a role in BTB restructuring via the action of interleukin-1 alpha (IL-1 alpha) since germ cells are known to control Sertoli cell production of this cytokine, and if yes, how these effects are mediated. When Sertoli cells were isolated from Sprague-Dawley rats and plated at high density, IL-1 alpha (100 pg/ml) was shown to "open" the Sertoli cell barrier when its integrity was assessed by transepithelial electrical resistance measurements. Further investigation of Sertoli cells treated with IL-1 alpha revealed striking changes in the cellular distribution of actin filaments when compared to untreated cells. These effects at the Sertoli cell barrier were mediated, in part, by epidermal growth factor receptor pathway substrate 8 (Eps8; an actin bundling and barbed-end capping protein) and actin-related protein 3 (Arp3; a component of the actin nucleation machinery). As important, an increase in the kinetics of occludin internalization but a decrease in its rate of degradation was noted following IL-1 alpha treatment. These results indicate that IL-1 alpha is a critical regulator of BTB dynamics.-Lie, P. P. Y., Cheng, C. Y., Mruk, D. D. Interleukin-1 alpha is a regulator of the blood-testis barrier. FASEB J. 25, 1244-1253 (2011). www.fasebj.org	[Lie, Pearl P. Y.; Cheng, C. Yan; Mruk, Dolores D.] Populat Council, Ctr Biomed Res, New York, NY 10065 USA	Population Council	Mruk, DD (corresponding author), Populat Council, Ctr Biomed Res, 1230 York Ave, New York, NY 10065 USA.	mruk@popcbr.rockefeller.edu		Cheng, C Yan/0000-0003-3117-3791	National Institute of Child Health and Human Development, U.S. National Institutes of Health [R03 HD061401, R01 HD056034, R01 HD056034-02S1, U54 HD029990]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990, R01HD056034] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD061401] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported in part by the National Institute of Child Health and Human Development, U.S. National Institutes of Health (R03 HD061401 to D. D. M.; and R01 HD056034, R01 HD056034-02S1, and U54 HD029990 Project 5 to C.Y.C.) Population Council laboratories are located on the campus of The Rockefeller University. The authors are not affiliated with The Rockefeller University, and no support was received from The Rockefeller University.	Capaldo CT, 2009, BBA-BIOMEMBRANES, V1788, P864, DOI 10.1016/j.bbamem.2008.08.027; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; Chung NPY, 2001, BIOL REPROD, V65, P1340, DOI 10.1095/biolreprod65.5.1340; Cudicini C, 1997, ENDOCRINOLOGY, V138, P2863, DOI 10.1210/en.138.7.2863; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; Disanza A, 2006, NAT CELL BIOL, V8, P1337, DOI 10.1038/ncb1502; GALDIERI M, 1981, J ANDROL, V2, P249; HAUGEN TB, 1994, MOL CELL ENDOCRINOL, V105, pR19, DOI 10.1016/0303-7207(94)90177-5; Ivanov AI, 2010, AM J PATHOL, V177, P512, DOI 10.2353/ajpath.2010.100168; Kawaguchi Y, 2006, P NATL ACAD SCI USA, V103, P14501, DOI 10.1073/pnas.0603545103; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; Li MWM, 2006, J ENDOCRINOL, V190, P313, DOI 10.1677/joe.1.06781; Li MWM, 2009, CYTOKINE GROWTH F R, V20, P329, DOI 10.1016/j.cytogfr.2009.07.007; Lie PPY, 2010, P NATL ACAD SCI USA, V107, P11411, DOI 10.1073/pnas.1001823107; Lie PPY, 2010, INT J BIOCHEM CELL B, V42, P975, DOI 10.1016/j.biocel.2010.02.010; Lie PPY, 2009, FASEB J, V23, P2555, DOI 10.1096/fj.06-070573; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 2003, J ANDROL, V24, P510; Mruk DD, 2008, PHARMACOL REV, V60, P146, DOI 10.1124/pr.107.07105; Nehar D, 1998, BIOL REPROD, V59, P1425, DOI 10.1095/biolreprod59.6.1425; Papakonstanti EA, 2008, FEBS LETT, V582, P2120, DOI 10.1016/j.febslet.2008.02.064; PARVINEN M, 1982, ENDOCR REV, V3, P404, DOI 10.1210/edrv-3-4-404; Pollard TD, 2007, ANNU REV BIOPH BIOM, V36, P451, DOI 10.1146/annurev.biophys.35.040405.101936; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; Sarkar O, 2008, BIOL REPROD, V78, P445, DOI 10.1095/biolreprod.107.064501; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Siu MKY, 2003, ENDOCRINOLOGY, V144, P371, DOI 10.1210/en.2002-220786; Su LL, 2010, INT J BIOCHEM CELL B, V42, P1864, DOI 10.1016/j.biocel.2010.08.004; Svechnikov KV, 2001, MOL CELL ENDOCRINOL, V182, P193, DOI 10.1016/S0303-7207(01)00554-8; SYED V, 1995, ENDOCRINOLOGY, V136, P3070, DOI 10.1210/en.136.7.3070; Wahab-Wahlgren A, 2000, INT J ANDROL, V23, P360, DOI 10.1046/j.1365-2605.2000.t01-1-00253.x; Xia WL, 2006, J BIOL CHEM, V281, P16799, DOI 10.1074/jbc.M601618200; Xia WL, 2009, DEV BIOL, V327, P48, DOI 10.1016/j.ydbio.2008.11.028; Xia WL, 2005, CYTOKINE GROWTH F R, V16, P469, DOI 10.1016/j.cytogfr.2005.05.007; Xia WL, 2005, DEV BIOL, V280, P321, DOI 10.1016/j.ydbio.2004.12.036; Yan HHN, 2008, FASEB J, V22, P1945, DOI 10.1096/fj.06-070342; Yan HHN, 2005, P NATL ACAD SCI USA, V102, P11722, DOI 10.1073/pnas.0503855102	42	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1244	1253		10.1096/fj.10-169995	http://dx.doi.org/10.1096/fj.10-169995			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21191089	Green Published			2022-12-28	WOS:000288982800013
J	Garcia-Marcos, M; Jung, BH; Ear, J; Cabrera, B; Carethers, JM; Ghosh, P				Garcia-Marcos, Mikel; Jung, Barbara H.; Ear, Jason; Cabrera, Betty; Carethers, John M.; Ghosh, Pradipta			Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer	FASEB JOURNAL			English	Article						PI3K-Akt; guanine-nucleotide exchange factor; cell migration; growth factor receptors; cytoskeleton; G protein; microsatellite instability	ACTIN-BINDING PROTEIN; G-ALPHA-I; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; CELL-LINES; CHROMOSOMAL INSTABILITY; AKT; ACTIVATION; GIV; ASSOCIATION	Metastasis accounts for the majority of cancer-related deaths. Accurate prediction of metastatic potential of tumors has been elusive, and the search for clinically useful markers continues. We previously reported that GIV/Girdin triggers tumor cell migration by virtue of a C-terminal guanine-nucleotide exchange factor motif that activates G alpha i. Here we identify GIV as a metastasis-related protein whose full-length transcript (GIV-fl) is expressed exclusively in highly invasive colon, breast, and pancreatic carcinoma cells and not in their poorly invasive counterparts. A prospective, exploratory biomarker study conducted on a cohort of 56 patients with stage II colorectal cancer revealed a significant correlation between GIV-fl expression in tumor epithelium and shortened metastasis-free survival. Survival rate for patients with GIV-fl-positive tumors is significantly reduced compared with the patients with GIV-fl-negative tumors [P<0.0001; hazard ratio=0.076; CI=0.052-0.30 (95%)]. At the 5-yr mark, survival is 100% in the GIV-fl-negative group and 62 +/- 9% (mean +/- SE; P=6X10(-5)) in the GIV-fl-positive group. Furthermore, GIV-fl expression predicts a risk of mortality independent of the microsatellite stability status, a well-established prognosticator of colorectal cancers. We conclude that GIV-fl is a novel metastasis-related protein and an independent adverse prognosticator that may serve as a useful adjunct to traditional staging strategies in colorectal carcinoma.-Garcia-Marcos, M., Jung, B. H., Ear, J., Cabrera, B., Carethers, J. M., Ghosh, P. Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer. FASEB J. 25, 590-599 (2011). www.fasebj.org	[Garcia-Marcos, Mikel; Ghosh, Pradipta] Univ Calif San Diego, Dept Cellular & Mol Med, George E Palade Labs, San Diego, CA 92103 USA; [Jung, Barbara H.; Ear, Jason; Cabrera, Betty; Carethers, John M.; Ghosh, Pradipta] Univ Calif San Diego, Dept Med, Div Gastroenterol, San Diego, CA 92103 USA; [Carethers, John M.; Ghosh, Pradipta] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, San Diego, CA 92103 USA; [Jung, Barbara H.; Carethers, John M.; Ghosh, Pradipta] Vet Affairs San Diego Healthcare Syst, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Ghosh, P (corresponding author), Univ Calif San Diego, Sch Med, George E Palade Labs Cellular & Mol Med, 9500 Gilman Dr,Rm 333, La Jolla, CA 92093 USA.	prghosh@ucsd.edu		Garcia-Marcos, Mikel/0000-0001-9513-4826	Burroughs Wellcome Fund; American Gastroenterology Association; U.S. National Institutes of Health (NIH) [K08-DK-074019, R01-DK-067287]; University of California, San Diego, Digestive Diseases Research Development Center; U.S. Public Health Service [DK-080506]; Basque Government [BFI06.300]; Susan G. Komen [KG080079]; NIH [CA100768]; NATIONAL CANCER INSTITUTE [R01CA100768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK080506, K08DK074019, R01DK067287] Funding Source: NIH RePORTER	Burroughs Wellcome Fund(Burroughs Wellcome Fund); American Gastroenterology Association; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California, San Diego, Digestive Diseases Research Development Center; U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Basque Government(Basque Government); Susan G. Komen(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Marilyn G. Farquhar for scientific mentoring, advice, and thoughtful comments during preparation of this work. The authors thank Samuel B. Ho (University of California, San Diego) for the generous gift of paired tumor tissue samples from patients with Duke's D colorectal cancer with synchronous liver metastases and Michael Lam (University of California, San Diego) for advice and technical help with the real-time quantitative RT-PCR. This work was supported by awards from the Burroughs Wellcome Fund and American Gastroenterology Association to P.G.; U.S. National Institutes of Health (NIH) grants K08-DK-074019 and R01-DK-067287 to B.H.J and J.M.C, respectively; and the University of California, San Diego, Digestive Diseases Research Development Center, U.S. Public Health Service grant DK-080506. M.G.-M. was supported by Basque Government Postdoctoral Fellowship BFI06.300 and Susan G. Komen Postdoctoral Fellowship KG080079. J.E. is a recipient of a McNair Student Research Scholarship. The authors thank Erin P. Forry for help with tissue culture, and she was supported by NIH grant CA100768 to Marilyn Farquhar.	Anai M, 2005, J BIOL CHEM, V280, P18525, DOI 10.1074/jbc.M500586200; BAND V, 1990, CANCER RES, V50, P7351; Barbara JT, 2006, INT J CANCER, V118, P2509, DOI 10.1002/ijc.21710; Boland CR, 1998, CANCER RES, V58, P5248; BRESALIER RS, 1987, CANCER RES, V47, P1398; Carethers JM, 1998, GASTROENTEROLOGY, V114, P1188, DOI 10.1016/S0016-5085(98)70424-X; Duffy MJ, 2007, EUR J CANCER, V43, P1348, DOI 10.1016/j.ejca.2007.03.021; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Enomoto A, 2006, ANN NY ACAD SCI, V1086, P169, DOI 10.1196/annals.1377.016; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; ESTELLER M, 2007, Patent No. 2007122369; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Flatmark K, 2004, EUR J CANCER, V40, P1593, DOI 10.1016/j.ejca.2004.02.023; Garcia-Marcos M, 2010, J BIOL CHEM, V285, P12765, DOI 10.1074/jbc.M109.045161; Garcia-Marcos M, 2009, P NATL ACAD SCI USA, V106, P3178, DOI 10.1073/pnas.0900294106; Gervaz P, 2002, SURGERY, V131, P190, DOI 10.1067/msy.2002.119816; Ghosh P, 2008, J CELL BIOL, V182, P381, DOI 10.1083/jcb.200712066; Ghosh P, 2010, MOL BIOL CELL, V21, P2338, DOI 10.1091/mbc.E10-01-0028; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Grzesiak JJ, 2006, BRIT J CANCER, V94, P1311, DOI 10.1038/sj.bjc.6603088; Jiang P, 2008, CANCER RES, V68, P1310, DOI 10.1158/0008-5472.CAN-07-5111; Jung B, 2004, GASTROENTEROLOGY, V126, P654, DOI 10.1053/j.gastro.2004.01.008; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Le-Niculescu H, 2005, J BIOL CHEM, V280, P22012, DOI 10.1074/jbc.M501833200; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MILLER L, 2006, Patent No. 2007013671; MILLER L, 2006, Patent No. 20060074565; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.086; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Qiao M, 2007, CANCER RES, V67, P5293, DOI 10.1158/0008-5472.CAN-07-0877; Saglam O, 2007, CLIN COLORECTAL CANC, V6, P652, DOI 10.3816/CCC.2007.n.034; Simpson F, 2005, TRAFFIC, V6, P442, DOI 10.1111/j.1600-0854.2005.00289.x; Talmadge JE, 2007, CANCER RES, V67, P11471, DOI 10.1158/0008-5472.CAN-07-2496; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; VEZERIDIS MP, 1990, J SURG RES, V48, P51, DOI 10.1016/0022-4804(90)90145-R; Walther A, 2008, GUT, V57, P941, DOI 10.1136/gut.2007.135004; WENG L, CANC SCI, V101, P836	44	58	63	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					590	599		10.1096/fj.10-167304	http://dx.doi.org/10.1096/fj.10-167304			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20974669	Green Published			2022-12-28	WOS:000286724800017
J	Darbandi-Tehrani, K; Hermand, P; Carvalho, S; Dorgham, K; Couvineau, A; Lacapere, JJ; Combadiere, C; Deterre, P				Darbandi-Tehrani, Kevin; Hermand, Patricia; Carvalho, Stephanie; Dorgham, Karim; Couvineau, Alain; Lacapere, Jean-Jacques; Combadiere, Christophe; Deterre, Philippe			Subtle conformational changes between CX3CR1 genetic variants as revealed by resonance energy transfer assays	FASEB JOURNAL			English	Article						adherence; chemokine; GPCR; BRET; FRET	PROTEIN-COUPLED-RECEPTOR; LIVING CELLS; HETERO-OLIGOMERIZATION; DUFFY ANTIGEN/RECEPTOR; GPCR OLIGOMERIZATION; ANTITUMOR RESPONSES; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; BRET ANALYSIS; CHEMOKINE	The chemokine CX3CL1 is expressed as a membrane protein that forms a potent adhesive pair with its unique receptor CX3CR1. This receptor has 3 natural variants, V249-T280 (VT), I249-T280 (IT), and I249-M280 (IM), whose relative frequencies are significantly associated with the incidence of various inflammatory diseases. To assess the adhesive potency of CX3CR1 and the molecular diversity of its variants, we assayed their clustering status and their possible structural differences by fluorescence/bioluminescence resonance energy transfer (FRET or BRET) techniques. FRET assays by flow cytometry showed that the CX3CR1 variants cluster, in comparison with appropriate controls. BRET assays showed low nonspecific signals for VT and IT variants and high specific signals for IM, and thus pointed out a structural difference in this variant. We used molecular modeling to show how natural point mutations of CX3CR1 affect the packing of the 6th and 7th helices of this G-protein coupled receptor. Moreover, we found that the BRET technique is sensitive enough to detect these tiny changes. Consistently with our previous finding that CX3CL1 aggregates, our data here indicate that CX3CR1 clustering may contribute to the adhesiveness of the CX3CL1-CX3CR1 pair and may thus represent a new target for anti-inflammatory therapies.-Darbandi-Tehrani, K., Hermand, P., Carvalho, S., Dorgham, K., Couvineau, A., Lacapere, J.-J., Combadiere, C., Deterre, P. Subtle conformational changes between CX3CR1 genetic variants as revealed by resonance energy transfer assays. FASEB J. 24, 4585-4598 (2010). www.fasebj.org	[Deterre, Philippe] Univ Paris 06, INSERM, UMR S 945, Fac Med Pitie Salpetriere,Lab Immun & Infect, F-75013 Paris, France; [Couvineau, Alain; Lacapere, Jean-Jacques] INSERM, U773, Ctr Rech Biomed Bichat Beaujon CRB3, Paris, France; [Couvineau, Alain; Lacapere, Jean-Jacques] Univ Paris Diderot, Fac Med Xavier Bichat, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Deterre, P (corresponding author), Univ Paris 06, INSERM, UMR S 945, Fac Med Pitie Salpetriere,Lab Immun & Infect, 91 Blvd Hop, F-75013 Paris, France.	philippe.deterre@upmc.fr	Combadiere, Christophe/I-5639-2013; couvineau, alain/T-3466-2019; Deterre, Philippe/O-8984-2017; Dorgham, karim/A-2241-2016; couvineau, alain/G-3641-2013	Combadiere, Christophe/0000-0002-1755-4531; couvineau, alain/0000-0003-2912-5168; Deterre, Philippe/0000-0001-9303-0791; Dorgham, karim/0000-0001-9539-3203; couvineau, alain/0000-0003-2912-5168; HERMAND, Patricia/0000-0003-0628-9733	Association de Recherche contre le Cancer; Institut National de la Sante et de la Recherche Medicale; European FP6 [LSHB-CT-2005-518167]; ANR-Piribio [piribio09_443682]; Canceropole Ile-de-France; Ligue Nationale Contre le Cancer	Association de Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); European FP6(European Commission); ANR-Piribio(French National Research Agency (ANR)); Canceropole Ile-de-France(Region Ile-de-France); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	The authors thank Amanda E. Proudfoot (Merck Serono, Geneva, Switzerland) for her generous gift of CX3CL1, Stefano Marullo (Institut Cochin, Paris, France) for providing the pRLuc and pEYFP plasmids, and Jeffrey K. Harrison (University of Florida College of Medicine, Jacksonville, FL, USA) for his generous gift of the murine CX3CR1 construct. The authors also thank Mehdi Daoudi, Marie-Camille Delsuc, James Vigneron, and Tamara Lopez for preliminary experiments; Mariano Ostuni for his help in subcellular fractionation; and Christophe Parizot and Olivier Pelle for their advice about flow cytometry analysis. This work was supported by grants from the Association de Recherche contre le Cancer, the Institut National de la Sante et de la Recherche Medicale (Programme National de Recherche sur Les Maladies Cardiovasculaires), European FP6 contracts INNO-CHEM (LSHB-CT-2005-518167 to C.C.), and ANR-Piribio (piribio09_443682, Adhekines). J.J.L. and P.D. are researchers from the Centre National de la Recherche Scientifique (CNRS). K.D.-T. was supported by a doctoral fellowship from Canceropole Ile-de-France and Ligue Nationale Contre le Cancer. The authors acknowledge the local Post-Genomic Platform of Pitie-Salpetriere (P3S) for providing access to the Fusion Packard reader and the local Cellular Imaging Platform of Pitie-Salpetriere (PICPS) for providing access to the confocal microscope.	Achour L, 2009, BLOOD, V113, P1938, DOI 10.1182/blood-2008-02-141275; Allen SJ, 2009, PROTEIN EXPRES PURIF, V66, P73, DOI 10.1016/j.pep.2009.03.001; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2001, LIFE SCI, V68, P2243, DOI 10.1016/S0024-3205(01)01012-8; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2004, MOL PHARMACOL, V66, P312, DOI 10.1124/mol.104.000398; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Ayoub MA, 2007, MOL PHARMACOL, V71, P1329, DOI 10.1124/mol.106.030304; Batard P, 2002, CYTOMETRY, V48, P97, DOI 10.1002/cyto.10106; Bayburt TH, 2007, J BIOL CHEM, V282, P14875, DOI 10.1074/jbc.M701433200; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Berchiche YA, 2007, J BIOL CHEM, V282, P5111, DOI 10.1074/jbc.C600270200; Blanpain C, 2002, MOL BIOL CELL, V13, P723, DOI 10.1091/mbc.01-03-0129; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Boute N, 2003, EMBO REP, V4, P313, DOI 10.1038/sj.embor.embor767; Boute N, 2001, MOL PHARMACOL, V60, P640; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Bouvier M, 2007, NAT METHODS, V4, P3, DOI 10.1038/nmeth0107-3; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chabre M, 2005, BIOCHEMISTRY-US, V44, P9395, DOI 10.1021/bi050720o; Chabre M, 2009, TRENDS PHARMACOL SCI, V30, P182, DOI 10.1016/j.tips.2009.01.003; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Combadiere B, 2007, M S-MED SCI, V23, P173, DOI 10.1051/medsci/2007232173; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692; Daoudi M, 2004, J BIOL CHEM, V279, P19649, DOI 10.1074/jbc.M313457200; Davis CN, 2006, J PHARMACOL EXP THER, V316, P356, DOI 10.1124/jpet.105.093039; Dorsch S, 2009, NAT METHODS, V6, P225, DOI [10.1038/NMETH.1304, 10.1038/nmeth.1304]; Ernst OP, 2007, P NATL ACAD SCI USA, V104, P10859, DOI 10.1073/pnas.0701967104; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Fung JJ, 2009, EMBO J, V28, P3315, DOI 10.1038/emboj.2009.267; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; Garin A, 2003, J IMMUNOL, V171, P5305, DOI 10.4049/jimmunol.171.10.5305; Gurevich VV, 2008, TRENDS NEUROSCI, V31, P74, DOI 10.1016/j.tins.2007.11.007; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; Hattori H, 2005, NEUROSCI LETT, V374, P132, DOI 10.1016/j.neulet.2004.10.042; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Hermand P, 2008, J BIOL CHEM, V283, P30225, DOI 10.1074/jbc.M802638200; Hern JA, 2010, P NATL ACAD SCI USA, V107, P2693, DOI 10.1073/pnas.0907915107; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; James JR, 2006, NAT METHODS, V3, P1001, DOI 10.1038/nmeth978; Jin ZH, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-41; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Kuszak AJ, 2009, J BIOL CHEM, V284, P26732, DOI 10.1074/jbc.M109.026922; Langer HF, 2009, J CELL MOL MED, V13, P1211, DOI 10.1111/j.1582-4934.2009.00811.x; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lavergne E, 2003, CANCER RES, V63, P7468; Lavergne E, 2005, ARTERIOSCL THROM VAS, V25, P847, DOI 10.1161/01.ATV.0000157150.23641.36; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Levoye A, 2006, CHRONOBIOL INT, V23, P419, DOI 10.1080/07420520500521863; Ling WLW, 2002, GENE THER, V9, P907, DOI 10.1038/sj.gt.3301726; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Maggio R, 2005, FEBS J, V272, P2939, DOI 10.1111/j.1742-4658.2005.04729.x; Marullo S, 2007, TRENDS PHARMACOL SCI, V28, P362, DOI 10.1016/j.tips.2007.06.007; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; McDermott D H, 2000, Science, V290, P2031; McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790; McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Meyer BH, 2006, P NATL ACAD SCI USA, V103, P2138, DOI 10.1073/pnas.0507686103; Milligan G, 2003, LIFE SCI, V74, P181, DOI 10.1016/j.lfs.2003.09.005; Milligan G, 2001, J CELL SCI, V114, P1265; Milligan G, 2005, J MOL NEUROSCI, V26, P161, DOI 10.1385/JMN:26:2-3:161; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Nadif R, 2006, CYTOKINE, V33, P171, DOI 10.1016/j.cyto.2006.01.001; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200; Pfleger KDG, 2005, BIOCHEM J, V385, P625, DOI 10.1042/BJ20041361; Pin JP, 2004, BIOL CELL, V96, P335, DOI 10.1016/j.biolcel.2004.03.005; Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010; Riemann D, 2005, BIOCHEM BIOPH RES CO, V331, P1408, DOI 10.1016/j.bbrc.2005.04.061; Rodero M, 2008, J CLIN ONCOL, V26, P5957, DOI 10.1200/JCO.2008.17.2833; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Salahpour A, 2007, NAT METHODS, V4, P599, DOI 10.1038/nmeth0807-599; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Springael JY, 2007, PHARMACOL THERAPEUT, V115, P410, DOI 10.1016/j.pharmthera.2007.06.004; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Toth PT, 2004, J PHARMACOL EXP THER, V310, P8, DOI 10.1124/jpet.103.064956; Tournamille C, 2004, IMMUNOGENETICS, V55, P682, DOI 10.1007/s00251-003-0633-2; Tournamille C, 1997, J BIOL CHEM, V272, P16274, DOI 10.1074/jbc.272.26.16274; Tremblay K, 2006, GENES IMMUN, V7, P632, DOI 10.1038/sj.gene.6364340; VOGEL SS, 2006, SCI STKE, pRE2, DOI DOI 10.1126/STKE.3312006RE2; Wang DX, 2005, MOL PHARMACOL, V67, P2173, DOI 10.1124/mol.104.010272; Whorton MR, 2008, J BIOL CHEM, V283, P4387, DOI 10.1074/jbc.M703346200; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104; WOODCOCK S, 1992, PROTEIN ENG, V5, P629, DOI 10.1093/protein/5.7.629; WYNBERG H, 1980, NATURE, V286, P641, DOI 10.1038/286641a0; Yu YRA, 2007, INT J CANCER, V121, P316, DOI 10.1002/ijc.22660; Zhou JY, 2003, J PHARMACOL EXP THER, V305, P460, DOI 10.1124/jpet.102.048637	99	9	9	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4585	4598		10.1096/fj.10-156612	http://dx.doi.org/10.1096/fj.10-156612			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20667981				2022-12-28	WOS:000283861100043
J	Brizuela, L; Dayon, A; Doumerc, N; Ader, I; Golzio, M; Izard, JC; Hara, Y; Malavaud, B; Cuvillier, O				Brizuela, Leyre; Dayon, Audrey; Doumerc, Nicolas; Ader, Isabelle; Golzio, Muriel; Izard, Jean-Claude; Hara, Yukihiko; Malavaud, Bernard; Cuvillier, Olivier			The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer	FASEB JOURNAL			English	Article						resveratrol; EGCg; phospholipase D; ERK1/2	MYELOID-LEUKEMIA CELLS; NF-KAPPA-B; GREEN TEA; PHOSPHOLIPASE-D; INDUCED APOPTOSIS; VEGF EXPRESSION; HEPATOMA-CELLS; POOR SURVIVAL; CYCLE ARREST; RESVERATROL	The sphingosine kinase-1/sphingosine 1-phosphate (SphK1/S1P) pathway has been associated with cancer promotion and progression and resistance to treatments in a number of cancers, including prostate adenocarcinoma. Here we provide the first evidence that dietary agents, namely, epigallocatechin gallate (EGCg, IC50 approximate to 75 mu M), resveratrol (IC50 approximate to 40 mu M), or a mixture of polyphenols from green tea [polyphenon E (PPE), IC50 approximate to 70 mu M] or grapevine extract (vineatrol, IC50 approximate to 30 mu M), impede prostate cancer cell growth in vitro and in vivo by inhibiting the SphK1/S1P pathway. We establish that SphK1 is a downstream effector of the ERK/phospholipase D (PLD) pathway, which is inhibited by green tea and wine polyphenols. Enforced expression of SphK1 impaired the ability of green tea and wine polyphenols, as well as pharmacological inhibitors of PLD and ERK activities, to induce apoptosis in PC-3 and C4-2B cells. The therapeutic efficacy of these polyphenols on tumor growth and the SphK1/S1P pathway were confirmed in animals using a heterotopic PC-3 tumor in place model. PC-3/SphK1 cells implanted in animals developed larger tumors and resistance to treatment with polyphenols. Furthermore, using an orthotopic PC-3/GFP model, the chemopreventive effect of an EGCg or PPE diet was associated with SphK1 inhibition, a decrease in primary tumor volume, and occurrence and number of metastases. These results provide the first demonstration that the prosurvival, antiapoptotic SphK1/S1P pathway represents a target of dietary green tea and wine polyphenols in cancer.-Brizuela, L., Dayon, A., Doumerc, N., Ader, I., Golzio, M., Izard, J.-C., Hara, Y., Malavaud, B., Cuvillier, O. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. FASEB J. 24, 3882-3894 (2010). www.fasebj.org	[Cuvillier, Olivier] CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France; [Brizuela, Leyre; Dayon, Audrey; Doumerc, Nicolas; Ader, Isabelle; Golzio, Muriel; Malavaud, Bernard; Cuvillier, Olivier] Univ Toulouse 3, Inst Pharmacol & Biol Struct, Univ Toulouse, F-31062 Toulouse, France; [Doumerc, Nicolas; Malavaud, Bernard; Cuvillier, Olivier] Hop Rangueil, Serv Urol & Transplantat Renale, Toulouse, France; [Izard, Jean-Claude] Actichem SA, Montauban, France; [Hara, Yukihiko] Mitsui Norin Ltd, Tokyo, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Mitsui Norin Co. Ltd.	Cuvillier, O (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France.	olivier.cuvillier@ipbs.fr	CUVILLIER, Olivier/S-1631-2019; Ader-Perarnau, Isabelle/F-7160-2017; Golzio, Muriel/F-4715-2019; Brizuela, Leyre/B-1175-2010; CUVILLIER, Olivier/B-2567-2009	CUVILLIER, Olivier/0000-0003-3346-375X; Golzio, Muriel/0000-0002-7470-3708; CUVILLIER, Olivier/0000-0003-3346-375X; ADER, isabelle/0000-0001-5103-8509	Region Midi-Pyrenees	Region Midi-Pyrenees(Region OccitanieRegion Provence-Alpes-Cote d'Azur)	This work was supported by the Region Midi-Pyrenees (to O.C.).	Ader I, 2008, CANCER RES, V68, P8635, DOI 10.1158/0008-5472.CAN-08-0917; Ader I, 2009, CANCER RES, V69, P3723, DOI 10.1158/0008-5472.CAN-09-0389; Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Alvarez SE, 2007, TRENDS ENDOCRIN MET, V18, P300, DOI 10.1016/j.tem.2007.07.005; Aziz MH, 2005, FASEB J, V19, P1193, DOI 10.1096/fj.04-3582fje; Benitez DA, 2007, J ANDROL, V28, P282, DOI 10.2164/jandrol.106.000968; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonhoure E, 2008, LEUKEMIA, V22, P971, DOI 10.1038/leu.2008.95; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; Brown HA, 2007, METHOD ENZYMOL, V434, P49, DOI 10.1016/S0076-6879(07)34004-4; Colin D, 2009, INT J CANCER, V124, P2780, DOI 10.1002/ijc.24264; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Cuvillier Olivier, 2010, Curr Mol Pharmacol, V3, P53; Dayon A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008048; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Fitzpatrick JM, 2009, BJU INT, V103, pI, DOI 10.1111/j.1464-410X.2008.08369.x; Fulda S, 2006, CANCER DETECT PREV, V30, P217, DOI 10.1016/j.cdp.2006.03.007; Gioeli D, 1999, CANCER RES, V59, P279; Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098; Harper CE, 2007, CARCINOGENESIS, V28, P1946, DOI 10.1093/carcin/bgm144; Hastak K, 2003, ONCOGENE, V22, P4851, DOI 10.1038/sj.onc.1206708; Issuree PDA, 2009, FASEB J, V23, P2412, DOI 10.1096/fj.09-130542; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; Johnson JJ, 2010, PHYTOMEDICINE, V17, P3, DOI 10.1016/j.phymed.2009.09.011; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Ju J, 2005, CANCER RES, V65, P10623, DOI 10.1158/0008-5472.CAN-05-1949; Kang DW, 2008, J BIOL CHEM, V283, P4094, DOI 10.1074/jbc.M707416200; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05; Lee MH, 2009, CANCER RES, V69, P7449, DOI 10.1158/0008-5472.CAN-09-1266; Li W, 2009, CLIN CANCER RES, V15, P1393, DOI 10.1158/1078-0432.CCR-08-1158; MARTIN A, 1993, J BIOL CHEM, V268, P23924; Nava VE, 2000, CANCER RES, V60, P4468; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Paruch S, 2005, FASEB J, V19, P142, DOI 10.1096/fj.05-3881fje; Pchejetski D, 2005, CANCER RES, V65, P11667, DOI 10.1158/0008-5472.CAN-05-2702; Pchejetski D, 2008, MOL CANCER THER, V7, P1836, DOI 10.1158/1535-7163.MCT-07-2322; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Ruckhaberle E, 2008, BREAST CANCER RES TR, V112, P41, DOI 10.1007/s10549-007-9836-9; Sauer L, 2009, INT J CANCER, V125, P2728, DOI 10.1002/ijc.24640; Seeni A, 2008, ASIAN PAC J CANCER P, V9, P7; Shankar S, 2007, MOL CELL BIOCHEM, V304, P273, DOI 10.1007/s11010-007-9510-x; Shimizu M, 2005, CLIN CANCER RES, V11, P2735, DOI 10.1158/1078-0432.CCR-04-2014; Siddiqui IA, 2006, CARCINOGENESIS, V27, P833, DOI 10.1093/carcin/bgi323; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stewart JR, 2004, INVEST NEW DRUG, V22, P107, DOI 10.1023/B:DRUG.0000011787.75522.ec; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Vayalil PK, 2004, PROSTATE, V59, P33, DOI 10.1002/pros.10352; Xiao H, 2008, CARCINOGENESIS, V29, P113, DOI 10.1093/carcin/bgm204; Zhang QZ, 2006, MOL CANCER THER, V5, P1227, DOI 10.1158/1535-7163.MCT-05-0490; Zhang QZ, 2005, MOL CANCER THER, V4, P1465, DOI 10.1158/1535-7163.MCT-05-0198	57	53	54	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3882	3894		10.1096/fj.10-160838	http://dx.doi.org/10.1096/fj.10-160838			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20522783				2022-12-28	WOS:000285005900026
J	Ishimaru, Y; Katano, Y; Yamamoto, K; Akiba, M; Misaka, T; Roberts, RW; Asakura, T; Matsunami, H; Abe, K				Ishimaru, Yoshiro; Katano, Yuka; Yamamoto, Kurumi; Akiba, Masato; Misaka, Takumi; Roberts, Richard W.; Asakura, Tomiko; Matsunami, Hiroaki; Abe, Keiko			Interaction between PKD1L3 and PKD2L1 through their transmembrane domains is required for localization of PKD2L1 at taste pores in taste cells of circumvallate and foliate papillae	FASEB JOURNAL			English	Article						association; trafficking; sour taste receptor; polycystic kidney disease	TRANSIENT RECEPTOR; TRPP3 CHANNEL; POLYCYSTIN-L; KIDNEY; IDENTIFICATION; MEMBERS; FAMILY; MOUSE; ACID; MECHANOSENSATION	The polycystic kidney disease 1-like 3 (PKD1L3) and polycystic kidney disease 2-like 1 (PKD2L1) proteins have been proposed to form heteromers that function as sour taste receptors in mammals. Here, we show that PKD1L3 and PKD2L1 interact through their transmembrane domains, and not through the coiled-coil domain, by coimmunoprecipitation experiments using a series of deletion mutants. Deletion mutants lacking the critical interaction region were not transported to the cell surface and remained in the cytoplasm, whereas PKD1L3 and PKD2L1 proteins were expressed at the cell surface when both are transfected. Calcium imaging analysis revealed that neither the coiled-coil domain nor the EF-hand domain located in the C-terminal cytoplasmic tail of PKD2L1 was required for response on stimulation with an acidic solution. Finally, PKD2L1 did not localize to the taste pore but was distributed throughout the cytoplasm in taste cells of circumvallate and foliate papillae in PKD1L3(-/-) mice, whereas it localized to the taste pore in wild-type mice. Collectively, these results suggest that the interaction between PKD1L3 and PKD2L1 through their transmembrane domains is essential for proper trafficking of the channels to the cell surface in taste cells of circumvallate and foliate papillae and in cultured cells.-Ishimaru, Y., Katano, Y., Yamamoto, K., Akiba, M., Misaka, T., Roberts, R. W., Asakura, T., Matsunami, H., Abe, K. Interaction between PKD1L3 and PKD2L1 through their transmembrane domains is required for localization of PKD2L1 at taste pores in taste cells of circumvallate and foliate papillae. FASEB J. 24, 4058-4067 (2010). www.fasebj.org	[Ishimaru, Yoshiro; Abe, Keiko] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; [Ishimaru, Yoshiro; Roberts, Richard W.; Matsunami, Hiroaki] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA	University of Tokyo; Duke University	Ishimaru, Y (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	ayishi@mail.ecc.u-tokyo.ac.jp; aka7308@mail.ecc.u-tokyo.ac.jp	Ishimaru, Yoshiro/AAI-3049-2020	Misaka, Takumi/0000-0002-9547-5767	Japan Ministry of Education, Culture, Sports, Science, and Technology [20780089, 16108004, 20380183]; Kao Foundation for Arts and Sciences; Nestle Nutrition Council; Salt Science Research Foundation [0915]; U.S. National Institutes of Health [R21 DC008967]; Research and Development Program for New Bioindustry Initiatives; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R21DC008967, R01DC005782] Funding Source: NIH RePORTER	Japan Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kao Foundation for Arts and Sciences; Nestle Nutrition Council(Nestle SA); Salt Science Research Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research and Development Program for New Bioindustry Initiatives; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	The authors are grateful to Cheryl Bock and Mei Lang Flowers (Duke Transgenic Mouse Facility) for microinjection of the DNA construct into embryonic stem cells and to Frederick W. Alt (Harvard Medical School, Boston, MA, USA) for the EF1 embryonic stem cell line. The authors also thank Qiuyi Chi and Taeko Fukuda for expert technical assistance and members of the Taste Science and Abe laboratories for critical readings of the manuscript. This work was supported in part by Japan Ministry of Education, Culture, Sports, Science, and Technology Grant-in-Aid for Young Scientists (B) 20780089 to Y.I. and Grants-in-Aid for Scientific Research 16108004 and 20380183 to K.A.; a Kao Foundation for Arts and Sciences grant to Y.I.; a Nestle Nutrition Council grant to Y.I.; a Salt Science Research Foundation grant (0915) to Y.I; a U.S. National Institutes of Health grant (R21 DC008967) to H.M.; and a Research and Development Program for New Bioindustry Initiatives grant to K.A.	Asano-Miyoshi M, 2001, CHEM SENSES, V26, P259, DOI 10.1093/chemse/26.3.259; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Casuscelli J, 2009, AM J PHYSIOL-RENAL, V297, pF1310, DOI 10.1152/ajprenal.00412.2009; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Clapp TR, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-6; Dai XQ, 2007, MOL PHARMACOL, V72, P1576, DOI 10.1124/mol.107.037150; Dai XQ, 2006, BBA-BIOMEMBRANES, V1758, P197, DOI 10.1016/j.bbamem.2006.01.020; Delmas P, 2004, BIOCHEM BIOPH RES CO, V322, P1374, DOI 10.1016/j.bbrc.2004.08.044; Erler I, 2006, J BIOL CHEM, V281, P38396, DOI 10.1074/jbc.M607756200; Gao N, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-20; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Huang AL, 2006, NATURE, V442, P934, DOI [10.1038/nature05084, 10.1038/nature050084]; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; Inada H, 2008, EMBO REP, V9, P690, DOI 10.1038/embor.2008.89; Ishii S, 2009, BIOCHEM BIOPH RES CO, V385, P346, DOI 10.1016/j.bbrc.2009.05.069; Ishimaru Y, 2009, J DENT RES, V88, P212, DOI 10.1177/0022034508330212; Ishimaru Y, 2006, P NATL ACAD SCI USA, V103, P12569, DOI 10.1073/pnas.0602702103; Ishimaru Y, 2009, ODONTOLOGY, V97, P1, DOI 10.1007/s10266-008-0095-y; Kataoka S, 2008, CHEM SENSES, V33, P243, DOI 10.1093/chemse/bjm083; Kawaguchi H, 2010, J BIOL CHEM, V285, P17277, DOI 10.1074/jbc.C110.132944; Li AR, 2003, GENOMICS, V81, P596, DOI 10.1016/S0888-7543(03)00048-X; Li Q, 2002, FEBS LETT, V516, P270, DOI 10.1016/S0014-5793(02)02513-9; Li Q, 2007, J NEUROCHEM, V103, P2391, DOI 10.1111/j.1471-4159.2007.04940.x; LopezJimenez ND, 2006, J NEUROCHEM, V98, P68, DOI 10.1111/j.1471-4159.2006.03842.x; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Murakami M, 2005, J BIOL CHEM, V280, P5626, DOI 10.1074/jbc.M411496200; Nauli SM, 2004, BIOESSAYS, V26, P844, DOI 10.1002/bies.20069; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nauli SM, 2008, CIRCULATION, V117, P1161, DOI 10.1161/CIRCULATIONAHA.107.710111; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Phelps CB, 2007, J BIOL CHEM, V282, P36474, DOI 10.1074/jbc.M707205200; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Sharif-Naeini R, 2009, CELL, V139, P587, DOI 10.1016/j.cell.2009.08.045; Shimizu T, 2009, PFLUG ARCH EUR J PHY, V457, P795, DOI 10.1007/s00424-008-0558-6; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Tsuruda PR, 2006, NEURON, V51, P201, DOI 10.1016/j.neuron.2006.06.023; Yarmolinsky DA, 2009, CELL, V139, P234, DOI 10.1016/j.cell.2009.10.001; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0	41	29	32	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					4058	4067		10.1096/fj.10-162925	http://dx.doi.org/10.1096/fj.10-162925			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20538909	Green Published			2022-12-28	WOS:000285005900041
J	Caubet, C; Bousset, L; Clemmensen, O; Sourigues, Y; Bygum, A; Chavanas, S; Coudane, F; Hsu, CY; Betz, RC; Melki, R; Simon, M; Serre, G				Caubet, Cecile; Bousset, Luc; Clemmensen, Ole; Sourigues, Yannick; Bygum, Anette; Chavanas, Stephane; Coudane, Fanny; Hsu, Chiung-Yueh; Betz, Regina C.; Melki, Ronald; Simon, Michel; Serre, Guy			A new amyloidosis caused by fibrillar aggregates of mutated corneodesmosin	FASEB JOURNAL			English	Article						skin; keratinocytes; adhesion; conformational disease; protein misfolding	HEREDITARY HYPOTRICHOSIS SIMPLEX; LOCALIZED CUTANEOUS AMYLOIDOSIS; EPIDERMOLYSIS-BULLOSA SIMPLEX; PALMOPLANTAR KERATODERMA; COMMON MECHANISM; V2 DOMAIN; IN-VITRO; PROTEIN; MUTATIONS; SCALP	Heterozygous nonsense mutations in the CDSN gene encoding corneodesmosin (CDSN), an adhesive protein expressed in cornified epithelia and hair follicles, cause hypotrichosis simplex of the scalp (HSS), a nonsyndromic form of alopecia. Truncated mutants of CDSN ((CDSN)-C-mut), which bear the N-terminal adhesive Gly/Ser-rich domain (GS domain) of the protein, abnormally accumulate as amorphous deposits at the periphery of hair follicles and in the papillary dermis of the patient skin. Here, we present evidence that the (CDSN)-C-mut deposits display an affinity for amyloidophilic dyes, namely Congo red and thioflavin T. We also detected the serum amyloid protein component in the dermis of HSS patients. We demonstrated that recombinant forms of (CDSN)-C-mut and of the GS domain assemble in vitro into ring-shaped oligomeric structures and fibrils. The amyloid-like nature of the fibrils was demonstrated by dye binding and Fourier transform infrared spectrometry measurements. We showed that the ring-shaped oligomers of (CDSN)-C-mut, but not the fibrillar forms, are toxic to cultured keratinocytes. Finally, online algorithms predicted the GS domain to be a particularly disordered region of CDSN in agreement with circular dichroism measurements. This identifies HSS as a human amyloidosis related to the aggregation of natively unfolded (CDSN)-C-mut polypeptides into amyloid fibrils.-Caubet, C., Bousset, L., Clemmensen, O., Sourigues, Y., Bygum, A., Chavanas, S., Coudane, F., Hsu, C.-Y., Betz, R. C., Melki, R., Simon, M., Serre, G. A new amyloidosis caused by fibrillar aggregates of mutated corneodesmosin. FASEB J. 24, 3416-3426 (2010). www.fasebj.org	[Bousset, Luc; Sourigues, Yannick; Melki, Ronald] CNRS, Lab Enzymol & Biochim Struct, UPR3082, F-91198 Gif Sur Yvette, France; [Caubet, Cecile; Chavanas, Stephane; Coudane, Fanny; Hsu, Chiung-Yueh; Simon, Michel; Serre, Guy] Univ Toulouse 3, Inst Fed Rech IFR150, Ctr Hosp Univ, INSERM,CNRS,UMR5165, Toulouse, France; [Clemmensen, Ole] Odense Univ Hosp, Dept Clin Pathol, Odense, Denmark; [Bygum, Anette] Odense Univ Hosp, Dept Dermatol, Odense, Denmark; [Betz, Regina C.] Univ Bonn, Inst Human Genet, D-5300 Bonn, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Bonn	Melki, R (corresponding author), CNRS, Lab Enzymol & Biochim Struct, UPR3082, Batiment 34,Ave Terrasse, F-91198 Gif Sur Yvette, France.	melki@lebs.cnrs-gif.fr; serre@udear.cnrs.fr	Simon, Michel/B-7308-2011; Chavanas, stephane/K-1183-2014; Betz, Regina C/E-8591-2011	Simon, Michel/0000-0003-3655-6329; Betz, Regina C/0000-0001-5024-3623; bousset, luc/0000-0002-0433-4337; chavanas, stephane/0000-0003-4323-2656; HSU, Chiung-Yueh/0000-0002-4671-0919; Bygum, Anette/0000-0002-3004-0180	CNRS; INSERM; Toulouse III University; Toulouse University Hospital; Alopecia Areata Association; ANR [ANR-06-BLAN-0266]; German Research Foundation (DFG)	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Toulouse III University; Toulouse University Hospital; Alopecia Areata Association; ANR(French National Research Agency (ANR)); German Research Foundation (DFG)(German Research Foundation (DFG))	The authors thank Peter Faller (Laboratoire de Chimie de Coordination, CNRS UPR8241, Toulouse, France) for putting the Safas SP 2000 spectrofluorimeter at our disposal, Bruno Payre (Centre de Microscopie Electronique Appliquee a la Biologie, University of Toulouse III) for the use of the electron microscope, the IMAGIF facility for the use of the Jeol 1400 TEM, and Sophie Allard from the confocal microscopy facility (INSERM, IFR150). This work was supported by grants from CNRS, INSERM, Toulouse III University, Toulouse University Hospital, and the Alopecia Areata Association. L. B., Y.S., and R. M. are supported by CNRS and ANR (contract ANR-06-BLAN-0266). R. C. B. is a recipient of an Emmy Noether Grant from the German Research Foundation (DFG).	Apaydin R, 2004, J EUR ACAD DERMATOL, V18, P305, DOI 10.1111/j.1468-3083.2004.00905.x; Arita K, 2008, AM J HUM GENET, V82, P73, DOI 10.1016/j.ajhg.2007.09.002; Baglioni S, 2006, J NEUROSCI, V26, P8160, DOI 10.1523/JNEUROSCI.4809-05.2006; Bousset L, 2004, BIOCHEMISTRY-US, V43, P5022, DOI 10.1021/bi049828e; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Buxbaum JN, 2003, TRENDS BIOCHEM SCI, V28, P585, DOI 10.1016/j.tibs.2003.09.009; Caubet C, 2004, J INVEST DERMATOL, V122, P747, DOI 10.1111/j.0022-202X.2004.22331.x; Chang YT, 2004, ARCH DERMATOL RES, V296, P83, DOI 10.1007/s00403-004-0474-3; Chiang YY, 2008, BRIT J DERMATOL, V159, P1370, DOI 10.1111/j.1365-2133.2008.08801.x; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Davalos NO, 2005, BRIT J DERMATOL, V153, P1216, DOI 10.1111/j.1365-2133.2005.06958.x; Dosztanyi Z, 2005, BIOINFORMATICS, V21, P3433, DOI 10.1093/bioinformatics/bti541; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Fox Jeffrey D, 2003, Methods Mol Biol, V205, P99; Gu LH, 2003, J INVEST DERMATOL, V121, P482, DOI 10.1046/j.1523-1747.2003.12424.x; Guerrin M, 1998, J BIOL CHEM, V273, P22640, DOI 10.1074/jbc.273.35.22640; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Jonca N, 2002, J BIOL CHEM, V277, P5024, DOI 10.1074/jbc.M108438200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Khurana R, 2001, J BIOL CHEM, V276, P22715, DOI 10.1074/jbc.M011499200; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; KOBAYASHI H, 1983, J INVEST DERMATOL, V80, P66, DOI 10.1111/1523-1747.ep12531130; KOHN G, 1987, CLIN GENET, V32, P120; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Leclerc EA, 2009, J CELL SCI, V122, P2699, DOI 10.1242/jcs.050302; LESLIE AGW, 1992, JNT CCP4 ESF EAMCB N, V26, P27; Levy-Nissenbaum E, 2003, NAT GENET, V34, P151, DOI 10.1038/ng1163; Lugassy J, 2006, AM J HUM GENET, V79, P724, DOI 10.1086/507792; Lutz ME, 2002, J AM ACAD DERMATOL, V46, P434, DOI 10.1067/mjd.2002.110660; MASU SI, 1981, ACTA DERM-VENEREOL, V61, P381; Matsumoto M, 2008, P NATL ACAD SCI USA, V105, P6720, DOI 10.1073/pnas.0709345105; Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012; Richardson ES, 2006, J INVEST DERMATOL, V126, P79, DOI 10.1038/sj.jid.5700025; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; Simon M, 2001, J BIOL CHEM, V276, P20292, DOI 10.1074/jbc.M100201200; Simon M, 1997, J BIOL CHEM, V272, P31770, DOI 10.1074/jbc.272.50.31770; Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; Terrinoni A, 2000, J INVEST DERMATOL, V114, P1136, DOI 10.1046/j.1523-1747.2000.00983.x; TORIBIO J, 1974, BRIT J DERMATOL, V91, P687, DOI 10.1111/j.1365-2133.1974.tb12455.x; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Whittock NV, 2002, J INVEST DERMATOL, V118, P838, DOI 10.1046/j.1523-1747.2002.01750.x	45	20	22	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3416	3426		10.1096/fj.10-155622	http://dx.doi.org/10.1096/fj.10-155622			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20448140				2022-12-28	WOS:000281446400029
J	Yi, H; Xue, L; Guo, MX; Ma, JA; Zeng, Y; Wang, W; Cai, JY; Hu, HM; Shu, HB; Shi, YB; Li, WX				Yi, Hong; Xue, Lu; Guo, Ming-Xiong; Ma, Jian; Zeng, Yan; Wang, Wei; Cai, Jin-Yang; Hu, Hai-Ming; Shu, Hong-Bing; Shi, Yun-Bo; Li, Wen-Xin			Gene expression atlas for human embryogenesis	FASEB JOURNAL			English	Article						human embryonic development; gene regulation database; organogenesis; microarrays; maternal genes	HUMAN OOCYTES; TRANSCRIPTOME; FEATURES; ZNF268	Human embryogenesis is believed to involve an integrated set of complex yet coordinated development of different organs and tissues mediated by the changes in the spatiotemporal expression of many genes. Here, we report a genome-wide expression analysis during wk 4-9 of human embryogenesis, a critical period when most organs develop. About half of all human genes are expressed, and 18.6% of the expressed genes were significantly regulated during this important period. We further identified >5000 regulated genes, most of which previously were not known to be associated with animal development. Our study fills an important gap in mammalian developmental studies by identifying functional pathways involved in this critical but previously not studied period. Our study also revealed that the genes involved here are distinct from those during early embryogenesis, which include three groups of maternal genes. Furthermore, we discovered that genes in a given developmental process are regulated coordinately. This led us to develop an easily searchable database of this entire collection of gene expression profiles, allowing for the identification new genes important for a particular developmental process/pathway and deducing the potential function of a novel gene. The validity of the predictions from the database was demonstrated with two examples through spatiotemporal analyses of the two novel genes. Such a database should serve as a highly valuable resource for the molecular analysis of human development and pathogenesis.-Yi, H., Xue, L., Guo, M.-X. Ma, J., Zeng, Y., Wang, W., Cai, J.-Y. Hu, H.-M., Shu, H.-B. Shi, Y.-B., Li, W.-X. Gene expression atlas for human embryogenesis. FASEB J. 24, 3341-3350 (2010). www.fasebj.org	[Li, Wen-Xin] Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China; [Shi, Yun-Bo] NICHHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Wuhan University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Li, WX (corresponding author), Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China.	shi@helix.nih.gov; liwxlab@whu.edu.cn	Cai, Jinyang/HCH-0290-2022	Shi, Yun-Bo/0000-0002-6330-0639; Cai, Jinyang/0000-0002-7385-8281; Wang, Wei/0000-0001-7429-1013	National High Technology Research and Development Program of China (863 Program) [2006AA02A306]; National Natural Science Foundation of China [30871245]; Program of Introducing Talents of Discipline to Universities [B06018]; National Institute of Child Health and Human Development, National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER	National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Introducing Talents of Discipline to Universities(Ministry of Education, China - 111 Project); National Institute of Child Health and Human Development, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by National High Technology Research and Development Program of China (863 Program) grant 2006AA02A306, National Natural Science Foundation of China grant 30871245, Program of Introducing Talents of Discipline to Universities grant B06018. Y.-B. S. was supported by the National Institute of Child Health and Human Development Intramural Research Program, National Institutes of Health.	Arbeitman MN, 2002, SCIENCE, V297, P2270, DOI 10.1126/science.1072152; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Assou S, 2006, HUM REPROD, V21, P1705, DOI 10.1093/humrep/del065; Bermudez M, 2004, REPROD BIOMED ONLINE, V8, P325, DOI 10.1016/S1472-6483(10)60913-3; Cai JL, 2005, HUM MOL GENET, V14, P903, DOI 10.1093/hmg/ddi083; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; DARBY IA, 2000, SITU HYBRIDIZATION P; Dobson AT, 2004, HUM MOL GENET, V13, P1461, DOI 10.1093/hmg/ddh157; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Gaskell TL, 2004, BIOL REPROD, V71, P2012, DOI 10.1095/biolreprod.104.028381; Gou DM, 2001, GENE, V278, P141, DOI 10.1016/S0378-1119(01)00701-6; Gou DM, 2001, BBA-GENE STRUCT EXPR, V1518, P306, DOI 10.1016/S0167-4781(01)00194-4; Gu LH, 2007, CURR OPIN CELL BIOL, V19, P13, DOI 10.1016/j.ceb.2006.12.007; Guo MX, 2006, J BIOL CHEM, V281, P24623, DOI 10.1074/jbc.M602753200; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hill MA, 2007, CLIN OBSTET GYNECOL, V50, P2, DOI 10.1097/GRF.0b013e31802f119d; Horsford DJ, 2005, DEVELOPMENT, V132, P177, DOI 10.1242/dev.01571; Kennedy BN, 2004, DEV BIOL, V270, P336, DOI 10.1016/j.ydbio.2004.02.026; Kocabas AM, 2006, P NATL ACAD SCI USA, V103, P14027, DOI 10.1073/pnas.0603227103; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Li SSL, 2006, BIOCHEM BIOPH RES CO, V340, P48, DOI 10.1016/j.bbrc.2005.11.149; Lindsay S, 2005, TRENDS GENET, V21, P586, DOI 10.1016/j.tig.2005.08.011; LIU B, 1996, HUMAN EMBRYOLOGY; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; Piper K, 2004, J ENDOCRINOL, V181, P11, DOI 10.1677/joe.0.1810011; Salomonis N, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-217; Sarma S, 2005, BRAIN RES BULL, V66, P449, DOI 10.1016/j.brainresbull.2005.05.022; Schug J, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-4-r33; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Wang YP, 2002, NAT NEUROSCI, V5, P831, DOI 10.1038/nn911; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28; Zhang Wen, 2004, J Biol, V3, P21, DOI 10.1186/jbiol16	33	32	32	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3341	3350		10.1096/fj.10-158782	http://dx.doi.org/10.1096/fj.10-158782			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20430792	Green Published			2022-12-28	WOS:000281446400022
J	Armstrong, JS; Khdour, O; Hecht, SM				Armstrong, Jeffrey S.; Khdour, Omar; Hecht, Sidney M.			Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question	FASEB JOURNAL			English	Review						frataxin; hydrogen peroxide; superoxide; hydroxyl radical; antioxidants	SULFUR CLUSTER BIOSYNTHESIS; OXYGEN SPECIES GENERATION; MITOCHONDRIAL IRON; FRATAXIN DEFICIENCY; COMPLEX-I; YEAST FRATAXIN; GLUTATHIONE DEPLETION; LIPID-PEROXIDATION; SUPEROXIDE ANION; OXIDANT STRESS	Friedreich's ataxia (FRDA) is a hereditary neurodegenerative disease that frequently culminates in cardiac failure at an early age. FRDA is believed to arise from reduced synthesis of the mitochondrial iron chaperone frataxin due to impaired gene transcription, which leads to mitochondrial iron accumulation, dysfunction of mitochondrial Fe-S containing enzymes, and increased Fenton-mediated free radical production. Recent reports have challenged this generally accepted hypothesis, by suggesting that the oxidative stress component in FRDA is minimal and thereby questioning the benefit of antioxidant therapeutic strategies. We suggest that this apparent paradox results from the radically divergent chemistries of the participating reactive oxygen species (ROS), the major cellular subcompartments involved and the overall cellular responses to ROS. In this review, we consider these factors and conclude that oxidative stress does constitute a major contributing factor to FRDA pathology. This reaffirms the idea that the rational design of specific small molecule multifunctional antioxidants will benefit FRDA patients.-Armstrong, J. S., Khdour, O., Hecht, S. M. Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question. FASEB J. 24, 2152-2163 (2010). www.fasebj.org	[Armstrong, Jeffrey S.; Khdour, Omar; Hecht, Sidney M.] Arizona State Univ, Ctr BioEnerget, Biodesign Inst, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Armstrong, JS (corresponding author), Arizona State Univ, Ctr BioEnerget, Biodesign Inst, Tempe, AZ 85287 USA.	jeffrey.armstrong@asu.edu		Khdour, Omar/0000-0001-6428-8195				Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Adinolfi S, 2009, NAT STRUCT MOL BIOL, V16, P390, DOI 10.1038/nsmb.1579; Anderson PR, 2008, P NATL ACAD SCI USA, V105, P611, DOI 10.1073/pnas.0709691105; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; Auchere F, 2008, HUM MOL GENET, V17, P2790, DOI 10.1093/hmg/ddn178; Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; Bou-Abdallah F, 2005, J MOL BIOL, V347, P543, DOI 10.1016/j.jmb.2005.01.007; Bou-Abdallah F, 2004, J MOL BIOL, V341, P605, DOI 10.1016/j.jmb.2004.05.072; Boveris A, 2000, IUBMB LIFE, V50, P245, DOI 10.1080/15216540051080912; Bulteau AL, 2007, FREE RADICAL BIO MED, V42, P1561, DOI 10.1016/j.freeradbiomed.2007.02.014; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Campanella A, 2009, HUM MOL GENET, V18, P1, DOI 10.1093/hmg/ddn308; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Catala A, 2009, CHEM PHYS LIPIDS, V157, P1, DOI 10.1016/j.chemphyslip.2008.09.004; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; Cooper JM, 2008, EUR J NEUROL, V15, P1371, DOI 10.1111/j.1468-1331.2008.02318.x; Cossee M, 1999, ANN NEUROL, V45, P200, DOI 10.1002/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U; Dalle-Donne I, 2007, FREE RADICAL BIO MED, V43, P883, DOI 10.1016/j.freeradbiomed.2007.06.014; Fleming J, 2005, HUM GENE THER, V16, P947, DOI 10.1089/hum.2005.16.947; Fontecave M, 2008, ARCH BIOCHEM BIOPHYS, V474, P226, DOI 10.1016/j.abb.2007.12.014; Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; Grange PA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000527; GUSKOVA RA, 1984, BIOCHIM BIOPHYS ACTA, V778, P579, DOI 10.1016/0005-2736(84)90409-7; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; Halliwell B, 1988, FREE RADICALS BIOL M; Han D, 2003, MOL PHARMACOL, V64, P1136, DOI 10.1124/mol.64.5.1136; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Han D, 2002, METHOD ENZYMOL, V349, P271, DOI 10.1016/S0076-6879(02)49341-X; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Herman D, 2006, NAT CHEM BIOL, V2, P551, DOI 10.1038/nchembio815; Herrero E, 2007, CELL MOL LIFE SCI, V64, P1518, DOI 10.1007/s00018-007-6554-8; Huang MLH, 2009, P NATL ACAD SCI USA, V106, P16381, DOI 10.1073/pnas.0906784106; Huang TT, 1999, ANN NY ACAD SCI, V893, P95, DOI 10.1111/j.1749-6632.1999.tb07820.x; Isaya G, 2004, ACTA PAEDIATR, V93, P68, DOI 10.0180/08035320310021318; Jiralerspong S, 2001, FEBS LETT, V509, P101, DOI 10.1016/S0014-5793(01)03140-4; JOURDHEUIL D, 1997, FRONT BIOSCI, V2, P189; Kakhlon O, 2008, BLOOD, V112, P5219, DOI 10.1182/blood-2008-06-161919; King MS, 2009, BIOCHEMISTRY-US, V48, P2053, DOI 10.1021/bi802282h; Koutnikova H, 1998, HUM MOL GENET, V7, P1485, DOI 10.1093/hmg/7.9.1485; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; Lodi R, 2006, ANTIOXID REDOX SIGN, V8, P438, DOI 10.1089/ars.2006.8.438; Lu CY, 2007, ARCH BIOCHEM BIOPHYS, V457, P111, DOI 10.1016/j.abb.2006.09.010; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Napoli E, 2006, ANTIOXID REDOX SIGN, V8, P506, DOI 10.1089/ars.2006.8.506; Nichol H, 2003, BIOCHEMISTRY-US, V42, P5971, DOI 10.1021/bi027021l; Nohl H, 2005, BIOCHEM PHARMACOL, V69, P719, DOI 10.1016/j.bcp.2004.12.002; O'Neill HA, 2005, BIOCHEMISTRY-US, V44, P537, DOI 10.1021/bi048459j; Palau F, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-47; Pandolfo M, 2002, MITOCHONDRION, V2, P87, DOI 10.1016/S1567-7249(02)00039-9; Pandolfo M, 2009, J NEUROL, V256, P3, DOI 10.1007/s00415-009-1002-3; Park S, 2002, J BIOL CHEM, V277, P38589, DOI 10.1074/jbc.M206711200; Pastore A, 2003, J BIOL CHEM, V278, P42588, DOI 10.1074/jbc.M301872200; Paupe V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004253; Popescu BFG, 2007, J INORG BIOCHEM, V101, P957, DOI 10.1016/j.jinorgbio.2007.03.004; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Puccio H, 2009, J NEUROL, V256, P18, DOI 10.1007/s00415-009-1004-1; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Rai M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001958; Reboucas JS, 2008, J PHARMACEUT BIOMED, V48, P1046, DOI 10.1016/j.jpba.2008.08.005; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Santos MM, 2001, HUM MOL GENET, V10, P1935, DOI 10.1093/hmg/10.18.1935; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23; Schulz JB, 2000, NEUROLOGY, V55, P1719, DOI 10.1212/WNL.55.11.1719; Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042; Shan YX, 2007, HUM MOL GENET, V16, P929, DOI 10.1093/hmg/ddm038; Stehling O, 2004, HUM MOL GENET, V13, P3007, DOI 10.1093/hmg/ddh324; Sturm B, 2005, EUR J CLIN INVEST, V35, P711, DOI 10.1111/j.1365-2362.2005.01568.x; Sturm B, 2005, J BIOL CHEM, V280, P6701, DOI 10.1074/jbc.M408717200; Tan G, 2001, HUM MOL GENET, V10, P2099, DOI 10.1093/hmg/10.19.2099; Tan GL, 2003, HUM MOL GENET, V12, P1699, DOI 10.1093/hmg/ddg187; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vazquez-Manrique RP, 2005, FASEB J, V19, P172, DOI 10.1096/fj.05-4212fje; Walker DW, 2006, P NATL ACAD SCI USA, V103, P16382, DOI 10.1073/pnas.0607918103; Wang T, 2008, J BIOL CHEM, V283, P12674, DOI 10.1074/jbc.M800399200; Whitnall M, 2008, P NATL ACAD SCI USA, V105, P9757, DOI 10.1073/pnas.0804261105; Wilson RB, 2003, J NEUROL SCI, V207, P103, DOI 10.1016/S0022-510X(02)00432-X; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Yoon T, 2007, J BIOL INORG CHEM, V12, P535, DOI 10.1007/s00775-007-0205-2; Zanella I, 2008, BBA-MOL BASIS DIS, V1782, P90, DOI 10.1016/j.bbadis.2007.11.006; Zarse K, 2007, FASEB J, V21, P1271, DOI 10.1096/fj.06-6994com; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	101	85	90	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2152	2163		10.1096/fj.09-143222	http://dx.doi.org/10.1096/fj.09-143222			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20219987				2022-12-28	WOS:000279343600003
J	Cat, AND; Griol-Charhbili, V; Loufrani, L; Labat, C; Benjamin, L; Farman, N; Lacolley, P; Henrion, D; Jaisser, F				Cat, Aurelie Nguyen Dinh; Griol-Charhbili, Violaine; Loufrani, Laurent; Labat, Carlos; Benjamin, Laura; Farman, Nicolette; Lacolley, Patrick; Henrion, Daniel; Jaisser, Frederic			The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure	FASEB JOURNAL			English	Article						aldosterone; hypertension; myoendothelial crosstalk	SPONTANEOUSLY HYPERTENSIVE-RAT; ACTIVATED POTASSIUM CHANNELS; RENIN-ANGIOTENSIN SYSTEM; VASCULAR SMOOTH-MUSCLE; OXIDATIVE STRESS; TRANSGENIC MICE; HEART-FAILURE; ALDOSTERONE; EXPRESSION; KIDNEY	Pathophysiological aldosterone (aldo)/mineralocorticoid receptor (MR) signaling has significant effects on the cardiovascular system, resulting in hypertension and cardiovascular remodeling; however, the specific contribution of the vascular MR to blood pressure regulation remains to be established. To address this question, we generated a mouse model with conditional overexpression of the MR in endothelial cells (MR-EC). In basal conditions, MR-EC mice developed moderate hypertension that could be reversed by canrenoate, a pharmacological MR antagonist. MR-EC mice presented increased contractile response of resistance arteries to vaso-constrictors ( phenylephrine, thromboxane A(2) analog, angiotensin II, and endothelin 1) in the absence of vascular morphological alterations. The acute blood pressure response to angiotensin II or endothelin 1 infusion was increased in MR-EC mice compared with that in littermate controls. These observations demonstrate that enhanced MR activation in the endothelium generates an increase in blood pressure, independent of stimulation of renal tubular Na+ transport by aldo/MR or direct activation of smooth muscle MR and establish one mechanism by which endothelial MR activation per se may contribute to impaired vascular reactivity.-Nguyen Dinh Cat, A., Griol-Charhbili, V., Loufrani, L., Labat, C., Benjamin, L., Farman, N., Lacolley, P., Henrion, D., and Jaisser, F. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 24, 2454-2463 (2010). www.fasebj.org	[Jaisser, Frederic] Ctr Rech Cordeliers, INSERM, UMRS 872, Team 1,U872, F-75006 Paris, France; [Cat, Aurelie Nguyen Dinh; Griol-Charhbili, Violaine; Farman, Nicolette; Jaisser, Frederic] Univ Paris 06, Paris, France; [Loufrani, Laurent; Henrion, Daniel] Fac Med, CNRS, INSERM, UMR, Angers, France; [Labat, Carlos; Lacolley, Patrick] Fac Med Vandoeuvre Nancy, INSERM, U961, F-54505 Vandoeuvre Les Nancy, France; [Labat, Carlos; Lacolley, Patrick] Henri Poincare Univ, Nancy, France; [Benjamin, Laura] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Benjamin, Laura] Harvard Univ, Sch Med, Boston, MA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Universite de Lorraine; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Jaisser, F (corresponding author), Ctr Rech Cordeliers, INSERM, UMRS 872, Team 1,U872, 15 Rue Ecole Med, F-75006 Paris, France.	frederic.jaisser@crc.jussieu.fr	Henrion, Daniel/J-8141-2015; Henrion, Daniel/N-7023-2015; loufrani, laurent/K-1713-2015; Labat, Carlos/F-7492-2010; Jaisser, Frederic/P-4287-2017; Lacolley, Patrick/G-3118-2013; Henrion, Daniel/AAK-1995-2021; CAT, Aurelie NGUYEN DINH/H-8182-2013	Henrion, Daniel/0000-0003-1094-0285; Henrion, Daniel/0000-0003-1094-0285; Labat, Carlos/0000-0002-5275-3405; Jaisser, Frederic/0000-0001-9051-1901; Henrion, Daniel/0000-0003-1094-0285; 	Agence Nationale pour la Recherche [ANR005-PCOD005, ANR-09-BLAN-0156-01]; GENZYME; European Section of the Aldosterone Concil (ESAC); Leducq Fondation (Transatlantic Network of Excellence in Cardiovascular Disease); Fondation de France; Centre de Recherche Industrielle et Technique	Agence Nationale pour la Recherche(French National Research Agency (ANR)); GENZYME(Sanofi-AventisGenzyme Corporation); European Section of the Aldosterone Concil (ESAC); Leducq Fondation (Transatlantic Network of Excellence in Cardiovascular Disease); Fondation de France(Fondation de France); Centre de Recherche Industrielle et Technique	The authors are highly indebted to N. Panek-Huet for her major contribution in animal handling; S. Messaoudi, J. Faugeroux, S. El Moghrabi, and M. Muffat-Joly and the Centre d'Explorations Fonctionnelles Integrees at Bichat Federative Research Institute 02 helped with phenotypic characterization. A.N.D.C. held a Ph.D. grant from INSERM/Conseil Regional Ile de France; V.G.-C. held a Lefoulon-Delalande fellowship. This work was supported by grants from the Agence Nationale pour la Recherche (ANR005-PCOD005 and ANR-09-BLAN-0156-01), the GENZYME Research Innovation Program, the European Section of the Aldosterone Concil (ESAC), the Leducq Fondation (Transatlantic Network of Excellence in Cardiovascular Disease), the Fondation de France, and the Centre de Recherche Industrielle et Technique. The authors report no conflicts of interest.	Adler GK, 2007, HYPERTENSION, V50, P31, DOI 10.1161/HYPERTENSIONAHA.107.090894; Ambroisine ML, 2007, CIRCULATION, V116, P2435, DOI 10.1161/CIRCULATIONAHA.107.722009; Bichara M, 2006, GLYCOBIOLOGY, V16, P36, DOI 10.1093/glycob/cwj035; Cat AND, 2009, ENDOCRINOLOGY, V150, P2202, DOI 10.1210/en.2008-1531; Cat AND, 2009, HYPERTENSION, V54, pE126; Crowley SD, 2005, J CLIN INVEST, V115, P1092, DOI 10.1172/JCI200523378; Crowley SD, 2006, P NATL ACAD SCI USA, V103, P17985, DOI 10.1073/pnas.0605545103; Delano FA, 2004, MICROCIRCULATION, V11, P69, DOI 10.1080/10739680490266207; Farman N, 2001, AM J PHYSIOL-RENAL, V280, pF181, DOI 10.1152/ajprenal.2001.280.2.F181; Feletou M, 2009, BRIT J PHARMACOL, V156, P545, DOI 10.1111/j.1476-5381.2009.00052.x; Funder JW, 2007, AM J CARDIOVASC DRUG, V7, P151, DOI 10.2165/00129784-200707030-00001; Gomez-Sanchez CE, 2006, ENDOCRINOLOGY, V147, P1343, DOI 10.1210/en.2005-0860; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; Iglarz M, 2004, AM J HYPERTENS, V17, P597, DOI 10.1016/j.amjhyper.2004.04.005; Iwamoto T, 2004, NAT MED, V10, P1193, DOI 10.1038/nm1118; Konishi A, 2003, J STEROID BIOCHEM, V85, P439, DOI 10.1016/S0960-0760(03)00198-5; Ledoux J, 2006, PHYSIOLOGY, V21, P69, DOI 10.1152/physiol.00040.2005; Leopold JA, 2007, NAT MED, V13, P189, DOI 10.1038/nm1545; Loufrani L, 2002, CIRC RES, V91, P1183, DOI 10.1161/01.RES.0000047505.11002.81; Mercier N, 2006, CARDIOVASC RES, V72, P349, DOI 10.1016/j.cardiores.2006.08.008; Milik E, 2007, J PHYSIOL PHARMACOL, V58, P745; Montezano AC, 2008, HYPERTENSION, V52, P1016, DOI 10.1161/HYPERTENSIONAHA.108.121269; Mukai Y, 2006, J CLIN INVEST, V116, P334, DOI 10.1172/JCI26223; Nietlispach F, 2007, HYPERTENSION, V50, P82, DOI 10.1161/HYPERTENSIONAHA.107.088955; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Ohtani T, 2007, AM J PHYSIOL-REG I, V292, pR946, DOI 10.1152/ajpregu.00402.2006; Ouvrard-Pascaud A, 2005, CIRCULATION, V111, P3025, DOI 10.1161/CIRCULATIONAHA.104.503706; Park JB, 2001, HYPERTENSION, V37, P1444, DOI 10.1161/01.HYP.37.6.1444; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pu Q, 2003, HYPERTENSION, V42, P49, DOI 10.1161/01.HYP.0000078357.92682.EC; Quinkler M, 2005, CIRCULATION, V112, P1435, DOI 10.1161/CIRCULATIONAHA.105.539122; Sainte Marie Y, 2007, AM J PATHOL, V171, P846, DOI 10.2353/ajpath.2007.060991; Sato A, 2005, AM J HYPERTENS, V18, P44, DOI 10.1016/j.amjhyper.2004.06.029; Sato A, 2003, HYPERTENSION, V41, P64, DOI 10.1161/01.HYP.0000044937.95080.E9; Sausbier M, 2005, CIRCULATION, V112, P60, DOI 10.1161/01.CIR.0000156448.74296.FE; Si H, 2006, CIRC RES, V99, P537, DOI 10.1161/01.RES.0000238377.08219.0c; Skott O, 2006, PHARMACOL THERAPEUT, V111, P495, DOI 10.1016/j.pharmthera.2005.10.010; Struthers AD, 2004, MOL CELL ENDOCRINOL, V217, P239, DOI 10.1016/j.mce.2003.10.024; Takeda M, 2007, HYPERTENS RES, V30, P427, DOI 10.1291/hypres.30.427; Taylor MS, 2003, CIRC RES, V93, P124, DOI 10.1161/01.RES.0000081980.63146.69; Uhrenholt TR, 2003, CIRC RES, V93, P1258, DOI 10.1161/01.RES.0000106135.02935.E1; Virdis A, 2002, HYPERTENSION, V40, P504, DOI 10.1161/01.HYP.0000034738.79310.06; Wong S, 2007, ENDOCRINOLOGY, V148, P1511, DOI 10.1210/en.2006-0965	44	112	113	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2454	2463		10.1096/fj.09-147926	http://dx.doi.org/10.1096/fj.09-147926			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20299606				2022-12-28	WOS:000279343600032
J	Alzogaray, V; Danquah, W; Aguirre, A; Urrutia, M; Berguer, P; Vescovi, EG; Haag, F; Koch-Nolte, F; Goldbaum, FA				Alzogaray, Vanina; Danquah, Welbeck; Aguirre, Andres; Urrutia, Mariela; Berguer, Paula; Garcia Vescovi, Eleonora; Haag, Friedrich; Koch-Nolte, Friedrich; Goldbaum, Fernando A.			Single-domain llama antibodies as specific intracellular inhibitors of SpvB, the actin ADP-ribosylating toxin of Salmonella typhimurium	FASEB JOURNAL			English	Article						intrabodies; VHH; enzyme inhibition	VIRULENCE PLASMID; TUMOR-GROWTH; PROTEIN; INTRABODIES; SECRETION; ENZYME; POLYMERIZATION; IDENTIFICATION; CYTOPATHOLOGY; CYTOTOXICITY	ADP-ribosylation of host cell proteins is a common mode of cell intoxication by pathogenic bacterial toxins. Antibodies induced by immunization with inactivated ADP-ribosylating toxins provide efficient protection in case of some secreted toxins, e.g., diphtheria and pertussis toxins. However, other ADP-ribosylating toxins, such as Salmonella SpvB toxin, are secreted directly from the Salmonella-containing vacuole into the cytosol of target cells via the SPI-2 encoded bacterial type III secretion system, and thus are inaccessible to conventional antibodies. Small-molecule ADP-ribosylation inhibitors are fraught with potential side effects caused by inhibition of endogenous ADP-ribosyltransferases. Here, we report the development of a single-domain antibody from an immunized llama that blocks the capacity of SpvB to ADP-ribosylate actin at a molar ratio of 1:1. The single-domain antibody, when expressed as an intrabody, effectively protected cells from the cytotoxic activity of a translocation-competent chimeric C2IN-C/SpvB toxin. Transfected cells were also protected against cytoskeletal alterations induced by wild-type SpvB-expressing strains of Salmonella. This proof of principle paves the way for developing new antidotes against intracellular toxins.-Alzogaray, V., Danquah, W., Aguirre, A., Urrutia, M., Berguer, P., Garcia Vescovi, E., Haag, F., Koch-Nolte, F., Goldbaum, F. A. Single-domain llama antibodies as specific intracellular inhibitors of SpvB, the actin ADP-ribosylating toxin of Salmonella typhimurium. FASEB J. 25, 526-534 (2011). www.fasebj.org	[Alzogaray, Vanina; Urrutia, Mariela; Berguer, Paula; Goldbaum, Fernando A.] Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim Buenos Aires, Fdn Inst Leloir, RA-1405 Buenos Aires, DF, Argentina; [Danquah, Welbeck; Haag, Friedrich; Koch-Nolte, Friedrich] Univ Med Ctr, Inst Immunol, Hamburg, Germany; [Aguirre, Andres; Garcia Vescovi, Eleonora] Univ Nacl Rosario, Inst Biol Mol & Celular Rosario, RA-2000 Rosario, Santa Fe, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Hamburg; University Medical Center Hamburg-Eppendorf; National University of Rosario	Goldbaum, FA (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim Buenos Aires, Fdn Inst Leloir, Av Patricias Argentinas 435,C1405BWE, RA-1405 Buenos Aires, DF, Argentina.	fgoldbaum@leloir.org.ar	Berguer, Paula/AAI-6353-2020	Goldbaum, Fernando/0000-0001-6235-3002; Koch-Nolte, Friedrich/0000-0003-1730-6674; Garcia Vescovi, Eleonora/0000-0002-4431-8606; Urrutia, Mariela/0000-0002-5224-9735	Deutsche Forschungsgemeinschaft [310/4, 310/5]; Bundesministerium fur Wirtschafliche Zusammenarbeit; Fundacion YPF fellowship	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Wirtschafliche Zusammenarbeit; Fundacion YPF fellowship	This work was supported by grants 310/4 and 310/5 from the Deutsche Forschungsgemeinschaft and the Bundesministerium fur Wirtschafliche Zusammenarbeit to F.K.N. and F.G. The authors thank Fabienne Seyfried (Hamburg, Germany) for excellent technical assistance. The authors thank Drs. Bernhard Fleischer and Hans-Willi Mittrucker (Hamburg, Germany) for critical reading of the manuscript and for providing critical insight. V.A. is supported by a Fundacion YPF fellowship. The authors are grateful to Guillermo Vila Melo and Gonzalo Perez Zabala (Fundacion Biodiversidad, Buenos Aires, Argentina) for the helpful work with the immunizations of the llamas: for providing the llamas, the farm site, and veterinary care; and to Guillermo Lanuza and Hernan R. Bonomi for their help with the figures. F.H. and F.K.N. receive a share of antibody and protein sales via Analytical Services North GmbH, a wholly owned subsidiary of the University Medical Center Hamburg-Eppendorf. F.G. is cofounder of Inmunova, a wholly owned subsidiary of the Instituto Leloir, which provides molecular-assembly vaccines and llama immunizations.	AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Aktories K, 2005, NAT REV MICROBIOL, V3, P397, DOI 10.1038/nrmicro1150; Avignolo C, 2008, FASEB J, V22, P1237, DOI 10.1096/fj.07-8865com; Baral TN, 2006, NAT MED, V12, P580, DOI 10.1038/nm1395; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; BOERSMA WJA, 1992, RES IMMUNOL, V143, P503, DOI 10.1016/0923-2494(92)80061-O; Browne SH, 2008, FEMS IMMUNOL MED MIC, V52, P194, DOI 10.1111/j.1574-695X.2007.00364.x; Browne SH, 2002, INFECT IMMUN, V70, P7126, DOI 10.1128/IAI.70.12.7126-7135.2002; Chartier A, 2009, HUM MOL GENET, V18, P1849, DOI 10.1093/hmg/ddp101; Cohen-Saidon C, 2003, BLOOD, V102, P2506, DOI 10.1182/blood-2002-12-3921; Collier RJ, 2001, TOXICON, V39, P1793, DOI 10.1016/S0041-0101(01)00165-9; Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200; Coppieters K, 2006, ARTHRITIS RHEUM-US, V54, P1856, DOI 10.1002/art.21827; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; da Silva FA, 2004, J MOL BIOL, V340, P525, DOI 10.1016/j.jmb.2004.04.062; De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103; Delanote V, 2010, FASEB J, V24, P105, DOI 10.1096/fj.09-134304; Deng Q, 2008, ANNU REV MICROBIOL, V62, P271, DOI 10.1146/annurev.micro.62.081307.162848; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Dumoulin M, 2003, NATURE, V424, P783, DOI 10.1038/nature01870; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; Engel J, 2009, CURR OPIN MICROBIOL, V12, P61, DOI 10.1016/j.mib.2008.12.007; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FIERER J, 1992, J INFECT DIS, V166, P639, DOI 10.1093/infdis/166.3.639; Fierer J, 2001, J CLIN INVEST, V107, P775, DOI 10.1172/JCI12561; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Gotoh H, 2003, MICROB PATHOGENESIS, V34, P227, DOI 10.1016/S0882-4010(03)00034-2; Granelli-Piperno A, 2005, J IMMUNOL, V175, P4265, DOI 10.4049/jimmunol.175.7.4265; Gueorguieva D, 2006, FASEB J, V20, P2636, DOI 10.1096/fj.06-6306fje; Habicht G, 2007, P NATL ACAD SCI USA, V104, P19232, DOI 10.1073/pnas.0703793104; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2; Henry T, 2006, P NATL ACAD SCI USA, V103, P13497, DOI 10.1073/pnas.0605443103; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Jendreyko N, 2005, P NATL ACAD SCI USA, V102, P8293, DOI 10.1073/pnas.0503168102; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Koch-Nolte F, 2008, FRONT BIOSCI-LANDMRK, V13, P6716, DOI 10.2741/3184; Koch-Nolte F, 2007, FASEB J, V21, P3490, DOI 10.1096/fj.07-8661com; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kurita A, 2003, MICROB PATHOGENESIS, V35, P43, DOI 10.1016/S0882-4010(03)00066-4; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Lesnick ML, 2001, MOL MICROBIOL, V39, P1464, DOI 10.1046/j.1365-2958.2001.02360.x; Libby SJ, 2000, CELL MICROBIOL, V2, P49, DOI 10.1046/j.1462-5822.2000.00030.x; Lindgren SW, 1996, P NATL ACAD SCI USA, V93, P4197, DOI 10.1073/pnas.93.9.4197; Lo A. S. -Y., 2008, V181, P343; LOWY I, N ENGL J MED, V362, P197; Margarit SM, 2006, STRUCTURE, V14, P1219, DOI 10.1016/j.str.2006.05.022; Marquardt A, 2006, CHEM-EUR J, V12, P1915, DOI 10.1002/chem.200500785; Matsui H, 2001, J BACTERIOL, V183, P4652, DOI 10.1128/JB.183.15.4652-4658.2001; Muyldermans S, 2001, J Biotechnol, V74, P277; Muyldermans S, 2009, VET IMMUNOL IMMUNOP, V128, P178, DOI 10.1016/j.vetimm.2008.10.299; Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X; Otto H, 2000, MOL MICROBIOL, V37, P1106, DOI 10.1046/j.1365-2958.2000.02064.x; Paz K, 2005, MOL CANCER THER, V4, P1801, DOI 10.1158/1535-7163.MCT-05-0174; Pust S, 2007, J BIOL CHEM, V282, P10272, DOI 10.1074/jbc.M610254200; Ratier L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003524; Roovers RC, 2007, CANCER IMMUNOL IMMUN, V56, P303, DOI 10.1007/s00262-006-0180-4; Rothbauer U, 2006, NAT METHODS, V3, P887, DOI 10.1038/NMETH953; Serruys B, 2009, HEPATOLOGY, V49, P39, DOI 10.1002/hep.22609; Tezcan-Merdol D, 2001, MOL MICROBIOL, V39, P606, DOI 10.1046/j.1365-2958.2001.02258.x; Tijink BM, 2008, MOL CANCER THER, V7, P2288, DOI 10.1158/1535-7163.MCT-07-2384; Vassiloyanakopoulos AP, 1998, P NATL ACAD SCI USA, V95, P7676, DOI 10.1073/pnas.95.13.7676; VERCRUYSSE T, 2010, J BIOL CHEM; Wesolowski J, 2009, MED MICROBIOL IMMUN, V198, P157, DOI 10.1007/s00430-009-0116-7; Worley MJ, 2006, P NATL ACAD SCI USA, V103, P17915, DOI 10.1073/pnas.0604054103; Zarebski LM, 2005, J MOL BIOL, V349, P814, DOI 10.1016/j.jmb.2005.03.072	66	28	31	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					526	534		10.1096/fj.10-162958	http://dx.doi.org/10.1096/fj.10-162958			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20940265				2022-12-28	WOS:000286724800011
J	Leong, DJ; Li, YH; Gu, XI; Sun, L; Zhou, ZP; Nasser, P; Laudier, DM; Iqbal, J; Majeska, RJ; Schaffler, MB; Goldring, MB; Cardoso, L; Zaidi, M; Sun, HB				Leong, Daniel J.; Li, Yong H.; Gu, Xiang I.; Sun, Li; Zhou, Zuping; Nasser, Philip; Laudier, Damien M.; Iqbal, Jameel; Majeska, Robert J.; Schaffler, Mitchell B.; Goldring, Mary B.; Cardoso, Luis; Zaidi, Mone; Sun, Hui B.			Physiological loading of joints prevents cartilage degradation through CITED2	FASEB JOURNAL			English	Article						matrix metalloproteinases; mechanotransduction, chondrocyte regulation	ARTICULAR-CARTILAGE; MATRIX METALLOPROTEINASES; MECHANICAL REGULATION; COLLAGENASE MMP-1; MOLECULAR EVENTS; GENE-EXPRESSION; KNEE-JOINT; ARTHRITIS; PROTEIN; IMMOBILIZATION	Both overuse and disuse of joints up-regulate matrix metalloproteinases (MMPs) in articular cartilage and cause tissue degradation; however, moderate (physiological) loading maintains cartilage integrity. Here, we test whether CBP/p300-interacting transactivator with ED-rich tail 2 (CITED2), a mechanosensitive transcriptional coregulator, mediates this chondroprotective effect of moderate mechanical loading. In vivo, hind-limb immobilization of Sprague-Dawley rats up-regulates MMP-1 and causes rapid, histologically detectable articular cartilage degradation. One hour of daily passive joint motion prevents these changes and up-regulates articular cartilage CITED2. In vitro, moderate (2.5 MPa, 1 Hz) intermittent hydrostatic pressure (IHP) treatment suppresses basal MMP-1 expression and up-regulates CITED2 in human chondrocytes, whereas high IHP (10 MPa) down-regulates CITED2 and increases MMP-1. Competitive binding and transcription assays demonstrate that CITED2 suppresses MMP-1 expression by competing with MMP transactivator, Ets-1 for its coactivator p300. Furthermore, CITED2 up-regulation in vitro requires the p38 delta isoform, which is specifically phosphorylated by moderate IHP. Together, these studies identify a novel regulatory pathway involving CITED2 and p38 delta, which may be critical for the maintenance of articular cartilage integrity under normal physical activity levels.-Leong, D. J., Li, Y. H., Gu, X. I., Sun, L., Zhou, Z., Nasser, P., Laudier, D. M., Iqbal, J., Majeska, R. J., Schaffler, M. B., Goldring, M. B., Cardoso, L., Zaidi, M., Sun, H. B. Physiological loading of joints prevents cartilage degradation through CITED2. FASEB J. 25, 182-191 (2011). www.fasebj.org	[Leong, Daniel J.; Li, Yong H.; Zhou, Zuping; Nasser, Philip; Laudier, Damien M.; Sun, Hui B.] Mt Sinai Sch Med, Leni & Peter W May Dept Orthoped, New York, NY 10029 USA; [Leong, Daniel J.; Gu, Xiang I.; Majeska, Robert J.; Schaffler, Mitchell B.; Cardoso, Luis] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA; [Goldring, Mary B.] Hosp Special Surg, New York, NY 10021 USA; [Sun, Li; Iqbal, Jameel; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; City College of New York (CUNY); Icahn School of Medicine at Mount Sinai	Sun, HB (corresponding author), Mt Sinai Sch Med, Leni & Peter W May Dept Orthoped, 1 Gustave L Levy Pl,Box 1188, New York, NY 10029 USA.	herb.sun@mssm.edu	Cardoso, Luis/F-1234-2013	Cardoso, Luis/0000-0002-2252-7802	National Institutes of Health [AR47628, AR52743, DK804590, AG23176, DK70526, AG022021]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041210, R03AR047628, R01AR052743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023176, R56AG022021, R01AG022021] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grants from the National Institutes of Health to H. S. (AR47628 and AR52743), L. S. (DK804590), M.Z (AG23176, DK70526, and DK804590), and M. B. G. (AG022021).	Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Blain EJ, 2007, FRONT BIOSCI-LANDMRK, V12, P507, DOI 10.2741/2078; Buckwalter JA, 2006, BIORHEOLOGY, V43, P603; Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817; Cawston TE, 2006, BEST PRACT RES CL RH, V20, P983, DOI 10.1016/j.berh.2006.06.007; Coutinho EL, 2002, BRAZ J MED BIOL RES, V35, P1329, DOI 10.1590/S0100-879X2002001100010; Echtermeyer F, 2009, NAT MED, V15, P1072, DOI 10.1038/nm.1998; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Fanjul-Fernandez M, 2010, BBA-MOL CELL RES, V1803, P3, DOI 10.1016/j.bbamcr.2009.07.004; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; Favier FB, 2008, PFLUG ARCH EUR J PHY, V456, P587, DOI 10.1007/s00424-007-0423-z; Ferretti JL, 2003, MECH AGEING DEV, V124, P269, DOI 10.1016/S0047-6374(02)00194-X; Ferretti M, 2005, J ORTHOP RES, V23, P1165, DOI 10.1016/j.orthres.2005.01.025; Ferretti M, 2006, J IMMUNOL, V177, P8757, DOI 10.4049/jimmunol.177.12.8757; Fitzgerald JB, 2008, J BIOL CHEM, V283, P6735, DOI 10.1074/jbc.M708670200; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Fuentes MA, 2002, ARCH ORAL BIOL, V47, P643, DOI 10.1016/S0003-9969(02)00052-3; Goldring MB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2592; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; Gu XI, 2010, ANN BIOMED ENG, V38, P621, DOI 10.1007/s10439-009-9865-0; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Helmick CG, 2008, ARTHRITIS RHEUM-US, V58, P15, DOI 10.1002/art.23177; JURVELIN J, 1986, CLIN ORTHOP RELAT R, P246; Karalaki M, 2009, IN VIVO, V23, P779; Kim E. K., BIOCH BIOPHYS ACTA, V1802, P396; Leong DJ, 2010, MATRIX BIOL, V29, P420, DOI 10.1016/j.matbio.2010.02.004; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; Mengshol JA, 2002, ARTHRITIS RHEUM, V46, P13, DOI 10.1002/1529-0131(200201)46:1<13::AID-ART497>3.0.CO;2-S; Reuben PM, 2006, FRONT BIOSCI-LANDMRK, V11, P1199, DOI 10.2741/1873; Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721; Schaffler MB, 2003, OSTEOPOROSIS INT, V14, pS73; Shlopov BV, 1997, ARTHRITIS RHEUM-US, V40, P2065, DOI 10.1002/art.1780401120; Stremme S, 2003, CLIN EXP RHEUMATOL, V21, P205; Sun H. B., ANN NY ACAD SCI, V1192, P429; Sun HB, 2001, BONE, V28, P399, DOI 10.1016/S8756-3282(00)00459-2; Torzilli PA, 2010, OSTEOARTHR CARTILAGE, V18, P97, DOI 10.1016/j.joca.2009.07.012; Trindade MCD, 2004, OSTEOARTHR CARTILAGE, V12, P729, DOI 10.1016/j.joca.2004.05.008; Vanwanseele B, 2002, ARTHRITIS RHEUM-US, V46, P2073, DOI 10.1002/art.10462; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Wong M, 2003, BONE, V33, P1, DOI 10.1016/S8756-3282(03)00083-8; Wu W, 2002, ARTHRITIS RHEUM, V46, P2087, DOI 10.1002/art.10428; Yokota H, 2003, J BIOL CHEM, V278, P47275, DOI 10.1074/jbc.M304652200; Yoshida H, 2006, J BIOMECH, V39, P1996, DOI 10.1016/j.jbiomech.2005.06.026; Yoshida Mamoru, 2005, Mod Rheumatol, V15, P180, DOI 10.1007/s10165-005-0384-z; Ziegler N., BMC CELL BIOL, V11, P10	46	58	59	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					182	191		10.1096/fj.10-164277	http://dx.doi.org/10.1096/fj.10-164277			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20826544	Green Published			2022-12-28	WOS:000285869500017
J	van Lummel, M; van Blitterswijk, WJ; Vink, SR; Veldman, RJ; van der Valk, MA; Schipper, D; Dicheva, BM; Eggermont, AMM; ten Hagen, TLM; Verheij, M; Koning, GA				van Lummel, Menno; van Blitterswijk, Wim J.; Vink, Stefan R.; Veldman, Robert Jan; van der Valk, Martin A.; Schipper, Debby; Dicheva, Bilyana M.; Eggermont, Alexander M. M.; ten Hagen, Timo L. M.; Verheij, Marcel; Koning, Gerben A.			Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors	FASEB JOURNAL			English	Article						chemotherapy; liposome; nanomedicine; short-chain sphingolipid; cell membrane permeability	PEGYLATED LIPOSOMAL DOXORUBICIN; MURINE BREAST-CANCER; STEALTH LIPOSOMES; MICROVASCULAR PERMEABILITY; ANTHRACYCLINES; CYTOTOXICITY; CERAMIDE; THERAPY; PHARMACOKINETICS; IMMUNOLIPOSOMES	For amphiphilic anticancer drugs, such as the anthracyclin doxorubicin (Dox), uptake by tumor cells involves slow diffusion across the plasma membrane, a limiting factor in clinical oncology. Previously, we discovered that preinsertion of short-chain sphingolipids such as N-octanoyl-glucosylceramide (GC) in the tumor cell membrane enhances cellular Dox uptake. In the present study, we apply this strategy in vitro and in vivo by coadministering GC and Dox in a lipid nanovesicle (LNV). GC enrichment of Dox-LNVs strongly enhanced in vitro cytotoxicity toward B16 melanoma and A431 carcinoma, as evidenced by 6-fold decreased IC50 values compared with Dox-LNVs. This correlated with enhanced cellular Dox uptake observed by confocal microscopy. Intravital optical imaging in window chamber-bearing mice with orthotopically implanted B16 melanoma demonstrated enhanced GC-mediated Dox delivery to tumor cells. Treatment of nude mice bearing human A431 xenografts with 6 mg/kg GC-Dox-LNVs almost doubled the tumor growth delay compared with Dox-LNVs. A second administration of 5 mg/kg after 3 d induced even 3-fold delay in tumor growth, while no systemic toxicity was found. GC-enriched Dox-LNVs displayed superior in vitro and in vivo antitumor activity, without systemic toxicity. This new drug delivery concept, aiming at increased membrane permeability for amphiphilic drugs, provides an opportunity to improve cancer chemotherapy.-Van Lummel, M., van Blitterswijk, W. J., Vink, S. R., Veldman, R. J., van der Valk, M. A., Schipper, D., Dicheva, B. M., Eggermont, A. M. M., ten Hagen, T. L. M., Verheij, M., Koning, G. A. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J. 25, 280-289 (2011). www.fasebj.org	[Schipper, Debby; Dicheva, Bilyana M.; Eggermont, Alexander M. M.; ten Hagen, Timo L. M.; Koning, Gerben A.] Erasmus MC, Lab Expt Surg Oncol, Sect Surg Oncol, Dept Surg, NL-3000 CA Rotterdam, Netherlands; [van Lummel, Menno; van Blitterswijk, Wim J.; Vink, Stefan R.; Veldman, Robert Jan; Verheij, Marcel] Antoni Van Leeuwenhoek Hosp, Dept Cellular Biochem, Amsterdam, Netherlands; [van der Valk, Martin A.] Antoni Van Leeuwenhoek Hosp, Lab Expt Anim Pathol, Amsterdam, Netherlands; [Verheij, Marcel] Antoni Van Leeuwenhoek Hosp, Dept Radiat Oncol, Netherlands Canc Inst, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Netherlands Cancer Institute	Koning, GA (corresponding author), Erasmus MC, Lab Expt Surg Oncol, Sect Surg Oncol, Dept Surg, POB 2040, NL-3000 CA Rotterdam, Netherlands.	m.verheij@nki.nl; g.koning@erasmusmc.nl	Koning, Gerben A/K-2326-2012; Verheij, Marcel/O-9652-2018	Koning, Gerben A/0000-0003-3090-2403; 				Alberts DS, 2004, SEMIN ONCOL, V31, P53, DOI 10.1053/j.seminoncol.2004.08.010; Allen TM, 2004, SEMIN ONCOL, V31, P5, DOI 10.1053/j.seminoncol.2004.08.001; Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Charrois GJR, 2004, BBA-BIOMEMBRANES, V1663, P167, DOI 10.1016/j.bbamem.2004.03.006; DVORAK HF, 1988, AM J PATHOL, V133, P95; Elrick MJ, 2006, BIOPHYS J, V91, P1749, DOI 10.1529/biophysj.106.088443; Ewer MS, 2004, SEMIN ONCOL, V31, P161, DOI 10.1053/j.seminoncol.2004.08.006; Gabizon A, 2003, CLIN PHARMACOKINET, V42, P419, DOI 10.2165/00003088-200342050-00002; Gabizon AA, 2001, CLIN CANCER RES, V7, P223; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9; Harrington KJ, 2000, CLIN ONCOL-UK, V12, P2, DOI 10.1007/s001740050002; Harrington KJ, 2001, CLIN CANCER RES, V7, P243; Hussein MA, 2004, SEMIN ONCOL, V31, P147, DOI 10.1053/j.seminoncol.2004.08.005; Jacobson K, 2007, NAT CELL BIOL, V9, P7, DOI 10.1038/ncb0107-7; JAIN RK, 1990, CANCER METAST REV, V9, P253, DOI 10.1007/BF00046364; Koning GA, 1999, BBA-BIOMEMBRANES, V1420, P153, DOI 10.1016/S0005-2736(99)00091-7; Koning GA, 1999, BRIT J CANCER, V80, P1718, DOI 10.1038/sj.bjc.6690588; Koning GA, 2007, ANTI-CANCER AGENT ME, V7, P425; Krown SE, 2004, SEMIN ONCOL, V31, P36, DOI 10.1053/j.seminoncol.2004.08.003; Laginha KM, 2005, CLIN CANCER RES, V11, P6944, DOI 10.1158/1078-0432.CCR-05-0343; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Mulder WJM, 2007, FASEB J, V21, P378, DOI 10.1096/fj.06-6791com; Mulder WJM, 2005, FASEB J, V19, P2008, DOI 10.1096/fj.05-4145fje; Osheroff N, 1994, Adv Pharmacol, V29B, P105; Robert NJ, 2004, SEMIN ONCOL, V31, P106, DOI 10.1053/j.seminoncol.2004.09.018; Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Seynhaeve ALB, 2007, CANCER RES, V67, P9455, DOI 10.1158/0008-5472.CAN-07-1599; Siskind LJ, 2005, J BIOENERG BIOMEMBR, V37, P227, DOI 10.1007/s10863-005-6632-2; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Van der Graaf PH, 1999, J PHARMACOL TOXICOL, V41, P107, DOI 10.1016/S1056-8719(99)00026-X; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Veldman RJ, 2005, J PHARMACOL EXP THER, V315, P704, DOI 10.1124/jpet.105.087486; Veldman RJ, 2004, BRIT J CANCER, V90, P917, DOI 10.1038/sj.bjc.6601581; Verhaar-Langereis M, 2006, INT J GYNECOL CANCER, V16, P65, DOI 10.1111/j.1525-1438.2006.00298.x; WU NZ, 1993, CANCER RES, V53, P3765; YUAN F, 1994, CANCER RES, V54, P3352	41	47	48	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					280	289		10.1096/fj.10-163709	http://dx.doi.org/10.1096/fj.10-163709			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20876209				2022-12-28	WOS:000285869500025
J	Arvatz, G; Barash, U; Nativ, O; Ilan, N; Vlodavsky, I				Arvatz, Gil; Barash, Uri; Nativ, Ofer; Ilan, Neta; Vlodavsky, Israel			Post-transcriptional regulation of heparanase gene expression by a 3 ' AU-rich element	FASEB JOURNAL			English	Article						enzymatic activity; invasion; tumor xenograft; U87 glioma; luciferase	MAMMALIAN HEPARANASE; CANCER METASTASIS; SPLICE VARIANT; GROWTH; PHOSPHORYLATION; HEPARIN; CLONING; HYPOMETHYLATION; LOCALIZATION; ESTROGEN	Heparanase up-regulation was documented in an increasing number of human carcinomas, associated with poor prognosis. The purpose of the current study was to identify mechanisms responsible for heparanase induction. We provide evidence that heparanase expression is regulated at the post-transcriptional level by sequences at the 3' untranslated region (3' UTR) of the gene. Constructing the 3' UTR immediately following the heparanase cDNA reduces heparanase enzymatic activity and protein levels, resulting in decreased cellular invasion capacity. We further identified a 185-bp sequence within the 3' UTR that mediates heparanase down-regulation, and characterized an adenine (A)/uracil (U)-rich consensus element (ARE) within this region. Deletion of the entire 185-bp region or the ARE eliminated the inhibitory effect of the 3' UTR, resulting in elevated heparanase levels and formation of larger tumor xenografts indistinguishable from those produced by heparanase-overexpressing cells in terms of size, vascularization, and Akt activation. These results suggest that loss of the ARE is an important regulatory mechanism contributing to heparanase induction in human cancer.-Arvatz, G., Barash, U., Nativ, O., Ilan, N., Vlodavsky, I. Post-transcriptional regulation of heparanase gene expression by a 3' AU-rich element. FASEB J. 24, 4969-4976 (2010). www.fasebj.org	[Arvatz, Gil; Barash, Uri; Ilan, Neta; Vlodavsky, Israel] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; [Nativ, Ofer] Bnai Zion Med Ctr, Dept Urol, Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Bnai Zion Medical Center	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il		Barash, Uri/0000-0003-1049-270X	Israel Science Foundation [549/06]; National Cancer Institute; National Institutes of Health [CA106456]; Israel Cancer Research Fund (ICRF); Rappaport Family Institute; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Israel Cancer Research Fund (ICRF); Rappaport Family Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Joseph A. Madri (Yale University, New Haven, CT, USA) for providing us with anti-mouse PECAM-1 (CD31) antibodies. This work was supported by grants from the Israel Science Foundation (grant 549/06); the National Cancer Institute, the National Institutes of Health (grant CA106456); the Israel Cancer Research Fund (ICRF); and the Rappaport Family Institute Fund to I.V. I.V. is a Research Professor of the ICRF.	Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Barash U, 2010, FASEB J, V24, P1239, DOI 10.1096/fj.09-147074; Baraz L, 2006, ONCOGENE, V25, P3939, DOI 10.1038/sj.onc.1209425; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Borset M, 2000, BLOOD, V96, P2528; Casu B, 2007, PATHOPHYSIOL HAEMO T, V36, P195, DOI 10.1159/000175157; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cohen I, 2006, INT J CANCER, V118, P1609, DOI 10.1002/ijc.21552; Cohen I, 2007, CLIN CANCER RES, V13, P4069, DOI 10.1158/1078-0432.CCR-06-2546; Cohen-Kaplan V, 2008, CANCER RES, V68, P10077, DOI 10.1158/0008-5472.CAN-08-2910; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Dong J, 2000, GENE, V253, P171, DOI 10.1016/S0378-1119(00)00251-1; Eberhardt W, 2007, PHARMACOL THERAPEUT, V114, P56, DOI 10.1016/j.pharmthera.2007.01.002; Elkin M, 2003, CANCER RES, V63, P8821; Fux L, 2009, CANCER RES, V69, P1758, DOI 10.1158/0008-5472.CAN-08-1837; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; McKenzie EA, 2007, BRIT J PHARMACOL, V151, P1, DOI 10.1038/sj.bjp.0707182; Miao HQ, 2006, CURR MED CHEM, V13, P2101, DOI 10.2174/092986706777935230; Nasser NJ, 2007, BIOCHEM BIOPH RES CO, V354, P33, DOI 10.1016/j.bbrc.2006.12.189; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Sato M, 2008, CELL BIOCHEM FUNCT, V26, P676, DOI 10.1002/cbf.1492; Sharova LV, 2009, DNA RES, V16, P45, DOI 10.1093/dnares/dsn030; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Vlodavsky I, 2007, CURR PHARM DESIGN, V13, P2057; Vlodavsky I, 2006, PATHOPHYSIOL HAEMO T, V35, P116, DOI 10.1159/000093553; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796; Vreys V, 2007, J CELL MOL MED, V11, P427, DOI 10.1111/j.1582-4934.2007.00039.x; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zetser A, 2003, CANCER RES, V63, P7733	40	30	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4969	4976		10.1096/fj.10-156372	http://dx.doi.org/10.1096/fj.10-156372			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20798248	Green Published			2022-12-28	WOS:000284824400035
J	Al-Jamal, KT; Toma, FM; Yilmazer, A; Ali-Boucetta, H; Nunes, A; Herrero, MA; Tian, BW; Eddaoui, A; Al-Jamal, WT; Bianco, A; Prato, M; Kostarelos, K				Al-Jamal, Khuloud T.; Toma, Francesca M.; Yilmazer, Acelya; Ali-Boucetta, Hanene; Nunes, Antonio; Herrero, Maria-Antonia; Tian, Bowen; Eddaoui, Ayad; Al-Jamal, Wafa' T.; Bianco, Alberto; Prato, Maurizio; Kostarelos, Kostas			Enhanced cellular internalization and gene silencing with a series of cationic dendron-multiwalled carbon nanotube:siRNA complexes	FASEB JOURNAL			English	Article						RNA interference; gene transfer; knockdown; nanotechnology; nonviral	SMALL INTERFERING RNA; INTRACELLULAR DELIVERY; PLASMID DNA; SIRNA; TRANSPORTERS; APOPTOSIS; FUNCTIONALIZATION; NANOMATERIALS; CYTOTOXICITY; BINDING	One of the major obstacles to the clinical development of gene silencing by small interfering RNA (siRNA) is its effective cytoplasmic delivery. Carbon nanotubes have been proposed as novel nanomaterials that can offer significant advantages for the intracellular delivery of nucleic acids, such as siRNA. We recently demonstrated in a proof-of-principle study that amino-functionalized multiwalled carbon nanotubes (f-MWNT) can effectively deliver in vivo an siRNA sequence, triggering cell apoptosis that results in human lung xenograft eradication and prolonged survival. In the present study, we demonstrate how a newly synthesized series of polycationic dendron-MWNT constructs with a precisely tailored number of amino functions (dendron generations) can complex and effectively deliver double-stranded siRNA to achieve gene silencing in vitro. A systematic comparison between the f-MWNT series in terms of cellular uptake, cytotoxicity, and siRNA complexation is offered. Significant improvement in siRNA delivery with the dendron-MWNT conjugates is shown, and gene silencing was obtained in 2 human cell lines using 2 different siRNA sequences. The study reveals that through f-MWNT structure-biological function analysis novel nanotube-based siRNA transfer vectors can be designed with minimal cytotoxicity and effective delivery and gene-silencing capabilities.-Al-Jamal, K. T., Toma, F. M., Yilmazer, A., Ali-Boucetta, H., Nunes, A., Herrero, M.-A., Tian, B., Eddaoui, A., Al-Jamal, W. T., Bianco, A., Prato, M., Kostarelos, K. Enhanced cellular internalization and gene silencing with a series of cationic dendron-multiwalled carbon nanotube:siRNA complexes. FASEB J. 24, 4354-4365 (2010). www.fasebj.org	[Al-Jamal, Khuloud T.; Yilmazer, Acelya; Ali-Boucetta, Hanene; Nunes, Antonio; Tian, Bowen; Al-Jamal, Wafa' T.; Kostarelos, Kostas] Univ London, Nanomed Lab, Ctr Drug Delivery Res, Sch Pharm, London WC1N 1AX, England; [Toma, Francesca M.; Herrero, Maria-Antonia; Prato, Maurizio] Univ Trieste, Ctr Excellence Nanostruct Mat, Dept Pharmaceut Sci, I-34127 Trieste, Italy; [Herrero, Maria-Antonia] Univ Castilla La Mancha, Dept Quim Organ, Fac Quim, E-13071 Ciudad Real, Spain; [Eddaoui, Ayad] UCL, Flow Cytometry Core Facil, Inst Child Hlth, London, England; [Bianco, Alberto] CNRS, Inst Biol Mol & Cellulaire, UPR Immunol & Chim Therapeut 9021, F-67000 Strasbourg, France	University of London; University College London; University of London School of Pharmacy; University of Trieste; Universidad de Castilla-La Mancha; University of London; University College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kostarelos, K (corresponding author), Univ London, Nanomed Lab, Ctr Drug Delivery Res, Sch Pharm, London WC1N 1AX, England.	a.bianco@ibmc-cnrs.unistra.fr; prato@units.it; kostas.kostarelos@pharmacy.ac.uk	Kostarelos, Kostas/AAP-6879-2021; herrero, Maria Antonia/I-4245-2014; Yilmazer, Acelya/L-4562-2013; Al-Jamal, Khuloud/ABD-5668-2021; Toma, Francesca/AAH-4991-2021; Herrero, Maria Antonia/ABC-3466-2020; Ali-Boucetta, Hanene/AAW-4390-2020; Prato, Maurizio/G-7067-2012; Toma, Francesca Maria/AAH-6326-2021	Kostarelos, Kostas/0000-0002-2224-6672; herrero, Maria Antonia/0000-0002-8860-9325; Yilmazer, Acelya/0000-0003-2712-7450; Herrero, Maria Antonia/0000-0002-8860-9325; Ali-Boucetta, Hanene/0000-0002-5175-5716; Prato, Maurizio/0000-0002-8869-8612; Toma, Francesca Maria/0000-0003-2332-0798; AL-JAMAL, KHULOUD/0000-0001-5165-2699; Eddaoudi, Ayad/0000-0001-5272-6426; Nunes, Antonio/0000-0002-9014-9030	University of Trieste; Italian Ministry of Education MUR [2006034372, RBIN04HC3S]; Regione Friuli Venezia-Giulia; School of Pharmacy, University of London; CNRS; Agence Nationale de la Recherche [ANR-05-JCJC-0031-01]; European Union [NMP4-CT-2006-031847, NMP4-CT-2006-033378, HEALTH-2007-201587]; Junta de Comunidades de Castilla la Mancha (Spain)	University of Trieste; Italian Ministry of Education MUR(Ministry of Education, Universities and Research (MIUR)); Regione Friuli Venezia-Giulia(Regione Friuli Venezia Giulia); School of Pharmacy, University of London; CNRS(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de la Recherche(French National Research Agency (ANR)); European Union(European Commission); Junta de Comunidades de Castilla la Mancha (Spain)(Junta de Comunidades de Castilla-La Mancha)	This work was supported by the University of Trieste; Italian Ministry of Education MUR (cofin Prot. 2006034372 and Firb RBIN04HC3S); Regione Friuli Venezia-Giulia; The School of Pharmacy, University of London; CNRS; and Agence Nationale de la Recherche (grant ANR-05-JCJC-0031-01). Partial support is also acknowledged by the European Union FP6 NEURONANO (NMP4-CT-2006-031847), NINIVE (NMP4-CT-2006-033378) and FP7 ANTICARB (HEALTH-2007-201587) programs. M.A.H. acknowledges support by the Junta de Comunidades de Castilla la Mancha (Spain) for the award of a postdoctoral fellowship.	Ali-Boucetta H, 2008, CHEM COMMUN, P459, DOI 10.1039/b712350g; Herrero MA, 2009, J AM CHEM SOC, V131, P9843, DOI 10.1021/ja903316z; Becker ML, 2007, ADV MATER, V19, P939, DOI 10.1002/adma.200602667; Bianco A, 2005, CHEM COMMUN, P571, DOI 10.1039/b410943k; Bianco A, 2005, CURR OPIN CHEM BIOL, V9, P674, DOI 10.1016/j.cbpa.2005.10.005; Bianco A, 2008, EXPERT OPIN DRUG DEL, V5, P331, DOI 10.1517/17425247.5.3.331 ; Bottini M, 2006, TOXICOL LETT, V160, P121, DOI 10.1016/j.toxlet.2005.06.020; Cai D, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/34/345102; Campidelli S, 2006, J AM CHEM SOC, V128, P12544, DOI 10.1021/ja063697i; Chen JY, 2008, J AM CHEM SOC, V130, P16778, DOI 10.1021/ja805570f; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; Davoren M, 2007, TOXICOL IN VITRO, V21, P438, DOI 10.1016/j.tiv.2006.10.007; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Gao LZ, 2006, CHEMBIOCHEM, V7, P239, DOI 10.1002/cbic.200500227; Hampel S, 2008, NANOMEDICINE-UK, V3, P175, DOI 10.2217/17435889.3.2.175; Herzog E, 2007, TOXICOL LETT, V174, P49, DOI 10.1016/j.toxlet.2007.08.009; Isobe H, 2006, ANGEW CHEM INT EDIT, V45, P6676, DOI 10.1002/anie.200601718; Jevprasesphant R, 2003, INT J PHARM, V252, P263, DOI 10.1016/S0378-5173(02)00623-3; Kam NWS, 2004, J AM CHEM SOC, V126, P6850, DOI 10.1021/ja0486059; Kam NWS, 2006, ANGEW CHEM INT EDIT, V45, P577, DOI 10.1002/anie.200503389; Kam NWS, 2005, J AM CHEM SOC, V127, P6021, DOI 10.1021/ja050062v; Kam NWS, 2005, J AM CHEM SOC, V127, P12492, DOI 10.1021/ja053962k; Kang B, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/37/375103; Kateb B, 2007, NEUROIMAGE, V37, pS9, DOI 10.1016/j.neuroimage.2007.03.078; Kostarelos K, 2007, NAT NANOTECHNOL, V2, P108, DOI 10.1038/nnano.2006.209; Krajcik R, 2008, BIOCHEM BIOPH RES CO, V369, P595, DOI 10.1016/j.bbrc.2008.02.072; Lacerda L, 2007, NANO TODAY, V2, P38, DOI 10.1016/S1748-0132(07)70172-X; Lacerda L, 2007, ADV MATER, V19, P1480, DOI 10.1002/adma.200601412; Lacerda L, 2006, ADV DRUG DELIVER REV, V58, P1460, DOI 10.1016/j.addr.2006.09.015; Lanner JT, 2009, FASEB J, V23, P1728, DOI 10.1096/fj.08-116814; Liu Y, 2005, ANGEW CHEM INT EDIT, V44, P4782, DOI 10.1002/anie.200500042; Liu Z, 2008, CANCER RES, V68, P6652, DOI 10.1158/0008-5472.CAN-08-1468; Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295; Monteiro-Riviere NA, 2009, TOXICOL APPL PHARM, V234, P222, DOI 10.1016/j.taap.2008.09.030; Pantarotto D, 2004, ANGEW CHEM INT EDIT, V43, P5242, DOI 10.1002/anie.200460437; Pantarotto D, 2004, CHEM COMMUN, P16, DOI 10.1039/b311254c; Podesta JE, 2009, SMALL, V5, P1176, DOI 10.1002/smll.200801572; Singh R, 2005, J AM CHEM SOC, V127, P4388, DOI 10.1021/ja0441561; Smart SK, 2006, CARBON, V44, P1034, DOI 10.1016/j.carbon.2005.10.011; Wang XH, 2008, CHEMMEDCHEM, V3, P940, DOI 10.1002/cmdc.200700329; Worle-Knirsch JM, 2006, NANO LETT, V6, P1261, DOI 10.1021/nl060177c; Wu W, 2005, ANGEW CHEM INT EDIT, V44, P6358, DOI 10.1002/anie.200501613; YING Z, 2008, SCI CHINA SER B, V51, P1021; Yu BZ, 2007, CARBON, V45, P1921, DOI 10.1016/j.carbon.2007.06.015; Zhang ZH, 2006, CLIN CANCER RES, V12, P4933, DOI 10.1158/1078-0432.CCR-05-2831	46	68	69	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4354	4365		10.1096/fj.09-141036	http://dx.doi.org/10.1096/fj.09-141036			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20647548				2022-12-28	WOS:000283861100023
J	Huang, CY; Ogawa, R				Huang, Chenyu; Ogawa, Rei			Mechanotransduction in bone repair and regeneration	FASEB JOURNAL			English	Review						mechanical stimulation; mechanosensation; mechanotransductive pathways; skeletal adaptation; bone reparation and reconstruction	FOCAL ADHESION KINASE; MANDIBULAR DISTRACTION OSTEOGENESIS; IN-VIVO EVIDENCE; MECHANICAL STRAIN; NITRIC-OXIDE; TISSUE DIFFERENTIATION; RECEPTOR ACTIVATOR; STRUCTURAL BASIS; PROSTAGLANDIN SYNTHESIS; BIOPHYSICAL STIMULI	Mechanotransduction is the process by which physical forces are converted into biochemical signals that are then integrated into cellular responses. It plays a crucial role in bone repair and regeneration and thus has attracted a great deal of interest from researchers in various fields. This report reviews the current clinical evidence that shows the role mechanotransduction plays in bone processes such as physical adaptation, pathological fracture healing, and therapeutic distraction osteogenesis. We also outline the progress that has been made in understanding bone mechanotransduction from both the macro-and microperspectives. Specifically, we describe the theories that postulate how mechanical force exhibits effects on bone repair and regeneration (i.e., the tensegrity and mechanosome theories). We also summarize the recent advances in our understanding of the molecular signaling pathways of mechanotransduction, which include calcium ion channels, integrins, Wnt/beta-catenin, prostaglandin, and nitric oxide. A better understanding of skeletal mechanotransduction will facilitate research into this promising field and could lead to the development of applications that improve bone structures and functions.-Huang, C., Ogawa, R. Mechanotransduction in bone repair and regeneration. FASEB J. 24, 3625-3632 (2010). www.fasebj.org	[Huang, Chenyu] Nippon Med Sch, Dept Plast Reconstruct & Aesthet Surg, Bunkyo Ku, Tokyo 1138603, Japan; [Huang, Chenyu] Meitan Gen Hosp, Dept Plast Surg, Beijing, Peoples R China	Nippon Medical School	Huang, CY (corresponding author), Nippon Med Sch, Dept Plast Reconstruct & Aesthet Surg, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	huangchenyu2000@gmail.com	Huang, Chenyu/I-4410-2018; HUANG, CHENYU/GVT-7299-2022	Huang, Chenyu/0000-0001-9521-5650; 				Aguirre JI, 2007, J BIOL CHEM, V282, P25501, DOI 10.1074/jbc.M702231200; Alam I, 2005, J BONE MINER RES, V20, P438, DOI 10.1359/JBMR.041124; Baker AB, 2000, MICROVASC RES, V60, P177, DOI 10.1006/mvre.2000.2252; Bhatt KA, 2007, J SURG RES, V143, P329, DOI 10.1016/j.jss.2007.01.023; Carter DR, 1998, CLIN ORTHOP RELAT R, pS41; Chen NX, 2000, AM J PHYSIOL-CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989; Cheng BX, 2001, ENDOCRINOLOGY, V142, P3464, DOI 10.1210/en.142.8.3464; Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04-10-0912; Claes LE, 1999, J BIOMECH, V32, P255, DOI 10.1016/S0021-9290(98)00153-5; Cowin SC, 2007, J BIOMECH, V40, pS105, DOI 10.1016/j.jbiomech.2007.02.012; David V, 2006, AM J PHYSIOL-ENDOC M, V290, pE440, DOI 10.1152/ajpendo.00293.2004; de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016; El Haj AJ, 1999, MED BIOL ENG COMPUT, V37, P403, DOI 10.1007/BF02513320; Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736-0266(03)00011-1; Forwood MR, 1996, J BONE MINER RES, V11, pP210; Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119; Geiger B, 2002, CELL, V110, P139, DOI 10.1016/S0092-8674(02)00831-0; Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101; Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210; Huang HD, 2004, AM J PHYSIOL-CELL PH, V287, pC1, DOI 10.1152/ajpcell.00559.2003; Hung CT, 1996, J BIOMECH, V29, P1411, DOI 10.1016/0021-9290(96)84536-2; ILIZAROV GA, 1989, CLIN ORTHOP RELAT R, P249, DOI 10.1097/00003086-198901000-00038; ILIZAROV GA, 1989, CLIN ORTHOP RELAT R, P263; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360; Ingber DE, 2008, PROG BIOPHYS MOL BIO, V97, P163, DOI 10.1016/j.pbiomolbio.2008.02.005; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; Inoue M, 2000, BONE, V26, P281, DOI 10.1016/S8756-3282(99)00282-3; Isaksson H, 2006, J BIOMECH, V39, P1507, DOI 10.1016/j.jbiomech.2005.01.037; Jansen JHW, 2010, J ORTHOP RES, V28, P390, DOI 10.1002/jor.20991; Kanno T, 2005, J ORAL MAXIL SURG, V63, P499, DOI 10.1016/j.joms.2004.07.023; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004; Lacroix D, 2002, J BIOMECH, V35, P1163, DOI 10.1016/S0021-9290(02)00086-6; Lau KHW, 2006, J BIOL CHEM, V281, P9576, DOI 10.1074/jbc.M509205200; Leucht P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000390; Lewinson D, 2003, J HISTOCHEM CYTOCHEM, V51, P1161, DOI 10.1177/002215540305100906; Li J, 2002, J BONE MINER RES, V17, pS191; Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223-001-1025-y; Mi LY, 2005, BIOMECH MODEL MECHAN, V4, P132, DOI 10.1007/s10237-004-0066-3; Morgan EF, 2008, J BONE JOINT SURG AM, V90A, P25, DOI 10.2106/JBJS.G.01164; Mullender MG, 1997, BONE, V20, P527, DOI 10.1016/S8756-3282(97)00036-7; Myers KA, 2007, BIOCHEM CELL BIOL, V85, P543, DOI 10.1139/O07-108; Nichols DL, 2007, SPORTS MED, V37, P1001, DOI 10.2165/00007256-200737110-00006; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284; Ponik SM, 2004, J APPL PHYSIOL, V97, P135, DOI 10.1152/japplphysiol.01260.2003; Prendergast PJ, 1997, J BIOMECH, V30, P539, DOI 10.1016/S0021-9290(96)00140-6; Reich A, 2005, J APPL PHYSIOL, V98, P2381, DOI 10.1152/japplphysiol.01073.2004; Rezzonico R, 2003, J BONE MINER RES, V18, P1863, DOI 10.1359/jbmr.2003.18.10.1863; Rhee ST, 2006, PLAST RECONSTR SURG, V117, P2243, DOI 10.1097/01.prs.0000224298.93486.1b; Rhee ST, 2005, ANN PLAS SURG, V55, P207, DOI 10.1097/01.sap.0000164576.10754.aa; Riddle RC, 2007, J BONE MINER RES, V22, P589, DOI 10.1359/JBMR.070113; Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200; Robling AG, 2002, BONE, V31, P562, DOI 10.1016/S8756-3282(02)00871-2; Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545; Robling AG, 2002, MED SCI SPORT EXER, V34, P196, DOI 10.1097/00005768-200202000-00003; Robling AG, 2007, J BONE MINER RES, V22, P984, DOI 10.1359/JBMR.070327; Rubin J, 2003, J BIOL CHEM, V278, P34018, DOI 10.1074/jbc.M302822200; Salter DM, 1997, J BONE MINER RES, V12, P1133, DOI 10.1359/jbmr.1997.12.7.1133; Santos A, 2009, OSTEOPOROSIS INT, V20, P1027, DOI 10.1007/s00198-009-0858-5; Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200; Saxon LK, 2006, BONE, V39, P1261, DOI 10.1016/j.bone.2006.06.030; Saxon LK, 2005, BONE, V36, P454, DOI 10.1016/j.bone.2004.12.001; Seeman E, 2008, RHEUMATOLOGY, V47, P2, DOI 10.1093/rheumatology/ken177; Seeman E, 2008, J BONE MINER METAB, V26, P1, DOI 10.1007/s00774-007-0793-5; Seeman Ego, 2004, Curr Osteoporos Rep, V2, P90, DOI 10.1007/s11914-004-0016-0; Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077; Singh SP, 2007, J AM COLL SURGEONS, V204, P426, DOI 10.1016/j.jamcollsurg.2006.11.019; Smalt R, 1997, ADV EXP MED BIOL, V433, P311; Smith SM, 2005, J BONE MINER RES, V20, P208, DOI 10.1359/JBMR.041105; Spurney RF, 2002, J CLIN INVEST, V109, P1361, DOI 10.1172/JCI200214663; Tan SD, 2007, BONE, V41, P745, DOI 10.1016/j.bone.2007.07.019; Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001; Tong L, 2003, PLAST RECONSTR SURG, V111, P211, DOI 10.1097/01.PRS.0000033180.01581.9A; Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064; TURNER CH, 1995, J BONE MINER RES, V10, pS235; Turner CH, 1996, AM J PHYSIOL-ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634; van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614; Vezeridis PS, 2006, BIOCHEM BIOPH RES CO, V348, P1082, DOI 10.1016/j.bbrc.2006.07.146; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Westbroek I, 2000, BIOCHEM BIOPH RES CO, V268, P414, DOI 10.1006/bbrc.2000.2154; Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102; Zhang YL, 2009, AM J PHYSIOL-CELL PH, V296, pC1391, DOI 10.1152/ajpcell.00549.2008	84	118	126	2	74	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3625	3632		10.1096/fj.10-157370	http://dx.doi.org/10.1096/fj.10-157370			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20505115				2022-12-28	WOS:000285005900003
J	Kovacs, E; Harmat, V; Toth, J; Vertessy, BG; Modos, K; Kardos, J; Liliom, K				Kovacs, Erika; Harmat, Veronika; Toth, Judit; Vertessy, Beata G.; Modos, Karoly; Kardos, Jozsef; Liliom, Karoly			Structure and mechanism of calmodulin binding to a signaling sphingolipid reveal new aspects of lipid-protein interactions	FASEB JOURNAL			English	Article						X-ray crystallography; isothermal titration calorimetry; stopped flow; lipid binding; calcium signaling	IN-VITRO; SPHINGOSYLPHOSPHORYLCHOLINE; RELEASE; RECOGNITION; MODULATION; BRAIN	Lipid-protein interactions are rarely characterized at a structural molecular level due to technical difficulties; however, the biological significance of understanding the mechanism of these interactions is outstanding. In this report, we provide mechanistic insight into the inhibitory complex formation of the lipid mediator sphingosylphosphorylcholine with calmodulin, the most central and ubiquitous regulator protein in calcium signaling. We applied crystallographic, thermodynamic, kinetic, and spectroscopic approaches using purified bovine calmodulin and bovine cerebral microsomal fraction to arrive at our conclusions. Here we present 1) a 1.6-angstrom resolution crystal structure of their complex, in which the sphingolipid occupies the conventional hydrophobic binding site on calmodulin; 2) a peculiar stoichiometry-dependent binding process: at low or high protein-to-lipid ratio calmodulin binds lipid micelles or a few lipid molecules in a compact globular conformation, respectively, and 3) evidence that the sphingolipid displaces calmodulin from its targets on cerebral microsomes. We have ascertained the specificity of the interaction using structurally related lipids as controls. Our observations reveal the structural basis of selective calmodulin inhibition by the sphingolipid. On the basis of the crystallographic and biophysical characterization of the calmodulin-sphingosylphosphorylcholine interaction, we propose a novel lipid-protein binding model, which might be applicable to other interactions as well.-Kovacs, E., Harmat, V., Toth, J., Vertessy, B. G., Modos, K., Kardos, J., Liliom, K. Structure and mechanism of calmodulin binding to a signaling sphingolipid reveal new aspects of lipid-protein interactions. FASEB J. 24, 3829-3839 (2010). www.fasebj.org	[Kovacs, Erika; Toth, Judit; Vertessy, Beata G.; Liliom, Karoly] Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1113 Budapest, Hungary; [Harmat, Veronika] Eotvos Lorand Univ, Lab Struct Chem & Biol, Inst Chem, Budapest, Hungary; [Kardos, Jozsef] Eotvos Lorand Univ, Dept Biochem, Budapest, Hungary; [Harmat, Veronika] Eotvos Lorand Univ, Prot Modelling Res Grp, Hungarian Acad Sci, Budapest, Hungary; [Vertessy, Beata G.] Budapest Univ Technol & Econ, Dept Appl Biotechnol, H-1117 Budapest, Hungary; [Modos, Karoly] Semmelweis Univ, Inst Biophys & Radiat Biol, Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Hungarian Academy of Sciences; Eotvos Lorand University; Eotvos Lorand University; Hungarian Academy of Sciences; Budapest University of Technology & Economics; Semmelweis University	Kovacs, E (corresponding author), Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, Karolina Ut 29, H-1113 Budapest, Hungary.	kovacs@enzim.hu; liliom@enzim.hu	Liliom, Karoly/A-6563-2011; Kardos, József/J-1035-2017; Vertessy, Beata G/H-6202-2012; Harmat, Veronika/B-8033-2016	Liliom, Karoly/0000-0002-7177-6872; Kardos, József/0000-0002-2135-2932; Harmat, Veronika/0000-0002-1866-9904; Vertessy, Beata G./0000-0002-1288-2982	Hungarian Scientific Research Fund OTKA [61501, 67800, 67937, 72973, 68464, 81950, 72008, 68229, 78646]; U.S. National Institutes of Health [1R01TW008130-01]; Howard Hughes Medical Institutes [55000342]; EU [LSHG-CT-2006-031220]; Bolyai Fellowship; FOGARTY INTERNATIONAL CENTER [R01TW008130] Funding Source: NIH RePORTER	Hungarian Scientific Research Fund OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institutes(Howard Hughes Medical Institute); EU(European Commission); Bolyai Fellowship(Hungarian Academy of Sciences); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	The authors thank the European Synchrotron Radiation Facility for provision of synchrotron radiation facilities, and Juan Sanchez Weatherby for assistance in using beamline ID23-1. The authors thank Dr. Ferenc Tolgyesi and the Institute of Biophysics and Radiation Biology, Semmelweis University, for providing the instrumentation for calorimetry experiments. This work was supported by the Hungarian Scientific Research Fund OTKA (grants 61501 to K.L.; 67800, 67937, and 72973 to V.H.; 68464 and 81950 to J.K.; 72008 to J.T.; and 68229 and 78646 to B.G.V.), the U.S. National Institutes of Health (grant 1R01TW008130-01 to J.T.), the Howard Hughes Medical Institutes (grant 55000342 to B.G.V.), and the EU (FP6 SPINE2c LSHG-CT-2006-031220 to B.G.V.). J.T. is a recipient of the Bolyai Fellowship.	Abuin EB, 1997, J COLLOID INTERF SCI, V186, P332, DOI 10.1006/jcis.1996.4648; Andersen KK, 2009, J MOL BIOL, V391, P207, DOI 10.1016/j.jmb.2009.06.019; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balshaw DM, 2002, J MEMBRANE BIOL, V185, P1, DOI 10.1007/s00232-001-0111-4; Betto R, 1997, BIOCHEM J, V322, P327, DOI 10.1042/bj3220327; Brokx RD, 2001, J BIOL CHEM, V276, P14083, DOI 10.1074/jbc.M011026200; BRYAN RK, 1990, FUND THEOR, V39, P221; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Harmat V, 2000, J MOL BIOL, V297, P747, DOI 10.1006/jmbi.2000.3607; Heringdorf DMZ, 2002, BBA-MOL CELL BIOL L, V1582, P178, DOI 10.1016/S1388-1981(02)00154-3; Kovacs E, 2008, BIOCHEM J, V410, P427, DOI 10.1042/BJ20071019; Kovacs E, 2010, J BIOL CHEM, V285, P1799, DOI 10.1074/jbc.M109.053116; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, PROTEIN CRYSTALLOGR, V26, P27; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; Lucas JL, 2006, PHARM RES-DORDR, V23, P647, DOI 10.1007/s11095-006-9784-9; Martinez-Luis S, 2007, PHYTOCHEMISTRY, V68, P1882, DOI 10.1016/j.phytochem.2007.02.025; MASSOM L, 1990, BIOCHEMISTRY-US, V29, P671, DOI 10.1021/bi00455a012; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MOLNAR A, 1995, EUR J PHARM-MOLEC PH, V291, P73; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nixon GF, 2008, PROG LIPID RES, V47, P62, DOI 10.1016/j.plipres.2007.11.001; Okamoto R, 2003, J LIPID RES, V44, P93, DOI 10.1194/jlr.M200225-JLR200; Osawa M, 1998, J MOL BIOL, V276, P165, DOI 10.1006/jmbi.1997.1524; Pal-Gabor H, 2009, BIOCHEMISTRY-US, V48, P5689, DOI 10.1021/bi900356r; Papish AL, 2002, BIOPHYS J, V83, P1455, DOI 10.1016/S0006-3495(02)73916-7; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Rodriguez-Lafrasse C, 1999, NEUROCHEM RES, V24, P199, DOI 10.1023/A:1022501702403; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDONSELAAR M, 1994, NAT STRUCT BIOL, V1, P795, DOI 10.1038/nsb1194-795; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; Yoshii N, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2179074	39	7	7	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3829	3839		10.1096/fj.10-155614	http://dx.doi.org/10.1096/fj.10-155614			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20522785	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000285005900021
J	Sha, L; Farrugia, G; Linden, DR; Szurszewski, JH				Sha, L.; Farrugia, G.; Linden, D. R.; Szurszewski, J. H.			The transwall gradient across the mouse colonic circular muscle layer is carbon monoxide dependent	FASEB JOURNAL			English	Article						heme oxygenase-2; interstitial cells of Cajal; smooth muscle; submucosal ganglion neurons	MEMBRANE-POTENTIAL GRADIENT; CANINE PROXIMAL COLON; ELECTRICAL SLOW WAVES; K-CA CHANNELS; SMOOTH-MUSCLE; NITRIC-OXIDE; MYOELECTRIC COMPLEXES; INTERSTITIAL-CELLS; HEME OXYGENASE-2; SMALL-INTESTINE	Gastric and small intestinal circular smooth muscle layers have a transwall resting membrane potential (RMP) gradient that is dependent on release of carbon monoxide (CO) from interstitial cells of Cajal (ICCs). Our aim was to determine whether a RMP gradient exists in the mouse colon and whether the gradient is CO dependent. Microelectrodes were used to record RMPs from muscle cells at different depths of the circular muscle layer from wild-type and heme oxygenase-2-knockout (HO-2-KO) mice. A transwall RMP gradient was present in wild-type mice. The CO scavenger oxyhemoglobin (20 mu M) and the heme oxygenase inhibitor chromium mesoporphyrin IX (CrMP, 5 mu M) abolished the transwall gradient. The gradient was absent in HO-2-KO mice. Tetrodotoxin (1 mu M) caused a significant depolarization in circular smooth muscle cells throughout the circular muscle layer and abolished the transwall gradient. Removal of the submucosal neurons abolished the gradient. The majority of submucosal neurons contained HO-2 immunoreactivity (HO-2-IR), while ICCs did not. These data show for the first time that a transwall gradient exists across the circular smooth muscle layer of the mouse colon, that the gradient is due to CO, and that the source of CO is the submucosal neurons.-Sha, L., Farrugia, G., Linden, D. R., Szurszewski, J. H. The transwall gradient across the mouse colonic circular muscle layer is carbon monoxide dependent. FASEB J. 24, 3840-3849 (2010). www.fasebj.org	[Sha, L.; Farrugia, G.; Linden, D. R.; Szurszewski, J. H.] Mayo Clin, Dept Physiol & Biomed Engn, Coll Med, Rochester, MN 55905 USA; [Sha, L.; Farrugia, G.; Linden, D. R.; Szurszewski, J. H.] Mayo Clin, Enter NeuroSci Program, Coll Med, Rochester, MN 55905 USA; [Farrugia, G.; Szurszewski, J. H.] Mayo Clin, Div Gastroenterol & Hepatol, Coll Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Szurszewski, JH (corresponding author), Mayo Clin, Dept Physiol & Biomed Engn, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	gijoe@mayo.edu			U.S. National Institutes of Health [NIH DK17238]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017238, R37DK017238] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by U.S. National Institutes of Health grant NIH DK17238. The authors thank Dr. Solomon Snyder (Johns Hopkins University, Baltimore, MD, USA) for providing HO-2-KO mice and the antiserum used in this work. The authors thank Mr. William Harmsen for statistical analysis and Jan Applequist for her help in preparing this manuscript.	Appleton SD, 1999, DRUG METAB DISPOS, V27, P1214; BAUER AJ, 1985, J PHYSIOL-LONDON, V369, P283, DOI 10.1113/jphysiol.1985.sp015901; BAUER AJ, 1985, J PHYSIOL-LONDON, V366, P221, DOI 10.1113/jphysiol.1985.sp015793; BURKE EP, 1991, P NATL ACAD SCI USA, V88, P2370, DOI 10.1073/pnas.88.6.2370; BURKE EP, 1988, AM J PHYSIOL, V254, pC475, DOI 10.1152/ajpcell.1988.254.4.C475; BYWATER RAR, 1989, J PHYSIOL-LONDON, V413, P505, DOI 10.1113/jphysiol.1989.sp017666; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Farrugia G, 2003, P NATL ACAD SCI USA, V100, P8567, DOI 10.1073/pnas.1431233100; FARRUGIA G, 1993, AM J PHYSIOL, V264, pG1184; Flynn ERM, 1999, J PHYSIOL-LONDON, V518, P247, DOI 10.1111/j.1469-7793.1999.0247r.x; HARA Y, 1986, J PHYSIOL-LONDON, V372, P501, DOI 10.1113/jphysiol.1986.sp016022; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; KHARITONOV VG, 1995, P NATL ACAD SCI USA, V92, P2568, DOI 10.1073/pnas.92.7.2568; Liu HJ, 1999, J CLIN INVEST, V103, P963, DOI 10.1172/JCI5206; LIU LWC, 1993, J PHYSIOL-LONDON, V470, P445, DOI 10.1113/jphysiol.1993.sp019868; LYSTER DJK, 1995, GASTROENTEROLOGY, V108, P1371, DOI 10.1016/0016-5085(95)90684-3; NATHANSON JA, 1995, NEURON, V14, P781, DOI 10.1016/0896-6273(95)90222-8; Pasricha PJ, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-21; Piantadosi CA, 2002, NEW ENGL J MED, V347, P1054, DOI 10.1056/NEJMp020104; Piotrowska AP, 2003, J PEDIATR SURG, V38, P73, DOI 10.1053/jpsu.2003.50014; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; SERIO R, 1991, AM J PHYSIOL, V260, pG636, DOI 10.1152/ajpgi.1991.260.4.G636; Sha L, 2005, GASTROENTEROLOGY, V128, pA629; Sha L, 2007, AM J PHYSIOL-GASTR L, V293, pG438, DOI 10.1152/ajpgi.00037.2007; Shah V, 2004, GASTROENTEROLOGY, V126, P903, DOI 10.1053/j.gastro.2003.11.046; SMITH TK, 1988, AM J PHYSIOL, V255, pC828, DOI 10.1152/ajpcell.1988.255.6.C828; SMITH TK, 1987, AM J PHYSIOL, V252, pC290, DOI 10.1152/ajpcell.1987.252.3.C290; Spencer NJ, 1998, J AUTONOM NERV SYST, V71, P37, DOI 10.1016/S0165-1838(98)00063-0; Spencer NJ, 1998, NEUROSCI LETT, V250, P153, DOI 10.1016/S0304-3940(98)00461-3; SUZUKI N, 1986, AM J PHYSIOL, V250, pG287; Szurszewski JH, 1987, PHYSL GASTROINTESTIN, P383; Tang XD, 2004, ANNU REV PHYSIOL, V66, P131, DOI 10.1146/annurev.physiol.66.041002.142720; Wang R, 1997, PFLUG ARCH EUR J PHY, V434, P285, DOI 10.1007/s004240050398; Xi Q, 2004, AM J PHYSIOL-HEART C, V286, pH610, DOI 10.1152/ajpheart.00782.2003; Xue L, 2000, P NATL ACAD SCI USA, V97, P1851, DOI 10.1073/pnas.97.4.1851; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848	37	14	14	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2010	24	10					3840	3849		10.1096/fj.10-156232	http://dx.doi.org/10.1096/fj.10-156232			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20543114	Green Published			2022-12-28	WOS:000285005900022
J	Mailloux, RJ; Harper, ME				Mailloux, Ryan J.; Harper, Mary-Ellen			Glucose regulates enzymatic sources of mitochondrial NADPH in skeletal muscle cells; a novel role for glucose-6-phosphate dehydrogenase	FASEB JOURNAL			English	Article						glucose signaling; isocitrate dehydrogenase; oxidative stress	INSULIN-RESISTANCE; HEPG2 CELLS; METABOLISM; HEXOKINASES; SUSCEPTIBILITY; DEHYDROGENASE; ADAPTATION; EXPRESSION; OXIDATION; NETWORK	Reduced nicotinamide adenine dinucleotide ( NADPH) is a functionally important metabolite required to support numerous cellular processes. However, despite the identification of numerous NADPH-producing enzymes, the mechanisms underlying how the organellar pools of NADPH are maintained remain elusive. Here, we have identified glucose-6-phosphate dehydrogenase (G6PDH) as an important source of NADPH in mitochondria. Activity analysis, submitochondrial fractionation, fluorescence microscopy, and protease sensitivity assays revealed that G6PDH is localized to the mitochondrial matrix. 6-ANAM, a specific G6PDH inhibitor, depleted mitochondrial NADPH pools and increased oxidative stress revealing the importance of G6PDH in NADPH maintenance. We also show that glucose availability and differences in metabolic state modulate the enzymatic sources of NADPH in mitochondria. Indeed, cells cultured in high glucose (HG) not only adopted a glycolytic phenotype but also relied heavily on matrix-associated G6PDH as a source of NADPH. In contrast, cells exposed to low-glucose (LG) concentrations, which displayed increased oxygen consumption, mitochondrial metabolic efficiency, and decreased glycolysis, relied predominantly on isocitrate dehydrogenase ( ICDH) as the principal NADPH-producing enzyme in the mitochondria. Culturing glycolytic cells in LG for 48 h decreased G6PDH and increased ICDH protein levels in the mitochondria, further pointing to the regulatory role of glucose. 2-Deoxyglucose treatment also prevented the increase of mitochondrial G6PDH in response to HG. The role of glucose in regulating enzymatic sources of mitochondrial NADPH pool maintenance was confirmed using human myotubes from obese adults with a history of type 2 diabetes mellitus (post-T2DM). Myotubes from post-T2DM participants failed to increase mitochondrial G6PDH in response to HG in contrast to mitochondria in myotubes from control participants (non-T2DM). Hence, we not only identified a matrix-associated G6PDH but also provide evidence that metabolic state/glucose availability modulate enzymatic sources of NADPH.-Mailloux, R.J., Harper, M.-E. Glucose regulates enzymatic sources of mitochondrial NADPH in skeletal muscle cells; a novel role for glucose-6-phosphate dehydrogenase. FASEB J. 24, 2495-2506 (2010). www.fasebj.org	[Mailloux, Ryan J.; Harper, Mary-Ellen] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Harper, ME (corresponding author), Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	mharper@uottawa.ca	Harper, Mary-Ellen/C-3103-2009	Harper, Mary-Ellen/0000-0003-3864-5886; Mailloux, Ryan/0000-0003-3986-9830	Institute of Nutrition Metabolism and Diabetes [57810]; Heart and Stroke Foundation of Canada [PRG6242]	Institute of Nutrition Metabolism and Diabetes; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	This research was funded by a Canadian Institutes of Health Research: Institute of Nutrition Metabolism and Diabetes operating grant (57810; M.E.H.) and a Heart and Stroke Foundation of Canada program grant (PRG6242) supporting the fellowship of R.J.M. The authors are grateful to the patients and to Drs. Robert Dent (Ottawa Hospital and University of Ottawa) and Ruth McPherson (University of Ottawa Heart Institute) for initially providing and conducting the muscle biopsies, respectively, and to Dr. Sheila Costford (University of Ottawa) for the cell stock preparations.	CAMPBELL WH, 1979, MOL CELL BIOCHEM, V25, P33; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Corpeleijn E, 2009, OBES REV, V10, P178, DOI 10.1111/j.1467-789X.2008.00544.x; Costford SR, 2009, DIABETOLOGIA, V52, P2405, DOI 10.1007/s00125-009-1480-y; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Diaz-Ruiz R, 2008, J BIOL CHEM, V283, P26948, DOI 10.1074/jbc.M800408200; Dumollard R, 2007, DEVELOPMENT, V134, P455, DOI 10.1242/dev.02744; DWORKIN MB, 1990, DEV BIOL, V138, P177, DOI 10.1016/0012-1606(90)90187-N; Dykens JA, 2008, TOXICOL APPL PHARM, V233, P203, DOI 10.1016/j.taap.2008.08.013; Hiltunen JK, 2009, J BIOL CHEM, V284, P9011, DOI 10.1074/jbc.R800068200; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Kim SY, 2007, MOL CELL BIOCHEM, V302, P27, DOI 10.1007/s11010-007-9421-x; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Lemire J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001550; Lennon R, 2009, NEPHROL DIAL TRANSPL, V24, P3288, DOI 10.1093/ndt/gfp302; Li DY, 2009, CANCER BIOTHER RADIO, V24, P81, DOI 10.1089/cbr.2008.0494; Mailloux RJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000690; Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; Merritt TJS, 2009, GENETICS, V182, P565, DOI 10.1534/genetics.109.100677; Miyagi H, 2009, J BIOL CHEM, V284, P7553, DOI 10.1074/jbc.M804100200; Pollak N, 2007, BIOCHEM J, V402, P205, DOI 10.1042/BJ20061638; PROSTKO CR, 1989, BIOCHEM J, V258, P295, DOI 10.1042/bj2580295; Robey RB, 2005, CELL CYCLE, V4, P654, DOI 10.4161/cc.4.5.1678; Ronnebaum SM, 2006, J BIOL CHEM, V281, P30593, DOI 10.1074/jbc.M511908200; Salati LM, 2001, ANNU REV NUTR, V21, P121, DOI 10.1146/annurev.nutr.21.1.121; Sans CL, 2006, MOL CELL BIOL, V26, P4863, DOI 10.1128/MCB.00657-05; Santiago APSA, 2008, BIOCHIMIE, V90, P1566, DOI 10.1016/j.biochi.2008.06.013; Seifert EL, 2008, J BIOL CHEM, V283, P25124, DOI 10.1074/jbc.M803871200; Singh R, 2007, J BACTERIOL, V189, P6665, DOI 10.1128/JB.00555-07; Singh R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002682; Skaff DA, 2005, J BIOL CHEM, V280, P38403, DOI 10.1074/jbc.M506943200; Stoltzman CA, 2008, P NATL ACAD SCI USA, V105, P6912, DOI 10.1073/pnas.0712199105; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; Wagle A, 1998, J BIOL CHEM, V273, P14968, DOI 10.1074/jbc.273.24.14968; Ying J, 2007, FREE RADICAL BIO MED, V43, P1099, DOI 10.1016/j.freeradbiomed.2007.07.014; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; ZORATTI N, 1995, BIOCHIM BIOPHYS ACTA, V1241, P139	39	50	51	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2495	2506		10.1096/fj.09-151803	http://dx.doi.org/10.1096/fj.09-151803			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20228249				2022-12-28	WOS:000279343600036
J	Deamer, DW				Deamer, David W.			From "Banghasomes" to liposomes: A memoir of Alec Bangham, 1921-2010	FASEB JOURNAL			English	Biographical-Item									Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Deamer, DW (corresponding author), Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.	deamer@soe.ucsc.edu							0	69	71	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2010	24	5					1308	1310		10.1096/fj.10-0503	http://dx.doi.org/10.1096/fj.10-0503			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20430797				2022-12-28	WOS:000277158900003
J	Lachmann, PJ				Lachmann, Peter J.			Religion-An evolutionary adaptation	FASEB JOURNAL			English	Article									Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England	University of Cambridge	Lachmann, PJ (corresponding author), Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge CB3 0ES, England.	pjl1000@cam.ac.uk	Lachmann, P J/I-7968-2019	Lachmann, P J/0000-0003-2849-3524				Conze E., 1951, BUDDHISM ITS ESSENCE; Dawkins Richard, 1976, SELFISH GENE; DIAMOND J, 2005, COLLAPSE, pCH8; FITZGERALD E, 1868, RUBAIYAT OMAR KHAYYA, P108; GRAHAMSMITH F, 1994, POPULATION COMPLEX R; Lachmann PJ, 2009, AM J PSYCHOL, V122, P272; Lachmann P. J., 1983, CAMBRIDGE REV, V104, P22; LACHMANN PJ, 2010, EUR REV IN PRESS; Lumsden C. J., 1981, GENES MIND CULTURE; Oldstone-Moore J, 2002, CONFUCIANISM; POPPER KR, 1959, ECONOMETRICA; SMITH JM, 1964, NATURE, V201, P1145, DOI 10.1038/2011145a0; Wilson DS, 2007, Q REV BIOL, V82, P327, DOI 10.1086/522809; Wilson David Sloan., 2002, DARWINS CATHEDRAL	14	4	4	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2010	24	5					1301	1307		10.1096/fj.10-0502ufm	http://dx.doi.org/10.1096/fj.10-0502ufm			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20430796				2022-12-28	WOS:000277158900002
J	Luo, HM; Yang, J; Jin, HL; Huang, C; Fu, JW; Yang, F; Gong, H; Zeng, SQ; Luo, QM; Zhang, ZH				Luo, Haiming; Yang, Jie; Jin, Honglin; Huang, Chuan; Fu, Jianwei; Yang, Fei; Gong, Hui; Zeng, Shaoqun; Luo, Qingming; Zhang, Zhihong			Tetrameric far-red fluorescent protein as a scaffold to assemble an octavalent peptide nanoprobe for enhanced tumor targeting and intracellular uptake in vivo	FASEB JOURNAL			English	Article						optical imaging; multivalent probe; genetic engineering	CANCER; VISUALIZATION; SYSTEM; ORANGE; DRUGS	Relatively weak tumor affinities and short retention time in vivo hinder the application of targeting peptides in tumor molecular imaging. Multivalent strategies based on various scaffolds have been utilized to improve the ability of peptide-receptor binding or extend the clearance time of peptide-based probes. Here, we use a tetrameric far-red fluorescent protein (tfRFP) as a scaffold to create a self-assembled octavalent peptide fluorescent nanoprobe (Octa-FNP) using a genetic engineering approach. The multiligand connecting, fluorophore labeling and nanostructure formation of Octa-FNP were performed in one step. In vitro studies showed Octa-FNP is a 10-nm fluorescent probe with excellent serum stability. Cellular uptake of Octa-FNP by human nasopharyngeal cancer 5-8F cells is 15-fold of tetravalent probe, similar to 80-fold of monovalent probe and similar to 600-fold of nulvalent tfRFP. In vivo enhanced tumor targeting and intracellular uptake of Octa-FNP were confirmed using optical imaging and Western blot analysis. It achieved extremely high contrast of Octa-FNP signal between tumor tissue and normal organs, especially seldom Octa-FNP detected in liver and spleen. Owing to easy preparation, precise structural and functional control, and multivalent effect, Octa-FNP provides a powerful tool for tumor optical molecular imaging and evaluating the targeting ability of numerous peptides in vivo.-Luo, H., Yang, J., Jin, H., Huang, C., Fu, J., Yang, F., Gong, H., Zeng, S., Luo, Q., Zhang, Z. Tetrameric far-red fluorescent protein as a scaffold to assemble an octavalent peptide nanoprobe for enhanced tumor targeting and intracellular uptake in vivo. FASEB J. 25, 1865-1873 (2011). www.fasebj.org	[Luo, Haiming; Yang, Jie; Jin, Honglin; Huang, Chuan; Fu, Jianwei; Yang, Fei; Gong, Hui; Zeng, Shaoqun; Luo, Qingming; Zhang, Zhihong] Huazhong Univ Sci & Technol, Britton Chance Ctr Biomed Photon, Wuhan Natl Lab Optoelect, Wuhan 430074, Hubei, Peoples R China	Huazhong University of Science & Technology	Zhang, ZH (corresponding author), Huazhong Univ Sci & Technol, Britton Chance Ctr Biomed Photon, Wuhan Natl Lab Optoelect, Wuhan 430074, Hubei, Peoples R China.	czyzzh@mail.hust.edu.cn		Luo, Qingming/0000-0002-6725-9311; Jin, Honglin/0000-0002-4398-9539; Luo, Haiming/0000-0002-6226-5800	National Natural Science Foundation of China [30770525]; Program for New Century Excellent Talents in University of China [NCET-08-0220]; China-Canada Joint Health Research Initiative [NSFC30911120489]; CIHR [CCI-102936]; National High-Tech Research and Development Program of China [2006AA020801]; 111 Project of China [B07038]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University of China(Program for New Century Excellent Talents in University (NCET)); China-Canada Joint Health Research Initiative; CIHR(Canadian Institutes of Health Research (CIHR)); National High-Tech Research and Development Program of China(National High Technology Research and Development Program of China); 111 Project of China(Ministry of Education, China - 111 Project)	The authors thank Dr. Gang Zheng (University of Toronto, Toronto, ON, Canada) for discussion. The authors thank Prof. Yi-Xin Zeng and Prof. Mu-Sheng Zeng (Sun Yat-sen University Cancer Center, Guangzhou, China) for providing the 5-8F cell line, and Jiabin Huang for the schematic diagram of Octa-FNP. The authors also thank the Analytical and Testing Center (Huazhong University of Science and Technology) for spectral measurements. This work was supported by the National Natural Science Foundation of China (grant 30770525), the Program for New Century Excellent Talents in University of China (NCET-08-0220 to Z.H.Z.), the China-Canada Joint Health Research Initiative (NSFC30911120489; CIHR CCI-102936), the National High-Tech Research and Development Program of China (2006AA020801), and the 111 Project of China (B07038).	Chu J, 2009, BIOSENS BIOELECTRON, V25, P234, DOI 10.1016/j.bios.2009.06.008; Chudakov DM, 2004, NAT BIOTECHNOL, V22, P1435, DOI 10.1038/nbt1025; Cuesta AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005381; Dacosta RS, 2009, J INNOV OPT HEAL SCI, V2, P407, DOI 10.1142/S1793545809000759; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; Douglas T, 2006, SCIENCE, V312, P873, DOI 10.1126/science.1123223; Fan CY, 2008, FASEB J, V22, P3795, DOI 10.1096/fj.08-111484; Gao JH, 2010, BIOCONJUGATE CHEM, V21, P604, DOI 10.1021/bc900323v; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; Huang YF, 2009, J AM CHEM SOC, V131, P17328, DOI 10.1021/ja907125t; Kredel S, 2008, CHEM BIOL, V15, P224, DOI 10.1016/j.chembiol.2008.02.008; Lee S, 2010, CHEM REV, V110, P3087, DOI 10.1021/cr900361p; Liu W, 2009, ANGEW CHEM INT EDIT, V48, P7346, DOI 10.1002/anie.200903556; Montet X, 2006, J MED CHEM, V49, P6087, DOI 10.1021/jm060515m; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Reubi JC, 2003, ENDOCR REV, V24, P389, DOI 10.1210/er.2002-0007; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Shadidi M, 2002, FASEB J, V16, P256, DOI 10.1096/fj.02-0280fje; Shaner NC, 2008, NAT METHODS, V5, P545, DOI 10.1038/nmeth.1209; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shcherbo D, 2007, NAT METHODS, V4, P741, DOI 10.1038/NMETH1083; Shcherbo D, 2009, BIOCHEM J, V418, P567, DOI 10.1042/BJ20081949; Strack RL, 2009, BIOCHEMISTRY-US, V48, P8279, DOI 10.1021/bi900870u; Ueno Y, 2007, J ELECTRON MICROSC, V56, P103, DOI 10.1093/jmicro/dfm011; Voskuhl J, 2009, CHEM SOC REV, V38, P495, DOI 10.1039/b803782p; Wang LJ, 2009, MOL PHARMACEUT, V6, P231, DOI 10.1021/mp800150r; Wang XF, 2007, CANCER RES, V67, P3337, DOI 10.1158/0008-5472.CAN-06-2480; Werle M, 2006, AMINO ACIDS, V30, P351, DOI 10.1007/s00726-005-0289-3; Xiong T, 2005, ORAL ONCOL, V41, P709, DOI 10.1016/j.oraloncology.2005.03.012; Yan YJ, 2011, AMINO ACIDS, V41, P1081, DOI 10.1007/s00726-010-0546-y	30	26	28	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1865	1873		10.1096/fj.10-174318	http://dx.doi.org/10.1096/fj.10-174318			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21350116				2022-12-28	WOS:000291023800010
J	Tian, Y; Bustos, V; Flajolet, M; Greengard, P				Tian, Yuan; Bustos, Victor; Flajolet, Marc; Greengard, Paul			A small-molecule enhancer of autophagy decreases levels of A beta and APP-CTF via Atg5-dependent autophagy pathway	FASEB JOURNAL			English	Article						Alzheimer's disease; SMER28; Beclin1; Ulk1	LIFE-SPAN; AMYLOID PROTEIN; DISEASE; TOR; ENDOPROTEOLYSIS; LOCALIZATION; ACCUMULATION; PRESENILIN-1; TRAFFICKING; INDUCTION	The hallmarks of Alzheimer's disease are the aggregates of amyloid-beta (A beta) peptide and tau protein. Autophagy is one major cellular pathway leading to the removal of aggregated proteins. We examined the possibility of inducing autophagy to reduce A beta peptide and the amyloid precursor protein (APP)-derived fragment APP-CTF levels in cell lines and primary neuronal cultures. We found that induction of autophagy either by small-molecule enhancers of rapamycin (SMER)28, a small-molecule enhancer of autophagy, or following starvation greatly decreased the levels of A beta peptide (apparent EC50 of similar to 10 mu M) and APP-CTF (apparent EC50 of similar to 20 mu M) in a gamma-secretase-independent manner. Pharmacological inhibition of autophagy led to a significant accumulation of A beta peptide and APP-CTF and diminished the effect of SMER28. Three essential components of the autophagic pathway, autophagy-related protein (Atg)5, Beclin1, and Ulk1, were shown to be involved in the degradation of A beta and APP-CTF, and Atg5 was necessary for the effect of SMER28. In addition, the autophagic marker light chain 3-II cocompartmentalized with APP-CTF. These results support the involvement of autophagy in the clearance of A beta and APP-CTF. We therefore propose that small molecule enhancers of autophagy, such as SMER28, may have therapeutic potential for the treatment of Alzheimer's disease and other proteinopathies.-Tian, Y., Bustos, V., Flajolet, M., Greengard, P. A small-molecule enhancer of autophagy decreases levels of A beta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 25, 1934-1942 (2011). www.fasebj.org	[Tian, Yuan; Bustos, Victor; Flajolet, Marc; Greengard, Paul] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10065 USA	Rockefeller University	Flajolet, M (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10065 USA.	flajolm@rockefeller.edu; greengard@rockefeller.edu	Bustos, Victor/F-7080-2011	Greengard, Paul/0000-0002-4437-0893	U.S. National Institutes of Health [AG-09464]; Fisher Center for Alzheimer's Research Foundation; NATIONAL INSTITUTE ON AGING [P01AG009464] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fisher Center for Alzheimer's Research Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Drs. Wenjie Luo and William Netzer for sharing reagents and for helpful discussion, Dr. Zhenyu Yue (Mount Sinai Medical College, New York, NY, USA) for providing reagents, and Dr. Noboru Mizushima (Department of Physiology and Cell Biology, Tokyo Medical and Dental University, Tokyo, Japan) for the use of Atg5<SUP>+/+</SUP> and Atg5<SUP>-/-</SUP> MEF cells. This work was supported by U.S. National Institutes of Health grant AG-09464 and the Fisher Center for Alzheimer's Research Foundation.	Boland B, 2008, J NEUROSCI, V28, P6926, DOI 10.1523/JNEUROSCI.0800-08.2008; Caccamo A, 2010, J BIOL CHEM, V285, P13107, DOI 10.1074/jbc.M110.100420; Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017; Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Garcia-Arencibia M, 2010, SEMIN CELL DEV BIOL, V21, P691, DOI 10.1016/j.semcdb.2010.02.008; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080; Jaeger PA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011102; Jahreiss L, 2008, TRAFFIC, V9, P574, DOI 10.1111/j.1600-0854.2008.00701.x; Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255; Jiang Y, 2010, P NATL ACAD SCI USA, V107, P1630, DOI 10.1073/pnas.0908953107; Kaden D, 2009, J CELL SCI, V122, P368, DOI 10.1242/jcs.034058; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Liu H, 2009, FASEB J, V23, P3383, DOI 10.1096/fj.09-134296; Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004; Netzer WJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010943; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Spilman P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009979; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104; Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854	49	165	172	2	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1934	1942		10.1096/fj.10-175158	http://dx.doi.org/10.1096/fj.10-175158			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21368103	Green Published			2022-12-28	WOS:000291023800017
J	Lisse, TS; Liu, T; Irmler, M; Beckers, J; Chen, H; Adams, JS; Hewison, M				Lisse, Thomas S.; Liu, Ting; Irmler, Martin; Beckers, Johannes; Chen, Hong; Adams, John S.; Hewison, Martin			Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling	FASEB JOURNAL			English	Article						resistance; bone; vitamin D receptor	MESSENGER-RNA TRANSLATION; D-RECEPTOR; 1,25-DIHYDROXYVITAMIN D-3; MAMMALIAN TARGET; LIFE-SPAN; 24-HYDROXYLASE GENE; D RESISTANCE; CELL-GROWTH; DIFFERENTIATION; IDENTIFICATION	Transcriptional regulation by hormonal 1,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3] involves occupancy of vitamin D response elements (VDREs) by the VDRE binding protein (VDRE-BP) or 1,25(OH)(2)D-3-bound vitamin D receptor (VDR). This relationship is disrupted by elevated VDRE-BP, causing a form of hereditary vitamin D-resistant rickets (HVDRR). DNA array analysis showed that of 114 genes regulated by 1,25(OH)(2)D-3 in control cells, almost all (113) were rendered insensitive to the hormone in VDRE-BP-overexpressing HVDRR cells. Among these was the gene for DNA-damage-inducible transcript 4 (DDIT4), an inhibitor of mammalian target of rapamycin (mTOR) signaling. Chromatin immunoprecipitation PCR using 1,25(OH)(2)D-3-treated osteoblasts confirmed that VDR and VDRE-BP compete for binding to the DDIT4 gene promoter. Expression of DDIT4 mRNA in these cells was induced (1.6-6 fold) by 1,25(OH)(2)D-3 (10-100 nM), and Western blot and flow cytometry analysis showed that this response involved suppression of phosphorylated S6K1(T389) (a downstream target of mTOR) similar to rapamycin treatment. siRNA knockdown of DDIT4 completely abrogated antiproliferative responses to 1,25(OH) 2D3, whereas overexpression of VDRE-BP exerted a dominant-negative effect on transcription of 1,25(OH)(2)D-3-target genes. DDIT4, an inhibitor of mTOR signaling, is a direct target for 1,25(OH)(2)D-3 and VDRE-BP, and functions to suppress cell proliferation in response to vitamin D.-Lisse, T. S., Liu, T., Irmler, M., Beckers, J., Chen, H., Adams, J. S., Hewison, M. Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J. 25, 937-947 (2011). www.fasebj.org	[Lisse, Thomas S.; Liu, Ting; Adams, John S.; Hewison, Martin] Univ Calif Los Angeles, Orthopaed Hosp Res Ctr, Los Angeles, CA USA; [Adams, John S.; Hewison, Martin] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; [Irmler, Martin; Beckers, Johannes] German Res Ctr Environm Hlth, Inst Expt Genet, Helmholtz Zentrum Munich, Neuherberg, Germany; [Beckers, Johannes] Tech Univ Munich, Ctr Life & Food Sci, D-8050 Freising Weihenstephan, Germany; [Chen, Hong] Emory Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Emory University	Hewison, M (corresponding author), Univ Calif Los Angeles, Orthopaed Hosp Res Ctr, Rm 410D,615 Charles E Young Dr, S Los Angeles, CA 90095 USA.	mhewison@mednet.ucla.edu	Beckers, Johannes/K-7237-2012; Adams, John S/I-3365-2013; lisse, thomas/B-4847-2019; Irmler, Martin/B-3317-2013	Beckers, Johannes/0000-0001-7874-3822; Adams, John S/0000-0001-9607-5020; Irmler, Martin/0000-0003-3169-479X	U.S. National Institutes of Health [2R01AR037399-21]; German National Genome Research Network [01GS0850]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037399] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German National Genome Research Network; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Dr. Mark Meyer (University of Wisconsin, Madison, WI, USA) for help with analysis of VDREs, and Renata Pereira (UCLA) and Jeremy Laney (UCLA) for assistance with the human primary osteoblast cultures. This work is supported by U.S. National Institutes of Health grant 2R01AR037399-21 to J.S.A., and German National Genome Research Network NGFNplus grant 01GS0850 to J.B. The authors declare no conflicts of interest.	Abraham RT, 2007, CLIN CANCER RES, V13, P3109, DOI 10.1158/1078-0432.CCR-06-2798; Adams JS, 2004, J STEROID BIOCHEM, V89-90, P461, DOI 10.1016/j.jsbmb.2004.03.016; ADAMS JS, J IMMUNOL, V182, P4289; Alarid ET, 2006, MOL ENDOCRINOL, V20, P1972, DOI 10.1210/me.2005-0481; Alvarez-Garcia O, 2010, KIDNEY INT, V78, P561, DOI 10.1038/ki.2010.173; Arbelle JE, 1996, ENDOCRINOLOGY, V137, P786, DOI 10.1210/en.137.2.786; Banwell CM, 2006, CLIN CANCER RES, V12, P2004, DOI 10.1158/1078-0432.CCR-05-1218; Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052; Canaud G, 2010, AM J TRANSPLANT, V10, P1701, DOI 10.1111/j.1600-6143.2010.03152.x; Carlberg C, 2009, ANTICANCER RES, V29, P3485; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chen H, 2000, J BIOL CHEM, V275, P35557, DOI 10.1074/jbc.M007117200; Chen H, 2006, J BIOL CHEM, V281, P39114, DOI 10.1074/jbc.M608006200; Chung I, 2009, CANCER RES, V69, P967, DOI 10.1158/0008-5472.CAN-08-2307; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Ellisen LW, 2005, CELL CYCLE, V4, P1500, DOI 10.4161/cc.4.11.2139; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Fernandez-Garcia NI, 2005, ONCOGENE, V24, P6533, DOI 10.1038/sj.onc.1208801; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; HEWISON M, 1993, CLIN ENDOCRINOL, V39, P663, DOI 10.1111/j.1365-2265.1993.tb02424.x; Iacobazzi V, 2004, HUM MUTAT, V24, P312, DOI 10.1002/humu.20085; Jurutka PW, 2007, J BONE MINER RES, V22, pV2, DOI 10.1359/JBMR.07S216; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kovalenko PL, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-26; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Mahajan MC, 2005, P NATL ACAD SCI USA, V102, P15012, DOI 10.1073/pnas.0507596102; Malloy PJ, 1999, ENDOCR REV, V20, P156, DOI 10.1210/er.20.2.156; Meyer MB, 2010, J BIOL CHEM, V285, P15599, DOI 10.1074/jbc.M110.119958; Miller CW, 1997, MOL CARCINOGEN, V19, P254, DOI 10.1002/(SICI)1098-2744(199708)19:4<254::AID-MC6>3.0.CO;2-C; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; O'Kelly J, 2006, J STEROID BIOCHEM, V100, P107, DOI 10.1016/j.jsbmb.2006.04.003; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; OMDAHL J, 2005, VITAMIN D, V1, P85; Penning TM, 2008, MOL CELL ENDOCRINOL, V281, P1, DOI 10.1016/j.mce.2007.10.008; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Shibuya T, 2006, ARTERIOSCL THROM VAS, V26, P1051, DOI 10.1161/01.ATV.0000216747.66660.26; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAY N, 1992, J VIROL, V66, P6841, DOI 10.1128/JVI.66.12.6841-6848.1992; Thakur MK, 2009, HORM RES, V71, P194, DOI 10.1159/000201107; Tiscornia G, 2000, MOL CELL, V5, P959, DOI 10.1016/S1097-2765(00)80261-0; Tolnay M, 1999, BIOCHEM J, V338, P417, DOI 10.1042/0264-6021:3380417; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wang QM, 1996, CANCER RES, V56, P264; Yang J, 2010, EXP HEMATOL, V38, P666, DOI 10.1016/j.exphem.2010.03.020; YEN A, 1994, EXP CELL RES, V214, P250, DOI 10.1006/excr.1994.1255; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	58	87	91	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					937	947		10.1096/fj.10-172577	http://dx.doi.org/10.1096/fj.10-172577			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21123297	Green Published			2022-12-28	WOS:000287806200014
J	Narumiya, S; Furuyashiki, T				Narumiya, Shuh; Furuyashiki, Tomoyuki			Fever, inflammation, pain and beyond: prostanoid receptor research during these 25 years	FASEB JOURNAL			English	Review						prostaglandin; thromboxane; GPCR; immune inflammation; tissue remodeling; atherosclerosis	PROSTAGLANDIN RECEPTORS; THROMBOXANE A(2); MICE LACKING; SUBTYPE EP3; PROSTACYCLIN; DEFICIENT; NUCLEUS; ROLES		[Narumiya, Shuh] Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Furuyashiki, Tomoyuki/B-8760-2014; Furuyashiki, Tomoyuki/AAG-5283-2019	Furuyashiki, Tomoyuki/0000-0001-8089-8399; Furuyashiki, Tomoyuki/0000-0001-8089-8399				Ahmadi S, 2002, NAT NEUROSCI, V5, P34, DOI 10.1038/nn778; BERGSTROM S, 1968, PHARMACOL REV, V20, P1; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Esaki Y, 2010, P NATL ACAD SCI USA, V107, P12233, DOI 10.1073/pnas.0915112107; Funk CD, 2007, J CARDIOVASC PHARM, V50, P470, DOI 10.1097/FJC.0b013e318157f72d; FURUYASHIKI T, 2011, NAT REV END IN PRESS; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HOFFMAN F, 1984, HAEMODYNAMICS HORMON, V2, P555; Honda T, 2006, J EXP MED, V203, P325, DOI 10.1084/jem.20051310; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; KENNEDY I, 1982, PROSTAGLANDINS, V24, P667, DOI 10.1016/0090-6980(82)90036-3; Kobayashi T, 2004, J CLIN INVEST, V114, P784, DOI 10.1172/JCI200421446; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Lazarus M, 2007, NAT NEUROSCI, V10, P1131, DOI 10.1038/nn1949; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Matsuoka Y, 2003, P NATL ACAD SCI USA, V100, P4132, DOI 10.1073/pnas.0633341100; Moriyama T, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-3; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nakamura K, 2002, J NEUROSCI, V22, P4600, DOI 10.1523/JNEUROSCI.22-11-04600.2002; Narumiya S, 2007, P JPN ACAD B-PHYS, V83, P296, DOI [10.2183/pjab.83.296, 10.2183/pjab/83.296]; Oga T, 2009, NAT MED, V15, P1426, DOI 10.1038/nm.2066; SAUSSY DL, 1986, J BIOL CHEM, V261, P3025; Stone E., 1763, PHILOS T, V53, P195; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WOODWARD DF, 2010, PHARM REV IN PRESS; Yao CC, 2009, NAT MED, V15, P633, DOI 10.1038/nm.1968; Yuhki K, 2004, J PHARMACOL EXP THER, V311, P1218, DOI 10.1124/jpet.104.071548	30	49	52	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2011	25	3					813	818		10.1096/fj.11-0302ufm	http://dx.doi.org/10.1096/fj.11-0302ufm			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21357250				2022-12-28	WOS:000287806200002
J	Kaur, G; Jans, DA				Kaur, Gurpreet; Jans, David A.			Dual nuclear import mechanisms of sex determining factor SRY: intracellular Ca2+ as a switch	FASEB JOURNAL			English	Article						calmodulin; importin; NLS; nuclear localization; sex reversal	XY-GONADAL-DYSGENESIS; LOCALIZATION SIGNALS; DETERMINING REGION; DNA-BINDING; HMG-BOX; REVERSAL; SOX9; MUTATIONS; TRANSPORT; INHIBITION	The sex-determining region on the Y chromosome (SRY) has 2 nuclear localization signals (NLSs) that flank the DNA binding high mobility group (HMG) domain; the beta-NLS and the CaM-NLS, which mediate nuclear transport through importin beta 1 (Imp beta 1) and the calcium-binding protein calmodulin (CaM), respectively. Here we reconstitute the nuclear import mediated by the 2 NLSs for the first time in vitro, establishing Ran independence of CaM-NLS-dependent transport. The beta- and CaM-NLSs were found to be independently functional out of the context of the SRY HMG domain, dependent on Imp beta 1 and CaM binding, respectively. Intriguingly, direct protein binding assays also indicated competitive binding of Imp beta 1 and CaM to the SRY HMG domain. To assess the potential role of intracellular calcium in modulating SRY nuclear accumulation, Cos-7 cells expressing SRY and control constructs were treated with agents elevating or reducing intracellular Ca2+ levels. The in vivo results, supported by experiments in vitro where transport was assessed with or without 2 mu M Ca2+, indicate a Ca2+-dependent mode of nuclear transport via the CaM-NLS/CaM, with inhibition of beta-NLS/Imp beta 1-mediated nuclear import by intracellular Ca2+. The results imply mutual exclusivity of nuclear transport via the 2 NLSs with intracellular Ca2+ as the switch between the 2.-Kaur, G. Jans, D. A. Dual nuclear import mechanisms of sex determining factor SRY: intracellular Ca2+ as a switch. FASEB J. 25, 665-675 (2011). www.fasebj.org	[Kaur, Gurpreet] Monash Univ, Nucl Signalling Lab, Dept Biochem & Mol Biol, Monash, Vic 3800, Australia	Monash University	Jans, DA (corresponding author), Monash Univ, Nucl Signalling Lab, Dept Biochem & Mol Biol, Bldg 77, Monash, Vic 3800, Australia.	jans@med.monash.edu.au		Jans, David/0000-0001-5115-4745				Argentaro A, 2003, J BIOL CHEM, V278, P33839, DOI 10.1074/jbc.M302078200; Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Forwood Jade K., 2007, V390, P83; Forwood JK, 2002, BIOCHEMISTRY-US, V41, P9333, DOI 10.1021/bi025548s; Forwood JK, 2001, J BIOL CHEM, V276, P46575, DOI 10.1074/jbc.M101668200; Hanover JA, 2007, J BIOL CHEM, V282, P33743, DOI 10.1074/jbc.M705875200; Harley VR, 2003, ENDOCR REV, V24, P466, DOI 10.1210/er.2002-0025; Harley VR, 2003, P NATL ACAD SCI USA, V100, P7045, DOI 10.1073/pnas.1137864100; Harley VR, 1996, FEBS LETT, V391, P24, DOI 10.1016/0014-5793(96)00694-1; Hiramatsu R, 2009, DEVELOPMENT, V136, P129, DOI 10.1242/dev.029587; Kaur G, 2010, BIOCHEM J, V430, P39, DOI 10.1042/BJ20091758; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Mitchell CL, 2002, MOL GENET METAB, V77, P217, DOI 10.1016/S1096-7192(02)00165-8; Preiss S, 2001, J BIOL CHEM, V276, P27864, DOI 10.1074/jbc.M101278200; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Sweitzer TD, 1996, P NATL ACAD SCI USA, V93, P14574, DOI 10.1073/pnas.93.25.14574; Uehara S, 2002, J HUM GENET, V47, P279, DOI 10.1007/s100380200040; Wagstaff KM, 2006, ANAL BIOCHEM, V348, P49, DOI 10.1016/j.ab.2005.10.029; Wagstaff KM, 2005, J FLUORESC, V15, P469, DOI 10.1007/s10895-005-2819-5; Webb SE, 2003, NAT REV MOL CELL BIO, V4, P539, DOI 10.1038/nrm1149; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	24	19	20	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2011	25	2					665	675		10.1096/fj.10-173351	http://dx.doi.org/10.1096/fj.10-173351			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21051653				2022-12-28	WOS:000286724800024
J	Speidl, WS; Kastl, SP; Hutter, R; Katsaros, KM; Kaun, C; Bauriedel, G; Maurer, G; Huber, K; Badimon, JJ; Wojta, J				Speidl, Walter S.; Kastl, Stefan P.; Hutter, Randolph; Katsaros, Katharina M.; Kaun, Christoph; Bauriedel, Gerhard; Maurer, Gerald; Huber, Kurt; Badimon, Juan J.; Wojta, Johann			The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro	FASEB JOURNAL			English	Article						matrix metalloproteinase; plaque rupture; atherosclerosis	PLASMINOGEN-ACTIVATOR INHIBITOR-1; RECEPTOR-DEFICIENT MICE; KAPPA-B ACTIVATION; ATHEROSCLEROTIC PLAQUES; AP-1 ACTIVATION; MATRIX METALLOPROTEINASES; ENDOTHELIAL-CELLS; ONCOSTATIN-M; LOCALIZATION; INFLAMMATION	The complement component C5a is formed during activation of the complement cascade and exerts chemotactic and proinflammatory effects. Macrophages, which are localized in the rupture-prone shoulder regions of coronary plaques, are thought to play a major role in plaque destabilization and rupture through the production of matrix metalloproteinases (MMPs). When human monocyte-derived macrophages were stimulated in vitro with C5a, MMP-1 and MMP-9 mRNA levels were significantly increased. Furthermore, C5a up-regulated MMP-1 and MMP-9 antigens and activity, as determined by ELISA and specific activity assays. These effects were blocked by antibodies against the receptor C5aR/CD88. In addition, blocking experiments revealed that MMP-1 expression was mediated by activation of the transcription factor AP-1, and MMP-9 expression was induced by activation of NF-kappa B and AP-1. Immunohistochemical analysis of human coronary plaques demonstrated the colocalization of C5a, MMP-1, and MMP-9 in vivo. Together, these observations indicate that activation of the complement cascade and formation of C5a may play a role in the onset of acute coronary events by induction of MMPs in atherosclerotic lesions.-Speidl, W. S., Kastl, S. P., Hutter, R., Katsaros, K. M., Kaun, C., Bauriedel, G., Maurer, G., Huber, K., Badimon, J. J., Wojta, J. The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro. FASEB J. 25, 35-44 (2011). www.fasebj.org	[Speidl, Walter S.; Kastl, Stefan P.; Katsaros, Katharina M.; Kaun, Christoph; Maurer, Gerald; Wojta, Johann] Med Univ Vienna, Dept Internal Med 2, Vienna, Austria; [Kastl, Stefan P.; Wojta, Johann] Ludwig Boltzmann Cluster Cardiovasc Res, Vienna, Austria; [Speidl, Walter S.; Hutter, Randolph; Badimon, Juan J.] Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA; [Bauriedel, Gerhard] Univ Bonn, Dept Cardiol, Ctr Heart, D-5300 Bonn, Germany; [Huber, Kurt] Wilhelminenspital Stadt Wien, Dept Med Cardiol & Emergency Med 3, Vienna, Austria	Medical University of Vienna; Ludwig Boltzmann Institute; Icahn School of Medicine at Mount Sinai; University of Bonn; University of Hamburg; University Medical Center Hamburg-Eppendorf; Wilhelminenspital	Wojta, J (corresponding author), Univ Vienna, Dept Internal Med 2, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	johann.wojta@meduniwien.ac.at	Speidl, Walter S./AAU-8830-2020; Kaun, Christoph/L-7543-2015; Kastl, Stefan P/B-2695-2009; Wojta, Johann/AAC-8433-2020	Speidl, Walter S./0000-0002-7267-3138; Kaun, Christoph/0000-0003-3873-7246; Kastl, Stefan P/0000-0002-9682-0200; Wojta, Johann/0000-0002-1282-9276; Maurer, Gerald/0000-0002-9043-7657	Ludwig Boltzmann Foundation for Cardiovascular Research; Association for Promotion of Research in Arteriosclerosis, Thrombosis and Vascular Biology; Hans and Blanca Moser Foundation; International Society for Fibrinolysis and Proteolysis	Ludwig Boltzmann Foundation for Cardiovascular Research; Association for Promotion of Research in Arteriosclerosis, Thrombosis and Vascular Biology; Hans and Blanca Moser Foundation; International Society for Fibrinolysis and Proteolysis	This work was supported by the Ludwig Boltzmann Foundation for Cardiovascular Research; the Association for Promotion of Research in Arteriosclerosis, Thrombosis and Vascular Biology; and the Hans and Blanca Moser Foundation. S. P. K. was supported by a travel grant from the International Society for Fibrinolysis and Proteolysis. W. S. S., S. P. K., R. H., K. M. K., and C. K. performed experiments; W. S. S. and S. P. K. analyzed results and made the figures; G. B., G. M. and K. H. revised the paper critically; and J.J.B. and J.W. designed the research and wrote the paper.	Bhatia VK, 2007, AM J PATHOL, V170, P416, DOI 10.2353/ajpath.2007.060406; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; Clark IA, 2008, INT J BIOCHEM CELL B, V40, P1362, DOI 10.1016/j.biocel.2007.12.006; Davies MJ, 1998, CIRCULATION, V97, P2382, DOI 10.1161/01.CIR.97.24.2382; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, FASEB J, V9, P974, DOI 10.1096/fasebj.9.10.7615167; GEERTINGER P, 1970, ACTA PATH MICRO IM A, VA 78, P284; Gough PJ, 2006, J CLIN INVEST, V116, P59, DOI 10.1172/JCI25074; Iles KE, 2002, FREE RADICAL BIO MED, V32, P1304, DOI 10.1016/S0891-5849(02)00840-7; Kastl SP, 2006, J THROMB HAEMOST, V4, P1790, DOI 10.1111/j.1538-7836.2006.02046.x; Kastl SP, 2008, ARTERIOSCL THROM VAS, V28, P498, DOI 10.1161/ATVBAHA.107.160580; Kastl SP, 2009, BLOOD, V114, P2812, DOI 10.1182/blood-2009-01-200915; Kostner KM, 2004, EUR J CLIN INVEST, V34, P800, DOI 10.1111/j.1365-2362.2004.01431.x; Laine P, 2002, AM J CARDIOL, V90, P404, DOI 10.1016/S0002-9149(02)02498-0; Lewis MJ, 2009, CIRCULATION, V120, P417, DOI 10.1161/CIRCULATIONAHA.109.868158; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Nataf S, 1999, J IMMUNOL, V162, P4018; Niculescu F, 1999, MOL IMMUNOL, V36, P949, DOI 10.1016/S0161-5890(99)00117-0; Oksjoki R, 2003, CURR OPIN LIPIDOL, V14, P477, DOI 10.1097/00041433-200310000-00008; Oksjoki R, 2007, ATHEROSCLEROSIS, V195, P90, DOI 10.1016/j.atherosclerosis.2006.12.016; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; Park S, 2004, J CELL BIOCHEM, V91, P973, DOI 10.1002/jcb.10768; Patel S, 2001, BIOCHEM BIOPH RES CO, V286, P164, DOI 10.1006/bbrc.2001.5276; Rabiet MJ, 2008, J BIOL CHEM, V283, P31038, DOI 10.1074/jbc.M805260200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schmiedt W, 1998, ARTERIOSCL THROM VAS, V18, P1790, DOI 10.1161/01.ATV.18.11.1790; SCHULMAN ES, 1988, J CLIN INVEST, V81, P918, DOI 10.1172/JCI113403; SHAH PK, 1995, CIRCULATION, V92, P1565; Speidl WS, 2007, J ENDOVASC THER, V14, P62, DOI 10.1583/06-1946.1; Speidl WS, 2010, ATHEROSCLEROSIS, V208, P285, DOI 10.1016/j.atherosclerosis.2009.07.030; Speidl WS, 2005, EUR HEART J, V26, P2294, DOI 10.1093/eurheartj/ehi339; Speidl WS, 2004, FASEB J, V18, P603, DOI 10.1096/fj.03-0454fje; Takafuji S, 2003, J INVEST ALLERG CLIN, V13, P50; TIPPING PG, 1993, AM J PATHOL, V143, P875; Tobe M, 2003, BIOORGAN MED CHEM, V11, P383, DOI 10.1016/S0968-0896(02)00440-6; Torzewski J, 1997, ATHEROSCLEROSIS, V132, P131, DOI 10.1016/S0021-9150(97)00100-7; VLAICU R, 1985, ATHEROSCLEROSIS, V57, P163, DOI 10.1016/0021-9150(85)90030-9; Wojta J, 2002, BLOOD, V100, P517, DOI 10.1182/blood.V100.2.517; Yasojima K, 2001, ARTERIOSCL THROM VAS, V21, P1214, DOI 10.1161/hq0701.092160; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5; Zhang YH, 1998, J IMMUNOL, V161, P3071	43	70	72	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					35	44		10.1096/fj.10-156083	http://dx.doi.org/10.1096/fj.10-156083			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20813982				2022-12-28	WOS:000285869500004
J	Iizuka, Y; Okuno, T; Saeki, K; Uozaki, H; Okada, S; Misaka, T; Sato, T; Toh, H; Fukayama, M; Takeda, N; Kita, Y; Shimizu, T; Nakamura, M; Yokomizo, T				Iizuka, Yoshiko; Okuno, Toshiaki; Saeki, Kazuko; Uozaki, Hiroshi; Okada, Shinji; Misaka, Takumi; Sato, Tetsuya; Toh, Hiroyuki; Fukayama, Masashi; Takeda, Naoki; Kita, Yoshihiro; Shimizu, Takao; Nakamura, Motonao; Yokomizo, Takehiko			Protective role of the leukotriene B-4 receptor BLT2 in murine inflammatory colitis	FASEB JOURNAL			English	Article						arachidonic cascade; eicosanoids; G-protein-coupled receptor; inflammatory bowel diseases	T-CELL RECRUITMENT; COLONIC INFLAMMATION; ULCERATIVE-COLITIS; RESOLVIN E1; ACTIVATION; ACID; ANTAGONIST; PROLIFERATION; SC-41930; DISEASE	BLT2 is a low-affinity leukotriene B-4 (LTB4) receptor that is activated by 12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT) and LTB4. Despite the well-defined proinflammatory roles of BLT1, the in vivo functions of BLT2 remain elusive. To clarify the role of BLT receptors in intestinal inflammation, we assessed susceptibility to dextran sodium sulfate (DSS)-induced colitis in mice lacking either BLT1 or BLT2. BLT2(-/-) mice exhibited increased sensitivity to DSS as compared to wild-type and BLT1(-/-) mice, with more severe body weight loss and inflammation. Expression of inflammatory cytokines such as interferon (IFN)-gamma, interleukin (IL)-1 beta, and IL-6, chemokines such as CXC chemokine ligand 9 (CXCL9) and C-C motif chemokine 19 (CCL19), and metalloproteinases was highly up-regulated in the colons of DSS-treated BLT2(-/-) mice, and there was an enhanced accumulation of activated macrophages. Phosphorylation of the signal transducer and activator of transcription 3 (STAT3) was also markedly accelerated in the crypts of DSS-treated BLT2(-/-) mice. Madin-Darby canine kidney II (MDCKII) cells transfected with BLT2 exhibited enhanced barrier function as measured by transepithelial electrical resistance (TER) and FITC-dextran leakage through MDCK monolayers. Thus, BLT2 is expressed in colon cryptic cells and appears to protect against DSS-induced colitis, possibly by enhancing barrier function in epithelial cells of the colon. These novel results suggest a direct anti-inflammatory role of BLT2 that is distinct from the proinflammatory roles of BLT1.-Iizuka, Y., Okuno, T., Saeki, K., Uozaki, H., Okada, S., Misaka, T., Sato, T., Toh, H., Fukayama, M., Takeda, N., Kita, Y., Shimizu, T., Nakamura, M., Yokomizo, T. Protective role of the leukotriene B-4 receptor BLT2 in murine inflammatory colitis. FASEB J. 24, 4678-4690 (2010). www.fasebj.org	[Iizuka, Yoshiko; Kita, Yoshihiro; Shimizu, Takao; Nakamura, Motonao] Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, Fukuoka 8128582, Japan; [Iizuka, Yoshiko; Kita, Yoshihiro; Shimizu, Takao; Nakamura, Motonao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan; [Uozaki, Hiroshi; Fukayama, Masashi] Univ Tokyo, Fac Med, Dept Pathol, Tokyo 1130033, Japan; [Okada, Shinji; Misaka, Takumi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1130033, Japan; [Sato, Tetsuya; Toh, Hiroyuki] Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan; [Yokomizo, Takehiko] Japan Sci & Technol Agcy, Kawaguchi, Saitama, Japan; [Takeda, Naoki] Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto, Japan	Kyushu University; University of Tokyo; University of Tokyo; University of Tokyo; Kyushu University; Japan Science & Technology Agency (JST); Kumamoto University	Yokomizo, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	moto-nakamura@umin.net; yokomizo@med.kyushu-u.ac.jp	OKADA, Shinji/AFS-7710-2022; Yokomizo, Takehiko/P-5673-2016; Shimizu, Takao/AAV-7052-2021	OKADA, Shinji/0000-0002-4465-9961; Yokomizo, Takehiko/0000-0002-5219-1553; Misaka, Takumi/0000-0002-9547-5767	Japan Ministry of Education, Culture, Sports, Science, and Technology; Takeda Science Foundation; Mitsubishi Foundation; Uehara Memorial Foundation; Sankyo Foundation of Life Science; Japan Society for the Promotion of Science	Japan Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Mitsubishi Foundation; Uehara Memorial Foundation(Uehara Memorial Foundation); Sankyo Foundation of Life Science; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The authors thank T. Nakamura, M. Amago, and members of the Kyushu University Support Center for Education and Research for DNA microarray analysis; Dr. J. Miyazaki (Osaka University, Osaka, Japan) for pCXN vector; Drs. A. Yoshimura (Keio University, Tokyo, Japan), T. Chinen, K. Morohashi, and K. Miyabayashi (Kyushu University), K. Kabashima (Kyoto University, Kyoto, Japan), Y. Kurihara and M. Arita (Tokyo University, Tokyo, Japan), and our laboratory members for valuable advice and discussions. This work was supported by Grants-in-Aid for Scientific Research from the Japan Ministry of Education, Culture, Sports, Science, and Technology (to T.Y., M.N., T.O., K.S., and T.S.), and grants from Takeda Science Foundation, Mitsubishi Foundation, the Uehara Memorial Foundation, Sankyo Foundation of Life Science, and the Japan Society for the Promotion of Science (Global COE program) (to T.Y.).	Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; BOUCHELOUCHE PN, 1995, EUR J GASTROEN HEPAT, V7, P349; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Cho KJ, 2010, AM J RESP CELL MOL, V42, P294, DOI 10.1165/rcmb.2008-0445OC; COOPER HS, 1993, LAB INVEST, V69, P238; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; FRETLAND DJ, 1995, INFLAMMATION, V19, P503, DOI 10.1007/BF01539131; FRETLAND DJ, 1989, AGENTS ACTIONS, V27, P395, DOI 10.1007/BF01972832; FRETLAND DJ, 1990, J PHARMACOL EXP THER, V255, P572; GERTNER DJ, 1994, GUT, V35, P1429, DOI 10.1136/gut.35.10.1429; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; Hennig R, 2008, BRIT J CANCER, V99, P1064, DOI 10.1038/sj.bjc.6604655; Iizuka Y, 2005, J BIOL CHEM, V280, P24816, DOI 10.1074/jbc.M413257200; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kamohara M, 2000, J BIOL CHEM, V275, P27000; Kato K, 2000, J EXP MED, V192, P413, DOI 10.1084/jem.192.3.413; Kim GY, 2009, ARTERIOSCL THROM VAS, V29, P915, DOI 10.1161/ATVBAHA.109.185793; Kita Y, 2005, ANAL BIOCHEM, V342, P134, DOI 10.1016/j.ab.2005.03.048; LAURITSEN K, 1986, GASTROENTEROLOGY, V91, P837, DOI 10.1016/0016-5085(86)90684-0; Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058; LIN AH, 1984, PROSTAGLANDINS, V28, P837, DOI 10.1016/0090-6980(84)90038-8; Luster AD, 2004, NAT REV IMMUNOL, V4, P711, DOI 10.1038/nri1438; Morteau O, 2000, J CLIN INVEST, V105, P469, DOI 10.1172/JCI6899; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Okuno T, 2008, J EXP MED, V205, P759, DOI 10.1084/jem.20072329; Rigby RJ, 2007, ONCOGENE, V26, P4833, DOI 10.1038/sj.onc.1210286; Shao WH, 2006, J IMMUNOL, V176, P6254, DOI 10.4049/jimmunol.176.10.6254; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217; Toda A, 2010, BIOCHIMIE, V92, P682, DOI 10.1016/j.biochi.2009.12.002; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yoo MH, 2004, ONCOGENE, V23, P9259, DOI 10.1038/sj.onc.1208151	41	78	78	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4678	4690		10.1096/fj.10-165050	http://dx.doi.org/10.1096/fj.10-165050			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20667973				2022-12-28	WOS:000284824400009
J	Shaykhiev, R; Sierigk, J; Herr, C; Krasteva, G; Kummer, W; Bals, R				Shaykhiev, Renat; Sierigk, Johannes; Herr, Christian; Krasteva, Gabriela; Kummer, Wolfgang; Bals, Robert			The antimicrobial peptide cathelicidin enhances activation of lung epithelial cells by LPS	FASEB JOURNAL			English	Article						host defense; mucosal immunity; innate immunity; endotoxin; Toll-like receptor	TOLL-LIKE RECEPTOR-4; PROINFLAMMATORY GENE-EXPRESSION; INNATE IMMUNE RECOGNITION; GROWTH-FACTOR RECEPTOR; HOST-DEFENSE; DEPENDENT ENDOCYTOSIS; GOLGI-APPARATUS; BACTERIAL LIPOPOLYSACCHARIDE; ADAPTIVE IMMUNITY; DENDRITIC CELLS	Epithelial cells (ECs) are usually hyporesponsive to various microbial products. Detection of lipopolysaccharide (LPS), the major component of gram-negative bacteria, is impeded, at least in part, by intracellular sequestration of its receptor, Toll-like receptor-4 (TLR4). In this study, using human bronchial ECs (hBECs) as a model of mucosal epithelium, we tested the hypothesis that the human LPS-binding, membrane-active cationic host defense peptide cathelicidin LL-37 augments epithelial response to LPS by facilitating its delivery to TLR4-containing intracellular compartments. We found that LL-37 significantly increases uptake of LPS by ECs with subsequent targeting to cholera toxin subunit B-labeled structures and lysosomes. This uptake is peptide specific, dose and time dependent, and involves the endocytotic machinery, functional lipid rafts, and epidermal growth factor receptor signaling. Cathelicidin-dependent LPS internalization resulted in significant increased release of the inflammatory cytokines IL-6 and IL-8. This indicates that, in ECs, this peptide may replace LPS-binding protein functions. In polarized ECs, the effect of LL-37 was restricted to the basolateral compartment of the epithelial membrane, suggesting that LL-37-mediated activation of ECs by LPS may be relevant to disease conditions associated with damage to the epithelial barrier. In summary, our study identified a novel role of LL-37 in host-microbe interactions as a host factor that licenses mucosal ECs to respond to LPS.-Shaykhiev, R., Sierigk, J., Herr, C., Krasteva, G., Kummer, W., Bals, R. The antimicrobial peptide cathelicidin enhances activation of lung epithelial cells by LPS. FASEB J. 24, 4756-4766 (2010). www.fasebj.org	[Herr, Christian; Bals, Robert] Dept Internal Med V Pulmonol, D-66421 Homburg, Germany; [Shaykhiev, Renat; Sierigk, Johannes; Herr, Christian; Bals, Robert] Univ Marburg, Dept Internal Med, UGMLC, Div Pulmonol,Univ Hosp Giessen & Marburg, D-3550 Marburg, Germany; [Krasteva, Gabriela; Kummer, Wolfgang] Univ Giessen, UGMLC, Inst Anat & Cell Biol, Giessen, Germany	Philipps University Marburg; University Hospital of Giessen & Marburg; Justus Liebig University Giessen	Bals, R (corresponding author), Dept Internal Med V Pulmonol, D-66421 Homburg, Germany.	robert.bals@uks.eu	Krasteva-Christ, Gabriela/K-7253-2015; Krasteva-Christ, Gabriela/CAI-9036-2022; Shaykhiev, Renat/D-2855-2011; Herr, Christian/AAH-5291-2021	Krasteva-Christ, Gabriela/0000-0002-0113-521X; Krasteva-Christ, Gabriela/0000-0002-0113-521X; Herr, Christian/0000-0001-9422-6569; Kummer, Wolfgang/0000-0002-3946-0683	Bundesministerium fur Bildung und Forschung; Deutsche Forschungsgemeinschaft (DFG) [Ba 1641/8, SFB/TR 22 A8]; Excellence Cluster CardioPulmonary System (DFG); Medical Faculty of the Justus-Liebig-University (Giessen, Germany)	Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Excellence Cluster CardioPulmonary System (DFG)(German Research Foundation (DFG)); Medical Faculty of the Justus-Liebig-University (Giessen, Germany)	The authors thank Prof. Dr. Jurgen Behr (University of Munich, Munich, Germany) for providing ECs and Thomas Damm and Annette Puchner for excellent technical assistance. This study was funded by the Bundesministerium fur Bildung und Forschung (PROGRESS, C1; ASCONET/COSYCONET) to R.B., by the Deutsche Forschungsgemeinschaft (DFG; Ba 1641/8 and SFB/TR 22 A8) to R.B., and by the Excellence Cluster CardioPulmonary System (DFG) to W. K. G. K. was supported by a postdoctoral stipend from the DFG Excellence Cluster CardioPulmonary System and a young scientist's grant from the Medical Faculty of the Justus-Liebig-University (Giessen, Germany).	Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Agerberth B, 1999, AM J RESP CRIT CARE, V160, P283, DOI 10.1164/ajrccm.160.1.9807041; Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; Bals Robert, 2004, J Cyst Fibros, V3 Suppl 2, P49, DOI 10.1016/j.jcf.2004.05.010; Baranska-Rybak W, 2006, J ANTIMICROB CHEMOTH, V57, P260, DOI 10.1093/jac/dki460; Bartlett Jennifer A., 2008, V15, P147, DOI 10.1159/000136349; Cario E, 2007, GASTROENTEROLOGY, V132, P1359, DOI 10.1053/j.gastro.2007.02.056; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Davidson DJ, 2004, J IMMUNOL, V172, P1146, DOI 10.4049/jimmunol.172.2.1146; Durr UHN, 2006, BBA-BIOMEMBRANES, V1758, P1408, DOI 10.1016/j.bbamem.2006.03.030; Felgentreff K, 2006, PEPTIDES, V27, P3100, DOI 10.1016/j.peptides.2006.07.018; Fritz JH, 2008, TRENDS IMMUNOL, V29, P41, DOI 10.1016/j.it.2007.10.002; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Guttman JA, 2009, BBA-BIOMEMBRANES, V1788, P832, DOI 10.1016/j.bbamem.2008.10.028; Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x; Hornef MW, 2005, J ENDOTOXIN RES, V11, P124, DOI 10.1179/096805105X35224; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Hoshino K, 1999, J IMMUNOL, V162, P3749; Husebye H, 2006, EMBO J, V25, P683, DOI 10.1038/sj.emboj.7600991; Ishii KJ, 2008, CELL HOST MICROBE, V3, P352, DOI 10.1016/j.chom.2008.05.003; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Kandler K, 2006, INT IMMUNOL, V18, P1729, DOI 10.1093/intimm/dxl107; Kirikae T, 1998, INFECT IMMUN, V66, P1861, DOI 10.1128/IAI.66.5.1861-1868.1998; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Konig P, 2006, LAB INVEST, V86, P853, DOI 10.1038/labinvest.3700443; Lajoie P, 2007, J CELL MOL MED, V11, P644, DOI 10.1111/j.1582-4934.2007.00083.x; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; Lau YE, 2005, INFECT IMMUN, V73, P583, DOI 10.1128/IAI.73.1.583-591.2005; Lee J, 2006, NAT CELL BIOL, V8, P1327, DOI 10.1038/ncb1500; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Mookherjee N, 2006, J IMMUNOL, V176, P2455, DOI 10.4049/jimmunol.176.4.2455; Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Munford RS, 2008, INFECT IMMUN, V76, P454, DOI 10.1128/IAI.00939-07; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; Nejsum LN, 2009, FRONT BIOSCI-LANDMRK, V14, P1088, DOI 10.2741/3295; Pang H, 2004, J CELL SCI, V117, P1421, DOI 10.1242/jcs.01009; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Poussin C, 1998, J BIOL CHEM, V273, P20285, DOI 10.1074/jbc.273.32.20285; Puri C, 2005, MOL BIOL CELL, V16, P2704, DOI 10.1091/mbc.e04-07-0596; Sandgren S, 2004, J BIOL CHEM, V279, P17951, DOI 10.1074/jbc.M311440200; Schaller-Bals S, 2002, AM J RESP CRIT CARE, V165, P992, DOI 10.1164/ajrccm.165.7.200110-020; Shaykhiev R, 2005, AM J PHYSIOL-LUNG C, V289, pL842, DOI 10.1152/ajplung.00286.2004; Shaykhiev R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001393; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; Triantafilou M, 2002, J CELL SCI, V115, P2603; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; West MA, 2002, CRIT CARE MED, V30, pS64, DOI 10.1097/00003246-200201001-00009; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zanetti M, 2005, CURR ISSUES MOL BIOL, V7, P179, DOI 10.21775/cimb.007.179; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	58	32	34	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4756	4766		10.1096/fj.09-151332	http://dx.doi.org/10.1096/fj.09-151332			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20696857				2022-12-28	WOS:000284824400016
J	Takegahara, N; Kang, SJ; Nojima, S; Takamatsu, H; Okuno, T; Kikutani, H; Toyofuku, T; Kumanogoh, A				Takegahara, Noriko; Kang, Sujin; Nojima, Satoshi; Takamatsu, Hyota; Okuno, Tatsusada; Kikutani, Hitoshi; Toyofuku, Toshihiko; Kumanogoh, Atsushi			Integral roles of a guanine nucleotide exchange factor, FARP2, in osteoclast podosome rearrangements	FASEB JOURNAL			English	Article						small GTPases; integrin; bone resorption	ALDRICH-SYNDROME PROTEIN; BONE-RESORPTION; MATRIX DEGRADATION; DENDRITIC CELLS; KINASE-ACTIVITY; RHO GTPASES; ORGANIZATION; INVADOPODIA; ADHESION; DYNAMICS	Podosomes are recently rediscovered highly dynamic actin-rich structural and functional modules that form close contact with the surrounding substrate. They play a role in the control of migration, tissue invasion, and matrix remodeling of highly motile cells, including lymphocytes, macrophages, dendritic cells, and osteoclasts. In osteoclasts, the compaction of podosomes induces the formation of a tight adhesive contact, the sealing zone, which defines a subosteoclastic environment specialized for bone resorption. Integrins and the Rho family small GTPases are key regulators of podosome rearrangements. However, it remains to be determined how the activation of integrins and Rho family GTPases is regulated during osteoclast podosome rearrangements. Here, we demonstrate a crucial role for the FERM domain-containing guanine nucleotide exchange factor (GEF), FARP2, in osteoclast podosome rearrangements and resorbing activity. We determine by live cell imaging and biochemical assays that FARP2 is required for localized activation of GTP-bound Rac1 into podosome-ring like structures. In addition, FARP2 is relevant to integrin beta 3 activity during osteoclastogenesis. Furthermore, FARP2 deficiency results in reduced formation of multinucleated osteoclasts and resorption pits compared to wild-type osteoclasts (controls). Collectively, our findings reveal an integral role of FARP2 for regulation of Rac1 and integrin beta 3 throughout podosome rearrangement in osteoclastogenesis.-Takegahara, N., Kang, S., Nojima, S., Takamatsu, H., Okuno, T., Kikutani, H., Toyofuku, T., Kumanogoh, A. Integral roles of a guanine nucleotide exchange factor, FARP2, in osteoclast podosome rearrangements. FASEB J. 24, 4782-4792 (2010). www.fasebj.org	[Toyofuku, Toshihiko] Osaka Univ, Dept Immunopathol, World Premier Int Res Ctr, Immunol Frontier Res Ctr,Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; [Kikutani, Hitoshi] Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, Suita, Osaka 565, Japan; [Takegahara, Noriko] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Osaka University; Osaka University; University of Pennsylvania	Toyofuku, T (corresponding author), Osaka Univ, Dept Immunopathol, World Premier Int Res Ctr, Immunol Frontier Res Ctr,Res Inst Microbial Dis, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	toyofuku@ragtime.biken.osaka-u.ac.jp; kumanogo@ragtime.biken.osaka-u.ac.jp	Takegahara, Noriko/AAP-1694-2021		Ministry of Education, Culture, Sports, Science, and Technology of Japan; Japan Society for the Promotion of Science; Ministry of Health, Labor and Welfare; National Institute of Biomedical Innovation; CREST; Japan Science and Technology Agency; Takeda Scientific Foundation; Asahi Glass Foundation; Mochida Memorial Foundation; Kato Memorial Bioscience Foundation; Naito Foundation	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); CREST(Core Research for Evolutional Science and Technology (CREST)); Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); Takeda Scientific Foundation(Takeda Science Foundation (TSF)); Asahi Glass Foundation; Mochida Memorial Foundation; Kato Memorial Bioscience Foundation; Naito Foundation(Naito Memorial Foundation)	The authors thank T. Yazawa and T. Ishikawa for technical support. The authors are grateful to Y. Baba for critical advice, discussion, and encouragement. The authors are also grateful to Michiyuki Matsuda (Kyoto University, Kyoto, Japan) for providing materials. This work was supported by research grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and the Japan Society for the Promotion of Science to N.T., T.T. and A.K.; the Ministry of Health, Labor and Welfare, the program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation, CREST, and the Target Protein Research Program of the Japan Science and Technology Agency to A.K.; the Takeda Scientific Foundation, the Asahi Glass Foundation, and the Mochida Memorial Foundation to N.T. and A.K; and the Kato Memorial Bioscience Foundation and the Naito Foundation to N.T.	Alexander NR, 2008, CURR BIOL, V18, P1295, DOI 10.1016/j.cub.2008.07.090; Boettiger D, 2001, J BIOL CHEM, V276, P31684, DOI 10.1074/jbc.M103997200; Brass LF, 2008, ARTERIOSCL THROM VAS, V28, pS43, DOI 10.1161/ATVBAHA.107.161026; Brazier H, 2006, J BONE MINER RES, V21, P1387, DOI 10.1359/JBMR.060613; Brown JA, 2009, MOL BIOL CELL, V20, P1167, DOI 10.1091/mbc.E08-01-0065; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Calle Y, 2004, J PATHOL, V204, P460, DOI 10.1002/path.1651; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Carman CV, 2008, CURR OPIN CELL BIOL, V20, P533, DOI 10.1016/j.ceb.2008.05.007; Chabadel A, 2007, MOL BIOL CELL, V18, P4899, DOI 10.1091/mbc.E07-04-0378; Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chou HC, 2006, CURR BIOL, V16, P2337, DOI 10.1016/j.cub.2006.10.037; CLOVER J, 1992, J CELL SCI, V103, P267; Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07-03-0227; Evans JG, 2006, EUR J CELL BIOL, V85, P145, DOI 10.1016/j.ejcb.2005.08.006; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Gallo G, 2006, J CELL SCI, V119, P3413, DOI 10.1242/jcs.03084; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Koyano Y, 1997, BIOCHEM BIOPH RES CO, V241, P369, DOI 10.1006/bbrc.1997.7826; Kubo T, 2002, J NEUROSCI, V22, P8504; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; NESBITT S, 1993, J BIOL CHEM, V268, P16737; Ory S, 2000, J CELL SCI, V113, P1177; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Saltel F, 2008, EUR J CELL BIOL, V87, P459, DOI 10.1016/j.ejcb.2008.01.001; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Spinardi L, 2006, EUR J CELL BIOL, V85, P191, DOI 10.1016/j.ejcb.2005.08.005; Suto F, 2007, NEURON, V53, P535, DOI 10.1016/j.neuron.2007.01.028; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takegahara N, 2006, NAT CELL BIOL, V8, P615, DOI 10.1038/ncb1416; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Toyofuku T, 2005, NAT NEUROSCI, V8, P1712, DOI 10.1038/nn1596; Toyofuku T, 2004, GENE DEV, V18, P435, DOI 10.1101/gad.1167304; Woo S, 2006, J NEUROSCI, V26, P1418, DOI 10.1523/JNEUROSCI.4209-05.2006; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645	44	32	33	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4782	4792		10.1096/fj.10-158212	http://dx.doi.org/10.1096/fj.10-158212			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20702777				2022-12-28	WOS:000284824400018
J	Lorquet, S; Berndt, S; Blacher, S; Gengoux, E; Peulen, O; Maquoi, E; Noel, A; Foidart, JM; Munaut, C; Pequeux, C				Lorquet, Sophie; Berndt, Sarah; Blacher, Silvia; Gengoux, Emily; Peulen, Olivier; Maquoi, Erik; Noel, Agnes; Foidart, Jean-Michel; Munaut, Carine; Pequeux, Christel			Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment	FASEB JOURNAL			English	Article						mural cell migration; vessel normalization; eNOS; NO; S1P1	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; SPHINGOSINE-1-PHOSPHATE RECEPTORS; TUMOR VASCULATURE; VESSEL MATURATION; ANGIOGENESIS; NORMALIZATION; METASTASIS; INHIBITION; MEMBRANE	Two soluble forms of vascular endothelial growth factor (VEGF) receptors, sVEGFR-1 and sVEGFR-2, are physiologically released and overproduced in some pathologies. They are known to act as anti-VEGF agents. Here we report that these soluble receptors contribute to vessel maturation by mediating a dialogue between endothelial cells (ECs) and mural cells that leads to blood vessel stabilization. Through a multidisciplinary approach, we provide evidence that these soluble VEGF receptors promote mural cell migration through a paracrine mechanism involving interplay in ECs between VEGF/VEGFR-2 and sphingosine1-phosphate type-1 (S1P)/S1P1 pathways that leads to endothelial nitric oxyde synthase (eNOS) activation. This new paradigm is supported by the finding that sVEGFR-1 and -2 perform the following actions: 1) induce an eNOS-dependent outgrowth of a mural cell network in an ex vivo model of angiogenesis, 2) increase the mural cell coverage of neovessels in vitro and in vivo, 3) promote mural cell migration toward ECs, and 4) stimulate endothelial S1P1 overproduction and eNOS activation that promote the migration and the recruitment of neighboring mural cells. These findings provide new insights into mechanisms regulating physiological and pathological angiogenesis and vessel stabilization.-Lorquet, S., Berndt, S., Blacher, S., Gengoux, E., Peulen, O., Maquoi, E., Noel, A., Foidart, J.-M., Munaut, C., Pequeux, C. Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment. FASEB J. 24, 3782-3795 (2010). www.fasebj.org	[Lorquet, Sophie; Berndt, Sarah; Blacher, Silvia; Gengoux, Emily; Peulen, Olivier; Maquoi, Erik; Noel, Agnes; Foidart, Jean-Michel; Munaut, Carine; Pequeux, Christel] Univ Liege, Lab Tumor & Dev Biol, Inst Pathol, GIGA Canc, B-4000 Liege, Belgium; [Lorquet, Sophie; Foidart, Jean-Michel] Univ Liege, Dept Gynecol & Obstet, CHR Citadelle, B-4000 Liege, Belgium	University of Liege; University of Liege	Foidart, JM (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Inst Pathol, GIGA Canc, CHU B23, B-4000 Liege, Belgium.	jmfoidart@ulg.ac.be	Munaut, Carine/K-8138-2019; Peulen, Olivier/C-1250-2018	Peulen, Olivier/0000-0002-6933-0134; Pequeux, Christel/0000-0001-8275-1489; Noel, Agnes/0000-0002-7670-6179	European 7th Research Framework Programme [HEALTH-2007-2.4.1-6]; EMBIC [6-NOE LSHM-CT-2004-512040]; Fonds de la Recherche Scientifique Medicale; Fonds National de la Recherche Scientifique (FNRS; Belgium); Fondation contre le Cancer; Fonds speciaux Recherche (University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege); Region Wallonne (NEOANGIO); Fonds Social Europeen; Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium)	European 7th Research Framework Programme; EMBIC; Fonds de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Fonds National de la Recherche Scientifique (FNRS; Belgium)(Fonds de la Recherche Scientifique - FNRS); Fondation contre le Cancer; Fonds speciaux Recherche (University of Liege)(University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege)(University of Liege); Region Wallonne (NEOANGIO); Fonds Social Europeen(European Social Fund (ESF)); Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium)(Belgian Federal Science Policy Office)	The authors thank B. Brouwers, I. Dasoul, D. Gabriel-Delapierre, N. Lefin, M.-R. Pignon, E. Konradowski, F. Olivier, P. Gavitelli, and G. Rolland for their excellent technical assistance. Confocal microscopy was performed at CIL- and GIGA-Imaging and Flow Cytometry Facility. This work was supported by grants from the European 7th Research Framework Programme: HEALTH-2007-2.4.1-6 "MICROENVIMET," Framework Programme 6-NOE LSHM-CT-2004-512040, EMBIC, the Fonds de la Recherche Scientifique Medicale, the Fonds National de la Recherche Scientifique (FNRS; Belgium), the Fondation contre le Cancer, the Fonds speciaux Recherche (University of Liege), the Centre Anticancereux pres l'Universite de Liege, the Fonds Leon Fredericq (University of Liege), the DGTRE from the Region Wallonne (NEOANGIO), the Fonds Social Europeen, and the Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium). S.L. and C.P. performed all cellular experiments; S. Berndt performed the aortic ring assays; S. Blacher did all quantification based on image analysis; E.G. contributed to the mouse Matrigel plug assay; O.P., E.M., and A.N. contributed to the work with scientific advice; J.-M.F. supervised the study, provided scientific suggestions, and contributed to manuscript preparation and review; C.M. participated to data analysis; and C.P. designed the study, analyzed the data, and wrote the manuscript.	Albuquerque RJC, 2009, NAT MED, V15, P1023, DOI 10.1038/nm.2018; Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Berndt S, 2006, FASEB J, V20, P2630, DOI 10.1096/fj.06-5885fje; Bruyere F, 2008, NAT METHODS, V5, P431, DOI [10.1038/nmeth.1205, 10.1038/NMETH.1205]; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Chabottaux V, 2009, J CELL MOL MED, V13, P4002, DOI 10.1111/j.1582-4934.2009.00764.x; Chappell JC, 2009, DEV CELL, V17, P377, DOI 10.1016/j.devcel.2009.07.011; Dings RPM, 2007, CLIN CANCER RES, V13, P3395, DOI 10.1158/1078-0432.CCR-06-2441; Ebos JML, 2004, MOL CANCER RES, V2, P315; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Gerhardt H, 2008, J MOL MED, V86, P135, DOI 10.1007/s00109-007-0258-2; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Greenberg JI, 2008, NATURE, V456, P809, DOI 10.1038/nature07424; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100; Igarashi J, 2008, BBA-MOL CELL BIOL L, V1781, P489, DOI 10.1016/j.bbalip.2008.06.008; Jacobi J, 2004, CIRCULATION, V110, P2424, DOI 10.1161/01.CIR.0000145142.85645.EA; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005; Kappas NC, 2008, J CELL BIOL, V181, P847, DOI 10.1083/jcb.200709114; Kashiwagi S, 2005, J CLIN INVEST, V115, P1816, DOI 10.1172/JCI24015; Kashiwagi S, 2008, NAT MED, V14, P255, DOI 10.1038/nm1730; Kearney JB, 2004, BLOOD, V103, P4527, DOI 10.1182/blood-2003-07-2315; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200; Kou BJ, 2004, EXP MOL PATHOL, V76, P129, DOI 10.1016/j.yexmp.2003.10.010; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; Munaut C, 2008, HUM REPROD, V23, P1407, DOI 10.1093/humrep/den114; PASSANITI A, 1992, LAB INVEST, V67, P519; Peters SLM, 2007, CURR OPIN PHARMACOL, V7, P186, DOI 10.1016/j.coph.2006.09.008; Robak E, 2003, MEDIAT INFLAMM, V12, P293, DOI 10.1080/09629350310001619726; Roeckl W, 1998, EXP CELL RES, V241, P161, DOI 10.1006/excr.1998.4039; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416; Szentirmai O, 2008, J NEUROSURG, V108, P979, DOI 10.3171/JNS/2008/108/5/0979; Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074; Tsatsaris V, 2004, NEW ENGL J MED, V350, P2003; Wierzbowska A, 2003, EUR CYTOKINE NETW, V14, P149; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102	50	40	41	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2010	24	10					3782	3795		10.1096/fj.09-149070	http://dx.doi.org/10.1096/fj.09-149070			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20484670	Green Submitted			2022-12-28	WOS:000285005900017
J	Milkau, M; Kohler, R; de Wit, C				Milkau, Malte; Kohler, Ralf; de Wit, Cor			Crucial importance of the endothelial K+ channel SK3 and connexin40 in arteriolar dilations during skeletal muscle contraction	FASEB JOURNAL			English	Article						Ca2+-activated K+ channels; gap junctions; endothelium-derived hyperpolarizing factor; exercise hyperemia	MICROCIRCULATION IN-VIVO; NITRIC-OXIDE SYNTHASE; EXERCISING HUMAN LEG; BLOOD-FLOW; HYPERPOLARIZING FACTOR; POTASSIUM CHANNELS; GAP-JUNCTIONS; FEED ARTERIES; FUNCTIONAL HYPEREMIA; CONDUCTED RESPONSES	Skeletal muscle activity requires substantial increases in blood flow, and the underlying vasodilation involves endothelial activity, but the contribution of the endothelium-dependent hyperpolarizing factor (EDHF) is only poorly defined. In EDHF signaling, endothelial hyperpolarization mediated by the Ca2+-activated K+ channels SK3 and IK1 is a key step and also initiates gap junction-dependent conducted dilations. We assessed the role of SK3, IK1, and connexin40 (Cx40) in muscular contraction-induced dilations in the microcirculation in vivo. Hitherto, arterioles were observed in the electrically stimulated cremaster skeletal muscle of anesthetized mice lacking SK3, IK1, or Cx40 using intravital microscopy. Genetic deficiency of SK3, but not of IK1, strongly attenuated dilations to muscular contraction. Similarly, pharmacologic blockade of SK3 by the specific blocker UCL1684 impaired such dilations in wild-type and IK1-deficient mice. In contrast, IK1 was required for acetylcholine-induced dilations. Genetic deficiency of Cx40 also attenuated dilations induced by muscular contraction but not by acetylcholine. These data support the concept that endothelial hyperpolarization through activation of SK3 contributes to exercise hyperemia and the hyperpolarization ascends the vascular tree through gap junctions formed by Cx40 to orchestrate dilation. The differential impact of SK3- and IK1-deficiency on dilations to distinct stimuli suggests stimulus-dependent activation of these endothelial channels.-Milkau, M., Kohler, R., de Wit, C. Crucial importance of the endothelial K+ channel SK3 and connexin40 in arteriolar dilations during skeletal muscle contraction. FASEB J. 24, 3572-3579 (2010). www.fasebj.org	[Milkau, Malte; de Wit, Cor] Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany; [Kohler, Ralf] Univ So Denmark, Inst Mol Med, Odense, Denmark	University of Lubeck; University of Southern Denmark	de Wit, C (corresponding author), Univ Lubeck, Inst Physiol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	dewit@uni-luebeck.de	babakinejad, babak/G-2674-2012; de Wit, Cor/A-5560-2009	de Wit, Cor/0000-0003-4621-0399; Kohler, Ralf/0000-0001-9563-2913	Deutsche Forschungsgemeinschaft [WI 2071/2-1, KO1899/10-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Rita Meuer for excellent technical assistance. This work was supported by grants of the Deutsche Forschungsgemeinschaft (WI 2071/2-1 and KO1899/10-1).	Boushel R, 2002, J PHYSIOL-LONDON, V543, P691, DOI 10.1113/jphysiol.2002.021477; Brahler S, 2009, CIRCULATION, V119, P2323, DOI 10.1161/CIRCULATIONAHA.108.846634; Busse R, 2002, TRENDS PHARMACOL SCI, V23, P374, DOI 10.1016/S0165-6147(02)02050-3; Clifford PS, 2007, J PHYSIOL-LONDON, V583, P825, DOI 10.1113/jphysiol.2007.135673; Clifford PS, 2006, J PHYSIOL-LONDON, V572, P561, DOI 10.1113/jphysiol.2005.099507; Clifford PS, 2004, J APPL PHYSIOL, V97, P393, DOI 10.1152/japplphysiol.00179.2004; de Wit C, 2004, NEWS PHYSIOL SCI, V19, P148, DOI 10.1152/nips.01520.2004; de Wit C, 2000, CIRC RES, V86, P649, DOI 10.1161/01.RES.86.6.649; de Wit C, 2007, CURR PHARM BIOTECHNO, V8, P11; de Wit C, 2010, CARDIOVASC RES, V85, P604, DOI 10.1093/cvr/cvp340; de Wit C, 2008, CELL COMMUN ADHES, V15, P231, DOI 10.1080/15419060802440260; Dora KA, 2008, CIRC RES, V102, P1247, DOI 10.1161/CIRCRESAHA.108.172379; Dua AK, 2009, AM J PHYSIOL-HEART C, V297, pH433, DOI 10.1152/ajpheart.00216.2009; Duza T, 2004, J PHYSIOL-LONDON, V555, P459, DOI 10.1113/jphysiol.2003.051029; Feletou M, 2009, CLIN SCI, V117, P139, DOI 10.1042/CS20090096; Frandsen U, 2001, J PHYSIOL-LONDON, V531, P257, DOI 10.1111/j.1469-7793.2001.0257j.x; GILLIGAN DM, 1994, CIRCULATION, V90, P2853, DOI 10.1161/01.CIR.90.6.2853; Grgic I, 2009, BRIT J PHARMACOL, V157, P509, DOI 10.1111/j.1476-5381.2009.00132.x; Griffith TM, 2004, BRIT J PHARMACOL, V141, P881, DOI 10.1038/sj.bjp.0705698; Hamann JJ, 2004, J PHYSIOL-LONDON, V557, P1013, DOI 10.1113/jphysiol.2004.062836; Hartmannsgruber V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000827; HESTER RL, 1993, AM J PHYSIOL, V265, pH146; Hillig T, 2003, J PHYSIOL-LONDON, V546, P307, DOI 10.1113/jphysiol.2002.030833; Inoue R, 2006, CIRC RES, V99, P119, DOI 10.1161/01.RES.0000233356.10630.8a; Joyner MJ, 2007, J PHYSIOL-LONDON, V583, P855, DOI 10.1113/jphysiol.2007.135889; Kirby BS, 2007, J PHYSIOL-LONDON, V583, P861, DOI 10.1113/jphysiol.2007.131250; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; Kohler R, 2007, KIDNEY INT, V72, P145, DOI 10.1038/sj.ki.5002303; Koller A, 2002, AM J PHYSIOL-HEART C, V283, pH2250, DOI 10.1152/ajpheart.00545.2002; LAMONTAGNE D, 1992, CIRC RES, V70, P123, DOI 10.1161/01.RES.70.1.123; Lau KS, 2000, PHYSIOL GENOMICS, V2, P21, DOI 10.1152/physiolgenomics.2000.2.1.21; Ledoux J, 2008, P NATL ACAD SCI USA, V105, P9627, DOI 10.1073/pnas.0801963105; Marvar PJ, 2007, MICROCIRCULATION, V14, P779, DOI 10.1080/10739680701444057; Mather S, 2005, CIRC RES, V97, P399, DOI 10.1161/01.RES.0000178008.46759.d0; Maxwell AJ, 1998, CIRCULATION, V98, P369, DOI 10.1161/01.CIR.98.4.369; McKay MK, 1998, HYPERTENSION, V31, P213, DOI 10.1161/01.HYP.31.1.213; Merkus D, 2006, AM J PHYSIOL-HEART C, V291, pH2090, DOI 10.1152/ajpheart.00315.2006; Mortensen SP, 2007, J PHYSIOL-LONDON, V581, P853, DOI 10.1113/jphysiol.2006.127423; Mortensen SP, 2009, HYPERTENSION, V53, P993, DOI 10.1161/HYPERTENSIONAHA.109.130880; Murrant CL, 2000, ACTA PHYSIOL SCAND, V168, P531, DOI 10.1046/j.1365-201x.2000.00706.x; Murrant CL, 2000, AM J PHYSIOL-HEART C, V279, pH2285, DOI 10.1152/ajpheart.2000.279.5.H2285; Murrant CL, 2002, AM J PHYSIOL-REG I, V282, pR969, DOI 10.1152/ajpregu.00405.2001; Musch TI, 2001, EXP PHYSIOL, V86, P749, DOI 10.1111/j.1469-445X.2001.tb00040.x; Radegran G, 1999, AM J PHYSIOL-HEART C, V276, pH1951, DOI 10.1152/ajpheart.1999.276.6.H1951; Ray CJ, 2009, J PHYSIOL-LONDON, V587, P1579, DOI 10.1113/jphysiol.2008.163691; Rosa JC, 1998, J MED CHEM, V41, P2, DOI 10.1021/jm970571a; Rowell LB, 2004, J APPL PHYSIOL, V97, P384, DOI 10.1152/japplphysiol.01220.2003; SAGACH VF, 1992, J CARDIOVASC PHARM, V20, pS170, DOI 10.1097/00005344-199204002-00048; Saltin B, 1998, ACTA PHYSIOL SCAND, V162, P421, DOI 10.1046/j.1365-201X.1998.0293e.x; Sandow SL, 2006, J ANAT, V209, P689, DOI 10.1111/j.1469-7580.2006.00647.x; Sandow SL, 2003, CARDIOVASC RES, V60, P643, DOI 10.1016/j.cardiores.2003.09.017; Sankaranarayanan A, 2009, MOL PHARMACOL, V75, P281, DOI 10.1124/mol.108.051425; Saunders NR, 2005, AM J PHYSIOL-HEART C, V288, pH214, DOI 10.1152/ajpheart.00762.2004; Schrage WG, 2006, J APPL PHYSIOL, V100, P1506, DOI 10.1152/japplphysiol.01639.2005; Segal SS, 2005, MICROCIRCULATION, V12, P33, DOI 10.1080/10739680590895028; Segal SS, 2001, J PHYSIOL-LONDON, V536, P937, DOI 10.1111/j.1469-7793.2001.00937.x; Segal SS, 2000, ACTA PHYSIOL SCAND, V168, P511, DOI 10.1046/j.1365-201x.2000.00703.x; Si H, 2006, CIRC RES, V99, P537, DOI 10.1161/01.RES.0000238377.08219.0c; Siegl D, 2005, CIRC RES, V97, P781, DOI 10.1161/01.RES.0000186193.22438.6c; Welsh DG, 1997, AM J PHYSIOL-HEART C, V273, pH156, DOI 10.1152/ajpheart.1997.273.1.H156; Welsh DG, 1998, AM J PHYSIOL-HEART C, V274, pH178, DOI 10.1152/ajpheart.1998.274.1.H178; Wolfle SE, 2007, CIRC RES, V101, P1292, DOI 10.1161/CIRCRESAHA.107.163279; Wolfle SE, 2009, CARDIOVASC RES, V82, P476, DOI 10.1093/cvr/cvp060; Wolfle SE, 2005, J VASC RES, V42, P475, DOI 10.1159/000088101	64	56	60	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3572	3579		10.1096/fj.10-158956	http://dx.doi.org/10.1096/fj.10-158956			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20427707				2022-12-28	WOS:000281446400044
J	Walter, A; Etienne-Selloum, N; Brasse, D; Khallouf, H; Bronner, C; Rio, MC; Beretz, A; Schini-Kerth, VB				Walter, Allison; Etienne-Selloum, Nelly; Brasse, David; Khallouf, Hadeel; Bronner, Christian; Rio, Marie-Christine; Beretz, Alain; Schini-Kerth, Valerie B.			Intake of grape-derived polyphenols reduces C26 tumor growth by inhibiting angiogenesis and inducing apoptosis	FASEB JOURNAL			English	Article						colon cancer; red wine polyphenols; neovascularization; tumor suppressor gene; metastasis; aberrant crypt foci	ABERRANT CRYPT FOCI; CELL-CYCLE ARREST; COLORECTAL-CANCER; (-)-EPIGALLOCATECHIN GALLATE; CYCLOOXYGENASE-2 EXPRESSION; GENE-EXPRESSION; ANGIOTENSIN-II; COLON; P53; CARCINOGENESIS	This study evaluated the in vivo antitumor activity of grape-derived polyphenols. BALB/c mice were subcutaneously implanted with C26 colon carcinoma cells, and 2 d later they received either solvent or red wine polyphenols (RWPs) (100 mg/kg/d, human equivalent dose approximate to 500 mg/d) in the drinking water for 25 d. Wistar rats received either solvent or RWPs (100 mg/kg/d, human equivalent dose approximate to 1000 mg/d) in the drinking water 1 wk before injection of azoxymethane and were studied 10 wk later. In mice, RWPs inhibited tumor growth by 31%, reduced tumor vascularization and the number of lung metastases, decreased proliferation as indicated by down-regulation of Ki67, cyclin D1, and UHRF1, and increased apoptosis as indicated by TUNEL staining and active caspase-3 levels in tumor cells. RWPs reduced expression of VEGF, matrix metalloproteinase (MMP)-2, MMP-9, and cyclooxygenase-2 and increased expression of tumor suppressor genes p16(INK4A), p53, and p73 in tumor cells. In rats, RWPs reduced by 49% the number of azoxymethane-induced aberrant crypt foci (preneoplastic lesions) in colon. Thus, RWPs effectively reduced the development of colon carcinoma tumors in vivo by blunting tumor vascularization and by inhibiting proliferation and promoting apoptosis of tumor cells subsequent to an up-regulation of tumor suppressor genes.-Walter, A., Etienne-Selloum, N., Brasse, D., Khallouf, H., Bronner, C., Rio, M.-C., Beretz, A., Schini-Kerth, V. B. Intake of grape-derived polyphenols reduces C26 tumor growth by inhibiting angiogenesis and inducing apoptosis. FASEB J. 24, 3360-3369 (2010). www.fasebj.org	[Walter, Allison; Etienne-Selloum, Nelly; Khallouf, Hadeel; Bronner, Christian; Beretz, Alain; Schini-Kerth, Valerie B.] Univ Strasbourg, CNRS, UMR 7213, Lab Biophoton & Pharmacol,Fac Pharm, F-67401 Illkirch Graffenstaden, France; [Brasse, David] UDS, IN2P3, CNRS, Inst Pluridisciplinaire Hubert Curien,UMR 7178, Strasbourg, France; [Rio, Marie-Christine] Univ Strasbourg, Inst Genet & Biol Mol & Cellulaire, INSERM, CNRS,UMR 7104,U964, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Schini-Kerth, VB (corresponding author), Univ Strasbourg, CNRS, UMR 7213, Lab Biophoton & Pharmacol,Fac Pharm, 74 Route Rhin, F-67401 Illkirch Graffenstaden, France.	valerie.schini-kerth@unistra.fr	Bronner, Christian/R-8488-2016; Brasse, David/AAU-3671-2020; Beretz, Alain/ABA-3589-2020	Bronner, Christian/0000-0002-3101-9279; Beretz, Alain/0000-0002-1479-1697	Ligue Nationale Francaise contre le Cancer; Comite du Haut-Rhin de la Ligue contre le Cancer; Association pour la Recherche contre le Cancer; VINIFLHOR (Ministry of Agriculture, France)	Ligue Nationale Francaise contre le Cancer(Ligue nationale contre le cancer); Comite du Haut-Rhin de la Ligue contre le Cancer; Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); VINIFLHOR (Ministry of Agriculture, France)	The authors thank Isabelle Stoll and Sara Zgheib for providing valuable technical help. This work was supported by Ligue Nationale Francaise contre le Cancer, Comite du Haut-Rhin de la Ligue contre le Cancer, Association pour la Recherche contre le Cancer, and VINIFLHOR (Ministry of Agriculture, France).	Achour M, 2008, ONCOGENE, V27, P2187, DOI 10.1038/sj.onc.1210855; Bouvet M, 1998, ANN SURG ONCOL, V5, P681, DOI 10.1007/BF02303477; Boyle P, 2000, BRIT MED J, V321, P805, DOI 10.1136/bmj.321.7264.805; Brasse D, 2005, PHYS MED BIOL, V50, P5799, DOI 10.1088/0031-9155/50/24/003; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003; Calbo J, 2001, CANCER GENE THER, V8, P740, DOI 10.1038/sj.cgt.7700374; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CORBETT TH, 1975, CANCER RES, V35, P2434; Dashwood RH, 1998, CANCER RES, V58, P1127; Des Guetz G, 2006, BRIT J CANCER, V94, P1823, DOI 10.1038/sj.bjc.6603176; Dolara P, 2005, MUTAT RES-FUND MOL M, V591, P237, DOI 10.1016/j.mrfmmm.2005.04.022; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fini L, 2007, J NUTR, V137, P2622, DOI 10.1093/jn/137.12.2622; Fresco P, 2006, MED RES REV, V26, P747, DOI 10.1002/med.20060; Glade M.J., 1997, AM I CANC RES CANC R, V15, P523, DOI [10.1016/s0899-9007(99)00021-0, DOI 10.1016/S0899-9007(99)00021-0]; Gosse F, 2005, CARCINOGENESIS, V26, P1291, DOI 10.1093/carcin/bgi074; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Gronbaek M, 2000, ANN INTERN MED, V133, P411, DOI 10.7326/0003-4819-133-6-200009190-00008; Hilska M, 2005, DIS COLON RECTUM, V48, P2197, DOI 10.1007/s10350-005-0202-x; Hoensch H, 2008, WORLD J GASTROENTERO, V14, P2187, DOI 10.3748/wjg.14.2187; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Izawa H, 2005, INT J ONCOL, V27, P69; John Anitha, 2001, Pathology and Oncology Research, V7, P14; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kim KC, 2006, ARCH PHARM RES, V29, P152, DOI 10.1007/BF02974277; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 2001, HUM GENE THER, V12, P515, DOI 10.1089/104303401300042429; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; Marques-Vidal P, 2006, CLIN NUTR, V25, P14, DOI 10.1016/j.clnu.2005.09.008; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Oak MH, 2004, CIRCULATION, V110, P1861, DOI 10.1161/01.CIR.0000142617.52881.F4; Oak MH, 2003, ARTERIOSCL THROM VAS, V23, P1001, DOI 10.1161/01.ATV.0000070101.70534.38; Ohishi T, 2002, CANCER LETT, V177, P49, DOI 10.1016/S0304-3835(01)00767-4; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Potter JD, 1996, CANCER CAUSE CONTROL, V7, P127, DOI 10.1007/BF00115644; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Sengottuvelan M, 2006, CARCINOGENESIS, V27, P1038, DOI 10.1093/carcin/bgi286; Shapiro GI, 2000, CELL BIOCHEM BIOPHYS, V33, P189, DOI 10.1385/CBB:33:2:189; SHARIF T, EUR J CANC, V46, P983; Sheng HM, 1998, CANCER RES, V58, P362; Tseng SH, 2004, CLIN CANCER RES, V10, P2190, DOI 10.1158/1078-0432.CCR-03-0105; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Walter A, 2008, J VASC RES, V45, P386, DOI 10.1159/000121408; Walter A, 2009, J PHARMACOL EXP THER, V329, P699, DOI 10.1124/jpet.108.148080; Wiese FW, 2001, CARCINOGENESIS, V22, P5, DOI 10.1093/carcin/22.1.5; Xiao H, 2008, CARCINOGENESIS, V29, P113, DOI 10.1093/carcin/bgm204; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	58	43	45	2	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3360	3369		10.1096/fj.09-149419	http://dx.doi.org/10.1096/fj.09-149419			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20442318				2022-12-28	WOS:000281446400024
J	Himer, L; Csoka, B; Selmeczy, Z; Koscso, B; Pocza, T; Pacher, P; Nemeth, ZH; Deitch, EA; Vizi, ES; Cronstein, BN; Hasko, G				Himer, Leonora; Csoka, Balazs; Selmeczy, Zsolt; Koscso, Balazs; Pocza, Timea; Pacher, Pal; Nemeth, Zoltan H.; Deitch, Edwin A.; Vizi, E. Sylvester; Cronstein, Bruce N.; Hasko, Gyoergy			Adenosine A(2A) receptor activation protects CD4(+) T lymphocytes against activation-induced cell death	FASEB JOURNAL			English	Article						inflammation; apoptosis; anergy	FAS-LIGAND EXPRESSION; VASOACTIVE-INTESTINAL-PEPTIDE; DEFICIENT MICE REVEALS; FACTOR-KAPPA-B; EXTRACELLULAR ADENOSINE; ADENYLATE-CYCLASE; DEAMINASE DEFICIENCY; MEDIATED ACTIVATION; DNA FRAGMENTATION; MOUSE THYMOCYTES	Activation-induced cell death (AICD) is initiated by T-cell receptor (TCR) restimulation of already activated and expanded peripheral T cells and is mediated through Fas/Fas ligand (FasL) interactions. Adenosine is a purine nucleoside signaling molecule, and its immunomodulatory effects are mediated by 4 G-protein-coupled receptors: A(1), A(2A), A(2B), and A(3). In this study, we investigated the role of A(2A) receptors in regulating CD4(+) T lymphocyte AICD. Our results showed that the selective A(2A) receptor agonist CGS21680 (EC50 = 15.2-32.6 nM) rescued mouse CD4(+) hybridomas and human Jurkat cells from AICD and that this effect was reversed by the selective A(2A) receptor antagonist ZM241385 (EC50 = 2.3 nM). CGS21680 decreased phosphatidylserine exposure on the membrane, as well as the cleavage of caspase-3, caspase-8 and poly(ADP-ribose) polymerase indicating that A2A receptor stimulation blocks the extrinsic apoptotic pathway. In addition, CGS21680 attenuated both Fas and FasL mRNA expression. This decrease in FasL expression was associated with decreased activation of the transcription factor systems NF-kappa B, NF-ATp, early growth response (Egr)-1, and Egr-3. The antiapoptotic effect of A(2A) receptor stimulation was mediated by protein kinase A. Together, these results demonstrate that A(2A) receptor activation suppresses the AICD of peripheral T cells.-Himer, L., Csoka, B., Selmeczy, Z., Koscso, B., Pocza, T., Pacher, P., Nemeth, Z. H., Deitch, E. A., Vizi, E. S., Cronstein, B. N., Hasko, G. Adenosine A(2A) receptor activation protects CD4(+) T lymphocytes against activation-induced cell death. FASEB J. 24, 2631-2640 (2010). www.fasebj.org	[Csoka, Balazs; Nemeth, Zoltan H.; Deitch, Edwin A.; Hasko, Gyoergy] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; [Himer, Leonora; Selmeczy, Zsolt; Koscso, Balazs; Pocza, Timea; Vizi, E. Sylvester] Hungarian Acad Sci, Inst Expt Med, Dept Pharmacol, Budapest, Hungary; [Pacher, Pal] NIAAA, Sect Oxidat Stress Tissue Injury, Lab Physiol Studies, NIH, Bethesda, MD USA; [Nemeth, Zoltan H.] Morristown Mem Hosp, Dept Surg, Morristown, NJ USA; [Cronstein, Bruce N.] NYU, Sch Med, Dept Med, Div Clin Pharmacol, New York, NY USA; [Hasko, Gyoergy] Univ Debrecen, Med & Hlth Sci Ctr, Dept Med Chem, H-4012 Debrecen, Hungary	Rutgers State University New Brunswick; Rutgers State University Medical Center; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Atlantic Health System; New York University; University of Debrecen	Hasko, G (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.	haskoge@umdnj.edu	Cronstein, Bruce N/D-4678-2011; Pacher, Pal/B-6378-2008	Cronstein, Bruce N/0000-0002-4295-7383; Pacher, Pal/0000-0001-7036-8108; Csoka, Balazs/0000-0002-7562-1130; Koscso, Balazs/0000-0001-9676-2066	U.S. National Institutes of Health (NIH) [R01 GM66189]; NIH, National Institute on Alcohol Abuse and Alcoholism; OTKA [73110, 78275]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000375] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH, National Institute on Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by the U.S. National Institutes of Health (NIH; grant R01 GM66189), the Intramural Research Program of NIH, National Institute on Alcohol Abuse and Alcoholism, and the Hungarian Research Fund OTKA (73110 and 78275).	Abe K, 2000, NEUROSCI RES, V38, P325, DOI 10.1016/S0168-0102(00)00188-7; Apasov S, 2000, BLOOD, V95, P3859; Apasov SG, 1999, INT IMMUNOL, V11, P179, DOI 10.1093/intimm/11.2.179; Apasov SG, 2001, J CLIN INVEST, V108, P131, DOI 10.1172/JCI10360; Apasov SG, 2000, BRIT J PHARMACOL, V131, P43, DOI 10.1038/sj.bjp.0703532; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; Barbieri D, 1998, NEUROCHEM INT, V32, P493, DOI 10.1016/S0197-0186(97)00129-0; Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Bshesh K, 2002, J LEUKOCYTE BIOL, V72, P1027; Csoka B, 2008, FASEB J, V22, P3491, DOI 10.1096/fj.08-107458; Delgado M, 2001, J IMMUNOL, V166, P1028, DOI 10.4049/jimmunol.166.2.1028; Delgado M, 2000, J IMMUNOL, V165, P114, DOI 10.4049/jimmunol.165.1.114; Erdmann AA, 2005, BLOOD, V105, P4707, DOI 10.1182/blood-2004-04-1407; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Genestier L, 1998, J CLIN INVEST, V102, P322, DOI 10.1172/JCI2676; Gessi S, 2000, BRIT J PHARMACOL, V129, P2, DOI 10.1038/sj.bjp.0703045; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hasko G, 1996, J IMMUNOL, V157, P4634; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; Ishimaru N, 2001, J IMMUNOL, V167, P6031, DOI 10.4049/jimmunol.167.10.6031; Jacobson KA, 1999, APOPTOSIS, V4, P197, DOI 10.1023/A:1009666707307; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kiss I, 2006, EUR J IMMUNOL, V36, P1559, DOI 10.1002/eji.200535334; KIZAKI H, 1988, J IMMUNOL, V141, P1652; Koshiba M, 1997, J BIOL CHEM, V272, P25881, DOI 10.1074/jbc.272.41.25881; Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Li-Weber M, 2002, CELL DEATH DIFFER, V9, P1256, DOI 10.1038/sj.cdd.4401102; Li-Weber M, 2002, J CLIN INVEST, V110, P681, DOI [10.1172/JCI0215073, 10.1172/JCI200215073]; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Lukashev DE, 2003, BIOCHEM PHARMACOL, V65, P2081, DOI 10.1016/S0006-2952(03)00158-8; Minguet S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/eji.200425524; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Naganuma M, 2006, J IMMUNOL, V177, P2765, DOI 10.4049/jimmunol.177.5.2765; Nemeth ZH, 2003, J PHARMACOL EXP THER, V306, P1042, DOI 10.1124/jpet.103.052944; Nemeth ZH, 2007, FASEB J, V21, P2379, DOI 10.1096/fj.07-8213com; Norian LA, 1998, J IMMUNOL, V161, P1078; Pinhal-Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002-9440(10)63698-X; Raskovalova T, 2007, CANCER RES, V67, P5949, DOI 10.1158/0008-5472.CAN-06-4249; Scheibner KA, 2009, AM J RESP CELL MOL, V40, P251, DOI 10.1165/rcmb.2008-0168OC; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; Sevigny CP, 2007, J IMMUNOL, V178, P4240, DOI 10.4049/jimmunol.178.7.4240; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1990, J IMMUNOL, V144, P3326; Sitkovsky MV, 2009, TRENDS IMMUNOL, V30, P102, DOI 10.1016/j.it.2008.12.002; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Suarez A, 2002, J IMMUNOL, V169, P1159, DOI 10.4049/jimmunol.169.3.1159; SZONDY Z, 1994, BIOCHEM J, V304, P877, DOI 10.1042/bj3040877; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646; Zhang J, 2004, CELL MOL IMMUNOL, V1, P186	63	58	60	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2631	2640		10.1096/fj.10-155192	http://dx.doi.org/10.1096/fj.10-155192			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371613	Green Published			2022-12-28	WOS:000285005400005
J	Kwon, RY; Temiyasathit, S; Tummala, P; Quah, CC; Jacobs, CR				Kwon, Ronald Y.; Temiyasathit, Sara; Tummala, Padmaja; Quah, Clarence C.; Jacobs, Christopher R.			Primary cilium-dependent mechanosensing is mediated by adenylyl cyclase 6 and cyclic AMP in bone cells	FASEB JOURNAL			English	Article						mechanotransduction; fluid flow; osteocyte; osteoporosis	POLYCYSTIC KIDNEY-DISEASE; OSCILLATORY FLUID-FLOW; LEFT-RIGHT ASYMMETRY; INTRAFLAGELLAR TRANSPORT; MC3T3-E1 OSTEOBLASTS; SIGNALING PATHWAY; PROTEIN-KINASE; DETECT CHANGES; SHEAR-STRESS; OSTEOCYTES	Primary cilia are chemosensing and mechanosensing organelles that regulate remarkably diverse processes in a variety of cells. We previously showed that primary cilia play a role in mediating mechanosensing in bone cells through an unknown mechanism that does not involve extracellular Ca2+-dependent intracellular Ca2+ release, which has been implicated in all other cells that transduce mechanical signals via the cilium. Here, we identify a molecular mechanism linking primary cilia and bone cell mechanotransduction that involves adenylyl cyclase 6 (AC6) and cAMP. Intracellular cAMP was quantified in MLO-Y4 cells exposed to dynamic flow, and AC6 and primary cilia were inhibited using RNA interference. When exposed to flow, cells rapidly (<2 min) and transiently decreased cAMP production in a primary cilium-dependent manner. RT-PCR revealed differential expression of the membrane-bound isoforms of adenylyl cyclase, while immunostaining revealed one, AC6, preferentially localized to the cilium. Further studies showed that decreases in cAMP in response to flow were dependent on AC6 and Gd3+-sensitive channels but not intracellular Ca2+ release and that this response mediated flow-induced COX-2 gene expression. The signaling events identified provide important details of a novel early mechanosensing mechanism in bone and advances our understanding of how signal transduction occurs at the primary cilium.-Kwon, R. Y., Temiyasathit, S., Tummala, P., Quah, C. C., Jacobs, C. R. Primary cilium-dependent mechanosensing is mediated by adenylyl cyclase 6 and cyclic AMP in bone cells. FASEB J. 24, 2859-2868 (2010). www.fasebj.org	[Kwon, Ronald Y.; Temiyasathit, Sara; Tummala, Padmaja; Quah, Clarence C.; Jacobs, Christopher R.] Bone & Joint Rehabil R&D Ctr, Dept Vet Affairs, Palo Alto, CA USA; [Kwon, Ronald Y.; Jacobs, Christopher R.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Temiyasathit, Sara; Jacobs, Christopher R.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Jacobs, Christopher R.] Columbia Univ, Dept Biomed Engn, New York, NY USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University; Columbia University	Jacobs, CR (corresponding author), 351 Engn Terr,1210 Amsterdam Ave,Mail Code 8904, New York, NY 10027 USA.	crj2111@columbia.edu			Department of Veterans Affairs, the National Institutes of Health [AR045989, AR054156]; National Science Foundation; Department of Veterans Affairs; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR054156, R01AR045989] Funding Source: NIH RePORTER	Department of Veterans Affairs, the National Institutes of Health(US Department of Veterans Affairs); National Science Foundation(National Science Foundation (NSF)); Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Drs. Tim Stearns and Charlie Anderson for helpful discussions. This study was supported by the Department of Veterans Affairs, the National Institutes of Health (grants AR045989 and AR054156 to C.R.J.), a National Science Foundation Graduate Fellowship (to R.Y.K.), and a Department of Veterans Affairs Pre-Doctoral Associated Health Rehabilitation Research Fellowship (to S.T.).	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bishop GA, 2007, J COMP NEUROL, V505, P562, DOI 10.1002/cne.21510; Caldwell RA, 1998, AM J PHYSIOL-CELL PH, V275, pC619, DOI 10.1152/ajpcell.1998.275.2.C619; Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Davenport JR, 2005, AM J PHYSIOL-RENAL, V289, pF1159, DOI 10.1152/ajprenal.00118.2005; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Dunn TA, 2006, J NEUROSCI, V26, P12807, DOI 10.1523/JNEUROSCI.3238-06.2006; Follit JA, 2006, MOL BIOL CELL, V17, P3781, DOI 10.1091/mbc.E06-02-0133; Gattone VH, 2003, NAT MED, V9, P1323, DOI 10.1038/nm935; Gorbunova YV, 2002, NATURE, V418, P93, DOI 10.1038/nature00835; Gradilone SA, 2007, P NATL ACAD SCI USA, V104, P19138, DOI 10.1073/pnas.0705964104; Handel M, 1999, NEUROSCIENCE, V89, P909, DOI 10.1016/S0306-4522(98)00354-6; Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732; Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333; Ishijima M, 2002, J BONE MINER RES, V17, P661, DOI 10.1359/jbmr.2002.17.4.661; Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021-9290(98)00114-6; Johnston CA, 2004, J NEUROCHEM, V88, P1497, DOI 10.1046/j.1471-4159.2004.02285.x; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; Kotttgen M, 2008, J CELL BIOL, V182, P437, DOI 10.1083/jcb.200805124; Kwon RY, 2010, J BONE MINER RES, V25, P1798, DOI 10.1002/jbmr.74; Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058; Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104; Masyuk AI, 2008, AM J PHYSIOL-GASTR L, V295, pG725, DOI 10.1152/ajpgi.90265.2008; Masyuk AI, 2006, GASTROENTEROLOGY, V131, P911, DOI 10.1053/j.gastro.2006.07.003; McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930; McGrath J, 2003, CELL, V114, P61, DOI 10.1016/S0092-8674(03)00511-7; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nauli SM, 2008, CIRCULATION, V117, P1161, DOI 10.1161/CIRCULATIONAHA.107.710111; Nonaka S, 2005, PLOS BIOL, V3, P1467, DOI 10.1371/journal.pbio.0030268; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Phillips JA, 2008, MATRIX BIOL, V27, P609, DOI 10.1016/j.matbio.2008.05.003; Ponik SM, 2007, J CELL BIOCHEM, V100, P794, DOI 10.1002/jcb.21089; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Praetorius HA, 2003, J MEMBRANE BIOL, V191, P69, DOI 10.1007/s00232-002-1042-4; Qin YX, 2003, J BIOMECH, V36, P1427, DOI 10.1016/S0021-9290(03)00127-1; Raychowdhury MK, 2009, AM J PHYSIOL-RENAL, V296, pF87, DOI 10.1152/ajprenal.90509.2008; REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113; RODAN GA, 1975, SCIENCE, V189, P467, DOI 10.1126/science.168639; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Ryder KD, 2001, J BONE MINER RES, V16, P240, DOI 10.1359/jbmr.2001.16.2.240; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Tan SD, 2007, BONE, V41, P745, DOI 10.1016/j.bone.2007.07.019; Tang T, 2008, CIRCULATION, V117, P61, DOI 10.1161/CIRCULATIONAHA.107.730069; Tate MLK, 2003, J BIOMECH, V36, P1409, DOI 10.1016/S0021-9290(03)00123-4; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; Vezeridis PS, 2006, BIOCHEM BIOPH RES CO, V348, P1082, DOI 10.1016/j.bbrc.2006.07.146; Wadhwa S, 2002, BIOCHEM BIOPH RES CO, V297, P46, DOI 10.1016/S0006-291X(02)02124-1; Willoughby D, 2007, PHYSIOL REV, V87, P965, DOI 10.1152/physrev.00049.2006; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Yoder BK, 2007, J AM SOC NEPHROL, V18, P1381, DOI 10.1681/ASN.2006111215; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; You J, 2000, J BIOMECH ENG-T ASME, V122, P387, DOI 10.1115/1.1287161; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200; You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047; Zhang JS, 2006, J BONE MINER RES, V21, P1729, DOI 10.1359/JBMR.060722; Zhang QH, 2003, DEV DYNAM, V227, P78, DOI 10.1002/dvdy.10289	59	97	101	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2859	2868		10.1096/fj.09-148007	http://dx.doi.org/10.1096/fj.09-148007			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371630	Green Published			2022-12-28	WOS:000285005400026
J	Liu, WY; Collodi, P				Liu, Weiyi; Collodi, Paul			Zebrafish dead end possesses ATPase activity that is required for primordial germ cell development	FASEB JOURNAL			English	Article						rescue; vasa; nanos1; TDRD7; miRNA	HELICASE ACTIVITY; BOX PROTEINS; RNA; VASA; GENE; EXPRESSION; HOMOLOG; COMPONENTS; APOBEC3G; PRODUCT	Zebrafish dead end (dnd) mRNA is specifically expressed in primordial germ cells (PGCs) and is required for PGC migration and survival. Previous studies have shown that zebrafish Dnd functions by protecting the 3'UTRs of nanos1 and TDRD7 from miR-430b-mediated RNA deadenylation. In this work, we demonstrate that zebrafish Dnd protein possesses Mg2+-dependent ATPase activity that is required for PGC formation. Michaelis-Menten analysis revealed that the ATPase has a k(cat) of 0.632 +/- 0.036/min under optimal conditions, and mapping studies using Dnd truncates showed that ATPase resides in the last 91 aa of the Dnd C terminus. Internal deletion and point mutagenesis analysis of this region were used to identify key amino acids required for ATPase activity. Rescue experiments conducted by injecting mRNAs encoding the Dnd ATPase mutants into embryos in which the endogenous dnd expression was inhibited demonstrated that the ATPase activity is required for normal zebrafish PGC survival. Real-time PCR analysis showed that the expression of PGC markers nanos1 and TDRD7 but not vasa were down-regulated when dnd mutant proteins lacking ATPase were expressed in the rescued embryos, indicating that the Dnd ATPase is involved in protecting nanos1 and TDRD7 transcripts.-Liu, W., Collodi, P. Zebrafish dead end possesses ATPase activity that is required for primordial germ cell development. FASEB J. 24, 2641-2650 (2010). www.fasebj.org	[Liu, Weiyi; Collodi, Paul] Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Collodi, P (corresponding author), Purdue Univ, Dept Anim Sci, 915 W State St, W Lafayette, IN 47907 USA.	pcollodi@purdue.edu	liu, weiyi/B-2053-2014; liu, weiyi/G-2730-2012		National Institutes of Health [R01GM069384]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069384] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Lisbeth Olsen (University of Bergen, Bergen, Norway) for the vasa: EGFP transgenic zebrafish and Ten-tsao Wong (Purdue University) for the pBSK-dnd3'UTR. This work was supported by a grant from the National Institutes of Health (R01GM069384).	ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; Bernstein J, 2008, J BIOL CHEM, V283, P4930, DOI 10.1074/jbc.M706677200; Bhattacharya C, 2007, BIOCHEM BIOPH RES CO, V355, P194, DOI 10.1016/j.bbrc.2007.01.138; Bhattacharya C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002315; Bleichert F, 2007, MOL CELL, V27, P339, DOI 10.1016/j.molcel.2007.07.014; Braat AK, 2001, GENESIS, V30, P183, DOI 10.1002/gene.1060; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; Chene P, 2002, NAT REV DRUG DISCOV, V1, P665, DOI 10.1038/nrd894; Draper BW, 2007, DEV BIOL, V305, P589, DOI 10.1016/j.ydbio.2007.03.007; Extavour CG, 2003, DEVELOPMENT, V130, P5869, DOI 10.1242/dev.00804; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; Gallois-Montbrun S, 2007, J VIROL, V81, P2165, DOI 10.1128/JVI.02287-06; Granneman S, 2006, NUCLEIC ACIDS RES, V34, P3189, DOI 10.1093/nar/gkl419; Gruidl ME, 1996, P NATL ACAD SCI USA, V93, P13837, DOI 10.1073/pnas.93.24.13837; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Huang J, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M705116200; Ikenishi K, 1997, DEV GROWTH DIFFER, V39, P625; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Ketting RF, 2007, CELL, V131, P1226, DOI 10.1016/j.cell.2007.12.004; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Knaut H, 2000, J CELL BIOL, V149, P875, DOI 10.1083/jcb.149.4.875; Krovel AV, 2002, MECH DEVELOP, V116, P141, DOI 10.1016/S0925-4773(02)00154-5; Kuznicki KA, 2000, DEVELOPMENT, V127, P2907; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEBEL D, 1980, J BIOL CHEM, V255, P1227; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Linger R, 2008, GENE CHROMOSOME CANC, V47, P247, DOI 10.1002/gcc.20526; Liu LX, 2009, GENE EXPR PATTERNS, V9, P541, DOI 10.1016/j.gep.2009.06.008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lorsch JR, 2002, CELL, V109, P797, DOI 10.1016/S0092-8674(02)00804-8; Mishima Y, 2006, CURR BIOL, V16, P2135, DOI 10.1016/j.cub.2006.08.086; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; Sakowicz R, 1998, SCIENCE, V280, P292, DOI 10.1126/science.280.5361.292; Sengoku T, 2006, CELL, V125, P287, DOI 10.1016/j.cell.2006.01.054; Shen JP, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702304200; Slanchev K, 2009, MECH DEVELOP, V126, P270, DOI 10.1016/j.mod.2008.10.006; Strome S, 2007, SCIENCE, V316, P392, DOI 10.1126/science.1140846; Tanaka SS, 2000, GENE DEV, V14, P841; Tourneur L, 2008, J BIOL CHEM, V283, P17929, DOI 10.1074/jbc.M802263200; Tsuda M, 2003, SCIENCE, V301, P1239, DOI 10.1126/science.1085222; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang Z, 2004, SCIENCE, V303, P2016, DOI 10.1126/science.1093983; Weidinger G, 2003, CURR BIOL, V13, P1429, DOI 10.1016/S0960-9822(03)00537-2; Weirich CS, 2006, NAT CELL BIOL, V8, P668, DOI 10.1038/ncb1424; Wylie C, 1999, CELL, V96, P165, DOI 10.1016/S0092-8674(00)80557-7; Yoon C, 1997, DEVELOPMENT, V124, P3157; Youngren KK, 2005, NATURE, V435, P360, DOI 10.1038/nature03595	50	35	37	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2641	2650		10.1096/fj.09-148403	http://dx.doi.org/10.1096/fj.09-148403			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371629	Green Published			2022-12-28	WOS:000285005400006
J	Rossi, A; Schenone, S; Angelucci, A; Cozzi, M; Caracciolo, V; Pentimalli, F; Puca, A; Pucci, B; La Montagna, R; Bologna, M; Botta, M; Giordano, A				Rossi, Alessandra; Schenone, Silvia; Angelucci, Adriano; Cozzi, Martina; Caracciolo, Valentina; Pentimalli, Francesca; Puca, Andrew; Pucci, Biagio; La Montagna, Raffaele; Bologna, Mauro; Botta, Maurizio; Giordano, Antonio			New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells	FASEB JOURNAL			English	Article						tyrosine kinase inhibitors; apoptosis; cancer therapy; brain tumors; cdc2	ANTIPROLIFERATIVE ACTIVITY; BRAIN-TUMORS; CANCER CELLS; TYROSINE KINASES; CARCINOMA-CELLS; BCR-ABL; PHOSPHORYLATION; APOPTOSIS; CHEMOTHERAPY; THERAPY	Medulloblastoma is the most common malignant brain tumor in children, and despite improvements in the overall survival rate, it still lacks an effective treatment. Src plays an important role in cancer, and recently high Src activity was documented in medulloblastoma. In this report, we examined the effects of novel pyrazolo-[3,4-d]-pyrimidine derivative Src inhibitors in medulloblastoma. By MTS assay, we showed that the pyrimidine derivatives indicated as S7, S29, and SI163 greatly reduce the growth rate of medulloblastoma cells by inhibiting Src phosphorylation, compared with HT22 non-neoplastic nerve cells. These compounds also halt cells in the G2/M phase, and this effect likely occurs through the regulation of cdc2 and CDC25C phosphorylation, as shown by Western blot. Moreover, the exposure to pyrimidine derivatives induces apoptosis, assayed by the supravital propidium iodide assay, through modulation of the apoptotic proteins Bax and Bc12, and inhibits tumor growth in vivo in a mouse model. Notably, S7, S29, and SI163 show major inhibitory effects on medulloblastoma cell growth compared with the chemotherapeutic agents cisplatin and etoposide. In conclusion, our results suggest that S7, S29, and SI163 could be novel attractive candidates for the treatment of medulloblastoma or tumors characterized by high Src activity.-Rossi, A., Schenone, S., Angelucci, A., Cozzi, M., Caracciolo, V., Pentimalli, F., Puca, A., Pucci, B., La Montagna, R., Bologna, M., Botta, M., Giordano, A. New pyrazolo[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB J. 24, 2881-2892 (2010). www.fasebj.org	[Rossi, Alessandra; Caracciolo, Valentina; Pentimalli, Francesca; Puca, Andrew; La Montagna, Raffaele; Giordano, Antonio] Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; [Rossi, Alessandra; Cozzi, Martina; Giordano, Antonio] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; [Botta, Maurizio] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy; [Schenone, Silvia] Univ Genoa, Dept Pharmaceut Sci, Genoa, Italy; [Angelucci, Adriano; Bologna, Mauro] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; [Pentimalli, Francesca; Pucci, Biagio; Giordano, Antonio] CROM Ctr Oncol Res Mercogliano, Avellino, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; University of Siena; University of Genoa; University of L'Aquila	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, BioLife Sci Bldg,Ste 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	pucci, biagio/AAA-9268-2020; Giordano, Antonio/F-1927-2010; Rossi, Alessandra/A-7823-2013; Pentimalli, Francesca/K-4936-2014; Angelucci, Adriano/B-7134-2013; Pucci, Biagio/AAS-7502-2021	pucci, biagio/0000-0003-4502-1748; Giordano, Antonio/0000-0002-5959-016X; Rossi, Alessandra/0000-0002-9527-4658; Pentimalli, Francesca/0000-0003-4740-6801; Angelucci, Adriano/0000-0002-8755-1889; BOLOGNA, Mauro/0000-0002-6306-6897	U.S. National Institutes of Health; Sbarro Health Research Organization; Human Health Foundation Onlus Spoleto, Italy; Teresa and Luigi de Beaumont Bonelli Foundation	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sbarro Health Research Organization; Human Health Foundation Onlus Spoleto, Italy; Teresa and Luigi de Beaumont Bonelli Foundation	This study was supported by U.S. National Institutes of Health grants and by the Sbarro Health Research Organization (http://www.shro.org), the Human Health Foundation Onlus Spoleto, Italy (http://www.hhfonlus.org), and the Teresa and Luigi de Beaumont Bonelli Foundation (to A.G.). The authors also thank Dr. A. Cuppone for assistance with flow cytometry analysis.	Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Angelucci A, 2006, EUR J CANCER, V42, P2838, DOI 10.1016/j.ejca.2006.06.024; Banavali NK, 2009, PROTEINS, V74, P378, DOI 10.1002/prot.22153; Bennett JJ, 2004, FASEB J, V18, P1001, DOI 10.1096/fj.02-1080fje; Bondavalli F, 2002, J MED CHEM, V45, P4875, DOI 10.1021/jm0209580; Carraro F, 2006, J MED CHEM, V49, P1549, DOI 10.1021/jm050603r; Carraro F, 2004, J MED CHEM, V47, P1595, DOI 10.1021/jm034257u; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Chetty C, 2009, INT J CANCER, V124, P2468, DOI 10.1002/ijc.24209; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; de Groot J, 2009, J NEURO-ONCOL, V95, P151, DOI 10.1007/s11060-009-9916-2; Decleves X, 2006, CURR CANCER DRUG TAR, V6, P433, DOI 10.2174/156800906777723930; Donnini S, 2007, INT J CANCER, V120, P995, DOI 10.1002/ijc.22410; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; El Touny LH, 2006, PROSTATE, V66, P1542, DOI 10.1002/pros.20495; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guessous F, 2008, J CELL PHYSIOL, V217, P577, DOI 10.1002/jcp.21542; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; Johnston DL, 2009, J NEURO-ONCOL, V94, P51, DOI 10.1007/s11060-009-9799-2; Khan N, 2007, CARCINOGENESIS, V28, P233, DOI 10.1093/carcin/bgl243; Leskov KS, 2001, SEMIN RADIAT ONCOL, V11, P352, DOI 10.1053/srao.2001.26912; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Liao CH, 2005, J CELL BIOCHEM, V96, P155, DOI 10.1002/jcb.20540; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Ma WW, 2009, CA-CANCER J CLIN, V59, P111, DOI 10.3322/caac.20003; Mahon FX, 2008, CANCER RES, V68, P9809, DOI 10.1158/0008-5472.CAN-08-1008; Manetti F, 2007, CHEMMEDCHEM, V2, P343, DOI 10.1002/cmdc.200600214; Mazoochi T, 2009, MOL HUM REPROD, V15, P155, DOI 10.1093/molehr/gap002; Mizenina OA, 2004, CELL CYCLE, V3, P796; Moasser MM, 1999, CANCER RES, V59, P6145; Nieder C, 2009, CLIN ONCOL-UK, V21, P515, DOI 10.1016/j.clon.2009.05.003; Packer RJ, 2006, J CLIN ONCOL, V24, P4202, DOI 10.1200/JCO.2006.06.4980; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Rossi A, 2008, CLIN CANCER RES, V14, P971, DOI 10.1158/1078-0432.CCR-07-2072; Rossi A, 2009, INT J CANCER, V125, P235, DOI 10.1002/ijc.24331; Schenone S, 2004, EUR J MED CHEM, V39, P939, DOI 10.1016/j.ejmech.2004.07.010; Schenone S, 2004, BIOORG MED CHEM LETT, V14, P2511, DOI 10.1016/j.bmcl.2004.03.013; Schenone S, 2008, EUR J MED CHEM, V43, P2665, DOI 10.1016/j.ejmech.2008.01.034; Sikkema AH, 2009, CANCER RES, V69, P5987, DOI 10.1158/0008-5472.CAN-08-3660; Spreafico A, 2008, FASEB J, V22, P1560, DOI 10.1096/fj.07-9873com; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Taylor RE, 2003, J CLIN ONCOL, V21, P1581, DOI 10.1200/JCO.2003.05.116; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Warren K, 2006, CANCER CHEMOTH PHARM, V58, P343, DOI 10.1007/s00280-005-0172-7; Xu NH, 2007, CELL CYCLE, V6, P1639, DOI 10.4161/cc.6.13.4385; Yamaguchi H, 2008, J BIOL CHEM, V283, P19112, DOI 10.1074/jbc.M709882200; Zamai L, 2001, CYTOMETRY, V44, P57, DOI 10.1002/1097-0320(20010501)44:1<57::AID-CYTO1082>3.3.CO;2-F	53	26	26	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2881	2892		10.1096/fj.09-148593	http://dx.doi.org/10.1096/fj.09-148593			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20354138	Green Published			2022-12-28	WOS:000285005400028
J	Sha, W; da Costa, KA; Fischer, LM; Milburn, MV; Lawton, KA; Berger, A; Jia, W; Zeisel, SH				Sha, Wei; da Costa, Kerry-Ann; Fischer, Leslie M.; Milburn, Michael V.; Lawton, Kay A.; Berger, Alvin; Jia, Wei; Zeisel, Steven H.			Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline	FASEB JOURNAL			English	Article						fatty liver; metabolomics; plasma; PEMT	N-METHYLTRANSFERASE GENE; COA DESATURASE ACTIVITY; NONALCOHOLIC FATTY; HOMOCYSTEINE CONCENTRATION; PARENTERAL-NUTRITION; OSMOTIC REGULATION; FOLATE CONTENT; DEFICIENCY; BETAINE; TRANSPORT	Choline is an essential nutrient, and deficiency causes liver and muscle dysfunction. Common genetic variations alter the risk of developing organ dysfunction when choline deficient, probably by causing metabolic inefficiencies that should be detectable even while ingesting a normal choline-adequate diet. We determined whether metabolomic profiling of plasma at baseline could predict whether humans will develop liver dysfunction when deprived of dietary choline. Fifty-three participants were fed a diet containing 550 mg choline/70 kg/d for 10 d and then fed <50 mg choline/70 kg/d for up to 42 d. Participants who developed organ dysfunction on this diet were repleted with a choline-adequate diet for >= 3 d. Plasma samples, obtained at baseline, end of depletion, and end of repletion, were used for targeted and nontargeted metabolomic profiling. Liver fat was assessed using magnetic resonance spectroscopy. Metabolomic profiling and targeted biochemical analyses were highly correlated for the analytes assessed by both procedures. In addition, we report relative concentration changes of other small molecules detected by the nontargeted metabolomic analysis after choline depletion. Finally, we show that metabolomic profiles of participants when they were consuming a control baseline diet could predict whether they would develop liver dysfunction when deprived of dietary choline.-Sha, W., da Costa, K., Fischer, L. M., Milburn, M. V., Lawton, K. A., Berger, A., Jia, W., Zeisel, S. H. Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB J. 24, 2962-2975 (2010). www.fasebj.org	[Zeisel, Steven H.] Univ N Carolina Chapel Hill, Nutr Res Inst, Kannapolis, NC 28081 USA; [Sha, Wei] Univ N Carolina Charlotte, Bioinformat Res Ctr, Kannapolis, NC USA; [Jia, Wei] Univ N Carolina Greensboro, Dept Nutr, Kannapolis, NC USA; [da Costa, Kerry-Ann; Fischer, Leslie M.; Zeisel, Steven H.] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; [da Costa, Kerry-Ann; Fischer, Leslie M.; Zeisel, Steven H.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Milburn, Michael V.; Lawton, Kay A.; Berger, Alvin] Metabolon Inc, Durham, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Charlotte; University of North Carolina; University of North Carolina Greensboro; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Metabolon	Zeisel, SH (corresponding author), Univ N Carolina Chapel Hill, Nutr Res Inst, 500 Laureate Way, Kannapolis, NC 28081 USA.	steven_zeisel@unc.edu	Berger, Alvin/AAE-5353-2022; Jia, Wei/AAN-5102-2020	Jia, Wei/0000-0002-3739-8994	Mead Johnson Nutritionals; Balchem; Egg Nutrition Research Center; National Institutes of Health [DK55865, DK56350, RR00046]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350, R01DK055865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	Mead Johnson Nutritionals; Balchem; Egg Nutrition Research Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Yunping Qiu for the PCA and PLS-DA analyses. W.S. performed the statistical computations for data analysis and was responsible for the preparation of the manuscript. K.D. supervised the sample collection and targeted analyses and assisted in the data interpretation and writing of the manuscript. L.M.F. oversaw recruitment of subjects into the study, compliance and safety monitoring. A.B., M.M., and K.L. were responsible for the metabolomic analyses; A.B. also participated in the interpretation of the data. W.J. supervised the PCA and PLS-DA analyses. S.H.Z. was responsible for the conceptualization, funding, implementation and design of the human study, participated in statistical analyses and data interpretation, and provided major input in the writing of the manuscript. There is no financial conflict of interest in relation to this study (S.H.Z. received grant support from Mead Johnson Nutritionals, Balchem, and the Egg Nutrition Research Center for studies other than those described in this paper; S.H.Z. serves on the scientific advisory boards of Metabolon, Inc. and Dupont). This study was funded by grants from the National Institutes of Health to S.H.Z. (DK55865, DK56350, RR00046).	ACARA M, 1979, AM J PHYSIOL, V236, pF112; Albright CD, 1998, J NUTR BIOCHEM, V9, P476, DOI 10.1016/S0955-2863(98)00047-3; Atkinson W, 2007, EUR J NUTR, V46, P446, DOI 10.1007/s00394-007-0684-5; Attie AD, 2002, J LIPID RES, V43, P1899, DOI 10.1194/jlr.M200189-JLR200; Barrett T., 2008, U.S. Patent, Patent No. [7,433,787, 7433787]; Beger RD, 2010, TOXICOL APPL PHARM, V243, P154, DOI 10.1016/j.taap.2009.11.019; BLUSZTAJN JK, 1985, BIOCHEM J, V232, P505, DOI 10.1042/bj2320505; Boudonck KJ, 2009, TOXICOL PATHOL, V37, P280, DOI 10.1177/0192623309332992; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; Buchman AL, 2001, JPEN-PARENTER ENTER, V25, P260, DOI 10.1177/0148607101025005260; Busby MG, 2004, J AM DIET ASSOC, V104, P1836, DOI 10.1016/j.jada.2004.09.027; CARTER AL, 1978, J NUTR, V108, P1748, DOI 10.1093/jn/108.11.1748; Cho E, 2006, AM J CLIN NUTR, V83, P905, DOI 10.1093/ajcn/83.4.905; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; da Costa KA, 2006, FASEB J, V20, pA606; da Costa KA, 2005, AM J CLIN NUTR, V81, P440; da Costa KA, 2004, AM J CLIN NUTR, V80, P163; da Costa KA, 2006, AM J CLIN NUTR, V84, P88, DOI 10.1093/ajcn/84.1.88; DACOSTA KA, 1993, J BIOL CHEM, V268, P2100; Dobrzyn A, 2005, J BIOL CHEM, V280, P23356, DOI 10.1074/jbc.M502436200; Dong H, 2007, J HEPATOL, V46, P915, DOI 10.1016/j.jhep.2006.12.012; Duarte IF, 2005, ANAL CHEM, V77, P5570, DOI 10.1021/ac050455c; Dzurik R, 2001, KIDNEY INT, V59, pS278; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Ferrara F, 2005, DRUG EXP CLIN RES, V31, P109; Finkelstein JD, 2000, SEMIN THROMB HEMOST, V26, P219, DOI 10.1055/s-2000-8466; Fischer LM, 2007, AM J CLIN NUTR, V85, P1275; Fishbein MH, 1997, MAGN RESON IMAGING, V15, P287, DOI 10.1016/S0730-725X(96)00224-X; Griffin JL, 2004, PHYSIOL GENOMICS, V17, P140, DOI 10.1152/physiolgenomics.00158.2003; Horio M, 1997, AM J PHYSIOL-CELL PH, V272, pC804, DOI 10.1152/ajpcell.1997.272.3.C804; Jacobs A, 2009, TOXICOL LETT, V186, P32, DOI 10.1016/j.toxlet.2008.08.013; Jensen LJ, 2007, FASEB J, V21, pA519; Jun DW, 2009, EUR J GASTROEN HEPAT, V21, P667, DOI 10.1097/MEG.0b013e3283196adc; Kempson SA, 2004, PFLUG ARCH EUR J PHY, V449, P227, DOI 10.1007/s00424-004-1338-6; Keun HC, 2007, PHARMACOGENOMICS, V8, P731, DOI 10.2217/14622416.8.7.731; KIM YI, 1994, J NUTR, V124, P2197, DOI 10.1093/jn/124.11.2197; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; Kohlmeier M, 2005, P NATL ACAD SCI USA, V102, P16025, DOI 10.1073/pnas.0504285102; Kovacic P, 2005, MED HYPOTHESES, V65, P90, DOI 10.1016/j.mehy.2005.01.031; Launay-Vacher V, 2006, NEPHRON PHYSIOL, V103, P97, DOI 10.1159/000092212; Lawton KA, 2008, PHARMACOGENOMICS, V9, P383, DOI 10.2217/14622416.9.4.383; Ma XZ, 2009, RADIOGRAPHICS, V29, P1253, DOI 10.1148/rg.295085186; Maddox JF, 2006, TOXICOL APPL PHARM, V212, P35, DOI 10.1016/j.taap.2005.06.021; MICHAEL UF, 1975, P SOC EXP BIOL MED, V150, P672, DOI 10.3181/00379727-150-39103; *NAT AC SCI US, 1998, DIET REF INT FOL THI, V1, P390; Nehra V, 2001, DIGEST DIS SCI, V46, P2347, DOI 10.1023/A:1012338828418; Niculescu MD, 2002, J NUTR, V132, p2333S, DOI 10.1093/jn/132.8.2333S; Paillard F, 2008, NUTR METAB CARDIOVAS, V18, P436, DOI 10.1016/j.numecd.2007.02.017; PONTREMOLI S, 1990, BIOCHEM BIOPH RES CO, V167, P373, DOI 10.1016/0006-291X(90)91775-N; Resseguie ME, 2007, FASEB J, V21, pA61; Romeo S, 2006, FASEB J, V20, P2180, DOI 10.1096/fj.06-1004ufm; Rubino FM, 2009, MASS SPECTROM REV, V28, P725, DOI 10.1002/mas.20207; Saadeh S, 2002, GASTROENTEROLOGY, V123, P745, DOI 10.1053/gast.2002.35354; Savendahl L, 1997, AM J CLIN NUTR, V66, P622, DOI 10.1093/ajcn/66.3.622; SELHUB J, 1991, CANCER RES, V51, P16; Shaw GM, 2006, EPIDEMIOLOGY, V17, P285, DOI 10.1097/01.ede.0000208348.30012.35; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; SHEARD NF, 1986, AM J CLIN NUTR, V43, P219, DOI 10.1093/ajcn/43.2.219; SHEARD NF, 1994, J NUTR, V124, P738, DOI 10.1093/jn/124.5.738; Song JN, 2005, FASEB J, V19, pA1037; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Srimaroeng C, 2008, XENOBIOTICA, V38, P889, DOI [10.1080/00498250801927435, 10.1080/00498250801927435 ]; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Urakami Y, 2004, PHARM RES-DORDR, V21, P976, DOI 10.1023/B:PHAM.0000029286.45788.ad; van Ginneken V, 2007, BBA-MOL CELL BIOL L, V1771, P1263, DOI 10.1016/j.bbalip.2007.07.007; VARELAMOREIRAS G, 1992, J NUTR BIOCHEM, V3, P519, DOI 10.1016/0955-2863(92)90073-R; Wagner CA, 2000, AM J PHYSIOL-RENAL, V279, pF584, DOI 10.1152/ajprenal.2000.279.3.F584; Xu XR, 2009, FASEB J, V23, P4022, DOI 10.1096/fj.09-136507; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Yeung KY, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-r34; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; ZEISEL SH, 1989, BIOCHEM J, V259, P725, DOI 10.1042/bj2590725; Zeisel SH, 2007, AM J CLIN NUTR, V86, P542, DOI 10.1093/ajcn/86.3.542; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156; Zeisel SH, 2006, FASEB J, V20, P2181, DOI 10.1096/fj.06-1005ufm	75	83	89	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2962	2975		10.1096/fj.09-154054	http://dx.doi.org/10.1096/fj.09-154054			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371621	Green Published, Green Submitted			2022-12-28	WOS:000285005400035
J	Alattia, JR; Kuraishi, T; Dimitrov, M; Chang, I; Lemaitre, B; Fraering, PC				Alattia, Jean-Rene; Kuraishi, Takayuki; Dimitrov, Mitko; Chang, Isabelle; Lemaitre, Bruno; Fraering, Patrick C.			Mercury is a direct and potent gamma-secretase inhibitor affecting Notch processing and development in Drosophila	FASEB JOURNAL			English	Article						enzyme assay; metal toxicity; Notch signaling; embryonic neurodevelopment	MEDIATED TRANSMEMBRANE CLEAVAGE; SYNAPTIC PLASTICITY; METHYLMERCURY; RECEPTOR; PURIFICATION; MELANOGASTER; ACTIVATION; NICASTRIN; PATHOLOGY; EXPOSURE	Prenatal exposure to mercury causes neurodevelopmental disorders and neurological pathologies in infants, such as microcephaly and mental retardation. Despite critical importance, the molecular interactions leading to mercury toxicity are yet to be elucidated. We first used a cell-free assay to investigate mercury effects on purified gamma-secretase activity. Next, we treated adult Drosophila melanogaster with mercury and collected control and mercury-treated embryos, which were subjected to mild hypotonic protein extraction, or immunostained to reveal nervous system morphology. Embryos left to develop into adults were examined for wing phenotypes. Relative to control metals, we found that mercury strongly inhibits in vitro gamma-secretase processing of both amyloid-beta precursor protein (APP) and Notch. Mercury inhibited APP and Notch cleavage in a dose-dependent manner, with IC50 values of 50-125 nM, and is therefore comparable in potency to benchmark gamma-secretase inhibitors. Immunoblot analysis of embryonic protein extracts showed that mercury inhibits Notch cleavage by gamma-secretase in vivo. This is accompanied by severe neurodevelopmental abnormalities in embryos and adult wing-notching phenotypes. Our findings provide first evidence that mercury is a direct and potent gamma-secretase inhibitor and suggest that inhibition of gamma-secretase and disruption of the Notch developmental pathway potentially contribute to mercury-induced toxicity in the nervous system.-Alattia, J-R., Kuraishi, T., Dimitrov, M., Chang, I., Lemaitre, B., Fraering, P. C. Mercury is a direct and potent gamma-secretase inhibitor affecting Notch processing and development in Drosophila. FASEB J. 25, 2287-2295 (2011). www.fasebj.org	[Alattia, Jean-Rene; Dimitrov, Mitko; Chang, Isabelle; Fraering, Patrick C.] Swiss Fed Inst Technol, Brain Mind Inst, CH-1015 Lausanne, Switzerland; [Kuraishi, Takayuki; Lemaitre, Bruno] Swiss Fed Inst Technol, Global Hlth Inst, Sch Life Sci, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Fraering, PC (corresponding author), Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol, Stn 15, CH-1015 Lausanne, Switzerland.	patrick.fraering@epfl.ch	Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667; Fraering, Patrick/0000-0002-5841-5327	Swiss National Science Foundation; Swiss National Centres of Competence in Research, Neural Plasticity and Repair; EPFL-Merck-Serono; Grants-in-Aid for Scientific Research [23890014] Funding Source: KAKEN	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss National Centres of Competence in Research, Neural Plasticity and Repair; EPFL-Merck-Serono; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The C17.9C6 antibody developed by Prof. Spyros Artavanis-Tsakonas was obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA, USA), developed under the auspices of the U. S. National Institute of Child Health and Human Development and maintained by the University of Iowa Department of Biology. The authors thank M. Moniatte and D. Chiappe [Proteomics Core Facility, School of Life Sciences, Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland] for technical assistance with mass spectrometry. The authors also thank F. Schweisguth for critical discussions. This work was supported by the Swiss National Science Foundation (P. C. F., B. L.); the Swiss National Centres of Competence in Research, Neural Plasticity and Repair (P. C. F.); and an EPFL-Merck-Serono grant (J.R.A. and M. D.).	APOSHIAN HV, 1995, TOXICOLOGY, V97, P23, DOI 10.1016/0300-483X(95)02965-B; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; Bland C, 2006, NEUROTOXICOLOGY, V27, P982, DOI 10.1016/j.neuro.2006.04.005; Cacquevel M, 2008, J NEUROCHEM, V104, P210, DOI 10.1111/j.1471-4159.2007.05041.x; Castoldi AF, 2008, REGUL TOXICOL PHARM, V51, P201, DOI 10.1016/j.yrtph.2008.01.016; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Costa RM, 2003, CURR BIOL, V13, P1348, DOI 10.1016/S0960-9822(03)00492-5; Eto K, 1997, TOXICOL PATHOL, V25, P614, DOI 10.1177/019262339702500612; Fok TF, 2007, ENVIRON INT, V33, P84, DOI 10.1016/j.envint.2006.08.002; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Fraering PC, 2005, J BIOL CHEM, V280, P41987, DOI 10.1074/jbc.M501368200; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kim D, 2009, CELL, V137, P997, DOI 10.1016/j.cell.2009.05.042; Korbas M, 2010, ACS CHEM NEUROSCI, V1, P810, DOI 10.1021/cn1000765; Kukar TL, 2008, NATURE, V453, P925, DOI 10.1038/nature07055; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; Micchelli CA, 2002, FASEB J, V16, P79, DOI 10.1096/fj.02-0394fje; MULLER A, 1993, J BIOL CHEM, V268, P26150; National Research Council, 2000, TOX EFF METH MERC; PANGBURN MK, 1975, BIOCHEMISTRY-US, V14, P4050, DOI 10.1021/bi00689a019; Rand MD, 2008, TOXICOL SCI, V104, P163, DOI 10.1093/toxsci/kfn060; Rush T, 2009, NEUROTOXICOLOGY, V30, P47, DOI 10.1016/j.neuro.2008.10.009; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; SCHEUHAMMER AM, 1987, ENVIRON POLLUT, V46, P263, DOI 10.1016/0269-7491(87)90173-4; Struhl G, 2001, P NATL ACAD SCI USA, V98, P229, DOI 10.1073/pnas.011530298; SUN BH, 1995, J NEUROCHEM, V65, P434, DOI 10.1046/j.1471-4159.1995.65010434.x; Vaccari T, 2008, J CELL BIOL, V180, P755, DOI 10.1083/jcb.200708127; Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101; WELLS TNC, 1994, BIOCHEMISTRY-US, V33, P7641, DOI 10.1021/bi00190a018; Wines-Samuelson M, 2005, NEUROSCIENTIST, V11, P441, DOI 10.1177/1073858405278922; Wolfe MS, 2009, SEMIN CELL DEV BIOL, V20, P219, DOI 10.1016/j.semcdb.2008.12.011; Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475	34	21	21	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2287	2295		10.1096/fj.10-174078	http://dx.doi.org/10.1096/fj.10-174078			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21415381				2022-12-28	WOS:000292242200020
J	Murray, LM; Comley, LH; Gillingwater, TH; Parson, SH				Murray, Lyndsay M.; Comley, Laura H.; Gillingwater, Thomas H.; Parson, Simon H.			The response of neuromuscular junctions to injury is developmentally regulated	FASEB JOURNAL			English	Article						hypoxia; vulnerability; motor neuron; Wallerian degeneration	SPINAL MUSCULAR-ATROPHY; AFFINITY NEUROTROPHIN RECEPTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; GUILLAIN-BARRE-SYNDROME; SCHWANN-CELL APOPTOSIS; MOTOR-NERVE TERMINALS; SELECTIVE VULNERABILITY; WALLERIAN DEGENERATION; SYNAPTIC VULNERABILITY; MOTONEURON DEATH	It is well established that developmental maturity is a key factor regulating the response of lower motor neurons to injury. The influence of age on the survival of motor neuron cell somata following axotomy is well documented, but it remains unclear whether maturity also influences the degeneration of axonal and synaptic compartments at the neuromuscular junction. Such information is important for our interpretation of data suggesting that neonatal neuromuscular junctions are particularly vulnerable in neurodegenerative conditions that affect the developing postnatal nervous system, such as spinal muscular atrophy. Here, we have examined the role of development in regulating the vulnerability of mouse neuromuscular junctions to two mechanistically distinct degenerative insults: hypoxia and peripheral nerve injury. We report that neuromuscular junctions in neonatal mice are significantly more resistant to both hypoxia and nerve injury than those in adult mice, with a transition from the neonatal to adult phenotype occurring at 2-3 wk of age. We also demonstrate that the reduced vulnerability of neuromuscular junctions observed in neonatal mice is not determined by the maturity of the synapse per se, suggesting that properties associated with the neonatal environment and/or age of the neuron are responsible for modulating vulnerability. Our results are in stark contrast to previous studies showing that motor neuron cell somata are markedly more vulnerable to axotomy in neonatal mice. We conclude that neonatal neuromuscular junctions are resistant to a range of neurodegenerative insults in vivo and that this resistance is developmentally regulated.-Murray, L. M., Comley, L. H., Gillingwater, T. H., Parson, S. H. The response of neuromuscular junctions to injury is developmentally regulated. FASEB J. 25, 1306-1313 (2011). www.fasebj.org	Univ Edinburgh, Sch Med, Euan MacDonald Ctr Motor Neurone Dis Res, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Sch Med, Ctr Integrat Physiol, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Parson, SH (corresponding author), Univ Edinburgh, Old Med Sch, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.h.parson@ed.ac.uk	Gillingwater, Thomas/G-2880-2011	Gillingwater, Thomas/0000-0002-0306-5577; Parson, Simon/0000-0002-8848-8738	Euan MacDonald Centre for Motor Neurone Disease Research (Edinburgh, UK); Biotechnology and Biological Sciences Research Council; SMA Trust; Wellcome Trust	Euan MacDonald Centre for Motor Neurone Disease Research (Edinburgh, UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); SMA Trust; Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank Derek Thomson for assistance with animals and members of the S. H. P. and T. H. G. laboratories for helpful advice on the current study. L. M. M. and S. H. P. were supported by Seedcorn funds from the Euan MacDonald Centre for Motor Neurone Disease Research (Edinburgh, UK). L. H. C. is supported by a Biotechnology and Biological Sciences Research Council Ph.D. studentship. T. H. G. is supported by The SMA Trust and The Wellcome Trust.	Baumer D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000773; Baxter B, 2008, J ANAT, V212, P827, DOI 10.1111/j.1469-7580.2008.00909.x; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BROWN MC, 1978, J PHYSIOL-LONDON, V278, P325, DOI 10.1113/jphysiol.1978.sp012307; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Gillingwater TH, 2002, J PHYSIOL-LONDON, V543, P739, DOI 10.1113/jphysiol.2002.022343; Gillingwater TH, 2001, J PHYSIOL-LONDON, V534, P627, DOI 10.1111/j.1469-7793.2001.00627.x; Ho TW, 1999, ANN NEUROL, V45, P168, DOI 10.1002/1531-8249(199902)45:2<168::AID-ANA6>3.0.CO;2-6; Kapoukranidou D, 2005, MED SCI MONITOR, V11, pBR373; Kong LL, 2009, J NEUROSCI, V29, P842, DOI 10.1523/JNEUROSCI.4434-08.2009; Li LX, 1998, J COMP NEUROL, V396, P158; LICHTMAN JW, 1996, SEMIN DEV BIOL, V6, P195; LOWRIE MB, 1994, DEV NEUROSCI-BASEL, V16, P279, DOI 10.1159/000112120; Malik RQ, 2000, J PHYSIOL-LONDON, V528P, p79P; Murray LM, 2010, NEUROMUSCULAR DISORD, V20, P740, DOI 10.1016/j.nmd.2010.06.013; Murray LM, 2010, NEUROPATH APPL NEURO, V36, P133, DOI [10.1111/j.1365-2990.2009.01061.x, 10.1111/j.1365-2990.2010.01061.x]; Murray LM, 2008, HUM MOL GENET, V17, P949, DOI 10.1093/hmg/ddm367; Murray LM, 2010, HUM MOL GENET, V19, P420, DOI 10.1093/hmg/ddp506; Murray LM, 2008, J ANAT, V213, P633, DOI 10.1111/j.1469-7580.2008.01007.x; Petratos S, 2003, J NEUROPATH EXP NEUR, V62, P398, DOI 10.1093/jnen/62.4.398; POLLIN MM, 1991, DEVELOPMENT, V112, P83; Pun S, 2006, NAT NEUROSCI, V9, P408, DOI 10.1038/nn1653; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; SAUNDERS KC, 1979, CLIN ORTHOP RELAT R, P194; SON YJ, 1995, NEURON, V14, P125, DOI 10.1016/0896-6273(95)90246-5; SON YJ, 1995, NEURON, V14, P133, DOI 10.1016/0896-6273(95)90247-3; Syroid DE, 2000, J NEUROSCI, V20, P5741, DOI 10.1523/JNEUROSCI.20-15-05741.2000; THOMPSON W, 1977, NEUROSCIENCE, V2, P523, DOI 10.1016/0306-4522(77)90049-5; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; Waller A., 1850, PHIL T R SOC, V140, P423, DOI DOI 10.1098/RSTL.1850.0021; Willison HJ, 2008, J NEUROIMMUNOL, V201, P172, DOI 10.1016/j.jneuroim.2008.05.028; Wishart TM, 2006, J NEUROPATH EXP NEUR, V65, P733, DOI 10.1097/01.jnen.0000228202.35163.c4	32	8	8	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1306	1313		10.1096/fj.10-171934	http://dx.doi.org/10.1096/fj.10-171934			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21228222	Green Accepted			2022-12-28	WOS:000288982800019
J	Ni, CL; Shi, HP; Yu, HM; Chang, YC; Chen, YR				Ni, Chun-Lun; Shi, Hoi-Ping; Yu, Hui-Ming; Chang, Yun-Chorng; Chen, Yun-Ru			Folding stability of amyloid-beta 40 monomer is an important determinant of the nucleation kinetics in fibrillization	FASEB JOURNAL			English	Article						Alzheimer's disease; protein aggregation; protein conformation; natively unfolded	HEREDITARY CEREBRAL-HEMORRHAGE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; AGGREGATION PROPERTIES; DUTCH TYPE; WILD-TYPE; FIBRILS; PEPTIDE; MUTATION; MECHANISM	Amyloid formation is initiated by protein misfolding, followed by self-association to ultimately form amyloid fibrils. The discovery of toxic prefibrillar oligomers in many amyloidosis underscores the importance of understanding the folding mechanism prior to such aggregation. Here, we investigated the folding properties of the natively unfolded amyloid-beta (A beta) peptide and the familial variants (A21G, E22Q, E22G, E22K, and D23N) in Alzheimer's disease (AD). In combinations of native electrophoresis, analytical ultracentrifugation, fluorescence emission, and far-UV circular dichroism, we showed that all A beta 40 variants are predominantly monomeric with similar residual secondary structures, but distinct hydrophobic-exposed protein surfaces. Guanidine hydrochloride (GdnHCl) denaturation in the absence and presence of trifluoroethanol (TFE) showed that A beta variants adopt an apparent 2-state equilibrium model with different stabilities, in which wild type is less stable than A21G but more stable than D23N and E22 mutants. By correlating the folding stability with the nucleation phase in fibrillization, we found the more stable the variant, the slower the nucleation, except for D23N. Besides, the unfolding of A beta conformation leads to reduced formation of mature fibrils, but an increase in nonfibrillar, amorphous type of aggregates. Overall, we demonstrated that folding stability of A beta is an important determinant of the nucleation kinetics.-Ni, C.-L., Shi, H.-P., Yu, H.-M., Chang, Y.-C., and Chen, Y.-R. Folding stability of amyloid-beta 40 monomer is an important determinant of the nucleation kinetics in fibrillization. FASEB J. 25, 1390-1401 (2011). www.fasebj.org	[Ni, Chun-Lun; Shi, Hoi-Ping; Yu, Hui-Ming; Chen, Yun-Ru] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Chang, Yun-Chorng] Natl Cheng Kung Univ, Inst Electroopt Sci & Engn, Tainan 70101, Taiwan	Academia Sinica - Taiwan; National Cheng Kung University	Chen, YR (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sec 2, Taipei 115, Taiwan.	yrchen@gate.sinica.edu.tw	Chang, Yun-Chorng/A-5832-2011; Chen, Yun-Ru/C-9304-2014	Chang, Yun-Chorng/0000-0002-2862-9789; Chen, Yun-Ru/0000-0002-6596-6338; Ni, Chun-Lun/0000-0002-6960-3972	Genomics Research Center, Academia Sinica, Taiwan; National Science Council, Taiwan [NSC 96-2113-M-001-030-MY2]	Genomics Research Center, Academia Sinica, Taiwan(Academia Sinica - Taiwan); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	The authors thank Dr. Ming-Dow Tsai (Institute of Biochemical Science, Academia Sinica) and Dr. An-Suei Yang (Genomics Research Center, Academia Sinica) for critical reading. The authors thank Dr. Leonid Breydo (University of California, Irvine, CA, USA) for suggestions. This work was supported by the Genomics Research Center, Academia Sinica, Taiwan, and the National Science Council, Taiwan (NSC 96-2113-M-001-030-MY2).	Betts V, 2008, NEUROBIOL DIS, V31, P442, DOI 10.1016/j.nbd.2008.06.001; Bibl M, 2007, J NEUROCHEM, V103, P467, DOI 10.1111/j.1471-4159.2007.04763.x; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bornebroek M, 1996, BRAIN PATHOL, V6, P111, DOI 10.1111/j.1750-3639.1996.tb00793.x; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; BURDICK D, 1992, J BIOL CHEM, V267, P546; Chen YR, 2006, J BIOL CHEM, V281, P24414, DOI 10.1074/jbc.M602363200; De Jonghe C, 1998, NEUROBIOL DIS, V5, P281, DOI 10.1006/nbdi.1998.0202; ENGELHARD M, 1995, PROTEIN SCI, V4, P1553, DOI 10.1002/pro.5560040813; Ferrao-Gonzales AD, 2005, J BIOL CHEM, V280, P34747, DOI 10.1074/jbc.M501651200; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Frieden C, 2007, PROTEIN SCI, V16, P2334, DOI 10.1110/ps.073164107; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; Grant MA, 2007, P NATL ACAD SCI USA, V104, P16522, DOI 10.1073/pnas.0705197104; Guo JT, 2004, PROTEINS, V57, P357, DOI 10.1002/prot.20222; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Hou LM, 2004, J AM CHEM SOC, V126, P1992, DOI 10.1021/ja036813f; Jahn TR, 2005, FEBS J, V272, P5962, DOI 10.1111/j.1742-4658.2005.05021.x; Kajava AV, 2010, FASEB J, V24, P1311, DOI 10.1096/fj.09-145979; KAMINO K, 1992, AM J HUM GENET, V51, P998; Krone MG, 2008, J MOL BIOL, V381, P221, DOI 10.1016/j.jmb.2008.05.069; Kumar-Singh S, 2002, NEUROBIOL DIS, V11, P330, DOI 10.1006/nbdi.2002.0529; Lazo ND, 2005, PROTEIN SCI, V14, P1581, DOI 10.1110/ps.041292205; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Povey JF, 2007, J STRUCT BIOL, V157, P329, DOI 10.1016/j.jsb.2006.07.008; Rambaran RN, 2008, PRION, V2, P112, DOI 10.4161/pri.2.3.7488; Riek R, 2001, EUR J BIOCHEM, V268, P5930, DOI 10.1046/j.0014-2956.2001.02537.x; Roccatano D, 2002, P NATL ACAD SCI USA, V99, P12179, DOI 10.1073/pnas.182199699; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Rossi G, 1998, NEUROLOGY, V50, P688, DOI 10.1212/WNL.50.3.688; Roychaudhuri R, 2009, J BIOL CHEM, V284, P4749, DOI 10.1074/jbc.R800036200; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Schoonenboom NS, 2005, ANN NEUROL, V58, P139, DOI 10.1002/ana.20508; Sciarretta KL, 2005, BIOCHEMISTRY-US, V44, P6003, DOI 10.1021/bi0474867; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; Tarus B, 2008, J MOL BIOL, V379, P815, DOI 10.1016/j.jmb.2008.04.028; Tian Y, 2010, NAT STRUCT MOL BIOL, V17, P151, DOI 10.1038/nsmb.1743; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tycko R, 2006, Q REV BIOPHYS, V39, P1, DOI 10.1017/S0033583506004173; Tycko R, 2009, BIOCHEMISTRY-US, V48, P6072, DOI 10.1021/bi9002666; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Weiner HL, 2006, NAT REV IMMUNOL, V6, P404, DOI 10.1038/nri1843; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; Yang MF, 2008, J MOL BIOL, V384, P450, DOI 10.1016/j.jmb.2008.09.039	54	32	32	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1390	1401		10.1096/fj.10-175539	http://dx.doi.org/10.1096/fj.10-175539			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21209058				2022-12-28	WOS:000288982800028
J	Rautenberg, M; Joo, HS; Otto, M; Peschel, A				Rautenberg, Maren; Joo, Hwang-Soo; Otto, Michael; Peschel, Andreas			Neutrophil responses to staphylococcal pathogens and commensals via the formyl peptide receptor 2 relates to phenol-soluble modulin release and virulence	FASEB JOURNAL			English	Article						pathogen-associated molecular patterns; coagulase-negative staphylococci; skin microbiota; neutrophil chemotaxis	LIPOXIN A(4) RECEPTOR; COAGULASE-NEGATIVE STAPHYLOCOCCI; ACTIVATES NEUTROPHILS; MOLECULAR-PATTERNS; IMMUNE EVASION; AUREUS; LUGDUNENSIS; EPIDERMIDIS; RECOGNITION; CHEMOTAXIS	The mechanisms used by the immune system to discriminate between pathogenic and commensal bacteria have remained largely unclear. Recently, we have shown that virulence of Staphylococcus aureus depends on secretion of phenol-soluble modulin (PSM) peptides that disrupt neutrophils at micromolar concentrations. Moreover, all S. aureus PSMs stimulate and attract neutrophils at nanomolar concentrations via interaction with the formyl-peptide receptor 2 (FPR2). Here, we demonstrate that FPR2 allows neutrophils to adjust their responses in relation to the aggressiveness of staphylococcal species, which differ largely in their capacity to infect or colonize humans and animals. PSM-related peptides were detected in all human and animal pathogenic staphylococci, but were absent from most commensal species. Three PSM beta-like peptides produced by the serious human pathogen Staphylococcus lugdunensis were identified as the previously described S. lugdunensis-synergistic hemolysins (SLUSHs). SLUSHs attracted and stimulated human leukocytes in a FPR2-dependent manner, indicating that FPR2 is a general receptor for all PSM-like peptide toxins. Remarkably, the release of PSMs correlated closely with the apparent capacity of staphylococcal species to cause invasive infections and with their ability to activate FPR2. These findings suggest that the innate immune system may be able to respond in different ways to pathogenic or innocuous staphylococci by monitoring the presence of PSMs via FPR2.-Rautenberg, M., Joo, H. S., Otto, M., Peschel, A. Neutrophil responses to staphylococcal pathogens and commensals via the formyl peptide receptor 2 relates to phenol-soluble modulin release and virulence. FASEB J. 25, 1254-1263 (2011). www.fasebj.org	[Rautenberg, Maren; Peschel, Andreas] Univ Tubingen, Interfac Inst Microbiol & Infect Med, Cellular & Mol Microbiol Div, D-72076 Tubingen, Germany; [Joo, Hwang-Soo; Otto, Michael] NIAID, Lab Human Bacterial Pathogenesis, US Natl Inst Hlth, Bethesda, MD 20892 USA	Eberhard Karls University of Tubingen; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Peschel, A (corresponding author), Univ Tubingen, Interfac Inst Microbiol & Infect Med, Cellular & Mol Microbiol Div, Elfriede Aulhorn Str 6, D-72076 Tubingen, Germany.	motto@niaid.nih.gov; andreas.peschel@uni-tuebingen.de		Otto, Michael/0000-0002-2222-4115; JOO, HWANG-SOO/0000-0003-4668-3225	German Research Foundation [SFB685, GRK685, TR34]; German Ministry of Education and Research; Medical Faculty, University of Tubingen; National Institutes of Allergy and Infectious Diseases, U.S. National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000904] Funding Source: NIH RePORTER	German Research Foundation(German Research Foundation (DFG)); German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Medical Faculty, University of Tubingen; National Institutes of Allergy and Infectious Diseases, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Nele Nikola for excellent technical help, Jos van Strijp (Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands) for CHIPS, Francois Boulay (Universite Joseph Fourier, Grenoble, France) for FPR1 and FPR2-transfected cell lines, and Bernhard Krismer (Interfaculty Institute of Microbiology and Infection Medicine, University of Tuebingen, Tuebingen, Germany) for staphylococcal strains. This research is supported by grants from the German Research Foundation (SFB685, GRK685, TR34), the German Ministry of Education and Research (SkinStaph Menage), and the IZKF program of the Medical Faculty, University of Tubingen, to A. P. and from the Intramural Program of the National Institutes of Allergy and Infectious Diseases, U.S. National Institutes of Health, to M.O.	Betten A, 2001, J CLIN INVEST, V108, P1221, DOI 10.1172/JCI200113430; Boller T, 2009, ANNU REV PLANT BIOL, V60, P379, DOI 10.1146/annurev.arplant.57.032905.105346; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; Cheung GYC, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001133; Christophe T, 2001, J BIOL CHEM, V276, P21585, DOI 10.1074/jbc.M007769200; Cogen AL, 2010, J INVEST DERMATOL, V130, P192, DOI 10.1038/jid.2009.243; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; de Haas CJC, 2004, J EXP MED, V199, P687, DOI 10.1084/jem.20031636; DeLeo FR, 2010, LANCET, V375, P1557, DOI 10.1016/S0140-6736(09)61999-1; Donvito B, 1997, INFECT IMMUN, V65, P95, DOI 10.1128/IAI.65.1.95-100.1997; Durr MC, 2006, CELL MICROBIOL, V8, P207, DOI 10.1111/j.1462-5822.2005.00610.x; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Foster TJ, 2005, NAT REV MICROBIOL, V3, P948, DOI 10.1038/nrmicro1289; Frank KL, 2008, CLIN MICROBIOL REV, V21, P111, DOI 10.1128/CMR.00036-07; FRENEY J, 1988, INT J SYST BACTERIOL, V38, P168, DOI 10.1099/00207713-38-2-168; Fu HM, 2006, J LEUKOCYTE BIOL, V79, P247, DOI 10.1189/jlb.0905498; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Huebner J, 1999, ANNU REV MED, V50, P223, DOI 10.1146/annurev.med.50.1.223; Kretschmer D, 2010, CELL HOST MICROBE, V7, P463, DOI 10.1016/j.chom.2010.05.012; Le YY, 2001, CYTOKINE GROWTH F R, V12, P91, DOI 10.1016/S1359-6101(01)00003-X; Loffler B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000715; Mader D, 2010, MICROBES INFECT, V12, P415, DOI 10.1016/j.micinf.2010.01.014; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Mehlin C, 1999, J EXP MED, V189, P907, DOI 10.1084/jem.189.6.907; Migeotte I, 2006, CYTOKINE GROWTH F R, V17, P501, DOI 10.1016/j.cytogfr.2006.09.009; Otto M, 2009, NAT REV MICROBIOL, V7, P555, DOI 10.1038/nrmicro2182; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Queck SY, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000533; Queck Shu Yeong, 2008, P227; Rasmussen TT, 2000, APMIS, V108, P663, DOI 10.1034/j.1600-0463.2000.d01-13.x; Rooijakkers SHM, 2005, TRENDS MICROBIOL, V13, P596, DOI 10.1016/j.tim.2005.10.002; Shin EH, 2006, BIOCHEM BIOPH RES CO, V341, P1317, DOI 10.1016/j.bbrc.2006.01.098; Shopsin B, 2008, J INFECT DIS, V198, P1171, DOI 10.1086/592051; Somerville GA, 2003, J BACTERIOL, V185, P6686, DOI 10.1128/JB.185.22.6686-6694.2003; Somerville GA, 2002, J BACTERIOL, V184, P1430, DOI 10.1128/JB.184.5.1430-1437.2002; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; van der Mee-Marquet N, 2003, J CLIN MICROBIOL, V41, P1404, DOI 10.1128/JCM.41.4.1404-1409.2003; von Eiff C, 2002, LANCET INFECT DIS, V2, P677, DOI 10.1016/S1473-3099(02)00438-3; Vuong C, 2004, CELL MICROBIOL, V6, P753, DOI 10.1111/j.1462-5822.2004.00401.x; Wang R, 2007, NAT MED, V13, P1510, DOI 10.1038/nm1656; WATSON DC, 1988, BIOCHEM J, V252, P87, DOI 10.1042/bj2520087; Wenzel A, 2009, AUTOIMMUNITY, V42, P331, DOI 10.1080/08916930902828239; Yao YF, 2005, J INFECT DIS, V191, P289, DOI 10.1086/426945; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578	44	77	83	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1254	1263		10.1096/fj.10-175208	http://dx.doi.org/10.1096/fj.10-175208			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21183593	Green Published, Bronze			2022-12-28	WOS:000288982800014
J	D'Aniello, S; Somorjai, I; Garcia-Fernandez, J; Topo, E; D'Aniello, A				D'Aniello, Salvatore; Somorjai, Ildiko; Garcia-Fernandez, Jordi; Topo, Enza; D'Aniello, Antimo			D-Aspartic acid is a novel endogenous neurotransmitter	FASEB JOURNAL			English	Article						nervous system; D-amino acids; L-amino acids; synaptic vesicles; receptors	L-AMINO-ACIDS; D-SERINE; LUTEINIZING-HORMONE; CEREBROSPINAL-FLUID; POSTNATAL CHANGES; INDUCED RELEASE; RAT-BRAIN; OXIDASE; GLUTAMATE; ALZHEIMER	D-Aspartic acid (D-Asp) is present in invertebrate and vertebrate neuroendocrine tissues, where it carries out important physiological functions and is implicated in nervous system development. We show here that D-Asp is a novel endogenous neurotransmitter in two distantly related animals, a mammal (Rattus norvegicus) and a mollusk (Loligo vulgaris). Our main findings demonstrate that D-Asp is present in high concentrations in the synaptic vesicles of axon terminals; synthesis for this amino acid occurs in neurons by conversion of L-Asp to D-Asp via D-aspartate racemase; depolarization of nerve endings with K+ ions evokes an immediate release of D-Asp in a Ca2+ dependent manner; specific receptors for D-Asp occur at the postsynaptic membrane, as demonstrated by binding assays and by the expansion of squid skin chromatophores; D-aspartate oxidase, the specific enzyme that oxidizes D-Asp, is present in the postsynaptic membranes; and stimulation of nerve endings with D-Asp triggers signal transduction by increasing the second messenger cAMP. Taken together, these data demonstrate that D-Asp fulfills all criteria necessary to be considered a novel endogenous neurotransmitter. Given its known role in neurogenesis, learning, and neuropathologies, our results have important implications for biomedical and clinical research.-D'Aniello, S., Somorjai, I., Garcia-Fernandez, J., Topo, E., D'Aniello, A. D-Aspartic acid is a novel endogenous neurotransmitter. FASEB J. 25, 1014-1027 (2011). www.fasebj.org	[Topo, Enza; D'Aniello, Antimo] Stn Zool A Dohrn, Dept Neurobiol, I-80121 Naples, Italy; [D'Aniello, Salvatore; Somorjai, Ildiko; Garcia-Fernandez, Jordi] Univ Barcelona, Fac Biol, Dept Genet, Inst Biomed, Barcelona, Spain; [D'Aniello, Salvatore] Stn Zool A Dohrn, Dept Cellular & Dev Biol, I-80121 Naples, Italy; [D'Aniello, Antimo] Ist Nazl Previdenza Sociale, Rome, Italy	Stazione Zoologica Anton Dohrn di Napoli; University of Barcelona; Stazione Zoologica Anton Dohrn di Napoli	D'Aniello, A (corresponding author), Stn Zool A Dohrn, Dept Neurobiol, I-80121 Naples, Italy.	daniello.antimo@gmail.com	Garcia-Fernandez, Jordi/B-3839-2013	Garcia-Fernandez, Jordi/0000-0001-5677-5970; Somorjai, Ildiko/0000-0001-5243-6664	Spanish Ministerior de Ciencia e Innovacion [BMC2008-03776]; Institucio Catalana de Recerca i Estudis Avancats (ICREA) Academia Prize (Generalitat de Catalunya)	Spanish Ministerior de Ciencia e Innovacion; Institucio Catalana de Recerca i Estudis Avancats (ICREA) Academia Prize (Generalitat de Catalunya)(ICREAGeneralitat de Catalunya)	The authors thank Dr. Euan Brown (Animal Physiology and Evolution Department, Zoological Station Anton Dohrn, Naples, Italy) for useful discussions about the manuscript. The authors also thank Franco Iamunno for technical assistance in electron microscopy and Gabriele Ferrandino for technical assistance in HPLC analysis. The J.G.-F. laboratory is funded by grant BMC2008-03776 from the Spanish Ministerior de Ciencia e Innovacion and by the Institucio Catalana de Recerca i Estudis Avancats (ICREA) Academia Prize (Generalitat de Catalunya).	Cavallero A, 2009, J NEUROCHEM, V110, P924, DOI 10.1111/j.1471-4159.2009.06187.x; D'Aniello A, 1998, NEUROSCI LETT, V250, P131, DOI 10.1016/S0304-3940(98)00451-0; D'Aniello A, 2000, FASEB J, V14, P699, DOI 10.1096/fasebj.14.5.699; D'Aniello A, 1998, FEBS LETT, V436, P23, DOI 10.1016/S0014-5793(98)01087-4; D'Aniello A, 2003, FEBS LETT, V552, P193, DOI 10.1016/S0014-5793(03)00921-9; D'Aniello A, 2007, BRAIN RES REV, V53, P215, DOI 10.1016/j.brainresrev.2006.08.005; D'Aniello S, 2007, AMINO ACIDS, V32, P21, DOI 10.1007/s00726-006-0347-5; D'Aniello S, 2005, BIOCHEM J, V386, P331, DOI 10.1042/BJ20041070; DAniello A, 1996, LIFE SCI, V59, P97, DOI 10.1016/0024-3205(96)00266-4; DANIELLO A, 1977, J NEUROCHEM, V29, P1053, DOI 10.1111/j.1471-4159.1977.tb06508.x; DANIELLO A, 1993, COMP BIOCHEM PHYS B, V105, P731, DOI 10.1016/0305-0491(93)90113-J; DANIELLO A, 1993, J BIOL CHEM, V268, P26941; DAVIES LP, 1975, J NEUROCHEM, V25, P299; DOWDALL MJ, 1973, J NEUROCHEM, V20, P921, DOI 10.1111/j.1471-4159.1973.tb00063.x; DUNLOP DS, 1986, BIOCHEM BIOPH RES CO, V141, P27, DOI 10.1016/S0006-291X(86)80329-1; Errico F, 2008, J NEUROSCI, V28, P10404, DOI 10.1523/JNEUROSCI.1618-08.2008; Errico F, 2008, MOL CELL NEUROSCI, V37, P236, DOI 10.1016/j.mcn.2007.09.012; Errico F, 2011, NEUROBIOL AGING, V32, P2229, DOI 10.1016/j.neurobiolaging.2010.01.002; Fisher G, 1998, AMINO ACIDS, V15, P263, DOI 10.1007/BF01318865; FISHER GH, 1994, MOL CHEM NEUROPATHOL, V23, P115, DOI 10.1007/BF02815405; FISHER GH, 1991, BRAIN RES BULL, V26, P983, DOI 10.1016/0361-9230(91)90266-M; FOSTER AC, 1987, EUR J PHARMACOL, V133, P291, DOI 10.1016/0014-2999(87)90025-2; GUNDERSEN V, 1995, J NEUROSCI, V15, P4417; HASHIMOTO A, 1993, J NEUROCHEM, V61, P348, DOI 10.1111/j.1471-4159.1993.tb03575.x; HASHIMOTO A, 1993, FEBS LETT, V331, P4, DOI 10.1016/0014-5793(93)80286-4; HASHIMOTO A, 1995, EUR J NEUROSCI, V7, P1657, DOI 10.1111/j.1460-9568.1995.tb00687.x; Hashimoto K, 2003, ARCH GEN PSYCHIAT, V60, P572, DOI 10.1001/archpsyc.60.6.572; HOLOPAINEN I, 1990, NEUROSCIENCE, V36, P115, DOI 10.1016/0306-4522(90)90355-8; IMAI K, 1995, BIOMED CHROMATOGR, V9, P106, DOI 10.1002/bmc.1130090211; ISHIDA AT, 1981, P NATL ACAD SCI-BIOL, V78, P5890, DOI 10.1073/pnas.78.9.5890; KANAY Y, 1992, NATURE, V30, P467; Kim PM, 2010, P NATL ACAD SCI USA, V107, P3175, DOI 10.1073/pnas.0914706107; Lima PA, 2003, EUR J NEUROSCI, V17, P507, DOI 10.1046/j.1460-9568.2003.02477.x; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P245, DOI 10.1113/jphysiol.1986.sp016007; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; Messenger JB, 2001, BIOL REV, V76, P473, DOI 10.1017/S1464793101005772; Miao H, 2006, J NEUROCHEM, V97, P595, DOI 10.1111/j.1471-4159.2006.03791.x; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Nagata Y, 1999, FEBS LETT, V444, P160, DOI 10.1016/S0014-5793(99)00045-9; NEIDLE A, 1990, LIFE SCI, V46, P1517, DOI 10.1016/0024-3205(90)90424-P; Pampillo M, 2002, NEUROREPORT, V13, P2341, DOI 10.1097/00001756-200212030-00034; Raiteri L, 2007, J NEUROCHEM, V103, P952, DOI 10.1111/j.1471-4159.2007.04784.x; Raucci F, 2005, J ENDOCRINOL, V187, P347, DOI 10.1677/joe.1.06115; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Schell MJ, 1997, P NATL ACAD SCI USA, V94, P2013, DOI 10.1073/pnas.94.5.2013; Shibata K, 2003, COMP BIOCHEM PHYS B, V134, P307, DOI 10.1016/S1096-4959(02)00267-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snyder SH, 2000, NEUROCHEM RES, V25, P553, DOI 10.1023/A:1007586314648; Spinelli P, 2006, J CELL PHYSIOL, V206, P672, DOI 10.1002/jcp.20513; TEDESCHI G, 1994, BBA-PROTEIN STRUCT M, V1207, P217, DOI 10.1016/0167-4838(94)00071-9; Topo E, 2010, AMINO ACIDS, V38, P1561, DOI 10.1007/s00726-009-0369-x; Tsai GC, 1998, BIOL PSYCHIAT, V44, P1081, DOI 10.1016/S0006-3223(98)00279-0; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WHITTAKER VP, 1964, BIOCHEM J, V90, P293, DOI 10.1042/bj0900293; Wolosker H, 2000, NEUROSCIENCE, V100, P183, DOI 10.1016/S0306-4522(00)00321-3; Zaar K, 2002, J COMP NEUROL, V450, P272, DOI 10.1002/cne.10320	56	74	75	2	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1014	1027		10.1096/fj.10-168492	http://dx.doi.org/10.1096/fj.10-168492			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21163862				2022-12-28	WOS:000287806200021
J	Shuvaev, VV; Han, JY; Yu, KJ; Huang, SH; Hawkins, BJ; Madesh, M; Nakada, M; Muzykantov, VR				Shuvaev, Vladimir V.; Han, Jingyan; Yu, Kevin J.; Huang, Shaohui; Hawkins, Brian J.; Madesh, Muniswamy; Nakada, Marian; Muzykantov, Vladimir R.			PECAM-targeted delivery of SOD inhibits endothelial inflammatory response	FASEB JOURNAL			English	Article						drug delivery; oxidative stress; superoxide anion; endocytosis	ALLEVIATES OXIDATIVE STRESS; CELL-ADHESION MOLECULE-1; SUPEROXIDE-DISMUTASE; NADPH OXIDASE; GENE-THERAPY; INTRACELLULAR SUPEROXIDE; SIGNAL-TRANSDUCTION; ANGIOTENSIN-II; IN-VITRO; MNSOD-PL	Elevated generation of reactive oxygen species (ROS) by endothelial enzymes, including NADPH-oxidase, is implicated in vascular oxidative stress and endothelial proinflammatory activation involving exposure of vascular cell adhesion molecule-1 (VCAM-1). Catalase and superoxide dismutase (SOD) conjugated with antibodies to platelet/endothelial cell adhesion molecule 1 (PECAM-1) bind specifically to endothelium and inhibit effects of corresponding ROS, H2O2, and superoxide anion. In this study, anti-PECAM/SOD, but not anti-PECAM/catalase or nontargeted enzymes, including polyethylene glycol (PEG)-SOD, inhibited 2- to 3-fold VCAM expression caused by tumor necrosis factor (TNF), interleukin-1 beta, and lipopolysaccharide. Anti-PECAM/SOD, but not nontargeted counterparts, accumulated in vascular endothelium after intravenous injection, localized in endothelial endosomes, and inhibited by 70% lipopolysaccharide-caused VCAM-1 expression in mice. Anti-PECAM/SOD colocalized with EEA-1-positive endothelial vesicles and quenched ROS produced in response to TNF. Inhibitors of NADPH oxidase and anion channel ClC3 blocked TNF-induced VCAM expression, affirming that superoxide produced and transported by these proteins, respectively, mediates inflammatory signaling. Anti-PECAM/SOD abolished VCAM expression caused by poly(I:C)-induced activation of toll-like receptor 3 localized in intracellular vesicles. These results directly implicate endosomal influx of superoxide in endothelial inflammatory response and suggest that site-specific interception of this signal attained by targeted delivery of anti-PECAM/SOD into endothelial endosomes may have anti-inflammatory effects.-Shuvaev, V. V., Han, J., Yu, K. J., Huang, S., Hawkins, B. J., Madesh, M., Nakada, M., and Muzykantov, V. R. PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J. 25, 348-357 (2011). www.fasebj.org	[Shuvaev, Vladimir V.; Han, Jingyan; Yu, Kevin J.; Huang, Shaohui; Hawkins, Brian J.; Madesh, Muniswamy; Muzykantov, Vladimir R.] Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA; [Shuvaev, Vladimir V.; Han, Jingyan; Muzykantov, Vladimir R.] Univ Penn, Sch Med, Dept Pharmacol, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA; [Hawkins, Brian J.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Madesh, Muniswamy] Temple Univ, Dept Biochem, Philadelphia, PA 19122 USA; [Nakada, Marian] Centocor Inc, Malvern, PA 19355 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Muzykantov, VR (corresponding author), Univ Penn, Sch Med, Inst Environm Med, 1 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	muzykant@mail.med.upenn.edu	Shuvaev, Vladimir/O-1719-2014; Shaohui Huang, Shaohui Huang Huang Shaohui/AAW-4531-2021		U.S. National Institutes of Health [RO1 HL073940, HL087036, PO1 HL079063, K99HL094536, HL086699, 1S10RR022511]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR022511] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL094536, R00HL094536, P01HL079063, R01HL073940, R01HL087036, R01HL086699] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors are grateful to Drs. T. Dziubla and E. Simone for experiments with isotope-labeled PEG enzymes, Dr. M. Christofidou-Solomidou for help in visualization of SOD conjugates in mice, and E. Arguiri for technical assistance in animal studies. The authors thank Drs. A. Fisher, S. Albelda, and H. Ischiropoulos for their expert advice and stimulating discussions. This work was supported, in whole or in part, by U.S. National Institutes of Health grants RO1 HL073940 and HL087036 and Project 4 of PO1 HL079063 (to V.R.M.), K99HL094536 (to B.G.H.), and HL086699 and 1S10RR022511 (to M.M.).	BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; Botos I, 2009, BBA-GENE REGUL MECH, V1789, P667, DOI 10.1016/j.bbagrm.2009.06.005; Buetler TM, 2004, NEWS PHYSIOL SCI, V19, P120, DOI 10.1152/nips.01514.2003; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Cook-Mills JM, 2006, CELL MOL BIOL, V52, P8, DOI 10.1170/T721; Ding BS, 2006, MOL INTERV, V6, P98, DOI 10.1124/mi.6.2.7; Epperly MW, 2008, RADIAT RES, V170, P437, DOI 10.1667/RR1286.1; Epperly MW, 2003, GENE THER, V10, P163, DOI 10.1038/sj.gt.3301852; Epperly MW, 2002, BIOL BLOOD MARROW TR, V8, P175, DOI 10.1053/bbmt.2002.v8.pm12014807; Forman HJ, 2010, BIOCHEMISTRY-US, V49, P835, DOI 10.1021/bi9020378; Frey RS, 2009, ANTIOXID REDOX SIGN, V11, P791, DOI [10.1089/ars.2008.2220, 10.1089/ARS.2008.2220]; Gao BF, 2003, AM J PHYSIOL-LUNG C, V284, pL917, DOI 10.1152/ajplung.00374.2002; Gongora MC, 2006, HYPERTENSION, V48, P473, DOI 10.1161/01.HYP.0000235682.47673.ab; Gow AJ, 2004, AM J PHYSIOL-LUNG C, V287, pL262, DOI 10.1152/ajplung.00295.2003; Hagiwara S, 2010, SHOCK, V33, P282, DOI 10.1097/SHK.0b013e3181b0ef7b; Hawkins BJ, 2007, MOL BIOL CELL, V18, P2002, DOI 10.1091/mbc.E06-09-0830; Ichimura H, 2003, J CLIN INVEST, V111, P691, DOI 10.1172/JCI200317271; Janssen-Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011; Kim DW, 2008, BMB REP, V41, P170, DOI 10.5483/BMBRep.2008.41.2.170; Kozower BD, 2003, NAT BIOTECHNOL, V21, P392, DOI 10.1038/nbt806; Lee S, 2007, BIOCONJUGATE CHEM, V18, P4, DOI 10.1021/bc060259s; Li QA, 2006, MOL CELL BIOL, V26, P140, DOI 10.1128/MCB.26.1.140-154.2006; Li Q, 2009, ANTIOXID REDOX SIGN, V11, P1249, DOI 10.1089/ARS.2008.2407; Lin SJ, 2007, ATHEROSCLEROSIS, V190, P124, DOI 10.1016/j.atherosclerosis.2006.02.044; Matsuda JJ, 2010, J BIOL CHEM, V285, P2569, DOI 10.1074/jbc.M109.018002; Matsui T, 2007, J INT MED RES, V35, P886, DOI 10.1177/147323000703500617; McCord J M, 1985, Adv Myocardiol, V5, P183; Mumbengegwi DR, 2008, MOL CELL BIOL, V28, P3700, DOI 10.1128/MCB.02038-07; Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Muro Silvia, 2004, V283, P21; Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379; Oakley FD, 2009, ANTIOXID REDOX SIGN, V11, P1313, DOI 10.1089/ARS.2008.2363; Oakley FD, 2009, J BIOL CHEM, V284, P33255, DOI 10.1074/jbc.M109.042127; Pratico D, 2005, ATHEROSCLEROSIS, V181, P215, DOI 10.1016/j.atherosclerosis.2005.03.005; Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Rosenbaugh EG, 2010, BIOMATERIALS, V31, P5218, DOI 10.1016/j.biomaterials.2010.03.026; Rudolph TK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.290re7; Sana TR, 2005, CYTOKINE, V29, P256, DOI 10.1016/j.cyto.2004.11.003; Scherpereel A, 2002, J PHARMACOL EXP THER, V300, P777, DOI 10.1124/jpet.300.3.777; Shuvaev VV, 2007, J PHARMACOL EXP THER, V323, P450, DOI 10.1124/jpet.107.127126; Shuvaev VV, 2009, J PHARMACOL EXP THER, V331, P404, DOI 10.1124/jpet.109.156877; Supinski GS, 2006, AM J RESP CRIT CARE, V173, P1240, DOI 10.1164/rccm.200410-1346OC; Thomas SR, 2008, ANTIOXID REDOX SIGN, V10, P1713, DOI 10.1089/ars.2008.2027; Van Buul JD, 2005, ANTIOXID REDOX SIGN, V7, P308, DOI 10.1089/ars.2005.7.308; Wang ZJ, 2009, ACS NANO, V3, P4110, DOI 10.1021/nn9012274; Watanabe N, 2003, BIOCHEM BIOPH RES CO, V303, P287, DOI 10.1016/S0006-291X(03)00335-8; WHITE CW, 1989, J APPL PHYSIOL, V66, P584, DOI 10.1152/jappl.1989.66.2.584; Yamagishi S, 2008, CURR MED CHEM, V15, P172, DOI 10.2174/092986708783330557; Yao H, 2007, BIOCHEM SOC T, V35, P1151, DOI 10.1042/BST0351151; Yi XA, 2010, FREE RADICAL BIO MED, V49, P548, DOI 10.1016/j.freeradbiomed.2010.04.039; Yun J, 2009, ANTIOXID REDOX SIGN, V11, P1961, DOI 10.1089/ARS.2009.2476; Zhang XC, 2008, HUM GENE THER, V19, P820, DOI 10.1089/hum.2007.141; Zimmerman MC, 2004, CIRC RES, V95, P532, DOI 10.1161/01.RES.0000139957.22530.b9	55	77	78	3	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2011	25	1					348	357		10.1096/fj.10-169789	http://dx.doi.org/10.1096/fj.10-169789			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20876216	Green Published			2022-12-28	WOS:000285869500031
J	Sivamani, RK; Schwartz, MP; Anseth, KS; Isseroff, RR				Sivamani, Raja K.; Schwartz, Michael P.; Anseth, Kristi S.; Isseroff, R. Rivkah			Keratinocyte proximity and contact can play a significant role in determining mesenchymal stem cell fate in human tissue	FASEB JOURNAL			English	Article						wound; healing; ex vivo; skin; coculture	MARROW-DERIVED CELLS; BONE-MARROW; STROMAL CELLS; IN-VITRO; GROWTH-FACTOR; EPITHELIAL-CELLS; DIFFERENTIATION; FUSION; SKIN; PHENOTYPE	Bone marrow-derived human mesenchymal stem cells (hMSCs) possess multipotent differentiation capabilities and are a potent source of paracrine factors. We show how the epidermal keratinocyte can direct hMSC differentiation selectively. Keratinocytes and hMSCs were either cocultured in physical contact (contact cocultures), or separated without physical contact using a transwell insert (noncontact cocultures). We also delivered hMSCs into an ex vivo human excisional wound where subpopulations of the hMSCs were either in contact or were physically separated from the epidermal keratinocytes. In comparison to control hMSCs that were not cocultured, contact cocultured hMSCs adopted an epithelial morphology and expressed keratinocyte markers while noncontact coculutred hMSCs, surprisingly, adopted phenotypes that resembled myofibroblast and early neural lineage, both of which are of dermal origin. Cell fusion was not a requirement in in vitro contact cocultures, as determined by fluorescence-activated cell sorting (FACS) and fluorescence in situ hybridization analysis (FISH). To the best of our knowledge, this work provides the first example of hMSC differentiation into different lineages depending on their proximity to a single cell type.-Sivamani, R. K., Schwartz, M. P., Anseth, K. S., Isseroff, R. R., Keratinocyte proximity and contact can play a significant role in determining mesenchymal stem cell fate in human tissue, FASEB J. 25, 122-131 (2011). www.fasebj.org	[Sivamani, Raja K.; Isseroff, R. Rivkah] Univ Calif Davis, Sch Med, Dept Dermatol, Davis, CA 95616 USA; [Sivamani, Raja K.; Schwartz, Michael P.; Anseth, Kristi S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA; [Schwartz, Michael P.; Anseth, Kristi S.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of California System; University of California Davis; University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Isseroff, RR (corresponding author), Univ Calif Davis, Sch Med, Dept Dermatol, TB 192,1 Shields Ave, Davis, CA 95616 USA.	rrisseroff@ucdavis.edu	Schwartz, Mike/O-7963-2016; Schwartz, Michael/GNW-3991-2022; Schwartz, Michael P/B-3417-2008; Isseroff, Roslyn Rivkah/AAD-8478-2021	Schwartz, Mike/0000-0003-3785-6606; Schwartz, Michael/0000-0003-3785-6606; Schwartz, Michael P/0000-0003-3785-6606; Isseroff, Roslyn Rivkah/0000-0001-7813-0858	Howard Hughes Medical Institute; National Science Foundation [EEC 444771]; National Institutes of Health (NIH) [AR 44518]; Shiners Hospitals for Children [4450]; NIH National Center for Research Resources [P40RR017447]; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR017447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044518] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Science Foundation(National Science Foundation (NSF)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Shiners Hospitals for Children; NIH National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors are indebted to Theresa Naherini for technical expertise and assistance with FACS and to Dr. Jeffrey Spees for his helpful discussion in assistance with the FISH analysis. The authors thank Dr. Jan Nolta for her critical review of this manuscript. Support for this work was kindly provided in part by a Howard Hughes Medical Institute Research Training Fellowship (R. K. S.), a grant from the National Science Foundation (EEC 444771; K. S. A.), a grant from the National Institutes of Health (NIH; AR 44518; R. R. I.), and a grant from the Shiners Hospitals for Children (4450; R. R. I.). Some of the materials employed in this work were provided by the Tulane Center for Gene Therapy through a grant from the NIH National Center for Research Resources (P40RR017447). The funding sources had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflicts of interest.	Aberdam D, 2007, CELL CYCLE, V6, P291, DOI 10.4161/cc.6.3.3800; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; ANSEL JC, 1993, J CLIN INVEST, V92, P671, DOI 10.1172/JCI116636; Badiavas EV, 2003, J CELL PHYSIOL, V196, P245, DOI 10.1002/jcp.10260; Badiavas EV, 2003, ARCH DERMATOL, V139, P510, DOI 10.1001/archderm.139.4.510; Ball SG, 2004, INT J BIOCHEM CELL B, V36, P714, DOI 10.1016/j.biocel.2003.10.015; Borue X, 2004, AM J PATHOL, V165, P1767, DOI 10.1016/S0002-9440(10)63431-1; Bossolasco P, 2005, EXP NEUROL, V193, P312, DOI 10.1016/j.expneurol.2004.12.013; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886; COOK PW, 1990, MOL ENDOCRINOL, V4, P1377, DOI 10.1210/mend-4-9-1377; Dai YC, 2007, BURNS, V33, P418, DOI 10.1016/j.burns.2006.08.028; De Ugarte DA, 2003, CELLS TISSUES ORGANS, V174, P101, DOI 10.1159/000071150; Emanuelsson P, 1997, BURNS, V23, P32, DOI 10.1016/S0305-4179(96)00073-3; Falanga V, 2007, TISSUE ENG, V13, P1299, DOI 10.1089/ten.2006.0278; Gregory Carl A, 2005, Sci STKE, V2005, ppe37, DOI 10.1126/stke.2942005pe37; Han CM, 2007, DIFFERENTIATION, V75, P292, DOI 10.1111/j.1432-0436.2006.00140.x; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; Hashimoto K, 2000, J DERMATOL SCI, V24, pS46, DOI 10.1016/S0923-1811(00)00141-9; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Hoogduijn MJ, 2006, STEM CELLS DEV, V15, P49, DOI 10.1089/scd.2006.15.49; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kim WS, 2009, EXPERT OPIN BIOL TH, V9, P879, DOI 10.1517/14712590903039684; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li XH, 2007, J MOL CELL CARDIOL, V42, P295, DOI 10.1016/j.yjmcc.2006.07.002; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; Lorenz K, 2008, EXP DERMATOL, V17, P925, DOI 10.1111/j.1600-0625.2008.00724.x; Paunescu V, 2007, J CELL MOL MED, V11, P502, DOI 10.1111/j.1582-4934.2007.00041.x; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Potapova IA, 2007, STEM CELLS, V25, P1761, DOI 10.1634/stemcells.2007-0022; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Walter M. N., 2010, EXP CELL RES; Wang GS, 2005, P NATL ACAD SCI USA, V102, P186, DOI 10.1073/pnas.0406266102; Wang TZ, 2006, INT J CARDIOL, V109, P74, DOI 10.1016/j.ijcard.2005.05.072; Wang Y, 2007, J TISSUE ENG REGEN M, V1, P39, DOI 10.1002/term.6; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226; Xu MF, 2004, CIRCULATION, V110, P2658, DOI 10.1161/01.CIR.0000145609.20435.36; Yamaguchi Y, 2004, BRIT J DERMATOL, V151, P1019, DOI 10.1111/j.1365-2133.2004.06170.x; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	48	24	24	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					122	131		10.1096/fj.09-148775	http://dx.doi.org/10.1096/fj.09-148775			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20847231	Green Published			2022-12-28	WOS:000285869500012
J	Takacs, B; O'Neall-Hennessey, E; Hetenyi, C; Kardos, J; Szent-Gyorgyi, AG; Kovacs, M				Takacs, Balazs; O'Neall-Hennessey, Elizabeth; Hetenyi, Csaba; Kardos, Jozsef; Szent-Gyoergyi, Andrew G.; Kovacs, Mihaly			Myosin cleft closure determines the energetics of the actomyosin interaction	FASEB JOURNAL			English	Article						structure; kinetics; mechanism	RABBIT SKELETAL-MUSCLE; ACTIN-BINDING CLEFT; F-ACTIN; KINETIC CHARACTERIZATION; MOTOR; DICTYOSTELIUM; SUBFRAGMENT-1; MECHANISM; COMPLEX; FRAGMENTS	Formation of the strong binding interaction between actin and myosin is essential for force generation in muscle and in cytoskeletal motor systems. To clarify the role of the closure of myosin's actin-binding cleft in the actomyosin interaction, we performed rapid kinetic, spectroscopic, and calorimetric experiments and atomic-level energetic calculations on a variety of myosin isoforms for which atomic structures are available. Surprisingly, we found that the endothermic actin-binding profile of vertebrate skeletal muscle myosin subfragment-1 is unique among studied myosins. We show that the diverse propensity of myosins for cleft closure determines different energetic profiles as well as structural and kinetic pathways of actin binding. Depending on the type of myosin, strong actin binding may occur via induced-fit or conformational preselection mechanisms. However, cleft closure does not directly determine the kinetics and affinity of actin binding. We also show that cleft closure is enthalpically unfavorable, reflecting the development of an internal strain within myosin in order to adopt precise steric complementarity to the actin filament. We propose that cleft closure leads to an increase in the torsional strain of myosin's central beta-sheet that has been proposed to serve as an allosteric energy-transducing spring during force generation.-Takacs, B., O'Neall-Hennessey, E., Hetenyi, C., Kardos, J., Szent-Gyorgyi, A. G., Kovacs, M. Myosin cleft closure determines the energetics of the actomyosin interaction. FASEB J. 25, 111-121 (2011). www.fasebj.org	[Takacs, Balazs; Kardos, Jozsef; Kovacs, Mihaly] Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary; [Hetenyi, Csaba] Eotvos Lorand Univ, Dept Genet, H-1117 Budapest, Hungary; [O'Neall-Hennessey, Elizabeth; Szent-Gyoergyi, Andrew G.] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	Eotvos Lorand University; Eotvos Lorand University; Brandeis University	Kovacs, M (corresponding author), Eotvos Lorand Univ, Dept Biochem, Pazmany Peter Setany 1-C, H-1117 Budapest, Hungary.	kovacsm@elte.hu	Hetenyi, Csaba/G-5249-2010; Kovacs, Mihaly/A-6841-2011; Kardos, József/J-1035-2017	Hetenyi, Csaba/0000-0002-8013-971X; Kardos, József/0000-0002-2135-2932; Kovacs, Mihaly/0000-0002-1200-4741	Hungarian Scientific Research Fund (OTKA) [K68464, K71915, NNF78783]; Fogarty International Center; U.S. National Heart, Lung, and Blood Institute [1 R01-TW-007241]; European Molecular Biology Organization-Howard Hughes Medical Institute; FOGARTY INTERNATIONAL CENTER [R01TW007241] Funding Source: NIH RePORTER	Hungarian Scientific Research Fund (OTKA)(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); European Molecular Biology Organization-Howard Hughes Medical Institute(Howard Hughes Medical InstituteEuropean Molecular Biology Organization (EMBO)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This work was supported by Hungarian Scientific Research Fund (OTKA) grant K68464 (to J.K.); the Fogarty International Center, U.S. National Heart, Lung, and Blood Institute grant 1 R01-TW-007241, an European Molecular Biology Organization-Howard Hughes Medical Institute startup grant, and OTKA grants K71915 and NNF78783 (to M. K.). C. H. and M. K. are Bolyai Fellows of the Hungarian Academy of Sciences. The authors thank Drs. Judit Fidy and Ferenc Tolgyesi (Semmelweis University, Budapest, Hungary) for providing the ITC instrument and Andras Malnasi-Csizmadia for discussions. The authors declare no competing financial interests.	Atkins PW., 1990, PHYS CHEM; Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Camacho CJ, 2005, BIOINFORMATICS, V21, P2534, DOI 10.1093/bioinformatics/bti322; Cecchini M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000129; Champ PC, 2007, NUCLEIC ACIDS RES, V35, pW556, DOI 10.1093/nar/gkm326; COATES JH, 1985, BIOCHEM J, V232, P351, DOI 10.1042/bj2320351; Conibear PB, 2003, NAT STRUCT BIOL, V10, P831, DOI 10.1038/nsb986; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; EIGEN M, 1964, PROG REACT KINET MEC, V2, P285; Fersht A., 1977, ENZYME STRUCURE MECH, P147; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; GEEVES MA, 1988, BIOCHEM J, V256, P41, DOI 10.1042/bj2560041; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; Hetenyi C, 2007, BIOINFORMATICS, V23, P2678, DOI 10.1093/bioinformatics/btm431; HIGHSMITH S, 1977, ARCH BIOCHEM BIOPHYS, V180, P404, DOI 10.1016/0003-9861(77)90054-6; Holmes KC, 2004, PHILOS T ROY SOC B, V359, P1819, DOI 10.1098/rstb.2004.1566; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Kalabokis VN, 1997, BIOCHEMISTRY-US, V36, P15834, DOI 10.1021/bi971932r; Karatzaferi C, 2004, BIOPHYS J, V87, P2532, DOI 10.1529/biophygj.104.039909; Kintses B, 2007, EMBO J, V26, P265, DOI 10.1038/sj.emboj.7601482; Klein JC, 2008, P NATL ACAD SCI USA, V105, P12867, DOI 10.1073/pnas.0802286105; KONRAD M, 1982, EUR J BIOCHEM, V128, P547; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; Lin SH, 2005, BIOCHEMISTRY-US, V44, P1482, DOI 10.1021/bi040018c; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MANSTEIN DJ, 1995, J MUSCLE RES CELL M, V16, P325, DOI 10.1007/BF00121141; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MARGOSSIAN SS, 1978, BIOCHEMISTRY-US, V17, P5431, DOI 10.1021/bi00618a017; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Menetrey J, 2005, NATURE, V435, P779, DOI 10.1038/nature03592; OKAMOTO Y, 1985, J BIOCHEM-TOKYO, V98, P1143, DOI 10.1093/oxfordjournals.jbchem.a135365; Prochniewicz E, 2010, J MOL BIOL, V396, P501, DOI 10.1016/j.jmb.2009.11.063; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Reubold TF, 2003, NAT STRUCT BIOL, V10, P826, DOI 10.1038/nsb987; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SMITH SJ, 1984, J BIOL CHEM, V259, P303; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1979, BIOCHEMISTRY-US, V18, P5273, DOI 10.1021/bi00591a002; Sweeney HL, 2004, PHILOS T R SOC B, V359, P1829, DOI 10.1098/rstb.2004.1576; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Yang YT, 2007, STRUCTURE, V15, P553, DOI 10.1016/j.str.2007.03.010; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l	54	16	16	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					111	121		10.1096/fj.10-164871	http://dx.doi.org/10.1096/fj.10-164871			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20837775	Green Published			2022-12-28	WOS:000285869500011
J	Zhou, P; Gross, S; Liu, JH; Yu, BY; Feng, LL; Nolta, J; Sharma, V; Piwnica-Worms, D; Qiu, SX				Zhou, Ping; Gross, Shimon; Liu, Ji-Hua; Yu, Bo-Yang; Feng, Ling-Ling; Nolta, Jan; Sharma, Vijay; Piwnica-Worms, David; Qiu, Samuel X.			Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappa B and MAPK signaling pathways	FASEB JOURNAL			English	Article						hepatocellular toxin; apoptosis; TNF-alpha, herb products; bioluminescence imaging	TUMOR-NECROSIS-FACTOR; GENETICALLY ENCODED REPORTERS; SEVERE LIVER DEGENERATION; ALPHA-INDUCED APOPTOSIS; TNF-INDUCED APOPTOSIS; PIPER-METHYSTICUM; GLUTATHIONE DEPLETION; JNK ACTIVATION; EMBRYONIC LETHALITY; PROTEASOME ACTIVITY	Kava (Piper methysticum Foster, Piperaceae) organic solvent-extract has been used to treat mild to moderate anxiety, insomnia, and muscle fatigue in Western countries, leading to its emergence as one of the 10 best-selling herbal preparations. However, several reports of severe hepatotoxicity in kava consumers led the U. S. Food and Drug Administration and authorities in Europe to restrict sales of kava-containing products. Herein we demonstrate that flavokawain B (FKB), a chalcone from kava root, is a potent hepatocellular toxin, inducing cell death in HepG2 (LD50 = 15.3 +/- 0.2 mu M) and L-02 (LD50 = 32 mu M) cells. Hepatocellular toxicity of FKB is mediated by induction of oxidative stress, depletion of reduced glutathione (GSH), inhibition of IKK activity leading to NF-kappa B transcriptional blockade, and constitutive TNF-alpha-independent activation of mitogen-activated protein kinase (MAPK) signaling pathways, namely, ERK, p38, and JNK. We further demonstrate by noninvasive bioluminescence imaging that oral consumption of FKB leads to inhibition of hepatic NF-kappa B transcriptional activity in vivo and severe liver damage. Surprisingly, replenishment with exogenous GSH normalizes both TNF-alpha-dependent NF-kappa B as well as MAPK signaling and rescues hepatocytes from FKB-induced death. Our data identify FKB as a potent GSH-sensitive hepatotoxin, levels of which should be specifically monitored and controlled in kava-containing herb products.-Zhou, P., Gross, S., Liu, J.-H., Yu, B.-Y., Feng, L.-L., Nolta, J., Sharma, V., Piwnica-Worms, D., Qiu, S. X. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappa B and MAPK signaling pathways. FASEB J. 24, 4722-4732 (2010). www.fasebj.org	[Feng, Ling-Ling; Qiu, Samuel X.] Chinese Acad Sci, S China Bot Garden, Key Lab Plant Resources Conservat & Sustainable U, Guangzhou 510650, Guangdong, Peoples R China; [Zhou, Ping; Nolta, Jan] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA; [Gross, Shimon; Piwnica-Worms, David] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO USA; [Gross, Shimon; Sharma, Vijay; Piwnica-Worms, David] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO USA; [Zhou, Ping; Nolta, Jan] Univ Calif Davis, Stem Cell Program, Dept Internal Med, Sacramento, CA 95817 USA; [Liu, Ji-Hua; Yu, Bo-Yang] China Pharmaceut Univ, Sch Tradit Chinese Pharm, Nanjing 210009, Peoples R China	Chinese Academy of Sciences; South China Botanical Garden, CAS; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California Davis; China Pharmaceutical University	Qiu, SX (corresponding author), Chinese Acad Sci, S China Bot Garden, Key Lab Plant Resources Conservat & Sustainable U, Guangzhou 510650, Guangdong, Peoples R China.	sxqiu@scbg.ac.cn		Nolta, Jan/0000-0003-4576-8542	U.S. National Institutes of Health [P50 CA94056]; National Natural Science Foundation of China [30572320, 30973635]; Chinese Academy of Sciences [KSCX2-YW-R-217]; NATIONAL CANCER INSTITUTE [P50CA094056] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061848] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This project was jointly funded by U.S. National Institutes of Health grant P50 CA94056, National Natural Science Foundation of China grants (30572320, 30973635), a Chinese Academy of Sciences 100 Talents Program Endowment award to S.X.Q., and a grant from the Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-R-217).	BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bilia AR, 2002, LIFE SCI, V70, P2581, DOI 10.1016/S0024-3205(02)01555-2; *BUND ARZN MED, 2002, A VONARZNEIMITTELRIS; Cairney S, 2002, AUST NZ J PSYCHIAT, V36, P657, DOI 10.1046/j.1440-1614.2002.01027.x; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Collett GP, 2004, CARCINOGENESIS, V25, P2183, DOI 10.1093/carcin/bgh233; Cuadrado A, 2004, ONCOGENE, V23, P4673, DOI 10.1038/sj.onc.1207636; Currie BJ, 2003, MED J AUSTRALIA, V178, P421, DOI 10.5694/j.1326-5377.2003.tb05279.x; Dharmaratne HRW, 2002, PHYTOCHEMISTRY, V59, P429; Ding WX, 2004, J CELL MOL MED, V8, P445, DOI 10.1111/j.1582-4934.2004.tb00469.x; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Dragull K, 2003, PHYTOCHEMISTRY, V63, P193, DOI 10.1016/S0031-9422(03)00111-0; FDA,, 2003, FDA CONS ADV; Femandez-Checa JC, 2005, TOXICOL APPL PHARM, V204, P263, DOI 10.1016/j.taap.2004.10.001; Folmer F, 2006, BIOCHEM PHARMACOL, V71, P1206, DOI 10.1016/j.bcp.2005.12.032; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Gow PJ, 2003, MED J AUSTRALIA, V178, P442, DOI 10.5694/j.1326-5377.2003.tb05286.x; Gross S, 2005, METHOD ENZYMOL, V399, P512, DOI 10.1016/S0076-6879(05)99035-6; Gross S, 2005, NAT METHODS, V2, P607, DOI 10.1038/NMETH779; Gross S, 2005, CANCER CELL, V7, P5, DOI 10.1016/j.ccr.2004.12.011; Gross S, 2006, CURR OPIN CHEM BIOL, V10, P334, DOI 10.1016/j.cbpa.2006.06.028; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu XT, 2001, CANCER RES, V61, P6290; Humberston CL, 2003, J TOXICOL-CLIN TOXIC, V41, P109, DOI 10.1081/CLT-120019123; Johnson BM, 2003, CHEM RES TOXICOL, V16, P733, DOI 10.1021/tx020113r; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; Lash LH, 2006, CHEM-BIOL INTERACT, V163, P54, DOI 10.1016/j.cbi.2006.03.001; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lim STS, 2007, TOXICOL SCI, V97, P214, DOI 10.1093/toxsci/kfm035; Luedde T, 2005, J CLIN INVEST, V115, P849, DOI 10.1172/JCI200523493; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luo JL, 2005, J CLIN IMMUNOL, V25, P541, DOI 10.1007/s10875-005-8217-6; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Mathews JM, 2002, DRUG METAB DISPOS, V30, P1153, DOI 10.1124/dmd.30.11.1153; Matsumaru K, 2003, HEPATOLOGY, V37, P1425, DOI 10.1053/jhep.2003.50230; McGhee HW, 2003, JAMA-J AM MED ASSOC, V289, P36; *MMWR, 2002, MMWR-MORBID MORTAL W, V51, P1065; Nagai H, 2002, HEPATOLOGY, V36, P55, DOI 10.1053/jhep.2002.33995; Nerurkar PV, 2004, TOXICOL SCI, V79, P106, DOI 10.1093/toxsci/kfh067; Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6; Rex A, 2002, PROG NEURO-PSYCHOPH, V26, P855, DOI 10.1016/S0278-5846(01)00330-X; Rudolph D, 2000, GENE DEV, V14, P854; Russmann S, 2001, ANN INTERN MED, V135, P68, DOI 10.7326/0003-4819-135-1-200107030-00036; Singh YN, 2003, PLANTA MED, V69, P496, DOI 10.1055/s-2003-40658; Singh YN, 2002, CNS DRUGS, V16, P731, DOI 10.2165/00023210-200216110-00002; SINGH YN, 1992, J ETHNOPHARMACOL, V37, P13, DOI 10.1016/0378-8741(92)90003-A; Singh YN, 1997, HERBALGRAM, V39, P33; Stickel F, 2003, J HEPATOL, V39, P62, DOI 10.1016/S0168-8278(03)00175-2; STOLLER R, 2000, SCHWEIZERISCHE ARZTE, V81, P1335; Titcomb M, 1948, J POLYNESIAN SOC, V57, P105; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Whitton PA, 2003, PHYTOCHEMISTRY, V64, P673, DOI 10.1016/S0031-9422(03)00381-9; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wu DF, 2003, J BIOL CHEM, V278, P1115, DOI 10.1074/jbc.M207856200; Wullaert A, 2006, BIOCHEM PHARMACOL, V72, P1090, DOI 10.1016/j.bcp.2006.07.003; Zhou P, 2006, J IMMUNOL, V177, P8777, DOI 10.4049/jimmunol.177.12.8777	60	81	86	1	42	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4722	4732		10.1096/fj.10-163311	http://dx.doi.org/10.1096/fj.10-163311			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20696856	Green Published			2022-12-28	WOS:000284824400013
J	Ponsaerts, R; De Vuyst, E; Retamal, M; D'hondt, C; Vermeire, D; Wang, N; De Smedt, H; Zimmermann, P; Himpens, B; Vereecke, J; Leybaert, L; Bultynck, G				Ponsaerts, Raf; De Vuyst, Elke; Retamal, Mauricio; D'hondt, Catheleyne; Vermeire, Dieter; Wang, Nan; De Smedt, Humbert; Zimmermann, Pascale; Himpens, Bernard; Vereecke, Johan; Leybaert, Luc; Bultynck, Geert			Intramolecular loop/tail interactions are essential for connexin 43-hemichannel activity	FASEB JOURNAL			English	Article						intercellular communication; actomyosin contractility; intracellular calcium; purinergic signaling	GAP-JUNCTION PROTEIN; CORNEAL ENDOTHELIAL-CELLS; INTERCELLULAR CALCIUM WAVE; C6 GLIOMA-CELLS; THROMBIN-INDUCED INHIBITION; OCULODENTODIGITAL DYSPLASIA; ZONULA OCCLUDENS-1; CARBOXYL-TERMINUS; CARDIAC MYOCYTES; ATP RELEASE	Connexin-assembled gap junctions (GJs) and hemichannels coordinate intercellular signaling processes. Although the regulation of connexins in GJs has been well characterized, the molecular determinants controlling connexin-hemichannel activity are unresolved. Here we investigated the regulation of Cx43-hemichannel activity by actomyosin contractility and intracellular [Ca2+] ([Ca2+](i)) using plasma membrane-permeable TAT peptides (100 mu M) designed to interfere with interactions between the cytoplasmic loop (CL) and carboxy-terminal (CT) in primary bovine corneal endothelial cells and HeLa, C6 glioma, and Xenopus oocytes ectopically expressing Cx43. Peptides corresponding to the last 10 CT aa (TAT-Cx43CT) prevented the inhibition of Cx43-hemichannel activity by contractility/high [Ca2+](i), whereas a reverse peptide (TAT-Cx43CTrev) did not. These effects were independent of zonula occludens-1, a cytoskeletal-associated Cx43-binding protein. In contrast, peptides corresponding to CL (TAT-L2) inhibited Cx43-hemichannel responses, whereas a mutant peptide (TAT-L2(H126K/I130N)) did not inhibit. In these assays, TAT-Cx43CT acted as a scaffold for TAT-L2 and vice versa, a finding supported by surface plasmon resonance measurements. Loop/tail interactions appeared essential for Cx43-hemichannel activity, because TAT-Cx43CT restored the activity of nonfunctional hemichannels, consisting of either Cx43 lacking the C-terminal tail (Cx43(M239)) or intact Cx43 ectopically expressed in Xenopus oocytes. We conclude that intramolecular loop/tail interactions control Cx43-hemichannel activity, laying the basis for developing hemichannel-specific blockers.-Ponsaerts, R., De Vuyst, E., Retamal, M., D'hondt, C., Vermeire, D., Wang, N., De Smedt, H., Zimmermann, P., Himpens, B., Vereecke, J., Leybaert, L., Bultynck, G. Intramolecular loop/tail interactions are essential for connexin 43-hemichannel activity. FASEB J. 24, 4378-4395 (2010). www.fasebj.org	[Ponsaerts, Raf; D'hondt, Catheleyne; De Smedt, Humbert; Himpens, Bernard; Vereecke, Johan; Bultynck, Geert] Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Mol Cell Biol, BE-3000 Louvain, Belgium; [Vermeire, Dieter; Zimmermann, Pascale] Katholieke Univ Leuven, Dept Human Genet, Lab Signal Integrat Cell Fate Decis, BE-3000 Louvain, Belgium; [De Vuyst, Elke; Wang, Nan; Leybaert, Luc] Univ Ghent, Dept Basic Med Sci, Physiol Grp, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; [Retamal, Mauricio] Clin Alemana Univ Desarrollo, Lab Fisiol, Santiago, Chile	KU Leuven; KU Leuven; Ghent University; Universidad del Desarrollo	Bultynck, G (corresponding author), Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Mol Cell Biol, Campus Gasthuisberg O-N-1 Bus 802,Herestr 49, BE-3000 Louvain, Belgium.	geert.bultynck@med.kuleuven.be	Leybaert, Luc/F-4079-2015; Zimmermann, Pascale/P-4190-2017	Leybaert, Luc/0000-0001-6452-6982; Retamal, Mauricio A./0000-0003-2562-6686; Bultynck, Geert/0000-0002-5968-4828	Concerted Actions of the K.U. Leuven [GOA/09/012]; F.W.O. (Fund for Scientific Research Flanders) [G.0545.08, G.0354.07, G.0140.08, G.0134.09]; Interuniversity Attraction Poles Program [P6/28, P6/31]; Fondecyt de Iniciacion [11080061]	Concerted Actions of the K.U. Leuven; F.W.O. (Fund for Scientific Research Flanders)(FWO); Interuniversity Attraction Poles Program(Belgian Federal Science Policy Office); Fondecyt de Iniciacion(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT)	The authors thank Dr. Bernd Nilius and Dr. Ludwig Missiaen for critical reading of the paper. This work was supported by Concerted Actions of the K.U. Leuven (grant GOA/09/012) to H.D.S.; by F.W.O. (Fund for Scientific Research Flanders; G.0545.08 to B.H. and J.V.; G.0354.07, G.0140.08, and G.0134.09 to L.L.); by the Interuniversity Attraction Poles Program (Belgian Science Policy; P6/28 to H.D.S. and B.H.; P6/31 to L.L.); and by the Fondecyt de Iniciacion (11080061 to M.R.). The authors do not have any commercial affiliations or conflict of interests.	Bao XY, 2004, J BIOL CHEM, V279, P9689, DOI 10.1074/jbc.M311438200; Bao XY, 2004, AM J PHYSIOL-CELL PH, V286, pC647, DOI 10.1152/ajpcell.00295.2003; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Bouvier D, 2008, CELL COMMUN ADHES, V15, P107, DOI 10.1080/15419060802014347; Bukauskas FF, 2000, P NATL ACAD SCI USA, V97, P2556, DOI 10.1073/pnas.050588497; Butkevich E, 2004, CURR BIOL, V14, P650, DOI 10.1016/j.cub.2004.03.063; Clarke TC, 2009, EUR J PHARMACOL, V605, P9, DOI 10.1016/j.ejphar.2008.12.005; Contreras JE, 2004, BRAIN RES REV, V47, P290, DOI 10.1016/j.brainresrev.2004.08.002; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; D'hondt C, 2007, INVEST OPHTH VIS SCI, V48, P1518, DOI 10.1167/iovs.06-1062; D'hondt C, 2007, INVEST OPHTH VIS SCI, V48, P120, DOI 10.1167/iovs.06-0770; De Vuyst E, 2006, EMBO J, V25, P34, DOI 10.1038/sj.emboj.7600908; De Vuyst E, 2007, MOL BIOL CELL, V18, P34, DOI 10.1091/mbc.E06-03-0182; De Vuyst E, 2009, CELL CALCIUM, V46, P176, DOI 10.1016/j.ceca.2009.07.002; Decrock E, 2009, CELL DEATH DIFFER, V16, P524, DOI 10.1038/cdd.2008.196; Delmar M, 2004, CARDIOVASC RES, V62, P268, DOI 10.1016/j.cardiores.2003.12.030; Derangeon M, 2008, J BIOL CHEM, V283, P30754, DOI 10.1074/jbc.M801556200; Dobrowolski R, 2008, HUM MOL GENET, V17, P539, DOI 10.1093/hmg/ddm329; Dobrowolski R, 2007, J MEMBRANE BIOL, V219, P9, DOI 10.1007/s00232-007-9055-7; Duffy HS, 2004, CIRC RES, V94, P215, DOI 10.1161/01.RES.0000113924.06926.11; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; Evans WH, 2006, BIOCHEM J, V397, P1, DOI 10.1042/BJ20060175; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Flores CE, 2008, P NATL ACAD SCI USA, V105, P12545, DOI 10.1073/pnas.0804793105; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Gellhaus A, 2004, J BIOL CHEM, V279, P36931, DOI 10.1074/jbc.M404073200; Giepmans BNG, 2006, ADV CARDIOL, V42, P41, DOI 10.1159/000092561; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gomes P, 2005, INVEST OPHTH VIS SCI, V46, P1208, DOI 10.1167/iovs.04-1181; Gomes P, 2005, INVEST OPHTH VIS SCI, V46, P104, DOI 10.1167/iovs.04-0846; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Herve JC, 2007, PROG BIOPHYS MOL BIO, V94, P29, DOI 10.1016/j.pbiomolbio.2007.03.010; Hirst-Jensen BJ, 2007, J BIOL CHEM, V282, P5801, DOI 10.1074/jbc.M605233200; Homma N, 1998, CIRC RES, V83, P27, DOI 10.1161/01.RES.83.1.27; Hunter AW, 2005, MOL BIOL CELL, V16, P5686, DOI 10.1091/mbc.E05-08-0737; Hunter AW, 2003, CELL COMMUN ADHES, V10, P211, DOI 10.1080/714040429; Iyer S, 2007, COMPUT METH PROG BIO, V85, P203, DOI 10.1016/j.cmpb.2006.11.004; Kalcheva N, 2007, P NATL ACAD SCI USA, V104, P20512, DOI 10.1073/pnas.0705472105; Kang J, 2008, J NEUROSCI, V28, P4702, DOI 10.1523/JNEUROSCI.5048-07.2008; KONIG N, 1995, J CELL SCI, V108, P3091; Lai A, 2006, J CELL SCI, V119, P532, DOI 10.1242/jcs.02770; Laird DW, 2010, TRENDS CELL BIOL, V20, P92, DOI 10.1016/j.tcb.2009.11.001; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Lan Z, 2005, BIOCHEMISTRY-US, V44, P2385, DOI 10.1021/bi048306w; Laux-Fenton WT, 2003, CORNEA, V22, P457, DOI 10.1097/00003226-200307000-00012; Levesque SA, 2007, BRIT J PHARMACOL, V152, P141, DOI 10.1038/sj.bjp.0707361; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Limouze J, 2004, J MUSCLE RES CELL M, V25, P337, DOI 10.1007/s10974-004-6060-7; Liu F, 2006, J BIOL CHEM, V281, P23207, DOI 10.1074/jbc.M605048200; Maass K, 2007, CIRC RES, V101, P1283, DOI 10.1161/CIRCRESAHA.107.162818; Moreno AP, 2002, CIRC RES, V90, P450, DOI 10.1161/hh0402.105667; Morley GE, 1996, BIOPHYS J, V70, pMP318; Omori Y, 1999, CARCINOGENESIS, V20, P1913, DOI 10.1093/carcin/20.10.1913; Orellana JA, 2009, ANTIOXID REDOX SIGN, V11, P369, DOI 10.1089/ars.2008.2130; Owens LM, 1996, CIRCULATION, V94, P10, DOI 10.1161/01.CIR.94.1.10; Ponsaerts R, 2008, INVEST OPHTH VIS SCI, V49, P4816, DOI 10.1167/iovs.07-1533; Ponsaerts R, 2010, EXTRACELLULAR ATP AND ADENOSINE AS REGULATORS OF ENDOTHELIAL CELL FUNCTION, P161, DOI 10.1007/978-90-481-3435-9_10; Retamal MA, 2006, P NATL ACAD SCI USA, V103, P4475, DOI 10.1073/pnas.0511118103; Retamal MA, 2007, J NEUROSCI, V27, P13781, DOI 10.1523/JNEUROSCI.2042-07.2007; Retamal MA, 2007, J MEMBRANE BIOL, V218, P49, DOI 10.1007/s00232-007-9043-y; Retamal MA, 2007, P NATL ACAD SCI USA, V104, P8322, DOI 10.1073/pnas.0702456104; Retamal MA, 2009, AM J PHYSIOL-CELL PH, V296, pC1356, DOI 10.1152/ajpcell.00054.2009; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Scemes E, 2007, NEURON GLIA BIOL, V3, P199, DOI 10.1017/S1740925X08000069; Scemes E, 2009, PFLUG ARCH EUR J PHY, V457, P1207, DOI 10.1007/s00424-008-0591-5; Seki A, 2004, CIRC RES, V95, P22, DOI 10.1161/01.RES.0000140737.62245.c5; Shibayama J, 2006, BIOPHYS J, V91, P4054, DOI 10.1529/biophysj.106.085787; Sin WC, 2008, J CELL BIOCHEM, V103, P1772, DOI 10.1002/jcb.21571; Sorgen PL, 2004, J BIOL CHEM, V279, P54695, DOI 10.1074/jbc.M409552200; Spray DC, 2006, GLIA, V54, P758, DOI 10.1002/glia.20429; Suadicani SO, 2006, J NEUROSCI, V26, P1378, DOI 10.1523/JNEUROSCI.3902-05.2006; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Verselis VK, 2008, J GEN PHYSIOL, V132, P315, DOI 10.1085/jgp.200810029; Vitale ML, 2009, MICROSC RES TECHNIQ, V72, P856, DOI 10.1002/jemt.20771; White TW, 1999, EUR J NEUROSCI, V11, P1883, DOI 10.1046/j.1460-9568.1999.00607.x; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Yokota H, 2000, CRIT CARE MED, V28, P3275, DOI 10.1097/00003246-200009000-00025; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	84	123	127	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4378	4395		10.1096/fj.09-153007	http://dx.doi.org/10.1096/fj.09-153007			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20634352	Green Accepted			2022-12-28	WOS:000283861100025
J	Zadravec, D; Brolinson, A; Fisher, RM; Carneheim, C; Csikasz, RI; Bertrand-Michel, J; Boren, J; Guillou, H; Rudling, M; Jacobsson, A				Zadravec, Damir; Brolinson, Annelie; Fisher, Rachel M.; Carneheim, Claes; Csikasz, Robert I.; Bertrand-Michel, Justine; Boren, Jan; Guillou, Herve; Rudling, Mats; Jacobsson, Anders			Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity	FASEB JOURNAL			English	Article						fatty acid synthesis; gender; obesity; VLCFA	BROWN ADIPOSE-TISSUE; GLUCOSE-HOMEOSTASIS; INSULIN-RESISTANCE; BETA-OXIDATION; DEFICIENT MICE; RAT-HEART; LIVER; METABOLISM; PROTEIN; LEPTIN	Although saturated and monounsaturated very-long-chain fatty acids (VLCFAs) have long been associated with undesirable effects on health, including obesity, heart failure, and atherosclerosis, the physiological role of endogenous synthesis is largely unknown. The fatty acid elongase ELOVL3 is involved in the synthesis of C20-C24 saturated and monounsaturated VLCFAs mainly in liver, brown and white adipose tissue, and triglyceride-rich glands such as the sebaceous and meibomian glands. Here we show that ablation of ELOVL3 leads to reduced adiponectin levels, constrained expansion of adipose tissue, and resistance against diet-induced obesity, a situation that is more exaggerated in female mice. Both female and male knockout mice show reduced hepatic lipogenic gene expression and triglyceride content, a situation that is associated with reduced de novo fatty acid synthesis and uptake. As a consequence, the VLDL-triglyceride level in serum is significantly reduced. Remarkably, despite increased energy expenditure, markedly reduced serum levels of leptin, and increased expression of orexigenic peptides in the hypothalamus, the Elovl3(-/-) mice do not compensate by increased food intake. Thus, these results reveal that C20-C22 saturated and monounsaturated VLCFAs produced by ELOVL3 are indispensable for appropriate synthesis of liver triglycerides, fatty acid uptake, and storage in adipose tissue.-Zadravec, D., Brolinson, A., Fisher, R. M., Carneheim, C., Csikasz, R. I., Bertrand-Michel, J., Boren, J., Guillou, H., Rudling, M., Jacobsson, A. Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity. FASEB J. 24, 4366-4377 (2010). www.fasebj.org	[Zadravec, Damir; Brolinson, Annelie; Carneheim, Claes; Csikasz, Robert I.; Jacobsson, Anders] Stockholm Univ, Wenner Gren Inst, Labs F3, SE-10691 Stockholm, Sweden; [Fisher, Rachel M.] Karolinska Inst, Atherosclerosis Res Unit, Dept Med Solna, Karolinska Univ Hosp, Stockholm, Sweden; [Bertrand-Michel, Justine] CHU Purpan Toulouse, IFR150, Inst Federatif Rech Biomed Toulouse, Toulouse, France; [Boren, Jan] Sahlgrens Univ Hosp, Wallenberg Lab, Sahlgrenska Ctr Cardiovasc & Metab Res, Gothenburg, Sweden; [Guillou, Herve] INRA, Lab Pharmacol & Toxicol, UR66, F-31931 Toulouse, France; [Rudling, Mats] Karolinska Inst, Dept Endocrinol Metab & Diabet, Mol Nutr Unit, Karolinska Univ Hosp Huddinge, Stockholm, Sweden	Stockholm University; Karolinska Institutet; Karolinska University Hospital; CHU de Toulouse; Sahlgrenska University Hospital; INRAE; Karolinska Institutet; Karolinska University Hospital	Jacobsson, A (corresponding author), Stockholm Univ, Wenner Gren Inst, Arrhenius Labs F3, SE-10691 Stockholm, Sweden.	anders.jacobsson@wgi.su.se	Guillou, Herve/AAG-2826-2020; Guillou, Hervé/AGL-0750-2022	Guillou, Herve/0000-0002-5363-9081; Guillou, Hervé/0000-0002-5363-9081; Fisher, Rachel/0000-0002-6031-5288	Swedish Research Council; INRA and Formas	Swedish Research Council(Swedish Research CouncilEuropean Commission); INRA and Formas	The authors thank B. Leksell, V. Roques, and S. Ixenmaier for technical assistance and Biovitrum for access to their DEXA apparatus. This work was supported by grants from the Swedish Research Council (A.J., project 15352, R.F.) and from INRA and Formas (H.G., A.J.).	ALBERTS P, 2006, CURRENT PROTOCOLS NE; Almind K, 2007, P NATL ACAD SCI USA, V104, P2366, DOI 10.1073/pnas.0610416104; Anzulovich A, 2006, J LIPID RES, V47, P2690, DOI 10.1194/jlr.M600230-JLR200; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; BLOMSTRAND R, 1983, LIPIDS, V18, P151, DOI 10.1007/BF02534543; Brolinson A, 2008, ENDOCRINOLOGY, V149, P3158, DOI 10.1210/en.2007-1402; Bryzgalova G, 2006, DIABETOLOGIA, V49, P588, DOI 10.1007/s00125-005-0105-3; Buettner C, 2008, NAT MED, V14, P667, DOI 10.1038/nm1775; Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002; CHARLTON KM, 1975, CAN J COMP MED, V39, P261; Combs TP, 2003, DIABETES, V52, P268, DOI 10.2337/diabetes.52.2.268; Denic V, 2007, CELL, V130, P663, DOI 10.1016/j.cell.2007.06.031; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Dolezalova R, 2007, CLIN ENDOCRINOL, V67, P674, DOI 10.1111/j.1365-2265.2007.02944.x; FLATMARK T, 1983, BIOCHIM BIOPHYS ACTA, V753, P460, DOI 10.1016/0005-2760(83)90071-1; Jakobsson A, 2005, AM J PHYSIOL-ENDOC M, V289, pE517, DOI 10.1152/ajpendo.00045.2005; Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004; Jorgensen JA, 2007, AM J PHYSIOL-ENDOC M, V293, pE1159, DOI 10.1152/ajpendo.00213.2007; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Kitazawa H, 2009, LIPIDS, V44, P765, DOI 10.1007/s11745-009-3320-8; Kobayashi T, 2007, FEBS LETT, V581, P3157, DOI 10.1016/j.febslet.2007.05.081; Koch L, 2008, J CLIN INVEST, V118, P2132, DOI 10.1172/JCI31073; KRAMER JKG, 1979, J NUTR, V109, P202, DOI 10.1093/jn/109.2.202; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Kuriyama H, 2005, CELL METAB, V1, P41, DOI 10.1016/j.cmet.2004.11.004; Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7; Matsusue K, 2008, CELL METAB, V7, P302, DOI 10.1016/j.cmet.2008.03.003; Matsuzaka T, 2007, NAT MED, V13, P1193, DOI 10.1038/nm1662; Mizuno TM, 1999, ENDOCRINOLOGY, V140, P4551, DOI 10.1210/en.140.10.4551; Moon YA, 2009, J LIPID RES, V50, P412, DOI 10.1194/jlr.M800383-JLR200; NORSETH J, 1983, BIOCHIM BIOPHYS ACTA, V751, P312, DOI 10.1016/0005-2760(83)90289-8; OSEI P, 1989, J BIOL CHEM, V264, P6844; Parini P, 2006, EUR J CLIN INVEST, V36, P98, DOI 10.1111/j.1365-2362.2006.01597.x; Prieur X, 2008, ENDOCRINOLOGY, V149, P5432, DOI 10.1210/en.2008-0498; PULLEN DL, 1990, J ANIM SCI, V68, P1395; Puri V, 2007, J BIOL CHEM, V282, P34213, DOI 10.1074/jbc.M707404200; Qiang L, 2007, MOL CELL BIOL, V27, P4698, DOI 10.1128/MCB.02279-06; Rebouissou S, 2007, J BIOL CHEM, V282, P14437, DOI 10.1074/jbc.M610725200; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; Wang H, 2008, MOL CELL BIOL, V28, P188, DOI 10.1128/MCB.00992-07; Wang Y, 2008, J LIPID RES, V49, P1538, DOI 10.1194/jlr.M800123-JLR200; Westerberg R, 2006, J BIOL CHEM, V281, P4958, DOI 10.1074/jbc.M511588200; Westerberg R, 2004, J BIOL CHEM, V279, P5621, DOI 10.1074/jbc.M310529200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	44	70	72	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4366	4377		10.1096/fj.09-152298	http://dx.doi.org/10.1096/fj.09-152298			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20605947				2022-12-28	WOS:000283861100024
J	Xu, JQ; Sato, S; Okuyama, S; Swan, RJ; Jacobsen, MT; Strunk, E; Ikezu, T				Xu, Jiqing; Sato, Shinji; Okuyama, Satoshi; Swan, Russell J.; Jacobsen, Michael T.; Strunk, Elena; Ikezu, Tsuneya			Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice	FASEB JOURNAL			English	Article						transgenic mouse model; neurodegeneartion; protein kinase; frontotemporal dementia; tauopathy; cyclin-dependent kinase 5	GLYCOGEN-SYNTHASE KINASE-3-BETA; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; TRANSGENIC MICE; MOUSE MODEL; DEPOSITION PRECEDES; AMYLOID DEPOSITION; TYROSINE KINASE; PROTEIN-KINASES; PHOSPHORYLATION	Tau-tubulin kinase-1 (TTBK1) phosphorylates microtubule-associated protein tau at specific serine/threonine residues found in paired helical filaments (PHFs), and its expression is up-regulated in the brain in Alzheimer disease, suggesting its role in tauopathy pathogenesis. To understand the effects of TTBK1 on tauopathy in vivo, we have developed bigenic mice overexpressing full-length TTBK1 and the P301L tau mutant. The bigenic mice show enhanced tau phosphorylation at multiple sites (AT8, 12E8, PHF-1, and pS422), tauC3-immunoreactive tau fragmentation, and accumulation of tau aggregates in cortical and hippocampal neurons at 12-13 mo of age. However, the phosphorylated tau aggregates were predominantly sarkosyl soluble and migrated in the light sucrose density fraction after discontinuous sucrose gradient ultracentrifugation, which suggests that they form small oligomers. The bigenic mice show significant locomotor dysfunction as determined by both rotorod and grip strength tests, as well as enhanced loss of motor neurons in the L4-L5 spinal cord. This neuronal dysfunction and degeneration was associated with increased levels of tau oligomers, cyclin-dependent protein kinase 5 activators p35 and p25, and pY216 phosphorylated glycogen synthase kinase 3-beta. These data suggest that TTBK1 up-regulation enhances tau phosphorylation and oligomerization, whose toxicity results in enhanced neurodegeneration and locomotor dysfunction in a tauopathy animal model.-Xu, J., Sato, S., Okuyama, S., Swan, R. J., Jacobsen, M. T., Strunk, E., Ikezu, T. Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice. FASEB J. 24, 2904-2915 (2010). www.fasebj.org	Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA; Univ Nebraska Med Ctr, Ctr Neurodegenerat Disorders, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Ikezu, T (corresponding author), 985930 Nebraska Med Ctr, Omaha, NE 68198 USA.	tikezu@unmc.edu		Ikezu, Tsuneya/0000-0002-3979-8596	University of Nebraska Medical Center; John Douglas French Alzheimer's Foundation; Vada Oldfield Alzheimer's Research Awards	University of Nebraska Medical Center; John Douglas French Alzheimer's Foundation; Vada Oldfield Alzheimer's Research Awards	The authors thank D. Morgan for the consultation in spatial learning tests; A. Takashima for the consultation in sucrose gradient fractionation of tau oligomers; P. Davies (Albert Einstein College of Medicine, Bronx, NY, USA) for PHF-1 and TG2 antibodies; A. Delacourte (INSERM, Lille, France) and M. Hasegawa (University of Tokyo, Tokyo, Japan) for pS422 antibody; P. Schubert (Athena Neurosciences Inc., South San Francisco, CA, USA) for 12E8 antibody; L. Binder (Northwestern University, Chicago, IL, USA) and M. Novak (Medical Research Council Laboratory of Molecular Biology, Cambridge, UK) for tau66, tauC3, and MN423 antibodies; A. LeBlanc (McGill University, Montreal, QC, Canada) for tauC6 antibody; J. Davis (University of Nebraska Medical Center, Omaha, NE, USA) for GSK3 antibodies; and M. Marquardt, K. Estes, and T. Smith for manuscript editing. This work was supported by University of Nebraska Medical Center Faculty Retention Fund (T.I.), John Douglas French Alzheimer's Foundation (S.S.), and Vada Oldfield Alzheimer's Research Awards (S.S. and T.I.).	Arendash GW, 2004, BRAIN RES, V1012, P29, DOI 10.1016/j.brainres.2004.02.081; ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; Berger Z, 2007, J NEUROSCI, V27, P3650, DOI 10.1523/JNEUROSCI.0587-07.2007; Bhaskar K, 2005, J BIOL CHEM, V280, P35119, DOI 10.1074/jbc.M505895200; BRAAK H, 1995, ACTA NEUROPATHOL, V16, P278; Bussiere T, 1999, ACTA NEUROPATHOL, V97, P221, DOI 10.1007/s004010050978; Cho JH, 2004, J BIOL CHEM, V279, P54716, DOI 10.1074/jbc.M403364200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dickey CA, 2007, J CLIN INVEST, V117, P648, DOI 10.1172/JCI29715; Dickey CA, 2006, FASEB J, V20, P753, DOI 10.1096/fj.05-5343fje; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Guo HS, 2004, AM J PATHOL, V165, P523, DOI 10.1016/S0002-9440(10)63317-2; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Houlden H, 2007, NAT GENET, V39, P1434, DOI 10.1038/ng.2007.43; Imahori K, 1997, J BIOCHEM, V121, P179; ISHIGURO K, 1992, NEUROSCI LETT, V148, P202, DOI 10.1016/0304-3940(92)90839-Y; Ishizawa T, 2003, AM J PATHOL, V163, P1057, DOI 10.1016/S0002-9440(10)63465-7; Lee G, 2004, J NEUROSCI, V24, P2304, DOI 10.1523/JNEUROSCI.4162-03.2004; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Lippa CF, 1998, LANCET, V352, P1117, DOI 10.1016/S0140-6736(05)79757-9; Lochhead PA, 2006, MOL CELL, V24, P627, DOI 10.1016/j.molcel.2006.10.009; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Maeda S, 2007, BIOCHEMISTRY-US, V46, P3856, DOI 10.1021/bi061359o; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Ramsden M, 2005, J NEUROSCI, V25, P10637, DOI 10.1523/JNEUROSCI.3279-05.2005; Sahara N, 2002, J NEUROCHEM, V83, P1498, DOI 10.1046/j.1471-4159.2002.01241.x; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Sato S, 2006, J NEUROCHEM, V98, P1573, DOI 10.1111/j.1471-4159.2006.04059.x; Sato S, 2008, J NEUROSCI, V28, P14511, DOI 10.1523/JNEUROSCI.3417-08.2008; Sayas CL, 2006, MOL BIOL CELL, V17, P1834, DOI 10.1091/mbc.E05-07-0688; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Terwel D, 2008, AM J PATHOL, V172, P786, DOI 10.2353/ajpath.2008.070904; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Yamamoto M, 2005, AM J PATHOL, V166, P1475, DOI 10.1016/S0002-9440(10)62364-4; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Yusta B, 2002, J BIOL CHEM, V277, P24896, DOI 10.1074/jbc.M201358200	47	26	27	4	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2904	2915		10.1096/fj.09-150144	http://dx.doi.org/10.1096/fj.09-150144			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20354135				2022-12-28	WOS:000285005400030
J	Zhang, S; Rattanatray, L; MacLaughlin, SM; Cropley, JE; Suter, CM; Molloy, L; Kleemann, D; Walker, SK; Muhlhausler, BS; Morrison, JL; McMillen, IC				Zhang, Song; Rattanatray, Leewen; MacLaughlin, Severence M.; Cropley, Jennifer E.; Suter, Catherine M.; Molloy, Laura; Kleemann, Dave; Walker, Simon K.; Muhlhausler, Beverly S.; Morrison, Janna L.; McMillen, I. Caroline			Periconceptional undernutrition in normal and overweight ewes leads to increased adrenal growth and epigenetic changes in adrenal IGF2/H19 gene in offspring	FASEB JOURNAL			English	Article						fetus; embryo; hypothalamo-pituitary axis; cortisol; DNA methylation	MESSENGER-RIBONUCLEIC-ACID; SHEEP FETUS; MATERNAL UNDERNUTRITION; LATE-GESTATION; FETAL SHEEP; RNA LEVELS; IGF-II; AXIS; EXPRESSION; CORTISOL	Adverse conditions in early life result in increased activation of the hypothalamo-pituitary-adrenal axis and in stress responsiveness in offspring. We have developed a model in which "donor" ewes are either normally nourished or overnourished prior to a period of dietary restriction, before transfer of the embryo at 6-7 d after conception to a ewe of normal weight and nutritional history. A moderate restriction of energy intake during the periconceptional period in both normal weight and overweight ewes resulted in increased adrenal mass in male and female lambs and an increased cortisol response to stress in female lambs. The increase in adrenal weight in lambs exposed to periconceptional undernutrition was associated with a decrease in the adrenal mRNA expression of IGF2 and decreased methylation in the proximal CTCF-binding site in the differentially methylated region of the IGF2/H19 gene. Thus, weight loss in both normal and overweight mothers during the periconceptional period results in epigenetic modification of IGF2 in the adrenal gland, adrenal overgrowth, and increased vulnerability to stress in offspring. Determining the appropriate approach to weight loss in the periconceptional period may therefore be important in overweight or obese women seeking to become pregnant.-Zhang, S., Rattanatray, L., MacLaughlin, S. M., Cropley, J. E., Suter, C. M., Molloy, L., Kleemann, D., Walker, S. K., Muhlhausler, B. S., Morrison, J. L., and McMillen, I. C. Periconceptional undernutrition in normal and overweight ewes leads to increased adrenal growth and epigenetic changes in adrenal IGF2/H19 gene in offspring. FASEB J. 24, 2772-2782 (2010). www.fasebj.org	[Zhang, Song; Rattanatray, Leewen; MacLaughlin, Severence M.; Muhlhausler, Beverly S.; Morrison, Janna L.; McMillen, I. Caroline] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst Hlth Res, The Chancellery, Adelaide, SA 5005, Australia; [Rattanatray, Leewen] Univ Adelaide, Sch Mol & Biomed Sci, Discipline Physiol, Adelaide, SA, Australia; [Cropley, Jennifer E.; Suter, Catherine M.; Molloy, Laura] Victor Chang Cardiac Res Inst, Darlinghurst, NSW, Australia; [Suter, Catherine M.] Univ New S Wales, Kensington, NSW 2033, Australia; [Kleemann, Dave; Walker, Simon K.] S Australian Res & Dev Inst, Turretfield Res Ctr, Rosedale, SA, Australia	University of South Australia; University of Adelaide; Victor Chang Cardiac Research Institute; University of New South Wales Sydney	McMillen, IC (corresponding author), Univ S Australia, Sch Pharm & Med Sci, Sansom Inst Hlth Res, The Chancellery, 160 Currie St, Adelaide, SA 5005, Australia.	caroline.mcmillen@unisa.edu.au	Morrison, Janna/B-8308-2009; McMillen, Isabella Caroline/N-5540-2019	Morrison, Janna/0000-0002-8602-8519; Muhlhausler, Beverly/0000-0002-9021-6790; Cropley, Jennifer/0000-0001-6078-2604	Brailsford Robertson Trust; National Health and Medical Research Council	Brailsford Robertson Trust; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The authors gratefully acknowledge the technical assistance provided by Laura O'Carroll, Pamela Sim, and Bernard Chuang during the course of this study. This study was supported by funding from the Brailsford Robertson Trust and from the National Health and Medical Research Council.	AFRC (Agricultural and Food Research Council), 1993, EN PROT REQ RUM ADV, P100; Bloomfield FH, 2004, ENDOCRINOLOGY, V145, P4278, DOI 10.1210/en.2004-0424; Bloomfield FH, 2003, SCIENCE, V300, P606, DOI 10.1126/science.1080803; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; Butler TG, 2002, J CLIN INVEST, V110, P783, DOI 10.1172/JCI200215563; Canny BJ, 1999, J ENDOCRINOL, V162, P215, DOI 10.1677/joe.0.1620215; Chadio SE, 2007, J ENDOCRINOL, V192, P495, DOI 10.1677/JOE-06-0172; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Coulter CL, 2003, MOL CELL ENDOCRINOL, V206, P85, DOI 10.1016/S0303-7207(03)00214-4; de Vries A, 2007, J CLIN INVEST, V117, P1058, DOI 10.1172/JCI30982; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; Edwards LJ, 2002, AM J PHYSIOL-REG I, V283, pR669, DOI 10.1152/ajpregu.00736.2001; Edwards LJ, 2002, BIOL REPROD, V66, P1562, DOI 10.1095/biolreprod66.5.1562; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fu Q, 2009, FASEB J, V23, P2438, DOI 10.1096/fj.08-124768; Gardner DS, 2006, J ENDOCRINOL, V190, P203, DOI 10.1677/joe.1.06751; HAN VKM, 1992, ENDOCRINOLOGY, V131, P3100, DOI 10.1210/en.131.6.3100; HAN VKM, 1988, J CLIN ENDOCR METAB, V66, P422, DOI 10.1210/jcem-66-2-422; Hawkins P, 2000, REPROD FERT DEVELOP, V12, P443, DOI 10.1071/RD99071; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Kakar MA, 2005, THERIOGENOLOGY, V64, P1090, DOI 10.1016/j.theriogenology.2004.12.017; LaCoursiere DY, 2005, AM J OBSTET GYNECOL, V192, P832, DOI 10.1016/j.ajog.2004.11.034; Levitt NS, 1996, NEUROENDOCRINOLOGY, V64, P412, DOI 10.1159/000127146; Lund TD, 2004, J NEUROENDOCRINOL, V16, P272, DOI 10.1111/j.0953-8194.2004.01167.x; MacLaughlin SM, 2007, ENDOCRINOLOGY, V148, P1911, DOI 10.1210/en.2006-0761; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; *MIN AGR FISH FOOD, 1984, EN ALL FEED SYST RUM; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Owen D, 2003, ENDOCRINOLOGY, V144, P2775, DOI 10.1210/en.2002-0145; PHAMHUUTRUNG MT, 1991, J STEROID BIOCHEM, V39, P903, DOI 10.1016/0960-0760(91)90348-9; Phillips DIW, 2007, J INTERN MED, V261, P453, DOI 10.1111/j.1365-2796.2007.01801.x; Phillips DIW, 2000, HYPERTENSION, V35, P1301, DOI 10.1161/01.HYP.35.6.1301; Phillips ID, 1996, J PHYSIOL-LONDON, V491, P871, DOI 10.1113/jphysiol.1996.sp021264; Reik W, 2003, J PHYSIOL-LONDON, V547, P35, DOI 10.1113/jphysiol.2002.033274; Ross JT, 2007, ENDOCRINOLOGY, V148, P5424, DOI 10.1210/en.2006-1573; Ross JT, 2000, J NEUROENDOCRINOL, V12, P79; Ross JT, 2000, ENDOCRINOLOGY, V141, P2153, DOI 10.1210/en.141.6.2153; RUSSEL AJF, 1969, J AGR SCI, V72, P451, DOI 10.1017/S0021859600024874; Sanchez C, 2009, STEM CELLS, V27, P375, DOI 10.1634/stemcells.2008-0546; Silva C, 2002, ANN NY ACAD SCI, V966, P68, DOI 10.1111/j.1749-6632.2002.tb04203.x; van Lier E, 2003, ANIM REPROD SCI, V79, P81, DOI 10.1016/S0378-4320(03)00083-6; Viau V, 1996, J NEUROSCI, V16, P1866; Warnes KE, 2004, BIOL REPROD, V71, P620, DOI 10.1095/biolreprod.103.025197; Weaver IC, 2004, NAT NEUROSCI, V7, P791; Whittle WL, 2001, BIOL REPROD, V64, P1019, DOI 10.1095/biolreprod64.4.1019; Wood AJ, 2006, PLOS GENET, V2, P1677, DOI 10.1371/journal.pgen.0020147; Worthman CM, 2005, AM J HUM BIOL, V17, P95, DOI 10.1002/ajhb.20096; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769	50	83	87	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2772	2782		10.1096/fj.09-154294	http://dx.doi.org/10.1096/fj.09-154294			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371620				2022-12-28	WOS:000285005400018
J	Liu, HJ; Niu, AR; Chen, SE; Li, YP				Liu, Huijie; Niu, Airu; Chen, Shuen-Ei; Li, Yi-Ping			beta 3-Integrin mediates satellite cell differentiation in regenerating mouse muscle	FASEB JOURNAL			English	Article						myogenic gene expression; myoblast migration; myoblast fusion; focal adhesion; Rac1	ALPHA-V-BETA-3 INTEGRIN; RHO-FAMILY; MYOGENESIS; ACTIVATION; EXPRESSION; REGULATORS; SARCOMERE; MYOBLASTS; ADHESION; GTPASES	Skeletal muscle satellite cells can sense various forms of environmental cues and initiate coordinated signaling that activates myogenesis. Although this process involves cellular membrane receptor integrins, the role of integrins in myogenesis is not well defined. Here, we report a regulatory role of beta 3-integrin, which was previously thought not expressed in muscle, in the initiation of satellite cell differentiation. Undetected in normal muscle, beta 3-integrin expression in mouse hindlimb muscles is induced dramatically from 1 to 3 d after injury by cardiotoxin. The source of beta 3-integrin expression is found to be activated satellite cells. Proliferating C2C12 myoblasts also express beta 3-integrin, which is further up-regulated transiently on differentiation. Knockdown of beta 3-integrin expression attenuates Rac1 activity, impairs myogenic gene expression, and disrupts focal adhesion formation and actin organization, resulting in impaired myoblast migration and myotube formation. Conversely, overexpression of constitutively active Rac1 rescues myotube formation. In addition, a beta 3-integrin-neutralizing antibody similarly blocked myotube formation. Comparing with wild-type littermates, myogenic gene expression and muscle regeneration in cardiotoxin-injured beta 3-integrin-null mice are impaired, as indicated by depressed expression of myogenic markers and morphological disparities. Thus, beta 3-integrin is a mediator of satellite cell differentiation in regenerating muscle.-Liu, H., Niu, A., Chen, S.-E., Li, Y.-P. beta 3-Integrin mediates satellite cell differentiation in regenerating mouse muscle. FASEB J. 25, 1914-1921 (2011). www.fasebj.org	[Liu, Huijie; Niu, Airu; Li, Yi-Ping] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Chen, Shuen-Ei] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine	Li, YP (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.	yi-ping.li@uth.tmc.edu	Chen, Shuen-Ei/AAE-3574-2019; Chen, Shuen-Ei/B-2341-2019; Li, Yi-Ping/ABF-9245-2020	Chen, Shuen-Ei/0000-0003-1737-2591; 	National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR049022]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049022] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01 AR049022 to Y.-P.L.	Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Blaschuk KL, 1997, DEV BIOL, V184, P266, DOI 10.1006/dbio.1997.8527; Bryan BA, 2005, CELL MOL LIFE SCI, V62, P1547, DOI 10.1007/s00018-005-5029-z; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen SE, 2005, AM J PHYSIOL-CELL PH, V289, pC1179, DOI 10.1152/ajpcell.00062.2005; Clemmons DR, 2005, MOL ENDOCRINOL, V19, P1, DOI 10.1210/me.2004-0376; de Virgilio M, 2004, J CELL BIOL, V165, P305, DOI 10.1083/jcb.200402064; Grounds MD, 2005, SCAND J MED SCI SPOR, V15, P381, DOI 10.1111/j.1600-0838.2005.00467.x; GULLBERG D, 1998, FRONT BIOSCI, V3, P1039; Hirsch E, 1998, J CELL SCI, V111, P2397; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Konttinen YT, 2004, RHEUMATOL INT, V24, P333, DOI 10.1007/s00296-003-0379-z; Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Nodari A, 2007, J CELL BIOL, V177, P1063, DOI 10.1083/jcb.200610014; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; Silver Frederick H, 2003, Crit Rev Biomed Eng, V31, P255, DOI 10.1615/CritRevBiomedEng.v31.i4.10; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021; Wei L, 2000, AM J PHYSIOL-HEART C, V278, pH1736, DOI 10.1152/ajpheart.2000.278.6.H1736; Zhan M, 2007, J CELL SCI, V120, P692, DOI 10.1242/jcs.03372	21	47	49	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1914	1921		10.1096/fj.10-170449	http://dx.doi.org/10.1096/fj.10-170449			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21350117	Green Published, Bronze			2022-12-28	WOS:000291023800015
J	MacManus, CF; Campbell, EL; Keely, S; Burgess, A; Kominsky, DJ; Colgan, SP				MacManus, Christopher F.; Campbell, Eric L.; Keely, Simon; Burgess, Adrianne; Kominsky, Douglas J.; Colgan, Sean P.			Anti-inflammatory actions of adrenomedullin through fine tuning of HIF stabilization	FASEB JOURNAL			English	Article						endothelia; epithelia; hypoxia; inflammation; mucosa	SMOOTH-MUSCLE-CELLS; EXPERIMENTAL COLITIS; MURINE MODEL; IN-VITRO; HYPOXIA; INDUCTION; PROTEINS; RECEPTOR; HYDROXYLATION; EXPRESSION	In intact mucosal tissues, epithelial cells are anatomically positioned in proximity to a number of subepithelial cell types, including endothelia. A number of recent studies have suggested that imbalances between energy supply and demand can result in "inflammatory hypoxia." Given these associations, we hypothesized that endothelial-derived, hypoxia-inducible mediators might influence epithelial function. Guided by cDNA microarray analysis of human microvascular endothelial cells (HMEC-1 line) subjected to hypoxia (pO(2) 20 torr, 8 h), we identified adrenomedullin (ADM) as a prominent hypoxia-inducible factor (HIF) that acts on epithelial cells through cell surface receptors. We assessed the functional ability for exogenous ADM to signal in human intestinal Caco2 cells in vitro by demonstrating a dose-dependent induction of Erk1/2phosphorylation. Further analysis revealed that ADM deneddylates cullin-2 (Cul2), whose action has been demonstrated to control the activity of HIF. Caco2 cells stably expressing a hypoxic response element (HRE)-driven luciferase promoter confirmed that ADM activates the HIF signaling pathway. Extensions of these studies revealed an increase in canonical HIF-1-dependent genes following stimulation with ADM. To define physiological relevance, we investigated the effect of ADM in a DSS model of murine colitis. Administration of ADM resulted in reduced inflammatory indices and less severe histological inflammation compared to vehicle controls. Analysis of tissue and serum cytokines showed a marked and significant inhibition of colitis-associated TNF-alpha, IL-1 beta, and KC. Analysis of circulating ADM demonstrated an increase in serum ADM in murine models of colitis. Taken together, these results identify ADM as an endogenously generated vascular mediator that functions as a mucosal protective factor through fine tuning of HIF activity.-MacManus, C.F., Campbell, E.L., Keely, S., Burgess, A., Kominsky, D.J., Colgan, S.P. Antiinflammatory actions of adrenomedullin through fine tuning of HIF stabilization. FASEB J. 25, 1856-1864 (2011). www.fasebj.org	[MacManus, Christopher F.; Campbell, Eric L.; Keely, Simon; Burgess, Adrianne; Kominsky, Douglas J.; Colgan, Sean P.] Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Aurora, CO 80045 USA; [MacManus, Christopher F.; Campbell, Eric L.; Keely, Simon; Burgess, Adrianne; Colgan, Sean P.] Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO 80045 USA; [Kominsky, Douglas J.] Univ Colorado, Hlth Sci Ctr, Dept Anesthesiol & Perioperat Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Colgan, SP (corresponding author), Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, 12700 E 19th Ave, Aurora, CO 80045 USA.	sean.colgan@ucdenver.edu	Keely, Simon/AAV-9973-2020; Campbell, Eric/N-5357-2015	Keely, Simon/0000-0002-1248-9590; Campbell, Eric/0000-0003-0744-6577	U.S. National Institutes of Health [DK50189, DE016191, HL60569]; Crohn's and Colitis Foundation of America; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050189, R37DK050189, R01DK050189] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants DK50189, DE016191, and HL60569 and by grants from the Crohn's and Colitis Foundation of America. The authors declare no financial interests in any of the work submitted here.	ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Andreis PG, 2000, ENDOCRINOLOGY, V141, P2098, DOI 10.1210/en.141.6.2098; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Cueille C, 2005, BIOCHEM BIOPH RES CO, V326, P23, DOI 10.1016/j.bbrc.2004.10.205; Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; Eltzschig HK, 2009, EXPERT OPIN THER TAR, V13, P1267, DOI 10.1517/14728220903241666; Gonzalez-Rey E, 2006, GUT, V55, P824, DOI 10.1136/gut.2005.084525; Gonzalez-Rey E, 2007, AM J PATHOL, V170, P263, DOI 10.2353/ajpath.2007.060596; Hatoum OA, 2003, AM J PHYSIOL-HEART C, V285, pH1791, DOI 10.1152/ajpheart.00552.2003; Hirota SA, 2010, GASTROENTEROLOGY, V139, P259, DOI 10.1053/j.gastro.2010.03.045; Iwasaki H, 2001, ENDOCRINOLOGY, V142, P564, DOI 10.1210/en.142.2.564; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Keely S, 2009, FASEB J, V23, P1338, DOI 10.1096/fj.08-125344; Khoury J, 2007, J CLIN INVEST, V117, P703, DOI 10.1172/JCI30049; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Kruschewski M, 2001, DIGEST DIS SCI, V46, P2336, DOI 10.1023/A:1012334727509; Kuwasako K, 2004, PEPTIDES, V25, P2003, DOI 10.1016/j.peptides.2004.06.002; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Mikus P, 2005, SEMIN CELL DEV BIOL, V16, P462, DOI 10.1016/j.semcdb.2005.03.002; Mittra S, 2006, AM J PHYSIOL-HEART C, V290, pH1842, DOI 10.1152/ajpheart.00388.2005; Miyashita K, 2003, FEBS LETT, V544, P86, DOI 10.1016/S0014-5793(03)00484-8; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Nikitenko LL, 2003, FASEB J, V17, P1499, DOI 10.1096/fj.02-0993fje; Parry G, 2004, SEMIN CELL DEV BIOL, V15, P221, DOI 10.1016/j.semcdb.2003.12.003; Pio R, 2001, J BIOL CHEM, V276, P12292, DOI 10.1074/jbc.M007822200; Qi T, 2010, BRIT J PHARMACOL, V159, P1059, DOI 10.1111/j.1476-5381.2009.00541.x; Robinson A, 2008, GASTROENTEROLOGY, V134, P145, DOI 10.1053/j.gastro.2007.09.033; Shichiri M, 2003, REGUL PEPTIDES, V112, P167, DOI 10.1016/S0167-0115(03)00036-3; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Talero E, 2008, PEPTIDES, V29, P2001, DOI 10.1016/j.peptides.2008.07.013; Temmesfeld-Wollbruck B, 2009, AM J PHYSIOL-GASTR L, V297, pG43, DOI 10.1152/ajpgi.90532.2008; Wu K, 2003, J BIOL CHEM, V278, P28882, DOI 10.1074/jbc.M302888200; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhao L, 1996, AM J PHYSIOL-HEART C, V271, pH622, DOI 10.1152/ajpheart.1996.271.2.H622; Zudaire E, 2006, J LEUKOCYTE BIOL, V80, P237, DOI 10.1189/jlb.0206123	40	37	38	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2011	25	6					1856	1864		10.1096/fj.10-170316	http://dx.doi.org/10.1096/fj.10-170316			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21350119	Green Published			2022-12-28	WOS:000291023800009
J	Chang, TJ; Wang, R; Olson, DJH; Mousseau, DD; Ross, ARS; Wu, LY				Chang, Tuanjie; Wang, Rui; Olson, Douglas J. H.; Mousseau, Darrell D.; Ross, Andrew R. S.; Wu, Lingyun			Modification of Akt1 by methylglyoxal promotes the proliferation of vascular smooth muscle cells	FASEB JOURNAL			English	Article						cell signaling; cell cycle; hypertension	AKT/PROTEIN KINASE-B; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RESISTANCE; OXIDATIVE STRESS; SKELETAL-MUSCLE; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; HYPERTENSION	Methylglyoxal (MG), a reactive dicarbonyl molecule, can modify protein to form advanced glycation endproducts. Increased MG level has been implicated in proliferative vascular diseases, but the underlying mechanisms are not clear yet. The serine/threonine kinase, Akt, regulates multiple signaling pathways that control cell proliferation. Using mass spectrometric analysis, we have detected the modification of Akt1 by MG at Cys(77). This structural modification increased Akt1 phosphorylation at Ser(473) and Thr(308). Akt1 phosphorylation and activity were also increased by MG treatment (< 50 mu M) in cultured vascular smooth muscle cells (VSMCs). MG treatment of VSMCs led to increased DNA synthesis (EC50 = 5.8 mu M), cell proliferation, phosphorylation of p21 and glycogen synthase kinase-3 alpha/beta (GSK-3 alpha/beta), and increased cyclin-dependent kinase 2 (CDK2) activity. These effects of MG were significantly inhibited by silencing Akt1 or by an Akt inhibitor. Overexpression of Akt1 Cys(77)Ser mutant in HEK-293 cells increased cell proliferation and DNA synthesis, concurrent with an increase in Akt1 activity, which could not be further augmented by MG treatment. It is concluded that MG-induced VSMC proliferation is mediated by the activation of Akt1 via the modification of Akt1 at Cys(77).-Chang, T., Wang, R., Olson, D.J.H., Mousseau, D.D., Ross, A.R.S., Wu, L. Modification of Akt1 by methylglyoxal promotes the proliferation of vascular smooth muscle cells. FASEB J. 25, 1746-1757 (2011). www.fasebj.org	[Chang, Tuanjie; Wu, Lingyun] Univ Saskatchewan, Dept Pharmacol, Coll Med, Saskatoon, SK S7N 5E5, Canada; [Mousseau, Darrell D.] Univ Saskatchewan, Cell Signalling Lab, Saskatoon, SK S7N 5E5, Canada; [Wang, Rui] Lakehead Univ, Dept Biol, Fac Sci & Environm Study, Thunder Bay, ON P7B 5E1, Canada; [Olson, Douglas J. H.] CNR, Inst Plant Biotechnol, Saskatoon, SK, Canada; [Ross, Andrew R. S.] Fisheries & Oceans Canada, Inst Ocean Sci, Sidney, BC, Canada	University of Saskatchewan; University of Saskatchewan; Lakehead University; Fisheries & Oceans Canada	Wu, LY (corresponding author), Univ Saskatchewan, Dept Pharmacol, Coll Med, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	lily.wu@usask.ca	Wang, Rui/C-7824-2012	Wang, Rui/0000-0003-3825-3620	Canadian Institutes of Health Research (CIHR) [MOP-68938]; Heart and Stroke Foundation of Canada; Heart and Stroke Foundation of Saskatchewan	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); Heart and Stroke Foundation of Saskatchewan	T.C. was supported by a postdoctoral fellowship from the Gasotransmitter Research and Training (GREAT) program of the Canadian Institutes of Health Research (CIHR) and Heart and Stroke Foundation of Canada. This work was supported by operating grants from CIHR (MOP-68938) and the Heart and Stroke Foundation of Saskatchewan to L.W.	Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2; Beisswenger PJ, 1999, DIABETES, V48, P198, DOI 10.2337/diabetes.48.1.198; Benkirane K, 2006, HYPERTENSION, V47, P102, DOI 10.1161/01.HYP.0000196728.05488.c3; Biswas A, 2008, BIOCHEM J, V409, P771, DOI 10.1042/BJ20071006; Cantero AV, 2007, FASEB J, V21, P3096, DOI 10.1096/fj.06-7536com; Chang TJ, 2005, FREE RADICAL BIO MED, V38, P286, DOI 10.1016/j.freeradbiomed.2004.10.034; Chang TJ, 2006, CAN J PHYSIOL PHARM, V84, P1229, DOI 10.1139/Y06-077; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cozzone D, 2008, DIABETOLOGIA, V51, P512, DOI 10.1007/s00125-007-0913-8; Dai YX, 2007, J PSYCHIATR NEUROSCI, V32, P323; DHAR A, 2011, DIABETES IN PRESS; Du J, 2000, J CELL BIOCHEM, V77, P333, DOI 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-Q; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Gao Y, 2006, BIOCHEMISTRY-US, V45, P15654, DOI 10.1021/bi061410o; GILGOMEZ G, 2003, METH MOL B, V282, P131; HADRAVA V, 1989, HYPERTENSION, V13, P589, DOI 10.1161/01.HYP.13.6.589; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Heron-Milhavet L, 2006, MOL CELL BIOL, V26, P8267, DOI 10.1128/MCB.00201-06; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Hsuuw YD, 2005, J CELL PHYSIOL, V205, P379, DOI 10.1002/jcp.20408; Intengan HD, 2001, HYPERTENSION, V38, P581, DOI 10.1161/hy09t1.096249; Jia XM, 2006, FASEB J, V20, P1555, DOI 10.1096/fj.05-5478fje; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mostafa AA, 2007, MOL CELL BIOCHEM, V302, P35, DOI 10.1007/s11010-007-9422-9; Nagaraj RH, 2002, ARCH BIOCHEM BIOPHYS, V402, P110, DOI 10.1016/S0003-9861(02)00067-X; Ndisang JF, 2003, BLOOD, V101, P3893, DOI 10.1182/blood-2002-08-2608; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Ogihara T, 2002, HYPERTENSION, V40, P83, DOI 10.1161/01.HYP.0000022880.45113.C9; Riboulet-Chavey A, 2006, DIABETES, V55, P1289, DOI 10.2337/db05-0857; Rondinone CM, 1999, DIABETOLOGIA, V42, P819, DOI 10.1007/s001250051232; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Stabile E, 2003, CIRC RES, V93, P1059, DOI 10.1161/01.RES.0000105086.31909.1B; Tanner FC, 2003, HYPERTENSION, V42, P184, DOI 10.1161/01.HYP.0000082360.65547.7C; THORNALLEY PJ, 1989, DIABETES RES CLIN PR, V7, P115, DOI 10.1016/0168-8227(89)90101-0; Wang H, 2007, CLIN BIOCHEM, V40, P1232, DOI 10.1016/j.clinbiochem.2007.07.016; Wang XX, 2008, J HYPERTENS, V26, P765, DOI 10.1097/HJH.0b013e3282f4a13c; Wang XX, 2005, J HYPERTENS, V23, P1565, DOI 10.1097/01.hjh.0000173778.85233.1b; Wei ZL, 2009, CELL SIGNAL, V21, P161, DOI 10.1016/j.cellsig.2008.10.005; Wu LY, 2006, CAN J PHYSIOL PHARM, V84, P129, DOI 10.1139/Y05-137; Yang GD, 2004, FASEB J, V18, P1782, DOI 10.1096/fj.04-2279fje; Yang GD, 2004, J BIOL CHEM, V279, P49199, DOI 10.1074/jbc.M408997200; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Zeng JM, 2005, CHEM RES TOXICOL, V18, P1232, DOI 10.1021/tx050074u; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	49	38	41	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1746	1757		10.1096/fj.10-178053	http://dx.doi.org/10.1096/fj.10-178053			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21321187				2022-12-28	WOS:000290023800030
J	Goodman, CA; Mabrey, DM; Frey, JW; Miu, MH; Schmidt, EK; Pierre, P; Hornberger, TA				Goodman, Craig A.; Mabrey, Danielle M.; Frey, John W.; Miu, Man Hing; Schmidt, Enrico K.; Pierre, Philippe; Hornberger, Troy A.			Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique	FASEB JOURNAL			English	Article						hypertrophy; atrophy; growth	PHOSPHOINOSITIDE 3-KINASE; HYPERTROPHY; ATROPHY; TISSUES; PATHWAY; KINASE; RATS; RHEB	In this study, the principles of surface sensing of translation (SUnSET) were used to develop a nonradioactive method for ex vivo and in vivo measurements of protein synthesis (PS). Compared with controls, we first demonstrate excellent agreement between SUnSET and a [H-3] phenylalanine method when detecting synergist ablation-induced increases in skeletal muscle PS ex vivo. We then show that SUnSET can detect the same synergist ablation-induced increase in PS when used in vivo (IV-SUnSET). In addition, IV-SUnSET detected food deprivation-induced decreases in PS in the heart, kidney, and skeletal muscles, with similar changes being visualized with an immunohistochemical version of IV-SUnSET (IV-IHC-SUnSET). By combining IV-IHC-SUnSET with in vivo transfection, we demonstrate that constitutively active PKB induces a robust increase in skeletal muscle PS. Furthermore, transfection with Ras homolog enriched in brain (Rheb) revealed that a PKB-independent activation of mammalian target of rapamycin is also sufficient to induce an increase in skeletal muscle PS. Finally, IV-IHC-SUnSET exposed the existence of fiber type-dependent differences in skeletal muscle PS, with PS in type 2B and 2X fibers being significantly lower than that in type 2A fibers within the same muscle. Thus, our nonradioactive method allowed us to accurately visualize and quantify PS under various ex vivo and in vivo conditions and revealed novel insights into the regulation of PS in skeletal muscle.-Goodman, C. A., Mabrey, D. M., Frey, J. W., Miu, M. H., Schmidt, E. K., Pierre, P., Hornberger, T. A. Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. FASEB J. 25, 1028-1039 (2011). www.fasebj.org	[Goodman, Craig A.; Mabrey, Danielle M.; Frey, John W.; Miu, Man Hing; Hornberger, Troy A.] Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA; [Schmidt, Enrico K.; Pierre, Philippe] Univ Mediterranee, Ctr Immunol Marseille Luminy, Marseille, France; [Schmidt, Enrico K.; Pierre, Philippe] INSERM, U631, F-13258 Marseille, France; [Schmidt, Enrico K.; Pierre, Philippe] CNRS, UMR6102, Marseille, France	University of Wisconsin System; University of Wisconsin Madison; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)	Hornberger, TA (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	thornb1@svm.vetmed.wisc.edu	Goodman, Craig/H-8085-2019	Goodman, Craig/0000-0002-5874-7743; pierre, philippe/0000-0003-0863-8255; Hornberger, Troy/0000-0002-2349-1899	U.S. National Institutes of Health [AR057347]; Agence Nationale de la Recherche DC-trans; Human Frontier Science Program Organization [RGP0045/2005]; Eunice Kennedy Shriver National Institute of Child Health and Human Development; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR057347] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Agence Nationale de la Recherche DC-trans(French National Research Agency (ANR)); Human Frontier Science Program Organization(Human Frontier Science Program); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The type 1, 2a, and 2b MHC monoclonal antibodies developed by S. Schiaffino and the type 2x MHC monoclonal antibody developed by C. Lucas were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and maintained by the University of Iowa Department of Biology (Ames, IA, USA). This work was supported by U.S. National Institutes of Health grant AR057347 to T.A.H. and Agence Nationale de la Recherche DC-trans and Human Frontier Science Program Organization grant RGP0045/2005 to P.P.	Adams GR, 2002, AM J PHYSIOL-CELL PH, V283, pC1182, DOI 10.1152/ajpcell.00173.2002; ARMSTRONG RB, 1985, J EXP BIOL, V115, P201; AUGERT G, 1986, DIABETOLOGIA, V29, P248, DOI 10.1007/BF00454885; Avruch J, 2009, BIOCHEM SOC T, V37, P223, DOI 10.1042/BST0370223; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Erbay E, 2003, J CELL BIOL, V163, P931, DOI 10.1083/jcb.200307158; GARLICK PJ, 1975, BIOCHIM BIOPHYS ACTA, V414, P71, DOI 10.1016/0005-2787(75)90126-4; GARLICK PJ, 1980, BIOCHEM J, V192, P719, DOI 10.1042/bj1920719; GOLDBERG AL, 1967, NATURE, V216, P1219, DOI 10.1038/2161219a0; Goodman CA, 2010, MOL BIOL CELL, V21, P3258, DOI 10.1091/mbc.E10-05-0454; Habets PEMH, 1999, J HISTOCHEM CYTOCHEM, V47, P995, DOI 10.1177/002215549904700803; Hornberger TA, 2004, BIOCHEM J, V380, P795, DOI 10.1042/BJ20040274; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; MCALLISTER RM, 1993, J RECONSTR MICROSURG, V9, P313, DOI 10.1055/s-2007-1006673; Nader GA, 2005, INT J BIOCHEM CELL B, V37, P1985, DOI 10.1016/j.biocel.2005.02.026; NAKANO K, 1979, BIOCHEM J, V184, P663, DOI 10.1042/bj1840663; NATHANS D, 1964, P NATL ACAD SCI USA, V51, P585, DOI 10.1073/pnas.51.4.585; O'Neil TK, 2009, J PHYSIOL-LONDON, V587, P3691, DOI 10.1113/jphysiol.2009.173609; Sandri M, 2008, PHYSIOLOGY, V23, P160, DOI 10.1152/physiol.00041.2007; Schakman O, 2008, ENDOCRINOLOGY, V149, P3900, DOI 10.1210/en.2008-0439; Schiaffino S, 2007, PHYSIOLOGY, V22, P269, DOI 10.1152/physiol.00009.2007; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; van Wessel T, 2010, EUR J APPL PHYSIOL, V110, P665, DOI 10.1007/s00421-010-1545-0; Wolfe RR., 2005, ISOTOPE TRACERS META, V2	25	316	322	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1028	1039		10.1096/fj.10-168799	http://dx.doi.org/10.1096/fj.10-168799			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21148113	Green Published			2022-12-28	WOS:000287806200022
J	Tinnes, S; Schafer, MKE; Flubacher, A; Munzner, G; Frotscher, M; Haas, CA				Tinnes, Stefanie; Schaefer, Michael K. E.; Flubacher, Armin; Muenzner, Gert; Frotscher, Michael; Haas, Carola A.			Epileptiform activity interferes with proteolytic processing of Reelin required for dentate granule cell positioning	FASEB JOURNAL			English	Article						hippocampus; dispersion; kainate; lamination; organotypic slice cultures	TEMPORAL-LOBE EPILEPSY; METALLOPROTEINASES-1 TIMP-1; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; KNOCKOUT MICE; MUTANT MICE; NEURONS; HIPPOCAMPUS; DISPERSION; PROTEIN	The extracellular matrix protein Reelin is an essential regulator of neuronal migration and lamination in the developing and mature brain. Lack of Reelin causes severe disturbances in cerebral layering, such as the reeler phenotype and granule cell dispersion in temporal lobe epilepsy. Reelin is synthesized and secreted by Cajal-Retzius cells and GABAergic interneurons, and its function depends on proteolytic cleavage after secretion. The mechanisms regulating these processes are largely unknown. Here, we used rat hippocampal slice cultures to investigate the effect of neuronal activation and hyperexcitation on Reelin synthesis, secretion, and proteolytic processing. We show that enhanced neuronal activity does not modulate Reelin synthesis or secretion. Moreover, we found that intracellular Reelin resides predominantly in the endoplasmic reticulum before it is constitutively secreted via the early secretory pathway. Epileptiform activity, however, impairs the proteolytic processing of Reelin and leads to accumulation of Reelin in the extracellular matrix. We found that both conditions, epileptiform activity and impaired proteolytic cleavage of Reelin, cause granule cell dispersion via inhibition of metalloproteinases. Taken together, our results strongly suggest that secretion of Reelin is activity-independent and that proteolytic processing of Reelin is required for the maintenance of granule cell lamination in the dentate gyrus.-Tinnes, S., Schafer, M. K. E., Flubacher, A., Munzner, G., Frotscher, M., Haas, C. A. Epileptiform activity interferes with proteolytic processing of Reelin required for dentate granule cell positioning. FASEB J. 25, 1002-1013 (2011). www.fasebj.org	[Tinnes, Stefanie; Flubacher, Armin; Muenzner, Gert; Haas, Carola A.] Univ Clin Freiburg, Neuroctr, Expt Epilepsy Grp, Freiburg, Germany; [Schaefer, Michael K. E.; Frotscher, Michael] Univ Clin Freiburg, Inst Anat & Cell Biol, Freiburg, Germany	University of Freiburg; University of Freiburg	Haas, CA (corresponding author), Univ Clin Freiburg, Neuroctr, Expt Epilepsy Grp, Freiburg, Germany.	carola.haas@uniklinik-freiburg.de	Schaefer, Michael K.E./S-1715-2019	Schaefer, Michael K.E./0000-0001-6055-6244	Deutsche Forschungsgemeinschaft (DFG) [SFB TR3, SFB 780]; German Federal Ministery of Education and Research [01GQ0420]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Federal Ministery of Education and Research	The authors thank Dr. Hans Bock (Institute of Anatomy and Cell Biology, University of Freiburg, Freiburg, Germany) for the gift of recombinant Reelin and S. Huber and F. Moos for excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (DFG; Transregio SFB TR3; SFB 780) and the German Federal Ministery of Education and Research (grant 01GQ0420).	Alcantara S, 1998, J NEUROSCI, V18, P7779; Bouilleret V, 1999, NEUROSCIENCE, V89, P717, DOI 10.1016/S0306-4522(98)00401-1; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; de Bergeyck V, 1998, J NEUROSCI METH, V82, P17, DOI 10.1016/S0165-0270(98)00024-7; de Rouvroit CL, 1999, EXP NEUROL, V156, P214, DOI 10.1006/exnr.1998.7007; deBergeyck V, 1997, MOL BRAIN RES, V50, P85, DOI 10.1016/S0169-328X(97)00166-6; Derer P, 2001, J COMP NEUROL, V440, P136, DOI 10.1002/cne.1375; Drakew A, 2002, EXP NEUROL, V176, P12, DOI 10.1006/exnr.2002.7918; Duveau V, 2011, HIPPOCAMPUS, V21, P935, DOI 10.1002/hipo.20793; Dzwonek J, 2004, FEBS LETT, V567, P129, DOI 10.1016/j.febslet.2004.03.070; Forster E, 2006, NAT REV NEUROSCI, V7, P259, DOI 10.1038/nrn1882; Frotscher M, 2003, CEREB CORTEX, V13, P634, DOI 10.1093/cercor/13.6.634; Frotscher M, 2010, TRENDS NEUROSCI, V33, P407, DOI 10.1016/j.tins.2010.06.001; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Gong C, 2007, J NEUROSCI, V27, P1803, DOI 10.1523/JNEUROSCI.3111-06.2007; Haas CA, 2002, J NEUROSCI, V22, P5797; Haas CA, 2010, EXP BRAIN RES, V200, P141, DOI 10.1007/s00221-009-1948-5; Heinrich C, 2006, J NEUROSCI, V26, P4701, DOI 10.1523/JNEUROSCI.5516-05.2006; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; HOUSER CR, 1990, BRAIN RES, V535, P195, DOI 10.1016/0006-8993(90)91601-C; Jossin Y, 2007, J NEUROSCI, V27, P4243, DOI 10.1523/JNEUROSCI.0023-07.2007; Jourquin J, 2005, EUR J NEUROSCI, V22, P2569, DOI 10.1111/j.1460-9568.2005.04426.x; Lacor PN, 2000, P NATL ACAD SCI USA, V97, P3556, DOI 10.1073/pnas.050589597; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lugli Giovanni, 2003, BMC Biochem, V4, P9, DOI 10.1186/1471-2091-4-9; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; Mimura N, 2008, MOL CELL BIOL, V28, P293, DOI 10.1128/MCB.00473-07; Muller MC, 2009, EXP NEUROL, V216, P390, DOI 10.1016/j.expneurol.2008.12.029; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakano Y, 2007, J BIOL CHEM, V282, P20544, DOI 10.1074/jbc.M702300200; Pesold C, 1998, P NATL ACAD SCI USA, V95, P3221, DOI 10.1073/pnas.95.6.3221; Ramos-Moreno T, 2006, EUR J NEUROSCI, V23, P401, DOI 10.1111/j.1460-9568.2005.04567.x; Rivera S, 1997, J NEUROSCI, V17, P4223; Routbort MJ, 1999, NEUROSCIENCE, V94, P755, DOI 10.1016/S0306-4522(99)00358-9; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; STANFIELD BB, 1979, J COMP NEUROL, V185, P393, DOI 10.1002/cne.901850302; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Wilczynski GM, 2008, J CELL BIOL, V180, P1021, DOI 10.1083/jcb.200708213; Yasui N, 2007, P NATL ACAD SCI USA, V104, P9988, DOI 10.1073/pnas.0700438104	43	46	48	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1002	1013		10.1096/fj.10-168294	http://dx.doi.org/10.1096/fj.10-168294			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21148112				2022-12-28	WOS:000287806200020
J	Khau, T; Langenbach, SY; Schuliga, M; Harris, T; Johnstone, CN; Anderson, RL; Stewart, AG				Khau, Thippadey; Langenbach, Shenna Y.; Schuliga, Michael; Harris, Trudi; Johnstone, Cameron N.; Anderson, Robin L.; Stewart, Alastair G.			Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2	FASEB JOURNAL			English	Article						MCF-7; cell cycle; cyclin D; apoptosis; estradiol; lipoxin A(4)	A1 DOWN-REGULATION; CYCLE PROGRESSION; GROWTH ARREST; GLIOMA-CELLS; IN-VIVO; EXPRESSION; CANCER; DIFFERENTIATION; ESTROGEN; LIGAND	The role of the calcium-and phospholipid-binding protein annexin I (ANXA1) in cell cycle regulation has been investigated in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast tumor cell lines. In MCF-7 cells, ANXA1-targeting small interfering RNA (siRNA) reduced ANXA1 mRNA and protein levels and attenuated cell proliferation induced by FCS, estradiol, or epidermal growth factor. Well-characterized agonists for the known ANXA1 receptor, FPR2, including the ANXA1 N-terminal proteolytic product ANXA1(2-26), lipoxin A(4) (LXA(4)), and the synthetic peptide, Trp-Lys-Tyr-Met-Val-D-Met (WKYMVm), stimulated proliferation of MCF-7 and MDA-MB-231 cells that was attenuated by incubation with FPR2 antagonists WRW4 (1 mu M) or Boc2 (100 nM) or by siRNA against FPR2. FCS-induced mitogenic responses were attenuated by each of the FPR antagonists and by siRNA against FPR2 and, to a lesser extent, FPR1. LXA(4) increased phosphorylation of Akt, p70(S6K) but not ERK1/2. Increases in cyclin D1 protein induced by FCS or LXA(4) were blocked by the PI3 kinase inhibitor, LY294002, and attenuated by FPR2 antagonism using Boc2. In invasive breast cancer, immunohistochemistry revealed the presence of ANXA1 and its receptor, FPR2, in both tumor epithelium and stromal cells. These observations suggest a novel signaling role for ANXA1 in mitogen-activated proliferation of breast tumor epithelial cells that is mediated via activation of FPR1 and FPR2.-Khau, T., Langenbach, S. Y., Schuliga, M., Harris, T., Johnstone, C. N., Anderson, R. L., Stewart, A. G. Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2. FASEB J. 25, 483-496 (2011). www.fasebj.org	[Khau, Thippadey; Langenbach, Shenna Y.; Schuliga, Michael; Harris, Trudi; Stewart, Alastair G.] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia; [Anderson, Robin L.] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; [Johnstone, Cameron N.; Anderson, Robin L.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia	University of Melbourne; University of Melbourne; Peter Maccallum Cancer Center	Stewart, AG (corresponding author), Univ Melbourne, Dept Pharmacol, Parkville Campus,Level 8 Med Bldg,Grattan St, Parkville, Vic 3010, Australia.	astew@unimelb.edu.au	Schuliga, Michael/ABC-4802-2021; Anderson, Robin/I-2306-2013; Anderson, Robin/K-6966-2019; Anderson, Robin/S-1005-2017	Schuliga, Michael/0000-0001-6742-5028; stewart, alastair/0000-0002-2271-5942; Anderson, Robin/0000-0002-6841-7422	Australia National Health and Medical Research Council [566776]; National Breast Cancer Foundation	Australia National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation	This work was supported a grant from the Australia National Health and Medical Research Council (566776) and by a fellowship from the National Breast Cancer Foundation to R.L.A.	Alldridge LC, 2003, EXP CELL RES, V290, P93, DOI 10.1016/S0014-4827(03)00310-0; Alldridge LC, 1999, J BIOL CHEM, V274, P37620, DOI 10.1074/jbc.274.53.37620; Ang EZF, 2009, MOL CANCER RES, V7, P266, DOI 10.1158/1541-7786.MCR-08-0147; Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; Babbin BA, 2006, J BIOL CHEM, V281, P19588, DOI 10.1074/jbc.M513025200; Bae YS, 2004, J IMMUNOL, V173, P607, DOI 10.4049/jimmunol.173.1.607; Bae YS, 2003, MOL PHARMACOL, V64, P721, DOI 10.1124/mol.64.3.721; Bai XF, 2004, WORLD J GASTROENTERO, V10, P1466; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1; Cao Y, 2008, APPL IMMUNOHISTO M M, V16, P530, DOI 10.1097/PAI.0b013e31817432c3; Castro-Caldas M, 2001, MEDIAT INFLAMM, V10, P245, DOI 10.1080/09629350120093713; Chang HL, 2009, ANTICANCER RES, V29, P3195; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Christophe T, 2001, J BIOL CHEM, V276, P21585, DOI 10.1074/jbc.M007769200; CROXTALL JD, 1992, P NATL ACAD SCI USA, V89, P3571, DOI 10.1073/pnas.89.8.3571; de Coupade C, 2000, HEPATOLOGY, V31, P371, DOI 10.1002/hep.510310217; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; Ernst S, 2004, J IMMUNOL, V172, P7669, DOI 10.4049/jimmunol.172.12.7669; Frey BM, 1999, FASEB J, V13, P2235, DOI 10.1096/fasebj.13.15.2235; Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Gavins FNE, 2005, PROSTAG LEUKOTR ESS, V73, P211, DOI 10.1016/j.plefa.2005.05.008; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Hannon R, 2002, FASEB J, V16, P253, DOI 10.1096/fj.02-0239fje; Horman S, 2000, CELL PROLIFERAT, V33, P331, DOI 10.1046/j.1365-2184.2000.00188.x; Huang J, 2008, CANCER LETT, V267, P254, DOI 10.1016/j.canlet.2008.03.014; Huo XF, 2005, BIOCHEM BIOPH RES CO, V331, P1346, DOI 10.1016/j.bbrc.2005.04.049; Khau T, 2008, EJC SUPPL, V6, P118, DOI 10.1016/S1359-6349(08)72309-7; Kwon MJ, 2005, FRONT BIOSCI-LANDMRK, V10, P300, DOI 10.2741/1529; Le YY, 2001, CYTOKINE GROWTH F R, V12, P91, DOI 10.1016/S1359-6101(01)00003-X; Lecona E, 2008, MOL CELL BIOL, V28, P4665, DOI 10.1128/MCB.00650-07; Luthra R, 2008, ONCOGENE, V27, P6667, DOI 10.1038/onc.2008.256; Maggiolini M, 2002, J STEROID BIOCHEM, V82, P315, DOI 10.1016/S0960-0760(02)00230-3; MCLEOD JD, 1995, BIOCHEM PHARMACOL, V50, P1103, DOI 10.1016/0006-2952(95)00234-Q; Migeotte I, 2006, CYTOKINE GROWTH F R, V17, P501, DOI 10.1016/j.cytogfr.2006.09.009; Minghetti L, 1999, BRIT J PHARMACOL, V126, P1307, DOI 10.1038/sj.bjp.0702423; Mitchell D, 2004, AM J PATHOL, V164, P937, DOI 10.1016/S0002-9440(10)63181-1; Mulla A, 2004, CLIN ENDOCRINOL, V60, P107, DOI 10.1111/j.1365-2265.2004.01936.x; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Paweletz CP, 2000, CANCER RES, V60, P6293; Pedrero JMG, 2004, AM J PATHOL, V164, P73, DOI 10.1016/S0002-9440(10)63098-2; PEERS SH, 1993, BRIT J PHARMACOL, V108, P66, DOI 10.1111/j.1476-5381.1993.tb13441.x; Pencil SD, 1998, CLIN EXP METASTAS, V16, P113, DOI 10.1023/A:1021917017109; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Roviezzo F, 2002, J PHYSIOL PHARMACOL, V53, P541; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Selvatici R, 2006, EUR J PHARMACOL, V534, P1, DOI 10.1016/j.ejphar.2006.01.034; Shen DJ, 2006, HUM PATHOL, V37, P1583, DOI 10.1016/j.humpath.2006.06.001; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; SOTO AM, 1985, J STEROID BIOCHEM, V23, P87, DOI 10.1016/0022-4731(85)90265-1; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; Sutherland TE, 2005, CLIN CANCER RES, V11, P1722, DOI 10.1158/1078-0432.CCR-04-1789; Vishwanatha JK, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-8; Vong L, 2007, J BIOL CHEM, V282, P29998, DOI 10.1074/jbc.M702876200; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Wang YA, 2008, INT J CANCER, V123, P1536, DOI 10.1002/ijc.23671; Yang D, 2001, J IMMUNOL, V166, P4092, DOI 10.4049/jimmunol.166.6.4092	63	80	87	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					483	496		10.1096/fj.09-154096	http://dx.doi.org/10.1096/fj.09-154096			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20930115				2022-12-28	WOS:000286724800007
J	Recchiuti, A; Krishnamoorthy, S; Fredman, G; Chiang, N; Serhan, CN				Recchiuti, Antonio; Krishnamoorthy, Sriram; Fredman, Gabrielle; Chiang, Nan; Serhan, Charles N.			MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits	FASEB JOURNAL			English	Article						GPCR; resolution indices; lipid mediators; 5-lipoxygenase; cytokines; transcription factors	ANTIINFLAMMATORY PROPERTIES; LIPID MEDIATORS; ASPIRIN; 5-LIPOXYGENASE; LEUKOTRIENES; EXPRESSION; LIPOXINS; TARGETS; D1	Mechanisms controlling resolution of acute inflammation are of wide interest. Here, we investigated microRNAs (miRNAs) in self-limited acute inflammatory exudates and their regulation by resolvin D1 (RvD1). Using real-time PCR analysis, we found in resolving exudates that miR-21, miR-146b, miR-208a, miR-203, miR-142, miR-302d, and miR-219 were selectively regulated (P<0.05) in self-limited murine peritonitis. RvD1 (300 ng/mouse or 15 mu g kg(-1)) reduced zymosan-elicited neutrophil infiltration into the peritoneum 25-50% and shortened the resolution interval (R-i) by similar to 4 h. In peritonitis at 12 h, RvD1 up-regulated miR-21, miR-146b, and miR-219 and down-regulated miR-208a in vivo. In human macrophages overexpressing recombinant RvD1 receptors ALX/FPR2 or GPR32, these same miRNAs were significantly regulated (P<0.05) by RvD1 at concentrations as low as 10 nM, recapitulating the in vivo circuit. In addition, RvD1-miRNAs identified herein target cytokines and proteins involved in the immune system, e. g., miR-146b targeted NF-kappa B signaling, and miR-219 targeted 5-lipoxygenase and reduced leukotriene production. RvD1 also reduced nuclear translocation of NF-kappa B and SMAD and down-regulated phospho-I kappa B. Taken together, these results indicate that resolvin-regulated specific miRNAs target genes involved in resolution and establish a novel resolution circuit involving RvD1 receptor-dependent regulation of specific miRNAs.-Recchiuti, A., Krishnamoorthy, S., Fredman, G., Chiang, N., and Serhan, C. N. MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J. 25, 544-560 (2011). www.fasebj.org	[Serhan, Charles N.] Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 77 Ave Louis Pasteur,Harvard Inst Med 829, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Chiang, Nan/ABA-4924-2021; Recchiuti, Antonio/K-7670-2016	Chiang, Nan/0000-0003-1963-1585; Recchiuti, Antonio/0000-0002-1409-5261	U.S. National Institutes of Health (NIH) [R37GM38765, R01DK074448, R01DE019938]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R01GM038765] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Thad Vickery for LC-MS-MS lipidomics, Dr. Sungwhan F. Oh for generating the transcription factor heat map, Padmini S. Pillai for helping with animal experiments, and Mary H Small for assistance with manuscript preparation. The authors also acknowledge the Institute of Chemistry and Cell Biology (ICCB)-Longwood for the use of their real-time PCR equipment and IPA software license. This work was supported by U.S. National Institutes of Health (NIH) grants R37GM38765, R01DK074448, and R01DE019938. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Science, the National Institute of Diabetes and Digestive and Kidney Diseases, or the NIH. C.N.S. is the inventor on patents assigned to Brigham and Women's Hospital and Partners HealthCare on the composition of matter, uses, and clinical development of anti-inflammatory and proresolving lipid mediators. These are licensed for clinical development. C.N.S. retains founder stock in Resolvyx Pharmaceuticals.	Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Bannenberg G, 2004, BRIT J PHARMACOL, V143, P43, DOI 10.1038/sj.bjp.0705912; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Callis TE, 2009, J CLIN INVEST, V119, P2772, DOI 10.1172/JCI36154; Chiang N, 2004, P NATL ACAD SCI USA, V101, P15178, DOI 10.1073/pnas.0405445101; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; Dincbas-Renqvist V, 2009, BBA-GENE REGUL MECH, V1789, P99, DOI 10.1016/j.bbagrm.2008.10.002; Dugas JC, 2010, NEURON, V65, P597, DOI 10.1016/j.neuron.2010.01.027; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Kasuga K, 2008, J IMMUNOL, V181, P8677, DOI 10.4049/jimmunol.181.12.8677; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; MAJNO G, 1982, CURRENT TOPICS INFLA, P1; MAJNO G, 1982, CURRENT TOPICS INFLA, V23; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Morris T, 2009, J IMMUNOL, V183, P2089, DOI 10.4049/jimmunol.0900477; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Navarro-Xavier RA, 2010, J IMMUNOL, V184, P1516, DOI 10.4049/jimmunol.0902866; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Prasad SVN, 2009, J BIOL CHEM, V284, P27487, DOI 10.1074/jbc.M109.036541; Radmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002; Randolph GJ, 2009, J THROMB HAEMOST, V7, P28, DOI 10.1111/j.1538-7836.2009.03423.x; Rossi A, 2008, RESOLUTION INFLAMMAT; RYAN GB, 1977, AM J PATHOL, V86, P183; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2009, J THROMB HAEMOST, V7, P44, DOI 10.1111/j.1538-7836.2009.03396.x; Serhan CN, 2007, METHOD ENZYMOL, V432, P275, DOI 10.1016/S0076-6879(07)32012-0; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Sheedy FJ, 2008, ANN RHEUM DIS, V67, P50, DOI 10.1136/ard.2008.100289; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675; Winyard P. G., 2003, INFLAMMATION PROTOCO; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003	50	226	231	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					544	560		10.1096/fj.10-169599	http://dx.doi.org/10.1096/fj.10-169599			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20956612	Green Published			2022-12-28	WOS:000286724800013
J	Martino, MM; Hubbell, JA				Martino, Mikael M.; Hubbell, Jeffrey A.			The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain	FASEB JOURNAL			English	Article						extracellular matrix; heparin-binding domain; tissue engineering	HEPARAN-SULFATE; CELL-MIGRATION; EXTRACELLULAR-MATRIX; BIOLOGICAL-ACTIVITY; CONTROLLED-RELEASE; ENDOTHELIAL-CELLS; FIBRIN GELS; VITRONECTIN; PROTEIN; DIFFERENTIATION	It has recently been shown that some growth factors (GFs) have strong interactions with nonproteoglycan extracellular matrix proteins. Relevant here, the 12th-14th type three repeats of fibronectin (FN III12-14) have been shown to bind insulin-like growth factor binding-protein-3, fibroblast growth factor (FGF)-2, and vascular endothelial growth factor (VEGF)-A with high affinity. Since FN III12-14 is known to bind GFs from different families, we hypothesized that this domain could be highly promiscuous in its GF-binding capacity. We used biochemical approaches and surface plasmon resonance to investigate such interactions with recombinant FN III12-14. We found that FN III12-14 binds most of the GFs from the platelet-derived growth factor (PDGF)/VEGF and FGF families and some GFs from the transforming growth factor-beta and neurotrophin families, with K-D values in the nanomolar range, without inhibiting GF activity. Overall, 25 new binding interactions were identified. In a clinically relevant fibrin matrix, a fibrin-binding variant of FN III12-14 was highly effective as a GF delivery system. For instance, in matrices functionalized with FN III12-14, PDGF-BB-induced sprouting of human smooth muscle cell spheroids was greatly enhanced. We show that FN III12-14 is a highly promiscuous ligand for GFs and also holds great potential in clinical healing applications.-Martino, M. M., Hubbell, J. A. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor binding domain. FASEB J. 24, 4711-4721 (2010). www.fasebj.org	[Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Inst Bioengn, Lab Regenerat Med & Pharmacobiol, CH-1015 Lausanne, Switzerland; [Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Inst Chem Sci & Engn, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Hubbell, JA (corresponding author), Ecole Polytech Fed Lausanne, Inst Bioengn, Lab Regenerat Med & Pharmacobiol, Stn 15, CH-1015 Lausanne, Switzerland.	jeffrey.hubbell@epfl.ch	Hubbell, Jeffrey A/A-9266-2008; Martino, Mikaël M/N-9345-2013	Hubbell, Jeffrey A/0000-0003-0276-5456; Martino, Mikaël M/0000-0002-5012-4605	European Community [NMP-LA-2008-214402]; Swiss National Science Foundation	European Community(European Commission); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	The authors thank the Proteomic Core Facility of the Ecole Polytechnique Federale de Lausanne for MALDI-TOF analysis. This work was funded in part by the European Community's Seventh Framework Programme in the project Angioscaff NMP-LA-2008-214402 and by the Swiss National Science Foundation.	BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bossard C, 2004, CANCER RES, V64, P7507, DOI 10.1158/0008-5472.CAN-04-0287; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Droguett R, 2006, MATRIX BIOL, V25, P332, DOI 10.1016/j.matbio.2006.04.004; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Hoshijima M, 2006, FEBS LETT, V580, P1376, DOI 10.1016/j.febslet.2006.01.061; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Kricker JA, 2003, ENDOCRINOLOGY, V144, P2807, DOI 10.1210/en.2002-221086; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; Macri L, 2007, ADV DRUG DELIVER REV, V59, P1366, DOI 10.1016/j.addr.2007.08.015; Mao Y, 2005, MATRIX BIOL, V24, P389, DOI 10.1016/j.matbio.2005.06.008; Martin JA, 2002, OSTEOARTHR CARTILAGE, V10, P556, DOI 10.1053/joca.2002.0791; Martino MM, 2009, BIOMATERIALS, V30, P1089, DOI 10.1016/j.biomaterials.2008.10.047; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; Meijering E, 2004, CYTOM PART A, V58A, P167, DOI 10.1002/cyto.a.20022; Mitsi M, 2006, BIOCHEMISTRY-US, V45, P10319, DOI 10.1021/bi060974p; Mitsi M, 2008, J BIOL CHEM, V283, P34796, DOI 10.1074/jbc.M806692200; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MOSHER DF, 1976, J BIOL CHEM, V251, P1639; Noble A, 2003, ENDOCRINOLOGY, V144, P2417, DOI 10.1210/en.2002-221138; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Patterson J, 2010, MATER TODAY, V13, P14, DOI 10.1016/S1369-7021(10)70013-4; Peng H, 2004, BLOOD, V103, P2114, DOI 10.1182/blood-2003-08-2638; Rahman S, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-8; Sahni A, 2006, BLOOD, V107, P126, DOI 10.1182/blood-2005-06-2460; Sahni A, 1998, J BIOL CHEM, V273, P7554, DOI 10.1074/jbc.273.13.7554; Sakiyama-Elbert SE, 2000, J CONTROL RELEASE, V69, P149, DOI 10.1016/S0168-3659(00)00296-0; Schense JC, 1999, BIOCONJUGATE CHEM, V10, P75, DOI 10.1021/bc9800769; Schoppet M, 2002, LAB INVEST, V82, P37, DOI 10.1038/labinvest.3780393; Schultz GS, 2009, WOUND REPAIR REGEN, V17, P153, DOI 10.1111/j.1524-475X.2009.00466.x; Smith EM, 2009, P NATL ACAD SCI USA, V106, P21683, DOI 10.1073/pnas.0902510106; Taylor SJ, 2004, J CONTROL RELEASE, V98, P281, DOI 10.1016/j.jconrel.2004.05.003; Wijelath ES, 2006, CIRC RES, V99, P853, DOI 10.1161/01.RES.0000246849.17887.66; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Xu QJ, 2004, J BIOL CHEM, V279, P4269, DOI 10.1074/jbc.M311586200; Zisch AH, 2001, J CONTROL RELEASE, V72, P101, DOI 10.1016/S0168-3659(01)00266-8	40	227	232	1	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4711	4721		10.1096/fj.09-151282	http://dx.doi.org/10.1096/fj.09-151282			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20671107				2022-12-28	WOS:000284824400012
J	Mroz, P; Huang, YY; Szokalska, A; Zhiyentayev, T; Janjua, S; Nifli, AP; Sherwood, ME; Ruzie, C; Borbas, KE; Fan, DZ; Krayer, M; Balasubramanian, T; Yang, E; Kee, HL; Kirmaier, C; Diers, JR; Bocian, DF; Holten, D; Lindsey, JS; Hamblin, MR				Mroz, Pawel; Huang, Ying-Ying; Szokalska, Angelika; Zhiyentayev, Timur; Janjua, Sahar; Nifli, Artemissia-Phoebe; Sherwood, Margaret E.; Ruzie, Christian; Borbas, K. Eszter; Fan, Dazhong; Krayer, Michael; Balasubramanian, Thiagarajan; Yang, Eunkyung; Kee, Hooi Ling; Kirmaier, Christine; Diers, James R.; Bocian, David F.; Holten, Dewey; Lindsey, Jonathan S.; Hamblin, Michael R.			Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy	FASEB JOURNAL			English	Article						multidrug resistance; melanosomes; electron microscopy	OVARIAN-CARCINOMA CELLS; MALIGNANT-MELANOMA; ANTITUMOR IMMUNITY; MELANOGENESIS; PHOTOSENSITIZERS; CANCER; OXYGEN; CYCLOPHOSPHAMIDE; SUBSTITUENTS; MELANOCYTES	Cutaneous malignant melanoma remains a therapeutic challenge, and patients with advanced disease have limited survival. Photodynamic therapy (PDT) has been successfully used to treat many malignancies, and it may show promise as an antimelanoma modality. However, high melanin levels in melanomas can adversely affect PDT effectiveness. Herein the extent of melanin contribution to melanoma resistance to PDT was investigated in a set of melanoma cell lines that markedly differ in the levels of pigmentation; 3 new bacteriochlorins successfully overcame the resistance. Cell killing studies determined that bacteriochlorins are superior at (LD50 approximate to 0.1 mu M) when compared with controls such as the FDA-approved Photofrin (LD50 approximate to 10 mu M) and clinically tested LuTex (LD50 approximate to 1 mu M). The melanin content affects PDT effectiveness, but the degree of reduction is significantly lower for bacteriochlorins than for Photofrin. Microscopy reveals that the least effective bacteriochlorin localizes predominantly in lysosomes, while the most effective one preferentially accumulates in mitochondria. Interestingly all bacteriochlorins accumulate in melanosomes, and subsequent illumination leads to melanosomal damage shown by electron microscopy. Fluorescent probes show that the most effective bacteriochlorin produces significantly higher levels of hydroxyl radicals, and this is consistent with the redox properties suggested by molecular-orbital calculations. The best in vitro performing bacteriochlorin was tested in vivo in a mouse melanoma model using spectrally resolved fluorescence imaging and provided significant survival advantage with 20% of cures (P<0.01).-Mroz, P., Huang, Y.-Y., Szokalska, A., Zhiyentayev, T., Janjua, S., Nifli, A.-P., Sherwood, M. E., Ruzie, C., Borbas, K. E., Fan, D., Krayer, M., Balasubramanian, T., Yang, E., Kee, H. L., Kirmaier, C., Diers, J. R., Bocian, D. F., Holten, D., Lindsey, J. S., Hamblin, M. R. Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy. FASEB J. 24, 3160-3170 (2010). www.fasebj.org	[Mroz, Pawel; Huang, Ying-Ying; Szokalska, Angelika; Zhiyentayev, Timur; Janjua, Sahar; Nifli, Artemissia-Phoebe; Sherwood, Margaret E.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Mroz, Pawel; Huang, Ying-Ying; Nifli, Artemissia-Phoebe; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Szokalska, Angelika] Med Univ Warsaw, Dept Immunol, Ctr Biostruct, Warsaw, Poland; [Zhiyentayev, Timur] MIT, Dept Chem, Cambridge, MA 02139 USA; [Janjua, Sahar] Aga Khan Med Coll, Karachi, Pakistan; [Ruzie, Christian; Borbas, K. Eszter; Fan, Dazhong; Krayer, Michael; Lindsey, Jonathan S.] N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA; [Balasubramanian, Thiagarajan] NIRvana Pharmaceut Inc, Raleigh, NC USA; [Yang, Eunkyung; Kee, Hooi Ling; Kirmaier, Christine; Holten, Dewey] Washington Univ, Dept Chem, St Louis, MO 63130 USA; [Diers, James R.; Bocian, David F.] Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Guangxi Medical University; Medical University of Warsaw; Massachusetts Institute of Technology (MIT); University of North Carolina; North Carolina State University; Washington University (WUSTL); University of California System; University of California Riverside; Harvard University; Massachusetts Institute of Technology (MIT)	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019; Mroz, Pawel/P-1258-2019; Muchowicz, Angelika/J-7494-2012; Huang, yingying/J-7329-2012; Lindsey, Jonathan S/J-7761-2012; Nifli, Artemissia-Phoebe/H-6171-2019; Hamblin, Mike/AAB-2511-2022; Huang, Ying-ying/G-3153-2011	Hamblin, Michael R/0000-0001-6431-4605; Muchowicz, Angelika/0000-0003-4707-1722; Huang, yingying/0000-0002-4038-0277; Nifli, Artemissia-Phoebe/0000-0002-8829-7894; Huang, Ying-ying/0000-0003-3066-6981; Krayer, Michael/0000-0002-1945-1181; Mroz, Pawel/0000-0003-3838-4743	NIH [R01GM36238, R01AI050875]; Burroughs-Wellcome fellowship; Jimmy V. NCSU Cancer Therapeutics Training Program; National Institute of Allergy and Infectious Diseases [R41AI072854]; Genzyme-Partners Translational Research; Foundation for Polish Science; International Union against Cancer; European Structural Fund; Division of Chemical Sciences, Geosciences and Biosciences Division, Office of Basic Energy Sciences of the U.S. Department of Energy [DE-FG02-05ER15660, DE-FG02-05ER15661]; NATIONAL CANCER INSTITUTE [R01CA083882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI072854, R01AI050875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036238] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs-Wellcome fellowship(Burroughs Wellcome Fund); Jimmy V. NCSU Cancer Therapeutics Training Program; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Genzyme-Partners Translational Research; Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); International Union against Cancer; European Structural Fund; Division of Chemical Sciences, Geosciences and Biosciences Division, Office of Basic Energy Sciences of the U.S. Department of Energy(United States Department of Energy (DOE)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the NIH (R01GM36238 to J.S.L. and R01AI050875 to M. R. H.), a Burroughs-Wellcome fellowship (to M. K.), and the Jimmy V. NCSU Cancer Therapeutics Training Program. P. M. and T. B. were supported by a grant (R41AI072854) from the National Institute of Allergy and Infectious Diseases to NIRvana Pharmaceuticals. P. M. was partly supported by Genzyme-Partners Translational Research Grant. A. S. was supported by the Foundation for Polish Science, the International Union against Cancer, and the European Structural Fund: Mazowieckie Stypendium Doktoranckie. Characterization of the photophysical and redox properties of the bacteriochlorins described herein was initially motivated by solar-energy studies and supported by grants from the Division of Chemical Sciences, Geosciences and Biosciences Division, Office of Basic Energy Sciences of the U.S. Department of Energy to D. F. B. (DE-FG02-05ER15660) and D. H. (DE-FG02-05ER15661). The authors thank Pharmacyclics (Sunnyvale, CA, USA) for the gift of LuTex and loan of 730-nm laser and QLT (Vancouver, BC, Canada) for the gift of Photofrin.	Ashur I, 2009, J PHYS CHEM A, V113, P8027, DOI 10.1021/jp900580e; Biolo R, 1996, PHOTOCHEM PHOTOBIOL, V63, P224, DOI 10.1111/j.1751-1097.1996.tb03018.x; Borbas KE, 2008, ORG LETT, V10, P1931, DOI 10.1021/ol800436u; Brozyna AA, 2008, INT J CANCER, V123, P1448, DOI 10.1002/ijc.23664; Busetti A, 1999, BRIT J CANCER, V79, P821, DOI 10.1038/sj.bjc.6690131; Carlson JA, 2005, J AM ACAD DERMATOL, V52, P743, DOI 10.1016/j.jaad.2004.08.034; Castano AP, 2008, P NATL ACAD SCI USA, V105, P5495, DOI 10.1073/pnas.0709256105; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4; Chang SK, 2008, CLIN CANCER RES, V14, P4146, DOI 10.1158/1078-0432.CCR-07-4536; Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103; Chen KG, 2009, PIGM CELL MELANOMA R, V22, P740, DOI 10.1111/j.1755-148X.2009.00630.x; Cummins DL, 2006, MAYO CLIN PROC, V81, P500, DOI 10.4065/81.4.500; Dellian M, 1996, INT J CANCER, V65, P246; Fan DZ, 2007, J ORG CHEM, V72, P5350, DOI 10.1021/jo070785s; GRADYUSHKO AT, 1970, PHOTOCHEM PHOTOBIOL, V11, P387, DOI 10.1111/j.1751-1097.1970.tb06011.x; HOLTEN D, 1976, PHOTOCHEM PHOTOBIOL, V23, P415, DOI 10.1111/j.1751-1097.1976.tb07275.x; Hong L, 2006, PHOTOCHEM PHOTOBIOL, V82, P1475, DOI 10.1562/2006-03-14-RA-846; Kee HL, 2007, PHOTOCHEM PHOTOBIOL, V83, P1125, DOI 10.1111/j.1751-1097.2007.00151.x; Kee HL, 2008, J PHOTOCH PHOTOBIO A, V200, P346, DOI 10.1016/j.jphotochem.2008.08.006; Kim HJ, 2005, J ORG CHEM, V70, P5475, DOI 10.1021/jo050467y; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kuroda TS, 2005, METHOD ENZYMOL, V403, P419, DOI 10.1016/S0076-6879(05)03037-5; Lapouge K, 1999, BIOCHEMISTRY-US, V38, P11115, DOI 10.1021/bi990723z; Liu WG, 2007, CLIN CANCER RES, V13, P2463, DOI 10.1158/1078-0432.CCR-06-1599; Liu Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P135, DOI 10.1562/2004-08-03-RA-259.1; Mazor O, 2005, PHOTOCHEM PHOTOBIOL, V81, P342, DOI 10.1562/2004-06-14-RA-199.1; Mennel S, 2007, OPHTHALMOLOGICA, V221, P216, DOI 10.1159/000101922; MROZ P, 2009, P SPIE, V7380; Mroz P, 2009, CANCER LETT, V282, P63, DOI 10.1016/j.canlet.2009.02.054; NAKAYASU M, 1977, J CELL PHYSIOL, V92, P49, DOI 10.1002/jcp.1040920107; *NAT COMPR CANC NE, 2009, NCCN CLIN PRACT GUID; Naylor MF, 2006, BRIT J DERMATOL, V155, P1287, DOI 10.1111/j.1365-2133.2006.07514.x; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; Price M, 2009, PHOTOCHEM PHOTOBIOL, V85, P1177, DOI 10.1111/j.1751-1097.2009.00555.x; Riley PA, 2003, PIGM CELL RES, V16, P548, DOI 10.1034/j.1600-0749.2003.00069.x; Ruzie C, 2008, J ORG CHEM, V73, P5806, DOI 10.1021/jo800736c; Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102; Safaei R, 2005, CLIN CANCER RES, V11, P756; Sapan CV, 1999, BIOTECHNOL APPL BIOC, V29, P99; Setsukinai K, 2003, J BIOL CHEM, V278, P3170, DOI 10.1074/jbc.M209264200; Shao Y, 2006, PHYS CHEM CHEM PHYS, V8, P3172, DOI 10.1039/b517914a; Sheleg SV, 2004, PHOTODERMATOL PHOTO, V20, P21, DOI 10.1111/j.1600-0781.2004.00078.x; Simon JD, 2009, PIGM CELL MELANOMA R, V22, P563, DOI 10.1111/j.1755-148X.2009.00610.x; SLOMINSKI A, 1993, J THEOR BIOL, V164, P103, DOI 10.1006/jtbi.1993.1142; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2001, ARCH PATHOL LAB MED, V125, P1295; Slominski A, 2009, INT J CANCER, V124, P1470, DOI 10.1002/ijc.24005; SOLCA FF, 1993, FEBS LETT, V322, P177, DOI 10.1016/0014-5793(93)81563-F; Su JF, 2008, J NANOSCI NANOTECHNO, V8, P1174, DOI 10.1166/jnn.2008.317; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Szakacs G, 2004, MOL INTERV, V4, P323, DOI 10.1124/mi.4.6.5; Taniguchi M, 2008, NEW J CHEM, V32, P947, DOI 10.1039/b717803d; Trachtenberg J, 2008, BJU INT, V102, P556, DOI 10.1111/j.1464-410X.2008.07753.x; WEBER G, 1957, T FARADAY SOC, V53, P646, DOI 10.1039/tf9575300646; Woodburn KW, 1998, J INVEST DERMATOL, V110, P746, DOI 10.1046/j.1523-1747.1998.00182.x; Yeung P F, 2001, IDrugs, V4, P351	58	78	80	0	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3160	3170		10.1096/fj.09-152587	http://dx.doi.org/10.1096/fj.09-152587			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20385618	Green Published			2022-12-28	WOS:000281446400006
J	Ohnishi, M; Razzaque, MS				Ohnishi, Mutsuko; Razzaque, M. Shawkat			Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging	FASEB JOURNAL			English	Article						klotho; NaPi2a; survival; fertility; emphysema; calcification	SOFT-TISSUE CALCIFICATION; AGE-ASSOCIATED INCREASES; KLOTHO MUTANT MICE; OXIDATIVE STRESS; VITAMIN-D; HOMEOSTASIS; PROTEIN; LEADS; COTRANSPORTER; TRANSCRIPTION	Identifying factors that accelerate the aging process can provide important therapeutic targets for slowing down this process. Misregulation of phosphate homeostasis has been noted in various skeletal, cardiac, and renal diseases, but the exact role of phosphate toxicity in mammalian aging is not clearly defined. Phosphate is widely distributed in the body and is involved in cell signaling, energy metabolism, nucleic acid synthesis, and the maintenance of acid-base balance by urinary buffering. In this study, we used an in vivo genetic approach to determine the role of phosphate toxicity in mammalian aging. Klotho-knockout mice (klotho(-/-)) have a short life span and show numerous physical, biochemical, and morphological features consistent with premature aging, including kyphosis, uncoordinated movement, hypogonadism, infertility, severe skeletal muscle wasting, emphysema, and osteopenia, as well as generalized atrophy of the skin, intestine, thymus, and spleen. Molecular and biochemical analyses suggest that increased renal activity of sodium-phosphate cotransporters (NaPi2a) leads to severe hyperphosphatemia in klotho(-/-) mice. Genetically reducing serum phosphate levels in klotho(-/-) mice by generating a NaPi2a and klotho double-knockout (NaPi2a(-/-)/klotho(-/-)) strain resulted in amelioration of premature aging-like features. The NaPi2a(-/-)/klotho(-/-) double-knockout mice regained reproductive ability, recovered their body weight, reduced their organ atrophy, and suppressed ectopic calcifications, with the resulting effect being prolonged survival. More important, when hyperphosphatemia was induced in NaPi2a(-/-)/klotho(-/-) mice by feeding with a high-phosphate diet, premature aging-like features reappeared, clearly suggesting that phosphate toxicity is the main cause of premature aging in klotho(-/-) mice. The results of our dietary and genetic manipulation studies provide in vivo evidence for phosphate toxicity accelerating the aging process and suggest a novel role for phosphate in mammalian aging.-Ohnishi, M., Razzaque, M. S. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 24, 3562-3571 (2010). www.fasebj.org	[Ohnishi, Mutsuko; Razzaque, M. Shawkat] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA; [Razzaque, M. Shawkat] Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol, Nagasaki 852, Japan	Harvard University; Harvard School of Dental Medicine; Nagasaki University	Razzaque, MS (corresponding author), Harvard Univ, Sch Dent Med, Dept Med Infect & Immun, Res & Educ Bldg,Rm 304,190 Longwood Ave, Boston, MA 02115 USA.	mrazzaque@hms.harvard.edu	Razzaque, Mohammed S./K-4282-2019		National Institute of Diabetes and Digestive and Kidney Disease [R01-DK-077276]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077276] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Parts of this research were supported by National Institute of Diabetes and Digestive and Kidney Disease grant R01-DK-077276 (to M. S. R.).	Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; Edwards MG, 2003, PHYSIOL GENOMICS, V13, P119, DOI 10.1152/physiolgenomics.00172.2002; EVERS BM, 1994, SURG CLIN N AM, V74, P23; Gaasbeek A, 2005, AM J MED, V118, P1094, DOI 10.1016/j.amjmed.2005.02.014; Jang YC, 2010, FASEB J, V24, P1376, DOI 10.1096/fj.09-146308; Judge S, 2005, FASEB J, V19, P419, DOI 10.1096/fj.04-2622fje; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lanske B, 2007, AGEING RES REV, V6, P73, DOI 10.1016/j.arr.2007.02.002; Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91; MARTIN CJ, 1977, AM REV RESPIR DIS, V115, P981; Nakatani T, 2009, FASEB J, V23, P3702, DOI 10.1096/fj.08-123992; Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08-114397; Ohnishi M, 2009, CIRC-CARDIOVASC GENE, V2, P583, DOI 10.1161/CIRCGENETICS.108.847814; Ohnishi M, 2009, KIDNEY INT, V75, P1166, DOI 10.1038/ki.2009.24; Radak Z, 2004, FASEB J, V18, P749, DOI 10.1096/fj.03-0509fje; Rauser CL, 2003, EXP GERONTOL, V38, P27, DOI 10.1016/S0531-5565(02)00148-1; Razzaque MS, 2007, AGEING RES REV, V6, P211, DOI 10.1016/j.arr.2007.06.001; Razzaque MS, 2009, NAT REV ENDOCRINOL, V5, P611, DOI 10.1038/nrendo.2009.196; Razzaque MS, 2009, AM J PHYSIOL-RENAL, V296, pF470, DOI 10.1152/ajprenal.90538.2008; Razzaque MS, 2007, J ENDOCRINOL, V194, P1, DOI 10.1677/JOE-07-0095; Razzaque MS, 2006, TRENDS MOL MED, V12, P298, DOI 10.1016/j.molmed.2006.05.002; Razzaque MS, 1998, NEPHRON, V80, P434, DOI 10.1159/000045217; Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05-5432fje; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; Razzaque MS, 2005, NEPHROL DIAL TRANSPL, V20, P2032, DOI 10.1093/ndt/gfh991; Razzaque MS, 1997, J PATHOL, V183, P24; Razzaque MS, 1999, HISTOCHEM CELL BIOL, V111, P359, DOI 10.1007/s004180050368; Salmon AB, 2009, FASEB J, V23, P3601, DOI 10.1096/fj.08-127415; Segawa H, 2007, AM J PHYSIOL-RENAL, V292, pF769, DOI 10.1152/ajprenal.00248.2006; Sitara D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000154; Tarry-Adkins JL, 2009, FASEB J, V23, P1521, DOI 10.1096/fj.08-122796; Tenenhouse HS, 2005, ANNU REV NUTR, V25, P197, DOI 10.1146/annurev.nutr.25.050304.092642; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Zha Y, 2006, ENDOCRINOLOGY, V147, P5690, DOI 10.1210/en.2006-0302	39	185	191	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3562	3571		10.1096/fj.09-152488	http://dx.doi.org/10.1096/fj.09-152488			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20418498	Green Published			2022-12-28	WOS:000281446400043
J	Yang, CB; Yang, Y; Brennan, L; Bouhassira, EE; Kantorow, M; Cvekl, A				Yang, Chunbo; Yang, Ying; Brennan, Lisa; Bouhassira, Eric E.; Kantorow, Marc; Cvekl, Ales			Efficient generation of lens progenitor cells and lentoid bodies from human embryonic stem cells in chemically defined conditions	FASEB JOURNAL			English	Article						cataract; crystallins; growth factors; Pax6	ALPHA-B-CRYSTALLIN; DIRECTED DIFFERENTIATION; A-CRYSTALLIN; INDUCTION; FGF; MOUSE; GENE; EXPRESSION; CATARACT; NETWORKS	The eye lens is an encapsulated avascular organ whose function is to focus light on the retina. Lens comprises a single progenitor cell lineage in multiple states of differentiation. Disruption of lens function leading to protein aggregation and opacity results in age-onset cataract. Cataract is a complex disease involving genetic and environmental factors. Here, we report the development of a new 3-stage system that differentiates human embryonic stem cells (hESCs) into large quantities of lens progenitor-like cells and differentiated 3-dimensional lentoid bodies. Inhibition of BMP signaling by noggin triggered differentiation of hESCs toward neuroectoderm. Subsequent reactivation of BMP and activation of FGF signaling stimulated formation of lens progenitor cells marked by the expression of PAX6 and alpha-crystallins. The formation of lentoid bodies was most efficient in the presence of FGF2 and Wnt-3a, yielding similar to 1000 lentoid bodies/30-mm well. Lentoid bodies expressed and accumulated lens-specific markers including alpha A-, alpha B-, beta-, and gamma-crystallins, filensin, CP49, and MIP/aquaporin 0. Collectively, these studies identify a novel procedure to generate lens cells from hESCs that can be applied for studies of lens differentiation and cataractogenesis using induced pluripotent stem (iPS) cells derived from various cataract patients.-Yang, C., Yang, Y., Brennan, L., Bouhassira, E. E., Kantorow, M., and Cvekl, A. Efficient generation of lens progenitor cells and lentoid bodies from human embryonic stem cells in chemically defined conditions. FASEB J. 24, 3274-3283 (2010). www.fasebj.org	[Yang, Chunbo; Yang, Ying; Cvekl, Ales] Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci, Bronx, NY 10461 USA; [Yang, Ying; Cvekl, Ales] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA; [Bouhassira, Eric E.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Bouhassira, Eric E.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; [Brennan, Lisa; Kantorow, Marc] Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; State University System of Florida; Florida Atlantic University	Cvekl, A (corresponding author), Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ales.cvekl@einstein.yu.edu	Cvekl, Ales/B-2427-2013; Bouhassira, Eric/AAZ-4184-2021		National Institutes of Health [EY012200, EY014237, EY013022]; Department of Ophthalmology and Visual Sciences of the Albert Einstein College of Medicine; New York State Stem Cell Science (NYSTEM) [N08S-001, N08T-006]; Einstein Human Pluripotent Stem Cell Center [N08S-001]; NATIONAL EYE INSTITUTE [R01EY012200, R01EY013022, R01EY014237] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Ophthalmology and Visual Sciences of the Albert Einstein College of Medicine; New York State Stem Cell Science (NYSTEM); Einstein Human Pluripotent Stem Cell Center; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research for use of their core services. The authors are grateful to Dr. Roy Quinlan for filensin and CP49 antibodies. The authors also thank the West Virginia Eye Bank and Lions Eye Bank of Oregon for providing the human lenses used in this study. This work was supported by National Institutes of Health grants EY012200 (A. C.), EY014237 (A. C.), and EY013022 (M. K.) and the Sisenwein Family Endowment to the Department of Ophthalmology and Visual Sciences of the Albert Einstein College of Medicine. E. E. B. is supported in part by New York State Stem Cell Science (NYSTEM) grants N08S-001 and N08T-006. ESCs were produced by the NSTEM-supported Einstein Human Pluripotent Stem Cell Center (N08S-001).	Bassnett S, 2009, EXP EYE RES, V88, P133, DOI 10.1016/j.exer.2008.08.017; Boswell BA, 2008, DEV BIOL, V324, P202, DOI 10.1016/j.ydbio.2008.09.003; Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018; Chen YJ, 2008, DEV BIOL, V324, P161, DOI 10.1016/j.ydbio.2008.09.002; Cvekl A, 2007, PROG RETIN EYE RES, V26, P555, DOI 10.1016/j.preteyeres.2007.07.002; Dai B, 2007, STEM CELLS, V25, P2567, DOI 10.1634/stemcells.2007-0131; de Longh RU, 2001, DEVELOPMENT, V128, P3995; De Maria A, 2007, INVEST OPHTH VIS SCI, V48, P5638, DOI 10.1167/iovs.07-0782; Faber SC, 2002, DEVELOPMENT, V129, P3727; Furuta Y, 1998, GENE DEV, V12, P3764, DOI 10.1101/gad.12.23.3764; Golebiewska A, 2009, STEM CELLS, V27, P1298, DOI 10.1002/stem.59; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; Hutchins AP, 2009, CELL STEM CELL, V5, P126, DOI 10.1016/j.stem.2009.07.007; Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P973; Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103; Lang RA, 2004, INT J DEV BIOL, V48, P783, DOI 10.1387/ijdb.041903rl; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Litsiou A, 2005, DEVELOPMENT, V132, P4051, DOI 10.1242/dev.01964; Liu Chenglong, 2006, AIDS Res Ther, V3, P6, DOI 10.1186/1742-6405-3-6; Lovicu FJ, 2005, DEV BIOL, V280, P1, DOI 10.1016/j.ydbio.2005.01.020; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Lyu J, 2004, DEVELOPMENT, V131, P1813, DOI 10.1242/dev.01060; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Nishimoto S, 2003, NATURE, V424, P1071, DOI 10.1038/nature01895; Nishiyama A, 2009, CELL STEM CELL, V5, P420, DOI 10.1016/j.stem.2009.07.012; O'Connor MD, 2007, INVEST OPHTH VIS SCI, V48, P1245, DOI 10.1167/iovs.06-0949; Ooto S, 2003, INVEST OPHTH VIS SCI, V44, P2689, DOI 10.1167/iovs.02-1168; Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384; Rajagopal R, 2009, DEV BIOL, V335, P305, DOI 10.1016/j.ydbio.2009.08.027; Robinson ML, 2006, SEMIN CELL DEV BIOL, V17, P726, DOI 10.1016/j.semcdb.2006.10.002; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; SANDILANDS A, 1995, J CELL SCI, V108, P1397; SCHULZ MW, 1993, DEVELOPMENT, V118, P117; Shiels A, 2007, ARCH OPHTHALMOL-CHIC, V125, P165, DOI 10.1001/archopht.125.2.165; Smith AN, 2010, DEV BIOL, V337, P195, DOI 10.1016/j.ydbio.2009.11.009; Stark MR, 2000, MECH DEVELOP, V93, P195, DOI 10.1016/S0925-4773(00)00263-X; Streit A, 2004, DEV BIOL, V276, P1, DOI 10.1016/j.ydbio.2004.08.037; Stump RJW, 2003, DEV BIOL, V259, P48, DOI 10.1016/S0012-1606(03)00179-9; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; VALENZUELA DM, 1995, J NEUROSCI, V15, P6077; VRENSEN GFJM, 1991, EXP EYE RES, V52, P647, DOI 10.1016/0014-4835(91)90017-9; Wagner LM, 2001, MOL VIS, V7, P57; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Wolf L, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-88; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhao HT, 2008, DEV BIOL, V318, P276, DOI 10.1016/j.ydbio.2008.03.028	50	77	87	2	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3274	3283		10.1096/fj.10-157255	http://dx.doi.org/10.1096/fj.10-157255			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20410439	Green Published			2022-12-28	WOS:000281446400016
J	Pastorino, S; Renganathan, H; Caliva, MJ; Filbert, EL; Opoku-Ansah, J; Sulzmaier, FJ; Gawecka, JE; Werlen, G; Shaw, AS; Ramos, JW				Pastorino, Sandra; Renganathan, Hemamalini; Caliva, Maisel J.; Filbert, Erin L.; Opoku-Ansah, John; Sulzmaier, Florian J.; Gawecka, Joanna E.; Werlen, Guy; Shaw, Andrey S.; Ramos, Joe W.			The death effector domain protein PEA-15 negatively regulates T-cell receptor signaling	FASEB JOURNAL			English	Article						ERK MAP kinase; IL-2; proliferation; Jurkat T cells	MAP KINASE; ACTIVATION; PROLIFERATION; EXPRESSION; SELECTION; FAMILY; PHOSPHORYLATION; TRANSCRIPTION; SPECIFICITY; ASTROCYTES	PEA-15 is a death effector domain-containing phosphoprotein that binds ERK and restricts it to the cytoplasm. PEA-15 also binds to FADD and thereby blocks apoptosis induced by death receptors. Abnormal expression of PEA-15 is associated with type II diabetes and some cancers; however, its physiological function remains unclear. To determine the function of PEA-15 in vivo, we used C57BL/6 mice in which the PEA-15 coding region was deleted. We thereby found that PEA-15 regulates T-cell proliferation. PEA-15-null mice did not have altered thymic or splenic lymphocyte cellularity or differentiation. However, PEA-15 deficient T cells had increased CD3/CD28-induced nuclear translocation of ERK and increased activation of IL-2 transcription and secretion in comparison to control wild-type littermates. Indeed, activation of the T-cell receptor in wild-type mice caused PEA-15 release of ERK. In contrast, overexpression of PEA-15 in Jurkat T cells blocked nuclear translocation of ERK and IL-2 transcription. Finally, PEA-15-null T cells showed increased IL-2 dependent proliferation on stimulation. No differences in T cell susceptibility to apoptosis were found. Thus, PEA-15 is a novel player in T-cell homeostasis. As such this work may have far reaching implications in understanding how the immune response is controlled.-Pastorino, S., Renganathan, H., Caliva, M. J., Filbert, E. L., Opoku-Ansah, J., Sulzmaier, F. J., Gawecka, J. E., Werlen, G., Shaw, A. S., Ramos, J. W. The death effector domain protein PEA-15 negatively regulates T-cell receptor signaling. FASEB J. 24, 2818-2828 (2010). www.fasebj.org	[Pastorino, Sandra; Renganathan, Hemamalini; Caliva, Maisel J.; Opoku-Ansah, John; Sulzmaier, Florian J.; Gawecka, Joanna E.; Ramos, Joe W.] Univ Hawaii Manoa, Canc Res Ctr Hawaii, Nat Prod & Canc Biol Program, Honolulu, HI 96813 USA; [Filbert, Erin L.; Shaw, Andrey S.] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA; [Werlen, Guy] Rutgers State Univ, Canc Inst New Jersey, Dept Cell Biol & Neurosci, Piscataway, NJ USA; [Shaw, Andrey S.] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; Washington University (WUSTL); Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Howard Hughes Medical Institute; Washington University (WUSTL)	Ramos, JW (corresponding author), Univ Hawaii Manoa, Canc Res Ctr Hawaii, Nat Prod & Canc Biol Program, Biosci Bldg,Rm 241C,651 Ilalo St, Honolulu, HI 96813 USA.	jramos@crch.hawaii.edu	Ramos, Joe/G-4074-2010	Ramos, Joe/0000-0002-9708-2115	New Jersey Commission on Cancer Research [08-1089-CCR-EO]; National Cancer Institute of the NIH [CA03849]; NATIONAL CANCER INSTITUTE [R01CA093849] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003061, P20RR018727] Funding Source: NIH RePORTER	New Jersey Commission on Cancer Research; National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The authors thank Dr. Herve Chneiweiss (Centre Paul Broca, Paris, France) for providing the original PEA-15<SUP>-/-</SUP> mice. The authors thank E. Collier for expert technical assistance and Dr. P. Hoffmann for helpful suggestions. The authors also thank Drs. Y. Shimizu and M. Matter for critically reviewing this manuscript. The authors thank the staff of the University of Hawaii at Manoa Centers of Biomedical Research Excellence (COBRE; P20RR018727) and Research Centers in Minority Institutions (RCMI; G12RR003061), National Center for Resource Resources, NIH flow cytometry core facility for excellent technical assistance. G.W. is supported by the New Jersey Commission on Cancer Research, grant 08-1089-CCR-EO. This work was supported by the National Cancer Institute of the NIH (CA03849 to J.W.R.). S.P. designed and performed experiments, analyzed the data, and wrote the manuscript; H.R., M.J.C., F.J.S., and E.L.F. designed and performed experiments and analyzed the data; J.E.G. and J.O-A. performed experiments; J.W.R., G.W., and A.S.S. designed experiments, analyzed the data and edited the manuscript. The authors declare that they have no competing financial interests.	Agrawal A, 2006, J IMMUNOL, V176, P5788, DOI 10.4049/jimmunol.176.10.5788; Alberola-Ila J, 2003, IMMUNOL REV, V191, P79, DOI 10.1034/j.1600-065X.2003.00012.x; Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Chou FL, 2003, J BIOL CHEM, V278, P52587, DOI 10.1074/jbc.M309322200; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Daniels MA, 2006, NATURE, V444, P724, DOI 10.1038/nature05269; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Dumont FJ, 1998, J IMMUNOL, V160, P2579; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Fischer AM, 2005, IMMUNITY, V23, P431, DOI 10.1016/j.immuni.2005.08.013; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Gervais M, 2006, MOL BIOL CELL, V17, P3940, DOI 10.1091/mbc.E06-06-0501; Horejsi V, 2004, NAT REV IMMUNOL, V4, P603, DOI 10.1038/nri1414; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Krueger J, 2005, MOL BIOL CELL, V16, P3552, DOI 10.1091/mbc.E04-11-1007; Li YQ, 1999, IMMUNOLOGY, V96, P524; Luschen S, 2005, EXP CELL RES, V310, P33, DOI 10.1016/j.yexcr.2005.07.022; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McNeil LK, 2005, P NATL ACAD SCI USA, V102, P13574, DOI 10.1073/pnas.0505110102; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; PARK JH, 1993, BLOOD, V82, P2470; Ramos Joe W, 2005, Hawaii Med J, V64, P77; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Vaidyanathan H, 2007, P NATL ACAD SCI USA, V104, P19837, DOI 10.1073/pnas.0704514104; Valmiki MG, 2009, CELL MOL LIFE SCI, V66, P814, DOI 10.1007/s00018-008-8489-0; Wang XQ, 2008, J IMMUNOL, V180, P6703, DOI 10.4049/jimmunol.180.10.6703; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; Wu JN, 2004, SEMIN IMMUNOL, V16, P379, DOI 10.1016/j.smim.2004.08.018; Zhong XP, 2003, NAT IMMUNOL, V4, P882, DOI 10.1038/ni958	41	15	15	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2818	2828		10.1096/fj.09-144295	http://dx.doi.org/10.1096/fj.09-144295			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20354143	Green Published			2022-12-28	WOS:000285005400022
J	Harper, JM; Wilkinson, JE; Miller, RA				Harper, James M.; Wilkinson, J. Erby; Miller, Richard A.			Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction	FASEB JOURNAL			English	Article						MIF; CR; life span; cancer; inflammation	AUGSBURG CASE-COHORT; FACTOR MIF; LIFE-SPAN; FACTOR GENE; RHEUMATOID-ARTHRITIS; PROSTATE-CANCER; GROWTH; INFLAMMATION; EXPRESSION; GLUCOSE	Macrophage migration inhibitory factor (MIF) affects inflammation, glucose homeostasis, and cellular proliferation in mammals. Previously, we found that MIF was significantly elevated in multiple long-lived mouse models, including calorie restriction (CR), which led us to hypothesize that MIF might be important in the control of mammalian life span and be necessary for the life-extending effects of CR. To test this hypothesis, we examined the life span of mice with a targeted deletion of the Mif gene on a segregating B6 x 129/Sv background (MIF-KO) under ad libitum (AL) feeding and CR conditions. Control mice were generated by mating C57BL/6J females with 129/SvJ males to make an F1 hybrid, and crossing F1 males to F1 females to produce segregating F2 mice homozygous for the normal MIF allele. Not only did MIF-KO mice show a life span extension in response to CR, they were, unexpectedly, longer lived than controls under standard AL conditions. MIF-KO mice were significantly protected against lethal hemangiosarcoma, but more likely than controls to die of disseminated amyloid, an age-related inflammatory syndrome. Overall, these data refute the suggestion that MIF is required for the CR effect on life span, but raise the possibility that MIF may limit life span in normal mice.-Harper, J.M., Wilkinson, J.E., Miller, R.A. Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction. FASEB J. 24, 2436-2442 (2010). www.fasebj.org	[Harper, James M.; Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Harper, James M.; Miller, Richard A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA; [Wilkinson, J. Erby] Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA; [Miller, Richard A.] Ann Arbor Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Harper, JM (corresponding author), Rm 3005,BSRB,Box 2200,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	jmharper@umich.edu		Harper, James/0000-0003-0765-8828	U.S. National Institutes of Health [AG023122, AG024824, AG013283]; NATIONAL INSTITUTE ON AGING [P30AG013283, U19AG023122, P30AG024824] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Melissa Burns, Maggie Lauderdale, and Jessica Sewald for technical assistance. The work was supported by U.S. National Institutes of Health grants AG023122, AG024824, and AG013283. The authors report no conflict of interest.	Al-Regaiey KA, 2007, J GERONTOL A-BIOL, V62, P18, DOI 10.1093/gerona/62.1.18; Anahara R, 2006, REPROD TOXICOL, V21, P167, DOI 10.1016/j.reprotox.2005.08.001; Awandare GA, 2009, J INFECT DIS, V200, P629, DOI 10.1086/600894; Bach JP, 2008, ONCOLOGY-BASEL, V75, P127, DOI 10.1159/000155223; Bacher M, 1997, AM J PATHOL, V150, P235; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Bell EL, 2007, MOL CELL BIOL, V27, P5737, DOI 10.1128/MCB.02265-06; Bocheva A., 2008, Autonomic & Autacoid Pharmacology, V28, P117, DOI 10.1111/j.1474-8673.2008.00425.x; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Bucala R, 1996, FASEB J, V10, P1607, DOI 10.1096/fasebj.10.14.9002552; Burger-Kentischer A, 2002, CIRCULATION, V105, P1561, DOI 10.1161/01.CIR.0000012942.49244.82; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Cavigelli SA, 2003, P NATL ACAD SCI USA, V100, P16131, DOI 10.1073/pnas.2535721100; Cavigelli SA, 2006, HORM BEHAV, V50, P454, DOI 10.1016/j.yhbeh.2006.06.001; Cvetkovic I, 2006, INT IMMUNOPHARMACOL, V6, P1527, DOI 10.1016/j.intimp.2006.06.009; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Denz A, 2010, J SURG RES, V160, P29, DOI 10.1016/j.jss.2009.03.048; Ding GX, 2009, J SURG ONCOL, V100, P106, DOI 10.1002/jso.21304; Fingerle-Rowson G, 2003, AM J PATHOL, V162, P47, DOI 10.1016/S0002-9440(10)63797-2; Fingerle-Rowson GR, 2001, IMMUNOL CELL BIOL, V79, P368, DOI 10.1046/j.1440-1711.2001.01024.x; Fingerle-Rowson G, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-22; Flaster H, 2007, MOL ENDOCRINOL, V21, P1267, DOI 10.1210/me.2007-0065; GANGULY R, 1986, ALLERGOL IMMUNOPATH, V14, P1; GANGULY R, 1985, Allergie und Immunologie (Leipzig), V31, P203; Hagemann T, 2007, MOL CANCER THER, V6, P1993, DOI 10.1158/1535-7163.MCT-07-0118; Hardman MJ, 2005, AM J PATHOL, V167, P1561, DOI 10.1016/S0002-9440(10)61241-2; Herder C, 2008, DIABETOLOGIA, V51, P276, DOI 10.1007/s00125-007-0800-3; Herder C, 2006, DIABETES CARE, V29, P368, DOI 10.2337/diacare.29.02.06.dc05-1474; HOGENESCH H, 1993, VIRCHOWS ARCH B, V64, P37, DOI 10.1007/BF02915094; Honda A, 2009, CARCINOGENESIS, V30, P1597, DOI 10.1093/carcin/bgp160; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; HUAXIANG XH, 2009, CANCER, V115, P5441; Koska J, 2009, INT J OBESITY, V33, P842, DOI 10.1038/ijo.2009.106; Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248; Martin J, 2009, FASEB J, V23, P720, DOI 10.1096/fj.08-119628; Masternak MM, 2006, EXP GERONTOL, V41, P417, DOI 10.1016/j.exger.2006.01.009; Mehta R, 2009, SCIENCE, V324, P1196, DOI 10.1126/science.1173507; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x; Miller RA, 2002, MOL ENDOCRINOL, V16, P2657, DOI 10.1210/me.2002-0142; Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002; Mizue Y, 2000, INT J MOL MED, V5, P397; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Morand EF, 2005, INTERN MED J, V35, P419, DOI 10.1111/j.1445-5994.2005.00853.x; Nemajerova A, 2007, EMBO J, V26, P987, DOI 10.1038/sj.emboj.7601564; Ohkawara T, 2008, SCAND J GASTROENTERO, V43, P1497, DOI 10.1080/00365520802273017; Paiva CN, 2009, J LEUKOCYTE BIOL, V85, P855, DOI 10.1189/jlb.0108009; Pan JH, 2004, CIRCULATION, V109, P3149, DOI 10.1161/01.CIR.0000134704.84454.D2; RACHELLE D, 2002, ARTHRITIS RHEUM, V46, P2402; Radstake TRDJ, 2005, ARTHRITIS RHEUM, V52, P3020, DOI 10.1002/art.21285; Rendon BE, 2009, EXP MOL PATHOL, V86, P180, DOI 10.1016/j.yexmp.2009.01.001; Rohrbach S, 2008, BIOGERONTOLOGY, V9, P169, DOI 10.1007/s10522-008-9126-x; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Stosic-Grujicic S, 2008, J CELL PHYSIOL, V215, P665, DOI 10.1002/jcp.21346; Stosic-Grujicic S, 2009, AUTOIMMUN REV, V8, P244, DOI 10.1016/j.autrev.2008.07.037; Taylor JA, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-135; Thorand B, 2007, DIABETES CARE, V30, P854, DOI 10.2337/dc06-1693; Toso C, 2008, DIABETOLOGIA, V51, P1937, DOI 10.1007/s00125-008-1063-3; Turturro A, 2002, J GERONTOL A-BIOL, V57, pB379, DOI 10.1093/gerona/57.11.B379; Verschuren L, 2009, CIRC RES, V105, P99, DOI 10.1161/CIRCRESAHA.109.199166; Wang CX, 2004, MECH AGEING DEV, V125, P629, DOI 10.1016/j.mad.2004.07.003; Weindruch R., 1988, RETARDATION AGING DI; Welford SM, 2006, GENE DEV, V20, P3366, DOI 10.1101/gad.1471106; Wilson JM, 2005, GASTROENTEROLOGY, V129, P1485, DOI 10.1053/j.gastro.2005.07.061; Winner M, 2008, CANCER RES, V68, P7253, DOI 10.1158/0008-5472.CAN-07-6227; Xu XD, 2008, CANCER LETT, V261, P147, DOI 10.1016/j.canlet.2007.11.028; Yabunaka N, 2000, DIABETES CARE, V23, P256, DOI 10.2337/diacare.23.2.256; Yee JR, 2008, PSYCHOSOM MED, V70, P1050, DOI 10.1097/PSY.0b013e31818425fb; YOSHITAKA S, 2003, GASTROENTEROLOGY, V124, P725; Zhang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006348	71	50	52	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2436	2442		10.1096/fj.09-152223	http://dx.doi.org/10.1096/fj.09-152223			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20219983	Green Submitted, Green Published			2022-12-28	WOS:000279343600030
J	Kalinowski, A; Plowes, NJR; Huang, QH; Berdejo-Izquierdo, C; Russell, RR; Russell, KS				Kalinowski, April; Plowes, Nicola J. R.; Huang, Qunhua; Berdejo-Izquierdo, Carla; Russell, Raymond R.; Russell, Kerry S.			Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells	FASEB JOURNAL			English	Article						epidermal growth factors; cytokines; inflammation; angiogenesis	AMYLOID PRECURSOR PROTEIN; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR; INTERFERON-GAMMA; CYTOPLASMIC TAIL; KINASE-C; HB-EGF; ANGIOGENESIS; INTERLEUKIN-6; EXPRESSION	Inflammation is often accompanied by robust angiogenesis. Vascular endothelial cells (ECs) express erbB receptors and their ligand, neuregulin-1, and can respond to neuregulin by proliferation and angiogenesis. We hypothesized that some growth factor-like responses of ECs to inflammatory cytokines can be explained by cleavage of transmembrane neuregulin with subsequent release of its extracellular epidermal growth factor-like-containing domain and autocrine activation. Using a model of cultured human ECs, we found that interleukin-6 or interferon-gamma causes rapid cleavage and release of transmembrane neuregulin. Inhibitors of metalloproteinases abolish this effect. The addition of an inhibitor of tumor necrosis factor-alpha converting enzyme (TACE) blocks cytokine-induced neuregulin release. Silencing of TACE expression increases the amount of basal proneuregulin present in ECs but does not block neuregulin release in response to phorbol myristate acetate (PMA), suggesting that other proteinases are responsible for mediating protein kinase C-dependent cleavage. Cytokines capable of inducing neuregulin cleavage stimulated ERK activation and in vitro angiogenesis (Matrigel cord formation). This effect is blocked by inhibitors that block neuregulin cleavage, erbB protein tyrosine kinase inhibitors, or antineuregulin-neutralizing antibodies. Cytokine-activated metalloproteinase cleavage of neuregulin may play an important role in autocrine activation of EC signaling pathways, contributing to key biological effects, perhaps including inflammation-associated angiogenesis.-Kalinowski, A., Plowes, N.J.R., Huang, Q., Berdejo-Izquierdo, C., Russell, R. R., Russell, K. S. Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. FASEB J. 24, 2567-2575 (2010). www.fasebj.org	[Kalinowski, April; Plowes, Nicola J. R.; Huang, Qunhua; Berdejo-Izquierdo, Carla; Russell, Raymond R.; Russell, Kerry S.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA	Yale University	Russell, KS (corresponding author), 316 FMP,333 Cedar St, New Haven, CT 06520 USA.	kerry.russell@yale.edu	Plowes, Nicola/N-9748-2019	Plowes, Nicola/0000-0003-2187-499X	U.S. National Heart, Lung, and Blood Institute [K08 HL004429, R01 HL080176]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080176, K08HL004429] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Lawrence H. Young, David F. Stern, and Jeffrey R. Bender for helpful suggestions. This study was supported by U.S. National Heart, Lung, and Blood Institute grants K08 HL004429 and R01 HL080176 (to K.S.R.).	Barillari G, 1999, J IMMUNOL, V163, P1929; Ben-Hur T, 2006, J NEUROIMMUNOL, V175, P12, DOI 10.1016/j.jneuroim.2006.02.002; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Cote GM, 2005, EXP CELL RES, V311, P135, DOI 10.1016/j.yexcr.2005.08.017; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Fan F, 2004, CANCER RES, V64, P3186, DOI 10.1158/0008-5472.CAN-03-0407; Hernandez-Rodriguez J, 2003, CIRCULATION, V107, P2428, DOI 10.1161/01.CIR.0000066907.83923.32; Herrlich A, 2004, P NATL ACAD SCI USA, V101, P15799, DOI 10.1073/pnas.0406853101; Herrlich A, 2008, FASEB J, V22, P4281, DOI 10.1096/fj.08-113852; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kuramochi Y, 2004, J BIOL CHEM, V279, P51141, DOI 10.1074/jbc.M408662200; Kurohara K, 2004, DEV BIOL, V267, P14, DOI 10.1016/j.ydbio.2003.10.021; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; Penkowa M, 2003, J NEUROSCI RES, V73, P481, DOI 10.1002/jnr.10681; PFAU S, 1995, J CELL BIOL, V128, P969, DOI 10.1083/jcb.128.5.969; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; Sanderson MP, 2006, GROWTH FACTORS, V24, P121, DOI 10.1080/08977190600634373; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Singh RJR, 2005, CARDIOVASC RES, V67, P39, DOI 10.1016/j.cardiores.2005.02.020; Trompezinski S, 2002, EXP DERMATOL, V11, P224, DOI 10.1034/j.1600-0625.2002.110305.x; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Wessely R, 2005, CARDIOVASC RES, V66, P433, DOI 10.1016/j.cardiores.2005.03.013; Wu AJ, 1997, J CELL PHYSIOL, V171, P117, DOI 10.1002/(SICI)1097-4652(199705)171:2<117::AID-JCP1>3.0.CO;2-R; Zhou HM, 2004, MOL CELL BIOL, V24, P96, DOI 10.1128/MCB.24.1.96-104.2004	33	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2567	2575		10.1096/fj.08-129072	http://dx.doi.org/10.1096/fj.08-129072			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20215529	Green Published			2022-12-28	WOS:000279343600043
J	Ghosh, A; Chawla-Sarkar, M; Stuehr, DJ				Ghosh, Arnab; Chawla-Sarkar, Mamta; Stuehr, Dennis J.			Hsp90 interacts with inducible NO synthase client protein in its heme-free state and then drives heme insertion by an ATP-dependent process	FASEB JOURNAL			English	Article						heme-deficient; heme-replete; chaperone; cytokines; cardiovascular	NITRIC-OXIDE SYNTHASE; HEAT-SHOCK-PROTEIN; CHAPERONE MACHINERY; DIMERIZATION INHIBITORS; PROTEOLYTIC DEGRADATION; SUPEROXIDE GENERATION; SUBUNIT DIMERIZATION; MOLECULAR CHAPERONE; ENDOTHELIAL-CELLS; ABC TRANSPORTER	Maturation of NOS enzymes requires that they incorporate heme to become active, but how this cellular process occurs is unclear. We investigated a role for chaperone heat shock protein 90 (hsp90) in enabling heme insertion into the cytokine-inducible mouse NOS. We used macrophage cell line RAW 264.7 and human embryonic kidney HEK293T cells and studied insertion of native heme during iNOS expression and insertion of exogenous heme into preformed apo-iNOS. Pulldown experiments showed that the hsp90-iNOS complex was present in cells, but the extent of their association was inversely related to iNOS heme content. Hsp90 was primarily associated with apo-iNOS monomer and was associated 11-fold less with heme-containing iNOS monomer or dimer in cells. Kinetic studies showed that hsp90 dissociation occurred coincident with cellular heme insertion into apo-iNOS (0.8 h(-1)). The hsp90 inhibitor radicicol or coexpression of an ATPase-defective hsp90 blocked heme insertion into apo-iNOS by 90 and 75%, respectively. The ATPase activity of hsp90 was not required for complex formation with iNOS but was essential for heme insertion to occur. We conclude that hsp90 plays a primary role in maturation of iNOS protein by interacting with the apoenzyme in cells and then driving heme insertion in an ATP-dependent manner.-Ghosh, A., Chawla-Sarkar, M., Stuehr, D. J. Hsp90 interacts with inducible NO synthase client protein in its heme-free state and then drives heme insertion by an ATP-dependent process. FASEB J. 25, 2049-2060 (2011). www.fasebj.org	[Ghosh, Arnab; Stuehr, Dennis J.] Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA; [Chawla-Sarkar, Mamta] Natl Inst Cholera & Enter Dis, Div Virol, Kolkata, India	Cleveland Clinic Foundation; Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED)	Stuehr, DJ (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Pathobiol NC22, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org		GHOSH, ARNAB/0000-0002-7498-1994	U.S. National Institutes of Health [CA53914, GM51491, HL076491]; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs. W. Sessa and A. Papapetropoulos for providing hsp90 constructs. This work was supported by U.S. National Institutes of Health grants CA53914, GM51491, and HL076491 (to D.J.S.).	Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; Antonova G, 2007, CLIN HEMORHEOL MICRO, V37, P19; Aschner JL, 2009, AM J PHYSIOL-LUNG C, V296, pL555, DOI 10.1152/ajplung.90456.2008; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Billecke SS, 2004, J BIOL CHEM, V279, P30252, DOI 10.1074/jbc.M403864200; Blasko E, 2002, J BIOL CHEM, V277, P295, DOI 10.1074/jbc.M105691200; Burkhard KA, 2008, BIOCHEMISTRY-US, V47, P7977, DOI 10.1021/bi801005u; Chakravarti R, 2010, P NATL ACAD SCI USA, V107, P18004, DOI 10.1073/pnas.1008133107; Clapp KM, 2010, J BIOL CHEM, V285, P33642, DOI 10.1074/jbc.M110.159178; Daff S, 2010, NITRIC OXIDE-BIOL CH, V23, P1, DOI 10.1016/j.niox.2010.03.001; DeZwaan DC, 2008, CELL CYCLE, V7, P1006, DOI 10.4161/cc.7.8.5723; Dunbar AY, 2004, MOL PHARMACOL, V66, P964, DOI 10.1124/mol.104.000125; Fairchild TA, 2001, J BIOL CHEM, V276, P26674, DOI 10.1074/jbc.M103647200; Feissner RE, 2006, MOL MICROBIOL, V61, P219, DOI 10.1111/j.1365-2958.2006.05221.x; Fleming I, 2010, PFLUG ARCH EUR J PHY, V459, P793, DOI 10.1007/s00424-009-0767-7; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Hemmens B, 1998, BIOCHEM J, V332, P337, DOI 10.1042/bj3320337; Joly AL, 2010, J INNATE IMMUN, V2, P238, DOI 10.1159/000296508; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Kolodziejski PJ, 2004, P NATL ACAD SCI USA, V101, P18141, DOI 10.1073/pnas.0406711102; Kone BC, 2003, AM J PHYSIOL-RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003; Marozkina NV, 2010, P NATL ACAD SCI USA, V107, P11393, DOI 10.1073/pnas.0909128107; Martinez-Ruiz A, 2005, P NATL ACAD SCI USA, V102, P8525, DOI 10.1073/pnas.0407294102; Miao RQ, 2008, ARTERIOSCL THROM VAS, V28, P105, DOI 10.1161/ATVBAHA.107.155499; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Nedvetsky PI, 2008, FEBS LETT, V582, P327, DOI 10.1016/j.febslet.2007.12.025; Noguchi S, 2000, J BIOL CHEM, V275, P2376, DOI 10.1074/jbc.275.4.2376; Osawa Y, 2003, J PHARMACOL EXP THER, V304, P493, DOI 10.1124/jpet.102.035055; Panda K, 2005, P NATL ACAD SCI USA, V102, P10117, DOI 10.1073/pnas.0408972102; Panda K, 2006, J BIOL CHEM, V281, P36819, DOI 10.1074/jbc.M606129200; Pant K, 2005, J MOL BIOL, V352, P932, DOI 10.1016/j.jmb.2005.07.070; Papapetropoulos A, 2005, MOL PHARMACOL, V68, P1133, DOI 10.1124/mol.105.012682; Porter JR, 2010, CURR OPIN CHEM BIOL, V14, P412, DOI 10.1016/j.cbpa.2010.03.019; Pratt WB, 2008, J BIOL CHEM, V283, P22885, DOI 10.1074/jbc.R800023200; Pratt WB, 2010, EXP BIOL MED, V235, P278, DOI 10.1258/ebm.2009.009250; Prodromou C, 2009, CURR TOP MED CHEM, V9, P1352, DOI 10.2174/156802609789895656; Retzlaff M, 2009, EMBO REP, V10, P1147, DOI 10.1038/embor.2009.153; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Sennequier N, 1999, J BIOL CHEM, V274, P930, DOI 10.1074/jbc.274.2.930; Severance S, 2009, CHEM REV, V109, P4596, DOI 10.1021/cr9001116; Song Y, 2002, BIOCHEMISTRY-US, V41, P10616, DOI 10.1021/bi026060u; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Sud N, 2007, AM J PHYSIOL-LUNG C, V293, pL1444, DOI 10.1152/ajplung.00175.2007; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Vaughan CK, 2010, NAT STRUCT MOL BIOL, V17, P1400, DOI 10.1038/nsmb1210-1400; Waheed SM, 2010, FREE RADICAL BIO MED, V48, P1548, DOI 10.1016/j.freeradbiomed.2010.02.038; Walerych D, 2010, J BIOL CHEM, V285, P32020, DOI 10.1074/jbc.M110.112110; Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200; Xu H, 2007, J BIOL CHEM, V282, P37567, DOI 10.1074/jbc.M706464200; Yoshida M, 2003, J BIOL CHEM, V278, P36953, DOI 10.1074/jbc.M305214200	55	52	52	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					2049	2060		10.1096/fj.10-180554	http://dx.doi.org/10.1096/fj.10-180554			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21357526	Green Published			2022-12-28	WOS:000291023800027
J	Chang, WP; Huang, XP; Downs, D; Cirrito, JR; Koelsch, G; Holtzman, DM; Ghosh, AK; Tang, J				Chang, Wan-Pin; Huang, Xiangping; Downs, Deborah; Cirrito, John R.; Koelsch, Gerald; Holtzman, David M.; Ghosh, Arun K.; Tang, Jordan			beta-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice	FASEB JOURNAL			English	Article						Alzheimer's disease; Tg2576; memapsin 2	AMYLOID PRECURSOR PROTEIN; TG2576 MOUSE MODEL; ALZHEIMERS-DISEASE; A-BETA; MEMORY DEFICITS; KNOCKOUT MICE; BRAIN; BACE1; IDENTIFICATION; THERAPEUTICS	Alzheimer disease is intimately linked to an excess amount of amyloid-beta (A beta) in the brain. Thus, therapeutic inhibition of A beta production is an attractive clinical approach to treat this disease. Here we provide the first direct experimental evidence that the treatment of Tg2576 transgenic mice with an inhibitor of beta-secretase, GRL-8234, rescues the age-related cognitive decline. We demonstrated that the injected GRL-8234 effectively enters the brain and rapidly decreases soluble A beta in the brain of Tg2576 mice. The rescue of cognition, which was observed only after long-term inhibitor treatment ranging from 5 to 7.5 mo, was associated with a decrease of brain amyloid-beta plaque load. We also found no accumulation of amyloid-beta precursor protein after several months of inhibitor treatment. These observations substantiate the idea that A beta accumulation plays a major role in the cognitive decline of Tg2576 mice and support the concept of A beta reduction therapy as a treatment of AD.-Chang, W.-P., Huang, X., Downs, D., Cirrito, J. R., Koelsch, G., Holtzman, D. M. Ghosh, A. K., Tang, J. beta-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 25, 775-784 (2011). www.fasebj.org	[Chang, Wan-Pin; Huang, Xiangping; Downs, Deborah; Tang, Jordan] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA; [Tang, Jordan] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; [Cirrito, John R.; Holtzman, David M.] Washington Univ, Sch Med, Microdialysis Core Facil, Dept Neurol, St Louis, MO USA; [Koelsch, Gerald] CoMentis Inc, Oklahoma City, OK USA; [Ghosh, Arun K.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Washington University (WUSTL); Purdue University System; Purdue University; Purdue University West Lafayette Campus	Tang, J (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Prot Studies Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	jordan-tang@omrf.org			U.S. National Institutes of Health (NIH) [AG-18933]; Alzheimer Association; NIH [P20 RR 15577-07]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018933] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer Association(Alzheimer's AssociationBrightFocus Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Michelle Nicolle for comments and suggestions; Dr. J. Donald Capra for critical reading of the manuscript; Dr. Geoffrey Bilcer for arranging the synthesis of the inhibitor; Dr. William Sonntag, Dr. Matthew Mitschelen, and Julie Farley for the use of facility and advice; and Huining Da and Darby Kinsey for excellent technical assistance. This work was supported in part by U.S. National Institutes of Health (NIH) grant AG-18933 and an Alzheimer Association Pioneer Award (to J. T.) and NIH COBRE/IDeA grant P20 RR 15577-07 (to W.-P. C.). J. T. is holder of the J. G. Puterbaugh Chair in Biomedical Research at the Oklahoma Medical Research Foundation.	Barten Donna M, 2006, Drugs R D, V7, P87, DOI 10.2165/00126839-200607020-00003; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chang WP, 2004, J NEUROCHEM, V89, P1409, DOI 10.1111/j.1471-4159.2004.02452.x; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Comery TA, 2005, J NEUROSCI, V25, P8898, DOI 10.1523/JNEUROSCI.2693-05.2005; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; Garcia MF, 2004, NEUROREPORT, V15, P73, DOI 10.1097/00001756-200401190-00015; Ghosh AK, 2008, NEUROTHERAPEUTICS, V5, P399, DOI 10.1016/j.nurt.2008.05.007; Ghosh AK, 2008, CURR ALZHEIMER RES, V5, P121, DOI 10.2174/156720508783954730; Ghosh AK, 2008, BIOORG MED CHEM LETT, V18, P1031, DOI 10.1016/j.bmcl.2007.12.028; Han BH, 2008, J NEUROSCI, V28, P13542, DOI 10.1523/JNEUROSCI.4686-08.2008; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P646, DOI 10.1016/S1044-7431(03)00227-6; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hu XY, 2010, J NEUROSCI, V30, P8819, DOI 10.1523/JNEUROSCI.1334-10.2010; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Laird FM, 2005, J NEUROSCI, V25, P11693, DOI 10.1523/JNEUROSCI.2766-05.2005; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; REMY C, 2000, P INT SOC MAG RESON, V8, P100; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vetrivel KS, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-4; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Whitehouse PJ, 1998, ALZ DIS ASSOC DIS, V12, P281, DOI 10.1097/00002093-199812000-00007; Wolfe MS, 2008, CURR ALZHEIMER RES, V5, P158, DOI 10.2174/156720508783954767; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	36	88	95	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					775	784		10.1096/fj.10-167213	http://dx.doi.org/10.1096/fj.10-167213			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21059748	Green Published, Bronze			2022-12-28	WOS:000286724800034
J	Stow, LR; Jacobs, ME; Wingo, CS; Cain, BD				Stow, Lisa R.; Jacobs, Mollie E.; Wingo, Charles S.; Cain, Brian D.			Endothelin-1 gene regulation	FASEB JOURNAL			English	Review						preproendothelin-1; edn1 promoter; transcription factors; ET-1	PROTEIN-KINASE-C; MESSENGER-RNA EXPRESSION; OBSTRUCTIVE SLEEP-APNEA; COLLECTING DUCT CELLS; GATA-BINDING PROTEIN; INDUCIBLE FACTOR-I; PREPROENDOTHELIN-1 GENE; TRANSCRIPTION FACTOR; ACTIVATOR PROTEIN-1; SMOOTH-MUSCLE	Over two decades of research have demonstrated that the peptide hormone endothelin-1 (ET-1) plays multiple, complex roles in cardiovascular, neural, pulmonary, reproductive, and renal physiology. Differential and tissue-specific production of ET-1 must be tightly regulated in order to preserve these biologically diverse actions. The primary mechanism thought to control ET-1 bioavailability is the rate of transcription from the ET-1 gene (edn1). Studies conducted on a variety of cell types have identified key transcription factors that govern edn1 expression. With few exceptions, the cis-acting elements bound by these factors have been mapped in the edn1 regulatory region. Recent evidence has revealed new roles for some factors originally believed to regulate edn1 in a tissue or hormone-specific manner. In addition, other mechanisms involved in epigenetic regulation and mRNA stability have emerged as important processes for regulated edn1 expression. The goal of this review is to provide a comprehensive overview of the specific factors and signaling systems that govern edn1 activity at the molecular level.-Stow, L. R., Jacobs, M. E., Wingo, C. S., Cain, B. D. Endothelin-1 gene regulation. FASEB J. 25, 16-28 (2011). www.fasebj.org	[Stow, Lisa R.; Jacobs, Mollie E.; Cain, Brian D.] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; [Stow, Lisa R.; Wingo, Charles S.] Univ Florida, Dept Med, Gainesville, FL 32610 USA; [Wingo, Charles S.] N Florida S Georgia Vet Affairs Med Ctr, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cain, BD (corresponding author), Univ Florida, Dept Biochem & Mol Biol, POB 100245, Gainesville, FL 32610 USA.	bcain@ufl.edu			U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Disease [1R01DK082680]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082680] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Financial support for this work was provided by U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Disease grant 1R01DK082680.	Abman SH, 2009, ANNU REV MED, V60, P13, DOI 10.1146/annurev.med.59.110106.212434; Aharinejad S, 2005, AM J TRANSPLANT, V5, P2185, DOI 10.1111/j.1600-6143.2005.01006.x; Aitsebaomo J, 2004, J BIOL CHEM, V279, P17963, DOI 10.1074/jbc.M311721200; Aitsebaomo J, 2001, J BIOL CHEM, V276, P39197, DOI 10.1074/jbc.M105166200; Aydemir ABC, 2010, BONE, V46, P167, DOI 10.1016/j.bone.2009.08.061; Bagnato A, 2008, CAN J PHYSIOL PHARM, V86, P473, DOI 10.1139/Y08-058; Barton M, 2008, CAN J PHYSIOL PHARM, V86, P485, DOI 10.1139/Y08-059; Barton M, 2008, NAT CLIN PRACT NEPHR, V4, P490, DOI 10.1038/ncpneph0891; Belaidi E, 2009, J AM COLL CARDIOL, V53, P1309, DOI 10.1016/j.jacc.2008.12.050; BENATTI L, 1993, J CLIN INVEST, V91, P1149, DOI 10.1172/JCI116274; Blais V, 2002, FEBS LETT, V524, P43, DOI 10.1016/S0014-5793(02)02998-8; Bohm F, 2007, CARDIOVASC RES, V76, P8, DOI 10.1016/j.cardiores.2007.06.004; Boesen EI, 2008, AM J PHYSIOL-RENAL, V295, pF446, DOI 10.1152/ajprenal.00095.2008; Brewer Alison, 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000093; Bu X, 1997, J BIOL CHEM, V272, P32613, DOI 10.1074/jbc.272.51.32613; Bulow R, 2007, BIOCHEM PHARMACOL, V74, P1747, DOI 10.1016/j.bcp.2007.08.023; Castanares C, 2007, J CELL SCI, V120, P1256, DOI 10.1242/jcs.03419; Castro MG, 2007, ANN HUM GENET, V71, P601, DOI 10.1111/j.1469-1809.2007.00351.x; Cernacek P, 2003, CAN J PHYSIOL PHARM, V81, P598, DOI 10.1139/Y03-052; Chao HH, 2005, EUR J PHARMACOL, V515, P1, DOI 10.1016/j.ejphar.2005.03.035; Chao HH, 2007, EUR J PHARMACOL, V573, P49, DOI 10.1016/j.ejphar.2007.06.051; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chauhan BC, 2008, CAN J OPHTHALMOL, V43, P356, DOI 10.3129/i08-060; Chen SL, 2010, AM J PHYSIOL-ENDOC M, V298, pE127, DOI 10.1152/ajpendo.00432.2009; Cheng TH, 2001, J MOL CELL CARDIOL, V33, P1805, DOI 10.1006/jmcc.2001.1444; Comellas AP, 2009, TRANSL RES, V153, P263, DOI 10.1016/j.trsl.2009.02.007; Corder R, 2001, NATURE, V414, P863, DOI 10.1038/414863a; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Dashwood MR, 2010, J CELL COMMUN SIGNAL, V4, P51, DOI 10.1007/s12079-009-0073-3; Davenport AP, 2002, PHARMACOL REV, V54, P219, DOI 10.1124/pr.54.2.219; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Dhaun N, 2008, HYPERTENSION, V52, P452, DOI 10.1161/HYPERTENSIONAHA.108.117366; Dickson J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000804; Doi T, 2008, AM J PHYSIOL-HEART C, V295, pH1279, DOI 10.1152/ajpheart.00148.2008; Doi Y, 2004, J CARDIOVASC PHARM, V44, pS207, DOI 10.1097/01.fjc.0000166235.18959.2a; Doi Y, 2002, HISTOL HISTOPATHOL, V17, P97, DOI 10.14670/HH-17.97; Donckier JE, 2006, CLIN ENDOCRINOL, V64, P703, DOI 10.1111/j.1365-2265.2006.02535.x; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; Douglas ML, 2004, CANCER-AM CANCER SOC, V100, P2118, DOI 10.1002/cncr.20222; Drunat S, 2002, FREE RADICAL BIO MED, V33, P659, DOI 10.1016/S0891-5849(02)00957-7; Dschietzig T, 2001, BIOCHEM BIOPH RES CO, V289, P245, DOI 10.1006/bbrc.2001.5946; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Ergul A, 2000, J CARD FAIL, V6, P314, DOI 10.1054/jcaf.2000.19227; FABBRINI MS, 1991, FEBS LETT, V286, P91, DOI 10.1016/0014-5793(91)80948-3; Foschi M, 2001, J AM SOC NEPHROL, V12, P1137, DOI 10.1681/ASN.V1261137; Geese WJ, 2008, PHARMACOGENET GENOM, V18, P903, DOI 10.1097/FPC.0b013e32830a6ea0; Gitton Y, 2010, SEMIN CELL DEV BIOL, V21, P301, DOI 10.1016/j.semcdb.2010.01.008; Glenn DJ, 2009, CARDIOVASC RES, V84, P209, DOI 10.1093/cvr/cvp208; Golden CL, 1998, AM J PHYSIOL-LUNG C, V274, pL854, DOI 10.1152/ajplung.1998.274.5.L854; Good TJ, 2010, EXPERT OPIN THER TAR, V14, P647, DOI 10.1517/14728222.2010.487065; Gowher H, 2008, GENE DEV, V22, P2075, DOI 10.1101/gad.1658408; Gumz ML, 2003, AM J PHYSIOL-RENAL, V285, pF664, DOI 10.1152/ajprenal.00353.2002; Hans G, 2009, BRAIN RES REV, V60, P36, DOI 10.1016/j.brainresrev.2008.12.008; HARRISON VJ, 1995, P NATL ACAD SCI USA, V92, P6344, DOI 10.1073/pnas.92.14.6344; Herrera M, 2005, AM J PHYSIOL-RENAL, V288, pF58, DOI 10.1152/ajprenal.00209.2004; HU RM, 1994, J CLIN INVEST, V93, P1056, DOI 10.1172/JCI117055; IMAI T, 1992, HYPERTENSION, V19, P753, DOI 10.1161/01.HYP.19.6.753; INOUE A, 1989, J BIOL CHEM, V264, P14954; Ivey ME, 2008, ATHEROSCLEROSIS, V199, P237, DOI 10.1016/j.atherosclerosis.2008.03.006; Jimenez R, 2007, FREE RADICAL BIO MED, V43, P462, DOI 10.1016/j.freeradbiomed.2007.05.007; Karkoulias K, 2010, CURR MED CHEM, V17, P1059; KAWAGUCHI Y, 1994, ANN RHEUM DIS, V53, P506, DOI 10.1136/ard.53.8.506; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Khan ZA, 2006, EXP BIOL MED, V231, P1022; Khimji AK, 2010, CELL SIGNAL, V22, P1615, DOI 10.1016/j.cellsig.2010.05.002; KITAZUMI K, 1993, BIOCHEM PHARMACOL, V46, P455; Kohan DE, 2006, CURR OPIN NEPHROL HY, V15, P34, DOI 10.1097/01.mnh.0000186852.15889.1a; Kohan DE, 2010, CURR OPIN NEPHROL HY, V19, P134, DOI 10.1097/MNH.0b013e328335f91f; Kohan DE, 2009, KIDNEY INT, V76, P481, DOI 10.1038/ki.2009.203; Kugelmeier P, 2008, J PANCREAS, V9, P133; KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Kuwahara-Watanabe K, 2005, J VASC RES, V42, P183, DOI 10.1159/000084656; Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; Lehrke I, 2001, J AM SOC NEPHROL, V12, P2321, DOI 10.1681/ASN.V12112321; Liu JC, 2003, HYPERTENSION, V42, P1198, DOI 10.1161/01.HYP.0000103162.76220.51; Lowenstein CJ, 2005, TRENDS CARDIOVAS MED, V15, P302, DOI 10.1016/j.tcm.2005.09.005; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MARSDEN PA, 1991, AM J PHYSIOL, V261, pF117, DOI 10.1152/ajprenal.1991.261.1.F117; MARSEN TA, 1995, CIRC RES, V76, P987, DOI 10.1161/01.RES.76.6.987; Mawji IA, 2004, J BIOL CHEM, V279, P8655, DOI 10.1074/jbc.M312190200; Meidan R, 2007, TRENDS ENDOCRIN MET, V18, P379, DOI 10.1016/j.tem.2007.09.002; MIGAS I, 1995, AM J HYPERTENS, V8, P748, DOI 10.1016/0895-7061(95)00115-6; Miller RL, 1998, J LAB CLIN MED, V131, P45, DOI 10.1016/S0022-2143(98)90076-2; Minchenko A, 2000, MOL CELL BIOCHEM, V208, P53, DOI 10.1023/A:1007042729486; Moretti S, 2009, HISTOL HISTOPATHOL, V24, P849, DOI 10.14670/HH-24.849; NAKAMURA T, 1993, LANCET, V342, P1147, DOI 10.1016/0140-6736(93)92126-E; Nemer G, 2002, DEVELOPMENT, V129, P4045; Nicholson SK, 2010, BRIT J NUTR, V103, P1398, DOI 10.1017/S0007114509993485; OHTA K, 1990, BIOCHEM BIOPH RES CO, V169, P578, DOI 10.1016/0006-291X(90)90370-3; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; Park JY, 2003, BIOCHEM BIOPH RES CO, V303, P891, DOI 10.1016/S0006-291X(03)00436-4; Patel N, 2008, BLOOD, V112, P856, DOI 10.1182/blood-2007-12-130567; Pegorier S, 2007, J ALLERGY CLIN IMMUN, V120, P1301, DOI 10.1016/j.jaci.2007.09.023; Phillips BG, 1999, J HYPERTENS, V17, P61, DOI 10.1097/00004872-199917010-00010; Pickering V, 2007, ORAL ONCOL, V43, P37, DOI 10.1016/j.oraloncology.2005.12.027; Pitts KR, 2009, EXPERT OPIN INV DRUG, V18, P135, DOI [10.1517/13543780802680186, 10.1517/13543780802680186 ]; Popowski K, 2003, PHARMACOGENETICS, V13, P445, DOI 10.1097/00008571-200308000-00002; Porter KE, 2009, PHARMACOL THERAPEUT, V123, P255, DOI 10.1016/j.pharmthera.2009.05.002; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; Quehenberger P, 2002, CIRC RES, V90, P711, DOI 10.1161/01.RES.0000014226.74709.90; Ramos-Casals M, 2010, NAT REV RHEUMATOL, V6, P269, DOI 10.1038/nrrheum.2010.48; Rehsia NS, 2010, HEART FAIL REV, V15, P85, DOI 10.1007/s10741-009-9152-z; Reiter CEN, 2010, ENDOCRINOLOGY, V151, P103, DOI 10.1210/en.2009-0997; Rodriguez-Pascual F, 2003, CIRC RES, V92, P1288, DOI 10.1161/01.RES.0000078491.79697.7F; Rodriguez-Pascual F, 2008, MOL CELL BIOL, V28, P7139, DOI 10.1128/MCB.01145-08; Ross B, 2010, AM J RESP CELL MOL, V42, P16, DOI 10.1165/rcmb.2009-0175TR; SAITO S, 1995, J CARDIOVASC PHARM, V26, pS84; Schnermann JB, 1996, ENDOCRINOLOGY, V137, P5000, DOI 10.1210/en.137.11.5000; Shichiri M, 1997, ENDOCRINOLOGY, V138, P4584, DOI 10.1210/en.138.11.4584; SHIMADA K, 1995, BIOCHEM BIOPH RES CO, V207, P807, DOI 10.1006/bbrc.1995.1258; Spirig R, 2009, MOL IMMUNOL, V46, P3178, DOI 10.1016/j.molimm.2009.05.179; Stow LR, 2009, J BIOL CHEM, V284, P30087, DOI 10.1074/jbc.M109.030718; Strait KA, 2007, AM J PHYSIOL-RENAL, V293, pF601, DOI 10.1152/ajprenal.00085.2007; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Strzalka-Mrozik B, 2010, MOL VIS, V16, P1272; Takanashi M, 2004, J CARDIOVASC PHARM, V44, pS268, DOI 10.1097/01.fjc.0000166282.01034.8f; Terragni J, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-6; Thaete LG, 2007, BIOL REPROD, V77, P526, DOI 10.1095/biolreprod.107.061820; Thorin E, 2010, PFLUG ARCH EUR J PHY, V459, P951, DOI 10.1007/s00424-009-0763-y; ToddTurla KM, 1996, AM J PHYSIOL-RENAL, V271, pF330, DOI 10.1152/ajprenal.1996.271.2.F330; Tsai YH, 2006, EXP BIOL MED, V231, P813; Vallender TW, 2006, FEBS LETT, V580, P4560, DOI 10.1016/j.febslet.2006.07.017; Vieux-Rochas M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000510; Viger RS, 2008, MOL ENDOCRINOL, V22, P781, DOI 10.1210/me.2007-0513; Vollmar B, 2009, PHYSIOL REV, V89, P1269, DOI 10.1152/physrev.00027.2008; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; Winker R, 2005, AM J MED SCI, V330, P166, DOI 10.1097/00000441-200510000-00003; Wolf SC, 2006, BIOCHEM PHARMACOL, V71, P1175, DOI 10.1016/j.bcp.2006.01.001; Wort SJ, 2009, J BIOL CHEM, V284, P24297, DOI 10.1074/jbc.M109.032524; Xiong JW, 1999, DEV BIOL, V206, P123, DOI 10.1006/dbio.1998.9144; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yang Z, 2008, LIFE SCI, V82, P512, DOI 10.1016/j.lfs.2007.12.005; Yeligar S, 2009, J IMMUNOL, V183, P5232, DOI 10.4049/jimmunol.0901084; Yokota J, 2001, ATHEROSCLEROSIS, V159, P491, DOI 10.1016/S0021-9150(01)00530-5; Zhang JL, 2009, INT J CLIN EXP MED, V2, P87; Zhang Y, 2006, PEPTIDES, V27, P3003, DOI 10.1016/j.peptides.2006.04.014; Zhang ZF, 2006, BRIT J NUTR, V96, P418, DOI 10.1079/BJN20061854; Zhu G, 2008, GENES IMMUN, V9, P23, DOI 10.1038/sj.gene.6364441	146	150	155	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					16	28		10.1096/fj.10-161612	http://dx.doi.org/10.1096/fj.10-161612			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20837776	Green Published			2022-12-28	WOS:000285869500002
J	Garcia-Haro, L; Garcia-Gimeno, MA; Neumann, D; Beullens, M; Bollen, M; Sanz, P				Garcia-Haro, Luisa; Garcia-Gimeno, Maria Adelaida; Neumann, Dietbert; Beullens, Monique; Bollen, Mathieu; Sanz, Pascual			The PP1-R6 protein phosphatase holoenzyme is involved in the glucose-induced dephosphorylation and inactivation of AMP-activated protein kinase, a key regulator of insulin secretion, in MIN6 beta cells	FASEB JOURNAL			English	Article						beta-cell function; glucose regulation; metabolic regulation; energy metabolism	SKELETAL-MUSCLE; SNF1; PHOSPHORYLATION; SUBUNIT; ENERGY; BINDING; ROLES; LKB1; INHIBITION; UPSTREAM	Mammalian AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase that acts as a sensor of cellular energy status. It is activated by phosphorylation of the catalytic subunit on Thr172. The main objective of this study was the identification of a phosphatase involved in the regulation of AMPK activity. Mouse MIN6 beta cells were used to study the glucose-induced regulation of the phosphorylation of AMPK. Small interfering RNA (siRNA) technology was used to deplete putative phosphatase candidate genes that could affect AMPK regulation. The effect of the siRNAs used in the study was compared with the effect observed using a negative control siRNA. A protein phosphatase complex composed of the catalytic subunit of protein phosphatase-1 (PP1) and the regulatory subunit R6 participates in the glucose-induced dephosphorylation of AMPK. R6 interacts physically with the beta-subunit of the AMPK complex and recruits PP1 to dephosphorylate the catalytic alpha-subunit on Thr172. siRNA depletion of R6 decreases glucose-induced insulin secretion due to the presence of a constitutively active AMPK complex. The characterization of the PP1-R6 complex identifies this holoenzyme as a possible target for therapeutic intervention with the aim of regulating the activity of AMPK in pancreatic beta cells.-Garcia- Haro, L., Garcia-Gimeno, M. A., Neumann, D., Beullens, M., Bollen, M., Sanz, P. The PP1-R6 protein phosphatase holoenzyme is involved in the glucoseinduced dephosphorylation and inactivation of AMP activated protein kinase, a key regulator of insulin secretion, in MIN6 beta cells. FASEB J. 24, 5080-5091 (2010). www.fasebj.org	[Garcia-Haro, Luisa; Garcia-Gimeno, Maria Adelaida; Sanz, Pascual] CSIC, Inst Biomed Valencia, Valencia 46010, Spain; [Garcia-Haro, Luisa; Garcia-Gimeno, Maria Adelaida; Sanz, Pascual] Ctr Invest Red Enfermecedes Raras, Valencia, Spain; [Neumann, Dietbert] Swiss Fed Inst Technol, Inst Cell Biol, Zurich, Switzerland; [Beullens, Monique; Bollen, Mathieu] Univ Leuven, Dept Mol Cell Biol, Lab Biosignaling & Therapeut, Leuven, Belgium	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Swiss Federal Institutes of Technology Domain; ETH Zurich; KU Leuven	Sanz, P (corresponding author), CSIC, Inst Biomed Valencia, Jaime Roig 11, Valencia 46010, Spain.	sanz@ibv.csic.es	García-Gimeno, María Adelaida/K-9855-2014; Sanz, Pascual/K-2751-2014	García-Gimeno, María Adelaida/0000-0002-6483-3912; Sanz, Pascual/0000-0002-2399-4103; , Luisa/0000-0003-0519-9322; Neumann, Dietbert/0000-0002-4316-684X	Spanish Ministry of Education and Science [SAF2008-01907]; Generalitat Valenciana (Prometeo) [2009/051]; European Commission [LSHM-CT-2004-005272]	Spanish Ministry of Education and Science(Spanish Government); Generalitat Valenciana (Prometeo)(Center for Forestry Research & Experimentation (CIEF)); European Commission(European CommissionEuropean Commission Joint Research Centre)	The authors thank Dr. Jun-Ichi Miyazaki (Osaka University, Osaka, Japan) for the MIN6 beta cells, Dr. Joan Guinovart (Institute for Research in Biomedicine, Barcelona, Spain) for the generous gift of anti-glucokinase antibodies, and Dr. Matthew Gentry (University of Kentucky, Lexington, KY, USA) for the pcDNA3.1/myc-His-R6 plasmid. This work was supported by a grant from the Spanish Ministry of Education and Science (SAF2008-01907), by a grant from Generalitat Valenciana (Prometeo 2009/051), and by EXGENESIS, an Integrated Project (LSHM-CT-2004-005272) of the European Commission (to P.S.).	Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Bollen M, 2010, TRENDS BIOCHEM SCI, V35, P450, DOI 10.1016/j.tibs.2010.03.002; Browne GJ, 2001, BIOCHEM J, V360, P449, DOI 10.1042/0264-6021:3600449; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; da Silva Xavier Gabriela, 2003, Biochem J, V371, P761, DOI 10.1042/BJ20021812; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Gimeno-Alcaniz JV, 2003, J MOL BIOL, V333, P201, DOI 10.1016/j.jmb.2003.08.022; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hendrickx A, 2009, CHEM BIOL, V16, P365, DOI 10.1016/j.chembiol.2009.02.012; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Itani SI, 2003, DIABETES, V52, P1635, DOI 10.2337/diabetes.52.7.1635; Kimball SR, 2004, J BIOL CHEM, V279, P54103, DOI 10.1074/jbc.M410755200; Leclerc I, 2004, DIABETES, V53, pS67, DOI 10.2337/diabetes.53.suppl_3.S67; Lesage B, 2007, BIOCHEMISTRY-US, V46, P8909, DOI 10.1021/bi7003119; Leturque A, 2009, AM J PHYSIOL-ENDOC M, V296, pE985, DOI 10.1152/ajpendo.00004.2009; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; Mangat S, 2010, EUKARYOT CELL, V9, P173, DOI 10.1128/EC.00267-09; Matschinsky FM, 2009, NAT REV DRUG DISCOV, V8, P399, DOI 10.1038/nrd2850; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Momcilovic M, 2008, J BIOL CHEM, V283, P19521, DOI 10.1074/jbc.M803624200; Mountjoy PD, 2007, DIABETOLOGIA, V50, P168, DOI 10.1007/s00125-006-0473-3; Mukhtar MH, 2008, AM J PHYSIOL-REG I, V294, pR766, DOI 10.1152/ajpregu.00593.2007; Munro S, 2005, FEBS J, V272, P1478, DOI 10.1111/j.1742-4658.2005.04585.x; Orlova M, 2008, YEAST, V25, P745, DOI 10.1002/yea.1628; Rubenstein EM, 2008, J BIOL CHEM, V283, P222, DOI 10.1074/jbc.M707957200; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; Rutter GA, 2004, DIABETOLOGIA, V47, P1861, DOI 10.1007/s00125-004-1541-1; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Sanz P, 2008, CURR PROTEIN PEPT SC, V9, P478, DOI 10.2174/138920308785915254; Scholz R, 2009, J BIOL CHEM, V284, P27425, DOI 10.1074/jbc.M109.047670; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Steinberg GR, 2006, CELL METAB, V4, P465, DOI 10.1016/j.cmet.2006.11.005; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Sugden C, 1999, PLANT J, V19, P433, DOI 10.1046/j.1365-313X.1999.00532.x; Sun G, 2010, DIABETOLOGIA, V53, P924, DOI 10.1007/s00125-010-1692-1; Sun G, 2010, AM J PHYSIOL-ENDOC M, V298, pE1261, DOI 10.1152/ajpendo.00100.2010; Suter M, 2006, J BIOL CHEM, V281, P32207, DOI 10.1074/jbc.M606357200; TANG PM, 1991, J BIOL CHEM, V266, P15782; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Tsuboi T, 2003, J BIOL CHEM, V278, P52042, DOI 10.1074/jbc.M307800200; Vernia S, 2009, J BIOL CHEM, V284, P8247, DOI 10.1074/jbc.M808492200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Xie Z, 2008, CIRCULATION, V117, P952, DOI 10.1161/CIRCULATIONAHA.107.744490	56	57	57	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5080	5091		10.1096/fj.10-166306	http://dx.doi.org/10.1096/fj.10-166306			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20724523				2022-12-28	WOS:000284824400046
J	Hegge, S; Kudryashev, M; Barniol, L; Frischknecht, F				Hegge, Stephan; Kudryashev, Mikhail; Barniol, Luis; Frischknecht, Friedrich			Key factors regulating Plasmodium berghei sporozoite survival and transformation revealed by an automated visual assay	FASEB JOURNAL			English	Article						glucose; bicarbonate; screening; Apicomplexa; differentiation	MALARIA PARASITES; TRANSCRIPTION FACTOR; MOSQUITO; CELLS; STAGE; IDENTIFICATION; TRANSMISSION; FALCIPARUM; THOUSANDS; TARGET	Malaria is transmitted to the host when Plasmodium sporozoites are injected by a mosquito vector. Sporozoites eventually enter hepatocytes, where they differentiate into liver-stage parasites. During the first hours after hepatocyte invasion, the crescent-shaped sporozoites transform into spherical intracellular exoerythrocytic parasites. This process, which precedes genome replication, can be mimicked in vitro in the absence of host cells. Here, we developed an automated method to follow transformation and cell death of sporozoites in vitro. This assay provides a rapid tool to test sporozoite survival and to screen for antiparasitic drugs. We found that extracellular bicarbonate and high temperature trigger transformation, whereas physiological serum albumin concentrations and media lacking bicarbonate delayed sporozoite death. Because bicarbonate also triggers ookinete transformation and exflagellation of gametocytes, we suggest that a common molecular mechanism regulates similar aspects of stage conversion in Plasmodium.-Hegge, S., Kudryashev, M., Barniol, L., Frischknecht, F. Key factors regulating Plasmodium berghei sporozoite survival and transformation revealed by an automated visual assay. FASEB J. 24, 5003-5012 (2010). www.fasebj.org	[Hegge, Stephan; Kudryashev, Mikhail; Barniol, Luis; Frischknecht, Friedrich] Univ Heidelberg, Sch Med, Dept Infect Dis, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Frischknecht, F (corresponding author), Univ Heidelberg, Sch Med, Dept Infect Dis, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	freddy.frischknecht@med.uni-heidelberg.de		Kudryashev, Misha/0000-0003-3550-6274; Frischknecht, Friedrich/0000-0002-8332-6668	Federal German Ministry for Education and Research (BioFuture and National Genome Research Network); German Research Foundation [SFB544]; University of Heidelberg Medical School; Cluster of Excellence CellNetworks; Chica and Heinz Schaller Foundation	Federal German Ministry for Education and Research (BioFuture and National Genome Research Network)(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG)); University of Heidelberg Medical School; Cluster of Excellence CellNetworks; Chica and Heinz Schaller Foundation	The authors thank Jenny Pestel for help with the experiments, Diana Scheppan and Iris Arnold for mosquito infection, Alexander Rotmann for discussion, and Ann-Kristin Muller, Claudia Kuss, Steffen Borrmann, Maria Mota, and Carina Gomes-Santos for comments on the article. This work was funded by the Federal German Ministry for Education and Research (BioFuture and National Genome Research Network) and the German Research Foundation through SFB544. Support from the University of Heidelberg Medical School, the Cluster of Excellence CellNetworks, and the Chica and Heinz Schaller Foundation is gratefully acknowledged. F. F. is a member of the European Network of Excellence European Virtual Institute of Malaria Research.	Amino R, 2006, NAT MED, V12, P220, DOI 10.1038/nm1350; Butcher GA, 1996, EXP PARASITOL, V84, P371, DOI 10.1006/expr.1996.0125; Cunha-Rodrigues Margarido, 2006, Biotechnology Journal, V1, P321, DOI 10.1002/biot.200500038; Ejigiri I, 2009, CURR OPIN MICROBIOL, V12, P401, DOI 10.1016/j.mib.2009.06.006; Frischknecht F, 2004, CELL MICROBIOL, V6, P687, DOI 10.1111/j.1462-5822.2004.00395.x; Gamo FJ, 2010, NATURE, V465, P305, DOI 10.1038/nature09107; Guiguemde WA, 2010, NATURE, V465, P311, DOI 10.1038/nature09099; Kaiser K, 2003, J EXP MED, V197, P1045, DOI 10.1084/jem.20022100; Lingelbach K, 1998, J CELL SCI, V111, P1467; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; MEIS JFGM, 1983, NATURE, V302, P424, DOI 10.1038/302424a0; NIJHOUT MM, 1978, PARASITOLOGY, V76, P39, DOI 10.1017/S0031182000047375; Prudencio M, 2006, NAT REV MICROBIOL, V4, P849, DOI 10.1038/nrmicro1529; Prudencio M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000201; RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706; Rodrigues CD, 2008, CELL HOST MICROBE, V4, P271, DOI 10.1016/j.chom.2008.07.012; Sidjanski S, 1997, AM J TROP MED HYG, V57, P426, DOI 10.4269/ajtmh.1997.57.426; Silvie O, 2006, CELL MICROBIOL, V8, P1134, DOI 10.1111/j.1462-5822.2006.00697.x; TSUJI M, 1994, PARASITOL RES, V80, P16, DOI 10.1007/BF00932618; Vanderberg JP, 2004, INT J PARASITOL, V34, P991, DOI 10.1016/j.ijpara.2004.05.005; Yuda M, 2010, MOL MICROBIOL, V75, P854, DOI 10.1111/j.1365-2958.2009.07005.x; Yuda M, 2009, MOL MICROBIOL, V71, P1402, DOI 10.1111/j.1365-2958.2009.06609.x; Zhang M, 2010, J EXP MED, V207, P1, DOI 10.1084/jem.20091975	23	16	16	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5003	5012		10.1096/fj.10-164814	http://dx.doi.org/10.1096/fj.10-164814			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20798246				2022-12-28	WOS:000284824400038
J	Li, B; Castano, AP; Hudson, TE; Nowlin, BT; Lin, SL; Bonventre, JV; Swanson, KD; Duffield, JS				Li, Bing; Castano, Ana P.; Hudson, Thomas E.; Nowlin, Brian T.; Lin, Shuei-Liong; Bonventre, Joseph V.; Swanson, Kenneth D.; Duffield, Jeremy S.			The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair	FASEB JOURNAL			English	Article						autophagy; macrophages; phagocytosis	EPITHELIAL-CELLS; APOPTOTIC CELLS; KIDNEY INJURY; DICTYOSTELIUM-DISCOIDEUM; PHAGOSOME MATURATION; THERAPEUTIC TARGET; IN-VIVO; MACROPHAGES; AUTOPHAGY; PATHWAY	Kidney damage due to injury rarely resolves completely, and there are currently no therapies capable of promoting repair. In addition to understanding mechanisms by which tissues are damaged, illuminating mechanisms of repair and regeneration is also of great importance. Here we show that the melanoma-associated, transmembrane glycoprotein, Gpnmb, is up-regulated 15-fold following ischemic damage in kidney tissue and by more than 10-fold in macrophages and 3-fold in surviving epithelial cells. Gpnmb-expressing macrophages and epithelial cells were found to contain apoptotic bodies at 3 times the rate of non-expressing cells. Either mutation of Gpnmb or ablation of inflammatory macrophages prevents normal repair of the kidney. Significantly, the kidneys from postischemic Gpnmb mutant mice exhibited a 5-fold increase in apoptotic cellular debris compared to wild-type mice. These mice also experienced an 85% increase in mortality following bilateral ischemic kidney. Finally, we demonstrate that Gpnmb is a phagocytic protein that is necessary for recruitment of the autophagy protein LC3 to the phagosome where these proteins are colocalized and for lysosomal fusion with the phagosome and hence bulk degradation of their content. Therefore, Gpnmb is a novel prorepair gene that is necessary for crosstalk between the macroautophagic degradation pathway and phagocytosis.-Li, B., Castano, A. P., Hudson, T. E., Nowlin, B. T., Lin, S.-L., Bonventre, J. V., Swanson, K. D., Duffield, J. S. The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J. 24, 4767-4781 (2010). www.fasebj.org	[Duffield, Jeremy S.] Brigham & Womens Hosp, Inflammat Res Lab, Div Renal, Boston, MA 02115 USA; [Li, Bing; Castano, Ana P.; Hudson, Thomas E.; Nowlin, Brian T.; Lin, Shuei-Liong; Bonventre, Joseph V.; Duffield, Jeremy S.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Li, Bing] Harbin Med Coll, Affiliated Hosp 2, Dept Nephrol, Harbin, Peoples R China; [Swanson, Kenneth D.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harbin Medical University; Harvard University; Beth Israel Deaconess Medical Center	Duffield, JS (corresponding author), Brigham & Womens Hosp, Inflammat Res Lab, Div Renal, 5th Floor,4 Blackfan Circle, Boston, MA 02115 USA.	kswanson@bidmc.harvard.edu; jduffield@rics.bwh.harvard.edu	Lin, Shuei-Liong/AGR-2002-2022	Lin, Shuei-Liong/0000-0002-1041-5571	U.S. National Institutes of Health (NIH) [DK073299, DK84077]; American Society of Nephrology; Kidney Research UK; NIH [GM041890]; Genzyme Renal Initiatives Program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK084077, R01DK072381, K08DK073299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Society of Nephrology; Kidney Research UK(Kidney Research UK (KRUK)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genzyme Renal Initiatives Program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Ira Tabas (Columbia University, New York, NY, USA) for advice, Dr. Eileen O'Leary [Harvard Medical School (HMS)] for assistance with constructs, Dr. Peter Libby (HMS) and Galina Sukhova (HMS) for mouse aorta tissue sections, Dr. Noburu Mizushima (Tokyo Metropolitan Institutes of Science, Tokyo, Japan) for the LC3-EGFP-C1 construct, Dr. Jagesh S. Shah (HMS) for the RFP construct, Dr. Ben Humphreys (HMS) for KIM-1-GFP vector, Dr. Toshio Kitamura (University of Tokyo, Tokyo, Japan) for pMXs-puro vector, Dr. Martin Pollak (HMS) and Dr. Johannes Schlondorff (HMS) for advice, Dr. Joel Henderson and Dr. Helmut Rennke (HMS) for assistance with electronmicroscopy, and Dr. Lewis Cantley for his support of K. D. S. This work was supported by U.S. National Institutes of Health (NIH) grants DK073299 and DK84077, a Gottschalk award from the American Society of Nephrology, Genzyme Renal Initiatives Program, and a Kidney Research UK Senior Fellowship. K.D.S. was supported by an NIH grant (GM041890) to Lewis C. Cantley.	Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794; Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Arnoult D, 2001, MOL BIOL CELL, V12, P3016, DOI 10.1091/mbc.12.10.3016; Blander JM, 2006, NAT IMMUNOL, V7, P1029, DOI 10.1038/ni1006-1029; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Castano AP, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000111; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Duffield JS, 2006, J IMMUNOL, V177, P5902, DOI 10.4049/jimmunol.177.9.5902; Duffield JS, 2005, AM J PATHOL, V167, P1207, DOI 10.1016/S0002-9440(10)61209-6; Duffield JS, 2005, J CLIN INVEST, V115, P1743, DOI 10.1172/JCI22593; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Fallowfield JA, 2007, J IMMUNOL, V178, P5288, DOI 10.4049/jimmunol.178.8.5288; Furochi H, 2007, FEBS LETT, V581, P5743, DOI 10.1016/j.febslet.2007.11.036; Hanayama R, 2006, CURR DIRECT AUTOIMMU, V9, P162; HOASHI T, FASEB J, V24, P1616; Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; ICHIMURA T, 2004, J AM SOC NEPHROL, V15, pA716; Ichimura T, 2008, J CLIN INVEST, V118, P1657, DOI 10.1172/JCI34487; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; KEVANY BM, PHYSL BETHESDA, V25, P8; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078-0432.CCR-05-2797; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lin SL, 2009, J IMMUNOL, V183, P6733, DOI 10.4049/jimmunol.0901473; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Oda T, 1998, KIDNEY INT, V53, P1190, DOI 10.1046/j.1523-1755.1998.00886.x; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044; Rees AJ, 2008, NEPHROL DIAL TRANSPL, V23, P3394, DOI 10.1093/ndt/gfn480; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; Zatloukal K, 2007, EXP CELL RES, V313, P2033, DOI 10.1016/j.yexcr.2007.04.024	42	92	95	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4767	4781		10.1096/fj.10-154757	http://dx.doi.org/10.1096/fj.10-154757			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20709912	Green Published			2022-12-28	WOS:000284824400017
J	Ricci-Vitiani, L; Mollinari, C; di Martino, S; Biffoni, M; Pilozzi, E; Pagliuca, A; de Stefano, MC; Circo, R; Merlo, D; De Maria, R; Garaci, E				Ricci-Vitiani, Lucia; Mollinari, Cristiana; di Martino, Simona; Biffoni, Mauro; Pilozzi, Emanuela; Pagliuca, Alfredo; de Stefano, Maria Chiara; Circo, Rita; Merlo, Daniela; De Maria, Ruggero; Garaci, Enrico			Thymosin beta 4 targeting impairs tumorigenic activity of colon cancer stem cells	FASEB JOURNAL			English	Article						actin cytoskeleton; cell cycle; tumor growth; target therapy	INTEGRIN-LINKED KINASE; THERAPEUTIC TARGET; EXPRESSION; OVEREXPRESSION; METASTASIS; GENE; SURVIVAL; BETA(4); CYTOSKELETON; CARCINOMA	Thymosin beta 4 (T beta 4) is an actin-binding peptide overexpressed in several tumors, including colon carcinomas. The aim of this study was to investigate the role of T beta 4 in promoting the tumorigenic properties of colorectal cancer stem cells (CR-CSCs), which are responsible for tumor initiation and growth. We first found that CR-CSCs from different patients have higher T beta 4 levels than normal epithelial cells. Then, we used a lentiviral strategy to down-regulate T beta 4 expression in CR-CSCs and analyzed the effects of such modulation on proliferation, survival, and tumorigenic activity of CR-CSCs. Empty vector-transduced CR-CSCs were used as a control. Targeting of the T beta 4 produced CR-CSCs with a lower capacity to grow and migrate in culture and, interestingly, reduced tumor size and aggressiveness of CR-CSC-based xenografts in mice. Moreover, such loss in tumorigenic activity was accompanied by a significant increase of phosphatase and tensin homologue (PTEN) and a concomitant reduction of the integrin-linked kinase (ILK) expression, which resulted in a decreased activation of protein kinase B (Akt). Accordingly, exogenous expression of an active form of Akt rescued all the protumoral features lost after T beta 4 targeting in CR-CSCs. In conclusion, T beta 4 may have important implications for therapeutic intervention for treatment of human colon carcinoma.-Ricci-Vitiani, L., Mollinari, C., di Martino, S., Biffoni, M., Pilozzi, E., Pagliuca, A., Chiara de Stefano, M., Circo, R., Merlo, D., De Maria, R., Garaci, E. Thymosin beta 4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB J. 24, 4291-4301 (2010). www.fasebj.org	[Ricci-Vitiani, Lucia; di Martino, Simona; Biffoni, Mauro; Pagliuca, Alfredo; De Maria, Ruggero] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Mollinari, Cristiana; de Stefano, Maria Chiara; Merlo, Daniela] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; [Mollinari, Cristiana] CNR, Dept Neurobiol & Mol Med, Rome, Italy; [Pilozzi, Emanuela] Univ Roma La Sapienza, Dept Lab Med & Pathol, St Andrea Hosp, Rome, Italy; [De Maria, Ruggero] Mediterranean Inst Oncol, Catania, Italy; [Merlo, Daniela] IRCCS San Raffaele Pisana, Rome, Italy; [Garaci, Enrico] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Mediterranean Institute of Oncology; IRCCS San Raffaele Pisana; University of Rome Tor Vergata	De Maria, R (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	demaria@iss.it; garaci@tiscali.it	PILOZZI, Emanuela/AAC-1854-2022; de Stefano, Maria Chiara/N-6492-2017; De Maria, Ruggero/S-6385-2019; Merlo, Daniela/K-7986-2016; Pagliuca, Alfredo/AAI-3689-2020; Ricci Vitiani, Lucia/J-8320-2016; di Martino, Simona SdM/K-9304-2016; pagliuca, alfredo/J-3107-2012; Biffoni, Mauro/J-8318-2016; GARACI, ENRICO/AAB-3349-2021; Mollinari, Cristiana/K-4131-2016	PILOZZI, Emanuela/0000-0002-7110-9172; de Stefano, Maria Chiara/0000-0002-0770-1411; De Maria, Ruggero/0000-0003-2255-0583; Merlo, Daniela/0000-0003-4240-5762; Ricci Vitiani, Lucia/0000-0001-7336-5615; di Martino, Simona SdM/0000-0003-4533-3776; pagliuca, alfredo/0000-0002-8703-2077; Biffoni, Mauro/0000-0002-1304-9060; Mollinari, Cristiana/0000-0001-8112-5427	Italian Ministry of Health; Italian Ministry for University and Research [FIRB_RBIP06ZJ78]; Italian Association for Cancer Research (AIRC)	Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry for University and Research(Ministry of Education, Universities and Research (MIUR)); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	The authors thank the Italian Ministry of Health, the Italian Ministry for University and Research (FIRB_RBIP06ZJ78) and the Italian Association for Cancer Research (AIRC) for supporting the colon CSC research. The authors thank Dr. Enrico Duranti for technical assistance.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bednarek R, 2008, J BIOL CHEM, V283, P1534, DOI 10.1074/jbc.M707539200; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Brieger A, 2007, BIOCHEM BIOPH RES CO, V364, P731, DOI 10.1016/j.bbrc.2007.10.010; Cha HJ, 2003, J NATL CANCER I, V95, P1674, DOI 10.1093/jnci/djg100; Crowder RJ, 1998, J NEUROSCI, V18, P2933; DECLOITRE F, 1991, TUMOR BIOL, V12, P111, DOI 10.1159/000217695; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goldstein AL, 2005, TRENDS MOL MED, V11, P421, DOI 10.1016/j.molmed.2005.07.004; Golla R, 1997, CELL MOTIL CYTOSKEL, V38, P187, DOI 10.1002/(SICI)1097-0169(1997)38:2<187::AID-CM7>3.0.CO;2-4; Grant D S, 1999, Angiogenesis, V3, P125, DOI 10.1023/A:1009041911493; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Ho JH, 2010, J ORTHOP RES, V28, P131, DOI 10.1002/jor.20956; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Huang HC, 2007, ONCOGENE, V26, P2781, DOI 10.1038/sj.onc.1210078; Huang WQ, 2006, CELL BIOL INT, V30, P514, DOI 10.1016/j.cellbi.2006.01.009; Iguchi K, 1999, BIOCHEM PHARMACOL, V57, P1105, DOI 10.1016/S0006-2952(99)00030-1; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Koutrafouri V, 2001, BBA-GEN SUBJECTS, V1568, P60, DOI 10.1016/S0304-4165(01)00200-8; LOW TLK, 1982, J BIOL CHEM, V257, P1000; Madsen J, 2007, J HISTOCHEM CYTOCHEM, V55, P505, DOI 10.1369/jhc.6A7100.2007; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Mollinari C, 2009, J CELL SCI, V122, P4195, DOI 10.1242/jcs.056895; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Philp D, 2003, FASEB J, V17, P385, DOI 10.1096/fj.03-0244fje; Qiu FY, 2009, J CARDIOVASC PHARM, V53, P209, DOI 10.1097/FJC.0b013e318199f326; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Ricci-Vitiani L, 2008, GUT, V57, P538, DOI 10.1136/gut.2007.127837; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; SANGER JM, 1995, CELL MOTIL CYTOSKEL, V31, P307, DOI 10.1002/cm.970310407; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Sosne G, 2001, EXP EYE RES, V72, P605, DOI 10.1006/exer.2000.0985; Steiniger SCJ, 2008, STEM CELLS, V26, P3037, DOI 10.1634/stemcells.2008-0397; Sun W, 2007, ANN NY ACAD SCI, V1112, P210, DOI 10.1196/annals.1415.013; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang WS, 2004, ONCOGENE, V23, P6666, DOI 10.1038/sj.onc.1207888; Wang WS, 2003, ONCOGENE, V22, P3297, DOI 10.1038/sj.onc.1206404; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Xie D, 2002, INT J ONCOL, V21, P499; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; Yoganathan N, 2002, PHARMACOL THERAPEUT, V93, P233, DOI 10.1016/S0163-7258(02)00192-4; Zhang YQ, 2008, CANCER BIOL THER, V7, P419, DOI 10.4161/cbt.7.3.5415	51	32	34	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4291	4301		10.1096/fj.10-159970	http://dx.doi.org/10.1096/fj.10-159970			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20566622	Bronze			2022-12-28	WOS:000283861100017
J	Castelnuovo, M; Massone, S; Tasso, R; Fiorino, G; Gatti, M; Robello, M; Gatta, E; Berger, A; Strub, K; Florio, T; Dieci, G; Cancedda, R; Pagano, A				Castelnuovo, Manuele; Massone, Sara; Tasso, Roberta; Fiorino, Gloria; Gatti, Monica; Robello, Mauro; Gatta, Elena; Berger, Audrey; Strub, Katharina; Florio, Tullio; Dieci, Giorgio; Cancedda, Ranieri; Pagano, Aldo			An Alu-like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells	FASEB JOURNAL			English	Article						anticancer drugs; ncRNA; neuroblastoma differentiation; RNA polymerase III	POLYMERASE-III; STEM-CELLS; GROWTH; CANCER; PROLIFERATION; TRANSCRIPTION; PROGNOSIS; RECEPTOR; GENE	Neuroblastoma (NB) is a pediatric cancer characterized by remarkable cell heterogeneity within the tumor nodules. Here, we demonstrate that the synthesis of a pol III-transcribed noncoding (nc) RNA (NDM29) strongly restricts NB development by promoting cell differentiation, a drop of malignancy processes, and a dramatic reduction of the tumor initiating cell (TIC) fraction in the NB cell population. Notably, the overexpression of NDM29 also confers to malignant NB cells an unpredicted susceptibility to the effects of antiblastic drugs used in NB therapy. Altogether, these results suggest the induction of NDM29 expression as possible treatment to increase cancer cells vulnerability to therapeutics and the measure of its synthesis in NB explants as prognostic factor of this cancer type.-Castelnuovo, M., Massone, S., Tasso, R., Fiorino, G., Gatti, M., Robello, M., Gatta, E., Berger, A., Strub, K., Florio, T., Dieci, G., Cancedda, R., Pagano, A. An Alu-like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells. FASEB J. 24, 4033-4046 (2010). www.fasebj.org	[Castelnuovo, Manuele; Massone, Sara; Tasso, Roberta; Gatti, Monica; Florio, Tullio; Cancedda, Ranieri; Pagano, Aldo] Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; [Robello, Mauro; Gatta, Elena] Univ Genoa, Dept Phys, I-16132 Genoa, Italy; [Castelnuovo, Manuele; Massone, Sara; Tasso, Roberta; Cancedda, Ranieri; Pagano, Aldo] Natl Inst Canc Res Genoa, Genoa, Italy; [Fiorino, Gloria; Dieci, Giorgio] Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; [Berger, Audrey; Strub, Katharina] Univ Geneva, Dept Cell Biol, Geneva, Switzerland	University of Genoa; University of Genoa; University of Genoa; IRCCS AOU San Martino IST; University of Parma; University of Geneva	Pagano, A (corresponding author), Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy.	aldo.pagano@unige.it	Pagano, Aldo/AAF-3974-2019; Florio, Tullio/A-2211-2012; Tasso, Roberta/J-7237-2016; Dieci, Giorgio/B-3434-2012; Tasso, Roberta/AFL-4297-2022; FLORIO, TULLIO/ABG-3182-2020	Pagano, Aldo/0000-0001-8035-9299; Florio, Tullio/0000-0002-2394-996X; Tasso, Roberta/0000-0003-0956-7006; Dieci, Giorgio/0000-0002-8792-3961; Monica, Gatti/0000-0002-2016-0285	Italian Ministry of University and Research-MIUR; Associazione Italiana Ricerca sul Cancro [IG9378, IG9089]	Italian Ministry of University and Research-MIUR(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	The authors thank Dr. Alessandro Poggi (National Institute for Cancer Research, Genoa, Italy) for help in FACS analysis, and Dr. Gregory Hannon, (Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, USA) for providing the pSHAG-ff1 plasmid. A.P. and R.C. were supported by the Italian Ministry of University and Research-MIUR (2007 International FIRB Program, 2007 PRIN Program). A.P. was also supported by the Associazione Italiana Ricerca sul Cancro (2009 AIRC Program no. IG9378). G.D. was supported by the Italian Ministry of University and Research (2007 PRIN Program). T.F. was supported by the Associazione Italiana Ricerca sul Cancro (2009 AIRC Program no. IG9089).	Amid C, 2001, CYTOGENET CELL GENET, V93, P284, DOI 10.1159/000056999; Brown TRP, 2000, GENE EXPRESSION, V9, P15; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; De Preter K, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-97; Dieci G, 2007, TRENDS GENET, V23, P614, DOI 10.1016/j.tig.2007.09.001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; George RE, 2001, MED PEDIATR ONCOL, V36, P169, DOI 10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U; HAURIE V, P NATL ACAD SCI US, V107, P4176; MCCLAY DR, 1981, P NATL ACAD SCI-BIOL, V78, P4975, DOI 10.1073/pnas.78.8.4975; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakai E, 2009, CANCER INVEST, V27, P901, DOI 10.3109/07357900801946679; Pagano A, 2007, PLOS GENET, V3, P174, DOI 10.1371/journal.pgen.0030001; Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014; Pattarozzi A, 2008, MOL PHARMACOL, V73, P191, DOI 10.1124/mol.107.039974; Perrone-Bizzozero N, 2002, J NEUROSCI RES, V68, P121, DOI 10.1002/jnr.10175; ROBELLO M, 1993, NEUROSCIENCE, V53, P131, DOI 10.1016/0306-4522(93)90291-M; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Ross RA, 2007, SEMIN CANCER BIOL, V17, P241, DOI 10.1016/j.semcancer.2006.04.006; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Wu LP, 2003, EUKARYOT CELL, V2, P256, DOI 10.1128/EC.2.2.256-264.2003	21	59	62	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					4033	4046		10.1096/fj.10-157032	http://dx.doi.org/10.1096/fj.10-157032			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20581224	Green Published			2022-12-28	WOS:000285005900039
J	Tan, KM; Tesar, C; Wilton, R; Keigher, L; Babnigg, G; Joachimiak, A				Tan, Kemin; Tesar, Christine; Wilton, Rosemarie; Keigher, Laura; Babnigg, Gyorgy; Joachimiak, Andrzej			Novel alpha-glucosidase from human gut microbiome: substrate specificities and their switch	FASEB JOURNAL			English	Article						substrate selection and switch; glycoside hydrolase; GH31 family; isomannose binding; carbohydrate metabolism	MALTASE-GLUCOAMYLASE; DIVERSITY; GENE; ISOMALTASE; INTESTINE; SUBUNIT; CLONING; HEALTH; MODEL	The human intestine harbors a large number of microbes forming a complex microbial community that greatly affects the physiology and pathology of the host. In the human gut microbiome, the enrichment in certain protein gene families appears to be widespread. They include enzymes involved in carbohydrate metabolism such as glucoside hydrolases of dietary polysaccharides and glycoconjugates. We report the crystal structures (wild type, 2 mutants, and a mutant/substrate complex) and the enzymatic activity of a recombinant alpha-glucosidase from human gut bacterium Ruminococcus obeum. The first ever protein structures from this bacterium reveal a structural homologue to human intestinal maltase-glucoamylase with a highly conserved catalytic domain and reduced auxiliary domains. The alpha-glucosidase, a member of GH31 family, shows substrate preference for alpha(1-6) over alpha(1-4) glycosidic linkages and produces glucose from isomaltose as well as maltose. The preference can be switched by a single mutation at its active site, suggestive of widespread adaptation to utilization of a variety of polysaccharides by intestinal micro-organisms as energy resources.-Tan, K., Tesar, C., Wilton, R., Keigher, L., Babnigg, G., Joachimiak, A. Novel alpha-glucosidase from human gut microbiome: substrate specificities and their switch. FASEB J. 24, 3939-3949 (2010). www.fasebj.org	[Tan, Kemin; Tesar, Christine; Wilton, Rosemarie; Keigher, Laura; Babnigg, Gyorgy; Joachimiak, Andrzej] Argonne Natl Lab, Midwest Ctr Struct Genom & Struct Biol Ctr, Argonne, IL 60439 USA	United States Department of Energy (DOE); Argonne National Laboratory	Joachimiak, A (corresponding author), Argonne Natl Lab, Midwest Ctr Struct Genom & Struct Biol Ctr, 9700 S Cass Ave, Argonne, IL 60439 USA.	andrzejj@anl.gov		Wilton, Rosemarie/0000-0001-5221-6354	National Institutes of Health [GM074942]; U.S. Department of Energy, Office of Biological and Environmental Research [DE-AC02-06CH11357]; U.S. Department of Energy Office of Science [DE-AC02-06CH11357]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM094585, U54GM074942] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Energy, Office of Biological and Environmental Research(United States Department of Energy (DOE)); U.S. Department of Energy Office of Science(United States Department of Energy (DOE)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank members of the Structural Biology Center at Argonne National Laboratory for their help with data collection at the 19-ID beamline. The authors also thank Lindsey Butler for help in the preparation of this manuscript. This work was supported by National Institutes of Health grant GM074942 and by the U.S. Department of Energy, Office of Biological and Environmental Research, under contract DE-AC02-06CH11357. The atomic coordinates and structural factors of the wild-type Ro-aG1, D73A, and D307 mutants and D307/isomaltose complex have been deposited in the PDB databank under accession codes 3N04, 3M46, 3M6D, and 3MKK, respectively. The submitted manuscript has been created by UChicago Argonne, LLC, Operator of Argonne National Laboratory ("Argonne"). Argonne, a U.S. Department of Energy Office of Science laboratory, is operated under contract DE-AC02-06CH11357. The U.S. Government retains for itself, and others acting on its behalf, a paid-up nonexclusive, irrevocable worldwide license in said article to reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly, by or on behalf of the Government.	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blaut M, 2007, J NUTR, V137, p751S, DOI 10.1093/jn/137.3.751S; Booijink CCGM, 2007, FUTURE MICROBIOL, V2, P285, DOI 10.2217/17460913.2.3.285; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Cantarel BL, 2009, NUCLEIC ACIDS RES, V37, pD233, DOI 10.1093/nar/gkn663; Cohen SX, 2004, ACTA CRYSTALLOGR D, V60, P2222, DOI 10.1107/S0907444904027556; DAHLQVIST A, 1961, BIOCHEM J, V80, P547, DOI 10.1042/bj0800547; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ernst HA, 2006, J MOL BIOL, V358, P1106, DOI 10.1016/j.jmb.2006.02.056; Gerlt JA, 2003, CURR OPIN CHEM BIOL, V7, P252, DOI 10.1016/S1367-5931(03)00019-X; Hayashi H, 2005, J MED MICROBIOL, V54, P1093, DOI 10.1099/jmm.0.45935-0; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Hill MJ, 1997, EUR J CANCER PREV, V6, pS43, DOI 10.1097/00008469-199703001-00009; Hooper LV, 1998, BIOESSAYS, V20, P336, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;336::AID-BIES10&gt;3.0.CO;2-3; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Kim Youngchang, 2004, Journal of Structural and Functional Genomics, V5, P111, DOI 10.1023/B:JSFG.0000029206.07778.fc; Klock Heath E., 2009, V498, P91, DOI 10.1007/978-1-59745-196-3_6; Kurakata Y, 2008, J MOL BIOL, V381, P116, DOI 10.1016/j.jmb.2008.05.061; Kurokawa K, 2007, DNA RES, V14, P169, DOI 10.1093/dnares/dsm018; LIN SL, 1995, J MOL BIOL, V248, P151, DOI 10.1006/jmbi.1995.0208; Lovering AL, 2005, J BIOL CHEM, V280, P2105, DOI 10.1074/jbc.M410468200; Mai V, 2009, WORLD J GASTROENTERO, V15, P81, DOI 10.3748/wjg.15.81; Markowitz VM, 2010, NUCLEIC ACIDS RES, V38, pD382, DOI 10.1093/nar/gkp887; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Membrez M, 2008, FASEB J, V22, P2416, DOI 10.1096/fj.07-102723; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nichols BL, 2003, P NATL ACAD SCI USA, V100, P1432, DOI 10.1073/pnas.0237170100; QIN J, NATURE, V464, P59; Scheffel F, 2004, BBA-BIOENERGETICS, V1656, P57, DOI 10.1016/j.bbabio.2004.01.005; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sim L, 2008, J MOL BIOL, V375, P782, DOI 10.1016/j.jmb.2007.10.069; Singh V, 2009, FEMS IMMUNOL MED MIC, V55, P6, DOI 10.1111/j.1574-695X.2008.00497.x; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Ventura M, 2009, NAT REV MICROBIOL, V7, P61, DOI 10.1038/nrmicro2047; Wang M, 2005, FEMS MICROBIOL ECOL, V54, P219, DOI 10.1016/j.femsec.2005.03.012	41	41	42	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3939	3949		10.1096/fj.10-156257	http://dx.doi.org/10.1096/fj.10-156257			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20581222	Green Published			2022-12-28	WOS:000285005900031
J	Zhuo, JM; Pratico, D				Zhuo, Jia-Min; Pratico, Domenico			Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						amyloid-beta; APP metabolism; fear-conditioning test	FOLIC-ACID SUPPLEMENTATION; ELEVATED PLASMA HOMOCYSTEINE; PRECURSOR PROTEIN; OXIDATIVE STRESS; PLAQUE-FORMATION; CONTROLLED-TRIAL; RISK-FACTOR; DEMENTIA; MICE; VITAMIN-B-12	Hyperhomocysteine (HHcy) is a risk factor for developing Alzheimer's disease (AD). Previously, we showed that diet-induced HHcy accelerated the AD-like phenotype of a transgenic mouse model, i.e., Tg2576. In the present work, we tested whether an HHcy-lowering strategy in this model would be beneficial. Tg2576 mice received methionine-rich or regular chow diet for 5 mo. Next, while the chow control group was kept on the same regimen, the other mice were randomized into two groups: one was kept on the methionine-rich diet (Met On), the other switched to chow (Met Off). Compared with controls, 5 mo on the methionine-rich diet resulted in HHcy (plasma Hcy level, treated: 12.7 +/- 1.2 mu M vs. control: 3.1 +/- 0.4 mu M) and significant behavioral impairments (% freezing, treated: 2.4 +/- 1.4% vs. control: 19.9 +/- 6.9%). At the end of the study, while the Met On group kept Hcy level elevated, the Met Off group had these values indistinguishable from the controls. The reduction in Hcy levels resulted in a significant improvement of the fear-conditioning performance, and an amelioration of the brain amyloidosis. Our results demonstrate that lowering HHcy in a transgenic AD-mouse model is beneficial since it significantly improves behavior deficits and brain amyloidosis. Our findings provide new biological insights for future clinical trials aimed at lowering this modifiable risk factor in human AD.-Zhuo, J.-M., Pratico, D. Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. FASEB J. 24, 3895-3902 (2010). www.fasebj.org	[Zhuo, Jia-Min; Pratico, Domenico] Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Pratico, D (corresponding author), 706A,MRB,3420 North,Broad St, Philadelphia, PA 19140 USA.	praticod@temple.edu	Zhuo, Jia-Min/M-7546-2014; Pratico, Domenico/ABA-9590-2020	Zhuo, Jia-Min/0000-0001-9199-5485; 	National Institutes of Health [AG-22512]; NATIONAL INSTITUTE ON AGING [R01AG022512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Ms. Ni Meng for technical assistance. This work was funded by a grant from the National Institutes of Health, AG-22512 (to D.P.)	Aisen PS, 2008, JAMA-J AM MED ASSOC, V300, P1774, DOI 10.1001/jama.300.15.1774; Balk EM, 2007, ARCH INTERN MED, V167, P21, DOI 10.1001/archinte.167.1.21; Boldyrev AA, 2007, J ALZHEIMERS DIS, V11, P219; Bryan J, 2002, J NUTR, V132, P1345, DOI 10.1093/jn/132.6.1345; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Durga J, 2007, LANCET, V369, P208, DOI 10.1016/S0140-6736(07)60109-3; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Firuzi O, 2008, FASEB J, V22, P1169, DOI 10.1096/fj.07-9131.com; Fuso A, 2005, MOL CELL NEUROSCI, V28, P195, DOI 10.1016/j.mcn.2004.09.007; Fuso A, 2008, MOL CELL NEUROSCI, V37, P731, DOI 10.1016/j.mcn.2007.12.018; Gottfries CG, 1998, J NEURAL TRANSM, V105, P773, DOI 10.1007/s007020050094; Herrmann N, 2002, CAN J PSYCHIAT, V47, P715, DOI 10.1177/070674370204700802; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hvas AM, 2004, J AFFECT DISORDERS, V81, P269, DOI 10.1016/S0165-0327(03)00169-1; Jacobsen DW, 2000, ARTERIOSCL THROM VAS, V20, P1182, DOI 10.1161/01.ATV.20.5.1182; Jakubowski H, 2009, FASEB J, V23, P1721, DOI 10.1096/fj.08-127548; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; McCaddon A, 1998, INT J GERIATR PSYCH, V13, P235, DOI 10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8; Morris MS, 2003, LANCET NEUROL, V2, P425, DOI 10.1016/S1474-4422(03)00438-1; Morris MS, 2001, AM J CLIN NUTR, V73, P927; Nilsson K, 2001, INT J GERIATR PSYCH, V16, P609, DOI 10.1002/gps.388; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Poirier R, 2007, FRONT BEHAV NEUROSCI, V1, DOI [10.3389/neuro.08/006.2007, 10.3389/neuro.08.006.2007]; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2008, TRENDS PHARMACOL SCI, V29, P609, DOI 10.1016/j.tips.2008.09.001; Pratico D, 2009, JAMA-J AM MED ASSOC, V301, P1020, DOI 10.1001/jama.2009.211; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Seshadri S, 2006, J ALZHEIMERS DIS, V9, P393; Sommer BR, 2003, J GERIATR PSYCH NEUR, V16, P156, DOI 10.1177/0891988703256052; Sung S, 2004, AM J PATHOL, V165, P2197, DOI 10.1016/S0002-9440(10)63269-5; Suszynska J, 2010, J ALZHEIMERS DIS, V19, P1177, DOI 10.3233/JAD-2010-1311; Troen AM, 2008, P NATL ACAD SCI USA, V105, P12474, DOI 10.1073/pnas.0805350105; Van Dam F, 2009, ARCH GERONTOL GERIAT, V48, P425, DOI 10.1016/j.archger.2008.03.009; Zhang CE, 2009, AM J PATHOL, V174, P1481, DOI 10.2353/ajpath.2009.081036; Zhuo JM, 2010, CURR ALZHEIMER RES, V7, P140, DOI 10.2174/156720510790691326; Zhuo JM, 2010, EXP GERONTOL, V45, P195, DOI 10.1016/j.exger.2009.12.005	41	23	25	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3895	3902		10.1096/fj.10-161828	http://dx.doi.org/10.1096/fj.10-161828			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20519634	Green Published			2022-12-28	WOS:000285005900027
J	Foller, M; Mahmud, H; Qadri, SM; Gu, SC; Braun, M; Bobbala, D; Hocher, B; Lang, F				Foeller, Michael; Mahmud, Hasan; Qadri, Syed M.; Gu, Shuchen; Braun, Manuel; Bobbala, Diwakar; Hocher, Berthold; Lang, Florian			Endothelin B receptor stimulation inhibits suicidal erythrocyte death	FASEB JOURNAL			English	Article						anemia; cell membrane scrambling; splenomegaly; ETB receptor; Ca2+; sarafotoxin 6c	PROGRAMMED CELL-DEATH; RED-BLOOD-CELLS; PHOSPHATIDYLSERINE EXPOSURE; PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; CATION CONDUCTANCE; BETA-THALASSEMIA; NITRIC-OXIDE; SURVIVAL; HEMOGLOBIN	Endothelins (ETs), potent endothelium-derived mediators, stimulate formation of nitric oxide, which, in turn, protects against suicidal erythrocyte death or eryptosis, characterized by phosphatidylserine exposure at the erythrocyte surface and triggered by increase in cytosolic Ca2+ ([Ca2+](i)). The present study explored whether the ET1-receptor ETB influences suicidal erythrocyte death. To this end, [Ca2+](i) (Fluo3-fluorescence) and phosphatidylserine exposure (annexin V-binding) were determined utilizing FACS analysis. Energy depletion increased [Ca2+]i and phosphatidylserine-exposure, effects significantly blunted by ET1 (IC50 approximate to 100 nM) and the ETB receptor-agonist sarafotoxin 6c (IC50 approximate to 10 nM) but not by ET2 and ET3. ET1 and sarafotoxin significantly delayed the kinetics of suicidal erythrocyte death following energy depletion. ETB stimulation did not blunt the effect of Ca2+-ionophore ionomycin (1 mu M) on phosphatidylserine exposure. The in vivo significance was tested using rescued ETB-knockout (etb(-/-)) and wild-type (etb(+/+)) mice. The number of phosphatidylserine-exposing erythrocytes, of reticulocytes and spleen size were significantly larger in etb(-/-) mice than in etb(+/+)-mice. The etb(-/-) erythrocytes were more susceptible to the eryptotic effect of oxidative stress and more rapidly cleared from circulating blood than etb(+/+) erythrocytes. Finally, the spleens from etb(-/-) mice were enlarged and contained markedly more phosphatidylserine- exposing erythrocytes than spleens from etb(+/+) mice. The observations disclose a novel function of ET1, i. e., protection from suicidal erythrocyte death.-Foller, M., Mahmud, H., Qadri, S. M., Gu, S., Braun, M., Bobbala, D., Hocher, B., Lang, F. Endothelin B receptor stimulation inhibits suicidal erythrocyte death. FASEB J. 24, 3351-3359 (2010). www.fasebj.org	[Lang, Florian] Univ Tubingen, Inst Physiol, Dept Physiol, D-72076 Tubingen, Germany; [Hocher, Berthold] Univ Potsdam, Inst Nutr Sci, Potsdam, Germany; [Hocher, Berthold] Charite, Dept Pharmacol & Toxicol, Cardiovasc Res Ctr, Berlin, Germany	Eberhard Karls University of Tubingen; University of Potsdam; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Lang, F (corresponding author), Univ Tubingen, Inst Physiol, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	Hocher, Berthold/AAC-3510-2020	Hocher, Berthold/0000-0001-8143-0579	Carl-Zeiss-Stiftung; Deutsche Forschungsgemeinschaft [La 315/4-3, La 315/6-1]	Carl-Zeiss-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors acknowledge the technical assistance of E. Faber and the meticulous preparation of the manuscript by Tanja Loch. This study was supported by the Carl-Zeiss-Stiftung and the Deutsche Forschungsgemeinschaft, Nr. La 315/4-3 and La 315/6-1.	Andrews D A, 1999, Curr Opin Hematol, V6, P76, DOI 10.1097/00062752-199903000-00004; Angelo M, 2006, P NATL ACAD SCI USA, V103, P8366, DOI 10.1073/pnas.0600942103; Ayi K, 2004, BLOOD, V104, P3364, DOI 10.1182/blood-2003-11-3820; Basu S, 2010, GLYCOCONJUGATE J, V27, P717, DOI 10.1007/s10719-009-9257-6; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; Birka C, 2004, PFLUG ARCH EUR J PHY, V448, P471, DOI 10.1007/s00424-004-1289-y; Boas FE, 1998, P NATL ACAD SCI USA, V95, P3077, DOI 10.1073/pnas.95.6.3077; Bookchin R M, 1987, Prog Clin Biol Res, V240, P193; Bosman GJCGM, 2005, CELL PHYSIOL BIOCHEM, V16, P1, DOI 10.1159/000087725; Brand VB, 2003, CELL PHYSIOL BIOCHEM, V13, P347, DOI 10.1159/000075122; Brand V, 2008, CELL PHYSIOL BIOCHEM, V22, P405, DOI 10.1159/000185482; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; Browning JA, 2007, CELL PHYSIOL BIOCHEM, V19, P165, DOI 10.1159/000099204; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; Cappadoro M, 1998, BLOOD, V92, P2527, DOI 10.1182/blood.V92.7.2527.2527_2527_2534; Chadebech P, 2009, TRANSFUSION, V49, P1785, DOI 10.1111/j.1537-2995.2009.02199.x; Chung SM, 2007, ARTERIOSCL THROM VAS, V27, P414, DOI 10.1161/01.ATV.0000252898.48084.6a; Cimen MYB, 2008, CLIN CHIM ACTA, V390, P1, DOI 10.1016/j.cca.2007.12.025; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; Davenport AP, 2004, J CARDIOVASC PHARM, V44, pS276, DOI 10.1097/01.fjc.0000166284.08657.64; de Jong K, 2001, BLOOD, V98, P1577, DOI 10.1182/blood.V98.5.1577; Dejam A, 2005, BLOOD, V106, P734, DOI 10.1182/blood-2005-02-0567; Diesen D, 2007, J MOL CELL CARDIOL, V42, P921, DOI 10.1016/j.yjmcc.2007.03.739; Duranton C, 2002, J PHYSIOL-LONDON, V539, P847, DOI 10.1113/jphysiol.2001.013040; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Foller M, 2008, P NATL ACAD SCI USA, V105, P6771, DOI 10.1073/pnas.0708940105; Foeller M, 2008, EUR J PHARMACOL, V581, P13, DOI 10.1016/j.ejphar.2007.11.051; Foller M, 2007, CELL PHYSIOL BIOCHEM, V20, P1051, DOI 10.1159/000110715; Foller M, 2009, CELL PHYSIOL BIOCHEM, V24, P133, DOI 10.1159/000233238; Foller M, 2009, FASEB J, V23, P1072, DOI 10.1096/fj.08-121772; Gatidis S, 2009, ANN HEMATOL, V88, P721, DOI 10.1007/s00277-009-0697-7; Grimshaw MJ, 2007, ENDOCR-RELAT CANCER, V14, P233, DOI 10.1677/ERC-07-0057; Grubina R, 2007, J BIOL CHEM, V282, P12916, DOI 10.1074/jbc.M700546200; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Huber SM, 2001, PFLUG ARCH EUR J PHY, V441, P551, DOI 10.1007/s004240000456; Kean LS, 2002, EXP HEMATOL, V30, P394, DOI 10.1016/S0301-472X(02)00780-4; Kempe DS, 2007, J MOL MED-JMM, V85, P269, DOI 10.1007/s00109-006-0123-8; Kempe DS, 2006, FASEB J, V20, P368, DOI 10.1096/fj.05-4872fje; Klarl BA, 2006, AM J PHYSIOL-CELL PH, V290, pC244, DOI 10.1152/ajpcell.00283.2005; Koka S, 2008, CELL PHYSIOL BIOCHEM, V21, P481, DOI 10.1159/000129641; Koka S, 2009, CELL PHYSIOL BIOCHEM, V23, P191, DOI 10.1159/000204107; Kriebardis AG, 2007, J CELL MOL MED, V11, P148, DOI 10.1111/j.1582-4934.2007.00008.x; Kuypers FA, 1998, BLOOD, V91, P3044, DOI 10.1182/blood.V91.8.3044.3044_3044_3051; Lang F, 2008, CELL PHYSIOL BIOCHEM, V22, P373, DOI 10.1159/000185448; Lang KS, 2005, CELL PHYSIOL BIOCHEM, V15, P195, DOI 10.1159/000086406; Lang KS, 2003, CELL DEATH DIFFER, V10, P249, DOI 10.1038/sj.cdd.4401144; Lang KS, 2002, CELL PHYSIOL BIOCHEM, V12, P365, DOI 10.1159/000067907; Lang PA, 2003, CELL PHYSIOL BIOCHEM, V13, P337, DOI 10.1159/000075121; Lang PA, 2003, AM J PHYSIOL-CELL PH, V285, pC1553, DOI 10.1152/ajpcell.00186.2003; Lang PA, 2007, NAT MED, V13, P164, DOI 10.1038/nm1539; Lang PA, 2006, CELL PHYSIOL BIOCHEM, V18, P151, DOI 10.1159/000095190; Lang PA, 2006, J MOL MED, V84, P378, DOI 10.1007/s00109-006-0058-0; Lang PA, 2009, CELL PHYSIOL BIOCHEM, V24, P415, DOI 10.1159/000257529; Lion N, 2010, J PROTEOMICS, V73, P374, DOI 10.1016/j.jprot.2009.11.001; Mahmud H, 2009, CELL PHYSIOL BIOCHEM, V24, P263, DOI 10.1159/000233251; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Nicolay JP, 2008, PFLUG ARCH EUR J PHY, V456, P293, DOI 10.1007/s00424-007-0393-1; Niemoeller OM, 2008, CELL PHYSIOL BIOCHEM, V21, P193, DOI 10.1159/000113761; Pandolfi A, 2007, J CELL PHYSIOL, V213, P699, DOI 10.1002/jcp.21138; Pollock JS, 2008, CURR OPIN NEPHROL HY, V17, P70, DOI 10.1097/MNH.0b013e3282f34b02; Power GG, 2007, J APPL PHYSIOL, V103, P1359, DOI 10.1152/japplphysiol.00443.2007; Quaschning T, 2005, J HYPERTENS, V23, P979, DOI 10.1097/01.hjh.0000166838.55688.7e; Reynolds JD, 2007, P NATL ACAD SCI USA, V104, P17058, DOI 10.1073/pnas.0707958104; Rivera A, 2002, BLOOD, V99, P357, DOI 10.1182/blood.V99.1.357; Rivera A, 2007, AM J PHYSIOL-CELL PH, V293, pC960, DOI 10.1152/ajpcell.00530.2006; RIVERS DB, 1999, TRENDS ENTOMOL, V2, P1; Sampaio ALF, 2004, J LEUKOCYTE BIOL, V76, P210, DOI 10.1189/jlb.1003504; Sarafidis PA, 2007, J CLIN ENDOCR METAB, V92, P379, DOI 10.1210/jc.2006-1819; Schneider J, 2007, CELL PHYSIOL BIOCHEM, V20, P35, DOI 10.1159/000104151; Shaw Sidney G., 2005, Current Vascular Pharmacology, V3, P359, DOI 10.2174/157016105774329471; Villeneuve A, 2000, J CARDIOVASC PHARM, V36, pS238, DOI 10.1097/00005344-200036001-00070; Wood BL, 1996, BLOOD, V88, P1873; Yang, 1996, J Cardiovasc Pharmacol Ther, V1, P297; Zappulla Donatella, 2008, J Cardiometab Syndr, V3, P30, DOI 10.1111/j.1559-4572.2008.07263.x	74	20	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3351	3359		10.1096/fj.10-159483	http://dx.doi.org/10.1096/fj.10-159483			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20427706				2022-12-28	WOS:000281446400023
J	Donnini, S; Solito, R; Cetti, E; Corti, F; Giachetti, A; Carra, S; Beltrame, M; Cotelli, F; Ziche, M				Donnini, Sandra; Solito, Raffaella; Cetti, Elisa; Corti, Federico; Giachetti, Antonio; Carra, Silvia; Beltrame, Monica; Cotelli, Franco; Ziche, Marina			A beta peptides accelerate the senescence of endothelial cells in vitro and in vivo, impairing angiogenesis	FASEB JOURNAL			English	Article						aging; cerebral amyloid angiopathy; Alzheimer's disease	CEREBRAL AMYLOID ANGIOPATHY; CELLULAR SENESCENCE; ALZHEIMERS-DISEASE; PLAQUE-FORMATION; BRAIN; EXPRESSION; ZEBRAFISH; DUTCH; MECHANISMS; DEPOSITION	Cerebral amyloid angiopathy (CAA) caused by amyloid beta (A beta) deposition around brain microvessels results in vascular degenerative changes. Antiangiogenic A beta properties are known to contribute to the compromised cerebrovascular architecture. Here we hypothesize that A beta peptides impair angiogenesis by causing endothelial cells to enter senescence at an early stage of vascular development. Wild-type (WT) A beta and its mutated variant E22Q peptide, endowed with marked vascular tropism, were used in this study. In vivo, in zebrafish embryos, the WT or E22Q peptides reduced embryo survival with an IC50 of 6.1 and 4.7 mu M, respectively. The 2.5 mu M concentration, showing minimal toxicity, was chosen. Alkaline phosphatase staining revealed disorganized vessel patterning, narrowing, and reduced branching of vessels. beta-Galactosidase staining and the cyclin-dependent kinase inhibitor p21 expression, indicative of senescence, were increased. In vitro, WT and E22Q reduced endothelial cell survival with an IC50 of 12.3 and 8.8 mu M, respectively. The 5 mu M concentration, devoid of acute effects on the endothelium, was applied chronically to long-term cultured human umbilical vein endothelial cells (HUVECs). We observed reduced cumulative population doubling, which coincided with beta-galactosidase accumulation, down-regulation of telomerase reverse-transcriptase mRNA expression, decreased telomerase activity, and p21 activation. Senescent HUVECs showed marked angiogenesis impairment, as A beta treatment reduced tube sprouting. The endothelial injuries caused by the E22Q peptide were much more aggressive than those induced by the WT peptide. Premature A beta-induced senescence of the endothelium, producing progressive alterations of microvessel morphology and functions, may represent one of the underlying mechanisms for sporadic or heritable CAA.-Donnini, S., Solito, R., Cetti, E., Corti, F., Giachetti, A., Carra, S., Beltrame, M., Cotelli, F., Ziche, M. A beta peptides accelerate the senescence of endothelial cells in vitro and in vivo, impairing angiogenesis. FASEB J. 24, 2385-2395 (2010). www.fasebj.org	[Donnini, Sandra; Solito, Raffaella; Cetti, Elisa; Corti, Federico; Giachetti, Antonio; Ziche, Marina] Univ Siena, Dept Mol Biol, I-53100 Siena, Italy; [Carra, Silvia; Cotelli, Franco] Univ Milan, Dept Biol, Milan, Italy; [Beltrame, Monica] Univ Milan, Dept Biomol Sci & Biotechnol, Milan, Italy	University of Siena; University of Milan; University of Milan	Ziche, M (corresponding author), Univ Siena, Dept Mol Biol, Via Aldo Moro 2, I-53100 Siena, Italy.	ziche@unisi.it	Donnini, Sandra/K-9252-2019; Corti, Federico/R-6262-2016; Carra, Silvia/K-4643-2016; Beltrame, Monica/D-8093-2017; Corti, Federico/A-8918-2011; Carra, Silvia/P-2627-2019	Donnini, Sandra/0000-0001-6617-1644; Corti, Federico/0000-0003-2160-245X; Carra, Silvia/0000-0002-9321-9508; Carra, Silvia/0000-0002-9321-9508; Beltrame, Monica/0000-0001-5094-3494	Telethon [GGP06148]; CARIPLO Foundation [2006.0807]; CARIPLO N.O.B.E.L Biological and Molecular Characterization of Cancer Stem Cells	Telethon(Fondazione Telethon); CARIPLO Foundation(Fondazione Cariplo); CARIPLO N.O.B.E.L Biological and Molecular Characterization of Cancer Stem Cells	The authors thank Dr. M. Mione (University of Milan, Milan, Italy) for kindly providing the p21 probe for ISH, and Dr. E. Foglia for the technical assistance for histological analysis in zebrafish. This work was supported by Telethon-Project No. GGP06148. M. B. and F. C. acknowledge financial support from the CARIPLO Foundation (grant 2006.0807) and CARIPLO N.O.B.E.L Biological and Molecular Characterization of Cancer Stem Cells, respectively.	Bell RD, 2009, ACTA NEUROPATHOL, V118, P103, DOI 10.1007/s00401-009-0522-3; Cantara S, 2004, FASEB J, V18, P1943, DOI 10.1096/fj.04-2114fje; Cirrito JR, 2005, J CLIN INVEST, V115, P3285, DOI 10.1172/JCI25247; Donnini S, 2006, CELL DEATH DIFFER, V13, P1088, DOI 10.1038/sj.cdd.4401803; Erusalimsky JD, 2009, EXP PHYSIOL, V94, P299, DOI 10.1113/expphysiol.2008.043133; Farris W, 2007, AM J PATHOL, V171, P241, DOI 10.2353/ajpath.2007.070105; Garcia-Osta A, 2009, LEARN MEMORY, V16, P267, DOI 10.1101/lm.1310209; Hayashi S, 2009, ARTERIOSCL THROM VAS, V29, P1909, DOI 10.1161/ATVBAHA.109.188516; Hull MA, 1999, GUT, V45, P529, DOI 10.1136/gut.45.4.529; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Isogai S, 2001, DEV BIOL, V230, P278, DOI 10.1006/dbio.2000.9995; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kishi S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000152; Kurz DJ, 2004, J CELL SCI, V117, P2417, DOI 10.1242/jcs.01097; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; Kurz DJ, 2000, J CELL SCI, V113, P3613; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Maat-Schieman M, 2005, NEUROPATHOLOGY, V25, P288, DOI 10.1111/j.1440-1789.2005.00631.x; Maia LF, 2007, J NEUROL SCI, V257, P23, DOI 10.1016/j.jns.2007.01.054; Miao J, 2005, AM J PATHOL, V167, P505, DOI 10.1016/S0002-9440(10)62993-8; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Muller M, 2009, ANTIOXID REDOX SIGN, V11, P59, DOI 10.1089/ars.2008.2104; Murakami M, 2008, J CLIN INVEST, V118, P3355, DOI 10.1172/JCI35298; Paris D, 2005, MOL BRAIN RES, V136, P212, DOI 10.1016/j.molbrainres.2005.02.011; Paris D, 2003, NEUROL RES, V25, P642, DOI 10.1179/016164103101201940; Paris Daniel, 2004, Angiogenesis, V7, P75, DOI 10.1023/B:AGEN.0000037335.17717.bf; Patel NS, 2010, J NEUROCHEM, V112, P66, DOI 10.1111/j.1471-4159.2009.06426.x; Pezzatini S, 2007, BONE, V41, P523, DOI 10.1016/j.bone.2007.06.016; Revesz T, 2003, J NEUROPATH EXP NEUR, V62, P885, DOI 10.1093/jnen/62.9.885; Revesz T, 2009, ACTA NEUROPATHOL, V118, P115, DOI 10.1007/s00401-009-0501-8; Santoriello C, 2009, DIS MODEL MECH, V2, P56, DOI 10.1242/dmm.001016; Serbedzija G N, 1999, Angiogenesis, V3, P353, DOI 10.1023/A:1026598300052; Solito R, 2009, EXP CELL RES, V315, P385, DOI 10.1016/j.yexcr.2008.11.002; THISSE C, 1993, DEVELOPMENT, V119, P1203; Weller RO, 2008, BRAIN PATHOL, V18, P253, DOI 10.1111/j.1750-3639.2008.00133.x; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Zacchigna S, 2008, NAT REV NEUROSCI, V9, P169, DOI 10.1038/nrn2336; Zipfel GJ, 2009, STROKE, V40, pS16, DOI 10.1161/STROKEAHA.108.533174; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606	42	67	68	2	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2385	2395		10.1096/fj.09-146456	http://dx.doi.org/10.1096/fj.09-146456			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20207941				2022-12-28	WOS:000279343600025
J	Krishnamurthy, P; Lambers, E; Verma, S; Thorne, T; Qin, GJ; Losordo, DW; Kishore, R				Krishnamurthy, Prasanna; Lambers, Erin; Verma, Suresh; Thorne, Tina; Qin, Gangjian; Losordo, Douglas W.; Kishore, Raj			Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice	FASEB JOURNAL			English	Article						myocardial infarction; cytokines; inflammation; fibrosis; apoptosis	NECROSIS-FACTOR-ALPHA; TO-MESENCHYMAL TRANSITION; HEART-FAILURE; NITRIC-OXIDE; KAPPA-B; TARGETED DELETION; CARDIAC-FUNCTION; INFARCTION; INTERLEUKIN-10; EXPRESSION	Prolonged inflammatory response is associated with left ventricular (LV) dysfunction and adverse remodeling following myocardial infarction (MI). IL-10 inhibits inflammation by suppressing HuR-mediated mRNA stabilization of proinflammatory cytokines. Here we report that following MI, IL-10(-/-) mice showed exaggerated LV dysfunction, fibrosis, and cardiomyocyte apoptosis. Short-hairpin RNA (shRNA)-mediated knockdown of HuR in the myocardium significantly reversed MI-induced LV dysfunctions and LV remodeling. HuR knockdown significantly reduced MI-induced cardiomyocyte apoptosis concomitant with reduced p53 expression. Moreover, HuR knockdown significantly reduced infarct size and fibrosis area, which in turn was associated with decreased TGF-beta expression. In vitro, stable knockdown of HuR in mouse macrophage cell line RAW 264.7 corroborated in vivo data and revealed reduced mRNA expression of TNF-alpha, TGF-beta, and p53 following LPS challenge, which was associated with a marked reduction in the mRNA stability of these genes. Taken together, our studies suggest that HuR is a direct target of IL-10, and HuR knockdown mimics anti-inflammatory effects of IL10.-Krishnamurthy, P., Lambers, E., Verma, S., Thorne, T., Qin, G., Losordo, D. W., Kishore, R. Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice. FASEB J. 24, 2484-2494 (2010). www.fasebj.org	[Krishnamurthy, Prasanna; Lambers, Erin; Verma, Suresh; Thorne, Tina; Qin, Gangjian; Losordo, Douglas W.; Kishore, Raj] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Krishnamurthy, P (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Cardiol, Feinberg Cardiovasc Res Inst, 303 E Chicago Ave, Chicago, IL 60611 USA.	p-krishnamurthy@northwestern.edu; r-kishore@northwestern.edu	Losordo, Douglas W/F-9782-2011; Verma, Suresh/AAU-9979-2020	Losordo, Douglas/0000-0002-6857-7506; Verma, Suresh Kumar/0000-0002-0739-1302; KRISHNAMURTHY, PRASANNA/0000-0002-4842-6364	American Heart Association-Davee Foundation [0930219N]; National Institute of Health [AA014575, HL091983]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093439, R01HL091983, R01HL053354, R01HL080137, R01HL095874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA014575] Funding Source: NIH RePORTER	American Heart Association-Davee Foundation(American Heart Association); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The reported work was supported in part by American Heart Association-Davee Foundation scientist development grant (SDG) 0930219N (P.K.) and National Institute of Health grants AA014575 and HL091983 (R.K.). The authors declare no competing interests. All authors contributed substantially to this work. R.K. and P.K. conceptualized the experiments. P. K. performed all animal surgical procedures and histological analysis. E.L., S.V., and T.T. generated stable clones, performed Western blots, and provided technical assistance with in vitro experiments. P.K. wrote the manuscript, and R.K. edited it. G.Q. and D.W.L. read the manuscript and provided critical appraisal and conceptual insights. All authors discussed the results and implications and commented on the manuscript at all stages.	Abdelmohsen K, 2008, P NATL ACAD SCI USA, V105, P20297, DOI 10.1073/pnas.0809376106; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Birks EJ, 2008, CARDIOVASC RES, V79, P472, DOI 10.1093/cvr/cvn083; Bujak M, 2007, CIRCULATION, V116, P2127, DOI 10.1161/CIRCULATIONAHA.107.704197; Burchfield JS, 2008, CIRC RES, V103, P203, DOI 10.1161/CIRCRESAHA.108.178475; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Cohen SL, 2004, INFLAMM BOWEL DIS, V10, P557, DOI 10.1097/00054725-200409000-00009; Di Marco S, 2005, MOL CELL BIOL, V25, P6533, DOI 10.1128/MCB.25.15.6533-6545.2005; Duncan DJ, 2007, BRIT J PHARMACOL, V150, P720, DOI 10.1038/sj.bjp.0707147; Finsen AV, 2005, J APPL PHYSIOL, V98, P680, DOI 10.1152/japplphysiol.00924.2004; Frangogiannis NG, 2000, J IMMUNOL, V165, P2798, DOI 10.4049/jimmunol.165.5.2798; Frangogiannis NG, 2006, CURR MED CHEM, V13, P1877, DOI 10.2174/092986706777585086; Girndt M, 2002, KIDNEY INT, V62, P949, DOI 10.1046/j.1523-1755.2002.00504.x; Hamid T, 2009, CIRCULATION, V119, P1386, DOI 10.1161/CIRCULATIONAHA.108.802918; Hasegawa H, 2009, BRIT J CANCER, V100, P1943, DOI 10.1038/sj.bjc.6605084; Hilfiker-Kleiner D, 2004, CIRC RES, V95, P187, DOI 10.1161/01.RES.0000134921.50377.61; Huwiler A, 2003, J BIOL CHEM, V278, P51758, DOI 10.1074/jbc.M305722200; Ii M, 2005, CIRCULATION, V111, P1114, DOI 10.1161/01.CIR.0000157144.24888.7E; Ing DJ, 1999, CIRC RES, V84, P21; Kishore R, 1999, J IMMUNOL, V162, P2457; Krishnamurthy P, 2006, HEART, V92, P1309, DOI 10.1136/hrt.2005.071001; Kuga S, 1996, EXP HEMATOL, V24, P151; Li YW, 2006, CARDIOVASC RES, V71, P684, DOI 10.1016/j.cardiores.2006.06.003; Li ZH, 2006, AM J PHYSIOL-HEART C, V291, pH1972, DOI 10.1152/ajpheart.00043.2006; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Lopes SMCDS, 2004, DEV DYNAM, V231, P542, DOI 10.1002/dvdy.20162; Matsumura S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304; Matsusaka H, 2006, CARDIOVASC RES, V70, P457, DOI 10.1016/j.cardiores.2006.02.001; Mayer B, 2005, INT J CARDIOL, V103, P182, DOI 10.1016/j.ijcard.2004.08.053; Ono K, 1998, CIRCULATION, V98, P149, DOI 10.1161/01.CIR.98.2.149; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Rajasingh J, 2006, FASEB J, V20, P2112, DOI 10.1096/fj.06-6084fje; Sugishita K, 1999, J MOL CELL CARDIOL, V31, P1457, DOI 10.1006/jmcc.1999.0989; Sun M, 2004, CIRCULATION, V110, P3221, DOI 10.1161/01.CIR.0000147233.10318.23; Sun M, 2007, CIRCULATION, V115, P1398, DOI 10.1161/CIRCULATIONAHA.106.643585; SUZUKI K, 2001, CIRCULATION S1, V104, P308; Tao ZY, 2004, LIFE SCI, V74, P1561, DOI 10.1016/j.lfs.2003.09.042; Timmers L, 2008, CIRC RES, V102, P257, DOI 10.1161/CIRCRESAHA.107.158220; Wang MJ, 2005, ANN THORAC SURG, V80, P2235, DOI 10.1016/j.athoracsur.2005.05.070; Yang ZQ, 2000, CIRCULATION, V101, P1019, DOI 10.1161/01.CIR.101.9.1019; Yao L, 2008, INT J CARDIOL, V123, P366, DOI 10.1016/j.ijcard.2007.06.069; Yarovinsky TO, 2006, J IMMUNOL, V177, P4426, DOI 10.4049/jimmunol.177.7.4426; Yeh CH, 2005, J SURG RES, V125, P109, DOI 10.1016/j.jss.2004.11.009; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613; Zhao J, 2008, CANCER RES, V68, P4133, DOI 10.1158/0008-5472.CAN-08-0432; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499	47	57	57	4	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2010	24	7					2484	2494		10.1096/fj.09-149815	http://dx.doi.org/10.1096/fj.09-149815			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20219984	Green Published			2022-12-28	WOS:000279343600035
J	Kommaddi, RP; Thomas, R; Ceni, C; Daigneault, K; Barker, PA				Kommaddi, Reddy P.; Thomas, Rhalena; Ceni, Claire; Daigneault, Kathleen; Barker, Philip A.			Trk-dependent ADAM17 activation facilitates neurotrophin survival signaling	FASEB JOURNAL			English	Article						p75NTR; NGF; BDNF; alpha-secretase; gamma-secretase; TrkA	NECROSIS-FACTOR-ALPHA; NERVE GROWTH-FACTOR; INTRACELLULAR DOMAIN; SYMPATHETIC NEURONS; NUCLEAR TRANSLOCATION; CONVERTING ENZYME; RECEPTOR P75(NTR); POTENTIAL ROLE; P75 RECEPTOR; PC12 CELLS	Signaling by TrkA and TrkB receptor tyrosine kinase is required for peripheral neuron survival. TrkA and TrkB signaling is facilitated by the p75 neurotrophin receptor (p75NTR), a member of the tumor necrosis factor (TNF) receptor superfamily, through mechanisms that remain obscure. Here, we demonstrate that TrkA and TrkB induces MEK-dependent phosphorylation of the transmembrane cysteine protease ADAM17 (a disintegrin and metalloprotease 17) at the intracellular residue threonine 735. Phosphorylation at this site activates ADAM17 and causes cleavage of p75NTR and production of the receptors' intracellular domain (p75NTR(ICD)) in PC12 cells and in primary cerebellar granule neurons. We show that Trk-induced ADAM17 phosphorylation and generation of the p75NTRICD is required for neurotrophin-induced Erk and Akt activation and for neurotrophin-dependent survival signaling. Survival of PC12 cells maintained in 10 ng/ml nerve growth factor drops by 47% in cells depleted of ADAM17; this survival deficit is resolved if the p75NTRICD is overexpressed in the ADAM17 depleted cells. These studies identify a novel signaling circuit in which Trk activates ADAM17-dependent p75NTRICD production to feedback to sustain Trk signaling and Trk-dependent survival.-Kommaddi, R. P., Thomas, R., Ceni, C., Daigneault, K., Barker, P. A. Trk-dependent ADAM17 activation facilitates neurotrophin survival signaling. FASEB J. 25, 2061-2070 (2011). www.fasebj.org	[Kommaddi, Reddy P.; Thomas, Rhalena; Ceni, Claire; Daigneault, Kathleen; Barker, Philip A.] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	Barker, PA (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	phil.barker@mcgill.ca	Thomas, Rhalena/AAT-2032-2021	Thomas, Rhalena/0000-0002-5396-7587	Canadian Institute of Health Research (CIHR) [MOP37850]; McGill studentships	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); McGill studentships	The authors are thankful to Dr. Atanasio Pandiella (University of Salamanca, Salamanca, Spain), Dr. Moses Chao (New York University, New York, NY, USA), and Anthony Oliva (University of Miami, Miami, FL, USA) for kindly providing valuable reagents. R. P. K. was supported by a Canadian Institute of Health Research (CIHR)-HOPE Fellowship, and R. T. was supported by CIHR and McGill studentships. P. A. B. is a Chercheur Nationaux of the Fonds de Recherche en Sante du Quebec and William Dawson Scholar of McGill University. This project was supported by CIHR grant MOP37850.	BANDTLOW C, 2004, SCI STKE, pPE24, DOI DOI 10.1126/STKE.2352004PE24; Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001; Barker PA, 2007, NEURON, V53, P1, DOI 10.1016/j.neuron.2006.12.018; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Ceni C, 2010, J CELL SCI, V123, P2299, DOI 10.1242/jcs.062612; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Domeniconi M, 2005, NEURON, V46, P849, DOI 10.1016/j.neuron.2005.05.029; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Frade JM, 2005, J NEUROSCI, V25, P1407, DOI 10.1523/JNEUROSCI.3798-04.2005; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Ito H, 2003, J NEUROSCI RES, V72, P211, DOI 10.1002/jnr.10564; Ito H, 2002, J NEUROSCI RES, V69, P653, DOI 10.1002/jnr.10359; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; Kenchappa RS, 2010, J BIOL CHEM, V285, P20358, DOI 10.1074/jbc.M109.082834; Kenchappa RS, 2006, NEURON, V50, P219, DOI 10.1016/j.neuron.2006.03.011; Le Gall SM, 2009, MOL BIOL CELL, V20, P1785, DOI 10.1091/mbc.E08-11-1135; LEE KF, 1994, DEVELOPMENT, V120, P1027; Majdan M, 1997, J NEUROSCI, V17, P6988; Nykjaer A, 2005, CURR OPIN NEUROBIOL, V15, P49, DOI 10.1016/j.conb.2005.01.004; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Pruessmeyer J, 2009, SEMIN CELL DEV BIOL, V20, P164, DOI 10.1016/j.semcdb.2008.09.005; Rousseau S, 2008, J CELL SCI, V121, P149, DOI 10.1242/jcs.018671; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soond SM, 2005, J CELL SCI, V118, P2371, DOI 10.1242/jcs.02357; Urra S, 2007, J BIOL CHEM, V282, P7606, DOI 10.1074/jbc.M610458200; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; Zampieri N, 2005, J BIOL CHEM, V280, P14563, DOI 10.1074/jbc.M412957200	31	29	29	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2011	25	6					2061	2070		10.1096/fj.10-173740	http://dx.doi.org/10.1096/fj.10-173740			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21411748				2022-12-28	WOS:000291023800028
J	Dallas, ML; Boyle, JP; Milligan, CJ; Sayer, R; Kerrigan, TL; McKinstry, C; Lu, PY; Mankouri, J; Harris, M; Scragg, JL; Pearson, HA; Peers, C				Dallas, Mark L.; Boyle, John P.; Milligan, Carol J.; Sayer, Rachael; Kerrigan, Talitha L.; McKinstry, Connor; Lu, Peiyuan; Mankouri, Jamel; Harris, Mark; Scragg, Jason L.; Pearson, Hugh A.; Peers, Chris			Carbon monoxide protects against oxidant-induced apoptosis via inhibition of K(v)2.1	FASEB JOURNAL			English	Article						potassium channel; hippocampal neuron; heme oxygenase	NEURONAL APOPTOSIS; OXIDATIVE STRESS; HEME OXYGENASE-1; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; POTASSIUM CHANNEL; NITRIC-OXIDE; K+ CHANNEL; KV2.1; BRAIN	Oxidative stress induces neuronal apoptosis and is implicated in cerebral ischemia, head trauma, and age-related neurodegenerative diseases. An early step in this process is the loss of intracellular K+ via K+ channels, and evidence indicates that K(v)2.1 is of particular importance in this regard, being rapidly inserted into the plasma membrane in response to apoptotic stimuli. An additional feature of neuronal oxidative stress is the up-regulation of the inducible enzyme heme oxygenase-1 (HO-1), which catabolizes heme to generate biliverdin, Fe2+, and carbon monoxide (CO). CO provides neuronal protection against stresses such as stroke and excitotoxicity, although the underlying mechanisms are not yet elucidated. Here, we demonstrate that CO reversibly inhibits K(v)2.1. Channel inhibition by CO involves reactive oxygen species and protein kinase G activity. Overexpression of K(v)2.1 in HEK293 cells increases their vulnerability to oxidant-induced apoptosis, and this is reversed by CO. In hippocampal neurons, CO selectively inhibits K(v)2.1, reverses the dramatic oxidant-induced increase in K+ current density, and provides marked protection against oxidant-induced apoptosis. Our results provide a novel mechanism to account for the neuroprotective effects of CO against oxidative apoptosis, which has potential for therapeutic exploitation to provide neuronal protection in situations of oxidative stress.-Dallas, M. L., Boyle, J. P., Milligan, C. J., Sayer, R., Kerrigan, T. L., McKinstry, C., Lu, P., Mankouri, J., Harris, M., Scragg, J. L., Pearson, H. A., Peers, C. Carbon monoxide protects against oxidant-induced apoptosis via inhibition of K(v)2.1. FASEB J. 25, 1519-1530 (2011). www.fasebj.org	[Dallas, Mark L.; Boyle, John P.; McKinstry, Connor; Scragg, Jason L.; Peers, Chris] Univ Leeds, Fac Med & Hlth, Div Cardiovasc & Neuronal Remodelling, Leeds LS2 9JT, W Yorkshire, England; [Milligan, Carol J.; Sayer, Rachael; Kerrigan, Talitha L.; Mankouri, Jamel; Harris, Mark; Pearson, Hugh A.] Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England; [Lu, Peiyuan] Hebei Gen Hosp, Dept Neurol, Shijiazhuang, Hebei, Peoples R China	University of Leeds; University of Leeds	Peers, C (corresponding author), Univ Leeds, Fac Med & Hlth, Div Cardiovasc & Neuronal Remodelling, Leeds LS2 9JT, W Yorkshire, England.	c.s.peers@leeds.ac.uk	Boyle, John/N-4868-2016; Dallas, Mark L/A-6654-2013; Kerrigan, Talitha/C-3759-2016; Dallas, Mark/Q-6117-2019	Dallas, Mark/0000-0002-5190-0522; Kerrigan, Talitha/0000-0003-2158-567X; Peers, Chris/0000-0002-8354-346X; Harris, Mark/0000-0002-9821-1003; Mankouri, Jamel/0000-0002-4325-3687	Medical Research Council; Wellcome Trust; British Heart Foundation; Department of International Cooperation, Hebei Province Science and Technology Research Council, China [09396427D]; MRC [G0600936] Funding Source: UKRI; British Heart Foundation [PG/09/013/26885] Funding Source: researchfish; Medical Research Council [G0600936] Funding Source: researchfish; Alzheimer&quot;s Society [121] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); British Heart Foundation(British Heart Foundation); Department of International Cooperation, Hebei Province Science and Technology Research Council, China; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Alzheimer&quot;s Society	This work was supported by the Medical Research Council, Wellcome Trust, and British Heart Foundation, and the Department of International Cooperation, Hebei Province Science and Technology Research Council, China (09396427D). The authors are most grateful to Dr. James S. Trimmer (University of California, Davis, CA, USA) for the K<INF>v</INF>2.1-expressing HEK293 cell line and to R. Suman for technical assistance.	Ahmad AS, 2006, NEUROSCIENCE, V141, P1703, DOI 10.1016/j.neuroscience.2006.05.035; Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Bortner CD, 2002, ANNU REV PHARMACOL, V42, P259, DOI 10.1146/annurev.pharmtox.42.083101.143836; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Chen CY, 2005, BIOCHEM BIOPH RES CO, V331, P993, DOI 10.1016/j.bbrc.2005.03.237; Chien WL, 2003, MOL PHARMACOL, V63, P1322, DOI 10.1124/mol.63.6.1322; Chung SW, 2008, J CLIN INVEST, V118, P239, DOI 10.1172/JCI32730; Dai XQ, 2009, J CELL SCI, V122, P775, DOI 10.1242/jcs.036632; Dallas ML, 2008, NEUROREPORT, V19, P345, DOI 10.1097/WNR.0b013e3282f51045; Dennery PA, 2000, CURR TOP CELL REGUL, V36, P181; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dore S, 2000, NEUROSCIENCE, V99, P587, DOI 10.1016/S0306-4522(00)00216-5; Droge W, 2007, AGING CELL, V6, P361, DOI 10.1111/j.1474-9726.2007.00294.x; Du J, 1998, NEUROSCIENCE, V84, P37, DOI 10.1016/S0306-4522(97)00519-8; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Giorgio M, 2007, NAT REV MOL CELL BIO, V8, p722A; Hou ST, 2002, INT REV CYTOL, V221, P93; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Imuta N, 2007, ANTIOXID REDOX SIGN, V9, P543, DOI 10.1089/ars.2006.1519; Jaggar JH, 2005, CIRC RES, V97, P805, DOI 10.1161/01.RES.0000186180.47148.7b; Kim HP, 2006, ANNU REV PHARMACOL, V46, P411, DOI 10.1146/annurev.pharmtox.46.120604.141053; Michelakis ED, 2002, CIRC RES, V91, P478, DOI 10.1161/01.RES.0000035057.63303.D1; Misonou H, 2006, J NEUROSCI, V26, P13505, DOI 10.1523/JNEUROSCI.3970-06.2006; Motterlini R, 2010, NAT REV DRUG DISCOV, V9, P728, DOI 10.1038/nrd3228; Murakoshi H, 1999, J NEUROSCI, V19, P1728; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; O'Connell KMS, 2010, P NATL ACAD SCI USA, V107, P12351, DOI 10.1073/pnas.1003028107; Okouchi M, 2007, ANTIOXID REDOX SIGN, V9, P1059, DOI 10.1089/ars.2007.1511; Ota KT, 2008, LEARN MEMORY, V15, P792, DOI 10.1101/lm.1114808; Pal S, 2003, J NEUROSCI, V23, P4798; Pal SK, 2006, CELL DEATH DIFFER, V13, P661, DOI 10.1038/sj.cdd.4401792; Pappolla MA, 1998, AM J PATHOL, V152, P871; Park KS, 2006, SCIENCE, V313, P976, DOI 10.1126/science.1124254; Plant LD, 2006, NEUROBIOL AGING, V27, P1673, DOI 10.1016/j.neurobiolaging.2005.09.038; Redman PT, 2007, P NATL ACAD SCI USA, V104, P3568, DOI 10.1073/pnas.0610159104; Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Schipper HM, 2009, J NEUROCHEM, V110, P469, DOI 10.1111/j.1471-4159.2009.06160.x; Scragg JL, 2008, J BIOL CHEM, V283, P24412, DOI 10.1074/jbc.M803037200; Sesti F, 2010, TRENDS CELL BIOL, V20, P45, DOI 10.1016/j.tcb.2009.09.008; Toyoda H, 2010, J NEUROSCI, V30, P5677, DOI 10.1523/JNEUROSCI.5407-09.2010; Wei L, 2003, STROKE, V34, P1281, DOI 10.1161/01.STR.0000065828.18661.FE; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Wu LY, 2005, PHARMACOL REV, V57, P585, DOI 10.1124/pr.57.4.3; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3; Yu SP, 2003, PROG NEUROBIOL, V70, P363, DOI 10.1016/S0301-0082(03)00090-X; Zeynalov E, 2009, NEUROTOX RES, V15, P133, DOI 10.1007/s12640-009-9014-4; Zuckerbraun BS, 2007, FASEB J, V21, P1099, DOI 10.1096/fj.06-6644com	49	72	74	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1519	1530		10.1096/fj.10-173450	http://dx.doi.org/10.1096/fj.10-173450			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21248240				2022-12-28	WOS:000290023800010
J	Hobbs, RP; Amargo, EV; Somasundaram, A; Simpson, CL; Prakriya, M; Denning, MF; Green, KJ				Hobbs, Ryan P.; Amargo, Evangeline V.; Somasundaram, Agila; Simpson, Cory L.; Prakriya, Murali; Denning, Mitchell F.; Green, Kathleen J.			The calcium ATPase SERCA2 regulates desmoplakin dynamics and intercellular adhesive strength through modulation of PKC alpha signaling	FASEB JOURNAL			English	Article						desmosome; Darier's disease; intracellular Ca2+; cell-cell contact	HAILEY-HAILEY-DISEASE; PROTEIN-KINASE-C; INTERMEDIATE-FILAMENT NETWORKS; CULTURED EPITHELIAL-CELLS; DARIERS-DISEASE; IN-VITRO; HUMAN KERATINOCYTES; TOPICAL CALCITRIOL; PLASMA-MEMBRANE; DESMOSOMES	Darier's disease (DD) is an inherited autosomal-dominant skin disorder characterized histologically by loss of adhesion between keratinocytes. DD is typically caused by mutations in sarcoendoplasmic reticulum Ca2+-ATPase isoform 2 (SERCA2), a major regulator of intracellular Ca2+ homeostasis in the skin. However, a defined role for SERCA2 in regulating intercellular adhesion remains poorly understood. We found that diminution of SERCA2 function by pharmacological inhibition or siRNA silencing in multiple human epidermal-derived cell lines was sufficient to disrupt desmosome assembly and weaken intercellular adhesive strength. Specifically, SERCA2-deficient cells exhibited up to a 60% reduction in border translocation of desmoplakin (DP), the desmosomal cytolinker protein necessary for intermediate filament (IF) anchorage to sites of robust cell-cell adhesion. In addition, loss of SERCA2 impaired the membrane translocation of protein kinase C alpha (PKC alpha), a known regulator of DP-IF association and desmosome assembly, to the plasma membrane by up to 70%. Exogenous activation of PKC alpha in SERCA2-deficient cells was sufficient to rescue the defective DP localization, desmosome assembly, and intercellular adhesive strength to levels comparable to controls. Our findings indicate that SERCA2-deficiency is sufficient to impede desmosome assembly and weaken intercellular adhesive strength via a PKC alpha-dependent mechanism, implicating SERCA2 as a novel regulator of PKC alpha signaling.-Hobbs, R. P., Amargo, E. V., Somasundaram, A., Simpson, C. L., Prakriya, M., Denning, M. F., Green, K. J. The calcium ATPase SERCA2 regulates desmoplakin dynamics and intercellular adhesive strength through modulation of PKC alpha signaling. FASEB J. 25, 990-1001 (2011). www.fasebj.org	[Hobbs, Ryan P.; Amargo, Evangeline V.; Simpson, Cory L.; Green, Kathleen J.] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; [Somasundaram, Agila; Prakriya, Murali] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; [Green, Kathleen J.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Green, Kathleen J.] Northwestern Univ, Feinberg Sch Med, RH Lurie Canc Ctr, Chicago, IL 60611 USA; [Denning, Mitchell F.] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Loyola University Chicago	Green, KJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	kgreen@northwestern.edu		Simpson, Cory/0000-0002-3933-6404; Prakriya, Murali/0000-0003-0781-4480	NIH [RO1 AR043380, RO1 AR041836, RO1 NS057499, F30 ES14990]; American Heart Association [0810061Z]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR043380, R01AR041836, R01AR043380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F30ES014990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM082133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057499] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Lisa Godsel and Spiro Getsios (Northwestern University) for their valued advice, support, and comments on the paper. This work was supported by NIH grants to K.J.G. (RO1 AR043380 and RO1 AR041836), M.P. (RO1 NS057499), and C.L.S. (F30 ES14990), as well as an American Heart Association fellowship to R.P.H (0810061Z). The authors declare no conflicts of interest.	Amagai M, 2003, J AM ACAD DERMATOL, V48, P244, DOI 10.1067/mjd.2003.7; ANGST BD, 1990, J CELL SCI, V97, P247; Aoki T, 1998, BRIT J DERMATOL, V139, P897; Bass-Zubek AE, 2008, J CELL BIOL, V181, P605, DOI 10.1083/jcb.200712133; Bianchi L, 2004, J AM ACAD DERMATOL, V51, P475, DOI 10.1016/j.jaad.2003.10.668; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; BURGE SM, 1991, BRIT J DERMATOL, V124, P242, DOI 10.1111/j.1365-2133.1991.tb00568.x; Cooper SM, 2003, AM J CLIN DERMATOL, V4, P97, DOI 10.2165/00128071-200304020-00003; DEDOBBELEER G, 1979, J CUTAN PATHOL, V6, P418; Denning MF, 2004, INT J BIOCHEM CELL B, V36, P1141, DOI 10.1016/j.biocel.2003.12.004; Dhitavat J, 2004, BRIT J DERMATOL, V150, P821, DOI 10.1111/j.1365-2133.2004.05904.x; Dhitavat J, 2003, J INVEST DERMATOL, V121, P1349, DOI 10.1046/j.1523-1747.2003.12557.x; Foggia L, 2006, J CELL SCI, V119, P671, DOI 10.1242/jcs.02781; Foggia L, 2004, AM J MED GENET C, V131C, P20, DOI 10.1002/ajmg.c.30031; Garrod D, 2008, BBA-BIOMEMBRANES, V1778, P572, DOI 10.1016/j.bbamem.2007.07.014; Garrod DR, 2005, J CELL SCI, V118, P5743, DOI 10.1242/jcs.02700; Getsios S, 2009, J CELL BIOL, V185, P1243, DOI 10.1083/jcb.200809044; Godsel LM, 2010, MOL BIOL CELL, V21, P2844, DOI 10.1091/mbc.E10-02-0131; Godsel LM, 2005, J CELL BIOL, V171, P1045, DOI 10.1083/jcb.200510038; Green KJ, 2007, J INVEST DERMATOL, V127, P2499, DOI 10.1038/sj.jid.5701015; HANAFIN NM, 1995, J CELL BIOCHEM, V57, P362, DOI 10.1002/jcb.240570220; Hayashi K, 1999, J CELL SCI, V112, P1149; HEDBLAD MA, 1991, ACTA DERM-VENEREOL, V71, P108; Hovnanian A., 2007, V45, P337; Hudson TY, 2004, METHOD CELL BIOL, V78, P757; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Ishii K, 2005, J INVEST DERMATOL, V124, P939, DOI 10.1111/j.0022-202X.2005.23714.x; JEGASOTHY BV, 1981, J INVEST DERMATOL, V76, P129, DOI 10.1111/1523-1747.ep12525466; Jerome-Morais A, 2009, J INVEST DERMATOL, V129, P2365, DOI 10.1038/jid.2009.74; Lai-Cheong JE, 2007, J INVEST DERMATOL, V127, P2713, DOI 10.1038/sj.jid.5700727; Leinonen PT, 2009, J INVEST DERMATOL, V129, P1379, DOI 10.1038/jid.2008.381; Mayuzumi N, 2005, BRIT J DERMATOL, V152, P920, DOI 10.1111/j.1365-2133.2005.06394.x; Meng JJ, 1997, J BIOL CHEM, V272, P21495, DOI 10.1074/jbc.272.34.21495; Muller EJ, 2006, J INVEST DERMATOL, V126, P721, DOI 10.1038/sj.jid.5700091; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Pani B, 2008, CELL MOL LIFE SCI, V65, P205, DOI 10.1007/s00018-007-7397-z; Pani B, 2006, MOL BIOL CELL, V17, P4446, DOI 10.1091/mbc.E06-03-0251; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V30, P108, DOI 10.1002/cm.970300203; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; Prasad V, 2004, BIOCHEM BIOPH RES CO, V322, P1192, DOI 10.1016/j.bbrc.2004.07.156; Rajpara SM, 2005, BRIT J DERMATOL, V152, P816, DOI 10.1111/j.1365-2133.2005.06489.x; Rasband W., 2006, IMAGEJ; Sabala Pawel, 1993, Acta Biochimica Polonica, V40, P309; SHEU HM, 1989, EXP CELL RES, V185, P176, DOI 10.1016/0014-4827(89)90047-5; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; Shull GE, 2003, ANN NY ACAD SCI, V986, P453, DOI 10.1111/j.1749-6632.2003.tb07229.x; Sonnenberg A, 2007, EXP CELL RES, V313, P2189, DOI 10.1016/j.yexcr.2007.03.039; STAPPENBECK TS, 1994, J BIOL CHEM, V269, P29351; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; Stokes DL, 2007, CURR OPIN CELL BIOL, V19, P565, DOI 10.1016/j.ceb.2007.09.003; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; Usachev YM, 2006, J NEUROSCI, V26, P311, DOI 10.1523/JNEUROSCI.2920-05.2006; VANDERZWAAG P, 2010, ARVC DATABASE; Wallis S, 2000, MOL BIOL CELL, V11, P1077, DOI 10.1091/mbc.11.3.1077; Yang Z, 2006, CIRC RES, V99, P646, DOI 10.1161/01.RES.0000241482.19382.c6	55	45	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					990	1001		10.1096/fj.10-163261	http://dx.doi.org/10.1096/fj.10-163261			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21156808	Green Published, Bronze			2022-12-28	WOS:000287806200019
J	Delgado, VMC; Nugnes, LG; Colombo, LL; Troncoso, MF; Fernandez, MM; Malchiodi, EL; Frahm, I; Croci, DO; Compagno, D; Rabinovich, GA; Wolfenstein-Todel, C; Elola, MT				Cardenas Delgado, Victor M.; Nugnes, Lorena G.; Colombo, Lucas L.; Troncoso, Maria F.; Fernandez, Marisa M.; Malchiodi, Emilio L.; Frahm, Isabel; Croci, Diego O.; Compagno, Daniel; Rabinovich, Gabriel A.; Wolfenstein-Todel, Carlota; Elola, Maria T.			Modulation of endothelial cell migration and angiogenesis: a novel function for the "tandem-repeat" lectin galectin-8	FASEB JOURNAL			English	Article						glycan-binding proteins; capillary formation; invasion	CARBOHYDRATE-RECOGNITION; ADHESION MOLECULE; PROSTATE-CANCER; IN-VITRO; EXPRESSION; BINDING; AFFINITY; MORPHOGENESIS; INFLAMMATION; INTEGRINS	Angiogenesis, the growth OF new capillaries from preexisting blood vessels, is a complex process involving endothelial cell (EC) activation, disruption of vascular basement membranes, and migration and proliferation of ECs. Glycan-mediated recognition has been proposed to play an instrumental role in mediating cell-cell and cell-matrix interactions. Galectins (Gal), a family of glycan-binding proteins with affinity for beta-galactosides and a conserved sequence motif, can decipher glycan-containing information and mediate cell-cell communication. Galectin-8 (Gal-8), a member of this family, is a bivalent "tandem-repeat"-type galectin, which possesses 2 CRDs connected by a linker peptide. Here, we show that Gal-8 is endowed with proangiogeneic properties. Functional assays revealed a critical role for this lectin in the regulation of capillary-tube formation and EC migration. Moreover, Matrigel, either supplemented with Gal-8 or vascular endothelial growth factor (VEGF), injected in mice resulted in induction of in vivo angiogenesis. Remarkably, Gal-8 was expressed both in the cytoplasm and nucleus in ECs of normal and tumor vessels. Furthermore, CD166 [activated leukocyte cell adhesion molecule (ALCAM)] was identified as a specific Gal-8-binding partner in normal vascular ECs. Collectively, these data provide the first evidence demonstrating an essential role for Gal-8 in the regulation of angiogenesis with critical implications in tumor biology.-Cardenas Delgado, V. M., Nugnes, L. G., Colombo, L. L., Troncoso, M. F., Fernandez, M. M., Malchiodi, E. L., Frahm, I., Croci, D. O., Compagno, D., Rabinovich, G. A., Wolfenstein-Todel, C., Elola, M. T. Modulation of endothelial cell migration and angiogenesis: a novel function for the "tandem-repeat" lectin galectin-8. FASEB J. 25, 242-254 (2011). www.fasebj.org	[Cardenas Delgado, Victor M.; Nugnes, Lorena G.; Troncoso, Maria F.; Wolfenstein-Todel, Carlota; Elola, Maria T.] Univ Buenos Aires, Inst Quim & Fis Quim Biol, Fac Farm & Bioquim, Consejo Nacl Invest Cient & Tecn UBA CONICET, Buenos Aires, DF, Argentina; [Fernandez, Marisa M.; Malchiodi, Emilio L.] Univ Buenos Aires, Catedra Inmunol, Fac Farm & Bioquim,Inst Estudios Inmunidad Humora, Consejo Nacl Invest Cient & Tecn UBA CONICET, Buenos Aires, DF, Argentina; [Colombo, Lucas L.] Univ Buenos Aires, Area Invest, Inst Oncolo AH Roffo, Buenos Aires, DF, Argentina; [Compagno, Daniel; Rabinovich, Gabriel A.] Univ Buenos Aires, Lab Modulac Genet & Inmunol, Dept Quim Biol, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina; [Frahm, Isabel] Sanatorio Mater Dei, Dept Patol, Buenos Aires, DF, Argentina; [Croci, Diego O.; Rabinovich, Gabriel A.] Inst Biol & Med Expt IBYME CONICET, Lab Inmunopatol, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine	Elola, MT (corresponding author), Univ Buenos Aires, Inst Quim & Fis Quim Biol UBA CONICET, Fac Farm & Bioquim, Junin 956,C1113, Buenos Aires, DF, Argentina.	mt_elola@yahoo.com	Croci, Diego/AAJ-5709-2021; Cárdenas Delgado, Víctor Manuel/GRY-5060-2022	Croci, Diego/0000-0002-8623-0645; Malchiodi, Emilio/0000-0001-7501-3330; Fernandez, Marisa/0000-0002-7480-5907; Troncoso, Maria Fernanda/0000-0002-4919-9976; Compagno, Daniel/0000-0002-7589-7217	Argentinean National Agency for Promotion of Science and Technology; University of Buenos Aires; Argentinean National Research Council (CONICET); Sales Foundation	Argentinean National Agency for Promotion of Science and Technology; University of Buenos Aires(University of Buenos Aires); Argentinean National Research Council (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Sales Foundation	The authors thank Guillermo Peluffo (Instituto Roffo, Buenos Aires, Argentina) who provided BAECs. This work was supported by grants from the Argentinean National Agency for Promotion of Science and Technology, the University of Buenos Aires, the Argentinean National Research Council (CONICET), and the Sales Foundation.	Ahmed H, 2007, BIOCHEM BIOPH RES CO, V358, P241, DOI 10.1016/j.bbrc.2007.04.114; AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Bidon N, 2001, INT J MOL MED, V8, P245; Bidon-Wagner N, 2002, GLYCOCONJUGATE J, V19, P557, DOI 10.1023/B:GLYC.0000014086.38343.98; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camby I, 2001, BRAIN PATHOL, V11, P12; Carcamo C, 2006, EXP CELL RES, V312, P374, DOI 10.1016/j.yexcr.2005.10.025; Carlsson S, 2007, GLYCOBIOLOGY, V17, P663, DOI 10.1093/glycob/cwm026; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cueni LN, 2009, EXP CELL RES, V315, P1715, DOI 10.1016/j.yexcr.2009.02.021; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Elola MT, 2007, CELL MOL LIFE SCI, V64, P1679, DOI 10.1007/s00018-007-7044-8; Elola MT, 2005, J BIOMED SCI, V12, P13, DOI 10.1007/s11373-004-8169-5; Fernandez MM, 2007, PROTEINS, V68, P389, DOI 10.1002/prot.21388; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Francis ME, 2008, TISSUE ENG PART B-RE, V14, P19, DOI 10.1089/teb.2007.0115; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Hadari YR, 2000, J CELL SCI, V113, P2385; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; He J, 2006, LAB INVEST, V86, P578, DOI 10.1038/labinvest.3700420; He JL, 2004, J BIOL CHEM, V279, P4705, DOI 10.1074/jbc.M311183200; Ideo H, 2003, GLYCOBIOLOGY, V13, P713, DOI 10.1093/glycob/cwg094; Ikeda K, 2004, J BIOL CHEM, V279, P55315, DOI 10.1074/jbc.M407776200; Institute of Laboratory Animal Resources CoLSNRC, 1996, GUID CAR US LAB AN; Le Mercier M, 2008, J NEUROPATH EXP NEUR, V67, P456, DOI 10.1097/NEN.0b013e318170f892; Le Mercier M, 2009, NEOPLASIA, V11, P485, DOI 10.1593/neo.81526; Levy Y, 2001, J BIOL CHEM, V276, P31285, DOI 10.1074/jbc.M100340200; Levy Y, 2003, J BIOL CHEM, V278, P14533, DOI 10.1074/jbc.M207380200; Markowska AI, 2010, J EXP MED, V207, P1981, DOI 10.1084/jem.20090121; Masedunskas A, 2006, FEBS LETT, V580, P2637, DOI 10.1016/j.febslet.2006.04.013; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; Nangia-Makker P, 2000, CANCER METAST REV, V19, P51, DOI 10.1023/A:1026540129688; Nguyen M, 1996, BIOCHEM BIOPH RES CO, V228, P716, DOI 10.1006/bbrc.1996.1722; Nishi N, 2003, GLYCOBIOLOGY, V13, P755, DOI 10.1093/glycob/cwg102; Norling LV, 2008, FASEB J, V22, P682, DOI 10.1096/fj.07-9268com; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134; Rabinovich GA, 2006, GLYCOBIOLOGY, V16, P210, DOI 10.1093/glycob/cwj056; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Sebban LE, 2007, J IMMUNOL, V179, P1225, DOI 10.4049/jimmunol.179.2.1225; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Thijssen VL, 2008, AM J PATHOL, V172, P545, DOI 10.2353/ajpath.2008.070938; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Tribulatti M. V., 2009, J LEUKOCYTE BIOL, V86, P1; Yang Ri-Yao, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000719; Zick Y, 2002, GLYCOCONJUGATE J, V19, P517, DOI 10.1023/B:GLYC.0000014081.55445.af	46	105	110	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					242	254		10.1096/fj.09-144907	http://dx.doi.org/10.1096/fj.09-144907			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20876211				2022-12-28	WOS:000285869500022
J	Doumazane, E; Scholler, P; Zwier, JM; Trinquet, E; Rondard, P; Pin, JP				Doumazane, Etienne; Scholler, Pauline; Zwier, Jurriaan M.; Trinquet, Eric; Rondard, Philippe; Pin, Jean-Philippe			A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors	FASEB JOURNAL			English	Article						GPCR; oligomerization; heteromerization; multilabeling; time-resolved fluorescence resonance energy transfer	RESONANCE ENERGY-TRANSFER; HIGHER-ORDER OLIGOMERS; TIME-RESOLVED FRET; COUPLED RECEPTORS; LIVING CELLS; GABA(B) RECEPTOR; GPCR; EXPRESSION; ACTIVATION; SUBTYPES	G-protein-coupled receptors (GPCRs) can form heteromeric complexes. Herein, we describe a new approach to test the heteromerization of 2 receptors, or 2 receptor subunits, and to study the stoichiometry of the resulting complexes. As a proof-of-concept study, we investigated whether metabotropic glutamate receptors (mGluRs), in addition to being well-known homodimers, can form heteromers. To that aim, we combine the benefits of time-resolved fluorescence resonance energy transfer (trFRET) with the specific, cell-surface labeling of SNAP- and CLIP-tagged rat mGluR subunits, expressed in a mammalian cell line. First, we show that mGlu2 and mGlu4 subunits (but not mGlu2 and mGlu1) can heteromerize. Moreover, our trFRET data are consistent with mGluR subunits forming strict homodimeric receptors on single expression, and a combination of strict heterodimeric and strict homodimeric receptors on coexpression. Second, a comprehensive analysis reveals that from the 21 possible pairs of 2 mGluR subunits out of 7 subtypes (mGlu1 to 8, but not 6), only 11 are able to form heterodimers. These findings were further validated by biochemical and functional complementation studies. In addition to describing a new method to analyze cell-surface receptor complexes, our data reveal a new level of complexity within the mGluR family.-Doumazane, E., Scholler, P., Zwier, J. M., Trinquet, E., Rondard, P., Pin, J.-P. A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors. FASEB J. 25, 66-77 (2011). www.fasebj.org	[Doumazane, Etienne; Scholler, Pauline; Rondard, Philippe; Pin, Jean-Philippe] CNRS, Inst Genom Fonct, UMR 5203, F-34094 Montpellier, France; [Doumazane, Etienne; Scholler, Pauline; Rondard, Philippe; Pin, Jean-Philippe] Inst Natl Sante & Rech Med, Unite 661, Montpellier, France; [Zwier, Jurriaan M.; Trinquet, Eric] Cisbio Bioassays, Bagnols Sur Ceze, France; [Doumazane, Etienne; Scholler, Pauline; Rondard, Philippe; Pin, Jean-Philippe] Univ Montpellier 1 & 2, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Rondard, P (corresponding author), CNRS, Inst Genom Fonct, UMR 5203, 141 Rue Cardonille, F-34094 Montpellier, France.	philippe.rondard@igf.cnrs.fr; jean-philippe.pin@igf.cnrs.fr	Rondard, Philippe/N-9720-2018; Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; Zwier, Jurriaan/0000-0001-9017-5856; RONDARD, Philippe/0000-0003-1134-2738	Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; French Ministry of Research; Cisbio Bioassays; Agence Nationale pour la Recherche [06-BLANC-0087, 09-BLANC-0272]	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Cisbio Bioassays; Agence Nationale pour la Recherche(French National Research Agency (ANR))	The authors thank Drs. Carsten Brock and Marie-Laure Rives [Institut de Genomique Fonctionnelle (IGF), Montpellier, France] for plasmids; Dr. Damien Maurel and Laetitia Comps-Agrar for initial work; and Dr. Kai Johnsson (Ecole Polytechnique Federale, Lausanne, Switzerland) for the CLIP plasmid. The authors also thank Drs. Sebastien Granier, Laurent Prezeau, Thierry Durroux, and Gregory D. Stewart (IGF) for helpful comments on the manuscript, and Francesco Ferraguti (University of Innsbruck, Innsbruck, Austria) for constructive discussions. The authors thank Claire Vol, Isabelle Brabet, and the screening facilities of the IGF (Plate-forme Pharmacologie Criblage Interactome, Montpellier, France). This work was supported by grants from Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, French Ministry of Research, Cisbio Bioassays, and the Agence Nationale pour la Recherche (contracts 06-BLANC-0087 and 09-BLANC-0272). Lumi4 is a registered trademark of Lumiphore, Inc.	Albizu L, 2010, NAT CHEM BIOL, V6, P587, DOI [10.1038/NCHEMBIO.396, 10.1038/nchembio.396]; Altier C, 2006, NAT NEUROSCI, V9, P31, DOI 10.1038/nn1605; Bazin H, 2002, J Biotechnol, V82, P233, DOI 10.1016/S1389-0352(01)00040-X; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Brock C, 2005, MOL BIOL CELL, V16, P5572, DOI 10.1091/mbc.E05-05-0400; Brock C, 2007, J BIOL CHEM, V282, P33000, DOI 10.1074/jbc.M702542200; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Cabello N, 2009, J NEUROCHEM, V109, P1497, DOI 10.1111/j.1471-4159.2009.06078.x; Carriba P, 2008, NAT METHODS, V5, P727, DOI 10.1038/nmeth.1229; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Cottet M, 2010, CURR OPIN PHARMACOL, V10, P59, DOI 10.1016/j.coph.2009.10.003; Degorce Francois, 2009, Curr Chem Genomics, V3, P22, DOI 10.2174/1875397300903010022; Ernst OP, 2007, P NATL ACAD SCI USA, V104, P10859, DOI 10.1073/pnas.0701967104; Ferraguti F, 2005, J NEUROSCI, V25, P10520, DOI 10.1523/JNEUROSCI.2547-05.2005; Ferraguti F, 2001, EXP BRAIN RES, V137, P1, DOI 10.1007/s002210000633; Ferraguti F, 2006, CELL TISSUE RES, V326, P483, DOI 10.1007/s00441-006-0266-5; Ferre S, 2009, NAT CHEM BIOL, V5, P131, DOI 10.1038/nchembio0309-131; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Frauli M, 2006, NEUROPHARMACOLOGY, V50, P245, DOI 10.1016/j.neuropharm.2005.09.016; Fung JJ, 2009, EMBO J, V28, P3315, DOI 10.1038/emboj.2009.267; Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200; Gautier A, 2008, CHEM BIOL, V15, P128, DOI 10.1016/j.chembiol.2008.01.007; Gonzalez-Maeso J, 2008, NATURE, V452, P93, DOI 10.1038/nature06612; Goudet C, 2005, J BIOL CHEM, V280, P24380, DOI 10.1074/jbc.M502642200; Guo W, 2008, EMBO J, V27, P2293, DOI 10.1038/emboj.2008.153; Gurevich VV, 2008, TRENDS NEUROSCI, V31, P74, DOI 10.1016/j.tins.2007.11.007; Hern JA, 2010, P NATL ACAD SCI USA, V107, P2693, DOI 10.1073/pnas.0907915107; Hlavackova V, 2005, EMBO J, V24, P499, DOI 10.1038/sj.emboj.7600557; Iacovelli L, 2009, MOL PHARMACOL, V75, P991, DOI 10.1124/mol.108.052316; Jingami H, 2003, CURR OPIN NEUROBIOL, V13, P271, DOI 10.1016/S0959-4388(03)00067-9; Juillerat A, 2003, CHEM BIOL, V10, P313, DOI 10.1016/S1074-5521(03)00068-1; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; Kniazeff J, 2004, NAT STRUCT MOL BIOL, V11, P706, DOI 10.1038/nsmb794; Koulen P, 1997, J NEUROSCI, V17, P2200; Kubo Y, 2005, CURR OPIN NEUROBIOL, V15, P289, DOI 10.1016/j.conb.2005.05.011; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Maurel D, 2004, ANAL BIOCHEM, V329, P253, DOI 10.1016/j.ab.2004.02.013; Maurel D, 2008, NAT METHODS, V5, P561, DOI [10.1038/nmeth.1213, 10.1038/NMETH.1213]; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Melchiorri D, 2007, NEUROPHARMACOLOGY, V53, P473, DOI 10.1016/j.neuropharm.2007.05.031; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Meyer BH, 2006, P NATL ACAD SCI USA, V103, P2138, DOI 10.1073/pnas.0507686103; Milligan G, 2007, TRENDS PHARMACOL SCI, V28, P615, DOI 10.1016/j.tips.2007.11.001; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Niswender CM, 2010, ANNU REV PHARMACOL, V50, P295, DOI 10.1146/annurev.pharmtox.011008.145533; O'Hare HM, 2007, CURR OPIN STRUC BIOL, V17, P488, DOI 10.1016/j.sbi.2007.07.005; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Patil ST, 2007, NAT MED, V13, P1102, DOI 10.1038/nm1632; Pfleger KDG, 2006, NAT METHODS, V3, P165, DOI 10.1038/nmeth841; Pin JP, 2005, FEBS J, V272, P2947, DOI 10.1111/j.1742-4658.2005.04728.x; Pisterzi LF, 2010, J BIOL CHEM, V285, P16723, DOI 10.1074/jbc.M109.069443; Prezeau L, 2010, CURR OPIN PHARMACOL, V10, P6, DOI 10.1016/j.coph.2009.10.009; Raicu V, 2007, J BIOL PHYS, V33, P109, DOI 10.1007/s10867-007-9046-z; Rajapakse HE, 2010, P NATL ACAD SCI USA, V107, P13582, DOI 10.1073/pnas.1002025107; Rives ML, 2009, EMBO J, V28, P2195, DOI 10.1038/emboj.2009.177; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Rozenfeld R, 2010, TRENDS PHARMACOL SCI, V31, P124, DOI 10.1016/j.tips.2009.11.008; Salter MW, 2003, TRENDS NEUROSCI, V26, P235, DOI 10.1016/S0166-2236(03)00081-X; Selvin PR, 2002, ANNU REV BIOPH BIOM, V31, P275, DOI 10.1146/annurev.biophys.31.101101.140927; Swanson CJ, 2005, NAT REV DRUG DISCOV, V4, P131, DOI 10.1038/nrd1630; Tallaksen-Greene SJ, 1998, BRAIN RES, V780, P210, DOI 10.1016/S0006-8993(97)01141-4; Thoreson WB, 1999, PROG RETIN EYE RES, V18, P765, DOI 10.1016/S1350-9462(98)00031-7; van Hooft JA, 2000, J NEUROSCI, V20, P3544, DOI 10.1523/JNEUROSCI.20-10-03544.2000; VEATCH W, 1977, J MOL BIOL, V113, P89, DOI 10.1016/0022-2836(77)90042-0; VOGEL SS, 2006, SCI STKE, pRE2, DOI DOI 10.1126/STKE.3312006RE2; Volk LJ, 2006, J NEUROPHYSIOL, V95, P2427, DOI 10.1152/jn.00383.2005; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104	71	209	226	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					66	77		10.1096/fj.10-163147	http://dx.doi.org/10.1096/fj.10-163147			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20826542				2022-12-28	WOS:000285869500007
J	Gimm, T; Wiese, M; Teschemacher, B; Deggerich, A; Schodel, J; Knaup, KX; Hackenbeck, T; Hellerbrand, C; Amann, K; Wiesener, MS; Honing, S; Eckardt, KU; Warnecke, C				Gimm, Tina; Wiese, Melanie; Teschemacher, Barbara; Deggerich, Anke; Schoedel, Johannes; Knaup, Karl X.; Hackenbeck, Thomas; Hellerbrand, Claus; Amann, Kerstin; Wiesener, Michael S.; Hoening, Stefan; Eckardt, Kai-Uwe; Warnecke, Christina			Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1	FASEB JOURNAL			English	Article						renal clear-cell carcinoma; gene expression; promoter; lipid metabolism	RENAL-CELL CARCINOMA; DIFFERENTIATION-RELATED PROTEIN; FACTOR (HIF)-1-ALPHA; TRANSCRIPTION FACTORS; INSULIN-RESISTANCE; RNA INTERFERENCE; LIVER-CELLS; DNA-BINDING; FOAM CELLS; EXPRESSION	Hypoxia-inducible protein 2 (HIG2) has been implicated in canonical Wnt signaling, both as target and activator. The potential link between hypoxia and an oncogenic signaling pathway might play a pivotal role in renal clear-cell carcinoma characterized by constitutive activation of hypoxia-inducible factors (HIFs), and hence prompted us to analyze HIG2 regulation and function in detail. HIG2 was up-regulated by hypoxia and HIF inducers in all cell types and mouse organs investigated and abundantly expressed in renal clear-cell carcinomas. Promoter analyses, gel shifts, and siRNA studies revealed that HIG2 is a direct and specific target of HIF-1, but not responsive to HIF-2. Surprisingly, HIG2 was not secreted, and HIG2 overexpression neither stimulated proliferation nor activated Wnt signaling. Instead, we show that HIG2 decorates the hemimembrane of lipid droplets, whose number and size increase on hypoxic inhibition of fatty acid beta-oxidation, and colocalizes with the lipid droplet proteins adipophilin and TIP47. Normoxic overexpression of HIG2 was sufficient to increase neutral lipid deposition in HeLa cells and stimulated cytokine expression. HIG2 could be detected in atherosclerotic arteries and fatty liver disease, suggesting that this ubiquitously inducible HIF-1 target gene may play an important functional role in diseases associated with pathological lipid accumulation.-Gimm, T., Wiese, M., Teschemacher, B., Deggerich, A., Schodel, J., Knaup, K. X., Hackenbeck, T., Hellerbrand, C., Amann, K., Wiesener, M. S., Honing, S., Eckardt, K.-U., Warnecke, C. Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1. FASEB J. 24, 4443-4458 (2010). www.fasebj.org	[Warnecke, Christina] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Renal Res Labs, D-91054 Erlangen, Germany; [Knaup, Karl X.; Hackenbeck, Thomas; Wiesener, Michael S.] Univ Erlangen Nurnberg, Interdisciplinary Ctr Clin Res IZKF, D-91054 Erlangen, Germany; [Deggerich, Anke; Hoening, Stefan] Univ Cologne, Inst Biochem 1, Cologne, Germany; [Deggerich, Anke; Hoening, Stefan] Univ Cologne, Ctr Mol Med, Cologne, Germany; [Schoedel, Johannes] Univ Oxford, Oxford, England; [Hellerbrand, Claus] Univ Hosp Regensburg, Dept Internal Med 1, Regensburg, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Cologne; University of Cologne; University of Oxford; University of Regensburg	Warnecke, C (corresponding author), Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Renal Res Labs, Loschgestr 8, D-91054 Erlangen, Germany.	christina.warnecke@uk-erlangen.de		Knaup, Karl/0000-0003-1803-4463; Schodel, Johannes/0000-0002-3587-8839	Wilhelm Sander-Foundation; Roche Foundation for Anemia Research	Wilhelm Sander-Foundation; Roche Foundation for Anemia Research	This study was supported by grants of the Wilhelm Sander-Foundation and the Roche Foundation for Anemia Research to C.W. The authors thank H. Sticht (Department of Biochemistry, University of Erlangen-Nuremberg) for protein structure analysis. The authors thank M. Reutelshofer and A. Ludke for excellent technical assistance.	Aprelikova O, 2006, CANCER RES, V66, P5641, DOI 10.1158/0008-5472.CAN-05-3345; Belanger AJ, 2007, BIOCHEM BIOPH RES CO, V364, P567, DOI 10.1016/j.bbrc.2007.10.062; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Bell M, 2008, DIABETES, V57, P2037, DOI 10.2337/db07-1383; Bickel PE, 2009, BBA-MOL CELL BIOL L, V1791, P419, DOI 10.1016/j.bbalip.2009.04.002; Bostrom P, 2006, ARTERIOSCL THROM VAS, V26, P1871, DOI 10.1161/01.ATV.0000229665.78997.0b; Bostrom P, 2009, BIOCHEM SOC T, V37, P981, DOI 10.1042/BST0370981; Bulankina AV, 2009, J CELL BIOL, V185, P641, DOI 10.1083/jcb.200812042; Byrne CD, 2010, CLIN SCI, V118, P397, DOI 10.1042/CS20090565; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Denko N, 2000, CLIN CANCER RES, V6, P480; Ducharme NA, 2008, ENDOCRINOLOGY, V149, P942, DOI 10.1210/en.2007-1713; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Fan B, 2009, AM J PHYSIOL-ENDOC M, V297, pE112, DOI 10.1152/ajpendo.00119.2009; GORDON GB, 1977, AM J PATHOL, V88, P663; Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104; Hagist S, 2009, HEPATOLOGY, V49, P378, DOI 10.1002/hep.22677; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hull F E, 1975, Recent Adv Stud Cardiac Struct Metab, V7, P13; Imamura T, 2009, INT J CANCER, V124, P763, DOI 10.1002/ijc.24032; Jiang GJ, 2007, EUR J PHARMACOL, V562, P183, DOI 10.1016/j.ejphar.2007.01.066; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kenny PA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-3; Krishnan J, 2009, CELL METAB, V9, P512, DOI 10.1016/j.cmet.2009.05.005; Lei L, 2008, MOL CELL BIOL, V28, P3790, DOI 10.1128/MCB.01580-07; Listenberger LL, 2007, J LIPID RES, V48, P2751, DOI 10.1194/jlr.M700359-JLR200; Maxwell P, 2003, J AM SOC NEPHROL, V14, P2712, DOI 10.1097/01.ASN.0000092792.97122.E0; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Miyanari Y, 2007, NAT CELL BIOL, V9, P1089, DOI 10.1038/ncb1631; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Rankin EB, 2009, MOL CELL BIOL, V29, P4527, DOI 10.1128/MCB.00200-09; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Sluimer JC, 2009, J PATHOL, V218, P7, DOI 10.1002/path.2518; Sowter HM, 2003, CANCER RES, V63, P6130; Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120; Varela GM, 2008, AM J PHYSIOL-GASTR L, V295, pG621, DOI 10.1152/ajpgi.90204.2008; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; Warnecke C, 2008, EXP CELL RES, V314, P2016, DOI 10.1016/j.yexcr.2008.03.003; Weidemann A, 2008, BIOCHEM J, V409, P233, DOI 10.1042/BJ20070629; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WHITMER JT, 1978, J BIOL CHEM, V253, P4305; Wiesener MS, 2001, CANCER RES, V61, P5215; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Yao M, 2005, J PATHOL, V205, P377, DOI 10.1002/path.1693; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhao HJ, 2006, PLOS MED, V3, P115, DOI 10.1371/journal.pmed.0030013	52	101	108	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4443	4458		10.1096/fj.10-159806	http://dx.doi.org/10.1096/fj.10-159806			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20624928				2022-12-28	WOS:000283861100030
J	Feng, L; Sun, H; Zhang, Y; Li, DF; Wang, DC				Feng, Lei; Sun, Hui; Zhang, Ying; Li, De-Feng; Wang, Da-Cheng			Structural insights into the recognition mechanism between an antitumor galectin AAL and the Thomsen-Friedenreich antigen	FASEB JOURNAL			English	Article						glycan target for tumor on cell surface; complex structure between tumor-related protein and glycan; protein-glycan interaction mode	TF ANTIGEN; CANCER; BINDING; LECTIN; MUC1	Thomsen-Friedenreich (TF) antigen, which plays an important role in the regulation of cancer cell proliferation, occurs in similar to 90% of all human cancers and precancerous conditions. Although TF antigen has been known for almost 80 yr as a pancarcinoma antigen, the recognition mechanism between TF antigen and target protein has not been structurally characterized. A number of studies indicated that TF disaccharide is a potential ligand of the galactoside-binding galectins. In this work, we identified the TF antigen as a potential ligand of the antitumor galectin AAL (Agrocybe aegerita lectin) through glycan array analysis and reported the crystal structure of AAL complexed with the TF antigen. The structure provides a first look at the recognition mode between AAL and TF antigen, which is unique in a conservative (Glu-water-Arg-water) structural motif-based hydrogen bond network. Structure-based mutagenesis analysis further revealed the residues responsible for recognition specificity and binding affinity. Crystal structures of AAL complexed with two other TF-containing glycans showed that the unique TF recognition mode is kept intact, which may be commonly adopted in some cancer-related galectins. The finding provided the new target and approach for the antitumor drug design and relative strategy based on the AAL-TF recognition mode as a prototype model.-Feng, L., Sun, H., Zhang, Y., Li, D.-F., Wang, D.-C. Structural insights into the recognition mechanism between an antitumor galectin AAL and the Thomsen-Friedenreich antigen. FASEB J. 24, 3861-3868 (2010). www.fasebj.org	[Feng, Lei; Zhang, Ying; Li, De-Feng; Wang, Da-Cheng] Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China; [Feng, Lei] Chinese Acad Sci, Grad Sch, Beijing 100101, Peoples R China; [Sun, Hui] Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Wuhan University	Li, DF (corresponding author), Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, 15 Datun Rd, Beijing 100101, Peoples R China.	dcwang@ibp.ac.cn			"973" and "863" Research Programs of China [2006CB806502, 2006CB910901, 2006AA02E135]; Ministry of Health, China [2009ZX09103676]; National Institute of General Medical Sciences [GM62116]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	"973" and "863" Research Programs of China(Ministry of Science and Technology, China); Ministry of Health, China; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the "973" and "863" Research Programs of China (2006CB806502, 2006CB910901, 2006AA02E135) and the Ministry of Health, China (2009ZX09103676). The glycan array analysis was conducted by the Protein-Carbohydrate Interaction Core, and the TF antigen and GM1 pentasaccharide were provided by the Carbohydrate Synthesis/Protein Expression Core of the Consortium for Functional Glycomics (CFG), funded by the National Institute of General Medical Sciences grant GM62116. The authors thank David F. Smith and Jamie Heimburg-Molinaro (Consortium for Functional Glycomics) for screening the glycan array, and Yi Han, Yanxia Jia, and Chunchun Liu (Institute of Biophysics, Chinese Academy of Sciences) for their help with in-house X-ray data collection, ITC assay, and flow cytometric assay, respectively. The authors are also grateful to the Photo Factory (08G007; KEK, Tsukuba, Japan), and the Beijing and Shanghai Synchrotron Radiation Facility for providing access to the synchrotron radiation facilities for the X-ray diffraction experiment. The authors also thank Dr. Yonglin Hu for carefully checking and editing the manuscript.	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldus SE, 2004, CRIT REV CL LAB SCI, V41, P189, DOI 10.1080/10408360490452040; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano WL, 2005, PYMOL V 0 98; Gauto DF, 2009, J PHYS CHEM B, V113, P8717, DOI 10.1021/jp901196n; Hanisch FG, 1997, HISTOL HISTOPATHOL, V12, P263; Jeschke U, 2006, HISTOCHEM CELL BIOL, V126, P437, DOI 10.1007/s00418-006-0178-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEFFLER H, 1986, J BIOL CHEM, V261, P119; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Nagae M, 2006, J BIOL CHEM, V281, P35884, DOI 10.1074/jbc.M606648200; Natchiar SK, 2006, ACTA CRYSTALLOGR D, V62, P1413, DOI 10.1107/S0907444906035712; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Slovin SF, 2005, CANCER IMMUNOL IMMUN, V54, P694, DOI 10.1007/s00262-004-0598-5; Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walser PJ, 2004, STRUCTURE, V12, P689, DOI 10.1016/j.str.2004.03.002; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yang N, 2005, J BIOCHEM, V138, P145, DOI 10.1093/jb/mvi109; Yang N, 2005, BBA-PROTEINS PROTEOM, V1751, P209, DOI 10.1016/j.bbapap.2005.06.003; Yang N, 2009, J MOL BIOL, V387, P694, DOI 10.1016/j.jmb.2009.02.002; YU BJL, 1998, INT J CANCER, V73, P424; Yu LG, 2007, GLYCOCONJUGATE J, V24, P411, DOI 10.1007/s10719-007-9034-3; Yu LG, 2007, J BIOL CHEM, V282, P773, DOI 10.1074/jbc.M606862200; Zhao CG, 2003, BIOCHEM J, V374, P321, DOI 10.1042/BJ20030300	27	31	32	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3861	3868		10.1096/fj.10-159111	http://dx.doi.org/10.1096/fj.10-159111			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20530247	Green Published			2022-12-28	WOS:000285005900024
J	Deidda, G; Rossi, N; Putti, S; Tocchini-Valentini, GP				Deidda, Giancarlo; Rossi, Nicoletta; Putti, Sabrina; Tocchini-Valentini, Glauco P.			ARCHAEA-ExPRESs targeting of alpha-tubulin 4 mRNA: a model for high-specificity trans-splicing	FASEB JOURNAL			English	Article						mRNA reprogramming; bulge-helix-bulge; tRNA endonuclease; Methanocaldococcus jannaschii; RNA targeting	RIBOZYME-MEDIATED REPAIR	Effectiveness of trans-splicing-mediated mRNA reprogramming depends on specificity and efficiency. We have previously developed a new strategy (ARCHAEA-ExPRESs) that uses a tRNA endonuclease derived from Archaea and its natural substrate, the bulge-helix-bulge (BHB) structure. ARCHAEA-ExPRESs provides increased specificity in functional targeting. In fact, this system is based on a double check, the base pairing and the formation of a BHB structure between the target mRNA and the targeting RNA. In this study, we demonstrate the high specificity of ARCHAEA-ExPRESs by tagging the endogenous alpha-tubulin 4 via trans-splicing. alpha-Tubulin 4 belongs to a gene family sharing high degree of nucleotide sequence homology. The formation of a perfect BHB structure between targeting RNAs and the isotype alpha-tubulin 4 enables selective trans-splicing. Most important, ARCHAEA-ExPRESs functionality is conserved in vivo following transient expression of archaeal tRNA endonuclease in mouse liver. Production of the recombinant protein is strictly dependent on the expression of the archaeal endonuclease, and the efficiency of the system depends on the relative amount of the target and targeting mRNAs. These data prove the effectiveness of ARCHAEA-ExPRESs in an endogenous highly demanding context and disclose the possibility to utilize this system in a variety of technological or therapeutic applications.-Deidda, G., Rossi, N., Putti, S., Tocchini-Valentini, G. P. ARCHAEA-ExPRESs targeting of alpha-tubulin 4 mRNA: a model for high-specificity trans-splicing. FASEB J. 24, 2976-2984 (2010). www.fasebj.org	[Deidda, Giancarlo; Rossi, Nicoletta; Putti, Sabrina; Tocchini-Valentini, Glauco P.] CNR, Ist Biol Cellulare, I-00015 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR)	Deidda, G (corresponding author), CNR, Ist Biol Cellulare, Campus A Buzzati Traverso,Via E Ramarini 32, I-00015 Rome, Italy.	gdeidda@ibc.cnr.it	putti, sabrina/H-2574-2019	putti, sabrina/0000-0003-3335-043X; DEIDDA, GIANCARLO/0000-0002-0828-5800	Italian Ministry of Research; European Framework 6 Programme	Italian Ministry of Research(Ministry of Education, Universities and Research (MIUR)); European Framework 6 Programme	The authors thank the members of their laboratory for helpful discussions. The authors greatly thank G. Di Franco and A. Braconcini for excellent technical assistance and, A. Ferrara and T. Cuccurullo for secretarial work. This work was supported by the Italian Ministry of Research Fund for Basic Research grants (FIRB-G. Armenise-Harvard Foundation, FIRB-Idee Progettuali 2005) and European Framework 6 Programme contracts (Mutants Mouse Models of Human Immunological Disease, MUGEN, Alternative Splicing Network of Excellence, European Conditional Mouse Mutagenesis, and European Mouse Disease Clinic).	Chao HJ, 2003, NAT MED, V9, P1015, DOI 10.1038/nm900; Deidda G, 2003, NAT BIOTECHNOL, V21, P1499, DOI 10.1038/nbt908; Diener JL, 1998, MOL CELL, V1, P883, DOI 10.1016/S1097-2765(00)80087-8; Garcia-Blanco MA, 2003, NAT BIOTECHNOL, V21, P1448, DOI 10.1038/nbt1203-1448; Garcia-Blanco MA, 2003, J CLIN INVEST, V112, P474, DOI 10.1172/JCI200319462; Jung HS, 2006, BIOCHEM BIOPH RES CO, V349, P556, DOI 10.1016/j.bbrc.2006.08.073; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Liu XM, 2002, NAT BIOTECHNOL, V20, P47, DOI 10.1038/nbt0102-47; McKean PG, 2001, J CELL SCI, V114, P2723; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Phylactou LA, 1998, NAT GENET, V18, P378, DOI 10.1038/ng0498-378; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; Puttaraju M, 2001, MOL THER, V4, P105, DOI 10.1006/mthe.2001.0426; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stanchi F, 2000, BIOCHEM BIOPH RES CO, V270, P1111, DOI 10.1006/bbrc.2000.2571; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; Tahara M, 2004, NAT MED, V10, P835, DOI 10.1038/nm1086; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; Wang QQ, 2004, MICROBIOL MOL BIOL R, V68, P432, DOI 10.1128/MMBR.68.3.432-452.2004; Wood M, 2007, PLOS GENET, V3, P845, DOI 10.1371/journal.pgen.0030109; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	22	3	3	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2976	2984		10.1096/fj.10-154658	http://dx.doi.org/10.1096/fj.10-154658			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371619	Bronze			2022-12-28	WOS:000285005400036
J	Johnson, AR; Craciunescu, CN; Guo, Z; Teng, YW; Thresher, RJ; Blusztajn, JK; Zeisel, SH				Johnson, Amy R.; Craciunescu, Corneliu N.; Guo, Zhong; Teng, Ya-Wen; Thresher, Randy J.; Blusztajn, Jan K.; Zeisel, Steven H.			Deletion of murine choline dehydrogenase results in diminished sperm motility	FASEB JOURNAL			English	Article						betaine; mitochondria	RAT-LIVER MITOCHONDRIA; PRESSURE LIQUID-CHROMATOGRAPHY; S-ADENOSYLHOMOCYSTEINE; PLASMA HOMOCYSTEINE; BETAINE ALDEHYDE; OXIDATION; OXIDASE; INFERTILITY; ASSAY; ADENOSYLMETHIONINE	Choline dehydrogenase (CHDH) catalyzes the conversion of choline to betaine, an important methyl donor and organic osmolyte. We have previously identified single nucleotide polymorphisms (SNPs) in the human CHDH gene that, when present, seem to alter the activity of the CHDH enzyme. These SNPs occur frequently in humans. We created a Chdh(-/-) mouse to determine the functional effects of mutations that result in decreased CHDH activity. Chdh deletion did not affect fetal viability or alter growth or survival of these mice. Only one of eleven Chdh(-/-) males was able to reproduce. Loss of CHDH activity resulted in decreased testicular betaine and increased choline and PCho concentrations. Chdh(-/-) and Chdh(-/-) mice produced comparable amounts of sperm; the impaired fertility was due to diminished sperm motility in the Chdh(-/-) males. Transmission electron microscopy revealed abnormal mitochondrial morphology in Chdh(-/-) sperm. ATP content, total mitochondrial dehydrogenase activity and inner mitochondrial membrane polarization were all significantly reduced in sperm from Chdh(-/-) animals. Mitochondrial changes were also detected in liver, kidney, heart, and testis tissues. We suggest that men who have SNPs in CHDH that decrease the activity of the CHDH enzyme could have decreased sperm motility and fertility.-Johnson, A. R., Craciunescu, C. N., Guo, Z., Teng, Y.-W., Thresher, R. J., Blusztajn, J. K., Zeisel, S. H. Deletion of murine choline dehydrogenase results in diminished sperm motility. FASEB J. 24, 2752-2761 (2010). www.fasebj.org	[Johnson, Amy R.; Craciunescu, Corneliu N.; Guo, Zhong; Teng, Ya-Wen; Zeisel, Steven H.] Univ N Carolina, Gillings Sch Global Publ Hlth, Inst Nutr Res, Dept Nutr, Chapel Hill, NC USA; [Thresher, Randy J.] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC USA; [Blusztajn, Jan K.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Boston University	Zeisel, SH (corresponding author), UNC Nutr Res Inst, 500 Laureate Way, Kannapolis, NC 28081 USA.	steven_zeisel@unc.edu	Ariel, Pablo/AGJ-4118-2022	/0000-0001-8438-3122	National Institutes of Health [AG09525, DK55865, DK56350]; Balchem Corporation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Balchem Corporation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Deborah O'Brien for her guidance with the sperm techniques, Drs. Neil Kowall and Virginia Godfrey for their histology expertise, and Sergei Baranov (Kristal Lab) for the mitochondrial respiration data. This work is supported by grants from the National Institutes of Health to S.H.Z. (AG09525, DK55865, DK56350). A.R.J. is supported by a scholarship from the Balchem Corporation. A.R.J. conducted all experiments unless otherwise noted and wrote the manuscript. C.N.C. established the Chdh animal colony and assisted with experiments. Z.G. performed all choline metabolite analyses. Y.-W.T. performed urinalysis and liver histology studies. R.J.T. generated the Chdh chimeric mice. J.K.B. contributed to the experimental design. S.H.Z. developed the idea for these studies, contributed to the experimental design, assisted with data analysis, and helped write the manuscript. All authors reviewed and approved the manuscript.	Adham IM, 2001, MOL HUM REPROD, V7, P513, DOI 10.1093/molehr/7.6.513; Alfie ME, 1999, HYPERTENSION, V33, P1436, DOI 10.1161/01.HYP.33.6.1436; Bodrova ME, 1998, FEBS LETT, V435, P269, DOI 10.1016/S0014-5793(98)01072-2; BRAUN RE, 1989, NATURE, V337, P373, DOI 10.1038/337373a0; Chern MK, 2000, BIOCHEM PHARMACOL, V60, P1629, DOI 10.1016/S0006-2952(00)00469-X; Cohen G, 1999, ANN NY ACAD SCI, V893, P273, DOI 10.1111/j.1749-6632.1999.tb07835.x; Craig SAS, 2004, AM J CLIN NUTR, V80, P539; da Costa KA, 2006, FASEB J, V20, pA606; DERIDDER JJ, 1973, BIOCHIM BIOPHYS ACTA, V291, P557, DOI 10.1016/0005-2736(73)90507-5; DERIDDER JJM, 1975, BIOCHIM BIOPHYS ACTA, V408, P112, DOI 10.1016/0005-2728(75)90003-1; Devin A, 1997, J BIOENERG BIOMEMBR, V29, P579, DOI 10.1023/A:1022435102552; Eddy EM, 2003, MICROSC RES TECHNIQ, V61, P103, DOI 10.1002/jemt.10320; Ford WCL, 2006, HUM REPROD UPDATE, V12, P269, DOI 10.1093/humupd/dmi053; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; GARCIAPEREZ A, 1991, J MEMBRANE BIOL, V119, P1, DOI 10.1007/BF01868535; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; GLUECK CJ, 1995, AM J CARDIOL, V75, P132, DOI 10.1016/S0002-9149(00)80061-2; GROSSMAN EB, 1989, AM J PHYSIOL, V256, pF107; HAUBRICH DR, 1981, BIOCHEM PHARMACOL, V30, P2993, DOI 10.1016/0006-2952(81)90265-3; Huang SB, 2003, BIOCHEM BIOPH RES CO, V309, P344, DOI 10.1016/j.bbrc.2003.08.010; IKUTA S, 1977, J BIOCHEM-TOKYO, V82, P157, DOI 10.1093/oxfordjournals.jbchem.a131664; IKUTA S, 1977, J BIOCHEM-TOKYO, V82, P1741, DOI 10.1093/oxfordjournals.jbchem.a131872; Jacobsen DW, 1996, AM J CLIN NUTR, V64, P641, DOI 10.1093/ajcn/64.4.641; KAGAWA T, 1965, J BIOL CHEM, V240, P1836; Kelly TLJ, 2005, BIOL REPROD, V72, P667, DOI 10.1095/biolreprod.104.035238; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; Lawson-Yuen A, 2006, MOL GENET METAB, V88, P201, DOI 10.1016/j.ymgme.2006.02.004; LIN CS, 1986, J PROTEIN CHEM, V5, P193, DOI 10.1007/BF01025488; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maconochie N, 2004, BRIT MED J, V329, P196, DOI 10.1136/bmj.38163.620972.AE; Mann PJG, 1937, BIOCHEM J, V31, P869, DOI 10.1042/bj0310869; Melenovsky V, 2003, AM HEART J, V146, P110, DOI 10.1016/S0002-8703(03)00122-4; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; MOLLOY AM, 1990, BIOMED CHROMATOGR, V4, P257, DOI 10.1002/bmc.1130040611; Nasr-Esfahani MH, 2002, J ASSIST REPROD GEN, V19, P477, DOI 10.1023/A:1020310503143; OHTAFUKUYAMA M, 1980, J BIOCHEM-TOKYO, V88, P197; Olthof MR, 2005, CURR DRUG METAB, V6, P15, DOI 10.2174/1389200052997366; POMFRET EA, 1989, ANAL BIOCHEM, V180, P85, DOI 10.1016/0003-2697(89)90091-2; Rajapakse N, 2001, BRAIN RES PROTOC, V8, P176, DOI 10.1016/S1385-299X(01)00108-8; ROZWADOWSKI KL, 1991, J BACTERIOL, V173, P472, DOI 10.1128/jb.173.2.472-478.1991; Schwahn BC, 2004, BIOCHEM J, V382, P831, DOI 10.1042/BJ20030822; Schwahn BC, 2003, FASEB J, V17, P512, DOI 10.1096/fj.02-0456fje; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; Sipila P, 2009, REPRODUCTION, V137, P379, DOI 10.1530/REP-08-0132; Steenge GR, 2003, J NUTR, V133, P1291; STOREY BT, 1975, FERTIL STERIL, V26, P1257; SVANBORG A, 1961, ACTA MED SCAND, V169, P43; THONNEAU P, 1991, HUM REPROD, V6, P811, DOI 10.1093/oxfordjournals.humrep.a137433; Turner RM, 2003, J ANDROL, V24, P790; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; Ventela S, 2003, MOL BIOL CELL, V14, P2768, DOI 10.1091/mbc.E02-10-0647; WENDEL U, 1984, EUR J PEDIATR, V142, P147, DOI 10.1007/BF00445602; *WHO, 1990, PROGR RES 1989 1990, P15; Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279; Yeung CH, 2004, J ANDROL, V25, P216; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zeisel SH, 2003, J NUTR, V133, P1302; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156; ZHANG J, 1992, BIOCHIM BIOPHYS ACTA, V1117, P333, DOI 10.1016/0304-4165(92)90033-Q	59	49	53	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2752	2761		10.1096/fj.09-153718	http://dx.doi.org/10.1096/fj.09-153718			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20371614	Green Published, Green Submitted			2022-12-28	WOS:000285005400016
J	Strathmann, J; Klimo, K; Sauer, SW; Okun, JG; Prehn, JHM; Gerhauser, C				Strathmann, Julia; Klimo, Karin; Sauer, Sven W.; Okun, Juergen G.; Prehn, Jochen H. M.; Gerhaeuser, Clarissa			Xanthohumol-induced transient superoxide anion radical formation triggers cancer cells into apoptosis via a mitochondria-mediated mechanism	FASEB JOURNAL			English	Article						polyphenols; oxidative stress; chemoprevention	OXIDATIVE STRESS; INTRACELLULAR SUPEROXIDE; PERMEABILITY TRANSITION; TRANSFORMED-CELLS; HYDROGEN-PEROXIDE; KAPPA-B; OXYGEN; DEATH; AUTOPHAGY; ROS	Oxidative stress and increased release of reactive oxygen species (ROS) are associated with apoptosis induction. Here we report ROS-mediated induction of apoptosis by xanthohumol (XN) from hops. XN at concentrations of 1.6-25 mu M induced an immediate and transient increase in superoxide anion radical (O-2(-center dot)) formation in 3 human cancer cell lines (average +/- SD EC50 of maximum O-2(-center dot) induction=3.1 +/- 0.8 mu M), murine macrophages (EC50=4.0 +/- 0.3 mu M), and BPH-1 benign prostate hyperplasia cells (EC50=4.3 +/- 0.1 mu M), as evidenced by the O-2(-center dot)-specific indicator dihydroethidium. MitoSOX Red costaining and experiments using isolated mouse liver mitochondria (EC50=11.4 +/- 1.8 mu M) confirmed mitochondria as the site of intracellular O-2(-center dot) formation. Antimycin A served as positive control (EC50=12.4 +/- 0.9 mu M). XN-mediated O-2(-center dot) release was significantly reduced in BPH-1 rho(0) cells harboring nonfunctional mitochondria (EC50>25 mu M) and by treatment of BPH-1 cells with vitamin C, N-acetylcysteine (NAC), or the superoxide dismutase mimetic MnTMPyP. In addition, we demonstrated a rapid 15% increase in oxidized glutathione and a dose-dependent overall thiol depletion within 6 h (IC50=24.3 +/- 11 mu M). Respiratory chain complexes I-III were weakly inhibited by XN in bovine heart submitochondrial particles, but electron flux from complex I and II to complex III was significantly inhibited in BPH-1 cells, with IC50 values of 28.1 +/- 2.4 and 24.4 +/- 5.2 mu M, respectively. Within 15 min, intracellular ATP levels were significantly reduced by XN at 12.5 to 50 mu M concentrations (IC50=26.7 +/- 3.7 mu M). Concomitantly, XN treatment caused a rapid breakdown of the mitochondrial membrane potential and the release of cytochrome c, leading to apoptosis induction. Pre- or coincubation with 2 mM NAC and 50 mu M MnTMPyP at various steps increased XN-mediated IC50 values for cytotoxicity in BPH-1 cells from 6.7 +/- 0.2 to 12.2 +/- 0.1 and 41.4 +/- 7.6 mu M, and it confirmed XN-induced O-2(-center dot) as an essential trigger for apoptosis induction. In summary, we have identified mitochondria as a novel cellular target of XN action, resulting in increased O-2(-center dot) production, disruption of cellular redox balance and mitochondrial integrity, and subsequent apoptosis.-Strathmann, J., Klimo, K., Sauer, S. W., Okun, J. G., Prehn, J. H. M., Gerha " user, C. Xanthohumol-induced transient superoxide anion radical formation triggers cancer cells into apoptosis via a mitochondria-mediated mechanism. FASEB J. 24, 2938-2950 (2010). www.fasebj.org	[Strathmann, Julia; Klimo, Karin; Gerhaeuser, Clarissa] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Sauer, Sven W.; Okun, Juergen G.] Univ Childrens Hosp, Heidelberg, Germany; [Prehn, Jochen H. M.] Royal Coll Surgeons Ireland, Dublin 2, Ireland	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Royal College of Surgeons - Ireland	Gerhauser, C (corresponding author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	c.gerhauser@dkfz.de	Prehn, Jochen HM/A-3928-2010	Prehn, Jochen HM/0000-0003-3479-7794; Gerhauser, Clarissa/0000-0002-5792-3901	Deutsches Krebsforschungszentrum (DKFZ) Light Microscopy Facility (Heidelberg, Germany)	Deutsches Krebsforschungszentrum (DKFZ) Light Microscopy Facility (Heidelberg, Germany)	Support by the Deutsches Krebsforschungszentrum (DKFZ) Light Microscopy Facility (Heidelberg, Germany) is gratefully acknowledged. The authors thank Dr. Matthew Whiteman for critical reviewing of the manuscript and valuable suggestions.	Antosiewicz J, 2008, PLANTA MED, V74, P1570, DOI 10.1055/s-2008-1081307; Bellion P, 2009, MOL NUTR FOOD RES, V53, P1226, DOI 10.1002/mnfr.200800456; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Blair IA, 2006, CURR DRUG METAB, V7, P853, DOI 10.2174/138920006779010601; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Dussmann H, 2003, J BIOL CHEM, V278, P12645, DOI 10.1074/jbc.M210826200; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Galati G, 2002, TOXICOLOGY, V177, P91, DOI 10.1016/S0300-483X(02)00198-1; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Gerhauser C, 2005, EUR J CANCER, V41, P1941, DOI 10.1016/j.ejca.2005.04.012; Gerhauser C, 2002, MOL CANCER THER, V1, P959; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo ML, 2007, DALTON T, P4951, DOI 10.1039/b705136k; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; Harikumar KB, 2009, BLOOD, V113, P2003, DOI 10.1182/blood-2008-04-151944; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; Hussong R, 2005, MOL NUTR FOOD RES, V49, P861, DOI 10.1002/mnfr.200500089; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kaminski M, 2007, MOL CELL BIOL, V27, P3625, DOI 10.1128/MCB.02295-06; Khan N, 2008, ANTIOXID REDOX SIGN, V10, P475, DOI 10.1089/ars.2007.1740; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Knudson C. Michael, 2008, V414, P95; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Ladas EJ, 2004, J CLIN ONCOL, V22, P517, DOI 10.1200/JCO.2004.03.086; Lau ATY, 2008, J CELL BIOCHEM, V104, P657, DOI 10.1002/jcb.21655; Lee KW, 2006, BIOFACTORS, V26, P105, DOI 10.1002/biof.5520260202; Ligeret H, 2004, FREE RADICAL BIO MED, V36, P919, DOI 10.1016/j.freeradbiomed.2003.12.018; Lim HW, 2009, BIOCHEM BIOPH RES CO, V389, P187, DOI 10.1016/j.bbrc.2009.08.121; Lust S, 2009, ANTICANCER RES, V29, P3797; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Monteghirfo S, 2008, MOL CANCER THER, V7, P2692, DOI 10.1158/1535-7163.MCT-08-0132; Neuzil J, 2006, FEBS LETT, V580, P5125, DOI 10.1016/j.febslet.2006.05.072; Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122; Pan L, 2005, MOL NUTR FOOD RES, V49, P837, DOI 10.1002/mnfr.200500065; Pang Y, 2007, MOL NUTR FOOD RES, V51, P872, DOI 10.1002/mnfr.200600252; Pani G, 2009, INT J BIOCHEM CELL B, V41, P1002, DOI 10.1016/j.biocel.2008.10.011; Pappa G, 2007, MOL NUTR FOOD RES, V51, P977, DOI 10.1002/mnfr.200700115; Pappa G, 2007, CARCINOGENESIS, V28, P1471, DOI 10.1093/carcin/bgm044; Pappa G, 2006, MUTAT RES-FUND MOL M, V599, P76, DOI 10.1016/j.mrfmmm.2006.01.007; Perez CA, 2009, J INORG BIOCHEM, V103, P326, DOI 10.1016/j.jinorgbio.2008.11.003; Pervaiz S, 2002, BIOCHEM BIOPH RES CO, V290, P1145, DOI 10.1006/bbrc.2001.6274; Ralph SJ, 2009, MOL NUTR FOOD RES, V53, P9, DOI 10.1002/mnfr.200800044; Reddy VP, 2009, J ALZHEIMERS DIS, V16, P763, DOI 10.3233/JAD-2009-1013; Rehm M, 2003, J CELL BIOL, V162, P1031, DOI 10.1083/jcb.200303123; Sauer SW, 2008, BBA-BIOENERGETICS, V1777, P1276, DOI 10.1016/j.bbabio.2008.05.447; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Storz P., 2006, SCI STKE, V2006, pre3, DOI DOI 10.1126/STKE.3322006RE3; Strathmann J, 2009, ACTA HORTIC, V848, P179, DOI 10.17660/ActaHortic.2009.848.20; TERADA H, 1990, ENVIRON HEALTH PERSP, V87, P213, DOI 10.2307/3431027; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; Yang JY, 2007, APOPTOSIS, V12, P1953, DOI 10.1007/s10495-007-0130-4; Yuen B, 2005, Ther Umsch, V62, P615, DOI 10.1024/0040-5930.62.9.615; Zhao HT, 2005, P NATL ACAD SCI USA, V102, P5727, DOI 10.1073/pnas.0501719102	68	72	73	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2938	2950		10.1096/fj.10-155846	http://dx.doi.org/10.1096/fj.10-155846			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20335224				2022-12-28	WOS:000285005400033
J	Takanaga, H; Frommer, WB				Takanaga, Hitomi; Frommer, Wolf B.			Facilitative plasma membrane transporters function during ER transit	FASEB JOURNAL			English	Article						endoplasmic reticulum; uniporter; sodium-cotransporter; fluoresecence resonance energy transfer; sensor	ENDOPLASMIC-RETICULUM MEMBRANE; GLUCOSE-RELEASE; GLUCOSE-6-PHOSPHATASE SYSTEM; GLUT2-NULL HEPATOCYTES; GLUT1; PROTEIN; CELLS; RAT; EXPRESSION; SENSORS	Although biochemical studies suggested a high permeability of the endoplasmic reticulum (ER) membrane for small molecules, proteomics identified few specialized ER transporters. To test functionality of transporters during ER passage, we tested whether glucose transporters (GLUTs, SGLTs) destined for the plasma membrane are active during ER transit. HepG2 cells were characterized by low-affinity ER transport activity, suggesting that ER uptake is protein mediated. The much-reduced capacity of HEK293T cells to take up glucose across the plasma membrane correlated with low ER transport. Ectopic expression of GLUT1, -2, -4, or -9 induced GLUT isoform-specific ER transport activity in HEK293T cells. In contrast, the Na+-glucose cotransporter SGLT1 mediated efficient plasma membrane glucose transport but no detectable ER uptake, probably because of lack of a sufficient sodium gradient across the ER membrane. In conclusion, we demonstrate that GLUTs are sufficient for mediating ER glucose transport en route to the plasma membrane. Because of the low volume of the ER, trace amounts of these uniporters contribute to ER solute import during ER transit, while uniporters and cation-coupled transporters carry out export from the ER, together potentially explaining the low selectivity of ER transport. Expression levels and residence time of transporters in the ER, as well as their coupling mechanisms, could be key determinants of ER permeability.-Takanaga, H., Frommer, W. B. Facilitative plasma membrane transporters function during ER transit. FASEB J. 24, 2849-2858 (2010). www.fasebj.org	[Takanaga, Hitomi; Frommer, Wolf B.] Carnegie Inst Sci, Dept Plant Biol, Stanford, CA USA	Carnegie Institution for Science	Frommer, WB (corresponding author), 260 Panama St, Stanford, CA 94305 USA.	wfrommer@carnegiescience.edu	Frommer, Wolf B/K-5042-2017; Frommer, Wolf B/A-8256-2008	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115	U.S. National Institutes of Health (NIDDK) [1RO1DK079109]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK079109] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Oliver Schweissgut (Siegen, Germany) for writing the Matlab script for the baseline correction. The authors thank Li-Qing Chen (Carnegie Institution for Science, Stanford, CA, USA) for carrying out the RT-PCR. This work was funded by a grant from the U.S. National Institutes of Health to W.B.F. (NIDDK; 1RO1DK079109).	ARION WJ, 1980, J BIOL CHEM, V255, P396; Brockmann K, 2001, ANN NEUROL, V50, P476, DOI 10.1002/ana.1222; Burcelin R, 2000, DIABETES, V49, P1643, DOI 10.2337/diabetes.49.10.1643; Burcelin R, 2000, J BIOL CHEM, V275, P10930, DOI 10.1074/jbc.275.15.10930; Burdakov D, 2005, CELL CALCIUM, V38, P303, DOI 10.1016/j.ceca.2005.06.010; Chandra P, 2004, PHARM RES-DORDR, V21, P719, DOI 10.1023/B:PHAM.0000026420.79421.8f; Chen SY, 2008, FASEB J, V22, P2206, DOI 10.1096/fj.07-104851; Csala M, 2006, FEBS LETT, V580, P2160, DOI 10.1016/j.febslet.2006.03.050; Deuschle K, 2005, PROTEIN SCI, V14, P2304, DOI 10.1110/ps.051508105; Deuschle K, 2005, CYTOM PART A, V64A, P3, DOI 10.1002/cyto.a.20119; Eskandari S, 2005, J MEMBRANE BIOL, V204, P23, DOI 10.1007/s00232-005-0743-x; Fehr M, 2005, MOL CELL BIOL, V25, P11102, DOI 10.1128/MCB.25.24.11102-11112.2005; Fehr M, 2005, BIOCHEM SOC T, V33, P287, DOI 10.1042/BST0330287; Fehr M, 2004, J FLUORESC, V14, P603, DOI 10.1023/B:JOFL.0000039347.94943.99; Fehr M, 2003, J BIOL CHEM, V278, P19127, DOI 10.1074/jbc.M301333200; Fehr M, 2002, P NATL ACAD SCI USA, V99, P9846, DOI 10.1073/pnas.142089199; Foster JA, 2002, EXP BIOL MED, V227, P601, DOI 10.1177/153537020222700807; Gao BB, 2008, MOL CELL PROTEOMICS, V7, P2399, DOI 10.1074/mcp.M800104-MCP200; Guerra G, 2007, BBA-BIOMEMBRANES, V1768, P2383, DOI 10.1016/j.bbamem.2007.04.029; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; HOOPER G, 1976, J GEN PHYSIOL, V67, P469, DOI 10.1085/jgp.67.4.469; Hosokawa M, 2002, AM J PHYSIOL-ENDOC M, V282, pE794, DOI 10.1152/ajpendo.00374.2001; Kasahara T, 1996, BIOCHEM J, V315, P177, DOI 10.1042/bj3150177; Lager I, 2003, FEBS LETT, V553, P85, DOI 10.1016/S0014-5793(03)00976-1; Le Gall S, 2004, MOL BIOL CELL, V15, P447, DOI 10.1091/mbc.E03-05-0325; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; Lippincott-Schwartz J, 2000, BIOPHYS J, V78, p138A; Lizak B, 2008, MOL MEMBR BIOL, V25, P95, DOI 10.1080/09687680701670481; Matern D, 2002, EUR J PEDIATR, V161, pS10, DOI 10.1007/s00431-002-0998-5; Mechin MC, 2000, PROTEINS, V41, P164, DOI 10.1002/1097-0134(20001101)41:2<164::AID-PROT20>3.0.CO;2-2; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Pascual JM, 2008, J BIOL CHEM, V283, P16732, DOI 10.1074/jbc.M801403200; Santer R, 2002, HUM GENET, V110, P21, DOI 10.1007/s00439-001-0638-6; Takanaga H, 2008, BBA-BIOMEMBRANES, V1778, P1091, DOI 10.1016/j.bbamem.2007.11.015; Uldry M, 2004, PFLUG ARCH EUR J PHY, V447, P480, DOI 10.1007/s00424-003-1085-0; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Wong HY, 2007, MOL GENET METAB, V90, P193, DOI 10.1016/j.ymgme.2006.09.002	39	51	53	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2849	2858		10.1096/fj.09-146472	http://dx.doi.org/10.1096/fj.09-146472			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20354141	Green Published, hybrid			2022-12-28	WOS:000285005400025
J	Kuhr, FK; Zhang, YK; Brovkovych, V; Skidgel, RA				Kuhr, Frank K.; Zhang, Yongkang; Brovkovych, Viktor; Skidgel, Randal A.			beta-Arrestin 2 is required for B1 receptor-dependent post-translational activation of inducible nitric oxide synthase	FASEB JOURNAL			English	Article						kinins; G-protein-coupled receptor; extracellular signal-regulated kinase; inflammation; endothelial cells	PROTEIN-COUPLED RECEPTORS; CONVERTING-ENZYME INHIBITORS; SIGNAL-REGULATED KINASES; BRADYKININ B2 RECEPTOR; ENDOTHELIAL-CELLS; S-NITROSYLATION; IN-VIVO; B-1 RECEPTORS; NULL MICE; APOPTOSIS	A major source of "high-output" NO in inflammation is inducible nitric oxide synthase ( iNOS). iNOS is primarily transcriptionally regulated and is thought to function as an uncontrolled generator of high NO. We found that iNOS in cytokine-stimulated human lung microvascular endothelial cells (HLMVECs) is highly regulated post-translationally via activation of the B1 kinin G protein-coupled receptor (B1R). We report here that B1R-mediated iNOS activation was significantly inhibited by knockdown of beta-arrestin 2 with siRNA in cytokine-treated HLMVECs or HEK293 cells transfected with iNOS and B1R. In contrast, beta-arrestin 1 siRNA had no effect. The prolonged phase of B1R-dependent ERK activation was also inhibited by beta-arrestin 2 knockdown. Furthermore, robust ERK activation by the epidermal growth factor receptor (a beta-arrestin 2 independent pathway) had no effect on iNOS-derived NO production. beta-arrestin 2 and iNOS coimmunoprecipitated, and there was significant fluorescence resonance energy transfer between CFP-iNOS and beta-arrestin 2-YFP ( but not beta-arrestin 1-YFP) that increased 3-fold after B1R stimulation. These data show that beta-arrestin 2 mediates B1R-dependent high-output NO by scaffolding iNOS and ERK to allow post-translational activation of iNOS. This could play a critical role in mediating endothelial function in inflammation.-Kuhr, F.K., Zhang, Y., Brovkovych, V., Skidgel, R.A. beta-Arrestin 2 is required for B1 receptor-dependent post-translational activation of inducible nitric oxide synthase. FASEB J. 24, 2475-2483 (2010). www.fasebj.org	[Kuhr, Frank K.; Zhang, Yongkang; Brovkovych, Viktor; Skidgel, Randal A.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Skidgel, RA (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott,M-C 868, Chicago, IL 60612 USA.	rskidgel@uic.edu			U.S. National Institutes of Health [HL60678, DK41431]; American Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK041431, R29DK041431, R01DK041431] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Fulong Tan (Department of Pharmacology, University of Illinois at Chicago) for cloning beta-arrestin 2 and making initial constructs and Dr. Tiffany Sharma and Debra Salvi (Molecular Resources Core, Department of Pharmacology, University of Illinois at Chicago) for generating tagged beta-arrestin 2 and iNOS constructs. The authors are grateful to Svitlana Brovkovych for excellent technical assistance. This work was supported by U.S. National Institutes of Health grants HL60678 and DK41431. F.K.K. is the recipient of an American Heart Association predoctoral fellowship.	Adomeit A, 1999, MOL CELL BIOL, V19, P5289; Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Brovkovych V, 1999, J PHARMACEUT BIOMED, V19, P135, DOI 10.1016/S0731-7085(98)00090-9; BROVKOVYCH V, 2009, J CELL MOL MED, DOI DOI 10.1111/J.1582-4934.2009.00992.X; Brovkovych V, 2008, AM J PHYSIOL-LUNG C, V295, pL96, DOI 10.1152/ajplung.00450.2007; Cao S, 2001, J BIOL CHEM, V276, P14249, DOI 10.1074/jbc.M006258200; Choy JC, 2007, P NATL ACAD SCI USA, V104, P1313, DOI 10.1073/pnas.0607731104; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Geiger M, 1997, AM J PHYSIOL-LUNG C, V273, pL275, DOI 10.1152/ajplung.1997.273.1.L275; Golser R, 2000, J BIOL CHEM, V275, P5291, DOI 10.1074/jbc.275.8.5291; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hoffman RA, 1997, AM J PHYSIOL-GASTR L, V272, pG383, DOI 10.1152/ajpgi.1997.272.2.G383; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Ignjatovic T, 2004, MOL PHARMACOL, V66, P1310, DOI 10.1124/mol.104.001990; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kokkola T, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-21; Kubes Pal, 1995, Microcirculation (New York), V2, P235, DOI 10.3109/10739689509146769; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Liu J, 2004, J BIOL CHEM, V279, P55924, DOI 10.1074/jbc.M410024200; Lohse MJ, 2007, CURR OPIN PHARMACOL, V7, P547, DOI 10.1016/j.coph.2007.08.007; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Marjanovic JA, 2008, J BIOL CHEM, V283, P28827, DOI 10.1074/jbc.M801646200; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; MONCADA S, 1991, PHARMACOL REV, V43, P109; Ozawa K, 2008, MOL CELL, V31, P395, DOI 10.1016/j.molcel.2008.05.024; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004; Razavi HM, 2005, PHARMACOL THERAPEUT, V106, P147, DOI 10.1016/j.pharmthera.2004.11.006; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Sangsree S, 2003, AM J PHYSIOL-HEART C, V284, pH1959, DOI 10.1152/ajpheart.00036.2003; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; SIEGEL RM, 2000, SCI STKE, pPL1; Stanisavljevic S, 2006, J PHARMACOL EXP THER, V316, P1153, DOI 10.1124/jpet.105.093849; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Ushio-Fukai M, 2009, CURR OPIN NEPHROL HY, V18, P153, DOI 10.1097/MNH.0b013e3283252efe; Vodovotz Y, 2004, CURR MOL MED, V4, P753, DOI 10.2174/1566524043359944; Wang GF, 2006, P NATL ACAD SCI USA, V103, P1295, DOI 10.1073/pnas.0508354103; Whalen EJ, 2007, CELL, V129, P511, DOI 10.1016/j.cell.2007.02.046; Zhang YK, 2007, J BIOL CHEM, V282, P32453, DOI 10.1074/jbc.M706242200	53	23	24	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2475	2483		10.1096/fj.09-148783	http://dx.doi.org/10.1096/fj.09-148783			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20228252	Green Published			2022-12-28	WOS:000279343600034
J	Sato, M; Kawakami, T; Kondoh, M; Takiguchi, M; Kadota, Y; Himeno, S; Suzuki, S				Sato, Masao; Kawakami, Takashige; Kondoh, Masuo; Takiguchi, Masufumi; Kadota, Yoshito; Himeno, Seiichiro; Suzuki, Shinya			Development of high-fat-diet-induced obesity in female metallothionein-null mice	FASEB JOURNAL			English	Article						mesoderm-specific transcript; adipose tissues; leptin resistance; oxidative stress	ENDOPLASMIC-RETICULUM STRESS; MESSENGER-RNA EXPRESSION; INSULIN-RESISTANCE; PPAR-GAMMA; GENE-EXPRESSION; OXIDATIVE STRESS; ADIPOCYTE DIFFERENTIATION; METABOLIC SYNDROME; ADIPOSE-TISSUE; ER STRESS	Oxidative stress accelerates adipocyte differentiation and lipid accumulation, leading to endoplasmic reticulum (ER) stress, which causes insulin resistance. Because metallothionein (MT) has a role in prevention of oxidative and ER stress, we examined the effects of MT on the development of obesity induced by 27 wk of a high-fat diet (HFD) in female MT-I- and MT-II-null (MT-/-) and wild-type (MT+/+) mice. Body weight, fat mass, and plasma cholesterol increased at a greater rate in MT-/- mice fed an HFD than in MT-/- mice fed a control diet (CD) and MT+/+ mice fed an HFD, indicating that MT-/- mice fed an HFD became obese and hypercholesterolemic and that MT could prevent HFD-induced obesity. The observed increases in the levels of plasma leptin and leptin mRNA in the white adipose tissue of MT-/- mice fed the HFD suggested a leptin-resistant state. Enhanced expression of a mesoderm-specific transcript, which regulates the enlargement of fat cells, was accompanied by enlarged adipocytes in the white adipose tissue of young MT-/- mice before obesity developed after 3 and 8 wk of feeding the HFD. Thus, MT may have a preventive role against HFD-induced obesity by regulating adipocyte enlargement and leptin signaling.-Sato, M., Kawakami, T., Kondoh, M., Takiguchi, M., Kadota, Y., Himeno, S., Suzuki, S. Development of high-fat-diet-induced obesity in female metallothionein-null mice. FASEB J. 24, 2375-2384 (2010). www.fasebj.org	[Sato, Masao; Kawakami, Takashige; Kondoh, Masuo; Takiguchi, Masufumi; Kadota, Yoshito; Himeno, Seiichiro; Suzuki, Shinya] Tokushima Bunri Univ, Fac Pharmaceut Sci, Tokushima 7708514, Japan	Tokushima Bunri University	Sato, M (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, 180 Yamashiro Cho, Tokushima 7708514, Japan.	msato@ph.bunri-u.ac.jp	Himeno, Seiichiro/AAW-3421-2020	Himeno, Seiichiro/0000-0002-0773-2373	Ministry of Education, Science, Sports, and Culture of Japan [1430767]	Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The authors thank K. Setsu, M. Inoue, T. Abe (Tokushima Bunri University, Tokushima, Japan) and K. Suzuki (Gunma University, Maebashi, Japan) for their assistance in histology, and M. Higashimoto, M. Mori, S. Ishibashi, Y. Wakuta, Y. Tsubakizaki, and K. Yoshikawa (Tokushima Bunri University) and M. Mita (Kitasato University, Tokyo, Japan) for their excellent technical assistance and mouse husbandry. This work was supported in part by a Grant-in-Aid for General Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan (1430767; to M. S.). All authors contributed equally to this work.	Beattie JH, 1996, AM J PHYSIOL-REG I, V270, pR971, DOI 10.1152/ajpregu.1996.270.5.R971; Beattie JH, 1998, P NATL ACAD SCI USA, V95, P358, DOI 10.1073/pnas.95.1.358; Binz PA, 1999, METALLOTHIONEIN IV, P7; Davis SR, 2000, J NUTR, V130, P1085; Do MS, 2002, HORM METAB RES, V34, P348, DOI 10.1055/s-2002-33254; Dong F, 2007, DIABETES, V56, P2201, DOI 10.2337/db06-1596; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; Feng W, 2005, BIOCHEM BIOPH RES CO, V332, P853, DOI 10.1016/j.bbrc.2005.04.170; Friedman JM, 2003, SCIENCE, V299, P856, DOI 10.1126/science.1079856; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Futakawa N, 2006, BIOL PHARM BULL, V29, P2016, DOI 10.1248/bpb.29.2016; Guo KY, 2004, AM J PHYSIOL-REG I, V287, pR112, DOI 10.1152/ajpregu.00028.2004; Jones JR, 2005, P NATL ACAD SCI USA, V102, P6207, DOI 10.1073/pnas.0306743102; Kim DS, 2007, BIOCHEM BIOPH RES CO, V363, P140, DOI 10.1016/j.bbrc.2007.08.151; Kita K, 2006, HUM GENET, V120, P553, DOI 10.1007/s00439-006-0238-6; Kondoh M, 2004, TOXICOL LETT, V148, P133, DOI 10.1016/j.toxlet.2003.12.066; Koza RA, 2006, PLOS GENET, V2, P769, DOI 10.1371/journal.pgen.0020081; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kuo LE, 2007, NAT MED, V13, P803, DOI 10.1038/nm1611; Lee H, 2009, J BIOL CHEM, V284, P10601, DOI 10.1074/jbc.M808742200; Levin BE, 2003, AM J PHYSIOL-ENDOC M, V285, pE949, DOI 10.1152/ajpendo.00186.2003; Lin S, 2000, BRAIN RES, V875, P89, DOI 10.1016/S0006-8993(00)02580-4; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; Miura N, 2005, BIOCHEM BIOPH RES CO, V332, P949, DOI 10.1016/j.bbrc.2005.05.043; Mocchegiani E, 2007, ANN NY ACAD SCI, V1119, P129, DOI 10.1196/annals.1404.030; Nakatani Y, 2005, J BIOL CHEM, V280, P847, DOI 10.1074/jbc.M411860200; Netea MG, 2006, NAT MED, V12, P650, DOI 10.1038/nm1415; Nikonova L, 2008, FASEB J, V22, P3925, DOI 10.1096/fj.08-108266; OH SH, 1978, AM J PHYSIOL, V234, pE282, DOI 10.1152/ajpendo.1978.234.3.E282; Oike Y, 2005, NAT MED, V11, P400, DOI 10.1038/nm1214; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Sato M, 2002, TOHOKU J EXP MED, V196, P9, DOI 10.1620/tjem.196.9; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schott-Ohly P, 2004, EXP BIOL MED, V229, P1177, DOI 10.1177/153537020422901113; Sekiya M, 2008, BIOCHEM BIOPH RES CO, V375, P602, DOI 10.1016/j.bbrc.2008.08.068; Snyder EE, 2004, OBES RES, V12, P369, DOI 10.1038/oby.2004.47; SUGIHARA H, 1987, J LIPID RES, V28, P1038; Takahashi M, 2005, AM J PHYSIOL-ENDOC M, V288, pE117, DOI 10.1152/ajpendo.00244.2004; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Trayhurn P, 2000, AM J PHYSIOL-REG I, V279, pR2329, DOI 10.1152/ajpregu.2000.279.6.R2329; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Wang MY, 2005, P NATL ACAD SCI USA, V102, P18011, DOI 10.1073/pnas.0509001102; Ye B, 2001, P NATL ACAD SCI USA, V98, P2317, DOI 10.1073/pnas.041619198; Yoshida M, 1998, BIOL TRACE ELEM RES, V63, P167, DOI 10.1007/BF02778875; Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043	51	54	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2375	2384		10.1096/fj.09-145466	http://dx.doi.org/10.1096/fj.09-145466			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20219986				2022-12-28	WOS:000279343600024
J	Wu, F; Schweizer, C; Rudinskiy, N; Taylor, DM; Kazantsev, A; Luthi-Carter, R; Fraering, PC				Wu, Fang; Schweizer, Claude; Rudinskiy, Nikita; Taylor, David M.; Kazantsev, Aleksey; Luthi-Carter, Ruth; Fraering, Patrick C.			Novel gamma-secretase inhibitors uncover a common nucleotide-binding site in JAK3, SIRT2, and PS1	FASEB JOURNAL			English	Article						Alzheimer's disease; amyloid-beta peptides; presenilin-1; off-target effect; substrate-binding sites	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; IDENTIFICATION; DEACETYLASES; KINASE; NICOTINAMIDE; MECHANISM; COMPLEX; DOMAIN; ALPHA	gamma-Secretase is an intramembrane-cleaving protease responsible for the final proteolytic event in the production of the amyloid-beta peptides (A beta) implicated in Alzheimer's disease ( AD). Inhibition of gamma-secretase activity is thus an attractive therapeutic strategy to slow down the pathogenesis of AD. Drugs often target more than one biomolecule because of conserved 3-dimensional structures in prospective protein binding sites. We have capitalized on this phenomenon of nature to identify new gamma-secretase inhibitors. Here we show that 2-hydroxy naphthyl derivatives, a previously identified subclass of NAD(+) analog inhibitors of sirtuin 2 (SIRT2), are direct gamma-secretase inhibitors. Subsequent structure-activity relationship studies further showed that 2-hydroxy-1-naphthaldehyde is the minimal pharmacophore for gamma-secretase inhibition. In evaluating target protein determinants of inhibition, we identified a common GXG signature nucleotide-binding site (NBS) shared by the gamma-secretase subunit presenilin-1 C-terminal fragment (PS1-CTF), SIRT2, and Janus kinase 3 (JAK3). Because a detailed 3-dimensional structure of gamma-secretase is beyond our knowledge, we took advantage of the known crystal structure of human JAK3 to model the NBS of the PS1-CTF, which includes the catalytic residue D385. Our results suggest that the flexible PS1-CTF 381LGLG384 loop comprises a substrate-docking site capable of recognizing specifically different gamma-secretase substrates.-Wu, F., Schweizer, C., Rudinskiy, N., Taylor, D. M., Kazantsev, A., Luthi-Carter, R., Fraering, P.C. Novel gamma-secretase inhibitors uncover a common nucleotide-binding site in JAK3, SIRT2, and PS1. FASEB J. 24, 2464-2474 (2010). www.fasebj.org	[Wu, Fang; Schweizer, Claude; Fraering, Patrick C.] Swiss Fed Inst Technol, Brain Mind Inst, Lab Mol & Cellular Biol Alzheimers Dis, CH-1015 Lausanne, Switzerland; [Rudinskiy, Nikita; Taylor, David M.; Luthi-Carter, Ruth] Swiss Fed Inst Technol, Brain Mind Inst, Lab Funct Neurogenom, CH-1015 Lausanne, Switzerland; Swiss Fed Inst Technol, Sch Life Sci, CH-1015 Lausanne, Switzerland; [Kazantsev, Aleksey] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Massachusetts Gen Inst Neurodegenerat Dis, Charlestown, MA USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Harvard University; Massachusetts General Hospital	Fraering, PC (corresponding author), Swiss Fed Inst Technol EPFL, Brain Mind Inst, CH-1015 Lausanne, Switzerland.	patrick.fraering@epfl.ch	Wu, Fang/B-1945-2008	Wu, Fang/0000-0002-4194-2243; Fraering, Patrick/0000-0002-5841-5327	Swiss National Science Foundation [310000-116652/1]; National Center for Competence in Research (NCCR); Strauss Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); National Center for Competence in Research (NCCR)(Swiss National Science Foundation (SNSF)); Strauss Foundation	The authors thank Dr. M.S. Wolfe (Center for Neurological Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA) for the T20 cells, Dr. Helena Karlstrom (Karolinska Institute, Stockholm, Sweden) for the Pen-2 antibody UD-1, L. Aeschbach for excellent technical support, and Dr. J.R. Alattia for helpful discussions. This work was supported by the Swiss National Science Foundation (to P.C.F.; grant 310000-116652/1) and the National Center for Competence in Research (NCCR; Neural Plasticity and Repair; to P.C.F), and the Strauss Foundation (to P.C.F. and C.S.).	ADAM J, 1997, UNDERSTANDING ORGANI, P132; Asberom T, 2007, BIOORG MED CHEM LETT, V17, P205, DOI 10.1016/j.bmcl.2006.09.064; Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022; Bai JF, 2002, GENOME RES, V12, P1871, DOI 10.1101/gr.454902; Bakshi P, 2005, J BIOMOL SCREEN, V10, P1, DOI 10.1177/1087057104270068; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Beel AJ, 2008, BIOCHEMISTRY-US, V47, P9428, DOI 10.1021/bi800993c; Boggon TJ, 2005, BLOOD, V106, P996, DOI 10.1182/blood-2005-02-0707; Boulton ME, 2008, J CELL MOL MED, V12, P781, DOI 10.1111/j.1582-4934.2008.00274.x; Brown GR, 2000, BIOORG MED CHEM LETT, V10, P575, DOI 10.1016/S0960-894X(00)00051-2; Cacquevel M, 2008, J NEUROCHEM, V104, P210, DOI 10.1111/j.1471-4159.2007.05041.x; Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140; Chopra V, 2007, P NATL ACAD SCI USA, V104, P16685, DOI 10.1073/pnas.0707842104; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Fraering PC, 2007, CURR GENOMICS, V8, P531, DOI 10.2174/138920207783769521; Fraering PC, 2005, J BIOL CHEM, V280, P41987, DOI 10.1074/jbc.M501368200; Goslin K., 1998, CULTURING NERVE CELL, P339; Green KN, 2008, J NEUROSCI, V28, P11500, DOI 10.1523/JNEUROSCI.3203-08.2008; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Hemming ML, 2008, PLOS BIOL, V6, P2314, DOI 10.1371/journal.pbio.0060257; Imamura Y, 2009, J AM CHEM SOC, V131, P7353, DOI 10.1021/ja9001458; Jakob-Roetne R, 2009, ANGEW CHEM INT EDIT, V48, P3030, DOI 10.1002/anie.200802808; Kinoshita K, 1999, PROTEIN ENG, V12, P11, DOI 10.1093/protein/12.1.11; Kukar TL, 2008, NATURE, V453, P925, DOI 10.1038/nature07055; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790; Neugebauer RC, 2008, J MED CHEM, V51, P1203, DOI 10.1021/jm700972e; Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780; Pandithage R, 2008, J CELL BIOL, V180, P915, DOI 10.1083/jcb.200707126; Pissarnitski DA, 2007, BIOORG MED CHEM LETT, V17, P57, DOI 10.1016/j.bmcl.2006.09.094; Sato C, 2006, J NEUROSCI, V26, P12081, DOI 10.1523/JNEUROSCI.3614-06.2006; Shindler KS, 2007, INVEST OPHTH VIS SCI, V48, P3602, DOI 10.1167/iovs.07-0131; Siemers ER, 2006, NEUROLOGY, V66, P602, DOI 10.1212/01.WNL.0000198762.41312.E1; STEINER H, 2008, ALZHEIMERS DEMENT, V4, pT189; Taylor DM, 2008, CELL MOL LIFE SCI, V65, P4000, DOI 10.1007/s00018-008-8357-y; Tolia A, 2006, J BIOL CHEM, V281, P27633, DOI 10.1074/jbc.M604997200; Trapp J, 2006, J MED CHEM, V49, P7307, DOI 10.1021/jm060118b; Vickers AEM, 2001, DRUG METAB DISPOS, V29, P1269; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wolfe MS, 2008, NEUROTHERAPEUTICS, V5, P391, DOI 10.1016/j.nurt.2008.05.010; Wolfe MS, 2009, CHEM REV, V109, P1599, DOI 10.1021/cr8004197; Wolfe MS, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S4; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wu F, 2008, FASEB J, V22, P890, DOI 10.1096/fj.07-9566com; Yamasaki A, 2006, J NEUROSCI, V26, P3821, DOI 10.1523/JNEUROSCI.5354-05.2006; Zala D, 2005, NEUROBIOL DIS, V20, P785, DOI 10.1016/j.nbd.2005.05.017	46	20	22	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2464	2474		10.1096/fj.09-148031	http://dx.doi.org/10.1096/fj.09-148031			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20237298				2022-12-28	WOS:000279343600033
J	Matthews, EE; Thevenin, D; Rogers, JM; Gotow, L; Lira, PD; Reiter, LA; Brissette, WH; Engelman, DM				Matthews, Erin E.; Thevenin, Damien; Rogers, Julia M.; Gotow, Lisa; Lira, Paul D.; Reiter, Lawrence A.; Brissette, William H.; Engelman, Donald M.			Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation	FASEB JOURNAL			English	Article						transmembrane domain; small-molecule agonist; disulfide bond cross-linking; TOXCAT	GROWTH-HORMONE RECEPTOR; ERYTHROPOIETIN RECEPTOR; EXTRACELLULAR JUXTAMEMBRANE; LEUCINE-ZIPPER; DOMAIN; AGONISTS; IDENTIFICATION; MEMBRANE; MIMICS; MEGAKARYOCYTOPOIESIS	We report how rotational variations in transmembrane (TM) helix interactions participate in the activity states of the thrombopoietin receptor (TpoR), a type 1 cytokine receptor that controls the production of blood platelets. We also explore the mechanism of small-molecule agonists that do not mimic the natural ligand. We show, by a combination of cysteine cross-linking, alanine-scanning mutagenesis, and computational simulations, that the TpoR TM dimerizes strongly and can adopt 3 different stable, rotationally related conformations, which may correspond to specific states of the full-length receptor (active, inactive, and partially active). Thus, our data suggest that signaling and inactive states of the receptor are related by receptor subunit rotations, rather than a simple monomer-dimer transition. Moreover, results from experiments with and without agonists in vitro and in cells allow us to propose a novel allosteric mechanism of action for a class of small molecules, in which they activate TpoR by binding to the TM region and by exploiting the rotational states of the dimeric receptor. Overall, our results support the emerging view of the participation of mutual rotations of the TM domains in cytokine receptor activation.-Matthews, E. E., Thevenin, D., Rogers, J. M., Gotow, L., Lira, P. D., Reiter, L. A., Brissette, W. H., Engelman, D. M. Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J. 25, 2234-2244 (2011). www.fasebj.org	[Matthews, Erin E.; Thevenin, Damien; Rogers, Julia M.; Engelman, Donald M.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Gotow, Lisa; Lira, Paul D.; Reiter, Lawrence A.; Brissette, William H.] Pfizer Global Res & Dev, Groton Labs, Groton, CT USA	Yale University; Pfizer	Engelman, DM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114, New Haven, CT 06520 USA.	donald.engelman@yale.edu		Rogers, Julia M/0000-0001-6518-5470; Thevenin, Damien/0000-0002-1866-0694	U.S. National Institutes of Health [GM073857, CA133890]; Pfizer [N-926702]; NATIONAL CANCER INSTITUTE [R01CA133890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073857] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer(Pfizer); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the U.S. National Institutes of Health (grants GM073857 and CA133890) and by Pfizer (grant N-926702).	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Adams PD, 1996, PROTEINS, V26, P257, DOI 10.1002/(SICI)1097-0134(199611)26:3<257::AID-PROT2>3.0.CO;2-B; ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Brooks AJ, 2008, INT J BIOCHEM CELL B, V40, P1984, DOI 10.1016/j.biocel.2007.07.008; Brown RJ, 2005, NAT STRUCT MOL BIOL, V12, P814, DOI 10.1038/nsmb977; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; de Sauvage FJ, 1998, J LAB CLIN MED, V131, P496, DOI 10.1016/S0022-2143(98)90057-9; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Ding F, 2004, BLOOD, V103, P4198, DOI 10.1182/blood-2003-10-3471; Ding JM, 2009, BLOOD, V114, P3325, DOI 10.1182/blood-2008-04-149047; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Duffy KJ, 2002, J MED CHEM, V45, P3573, DOI 10.1021/jm025535c; Duffy KJ, 2002, J MED CHEM, V45, P3576, DOI 10.1021/jm0255365; Duffy KJ, 2001, J MED CHEM, V44, P3730, DOI 10.1021/jm010283l; Fox NE, 2010, EXP HEMATOL, V38, P384, DOI 10.1016/j.exphem.2010.02.007; Gadd SL, 2006, MOL ENDOCRINOL, V20, P2734, DOI 10.1210/me.2006-0114; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; Kim MJ, 2007, J BIOL CHEM, V282, P14253, DOI 10.1074/jbc.M611616200; Kubatzky KF, 2005, J BIOL CHEM, V280, P14844, DOI 10.1074/jbc.M411251200; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Kuter DJ, 2007, BLOOD, V109, P4607, DOI 10.1182/blood-2006-10-019315; Kuter DJ, 2009, ANNU REV MED, V60, P193, DOI 10.1146/annurev.med.60.042307.181154; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lu XH, 2006, J BIOL CHEM, V281, P7002, DOI 10.1074/jbc.M512638200; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Munchhof MJ, 2009, BIOORG MED CHEM LETT, V19, P1428, DOI 10.1016/j.bmcl.2009.01.032; Nakamura T, 2006, BLOOD, V107, P4300, DOI 10.1182/blood-2005-11-4433; Nogami W, 2008, HAEMATOL-HEMATOL J, V93, P1495, DOI 10.3324/haematol.12752; Noordeen NA, 2006, J BIOL CHEM, V281, P22744, DOI 10.1074/jbc.M603233200; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Qazi AM, 2006, MOL ENDOCRINOL, V20, P1912, DOI 10.1210/me.2005-0291; Reiter LA, 2008, BIOORG MED CHEM LETT, V18, P3000, DOI 10.1016/j.bmcl.2008.03.052; Reiter LA, 2007, BIOORG MED CHEM LETT, V17, P5447, DOI 10.1016/j.bmcl.2007.07.038; Richter L, 2010, P NATL ACAD SCI USA, V107, P14597, DOI 10.1073/pnas.1003026107; Ruan WM, 2004, J BIOL CHEM, V279, P3273, DOI 10.1074/jbc.M309311200; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Safonov IG, 2006, BIOORG MED CHEM LETT, V16, P1212, DOI 10.1016/j.bmcl.2005.11.096; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Staerk J, 2006, BLOOD, V107, P1864, DOI 10.1182/blood-2005-06-2600; Stasi R, 2008, DRUGS, V68, P901, DOI 10.2165/00003495-200868070-00002; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tarasova A, 2009, CHEMMEDCHEM, V4, P2002, DOI 10.1002/cmdc.200900340; Yamane N, 2008, EUR J PHARMACOL, V586, P44, DOI 10.1016/j.ejphar.2008.02.060; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	48	50	51	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2234	2244		10.1096/fj.10-178673	http://dx.doi.org/10.1096/fj.10-178673			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21402716	Green Published			2022-12-28	WOS:000292242200015
J	Chen, KC; Wang, YS; Hu, CY; Chang, WC; Liao, YC; Dai, CY; Juo, SHH				Chen, Ku-Chung; Wang, Yung-Song; Hu, Ching-Yu; Chang, Wei-Chiao; Liao, Yi-Chu; Dai, Chia-Yen; Juo, Suh-Hang Hank			OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases	FASEB JOURNAL			English	Article						DNA methylation; DNMT3b; atherosclerosis	LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; MATRIX-METALLOPROTEINASE EXPRESSION; TUMOR-SUPPRESSOR GENES; DNA METHYLTRANSFERASES; OXIDIZED LDL; LUNG-CANCER; IN-VITRO; ATHEROSCLEROSIS; METHYLATION	MicroRNAs (miRNAs), small noncoding RNAs, can control gene expression by binding to their target genes for degradation and/or translational repression. Epigenetic mechanisms are defined as heritable changes in gene expression that do not involve coding sequence modifications. Both mechanisms play an important role in maintaining physiological functions and are also related to disease development. However, few studies report that miRNA-mediated epigenetic regulations are involved in atherosclerosis. In the present study, oxidized low-density lipoprotein (oxLDL) significantly increased primary human aortic smooth muscle cell (HASMC) migration through MMP-2/MMP-9 up-regulation associated with decreased DNA methylation levels. Either mRNA or protein level of DNA methyltransferase 3b (DNMT3b) showed a dose-dependent down-regulation in oxLDL-mediated HASMCs. Knockdown DNMT3b expression enhanced oxLDL-induced DNA demethylation levels of MMP-2/MMP-9. The expression of miRNA-29b (miR-29b), directly targeting DNMT3b, was up-regulated by oxLDL treatment in a dose-dependent manner. OxLDL-mediated MMP-2/MMP-9 up-regulation, DNMT3b down-regulation, and DNA demethylation were all attenuated after knockdown miR-29b expression by antagomiR-29b. We find that oxLDL can up-regulate miR-29b expression, resulting in DNMT3b down-regulation in HASMCs and epigenetically regulated MMP2/MMP-9 genes involved in cell migration. These results show that miRNA-mediated epigenetic regulation may be a novel mechanism in atherosclerosis.-Chen, K.-C., Wang, Y.-S., Hu, C.-Y., Chang, W.-C., Liao, Y C., Dai, C.-Y., Juo, S.-H. H. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J. 25, 1718-1728 (2011). www.fasebj.org	[Chen, Ku-Chung; Wang, Yung-Song; Chang, Wei-Chiao; Juo, Suh-Hang Hank] Kaohsiung Med Univ, Dept Med Genet, Kaohsiung 807, Taiwan; [Hu, Ching-Yu; Liao, Yi-Chu] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan; [Dai, Chia-Yen] Kaohsiung Med Univ, Fac Internal Med, Coll Med, Kaohsiung 807, Taiwan; [Dai, Chia-Yen] Kaohsiung Med Univ, Dept Internal Med, Hepatobiliary Div, Kaohsiung 807, Taiwan; [Dai, Chia-Yen] Kaohsiung Med Univ, Dept Occupat & Environm Med, Kaohsiung 807, Taiwan; [Chen, Ku-Chung; Wang, Yung-Song; Juo, Suh-Hang Hank] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Liao, Yi-Chu] Taichung Vet Gen Hosp, Neurol Sect, Taichung, Taiwan; [Liao, Yi-Chu] Natl Yang Ming Univ, Dept Neurol, Sch Med, Taipei 112, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University	Juo, SHH (corresponding author), Kaohsiung Med Univ, Dept Med Genet, 100 TzYou 1st Rd, Kaohsiung 807, Taiwan.	hjuo@kmu.edu.tw	Huang, Jee-Fu/AAX-4622-2020; Juo, Suh-Hang/C-9545-2009; Chuang, Wan-Long/ABF-7427-2021	Huang, Jee-Fu/0000-0002-2752-7051; Chuang, Wan-Long/0000-0002-2376-421X; Liao, Yi-Chu/0000-0002-9644-2086; Chang, Wei-Chiao/0000-0002-8573-5924	National Health Research Institutes, Taiwan [NHRI-Ex96-9607PI]; National Science Council, Taiwan [NSC 98-2314-B-037-048]; Kaohsiung Medical University Hospital [KMUH98-8I11]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University Hospital	The study is supported by grants from the National Health Research Institutes, Taiwan (NHRI-Ex96-9607PI), the National Science Council, Taiwan (NSC 98-2314-B-037-048), and Kaohsiung Medical University Hospital (intramural grant KMUH98-8I11).	Aoyagi M, 1998, HISTOCHEM CELL BIOL, V109, P97, DOI 10.1007/s004180050206; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381; Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957; Chahine MN, 2009, J MOL CELL CARDIOL, V46, P431, DOI 10.1016/j.yjmcc.2008.10.009; Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC; Chen JH, 2010, J LIPID RES, V51, P991, DOI 10.1194/jlr.M000398; Cheng XD, 2008, STRUCTURE, V16, P341, DOI 10.1016/j.str.2008.01.004; Chernov AV, 2009, J BIOL CHEM, V284, P12727, DOI 10.1074/jbc.M900273200; Chien MW, 2003, J LIPID RES, V44, P1667, DOI 10.1194/jlr.M300006-JLR200; Cui M, 2009, MOL BIOL REP, V36, P2201, DOI 10.1007/s11033-008-9435-9; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Hojo Y, 2002, ATHEROSCLEROSIS, V161, P185, DOI 10.1016/S0021-9150(01)00615-3; Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Huang YS, 2007, ACTA BIOCH BIOPH SIN, V39, P19, DOI 10.1111/j.1745-7270.2007.00251.x; Janicki JS, 2004, HEART FAIL REV, V9, P33, DOI 10.1023/B:HREV.0000011392.03037.7e; Kalela A, 2002, SCAND J CLIN LAB INV, V62, P337, DOI 10.1080/00365510260296483; Kita T, 2001, ANN NY ACAD SCI, V947, P199; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011; Kwon YM, 2007, J CANCER RES CLIN, V133, P219, DOI 10.1007/s00432-006-0160-2; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200; Lin Y, 2009, J BIOL CHEM, V284, P7903, DOI 10.1074/jbc.M806920200; Liu XQ, 2009, NAT MED, V15, P1357, DOI 10.1038/nm1209-1357; Maziere C, 2010, FREE RADICAL BIO MED, V48, P1382, DOI 10.1016/j.freeradbiomed.2010.02.022; Maziere C, 2009, FREE RADICAL BIO MED, V46, P127, DOI 10.1016/j.freeradbiomed.2008.10.024; Mokarram P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007012; Momi S, 2009, J EXP MED, V206, P2365, DOI 10.1084/jem.20090687; Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493; Mukhopadhyay P, 2009, AM J PHYSIOL-HEART C, V296, pH1466, DOI 10.1152/ajpheart.00795.2008; Pogribny IP, 2009, CELL MOL LIFE SCI, V66, P2249, DOI 10.1007/s00018-009-0015-5; Quintavalle M, 2010, J CELL BIOL, V189, P13, DOI 10.1083/jcb.200912096; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sun YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003656; Takada S, 2009, RNA, V15, P1507, DOI 10.1261/rna.1418309; Tan KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007689; Turunen MP, 2009, BBA-GEN SUBJECTS, V1790, P886, DOI 10.1016/j.bbagen.2009.02.008; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103; Xiong YN, 2005, GYNECOL ONCOL, V96, P601, DOI 10.1016/j.ygyno.2004.11.047; Yang Shengbo, 2009, Zhongguo Zhong Yao Za Zhi, V34, P611; Zaina S, 2005, J NUTR, V135, P5, DOI 10.1093/jn/135.1.5; Zhang CX, 2009, GENOME MED, V1, DOI 10.1186/gm85	47	171	179	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1718	1728		10.1096/fj.10-174904	http://dx.doi.org/10.1096/fj.10-174904			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21266537				2022-12-28	WOS:000290023800027
J	Li, Y; Xu, SQ; Giles, A; Nakamura, K; Lee, JW; Hou, XY; Donmez, G; Li, J; Luo, ZJ; Walsh, K; Guarente, L; Zang, MW				Li, Yu; Xu, Shanqin; Giles, Amber; Nakamura, Kazuto; Lee, Jong Woo; Hou, Xiuyun; Donmez, Gizem; Li, Ji; Luo, Zhijun; Walsh, Kenneth; Guarente, Leonard; Zang, Mengwei			Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver	FASEB JOURNAL			English	Article						unfolded protein response; XBP-1 splicing; mTORC1; hepatic steatosis; insulin signaling	UNFOLDED PROTEIN RESPONSE; SMALL-MOLECULE ACTIVATORS; DIET-INDUCED OBESITY; ER STRESS; GLUCOSE-HOMEOSTASIS; METABOLIC DISEASE; MOUSE MODELS; LDL RECEPTOR; LIFE-SPAN; KINASE	Endoplasmic reticulum (ER) stress has been implicated in the pathophysiology of human type 2 diabetes (T2DM). Although SIRT1 has a therapeutic effect on metabolic deterioration in T2DM, the precise mechanisms by which SIRT1 improves insulin resistance remain unclear. Here, we demonstrate that adenovirus-mediated overexpression of SIRT1 in the liver of diet-induced insulin-resistant low-density lipoprotein receptor-deficient mice and of genetically obese ob/ob mice attenuates hepatic steatosis and ameliorates systemic insulin resistance. These beneficial effects were associated with decreased mammalian target of rapamycin complex 1 (mTORC1) activity, inhibited the unfolded protein response (UPR), and enhanced insulin receptor signaling in the liver, leading to decreased hepatic gluconeogenesis and improved glucose tolerance. The tunicamycin-induced splicing of X-box binding protein-1 and expression of GRP78 and CHOP were reduced by resveratrol in cultured cells in a SIRT1-dependent manner. Conversely, SIRT1-deficient mouse embryonic fibroblasts challenged with tunicamycin exhibited markedly increased mTORC1 activity and impaired ER homeostasi and insulin signaling. These effects were abolished by mTORC1 inhibition by rapamycin in human HepG2 cells. These studies indicate that SIRT1 serves as a negative regulator of UPR signaling in T2DM and that SIRT1 attenuates hepatic steatosis, ameliorates insulin resistance, and restores glucose homeostasis, largely through the inhibition of mTORC1 and ER stress.-Li, Y., Xu, S., Giles, A., Nakamura, K., Lee, J. W., Hou, X., Donmez, G., Li,J., Luo, Z., Walsh, K., Guarente, L., Zang, M. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J. 25, 1664-1679 (2011). www.fasebj.org	[Zang, Mengwei] Boston Univ, Sch Med, Dept Med, Vasc Biol Sect,Whitaker Cardiovasc Inst, Boston, MA 02118 USA; [Luo, Zhijun] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Donmez, Gizem; Guarente, Leonard] MIT, Dept Biol, Paul F Glenn Lab, Cambridge, MA USA; [Li, Ji] SUNY Buffalo, Sch Med & Biomed Sci, Dept Pharmacol & Toxicol, Buffalo, NY 14260 USA	Boston University; Boston University; Massachusetts Institute of Technology (MIT); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Zang, MW (corresponding author), Boston Univ, Sch Med, Dept Med, Vasc Biol Sect,Whitaker Cardiovasc Inst, 650 Albany St,X725, Boston, MA 02118 USA.	mwzang1@bu.edu	Li, Yu/B-1071-2014; Luo, Zhijun/AAE-9302-2019; Yalcin, Gizem Donmez/AAG-5056-2019	Luo, Zhijun/0000-0001-8105-5289; Yalcin, Gizem Donmez/0000-0002-5121-8232; Giles, Amber/0000-0002-8721-1825; Li, Yu/0000-0001-6910-5933; Luo, Zhijun/0000-0003-3509-4046; Zang, Mengwei/0000-0002-2502-2586	National Institutes of Health (NIH) [DK 076942, PO1HL068758]; Robert Dawson Evans Junior Faculty; Paul F. Glenn Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076942] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert Dawson Evans Junior Faculty; Paul F. Glenn Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors greatly appreciate Dr. Richard A. Cohen for insightful advice. The authors also thank Dr. Pere Puigserver (Harvard Medical School, Boston, MA, USA) for kindly providing the adenoviral vector encoding Flag-tagged SIRT1 and Dr. Ling Qi (Cornell University, Ithaca, NY, USA) for important suggestions. The authors are grateful to Kimberly Wong and Karlene A. Maitland-Toolan for technical assistance. This work is supported by National Institutes of Health (NIH) grants DK 076942 and PO1HL068758 and the Robert Dawson Evans Junior Faculty Merit Award to M.Z. and by grants from NIH and the Paul F. Glenn Foundation to L. G.	Ajmo JM, 2008, AM J PHYSIOL-GASTR L, V295, pG833, DOI 10.1152/ajpgi.90358.2008; Armour SM, 2009, AGING-US, V1, P515, DOI 10.18632/aging.100056; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Birkenfeld AL, 2009, DIABETES, V58, pA387; Boden G, 2008, DIABETES, V57, P2438, DOI 10.2337/db08-0604; Escande C, 2010, J CLIN INVEST, V120, P545, DOI 10.1172/JCI39319; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199; Gregor MF, 2009, DIABETES, V58, P693, DOI 10.2337/db08-1220; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hotamisligil GS, 2010, NAT MED, V16, P396, DOI 10.1038/nm0410-396; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Kennedy AJ, 2010, DIS MODEL MECH, V3, P156, DOI 10.1242/dmm.003467; Krebs M, 2007, DIABETES, V56, P1600, DOI 10.2337/db06-1016; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Li X, 2007, MOL CELL, V28, P91, DOI 10.1016/j.molcel.2007.07.032; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Ozean U, 2008, MOL CELL, V29, P541, DOI [10.1016/j.moicel.2007.12.023, 10.1016/j.molcel.2007.12.023]; Petersen KF, 2005, DIABETES, V54, P603, DOI 10.2337/diabetes.54.3.603; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rodriguez-Sanabria F, 2010, MOL CELL BIOCHEM, V343, P59, DOI 10.1007/s11010-010-0498-2; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Schreyer SA, 2002, AM J PHYSIOL-ENDOC M, V282, pE207, DOI 10.1152/ajpendo.2002.282.1.E207; Sha HB, 2009, CELL METAB, V9, P556, DOI 10.1016/j.cmet.2009.04.009; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Viswanathan M, 2005, DEV CELL, V9, P605, DOI 10.1016/j.devcel.2005.09.017; Winnay JN, 2010, NAT MED, V16, P438, DOI 10.1038/nm.2121; Wouters K, 2008, HEPATOLOGY, V48, P474, DOI 10.1002/hep.22363; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Xu F, 2010, ENDOCRINOLOGY, V151, P2504, DOI 10.1210/en.2009-1013; Yang L, 2010, CELL METAB, V11, P467, DOI 10.1016/j.cmet.2010.04.005; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zang MW, 2008, J BIOL CHEM, V283, P31429, DOI 10.1074/jbc.M802855200; Zang MW, 2006, DIABETES, V55, P2180, DOI 10.2337/db05-1188; Zang MW, 2004, J BIOL CHEM, V279, P47898, DOI 10.1074/jbc.M408149200; Zuccollo A, 2005, CIRCULATION, V112, P3001, DOI 10.1161/CIRCULATIONAHA.105.581892	53	226	245	1	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1664	1679		10.1096/fj.10-173492	http://dx.doi.org/10.1096/fj.10-173492			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21321189	Green Published			2022-12-28	WOS:000290023800023
J	White, RE; Powell, DJ; Berry, C				White, Rhian E.; Powell, David J.; Berry, Colin			HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites	FASEB JOURNAL			English	Article						proteasome; HAART	FALCIPARUM IN-VITRO; CELL-CYCLE CONTROL; PLASMODIUM-FALCIPARUM; ANTIMALARIAL ACTIVITY; ASPARTIC PROTEASE; CANDIDA; VIVO; CHLOROQUINE; SAQUINAVIR; UBIQUITIN	HIV proteinase inhibitors reduce the levels of Leishmania parasites in vivo and in vitro, but their biochemical target is unknown. We have identified an ortholog of the yeast Ddi1 protein as the only member of the aspartic proteinase family in Leishmania parasites, and in this study we investigate this protein as a potential target for the drugs. To date, no enzyme assay has been developed for the Ddi1 proteins, but Saccharomyces cerevisiae lacking the DDI1 gene secrete high levels of protein into the medium. We developed an assay in which these knockout yeast were functionally complemented to low secretion by introduction of genes encoding Ddi1 orthologs from Leishmania major or humans. Plasmid alone controls gave no complementation. Treatment of the Ddi1 transformants with HIV proteinase inhibitors showed differential effects dependent on the origin of the Ddi1. Dose responses allowed calculation of IC(50) values; e.g., for nelfinavir, of 3.4 mu M (human Ddi1) and 0.44 mu M (Leishmania Ddi1). IC(50) values with Leishmania constructs mirror the potency of inhibitors against parasites. Our results show that Ddi1 proteins are targets of HIV proteinase inhibitors and indicates the Leishmania Ddi1 as the likely target for these drugs and a potential target for antiparasitic therapy.-White, R.E., Powell, D.J., Berry, C. HIV proteinase inhibitors target the Ddi1-Like protein of Leishmania parasites. FASEB J. 25, 1729-1736 (2011). www.fasebj.org	[White, Rhian E.; Berry, Colin] Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3AT, S Glam, Wales; [Powell, David J.] GlaxoSmithKline Inc, Med Res Ctr, Stevenage, Herts, England	Cardiff University; GlaxoSmithKline	Berry, C (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Pk Pl, Cardiff CF10 3AT, S Glam, Wales.	berry@cf.ac.uk	Berry, Colin/A-4338-2010	Berry, Colin/0000-0002-9943-548X; Plummer, Beverley/0000-0002-6559-7237	Biotechnology and Biological Sciences Research Council [BB/D526137/1]	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by Biotechnology and Biological Sciences Research Council Collaborative Award in Science and Engineering BB/D526137/1 to R.E.W.	Alves CR, 2005, EXP PARASITOL, V109, P38, DOI 10.1016/j.exppara.2004.10.005; Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; Andrews KT, 2006, ANTIMICROB AGENTS CH, V50, P639, DOI 10.1128/AAC.50.2.639-648.2006; Barrett A. J., 2004, HDB PROTEOLYTIC ENZY, V1; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Cassone A, 1999, J INFECT DIS, V180, P448, DOI 10.1086/314871; Cassone A, 2002, TRENDS MICROBIOL, V10, P177, DOI 10.1016/S0966-842X(02)02341-7; Cassone A, 2002, J INFECT DIS, V185, P188, DOI 10.1086/338445; Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2; Diaz-Martinez LA, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-28; Fatimababy AS, 2010, FEBS J, V277, P796, DOI 10.1111/j.1742-4658.2009.07531.x; Gabriely G, 2008, MOL BIOL CELL, V19, P3625, DOI 10.1091/mbc.E07-05-0462; He ZX, 2008, ANTIMICROB AGENTS CH, V52, P2653, DOI 10.1128/AAC.01329-07; He ZX, 2010, INT J ANTIMICROB AG, V35, P191, DOI 10.1016/j.ijantimicag.2009.09.016; He ZX, 2009, EXP PARASITOL, V123, P122, DOI 10.1016/j.exppara.2009.06.008; Hobbs CV, 2009, J INFECT DIS, V199, P134, DOI 10.1086/594369; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Ivantsiv Y, 2006, MOL CELL BIOL, V26, P1579, DOI 10.1128/MCB.26.5.1579-1588.2006; Kaplun L, 2005, MOL CELL BIOL, V25, P5355, DOI 10.1128/MCB.25.13.5355-5362.2005; Krylov DM, 2001, CURR BIOL, V11, pR584, DOI 10.1016/S0960-9822(01)00357-8; Lek-Uthai U, 2008, ANTIMICROB AGENTS CH, V52, P2435, DOI 10.1128/AAC.00169-08; Lustgarten V, 1999, MOL CELL BIOL, V19, P4480; Martins TM, 2006, ACTA TROP, V97, P212, DOI 10.1016/j.actatropica.2005.11.001; Melcher K, 2000, ANAL BIOCHEM, V277, P109, DOI 10.1006/abio.1999.4383; Nathoo S, 2003, LANCET, V362, P1039, DOI 10.1016/S0140-6736(03)14414-5; Parikh S, 2006, ANTIMICROB AGENTS CH, V50, P2207, DOI 10.1128/AAC.00022-06; Parikh S, 2005, ANTIMICROB AGENTS CH, V49, P2983, DOI 10.1128/AAC.49.7.2983-2985.2005; Peatey CL, 2010, ANTIMICROB AGENTS CH, V54, P1334, DOI 10.1128/AAC.01512-09; Piccinini M, 2002, AIDS, V16, P693, DOI 10.1097/00002030-200203290-00004; Piccinini M, 2005, ANTIVIR THER, V10, P215; Pozio E, 2005, TRENDS PARASITOL, V21, P58, DOI 10.1016/j.pt.2004.11.003; Redmond AM, 2007, AIDS, V21, P763, DOI 10.1097/QAD.0b013e328031f41a; Rogers B, 2001, J MOL MICROB BIOTECH, V3, P207; Santos LO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004918; Savoia D, 2005, INT J ANTIMICROB AG, V26, P92, DOI 10.1016/j.ijantimicag.2005.04.003; Skinner-Adams TS, 2007, ANTIMICROB AGENTS CH, V51, P759, DOI 10.1128/AAC.00840-06; Skinner-Adams TS, 2004, J INFECT DIS, V190, P1998, DOI 10.1086/425584; Skrbec D, 2002, BIOCHEM BIOPH RES CO, V297, P1350, DOI 10.1016/S0006-291X(02)02372-0; Trudel N, 2008, J INFECT DIS, V198, P1292, DOI 10.1086/592280; Valdivieso E, 2007, EXP PARASITOL, V116, P77, DOI 10.1016/j.exppara.2006.10.006; Valdivieso E, 2010, EXP PARASITOL, V126, P557, DOI 10.1016/j.exppara.2010.06.002; White RE, 2011, FEBS LETT, V585, P139, DOI 10.1016/j.febslet.2010.11.026; Wilson SI, 1997, BBA-PROTEIN STRUCT M, V1339, P113, DOI 10.1016/S0167-4838(96)00224-5	43	38	40	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1729	1736		10.1096/fj.10-178947	http://dx.doi.org/10.1096/fj.10-178947			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21266539	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000290023800028
J	Osawa, Y; Seki, E; Kodama, Y; Suetsugu, A; Miura, K; Adachi, M; Ito, H; Shiratori, Y; Banno, Y; Olefsky, JM; Nagaki, M; Moriwaki, H; Brenner, DA; Seishima, M				Osawa, Yosuke; Seki, Ekihiro; Kodama, Yuzo; Suetsugu, Atsushi; Miura, Kouichi; Adachi, Masayuki; Ito, Hiroyasu; Shiratori, Yoshimune; Banno, Yoshiko; Olefsky, Jerrold M.; Nagaki, Masahito; Moriwaki, Hisataka; Brenner, David A.; Seishima, Mitsuru			Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression	FASEB JOURNAL			English	Article						sphingosine-1-phosphate; glucose intolerance; glucose transporter 2; glycogen synthase kinase-3 beta	SPHINGOSINE 1-PHOSPHATE; INSULIN-RESISTANCE; SKELETAL-MUSCLE; FATTY LIVER; TNF-ALPHA; CELLS; CERAMIDE; PATHWAY; ROLES; TRANSLOCATION	Acid sphingomyelinase (ASM) regulates the homeostasis of sphingolipids, including ceramides and sphingosine-1-phosphate (S1P). Because sphingolipids regulate AKT activation, we investigated the role of ASM in hepatic glucose and lipid metabolism. Initially, we overexpressed ASM in the livers of wild-type and diabetic db/db mice by adenovirus vector (Ad5ASM). In these mice, glucose tolerance was improved, and glycogen and lipid accumulation in the liver were increased. Using primary cultured hepatocytes, we confirmed that ASM increased glucose uptake, glycogen deposition, and lipid accumulation through activation of AKT and glycogen synthase kinase-3 beta. In addition, ASM induced up-regulation of glucose transporter 2 accompanied by suppression of AMP-activated protein kinase (AMPK) phosphorylation. Loss of sphingosine kinase-1 (SphK1) diminished ASM-mediated AKT phosphorylation, but exogenous S1P induced AKT activation in hepatocytes. In contrast, SphK1 deficiency did not affect AMPK activation. These results suggest that the SphK/S1P pathway is required for ASM-mediated AKT activation but not for AMPK inactivation. Finally, we found that treatment with high-dose glucose increased glycogen deposition and lipid accumulation in wild-type hepatocytes but not in ASM(-/-) cells. This result is consistent with glucose intolerance in ASM(-/-) mice. In conclusion, ASM modulates AKT activation and AMPK inactivation, thus regulating glucose and lipid metabolism in the liver.-Osawa, Y., Seki, E., Kodama, Y., Suetsugu, A., Miura, K., Adachi, M., Ito, H., Shiratori, Y., Banno, Y., Olefsky, J. M., Nagaki, M., Moriwaki, H., Brenner, D. A., Seishima, M. Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression. FASEB J. 25, 1133-1144 (2011). www.fasebj.org	[Osawa, Yosuke; Ito, Hiroyasu; Seishima, Mitsuru] Gifu Univ, Grad Sch Med, Dept Informat Clin Med, Gifu 5011194, Japan; [Osawa, Yosuke; Suetsugu, Atsushi; Shiratori, Yoshimune; Nagaki, Masahito; Moriwaki, Hisataka] Gifu Univ, Grad Sch Med, Dept Gastroenterol, Gifu 5011194, Japan; [Banno, Yoshiko] Gifu Univ, Grad Sch Med, Dept Cell Signaling, Gifu 5011194, Japan; [Seki, Ekihiro; Kodama, Yuzo; Miura, Kouichi; Adachi, Masayuki; Olefsky, Jerrold M.; Brenner, David A.] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Gifu University; Gifu University; Gifu University; University of California System; University of California San Diego	Osawa, Y (corresponding author), Gifu Univ, Grad Sch Med, Dept Informat Clin Med, 1-1 Yanagido, Gifu 5011194, Japan.	osawa-gif@umin.ac.jp	Seki, Ekihiro/K-2481-2016; Shiratori, Yoshimune/I-6206-2014	Seki, Ekihiro/0000-0002-9472-6085; Brenner, David/0000-0003-2573-525X	Mitsubishi Pharma Research Foundation; Ministry of Education, Culture, Sports, Science, and Technology of Japan [19790478, 21790657, 21390179]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD012303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085252, R24DK090962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA020172] Funding Source: NIH RePORTER	Mitsubishi Pharma Research Foundation; Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The authors thank Dr. Jacek Bielawski (Medical University of South Carolina, Charleston, SC, USA) for sphingolipid measurement, Dr. Yoko Sugiyama (Gifu University Graduate School of Medicine, Gifu, Japan) for measurement of adenylate cyclase activity, and Dr. Kenneth Walsh (Boston University, Boston, MA, USA) for adenoviruses encoding CA-AMPK and DN-AMPK. This work was supported by grants from Mitsubishi Pharma Research Foundation and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (19790478 and 21790657 to Y.O. and 21390179 to M.S.).	Adachi M, 2008, HEPATOLOGY, V47, P677, DOI 10.1002/hep.21991; Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Al-Makdissy N, 2003, CELL SIGNAL, V15, P1019, DOI 10.1016/S0898-6568(03)00070-6; Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; David TS, 1998, AM J PHYSIOL-REG I, V274, pR1446, DOI 10.1152/ajpregu.1998.274.5.R1446; Deevska GM, 2009, J BIOL CHEM, V284, P8359, DOI 10.1074/jbc.M807800200; Foretz M, 2005, DIABETES, V54, P1331, DOI 10.2337/diabetes.54.5.1331; Glimcher LH, 2009, ANN NY ACAD SCI, V1173, pE2, DOI 10.1111/j.1749-6632.2009.04956.x; Gonzalez AA, 2004, AM J PHYSIOL-ENDOC M, V287, pE1032, DOI 10.1152/ajpendo.00172.2004; Gorska M, 2003, HORM METAB RES, V35, P506; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Holland WL, 2008, ENDOCR REV, V29, P381, DOI 10.1210/er.2007-0025; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Igarashi J, 2009, AM J PHYSIOL-CELL PH, V297, pC1263, DOI 10.1152/ajpcell.00109.2009; Jenkins RW, 2009, CELL SIGNAL, V21, P836, DOI 10.1016/j.cellsig.2009.01.026; Leclerc I, 2001, DIABETES, V50, P1515, DOI 10.2337/diabetes.50.7.1515; LIANGPUNSAKUL S, AM J PHYSL GASTROINT, V298, pG1004; Liu P, 2004, AM J PHYSIOL-CELL PH, V286, pC317, DOI 10.1152/ajpcell.00073.2003; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Osawa Y, 2005, HEPATOLOGY, V42, P1320, DOI 10.1002/hep.20967; Osawa Y, 2005, J BIOL CHEM, V280, P27879, DOI 10.1074/jbc.M503002200; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Rapizzi E, 2009, CELL MOL LIFE SCI, V66, P3207, DOI 10.1007/s00018-009-0106-3; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; Sebastian BM, 2005, AM J PHYSIOL-ENDOC M, V289, pE1077, DOI 10.1152/ajpendo.00296.2005; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Smith EL, 2008, FASEB J, V22, P3419, DOI 10.1096/fj.08-108043; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Stratford S, 2001, BIOCHEM J, V354, P359, DOI 10.1042/0264-6021:3540359; Summers SA, 2005, DIABETES, V54, P591, DOI 10.2337/diabetes.54.3.591; Tani M, 2007, CELL SIGNAL, V19, P229, DOI 10.1016/j.cellsig.2006.07.001; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Wojtaszewski JFP, 2002, DIABETES, V51, P284, DOI 10.2337/diabetes.51.2.284; Wu Y, 2007, J BIOL CHEM, V282, P9777, DOI 10.1074/jbc.M608310200; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; Yang AH, 2002, BBA-MOL CELL BIOL L, V1582, P197, DOI 10.1016/S1388-1981(02)00172-5; Zang MW, 2004, J BIOL CHEM, V279, P47898, DOI 10.1074/jbc.M408149200; Zeidan YH, 2010, CURR MOL MED, V10, P454, DOI 10.2174/156652410791608225	44	39	40	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2011	25	4					1133	1144		10.1096/fj.10-168351	http://dx.doi.org/10.1096/fj.10-168351			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21163859	hybrid, Green Published			2022-12-28	WOS:000288982800003
J	Edwards, LM; Murray, AJ; Holloway, CJ; Carter, EE; Kemp, GJ; Codreanu, I; Brooker, H; Tyler, DJ; Robbins, PA; Clarke, K				Edwards, Lindsay M.; Murray, Andrew J.; Holloway, Cameron J.; Carter, Emma E.; Kemp, Graham J.; Codreanu, Ion; Brooker, Helen; Tyler, Damian J.; Robbins, Peter A.; Clarke, Kieran			Short-term consumption of a high-fat diet impairs whole-body efficiency and cognitive function in sedentary men	FASEB JOURNAL			English	Article						exercise; magnetic resonance; nutrition; mitochondria	ACTIVATED RECEPTOR-ALPHA; SKELETAL-MUSCLE; DECREASED EFFICIENCY; UNCOUPLING PROTEINS; CYCLING EFFICIENCY; MITOCHONDRIAL; PERFORMANCE; METABOLISM; ACIDS; EXERCISE	We recently showed that a short-term high-fat diet blunted exercise performance in rats, accompanied by increased uncoupling protein levels and greater respiratory uncoupling. In this study, we investigated the effects of a similar diet on physical and cognitive performance in humans. Twenty sedentary men were assessed when consuming a standardized, nutritionally balanced diet (control) and after 7 d of consuming a diet comprising 74% kcal from fat. Efficiency was measured during a standardized exercise task, and cognition was assessed using a computerized assessment battery. Skeletal muscle mitochondrial function was measured using P-31 magnetic resonance spectroscopy. The diet increased mean +/- SE plasma free fatty acids by 44% (0.32 +/- 0.03 vs. 0.46 +/- 0.05 mM; P < 0.05) and decreased whole-body efficiency by 3% (21 +/- 1 vs. 18 +/- 1%; P < 0.05), although muscle uncoupling protein (UCP3) content and maximal mitochondrial function were unchanged. High-fat diet consumption also increased subjects' simple reaction times (P < 0.01) and decreased power of attention (P < 0.01). Thus, we have shown that a high-fat diet blunts whole-body efficiency and cognition in sedentary men. We suggest that this effect may be due to increased respiratory uncoupling.-Edwards, L. M., Murray, A. J., Holloway, C. J., Carter, E. E., Kemp, G. J., Codreanu, I., Brooker, H., Tyler, D. J. Tyler, Robbins, P. A., Clarke, K. Short-term consumption of a high-fat diet impairs whole-body efficiency and cognitive function in sedentary men. FASEB J. 25, 1088-1096 (2011). www.fasebj.org	[Edwards, Lindsay M.; Carter, Emma E.; Tyler, Damian J.; Robbins, Peter A.; Clarke, Kieran] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England; [Edwards, Lindsay M.; Holloway, Cameron J.; Codreanu, Ion] John Radcliffe Hosp, Oxford Ctr Clin Magnet Resonance Res, Oxford OX3 9DU, England; [Murray, Andrew J.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England; [Kemp, Graham J.] Univ Liverpool, Inst Ageing & Chron Dis, Fac Hlth & Life Sci, Liverpool L69 3BX, Merseyside, England; [Brooker, Helen] Cognit Drug Res Ltd, Goring On Thames, England	University of Oxford; University of Oxford; University of Cambridge; University of Liverpool	Edwards, LM (corresponding author), Univ Tasmania, Sch Med, Private Bag 34,Med Sci 1, Hobart, Tas 7001, Australia.	l.m.edwards@utas.edu.au	Kemp, Graham J/A-7540-2008; Murray, Andrew/B-3130-2010; Codreanu, Ion/AAS-4378-2020; Tyler, Damian/E-6296-2011; Robbins, Peter/C-7846-2016	Kemp, Graham J/0000-0002-8324-9666; Murray, Andrew/0000-0002-0929-9315; Codreanu, Ion/0000-0002-2644-5572; Tyler, Damian/0000-0002-0780-8905; Robbins, Peter/0000-0002-4975-0609	British Heart Foundation [FS/10/002/28078, PS/02/002/14893, RG/07/004/22659] Funding Source: Medline; Medical Research Council [G0601490] Funding Source: Medline	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AHMAD ER, 2010, P JOINT ANN M INT SO; AMIEL SA, 1995, P NUTR SOC, V54, P151, DOI 10.1079/PNS19950044; ATKINS RC, 2003, ATKINS NEW DIET REVO; Azzu V, 2010, BIOCHEM J, V426, P13, DOI 10.1042/BJ20091321; Benedict FG, 1913, MUSCULAR WORK METABO; Bigrigg JK, 2009, AM J PHYSIOL-REG I, V297, pR885, DOI 10.1152/ajpregu.90604.2008; Boehm EA, 2001, AM J PHYSIOL-HEART C, V280, pH977, DOI 10.1152/ajpheart.2001.280.3.H977; Boudina S, 2007, DIABETES, V56, P2457, DOI 10.2337/db07-0481; Burke LM, 2006, J APPL PHYSIOL, V100, P7, DOI 10.1152/japplphysiol.01238.2005; Coyle E F, 1999, J Sci Med Sport, V2, P181; COYLE EF, 1992, MED SCI SPORT EXER, V24, P782; Edwards LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010681; Edwards LM, 2009, J SPORT SCI, V27, P319, DOI 10.1080/02640410802526916; Erlenbusch M, 2005, INT J SPORT NUTR EXE, V15, P1, DOI 10.1123/ijsnem.15.1.1; FEINSTEIN AR, 2001, MED STAT; Gardner AS, 2004, MED SCI SPORT EXER, V36, P1252, DOI 10.1249/01.MSS.0000132380.21785.03; Goldsmith R, 2010, AM J PHYSIOL-REG I, V298, pR79, DOI 10.1152/ajpregu.00053.2009; Greenwood CE, 2005, NEUROBIOL AGING, V26, pS42, DOI 10.1016/j.neurobiolaging.2005.08.017; Harridge SDR, 1996, PFLUG ARCH EUR J PHY, V432, P913, DOI 10.1007/s004240050215; Helge JW, 1996, J PHYSIOL-LONDON, V492, P293, DOI 10.1113/jphysiol.1996.sp021309; Helge JW, 2001, J PHYSIOL-LONDON, V537, P1009, DOI 10.1113/jphysiol.2001.012933; HERMANSE.L, 1967, ACTA PHYSIOL SCAND, V71, P129, DOI 10.1111/j.1748-1716.1967.tb03719.x; Hesselink MKC, 2003, J CLIN INVEST, V111, P479, DOI 10.1172/JCI16653; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; Hirabara SM, 2006, BBA-BIOENERGETICS, V1757, P57, DOI 10.1016/j.bbabio.2005.11.007; HULTMAN E, 1967, ACTA MED SCAND, V182, P109; HULTMAN E, 1967, SCAND J CLIN LAB INV, VS 19, P11; Institute of Medicine Food and Nutrition Board, 2002, DIET REF INT EN CARB, P1; KEMP GJ, 1994, MAGN RESON QUART, V10, P43; Kemp G, 2008, AM J PHYSIOL-CELL PH, V295, pC844, DOI 10.1152/ajpcell.00264.2008; Kemp GJ, 2007, NMR BIOMED, V20, P555, DOI 10.1002/nbm.1192; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; MARKS MR, 1951, PSYCHOL REV, V58, P179, DOI 10.1037/h0055614; Mogensen M, 2006, J PHYSIOL-LONDON, V571, P669, DOI 10.1113/jphysiol.2005.101691; Moseley L, 2001, MED SCI SPORT EXER, V33, P621; Murray AJ, 2005, DIABETES, V54, P3496, DOI 10.2337/diabetes.54.12.3496; Murray AJ, 2008, J MOL CELL CARDIOL, V44, P694, DOI 10.1016/j.yjmcc.2008.01.008; Murray AJ, 2007, CURR OPIN CLIN NUTR, V10, P704, DOI 10.1097/MCO.0b013e3282f0ecbe; Murray AJ, 2009, FASEB J, V23, P4353, DOI 10.1096/fj.09-139691; Nabben M, 2008, FEBS LETT, V582, P4147, DOI 10.1016/j.febslet.2008.11.016; Naressi A, 2001, COMPUT BIOL MED, V31, P269, DOI 10.1016/S0010-4825(01)00006-3; Nicholls DG, 2006, BBA-BIOENERGETICS, V1757, P459, DOI 10.1016/j.bbabio.2006.02.005; Parrott AC, 1996, HUM PSYCHOPHARM CLIN, V11, P391; Paton CD, 2006, INT J SPORTS MED, V27, P444, DOI 10.1055/s-2005-865781; PERONNET F, 1991, CAN J SPORT SCI, V16, P23; Priego T, 2008, OBESITY, V16, P819, DOI 10.1038/oby.2007.117; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; SIMPSON PM, 1991, INT J GERIATR PSYCH, V6, P95, DOI 10.1002/gps.930060208; Stavinoha MA, 2004, AM J PHYSIOL-ENDOC M, V287, pE888, DOI 10.1152/ajpendo.00190.2004; Tran TK, 1999, AM J PHYSIOL-REG I, V276, pR1682, DOI 10.1152/ajpregu.1999.276.6.R1682; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; WAHREN J, 1984, J CLIN INVEST, V73, P1367, DOI 10.1172/JCI111340; Walker MP, 1999, HUM PSYCHOPHARM CLIN, V14, P483, DOI 10.1002/(SICI)1099-1077(199910)14:7<483::AID-HUP133>3.0.CO;2-T; Wesnes KA, 2000, PSYCHOPHARMACOLOGY, V152, P353, DOI 10.1007/s002130000533; Wesnes KA, 1997, BRIT J SURG, V84, P493; WING RR, 1995, INT J OBESITY, V19, P811; Winocur G, 2005, NEUROBIOL AGING, V26, pS46, DOI 10.1016/j.neurobiolaging.2005.09.003; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; Young ME, 2001, FASEB J, V15, P833, DOI 10.1096/fj.00-0351com; Zhang J, 2006, NUTR NEUROSCI, V9, P179, DOI 10.1080/10284150600955172	60	84	85	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					1088	1096		10.1096/fj.10-171983	http://dx.doi.org/10.1096/fj.10-171983			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21106937				2022-12-28	WOS:000287806200028
J	Freeman, KW; Bowman, BR; Zetter, BR				Freeman, Kevin W.; Bowman, Brian R.; Zetter, Bruce R.			Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling	FASEB JOURNAL			English	Article						ATP synthase; ATPase inhibitory factor 1; angiogenesis; wound healing; migration	ENDOTHELIAL-CELL SURFACE; ATP SYNTHASE; SUBUNIT; NEOVASCULARIZATION; MITOCHONDRIA; ANGIOSTATIN; F-1-ATPASE; RECEPTORS; MIGRATION; SURVIVAL	By an unknown mechanism, beta-thymosins are extracellular modulators of angiogenesis, inflammation, wound healing, and development. We were interested in identifying beta-thymosin interactors and determining their importance in beta-thymosins signaling in human vein endothelial cells (HUVECs). We performed pulldown experiments with biotinylated thymosin beta-4 (T beta 4) in comparison to neutravidin beads alone and used mass spectrometric analysis to identify differentially interacting proteins. By this method, we identified F1-F0 ATP synthase, a known target of antiangiogenic angiostatin. By surface plasmon resonance, we determined for T beta 4 binding to the beta subunit of ATP synthase a K-D of 12 nM. Blocking antibodies and antagonists (oligomycin, IC50 similar to 1.8 mu M; piceatannol, IC50 similar to 1.05 mu M; and angiostatin, IC50 similar to 2.9 mu g/ml) of ATP synthase inhibited the T beta 4-induced increase in cell surface ATP levels, as measured by luciferase assay, and the T beta 4-induced increase in HUVEC migration, as measured by transwell migration assay. Silencing of the ATP-responsive purinergic receptor P2X4 with siRNA also blocked T beta 4-induced HUVEC migration in a transwell assay. Furthermore, in silico we identified common amphiphilic alpha-helical structural similarities between beta-thymosins and the inhibitory factor 1 (IF1), an inhibitor of ATP synthase hydrolysis. In summary, we have identified an extracellular signaling pathway where T beta 4 increases cell surface ATP levels via ATP synthase and have shown further that ATP-responsive P2X4 receptor is required for T beta 4-induced HUVEC migration.-Freeman, K. W., Bowman, B. R., Zetter, B. R. Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. FASEB J. 25, 907-915 (2011). www.fasebj.org	[Freeman, Kevin W.; Zetter, Bruce R.] Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; [Freeman, Kevin W.; Zetter, Bruce R.] Childrens Hosp, Dept Surg, Boston, MA 02115 USA; [Freeman, Kevin W.; Zetter, Bruce R.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Bowman, Brian R.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University	Zetter, BR (corresponding author), Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA.	bruce.zetter@childrens.harvard.edu						Ausiello G, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-S1-S24; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Burwick NR, 2005, J BIOL CHEM, V280, P1740, DOI 10.1074/jbc.M405947200; Campanella M, 2009, TRENDS BIOCHEM SCI, V34, P343, DOI 10.1016/j.tibs.2009.03.006; Chang SY, 2002, J BIOL CHEM, V277, P8388, DOI 10.1074/jbc.M108792200; Chi SL, 2007, CANCER RES, V67, P4716, DOI 10.1158/0008-5472.CAN-06-1094; Chi SL, 2006, ANN MED, V38, P429, DOI 10.1080/07853890600928698; Duda DG, 2004, TRENDS MOL MED, V10, P143, DOI 10.1016/j.molmed.2004.02.001; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fan Y, 2009, DEV CELL, V16, P661, DOI 10.1016/j.devcel.2009.03.009; Feng JW, 2005, IMMUNITY, V22, P427, DOI 10.1016/j.immuni.2005.02.005; Freeman KW, 2009, FUTURE ONCOL, V5, P755, DOI [10.2217/fon.09.71, 10.2217/FON.09.71]; Gledhill JR, 2007, P NATL ACAD SCI USA, V104, P15671, DOI 10.1073/pnas.0707326104; Gledhill JR, 2005, BIOCHEM J, V386, P591, DOI 10.1042/BJ20041513; GOLDSTEIN AL, 2005, ANN NY ACAD SCI, V11, P171; Huang CM, 2006, PROTEOMICS, V6, P5805, DOI 10.1002/pmic.200600163; Irobi E, 2004, EMBO J, V23, P3599, DOI 10.1038/sj.emboj.7600372; Kim KB, 2006, PROTEOMICS, V6, P2444, DOI 10.1002/pmic.200500574; Kim SH, 2004, MICROBIOL-SGM, V150, P2493, DOI 10.1099/mic.0.27312-0; Mangiullo R, 2008, BBA-BIOENERGETICS, V1777, P1326, DOI 10.1016/j.bbabio.2008.08.003; Mannherz HG, 2009, CELL MOTIL CYTOSKEL, V66, P839, DOI 10.1002/cm.20371; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; Marx J, 2007, SCIENCE, V316, P682, DOI 10.1126/science.316.5825.682; Mollinari C, 2009, J CELL SCI, V122, P4195, DOI 10.1242/jcs.056895; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Philp D, 2003, WOUND REPAIR REGEN, V11, P19, DOI 10.1046/j.1524-475X.2003.11105.x; Roth LWA, 1999, DEVELOPMENT, V126, P1365; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Sonin D, 2008, AM J PHYSIOL-HEART C, V295, pH1191, DOI 10.1152/ajpheart.00577.2008; Sosne G, 2007, CLIN OPHTHALMOL, V1, P201; Stoll R, 1997, BIOPOLYMERS, V41, P623, DOI 10.1002/(SICI)1097-0282(199705)41:6<623::AID-BIP3>3.0.CO;2-S; Veitonmaki N, 2004, CANCER RES, V64, P3679, DOI 10.1158/0008-5472.CAN-03-1754; Yamamoto K, 2006, NAT MED, V12, P133, DOI 10.1038/nm1338; Yamamoto K, 2007, AM J PHYSIOL-HEART C, V293, pH1646, DOI 10.1152/ajpheart.01385.2006; Yang H, 2008, NEUROCHEM RES, V33, P2269, DOI 10.1007/s11064-008-9712-y	35	52	55	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					907	915		10.1096/fj.10-169417	http://dx.doi.org/10.1096/fj.10-169417			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21106936				2022-12-28	WOS:000287806200011
J	Strebovsky, J; Walker, P; Lang, R; Dalpke, AH				Strebovsky, Julia; Walker, Patrick; Lang, Roland; Dalpke, Alexander H.			Suppressor of cytokine signaling 1 (SOCS1) limits NF kappa B signaling by decreasing p65 stability within the cell nucleus	FASEB JOURNAL			English	Article						cell activation; inflammation; signal transduction; nuclear factor kappa B; ubiquitination	UBIQUITIN-LIGASE; LOCALIZATION SIGNAL; NEGATIVE REGULATION; EXPORT SIGNAL; DEGRADATION; PROTEIN; RECEPTOR; ACTIVATION; TERMINATION; DOMAIN	Suppressor of cytokine signaling (SOCS) proteins are inhibitors of cytoplasmic Janus kinases (Jak) and signal transducer and activator of transcription (STAT) signaling pathways. Previously the authors surprisingly observed that SOCS1 translocated into the nucleus, which was because of the presence of a nuclear localization sequence. This report now hypothesizes that SOCS1 mediates specific functions within the nuclear compartment because it is instantly transported into the nucleus, as shown by photoactivation and live cell imaging in human HEK293 cells. The NF kappa B component p65 is identified as an interaction partner for SOCS1 but not for other members of the SOCS family. SOCS1 bound to p65 only within the nucleus. By means of its SOCS box domain, SOCS1 operated as a ubiquitin ligase, leading to polyubiquitination and proteasomal degradation of nuclear p65. Thus, SOCS1 limited prolonged p65 signaling and terminated expression of NF kappa B inducible genes. Using mutants that lack either nuclear translocation or a functional SOCS box, this report identifies genes that are regulated in a manner dependent on the nuclear availability of SOCS1. Data show that beyond its receptor-proximal function in Jak/STAT signaling, SOCS1 also regulates the duration of NF kappa B signaling within the cell nucleus, thus exerting a heretofore unrecognized function.-Strebovsky, J., Walker, P., Lang, R., Dalpke, A. H. Suppressor of cytokine signaling 1 (SOCS1) limits NF kappa B signaling by decreasing p65 stability within the cell nucleus. FASEB J. 25, 863-874 (2011). www.fasebj.org	[Strebovsky, Julia; Walker, Patrick; Dalpke, Alexander H.] Heidelberg Univ, Dept Infect Dis Med Microbiol & Hyg, D-69120 Heidelberg, Germany; [Lang, Roland] Univ Hosp Erlangen, Inst Clin Microbiol Immunol & Hyg, Erlangen, Germany	Ruprecht Karls University Heidelberg; University of Erlangen Nuremberg	Dalpke, AH (corresponding author), Heidelberg Univ, Dept Infect Dis Med Microbiol & Hyg, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	alexander.dalpke@med.uni-heidelberg.de	Lang, Roland/C-3287-2011		Deutsche Forschungsgemeinschaft [Da592/4]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank M. L. Schmitz and T. Wittwer for help with NiNTA assays and for fruitful discussions, as well as K. Bode for auxiliary advice. The authors appreciate excellent technical support by A. Elfner. This work was supported by a grant from Deutsche Forschungsgemeinschaft to A.D. (Da592/4). The authors report no conflicting financial interests.	Baens M, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000054; Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; Baetz A, 2008, FASEB J, V22, P4296, DOI 10.1096/fj.08-116079; Bartz H, 2006, BLOOD, V108, P4102, DOI 10.1182/blood-2006-03-008946; Bayle J, 2006, FEBS LETT, V580, P2609, DOI 10.1016/j.febslet.2006.03.093; Bode KA, 2009, J IMMUNOL, V182, P2176, DOI 10.4049/jimmunol.0802560; Calabrese V, 2009, MOL CELL, V36, P754, DOI 10.1016/j.molcel.2009.09.044; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Geng H, 2009, EMBO REP, V10, P381, DOI 10.1038/embor.2009.10; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Gingras S, 2004, J BIOL CHEM, V279, P54702, DOI 10.1074/jbc.M411043200; Haffner MC, 2008, J BIOL CHEM, V283, P22089, DOI 10.1074/jbc.M801041200; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Hwang MN, 2007, BIOCHEM BIOPH RES CO, V360, P333, DOI 10.1016/j.bbrc.2007.06.062; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kamio M, 2004, ONCOGENE, V23, P3107, DOI 10.1038/sj.onc.1207453; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Koelsche C, 2009, MOL IMMUNOL, V46, P2474, DOI 10.1016/j.molimm.2009.05.020; Lee KH, 2008, FEBS LETT, V582, P2319, DOI 10.1016/j.febslet.2008.05.039; Madonna S, 2010, J IMMUNOL, V185, P2467, DOI 10.4049/jimmunol.1001426; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Natoli G, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.11pe1; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nihira K, 2010, CELL DEATH DIFFER, V17, P689, DOI 10.1038/cdd.2009.174; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Prele CM, 2008, J IMMUNOL, V181, P8018, DOI 10.4049/jimmunol.181.11.8018; Rodrigues L, 2009, EMBO J, V28, P1283, DOI 10.1038/emboj.2009.74; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sui SG, 2007, J CELL BIOL, V178, P231, DOI 10.1083/jcb.200611081; Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464; Toniato E, 2002, J BIOL CHEM, V277, P37315, DOI 10.1074/jbc.M205900200; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309	45	120	123	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					863	874		10.1096/fj.10-170597	http://dx.doi.org/10.1096/fj.10-170597			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21084693				2022-12-28	WOS:000287806200007
J	Holloway, CJ; Montgomery, HE; Murray, AJ; Cochlin, LE; Codreanu, I; Hopwood, N; Johnson, AW; Rider, OJ; Levett, DZH; Tyler, DJ; Francis, JM; Neubauer, S; Grocott, MPW; Clarke, K				Holloway, Cameron J.; Montgomery, Hugh E.; Murray, Andrew J.; Cochlin, Lowri E.; Codreanu, Ion; Hopwood, Naomi; Johnson, Andrew W.; Rider, Oliver J.; Levett, Denny Z. H.; Tyler, Damian J.; Francis, Jane M.; Neubauer, Stefan; Grocott, Michael P. W.; Clarke, Kieran		Caudwell Xtreme Everest Res Grp	Cardiac response to hypobaric hypoxia: persistent changes in cardiac mass, function, and energy metabolism after a trek to Mt. Everest Base Camp	FASEB JOURNAL			English	Article						cardiac function; cardiac energy metabolism	MAGNETIC-RESONANCE-SPECTROSCOPY; PULMONARY-ARTERY PRESSURE; HIGH-ALTITUDE; HEART-FAILURE; DOPPLER; DISEASE	We postulated that changes in cardiac high-energy phosphate metabolism may underlie the myocardial dysfunction caused by hypobaric hypoxia. Healthy volunteers (n=14) were studied immediately before, and within 4 d of return from, a 17-d trek to Mt. Everest Base Camp (5300 m). (31)P magnetic resonance (MR) spectroscopy was used to measure cardiac phosphocreatine (PCr)/ATP, and MR imaging and echocardiography were used to assess cardiac volumes, mass, and function. Immediately after returning from Mt. Everest, total body weight had fallen by 3% (P<0.05), but left ventricular mass, adjusted for changes in body surface area, had disproportionately decreased by 11% (P<0.05). Alterations in diastolic function were also observed, with a reduction in peak left ventricular filling rates and mitral inflow E/A, by 17% (P<0.05) and 24% (P<0.01), respectively, with no change in hydration status. Compared with pretrek, cardiac PCr/ATP ratio had decreased by 18% (P<0.01). Whether the abnormalities were even greater at altitude is unknown, but all had returned to pretrek levels after 6 mo. The alterations in cardiac morphology, function, and energetics are similar to findings in patients with chronic hypoxia. Thus, a decrease in cardiac PCr/ATP may be a universal response to periods of sustained low oxygen availability, underlying hypoxia-induced cardiac dysfunction in healthy human heart and in patients with cardiopulmonary diseases.-Holloway, C. J., Montgomery, H. U., Murray, A. J., Cochlin, L. E., Codreanu, I. Hopwood, N., Johnson, A. W., Rider, O. J., Levett, D. Z. H., Tyler, D. J., Francis, J. M., Neubauer, S., Grocott, M. P. W., Clarke, K., for the Caudwell Xtreme Everest Research Group. Cardiac response to hypobaric hypoxia: persistent changes in cardiac mass, function, and energy metabolism after a trek to Mt. Everest Base Camp. FASEB J. 25, 792-796 (2011). www.fasebj.org	[Holloway, Cameron J.; Murray, Andrew J.; Cochlin, Lowri E.; Hopwood, Naomi; Johnson, Andrew W.; Tyler, Damian J.; Clarke, Kieran] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Holloway, Cameron J.; Murray, Andrew J.; Cochlin, Lowri E.; Codreanu, Ion; Johnson, Andrew W.; Rider, Oliver J.; Tyler, Damian J.; Francis, Jane M.; Neubauer, Stefan] Univ Oxford, Ctr Clin Magnet Resonance Res, Oxford OX1 3PT, England; [Montgomery, Hugh E.; Levett, Denny Z. H.; Grocott, Michael P. W.] UCL, Ctr Altitude Space & Extreme Environm Med, London, England	University of Oxford; University of Oxford; University of London; University College London	Holloway, CJ (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Sherrington Bldg, Oxford OX1 3PT, England.	cameron.holloway@dpag.ox.ac.uk	Grocott, Michael/C-4394-2008; Levett, Denny/F-4474-2011; Mythen, Michael G/G-8682-2011; Levett, Denny Zelda Hope/AAY-4627-2021; Codreanu, Ion/AAS-4378-2020; Levett, Denny/D-2239-2017; Tyler, Damian/E-6296-2011; Neubauer, Stefan/B-8448-2011; Montgomery, Hugh/L-1229-2019; Murray, Andrew/B-3130-2010; Montgomery, Hugh/C-2592-2008	Grocott, Michael/0000-0002-9484-7581; Levett, Denny/0000-0002-8418-1675; Levett, Denny Zelda Hope/0000-0002-8418-1675; Codreanu, Ion/0000-0002-2644-5572; Levett, Denny/0000-0002-8418-1675; Tyler, Damian/0000-0002-0780-8905; Murray, Andrew/0000-0002-0929-9315; Neubauer, Stefan/0000-0001-9017-5645; Montgomery, Hugh/0000-0001-8797-5019; Harvey, John Julian/0000-0001-5866-5847; O'Dwyer, Michael J/0000-0003-4038-5745	British Heart Foundation; Medical Research Council [Medical Research Council, grant G0601490]; Rolex Foundation; Association of Anesthetists of Great Britain; Association of Anesthetists of Ireland; UK Intensive Care Foundation; Sir Halley Stuart Trust; British Heart Foundation [PS/02/002/14893, RG/07/004/22659, FS/10/002/28078] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Rolex Foundation; Association of Anesthetists of Great Britain; Association of Anesthetists of Ireland; UK Intensive Care Foundation; Sir Halley Stuart Trust; British Heart Foundation(British Heart Foundation)	The authors thank the Caudwell Xtreme Everest Project Manager, Kay Mitchell, for her tireless work that made the expedition possible and particularly her invaluable assistance with subject recruitment. The authors thank everyone involved with blood sample collection and plasma preparation in the field. Emma Carter is thanked for plasma metabolite analyses. The British Heart Foundation supported this study. D.J.T. was funded by the Medical Research Council, grant G0601490. Caudwell Xtreme Everest (CXE) is a research project coordinated by the UCL Centre for Altitude, Space, and Extreme Environment Medicine. The aim of CXE is to conduct research into hypoxia and human performance at high altitude in order to improve understanding of hypoxia in critical illness. Membership, roles, and responsibilities of the CXE Research Group can be found online (http://www.caudwell-xtreme-everest.co.uk/team). The research was funded from a variety of sources, none of which are public. The entrepreneur John Caudwell, whose name the expedition carries, donated 500,000 pound specifically to support the research. BOC Medical, now part of Linde Gas Therapeutics, generously supported the early research and continues to do so. Lilly Critical Care, The London Clinic (a private hospital), Smiths Medical, Deltex Medical, and The Rolex Foundation have also donated money to support the research and logistics. All monies were given as unrestricted grants. Specific research grants were awarded by the Association of Anesthetists of Great Britain and Ireland, the UK Intensive Care Foundation, and the Sir Halley Stuart Trust. The CXE volunteers who trekked to Mt. Everest Base Camp also kindly donated to support the research.	Allemann Y, 2000, AM J PHYSIOL-HEART C, V279, pH2013, DOI 10.1152/ajpheart.2000.279.4.H2013; Boussuges A, 2000, AM J RESP CRIT CARE, V161, P264, DOI 10.1164/ajrccm.161.1.9902096; Dubowitz G, 2007, WILD ENVIRON MED, V18, P305, DOI 10.1580/07-WEME-OR-094R1.1; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Grocott M, 2007, CRIT CARE, V11, DOI 10.1186/cc5921; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P1215, DOI 10.1073/pnas.93.3.1215; HOON RS, 1977, J APPL PHYSIOL, V42, P722, DOI 10.1152/jappl.1977.42.5.722; Howald H, 2003, EUR J APPL PHYSIOL, V90, P360, DOI 10.1007/s00421-003-0872-9; Hudsmith LE, 2006, J MAGN RESON IMAGING, V24, P312, DOI 10.1002/jmri.20638; Kelly DP, 2008, NAT GENET, V40, P132, DOI 10.1038/ng0208-132; Kjaergaard J, 2006, EUR J APPL PHYSIOL, V98, P411, DOI 10.1007/s00421-006-0299-1; Maeder MT, 2009, J AM COLL CARDIOL, V53, P905, DOI 10.1016/j.jacc.2008.12.007; Murray AJ, 2009, GENOME MED, V1, DOI 10.1186/gm117; Neubauer S, 2007, NEW ENGL J MED, V356, P1140, DOI 10.1056/NEJMra063052; Portman MA, 1996, AM J PHYSIOL-HEART C, V270, pH216, DOI 10.1152/ajpheart.1996.270.1.H216; Tian R, 1997, CIRCULATION, V96, P1313, DOI 10.1161/01.CIR.96.4.1313; Tyler DJ, 2009, NMR BIOMED, V22, P405, DOI 10.1002/nbm.1350; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	19	73	77	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2011	25	2					792	796		10.1096/fj.10-172999	http://dx.doi.org/10.1096/fj.10-172999			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20978235				2022-12-28	WOS:000286724800036
J	Iscla, I; Wray, R; Blount, P				Iscla, Irene; Wray, Robin; Blount, Paul			An in vivo screen reveals protein-lipid interactions crucial for gating a mechanosensitive channel	FASEB JOURNAL			English	Article						methanethiosulfonate modification; osmoregulation; MscL	LARGE-CONDUCTANCE MSCL; MEMBRANE-PROTEIN; FLUORESCENCE; RESIDUES; IDENTIFICATION; TENSION; DOMAIN	The bacterial mechanosensitive channel MscL is the best-studied mechanosensor, thus serving as a paradigm of how a protein senses and responds to mechanical force. Models for the transition of Escherichia coli MscL from closed to open states propose a tilting of the transmembrane domains in the plane of the membrane, suggesting dynamic protein-lipid interactions. Here, we used a rapid in vivo assay to assess the function of channels that were post-translationally modified at several different sites in a region just distal to the cytoplasmic end of the second transmembrane helix. We utilized multiple probes with various affinities for the membrane environment. The in vivo functional data, combined with site-directed mutagenesis, single-channel analyses, and tryptophan fluorescence measurements, confirmed that lipid interactions within this region are critical for MscL gating. The data suggest a model in which this region acts as an anchor for the transmembrane domain tilting during gating. Furthermore, the conservation of analogous motifs among many other channels suggests a conserved protein-lipid dynamic mechanism.-Iscla, I., Wray, R., Blount, P. An in vivo screen reveals protein-lipid interactions crucial for gating a mechanosensitive channel. FASEB J. 25, 694-702 (2011). www.fasebj.org	[Iscla, Irene; Wray, Robin; Blount, Paul] UT SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Blount, P (corresponding author), UT SW Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	paul.blount@utsouthwestern.edu	Iscla, Irene/B-8594-2013	Iscla, Irene/0000-0001-8936-430X	Welch Foundation [I-1420]; U.S. National Aeronautics and Space Administration [NNH08ZTT003N NRA]; Cancer Prevention and Research Institute of Texas, (CPRIT) [RP100146]; U.S. National Institutes of Health [GM61028]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); U.S. National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); Cancer Prevention and Research Institute of Texas, (CPRIT); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Christina Eaton for technical support and Michael Dorwart for helpful discussions. This work was supported by the Welch Foundation (grant I-1420), the U.S. National Aeronautics and Space Administration (grant NNH08ZTT003N NRA), the Cancer Prevention and Research Institute of Texas, (CPRIT; grant RP100146), and the U.S. National Institutes of Health (grant GM61028 and its supplement). R. W. generated all MscL mutants and performed and analyzed the in vivo screening with MTS probes. I. I. performed and analyzed the in vivo experiments for the single mutants and designed, performed, and analyzed patch-clamp experiments, tryptophan fluorescence measurements, and the calcein flux experiments. P. B. and I. I. wrote the manuscript. P. B. coordinated and oversaw the project.	Bartlett JL, 2004, P NATL ACAD SCI USA, V101, P10161, DOI 10.1073/pnas.0402040101; Batiza AF, 2002, P NATL ACAD SCI USA, V99, P5643, DOI 10.1073/pnas.082092599; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Blount P, 1999, Methods Enzymol, V294, P458; Blount P, 1996, BIOL CELL, V87, P1, DOI 10.1016/S0248-4900(97)89832-2; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Blount P, 2007, CURR TOP MEMBR, V58, P201, DOI 10.1016/S1063-5823(06)58008-1; Blount Paul, 2008, V11, P25; Blount Paul, 2008, V1, P71; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; CARNEY J, 2006, CURR PROTOC PROTEIN, P12; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chiang CS, 2005, BIOCHEMISTRY-US, V44, P12589, DOI 10.1021/bi050750r; Clark EH, 2003, BIOCHEMISTRY-US, V42, P11065, DOI 10.1021/bi034607e; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; Elmore DE, 2003, BIOPHYS J, V85, P1512, DOI 10.1016/S0006-3495(03)74584-6; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Iscla I, 2008, BIOPHYS J, V95, P2283, DOI 10.1529/biophysj.107.127423; Jeon J, 2008, BIOPHYS J, V94, P3497, DOI 10.1529/biophysj.107.109850; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kloda A, 2006, BIOPHYS J, V90, P1992, DOI 10.1529/biophysj.105.075481; Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7; Levin G, 2004, BIOPHYS J, V86, P2862, DOI 10.1016/S0006-3495(04)74338-6; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Li YZ, 2009, FASEB J, V23, P2197, DOI 10.1096/fj.09-129296; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; Moe P, 2005, BIOCHEMISTRY-US, V44, P12239, DOI 10.1021/bi0509649; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Perozo E, 2001, J GEN PHYSIOL, V118, P193, DOI 10.1085/jgp.118.2.193; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Powl AM, 2005, BIOCHEMISTRY-US, V44, P5873, DOI 10.1021/bi047439e; Powl AM, 2005, BIOCHEMISTRY-US, V44, P5713, DOI 10.1021/bi047338g; Steinbacher S, 2007, CURR TOP MEMBR, V58, P1, DOI 10.1016/S1063-5823(06)58001-9; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	40	20	21	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					694	702		10.1096/fj.10-170878	http://dx.doi.org/10.1096/fj.10-170878			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21068398	Green Published			2022-12-28	WOS:000286724800027
J	Peeters, MC; van Westen, GJP; Guo, D; Wisse, LE; Muller, CE; Beukers, MW; IJzerman, AP				Peeters, Miriam C.; van Westen, Gerard J. P.; Guo, Dong; Wisse, Lisanne E.; Mueller, Christa E.; Beukers, Margot W.; IJzerman, Adriaan P.			GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A(2B) receptor	FASEB JOURNAL			English	Article						mutagenesis; G protein-coupled receptors; S. cerevisiae; receptor activation; constitutive activity	DOMINANT RETINITIS-PIGMENTOSA; PROTEIN-COUPLED RECEPTORS; LIGAND-BINDING; C5A RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; THYROTROPIN RECEPTOR; RANDOM MUTAGENESIS; RHODOPSIN GENE; YEAST; IDENTIFICATION	The highly variable extracellular loops in G protein-coupled receptors (GPCRs) have been implicated in receptor activation, the mechanism of which is poorly understood. In a random mutagenesis screen on the human adenosine A(2B) receptor (A(2B)R) using the MMY24 Saccharomyces cerevisiae strain as a read-out system, we found that two residues in the first extracellular loop, a phenylalanine and an aspartic acid at positions 71 and 74, respectively, are involved in receptor activation. We subsequently performed further site-directed and site-saturation mutagenesis. These experiments revealed that the introduction of mutations at either of the identified positions results in a wide variety of receptor activation profiles, with changes in agonist potency, constitutive activity, and intrinsic activity. Radioligand binding studies showed that the changes in activation were not due to changes in receptor expression. We interpret these data in the light of the recently revealed structure of the adenosine A(2A)R, the closest homologue of the A(2B)R. The two residues are suggested to be vital in maintaining the tertiary structure of a beta sheet in the extracellular domain of the A(2B)R. We hypothesize that deterioration of structure in the extracellular domains of GPCRs compromises overall receptor structure with profound consequences for receptor activation and constitutive activity.-Peeters, M. C., van Westen, G. J. P., Guo, D., Wisse, L. E., Muller, C. E., Beukers, M. W., IJzerman, A. P. GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A(2B) receptor. FASEB J. 25, 632-643 (2011). www.fasebj.org	[Peeters, Miriam C.; van Westen, Gerard J. P.; Guo, Dong; Wisse, Lisanne E.; Beukers, Margot W.; IJzerman, Adriaan P.] Ctr Biopharmaceut Sci, Div Med Chem, Leiden Amsterdam Ctr Drug Res, NL-2300 RA Leiden, Netherlands; [Mueller, Christa E.] Univ Bonn, Inst Pharmazeut, PharmaCtr Bonn, D-5300 Bonn, Germany	Leiden University; Leiden University - Excl LUMC; University of Bonn	IJzerman, AP (corresponding author), Ctr Biopharmaceut Sci, Div Med Chem, Leiden Amsterdam Ctr Drug Res, POB 9502, NL-2300 RA Leiden, Netherlands.	ijzerman@lacdr.leidenuniv.nl	van Westen, Gerard JP/D-7432-2011; Müller, Christa Elisabeth/C-7748-2014; Guo, Dong/T-6126-2019; van Westen, Gerard/HHZ-3762-2022; IJzerman, Ad/ABG-1353-2020	van Westen, Gerard JP/0000-0003-0717-1817; Müller, Christa Elisabeth/0000-0002-0013-6624; Guo, Dong/0000-0001-6142-4825; IJzerman, Ad/0000-0002-1182-2259	Dutch Top Institute Pharma [D1-105]	Dutch Top Institute Pharma	This research was performed under the auspices of the GPCR Forum, a program funded by the Dutch Top Institute Pharma (project D1-105).	Archer-Lahlou E, 2005, J MED CHEM, V48, P180, DOI 10.1021/jm049886y; Bajaj A, 2007, BBA-MOL CELL RES, V1773, P707, DOI 10.1016/j.bbamcr.2007.02.002; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Beukers MW, 2005, TRENDS PHARMACOL SCI, V26, P533, DOI 10.1016/j.tips.2005.08.005; Beukers MW, 2004, MOL PHARMACOL, V65, P702, DOI 10.1124/mol.65.3.702; Borrmann T, 2009, J MED CHEM, V52, P3994, DOI 10.1021/jm900413e; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; Cain SA, 2001, BIOCHEM PHARMACOL, V61, P1571, DOI 10.1016/S0006-2952(01)00608-6; *CHEM COMP GROUP I, 2008, 200810 CHEM COMP GRO; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697; FISHMAN GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P646, DOI 10.1001/archopht.1992.01080170068026; Fredholm BB, 2000, N-S ARCH PHARMACOL, V362, P364, DOI 10.1007/s002100000313; Fredholm BB, 2001, PHARMACOL REV, V53, P527; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Genoud S, 1999, J VIROL, V73, P1645, DOI 10.1128/JVI.73.2.1645-1648.1999; Harterich S, 2008, BIOORGAN MED CHEM, V16, P9359, DOI 10.1016/j.bmc.2008.08.051; Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638; HAUSER M, 2007, J BIOL CHEM; Hawtin SR, 2006, J BIOL CHEM, V281, P38478, DOI 10.1074/jbc.M607639200; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Klco JM, 2006, J BIOL CHEM, V281, P12010, DOI 10.1074/jbc.M600548200; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Kleinau G, 2008, FASEB J, V22, P2798, DOI 10.1096/fj.07-104711; Labrou NE, 2001, J BIOL CHEM, V276, P37944; Langer I, 2005, J BIOL CHEM, V280, P22198, DOI 10.1074/jbc.M501786200; Langer I, 2003, NEUROPHARMACOLOGY, V44, P125, DOI 10.1016/S0028-3908(02)00233-2; Li QL, 2007, J PHARMACOL EXP THER, V320, P637, DOI 10.1124/jpet.106.111203; Massotte D, 2005, NAT STRUCT MOL BIOL, V12, P287, DOI 10.1038/nsmb0405-287; Mizutori Y, 2008, MOL ENDOCRINOL, V22, P1171, DOI 10.1210/me.2007-0407; Moro S, 1999, BIOCHEMISTRY-US, V38, P3498, DOI 10.1021/bi982369v; NODA K, 1994, J BIOL CHEM, V269, P6743; Nurwakagari P, 2007, J MOL ENDOCRINOL, V38, P259, DOI 10.1677/jme.1.02160; OLAH ME, 1994, J BIOL CHEM, V269, P24692; Olesnicky NS, 1999, EMBO J, V18, P2756, DOI 10.1093/emboj/18.10.2756; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Pasel K, 2000, J CLIN ENDOCR METAB, V85, P1703, DOI 10.1210/jc.85.4.1703; Spicuzza L, 2006, EUR J PHARMACOL, V533, P77, DOI 10.1016/j.ejphar.2005.12.056; Stewart GD, 2009, J PHARMACOL EXP THER, V331, P277, DOI 10.1124/jpet.109.158667; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; Sura-Trueba S, 2009, ENDOCRINOLOGY, V150, P1043, DOI 10.1210/en.2008-1145; Tenenbaum-Rakover Y, 2007, J CLIN ENDOCR METAB, V92, P1137, DOI 10.1210/jc.2006-2147; VAITHINATHAN R, 1994, GENOMICS, V21, P461, DOI 10.1006/geno.1994.1301; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Wilson CN, 2008, BRIT J PHARMACOL, V155, P475, DOI 10.1038/bjp.2008.361	48	38	38	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2011	25	2					632	643		10.1096/fj.10-164319	http://dx.doi.org/10.1096/fj.10-164319			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21030693				2022-12-28	WOS:000286724800021
J	Sever, D; Eldor, R; Sadoun, G; Amior, L; Dubois, D; Boitard, C; Aflalo, C; Melloul, D				Sever, Dror; Eldor, Roy; Sadoun, Gadi; Amior, Livnat; Dubois, Daniele; Boitard, Christian; Aflalo, Claude; Melloul, Danielle			Evaluation of impaired beta-cell function in nonobese-diabetic (NOD) mouse model using bioluminescence imaging	FASEB JOURNAL			English	Article						diabetes mellitus; beta-cell mass; firefly luciferase; cytokines	LOCALIZED FIREFLY LUCIFERASE; IN-VIVO; INSULIN-SECRETION; PANCREATIC-ISLETS; INFLAMMATION; MASS; ONSET; TRANSPLANTATION; AUTOIMMUNITY; PROGRESSION	Insulin-producing pancreatic beta cells are functionally impaired or destroyed in diabetes mellitus. The onset of type 1 diabetes (T1D) represents the culmination of a prolonged prediabetic phase of immune-mediated beta-cell destruction. To assess the in vivo metabolic status of these cells, we used the ATP-sensitive firefly luciferase bioluminescence imaging approach, as a noninvasive probe to monitor pathological alterations in beta-cell function in the nonobese-diabetic (NOD) mouse model of T1D. Hence, we generated the ToI beta-NOD transgenic mice in which doxycycline-inducible luciferase gene is selectively expressed in beta cells. A sharp reduction in bioluminescence emitted in vivo from beta cells at the early stages, preceded by several weeks of a limited reduction in beta-cell mass. Since this decline could be due to the ongoing inflammatory process occurring in vivo, we exposed control islets to inflammatory cytokines and observed a dramatic decrease in luciferase luminescence, which appears to be due in part to a decrease in protein levels and a drop in intracellular ATP levels. This is the first evidence that selective expression of the luciferase gene represents a sensitive method for noninvasive in vivo monitoring of early beta-cell dysfunction, subtle metabolic changes, such as endogenous ATP levels, indicative of a pathological condition in a tissue at the cellular level.-Sever, D., Eldor, R., Sadoun, G., Amior, L., Dubois, D., Boitard, C., Aflalo, C., Melloul, D. Evaluation of impaired beta-cell function in nonobese-diabetic (NOD) mouse model using bioluminescence imaging. FASEB J. 25, 676-684 (2011). www.fasebj.org	[Sever, Dror; Eldor, Roy; Sadoun, Gadi; Amior, Livnat; Melloul, Danielle] Hadassah Univ Hosp, Dept Endocrinol, IL-91120 Jerusalem, Israel; [Dubois, Daniele; Boitard, Christian] Cochin St Vincent de Paul, INSERM, U561, Paris, France; [Aflalo, Claude] Ben Gurion Univ Negev, Inst Agr & Biotechnol Drylands, Blaustein Inst Desert Res, Sede Boqer, Israel	Hebrew University of Jerusalem; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Ben Gurion University	Melloul, D (corresponding author), Hadassah Univ Hosp, Dept Endocrinol, POB 12000, IL-91120 Jerusalem, Israel.	daniellem@ekmd.huji.ac.il	Eldor, Roy/AAD-4397-2022; Aflalo, Claude/H-4638-2011	Aflalo, Claude/0000-0002-3864-0666; Dubois-Laforgue, Daniele/0000-0003-3287-6309; BOITARD, Christian/0000-0003-3985-9405	Juvenile Diabetes Research Foundation [1-2007-60]; European Union [036903]; Israel Ministry of Health	Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); European Union(European Commission); Israel Ministry of Health	The authors thank Decio Eizirik, Chantal Mathieu, and Guy Rutter for helpful discussions. The authors thank Dr. Ronit Sionov for critical reading of the manuscript; Eli Reich, Roy Abel, Adi Tamari, and Nilly Lador-Carp for excellent assistance; and Evelyne Zeira and Hagit Yotfat for assistance with the bioluminescence imaging; as well as Hadas Zohar for helping with graphic design. The authors also thank Yael Morgenstern for the maintenance of the ToI beta-NOD colony. This work was supported by grants from the Juvenile Diabetes Research Foundation (1-2007-60), the European Union (STREP Savebeta, contract 036903) in Framework Programme 6, and the Israel Ministry of Health.	Achenbach P, 2005, DIABETES, V54, pA312; Aflalo C, 1997, J BIOENERG BIOMEMBR, V29, P549, DOI 10.1023/A:1022478917573; AFLALO C, 1991, INT REV CYTOL, V130, P269, DOI 10.1016/S0074-7696(08)61506-5; Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I; Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146/annurev.immunol.23.021704.115643; Antkowiak PF, 2009, AM J PHYSIOL-ENDOC M, V296, pE573, DOI 10.1152/ajpendo.90336.2008; Chen XJ, 2006, TRANSPLANTATION, V81, P1421, DOI 10.1097/01.tp.0000206109.71181.bf; Denis MC, 2004, P NATL ACAD SCI USA, V101, P12634, DOI 10.1073/pnas.0404307101; Dotta F, 2007, P NATL ACAD SCI USA, V104, P5115, DOI 10.1073/pnas.0700442104; Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21; Eldor R, 2006, P NATL ACAD SCI USA, V103, P5072, DOI 10.1073/pnas.0508166103; Faideau B, 2005, DIABETES, V54, pS87, DOI 10.2337/diabetes.54.suppl_2.S87; Fowler M, 2005, TRANSPLANTATION, V79, P768, DOI 10.1097/01.TP.0000152798.03204.5C; Gimi B, 2006, CELL TRANSPLANT, V15, P195, DOI 10.3727/000000006783982151; Honigman A, 2001, MOL THER, V4, P239, DOI 10.1006/mthe.2001.0437; Kawasaki E, 2004, DIABETES RES CLIN PR, V66, pS27, DOI 10.1016/j.diabres.2003.09.015; Kay TWH, 2000, TRENDS ENDOCRIN MET, V11, P11, DOI 10.1016/S1043-2760(99)00210-6; Klinke DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001374; Lin M, 2008, FRONT BIOSCI-LANDMRK, V13, P4558, DOI 10.2741/3023; Lundin A, 2000, METHOD ENZYMOL, V305, P346; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Mauricio D, 1998, DIABETES, V47, P1537, DOI 10.2337/diabetes.47.10.1537; Meier JJ, 2006, DIABETOLOGIA, V49, P1838, DOI 10.1007/s00125-006-0308-2; Meier JJ, 2005, DIABETOLOGIA, V48, P2221, DOI 10.1007/s00125-005-1949-2; Meredith M, 1996, DIABETES, V45, P1783, DOI 10.2337/diabetes.45.12.1783; Park SY, 2009, HORM METAB RES, V41, P1, DOI 10.1055/s-0028-1087209; Park SY, 2005, GENESIS, V43, P80, DOI 10.1002/gene.20157; Paty BW, 2004, TRANSPLANTATION, V77, P1133, DOI 10.1097/01.TP.0000113231.90613.0E; Pipeleers D, 2008, DIABETES OBES METAB, V10, P54, DOI 10.1111/j.1463-1326.2008.00941.x; Reddy S, 2008, J MOL HISTOL, V39, P25, DOI 10.1007/s10735-007-9122-5; Sherry NA, 2005, DIABETES, V54, pS32, DOI 10.2337/diabetes.54.suppl_2.S32; Sherry NA, 2006, DIABETES, V55, P3238, DOI 10.2337/db05-1034; Shimada A, 1996, DIABETES, V45, P1063, DOI 10.2337/diabetes.45.8.1063; Smith SJ, 2006, MOL IMAGING, V5, P65, DOI 10.2310/7290.2006.00007; Sreenan S, 1999, DIABETES, V48, P989, DOI 10.2337/diabetes.48.5.989; Steele C, 2004, DIABETES, V53, P426, DOI 10.2337/diabetes.53.2.426; STRANDELL E, 1990, J CLIN INVEST, V85, P1944, DOI 10.1172/JCI114657; Thebault-Baumont K, 2003, J CLIN INVEST, V111, P851, DOI 10.1172/JCI200316584; Turvey SE, 2005, J CLIN INVEST, V115, P2454, DOI 10.1172/JCI25048; Virostko J, 2004, MOL IMAGING, V3, P333, DOI 10.1162/1535350042973508; Virostko J, 2009, MOL IMAGING BIOL, V11, P204, DOI 10.1007/s11307-008-0193-9; Willcox A, 2009, CLIN EXP IMMUNOL, V155, P173, DOI 10.1111/j.1365-2249.2008.03860.x	42	20	21	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					676	684		10.1096/fj.10-158121	http://dx.doi.org/10.1096/fj.10-158121			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21118902				2022-12-28	WOS:000286724800025
J	Ward, JBJ; Lawler, K; Amu, S; Taylor, CT; Fallon, PG; Keely, SJ				Ward, Joseph B. J.; Lawler, Karen; Amu, Sylvie; Taylor, Cormac T.; Fallon, Padraic G.; Keely, Stephen J.			Hydroxylase inhibition attenuates colonic epithelial secretory function and ameliorates experimental diarrhea	FASEB JOURNAL			English	Article						chloride secretion; dimethyloxallyl glycine; Na+/K+-ATPase	TRANSMEMBRANE CONDUCTANCE REGULATOR; INDUCIBLE FACTOR-I; CYSTIC-FIBROSIS; ION-TRANSPORT; INTESTINAL EPITHELIUM; CHLORIDE SECRETION; OXYGEN SENSORS; CL-SECRETION; MAST-CELLS; BLOOD-FLOW	Hydroxylases are oxygen-sensing enzymes that regulate cellular responses to hypoxia. Transepithelial Cl- secretion, the driving force for fluid secretion, is dependent on O-2 availability for generation of cellular energy. Here, we investigated the role of hydroxylases in regulating epithelial secretion and the potential for targeting these enzymes in treatment of diarrheal disorders. Ion transport was measured as short-circuit current changes across voltage-clamped monolayers of T-84 cells and mouse colon. The antidiarrheal efficacy of dimethyloxallyl glycine (DMOG) was tested in a mouse model of allergic disease. Hydroxylase inhibition with DMOG attenuated Ca2+ - and cAMP-dependent secretory responses in voltage-clamped T-84 cells to 20.2 +/- 2.6 and 38.8 +/- 6.7% (n=16; P <= 0.001) of those in control cells, respectively. Antisecretory actions of DMOG were time and concentration dependent, being maximal after 18 h of DMOG (1 mM) treatment. DMOG specifically inhibited Na+/K+-ATPase pump activity without altering its expression or membrane localization. In mice, DMOG inhibited agonist-induced secretory responses ex vivo and prevented allergic diarrhea in vivo. In conclusion, hydroxylases are important regulators of epithelial Cl- and fluid secretion and present a promising target for development of new drugs to treat transport disorders.-Ward, J. B. J., Lawler, K., Amu, S., Taylor, C. T., Fallon, P. G., Keely, S. J. Hydroxylase inhibition attenuates colonic epithelial secretory function and ameliorates experimental diarrhea. FASEB J. 25, 535-543 (2011). www.fasebj.org	[Keely, Stephen J.] Beaumont Hosp, RCSI Educ & Res Ctr, Mol Med Labs, Royal Coll Surg Ireland, Dublin 9, Ireland; [Amu, Sylvie; Fallon, Padraic G.] Trinity Coll Dublin, Inst Mol Med, Sch Med, Dublin, Ireland; [Taylor, Cormac T.] Univ Coll Dublin, Conway Inst, Sch Med & Life Sci, Coll Life Sci, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Trinity College Dublin; University College Dublin	Keely, SJ (corresponding author), Beaumont Hosp, RCSI Educ & Res Ctr, Mol Med Labs, Royal Coll Surg Ireland, Smurfit Bldg, Dublin 9, Ireland.	skeely@rcsi.ie	Fallon, Padraic/Y-2711-2019; Tuluc, Petronel/C-2527-2011	Fallon, Padraic/0000-0002-8401-7293; Keely, Stephen/0000-0002-6315-3587; Amu, Sylvie/0000-0001-9593-7952; Taylor, Cormac/0000-0002-0946-1247	Science Foundation Ireland; National Biophotonics Imaging Platform Ireland; Irish government's Programme for Research in Third Level Institutions	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); National Biophotonics Imaging Platform Ireland; Irish government's Programme for Research in Third Level Institutions	This work was supported by Science Foundation Ireland Principal Investigator and Research Frontiers Programme awards to S.J.K. and by National Biophotonics Imaging Platform Ireland, and funded by the Irish government's Programme for Research in Third Level Institutions, Cycle 4, National Development Plan 2007-2013.	Asikainen TM, 2005, FREE RADICAL BIO MED, V38, P1002, DOI 10.1016/j.freeradbiomed.2004.12.004; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; Bijvelds MJC, 2009, GASTROENTEROLOGY, V137, P976, DOI 10.1053/j.gastro.2009.05.037; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bystriansky JS, 2007, J BIOENERG BIOMEMBR, V39, P373, DOI 10.1007/s10863-007-9100-3; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; CHOW DC, 1995, J EXP BIOL, V198, P1; Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012; CUTHBERT AW, 1994, PFLUG ARCH EUR J PHY, V428, P508, DOI 10.1007/BF00374572; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Dada LA, 2007, ADV EXP MED BIOL, V618, P159; DEJONGE HR, 2006, PED PULMONOL S, V29, P148; Del Castillo IC, 2005, AM J PHYSIOL-CELL PH, V289, pC1332, DOI 10.1152/ajpcell.00580.2004; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Floyd ZE, 2007, J CELL BIOCHEM, V101, P1545, DOI 10.1002/jcb.21266; Fraisl P, 2009, NAT REV DRUG DISCOV, V8, P139, DOI 10.1038/nrd2761; Garty H, 2006, ANNU REV PHYSIOL, V68, P431, DOI 10.1146/annurev.physiol.68.040104.131852; Genetos DC, 2009, J CELL BIOCHEM, V107, P233, DOI 10.1002/jcb.22119; Hirota K, 2005, BIOCHEM BIOPH RES CO, V338, P610, DOI 10.1016/j.bbrc.2005.08.193; Ibla JC, 2006, AM J PHYSIOL-CELL PH, V291, pC282, DOI 10.1152/ajpcell.00564.2005; KIRK KL, 1983, J GEN PHYSIOL, V82, P297, DOI 10.1085/jgp.82.3.297; Lam RS, 2003, J PHYSIOL-LONDON, V548, P475, DOI 10.1113/jphysiol.2002.036806; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Liu J, 2002, KIDNEY INT, V62, P2118, DOI 10.1046/j.1523-1755.2002.00672.x; Lomb DJ, 2007, J NEUROCHEM, V103, P1897, DOI 10.1111/j.1471-4159.2007.04873.x; Matheson PJ, 2000, J SURG RES, V93, P182, DOI 10.1006/jsre.2000.5862; Metzen E, 2004, BIOL CHEM, V385, P223, DOI 10.1515/BC.2004.016; MUSCH TI, 1987, J APPL PHYSIOL, V63, P2269, DOI 10.1152/jappl.1987.63.6.2269; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; PERDUE MH, 1991, J CLIN INVEST, V87, P687, DOI 10.1172/JCI115047; Ratcliffe PJ, 2006, CLIN MED, V6, P573, DOI 10.7861/clinmedicine.6-6-573; Robinson A, 2008, GASTROENTEROLOGY, V134, P145, DOI 10.1053/j.gastro.2007.09.033; ROCHWERGER L, 1994, J CELL SCI, V107, P2439; Schodel J, 2009, AM J PATHOL, V174, P1663, DOI 10.2353/ajpath.2009.080687; Schoots VG, 2006, SURGERY, V139, P244, DOI 10.1016/j.surg.2005.07.032; Schultz K, 2009, AM J PHYSIOL-LUNG C, V296, pL921, DOI 10.1152/ajplung.90393.2008; Takeda K, 2009, ARTERIOSCL THROM VAS, V29, P2132, DOI 10.1161/ATVBAHA.109.196071; Taylor CT, 1998, J PHARMACOL EXP THER, V284, P568; Yoon T, 2006, FEBS LETT, V580, P3558, DOI 10.1016/j.febslet.2006.05.042; Zheng W, 2009, FASEB J, V23, P204, DOI 10.1096/fj.08-110221	42	9	9	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					535	543		10.1096/fj.10-166983	http://dx.doi.org/10.1096/fj.10-166983			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20944011				2022-12-28	WOS:000286724800012
J	Belleudi, F; Purpura, V; Scrofani, C; Persechino, F; Leone, L; Torrisi, MR				Belleudi, Francesca; Purpura, Valeria; Scrofani, Cristina; Persechino, Flavia; Leone, Laura; Torrisi, Maria Rosaria			Expression and signaling of the tyrosine kinase FGFR2b/KGFR regulates phagocytosis and melanosome uptake in human keratinocytes	FASEB JOURNAL			English	Article						KGF; FGF10; melanosome transfer; PLC gamma; HaCaT cells	GROWTH-FACTOR RECEPTOR; CORTACTIN; SKIN; MELANOCYTES; ENDOCYTOSIS; EPIDERMIS; DYNAMICS; INVASION; PATHWAY; CELLS	Membrane and actin cytoskeleton dynamics during phagocytosis can be triggered and amplified by the signal transduction of receptor tyrosine kinases. The epidermal keratinocytes appear to use the phagocytic mechanism of uptake to ingest melanosomes released by the melanocytes and play a pivotal role in the transfer process. We have previously demonstrated that the keratinocyte growth factor KGF/FGF7 promotes the melanosome uptake through activation of its receptor tyrosine kinase FGFR2b/KGFR. The aim of the present study was to investigate the contribution of KGFR expression, activation, and signaling in regulating the phagocytic process and the melanosome transfer. Phagocytosis was analyzed in vitro using fluorescent latex beads on human keratinocytes induced to differentiate. Melanosome transfer was investigated in keratinocyte-melanocyte cocultures. KGFR depletion by small interfering RNA microinjection and overexpression by transfection of wild type or defective mutant KGFR were performed to demonstrate the direct effect of the receptor on phagocytosis and melanosome transfer. Colocalization of the phagocytosed beads with the internalized receptors in phagolysosomes was analyzed by optical sectioning and 3-dimensional reconstruction. KGFR ligands triggered phagocytosis and melanosome transfer in differentiated keratinocytes, and receptor kinase activity and signaling were required for these effects, suggesting that FGFR2b/KGFR expression/activity and PLC gamma signaling pathway play crucial roles in phagocytosis.-Belleudi, F., Purpura, V., Scrofani, C., Persechino, F., Leone, L., and Torrisi, M. R. Expression and signaling of the tyrosine kinase FGFR2b/KGFR regulates phagocytosis and melanosome uptake in human keratinocytes. FASEB J. 25, 170-181 (2011). www.fasebj.org	[Belleudi, Francesca; Purpura, Valeria; Scrofani, Cristina; Persechino, Flavia; Leone, Laura; Torrisi, Maria Rosaria] Univ Roma La Sapienza, Ist Pasteur, Dipartimento Med Clin & Mol, Fdn Cenci Bolognetti, Rome, Italy; [Torrisi, Maria Rosaria] Azienda Osped StAndrea, Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome	Torrisi, MR (corresponding author), Dip Med Clin & Mol, Piazza Sassari 3, I-00161 Rome, Italy.	mara.torrisi@uniroma1.it	Purpura, Valeria/K-3052-2018	PURPURA, VALERIA/0000-0002-1272-313X	Ministro dell'Istruzione, dell'Universita e della Ricerca (MIUR); Ministero della Salute [RF-IMG-2006-406655]; Associazione Italiana per la Ricerca sul Cancro (AIRC), Italy	Ministro dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR)); Ministero della Salute(Ministry of Health, Italy); Associazione Italiana per la Ricerca sul Cancro (AIRC), Italy(Fondazione AIRC per la ricerca sul cancro)	This work was partially supported by grants from Ministro dell'Istruzione, dell'Universita e della Ricerca (MIUR), from Ministero della Salute (RF-IMG-2006-406655), and from Associazione Italiana per la Ricerca sul Cancro (AIRC), Italy.	Ando H, 2010, PIGM CELL MELANOMA R, V23, P129, DOI 10.1111/j.1755-148X.2009.00640.x; Belleudi F, 2007, TRAFFIC, V8, P1854, DOI 10.1111/j.1600-0854.2007.00651.x; Belleudi F, 2006, FASEB J, V20, P395, DOI 10.1096/fj.05-3934fje; Boissy RE, 2003, EXP DERMATOL, V12, P5, DOI 10.1034/j.1600-0625.12.s2.1.x; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Braun S, 2006, J CELL SCI, V119, P4841, DOI 10.1242/jcs.03259; Capone A, 2000, CELL GROWTH DIFFER, V11, P607; Cardinali G, 2005, J INVEST DERMATOL, V125, P1190, DOI 10.1111/j.0022-202X.2005.23929.x; Cardinali G, 2008, J INVEST DERMATOL, V128, P558, DOI 10.1038/sj.jid.5701063; Ceccarelli S, 2007, EXP CELL RES, V313, P1758, DOI 10.1016/j.yexcr.2007.03.013; Ceridono M, 2005, BIOCHEM BIOPH RES CO, V327, P523, DOI 10.1016/j.bbrc.2004.12.031; Cha JYY, 2009, J BIOL CHEM, V284, P6227, DOI 10.1074/jbc.M803998200; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Desjardins M, 2003, CURR OPIN CELL BIOL, V15, P498, DOI 10.1016/S0955-0674(03)00083-8; Duval C, 2001, PIGM CELL RES, V14, P348, DOI 10.1034/j.1600-0749.2001.140506.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Imokawa G, 2004, PIGM CELL RES, V17, P96, DOI 10.1111/j.1600-0749.2003.00126.x; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Keller UAD, 2004, EUR J CELL BIOL, V83, P607; Lambotin M, 2005, J CELL SCI, V118, P3805, DOI 10.1242/jcs.02514; Marchese C, 1998, J CELL SCI, V111, P3517; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; Olazabal IM, 2001, J CELL BIOL, V154, P679, DOI 10.1083/jcb.200105061; Scott G, 2002, PIGM CELL RES, V15, P322, DOI 10.1034/j.1600-0749.2002.02056.x; Seiberg M, 2000, J INVEST DERMATOL, V115, P162, DOI 10.1046/j.1523-1747.2000.00035.x; Seiberg M, 2000, EXP CELL RES, V254, P25, DOI 10.1006/excr.1999.4692; Sharlow ER, 2000, J CELL SCI, V113, P3093; Swanson JA, 2008, NAT REV MOL CELL BIO, V9, P639, DOI 10.1038/nrm2447; Van den Bossche K, 2006, TRAFFIC, V7, P769, DOI 10.1111/j.1600-0854.2006.00425.x; Virador VM, 2001, FASEB J, V15, P105, DOI 10.1096/fj.01-0518fje; Wasmeier C, 2008, J CELL SCI, V121, P3995, DOI 10.1242/jcs.040667; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; WOLFF K, 1972, J ULTRA MOL STRUCT R, V39, P262, DOI 10.1016/S0022-5320(72)90022-6	35	27	28	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					170	181		10.1096/fj.10-162156	http://dx.doi.org/10.1096/fj.10-162156			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20844240				2022-12-28	WOS:000285869500016
J	Danzer, KM; Ruf, WP; Putcha, P; Joyner, D; Hashimoto, T; Glabe, C; Hyman, BT; McLean, PJ				Danzer, Karin M.; Ruf, Wolfgang P.; Putcha, Preeti; Joyner, Daniel; Hashimoto, Tadafumi; Glabe, Charles; Hyman, Bradley T.; McLean, Pamela J.			Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity	FASEB JOURNAL			English	Article						Parkinson's disease; aggregation; microfluidic culture system; protein complementation	PARKINSONS-DISEASE; INCLUSION FORMATION; MAMMALIAN-CELLS; LEWY BODIES; PROTEIN; HSP70; STRESS; RELEASE; PATHOLOGY; GLIA	The paradoxical appearance of aggregated alpha-synuclein (alpha syn) in naive transplanted embryonic stem cells in Parkinson's disease (PD) brains has recently been reported, highlighting the possibility of neuron to neuron transmission of alpha syn in PD. Here, we demonstrate in a cellular model the presence of alpha syn oligomers in the extracellular space, their uptake by neurons, retrograde axonal transport to cell soma, and detrimental effects on neighboring cells. Moreover, we demonstrate that Hsp70 chaperones alpha syn in the extracellular space and reduces extracellular alpha syn oligomer formation and related toxicity. These novel findings provide evidence that extracellular alpha syn oligomers may represent a crucial player in the propagation of pathology in PD, with their modulation by Hsp70 representing a potential new target for therapeutic interventions.-Danzer, K. M., Ruf, W. P., Putcha, P., Joyner, D., Hashimoto, T., Glabe, C., Hyman, B. T., McLean, P. J. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J. 25, 326-336 (2011). www.fasebj.org	[Danzer, Karin M.; Ruf, Wolfgang P.; Putcha, Preeti; Joyner, Daniel; Hashimoto, Tadafumi; Hyman, Bradley T.; McLean, Pamela J.] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis,Med Sch, Charlestown, MA 02129 USA; [Glabe, Charles] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA	Harvard University; Massachusetts General Hospital; University of California System; University of California Irvine	McLean, PJ (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis,Med Sch, 114 16th St, Charlestown, MA 02129 USA.	pmclean@partners.org	Hashimoto, Tadafumi/A-7723-2013	Hashimoto, Tadafumi/0000-0001-5442-4800; Ruf, Wolfgang/0000-0002-8105-6123; McLean, Pamela/0000-0003-4870-5715	U.S. National Institutes of Health (NIH) [NS063963]; BioMEMS Resource Center [P41 EB002503]; Massachusetts General Hospital-Massachusetts Institute of Technology Udall Center for Excellence in Parkinson Disease Research [NIH NS038372]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038372, R01NS063963] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BioMEMS Resource Center; Massachusetts General Hospital-Massachusetts Institute of Technology Udall Center for Excellence in Parkinson Disease Research; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Jon Edd and Daniel Irima for help and advice on the microfluid chamber production. This work was supported by the U.S. National Institutes of Health (NIH; NS063963 to P.J.M.), the BioMEMS Resource Center (P41 EB002503 to J.E. and D.I.), and the Massachusetts General Hospital-Massachusetts Institute of Technology Udall Center for Excellence in Parkinson Disease Research (NIH NS038372).	Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Barreto A, 2003, CELL IMMUNOL, V222, P97, DOI 10.1016/S0008-8749(03)00115-1; Bodner RA, 2006, P NATL ACAD SCI USA, V103, P4246, DOI 10.1073/pnas.0511256103; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Broquet AH, 2003, J BIOL CHEM, V278, P21601, DOI 10.1074/jbc.M302326200; Brundin P, 2008, NAT REV NEUROSCI, V9, P741, DOI 10.1038/nrn2477; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Calderwood SK, 2005, EUR J IMMUNOL, V35, P2518, DOI 10.1002/eji.200535002; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Danzer KM, 2007, J NEUROSCI, V27, P9220, DOI 10.1523/JNEUROSCI.2617-07.2007; Danzer KM, 2009, J NEUROCHEM, V111, P192, DOI 10.1111/j.1471-4159.2009.06324.x; Dedmon MM, 2005, J BIOL CHEM, V280, P14733, DOI 10.1074/jbc.m413024200; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com; Febbraio MA, 2002, J PHYSIOL-LONDON, V544, P957, DOI 10.1113/jphysiol.2002.025148; Fleshner M, 2004, PSYCHONEUROENDOCRINO, V29, P1142, DOI 10.1016/j.psyneuen.2004.01.007; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; Hawkes CH, 2007, NEUROPATH APPL NEURO, V33, P599, DOI 10.1111/j.1365-2990.2007.00874.x; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; Hunter-Lavin C, 2004, BIOCHEM BIOPH RES CO, V324, P511, DOI 10.1016/j.bbrc.2004.09.075; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kerppola TK, 2006, NAT REV MOL CELL BIO, V7, P449, DOI 10.1038/nrm1929; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Kordower JH, 2008, NAT MED, V14, P504, DOI 10.1038/nm1747; Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Liu J, 2009, J NEUROSCI, V29, P1480, DOI 10.1523/JNEUROSCI.6202-08.2009; Luk KC, 2009, P NATL ACAD SCI USA, V106, P20051, DOI 10.1073/pnas.0908005106; Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849; Marnbula SS, 2007, METHODS, V43, P168, DOI 10.1016/j.ymeth.2007.06.009; Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Mollenhauer B, 2008, EXP NEUROL, V213, P315, DOI 10.1016/j.expneurol.2008.06.004; Outeiro TF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001867; Park JY, 2003, BIOCHEMISTRY-US, V42, P3696, DOI 10.1021/bi020604a; Putcha P., 2009, J PHARMACOL EXP THER, V332, P847; Remy I, 2004, METHODS, V32, P381, DOI 10.1016/j.ymeth.2003.10.011; Remy I, 2006, NAT METHODS, V3, P977, DOI 10.1038/nmeth979; Ren PH, 2009, NAT CELL BIOL, V11, P219, DOI 10.1038/ncb1830; Rhee SW, 2005, LAB CHIP, V5, P102, DOI 10.1039/b403091e; St Martin JL, 2007, J NEUROCHEM, V100, P1449, DOI 10.1111/j.1471-4159.2006.04310.x; Stagg J, 2010, ONCOGENE, V29, P5346, DOI 10.1038/onc.2010.292; Stoothoff W, 2009, J NEUROCHEM, V111, P417, DOI 10.1111/j.1471-4159.2009.06316.x; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; Taylor AM, 2003, LANGMUIR, V19, P1551, DOI 10.1021/la026417v; Tetzlaff JE, 2008, J BIOL CHEM, V283, P17962, DOI 10.1074/jbc.M802283200; TYTELL M, 1986, BRAIN RES, V363, P161, DOI 10.1016/0006-8993(86)90671-2; Vega VL, 2008, J IMMUNOL, V180, P4299, DOI 10.4049/jimmunol.180.6.4299; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398	56	231	235	2	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					326	336		10.1096/fj.10-164624	http://dx.doi.org/10.1096/fj.10-164624			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20876215	Green Published			2022-12-28	WOS:000285869500029
J	Ding, B; Gibbs, PEM; Brookes, PS; Maines, MD				Ding, Bo; Gibbs, Peter E. M.; Brookes, Paul S.; Maines, Mahin D.			The coordinated increased expression of biliverdin reductase and heme oxygenase-2 promotes cardiomyocyte survival: a reductase-based peptide counters beta-adrenergic receptor ligand-mediated cardiac dysfunction	FASEB JOURNAL			English	Article						apoptosis; antioxidants; heart failure	ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; EARLY REPRESSOR ICER; CARBON-MONOXIDE; HEART-FAILURE; RAT-BRAIN; ISCHEMIA/REPERFUSION INJURY; CARDIOVASCULAR-DISEASE; REGULATORY MOTIFS; MESSENGER-RNA	HO-2 oxidizes heme to CO and biliverdin; the latter is reduced to bilirubin by biliverdin reductase (BVR). In addition, HO-2 is a redox-sensitive K/Ca-2-associated protein, and BVR is an S/T/Y kinase. The two enzymes are components of cellular defense mechanisms. This is the first reporting of regulation of HO-2 by BVR and that their coordinated increase in isolated myocytes and intact heart protects against cardiotoxicity of beta-adrenergic receptor activation by isoproterenol (ISO). The induction of BVR mRNA, protein, and activity and HO-2 protein was maintained for >= 96 h; increase in HO-1 was modest and transient. In isolated cardiomyocytes, experiments with cycloheximide, proteasome inhibitor MG-132, and siBVR suggested BVR-mediated stabilization of HO-2. In both models, activation of BVR offered protection against the ligand's stimulation of apoptosis. Two human BVR-based peptides known to inhibit and activate the reductase, KKRILHC281 and KYCCSRK296, respectively, were tested in the intact heart. Perfusion of the heart with the inhibitory peptide blocked ISO-mediated BVR activation and augmented apoptosis; conversely, perfusion with the activating peptide inhibited apoptosis. At the functional level, peptide-mediated inhibition of BVR was accompanied by dysfunction of the left ventricle and decrease in HO-2 protein levels. Perfusion of the organ with the activating peptide preserved the left ventricular contractile function and was accompanied by increased levels of HO-2 protein. Finding that BVR and HO-2 levels, myocyte apoptosis, and contractile function of the heart can be modulated by small human BVR-based peptides offers a promising therapeutic approach for treatment of cardiac dysfunctions.-Ding, B., Gibbs, P. E. M., Brookes, P. S., Maines, M. D. The coordinated increased expression of biliverdin reductase and heme oxygenase-2 promotes cardiomyocyte survival; a reductase-based peptide counters beta-adrenergic receptor ligand-mediated cardiac dysfunction. FASEB J. 25, 301-313 (2011). www.fasebj.org	[Ding, Bo; Gibbs, Peter E. M.; Maines, Mahin D.] Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; [Brookes, Paul S.] Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Maines, MD (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.	mahin_maines@urmc.rochester.edu		Brookes, Paul/0000-0002-8639-8413	National Institute of Environmental Health Sciences [ES04066, ES012187]; American Heart Association [AHA0635312N]; National Institutes of Health [RO1-HL071158]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066, R01ES012187] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the National Institute of Environmental Health Sciences grants ES04066 and ES012187 and American Heart Association grant AHA0635312N. Work in the laboratory of P.S.B. is supported by National Institutes of Health grant RO1-HL071158. The assistance and advice of Dr. Sergiy Nadtochiy in setting up the heart perfusion experiments are gratefully acknowledged.	Abuarqoub H, 2007, EXP MOL MED, V39, P139, DOI 10.1038/emm.2007.16; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Bolognesi M, 2007, J PHARMACOL EXP THER, V321, P187, DOI 10.1124/jpet.106.116665; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; Brunt KR, 2009, EXP BIOL MED, V234, P582, DOI 10.3181/0810-RM-312; Carnegie GK, 2009, IUBMB LIFE, V61, P394, DOI 10.1002/iub.168; Choi AMK, 2001, CIRC RES, V89, P105, DOI 10.1161/res.89.2.105; Chung HT, 2008, METHOD ENZYMOL, V441, P329, DOI 10.1016/S0076-6879(08)01218-4; Das DK, 2006, CARDIOVASC RES, V70, P254, DOI 10.1016/j.cardiores.2006.02.023; DELMONTE F, 1993, CIRCULATION, V88, P854, DOI 10.1161/01.CIR.88.3.854; Ding B, 2005, P NATL ACAD SCI USA, V102, P14771, DOI 10.1073/pnas.0506489102; Ding B, 2005, CIRCULATION, V111, P2469, DOI 10.1161/01.CIR.0000165128.39715.87; Ding Y, 1999, EUR J BIOCHEM, V264, P854, DOI 10.1046/j.1432-1327.1999.00677.x; Erusalimsky JD, 2007, ARTERIOSCL THROM VAS, V27, P2524, DOI 10.1161/ATVBAHA.107.151167; EWING JF, 1994, J PHARMACOL EXP THER, V271, P408; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; Ferreira AJ, 2007, LIFE SCI, V81, P916, DOI 10.1016/j.lfs.2007.07.022; Florczyk UM, 2008, PHARMACOL REP, V60, P38; Giannini L, 2005, CELL MOL BIOL, V51, P393, DOI 10.1170/T643; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Grimm D, 1998, CARDIOVASC RES, V37, P91, DOI 10.1016/S0008-6363(97)00212-5; HAYES JS, 1986, J PHARMACOL EXP THER, V237, P757; Hu AH, 2006, J PHARMACOL EXP THER, V318, P469, DOI 10.1124/jpet.106.102160; Hu CM, 2004, CIRCULATION, V110, P309, DOI 10.1161/01.CIR.0000135475.35758.23; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; Immenschuh S, 2006, HISTOL HISTOPATHOL, V21, P679, DOI 10.14670/HH-21.679; Jadhav A, 2008, HYPERTENSION, V52, P910, DOI 10.1161/HYPERTENSIONAHA.108.114801; Kapitulnik J, 2009, TRENDS PHARMACOL SCI, V30, P129, DOI 10.1016/j.tips.2008.12.003; Kemp PJ, 2005, BIOCHEM BIOPH RES CO, V338, P648, DOI 10.1016/j.bbrc.2005.08.110; Kim YS, 2005, FREE RADICAL BIO MED, V38, P85, DOI 10.1016/j.freeradbiomed.2004.09.031; Kinobe RT, 2008, CAN J PHYSIOL PHARM, V86, P577, DOI 10.1139/y08-066; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; Lerner-Marmarosh N, 2005, P NATL ACAD SCI USA, V102, P7109, DOI 10.1073/pnas.0502173102; Lerner-Marmarosh N, 2008, P NATL ACAD SCI USA, V105, P6870, DOI 10.1073/pnas.0800750105; Lerner-Marmarosh N, 2007, FASEB J, V21, P3949, DOI 10.1096/fj.07-8544com; Li Volti G, 2006, NEPHRON EXP NEPHROL, V104, pE135, DOI 10.1159/000094964; Maghzal GJ, 2009, J BIOL CHEM, V284, P29251, DOI 10.1074/jbc.M109.037119; Maines MD, 2007, ANTIOXID REDOX SIGN, V9, P2187, DOI 10.1089/ars.2007.1805; Maines MD, 2007, J BIOL CHEM, V282, P8110, DOI 10.1074/jbc.M513427200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Marshall D, 2000, HEART, V84, P355, DOI 10.1136/heart.84.4.355; Masini E, 2003, EXP BIOL MED, V228, P546, DOI 10.1177/15353702-0322805-25; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; Miller SM, 1998, GASTROENTEROLOGY, V114, P239, DOI 10.1016/S0016-5085(98)70473-1; Miralem T, 2005, J BIOL CHEM, V280, P17084, DOI 10.1074/jbc.M413121200; Nakao A, 2005, AM J TRANSPLANT, V5, P282, DOI 10.1111/j.1600-6143.2004.00695.x; Nikolaev VO, 2010, SCIENCE, V327, P1653, DOI 10.1126/science.1185988; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Oudit GY, 2003, CIRCULATION, V108, P2147, DOI 10.1161/01.CIR.0000091403.62293.2B; Alok SP, 2007, J MOL CELL CARDIOL, V43, P580, DOI 10.1016/j.yjmcc.2007.08.003; Pachori AS, 2004, P NATL ACAD SCI USA, V101, P12282, DOI 10.1073/pnas.0404616101; Panahian N, 2001, J NEUROCHEM, V76, P539, DOI 10.1046/j.1471-4159.2001.00023.x; PRABHAKAR NR, 1995, P NATL ACAD SCI USA, V92, P1994, DOI 10.1073/pnas.92.6.1994; Prabhakar NR, 1999, RESP PHYSIOL, V115, P161, DOI 10.1016/S0034-5687(99)00019-5; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; RUBLEVSKAYA I, 1994, J BIOL CHEM, V269, P26390; Ryter SW, 2007, AM J RESP CELL MOL, V36, P175, DOI 10.1165/rcmb.2006-0333TR; Ryter SW, 2009, AM J RESP CELL MOL, V41, P251, DOI 10.1165/rcmb.2009-0170TR; Sedlak TW, 2009, P NATL ACAD SCI USA, V106, P5171, DOI 10.1073/pnas.0813132106; Sethi R, 1995, J Card Fail, V1, P391, DOI 10.1016/S1071-9164(05)80008-9; Slebos DJ, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-7; Steinberg SF, 1999, CIRC RES, V85, P1101; Tomita H, 2003, CIRC RES, V93, P12, DOI 10.1161/01.RES.0000079794.57578.F1; Tompkins AJ, 2006, BBA-MOL BASIS DIS, V1762, P223, DOI 10.1016/j.bbadis.2005.10.001; Tudor C, 2008, BIOCHEM J, V413, P405, DOI 10.1042/BJ20080018; van Empel VPM, 2004, CARDIOVASC RES, V63, P487, DOI 10.1016/j.cardiores.2004.02.013; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Volti GL, 2007, TRANSPL P, V39, P2986, DOI 10.1016/j.transproceed.2007.09.047; Walker BR, 2007, EUR J ENDOCRINOL, V157, P545, DOI 10.1530/EJE-07-0455; Wegiel B, 2009, J BIOL CHEM, V284, P21369, DOI 10.1074/jbc.M109.027433; Whelan RS, 2010, ANNU REV PHYSIOL, V72, P19, DOI 10.1146/annurev.physiol.010908.163111; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Xu WM, 2004, NAT CELL BIOL, V6, P1129, DOI 10.1038/ncb1188; Yamashita K, 2006, FASEB J, V20, P776, DOI 10.1096/fj.05-4791fje; Yano Y, 2006, GENES CELLS, V11, P791, DOI 10.1111/j.1365-2443.2006.00979.x; Yeh CH, 2009, J SURG RES, V155, P147, DOI 10.1016/j.jss.2008.07.044; Yi L, 2009, J BIOL CHEM, V284, P20556, DOI 10.1074/jbc.M109.015651; Zaugg M, 2000, CIRCULATION, V102, P344	81	25	26	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					301	313		10.1096/fj.10-166454	http://dx.doi.org/10.1096/fj.10-166454			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20876213	Green Published			2022-12-28	WOS:000285869500027
J	Ioannidis, JPA				Ioannidis, John P. A.			Is there a glass ceiling for highly cited scientists at the top of research universities?	FASEB JOURNAL			English	Article						leaders; citation impact	5 FUTURES; CITATIONS; LEADERS; INDEX	University leaders aim to protect, shape, and promote the missions of their institutions. I evaluated whether top highly cited scientists are likely to occupy these positions. Of the current leaders of 96 U. S. high research activity universities, only 6 presidents or chancellors were found among the 4009 U. S. scientists listed in the ISIHighlyCited.com database. Of the current leaders of 77 UK universities, only 2 vice-chancellors were found among the 483 UK scientists listed in the same database. In a sample of 100 top-cited clinical medicine scientists and 100 top-cited biology and biochemistry scientists, only 1 and 1, respectively, had served at any time as president of a university. Among the leaders of 25 U. S. universities with the highest citation volumes, only 12 had doctoral degrees in life, natural, physical or computer sciences, and 5 of these 12 had a Hirsch citation index m < 1.0. The participation of highly cited scientists in the top leadership of universities is limited. This could have consequences for the research and overall mission of universities.-Ioannidis, J. P. A. Is there a glass ceiling for highly cited scientists at the top of research universities? FASEB J. 24, 4635-4638 (2010). www.fasebj.org	[Ioannidis, John P. A.] Univ Ioannina, Sch Med, Clin & Mol Epidemiol Unit, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; [Ioannidis, John P. A.] Fdn Res & Technol Hellas, Biomed Res Inst, Ioannina, Greece; [Ioannidis, John P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; [Ioannidis, John P. A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Tufts University; Harvard University; Harvard T.H. Chan School of Public Health	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Clin & Mol Epidemiol Unit, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011					Awasthi S, 2005, PLOS MED, V2, P606, DOI 10.1371/journal.pmed.0020207; Bornmann L, 2007, J AM SOC INF SCI TEC, V58, P1381, DOI 10.1002/asi.20609; *CARN FDN ADV TEAC, 2009, CLASS U; Clark J, 2005, BRIT MED J, V331, P101, DOI 10.1136/bmj.331.7508.101; Goodall AH, 2006, J DOC, V62, P388, DOI 10.1108/00220410610666529; Goodall AH, 2009, RES POLICY, V38, P1079, DOI 10.1016/j.respol.2009.04.002; HAMBRICK DC, 1984, ACAD MANAGE REV, V9, P193, DOI 10.2307/258434; Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102; Ioannidis JPA, 2007, BRIT MED J, V334, P191, DOI 10.1136/bmj.39043.676898.94; Ioannidis JPA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002778; Ioannidis JP, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-30; Ioannidis JPA, 2004, FASEB J, V18, P936, DOI 10.1096/fj.03-1394lfe; Ioannidis JPA, 2004, BMJ-BRIT MED J, V329, P789; *ISI WEB KNOWL, 2009, SCI CIT IND; ISI Web of Knowledge, 2009, ESS SCI IND; Kelly CD, 2006, TRENDS ECOL EVOL, V21, P167, DOI 10.1016/j.tree.2006.01.005; Kulkarni AV, 2009, JAMA-J AM MED ASSOC, V302, P1092, DOI 10.1001/jama.2009.1307; Van Raan AFJ, 2005, SCIENTOMETRICS, V62, P133, DOI 10.1007/s11192-005-0008-6; *WIK, 2009, LIST BRIT U CHANC VI	19	9	10	2	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4635	4638		10.1096/fj.10-162974	http://dx.doi.org/10.1096/fj.10-162974			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20686108				2022-12-28	WOS:000284824400004
J	Teng, ACT; Kuraitis, D; Deeke, SA; Ahmadi, A; Dugan, SG; Cheng, BLM; Crowson, MG; Burgon, PG; Suuronen, EJ; Chen, HH; Stewart, AFR				Teng, Allen C. T.; Kuraitis, Drew; Deeke, Shelley A.; Ahmadi, Ali; Dugan, Stephen G.; Cheng, Brian L. M.; Crowson, Matthew G.; Burgon, Patrick G.; Suuronen, Erik J.; Chen, Hsiao-Huei; Stewart, Alexandre F. R.			IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression	FASEB JOURNAL			English	Article						vascular endothelial growth factor; transcription factors; VGLL4; TEAD4	ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR RTEF-1; ENHANCER FACTOR-I; GENE-EXPRESSION; CHORIORETINAL ATROPHY; WING FORMATION; TEF-1 FAMILY; PROTEIN; DIFFERENTIATION; IDENTIFICATION	We sought to identify an essential component of the TEAD4/VGLL4 transcription factor complex that controls vascular endothelial growth factor A (VEGFA) expression in muscle. A yeast 2-hybrid screen was used to clone a novel component of the TEAD4 complex from a human heart cDNA library. We identified interferon response factor 2 binding protein 2 (IRF2BP2) and confirmed its presence in the TEAD4/VGLL4 complex in vivo by coimmunoprecipitation and mammalian 2-hybrid assays. Coexpression of IRF2BP2 with TEAD4/VGLL4 or TEAD1 alone potently activated, whereas knockdown of IRF2BP2 reduced, VEGFA expression in C2C12 muscle cells. Thus, IRF2BP2 is required to activate VEGFA expression. In mouse embryos, IRF2BP2 was ubiquitously expressed but became progressively enriched in the fetal heart, skeletal muscles, and lung. Northern blot analysis revealed high levels of IRF2BP2 mRNA in adult human heart and skeletal muscles, but immunoblot analysis showed low levels of IRF2BP2 protein in skeletal muscle, indicating post-transcriptional regulation of IRF2BP2 expression. IRF2BP2 protein levels are markedly increased by ischemia in skeletal and cardiac muscle compared to normoxic controls. IRF2BP2 is a novel ischemia-induced coactivator of VEGFA expression that may contribute to revascularization of ischemic cardiac and skeletal muscles.-Teng, A. C. T., Kuraitis, D., Deeke, S. A., Ahmadi, A., Dugan, S. G., Cheng, B. L. M., Crowson, M. G., Burgon, P. G., Suuronen, E. J., Chen, H.-H., Stewart, A. F. R. IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression. FASEB J. 24, 4825-4834 (2010). www.fasebj.org	[Teng, Allen C. T.; Kuraitis, Drew; Deeke, Shelley A.; Ahmadi, Ali; Dugan, Stephen G.; Cheng, Brian L. M.; Crowson, Matthew G.; Burgon, Patrick G.; Suuronen, Erik J.; Stewart, Alexandre F. R.] Univ Ottawa, Inst Heart, Ottawa, ON K1Y 4W7, Canada; [Chen, Hsiao-Huei] Ottawa Hosp Res Inst, Ottawa, ON, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; Ottawa Hospital Research Institute	Stewart, AFR (corresponding author), Univ Ottawa, Inst Heart, 40 Ruskin Rd,H3100, Ottawa, ON K1Y 4W7, Canada.	astewart@ottawaheart.ca	Crowson, Matthew/L-7356-2013; Stewart, Alexandre F.R./A-5677-2011; Crowson, Matthew/X-6751-2019; Burgon, Patrick/ABB-1027-2021	Crowson, Matthew/0000-0001-9950-0985; Crowson, Matthew/0000-0001-9950-0985; Stewart, Alexandre/0000-0003-2673-9164; Burgon, Patrick/0000-0003-4771-023X; Chen, Hsiao-Huei/0000-0003-2914-6057	Canadian Institutes of Health Research [AFRS MOP77682, PGB MOP82748, HHC MOP179197]; Heart and Stroke Foundation of Ontario [ES NA6121, HHC NA6301]; Ontario Graduate Scholarship in Science and Technology	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Ontario Graduate Scholarship in Science and Technology	This work was supported by operating grants from the Canadian Institutes of Health Research (AFRS MOP77682, PGB MOP82748, HHC MOP179197), by a grant in aid from the Heart and Stroke Foundation of Ontario (ES NA6121, HHC NA6301), by a master's studentship award from the Heart and Stroke Foundation of Ontario (D.K.), and by an Ontario Graduate Scholarship in Science and Technology (A.T.).	Appukuttan B, 2007, INVEST OPHTH VIS SCI, V48, P3775, DOI 10.1167/iovs.06-1172; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Barth AS, 2009, CIRC-CARDIOVASC GENE, V2, P371, DOI 10.1161/CIRCGENETICS.108.832345; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Brasen JH, 2001, ARTERIOSCL THROM VAS, V21, P1720, DOI 10.1161/hq1101.098230; Breen E, 2008, HIGH ALT MED BIOL, V9, P158, DOI 10.1089/ham.2008.1010; Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen HH, 2004, GENESIS, V39, P273, DOI 10.1002/gene.20055; Chen HH, 2004, J BIOL CHEM, V279, P30800, DOI 10.1074/jbc.M400154200; Childs KS, 2003, NUCLEIC ACIDS RES, V31, P3016, DOI 10.1093/nar/gkg431; Desper R, 2004, MOL BIOL EVOL, V21, P587, DOI 10.1093/molbev.msh049; Dix MM, 2008, CELL, V134, P679, DOI 10.1016/j.cell.2008.06.038; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Faresse N, 2008, EMBO J, V27, P1804, DOI 10.1038/emboj.2008.109; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fossdal R, 2004, HUM MOL GENET, V13, P975, DOI 10.1093/hmg/ddh106; Gunther S, 2004, NUCLEIC ACIDS RES, V32, P791, DOI 10.1093/nar/gkh248; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; Harpster MH, 2006, MAMM GENOME, V17, P701, DOI 10.1007/s00335-005-0120-1; Heger S, 2007, J CLIN INVEST, V117, P2145, DOI 10.1172/JCI31752; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Jonasson F, 2007, ACTA OPHTHALMOL SCAN, V85, P862, DOI 10.1111/j.1600-0420.2007.01002.x; Koeppel M, 2009, NUCLEIC ACIDS RES, V37, P322, DOI 10.1093/nar/gkn940; Krishnan J, 2008, CIRC RES, V103, P1139, DOI 10.1161/01.RES.0000338613.89841.c1; Larsen BD, 2010, P NATL ACAD SCI USA, V107, P4230, DOI 10.1073/pnas.0913089107; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434; Mielcarek M, 2002, MECH DEVELOP, V119, pS269, DOI 10.1016/S0925-4773(03)00127-8; Mielcarek M, 2009, GENE EXPR PATTERNS, V9, P129, DOI 10.1016/j.gep.2008.12.002; Olfert IM, 2009, J PHYSIOL-LONDON, V587, P1755, DOI 10.1113/jphysiol.2008.164384; Papadopoulos JS, 2007, BIOINFORMATICS, V23, P1073, DOI 10.1093/bioinformatics/btm076; Shie JL, 2004, J BIOL CHEM, V279, P25010, DOI 10.1074/jbc.M403103200; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Sudarsan V, 2001, DEV CELL, V1, P829, DOI 10.1016/S1534-5807(01)00089-2; Teng ACT, 2009, FASEB J, V23, P1705, DOI 10.1096/fj.08-120998; Tsika RW, 2008, J BIOL CHEM, V283, P36154, DOI 10.1074/jbc.M807461200; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vaudin P, 1999, DEVELOPMENT, V126, P4807; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; Yoshida T, 2008, ARTERIOSCL THROM VAS, V28, P8, DOI 10.1161/ATVBAHA.107.155788; Young RM, 2008, J BIOL CHEM, V283, P16309, DOI 10.1074/jbc.M710079200	47	50	53	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4825	4834		10.1096/fj.10-167049	http://dx.doi.org/10.1096/fj.10-167049			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20702774				2022-12-28	WOS:000284824400022
J	Valle-Delgado, JJ; Alfonso-Prieto, M; de Groot, NS; Ventura, S; Samitier, J; Rovira, C; Fernandez-Busquets, X				Jose Valle-Delgado, Juan; Alfonso-Prieto, Mercedes; de Groot, Natalia S.; Ventura, Salvador; Samitier, Josep; Rovira, Carme; Fernandez-Busquets, Xavier			Modulation of A beta(42) fibrillogenesis by glycosaminoglycan structure	FASEB JOURNAL			English	Article						Alzheimer's disease; amyloid fibril structure; fibrillogenesis enhancers and inhibitors; polysaccharides	HEPARAN-SULFATE PROTEOGLYCANS; MEROZOITE SURFACE PROTEIN-2; ATOMIC-FORCE MICROSCOPY; SOLUBLE AMYLOID OLIGOMERS; X-RAY-DIFFRACTION; ALZHEIMERS-DISEASE; CHONDROITIN-SULFATE; PLASMODIUM-FALCIPARUM; A-BETA; FIBRIL FORMATION	The role of amyloid beta (A beta) peptide in the onset and progression of Alzheimer's disease is linked to the presence of soluble A beta species. Sulfated glycosaminoglycans (GAGs) promote A beta fibrillogenesis and reduce the toxicity of the peptide in neuronal cell cultures, but a satisfactory rationale to explain these effects at the molecular level has not been provided yet. We have used circular dichroism, Fourier transform infrared spectroscopy, fluorescence microscopy and spectroscopy, protease digestion, atomic force microscopy (AFM), and molecular dynamics simulations to characterize the association of the 42-residue fragment A beta(42) with sulfated GAGs, hyaluronan, chitosan, and poly(vinyl sulfate) (PVS). Our results indicate that the formation of stable A beta(42) fibrils is promoted by polymeric GAGs with negative charges placed in-frame with the 4.8-angstrom separating A beta(42) monomers within protofibrillar beta-sheets. Incubation of A beta(42) with excess sulfated GAGs and hyaluronan increased amyloid fibril content and resistance to proteolysis 2- to 5-fold, whereas in the presence of the cationic polysaccharide chitosan, A beta(42) fibrillar species were reduced by 25% and sensitivity to protease degradation increased similar to 3-fold. Fibrils of intermediate stability were obtained in the presence of PVS, an anionic polymer with more tightly packed charges than GAGs. Important structural differences between A beta(42) fibrils induced by PVS and A beta(42) fibrils obtained in the presence of GAGs and hyaluronan were observed by AFM, whereas mainly precursor protofibrillar forms were detected after incubation with chitosan. Computed binding energies per peptide from -11.2 to -13.5 kcal/mol were calculated for GAGs and PVS, whereas a significantly lower value of -7.4 kcal/mol was obtained for chitosan. Taken together, our data suggest a simple and straightforward mechanism to explain the role of GAGs as enhancers of the formation of insoluble A beta(42) fibrils trapping soluble toxic forms.-Valle-Delgado, J. J., Alfonso-Prieto, M., de Groot, N. S., Ventura, S., Samitier, J., Rovira, C., Fernandez-Busquets, X. Modulation of A beta(42) fibrillo-genesis by glycosaminoglycan structure. FASEB J. 24, 4250-4261 (2010). www.fasebj.org	[Jose Valle-Delgado, Juan; Samitier, Josep; Fernandez-Busquets, Xavier] Inst Bioengn Catalonia, Nanobioengn Grp, E-08028 Barcelona, Spain; [Jose Valle-Delgado, Juan; Fernandez-Busquets, Xavier] Univ Barcelona, Biomol Interact Team, Nanosci & Nanotechnol Inst, Barcelona, Spain; [Alfonso-Prieto, Mercedes; Rovira, Carme] Univ Barcelona, Inst Quim Teor & Computac, Barcelona, Spain; [Samitier, Josep] Univ Barcelona, Dept Elect, Barcelona, Spain; [Alfonso-Prieto, Mercedes; Rovira, Carme] CoSMo LAB, Barcelona, Spain; [de Groot, Natalia S.; Ventura, Salvador] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra, Spain; [de Groot, Natalia S.; Ventura, Salvador] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra, Spain; [Rovira, Carme] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Barcelona Institute of Science & Technology; Catalan Institute of Nanoscience & Nanotechnology (ICN2); Institut de Bioenginyeria de Catalunya; University of Barcelona; University of Barcelona; University of Barcelona; University of Barcelona; University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; ICREA	Valle-Delgado, JJ (corresponding author), Inst Bioengn Catalonia, Nanobioengn Grp, Baldiri Reixac 10-12, E-08028 Barcelona, Spain.	jjvalle@pcb.ub.es; xfernandez_busquets@ub.edu	Fernàndez-Busquets, Xavier/K-1323-2014; de Groot, Natalia Sanchez/J-8212-2014; Ventura, Salvador/AAY-3170-2021; Valle-Delgado, Juan Jose/H-8857-2013; Ventura, Salvador/C-7021-2008; Rovira, Carme/K-5195-2014; de Groot, Natalia Sanchez/AFN-2768-2022; Alfonso-Prieto, Mercedes/M-3376-2014	Fernàndez-Busquets, Xavier/0000-0002-4622-9631; de Groot, Natalia Sanchez/0000-0002-0492-5532; Ventura, Salvador/0000-0002-9652-6351; Valle-Delgado, Juan Jose/0000-0002-4808-1730; Ventura, Salvador/0000-0002-9652-6351; Rovira, Carme/0000-0003-1477-5010; de Groot, Natalia Sanchez/0000-0002-0492-5532; Alfonso-Prieto, Mercedes/0000-0003-4509-4517	Ministerio de Ciencia e Innovacion, Spain [BIO2005-01591, BIO2007-68046, BIO2008-01184, FIS2008-03845, CSD2006-00012]; Generalitat de Catalunya (GENCAT), Spain [2009SGR-760, 2009SGR-1309]; GENCAT; ICREA ACADEMIA; ICREA Funding Source: Custom	Ministerio de Ciencia e Innovacion, Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Generalitat de Catalunya (GENCAT), Spain(Generalitat de Catalunya); GENCAT; ICREA ACADEMIA(ICREA); ICREA(ICREA)	This work was supported by grants BIO2005-01591, BIO2007-68046, BIO2008-01184, FIS2008-03845, and CSD2006-00012 from the Ministerio de Ciencia e Innovacion, Spain, which included FEDER funds, and by grants 2009SGR-760 and 2009SGR-1309 from the Generalitat de Catalunya (GENCAT), Spain. A fellowship of the F.I. program from GENCAT (to M.A.-P) and the financial support from Juan de la Cierva Programme of the Ministerio de Ciencia e Innovacion, Spain (to J.J.V.-D.) are acknowledged. S.V. was granted an ICREA ACADEMIA award (ICREA). The computer support, technical expertise, and assistance provided by the Barcelona Supercomputing Center-Centro Nacional de Supercomputacion (BSC-CNS), the Scientific and Technical Services of the University of Barcelona, and the Proteomics Platform of the Barcelona Science Park are also acknowledged.	Adda CG, 2009, MOL BIOCHEM PARASIT, V166, P159, DOI 10.1016/j.molbiopara.2009.03.012; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alexandrescu AT, 2005, PROTEIN SCI, V14, P1; Almond A, 2000, GLYCOBIOLOGY, V10, P329, DOI 10.1093/glycob/10.3.329; Ancsin JB, 1999, J BIOL CHEM, V274, P7172, DOI 10.1074/jbc.274.11.7172; Ancsin JB, 2003, AMYLOID, V10, P67, DOI 10.3109/13506120309041728; Andrews KT, 2005, INFECT IMMUN, V73, P4288, DOI 10.1128/IAI.73.7.4288-4294.2005; Antzutkin ON, 2004, MAGN RESON CHEM, V42, P231, DOI 10.1002/mrc.1341; Arimon M, 2005, FASEB J, V19, P1344, DOI 10.1096/fj.04-3137fje; Barragan A, 2000, BLOOD, V95, P3594, DOI 10.1182/blood.V95.11.3594.011k21_3594_3599; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Borysik AJ, 2007, KIDNEY INT, V72, P174, DOI 10.1038/sj.ki.5002270; Bravo R, 2008, J BIOL CHEM, V283, P32471, DOI 10.1074/jbc.M709870200; Bruckner G, 1999, NEUROSCIENCE, V92, P791, DOI 10.1016/S0306-4522(99)00071-8; Calamai M, 2006, BIOCHEMISTRY-US, V45, P12806, DOI 10.1021/bi0610653; Castillo GM, 1998, DIABETES, V47, P612, DOI 10.2337/diabetes.47.4.612; Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; Cooke BM, 2004, TRENDS PARASITOL, V20, P581, DOI 10.1016/j.pt.2004.09.008; DeGroot J, 2004, CURR OPIN PHARMACOL, V4, P301, DOI 10.1016/j.coph.2004.01.007; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; Diaz-Nido J, 2002, PEPTIDES, V23, P1323, DOI 10.1016/S0196-9781(02)00068-2; Fernandez-Busquets X, 2010, CURR ALZHEIMER RES, V7, P428, DOI 10.2174/156720510791383787; Fernandez-Busquets X, 2008, CURR MED CHEM, V15, P1336, DOI 10.2174/092986708784534938; Ferreira ST, 2007, IUBMB LIFE, V59, P332, DOI 10.1080/15216540701283882; Fraser PE, 2001, J BIOL CHEM, V276, P6412, DOI 10.1074/jbc.M008128200; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; Goldsbury CS, 2000, J STRUCT BIOL, V130, P217, DOI 10.1006/jsbi.2000.4259; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Haxaire K, 2000, GLYCOBIOLOGY, V10, P587, DOI 10.1093/glycob/10.6.587; Hirschfield GM, 2003, INT J BIOCHEM CELL B, V35, P1608, DOI 10.1016/S1357-2725(03)00169-9; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Low A, 2007, BIOPOLYMERS, V87, P12, DOI 10.1002/bip.20764; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Mastrangelo IA, 2006, J MOL BIOL, V358, P106, DOI 10.1016/j.jmb.2006.01.042; Mattson MP, 2007, AGING CELL, V6, P337, DOI 10.1111/j.1474-9726.2007.00275.x; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McLaurin J, 2000, EUR J BIOCHEM, V267, P6353, DOI 10.1046/j.1432-1327.2000.01725.x; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; Mudher A, 2002, TRENDS NEUROSCI, V25, P22, DOI 10.1016/S0166-2236(00)02031-2; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Naito A, 2007, BBA-BIOMEMBRANES, V1768, P1900, DOI 10.1016/j.bbamem.2007.03.025; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; POLLACK SJ, 1995, NEUROSCI LETT, V184, P113, DOI 10.1016/0304-3940(94)11182-I; Potter-Perigo S, 2003, ARCH BIOCHEM BIOPHYS, V413, P182, DOI 10.1016/S0003-9861(03)00116-4; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Rodriguez-Carvajal MA, 2003, BIOPOLYMERS, V69, P15, DOI 10.1002/bip.10304; Roher AE, 2000, BBA-MOL BASIS DIS, V1502, P31, DOI 10.1016/S0925-4439(00)00030-2; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Silva JL, 2008, TRENDS BIOCHEM SCI, V33, P132, DOI 10.1016/j.tibs.2007.11.003; Singh K, 2008, NAT STRUCT MOL BIOL, V15, P932, DOI 10.1038/nsmb.1479; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Snow AD, 1996, EXP NEUROL, V138, P305, DOI 10.1006/exnr.1996.0069; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; SNOW AD, 1988, AM J PATHOL, V133, P456; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Supattapone S, 2004, J MOL MED, V82, P348, DOI 10.1007/s00109-004-0534-3; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Timmer NM, 2010, NEUROSCI RES, V66, P380, DOI 10.1016/j.neures.2009.12.012; Valente T, 2010, NEUROBIOL DIS, V37, P67, DOI 10.1016/j.nbd.2009.09.008; van Horssen J, 2003, LANCET NEUROL, V2, P482, DOI 10.1016/S1474-4422(03)00484-8; Wenk GL, 2003, J CLIN PSYCHIAT, V64, P7; WOODS AG, 1995, BRAIN RES, V697, P53, DOI 10.1016/0006-8993(95)00775-L; Yang X, 2007, J PEPT SCI, V13, P839, DOI 10.1002/psc.910; YUI T, 1994, MACROMOLECULES, V27, P7601, DOI 10.1021/ma00104a014	78	62	61	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4250	4261		10.1096/fj.09-153551	http://dx.doi.org/10.1096/fj.09-153551			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20585030				2022-12-28	WOS:000283861100013
J	van Ham, TJ; Mapes, J; Kokel, D; Peterson, RT				van Ham, Tjakko J.; Mapes, James; Kokel, David; Peterson, Randall T.			Live imaging of apoptotic cells in zebrafish	FASEB JOURNAL			English	Article						neuronal cell death; in vivo microscopy; vertebrate model; neurotoxicity; p53; DNA damage response	DNA FRAGMENTATION; GENE-EXPRESSION; DEATH; EMBRYO; PHOSPHATIDYLSERINE; NEURONS; BRAIN; MODEL	Many debilitating diseases, including neurodegenerative diseases, involve apoptosis. Several methods have been developed for visualizing apoptotic cells in vitro or in fixed tissues, but few tools are available for visualizing apoptotic cells in live animals. Here we describe a genetically encoded fluorescent reporter protein that labels apoptotic cells in live zebrafish embryos. During apoptosis, the phospholipid phosphatidylserine (PS) is exposed on the outer leaflet of the plasma membrane. The calcium-dependent protein Annexin V (A5) binds PS with high affinity, and biochemically purified, fluorescently labeled A5 probes have been widely used to detect apoptosis in vitro. Here we show that secreted A5 fused to yellow fluorescent protein specifically labels apoptotic cells in living zebrafish. We use this fluorescent probe to characterize patterns of apoptosis in living zebrafish larvae and to visualize neuronal cell death at single-cell resolution in vivo.-Van Ham, T. J., Mapes, J., Kokel, D., Peterson, R. T. Live imaging of apoptotic cells in zebrafish. FASEB J. 24, 4336-4342 (2010). www.fasebj.org	[van Ham, Tjakko J.; Kokel, David; Peterson, Randall T.] Harvard Univ, Cardiovasc Res Ctr, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA; [van Ham, Tjakko J.; Kokel, David; Peterson, Randall T.] Harvard Univ, Div Cardiol, Massachusetts Gen Hosp, Sch Med,Dept Med, Charlestown, MA 02129 USA; [van Ham, Tjakko J.; Kokel, David; Peterson, Randall T.] Broad Inst, Cambridge, MA USA; [Mapes, James] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of Colorado System; University of Colorado Boulder	Peterson, RT (corresponding author), Harvard Univ, Cardiovasc Res Ctr, Massachusetts Gen Hosp, Sch Med, 149 13th St, Charlestown, MA 02129 USA.	peterson@cvrc.mgh.harvard.edu	van Ham, Tjakko/I-2382-2013; van Ham, Tjakko/A-1989-2015; van Ham, Tjakko/W-8614-2019	van Ham, Tjakko/0000-0002-2175-8713; van Ham, Tjakko/0000-0002-2175-8713; kokel, david/0000-0002-1981-1511; Peterson, Randall/0000-0003-0727-3469	National Institutes of Health (NIH) [NS063733, MH086867]; NIH/National Cancer for Research Resources Centers of Biomedical Research Excellence in Obesity and Cardiovascular Disease [P20 RR021954]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH091449, R01MH086867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS063733] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Cancer for Research Resources Centers of Biomedical Research Excellence in Obesity and Cardiovascular Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank the members of the R.T.P. laboratory for technical assistance and advice, Lindsay Cade for graphical expertise, Ding Xue (University of Colorado, Boulder, CO, USA) for helpful comments, David Langenau and Myron Ignatius (Massachusetts General Hospital Cancer Center, Charlestown, MA, USA) for p53 mutant animals, Chetana Satchidanandan (Institute of Genomics and Integrative Biology, Delhi, India) and Martin Distel and Reinhard Koester (Helmholtz Institute, Munich, Germany) for transgenic animals, the Koichi Kawakami laboratory (National Institute of Genetics, Mishima, Japan) for reagents, Anne Hart for use of equipment, the Michael L. Nonet laboratory (Washington University, St. Louis, MO, USA) for plasmids, and Iain Drummond (Massachusetts General Hospital, Charlestown, MA, USA) for advice on microscopy. This work was supported by National Institutes of Health (NIH) grants NS063733 and MH086867. This work was supported in part by the NIH/National Cancer for Research Resources Centers of Biomedical Research Excellence in Obesity and Cardiovascular Disease, grant P20 RR021954.	Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Burket CT, 2008, TRANSGENIC RES, V17, P265, DOI 10.1007/s11248-007-9152-5; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Distel M, 2009, P NATL ACAD SCI USA, V106, P13365, DOI 10.1073/pnas.0903060106; FADOK VA, 1992, J IMMUNOL, V148, P2207; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; Granato M, 1996, DEVELOPMENT, V123, P399; GRUNWALD DJ, 1988, DEV BIOL, V126, P115, DOI 10.1016/0012-1606(88)90245-X; Hale ME, 2001, J COMP NEUROL, V437, P1, DOI 10.1002/cne.1266; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Kawakami K, 2004, METHOD CELL BIOL, V77, P201; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMMEL CB, 1993, ANNU REV NEUROSCI, V16, P707, DOI 10.1146/annurev.ne.16.030193.003423; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAMBORGHINI JE, 1987, J COMP NEUROL, V264, P47, DOI 10.1002/cne.902640105; Lecoeur H, 2002, EXP CELL RES, V277, P1, DOI 10.1006/excr.2002.5537; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; Lowery LA, 2005, DEVELOPMENT, V132, P2057, DOI 10.1242/dev.01791; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Paquet D, 2009, J CLIN INVEST, V119, P1382, DOI 10.1172/JCI37537; ROBERTSON AMG, 1978, J PATHOL, V126, P181, DOI 10.1002/path.1711260307; Scheer N, 1999, MECH DEVELOP, V80, P153, DOI 10.1016/S0925-4773(98)00209-3; SCHOENWOLF GC, 1981, ANAT EMBRYOL, V162, P183, DOI 10.1007/BF00306490; SOLNICAKREZEL L, 1995, BIOESSAYS, V17, P931, DOI 10.1002/bies.950171106; Song J, 2008, NEUROSCIENCE, V156, P722, DOI 10.1016/j.neuroscience.2008.07.024; van Eeden FJM, 1999, METHOD CELL BIOL, V60, P21; van Genderen H, 2006, NAT PROTOC, V1, P363, DOI 10.1038/nprot.2006.55; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606	35	86	87	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4336	4342		10.1096/fj.10-161018	http://dx.doi.org/10.1096/fj.10-161018			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20601526	Green Published			2022-12-28	WOS:000283861100021
J	Smith, AJ; Lippiat, JD				Smith, Andrew J.; Lippiat, Jonathan D.			Voltage-dependent charge movement associated with activation of the CLC-5 2Cl(-)/1H(+) exchanger	FASEB JOURNAL			English	Article						chloride channel; chloride transport; gating charge; voltage sensor	CHLORIDE CHANNEL; DENTS-DISEASE; PROKARYOTIC HOMOLOG; MOLECULAR-BASIS; CL-CHANNELS; ANION; ANTIPORTER; MUTATIONS; PROTEINS; MOUSE	The family of CLC proteins comprises both Cl- channels and Cl-/H+ exchange transporters with varying degrees of voltage dependence. The human CLC-5 is an electrogenic voltage-dependent 2Cl(-)/1H(+) exchanger that gives rise to strongly outwardly rectifying currents when expressed. We conducted whole-cell recordings from HEK293 cells transiently transfected with either wild-type CLC-5 or a permeation-deficient mutant, E268A. With E268A CLC-5 we recorded transient voltage-dependent currents that represent the gating currents associated with CLC-5 activation and had kinetics that could be described by voltage-dependent forward and reverse transition rates. In extracellular solutions rich in Cl- or Br-, CLC-5 exhibited a gating charge of 1.3, but this was reduced to 0.9 in solutions comprising the impermeant anions aspartate, methanesulfonate, sulfate, or HEPES. Extracellular ion depletion by local perfusion with isotonic mannitol failed to reduce the gating charge further. Lowering intracellular pH from 7.4 to 5.4 did not shift the voltage-dependence of the gating currents, but reducing and increasing intracellular Cl- shifted the charge-voltage relationship to more negative and positive potentials, respectively. Our data suggest that voltage sensing is an intrinsic property of the CLC-5 protein and that permeant anions, particularly Cl-, modulate a voltage-dependent transition to an activated state from which Cl-/H- exchange can occur.-Smith, A. J., Lippiat, J. D. Voltage-dependent charge movement associated with activation of the CLC-5 2Cl(-)/1H(+) exchanger. FASEB J. 24, 3696-3705 (2010). www.fasebj.org	[Smith, Andrew J.; Lippiat, Jonathan D.] Univ Leeds, Inst Membrane & Syst Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Lippiat, JD (corresponding author), Univ Leeds, Inst Membrane & Syst Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England.	j.d.lippiat@leeds.ac.uk		Lippiat, Jonathan/0000-0003-3748-7345	Wellcome Trust [076545/Z/05/Z]; BBSRC [BB/D524875/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D524875/1] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This study is supported by the Wellcome Trust grant number 076545/Z/05/Z. We thank Dr. Malcolm Hunter (University of Leeds) for helpful discussions during the experimental work and for comments on the manuscript.	Accardi A, 2005, J GEN PHYSIOL, V126, P563, DOI 10.1085/jgp.200509417; Accardi A, 2004, J GEN PHYSIOL, V123, P109, DOI 10.1085/jgp.200308935; Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; de Santiago JA, 2005, J GEN PHYSIOL, V126, P591, DOI 10.1085/jgp.200509310; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Gadsby DC, 2004, NATURE, V427, P795, DOI 10.1038/427795a; Gunther W, 2003, PFLUG ARCH EUR J PHY, V445, P456, DOI 10.1007/s00424-002-0950-6; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hebeisen S, 2003, BIOPHYS J, V84, P2306, DOI 10.1016/S0006-3495(03)75036-X; Jentsch TJ, 2005, CURR OPIN NEUROBIOL, V15, P319, DOI 10.1016/j.conb.2005.05.002; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Lisal J, 2008, NAT STRUCT MOL BIOL, V15, P805, DOI 10.1038/nsmb.1466; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Ludewig U, 1997, J GEN PHYSIOL, V110, P165, DOI 10.1085/jgp.110.2.165; Ludwig M, 2005, HUM GENET, V117, P228, DOI 10.1007/s00439-005-1303-2; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; Nguitragool W, 2006, J MOL BIOL, V362, P682, DOI 10.1016/j.jmb.2006.07.006; Peres A, 2004, NEWS PHYSIOL SCI, V19, P80, DOI 10.1152/nips.01504.2003; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; Smith AJ, 2009, AM J PHYSIOL-RENAL, V296, pF390, DOI 10.1152/ajprenal.90526.2008; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; Zdebik AA, 2008, J BIOL CHEM, V283, P4219, DOI 10.1074/jbc.M708368200; Zifarelli G, 2009, EMBO J, V28, P175, DOI 10.1038/emboj.2008.284	34	34	35	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2010	24	10					3696	3705		10.1096/fj.09-150649	http://dx.doi.org/10.1096/fj.09-150649			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20501796	hybrid, Green Published			2022-12-28	WOS:000285005900010
J	Ayoub, MA; Trinquet, E; Pfleger, KDG; Pin, JP				Ayoub, Mohammed Akli; Trinquet, Eric; Pfleger, Kevin D. G.; Pin, Jean-Philippe			Differential association modes of the thrombin receptor PAR(1) with G alpha i1, G alpha 12, and beta-arrestin 1	FASEB JOURNAL			English	Article						BRET; GPCRs; G proteins; TR-FRET	PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; RESONANCE ENERGY-TRANSFER; LIVING CELLS; ACTIVATED RECEPTOR-1; G(12) FAMILY; COMPLEXES; INTERNALIZATION; PHOSPHORYLATION; BETA-ARRESTIN-2	Although many G protein-coupled receptors (GPCRs) are known to activate multiple signaling pathways by coupling to different types of G proteins or by promoting G protein-independent events, how this occurs remains unclear. Using bioluminescence resonance energy transfer and time-resolved fluorescence resonance energy transfer, we provide evidence for protease-activated receptor 1 (PAR(1)) forming preassembled complexes with G alpha i1 but not G alpha 12. PAR(1) activation appears to rapidly induce transient G alpha i1 activation (t(1/2) = 4.13 s) but late and stable recruitment of G alpha 12 (t(1/2) = 8.8 min) in parallel with beta-arrestin 1 (t(1/2) = 7.5 min). However, there is no significant difference in the potency of the agonist-dependent response between G alpha i1, G alpha 12, and beta-arrestin 1 (EC50 values 0.48, 0.30, and 0.15 nM, respectively). Although it seems beta-arrestin 1 is recruited to preassembled PAR(1)-G alpha i1 complexes, this appears unlikely with G alpha 12, suggesting 2 distinct receptor populations. Of note, we observed a different G alpha 12 association mode with other GPCRs, indicating that preassembly and association dynamics may be specific properties of a receptor-G protein pair. Furthermore, the G alpha C terminus appears to play different roles in the distinct association modes. Consequently, G protein preassembly or recruitment may constitute novel mechanisms for controlling the kinetics and multitude of GPCR signaling pathways.-Ayoub, M. A., Trinquet, E., Pfleger K. D. G., Pin, J.-P. Differential association modes of the thrombin receptor PAR(1) with G alpha i1, G alpha 12, and beta-arrestin 1. FASEB J. 24, 3522-3535 (2010). www.fasebj.org	[Ayoub, Mohammed Akli; Pin, Jean-Philippe] Univ Montpellier 2, Inst Genom Fonct, Dept Mol Pharmacol, F-34094 Montpellier 5, France; [Ayoub, Mohammed Akli; Pin, Jean-Philippe] Univ Montpellier I, CNRS, INSERM, UMR5203,U661, Montpellier, France; [Ayoub, Mohammed Akli; Pfleger, Kevin D. G.] Univ Western Australia, Lab Mol Endocrinol GPCRs, Western Australian Inst Med Res, Perth, WA 6009, Australia; [Ayoub, Mohammed Akli; Pfleger, Kevin D. G.] Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia; [Trinquet, Eric] Cisbio Bioassays, Bagnols Sur Ceze, France	Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Western Australia; University of Western Australia	Pin, JP (corresponding author), Univ Montpellier 2, Inst Genom Fonct, Dept Mol Pharmacol, 141 Rue Cardonille, F-34094 Montpellier 5, France.	jppin@igf.cnrs.fr	Pin, Jean-Philippe/Y-6668-2019; Pfleger, Kevin/H-5629-2014	Pin, Jean-Philippe/0000-0002-1423-345X; Pfleger, Kevin/0000-0001-8261-9189; AYOUB, Mohammed Akli/0000-0003-0022-578X	CNRS; INSERM; French Ministry of Research; Cisbio International; Agence Nationale pour la Recherche [ANR-05-PRIB-02502]	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Cisbio International; Agence Nationale pour la Recherche(French National Research Agency (ANR))	The authors thank Cisbio Bioassays for continuous strong support of this work. The authors also thank Drs. Laurent Prezeau, Sebastien Granier, and Thierry Durroux (IGF, Montpellier, France) for helpful discussions and Montpellier RIO imaging for confocal analysis. The authors thank Claire Vol, Isabelle Brabet, and the medium screening facilities of the IGF (Plate-forme Pharmacologie Criblage Interactome, Montpellier, France). This work was supported by grants from the CNRS, INSERM, French Ministry of Research, Cisbio International, and the Agence Nationale pour la Recherche (contract ANR-05-PRIB-02502).	Arora P, 2008, ONCOGENE, V27, P4434, DOI 10.1038/onc.2008.84; Audet N, 2008, J BIOL CHEM, V283, P15078, DOI 10.1074/jbc.M707941200; Ayoub MA, 2007, MOL PHARMACOL, V71, P1329, DOI 10.1124/mol.106.030304; Ayoub MA, 2010, CURR OPIN PHARMACOL, V10, P44, DOI 10.1016/j.coph.2009.09.012; Ayoub MA, 2009, J BIOL CHEM, V284, P29136, DOI 10.1074/jbc.M109.042333; Bockaert J, 1991, Curr Opin Neurobiol, V1, P32, DOI 10.1016/0959-4388(91)90008-U; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Chen CH, 2004, J BIOL CHEM, V279, P10020, DOI 10.1074/jbc.M310590200; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dowal L, 2006, J BIOL CHEM, V281, P23999, DOI 10.1074/jbc.M512330200; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Firth TA, 2001, NEUROPHARMACOLOGY, V40, P358, DOI 10.1016/S0028-3908(00)00161-1; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P9308, DOI 10.1021/bi9902236; Hein P, 2005, EMBO J, V24, P4106, DOI 10.1038/sj.emboj.7600870; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; JEFFERY DR, 1980, J BIOL CHEM, V255, P5015; Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kuo FT, 2006, CELL SIGNAL, V18, P1914, DOI 10.1016/j.cellsig.2006.02.009; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; Limbird LE, 2004, MOL INTERV, V4, P326, DOI 10.1124/mi.4.6.6; Lohse MJ, 2008, TRENDS PHARMACOL SCI, V29, P159, DOI 10.1016/j.tips.2007.12.002; Maurel D, 2004, ANAL BIOCHEM, V329, P253, DOI 10.1016/j.ab.2004.02.013; Maurel D, 2008, NAT METHODS, V5, P561, DOI [10.1038/nmeth.1213, 10.1038/NMETH.1213]; McGrew L, 2002, MOL PHARMACOL, V62, P1339, DOI 10.1124/mol.62.6.1339; Meyer BH, 2008, J CELL BIOCHEM, V104, P1660, DOI 10.1002/jcb.21732; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Paing MM, 2006, MOL CELL BIOL, V26, P3231, DOI 10.1128/MCB.26.8.3231-3242.2006; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Perez DM, 2005, PHARMACOL REV, V57, P147, DOI 10.1124/pr.57.2.2; Pfleger KDG, 2005, BIOCHEM J, V385, P625, DOI 10.1042/BJ20041361; Prevost GP, 2006, CANCER RES, V66, P9227, DOI 10.1158/0008-5472.CAN-05-4205; Qin K, 2008, FASEB J, V22, P2920, DOI 10.1096/fj.08-105775; Rebois RV, 2006, J CELL SCI, V119, P2807, DOI 10.1242/jcs.03021; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330; SCHULSTER D, 1978, J BIOL CHEM, V253, P1201; Shea LD, 2000, LIFE SCI, V68, P647, DOI 10.1016/S0024-3205(00)00977-2; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Tanabe S, 2004, METHOD ENZYMOL, V390, P285; Vanderbeld B, 2000, BIOCHEM CELL BIOL, V78, P537, DOI 10.1139/o00-075; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5	54	53	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3522	3535		10.1096/fj.10-154997	http://dx.doi.org/10.1096/fj.10-154997			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20410441				2022-12-28	WOS:000281446400039
J	Gora, S; Maouche, S; Atout, R; Wanherdrick, K; Lambeau, G; Cambien, F; Ninio, E; Karabina, SA				Gora, Sarah; Maouche, Seraya; Atout, Rajai; Wanherdrick, Kristell; Lambeau, Gerard; Cambien, Francois; Ninio, Ewa; Karabina, Sonia-Athina			Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling	FASEB JOURNAL			English	Article						unfolded protein response; inflammation; secreted phospholipase A2 group X; hGX sPLA2; modified LDL; atherosclerosis	UNFOLDED PROTEIN RESPONSE; LOW-DENSITY-LIPOPROTEIN; GROUP-X; GROUP-V; SECRETORY PHOSPHOLIPASE-A(2); GROUP-IIA; A(2); ATHEROSCLEROSIS; HYDROLYSIS; PATHWAYS	Secreted phospholipases A2 (sPLA2s) are present in atherosclerotic plaques and are now considered novel attractive therapeutic targets and potential biomarkers as they contribute to the development of atherosclerosis through lipoprotein-dependent and independent mechanisms. We have previously shown that hGX-sPLA2-phospholipolyzed LDL (LDL-X) induces proinflammatory responses in human umbilical endothelial cells (HUVECs); here we explore the molecular mechanisms involved. Global transcriptional gene expression profiling of the response of endothelial cells exposed to either LDL or LDL-X revealed that LDL-X activates multiple distinct cellular pathways including the unfolded protein response (UPR). Mechanistic insight showed that LDL-X activates UPR through calcium depletion of intracellular stores, which in turn disturbs cytoskeleton organization. Treatment of HUVECs and aortic endothelial cells (HAECs) with LDL-X led to activation of all 3 proximal initiators of UPR: eIF-2 alpha, IRE1 alpha, and ATF6. In parallel, we observed a sustained phosphorylation of the p38 pathway resulting in the phosphorylation of AP-1 downstream targets. This was accompanied by significant production of the proinflammatory cytokines IL-6 and IL-8. Our study demonstrates that phospholipolyzed LDL uses a range of molecular pathways including UPR to initiate endothelial cell perturbation and thus provides an LDL oxidation-independent mechanism for the initiation of vascular inflammation in atherosclerosis.- Gora, S., Maouche, S., Atout, R., Wanherdrick, K., Lambeau, G., Cambien, F., Ninio, E., Karabina, S.-A. Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling. FASEB J. 24, 3284-3297 (2010). www.fasebj.org	[Gora, Sarah; Maouche, Seraya; Atout, Rajai; Cambien, Francois; Ninio, Ewa; Karabina, Sonia-Athina] INSERM, UMRS 937, F-75634 Paris 13, France; [Wanherdrick, Kristell] Univ Paris 06, Fac Med Pierre & Marie Curie, Paris, France; [Lambeau, Gerard] Univ Nice Sophia Antipolis, CNRS, UMR 6097, Inst Pharmacol Mol & Cellulaire, Valbonne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Karabina, SA (corresponding author), INSERM, U937, Fac Med Pitie Salpetriere, 91 Blvd Hop, F-75634 Paris 13, France.	sonia.karabina@upmc.fr	Lambeau, Gerard/GRJ-5624-2022; Cambien, Francois/AAP-9751-2020	Maouche, Seraya/0000-0001-8186-1635; Lambeau, Gerard/0000-0002-9239-518X	Institut National de la Sante Et de la Recherche Medicale; Fondation pour la Recherche Medicale [SPF20080512033, FDT200910244, FDT20070910166]; European Union; ANR; Centre National de la Recherche Scientifique (CNRS); Association pour la Recherche sur le Cancer	Institut National de la Sante Et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); European Union(European Commission); ANR(French National Research Agency (ANR)); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	This study was supported by the Institut National de la Sante Et de la Recherche Medicale and by fellowships from the Fondation pour la Recherche Medicale (SPF20080512033) to S. A. K., (FDT200910244) to S. G., and (FDT20070910166) to S. M. The study was also supported by the European Union STREP Programme CVDIMMUNE (2006-2009) to E.N., by an ANR program (ANR 2006 Physio-pathologie des maladies humaines: sPLA2/ATHEROSCLEROSE) to G. L. and E.N., and by the Centre National de la Recherche Scientifique (CNRS) and the Association pour la Recherche sur le Cancer to G. L. E.N. and G. L. are Directors of Research at CNRS. The authors acknowledge the excellent technical assistance of Monique Agrapart and Herve Durand.	Asatryan L, 2005, J LIPID RES, V46, P115, DOI 10.1194/jlr.M400306-JLR200; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chadjichristos CE, 2006, ADV CARDIOL, V42, P255, DOI 10.1159/000092574; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Curfs DMJ, 2008, J BIOL CHEM, V283, P21640, DOI 10.1074/jbc.M710584200; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Fujioka D, 2008, CIRCULATION, V117, P2977, DOI 10.1161/CIRCULATIONAHA.107.743997; Gargalovic PS, 2006, ARTERIOSCL THROM VAS, V26, P2490, DOI 10.1161/01.ATV.0000242903.41158.a1; Glembotski CC, 2008, J MOL CELL CARDIOL, V44, P453, DOI 10.1016/j.yjmcc.2007.10.017; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Henderson WR, 2007, J EXP MED, V204, P865, DOI 10.1084/jem.20070029; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jagavelu K, 2007, CIRC RES, V101, P1104, DOI 10.1161/CIRCRESAHA.107.156075; Karabina SA, 2006, FASEB J, V20, P2547, DOI 10.1096/fj.06-6018fje; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Matsumoto T, 2007, CURR MED CHEM, V14, P3209, DOI 10.2174/092986707782793899; Myoishi M, 2007, CIRCULATION, V116, P1226, DOI 10.1161/CIRCULATIONAHA.106.682054; Oskolkova OV, 2008, BLOOD, V112, P330, DOI 10.1182/blood-2007-09-112870; Pan YH, 2002, J BIOL CHEM, V277, P29086, DOI 10.1074/jbc.M202531200; Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171; Pruzanski W, 2005, BBA-MOL CELL BIOL L, V1736, P38, DOI 10.1016/j.bbalip.2005.07.005; PUHL H, 1994, METHOD ENZYMOL, V233, P425; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosengren B, 2006, BBA-MOL CELL BIOL L, V1761, P1301, DOI 10.1016/j.bbalip.2006.06.008; Sanson M, 2009, CIRC RES, V104, P328, DOI 10.1161/CIRCRESAHA.108.183749; SANTANAM N, 1995, J CLIN INVEST, V95, P2594, DOI 10.1172/JCI117961; Sato H, 2008, J BIOL CHEM, V283, P33483, DOI 10.1074/jbc.M804628200; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Seimon TA, 2009, J CLIN INVEST, V119, P886, DOI 10.1172/JCI37262; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Smyth G, 2005, LIMMA LINEAR MODELS; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Spandidos A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-633; Tabas I, 1999, ANNU REV NUTR, V19, P123, DOI 10.1146/annurev.nutr.19.1.123; Tian L, 2005, P NATL ACAD SCI USA, V102, P13544, DOI 10.1073/pnas.0506577102; Treiman M, 2002, TRENDS CARDIOVAS MED, V12, P57, DOI 10.1016/S1050-1738(01)00147-5; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Wooton-Kee CR, 2004, ARTERIOSCL THROM VAS, V24, P762, DOI 10.1161/01.ATV.0000122363.02961.c1; Yamamoto K, 2003, J BIOL CHEM, V278, P34525, DOI 10.1074/jbc.M304188200; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97	56	42	45	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3284	3297		10.1096/fj.09-146852	http://dx.doi.org/10.1096/fj.09-146852			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20430794				2022-12-28	WOS:000281446400017
J	He, LH; Aleksandrov, LA; Cui, LY; Jensen, TJ; Nesbitt, KL; Riordan, JR				He, Lihua; Aleksandrov, Luba A.; Cui, Liying; Jensen, Timothy J.; Nesbitt, Kenneth L.; Riordan, John R.			Restoration of domain folding and interdomain assembly by second-site suppressors of the Delta F508 mutation in CFTR	FASEB JOURNAL			English	Article						cystic fibrosis; interdomain interactions; cysteine accessibility; cysteine cross-linking	TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAIN-1; CYSTIC-FIBROSIS MUTATION; CHLORIDE CHANNEL; QUALITY-CONTROL; DEFECTS	Deletion of PHE508 (Delta F508) from the first nucleotide-binding domain (NBD1) of CFTR, which causes most cystic fibrosis, disrupts the folding and assembly of the protein. Although the folding pathways and yield of isolated NBD1 are altered, its global structure is not, and details of the changes in the rest of the protein remain unclear. To gain further insight into how the whole mutant protein is altered, we have determined the influence of known second-site suppressor mutations in NBD1 on the conformation of this domain and key interfaces between domains. We found that the suppressors restored maturation of only those processing mutations located in NBD1, but not in other domains, including those in the C-terminal cytoplasmic loop of the second membrane-spanning domain, which forms an interface with the NBD1 surface. Nevertheless, the suppressors promoted the formation of this interface and others in the absence of F508. The suppressors restored maturation in a Delta F508 construct from which NBD2 was absent but to a lesser extent than in the full-length, indicating that Delta F508 disrupts interactions involving NBD2, as well as other domains. Rescue of Delta F508-CFTR by suppressors required the biosynthesis of the entire full-length protein in continuity, as it did not occur when N- and C-terminal "halves" were coexpressed. Simultaneous with these interdomain perturbations, Delta F508 resulted in suppressor reversed alterations in accessibility of residues both in the F508-containing NBD1 surface loop and in the Q loop within the domain core. Thus, in the context of the full-length protein, Delta F508 mutation causes detectable changes in NBD1 conformation, as well as interdomain interactions.-He, L., Aleksandrov, L. A., Cui, L., Jensen, T. J., Nesbitt, K. L., Riordan, J. R. Restoration of domain folding and interdomain assembly by second-site suppressors of the Delta F508 mutation in CFTR. FASEB J. 24, 3103-3112 (2010). www.fasebj.org	[Riordan, John R.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Riordan, JR (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 6103 Thurston Bowles,CB 7260, Chapel Hill, NC 27599 USA.	jack_riordan@med.unc.edu			U.S. National Institutes of Health [DK051870]; CFF; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051619, R01DK051870] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CFF; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study is supported by grants from the U.S. National Institutes of Health (DK051870) and the CFF. The authors also thank Drs. Tamas Hegedus and Adrian W. R. Serohijos for reading the manuscript.	Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Chen EY, 2004, J BIOL CHEM, V279, P39620, DOI 10.1074/jbc.M407887200; Cui L, 2006, J PHYSIOL-LONDON, V572, P347, DOI 10.1113/jphysiol.2005.099457; Cui LY, 2007, J MOL BIOL, V365, P981, DOI 10.1016/j.jmb.2006.10.086; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; deCarvalho ACV, 2002, J BIOL CHEM, V277, P35896, DOI 10.1074/jbc.M205644200; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; Du K, 2009, MOL BIOL CELL, V20, P1903, DOI 10.1091/mbc.E08-09-0950; He LH, 2008, J BIOL CHEM, V283, P26383, DOI 10.1074/jbc.M803894200; Hegedus T, 2006, BBA-BIOMEMBRANES, V1758, P565, DOI 10.1016/j.bbamem.2006.03.006; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Lewis HA, 2010, J MOL BIOL, V396, P406, DOI 10.1016/j.jmb.2009.11.051; Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Loo TW, 2009, BIOCHEMISTRY-US, V48, P9882, DOI 10.1021/bi9004842; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Riordan JR, 2008, ANNU REV BIOCHEM, V77, P701, DOI 10.1146/annurev.biochem.75.103004.142532; Rosser MFN, 2008, MOL BIOL CELL, V19, P4570, DOI 10.1091/mbc.E08-04-0357; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; Serohijos AWR, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000008; Serohijos AWR, 2008, P NATL ACAD SCI USA, V105, P3256, DOI 10.1073/pnas.0800254105; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; Teem JL, 1996, RECEPTOR CHANNEL, V4, P63; THOMAS PJ, 2008, 2 FEBS SPEC M ABC PR, P69; WANG X, 2008, PEDIATR PULM, V31, P121; Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041	29	56	58	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					3103	3112		10.1096/fj.09-141788	http://dx.doi.org/10.1096/fj.09-141788			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20233947	Green Published			2022-12-28	WOS:000285005400046
J	Waluk, DP; Schultz, N; Hunt, MC				Waluk, Dominik P.; Schultz, Niklas; Hunt, Mary C.			Identification of glycine N-acyltransferase-like 2 (GLYATL2) as a transferase that produces N-acyl glycines in humans	FASEB JOURNAL			English	Article						N-oleoyl glycine; N-arachidonoyl glycine; endocannabinoids; N-acyl amino acids; endoplasmic reticulum	ALPHA-AMIDATING MONOOXYGENASE; IN-VITRO SYNTHESIS; ENDOPLASMIC-RETICULUM; ARACHIDONOYL GLYCINE; N(18)TG(2) CELLS; AMINO-ACIDS; FATTY-ACIDS; CONJUGATION; METABOLISM; COA	The discovery of glycine conjugates of long-chain fatty acids (N-acyl glycines) in the brain and other non-neuronal tissues has led to the identification of an emerging class of bioactive lipids. The biological activities of N-acyl glycines include antinociceptive, anti-inflammatory and antiproliferative effects, and activation of G-protein-coupled receptors. However, despite the fact that N-acyl glycines are emerging as a distinct lipid signaling family, pathways for their production are not fully elucidated. Here we report on the characterization of human glycine N-acyltransferase-like 2 (hGLYATL2), a member of a gene family of 4 putative glycine conjugating enzymes, and show that it synthesizes various N-acyl glycines. Recombinantly expressed hGLYATL2 efficiently conjugated oleoyl-CoA, arachidonoyl-CoA, and other medium-and long-chain acyl-CoAs to glycine. The enzyme was specific for glycine as an acceptor molecule, and preferentially produced N-oleoyl glycine. The hGLYATL2 enzyme is localized to the endoplasmic reticulum, and the mRNA shows highest expression in salivary gland and trachea, but is also detected in spinal cord and skin fibroblasts. The expression pattern and the identification of high levels of N-acyl glycines in skin and lung may indicate a role for N-acyl glycines in barrier function/immune response and the potential role of hGLYATL2 in this regard is discussed.-Waluk, D. P., Schultz, N., Hunt, M. C. Identification of glycine N-acyltransferase-like 2 (GLYATL2) as a transferase that produces N-acyl glycines in humans. FASEB J. 24, 2795-2803 (2010). www.fasebj.org	[Hunt, Mary C.] Stockholm Univ, Dept Genet Microbiol & Toxicol, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden	Stockholm University	Hunt, MC (corresponding author), Stockholm Univ, Dept Genet Microbiol & Toxicol, Arrhenius Labs Nat Sci, Svante Arrhenius Vag 20C, SE-10691 Stockholm, Sweden.	mary.hunt@gmt.su.se	Schultz, Niklas/AFQ-8244-2022	Hunt, Mary/0000-0001-6415-2992	Swedish Research Council; Carl Trygger Foundation; Professor Nanna Svartz Fond; Ake Wibergs stiftelse	Swedish Research Council(Swedish Research CouncilEuropean Commission); Carl Trygger Foundation; Professor Nanna Svartz Fond; Ake Wibergs stiftelse	The authors are grateful to Professor Stefan Alexson, Karolinska Institutet, for excellent critical discussion on the manuscript and for use of the mass spectrometer. This work was supported by the Swedish Research Council, Carl Trygger Foundation, Professor Nanna Svartz Fond, and Ake Wibergs stiftelse.	Aneetha H, 2009, BIOORG MED CHEM LETT, V19, P237, DOI 10.1016/j.bmcl.2008.10.087; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRAAS KM, 1992, ENDOCRINOLOGY, V130, P2778, DOI 10.1210/en.130.5.2778; Bradshaw HB, 2009, VITAM HORM, V81, P191, DOI 10.1016/S0083-6729(09)81008-X; Bradshaw HB, 2009, BMC BIOCHEM, V10, DOI 10.1186/1471-2091-10-14; Burstein SH, 2000, PROSTAG OTH LIPID M, V61, P29, DOI 10.1016/S0090-6980(00)00053-8; Burstein S, 2008, NEUROPHARMACOLOGY, V55, P1259, DOI 10.1016/j.neuropharm.2007.11.011; Carter SMB, 1996, J CHROMATOGR B, V677, P29, DOI 10.1016/0378-4347(95)00415-7; Cascio MG, 2004, BIOCHEM BIOPH RES CO, V314, P192, DOI 10.1016/j.bbrc.2003.12.075; Chaturvedi S, 2006, PROSTAG OTH LIPID M, V81, P136, DOI 10.1016/j.prostaglandins.2006.09.001; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; GREGERSEN N, 1986, BIOCHEM MED METAB B, V35, P210, DOI 10.1016/0885-4505(86)90076-9; Huang SM, 2001, J BIOL CHEM, V276, P42639, DOI 10.1074/jbc.M107351200; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; KELLER W, 1842, ANN CHEM PHARM, V43, P108; Knights KM, 2007, EXPERT OPIN DRUG MET, V3, P159, DOI 10.1517/17425255.3.2.159; Kohno M, 2006, BIOCHEM BIOPH RES CO, V347, P827, DOI 10.1016/j.bbrc.2006.06.175; Lefebvre P, 2009, PHYSIOL REV, V89, P147, DOI 10.1152/physrev.00010.2008; Mccue JM, 2008, BIOCHEM BIOPH RES CO, V365, P322, DOI 10.1016/j.bbrc.2007.10.175; Merkler DJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P430, DOI 10.1006/abbi.1996.0272; Merkler DJ, 2004, BIOCHEMISTRY-US, V43, P12667, DOI 10.1021/bi049529p; Mueller GP, 2007, J BIOL CHEM, V282, P22364, DOI 10.1074/jbc.M701801200; NANDI DL, 1979, J BIOL CHEM, V254, P7230; O'Byrne J, 2003, J BIOL CHEM, V278, P34237, DOI 10.1074/jbc.M300987200; Oh DY, 2008, J BIOL CHEM, V283, P21054, DOI 10.1074/jbc.M708908200; Reilly SJ, 2007, FASEB J, V21, P99, DOI 10.1096/fj.06-6919com; Rimmerman N, 2008, MOL PHARMACOL, V74, P213, DOI 10.1124/mol.108.045997; Ritenour-Rodgers KJ, 2000, BIOCHEM BIOPH RES CO, V267, P521, DOI 10.1006/bbrc.1999.1977; Roy M.-O., 2007, Can. Patent Appl., Patent No. [CA2589393, 2589393]; SCHACHTER D, 1954, J BIOL CHEM, V208, P263; Tan B, 2010, J LIPID RES, V51, P112, DOI 10.1194/jlr.M900198-JLR200; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; van der Westhuizen FH, 2000, J BIOCHEM MOL TOXIC, V14, P102, DOI 10.1002/(SICI)1099-0461(2000)14:2<102::AID-JBT6>3.0.CO;2-H; WEBSTER LT, 1976, J BIOL CHEM, V251, P3352; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198; Zhang HX, 2007, INT J MOL SCI, V8, P433, DOI 10.3390/i8050433	38	39	45	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2795	2803		10.1096/fj.09-148551	http://dx.doi.org/10.1096/fj.09-148551			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20305126				2022-12-28	WOS:000285005400020
J	Lee, M; Cho, T; Jantaratnotai, N; Wang, YT; McGeer, E; McGeer, PL				Lee, Moonhee; Cho, Taesup; Jantaratnotai, Nattinee; Wang, Yu Tian; McGeer, Edith; McGeer, Patrick L.			Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases	FASEB JOURNAL			English	Article						microglia; astroglia; buthionine-S,R-sulfoximine; neuroinflammation; clotrimazole; TRPM2	NECROSIS-FACTOR-ALPHA; OXIDATIVE STRESS; NITRIC-OXIDE; ADP-RIBOSE; REDUCED GLUTATHIONE; CEREBROSPINAL-FLUID; CALCIUM INFLUX; RAT-BRAIN; IN-VIVO; EXPRESSION	Oxidative stress induced by inhibition of glutathione (GSH) biosynthesis with D,L-buthionine-S,R-sulfoximine (BSO) causes human microglia, human astrocytes, THP-1 cells, and U373 cells to secrete materials toxic to human neuroblastoma SH-SY5Y cells and stimulates them to release TNF-alpha, IL-6, and nitrite ions. The effect is correlated with activation of the inflammatory pathways P38 MAP-kinase, Jun-N-terminal kinase, and NF-kappa B. The effect is reduced by adding to the medium GSH or clotrimazole (CTM), an inhibitor of Ca2+-influx through TRPM2 channels. It is also produced by inhibiting TRPM2 protein expression in microglia and astrocytes through introduction of its small inhibitory RNA (siRNA). TRPM2 mRNA is expressed by glial cells but not by SH-SY5Y cells. BSO in the culture medium causes an almost 3-fold increase in [Ca2+](i) in microglia and astrocytes over a 24-h period, which is reduced to half by the addition of CTM. The data strongly suggest that inhibiting intracellular GSH synthesis induces a neuroinflammatory response in human microglia and astrocytes, which is linked to Ca2+ influx through TRPM2 channels. It represents a new model for inducing neuroinflammation and suggests that increasing GSH levels in glial cells may confer neuroprotection in neurodegenerative diseases, such as Alzheimer disease, which have a prominent neuroinflammatory component.-Lee, M., Cho, T., Jantaratnotai, N., Wang, Y.T., McGeer, E., McGeer, P. L. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J. 24, 2533-2545 (2010). www.fasebj.org	[Lee, Moonhee; McGeer, Edith; McGeer, Patrick L.] Univ British Columbia, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada; [Cho, Taesup; Wang, Yu Tian] Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; [Jantaratnotai, Nattinee] Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	McGeer, PL (corresponding author), Univ British Columbia, Kinsmen Lab Neurol Res, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	mcgeerpl@interchange.ubc.ca	Wang, Yu Tian/J-8255-2015; Wang, Yu Tian/A-4729-2008		Pacific Alzheimer Research Foundation	Pacific Alzheimer Research Foundation	This research was supported by the Pacific Alzheimer Research Foundation.	Andersson P, 1998, PROG SYST C, V24, P1; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Cao BJ, 2002, EUR J PHARMACOL, V448, P27, DOI 10.1016/S0014-2999(02)01908-8; Chen Y, 2008, BIOL PHARM BULL, V31, P1496, DOI 10.1248/bpb.31.1496; Choi HB, 2002, J NEUROCHEM, V83, P546, DOI 10.1046/j.1471-4159.2002.01122.x; COOPER AJL, 1980, J NEUROCHEM, V35, P1242, DOI 10.1111/j.1471-4159.1980.tb07882.x; Cudkowicz ME, 1999, NEUROLOGY, V52, P1492, DOI 10.1212/WNL.52.7.1492; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Fuller S, 2010, MUTAT RES-FUND MOL M, V690, P40, DOI 10.1016/j.mrfmmm.2009.08.016; Gay C, 1999, ANAL BIOCHEM, V273, P143, DOI 10.1006/abio.1999.4207; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Hashioka S, 2007, EXP NEUROL, V206, P33, DOI 10.1016/j.expneurol.2007.03.022; Hecquet CM, 2008, CIRC RES, V102, P347, DOI 10.1161/CIRCRESAHA.107.160176; Heiner I, 2003, CELL CALCIUM, V33, P533, DOI 10.1016/S0143-4160(03)00058-7; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; Hill K, 2004, N-S ARCH PHARMACOL, V370, P227, DOI 10.1007/s00210-004-0981-y; Hirrlinger J, 2002, J NEUROSCI RES, V69, P318, DOI 10.1002/jnr.10308; Hirsch EC, 2005, PARKINSONISM RELAT D, V11, pS9, DOI 10.1016/j.parkreldis.2004.10.013; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Hunot S, 1999, J NEUROSCI, V19, P3440; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kim YJ, 2006, BIOCHEM BIOPH RES CO, V347, P731, DOI 10.1016/j.bbrc.2006.06.149; Klegeris A, 1999, NEUROPHARMACOLOGY, V38, P1017, DOI 10.1016/S0028-3908(99)00014-3; Klegeris A, 2006, FASEB J, V20, P2000, DOI 10.1096/fj.06-6183com; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kuhn FJP, 2005, PFLUG ARCH EUR J PHY, V451, P212, DOI 10.1007/s00424-005-1446-y; Lee M, 2008, BRAIN RES, V1195, P1, DOI 10.1016/j.brainres.2007.12.023; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; LOEFFLER DA, 1994, CLIN NEUROPHARMACOL, V17, P370, DOI 10.1097/00002826-199408000-00009; Lovell MA, 1998, NEUROLOGY, V51, P1562, DOI 10.1212/WNL.51.6.1562; McGeer PL, 2008, MOVEMENT DISORD, V23, P474, DOI 10.1002/mds.21751; Meister A, 1981, Curr Top Cell Regul, V18, P21; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Moller T, 2002, GLIA, V40, P184, DOI 10.1002/glia.10152; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; MUFSON RA, 1992, METHODS CELL SCI, V14, P37; Paredes RM, 2008, METHODS, V46, P143, DOI 10.1016/j.ymeth.2008.09.025; Perea G, 2005, CELL CALCIUM, V38, P375, DOI 10.1016/j.ceca.2005.06.015; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; REHNCRONA S, 1980, J NEUROCHEM, V34, P477, DOI 10.1111/j.1471-4159.1980.tb11170.x; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; SLIVKA A, 1987, BRAIN RES, V409, P275, DOI 10.1016/0006-8993(87)90712-8; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Theodore S, 2008, J NEUROPATH EXP NEUR, V67, P1149, DOI 10.1097/NEN.0b013e31818e5e99; Tohgi H, 1999, ANN NEUROL, V46, P129, DOI 10.1002/1531-8249(199907)46:1<129::AID-ANA21>3.0.CO;2-Y; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179	56	172	177	4	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2533	2545		10.1096/fj.09-149997	http://dx.doi.org/10.1096/fj.09-149997			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20228251				2022-12-28	WOS:000279343600040
J	McDonald, JU; Cortini, A; Rosas, M; Fossati-Jimack, L; Ling, GS; Lewis, KJ; Dewitt, S; Liddiard, K; Brown, GD; Jones, SA; Hallett, MB; Botto, M; Taylor, PR				McDonald, Jacqueline U.; Cortini, Andrea; Rosas, Marcela; Fossati-Jimack, Liliane; Ling, Guang Sheng; Lewis, Kimberley J.; Dewitt, Sharon; Liddiard, Kate; Brown, Gordon D.; Jones, Simon A.; Hallett, Maurice B.; Botto, Marina; Taylor, Philip R.			In vivo functional analysis and genetic modification of in vitro-derived mouse neutrophils	FASEB JOURNAL			English	Article						inflammation; animal models; conditional immortalization	BETA-GLUCAN RECEPTOR; EX-VIVO; DECTIN-1; INFLAMMATION; MACROPHAGES; PHAGOCYTOSIS; RECOGNITION; EXPRESSION; CELLS	Mature neutrophils are notoriously short-lived immune cells that cannot be genetically manipulated. Analysis of gene function therefore requires genetically modified animals, which is expensive, time-consuming, and costly in animal life. Analysis of gene function in neutrophils in a physiologically relevant context thus represents a significant problem in the field. We sought to overcome this obstruction in the field by developing a strategy for the analysis of gene function in neutrophils in a physiologically relevant context. Here, we demonstrate the functional relevance of in vitro conditional-Hoxb8 immortalized precursor-derived neutrophils. In vitro-derived neutrophils functionally resembled primary neutrophils, but critically, neutrophils generated in this way can be adoptively transferred into live animals and tracked during inflammatory responses using single-cell analysis to define functional attributes. We have validated this approach using CD11b-deficient neutrophils and replicated the key findings observed in gene-targeted animals and in naturally CD11b-deficient humans. Furthermore, we show that by retroviral transduction, one can generate stable alterations in the precursor cell lines and thus a continuous supply of functionally altered neutrophils. This novel technological advance offers for the first time the possibility of applying higher-throughput genetic modification and in vivo functional analysis to the neutrophil-lineage.-McDonald, J. U., Cortini, A., Rosas, M., Fossati-Jimack, L., Ling, G. S., Lewis, K. J., Dewitt, S., Liddiard, K., Brown, G. D., Jones, S. A., Hallett, M. B., Botto, M., Taylor, P. R. In vivo functional analysis and genetic modification of in vitro-derived mouse neutrophils. FASEB J. 25, 1972-1982 (2011). www.fasebj.org	[McDonald, Jacqueline U.; Rosas, Marcela; Liddiard, Kate; Jones, Simon A.; Taylor, Philip R.] Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff CF14 4XN, S Glam, Wales; [Lewis, Kimberley J.; Dewitt, Sharon; Hallett, Maurice B.] Cardiff Univ, Sch Med, Dept Surg, Cardiff CF14 4XN, S Glam, Wales; [Cortini, Andrea; Fossati-Jimack, Liliane; Ling, Guang Sheng; Botto, Marina] Univ London Imperial Coll Sci Technol & Med, Ctr Complement & Inflammat Res, Div Immunol & Inflammat, London, England; [Brown, Gordon D.] Univ Aberdeen, Sect Infect & Immun, Inst Med Sci, Aberdeen, Scotland	Cardiff University; Cardiff University; Imperial College London; University of Aberdeen	Taylor, PR (corresponding author), Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Tenovus Bldg,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	taylorpr@cf.ac.uk	brown, gordon/B-4249-2012; Hallett, Maurice/I-6866-2012; Rosas Nexticapa, Marcela/HGU-1088-2022; Jones, Simon Arnett/Q-7017-2018	Hallett, Maurice/0000-0001-8197-834X; Taylor, Philip/0000-0003-0163-1421; Dewitt, Sharon/0000-0001-8169-8241; brown, gordon/0000-0002-0287-5383; Jones, Simon Arnett/0000-0001-7297-9711	MRC; Wellcome Trust; Medical Research Council [G0601617] Funding Source: researchfish; MRC [G0601617] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	P.R.T. is a Medical Research Council (MRC; UK) Senior Non-Clinical Fellow (G0601617). J.U.M. and K.J.L. are the recipients of MRC-funded Ph.D. studentships. S.D. was funded by the Wellcome Trust. All work with animals was conducted in accordance with institutional and UK Home Office guidelines. The authors thank the staff of their institutional animal facilities for the care of the animals used in these studies. The authors also thank Prof. Ian Sabroe for his critical review of the manuscript.	Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Dewitt S, 2003, J CELL SCI, V116, P2857, DOI 10.1242/jcs.00499; Dewitt S, 2002, J CELL BIOL, V159, P181, DOI 10.1083/jcb.200206089; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Heinsbroek SEM, 2006, J IMMUNOL, V176, P5513, DOI 10.4049/jimmunol.176.9.5513; Kitamura T, 1998, INT J HEMATOL, V67, P351; Koedel U, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000461; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Nuzzi PA, 2007, MOL BIOL CELL, V18, P795, DOI 10.1091/mbc.E06-09-0876; Rosas M, 2008, J IMMUNOL, V181, P3549, DOI 10.4049/jimmunol.181.5.3549; Rosas M, 2010, J LEUKOCYTE BIOL, V88, P169, DOI 10.1189/jlb.0809548; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Taylor PR, 2004, J IMMUNOL, V172, P1157, DOI 10.4049/jimmunol.172.2.1157; Taylor PR, 2003, EUR J IMMUNOL, V33, P2090, DOI 10.1002/eji.200324003; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Wang GG, 2006, NAT METHODS, V3, P287, DOI 10.1038/NMETH865	20	28	28	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2011	25	6					1972	1982		10.1096/fj.10-178517	http://dx.doi.org/10.1096/fj.10-178517			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21368104				2022-12-28	WOS:000291023800020
J	Montanuy, I; Alejo, A; Alcami, A				Montanuy, Imma; Alejo, Ali; Alcami, Antonio			Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses	FASEB JOURNAL			English	Article						immune evasion; cytokine; smallpox; innate immunity	VACCINIA VIRUS; HEPARAN-SULFATE; ALPHA/BETA INTERFERON; ECTROMELIA-VIRUS; HUMAN MONKEYPOX; A27L PROTEIN; MICE LACKING; PROTEOGLYCANS; RECEPTOR; INHIBITION	Eradication of smallpox was accomplished 30 yr ago, but poxviral infections still represent a public health concern due to the potential release of variola virus or the emergence of zoonotic poxviruses, such as monkeypox virus. A critical determinant of poxvirus virulence is the inhibition of interferons (IFNs) by the virus-encoded type I IFN-binding protein (IFN alpha/beta BP). This immunomodulatory protein is secreted and has the unique property of interacting with the cell surface in order to prevent IFN-mediated antiviral responses. However, the mechanism of its attachment to the cell surface remains unknown. Using surface plasmon resonance and cell-binding assays, we report that the IFN alpha/beta BP from vaccinia virus, the smallpox vaccine, interacts with cell surface glycosaminoglycans (GAGs). Analysis of the contribution of different regions of the protein to cell surface binding demonstrated that clusters of basic residues in the first immunoglobulin domain mediate GAG interactions. Furthermore, mutation of the GAG-interaction motifs does not affect its IFN-binding and -blocking capacity. Functional conservation of GAG-binding sites is demonstrated for the IFN alpha/beta BP from variola and monkeypox viruses, extending our understanding of immune modulation by the most virulent human poxviruses. These results are relevant for the design of improved vaccines and intervention strategies.-Montanuy, I., Alejo, A., Alcami, A. Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses. FASEB J. 25, 1960-1971 (2011). www.fasebj.org	[Montanuy, Imma; Alcami, Antonio] CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Montanuy, Imma; Alcami, Antonio] Univ Autonoma Madrid, Madrid, Spain; [Alejo, Ali] Inst Nacl Invest & Tecnol Agr & Alimentaria, Ctr Invest Sanidad Anim, Madrid, Spain; [Alcami, Antonio] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA); Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Alcami, A (corresponding author), Ctr Biol Mol Severo Ochoa CSIC UAM, 1 Campus Cantoblanco, Madrid 28049, Spain.	aalcami@cbm.uam.es	Alcami, Antonio/F-8512-2015; Alejo, Ali/AAF-1477-2020	Alcami, Antonio/0000-0002-3333-6016; Alejo, Ali/0000-0002-1613-6063; Montanuy Sellart, Inmaculada/0000-0001-9743-112X	U.S. National Institute of Allergy and Infectious Diseases [U54AI057160-07]; Wellcome Trust; Comunidad de Madrid; MRC [G9800943] Funding Source: UKRI; Medical Research Council [G9800943] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057160] Funding Source: NIH RePORTER	U.S. National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); Comunidad de Madrid(Comunidad de Madrid); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank members of the laboratory for helpful suggestions and R. Martin for technical assistance. This work was supported by U.S. National Institute of Allergy and Infectious Diseases grant U54AI057160-07 to the Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases and grants from the Wellcome Trust and Comunidad de Madrid.	Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; Alcami A, 2000, J VIROL, V74, P11230, DOI 10.1128/JVI.74.23.11230-11239.2000; Antoine G, 1998, VIROLOGY, V244, P365, DOI 10.1006/viro.1998.9123; Avirutnan P, 2007, PLOS PATHOG, V3, P1798, DOI 10.1371/journal.ppat.0030183; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Bartlett AH, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001367; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COLAMONICI OR, 1995, J BIOL CHEM, V270, P15974, DOI 10.1074/jbc.270.27.15974; Copeland R, 2008, BIOCHEMISTRY-US, V47, P5774, DOI 10.1021/bi800205t; de Marco MDF, 2010, FASEB J, V24, P1479, DOI 10.1096/fj.09-144733; Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000; Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9; Esteban DJ, 2005, J GEN VIROL, V86, P2645, DOI 10.1099/vir.0.81090-0; Esteban DJ, 2004, J GEN VIROL, V85, P1291, DOI 10.1099/vir.0.79902-0; Gandhi NS, 2008, CHEM BIOL DRUG DES, V72, P455, DOI 10.1111/j.1747-0285.2008.00741.x; Golden JW, 2010, CLIN VACCINE IMMUNOL, V17, P1656, DOI 10.1128/CVI.00235-10; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; Hsiao JC, 1998, J VIROL, V72, P8374, DOI 10.1128/JVI.72.10.8374-8379.1998; Huang JY, 2007, P NATL ACAD SCI USA, V104, P9822, DOI 10.1073/pnas.0610352104; KARUPIAH G, 1993, J VIROL, V67, P4214, DOI 10.1128/JVI.67.7.4214-4226.1993; Likos AM, 2005, J GEN VIROL, V86, P2661, DOI 10.1099/vir.0.81215-0; Lin CL, 2000, J VIROL, V74, P3353, DOI 10.1128/JVI.74.7.3353-3365.2000; Liszewski MK, 2008, J IMMUNOL, V181, P4199, DOI 10.4049/jimmunol.181.6.4199; Meng XZ, 2009, J VIROL, V83, P10627, DOI 10.1128/JVI.01260-09; MORIKAWA S, 1993, VIROLOGY, V193, P753, DOI 10.1006/viro.1993.1184; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Perdiguero B, 2009, J INTERF CYTOK RES, V29, P581, DOI 10.1089/jir.2009.0073; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299; Rimoin AW, 2010, P NATL ACAD SCI USA, V107, P16262, DOI 10.1073/pnas.1005769107; RODRIGUEZ JR, 1991, VIROLOGY, V185, P929, DOI 10.1016/0042-6822(91)90575-V; Ruiz-Arguello MB, 2008, J VIROL, V82, P917, DOI 10.1128/JVI.02111-07; Sambrook J., 2001, MOL CLONING LAB MANU; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shih PC, 2009, J BIOL CHEM, V284, P36535, DOI 10.1074/jbc.M109.037267; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; Smith GL, 2002, NAT REV IMMUNOL, V2, P521, DOI 10.1038/nri845; Smith SA, 2000, J VIROL, V74, P5659, DOI 10.1128/JVI.74.12.5659-5666.2000; Smith VP, 2002, J VIROL, V76, P1124, DOI 10.1128/JVI.76.3.1124-1134.2002; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; Urbinati C, 2004, FEBS LETT, V568, P171, DOI 10.1016/j.febslet.2004.05.033; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; Versteeg GA, 2010, CURR OPIN MICROBIOL, V13, P508, DOI 10.1016/j.mib.2010.05.009; Xiang Y, 2003, J VIROL, V77, P2623, DOI 10.1128/JVI.77.4.2623-2630.2003; Xu RH, 2008, J EXP MED, V205, P981, DOI 10.1084/jem.20071854; Zhang LJ, 2006, METHOD ENZYMOL, V416, P205, DOI 10.1016/S0076-6879(06)16013-9	53	33	34	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1960	1971		10.1096/fj.10-177188	http://dx.doi.org/10.1096/fj.10-177188			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21372110	Green Published			2022-12-28	WOS:000291023800019
J	Li, LH; Zhang, H; Varrin-Doyer, M; Zamvil, SS; Verkman, AS				Li, Lihua; Zhang, Hua; Varrin-Doyer, Michel; Zamvil, Scott S.; Verkman, A. S.			Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation	FASEB JOURNAL			English	Article						water channel; neuromyelitis optics; astrocyte; EAE	NEUROMYELITIS-OPTICA; EXTRACELLULAR-SPACE; WATER; MICE; BRAIN; LACKING; MOUSE; EXPRESSION; DELETION; LESIONS	Aquaporin-4 (AQP4) deficiency in mice reduces neuroinflammation in experimental autoimmune encephalomyelitis (EAE) produced by active immunization with myelin oligodendrocyte glycoprotein peptide (MOG). Potential mechanisms for the protective effect of AQP4 deficiency were investigated, including AQP4-dependent leukocyte and microglia cell function, immune cell entry in the central nervous system (CNS), intrinsic neuroinflammation, and humoral immune response. As we found with active-immunization EAE, neuroinflammation was greatly reduced in AQP4-knockout mice in adoptive-transfer EAE. AQP4 was absent in immune cells, including activated T lymphocytes. The CNS migration of fluorescently labeled, MOG-sensitized T lymphocytes was comparable in wild-type and AQP4-knockout mice. Microglia did not express AQP4. Serum anti-AQP4 antibodies were absent in EAE. Remarkably, intracerebral injection of LPS produced much greater neuroinflammation in wild-type than in AQP4-knockout mice, and cytokine (TNF-alpha and IL-6) secretion was reduced in astrocyte cultures from AQP4-knockout mice. Adenovirus-mediated expression of AQP4, or of an unrelated aquaporin, AQP1, increased cytokine secretion in astrocyte and nonastrocyte cell cultures, supporting the involvement of aquaporin water permeability in cytokine secretion. Our data suggest an intrinsic proinflammatory role of AQP4 involving AQP4-dependent astrocyte swelling and cytokine release. Reduction in AQP4 water transport may be protective in neuroinflammatory CNS diseases.-Li, L., Zhang, H., Varrin-Doyer, M., Zamvil, S. S., Verkman, A. S. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J. 25, 1556-1566 (2011). www.fasebj.org	[Li, Lihua; Zhang, Hua; Verkman, A. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Li, Lihua; Zhang, Hua; Verkman, A. S.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Varrin-Doyer, Michel; Zamvil, Scott S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu			Guthy-Jackson Charitable Foundation; U.S. National Institutes of Health (NIH) [DK35124, EY13574, HL73856, DK72517, DK86125, EB00415]; NIH [AI73737, NS63008]; National Multiple Sclerosis Society [RG4124]; Maisin Foundation; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, RC1DK086125, R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS063008] Funding Source: NIH RePORTER	Guthy-Jackson Charitable Foundation; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society); Maisin Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the Guthy-Jackson Charitable Foundation (A. S. V. and S.S.Z.); U.S. National Institutes of Health (NIH) grants DK35124, EY13574, HL73856, DK72517, DK86125, and EB00415 (A. S. V.); and NIH grants AI73737 and NS63008, National Multiple Sclerosis Society grant RG4124, and the Maisin Foundation (S.S.Z.).	Auguste KI, 2007, FASEB J, V21, P108, DOI 10.1096/fj.06-6848com; Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; Bennett JL, 2009, ANN NEUROL, V66, P617, DOI 10.1002/ana.21802; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Bloch O, 2006, J CEREBR BLOOD F MET, V26, P1527, DOI 10.1038/sj.jcbfm.9600306; Cho SJ, 2002, P NATL ACAD SCI USA, V99, P4720, DOI 10.1073/pnas.072083499; Martin MD, 2007, FRONT BIOSCI-LANDMRK, V12, P2735, DOI 10.2741/2268; Kimura A, 2010, ANN NEUROL, V67, P794, DOI 10.1002/ana.22023; Kinoshita M, 2009, BIOCHEM BIOPH RES CO, V386, P623, DOI 10.1016/j.bbrc.2009.06.085; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kroenke MA, 2008, J EXP MED, V205, P1535, DOI 10.1084/jem.20080159; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Li J, 2002, INVEST OPHTH VIS SCI, V43, P573; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; Li LH, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-94; Lu DC, 2008, FASEB J, V22, P3216, DOI 10.1096/fj.07-104836; Lyons JA, 2002, EUR J IMMUNOL, V32, P1905, DOI 10.1002/1521-4141(200207)32:7<1905::AID-IMMU1905>3.0.CO;2-L; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mills SY, 2007, COMPLEMENT THER MED, V15, P1, DOI [10.1002/0471142735.im1501s77, 10.1002/0471142735.im1501s88]; Misu T, 2007, BRAIN, V130, P1224, DOI 10.1093/brain/awm047; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Ransohoff RM, 2006, J CLIN INVEST, V116, P2313, DOI 10.1172/JCI29834; Roemer SF, 2007, BRAIN, V130, P1194, DOI 10.1093/brain/awl371; Saadoun S, 2009, NEUROSCIENCE, V161, P764, DOI 10.1016/j.neuroscience.2009.03.069; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Saadoun S, 2010, BRAIN, V133, P349, DOI 10.1093/brain/awp309; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Sugiya H, 2006, J MEMBRANE BIOL, V210, P155, DOI 10.1007/s00232-005-0853-5; Swanson RA, 1997, J NEUROSCI, V17, P932; Tomas-Camardiel M, 2004, J NEUROCHEM, V91, P891, DOI 10.1111/j.1471-4159.2004.02759.x; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Weber MS, 2010, ANN NEUROL, V68, P369, DOI 10.1002/ana.22081; Weinshenker BG, 2006, DIS MARKERS, V22, P197, DOI 10.1155/2006/586306; Yao XM, 2008, J NEUROSCI, V28, P5460, DOI 10.1523/JNEUROSCI.0257-08.2008; Zhang H, 2010, BIOPHYS J, V99, P1284, DOI 10.1016/j.bpj.2010.06.023	38	133	149	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1556	1566		10.1096/fj.10-177279	http://dx.doi.org/10.1096/fj.10-177279			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21257712	Green Published			2022-12-28	WOS:000290023800013
J	Kraemer, S; Lue, HQ; Zernecke, A; Kapurniotu, A; Andreetto, E; Frank, R; Lennartz, B; Weber, C; Bernhagen, J				Kraemer, Sandra; Lue, Hongqi; Zernecke, Alma; Kapurniotu, Aphrodite; Andreetto, Erika; Frank, Ronald; Lennartz, Birgitt; Weber, Christian; Bernhagen, Juergen			MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism	FASEB JOURNAL			English	Article						CLF chemokine; G-protein-coupled receptor; cytokine; domain analysis; structure-activity analysis	MIGRATION INHIBITORY FACTOR; PROTEIN-COUPLED RECEPTOR; IMMATURE DENDRITIC CELLS; TRANSFER-RNA SYNTHETASE; CRYSTAL-STRUCTURE; AMINO-TERMINUS; HIV-1 ENTRY; INTERLEUKIN-8 RECEPTOR; MOLECULAR-DYNAMICS; LIGAND SELECTIVITY	Macrophage migration inhibitory factor (MIF) is a cytokine that mediates inflammatory diseases. MIF promotes atherogenic leukocyte recruitment through a promiscuous, yet highly affine, interaction with CXCR2 and CXCR4. Binding to CXCR2 is dependent on a pseudo-(E)LR motif in MIF, but a second interaction site has been elusive. Here we identified an N-like loop in MIF, suggesting that MIF binding to CXCR2 follows the 2-site binding mode of bona fide chemokines. For MIF, the model predicts interactions between the N-like loop and the CXCR2 N domain (site 1) and pseudo-(E) LR and extracellular loops (ELs) of CXCR2 (site 2). Applying biophysical and peptide array analysis, we demonstrated an interaction between MIF and the CXCR2 N domain, which was pseudo-(E) LR independent. Peptide array analysis also indicated that the pseudo-(E) LR motif is responsible for MIF binding to EL2 and 3. Notably, peptides MIF-(40-49) and MIF-(47-56), representing N-like-loop-derived peptides, but not a scrambled control peptide, significantly blocked MIF/CXCR2 binding, MIF-mediated monocyte arrest under flow on aortic endothelial cells in vitro (IC50: 1.24x10(-6) M), and MIF-dependent monocyte adhesion to atherosclerotic mouse carotid arteries in vivo. Thus, the N-like loop in MIF is critical for MIF's noncognate interaction with CXCR2 and proatherogenic functions. The 2-site binding model that explains chemokine receptor activation also applies to MIF.-Kraemer, S., Lue, H., Zernecke, A., Kapurniotu, A., Andreetto, E., Frank, R., Lennartz, B., Weber, C., Bernhagen, J. MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. FASEB J. 25, 894-906 (2011). www.fasebj.org	[Kraemer, Sandra; Lue, Hongqi; Lennartz, Birgitt; Bernhagen, Juergen] Rhein Westfal TH Aachen, Inst Biochem & Mol Cell Biol, D-52074 Aachen, Germany; [Zernecke, Alma] Univ Wurzburg, Rudolf Virchow Ctr, Deutsch Forsch Gemeinschaft Res Ctr Expt Biomed, Wurzburg, Germany; [Kapurniotu, Aphrodite; Andreetto, Erika] Tech Univ Munich, Div Peptide Biochem, Munich, Germany; [Frank, Ronald] Helmholtz Ctr Infect Res, Dept Biol Chem, Braunschweig, Germany; [Weber, Christian] Univ Munich, Inst Cardiovasc Prevent, Munich, Germany	RWTH Aachen University; University of Wurzburg; Technical University of Munich; Helmholtz Association; Helmholtz-Center for Infection Research; University of Munich	Bernhagen, J (corresponding author), Rhein Westfal TH Aachen, Inst Biochem & Mol Cell Biol, Pauwelsstr 30, D-52074 Aachen, Germany.	jbernhagen@ukaachen.de	Weber, Christian/AAW-2153-2020	Weber, Christian/0000-0003-4610-8714	Deutsche Forschungsgemeinschaft (DFG) [DFG-FOR809, Be1977/4-2, TP1, Ze 827/1-1, TP3, We 1913/11-1, TP4]; Carolus Therapeutics (San Diego, CA, USA)	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Carolus Therapeutics (San Diego, CA, USA)	The authors thank M. Dewor, Sabine Winkler, Susan Daenicke, and M. Drechsler for technical assistance and helpful advice with the cell culture, peptide handling, and mice. The authors also thank Javier Navarro (University of Texas Medical Branch, Galveston, TX, USA) for kindly providing the CXCR1/CXCR2 chimera constructs and M. Fioroni and U. Schwaneberg for help with the VMD structural analysis software. The authors are grateful to J. Schultz for invaluable discussions on the MIF peptides and ligand/receptor interface. This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) to J.B., C.W., and A.Z. (DFG-FOR809 projects: Be1977/4-2, TP1; Ze 827/1-1, TP3; We 1913/11-1, TP4) and in part by Carolus Therapeutics (San Diego, CA, USA; peptide supply and spot arrays).	Andreetto E, 2010, ANGEW CHEM INT EDIT, V49, P3081, DOI 10.1002/anie.200904902; Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Booth V, 2002, BIOCHEMISTRY-US, V41, P10418, DOI 10.1021/bi026020q; Burger-Kentischer A, 2002, CIRCULATION, V105, P1561, DOI 10.1161/01.CIR.0000012942.49244.82; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Degryse B, 2003, FEBS LETT, V553, P11, DOI 10.1016/S0014-5793(03)01027-5; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Hammond MEW, 1996, J BIOL CHEM, V271, P8228, DOI 10.1074/jbc.271.14.8228; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Heveker N, 2001, MOL PHARMACOL, V59, P1418, DOI 10.1124/mol.59.6.1418; Hoover DM, 2002, J BIOL CHEM, V277, P37647, DOI 10.1074/jbc.M203907200; Howard OMZ, 2002, J EXP MED, V196, P781, DOI 10.1084/jem.20020186; Huang XQ, 2003, BIOPHYS J, V84, P171, DOI 10.1016/S0006-3495(03)74840-1; Huynh N, 2008, BIOPOLYMERS, V89, P52, DOI 10.1002/bip.20851; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Katancik JA, 2000, CYTOKINE, V12, P1480, DOI 10.1006/cyto.2000.0742; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Murphy PM, 2000, PHARMACOL REV, V52, P145; Noels H, 2009, TRENDS CARDIOVAS MED, V19, P76, DOI 10.1016/j.tcm.2009.05.002; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perez-Canadillas JM, 2001, J BIOL CHEM, V276, P28372, DOI 10.1074/jbc.M103121200; Prado GN, 2007, BIOCHEMISTRY-US, V46, P8961, DOI 10.1021/bi7004043; Qian YQ, 1999, J MOL BIOL, V294, P1065, DOI 10.1006/jmbi.1999.3333; Rajagopalan L, 2004, J BIOL CHEM, V279, P30000, DOI 10.1074/jbc.M313883200; Rajagopalan L, 2006, BIOSCIENCE REP, V26, P325, DOI 10.1007/s10540-006-9025-9; Rajarathnam K, 2006, BIOCHEMISTRY-US, V45, P7882, DOI 10.1021/bi0605944; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Sallusto F, 2008, NAT IMMUNOL, V9, P949, DOI 10.1038/ni.f.214; Schwartz V, 2009, FEBS LETT, V583, P2749, DOI 10.1016/j.febslet.2009.07.058; Serrano-Vega MJ, 2008, P NATL ACAD SCI USA, V105, P877, DOI 10.1073/pnas.0711253105; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Taylor K, 2008, J BIOL CHEM, V283, P6631, DOI 10.1074/jbc.M709238200; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Veldkamp CT, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1160755; Veldkamp CT, 2006, J MOL BIOL, V359, P1400, DOI 10.1016/j.jmb.2006.04.052; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; WEBER C, 1993, EUR J IMMUNOL, V23, P852, DOI 10.1002/eji.1830230413; Weber C, 2008, P NATL ACAD SCI USA, V105, P16278, DOI 10.1073/pnas.0804017105; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zernecke A, 2008, CIRCULATION, V117, P1594, DOI 10.1161/CIRCULATIONAHA.107.729125	74	43	43	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2011	25	3					894	906		10.1096/fj.10-168559	http://dx.doi.org/10.1096/fj.10-168559			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21106938				2022-12-28	WOS:000287806200010
J	Louboutin, JP; Chekmasova, A; Marusich, E; Agrawal, L; Strayer, DS				Louboutin, Jean-Pierre; Chekmasova, Alena; Marusich, Elena; Agrawal, Lokesh; Strayer, David S.			Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage	FASEB JOURNAL			English	Article						chemokine receptors; neuroregeneration; bone marrow	BLOOD-BRAIN-BARRIER; TEMPORAL-LOBE EPILEPSY; FOCAL CEREBRAL-ISCHEMIA; CHEMOKINE RECEPTOR CCR5; CENTRAL-NERVOUS-SYSTEM; MONOCYTE CHEMOATTRACTANT PROTEIN-1; SECRETORY PHOSPHOLIPASE A(2); INDUCED STATUS EPILEPTICUS; VIVO GENE-TRANSFER; ENDOTHELIAL-CELLS	Chemokines may play a role in leukocyte migration across the blood-brain barrier (BBB) during neuroinflammation and other neuropathological processes, such as epilepsy. We investigated the role of the chemokine receptor CCR5 in seizures. We used a rat model based on intraperitoneal kainic acid (KA) administration. Four months before KA injection, adult rats were given femoral intramarrow inoculations of SV (RNAiR5-RevM10.AU1), which carries an interfering RNA (RNAi) against CCR5, plus a marker epitope (AU1), or its monofunctional RNAi-carrying homologue, SV(RNAiR5). This treatment lowered expression of CCR5 in circulating cells. In control rats, seizures induced elevated expression of CCR5 ligands MIP-1 alpha and RANTES in the microvasculature, increased BBB leakage and CCR5(+) cells, as well as neuronal loss, inflammation, and gliosis in the hippocampi. Animals given either the bifunctional or the monofunctional vector were largely protected from KA-induced seizures, neuroinflammation, BBB damage, and neuron loss. Brain CCR5 mRNA was reduced. Rats receiving RNAiR5-bearing vectors showed far greater repair responses: increased neuronal proliferation, and decreased production of MIP-1 alpha and RANTES. Controls received unrelated SV(BUGT) vectors. Decrease in CCR5 in circulating cells strongly protected from excitotoxin-induced seizures, BBB leakage, CNS injury, and inflammation, and facilitated neurogenic repair.-Louboutin, J.-P., Chekmasova, A., Marusich, E., Agrawal, L., Strayer, D. S. Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage. FASEB J. 25, 737-753 (2011). www.fasebj.org	[Louboutin, Jean-Pierre; Chekmasova, Alena; Marusich, Elena; Agrawal, Lokesh; Strayer, David S.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol, Philadelphia, PA 19107 USA	Jefferson University	Louboutin, JP (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol, 1020 Locust St,Rm 251, Philadelphia, PA 19107 USA.	jplouboutin@hotmail.com		MARUSICH, ELENA/0000-0003-1943-6245	National Institutes of Health [MH70287]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH070287] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The anti-alpha 4 integrin antibody was a kind gift from Dr. A. Aplin (Thomas Jefferson University). This work was supported by grant MH70287 from the National Institutes of Health.	Agrawal L, 2006, GENE THER, V13, P1645, DOI 10.1038/sj.gt.3302821; Agrawal L, 2009, J GEN VIROL, V90, P710, DOI 10.1099/vir.0.006205-0; Andjelkovic AV, 2000, J NEUROCHEM, V75, P1898, DOI 10.1046/j.1471-4159.2000.0751898.x; Andjelkovic AV, 1999, J CELL BIOL, V145, P403, DOI 10.1083/jcb.145.2.403; Arganaraz GA, 2004, BRAIN RES, V1013, P30, DOI 10.1016/j.brainres.2004.03.046; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Balistreri CR, 2006, ANN NY ACAD SCI, V1089, P454, DOI 10.1196/annals.1386.012; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Bigini P, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-71; Bolton SJ, 1998, EXP NEUROL, V154, P231, DOI 10.1006/exnr.1998.6927; Bonde S, 2006, EUR J NEUROSCI, V23, P965, DOI 10.1111/j.1460-9568.2006.04635.x; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Bregola G, 1999, NEUROSCIENCE, V92, P1043, DOI 10.1016/S0306-4522(99)00075-5; Briones MA, 2001, CORONARY ARTERY DIS, V12, P179, DOI 10.1097/00019501-200105000-00004; Chen ZG, 2003, J NEUROCHEM, V86, P61, DOI 10.1046/j.1471-4159.2003.01807.x; Chui R, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-1; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; Combarros O, 2004, NEUROSCI LETT, V366, P312, DOI 10.1016/j.neulet.2004.05.058; Cordelier P, 2004, GENE THER, V11, P1627, DOI 10.1038/sj.gt.3302329; Couture R, 2001, EUR J PHARMACOL, V429, P161, DOI 10.1016/S0014-2999(01)01318-8; Cowell RM, 2002, STROKE, V33, P795, DOI 10.1161/hs0302.103740; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; Dos Santos AC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-49; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Ekdahl CT, 2001, EUR J NEUROSCI, V14, P937, DOI 10.1046/j.0953-816x.2001.01713.x; Fabene PF, 2008, NAT MED, V14, P1377, DOI 10.1038/nm.1878; Farooqui AA, 2010, MOL NEUROBIOL, V41, P267, DOI 10.1007/s12035-009-8091-y; Frank S, 2000, BIOCHEM J, V347, P265, DOI 10.1042/0264-6021:3470265; Galasso JM, 1998, AM J PATHOL, V153, P1631, DOI 10.1016/S0002-9440(10)65752-5; Galimberti D, 2004, J NEUROL SCI, V225, P79, DOI 10.1016/j.jns.2004.07.005; Gorter JA, 2006, J NEUROSCI, V26, P11083, DOI 10.1523/JNEUROSCI.2766-06.2006; Gourmala NG, 1999, NEUROSCIENCE, V88, P1255, DOI 10.1016/S0306-4522(98)00295-4; Greenwood J, 2002, VASC PHARMACOL, V38, P315, DOI 10.1016/S1537-1891(02)00199-4; Hattiangady B, 2004, NEUROBIOL DIS, V17, P473, DOI 10.1016/j.nbd.2004.08.008; KIM JS, 1995, J NEUROIMMUNOL, V56, P127, DOI 10.1016/0165-5728(94)00138-E; Kleen JK, 2008, NAT MED, V14, P1309, DOI 10.1038/nm1208-1309; Kotani A, 2002, IMMUNOL LETT, V84, P1, DOI 10.1016/S0165-2478(02)00082-2; Kremlev SG, 2004, J NEUROIMMUNOL, V149, P1, DOI 10.1016/j.jneuroim.2003.11.012; Lee TS, 2007, MOL MED, V13, P1, DOI 10.2119/2006-00079.Lee; Li M, 2009, J IMMUNOL, V182, P5778, DOI 10.4049/jimmunol.0803013; Liu BL, 2005, BLOOD, V106, P2655, DOI 10.1182/blood-2005-01-0028; Liu JL, 1998, J NEUROSCI, V18, P7768; Louboutin JP, 2007, GENE THER, V14, P1650, DOI 10.1038/sj.gt.3303030; Louboutin JP, 2007, GENE THER, V14, P939, DOI 10.1038/sj.gt.3302939; Louboutin JP, 2007, J GENE MED, V9, P843, DOI 10.1002/jgm.1084; Louboutin JP, 2006, STEM CELLS, V24, P2801, DOI 10.1634/stemcells.2006-0124; Louboutin JP, 2010, NEUROBIOL DIS, V38, P313, DOI 10.1016/j.nbd.2010.02.007; Louboutin JP, 2009, NEUROBIOL DIS, V34, P462, DOI 10.1016/j.nbd.2009.03.003; Man SM, 2007, BRAIN PATHOL, V17, P243, DOI 10.1111/j.1750-3639.2007.00067.x; Mandel RJ, 1998, J NEUROSCI, V18, P4271; Manley NC, 2007, BRAIN RES, V1182, P138, DOI 10.1016/j.brainres.2007.08.092; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Mazzuferi M, 2005, NEUROSCIENCE, V135, P979, DOI 10.1016/j.neuroscience.2005.06.070; Mennicken F, 2002, GLIA, V37, P124, DOI 10.1002/glia.10021; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mohapel P, 2004, NEUROBIOL DIS, V15, P196, DOI 10.1016/j.nbd.2003.11.010; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morinville A, 2004, J NEUROSCI, V24, P5549, DOI 10.1523/JNEUROSCI.2719-03.2004; Murugesan G, 2003, J MOL CELL CARDIOL, V35, P1375, DOI 10.1016/j.yjmcc.2003.08.004; Nikonov AA, 2005, P NATL ACAD SCI USA, V102, P18688, DOI 10.1073/pnas.0505241102; Parathath SR, 2006, J CELL SCI, V119, P339, DOI 10.1242/jcs.02734; Perosa SR, 2007, HIPPOCAMPUS, V17, P26, DOI 10.1002/hipo.20239; Pocock J M, 2001, Prog Brain Res, V132, P555; Quandt J, 2004, J NEUROPATH EXP NEUR, V63, P350, DOI 10.1093/jnen/63.4.350; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rizzi M, 2003, NEUROBIOL DIS, V14, P494, DOI 10.1016/j.nbd.2003.08.001; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; Rosell DR, 2003, NEUROSCIENCE, V122, P329, DOI 10.1016/S0306-4522(03)00593-1; Rouger K, 2001, AM J PATHOL, V158, P355, DOI 10.1016/S0002-9440(10)63976-4; Sandhya TL, 1998, BRAIN RES, V788, P223, DOI 10.1016/S0006-8993(97)01552-7; Sauter BV, 2000, GASTROENTEROLOGY, V119, P1348, DOI 10.1053/gast.2000.19577; Sawa Y, 2008, CELL TISSUE RES, V333, P237, DOI 10.1007/s00441-008-0625-5; Schober A, 2008, ARTERIOSCL THROM VAS, V28, P1950, DOI 10.1161/ATVBAHA.107.161224; Schreiber TH, 2007, BLOOD, V109, P1381, DOI 10.1182/blood-2006-07-032995; Seguin R, 2003, J NEUROPATH EXP NEUR, V62, P412, DOI 10.1093/jnen/62.4.412; Shukaliak JA, 2000, J NEUROPATH EXP NEUR, V59, P339, DOI 10.1093/jnen/59.5.339; Signoret N, 1998, J CELL SCI, V111, P2819; Strayer DA, 1999, J CELL PHYSIOL, V181, P375, DOI 10.1002/(SICI)1097-4652(199912)181:3<375::AID-JCP1>3.0.CO;2-8; Strayer DS, 1997, GENE THER, V4, P219, DOI 10.1038/sj.gt.3300368; Strayer DS, 2001, METH MOL B, V165, P103; Subileau EA, 2009, J NEUROPATH EXP NEUR, V68, P227, DOI 10.1097/NEN.0b013e318197eca7; Takami S, 2002, J CEREBR BLOOD F MET, V22, P780, DOI 10.1097/00004647-200207000-00003; THEELE DP, 1993, GLIA, V7, P5, DOI 10.1002/glia.440070104; Thwin MM, 2003, EXP BRAIN RES, V150, P427, DOI 10.1007/s00221-003-1476-7; Tripathy D, 2007, J ALZHEIMERS DIS, V11, P447; Ubogu EE, 2006, CELL IMMUNOL, V243, P19, DOI 10.1016/j.cellimm.2006.12.001; Ubogu EE, 2006, J NEUROIMMUNOL, V179, P132, DOI 10.1016/j.jneuroim.2006.06.004; van Gassen KLI, 2008, EPILEPSIA, V49, P1055, DOI 10.1111/j.1528-1167.2007.01470.x; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vezzani A, 1999, J NEUROSCI, V19, P5054; Wang HK, 2008, J NEUROSCI, V28, P1721, DOI 10.1523/JNEUROSCI.4973-07.2008; Won SJ, 1999, NEUROSCIENCE, V94, P83, DOI 10.1016/S0306-4522(99)00196-7; Xia MQ, 1998, AM J PATHOL, V153, P31, DOI 10.1016/S0002-9440(10)65542-3; Xu JH, 2009, NEUROPATH APPL NEURO, V35, P496, DOI 10.1111/j.1365-2990.2009.01022.x; YABUUCHI K, 1993, MOL BRAIN RES, V20, P153, DOI 10.1016/0169-328X(93)90121-5; Yegin A, 2002, ACTA NEUROL SCAND, V106, P258, DOI 10.1034/j.1600-0404.2002.01238.x; Yeligar SM, 2009, J IMMUNOL, V183, P5964, DOI 10.4049/jimmunol.0901564; Youssef S, 1999, J AUTOIMMUN, V13, P21, DOI 10.1006/jaut.1999.0306; Zozulya AL, 2007, J IMMUNOL, V178, P520, DOI 10.4049/jimmunol.178.1.520	101	57	59	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2011	25	2					737	753		10.1096/fj.10-161851	http://dx.doi.org/10.1096/fj.10-161851			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20940264	Green Published			2022-12-28	WOS:000286724800031
J	Foretz, M; Hebrard, S; Guihard, S; Leclerc, J; Do Cruzeiro, M; Hamard, G; Niedergang, F; Gaudry, M; Viollet, B				Foretz, Marc; Hebrard, Sophie; Guihard, Soizic; Leclerc, Jocelyne; Do Cruzeiro, Marcio; Hamard, Ghislaine; Niedergang, Florence; Gaudry, Muriel; Viollet, Benoit			The AMPK gamma 1 subunit plays an essential role in erythrocyte membrane elasticity, and its genetic inactivation induces splenomegaly and anemia	FASEB JOURNAL			English	Article						knockout mice; protein kinase; RBC; membrane deformability; osmotic resistance	ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE; UPSTREAM KINASE; DISEASE; CELLS; MUTATION; GAMMA-3; BINDING; DEFORMABILITY; GENERATION	AMP-activated protein kinase (AMPK) is an alpha beta gamma heterotrimer conserved throughout evolution and important for energy sensing in all eukaryote cells. AMPK controls metabolism and various cellular events in response to both hormones and changes in cellular energy status. The gamma subunit senses intracellular energy status through the competitive binding of AMP and ATP. We show here that targeted disruption of the mouse AMPK gamma 1 gene (Prkag1) causes regenerative hemolytic anemia by increasing the sequestration of abnormal erythrocytes. Prkag1(-/-) mice displayed splenomegaly and iron accumulation due to compensatory splenic erythropoiesis and erythrophagocytosis. Moreover, AMPK gamma 1-deficient erythrocytes were highly resistant to osmotic hemolysis and poorly deformable in response to increasing shear stress, consistent with greater membrane rigidity. No change in cytoskeletal protein composition was observed; however, the phosphorylation level of adducin, a protein promoting the binding of spectrin to actin, was higher in AMPK gamma 1-deficient erythrocytes. Together, these results demonstrate that AMPK gamma 1 subunit is required for the maintenance of erythrocyte membrane elasticity.-Foretz, M., Hebrard, S., Guihard, S., Leclerc, J., Do Cruzeiro, M., Hamard, G., Niedergang, F., Gaudry, M., Viollet, B. The AMPK gamma 1 subunit plays an essential role in erythrocyte membrane elasticity, and its genetic inactivation induces splenomegaly and anemia. FASEB J. 25, 337-347 (2011). www.fasebj.org	[Foretz, Marc] Univ Paris 05, Inst Cochin, Dept Endocrinol Metab & Canc, CNRS,UMR 8104, F-75014 Paris, France; [Foretz, Marc; Hebrard, Sophie; Guihard, Soizic; Leclerc, Jocelyne; Do Cruzeiro, Marcio; Hamard, Ghislaine; Niedergang, Florence; Gaudry, Muriel; Viollet, Benoit] INSERM, U1016, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Foretz, M (corresponding author), Univ Paris 05, Inst Cochin, Dept Endocrinol Metab & Canc, CNRS,UMR 8104, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	marc.foretz@inserm.fr	FORETZ, Marc/O-7334-2017; Viollet, Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017; Gaudry, Murielle/N-5934-2018	FORETZ, Marc/0000-0001-7017-9032; Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Gaudry, Murielle/0000-0002-9281-2334; Niedergang, Florence/0000-0002-7064-830X	European Commission [LSHM-CT-2004-005272]	European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported by a European Commission integrated project (LSHM-CT-2004-005272). The authors thank Pierre Billuart (Institut Cochin, Paris, France) and Grahame Hardie (University of Dundee, Dundee, UK) for providing reagents. The authors also thank Virginie Siguret (Hopital Charles Foix, Ivry-sur-Seine, France) and Pierre Buffet (Institut Pasteur, Paris, France) for access to the Advia and the LORCA, respectively. The authors are grateful to Marc Uldry for critical reading of the manuscript.	Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Barnes BR, 2004, J BIOL CHEM, V279, P38441, DOI 10.1074/jbc.M405533200; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Boas FE, 1998, P NATL ACAD SCI USA, V95, P3077, DOI 10.1073/pnas.95.6.3077; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; COHEN CM, 1992, SEMIN HEMATOL, V29, P244; Costford SR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000903; Foller M, 2009, FASEB J, V23, P1072, DOI 10.1096/fj.08-121772; Gollob MH, 2001, CIRCULATION, V104, P3030, DOI 10.1161/hc5001.102111; Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Holzenberger M, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e92; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kalfa TA, 2006, BLOOD, V108, P3637, DOI 10.1182/blood-2006-03-005942; Kemp BE, 2004, J CLIN INVEST, V113, P182, DOI 10.1172/JCI200420846; Kress C, 1998, MAMM GENOME, V9, P998, DOI 10.1007/s003359900914; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Lee YM, 2008, J BIOL CHEM, V283, P33969, DOI 10.1074/jbc.M804469200; LIPOWSKY HH, 1986, AM J PHYSIOL, V250, pH908, DOI 10.1152/ajpheart.1986.250.6.H908; Liu Y, 2006, BLOOD, V108, P123, DOI 10.1182/blood-2005-11-4458; Mahlapuu M, 2004, AM J PHYSIOL-ENDOC M, V286, pE194, DOI 10.1152/ajpendo.00147.2003; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; Poueymirou WT, 2007, NAT BIOTECHNOL, V25, P91, DOI 10.1038/nbt1263; REINHART WH, 1990, EUR J CLIN INVEST, V20, P458, DOI 10.1111/j.1365-2362.1990.tb01884.x; Schaft J, 2001, GENESIS, V31, P6, DOI 10.1002/gene.1076; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stapleton D, 1997, FEBS LETT, V409, P452, DOI 10.1016/S0014-5793(97)00569-3; Torrance JD, 1980, IRON, P90; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Yu HY, 2004, AM J PHYSIOL-CELL PH, V286, pC283, DOI 10.1152/ajpcell.00319.2003	38	30	30	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					337	347		10.1096/fj.10-169383	http://dx.doi.org/10.1096/fj.10-169383			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20881209				2022-12-28	WOS:000285869500030
J	Guan, F; Schaffer, L; Handa, K; Hakomori, SI				Guan, Feng; Schaffer, Lana; Handa, Kazuko; Hakomori, Sen-itiroh			Functional role of gangliotetraosylceramide in epithelial-to-mesenchymal transition process induced by hypoxia and by TGF-beta	FASEB JOURNAL			English	Article						cobalt chloride; epithelial molecule; gene transfection; glycogene; glycosphingolipid	EMBRYONIC CORNEAL EPITHELIUM; CELL MOTILITY; CANCER-CELLS; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODIES; GM3 GANGLIOSIDE; CARCINOMA CELLS; UP-REGULATION; EXPRESSION; MECHANISMS	The epithelial-to-mesenchymal transition (EMT) is a basic cellular process that plays a key role in normal embryonic development and in cancer progression/metastasis. Our previous study indicated that EMT processes of mouse and human epithelial cells induced by TGF-beta display clear reduction of gangliotetraosylceramide (Gg4) and ganglioside GM2, suggesting a close association of glycosphingolipids (GSLs) with EMT. In the present study, using normal murine mammary gland (NMuMG) cells, we found that levels of Gg4 and of mRNA for the UDP-Gal: beta 1-3galactosyltransferase-4 (beta 3GalT4) gene, responsible for reduction of Gg4, were reduced in EMT induced by hypoxia (similar to 1% O-2) or CoCl2 (hypoxia mimic), similarly to that for TGF-beta-induced EMT. An increase in the Gg4 level by its exogenous addition or by transfection of the beta 3GalT4 gene inhibited the hypoxia-induced or TGF-beta-induced EMT process, including changes in epithelial cell morphology, enhanced motility, and associated changes in epithelial vs. mesenchymal molecules. We also found that Gg4 is closely associated with E-cadherin and beta-catenin. These results suggest that the beta 3GalT4 gene, responsible for Gg4 expression, is down-regulated in EMT; and Gg4 has a regulatory function in the EMT process in NMuMG cells, possibly through interaction with epithelial molecules important to maintain epithelial cell membrane organization.-Guan, F., Schaffer, L., Handa, K., and Hakomori, S. Functional role of gangliotetraosylceramide in epithelialto-mesenchymal transition process induced by hypoxia and by TGF-beta. FASEB J. 24, 4889-4903 (2010). www.fasebj.org	[Guan, Feng; Handa, Kazuko; Hakomori, Sen-itiroh] Pacific NW Res Fdn, Div Biomembrane Res, Seattle, WA 98122 USA; [Guan, Feng; Handa, Kazuko; Hakomori, Sen-itiroh] Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; [Guan, Feng; Handa, Kazuko; Hakomori, Sen-itiroh] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Schaffer, Lana] Scripps Res Inst, DNA Array Core Facil, La Jolla, CA 92037 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Scripps Research Institute	Hakomori, SI (corresponding author), Pacific NW Res Fdn, Div Biomembrane Res, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu			U.S. National Institutes of Health (NIH) National Cancer Institute [2R01-CA080054]; NIH National Institute of General Medical Sciences [GM62116]; NATIONAL CANCER INSTITUTE [R01CA080054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Ronald L. Schnaar (The Johns Hopkins University, Baltimore, MD, USA) for the kind donation of GD1a-1 and anti-GD1a antibody, Levi Lowder for construction of the expression vector, and Steve Anderson for assistance with preparation of the manuscript and figures. This work was funded primarily by the U.S. National Institutes of Health (NIH) National Cancer Institute (grant 2R01-CA080054 to S. H.) and in part by the NIH National Institute of General Medical Sciences (grant GM62116 to the Consortium for Functional Glycomics).	Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Bektas M, 2003, GLYCOCONJUGATE J, V20, P39, DOI 10.1023/B:GLYC.0000016741.88476.8b; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chachami G, 2004, AM J RESP CELL MOL, V31, P544, DOI 10.1165/rcmb.2003-0426OC; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; GOODMAN SL, 1985, CELL, V41, P1029, DOI 10.1016/S0092-8674(85)80083-0; Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C; Guan F, 2009, P NATL ACAD SCI USA, V106, P7461, DOI 10.1073/pnas.0902368106; Haase VH, 2009, KIDNEY INT, V76, P492, DOI 10.1038/ki.2009.222; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; HAKOMORI SI, 1977, VIROLOGY, V76, P485, DOI 10.1016/0042-6822(77)90231-8; HAKOMORI SI, 1971, VIROLOGY, V44, P609, DOI 10.1016/0042-6822(71)90375-8; HANSEN JES, 1990, J VIROL, V64, P2833, DOI 10.1128/JVI.64.6.2833-2840.1990; Hay ED, 2005, DEV DYNAM, V233, P706, DOI 10.1002/dvdy.20345; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Kirkland SC, 2009, BRIT J CANCER, V101, P320, DOI 10.1038/sj.bjc.6605143; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Koike T, 2004, P NATL ACAD SCI USA, V101, P8132, DOI 10.1073/pnas.0402088101; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Lester RD, 2007, J CELL BIOL, V178, P425, DOI 10.1083/jcb.200701092; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lopez PHH, 2008, BRAIN, V131, P1926, DOI 10.1093/brain/awn074; MAXZUD MK, 1995, J BIOL CHEM, V270, P20207, DOI 10.1074/jbc.270.34.20207; Mitsuzuka K, 2005, J BIOL CHEM, V280, P35545, DOI 10.1074/jbc.M505630200; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Prinetti A, 2010, GLYCOBIOLOGY, V20, P62, DOI 10.1093/glycob/cwp143; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Rofstad EK, 2002, CANCER RES, V62, P1847; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; STRAUS AH, 1989, EXP CELL RES, V183, P126, DOI 10.1016/0014-4827(89)90423-0; SUGRUE SP, 1982, DEV BIOL, V92, P97, DOI 10.1016/0012-1606(82)90154-3; SUGRUE SP, 1986, J CELL BIOL, V102, P1907, DOI 10.1083/jcb.102.5.1907; SUGRUE SP, 1981, J CELL BIOL, V91, P45, DOI 10.1083/jcb.91.1.45; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Todeschini AR, 2008, P NATL ACAD SCI USA, V105, P1925, DOI 10.1073/pnas.0709619104; Todeschini AR, 2007, J BIOL CHEM, V282, P8123, DOI 10.1074/jbc.M611407200; Toledo MS, 2005, J BIOL CHEM, V280, P16227, DOI 10.1074/jbc.M413713200; Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089; Uliana AS, 2006, TRAFFIC, V7, P604, DOI 10.1111/j.1600-0854.2006.00413.x; VANGSTED AJ, 1991, CANCER RES, V51, P2879; Vengellur A, 2004, TOXICOL SCI, V82, P638, DOI 10.1093/toxsci/kfh278; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yin J, 2006, CANCER RES, V66, P2937, DOI 10.1158/0008-5472.CAN-05-2615; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YOUNG WW, 1979, J EXP MED, V150, P1008, DOI 10.1084/jem.150.4.1008; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613	63	50	52	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4889	4903		10.1096/fj.10-162107	http://dx.doi.org/10.1096/fj.10-162107			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20720159	Green Published			2022-12-28	WOS:000284824400028
J	Messadi, E; Vincent, MP; Griol-Charhbili, V; Mandet, C; Colucci, J; Krege, JH; Bruneval, P; Bouby, N; Smithies, O; Alhenc-Gelas, F; Richer, C				Messadi, Erij; Vincent, Marie-Pascale; Griol-Charhbili, Violaine; Mandet, Chantal; Colucci, Juliana; Krege, John H.; Bruneval, Patrick; Bouby, Nadine; Smithies, Oliver; Alhenc-Gelas, Francois; Richer, Christine			Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia	FASEB JOURNAL			English	Article						renin inhibition; kinins; genetically modified mice	CORONARY-ARTERY-DISEASE; TISSUE KALLIKREIN; KNOCKOUT MICE; CARDIOVASCULAR HOMEOSTASIS; DELETION POLYMORPHISM; CARDIAC-HYPERTROPHY; GENE POLYMORPHISM; BLOOD PRESSURES; INFARCTION; BRADYKININ	Angiotensin I-converting enzyme (ACE; kininase II) levels in humans are genetically determined. ACE levels have been linked to risk of myocardial infarction, but the association has been inconsistent, and the causality underlying it remains undocumented. We tested the hypothesis that genetic variation in ACE levels influences myocardial tolerance to ischemia. We studied ischemia-reperfusion injury in mice bearing 1 (ACE1c), 2 (ACE2c, wild type), or 3 (ACE3c) functional copies of the ACE gene and displaying an ACE level range similar to humans. Infarct size in ACE1c was 29% lower than in ACE2c (P<0.05). Pretreatment with a kinin B2 receptor antagonist suppressed this reduction. In ACE3c, infarct size was the same as in ACE2c. But ischemic preconditioning, which reduced infarct size in ACE2c (similar to 63%, P<0.001) and ACE1c (-52%, P<0.05), was not efficient in ACE3c (-2%, NS, P<0.01 vs. ACE2c). In ACE3c, ischemic preconditioning did not decrease myocardial inflammation or cardiomyocyte apoptosis. Pretreatment with a renin inhibitor had no cardioprotective effect in ACE2c, but in ACE3c partially restored (38%) the cardioprotection of ischemic preconditioning. Thus, a modest genetic increase in ACE impairs myocardial tolerance to ischemia. ACE level plays a critical role in cardiac ischemia, through both kinin and angiotensin mediated mechanisms.-Messadi, E., Vincent, M.-P., Griol-Charhbili, V., Mandet, C., Colucci, J., Krege, J. H., Bruneval, P., Bouby, N., Smithies, O., Alhenc-Gelas, F., Richer, C. Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J. 24, 4691-4700 (2010). www.fasebj.org	[Messadi, Erij; Vincent, Marie-Pascale; Griol-Charhbili, Violaine; Mandet, Chantal; Colucci, Juliana; Bruneval, Patrick; Bouby, Nadine; Alhenc-Gelas, Francois; Richer, Christine] Ctr Rech Cordeliers, INSERM, U872, F-75270 Paris, France; [Mandet, Chantal; Bruneval, Patrick; Alhenc-Gelas, Francois] Univ Paris 05, Paris, France; [Krege, John H.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; [Bruneval, Patrick; Alhenc-Gelas, Francois; Richer, Christine] AP HP, Paris, France; [Smithies, Oliver] Univ N Carolina, Dept Pathol, Chapel Hill, NC USA; [Richer, Christine] Univ Paris Sud, F-94275 Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Eli Lilly; Assistance Publique Hopitaux Paris (APHP); University of North Carolina; University of North Carolina Chapel Hill; UDICE-French Research Universities; Universite Paris Saclay	Richer, C (corresponding author), Ctr Rech Cordeliers, INSERM, U872, 15 Rue Ecole Med, F-75270 Paris, France.	christine.giudicelli@crc.jussieu.fr	BOUBY, Nadine/AAF-5565-2021; Alhenc-Gelas, Francois/F-9511-2017; Bouby, Nadine/G-8621-2013; Colucci, Juliana/B-4513-2012	BOUBY, Nadine/0000-0002-2338-9480; Colucci, Juliana/0000-0003-3078-0514	INSERM; National Research Agency [ANR 05-PCOD-029]; Universities Paris-Descartes; Pierre and Marie Curie; Paris-Sud; European Community [LSHM-CT-2003-503254]; Ministere de la Recherche; Academie of Medecine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049277] Funding Source: NIH RePORTER	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); National Research Agency(French National Research Agency (ANR)); Universities Paris-Descartes; Pierre and Marie Curie; Paris-Sud; European Community(European Commission); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); Academie of Medecine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Georges Zadigue for his excellent technical assistance. This study was supported by INSERM, the National Research Agency (ANR 05-PCOD-029), Universities Paris-Descartes, Pierre and Marie Curie, and Paris-Sud. This study was performed in the European Vascular Genomics Network, a Network of Excellence supported by the European Community's Sixth Framework Program for Research Priority 1 "Life sciences, genomics and biotechnology for health" (contract no, LSHM-CT-2003-503254). E. M. and V.G.-C. were supported by fellowships from the Ministere de la Recherche and from Academie of Medecine. The results were presented in part at the High Blood Pressure Research Conference 2008 (Atlanta, GA, USA).	ALHENCGELAS F, 2000, HDB PHYSL 7, V3, P81; Aouam K, 2005, AM J PHYSIOL-HEART C, V288, pH2763, DOI 10.1152/ajpheart.00657.2004; Bergaya S, 2001, CIRC RES, V88, P593, DOI 10.1161/01.RES.88.6.593; Bodin S, 2009, KIDNEY INT, V76, P395, DOI 10.1038/ki.2009.208; Brown NJ, 2000, CIRCULATION, V102, P2190; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAMBIEN F, 1988, AM J HUM GENET, V43, P774; COSTEROUSSE O, 1994, AM J PHYSIOL-ENDOC M, V267, pE745, DOI 10.1152/ajpendo.1994.267.5.E745; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; DANSER AHJ, 1995, CIRCULATION, V92, P1387, DOI 10.1161/01.CIR.92.6.1387; Dzau VJ, 2001, AM J CARDIOL, V88, p1L; Eckle T, 2006, AM J PHYSIOL-HEART C, V291, pH2533, DOI 10.1152/ajpheart.00472.2006; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; Evangelista FS, 2006, PHYSIOL GENOMICS, V27, P231, DOI 10.1152/physiolgenomics.00022.2006; FALKENHAHN M, 1995, HYPERTENSION, V25, P219, DOI 10.1161/01.HYP.25.2.219; GOTO M, 1995, CIRC RES, V77, P611, DOI 10.1161/01.RES.77.3.611; Huang W, 2001, P NATL ACAD SCI USA, V98, P13330, DOI 10.1073/pnas.231476798; Krege JH, 1997, HYPERTENSION, V29, P150, DOI 10.1161/01.HYP.29.1.150; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUDBROOK J, 1994, CARDIOVASC RES, V28, P303, DOI 10.1093/cvr/28.3.303; MATTU RK, 1995, CIRCULATION, V91, P270, DOI 10.1161/01.CIR.91.2.270; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; Messadi-Laribi E, 2007, J PHARMACOL EXP THER, V323, P210, DOI 10.1124/jpet.107.124859; Muller DN, 1997, HYPERTENSION, V29, P98, DOI 10.1161/01.HYP.29.1.98; Oldenburg O, 2004, AM J PHYSIOL-HEART C, V286, pH468, DOI 10.1152/ajpheart.00360.2003; Pan HL, 2000, AM J PHYSIOL-HEART C, V279, pH116; Pons S, 2008, EUR J HEART FAIL, V10, P343, DOI 10.1016/j.ejheart.2008.02.002; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708; Sato M, 2000, CIRCULATION, V102, P346; Sayed-Tabatabaei FA, 2006, CIRC RES, V98, P1123, DOI 10.1161/01.RES.0000223145.74217.e7; SUN Y, 1994, CARDIOVASC RES, V28, P1623, DOI 10.1093/cvr/28.11.1623; Takahashi N, 2003, ENDOCRINOLOGY, V144, P2184, DOI 10.1210/en.2002-221045; Tian BH, 1997, HYPERTENSION, V30, P128, DOI 10.1161/01.HYP.30.1.128; Tschope C, 2000, J HYPERTENS, V18, P223, DOI 10.1097/00004872-200018020-00014; Tschope C, 2000, BRIT J PHARMACOL, V129, P1537, DOI 10.1038/sj.bjp.0703239; Xiao HD, 2008, AM J PHYSIOL-HEART C, V294, pH659, DOI 10.1152/ajpheart.01147.2007; Yang XP, 1997, HYPERTENSION, V30, P735, DOI 10.1161/01.HYP.30.3.735; Yang XP, 1999, HYPERTENSION, V34, P24, DOI 10.1161/01.HYP.34.1.24; YELLON DM, 1993, LANCET, V342, P276, DOI 10.1016/0140-6736(93)91819-8; Zintzaras E, 2008, ARCH INTERN MED, V168, P1077, DOI 10.1001/archinte.168.10.1077	43	19	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4691	4700		10.1096/fj.10-165902	http://dx.doi.org/10.1096/fj.10-165902			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20667972	Green Published			2022-12-28	WOS:000284824400010
J	Kohan, M; Muro, AF; White, ES; Berkman, N				Kohan, Martin; Muro, Andres F.; White, Eric S.; Berkman, Neville			EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha(4)beta(7) integrin receptor and MAPK/Erk 1/2-dependent signaling	FASEB JOURNAL			English	Article						myofibroblasts; fibrosis; extracellular matrix	MONOCLONAL-ANTIBODIES; EIIIA SEGMENT; ADHESION; MYOFIBROBLAST; MATRIX; MODEL; EOSINOPHILS; EXPRESSION; MIGRATION; VCAM-1	Fibroblast differentiation is an essential step during wound healing and fibrosis. Fibronectin (FN) is a major component of the extracellular matrix and occurs in two main forms: plasma and cellular FN. The latter includes the alternatively spliced domain A (EDA). Although EDA-containing cellular fibronectin (EDA-FN) is associated with fibroblast differentiation, how EDA-FN promotes differentiation is incompletely understood. In this study, we investigate the mechanism by which EDA-FN contributes to fibroblast differentiation with emphasis on the characterization of the EDA-FN receptor. We show that EDA-FN increases alpha-SMA expression (immunofluorescence), collagen deposition, cell contractility, and focal adhesion kinase (FAK) activation (immunoblotting); whereas plasma FN, a form lacking EDA, shows no effect. Primary lung fibroblasts constitutively express alpha(4)beta(7) integrin receptor (FACS and RT-PCR). Blocking of alpha(4)beta(7) reduces fibroblast adhesion to EDA-FN and inhibits alpha-SMA expression, collagen deposition, and FAK activation induced by EDA-FN. Using recombinant EDA-containing peptides, we demonstrate that the EDA segment is sufficient to induce fibroblast differentiation via binding to alpha(4)beta(7). EDA-FN induces MAPK-Erk1/2 activation and inhibition of MEK1/2 attenuates EDA-FN-induced alpha-SMA expression. Our findings demonstrate that EDA-FN induces fibroblast differentiation by a mechanism that involves binding of EDA to alpha(4)beta(7) integrin followed by activation of FAK and MAPK-associated signaling pathways.-Kohan, M., Muro, A. F., White, E. S., Berkman, N. EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha(4)beta(7) integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J. 24, 4503-4512 (2010). www.fasebj.org	[Kohan, Martin; Berkman, Neville] Hadassah Hebrew Univ Med Ctr, Inst Pulmonol, Lung Cellular & Mol Biol Lab, IL-91120 Jerusalem, Israel; [Muro, Andres F.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; [White, Eric S.] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA	Hebrew University of Jerusalem; International Center for Genetic Engineering & Biotechnology (ICGEB); University of Michigan System; University of Michigan	Berkman, N (corresponding author), Hadassah Hebrew Univ Med Ctr, Inst Pulmonol, Lung Cellular & Mol Biol Lab, POB 12000, IL-91120 Jerusalem, Israel.	neville@hadassah.org.il	Muro, Andrés F/K-3156-2016	Muro, Andrés F/0000-0002-9628-0494; White, Eric/0000-0003-4060-8443	Israel Science Foundation [1408/08]; Chief Scientist Office of the Ministry of Health, Israel [4921]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007749, R01HL085083] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Chief Scientist Office of the Ministry of Health, Israel; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was supported by grants from the Israel Science Foundation (1408/08) and the Chief Scientist Office of the Ministry of Health, Israel (4921). The authors are grateful to Ashley M. Cornett, M. Sc., for her technical assistance in performing cell adhesion assays. The authors declare no conflict of interest.	AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Brandt EB, 2006, CLIN EXP ALLERGY, V36, P543, DOI 10.1111/j.1365-2222.2006.02456.x; Brezinschek RI, 1996, AM J PATHOL, V149, P1651; Chauhan AK, 2004, GENE, V324, P55, DOI 10.1016/j.gene.2003.09.026; Fernandes DJ, 2006, CURR DRUG TARGETS, V7, P567, DOI 10.2174/138945006776818700; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Garcia AJ, 1999, BIOMATERIALS, V20, P2427, DOI 10.1016/S0142-9612(99)00170-2; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Hynes RO, 1990, FIBRONECTINS; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Kanayama M, 2009, J IMMUNOL, V182, P8015, DOI 10.4049/jimmunol.0900725; Kohan M, 2009, AM J RESP CELL MOL, V41, P290, DOI 10.1165/rcmb.2008-0307OC; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Leiss M, 2008, CURR OPIN CELL BIOL, V20, P502, DOI 10.1016/j.ceb.2008.06.001; Liao YF, 2002, J BIOL CHEM, V277, P14467, DOI 10.1074/jbc.M201100200; Lundahl J, 2000, ALLERGY, V55, P865, DOI 10.1034/j.1398-9995.2000.00574.x; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; Meerschaert J, 1999, J IMMUNOL, V163, P6217; Moyano JV, 1997, J BIOL CHEM, V272, P24832, DOI 10.1074/jbc.272.40.24832; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Muro AF, 1998, FEBS LETT, V437, P137, DOI 10.1016/S0014-5793(98)01201-0; Muro AF, 2008, AM J RESP CRIT CARE, V177, P638, DOI 10.1164/rccm.200708-1291OC; OYAMA F, 1989, BIOCHEMISTRY-US, V28, P1428, DOI 10.1021/bi00429a072; PAGANI F, 1991, J CELL BIOL, V113, P1223, DOI 10.1083/jcb.113.5.1223; Puxeddu I, 2006, J ALLERGY CLIN IMMUN, V117, P103, DOI 10.1016/j.jaci.2005.08.057; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Shaw S K, 1995, Semin Immunol, V7, P335, DOI 10.1016/1044-5323(95)90014-4; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Walsh GM, 1996, IMMUNOLOGY, V89, P112, DOI 10.1046/j.1365-2567.1996.d01-713.x; White ES, 2008, J PATHOL, V216, P1, DOI 10.1002/path.2388; White ES, 2003, AM J RESP CRIT CARE, V168, P436, DOI 10.1164/rccm.200301-041OC; XIA P, 1995, EXP CELL RES, V217, P517, DOI 10.1006/excr.1995.1117; Zhang Y, 2007, CELL MOL LIFE SCI, V64, P2771, DOI 10.1007/s00018-007-7012-3	39	104	106	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4503	4512		10.1096/fj.10-154435	http://dx.doi.org/10.1096/fj.10-154435			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20643910	Green Published, Green Submitted			2022-12-28	WOS:000283861100035
J	Lam, WWL; Woo, EJ; Kotaka, M; Tam, WK; Leung, YC; Ling, TKW; Au, SWN				Lam, Wendy Wai Ling; Woo, Eui Jeon; Kotaka, Masayo; Tam, Wai Kwan; Leung, Yun Chung; Ling, Thomas Kin Wah; Au, Shannon Wing Ngor			Molecular interaction of flagellar export chaperone FliS and cochaperone HP1076 in Helicobacter pylori	FASEB JOURNAL			English	Article						protein-protein interaction; type III secretion system; bacterial motility; virulence factor	III SECRETION SYSTEM; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; SIGMA-FACTOR; GENES; COLONIZATION; PROTEINS; BACTERIA; COMPLEX; IDENTIFICATION	Flagellar export chaperone FliS prevents premature polymerization of flagellins and is critical for flagellar assembly and bacterial colonization. Previously, a yeast 2-hybrid study identified various FliS-associated proteins in Helicobacter pylori, but the implications of these interactions are not known. Here we demonstrate the biophysical interaction of FliS (HP0753) and the uncharacterized protein HP1076 from H. pylori. HP1076 possesses a cochaperone activity that promotes the folding and chaperone activity of FliS. We further determined the crystal structures of FliS, HP1076, and the binary complex at 2.7, 1.8, and 2.7 angstrom resolution, respectively. HP1076 adopts a helix-rich bundle structure and interestingly shares a similar fold with a flagellin homologue, hook-associated protein, and FliS. The FliS-HP1076 complex revealed an extensive electrostatic and hydrophobic binding interface, which is distinct from the flagellin binding pocket in FliS. The helical stacking interaction between HP1076 and FliS suggests that HP1076 stabilizes 2 alpha helices of FliS and therefore the overall structure of the bundle. Our findings provide new insights into flagellar export chaperones and may have implications for other secretion chaperones in the type III secretion system.-Lam, W. W. L., Woo, E. J., Kotaka, M., Tam, W. K., Leung, Y. C., Ling, T. K. W., Au, S. W. N. Molecular interaction of flagellar export chaperone FliS and cochaperone HP1076 in Helicobacter pylori. FASEB J. 24, 4020-4032 (2010). www.fasebj.org	[Lam, Wendy Wai Ling; Au, Shannon Wing Ngor] Chinese Univ Hong Kong, Dept Biochem, Fac Sci, Ctr Prot Sci & Crystallog, Hong Kong, Hong Kong, Peoples R China; [Tam, Wai Kwan; Ling, Thomas Kin Wah] Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; [Woo, Eui Jeon] Korea Res Inst Biosci & Biotechnol, Med Prote Res Ctr, Taejon, South Korea; [Kotaka, Masayo] Univ Hong Kong, Fac Med, Dept Physiol, Hong Kong, Hong Kong, Peoples R China; [Leung, Yun Chung] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Hong Kong; Hong Kong Polytechnic University	Au, SWN (corresponding author), Chinese Univ Hong Kong, Dept Biochem, Fac Sci, Ctr Prot Sci & Crystallog, Hong Kong, Hong Kong, Peoples R China.	shannon-au@cuhk.edu.hk		Woo, Eui-Jeon/0000-0001-6983-0270; Leung, Yun-chung/0000-0003-3590-7027	Research Grants Council of Hong Kong [CUHK 4592/06M]; University Grants Council of the Hong Kong [SEG CUHK08]	Research Grants Council of Hong Kong(Hong Kong Research Grants Council); University Grants Council of the Hong Kong	This work was supported by a Competitive Earmarked Research grant (CUHK 4592/06M) from the Research Grants Council of Hong Kong. The authors thank the University Grants Council of the Hong Kong Special Administrative Region One-Off Special Equipment Grant (SEG CUHK08) for the equipment used in this work. W.W.L. performed the molecular and biochemical experiments, crystallization, and data analysis and prepared the manuscript; E.J.W. contributed to the data collection and phase determination of HP1076; M.K. contributed to the data collection of the binary complex; Y.C.L. assisted in the ITC assay; W.K.T. assisted the molecular cloning; K.W.L. was involved in collaboration and discussion; and S.W.N.A. supervised the research and prepared the manuscript.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Allan E, 2000, J BACTERIOL, V182, P5274, DOI 10.1128/JB.182.18.5274-5277.2000; Andersen-Nissen E, 2005, P NATL ACAD SCI USA, V102, P9247, DOI 10.1073/pnas.0502040102; Auvray F, 2001, J MOL BIOL, V308, P221, DOI 10.1006/jmbi.2001.4597; Bennett JCQ, 2000, TRENDS MICROBIOL, V8, P202, DOI 10.1016/S0966-842X(00)01751-0; Bennett JCQ, 2001, MOL MICROBIOL, V39, P781, DOI 10.1046/j.1365-2958.2001.02268.x; CHEN L, 1994, J BACTERIOL, V176, P3093, DOI 10.1128/jb.176.11.3093-3101.1994; DeLano W.L, PYMOL MOL GRAPHICS S; Douillard FP, 2009, MICROBIOL-SGM, V155, P1901, DOI 10.1099/mic.0.026062-0; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans LDB, 2006, P NATL ACAD SCI USA, V103, P17474, DOI 10.1073/pnas.0605197103; Evans LDB, 2009, FEMS MICROBIOL LETT, V293, P292, DOI 10.1111/j.1574-6968.2009.01535.x; Evdokimov AG, 2003, NAT STRUCT BIOL, V10, P789, DOI 10.1038/nsb982; Fraser GM, 1999, MOL MICROBIOL, V32, P569, DOI 10.1046/j.1365-2958.1999.01372.x; Galkin VE, 2008, SCIENCE, V320, P382, DOI 10.1126/science.1155307; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Ibuki T, 2009, ACTA CRYSTALLOGR F, V65, P47, DOI 10.1107/S1744309108039882; Kavermann H, 2003, J EXP MED, V197, P813, DOI 10.1084/jem.20021531; KAWAGISHI I, 1992, J GEN MICROBIOL, V138, P1051, DOI 10.1099/00221287-138-6-1051; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91; Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860; Leslie AGW, 1992, PROTEIN CRYSTALLOGR, V26, P27; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Muskotal A, 2006, FEBS LETT, V580, P3916, DOI 10.1016/j.febslet.2006.06.024; Niehus E, 2004, MOL MICROBIOL, V52, P947, DOI 10.1111/j.1365-2958.2004.04006.x; Niehus E, 2002, MICROBIOL-SGM, V148, P3827, DOI 10.1099/00221287-148-12-3827; Ottemann KM, 2002, INFECT IMMUN, V70, P1984, DOI 10.1128/IAI.70.4.1984-1990.2002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parrish JR, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r130; Quinaud M, 2005, J BIOL CHEM, V280, P36293, DOI 10.1074/jbc.M508089200; Quinaud M, 2007, P NATL ACAD SCI USA, V104, P7803, DOI 10.1073/pnas.0610098104; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; SANGER F, 1949, BIOCHEM J, V44, P126, DOI 10.1042/bj0440126; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Steele-Mortimer O, 2002, CELL MICROBIOL, V4, P43, DOI 10.1046/j.1462-5822.2002.00170.x; Sun P, 2008, J MOL BIOL, V377, P819, DOI 10.1016/j.jmb.2007.12.067; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; Wilharm G, 2007, INT J MED MICROBIOL, V297, P27, DOI 10.1016/j.ijmm.2006.10.003; Yokoseki T, 1996, J BACTERIOL, V178, P899, DOI 10.1128/jb.178.3.899-901.1996; YOKOSEKI T, 1995, MICROBIOL-SGM, V141, P1715, DOI 10.1099/13500872-141-7-1715	48	16	19	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					4020	4032		10.1096/fj.10-155242	http://dx.doi.org/10.1096/fj.10-155242			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20581225				2022-12-28	WOS:000285005900038
J	Luchetti, F; Canonico, B; Betti, M; Arcangeletti, M; Pilolli, F; Piroddi, M; Canesi, L; Papa, S; Galli, F				Luchetti, Francesca; Canonico, Barbara; Betti, Michele; Arcangeletti, Marcella; Pilolli, Francesca; Piroddi, Marta; Canesi, Laura; Papa, Stefano; Galli, Francesco			Melatonin signaling and cell protection function	FASEB JOURNAL			English	Review						cell signaling; glutathione; reactive oxygen species; mitochondria; apoptosis; MAPK	NF-KAPPA-B; MITOCHONDRIAL PERMEABILITY TRANSITION; SUPEROXIDE ANION PRODUCTION; PROTEIN-COUPLED RECEPTORS; CEREBRAL ISCHEMIC-INJURY; OXIDATIVE STRESS; REACTIVE OXYGEN; TRANSDUCTION PATHWAYS; HYDROGEN-PEROXIDE; MESSENGER-RNA	Besides its well-known regulatory role on circadian rhythm, the pineal gland hormone melatonin has other biological functions and a distinct metabolism in various cell types and peripheral tissues. In different tissues and organs, melatonin has been described to act as a paracrine and also as an intracrine and autocrine agent with overall homeostatic functions and pleiotropic effects that include cell protection and prosurvival factor. These latter effects, documented in a number of in vitro and in vivo studies, are sustained through both receptor-dependent and -independent mechanisms that control detoxification and stress response genes, thus conferring protection against a number of xenobiotics and endobiotics produced by acute and chronic noxious stimuli. Redox-sensitive components are included in the cell protection signaling of melatonin and in the resulting transcriptional response that involves the control of NF-kappa B, AP-1, and Nrf2. By these pathways, melatonin stimulates the expression of antioxidant and detoxification genes, acting in turn as a glutathione system enhancer. A further and converging mechanism of cell protection by this indoleamine described in different models seems to lie in the control of damage and signaling function of mitochondria that involves decreased production of reactive oxygen species and activation of the antiapoptotic and redox-sensitive element Bcl2. Recent evidence suggests that upstream components in this mitochondrial route include the calmodulin pathway with its central role in melatonin signaling and the survival-promoting component of MAPKs, ERK1/2. In this review article, we will discuss these and other molecular aspects of melatonin signaling relevant to cell protection and survival mechanisms.-Luchetti, F., Canonico, B., Betti, M., Arcangeletti, M., Pilolli, F., Piroddi, M., Canesi, L., Papa, S., Galli, F. Melatonin signaling and cell protection function. FASEB J. 24, 3603-3624 (2010). www.fasebj.org	[Luchetti, Francesca; Canonico, Barbara; Betti, Michele; Arcangeletti, Marcella; Papa, Stefano] Univ Urbino Carlo Bo, Dipartimento Sci Uomo Ambiente & Nat, Urbino, Italy; [Pilolli, Francesca; Piroddi, Marta; Galli, Francesco] Univ Perugia, Dipartimento Med Interna, Lab Biochim Clin & Nutr, I-06126 Perugia, Italy; [Canesi, Laura] Univ Genoa, Dipartimento Biol, Genoa, Italy	University of Urbino; University of Perugia; University of Genoa	Galli, F (corresponding author), Univ Perugia, Dept Internal Med, Lab Biochem & Nutr, Via Giochetto, I-06126 Perugia, Italy.	f.galli@unipg.it	Piroddi, Marta/K-5302-2016; Galli, Francesco/K-5048-2016	Piroddi, Marta/0000-0002-0880-0630; Galli, Francesco/0000-0003-3626-051X; Canonico, Barbara/0000-0003-3383-715X; Canesi, Laura/0000-0003-2061-3819				Agbas A, 2007, BIOCHEM J, V405, P51, DOI 10.1042/BJ20061202; Agez L, 2007, NEUROSCIENCE, V144, P522, DOI 10.1016/j.neuroscience.2006.09.030; Akbulut KG, 2008, BRAIN RES, V1238, P31, DOI 10.1016/j.brainres.2008.08.014; Aladag MA, 2009, NEUROCHEM RES, V34, P1935, DOI 10.1007/s11064-009-9979-7; Alarma-Estrany P, 2007, PHARMACOL THERAPEUT, V113, P507, DOI 10.1016/j.pharmthera.2006.11.003; Altun A, 2007, INT J CLIN PRACT, V61, P835, DOI 10.1111/j.1742-1241.2006.01191.x; Arnao MB, 2009, J PINEAL RES, V46, P295, DOI 10.1111/j.1600-079X.2008.00660.x; Ayoub MA, 2004, MOL PHARMACOL, V66, P312, DOI 10.1124/mol.104.000398; Bartosz G, 2009, BIOCHEM PHARMACOL, V77, P1303, DOI 10.1016/j.bcp.2008.11.009; Baydas G, 2005, NEUROSCIENCE, V135, P879, DOI 10.1016/j.neuroscience.2005.05.048; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; BENITEZKING G, 1993, EXPERIENTIA, V49, P635; Berndt C, 2008, BBA-MOL CELL RES, V1783, P641, DOI 10.1016/j.bbamcr.2008.02.003; Blask David E., 2002, Current Topics in Medicinal Chemistry, V2, P113, DOI 10.2174/1568026023394407; Bondi CD, 2008, J PINEAL RES, V44, P288, DOI 10.1111/j.1600-079X.2007.00525.x; Boutin JA, 2008, J PINEAL RES, V45, P524, DOI 10.1111/j.1600-079X.2008.00631.x; Brown DI, 2009, FREE RADICAL BIO MED, V47, P1239, DOI 10.1016/j.freeradbiomed.2009.07.023; Bruck R, 2004, J HEPATOL, V40, P86, DOI 10.1016/S0168-8278(03)00504-X; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Carretero M, 2009, J PINEAL RES, V47, P192, DOI 10.1111/j.1600-079X.2009.00700.x; Carrillo-Vico A, 2005, J CLIN ENDOCR METAB, V90, P992, DOI 10.1210/jc.2004-1429; Carrillo-Vico A, 2006, CURR OPIN INVEST DR, V7, P423; Castro LMR, 2005, J NEUROCHEM, V95, P1227, DOI 10.1111/j.1471-4159.2005.03457.x; Chan ASL, 2002, CELL SIGNAL, V14, P249, DOI 10.1016/S0898-6568(01)00240-6; Chetsawang B, 2009, J PINEAL RES, V46, P36, DOI 10.1111/j.1600-079X.2008.00605.x; Choi SI, 2008, J PINEAL RES, V44, P95; Chugunov AO, 2006, J BIOMOL STRUCT DYN, V24, P91, DOI 10.1080/07391102.2006.10507103; Colak C, 2007, MED SCI MONITOR, V13, pBR251; Costa EJX, 1997, FEBS LETT, V416, P103, DOI 10.1016/S0014-5793(97)01178-2; Cristofanon S, 2009, ANN NY ACAD SCI, V1171, P472, DOI 10.1111/j.1749-6632.2009.04896.x; Daulat AM, 2007, MOL CELL PROTEOMICS, V6, P835, DOI 10.1074/mcp.M600298-MCP200; Dawson D, 1998, ANN MED, V30, P95, DOI 10.3109/07853899808999390; del Rio B, 2004, J BIOL CHEM, V279, P38294, DOI 10.1074/jbc.M403140200; Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Dominguez-Rodriguez A, 2009, CURR VASC PHARMACOL, V7, P367, DOI 10.2174/157016109788340749; Dubocovich ML, 2005, ENDOCRINE, V27, P101, DOI 10.1385/ENDO:27:2:101; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; Esposito E, 2009, J PINEAL RES, V46, P79, DOI 10.1111/j.1600-079X.2008.00633.x; Farce A, 2008, EUR J MED CHEM, V43, P1926, DOI 10.1016/j.ejmech.2007.12.001; Fildes JE, 2009, IMMUNOLOGY, V127, P443, DOI 10.1111/j.1365-2567.2009.03113.x; Franco R, 2008, J BIOL CHEM, V283, P36071, DOI 10.1074/jbc.M807061200; Fujino G, 2007, MOL CELL BIOL, V27, P8152, DOI 10.1128/MCB.00227-07; Fukunaga K, 2002, J NEUROSCI RES, V70, P799, DOI 10.1002/jnr.10400; Fustin JM, 2009, FASEB J, V23, P764, DOI 10.1096/fj.08-121467; Galijasevic S, 2008, BIOCHEMISTRY-US, V47, P2668, DOI 10.1021/bi702016q; Galli F, 2007, CURR DRUG METAB, V8, P830, DOI 10.2174/138920007782798180; Gertz M, 2008, P NATL ACAD SCI USA, V105, P5705, DOI 10.1073/pnas.0800691105; Gillespie JMA, 2004, NEUROENDOCRINOLOGY, V79, P63, DOI 10.1159/000076629; Godson C, 1997, ENDOCRINOLOGY, V138, P397, DOI 10.1210/endo.138.1.4824; Grant SG, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000982; Gubitz AK, 1999, GENOMICS, V55, P248, DOI 10.1006/geno.1998.5661; Guillaume JL, 2008, J BIOL CHEM, V283, P16762, DOI 10.1074/jbc.M802069200; Hardeland R, 2005, ENDOCRINE, V27, P119, DOI 10.1385/ENDO:27:2:119; Hardeland R, 2009, BIOFACTORS, V35, P183, DOI 10.1002/biof.23; Hernandez-Pacheco A, 2008, EUR J PHARMACOL, V596, P70, DOI 10.1016/j.ejphar.2008.07.068; Hibaoui Y, 2009, J PINEAL RES, V47, P238, DOI 10.1111/j.1600-079X.2009.00707.x; Huang F, 2009, TOXICOLOGY, V256, P75, DOI 10.1016/j.tox.2008.11.005; Huang HR, 2007, J SURG RES, V142, P153, DOI 10.1016/j.jss.2006.12.553; Huang JY, 2009, J NEUROCHEM, V109, P1400, DOI 10.1111/j.1471-4159.2009.06061.x; HUERTODELGADILLO L, 1994, J PINEAL RES, V17, P55, DOI 10.1111/j.1600-079X.1994.tb00114.x; Izykowska I, 2008, POSTEP HIG MED DOSW, V62, P23; Janssen-Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011; Jockers R, 2008, BRIT J PHARMACOL, V154, P1182, DOI 10.1038/bjp.2008.184; Jou MJ, 2007, J PINEAL RES, V43, P389, DOI 10.1111/j.1600-079X.2007.00490.x; Jung KH, 2009, J PINEAL RES, V47, P173, DOI 10.1111/j.1600-079X.2009.00698.x; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karlsson AM, 2000, CELL SIGNAL, V12, P469, DOI 10.1016/S0898-6568(00)00089-9; Kato K, 2005, NEUROPHARMACOLOGY, V48, P301, DOI 10.1016/j.neuropharm.2004.09.007; Kaur C, 2008, BRAIN PATHOL, V18, P533, DOI 10.1111/j.1750-3639.2008.00156.x; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Kim EJ, 2008, ARTERIOSCL THROM VAS, V28, P1796, DOI 10.1161/ATVBAHA.108.171546; Kimball SR, 2008, J PINEAL RES, V44, P379, DOI 10.1111/j.1600-079X.2007.00539.x; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; Koh PO, 2008, J VET MED SCI, V70, P1219, DOI 10.1292/jvms.70.1219; Kokkola T, 1998, BIOCHEM BIOPH RES CO, V249, P531, DOI 10.1006/bbrc.1998.9182; Korkmaz A, 2008, NEUROENDOCRINOL LETT, V29, P614; Korkmaz A, 2009, MOL MED, V15, P43, DOI 10.2119/molmed.2008.00117; Korkmaz A, 2009, J PINEAL RES, V46, P115, DOI 10.1111/j.1600-079X.2008.00635.x; Lardone PJ, 2009, CELL MOL LIFE SCI, V66, P516, DOI 10.1007/s00018-008-8601-5; Lasbury ME, 2009, INFECT IMMUN, V77, P3344, DOI 10.1128/IAI.00299-09; Leon J, 2006, J NEUROCHEM, V98, P2023, DOI 10.1111/j.1471-4159.2006.04029.x; Levinthal DJ, 2005, J BIOL CHEM, V280, P5875, DOI 10.1074/jbc.M410771200; Levoye A, 2006, CHRONOBIOL INT, V23, P419, DOI 10.1080/07420520500521863; Levoye A, 2006, EMBO J, V25, P3012, DOI 10.1038/sj.emboj.7601193; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Lopez A, 2009, J PINEAL RES, V46, P188, DOI 10.1111/j.1600-079X.2008.00647.x; Luchetti F, 2007, TOXICOL IN VITRO, V21, P293, DOI 10.1016/j.tiv.2006.08.003; Luchetti F, 2006, J PINEAL RES, V40, P158, DOI 10.1111/j.1600-079X.2005.00293.x; Luchetti F, 2009, FREE RADICAL BIO MED, V46, P339, DOI 10.1016/j.freeradbiomed.2008.09.017; Ma J, 2009, PARKINSONISM RELAT D, V15, P307, DOI 10.1016/j.parkreldis.2008.07.008; Ma XC, 2005, DRUG METAB DISPOS, V33, P489, DOI 10.1124/dmd.104.002410; Macias M, 2003, EUR J BIOCHEM, V270, P832, DOI 10.1046/j.1432-1033.2003.03430.x; Mahipal SVK, 2007, BIOCHEM PHARMACOL, V74, P202, DOI 10.1016/j.bcp.2007.04.005; Manda K, 2007, J PINEAL RES, V42, P386, DOI 10.1111/j.1600-079X.2007.00432.x; Martin M, 2000, FASEB J, V14, P1677; Martin V, 2006, CANCER RES, V66, P1081, DOI 10.1158/0008-5472.CAN-05-2354; Martin V, 2010, CANCER LETT, V287, P216, DOI 10.1016/j.canlet.2009.06.016; Martinez-Cruz F, 2002, J NEUROSCI RES, V69, P550, DOI 10.1002/jnr.10307; Martinez-Cruz F, 2006, NEUROSCI LETT, V392, P1, DOI 10.1016/j.neulet.2005.02.073; Mates JM, 2008, ARCH TOXICOL, V82, P273, DOI 10.1007/s00204-008-0304-z; Mazna P, 2008, J PINEAL RES, V45, P361, DOI 10.1111/j.1600-079X.2008.00598.x; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Montilla P, 2003, J PHYSIOL BIOCHEM, V59, P263, DOI 10.1007/BF03179883; Murawska-Cialowicz E, 2008, J PHYSIOL PHARMACOL, V59, P717; Namgaladze D, 2002, J BIOL CHEM, V277, P5962, DOI 10.1074/jbc.M111268200; Nelson CS, 2001, MOL ENDOCRINOL, V15, P1306, DOI 10.1210/me.15.8.1306; Neumann CA, 2009, CELL CYCLE, V8, P4072, DOI 10.4161/cc.8.24.10242; Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200; Odagiri K, 2009, J MOL CELL CARDIOL, V46, P989, DOI 10.1016/j.yjmcc.2008.12.022; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; Ortiz GG, 2008, CURR NEUROPHARMACOL, V6, P203, DOI 10.2174/157015908785777201; Ozbek E, 2009, J ENDOUROL, V23, P1165, DOI 10.1089/end.2009.0035; Pandi-Perumal SR, 2008, PROG NEUROBIOL, V85, P335, DOI 10.1016/j.pneurobio.2008.04.001; Paulis L, 2009, J HYPERTENS, V27, pS11, DOI 10.1097/01.hjh.0000358831.33558.97; Paulsen CE, 2010, ACS CHEM BIOL, V5, P47, DOI 10.1021/cb900258z; Petrosillo G, 2009, FREE RADICAL BIO MED, V47, P969, DOI 10.1016/j.freeradbiomed.2009.06.032; Petrosillo G, 2009, AM J PHYSIOL-HEART C, V297, pH1487, DOI 10.1152/ajpheart.00163.2009; Pozo D, 2004, J PINEAL RES, V37, P48, DOI 10.1111/j.1600-079X.2004.00135.x; Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600-079X.2006.00318.x; Radogna F, 2009, TOXICOL APPL PHARM, V238, P170, DOI 10.1016/j.taap.2009.05.011; Radogna F, 2008, J PINEAL RES, V44, P316, DOI 10.1111/j.1600-079X.2007.00532.x; Radogna F, 2007, J PINEAL RES, V43, P154, DOI 10.1111/j.1600-079X.2007.00455.x; Radogna F, 2009, ANN NY ACAD SCI, V1171, P509, DOI 10.1111/j.1749-6632.2009.04900.x; Radogna F, 2009, TOXICOL APPL PHARM, V239, P37, DOI 10.1016/j.taap.2009.05.012; Rafii-El-Idrissi M, 1998, J NEUROIMMUNOL, V86, P190, DOI 10.1016/S0165-5728(98)00048-4; Raghavendra V, 2001, FREE RADICAL BIO MED, V30, P595, DOI 10.1016/S0891-5849(00)00447-0; Ralat LA, 2008, ARCH BIOCHEM BIOPHYS, V474, P109, DOI 10.1016/j.abb.2008.02.043; Ramirez-Rodriguez G, 2009, NEUROPSYCHOPHARMACOL, V34, P2180, DOI 10.1038/npp.2009.46; Raza H, 2008, TOXICOL APPL PHARM, V226, P161, DOI 10.1016/j.taap.2007.09.002; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; Reiter RJ, 2000, ANN NY ACAD SCI, V917, P376; Reiter RJ, 2008, NEUROENDOCRINOL LETT, V29, P391; Reiter RJ, 2009, CRIT REV BIOCHEM MOL, V44, P175, DOI 10.1080/10409230903044914; Reiter TA, 2002, J BIOL INORG CHEM, V7, P823, DOI 10.1007/s00775-002-0367-x; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; Reppert SM, 1997, J BIOL RHYTHM, V12, P528, DOI 10.1177/074873049701200606; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Rivara S, 2005, J MED CHEM, V48, P4049, DOI 10.1021/jm048956y; Rodriguez MI, 2007, FREE RADICAL RES, V41, P15, DOI 10.1080/10715760600936359; Ross AW, 1996, MOL CELL ENDOCRINOL, V123, P71, DOI 10.1016/0303-7207(96)03897-X; Rusnak F, 2000, TRENDS BIOCHEM SCI, V25, P527, DOI 10.1016/S0968-0004(00)01659-5; Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1; Semak I, 2008, J PINEAL RES, V45, P515, DOI 10.1111/j.1600-079X.2008.00630.x; Serin M, 2007, INT J RADIAT BIOL, V83, P187, DOI 10.1080/09553000601129093; Sethi S, 2008, J PINEAL RES, V45, P212, DOI 10.1111/j.1600-079X.2008.00579.x; Sliwinski T, 2007, MUTAT RES-GEN TOX EN, V634, P220, DOI 10.1016/j.mrgentox.2007.07.013; Srinivasan V, 2008, NEUROIMMUNOMODULAT, V15, P93, DOI 10.1159/000148191; Srinivasan V, 2008, INTEGR CANCER THER, V7, P189, DOI 10.1177/1534735408322846; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Sung JH, 2009, J PINEAL RES, V46, P300, DOI 10.1111/j.1600-079X.2008.00661.x; Szczepanik A, 2007, J PHYSIOL PHARMACOL, V58, P115; Takeda K, 2007, J BIOL CHEM, V282, P7522, DOI 10.1074/jbc.M607177200; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tapias V, 2009, J NEUROSCI RES, V87, P3002, DOI 10.1002/jnr.22123; Tomas-Zapico C, 2005, J PINEAL RES, V39, P99, DOI 10.1111/j.1600-079X.2005.00248.x; Ullrich V, 2003, TOXICOL LETT, V139, P107, DOI 10.1016/S0378-4274(02)00424-1; Urata Y, 1999, FREE RADICAL BIO MED, V27, P838, DOI 10.1016/S0891-5849(99)00131-8; Veneroso C, 2009, J PINEAL RES, V47, P184, DOI 10.1111/j.1600-079X.2009.00699.x; Venkataraman P, 2009, BASIC CLIN PHARMACOL, V105, P92, DOI 10.1111/j.1742-7843.2009.00406.x; von Gall C, 2002, CELL TISSUE RES, V309, P151, DOI 10.1007/s00441-002-0581-4; Voss P, 2007, AMINO ACIDS, V32, P527, DOI 10.1007/s00726-006-0428-5; Wang SH, 2007, NEUROCHEM RES, V32, P1329, DOI 10.1007/s11064-007-9308-y; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Wang X, 2009, STROKE, V40, P1877, DOI 10.1161/STROKEAHA.108.540765; Wang ZQ, 2009, J PINEAL RES, V46, P248, DOI 10.1111/j.1600-079X.2008.00624.x; Wisessmith W, 2009, J PINEAL RES, V46, P433, DOI 10.1111/j.1600-079X.2009.00680.x; Witt-Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5; Witt-Enderby PA, 2000, CELL MOTIL CYTOSKEL, V46, P28, DOI 10.1002/(SICI)1097-0169(200005)46:1<28::AID-CM4>3.0.CO;2-5; Won JS, 2000, HIPPOCAMPUS, V10, P236, DOI 10.1002/1098-1063(2000)10:3<236::AID-HIPO4>3.0.CO;2-B; Wong CM, 2008, CIRC RES, V102, P310, DOI 10.1161/CIRCRESAHA.107.159814; Yalcin A, 2004, NEUROSCI LETT, V359, P65, DOI 10.1016/j.neulet.2004.02.013; Yano S, 2004, FREE RADICAL BIO MED, V36, P1542, DOI 10.1016/j.freeradbiomed.2004.04.006; Ye LF, 2009, J LARYNGOL OTOL, V123, P598, DOI 10.1017/S002221510800385X; Yin J, 2006, J PINEAL RES, V41, P124, DOI 10.1111/j.1600-079X.2006.00343.x; Yoo YM, 2002, J PINEAL RES, V33, P146, DOI 10.1034/j.1600-079X.2002.02899.x; Zawilska JB, 2009, PHARMACOL REP, V61, P383, DOI 10.1016/S1734-1140(09)70081-7; Zhou JF, 2008, J PINEAL RES, V45, P157, DOI 10.1111/j.1600-079X.2008.00570.x; Zhu HQ, 2008, J PINEAL RES, V45, P328, DOI 10.1111/j.1600-079X.2008.00595.x; Zmijewski MA, 2009, MOL CELL ENDOCRINOL, V307, P211, DOI 10.1016/j.mce.2009.04.010	184	262	271	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3603	3624		10.1096/fj.10-154450	http://dx.doi.org/10.1096/fj.10-154450			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20534884				2022-12-28	WOS:000285005900002
J	Luig, C; Kother, K; Dudek, SE; Gaestel, M; Hiscott, J; Wixler, V; Ludwig, S				Luig, Christina; Koether, Katharina; Dudek, Sabine Eva; Gaestel, Matthias; Hiscott, John; Wixler, Viktor; Ludwig, Stephan			MAP kinase-activated protein kinases 2 and 3 are required for influenza A virus propagation and act via inhibition of PKR	FASEB JOURNAL			English	Article						MAPKAPK; tetrameric protein complex	DOUBLE-STRANDED-RNA; RAS SIGNALING PATHWAY; TUMOR-NECROSIS-FACTOR; P58(IPK); MK2; STABILIZATION; BIOSYNTHESIS; EXPRESSION; INDUCTION; ONCOLYSIS	Influenza viruses have to overcome the type I interferon induced antiviral response to successfully propagate in target cells. A major antiviral factor induced by interferons is the protein kinase R (PKR) that is further activated by dsRNA and phosphorylates the eukaryotic initiation factor 2 (eIF2 alpha). This results in inhibition of protein translation thereby limiting viral replication. Here we describe a novel mechanism by which influenza A viruses escape the antiviral action of PKR. We demonstrate that the mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) MK2 and MK3 are activated on virus infection and, in their active form, directly interact with the repressor of the inhibitor of PKR p88(rIPK). This leads to recruitment of a tetrameric protein complex consisting of p88(rIPK), the inhibitor of PKR p58(IPK) and PKR itself, and finally results in inhibition of the kinase. The importance of MKs for influenza virus propagation was further underscored by demonstrating reduced viral progeny in cells genetically deficient in MK2 or MK3 genes as well as in highly proliferating tumor cells, in which expression of MKs was diminished by specific small interfering RNA. Accordingly, knockdown of MKs resulted in enhanced phosphorylation of PKR and its substrate eIF2 alpha.-Luig, C., Kother, K., Dudek, S. E., Gaestel, M., Hiscott, J., Wixler, V., Ludwig, S. MAP kinase-activated protein kinases 2 and 3 are required for influenza A virus propagation and act via inhibition of PKR. FASEB J. 24, 4068-4077 (2010). www.fasebj.org	[Luig, Christina; Koether, Katharina; Dudek, Sabine Eva; Wixler, Viktor; Ludwig, Stephan] Univ Munster, Inst Mol Virol, D-48149 Munster, Germany; [Luig, Christina; Koether, Katharina; Dudek, Sabine Eva; Wixler, Viktor; Ludwig, Stephan] Univ Munster, Interdisciplinary Ctr Clin Res, D-48149 Munster, Germany; [Gaestel, Matthias] Hannover Med Sch, Inst Biochem, D-3000 Hannover, Germany; [Hiscott, John] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	University of Munster; University of Munster; Hannover Medical School; Lady Davis Institute; McGill University	Ludwig, S (corresponding author), Univ Munster, Inst Mol Virol, Von Esmarch Str 56, D-48149 Munster, Germany.	ludwigs@uni-muenster.de	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652; Ludwig, Stephan/0000-0003-4490-3052	German Ministry of Education and Research (BMBF); Deutsche Forschungsgemeinschaft (DFG) [GRK1409]; Interdisciplinary Clinical Research Centre (IZKF) of the University of Munster	German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Interdisciplinary Clinical Research Centre (IZKF) of the University of Munster	The authors thank Michael Gale (Department of Immunology, University of Washington School of Medicine, Seattle, WA, USA) for providing the pCMVflag-p58<SUP>rIPK</SUP> plasmid. This work was supported by the Graduate School GRK1409 from the Deutsche Forschungsgemeinschaft (DFG); the Interdisciplinary Clinical Research Centre (IZKF) of the University of Munster; and the FluResearchNet, funded by the German Ministry of Education and Research (BMBF).	Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Ehrhardt C., 2006, SIGNAL TRANSDUCT BAN, V6, P179, DOI [10.1002/sita.200500073, DOI 10.1002/SITA.200500073]; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; Gale M, 2002, BIOCHEMISTRY-US, V41, P11878, DOI 10.1021/bi020397e; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kotlyarov A, 2002, BIOCHEM SOC T, V30, P959, DOI 10.1042/BST0300959; Kujime K, 2000, J IMMUNOL, V164, P3222, DOI 10.4049/jimmunol.164.6.3222; Ludwig S, 2006, CELL MICROBIOL, V8, P375, DOI 10.1111/j.1462-5822.2005.00678.x; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 2004, FEBS LETT, V561, P37, DOI 10.1016/S0014-5793(04)00108-5; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Ludwig S, 2002, J VIROL, V76, P11166, DOI 10.1128/JVI.76.21.11166-11171.2002; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; Mazur I, 2007, CELL MICROBIOL, V9, P1683, DOI 10.1111/j.1462-5822.2007.00902.x; Mizumura K, 2003, CLIN EXP ALLERGY, V33, P1244, DOI 10.1046/j.1365-2222.2003.01750.x; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Olschlager V, 2004, ONCOGENE, V23, P6639, DOI 10.1038/sj.onc.1207883; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; Ronkina N, 2007, MOL CELL BIOL, V27, P170, DOI 10.1128/MCB.01456-06; Smith KD, 2006, J VIROL, V80, P1110, DOI 10.1128/JVI.80.3.1110-1120.2006; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Voncken JW, 2005, J BIOL CHEM, V280, P5178, DOI 10.1074/jbc.M407155200; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Zakowski V, 2004, EXP CELL RES, V299, P101, DOI 10.1016/j.yexcr.2004.05.027	33	25	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					4068	4077		10.1096/fj.10-158766	http://dx.doi.org/10.1096/fj.10-158766			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20484669				2022-12-28	WOS:000285005900042
J	Mattoscio, D; Evangelista, V; De Cristofaro, R; Recchiuti, A; Pandolfi, A; Di Silvestre, S; Manarini, S; Martelli, N; Rocca, B; Petrucci, G; Angelini, DF; Battistini, L; Robuffo, I; Pensabene, T; Pieroni, L; Furnari, ML; Pardo, F; Quattrucci, S; Lancellotti, S; Davi, G; Romano, M				Mattoscio, Domenico; Evangelista, Virgilio; De Cristofaro, Raimondo; Recchiuti, Antonio; Pandolfi, Assunta; Di Silvestre, Sara; Manarini, Stefano; Martelli, Nicola; Rocca, Bianca; Petrucci, Giovanna; Angelini, Daniela F.; Battistini, Luca; Robuffo, Iole; Pensabene, Tiziana; Pieroni, Luisa; Furnari, Maria Lucia; Pardo, Francesca; Quattrucci, Serena; Lancellotti, Stefano; Davi, Giovanni; Romano, Mario			Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response	FASEB JOURNAL			English	Article						inflammation resolution; lipoxin; nitric oxide; platelet-leukocyte interaction	NITRIC-OXIDE PRODUCTION; P-SELECTIN; CELLS; NEUTROPHILS; ACTIVATION; 12-LIPOXYGENASE; MACROPHAGES; INHIBITION; SECRETION; AIRWAY	Inflammatory lung disease is a primary cause of morbidity and mortality in cystic fibrosis (CF). Mechanisms of unresolved acute inflammation in CF are not completely known, although the involvement of cystic fibrosis transmembrane conductance regulator (CFTR) in nonrespiratory cells is emerging. Here we examined CFTR expression and function in human platelets (PLTs) and found that they express a biologically active CFTR. CFTR blockade gave an similar to 50% reduction in lipoxin A(4) (LXA(4)) formation during PLT/polymorphonuclear leukocytes (PMN) coincubations by inhibiting the lipoxin synthase activity of PLT 12-lipoxygenase. PLTs from CF patients generated similar to 40% less LXA(4) compared to healthy subject PLTs. CFTR inhibition increased PLT-dependent PMN viability (33.0 +/- 5.7 vs. 61.2 +/- 8.2%; P=0.033), suppressed nitric oxide generation (0.23 +/- 0.04 vs. 0.11 +/- 0.002 pmol/10(8) PLTs; P=0.004), while reducing AKT (1.02 +/- 0.12 vs. 0.71 +/- 0.007 U; P=0.04), and increasing p38 MAPK phosphorylation (0.650 +/- 0.09 vs. 1.04 +/- 0.24 U; P=0.03). Taken together, these findings indicate that PLTs from CF patients are affected by the molecular defect of CFTR. Moreover, this CF PLT abnormality may explain the failure of resolution in CF.-Mattoscio, D., Evangelista, V., De Cristofaro, R., Recchiuti, A., Pandolfi, A., Di Silvestre, S., Manarini, S., Martelli, N., Rocca, B., Petrucci, B., Angelini, D. F., Battistini, L., Robuffo, I., Pensabene, T., Pieroni, L., Furnari, M. L., Pardo, F., Quattrucci, S., Lancellotti, S., Davi, G., Romano, M. Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB J. 24, 3970-3980 (2010). www.fasebj.org	[Mattoscio, Domenico; Recchiuti, Antonio; Pandolfi, Assunta; Di Silvestre, Sara; Pieroni, Luisa; Romano, Mario] Gabriele DAnnunzio Univ Fdn, Dept Biomed Sci, Aging Res Ctr, CeSI, I-66013 Chieti, Italy; [Davi, Giovanni] Gabriele DAnnunzio Univ Fdn, Dept Med & Aging, Aging Res Ctr, CeSI, I-66013 Chieti, Italy; [Evangelista, Virgilio; Manarini, Stefano; Martelli, Nicola] Consorzio Mario Negri Sud, Lab Vasc Biol & Pharmacol, Chieti, Italy; [De Cristofaro, Raimondo; Lancellotti, Stefano] Catholic Univ, Sch Med, Inst Internal Med, Rome, Italy; [De Cristofaro, Raimondo; Lancellotti, Stefano] Catholic Univ, Sch Med, Geriatr & Haemostasis Res Ctr, Rome, Italy; [Rocca, Bianca; Petrucci, Giovanna] Catholic Univ, Sch Med, Inst Pharmacol, Rome, Italy; [Angelini, Daniela F.; Battistini, Luca] Inst Sci, Santa Lucia Fdn, Neuroimmunol Unit, Rome, Italy; [Robuffo, Iole] CNR, Inst Mol Genet, Chieti, Italy; [Quattrucci, Serena] Univ Roma La Sapienza, Cyst Fibrosis Res Ctr, Rome, Italy; [Pieroni, Luisa] IRCCS Fdn S Lucia, Lab Prote & Metabon, Rome, Italy; [Pensabene, Tiziana; Furnari, Maria Lucia; Pardo, Francesca] ARNAS, Children Hosp Di Cristina, Palermo, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Consorzio Mario Negri Sud; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Santa Lucia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Sapienza University Rome; IRCCS Santa Lucia	Romano, M (corresponding author), Gabriele DAnnunzio Univ Fdn, Dept Biomed Sci, Aging Res Ctr, CeSI, Via Colle Ara, I-66013 Chieti, Italy.	mromano@unich.it	Lancellotti, Stefano/K-3939-2018; Battistini, Luca/D-6920-2014; LANCELLOTTI, Stefano/AAA-2950-2022; Angelini, Daniela F/J-8001-2018; Battistini, luca/ABE-1882-2021; Robuffo, Iole/O-2918-2015; rocca, bianca/K-3922-2018; Recchiuti, Antonio/K-7670-2016; Romano, Mario/I-7986-2012; pandolfi, assunta/K-4595-2016; Pieroni, Luisa/Q-6315-2019; De Cristofaro, Raimondo/K-3942-2018; Mattoscio, Domenico/K-1411-2018; Pieroni, Luisa/J-8651-2018; Petrucci, Giovanna/AAB-9192-2022; Davi, Giovanni/K-7659-2016	Battistini, Luca/0000-0002-6488-4891; LANCELLOTTI, Stefano/0000-0002-8090-9040; Angelini, Daniela F/0000-0003-4552-9226; Robuffo, Iole/0000-0001-5883-4225; Recchiuti, Antonio/0000-0002-1409-5261; Romano, Mario/0000-0001-8512-1458; pandolfi, assunta/0000-0003-4135-7631; Pieroni, Luisa/0000-0001-7141-1817; De Cristofaro, Raimondo/0000-0002-8066-8849; Mattoscio, Domenico/0000-0002-2149-2855; Pieroni, Luisa/0000-0001-7141-1817; Petrucci, Giovanna/0000-0002-9280-3673; Davi, Giovanni/0000-0002-3044-0870	Italian Foundation for Cystic Fibrosis Research [FFC 12/2005, FFC 15/2007]; Italian Ministry of University and Research [CEPR D.D. 484/Ric 2008]	Italian Foundation for Cystic Fibrosis Research; Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR))	This work was supported by the Italian Foundation for Cystic Fibrosis Research (grants FFC 12/2005 and FFC 15/2007 to M. R.) and by the Italian Ministry of University and Research (CEPR D.D. 484/Ric 2008 to V.E.). The authors thank Stefano Lattanzio, Irene Recchia, Elisabetta Ferrante, and Eleonora Cianci for technical assistance; Andrea Urbani for helpful discussion; and Mirella Collura for patient referral. The authors declare no conflicts of interest in connection with this manuscript.	ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BalfourLynn IM, 1996, ARCH DIS CHILD, V75, P319, DOI 10.1136/adc.75.4.319; Barton GM, 2008, J CLIN INVEST, V118, P413, DOI 10.1172/JCI34431; Bozza FA, 2009, AM J RESP CELL MOL, V40, P123, DOI 10.1165/rcmb.2008-0241TR; Brunetti M, 2000, THROMB HAEMOSTASIS, V84, P478; Caci E, 2008, BIOCHEM J, V413, P135, DOI 10.1042/BJ20080029; Carrabino S, 2006, J CYST FIBROS, V5, P113, DOI 10.1016/j.jcf.2005.12.003; Ciabattoni G, 2000, AM J RESP CRIT CARE, V162, P1195, DOI 10.1164/ajrccm.162.4.9911071; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; Di A, 2006, NAT CELL BIOL, V8, P933, DOI 10.1038/ncb1456; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gangemi S, 2003, J APPL PHYSIOL, V94, P2237, DOI 10.1152/japplphysiol.01004.2002; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; HILL TD, 1989, PROSTAGLANDINS, V38, P21, DOI 10.1016/0090-6980(89)90013-0; Hopkins N, 2006, J PATHOL, V209, P198, DOI 10.1002/path.1963; Jean D, 2002, CRIT CARE MED, V30, P442, DOI 10.1097/00003246-200202000-00029; Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056; Kato H, 2008, ARCH BIOCHEM BIOPHYS, V475, P80, DOI 10.1016/j.abb.2008.04.023; Li GL, 2007, ENDOCRINOLOGY, V148, P3356, DOI 10.1210/en.2006-1441; McKeon DJ, 2008, THORAX, V63, P660, DOI 10.1136/thx.2008.096834; O'Sullivan BP, 2005, BLOOD, V105, P4635, DOI 10.1182/blood-2004-06-2098; Painter RG, 2006, BIOCHEMISTRY-US, V45, P10260, DOI 10.1021/bi060490t; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Perez A, 2007, AM J PHYSIOL-LUNG C, V292, pL383, DOI 10.1152/ajplung.00403.2005; Piccardoni P, 2001, BLOOD, V98, P108, DOI 10.1182/blood.V98.1.108; RIORDAN JR, 1989, SCIENCE, V245, P1066; Robroeks CMHHT, 2008, PEDIAT ALLERG IMM-UK, V19, P652, DOI 10.1111/j.1399-3038.2007.00693.x; ROMANO M, 1992, BIOCHEMISTRY-US, V31, P8269, DOI 10.1021/bi00150a021; ROMANO M, 1993, BIOCHEM J, V296, P127, DOI 10.1042/bj2960127; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; SERHAN CN, 1990, J CLIN INVEST, V85, P772, DOI 10.1172/JCI114503; Spalding A, 1998, HYPERTENSION, V31, P603, DOI 10.1161/01.HYP.31.2.603; von Hundelshausen P, 2007, CIRC RES, V100, P27, DOI 10.1161/01.RES.0000252802.25497.b7; Wang HB, 2007, NAT IMMUNOL, V8, P882, DOI 10.1038/ni1491; Weissmuller T, 2008, J CLIN INVEST, V118, P3682, DOI 10.1172/JCI35874; Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003	36	61	63	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3970	3980		10.1096/fj.10-159921	http://dx.doi.org/10.1096/fj.10-159921			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20530751				2022-12-28	WOS:000285005900034
J	Barksdale, KA; Perez-Costas, E; Gandy, JC; Melendez-Ferro, M; Roberts, RC; Bijur, GN				Barksdale, Keri A.; Perez-Costas, Emma; Gandy, Johanna C.; Melendez-Ferro, Miguel; Roberts, Rosalinda C.; Bijur, Gautam N.			Mitochondrial viability in mouse and human postmortem brain	FASEB JOURNAL			English	Article						ATP; cortex; electron microscopy; membrane potential; rhodamine	CYTOCHROME-C RELEASE; OXIDATIVE-PHOSPHORYLATION; SYNAPTIC MITOCHONDRIA; CRYOPRESERVATION; ACCUMULATION; DISEASE; AKT	Neuronal function in the brain requires energy in the form of ATP, and mitochondria are canonically associated with ATP production in neurons. The electrochemical gradient, which underlies the mitochondrial transmembrane potential (Delta Psi(mem)), is harnessed for ATP generation. Here we show that Delta Psi(mem) and ATP-production can be engaged in mitochondria isolated from human brains up to 8.5 h postmortem. Also, a time course of postmortem intervals from 0 to 24 h using mitochondria isolated from mouse cortex reveals that Delta Psi(mem) in mitochondria can be reconstituted beyond 10 h postmortem. It was found that complex I of the mitochondrial electron transport chain was affected adversely with increasing postmortem intervals. Mitochondria isolated from postmortem mouse brains maintain the ability to produce ATP, but rates of production decreased with longer postmortem intervals. Furthermore, we show that postmortem brain mitochondria retain their Delta Psi(mem) and ATP-production capacities following cryopreservation. Our finding that Delta Psi(mem) and ATP-generating capacity can be reinitiated in brain mitochondria hours after death indicates that human postmortem brains can be an abundant source of viable mitochondria to study metabolic processes in health and disease. It is also possible to archive these mitochondria for future studies.-Barksdale, K. A., Perez-Costas, E., Gandy, J. C., Melendez-Ferro, M., Roberts, R. C., Bijur, G. N. Mitochondrial viability in mouse and human postmortem brain. FASEB J. 24, 3590-3599 (2010). www.fasebj.org	[Barksdale, Keri A.; Perez-Costas, Emma; Gandy, Johanna C.; Melendez-Ferro, Miguel; Roberts, Rosalinda C.; Bijur, Gautam N.] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Roberts, RC (corresponding author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Sparks Ctr 1017,1720 7th Ave S, Birmingham, AL 35294 USA.	rcusidor@uab.edu; gautam@uab.edu		PEREZ-COSTAS, EMMA/0000-0002-9050-9593	U.S. National Institutes of Health (NIH) [NS044853]; Gary Drummond, Jr. Memorial Research Award; NIH [MH60744]; Cellular and Molecular Biology Program [GM008111]; Civitan International Research Center; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044853] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gary Drummond, Jr. Memorial Research Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cellular and Molecular Biology Program; Civitan International Research Center; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Joy K. Roche for assistance in processing of electron microscopy samples. This work was supported by U.S. National Institutes of Health (NIH) grant NS044853 and the Gary Drummond, Jr. Memorial Research Award to G.N.B., and NIH grant MH60744 to R. C. R. J.C.G. is supported by the Cellular and Molecular Biology Program training grant GM008111 and the Civitan International Research Center Emerging Scholars Award.	Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Barksdale KA, 2009, J NEUROCHEM, V108, P1289, DOI 10.1111/j.1471-4159.2009.05878.x; Begley JG, 1998, BRAIN RES PROTOC, V3, P76, DOI 10.1016/S1385-299X(98)00024-5; Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Caspersen C, 2005, FASEB J, V19, P2040, DOI 10.1096/fj.05-3735fje; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; DENNIS SC, 1977, BIOCHEM J, V164, P727, DOI 10.1042/bj1640727; Devi L, 2008, J BIOL CHEM, V283, P9089, DOI 10.1074/jbc.M710012200; Foster KA, 2006, PROG NEUROBIOL, V79, P136, DOI 10.1016/j.pneurobio.2006.07.001; GERARDS M, 2009, J MED GENET; Gill-King H., 1997, FORENSIC TAPHONOMY P, P93, DOI DOI 10.1201/9781439821923.SEC2; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; GREIFF D, 1961, NATURE, V190, P1202, DOI 10.1038/1901202b0; GREIFF D, 1961, BIOCHIM BIOPHYS ACTA, V50, P233, DOI 10.1016/0006-3002(61)90321-3; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Huttemann M, 2008, J BIOENERG BIOMEMBR, V40, P445, DOI 10.1007/s10863-008-9169-3; Kuznetsov AV, 2003, ANAL BIOCHEM, V319, P296, DOI 10.1016/S0003-2697(03)00326-9; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nukala VN, 2006, J NEUROSCI METH, V152, P48, DOI 10.1016/j.jneumeth.2005.08.017; Park LCH, 2001, J NEUROSCI RES, V66, P1028, DOI 10.1002/jnr.10062; Rollins B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004913; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; SAKAMOTO J, 1984, J BIOCHEM-TOKYO, V96, P483, DOI 10.1093/oxfordjournals.jbchem.a134860; Schild L, 2001, FASEB J, V15, P565; Sheleg S, 2008, INT J CLIN EXP PATHO, V1, P440; Verkhratsky A, 2008, CELL CALCIUM, V44, P112, DOI 10.1016/j.ceca.2007.11.010; Vila M, 2008, J NEUROCHEM, V107, P317, DOI 10.1111/j.1471-4159.2008.05604.x; Wang XL, 2009, J NEUROCHEM, V109, P153, DOI 10.1111/j.1471-4159.2009.05867.x	29	31	31	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3590	3599		10.1096/fj.09-152108	http://dx.doi.org/10.1096/fj.09-152108			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20466876	Green Published			2022-12-28	WOS:000281446400046
J	Huang, LQ; Jin, R; Li, JR; Luo, K; Huang, T; Wu, D; Wang, WX; Chen, R; Xiao, GF				Huang, Liqin; Jin, Rui; Li, Jiarui; Luo, Kan; Huang, Tao; Wu, Di; Wang, Wenxi; Chen, Rui; Xiao, Gengfu			Macromolecular crowding converts the human recombinant PrPC to the soluble neurotoxic beta-oligomers	FASEB JOURNAL			English	Article						prion protein; thermodynamic stability; neurotoxicity; crowded environment; oligomerization	PRION PROTEIN; INSERTION MUTATIONS; ALPHA-SYNUCLEIN; CONFORMATION; AGGREGATION; FIBRILLIZATION; TRANSITION; STABILITY; VOLUME; FORM	Prion diseases are fatal neurodegenerative disorders and are linked with the conversion of the cellular isoform of the prion protein (PrPC) into the abnormal beta-sheet-rich isoform. It is widely accepted that the soluble oligomers of beta-PrP are neurotoxic and that they are more pathologically significant. To unravel the molecular mechanism under the conversion process, it is critical to identify the factors that can promote the conversion from PrPC to the beta-oligomers. By recording circular dichroism spectra and performing a size-exclusion HPLC assay, we found that the conformation of the recombinant human prion protein (rPrP(C)) was converted from an alpha-helical conformation into beta-sheet oligomers under a macromolecular crowding condition. The soluble beta-oligomers of rPrP were resistant to proteinase K digestion and could bind to the dyes thioflavin T and 8-anilino-1-naphthalene sulfonate. Furthermore, by the 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay, we showed that the soluble beta-oligomers were neurotoxic. These results suggest that macromolecular crowding, which has not been considered before, is a key intracellular factor in the formation of soluble neurotoxic beta-oligomers in prion diseases.-Huang, L., Jin, R., Li, J., Luo, K., Huang, T., Wu, D., Wang, W., Chen, R., Xiao, G. Macromolecular crowding converts the human recombinant PrPC to the soluble neurotoxic beta-oligomers. FASEB J. 24, 3536-3543 (2010). www.fasebj.org	[Jin, Rui; Xiao, Gengfu] Wuhan Univ, Chinese Acad Sci, State Key Lab Virol, Wuhan Inst Virol, Wuhan 430071, Hubei, Peoples R China; [Huang, Liqin; Li, Jiarui; Luo, Kan; Huang, Tao; Wu, Di; Wang, Wenxi; Chen, Rui; Xiao, Gengfu] Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430071, Hubei, Peoples R China	Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Wuhan University; Wuhan University	Xiao, GF (corresponding author), Wuhan Univ, Chinese Acad Sci, State Key Lab Virol, Wuhan Inst Virol, Wuhan 430071, Hubei, Peoples R China.	xiaogf@wh.iov.cn			National Key Scientific Program (973)-Nanoscience and Nanotechnology [2006CB933100]; National Natural Science Foundation of China [30970150]; Program for New Century Excellent Talents in University [NCET-06-0620]; Program for Changjiang Scholars and Innovative Research Team in University [IRT 0745]	National Key Scientific Program (973)-Nanoscience and Nanotechnology(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT))	This study was supported by National Key Scientific Program (973)-Nanoscience and Nanotechnology (2006CB933100), a grant from the National Natural Science Foundation of China (30970150), the Program for New Century Excellent Talents in University (NCET-06-0620), and the Program for Changjiang Scholars and Innovative Research Team in University (IRT 0745).	Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chesebro B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000800; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Grasbon-Frodl E, 2004, NEUROGENETICS, V5, P249, DOI 10.1007/s10048-004-0196-x; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; Huang Z, 1996, CURR TOP MICROBIOL, V207, P49; Irvine GB, 2008, MOL MED, V14, P451, DOI 10.2119/2007-00100.Irvine; Kazlauskaite J, 2005, BIOCHEM BIOPH RES CO, V328, P292, DOI 10.1016/j.bbrc.2004.12.172; Leffers KW, 2004, J MOL BIOL, V344, P839, DOI 10.1016/j.jmb.2004.09.071; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Minton AP, 1997, CURR OPIN BIOTECH, V8, P65, DOI 10.1016/S0958-1669(97)80159-0; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Mukherjee S, 2009, J MOL BIOL, V393, P227, DOI 10.1016/j.jmb.2009.08.016; Munishkina LA, 2004, J MOL RECOGNIT, V17, P456, DOI 10.1002/jmr.699; Nandi PK, 2006, J MOL BIOL, V362, P810, DOI 10.1016/j.jmb.2006.07.060; Novitskaya V, 2006, J BIOL CHEM, V281, P13828, DOI 10.1074/jbc.M511174200; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Perham M, 2007, FEBS LETT, V581, P5065, DOI 10.1016/j.febslet.2007.09.049; Peters PJ, 2003, J CELL BIOL, V162, P703, DOI 10.1083/jcb.200304140; Polyakova O, 2009, EUR BIOPHYS J BIOPHY, V38, P209, DOI 10.1007/s00249-008-0371-3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rezaei H, 2005, J MOL BIOL, V347, P665, DOI 10.1016/j.jmb.2005.01.043; Rivas German, 2004, EMBO Reports, V5, P23, DOI 10.1038/sj.embor.7400056; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Sasahara K, 2003, J MOL BIOL, V326, P1227, DOI 10.1016/S0022-2836(02)01443-2; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Simoneau S, 2007, PLOS PATHOG, V3, P1175, DOI 10.1371/journal.ppat.0030125; Stagg L, 2007, P NATL ACAD SCI USA, V104, P18976, DOI 10.1073/pnas.0705127104; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Tokuriki N, 2004, PROTEIN SCI, V13, P125, DOI 10.1110/ps.03288104; Uversky VN, 2002, FEBS LETT, V515, P99, DOI 10.1016/S0014-5793(02)02446-8; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; Yin SM, 2006, J BIOL CHEM, V281, P10698, DOI 10.1074/jbc.M511819200; Yu SL, 2007, BIOCHEM J, V403, P343, DOI 10.1042/BJ20061592; Yu SL, 2004, EUR J HUM GENET, V12, P867, DOI 10.1038/sj.ejhg.5201245; Zhou Z, 2009, J BIOL CHEM, V284, P30148, DOI 10.1074/jbc.M109.002832	42	34	35	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3536	3543		10.1096/fj.09-150987	http://dx.doi.org/10.1096/fj.09-150987			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20400537				2022-12-28	WOS:000281446400040
J	Lopez-Ramos, M; Prudent, R; Moucadel, V; Sautel, CF; Barette, C; Lafanechere, L; Mouawad, L; Grierson, D; Schmidt, F; Florent, JC; Filippakopoulos, P; Bullock, AN; Knapp, S; Reiser, JB; Cochet, C				Lopez-Ramos, Miriam; Prudent, Renaud; Moucadel, Virginie; Sautel, Celine F.; Barette, Caroline; Lafanechere, Laurence; Mouawad, Liliane; Grierson, David; Schmidt, Frederic; Florent, Jean-Claude; Filippakopoulos, Panagis; Bullock, Alex N.; Knapp, Stefan; Reiser, Jean-Baptiste; Cochet, Claude			New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights	FASEB JOURNAL			English	Article						X-ray crystallography; binding mode; comparative structural study; high-throughput screening; selective inhibition	FACTOR-KAPPA-B; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; CONSTITUTIVE ACTIVITY; PROTOONCOGENE PIM-1; PHOSPHORYLATES BAD; PROGNOSTIC MARKER; CASEIN KINASE-2; ALPHA-SUBUNIT; PROTEIN	Protein kinase casein kinase 2 (CK2) is a serine/threonine kinase with evidence of implication in growth dysregulation and apoptosis resistance, making it a relevant target for cancer therapy. Several CK2 inhibitors have been developed showing variable efficiency, emphasizing the need to expand the chemical diversity of those inhibitors. We report the identification and characterization of 2,8-difurandicarboxylic acid derivatives as a new class of nanomolar ATP-competitive inhibitors. Selectivity profiling pointed out proviral insertion Moloney virus kinases (Pim kinases) as the only other kinases that are significantly inhibited. By combining structure-activity relationship analysis with structural determination, we were able to determine the binding mode of these inhibitors for both kinases and to explain their strong inhibitory potency. Essential chemical features necessary for activity on both kinases were then identified. The described compounds are not cell permeable: however, they could provide a lead for developing novel inhibitors usable also in vivo. Given the similar but not redundant pathophysiological functions of CK2 and Pim family members, such inhibitors would provide new attractive leads for targeted cancer therapy. This work highlights that 2 functionally related kinases from different kinome branches display exquisite sensitivity to a common inhibitor.-Lopez-Ramos, M., Prudent, R., Moucadel, V., Sautel, C. F., Barette, C., Lafanechere, L., Mouawad, L., Grierson, D., Schmidt, F., Florent, J.-C., Filippakopoulos, P., Bullock, A. N., Knapp, S., Reiser, J.-B., Cochet, C. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights. FASEB J. 24, 3171-3185 (2010). www.fasebj.org	[Prudent, Renaud; Moucadel, Virginie; Sautel, Celine F.; Cochet, Claude] INSERM, U873, F-38054 Grenoble, France; [Lopez-Ramos, Miriam; Grierson, David; Schmidt, Frederic; Florent, Jean-Claude] Inst Curie, Ctr Rech, Paris, France; [Lopez-Ramos, Miriam; Grierson, David; Schmidt, Frederic; Florent, Jean-Claude] CNRS, UMR 176, Paris, France; [Lopez-Ramos, Miriam; Mouawad, Liliane] Univ Paris 11, Inst Curie, Ctr Rech, Orsay, France; [Lopez-Ramos, Miriam; Mouawad, Liliane] Univ Paris 11, INSERM, U759, F-91405 Orsay, France; [Prudent, Renaud; Moucadel, Virginie; Sautel, Celine F.; Cochet, Claude] CEA, iRTSV, Lab Transduct Signal, Grenoble, France; [Barette, Caroline; Lafanechere, Laurence] CEA, DSV, iRTSV, Ctr Criblage Mol Bioact, Grenoble, France; [Barette, Caroline; Lafanechere, Laurence] CEA, DSV, iRTSV, CMBA,CNRS,UMR 5168, Grenoble, France; [Filippakopoulos, Panagis; Bullock, Alex N.; Knapp, Stefan] Univ Oxford, Nuffield Dept Clin Med, Oxford, England; [Knapp, Stefan] Univ Oxford, Dept Clin Pharmacol, Oxford, England; [Reiser, Jean-Baptiste] UJF, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, F-38027 Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; CEA; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; University of Oxford; University of Oxford; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Cochet, C (corresponding author), INSERM, U873, F-38054 Grenoble, France.	jean-baptiste.reiser@ibs.fr; ccochet1@cea.fr	Knapp, Stefan/AAG-2347-2019; Schmidt, Frederic/F-8946-2016; Reiser, Jean-Baptiste/W-7683-2019; Lafanechère, Laurence MP/N-7474-2013; Mouawad, Liliane/N-1945-2018	Knapp, Stefan/0000-0001-5995-6494; Schmidt, Frederic/0000-0002-1537-3585; Reiser, Jean-Baptiste/0000-0001-6926-9137; Lafanechère, Laurence MP/0000-0002-7902-7630; Mouawad, Liliane/0000-0002-7155-9712; florent, jean-claude/0000-0001-9837-5094; BARETTE, Caroline/0000-0003-0999-7751; Filippakopoulos, Panagis/0000-0002-1515-1317; Cochet, Claude/0000-0002-1772-4270	INSERM; CNRS; CEA; Institut Curie; Ligue Nationale Contre le Cancer; Institut National du Cancer; Fondation pour la Recherche Medicale; Structural Genomics Consortium [1097737]; Canadian Institutes for Health Research; Canadian Foundation for Innovation; Genome Canada through the Ontario Genomics Institute; GlaxoSmithKline; Karolinska Institutet; Knut and Alice Wallenberg Foundation; Ontario Innovation Trust; Ontario Ministry for Research and Innovation; Merck Co Inc.; Novartis Research Foundation; Swedish Agency for Innovation Systems; Swedish Foundation for Strategic Research; Wellcome Trust	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); CEA(French Atomic Energy Commission); Institut Curie; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Structural Genomics Consortium(University of Toronto); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Genome Canada through the Ontario Genomics Institute(Genome Canada); GlaxoSmithKline(GlaxoSmithKline); Karolinska Institutet(Karolinska Institutet); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Ontario Innovation Trust; Ontario Ministry for Research and Innovation(Ministry of Research and Innovation, Ontario); Merck Co Inc.(Merck & Company); Novartis Research Foundation; Swedish Agency for Innovation Systems(Vinnova); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Wellcome Trust(Wellcome Trust)	This work was supported by INSERM, CNRS, CEA, the Institut Curie, the Ligue Nationale Contre le Cancer (equipe labelisee 2007), the Institut National du Cancer (grant 57). R. P. is the recipient of a fellowship from the Fondation pour la Recherche Medicale. The authors thank Sylvie Dubruille for assessing the purity of all synthesized compounds by HPLC. The authors also thank the ChemAxon company (http://www.chemaxon.com) that has allowed the academic TAMIS software team (especially S. Wieczorek, S. Aci, C. Charavay, and S. Roy) to freely use the MarvinView package, a helpful graphic user interface for viewing structure files and query results. The authors are also indebted to Dr. J. Schwaller and S. Ehret for cellular Pim-1 kinase assays and to Dr. Michael Lilly (Loma Linda University School of Medicine, Loma Linda, CA, USA) for providing us with BaF3/Pim-1 cells. The authors thank Juan-Carlos Fontecilla-Camps and his group (Laboratoire de Cristallogenese et Cristallographie des Proteines, Institut de Biologie Structurale Jean-Pierre Ebel, Grenoble, France) for laboratory technical support. The authors thank the SLS and ESRF MX team and local contacts for support during diffraction data collections on beamlines. The Structural Genomics Consortium is a registered charity (No. 1097737) that receives funds from the Canadian Institutes for Health Research, the Canadian Foundation for Innovation, Genome Canada through the Ontario Genomics Institute, GlaxoSmithKline, Karolinska Institutet, the Knut and Alice Wallenberg Foundation, the Ontario Innovation Trust, the Ontario Ministry for Research and Innovation, Merck & Co Inc., the Novartis Research Foundation, the Swedish Agency for Innovation Systems, the Swedish Foundation for Strategic Research, and the Wellcome Trust.	Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Aho TL, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-21; ANDERES K, 2009, AM ASS CANC RES AACR; Arrault A, 1999, SYNTHESIS-STUTTGART, P1241; AUGUSTIN S, 2005, FLEXX; Ayala GE, 2004, CANCER RES, V64, P6082, DOI 10.1158/0008-5472.CAN-04-0838; Azam M, 2008, NAT STRUCT MOL BIOL, V15, P1109, DOI 10.1038/nsmb.1486; Azam M, 2010, CHEM BIOL DRUG DES, V75, P223, DOI 10.1111/j.1747-0285.2009.00911.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battistutta R, 2000, J BIOL CHEM, V275, P29618, DOI 10.1074/jbc.M004257200; Battistutta R, 2005, CHEM BIOL, V12, P1211, DOI 10.1016/j.chembiol.2005.08.015; Battistutta R, 2009, CELL MOL LIFE SCI, V66, P1868, DOI 10.1007/s00018-009-9155-x; Battistutta R, 2001, PROTEIN SCI, V10, P2200, DOI 10.1110/ps.19601; Bibby AC, 2005, INT J BIOL SCI, V1, P67; BILGER C, 1987, EUR J MED CHEM, V22, P213, DOI 10.1016/0223-5234(87)90052-3; Bullock AN, 2005, J BIOL CHEM, V280, P41675, DOI 10.1074/jbc.M510711200; Chen J, 2009, ONCOGENE, V28, P2581, DOI 10.1038/onc.2009.124; Cheney IW, 2007, BIOORG MED CHEM LETT, V17, P1679, DOI 10.1016/j.bmcl.2006.12.086; Cibull TL, 2006, J CLIN PATHOL, V59, P285, DOI 10.1136/jcp.2005.027672; COZZA G, 2009, MED RES REV IN PRESS, DOI DOI 10.1002/MED.20164; Debreczeni JE, 2006, ANGEW CHEM INT EDIT, V45, P1580, DOI 10.1002/anie.200503468; Duncan JS, 2008, BBA-PROTEINS PROTEOM, V1784, P33, DOI 10.1016/j.bbapap.2007.08.017; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ermakova I, 2003, J MOL BIOL, V330, P925, DOI 10.1016/S0022-2836(03)00638-7; Evans P., 2007, SCALA SCALE TOGETHER; Feng BY, 2007, J MED CHEM, V50, P2385, DOI 10.1021/jm061317y; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; Frisch M. J., 2004, GAUSSIAN 03W; Gerber DA, 2000, J BIOL CHEM, V275, P23919, DOI 10.1074/jbc.M002697200; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hubert A, 2006, J CELL SCI, V119, P3351, DOI 10.1242/jcs.03069; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kallergi G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2452; Kim JS, 2007, CLIN CANCER RES, V13, P1019, DOI 10.1158/1078-0432.CCR-06-1602; Klumpp S, 2004, NEUROCHEM INT, V45, P747, DOI 10.1016/j.neuint.2004.02.006; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; Landesman-Bollag E, 2001, MOL CELL BIOCHEM, V227, P153, DOI 10.1023/A:1013108822847; Laramas M, 2007, EUR J CANCER, V43, P928, DOI 10.1016/j.ejca.2006.11.021; LESLIE AGW, 2007, MOSFLM; Liao JJL, 2007, J MED CHEM, V50, P409, DOI 10.1021/jm0608107; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mazzorana M, 2008, MOL CELL BIOCHEM, V316, P57, DOI 10.1007/s11010-008-9822-5; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268; Moustakas DT, 2006, J COMPUT AID MOL DES, V20, P601, DOI 10.1007/s10822-006-9060-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niefind K, 2009, CELL MOL LIFE SCI, V66, P1800, DOI 10.1007/s00018-009-9149-8; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Niefind K, 2007, J MOL BIOL, V370, P427, DOI 10.1016/j.jmb.2007.04.068; O-charoenrat P, 2004, CLIN CANCER RES, V10, P5792, DOI 10.1158/1078-0432.CCR-03-0317; Pagano MA, 2006, BIOCHEM SOC T, V34, P1303, DOI 10.1042/BST0341303; Pagano MA, 2008, BIOCHEM J, V415, P353, DOI 10.1042/BJ20080309; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Pierce AC, 2008, J MED CHEM, V51, P1972, DOI 10.1021/jm701248t; Pogacic V, 2007, CANCER RES, V67, P6916, DOI 10.1158/0008-5472.CAN-07-0320; Prudent R, 2008, BBA-GEN SUBJECTS, V1780, P1412, DOI 10.1016/j.bbagen.2008.06.010; Prudent R, 2008, MOL CELL BIOCHEM, V316, P71, DOI 10.1007/s11010-008-9828-z; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Raaf J, 2008, MOL CELL BIOCHEM, V316, P15, DOI 10.1007/s11010-008-9826-1; Raaf J, 2008, CHEM BIOL, V15, P111, DOI 10.1016/j.chembiol.2007.12.012; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Reiser-Erkan C, 2008, CANCER BIOL THER, V7, P1352, DOI 10.4161/cbt.7.9.6418; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; RUZZENE M, 2009, BIOCHIM BIOPHYS ACTA, V1804, P499; Ryan AJ, 2003, J MED CHEM, V46, P3448, DOI 10.1021/jm0340896; Sarno S, 2005, MOL CELL BIOCHEM, V274, P69, DOI 10.1007/s11010-005-3079-z; Sarno S, 2002, J BIOL CHEM, V277, P22509, DOI 10.1074/jbc.M200486200; Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r; Shoichet BK, 2006, J MED CHEM, V49, P7274, DOI 10.1021/jm061103g; Slaton JW, 2004, MOL CANCER RES, V2, P712; SYBYL Tripos Inc, SYBYL, P63144; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; Vedadi M, 2006, P NATL ACAD SCI USA, V103, P15835, DOI 10.1073/pnas.0605224103; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Xie Y, 2006, ONCOGENE, V25, P70, DOI 10.1038/sj.onc.1209058; Xu Y, 2005, J SURG ONCOL, V92, P326, DOI 10.1002/jso.20325; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Zemskova M, 2008, J BIOL CHEM, V283, P20635, DOI 10.1074/jbc.M709479200	88	51	55	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3171	3185		10.1096/fj.09-143743	http://dx.doi.org/10.1096/fj.09-143743			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20400536				2022-12-28	WOS:000281446400007
J	Lage, R; Vazquez, MJ; Varela, L; Saha, AK; Vidal-Puig, A; Nogueiras, R; Dieguez, C; Lopez, M				Lage, Ricardo; Vazquez, Maria J.; Varela, Luis; Saha, Asish K.; Vidal-Puig, Antonio; Nogueiras, Ruben; Dieguez, Carlos; Lopez, Miguel			Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender	FASEB JOURNAL			English	Article						AMPK; CREB; dimorphism; FoxO1	ENDOPLASMIC-RETICULUM STRESS; AGOUTI-RELATED PROTEIN; MELANIN-CONCENTRATING HORMONE; MESSENGER-RNA LEVELS; DIET-INDUCED OBESITY; FOOD-INTAKE; ENERGY HOMEOSTASIS; LEPTIN RESISTANCE; ARCUATE NUCLEUS; SECRETAGOGUE RECEPTOR	The orexigenic effect of ghrelin is mediated by neuropeptide Y (NPY) and agouti-related protein (AgRP) in the hypothalamic arcuate nucleus (ARC). Recent evidence also indicates that ghrelin promotes feeding through a mechanism involving activation of hypothalamic AMP-activated protein kinase (AMPK) and inactivation of acetyl-CoA carboxylase and fatty acid synthase (FAS). This results in decreased hypothalamic levels of malonyl-CoA, increased carnitine palmitoyltransferase 1 (CPT1) activity, and mitochondrial production of reactive oxygen species. We evaluated whether these molecular events are part of a unique signaling cascade or whether they represent alternative pathways mediating the orexigenic effect of ghrelin. Moreover, we examined the gender dependency of these mechanisms, because recent evidence has proposed that ghrelin orexigenic effect is reduced in female rats. We studied in both genders the effect of ghrelin on the expression of AgRP and NPY, as well as their transcription factors: cAMP response-element binding protein (CREB and its phosphorylated form, pCREB), forkhead box O1 (FoxO1 and its phosphorylated form, pFoxO1), and brain-specific homeobox transcription factor (BSX). In addition, to establish a mechanistic link between ghrelin, fatty acid metabolism, and neuropeptides, we evaluated the effect of ghrelin after blockage of hypothalamic fatty acid beta oxidation, by using the CPT1 inhibitor etomoxir. Ghrelin-induced changes in the AMPK-CPT1 pathway are associated with increased levels of AgRP and NPY mRNA expression through modulation of BSX, pCREB, and FoxO1, as well as decreased expression of endoplasmic reticulum (ER) stress markers in a gender-independent manner. In addition, blockage of hypothalamic fatty acid-oxidation prevents the ghrelin-promoting action on AgRP and NPY mRNA expression, also in a gender-independent manner. Notably, this effect is associated with decreased BSX expression and reduced food intake. Overall, our data suggest that BSX integrates changes in neuronal metabolic status with ARC-derived neuropeptides in a gender-independent manner.-Lage, R., Vazquez, M.J., Varela, L., Saha, A. K., Vidal-Puig, A., Nogueiras, R., Dieguez, C., Lopez, M. Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J. 24, 2670-2679 (2010). www.fasebj.org	[Lage, Ricardo; Vazquez, Maria J.; Varela, Luis; Nogueiras, Ruben; Dieguez, Carlos; Lopez, Miguel] Univ Santiago de Compostela, Sch Med, Dept Physiol, Inst Invest Sanitaria, Santiago De Compostela 15782, A Coruna, Spain; [Lage, Ricardo; Vazquez, Maria J.; Varela, Luis; Nogueiras, Ruben; Dieguez, Carlos; Lopez, Miguel] CIBERobn, CIBER Fisiopatol Obesidad & Nutr, Santiago De Compostela, A Coruna, Spain; [Saha, Asish K.] Boston Med Ctr, Diabet Res Unit, Boston, MA USA; [Vidal-Puig, Antonio] Univ Cambridge, Addenbrookes Hosp, Metab Res Labs, Inst Metab Sci, Cambridge CB2 2QQ, England	Universidade de Santiago de Compostela; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Boston Medical Center; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Lopez, M (corresponding author), Univ Santiago de Compostela, Sch Med, Dept Physiol, Inst Invest Sanitaria, S Francisco S-N, Santiago De Compostela 15782, A Coruna, Spain.	m.lopez@usc.es	Varela, Luis/ABG-7581-2020; Nogueiras, Ruben/AAS-9427-2021; López, Miguel/ABF-4844-2021	Varela, Luis/0000-0001-7794-7241; Nogueiras, Ruben/0000-0002-9976-9930; López, Miguel/0000-0002-7823-1648; Saha, Asish/0000-0003-1001-5110; Vidal-Puig, Antonio/0000-0003-4220-9577; dieguez, carlos/0000-0002-0919-4337; Lage Fernandez, Ricardo/0000-0002-8779-7723	Fondo Investigationes Sanitarias [PI061700, PS09/01880]; Ministerio de Educacion y Ciencia [BFU2008, RyC-2007-00211, RyC-2008-02219]; European Union [Health-F2-2008-223713, AVP FP7MITIN, LSHM-CT-2005-018734]; U.K. Medical Research Council; Wellcome Trust; U.S. Public Health Service [K-19514, DK-67509]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067509] Funding Source: NIH RePORTER; Medical Research Council [G0600717, G0802051] Funding Source: researchfish; MRC [G0600717, G0802051] Funding Source: UKRI	Fondo Investigationes Sanitarias(Instituto de Salud Carlos III); Ministerio de Educacion y Ciencia(Spanish Government); European Union(European Commission); U.K. Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Pablo B. Martinez de Morentin for his technical assistance. This work has been supported by grants from Fondo Investigationes Sanitarias (M.L.: PI061700 and PS09/01880), Ministerio de Educacion y Ciencia (C.D.: BFU2008; M.L.: RyC-2007-00211; R.N.: RyC-2008-02219), the European Union (C.D., M.L., and R.N.: Health-F2-2008-223713, Reprobesity; AVP FP7MITIN and LSHM-CT-2005-018734, Hepadip, http://www.hepadip.org), the U.K. Medical Research Council (A.V.P.), The Wellcome Trust (A.V.P.), and the U.S. Public Health Service (A.K.S.: K-19514 and DK-67509). CIBER de Fisiopatologia de la Obesidad y Nutricion is an initiative of Instituto de Salud Carlos III.	Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Andrews ZB, 2008, NATURE, V454, P846, DOI 10.1038/nature07181; Archer ZA, 2004, J ENDOCRINOL, V182, P409, DOI 10.1677/joe.0.1820409; Belgardt BF, 2008, CELL METAB, V7, P291, DOI 10.1016/j.cmet.2008.01.006; BIEBER LL, 1972, ANAL BIOCHEM, V50, P509, DOI 10.1016/0003-2697(72)90061-9; Blaak E, 2001, CURR OPIN CLIN NUTR, V4, P499, DOI 10.1097/00075197-200111000-00006; Chakravarthy MV, 2007, J CLIN INVEST, V117, P2539, DOI 10.1172/JCI31183; Chen HY, 2004, ENDOCRINOLOGY, V145, P2607, DOI 10.1210/en.2003-1596; Clegg DJ, 2007, DIABETES, V56, P1051, DOI 10.2337/db06-0015; Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714; Ernst MB, 2009, J NEUROSCI, V29, P11582, DOI 10.1523/JNEUROSCI.5712-08.2009; Fodor M, 2001, NEUROREPORT, V12, P3989, DOI 10.1097/00001756-200112210-00027; Foster-Schubert KE, 2006, ENDOCR REV, V27, P779, DOI 10.1210/er.2006-0041; Gao Q, 2008, AM J PHYSIOL-ENDOC M, V294, pE817, DOI 10.1152/ajpendo.00733.2007; Gao Q, 2007, NAT MED, V13, P89, DOI 10.1038/nm1525; Gao S, 2007, P NATL ACAD SCI USA, V104, P17358, DOI 10.1073/pnas.0708385104; Hosoi T, 2008, MOL PHARMACOL, V74, P1610, DOI 10.1124/mol.108.050070; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kamegai J, 1999, J NEUROENDOCRINOL, V11, P299; Kamegai J, 2001, DIABETES, V50, P2438, DOI 10.2337/diabetes.50.11.2438; Kim MS, 2006, ELECTROCHEM SOLID ST, V9, pG56, DOI 10.1149/1.2142155; Kirchner H, 2009, NAT MED, V15, P741, DOI 10.1038/nm.1997; Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392; Kleinridders A, 2009, CELL METAB, V10, P249, DOI 10.1016/j.cmet.2009.08.013; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kola B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001797; Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006; Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007; Lee Geung-Joo, 2007, V2, P1; Lopez M, 2006, DIABETES, V55, P1327, DOI 10.2337/db05-1356; Lopez M, 2008, CELL METAB, V7, P389, DOI 10.1016/j.cmet.2008.03.006; de Morentin PBM, 2010, BBA-MOL CELL BIOL L, V1801, P350, DOI 10.1016/j.bbalip.2009.09.016; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Mogi K, 2005, ENDOCRINOLOGY, V146, P3325, DOI 10.1210/en.2005-0078; Mystkowski P, 2000, J NEUROSCI, V20, P8637, DOI 10.1523/JNEUROSCI.20-22-08637.2000; Nazarian A, 2009, PSYCHOPHARMACOLOGY, V203, P641, DOI 10.1007/s00213-008-1411-5; Nogueiras R, 2008, ENDOCRINOLOGY, V149, P3009, DOI 10.1210/en.2007-1684; Olofsson LE, 2009, P NATL ACAD SCI USA, V106, P15932, DOI 10.1073/pnas.0904747106; Ozcan L, 2009, CELL METAB, V9, P35, DOI 10.1016/j.cmet.2008.12.004; Plum L, 2009, NAT MED, V15, P1195, DOI 10.1038/nm.2026; Sakkou M, 2007, CELL METAB, V5, P450, DOI 10.1016/j.cmet.2007.05.007; Sangiao-Alvarellos S, 2009, ENDOCRINOLOGY, V150, P4562, DOI 10.1210/en.2009-0482; Santollo J, 2008, BEHAV BRAIN RES, V191, P173, DOI 10.1016/j.bbr.2008.03.019; Santos CXC, 2009, ANTIOXID REDOX SIGN, V11, P2409, DOI 10.1089/ARS.2009.2625; Shimizu H, 1996, NEUROSCI LETT, V204, P81, DOI 10.1016/0304-3940(96)12322-3; Shimizu-Albergine M, 2001, J NEUROSCI, V21, P1238; Sun YX, 2004, P NATL ACAD SCI USA, V101, P4679, DOI 10.1073/pnas.0305930101; Tagawa Y, 2008, FREE RADICAL BIO MED, V45, P50, DOI 10.1016/j.freeradbiomed.2008.03.003; Tannenbaum GS, 1998, ENDOCRINOLOGY, V139, P4420, DOI 10.1210/en.139.10.4420; Theander-Carrillo C, 2006, J CLIN INVEST, V116, P1983, DOI 10.1172/JCI25811; Tschop M, 2001, DIABETES, V50, P707, DOI 10.2337/diabetes.50.4.707; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Wang W, 2010, REGUL PEPTIDES, V161, P43, DOI 10.1016/j.regpep.2009.12.017; Wang W, 2010, PEPTIDES, V31, P307, DOI 10.1016/j.peptides.2009.11.011; Wortley KE, 2005, J CLIN INVEST, V115, P3573, DOI 10.1172/JCI26003; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; ZAMMIT VA, 1979, BIOCHEM J, V184, P313, DOI 10.1042/bj1840313; Zhang GG, 2009, PEPTIDES, V30, P1109, DOI 10.1016/j.peptides.2009.03.024; Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043; Zigman JM, 2006, J COMP NEUROL, V494, P528, DOI 10.1002/cne.20823; Zigman JM, 2005, J CLIN INVEST, V115, P3564, DOI 10.1172/JCI26002; Zorrilla EP, 2006, P NATL ACAD SCI USA, V103, P13226, DOI 10.1073/pnas.0605376103	62	92	95	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2010	24	8					2670	2679		10.1096/fj.09-150672	http://dx.doi.org/10.1096/fj.09-150672			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20335227	Green Published			2022-12-28	WOS:000285005400009
J	Mathew, R; Jia, WW; Sharma, A; Zhao, YJ; Clarke, LE; Cheng, XA; Wang, HY; Salli, U; Vrana, KE; Robertson, GP; Zhu, JY; Wang, SW				Mathew, Renjith; Jia, Wenwen; Sharma, Arati; Zhao, Yuanjun; Clarke, Loren E.; Cheng, Xiang; Wang, Huayan; Salli, Ugur; Vrana, Kent E.; Robertson, Gavin P.; Zhu, Jiyue; Wang, Shuwen			Robust activation of the human but not mouse telomerase gene during the induction of pluripotency	FASEB JOURNAL			English	Article						pluripotent stem cells; reprogramming; promoter	REVERSE-TRANSCRIPTASE; STEM-CELLS; LIFE-SPAN; CATALYTIC SUBUNIT; HTERT GENE; HUMAN FIBROBLASTS; DNA METHYLATION; EXPRESSION; PROTEIN; LENGTH	Pluripotent stem cells (PSCs) express telomerase and have unlimited proliferative potential. To study telomerase activation during reprogramming, 3 classes of embryonic stem cell (ESC)-like clones were isolated from mouse fibroblasts containing a transgenic hTERT reporter. Class I expressed few pluripotency markers, whereas class II contained many, but not Oct4, Nanog, and Sox2. Neither class of cells differentiated efficiently. Class III cells, the fully reprogrammed induced PSCs (iPSCs), expressed all pluripotency markers, formed teratomas indistinguishable from those of mESCs, and underwent efficient osteogenic differentiation in vitro. Interestingly, whereas the endogenous mTERT gene expression was only moderately increased during reprogramming, the hTERT promoter was strongly activated in class II cells and was further elevated in class III cells. Treatment of class II cells with chemical inhibitors of MEKs and glycogen synthase kinase 3 resulted in their further reprogramming into class III cells, accompanied by a strong activation of hTERT promoter. In reprogrammed human cells, the endogenous telomerase level, although variable among different clones, was dramatically elevated. Only in cells with the highest telomerase were telomeres restored to the lengths in hESCs. Our data, for the first time, demonstrated that the hTERT promoter was strongly activated in discrete steps, revealing a critical difference in human and mouse cell reprogramming. Because telomere elongation is crucial for self-renewal of hPSCs and replicative aging of their differentiated progeny, these findings have important implications in the generation and applications of iPSCs.-Mathew, R., Jia, W., Sharma, A., Zhao, Y., Clarke, L. E., Cheng, X., Wang, H., Salli, U., Vrana, K. E., Robertson, G. P., Zhu, J., Wang, S. Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J. 24, 2702-2715 (2010). www.fasebj.org	[Mathew, Renjith; Jia, Wenwen; Zhao, Yuanjun; Wang, Huayan; Zhu, Jiyue; Wang, Shuwen] Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA USA; [Sharma, Arati; Salli, Ugur; Vrana, Kent E.; Robertson, Gavin P.] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA USA; [Clarke, Loren E.] Penn State Univ, Coll Med, Dept Pathol, Hershey, PA USA; [Jia, Wenwen; Cheng, Xiang] NW Univ Agr & Forestry, Anim Med Coll, Natl Stem Cell Engn & Technol Ctr, Shaanxi Branch, Yangling, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Northwest A&F University - China	Wang, SW (corresponding author), 500 Univ Dr,C4605, Hershey, PA 17033 USA.	sqw10@psu.edu	Mathew, Renjith/N-4285-2013; zhu, ji/HDM-1538-2022; cheng, xiang/C-9987-2016; Robertson, Gavin P./A-6106-2017	Vrana, Kent/0000-0003-4902-7733; cheng, xiang/0000-0001-5315-9830; Robertson, Gavin P./0000-0003-0152-2997; sharma, arati/0000-0001-7178-949X	National Institutes of Health (NIH) [GM071725-S1, R03 CA142060-01, CA-127892-01A, GM38931-S1]; Penn State Cancer Institute Experimental Therapeutic research initiative; Dean's feasibility; Chinese National Natural Science Foundation [30871786]; Chinese National Programs for Fundamental Research and Development (973 plan) [2009CB941002]; NATIONAL CANCER INSTITUTE [R01CA127892, R03CA142060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071725, R01GM038931] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Penn State Cancer Institute Experimental Therapeutic research initiative; Dean's feasibility; Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Chinese National Programs for Fundamental Research and Development (973 plan)(National Basic Research Program of China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. James Thomson (University of Wisconsin, Madison, WI, USA) for the generous gift of hiPSC clones. The authors are also grateful to the Carrel Laboratory at Penn State College of Medicine for their technical help with pyrosequencing. The work was supported in part by National Institutes of Health (NIH) grant GM071725-S1 (J.Z.), a Penn State Cancer Institute Experimental Therapeutic research initiative (J.Z.), and a Dean's feasibility grant (S.W.). J.Z. was a research scholar of the American Cancer Society (RSG-04-197-01-MGO). A.S., G.P.R., and K.E.V. were supported by NIH grants R03 CA142060-01, CA-127892-01A, and GM38931-S1, respectively. H.W. was supported by grants from the Chinese National Natural Science Foundation (30871786) and the Chinese National Programs for Fundamental Research and Development (973 plan, 2009CB941002).	Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884; Armanios M, 2005, COLD SH Q B, V70, P205, DOI 10.1101/sqb.2005.70.030; Armstrong L, 2000, MECH DEVELOP, V97, P109, DOI 10.1016/S0925-4773(00)00423-8; Bekaert S, 2004, DEV BIOL, V274, P15, DOI 10.1016/j.ydbio.2004.06.023; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Blackburn EH, 2000, COLD SPRING HARB SYM, V65, P253, DOI 10.1101/sqb.2000.65.253; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; CHADENEAU C, 1995, ONCOGENE, V11, P893; Clark AJ, 2003, NAT CELL BIOL, V5, P535, DOI 10.1038/ncb992; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Cristofari G, 2006, EMBO J, V25, P565, DOI 10.1038/sj.emboj.7600952; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Forsyth NR, 2005, MECH AGEING DEV, V126, P685, DOI 10.1016/j.mad.2005.01.003; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1999, TRENDS GENET, V15, P109, DOI 10.1016/S0168-9525(98)01681-3; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Gunes C, 2000, CANCER RES, V60, P2116; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herzig M, 2002, BBA-REV CANCER, V1602, P97, DOI 10.1016/S0304-419X(02)00039-2; Horikawa L, 2005, P NATL ACAD SCI USA, V102, P18437, DOI 10.1073/pnas.0508964102; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kozik A, 1998, MOL REPROD DEV, V51, P98, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;98::AID-MRD12&gt;3.0.CO;2-Q; Lansdorp PM, 2008, BLOOD, V111, P1759, DOI 10.1182/blood-2007-09-084913; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Liu L, 2004, GENE CHROMOSOME CANC, V41, P26, DOI 10.1002/gcc.20058; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Marion RM, 2009, CELL STEM CELL, V4, P141, DOI 10.1016/j.stem.2008.12.010; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Peters LL, 2007, NAT REV GENET, V8, P58, DOI 10.1038/nrg2025; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Ulaner GA, 1998, CANCER RES, V58, P4168; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Venteicher AS, 2009, SCIENCE, V323, P644, DOI 10.1126/science.1165357; Wakayama T, 2000, NATURE, V407, P318, DOI 10.1038/35030301; Wang SW, 2004, J BIOL CHEM, V279, P55401, DOI 10.1074/jbc.M411352200; Wang SW, 2003, J BIOL CHEM, V278, P18842, DOI 10.1074/jbc.M209544200; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Wright WE, 1996, DEV GENET, V18, P173; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhao YJ, 2009, GENE CHROMOSOME CANC, V48, P963, DOI 10.1002/gcc.20698; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	72	37	41	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2702	2715		10.1096/fj.09-148973	http://dx.doi.org/10.1096/fj.09-148973			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20354136	Green Published			2022-12-28	WOS:000285005400012
J	Okada, H; Zhang, WZ; Peterhoff, C; Hwang, JC; Nixon, RA; Ryu, SH; Kim, TW				Okada, Hirokazu; Zhang, Wenzhu; Peterhoff, Corrinne; Hwang, Jeremy C.; Nixon, Ralph A.; Ryu, Sung H.; Kim, Tae-Wan			Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing	FASEB JOURNAL			English	Article						protein trafficking; Alzheimer's disease; endosome; trans-Golgi network; retromer	AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE PATHOGENESIS; TRANS-GOLGI NETWORK; GGA PROTEINS; CLEAVING ENZYME; CYTOSOLIC DOMAIN; VHS DOMAIN; TRAFFICKING; RETROMER	The beta-site APP cleaving enzyme-1 (BACE1) mediates the first cleavage of the beta-amyloid precursor protein (APP) to yield the amyloid beta-peptide (A beta), a key pathogenic agent in Alzheimer's disease (AD). Using a proteomic approach based on in-cell chemical cross-linking and tandem affinity purification (TAP), we herein identify sorting nexin 6 (SNX6) as a BACE1-associated protein. SNX6, a PX domain protein, is a putative component of retromer, a multiprotein cargo complex that mediates the retrograde trafficking of the cation-independent mannose-6-phosphate receptor (CI-MPR) and sortilin. RNA interference suppression of SNX6 increased BACE1-dependent secretion of soluble APP (sAPP beta) and cell-associated fragments (C99), resulting in increased A beta secretion. Furthermore, SNX6 reduction led to elevated steady-state BACE1 levels as well as increased retrograde transport of BACE1 in the endocytic pathway, suggesting that SNX6 modulates the retrograde trafficking and basal levels of BACE1, thereby regulating BACE1-mediated APP processing and A beta biogenesis. Our study identifies a novel cellular pathway by which SNX6 negatively modulates BACE1-mediated cleavage of APP.-Okada, H., Zhang, W., Peterhoff, C., Hwang, J. C., Nixon, R. A., Ryu, S. H., Kim, T.-W. Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing. FASEB J. 24, 2783-2794 (2010). www.fasebj.org	[Zhang, Wenzhu; Kim, Tae-Wan] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Okada, Hirokazu; Hwang, Jeremy C.; Kim, Tae-Wan] Columbia Univ, Med Ctr, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; [Kim, Tae-Wan] Columbia Univ, Med Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; [Peterhoff, Corrinne; Nixon, Ralph A.] Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, Orangeburg, NY 10962 USA; [Ryu, Sung H.] Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang, South Korea; [Ryu, Sung H.] Pohang Univ Sci & Technol, Dept Life Sci, Pohang, South Korea	Columbia University; Columbia University; Columbia University; Nathan Kline Institute for Psychiatric Research; Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Kim, TW (corresponding author), Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, 630 W 168th St,P&S 12-430, New York, NY 10032 USA.	twk16@columbia.edu		Okada, Hirokazu/0000-0002-1065-2470; Ryu, Sung Ho/0000-0003-0913-3048	U.S. National Institutes of Health [AG-09702]; American Health Assistance Foundation	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Health Assistance Foundation(BrightFocus Foundation)	This study was supported by an Alzheimer's Disease Research Center grant from the U.S. National Institutes of Health (AG-09702) and by the American Health Assistance Foundation to T.-W.K. The authors thank G. Finan for critical reading of the manuscript, I.S. Kim for technical assistance with molecular biology, and A. Zenobia Moore for assistance with cell culture.	Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2008, CURR OPIN CELL BIOL, V20, P427, DOI 10.1016/j.ceb.2008.03.009; Carlton J, 2005, TRAFFIC, V6, P75, DOI 10.1111/j.1600-0854.2005.00260.x; Carlton J, 2004, CURR BIOL, V14, P1791, DOI 10.1016/j.cub.2004.09.077; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; He XY, 2005, J BIOL CHEM, V280, P11696, DOI 10.1074/jbc.M411296200; He XY, 2003, BIOCHEMISTRY-US, V42, P12174, DOI 10.1021/bi035199h; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Huse JT, 2001, TRAFFIC, V2, P75, DOI 10.1034/j.1600-0854.2001.020201.x; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Koh YH, 2005, J BIOL CHEM, V280, P32499, DOI 10.1074/jbc.M506199200; KOO EH, 1994, J BIOL CHEM, V269, P17386; Landman N, 2006, P NATL ACAD SCI USA, V103, P19524, DOI 10.1073/pnas.0604954103; Lee EB, 2003, J BIOL CHEM, V278, P4458, DOI 10.1074/jbc.M210105200; Lee JY, 2008, J BIOL CHEM, V283, P11501, DOI 10.1074/jbc.M800642200; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Offe K, 2006, J NEUROSCI, V26, P1596, DOI 10.1523/JNEUROSCI.4946-05.2006; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943; Schneider A, 2008, J NEUROSCI, V28, P2874, DOI 10.1523/JNEUROSCI.5345-07.2008; Schobel S, 2008, J BIOL CHEM, V283, P14257, DOI 10.1074/jbc.M801531200; Seaman MNJ, 2005, TRENDS CELL BIOL, V15, P68, DOI 10.1016/j.tcb.2004.12.004; Seet LF, 2006, BBA-MOL CELL BIOL L, V1761, P878, DOI 10.1016/j.bbalip.2006.04.011; Shiba T, 2004, TRAFFIC, V5, P437, DOI 10.1111/j.1600-0854.2004.00188.x; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Small SA, 2005, ANN NEUROL, V58, P909, DOI 10.1002/ana.20667; Spoelgen R, 2006, J NEUROSCI, V26, P418, DOI 10.1523/JNEUROSCI.3882-05.2006; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Vasilescu J, 2004, PROTEOMICS, V4, P3845, DOI 10.1002/pmic.200400856; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Velliquette RA, 2005, J NEUROSCI, V25, P10874, DOI 10.1523/JNEUROSCI.2350-05.2005; Wahle T, 2005, MOL CELL NEUROSCI, V29, P453, DOI 10.1016/j.mcn.2005.03.014; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wassmer T, 2007, J CELL SCI, V120, P45, DOI 10.1242/jcs.03302; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhao J, 2007, J NEUROSCI, V27, P3639, DOI 10.1523/JNEUROSCI.4396-06.2007	48	77	86	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2783	2794		10.1096/fj.09-146357	http://dx.doi.org/10.1096/fj.09-146357			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20354142	Green Published			2022-12-28	WOS:000285005400019
J	Carvalho, CML; Lu, J; Zhang, X; Arner, ESJ; Holmgren, A				Carvalho, Cristina M. L.; Lu, Jun; Zhang, Xu; Arner, Elias S. J.; Holmgren, Arne			Effects of selenite and chelating agents on mammalian thioredoxin reductase inhibited by mercury: implications for treatment of mercury poisoning	FASEB JOURNAL			English	Article						mercury toxicity; selenium; antidotes; thioredoxin system; selenoproteins	INORGANIC MERCURY; METHYLMERCURY; RAT; GLUTATHIONE; METABOLISM; HEALTH; LIVER; ACID; PURIFICATION; TOXICOLOGY	Mercury toxicity is a highly interesting topic in biomedicine due to the severe endpoints and treatment limitations. Selenite serves as an antagonist of mercury toxicity, but the molecular mechanism of detoxification is not clear. Inhibition of the selenoenzyme thioredoxin reductase (TrxR) is a suggested mechanism of toxicity. Here, we demonstrated enhanced inhibition of activity by inorganic and organic mercury compounds in NADPH-reduced TrxR, consistent with binding of mercury also to the active site selenolthiol. On treatment with 5 mu M selenite and NADPH, TrxR inactivated by HgCl2 displayed almost full recovery of activity. Structural analysis indicated that mercury was complexed with TrxR, but enzyme-generated selenide removed mercury as mercury selenide, regenerating the active site selenocysteine and cysteine residues required for activity. The antagonistic effects on TrxR inhibition were extended to endogenous antioxidants, such as GSH, and clinically used exogenous chelating agents BAL, DMPS, DMSA, and alpha-lipoic acid. Consistent with the in vitro results, recovery of TrxR activity and cell viability by selenite was observed in HgCl2-treated HEK 293 cells. These results stress the role of TrxR as a target of mercurials and provide the mechanism of selenite as a detoxification agent for mercury poisoning.-Carvalho, C. M. L., Lu, J., Zhang, X., Arner, E. S. J., Holmgren, A. Effects of selenite and chelating agents on mammalian thioredoxin reductase inhibited by mercury: implications for treatment of mercury poisoning. FASEB J. 25, 370-381 (2011). www.fasebj.org	[Carvalho, Cristina M. L.; Lu, Jun; Zhang, Xu; Arner, Elias S. J.; Holmgren, Arne] Karolinska Inst, Div Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; [Carvalho, Cristina M. L.] Univ Lisbon, Fac Pharm, Res Inst Med & Pharmaceut Sci, P-1649003 Lisbon, Portugal	Karolinska Institutet; Universidade de Lisboa	Holmgren, A (corresponding author), Karolinska Inst, Div Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	cristina.carvalho@ff.ul.pt; arne.holmgren@ki.se	Lu, Jun/E-9701-2017; Carvalho, Cristina/E-3379-2014; Zhang, Xu/F-4324-2018; iMed.ULisboa, CBT/B-4215-2014; Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012	Lu, Jun/0000-0002-1699-8835; Carvalho, Cristina/0000-0002-1097-7910; Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114	Swedish Cancer Society [961]; Swedish Research Council Medicine [13x-3529]; K. A. Wallenberg Foundation; Karolinska Institutet	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council Medicine(Swedish Research Council); K. A. Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Karolinska Institutet(Karolinska Institutet)	The authors thank Mr. Sergio J. Montano (Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet) for his excellent assistance in measuring TrxR activity. This research was supported by grants from the Swedish Cancer Society (961), the Swedish Research Council Medicine (13x-3529), The K. A. Wallenberg Foundation, and the Karolinska Institutet.	Agarwal R, 2007, IND HEALTH, V45, P388, DOI 10.2486/indhealth.45.388; Amer E. S. J., 2000, CURRENT PROTOCOLS S5, P741; [Anonymous], 2000, AIR QUAL GUID EUR; APOSHIAN HV, 1995, TOXICOLOGY, V97, P23, DOI 10.1016/0300-483X(95)02965-B; APOSHIAN HV, 1990, ANNU REV PHARMACOL, V30, P279; APOSHIAN HV, 1982, ADV ENZYME REGUL, V20, P301; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; BALLATORI N, 1985, FUND APPL TOXICOL, V5, P816, DOI 10.1016/0272-0590(85)90165-4; BJORKMAN L, 1995, ARCH TOXICOL, V69, P228, DOI 10.1007/s002040050163; Bjornstedt M., 1985, METHOD ENZYMOL, V252, P209; Boelsterli UA, 2003, MECH TOXICOLOGY; Carvalho CML, 2008, J BIOL CHEM, V283, P11913, DOI 10.1074/jbc.M710133200; Chapman L, 2000, ENVIRON HEALTH PERSP, V108, P29, DOI [10.2307/3454631, 10.2307/3454292]; Cherdwongcharoensuk D, 2010, BIOL TRACE ELEM RES, V136, P197, DOI 10.1007/s12011-009-8532-5; Choi AL, 2008, ENVIRON RES, V107, P45, DOI 10.1016/j.envres.2007.07.006; Clarkson TW, 2006, CRIT REV TOXICOL, V36, P609, DOI 10.1080/10408440600845619; Clarkson TW, 2002, ENVIRON HEALTH PERSP, V110, P11, DOI 10.1289/ehp.02110s111; Clarkson TW, 2003, J TRACE ELEM EXP MED, V16, P321, DOI 10.1002/jtra.10050; CUVINARALAR MLA, 1991, ECOTOX ENVIRON SAFE, V21, P348, DOI 10.1016/0147-6513(91)90074-Y; dos Santos APM, 2007, TOXICOL LETT, V169, P121, DOI 10.1016/j.toxlet.2006.12.007; Dumont E, 2006, ANAL BIOANAL CHEM, V385, P1304, DOI 10.1007/s00216-006-0529-8; Farina M, 2004, TOXICOL LETT, V146, P227, DOI 10.1016/j.toxlet.2003.10.001; FRIEDHEIM EAH, 1954, AM J TROP MED HYG, V3, P714, DOI 10.4269/ajtmh.1954.3.714; Gailer J, 2000, CHEM RES TOXICOL, V13, P1135, DOI 10.1021/tx000050h; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; GANTHER HE, 1972, SCIENCE, V175, P1122, DOI 10.1126/science.175.4026.1122; GASIEWICZ TA, 1978, CHEM-BIOL INTERACT, V21, P299, DOI 10.1016/0009-2797(78)90028-5; GOYER R, 1995, METAL TOXICOLOGY, P35; GREGUS Z, 1992, TOXICOL APPL PHARM, V114, P88, DOI 10.1016/0041-008X(92)90100-7; Heinz GH, 1998, ENVIRON TOXICOL CHEM, V17, P139; Hoffman DJ, 1998, ENVIRON TOXICOL CHEM, V17, P161, DOI 10.1002/etc.5620170204; Hol PJ, 2001, ENVIRON RES, V87, P141, DOI 10.1006/enrs.2001.4308; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MEDINA D, 1984, CANCER RES, V44, P4361; Melchart D, 2008, J DENT RES, V87, P349, DOI 10.1177/154405910808700410; PARIZEK J, 1967, EXPERIENTIA, V23, P142, DOI 10.1007/BF02135970; PETERS RA, 1945, NATURE, V156, P616, DOI 10.1038/156616a0; Petrunkin VE, 1956, UKR KHIM ZH, V22, P603; Ralston NVC, 2008, NEUROTOXICOLOGY, V29, P802, DOI 10.1016/j.neuro.2008.07.007; RIVERA M, 1989, TOXICOL APPL PHARM, V100, P96, DOI 10.1016/0041-008X(89)90094-X; Rooney JPK, 2007, TOXICOLOGY, V234, P145, DOI 10.1016/j.tox.2007.02.016; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; Rush T, 2009, NEUROTOXICOLOGY, V30, P47, DOI 10.1016/j.neuro.2008.10.009; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; World Health Organization, 2003, SUM CONCL 61 M FAO W; Yang DY, 2008, ENVIRON REV, V16, P71, DOI 10.1139/A08-001; Yoneda S, 1997, TOXICOL APPL PHARM, V143, P274, DOI 10.1006/taap.1996.8095; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	52	85	88	1	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					370	381		10.1096/fj.10-157594	http://dx.doi.org/10.1096/fj.10-157594			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20810785				2022-12-28	WOS:000285869500033
J	Goldblum, SE; Rai, U; Tripathi, A; Thakar, M; De Leo, L; Di Toro, N; Not, T; Ramachandran, R; Puche, AC; Hollenberg, MD; Fasano, A				Goldblum, Simeon E.; Rai, Usha; Tripathi, Amit; Thakar, Manjusha; De Leo, Luigina; Di Toro, Nicola; Not, Tarcisio; Ramachandran, Rithwik; Puche, Adam C.; Hollenberg, Morley D.; Fasano, Alessio			The active Zot domain (aa 288-293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation	FASEB JOURNAL			English	Article						intestinal permeability; protein-protein interaction; zonula occludens 1	ZONULA OCCLUDENS TOXIN; TRANSMEMBRANE PROTEINS; SCAFFOLDING PROTEIN; GUT-PERMEABILITY; BARRIER FUNCTION; KINASE; EXPRESSION; CELL; LOCALIZATION; INVOLVEMENT	Vibrio cholerae-derived zonula occludins toxin (Zot) is a multifunctional protein that reversibly disassembles intestinal tight junctions (tjs). Zot structure-function analysis has mapped this activity to aa 288-293, named AT1002. AT1002 reduced transepithelial electrical resistance across rat small intestine, ex vivo, as did Zot and its processed mature form, Delta G. AT1002 increased in vivo permeability to sugar tracers, whereas scrambled control peptides did not. Binding and barrier assays in proteinase activated receptor (PAR)(2)-expressing and PAR(2)-null cells established AT1002 activity to be PAR(2) dependent. Coincident with the increased intestinal permeability, confocal microscopy of AT1002-exposed rat intestinal IEC6 cells revealed displacement of ZO-1 and occludin from intercellular boundaries. In coimmunoprecipitation assays, AT1002 decreased ZO-1-occludin and ZO-1-claudin 1 interactions coincident with PKC alpha-dependent ZO-1 serine/threonine phosphorylation. Further, AT1002 increased serine phosphorylation of myosin 1C and, at the same time, transiently diminished its association with ZO-1. The COOH-terminal domain of ZO-1 was required for its association with myosin 1C. These data indicate that the NH2-terminal portion of active Zot contains a PAR(2)-activating motif, FCIGRL, that increases PKC alpha-dependent ZO-1 and myosin 1C serine/threonine phosphorylation. These modifications provoke selective disengagement of ZO-1 from its binding partners, occludin, claudin 1, and myosin 1C, coincident with opening of tjs.-Goldblum, S. E., Rai, U., Tripathi, A., Thakar, M., De Leo, L., Di Toro, N., Not, T., Ramachandran, R., Puche, A. C., Hollenberg, M. D., Fasano, A. The active Zot domain (aa 288-293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation. FASEB J. 25, 144-158 (2011). www.fasebj.org	[Goldblum, Simeon E.; Rai, Usha; Tripathi, Amit; Thakar, Manjusha; Fasano, Alessio] Univ Maryland, Sch Med, Mucosal Biol Res Ctr, Baltimore, MD 21201 USA; [Puche, Adam C.; Hollenberg, Morley D.] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; [De Leo, Luigina; Di Toro, Nicola; Not, Tarcisio] Univ Trieste, Dept Reprod & Dev Sci, Trieste, Italy; [De Leo, Luigina; Di Toro, Nicola; Not, Tarcisio] Children Hosp Ist Recovero & Cura Carattere Sci B, Trieste, Italy; [Ramachandran, Rithwik] Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada; [Ramachandran, Rithwik] Univ Calgary, Dept Med, Calgary, AB, Canada	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Trieste; University of Calgary; University of Calgary	Fasano, A (corresponding author), Univ Maryland, Sch Med, Mucosal Biol Res Ctr, 20 Penn St,Rm 345, Baltimore, MD 21201 USA.	afasano@mbrc.umaryland.edu	Not, Tarcisio/K-2616-2018; Ramachandran, Rithwik/N-7815-2015; De Leo, Luigina/K-9513-2016; Hollenberg, Morley/AFV-6966-2022; Fasano, Alessio/K-5486-2016; De leo, Luigina/AAC-3321-2022	Not, Tarcisio/0000-0003-1059-3009; Ramachandran, Rithwik/0000-0001-9557-9905; De Leo, Luigina/0000-0003-4013-1630; Fasano, Alessio/0000-0002-2134-0261; 	U.S. National Institutes of Health [DK048373]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048373] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by the U.S. National Institutes of Health (grant DK048373 to A.F.).	Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753; Amadesi S, 2006, J PHYSIOL-LONDON, V575, P555, DOI 10.1113/jphysiol.2006.111534; ANDERSON JM, 1995, BIOCHEM SOC T, V23, P470, DOI 10.1042/bst0230470; ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X; Benais-Pont G., 2001, TIGHT JUNCTIONS, P367; Bueno L, 2008, NEUROGASTROENT MOTIL, V20, P580, DOI 10.1111/j.1365-2982.2008.01139.x; Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; Di Pierro M, 2001, J BIOL CHEM, V276, P19160, DOI 10.1074/jbc.M009674200; El Asmar R, 2002, GASTROENTEROLOGY, V123, P1607, DOI 10.1053/gast.2002.36578; Fanning AS, 2007, MOL BIOL CELL, V18, P721, DOI 10.1091/mbc.E06-08-0764; Fanning Alan S., 2006, P64; Fanning AS, 2002, FASEB J, V16, P1835, DOI 10.1096/fj.02-0121fje; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FASANO A, 1995, J CLIN INVEST, V96, P710, DOI 10.1172/JCI118114; FASANO A, 1991, P NATL ACAD SCI USA, V88, P5242, DOI 10.1073/pnas.88.12.5242; Gonzalez-Mariscal L, 2006, TIGHT JUNCTIONS; Gopalakrishnan S, 2009, INT J PHARMACEUT, V365, P121, DOI 10.1016/j.ijpharm.2008.08.047; Hirata H, 2008, J CELL SCI, V121, P2795, DOI 10.1242/jcs.030320; Hollenberg MD, 2003, LIFE SCI, V74, P237, DOI 10.1016/j.lfs.2003.09.010; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Katouzian F, 2005, CLIN CHIM ACTA, V352, P191, DOI 10.1016/j.cccn.2004.09.023; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Liu AG, 2009, J BIOL CHEM, V284, P6389, DOI 10.1074/jbc.M809198200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Machesky LM, 2000, J CELL BIOL, V148, P219, DOI 10.1083/jcb.148.2.219; Medina R, 2000, J MEMBRANE BIOL, V178, P235, DOI 10.1007/s002320010031; Meyer TN, 2002, J BIOL CHEM, V277, P24855, DOI 10.1074/jbc.C200240200; Mitic LL, 1999, J CELL BIOL, V146, P683, DOI 10.1083/jcb.146.3.683; Mullin JM, 2000, ANN NY ACAD SCI, V915, P231, DOI 10.1111/j.1749-6632.2000.tb05246.x; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Redowicz MJ, 2001, J MUSCLE RES CELL M, V22, P163; Sambuy Y, 2005, CELL BIOL TOXICOL, V21, P1, DOI 10.1007/s10565-005-0085-6; Sato S, 2005, BRIT J PHARMACOL, V146, P397, DOI 10.1038/sj.bjp.0706330; Sharlow ER, 2000, J CELL SCI, V113, P3093; Shen L, 2006, J CELL SCI, V119, P2095, DOI 10.1242/jcs.02915; Sheth B, 1997, DEVELOPMENT, V124, P2027; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Su LP, 2009, GASTROENTEROLOGY, V136, P551, DOI 10.1053/j.gastro.2008.10.081; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Utepbergenov DI, 2006, J BIOL CHEM, V281, P24671, DOI 10.1074/jbc.M512820200; Uzzau S, 1999, MICROB PATHOGENESIS, V27, P377, DOI 10.1006/mpat.1999.0312; Van Itallie CM, 2008, J CELL SCI, V121, P298, DOI 10.1242/jcs.021485; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wagner MC, 1997, AM J PHYSIOL-CELL PH, V272, pC1680, DOI 10.1152/ajpcell.1997.272.5.C1680; Young BA, 1998, BIOCHEM BIOPH RES CO, V251, P320, DOI 10.1006/bbrc.1998.9475	48	68	75	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					144	158		10.1096/fj.10-158972	http://dx.doi.org/10.1096/fj.10-158972			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20852064	Green Published			2022-12-28	WOS:000285869500014
J	Masino, L; Nicastro, G; Calder, L; Vendruscolo, M; Pastore, A				Masino, Laura; Nicastro, Giuseppe; Calder, Lesley; Vendruscolo, Michele; Pastore, Annalisa			Functional interactions as a survival strategy against abnormal aggregation	FASEB JOURNAL			English	Article						ataxin-3; fibrillogenesis; native-like aggregation; neurodegeneration; polyglutamine proteins; structure	JOSEPHIN DOMAIN; PROTEIN ATAXIN-3; POLYGLUTAMINE PROTEIN; UBIQUITIN-BINDING; DISEASE; FIBRILLOGENESIS; PREDICTION; FIBRILS; PATHWAY; PROTEOSTASIS	Protein aggregation is under intense scrutiny because of its role in human disease. Although increasing evidence indicates that protein native states are highly protected against aggregation, the specific protection mechanisms are poorly understood. Insight into such mechanisms can be gained through study of the relatively few proteins that aggregate under native conditions. Ataxin-3, the protein responsible for Spinocerebellar ataxia type 3, a polyglutamine expansion disease, represents one of such examples. Polyglutamine expansion is central for determining solubility and aggregation rates of ataxin-3, but these properties are profoundly modulated by its N-terminal Josephin domain. This work aims at identifying the regions that promote Josephin fibrillogenesis and rationalizing the mechanisms that protect Josephin and nonexpanded ataxin-3 from aberrant aggregation. Using different biophysical techniques, aggregation propensity predictions and rational design of amino acid substitutions, we show that Josephin has an intrinsic tendency to fibrillize under native conditions and that fibrillization is promoted by two solvent-exposed patches, which are also involved in recognition of natural substrates, such as ubiquitin. Indeed, designed mutations at these patches or substrate binding significantly reduce Josephin aggregation kinetics. Our results provide evidence that protein nonpathologic function can play an active role in preventing aberrant fibrillization and suggest the molecular mechanism whereby this occurs in ataxin-3.-Masino, L., Nicastro, G., Calder, L., Vendruscolo, M., Pastore, A. Functional interactions as a survival strategy against abnormal aggregation. FASEB J. 25, 45-54 (2011). www.fasebj.org	[Masino, Laura; Nicastro, Giuseppe; Calder, Lesley; Pastore, Annalisa] Natl Inst Med Res, MRC, London NW7 1AA, England; [Vendruscolo, Michele] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	MRC National Institute for Medical Research; University of Cambridge	Pastore, A (corresponding author), Natl Inst Med Res, MRC, Ridgeway,Mill Hill, London NW7 1AA, England.	apastor@nimr.mrc.ac.uk	Vendruscolo, Michele/F-5901-2012	Vendruscolo, Michele/0000-0002-3616-1610; Masino, Laura/0000-0002-5326-7003	MRC [U117584256]; MRC [MC_U117533887, MC_U117584256] Funding Source: UKRI; Medical Research Council [MC_U117584256, MC_U117533887] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors are very thankful to Xavier Daura and Oscar Conchillo Sole for help with the Aggrescan Web server and to the Medical Research Council (MRC) Biomedical NMR Centre for technical support. The authors acknowledge support from the MRC (grant U117584256).	Albrecht M, 2004, EUR J BIOCHEM, V271, P3155, DOI 10.1111/j.1432-1033.2004.04245.x; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Boeddrich A, 2006, EMBO J, V25, P1547, DOI 10.1038/sj.emboj.7601043; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Chai YH, 2004, J BIOL CHEM, V279, P3605, DOI 10.1074/jbc.M310939200; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Chiti F, 2009, NAT CHEM BIOL, V5, P15, DOI 10.1038/nchembio.131; Chow M. K., 2004, J BIOL CHEM, V1, P1; Chow MKM, 2004, J MOL BIOL, V335, P333, DOI 10.1016/j.jmb.2003.08.064; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Conchillo-Sole O, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-65; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; de Chiara C, 2005, J MOL BIOL, V354, P883, DOI 10.1016/j.jmb.2005.09.083; de Chiara C, 2003, FEBS LETT, V551, P107, DOI 10.1016/S0014-5793(03)00818-4; de Chiara C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008372; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Ehrnhoefer DE, 2008, NAT STRUCT MOL BIOL, V15, P558, DOI 10.1038/nsmb.1437; Ellisdon AM, 2007, J MOL BIOL, V368, P595, DOI 10.1016/j.jmb.2007.02.058; Ellisdon AM, 2006, J BIOL CHEM, V281, P16888, DOI 10.1074/jbc.M601470200; Evert BO, 2006, J NEUROSCI, V26, P11474, DOI 10.1523/JNEUROSCI.2053-06.2006; Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012; Fowler DM, 2007, TRENDS BIOCHEM SCI, V32, P217, DOI 10.1016/j.tibs.2007.03.003; Gales L., 2005, J MOL BIOL, V26, P26; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; Marchal S, 2003, J BIOL CHEM, V278, P31554, DOI 10.1074/jbc.M304205200; Marshall KE, 2009, BIOCHEM SOC T, V37, P671, DOI 10.1042/BST0370671; Masino L, 2004, J MOL BIOL, V344, P1021, DOI 10.1016/j.jmb.2004.09.065; Masino L, 2003, FEBS LETT, V549, P21, DOI 10.1016/S0014-5793(03)00748-8; Nelson R, 2006, ADV PROTEIN CHEM, V73, P235, DOI 10.1016/S0065-3233(06)73008-X; Nicastro G, 2005, P NATL ACAD SCI USA, V102, P10493, DOI 10.1073/pnas.0501732102; Nicastro G, 2004, J BIOMOL NMR, V30, P457, DOI 10.1007/s10858-004-4343-3; Nicastro G, 2006, J BIOMOL NMR, V36, P267, DOI 10.1007/s10858-006-9092-z; Nicastro G, 2009, BIOPOLYMERS, V91, P1203, DOI 10.1002/bip.21210; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Pechmann S, 2009, P NATL ACAD SCI USA, V106, P10159, DOI 10.1073/pnas.0812414106; Powers ET, 2009, ANNU REV BIOCHEM, V78, P959, DOI 10.1146/annurev.biochem.052308.114844; Reumers J, 2008, NUCLEIC ACIDS RES, V36, pD825, DOI 10.1093/nar/gkm979; Riess O, 2008, CEREBELLUM, V7, P125, DOI 10.1007/s12311-008-0013-4; Saunders HM, 2009, PROTEIN ENG DES SEL, V22, P447, DOI 10.1093/protein/gzp033; Shao J, 2007, HUM MOL GENET, V16, pR115, DOI 10.1093/hmg/ddm213; Shehi E, 2003, BIOCHEMISTRY-US, V42, P14626, DOI 10.1021/bi0352825; Tartaglia GG, 2008, CHEM SOC REV, V37, P1395, DOI 10.1039/b706784b; Tartaglia GG, 2008, J MOL BIOL, V380, P425, DOI 10.1016/j.jmb.2008.05.013; Trovato A, 2007, PROTEIN ENG DES SEL, V20, P521, DOI 10.1093/protein/gzm042; Uversky VN, 2009, FRONT BIOSCI-LANDMRK, V14, P5188, DOI 10.2741/3594; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874	51	64	64	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					45	54		10.1096/fj.10-161208	http://dx.doi.org/10.1096/fj.10-161208			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20810784	Green Published			2022-12-28	WOS:000285869500005
J	Arechaga, I; Martinez-Costa, OH; Ferreras, C; Carrascosa, JL; Aragon, JJ				Arechaga, Ignacio; Martinez-Costa, Oscar H.; Ferreras, Cristina; Carrascosa, Jose L.; Aragon, Juan J.			Electron microscopy analysis of mammalian phosphofructokinase reveals an unusual 3-dimensional structure with significant implications for enzyme function	FASEB JOURNAL			English	Article						glycolysis; enzyme regulation; allostery; 3-D reconstruction; structure/function relationships	FRUCTOSE 2,6-BISPHOSPHATE; LIVER PHOSPHOFRUCTOKINASE; ALLOSTERIC TRANSITIONS; ACTIVE FORM; BINDING; IMAGE; 6-PHOSPHATE; ATP; CRYSTALLIZATION; CLASSIFICATION	Phosphofructokinase is a sophisticated allosteric enzyme that is fundamental for the control of glycolysis. The structure of the bacterial enzyme is well characterized. However, little is known about the structural organization of the more complex enzyme from mammals. We have obtained the structure of human muscle phosphofructokinase in the presence of fructose 6-phosphate at a resolution of 1.8 nm by electron microscopy (EM). Particles of the tetrameric enzyme corresponded to an elongated molecule (14.5x9 nm) arranged into 2 dimeric subdomains. Image analysis and 3-dimensional reconstruction showed the presence of a prominent channel in one of the dimers but not in the opposite one, revealing that they are in greatly different conformations. Fitting of bacterial structures into the EM model suggested disruption of the fructose 6-phosphate catalytic and the fructose 2,6-bisphophate allosteric sites in the cavity-containing dimer. Therefore, the reported structure might have major implications for the function of mammalian phosphofructokinase.-Arechaga, I., Martinez-Costa, O. H., Ferreras, C., Carrascosa, J. L., Aragon, J. J. Electron microscopy analysis of mammalian phosphofructokinase reveals an unusual 3-dimensional structure with significant implications for enzyme function. FASEB J. 24, 4960-4968 (2010). www.fasebj.org	[Martinez-Costa, Oscar H.; Ferreras, Cristina; Aragon, Juan J.] UAM, Dept Bioquim, Madrid 28029, Spain; [Martinez-Costa, Oscar H.; Ferreras, Cristina; Aragon, Juan J.] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, Fac Med, Madrid 28029, Spain; [Arechaga, Ignacio; Carrascosa, Jose L.] Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Aragon, JJ (corresponding author), UAM, Dept Bioquim, Madrid 28029, Spain.	jlcarrascosa@cnb.csic.es; juanjose.aragon@uam.es	Martinez-Costa, Oscar/B-7275-2014; Arechaga, Ignacio/K-2198-2014	Martinez-Costa, Oscar/0000-0003-4893-2205; Arechaga, Ignacio/0000-0002-1342-9370	Ministerio de Ciencia e Innovacion (MICINN) [BFU2008-02328/BMG, CSD2007-00010, BFU2005-09071, BFU2008-02364, BFU2009-13114]; Direccion General de Universidades of the Comunidad de Madrid [S2009/MAT-1507]	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Direccion General de Universidades of the Comunidad de Madrid	The authors thank Valentina Sanchez for help with protein purification and Jaime Martin-Benito for help with the 3-D image reconstruction analysis. This work was supported by grants BFU2008-02328/BMG and Consolider CSD2007-00010 from the Ministerio de Ciencia e Innovacion (MICINN) and S2009/MAT-1507 from the Direccion General de Universidades of the Comunidad de Madrid to J.LC., and BFU2005-09071, BFU2008-02364 and BFU2009-13114 from MICINN to J.J.A.	ARAGON JJ, 1991, FASEB J, V5, P2945, DOI 10.1096/fasebj.5.14.1752361; AUZAT I, 1995, BIOCHEMISTRY-US, V34, P7062, DOI 10.1021/bi00021a018; Auzat I, 1997, J MOL BIOL, V267, P476, DOI 10.1006/jmbi.1997.0883; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANUELOS M, 1977, J BIOL CHEM, V252, P6394; Barcena M, 2007, J STRUCT BIOL, V159, P135, DOI 10.1016/j.jsb.2007.03.004; Benjamin S, 2007, J STRUCT BIOL, V159, P498, DOI 10.1016/j.jsb.2007.06.001; Benjamin S, 2009, J STRUCT BIOL, V168, P345, DOI 10.1016/j.jsb.2009.06.014; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLOMBO G, 1975, J BIOL CHEM, V250, P9404; DUNAWAY GA, 1988, BIOCHEM J, V251, P677, DOI 10.1042/bj2510677; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; Ferreras C, 2009, J BIOL CHEM, V284, P9124, DOI 10.1074/jbc.M807737200; FOE LG, 1980, J BIOL CHEM, V255, P537; FOE LG, 1985, J BIOL CHEM, V260, P726; FRIEDEN C, 1976, J BIOL CHEM, V251, P5644; Heinisch JJ, 1996, J BIOL CHEM, V271, P15928, DOI 10.1074/jbc.271.27.15928; HESTERBERG LK, 1980, BIOCHEMISTRY-US, V19, P2030, DOI 10.1021/bi00551a004; HESTERBERG LK, 1981, J BIOL CHEM, V256, P9724; Heymann JB, 2001, J STRUCT BIOL, V133, P156, DOI 10.1006/jsbi.2001.4339; HILL DE, 1975, BIOCHEMISTRY-US, V14, P203, DOI 10.1021/bi00673a003; KARADSHEH NS, 1977, J BIOL CHEM, V252, P3515; KEMP RG, 1983, MOL CELL BIOCHEM, V57, P147, DOI 10.1007/BF00849191; Kemp RG, 2002, BIOCHEMISTRY-US, V41, P9426, DOI 10.1021/bi020110d; KEMP RG, 1967, BIOCHEMISTRY-US, V6, P423, DOI 10.1021/bi00854a009; KITAJIMA S, 1983, J BIOL CHEM, V258, P7352; KONO N, 1973, J BIOL CHEM, V248, P8592; KOPPERSCHLAGER G, 1968, Febs Letters, V1, P137, DOI 10.1016/0014-5793(68)80041-9; Li YL, 1999, BIOCHEMISTRY-US, V38, P16407, DOI 10.1021/bi991761l; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Martinez-Costa OH, 2004, BIOCHEM J, V377, P77, DOI 10.1042/BJ20031032; Martinez-Costa OH, 2007, FEBS LETT, V581, P3033, DOI 10.1016/j.febslet.2007.05.059; Martinez-Oyanedel J, 2007, J MOL BIOL, V366, P1185, DOI 10.1016/j.jmb.2006.10.019; MARTINEZCOSTA OH, 1994, EUR J BIOCHEM, V226, P1007, DOI 10.1111/j.1432-1033.1994.01007.x; Mindell JA, 2003, J STRUCT BIOL, V142, P334, DOI 10.1016/S1047-8477(03)00069-8; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Ortigosa AD, 2004, BIOCHEMISTRY-US, V43, P577, DOI 10.1021/bi035077p; PARMEGGIANI A, 1966, J BIOL CHEM, V241, P4625; Pascual-Montano A, 2001, J STRUCT BIOL, V133, P233, DOI 10.1006/jsbi.2001.4369; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1477, DOI 10.1021/bi00548a034; Ruiz T, 2003, J STRUCT BIOL, V143, P124, DOI 10.1016/S1047-8477(03)00140-0; Ruiz T, 2001, J STRUCT BIOL, V136, P167, DOI 10.1006/jsbi.2002.4440; Sanchez-Martinez C, 2000, BIOCHEM BIOPH RES CO, V271, P635, DOI 10.1006/bbrc.2000.2681; Santamaria B, 2002, J BIOL CHEM, V277, P1210, DOI 10.1074/jbc.M109480200; Scheres SHW, 2005, J MOL BIOL, V348, P139, DOI 10.1016/j.jmb.2005.02.031; Scheres SHW, 2008, NAT PROTOC, V3, P977, DOI 10.1038/nprot.2008.62; Scheres SHW, 2007, STRUCTURE, V15, P1167, DOI 10.1016/j.str.2007.09.003; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; Sorzano COS, 2004, J STRUCT BIOL, V148, P194, DOI 10.1016/j.jsb.2004.06.006; TELFORD JN, 1975, P NATL ACAD SCI USA, V72, P3054, DOI 10.1073/pnas.72.8.3054; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; Wriggers W, 1999, J STRUCT BIOL, V125, P185, DOI 10.1006/jsbi.1998.4080	57	6	6	4	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4960	4968		10.1096/fj.10-165845	http://dx.doi.org/10.1096/fj.10-165845			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20732951				2022-12-28	WOS:000284824400034
J	Woo, CH; Le, NT; Shishido, T; Chang, E; Lee, H; Heo, KS; Mickelsen, DM; Lu, Y; McClain, C; Spangenberg, T; Yan, C; Molina, CA; Yang, J; Patterson, C; Abe, J				Woo, Chang-Hoon; Le, Nhat-Tu; Shishido, Tetsuro; Chang, Eugene; Lee, Hakjoo; Heo, Kyung-Sun; Mickelsen, Deanne M.; Lu, Yan; McClain, Carolyn; Spangenberg, Thomas; Yan, Chen; Molina, Carlos A.; Yang, Jay; Patterson, Cam; Abe, Jun-ichi			Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin ligase on inhibiting cardiac apoptosis and dysfunction via regulating ERK5-mediated degradation of inducible cAMP early repressor	FASEB JOURNAL			English	Article						cell signaling; MAP kinase; ICER; cardiomyocyte apoptosis	HEAT-SHOCK PROTEINS; QUALITY CONTROL; MYOCARDIAL-INFARCTION; CARDIOMYOCYTE APOPTOSIS; CHAPERONE FUNCTIONS; ENDOTHELIAL-CELLS; TRANSGENIC MICE; ISCHEMIC-INJURY; FEEDBACK LOOP; IN-VIVO	Growing evidence indicates a critical role of ubiquitin-proteosome system in apoptosis regulation. A cardioprotective effect of ubiquitin (Ub) ligase of the C terminus of Hsc70-interacting protein (CHIP) on myocytes has been reported. In the current study, we found that the cardioprotective effect of insulin growth factor-1 (IGF-1) was mediated by ERK5-CHIP signal module via inducible cAMP early repressor (ICER) destabilization. In vitro runoff assay and Ub assay showed ICER as a substrate of CHIP Ub ligase. Both disruption of ERK5-CHIP binding with inhibitory helical linker domain fragment (aa 101-200) of CHIP and the depletion of ERK5 by siRNA inhibited CHIP Ub ligase activity, which suggests an obligatory role of ERK5 on CHIP activation. Depletion of CHIP, using siRNA, inhibited IGF-1-mediated reduction of isoproterenol-mediated ICER induction and apoptosis. In diabetic mice subjected to myocardial infarction, the CHIP Ub ligase activity was decreased, with an increase in ICER expression. These changes were attenuated significantly in a cardiac-specific constitutively active form of MEK5 alpha transgenic mice (CA-MEK5 alpha-Tg) previously shown to have greater functional recovery. Furthermore, pressure overload-mediated ICER induction was enhanced in heterozygous CHIP+/- mice. We identified ICER as a novel CHIP substrate and that the ERK5-CHIP complex plays an obligatory role in inhibition of ICER expression, cardiomyocyte apoptosis, and cardiac dysfunction.-Woo, C.-H., Le, N.-T., Shishido, T., Chang, E., Lee, H., Heo, K.-S., Mickelsen, D. M., Lu, Y., McClain, C., Spangenberg, T., Yan, C., Molina, C. A., Yang, J., Patterson, C., Abe, J.-I. Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin ligase on inhibiting cardiac apoptosis and dysfunction via regulating ERK5-mediated degradation of inducible cAMP early repressor. FASEB J. 24, 4917-4928 (2010). www.fasebj.org	[Abe, Jun-ichi] Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14642 USA; [Shishido, Tetsuro; Abe, Jun-ichi] Yamagata Univ, Sch Med, Dept Cardiol Pulmonol & Nephrol, Yamagata 99023, Japan; [Molina, Carlos A.] Montclair State Univ, Dept Biol & Mol Biol, Montclair, NJ USA; [Yang, Jay] Univ Wisconsin, Dept Anesthesiol, Madison, WI USA; [Patterson, Cam] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA	University of Rochester; Yamagata University; Montclair State University; University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; University of North Carolina Chapel Hill	Abe, J (corresponding author), Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, 601 Elmwood Ave,Box CVRI, Rochester, NY 14642 USA.			Heo, Kyung-Sun/0000-0003-3800-7665; Yan, Chen/0000-0002-1397-6358	American Heart Association [0930360N, 0740013N]; U.S. National Institutes of Health [HL-88637, HL-077789]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088400, R01HL108551, P01HL077789, R01HL102746, R37HL065619, R01HL088637, R01HL064839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061728] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported by grants from the American Heart Association to C.-H. W. (Scientist Development grant 0930360N) and J.-I.A. (Established Investigator Award 0740013N), and from the U.S. National Institutes of Health to J.-I.A.(HL-88637 and HL-077789). The authors declare no conflicts of interest.	Akaike M, 2004, MOL CELL BIOL, V24, P8691, DOI 10.1128/MCB.24.19.8691-8704.2004; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Cameron SJ, 2004, FEBS LETT, V566, P255, DOI 10.1016/j.febslet.2004.03.120; Chlopcikova Sarka, 2001, Biomedical Papers (Olomouc), V145, P49; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Ding B, 2000, CIRCULATION, V101, P2854, DOI 10.1161/01.CIR.101.24.2854; Ding B, 2005, P NATL ACAD SCI USA, V102, P14771, DOI 10.1073/pnas.0506489102; Ding B, 2005, CIRCULATION, V111, P2469, DOI 10.1161/01.CIR.0000165128.39715.87; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Hwang JR, 2005, CELL STRESS CHAPERON, V10, P147, DOI 10.1379/CSC-90R.1; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; KIMURA TE, CIRC RES, V106, P961; Lips DJ, 2004, CIRCULATION, V109, P1938, DOI 10.1161/01.CIR.0000127126.73759.23; Liu QH, 2009, CIRC RES, V105, pE19; Martin JL, 1997, CIRCULATION, V96, P4343; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Matsusaka H, 2006, CARDIOVASC RES, V70, P457, DOI 10.1016/j.cardiores.2006.02.001; Min JN, 2008, MOL CELL BIOL, V28, P4018, DOI 10.1128/MCB.00296-08; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Patterson C, 2007, CIRCULATION, V115, P1456, DOI 10.1161/CIRCULATIONAHA.106.649863; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Rosser MFN, 2007, J BIOL CHEM, V282, P22267, DOI 10.1074/jbc.M700513200; Shishido T, 2008, CIRC RES, V102, P1416, DOI 10.1161/CIRCRESAHA.107.168138; Tomita H, 2003, CIRC RES, V93, P12, DOI 10.1161/01.RES.0000079794.57578.F1; Trost SU, 1998, J CLIN INVEST, V101, P855, DOI 10.1172/JCI265; Truman AW, 2006, EUKARYOT CELL, V5, P1914, DOI 10.1128/EC.00263-06; Wang XJ, 2008, J MOL CELL CARDIOL, V45, P11, DOI 10.1016/j.yjmcc.2008.03.025; Wang XJ, 2006, CIRC RES, V99, P1315, DOI 10.1161/01.RES.0000252342.61447.a2; Woo CH, 2008, CIRC RES, V102, P538, DOI 10.1161/CIRCRESAHA.107.156877; Xu Z, 2006, BIOCHEMISTRY-US, V45, P4749, DOI 10.1021/bi0601508; Xu Z, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-26; Yan C, 2007, CIRC RES, V100, P510, DOI 10.1161/01.RES.0000259045.49371.9c; Yehia G, 2001, J BIOL CHEM, V276, P35272, DOI 10.1074/jbc.M105404200; Zhang CL, 2005, AM J PHYSIOL-HEART C, V288, pH2836, DOI 10.1152/ajpheart.01122.2004	38	38	39	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4917	4928		10.1096/fj.10-162636	http://dx.doi.org/10.1096/fj.10-162636			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20724525	Green Published			2022-12-28	WOS:000284824400030
J	Wuertz, CM; Lorincz, A; Vettel, C; Thomas, MA; Wieland, T; Lutz, S				Wuertz, Christina M.; Lorincz, Akos; Vettel, Christiane; Thomas, Martin A.; Wieland, Thomas; Lutz, Susanne			p63RhoGEF-a key mediator of angiotensin II-dependent signaling and processes in vascular smooth muscle cells	FASEB JOURNAL			English	Article						G-protein-coupled receptors; RhoA; guanine nucleotide exchange factor; contraction; proliferation	NUCLEOTIDE-EXCHANGE FACTORS; STRESS FIBER FORMATION; RAT UTERINE MYOCYTES; LIGHT-CHAIN KINASE; TYPE-1 RECEPTOR; RHOA ACTIVATION; G-PROTEINS; INDUCED MIGRATION; INVOLVEMENT; TRANSFORMATION	The purpose of our study was to investigate the role of endogenous p63RhoGEF in G(q/11)-dependent RhoA activation and signaling in rat aortic smooth muscle cells (RASMCs). Therefore, we studied the expression and subcellular localization in freshly isolated RASMCs and performed loss of function experiments to analyze its contribution to RhoGTPase activation and functional responses such as proliferation and contraction. By this, we could show that p63RhoGEF is endogenously expressed in RASMCs and acts there as the dominant mediator of the fast angiotensin II (ANG II)-dependent but not of the sphingosine-1-phosphate (S1P)-dependent RhoA activation. p63RhoGEF is not an activator of the concomitant Rac1 activation and functions independently of caveolae. The knockdown of endogenous p63RhoGEF significantly reduced the mitogenic response of ANG II, abolished ANG II-induced stress fiber formation and cell elongation in 2-D culture, and impaired the ANG II-driven contraction in a collagen-based 3-D model. In conclusion, our data provide for the first time evidence that p63RhoGEF is an important mediator of ANG II-dependent RhoA activation in RASMCs and therewith a leading actor in the subsequently triggered cellular processes, such as proliferation and contraction.-Wuertz, C. M., Lorincz, A., Vettel, C., Thomas, M. A., Wieland, T., Lutz, S. p63RhoGEF-a key mediator of angiotensin II-dependent signaling and processes in vascular smooth muscle cells. FASEB J. 24, 4865-4876 (2010). www.fasebj.org	[Lutz, Susanne] Univ Gottingen, Dept Pharmacol, Med Fac Goettingen, D-37075 Gottingen, Germany; [Wuertz, Christina M.; Lorincz, Akos; Vettel, Christiane; Thomas, Martin A.; Wieland, Thomas] Heidelberg Univ, Inst Expt & Clin Pharmacol & Toxicol, Med Fac Mannheim, Heidelberg, Germany	University of Gottingen; Ruprecht Karls University Heidelberg	Lutz, S (corresponding author), Univ Gottingen, Dept Pharmacol, Med Fac Goettingen, Robert Koch Str 40, D-37075 Gottingen, Germany.	susanne.lutz@med.uni-goettingen.de	Lőrincz, Ákos M./N-9929-2017; Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Lőrincz, Ákos M./0000-0002-2819-5116; Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261	Deutsche Forschungsgemeinschaft [Lu1486/1-1, SFB TR 23 TP B6]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank S. Gorbey for the coordination of the animal facility, Z. Baraniak and H. Scheffel for the help with the animal work, and W. Greffrath for the help with the calcium assay. This work was supported by Deutsche Forschungsgemeinschaft grants Lu1486/1-1 and SFB TR 23 TP B6 (to S.L. and T.W).	Allen CL, 2008, J MOL CELL CARDIOL, V45, P198, DOI 10.1016/j.yjmcc.2008.05.021; Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200; Bregeon J, 2009, AM J PHYSIOL-CELL PH, V297, pC1062, DOI 10.1152/ajpcell.00174.2009; Bryan B, 2004, J BIOL CHEM, V279, P45824, DOI 10.1074/jbc.M406216200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Coussin F, 2002, CIRC RES, V91, P151, DOI 10.1161/01.RES.0000028150.51130.36; Cuello F, 2007, CIRC RES, V100, P864, DOI 10.1161/01.RES.0000260809.15393.fa; Friedrich EB, 2006, BIOCHEM BIOPH RES CO, V349, P883, DOI 10.1016/j.bbrc.2006.07.217; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Guilluy C, 2010, NAT MED, V16, P183, DOI 10.1038/nm.2079; Guo XG, 2003, J BIOL CHEM, V278, P13207, DOI 10.1074/jbc.M208896200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Horiuchi M, 2003, CIRCULATION, V107, P106, DOI 10.1161/01.CIR.0000043244.13596.20; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Jia GH, 2008, J MOL CELL CARDIOL, V44, P882, DOI 10.1016/j.yjmcc.2008.03.002; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Ladwein M, 2008, FEBS LETT, V582, P2066, DOI 10.1016/j.febslet.2008.04.033; Liu HW, 2002, HYPERTENSION, V40, P451, DOI 10.1161/01.HYP.0000033466.05496.89; Lutz S, 2005, J BIOL CHEM, V280, P11134, DOI 10.1074/jbc.M411322200; Lutz S, 2004, N-S ARCH PHARMACOL, V369, pR52; Lutz S, 2007, SCIENCE, V318, P1923, DOI 10.1126/science.1147554; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Mendez-Bolaina E, 2007, AM J PHYSIOL-CELL PH, V293, pC1953, DOI 10.1152/ajpcell.00519.2006; Min LJ, 2005, CIRC RES, V97, P434, DOI 10.1161/01.RES.0000180753.63183.95; Mizuno Y, 2008, AM J PHYSIOL-CELL PH, V295, pC358, DOI 10.1152/ajpcell.90645.2007; Moepps B, 2008, CELL SIGNAL, V20, P1528, DOI 10.1016/j.cellsig.2008.04.010; Murthy KS, 2003, BIOCHEM J, V374, P145, DOI 10.1042/BJ20021274; Naito H, 2006, CIRCULATION, V114, pI72, DOI 10.1161/CIRCULATIONAHA.105.001560; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Ohtsu H, 2005, ARTERIOSCL THROM VAS, V25, P1831, DOI 10.1161/01.ATV.0000175749.41799.9b; Ohtsu H, 2008, ENDOCRINOLOGY, V149, P3569, DOI 10.1210/en.2007-1694; PAN P, BMC CELL BIOL, V11, P36; Patel H. H., 2008, V186, P167, DOI 10.1007/978-3-540-72843-6_7; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; Peifley KA, 1998, BIOCHEM BIOPH RES CO, V242, P202, DOI 10.1006/bbrc.1997.7940; Ridley AJ, 1997, INT J BIOCHEM CELL B, V29, P1225, DOI 10.1016/S1357-2725(97)00052-6; Rojas RJ, 2007, J BIOL CHEM, V282, P29201, DOI 10.1074/jbc.M703458200; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Shin EY, 2009, EXP MOL MED, V41, P387, DOI 10.3858/emm.2009.41.6.044; Siderovski DP, 2005, INT J BIOL SCI, V1, P51, DOI 10.7150/ijbs.1.51; Souchet M, 2002, J CELL SCI, V115, P629; Sriwai W, 2008, BIOCHEM J, V411, P543, DOI [10.1042/BJ20071299, 10.1042/bj20071299]; Steffens F, 2003, MOL ENDOCRINOL, V17, P2103, DOI 10.1210/me.2003-0047; Sternweis PC, 2007, ADV PROTEIN CHEM, V74, P189, DOI 10.1016/S0065-3233(07)74006-8; Suzuki H, 2009, ARTERIOSCL THROM VAS, V29, P217, DOI 10.1161/ATVBAHA.108.181024; Takashima S, 2008, CARDIOVASC RES, V79, P689, DOI 10.1093/cvr/cvn118; Taylor DS, 1999, P NATL ACAD SCI USA, V96, P1633, DOI 10.1073/pnas.96.4.1633; Thomas CM, 2008, J CELL MOL MED, V12, P796, DOI 10.1111/j.1582-4934.2008.00295.x; Ueda H, 2004, EXP CELL RES, V298, P207, DOI 10.1016/j.yexcr.2004.04.015; Vogt A, 2007, CELL SIGNAL, V19, P1229, DOI 10.1016/j.cellsig.2007.01.003; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; White CD, 2008, NEUROENDOCRINOLOGY, V88, P67, DOI 10.1159/000119093; Wirth A, 2008, NAT MED, V14, P64, DOI 10.1038/nm1666; Ying ZK, 2009, ARTERIOSCL THROM VAS, V29, pE48; Yoneda A, 2005, J CELL BIOL, V170, P443, DOI 10.1083/jcb.200412043; Zhou XB, 2007, MOL ENDOCRINOL, V21, P740, DOI 10.1210/me.2006-0220; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zuo L, 2005, ARTERIOSCL THROM VAS, V25, P1824, DOI 10.1161/01.ATV.0000175295.09607.18	61	49	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					4865	4876		10.1096/fj.10-155499	http://dx.doi.org/10.1096/fj.10-155499			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20739613				2022-12-28	WOS:000284824400026
J	Balogh, Z; Lautner, G; Bardoczy, V; Komorowska, B; Gyurcsanyi, RE; Meszaros, T				Balogh, Zsofia; Lautner, Gergely; Bardoczy, Viola; Komorowska, Beata; Gyurcsanyi, Robert. E.; Meszaros, Tamas			Selection and versatile application of virus-specific aptamers	FASEB JOURNAL			English	Article						DOS-ELONA; SELEX; immunoblot; virus coat protein	QUADRUPLEX STRUCTURE; DNA APTAMERS; PROTEIN; EVOLUTION; ANTIGEN	Although the significance of molecular diagnostics in routine plant virus detection is rapidly growing, the preferred methods are still antibody-based enzyme immunoassays. In the past decade, aptamers have been demonstrated to be viable alternatives of antibodies in many applications. We set out to select apple stem pitting virus (ASPV)-specific aptamers and to apply them as antibody substitutes in various immunoassay methods. The applied systematic evolution of ligands by exponential enrichment (SELEX) procedure resulted in highly discriminative aptamers selectively binding to the target virus coat protein even in complex protein matrixes. We developed protocols for exploitation of aptamers in diverse plant virus diagnosis methods, such as dot and Western blot analyses and enzyme-linked oligonucleotide assay (ELONA). Our selected aptamers proved to be superior to the available antibody in all aspects. In contrast to the antibody, the aptamers decorate both native and denaturated proteins, and ELONA produces higher signal intensity than traditional enzyme-linked immunosorbent assay (ELISA) with virus-infected plant extract. Summarily, our results present the selection and practical utilization of first plant virus-specific aptamers. Most important, the first application of ELONA for virus detection is demonstrated, which proposes a novel, more flexible, and cost-effective means of virus diagnostics.-Balogh, Z., Lautner, G., Bardoczy, V., Komorowska, B., Gyurcsanyi, R. E., Meszaros, T. Selection and versatile application of virus-specific aptamers. FASEB J. 24, 4187-4195 (2010). www.fasebj.org	[Balogh, Zsofia; Meszaros, Tamas] Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1094 Budapest, Hungary; [Lautner, Gergely; Gyurcsanyi, Robert. E.] Budapest Univ Technol & Econ, Dept Inorgan & Analyt Chem, H-1117 Budapest, Hungary; [Bardoczy, Viola] Budapest Univ Technol & Econ, Dept Appl Biotechnol & Food Sci, H-1117 Budapest, Hungary; [Komorowska, Beata] Res Inst Pomol & Floriculture, Skierniewice, Poland; [Gyurcsanyi, Robert. E.; Meszaros, Tamas] Hungarian Acad Sci, Res Grp Tech Analyt Chem, Budapest, Hungary	Semmelweis University; Budapest University of Technology & Economics; Budapest University of Technology & Economics; Hungarian Academy of Sciences	Meszaros, T (corresponding author), Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, Tuzolto U 37-47, H-1094 Budapest, Hungary.	tamas.meszaros@eok.sote.hu	Lautner, Gergely/F-7150-2010; Meszaros, Tamas/A-9647-2014; Komorowska, Beata/U-9022-2018; Gyurcsányi, Róbert E./ABD-6643-2021; Gyurcsanyi, Robert/F-5865-2010	Meszaros, Tamas/0000-0002-7396-9678; Komorowska, Beata/0000-0002-0093-3842; Gyurcsanyi, Robert/0000-0002-9929-7865	Hungarian Scientific Fund OTKA [NF 69262]; NKTH-OTKA [K68161]; Bolyai Janos Fellowship	Hungarian Scientific Fund OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); NKTH-OTKA(National Office for Research and TechnologyOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Bolyai Janos Fellowship(Hungarian Academy of Sciences)	The authors thank Wilhelm Jelkmann (Julius Kuehn Institute-Federal Research Center for Cultivated Plants, Institute for Plant Protection in Fruit Crops and Viticulture, Dossenheim, Germany) for kindly providing PSA-H-infected plants. This work was supported by the Hungarian Scientific Fund OTKA (NF 69262) and NKTH-OTKA (K68161). T.M. gratefully acknowledges the support of the Bolyai Janos Fellowship.	Ahn DG, 2009, ANALYST, V134, P1896, DOI 10.1039/b906788d; Balamurugan S, 2008, ANAL CHEM, V80, P9630, DOI 10.1021/ac8009559; Baldrich E, 2004, ANAL CHEM, V76, P7053, DOI 10.1021/ac049258o; Bonhoeffer S, 2002, NATURE, V420, P367, DOI 10.1038/420367a; Bunka DHJ, 2006, NAT REV MICROBIOL, V4, P588, DOI 10.1038/nrmicro1458; CAMERON HR, 1989, VIRUS VIRUSLIKE DIS, P175; Charlton B, 2009, COMP IMMUNOL MICROB, V32, P341, DOI 10.1016/j.cimid.2008.01.009; Chen F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006830; Croft H, 2008, J VIROL METHODS, V153, P203, DOI 10.1016/j.jviromet.2008.07.016; Dausse E, 2009, CURR OPIN PHARMACOL, V9, P602, DOI 10.1016/j.coph.2009.07.006; Dougan H, 2000, NUCL MED BIOL, V27, P289, DOI 10.1016/S0969-8051(99)00103-1; Drolet DW, 1996, NAT BIOTECHNOL, V14, P1021, DOI 10.1038/nbt0896-1021; Ferreira CSM, 2008, ANAL BIOANAL CHEM, V390, P1039, DOI 10.1007/s00216-007-1470-1; Gatto B, 2009, CURR MED CHEM, V16, P1248, DOI 10.2174/092986709787846640; Gopinath SCB, 2006, J GEN VIROL, V87, P479, DOI 10.1099/vir.0.81508-0; Gopinath SCB, 2007, ANAL BIOANAL CHEM, V387, P171, DOI 10.1007/s00216-006-0826-2; Gugerli P, 2004, ACTA HORTIC, P59, DOI 10.17660/ActaHortic.2004.657.6; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; Ikebukuro K, 2004, ANAL LETT, V37, P2901, DOI 10.1081/AL-200035778; Jayasena SD, 1999, CLIN CHEM, V45, P1628; Jones LA, 2006, ANTIMICROB AGENTS CH, V50, P3019, DOI 10.1128/AAC.01603-05; Kikin O, 2006, NUCLEIC ACIDS RES, V34, pW676, DOI 10.1093/nar/gkl253; Klerks MM, 2001, PHYTOPATHOLOGY, V91, P1085, DOI 10.1094/PHYTO.2001.91.11.1085; Komorowska B, 2010, J VIROL METHODS, V168, P242, DOI 10.1016/j.jviromet.2010.04.024; KUMMERT J, 2004, ACTA HORT ISHS, V657, P541; KUMMERT J, 1998, ACTA HORTIC, V472, P97; Lautner G, 2010, ANALYST, V135, P918, DOI 10.1039/b922829b; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; MacKenzie DJ, 1997, PLANT DIS, V81, P222, DOI 10.1094/PDIS.1997.81.2.222; Mairal T, 2008, ANAL BIOANAL CHEM, V390, P989, DOI 10.1007/s00216-007-1346-4; Martelli GP, 1998, ARCH VIROL, V143, P1245, DOI 10.1007/s007050050372; Murphy MB, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng110; Nadala ECB, 2000, J VIROL METHODS, V84, P175, DOI 10.1016/S0166-0934(99)00140-8; NEMETH M, 1986, VIRUS MYCOPLASMA RIC, P216; NIVISON T, 1987, PLANT MOL BIOL REP, V5, P295; Papamichael KI, 2007, SENSOR ACTUAT B-CHEM, V121, P178, DOI 10.1016/j.snb.2006.09.024; Reina J, 2002, J CLIN MICROBIOL, V40, P3515, DOI 10.1128/JCM.40.9.3515-3517.2002; ROSENTHAL A, 1993, NUCLEIC ACIDS RES, V21, P173, DOI 10.1093/nar/21.1.173; Skottrup PD, 2008, BIOSENS BIOELECTRON, V24, P339, DOI 10.1016/j.bios.2008.06.045; Takahashi M, 2005, J CLIN MICROBIOL, V43, P186, DOI 10.1128/JCM.43.1.186-191.2005; Thompson RL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000352; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Vivekananda J, 2006, LAB INVEST, V86, P610, DOI 10.1038/labinvest.3700417; YOSHIKAWA N, 2001, ACTA HORTIC ISHS, V1, P285	44	33	37	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4187	4195		10.1096/fj.09-144246	http://dx.doi.org/10.1096/fj.09-144246			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20624933				2022-12-28	WOS:000283861100007
J	Liu, QQ; Gauthier, MS; Sun, L; Ruderman, N; Lodish, H				Liu, Qingqing; Gauthier, Marie-Soleil; Sun, Lei; Ruderman, Neil; Lodish, Harvey			Activation of AMP-activated protein kinase signaling pathway by adiponectin and insulin in mouse adipocytes: requirement of acyl-CoA synthetases FATP1 and Acsl1 and association with an elevation in AMP/ATP ratio	FASEB JOURNAL			English	Article						acyl-CoA synthetases; adipokine	FATTY-ACID TRANSPORT; SKELETAL-MUSCLE CELLS; MEMBRANE-TRANSPORT; PLASMA-MEMBRANE; GLUCOSE-UPTAKE; OXIDATION; METABOLISM; CARBOXYLASE; INHIBITION; EXPRESSION	Adiponectin activates AMP-activated protein kinase (AMPK) in adipocytes, but the underlying mechanism remains unclear. Here we tested the hypothesis that AMP, generated in activating fatty acids to their CoA derivatives, catalyzed by acyl-CoA synthetases, is involved in AMPK activation by adiponectin. Moreover, in adipocytes, insulin affects the subcellular localization of acyl-CoA synthetase FATP1. Thus, we also tested whether insulin activates AMPK in these cells and, if so, whether it activates through a similar mechanism. We examined these hypotheses by measuring the AMP/ATP ratio and AMPK activation on adiponectin and insulin stimulation and after knocking down acyl-CoA synthetases in adipocytes. We show that adiponectin activation of AMPK is accompanied by an similar to 2-fold increase in the cellular AMP/ATP ratio. Moreover, FATP1 and Acsl1, the 2 major acyl-CoA synthetase isoforms in adipocytes, are essential for AMPK activation by adiponectin. We also show that after 40 min. insulin activated AMPK in adipocytes, which was coupled with a 5-fold increase in the cellular AMP/ATP ratio. Knockdown studies show that FATP1 and Acsl1 are required for these processes, as well as for stimulation of long-chain fatty acid uptake by adiponection and insulin. These studies demonstrate that a change in cellular energy state is associated with AMPK activation by both adiponectin and insulin, which requires the activity of FATP1 and Acsl1.-Liu, Q., Gauthier, M.-L., Sun, L., Ruderman, N., Lodish, H. Activation of AMP-activated protein kinase signaling pathway by adiponectin and insulin in mouse adipocytes: requirement of acyl-CoA synthetases FATP1 and Acsl1 and association with an elevation in AMP/ATP ratio. FASEB J. 24, 4229-4239 (2010). www.fasebj.org	[Liu, Qingqing; Sun, Lei; Lodish, Harvey] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Gauthier, Marie-Soleil; Ruderman, Neil] Boston Univ, Sch Med, Dept Med, Endocrinol Sect,Diabet Res Unit, Boston, MA 02118 USA; [Lodish, Harvey] MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Boston University; Massachusetts Institute of Technology (MIT)	Lodish, H (corresponding author), Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.	lodish@wi.mit.edu	liu, qingqing/HHD-0360-2022	Ruderman, Neil/0000-0002-6589-6587	American Diabetes Association [7-04-MN-27]; National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases [2R01 DK0467618-20]; NIH/National Heart, Lung, and Blood Institute [P01 HL 066105]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066105] Funding Source: NIH RePORTER	American Diabetes Association(American Diabetes Association); National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Tsu-Shuen Tsao (University of Arizona, Tucson, AZ, USA) for providing the adiponectin C22A expression vector, Dr. Kelly Wong and Dr. Yutong Sun for insightful discussions and critical reading of the manuscript, and Dr. Julia Xu for technical assistance for nucleotide studies. This work was supported by a mentor-based fellowship from the American Diabetes Association, award 7-04-MN-27; National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases grant 2R01 DK0467618-20 (to H.F.L.); and NIH/National Heart, Lung, and Blood Institute grant P01 HL 066105 (to M.K.).	Berggreen C, 2009, AM J PHYSIOL-ENDOC M, V296, pE635, DOI 10.1152/ajpendo.90596.2008; Black Paul N, 2007, Novartis Found Symp, V286, P127; BLACK PN, 2007, NOVART FDN SYMP, V286, P162; BLACK PN, 2007, NOVART FDN SYMP, V286, P138; BLACK PN, 2007, NOVART FDN SYMP, V286, P196; Bonen A, 2007, PHYSIOLOGY, V22, P15, DOI 10.1152/physiologyonline.2007.22.1.15; Campbell SE, 2004, J BIOL CHEM, V279, P36235, DOI 10.1074/jbc.M400566200; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Folmes CDL, 2006, CIRC RES, V99, P61, DOI 10.1161/01.RES.0000229656.05244.11; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; Gargiulo CE, 1999, J LIPID RES, V40, P881; Gauthier MS, 2008, J BIOL CHEM, V283, P16514, DOI 10.1074/jbc.M708177200; Gimeno RE, 2003, J BIOL CHEM, V278, P49512, DOI 10.1074/jbc.M309759200; Hall AM, 2005, J BIOL CHEM, V280, P11948, DOI 10.1074/jbc.M412629200; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; HESLER CB, 1990, J BIOL CHEM, V265, P6600; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Kampf JP, 2007, PHYSIOLOGY, V22, P7, DOI 10.1152/physiol.00011.2006; Kawaguchi T, 2002, J BIOL CHEM, V277, P3829, DOI 10.1074/jbc.M107895200; Kelly M, 2009, DIABETES, V58, P1953, DOI 10.2337/db08-1293; Koh HJ, 2007, BIOCHEM J, V403, P473, DOI 10.1042/BJ20061479; Li LO, 2006, J BIOL CHEM, V281, P37246, DOI 10.1074/jbc.M604427200; Mao XM, 2006, NAT CELL BIOL, V8, P516, DOI 10.1038/ncb1404; Mashek DG, 2006, J LIPID RES, V47, P2004, DOI 10.1194/jlr.M600150-JLR200; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Palanivel R, 2005, FEBS LETT, V579, P5049, DOI 10.1016/j.febslet.2005.08.011; Passonneau J. V., 1993, ENZYMATIC ANAL PRACT, p[157, 272]; Rajala MW, 2004, DIABETES, V53, P1671, DOI 10.2337/diabetes.53.7.1671; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Richards MR, 2006, J LIPID RES, V47, P665, DOI 10.1194/jlr.M500514-JLR200; RODBELL M, 1964, J BIOL CHEM, V239, P375; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Sebastian D, 2009, J LIPID RES, V50, P1789, DOI 10.1194/jlr.M800535-JLR200; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Suzuki S, 2007, FEBS LETT, V581, P809, DOI 10.1016/j.febslet.2007.01.046; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tong FM, 2006, ARCH BIOCHEM BIOPHYS, V447, P46, DOI 10.1016/j.abb.2006.01.005; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; Wiczer BM, 2009, BIOCHEM BIOPH RES CO, V387, P234, DOI 10.1016/j.bbrc.2009.06.114; Winder WW, 2000, J APPL PHYSIOL, V89, P2430, DOI 10.1152/jappl.2000.89.6.2430; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; Wong KA, 2006, J BIOL CHEM, V281, P36434, DOI 10.1074/jbc.M607410200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Wu QW, 2006, MOL CELL BIOL, V26, P3455, DOI 10.1128/MCB.26.9.3455-3467.2006; Wu XD, 2003, DIABETES, V52, pA1; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	60	53	53	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4229	4239		10.1096/fj.10-159723	http://dx.doi.org/10.1096/fj.10-159723			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20667975	Green Published			2022-12-28	WOS:000283861100011
J	Wang, XC; Blanchard, J; Kohlbrenner, E; Clement, N; Linden, RM; Radu, A; Grundke-Iqbal, I; Iqbal, K				Wang, Xiaochuan; Blanchard, Julie; Kohlbrenner, Erik; Clement, Nathalie; Linden, R. Michael; Radu, Aurelian; Grundke-Iqbal, Inge; Iqbal, Khalid			The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment	FASEB JOURNAL			English	Article						A beta; adeno-associated virus-induced expression; glycogen synthase kinase-3 beta; hyperphosphorylation of tau; neurofibrillary degeneration; nontransgenic rat model of Alzheimer disease; SET	GLYCOGEN-SYNTHASE KINASE-3-BETA; ABNORMALLY PHOSPHORYLATED-TAU; INCREASES PHOSPHORYLATION; KINASE 3-BETA; UP-REGULATION; P70 S6; 2A; HYPERPHOSPHORYLATION; ACTIVATION; BRAIN	Development of rational therapeutic treatments of Alzheimer disease (AD) requires the elucidation of the etiopathogenic mechanisms of neurofibrillary degeneration and beta-amyloidosis, the two hallmarks of this disease. Here we show, employing an adeno-associated virus serotype 1 (AAV1)-induced expression of the C-terminal fragment (I-2CTF) of I-2(PP2A), also called SET, in rat brain, decrease in protein phosphatase 2A (PP2A) activity, abnormal hyperphosphorylation of tau, and neurodegeneration; littermates treated identically but with vector only, i.e., AAV1-enhanced green fluorescent protein (GFP), served as a control. Furthermore, there was an increase in the level of activated glycogen synthase kinase-3 beta and enhanced expression of intraneuronal A beta in AAV1-I-2CTF animals. Morris water maze behavioral test revealed that infection with AAV1-I-2CTF induced spatial reference memory and memory consolidation deficits and a decrease in the brain level of pSer133-CREB. These findings suggest a novel etiopathogenic mechanism of AD, which is initiated by the cleavage of I-2(PP2A), producing I-2CTF, and describe a novel disease-relevant nontransgenic animal model of AD.-Wang, X., Blanchard, J., Kohlbrenner, E., Clement, N., Linden, R. M., Radu, A., Grundke-Iqbal, I., Iqbal, K. The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J. 24, 4420-4432 (2010). www.fasebj.org	[Wang, Xiaochuan; Blanchard, Julie; Grundke-Iqbal, Inge; Iqbal, Khalid] New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA; [Kohlbrenner, Erik; Clement, Nathalie; Linden, R. Michael] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY USA; [Radu, Aurelian] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY USA	Institute for Basic Research in Developmental Disabilities; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Iqbal, K (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	khalid.iqbal.ibr@gmail.com			New York State Office of Mental Retardation and Developmental Disabilities; National Institutes of Health/National Institute of Aging [AG019158]; National Natural Science Foundation of China [30871259]; Education Ministry of China [NCET-07-0332]; NATIONAL INSTITUTE ON AGING [R01AG019158] Funding Source: NIH RePORTER	New York State Office of Mental Retardation and Developmental Disabilities; National Institutes of Health/National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Education Ministry of China(Ministry of Education, China); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are grateful to Dr. Jian-Zhi Wang (Tongji Medical College, Wuhan, China) for a kind gift of HEK293/tau cells; to Drs. Fei Liu, Bin Li, and Guo-Hua Fan for helpful technical suggestions during the conduct of this study; to Dr. Ezzat El-Akkad for preparation of digital images; and to Ms. Janet Murphy for secretarial assistance. This work was supported in part by the New York State Office of Mental Retardation and Developmental Disabilities and a research grant from the National Institutes of Health/National Institute of Aging, grant AG019158, and a 1-yr fellowship to Dr. Xiaochuan Wang from the National Natural Science Foundation of China (30871259) and the Education Ministry of China (NCET-07-0332). Author contributions: X.W. performed most of the experiments and analyses; J.B. carried out some of the immunohistochemical and all behavioral studies and analyses; E. K., N.C., and R.M.L. generated recombinant AAV1 and did the vector packaging and tittering; A.R. directed the generation of the I<INF>2CTF</INF> recombinant plasmids; I.G.I. directed and analyzed all immunohistochemical and immunochemical studies and the preparation of the manuscript; K.I. designed and oversaw the research project and directed most of the experiments, analyses, and writing.	ALAFUZOFF I, 1987, ACTA NEUROPATHOL, V74, P209, DOI 10.1007/BF00688184; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Alonso AD, 2006, P NATL ACAD SCI USA, V103, P8864, DOI 10.1073/pnas.0603214103; An WL, 2003, AM J PATHOL, V163, P591, DOI 10.1016/S0002-9440(10)63687-5; Avila J, 2010, EXPERT REV NEUROTHER, V10, P703, DOI 10.1586/ERN.10.40; Barco A, 2003, EXPERT OPIN THER TAR, V7, P101, DOI 10.1517/14728222.7.1.101; Bennecib M, 2001, FEBS LETT, V490, P15, DOI 10.1016/S0014-5793(01)02127-5; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Chen S, 2008, J BIOL CHEM, V283, P10513, DOI 10.1074/jbc.M709852200; Davis GW, 1996, NEURON, V17, P669, DOI 10.1016/S0896-6273(00)80199-3; GANDY SE, 1993, ANN NY ACAD SCI, V695, P117, DOI 10.1111/j.1749-6632.1993.tb23038.x; Gantier R, 2000, NEUROSCI LETT, V283, P217, DOI 10.1016/S0304-3940(00)00949-6; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1994, NEUROSCIENCE, V61, P765, DOI 10.1016/0306-4522(94)90400-6; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; Henckaerts E, 2009, P NATL ACAD SCI USA, V106, P7571, DOI 10.1073/pnas.0806821106; Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje; Horike N, 2008, J BIOL CHEM, V283, P33902, DOI 10.1074/jbc.M802537200; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Iqbal K, 2005, ANN NEUROL, V58, P748, DOI 10.1002/ana.20639; Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3; Katayose Y, 2000, J BIOL CHEM, V275, P9209, DOI 10.1074/jbc.275.13.9209; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; Lawlor PA, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-11; Li B, 2008, J NEUROPATH EXP NEUR, V67, P78, DOI 10.1097/nen.0b013e318160c5db; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Liang L, 2004, FEBS LETT, V566, P261, DOI 10.1016/j.febslet.2004.04.047; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu GP, 2008, NEUROBIOL AGING, V29, P1348, DOI 10.1016/j.neurobiolaging.2007.03.012; Liu ZX, 2008, MOL CELL, V29, P665, DOI 10.1016/j.molcel.2008.02.017; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; Nicolia V, 2010, J ALZHEIMERS DIS, V19, P895, DOI 10.3233/JAD-2010-1284; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Pei JJ, 2003, AM J PATHOL, V163, P845, DOI 10.1016/S0002-9440(10)63445-1; Pei JJ, 1998, J NEURAL TRANSM, V105, P69, DOI 10.1007/s007020050039; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Planel E, 2001, J BIOL CHEM, V276, P34298, DOI 10.1074/jbc.M102780200; Rezai-Zadeh K, 2009, J CELL MOL MED, V13, P574, DOI 10.1111/j.1582-4934.2008.00344.x; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sengupta A, 2006, NEUROCHEM RES, V31, P1473, DOI 10.1007/s11064-006-9205-9; Small SA, 2006, NEURON, V52, P15, DOI 10.1016/j.neuron.2006.09.001; Sontag JM, 2008, J NEUROSCI, V28, P11477, DOI 10.1523/JNEUROSCI.2816-08.2008; Sun L, 2003, NEUROSCIENCE, V118, P1175, DOI 10.1016/S0306-4522(02)00697-8; Suzuki T, 1997, BIOCHEMISTRY-US, V36, P4643, DOI 10.1021/bi962618k; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Tanimukai H, 2005, AM J PATHOL, V166, P1761, DOI 10.1016/S0002-9440(10)62486-8; Tsujio I, 2005, FEBS LETT, V579, P363, DOI 10.1016/j.febslet.2004.11.097; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Zhang YH, 2005, FEBS LETT, V579, P6230, DOI 10.1016/j.febslet.2005.09.095; Zolotukhin S, 2002, METHODS, V28, P158, DOI 10.1016/S1046-2023(02)00220-7	61	69	74	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4420	4432		10.1096/fj.10-158477	http://dx.doi.org/10.1096/fj.10-158477			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20651003	Green Published			2022-12-28	WOS:000283861100028
J	Gibert, Y; Bernard, L; Debiais-Thibaud, M; Bourrat, F; Joly, JS; Pottin, K; Meyer, A; Retaux, S; Stock, DW; Jackman, WR; Seritrakul, P; Begemann, G; Laudet, V				Gibert, Yann; Bernard, Laure; Debiais-Thibaud, Melanie; Bourrat, Franck; Joly, Jean-Stephane; Pottin, Karen; Meyer, Axel; Retaux, Sylvie; Stock, David W.; Jackman, William R.; Seritrakul, Pawat; Begemann, Gerrit; Laudet, Vincent			Formation of oral and pharyngeal dentition in teleosts depends on differential recruitment of retinoic acid signaling	FASEB JOURNAL			English	Article						tooth; Astyanax; FGF; zebrafish	MEDAKA ORYZIAS-LATIPES; ZEBRAFISH DANIO-RERIO; PECTORAL FIN BUD; TOOTH DEVELOPMENT; FOREBRAIN DEVELOPMENT; GENE-EXPRESSION; SONIC-HEDGEHOG; IN-VIVO; FGF; RECEPTORS	One of the goals of evolutionary developmental biology is to link specific adaptations to changes in developmental pathways. The dentition of cypriniform fishes, which in contrast to many other teleost fish species possess pharyngeal teeth but lack oral teeth, provides a suitable model to study the development of feeding adaptations. Here, we have examined the involvement of retinoic acid (RA) in tooth development and show that RA is specifically required to induce the pharyngeal tooth developmental program in zebrafish. Perturbation of RA signaling at this stage abolished tooth induction without affecting the development of tooth-associated ceratobranchial bones. We show that this inductive event is dependent on RA synthesis from aldh1a2 in the ventral posterior pharynx. Fibroblast growth factor (FGF) signaling has been shown to be critical for tooth induction in zebrafish, and its loss has been associated with oral tooth loss in cypriniform fishes. Pharmacological treatments targeting the RA and FGF pathways revealed that both pathways act independently during tooth induction. In contrast, we find that in Mexican tetra and medaka, species that also possess oral teeth, both oral and pharyngeal teeth are induced independently of RA. Our analyses suggest an evolutionary scenario in which the gene network controlling tooth development obtained RA dependency in the lineage leading to the cypriniforms. The loss of pharyngeal teeth in this group was cancelled out through a shift in aldh1a2 expression, while oral teeth might have been lost ultimately due to deficient RA signaling in the oral cavity.-Gibert, Y., Bernard, L., Debiais-Thibaud, M., Bourrat, F., Joly, J.-S., Pottin, K., Meyer, A., Retaux, S., Stock, D. W., Jackman, W. R., Seritrakul, P., Begemann, G., Laudet, V. Formation of oral and pharyngeal dentition in teleosts depends on differential recruitment of retinoic acid signaling. FASEB J. 24, 3298-3309 (2010). www.fasebj.org	[Gibert, Yann; Bernard, Laure; Laudet, Vincent] Univ Lyon, CNRS, Ecole Normale Super Lyon, INRA,Mol Zool Grp,Inst Genom Fonct Lyon,UCB Lyon, F-69364 Lyon 07, France; [Debiais-Thibaud, Melanie] CNRS, UPR 9034, Equipe Genome Dev & Evolut, Gif Sur Yvette, France; [Pottin, Karen; Retaux, Sylvie] CNRS, UPR 3294, Inst Neurobiol A Fessard, Equipe DECA, Gif Sur Yvette, France; [Bourrat, Franck; Joly, Jean-Stephane] INRA, Grp U1126, Paris, France; [Meyer, Axel; Begemann, Gerrit] Univ Konstanz, Dept Biol, Constance, Germany; [Stock, David W.] Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA; [Jackman, William R.; Seritrakul, Pawat] Bowdoin Coll, Dept Biol, Brunswick, ME 04011 USA	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; INRAE; University of Konstanz; University of Colorado System; University of Colorado Boulder; Bowdoin College	Laudet, V (corresponding author), Univ Lyon, CNRS, Ecole Normale Super Lyon, INRA,Mol Zool Grp,Inst Genom Fonct Lyon,UCB Lyon, F-69364 Lyon 07, France.	vincent.laudet@ens-lyon.fr	Begemann, Gerrit/C-6223-2011; Meyer, Axel/C-9826-2009	Begemann, Gerrit/0000-0001-7822-7617; Meyer, Axel/0000-0002-0888-8193; Pottin, Karen/0000-0001-9491-4660; Seritrakul, Pawat/0000-0002-8320-6789; Debiais-Thibaud, Melanie/0000-0002-1377-2515	Deutsche Forschungsgemeinschaft; ENS Lyon; ANR program; French Ministry of Research; ANR-Neuro; INRA; CNRS; ANR Grant Choregnet; Marine Genomics Center of Excellence; FP6 STREP Plurigenes; NIH [5F32DE015029, P20RR016463]; NSF [IOS-0446720]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE015029] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); ENS Lyon; ANR program(French National Research Agency (ANR)); French Ministry of Research(Ministry of Research, FranceEuropean Commission); ANR-Neuro(French National Research Agency (ANR)); INRA; CNRS(Centre National de la Recherche Scientifique (CNRS)); ANR Grant Choregnet(French National Research Agency (ANR)); Marine Genomics Center of Excellence; FP6 STREP Plurigenes; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by an ARC fellowship (to Y.G.), funding from the Deutsche Forschungsgemeinschaft (to G. B.), funding from the ENS Lyon, the ANR program and the French Ministry of Research (to V. L.), an ANR-Neuro (to S. R.), INRA, CNRS, the ANR Grant Choregnet, the Marine Genomics Center of Excellence, the FP6 STREP Plurigenes (to J.-S.J.), and NIH 5F32DE015029 and P20RR016463 (to W.R.J.), and a NSF IOS-0446720 (to D. W. S.). The authors thank Pierre Germain (Centre de Biochimie Structurale, Montpellier, France) for his kind gift of the RARa and RARg selective agonists and antagonists. Thanks to Matthieu Simion and Laurent Legendre for expert animal care in Gif.	Ahn DG, 2002, NATURE, V417, P754, DOI 10.1038/nature00814; AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; Begemann G, 2001, DEVELOPMENT, V128, P3081; Begemann G, 2004, DEV BIOL, V271, P119, DOI 10.1016/j.ydbio.2004.03.033; Bertrand S, 2007, PLOS GENET, V3, P2085, DOI 10.1371/journal.pgen.0030188; Borday-Birraux V, 2006, EVOL DEV, V8, P130, DOI 10.1111/j.1525-142X.2006.00084.x; Canestro C, 2006, EVOL DEV, V8, P394, DOI 10.1111/j.1525-142X.2006.00113.x; de Lera AR, 2007, NAT REV DRUG DISCOV, V6, P811, DOI 10.1038/nrd2398; Debiais-Thibaud M, 2008, EVOL DEV, V10, P464, DOI 10.1111/j.1525-142X.2008.00257.x; Debiais-Thibaud M, 2007, J EXP ZOOL PART B, V308B, P693, DOI 10.1002/jez.b.21183; Escriva H, 2002, DEVELOPMENT, V129, P2905; Escriva H, 2006, PLOS GENET, V2, P955, DOI 10.1371/journal.pgen.0020102; Fisher S, 1999, NAT GENET, V23, P442, DOI 10.1038/70557; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Germain P, 2006, PHARMACOL REV, V58, P712, DOI 10.1124/pr.58.4.4; Gibert Y, 2006, DEVELOPMENT, V133, P2649, DOI 10.1242/dev.02438; Grandel H, 2002, DEVELOPMENT, V129, P2851; Hale LA, 2006, GENE EXPR PATTERNS, V6, P546, DOI 10.1016/j.modgep.2005.10.007; Halloran MC, 2000, DEVELOPMENT, V127, P1953; Hamade A, 2006, DEV BIOL, V289, P127, DOI 10.1016/j.ydbio.2005.10.019; Hernandez RE, 2004, DEVELOPMENT, V131, P4511, DOI 10.1242/dev.01297; Huysseune A, 1998, ANAT EMBRYOL, V198, P289, DOI 10.1007/s004290050185; Iwamatsu T, 2004, MECH DEVELOP, V121, P605, DOI 10.1016/j.mod.2004.03.012; Jackman WR, 2004, DEV BIOL, V274, P139, DOI 10.1016/j.ydbio.2004.07.003; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klein OD, 2006, DEV CELL, V11, P181, DOI 10.1016/j.devcel.2006.05.014; Kopinke D, 2006, DEV DYNAM, V235, P2695, DOI 10.1002/dvdy.20905; Laurenti P, 2004, DEV DYNAM, V230, P727, DOI 10.1002/dvdy.20080; Liang D, 2008, GENE EXPR PATTERNS, V8, P248, DOI 10.1016/j.gep.2007.12.007; Linville A, 2009, DEV BIOL, V325, P60, DOI 10.1016/j.ydbio.2008.09.022; Mandler M, 2001, DEV BIOL, V240, P548, DOI 10.1006/dbio.2001.0490; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Matt N, 2003, DEVELOPMENT, V130, P2083, DOI 10.1242/dev.00428; Menuet A, 2007, DEVELOPMENT, V134, P845, DOI 10.1242/dev.02780; Miletich Isabelle, 2004, Birth Defects Res C Embryo Today, V72, P200, DOI 10.1002/bdrc.20012; Mitsiadis TA, 2006, J EXP ZOOL PART B, V306B, P177, DOI 10.1002/jez.b.21104; Morriss-Kay GM, 1999, INT REV CYTOL, V188, P73; Nelson JS, 2006, FISHES WORLD, DOI DOI 10.1002/9781119174844; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Peterkova R, 2006, J EXP ZOOL PART B, V306B, P234, DOI 10.1002/jez.b.21093; Pittlik S, 2008, GENE EXPR PATTERNS, V8, P141, DOI 10.1016/j.gep.2007.11.003; Ribes V, 2006, DEVELOPMENT, V133, P351, DOI 10.1242/dev.02204; Schilling TF, 1996, DEVELOPMENT, V123, P329; Sirbu IO, 2006, NAT CELL BIOL, V8, P271, DOI 10.1038/ncb1374; Smith MM, 2009, J EXP ZOOL PART B, V312B, P260, DOI 10.1002/jez.b.21272; Stock DW, 2007, J EXP ZOOL PART B, V308B, P523, DOI 10.1002/jez.b.21187; Stock DW, 2006, DEVELOPMENT, V133, P3127, DOI 10.1242/dev.02459; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Tompkins K, 2006, CONNECT TISSUE RES, V47, P111, DOI 10.1080/03008200600727756; Van der Heyden C, 2000, CELL TISSUE RES, V302, P205, DOI 10.1007/s004410000180; White RJ, 2007, PLOS BIOL, V5, P2522, DOI 10.1371/journal.pbio.0050304	51	23	24	3	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3298	3309		10.1096/fj.09-147488	http://dx.doi.org/10.1096/fj.09-147488			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20445074	Green Published			2022-12-28	WOS:000281446400018
J	Han, XB; Kitamoto, S; Wang, HW; Boisvert, WA				Han, Xinbing; Kitamoto, Shiro; Wang, Hongwei; Boisvert, William A.			Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice	FASEB JOURNAL			English	Article						macrophage-specific retroviral transduction; foam cell formation; cholesterol efflux; inflammation; apoptosis	FOAM-CELL-FORMATION; SCAVENGER RECEPTOR-A; E-DEFICIENT MICE; E KNOCKOUT MICE; CHOLESTEROL EFFLUX; INHIBITS ATHEROSCLEROSIS; LIPOPROTEIN METABOLISM; DENSITY-LIPOPROTEINS; TRANSGENIC MICE; GENE-TRANSFER	In atherogenesis, macrophage foam cell formation is modulated by pathways involving both the uptake and efflux of cholesterol. We recently showed that interleukin-10 (IL-10) modulates lipid metabolism by enhancing both uptake and efflux of cholesterol in macrophages. However, the mechanistic details of these properties in vivo have been unclear. Thus, the purpose of this study was to determine whether expression of IL-10 in macrophages would alter susceptibility to atherosclerosis and whether IL-10 exerts its antiatherosclerotic properties by modulating lipid metabolism in macrophages. We utilized a macrophage-specific retroviral vector that allows long-term in vivo expression of IL-10 in macrophages through transplantation of retrovirally transduced bone marrow cells (BMCs). IL-10 expressed by macrophages derived from transduced BMCs inhibited atherosclerosis in LDLR-/- mice by reducing cholesteryl ester accumulation in atherosclerotic sites. Experiments with primary macrophages indicated that macrophage source of IL-10 stimulated both the uptake (by up-regulating scavenger receptors) and efflux of cholesterol (by activating the PPAR gamma-LXR-ABCA1/ABCG1 pathway), thereby reducing inflammation and apoptosis in atherosclerosis. These findings indicate that BMC-transduced macrophage IL-10 production can act as a strong antiatherogenic agent, and they highlight a novel antiatherosclerotic therapy using a simple, yet effective, stem cell transduction system that facilitates long-term expression of IL-10 in macrophages.-Han, X., Kitamoto, S., Wang, H., Boisvert, W. A. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J. 24, 2869-2880 (2010). www.fasebj.org	[Boisvert, William A.] Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, Honolulu, HI 96813 USA; [Han, Xinbing; Kitamoto, Shiro; Wang, Hongwei; Boisvert, William A.] Harvard Univ, Sch Med, Brigham Womens Hosp, Vasc Med Res Unit, Cambridge, MA 02138 USA	University of Hawaii System; Harvard University; Brigham & Women's Hospital	Boisvert, WA (corresponding author), Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, 651 Ilalo St,BSB 311-C, Honolulu, HI 96813 USA.	wab@hawaii.edu			National Institutes of Health [HL075677]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075677] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank E. Raines (University of Washington, Seattle, WA, USA) for providing the CD68S-containing retroviral vector, as well as for valuable comments. The authors are grateful to D. Ahl for assistance with BMT. This study was supported by National Institutes of Health grant HL075677 (to W.A.B.).	Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Blankenberg S, 2003, CIRCULATION, V107, P1579, DOI 10.1161/01.CIR.0000058700.41738.12; BOLTZNITULESCU G, 1987, J LEUKOCYTE BIOL, V41, P83, DOI 10.1002/jlb.41.1.83; Caligiuri G, 2003, MOL MED, V9, P10, DOI 10.1007/BF03402102; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; de Winther MPJ, 1999, ATHEROSCLEROSIS, V144, P315, DOI 10.1016/S0021-9150(98)00332-3; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; Gough PJ, 2006, J CLIN INVEST, V116, P59, DOI 10.1172/JCI25074; Gough PJ, 2003, BLOOD, V101, P485, DOI 10.1182/blood-2002-07-2131; Halvorsen B, 2005, J LIPID RES, V46, P211, DOI 10.1194/jlr.M400324-JLR200; Han XB, 2009, J BIOL CHEM, V284, P32950, DOI 10.1074/jbc.M109.040899; Herijgers N, 2000, J LIPID RES, V41, P1402; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Klappacher GW, 2002, CURR OPIN LIPIDOL, V13, P305, DOI 10.1097/00041433-200206000-00011; KRUTH HS, 1984, AM J PATHOL, V114, P201; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200; Liu Y, 2006, ATHEROSCLEROSIS, V188, P19, DOI 10.1016/j.atherosclerosis.2005.10.029; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Mallat Z, 1999, ARTERIOSCL THROM VAS, V19, P611, DOI 10.1161/01.ATV.19.3.611; Moore KJ, 2006, ARTERIOSCL THROM VAS, V26, P1702, DOI 10.1161/01.ATV.0000229218.97976.43; Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Oslund LJP, 1999, ARTERIOSCL THROM VAS, V19, P2847, DOI 10.1161/01.ATV.19.12.2847; Pinderski LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA; Ricci R, 2004, SCIENCE, V306, P1558, DOI 10.1126/science.1101909; Roselaar SE, 1996, ARTERIOSCL THROM VAS, V16, P1013, DOI 10.1161/01.ATV.16.8.1013; Rubic T, 2006, CARDIOVASC RES, V69, P527, DOI 10.1016/j.cardiores.2005.10.018; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Teupser D, 1999, ARTERIOSCL THROM VAS, V19, P1299, DOI 10.1161/01.ATV.19.5.1299; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Van Eck M, 2000, ARTERIOSCL THROM VAS, V20, pE53, DOI 10.1161/01.ATV.20.9.e53; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; von der Thusen JH, 2001, FASEB J, V15, P2730, DOI 10.1096/fj.01-0483fje; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Yoshioka T, 2004, GENE THER, V11, P1772, DOI 10.1038/sj.gt.3302348; Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216	44	94	104	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2869	2880		10.1096/fj.09-148155	http://dx.doi.org/10.1096/fj.09-148155			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20354139	Green Published			2022-12-28	WOS:000285005400027
J	Ashkenazi, A; Viard, M; Wexler-Cohen, Y; Blumenthal, R; Shai, Y				Ashkenazi, Avraham; Viard, Mathias; Wexler-Cohen, Yael; Blumenthal, Robert; Shai, Yechiel			Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41	FASEB JOURNAL			English	Article						HIV-1 fusion inhibitor; peptide-membrane interaction	IMMUNODEFICIENCY-VIRUS TYPE-1; DISULFIDE-ISOMERASE; INFLUENZA HEMAGGLUTININ; ATOMIC-STRUCTURE; 6-HELIX BUNDLE; CORE STRUCTURE; CELL FUSION; ENTRY; RECEPTOR; GLYCOPROTEIN	Fusion of human immunodeficiency virus (HIV-1) with target cells is mediated by the gp41 transmembrane envelope protein. The loop region within gp41 contains 2 crucial cysteines that play an unknown role in HIV-cell fusion. On the basis of cell-cell fusion assay, using human T-cell lines [Jurkat E6-1 and Jurkat HXBc2(4)], and virus-cell fusion assay, using fully infectious HIV-1 HXBc2 virus and TZM-bl human cell line, we provide evidence that the oxidation state of the disulfide bond within a loop domain peptide determines its activity. The oxidized (closed) form inhibits fusion, while the reduced (opened) form enhances hemifusion. These opposite activities reach 60% difference in viral fusion. Both forms of the loop domain interact with gp41: the opened form enhances gp41 folding into a bundle, whereas the closed form inhibits this folding. Therefore, the transformation of the cysteines from a reduced to an oxidized state enables the loop to convert from opened to closed conformations, which assists gp41 to fold and induces hemifusion. The significant conservation of the loop region within many envelope proteins suggests a general mechanism, which is exploited by viruses to enhance entry into their host cells.-Ashkenazi, A., Viard, M., Wexler-Cohen, Y., Blumenthal, R., Shai, Y. Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41. FASEB J. 25, 2156-2166 (2011). www.fasebj.org	[Ashkenazi, Avraham; Wexler-Cohen, Yael; Shai, Yechiel] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; [Viard, Mathias; Blumenthal, Robert] NCI, Ctr Canc Res, Nanobiol Program, Frederick, MD 21701 USA; [Viard, Mathias] Natl Canc Inst Frederick, SAIC Frederick Inc, Basic Res Program, Frederick, MD 21701 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	yechiel.shai@weizmann.ac.il		Ashkenazi, Avraham/0000-0002-1253-497X	Israel Science Foundation; National Cancer Institute, U.S. National Institutes of Health (NIH) [HHSN26120080001E]; NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC008303] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); National Cancer Institute, U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Batya Zarmi for her valuable help with peptide purification, Dr. Ayala Sharp and Eitan Ariel, and the staff of the flow cytometry unit at the Weizmann Institute of Science for their valuable technical assistance and advice. This study was supported by the Israel Science Foundation and also has been funded, in part, with federal funds from the National Cancer Institute, U.S. National Institutes of Health (NIH), under contract HHSN26120080001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does it mention any trade names, commercial products, or organizations or imply endorsement by the U. S. Government. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. Y.S. is the incumbent of the Harold S. and Harriet B. Brady Professorial Chair in Cancer Research.	Ashkenazi A, 2011, EUR BIOPHYS J BIOPHY, V40, P349, DOI 10.1007/s00249-010-0666-z; Bar S, 2004, J VIROL, V78, P811, DOI 10.1128/JVI.78.2.811-820.2004; Barbouche R, 2003, J BIOL CHEM, V278, P3131, DOI 10.1074/jbc.M205467200; Bellamy-McIntyre AK, 2010, BIOCHEM BIOPH RES CO, V394, P904, DOI 10.1016/j.bbrc.2010.03.071; Billington J, 2007, J VIROL, V81, P4604, DOI 10.1128/JVI.02138-06; Blumenthal R, 2002, CHEM PHYS LIPIDS, V116, P39, DOI 10.1016/S0009-3084(02)00019-1; Bomsel M, 2003, NAT REV MOL CELL BIO, V4, P57, DOI 10.1038/nrm1005; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 2001, BBA-MOL BASIS DIS, V1536, P116, DOI 10.1016/S0925-4439(01)00042-4; Cao J, 1996, J VIROL, V70, P1340, DOI 10.1128/JVI.70.3.1340-1354.1996; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455; Chernomordik LV, 2006, J CELL BIOL, V175, P201, DOI 10.1083/jcb.200607083; Chernomordik LV, 2005, CELL, V123, P375, DOI 10.1016/j.cell.2005.10.015; Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/0022-1317-83-8-1809; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Fenouillet E, 2007, ANTIOXID REDOX SIGN, V9, P1009, DOI 10.1089/ars.2007.1639; Finzi A, 2010, MOL CELL, V37, P656, DOI 10.1016/j.molcel.2010.02.012; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Gallo SA, 2001, BIOCHEMISTRY-US, V40, P12231, DOI 10.1021/bi0155596; Garg H, 2007, J BIOL CHEM, V282, P16899, DOI 10.1074/jbc.M701701200; He YX, 2008, J VIROL, V82, P6349, DOI 10.1128/JVI.00319-08; Huerta L, 2002, CYTOMETRY, V47, P100, DOI 10.1002/cyto.10051; Jacobs A, 2005, J BIOL CHEM, V280, P27284, DOI 10.1074/jbc.M414411200; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Leikina E, 2001, BIOCHEMISTRY-US, V40, P8378, DOI 10.1021/bi010466+; Li KJ, 2008, J VIROL, V82, P7135, DOI 10.1128/JVI.00448-08; Liu J, 2010, J VIROL, V84, P201, DOI 10.1128/JVI.01558-09; Liu SW, 2007, J BIOL CHEM, V282, P9612, DOI 10.1074/jbc.M609148200; Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Maerz AL, 2000, J VIROL, V74, P6614, DOI 10.1128/JVI.74.14.6614-6621.2000; Maerz AL, 2001, J VIROL, V75, P6635, DOI 10.1128/JVI.75.14.6635-6644.2001; Markovic I, 2004, BLOOD, V103, P1586, DOI 10.1182/blood-2003-05-1390; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Miyauchi K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000585; MORRIS SJ, 1989, J BIOL CHEM, V264, P3972; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Okumura Y, 1999, FEBS LETT, V442, P39, DOI 10.1016/S0014-5793(98)01612-3; Ou W, 2006, VIROLOGY, V350, P406, DOI 10.1016/j.virol.2006.01.041; Peisajovich SG, 2003, J MOL BIOL, V326, P1489, DOI 10.1016/S0022-2836(03)00040-8; Perfettini JL, 2005, CELL DEATH DIFFER, V12, P916, DOI 10.1038/sj.cdd.4401584; Pinter A, 1997, J VIROL, V71, P8073, DOI 10.1128/JVI.71.10.8073-8077.1997; Poranen MM, 2002, ANNU REV MICROBIOL, V56, P521, DOI 10.1146/annurev.micro.56.012302.160643; Poumbourios P, 2003, J BIOL CHEM, V278, P42149, DOI 10.1074/jbc.M305223200; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; SCHULZ TF, 1992, AIDS RES HUM RETROV, V8, P1571, DOI 10.1089/aid.1992.8.1571; Sen J, 2007, PROTEIN SCI, V16, P1236, DOI 10.1110/ps.072771407; SYU WJ, 1991, J VIROL, V65, P6349, DOI 10.1128/JVI.65.11.6349-6352.1991; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Viard Mathias, 2004, Glycoconj J, V20, P213; Wallin M, 2004, EMBO J, V23, P54, DOI 10.1038/sj.emboj.7600012; WEISS A, 1984, J IMMUNOL, V133, P123; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com; Wexler-Cohen Y, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000509; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803	70	15	15	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2156	2166		10.1096/fj.10-175752	http://dx.doi.org/10.1096/fj.10-175752			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21429941	Green Published			2022-12-28	WOS:000292242200008
J	Krymskaya, VP; Snow, J; Cesarone, G; Khavin, I; Goncharov, DA; Lim, PN; Veasey, SC; Ihida-Stansbury, K; Jones, PL; Goncharova, EA				Krymskaya, Vera P.; Snow, Jennifer; Cesarone, Gregory; Khavin, Irene; Goncharov, Dmitry A.; Lim, Poay N.; Veasey, Sigrid C.; Ihida-Stansbury, Kaori; Jones, Peter L.; Goncharova, Elena A.			mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia	FASEB JOURNAL			English	Article						pulmonary hypertension; mTORC1; mTORC2; rictor; Akt	MAMMALIAN TARGET; RAPAMYCIN MTOR; LYMPHANGIOLEIOMYOMATOSIS LAM; IN-VITRO; ACTIVATION; PHOSPHORYLATION; HYPERTENSION; PROMOTES; GROWTH; METFORMIN	Pulmonary arterial vascular smooth muscle (PAVSM) cell proliferation is a key pathophysiological component of vascular remodeling in pulmonary arterial hypertension (PAH) for which cellular and molecular mechanisms are poorly understood. The goal of our study was to determine the role of mammalian target of rapamycin (mTOR) in PAVSM cell proliferation, a major pathological manifestation of vascular remodeling in PAH. Our data demonstrate that chronic hypoxia promoted mTOR(Ser-2481) phosphorylation, an indicator of mTOR intrinsic catalytic activity, mTORC1-specific S6 and mTORC2-specific Akt (Ser-473) phosphorylation, and proliferation of human and rat PAVSM cells that was inhibited by siRNA mTOR. PAVSM cells derived from rats exposed to chronic hypoxia (VSM-H cells) retained increased mTOR(Ser-2481), S6, Akt (Ser-473) phosphorylation, and DNA synthesis compared to cells from normoxia-exposed rats. Suppression of mTORC2 signaling with siRNA rictor, or inhibition of mTORC1 signaling with rapamycin and metformin, while having little effect on other complex activities, inhibited VSM-H and chronic hypoxia-induced human and rat PAVSM cell proliferation. Collectively, our data demonstrate that up-regulation of mTOR activity and activation of both mTORC1 and mTORC2 are required for PAVSM cell proliferation induced by in vitro and in vivo chronic hypoxia and suggest that mTOR may serve as a potential therapeutic target to inhibit vascular remodeling in PAH.-Krymskaya, V. P., Snow, J., Cesarone, G., Khavin, I., Goncharov, D. A., Lim, P. N., Veasey, S. C., Ihida-Stansbury, K., Jones, P. L., Goncharova, E. A. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J. 25, 1922-1933 (2011). www.fasebj.org	[Goncharova, Elena A.] Univ Penn, Translat Res Labs, Pulm Allergy & Crit Care Div, Dept Med, Philadelphia, PA 19104 USA; [Krymskaya, Vera P.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Krymskaya, Vera P.] Univ Penn, Cardiovasc Inst, Philadelphia, PA 19104 USA; [Veasey, Sigrid C.] Univ Penn, Ctr Sleep & Resp Neurobiol, Dept Med, Philadelphia, PA 19104 USA; [Ihida-Stansbury, Kaori; Jones, Peter L.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Goncharova, EA (corresponding author), Univ Penn, Translat Res Labs, Pulm Allergy & Crit Care Div, Dept Med, Rm 1214,125 S 31st St, Philadelphia, PA 19104 USA.	goncharo@mail.med.upenn.edu		Jones, Peter Lloyd/0000-0003-1445-4081	Gilead Science Research Scholars grant; U.S. National Institutes of Health (NIH)/National Heart Lung and Blood Institute [2R01HL071106, R01HL090829, LAM07-001, NIH HL080492]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080492, R01HL090829, R01HL071106] Funding Source: NIH RePORTER	Gilead Science Research Scholars grant(Gilead Sciences); U.S. National Institutes of Health (NIH)/National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Andrew Eszterhas for critical reading of the manuscript. This work was supported by a Gilead Science Research Scholars grant (E.G.) and in part by U.S. National Institutes of Health (NIH)/National Heart Lung and Blood Institute grants 2R01HL071106 (V.P.K.), R01HL090829 (V.P.K.), LAM07-001 (E.G.), and NIH HL080492 (S.C.V). E.G. is a Parker B. Francis Fellow in Pulmonary Research.	Agard C, 2009, BRIT J PHARMACOL, V158, P1285, DOI 10.1111/j.1476-5381.2009.00445.x; Barbera JA, 2003, EUR RESPIR J, V21, P892, DOI 10.1183/09031936.03.00115402; Barst RJ, 2005, J CLIN INVEST, V115, P2691, DOI 10.1172/JCI26593; Chen B, 2009, AM J PHYSIOL-LUNG C, V297, pL1151, DOI 10.1152/ajplung.00183.2009; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200; Cogo A, 2003, J APPL PHYSIOL, V94, P1403, DOI 10.1152/japplphysiol.00363.2002; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fraser KL, 1999, CHEST, V115, P1321, DOI 10.1378/chest.115.5.1321; Gerasimovskaya EV, 2005, J APPL PHYSIOL, V98, P722, DOI 10.1152/japplphysiol.00715.2004; Goncharova E, 2004, J CELL BIOL, V167, P1171, DOI 10.1083/jcb.200405130; Goncharova EA, 2002, AM J PHYSIOL-LUNG C, V283, pL354, DOI 10.1152/ajplung.00010.2002; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Goncharova EA, 2008, J CELL BIOCHEM, V103, P369, DOI 10.1002/jcb.21419; Goncharova EA, 2009, MOL PHARMACOL, V76, P766, DOI 10.1124/mol.109.057042; Hickey MM, 2010, J CLIN INVEST, V120, P827, DOI 10.1172/JCI36362; Hietakangas V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-282; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Ihida-Stansbury K, 2006, AM J PHYSIOL-LUNG C, V291, pL694, DOI 10.1152/ajplung.00119.2006; Incalzi RA, 1999, CIRCULATION, V99, P1600, DOI 10.1161/01.CIR.99.12.1600; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; Kirtane AJ, 2007, CARDIOVASC DRUG REV, V25, P316, DOI 10.1111/j.1527-3466.2007.00024.x; Krymskaya VP, 2009, CELL CYCLE, V8, P403, DOI 10.4161/cc.8.3.7555; Krymskaya VP, 2004, FASEB J, V18, P428, DOI 10.1096/fj.04-2869fje; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Li WM, 2007, CIRC RES, V100, P79, DOI 10.1161/01.RES.0000253094.03023.3f; Li XD, 2009, NAT MED, V15, P1289, DOI 10.1038/nm.2021; Liu YL, 2006, AM J RESP CELL MOL, V34, P182, DOI 10.1165/rcmb.2005-0163OC; MacEachern PR, 2004, CHEST, V126, p978S, DOI 10.1378/chest.126.4_MeetingAbstracts.978S; MARTI HH, 1994, PFLUG ARCH EUR J PHY, V429, P216, DOI 10.1007/BF00374315; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Paddenberg R, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-15; Pak O, 2007, EUR RESPIR J, V30, P364, DOI 10.1183/09031936.00128706; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; PAUL RJ, 1989, ANNU REV PHYSIOL, V51, P331, DOI 10.1146/annurev.physiol.51.1.331; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Roulin D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-57; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Schultz K, 2006, AM J PHYSIOL-HEART C, V290, pH2528, DOI 10.1152/ajpheart.01077.2005; Simonneau G, 2009, J AM COLL CARDIOL, V54, pS43, DOI [10.1016/j.jacc.2009.04.012, 10.1016/j.jacc.2013.10.029]; Soliman GA, 2010, J BIOL CHEM, V285, P7866, DOI 10.1074/jbc.M109.096222; Stenmark KR, 2006, CIRC RES, V99, P675, DOI 10.1161/01.RES.0000243584.45145.3f; Stenmark KR, 2009, AM J PHYSIOL-LUNG C, V297, pL1013, DOI 10.1152/ajplung.00217.2009; Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Zeng ZH, 2007, BLOOD, V109, P3509, DOI 10.1182/blood-2006-06-030833	50	81	86	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1922	1933		10.1096/fj.10-175018	http://dx.doi.org/10.1096/fj.10-175018			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21368105	Green Published			2022-12-28	WOS:000291023800016
J	Sun, Y; Li, WP; Lu, ZD; Chen, R; Ling, J; Ran, QT; Jilka, RL; Chen, XD				Sun, Yun; Li, Weiping; Lu, Zhengding; Chen, Richard; Ling, Jian; Ran, Qitao; Jilka, Robert L.; Chen, Xiao-Dong			Rescuing replication and osteogenesis of aged mesenchymal stem cells by exposure to a young extracellular matrix	FASEB JOURNAL			English	Article						reactive oxygen species; tissue regeneration; niche	MOUSE BONE-MARROW; SUPEROXIDE DISMUTASE; OXIDATIVE STRESS; DIFFERENTIATION; PROGENITORS; NEIGHBORS; CULTURE; SSEA-4; NICHES; OXYGEN	This study aimed to determine whether aging negatively affects MSC replication and osteogenesis and whether these features could be altered by exposure to an extracellular matrix (ECM) generated by marrow cells from young or old mice. A cell-free ECM was prepared from cultured femoral marrow cells from either 3- or 18-mo-old C57BL/6 mice (young-ECM or old-ECM, respectively). The replication and osteogenesis of young or old MSCs maintained on young-ECM vs. old-ECM as well as plastic were examined in vitro and in vivo. We found that the frequency of MSCs in marrow from old mice, measured by colony-forming cells, was only marginally lower than that of young mice. In contrast, defects in the self-renewal and bone formation capacity of old MSCs were remarkable. These defects were corrected by provision of a young-ECM but not old-ECM. In parallel cultures maintained on a young-ECM, the intracellular levels of reactive oxygen species from both old and young mice were reduced 30-50% compared to those maintained on old-ECM or plastic. We concluded that aging negatively affects the formation of an ECM that normally preserves MSC function, and aged MSCs can be rejuvenated by culture on a young-ECM.-Sun, Y., Li, W., Lu, Z., Chen, Z., Ling, J., Ran, O., Jilka, R. L., Chen, X. D. Rescuing replication and osteogenesis of aged mesenchymal stem cells by exposure to a young extracellular matrix. FASEB J. 25, 1474-1485 (2011). www.fasebj.org	[Sun, Yun; Lu, Zhengding; Chen, Richard; Chen, Xiao-Dong] Univ Texas San Antonio, Dept Comprehens Dent, Div Res, San Antonio, TX 78229 USA; [Ran, Qitao] Univ Texas San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Sun, Yun] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Reprod Med, Shanghai 200030, Peoples R China; [Li, Weiping] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Obstet & Gynecol, Shanghai 200030, Peoples R China; [Ling, Jian] SW Res Inst, San Antonio, TX USA; [Jilka, Robert L.] Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA	University of Texas System; University of Texas at San Antonio (UTSA); University of Texas System; University of Texas at San Antonio (UTSA); Shanghai Jiao Tong University; Shanghai Jiao Tong University; Southwest Research Institute; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Chen, XD (corresponding author), Univ Texas San Antonio, Dept Comprehens Dent, Div Res, Mail Code 7890,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liweiping@smhb.gov.ch; chenx4@uthscsa.edu		Chen, Xiao-Dong/0000-0003-1602-806X	University Research Council at UTHSCSA; National Institutes of Health [R21 AG025466]	University Research Council at UTHSCSA; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Dr. Valerie A. Lee [University of Texas Health Science Center at San Antonio (UTHSCSA)] for her careful review of the manuscript, and Dr. Sergey Leikin [U.S. National Instiute of Child Health and Human Development/National Institutes of Health (NIH)] for his critical discussion about the analysis of Raman spectrum. This work was supported by a grant from the University Research Council Grants Program at UTHSCSA (X. D. C.), and supported by the National Institutes of Health (R21 AG025466; X. D. C.). Analysis of mu CT was performed in the Core Small Animal Imaging Facility, Greehey Children Cancer Research Institute of UTHSCSA.	Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Behonick DJ, 2003, MECH DEVELOP, V120, P1327, DOI 10.1016/j.mod.2003.05.002; Bi YM, 2005, J BIOL CHEM, V280, P30481, DOI 10.1074/jbc.M500573200; Blazsek I, 2000, BLOOD, V96, P3763, DOI 10.1182/blood.V96.12.3763.h8003763_3763_3771; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Carlson ME, 2007, AGING CELL, V6, P371, DOI 10.1111/j.1474-9726.2007.00286.x; Chen TL, 2004, BONE, V35, P83, DOI 10.1016/j.bone.2004.03.019; Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725; Cong YS, 2008, CELL RES, V18, P725, DOI 10.1038/cr.2008.74; D'Ippolito G, 2006, BONE, V39, P513, DOI 10.1016/j.bone.2006.02.061; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; Di Gregorio GB, 2001, J CLIN INVEST, V107, P803, DOI 10.1172/JCI11653; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gang EJ, 2007, BLOOD, V109, P1743, DOI 10.1182/blood-2005-11-010504; Hocking AM, 1998, MATRIX BIOL, V17, P1; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027; Knopp E, 2005, ENDOCRINOLOGY, V146, P1983, DOI 10.1210/en.2004-0770; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Lai YL, 2010, STEM CELLS DEV, V19, P1095, DOI 10.1089/scd.2009.0217; Lareu RR, 2007, TISSUE ENG, V13, P385, DOI 10.1089/ten.2006.0224; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pioletti DP, 2000, BIOMATERIALS, V21, P1103, DOI 10.1016/S0142-9612(99)00250-1; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ran QT, 2004, J BIOL CHEM, V279, P55137, DOI 10.1074/jbc.M410387200; Reems JA, 2008, TRANSFUSION, V48, P620, DOI 10.1111/j.1537-2995.2007.01586.x; Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001; Smith JR, 2004, STEM CELLS, V22, P823, DOI 10.1634/stemcells.22-5-823; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6	37	141	155	1	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1474	1485		10.1096/fj.10-161497	http://dx.doi.org/10.1096/fj.10-161497			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21248241	Green Published			2022-12-28	WOS:000290023800006
J	Lin, CT; Datta, V; Okwan-Duodu, D; Chen, X; Fuchs, S; Alsabeh, R; Billet, S; Bernstein, KE; Shen, XZ				Lin, Chentao; Datta, Vivekanand; Okwan-Duodu, Derick; Chen, Xu; Fuchs, Sebastien; Alsabeh, Randa; Billet, Sandrine; Bernstein, Kenneth E.; Shen, Xiao Z.			Angiotensin-converting enzyme is required for normal myelopoiesis	FASEB JOURNAL			English	Article						myeloid proliferation; myelodifferentiation; substance P	HEMATOPOIETIC STEM-CELLS; SUBSTANCE-P; BONE-MARROW; DEFICIENT MICE; UP-REGULATION; II RECEPTOR; 1A RECEPTOR; EXPRESSION; SYSTEM; PROLIFERATION	Inhibition of angiotensin-converting enzyme (ACE) induces anemia in humans and mice, but it is unclear whether ACE is involved in other aspects of hematopoiesis. Here, we systemically evaluated ACE-knockout (KO) mice and found myelopoietic abnormalities characterized by increased bone marrow myeloblasts and myelocytes, as well as extramedullary myelopoiesis. Peritoneal macrophages from ACE-KO mice were deficient in the production of effector molecules, such as tumor necrosis factor-alpha, interleukin-12p40, and CD86 when stimulated with lipopolysaccharide and interferon-gamma. ACE-KO mice were more susceptible to Staphylococcus aureus infection. Further studies using total or fractionated bone marrows revealed that ACE regulates myeloid proliferation, differentiation, and functional maturation via angiotensin II and substance P and through the angiotensin II receptor type 1 and substance P neurokinin 1 receptors. Angiotensin II was correlated with CCAAT-enhancer-binding protein-alpha up-regulation during myelopoiesis. Angiotensin II supplementation of ACE-KO mice rescued macrophage functional maturation. These results demonstrate a previous unrecognized significant role for ACE in myelopoiesis and imply new perspectives for manipulating myeloid cell expansion and maturation.-Lin, C., Datta, V., Okwan-Duodu, D., Chen, X., Fuchs, S., Alsabeh, R., Billet, S., Bernstein, K. E., Shen, X. Z. Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J. 25, 1145-1155 (2011). www.fasebj.org	[Lin, Chentao; Okwan-Duodu, Derick; Chen, Xu; Fuchs, Sebastien; Billet, Sandrine; Bernstein, Kenneth E.; Shen, Xiao Z.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Datta, Vivekanand; Fuchs, Sebastien; Alsabeh, Randa; Bernstein, Kenneth E.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Okwan-Duodu, Derick] Emory Univ, Sch Med, Atlanta, GA USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Emory University	Shen, XZ (corresponding author), 8700 Beverly Blvd,Davis Bldg 2019, Los Angeles, CA 90048 USA.	xiao.shen@cshs.org		Bernstein, Kenneth/0000-0001-8097-3272	U.S. National Institutes of Health [R01 DK-039777, R01 DK-051445]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051445, R01DK039777] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Kenneth Dorshkind (University of California, Los Angeles, CA, USA) for the S17 cell line, Ellan Bernstein for animal husbandry, and Patricia Lin for cell sorting. This work was supported by U.S. National Institutes of Health grants R01 DK-039777 and R01 DK-051445 (to K. E. Bernstein). The authors have no financial conflicts of interest.	Aksu S, 2006, LEUKEMIA LYMPHOMA, V47, P891, DOI 10.1080/10428190500399250; Alonso F, 2010, CARDIOVASC RES, V87, P166, DOI 10.1093/cvr/cvq031; Billet S, 2007, J CLIN INVEST, V117, P1914, DOI 10.1172/JCI28764; BONNET D, 1992, EXP HEMATOL, V20, P1165; Bramucci M, 1999, BIOCHEM MOL BIOL INT, V47, P107; Charrier S, 2004, BLOOD, V104, P978, DOI 10.1182/blood-2003-11-3828; Cole J, 2000, J CLIN INVEST, V106, P1391, DOI 10.1172/JCI10557; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Davies John Q, 2005, Methods Mol Biol, V290, P91; De Giorgio R, 1998, J NEUROIMMUNOL, V82, P175, DOI 10.1016/S0165-5728(97)00201-4; Esther CR, 1996, LAB INVEST, V74, P953; Garcia GE, 2010, AM J PHYSIOL-RENAL, V298, pF868, DOI 10.1152/ajprenal.00041.2010; GREENO EW, 1993, J EXP MED, V177, P1269, DOI 10.1084/jem.177.5.1269; GRIFFING GT, 1982, LANCET, V1, P1361; Haznedaroglu IC, 2003, INT J BIOCHEM CELL B, V35, P867, DOI 10.1016/S1357-2725(02)00278-9; Iwasaki H, 2007, IMMUNITY, V26, P726, DOI 10.1016/j.immuni.2007.06.004; Jokubaitis VJ, 2008, BLOOD, V111, P4055, DOI 10.1182/blood-2007-05-091710; Kato H, 2005, FASEB J, V19, P2023, DOI 10.1096/fj.05-3820fje; Mrug M, 1997, J CLIN INVEST, V100, P2310, DOI 10.1172/JCI119769; Nagai Y, 2006, IMMUNITY, V24, P801, DOI 10.1016/j.immuni.2006.04.008; Nowicki M, 2007, J CLIN PATHOL, V60, P749, DOI 10.1136/jcp.2006.041475; Park TS, 2009, HAEMATOL-HEMATOL J, V94, P745, DOI 10.3324/haematol.2009.006965; PASCUAL DW, 1990, IMMUNOLOGY, V71, P52; PRATT MC, 1992, BRIT J CLIN PHARMACO, V34, P363, DOI 10.1111/j.1365-2125.1992.tb05644.x; RAMESHWAR P, 1993, BLOOD, V81, P391; RAMESHWAR P, 1995, BLOOD, V86, P482, DOI 10.1182/blood.V86.2.482.bloodjournal862482; Re RN, 2001, CURR OPIN CARDIOL, V16, P317, DOI 10.1097/00001573-200111000-00002; Riviere G, 2007, GENE, V399, P81, DOI 10.1016/j.gene.2007.05.010; Rodgers K, 2003, CANCER CHEMOTH PHARM, V51, P97, DOI 10.1007/s00280-002-0509-4; Rodgers KE, 2000, STEM CELLS, V18, P287, DOI 10.1634/stemcells.18-4-287; Rousseau-Plasse A, 1998, EXP HEMATOL, V26, P1074; Scholzen TE, 2004, EXP DERMATOL, V13, P22, DOI 10.1111/j.1600-0625.2004.00260.x; Shen XZ, 2008, J BIOL CHEM, V283, P9957, DOI 10.1074/jbc.M709574200; Strawn WB, 2004, BRIT J HAEMATOL, V126, P120, DOI 10.1111/j.1365-2141.2004.04998.x; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; Tsubakimoto Y, 2009, ARTERIOSCL THROM VAS, V29, P1529, DOI 10.1161/ATVBAHA.109.187732; Ueda Y, 2009, J IMMUNOL, V182, P6477, DOI 10.4049/jimmunol.0803961; Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200; Zambidis ET, 2008, BLOOD, V112, P3601, DOI 10.1182/blood-2008-03-144766; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173	41	45	47	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1145	1155		10.1096/fj.10-169433	http://dx.doi.org/10.1096/fj.10-169433			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21148418	Green Published			2022-12-28	WOS:000288982800004
J	Pellegatti, P; Falzoni, S; Donvito, G; Lemaire, I; Di Virgilio, F				Pellegatti, Patrizia; Falzoni, Simonetta; Donvito, Giovanna; Lemaire, Irma; Di Virgilio, Francesco			P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration	FASEB JOURNAL			English	Article						purinergic receptors; cell fusion; giant cells; bone metabolism; inflammation	GIANT-CELL FORMATION; P2X(7) RECEPTOR; MACROPHAGE FUSION; PLASMA-MEMBRANE; IN-VITRO; BONE; ATP; DIFFERENTIATION; ACTIVATION; EXPRESSION	Defects in bone homeostasis are a major health problem. Osteoclast differentiation and activation have a crucial role in bone remodeling in health and disease. Osteoclasts are bone-resorbing cells derived from mononuclear phagocyte progenitors. The key event in osteoclast formation is fusion of mononucleate precursors to form mature multinucleated osteclasts. Here we provide evidence of an absolute requirement for the P2X7 receptor, ATP release, and adenosine signaling in human osteoclast formation, as shown by the following findings: macrophage-colony stimulating factor/receptor activator for nuclear factor-kappa B ligand (M-CSF/RANKL)-stimulated fusion of human monocytes is fully prevented by an anti-P2X7 mAb, by specific P2X7 pharmacological antagonists, or by inhibition of CD39/NTPDase; fusion-competent monocytes release ATP via the P2X7 receptor; accelerated degradation of released ATP by addition of either apyrase or hexokinase strongly increases fusion; removal of extracellular adenosine by adenosine deaminase blocks, while addition of exogenous adenosine strongly potentiates, fusion; and pharmacologic stimulation of the adenosine A2A receptor increases, while selective A2A blockade inhibits, fusion. These results show that the purinergic axis plays a crucial and as yet undescribed role in osteoclast formation and reconcile previous evidence advocating a key role for either ATP or adenosine receptors in multinucleated giant cell formation.-Pellegatti, P., Falzoni, S., Donvito, G., Lemaire, I., Di Virgilio, F. P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB J. 25, 1264-1274 (2011). www.fasebj.org	[Pellegatti, Patrizia; Falzoni, Simonetta; Donvito, Giovanna; Di Virgilio, Francesco] Univ Ferrara, Interdisciplinary Ctr Study Inflammat, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; [Lemaire, Irma] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada	University of Ferrara; University of Ottawa	Di Virgilio, F (corresponding author), Univ Ferrara, Interdisciplinary Ctr Study Inflammat, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.	fdv@unife.it	DI VIRGILIO, Francesco/O-4634-2019; Di Virgilio, Francesco/J-3754-2018	DI VIRGILIO, Francesco/0000-0003-3566-1362; Di Virgilio, Francesco/0000-0003-3566-1362; Falzoni, Simonetta/0000-0002-6594-0357	Italian Association for Cancer Research [IG 5354]; Telethon of Italy [GGP06070]; Italian Space Agency (ASI-OSMA); Commission of European Communities [HEALTH-F2-2007-202231]; Regione Emilia Romagna; University of Ferrara	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Telethon of Italy(Fondazione Telethon); Italian Space Agency (ASI-OSMA)(Agenzia Spaziale Italiana (ASI)); Commission of European Communities(European Commission); Regione Emilia Romagna(Regione Emilia Romagna); University of Ferrara	This research was supported by grants from the Italian Association for Cancer Research (IG 5354), Telethon of Italy (GGP06070), the Italian Space Agency (ASI-OSMA), the Commission of European Communities (7th Framework Program HEALTH-F2-2007-202231), the Regione Emilia Romagna (Innovative Approaches to the Diagnosis of Inflammatory Diseases and Moniter research programs), and institutional funds from the University of Ferrara. F. D. V. acts as a consultant of Cordex Pharma and Affectis Pharma, biotech companies involved in the development of ATP-based drugs.	Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Bar-Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553; Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002; Donnelly-Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Falzoni S, 2000, MOL BIOL CELL, V11, P3169, DOI 10.1091/mbc.11.9.3169; Ferrari D, 1997, J IMMUNOL, V159, P1451; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Gartland A, 2003, CRIT REV EUKAR GENE, V13, P243, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.150; Gartland A, 2003, CALCIFIED TISSUE INT, V73, P361, DOI 10.1007/s00223-002-2098-y; Grol MW, 2009, PURINERG SIGNAL, V5, P205, DOI 10.1007/s11302-009-9139-1; Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005; Helming L, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159665; Helming L, 2009, J CELL SCI, V122, P453, DOI 10.1242/jcs.037200; Hiken JF, 2004, AM J PHYSIOL-CELL PH, V287, pC403, DOI 10.1152/ajpcell.00361.2003; Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165-6147(03)00123-8; Inui M, 2009, P NATL ACAD SCI USA, V106, P4816, DOI 10.1073/pnas.0900463106; Kara FM, 2010, FASEB J, V24, P2325, DOI 10.1096/fj.09-147447; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lemaire I, 2006, J IMMUNOL, V177, P7257, DOI 10.4049/jimmunol.177.10.7257; Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200; MacLauchlan S, 2009, J LEUKOCYTE BIOL, V85, P617, DOI 10.1189/jlb.1008588; MARKS SC, 1988, AM J ANAT, V183, P1, DOI 10.1002/aja.1001830102; Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586; Merrill JT, 1997, ARTHRITIS RHEUM, V40, P1308, DOI 10.1002/1529-0131(199707)40:7<1308::AID-ART16>3.0.CO;2-M; Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05-03-0222; Schwarz N, 2009, PURINERG SIGNAL, V5, P139, DOI 10.1007/s11302-009-9135-5; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Surprenant A, 2009, ANNU REV PHYSIOL, V71, P333, DOI 10.1146/annurev.physiol.70.113006.100630; Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123; Vignery A, 2005, TRENDS CELL BIOL, V15, P188, DOI 10.1016/j.tcb.2005.02.008; Westfall TD, 1997, EUR J PHARMACOL, V329, P169, DOI 10.1016/S0014-2999(97)89178-9; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yegutkin GG, 2008, BBA-MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	43	73	73	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2011	25	4					1264	1274		10.1096/fj.10-169854	http://dx.doi.org/10.1096/fj.10-169854			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21233486				2022-12-28	WOS:000288982800015
J	Amengual, J; Lobo, GP; Golczak, M; Li, HNM; Klimova, T; Hoppel, CL; Wyss, A; Palczewski, K; von Lintig, J				Amengual, Jaume; Lobo, Glenn P.; Golczak, Marcin; Li, Hua Nan M.; Klimova, Tatyana; Hoppel, Charles L.; Wyss, Adrian; Palczewski, Krzysztof; von Lintig, Johannes			A mitochondrial enzyme degrades carotenoids and protects against oxidative stress	FASEB JOURNAL			English	Article						carotenoid-oxygenases; apocarotenoids; respiration; reactive oxygen species	VITAMIN-A PRODUCTION; BETA-CAROTENE; RETINOID ISOMERASE; GENE-EXPRESSION; PLASMA KINETICS; VISUAL CYCLE; IDENTIFICATION; ZEAXANTHIN; OXYGENASE; 15,15-MONOOXYGENASE	Carotenoids are the precursors for vitamin A and are proposed to prevent oxidative damage to cells. Mammalian genomes encode a family of structurally related nonheme iron oxygenases that modify double bonds of these compounds by oxidative cleavage and cis-to-trans isomerization. The roles of the family members BCMO1 and RPE65 for vitamin A production and vision have been well established. Surprisingly, we found that the third family member, beta,beta-carotene-9',10'-oxygenase (BCDO2), is a mitochondrial carotenoid-oxygenase with broad substrate specificity. In BCDO2-deficient mice, carotenoid homeostasis was abrogated, and carotenoids accumulated in several tissues. In hepatic mitochondria, accumulated carotenoids induced key markers of mitochondrial dysfunction, such as manganese superoxide dismutase (9-fold), and reduced rates of ADP-dependent respiration by 30%. This impairment was associated with an 8- to 9-fold induction of phosphor-MAP kinase and phosphor-AKT, markers of cell signaling pathways related to oxidative stress and disease. Administration of carotenoids to human HepG2 cells depolarized mitochondrial membranes and resulted in the production of reactive oxygen species. Thus, our studies in BCDO2-deficient mice and human cell cultures indicate that carotenoids can impair respiration and induce oxidative stress. Mammalian cells thus express a mitochondrial carotenoid-oxygenase that degrades carotenoids to protect these vital organelles.-Amengual, J., Lobo, G. P., Golczak, M., Li, H. N. M., Klimova, T., Hoppel, C. L., Wyss, A., Palczewski, K., von Lintig, J. A mitochondrial enzyme degrades carotenoids and protects against oxidative stress. FASEB J. 25, 948-959 (2011). www.fasebj.org	[Amengual, Jaume; Lobo, Glenn P.; Golczak, Marcin; Li, Hua Nan M.; Klimova, Tatyana; Hoppel, Charles L.; Palczewski, Krzysztof; von Lintig, Johannes] Case Western Reserve Univ, Sch Med, Dept Pharmacol W333, Cleveland, OH 44160 USA; [Wyss, Adrian] DSM Nutr Prod Ltd, Res & Dev, Human Nutr & Hlth, Basel, Switzerland	Case Western Reserve University; DSM NV	von Lintig, J (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol W333, 10900 Euclid Ave, Cleveland, OH 44160 USA.	johannes.vonlintig@case.edu	Lobo, Glenn P./AAI-9736-2020	von Lintig, Johannes/0000-0002-2079-2143	U.S. National Institute of Health [EY019641, EY009339, P30 EY11373]; Research to Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY009339, P30EY011373, R01EY019641] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank Drs. L. T. Webster and M. Maguire for helpful manuscript comments. The authors also thank Catherine Doller (Case Western Reserve University) for performing histological analyses. This work was supported by U.S. National Institute of Health grants EY019641 (to J.V.L.), EY009339, and P30 EY11373, and by a Research to Prevent Blindness grant (to K.P.).	Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003; Berry SD, 2009, GENETICS, V182, P923, DOI 10.1534/genetics.109.101741; Bhosale P, 2007, ARCH BIOCHEM BIOPHYS, V458, P121, DOI 10.1016/j.abb.2006.10.005; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Demmig-Adams B, 2002, SCIENCE, V298, P2149, DOI 10.1126/science.1078002; Eriksson J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000010; Ferrucci L, 2009, AM J HUM GENET, V84, P123, DOI 10.1016/j.ajhg.2008.12.019; Greenwald Peter, 2003, J Natl Cancer Inst, V95, pE1; Hantz HL, 2005, EXP BIOL MED, V230, P171; Hartmann D, 2004, AM J CLIN NUTR, V79, P410; He MA, 2010, ARTERIOSCL THROM VAS, V30, P885, DOI 10.1161/ATVBAHA.109.199422; Hessel S, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706763200; Hoppel CL, 1998, J BIOL CHEM, V273, P23495, DOI 10.1074/jbc.273.36.23495; Hu KQ, 2006, J BIOL CHEM, V281, P19327, DOI 10.1074/jbc.M512095200; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Kiser PD, 2009, P NATL ACAD SCI USA, V106, P17325, DOI 10.1073/pnas.0906600106; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307; Leung WC, 2009, FASEB J, V23, P1041, DOI 10.1096/fj.08-121962; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; Lindqvist A, 2005, J HISTOCHEM CYTOCHEM, V53, P1403, DOI 10.1369/jhc.5A6705.2005; Lindqvist A, 2007, J NUTR, V137, P2346, DOI 10.1093/jn/137.11.2346; Liu C, 2000, CARCINOGENESIS, V21, P2245, DOI 10.1093/carcin/21.12.2245; Lobo GP, 2010, FASEB J, V24, P1656, DOI 10.1096/fj.09-150995; Ma Q, 2010, PHARMACOL THERAPEUT, V125, P376, DOI 10.1016/j.pharmthera.2009.11.004; Mantena SK, 2008, FREE RADICAL BIO MED, V44, P1259, DOI 10.1016/j.freeradbiomed.2007.12.029; Moise AR, 2005, TRENDS PLANT SCI, V10, P178, DOI 10.1016/j.tplants.2005.02.006; Oberhauser V, 2008, P NATL ACAD SCI USA, V105, P19000, DOI 10.1073/pnas.0807805105; Paolini M, 2001, CARCINOGENESIS, V22, P1483, DOI 10.1093/carcin/22.9.1483; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Thurmann PA, 2005, AM J CLIN NUTR, V82, P88; Tian R, 2010, ANIM GENET, V41, P253, DOI 10.1111/j.1365-2052.2009.01990.x; VAGE DI, BMC GENET, V11, P10; von Lintig J, 2010, ANNU REV NUTR, V30, P35, DOI 10.1146/annurev-nutr-080508-141027; von Lintig J, 2010, TRENDS BIOCHEM SCI, V35, P400, DOI 10.1016/j.tibs.2010.01.005; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang SS, 2007, CIRC RES, V101, pE11, DOI 10.1161/CIRCRESAHA.107.152975	42	215	220	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2011	25	3					948	959		10.1096/fj.10-173906	http://dx.doi.org/10.1096/fj.10-173906			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21106934	Green Published			2022-12-28	WOS:000287806200015
J	Schupp, N; Kolkhof, P; Queisser, N; Gartner, S; Schmid, U; Kretschmer, A; Hartmann, E; Oli, RG; Schafer, S; Stopper, H				Schupp, Nicole; Kolkhof, Peter; Queisser, Nina; Gaertner, Sabine; Schmid, Ursula; Kretschmer, Axel; Hartmann, Elke; Oli, Rajaraman G.; Schaefer, Stefan; Stopper, Helga			Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats	FASEB JOURNAL			English	Article						8-oxodG; double-strand breaks; hypertension; oxidative DNA damage; oxidative stress	OXIDATIVE STRESS; IN-VITRO; ARTIFACTUAL OXIDATION; ALDOSTERONE BLOCKADE; CHROMOSOMAL DAMAGE; DOCA/SALT RATS; STRAND BREAKS; RENAL DAMAGE; INJURY; CANCER	Epidemiological studies exploring the connection between hypertension and cancer demonstrate a higher cancer incidence, especially of kidney cancer, and a higher cancer mortality in hypertensive patients. Hormones elevated in hypertension, i.e., aldosterone and angiotensin II, which exert genotoxic effects in vitro, could contribute to carcinogenesis in hypertension. The present study was conducted to investigate the possible DNA-damaging effect of aldosterone receptor activation in vivo. Crl:CD (Sprague-Dawley) rats were treated for 6 wk with desoxycorticosterone acetate (DOCA) and salt to induce a mineralocorticoid-dependent hypertension. DOCA-salt treatment caused increased blood pressure (+26 mmHg) compared to untreated rats, elevated markers of kidney failure (up to 62-fold for Kim-1), and the induction of several proinflammatory genes and proteins (up to 2.6-fold for tissue MCP-1). The mineralocorticoid receptor (MR) antagonist spironolactone (MR IC(50) 24 nM) and the novel nonsteroidal antagonist BR-4628 (MR IC(50) 28 nM) decreased these damage markers. DOCA-salt treatment also caused 8.8-fold increased structural DNA damage, determined with the comet assay, double-strand breaks (3.5-fold), detected immunohistochemically, and oxidative stress. Furthermore, the oxidatively modified mutagenic DNA base 7,8-dihydro-8-oxo-guanine (8-oxodG), quantified by LC-MS/MS, was almost 2-fold higher in DOCA-salt-treated kidneys. Our results suggest a mutagenic potential of high mineralocorticoid levels, frequent in hypertensive individuals.-Schupp, N., Kolkhof, P., Queisser, N., Gartner, S., Schmid, U., Kretschmer, A., Hartmann, E., Oli, R G., Schafer, S., Stopper, H. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J. 25, 968-978 (2011). www.fasebj.org	[Schupp, Nicole; Queisser, Nina; Gaertner, Sabine; Schmid, Ursula; Oli, Rajaraman G.; Stopper, Helga] Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; [Kolkhof, Peter; Schaefer, Stefan] Bayer Schering Pharma AG, Cardiol Res, Wuppertal, Germany; [Kretschmer, Axel] Bayer Schering Pharma AG, Target Discovery, Wuppertal, Germany; [Hartmann, Elke] Bayer Schering Pharma AG, Inst Toxicol, Global Drug Discovery, Wuppertal, Germany	University of Wurzburg; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals	Schupp, N (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.	nicole.schupp@toxi.uni-wuerzburg.de		Schupp, Nicole/0000-0002-1836-6348	Bayer Schering Pharma AG; Deutsche Forschungsgemeinschaft [SCHU 2367/1-1]	Bayer Schering Pharma AG(Bayer AG); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors acknowledge the excellent technical assistance of Michaela Wolf, Thomas Budel, Elisabeth Stein, and Maria Scheurich at the Institute of Toxicology, University of Wurzburg, Germany and of Petra Ammelung, Dorota Chodor, Andreas Gotte, and Isabella Hutmacher at Bayer Schering Pharma AG. This work was supported by Bayer Schering Pharma AG and by the Deutsche Forschungsgemeinschaft (grant SCHU 2367/1-1). P.K., A.K., and E.H. are employees of Bayer Schering Pharma AG, and P.K. and E.H. hold stock options of Bayer Schering Pharma AG. S.S. is a former employee of Bayer Schering Pharma AG and holds stock options of Bayer Schering Pharma AG. P.K. is coinventor of patent WO2007/025604. The other authors report no conflicts of interest. Parts of this work were presented at Eurotox2009 (54) and at the 51st Meeting of the German Society of Pharmacology and Toxicology 2010 (55).	Almeida MR, 2008, MUTAT RES-GEN TOX EN, V657, P155, DOI 10.1016/j.mrgentox.2008.09.005; BATLLE DC, 1990, KIDNEY INT, V37, P21, DOI 10.1038/ki.1990.3; Beswick RA, 2001, HYPERTENSION, V38, P1107, DOI 10.1161/hy1101.093423; Bianchi S, 2005, AM J KIDNEY DIS, V46, P45, DOI 10.1053/j.ajkd.2005.03.007; Brink A, 2006, J CHROMATOGR B, V830, P255, DOI 10.1016/j.jchromb.2005.10.046; Burniston JG, 2005, J MOL CELL CARDIOL, V39, P395, DOI 10.1016/j.yjmcc.2005.04.001; Calhoun DA, 2006, CLIN J AM SOC NEPHRO, V1, P1039, DOI 10.2215/CJN.01060306; Chao MR, 2008, FREE RADICAL BIO MED, V44, P464, DOI 10.1016/j.freeradbiomed.2007.10.003; Corrao G, 2007, CURR DRUG SAF, V2, P125, DOI 10.2174/157488607780598296; Devarajan Prasad, 2007, Cancer Ther, V5, P463; Devarajan P, 2007, CONTRIB NEPHROL, V156, P203; Eddy AA, 1996, KIDNEY INT, V50, P1139, DOI 10.1038/ki.1996.421; Epstein M, 2006, AM J MED, V119, P912, DOI 10.1016/j.amjmed.2006.03.038; Espinosa O, 2007, FREE RADICAL RES, V41, P546, DOI 10.1080/10715760601164050; Fagart J, 2010, J BIOL CHEM, V285, P29932, DOI 10.1074/jbc.M110.131342; Feldt S, 2008, J AM SOC NEPHROL, V19, P743, DOI 10.1681/ASN.2007091030; Friis S, 2001, CANCER-AM CANCER SOC, V92, P2462, DOI 10.1002/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L; Grossman E, 2002, AM J MED, V112, P479, DOI 10.1016/S0002-9343(02)01049-5; Gur M, 2007, CLIN BIOCHEM, V40, P454, DOI 10.1016/j.clinbiochem.2006.10.024; Han WK, 2002, KIDNEY INT, V62, P237, DOI 10.1046/j.1523-1755.2002.00433.x; Hofstra JM, 2008, NEPHROL DIAL TRANSPL, V23, P3160, DOI 10.1093/ndt/gfn190; Huang X, 2005, CELL PROLIFERAT, V38, P223, DOI 10.1111/j.1365-2184.2005.00344.x; Ichino M, 2009, J UROLOGY, V181, P2326, DOI 10.1016/j.juro.2009.01.010; Ishikawa Y, 2006, HYPERTENSION, V47, P1075, DOI 10.1161/01.HYP.0000221605.94532.71; Ismail IH, 2008, ENVIRON MOL MUTAGEN, V49, P73, DOI 10.1002/em.20358; Jin L, 2006, J PHYSIOL PHARMACOL, V57, P343; Johnston NIF, 2008, FRONT BIOSCI-LANDMRK, V13, P4361, DOI 10.2741/3009; Manning RD, 2005, AM J NEPHROL, V25, P311, DOI 10.1159/000086411; Marney AM, 2007, CLIN SCI, V113, P267, DOI 10.1042/CS20070123; Mathew JT, 2008, AM J PHYSIOL-RENAL, V295, pF73, DOI 10.1152/ajprenal.00435.2007; Moore LE, 2005, CANCER INVEST, V23, P240, DOI 10.1081/CNV-200055962; Nakabeppu Y, 2006, BIOL CHEM, V387, P373, DOI 10.1515/BC.2006.050; Ndisang JF, 2008, J HYPERTENS, V26, P1188, DOI 10.1097/HJH.0b013e3282fad93d; Nishiyama A, 2006, J PHARMACOL SCI, V100, P9, DOI 10.1254/jphs.FMJ05003X3; Oli RG, 2010, J NEURAL TRANSM, V117, P737, DOI 10.1007/s00702-010-0401-z; Orend G, 2005, INT J BIOCHEM CELL B, V37, P1066, DOI 10.1016/j.biocel.2004.12.002; Park E, 2005, J NUTR SCI VITAMINOL, V51, P254, DOI 10.3177/jnsv.51.254; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rasband W., 2006, IMAGEJ; Ravanat JL, 2002, CARCINOGENESIS, V23, P1911, DOI 10.1093/carcin/23.11.1911; Remuzzi G, 2008, J AM SOC NEPHROL, V19, P1459, DOI 10.1681/ASN.2007101079; Rossi GP, 2006, J AM COLL CARDIOL, V48, P2293, DOI 10.1016/j.jacc.2006.07.059; Schmid U, 2008, CANCER RES, V68, P9239, DOI 10.1158/0008-5472.CAN-08-1310; Schupp N, 2010, N-S ARCH PHARMACOL, V381, P66; Schupp N, 2010, HORM METAB RES, V42, P458, DOI 10.1055/s-0029-1243253; Schupp N, 2007, AM J PHYSIOL-RENAL, V292, pF1427, DOI 10.1152/ajprenal.00458.2006; Schupp N, 2009, TOXICOL LETT, V189, pS98, DOI 10.1016/j.toxlet.2009.06.319; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; STANTON HC, 1971, EXPT HYPERTENSION, V1; Terada Y, 2005, J AM SOC NEPHROL, V16, P2296, DOI 10.1681/ASN.2005020129; Trapp C, 2007, CANCER RES, V67, P5156, DOI 10.1158/0008-5472.CAN-07-0335; Tylicki L, 2008, AM J KIDNEY DIS, V52, P486, DOI 10.1053/j.ajkd.2008.02.297; Untergasser A, 2007, NUCLEIC ACIDS RES, V35, pW71, DOI 10.1093/nar/gkm306; Vaidya VS, 2008, ANNU REV PHARMACOL, V48, P463, DOI 10.1146/annurev.pharmtox.48.113006.094615; Weber KT, 2001, NEW ENGL J MED, V345, P1689, DOI 10.1056/NEJMra000050	55	56	58	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2011	25	3					968	978		10.1096/fj.10-173286	http://dx.doi.org/10.1096/fj.10-173286			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	727MZ	21135038				2022-12-28	WOS:000287806200017
J	Chen, P; Vericel, E; Lagarde, M; Guichardant, M				Chen, Ping; Vericel, Evelyne; Lagarde, Michel; Guichardant, Michel			Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation	FASEB JOURNAL			English	Article						docosahexaenoic acid; 15-lipoxygenase; docosatrienes; thromboxane receptor	DOCOSAHEXAENOIC ACID; CARDIOVASCULAR-DISEASE; LIPOXYGENASE PRODUCTS; LIPID MEDIATORS; CELL; RESPONSES; BRAIN; NEUROPROTECTIN-D1; SUPPLEMENTATION; CHOLESTEROL	Docosahexaenoic acid (DHA), an important component of marine lipids, exhibits anti-inflammatory activity related to some of its oxygenated metabolites, such as neuroprotectin/protectin D1 [NPD1/PD1; 10(R), 17(S)-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid] produced through the 15-lipoxygenase pathway. However, other metabolites from DHA can be produced through this pathway, and other polyunsaturated fatty acids (PUFAs) of nutritional value may be oxygenated as well. Their biological activities remain unknown. Isomers of protectin D1 were synthesized using soybean lipoxygenase and tested for their ability to inhibit human blood platelet aggregation. A geometric isomer called PDX, previously described with the 11E,13Z,15E geometry, instead of 11E, 13E, 15Z in PD1, inhibited platelet aggregation at submicromolar concentrations when induced by either collagen, arachidonic acid, or thromboxane. The inhibition occurred at the level of both the cyclooxygenase activity and thromboxane receptor site. Interestingly, all the metabolites tested exhibiting the E,Z,E-conjugated triene were active, whereas E, E, Z trienes (as in PD1) or all-trans (E, E, E) trienes were inactive. We conclude that PDX and other oxygenated products from PUFAs of nutritional interest, having the E, Z, E-conjugated triene motif and collectively named poxytrins (PUFA oxygenated trienes), might have antithrombotic potential.-Chen, P., Vericel, E., Lagarde, M., Guichardant, M. Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation. FASEB J. 25, 382-388 (2011). www.fasebj.org	[Lagarde, Michel] Univ Lyon, Unite Mixte Rech UMR 870, INSERM, Insa Lyon, F-69621 Villeurbanne, France; INRA, UMR 1235, F-69621 Villeurbanne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; INRAE	Lagarde, M (corresponding author), Univ Lyon, Unite Mixte Rech UMR 870, INSERM, Insa Lyon, Bldg IMBL,20 Ave A Einstein, F-69621 Villeurbanne, France.	michel.lagarde@insa-lyon.fr	Vericel, Evelyne/M-4187-2018		INSERM; Ministry of Education and Research; Lipides pour l'Industrie et la Sante (LISA) Carnot Institute; Chinese Educational Council	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ministry of Education and Research; Lipides pour l'Industrie et la Sante (LISA) Carnot Institute; Chinese Educational Council	This work was supported by INSERM, the Ministry of Education and Research, and the Lipides pour l'Industrie et la Sante (LISA) Carnot Institute. P.C. received a grant from the Chinese Educational Council.	AVELDANO MI, 1983, J BIOL CHEM, V258, P9339; Bazan NG, 2005, MOL NEUROBIOL, V32, P89, DOI 10.1385/MN:32:1:089; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Bazan NG, 2008, ADV EXP MED BIOL, V613, P39; BORGEAT P, 1982, PROSTAGLANDINS, V23, P713, DOI 10.1016/S0090-6980(82)80009-9; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BOUKHCHACHE D, 1982, BIOCHIM BIOPHYS ACTA, V713, P386, DOI 10.1016/0005-2760(82)90257-0; Butovich IA, 2006, J LIPID RES, V47, P854, DOI 10.1194/jlr.D500042-JLR200; Butovich IA, 2006, J LIPID RES, V47, P2462, DOI 10.1194/jlr.M600280-JLR200; Chen P, 2009, FEBS LETT, V583, P3478, DOI 10.1016/j.febslet.2009.10.004; CROSET M, 1983, BIOCHEM BIOPH RES CO, V112, P878, DOI 10.1016/0006-291X(83)91699-6; CROSET M, 1988, BIOCHEM PHARMACOL, V37, P1275, DOI 10.1016/0006-2952(88)90782-4; Dangi B, 2009, J BIOL CHEM, V284, P14744, DOI 10.1074/jbc.M809014200; de Turco EBR, 2002, J NEUROCHEM, V83, P515, DOI 10.1046/j.1471-4159.2002.01121.x; Deckelbaum RJ, 2008, AM J CLIN NUTR, V87, p2010S, DOI 10.1093/ajcn/87.6.2010S; Dona M, 2008, BLOOD, V112, P848, DOI 10.1182/blood-2007-11-122598; Elvevoll EO, 2008, ATHEROSCLEROSIS, V200, P396, DOI 10.1016/j.atherosclerosis.2007.12.021; Galarraga B, 2008, RHEUMATOLOGY, V47, P665, DOI 10.1093/rheumatology/ken024; GALGANI JE, 2008, BR J NUTR, V8, P1; Gonzalez-Periz A, 2006, FASEB J, V20, P2537, DOI 10.1096/fj.06-6250fje; GORDON WC, 1990, J NEUROSCI, V10, P2190; Guillot N, 2009, FASEB J, V23, P2909, DOI 10.1096/fj.09-133421; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; KIM HY, 1990, PROSTAGLANDINS, V40, P539, DOI 10.1016/0090-6980(90)90115-C; LAGARDE M, 1980, THROMB RES, V17, P581, DOI 10.1016/0049-3848(80)90098-5; LAGARDE M, 1989, BIOCHEM PHARMACOL, V38, P1863, DOI 10.1016/0006-2952(89)90422-X; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Leaf A, 2008, CURR VASC PHARMACOL, V6, P1, DOI 10.2174/157016108783331286; MARQUIS NR, 1969, BIOCHEM BIOPH RES CO, V36, P965, DOI 10.1016/0006-291X(69)90298-8; McCann K, 2007, EXPLORE-NY, V3, P616, DOI 10.1016/j.explore.2007.09.009; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Merzouk SA, 2008, LIPIDS, V43, P485, DOI 10.1007/s11745-008-3176-3; Mickleborough TD, 2005, J ASTHMA, V42, P305, DOI 10.1081/JAS-200062950; MILLER CC, 1989, LIPIDS, V24, P998, DOI 10.1007/BF02544068; Mirnikjoo B, 2001, J BIOL CHEM, V276, P10888, DOI 10.1074/jbc.M008150200; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Serhan CN, 2008, BRIT J PHARMACOL, V153, pS200, DOI 10.1038/sj.bjp.0707489; Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Stark KD, 2004, AM J CLIN NUTR, V79, P765; Torrejon C, 2007, PROSTAG LEUKOTR ESS, V77, P319, DOI 10.1016/j.plefa.2007.10.014; Volcik KA, 2008, AM J CLIN NUTR, V87, P1926, DOI 10.1093/ajcn/87.6.1926	44	57	58	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					382	388		10.1096/fj.10-161836	http://dx.doi.org/10.1096/fj.10-161836			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20833872				2022-12-28	WOS:000285869500034
J	Pavlov, PF; Wiehager, B; Sakai, J; Frykman, S; Behbahani, H; Winblad, B; Ankarcrona, M				Pavlov, Pavel F.; Wiehager, Birgitta; Sakai, Jun; Frykman, Susanne; Behbahani, Homira; Winblad, Bengt; Ankarcrona, Maria			Mitochondrial gamma-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein	FASEB JOURNAL			English	Article						Alzheimer's disease; APP processing	CYTOCHROME-C-OXIDASE; ALZHEIMERS-DISEASE; BETA-PROTEIN; A-BETA; BRAIN; CLEAVAGE; ACCUMULATION; PRESENILIN; ISOFORM; PEPTIDE	Intracellular amyloid-beta peptide (A beta) has been implicated in the pathogenesis of Alzheimer's disease (AD). Mitochondria were found to be the target both for amyloid precursor protein (APP) that accumulates in the mitochondrial import channels and for A beta that interacts with several proteins inside mitochondria and leads to mitochondrial dysfunction. Here, we have studied the role of mitochondrial gamma-secretase in processing different substrates. We found that a significant proportion of APP is associated with mitochondria in cultured cells and that gamma-secretase cleaves the shedded C-terminal part of APP identified as C83 associated with the outer membrane of mitochondria (OMM). Moreover, we have established the topology of the C83 in the OMM and found the APP intracellular domain (AICD) to be located inside mitochondria. Our data show for the first time that APP is a substrate for the mitochondrial gamma-secretase and that AICD is produced inside mitochondria. Thus, we provide a mechanistic view of the mitochondria-associated APP metabolism where AICD, P3 peptide and potentially A beta are produced locally and may contribute to mitochondrial dysfunction in AD.-Pavlov, P. F., Wiehager, B., Sakai, J., Frykman, S., Behbahani, H., Winblad, B., Ankarcrona, M. Mitochondrial gamma-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. FASEB J. 25, 78-88 (2011). www.fasebj.org	[Pavlov, Pavel F.; Wiehager, Birgitta; Frykman, Susanne; Behbahani, Homira; Winblad, Bengt; Ankarcrona, Maria] Karolinska Inst, Dainippon Sumitomo Pharma Alzheimer Ctr, Dept Neurobiol Care Sci & Soc, SE-14157 Huddinge, Sweden; [Sakai, Jun] Dainippon Sumitomo Pharma, Osaka, Japan	Karolinska Institutet	Pavlov, PF (corresponding author), Karolinska Inst, KASPAC, Novum Floor 5, SE-14157 Huddinge, Sweden.	pavel.pavlov@ki.se		Ankarcrona, Maria/0000-0002-7022-3694	Dainippon Sumitomo Pharma (Osaka, Japan)	Dainippon Sumitomo Pharma (Osaka, Japan)	The authors thank Dr. P. M. Mathews (Nathan Kline Institute, Orangeburg, NY, USA) for C1/6.1 antibody, and Dr. Sam Gandy (Thomas Jefferson University, Philadelphia, PA, USA) for G369 antibody. Wild-type MEFs and PS<SUP>-</SUP> cells were provided by Dr. B. De Strooper (Katholieke Universiteit Leuven, Leuven, Belgium). The authors thank Dr. Helena Karlstrom (Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden) for providing BD8 and BD8 up arrow cells. The authors thank Dr. Kjell Hultenby (Karolinska Institutet, Stockholm, Sweden) for excellent help with electron microscopy. This work was supported by Dainippon Sumitomo Pharma (Osaka, Japan).	Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Area-Gomez E, 2009, AM J PATHOL, V175, P1810, DOI 10.2353/ajpath.2009.090219; Behbahani H, 2006, J NEUROSCI RES, V84, P891, DOI 10.1002/jnr.20990; Caspersen C, 2005, FASEB J, V19, P2040, DOI 10.1096/fj.05-3735fje; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cottrell DA, 2002, NEUROPATH APPL NEURO, V28, P390, DOI 10.1046/j.1365-2990.2002.00414.x; Crouch PJ, 2005, J NEUROSCI, V25, P672, DOI 10.1523/JNEUROSCI.4276-04.2005; Deane R, 2008, J CLIN INVEST, V118, P4002, DOI 10.1172/JCI36663; Devi L, 2006, J NEUROSCI, V26, P9057, DOI 10.1523/JNEUROSCI.1469-06.2006; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Falkevall A, 2006, J BIOL CHEM, V281, P29096, DOI 10.1074/jbc.M602532200; Franberg J, 2007, BIOCHEMISTRY-US, V46, P7647, DOI 10.1021/bi0621258; Franberg J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009772; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Hansson CA, 2004, J BIOL CHEM, V279, P51654, DOI 10.1074/jbc.M404500200; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Hartmann T, 1999, EUR ARCH PSY CLIN N, V249, P291, DOI 10.1007/s004060050102; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hayashi T, 2009, TRENDS CELL BIOL, V19, P81, DOI 10.1016/j.tcb.2008.12.002; Jager S, 2009, J NEUROCHEM, V111, P1369, DOI 10.1111/j.1471-4159.2009.06420.x; KOO EH, 1994, J BIOL CHEM, V269, P17386; Leissring MA, 2004, BIOCHEM J, V383, P439, DOI 10.1042/BJ20041081; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lin MT, 2006, NAT MED, V12, P1241, DOI 10.1038/nm1106-1241; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066; Park HJ, 2006, J BIOL CHEM, V281, P34277, DOI 10.1074/jbc.M603443200; Petersen CAH, 2008, P NATL ACAD SCI USA, V105, P13145, DOI 10.1073/pnas.0806192105; Radke S, 2008, J BIOL CHEM, V283, P12681, DOI 10.1074/jbc.C800036200; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; Sandebring A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005701; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takuma K, 2009, P NATL ACAD SCI USA, V106, P20021, DOI 10.1073/pnas.0905686106; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Valla J, 2006, MITOCHONDRION, V6, P323, DOI 10.1016/j.mito.2006.10.004; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Wilson CA, 1999, J NEUROPATH EXP NEUR, V58, P787, DOI 10.1097/00005072-199908000-00001; Yamada K, 2008, J BIOL CHEM, V283, P34554, DOI 10.1074/jbc.M801487200; Yao J, 2009, P NATL ACAD SCI USA, V106, P14670, DOI 10.1073/pnas.0903563106	44	95	97	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					78	88		10.1096/fj.10-157230	http://dx.doi.org/10.1096/fj.10-157230			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20833873				2022-12-28	WOS:000285869500008
J	Acin-Perez, R; Hoyos, B; Gong, JL; Vinogradov, V; Fischman, DA; Leitges, M; Borhan, B; Starkov, A; Manfredi, G; Hammerling, U				Acin-Perez, Rebeca; Hoyos, Beatrice; Gong, Jianli; Vinogradov, Valerie; Fischman, Donald A.; Leitges, Michael; Borhan, Babak; Starkov, Anatoly; Manfredi, Giovanni; Hammerling, Ulrich			Regulation of intermediary metabolism by the PKC delta signalosome in mitochondria	FASEB JOURNAL			English	Article						energy homeostasis; pyruvate dehydrogenase complex; Krebs cycle control; cytochrome c; vitamin A	PROTEIN-KINASE-C; OXIDATIVE-PHOSPHORYLATION; REPERFUSION INJURY; REACTIVE OXYGEN; CYTOCHROME-C; ACTIVATION; MECHANISMS; CELLS; CARDIOPROTECTION; DYSFUNCTION	PKC delta has emerged as a novel regulatory molecule of oxidative phosphorylation by targeting the pyruvate dehydrogenase complex (PDHC). We showed that activation of PKC delta leads to the dephosphorylation of pyruvate dehydrogenase kinase 2 (PDK2), thereby decreasing PDK2 activity and increasing PDH activity, accelerating oxygen consumption, and augmenting ATP synthesis. However, the molecular components that mediate PKC delta signaling in mitochondria have remained elusive so far. Here, we identify for the first time a functional complex, which includes cytochrome c as the upstream driver of PKC delta, and uses the adapter protein p66Shc as a platform with vitamin A (retinol) as a fourth partner. All four components are necessary for the activation of the PKC delta signal chain. Genetic ablation of any one of the three proteins, or retinol depletion, silences signaling. Furthermore, mutations that disrupt the interaction of cytochrome c with p66Shc, of p66Shc with PKC delta, or the deletion of the retinol-binding pocket on PKC delta, attenuate signaling. In cytochrome c-deficient cells, reintroduction of cytochrome c Fe3+ protein restores PKC delta signaling. Taken together, these results indicate that oxidation of PKC delta is key to the activation of the pathway. The PKC delta/p66Shc/cytochrome c signalosome might have evolved to effect site-directed oxidation of zinc-finger structures of PKC delta, which harbor the activation centers and the vitamin A binding sites. Our findings define the molecular mechanisms underlying the signaling function of PKC delta in mitochondria.- Acin-Perez, R., Hoyos, B., Gong, J., Vinogradov, V., Fischman, D. A., Leitges, M., Borhan, B., Starkov, A., Manfredi, G., Hammerling, U. Regulation of intermediary metabolism by the PKC delta signalosome in mitochondria. FASEB J. 24, 5033-5042 (2010). www.fasebj.org	[Acin-Perez, Rebeca; Starkov, Anatoly; Manfredi, Giovanni] Weill Cornell Med Sch, Dept Neurol & Neurobiol, New York, NY USA; [Fischman, Donald A.] Weill Cornell Med Sch, Dept Cell & Dev Biol, New York, NY USA; [Hoyos, Beatrice; Gong, Jianli; Vinogradov, Valerie; Hammerling, Ulrich] Sloan Kettering Inst Canc Res, Program Immunol, New York, NY USA; [Leitges, Michael] Univ Oslo, Biotechnol Ctr Oslo, Oslo, Norway; [Borhan, Babak] Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Memorial Sloan Kettering Cancer Center; University of Oslo; Michigan State University	Acin-Perez, R (corresponding author), Weill Cornell Med Sch, Dept Neurol & Neurobiol, New York, NY USA.	u-hammerling@ski.mskcc.org	Acin-Perez, Rebeca/H-6160-2015; Leitges, Michael/AAN-1953-2021; Acin-Perez, Rebeca/AAU-4913-2020; Starkov, Anatoly/B-2688-2012; Gong, Jianli/G-1212-2011	Acin-Perez, Rebeca/0000-0001-9553-8337; Acin-Perez, Rebeca/0000-0001-9553-8337; Starkov, Anatoly/0000-0002-1334-4828; Leitges, Michael/0000-0003-4203-6995	U.S. National Institutes of Health [NIH R01 GM088999, NIH R01 DK 069348, NIH RO1 CA089362]; Muscular Dystrophy Association; United Mitochondrial Disease Foundation; NATIONAL CANCER INSTITUTE [R01CA089362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088999] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); United Mitochondrial Disease Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs. Pier Paolo Pandolfi (Harvard University, Boston, MA, USA) and Guiseppe Pelicci (University of Milan, Milan, Italy) for donating p66Shc<SUP>-/-</SUP> mice to Sloan-Kettering Institute. The authors also thank Dr. Ushio Kikkawa (Kobe University, Kobe, Japan) for his generous gift of mutant PKC delta expression vectors, and K. Nakanishi for his valuable suggestions regarding the synthesis and use of retinoids. Special thanks go to Dr. Silke Vogel (Columbia University, New York, NY, USA) for RBP and CRPB expression vectors and to Tony Riley (Sloan-Kettering Institute, New York, NY, USA) for expert medical illustration. This work was supported by U.S. National Institutes of Health grants NIH R01 GM088999 (G. M.), NIH R01 DK 069348 (U. H.), and NIH RO1 CA089362 (U. H.); the Muscular Dystrophy Association (G. M.); and the United Mitochondrial Disease Foundation (R.A.-P.).	Acin-Perez R, 2010, FASEB J, V24, P627, DOI 10.1096/fj.09-142281; Acin-Perez R, 2009, CELL METAB, V9, P265, DOI 10.1016/j.cmet.2009.01.012; Arany I, 2010, AM J PHYSIOL-RENAL, V298, pF1214, DOI 10.1152/ajprenal.00639.2009; Bright R, 2005, STROKE, V36, P2781, DOI 10.1161/01.STR.0000189996.71237.f7; Budas GR, 2007, PHARMACOL RES, V55, P523, DOI 10.1016/j.phrs.2007.04.005; Chiu HJ, 2008, FASEB J, V22, P3878, DOI 10.1096/fj.08-112375; Churchill EN, 2005, CIRC RES, V97, P78, DOI 10.1161/01.RES.0000173896.32522.6e; D'Aurelio M, 2001, J BIOL CHEM, V276, P46925, DOI 10.1074/jbc.M106429200; Fernandez-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Gopalakrishna R, 2008, J BIOL CHEM, V283, P14430, DOI 10.1074/jbc.M801519200; Graumann J, 2001, STRUCTURE, V9, P377, DOI 10.1016/S0969-2126(01)00599-8; Gray MO, 2004, J BIOL CHEM, V279, P3596, DOI 10.1074/jbc.M311459200; Hanlon PR, 2005, FASEB J, V19, P1323, DOI 10.1096/fj.04-3545fje; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; Hoyos B, 2005, J BIOL CHEM, V280, P6872, DOI 10.1074/jbc.M412695200; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; Imam A., 2000, FASEB J, V2000, DOI [10.1096/0E1000-13290e, DOI 10.1096/FJF.1000-1329FJE]; Inagaki K, 2003, CIRCULATION, V108, P2304, DOI 10.1161/01.CIR.0000101682.24138.36; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Mayr M, 2004, AM J PHYSIOL-HEART C, V287, pH937, DOI 10.1152/ajpheart.00877.2003; Morita M, 2008, J BIOCHEM, V143, P31, DOI 10.1093/jb/mvm190; Nathan C, 2003, J CLIN INVEST, V111, P769, DOI 10.1172/JCI200318174; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; Tan Q, 1997, ANGEW CHEM INT EDIT, V36, P2089, DOI 10.1002/anie.199720891; Vives-Bauza C, 2007, METHOD CELL BIOL, V80, P155, DOI 10.1016/S0091-679X(06)80007-5; Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	36	33	34	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2010	24	12					5033	5042		10.1096/fj.10-166934	http://dx.doi.org/10.1096/fj.10-166934			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20798245	Green Published			2022-12-28	WOS:000284824400041
J	Baker, PJ				Baker, Phillip J.			Chronic Lyme disease: in defense of the scientific enterprise	FASEB JOURNAL			English	Article						evidence-based research; antibiotic therapy	NEUROPROTECTION; GUIDELINES; HISTORY	There is no better example of a relentless attack on evidence-based biomedical research and the integrity of outstanding scientists than that associated with the treatment of a poorly defined condition called "chronic Lyme disease." Here, a scientifically naive general population, the lay press, and legislators, who in most instances are unable to evaluate and judge scientific evidence properly, have been misled by patient advocate groups to believe that extended antibiotic therapy is the best and only solution to this condition. This has resulted in the unprecedented intrusion of government and the legal systems into the practice of medicine and scientific research. Because there is no clinical evidence that this condition is due to a persistent infection, advocating extended antibiotic therapy is not justified and has been shown to be harmful and of no benefit.-Baker, P. J. Chronic Lyme disease: in defense of the scientific enterprise. FASEB J. 24, 4175-4177 (2010). www.fasebj.org	Amer Lyme Dis Fdn, Lyme, CT 06371 USA		Baker, PJ (corresponding author), Amer Lyme Dis Fdn, POB 466, Lyme, CT 06371 USA.	executivedir@aldf.com						Baker PJ, 2008, AM J MED, V121, P562, DOI 10.1016/j.amjmed.2008.02.013; Chandra A, 2010, BRAIN BEHAV IMMUN, V24, P1018, DOI 10.1016/j.bbi.2010.03.002; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Fallon BA, 2008, NEUROLOGY, V70, P992, DOI 10.1212/01.WNL.0000284604.61160.2d; Halperin JJ, 2007, NEUROLOGY, V69, P91, DOI 10.1212/01.wnl.0000265517.66976.28; HASSETT A, 2009, ARTHRITIS RHEUM, V59, P1742; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Kraemer JD, 2009, JAMA-J AM MED ASSOC, V301, P665, DOI 10.1001/jama.301.6.665; Krupp LB, 2003, NEUROLOGY, V60, P1923, DOI 10.1212/01.WNL.0000071227.23769.9E; Kuschak T, 2007, CAN J INFECT DIS MED, V18, P145; Lantos PM, 2010, CLIN INFECT DIS, V51, P1, DOI 10.1086/654809; Mygland A, 2010, EUR J NEUROL, V17, P8, DOI 10.1111/j.1468-1331.2009.02862.x; Nau R, 2009, DTSCH ARZTEBL INT, V106, P72, DOI 10.3238/arztebl.2009.0072; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Sigal L, 2007, ANN INTERN MED, V120, pS4; Weissenbacher S, 2005, DERMATOLOGY, V211, P123, DOI 10.1159/000086441; Weissmann G, 2007, FASEB J, V21, P299, DOI 10.1096/fj.07-0201ufm; Wormser GP, 2006, CLIN INFECT DIS, V43, P1089, DOI 10.1086/508667; EUROPEAN UNION CONCE	19	7	7	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4175	4177		10.1096/fj.10-167247	http://dx.doi.org/10.1096/fj.10-167247			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20631327				2022-12-28	WOS:000283861100005
J	Lalevee, S; Bour, G; Quinternet, M; Samarut, E; Kessler, P; Vitorino, M; Bruck, N; Delsuc, MA; Vonesch, JL; Kieffer, B; Rochette-Egly, C				Lalevee, Sebastien; Bour, Gaetan; Quinternet, Marc; Samarut, Eric; Kessler, Pascal; Vitorino, Marc; Bruck, Nathalie; Delsuc, Marc-Andre; Vonesch, Jean-Luc; Kieffer, Bruno; Rochette-Egly, Cecile			Vinexin beta, an atypical "sensor" of retinoic acid receptor gamma signaling: union and sequestration, separation, and phosphorylation	FASEB JOURNAL			English	Article						nuclear receptors; coregulators; retinoic acid; transcription	PROLINE-RICH MOTIFS; RAR-GAMMA; OF-PHARMACOLOGY; TRANSCRIPTION; DOMAIN; ALPHA; RECRUITMENT; INTERACTS; PROTEINS; DIFFERENTIATION	The transcriptional activity of nuclear retinoic acid receptors (RARs) relies on the association/dissociation of coregulators at the ligand-binding domain. However, we determined that the N-terminal domain (NTD) also plays a role through its phosphorylation, and we isolated vinexin beta, a cytoskeleton protein with three SH3 domains, as a new partner of the RAR gamma NTD. Here we deciphered the mechanism of the interaction and its role in RAR gamma-mediated transcription. By combining molecular and biophysical (surface plasmon resonance, NMR, and fluorescence resonance energy transfer) approaches, we demonstrated that the third SH3 domain of vinexin beta interacts with a proline-rich domain (PRD) located in RAR gamma NTD and that phosphorylation at a serine located in the PRD abrogates the interaction. The affinity of the interaction was also evaluated. In vivo, vinexin beta represses RAR gamma-mediated transcription and we dissected the underlying mechanism in chromatin immunoprecipitation experiments performed with F9 cells expressing RAR gamma wild type or mutated at the phosphorylation site. In the absence of retinoic acid (RA), vinexin beta does not occupy RAR gamma target gene promoters and sequesters non-phosphorylated RAR gamma out of promoters. In response to RA, RAR gamma becomes phosphorylated and dissociates from vinexin beta. This separation allows RAR gamma to occupy promoters. This is the first report of an RAR corepressor association/dissociation out of promoters and regulated by phosphorylation.-Lalevee, S., Bour, G., Quinternet, M., Samarut, E., Kessler, P., Vitorino, M., Bruck, N., Delsuc, M.-A., Vonesch, J.-L., Kieffer, B., Rochette-Egly, C. Vinexin beta, an atypical "sensor" of retinoic acid receptor gamma signaling: union and sequestration, separation, and phosphorylation. FASEB J. 24, 4523-4534 (2010). www.fasebj.org	[Rochette-Egly, Cecile] Univ Strasbourg, INSERM, IGBMC, U596, F-67404 Illkirch Graffenstaden, France; Univ Strasbourg, CNRS, UMR 7104, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), Univ Strasbourg, INSERM, IGBMC, U596, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.fr	Kessler, Pascal/ABF-6615-2021; Kieffer, Bruno/AAE-8999-2019; Delsuc, Marc-André/ABI-5400-2020	Delsuc, Marc-André/0000-0002-1400-5326; SAMARUT, ERIC/0000-0001-7818-2009; QUINTERNET, Marc/0000-0002-8299-7136; Kieffer, Bruno/0000-0002-2033-4679	Centre National de la Recherche Scientifique, INSERM; Agence Nationale pour la Recherche [ANR-05-BLAN- 0390-02, ANR-09-BLAN-0297-01]; Association pour la Recherche sur le Cancer [ARC-07-1-3169]; Foundation pour la Recherche Medicale (FRM) [DEQ 20090515423]; Institut National du Cancer [INCa-PL06-095, PL07-96099]; Ministere de l'Enseignement Superieur et de la Recherche; ARC	Centre National de la Recherche Scientifique, INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)Centre National de la Recherche Scientifique (CNRS)); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Foundation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer(Institut National du Cancer (INCA) France); Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); ARC(Australian Research Council)	The authors thank Dr. N. Kioka (Kyoto University, Kyoto, Japan) for the gift of the vinexin beta vector, M. Oulad Abdelghani (IGBMC) for the mouse monoclonal antibodies, and P. Eberling (IGBMC) for the synthetic peptides. The authors are also grateful to D. Altschuh and the Biacore platform (UMR 7100 Illkirch). The authors warmly acknowledge Regis Lutzing, Julie Goepp, Hussein Raad, Xiaojun Gao, Anne Chapelle, and members of the cell culture facilities for help. We give special thanks to Christine Ferry and Ali Hamiche for fruitful discussions and suggestions. This work was supported by funds from Centre National de la Recherche Scientifique, INSERM, the Agence Nationale pour la Recherche (ANR-05-BLAN- 0390-02 and ANR-09-BLAN-0297-01), the Association pour la Recherche sur le Cancer (ARC-07-1-3169), the Foundation pour la Recherche Medicale (FRM; DEQ 20090515423), and the Institut National du Cancer (INCa-PL06-095 and PL07-96099). S.L. was supported by the Ministere de l'Enseignement Superieur et de la Recherche and ARC.	Altschuh D, 2006, J MOL RECOGNIT, V19, P459, DOI 10.1002/jmr.807; Ball LJ, 2005, ANGEW CHEM INT EDIT, V44, P2852, DOI 10.1002/anie.200400618; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Bour G, 2005, J BIOL CHEM, V280, P17027, DOI 10.1074/jbc.M501344200; Bour G, 2006, AD DEV BIOL, V16, P211, DOI 10.1016/S1574-3349(06)16007-X; Bruck N, 2009, EMBO J, V28, P34, DOI 10.1038/emboj.2008.256; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Farboud B, 2003, MOL CELL BIOL, V23, P2844, DOI 10.1128/MCB.23.8.2844-2858.2003; Gaillard E, 2006, P NATL ACAD SCI USA, V103, P9548, DOI 10.1073/pnas.0509717103; Germain P, 2006, PHARMACOL REV, V58, P712, DOI 10.1124/pr.58.4.4; Germain P, 2006, PHARMACOL REV, V58, P760, DOI 10.1124/pr.58.4.7; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gillespie RF, 2007, J BIOL CHEM, V282, P33421, DOI 10.1074/jbc.M704845200; Gillespie RF, 2007, J MOL BIOL, V372, P298, DOI 10.1016/j.jmb.2007.06.079; Hauksdottir H, 2003, MOL ENDOCRINOL, V17, P373, DOI 10.1210/me.2002-0340; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Lavery DN, 2005, BIOCHEM J, V391, P449, DOI 10.1042/BJ20050872; Liu JG, 2006, BIOCHEMISTRY-US, V45, P6873, DOI 10.1021/bi0602718; Mitsushima M, 2006, GENES CELLS, V11, P281, DOI 10.1111/j.1365-2443.2006.00932.x; Mitsushima M, 2006, FEBS LETT, V580, P4288, DOI 10.1016/j.febslet.2006.06.072; Ouararhni K, 2006, GENE DEV, V20, P3324, DOI 10.1101/gad.396106; Plassat JL, 2000, J CELL SCI, V113, P2887; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rochette-Egly Cecile, 2009, Nucl Recept Signal, V7, pe005, DOI 10.1621/nrs.07005; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Zhang JH, 2007, BIOCHEM BIOPH RES CO, V357, P931, DOI 10.1016/j.bbrc.2007.04.029; Zheng B, 2009, FEBS J, V276, P2669, DOI 10.1111/j.1742-4658.2009.06986.x	30	22	22	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4523	4534		10.1096/fj.10-160572	http://dx.doi.org/10.1096/fj.10-160572			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20634350				2022-12-28	WOS:000283861100037
J	Melotte, V; Qu, XH; Ongenaert, M; van Criekinge, W; de Bruine, AP; Baldwin, HS; van Engeland, M				Melotte, Veerle; Qu, Xianghu; Ongenaert, Mate; van Criekinge, Wim; de Bruine, Adriaan P.; Baldwin, H. Scott; van Engeland, Manon			The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications	FASEB JOURNAL			English	Review						proliferation; differentiation; stress response; cancer; biomarker	METASTASIS-SUPPRESSOR GENE; DIFFERENTIALLY EXPRESSED GENES; TERM HUMAN TROPHOBLASTS; QT INTERVAL DURATION; TUMOR-METASTASIS; DOWN-REGULATION; PANCREATIC-CANCER; HEREDITARY MOTOR; COMMON VARIANTS; POOR-PROGNOSIS	The N-myc downstream regulated gene (NDRG) family of proteins consists of 4 members, NDRG1-4, which are well conserved through evolution. The first member to be discovered and responsible for the family name was NDRG1, because its expression is repressed by the proto-oncogenes MYCN and MYC. All family members are characterized by an alpha/beta hydrolase-fold motif; however, the precise molecular and cellular function of these family members has not been fully elucidated. Although the exact function of NDRG family members has not been clearly elucidated, emerging evidence suggests that mutations in these genes are associated with diverse neurological and electrophysiological syndromes. In addition, aberrant expression as well as tumor suppressor and oncogenic functions affecting key hallmarks of carcinogenesis such as cell proliferation, differentiation, migration, invasion, and stress response have been reported for several of the NDRG proteins. In this review, we summarize the current literature on the NDRG family members concerning their structure, origin, and tissue distribution. In addition, we review the current knowledge regarding the regulation and signaling of the NDRG family members in development and normal physiology. Finally, their role in disease and potential clinical applications (their role as detection or prognostic markers) are discussed.-Melotte, V., Qu, X., Ongenaert, M., van Criekinge, W., de Bruine, A. P., Baldwin, H. S., van Engeland, M. The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J. 24, 4153-4166 (2010). www.fasebj.org	[van Engeland, Manon] Maastricht Univ Med Ctr, Dept Pathol, GROW, Res Inst Growth & Dev GROW,Sch Oncol & Dev Biol, NL-6200 MD Maastricht, Netherlands; [Qu, Xianghu; Baldwin, H. Scott] Vanderbilt Univ, Med Ctr, Dept Pediat Cardiol, Nashville, TN USA; [Qu, Xianghu; Baldwin, H. Scott] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN USA; [Ongenaert, Mate; van Criekinge, Wim] Univ Ghent, Dept Mol Biotechnol, Fac BioSci Engn, B-9000 Ghent, Belgium	Maastricht University; Maastricht University Medical Centre (MUMC); Vanderbilt University; Vanderbilt University; Ghent University	van Engeland, M (corresponding author), Maastricht Univ Med Ctr, Dept Pathol, GROW, Res Inst Growth & Dev GROW,Sch Oncol & Dev Biol, POB 616, NL-6200 MD Maastricht, Netherlands.	manon.van.engeland@mumc.nl	Ongenaert, Maté/AAA-2826-2019; van Engeland, Manon/A-7479-2009	van Engeland, Manon/0000-0002-7952-6843; melotte, veerle/0000-0002-9459-123X; Ongenaert, Mate/0000-0001-7520-871X				Akiba J, 2008, ONCOL REP, V20, P1329, DOI 10.3892/or_00000148; Ando T, 2006, DIS ESOPHAGUS, V19, P454, DOI 10.1111/j.1442-2050.2006.00618.x; Angst E, 2006, BRIT J CANCER, V95, P307, DOI 10.1038/sj.bjc.6603256; Assamaki R, 2007, GENE CHROMOSOME CANC, V46, P564, DOI 10.1002/gcc.20439; Bandyopadhyay S, 2004, CANCER RES, V64, P7655, DOI 10.1158/0008-5472.CAN-04-1623; Bandyopadhyay S, 2004, ONCOGENE, V23, P5675, DOI 10.1038/sj.onc.1207734; Bandyopadhyay S, 2003, CANCER RES, V63, P1731; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; Berger P, 2004, NEUROBIOL DIS, V17, P290, DOI 10.1016/j.nbd.2004.07.014; Bhaduri A, 2003, J MOL MODEL, V9, P3, DOI 10.1007/s00894-002-0102-0; Boulkroun S, 2002, J BIOL CHEM, V277, P31506, DOI 10.1074/jbc.M200272200; Boutet Emmanuel, 2007, V406, P89; Burchfield JG, 2004, J BIOL CHEM, V279, P18623, DOI 10.1074/jbc.M401504200; Cangul H, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-27; Chang JT, 2005, INT J CANCER, V114, P942, DOI 10.1002/ijc.20663; Chen B, 2006, J BIOL CHEM, V281, P2764, DOI 10.1074/jbc.M507330200; Choi SC, 2003, FEBS LETT, V553, P413, DOI 10.1016/S0014-5793(03)01030-5; Choi SC, 2007, EXP MOL MED, V39, P705, DOI 10.1038/emm.2007.77; Choi SC, 2008, J LEUKOCYTE BIOL, V83, P89, DOI 10.1189/jlb.0507300; Chua MS, 2007, MODERN PATHOL, V20, P76, DOI 10.1038/modpathol.3800711; Dang C, 2006, ONCOL REP, V16, P513; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Fujii T, 2008, CURR MED CHEM, V15, P528, DOI 10.2174/092986708783769759; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gratton RJ, 2004, PLACENTA, V25, P62, DOI 10.1016/S0143-4004(03)00216-9; GUAO RJ, 2000, CANCER RES, V60, P749; Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032; Hirata K, 2004, GLIA, V47, P325, DOI 10.1002/glia.20037; Hongo S, 2006, J CELL BIOCHEM, V98, P185, DOI 10.1002/jcb.20763; Hosoi F, 2009, CANCER RES, V69, P4983, DOI 10.1158/0008-5472.CAN-08-4882; Hu XL, 2006, CELL TISSUE RES, V325, P67, DOI 10.1007/s00441-005-0137-5; Hu XL, 2004, WORLD J GASTROENTERO, V10, P3518; Hunter M, 2005, BIOCHEM BIOPH RES CO, V332, P982, DOI 10.1016/j.bbrc.2005.05.050; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; Kim A, 2009, CARCINOGENESIS, V30, P927, DOI 10.1093/carcin/bgp072; Kim YJ, 2009, INT J CANCER, V124, P7, DOI 10.1002/ijc.23945; Kim YJ, 2009, CARCINOGENESIS, V30, P598, DOI 10.1093/carcin/bgp047; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Koshiji M, 2007, WORLD J GASTROENTERO, V13, P2803, DOI 10.3748/wjg.v13.i20.2803; Kovacevic Z, 2008, BBA-MOL CELL RES, V1783, P1981, DOI 10.1016/j.bbamcr.2008.05.016; Kurdistani SK, 1998, CANCER RES, V58, P4439; Kyuno J, 2003, BIOCHEM BIOPH RES CO, V309, P52, DOI 10.1016/S0006-291X(03)01522-5; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Le NTV, 2004, BLOOD, V104, P2967, DOI 10.1182/blood-2004-05-1866; Lee DC, 2008, CANCER RES, V68, P4210, DOI 10.1158/0008-5472.CAN-07-5040; Li J, 2003, MOL CELL BIOCHEM, V250, P91, DOI 10.1023/A:1024918328162; Lind GE, 2006, CELL ONCOL, V28, P259; Liu N, 2007, BIOCHEM BIOPH RES CO, V358, P164, DOI 10.1016/j.bbrc.2007.04.089; LIU S, 2009, BIOCHIM BIOPHYS ACTA, V1801, P106; Lorentzen A, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-192; Lusis EA, 2005, CANCER RES, V65, P7121, DOI 10.1158/0008-5472.CAN-05-0043; Ma JJ, 2008, BIOL PHARM BULL, V31, P1316, DOI 10.1248/bpb.31.1316; Maruyama Y, 2006, CANCER RES, V66, P6233, DOI 10.1158/0008-5472.CAN-06-0183; Masuda K, 2003, INT J CANCER, V105, P803, DOI 10.1002/ijc.11152; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Melotte V, 2009, JNCI-J NATL CANCER I, V101, P916, DOI 10.1093/jnci/djp131; Milan DJ, 2003, CIRCULATION, V107, P1355, DOI 10.1161/01.CIR.0000061912.88753.87; Mitchelmore C, 2004, NEUROBIOL DIS, V16, P48, DOI 10.1016/j.nbd.2004.01.003; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Newton-Cheh C, 2009, NAT GENET, V41, P399, DOI 10.1038/ng.364; Nichols NR, 2005, BRAIN RES REV, V48, P287, DOI 10.1016/j.brainresrev.2004.12.019; Nishio S, 2008, CANCER LETT, V264, P36, DOI 10.1016/j.canlet.2008.01.020; Ohki T, 2002, DEV BRAIN RES, V135, P55; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; Okuda T, 2004, MOL CELL BIOL, V24, P3949, DOI 10.1128/MCB.24.9.3949-3956.2004; Okuda T, 2008, J HISTOCHEM CYTOCHEM, V56, P175, DOI 10.1369/jhc.7A7323.2007; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Park YJ, 2007, BIOCHEM BIOPH RES CO, V363, P361, DOI 10.1016/j.bbrc.2007.08.195; Pfeufer A, 2009, NAT GENET, V41, P407, DOI 10.1038/ng.362; Piepoli A, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-11; Qu XH, 2002, MOL CELL BIOCHEM, V229, P35, DOI 10.1023/A:1017934810825; Qu XH, 2008, DEV BIOL, V317, P486, DOI 10.1016/j.ydbio.2008.02.044; Ring BZ, 2006, J CLIN ONCOL, V24, P3039, DOI 10.1200/JCO.2006.05.6564; Roh CR, 2005, PLACENTA, V26, P319, DOI 10.1016/j.placenta.2004.06.013; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Salnikow K, 2000, CANCER RES, V60, P38; Salnikow K, 2008, CARCINOGENESIS, V29, P1493, DOI 10.1093/carcin/bgn088; Schilling SH, 2009, J BIOL CHEM, V284, P25160, DOI 10.1074/jbc.M109.012484; Shah MA, 2005, CLIN CANCER RES, V11, P3296, DOI 10.1158/1078-0432.CCR-04-2417; Shaw E, 2002, PROTEINS, V47, P163, DOI 10.1002/prot.10083; Shimono A, 1999, MECH DEVELOP, V83, P39, DOI 10.1016/S0925-4773(99)00025-8; Shon SK, 2009, BIOCHEM BIOPH RES CO, V385, P198, DOI 10.1016/j.bbrc.2009.05.038; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Song JY, 2008, INT J GYNECOL CANCER, V18, P1051, DOI 10.1111/j.1525-1438.2007.01164.x; Stein S, 2004, J BIOL CHEM, V279, P48930, DOI 10.1074/jbc.M400386200; Strzelczyk B, 2009, ANN SURG ONCOL, V16, P1287, DOI 10.1245/s10434-009-0381-0; Sugiki T, 2004, BIOL PHARM BULL, V27, P624, DOI 10.1248/bpb.27.624; Sugiki T, 2004, BIOL PHARM BULL, V27, P628, DOI 10.1248/bpb.27.628; Sun BQ, 2009, J NEURO-ONCOL, V94, P213, DOI 10.1007/s11060-009-9859-7; Svensson E, 2007, DNA CELL BIOL, V26, P589, DOI 10.1089/dna.2007.0586; Takahashi K, 2005, NEUROSCI LETT, V388, P157, DOI 10.1016/j.neulet.2005.06.055; Taketomi Y, 2003, BIOCHEM BIOPH RES CO, V306, P339, DOI 10.1016/S0006-291X(03)00942-2; Taketomi Y, 2007, J IMMUNOL, V178, P7042, DOI 10.4049/jimmunol.178.11.7042; Tepel M, 2008, INT J CANCER, V123, P2080, DOI 10.1002/ijc.23705; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; vanBelzen N, 1997, LAB INVEST, V77, P85; Wang LF, 2008, CELL PHYSIOL BIOCHEM, V21, P239, DOI 10.1159/000113765; Wang WQ, 2009, INT J CANCER, V124, P521, DOI 10.1002/ijc.23961; Wielputz MO, 2007, J BIOL CHEM, V282, P28264, DOI 10.1074/jbc.M702168200; WILSON AJ, CANC RES, V70, P609; Xu B, 1999, BIOL REPROD, V61, P681, DOI 10.1095/biolreprod61.3.681; Yan XR, 2008, CANCER LETT, V262, P133, DOI 10.1016/j.canlet.2007.12.010; Zhang J, 2006, J BIOL CHEM, V281, P39159, DOI 10.1074/jbc.M605820200; Zhang P, 2007, CANCER RES, V67, P9125, DOI 10.1158/0008-5472.CAN-07-1525; Zhao W, 2001, BBA-GENE STRUCT EXPR, V1519, P134, DOI 10.1016/S0167-4781(01)00210-X; Zhou DJ, 1998, CANCER RES, V58, P2182; Zhou RH, 2001, GENOMICS, V73, P86, DOI 10.1006/geno.2000.6496	109	213	219	2	36	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4153	4166		10.1096/fj.09-151464	http://dx.doi.org/10.1096/fj.09-151464			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20667976				2022-12-28	WOS:000283861100003
J	Van Goietsenoven, G; Hutton, J; Becker, JP; Lallemand, B; Robert, F; Lefranc, F; Pirker, C; Vandenbussche, G; Van Antwerpen, P; Evidente, A; Berger, W; Prevost, M; Pelletier, J; Kiss, R; Kinzy, TG; Kornienko, A; Mathieu, V				Van Goietsenoven, Gwendoline; Hutton, Jenna; Becker, Jean-Paul; Lallemand, Benjamin; Robert, Francis; Lefranc, Florence; Pirker, Christine; Vandenbussche, Guy; Van Antwerpen, Pierre; Evidente, Antonio; Berger, Walter; Prevost, Martine; Pelletier, Jerry; Kiss, Robert; Kinzy, Terri Goss; Kornienko, Alexander; Mathieu, Veronique			Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas	FASEB JOURNAL			English	Article						narciclasine; growth inhibition; apoptosis resistance; actin	ACTIN-BINDING PROTEIN; ELONGATION-FACTOR 1A; CANCER-CELLS; TRANSLATION ELONGATION; APOPTOSIS; NARCICLASINE; CYTOSKELETON; MITOCHONDRIA; RESISTANCE; LYCORINE	Melanomas display poor response rates to adjuvant therapies because of their intrinsic resistance to proapoptotic stimuli. This study indicates that such resistance can be overcome, at least partly, through the targeting of eEF1A elongation factor with narciclasine, an Amaryllidaceae isocarbostyril controlling plant growth. Narciclasine displays IC50 growth inhibitory values between 30-100 nM in melanoma cell lines, irrespective of their levels of resistance to proapoptotic stimuli. Normal noncancerous cell lines are much less affected. At nontoxic doses, narciclasine also significantly improves (P=0.004) the survival of mice bearing metastatic apoptosis-resistant melanoma xeno-grafts in their brain. The eEF1A targeting with narciclasine (50 nM) leads to 1) marked actin cytoskeleton disorganization, resulting in cytokinesis impairment, and 2) protein synthesis impairment (elongation and initiation steps), whereas apoptosis is induced at higher doses only (>= 200 nM). In addition to molecular docking validation and identification of potential binding sites, we biochemically confirmed that narciclasine directly binds to human recombinant and yeast-purified eEF1A in a nanomolar range, but not to actin or elongation factor 2, and that 5 nM narciclasine is sufficient to impair eEF1A-related actin bundling activity. eEF1A is thus a potential target to combat melanomas regardless of their apoptosis-sensitivity, and this finding reconciles the pleiotropic cytostatic of narciclasine.-Van Goietsenoven, G., Hutton, J., Becker, J.-P., Lallemand, B., Robert, F., Lefranc, F., Pirker, C., Vandenbussche, G., Van Antwerpen, P., Evidente, A., Berger, W., Prevost, M., Pelletier, J., Kiss, R., Goss Kinzy, T., Kornienko, A., Mathieu, V. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J. 24, 4575-4584 (2010). www.fasebj.org	[Kiss, Robert] Univ Libre Bruxelles, Inst Pharm, Toxicol Lab, B-1050 Brussels, Belgium; [Lallemand, Benjamin] Univ Libre Bruxelles, Lab Bioanalyt Chem Toxicol & Appl Chem, B-1050 Brussels, Belgium; [Van Antwerpen, Pierre] Univ Libre Bruxelles, Inst Pharm, Lab Pharmaceut Chem, B-1050 Brussels, Belgium; [Becker, Jean-Paul; Vandenbussche, Guy; Prevost, Martine] Univ Libre Bruxelles, Lab Struct & Funct Biol Membranes, Ctr Struct Biol & Bioinformat, B-1050 Brussels, Belgium; [Hutton, Jenna; Kinzy, Terri Goss] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA; [Robert, Francis; Pelletier, Jerry] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Lefranc, Florence] Erasme Univ Hosp, Dept Neurosurg, B-1070 Brussels, Belgium; [Pirker, Christine; Berger, Walter] Med Univ Vienna, Inst Canc Res, Dept Med 1, Vienna, Austria; [Evidente, Antonio] Univ Naples Federico II, Dipartimento Sci Suolo Pianta Ambiente & Prod Ani, Portici, Italy; [Kornienko, Alexander] New Mexico Inst Min & Technol, Dept Chem, Socorro, NM 87801 USA	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Rutgers State University New Brunswick; Rutgers State University Medical Center; McGill University; Universite Libre de Bruxelles; Medical University of Vienna; University of Naples Federico II; New Mexico Institute of Mining Technology	Kiss, R (corresponding author), Univ Libre Bruxelles, Inst Pharm, Toxicol Lab, Campus Plaine,Blvd Triomphe, B-1050 Brussels, Belgium.	rkiss@ulb.ac.be	Kornienko, Alexander/AAE-1870-2020; Evidente, Antonio/N-9357-2013	Kornienko, Alexander/0000-0003-2041-7367; Evidente, Antonio/0000-0001-9110-1656; Van Antwerpen, Pierre/0000-0002-4934-8863; Kinzy, Terri/0000-0003-1394-9226; Pirker, Christine/0000-0001-7104-4404; Berger, Walter/0000-0003-0014-1658; Vandenbussche, Guy/0000-0001-9592-2304	Fonds Yvonne Boel (Brussels, Belgium); Fonds National de la Recherche Scientifique (FNRS; Brussels, Belgium); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057483] Funding Source: NIH RePORTER	Fonds Yvonne Boel (Brussels, Belgium); Fonds National de la Recherche Scientifique (FNRS; Brussels, Belgium)(Fonds de la Recherche Scientifique - FNRS); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Jean-Francois Gaussin and Sebastien Sauvage for the in vivo experiment. The present work has been supported partly by grants awarded by the Fonds Yvonne Boel (Brussels, Belgium) and by the Fonds National de la Recherche Scientifique (FNRS; Brussels, Belgium). F.L. is a clinical research fellow, V.M. is a senior research assistant, and R.K. is a director of research with the FNRS.	Atallah Ehab, 2005, Curr Treat Options Oncol, V6, P185; Berger W, 1997, INT J CANCER, V71, P108, DOI 10.1002/(SICI)1097-0215(19970328)71:1<108::AID-IJC18>3.0.CO;2-E; Bi YR, 2003, J PLANT PHYSIOL, V160, P1041, DOI 10.1078/0176-1617-00911; Boldogh IR, 2006, BBA-MOL CELL RES, V1763, P450, DOI 10.1016/j.bbamcr.2006.02.014; CARRASCO L, 1975, FEBS LETT, V52, P236, DOI 10.1016/0014-5793(75)80813-1; CERIOTTI G, 1967, NATURE, V213, P595, DOI 10.1038/213595a0; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; de Heredia ML, 2004, CURR OPIN CELL BIOL, V16, P80, DOI 10.1016/j.ceb.2003.11.002; Dumont P, 2007, NEOPLASIA, V9, P766, DOI 10.1593/neo.07535; Duttaroy A, 1998, EXP CELL RES, V238, P168, DOI 10.1006/excr.1997.3819; Eberle J, 2007, DRUG RESIST UPDATE, V10, P218, DOI 10.1016/j.drup.2007.09.001; Edmonds BT, 1996, J CELL SCI, V109, P2705; EVIDENTE A, 1991, PLANTA MED, V57, P293, DOI 10.1055/s-2006-960098; Franklin-Tong VE, 2008, BIOCHEM J, V413, P389, DOI 10.1042/BJ20080320; Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o; Gerweck LE, 1996, CANCER RES, V56, P1194; GHEORGHUI A, 1962, ANN PHARM FR, V20, P531; Grassi G, 2007, BIOCHIMIE, V89, P1544, DOI 10.1016/j.biochi.2007.07.007; Gross SR, 2005, NAT STRUCT MOL BIOL, V12, P772, DOI 10.1038/nsmb979; Gross SR, 2007, MOL CELL BIOL, V27, P1974, DOI 10.1128/MCB.00832-06; Hamm C, 2008, CANCER TREAT REV, V34, P145, DOI 10.1016/j.ctrv.2007.10.003; Hayot C, 2006, TOXICOL APPL PHARM, V211, P30, DOI 10.1016/j.taap.2005.06.006; Ingrassia L, 2009, J MED CHEM, V52, P1100, DOI 10.1021/jm8013585; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; JIMENEZ A, 1976, BIOCHIM BIOPHYS ACTA, V425, P342, DOI 10.1016/0005-2787(76)90261-6; Kornienko A, 2008, CHEM REV, V108, P1982, DOI 10.1021/cr078198u; La Porta CAM, 2007, CURR MED CHEM, V14, P387; Lamoral-Theys D, 2009, J MED CHEM, V52, P6244, DOI 10.1021/jm901031h; Lefranc F, 2009, MOL CANCER THER, V8, P1739, DOI 10.1158/1535-7163.MCT-08-0932; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; Liu J, 2007, BIOMED PHARMACOTHER, V61, P229, DOI 10.1016/j.biopha.2007.01.003; Liu XS, 2009, CANCER LETT, V274, P16, DOI 10.1016/j.canlet.2008.08.029; Mathieu V, 2009, J CELL MOL MED, V13, P3960, DOI 10.1111/j.1582-4934.2009.00708.x; McLachlan A, 2005, APOPTOSIS, V10, P619, DOI 10.1007/s10495-005-1896-x; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; Noble CG, 2008, CELL MOL LIFE SCI, V65, P1335, DOI 10.1007/s00018-008-7495-6; Pelletier CL, 2007, CANCER RES, V67, P1609, DOI 10.1158/0008-5472.CAN-06-2875; Pettit GR, 2009, J NAT PROD, V72, P1279, DOI 10.1021/np9001948; PETTIT GR, 1986, J NAT PROD, V49, P995, DOI 10.1021/np50048a005; Pinke DE, 2008, GYNECOL ONCOL, V108, P561, DOI 10.1016/j.ygyno.2007.11.019; Pittman YR, 2009, J BIOL CHEM, V284, P4739, DOI 10.1074/jbc.M807945200; SADOWSKI J, 1993, CHEM REV, V93, P2567, DOI 10.1021/cr00023a012; Siedlakowski P, 2008, CANCER BIOL THER, V7, P376, DOI 10.4161/cbt.7.3.5364; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Wang CH, 2008, J CELL SCI, V121, P2913, DOI 10.1242/jcs.023911; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	48	99	99	0	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4575	4584		10.1096/fj.10-162263	http://dx.doi.org/10.1096/fj.10-162263			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20643906	Green Published			2022-12-28	WOS:000283861100042
J	Elson, AET; Dotson, CD; Egan, JM; Munger, SD				Elson, Amanda E. T.; Dotson, Cedrick D.; Egan, Josephine M.; Munger, Steven D.			Glucagon signaling modulates sweet taste responsiveness	FASEB JOURNAL			English	Article						proglucagon; glucagon receptor; gustation; 7B2; behavior	VASOACTIVE-INTESTINAL-PEPTIDE; RECEPTOR-CELLS; GUSTATORY RESPONSIVENESS; PROHORMONE CONVERTASE-2; COEXPRESSION PATTERNS; BITTER TASTE; ALPHA-CELLS; NULL MICE; RAT; BUDS	The gustatory system provides critical information about the quality and nutritional value of food before it is ingested. Thus, physiological mechanisms that modulate taste function in the context of nutritional needs or metabolic status could optimize ingestive decisions. We report that glucagon, which plays important roles in the maintenance of glucose homeostasis, enhances sweet taste responsiveness through local actions in the mouse gustatory epithelium. Using immunohistochemistry and confocal microscopy, we found that glucagon and its receptor (GlucR) are coexpressed in a subset of mouse taste receptor cells. Most of these cells also express the T1R3 taste receptor implicated in sweet and/or umami taste. Genetic or pharmacological disruption of glucagon signaling in behaving mice indicated a critical role for glucagon in the modulation of taste responsiveness. Scg5(-/-) mice, which lack mature glucagon, had significantly reduced responsiveness to sucrose as compared to wild-type littermates in brief-access taste tests. No significant differences were seen in responses to prototypical salty, sour, or bitter stimuli. Taste responsiveness to sucrose was similarly reduced upon acute and local disruption of glucagon signaling by the GlucR antagonist L-168,049. Together, these data indicate a role for local glucagon signaling in the peripheral modulation of sweet taste responsiveness.-Elson, A.E.T., Dotson, C.D., Egan, J.M., Munger, S.D. Glucagon signaling modulates sweet taste responsiveness. FASEB J. 24, 3960-3969 (2010). www.fasebj.org	[Elson, Amanda E. T.; Dotson, Cedrick D.; Munger, Steven D.] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; [Egan, Josephine M.] NIA, NIH, Baltimore, MD 21224 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Munger, SD (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, 20 S Penn St,Rm S251, Baltimore, MD 21201 USA.	smung001@umaryland.edu		Dotson, Cedrick/0000-0003-0992-1191; Elson, Amanda/0000-0002-5744-5954	National Institute on Deafness and Communication Disorders [DC010110, DC010113]; Ajinomoto Amino Acid Research Program; National Institute on Aging; NATIONAL INSTITUTE ON AGING [ZIAAG000291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010110, F31DC010113] Funding Source: NIH RePORTER	National Institute on Deafness and Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Ajinomoto Amino Acid Research Program; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	The authors thank Iris Lindberg (University of Maryland School of Medicine) and the S.D.M. laboratory for helpful comments on the manuscript, and Iris Lindberg, Maureen Charron (Albert Einstein School of Medicine, New York, NY, USA), and Charles Zuker (Columbia University, New York, NY, USA) for generous gifts of reagents. This work was supported by the National Institute on Deafness and Communication Disorders (DC010110, S. D. M.; DC010113, A.E.T.E.), the Ajinomoto Amino Acid Research Program (S.D.M.) and the National Institute on Aging Intramural Program (J.M.E.).	Asano-Miyoshi M, 2001, CHEM SENSES, V26, P259, DOI 10.1093/chemse/26.3.259; Behrens M, 2009, RESULTS PROBL CELL D, V47, P203, DOI 10.1007/400_2008_5; Boughter JD, 2002, CHEM SENSES, V27, P133, DOI 10.1093/chemse/27.2.133; Cascieri MA, 1999, J BIOL CHEM, V274, P8694, DOI 10.1074/jbc.274.13.8694; Dallas-Yang Q, 2002, ANAL BIOCHEM, V301, P156, DOI 10.1006/abio.2001.5483; de Laszlo SE, 1999, BIOORG MED CHEM LETT, V9, P641, DOI 10.1016/S0960-894X(99)00081-5; DEJONG A, 1977, AM J PHYSIOL, V233, pE380, DOI 10.1152/ajpendo.1977.233.5.E380; Dvoryanchikov G, 2007, J COMP NEUROL, V505, P302, DOI 10.1002/cne.21494; Egan JM, 2008, MOL INTERV, V8, P78, DOI 10.1124/mi.8.2.5; Feng XH, 2008, ACTA HISTOCHEM, V110, P151, DOI 10.1016/j.acthis.2007.10.005; Finger TE, 2005, CHEM SENSES, V30, pI54, DOI 10.1093/chemse/bjh110; GEARY N, 1993, AM J PHYSIOL, V264, pR116, DOI 10.1152/ajpregu.1993.264.1.R116; GEARY N, 1990, NEUROSCI BIOBEHAV R, V14, P323, DOI 10.1016/S0149-7634(05)80042-9; Gelling RW, 2009, AM J PHYSIOL-ENDOC M, V297, pE695, DOI 10.1152/ajpendo.00082.2009; Gelling RW, 2003, P NATL ACAD SCI USA, V100, P1438, DOI 10.1073/pnas.0237106100; Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JCI200422098; GIZA BK, 1993, AM J PHYSIOL, V265, pR1231, DOI 10.1152/ajpregu.1993.265.6.R1231; GIZA BK, 1992, BRAIN RES BULL, V28, P637, DOI 10.1016/0361-9230(92)90116-F; Glendinning JI, 2002, CHEM SENSES, V27, P461, DOI 10.1093/chemse/27.5.461; Gonzalez-Munoz C, 2008, EUR J PHARMACOL, V587, P243, DOI 10.1016/j.ejphar.2008.04.001; Gromada J, 2007, ENDOCR REV, V28, P84, DOI 10.1210/er.2006-0007; Heppner KM, 2010, PHYSIOL BEHAV, V100, P545, DOI 10.1016/j.physbeh.2010.03.019; Herness S, 2002, J NEUROSCI, V22, P10018; Herness S, 2009, PHYSIOL BEHAV, V97, P581, DOI 10.1016/j.physbeh.2009.02.043; Karasawa N, 1997, J NEURAL TRANSM, V104, P1267, DOI 10.1007/BF01294727; Katayama T, 2007, BIOCHEM BIOPH RES CO, V357, P865, DOI 10.1016/j.bbrc.2007.04.001; Kawai K, 2000, P NATL ACAD SCI USA, V97, P11044, DOI 10.1073/pnas.190066697; Kaya N, 2004, AM J PHYSIOL-REG I, V286, pR649, DOI 10.1152/ajpregu.00572.2003; Kieffer TJ, 1996, ENDOCRINOLOGY, V137, P5119, DOI 10.1210/en.137.11.5119; LANGHANS W, 1982, SCIENCE, V218, P894, DOI 10.1126/science.7134979; Laurent V, 2004, ENDOCRINOLOGY, V145, P519, DOI 10.1210/en.2003-0829; Lee SN, 2008, ENDOCRINOLOGY, V149, P4116, DOI 10.1210/en.2008-0064; Lu SG, 2003, NEUROSCI LETT, V351, P157, DOI 10.1016/j.neulet.2003.07.016; Ma HZ, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-5; Ma J, 2009, AM J PHYSIOL-GASTR L, V296, pG735, DOI 10.1152/ajpgi.90708.2008; Ma XS, 2005, MOL ENDOCRINOL, V19, P198, DOI 10.1210/me.2004-0059; Maeda T, 2003, NEUROSCI LETT, V343, P17, DOI 10.1016/S0304-3940(03)00295-7; Martin B, 2010, DIABETES, V59, P1143, DOI 10.2337/db09-0807; Martin B, 2009, ANN NY ACAD SCI, V1170, P98, DOI 10.1111/j.1749-6632.2009.03920.x; Meier JJ, 2006, GASTROENTEROLOGY, V130, P44, DOI 10.1053/j.gastro.2005.10.004; Nakagawa Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005106; Nakamura Y, 2008, DIABETES, V57, P2661, DOI 10.2337/db07-1103; Nelson TM, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-32; Nelson TM, 2003, CHEM SENSES, V28, P695, DOI 10.1093/chemse/bjg062; Peinado JR, 2005, ENDOCRINOLOGY, V146, P3438, DOI 10.1210/en.2004-1289; Reimann F, 2008, CELL METAB, V8, P532, DOI 10.1016/j.cmet.2008.11.002; Rozengurt E, 2007, CURR OPIN PHARMACOL, V7, P557, DOI 10.1016/j.coph.2007.10.002; Seta Y, 2006, ARCH HISTOL CYTOL, V69, P273, DOI 10.1679/aohc.69.273; Shen T, 2005, NEUROSCIENCE, V130, P229, DOI 10.1016/j.neuroscience.2004.09.017; Shigemura N, 2004, ENDOCRINOLOGY, V145, P839, DOI 10.1210/en.2003-0602; Shin YK, 2008, J NEUROCHEM, V106, P455, DOI 10.1111/j.1471-4159.2008.05397.x; Sutherland K, 2007, AM J PHYSIOL-GASTR L, V292, pG1420, DOI 10.1152/ajpgi.00504.2006; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Woods SC, 2006, PHILOS T R SOC B, V361, P1219, DOI 10.1098/rstb.2006.1858; Yang RB, 2000, J COMP NEUROL, V425, P139, DOI 10.1002/1096-9861(20000911)425:1<139::AID-CNE12>3.0.CO;2-#; Yang RB, 2007, J COMP NEUROL, V502, P883, DOI 10.1002/cne.21317; Yee CL, 2001, J COMP NEUROL, V440, P97, DOI 10.1002/cne.1372; Yoshida R, 2010, P NATL ACAD SCI USA, V107, P935, DOI 10.1073/pnas.0912048107; Zhao FL, 2005, P NATL ACAD SCI USA, V102, P11100, DOI 10.1073/pnas.0501988102; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	60	51	52	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3960	3969		10.1096/fj.10-158105	http://dx.doi.org/10.1096/fj.10-158105			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20547661	Green Published			2022-12-28	WOS:000285005900033
J	Khurshid, N; Hameed, LS; Mohanasundaram, S; Iyengar, S				Khurshid, Nazia; Hameed, L. Shahul; Mohanasundaram, Sivaraj; Iyengar, Soumya			Opioid modulation of cell proliferation in the ventricular zone of adult zebra finches (Taenopygia guttata)	FASEB JOURNAL			English	Article						song control system; naloxone; met-enkephalin	MESSENGER-RNA EXPRESSION; VOCAL CONTROL-SYSTEM; FEMALE CANARY BRAIN; NEURAL STEM-CELLS; HIPPOCAMPAL NEUROGENESIS; SUBVENTRICULAR ZONE; SUBGRANULAR ZONE; RAT HIPPOCAMPUS; NEURONAL RECRUITMENT; GENE-EXPRESSION	Besides modulating pain, stress, physiological functions, motivation, and reward, the opioid system has been implicated in developmental and adult mammalian neurogenesis and gliogenesis. In adult male songbirds including zebra finches, neurons generated from the ventricular zone (VZ) of the lateral ventricles are incorporated throughout the telencephalon, including the song control nuclei, HVC, and area X. Although the endogenous opioid met-enkephalin is present in neurons adjacent to the VZ and is upregulated in song control regions during singing, it is not known whether the opioid system can modulate adult neurogenesis/gliogenesis in zebra finches. We used quantitative RT-PCR and in situ hybridization to demonstrate that mu- and delta-opioid receptors are expressed by the VZ of adult male zebra finches. Treating cultured VZ cells from male birds with the opioid antagonist naloxone led to an increase in cell proliferation measured by 5-bromo-2-deoxyuridine incorporation, whereas administering met-enkephalin had the opposite effect, compared with saline-treated cultures. Systemically administering naloxone (2.5 mg/kg body wt) to adult male zebra finches for 4 d also led to a significant increase in cell proliferation in the ventral VZ of these birds, compared with saline-treated controls. Our results show that cell proliferation is augmented by naloxone in the VZ adjacent to the anterior commissure, suggesting that the endogenous opioids modulate adult neurogenesis/gliogenesis by inhibiting cell proliferation in songbirds.-Khurshid, N., Hameed, L. S., Mohanasundaram, S., Iyengar, S. Opioid modulation of cell proliferation in the ventricular zone of adult zebra finches (Taenopygia guttata). FASEB J. 24, 3681-3695 (2010). www.fasebj.org	[Khurshid, Nazia; Hameed, L. Shahul; Mohanasundaram, Sivaraj; Iyengar, Soumya] Natl Brain Res Ctr, Div Syst Neurosci, Manesar, India	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC)	Iyengar, S (corresponding author), Deemed Univ, Natl Brain Res Ctr, NH-8, Gurgaon 122050, Haryana, India.	soumya@nbrc.ac.in	Sundaram, Sivaraj/AAB-5852-2022; Sundaram, Sivaraj Mohana/R-9681-2019	Sundaram, Sivaraj Mohana/0000-0003-2120-9420	Department of Biotechnology, India [BT/PR6615/MED/14/857/2005]; NBRC (Manesar, India)	Department of Biotechnology, India(Department of Biotechnology (DBT) India); NBRC (Manesar, India)	The authors gratefully acknowledge the expert technical support provided by Shalini Sharma, Naveen Jayaprakash, and Khader Valli (NBRC). The authors also thank Uzma Saeed (NBRC) and two anonymous reviewers for their insightful comments which helped improve this manuscript. This study was supported by a grant from the Department of Biotechnology, India (BT/PR6615/MED/14/857/2005; to S.I.), and funds from NBRC (Manesar, India).	Adar E, 2008, J NEUROSCI, V28, P5394, DOI 10.1523/JNEUROSCI.5706-07.2008; ALTMAN J, 1965, NATURE, V207, P953, DOI 10.1038/207953a0; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; ALVAREZBUYLLA A, 1990, NEURON, V5, P101, DOI 10.1016/0896-6273(90)90038-H; ARAI O, 1995, NEUROSCI LETT, V198, P135, DOI 10.1016/0304-3940(95)11989-A; Arguello AA, 2008, NEUROSCIENCE, V157, P70, DOI 10.1016/j.neuroscience.2008.08.064; Barkan S, 2007, DEV NEUROBIOL, V67, P687, DOI 10.1002/dneu.20379; Barnea A, 2006, BEHAV BRAIN RES, V167, P63, DOI 10.1016/j.bbr.2005.08.018; BARNEA A, 1994, P NATL ACAD SCI USA, V91, P11217, DOI 10.1073/pnas.91.23.11217; BERKOWITZ BA, 1975, CLIN PHARMACOL THER, V17, P629; Bonfanti L, 2007, PROG NEUROBIOL, V83, P24, DOI 10.1016/j.pneurobio.2006.11.002; Bottjer SW, 1997, J NEUROBIOL, V33, P602, DOI 10.1002/(SICI)1097-4695(19971105)33:5<602::AID-NEU8>3.0.CO;2-8; BOTTJER SW, 1995, BRAIN BEHAV EVOLUT, V45, P153, DOI 10.1159/000113547; BOULDER C, 1970, ANAT REC, V166, P257; BROWN SD, 1993, J NEUROSCI, V13, P2024; Bungo T, 2005, PHYSIOL BEHAV, V85, P519, DOI 10.1016/j.physbeh.2005.05.015; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Charvet CJ, 2008, BRAIN BEHAV EVOLUT, V72, P295, DOI 10.1159/000184744; Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x; Chen YL, 2008, CURR MED CHEM, V15, P772, DOI 10.2174/092986708783955518; CSILLAG A, 1990, J COMP NEUROL, V302, P543, DOI 10.1002/cne.903020310; De Vries TJ, 2002, J NEUROSCI, V22, P3321; Deviche P, 1997, BRAIN RES, V757, P276, DOI 10.1016/S0006-8993(97)00298-9; DeWulf V, 2005, J COMP NEUROL, V481, P70, DOI 10.1002/cne.20352; DeWulf V, 2002, J NEUROSCI, V22, P4080, DOI 10.1523/JNEUROSCI.22-10-04080.2002; Doupe AJ, 1999, ANNU REV NEUROSCI, V22, P567, DOI 10.1146/annurev.neuro.22.1.567; Dreborg S, 2008, P NATL ACAD SCI USA, V105, P15487, DOI 10.1073/pnas.0805590105; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fields HL, 2007, REGION ANESTH PAIN M, V32, P242, DOI 10.1016/j.rapm.2007.01.001; Fischer SJ, 2008, NEUROSCIENCE, V151, P1217, DOI 10.1016/j.neuroscience.2007.11.035; FORD DH, 1979, ACTA NEUROL SCAND, V59, P248; Freeman FM, 2000, LEARN MEMORY, V7, P213, DOI 10.1101/lm.7.4.213; Ganapathy V, 2005, AAPS J, V7, pE852, DOI 10.1208/aapsj070482; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GOLDMAN SA, 1985, DEV BRAIN RES, V22, P237, DOI 10.1016/0165-3806(85)90175-0; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; GULLEDGE CC, 1995, J COMP NEUROL, V356, P408, DOI 10.1002/cne.903560308; Gulledge CC, 1999, J COMP NEUROL, V404, P505; HAMMER RP, 1993, MOL BRAIN RES, V19, P129, DOI 10.1016/0169-328X(93)90157-K; Hauser KF, 2000, EUR J NEUROSCI, V12, P1281, DOI 10.1046/j.1460-9568.2000.01015.x; HIDALGO A, 1995, J NEUROBIOL, V27, P470, DOI 10.1002/neu.480270404; Holmes MM, 2002, BEHAV NEUROSCI, V116, P160, DOI 10.1037//0735-7044.116.1.160; Holzenberger M, 1997, J NEUROSCI, V17, P6974; Hu SX, 2002, NEUROPHARMACOLOGY, V42, P829, DOI 10.1016/S0028-3908(02)00030-8; Hurley P, 2008, BRAIN BEHAV EVOLUT, V71, P263, DOI 10.1159/000127046; Jiang JW, 1998, J NEUROBIOL, V36, P1, DOI 10.1002/(SICI)1097-4695(199807)36:1<1::AID-NEU1>3.0.CO;2-6; Kahn L, 2005, EUR J NEUROSCI, V21, P493, DOI 10.1111/j.1460-9568.2005.03883.x; Katz A, 2008, EUR J NEUROSCI, V28, P99, DOI 10.1111/j.1460-9568.2008.06303.x; KEMENADE V, 2009, ANN NY ACAD SCI, V1163, P528; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Khurshid N, 2010, BEHAV BRAIN RES, V208, P359, DOI 10.1016/j.bbr.2009.12.003; Khurshid N, 2009, J CHEM NEUROANAT, V37, P158, DOI 10.1016/j.jchemneu.2008.12.001; Kim E, 2006, J BIOL CHEM, V281, P33749, DOI 10.1074/jbc.M603862200; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Lagace DC, 2010, P NATL ACAD SCI USA, V107, P4436, DOI 10.1073/pnas.0910072107; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Law PY, 1997, MOL PHARMACOL, V51, P152, DOI 10.1124/mol.51.1.152; Leslie FM, 1998, CAN J PHYSIOL PHARM, V76, P284, DOI 10.1139/cjpp-76-3-284; Li X, 1996, J MOL EVOL, V43, P179, DOI 10.1007/BF02338825; Li Y, 2009, BIOCHEM BIOPH RES CO, V378, P857, DOI 10.1016/j.bbrc.2008.12.001; Lipkind D, 2002, BEHAV BRAIN RES, V133, P31, DOI 10.1016/S0166-4328(01)00416-8; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Lowery JJ, 2007, CHEM BIOL DRUG DES, V69, P41, DOI 10.1111/j.1747-0285.2007.00462.x; Lu M, 2008, J NEUROSCI METH, V167, P376, DOI 10.1016/j.jneumeth.2007.08.015; Lucas NN, 2009, NEUROREPORT, V20, P1066, DOI 10.1097/WNR.0b013e32832e0c2b; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Mandyam CD, 2004, J NEUROSCI RES, V76, P783, DOI 10.1002/jnr.20090; MINAMI M, 1995, FEBS LETT, V364, P23, DOI 10.1016/0014-5793(95)00340-F; Mollereau C, 2005, MOL PHARMACOL, V67, P965, DOI 10.1124/mol.104.004614; NGAI SH, 1976, ANESTHESIOLOGY, V44, P398, DOI 10.1097/00000542-197605000-00008; NORDEEN KW, 1988, NATURE, V334, P149, DOI 10.1038/334149a0; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; Nottebohm F, 2004, ANN NY ACAD SCI, V1016, P628, DOI 10.1196/annals.1298.027; Olmstead MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004410; OLSON GA, 1992, PEPTIDES, V13, P1247, DOI 10.1016/0196-9781(92)90036-3; Persson AI, 2003, EUR J NEUROSCI, V17, P1159, DOI 10.1046/j.1460-9568.2003.02538.x; Przewlocki R, 2004, EUR J PHARMACOL, V500, P331, DOI 10.1016/j.ejphar.2004.07.036; Pytte CL, 2007, DEV NEUROBIOL, V67, P1699, DOI 10.1002/dneu.20520; Ra SM, 2002, NEUROSCI LETT, V333, P123, DOI 10.1016/S0304-3940(02)01031-5; Rasika S, 1999, NEURON, V22, P53, DOI 10.1016/S0896-6273(00)80678-9; RASIKA S, 1994, P NATL ACAD SCI USA, V91, P7854, DOI 10.1073/pnas.91.17.7854; REINER A, 1989, J COMP NEUROL, V280, P359, DOI 10.1002/cne.902800304; Reznikov K, 1999, EUR J NEUROSCI, V11, P2711, DOI 10.1046/j.1460-9568.1999.00680.x; Riquelme PA, 2008, PHILOS T R SOC B, V363, P123, DOI 10.1098/rstb.2006.2016; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sargeant TJ, 2008, J NEUROCHEM, V107, P883, DOI 10.1111/j.1471-4159.2008.05671.x; Sargeant TJ, 2007, BRAIN RES, V1175, P28, DOI 10.1016/j.brainres.2007.07.091; Scott BB, 2007, J COMP NEUROL, V502, P202, DOI 10.1002/cne.21296; Scotto-Lomassese S, 2007, EUR J NEUROSCI, V25, P1663, DOI 10.1111/j.1460-9568.2007.05418.x; SEATRIZ JV, 1993, BRAIN RES BULL, V30, P523, DOI 10.1016/0361-9230(93)90078-P; Stefano GB, 2008, NEUROCHEM RES, V33, P1933, DOI 10.1007/s11064-008-9674-0; Stevens Craig W., 2005, P13; Stiene-Martin A, 2001, GLIA, V36, P78, DOI 10.1002/glia.1097; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; TAKAHASHI T, 1993, J NEUROSCI, V13, P820; Tegeder I, 2004, PHARMACOL REV, V56, P351, DOI 10.1124/pr.56.3.2; Tekumalla PK, 2002, J NEUROBIOL, V51, P323, DOI 10.1002/neu.10053; Tripathi A, 2008, NEUROSCI RES, V61, P257, DOI 10.1016/j.neures.2008.03.002; Vaidya V. A., 2007, CNS & Neurological Disorders-Drug Targets, V6, P358, DOI 10.2174/187152707783220910; Vaidya Vidita A, 2007, Expert Rev Neurother, V7, P853, DOI 10.1586/14737175.7.7.853; Wada K, 2006, P NATL ACAD SCI USA, V103, P15212, DOI 10.1073/pnas.0607098103; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; Wang X, 2006, PHARMACOGENOMICS J, V6, P255, DOI 10.1038/sj.tpj.6500375; Wilbrecht L, 2004, ANN NY ACAD SCI, V1016, P659, DOI 10.1196/annals.1298.024; Xi ZX, 2002, ALCOHOL ALCOHOLISM, V37, P485, DOI 10.1093/alcalc/37.5.485; Zagon IS, 2005, NEUROPEPTIDES, V39, P495, DOI 10.1016/j.npep.2005.07.001; ZAGON IS, 1987, BRAIN RES, V412, P68, DOI 10.1016/0006-8993(87)91440-5; ZAGON IS, 1977, PHARMACOLOGY, V15, P302, DOI 10.1159/000136703; ZAGON IS, 1991, BRAIN RES, V542, P318, DOI 10.1016/0006-8993(91)91585-O	117	10	10	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					3681	3695		10.1096/fj.09-146746	http://dx.doi.org/10.1096/fj.09-146746			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20495180				2022-12-28	WOS:000285005900009
J	Peng, C; Cho, YY; Zhu, F; Xu, YM; Wen, WH; Ma, WY; Bode, AM; Dong, ZG				Peng, Cong; Cho, Yong-Yeon; Zhu, Feng; Xu, Yan-Ming; Wen, Weihong; Ma, Wei-Ya; Bode, Ann M.; Dong, Zigang			RSK2 mediates NF-kappa B activity through the phosphorylation of I kappa B alpha in the TNF-R1 pathway	FASEB JOURNAL			English	Article						apoptosis; cell survival; serine/threonine kinases; tumor promoter	RIBOSOMAL S6 KINASE; INDUCED APOPTOSIS; TARGETING DEATH; CELL-SURVIVAL; MAPK PATHWAY; DOCKING SITE; HISTONE H3; ACTIVATION; PROTEIN; IDENTIFICATION	The ribosomal S6 kinase 2 (RSK2) is a well-known serine/threonine kinase and a member of the p90 ribosomal S6 kinase (p90RSK) family of proteins. It is activated downstream of the MEK/ERKs cascade by mitogenic stimuli such as EGF or TPA. Here, we show that RSK2 is activated by treatment with tumor necrosis factor-alpha (TNF-alpha) and directly phosphorylates I kappa B alpha at Ser-32, leading to I kappa B alpha degradation. The phosphorylation of I kappa B alpha promotes the activation and translocation of the nuclear factor-kappa B (NF-kappa B) subunits p65 and p50 to the nucleus. The net result is an increased NF-kappa B activity, which serves as a mechanism for RSK2 blockade of TNF-alpha-induced apoptosis and enhanced cell survival.-Peng, C., Cho, Y.-Y., Zhu, F., Xu, Y.-M., Wen, W., Ma, W.-Y., Bode, A. M., Dong, Z. RSK2 mediates NF-kappa B activity through the phosphorylation of I kappa B alpha in the TNF-R1 pathway. FASEB J. 24, 3490-3499 (2010). www.fasebj.org	[Peng, Cong; Cho, Yong-Yeon; Zhu, Feng; Xu, Yan-Ming; Wen, Weihong; Ma, Wei-Ya; Bode, Ann M.; Dong, Zigang] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	ZHU, Feng/G-3567-2010; Cho, Yong-Yeon/AAD-4263-2020; peng, cong/A-9454-2012; ZHU, Feng/C-1303-2010; 温, 家琦/GYV-3177-2022	Cho, Yong-Yeon/0000-0003-1107-2651; Zhu, Feng/0000-0003-1172-0102	Hormel Foundation; U.S. National Institutes of Health [CA077646, CA111536, CA120388, R37CA081064, ES016548]; NATIONAL CANCER INSTITUTE [R01CA077646, R01CA120388, R01CA111536, R37CA081064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016548] Funding Source: NIH RePORTER	Hormel Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by The Hormel Foundation and U.S. National Institutes of Health grants CA077646, CA111536, CA120388, R37CA081064, and ES016548.	Anjum R, 2005, CURR BIOL, V15, P1762, DOI 10.1016/j.cub.2005.08.050; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bignone PA, 2007, ONCOGENE, V26, P683, DOI 10.1038/sj.onc.1209827; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen NY, 2001, CANCER RES, V61, P3908; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cho YY, 2007, CANCER RES, V67, P8104, DOI 10.1158/0008-5472.CAN-06-4668; Cho YY, 2007, J BIOL CHEM, V282, P8380, DOI 10.1074/jbc.M611322200; Cho YY, 2005, CANCER RES, V65, P3596, DOI 10.1158/0008-5472.CAN-04-3935; Choi HS, 2009, MOL CELL BIOL, V29, P2168, DOI 10.1128/MCB.01508-08; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Eisinger-Mathason TSK, 2008, MOL CELL, V31, P722, DOI 10.1016/j.molcel.2008.06.025; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Geisler F, 2007, GASTROENTEROLOGY, V132, P2489, DOI 10.1053/j.gastro.2007.03.033; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kwon B, 2003, EXP MOL MED, V35, P8, DOI 10.1038/emm.2003.2; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mahadevan Louis C, 2004, Novartis Found Symp, V259, P102; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Nakajima A, 2006, EMBO J, V25, P5549, DOI 10.1038/sj.emboj.7601423; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sethi G, 2007, ONCOGENE, V26, P7324, DOI 10.1038/sj.onc.1210544; She QB, 2002, CANCER RES, V62, P1343; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang P, 2004, INVEST OPHTH VIS SCI, V45, P2438, DOI 10.1167/iovs.03-0805; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7	47	37	39	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3490	3499		10.1096/fj.09-151290	http://dx.doi.org/10.1096/fj.09-151290			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20385620	Green Published			2022-12-28	WOS:000281446400036
J	Massie, A; Schallier, A; Kim, SW; Fernando, R; Kobayashi, S; Beck, H; De Bundel, D; Vermoesen, K; Bannai, S; Smolders, I; Conrad, M; Plesnila, N; Sato, H; Michotte, Y				Massie, Ann; Schallier, Anneleen; Kim, Seong Woong; Fernando, Ruani; Kobayashi, Sho; Beck, Heike; De Bundel, Dimitri; Vermoesen, Katia; Bannai, Shiro; Smolders, Ilse; Conrad, Marcus; Plesnila, Nikolaus; Sato, Hideyo; Michotte, Yvette			Dopaminergic neurons of system x(c)(-)-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity	FASEB JOURNAL			English	Article						xCT; glutathione; glutamate; Parkinson's disease	METABOTROPIC GLUTAMATE RECEPTORS; TIME-DEPENDENT CHANGES; MOUSE SPINAL-CORD; PARKINSONS-DISEASE; IN-VIVO; GLUTATHIONE DEFICIENCY; SUBTHALAMIC NUCLEUS; TRANSGENIC MICE; CYSTEINE UPTAKE; TRANSPORTER	Malfunctioning of system x(c)(-), responsible for exchanging intracellular glutamate for extracellular cystine, can cause oxidative stress and excitotoxicity, both important phenomena in the pathogenesis of Parkinson's disease (PD). We used mice lacking xCT (xCT(-/-) mice), the specific subunit of system x(c)(-), to investigate the involvement of this antiporter in PD. Although cystine that is imported via system x(c)(-) is reduced to cysteine, the rate-limiting substrate in the synthesis of glutathione, deletion of xCT did not result in decreased glutathione levels in striatum. Accordingly, no signs of increased oxidative stress could be observed in striatum or substantia nigra of xCT(-/-) mice. In sharp contrast to expectations, xCT(-/-) mice were less susceptible to 6-hydroxydopamine (6-OHDA)-induced neurodegeneration in the substantia nigra pars compacta compared to their age-matched wild-type littermates. This reduced sensitivity to a PD-inducing toxin might be related to the decrease of 70% in striatal extracellular glutamate levels that was observed in mice lacking xCT. The current data point toward system x(c)(-) as a possible target for the development of new pharmacotherapies for the treatment of PD and emphasize the need to continue the search for specific ligands for system x(c)(-).-Massie, A., Schallier, A., Kim, S. W., Fernando, R., Kobayashi, S., Beck, H., De Bundel, D., Vermoesen, K., Bannai, S., Smolders, I., Conrad, M., Plesnila, N., Sato, H., Michotte, Y. Dopaminergic neurons of system x(c)(-)-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. FASEB J. 25, 1359-1369 (2011). www.fasebj.org	[Massie, Ann; Schallier, Anneleen; De Bundel, Dimitri; Vermoesen, Katia; Smolders, Ilse; Michotte, Yvette] Vrije Univ Brussel, Dept Pharmaceut Chem & Drug Anal, Res Grp Expt Pharmacol, B-1090 Brussels, Belgium; [Kim, Seong Woong; Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dublin 2, Ireland; [Fernando, Ruani] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden; [Kobayashi, Sho; Bannai, Shiro; Sato, Hideyo] Yamagata Univ, Fac Agr, Dept Food & Appl Life Sci, Yamagata 990, Japan; [Beck, Heike] Univ Munich, Walter Brendel Ctr Expt Med, Munich, Germany; [Conrad, Marcus] Inst Clin Mol Biol & Tumor Genet, Helmholtz Ctr Munich, Munich, Germany	Vrije Universiteit Brussel; Royal College of Surgeons - Ireland; Karolinska Institutet; Yamagata University; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Massie, A (corresponding author), Vrije Univ Brussel, Dept Pharmaceut Chem & Drug Anal, Res Grp Expt Pharmacol, Laarbeeklaan 103, B-1090 Brussels, Belgium.	amassie@vub.ac.be	Smolders, Ilse J/J-9399-2013; Michotte, Yvette/G-9818-2013; Plesnila, Nikolaus/T-7522-2019; De Bundel, Dimitri/AAG-9453-2020; Massie, Ann/F-1039-2013; De Bundel, Dimitri/C-5701-2015; Conrad, Marcus/E-8792-2015	Smolders, Ilse J/0000-0003-2140-0751; Conrad, Marcus/0000-0003-1140-5612; Massie, Ann/0000-0002-8418-5879; De Bundel, Dimitri/0000-0002-6234-9908	Brussels Capital Region; Fonds voor Wetenschappelijk Onderzoek (FWO)-Flanders; Vrije Universiteit Brussel	Brussels Capital Region; Fonds voor Wetenschappelijk Onderzoek (FWO)-Flanders(FWO); Vrije Universiteit Brussel	This work was supported by grants of the Brussels Capital Region (Prospective Research for Brussels), Fonds voor Wetenschappelijk Onderzoek (FWO)-Flanders, and the Vrije Universiteit Brussel. A. S. is a research assistant of the FWO-Flanders and K. V. is a research assistant of the Agentschap voor Innovatie door Wetenschap en Technologie (IWT)-Flanders. The authors thank Mr. G. De Smet and Ms. A. De Smet for excellent technical assistance, as well as Dr. M. Watanabe (Hokkaido University School of Medicine, Sapporo, Japan) for providing antibodies.	Albrecht P, 2010, CNS NEUROL DISORD-DR, V9, P373, DOI 10.2174/187152710791292567; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Asanuma M, 1998, NEUROSCIENCE, V85, P907, DOI 10.1016/S0306-4522(97)00665-9; Augustin H, 2007, J NEUROSCI, V27, P111, DOI 10.1523/JNEUROSCI.4770-06.2007; Baker DA, 2002, J NEUROSCI, V22, P9134; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Battaglia G, 2004, J NEUROSCI, V24, P828, DOI 10.1523/JNEUROSCI.3831-03.2004; Bensadoun JC, 1998, EUR J NEUROSCI, V10, P3231, DOI 10.1046/j.1460-9568.1998.00345.x; Blandini F, 2001, FUNCT NEUROL, V16, P99; Blandini F, 2000, PROG NEUROBIOL, V62, P63, DOI 10.1016/S0301-0082(99)00067-2; Chen YM, 2003, J NEUROCHEM, V84, P1332, DOI 10.1046/j.1471-4159.2003.01630.x; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Himi T, 2003, J NEURAL TRANSM, V110, P1337, DOI 10.1007/s00702-003-0049-z; Jakel RJ, 2007, BRAIN RES, V1144, P192, DOI 10.1016/j.brainres.2007.01.131; Lewerenz J, 2009, J BIOL CHEM, V284, P1106, DOI 10.1074/jbc.M807325200; LINDEFORS N, 1990, NEUROSCI LETT, V115, P248, DOI 10.1016/0304-3940(90)90463-J; Mandal PK, 2010, J BIOL CHEM, V285, P22244, DOI 10.1074/jbc.M110.121327; Massie A, 2008, NEUROREPORT, V19, P1589, DOI 10.1097/WNR.0b013e328312181c; Massie A, 2010, NEUROCHEM INT, V57, P111, DOI 10.1016/j.neuint.2010.04.019; Meshul CK, 1999, NEUROSCIENCE, V88, P1, DOI 10.1016/S0306-4522(98)00189-4; Paxinos G, 2007, MOUSE BRAIN STEREOTA; Qin S, 2006, J NEUROSCI, V26, P3345, DOI 10.1523/JNEUROSCI.5186-05.2006; Rodriguez MC, 1998, ANN NEUROL, V44, pS175, DOI 10.1002/ana.410440726; Rouse ST, 2000, PHARMACOL THERAPEUT, V88, P427, DOI 10.1016/S0163-7258(00)00098-X; Savaskan NE, 2008, NAT MED, V14, P629, DOI 10.1038/nm1772; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Shanker G, 2001, BRAIN RES, V902, P156, DOI 10.1016/S0006-8993(01)02342-3; Shibata T, 1997, J NEUROSCI, V17, P9212; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Sontheimer H, 2003, TRENDS NEUROSCI, V26, P543, DOI 10.1016/j.tins.2003.08.007; Van Hemelrijek A, 2005, J NEUROSCI METH, V144, P63, DOI 10.1016/j.jneumeth.2004.10.013; Vernon AC, 2007, J NEUROCHEM, V103, P1075, DOI 10.1111/j.1471-4159.2007.04860.x; Yamada K, 1998, J NEUROSCI, V18, P5706	36	96	99	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2011	25	4					1359	1369		10.1096/fj.10-177212	http://dx.doi.org/10.1096/fj.10-177212			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21191088				2022-12-28	WOS:000288982800025
J	Kremerskothen, J; Stolting, M; Wiesner, C; Korb-Pap, A; van Vliet, V; Linder, S; Huber, TB; Rottiers, P; Reuzeau, E; Genot, E; Pavenstadt, H				Kremerskothen, Joachim; Stoelting, Miriam; Wiesner, Christiane; Korb-Pap, Adelheid; van Vliet, Vanessa; Linder, Stefan; Huber, Tobias B.; Rottiers, Patricia; Reuzeau, Edith; Genot, Elisabeth; Pavenstaedt, Hermann			Zona occludens proteins modulate podosome formation and function	FASEB JOURNAL			English	Article						podosomes; ZO-1; cortactin; actin assembly	SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX DEGRADATION; TIGHT JUNCTIONS; ACTIN CYTOSKELETON; DISCRETE MICRODOMAINS; EPITHELIAL-CELLS; DORSAL RUFFLES; DIRECT BINDING; ZO-1; CORTACTIN	Podosomes are highly dynamic structures that are involved in cell adhesion and extracellular matrix remodeling. They present as intracellular columns composed of an actin-rich core region and a surrounding ring-like structure containing focal adhesion proteins, actin binders as well as cell signaling molecules. A key player in podosome biogenesis is the scaffolding protein cortactin, which is thought to control actin assembly at the core region. We show that the zona occludens protein 1 (ZO-1), a pivotal tight junction protein and known binding partner of cortactin, is a component of podosomes. In the smooth muscle cell line A7r5, phorbol ester treatment induced a rapid relocation of ZO-1 from the cell cortex and cytosolic pools toward newly formed podosomes. Podosomal localization was also observed for the known ZO-1-binding proteins l-afadin, alpha-catenin, and phospho-connexin 43. Truncation studies revealed that the actin-binding domain but not the association with cortactin is necessary for ZO-1 recruitment to podosomes. Moreover, impaired ZO-1 expression leads to significantly reduced podosome formation and concomitant decreased matrix degradation at podosomes. Our findings demonstrate that besides their known function in tight junction assembly and intercellular communication, zona occludens proteins and their binding partners may play a novel role in podosome formation and associated function, thus regulating cell adhesion and matrix remodeling.-Kremerskothen, J., Stolting, M., Wiesner, C., Korb-Pap, A., van Vliet, V., Linder, S., Huber, T. B., Rottiers, P., Reuzeau, E., Genot, E., Pavenstadt, H. Zona occludens proteins modulate podosome formation and function. FASEB J. 25, 505-514 (2011). www.fasebj.org	[Kremerskothen, Joachim; Stoelting, Miriam; Korb-Pap, Adelheid; Pavenstaedt, Hermann] Univ Clin Munster, Dept Mol Nephrol, D-48149 Munster, Germany; [Wiesner, Christiane; van Vliet, Vanessa; Linder, Stefan] Univ Clin Hamburg Eppendorf, Inst Med Microbiol Virol & Hyg, Hamburg, Germany; [Huber, Tobias B.] Univ Med Ctr Freiburg, Dept Nephrol, Freiburg, Germany; [Rottiers, Patricia; Reuzeau, Edith; Genot, Elisabeth] European Inst Biol & Chem, Dept Mol & Cellular Biol, INSERM, U889, Pessac, France	University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg; Institut National de la Sante et de la Recherche Medicale (Inserm)	Kremerskothen, J (corresponding author), Univ Clin Munster, Dept Mol Nephrol, Domagkstr 3A, D-48149 Munster, Germany.	joachim.kremerskothen@uni-muenster.de	Genot, Elisabeth/G-8031-2014	Huber, Tobias B./0000-0001-7175-5062	 [IMF KR-110904];  [ARC3549];  [ANR-06-BLAN-0362]	; ; 	The authors thank Alan Fanning (University of North Carolina, Chapel Hill, NC, USA) and Alan Mak (Queen's University, Kingston, ON, Canada) for ZO-1 and cortactin constructs, respectively. The authors gratefully acknowledge Angelika Barnekow (University of Muenster, Muenster, Germany) for the LA90-RSV cells and Guido Bose (Nanospot, Muenster, Germany) for use of the TIRF microscope. The authors thank Christine Varon and Fabien Guegan (INSERM, Pessac, France) for help with preliminary experiments. The authors are grateful to Jens Cornils (University Clinic Hamburg, Hamburg, Germany) for excellent technical assistance. This research was funded by grants IMF KR-110904 to J.K. and ARC3549 and ANR-06-BLAN-0362 to E.G.	Adamopoulos IE, 2006, HUM PATHOL, V37, P1176, DOI 10.1016/j.humpath.2006.04.007; Akoyev V, 2007, CELL SIGNAL, V19, P958, DOI 10.1016/j.cellsig.2006.11.007; ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; Balda MS, 2003, J CELL BIOL, V160, P423, DOI 10.1083/jcb.200210020; BALDA MS, 1993, AM J PHYSIOL, V264, pC918, DOI 10.1152/ajpcell.1993.264.4.C918; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; Benezra M, 2007, INVEST OPHTH VIS SCI, V48, P2043, DOI 10.1167/iovs.06-0754; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Burgstaller G, 2004, J CELL SCI, V117, P223, DOI 10.1242/jcs.00839; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Ebnet K, 2008, HISTOCHEM CELL BIOL, V130, P1, DOI 10.1007/s00418-008-0418-7; Fanning AS, 2007, J BIOL CHEM, V282, P37710, DOI 10.1074/jbc.M707255200; Fanning AS, 2002, FASEB J, V16, P1835, DOI 10.1096/fj.02-0121fje; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fultz ME, 2000, J MUSCLE RES CELL M, V21, P775, DOI 10.1023/A:1010396429297; Gaidos G, 2007, J CELL SCI, V120, P2366, DOI 10.1242/jcs.004333; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gimona M, 2003, MOL BIOL CELL, V14, P2482, DOI 10.1091/mbc.E02-11-0743; Gimona M, 2008, SEMIN CANCER BIOL, V18, P23, DOI 10.1016/j.semcancer.2007.08.005; Goicoechea S, 2006, J CELL SCI, V119, P3316, DOI 10.1242/jcs.03076; GRAY GM, 1989, ONCOGENE, V4, P1213; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Hai CM, 2002, EXP CELL RES, V280, P64, DOI 10.1006/excr.2002.5592; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Ikenouchi J, 2007, J CELL BIOL, V176, P779, DOI 10.1083/jcb.200612080; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Katsuno T, 2008, MOL BIOL CELL, V19, P2465, DOI 10.1091/mbc.E07-12-1215; Kaverina I, 2003, J CELL SCI, V116, P4915, DOI 10.1242/jcs.00818; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; McNeil E, 2006, MOL BIOL CELL, V17, P1922, DOI 10.1091/mbc.E05-07-0650; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Oikawa T, 2008, J CELL BIOL, V182, P157, DOI 10.1083/jcb.200801042; Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X; Spray DC, 2006, GLIA, V54, P758, DOI 10.1002/glia.20429; Taliana L, 2005, INVEST OPHTH VIS SCI, V46, P96, DOI 10.1167/iovs.04-0145; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Webb BA, 2005, AM J PHYSIOL-CELL PH, V289, pC898, DOI 10.1152/ajpcell.00095.2005; Webb BA, 2006, ARCH BIOCHEM BIOPHYS, V456, P183, DOI 10.1016/j.abb.2006.06.011; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Wiesner C, 2010, BLOOD, V116, P1559, DOI 10.1182/blood-2009-12-257089; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Xu JL, 2008, MOL CELL BIOL, V28, P1669, DOI 10.1128/MCB.00891-07; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; Zhou ST, 2006, AM J PHYSIOL-CELL PH, V290, pC463, DOI 10.1152/ajpcell.00350.2005	56	18	18	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2011	25	2					505	514		10.1096/fj.10-155598	http://dx.doi.org/10.1096/fj.10-155598			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	20930113				2022-12-28	WOS:000286724800009
J	Veitia, RA; Vaiman, D				Veitia, Reiner A.; Vaiman, Daniel			Exploring the mechanistic bases of heterosis from the perspective of macromolecular complexes	FASEB JOURNAL			English	Article						dominant-negative effects; gene dosage	OVERDOMINANT EPISTATIC LOCI; PRIMARY GENETIC-BASIS; INBREEDING DEPRESSION; MOLECULAR-BASIS; HYBRID; RICE; EXPRESSION; AUTOTETRAPLOIDS; DOMINANCE; PATTERNS	Heterosis is defined as greater biomass, fertility or other traits in heterozygotes, polyploids or hybrids compared to their genetically divergent (often homozygous) parents. Heterosis was noticed by various civilizations and scientifically reported by Darwin himself. Despite the importance of heterosis, its molecular bases are still enigmatic. Several genetic models have been proposed but fail to give mechanistic insights. Here we show how dominant negative interactions might give rise to heterotic responses. We also explore a biochemical model of gene dosage effects in macromolecular complexes in a similar context. With the help of heuristic examples and computer simulations we find that heterotic individuals display higher allelic diversity and smaller average multimer concentrations than nonheterotic ones. As intuitively expected, the existence of heterosis involving multimeric complexes arises when the inbred parents have on average smaller genetic values than the maximum possible. Despite its simplicity, the dosage model accounts for the puzzling phenomenon of "progressive heterosis" in which polyploids with increasing genetic diversity exhibit progressively greater heterosis.-Veitia, R. A., Vaiman, D. Exploring the mechanistic bases of heterosis from the perspective of macromolecular complexes. FASEB J. 25, 476-482 (2011). www.fasebj.org	[Veitia, Reiner A.] Inst Jacques Monod, CNRS, UMR 7592, Paris 13, France; [Veitia, Reiner A.] Univ Paris 07, Paris, France; [Vaiman, Daniel] Inst Cochin Genet Mol, Inst Natl Sante & Rech Med INSERM, CNRS, U1016,UMR8104, F-75014 Paris, France; [Vaiman, Daniel] Univ Paris 05, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Veitia, RA (corresponding author), Inst Jacques Monod, CNRS, UMR 7592, Batiment Buffon,15 Rue Helene Brion, Paris 13, France.	veitia.reiner@ijm.univ-paris-diderot.fr	Vaiman, Daniel/O-6030-2015	Vaiman, Daniel/0000-0002-1915-0717	Centre National de la Recherche Scientifique; Universite Paris-Diderot; Association pour la Recherche sur le Cancer, la Fondation pour la Recherche Medicale; Institut Universitaire de France	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Universite Paris-Diderot; Association pour la Recherche sur le Cancer, la Fondation pour la Recherche Medicale(Fondation ARC pour la Recherche sur le CancerFondation pour la Recherche Medicale); Institut Universitaire de France	The research of R.A.V. is funded by the Centre National de la Recherche Scientifique, the Universite Paris-Diderot, the Association pour la Recherche sur le Cancer, la Fondation pour la Recherche Medicale, and the Institut Universitaire de France. The authors gratefuly thank Jim Birchler and Victoria Lebed for sharing helpful thoughts and comments on the manuscript.	Adams KL, 2005, TRENDS GENET, V21, P539, DOI 10.1016/j.tig.2005.07.009; Alexander D. E., 1961, MAIZE GENET COOP NEW, V35; [Anonymous], 1910, Science, V32, P627; BINGHAM ET, 1994, CROP SCI, V34, P823, DOI 10.2135/cropsci1994.0011183X003400040001x; Birchler JA, 2003, PLANT CELL, V15, P2236, DOI 10.1105/tpc.151030; Birchler JA, 2010, PLANT CELL, V22, P2105, DOI 10.1105/tpc.110.076133; BUSBICE TH, 1966, EUPHYTICA, V15, P52; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Chen ZJ, 2010, TRENDS PLANT SCI, V15, P57, DOI 10.1016/j.tplants.2009.12.003; Comai L, 2000, PLANT MOL BIOL, V43, P387, DOI 10.1023/A:1006480722854; CROW JF, 1948, GENETICS, V33, P477; Darwin CR, 1876, EFFECTS CROSS SELF F; Davenport CB, 1908, SCIENCE, V28, P454, DOI 10.1126/science.28.718.454-b; DOBZHANSKY T, 1950, GENETICS, V35, P288; EAST E.M., 1908, CONN AGR EXP STN REP, P419; East EM, 1936, GENETICS, V21, P375; GROOSE RW, 1989, CROP SCI, V29, P1173, DOI 10.2135/cropsci1989.0011183X002900050015x; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hochholdinger F, 2007, TRENDS PLANT SCI, V12, P427, DOI 10.1016/j.tplants.2007.08.005; Hua JP, 2003, P NATL ACAD SCI USA, V100, P2574, DOI 10.1073/pnas.0437907100; Jones DF, 1917, GENETICS, V2, P466; LEVINGS CS, 1967, CROP SCI, V7, P72, DOI 10.2135/cropsci1967.0011183X000700010025x; Li XH, 2009, BMC PLANT BIOL, V9, DOI 10.1186/1471-2229-9-107; Li ZK, 2001, GENETICS, V158, P1737; Lippman ZB, 2007, TRENDS GENET, V23, P60, DOI 10.1016/j.tig.2006.12.006; Luo LJ, 2001, GENETICS, V158, P1755; Milborrow BV, 1998, J EXP BOT, V49, P1063, DOI 10.1093/jexbot/49.324.1063; MOK DWS, 1975, THEOR APPL GENET, V46, P307, DOI 10.1007/BF00281153; MULLER HJ, 1932, P INT C GENET, V6, P213; Powers L, 1944, AM NAT, V78, P275, DOI 10.1086/281199; RANDOLPH L. F., 1942, GENETICS, V27, P163; REDEI GP, 1962, Z VEREBUNGSL, V93, P164; RICE JS, 1974, CROP SCI, V14, P390, DOI 10.2135/cropsci1974.0011183X001400030015x; Riddle NC, 2010, THEOR APPL GENET, V120, P341, DOI 10.1007/s00122-009-1113-3; Semel Y, 2006, P NATL ACAD SCI USA, V103, P12981, DOI 10.1073/pnas.0604635103; SHULL G.H., 1908, J HERED, V4, P296; STUBER CW, 1992, GENETICS, V132, P823; Stupar RM, 2006, GENETICS, V173, P2199, DOI 10.1534/genetics.106.060699; Swanson-Wagner RA, 2006, P NATL ACAD SCI USA, V103, P6805, DOI 10.1073/pnas.0510430103; TSAFTARIS SA, 1995, PHYSIOL PLANTARUM, V94, P362, DOI 10.1111/j.1399-3054.1995.tb05324.x; van Zanten M, 2009, TRENDS PLANT SCI, V14, P214, DOI 10.1016/j.tplants.2009.01.010; Veitia RA, 2003, BIOL REV, V78, P149, DOI 10.1017/S1464793102006036; Veitia RA, 2010, FASEB J, V24, P994, DOI 10.1096/fj.09-146969; Veitia RA, 2009, J PATHOL, V218, P409, DOI 10.1002/path.2583; Wendel JF, 2000, PLANT MOL BIOL, V42, P225, DOI 10.1023/A:1006392424384; Woolf Charles M., 2003, P99; Yu SB, 1997, P NATL ACAD SCI USA, V94, P9226, DOI 10.1073/pnas.94.17.9226	47	13	14	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					476	482		10.1096/fj.10-170639	http://dx.doi.org/10.1096/fj.10-170639			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21062972				2022-12-28	WOS:000286724800006
J	Krejbich-Trotot, P; Denizot, M; Hoarau, JJ; Jaffar-Bandjee, MC; Das, T; Gasque, P				Krejbich-Trotot, Pascale; Denizot, Melanie; Hoarau, Jean-Jacques; Jaffar-Bandjee, Marie-Christine; Das, Trina; Gasque, Philippe			Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses	FASEB JOURNAL			English	Article						alphavirus; blebs; macrophages; innate immunity; caspases; persistence	SEMLIKI-FOREST-VIRUS; PERSISTENT ALPHAVIRUS INFECTION; EQUINE ENCEPHALITIS; DEATH; PHAGOCYTOSIS; MACROPHAGES; CLEARANCE; MACROPINOCYTOSIS; REPLICATION; ENGULFMENT	Chikungunya virus (CHIKV) surprised medical workers by a massive outbreak in the Indian Ocean region, reaching Europe in 2007, with exceptional pathologies in infants and elderly patients. Although CHIKV was recently shown to persist in myo-blasts, monocytes, and macrophages, we argued that robust antiviral mechanisms, including apoptosis, are essential to ward off the virus. Herein, we tested the capacity of CHIKV to mobilize the apoptotic machinery in HeLa cells as well as primary fibroblasts, making use of several inhibitors of caspases, cell blebbing, and engulfment of the apoptotic blebs by neighboring cells. CHIKV triggered apoptosis through intrinsic and extrinsic pathways. Bystander apoptosis was also evidenced in neighboring cells in a caspase-8-dependent manner. Remarkably, by hiding in apoptotic blebs, CHIKV was able to infect neighboring cells. In HeLa cells, these events were inhibited specifically by zVAD-fmk and DEVD-cho (caspase inhibitors), blebbistatin, Y-27632 (ROCK inhibitor), and genistein, annexin V, and cytochalasin B (inhibitors of blebbing and engulfment). These CHIKV-apoptotic blebs were also capable of infecting macrophages (primary cultures, MM6- and THP1-PMA differentiated cells) otherwise refractory to infection by CHIKV alone. Remarkably, viral replication in macrophages did not yield a proinflammatory response. We describe a novel infectious mechanism by which CHIKV invades host cells and escapes the host response.-Krejbich-Trotot, P., Denizot, M., Hoarau, J.-J., Jaffar-Bandjee, M.-C., Das, T., Gasque, P. Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses. FASEB J. 25, 314-325 (2011). www.fasebj.org	[Krejbich-Trotot, Pascale; Denizot, Melanie; Hoarau, Jean-Jacques; Jaffar-Bandjee, Marie-Christine; Das, Trina; Gasque, Philippe] CHR, Grp Rech Immunopathol & Malad Infect GRI, St Denis, Reunion, France; [Jaffar-Bandjee, Marie-Christine] CHR, Biol Unit, St Denis, Reunion, France; [Jaffar-Bandjee, Marie-Christine] CHR, Microbiol Unit, St Denis, Reunion, France; [Jaffar-Bandjee, Marie-Christine] CHR, Virol Unit, St Denis, Reunion, France; [Jaffar-Bandjee, Marie-Christine] CHR, Biochem Unit, St Denis, Reunion, France; [Krejbich-Trotot, Pascale; Denizot, Melanie; Hoarau, Jean-Jacques; Jaffar-Bandjee, Marie-Christine; Das, Trina; Gasque, Philippe] Univ La Reunion, St Denis, Reunion, France	CHU Reunion; CHU Reunion; CHU Reunion; CHU Reunion; CHU Reunion; University of La Reunion	Krejbich-Trotot, P (corresponding author), Univ La Reunion, GRI IRG Immunopathol & Infect Res Grouping, CYROI, 2 Rue Maxime Riviere, St Clothilde 97491, Reunion, France.	pascale.krejbich-trotot@chr-reunion.fr; gasque@univ-reunion.fr		HOARAU, Jean-Jacques/0000-0002-7612-2018; Krejbich Trotot, Pascale/0000-0001-7329-1716	Institut National de la Sante et de la Recherche Medicale Contrat d'Interface; Regional Council fellowship; Contrat de Projets Etat-Region/Fonds Europeen de Developpement Regional; Ministere de l'Outre Mer; Programme Hospitalier de Recherche Clinique; Institut National de la Sante et de la Recherche Medicale Contrat d'Interface; Regional Council fellowship; Contrat de Projets Etat-Region/Fonds Europeen de Developpement Regional; Ministere de l'Outre Mer; Programme Hospitalier de Recherche Clinique	Institut National de la Sante et de la Recherche Medicale Contrat d'Interface(Institut National de la Sante et de la Recherche Medicale (Inserm)); Regional Council fellowship; Contrat de Projets Etat-Region/Fonds Europeen de Developpement Regional; Ministere de l'Outre Mer; Programme Hospitalier de Recherche Clinique; Institut National de la Sante et de la Recherche Medicale Contrat d'Interface(Institut National de la Sante et de la Recherche Medicale (Inserm)); Regional Council fellowship; Contrat de Projets Etat-Region/Fonds Europeen de Developpement Regional; Ministere de l'Outre Mer; Programme Hospitalier de Recherche Clinique	The authors thank Prof. Xavier de Lamballerie (Unite des Virus Emergents, Marseille, France), Biomerieux (Marcy l'Etoile, France), Prof. Vaclav Horejsi (Institute of Molecular Genetics, Prague, Czech Republic), and Dr. Marc Grandadam (Institut Pasteur, CNR Arbovirus, Paris, France) for kindly providing reagents used in this study. Financial support was provided by an Institut National de la Sante et de la Recherche Medicale Contrat d'Interface to P.G., a Regional Council fellowship to T.D., and laboratory funding from Contrat de Projets Etat-Region/Fonds Europeen de Developpement Regional, Ministere de l'Outre Mer, and Programme Hospitalier de Recherche Clinique. The authors declare no commercial connections that may pose a conflict of interest.	Callus BA, 2007, CELL DEATH DIFFER, V14, P73, DOI 10.1038/sj.cdd.4402034; Chen YB, 2006, CELL DEATH DIFFER, V13, P1318, DOI 10.1038/sj.cdd.4401964; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Couderc T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040029; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Das T, 2010, PROG NEUROBIOL, V91, P121, DOI 10.1016/j.pneurobio.2009.12.006; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; Fazakerley JK, 2001, CURR TOP MICROBIOL, V253, P95; Fujimoto I, 2000, J VIROL, V74, P3399, DOI 10.1128/JVI.74.7.3399-3403.2000; Galluzzi L, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000018; Garen PD, 1999, MODERN PATHOL, V12, P646; Glasgow GM, 1998, J GEN VIROL, V79, P2405, DOI 10.1099/0022-1317-79-10-2405; Griffin DE, 1997, ANNU REV MICROBIOL, V51, P565, DOI 10.1146/annurev.micro.51.1.565; Hashimoto Y, 2007, J IMMUNOL, V178, P2448, DOI 10.4049/jimmunol.178.4.2448; Her ZS, 2010, J IMMUNOL, V184, P5903, DOI 10.4049/jimmunol.0904181; Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Jackson AC, 1997, ACTA NEUROPATHOL, V93, P349, DOI 10.1007/s004010050626; Jaffar-Bandjee MC, 2009, MICROBES INFECT, V11, P1206, DOI 10.1016/j.micinf.2009.10.001; Jan JT, 1999, J VIROL, V73, P10296, DOI 10.1128/JVI.73.12.10296-10302.1999; Kenis H, 2006, EXP CELL RES, V312, P719, DOI 10.1016/j.yexcr.2005.11.023; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Labadie K, 2010, J CLIN INVEST, V120, P894, DOI 10.1172/JCI40104; Lee HK, 2008, CURR OPIN IMMUNOL, V20, P23, DOI 10.1016/j.coi.2008.01.001; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Mercer J, 2008, SCIENCE, V320, P531, DOI 10.1126/science.1155164; Michallet MC, 2008, IMMUNITY, V28, P651, DOI 10.1016/j.immuni.2008.03.013; Moriishi K, 2002, VIROLOGY, V292, P258, DOI 10.1006/viro.2001.1206; Ndozangue-Touriguine O, 2008, BIOCHEM PHARMACOL, V76, P11, DOI 10.1016/j.bcp.2008.03.016; Orlando KA, 2006, EXP CELL RES, V312, P5, DOI 10.1016/j.yexcr.2005.09.012; Ozden S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000527; Pialoux G, 2007, LANCET INFECT DIS, V7, P319, DOI 10.1016/S1473-3099(07)70107-X; Poon I. K., CELL DEATH DIFFER, V17, P381; Powers AM, 2007, J GEN VIROL, V88, P2363, DOI 10.1099/vir.0.82858-0; Ravichandran KS, 2007, NAT REV IMMUNOL, V7, P964, DOI 10.1038/nri2214; Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; Sammin DJ, 1999, NEUROPATH APPL NEURO, V25, P236, DOI 10.1046/j.1365-2990.1999.00170.x; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schilte C, 2010, J EXP MED, V207, P429, DOI 10.1084/jem.20090851; Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263; Solignat M, 2009, VIROLOGY, V393, P183, DOI 10.1016/j.virol.2009.07.024; Sourisseau M, 2007, PLOS PATHOG, V3, P804, DOI 10.1371/journal.ppat.0030089; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Urban C, 2008, CELL DEATH DIFFER, V15, P1396, DOI 10.1038/cdd.2008.61; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; Wang E, 2008, VACCINE, V26, P5030, DOI 10.1016/j.vaccine.2008.07.054; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; Wilson NS, 2009, NAT IMMUNOL, V10, P348, DOI 10.1038/ni.1714; Ziegler SA, 2008, AM J TROP MED HYG, V79, P133, DOI 10.4269/ajtmh.2008.79.133	51	95	97	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					314	325		10.1096/fj.10-164178	http://dx.doi.org/10.1096/fj.10-164178			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20881210	Bronze			2022-12-28	WOS:000285869500028
J	Marchesi, VT				Marchesi, Vincent T.			Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy	FASEB JOURNAL			English	Review						Alzheimer's disease; Amyloid abeta peptides; somatic mutations	BETA-PROTEIN; PRECURSOR PROTEIN; BRAIN; OLIGOMERS; MICE; DNA; MICROVASCULATURE; MOSAICISM; MUTATION; ENZYMES	There is a widely shared view among Alzheimer's disease (AD) investigators that the amyloid hypothesis best describes the pathogenic cascade that leads, ultimately, to neuronal degeneration and irreversible dementia. The most persuasive evidence comes from studies of damaged brains of patients in the late stages of AD and from animal studies that attempt to mimic the hereditary forms of early-onset dementia. Despite this impressive body of knowledge, we still lack the means to either arrest or prevent this horrible contagion. This essay attempts to describe what we know, and do not know, about the earliest stages of the disease, focusing on the possibility that the initial pathological changes involve oxidative-induced inflammatory damage to small blood vessels. The resulting ischemia activates amyloid-processing enzymes and other proinflammatory factors that eventually compromise neuronal functions, leading, over time, to the complex lesions that characterize advanced disease. The idea that blood vessel damage is primary has a long history and many prior advocates. The novel addition offered here is the speculation that low-abundance, gain-of-function somatic mutations of the amyloid precursor protein may be part of the triggering mechanism.-Marchesi, V. T. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J. 25, 5-13 (2011). www.fasebj.org	[Marchesi, Vincent T.] Yale Univ, Boyer Ctr Mol Med, New Haven, CT 06536 USA; [Marchesi, Vincent T.] Yale Univ, Dept Pathol, New Haven, CT 06536 USA	Yale University; Yale University	Marchesi, VT (corresponding author), Yale Univ, Boyer Ctr Mol Med, 295 Congress Ave,POB 9812, New Haven, CT 06536 USA.	vincent.marchesi@yale.edu						Arostegui JI, 2010, ARTHRITIS RHEUM-US, V62, P1158, DOI 10.1002/art.27342; Bartzokis G., 2009, NEUROBIOL AGING; Randall JB, 2006, NAT MED, V12, P856, DOI 10.1038/nm1438; Bell RD, 2009, ACTA NEUROPATHOL, V118, P103, DOI 10.1007/s00401-009-0522-3; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; Cortes-Canteli M, 2010, NEURON, V66, P695, DOI 10.1016/j.neuron.2010.05.014; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; De Meyer G, 2010, ARCH NEUROL-CHICAGO, V67, P949, DOI 10.1001/archneurol.2010.179; De Strooper B, 2010, NAT REV NEUROL, V6, P99, DOI 10.1038/nrneurol.2009.218; Evin G, 2003, J NEUROSCI RES, V74, P386, DOI 10.1002/jnr.10745; FISCHER VW, 1990, ACTA NEUROPATHOL, V79, P672, DOI 10.1007/BF00294246; Frank SA, 2010, P NATL ACAD SCI USA, V107, P1725, DOI 10.1073/pnas.0909343106; Guglielmotto M, 2009, J NEUROCHEM, V108, P1045, DOI 10.1111/j.1471-4159.2008.05858.x; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hardy J, 2009, J NEUROCHEM, V110, P1129, DOI 10.1111/j.1471-4159.2009.06181.x; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106; Klunk WE, 2008, CURR OPIN NEUROL, V21, P683, DOI 10.1097/WCO.0b013e3283168e1a; Larsen E, 2006, ONCOGENE, V25, P2425, DOI 10.1038/sj.onc.1209284; Lebson L, 2010, J NEUROSCI, V30, P9651, DOI 10.1523/JNEUROSCI.0329-10.2010; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lovell MA, 2001, ARCH NEUROL-CHICAGO, V58, P392, DOI 10.1001/archneur.58.3.392; Lynch M, 2010, P NATL ACAD SCI USA, V107, P961, DOI 10.1073/pnas.0912629107; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Meng GX, 2010, EUR J IMMUNOL, V40, P649, DOI 10.1002/eji.200940191; Miao J, 2005, AM J PATHOL, V167, P505, DOI 10.1016/S0002-9440(10)62993-8; Ohno M, 2006, GENOME RES, V16, P567, DOI 10.1101/gr.4769606; Parker CJ, 2009, HEMATOL ONCOL CLIN N, V23, P333, DOI 10.1016/j.hoc.2009.01.014; Patten DA, 2010, J ALZHEIMERS DIS, V20, pS357, DOI 10.3233/JAD-2010-100498; Rogers J, 2000, ANN NY ACAD SCI, V924, P132; Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001; Salminen A, 2008, J CELL MOL MED, V12, P2255, DOI 10.1111/j.1582-4934.2008.00496.x; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Singh M, 2010, J ALZHEIMERS DIS, V21, P741, DOI 10.3233/JAD-2010-100405; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Tang K, 2006, J NEUROL SCI, V240, P53, DOI 10.1016/j.jns.2005.09.002; Tian Y, 2010, NAT STRUCT MOL BIOL, V17, P151, DOI 10.1038/nsmb.1743; Tsai HHG, 2010, PROTEINS, V78, P1909, DOI 10.1002/prot.22705; Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Weissman L, 2007, NUCLEIC ACIDS RES, V35, P5545, DOI 10.1093/nar/gkm605; Weller RO, 2009, ACTA NEUROPATHOL, V118, P87, DOI 10.1007/s00401-009-0498-z; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Yin XL, 2010, AM J PATHOL, V176, P1600, DOI 10.2353/ajpath.2010.090406; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	46	171	176	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					5	13		10.1096/fj.11-0102ufm	http://dx.doi.org/10.1096/fj.11-0102ufm			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	21205781	Bronze			2022-12-28	WOS:000285869500001
J	Yan, SJ; Lim, SJ; Shi, S; Dutta, P; Li, WX				Yan, Shian-Jang; Lim, Su Jun; Shi, Song; Dutta, Pranabananda; Li, Willis X.			Unphosphorylated STAT and heterochromatin protect genome stability	FASEB JOURNAL			English	Article						Drosophila; DNA damage; JAK; HP1; Su(var)205	DROSOPHILA; MECHANISMS; PATHWAY	Heterochromatin is a form of highly compacted chromatin associated with epigenetic gene silencing and chromosome organization. We have previously shown that unphosphorylated nuclear signal transducer and activator of transcription (STAT) physically interacts with heterochromatin protein 1 (HP1) to promote heterochromatin stability. To understand whether STAT and heterochromatin are important for maintenance of genome stability, we genetically manipulated the levels of unphosphorylated STAT and HP1 [encoded by Su(var)205] in Drosophila and examined the effects on chromosomal morphology and resistance to DNA damage under conditions of genotoxic stress. Here we show that, compared with wild-type controls, Drosophila mutants with reduced levels of unphosphorylated STAT or heterochromatin are more sensitive to radiation-induced cell cycle arrest, have higher levels of spontaneous and radiation-induced DNA damage, and exhibit defects in chromosomal compaction and segregation during mitosis. Conversely, animals with increased levels of heterochromatin exhibit less DNA damage and increased survival rate after irradiation. These results suggest that maintaining genome stability by heterochromatin formation and correct chromosomal packaging is essential for normal cellular functions and for survival of animals under genotoxic stress.-Yan, S.-J., Lim, S. J., Shi, S., Dutta, P., Li, W. X. Unphosphorylated STAT and heterochromatin protect genome stability. FASEB J. 25, 232-241 (2011). www.fasebj.org	[Yan, Shian-Jang; Lim, Su Jun; Shi, Song; Dutta, Pranabananda; Li, Willis X.] Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA	University of Rochester	Li, WX (corresponding author), Univ Rochester, Med Ctr, Dept Biomed Genet, 601 Elmwood Ave,KMRB 2-9654, Rochester, NY 14642 USA.	willis_li@urmc.rochester.edu	Li, Willis/ABC-5695-2020; Li, Willis X/AAL-7212-2020	Li, Willis/0000-0001-9041-7341; Li, Willis X/0000-0001-9041-7341	U.S. National Institutes of Health (NIH) [T32CA009363]; American Cancer Society; Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [R01CA131326, T32CA009363] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors are grateful to Dr. Robert Glaser (Wadsworth Center, New York, NY, USA) for the gift of, and advice on, the phospho-Ser-137 H2Av (gamma-H2AX) antibodies; the Goldberg lab (Cornell University, Ithaca, NY, USA) for help and advice on larval brain squash preparations, and E. Rustchenko for help with pulsed field gel electrophoresis. The authors thank D. Guo, K. Larson, A. Tsurumi, and J. Liu for technical assistance and Lori Wallrath (University of Iowa, Iowa City, IA, USA), Gunter Reuter (Martin Luther University Halle, Halle, Germany), James Birchler (University of Missouri, Columbia, MO, USA), the Developmental Hybridoma Bank (Iowa City, IA, USA), and the Bloomington Drosophila Stock Center (Bloomington, IN, USA) for various Drosophila strains and reagents. The authors thank the Edith Lord laboratory (University of Rochester, Rochester, NY, USA) for a Cs-137 irradiator. S.J.Y. was supported in part by a postdoctoral training grant (T32CA009363) from the U.S. National Institutes of Health (NIH). This study was supported, in part, by grants from the NIH, an American Cancer Society Research Scholar grant, and a Leukemia and Lymphoma Society Research Scholar grant to W. X. L. The authors declare no competing interests.	Ahmad K, 1999, GENETICS, V151, P1041; Arbouzova NI, 2006, DEVELOPMENT, V133, P2605, DOI 10.1242/dev.02411; Bi XL, 2005, GENETICS, V171, P845, DOI 10.1534/genetics.105.047720; Brodsky MH, 2000, GENE DEV, V14, P666; Brown S, 2008, CURR OPIN GENET DEV, V18, P455, DOI 10.1016/j.gde.2008.09.002; EISSENBERG JC, 1992, GENETICS, V131, P345; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Jefford CE, 2006, CRIT REV ONCOL HEMAT, V59, P1, DOI 10.1016/j.critrevonc.2006.02.005; Johnson-Schlitz DM, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030050; Karsten P, 2006, CELL SIGNAL, V18, P819, DOI 10.1016/j.cellsig.2005.07.006; KELLUM R, 1995, J CELL SCI, V108, P1419; Laurencon A, 2003, GENETICS, V164, P589; Li WX, 2008, TRENDS CELL BIOL, V18, P545, DOI 10.1016/j.tcb.2008.08.008; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Madigan JP, 2002, NUCLEIC ACIDS RES, V30, P3698, DOI 10.1093/nar/gkf496; Marygold SJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r216; McNamee LM, 2009, GENETICS, V182, P423, DOI 10.1534/genetics.109.102327; Mogila V, 2006, DEV CELL, V11, P575, DOI 10.1016/j.devcel.2006.08.010; Peng JC, 2007, NAT CELL BIOL, V9, P25, DOI 10.1038/ncb1514; Peng JC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000435; Perrini B, 2004, MOL CELL, V15, P467, DOI 10.1016/j.molcel.2004.06.036; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Shi S, 2008, NAT CELL BIOL, V10, P491, DOI 10.1038/ncb1713; Shi S, 2006, NAT GENET, V38, P1071, DOI 10.1038/ng1860; Yan S. J., 2011, METHODS MOL IN PRESS	30	42	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2011	25	1					232	241		10.1096/fj.10-169367	http://dx.doi.org/10.1096/fj.10-169367			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	702BL	20847228	Green Published, Bronze			2022-12-28	WOS:000285869500021
J	Azam, L; Maskos, U; Changeux, JP; Dowell, CD; Christensen, S; De Biasi, M; McIntosh, JM				Azam, Layla; Maskos, Uwe; Changeux, Jean-Pierre; Dowell, Cheryl D.; Christensen, Sean; De Biasi, Mariella; McIntosh, J. Michael			alpha-Conotoxin BuIA[T5A;P6O]: a novel ligand that discriminates between alpha 6 beta 4 and alpha 6 beta 2 nicotinic acetylcholine receptors and blocks nicotine-stimulated norepinephrine release	FASEB JOURNAL			English	Article						nicotinic; alpha 6; Conus; hydroxyproline; hippocampus	VENTRAL TEGMENTAL AREA; SUBUNIT MESSENGER-RNAS; RAT STRIATAL SYNAPTOSOMES; DOPAMINE RELEASE; PARKINSONS-DISEASE; HIPPOCAMPAL SYNAPTOSOMES; CHOLINERGIC-RECEPTORS; ALZHEIMERS-DISEASE; LOCUS-COERULEUS; MUTANT MICE	alpha 6* (asterisk indicates the presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) are broadly implicated in catecholamine-dependent disorders that involve attention, motor movement, and nicotine self-administration. Different molecular forms of alpha 6 nAChRs mediate catecholamine release, but receptor differentiation is greatly hampered by a paucity of subtype selective ligands. alpha-Conotoxins are nAChR-targeted peptides used by Conus species to incapacitate prey. We hypothesized that distinct conotoxin-binding kinetics could be exploited to develop a series of selective probes to enable study of native receptor subtypes. Proline6 of alpha-conotoxin BuIA was found to be critical for nAChR selectivity; substitution of proline6 with 4-hydroyx-proline increased the IC(50) by 2800-fold at alpha 6/alpha 3 beta 2 beta 3 but only by 6-fold at alpha 6/alpha 3 beta 4 nAChRs (to 1300 and 12 nM, respectively). We used conotoxin probes together with subunit-null mice to interrogate nAChR subtypes that modulate hippocampal norepinephrine release. Release was abolished in alpha 6-null mutant mice. alpha-Conotoxin BuIA[T5A;P6O] partially blocked norepinephrine release in wild-type controls but failed to block release in beta 4(-/-) mice. In contrast, BuIA[T5A;P6O] failed to block dopamine release in the wild-type striatum known to contain alpha 6 beta 2* nAChRs. BuIA[T5A;P6O] is a novel ligand for distinguishing between closely related alpha 6* nAChRs; alpha 6 beta 4* nAChRs modulate norepinephrine release in hippocampus but not dopamine release in striatum.-Azam, L., Maskos, U., Changeux, J.-P., Dowell, C. D., Christensen, S., De Biasi, M., McIntosh, J. M. alpha-Conotoxin BuIA[T5A;P6O]: a novel ligand that discriminates between alpha 6 beta 4 and alpha 6 beta 2 nAChRs and blocks nicotine-stimulated norepinephrine release. FASEB J. 24, 5113-5123 (2010). www.fasebj.org	[Azam, Layla; Dowell, Cheryl D.; Christensen, Sean; McIntosh, J. Michael] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; [McIntosh, J. Michael] Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; [Maskos, Uwe; Changeux, Jean-Pierre] Inst Pasteur, Unite Neurobiol Integrat Syst Cholinerg, Paris, France; [De Biasi, Mariella] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [De Biasi, Mariella] Baylor Coll Med, Grad Program Translat Biol & Mol Med, Houston, TX 77030 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Baylor College of Medicine; Baylor College of Medicine	Azam, L (corresponding author), Univ Utah, Dept Biol, 257 S 1400 East, Salt Lake City, UT 84112 USA.	layla.azam@utah.edu	De Biasi, Mariella/M-7646-2017	De Biasi, Mariella/0000-0002-0687-8872	Kirschstein-National Research Service Award [DA 016835]; National Institutes of Health [DA017173, MH53631, GM48677]; Institut Pasteur; ANR; European Union [HEALTH-F2-2008-202088]; Centre National de la Recherche Scientifique; Agence Nationale de la Recherche Neurologie; European Commission; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA017173, F32DA016835] Funding Source: NIH RePORTER	Kirschstein-National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Institut Pasteur(European Commission); ANR(French National Research Agency (ANR)); European Union(European Commission); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de la Recherche Neurologie(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by Kirschstein-National Research Service Award Postdoctoral Fellowship DA 016835 (to L. A.), National Institutes of Health grants DA017173 (to M. D. B.) and MH53631 and GM48677 (to J.M.M.), and Institut Pasteur, Centre National de la Recherche Scientifique, Agence Nationale de la Recherche Neurologie 2005, European Commission European Research and Technological Development NeuroCypres, and ANR Blanc 2008 (to U. M. and J.P.C.). The research leading to these results received funding from the European Union Seventh Framework program under grant agreement HEALTH-F2-2008-202088 (NeuroCypres project).	Azam L, 2005, J BIOL CHEM, V280, P80, DOI 10.1074/jbc.M406281200; Azam L, 2005, J PHARMACOL EXP THER, V312, P231, DOI 10.1124/jpet.104.071456; Azam L, 2003, NEUROSCIENCE, V119, P965, DOI 10.1016/S0306-4522(03)00220-3; Azam L, 2002, J COMP NEUROL, V444, P260, DOI 10.1002/cne.10138; Azam L, 2008, J BIOL CHEM, V283, P11625, DOI 10.1074/jbc.M710288200; Azam L, 2006, MOL PHARMACOL, V70, P967, DOI 10.1124/mol.106.024513; Azam L, 2009, ACTA PHARMACOL SIN, V30, P771, DOI 10.1038/aps.2009.47; Berisio R, 2004, J AM CHEM SOC, V126, P11402, DOI 10.1021/ja047069h; Bordia T, 2007, MOL PHARMACOL, V72, P52, DOI 10.1124/mol.107.035998; Brunzell DH, 2010, NEUROPSYCHOPHARMACOL, V35, P665, DOI 10.1038/npp.2009.171; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Champtiaux N, 2003, J NEUROSCI, V23, P7820; Champtiaux N, 2002, J NEUROSCI, V22, P1208, DOI 10.1523/JNEUROSCI.22-04-01208.2002; Chi SW, 2006, BIOCHEM BIOPH RES CO, V349, P1228, DOI 10.1016/j.bbrc.2006.08.164; Clarke PBS, 1996, BRIT J PHARMACOL, V117, P595, DOI 10.1111/j.1476-5381.1996.tb15232.x; Cui CH, 2003, J NEUROSCI, V23, P11045; Ellison M, 2006, BIOCHEMISTRY-US, V45, P1511, DOI 10.1021/bi0520129; Goldner FM, 1997, NEUROREPORT, V8, P2739; Gotti C, 2007, BIOCHEM PHARMACOL, V74, P1102, DOI 10.1016/j.bcp.2007.05.023; Gotti C, 2006, TRENDS PHARMACOL SCI, V27, P482, DOI 10.1016/j.tips.2006.07.004; Gotti C, 2006, NEUROBIOL DIS, V23, P481, DOI 10.1016/j.nbd.2006.04.005; Gotti C, 2010, J NEUROSCI, V30, P5311, DOI 10.1523/JNEUROSCI.5095-09.2010; Gotti C, 2009, BIOCHEM PHARMACOL, V78, P703, DOI 10.1016/j.bcp.2009.05.024; Grady SR, 2007, BIOCHEM PHARMACOL, V74, P1235, DOI 10.1016/j.bcp.2007.07.032; Grady SR, 2010, J MOL NEUROSCI, V40, P91, DOI 10.1007/s12031-009-9263-y; Grady SR, 2002, J PHARMACOL EXP THER, V301, P651, DOI 10.1124/jpet.301.2.651; Innocent N, 2008, J PHARMACOL EXP THER, V327, P529, DOI 10.1124/jpet.108.142943; Jackson KJ, 2009, J PHARMACOL EXP THER, V331, P547, DOI 10.1124/jpet.109.155457; Kulak JM, 1997, J NEUROSCI, V17, P5263; LEE EHY, 1995, BRAIN RES BULL, V37, P411, DOI 10.1016/0361-9230(95)00039-9; LEE EHY, 1993, SYNAPSE, V14, P144, DOI 10.1002/syn.890140207; Lena C, 1999, P NATL ACAD SCI USA, V96, P12126, DOI 10.1073/pnas.96.21.12126; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; Lof E, 2007, PSYCHOPHARMACOLOGY, V195, P333, DOI 10.1007/s00213-007-0899-4; Lopez-Vera E, 2008, BIOCHEMISTRY-US, V47, P1741, DOI 10.1021/bi701934m; Luo SQ, 1998, J NEUROSCI, V18, P8571; Marritt AM, 2005, MOL PHARMACOL, V68, P1656, DOI 10.1124/mol.105.012380; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; Millar NS, 2009, NEUROPHARMACOLOGY, V56, P237, DOI 10.1016/j.neuropharm.2008.07.041; Moretti M, 2004, MOL PHARMACOL, V66, P85, DOI 10.1124/mol.66.1.85; Moroni M, 2006, J MOL NEUROSCI, V30, P95, DOI 10.1385/JMN:30:1:95; Nicke A, 2004, EUR J BIOCHEM, V271, P2305, DOI 10.1111/j.1432-1033.2004.04145.x; Perez XA, 2008, MOL PHARMACOL, V74, P844, DOI 10.1124/mol.108.048843; Perry DC, 2007, J PHARMACOL EXP THER, V322, P306, DOI 10.1124/jpet.107.121228; PETERKOFSKY B, 1991, AM J CLIN NUTR, V54, pS1135, DOI 10.1093/ajcn/54.6.1135s; Pimentel L, 2003, AM J EMERG MED, V21, P328, DOI 10.1016/S0735-6757(03)00083-4; Pons S, 2008, J NEUROSCI, V28, P12318, DOI 10.1523/JNEUROSCI.3918-08.2008; Quik M, 2006, J PHARMACOL EXP THER, V316, P481, DOI 10.1124/jpet.105.094375; Quik M, 2000, J COMP NEUROL, V425, P58, DOI 10.1002/1096-9861(20000911)425:1<58::AID-CNE6>3.0.CO;2-X; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; RAPIER C, 1988, J NEUROCHEM, V50, P1123, DOI 10.1111/j.1471-4159.1988.tb10582.x; Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526; Salminen O, 2007, MOL PHARMACOL, V71, P1563, DOI 10.1124/mol.106.031492; Scholze P, 2007, BRIT J PHARMACOL, V151, P414, DOI 10.1038/sj.bjp.0707236; Shiembob DL, 2006, BIOCHEMISTRY-US, V45, P11200, DOI 10.1021/bi0611715; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Vailati S, 1999, MOL PHARMACOL, V56, P11, DOI 10.1124/mol.56.1.11; Vincler MA, 2003, BRAIN RES, V974, P25, DOI 10.1016/S0006-8993(03)02546-0; Walsh H, 2008, J BIOL CHEM, V283, P6022, DOI 10.1074/jbc.M703432200; Weinshenker D, 2008, CURR ALZHEIMER RES, V5, P342, DOI 10.2174/156720508784533286; Whiteaker P, 2007, BIOCHEMISTRY-US, V46, P6628, DOI 10.1021/bi7004202; Xu W, 1999, J NEUROSCI, V19, P9298; Zoli M, 2002, J NEUROSCI, V22, P8785	64	57	59	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2010	24	12					5113	5123		10.1096/fj.10-166272	http://dx.doi.org/10.1096/fj.10-166272			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20739611	Green Published			2022-12-28	WOS:000284824400049
J	Sriram, K; Lin, GX; Jefferson, AM; Roberts, JR; Wirth, O; Hayashi, Y; Krajnak, KM; Soukup, JM; Ghio, AJ; Reynolds, SH; Castranova, V; Munson, AE; Antonini, JM				Sriram, Krishnan; Lin, Gary X.; Jefferson, Amy M.; Roberts, Jenny R.; Wirth, Oliver; Hayashi, Yusuke; Krajnak, Kristine M.; Soukup, Joleen M.; Ghio, Andrew J.; Reynolds, Steven H.; Castranova, Vincent; Munson, Albert E.; Antonini, James M.			Mitochondrial dysfunction and loss of Parkinson's disease-linked proteins contribute to neurotoxicity of manganese-containing welding fumes	FASEB JOURNAL			English	Article						brain; DJ-1; neurodegeneration; Park genes; proteasome; ubiquitin-proteasome pathway	EARLY-ONSET PARKINSONISM; OXIDATIVE STRESS; CELL-DEATH; NEURODEGENERATIVE DISEASES; PERMEABILITY TRANSITION; JUVENILE PARKINSONISM; NEUROLOGICAL DISEASE; CEREBROSPINAL-FLUID; S18Y POLYMORPHISM; ALPHA-SYNUCLEIN	Welding generates complex metal aerosols, inhalation of which is linked to adverse health effects among welders. An important health concern of welding fume (WF) exposure is neurological dysfunction akin to Parkinson's disease (PD), thought to be mediated by manganese (Mn) in the fumes. Also, there is a proposition that welding might accelerate the onset of PD. Our recent findings link the presence of Mn in the WF with dopaminergic neurotoxicity seen in rats exposed to manual metal arc-hard surfacing (MMA-HS) or gas metal arc-mild steel (GMA-MS) fumes. To elucidate the molecular mechanisms further, we investigated the association of PD-linked (Park) genes and mitochondrial function in causing dopaminergic abnormality. Repeated instillations of the two fumes at doses that mimic similar to 1 to 5 yr of worker exposure resulted in selective brain accumulation of Mn. This accumulation caused impairment of mitochondrial function and loss of tyrosine hydroxylase (TH) protein, indicative of dopaminergic injury. A fascinating finding was the altered expression of Parkin (Park2), Uchl1 (Park5), and Dj1 (Park7) proteins in dopaminergic brain areas. A similar regimen of manganese chloride (MnCl(2)) also caused extensive loss of striatal TH, mitochondrial electron transport components, and Park proteins. As mutations in PARK genes have been linked to early-onset PD in humans, and because welding is implicated as a risk factor for parkinsonism, PARK genes might play a critical role in WF-mediated dopaminergic dysfunction. Whether these molecular alterations culminate in neurobehavioral and neuropathological deficits reminiscent of PD remains to be ascertained.-Sriram, K., Lin, G. X., Jefferson, A. M., Roberts, J. R., Wirth, O., Hayashi, Y., Krajnak, K. M., Soukup, J. M., Ghio, A. J., Reynolds, S. H., Castranova, V., Munson, A. E., Antonini, J. M. Mitochondrial dysfunction and loss of Parkinson's disease-linked proteins contribute to neurotoxicity of manganese-containing welding fumes. FASEB J. 24, 4989-5002 (2010). www.fasebj.org	[Sriram, Krishnan] NIOSH, Toxicol & Mol Biol Branch, CDC, Hlth Effects Lab, Morgantown, WV 26505 USA; [Soukup, Joleen M.; Ghio, Andrew J.] US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); United States Environmental Protection Agency	Sriram, K (corresponding author), NIOSH, Toxicol & Mol Biol Branch, CDC, Hlth Effects Lab, Mailstop L-3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	kos4@cdc.gov	Sriram, Krishnan/F-1039-2014	Sriram, Krishnan/0000-0001-7005-1872				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Andres-Mateos E, 2007, P NATL ACAD SCI USA, V104, P14807, DOI 10.1073/pnas.0703219104; Antonini JM, 2010, INHAL TOXICOL, V22, P805, DOI 10.3109/08958371003621641; Antonini JM, 2006, J OCCUP ENVIRON HYG, V3, P194, DOI 10.1080/15459620600584352; Berlinger B, 2009, ANN OCCUP HYG, V53, P333, DOI 10.1093/annhyg/mep013; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bowler RM, 2007, OCCUP ENVIRON MED, V64, P167, DOI 10.1136/oem.2006.028761; Bowler RM, 2007, NEUROTOXICOLOGY, V28, P298, DOI 10.1016/j.neuro.2006.11.001; Bowler RM, 2006, NEUROTOXICOLOGY, V27, P315, DOI 10.1016/j.neuro.2005.10.007; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Couper J., 1837, BR ANN MED PHARM, V1, P41, DOI DOI 10.1002/JCP.22692; DAY INM, 1987, FEBS LETT, V210, P157, DOI 10.1016/0014-5793(87)81327-3; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; GALVANI P, 1995, EUR J PHARM-ENVIRON, V293, P377, DOI 10.1016/S0014-2999(95)80096-4; GAVIN CE, 1992, TOXICOL APPL PHARM, V115, P1, DOI 10.1016/0041-008X(92)90360-5; Gitler AD, 2009, NAT GENET, V41, P308, DOI 10.1038/ng.300; Goldberg MS, 2005, NEURON, V45, P489, DOI 10.1016/j.neuron.2005.01.041; Goldman SM, 2005, NEUROLOGY, V65, P1430, DOI 10.1212/01.wnl.0000180361.74060.70; Greenamyre JT, 2003, PARKINSONISM RELAT D, V9, pS59, DOI 10.1016/S1353-8020(03)00023-3; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; HaMai D, 2001, FREE RADICAL BIO MED, V31, P763, DOI 10.1016/S0891-5849(01)00639-6; Harris MK, 2005, J OCCUP ENVIRON HYG, V2, P375, DOI 10.1080/15459620591007736; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Hedrich K, 2004, NEUROLOGY, V62, P389, DOI 10.1212/01.WNL.0000113022.51739.88; Higashi Y, 2004, J NEUROCHEM, V89, P1490, DOI 10.1111/j.1471-4159.2004.02445.x; Hunot S, 2001, CLIN NEUROSCI RES, V1, P434, DOI 10.1016/S1566-2772(01)00022-6; HUSAIN R, 1976, B ENVIRON CONTAM TOX, V16, P118, DOI 10.1007/BF01753116; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; IWAMOTO N, 1984, T JWRI, V13, P21; Jenkins NT, 2005, WELD J, V84, p87S; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Josephs KA, 2005, NEUROLOGY, V64, pA419; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Kim YH, 1999, NEUROTOXICOLOGY, V20, P249; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitazawa M, 2002, J PHARMACOL EXP THER, V302, P26, DOI 10.1124/jpet.302.1.26; Korczynski R E, 2000, Appl Occup Environ Hyg, V15, P936, DOI 10.1080/104732200750051175; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Lucchini R, 1999, NEUROTOXICOLOGY, V20, P287; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; Mellick GD, 2000, NEUROSCI LETT, V293, P127, DOI 10.1016/S0304-3940(00)01510-X; Mergler D, 1997, ENVIRON RES, V73, P92, DOI 10.1006/enrs.1997.3710; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; MUKOYAMA M, 1989, ACTA NEUROPATHOL, V79, P294, DOI 10.1007/BF00294664; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; NELSON K, 1993, BRIT J IND MED, V50, P510; Neumann M, 2004, ACTA NEUROPATHOL, V107, P489, DOI 10.1007/s00401-004-0834-2; Olzmann JA, 2007, J COMP NEUROL, V500, P585, DOI 10.1002/cne.21191; Panov A, 2005, J BIOL CHEM, V280, P42026, DOI 10.1074/jbc.M508628200; Park J, 2006, NEUROTOXICOLOGY, V27, P445, DOI 10.1016/j.neuro.2006.01.005; Park RM, 2005, AM J IND MED, V48, P63, DOI 10.1002/ajim.20178; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Periquet M, 2003, BRAIN, V126, P1271, DOI 10.1093/brain/awg136; Prabhakaran K, 2009, NEUROTOXICOLOGY, V30, P414, DOI 10.1016/j.neuro.2009.02.012; Przedborski S, 2004, J BIOENERG BIOMEMBR, V36, P375, DOI 10.1023/B:JOBB.0000041771.66775.d5; Racette BA, 2005, NEUROLOGY, V64, P230, DOI 10.1212/01.WNL.0000149511.19487.44; Racette BA, 2001, NEUROLOGY, V56, P8, DOI 10.1212/WNL.56.1.8; Rao KVR, 2004, J BIOL CHEM, V279, P32333, DOI 10.1074/jbc.M402096200; Reaney SH, 2005, TOXICOL APPL PHARM, V205, P271, DOI 10.1016/j.taap.2004.10.013; Reaney SH, 2006, TOXICOL SCI, V93, P114, DOI 10.1093/toxsci/kfl028; Reasor MJ, 2000, J TOXICOL ENV HEAL A, V62, P9, DOI 10.1080/00984100050201631; Rizzu P, 2004, ANN NEUROL, V55, P113, DOI 10.1002/ana.10782; Roels H, 1997, ARCH TOXICOL, V71, P223, DOI 10.1007/s002040050380; ROELS HA, 1992, BRIT J IND MED, V49, P25; Roth JA, 2010, J NEUROCHEM, V113, P454, DOI 10.1111/j.1471-4159.2010.06607.x; Roth JA, 2009, NEUROMOL MED, V11, P281, DOI 10.1007/s12017-009-8088-8; Sadek AH, 2003, INT J TOXICOL, V22, P393, DOI 10.1080/713936672; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; SRIRAM K, ARCH TOXICOL, V84, P521; SRIRAM K, 2005, ROLE GLIA NEUROTOXIC, P141; Sriram K, 2006, FASEB J, V20, P670, DOI 10.1096/fj.05-5106com; Stampfer MJ, 2009, J OCCUP ENVIRON HYG, V6, P267, DOI 10.1080/15459620902754703; STONE KC, 1992, AM J RESP CELL MOL, V6, P235, DOI 10.1165/ajrcmb/6.2.235; Susi P, 2000, Appl Occup Environ Hyg, V15, P26; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Tanner CM, 2009, ARCH NEUROL-CHICAGO, V66, P1106, DOI 10.1001/archneurol.2009.195; Ved R, 2005, J BIOL CHEM, V280, P42655, DOI 10.1074/jbc.M505910200; WENNBERG A, 1991, SCAND J WORK ENV HEA, V17, P255, DOI 10.5271/sjweh.1705; Yin ZB, 2008, BRAIN RES, V1203, P1, DOI 10.1016/j.brainres.2008.01.079; Yokota T, 2003, BIOCHEM BIOPH RES CO, V312, P1342, DOI 10.1016/j.bbrc.2003.11.056; Zhang J, 2003, J NEUROCHEM, V84, P336, DOI 10.1046/j.1471-4159.2003.01525.x; Zhang L, 2005, HUM MOL GENET, V14, P2063, DOI 10.1093/hmg/ddi211; Zhang SR, 2004, TOXICOL IN VITRO, V18, P71, DOI 10.1016/j.tiv.2003.09.002; Zhang ZJ, 2008, NEUROSCI LETT, V442, P200, DOI 10.1016/j.neulet.2008.07.012; Zimmer AT, 2001, J AEROSOL SCI, V32, P993, DOI 10.1016/S0021-8502(01)00035-0	96	56	59	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2010	24	12					4989	5002		10.1096/fj.10-163964	http://dx.doi.org/10.1096/fj.10-163964			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	688BO	20798247				2022-12-28	WOS:000284824400037
J	Kallio, J; Myllymaki, H; Gronholm, J; Armstrong, M; Vanha-aho, LM; Makinen, L; Silvennoinen, O; Valanne, S; Ramet, M				Kallio, Jenni; Myllymaki, Henna; Gronholm, Juha; Armstrong, Morag; Vanha-aho, Leena-Maija; Makinen, Leena; Silvennoinen, Olli; Valanne, Susanna; Ramet, Mika			Eye transformer is a negative regulator of Drosophila JAK/STAT signaling	FASEB JOURNAL			English	Article						RNAi screen; cytokine signaling; stress response; Domeless; unpaired	JANUS KINASE/SIGNAL TRANSDUCER; HUMORAL STRESS-RESPONSE; WIDE RNAI ANALYSIS; PATHWAY; RECEPTOR; PROTEIN; GENES; IDENTIFICATION; EXPRESSION; COMPONENTS	JAK/STAT signaling pathway is evolutionarily conserved and tightly regulated. We carried out a reporter-based genome-wide RNAi in vitro screen to identify genes that regulate Drosophila JAK/STAT pathway and found 5 novel regulators. Of these, CG14225 is a negative regulator structurally related to the Drosophila JAK/STAT pathway receptor Domeless, especially in the extracellular domain, and to the mammalian IL-6 receptor and the signal transducer gp130. CG14225 coimmunoprecipitates with Domeless and its associated kinase hopscotch in S2 cells. CG14225 RNAi caused hyperphosphorylation of the transcription factor Stat92E in S2 cells on stimulation with the Drosophila JAK/STAT pathway ligand unpaired. CG14225 RNAi in vivo hyperactivated JAK/STAT target genes on septic injury and enhanced unpaired-induced eye overgrowth, and was thus named the eye transformer (ET). In the gastrointestinal infection model, where JAK/STAT signaling is important for stem cell renewal, CG14225/ET RNAi was protective in vivo. In conclusion, we have identified ET as a novel negative regulator of the Drosophila JAK/STAT pathway both in vitro and in vivo, and it functions in regulating Stat92E phosphorylation.-Kallio, J., Myllymaki, H., Gronholm, J., Armstrong, M., Vanha-aho, L.-M., Makinen, L., Silvennoinen, O., Valanne, S., Ramet, M. Eye transformer is a negative regulator of Drosophila JAK/STAT signaling. FASEB J. 24, 4467-4479 (2010). www.fasebj.org	[Kallio, Jenni; Myllymaki, Henna; Armstrong, Morag; Vanha-aho, Leena-Maija; Makinen, Leena; Valanne, Susanna; Ramet, Mika] Tampere Univ, Inst Med Technol, Expt Immunol Lab, FIN-33014 Tampere, Finland; [Gronholm, Juha; Silvennoinen, Olli] Tampere Univ, Inst Med Technol, Lab Mol Immunol & Cytokine Receptor Signaling, FIN-33014 Tampere, Finland; [Ramet, Mika] Tampere Univ Hosp, Dept Pediat, Tampere, Finland	Tampere University; Tampere University; Tampere University; Tampere University Hospital	Ramet, M (corresponding author), Tampere Univ, Inst Med Technol, Expt Immunol Lab, FIN-33014 Tampere, Finland.	mika.ramet@uta.fi	Valanne, Susanna/GZK-2381-2022; Grönholm, Juha/Q-4078-2017	Valanne, Susanna/0000-0003-0898-8423; Grönholm, Juha/0000-0002-4190-0000; Myllymaki, Henna/0000-0002-6936-4879; Vanha-aho, Leena-Maija/0000-0001-7933-7711	Academy of Finland; Foundation for Pediatric Research; Sigrid Juselius Foundation; Emil Aaltonen Foundation; Pirkanmaa Hospital District; Tampere Tuberculosis Foundation	Academy of Finland(Academy of Finland); Foundation for Pediatric Research; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Emil Aaltonen Foundation; Pirkanmaa Hospital District; Tampere Tuberculosis Foundation	The authors thank Prof. Bruno Lemaitre (Centre de Genetique Moleculaire, Gif-sur-Yvette, France) for C564-GAL4 fly stock and Prof. Howard Jacobs (University of Tampere, Tampere, France) for GeneSwitch-GAL4 fly stock. The authors thank Prof. Jean-Luc Imler (Universite Louis Pasteur, Strasbourg, France) for TotM-luciferase and hop<SUP>Tum-l</SUP> constructs, Prof. Michael Boutros (German Cancer Research Center, Heidelberg, Germany) for GMR-upd Delta 3' and ey-GAL4 fly stocks and pMT-upd and 3 x 2-Draf-luc constructs, and Erica Bach (New York University Langone Medical Center, New York, NY, USA) for 10xStat92E-luc reporter. The authors also thank Prof. Jussi Taipale, Dr. Minna Taipale, and Dr. Mikael Bjorklund (University of Helsinki, Helsinki, Finland) for their help in generating our dsRNA library. This research was supported by grants from the Academy of Finland, the Foundation for Pediatric Research, the Sigrid Juselius Foundation, the Emil Aaltonen Foundation (to M.R.), the Competitive Research Funding of the Pirkanmaa Hospital District, and the Tampere Tuberculosis Foundation (to M.R. and S.V.). The authors declare they have no conflicts of interest. All authors approved the final version of the text.	Agaisse H, 2003, DEV CELL, V5, P441, DOI 10.1016/S1534-5807(03)00244-2; Arbouzova NI, 2006, DEVELOPMENT, V133, P2605, DOI 10.1242/dev.02411; Arbouzova NI, 2006, CURR BIOL, V16, P80, DOI 10.1016/j.cub.2005.11.033; Bach EA, 2003, GENETICS, V165, P1149; Baeg GH, 2005, GENE DEV, V19, P1861, DOI 10.1101/gad.1320705; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Brown S, 2003, DEVELOPMENT, V130, P3077, DOI 10.1242/dev.00535; Brown S, 2001, CURR BIOL, V11, pR43, DOI 10.1016/S0960-9822(01)00007-0; Brun S, 2006, GENES CELLS, V11, P397, DOI 10.1111/j.1365-2443.2006.00953.x; Callus BA, 2002, ONCOGENE, V21, P4812, DOI 10.1038/sj.onc.1205618; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Cronin SJF, 2009, SCIENCE, V325, P340, DOI 10.1126/science.1173164; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015-007-0004-8; Ekengren S, 2001, BIOCHEM BIOPH RES CO, V284, P998, DOI 10.1006/bbrc.2001.5067; Ekengren S, 2001, CURR BIOL, V11, P714, DOI 10.1016/S0960-9822(01)00203-2; Gilbert MM, 2005, MECH DEVELOP, V122, P939, DOI 10.1016/j.mod.2005.03.004; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hombria JCG, 2005, DEV BIOL, V288, P420, DOI 10.1016/j.ydbio.2005.09.040; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014; Kallio J, 2005, MICROBES INFECT, V7, P811, DOI 10.1016/j.micinf.2005.03.014; Karsten P, 2002, MECH DEVELOP, V117, P343, DOI 10.1016/S0925-4773(02)00216-2; Kleino A, 2005, EMBO J, V24, P3423, DOI 10.1038/sj.emboj.7600807; Kleino A, 2008, J IMMUNOL, V180, P5413, DOI 10.4049/jimmunol.180.8.5413; Kocks C, 2005, CELL, V123, P335, DOI 10.1016/j.cell.2005.08.034; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mukherjee T, 2006, GENETICS, V172, P1683, DOI 10.1534/genetics.105.046904; Muller P, 2005, NATURE, V436, P871, DOI 10.1038/nature03869; Nehme NT, 2007, PLOS PATHOG, V3, P1694, DOI 10.1371/journal.ppat.0030173; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Singh SR, 2005, CELL RES, V15, P1, DOI 10.1038/sj.cr.7290255; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Ulvila J, 2006, J BIOL CHEM, V281, P14370, DOI 10.1074/jbc.M513868200; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Wang XQ, 2009, ANNU REV IMMUNOL, V27, P29, DOI 10.1146/annurev.immunol.24.021605.090616; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	56	36	36	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4467	4479		10.1096/fj.10-162784	http://dx.doi.org/10.1096/fj.10-162784			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20624926				2022-12-28	WOS:000283861100032
J	Li, X; Shridas, P; Forrest, K; Bailey, W; Webb, NR				Li, Xia; Shridas, Preetha; Forrest, Kathy; Bailey, William; Webb, Nancy R.			Group X secretory phospholipase A(2) negatively regulates adipogenesis in murine models	FASEB JOURNAL			English	Article						obesity; arachidonic acid; nuclear receptor	ACTIVATED-RECEPTOR-GAMMA; ELEMENT-BINDING PROTEIN-1; ADIPOSE-TISSUE; ADIPOCYTE DIFFERENTIATION; GENE-EXPRESSION; IN-VIVO; DENSITY-LIPOPROTEIN; PROMOTER ACTIVITY; CELL FUNCTION; PPAR-GAMMA	Studies in vitro indicate that group X secretory phospholipase A(2) (GX sPLA(2)) potently releases arachidonic acid (AA) and lysophosphatidylcholine from mammalian cell membranes. To define the function of GX sPLA(2) in vivo, our laboratory recently generated C57BL/6 mice with targeted deletion of GX sPLA(2) (GX(-/-) mice). When fed a normal rodent diet, GX(-/-) mice gained significantly more weight and had increased adiposity compared to GX(+/+) mice, which was not attributable to alterations in food consumption or energy expenditure. When treated with adipogenic stimuli ex vivo, stromal vascular cells isolated from adipose tissue of GX(-/-) mice accumulated significantly more (20%) triglyceride compared to cells from GX(+/+) mice. Conversely, overexpression of GX sPLA(2), but not catalytically inactive GX sPLA(2), resulted in a significant 50% reduction in triglyceride accumulation in OP9 adipocytes. The induction of genes encoding adipogenic proteins (PPAR gamma, SREBP-1c, SCD1, and FAS) was also significantly blunted by 50-80% in OP9 cells overexpressing GX sPLA(2). Activation of the liver X receptor (LXR), a nuclear receptor known to up-regulate adipogenic gene expression, was suppressed in 3T3-L1 and OP9 cells when GX sPLA(2) was overexpressed. Thus, hydrolytic products generated by GX sPLA(2) negatively regulate adipogenesis, possibly by suppressing LXR activation.-Li, X., Shridas, P., Forrest, K., Bailey, W., Webb, N. R. Group X secretory phospholipase A(2) negatively regulates adipogenesis in murine models. FASEB J. 24, 4313-4324 (2010). www.fasebj.org	[Li, Xia; Webb, Nancy R.] Univ Kentucky, Grad Ctr Nutr Sci, Med Ctr, Lexington, KY 40536 USA; [Shridas, Preetha; Forrest, Kathy; Bailey, William; Webb, Nancy R.] Univ Kentucky, Dept Internal Med, Div Endocrinol, Med Ctr, Lexington, KY 40536 USA; [Shridas, Preetha; Forrest, Kathy; Bailey, William; Webb, Nancy R.] Univ Kentucky, Med Ctr, Saha Cardiovasc Res Ctr, Lexington, KY 40536 USA; [Webb, Nancy R.] Dept Vet Affairs Med Ctr, Lexington, KY USA	University of Kentucky; University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	Webb, NR (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, Med Ctr, Rm 535,CT Wethington Bldg,900 S Limestone St, Lexington, KY 40536 USA.	nrwebb1@uky.edu	Webb, Nancy/AAL-7030-2021		U.S. National Institutes of Health [RO1 DK082419]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082419] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funding for this study was supported by U.S. National Institutes of Health grant RO1 DK082419 (to N.R.W.). This article is the result of work supported with resources and the use of facilities at the Lexington Veterans Affairs Medical Center.	Boyanovsky BB, 2009, CARDIOVASC DRUG THER, V23, P61, DOI 10.1007/s10557-008-6134-7; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Chu K, 2006, MOL CELL BIOL, V26, P6786, DOI 10.1128/MCB.00077-06; Cortes VA, 2009, CELL METAB, V9, P165, DOI 10.1016/j.cmet.2009.01.002; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; Darimont C, 2006, BIOCHIMIE, V88, P309, DOI 10.1016/j.biochi.2005.08.010; Duncan RE, 2008, J BIOL CHEM, V283, P25428, DOI 10.1074/jbc.M804146200; Elberg G, 2000, J BIOL CHEM, V275, P27815; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Fujioka D, 2008, CIRCULATION, V117, P2977, DOI 10.1161/CIRCULATIONAHA.107.743997; Gerin I, 2005, J BIOL CHEM, V280, P23024, DOI 10.1074/jbc.M412564200; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Halberg N, 2008, ENDOCRIN METAB CLIN, V37, P753, DOI 10.1016/j.ecl.2008.07.002; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; Hauner H, 2004, PHYSIOL BEHAV, V83, P653, DOI 10.1016/j.physbeh.2004.09.016; Hui DY, 2009, BRIT J PHARMACOL, V157, P1263, DOI 10.1111/j.1476-5381.2009.00308.x; Hummasti S, 2004, J LIPID RES, V45, P616, DOI 10.1194/jlr.M300312-JLR200; Jaworski K, 2009, NAT MED, V15, P159, DOI 10.1038/nm.1904; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Juvet LK, 2003, MOL ENDOCRINOL, V17, P172, DOI 10.1210/me.2001-0210; Karabina SA, 2006, FASEB J, V20, P2547, DOI 10.1096/fj.06-6018fje; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Labonte ED, 2006, DIABETES, V55, P935, DOI 10.2337/diabetes.55.04.06.db05-1286; Labonte ED, 2010, FASEB J, V24, P2516, DOI 10.1096/fj.09-144436; Lambeau G, 2008, ANNU REV BIOCHEM, V77, P495, DOI 10.1146/annurev.biochem.76.062405.154007; Lawson MA, 2009, J ADOLESCENT HEALTH, V44, P94, DOI 10.1016/j.jadohealth.2008.06.007; McLaugblin T, 2007, DIABETOLOGIA, V50, P1707, DOI 10.1007/s00125-007-0708-y; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47; Ohtsuki M, 2006, J BIOL CHEM, V281, P36420, DOI 10.1074/jbc.M607975200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rodeheffer MS, 2008, CELL, V135, P240, DOI 10.1016/j.cell.2008.09.036; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Seo JB, 2004, MOL CELL BIOL, V24, P3430, DOI 10.1128/MCB.24.8.3430-3444.2004; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Shridas P, 2010, J BIOL CHEM, V285, P20031, DOI 10.1074/jbc.M109.090423; Simon MF, 2005, J BIOL CHEM, V280, P14656, DOI 10.1074/jbc.M412585200; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Steffensen KR, 2003, BIOCHEM BIOPH RES CO, V310, P589, DOI 10.1016/j.bbrc.2003.08.139; Takeuchi Y, 2010, J BIOL CHEM, V285, P11681, DOI 10.1074/jbc.M109.096107; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Triggiani M, 2006, BBA-MOL CELL BIOL L, V1761, P1289, DOI 10.1016/j.bbalip.2006.07.003; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Wolins NE, 2006, J LIPID RES, V47, P450, DOI 10.1194/jlr.D500037-JLR200; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	55	26	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2010	24	11					4313	4324		10.1096/fj.10-154716	http://dx.doi.org/10.1096/fj.10-154716			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20585029	Green Published			2022-12-28	WOS:000283861100019
J	Canning, BJ; Mori, N				Canning, Brendan J.; Mori, Nanako			An essential component to brainstem cough gating identified in anesthetized guinea pigs	FASEB JOURNAL			English	Article						solitary tract; capsaicin; respiration; C fiber; bradykinin	NUCLEUS-TRACTUS-SOLITARIUS; AFFERENT NERVE SUBTYPES; EXCITATORY AMINO-ACIDS; RECEPTOR RELAY NEURONS; AXONAL HORSERADISH-PEROXIDASE; RAPIDLY ADAPTING RECEPTORS; SYNERGISTIC INTERACTIONS; CONVERGENCE PROPERTIES; MEDULLARY PROJECTIONS; SENSORY GANGLIA	Coughing protects and clears the airways and lungs of inhaled irritants, particulates, pathogens, and accumulated secretions. An initial urge to cough, and an almost binary output suggests gating mechanisms that encode and modulate this defensive reflex. Whether this "gate" has a physical location for the physiological barrier it poses to cough is unknown. Here we describe a critical component to cough gating, the central terminations of the cough receptors. A novel microinjection strategy defined coordinates for microinjection of glutamate receptor antagonists that nearly abolished cough evoked from the trachea and larynx in anesthetized guinea pigs while having no effect on basal respiratory rate and little or no effect on reflexes attributed to activating other afferent nerve subtypes. Comparable microinjections in adjacent brainstem locations (0.5-2 mm distal) were without effect on coughing. Subsequent transganglionic and dual tracing studies confirmed that the central terminations of the cough receptors and their primary relay neurons are found bilaterally within nucleus tractus solitarius (nTS), lateral to the commissural subnucleus and perhaps in the medial subnuclei. These synapses possess the physiological characteristics of a cough gate. Their localization should facilitate more mechanistic studies of the encoding and gating of cough.-Canning, B. J., Nanako Mori. An essential component to brainstem cough gating identified in anesthetized guinea pigs. FASEB J. 24, 3916-3926 (2010). www.fasebj.org	[Canning, Brendan J.; Mori, Nanako] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Canning, BJ (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	bjc@jhmi.edu	Canning, Brendan/AAM-9404-2021; Canning, Brendan/ABE-5261-2020	Canning, Brendan/0000-0003-4197-5560; 	National Institutes of Health (Bethesda, MD, USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083192] Funding Source: NIH RePORTER	National Institutes of Health (Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The research described in this manuscript was funded by a grant (HL083192) from the National Institutes of Health (Bethesda, MD, USA).	Allen WF, 1923, J COMP NEUROL, V35, P171, DOI 10.1002/cne.900350204; Allen WF, 1923, J COMP NEUROL, V35, P275, DOI 10.1002/cne.900350403; ALTSCHULER SM, 1989, J COMP NEUROL, V283, P248, DOI 10.1002/cne.902830207; Aylwin ML, 1997, J NEUROPHYSIOL, V77, P2539, DOI 10.1152/jn.1997.77.5.2539; Bolser DC, 2006, RESP PHYSIOL NEUROBI, V152, P255, DOI 10.1016/j.resp.2006.01.008; BONHAM AC, 1993, J PHYSIOL-LONDON, V464, P725, DOI 10.1113/jphysiol.1993.sp019660; BONHAM AC, 1991, J PHYSIOL-LONDON, V441, P95, DOI 10.1113/jphysiol.1991.sp018740; BONHAM AC, 1990, J PHYSIOL-LONDON, V427, P261, DOI 10.1113/jphysiol.1990.sp018171; Canning BJ, 2004, J PHYSIOL-LONDON, V557, P543, DOI 10.1113/jphysiol.2003.057885; Canning BJ, 2008, LUNG, V186, pS23, DOI 10.1007/s00408-007-9054-6; Canning BJ, 2006, RESP PHYSIOL NEUROBI, V152, P223, DOI 10.1016/j.resp.2006.03.001; Canning BJ, 2006, AM J PHYSIOL-REG I, V291, pR454, DOI 10.1152/ajpregu.00862.2005; Canning BJ, 2009, PULM PHARMACOL THER, V22, P75, DOI 10.1016/j.pupt.2009.01.003; Canning BJ, 2008, PULM PHARMACOL THER, V21, P702, DOI 10.1016/j.pupt.2008.01.004; Chianca DA, 1996, BRAIN RES, V718, P185, DOI 10.1016/0006-8993(96)00010-8; Chou YL, 2008, AM J PHYSIOL-REG I, V295, pR1572, DOI 10.1152/ajpregu.90382.2008; CHRISTIAN EP, 1993, J NEUROSCI METH, V47, P147, DOI 10.1016/0165-0270(93)90031-L; DAVIES A, 1981, J PHYSIOL-LONDON, V318, P17; DAVIES RO, 1986, J PHYSIOL-LONDON, V373, P63, DOI 10.1113/jphysiol.1986.sp016035; DAVIES RO, 1987, J PHYSIOL-LONDON, V383, P571; DEKIN MS, 1987, J NEUROPHYSIOL, V58, P195, DOI 10.1152/jn.1987.58.1.195; Doyle MW, 2004, J NEUROSCI METH, V137, P37, DOI 10.1016/j.jneumeth.2004.02.007; EZURE K, 1991, BRAIN RES, V564, P268, DOI 10.1016/0006-8993(91)91463-B; Ezure K, 1999, EXP BRAIN RES, V128, P471, DOI 10.1007/s002210050870; Gestreau C, 1997, J NEUROSCI, V17, P9340; GREEN JF, 1990, J APPL PHYSIOL, V68, P2186, DOI 10.1152/jappl.1990.68.5.2186; Haxhiu MA, 2000, J AUTONOM NERV SYST, V80, P22, DOI 10.1016/S0165-1838(99)00088-0; Irwin RS, 2006, CHEST, V129, p1S, DOI 10.1378/chest.129.1_suppl.1S; Jakus J, 2008, RESP PHYSIOL NEUROBI, V160, P289, DOI 10.1016/j.resp.2007.10.014; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; KALIA M, 1988, J COMP NEUROL, V274, P560, DOI 10.1002/cne.902740406; KALIA M, 1985, J COMP NEUROL, V241, P521, DOI 10.1002/cne.902410410; KALIA M, 1988, J COMP NEUROL, V274, P574, DOI 10.1002/cne.902740407; KALIA M, 1985, J COMP NEUROL, V241, P503, DOI 10.1002/cne.902410409; KARIUS DR, 1994, J APPL PHYSIOL, V76, P1293, DOI 10.1152/jappl.1994.76.3.1293; Kollarik M, 2002, J PHYSIOL-LONDON, V543, P591, DOI 10.1113/jphysiol.2002.022848; KUBIN L, 1991, J PHYSIOL-LONDON, V435, P207, DOI 10.1113/jphysiol.1991.sp018506; Kubin L, 2006, J APPL PHYSIOL, V101, P618, DOI 10.1152/japplphysiol.00252.2006; LIPSKI J, 1991, J PHYSIOL-LONDON, V443, P55, DOI 10.1113/jphysiol.1991.sp018822; Lu WY, 1998, AM J PHYSIOL-REG I, V274, pR1436; Mazzone SB, 2005, J PHYSIOL-LONDON, V569, P559, DOI 10.1113/jphysiol.2005.093153; Mazzone SB, 2002, AM J PHYSIOL-REG I, V283, pR86, DOI 10.1152/ajpregu.00007.2002; Mazzone SB, 2009, J NEUROSCI, V29, P13662, DOI 10.1523/JNEUROSCI.4354-08.2009; Mazzone Stuart B, 2008, Cough, V4, P9, DOI 10.1186/1745-9974-4-9; MIFFLIN SW, 1988, J PHYSIOL-LONDON, V399, P349; Morice AH, 2004, EUR RESPIR J, V24, P481, DOI 10.1183/09031936.04.00027804; Mutolo D, 2008, AM J PHYSIOL-REG I, V295, pR243, DOI 10.1152/ajpregu.00184.2008; Mutolo D, 2007, BRAIN RES BULL, V74, P284, DOI 10.1016/j.brainresbull.2007.07.001; Mutolo D, 2009, BRAIN RES BULL, V80, P22, DOI 10.1016/j.brainresbull.2009.05.022; Ohi Y, 2007, NEUROSCIENCE, V146, P1425, DOI 10.1016/j.neuroscience.2007.02.052; Ohi Y, 2005, NEUROSCI RES, V53, P201, DOI 10.1016/j.neures.2005.06.016; OTAKE K, 1992, J COMP NEUROL, V324, P365, DOI 10.1002/cne.903240307; Paton JFR, 1998, J PHYSIOL-LONDON, V508, P237, DOI 10.1111/j.1469-7793.1998.237br.x; PISARRI TE, 1986, RESP PHYSIOL, V64, P29, DOI 10.1016/0034-5687(86)90058-7; Riccio MM, 1996, J PHYSIOL-LONDON, V496, P521, DOI 10.1113/jphysiol.1996.sp021703; Seagard JL, 1999, J PHYSIOL-LONDON, V520, P243, DOI 10.1111/j.1469-7793.1999.00243.x; Sekizawa SI, 2008, EUR J NEUROSCI, V28, P771, DOI 10.1111/j.1460-9568.2008.06378.x; Silva-Carvalho L, 1998, J NEUROPHYSIOL, V79, P2374, DOI 10.1152/jn.1998.79.5.2374; VARDHAN A, 1993, BRAIN RES, V618, P23, DOI 10.1016/0006-8993(93)90424-L; Wank M, 2001, J COMP NEUROL, V435, P41, DOI 10.1002/cne.1192; WIDDICOMBE JG, 1954, J PHYSIOL-LONDON, V123, P55, DOI 10.1113/jphysiol.1954.sp005033; WIDDICOMBE JG, 1954, J PHYSIOL-LONDON, V123, P71, DOI 10.1113/jphysiol.1954.sp005034; Wilson CG, 1996, J PHYSIOL-LONDON, V496, P773, DOI 10.1113/jphysiol.1996.sp021726	63	52	54	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2010	24	10					3916	3926		10.1096/fj.09-151068	http://dx.doi.org/10.1096/fj.09-151068			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20581226	Green Published			2022-12-28	WOS:000285005900029
J	Cruse, G; Kaur, D; Leyland, M; Bradding, P				Cruse, Glenn; Kaur, Davinder; Leyland, Mark; Bradding, Peter			A novel Fc epsilon RI beta-chain truncation regulates human mast cell proliferation and survival	FASEB JOURNAL			English	Article						MS4A2; IgE receptor; cell cycle; G2 phase; cell membrane	CD20; ACTIVATION; RECEPTOR; IGE; IDENTIFICATION; EXPRESSION; HTM4; PROGRESSION; TRYPTASE; CHANNELS	Mast cells contribute to allergy through IgE-dependent activation via the high-affinity IgE receptor Fc epsilon RI. The role of the Fc epsilon RI beta chain (MS4A2) in mast cell function is not understood fully, although it serves to amplify Fc epsilon RI-dependent signaling. We demonstrate the expression of a novel MS4A2 truncation lacking exon 3 in human mast cells termed MS4A2(trunc). MS4A2(trunc) gene expression was regulated negatively by the mast cell growth factor stem cell factor (SCF), and its expression was not detected in the SCF receptor gain-of-function human mast cell line HMC-1. Unlike MS4A2, MS4A2(trunc) did not traffic to the cytoplasmic membrane but instead was associated with the nuclear membrane. Overexpression of MS4A2(trunc) induced human lung mast cell death and profoundly inhibited HMC-1 cell proliferation by inducing G(2)-phase cell cycle arrest and apoptosis. Thus, we have identified a novel splice variant of MS4A2 that might be important in the regulation of human mast cell proliferation and survival. This finding demonstrates that the MS4A2 gene has multiple roles, extending beyond the regulation of acute allergic responses. By understanding the mechanisms regulating its function, it might be possible to induce its expression in mast cells in vivo, which could lead to better treatments for diseases such as mastocytosis and asthma.-Cruse, G., Kaur, D., Leyland, M., Bradding, P. A novel Fc epsilon RI beta-chain truncation regulates human mast cell proliferation and survival. FASEB J. 24, 4047-4057 (2010). www.fasebj.org	[Leyland, Mark] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Cruse, Glenn; Kaur, Davinder; Bradding, Peter] Glenfield Gen Hosp, Inst Lung Hlth, Dept Infect Immun & Inflammat, Glenfield, England	University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Cruse, G (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Rm 11C205,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	glenncruse@hotmail.com	Cruse, Glenn/AAZ-1093-2021; Cruse, Glenn/B-4597-2012	Bradding, Peter/0000-0001-8403-0319; Cruse, Glenn/0000-0002-7511-0082	Novartis Pharmaceuticals	Novartis Pharmaceuticals(Novartis)	This study was funded in part by an unrestricted Ph.D. studentship (G.C.) from Novartis Pharmaceuticals. The authors are grateful to the Midlands Lung Tissue Consortium for the coordination of human lung tissue retrieval. The authors also thank Ryan Murray-Slater and Michelle Powell for assistance with the mast cell isolation and the Wolfson Foundation Light Microscopy Facility (Department of Biochemistry, University of Leicester) for the use of the scanning confocal microscope.	ALBER G, 1991, J BIOL CHEM, V266, P22613; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Bangur CS, 2004, INT J ONCOL, V25, P1583; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Bradding P., 2008, ALLERGY ALLERGIC DIS, P217; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; BUTTERFIELD JH, 1990, J LEUKOCYTE BIOL, V47, P409, DOI 10.1002/jlb.47.5.409; Chinami M, 2005, J BIOL CHEM, V280, P17235, DOI 10.1074/jbc.M413437200; Cruse G, 2006, THORAX, V61, P880, DOI 10.1136/thx.2006.060319; Cruse G, 2005, EUR RESPIR J, V25, P858, DOI 10.1183/09031936.05.00091704; Cruse G, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-2; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; Donato JL, 2002, J CLIN INVEST, V109, P51, DOI 10.1172/JCI200214025; Donnadieu E, 2003, IMMUNITY, V18, P665, DOI 10.1016/S1074-7613(03)00115-8; Duffy SM, 2003, J ALLERGY CLIN IMMUN, V112, P965, DOI 10.1016/j.jaci.2003.07.004; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Ishibashi K, 2001, GENE, V264, P87, DOI 10.1016/S0378-1119(00)00598-9; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kaur D, 2005, CLIN EXP ALLERGY, V35, P226, DOI 10.1111/j.1365-2222.2005.02161.x; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Koslowski M, 2008, CANCER RES, V68, P3458, DOI 10.1158/0008-5472.CAN-07-5768; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li HD, 2003, J BIOL CHEM, V278, P42427, DOI 10.1074/jbc.M308802200; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; RA C, 1989, J BIOL CHEM, V264, P15323; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Sanmugalingam D, 2000, J LEUKOCYTE BIOL, V68, P38; Singleton TE, 2009, MOL IMMUNOL, V46, P2333, DOI 10.1016/j.molimm.2009.03.023; Sorek R, 2001, NAT BIOTECHNOL, V19, P196, DOI 10.1038/85613; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; TETLOW LC, 1995, ANN RHEUM DIS, V54, P549, DOI 10.1136/ard.54.7.549; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wu YC, 2005, HUM EXP TOXICOL, V24, P41, DOI 10.1191/0960327105ht502oa; Wykes RCE, 2007, J IMMUNOL, V179, P4045, DOI 10.4049/jimmunol.179.6.4045	42	29	31	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2010	24	10					4047	4057		10.1096/fj.10-158378	http://dx.doi.org/10.1096/fj.10-158378			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20554927	Green Published			2022-12-28	WOS:000285005900040
J	Zeeuwen, PLJM; van Vlijmen-Willems, IMJJ; Cheng, T; Rodijk-Olthuis, D; Hitomi, K; Hara-Nishimura, I; John, S; Smyth, N; Reinheckel, T; Hendriks, WJAJ; Schalkwijk, J				Zeeuwen, Patrick L. J. M.; van Vlijmen-Willems, Ivonne M. J. J.; Cheng, Tsing; Rodijk-Olthuis, Diana; Hitomi, Kiyotaka; Hara-Nishimura, Ikuko; John, Susan; Smyth, Neil; Reinheckel, Thomas; Hendriks, Wiljan J. A. J.; Schalkwijk, Joost			The cystatin M/E-cathepsin L balance is essential for tissue homeostasis in epidermis, hair follicles, and cornea	FASEB JOURNAL			English	Article						differentiation; proteases; skin barrier; trans-glutaminases; mouse models	OF-FUNCTION MUTATIONS; DEFICIENT MICE; CROSS-LINKING; PROTEINASE-INHIBITOR; EPITHELIAL-CELLS; REACTIVE-SITE; TRANSGLUTAMINASE; ICHTHYOSIS; GENE; DIFFERENTIATION	Cystatin M/E (CST6) is a nonredundant, epithelium-specific protease inhibitor with a presumed role in epidermal differentiation and tumor suppression. We have previously reported that cystatin M/E deficiency in Cst6(-/-) mice causes neonatal lethality because of excessive transepidermal water loss. Biochemical evidence suggests that cystatin M/E controls the activity of legumain, cathepsin L, cathepsin V, and transglutaminase-3. Using a genetic approach we sought to define the role of cystatin M/E in epithelial biology by identification of its target proteases and their downstream functions. Ablation of cathepsin L in a Cst6(-/-) background (Cst6(-/-) Ctsl(-/-) double-knockout mice) restored viability and resulted in normalization of stratum corneum morphology. Ablation of legumain or transglutaminase-3 in Cst6(-/-) mice, however, did not rescue the lethal phenotype. Intriguingly, both Cst6(-/-) Ctsl(-/-) and Cst6(-/-) Ctsl(+/-) mice were viable, but the absence of cystatin M/E caused scarring alopecia in adult animals. In the cornea of Cst6(-/-) Ctsl(+/-) mice, we observed keratitis, hyperplasia, and transition to a cornified epithelium. Evidence is provided that activation of cathepsin D and transglutaminase-1 are downstream events, dependent of cathepsin L activity. We conclude that a tightly regulated balance between cathepsin L and cystatin M/E is essential for tissue integrity in epidermis, hair follicles, and corneal epithelium.-Zeeuwen, P. L. J. M., van Vlijmen-Willems, I. M. J. J., Cheng, T., Rodijk-Olthuis, D., Hitomi, K., Hara-Nishimura, I., John, S., Smyth, N., Reinheckel, T., Hendriks, W. J. A. J., Schalkwijk, J. The cystatin M/E-cathepsin L balance is essential for tissue homeostasis in epidermis, hair follicles and cornea. FASEB J. 24, 3744-3755 (2010). www.fasebj.org	[Zeeuwen, Patrick L. J. M.; van Vlijmen-Willems, Ivonne M. J. J.; Cheng, Tsing; Rodijk-Olthuis, Diana; Schalkwijk, Joost] Radboud Univ Nijmegen, Med Ctr, NCMLS, Dept Dermatol, NL-6500 HB Nijmegen, Netherlands; [Hendriks, Wiljan J. A. J.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands; [Hitomi, Kiyotaka] Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; [Hara-Nishimura, Ikuko] Kyoto Univ, Dept Bot, Grad Sch Sci, Kyoto, Japan; [John, Susan; Smyth, Neil] Univ Cologne, Ctr Biochem, Cologne, Germany; [John, Susan; Smyth, Neil] Univ Cologne, Ctr Mol Med, Cologne, Germany; [Reinheckel, Thomas] Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany	Radboud University Nijmegen; Radboud University Nijmegen; Nagoya University; Kyoto University; University of Cologne; University of Cologne; University of Freiburg	Zeeuwen, PLJM (corresponding author), Radboud Univ Nijmegen, Med Ctr, NCMLS, Dept Dermatol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.zeeuwen@ncmls.ru.nl	Reinheckel, Thomas/AAL-9761-2021; Schalkwijk, Joost/N-1774-2013; Schalkwijk, Joost/R-7509-2019; Hendriks, Wiljan/Q-4325-2019; Hendriks, Wiljan J.A.J./A-5214-2013; Zeeuwen, Patrick/N-1779-2013; van Vlijmen-Willems, Ivonne MJJ/P-5336-2015	Reinheckel, Thomas/0000-0001-9866-9105; Schalkwijk, Joost/0000-0002-1308-1319; Hendriks, Wiljan/0000-0001-9481-8281; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Zeeuwen, Patrick/0000-0002-6878-2438; van Vlijmen-Willems, Ivonne MJJ/0000-0002-3522-2573; Smyth, Neil/0000-0002-3734-2149; Cheng, Tsing/0000-0001-5191-3289	ZonMW, the Netherlands Organization for Health Research and Development [916.56.117]	ZonMW, the Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and DevelopmentNetherlands Government)	This paper is dedicated to the memory of Dr. Rosanne van Lingen (1979-2010), Department of Dermatology, Radboud University Nijmegen Medical Centre. The authors thank Debby Smits for assistance with the animal experiments. This work was supported by VENI-grant 916.56.117 from ZonMW, the Netherlands Organization for Health Research and Development (to P.L.J.M.Z.). This study was in part funded by the Alternatives to Animal Experiments program of ZonMW (to J.S. and P.L.J.M.Z.).	Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Basel-Vanagaite L, 2007, AM J HUM GENET, V80, P467, DOI 10.1086/512487; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; CHENG T, 2009, THESIS RADBOUD U NIJ; Cheng T, 2006, J BIOL CHEM, V281, P15893, DOI 10.1074/jbc.M600694200; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; Egberts F, 2004, J CELL SCI, V117, P2295, DOI 10.1242/jcs.01075; Hagemann S, 2004, EUR J CELL BIOL, V83, P775, DOI 10.1078/0171-9335-00404; Hiiragi T, 1999, J BIOL CHEM, V274, P34148, DOI 10.1074/jbc.274.48.34148; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; JOHN S, 2006, THESIS U COLOGNE GER; KIRSCHKE H, 2004, HDB PROTEOLYTIC ENZY, P1097; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Maehr R, 2005, J IMMUNOL, V174, P7066, DOI 10.4049/jimmunol.174.11.7066; Mirmirani P, 2005, J AM ACAD DERMATOL, V52, P637, DOI 10.1016/j.jaad.2004.07.069; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nakamura T, 2001, INVEST OPHTH VIS SCI, V42, P549; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pennacchio LA, 1998, NAT GENET, V20, P251, DOI 10.1038/3059; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Shirahama-Noda K, 2003, J BIOL CHEM, V278, P33194, DOI 10.1074/jbc.M302742200; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; Sugimura Y, 2008, FEBS J, V275, P5667, DOI 10.1111/j.1742-4658.2008.06692.x; Sundberg JP, 1997, AM J PATHOL, V151, P293; Sundberg JP, 2000, AM J PATHOL, V156, P2067, DOI 10.1016/S0002-9440(10)65078-X; Toomes C, 1999, NAT GENET, V23, P421, DOI 10.1038/70525; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Wille A, 2004, BIOL CHEM, V385, P665, DOI 10.1515/BC.2004.082; Yang JX, 2010, J CELL BIOL, V188, P935, DOI 10.1083/jcb.200910126; Zeeuwen PLJM, 2007, J INVEST DERMATOL, V127, P120, DOI 10.1038/sj.jid.5700480; Zeeuwen PLJM, 2009, J INVEST DERMATOL, V129, P1327, DOI 10.1038/jid.2009.40; Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388; Zeeuwen PLJM, 1997, J BIOL CHEM, V272, P20471, DOI 10.1074/jbc.272.33.20471; Zeeuwen PLJM, 2004, HUM MOL GENET, V13, P1069, DOI 10.1093/hmg/ddh115; Zeeuwen PLJM, 2002, HUM MOL GENET, V11, P2867, DOI 10.1093/hmg/11.23.2867; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x	38	29	32	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2010	24	10					3744	3755		10.1096/fj.10-155879	http://dx.doi.org/10.1096/fj.10-155879			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LI	20495178				2022-12-28	WOS:000285005900014
J	Lubos, E; Mahoney, CE; Leopold, JA; Zhang, YY; Loscalzo, J; Handy, DE				Lubos, Edith; Mahoney, Christopher E.; Leopold, Jane A.; Zhang, Ying-Yi; Loscalzo, Joseph; Handy, Diane E.			Glutathione peroxidase-1 modulates lipopolysaccharide-induced adhesion molecule expression in endothelial cells by altering CD14 expression	FASEB JOURNAL			English	Article						innate immunity; inflammation; ICAM-1; ROS	ACCELERATES ATHEROSCLEROSIS; SURFACE EXPRESSION; MICE DEFICIENT; RECEPTOR 4; KAPPA-B; LPS; ACTIVATION; RESPONSIVENESS; MD-2; GLUTATHIONE-PEROXIDASE-1	CD14 contributes to LPS signaling in leukocytes through formation of toll-like receptor 4/CD14 receptor complexes; however, a specific role for endogenous cell-surface CD14 in endothelial cells is unclear. We have found that suppression of glutathione peroxidase-1 (GPx-1) in human microvascular endothelial cells increases CD14 gene expression compared to untreated or siControl (siCtrl)-treated conditions. Following LPS treatment, GPx-1 deficiency augmented LPS-induced intracellular reactive oxygen species accumulation, CD14 expression, and intercellular adhesion molecule-1 (ICAM-1) mRNA and protein expression compared to LPS-treated control cells. GPx-1 deficiency also transiently augmented LPS-induced vascular cell adhesion molecule-1 (VCAM-1) expression. Adenoviral overexpression of GPx-1 significantly diminished LPS-mediated responses in adhesion molecule expression. Consistent with these findings, LPS responses were also greater in endothelial cells derived from GPx-1-knockout mice, whereas adhesion molecule expression was decreased in cells from GPx-1-overexpressing transgenic mice. Knockdown of CD14 attenuated LPS-mediated up-regulation of ICAM-1 and VCAM-1 mRNA and protein, and it mitigated the effects of GPx-1 deficiency on LPS-induced adhesion molecule expression. Taken together, these data suggest that GPx-1 modulates the endothelial cell response to LPS, in part, by altering CD14-mediated effects.-Lubos, E., Mahoney, C.E., Leopold, J.A., Zhang, Y.-Y., Loscalzo, J., Handy, D. E. Glutathione peroxidase-1 modulates lipopolysaccharide-induced adhesion molecule expression in endothelial cells by altering CD14 expression. FASEB J. 24, 2525-2532 (2010). www.fasebj.org	[Lubos, Edith; Mahoney, Christopher E.; Leopold, Jane A.; Zhang, Ying-Yi; Loscalzo, Joseph; Handy, Diane E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Handy, DE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, 77 Ave Louis Pasteur,NRB 0630L, Boston, MA 02115 USA.	dhandy@rics.bwh.harvard.edu	Loscalzo, Joseph/ABD-8980-2021	Handy, Diane/0000-0002-4310-8527	National Heart, Lung, and Blood Institute (NHLBI), U.S. National Institutes of Health [HL 61795, HV 28178, HL 81587]; Deutsche Forschungsgemeinschaft [LU 1452/1-1]; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028178, P01HL081587, R37HL061795, R01HL061795] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI), U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Stephanie Tribuna for expert assistance with manuscript preparation, and all other lab members for technical assistance and helpful discussions. In addition, the authors acknowledge Scott R. Oldebeken for his assistance with the design, execution, and analysis of experiments crucial to the completion of this report. This work was supported by U.S. National Institutes of Health grants HL 61795, HV 28178, and HL 81587 from the National Heart, Lung, and Blood Institute (NHLBI), and by Deutsche Forschungsgemeinschaft grant LU 1452/1-1 (to E.L.).	Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akira S, 2004, SEMIN IMMUNOL, V16, P1, DOI 10.1016/j.smim.2003.10.001; Allport JR, 2002, J LEUKOCYTE BIOL, V71, P821; Antal-Szalmas P, 2000, EUR J CLIN INVEST, V30, P167; BEEKHUIZEN H, 1991, J IMMUNOL, V147, P3761; Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008; Blankenberg S, 2003, NEW ENGL J MED, V349, P1605, DOI 10.1056/NEJMoa030535; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Crack PJ, 2001, J NEUROCHEM, V78, P1389, DOI 10.1046/j.1471-4159.2001.00535.x; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; FERRERO E, 1990, J IMMUNOL, V145, P331; FERRERO E, 1993, P NATL ACAD SCI USA, V90, P2380, DOI 10.1073/pnas.90.6.2380; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Forgione MA, 2002, CIRCULATION, V106, P1154, DOI 10.1161/01.CIR.0000026820.87824.6A; Forgione MA, 2002, AM J PHYSIOL-HEART C, V282, pH1255, DOI 10.1152/ajpheart.00598.2001; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Hack CE, 2001, CRIT CARE MED, V29, pS21, DOI 10.1097/00003246-200107001-00011; HAZIOT A, 1993, J IMMUNOL, V151, P1500; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Jersmann HPA, 2001, INFECT IMMUN, V69, P479, DOI 10.1128/IAI.69.1.479-485.2001; Jersmann HPA, 2005, IMMUNOL CELL BIOL, V83, P462, DOI 10.1111/j.1440-1711.2005.01370.x; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Landmann R, 1998, INFECT IMMUN, V66, P2264, DOI 10.1128/IAI.66.5.2264-2271.1998; Lapenna D, 1998, CIRCULATION, V97, P1930, DOI 10.1161/01.CIR.97.19.1930; Lehr HA, 2001, CIRCULATION, V104, P914, DOI 10.1161/hc3401.093153; Leopold JA, 2007, NAT MED, V13, P189, DOI 10.1038/nm1545; Lewis P, 2007, CIRCULATION, V115, P2178, DOI 10.1161/CIRCULATIONAHA.106.664250; Li Q, 2001, ANTIOXID REDOX SIGN, V3, P415, DOI 10.1089/15230860152409068; Lloyd KL, 2006, AM J PHYSIOL-HEART C, V291, pH473, DOI 10.1152/ajpheart.01234.2005; Lloyd-Jones KL, 2008, J IMMUNOL, V181, P1446, DOI 10.4049/jimmunol.181.2.1446; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Mullick AE, 2006, IMMUNOL RES, V34, P193, DOI 10.1385/IR:34:3:193; Nareika A, 2008, J ENDOCRINOL, V196, P45, DOI 10.1677/JOE-07-0145; Ostos MA, 2002, FEBS LETT, V519, P23, DOI 10.1016/S0014-5793(02)02692-3; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; RAES M, 1987, FREE RADICAL BIO MED, V3, P3, DOI 10.1016/0891-5849(87)90032-3; Resman N, 2009, J BIOL CHEM, V284, P15052, DOI 10.1074/jbc.M901429200; Roncon-Albuquerque R, 2008, LIFE SCI, V83, P502, DOI 10.1016/j.lfs.2008.07.021; Sawa Y, 2008, J HISTOCHEM CYTOCHEM, V56, P97, DOI 10.1369/jhc.7A7299.2007; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Song PI, 2001, INVEST OPHTH VIS SCI, V42, P2867; Sugawara S, 1998, INFECT IMMUN, V66, P3043, DOI 10.1128/IAI.66.7.3043-3049.1998; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Torzewski M, 2007, ARTERIOSCL THROM VAS, V27, P850, DOI 10.1161/01.ATV.0000258809.47285.07; URSINI F, 1995, METHOD ENZYMOL, V252, P38; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamada H, 2006, LIFE SCI, V78, P926, DOI 10.1016/j.lfs.2005.05.106; Zhang YF, 2005, CIRC RES, V96, P831, DOI 10.1161/01.RES.0000164401.21929.CF	53	30	30	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2525	2532		10.1096/fj.09-147421	http://dx.doi.org/10.1096/fj.09-147421			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20219985	Green Published			2022-12-28	WOS:000279343600039
J	Sharma, NS; Nagrath, D; Yarmush, ML				Sharma, Nripen S.; Nagrath, Deepak; Yarmush, Martin L.			Adipocyte-derived basement membrane extract with biological activity: applications in hepatocyte functional augmentation in vitro	FASEB JOURNAL			English	Article						Adipogel; natural biomaterials; metabolic analysis	ISOLATED RAT HEPATOCYTES; METABOLIC FLUX ANALYSIS; LONG-TERM CULTURE; EXTRACELLULAR-MATRIX; PROTEIN-SYNTHESIS; AMINO-ACIDS; SANDWICH CONFIGURATION; COLLAGEN SANDWICH; GROWTH-FACTORS; LIVER	Natural and synthetic biomaterials utilized in tissue engineering applications require a dynamic interplay of complex macromolecular compositions of hydrated extracellular matrices (ECMs) and soluble growth factors. The challenges in utilizing synthetic ECMs is the effective control of temporal and spatial complexity of multiple signal presentation, as compared to natural ECMs that possess the inherent properties of biological recognition, including presentation of receptor-binding ligands, susceptibility to cell-triggered proteolytic degradation, and remodeling. We have developed a murine preadipocyte differentiation system for generating a natural basement membrane extract (Adipogel) comprising ECM proteins (collagen IV, laminin, hyaluronan, and fibronectin) and including relevant growth factors (hepatocyte growth factor, vascular endothelial growth factor, and leukemia inhibitory factor). We have shown the effective utilization of the growth factor-enriched extracellular matrix for enhanced albumin synthesis rate of primary hepatocyte cultures for a period of 10 d as compared to collagen sandwich cultures and comparable or higher function as compared to Matrigel cultures. We have also demonstrated comparable cytochrome P450 1A1 activity for the collagen-Adipogel condition to the collagen double-gel and Matrigel culture conditions. A metabolic analysis revealed that utilization of Adipogel in primary hepatocyte cultures increased serine, glycine, threonine, alanine, tyrosine, valine, methionine, lysine, isoleucine, leucine, phenylalanine, taurine, cysteine, and glucose uptake rates to enhance hepatocyte protein synthesis as compared to collagen double-gel cultures. The demonstrated synthesis, isolation, characterization, and application of Adipogel provide immense potential for tissue engineering and regenerative medicine applications.-Sharma, N. S., Nagrath, D., Yarmush, M. L. Adipocyte-derived basement membrane extract with biological activity: applications in hepatocyte functional augmentation in vitro. FASEB J. 24, 2364-2374 (2010). www.fasebj.org	[Sharma, Nripen S.; Yarmush, Martin L.] Shriners Hosp Children, Boston, MA 02114 USA; [Sharma, Nripen S.; Yarmush, Martin L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Surg Serv, Boston, MA USA; [Sharma, Nripen S.; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA; [Nagrath, Deepak] Rice Univ, Dept Chem & Biomol Engn, Houston, TX USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Rutgers State University New Brunswick; Rice University	Yarmush, ML (corresponding author), Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA.	ireis@sbi.org		Yarmush, Martin/0000-0003-4986-8444; Nagrath, Deepak/0000-0002-8999-2282	U.S. National Institutes of Health [R01 DK059766, R01 AI063795]; Shriners Hospitals for Children; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059766, P30DK040561] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Shriners Hospitals for Children; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants R01 DK059766 and R01 AI063795, and grants from the Shriners Hospitals for Children. Resources were provided by the BioMEMS Resource Center (P41 EB-002503). The authors declare there are no conflicts of interest.	Abberton KM, 2008, CELLS TISSUES ORGANS, V188, P347, DOI 10.1159/000121575; Badylak SF, 2009, ACTA BIOMATER, V5, P1, DOI 10.1016/j.actbio.2008.09.013; Berthiaume F, 2003, METAB ENG, V5, P108, DOI 10.1016/S1096-7176(03)00010-7; Causa F, 2007, BIOMATERIALS, V28, P5093, DOI 10.1016/j.biomaterials.2007.07.030; Chan C, 2003, BIOTECHNOL BIOENG, V81, P33, DOI 10.1002/bit.10453; Chan C, 2003, METAB ENG, V5, P1, DOI 10.1016/S1096-7176(02)00011-3; Chan C, 2002, BIOTECHNOL BIOENG, V78, P753, DOI 10.1002/bit.10275; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; DUNN JCY, 1992, J CELL BIOL, V116, P1043, DOI 10.1083/jcb.116.4.1043; DUNN JCY, 1993, BIOTECHNOL BIOENG, V41, P593, DOI 10.1002/bit.260410512; Farkas D, 2005, CHEM RES TOXICOL, V18, P1132, DOI 10.1021/tx0500225; Farkas D, 2005, TOXICOL SCI, V85, P927, DOI 10.1093/toxsci/kfi145; Flaim CJ, 2005, NAT METHODS, V2, P119, DOI 10.1038/NMETH736; FLAIM KE, 1982, J BIOL CHEM, V257, P2939; FLAIM KE, 1982, J BIOL CHEM, V257, P2932; Freytes DO, 2008, J BIOMED MATER RES A, V87A, P862, DOI 10.1002/jbm.a.31821; Ijichi C, 2003, BIOCHEM BIOPH RES CO, V303, P59, DOI 10.1016/S0006-291X(03)00295-X; Kane BJ, 2006, ANAL CHEM, V78, P4291, DOI 10.1021/ac051856v; Kang YH, 2004, EXP CELL RES, V293, P239, DOI 10.1016/j.yexcr.2003.10.011; Karp JM, 2007, CURR OPIN BIOTECH, V18, P454, DOI 10.1016/j.copbio.2007.09.008; LEE JW, 1992, BIOTECHNOL BIOENG, V40, P298, DOI 10.1002/bit.260400214; Lee K, 2003, METAB ENG, V5, P221, DOI 10.1016/S1096-7176(03)00042-9; Lee K, 2003, BIOTECHNOL BIOENG, V83, P400, DOI 10.1002/bit.10682; Nagrath D, 2007, ANN BIOMED ENG, V35, P863, DOI 10.1007/s10439-007-9283-0; Nagrath D, 2009, METAB ENG, V11, P274, DOI 10.1016/j.ymben.2009.05.005; Nahmias Y, 2006, FASEB J, V20, P2531, DOI 10.1096/fj.06-6192fje; Reid L M, 1980, Ann N Y Acad Sci, V349, P70, DOI 10.1111/j.1749-6632.1980.tb29516.x; Revzin A, 2004, LANGMUIR, V20, P2999, DOI 10.1021/la035827w; Rosso F, 2005, J CELL PHYSIOL, V203, P465, DOI 10.1002/jcp.20270; ROTEM A, 1994, BIOTECHNOL BIOENG, V43, P654, DOI 10.1002/bit.260430715; RYAN CM, 1993, SURGERY, V113, P48; SEGLEN PO, 1978, BIOCHIM BIOPHYS ACTA, V520, P630, DOI 10.1016/0005-2787(78)90148-X; SEGLEN PO, 1978, EUR J BIOCHEM, V85, P15, DOI 10.1111/j.1432-1033.1978.tb12208.x; SELGEN PO, 1976, METHOD CELL BIOL, V13, P29; Sharma NS, 2005, BIOTECHNOL BIOENG, V92, P321, DOI 10.1002/bit.20586; VoytikHarbin SL, 1997, J CELL BIOCHEM, V67, P478, DOI 10.1002/(SICI)1097-4644(19971215)67:4<478::AID-JCB6>3.0.CO;2-P; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; Wang S, 2008, TISSUE ENG PT A, V14, P227, DOI 10.1089/tea.2007.0143; Washizu J, 2001, TISSUE ENG, V7, P691, DOI 10.1089/107632701753337654; Yamaguchi Y, 1997, SURGERY, V121, P295, DOI 10.1016/S0039-6060(97)90358-5	41	20	20	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2364	2374		10.1096/fj.09-135095	http://dx.doi.org/10.1096/fj.09-135095			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20233948	Green Published			2022-12-28	WOS:000279343600023
J	Tu, H; Hsuchou, H; Kastin, AJ; Wu, XJ; Pan, WH				Tu, Hong; Hsuchou, Hung; Kastin, Abba J.; Wu, Xiaojun; Pan, Weihong			Unique leptin trafficking by a tailless receptor	FASEB JOURNAL			English	Article						ObR; endocytosis motif	BLOOD-BRAIN-BARRIER; SIGNAL-TRANSDUCTION; OBESE MICE; OB-R; ENDOCYTOSIS; TRANSPORT; EXPRESSION; ISOFORMS; ACTIVATION; UROCORTIN	Impairment in blood-to-brain transport of leptin is a major cause as well as consequence of obesity. Leptin crosses the blood-brain barrier by transcytosis rather than undergoing intracellular degradation. Results from previous studies have indicated that the membrane juxtapositional cytoplasmic sequence of the leptin receptor ObR is responsible for leptin transport. To identify the specific structural domains, we generated a series of ObR truncates with different lengths of the intracellular sequence, overexpressed them in 3 types of mammalian cells including cerebral endothelia, and quantified leptin binding and endocytosis. All mutant ObRs were able to bind and mediate the internalization of leptin. Surprisingly, ObR860, a construct with no cytoplasmic sequence, could act like the classical ObRa transporter in internalizing leptin. There were some cell type-dependent variations in the intracellular trafficking of Alexa-labeled leptin when mediated by ObR860 or ObRa because of differential involvement of membrane microdomains, as shown by use of the clathrin inhibitor chlorpromazine and the dynamin inhibitor Dynasore. The clathrin-and dynamin-mediated endocytosis of leptin contrasts with the lack of effect of the caveolae inhibitors nystatin and filipin. Thus, leptin-induced internalization of the ligand-receptor complex can occur without specific sorting signals in the cytoplasmic region of ObR. This novel finding may have significant implications for leptin transport.-Tu, H., Hsuchou, H., Kastin, A. J., Wu, X., Pan, W. Unique leptin trafficking by a tailless receptor. FASEB J. 24, 2281-2291 (2010). www.fasebj.org	[Tu, Hong; Hsuchou, Hung; Kastin, Abba J.; Wu, Xiaojun; Pan, Weihong] Pennington Biomed Res Ctr, Blood Brain Barrier Grp, Baton Rouge, LA 70808 USA; [Tu, Hong] Shanghai Jiao Tong Univ, Inst Canc, State Key Lab Oncogene & Related Genes, Shanghai 200030, Peoples R China	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Shanghai Jiao Tong University	Pan, WH (corresponding author), Pennington Biomed Res Ctr, Blood Brain Barrier Grp, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	weihong.pan@pbrc.edu		Tu, Hong/0000-0002-8298-5207	U.S. National Institutes of Health [DK54880, NS62291, NS46528]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054880, R56DK054880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062291, R01NS046528] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by U.S. National Institutes of Health grants (DK54880 to A.J.K.; NS62291 and NS46528 to W. P.). The ObR plasmids were kindly provided by Dr. Christian Bjorbaek (Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA). The RBE4 cells were kindly provided by Dr. Pierre-Olivier Couraud (Institut Cochin, INSERM, Paris, France).	Ahima RS, 2004, PHYSIOL BEHAV, V81, P223, DOI 10.1016/j.physbeh.2004.02.014; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Banks WA, 2002, BRAIN RES, V950, P130, DOI 10.1016/S0006-8993(02)03013-5; Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; Belouzard S, 2006, EMBO J, V25, P932, DOI 10.1038/sj.emboj.7600989; Belouzard S, 2004, J BIOL CHEM, V279, P28499, DOI 10.1074/jbc.M400508200; Benmerah A, 2007, TRAFFIC, V8, P970, DOI 10.1111/j.1600-0854.2007.00585.x; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, ENDOCRINOLOGY, V139, P3485, DOI 10.1210/en.139.8.3485; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Harrold JA, 2006, PEPTIDES, V27, P365, DOI 10.1016/j.peptides.2005.01.030; Hegyi K, 2004, CELL BIOL INT, V28, P159, DOI 10.1016/j.cellbi.2003.12.003; Kastin AJ, 2006, ENDOCRINOLOGY, V147, P2086, DOI 10.1210/en.2006-0208; Kastin AJ, 2002, PEPTIDES, V23, P2189, DOI 10.1016/S0196-9781(02)00247-4; Kastin AJ, 1999, PEPTIDES, V20, P1449, DOI 10.1016/S0196-9781(99)00156-4; Kastin AJ, 2000, PEPTIDES, V21, P1811, DOI 10.1016/S0196-9781(00)00349-1; Kirchhausen T, 2008, METHOD ENZYMOL, V438, P77, DOI 10.1016/S0076-6879(07)38006-3; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Myers MG, 2004, RECENT PROG HORM RES, V59, P287, DOI 10.1210/rp.59.1.287; Pan WH, 2008, ENDOCRINOLOGY, V149, P2798, DOI 10.1210/en.2007-1673; Pan WH, 2008, ENDOCRINOLOGY, V149, P877, DOI 10.1210/en.2007-0893; Pan WH, 2007, CELL PHYSIOL BIOCHEM, V20, P559, DOI 10.1159/000107539; Pan WH, 2006, PEPTIDES, V27, P911, DOI 10.1016/j.peptides.2005.12.014; Pan WH, 2005, ENDOCRINOLOGY, V146, P4898, DOI 10.1210/en.2005-0587; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; SUBTIL A, 1994, J CELL SCI, V107, P3461; SWEEP F, 1991, ACTA ENDOCRINOL-COP, V125, P84; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Tu H, 2008, J CELL PHYSIOL, V214, P301, DOI 10.1002/jcp.21195; Tu H, 2007, J CELL PHYSIOL, V212, P215, DOI 10.1002/jcp.21020; Tu H, 2007, J MOL NEUROSCI, V31, P171, DOI 10.1385/JMN/31:02:171; Tu H, 2007, MOL ENDOCRINOL, V21, P700, DOI 10.1210/me.2005-0503; Uotani S, 1999, DIABETES, V48, P279, DOI 10.2337/diabetes.48.2.279; Van Hamme E, 2008, J GEN VIROL, V89, P2147, DOI 10.1099/vir.0.2008/001602-0; VAN HM, 1997, J CLIN INVEST, V99, P385; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Wilcke M, 2000, EUR J HISTOCHEM, V44, P325	46	29	30	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2281	2291		10.1096/fj.09-143487	http://dx.doi.org/10.1096/fj.09-143487			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20223942	Green Published			2022-12-28	WOS:000279343600015
